{"id": "0_0", "text": "Huntington's disease is a neurodegenerative autosomal disease results due to expansion of polymorphic CAG repeats in the huntingtin gene.", "tags": [{"end": 61, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 121, "tag": "GeneOrGenome"}, {"end": 113, "start": 102, "tag": "MolecularSequence"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 90, "tag": "CellFunction"}]}{"id": "0_1", "text": "Phosphorylation of the translation initiation factor 4E-BP results in the alteration of the translation control leading to unwanted protein synthesis and neuronal function.", "tags": [{"end": 15, "start": 0, "tag": "CellFunction"}, {"end": 52, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 23, "tag": "GeneOrGenome"}, {"end": 58, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 53, "tag": "GeneOrGenome"}, {"end": 111, "start": 92, "tag": "CellFunction"}, {"end": 149, "start": 123, "tag": "CellOrMolecularDysfunction"}, {"end": 84, "start": 74, "tag": "Finding"}, {"end": 171, "start": 154, "tag": "CellFunction"}, {"end": 149, "start": 132, "tag": "CellFunction"}]}{"id": "0_3", "text": "Variability of age of onset is an important factor of Huntington's disease separating adult and juvenile types.", "tags": [{"end": 11, "start": 0, "tag": "Finding"}, {"end": 91, "start": 86, "tag": "PopulationGroup"}, {"end": 104, "start": 96, "tag": "PopulationGroup"}, {"end": 27, "start": 15, "tag": "TemporalConcept"}, {"end": 74, "start": 54, "tag": "DiseaseOrSyndrome"}]}{"id": "0_4", "text": "The factors which are taken into account are-genetic modifiers, maternal protection i.e excessive paternal transmission, superior ageing genes and environmental threshold.", "tags": [{"end": 72, "start": 64, "tag": "PopulationGroup"}, {"end": 83, "start": 64, "tag": "BiologicFunction"}, {"end": 119, "start": 88, "tag": "PathologicFunction"}, {"end": 119, "start": 98, "tag": "NaturalPhenomenonOrProcess"}, {"end": 142, "start": 130, "tag": "GeneOrGenome"}, {"end": 170, "start": 147, "tag": "NaturalPhenomenonOrProcess"}, {"end": 62, "start": 45, "tag": "GeneOrGenome"}, {"end": 62, "start": 45, "tag": "CellFunction"}]}{"id": "0_5", "text": "A major focus has been given to the molecular pathogenesis which includes-motor disturbance, cognitive disturbance and neuropsychiatric disturbance.", "tags": [{"end": 114, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 74, "tag": "SignOrSymptom"}, {"end": 58, "start": 36, "tag": "PathologicFunction"}]}{"id": "0_6", "text": "The diagnosis part has also been taken care of.", "tags": [{"end": 13, "start": 4, "tag": "HealthCareActivity"}]}{"id": "0_8", "text": "The present review also focuses on the genetics and pathology of Huntington's disease.", "tags": [{"end": 47, "start": 39, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 47, "start": 39, "tag": "CellFunction"}, {"end": 85, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 52, "tag": "PathologicFunction"}, {"end": 61, "start": 52, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}]}{"id": "1_2", "text": "The symptoms of Huntington's disease are severe reduction in muscle control, emotional disturbance, and pathological disorders in brain cells.", "tags": [{"end": 12, "start": 4, "tag": "SignOrSymptom"}, {"end": 75, "start": 41, "tag": "Finding"}, {"end": 98, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 104, "tag": "PathologicFunction"}, {"end": 126, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 130, "tag": "Cell"}, {"end": 75, "start": 61, "tag": "BiologicFunction"}, {"end": 36, "start": 16, "tag": "DiseaseOrSyndrome"}]}{"id": "1_3", "text": "These diseases are caused by destruction of the cells that secrete a substance called dopamine.", "tags": [{"end": 78, "start": 69, "tag": "Substance"}, {"end": 53, "start": 29, "tag": "SignOrSymptom"}, {"end": 94, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 86, "tag": "Chemical"}, {"end": 94, "start": 86, "tag": "PharmacologicSubstance"}, {"end": 66, "start": 59, "tag": "CellFunction"}]}{"id": "1_6", "text": "Bifurcation analysis is carried out with respect to different parameters, providing full spectrum of the behavior for different parameter values.", "tags": [{"end": 97, "start": 89, "tag": "ResearchActivity"}, {"end": 20, "start": 0, "tag": "ResearchActivity"}, {"end": 113, "start": 105, "tag": "BiologicFunction"}, {"end": 113, "start": 105, "tag": "IndividualBehavior"}, {"end": 113, "start": 105, "tag": "ResearchActivity"}]}{"id": "2_0", "text": "Mitochondria play an essential role in supplying energy for the health and survival of neurons.", "tags": [{"end": 94, "start": 75, "tag": "CellFunction"}, {"end": 12, "start": 0, "tag": "CellComponent"}, {"end": 70, "start": 64, "tag": "HealthCareActivity"}]}{"id": "2_6", "text": "The findings will help identify the potential interventions of mitophagy regulation and treatment strategies of neurodegenerative diseases.", "tags": [{"end": 138, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 88, "tag": "HealthCareActivity"}, {"end": 97, "start": 88, "tag": "ResearchActivity"}, {"end": 72, "start": 63, "tag": "CellFunction"}, {"end": 59, "start": 46, "tag": "HealthCareActivity"}, {"end": 108, "start": 88, "tag": "HealthCareActivity"}, {"end": 108, "start": 88, "tag": "ResearchActivity"}, {"end": 59, "start": 46, "tag": "ResearchActivity"}]}{"id": "4_0", "text": "Olfactory dysfunction is a common symptom in patients with neurodegenerative disorders, including Huntington's disease (HD).", "tags": [{"end": 118, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 45, "tag": "PatientOrDisabledGroup"}, {"end": 41, "start": 34, "tag": "SignOrSymptom"}, {"end": 21, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 0, "tag": "PathologicFunction"}]}{"id": "4_4", "text": "For HD, data regarding prevalence rates are lacking and the scales used have been inconsistent or have been restructured due to concerns about cross-cultural understanding.", "tags": [{"end": 157, "start": 143, "tag": "HealthCareActivity"}, {"end": 157, "start": 143, "tag": "ResearchActivity"}, {"end": 12, "start": 8, "tag": "ResearchActivity"}, {"end": 6, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 23, "tag": "ResearchActivity"}]}{"id": "4_5", "text": "Pathogenic huntingtin deposits have been found in the olfactory bulb of individuals with HD, although no studies have correlated this with the grade of olfactory impairment.", "tags": [{"end": 68, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 152, "tag": "PathologicFunction"}, {"end": 112, "start": 105, "tag": "ResearchActivity"}, {"end": 91, "start": 72, "tag": "PatientOrDisabledGroup"}, {"end": 30, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 30, "start": 11, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "6_0", "text": "Neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington disease have serious concern due to its effect on the quality of life of affected persons.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 129, "tag": "Finding"}, {"end": 164, "start": 148, "tag": "PatientOrDisabledGroup"}, {"end": 82, "start": 64, "tag": "DiseaseOrSyndrome"}]}{"id": "6_1", "text": "They have some limitations at diagnostic as well as the treatment level.", "tags": [{"end": 71, "start": 66, "tag": "HealthCareActivity"}, {"end": 40, "start": 30, "tag": "HealthCareActivity"}]}{"id": "6_2", "text": "Introducing nanotechnology, for the treatment of these diseases may contribute significantly to solve the problem.", "tags": [{"end": 45, "start": 36, "tag": "HealthCareActivity"}, {"end": 45, "start": 36, "tag": "ResearchActivity"}]}{"id": "6_4", "text": "The present review highlights the application of nanotechnology during last the 20 years for the treatment of neurodegenerative diseases.", "tags": [{"end": 88, "start": 83, "tag": "TemporalConcept"}, {"end": 136, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 106, "start": 97, "tag": "HealthCareActivity"}, {"end": 106, "start": 97, "tag": "ResearchActivity"}]}{"id": "9_0", "text": "Recent genome-wide association studies of Huntington's disease (HD) primarily highlighted genes involved in DNA damage repair mechanisms as modifiers of age at onset and disease severity, consistent with evidence that more DNA repair genes are being implicated in late age-onset neurodegenerative diseases.", "tags": [{"end": 38, "start": 7, "tag": "ResearchActivity"}, {"end": 149, "start": 140, "tag": "Chemical"}, {"end": 239, "start": 223, "tag": "GeneOrGenome"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 186, "start": 170, "tag": "ClinicalAttribute"}, {"end": 165, "start": 160, "tag": "TemporalConcept"}, {"end": 278, "start": 273, "tag": "TemporalConcept"}, {"end": 186, "start": 170, "tag": "Finding"}, {"end": 156, "start": 153, "tag": "OrganismAttribute"}, {"end": 272, "start": 269, "tag": "OrganismAttribute"}, {"end": 212, "start": 204, "tag": "Finding"}, {"end": 125, "start": 108, "tag": "CellFunction"}, {"end": 305, "start": 279, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 64, "tag": "DiseaseOrSyndrome"}]}{"id": "9_1", "text": "This provides an exciting opportunity to advance therapeutic development in HD, as these pathways have already been under intense investigation in cancer research.", "tags": [{"end": 72, "start": 49, "tag": "ResearchActivity"}, {"end": 162, "start": 147, "tag": "ResearchActivity"}, {"end": 143, "start": 130, "tag": "ResearchActivity"}, {"end": 97, "start": 89, "tag": "CellFunction"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}]}{"id": "9_3", "text": "A potential universal trigger of oxidative DNA damage shared in these late age-onset diseases is the increase of reactive oxygen species (ROS) in human aging, defining an age-related mechanism that has defied other hypotheses of neurodegeneration.", "tags": [{"end": 21, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 33, "tag": "CellOrMolecularDysfunction"}, {"end": 157, "start": 152, "tag": "BiologicFunction"}, {"end": 157, "start": 152, "tag": "CellFunction"}, {"end": 84, "start": 79, "tag": "TemporalConcept"}, {"end": 136, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 113, "tag": "Chemical"}, {"end": 246, "start": 229, "tag": "CellOrMolecularDysfunction"}, {"end": 78, "start": 75, "tag": "OrganismAttribute"}, {"end": 141, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 138, "tag": "Chemical"}, {"end": 151, "start": 146, "tag": "Eukaryote"}, {"end": 174, "start": 171, "tag": "OrganismAttribute"}]}{"id": "9_4", "text": "We discuss the potential commonality of DNA damage repair pathways in HD and other neurodegenerative diseases.", "tags": [{"end": 66, "start": 40, "tag": "CellFunction"}, {"end": 109, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}]}{"id": "10_2", "text": "These include defining the point at which the preclinical data are sufficiently compelling to permit progression to the first clinical studies; scaling-up, characterization, quality control and validation of the cell product; design, validation and approval of the surgical device; and operative procedures for safe and effective delivery of cell product to the brain.", "tags": [{"end": 142, "start": 126, "tag": "ResearchActivity"}, {"end": 172, "start": 156, "tag": "ResearchActivity"}, {"end": 189, "start": 174, "tag": "ResearchActivity"}, {"end": 204, "start": 194, "tag": "ResearchActivity"}, {"end": 232, "start": 226, "tag": "ResearchActivity"}, {"end": 244, "start": 234, "tag": "ResearchActivity"}, {"end": 257, "start": 249, "tag": "ResearchActivity"}, {"end": 280, "start": 265, "tag": "ManufacturedObject"}, {"end": 306, "start": 286, "tag": "HealthCareActivity"}, {"end": 354, "start": 342, "tag": "HealthCareActivity"}, {"end": 338, "start": 330, "tag": "BiologicFunction"}, {"end": 154, "start": 144, "tag": "ResearchActivity"}, {"end": 224, "start": 212, "tag": "Cell"}, {"end": 367, "start": 362, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 46, "tag": "ResearchActivity"}, {"end": 112, "start": 101, "tag": "PathologicFunction"}, {"end": 112, "start": 101, "tag": "TemporalConcept"}]}{"id": "10_4", "text": "Here we set out the challenges associated with the clinical translation of cell therapy, using Huntington's disease as a specific example, and suggest potential strategies to address these challenges.", "tags": [{"end": 87, "start": 75, "tag": "HealthCareActivity"}, {"end": 71, "start": 51, "tag": "ResearchActivity"}, {"end": 115, "start": 95, "tag": "DiseaseOrSyndrome"}]}{"id": "10_5", "text": "Huntington's disease presents a clear unmet need, but, importantly, it is an autosomal dominant condition with a readily available gene test, full genetic penetrance and a wide range of associated animal models, which together mean that it is a powerful condition in which to develop principles and test experimental therapeutics.", "tags": [{"end": 140, "start": 131, "tag": "HealthCareActivity"}, {"end": 140, "start": 131, "tag": "ResearchActivity"}, {"end": 210, "start": 197, "tag": "ExperimentalModelOfDisease"}, {"end": 329, "start": 304, "tag": "ResearchActivity"}, {"end": 105, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 142, "tag": "Finding"}, {"end": 95, "start": 77, "tag": "CellFunction"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 38, "tag": "Finding"}]}{"id": "10_6", "text": "We propose that solving these challenges in Huntington's disease would provide a road map for many other neurological conditions.", "tags": [{"end": 89, "start": 81, "tag": "Finding"}, {"end": 128, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 44, "tag": "DiseaseOrSyndrome"}]}{"id": "10_7", "text": "This white paper represents a consensus opinion emerging from a series of meetings of the international translational platforms Stem Cells for Huntington's Disease and the European Huntington's Disease Network Advanced Therapies Working Group, established to identify the challenges of cell therapy, share experience, develop guidance, and highlight future directions, with the aim to expedite progress towards therapies for clinical benefit in Huntington's disease.", "tags": [{"end": 16, "start": 5, "tag": "ResearchActivity"}, {"end": 138, "start": 128, "tag": "Cell"}, {"end": 298, "start": 286, "tag": "HealthCareActivity"}, {"end": 316, "start": 306, "tag": "BiologicFunction"}, {"end": 334, "start": 326, "tag": "ClinicalAttribute"}, {"end": 420, "start": 411, "tag": "HealthCareActivity"}, {"end": 209, "start": 172, "tag": "HealthCareRelatedOrganization"}, {"end": 242, "start": 210, "tag": "HealthCareRelatedOrganization"}, {"end": 82, "start": 74, "tag": "ResearchActivity"}, {"end": 127, "start": 90, "tag": "HealthCareRelatedOrganization"}, {"end": 163, "start": 128, "tag": "HealthCareRelatedOrganization"}, {"end": 47, "start": 30, "tag": "ResearchActivity"}, {"end": 441, "start": 425, "tag": "Finding"}, {"end": 465, "start": 445, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 402, "start": 394, "tag": "TemporalConcept"}]}{"id": "10_8", "text": "Rosser et al.", "tags": []}{"id": "10_9", "text": "discuss the challenges associated with clinical translation of cell therapies, using Huntington's disease as the primary example.", "tags": [{"end": 77, "start": 63, "tag": "HealthCareActivity"}, {"end": 59, "start": 39, "tag": "ResearchActivity"}, {"end": 105, "start": 85, "tag": "DiseaseOrSyndrome"}]}{"id": "11_1", "text": "Recent studies have reported visual dysfunction in Huntington's disease (HD).", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 47, "start": 29, "tag": "PathologicFunction"}, {"end": 47, "start": 29, "tag": "DiseaseOrSyndrome"}]}{"id": "11_2", "text": "However, little is known about retinal structural changes in HD.", "tags": [{"end": 57, "start": 31, "tag": "CellOrMolecularDysfunction"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}]}{"id": "11_4", "text": "Unified Huntington's Disease Rating Score-Motor part was assessed in HD patients.", "tags": [{"end": 80, "start": 69, "tag": "PatientOrDisabledGroup"}, {"end": 28, "start": 8, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 0, "tag": "HealthCareActivity"}]}{"id": "11_6", "text": "Superficial and deep capillary plexus densities were measured using OCT angiography (OCTA).", "tags": [{"end": 37, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 0, "tag": "ClinicalAttribute"}, {"end": 83, "start": 68, "tag": "HealthCareActivity"}, {"end": 89, "start": 85, "tag": "HealthCareActivity"}]}{"id": "11_7", "text": "To account for inter-eye correlation, generalized estimating equation (GEE) model was used.", "tags": [{"end": 74, "start": 71, "tag": "ResearchActivity"}, {"end": 36, "start": 15, "tag": "ResearchActivity"}, {"end": 69, "start": 38, "tag": "ResearchActivity"}]}{"id": "11_8", "text": "Results HD patients had a significant reduction in macular thickness in both inner and outer superior sectors and the inferior outer sector.", "tags": [{"end": 19, "start": 8, "tag": "PatientOrDisabledGroup"}, {"end": 68, "start": 51, "tag": "ClinicalAttribute"}, {"end": 109, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 38, "tag": "Finding"}]}{"id": "11_9", "text": "Inferior pRNFLs were significantly decreased in thickness.", "tags": [{"end": 15, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 35, "tag": "Finding"}]}{"id": "11_10", "text": "There was no significant difference in retinal capillary plexus density between the two groups.", "tags": [{"end": 63, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 39, "tag": "ClinicalAttribute"}, {"end": 35, "start": 10, "tag": "Finding"}]}{"id": "11_12", "text": "However, the severity of motor involvement was not correlated with SD-OCT or OCTA parameters.", "tags": [{"end": 42, "start": 13, "tag": "Finding"}, {"end": 81, "start": 77, "tag": "HealthCareActivity"}, {"end": 73, "start": 67, "tag": "HealthCareActivity"}]}{"id": "11_13", "text": "Conclusions We observed attenuated pRNFL and macular retinal thickness in patients with HD, independent of macular capillary plexus parameters.", "tags": [{"end": 40, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 74, "tag": "PatientOrDisabledGroup"}, {"end": 70, "start": 61, "tag": "Finding"}, {"end": 40, "start": 24, "tag": "Finding"}, {"end": 70, "start": 45, "tag": "Finding"}, {"end": 34, "start": 24, "tag": "Finding"}]}{"id": "12_1", "text": "The prevention of neurodegenerative disorders has become an emerging public health challenge for our society.", "tags": [{"end": 14, "start": 4, "tag": "HealthCareActivity"}, {"end": 82, "start": 69, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 82, "start": 69, "tag": "HealthCareActivity"}, {"end": 45, "start": 18, "tag": "DiseaseOrSyndrome"}]}{"id": "12_4", "text": "Moreover, melatonin levels are decreased in patients with neurodegenerative diseases.", "tags": [{"end": 26, "start": 10, "tag": "ResearchActivity"}, {"end": 40, "start": 31, "tag": "Finding"}, {"end": 19, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 84, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 44, "tag": "PatientOrDisabledGroup"}, {"end": 19, "start": 10, "tag": "Chemical"}]}{"id": "12_5", "text": "In this review, we summarize current knowledge on the regulation, molecular mechanisms and biological functions of melatonin in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, vascular dementia and multiple sclerosis.", "tags": [{"end": 46, "start": 37, "tag": "Finding"}, {"end": 111, "start": 91, "tag": "BiologicFunction"}, {"end": 182, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 203, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 275, "start": 258, "tag": "DiseaseOrSyndrome"}, {"end": 298, "start": 280, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 66, "tag": "CellFunction"}, {"end": 36, "start": 29, "tag": "TemporalConcept"}, {"end": 225, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 115, "tag": "PharmacologicSubstance"}, {"end": 154, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 124, "start": 115, "tag": "Chemical"}]}{"id": "12_6", "text": "We also discuss the clinical application of melatonin in neurodegenerative disorders.", "tags": [{"end": 53, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 44, "tag": "PharmacologicSubstance"}, {"end": 84, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 20, "tag": "HealthCareActivity"}, {"end": 53, "start": 44, "tag": "Chemical"}]}{"id": "12_7", "text": "This information will lead to a better understanding of the regulation of melatonin in the brain and provide therapeutic options for the treatment of various neurodegenerative diseases.", "tags": [{"end": 128, "start": 109, "tag": "HealthCareActivity"}, {"end": 83, "start": 60, "tag": "BiologicFunction"}, {"end": 96, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 74, "tag": "PharmacologicSubstance"}, {"end": 184, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 137, "tag": "HealthCareActivity"}, {"end": 146, "start": 137, "tag": "ResearchActivity"}, {"end": 83, "start": 74, "tag": "Chemical"}]}{"id": "13_0", "text": "Huntington's disease (HD) is a neurodegenerative disorder caused by the aggregation of the mutant huntingtin (mHTT) protein in nerve cells.", "tags": [{"end": 138, "start": 127, "tag": "Cell"}, {"end": 114, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 110, "tag": "CellOrMolecularDysfunction"}, {"end": 108, "start": 72, "tag": "CellOrMolecularDysfunction"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 91, "tag": "CellOrMolecularDysfunction"}, {"end": 123, "start": 116, "tag": "CellOrMolecularDysfunction"}]}{"id": "13_1", "text": "mHTT self-aggregates to form soluble oligomers and insoluble fibrils, which interfere in a number of key cellular functions.", "tags": [{"end": 4, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 68, "start": 51, "tag": "CellComponent"}, {"end": 123, "start": 105, "tag": "CellFunction"}, {"end": 46, "start": 29, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "13_2", "text": "This leads to cell quiescence and ultimately cell death.", "tags": [{"end": 29, "start": 14, "tag": "CellFunction"}, {"end": 55, "start": 45, "tag": "CellFunction"}, {"end": 55, "start": 50, "tag": "BiologicFunction"}, {"end": 55, "start": 50, "tag": "PathologicFunction"}, {"end": 55, "start": 50, "tag": "CellFunction"}]}{"id": "13_4", "text": "This review summarizes the current state of knowledge of the mRNA targeting approaches such as antisense oligonucleotides and RNAi system; and the novel methods targeting mHTT and aggregates for degradation via the ubiquitin proteasome or the autophagy-lysosomal systems.", "tags": [{"end": 121, "start": 95, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 121, "start": 95, "tag": "PharmacologicSubstance"}, {"end": 121, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 153, "tag": "ResearchActivity"}, {"end": 175, "start": 171, "tag": "AminoAcidPeptideOrProtein"}, {"end": 175, "start": 171, "tag": "CellOrMolecularDysfunction"}, {"end": 65, "start": 61, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 235, "start": 225, "tag": "AminoAcidPeptideOrProtein"}, {"end": 235, "start": 225, "tag": "BiologicallyActiveSubstance"}, {"end": 224, "start": 215, "tag": "AminoAcidPeptideOrProtein"}, {"end": 224, "start": 215, "tag": "BiologicallyActiveSubstance"}, {"end": 270, "start": 243, "tag": "CellFunction"}, {"end": 206, "start": 195, "tag": "NaturalPhenomenonOrProcess"}, {"end": 53, "start": 44, "tag": "Finding"}, {"end": 34, "start": 27, "tag": "TemporalConcept"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 86, "start": 66, "tag": "ResearchActivity"}, {"end": 86, "start": 66, "tag": "HealthCareActivity"}, {"end": 137, "start": 126, "tag": "CellFunction"}]}{"id": "13_5", "text": "These methods include the proteolysis-targeting chimera, Trim-Away, autophagosome-tethering compound, autophagy-targeting chimera, lysosome-targeting chimera and approach targeting mHTT for chaperone-mediated autophagy.", "tags": [{"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 208, "start": 190, "tag": "CellFunction"}, {"end": 185, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 181, "tag": "CellOrMolecularDysfunction"}, {"end": 111, "start": 102, "tag": "CellFunction"}, {"end": 218, "start": 209, "tag": "CellFunction"}, {"end": 81, "start": 68, "tag": "CellComponent"}, {"end": 55, "start": 26, "tag": "Chemical"}, {"end": 66, "start": 57, "tag": "Chemical"}, {"end": 37, "start": 26, "tag": "CellFunction"}, {"end": 100, "start": 68, "tag": "Chemical"}, {"end": 129, "start": 102, "tag": "Chemical"}, {"end": 157, "start": 131, "tag": "Chemical"}]}{"id": "13_6", "text": "These molecular strategies provide a knowledge-based approach to target HD and other neurodegenerative diseases at the origin.", "tags": [{"end": 125, "start": 119, "tag": "TemporalConcept"}, {"end": 46, "start": 37, "tag": "Finding"}, {"end": 111, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}]}{"id": "14_0", "text": "Background Palliative care practices, including communication about patient-centered goals of care and advance care planning (ACP), have the potential to enhance care throughout the course of Huntington's disease (HD) and related disorders.", "tags": [{"end": 36, "start": 11, "tag": "HealthCareActivity"}, {"end": 61, "start": 48, "tag": "HealthCareActivity"}, {"end": 61, "start": 48, "tag": "CellFunction"}, {"end": 129, "start": 126, "tag": "HealthCareActivity"}, {"end": 124, "start": 103, "tag": "HealthCareActivity"}, {"end": 98, "start": 68, "tag": "HealthCareActivity"}, {"end": 166, "start": 162, "tag": "HealthCareActivity"}, {"end": 188, "start": 182, "tag": "TemporalConcept"}, {"end": 212, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 214, "tag": "DiseaseOrSyndrome"}]}{"id": "14_1", "text": "The goal of our project was to develop a pilot program that integrates primary palliative care practices with interdisciplinary care for HD.", "tags": [{"end": 8, "start": 4, "tag": "HealthCareActivity"}, {"end": 104, "start": 79, "tag": "HealthCareActivity"}, {"end": 132, "start": 128, "tag": "HealthCareActivity"}, {"end": 23, "start": 16, "tag": "ResearchActivity"}, {"end": 139, "start": 137, "tag": "DiseaseOrSyndrome"}]}{"id": "14_3", "text": "Methods We defined planning domains to expand care planning beyond end-of-life concerns.", "tags": [{"end": 59, "start": 46, "tag": "HealthCareActivity"}, {"end": 87, "start": 67, "tag": "HealthCareActivity"}]}{"id": "14_4", "text": "We created a patient and family guide to advance care planning in HD.", "tags": [{"end": 31, "start": 25, "tag": "PopulationGroup"}, {"end": 62, "start": 41, "tag": "HealthCareActivity"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 13, "tag": "PatientOrDisabledGroup"}]}{"id": "14_5", "text": "We conducted VitalTalk communications training with the HD team.", "tags": [{"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 13, "tag": "HealthCareActivity"}]}{"id": "14_6", "text": "We modified the interdisciplinary clinic workflow to include ACP and developed an EMR template for documentation.", "tags": [{"end": 64, "start": 61, "tag": "HealthCareActivity"}, {"end": 94, "start": 82, "tag": "HealthCareActivity"}, {"end": 112, "start": 99, "tag": "HealthCareActivity"}, {"end": 112, "start": 99, "tag": "Finding"}, {"end": 49, "start": 16, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "14_7", "text": "Results After communication training, more team members felt well prepared to discuss serious news (12.5% to 50%) and manage difficult conversations (25% to 62.5%).", "tags": [{"end": 36, "start": 14, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 55, "start": 43, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}{"id": "14_8", "text": "The proportion of clinic visits including advance care planning discussions increased from 12.5% to 30.6% during the pilot phase.", "tags": [{"end": 31, "start": 18, "tag": "HealthCareActivity"}, {"end": 63, "start": 42, "tag": "HealthCareActivity"}, {"end": 128, "start": 123, "tag": "TemporalConcept"}]}{"id": "14_10", "text": "Integration of palliative care practices into HD specialty care requires additional training and modification of clinic operations.", "tags": [{"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 11, "start": 0, "tag": "MachineActivity"}, {"end": 11, "start": 0, "tag": "BiologicFunction"}, {"end": 40, "start": 15, "tag": "HealthCareActivity"}, {"end": 63, "start": 49, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 92, "start": 84, "tag": "NaturalPhenomenonOrProcess"}, {"end": 130, "start": 113, "tag": "HealthCareActivity"}, {"end": 63, "start": 59, "tag": "HealthCareActivity"}, {"end": 48, "start": 46, "tag": "DiseaseOrSyndrome"}]}{"id": "15_0", "text": "Background: Although health-related quality of life is key for patients with long-term neurodegenerative conditions, measuring this is less straightforward and complex in Huntington's disease (HD).", "tags": [{"end": 86, "start": 77, "tag": "TemporalConcept"}, {"end": 51, "start": 36, "tag": "Finding"}, {"end": 27, "start": 21, "tag": "HealthCareActivity"}, {"end": 115, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 63, "tag": "PatientOrDisabledGroup"}, {"end": 191, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 193, "tag": "DiseaseOrSyndrome"}]}{"id": "15_1", "text": "Objectives: To refine and validate a fully patient-derived instrument, the Huntington's Disease health-related Quality of Life questionnaire (HDQoL), and to elucidate health domains that are meaningful to patients' lived experience.", "tags": [{"end": 231, "start": 221, "tag": "BiologicFunction"}, {"end": 95, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 75, "tag": "HealthCareActivity"}, {"end": 181, "start": 167, "tag": "HealthCareActivity"}, {"end": 213, "start": 205, "tag": "PatientOrDisabledGroup"}, {"end": 50, "start": 43, "tag": "PatientOrDisabledGroup"}, {"end": 147, "start": 142, "tag": "HealthCareActivity"}]}{"id": "15_2", "text": "Methods: Five-hundred forty-one participants, from premanifest to end-stage disease, completed the HDQoL, together with generic quality-of-life measures and in-person motor, cognitive, and behavioral assessments.", "tags": [{"end": 83, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 128, "tag": "Finding"}, {"end": 152, "start": 128, "tag": "HealthCareActivity"}, {"end": 211, "start": 189, "tag": "ResearchActivity"}, {"end": 44, "start": 32, "tag": "PopulationGroup"}, {"end": 104, "start": 99, "tag": "HealthCareActivity"}, {"end": 211, "start": 189, "tag": "HealthCareActivity"}]}{"id": "15_3", "text": "The psychometric properties of the HDQoL were examined using factor analysis and Rasch analysis.", "tags": [{"end": 76, "start": 61, "tag": "ResearchActivity"}, {"end": 95, "start": 81, "tag": "ResearchActivity"}, {"end": 40, "start": 35, "tag": "HealthCareActivity"}, {"end": 27, "start": 4, "tag": "HealthCareActivity"}]}{"id": "15_4", "text": "Results: Four HDQoL domains emerged, reflecting the classical triad of HD features; they were Physical-Functional, Cognitive, and 2 different behavioral aspects, that is, the Mood-Self domain and a distinct Worries domain.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 14, "tag": "HealthCareActivity"}, {"end": 191, "start": 175, "tag": "HealthCareActivity"}, {"end": 221, "start": 207, "tag": "HealthCareActivity"}]}{"id": "15_5", "text": "These domains clarify the behavioral sequelae as experienced by patients, and all showed good to excellent internal consistency.", "tags": [{"end": 72, "start": 64, "tag": "PatientOrDisabledGroup"}, {"end": 13, "start": 6, "tag": "Finding"}, {"end": 45, "start": 26, "tag": "Finding"}]}{"id": "15_6", "text": "Known-groups analyses illustrated significant and graded changes in clinical assessments and corresponding HDQoL domains across disease severity levels.", "tags": [{"end": 144, "start": 128, "tag": "ClinicalAttribute"}, {"end": 144, "start": 128, "tag": "Finding"}, {"end": 88, "start": 68, "tag": "HealthCareActivity"}, {"end": 21, "start": 13, "tag": "ResearchActivity"}, {"end": 120, "start": 107, "tag": "HealthCareActivity"}]}{"id": "15_7", "text": "Convergent and discriminant validity was demonstrated by the expected pattern of correlations between specific HDQoL domains and corresponding domain-relevant clinical assessments as well as patient-reported measures.", "tags": [{"end": 36, "start": 0, "tag": "Finding"}, {"end": 93, "start": 70, "tag": "ResearchActivity"}, {"end": 179, "start": 159, "tag": "HealthCareActivity"}, {"end": 198, "start": 191, "tag": "PatientOrDisabledGroup"}, {"end": 124, "start": 111, "tag": "HealthCareActivity"}, {"end": 216, "start": 191, "tag": "HealthCareActivity"}]}{"id": "15_8", "text": "The data demonstrate robust support for the refined HDQoL across disease stages.", "tags": [{"end": 79, "start": 65, "tag": "ClinicalAttribute"}, {"end": 79, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 57, "start": 52, "tag": "HealthCareActivity"}]}{"id": "15_9", "text": "Conclusions: The HDQoL, with its 2 distinct behavioral domains of Mood-Self and Worries as well as the Physical-Functional and Cognitive domains, is a relevant, reliable, and valid patient-derived instrument to measure the impact of HD across all severity stages.", "tags": [{"end": 87, "start": 80, "tag": "Finding"}, {"end": 262, "start": 256, "tag": "TemporalConcept"}, {"end": 255, "start": 247, "tag": "ClinicalAttribute"}, {"end": 255, "start": 247, "tag": "Finding"}, {"end": 235, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 181, "tag": "PatientOrDisabledGroup"}, {"end": 22, "start": 17, "tag": "HealthCareActivity"}, {"end": 75, "start": 66, "tag": "HealthCareActivity"}, {"end": 144, "start": 103, "tag": "HealthCareActivity"}]}{"id": "16_0", "text": "Neurodegenerative diseases affect millions of people worldwide, yet there are currently no effective treatments.", "tags": [{"end": 87, "start": 78, "tag": "TemporalConcept"}, {"end": 52, "start": 46, "tag": "PopulationGroup"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 101, "tag": "HealthCareActivity"}, {"end": 111, "start": 101, "tag": "ResearchActivity"}]}{"id": "16_1", "text": "Because risk of neurodegenerative disease substantially increases with age, greater life expectancy with a concomitant aging population means more individuals will be affected in the coming decades.", "tags": [{"end": 197, "start": 190, "tag": "TemporalConcept"}, {"end": 118, "start": 107, "tag": "TemporalConcept"}, {"end": 135, "start": 125, "tag": "PopulationGroup"}, {"end": 124, "start": 119, "tag": "BiologicFunction"}, {"end": 124, "start": 119, "tag": "CellFunction"}, {"end": 158, "start": 147, "tag": "PopulationGroup"}, {"end": 74, "start": 71, "tag": "OrganismAttribute"}, {"end": 12, "start": 8, "tag": "Finding"}, {"end": 99, "start": 84, "tag": "TemporalConcept"}, {"end": 88, "start": 84, "tag": "TemporalConcept"}, {"end": 41, "start": 16, "tag": "DiseaseOrSyndrome"}]}{"id": "16_2", "text": "Thus, there is an urgent need for understanding the mechanisms driving neurodegenerative diseases in order to develop improved treatment strategies.", "tags": [{"end": 147, "start": 127, "tag": "HealthCareActivity"}, {"end": 47, "start": 34, "tag": "BiologicFunction"}, {"end": 147, "start": 127, "tag": "ResearchActivity"}, {"end": 126, "start": 118, "tag": "Finding"}, {"end": 97, "start": 71, "tag": "DiseaseOrSyndrome"}]}{"id": "16_3", "text": "Inflammation in the nervous system, termed neuroinflammation, has become increasingly recognized as being associated with neurodegenerative diseases.", "tags": [{"end": 60, "start": 43, "tag": "PathologicFunction"}, {"end": 12, "start": 0, "tag": "PathologicFunction"}, {"end": 34, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 122, "tag": "DiseaseOrSyndrome"}]}{"id": "16_4", "text": "Early attention focused primarily on morphological changes in astrocytes and microglia; however, brain and CNS resident mast cells are now receiving attention as a result of being first responders to injury.", "tags": [{"end": 58, "start": 37, "tag": "Finding"}, {"end": 119, "start": 111, "tag": "PopulationGroup"}, {"end": 119, "start": 111, "tag": "HealthCareActivity"}, {"end": 130, "start": 120, "tag": "Cell"}, {"end": 130, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 77, "tag": "Cell"}, {"end": 206, "start": 200, "tag": "InjuryOrPoisoning"}, {"end": 102, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 62, "tag": "Cell"}, {"end": 15, "start": 6, "tag": "BiologicFunction"}, {"end": 158, "start": 149, "tag": "BiologicFunction"}, {"end": 185, "start": 180, "tag": "TemporalConcept"}]}{"id": "16_7", "text": "Here, we discuss the roles of mast cells in neuroinflammation and neurodegeneration with a focus on development and progression of four prominent neurodegenerative diseases: Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Huntington's Disease.", "tags": [{"end": 40, "start": 30, "tag": "Cell"}, {"end": 193, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 44, "tag": "PathologicFunction"}, {"end": 271, "start": 251, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 66, "tag": "CellOrMolecularDysfunction"}, {"end": 111, "start": 100, "tag": "BiologicFunction"}, {"end": 111, "start": 100, "tag": "CellFunction"}, {"end": 127, "start": 116, "tag": "PathologicFunction"}, {"end": 127, "start": 116, "tag": "TemporalConcept"}, {"end": 245, "start": 216, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 146, "tag": "DiseaseOrSyndrome"}]}{"id": "17_0", "text": "Huntington's disease (HD) is a devastating neurodegenerative disorder that urgently needs disease-modifying therapeutics.", "tags": [{"end": 69, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "17_1", "text": "To this end, collaboration to standardize clinical research practices in the field and drive progress in addressing drug development challenges is paramount.", "tags": [{"end": 59, "start": 42, "tag": "ResearchActivity"}, {"end": 132, "start": 116, "tag": "ResearchActivity"}, {"end": 143, "start": 133, "tag": "HealthCareActivity"}, {"end": 120, "start": 116, "tag": "PharmacologicSubstance"}, {"end": 101, "start": 93, "tag": "TemporalConcept"}]}{"id": "17_2", "text": "At a meeting in 2017 organized by CHDI Foundation and the Critical Path Institute, stakeholders across the pharmaceutical industry, academia, regulatory agencies, and patient advocacy groups discussed the need for and potential impact of a consortium dedicated to HD regulatory science.", "tags": [{"end": 12, "start": 5, "tag": "ResearchActivity"}, {"end": 130, "start": 107, "tag": "HealthCareRelatedOrganization"}, {"end": 250, "start": 240, "tag": "HealthCareRelatedOrganization"}, {"end": 266, "start": 264, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 34, "tag": "HealthCareRelatedOrganization"}, {"end": 81, "start": 58, "tag": "HealthCareRelatedOrganization"}, {"end": 140, "start": 132, "tag": "HealthCareRelatedOrganization"}, {"end": 161, "start": 142, "tag": "HealthCareRelatedOrganization"}, {"end": 190, "start": 167, "tag": "HealthCareRelatedOrganization"}]}{"id": "17_3", "text": "Consequently, the Huntington's Disease Regulatory Science Consortium (HD-RSC) was formed, a precompetitive consortium that is dedicated to building a regulatory strategy to expedite the approval of HD therapeutics.", "tags": [{"end": 213, "start": 201, "tag": "HealthCareActivity"}, {"end": 76, "start": 70, "tag": "HealthCareRelatedOrganization"}, {"end": 200, "start": 198, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 18, "tag": "HealthCareRelatedOrganization"}]}{"id": "24_0", "text": "Many neurodegenerative diseases are associated with pathological aggregation of proteins in neurons.", "tags": [{"end": 88, "start": 52, "tag": "CellOrMolecularDysfunction"}, {"end": 99, "start": 92, "tag": "Cell"}, {"end": 31, "start": 5, "tag": "DiseaseOrSyndrome"}]}{"id": "24_1", "text": "Autophagy is a natural self-cannibalization process that can act as a powerful mechanism to remove aged and damaged organelles as well as protein aggregates.", "tags": [{"end": 9, "start": 0, "tag": "CellFunction"}, {"end": 103, "start": 99, "tag": "TemporalConcept"}, {"end": 126, "start": 116, "tag": "CellComponent"}, {"end": 156, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 108, "tag": "CellOrMolecularDysfunction"}]}{"id": "24_2", "text": "It has been shown that promoting autophagy can attenuate or delay neurodegeneration by removing protein aggregates.", "tags": [{"end": 65, "start": 60, "tag": "TemporalConcept"}, {"end": 114, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 33, "tag": "CellFunction"}, {"end": 83, "start": 66, "tag": "CellOrMolecularDysfunction"}]}{"id": "24_3", "text": "In this paper, we will review the role of autophagy in Alzheimer's disease (AD), Parkinson's Disease (PD), and Huntington's Disease (HD) and discuss opportunities and challenges of targeting autophagy as a potential therapeutic avenue for treatment of these common neurodegenerative diseases.", "tags": [{"end": 74, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 167, "tag": "HealthCareActivity"}, {"end": 51, "start": 42, "tag": "CellFunction"}, {"end": 200, "start": 191, "tag": "CellFunction"}, {"end": 135, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 291, "start": 265, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 23, "tag": "ResearchActivity"}, {"end": 29, "start": 23, "tag": "HealthCareActivity"}, {"end": 248, "start": 239, "tag": "HealthCareActivity"}, {"end": 248, "start": 239, "tag": "ResearchActivity"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}]}{"id": "26_0", "text": "As the population ages, the incidence and prevalence of neurodegenerative disorders will continue to increase.", "tags": [{"end": 22, "start": 18, "tag": "Chemical"}, {"end": 17, "start": 7, "tag": "PopulationGroup"}, {"end": 37, "start": 28, "tag": "Finding"}, {"end": 83, "start": 56, "tag": "DiseaseOrSyndrome"}]}{"id": "26_1", "text": "Persons with neurodegenerative disease frequently experience sleep disorders, which not only affect quality of life, but potentially accelerate progression of the disease.", "tags": [{"end": 7, "start": 0, "tag": "PopulationGroup"}, {"end": 60, "start": 50, "tag": "BiologicFunction"}, {"end": 170, "start": 144, "tag": "PathologicFunction"}, {"end": 170, "start": 144, "tag": "TemporalConcept"}, {"end": 49, "start": 39, "tag": "TemporalConcept"}, {"end": 66, "start": 61, "tag": "BiologicFunction"}, {"end": 76, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 100, "tag": "Finding"}, {"end": 115, "start": 111, "tag": "TemporalConcept"}, {"end": 155, "start": 144, "tag": "PathologicFunction"}, {"end": 155, "start": 144, "tag": "TemporalConcept"}, {"end": 38, "start": 13, "tag": "DiseaseOrSyndrome"}]}{"id": "26_2", "text": "Unfortunately, pharmacological interventions are often futile or have adverse effects.", "tags": [{"end": 85, "start": 70, "tag": "PathologicFunction"}, {"end": 44, "start": 15, "tag": "HealthCareActivity"}]}{"id": "26_3", "text": "Therefore, investigation of non-pharmacological interventions has the potential to expand the treatment landscape for these disorders.", "tags": [{"end": 61, "start": 28, "tag": "HealthCareActivity"}, {"end": 24, "start": 11, "tag": "ResearchActivity"}, {"end": 103, "start": 94, "tag": "HealthCareActivity"}, {"end": 103, "start": 94, "tag": "ResearchActivity"}]}{"id": "26_4", "text": "The last decade has observed increasing recognition of the beneficial role of exercise in brain diseases, and neurodegenerative disorders in particular.", "tags": [{"end": 104, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 4, "tag": "TemporalConcept"}, {"end": 86, "start": 78, "tag": "HealthCareActivity"}, {"end": 51, "start": 40, "tag": "BiologicFunction"}, {"end": 137, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 59, "tag": "Finding"}]}{"id": "26_5", "text": "In this review, we will focus on the therapeutic role of exercise for sleep dysfunction in four neurodegenerative diseases, namely Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.", "tags": [{"end": 87, "start": 70, "tag": "SignOrSymptom"}, {"end": 87, "start": 70, "tag": "PathologicFunction"}, {"end": 65, "start": 57, "tag": "HealthCareActivity"}, {"end": 75, "start": 70, "tag": "BiologicFunction"}, {"end": 87, "start": 76, "tag": "PathologicFunction"}, {"end": 122, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 199, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 53, "start": 37, "tag": "Finding"}]}{"id": "26_6", "text": "Available data suggest that exercise may have the potential to improve sleep disorders and attenuate neurodegeneration, particularly in Alzheimer's disease and Parkinson's disease.", "tags": [{"end": 70, "start": 63, "tag": "Finding"}, {"end": 100, "start": 91, "tag": "Bacterium"}, {"end": 36, "start": 28, "tag": "HealthCareActivity"}, {"end": 76, "start": 71, "tag": "BiologicFunction"}, {"end": 86, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 101, "tag": "CellOrMolecularDysfunction"}, {"end": 14, "start": 10, "tag": "ResearchActivity"}, {"end": 179, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 136, "tag": "DiseaseOrSyndrome"}]}{"id": "27_0", "text": "Neurodegenerative disease is a kind of disease caused by the degeneration of neurons and myelin sheaths.", "tags": [{"end": 103, "start": 89, "tag": "CellComponent"}, {"end": 84, "start": 61, "tag": "CellOrMolecularDysfunction"}, {"end": 25, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "27_1", "text": "With the aging of the global population, the increase of the incidence of neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD), has become a great challenge for society at large.", "tags": [{"end": 39, "start": 29, "tag": "PopulationGroup"}, {"end": 14, "start": 9, "tag": "BiologicFunction"}, {"end": 14, "start": 9, "tag": "CellFunction"}, {"end": 221, "start": 212, "tag": "HealthCareActivity"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 61, "tag": "Finding"}, {"end": 233, "start": 226, "tag": "PopulationGroup"}, {"end": 100, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 110, "tag": "DiseaseOrSyndrome"}]}{"id": "27_2", "text": "Most of these diseases relate to misfolded proteins in the central nervous system, such as: amyloid-beta, tau, alpha-synuclein, huntingtin, and prion proteins.", "tags": [{"end": 158, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 33, "tag": "CellOrMolecularDysfunction"}, {"end": 109, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 128, "tag": "BiologicallyActiveSubstance"}]}{"id": "27_3", "text": "Additionally, there is a large amount of evidence linking vascular dysfunction and vascular risk factors with the pathogenesis of neurodegenerative diseases, such as vascular dementia (VAD).", "tags": [{"end": 78, "start": 58, "tag": "PathologicFunction"}, {"end": 188, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 92, "tag": "Finding"}, {"end": 126, "start": 114, "tag": "PathologicFunction"}, {"end": 183, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 166, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 183, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 67, "tag": "PathologicFunction"}, {"end": 49, "start": 41, "tag": "Finding"}, {"end": 156, "start": 130, "tag": "DiseaseOrSyndrome"}]}{"id": "27_4", "text": "It is also possible to detect neurodegenerative diseases by detecting angiogenesis biomarkers.", "tags": [{"end": 82, "start": 70, "tag": "BiologicFunction"}, {"end": 56, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 83, "tag": "ClinicalAttribute"}]}{"id": "27_5", "text": "As biomarkers of neurodegenerative diseases, detecting these proteins can potentially allow for the slowing down or prevent the onset of these diseases.", "tags": [{"end": 133, "start": 128, "tag": "TemporalConcept"}, {"end": 69, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 3, "tag": "ClinicalAttribute"}]}{"id": "28_0", "text": "Huntington's disease (HD) is a rare neurodegenerative disease of the central nervous system characterized by choreatic movements, behavioral disturbances, and neuropsychiatric sequelae.", "tags": [{"end": 128, "start": 109, "tag": "SignOrSymptom"}, {"end": 153, "start": 130, "tag": "SignOrSymptom"}, {"end": 91, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 31, "tag": "TemporalConcept"}, {"end": 184, "start": 159, "tag": "SignOrSymptom"}]}{"id": "28_2", "text": "Huntington's disease demonstrates the genetic principle of anticipation, where the larger the number of CAG repeats the earlier the signs and symptoms of the disease appear in subsequent generations.", "tags": [{"end": 115, "start": 104, "tag": "MolecularSequence"}, {"end": 137, "start": 132, "tag": "SignOrSymptom"}, {"end": 150, "start": 142, "tag": "SignOrSymptom"}, {"end": 127, "start": 120, "tag": "TemporalConcept"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 187, "tag": "TemporalConcept"}]}{"id": "28_3", "text": "The symptoms often consist of behavioral disturbances and learning disturbances.", "tags": [{"end": 53, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 4, "tag": "SignOrSymptom"}]}{"id": "28_4", "text": "The disease is suspected based on signs and symptoms and confirmed by genetic testing.", "tags": [{"end": 85, "start": 70, "tag": "HealthCareActivity"}, {"end": 39, "start": 34, "tag": "SignOrSymptom"}, {"end": 52, "start": 44, "tag": "SignOrSymptom"}]}{"id": "28_6", "text": "A significant risk of suicide in this population exists given the severity and unrelenting nature of the disease.", "tags": [{"end": 29, "start": 22, "tag": "Finding"}, {"end": 74, "start": 66, "tag": "ClinicalAttribute"}, {"end": 74, "start": 66, "tag": "Finding"}, {"end": 48, "start": 38, "tag": "PopulationGroup"}, {"end": 18, "start": 14, "tag": "Finding"}]}{"id": "28_7", "text": "Most patients will have multiple hospitalizations during the course of the illness.", "tags": [{"end": 49, "start": 33, "tag": "HealthCareActivity"}, {"end": 82, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 61, "tag": "TemporalConcept"}, {"end": 13, "start": 5, "tag": "PatientOrDisabledGroup"}]}{"id": "28_8", "text": "A consultant psychiatrist may be asked to evaluate and make recommendations for the treatment of acute agitation in HD patients.", "tags": [{"end": 12, "start": 2, "tag": "HealthCareActivity"}, {"end": 25, "start": 13, "tag": "HealthCareActivity"}, {"end": 112, "start": 103, "tag": "SignOrSymptom"}, {"end": 102, "start": 97, "tag": "TemporalConcept"}, {"end": 93, "start": 84, "tag": "HealthCareActivity"}, {"end": 93, "start": 84, "tag": "ResearchActivity"}, {"end": 127, "start": 116, "tag": "PatientOrDisabledGroup"}]}{"id": "28_9", "text": "This can be a challenging task given the limited number of studies and the complex nature of agitation in the hospital setting.", "tags": [{"end": 102, "start": 93, "tag": "SignOrSymptom"}, {"end": 66, "start": 59, "tag": "ResearchActivity"}]}{"id": "28_10", "text": "The aim of this review is to look at the currently available data for the treatment of acute agitation in patients with Huntington's disease.", "tags": [{"end": 102, "start": 93, "tag": "SignOrSymptom"}, {"end": 92, "start": 87, "tag": "TemporalConcept"}, {"end": 50, "start": 41, "tag": "TemporalConcept"}, {"end": 83, "start": 74, "tag": "HealthCareActivity"}, {"end": 83, "start": 74, "tag": "ResearchActivity"}, {"end": 65, "start": 61, "tag": "ResearchActivity"}, {"end": 114, "start": 106, "tag": "PatientOrDisabledGroup"}, {"end": 140, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 16, "tag": "ResearchActivity"}, {"end": 22, "start": 16, "tag": "HealthCareActivity"}]}{"id": "29_0", "text": "Background: Autonomy describes a psychological state of self-regulation of motivation and action, which is a central characteristic of healthy functioning.", "tags": [{"end": 52, "start": 33, "tag": "BiologicFunction"}, {"end": 71, "start": 56, "tag": "IndividualBehavior"}, {"end": 71, "start": 56, "tag": "BiologicFunction"}, {"end": 85, "start": 75, "tag": "BiologicFunction"}, {"end": 96, "start": 90, "tag": "BiologicFunction"}, {"end": 142, "start": 135, "tag": "OrganismAttribute"}, {"end": 20, "start": 12, "tag": "IndividualBehavior"}, {"end": 154, "start": 143, "tag": "BiologicFunction"}]}{"id": "29_1", "text": "In neurodegenerative diseases measures of self-perception have been found to be affected by the disease.", "tags": [{"end": 57, "start": 42, "tag": "BiologicFunction"}, {"end": 57, "start": 47, "tag": "BiologicFunction"}, {"end": 29, "start": 3, "tag": "DiseaseOrSyndrome"}]}{"id": "29_2", "text": "However, it has never been investigated whether measures of self-perception, like autonomy, is affected in Huntington's disease.", "tags": [{"end": 56, "start": 48, "tag": "HealthCareActivity"}, {"end": 75, "start": 60, "tag": "BiologicFunction"}, {"end": 75, "start": 65, "tag": "BiologicFunction"}, {"end": 127, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 82, "tag": "IndividualBehavior"}]}{"id": "29_3", "text": "Objective: We investigated whether autonomy is affected in Huntington's disease and if the degree of autonomy is associated with motor function, neuropsychiatric symptoms, cognitive impairments, and apathy.", "tags": [{"end": 193, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 145, "tag": "SignOrSymptom"}, {"end": 205, "start": 199, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 129, "tag": "BiologicFunction"}, {"end": 79, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 35, "tag": "IndividualBehavior"}, {"end": 109, "start": 101, "tag": "IndividualBehavior"}]}{"id": "29_4", "text": "Methods: We included 44 premanifest and motor-manifest Huntington's disease gene expansion carriers and 19 controls.", "tags": [{"end": 99, "start": 91, "tag": "PopulationGroup"}, {"end": 115, "start": 107, "tag": "PopulationGroup"}, {"end": 90, "start": 76, "tag": "CellOrMolecularDysfunction"}, {"end": 75, "start": 55, "tag": "PatientOrDisabledGroup"}, {"end": 35, "start": 24, "tag": "PatientOrDisabledGroup"}, {"end": 75, "start": 40, "tag": "PatientOrDisabledGroup"}]}{"id": "29_5", "text": "Autonomy was examined using two self-report questionnaires, the Autonomy-Connectedness Scale-30 and the Index of Autonomous Functioning.", "tags": [{"end": 58, "start": 32, "tag": "HealthCareActivity"}, {"end": 95, "start": 64, "tag": "HealthCareActivity"}, {"end": 135, "start": 104, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "IndividualBehavior"}]}{"id": "29_6", "text": "All participants were examined according to motor function, cognitive impairments, and neuropsychiatric symptoms, including apathy.", "tags": [{"end": 81, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 87, "tag": "SignOrSymptom"}, {"end": 130, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 4, "tag": "PopulationGroup"}, {"end": 58, "start": 44, "tag": "BiologicFunction"}]}{"id": "29_7", "text": "Results: Statistically significant differences were found between motor-manifest Huntington's disease gene expansion carriers and premanifest Huntington's disease gene expansion carriers or controls on two measures of autonomy.", "tags": [{"end": 125, "start": 117, "tag": "PopulationGroup"}, {"end": 186, "start": 178, "tag": "PopulationGroup"}, {"end": 214, "start": 206, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 46, "start": 9, "tag": "Finding"}, {"end": 198, "start": 190, "tag": "PopulationGroup"}, {"end": 116, "start": 102, "tag": "CellOrMolecularDysfunction"}, {"end": 162, "start": 130, "tag": "PatientOrDisabledGroup"}, {"end": 177, "start": 163, "tag": "CellOrMolecularDysfunction"}, {"end": 226, "start": 218, "tag": "IndividualBehavior"}, {"end": 101, "start": 66, "tag": "PatientOrDisabledGroup"}]}{"id": "29_8", "text": "Between 25-38% of motor-manifest Huntington's disease gene expansion carriers scored significantly below the normal level on subscales of autonomy as compared to controls.", "tags": [{"end": 77, "start": 69, "tag": "PopulationGroup"}, {"end": 170, "start": 162, "tag": "PopulationGroup"}, {"end": 53, "start": 18, "tag": "PatientOrDisabledGroup"}, {"end": 68, "start": 54, "tag": "CellOrMolecularDysfunction"}, {"end": 146, "start": 138, "tag": "IndividualBehavior"}]}{"id": "29_9", "text": "One autonomy subscale was associated with apathy (r = -0.65), but not with other symptoms of Huntington's disease.", "tags": [{"end": 48, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "SignOrSymptom"}, {"end": 113, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 4, "tag": "IndividualBehavior"}]}{"id": "29_10", "text": "Conclusion: This study provides evidence for impaired autonomy in individuals with Huntington's disease and an association between autonomy and apathy.", "tags": [{"end": 150, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 66, "tag": "PopulationGroup"}, {"end": 40, "start": 32, "tag": "Finding"}, {"end": 103, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}, {"end": 62, "start": 45, "tag": "PathologicFunction"}, {"end": 139, "start": 131, "tag": "IndividualBehavior"}]}{"id": "29_11", "text": "The results underline the importance of maintaining patient autonomy and involvement in care throughout the disease.", "tags": [{"end": 92, "start": 88, "tag": "HealthCareActivity"}, {"end": 84, "start": 73, "tag": "Finding"}, {"end": 59, "start": 52, "tag": "PatientOrDisabledGroup"}, {"end": 68, "start": 60, "tag": "IndividualBehavior"}]}{"id": "33_0", "text": "Huntington disease is an inherited, progressive, incurable neurodegenerative disorder that primarily affects cells in the brain.", "tags": [{"end": 34, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 109, "tag": "Cell"}, {"end": 127, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "33_1", "text": "Although the genetic basis for this condition has been known for nearly 30 years, how this causes disease is still unresolved.", "tags": [{"end": 26, "start": 13, "tag": "CellFunction"}, {"end": 80, "start": 75, "tag": "TemporalConcept"}]}{"id": "33_2", "text": "Of late there has been increasing evidence suggesting that dysfunction in macroautophagic/autophagic pathways may contribute to cellular dysfunction and death.", "tags": [{"end": 148, "start": 128, "tag": "CellOrMolecularDysfunction"}, {"end": 89, "start": 74, "tag": "CellFunction"}, {"end": 100, "start": 90, "tag": "CellFunction"}, {"end": 158, "start": 153, "tag": "CellFunction"}, {"end": 158, "start": 153, "tag": "PathologicFunction"}, {"end": 70, "start": 59, "tag": "PathologicFunction"}, {"end": 42, "start": 23, "tag": "Finding"}, {"end": 158, "start": 153, "tag": "BiologicFunction"}]}{"id": "33_3", "text": "In our recent work we highlight more precisely how and where this problem might arise in this pathway using directly reprogrammed neurons.", "tags": [{"end": 137, "start": 130, "tag": "Cell"}, {"end": 137, "start": 117, "tag": "ResearchActivity"}, {"end": 101, "start": 94, "tag": "CellFunction"}, {"end": 13, "start": 7, "tag": "TemporalConcept"}]}{"id": "36_1", "text": "Peroxiredoxins (PRDXs) are one of the enzymatic antioxidant mechanisms neutralizing reactive oxygen/nitrogen species.", "tags": [{"end": 14, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 0, "tag": "GeneOrGenome"}, {"end": 21, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 16, "tag": "GeneOrGenome"}, {"end": 59, "start": 48, "tag": "PharmacologicSubstance"}, {"end": 70, "start": 38, "tag": "CellFunction"}, {"end": 14, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 16, "tag": "BiologicallyActiveSubstance"}]}{"id": "36_3", "text": "An increasing number of studies suggests that these enzymes may be involved in the neurodegenerative process.", "tags": [{"end": 59, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 83, "tag": "CellOrMolecularDysfunction"}, {"end": 31, "start": 24, "tag": "ResearchActivity"}]}{"id": "36_4", "text": "This article reviews the current knowledge on the expression and putative roles of PRDXs in neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies, multiple sclerosis, amyotrophic lateral sclerosis and Huntington's disease.", "tags": [{"end": 20, "start": 13, "tag": "HealthCareActivity"}, {"end": 42, "start": 33, "tag": "Finding"}, {"end": 88, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 83, "tag": "GeneOrGenome"}, {"end": 147, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 187, "tag": "CellComponent"}, {"end": 218, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 220, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 5, "tag": "ResearchActivity"}, {"end": 32, "start": 25, "tag": "TemporalConcept"}, {"end": 274, "start": 254, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 83, "tag": "BiologicallyActiveSubstance"}]}{"id": "40_0", "text": "Cells have developed elaborate quality-control mechanisms for proteins and organelles to maintain cellular homeostasis.", "tags": [{"end": 5, "start": 0, "tag": "Cell"}, {"end": 118, "start": 98, "tag": "CellFunction"}, {"end": 85, "start": 75, "tag": "CellComponent"}, {"end": 70, "start": 31, "tag": "CellFunction"}]}{"id": "40_1", "text": "Such quality-control mechanisms are maintained by conformational folding via molecular chaperones and by degradation through the ubiquitin-proteasome or autophagy-lysosome system.", "tags": [{"end": 97, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 129, "tag": "CellFunction"}, {"end": 178, "start": 153, "tag": "CellFunction"}, {"end": 116, "start": 105, "tag": "NaturalPhenomenonOrProcess"}, {"end": 97, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 50, "tag": "CellFunction"}]}{"id": "40_2", "text": "Accumulating evidence suggests that impaired autophagy contributes to the accumulation of intracellular inclusion bodies consisting of misfolded proteins, which is a hallmark of most neurodegenerative diseases.", "tags": [{"end": 120, "start": 90, "tag": "CellComponent"}, {"end": 209, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 0, "tag": "Finding"}, {"end": 174, "start": 166, "tag": "Finding"}, {"end": 153, "start": 135, "tag": "CellOrMolecularDysfunction"}, {"end": 54, "start": 36, "tag": "CellOrMolecularDysfunction"}]}{"id": "40_3", "text": "In addition, genetic mutations in core autophagy-related genes have been reported to be linked to neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.", "tags": [{"end": 62, "start": 39, "tag": "GeneOrGenome"}, {"end": 200, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 39, "tag": "CellFunction"}, {"end": 30, "start": 13, "tag": "CellFunction"}]}{"id": "40_4", "text": "Conversely, the pathogenic proteins, such as amyloid beta and alpha-synuclein, are detrimental to the autophagy pathway.", "tags": [{"end": 35, "start": 16, "tag": "CellOrMolecularDysfunction"}, {"end": 57, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 102, "tag": "CellFunction"}]}{"id": "40_5", "text": "Here, we review the recent advances in understanding the relationship between autophagic defects and the pathogenesis of neurodegenerative diseases and suggest autophagy induction as a promising strategy for the treatment of these conditions.", "tags": [{"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 147, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 20, "tag": "TemporalConcept"}, {"end": 221, "start": 212, "tag": "HealthCareActivity"}, {"end": 221, "start": 212, "tag": "ResearchActivity"}, {"end": 117, "start": 105, "tag": "PathologicFunction"}, {"end": 169, "start": 160, "tag": "CellFunction"}, {"end": 35, "start": 27, "tag": "Finding"}, {"end": 69, "start": 57, "tag": "Finding"}, {"end": 96, "start": 78, "tag": "CellOrMolecularDysfunction"}, {"end": 179, "start": 160, "tag": "HealthCareActivity"}]}{"id": "45_1", "text": "Common elements in pathogenesis, pathological effects and protein-level behaviors exist between Alzheimer's Disease (AD), Parkinson's Disease (PD), Huntington's Disease (HD) and Amyotrophic Lateral Sclerosis (ALS).", "tags": [{"end": 31, "start": 19, "tag": "PathologicFunction"}, {"end": 53, "start": 33, "tag": "PathologicFunction"}, {"end": 115, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 148, "tag": "DiseaseOrSyndrome"}]}{"id": "45_2", "text": "These extend beyond the affected neurons to glial cells and processes.", "tags": [{"end": 40, "start": 33, "tag": "Cell"}, {"end": 55, "start": 44, "tag": "Cell"}]}{"id": "45_3", "text": "This results in a complicated system of disease progression, which often takes advantage of protective processes to promote the propagation of pathological protein aggregates.", "tags": [{"end": 174, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 143, "tag": "CellOrMolecularDysfunction"}, {"end": 59, "start": 40, "tag": "PathologicFunction"}, {"end": 59, "start": 48, "tag": "PathologicFunction"}, {"end": 59, "start": 48, "tag": "TemporalConcept"}]}{"id": "45_4", "text": "This review article provides a current snapshot of knowledge on these proteins and their intrinsic role in the pathogenesis and disease progression seen across NDs.", "tags": [{"end": 19, "start": 5, "tag": "ResearchActivity"}, {"end": 60, "start": 51, "tag": "Finding"}, {"end": 123, "start": 111, "tag": "PathologicFunction"}, {"end": 163, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 31, "tag": "TemporalConcept"}, {"end": 147, "start": 128, "tag": "PathologicFunction"}, {"end": 147, "start": 136, "tag": "PathologicFunction"}, {"end": 147, "start": 136, "tag": "TemporalConcept"}]}{"id": "47_0", "text": "Neurodegenerative diseases are neurological disorders characterized by progressive neuronal degeneration, such as Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis and Huntington's disease.", "tags": [{"end": 53, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 71, "tag": "CellOrMolecularDysfunction"}, {"end": 91, "start": 83, "tag": "Cell"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 71, "tag": "TemporalConcept"}, {"end": 104, "start": 83, "tag": "CellOrMolecularDysfunction"}, {"end": 104, "start": 92, "tag": "PathologicFunction"}, {"end": 210, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 135, "tag": "DiseaseOrSyndrome"}]}{"id": "47_2", "text": "These changes may cause glia to lose their ability to support and protect neurons and induce abnormal increases in levels of ions and metabolites, such as calcium ions, glutamate and ATP, around neurons.", "tags": [{"end": 121, "start": 93, "tag": "Finding"}, {"end": 129, "start": 125, "tag": "Chemical"}, {"end": 167, "start": 155, "tag": "PharmacologicSubstance"}, {"end": 167, "start": 155, "tag": "Chemical"}, {"end": 178, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 186, "start": 183, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 186, "start": 183, "tag": "PharmacologicSubstance"}, {"end": 186, "start": 183, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 24, "tag": "Cell"}, {"end": 145, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 43, "tag": "OrganismAttribute"}, {"end": 81, "start": 74, "tag": "Cell"}, {"end": 202, "start": 195, "tag": "Cell"}, {"end": 178, "start": 169, "tag": "BiologicallyActiveSubstance"}]}{"id": "47_3", "text": "These processes eventuallys lead to neuronal death.", "tags": [{"end": 50, "start": 36, "tag": "CellFunction"}]}{"id": "47_4", "text": "In the present review, the abnormal expression of connexin and its primary role in neurodegenerative diseases was investigated.", "tags": [{"end": 58, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 15, "tag": "ResearchActivity"}, {"end": 21, "start": 15, "tag": "HealthCareActivity"}, {"end": 46, "start": 27, "tag": "CellOrMolecularDysfunction"}]}{"id": "61_0", "text": "Neurodegenerative diseases are a major burden for our society, affecting millions of people worldwide.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 85, "tag": "PopulationGroup"}]}{"id": "61_1", "text": "A main goal of past and current research is to enhance our understanding of the mechanisms underlying proteotoxicity, a common theme among these incurable and debilitating conditions.", "tags": [{"end": 40, "start": 32, "tag": "ResearchActivity"}, {"end": 31, "start": 24, "tag": "TemporalConcept"}, {"end": 19, "start": 15, "tag": "TemporalConcept"}, {"end": 116, "start": 102, "tag": "CellOrMolecularDysfunction"}]}{"id": "61_2", "text": "Cell proteome alteration is considered to be one of the main driving forces that triggers neurodegeneration, and unraveling the biological complexity behind the affected molecular pathways constitutes a daunting challenge.", "tags": [{"end": 188, "start": 170, "tag": "CellFunction"}, {"end": 24, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 107, "start": 90, "tag": "CellOrMolecularDysfunction"}]}{"id": "61_3", "text": "This review summarizes the current state on key processes that lead to cellular proteotoxicity in Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, providing a comprehensive landscape of recent literature.", "tags": [{"end": 94, "start": 71, "tag": "CellOrMolecularDysfunction"}, {"end": 117, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 27, "tag": "TemporalConcept"}, {"end": 160, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 253, "start": 243, "tag": "ResearchActivity"}]}{"id": "61_4", "text": "A foundational understanding of how proteotoxicity affects disease etiology and progression may provide essential insight towards potential targets amenable of therapeutic intervention.", "tags": [{"end": 184, "start": 160, "tag": "HealthCareActivity"}, {"end": 91, "start": 80, "tag": "PathologicFunction"}, {"end": 91, "start": 80, "tag": "TemporalConcept"}, {"end": 50, "start": 36, "tag": "CellOrMolecularDysfunction"}]}{"id": "66_0", "text": "Epigenetic modifications in neurodegenerative diseases are just beginning to be studied; however, the growing interest in this phenomenon indicates its great importance in molecular mechanism of diseases and their phenotypical realization.", "tags": [{"end": 137, "start": 127, "tag": "NaturalPhenomenonOrProcess"}, {"end": 137, "start": 127, "tag": "Finding"}, {"end": 238, "start": 214, "tag": "Finding"}, {"end": 24, "start": 0, "tag": "CellFunction"}, {"end": 191, "start": 172, "tag": "CellFunction"}, {"end": 54, "start": 28, "tag": "DiseaseOrSyndrome"}]}{"id": "66_1", "text": "DNA methylation takes one of the central places in gene expression regulation.", "tags": [{"end": 77, "start": 51, "tag": "CellFunction"}, {"end": 15, "start": 0, "tag": "CellFunction"}]}{"id": "66_2", "text": "This review considers the main DNA methylation types and the mechanisms of methylation and demethylation and provides general information on epigenetic regulation in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and hereditary ataxias.", "tags": [{"end": 283, "start": 265, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 91, "tag": "CellFunction"}, {"end": 86, "start": 75, "tag": "CellFunction"}, {"end": 162, "start": 141, "tag": "CellFunction"}, {"end": 46, "start": 31, "tag": "CellFunction"}, {"end": 237, "start": 208, "tag": "DiseaseOrSyndrome"}, {"end": 259, "start": 239, "tag": "DiseaseOrSyndrome"}, {"end": 206, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}]}{"id": "66_3", "text": "Possible prospects for targeted epigenetic correction as a new approach to neurodegenerative disease therapy are discussed.", "tags": [{"end": 53, "start": 23, "tag": "HealthCareActivity"}, {"end": 100, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 101, "tag": "HealthCareActivity"}]}{"id": "67_0", "text": "Background Huntington's disease is a neurodegenerative disorder characterized by clinical alterations in the motor, behavioral, and cognitive domains.", "tags": [{"end": 31, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 81, "tag": "Finding"}, {"end": 149, "start": 142, "tag": "BiologicFunction"}, {"end": 114, "start": 109, "tag": "BiologicFunction"}, {"end": 149, "start": 142, "tag": "BiologicFunction"}, {"end": 126, "start": 116, "tag": "BiologicFunction"}, {"end": 149, "start": 132, "tag": "BiologicFunction"}]}{"id": "67_1", "text": "However, the structure and disruptions to large-scale brain cognitive networks have not yet been established.", "tags": [{"end": 22, "start": 13, "tag": "OrganismAttribute"}, {"end": 38, "start": 27, "tag": "PathologicFunction"}, {"end": 59, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "67_2", "text": "Objective We aimed to profile changes in large-scale cognitive networks in premanifest and symptomatic patients with Huntington's disease.", "tags": [{"end": 102, "start": 91, "tag": "SignOrSymptom"}, {"end": 111, "start": 103, "tag": "PatientOrDisabledGroup"}, {"end": 137, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 30, "tag": "Finding"}, {"end": 71, "start": 41, "tag": "BiologicFunction"}]}{"id": "67_3", "text": "Methods We prospectively recruited premanifest and symptomatic Huntington's disease mutation carriers as well as healthy controls.", "tags": [{"end": 101, "start": 93, "tag": "PopulationGroup"}, {"end": 62, "start": 51, "tag": "SignOrSymptom"}, {"end": 92, "start": 84, "tag": "CellOrMolecularDysfunction"}, {"end": 129, "start": 113, "tag": "PopulationGroup"}, {"end": 83, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 63, "tag": "PatientOrDisabledGroup"}, {"end": 46, "start": 35, "tag": "PatientOrDisabledGroup"}]}{"id": "67_4", "text": "Clinical and sociodemographic data were obtained from all participants, and resting-state functional connectivity data, using both time-averaged and dynamic functional connectivity, was acquired from whole-brain and cognitively oriented brain parcellations.", "tags": [{"end": 113, "start": 76, "tag": "HealthCareActivity"}, {"end": 70, "start": 58, "tag": "PopulationGroup"}, {"end": 113, "start": 90, "tag": "BiologicFunction"}, {"end": 180, "start": 157, "tag": "BiologicFunction"}, {"end": 211, "start": 206, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 242, "start": 237, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 13, "tag": "ResearchActivity"}, {"end": 118, "start": 114, "tag": "ResearchActivity"}, {"end": 135, "start": 131, "tag": "TemporalConcept"}, {"end": 34, "start": 30, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}]}{"id": "67_5", "text": "Results A total of 64 gene mutation carriers and 23 healthy controls were included; 21 patients with Huntington's disease were classified as premanifest and 43 as symptomatic Huntington's disease.", "tags": [{"end": 35, "start": 22, "tag": "CellOrMolecularDysfunction"}, {"end": 44, "start": 36, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 174, "start": 163, "tag": "SignOrSymptom"}, {"end": 68, "start": 52, "tag": "PopulationGroup"}, {"end": 95, "start": 87, "tag": "PatientOrDisabledGroup"}, {"end": 121, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 141, "tag": "PatientOrDisabledGroup"}]}{"id": "67_6", "text": "Compared with healthy controls, patients with Huntington's disease showed decreased network connectivity within the posterior hubs of the default-mode network and the medial prefrontal cortex, changes that correlated with cognitive (t = 2.25, P = 0.01) and disease burden scores (t = -2.42, P = 0.009).", "tags": [{"end": 191, "start": 167, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 216, "start": 206, "tag": "ResearchActivity"}, {"end": 271, "start": 257, "tag": "ResearchActivity"}, {"end": 30, "start": 14, "tag": "PopulationGroup"}, {"end": 40, "start": 32, "tag": "PatientOrDisabledGroup"}, {"end": 66, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 84, "tag": "BiologicFunction"}, {"end": 158, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 278, "start": 272, "tag": "Finding"}, {"end": 200, "start": 193, "tag": "Finding"}]}{"id": "67_7", "text": "The salience network showed decreased functional connectivity between insular and supramarginal cortices and also correlated with cognitive (t = 2.11, P = 0.02) and disease burden scores (t = -2.35, P = 0.01).", "tags": [{"end": 104, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 77, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 114, "tag": "ResearchActivity"}, {"end": 37, "start": 28, "tag": "Finding"}, {"end": 179, "start": 165, "tag": "ResearchActivity"}, {"end": 61, "start": 38, "tag": "BiologicFunction"}, {"end": 20, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "67_8", "text": "Dynamic analyses showed that network variability was decreased for default-central executive networks, a feature already present in premanifest mutation carriers (dynamic factor 8, P = 0.02).", "tags": [{"end": 161, "start": 153, "tag": "PopulationGroup"}, {"end": 48, "start": 29, "tag": "Finding"}, {"end": 62, "start": 53, "tag": "Finding"}, {"end": 152, "start": 144, "tag": "CellOrMolecularDysfunction"}, {"end": 16, "start": 0, "tag": "ResearchActivity"}, {"end": 101, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "67_9", "text": "Conclusions Huntington's disease shows an early and widespread disruption of large-scale cognitive networks.", "tags": [{"end": 73, "start": 63, "tag": "PathologicFunction"}, {"end": 32, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "67_10", "text": "Importantly, these changes are related to cognitive and disease burden scores, and novel dynamic functional analyses uncovered subtler network changes even in the premanifest stages.", "tags": [{"end": 181, "start": 163, "tag": "TemporalConcept"}, {"end": 70, "start": 56, "tag": "ResearchActivity"}, {"end": 116, "start": 89, "tag": "ResearchActivity"}, {"end": 150, "start": 135, "tag": "Finding"}]}{"id": "76_0", "text": "Huntington's disease is a neurodegenerative disorder involving psychiatric, cognitive and motor symptoms.", "tags": [{"end": 104, "start": 90, "tag": "SignOrSymptom"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 26, "tag": "DiseaseOrSyndrome"}]}{"id": "76_1", "text": "Huntington's disease is caused by a tandem-repeat expansion in the huntingtin gene, which is widely expressed throughout the brain and body, including the gastrointestinal system.", "tags": [{"end": 178, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 67, "tag": "GeneOrGenome"}, {"end": 139, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 100, "tag": "CellFunction"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 36, "tag": "CellOrMolecularDysfunction"}]}{"id": "76_2", "text": "There are currently no effective disease-modifying treatments available for this fatal disorder.", "tags": [{"end": 95, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 33, "tag": "HealthCareActivity"}, {"end": 19, "start": 10, "tag": "TemporalConcept"}, {"end": 61, "start": 51, "tag": "HealthCareActivity"}, {"end": 61, "start": 51, "tag": "ResearchActivity"}]}{"id": "76_3", "text": "Despite recent evidence of gut microbiome disruption in preclinical and clinical Huntington's disease, its potential as a target for therapeutic interventions has not been explored.", "tags": [{"end": 41, "start": 27, "tag": "Organism"}, {"end": 52, "start": 42, "tag": "PathologicFunction"}, {"end": 158, "start": 133, "tag": "HealthCareActivity"}, {"end": 23, "start": 15, "tag": "Finding"}, {"end": 14, "start": 8, "tag": "TemporalConcept"}, {"end": 101, "start": 81, "tag": "DiseaseOrSyndrome"}]}{"id": "76_5", "text": "We now show that faecal microbiota transplant (FMT) from wild-type into Huntington's disease mice positively modulates cognitive outcomes, particularly in females.", "tags": [{"end": 45, "start": 17, "tag": "HealthCareActivity"}, {"end": 50, "start": 47, "tag": "HealthCareActivity"}, {"end": 66, "start": 57, "tag": "ResearchActivity"}, {"end": 162, "start": 155, "tag": "OrganismAttribute"}, {"end": 97, "start": 93, "tag": "Eukaryote"}, {"end": 92, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 119, "tag": "Finding"}]}{"id": "76_7", "text": "This study demonstrates a role for gut microbiome modulation in ameliorating cognitive deficits modelling dementia in Huntington's disease.", "tags": [{"end": 49, "start": 35, "tag": "Organism"}, {"end": 95, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 96, "tag": "ResearchActivity"}, {"end": 114, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}]}{"id": "76_8", "text": "Our findings pave the way for the development of future therapeutic approaches, including FMT and other forms of gut microbiome modulation, as potential clinical interventions for Huntington's disease.", "tags": [{"end": 93, "start": 90, "tag": "HealthCareActivity"}, {"end": 127, "start": 113, "tag": "Organism"}, {"end": 175, "start": 153, "tag": "HealthCareActivity"}, {"end": 78, "start": 56, "tag": "HealthCareActivity"}, {"end": 45, "start": 34, "tag": "BiologicFunction"}, {"end": 45, "start": 34, "tag": "CellFunction"}, {"end": 55, "start": 49, "tag": "TemporalConcept"}, {"end": 200, "start": 180, "tag": "DiseaseOrSyndrome"}]}{"id": "76_9", "text": "Gubert et al.", "tags": []}{"id": "76_10", "text": "report that faecal microbiota transplant from wild-type into Huntington's disease mice positively modulates cognitive outcomes, particularly in females.", "tags": [{"end": 55, "start": 46, "tag": "ResearchActivity"}, {"end": 151, "start": 144, "tag": "OrganismAttribute"}, {"end": 6, "start": 0, "tag": "HealthCareActivity"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 86, "start": 82, "tag": "Eukaryote"}, {"end": 81, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 12, "tag": "HealthCareActivity"}, {"end": 126, "start": 108, "tag": "Finding"}]}{"id": "76_11", "text": "They demonstrate sexually dimorphic and progressive gut dysfunction, and microbial disruption, and provide the first evidence supporting microbiota manipulation as a therapeutic intervention for Huntington's disease, particularly cognitive symptoms.", "tags": [{"end": 35, "start": 17, "tag": "OrganismAttribute"}, {"end": 67, "start": 56, "tag": "PathologicFunction"}, {"end": 82, "start": 73, "tag": "Organism"}, {"end": 93, "start": 83, "tag": "PathologicFunction"}, {"end": 147, "start": 137, "tag": "Organism"}, {"end": 160, "start": 148, "tag": "HealthCareActivity"}, {"end": 248, "start": 230, "tag": "SignOrSymptom"}, {"end": 190, "start": 166, "tag": "HealthCareActivity"}, {"end": 51, "start": 40, "tag": "TemporalConcept"}, {"end": 125, "start": 117, "tag": "Finding"}, {"end": 116, "start": 111, "tag": "TemporalConcept"}, {"end": 215, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "77_0", "text": "DNA double-strand breaks (DSBs) are common events that were recognized as one of the most toxic lesions in eukaryotic cells.", "tags": [{"end": 24, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 30, "start": 26, "tag": "CellOrMolecularDysfunction"}, {"end": 95, "start": 90, "tag": "InjuryOrPoisoning"}, {"end": 123, "start": 107, "tag": "Cell"}, {"end": 103, "start": 96, "tag": "InjuryOrPoisoning"}]}{"id": "77_1", "text": "DSBs are widely involved in many physiological processes such as V(D)J recombination, meiotic recombination, DNA replication and transcription.", "tags": [{"end": 4, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 84, "start": 65, "tag": "CellFunction"}, {"end": 84, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 86, "tag": "CellFunction"}, {"end": 124, "start": 109, "tag": "CellFunction"}, {"end": 142, "start": 129, "tag": "CellFunction"}, {"end": 56, "start": 33, "tag": "BiologicFunction"}]}{"id": "77_2", "text": "Deregulation of DSBs has been reported in multiple diseases in human beings, such as the neurodegenerative diseases, with which the underlying mechanisms are needed to be illustrated.", "tags": [{"end": 12, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 20, "start": 16, "tag": "CellOrMolecularDysfunction"}, {"end": 59, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 63, "tag": "Eukaryote"}, {"end": 68, "start": 63, "tag": "Eukaryote"}, {"end": 115, "start": 89, "tag": "DiseaseOrSyndrome"}]}{"id": "77_3", "text": "Here, we reviewed the recent insights into the dysfunction of DSB formation and repair, contributing to the pathogenesis of neurodegenerative disorders including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) and ataxia telangiectasia (A-T).", "tags": [{"end": 276, "start": 255, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 62, "tag": "CellOrMolecularDysfunction"}, {"end": 17, "start": 9, "tag": "HealthCareActivity"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 261, "start": 255, "tag": "SignOrSymptom"}, {"end": 261, "start": 255, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 108, "tag": "PathologicFunction"}, {"end": 86, "start": 80, "tag": "BiologicFunction"}, {"end": 86, "start": 80, "tag": "HealthCareActivity"}, {"end": 58, "start": 47, "tag": "PathologicFunction"}, {"end": 185, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 22, "tag": "TemporalConcept"}, {"end": 245, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 247, "tag": "DiseaseOrSyndrome"}, {"end": 222, "start": 219, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 124, "tag": "DiseaseOrSyndrome"}]}{"id": "78_0", "text": "Neurodegenerative diseases are incongruous, commonly age-related disorders characterized by progressive neuronal loss, comprising the most prevalent being Alzheimer's disease, Parkinson's disease, and Huntington's disease.", "tags": [{"end": 117, "start": 104, "tag": "Finding"}, {"end": 112, "start": 104, "tag": "Cell"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 92, "tag": "TemporalConcept"}, {"end": 56, "start": 53, "tag": "OrganismAttribute"}, {"end": 221, "start": 201, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 53, "tag": "DiseaseOrSyndrome"}]}{"id": "78_1", "text": "Perilous health states are anticipated following the neurodegeneration.", "tags": [{"end": 22, "start": 16, "tag": "TemporalConcept"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 70, "start": 53, "tag": "CellOrMolecularDysfunction"}]}{"id": "78_2", "text": "Their etiology remains largely ambiguous, while various mechanisms are ascribed to their pathogenesis.", "tags": [{"end": 14, "start": 6, "tag": "Finding"}, {"end": 101, "start": 89, "tag": "PathologicFunction"}]}{"id": "78_3", "text": "A recommended conception is regarding the role of p53, as a transcription factor regulating numerous cellular pathways comprising apoptosis.", "tags": [{"end": 53, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 101, "tag": "CellFunction"}, {"end": 139, "start": 130, "tag": "CellFunction"}, {"end": 24, "start": 14, "tag": "BiologicFunction"}, {"end": 80, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 60, "tag": "BiologicallyActiveSubstance"}]}{"id": "78_4", "text": "Neuronal fates are a feasible occurrence that contributes to all neurodegenerative diseases.", "tags": [{"end": 40, "start": 30, "tag": "TemporalConcept"}, {"end": 91, "start": 65, "tag": "DiseaseOrSyndrome"}]}{"id": "78_5", "text": "In this work, we review the research investigated the potential role of p53 in the pathogenesis of these diseases.", "tags": [{"end": 75, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 83, "tag": "PathologicFunction"}, {"end": 23, "start": 17, "tag": "ResearchActivity"}, {"end": 23, "start": 17, "tag": "HealthCareActivity"}, {"end": 36, "start": 28, "tag": "ResearchActivity"}]}{"id": "78_7", "text": "Natural and synthetic medications regulating p53 expression are regarded as well.", "tags": [{"end": 48, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 12, "tag": "PharmacologicSubstance"}, {"end": 33, "start": 22, "tag": "PharmacologicSubstance"}, {"end": 7, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 59, "start": 49, "tag": "CellFunction"}]}{"id": "78_8", "text": "(C) 2021 Elsevier B.V.", "tags": []}{"id": "78_9", "text": "All rights reserved.", "tags": []}{"id": "80_0", "text": "Background: When developed properly, disease-specific patient reported outcome measures have the potential to measure relevant changes in how a patient feels and functions in the context of a therapeutic trial.", "tags": [{"end": 209, "start": 192, "tag": "ResearchActivity"}, {"end": 61, "start": 54, "tag": "PatientOrDisabledGroup"}, {"end": 151, "start": 144, "tag": "PatientOrDisabledGroup"}, {"end": 87, "start": 71, "tag": "Finding"}]}{"id": "80_1", "text": "The Huntington's Disease Health Index (HD-HI) is a multifaceted disease-specific patient reported outcome measure (PROM) designed specifically to satisfy previously published FDA guidance for developing PROMs for product development and labeling claims.", "tags": [{"end": 37, "start": 4, "tag": "HealthCareActivity"}, {"end": 44, "start": 39, "tag": "HealthCareActivity"}, {"end": 178, "start": 175, "tag": "HealthCareRelatedOrganization"}, {"end": 187, "start": 179, "tag": "ClinicalAttribute"}, {"end": 24, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 232, "start": 221, "tag": "BiologicFunction"}, {"end": 232, "start": 221, "tag": "CellFunction"}, {"end": 113, "start": 81, "tag": "HealthCareActivity"}, {"end": 119, "start": 115, "tag": "HealthCareActivity"}, {"end": 208, "start": 203, "tag": "HealthCareActivity"}]}{"id": "80_2", "text": "Objective: In preparation for clinical trials, we examine the validity, reliability, clinical relevance, and patient understanding of the Huntington's Disease Health Index (HD-HI).", "tags": [{"end": 83, "start": 72, "tag": "ResearchActivity"}, {"end": 178, "start": 173, "tag": "HealthCareActivity"}, {"end": 130, "start": 117, "tag": "BiologicFunction"}, {"end": 45, "start": 30, "tag": "ResearchActivity"}, {"end": 70, "start": 62, "tag": "Finding"}, {"end": 158, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 109, "tag": "PatientOrDisabledGroup"}, {"end": 171, "start": 138, "tag": "HealthCareActivity"}]}{"id": "80_3", "text": "Methods: We partnered with 389 people with Huntington's disease (HD) and caregivers to identify the most relevant questions for the HD-HI.", "tags": [{"end": 123, "start": 114, "tag": "Finding"}, {"end": 137, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 31, "tag": "PopulationGroup"}, {"end": 63, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 73, "tag": "HealthCareActivity"}]}{"id": "80_4", "text": "We subsequently utilized two rounds of factor analysis, cognitive interviews with fifteen individuals with HD, and test-retest reliability assessments with 25 individuals with HD to refine, evaluate, and optimize the HD-HI.", "tags": [{"end": 54, "start": 39, "tag": "ResearchActivity"}, {"end": 138, "start": 115, "tag": "ResearchActivity"}, {"end": 150, "start": 139, "tag": "HealthCareActivity"}, {"end": 150, "start": 139, "tag": "BiologicFunction"}, {"end": 222, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 159, "tag": "PatientOrDisabledGroup"}, {"end": 101, "start": 90, "tag": "PopulationGroup"}, {"end": 170, "start": 159, "tag": "PopulationGroup"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 56, "tag": "HealthCareActivity"}]}{"id": "80_5", "text": "Lastly, we determined the capability of the HD-HI to differentiate between groups of HD participants with high versus low total functional capacity score, prodromal versus manifest HD, and normal ambulation versus mobility impairment.", "tags": [{"end": 49, "start": 44, "tag": "HealthCareActivity"}, {"end": 110, "start": 106, "tag": "Finding"}, {"end": 164, "start": 155, "tag": "SignOrSymptom"}, {"end": 233, "start": 214, "tag": "Finding"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 66, "start": 53, "tag": "CellFunction"}, {"end": 100, "start": 88, "tag": "PopulationGroup"}, {"end": 180, "start": 172, "tag": "SignOrSymptom"}, {"end": 147, "start": 122, "tag": "HealthCareActivity"}, {"end": 195, "start": 189, "tag": "Finding"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 128, "tag": "Finding"}]}{"id": "80_6", "text": "Results: HD participants identified 13 relevant and unique symptomatic domains to be included as subscales in the HD-HI.", "tags": [{"end": 78, "start": 71, "tag": "MolecularSequence"}, {"end": 119, "start": 114, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 24, "start": 12, "tag": "PopulationGroup"}, {"end": 70, "start": 59, "tag": "SignOrSymptom"}, {"end": 11, "start": 9, "tag": "DiseaseOrSyndrome"}]}{"id": "80_7", "text": "All HD-HI subscales had a high level of internal consistency and reliability and were found by participants to have acceptable content, relevance, and usability.", "tags": [{"end": 9, "start": 4, "tag": "HealthCareActivity"}, {"end": 76, "start": 65, "tag": "ResearchActivity"}, {"end": 134, "start": 127, "tag": "BiologicFunction"}, {"end": 160, "start": 151, "tag": "ResearchActivity"}, {"end": 107, "start": 95, "tag": "PopulationGroup"}]}{"id": "80_8", "text": "The total HD-HI score and each subscale score statistically differentiated between groups of HD participants with high versus low disease burden.", "tags": [{"end": 15, "start": 10, "tag": "HealthCareActivity"}, {"end": 21, "start": 16, "tag": "Finding"}, {"end": 74, "start": 46, "tag": "CellFunction"}, {"end": 118, "start": 114, "tag": "Finding"}, {"end": 129, "start": 126, "tag": "Finding"}, {"end": 144, "start": 130, "tag": "ResearchActivity"}, {"end": 108, "start": 96, "tag": "PopulationGroup"}, {"end": 95, "start": 93, "tag": "DiseaseOrSyndrome"}]}{"id": "80_9", "text": "Conclusion: Initial evaluation of the HD-HI supports its validity and reliability as a PROM for assessing how individuals with HD feel and function.", "tags": [{"end": 43, "start": 38, "tag": "HealthCareActivity"}, {"end": 81, "start": 70, "tag": "ResearchActivity"}, {"end": 129, "start": 110, "tag": "PatientOrDisabledGroup"}, {"end": 30, "start": 20, "tag": "HealthCareActivity"}, {"end": 30, "start": 20, "tag": "ResearchActivity"}, {"end": 65, "start": 57, "tag": "Finding"}, {"end": 121, "start": 110, "tag": "PopulationGroup"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 87, "tag": "HealthCareActivity"}]}{"id": "81_0", "text": "Simple Summary Neurodegenerative diseases represent an important cause of morbidity and mortality worldwide.", "tags": [{"end": 70, "start": 65, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 83, "start": 74, "tag": "Finding"}, {"end": 41, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 88, "tag": "Finding"}]}{"id": "81_1", "text": "Existing therapeutic options are limited and focus mostly on improving symptoms and reducing exacerbations.", "tags": [{"end": 92, "start": 84, "tag": "Finding"}, {"end": 106, "start": 93, "tag": "Finding"}, {"end": 28, "start": 9, "tag": "HealthCareActivity"}, {"end": 79, "start": 71, "tag": "SignOrSymptom"}]}{"id": "81_2", "text": "The endocannabinoid system is involved in the pathophysiology of such disorders, an idea which has been highlighted by recent scientific work.", "tags": [{"end": 19, "start": 4, "tag": "Chemical"}, {"end": 26, "start": 4, "tag": "CellFunction"}, {"end": 19, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 46, "tag": "PathologicFunction"}, {"end": 61, "start": 46, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 125, "start": 119, "tag": "TemporalConcept"}, {"end": 141, "start": 126, "tag": "ResearchActivity"}]}{"id": "81_3", "text": "The current work focusses its attention on the importance and implications of this system and its synthetic and natural ligands in disorders such as Alzheimer's, Parkinson's, Huntington's and multiple sclerosis.", "tags": [{"end": 57, "start": 47, "tag": "Finding"}, {"end": 210, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 30, "tag": "BiologicFunction"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}, {"end": 173, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 112, "tag": "BiologicallyActiveSubstance"}]}{"id": "81_4", "text": "Neurodegenerative diseases are an increasing cause of global morbidity and mortality.", "tags": [{"end": 50, "start": 45, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 70, "start": 54, "tag": "Finding"}, {"end": 70, "start": 61, "tag": "Finding"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 34, "tag": "Finding"}, {"end": 84, "start": 75, "tag": "Finding"}]}{"id": "81_5", "text": "They occur in the central nervous system (CNS) and lead to functional and mental impairment due to loss of neurons.", "tags": [{"end": 91, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 107, "tag": "Cell"}, {"end": 114, "start": 99, "tag": "CellOrMolecularDysfunction"}, {"end": 40, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "81_6", "text": "Recent evidence highlights the link between neurodegenerative and inflammatory diseases of the CNS.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 87, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 7, "tag": "Finding"}, {"end": 98, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 44, "tag": "CellOrMolecularDysfunction"}]}{"id": "81_7", "text": "These are typically associated with several neurological disorders.", "tags": [{"end": 66, "start": 44, "tag": "DiseaseOrSyndrome"}]}{"id": "81_8", "text": "These diseases have fundamental differences regarding their underlying physiology and clinical manifestations, although there are aspects that overlap.", "tags": [{"end": 109, "start": 86, "tag": "SignOrSymptom"}, {"end": 81, "start": 71, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 81, "start": 71, "tag": "BiologicFunction"}, {"end": 43, "start": 32, "tag": "Finding"}]}{"id": "81_9", "text": "The endocannabinoid system (ECS) is comprised of receptors (type-1 (CB1R) and type-2 (CB2R) cannabinoid-receptors, as well as transient receptor potential vanilloid 1 (TRPV1)), endogenous ligands and enzymes that synthesize and degrade endocannabinoids (ECBs).", "tags": [{"end": 58, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 68, "tag": "GeneOrGenome"}, {"end": 84, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 195, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 235, "start": 228, "tag": "Finding"}, {"end": 252, "start": 236, "tag": "Chemical"}, {"end": 252, "start": 236, "tag": "BiologicallyActiveSubstance"}, {"end": 258, "start": 254, "tag": "Chemical"}, {"end": 258, "start": 254, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 4, "tag": "Chemical"}, {"end": 26, "start": 4, "tag": "CellFunction"}, {"end": 19, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 207, "start": 200, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 86, "tag": "GeneOrGenome"}]}{"id": "81_10", "text": "Recent studies revealed the involvement of the ECS in different pathological aspects of these neurodegenerative disorders.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 84, "start": 64, "tag": "PathologicFunction"}, {"end": 39, "start": 28, "tag": "Finding"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 121, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 47, "tag": "CellFunction"}]}{"id": "81_11", "text": "The present review will explore the roles of cannabinoid receptors (CBRs) and pharmacological agents that modulate CBRs or ECS activity with reference to Alzheimer's Disease (AD), Parkinson's Disease (PD), Huntington's Disease (HD) and multiple sclerosis (MS).", "tags": [{"end": 66, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 78, "tag": "PharmacologicSubstance"}, {"end": 173, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 199, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 258, "start": 256, "tag": "DiseaseOrSyndrome"}, {"end": 254, "start": 236, "tag": "DiseaseOrSyndrome"}, {"end": 226, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 228, "tag": "DiseaseOrSyndrome"}, {"end": 203, "start": 201, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 126, "start": 123, "tag": "CellFunction"}]}{"id": "84_0", "text": "Decades of research on the prion protein and its associated diseases have caused a paradigm shift in our understanding of infectious agents.", "tags": [{"end": 19, "start": 11, "tag": "ResearchActivity"}, {"end": 40, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 83, "tag": "ResearchActivity"}, {"end": 139, "start": 122, "tag": "Organism"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}]}{"id": "84_1", "text": "More recent years have been marked by a surge of studies supporting the application of these findings to a broad array of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases.", "tags": [{"end": 169, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 5, "tag": "TemporalConcept"}, {"end": 149, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 49, "tag": "ResearchActivity"}]}{"id": "84_2", "text": "Here, we present evidence to suggest that Huntington's disease, a monogenic disorder of the central nervous system, shares features with prion disorders and that, it too, may be governed by similar mechanisms.", "tags": [{"end": 114, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 17, "tag": "Finding"}, {"end": 62, "start": 42, "tag": "DiseaseOrSyndrome"}]}{"id": "84_3", "text": "We further posit that these similarities could suggest that, like other common neurodegenerative disorders, sporadic forms of Huntington's disease may exist.", "tags": [{"end": 146, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 79, "tag": "DiseaseOrSyndrome"}]}{"id": "86_0", "text": "Huntington's disease (HD) is an autosomal-dominant neurodegenerative disorder encoding a mutant form of the huntingtin protein (HTT).", "tags": [{"end": 95, "start": 89, "tag": "CellOrMolecularDysfunction"}, {"end": 41, "start": 32, "tag": "CellComponent"}, {"end": 86, "start": 78, "tag": "BiologicFunction"}, {"end": 126, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 42, "tag": "CellFunction"}, {"end": 131, "start": 128, "tag": "GeneOrGenome"}, {"end": 131, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 108, "tag": "GeneOrGenome"}, {"end": 77, "start": 51, "tag": "DiseaseOrSyndrome"}]}{"id": "86_1", "text": "HD is pathologically characterized by loss of neurons in the striatum and cortex, which leads to progressive motor dysfunction, cognitive decline and behavioral symptoms.", "tags": [{"end": 20, "start": 6, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 80, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 169, "start": 150, "tag": "SignOrSymptom"}, {"end": 126, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 115, "tag": "PathologicFunction"}, {"end": 108, "start": 97, "tag": "TemporalConcept"}, {"end": 53, "start": 46, "tag": "Cell"}, {"end": 53, "start": 38, "tag": "CellOrMolecularDysfunction"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "86_2", "text": "Stem cell-based therapy has emerged as a feasible therapeutic approach for the treatment of neurodegenerative diseases and may be effective in alleviating and/or halting the pathophysiological mechanisms underlying HD.", "tags": [{"end": 203, "start": 174, "tag": "PathologicFunction"}, {"end": 70, "start": 50, "tag": "HealthCareActivity"}, {"end": 88, "start": 79, "tag": "HealthCareActivity"}, {"end": 88, "start": 79, "tag": "ResearchActivity"}, {"end": 9, "start": 0, "tag": "Cell"}, {"end": 118, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 0, "tag": "HealthCareActivity"}]}{"id": "86_4", "text": "Here, we performed a systematic review of preclinical studies to estimate the treatment efficacy of stem cells in animal models of HD.", "tags": [{"end": 61, "start": 42, "tag": "ResearchActivity"}, {"end": 38, "start": 21, "tag": "ResearchActivity"}, {"end": 38, "start": 21, "tag": "HealthCareActivity"}, {"end": 110, "start": 100, "tag": "Cell"}, {"end": 87, "start": 78, "tag": "HealthCareActivity"}, {"end": 87, "start": 78, "tag": "ResearchActivity"}, {"end": 127, "start": 114, "tag": "ResearchActivity"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}]}{"id": "86_6", "text": "Although promising results were found, the design of animal studies, the types of transplanted cells and the route of administration are poorly standardized and this greatly complicates comparative analysis.", "tags": [{"end": 100, "start": 82, "tag": "Cell"}, {"end": 206, "start": 186, "tag": "ResearchActivity"}, {"end": 59, "start": 53, "tag": "Eukaryote"}, {"end": 49, "start": 43, "tag": "ResearchActivity"}, {"end": 49, "start": 43, "tag": "HealthCareActivity"}, {"end": 67, "start": 60, "tag": "ResearchActivity"}]}{"id": "90_0", "text": "Neurodegenerative diseases, including Alzheimer's, Parkinson's, Huntington's, and amyotrophic lateral sclerosis, are characterized by a progressive loss of selective neuron subtypes in the central nervous system (CNS).", "tags": [{"end": 172, "start": 166, "tag": "Cell"}, {"end": 49, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 136, "tag": "TemporalConcept"}, {"end": 76, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 189, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 216, "start": 213, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 82, "tag": "DiseaseOrSyndrome"}]}{"id": "90_1", "text": "Although various factors account for the initiation and development of these diseases, accumulating evidence shows that impaired mitochondrial function is a prominent and common mechanism.", "tags": [{"end": 108, "start": 87, "tag": "Finding"}, {"end": 51, "start": 41, "tag": "TemporalConcept"}, {"end": 67, "start": 56, "tag": "BiologicFunction"}, {"end": 67, "start": 56, "tag": "CellFunction"}, {"end": 151, "start": 120, "tag": "CellOrMolecularDysfunction"}]}{"id": "90_2", "text": "Mitochondria play a critical role in neurons and are involved in energy production, cellular metabolism regulation, intracellular calcium homeostasis, immune responses, and cell fate.", "tags": [{"end": 114, "start": 84, "tag": "CellFunction"}, {"end": 129, "start": 116, "tag": "CellComponent"}, {"end": 149, "start": 116, "tag": "CellFunction"}, {"end": 149, "start": 130, "tag": "BiologicFunction"}, {"end": 167, "start": 151, "tag": "BiologicFunction"}, {"end": 167, "start": 151, "tag": "CellFunction"}, {"end": 182, "start": 173, "tag": "CellFunction"}, {"end": 12, "start": 0, "tag": "CellComponent"}, {"end": 149, "start": 138, "tag": "BiologicFunction"}, {"end": 44, "start": 37, "tag": "Cell"}, {"end": 82, "start": 65, "tag": "CellFunction"}]}{"id": "90_3", "text": "Thus, cells in the CNS heavily rely on mitochondrial integrity.", "tags": [{"end": 52, "start": 39, "tag": "CellComponent"}, {"end": 11, "start": 6, "tag": "Cell"}, {"end": 22, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 39, "tag": "CellFunction"}]}{"id": "90_4", "text": "Many aspects of mitochondrial dysfunction are manifested in neurodegenerative diseases, including aberrant mitochondrial quality control (mitoQC), mitochondrial-driven inflammation, and bioenergetic defects.", "tags": [{"end": 144, "start": 138, "tag": "CellFunction"}, {"end": 198, "start": 186, "tag": "BiologicFunction"}, {"end": 206, "start": 199, "tag": "Finding"}, {"end": 136, "start": 121, "tag": "ResearchActivity"}, {"end": 41, "start": 16, "tag": "CellOrMolecularDysfunction"}, {"end": 120, "start": 107, "tag": "CellComponent"}, {"end": 160, "start": 147, "tag": "CellComponent"}, {"end": 180, "start": 168, "tag": "PathologicFunction"}, {"end": 86, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 107, "tag": "CellFunction"}, {"end": 136, "start": 98, "tag": "CellOrMolecularDysfunction"}]}{"id": "90_5", "text": "Herein, we briefly summarize the molecular basis of mitoQC, including mitochondrial proteostasis, biogenesis, dynamics, and organelle degradation.", "tags": [{"end": 58, "start": 52, "tag": "CellFunction"}, {"end": 145, "start": 124, "tag": "CellFunction"}, {"end": 96, "start": 84, "tag": "CellFunction"}, {"end": 83, "start": 70, "tag": "CellComponent"}, {"end": 108, "start": 98, "tag": "CellFunction"}, {"end": 118, "start": 110, "tag": "NaturalPhenomenonOrProcess"}, {"end": 18, "start": 11, "tag": "TemporalConcept"}]}{"id": "90_6", "text": "We also focus on the research, to date, regarding aberrant mitoQC and mitochondrial-driven inflammation in several common neurodegenerative diseases.", "tags": [{"end": 65, "start": 59, "tag": "CellFunction"}, {"end": 38, "start": 31, "tag": "TemporalConcept"}, {"end": 83, "start": 70, "tag": "CellComponent"}, {"end": 38, "start": 34, "tag": "TemporalConcept"}, {"end": 103, "start": 91, "tag": "PathologicFunction"}, {"end": 148, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 21, "tag": "ResearchActivity"}, {"end": 65, "start": 50, "tag": "CellOrMolecularDysfunction"}]}{"id": "90_7", "text": "In addition, we outline novel therapeutic strategies that target aberrant mitoQC in neurodegenerative diseases.", "tags": [{"end": 80, "start": 74, "tag": "CellFunction"}, {"end": 52, "start": 30, "tag": "HealthCareActivity"}, {"end": 110, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 65, "tag": "CellOrMolecularDysfunction"}]}{"id": "97_0", "text": "BACKGROUND: Huntington's disease (HD) is a devastating neurodegenerative disorder characterized by a selective loss of striatal medium spiny projection neurons (MSNs).", "tags": [{"end": 127, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 128, "tag": "Cell"}, {"end": 81, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 161, "tag": "Cell"}]}{"id": "97_1", "text": "Prodynorphin (PDYN) is enriched in a subpopulation of striatal MSNs.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 14, "tag": "GeneOrGenome"}, {"end": 50, "start": 37, "tag": "PopulationGroup"}, {"end": 62, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 63, "tag": "Cell"}]}{"id": "97_2", "text": "Postmortem brains of HD patients and rodent models have been demonstrated to have reduced levels of PDYN transcripts and the neuropeptide dynorphin.", "tags": [{"end": 104, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 100, "tag": "GeneOrGenome"}, {"end": 99, "start": 82, "tag": "Finding"}, {"end": 116, "start": 105, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 43, "start": 37, "tag": "Eukaryote"}, {"end": 10, "start": 0, "tag": "TemporalConcept"}, {"end": 32, "start": 21, "tag": "PatientOrDisabledGroup"}, {"end": 17, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 44, "tag": "ResearchActivity"}, {"end": 147, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 125, "tag": "BiologicallyActiveSubstance"}]}{"id": "97_3", "text": "METHODS: Given the unmet need for novel pharmacodynamic HD biomarkers in the context of experimental huntingtin (htt)-lowering therapies, we investigated the levels of PDYN-derived peptides and neurofilament light (NfL) chain in the cerebrospinal fluid (CSF) from HD patients (n = 16), matched controls (n = 55), and patients with other neurodegenerative disorders (n = 70).", "tags": [{"end": 55, "start": 40, "tag": "BiologicFunction"}, {"end": 55, "start": 40, "tag": "ResearchActivity"}, {"end": 29, "start": 19, "tag": "Finding"}, {"end": 116, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 101, "tag": "GeneOrGenome"}, {"end": 69, "start": 59, "tag": "ClinicalAttribute"}, {"end": 136, "start": 127, "tag": "HealthCareActivity"}, {"end": 100, "start": 88, "tag": "HealthCareActivity"}, {"end": 257, "start": 254, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 225, "start": 220, "tag": "AminoAcidPeptideOrProtein"}, {"end": 213, "start": 194, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 215, "tag": "BiologicallyActiveSubstance"}, {"end": 225, "start": 220, "tag": "BiologicallyActiveSubstance"}, {"end": 213, "start": 194, "tag": "BiologicallyActiveSubstance"}, {"end": 218, "start": 215, "tag": "AminoAcidPeptideOrProtein"}, {"end": 302, "start": 294, "tag": "PopulationGroup"}, {"end": 252, "start": 233, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 275, "start": 264, "tag": "PatientOrDisabledGroup"}, {"end": 364, "start": 337, "tag": "DiseaseOrSyndrome"}, {"end": 325, "start": 317, "tag": "PatientOrDisabledGroup"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 168, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 168, "tag": "GeneOrGenome"}]}{"id": "97_4", "text": "RESULTS: PDYN-derived peptide levels were found to be substantially decreased in HD patients (P< 0.0001 in comparison to controls), whereas the NfL levels were elevated in all neurodegenerative disorders.", "tags": [{"end": 29, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 107, "tag": "ResearchActivity"}, {"end": 147, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 121, "tag": "PopulationGroup"}, {"end": 92, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 203, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 9, "tag": "GeneOrGenome"}, {"end": 36, "start": 9, "tag": "ClinicalAttribute"}, {"end": 154, "start": 144, "tag": "ClinicalAttribute"}]}{"id": "97_5", "text": "CONCLUSIONS: Our study suggests decreased PDYN-derived peptide levels in the CSF as a more specific biomarker for HD in comparison to NfL.", "tags": [{"end": 62, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}, {"end": 109, "start": 100, "tag": "ClinicalAttribute"}, {"end": 80, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 120, "tag": "ResearchActivity"}, {"end": 137, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 42, "tag": "ClinicalAttribute"}]}{"id": "97_6", "text": "(c) 2020 The Authors.Movement Disorderspublished by Wiley Periodicals LLC.", "tags": [{"end": 29, "start": 21, "tag": "BiologicFunction"}, {"end": 29, "start": 21, "tag": "CellFunction"}, {"end": 29, "start": 21, "tag": "NaturalPhenomenonOrProcess"}, {"end": 39, "start": 21, "tag": "DiseaseOrSyndrome"}]}{"id": "97_7", "text": "on behalf of International Parkinson and Movement Disorder Society.", "tags": [{"end": 66, "start": 13, "tag": "HealthCareRelatedOrganization"}, {"end": 36, "start": 27, "tag": "DiseaseOrSyndrome"}]}{"id": "98_0", "text": "Huntington's disease (HD) is a rare neurodegenerative disease associated with disability and loss of patient independence.", "tags": [{"end": 35, "start": 31, "tag": "TemporalConcept"}, {"end": 121, "start": 109, "tag": "BiologicFunction"}, {"end": 61, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 78, "tag": "Finding"}, {"end": 108, "start": 101, "tag": "PatientOrDisabledGroup"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}]}{"id": "98_1", "text": "The caregivers of HD patients are at high risk for burnout.", "tags": [{"end": 58, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 4, "tag": "HealthCareActivity"}, {"end": 29, "start": 18, "tag": "PatientOrDisabledGroup"}, {"end": 46, "start": 37, "tag": "Finding"}]}{"id": "98_2", "text": "We aimed to identify variables that impact caregiver burden, as measured by the Modified Caregiver Strain Index (MCSI) and the Huntington's disease Quality of Life Battery for Carers Short Form (HD-SF).", "tags": [{"end": 111, "start": 80, "tag": "HealthCareActivity"}, {"end": 117, "start": 113, "tag": "HealthCareActivity"}, {"end": 59, "start": 43, "tag": "BiologicFunction"}, {"end": 147, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 127, "tag": "HealthCareActivity"}, {"end": 200, "start": 195, "tag": "HealthCareActivity"}]}{"id": "98_3", "text": "Total functional capacity and being sole caregiver were significantly associated with higher caregiver burden via MCSI.", "tags": [{"end": 118, "start": 114, "tag": "HealthCareActivity"}, {"end": 50, "start": 41, "tag": "HealthCareActivity"}, {"end": 25, "start": 6, "tag": "Finding"}, {"end": 109, "start": 93, "tag": "BiologicFunction"}]}{"id": "98_4", "text": "There was not good correlation between MCSI and HDQoLC-SF.", "tags": [{"end": 30, "start": 19, "tag": "ResearchActivity"}, {"end": 43, "start": 39, "tag": "HealthCareActivity"}]}{"id": "98_5", "text": "This study highlights the need for more research to effectively identify at-risk caregivers for early intervention.", "tags": [{"end": 114, "start": 96, "tag": "HealthCareActivity"}, {"end": 91, "start": 81, "tag": "HealthCareActivity"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 80, "start": 73, "tag": "Finding"}]}{"id": "99_0", "text": "Huntington's disease is a neurodegenerative disease caused by CAG repeat in the first exon of HTT (Huntingtin) gene, leading to abnormal form of Htt protein containing enlarged polyglutamine strands of variable length that stick together to form aggregates and is toxic to brain causing brain damage.", "tags": [{"end": 90, "start": 86, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 217, "start": 211, "tag": "ResearchActivity"}, {"end": 72, "start": 62, "tag": "MolecularSequence"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 278, "start": 273, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 94, "tag": "GeneOrGenome"}, {"end": 299, "start": 287, "tag": "InjuryOrPoisoning"}, {"end": 156, "start": 128, "tag": "CellOrMolecularDysfunction"}]}{"id": "99_1", "text": "Complete reversal of brain damage is not possible till date but recovery may be possible by peptide therapy.", "tags": [{"end": 17, "start": 0, "tag": "Finding"}, {"end": 59, "start": 55, "tag": "TemporalConcept"}, {"end": 72, "start": 64, "tag": "BiologicFunction"}, {"end": 72, "start": 64, "tag": "HealthCareActivity"}, {"end": 72, "start": 64, "tag": "TemporalConcept"}, {"end": 99, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 21, "tag": "InjuryOrPoisoning"}, {"end": 107, "start": 100, "tag": "HealthCareActivity"}]}{"id": "99_2", "text": "The peptide-based therapy for Huntington's disease includes both poly Q peptide as well as non poly Q peptides like (QBP1)2, p42, Exendin 4, ED11, CaM, BiP, Leuprorelin peptide.", "tags": [{"end": 128, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 4, "tag": "HealthCareActivity"}, {"end": 155, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 130, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 157, "tag": "BiologicallyActiveSubstance"}]}{"id": "99_3", "text": "The novel approach that is currently being tested in this article is the peptide-based therapy to target the mutated protein.", "tags": [{"end": 65, "start": 58, "tag": "ResearchActivity"}, {"end": 36, "start": 27, "tag": "TemporalConcept"}, {"end": 124, "start": 109, "tag": "CellOrMolecularDysfunction"}, {"end": 94, "start": 73, "tag": "HealthCareActivity"}, {"end": 124, "start": 109, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "99_4", "text": "This approach is based on the principle of preventing the aggregation of mutant Htt by blocking the potential sites responsible for protein aggregation and thereby ameliorating the disease symptoms.", "tags": [{"end": 197, "start": 181, "tag": "SignOrSymptom"}, {"end": 83, "start": 58, "tag": "CellOrMolecularDysfunction"}, {"end": 151, "start": 132, "tag": "CellFunction"}, {"end": 151, "start": 132, "tag": "CellOrMolecularDysfunction"}]}{"id": "99_5", "text": "Herein, we have screened a variety of potential peptides that were known to prevent the protein aggregation, comparatively analyzed their binding affinity with homology modeled Htt protein, designed novel peptides based upon conservation analysis among screened potential peptides as a therapeutic agent, comparatively analyzed the therapeutic potential of novel peptides against modeled Htt protein for investigating the therapeutic prospects of Huntington's disease.", "tags": [{"end": 24, "start": 16, "tag": "HealthCareActivity"}, {"end": 24, "start": 16, "tag": "ResearchActivity"}, {"end": 56, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 138, "tag": "CellFunction"}, {"end": 213, "start": 205, "tag": "AminoAcidPeptideOrProtein"}, {"end": 261, "start": 253, "tag": "HealthCareActivity"}, {"end": 261, "start": 253, "tag": "ResearchActivity"}, {"end": 280, "start": 272, "tag": "AminoAcidPeptideOrProtein"}, {"end": 303, "start": 286, "tag": "PharmacologicSubstance"}, {"end": 303, "start": 286, "tag": "BiologicallyActiveSubstance"}, {"end": 303, "start": 286, "tag": "HealthCareActivity"}, {"end": 303, "start": 286, "tag": "Chemical"}, {"end": 303, "start": 286, "tag": "InjuryOrPoisoning"}, {"end": 371, "start": 363, "tag": "AminoAcidPeptideOrProtein"}, {"end": 391, "start": 388, "tag": "GeneOrGenome"}, {"end": 188, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 391, "start": 388, "tag": "AminoAcidPeptideOrProtein"}, {"end": 467, "start": 447, "tag": "DiseaseOrSyndrome"}, {"end": 353, "start": 332, "tag": "HealthCareActivity"}, {"end": 246, "start": 225, "tag": "ResearchActivity"}, {"end": 107, "start": 88, "tag": "CellFunction"}, {"end": 107, "start": 88, "tag": "CellOrMolecularDysfunction"}, {"end": 303, "start": 298, "tag": "PharmacologicSubstance"}, {"end": 131, "start": 123, "tag": "ResearchActivity"}, {"end": 327, "start": 319, "tag": "ResearchActivity"}]}{"id": "99_6", "text": "We have designed a peptide for the therapy of Huntington's disease by comparing several peptides, which are already in use for Huntington's disease.", "tags": [{"end": 96, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 35, "tag": "HealthCareActivity"}]}{"id": "100_0", "text": "Huntington's disease (HD) is an inherited neurodegenerative disorder that usually starts during midlife with progressive alterations of motor and cognitive functions.", "tags": [{"end": 68, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 96, "tag": "TemporalConcept"}, {"end": 165, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "100_1", "text": "The disease is caused by a CAG repeat expansion within the huntingtin gene leading to severe striatal neurodegeneration.", "tags": [{"end": 74, "start": 59, "tag": "GeneOrGenome"}, {"end": 101, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 86, "tag": "Finding"}, {"end": 47, "start": 27, "tag": "CellOrMolecularDysfunction"}, {"end": 119, "start": 102, "tag": "CellOrMolecularDysfunction"}]}{"id": "100_2", "text": "Recent studies conducted on pre-HD children highlight early striatal developmental alterations starting as soon as 6 years old, the earliest age assessed.", "tags": [{"end": 126, "start": 115, "tag": "PopulationGroup"}, {"end": 122, "start": 117, "tag": "TemporalConcept"}, {"end": 82, "start": 60, "tag": "BiologicFunction"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 34, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 132, "tag": "TemporalConcept"}, {"end": 94, "start": 60, "tag": "CellOrMolecularDysfunction"}, {"end": 43, "start": 28, "tag": "PatientOrDisabledGroup"}, {"end": 144, "start": 141, "tag": "OrganismAttribute"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}]}{"id": "100_3", "text": "These findings, in line with data from mouse models of HD, raise the questions of when during development do the first disease-related striatal alterations emerge and whether they contribute to the later appearance of the neurodegenerative features of the disease.", "tags": [{"end": 33, "start": 29, "tag": "ResearchActivity"}, {"end": 51, "start": 39, "tag": "ExperimentalModelOfDisease"}, {"end": 214, "start": 204, "tag": "OrganismAttribute"}, {"end": 214, "start": 198, "tag": "Finding"}, {"end": 248, "start": 222, "tag": "CellOrMolecularDysfunction"}, {"end": 143, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 135, "tag": "CellOrMolecularDysfunction"}, {"end": 57, "start": 55, "tag": "DiseaseOrSyndrome"}]}{"id": "100_4", "text": "In this review we will describe the different stages of striatal network development and then discuss recent evidence for its alterations in rodent models of the disease.", "tags": [{"end": 52, "start": 46, "tag": "TemporalConcept"}, {"end": 154, "start": 141, "tag": "ExperimentalModelOfDisease"}, {"end": 84, "start": 56, "tag": "BiologicFunction"}, {"end": 108, "start": 102, "tag": "TemporalConcept"}, {"end": 117, "start": 109, "tag": "Finding"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "100_5", "text": "We argue that a better understanding of the striatum's development should help in assessing aberrant neurodevelopmental processes linked to the HD mutation.", "tags": [{"end": 129, "start": 92, "tag": "PathologicFunction"}, {"end": 129, "start": 101, "tag": "BiologicFunction"}, {"end": 66, "start": 44, "tag": "BiologicFunction"}, {"end": 146, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 147, "tag": "CellOrMolecularDysfunction"}, {"end": 52, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "101_0", "text": "With a large and increasing elderly population, neurodegenerative diseases such as Parkinson?s disease (PD), Huntington disease (HD), Alzheimer?s disease (AD), Amyotrophic lateral sclerosis (ALS) and Multiple sclerosis (MS) have become a major and growing health problem.", "tags": [{"end": 27, "start": 17, "tag": "Finding"}, {"end": 46, "start": 28, "tag": "PopulationGroup"}, {"end": 102, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 218, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 222, "start": 220, "tag": "DiseaseOrSyndrome"}, {"end": 270, "start": 256, "tag": "SignOrSymptom"}, {"end": 131, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 48, "tag": "DiseaseOrSyndrome"}]}{"id": "101_1", "text": "During the past few decades, the elderly population has grown 2.5 % every year.", "tags": [{"end": 51, "start": 33, "tag": "PopulationGroup"}, {"end": 78, "start": 74, "tag": "TemporalConcept"}]}{"id": "101_2", "text": "Unfortunately, there are no specific therapeutic remedies available to slow the onset or development of these diseases.", "tags": [{"end": 57, "start": 37, "tag": "HealthCareActivity"}, {"end": 85, "start": 80, "tag": "TemporalConcept"}]}{"id": "101_3", "text": "An aging brain causes many pathophysiological changes and is the major risk factor for most of the neurodegenerative disorders.", "tags": [{"end": 8, "start": 3, "tag": "BiologicFunction"}, {"end": 8, "start": 3, "tag": "CellFunction"}, {"end": 53, "start": 27, "tag": "PathologicFunction"}, {"end": 14, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 71, "tag": "Finding"}]}{"id": "101_4", "text": "Polyphenolic compounds such as flavonols have shown therapeutic potential and can contribute to the treatment of these diseases.", "tags": [{"end": 73, "start": 52, "tag": "HealthCareActivity"}, {"end": 22, "start": 0, "tag": "Chemical"}, {"end": 22, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 40, "start": 31, "tag": "Chemical"}, {"end": 40, "start": 31, "tag": "PharmacologicSubstance"}, {"end": 109, "start": 100, "tag": "HealthCareActivity"}, {"end": 109, "start": 100, "tag": "ResearchActivity"}]}{"id": "101_5", "text": "In this review, evidence for the beneficial neuroprotective effect of multiple flavonols is discussed and their multifactorial cellular pathways for the progressions of age-associated brain changes are identified.", "tags": [{"end": 144, "start": 127, "tag": "CellFunction"}, {"end": 165, "start": 153, "tag": "PathologicFunction"}, {"end": 197, "start": 169, "tag": "AnatomicalAbnormality"}, {"end": 189, "start": 184, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 16, "tag": "Finding"}, {"end": 88, "start": 79, "tag": "Chemical"}, {"end": 88, "start": 79, "tag": "PharmacologicSubstance"}, {"end": 66, "start": 44, "tag": "Finding"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "101_6", "text": "Moreover, the animal models of these diseases support the neuroprotective effect and target the potential of flavonols in the treatment of neurodegenerative diseases.", "tags": [{"end": 27, "start": 14, "tag": "ExperimentalModelOfDisease"}, {"end": 118, "start": 109, "tag": "Chemical"}, {"end": 118, "start": 109, "tag": "PharmacologicSubstance"}, {"end": 165, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 58, "tag": "Finding"}, {"end": 135, "start": 126, "tag": "HealthCareActivity"}, {"end": 135, "start": 126, "tag": "ResearchActivity"}]}{"id": "102_0", "text": "Neurologic and nonneurologic manifestations have been shown for Huntington disease (HD) as a genetic neurodegenerative disorder.", "tags": [{"end": 43, "start": 15, "tag": "SignOrSymptom"}, {"end": 127, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 64, "tag": "DiseaseOrSyndrome"}]}{"id": "102_3", "text": "All transient and chronic risk factors for development of these manifestations were ruled out.", "tags": [{"end": 13, "start": 4, "tag": "TemporalConcept"}, {"end": 78, "start": 64, "tag": "SignOrSymptom"}, {"end": 25, "start": 18, "tag": "TemporalConcept"}, {"end": 38, "start": 26, "tag": "Finding"}]}{"id": "102_4", "text": "According to the experimental evidences reviewed in this article, we suggest that HD itself could promote formation of CVT, iron-deficiency anemia and neutropenia through vascular and blood cell abnormalities.", "tags": [{"end": 48, "start": 40, "tag": "HealthCareActivity"}, {"end": 64, "start": 57, "tag": "ResearchActivity"}, {"end": 122, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 119, "tag": "PathologicFunction"}, {"end": 146, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 194, "start": 184, "tag": "Cell"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 39, "start": 17, "tag": "ResearchActivity"}, {"end": 121, "start": 106, "tag": "Finding"}, {"end": 208, "start": 184, "tag": "CellOrMolecularDysfunction"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 151, "tag": "AnatomicalAbnormality"}]}{"id": "102_5", "text": "Tweetable abstract: This article introduces the first case of a Huntington disease patient with cerebral venous thrombosis, iron-deficiency anemia and neutropenia.", "tags": [{"end": 32, "start": 25, "tag": "ResearchActivity"}, {"end": 122, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 96, "tag": "PathologicFunction"}, {"end": 146, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 151, "tag": "AnatomicalAbnormality"}, {"end": 90, "start": 83, "tag": "PatientOrDisabledGroup"}]}{"id": "102_6", "text": "We also review the evidences on how Huntington disease itself could promote these manifestations.", "tags": [{"end": 96, "start": 82, "tag": "SignOrSymptom"}, {"end": 54, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "103_0", "text": "As life expectancy increases worldwide, age-related neurodegenerative diseases will increasein parallel.The lack of effective treatment strategies may soonlead to an unprecedented health, social and economic crisis.", "tags": [{"end": 78, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 108, "tag": "Finding"}, {"end": 214, "start": 180, "tag": "HealthCareActivity"}, {"end": 18, "start": 3, "tag": "TemporalConcept"}, {"end": 78, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 126, "tag": "HealthCareActivity"}, {"end": 135, "start": 126, "tag": "ResearchActivity"}]}{"id": "103_1", "text": "Any attempt to halt the progression of these diseases requires a thorough knowledge of the pathophysiological mechanisms involved to facilitate the identification of new targets and the application of innovative therapeutic strategies.", "tags": [{"end": 83, "start": 74, "tag": "Finding"}, {"end": 120, "start": 91, "tag": "PathologicFunction"}, {"end": 177, "start": 148, "tag": "ResearchActivity"}, {"end": 234, "start": 201, "tag": "HealthCareActivity"}, {"end": 35, "start": 24, "tag": "PathologicFunction"}, {"end": 35, "start": 24, "tag": "TemporalConcept"}]}{"id": "103_2", "text": "The metzincin superfamily of metalloproteinases includes matrix metalloproteinases (MMP), a disintegrin and metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS).", "tags": [{"end": 25, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 4, "tag": "GeneOrGenome"}, {"end": 47, "start": 29, "tag": "GeneOrGenome"}, {"end": 82, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 57, "tag": "GeneOrGenome"}, {"end": 125, "start": 92, "tag": "GeneOrGenome"}, {"end": 125, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 127, "tag": "GeneOrGenome"}, {"end": 141, "start": 137, "tag": "GeneOrGenome"}, {"end": 131, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 170, "tag": "GeneOrGenome"}, {"end": 176, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 84, "tag": "GeneOrGenome"}, {"end": 87, "start": 84, "tag": "BiologicallyActiveSubstance"}]}{"id": "103_3", "text": "These multigenic and multifunctional proteinase families regulate the functions of an increasing number of signalling and scaffolding molecules involved in neuroinflammation, blood-brain barrier disruption, protein misfolding, synaptic dysfunction or neuronal death.", "tags": [{"end": 78, "start": 57, "tag": "BiologicFunction"}, {"end": 205, "start": 175, "tag": "InjuryOrPoisoning"}, {"end": 225, "start": 207, "tag": "CellOrMolecularDysfunction"}, {"end": 247, "start": 227, "tag": "CellOrMolecularDysfunction"}, {"end": 265, "start": 251, "tag": "CellFunction"}, {"end": 16, "start": 6, "tag": "CellFunction"}, {"end": 56, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 143, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 194, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 173, "start": 156, "tag": "PathologicFunction"}]}{"id": "103_4", "text": "Metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), are therefore, at the crossroads of molecular and cellular mechanisms that support neurodegenerative processes, and emerge as potential new therapeutic targets.", "tags": [{"end": 18, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 29, "tag": "Chemical"}, {"end": 218, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 267, "start": 234, "tag": "Finding"}, {"end": 106, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 59, "tag": "PharmacologicSubstance"}]}{"id": "103_5", "text": "We provide an overview of current knowledge on the role and regulation of metalloproteinases and TIMPs in four major neurodegenerative diseases: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and Huntington's disease.", "tags": [{"end": 43, "start": 14, "tag": "ResearchActivity"}, {"end": 92, "start": 60, "tag": "CellFunction"}, {"end": 92, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 26, "tag": "TemporalConcept"}, {"end": 241, "start": 221, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 97, "tag": "PharmacologicSubstance"}, {"end": 102, "start": 97, "tag": "BiologicallyActiveSubstance"}]}{"id": "104_0", "text": "Huntington disease (HD) is an inherited neurodegenerative disease characterized by a clinical triad of motor, psychiatric and cognitive symptoms.", "tags": [{"end": 65, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 126, "tag": "SignOrSymptom"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 136, "tag": "SignOrSymptom"}, {"end": 108, "start": 103, "tag": "SignOrSymptom"}, {"end": 144, "start": 136, "tag": "SignOrSymptom"}, {"end": 121, "start": 110, "tag": "SignOrSymptom"}]}{"id": "104_1", "text": "HD is caused by a CAG repeat expansion in the gene encoding the huntingtin protein.", "tags": [{"end": 59, "start": 51, "tag": "BiologicFunction"}, {"end": 38, "start": 18, "tag": "CellOrMolecularDysfunction"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 64, "tag": "BiologicallyActiveSubstance"}]}{"id": "104_2", "text": "Homozygosity for the HD-causing mutation is extremely rare; thus, the majority of HD patients express the mutant huntingtin protein in addition to reduced levels of the non-pathogenic huntingtin protein.", "tags": [{"end": 12, "start": 0, "tag": "OrganismAttribute"}, {"end": 93, "start": 82, "tag": "PatientOrDisabledGroup"}, {"end": 101, "start": 94, "tag": "CellFunction"}, {"end": 112, "start": 106, "tag": "CellOrMolecularDysfunction"}, {"end": 164, "start": 147, "tag": "Finding"}, {"end": 40, "start": 21, "tag": "CellOrMolecularDysfunction"}, {"end": 131, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 202, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 54, "tag": "TemporalConcept"}]}{"id": "104_3", "text": "Deficits in synaptic plasticity, including hippocampal long-term potentiation (LTP), have been identified in various mouse models of HD and are thought to contribute to the debilitating cognitive symptoms associated with the disease.", "tags": [{"end": 54, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 79, "tag": "BiologicFunction"}, {"end": 135, "start": 117, "tag": "ExperimentalModelOfDisease"}, {"end": 204, "start": 173, "tag": "SignOrSymptom"}, {"end": 77, "start": 55, "tag": "BiologicFunction"}, {"end": 31, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 135, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 12, "tag": "CellFunction"}, {"end": 31, "start": 12, "tag": "BiologicFunction"}]}{"id": "104_4", "text": "However, the bulk of these studies used N-terminal fragment or homozygous knock-in mouse models of HD at symptomatic ages, and our understanding of the onset and progression of synaptic plasticity deficits in the HD brain is lacking.", "tags": [{"end": 73, "start": 63, "tag": "OrganismAttribute"}, {"end": 82, "start": 74, "tag": "ResearchActivity"}, {"end": 121, "start": 105, "tag": "TemporalConcept"}, {"end": 59, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 83, "tag": "ExperimentalModelOfDisease"}, {"end": 205, "start": 177, "tag": "CellOrMolecularDysfunction"}, {"end": 221, "start": 216, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 152, "tag": "TemporalConcept"}, {"end": 173, "start": 162, "tag": "PathologicFunction"}, {"end": 173, "start": 162, "tag": "TemporalConcept"}, {"end": 34, "start": 27, "tag": "ResearchActivity"}, {"end": 196, "start": 177, "tag": "CellFunction"}, {"end": 196, "start": 177, "tag": "BiologicFunction"}]}{"id": "104_5", "text": "To better understand the time-course of synaptic plasticity deficits in HD, as well as the impact of heterozygous and homozygous huntingtin mutations, we quantified basal synaptic connectivity, presynaptic release probability, presynaptically mediated post-tetanic potentiation (PTP) and postsynaptically mediated LTP at presymptomatic, early symptomatic and late symptomatic ages in heterozygous and homozygous Q175FDN knock-in HD mice.", "tags": [{"end": 113, "start": 101, "tag": "OrganismAttribute"}, {"end": 128, "start": 118, "tag": "OrganismAttribute"}, {"end": 149, "start": 129, "tag": "CellOrMolecularDysfunction"}, {"end": 205, "start": 194, "tag": "CellComponent"}, {"end": 213, "start": 194, "tag": "CellFunction"}, {"end": 317, "start": 288, "tag": "BiologicFunction"}, {"end": 396, "start": 384, "tag": "OrganismAttribute"}, {"end": 411, "start": 401, "tag": "OrganismAttribute"}, {"end": 436, "start": 420, "tag": "ExperimentalModelOfDisease"}, {"end": 68, "start": 40, "tag": "CellOrMolecularDysfunction"}, {"end": 192, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 225, "start": 194, "tag": "ResearchActivity"}, {"end": 192, "start": 165, "tag": "ClinicalAttribute"}, {"end": 419, "start": 412, "tag": "ExperimentalModelOfDisease"}, {"end": 36, "start": 25, "tag": "TemporalConcept"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 431, "start": 429, "tag": "DiseaseOrSyndrome"}, {"end": 277, "start": 252, "tag": "BiologicFunction"}, {"end": 282, "start": 279, "tag": "BiologicFunction"}, {"end": 59, "start": 40, "tag": "CellFunction"}, {"end": 59, "start": 40, "tag": "BiologicFunction"}, {"end": 380, "start": 359, "tag": "PopulationGroup"}, {"end": 380, "start": 376, "tag": "PopulationGroup"}, {"end": 335, "start": 321, "tag": "PopulationGroup"}, {"end": 380, "start": 376, "tag": "PopulationGroup"}, {"end": 354, "start": 337, "tag": "PopulationGroup"}]}{"id": "104_6", "text": "Our results demonstrate clear age-dependent effects of the HD-causing mutation on both short and long-term plasticity that generally emerge earlier in homozygous mice.", "tags": [{"end": 51, "start": 30, "tag": "Finding"}, {"end": 117, "start": 97, "tag": "BiologicFunction"}, {"end": 161, "start": 151, "tag": "OrganismAttribute"}, {"end": 166, "start": 162, "tag": "Eukaryote"}, {"end": 147, "start": 140, "tag": "TemporalConcept"}, {"end": 78, "start": 59, "tag": "CellOrMolecularDysfunction"}]}{"id": "104_7", "text": "Interestingly, deficits in presynaptic short-term plasticity were more closely linked to disease progression than deficits in postsynaptic LTP, and heterozygous mice were more susceptible to an LTP deficit when induced by high frequency stimulation compared to theta burst stimulation.", "tags": [{"end": 38, "start": 27, "tag": "CellComponent"}, {"end": 60, "start": 39, "tag": "BiologicFunction"}, {"end": 160, "start": 148, "tag": "OrganismAttribute"}, {"end": 197, "start": 194, "tag": "BiologicFunction"}, {"end": 248, "start": 222, "tag": "ResearchActivity"}, {"end": 142, "start": 126, "tag": "BiologicFunction"}, {"end": 60, "start": 15, "tag": "CellOrMolecularDysfunction"}, {"end": 142, "start": 114, "tag": "CellOrMolecularDysfunction"}, {"end": 165, "start": 161, "tag": "Eukaryote"}, {"end": 108, "start": 89, "tag": "PathologicFunction"}, {"end": 236, "start": 227, "tag": "TemporalConcept"}, {"end": 205, "start": 194, "tag": "CellOrMolecularDysfunction"}, {"end": 284, "start": 261, "tag": "ResearchActivity"}, {"end": 138, "start": 126, "tag": "CellComponent"}]}{"id": "104_8", "text": "To the best of our knowledge, the present study represents the most thorough characterization to date of the onset and progression of hippocampal synaptic plasticity deficits in a mouse model of HD, and should prove valuable to future studies exploring cellular mechanisms underlying the debilitating cognitive decline in HD.", "tags": [{"end": 28, "start": 19, "tag": "Finding"}, {"end": 93, "start": 77, "tag": "ResearchActivity"}, {"end": 145, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 134, "tag": "Cell"}, {"end": 191, "start": 180, "tag": "ManufacturedObject"}, {"end": 174, "start": 146, "tag": "CellOrMolecularDysfunction"}, {"end": 318, "start": 288, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 324, "start": 322, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 109, "tag": "TemporalConcept"}, {"end": 130, "start": 119, "tag": "PathologicFunction"}, {"end": 130, "start": 119, "tag": "TemporalConcept"}, {"end": 47, "start": 42, "tag": "ResearchActivity"}, {"end": 242, "start": 235, "tag": "ResearchActivity"}, {"end": 165, "start": 146, "tag": "CellFunction"}, {"end": 165, "start": 146, "tag": "BiologicFunction"}, {"end": 101, "start": 94, "tag": "TemporalConcept"}, {"end": 197, "start": 180, "tag": "ExperimentalModelOfDisease"}, {"end": 234, "start": 228, "tag": "TemporalConcept"}]}{"id": "105_0", "text": "Berberine, as a natural alkaloid compound, is characterized by a diversity of pharmacological effects.", "tags": [{"end": 41, "start": 16, "tag": "Chemical"}, {"end": 101, "start": 65, "tag": "Finding"}, {"end": 9, "start": 0, "tag": "Chemical"}, {"end": 9, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "105_1", "text": "In recent years, many researches focused on the role of berberine in central nervous system diseases.", "tags": [{"end": 15, "start": 3, "tag": "TemporalConcept"}, {"end": 32, "start": 22, "tag": "ResearchActivity"}, {"end": 100, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 56, "tag": "Chemical"}, {"end": 65, "start": 56, "tag": "PharmacologicSubstance"}]}{"id": "105_2", "text": "Among them, the effect of berberine on neurodegenerative diseases has received widespread attention, for example Alzheimer's disease, Parkinson's disease, Huntington's disease, and so on.", "tags": [{"end": 99, "start": 90, "tag": "BiologicFunction"}, {"end": 132, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 26, "tag": "Chemical"}, {"end": 35, "start": 26, "tag": "PharmacologicSubstance"}, {"end": 175, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 39, "tag": "DiseaseOrSyndrome"}]}{"id": "105_3", "text": "Recent evidence suggests that berberine inhibits the production of neuroinflammation, oxidative, and endoplasmic reticulum stress.", "tags": [{"end": 129, "start": 101, "tag": "CellOrMolecularDysfunction"}, {"end": 122, "start": 101, "tag": "CellComponent"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 39, "start": 30, "tag": "Chemical"}, {"end": 39, "start": 30, "tag": "PharmacologicSubstance"}, {"end": 15, "start": 7, "tag": "Finding"}, {"end": 84, "start": 67, "tag": "PathologicFunction"}, {"end": 129, "start": 113, "tag": "CellOrMolecularDysfunction"}, {"end": 95, "start": 86, "tag": "CellOrMolecularDysfunction"}]}{"id": "105_4", "text": "These effects can further reduce neuron damage and apoptosis.", "tags": [{"end": 39, "start": 33, "tag": "Cell"}, {"end": 46, "start": 33, "tag": "CellOrMolecularDysfunction"}, {"end": 60, "start": 51, "tag": "CellFunction"}]}{"id": "105_5", "text": "Although the current research has made some progress, its specific mechanism still needs to be further explored.", "tags": [{"end": 29, "start": 21, "tag": "ResearchActivity"}, {"end": 52, "start": 44, "tag": "TemporalConcept"}, {"end": 20, "start": 13, "tag": "TemporalConcept"}]}{"id": "105_6", "text": "This review provides an overview of berberine in neurodegenerative diseases and its related mechanisms, and also provides new ideas for future research on berberine.", "tags": [{"end": 32, "start": 24, "tag": "ResearchActivity"}, {"end": 151, "start": 143, "tag": "ResearchActivity"}, {"end": 142, "start": 136, "tag": "TemporalConcept"}, {"end": 45, "start": 36, "tag": "Chemical"}, {"end": 164, "start": 155, "tag": "Chemical"}, {"end": 45, "start": 36, "tag": "PharmacologicSubstance"}, {"end": 164, "start": 155, "tag": "PharmacologicSubstance"}, {"end": 75, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}]}{"id": "106_0", "text": "The pathogenic mechanisms of these diseases must be well understood for the treatment of neurological disorders such as Huntington's disease.", "tags": [{"end": 25, "start": 4, "tag": "PathologicFunction"}, {"end": 111, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 76, "tag": "HealthCareActivity"}, {"end": 85, "start": 76, "tag": "ResearchActivity"}]}{"id": "106_1", "text": "Huntington's Disease (HD), a dominant and neurodegenerative disease, is characterized by the CAG re-expansion that occurs in the gene encoding the polyglutamine-expanded mutant Huntingtin (mHTT) protein.", "tags": [{"end": 37, "start": 29, "tag": "CellFunction"}, {"end": 67, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 134, "tag": "BiologicFunction"}, {"end": 109, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 202, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 147, "tag": "CellOrMolecularDysfunction"}]}{"id": "106_2", "text": "Genome editing approaches include zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and Clustered Regularly Interspaced Short Palindromic Repeats/Caspase 9 (CRISPR/Cas9) systems.", "tags": [{"end": 55, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 182, "start": 125, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 192, "start": 183, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 0, "tag": "ResearchActivity"}, {"end": 119, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 183, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 214, "start": 193, "tag": "HealthCareActivity"}, {"end": 214, "start": 193, "tag": "BiologicFunction"}, {"end": 214, "start": 193, "tag": "ResearchActivity"}]}{"id": "106_3", "text": "CRISPR/Cas9 technology allows effective gene editing in different cell types and organisms.", "tags": [{"end": 52, "start": 40, "tag": "ResearchActivity"}, {"end": 76, "start": 66, "tag": "Cell"}, {"end": 90, "start": 81, "tag": "Organism"}, {"end": 22, "start": 0, "tag": "ResearchActivity"}, {"end": 22, "start": 0, "tag": "HealthCareActivity"}]}{"id": "106_4", "text": "Through these systems are created isogenic control of human origin induced pluripotent stem cells (iPSCs).", "tags": [{"end": 50, "start": 34, "tag": "Cell"}, {"end": 97, "start": 67, "tag": "Cell"}, {"end": 59, "start": 54, "tag": "Eukaryote"}, {"end": 104, "start": 99, "tag": "Cell"}]}{"id": "106_5", "text": "In human and mouse models, HD-iPSC lines can be continuously corrected using these systems.", "tags": [{"end": 25, "start": 13, "tag": "ExperimentalModelOfDisease"}, {"end": 40, "start": 27, "tag": "ExperimentalModelOfDisease"}, {"end": 8, "start": 3, "tag": "Eukaryote"}]}{"id": "106_6", "text": "HD-iPSCs can be corrected through the CRISPR/Cas9 system and the cut-and-paste mechanism using isogenic control iPSCs.", "tags": [{"end": 88, "start": 65, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "ExperimentalModelOfDisease"}, {"end": 56, "start": 38, "tag": "BiologicFunction"}, {"end": 56, "start": 38, "tag": "HealthCareActivity"}, {"end": 56, "start": 38, "tag": "ResearchActivity"}, {"end": 117, "start": 95, "tag": "Cell"}]}{"id": "106_7", "text": "This mechanism is a piggyBac transposon-based selection system that can effectively switch between vectors and chromosomes.", "tags": [{"end": 106, "start": 99, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 122, "start": 111, "tag": "CellComponent"}, {"end": 62, "start": 20, "tag": "ResearchActivity"}]}{"id": "106_8", "text": "In studies conducted, it has been determined that in neural cells derived from HD-iPSC, there are isogenic controls as corrected lines recovered from phenotypic abnormalities and gene expression changes.", "tags": [{"end": 65, "start": 53, "tag": "Cell"}, {"end": 174, "start": 150, "tag": "AnatomicalAbnormality"}, {"end": 194, "start": 179, "tag": "CellFunction"}, {"end": 202, "start": 179, "tag": "ResearchActivity"}, {"end": 86, "start": 79, "tag": "ExperimentalModelOfDisease"}, {"end": 115, "start": 98, "tag": "Cell"}, {"end": 134, "start": 119, "tag": "Cell"}, {"end": 10, "start": 3, "tag": "ResearchActivity"}]}{"id": "106_9", "text": "It has been determined that trinucleotide repeat disorders occurring in HD can be cured by single-guide RNA (sgRNA) and normal exogenous DNA restoration, known as the single guideline RNA specific to Cas9.", "tags": [{"end": 58, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 167, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 187, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 204, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 204, "start": 200, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 109, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 114, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 137, "tag": "CellFunction"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 91, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 107, "start": 91, "tag": "BiologicallyActiveSubstance"}]}{"id": "106_10", "text": "The purpose of this review in addition to give general information about HD, a neurodegenerative disorder is to explained the role of CRISPR/Cas9 system with iPSCs in HD treatment.", "tags": [{"end": 105, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 167, "tag": "HealthCareActivity"}, {"end": 152, "start": 134, "tag": "BiologicFunction"}, {"end": 152, "start": 134, "tag": "ResearchActivity"}, {"end": 152, "start": 134, "tag": "HealthCareActivity"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 158, "tag": "Cell"}, {"end": 26, "start": 20, "tag": "ResearchActivity"}, {"end": 26, "start": 20, "tag": "HealthCareActivity"}]}{"id": "107_0", "text": "Animal models of human neurodegenerative disease have been investigated for several decades.", "tags": [{"end": 48, "start": 0, "tag": "ExperimentalModelOfDisease"}, {"end": 48, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 84, "tag": "TemporalConcept"}, {"end": 22, "start": 17, "tag": "Eukaryote"}]}{"id": "107_1", "text": "In recent years, zebrafish (Danio rerio) and medaka (Oryzias latipes) have become popular in pathogenic and therapeutic studies about human neurodegenerative diseases due to their small size, the optical clarity of embryos, their fast development, and their suitability to large-scale therapeutic screening.", "tags": [{"end": 15, "start": 3, "tag": "TemporalConcept"}, {"end": 103, "start": 93, "tag": "PathologicFunction"}, {"end": 127, "start": 108, "tag": "ResearchActivity"}, {"end": 190, "start": 180, "tag": "OrganismAttribute"}, {"end": 222, "start": 215, "tag": "EmbryonicStructure"}, {"end": 246, "start": 230, "tag": "OrganismAttribute"}, {"end": 39, "start": 28, "tag": "Eukaryote"}, {"end": 68, "start": 53, "tag": "Eukaryote"}, {"end": 211, "start": 196, "tag": "OrganismAttribute"}, {"end": 306, "start": 273, "tag": "ResearchActivity"}, {"end": 139, "start": 134, "tag": "Eukaryote"}, {"end": 51, "start": 45, "tag": "Eukaryote"}, {"end": 166, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 17, "tag": "Eukaryote"}]}{"id": "107_2", "text": "Following the emergence of a new generation of molecular biological technologies such as reverse and forward genetics, morpholino, transgenesis, and gene knockout, many human neurodegenerative disease models, such as Parkinson's, Huntington's, and Alzheimer's, were constructed in zebrafish and medaka.", "tags": [{"end": 43, "start": 14, "tag": "Finding"}, {"end": 80, "start": 47, "tag": "ResearchActivity"}, {"end": 129, "start": 119, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 143, "start": 131, "tag": "ResearchActivity"}, {"end": 162, "start": 149, "tag": "ResearchActivity"}, {"end": 200, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 201, "tag": "ManufacturedObject"}, {"end": 228, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 242, "start": 230, "tag": "DiseaseOrSyndrome"}, {"end": 259, "start": 248, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 169, "tag": "Eukaryote"}, {"end": 301, "start": 295, "tag": "Eukaryote"}, {"end": 117, "start": 101, "tag": "ResearchActivity"}, {"end": 290, "start": 281, "tag": "Eukaryote"}]}{"id": "107_3", "text": "These studies proved that zebrafish and medaka genes are functionally conserved in relation to their human homologues, so they exhibit similar neurodegenerative phenotypes to human beings.", "tags": [{"end": 117, "start": 107, "tag": "GeneOrGenome"}, {"end": 187, "start": 175, "tag": "Eukaryote"}, {"end": 171, "start": 143, "tag": "PathologicFunction"}, {"end": 106, "start": 101, "tag": "Eukaryote"}, {"end": 46, "start": 40, "tag": "Eukaryote"}, {"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 35, "start": 26, "tag": "Eukaryote"}]}{"id": "107_4", "text": "Therefore, fish are a suitable model for the investigation of pathologic mechanisms of neurodegenerative diseases and for the large-scale screening of drugs for potential therapy.", "tags": [{"end": 58, "start": 45, "tag": "ResearchActivity"}, {"end": 83, "start": 62, "tag": "PathologicFunction"}, {"end": 178, "start": 161, "tag": "HealthCareActivity"}, {"end": 156, "start": 126, "tag": "ResearchActivity"}, {"end": 156, "start": 151, "tag": "PharmacologicSubstance"}, {"end": 15, "start": 11, "tag": "Eukaryote"}, {"end": 113, "start": 87, "tag": "DiseaseOrSyndrome"}]}{"id": "107_5", "text": "In this review, we summarize the studies in modelling human neurodegenerative diseases in zebrafish and medaka in recent years.", "tags": [{"end": 126, "start": 114, "tag": "TemporalConcept"}, {"end": 59, "start": 54, "tag": "Eukaryote"}, {"end": 110, "start": 104, "tag": "Eukaryote"}, {"end": 86, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 40, "start": 33, "tag": "ResearchActivity"}, {"end": 99, "start": 90, "tag": "Eukaryote"}]}{"id": "108_0", "text": "Background: Huntington's disease (HD) is an inherited neurodegenerative disease and is characterized by atrophy of certain regions of the brain in a progressive manner.", "tags": [{"end": 79, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 149, "tag": "Finding"}, {"end": 111, "start": 104, "tag": "PathologicFunction"}, {"end": 111, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 12, "tag": "DiseaseOrSyndrome"}]}{"id": "108_1", "text": "HD patients experience behavioral changes and uncontrolled movements which can be primarily attributed to the atrophy of striatal neurons.", "tags": [{"end": 41, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 46, "tag": "SignOrSymptom"}, {"end": 137, "start": 121, "tag": "Cell"}, {"end": 41, "start": 12, "tag": "Finding"}, {"end": 117, "start": 110, "tag": "PathologicFunction"}, {"end": 117, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 0, "tag": "PatientOrDisabledGroup"}]}{"id": "108_2", "text": "Previous publications describe the models of the HD striatum using induced pluripotent stem cells (iPSCs) derived from HD patients with a juvenile onset (JHD).", "tags": [{"end": 21, "start": 9, "tag": "ResearchActivity"}, {"end": 152, "start": 138, "tag": "TemporalConcept"}, {"end": 152, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 97, "start": 67, "tag": "Cell"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 99, "tag": "Cell"}, {"end": 130, "start": 119, "tag": "PatientOrDisabledGroup"}, {"end": 60, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 35, "tag": "ExperimentalModelOfDisease"}]}{"id": "108_3", "text": "In this model, the JHD iPSC-derived striatal cultures had altered neurodevelopment and contained a high number of nestin expressing progenitor cells at 42 days of differentiation.", "tags": [{"end": 120, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 114, "tag": "GeneOrGenome"}, {"end": 131, "start": 121, "tag": "CellFunction"}, {"end": 148, "start": 132, "tag": "Cell"}, {"end": 159, "start": 155, "tag": "TemporalConcept"}, {"end": 178, "start": 163, "tag": "CellFunction"}, {"end": 53, "start": 23, "tag": "Cell"}, {"end": 22, "start": 19, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 66, "tag": "BiologicFunction"}, {"end": 53, "start": 23, "tag": "ResearchActivity"}]}{"id": "108_4", "text": "Objective: To further characterize the altered neurodevelopmental phenotype and evaluate potential phenotypic reversal.", "tags": [{"end": 75, "start": 66, "tag": "OrganismAttribute"}, {"end": 109, "start": 99, "tag": "OrganismAttribute"}, {"end": 118, "start": 89, "tag": "Finding"}, {"end": 75, "start": 39, "tag": "CellOrMolecularDysfunction"}]}{"id": "108_5", "text": "Methods: Differentiation of human iPSCs towards striatal fate and characterization by means of immunocytochemistry and stereological quantification.", "tags": [{"end": 24, "start": 9, "tag": "CellFunction"}, {"end": 82, "start": 66, "tag": "ResearchActivity"}, {"end": 114, "start": 95, "tag": "ResearchActivity"}, {"end": 61, "start": 48, "tag": "BiologicFunction"}, {"end": 147, "start": 119, "tag": "ResearchActivity"}, {"end": 39, "start": 28, "tag": "Cell"}]}{"id": "108_6", "text": "Results: Here this study demonstrates a distinct delay in the differentiation of the JHD neural progenitor population.", "tags": [{"end": 54, "start": 49, "tag": "TemporalConcept"}, {"end": 77, "start": 62, "tag": "CellFunction"}, {"end": 88, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 89, "tag": "Cell"}, {"end": 24, "start": 19, "tag": "ResearchActivity"}]}{"id": "108_7", "text": "However, reduction of the JHD aberrant progenitor populations can be accomplished either by targeting the canonical Notch signaling pathway or by treatment with HTT antisense oligonucleotides (ASOs).", "tags": [{"end": 61, "start": 39, "tag": "Cell"}, {"end": 139, "start": 106, "tag": "CellFunction"}, {"end": 191, "start": 161, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 197, "start": 193, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 197, "start": 193, "tag": "Chemical"}, {"end": 197, "start": 193, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 9, "tag": "Finding"}, {"end": 18, "start": 9, "tag": "NaturalPhenomenonOrProcess"}, {"end": 155, "start": 146, "tag": "HealthCareActivity"}, {"end": 155, "start": 146, "tag": "ResearchActivity"}, {"end": 191, "start": 161, "tag": "HealthCareActivity"}, {"end": 61, "start": 30, "tag": "CellOrMolecularDysfunction"}]}{"id": "108_8", "text": "Conclusions: In summary, this data is postulated to reflect a potential overall developmental delay in JHD.", "tags": [{"end": 34, "start": 30, "tag": "ResearchActivity"}, {"end": 99, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 103, "tag": "DiseaseOrSyndrome"}]}{"id": "109_0", "text": "Neurodegenerative diseases are gradually becoming the main burden of society.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 59, "tag": "Finding"}]}{"id": "109_1", "text": "The morbidity and mortality caused by neurodegenerative diseases remain significant health-care concerns.", "tags": [{"end": 13, "start": 4, "tag": "Finding"}, {"end": 27, "start": 18, "tag": "Finding"}, {"end": 64, "start": 38, "tag": "DiseaseOrSyndrome"}]}{"id": "109_2", "text": "For most neurodegenerative diseases, there are no effective treatments.", "tags": [{"end": 70, "start": 60, "tag": "HealthCareActivity"}, {"end": 70, "start": 60, "tag": "ResearchActivity"}, {"end": 35, "start": 9, "tag": "DiseaseOrSyndrome"}]}{"id": "109_3", "text": "Over the past few decades, in a quest to exploit efficacious diseasemodifying therapies for the treatment of neurodegenerative diseases, disease mechanisms, reliable biomarkers and therapeutic targets have become a research priority.", "tags": [{"end": 155, "start": 137, "tag": "ResearchActivity"}, {"end": 176, "start": 166, "tag": "ClinicalAttribute"}, {"end": 232, "start": 215, "tag": "ResearchActivity"}, {"end": 87, "start": 61, "tag": "HealthCareActivity"}, {"end": 200, "start": 181, "tag": "ResearchActivity"}, {"end": 25, "start": 9, "tag": "TemporalConcept"}, {"end": 135, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 96, "tag": "HealthCareActivity"}, {"end": 105, "start": 96, "tag": "ResearchActivity"}]}{"id": "109_4", "text": "At present, lncRNA is an area with potential research value.", "tags": [{"end": 59, "start": 45, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "109_5", "text": "In this article, we first summarize some of the existing results of research into lncRNAs, including origin, molecular characteristics, location types, and functional types.", "tags": [{"end": 76, "start": 68, "tag": "ResearchActivity"}, {"end": 89, "start": 82, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 107, "start": 101, "tag": "TemporalConcept"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 134, "start": 109, "tag": "CellFunction"}]}{"id": "109_6", "text": "We then introduce the possible functions of lncRNAs in different neurodegenerative diseases.", "tags": [{"end": 51, "start": 31, "tag": "CellFunction"}, {"end": 51, "start": 44, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 91, "start": 65, "tag": "DiseaseOrSyndrome"}]}{"id": "109_7", "text": "Furthermore, some lncRNAs which show promise as biomarkers or potential therapeutic targets are systematically summarized.", "tags": [{"end": 25, "start": 18, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 58, "start": 48, "tag": "ClinicalAttribute"}, {"end": 91, "start": 62, "tag": "ResearchActivity"}]}{"id": "110_0", "text": "Neurodegenerative diseases (NDs), such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), are disorders characterized by progressive degeneration of the nervous system.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 205, "tag": "PathologicFunction"}, {"end": 217, "start": 205, "tag": "CellOrMolecularDysfunction"}, {"end": 239, "start": 225, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 217, "start": 193, "tag": "Finding"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 94, "tag": "DiseaseOrSyndrome"}]}{"id": "110_1", "text": "Currently, there is no disease-modifying treatments for most NDs.", "tags": [{"end": 64, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 23, "tag": "HealthCareActivity"}]}{"id": "110_2", "text": "Meanwhile, numerous studies conducted on human and animal models over the past decades have showed that exercises had beneficial effects on NDs.", "tags": [{"end": 64, "start": 51, "tag": "ExperimentalModelOfDisease"}, {"end": 113, "start": 104, "tag": "HealthCareActivity"}, {"end": 143, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 118, "tag": "Finding"}, {"end": 46, "start": 41, "tag": "Eukaryote"}, {"end": 27, "start": 20, "tag": "ResearchActivity"}]}{"id": "110_3", "text": "Inter-tissue communication by myokine, a peptide produced and secreted by skeletal muscles during exercise, is thought to be an important underlying mechanism for the advantages.", "tags": [{"end": 37, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 98, "tag": "HealthCareActivity"}, {"end": 26, "start": 0, "tag": "BiologicFunction"}]}{"id": "110_4", "text": "Here, we reviewed studies about the effects of myokines regulated by exercise on NDs and their mechanisms.", "tags": [{"end": 55, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 69, "tag": "HealthCareActivity"}, {"end": 84, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 18, "tag": "ResearchActivity"}]}{"id": "110_5", "text": "Myokines could exert beneficial effects on NDs through a variety of regulatory mechanisms, including cell survival, neurogenesis, neuroinflammation, proteostasis, oxidative stress, and protein modification.", "tags": [{"end": 8, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 101, "tag": "CellFunction"}, {"end": 205, "start": 185, "tag": "CellFunction"}, {"end": 39, "start": 21, "tag": "Finding"}, {"end": 128, "start": 116, "tag": "BiologicFunction"}, {"end": 147, "start": 130, "tag": "PathologicFunction"}, {"end": 179, "start": 163, "tag": "CellOrMolecularDysfunction"}, {"end": 161, "start": 149, "tag": "CellFunction"}]}{"id": "110_6", "text": "Studies on exercise-induced myokines are expected to provide a novel strategy for treating NDs, for which there are no adequate treatments nowadays.", "tags": [{"end": 27, "start": 11, "tag": "Finding"}, {"end": 36, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 128, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 147, "start": 139, "tag": "TemporalConcept"}]}{"id": "110_7", "text": "To date, only a few myokines have been investigated for their effects on NDs and studies on mechanisms involved in them are in their infancy.", "tags": [{"end": 28, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 133, "tag": "TemporalConcept"}, {"end": 140, "start": 133, "tag": "PopulationGroup"}, {"end": 88, "start": 81, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}]}{"id": "110_8", "text": "Therefore, future studies are needed to discover more myokines and test their effects on NDs.", "tags": [{"end": 62, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 18, "tag": "ResearchActivity"}]}{"id": "111_0", "text": "Huntington's disease (HD) is a neurodegenerative, progressive disorder conditioned by a mutation in the HTT gene.", "tags": [{"end": 70, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 104, "tag": "GeneOrGenome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 88, "tag": "CellOrMolecularDysfunction"}]}{"id": "111_1", "text": "Its progression is dependent on the causative mutation extension.", "tags": [{"end": 64, "start": 46, "tag": "CellFunction"}, {"end": 15, "start": 4, "tag": "PathologicFunction"}, {"end": 15, "start": 4, "tag": "TemporalConcept"}]}{"id": "111_2", "text": "Caregivers of individuals affected by HD, most often patients' relatives, are burdened with the care.", "tags": [{"end": 72, "start": 53, "tag": "PopulationGroup"}, {"end": 10, "start": 0, "tag": "HealthCareActivity"}, {"end": 40, "start": 14, "tag": "PatientOrDisabledGroup"}, {"end": 40, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 63, "tag": "PopulationGroup"}]}{"id": "111_3", "text": "This study aims to assess the caregivers' burden cross-sectionally and longitudinally and look for biological and clinical patients-related burdening factors.", "tags": [{"end": 48, "start": 30, "tag": "BiologicFunction"}, {"end": 157, "start": 114, "tag": "ClinicalAttribute"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 157, "start": 150, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 99, "tag": "BiologicallyActiveSubstance"}]}{"id": "111_4", "text": "In total, 144 caregiver-patient pairs observed annually for up to 8 years were included in the study.", "tags": [{"end": 55, "start": 47, "tag": "TemporalConcept"}, {"end": 73, "start": 66, "tag": "TemporalConcept"}, {"end": 37, "start": 14, "tag": "PopulationGroup"}, {"end": 100, "start": 95, "tag": "ResearchActivity"}, {"end": 23, "start": 14, "tag": "HealthCareActivity"}]}{"id": "111_5", "text": "In all of the patients, demographic data were collected, Unified Huntington's Disease Rating Scale (UHDRS) assessments were conducted, and disease burden (DB) was calculated when caregivers were assessed in Caregiver Burden Inventory (CBI).", "tags": [{"end": 40, "start": 24, "tag": "ResearchActivity"}, {"end": 153, "start": 139, "tag": "ResearchActivity"}, {"end": 157, "start": 155, "tag": "ResearchActivity"}, {"end": 22, "start": 14, "tag": "PatientOrDisabledGroup"}, {"end": 98, "start": 57, "tag": "HealthCareActivity"}, {"end": 105, "start": 100, "tag": "HealthCareActivity"}, {"end": 238, "start": 235, "tag": "HealthCareActivity"}, {"end": 223, "start": 207, "tag": "BiologicFunction"}, {"end": 233, "start": 207, "tag": "HealthCareActivity"}, {"end": 189, "start": 179, "tag": "HealthCareActivity"}]}{"id": "111_6", "text": "Caregivers' burden measured in CBI at the first visit reached 18.7 +/- 18.4 scores.", "tags": [{"end": 18, "start": 0, "tag": "BiologicFunction"}, {"end": 34, "start": 31, "tag": "HealthCareActivity"}]}{"id": "111_7", "text": "Longitudinal observation showed no evidence for any discrepancy between clinical progression measured in UHDRS, nor biological progression measured in DB and the caregivers' burden progression measured in CBI.", "tags": [{"end": 63, "start": 32, "tag": "Finding"}, {"end": 24, "start": 0, "tag": "HealthCareActivity"}, {"end": 138, "start": 116, "tag": "TemporalConcept"}, {"end": 153, "start": 151, "tag": "ResearchActivity"}, {"end": 180, "start": 162, "tag": "BiologicFunction"}, {"end": 192, "start": 162, "tag": "ResearchActivity"}, {"end": 92, "start": 72, "tag": "TemporalConcept"}, {"end": 110, "start": 105, "tag": "HealthCareActivity"}, {"end": 208, "start": 205, "tag": "HealthCareActivity"}]}{"id": "111_8", "text": "Caregivers were burdened mostly by patients' dependence and a discrepancy between reality and life expectations.", "tags": [{"end": 44, "start": 35, "tag": "PopulationGroup"}, {"end": 73, "start": 62, "tag": "Finding"}, {"end": 55, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 0, "tag": "HealthCareActivity"}]}{"id": "111_9", "text": "This study indicates factors to be addressed to reduce caregivers' burden.", "tags": [{"end": 73, "start": 55, "tag": "BiologicFunction"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}]}{"id": "111_10", "text": "Strict relation between caregivers' burden and biological and clinical progression denies conception of overloaded with care tasks or adaptation to the burden.", "tags": [{"end": 144, "start": 134, "tag": "BiologicFunction"}, {"end": 158, "start": 134, "tag": "Finding"}, {"end": 42, "start": 24, "tag": "BiologicFunction"}, {"end": 130, "start": 120, "tag": "HealthCareActivity"}, {"end": 130, "start": 104, "tag": "Finding"}, {"end": 82, "start": 62, "tag": "TemporalConcept"}, {"end": 100, "start": 90, "tag": "BiologicFunction"}]}{"id": "112_0", "text": "Huntington's disease (HD), as well as Parkinson's disease and Alzheimer's disease, belong to a group of neurodegenerative diseases characterized by common features, such as the progressive loss of neurons and the presence of pathogenic forms of misfolded protein aggregates.", "tags": [{"end": 57, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 204, "start": 197, "tag": "Cell"}, {"end": 273, "start": 255, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 273, "start": 245, "tag": "CellOrMolecularDysfunction"}, {"end": 130, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 204, "start": 189, "tag": "CellOrMolecularDysfunction"}]}{"id": "112_1", "text": "A quality control system such as autophagy is crucial for the clearance of protein aggregates and dysfunctional organelles and thus essential for the maintenance of neuronal homeostasis.", "tags": [{"end": 71, "start": 62, "tag": "NaturalPhenomenonOrProcess"}, {"end": 93, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 98, "tag": "CellOrMolecularDysfunction"}, {"end": 122, "start": 112, "tag": "CellComponent"}, {"end": 161, "start": 150, "tag": "BiologicFunction"}, {"end": 42, "start": 33, "tag": "CellFunction"}, {"end": 185, "start": 165, "tag": "CellFunction"}]}{"id": "112_2", "text": "The constant high energy demand of neuronal tissue links neurodegeneration to mitochondria.", "tags": [{"end": 50, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 78, "tag": "CellComponent"}, {"end": 74, "start": 57, "tag": "CellOrMolecularDysfunction"}]}{"id": "112_3", "text": "Inefficient removal of damaged mitochondria is thought to contribute to the pathogenesis of neurodegenerative diseases such as HD.", "tags": [{"end": 19, "start": 0, "tag": "Finding"}, {"end": 88, "start": 76, "tag": "PathologicFunction"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 31, "tag": "CellComponent"}, {"end": 118, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 23, "tag": "CellOrMolecularDysfunction"}]}{"id": "112_4", "text": "In addition, direct involvement of the huntingtin protein in the autophagic machinery has been described.", "tags": [{"end": 85, "start": 65, "tag": "CellFunction"}, {"end": 57, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 13, "tag": "Finding"}]}{"id": "112_5", "text": "In this review, we focus on mitophagy, a selective form of autophagy responsible for mitochondrial turnover.", "tags": [{"end": 37, "start": 28, "tag": "CellFunction"}, {"end": 107, "start": 85, "tag": "CellFunction"}, {"end": 68, "start": 59, "tag": "CellFunction"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "112_6", "text": "We also discuss the relevance of pharmacological regulation of mitophagy in the future therapeutic approach to neurodegenerations, including HD.", "tags": [{"end": 72, "start": 63, "tag": "CellFunction"}, {"end": 107, "start": 87, "tag": "HealthCareActivity"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 111, "tag": "CellOrMolecularDysfunction"}, {"end": 59, "start": 33, "tag": "HealthCareActivity"}]}{"id": "113_0", "text": "While the root causes for individual neurodegenerative diseases are distinct, many shared pathological features and mechanisms contribute to neurodegeneration across diseases.", "tags": [{"end": 158, "start": 141, "tag": "CellOrMolecularDysfunction"}, {"end": 63, "start": 37, "tag": "DiseaseOrSyndrome"}]}{"id": "113_1", "text": "Altered levels of microRNAs, small non-coding RNAs involved in post transcriptional regulation of gene expression, are reported for numerous neurodegenerative diseases.", "tags": [{"end": 50, "start": 29, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 113, "start": 63, "tag": "CellFunction"}, {"end": 14, "start": 0, "tag": "Finding"}, {"end": 27, "start": 18, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 27, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 167, "start": 141, "tag": "DiseaseOrSyndrome"}]}{"id": "113_2", "text": "Yet, comparison between diseases to uncover commonly dysregulated microRNAs during neurodegeneration in general is lagging.", "tags": [{"end": 15, "start": 5, "tag": "ResearchActivity"}, {"end": 65, "start": 53, "tag": "PathologicFunction"}, {"end": 75, "start": 66, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 75, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 83, "tag": "CellOrMolecularDysfunction"}]}{"id": "113_3", "text": "We performed a systematic review of peer-reviewed publications describing differential microRNA expression in neurodegenerative diseases and related animal models.", "tags": [{"end": 32, "start": 15, "tag": "ResearchActivity"}, {"end": 95, "start": 87, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 106, "start": 74, "tag": "Finding"}, {"end": 106, "start": 87, "tag": "CellFunction"}, {"end": 162, "start": 149, "tag": "ManufacturedObject"}, {"end": 62, "start": 36, "tag": "ResearchActivity"}, {"end": 136, "start": 110, "tag": "DiseaseOrSyndrome"}]}{"id": "113_4", "text": "We compiled the results from studies covering the prevalent neurodegenerative diseases in the literature: Alzheimer's disease, amyotrophic lateral sclerosis, age-related macular degeneration, ataxia, dementia, myotonic dystrophy, epilepsy, glaucoma, Huntington's disease, multiple sclerosis, Parkinson's disease, and prion disorders.", "tags": [{"end": 125, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 192, "tag": "SignOrSymptom"}, {"end": 198, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 240, "tag": "DiseaseOrSyndrome"}, {"end": 290, "start": 272, "tag": "DiseaseOrSyndrome"}, {"end": 311, "start": 292, "tag": "DiseaseOrSyndrome"}, {"end": 332, "start": 317, "tag": "DiseaseOrSyndrome"}, {"end": 238, "start": 230, "tag": "DiseaseOrSyndrome"}, {"end": 238, "start": 230, "tag": "PathologicFunction"}, {"end": 270, "start": 250, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 29, "tag": "ResearchActivity"}]}{"id": "113_5", "text": "MicroRNAs which were dysregulated most often in these diseases and their models included miR-9-5p, miR-21-5p, the miR-29 family, miR-132-3p, miR-124-3p, miR-146a-5p, miR-155-5p, and miR-223-3p.", "tags": [{"end": 9, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 33, "start": 21, "tag": "PathologicFunction"}, {"end": 79, "start": 73, "tag": "ManufacturedObject"}, {"end": 151, "start": 141, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 97, "start": 89, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 108, "start": 99, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 127, "start": 114, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 139, "start": 129, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 192, "start": 182, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 97, "start": 89, "tag": "GeneOrGenome"}, {"end": 108, "start": 99, "tag": "GeneOrGenome"}, {"end": 127, "start": 114, "tag": "GeneOrGenome"}, {"end": 139, "start": 129, "tag": "GeneOrGenome"}, {"end": 151, "start": 141, "tag": "GeneOrGenome"}, {"end": 164, "start": 153, "tag": "GeneOrGenome"}, {"end": 164, "start": 153, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 176, "start": 166, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 176, "start": 166, "tag": "GeneOrGenome"}, {"end": 192, "start": 182, "tag": "GeneOrGenome"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "113_6", "text": "Common pathways targeted by these predominant miRNAs were identified and revealed great functional overlap across diseases.", "tags": [{"end": 15, "start": 7, "tag": "CellFunction"}, {"end": 52, "start": 46, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 106, "start": 88, "tag": "Finding"}]}{"id": "113_7", "text": "We also identified a strong role for each microRNA in both the neural and immune components of diseases.", "tags": [{"end": 50, "start": 42, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 50, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 74, "tag": "BiologicFunction"}, {"end": 91, "start": 63, "tag": "BiologicFunction"}, {"end": 32, "start": 21, "tag": "Finding"}]}{"id": "113_8", "text": "microRNAs regulate broad networks of genes and identifying microRNAs commonly dysregulated across neurodegenerative diseases could cultivate novel hypotheses related to common molecular mechanisms underlying neurodegeneration.", "tags": [{"end": 42, "start": 10, "tag": "Finding"}, {"end": 90, "start": 78, "tag": "PathologicFunction"}, {"end": 9, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 68, "start": 59, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 225, "start": 208, "tag": "CellOrMolecularDysfunction"}, {"end": 124, "start": 98, "tag": "DiseaseOrSyndrome"}]}{"id": "114_0", "text": "Huntington disease (HD) is a neurodegenerative disease associated with polyglutamine expansion in the protein huntingtin (HTT).", "tags": [{"end": 54, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 71, "tag": "PathologicFunction"}, {"end": 120, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 122, "tag": "GeneOrGenome"}, {"end": 125, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "114_1", "text": "Although the length of the polyglutamine repeat correlates with age at disease onset and severity, psychological, cognitive and behavioral complications point to the existence of disease modifiers.", "tags": [{"end": 84, "start": 71, "tag": "TemporalConcept"}, {"end": 152, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 89, "tag": "ClinicalAttribute"}, {"end": 67, "start": 64, "tag": "OrganismAttribute"}]}{"id": "114_2", "text": "Mitochondrial dysfunction and metabolic deregulation are both associated with the HD but, despite multi-omics characterization of patients and model systems, their mechanisms have remained elusive.", "tags": [{"end": 25, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 52, "start": 30, "tag": "CellOrMolecularDysfunction"}, {"end": 126, "start": 98, "tag": "ResearchActivity"}, {"end": 156, "start": 143, "tag": "ResearchActivity"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 130, "tag": "PatientOrDisabledGroup"}]}{"id": "114_3", "text": "Systems analysis of multiomics data and its validation by using a yeast model could help to elucidate pathways that modulate protein aggregation.", "tags": [{"end": 54, "start": 44, "tag": "ResearchActivity"}, {"end": 77, "start": 66, "tag": "ResearchActivity"}, {"end": 110, "start": 102, "tag": "CellFunction"}, {"end": 35, "start": 20, "tag": "ResearchActivity"}, {"end": 16, "start": 0, "tag": "ResearchActivity"}, {"end": 144, "start": 125, "tag": "CellFunction"}, {"end": 144, "start": 125, "tag": "CellOrMolecularDysfunction"}]}{"id": "114_4", "text": "Metabolomics analysis of HD patients and of a yeast model of HD was, therefore, carried out.", "tags": [{"end": 21, "start": 0, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 36, "start": 25, "tag": "PatientOrDisabledGroup"}, {"end": 63, "start": 46, "tag": "ExperimentalModelOfDisease"}]}{"id": "114_5", "text": "Our analysis showed a considerable overlap of deregulated metabolic pathways.", "tags": [{"end": 76, "start": 58, "tag": "CellFunction"}, {"end": 42, "start": 22, "tag": "Finding"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}]}{"id": "114_6", "text": "Further, the multi-omics analysis showed deregulated pathways common in human, mice and yeast model systems, and those that are unique to them.", "tags": [{"end": 83, "start": 79, "tag": "Eukaryote"}, {"end": 33, "start": 13, "tag": "ResearchActivity"}, {"end": 33, "start": 25, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "Eukaryote"}, {"end": 107, "start": 88, "tag": "ResearchActivity"}]}{"id": "114_7", "text": "The deregulated pathways include metabolic pathways of various amino acids, glutathione metabolism, longevity, autophagy and mitophagy.", "tags": [{"end": 51, "start": 33, "tag": "CellFunction"}, {"end": 74, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 76, "tag": "CellFunction"}, {"end": 109, "start": 100, "tag": "TemporalConcept"}, {"end": 134, "start": 125, "tag": "CellFunction"}, {"end": 120, "start": 111, "tag": "CellFunction"}, {"end": 24, "start": 4, "tag": "CellOrMolecularDysfunction"}]}{"id": "114_8", "text": "The addition of certainmetabolites as well as gene knockouts targeting the deregulated metabolic and autophagy pathways in the yeast model system showed that these pathways do modulate protein aggregation.", "tags": [{"end": 60, "start": 46, "tag": "ResearchActivity"}, {"end": 172, "start": 164, "tag": "CellFunction"}, {"end": 145, "start": 127, "tag": "ResearchActivity"}, {"end": 204, "start": 185, "tag": "CellFunction"}, {"end": 204, "start": 185, "tag": "CellOrMolecularDysfunction"}, {"end": 110, "start": 101, "tag": "CellFunction"}, {"end": 119, "start": 111, "tag": "CellOrMolecularDysfunction"}, {"end": 96, "start": 75, "tag": "CellOrMolecularDysfunction"}]}{"id": "114_9", "text": "Taken together, our results showed that the modulation of deregulated pathways influences protein aggregation in HD, and has implications for progression and prognosis.", "tags": [{"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 158, "tag": "HealthCareActivity"}, {"end": 153, "start": 142, "tag": "PathologicFunction"}, {"end": 153, "start": 142, "tag": "TemporalConcept"}, {"end": 109, "start": 90, "tag": "CellFunction"}, {"end": 109, "start": 90, "tag": "CellOrMolecularDysfunction"}, {"end": 78, "start": 58, "tag": "CellOrMolecularDysfunction"}]}{"id": "115_0", "text": "The distinguishing pathogenic features of neurodegenerative diseases include mitochondrial dysfunction and derived reactive oxygen species generation.", "tags": [{"end": 102, "start": 77, "tag": "CellOrMolecularDysfunction"}, {"end": 138, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 115, "tag": "BiologicFunction"}, {"end": 138, "start": 115, "tag": "Chemical"}, {"end": 68, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 19, "tag": "PathologicFunction"}]}{"id": "115_1", "text": "The neural tissue is highly sensitive to oxidative stress and this is a prominent factor in both chronic and acute neurodegeneration.", "tags": [{"end": 17, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 97, "tag": "TemporalConcept"}, {"end": 114, "start": 109, "tag": "TemporalConcept"}, {"end": 132, "start": 115, "tag": "CellOrMolecularDysfunction"}, {"end": 57, "start": 41, "tag": "CellOrMolecularDysfunction"}]}{"id": "115_2", "text": "Based on this, therapeutic strategies using antioxidant molecules towards redox equilibrium have been widely used for the treatment of several brain pathologies.", "tags": [{"end": 91, "start": 74, "tag": "BiologicFunction"}, {"end": 160, "start": 143, "tag": "PathologicFunction"}, {"end": 131, "start": 122, "tag": "HealthCareActivity"}, {"end": 131, "start": 122, "tag": "ResearchActivity"}, {"end": 37, "start": 15, "tag": "HealthCareActivity"}, {"end": 65, "start": 44, "tag": "PharmacologicSubstance"}]}{"id": "115_3", "text": "Globally, polyphenols, carotenes and vitamins are among the most typical exogenous antioxidant agents that have been tested in neurodegeneration as adjunctive therapies.", "tags": [{"end": 32, "start": 23, "tag": "Chemical"}, {"end": 45, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 73, "tag": "PharmacologicSubstance"}, {"end": 168, "start": 148, "tag": "HealthCareActivity"}, {"end": 32, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 127, "tag": "CellOrMolecularDysfunction"}, {"end": 21, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 21, "start": 10, "tag": "Chemical"}]}{"id": "115_4", "text": "However, other types of antioxidants, including hormones, such as the widely used melatonin, are also considered neuroprotective agents and have been used in different neurodegenerative contexts.", "tags": [{"end": 56, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 113, "tag": "PharmacologicSubstance"}, {"end": 194, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 24, "tag": "PharmacologicSubstance"}, {"end": 91, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 82, "tag": "PharmacologicSubstance"}, {"end": 91, "start": 82, "tag": "Chemical"}]}{"id": "115_5", "text": "This review highlights the most relevant mitochondrial antioxidant targets in the main neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, and Huntington's disease and also in the less represented amyotrophic lateral sclerosis, as well as traumatic brain injury, while summarizing the latest randomized placebo-controlled trials.", "tags": [{"end": 54, "start": 41, "tag": "CellComponent"}, {"end": 144, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 254, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 289, "start": 267, "tag": "InjuryOrPoisoning"}, {"end": 356, "start": 320, "tag": "ResearchActivity"}, {"end": 74, "start": 41, "tag": "Finding"}, {"end": 319, "start": 313, "tag": "TemporalConcept"}, {"end": 191, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}]}{"id": "116_0", "text": "Introduction Huntington's disease is a neurodegenerative disease that is characterized by motor dysfunction, behavioral/psychiatric symptoms, and cognitive impairment.", "tags": [{"end": 64, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 109, "tag": "SignOrSymptom"}, {"end": 33, "start": 13, "tag": "DiseaseOrSyndrome"}]}{"id": "116_1", "text": "Because of the lack of availability of curative or disease modifying treatments, much of clinical practice in HD care to date has focused on symptomatic treatment.", "tags": [{"end": 79, "start": 51, "tag": "HealthCareActivity"}, {"end": 125, "start": 118, "tag": "TemporalConcept"}, {"end": 162, "start": 141, "tag": "HealthCareActivity"}, {"end": 117, "start": 110, "tag": "HealthCareActivity"}, {"end": 106, "start": 89, "tag": "HealthCareActivity"}, {"end": 79, "start": 69, "tag": "HealthCareActivity"}, {"end": 47, "start": 39, "tag": "HealthCareActivity"}]}{"id": "116_2", "text": "Recent work has created optimism surrounding possible emerging disease modifying therapeutics.", "tags": [{"end": 32, "start": 24, "tag": "BiologicFunction"}, {"end": 93, "start": 63, "tag": "HealthCareActivity"}]}{"id": "116_3", "text": "HD is a developing therapeutic field with diverse and promising emerging therapies.", "tags": [{"end": 36, "start": 8, "tag": "ResearchActivity"}, {"end": 82, "start": 54, "tag": "HealthCareActivity"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "116_4", "text": "Areas covered A PubMed literature review was completed to discover pertinent reviews and analyses.", "tags": [{"end": 84, "start": 77, "tag": "HealthCareActivity"}, {"end": 40, "start": 16, "tag": "ResearchActivity"}, {"end": 84, "start": 77, "tag": "ResearchActivity"}, {"end": 22, "start": 16, "tag": "HealthCareRelatedOrganization"}]}{"id": "116_5", "text": "ClinicalTrials.gov was referenced to find updated information about ongoing and planned trials.", "tags": [{"end": 18, "start": 0, "tag": "HealthCareRelatedOrganization"}]}{"id": "116_6", "text": "Lastly, because of the rapidly evolving nature of HD treatments, drug manufacturer websites and press releases were reviewed to provide current information surrounding recently reported trial results.", "tags": [{"end": 63, "start": 50, "tag": "HealthCareActivity"}, {"end": 110, "start": 96, "tag": "ResearchActivity"}, {"end": 199, "start": 186, "tag": "ResearchActivity"}, {"end": 91, "start": 65, "tag": "HealthCareRelatedOrganization"}, {"end": 143, "start": 136, "tag": "TemporalConcept"}, {"end": 69, "start": 65, "tag": "PharmacologicSubstance"}]}{"id": "116_7", "text": "Expert opinion Recent setbacks involving antisense oligonucleotide research should not diminish enthusiasm and hope for the many other novel therapies currently being pursued.", "tags": [{"end": 75, "start": 67, "tag": "ResearchActivity"}, {"end": 106, "start": 96, "tag": "BiologicFunction"}, {"end": 150, "start": 141, "tag": "HealthCareActivity"}, {"end": 66, "start": 41, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 66, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 41, "tag": "Chemical"}, {"end": 115, "start": 111, "tag": "BiologicFunction"}, {"end": 160, "start": 151, "tag": "TemporalConcept"}]}{"id": "116_8", "text": "We remain optimistic about the many promising emerging therapies for HD, and we expect that growing knowledge about the pathophysiology of the underlying disease and constant advances in biotechnology will lead to therapies that have a meaningful impact in the lives of patients, their families, and those who care for them.", "tags": [{"end": 64, "start": 36, "tag": "HealthCareActivity"}, {"end": 135, "start": 120, "tag": "PathologicFunction"}, {"end": 200, "start": 187, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 223, "start": 214, "tag": "HealthCareActivity"}, {"end": 294, "start": 286, "tag": "PopulationGroup"}, {"end": 174, "start": 166, "tag": "TemporalConcept"}, {"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 278, "start": 270, "tag": "PatientOrDisabledGroup"}, {"end": 109, "start": 92, "tag": "Finding"}]}{"id": "117_0", "text": "Huntington disease is a rare genetic disorder characterized by motor, cognitive, and psychiatric impairments.", "tags": [{"end": 44, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 97, "tag": "SignOrSymptom"}, {"end": 68, "start": 63, "tag": "SignOrSymptom"}]}{"id": "117_1", "text": "Although the typical patient has a positive family history and initially presents with chorea between ages 30 and 50 years, some patients do not have a typical presentation.", "tags": [{"end": 58, "start": 35, "tag": "Finding"}, {"end": 122, "start": 107, "tag": "TemporalConcept"}, {"end": 172, "start": 152, "tag": "ClinicalAttribute"}, {"end": 93, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 87, "tag": "SignOrSymptom"}, {"end": 28, "start": 21, "tag": "PatientOrDisabledGroup"}, {"end": 137, "start": 129, "tag": "PatientOrDisabledGroup"}]}{"id": "117_2", "text": "Healthcare providers should know when to refer patients to neurology for testing for Huntington disease.", "tags": [{"end": 20, "start": 0, "tag": "HealthCareRelatedOrganization"}, {"end": 68, "start": 59, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 80, "start": 73, "tag": "HealthCareActivity"}, {"end": 103, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 47, "tag": "PatientOrDisabledGroup"}]}{"id": "117_3", "text": "The earlier the diagnosis is made, the earlier the patient and patient's family can receive education about the expected disease trajectory.", "tags": [{"end": 25, "start": 16, "tag": "HealthCareActivity"}, {"end": 79, "start": 63, "tag": "PopulationGroup"}, {"end": 101, "start": 92, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 58, "start": 51, "tag": "PatientOrDisabledGroup"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}, {"end": 46, "start": 39, "tag": "TemporalConcept"}]}{"id": "117_4", "text": "A multidisciplinary approach is required to mitigate symptoms as the disease progresses.", "tags": [{"end": 61, "start": 53, "tag": "SignOrSymptom"}, {"end": 28, "start": 2, "tag": "ResearchActivity"}]}{"id": "117_5", "text": "Although no cure exists, ongoing research is targeting genotypic abnormalities in hopes of finding a permanent treatment for Huntington disease.", "tags": [{"end": 16, "start": 9, "tag": "Finding"}, {"end": 41, "start": 33, "tag": "ResearchActivity"}, {"end": 78, "start": 55, "tag": "CellOrMolecularDysfunction"}, {"end": 120, "start": 101, "tag": "HealthCareActivity"}, {"end": 143, "start": 125, "tag": "DiseaseOrSyndrome"}]}{"id": "118_0", "text": "Background: Parkinson's disease (PD) and Huntington's disease (HD) are two neurodegenerative diseases affecting frontal-striatal function and memory ability.", "tags": [{"end": 31, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 112, "tag": "BiologicFunction"}, {"end": 156, "start": 142, "tag": "BiologicFunction"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 75, "tag": "DiseaseOrSyndrome"}]}{"id": "118_1", "text": "Studies using the original California Verbal Learning Test (CVLT) to examine recall and recognition abilities between these groups have produced mixed findings.", "tags": [{"end": 64, "start": 60, "tag": "HealthCareActivity"}, {"end": 83, "start": 77, "tag": "BiologicFunction"}, {"end": 109, "start": 88, "tag": "BiologicFunction"}, {"end": 58, "start": 27, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}{"id": "118_2", "text": "Some found that individuals with HD demonstrate worse recall and recognition than those with PD, whereas others reported comparable performance.", "tags": [{"end": 60, "start": 54, "tag": "BiologicFunction"}, {"end": 76, "start": 65, "tag": "BiologicFunction"}, {"end": 95, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 121, "tag": "Finding"}, {"end": 143, "start": 132, "tag": "ClinicalAttribute"}, {"end": 35, "start": 16, "tag": "PatientOrDisabledGroup"}, {"end": 60, "start": 48, "tag": "Finding"}]}{"id": "118_3", "text": "Objective: We utilized multiple indices of recall and recognition discriminability, provided by the second and third editions of the CVLT (CVLT-II and CVLT-3, respectively), that allow for a more thorough assessment of more nuanced aspects of verbal memory function.", "tags": [{"end": 49, "start": 43, "tag": "BiologicFunction"}, {"end": 137, "start": 133, "tag": "HealthCareActivity"}, {"end": 265, "start": 243, "tag": "BiologicFunction"}, {"end": 82, "start": 54, "tag": "BiologicFunction"}, {"end": 146, "start": 139, "tag": "HealthCareActivity"}, {"end": 157, "start": 151, "tag": "HealthCareActivity"}]}{"id": "118_4", "text": "Methods: We examined differences between individuals with PD (n = 72) and those with HD (n = 77) on CVLT-II indices of recall discriminability (immediate, short delay free and cued, long delay free and cued) and recognition discriminability (total, source, semantic, and novel) using standardized scores while controlling for education and Dementia Rating Scale-2 scores.", "tags": [{"end": 60, "start": 41, "tag": "PatientOrDisabledGroup"}, {"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 335, "start": 326, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 107, "start": 100, "tag": "HealthCareActivity"}, {"end": 142, "start": 119, "tag": "BiologicFunction"}, {"end": 363, "start": 340, "tag": "HealthCareActivity"}, {"end": 180, "start": 144, "tag": "HealthCareActivity"}, {"end": 206, "start": 182, "tag": "HealthCareActivity"}, {"end": 240, "start": 212, "tag": "BiologicFunction"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 276, "start": 242, "tag": "HealthCareActivity"}]}{"id": "118_5", "text": "Results: The HD group performed significantly worse than the PD group on all measures of recall and recognition discriminability (ps < 0.05), and group differences were associated with large Cohen's d effect sizes.", "tags": [{"end": 21, "start": 13, "tag": "PatientOrDisabledGroup"}, {"end": 69, "start": 61, "tag": "PatientOrDisabledGroup"}, {"end": 95, "start": 89, "tag": "BiologicFunction"}, {"end": 163, "start": 146, "tag": "Finding"}, {"end": 128, "start": 100, "tag": "BiologicFunction"}, {"end": 213, "start": 185, "tag": "ResearchActivity"}]}{"id": "118_6", "text": "Conclusions: Our findings suggest that individuals with HD are more impaired than individuals with PD in more nuanced aspects of recall and recognition memory function.", "tags": [{"end": 58, "start": 39, "tag": "PatientOrDisabledGroup"}, {"end": 76, "start": 63, "tag": "Finding"}, {"end": 135, "start": 129, "tag": "BiologicFunction"}, {"end": 167, "start": 140, "tag": "BiologicFunction"}, {"end": 101, "start": 82, "tag": "PatientOrDisabledGroup"}]}{"id": "118_7", "text": "These CVLT indices yield more thorough assessments of recall and recognition memory function and have the potential to improve efforts to characterize and distinguish profiles of memory loss in different neurodegenerative populations, including PD and HD.", "tags": [{"end": 10, "start": 6, "tag": "HealthCareActivity"}, {"end": 60, "start": 39, "tag": "HealthCareActivity"}, {"end": 60, "start": 54, "tag": "BiologicFunction"}, {"end": 92, "start": 65, "tag": "BiologicFunction"}, {"end": 175, "start": 167, "tag": "ResearchActivity"}, {"end": 190, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 179, "tag": "SignOrSymptom"}, {"end": 233, "start": 204, "tag": "DiseaseOrSyndrome"}, {"end": 247, "start": 245, "tag": "DiseaseOrSyndrome"}, {"end": 254, "start": 252, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 65, "tag": "HealthCareActivity"}, {"end": 50, "start": 39, "tag": "HealthCareActivity"}]}{"id": "119_0", "text": "Background Despite extensive research regarding the etiology of Huntington's disease, relatively little is known about the epidemiology of this rare disorder, particularly in the United States where there are no national-scale estimates of the disease.", "tags": [{"end": 37, "start": 29, "tag": "ResearchActivity"}, {"end": 60, "start": 52, "tag": "Finding"}, {"end": 135, "start": 123, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 157, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 179, "tag": "PopulationGroup"}, {"end": 236, "start": 212, "tag": "ResearchActivity"}, {"end": 84, "start": 64, "tag": "DiseaseOrSyndrome"}]}{"id": "119_1", "text": "Objectives To provide national-scale estimates of Huntington's disease in a U.S.", "tags": [{"end": 46, "start": 22, "tag": "ResearchActivity"}, {"end": 70, "start": 50, "tag": "DiseaseOrSyndrome"}]}{"id": "119_2", "text": "population and to test whether disease rates are increasing, and whether frequency varies by race, ethnicity, or other factors.", "tags": [{"end": 44, "start": 31, "tag": "Finding"}, {"end": 97, "start": 93, "tag": "PopulationGroup"}, {"end": 108, "start": 99, "tag": "PopulationGroup"}, {"end": 82, "start": 73, "tag": "TemporalConcept"}]}{"id": "119_3", "text": "Methods Using an insurance database of over 67 million enrollees, we retrospectively identified a cohort of 3,707 individuals diagnosed with Huntington's disease between 2003 and 2016.", "tags": [{"end": 104, "start": 98, "tag": "PopulationGroup"}, {"end": 26, "start": 17, "tag": "HealthCareRelatedOrganization"}, {"end": 161, "start": 114, "tag": "PatientOrDisabledGroup"}, {"end": 161, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 27, "tag": "ResearchActivity"}]}{"id": "119_4", "text": "We estimated annual incidence, annual diagnostic frequency, and tested for trends over time and differences in diagnostic frequency by sociodemographic characteristics.", "tags": [{"end": 29, "start": 13, "tag": "TemporalConcept"}, {"end": 58, "start": 31, "tag": "TemporalConcept"}, {"end": 81, "start": 75, "tag": "TemporalConcept"}, {"end": 91, "start": 87, "tag": "TemporalConcept"}, {"end": 107, "start": 96, "tag": "Finding"}, {"end": 131, "start": 111, "tag": "TemporalConcept"}, {"end": 167, "start": 135, "tag": "ResearchActivity"}]}{"id": "119_5", "text": "Results During the observation period, the age-adjusted cumulative incidence rate was1.22 per 100,000 persons (95% confidence interval: 1.53, 1.65), and age-adjusted diagnostic frequency was 6.52 per 100,000 persons (95% confidence interval: 5.31, 5.66); both rates remained relatively stable over the 14-year period.", "tags": [{"end": 37, "start": 19, "tag": "TemporalConcept"}, {"end": 109, "start": 102, "tag": "PopulationGroup"}, {"end": 215, "start": 208, "tag": "PopulationGroup"}, {"end": 316, "start": 310, "tag": "TemporalConcept"}, {"end": 81, "start": 43, "tag": "TemporalConcept"}, {"end": 134, "start": 115, "tag": "ResearchActivity"}, {"end": 240, "start": 221, "tag": "ResearchActivity"}, {"end": 186, "start": 153, "tag": "TemporalConcept"}]}{"id": "119_6", "text": "We identified several previously unreported differences in Huntington's disease frequency by self-reported sex, income, and race/ethnicity.", "tags": [{"end": 13, "start": 3, "tag": "Finding"}, {"end": 118, "start": 112, "tag": "OrganismAttribute"}, {"end": 138, "start": 124, "tag": "PopulationGroup"}, {"end": 89, "start": 80, "tag": "TemporalConcept"}, {"end": 79, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 107, "tag": "OrganismAttribute"}]}{"id": "119_7", "text": "However, racial/ethnic differences were of lower magnitude than have previously been reported in other country-level studies.", "tags": [{"end": 34, "start": 9, "tag": "Finding"}, {"end": 124, "start": 103, "tag": "ResearchActivity"}]}{"id": "119_8", "text": "Conclusions In these large-scale estimates of U.S.", "tags": [{"end": 50, "start": 46, "tag": "PopulationGroup"}, {"end": 42, "start": 21, "tag": "ResearchActivity"}]}{"id": "119_9", "text": "Huntington's disease epidemiology, we found stable disease frequency rates that varied by several sociodemographic factors.", "tags": [{"end": 33, "start": 21, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 74, "start": 44, "tag": "Finding"}, {"end": 74, "start": 59, "tag": "TemporalConcept"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 98, "tag": "Finding"}]}{"id": "119_10", "text": "These findings suggest that disease patterns may be more driven by social or environmental factors than has previously been appreciated.", "tags": [{"end": 98, "start": 77, "tag": "NaturalPhenomenonOrProcess"}, {"end": 98, "start": 77, "tag": "EnvironmentalEffectOfHumans"}]}{"id": "119_11", "text": "Results further demonstrate the potential utility of administrative Big Data in rare disease epidemiology when other data sources are unavailable.", "tags": [{"end": 92, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 93, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 76, "start": 53, "tag": "ResearchActivity"}, {"end": 129, "start": 117, "tag": "ResearchActivity"}]}{"id": "119_12", "text": "(c) 2019 International Parkinson and Movement Disorder Society", "tags": [{"end": 62, "start": 9, "tag": "HealthCareRelatedOrganization"}]}{"id": "120_0", "text": "Objective Huntington disease (HD) is an autosomal dominant neurodegenerative disease involving motor disturbances, cognitive decline and psychiatric symptoms.", "tags": [{"end": 84, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 137, "tag": "SignOrSymptom"}, {"end": 58, "start": 40, "tag": "CellFunction"}, {"end": 132, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 10, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 95, "tag": "SignOrSymptom"}]}{"id": "120_1", "text": "Psychotic symptoms occur in a significant proportion of patients.", "tags": [{"end": 18, "start": 0, "tag": "SignOrSymptom"}, {"end": 64, "start": 56, "tag": "PatientOrDisabledGroup"}]}{"id": "120_2", "text": "We sought to characterise the clinical outcomes of this group of patients.", "tags": [{"end": 73, "start": 56, "tag": "PatientOrDisabledGroup"}, {"end": 47, "start": 30, "tag": "ClinicalAttribute"}]}{"id": "120_3", "text": "Methods Data were drawn from the Cooperative Huntington Observational Research Trial, a prospective, multi-centre observational study.", "tags": [{"end": 12, "start": 8, "tag": "ResearchActivity"}, {"end": 133, "start": 88, "tag": "ResearchActivity"}, {"end": 99, "start": 88, "tag": "BiologicFunction"}, {"end": 84, "start": 33, "tag": "HealthCareRelatedOrganization"}, {"end": 84, "start": 33, "tag": "ResearchActivity"}]}{"id": "120_4", "text": "1082 patients with HD were recruited.", "tags": [{"end": 21, "start": 5, "tag": "PatientOrDisabledGroup"}]}{"id": "120_5", "text": "Measures of cognition, function, behavioural disturbance and motor function were completed annually over 5 years.", "tags": [{"end": 21, "start": 12, "tag": "BiologicFunction"}, {"end": 56, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 91, "tag": "TemporalConcept"}, {"end": 112, "start": 105, "tag": "TemporalConcept"}, {"end": 75, "start": 61, "tag": "BiologicFunction"}]}{"id": "120_6", "text": "Results Overall, 190 patients (17.6%) displayed psychotic symptoms.", "tags": [{"end": 66, "start": 48, "tag": "SignOrSymptom"}, {"end": 29, "start": 21, "tag": "PatientOrDisabledGroup"}]}{"id": "120_7", "text": "These patients demonstrated worse cognition, function and behavioural disturbances than patients without psychosis over time.", "tags": [{"end": 43, "start": 28, "tag": "Finding"}, {"end": 43, "start": 34, "tag": "BiologicFunction"}, {"end": 82, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 120, "tag": "TemporalConcept"}, {"end": 14, "start": 6, "tag": "PatientOrDisabledGroup"}, {"end": 96, "start": 88, "tag": "PatientOrDisabledGroup"}]}{"id": "120_8", "text": "Patients with psychosis also demonstrated lower levels of chorea than patients without psychosis, despite adjusting for concurrent antipsychotic and tetrabenazine use.", "tags": [{"end": 23, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 120, "tag": "TemporalConcept"}, {"end": 144, "start": 131, "tag": "PharmacologicSubstance"}, {"end": 64, "start": 42, "tag": "Finding"}, {"end": 64, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 58, "tag": "SignOrSymptom"}, {"end": 78, "start": 70, "tag": "PatientOrDisabledGroup"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 162, "start": 149, "tag": "PharmacologicSubstance"}, {"end": 162, "start": 149, "tag": "Chemical"}]}{"id": "120_9", "text": "Conclusions Psychosis in HD is associated with poorer outcomes in cognition, function and behavioural symptoms.", "tags": [{"end": 21, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 47, "tag": "Finding"}, {"end": 75, "start": 66, "tag": "BiologicFunction"}, {"end": 110, "start": 90, "tag": "SignOrSymptom"}, {"end": 27, "start": 25, "tag": "DiseaseOrSyndrome"}]}{"id": "120_10", "text": "Patients with psychotic symptoms may also have less chorea.", "tags": [{"end": 32, "start": 14, "tag": "SignOrSymptom"}, {"end": 58, "start": 47, "tag": "Finding"}, {"end": 58, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 52, "tag": "SignOrSymptom"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}]}{"id": "120_11", "text": "Altogether, the findings suggest patients with psychosis have a distinct clinical course.", "tags": [{"end": 56, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 73, "tag": "TemporalConcept"}, {"end": 88, "start": 64, "tag": "Finding"}, {"end": 41, "start": 33, "tag": "PatientOrDisabledGroup"}]}{"id": "121_0", "text": "Neurodegenerative diseases (NDDs), such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are disorders, which cause irreversible and progressive deterioration of the central nervous system.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 188, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 180, "start": 138, "tag": "Finding"}, {"end": 109, "start": 89, "tag": "DiseaseOrSyndrome"}]}{"id": "121_1", "text": "The pathophysiology of NDDs is still not fully explained; nevertheless, oxidative stress is considered as a critical mediator of cerebral degeneration, brain inflammation, as well as neuronal apoptosis.", "tags": [{"end": 19, "start": 4, "tag": "PathologicFunction"}, {"end": 27, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 129, "tag": "PathologicFunction"}, {"end": 191, "start": 183, "tag": "Cell"}, {"end": 201, "start": 192, "tag": "CellFunction"}, {"end": 170, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 152, "tag": "PathologicFunction"}, {"end": 88, "start": 72, "tag": "CellOrMolecularDysfunction"}]}{"id": "121_2", "text": "Therefore, it is not surprising that redox biomarkers are increasingly used in the diagnosis of neurodegenerative diseases.", "tags": [{"end": 42, "start": 37, "tag": "CellFunction"}, {"end": 53, "start": 43, "tag": "ClinicalAttribute"}, {"end": 92, "start": 83, "tag": "HealthCareActivity"}, {"end": 122, "start": 96, "tag": "DiseaseOrSyndrome"}]}{"id": "121_3", "text": "As saliva is a very easy to obtain bioliquid, it seems promising to use this biomaterial in the diagnosis of NDDs.", "tags": [{"end": 9, "start": 3, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 35, "tag": "Substance"}, {"end": 105, "start": 96, "tag": "HealthCareActivity"}, {"end": 113, "start": 109, "tag": "DiseaseOrSyndrome"}]}{"id": "121_4", "text": "Saliva collection is easy, cheap, stress-free, and non-infectious, and it does not require the help of a specialised medical personnel.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 0, "tag": "ResearchActivity"}, {"end": 134, "start": 105, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "121_5", "text": "Additionally, the concentrations of many salivary redox biomarkers correlate with their content in blood serum as well as the degree of disease progression, which makes them non-invasive indicators of NDDs.", "tags": [{"end": 49, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 50, "tag": "CellFunction"}, {"end": 66, "start": 56, "tag": "ClinicalAttribute"}, {"end": 110, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 174, "tag": "ClinicalAttribute"}, {"end": 197, "start": 174, "tag": "Chemical"}, {"end": 205, "start": 201, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 136, "tag": "PathologicFunction"}]}{"id": "121_6", "text": "This paper reviews the latest knowledge concerning the use of salivary redox biomarkers in the diagnosis and prognosis of selected neurodegenerative diseases.", "tags": [{"end": 18, "start": 11, "tag": "HealthCareActivity"}, {"end": 39, "start": 30, "tag": "Finding"}, {"end": 70, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 71, "tag": "CellFunction"}, {"end": 87, "start": 77, "tag": "ClinicalAttribute"}, {"end": 104, "start": 95, "tag": "HealthCareActivity"}, {"end": 29, "start": 23, "tag": "TemporalConcept"}, {"end": 157, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 109, "tag": "HealthCareActivity"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}]}{"id": "122_0", "text": "Neurodegenerative diseases represent a large group of disorders characterized by gradual loss of neurons and functions of the central nervous systems.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 97, "tag": "Cell"}, {"end": 149, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 89, "tag": "CellOrMolecularDysfunction"}]}{"id": "122_1", "text": "Their course is usually severe, leading to high morbidity and subsequent inability of patients to independent functioning.", "tags": [{"end": 12, "start": 6, "tag": "TemporalConcept"}, {"end": 30, "start": 24, "tag": "Finding"}, {"end": 57, "start": 48, "tag": "Finding"}, {"end": 94, "start": 86, "tag": "PatientOrDisabledGroup"}, {"end": 121, "start": 95, "tag": "Finding"}, {"end": 82, "start": 73, "tag": "Finding"}, {"end": 121, "start": 95, "tag": "Finding"}]}{"id": "122_2", "text": "Vast majority of neurodegenerative diseases is currently untreatable, and only some symptomatic drugs are available which efficacy is usually very limited.", "tags": [{"end": 101, "start": 84, "tag": "PharmacologicSubstance"}, {"end": 43, "start": 17, "tag": "DiseaseOrSyndrome"}]}{"id": "122_3", "text": "To develop novel therapies for this group of diseases, it is crucial to understand their pathogenesis and to recognize factors which can influence the disease course.", "tags": [{"end": 26, "start": 17, "tag": "HealthCareActivity"}, {"end": 101, "start": 89, "tag": "PathologicFunction"}, {"end": 165, "start": 151, "tag": "TemporalConcept"}]}{"id": "122_4", "text": "One of cellular structures which dysfunction appears to be relatively poorly understood in the light of neurodegenerative diseases is tubulin cytoskeleton.", "tags": [{"end": 26, "start": 7, "tag": "CellComponent"}, {"end": 141, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 142, "tag": "CellComponent"}, {"end": 44, "start": 33, "tag": "PathologicFunction"}, {"end": 130, "start": 104, "tag": "DiseaseOrSyndrome"}]}{"id": "122_5", "text": "On the other hand, its changes, both structural and functional, can considerably influence cell physiology, leading to pathological processes occurring also in neurons.", "tags": [{"end": 106, "start": 91, "tag": "CellFunction"}, {"end": 141, "start": 119, "tag": "PathologicFunction"}, {"end": 167, "start": 160, "tag": "Cell"}]}{"id": "122_6", "text": "In this review, we summarize and discuss dysfunctions of tubulin cytoskeleton in various neurodegenerative diseases different than primary tubulinopathies (caused by mutations in genes encoding the components of the tubulin cytoskeleton), especially Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, prion diseases, and neuronopathic mucopolysaccharidoses.", "tags": [{"end": 53, "start": 41, "tag": "PathologicFunction"}, {"end": 64, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 65, "tag": "CellComponent"}, {"end": 175, "start": 166, "tag": "CellFunction"}, {"end": 175, "start": 166, "tag": "CellOrMolecularDysfunction"}, {"end": 193, "start": 185, "tag": "BiologicFunction"}, {"end": 236, "start": 224, "tag": "CellComponent"}, {"end": 269, "start": 250, "tag": "DiseaseOrSyndrome"}, {"end": 290, "start": 271, "tag": "DiseaseOrSyndrome"}, {"end": 343, "start": 314, "tag": "DiseaseOrSyndrome"}, {"end": 359, "start": 345, "tag": "DiseaseOrSyndrome"}, {"end": 400, "start": 365, "tag": "DiseaseOrSyndrome"}, {"end": 312, "start": 292, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 154, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 216, "tag": "AminoAcidPeptideOrProtein"}, {"end": 223, "start": 216, "tag": "BiologicallyActiveSubstance"}]}{"id": "122_7", "text": "It is also proposed that correction of these disorders might attenuate the progress of specific diseases, thus, finding newly recognized molecular targets for potential drugs might become possible.", "tags": [{"end": 174, "start": 169, "tag": "PharmacologicSubstance"}, {"end": 83, "start": 75, "tag": "TemporalConcept"}]}{"id": "123_0", "text": "Ras homolog gene family member A (RhoA) is a small GTPase of the Rho family involved in regulating multiple signal transduction pathways that influence a diverse range of cellular functions.", "tags": [{"end": 32, "start": 0, "tag": "GeneOrGenome"}, {"end": 38, "start": 34, "tag": "GeneOrGenome"}, {"end": 38, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 65, "tag": "GeneOrGenome"}, {"end": 136, "start": 88, "tag": "CellFunction"}, {"end": 189, "start": 171, "tag": "CellFunction"}, {"end": 32, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 65, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "123_1", "text": "RhoA and many of its downstream effector proteins are highly expressed in the nervous system, implying an important role for RhoA signaling in neurons and glial cells.", "tags": [{"end": 4, "start": 0, "tag": "GeneOrGenome"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 61, "tag": "CellFunction"}, {"end": 92, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 143, "tag": "Cell"}, {"end": 166, "start": 155, "tag": "Cell"}, {"end": 49, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 125, "tag": "CellFunction"}]}{"id": "123_2", "text": "Indeed, emerging evidence points toward a role of aberrant RhoA signaling in neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis.", "tags": [{"end": 131, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 209, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 8, "tag": "Finding"}, {"end": 174, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 50, "tag": "CellOrMolecularDysfunction"}]}{"id": "123_3", "text": "In this review, we summarize the current knowledge of RhoA regulation and downstream cellular functions with an emphasis on the role of RhoA signaling in neurodegenerative diseases and the therapeutic potential of RhoA inhibition in neurodegeneration.", "tags": [{"end": 50, "start": 41, "tag": "Finding"}, {"end": 103, "start": 85, "tag": "CellFunction"}, {"end": 218, "start": 214, "tag": "GeneOrGenome"}, {"end": 218, "start": 214, "tag": "AminoAcidPeptideOrProtein"}, {"end": 229, "start": 219, "tag": "CellFunction"}, {"end": 40, "start": 33, "tag": "TemporalConcept"}, {"end": 250, "start": 233, "tag": "CellOrMolecularDysfunction"}, {"end": 180, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 150, "start": 136, "tag": "CellFunction"}]}{"id": "124_0", "text": "Mitochondria, the centers of energy metabolism, have been shown to participate in epigenetic regulation of neurodegenerative diseases.", "tags": [{"end": 12, "start": 0, "tag": "CellComponent"}, {"end": 46, "start": 29, "tag": "BiologicFunction"}, {"end": 103, "start": 82, "tag": "CellFunction"}, {"end": 133, "start": 107, "tag": "DiseaseOrSyndrome"}]}{"id": "124_1", "text": "Epigenetic modification of nuclear genes encoding mitochondrial proteins has an impact on mitochondria homeostasis, including mitochondrial biogenesis, and quality, which plays role in the pathogenesis of neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.", "tags": [{"end": 23, "start": 0, "tag": "CellFunction"}, {"end": 49, "start": 41, "tag": "BiologicFunction"}, {"end": 72, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 90, "tag": "CellFunction"}, {"end": 150, "start": 126, "tag": "CellFunction"}, {"end": 201, "start": 189, "tag": "PathologicFunction"}, {"end": 256, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 277, "start": 258, "tag": "DiseaseOrSyndrome"}, {"end": 334, "start": 305, "tag": "DiseaseOrSyndrome"}, {"end": 299, "start": 279, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 27, "tag": "GeneOrGenome"}]}{"id": "124_2", "text": "On the other hand, intermediate metabolites regulated by mitochondria such as acetyl-CoA and NAD(+), in turn, may regulate nuclear epigenome as the substrate for acetylation and a cofactor of deacetylation, respectively.", "tags": [{"end": 43, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 123, "tag": "GeneOrGenome"}, {"end": 157, "start": 148, "tag": "Chemical"}, {"end": 173, "start": 162, "tag": "CellFunction"}, {"end": 188, "start": 180, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 192, "tag": "CellFunction"}, {"end": 69, "start": 57, "tag": "CellComponent"}, {"end": 99, "start": 93, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 99, "start": 93, "tag": "PharmacologicSubstance"}, {"end": 99, "start": 93, "tag": "BiologicallyActiveSubstance"}]}{"id": "124_3", "text": "Thus, mitochondria are involved in epigenetic regulation through bidirectional communication between mitochondria and nuclear, which may provide a new strategy for neurodegenerative diseases treatment.", "tags": [{"end": 56, "start": 35, "tag": "CellFunction"}, {"end": 18, "start": 6, "tag": "CellComponent"}, {"end": 113, "start": 101, "tag": "CellComponent"}, {"end": 190, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 191, "tag": "HealthCareActivity"}, {"end": 200, "start": 191, "tag": "ResearchActivity"}]}{"id": "124_4", "text": "In addition, emerging evidence has suggested that the abnormal modification of mitochondria DNA contributes to disease development through mitochondria dysfunction.", "tags": [{"end": 75, "start": 54, "tag": "Finding"}, {"end": 130, "start": 111, "tag": "PathologicFunction"}, {"end": 30, "start": 13, "tag": "Finding"}, {"end": 163, "start": 139, "tag": "CellOrMolecularDysfunction"}, {"end": 95, "start": 79, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 95, "start": 79, "tag": "BiologicallyActiveSubstance"}]}{"id": "124_5", "text": "In this review, we provide an overview of how mitochondria are involved in epigenetic regulation and discuss the mechanisms of mitochondria in regulation of neurodegenerative diseases from epigenetic perspective.", "tags": [{"end": 38, "start": 30, "tag": "ResearchActivity"}, {"end": 96, "start": 75, "tag": "CellFunction"}, {"end": 58, "start": 46, "tag": "CellComponent"}, {"end": 139, "start": 127, "tag": "CellComponent"}, {"end": 183, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 211, "start": 200, "tag": "BiologicFunction"}]}{"id": "125_0", "text": "Trans-neuronal propagation of mutant huntingtin protein contributes to the organised spread of cortico-striatal degeneration and disconnection in Huntington's disease (HD).", "tags": [{"end": 55, "start": 30, "tag": "CellOrMolecularDysfunction"}, {"end": 170, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 95, "tag": "PathologicFunction"}, {"end": 142, "start": 129, "tag": "Finding"}, {"end": 26, "start": 0, "tag": "CellFunction"}, {"end": 91, "start": 75, "tag": "Finding"}]}{"id": "125_1", "text": "We investigated whether the network diffusion model, which models transneuronal spread as diffusion of pathological proteins via the brain connectome, can determine the severity of neural degeneration and disconnection in HD.", "tags": [{"end": 99, "start": 90, "tag": "NaturalPhenomenonOrProcess"}, {"end": 124, "start": 103, "tag": "PathologicFunction"}, {"end": 149, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 177, "start": 169, "tag": "Finding"}, {"end": 200, "start": 181, "tag": "CellOrMolecularDysfunction"}, {"end": 224, "start": 222, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 28, "tag": "ResearchActivity"}, {"end": 124, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 205, "tag": "Finding"}, {"end": 86, "start": 66, "tag": "CellFunction"}]}{"id": "125_2", "text": "We used structural magnetic resonance imaging (MRI) and high-angular resolution diffusion weighted imaging (DWI) data from symptomatic Huntington's disease (HD) (N = 26) and age-matched healthy controls (N = 26) to measure neural degeneration and disconnection in HD.", "tags": [{"end": 45, "start": 8, "tag": "HealthCareActivity"}, {"end": 50, "start": 47, "tag": "HealthCareActivity"}, {"end": 111, "start": 108, "tag": "HealthCareActivity"}, {"end": 242, "start": 223, "tag": "CellOrMolecularDysfunction"}, {"end": 260, "start": 247, "tag": "Finding"}, {"end": 106, "start": 56, "tag": "ManufacturedObject"}, {"end": 202, "start": 174, "tag": "PopulationGroup"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 266, "start": 264, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 8, "tag": "ManufacturedObject"}, {"end": 106, "start": 56, "tag": "HealthCareActivity"}, {"end": 111, "start": 108, "tag": "ManufacturedObject"}, {"end": 117, "start": 113, "tag": "ResearchActivity"}]}{"id": "125_3", "text": "The network diffusion model was used to test whether disease spread, via the human brain connectome, is a viable mechanism to explain the distribution of pathology across the brain.", "tags": [{"end": 67, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 180, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 4, "tag": "ResearchActivity"}, {"end": 163, "start": 154, "tag": "PathologicFunction"}]}{"id": "125_4", "text": "We found that an eigenmode identified in the healthy human brain connectome Laplacian matrix, accurately predicts the cortico-striatal spatial pattern of degeneration in HD.", "tags": [{"end": 52, "start": 45, "tag": "OrganismAttribute"}, {"end": 166, "start": 154, "tag": "CellOrMolecularDysfunction"}, {"end": 75, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 17, "tag": "ResearchActivity"}, {"end": 92, "start": 76, "tag": "ResearchActivity"}, {"end": 134, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "125_5", "text": "Furthermore, the spread of neural degeneration from sub-cortical brain regions, including the accumbens and thalamus, generates a spatial pattern which represents the typical neurodegenerative characteristics in HD.", "tags": [{"end": 46, "start": 27, "tag": "CellOrMolecularDysfunction"}, {"end": 78, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 214, "start": 212, "tag": "DiseaseOrSyndrome"}]}{"id": "125_6", "text": "The white matter connections connecting the nodes with the highest amount of disease factors, when diffusion based disease spread is initiated from the striatum, were found to be most vulnerable to disconnection in HD.", "tags": [{"end": 49, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 99, "tag": "NaturalPhenomenonOrProcess"}, {"end": 217, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 115, "tag": "PathologicFunction"}, {"end": 211, "start": 198, "tag": "Finding"}]}{"id": "125_7", "text": "These findings suggest that trans-neuronal diffusion of mutant huntingtin protein across the human brain connectome may explain the pattern of gray matter degeneration and white matter disconnection that are hallmarks of HD.", "tags": [{"end": 81, "start": 56, "tag": "CellOrMolecularDysfunction"}, {"end": 154, "start": 143, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 223, "start": 221, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 172, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 143, "tag": "PathologicFunction"}, {"end": 217, "start": 208, "tag": "Finding"}, {"end": 198, "start": 172, "tag": "PathologicFunction"}, {"end": 52, "start": 28, "tag": "CellFunction"}]}{"id": "126_0", "text": "Autophagy is an evolutionally conserved process by which cytoplasmic contents including protein aggregates and damaged organelles such as mitochondria and lysosomes, are sequestered by double-membrane structure, autophagosomes, and delivered to the lysosomes for degradation.", "tags": [{"end": 9, "start": 0, "tag": "CellFunction"}, {"end": 47, "start": 16, "tag": "CellFunction"}, {"end": 77, "start": 57, "tag": "CellComponent"}, {"end": 106, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 111, "tag": "CellOrMolecularDysfunction"}, {"end": 164, "start": 155, "tag": "CellComponent"}, {"end": 226, "start": 212, "tag": "CellComponent"}, {"end": 258, "start": 249, "tag": "CellComponent"}, {"end": 274, "start": 263, "tag": "NaturalPhenomenonOrProcess"}, {"end": 150, "start": 138, "tag": "CellComponent"}, {"end": 210, "start": 185, "tag": "CellComponent"}]}{"id": "126_1", "text": "Recently, considerable efforts have been made to reveal the role of autophagy in neurodegenerative diseases like Alzheimer's disease, Parkinson's disease and Huntington's disease.", "tags": [{"end": 132, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 68, "tag": "CellFunction"}, {"end": 178, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 81, "tag": "DiseaseOrSyndrome"}]}{"id": "126_2", "text": "Impairment of autophagy aggravates the accumulation of misfolded protein and damaged organelles in neurons, while sufficient autophagic activity reduces such accumulation in nervous system and ameliorates the pathology.", "tags": [{"end": 72, "start": 39, "tag": "CellOrMolecularDysfunction"}, {"end": 95, "start": 77, "tag": "CellOrMolecularDysfunction"}, {"end": 106, "start": 99, "tag": "Cell"}, {"end": 170, "start": 158, "tag": "Finding"}, {"end": 188, "start": 174, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 218, "start": 209, "tag": "PathologicFunction"}, {"end": 144, "start": 125, "tag": "CellFunction"}]}{"id": "126_3", "text": "Here we summarize recent progress regarding the role of autophagy in several neurodegenerative diseases and the potential autophagy-associated therapies for them.", "tags": [{"end": 65, "start": 56, "tag": "CellFunction"}, {"end": 131, "start": 122, "tag": "CellFunction"}, {"end": 103, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 18, "tag": "TemporalConcept"}, {"end": 152, "start": 122, "tag": "HealthCareActivity"}]}{"id": "127_0", "text": "Huntington's disease (HD) is a heritable and fatal neurodegenerative disease characterized by a triad of motor, cognitive and neuropsychiatric symptoms.", "tags": [{"end": 40, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 126, "tag": "SignOrSymptom"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "127_1", "text": "A common and particularly detrimental neuropsychiatric alteration in HD gene carriers is irritability, which frequently manifests as abrupt and unpredictable outbursts of anger.", "tags": [{"end": 101, "start": 89, "tag": "SignOrSymptom"}, {"end": 65, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 69, "tag": "PatientOrDisabledGroup"}, {"end": 177, "start": 133, "tag": "DiseaseOrSyndrome"}]}{"id": "127_2", "text": "This symptom increases the burden of HD in multiple ways, such as jeopardizing employment and straining familial or caregiver support.", "tags": [{"end": 12, "start": 5, "tag": "SignOrSymptom"}, {"end": 33, "start": 27, "tag": "ResearchActivity"}, {"end": 89, "start": 66, "tag": "Finding"}, {"end": 39, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 94, "tag": "Finding"}]}{"id": "127_3", "text": "Although irritability in HD is diagnosed by the administration of standardized rating scales and clinical expertise, measurement of severity and progression is complicated by several factors.", "tags": [{"end": 21, "start": 9, "tag": "SignOrSymptom"}, {"end": 140, "start": 132, "tag": "Finding"}, {"end": 27, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 145, "tag": "PathologicFunction"}, {"end": 156, "start": 145, "tag": "TemporalConcept"}, {"end": 92, "start": 48, "tag": "HealthCareActivity"}]}{"id": "127_4", "text": "Currently, individuals with HD who present with irritability may be managed with a variety of psychotropic medications, primarily antidepressants and antipsychotics.", "tags": [{"end": 30, "start": 11, "tag": "PatientOrDisabledGroup"}, {"end": 60, "start": 48, "tag": "SignOrSymptom"}, {"end": 118, "start": 94, "tag": "PharmacologicSubstance"}, {"end": 145, "start": 130, "tag": "PharmacologicSubstance"}, {"end": 164, "start": 150, "tag": "PharmacologicSubstance"}, {"end": 30, "start": 28, "tag": "DiseaseOrSyndrome"}]}{"id": "127_5", "text": "While these therapies offer relief to individuals suffering from irritability in HD, they are often not sufficient.", "tags": [{"end": 21, "start": 12, "tag": "HealthCareActivity"}, {"end": 34, "start": 28, "tag": "Finding"}, {"end": 49, "start": 38, "tag": "PopulationGroup"}, {"end": 59, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 65, "tag": "SignOrSymptom"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}]}{"id": "127_6", "text": "Here, we review irritability in the context of HD and emphasize the need for treatments that are better tailored to mitigate this troublesome symptom.", "tags": [{"end": 28, "start": 16, "tag": "SignOrSymptom"}, {"end": 87, "start": 77, "tag": "HealthCareActivity"}, {"end": 87, "start": 77, "tag": "ResearchActivity"}, {"end": 149, "start": 142, "tag": "SignOrSymptom"}, {"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}]}{"id": "127_7", "text": "An expeditious strategy in pursuit of this goal involves evaluating the efficacy of approved medications that are used to treat similar neuropsychiatric symptoms.", "tags": [{"end": 104, "start": 93, "tag": "PharmacologicSubstance"}, {"end": 161, "start": 136, "tag": "SignOrSymptom"}]}{"id": "128_0", "text": "Neurodegenerative diseases are characterized by a progressive loss of neuronal structures and functions.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 50, "tag": "Finding"}, {"end": 89, "start": 70, "tag": "CellComponent"}, {"end": 103, "start": 94, "tag": "CellFunction"}, {"end": 78, "start": 70, "tag": "CellFunction"}]}{"id": "128_1", "text": "Although all biochemical and/or physiological processes are not completely understood, it is known that the main neurodegenerative diseases, like Alzheimer's, Parkinson's, Huntington's, and prion diseases, and also amyotrophic lateral sclerosis (ALS) present certain obvious similarities.", "tags": [{"end": 55, "start": 32, "tag": "BiologicFunction"}, {"end": 157, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 204, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 244, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 246, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 113, "tag": "DiseaseOrSyndrome"}]}{"id": "128_2", "text": "Biometal microelements, such as copper, iron, manganese, and zinc, are crucial for many physiological functions, especially in the CNS.", "tags": [{"end": 38, "start": 32, "tag": "PharmacologicSubstance"}, {"end": 38, "start": 32, "tag": "Chemical"}, {"end": 44, "start": 40, "tag": "PharmacologicSubstance"}, {"end": 44, "start": 40, "tag": "Chemical"}, {"end": 55, "start": 46, "tag": "Chemical"}, {"end": 65, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 61, "tag": "Chemical"}, {"end": 111, "start": 88, "tag": "BiologicFunction"}, {"end": 134, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 0, "tag": "Chemical"}, {"end": 22, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 22, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 61, "tag": "PharmacologicSubstance"}]}{"id": "128_3", "text": "Shifts in the amounts of these metals are essential for the development and maintenance of numerous enzymatic activities, mitochondrial functions, neurotransmission, and also for memorization and learning.", "tags": [{"end": 6, "start": 0, "tag": "Finding"}, {"end": 37, "start": 31, "tag": "Chemical"}, {"end": 87, "start": 76, "tag": "BiologicFunction"}, {"end": 145, "start": 122, "tag": "CellFunction"}, {"end": 164, "start": 147, "tag": "CellFunction"}, {"end": 204, "start": 196, "tag": "BiologicFunction"}]}{"id": "128_4", "text": "However, with deregulations in their homeostasis, particularly in those connected with redox activity, there are consequent changes in the ion and microelement balance.", "tags": [{"end": 48, "start": 37, "tag": "BiologicFunction"}, {"end": 101, "start": 87, "tag": "CellFunction"}, {"end": 142, "start": 139, "tag": "Chemical"}, {"end": 167, "start": 139, "tag": "Finding"}]}{"id": "128_5", "text": "This redox activity may contribute to the production of free radicals that can react with various organic substrates, thus generating increased levels of oxidative stress.", "tags": [{"end": 19, "start": 5, "tag": "CellFunction"}, {"end": 69, "start": 42, "tag": "CellFunction"}, {"end": 150, "start": 134, "tag": "Finding"}, {"end": 170, "start": 154, "tag": "CellOrMolecularDysfunction"}, {"end": 69, "start": 56, "tag": "Chemical"}, {"end": 69, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 98, "tag": "Chemical"}]}{"id": "128_6", "text": "There is growing evidence that metal microelements play significant roles in the pathogenesis of neurodegenerative diseases.", "tags": [{"end": 50, "start": 31, "tag": "Chemical"}, {"end": 93, "start": 81, "tag": "PathologicFunction"}, {"end": 25, "start": 9, "tag": "Finding"}, {"end": 123, "start": 97, "tag": "DiseaseOrSyndrome"}]}{"id": "128_7", "text": "The interaction between metals and CNS proteins is crucial in the development or absence of neurodegeneration.", "tags": [{"end": 30, "start": 24, "tag": "Chemical"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 92, "tag": "CellOrMolecularDysfunction"}]}{"id": "128_8", "text": "In this way, homeostasis of metal microelements represents a mechanism of extreme importance.", "tags": [{"end": 24, "start": 13, "tag": "BiologicFunction"}, {"end": 47, "start": 28, "tag": "Chemical"}]}{"id": "128_9", "text": "Our paper aims at an updated and critical review of the role of the respective metals in neurodegenerative diseases and the main related pathogenic mechanisms.", "tags": [{"end": 85, "start": 79, "tag": "Chemical"}, {"end": 115, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 42, "tag": "ResearchActivity"}, {"end": 48, "start": 42, "tag": "HealthCareActivity"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 158, "start": 137, "tag": "PathologicFunction"}]}{"id": "129_0", "text": "The ubiquitin-proteasome system is the major pathway for the maintenance of protein homeostasis.", "tags": [{"end": 52, "start": 45, "tag": "CellFunction"}, {"end": 72, "start": 61, "tag": "BiologicFunction"}, {"end": 95, "start": 84, "tag": "BiologicFunction"}, {"end": 24, "start": 4, "tag": "CellFunction"}, {"end": 95, "start": 76, "tag": "CellFunction"}, {"end": 31, "start": 4, "tag": "CellFunction"}]}{"id": "129_1", "text": "Its inhibition causes accumulation of ubiquitinated proteins; this accumulation has been associated with several of the most common neurodegenerative diseases.", "tags": [{"end": 60, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 4, "tag": "CellFunction"}, {"end": 34, "start": 22, "tag": "Finding"}, {"end": 79, "start": 67, "tag": "Finding"}]}{"id": "129_2", "text": "Several genetic factors have been identified for most neurodegenerative diseases, however, most cases are considered idiopathic, thus making the study of the mechanisms of protein accumulation a relevant field of research.", "tags": [{"end": 127, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 145, "tag": "ResearchActivity"}, {"end": 221, "start": 213, "tag": "ResearchActivity"}, {"end": 192, "start": 180, "tag": "Finding"}]}{"id": "129_3", "text": "It is often mentioned that the biggest risk factor for neurodegenerative diseases is aging, and several groups have reported an age-related alteration of the expression of some of the 26S proteasome subunits and a reduction of its activity.", "tags": [{"end": 150, "start": 128, "tag": "PathologicFunction"}, {"end": 207, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 207, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 85, "tag": "BiologicFunction"}, {"end": 90, "start": 85, "tag": "CellFunction"}, {"end": 50, "start": 39, "tag": "Finding"}, {"end": 223, "start": 214, "tag": "Finding"}, {"end": 223, "start": 214, "tag": "NaturalPhenomenonOrProcess"}]}{"id": "129_4", "text": "Proteasome subunits interact with proteins that are known to accumulate in neurodegenerative diseases such as alpha-synuclein in Parkinson's, tau in Alzheimer's, and huntingtin in Huntington's diseases.", "tags": [{"end": 19, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 166, "tag": "GeneOrGenome"}, {"end": 125, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 110, "tag": "BiologicallyActiveSubstance"}]}{"id": "129_5", "text": "These interactions have been explored for several years, but only until recently, we are beginning to understand them.", "tags": [{"end": 18, "start": 6, "tag": "Finding"}, {"end": 55, "start": 50, "tag": "TemporalConcept"}, {"end": 80, "start": 72, "tag": "TemporalConcept"}]}{"id": "129_6", "text": "In this review, we discuss the known interactions, the underlying patterns, and the phenotypes associated with the 26S proteasome subunits in the etiology and progression of neurodegenerative diseases where there is evidence of proteasome involvement.", "tags": [{"end": 49, "start": 37, "tag": "Finding"}, {"end": 74, "start": 66, "tag": "ResearchActivity"}, {"end": 138, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 238, "start": 228, "tag": "AminoAcidPeptideOrProtein"}, {"end": 238, "start": 228, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 200, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 159, "tag": "PathologicFunction"}, {"end": 170, "start": 159, "tag": "TemporalConcept"}, {"end": 224, "start": 216, "tag": "Finding"}, {"end": 250, "start": 239, "tag": "Finding"}, {"end": 154, "start": 146, "tag": "Finding"}, {"end": 94, "start": 84, "tag": "OrganismAttribute"}]}{"id": "129_7", "text": "Special emphasis is made in reviewing proteasome subunits that interact with proteins known to have an age related altered expression or to be involved in neurodegenerative diseases to explore key effectors that may trigger or augment their progression.", "tags": [{"end": 57, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 206, "start": 197, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 252, "start": 241, "tag": "PathologicFunction"}, {"end": 252, "start": 241, "tag": "TemporalConcept"}, {"end": 85, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 103, "tag": "Finding"}]}{"id": "129_8", "text": "Interestingly, while the causes of age-related reduction of some of the proteasome subunits are not known, there are specific relationships between the observed neurodegenerative disease and the affected proteasome subunits.", "tags": [{"end": 91, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 126, "tag": "Finding"}, {"end": 223, "start": 204, "tag": "AminoAcidPeptideOrProtein"}, {"end": 223, "start": 204, "tag": "BiologicallyActiveSubstance"}, {"end": 186, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 35, "tag": "Finding"}]}{"id": "129_9", "text": "(C) 2020 IMSS.", "tags": []}{"id": "129_10", "text": "Published by Elsevier Inc.", "tags": []}{"id": "130_0", "text": "Neurodegenerative diseases, characterized by a progressive loss of brain function, affect the lives of millions of individuals worldwide.", "tags": [{"end": 99, "start": 94, "tag": "Finding"}, {"end": 81, "start": 67, "tag": "BiologicFunction"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 47, "tag": "TemporalConcept"}, {"end": 126, "start": 115, "tag": "PopulationGroup"}, {"end": 81, "start": 59, "tag": "PathologicFunction"}]}{"id": "130_1", "text": "The complexity of the brain poses a challenge for scientists trying to map the biochemical and physiological pathways to identify areas of pathological errors.", "tags": [{"end": 74, "start": 71, "tag": "ResearchActivity"}, {"end": 27, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 79, "tag": "CellFunction"}, {"end": 45, "start": 36, "tag": "HealthCareActivity"}]}{"id": "130_2", "text": "Brain samples of patients with neurodegenerative diseases have been shown to contain large amounts of misfolded and abnormally aggregated proteins, resulting in dysfunction in certain brain centers.", "tags": [{"end": 172, "start": 161, "tag": "PathologicFunction"}, {"end": 146, "start": 102, "tag": "CellOrMolecularDysfunction"}, {"end": 57, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 184, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 17, "tag": "PatientOrDisabledGroup"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "130_3", "text": "Removal of these abnormal molecules is essential in maintaining protein homeostasis and overall neuronal health.", "tags": [{"end": 35, "start": 17, "tag": "CellOrMolecularDysfunction"}, {"end": 104, "start": 96, "tag": "Cell"}, {"end": 111, "start": 105, "tag": "HealthCareActivity"}, {"end": 83, "start": 72, "tag": "BiologicFunction"}, {"end": 83, "start": 64, "tag": "CellFunction"}]}{"id": "130_4", "text": "Macroautophagy is a major route by which cells achieve this.", "tags": [{"end": 14, "start": 0, "tag": "CellFunction"}, {"end": 46, "start": 41, "tag": "Cell"}]}{"id": "130_5", "text": "Administration of certain autophagy-enhancing compounds has been shown to provide therapeutic effects for individuals with neurodegenerative conditions.", "tags": [{"end": 101, "start": 82, "tag": "Finding"}, {"end": 35, "start": 26, "tag": "CellFunction"}, {"end": 14, "start": 0, "tag": "HealthCareActivity"}, {"end": 151, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 106, "tag": "PopulationGroup"}, {"end": 55, "start": 26, "tag": "PharmacologicSubstance"}]}{"id": "130_6", "text": "SQSTM1/p62 is a scaffold protein closely involved in the macroautophagy process.", "tags": [{"end": 32, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 57, "tag": "CellFunction"}, {"end": 10, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "130_7", "text": "p62 functions to anchor the ubiquitinated proteins to the autophagosome membrane, promoting degradation of unwanted molecules.", "tags": [{"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 17, "tag": "HealthCareActivity"}, {"end": 23, "start": 17, "tag": "ManufacturedObject"}, {"end": 80, "start": 58, "tag": "CellComponent"}, {"end": 125, "start": 116, "tag": "Substance"}, {"end": 103, "start": 92, "tag": "NaturalPhenomenonOrProcess"}, {"end": 50, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 42, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "130_8", "text": "Modulators targeting p62 to induce autophagy and promote its protective pathways for aggregate protein clearance have high potential in the treatment of these conditions.", "tags": [{"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 61, "tag": "CellFunction"}, {"end": 44, "start": 35, "tag": "CellFunction"}, {"end": 149, "start": 140, "tag": "HealthCareActivity"}, {"end": 149, "start": 140, "tag": "ResearchActivity"}, {"end": 112, "start": 85, "tag": "CellFunction"}]}{"id": "130_9", "text": "Additionally, causal relationships have been found between errors in regulation of SQSTM1/p62 and the development of a variety of neurodegenerative disorders, including Alzheimer's, Parkinson's, Huntington's, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration.", "tags": [{"end": 65, "start": 59, "tag": "Finding"}, {"end": 277, "start": 244, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 14, "tag": "Finding"}, {"end": 193, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 238, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 102, "tag": "BiologicFunction"}, {"end": 113, "start": 102, "tag": "CellFunction"}, {"end": 93, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 207, "start": 195, "tag": "DiseaseOrSyndrome"}]}{"id": "130_10", "text": "Furthermore, SQSTM1/p62 also serves as a signaling hub for multiple pathways associated with neurodegeneration, providing a potential therapeutic target in the treatment of neurodegenerative diseases.", "tags": [{"end": 54, "start": 51, "tag": "GeneOrGenome"}, {"end": 54, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 41, "tag": "CellFunction"}, {"end": 199, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 76, "start": 68, "tag": "CellFunction"}, {"end": 169, "start": 160, "tag": "HealthCareActivity"}, {"end": 169, "start": 160, "tag": "ResearchActivity"}, {"end": 23, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 124, "tag": "Finding"}]}{"id": "130_11", "text": "However, rational design of a p62-oriented autophagy modulator that can balance the negative and positive functions of multiple domains in p62 requires further efforts in the exploration of the protein structure and pathological basis.", "tags": [{"end": 142, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 186, "start": 175, "tag": "HealthCareActivity"}, {"end": 24, "start": 18, "tag": "ResearchActivity"}, {"end": 24, "start": 18, "tag": "HealthCareActivity"}, {"end": 52, "start": 43, "tag": "CellFunction"}, {"end": 211, "start": 194, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 186, "start": 175, "tag": "ResearchActivity"}, {"end": 62, "start": 53, "tag": "BiologicallyActiveSubstance"}]}{"id": "131_0", "text": "MicroRNAs (miRNAs) are important regulators of several biological processes, such as cell growth, cell proliferation, embryonic development, tissue differentiation, and apoptosis.", "tags": [{"end": 9, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 11, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 17, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 55, "tag": "BiologicFunction"}, {"end": 96, "start": 85, "tag": "CellFunction"}, {"end": 116, "start": 98, "tag": "CellFunction"}, {"end": 139, "start": 118, "tag": "BiologicFunction"}, {"end": 163, "start": 141, "tag": "BiologicFunction"}, {"end": 178, "start": 169, "tag": "CellFunction"}]}{"id": "131_1", "text": "Currently, over 2000 mammalian miRNAs have been reported to regulate these biological processes.", "tags": [{"end": 30, "start": 21, "tag": "Eukaryote"}, {"end": 37, "start": 31, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 37, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 75, "tag": "BiologicFunction"}, {"end": 9, "start": 0, "tag": "TemporalConcept"}]}{"id": "131_2", "text": "A subset of microRNAs was found to be localized to human mitochondria (mitomiRs).", "tags": [{"end": 56, "start": 51, "tag": "Eukaryote"}, {"end": 21, "start": 12, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 21, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 57, "tag": "CellComponent"}, {"end": 79, "start": 71, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 79, "start": 71, "tag": "BiologicallyActiveSubstance"}]}{"id": "131_3", "text": "Through years of research, over 400 mitomiRs have been shown to modulate the translational activity of the mitochondrial genome.", "tags": [{"end": 13, "start": 8, "tag": "TemporalConcept"}, {"end": 25, "start": 17, "tag": "ResearchActivity"}, {"end": 99, "start": 77, "tag": "CellFunction"}, {"end": 127, "start": 107, "tag": "GeneOrGenome"}, {"end": 44, "start": 36, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 44, "start": 36, "tag": "BiologicallyActiveSubstance"}]}{"id": "131_4", "text": "While miRNAs have been studied for years, the function of mitomiRs and their role in neurodegenerative pathologies is not known.", "tags": [{"end": 12, "start": 6, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 12, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 40, "start": 35, "tag": "TemporalConcept"}, {"end": 66, "start": 46, "tag": "CellFunction"}, {"end": 66, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 58, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 114, "start": 85, "tag": "DiseaseOrSyndrome"}]}{"id": "131_5", "text": "The purpose of our article is to highlight recent findings that relate mitomiRs to neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's.", "tags": [{"end": 26, "start": 19, "tag": "ResearchActivity"}, {"end": 132, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 71, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 79, "start": 71, "tag": "BiologicallyActiveSubstance"}]}{"id": "131_6", "text": "We also discuss the involvement of mitomiRs in regulating the mitochondrial genome in age-related neurodegenerative diseases.", "tags": [{"end": 82, "start": 62, "tag": "GeneOrGenome"}, {"end": 124, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 35, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 43, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 86, "tag": "OrganismAttribute"}]}{"id": "132_0", "text": "Huntington's disease (HD) is a rare, incurable, inherited neurodegenerative disorder manifested by chorea, hyperkinetic, and hypokinetic movements.", "tags": [{"end": 57, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 107, "tag": "SignOrSymptom"}, {"end": 105, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 99, "tag": "SignOrSymptom"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 31, "tag": "TemporalConcept"}]}{"id": "132_1", "text": "The FDA has approved only two drugs, viz.", "tags": [{"end": 7, "start": 4, "tag": "HealthCareRelatedOrganization"}, {"end": 35, "start": 30, "tag": "PharmacologicSubstance"}]}{"id": "132_2", "text": "tetrabenazine, and deu-tetrabenazine, to manage the chorea associated with HD.", "tags": [{"end": 58, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 52, "tag": "SignOrSymptom"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 36, "start": 19, "tag": "PharmacologicSubstance"}, {"end": 13, "start": 0, "tag": "Chemical"}, {"end": 36, "start": 19, "tag": "Chemical"}]}{"id": "132_3", "text": "However, several other drugs are used as an off-label to manage chorea and other symptoms such as depression, anxiety, muscle tremors, and cognitive dysfunction associated with HD.", "tags": [{"end": 89, "start": 81, "tag": "SignOrSymptom"}, {"end": 108, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 119, "tag": "SignOrSymptom"}, {"end": 160, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 64, "tag": "SignOrSymptom"}, {"end": 28, "start": 23, "tag": "PharmacologicSubstance"}, {"end": 179, "start": 177, "tag": "DiseaseOrSyndrome"}]}{"id": "132_4", "text": "So far, there is no disease-modifying treatment available.", "tags": [{"end": 47, "start": 20, "tag": "HealthCareActivity"}]}{"id": "132_5", "text": "Drug repurposing has been a primary drive to search for new anti-HD drugs.", "tags": [{"end": 16, "start": 0, "tag": "HealthCareActivity"}, {"end": 51, "start": 45, "tag": "ResearchActivity"}, {"end": 73, "start": 68, "tag": "PharmacologicSubstance"}, {"end": 4, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}]}{"id": "132_6", "text": "Numerous molecular targets along with a wide range of small molecules and gene therapies are currently under clinical investigation.", "tags": [{"end": 26, "start": 9, "tag": "Chemical"}, {"end": 69, "start": 54, "tag": "Chemical"}, {"end": 88, "start": 74, "tag": "HealthCareActivity"}, {"end": 131, "start": 109, "tag": "ResearchActivity"}]}{"id": "132_7", "text": "More than 200 clinical studies are underway for HD, 75% are interventional, and 25% are observational studies.", "tags": [{"end": 30, "start": 14, "tag": "ResearchActivity"}, {"end": 109, "start": 88, "tag": "ResearchActivity"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}]}{"id": "132_8", "text": "The present review discusses the small molecule clinical pipeline and molecular targets for HD.", "tags": [{"end": 47, "start": 33, "tag": "Chemical"}, {"end": 87, "start": 70, "tag": "Chemical"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 65, "start": 48, "tag": "ResearchActivity"}]}{"id": "132_9", "text": "Furthermore, the biomarkers, diagnostic tests, gene therapies, behavioral and observational studies for HD were also deliberated.", "tags": [{"end": 27, "start": 17, "tag": "ClinicalAttribute"}, {"end": 45, "start": 29, "tag": "HealthCareActivity"}, {"end": 61, "start": 47, "tag": "HealthCareActivity"}, {"end": 99, "start": 78, "tag": "ResearchActivity"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}]}{"id": "133_0", "text": "Apathy is one of the most frequent, disabling and difficult to treat non-motor symptoms manifesting in many neurodegenerative diseases, particularly in Parkinson disease and Huntington disease.", "tags": [{"end": 6, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 26, "tag": "TemporalConcept"}, {"end": 87, "start": 69, "tag": "SignOrSymptom"}, {"end": 134, "start": 108, "tag": "DiseaseOrSyndrome"}]}{"id": "133_1", "text": "Aim is to evaluate and compare the clinical profile of apathy in patients with Parkinson disease (PD) and Huntington disease (HD).", "tags": [{"end": 124, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 35, "tag": "ClinicalAttribute"}, {"end": 96, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 65, "tag": "PatientOrDisabledGroup"}, {"end": 128, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}]}{"id": "133_2", "text": "Materials and methods.", "tags": [{"end": 21, "start": 14, "tag": "ResearchActivity"}]}{"id": "133_3", "text": "The individual registration card was filled in for each patient containing demographic data, clinical features of the disease, the results of validated scales and questionnaires evaluating motor activity (The Movement Disorder Society-Unified Parkinson's Disease Rating Scale - MDS-UPDRS, the Unified Huntington's Disease Rating Scale - UHDRS), cognitive functions (MoCA-test), anxiety-depressive symptoms (hospital scale for evaluating anxiety and depression, Beck's depression scale-II), apathy (apathy rating scale).", "tags": [{"end": 32, "start": 4, "tag": "HealthCareActivity"}, {"end": 203, "start": 189, "tag": "CellFunction"}, {"end": 203, "start": 189, "tag": "BiologicFunction"}, {"end": 364, "start": 345, "tag": "BiologicFunction"}, {"end": 421, "start": 407, "tag": "HealthCareRelatedOrganization"}, {"end": 91, "start": 75, "tag": "ResearchActivity"}, {"end": 342, "start": 337, "tag": "HealthCareActivity"}, {"end": 459, "start": 449, "tag": "DiseaseOrSyndrome"}, {"end": 478, "start": 468, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 163, "tag": "HealthCareActivity"}, {"end": 110, "start": 93, "tag": "ClinicalAttribute"}, {"end": 496, "start": 490, "tag": "DiseaseOrSyndrome"}, {"end": 504, "start": 498, "tag": "DiseaseOrSyndrome"}, {"end": 370, "start": 366, "tag": "HealthCareActivity"}, {"end": 405, "start": 397, "tag": "SignOrSymptom"}, {"end": 385, "start": 378, "tag": "DiseaseOrSyndrome"}, {"end": 444, "start": 437, "tag": "DiseaseOrSyndrome"}, {"end": 334, "start": 293, "tag": "HealthCareActivity"}, {"end": 63, "start": 56, "tag": "PatientOrDisabledGroup"}, {"end": 275, "start": 205, "tag": "HealthCareActivity"}, {"end": 287, "start": 278, "tag": "HealthCareActivity"}, {"end": 487, "start": 461, "tag": "HealthCareActivity"}]}{"id": "133_4", "text": "Patients with dementia or severe depression were excluded from the study.", "tags": [{"end": 43, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 32, "start": 26, "tag": "Finding"}, {"end": 72, "start": 67, "tag": "ResearchActivity"}]}{"id": "133_5", "text": "Results.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}]}{"id": "133_6", "text": "The study included 265 patients: 250 with PD and 15 with HD.", "tags": [{"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}]}{"id": "133_7", "text": "Apathy was diagnosed in 57.8% of cases in patients with neurodegenerative diseases (139 out of 250 patients with PD and 9 out of 15 patients with HD).", "tags": [{"end": 6, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 11, "tag": "HealthCareActivity"}, {"end": 82, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 42, "tag": "PatientOrDisabledGroup"}, {"end": 107, "start": 99, "tag": "PatientOrDisabledGroup"}, {"end": 140, "start": 132, "tag": "PatientOrDisabledGroup"}, {"end": 148, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}]}{"id": "133_8", "text": "In both groups of patients apathy was associated with the severity of motor manifestations.", "tags": [{"end": 90, "start": 70, "tag": "SignOrSymptom"}, {"end": 66, "start": 58, "tag": "ClinicalAttribute"}, {"end": 66, "start": 58, "tag": "Finding"}, {"end": 33, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 18, "tag": "PatientOrDisabledGroup"}]}{"id": "133_9", "text": "Patients with PD showed a positive correlation of apathy with more severe depression (r=0.488; p<0.0001), anxiety (r=0.300; p<0.0001) and drowsiness (r=0.254; p<0.0001); a negative correlation with a short duration of the disease (r=-0.160; p=0.021), a lower dose of dopaminergic drugs, LEDD (r=-0.203; p=0.03).", "tags": [{"end": 148, "start": 138, "tag": "Finding"}, {"end": 148, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 285, "start": 267, "tag": "PharmacologicSubstance"}, {"end": 84, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 206, "tag": "TemporalConcept"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 73, "start": 67, "tag": "Finding"}, {"end": 16, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 35, "tag": "ResearchActivity"}, {"end": 192, "start": 181, "tag": "ResearchActivity"}]}{"id": "133_10", "text": "In patients with HD, apathy was associated with disease duration (8 (4; 11) years in patients without apathy and 5 (3;9) years in patients with apathy, U =3791.5; p=0.020) and cognitive impairment (26 (19;37) points, without apathy - 18 (12;26), U =3548.5; p=0.003).", "tags": [{"end": 247, "start": 246, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 19, "start": 3, "tag": "PatientOrDisabledGroup"}, {"end": 27, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 48, "tag": "HealthCareActivity"}, {"end": 64, "start": 48, "tag": "TemporalConcept"}, {"end": 196, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 76, "tag": "TemporalConcept"}, {"end": 126, "start": 121, "tag": "TemporalConcept"}, {"end": 93, "start": 85, "tag": "PatientOrDisabledGroup"}, {"end": 138, "start": 130, "tag": "PatientOrDisabledGroup"}]}{"id": "133_11", "text": "Conclusions.", "tags": []}{"id": "133_12", "text": "Similar frequency of apathy was found in patients with PD and HD, but with different clinical correlations due to the involvement of different brain regions in the pathological process, which requires further research to develop targeted therapy.", "tags": [{"end": 184, "start": 164, "tag": "PathologicFunction"}, {"end": 245, "start": 229, "tag": "HealthCareActivity"}, {"end": 156, "start": 143, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 8, "tag": "TemporalConcept"}, {"end": 106, "start": 85, "tag": "ResearchActivity"}, {"end": 129, "start": 118, "tag": "Finding"}, {"end": 49, "start": 41, "tag": "PatientOrDisabledGroup"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 209, "tag": "ResearchActivity"}]}{"id": "134_0", "text": "Huntington's disease (HD) is a progressive neurodegenerative disorder which deteriorates the physical and mental abilities of the patients.", "tags": [{"end": 122, "start": 106, "tag": "OrganismAttribute"}, {"end": 42, "start": 31, "tag": "TemporalConcept"}, {"end": 138, "start": 130, "tag": "PatientOrDisabledGroup"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 93, "tag": "OrganismAttribute"}, {"end": 122, "start": 113, "tag": "OrganismAttribute"}]}{"id": "134_1", "text": "It is an autosomal dominant disorder and is mainly caused by the expansion of a repeating CAG triplet.", "tags": [{"end": 101, "start": 90, "tag": "MolecularSequence"}, {"end": 27, "start": 9, "tag": "CellFunction"}, {"end": 27, "start": 19, "tag": "CellFunction"}, {"end": 36, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 65, "tag": "CellOrMolecularDysfunction"}]}{"id": "134_2", "text": "A number of animal models ranging from worms, fruit flies, mice and rat, pig, sheep and monkeys are available, which have been helpful in understanding various pathways involved during the progression of the disease.", "tags": [{"end": 44, "start": 39, "tag": "Eukaryote"}, {"end": 57, "start": 46, "tag": "Eukaryote"}, {"end": 83, "start": 78, "tag": "Eukaryote"}, {"end": 95, "start": 88, "tag": "Eukaryote"}, {"end": 151, "start": 138, "tag": "BiologicFunction"}, {"end": 71, "start": 68, "tag": "Eukaryote"}, {"end": 215, "start": 189, "tag": "PathologicFunction"}, {"end": 63, "start": 59, "tag": "Eukaryote"}, {"end": 168, "start": 160, "tag": "CellFunction"}, {"end": 25, "start": 12, "tag": "ResearchActivity"}, {"end": 76, "start": 73, "tag": "Eukaryote"}]}{"id": "134_3", "text": "Drosophila is one of the most commonly used model organisms for biomedical science, due to low cost maintenance, short life span and easy implications of genetic tools.", "tags": [{"end": 82, "start": 64, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 59, "start": 50, "tag": "Organism"}, {"end": 10, "start": 0, "tag": "Eukaryote"}, {"end": 99, "start": 91, "tag": "Finding"}, {"end": 111, "start": 100, "tag": "BiologicFunction"}, {"end": 49, "start": 44, "tag": "ResearchActivity"}, {"end": 128, "start": 119, "tag": "TemporalConcept"}, {"end": 128, "start": 113, "tag": "Finding"}, {"end": 167, "start": 154, "tag": "ResearchActivity"}]}{"id": "134_4", "text": "The present review provides a brief description of HD and the studies carried out for HD to date, taking Drosophila as a model.", "tags": [{"end": 47, "start": 36, "tag": "ResearchActivity"}, {"end": 96, "start": 89, "tag": "TemporalConcept"}, {"end": 115, "start": 105, "tag": "Eukaryote"}, {"end": 96, "start": 92, "tag": "TemporalConcept"}, {"end": 126, "start": 121, "tag": "ResearchActivity"}, {"end": 69, "start": 62, "tag": "HealthCareActivity"}, {"end": 69, "start": 62, "tag": "ResearchActivity"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}]}{"id": "135_0", "text": "Transcranial sonography (TCS) is a diagnostic tool in mood and movement disorders.", "tags": [{"end": 23, "start": 0, "tag": "HealthCareActivity"}, {"end": 28, "start": 25, "tag": "HealthCareActivity"}, {"end": 50, "start": 35, "tag": "HealthCareActivity"}, {"end": 58, "start": 54, "tag": "BiologicFunction"}, {"end": 81, "start": 63, "tag": "DiseaseOrSyndrome"}]}{"id": "135_1", "text": "Alterations within the raphe mesencephalic nucleus in the brain have been reported not only in patients with major depression but in patients with depressive symptoms accompanying several neurodegenerative disorders.", "tags": [{"end": 11, "start": 0, "tag": "Finding"}, {"end": 50, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 147, "tag": "SignOrSymptom"}, {"end": 125, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 95, "tag": "PatientOrDisabledGroup"}, {"end": 141, "start": 133, "tag": "PatientOrDisabledGroup"}, {"end": 215, "start": 188, "tag": "DiseaseOrSyndrome"}]}{"id": "135_2", "text": "The aim of the study was to assess the echogenicity of the nucleus raphe and other basal ganglia in patients with Huntington's disease (HD).", "tags": [{"end": 72, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 100, "tag": "PatientOrDisabledGroup"}, {"end": 134, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 51, "start": 39, "tag": "ClinicalAttribute"}]}{"id": "135_3", "text": "TCS was performed in 127 HD patients participating in observational studies (Registry/Enroll-HD) in the Institute of Psychiatry and Neurology (Warsaw, Poland).", "tags": [{"end": 3, "start": 0, "tag": "HealthCareActivity"}, {"end": 75, "start": 54, "tag": "ResearchActivity"}, {"end": 36, "start": 25, "tag": "PatientOrDisabledGroup"}, {"end": 95, "start": 77, "tag": "ResearchActivity"}, {"end": 141, "start": 104, "tag": "HealthCareRelatedOrganization"}]}{"id": "135_4", "text": "Raphe hypoechogenicity was found in 78% of HD patients with current symptoms of depression (according to DSM-IV criteria), 57% of patients with a previous history of depression, and 56.8% patients who lacked signs or history of depression.", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 6, "tag": "Finding"}, {"end": 162, "start": 155, "tag": "Finding"}, {"end": 90, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 176, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 238, "start": 228, "tag": "DiseaseOrSyndrome"}, {"end": 213, "start": 208, "tag": "SignOrSymptom"}, {"end": 76, "start": 68, "tag": "SignOrSymptom"}, {"end": 224, "start": 217, "tag": "Finding"}, {"end": 138, "start": 130, "tag": "PatientOrDisabledGroup"}, {"end": 196, "start": 188, "tag": "PatientOrDisabledGroup"}, {"end": 67, "start": 60, "tag": "TemporalConcept"}, {"end": 54, "start": 43, "tag": "PatientOrDisabledGroup"}, {"end": 120, "start": 105, "tag": "HealthCareActivity"}]}{"id": "135_5", "text": "Patients with hypoechogenic raphe reported significantly higher depression as measured on the BDI (15.6 +/- 1.7) as compared to patients with normal echogenicity (9.5 +/- 1.2), (p = 0.023).", "tags": [{"end": 33, "start": 14, "tag": "Finding"}, {"end": 97, "start": 94, "tag": "HealthCareActivity"}, {"end": 74, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 148, "start": 142, "tag": "Finding"}, {"end": 136, "start": 128, "tag": "PatientOrDisabledGroup"}, {"end": 161, "start": 149, "tag": "ClinicalAttribute"}]}{"id": "135_6", "text": "The diameter of the third ventricle was negatively correlated with Mini-Mental State Examination (MMSE) (rho - 0.37) and total functional capacity (TFC) scores (rho - 0.26).", "tags": [{"end": 35, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 51, "tag": "ResearchActivity"}, {"end": 102, "start": 98, "tag": "HealthCareActivity"}, {"end": 96, "start": 67, "tag": "HealthCareActivity"}, {"end": 151, "start": 148, "tag": "HealthCareActivity"}, {"end": 159, "start": 153, "tag": "HealthCareActivity"}, {"end": 146, "start": 121, "tag": "HealthCareActivity"}, {"end": 35, "start": 4, "tag": "ClinicalAttribute"}]}{"id": "135_7", "text": "Hyperechogenic substantia nigra was visualized in 66,4% patients with HD and the degree of hyperechogenicity was correlated with the total motor score (TMS) (rho - 0.38).", "tags": [{"end": 123, "start": 113, "tag": "ResearchActivity"}, {"end": 72, "start": 56, "tag": "PatientOrDisabledGroup"}, {"end": 150, "start": 133, "tag": "HealthCareActivity"}, {"end": 155, "start": 152, "tag": "HealthCareActivity"}, {"end": 108, "start": 91, "tag": "ClinicalAttribute"}, {"end": 31, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 0, "tag": "Finding"}]}{"id": "135_8", "text": "Changes in echogenicity of the basal ganglia are related to both depressive and motor symptoms among patients with HD.", "tags": [{"end": 44, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 101, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "Finding"}, {"end": 94, "start": 65, "tag": "SignOrSymptom"}, {"end": 23, "start": 11, "tag": "ClinicalAttribute"}]}{"id": "136_0", "text": "Neurodegenerative diseases are conditions characterized by irreversible loss of neurons and loss of cognitive and motor function, mostly occurring in elderly people.", "tags": [{"end": 164, "start": 150, "tag": "PopulationGroup"}, {"end": 87, "start": 80, "tag": "Cell"}, {"end": 87, "start": 72, "tag": "CellOrMolecularDysfunction"}, {"end": 128, "start": 114, "tag": "BiologicFunction"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "136_1", "text": "The increasing age has been the most consistent risk factor for developing a neurodegenerative disorder.", "tags": [{"end": 103, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 4, "tag": "Finding"}, {"end": 18, "start": 15, "tag": "OrganismAttribute"}, {"end": 59, "start": 48, "tag": "Finding"}]}{"id": "136_2", "text": "Interlinking of oxidative stress and neurodegeneration is well established, indicating that the overproduction of reactive oxygen/nitrogen/sulfur species (ROS/RNS/RSS) correlates with progressive neurodegeneration.", "tags": [{"end": 110, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 16, "tag": "CellOrMolecularDysfunction"}, {"end": 54, "start": 37, "tag": "CellOrMolecularDysfunction"}, {"end": 213, "start": 196, "tag": "CellOrMolecularDysfunction"}, {"end": 195, "start": 184, "tag": "TemporalConcept"}, {"end": 158, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 155, "tag": "Chemical"}, {"end": 162, "start": 159, "tag": "Chemical"}, {"end": 162, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 163, "tag": "Chemical"}, {"end": 153, "start": 114, "tag": "Chemical"}, {"end": 153, "start": 114, "tag": "BiologicallyActiveSubstance"}]}{"id": "136_3", "text": "It is well defined that neurons are prone to oxidative damage due to the enrichment of neuronal membranes with polyunsaturated fatty acids (PUFA) along with highly dynamic and regiospecific oxygen consumption by brain cells and a weak antioxidant defense.", "tags": [{"end": 105, "start": 87, "tag": "CellComponent"}, {"end": 138, "start": 111, "tag": "Chemical"}, {"end": 144, "start": 140, "tag": "Chemical"}, {"end": 208, "start": 176, "tag": "ClinicalAttribute"}, {"end": 208, "start": 176, "tag": "HealthCareActivity"}, {"end": 254, "start": 235, "tag": "BiologicFunction"}, {"end": 61, "start": 45, "tag": "CellOrMolecularDysfunction"}, {"end": 223, "start": 212, "tag": "Cell"}, {"end": 31, "start": 24, "tag": "Cell"}, {"end": 95, "start": 87, "tag": "Cell"}, {"end": 105, "start": 96, "tag": "CellComponent"}, {"end": 254, "start": 230, "tag": "Finding"}]}{"id": "136_4", "text": "Oxidative stress (OS) refers to the condition where imbalance between oxidants and antioxidants leads to the elevation in ROS/RNS/RSS levels in biological systems.", "tags": [{"end": 16, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 16, "start": 0, "tag": "CellFunction"}, {"end": 20, "start": 18, "tag": "CellOrMolecularDysfunction"}, {"end": 20, "start": 18, "tag": "CellFunction"}, {"end": 78, "start": 70, "tag": "Chemical"}, {"end": 78, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 70, "tag": "PharmacologicSubstance"}, {"end": 118, "start": 109, "tag": "Finding"}, {"end": 162, "start": 144, "tag": "BiologicFunction"}, {"end": 95, "start": 83, "tag": "PharmacologicSubstance"}, {"end": 95, "start": 52, "tag": "CellOrMolecularDysfunction"}, {"end": 133, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 122, "tag": "Chemical"}]}{"id": "136_5", "text": "Increasing evidence has demonstrated the dysfunction of redox signaling and its regulation leads to oxidative stress in the cellular environment.", "tags": [{"end": 144, "start": 124, "tag": "CellFunction"}, {"end": 116, "start": 100, "tag": "CellOrMolecularDysfunction"}, {"end": 19, "start": 0, "tag": "Finding"}, {"end": 71, "start": 41, "tag": "CellOrMolecularDysfunction"}]}{"id": "136_6", "text": "Thus, disruption as well as dysregulation of redox signaling is found to be linked with various neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).", "tags": [{"end": 123, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 204, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 246, "tag": "DiseaseOrSyndrome"}, {"end": 244, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 28, "tag": "PathologicFunction"}]}{"id": "136_7", "text": "The present chapter gives insight about how redox mediated OS can lead to neurodegenerative diseases.", "tags": [{"end": 61, "start": 59, "tag": "CellOrMolecularDysfunction"}, {"end": 61, "start": 59, "tag": "CellFunction"}, {"end": 49, "start": 44, "tag": "CellFunction"}, {"end": 100, "start": 74, "tag": "DiseaseOrSyndrome"}]}{"id": "137_0", "text": "In this review, we shed light on recent advances regarding the characterization of biochemical pathways of cellular mechanosensing and mechanotransduction with particular attention to their role in neurodegenerative disease pathogenesis.", "tags": [{"end": 103, "start": 83, "tag": "CellFunction"}, {"end": 154, "start": 135, "tag": "CellFunction"}, {"end": 236, "start": 224, "tag": "PathologicFunction"}, {"end": 79, "start": 63, "tag": "ResearchActivity"}, {"end": 48, "start": 40, "tag": "Finding"}, {"end": 39, "start": 33, "tag": "TemporalConcept"}, {"end": 180, "start": 171, "tag": "BiologicFunction"}, {"end": 223, "start": 198, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "137_1", "text": "While the mechanistic components of these pathways are mostly uncovered today, the crosstalk between mechanical forces and soluble intracellular signaling is still not fully elucidated.", "tags": [{"end": 92, "start": 83, "tag": "CellFunction"}, {"end": 32, "start": 10, "tag": "Finding"}, {"end": 154, "start": 123, "tag": "CellFunction"}, {"end": 50, "start": 42, "tag": "CellFunction"}, {"end": 92, "start": 83, "tag": "Finding"}, {"end": 118, "start": 101, "tag": "NaturalPhenomenonOrProcess"}]}{"id": "137_2", "text": "Here, we recapitulate the general concepts of mechanobiology and the mechanisms that govern the mechanosensing and mechanotransduction processes, and we examine the crosstalk between mechanical stimuli and intracellular biochemical response, highlighting their effect on cellular organelles' homeostasis and dysfunction.", "tags": [{"end": 42, "start": 26, "tag": "Finding"}, {"end": 60, "start": 46, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 134, "start": 115, "tag": "CellFunction"}, {"end": 240, "start": 206, "tag": "CellFunction"}, {"end": 290, "start": 271, "tag": "CellComponent"}, {"end": 290, "start": 280, "tag": "CellComponent"}, {"end": 174, "start": 165, "tag": "CellFunction"}, {"end": 319, "start": 308, "tag": "PathologicFunction"}, {"end": 303, "start": 292, "tag": "BiologicFunction"}, {"end": 60, "start": 46, "tag": "CellFunction"}, {"end": 110, "start": 96, "tag": "CellFunction"}, {"end": 201, "start": 183, "tag": "NaturalPhenomenonOrProcess"}, {"end": 174, "start": 165, "tag": "Finding"}]}{"id": "137_3", "text": "In particular, we discuss the current knowledge about the translation of mechanosignaling into biochemical signaling, focusing on those diseases that encompass metabolic accumulation of mutant proteins and have as primary characteristics the formation of pathological intracellular aggregates, such as Alzheimer's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis and Parkinson's Disease.", "tags": [{"end": 169, "start": 160, "tag": "CellFunction"}, {"end": 169, "start": 160, "tag": "BiologicFunction"}, {"end": 201, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 186, "tag": "CellOrMolecularDysfunction"}, {"end": 321, "start": 302, "tag": "DiseaseOrSyndrome"}, {"end": 398, "start": 379, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 170, "tag": "Finding"}, {"end": 343, "start": 323, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 58, "tag": "CellFunction"}, {"end": 47, "start": 38, "tag": "Finding"}, {"end": 374, "start": 345, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 30, "tag": "TemporalConcept"}, {"end": 292, "start": 255, "tag": "CellOrMolecularDysfunction"}]}{"id": "137_4", "text": "Overall, recent findings elucidate how mechanosensing and mechanotransduction pathways may be crucial to understand the pathogenic mechanisms underlying neurodegenerative diseases and emphasize the importance of these pathways for identifying potential therapeutic targets.", "tags": [{"end": 141, "start": 120, "tag": "PathologicFunction"}, {"end": 272, "start": 253, "tag": "ResearchActivity"}, {"end": 272, "start": 243, "tag": "ResearchActivity"}, {"end": 86, "start": 58, "tag": "CellFunction"}, {"end": 226, "start": 218, "tag": "CellFunction"}, {"end": 15, "start": 9, "tag": "TemporalConcept"}, {"end": 179, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 39, "tag": "CellFunction"}]}{"id": "138_0", "text": "Prion diseases are fatal, transmissible neurodegenerative disorders whose pathogenesis is driven by the misfolding, self-templating and cell-to-cell spread of the prion protein.", "tags": [{"end": 14, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 74, "tag": "PathologicFunction"}, {"end": 114, "start": 104, "tag": "CellOrMolecularDysfunction"}, {"end": 155, "start": 136, "tag": "CellFunction"}, {"end": 176, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 40, "tag": "DiseaseOrSyndrome"}]}{"id": "138_1", "text": "Other neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and Huntington's disease, share some of these prion-like features, with different aggregation-prone proteins.", "tags": [{"end": 60, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 195, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "138_2", "text": "Consequently, researchers have begun to apply prion-specific techniques, like the prion organotypic slice culture assay (POSCA), to these disorders.", "tags": [{"end": 25, "start": 14, "tag": "ResearchActivity"}, {"end": 87, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 82, "tag": "ResearchActivity"}, {"end": 126, "start": 121, "tag": "ResearchActivity"}]}{"id": "138_3", "text": "In this review we explore the ways in which the prion phenomenon has been used in organotypic cultures to study neurodegenerative diseases from the perspective of protein aggregation and spreading, strain propagation, the role of glia in pathogenesis, and efficacy of drug treatments.", "tags": [{"end": 53, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 148, "tag": "BiologicFunction"}, {"end": 234, "start": 230, "tag": "Cell"}, {"end": 250, "start": 238, "tag": "PathologicFunction"}, {"end": 283, "start": 268, "tag": "HealthCareActivity"}, {"end": 272, "start": 268, "tag": "PharmacologicSubstance"}, {"end": 138, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 163, "tag": "CellFunction"}, {"end": 182, "start": 163, "tag": "CellOrMolecularDysfunction"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 111, "start": 106, "tag": "ResearchActivity"}, {"end": 102, "start": 82, "tag": "ResearchActivity"}]}{"id": "138_4", "text": "We also present an overview of the advantages and disadvantages of this culture system compared to in vivo and in vitro models and provide suggestions for new directions.", "tags": [{"end": 27, "start": 19, "tag": "ResearchActivity"}, {"end": 86, "start": 72, "tag": "ResearchActivity"}, {"end": 106, "start": 99, "tag": "ResearchActivity"}, {"end": 119, "start": 111, "tag": "ResearchActivity"}, {"end": 126, "start": 120, "tag": "ManufacturedObject"}]}{"id": "139_0", "text": "Neurodegenerative diseases are debilitating and currently incurable conditions causing severe cognitive and motor impairments, defined by the progressive deterioration of neuronal structure and function, eventually causing neuronal loss.", "tags": [{"end": 43, "start": 31, "tag": "SignOrSymptom"}, {"end": 125, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 48, "tag": "TemporalConcept"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 142, "tag": "TemporalConcept"}, {"end": 93, "start": 87, "tag": "Finding"}, {"end": 236, "start": 223, "tag": "CellOrMolecularDysfunction"}, {"end": 78, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 154, "tag": "CellOrMolecularDysfunction"}]}{"id": "139_1", "text": "Understand the molecular and cellular mechanisms underlying these disorders are essential to develop therapeutic approaches.", "tags": [{"end": 10, "start": 0, "tag": "BiologicFunction"}, {"end": 123, "start": 101, "tag": "HealthCareActivity"}]}{"id": "139_2", "text": "MicroRNAs (miRNAs) are short non-coding RNAs implicated in gene expression regulation at the post-transcriptional level.", "tags": [{"end": 113, "start": 93, "tag": "CellFunction"}, {"end": 44, "start": 29, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 9, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 11, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 17, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 59, "tag": "CellFunction"}]}{"id": "139_3", "text": "Moreover, miRNAs are crucial for different processes, including cell growth, signal transmission, apoptosis, cancer and aging-related neurodegenerative diseases.", "tags": [{"end": 52, "start": 43, "tag": "BiologicFunction"}, {"end": 52, "start": 43, "tag": "NaturalPhenomenonOrProcess"}, {"end": 96, "start": 77, "tag": "CellFunction"}, {"end": 115, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 98, "tag": "CellFunction"}, {"end": 75, "start": 64, "tag": "CellFunction"}, {"end": 125, "start": 120, "tag": "BiologicFunction"}, {"end": 125, "start": 120, "tag": "CellFunction"}, {"end": 16, "start": 10, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 16, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 134, "tag": "DiseaseOrSyndrome"}]}{"id": "139_4", "text": "Altered miRNAs levels have been associated with the formation of reactive oxygen species (ROS) and mitochondrial dysfunction.", "tags": [{"end": 124, "start": 99, "tag": "CellOrMolecularDysfunction"}, {"end": 14, "start": 8, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 14, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 65, "tag": "Chemical"}, {"end": 93, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 90, "tag": "Chemical"}, {"end": 21, "start": 0, "tag": "CellOrMolecularDysfunction"}]}{"id": "139_5", "text": "Mitochondrial dysfunction and ROS formation occur in many neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's diseases.", "tags": [{"end": 25, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 143, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 30, "tag": "Chemical"}, {"end": 84, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 30, "tag": "CellFunction"}, {"end": 117, "start": 106, "tag": "DiseaseOrSyndrome"}]}{"id": "139_6", "text": "The crosstalk existing among oxidative stress, mitochondrial dysfunction and miRNAs dysregulation plays a pivotal role in the onset and progression of neurodegenerative diseases.", "tags": [{"end": 72, "start": 47, "tag": "CellOrMolecularDysfunction"}, {"end": 13, "start": 4, "tag": "CellFunction"}, {"end": 83, "start": 77, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 83, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 126, "tag": "TemporalConcept"}, {"end": 45, "start": 29, "tag": "CellOrMolecularDysfunction"}, {"end": 147, "start": 136, "tag": "PathologicFunction"}, {"end": 147, "start": 136, "tag": "TemporalConcept"}, {"end": 177, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 77, "tag": "CellOrMolecularDysfunction"}, {"end": 13, "start": 4, "tag": "Finding"}]}{"id": "139_7", "text": "Based on this evidence, in this review, with a focus on miRNAs and their role in mitochondrial dysfunction in aging-related neurodegenerative diseases, with a focus on their potential as diagnostic biomarkers and therapeutic targets.", "tags": [{"end": 232, "start": 213, "tag": "ResearchActivity"}, {"end": 106, "start": 81, "tag": "CellOrMolecularDysfunction"}, {"end": 115, "start": 110, "tag": "BiologicFunction"}, {"end": 115, "start": 110, "tag": "CellFunction"}, {"end": 62, "start": 56, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 62, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 14, "tag": "Finding"}, {"end": 150, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 32, "tag": "ResearchActivity"}, {"end": 38, "start": 32, "tag": "HealthCareActivity"}, {"end": 208, "start": 187, "tag": "ClinicalAttribute"}]}{"id": "140_0", "text": "The growing and rapid development of high-throughput sequencing technologies have allowed a greater understanding of the mechanisms underlying gene expression regulation.", "tags": [{"end": 76, "start": 37, "tag": "ResearchActivity"}, {"end": 169, "start": 143, "tag": "CellFunction"}, {"end": 169, "start": 143, "tag": "ResearchActivity"}]}{"id": "140_1", "text": "Editing the epigenome and epitranscriptome directs the fate of the transcript influencing the functional outcome of each mRNA.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "CellFunction"}, {"end": 21, "start": 12, "tag": "GeneOrGenome"}, {"end": 42, "start": 26, "tag": "MolecularSequence"}, {"end": 77, "start": 67, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 125, "start": 121, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "140_2", "text": "In this context, non-coding RNAs play a decisive role in addressing the expression regulation at the gene and chromosomal levels.", "tags": [{"end": 32, "start": 17, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 32, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 72, "tag": "CellFunction"}]}{"id": "140_3", "text": "Long-noncoding RNAs, consisting of more than 200 nucleotides, have been shown to act as epigenetic regulators in several key molecular processes involving neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and Huntington's disease.", "tags": [{"end": 60, "start": 49, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 288, "start": 268, "tag": "DiseaseOrSyndrome"}, {"end": 232, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 263, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 19, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 88, "tag": "CellFunction"}]}{"id": "140_4", "text": "Long-noncoding RNAs are abundantly expressed in the central nervous system, suggesting that their deregulation could trigger neuronal degeneration through RNA modifications.", "tags": [{"end": 110, "start": 98, "tag": "BiologicFunction"}, {"end": 110, "start": 98, "tag": "CellOrMolecularDysfunction"}, {"end": 74, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 125, "tag": "CellOrMolecularDysfunction"}, {"end": 158, "start": 155, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 19, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 172, "start": 155, "tag": "CellFunction"}]}{"id": "140_5", "text": "The evaluation of their diagnostic significance and therapeutic potential could lead to new treatments for these diseases for which there is no cure.", "tags": [{"end": 14, "start": 4, "tag": "HealthCareActivity"}, {"end": 14, "start": 4, "tag": "ResearchActivity"}, {"end": 73, "start": 52, "tag": "HealthCareActivity"}, {"end": 102, "start": 92, "tag": "HealthCareActivity"}, {"end": 102, "start": 92, "tag": "ResearchActivity"}, {"end": 148, "start": 141, "tag": "Finding"}]}{"id": "141_0", "text": "In recent decades, our understanding of the molecular changes involved in neurodegenerative diseases has been transformed.", "tags": [{"end": 17, "start": 3, "tag": "TemporalConcept"}, {"end": 100, "start": 74, "tag": "DiseaseOrSyndrome"}]}{"id": "141_1", "text": "Single-cell RNA sequencing and single-nucleus RNA sequencing technologies have been applied to provide cellular and molecular details of the brain at the single-cell level.", "tags": [{"end": 165, "start": 154, "tag": "ResearchActivity"}, {"end": 26, "start": 0, "tag": "ResearchActivity"}, {"end": 60, "start": 31, "tag": "ResearchActivity"}, {"end": 45, "start": 38, "tag": "Chemical"}, {"end": 45, "start": 38, "tag": "CellComponent"}, {"end": 146, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 12, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 49, "start": 46, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "141_2", "text": "This has expanded our knowledge of the central nervous system and provided insights into the molecular vulnerability of brain cell types and underlying mechanisms in neurodegenerative diseases.", "tags": [{"end": 130, "start": 120, "tag": "Cell"}, {"end": 192, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 126, "tag": "Cell"}, {"end": 31, "start": 22, "tag": "Finding"}, {"end": 61, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "141_3", "text": "In this review, we highlight the recent advances and findings related to neurodegenerative diseases using these cutting-edge technologies.", "tags": [{"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 99, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 33, "tag": "TemporalConcept"}, {"end": 48, "start": 40, "tag": "Finding"}, {"end": 137, "start": 112, "tag": "ResearchActivity"}]}{"id": "141_4", "text": "(C) 2021 The Author(s).", "tags": []}{"id": "141_5", "text": "Published by Elsevier Ltd on behalf of IBRO.", "tags": []}{"id": "142_0", "text": "Cardiac impairment contributes significantly to the mortality associated with several neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD), primarily recognized as brain pathologies.", "tags": [{"end": 61, "start": 52, "tag": "Finding"}, {"end": 246, "start": 229, "tag": "PathologicFunction"}, {"end": 112, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}]}{"id": "142_1", "text": "These diseases may be caused by aggregation of a misfolded protein, most often, in the brain, although new evidence also reveals peripheral abnormalities.", "tags": [{"end": 153, "start": 129, "tag": "AnatomicalAbnormality"}, {"end": 66, "start": 32, "tag": "CellOrMolecularDysfunction"}, {"end": 115, "start": 107, "tag": "Finding"}, {"end": 92, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "142_2", "text": "After characterization of the cardiac involvement in neurodegenerative diseases, several studies concentrated on elucidating the cause of the impaired cardiac function.", "tags": [{"end": 37, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 151, "tag": "BiologicFunction"}, {"end": 22, "start": 6, "tag": "ResearchActivity"}, {"end": 79, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 38, "tag": "Finding"}, {"end": 96, "start": 89, "tag": "ResearchActivity"}, {"end": 167, "start": 142, "tag": "PathologicFunction"}]}{"id": "142_3", "text": "However, most of the current knowledge is focused on the mechanical aspects of the heart rather than the electrical disturbances.", "tags": [{"end": 88, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 105, "tag": "PathologicFunction"}, {"end": 38, "start": 29, "tag": "Finding"}, {"end": 28, "start": 21, "tag": "TemporalConcept"}]}{"id": "142_4", "text": "The main objective of this review is to summarize the most recent advances in the elucidation of cardiac electrical remodeling in the neurodegenerative environment.", "tags": [{"end": 74, "start": 66, "tag": "Finding"}, {"end": 33, "start": 27, "tag": "ResearchActivity"}, {"end": 33, "start": 27, "tag": "HealthCareActivity"}, {"end": 163, "start": 134, "tag": "CellOrMolecularDysfunction"}, {"end": 65, "start": 59, "tag": "TemporalConcept"}, {"end": 126, "start": 97, "tag": "PathologicFunction"}]}{"id": "142_5", "text": "We aimed to determine a crosstalk between the heart and the brain in three neurodegenerative conditions: AD, PD, and HD.", "tags": [{"end": 119, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 24, "tag": "BiologicFunction"}]}{"id": "142_6", "text": "We found that the most studies demonstrated important alterations in the electrocardiogram (ECG) of patients with neurodegeneration and in animal models of the conditions.", "tags": [{"end": 90, "start": 73, "tag": "HealthCareActivity"}, {"end": 90, "start": 73, "tag": "ManufacturedObject"}, {"end": 95, "start": 92, "tag": "HealthCareActivity"}, {"end": 95, "start": 92, "tag": "ManufacturedObject"}, {"end": 131, "start": 114, "tag": "CellOrMolecularDysfunction"}, {"end": 30, "start": 23, "tag": "ResearchActivity"}, {"end": 108, "start": 100, "tag": "PatientOrDisabledGroup"}, {"end": 152, "start": 139, "tag": "ResearchActivity"}]}{"id": "142_7", "text": "We also showed that little is described when considering excitability disruptions in cardiomyocytes, for example, action potential impairments.", "tags": [{"end": 99, "start": 85, "tag": "Cell"}, {"end": 130, "start": 114, "tag": "CellFunction"}, {"end": 81, "start": 57, "tag": "CellOrMolecularDysfunction"}, {"end": 142, "start": 114, "tag": "CellOrMolecularDysfunction"}]}{"id": "142_8", "text": "It is a matter of contention whether central nervous system abnormalities or the peripheral ones increase the risk of heart diseases in patients with neurodegenerative conditions.", "tags": [{"end": 28, "start": 18, "tag": "BiologicFunction"}, {"end": 114, "start": 110, "tag": "Finding"}, {"end": 132, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 136, "tag": "PatientOrDisabledGroup"}, {"end": 167, "start": 150, "tag": "CellOrMolecularDysfunction"}, {"end": 91, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 37, "tag": "PathologicFunction"}]}{"id": "142_9", "text": "To determine this notion, there is a need for new heart studies focusing specifically on the cardiac electrophysiology (e.g., ECG and cardiomyocyte excitability).", "tags": [{"end": 63, "start": 56, "tag": "HealthCareActivity"}, {"end": 118, "start": 93, "tag": "HealthCareActivity"}, {"end": 129, "start": 126, "tag": "HealthCareActivity"}, {"end": 129, "start": 126, "tag": "ManufacturedObject"}, {"end": 147, "start": 134, "tag": "Cell"}, {"end": 55, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 160, "start": 134, "tag": "CellFunction"}]}{"id": "142_10", "text": "This review could serve as an important guide in designing novel accurate approaches targeting the heart in neuronal conditions.", "tags": [{"end": 104, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 108, "tag": "Cell"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}]}{"id": "143_0", "text": "Huntington's disease (HD) is a debilitating inherited neurodegenerative disorder characterized by motor, cognitive and psychiatric deficits.", "tags": [{"end": 80, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 98, "tag": "Finding"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}]}{"id": "143_1", "text": "Microglial and astrocyte activation, part of the process termed neuroinflammation, is one hallmark of HD, and modulation of neuroinflammation has been suggested as a potential target for therapeutic intervention.", "tags": [{"end": 10, "start": 0, "tag": "Cell"}, {"end": 35, "start": 25, "tag": "CellFunction"}, {"end": 24, "start": 15, "tag": "Cell"}, {"end": 98, "start": 90, "tag": "Finding"}, {"end": 211, "start": 187, "tag": "HealthCareActivity"}, {"end": 81, "start": 64, "tag": "PathologicFunction"}, {"end": 141, "start": 124, "tag": "PathologicFunction"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 166, "tag": "Finding"}]}{"id": "143_2", "text": "Although the relationship between neuroinflammation markers and the disease pathology is not completely understood, there is now compelling evidence to suggest that microglial and astrocyte activation signatures, identified as soluble factors in the cerebrospinal fluid or blood, or identified using PET imaging, could be used as potential complementary biomarkers to monitor and evaluate disease progression in HD patients.", "tags": [{"end": 59, "start": 52, "tag": "ClinicalAttribute"}, {"end": 200, "start": 190, "tag": "CellFunction"}, {"end": 242, "start": 227, "tag": "CellComponent"}, {"end": 375, "start": 368, "tag": "HealthCareActivity"}, {"end": 375, "start": 368, "tag": "ManufacturedObject"}, {"end": 223, "start": 213, "tag": "Finding"}, {"end": 189, "start": 180, "tag": "Cell"}, {"end": 311, "start": 300, "tag": "HealthCareActivity"}, {"end": 25, "start": 13, "tag": "Finding"}, {"end": 278, "start": 273, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 175, "start": 165, "tag": "Cell"}, {"end": 51, "start": 34, "tag": "PathologicFunction"}, {"end": 85, "start": 68, "tag": "PathologicFunction"}, {"end": 408, "start": 389, "tag": "PathologicFunction"}, {"end": 148, "start": 140, "tag": "Finding"}, {"end": 364, "start": 354, "tag": "ClinicalAttribute"}, {"end": 269, "start": 250, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 423, "start": 412, "tag": "PatientOrDisabledGroup"}, {"end": 211, "start": 201, "tag": "ResearchActivity"}]}{"id": "143_3", "text": "Identification of neuroinflammation markers prior to clinical symptoms opens up the possibility of evaluating disease-modifying treatments in the premanifest phase.", "tags": [{"end": 14, "start": 0, "tag": "Finding"}, {"end": 43, "start": 36, "tag": "ClinicalAttribute"}, {"end": 138, "start": 110, "tag": "HealthCareActivity"}, {"end": 70, "start": 53, "tag": "SignOrSymptom"}, {"end": 35, "start": 18, "tag": "PathologicFunction"}, {"end": 163, "start": 146, "tag": "TemporalConcept"}]}{"id": "143_4", "text": "Hence, neuroinflammatory biofluid and imaging biomarkers could provide an objective measurement for assessing HD severity and would also be valuable in the clinical care of existing HD patients.", "tags": [{"end": 95, "start": 84, "tag": "ResearchActivity"}, {"end": 95, "start": 84, "tag": "HealthCareActivity"}, {"end": 121, "start": 113, "tag": "ClinicalAttribute"}, {"end": 121, "start": 113, "tag": "Finding"}, {"end": 169, "start": 156, "tag": "HealthCareActivity"}, {"end": 24, "start": 7, "tag": "PathologicFunction"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 38, "tag": "ClinicalAttribute"}, {"end": 193, "start": 182, "tag": "PatientOrDisabledGroup"}, {"end": 33, "start": 25, "tag": "Substance"}]}{"id": "143_5", "text": "Neuroinflammatory biomarkers would also be useful in a clinical trial context, potentially serving as surrogate endpoints.", "tags": [{"end": 17, "start": 0, "tag": "PathologicFunction"}, {"end": 111, "start": 102, "tag": "PopulationGroup"}, {"end": 111, "start": 102, "tag": "PharmacologicSubstance"}, {"end": 69, "start": 55, "tag": "ResearchActivity"}, {"end": 28, "start": 18, "tag": "ClinicalAttribute"}]}{"id": "143_6", "text": "This chapter will explore the evidence of roles for activated microglia, astrocytes, and peripheral immune cells in HD, and explore possible biomarkers of neuroinflammation.", "tags": [{"end": 112, "start": 100, "tag": "Cell"}, {"end": 172, "start": 155, "tag": "PathologicFunction"}, {"end": 71, "start": 52, "tag": "Cell"}, {"end": 38, "start": 30, "tag": "Finding"}, {"end": 99, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 73, "tag": "Cell"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 141, "tag": "ClinicalAttribute"}]}{"id": "144_0", "text": "Antisense oligonucleotides represent a novel therapeutic platform for the discovery of medicines that have the potential to treat most neurodegenerative diseases.", "tags": [{"end": 26, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 26, "start": 0, "tag": "Chemical"}, {"end": 26, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 74, "tag": "ResearchActivity"}, {"end": 161, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 87, "tag": "PharmacologicSubstance"}, {"end": 65, "start": 45, "tag": "HealthCareActivity"}]}{"id": "144_1", "text": "Antisense drugs are currently in development for the treatment of amyotrophic lateral sclerosis, Huntington's disease, and Alzheimer's disease, and multiple research programs are underway for additional neurodegenerative diseases.", "tags": [{"end": 117, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 53, "tag": "HealthCareActivity"}, {"end": 62, "start": 53, "tag": "ResearchActivity"}, {"end": 142, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 157, "tag": "ResearchActivity"}, {"end": 15, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 29, "start": 20, "tag": "TemporalConcept"}]}{"id": "144_2", "text": "One antisense drug, nusinersen, has been approved for the treatment of spinal muscular atrophy.", "tags": [{"end": 30, "start": 20, "tag": "Chemical"}, {"end": 94, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 58, "tag": "HealthCareActivity"}, {"end": 67, "start": 58, "tag": "ResearchActivity"}, {"end": 18, "start": 4, "tag": "PharmacologicSubstance"}, {"end": 30, "start": 20, "tag": "PharmacologicSubstance"}]}{"id": "144_3", "text": "Importantly, nusinersen improves disease symptoms when administered to symptomatic patients rather than just slowing the progression of the disease.", "tags": [{"end": 23, "start": 13, "tag": "Chemical"}, {"end": 49, "start": 33, "tag": "SignOrSymptom"}, {"end": 82, "start": 71, "tag": "SignOrSymptom"}, {"end": 132, "start": 121, "tag": "PathologicFunction"}, {"end": 132, "start": 121, "tag": "TemporalConcept"}, {"end": 91, "start": 83, "tag": "PatientOrDisabledGroup"}, {"end": 147, "start": 121, "tag": "PathologicFunction"}, {"end": 147, "start": 121, "tag": "TemporalConcept"}, {"end": 23, "start": 13, "tag": "PharmacologicSubstance"}]}{"id": "144_4", "text": "In addition to the benefit to spinal muscular atrophy patients, there are discoveries from nusinersen that can be applied to other neurological diseases, including method of delivery, doses, tolerability of intrathecally delivered antisense drugs, and the biodistribution of intrathecal dosed antisense drugs.", "tags": [{"end": 85, "start": 74, "tag": "ResearchActivity"}, {"end": 101, "start": 91, "tag": "Chemical"}, {"end": 170, "start": 164, "tag": "ResearchActivity"}, {"end": 170, "start": 164, "tag": "HealthCareActivity"}, {"end": 203, "start": 191, "tag": "ResearchActivity"}, {"end": 220, "start": 207, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 271, "start": 256, "tag": "BiologicFunction"}, {"end": 286, "start": 275, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 308, "start": 275, "tag": "HealthCareActivity"}, {"end": 182, "start": 174, "tag": "BiologicFunction"}, {"end": 246, "start": 231, "tag": "PharmacologicSubstance"}, {"end": 308, "start": 293, "tag": "PharmacologicSubstance"}, {"end": 53, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 54, "tag": "PatientOrDisabledGroup"}, {"end": 152, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 91, "tag": "PharmacologicSubstance"}]}{"id": "144_5", "text": "Based in part on the early success of nusinersen, antisense drugs hold great promise as a therapeutic platform for the treatment of neurological diseases.", "tags": [{"end": 48, "start": 38, "tag": "Chemical"}, {"end": 128, "start": 119, "tag": "HealthCareActivity"}, {"end": 128, "start": 119, "tag": "ResearchActivity"}, {"end": 65, "start": 50, "tag": "PharmacologicSubstance"}, {"end": 110, "start": 90, "tag": "HealthCareActivity"}, {"end": 153, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 38, "tag": "PharmacologicSubstance"}]}{"id": "145_0", "text": "Huntington's disease (HD) is an incurable neurodegenerative disorder caused by CAG trinucleotide expansions in the huntingtin gene.", "tags": [{"end": 107, "start": 79, "tag": "CellOrMolecularDysfunction"}, {"end": 130, "start": 115, "tag": "GeneOrGenome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 42, "tag": "DiseaseOrSyndrome"}]}{"id": "145_1", "text": "Markers of both systemic and CNS immune activation and inflammation have been widely noted in HD and mouse models of HD.", "tags": [{"end": 7, "start": 0, "tag": "ClinicalAttribute"}, {"end": 24, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 101, "tag": "ExperimentalModelOfDisease"}, {"end": 50, "start": 33, "tag": "BiologicFunction"}, {"end": 67, "start": 55, "tag": "PathologicFunction"}, {"end": 32, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}]}{"id": "145_2", "text": "In particular, elevation of the pro-inflammatory cytokine interleukin-6 (IL-6) is the earliest reported marker of immune activation in HD, and this elevation has been suggested to contribute to HD pathogenesis.", "tags": [{"end": 77, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 73, "tag": "GeneOrGenome"}, {"end": 77, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 86, "tag": "TemporalConcept"}, {"end": 131, "start": 114, "tag": "BiologicFunction"}, {"end": 209, "start": 197, "tag": "PathologicFunction"}, {"end": 48, "start": 32, "tag": "PathologicFunction"}, {"end": 110, "start": 104, "tag": "ClinicalAttribute"}, {"end": 24, "start": 15, "tag": "Finding"}, {"end": 157, "start": 148, "tag": "Finding"}, {"end": 137, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 196, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 49, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "145_3", "text": "To test the hypothesis that IL-6 deficiency would be protective against the effects of mutant huntingtin, we generated R6/2 HD model mice that lacked IL-6.", "tags": [{"end": 32, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 28, "tag": "GeneOrGenome"}, {"end": 32, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 150, "tag": "GeneOrGenome"}, {"end": 154, "start": 150, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 87, "tag": "CellOrMolecularDysfunction"}, {"end": 43, "start": 33, "tag": "Finding"}, {"end": 137, "start": 119, "tag": "ExperimentalModelOfDisease"}]}{"id": "145_4", "text": "Contrary to our prediction, IL-6 deficiency exacerbated HD-model associated behavioral phenotypes.", "tags": [{"end": 32, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 28, "tag": "GeneOrGenome"}, {"end": 43, "start": 33, "tag": "Finding"}, {"end": 97, "start": 76, "tag": "OrganismAttribute"}, {"end": 64, "start": 56, "tag": "ExperimentalModelOfDisease"}]}{"id": "145_5", "text": "Single nuclear RNA Sequencing (snRNA-seq) analysis of striatal cell types revealed that IL-6 deficiency led to the dysregulation of various genes associated with synaptic function, as well as the BDNF receptor Ntrk2.", "tags": [{"end": 92, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 88, "tag": "GeneOrGenome"}, {"end": 92, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 115, "tag": "Finding"}, {"end": 179, "start": 162, "tag": "CellFunction"}, {"end": 209, "start": 196, "tag": "AminoAcidPeptideOrProtein"}, {"end": 215, "start": 210, "tag": "GeneOrGenome"}, {"end": 215, "start": 210, "tag": "AminoAcidPeptideOrProtein"}, {"end": 215, "start": 210, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 63, "tag": "Cell"}, {"end": 103, "start": 93, "tag": "Finding"}, {"end": 200, "start": 196, "tag": "AminoAcidPeptideOrProtein"}, {"end": 200, "start": 196, "tag": "BiologicallyActiveSubstance"}, {"end": 209, "start": 201, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 42, "tag": "ResearchActivity"}, {"end": 62, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 0, "tag": "ResearchActivity"}, {"end": 40, "start": 31, "tag": "ResearchActivity"}]}{"id": "145_6", "text": "These data suggest that IL-6 deficiency exacerbates the effects of mutant huntingtin through dysregulation of genes of known relevance to HD pathobiology in striatal neurons, and further suggest that modulation of IL-6 to a level that promotes proper regulation of genes associated with synaptic function may hold promise as an HD therapeutic target.", "tags": [{"end": 28, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 24, "tag": "GeneOrGenome"}, {"end": 28, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 218, "start": 214, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 214, "tag": "GeneOrGenome"}, {"end": 218, "start": 214, "tag": "BiologicallyActiveSubstance"}, {"end": 304, "start": 287, "tag": "CellFunction"}, {"end": 84, "start": 67, "tag": "CellOrMolecularDysfunction"}, {"end": 39, "start": 29, "tag": "Finding"}, {"end": 173, "start": 166, "tag": "Cell"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 330, "start": 328, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 56, "tag": "Finding"}, {"end": 153, "start": 141, "tag": "PathologicFunction"}, {"end": 349, "start": 331, "tag": "Finding"}]}{"id": "146_0", "text": "Increased reactive oxygen species production and oxidative stress have been implicated in the pathogenesis of numerous neurodegenerative conditions including among others Alzheimer's disease, Parkinson's disease, Huntington's disease, Friedrich's ataxia, multiple sclerosis, and stroke.", "tags": [{"end": 44, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 44, "start": 10, "tag": "BiologicFunction"}, {"end": 106, "start": 94, "tag": "PathologicFunction"}, {"end": 147, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 253, "start": 235, "tag": "DiseaseOrSyndrome"}, {"end": 273, "start": 255, "tag": "DiseaseOrSyndrome"}, {"end": 285, "start": 279, "tag": "DiseaseOrSyndrome"}, {"end": 233, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 49, "tag": "CellOrMolecularDysfunction"}]}{"id": "146_1", "text": "The endogenous antioxidant response pathway protects cells from oxidative stress by increasing the expression of cytoprotective enzymes and is regulated by the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2).", "tags": [{"end": 58, "start": 53, "tag": "Cell"}, {"end": 109, "start": 84, "tag": "Finding"}, {"end": 224, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 230, "start": 226, "tag": "AminoAcidPeptideOrProtein"}, {"end": 230, "start": 226, "tag": "GeneOrGenome"}, {"end": 80, "start": 64, "tag": "CellOrMolecularDysfunction"}, {"end": 43, "start": 4, "tag": "CellFunction"}, {"end": 135, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 224, "start": 160, "tag": "GeneOrGenome"}, {"end": 224, "start": 160, "tag": "BiologicallyActiveSubstance"}, {"end": 230, "start": 226, "tag": "BiologicallyActiveSubstance"}]}{"id": "146_2", "text": "In addition to regulating the expression of antioxidant genes, NRF2 has also been shown to exert anti-inflammatory effects and modulate both mitochondrial function and biogenesis.", "tags": [{"end": 40, "start": 15, "tag": "CellFunction"}, {"end": 61, "start": 44, "tag": "GeneOrGenome"}, {"end": 67, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 63, "tag": "GeneOrGenome"}, {"end": 122, "start": 97, "tag": "BiologicFunction"}, {"end": 163, "start": 141, "tag": "CellFunction"}, {"end": 178, "start": 168, "tag": "CellFunction"}, {"end": 67, "start": 63, "tag": "BiologicallyActiveSubstance"}]}{"id": "146_3", "text": "This is because mitochondrial dysfunction and neuroinflammation are features of many neurodegenerative diseases as well NRF2 has emerged as a promising therapeutic target.", "tags": [{"end": 41, "start": 16, "tag": "CellOrMolecularDysfunction"}, {"end": 124, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 120, "tag": "GeneOrGenome"}, {"end": 111, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 46, "tag": "PathologicFunction"}, {"end": 124, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 142, "tag": "Finding"}]}{"id": "146_4", "text": "Here, we review evidence for a beneficial role of NRF2 in neurodegenerative conditions and the potential of specific NRF2 activators as therapeutic agents.", "tags": [{"end": 54, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 50, "tag": "GeneOrGenome"}, {"end": 86, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 136, "tag": "HealthCareActivity"}, {"end": 24, "start": 16, "tag": "Finding"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 54, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 117, "tag": "PharmacologicSubstance"}]}{"id": "147_0", "text": "Orexin is a neurotransmitter that mainly regulates sleep/wake cycle.", "tags": [{"end": 6, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 51, "tag": "BiologicFunction"}, {"end": 28, "start": 12, "tag": "BiologicallyActiveSubstance"}]}{"id": "147_1", "text": "In addition to its sleep cycle regulatory role, it is involved in regulation of attention, energy homeostasis, neurogenesis and cognition.", "tags": [{"end": 30, "start": 19, "tag": "BiologicFunction"}, {"end": 89, "start": 80, "tag": "BiologicFunction"}, {"end": 109, "start": 91, "tag": "BiologicFunction"}, {"end": 137, "start": 128, "tag": "BiologicFunction"}, {"end": 123, "start": 111, "tag": "BiologicFunction"}]}{"id": "147_2", "text": "Several evidences has shown the involvement of orexin in narcolepsy, but there are also growing evidences that shows the disturbance in orexin system in neurodegenerative diseases including Alzheimer's, Parkinson's, Epilepsy, Huntington's diseases and Amyotrophic lateral sclerosis.", "tags": [{"end": 43, "start": 32, "tag": "Finding"}, {"end": 53, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 121, "tag": "CellOrMolecularDysfunction"}, {"end": 201, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 247, "start": 226, "tag": "DiseaseOrSyndrome"}, {"end": 281, "start": 252, "tag": "DiseaseOrSyndrome"}, {"end": 224, "start": 216, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 88, "tag": "Finding"}]}{"id": "147_3", "text": "Pathogenesis and clinical symptoms of these disorders can be partly attributed from orexin system imbalance.", "tags": [{"end": 12, "start": 0, "tag": "PathologicFunction"}, {"end": 34, "start": 17, "tag": "SignOrSymptom"}, {"end": 107, "start": 84, "tag": "CellOrMolecularDysfunction"}]}{"id": "147_4", "text": "However, there are controversial reports on the exact relationship between orexin and these neurodegenerative diseases.", "tags": [{"end": 40, "start": 33, "tag": "HealthCareActivity"}, {"end": 40, "start": 33, "tag": "ResearchActivity"}, {"end": 81, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 92, "tag": "DiseaseOrSyndrome"}]}{"id": "147_5", "text": "Therefore, the aim of this review is to summarize the current evidences regarding the role of orexin in these neurodegenerative diseases.", "tags": [{"end": 100, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 54, "tag": "TemporalConcept"}, {"end": 136, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 27, "tag": "ResearchActivity"}, {"end": 33, "start": 27, "tag": "HealthCareActivity"}, {"end": 71, "start": 62, "tag": "Finding"}]}{"id": "148_0", "text": "A Westphal variant of Huntington's disease (HD) is an infrequent presentation of this inherited neurodegenerative disorder.", "tags": [{"end": 64, "start": 54, "tag": "TemporalConcept"}, {"end": 77, "start": 65, "tag": "Finding"}, {"end": 122, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 2, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 22, "tag": "DiseaseOrSyndrome"}]}{"id": "148_1", "text": "Here, we describe a 14-year-old girl who developed symptoms at the age of 7, with molecular evidence of abnormally expanded Cytosine-Adenine-Guanine (CAG) repeats in exon 1 of the Huntingtin gene.", "tags": [{"end": 36, "start": 32, "tag": "PopulationGroup"}, {"end": 59, "start": 51, "tag": "SignOrSymptom"}, {"end": 172, "start": 166, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 195, "start": 180, "tag": "GeneOrGenome"}, {"end": 148, "start": 124, "tag": "MolecularSequence"}, {"end": 70, "start": 67, "tag": "OrganismAttribute"}, {"end": 153, "start": 150, "tag": "MolecularSequence"}, {"end": 100, "start": 92, "tag": "Finding"}, {"end": 31, "start": 20, "tag": "PopulationGroup"}, {"end": 162, "start": 104, "tag": "CellOrMolecularDysfunction"}]}{"id": "148_2", "text": "We briefly review the classical features of this variant highlighting the importance of suspecting HD in a child with parkinsonism and a family history of movement disorder or dementia.", "tags": [{"end": 112, "start": 107, "tag": "PopulationGroup"}, {"end": 130, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 137, "tag": "Finding"}, {"end": 172, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 11, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "HealthCareActivity"}]}{"id": "149_0", "text": "In this review, we summarize the available published information on the neuroprotective effects of increasing nicotinamide adenine dinucleotide (NAD(+)) levels in Huntington's disease models.", "tags": [{"end": 143, "start": 110, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 143, "start": 110, "tag": "PharmacologicSubstance"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 95, "start": 72, "tag": "Finding"}, {"end": 64, "start": 43, "tag": "ResearchActivity"}, {"end": 143, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 163, "tag": "ExperimentalModelOfDisease"}, {"end": 148, "start": 145, "tag": "PharmacologicSubstance"}, {"end": 148, "start": 145, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 148, "start": 145, "tag": "BiologicallyActiveSubstance"}]}{"id": "149_1", "text": "We discuss the rationale of potential therapeutic benefit of administering nicotinamide riboside (NR), a safe and effective NAD(+) precursor.", "tags": [{"end": 96, "start": 75, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 100, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 98, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 140, "start": 124, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 57, "start": 28, "tag": "Finding"}, {"end": 96, "start": 75, "tag": "BiologicallyActiveSubstance"}]}{"id": "149_2", "text": "We discuss the agonistic effect on the Sirtuin1-PGC-1 alpha-PPAR pathway as well as Sirtuin 3, which converge in improving mitochondrial function, decreasing ROS production and ameliorating bioenergetics deficits.", "tags": [{"end": 93, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 158, "tag": "CellFunction"}, {"end": 203, "start": 190, "tag": "BiologicFunction"}, {"end": 212, "start": 204, "tag": "Finding"}, {"end": 145, "start": 123, "tag": "CellFunction"}, {"end": 72, "start": 65, "tag": "CellFunction"}, {"end": 161, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 158, "tag": "Chemical"}, {"end": 31, "start": 15, "tag": "Finding"}, {"end": 47, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 48, "tag": "GeneOrGenome"}]}{"id": "149_3", "text": "Also, we discuss the potential synergistic effect of increasing NAD+ combined with PARPs inhibitors, as a clinical therapeutic option not only in HD, but other neurodegenerative conditions.", "tags": [{"end": 68, "start": 64, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 68, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 83, "tag": "PharmacologicSubstance"}, {"end": 148, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 106, "tag": "HealthCareActivity"}, {"end": 68, "start": 64, "tag": "PharmacologicSubstance"}]}{"id": "150_0", "text": "SinceCaenorhabditis eleganswas first introduced as a genetic model organism by Sydney Brenner, researchers studying it have made significant contributions in numerous fields including investigations of the pathophysiology of neurodegenerative diseases.", "tags": [{"end": 27, "start": 5, "tag": "Eukaryote"}, {"end": 106, "start": 95, "tag": "ResearchActivity"}, {"end": 198, "start": 184, "tag": "ResearchActivity"}, {"end": 221, "start": 206, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 221, "start": 206, "tag": "PathologicFunction"}, {"end": 75, "start": 61, "tag": "ManufacturedObject"}, {"end": 251, "start": 225, "tag": "DiseaseOrSyndrome"}]}{"id": "150_1", "text": "The simple anatomy, optical transparency, and short life-span of this small nematode together with the development and curation of many openly shared resources (including the entire genome, cell lineage and the neural map of the animal) allow researchers usingC.", "tags": [{"end": 18, "start": 11, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 18, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 76, "tag": "Eukaryote"}, {"end": 188, "start": 182, "tag": "GeneOrGenome"}, {"end": 235, "start": 229, "tag": "Eukaryote"}, {"end": 254, "start": 243, "tag": "ResearchActivity"}, {"end": 40, "start": 20, "tag": "OrganismAttribute"}, {"end": 61, "start": 52, "tag": "TemporalConcept"}, {"end": 202, "start": 190, "tag": "ResearchActivity"}, {"end": 221, "start": 211, "tag": "ResearchActivity"}]}{"id": "150_2", "text": "elegansto move their research forward rapidly in an immensely collaborative community.", "tags": [{"end": 29, "start": 21, "tag": "ResearchActivity"}, {"end": 85, "start": 76, "tag": "HealthCareRelatedOrganization"}]}{"id": "150_3", "text": "These resources have allowed researchers to useC.", "tags": [{"end": 40, "start": 29, "tag": "ResearchActivity"}]}{"id": "150_4", "text": "elegansto study the cellular processes that may underlie human diseases.", "tags": [{"end": 38, "start": 20, "tag": "CellFunction"}, {"end": 71, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 57, "tag": "Eukaryote"}, {"end": 15, "start": 10, "tag": "ResearchActivity"}]}{"id": "150_5", "text": "Indeed, many disease-associated genes have orthologs inC.", "tags": [{"end": 37, "start": 13, "tag": "GeneOrGenome"}]}{"id": "150_6", "text": "elegans,allowing the effects of mutations in these genes to be studied in relevant and reproducible neuronal cell-types at single-cell resolutionin vivo.Here we review studies that have attempted to establish genetic models of specific human neurodegenerative diseases (ALS, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease) inC.", "tags": [{"end": 41, "start": 32, "tag": "CellFunction"}, {"end": 41, "start": 32, "tag": "CellOrMolecularDysfunction"}, {"end": 119, "start": 100, "tag": "Cell"}, {"end": 223, "start": 209, "tag": "ManufacturedObject"}, {"end": 273, "start": 270, "tag": "DiseaseOrSyndrome"}, {"end": 294, "start": 275, "tag": "DiseaseOrSyndrome"}, {"end": 315, "start": 296, "tag": "DiseaseOrSyndrome"}, {"end": 241, "start": 236, "tag": "Eukaryote"}, {"end": 337, "start": 317, "tag": "DiseaseOrSyndrome"}, {"end": 268, "start": 242, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 161, "tag": "ResearchActivity"}, {"end": 167, "start": 161, "tag": "HealthCareActivity"}, {"end": 175, "start": 168, "tag": "ResearchActivity"}, {"end": 145, "start": 123, "tag": "ResearchActivity"}]}{"id": "150_7", "text": "elegansand what they have contributed to understanding the molecular and genetic underpinnings of each disease.", "tags": []}{"id": "150_8", "text": "With continuous advances in genome engineering, research conducted using this small organism first established by Brenner, Sulston and their contemporaries will continue to contribute to the understanding of human nervous diseases.", "tags": [{"end": 15, "start": 5, "tag": "TemporalConcept"}, {"end": 24, "start": 16, "tag": "Finding"}, {"end": 46, "start": 28, "tag": "ResearchActivity"}, {"end": 56, "start": 48, "tag": "ResearchActivity"}, {"end": 92, "start": 84, "tag": "Organism"}, {"end": 230, "start": 214, "tag": "DiseaseOrSyndrome"}, {"end": 213, "start": 208, "tag": "Eukaryote"}]}{"id": "151_0", "text": "Increasing evidence in recent years indicates that protein misfolding and aggregation, leading to ER stress, are central factors of pathogenicity in neurodegenerative diseases.", "tags": [{"end": 35, "start": 23, "tag": "TemporalConcept"}, {"end": 69, "start": 51, "tag": "CellOrMolecularDysfunction"}, {"end": 100, "start": 98, "tag": "CellComponent"}, {"end": 107, "start": 98, "tag": "CellOrMolecularDysfunction"}, {"end": 145, "start": 132, "tag": "OrganismAttribute"}, {"end": 18, "start": 0, "tag": "Finding"}, {"end": 175, "start": 149, "tag": "DiseaseOrSyndrome"}]}{"id": "151_1", "text": "This is particularly true in Huntington's disease (HD), where in contrast with other disorders, the cause is monogenic.", "tags": [{"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 29, "tag": "DiseaseOrSyndrome"}]}{"id": "151_2", "text": "Mutant huntingtin interferes with many cellular processes, but the fact that modulation of ER stress and of the unfolded response pathways reduces the toxicity, places these mechanisms at the core and gives hope for potential therapeutic approaches.", "tags": [{"end": 17, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 17, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 7, "tag": "GeneOrGenome"}, {"end": 57, "start": 39, "tag": "CellFunction"}, {"end": 100, "start": 91, "tag": "CellOrMolecularDysfunction"}, {"end": 159, "start": 151, "tag": "InjuryOrPoisoning"}, {"end": 248, "start": 226, "tag": "HealthCareActivity"}, {"end": 93, "start": 91, "tag": "CellComponent"}, {"end": 137, "start": 112, "tag": "CellFunction"}, {"end": 211, "start": 207, "tag": "BiologicFunction"}]}{"id": "151_3", "text": "There is currently no effective treatment for HD and it has a fatal outcome a few years after the start of symptoms of cognitive and motor impairment.", "tags": [{"end": 75, "start": 62, "tag": "Finding"}, {"end": 87, "start": 82, "tag": "TemporalConcept"}, {"end": 115, "start": 107, "tag": "SignOrSymptom"}, {"end": 149, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 32, "tag": "HealthCareActivity"}, {"end": 41, "start": 32, "tag": "ResearchActivity"}]}{"id": "151_4", "text": "Here we will discuss recent findings that shed light on the mechanisms of protein misfolding and aggregation that give origin to ER stress in neurodegenerative diseases, focusing on Huntington's disease, on the cellular response and on how to use this knowledge for possible therapeutic strategies.", "tags": [{"end": 92, "start": 74, "tag": "CellOrMolecularDysfunction"}, {"end": 125, "start": 119, "tag": "TemporalConcept"}, {"end": 131, "start": 129, "tag": "CellComponent"}, {"end": 228, "start": 211, "tag": "CellFunction"}, {"end": 261, "start": 252, "tag": "Finding"}, {"end": 202, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 129, "tag": "CellOrMolecularDysfunction"}, {"end": 297, "start": 275, "tag": "HealthCareActivity"}]}{"id": "152_0", "text": "Neurodegenerative diseases are closely related to brain function and the progression of the diseases are irreversible.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 50, "tag": "BiologicFunction"}, {"end": 84, "start": 73, "tag": "PathologicFunction"}, {"end": 84, "start": 73, "tag": "TemporalConcept"}]}{"id": "152_1", "text": "Due to brain tissue being not easy to acquire, the study of the pathophysiology of neurodegenerative disorders has many limitations-lack of reliable early biomarkers and personalized treatment.", "tags": [{"end": 19, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 64, "tag": "PathologicFunction"}, {"end": 165, "start": 155, "tag": "ClinicalAttribute"}, {"end": 110, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 51, "tag": "ResearchActivity"}, {"end": 192, "start": 183, "tag": "HealthCareActivity"}, {"end": 192, "start": 183, "tag": "ResearchActivity"}]}{"id": "152_2", "text": "At the same time, the blood-brain barrier (BBB) limits most of the drug molecules into the damaged areas of the brain, which makes a big drop in the effect of drug treatment.", "tags": [{"end": 46, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 91, "tag": "InjuryOrPoisoning"}, {"end": 173, "start": 159, "tag": "HealthCareActivity"}, {"end": 173, "start": 159, "tag": "ResearchActivity"}, {"end": 41, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 67, "tag": "PharmacologicSubstance"}, {"end": 163, "start": 159, "tag": "PharmacologicSubstance"}]}{"id": "152_3", "text": "Exosomes, a kind of endogenous nanoscale vesicles, play a key role in cell signaling through the transmission of genetic information and proteins between cells.", "tags": [{"end": 8, "start": 0, "tag": "CellComponent"}, {"end": 84, "start": 70, "tag": "CellFunction"}, {"end": 132, "start": 97, "tag": "CellFunction"}, {"end": 159, "start": 154, "tag": "Cell"}, {"end": 132, "start": 97, "tag": "BiologicFunction"}]}{"id": "152_4", "text": "Because of the ability to cross the BBB, exosomes are expected to link peripheral changes to central nervous system (CNS) events as potential biomarkers, and can even be used as a therapeutic carrier to deliver molecules specifically to CNS.", "tags": [{"end": 39, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 41, "tag": "CellComponent"}, {"end": 115, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 142, "tag": "ClinicalAttribute"}, {"end": 199, "start": 180, "tag": "ManufacturedObject"}, {"end": 220, "start": 211, "tag": "Substance"}, {"end": 240, "start": 237, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "152_5", "text": "Here we summarize the role of exosomes in pathophysiology, diagnosis, prognosis, and treatment of some neurodegenerative diseases (Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis).", "tags": [{"end": 38, "start": 30, "tag": "CellComponent"}, {"end": 57, "start": 42, "tag": "PathologicFunction"}, {"end": 68, "start": 59, "tag": "HealthCareActivity"}, {"end": 150, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 224, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 70, "tag": "HealthCareActivity"}, {"end": 94, "start": 85, "tag": "HealthCareActivity"}, {"end": 94, "start": 85, "tag": "ResearchActivity"}]}{"id": "153_0", "text": "Huntington's disease (HD) is an inherited, autosomal dominant disorder that is characteristically thought of as a degenerative disorder.", "tags": [{"end": 135, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}]}{"id": "153_1", "text": "Despite cellular and molecular grounds suggesting HD could also impact normal development, there has been scarce systems-level data obtained from in vivo human studies supporting this hypothesis.", "tags": [{"end": 89, "start": 71, "tag": "Finding"}, {"end": 89, "start": 78, "tag": "BiologicFunction"}, {"end": 89, "start": 78, "tag": "CellFunction"}, {"end": 167, "start": 160, "tag": "ResearchActivity"}, {"end": 159, "start": 154, "tag": "Eukaryote"}, {"end": 153, "start": 146, "tag": "ResearchActivity"}, {"end": 77, "start": 71, "tag": "Finding"}, {"end": 131, "start": 113, "tag": "ResearchActivity"}, {"end": 52, "start": 50, "tag": "DiseaseOrSyndrome"}]}{"id": "153_2", "text": "Sulcus-specific morphometry analysis may help disentangle the contribution of coexisting neurodegenerative and neurodevelopmental processes, but such an approach has never been used in HD.", "tags": [{"end": 139, "start": 111, "tag": "BiologicFunction"}, {"end": 36, "start": 16, "tag": "ResearchActivity"}, {"end": 187, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 89, "tag": "CellOrMolecularDysfunction"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "153_3", "text": "Here, we investigated cortical sulcal depth, related to degenerative process, as well as cortical sulcal length, related to developmental process, in early-stage HD and age-matched healthy controls.", "tags": [{"end": 145, "start": 124, "tag": "BiologicFunction"}, {"end": 145, "start": 124, "tag": "CellFunction"}, {"end": 161, "start": 150, "tag": "TemporalConcept"}, {"end": 37, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 56, "tag": "PathologicFunction"}, {"end": 188, "start": 181, "tag": "OrganismAttribute"}, {"end": 197, "start": 181, "tag": "PopulationGroup"}, {"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 169, "tag": "OrganismAttribute"}, {"end": 43, "start": 22, "tag": "ClinicalAttribute"}, {"end": 111, "start": 89, "tag": "ClinicalAttribute"}]}{"id": "153_4", "text": "This morphometric analysis revealed significant differences in the HD participants compared with the healthy controls bilaterally in the central and infra-parietal sulcus, but also in the left intermediate frontal sulcus and calcarine fissure.", "tags": [{"end": 26, "start": 5, "tag": "ResearchActivity"}, {"end": 242, "start": 225, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 70, "tag": "PopulationGroup"}, {"end": 59, "start": 36, "tag": "Finding"}, {"end": 108, "start": 101, "tag": "OrganismAttribute"}, {"end": 117, "start": 101, "tag": "PopulationGroup"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 220, "start": 188, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "153_5", "text": "As the primary visual cortex is not connected to the striatum, the latter result adds to the increasing in vivo evidence for primary cortical degeneration in HD.", "tags": [{"end": 28, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 141, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 112, "tag": "Finding"}, {"end": 154, "start": 142, "tag": "PathologicFunction"}, {"end": 111, "start": 104, "tag": "ResearchActivity"}, {"end": 160, "start": 158, "tag": "DiseaseOrSyndrome"}]}{"id": "153_6", "text": "Those sulcal measures that differed between HD and healthy populations were mainly atrophy-related, showing shallower sulci in HD.", "tags": [{"end": 123, "start": 108, "tag": "Finding"}, {"end": 90, "start": 83, "tag": "PathologicFunction"}, {"end": 90, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 51, "tag": "OrganismAttribute"}, {"end": 46, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 59, "tag": "PopulationGroup"}]}{"id": "153_7", "text": "Conversely, the sulcal morphometry also revealed a crucial difference in the imprint of the Sylvian fissure that could not be related to loss of grey matter volume: an absence of asymmetry in the length of this fissure in HD.", "tags": [{"end": 34, "start": 16, "tag": "ResearchActivity"}, {"end": 84, "start": 77, "tag": "BiologicFunction"}, {"end": 107, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 218, "start": 179, "tag": "AnatomicalAbnormality"}, {"end": 224, "start": 222, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 145, "tag": "ClinicalAttribute"}, {"end": 175, "start": 168, "tag": "Finding"}]}{"id": "153_8", "text": "Strong asymmetry in that cortical region is typically observed in healthy development.", "tags": [{"end": 16, "start": 7, "tag": "Finding"}, {"end": 16, "start": 7, "tag": "AnatomicalAbnormality"}, {"end": 40, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 74, "tag": "BiologicFunction"}, {"end": 85, "start": 74, "tag": "CellFunction"}, {"end": 73, "start": 66, "tag": "OrganismAttribute"}]}{"id": "153_9", "text": "As the formation of the Sylvian fissure appears early in utero, and marked asymmetry is specifically found in this area of the neocortex in newborns, this novel finding likely indicates the foetal timing of a disease-specific, genetic interplay with neurodevelopment.", "tags": [{"end": 39, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 75, "tag": "Finding"}, {"end": 84, "start": 75, "tag": "AnatomicalAbnormality"}, {"end": 136, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 140, "tag": "PopulationGroup"}, {"end": 203, "start": 190, "tag": "TemporalConcept"}, {"end": 266, "start": 250, "tag": "BiologicFunction"}, {"end": 168, "start": 161, "tag": "Finding"}, {"end": 244, "start": 227, "tag": "Finding"}, {"end": 39, "start": 7, "tag": "BiologicFunction"}, {"end": 53, "start": 48, "tag": "TemporalConcept"}]}{"id": "154_0", "text": "(1) Background: Sleep patterns are frequently disrupted in neurodegenerative disorders such as Huntington disease (HD); however, they are still poorly understood, especially their association with clinic features.", "tags": [{"end": 30, "start": 16, "tag": "BiologicFunction"}, {"end": 55, "start": 46, "tag": "PathologicFunction"}, {"end": 212, "start": 197, "tag": "ClinicalAttribute"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 35, "tag": "TemporalConcept"}]}{"id": "154_1", "text": "Our study aimed to explore potential correlations between sleep features and motor, cognitive, behavioural and functional changes in manifest HD subjects.", "tags": [{"end": 153, "start": 142, "tag": "PatientOrDisabledGroup"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 63, "start": 58, "tag": "BiologicFunction"}, {"end": 129, "start": 77, "tag": "Finding"}]}{"id": "154_2", "text": "(2) Methods: We enrolled 42 patients who were assessed by the Pittsburgh Sleep Quality Index (PSQI) and Insomnia Severity Index (ISI) questionnaires; clinical features were evaluated by the validated ENROLL-HD platform assay, including the Unified Huntington's Disease Rating Scale (UHDRS) and the Problem Behaviours Assessment Short Form (PBA-s).", "tags": [{"end": 92, "start": 62, "tag": "HealthCareActivity"}, {"end": 98, "start": 94, "tag": "HealthCareActivity"}, {"end": 268, "start": 248, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 28, "tag": "PatientOrDisabledGroup"}, {"end": 148, "start": 134, "tag": "HealthCareActivity"}, {"end": 281, "start": 240, "tag": "HealthCareActivity"}, {"end": 288, "start": 283, "tag": "HealthCareActivity"}, {"end": 127, "start": 104, "tag": "HealthCareActivity"}, {"end": 132, "start": 129, "tag": "HealthCareActivity"}, {"end": 167, "start": 150, "tag": "ClinicalAttribute"}, {"end": 224, "start": 200, "tag": "ResearchActivity"}, {"end": 338, "start": 298, "tag": "HealthCareActivity"}, {"end": 345, "start": 340, "tag": "HealthCareActivity"}]}{"id": "154_3", "text": "(3) Results: We found a significant association between the patients' perception of sleep abnormalities and scores of impaired independence, cognitive and motor performances.", "tags": [{"end": 80, "start": 70, "tag": "BiologicFunction"}, {"end": 103, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 60, "tag": "PatientOrDisabledGroup"}, {"end": 173, "start": 108, "tag": "ResearchActivity"}]}{"id": "154_4", "text": "Specifically, sleep efficiency (PSQI-C4 subscores) and the use of sleep medications (PSQI-C6 subscores) seem to be more frequently associated with the severity of the disease progression.", "tags": [{"end": 30, "start": 14, "tag": "Finding"}, {"end": 83, "start": 66, "tag": "PharmacologicSubstance"}, {"end": 159, "start": 151, "tag": "Finding"}, {"end": 186, "start": 167, "tag": "PathologicFunction"}, {"end": 186, "start": 175, "tag": "TemporalConcept"}, {"end": 49, "start": 32, "tag": "ResearchActivity"}, {"end": 102, "start": 85, "tag": "ResearchActivity"}, {"end": 130, "start": 120, "tag": "TemporalConcept"}]}{"id": "154_5", "text": "(4) Conclusion: sleep abnormalities represent an important part of the HD clinical profile and can impair patients' quality of life by affecting their level of independence, cognition performance and mental well-being.", "tags": [{"end": 35, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 116, "tag": "Finding"}, {"end": 172, "start": 151, "tag": "Finding"}, {"end": 172, "start": 160, "tag": "BiologicFunction"}, {"end": 217, "start": 200, "tag": "Finding"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 106, "tag": "PatientOrDisabledGroup"}, {"end": 90, "start": 74, "tag": "ClinicalAttribute"}, {"end": 195, "start": 174, "tag": "Finding"}, {"end": 183, "start": 174, "tag": "BiologicFunction"}]}{"id": "155_0", "text": "Progressive abnormality and loss of axons and neurons in the central nervous system (CNS) cause neurodegenerative diseases (NDs).", "tags": [{"end": 41, "start": 36, "tag": "CellComponent"}, {"end": 53, "start": 46, "tag": "Cell"}, {"end": 83, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 28, "tag": "CellOrMolecularDysfunction"}, {"end": 23, "start": 12, "tag": "Finding"}, {"end": 11, "start": 0, "tag": "TemporalConcept"}, {"end": 53, "start": 46, "tag": "CellOrMolecularDysfunction"}, {"end": 32, "start": 28, "tag": "CellOrMolecularDysfunction"}]}{"id": "155_1", "text": "Protein misfolding and its collection are the most important pathological features of NDs.", "tags": [{"end": 18, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 89, "start": 86, "tag": "DiseaseOrSyndrome"}]}{"id": "155_2", "text": "Astrocytes are the most plentiful cells in the mammalian CNS (about 20-40% of the human brain) and have several central functions in the maintenance of the health and correct function of the CNS.", "tags": [{"end": 56, "start": 47, "tag": "Eukaryote"}, {"end": 148, "start": 137, "tag": "BiologicFunction"}, {"end": 162, "start": 156, "tag": "HealthCareActivity"}, {"end": 93, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 34, "tag": "Cell"}, {"end": 60, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 194, "start": 191, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 10, "start": 0, "tag": "Cell"}, {"end": 87, "start": 82, "tag": "Eukaryote"}]}{"id": "155_3", "text": "Astrocytes have an essential role in the preservation of brain homeostasis, and it is not surprising that these multifunctional cells have been implicated in the onset and progression of several NDs.", "tags": [{"end": 53, "start": 41, "tag": "ResearchActivity"}, {"end": 53, "start": 41, "tag": "HealthCareActivity"}, {"end": 133, "start": 112, "tag": "Cell"}, {"end": 74, "start": 57, "tag": "BiologicFunction"}, {"end": 167, "start": 162, "tag": "TemporalConcept"}, {"end": 10, "start": 0, "tag": "Cell"}, {"end": 183, "start": 172, "tag": "PathologicFunction"}, {"end": 183, "start": 172, "tag": "TemporalConcept"}, {"end": 198, "start": 195, "tag": "DiseaseOrSyndrome"}]}{"id": "155_4", "text": "Thus, they become an exciting target for the study of NDs.", "tags": [{"end": 57, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 45, "tag": "ResearchActivity"}]}{"id": "155_5", "text": "Over almost 15 years, it was revealed that curcumin has several therapeutic effects in a wide variety of diseases' treatment.", "tags": [{"end": 114, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 43, "tag": "Chemical"}, {"end": 51, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 83, "start": 64, "tag": "Finding"}, {"end": 124, "start": 115, "tag": "HealthCareActivity"}, {"end": 124, "start": 115, "tag": "ResearchActivity"}, {"end": 20, "start": 15, "tag": "TemporalConcept"}]}{"id": "155_6", "text": "Curcumin is a valuable ingredient present in turmeric spice and has several essential roles, including those which are anticarcinogenic, hepatoprotective, thrombosuppressive, cardioprotective, anti-arthritic, anti-inflammatory, antioxidant, chemopreventive, chemotherapeutic, and anti-infectious.", "tags": [{"end": 33, "start": 23, "tag": "Chemical"}, {"end": 135, "start": 119, "tag": "PharmacologicSubstance"}, {"end": 153, "start": 137, "tag": "PharmacologicSubstance"}, {"end": 191, "start": 175, "tag": "PharmacologicSubstance"}, {"end": 256, "start": 241, "tag": "PharmacologicSubstance"}, {"end": 256, "start": 241, "tag": "HealthCareActivity"}, {"end": 274, "start": 258, "tag": "PharmacologicSubstance"}, {"end": 274, "start": 258, "tag": "HealthCareActivity"}, {"end": 295, "start": 280, "tag": "PharmacologicSubstance"}, {"end": 226, "start": 209, "tag": "BiologicFunction"}, {"end": 226, "start": 209, "tag": "PharmacologicSubstance"}, {"end": 8, "start": 0, "tag": "Chemical"}, {"end": 8, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 239, "start": 228, "tag": "PharmacologicSubstance"}, {"end": 239, "start": 228, "tag": "CellFunction"}, {"end": 59, "start": 45, "tag": "Chemical"}, {"end": 59, "start": 45, "tag": "PharmacologicSubstance"}, {"end": 173, "start": 155, "tag": "PharmacologicSubstance"}, {"end": 207, "start": 193, "tag": "PharmacologicSubstance"}]}{"id": "155_7", "text": "Furthermore, curcumin can suppress inflammation; promote angiogenesis; and treat diabetes, pulmonary problems, and neurological dysfunction.", "tags": [{"end": 69, "start": 57, "tag": "BiologicFunction"}, {"end": 109, "start": 91, "tag": "Finding"}, {"end": 139, "start": 115, "tag": "PathologicFunction"}, {"end": 21, "start": 13, "tag": "Chemical"}, {"end": 21, "start": 13, "tag": "PharmacologicSubstance"}, {"end": 89, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 35, "tag": "PathologicFunction"}]}{"id": "155_8", "text": "Here, we review the effects of curcumin on astrocytes in NDs, with a focus on Alzheimer's disease, Parkinson's disease, multiple scleroses, Huntington's disease, and amyotrophic lateral sclerosis.", "tags": [{"end": 138, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 31, "tag": "Chemical"}, {"end": 39, "start": 31, "tag": "PharmacologicSubstance"}, {"end": 53, "start": 43, "tag": "Cell"}, {"end": 60, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}]}{"id": "156_0", "text": "Deutetrabenazine (DTBZ) is a US FDA-approved treatment for chorea in Huntington's disease.", "tags": [{"end": 16, "start": 0, "tag": "Chemical"}, {"end": 22, "start": 18, "tag": "Chemical"}, {"end": 65, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 59, "tag": "SignOrSymptom"}, {"end": 89, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 45, "tag": "HealthCareActivity"}, {"end": 54, "start": 45, "tag": "ResearchActivity"}, {"end": 16, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 22, "start": 18, "tag": "PharmacologicSubstance"}, {"end": 35, "start": 29, "tag": "HealthCareRelatedOrganization"}]}{"id": "156_1", "text": "The substitution of deuterium for hydrogen at specific positions imparts a longer half-life on DTBZ, allowing for less-frequent daily dosing.", "tags": [{"end": 29, "start": 20, "tag": "Chemical"}, {"end": 42, "start": 34, "tag": "Chemical"}, {"end": 91, "start": 82, "tag": "TemporalConcept"}, {"end": 99, "start": 95, "tag": "Chemical"}, {"end": 99, "start": 95, "tag": "PharmacologicSubstance"}, {"end": 140, "start": 114, "tag": "Finding"}]}{"id": "156_2", "text": "As a reversible vesicular monoamine transporter Type 2 inhibitor, DTBZ depletes monoamines at presynaptic nerve terminals.", "tags": [{"end": 70, "start": 66, "tag": "Chemical"}, {"end": 90, "start": 80, "tag": "Chemical"}, {"end": 121, "start": 94, "tag": "CellComponent"}, {"end": 64, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 54, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 66, "tag": "PharmacologicSubstance"}]}{"id": "156_3", "text": "DTBZ significantly improved chorea in Huntington's disease patients compared with placebo.", "tags": [{"end": 4, "start": 0, "tag": "Chemical"}, {"end": 34, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 28, "tag": "SignOrSymptom"}, {"end": 58, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 59, "tag": "PatientOrDisabledGroup"}, {"end": 4, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 89, "start": 82, "tag": "HealthCareActivity"}]}{"id": "156_4", "text": "This effect continued in an ongoing open-label extension study in the cohort who switched from tetrabenazine to DTBZ.", "tags": [{"end": 76, "start": 70, "tag": "PopulationGroup"}, {"end": 116, "start": 112, "tag": "Chemical"}, {"end": 62, "start": 36, "tag": "ResearchActivity"}, {"end": 108, "start": 95, "tag": "PharmacologicSubstance"}, {"end": 108, "start": 95, "tag": "Chemical"}, {"end": 116, "start": 112, "tag": "PharmacologicSubstance"}]}{"id": "156_5", "text": "Whereas there are currently no head-to-head studies to adequately compare safety profiles between tetrabenazine and DTBZ, an indirect comparison study suggested that the tolerability profile of DTBZ was similar to placebo.", "tags": [{"end": 89, "start": 74, "tag": "ResearchActivity"}, {"end": 120, "start": 116, "tag": "Chemical"}, {"end": 190, "start": 170, "tag": "ResearchActivity"}, {"end": 198, "start": 194, "tag": "Chemical"}, {"end": 150, "start": 125, "tag": "ResearchActivity"}, {"end": 51, "start": 31, "tag": "ResearchActivity"}, {"end": 111, "start": 98, "tag": "PharmacologicSubstance"}, {"end": 111, "start": 98, "tag": "Chemical"}, {"end": 120, "start": 116, "tag": "PharmacologicSubstance"}, {"end": 198, "start": 194, "tag": "PharmacologicSubstance"}, {"end": 221, "start": 214, "tag": "HealthCareActivity"}]}{"id": "156_6", "text": "In fact, there are currently no direct comparisons between vesicular monoamine transporter Type 2 inhibitors in humans.", "tags": [{"end": 108, "start": 59, "tag": "PharmacologicSubstance"}, {"end": 118, "start": 112, "tag": "Eukaryote"}, {"end": 97, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 59, "tag": "BiologicallyActiveSubstance"}]}{"id": "156_7", "text": "This review will explore DTBZ's pharmacological properties, drug interactions, administration and efficacy.", "tags": [{"end": 29, "start": 25, "tag": "Chemical"}, {"end": 64, "start": 60, "tag": "PharmacologicSubstance"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 29, "start": 25, "tag": "PharmacologicSubstance"}]}{"id": "157_0", "text": "MicroRNAs (miRNAs) are non-coding RNAs which are essential post-transcriptional gene regulators in various neuronal degenerative diseases and playact a key role in these physiological progresses.", "tags": [{"end": 95, "start": 59, "tag": "CellFunction"}, {"end": 38, "start": 23, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 137, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 11, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 17, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 107, "tag": "Cell"}]}{"id": "157_1", "text": "Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, and, stroke, are seriously threats to the life and health of all human health and life kind.", "tags": [{"end": 131, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 171, "tag": "HealthCareActivity"}, {"end": 197, "start": 191, "tag": "HealthCareActivity"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 185, "tag": "Eukaryote"}, {"end": 166, "start": 162, "tag": "TemporalConcept"}, {"end": 206, "start": 202, "tag": "TemporalConcept"}, {"end": 98, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 36, "tag": "DiseaseOrSyndrome"}]}{"id": "157_2", "text": "Recently, various studies have reported that some various miRNAs can regulate the development of neurodegenerative diseases as well as act as biomarkers to predict these neuronal diseases conditions.", "tags": [{"end": 77, "start": 69, "tag": "BiologicFunction"}, {"end": 198, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 58, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 64, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 82, "tag": "BiologicFunction"}, {"end": 93, "start": 82, "tag": "CellFunction"}, {"end": 25, "start": 18, "tag": "HealthCareActivity"}, {"end": 25, "start": 18, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 123, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 142, "tag": "ClinicalAttribute"}]}{"id": "157_3", "text": "Endogenic miRNAs such as miR-9, the miR-29 family, miR-15, and the miR-34 family are generally dysregulated in animal and cell models.", "tags": [{"end": 133, "start": 122, "tag": "ResearchActivity"}, {"end": 30, "start": 25, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 30, "start": 25, "tag": "GeneOrGenome"}, {"end": 49, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 51, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 57, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 67, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 80, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 95, "tag": "PathologicFunction"}, {"end": 49, "start": 36, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 16, "start": 10, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 16, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 111, "tag": "Eukaryote"}, {"end": 30, "start": 25, "tag": "BiologicallyActiveSubstance"}]}{"id": "157_4", "text": "They are involved in regulating the physiological and biochemical processes in the nervous system by targeting regulating different molecular targets and influencing a variety of pathways.", "tags": [{"end": 31, "start": 21, "tag": "BiologicFunction"}, {"end": 75, "start": 54, "tag": "CellFunction"}, {"end": 121, "start": 111, "tag": "BiologicFunction"}, {"end": 149, "start": 132, "tag": "Finding"}, {"end": 97, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 187, "start": 179, "tag": "CellFunction"}]}{"id": "157_5", "text": "Additionally, exogenous miRNAs derived from homologous plants and defined as botanmin, such as miR2911 and miR168, can be taken up and transferred by other species to be and then act analogously to endogenic miRNAs to regulate the physiological and biochemical processes.", "tags": [{"end": 113, "start": 107, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 226, "start": 218, "tag": "BiologicFunction"}, {"end": 270, "start": 249, "tag": "CellFunction"}, {"end": 61, "start": 55, "tag": "Eukaryote"}, {"end": 30, "start": 24, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 214, "start": 208, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 30, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 214, "start": 208, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 156, "tag": "OrganismAttribute"}, {"end": 102, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 95, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 85, "start": 77, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 85, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 107, "tag": "BiologicallyActiveSubstance"}]}{"id": "157_6", "text": "This review summarizes the mechanism and principle of miRNAs in the treatment of some neurodegenerative diseases, as well as discusses several types of miRNAs which were the most commonly reported in diseases.", "tags": [{"end": 60, "start": 54, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 158, "start": 152, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 60, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 68, "tag": "HealthCareActivity"}, {"end": 77, "start": 68, "tag": "ResearchActivity"}, {"end": 112, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}]}{"id": "157_7", "text": "These miRNAs could serve as a study provided some potential biomarkers in neurodegenerative diseases might be an ideal and/or therapeutic targets for neurodegenerative diseases.", "tags": [{"end": 145, "start": 126, "tag": "ResearchActivity"}, {"end": 12, "start": 6, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 12, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 176, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 30, "tag": "ResearchActivity"}, {"end": 70, "start": 60, "tag": "ClinicalAttribute"}]}{"id": "157_8", "text": "Finally, the role accounted of the prospective exogenous miRNAs involved in mammalian diseases is described.", "tags": [{"end": 85, "start": 76, "tag": "Eukaryote"}, {"end": 63, "start": 57, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 63, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 35, "tag": "BiologicFunction"}, {"end": 94, "start": 86, "tag": "DiseaseOrSyndrome"}]}{"id": "159_0", "text": "Mesenchymal stem cells (MSCs) are multipotent stem cells that have multilinear differentiation and self-renewal abilities.", "tags": [{"end": 121, "start": 112, "tag": "OrganismAttribute"}, {"end": 121, "start": 112, "tag": "Finding"}, {"end": 28, "start": 24, "tag": "Cell"}, {"end": 22, "start": 0, "tag": "Cell"}, {"end": 111, "start": 99, "tag": "CellFunction"}, {"end": 56, "start": 34, "tag": "Cell"}, {"end": 22, "start": 12, "tag": "Cell"}, {"end": 94, "start": 67, "tag": "CellFunction"}]}{"id": "159_1", "text": "These cells are immune-privileged as they express no or low level of class-II major histocompatibility complex (MHC-II) and other costimulatory molecules.", "tags": [{"end": 33, "start": 16, "tag": "BiologicFunction"}, {"end": 110, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 112, "tag": "CellComponent"}, {"end": 118, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 42, "tag": "CellFunction"}, {"end": 153, "start": 144, "tag": "Substance"}, {"end": 11, "start": 6, "tag": "Cell"}]}{"id": "159_2", "text": "Having neuroprotective and regenerative properties, MSCs can be used to ameliorate several intractable neurodegenerative disorders by affecting both innate and adaptive immune systems.", "tags": [{"end": 102, "start": 91, "tag": "SignOrSymptom"}, {"end": 143, "start": 134, "tag": "BiologicFunction"}, {"end": 183, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 52, "tag": "Cell"}, {"end": 22, "start": 7, "tag": "CellFunction"}, {"end": 130, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 27, "tag": "Finding"}]}{"id": "159_3", "text": "Several manipulations like pretreating MSCs with different conditions or agents, and using molecules derived from MSCs or genetically manipulating them, are the common and practical ways that can be used to strengthen MSCs survival and potency.", "tags": [{"end": 21, "start": 8, "tag": "HealthCareActivity"}, {"end": 21, "start": 8, "tag": "ResearchActivity"}, {"end": 79, "start": 73, "tag": "PharmacologicSubstance"}, {"end": 146, "start": 134, "tag": "HealthCareActivity"}, {"end": 43, "start": 39, "tag": "Cell"}, {"end": 118, "start": 114, "tag": "Cell"}, {"end": 222, "start": 218, "tag": "Cell"}, {"end": 231, "start": 223, "tag": "CellFunction"}, {"end": 100, "start": 91, "tag": "Substance"}]}{"id": "159_4", "text": "Improved MSCs can have significantly enhanced impacts on diseases compared to MSCs not manipulated.", "tags": [{"end": 13, "start": 9, "tag": "Cell"}, {"end": 82, "start": 78, "tag": "Cell"}]}{"id": "159_5", "text": "In this review, we describe some of the most important manipulations that have been exerted on MSCs to improve their therapeutic functions and their applications in ameliorating three prevalent neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Huntington's disease.", "tags": [{"end": 68, "start": 55, "tag": "HealthCareActivity"}, {"end": 68, "start": 55, "tag": "ResearchActivity"}, {"end": 138, "start": 117, "tag": "HealthCareActivity"}, {"end": 99, "start": 95, "tag": "Cell"}, {"end": 220, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 297, "start": 277, "tag": "DiseaseOrSyndrome"}, {"end": 271, "start": 252, "tag": "DiseaseOrSyndrome"}, {"end": 250, "start": 231, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "160_0", "text": "Huntington's disease (HD) is a fatal neurodegenerative disorder caused by an abnormal CAG repeat expansion in the HTT gene, that produces a mutant protein thought to directly cause brain cell damage.", "tags": [{"end": 85, "start": 77, "tag": "Finding"}, {"end": 154, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 140, "tag": "CellOrMolecularDysfunction"}, {"end": 106, "start": 86, "tag": "CellOrMolecularDysfunction"}, {"end": 191, "start": 181, "tag": "Cell"}, {"end": 122, "start": 114, "tag": "GeneOrGenome"}, {"end": 96, "start": 86, "tag": "MolecularSequence"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 192, "tag": "InjuryOrPoisoning"}]}{"id": "160_1", "text": "Premanifest carriers of the CAG expansion represent an ideal population to track the pathophysiological events responsible for the onset of clinical symptoms.", "tags": [{"end": 31, "start": 28, "tag": "MolecularSequence"}, {"end": 71, "start": 61, "tag": "PopulationGroup"}, {"end": 157, "start": 140, "tag": "SignOrSymptom"}, {"end": 136, "start": 131, "tag": "TemporalConcept"}, {"end": 110, "start": 85, "tag": "PathologicFunction"}, {"end": 41, "start": 28, "tag": "CellOrMolecularDysfunction"}, {"end": 20, "start": 0, "tag": "PatientOrDisabledGroup"}]}{"id": "160_2", "text": "Neuroimaging tools, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), are able to investigate in vivo structural, microstructural, and functional brain alterations up to a molecular level and have substantially contributed to understanding the pathophysiology of HD.", "tags": [{"end": 18, "start": 0, "tag": "HealthCareActivity"}, {"end": 56, "start": 28, "tag": "HealthCareActivity"}, {"end": 270, "start": 257, "tag": "BiologicFunction"}, {"end": 61, "start": 58, "tag": "HealthCareActivity"}, {"end": 98, "start": 95, "tag": "HealthCareActivity"}, {"end": 93, "start": 67, "tag": "HealthCareActivity"}, {"end": 290, "start": 275, "tag": "PathologicFunction"}, {"end": 290, "start": 275, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 182, "start": 177, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 125, "tag": "ResearchActivity"}, {"end": 296, "start": 294, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 183, "tag": "Finding"}]}{"id": "160_3", "text": "Neuroimaging techniques have identified potential biomarkers of early detection and progression of disease which can be translated into clinical trials with acceptable sample sizes.", "tags": [{"end": 23, "start": 0, "tag": "HealthCareActivity"}, {"end": 79, "start": 64, "tag": "HealthCareActivity"}, {"end": 151, "start": 136, "tag": "ResearchActivity"}, {"end": 106, "start": 84, "tag": "PathologicFunction"}, {"end": 174, "start": 168, "tag": "Substance"}, {"end": 174, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 50, "tag": "ClinicalAttribute"}]}{"id": "160_4", "text": "This chapter outlines the most important findings from PET and MRI research that has helped understand the pathophysiology of HD in the premanifest and manifest stages, and the translational potential of the neuroimaging biomarkers for the design of future clinical trials with disease-modifying agents.", "tags": [{"end": 167, "start": 161, "tag": "TemporalConcept"}, {"end": 58, "start": 55, "tag": "HealthCareActivity"}, {"end": 272, "start": 257, "tag": "ResearchActivity"}, {"end": 66, "start": 63, "tag": "HealthCareActivity"}, {"end": 220, "start": 208, "tag": "HealthCareActivity"}, {"end": 122, "start": 107, "tag": "PathologicFunction"}, {"end": 122, "start": 107, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 246, "start": 240, "tag": "ResearchActivity"}, {"end": 246, "start": 240, "tag": "HealthCareActivity"}, {"end": 256, "start": 250, "tag": "TemporalConcept"}, {"end": 128, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 221, "tag": "ClinicalAttribute"}, {"end": 75, "start": 67, "tag": "ResearchActivity"}, {"end": 200, "start": 177, "tag": "Finding"}, {"end": 302, "start": 278, "tag": "PharmacologicSubstance"}]}{"id": "162_0", "text": "Introduction Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and prion disease represent important public health concerns.", "tags": [{"end": 160, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 181, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 194, "start": 181, "tag": "HealthCareActivity"}, {"end": 152, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 49, "tag": "DiseaseOrSyndrome"}]}{"id": "162_1", "text": "Exposure to high levels of heavy metals such as manganese (Mn) may contribute to their development.", "tags": [{"end": 39, "start": 27, "tag": "InjuryOrPoisoning"}, {"end": 11, "start": 0, "tag": "InjuryOrPoisoning"}, {"end": 39, "start": 27, "tag": "Chemical"}, {"end": 61, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 59, "tag": "Chemical"}, {"end": 57, "start": 48, "tag": "Chemical"}, {"end": 57, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 87, "tag": "BiologicFunction"}, {"end": 98, "start": 87, "tag": "CellFunction"}]}{"id": "162_2", "text": "Areas covered In this critical review, we address the role of Mn in the etiology of neurodegenerative diseases and discuss emerging treatments of Mn overload, such as chelation therapy.", "tags": [{"end": 64, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 62, "tag": "Chemical"}, {"end": 148, "start": 146, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 146, "tag": "Chemical"}, {"end": 184, "start": 167, "tag": "HealthCareActivity"}, {"end": 80, "start": 72, "tag": "Finding"}, {"end": 142, "start": 132, "tag": "HealthCareActivity"}, {"end": 142, "start": 132, "tag": "ResearchActivity"}, {"end": 110, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 31, "tag": "ResearchActivity"}, {"end": 37, "start": 31, "tag": "HealthCareActivity"}]}{"id": "162_3", "text": "In addition, we discuss natural and synthetic compounds under development as prospective therapeutics.", "tags": [{"end": 101, "start": 77, "tag": "HealthCareActivity"}, {"end": 101, "start": 89, "tag": "HealthCareActivity"}, {"end": 73, "start": 62, "tag": "BiologicFunction"}, {"end": 73, "start": 62, "tag": "CellFunction"}, {"end": 55, "start": 36, "tag": "Substance"}, {"end": 55, "start": 46, "tag": "Substance"}, {"end": 31, "start": 24, "tag": "Substance"}]}{"id": "162_4", "text": "Moreover, bioinformatic approaches to identify new potential targets and therapeutic substances to reverse the neurodegenerative diseases are discussed.", "tags": [{"end": 34, "start": 10, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 95, "start": 73, "tag": "Chemical"}, {"end": 95, "start": 73, "tag": "PharmacologicSubstance"}, {"end": 137, "start": 111, "tag": "DiseaseOrSyndrome"}]}{"id": "162_5", "text": "Expert opinion Here, the authors highlight the importance of better understanding the molecular mechanisms of toxicity associated with neurodegenerative diseases, and the role of Mn in these diseases.", "tags": [{"end": 181, "start": 179, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 179, "tag": "Chemical"}, {"end": 81, "start": 68, "tag": "BiologicFunction"}, {"end": 106, "start": 86, "tag": "CellFunction"}, {"end": 118, "start": 110, "tag": "InjuryOrPoisoning"}, {"end": 161, "start": 135, "tag": "DiseaseOrSyndrome"}]}{"id": "162_6", "text": "Additional emphasis should be directed to the discovery of new agents to treat Mn-induced diseases, since present day chelator therapies have limited bioavailability.", "tags": [{"end": 69, "start": 63, "tag": "PharmacologicSubstance"}, {"end": 117, "start": 114, "tag": "TemporalConcept"}, {"end": 117, "start": 114, "tag": "HealthCareActivity"}, {"end": 126, "start": 118, "tag": "PharmacologicSubstance"}, {"end": 126, "start": 118, "tag": "Chemical"}, {"end": 165, "start": 150, "tag": "ResearchActivity"}, {"end": 136, "start": 118, "tag": "HealthCareActivity"}, {"end": 55, "start": 46, "tag": "ResearchActivity"}, {"end": 81, "start": 79, "tag": "Chemical"}, {"end": 81, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 79, "tag": "DiseaseOrSyndrome"}]}{"id": "162_7", "text": "Furthermore, the authors encourage the scientific community to develop research using libraries of compounds to screen those compounds that show efficacy in regulating brain Mn levels.", "tags": [{"end": 108, "start": 99, "tag": "Chemical"}, {"end": 108, "start": 99, "tag": "PharmacologicSubstance"}, {"end": 118, "start": 112, "tag": "ResearchActivity"}, {"end": 134, "start": 125, "tag": "Chemical"}, {"end": 134, "start": 125, "tag": "PharmacologicSubstance"}, {"end": 167, "start": 157, "tag": "BiologicFunction"}, {"end": 176, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 174, "tag": "Chemical"}, {"end": 59, "start": 39, "tag": "HealthCareRelatedOrganization"}, {"end": 173, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 71, "tag": "ResearchActivity"}, {"end": 153, "start": 145, "tag": "Finding"}, {"end": 183, "start": 168, "tag": "ClinicalAttribute"}]}{"id": "162_8", "text": "In addition, bioinformatics may provide novel insight for pathways and clinical treatments associated with Mn-induced neurodegeneration, leading to a new direction in Mn toxicological research.", "tags": [{"end": 27, "start": 13, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 90, "start": 71, "tag": "HealthCareActivity"}, {"end": 169, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 167, "tag": "Chemical"}, {"end": 135, "start": 118, "tag": "CellOrMolecularDysfunction"}, {"end": 66, "start": 58, "tag": "CellFunction"}, {"end": 90, "start": 80, "tag": "HealthCareActivity"}, {"end": 90, "start": 80, "tag": "ResearchActivity"}, {"end": 192, "start": 170, "tag": "ResearchActivity"}, {"end": 109, "start": 107, "tag": "Chemical"}, {"end": 109, "start": 107, "tag": "BiologicallyActiveSubstance"}]}{"id": "164_0", "text": "Gangliosides are cell membrane components, most abundantly in the central nervous system (CNS) where they exert among others neuro-protective and -restorative functions.", "tags": [{"end": 12, "start": 0, "tag": "Chemical"}, {"end": 41, "start": 17, "tag": "CellComponent"}, {"end": 88, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "164_1", "text": "Clinical development of ganglioside replacement therapy for several neurodegenerative diseases was impeded by the BSE crisis in Europe during the 1990s.", "tags": [{"end": 20, "start": 0, "tag": "ResearchActivity"}, {"end": 117, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 118, "tag": "Finding"}, {"end": 94, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 36, "tag": "HealthCareActivity"}, {"end": 35, "start": 24, "tag": "Chemical"}, {"end": 35, "start": 24, "tag": "PharmacologicSubstance"}, {"end": 151, "start": 146, "tag": "TemporalConcept"}]}{"id": "164_2", "text": "Nowadays, gangliosides are produced bovine-free and new pre-clinical and clinical data justify a reevaluation of their therapeutic potential in neurodegenerative diseases.", "tags": [{"end": 22, "start": 10, "tag": "Chemical"}, {"end": 68, "start": 56, "tag": "ResearchActivity"}, {"end": 140, "start": 119, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 86, "start": 73, "tag": "ResearchActivity"}, {"end": 170, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 42, "start": 36, "tag": "Eukaryote"}]}{"id": "164_3", "text": "Clinical experience is greatest with monosialo-tetrahexosyl-ganglioside (GM1) in the treatment of stroke.", "tags": [{"end": 19, "start": 0, "tag": "BiologicFunction"}, {"end": 71, "start": 37, "tag": "Chemical"}, {"end": 76, "start": 73, "tag": "Chemical"}, {"end": 104, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 85, "tag": "HealthCareActivity"}, {"end": 94, "start": 85, "tag": "ResearchActivity"}, {"end": 76, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 37, "tag": "PharmacologicSubstance"}, {"end": 76, "start": 73, "tag": "PharmacologicSubstance"}]}{"id": "164_4", "text": "Fourteen randomized controlled trials (RCTs) in overall >2,000 patients revealed no difference in survival, but consistently superior neurological outcomes vs.", "tags": [{"end": 43, "start": 39, "tag": "ResearchActivity"}, {"end": 106, "start": 98, "tag": "CellFunction"}, {"end": 37, "start": 9, "tag": "ResearchActivity"}, {"end": 71, "start": 63, "tag": "PatientOrDisabledGroup"}, {"end": 94, "start": 81, "tag": "Finding"}, {"end": 106, "start": 98, "tag": "BiologicFunction"}, {"end": 155, "start": 134, "tag": "Finding"}]}{"id": "164_5", "text": "placebo.", "tags": [{"end": 7, "start": 0, "tag": "HealthCareActivity"}]}{"id": "164_6", "text": "GM1 was shown to attenuate ischemic neuronal injuries in diabetes patients by suppression of ERK1/2 phosphorylation and reduction of stress to the endoplasmic reticulum.", "tags": [{"end": 3, "start": 0, "tag": "Chemical"}, {"end": 99, "start": 93, "tag": "CellFunction"}, {"end": 139, "start": 133, "tag": "Finding"}, {"end": 168, "start": 147, "tag": "CellComponent"}, {"end": 115, "start": 100, "tag": "CellFunction"}, {"end": 129, "start": 120, "tag": "Finding"}, {"end": 129, "start": 120, "tag": "NaturalPhenomenonOrProcess"}, {"end": 65, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 66, "tag": "PatientOrDisabledGroup"}, {"end": 53, "start": 27, "tag": "InjuryOrPoisoning"}, {"end": 139, "start": 133, "tag": "PathologicFunction"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "164_7", "text": "There is level-I evidence from 5 RCTs of a significantly faster recovery with GM1 vs.", "tags": [{"end": 37, "start": 33, "tag": "ResearchActivity"}, {"end": 81, "start": 78, "tag": "Chemical"}, {"end": 72, "start": 64, "tag": "BiologicFunction"}, {"end": 72, "start": 64, "tag": "HealthCareActivity"}, {"end": 72, "start": 64, "tag": "TemporalConcept"}, {"end": 25, "start": 17, "tag": "Finding"}, {"end": 81, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 78, "tag": "PharmacologicSubstance"}]}{"id": "164_8", "text": "placebo in patients with acute and chronic spinal cord injury (SCI), disturbance of consciousness after subarachnoid hemorrhage, or craniocerebral injuries due to closed head trauma.", "tags": [{"end": 66, "start": 63, "tag": "InjuryOrPoisoning"}, {"end": 97, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 117, "tag": "PathologicFunction"}, {"end": 127, "start": 117, "tag": "Finding"}, {"end": 155, "start": 132, "tag": "InjuryOrPoisoning"}, {"end": 181, "start": 170, "tag": "InjuryOrPoisoning"}, {"end": 30, "start": 25, "tag": "TemporalConcept"}, {"end": 54, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 43, "tag": "InjuryOrPoisoning"}, {"end": 7, "start": 0, "tag": "HealthCareActivity"}, {"end": 42, "start": 35, "tag": "TemporalConcept"}, {"end": 19, "start": 11, "tag": "PatientOrDisabledGroup"}]}{"id": "164_9", "text": "In Parkinson's disease (PD), two RCTs provided evidence of GM1 to be superior to placebo in improving motor symptoms and long-term to result in a slower than expected symptom progression, suggesting disease-modifying potential.", "tags": [{"end": 37, "start": 33, "tag": "ResearchActivity"}, {"end": 62, "start": 59, "tag": "Chemical"}, {"end": 88, "start": 81, "tag": "HealthCareActivity"}, {"end": 116, "start": 102, "tag": "SignOrSymptom"}, {"end": 130, "start": 121, "tag": "TemporalConcept"}, {"end": 174, "start": 167, "tag": "SignOrSymptom"}, {"end": 55, "start": 47, "tag": "Finding"}, {"end": 186, "start": 175, "tag": "PathologicFunction"}, {"end": 186, "start": 175, "tag": "TemporalConcept"}, {"end": 22, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 226, "start": 199, "tag": "Finding"}, {"end": 62, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 59, "tag": "PharmacologicSubstance"}]}{"id": "164_10", "text": "In Alzheimer's disease (AD), the role of gangliosides has been controversial, with some studies suggesting a seeding role for GM1 in amyloid beta polymerization into toxic forms, and others more recently suggesting a rather protective role in vivo.", "tags": [{"end": 53, "start": 41, "tag": "Chemical"}, {"end": 53, "start": 41, "tag": "PharmacologicSubstance"}, {"end": 129, "start": 126, "tag": "Chemical"}, {"end": 145, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 195, "tag": "TemporalConcept"}, {"end": 26, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 88, "tag": "ResearchActivity"}, {"end": 247, "start": 240, "tag": "ResearchActivity"}, {"end": 22, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 166, "tag": "InjuryOrPoisoning"}, {"end": 160, "start": 133, "tag": "CellFunction"}, {"end": 239, "start": 224, "tag": "Finding"}, {"end": 129, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 126, "tag": "PharmacologicSubstance"}]}{"id": "164_11", "text": "In Huntington's disease (HD), no clinical trials have been conducted yet.", "tags": [{"end": 48, "start": 33, "tag": "ResearchActivity"}, {"end": 23, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 25, "tag": "DiseaseOrSyndrome"}]}{"id": "164_12", "text": "However, low GM1 levels observed in HD cells were shown to increase cell susceptibility to apoptosis.", "tags": [{"end": 16, "start": 13, "tag": "Chemical"}, {"end": 87, "start": 73, "tag": "Finding"}, {"end": 100, "start": 91, "tag": "CellFunction"}, {"end": 44, "start": 39, "tag": "Cell"}, {"end": 38, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 13, "tag": "PharmacologicSubstance"}]}{"id": "164_13", "text": "Accordingly, treatment with GM1 increased survival of HD cells in vitro and consistently ameliorated pathological phenotypes in several murine HD models, with effects seen at molecular, cellular, and behavioral level.", "tags": [{"end": 31, "start": 28, "tag": "Chemical"}, {"end": 50, "start": 42, "tag": "CellFunction"}, {"end": 124, "start": 114, "tag": "OrganismAttribute"}, {"end": 62, "start": 57, "tag": "Cell"}, {"end": 22, "start": 13, "tag": "HealthCareActivity"}, {"end": 22, "start": 13, "tag": "ResearchActivity"}, {"end": 71, "start": 63, "tag": "ResearchActivity"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 146, "tag": "ResearchActivity"}, {"end": 124, "start": 101, "tag": "PathologicFunction"}, {"end": 142, "start": 136, "tag": "Eukaryote"}, {"end": 152, "start": 136, "tag": "ExperimentalModelOfDisease"}, {"end": 62, "start": 54, "tag": "ExperimentalModelOfDisease"}, {"end": 166, "start": 159, "tag": "Finding"}, {"end": 31, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 28, "tag": "PharmacologicSubstance"}]}{"id": "164_14", "text": "Given that in none of the clinical trials using GM1 any clinically relevant safety issues have occurred to date, current data supports expanding GM1 clinical research, particularly to conditions with high, unmet medical need.", "tags": [{"end": 51, "start": 48, "tag": "Chemical"}, {"end": 148, "start": 145, "tag": "Chemical"}, {"end": 111, "start": 104, "tag": "TemporalConcept"}, {"end": 166, "start": 149, "tag": "ResearchActivity"}, {"end": 82, "start": 76, "tag": "HealthCareActivity"}, {"end": 111, "start": 107, "tag": "TemporalConcept"}, {"end": 41, "start": 26, "tag": "ResearchActivity"}, {"end": 125, "start": 121, "tag": "ResearchActivity"}, {"end": 120, "start": 113, "tag": "TemporalConcept"}, {"end": 224, "start": 206, "tag": "Finding"}, {"end": 51, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 48, "tag": "PharmacologicSubstance"}, {"end": 148, "start": 145, "tag": "PharmacologicSubstance"}]}{"id": "170_0", "text": "A plethora of diseases are associated with our nervous system.", "tags": [{"end": 61, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "170_1", "text": "Neurodegenerative diseases include Parkinson's disease, epilepsy, Alzheimer's disease, Huntington's disease, schizophrenia and depression.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 56, "tag": "PathologicFunction"}, {"end": 107, "start": 87, "tag": "DiseaseOrSyndrome"}]}{"id": "170_2", "text": "Many plants are known to be beneficial against certain neurodegenerative disorders.", "tags": [{"end": 11, "start": 5, "tag": "Eukaryote"}, {"end": 82, "start": 55, "tag": "DiseaseOrSyndrome"}]}{"id": "170_3", "text": "This study provides an overview of such thirty-five plants whose part, from roots to seeds or their bio-chemicals extract are used for the treatment of multiple neurodegenerative disorders in Pakistan and beyond.", "tags": [{"end": 31, "start": 23, "tag": "ResearchActivity"}, {"end": 58, "start": 52, "tag": "Organism"}, {"end": 188, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 148, "start": 139, "tag": "HealthCareActivity"}, {"end": 148, "start": 139, "tag": "ResearchActivity"}, {"end": 121, "start": 100, "tag": "BiologicallyActiveSubstance"}]}{"id": "174_0", "text": "This review presents the potential effects of dietary antioxidants on neurodegenerative diseases.", "tags": [{"end": 66, "start": 46, "tag": "PharmacologicSubstance"}, {"end": 96, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}]}{"id": "174_1", "text": "The relationship between autoimmunity and antioxidants.", "tags": [{"end": 37, "start": 25, "tag": "PathologicFunction"}, {"end": 54, "start": 42, "tag": "PharmacologicSubstance"}]}{"id": "174_2", "text": "and their preventive effect on neurodegenerative diseases are evaluated.", "tags": [{"end": 57, "start": 31, "tag": "DiseaseOrSyndrome"}]}{"id": "174_3", "text": "The driven factors of neurodegeneration and the potential effects of natural antioxidants are summarized for Alzheimer's disease, Parkinson's disease, multiple sclerosis, spongiform encephalopathy, Huntington's disease, and amyotrophic lateral sclerosis.", "tags": [{"end": 89, "start": 69, "tag": "PharmacologicSubstance"}, {"end": 128, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 196, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 253, "start": 224, "tag": "DiseaseOrSyndrome"}, {"end": 218, "start": 198, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 22, "tag": "CellOrMolecularDysfunction"}]}{"id": "174_4", "text": "The effect of oxidative stress on neurodegenerative diseases and regulative effect of antioxidants on oxidative balance is discussed.", "tags": [{"end": 98, "start": 86, "tag": "PharmacologicSubstance"}, {"end": 60, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 14, "tag": "CellOrMolecularDysfunction"}, {"end": 119, "start": 102, "tag": "CellFunction"}]}{"id": "174_5", "text": "This review provides beneficial information for the possible cure of neurodegenerative diseases with dietary intake of antioxidants.", "tags": [{"end": 115, "start": 101, "tag": "Finding"}, {"end": 131, "start": 119, "tag": "PharmacologicSubstance"}, {"end": 95, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}]}{"id": "175_0", "text": "Huntington disease (HD) is an autosomal dominant progressive neurodegenerative disorder associated with expanded CAG repeat size in the huntingtin gene and usually presenting with movement disorder, psychiatric symptoms, and cognitive decline.", "tags": [{"end": 87, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 136, "tag": "GeneOrGenome"}, {"end": 197, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 199, "tag": "SignOrSymptom"}, {"end": 48, "start": 30, "tag": "CellFunction"}, {"end": 242, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 104, "tag": "CellOrMolecularDysfunction"}]}{"id": "175_1", "text": "Sleep problems, weight loss, and cachexia are also common.", "tags": [{"end": 14, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 16, "tag": "SignOrSymptom"}, {"end": 27, "start": 16, "tag": "HealthCareActivity"}, {"end": 41, "start": 33, "tag": "SignOrSymptom"}]}{"id": "175_2", "text": "Here, we report a patient presenting with hypothermia in late-stage HD.", "tags": [{"end": 67, "start": 57, "tag": "TemporalConcept"}, {"end": 70, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 42, "tag": "InjuryOrPoisoning"}, {"end": 53, "start": 42, "tag": "HealthCareActivity"}, {"end": 25, "start": 18, "tag": "PatientOrDisabledGroup"}]}{"id": "175_3", "text": "Although thermoregulatory defects were documented in animal models, this is the first report describing HD with hypothermia in humans.", "tags": [{"end": 66, "start": 53, "tag": "ManufacturedObject"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 127, "tag": "Eukaryote"}, {"end": 123, "start": 112, "tag": "InjuryOrPoisoning"}, {"end": 123, "start": 112, "tag": "HealthCareActivity"}, {"end": 33, "start": 9, "tag": "PathologicFunction"}]}{"id": "178_0", "text": "Huntington's disease is characterized by a triad of motor, cognitive and psychiatric impairments, as well as unintended weight loss.", "tags": [{"end": 131, "start": 109, "tag": "Finding"}, {"end": 96, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 120, "tag": "SignOrSymptom"}, {"end": 131, "start": 120, "tag": "HealthCareActivity"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "178_1", "text": "Although much of the research has focused on cognitive, motor and psychiatric symptoms, the extent of peripheral pathology and the relationship between these factors, and the core symptoms of Huntington's disease, are relatively unknown.", "tags": [{"end": 122, "start": 102, "tag": "PathologicFunction"}, {"end": 188, "start": 175, "tag": "SignOrSymptom"}, {"end": 86, "start": 66, "tag": "SignOrSymptom"}, {"end": 143, "start": 131, "tag": "Finding"}, {"end": 112, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 21, "tag": "ResearchActivity"}, {"end": 86, "start": 78, "tag": "SignOrSymptom"}, {"end": 61, "start": 56, "tag": "SignOrSymptom"}, {"end": 86, "start": 78, "tag": "SignOrSymptom"}, {"end": 54, "start": 45, "tag": "SignOrSymptom"}]}{"id": "178_2", "text": "Gut microbiota are key modulators of communication between the brain and gut, and alterations in microbiota composition (dysbiosis) can negatively affect cognition, behaviour and affective function, and may be implicated in disease progression.", "tags": [{"end": 14, "start": 0, "tag": "Organism"}, {"end": 33, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 37, "tag": "HealthCareActivity"}, {"end": 50, "start": 37, "tag": "CellFunction"}, {"end": 76, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 97, "tag": "Organism"}, {"end": 130, "start": 121, "tag": "PathologicFunction"}, {"end": 174, "start": 165, "tag": "BiologicFunction"}, {"end": 174, "start": 165, "tag": "IndividualBehavior"}, {"end": 174, "start": 165, "tag": "ResearchActivity"}, {"end": 197, "start": 179, "tag": "BiologicFunction"}, {"end": 163, "start": 154, "tag": "BiologicFunction"}, {"end": 243, "start": 224, "tag": "PathologicFunction"}, {"end": 68, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 243, "start": 232, "tag": "PathologicFunction"}, {"end": 243, "start": 232, "tag": "TemporalConcept"}, {"end": 93, "start": 82, "tag": "Finding"}]}{"id": "178_3", "text": "Furthermore, gut dysbiosis was recently reported in Huntington's disease transgenic mice.", "tags": [{"end": 26, "start": 13, "tag": "PathologicFunction"}, {"end": 88, "start": 73, "tag": "Eukaryote"}, {"end": 88, "start": 73, "tag": "ResearchActivity"}, {"end": 39, "start": 31, "tag": "TemporalConcept"}, {"end": 88, "start": 84, "tag": "Eukaryote"}, {"end": 72, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 52, "tag": "ExperimentalModelOfDisease"}]}{"id": "178_4", "text": "Our main objective was to characterize the gut microbiome in people with Huntington's disease and determine whether the composition of gut microbiota are significantly related to clinical indicators of disease progression.", "tags": [{"end": 57, "start": 43, "tag": "Organism"}, {"end": 149, "start": 135, "tag": "Organism"}, {"end": 67, "start": 61, "tag": "PopulationGroup"}, {"end": 221, "start": 202, "tag": "PathologicFunction"}, {"end": 221, "start": 210, "tag": "PathologicFunction"}, {"end": 221, "start": 210, "tag": "TemporalConcept"}, {"end": 93, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 179, "tag": "ClinicalAttribute"}]}{"id": "178_5", "text": "We compared 42 Huntington's disease gene expansion carriers, including 19 people who were diagnosed with Huntington's disease (Total Functional Capacity > 6) and 23 in the premanifest stage, with 36 age- and gender-matched healthy controls.", "tags": [{"end": 59, "start": 51, "tag": "PopulationGroup"}, {"end": 80, "start": 74, "tag": "PopulationGroup"}, {"end": 214, "start": 208, "tag": "OrganismAttribute"}, {"end": 202, "start": 199, "tag": "OrganismAttribute"}, {"end": 239, "start": 223, "tag": "PopulationGroup"}, {"end": 35, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 36, "tag": "CellOrMolecularDysfunction"}, {"end": 152, "start": 127, "tag": "HealthCareActivity"}, {"end": 189, "start": 172, "tag": "TemporalConcept"}]}{"id": "178_6", "text": "Participants were characterized clinically using a battery of cognitive tests and using results from 16S V3 to V4 rRNA sequencing of faecal samples to characterize the gut microbiome.", "tags": [{"end": 58, "start": 51, "tag": "ManufacturedObject"}, {"end": 182, "start": 168, "tag": "Organism"}, {"end": 77, "start": 62, "tag": "HealthCareActivity"}, {"end": 77, "start": 62, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "HealthCareActivity"}, {"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 147, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 101, "tag": "ResearchActivity"}]}{"id": "178_7", "text": "For gut microbiome measures, we found significant differences in the microbial communities (beta diversity) based on unweighted UniFrac distance (P = 0.001), as well as significantly lower alpha diversity (species richness and evenness) between our combined Huntington's disease gene expansion carrier group and healthy controls (P = 0.001).", "tags": [{"end": 18, "start": 4, "tag": "Organism"}, {"end": 27, "start": 4, "tag": "HealthCareActivity"}, {"end": 213, "start": 206, "tag": "OrganismAttribute"}, {"end": 307, "start": 302, "tag": "PopulationGroup"}, {"end": 61, "start": 50, "tag": "Finding"}, {"end": 319, "start": 312, "tag": "OrganismAttribute"}, {"end": 328, "start": 312, "tag": "PopulationGroup"}, {"end": 278, "start": 258, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 69, "tag": "Organism"}, {"end": 144, "start": 117, "tag": "ResearchActivity"}, {"end": 235, "start": 227, "tag": "Finding"}, {"end": 213, "start": 206, "tag": "Finding"}, {"end": 222, "start": 206, "tag": "Finding"}, {"end": 106, "start": 92, "tag": "Finding"}, {"end": 204, "start": 189, "tag": "Finding"}]}{"id": "178_8", "text": "We also found major shifts in the microbial community structure at Phylum and Family levels, and identified functional pathways and enzymes affected in our Huntington's disease gene expansion carrier group.", "tags": [{"end": 26, "start": 20, "tag": "Finding"}, {"end": 127, "start": 108, "tag": "CellFunction"}, {"end": 107, "start": 97, "tag": "Finding"}, {"end": 139, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 192, "tag": "PopulationGroup"}, {"end": 176, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 34, "tag": "OrganismAttribute"}, {"end": 191, "start": 177, "tag": "CellOrMolecularDysfunction"}, {"end": 73, "start": 67, "tag": "OrganismAttribute"}]}{"id": "178_10", "text": "Overall, our findings suggest an altered gut microbiome in Huntington's disease gene expansion carriers.", "tags": [{"end": 55, "start": 41, "tag": "Organism"}, {"end": 103, "start": 95, "tag": "PopulationGroup"}, {"end": 79, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 80, "tag": "CellOrMolecularDysfunction"}]}{"id": "178_11", "text": "These results highlight the importance of gut biomarkers and raise interesting questions regarding the role of the gut in Huntington's disease, and whether it may be a potential target for future therapeutic intervention.", "tags": [{"end": 88, "start": 79, "tag": "Finding"}, {"end": 118, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 220, "start": 196, "tag": "HealthCareActivity"}, {"end": 195, "start": 189, "tag": "TemporalConcept"}, {"end": 142, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 46, "tag": "ClinicalAttribute"}, {"end": 45, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "181_0", "text": "Huntington's disease is a severe and currently incurable neurodegenerative disease.", "tags": [{"end": 46, "start": 37, "tag": "TemporalConcept"}, {"end": 32, "start": 26, "tag": "Finding"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 57, "tag": "DiseaseOrSyndrome"}]}{"id": "181_1", "text": "An autosomal dominant mutation in the Huntingtin gene (HTT) causes an increase in the polyglutamine fragment length at the protein N-terminus.", "tags": [{"end": 141, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 3, "tag": "CellFunction"}, {"end": 21, "start": 13, "tag": "CellFunction"}, {"end": 108, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 38, "tag": "GeneOrGenome"}, {"end": 30, "start": 22, "tag": "CellOrMolecularDysfunction"}, {"end": 58, "start": 55, "tag": "GeneOrGenome"}, {"end": 58, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "BiologicallyActiveSubstance"}]}{"id": "181_2", "text": "The consequence of the mutation is the death of neurons, mostly striatal neurons, leading to the occurrence of a complex of motor, cognitive and emotional-volitional personality sphere disorders in carriers.", "tags": [{"end": 206, "start": 198, "tag": "PopulationGroup"}, {"end": 80, "start": 64, "tag": "Cell"}, {"end": 44, "start": 39, "tag": "BiologicFunction"}, {"end": 44, "start": 39, "tag": "PathologicFunction"}, {"end": 44, "start": 39, "tag": "CellFunction"}, {"end": 107, "start": 97, "tag": "TemporalConcept"}, {"end": 31, "start": 23, "tag": "CellOrMolecularDysfunction"}, {"end": 55, "start": 48, "tag": "Cell"}, {"end": 80, "start": 73, "tag": "Cell"}, {"end": 72, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 194, "start": 145, "tag": "DiseaseOrSyndrome"}]}{"id": "181_3", "text": "Despite intensive studies, the functions of both mutant and wild-type huntingtin remain poorly understood.", "tags": [{"end": 69, "start": 60, "tag": "ResearchActivity"}, {"end": 55, "start": 49, "tag": "CellOrMolecularDysfunction"}, {"end": 25, "start": 18, "tag": "ResearchActivity"}, {"end": 80, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 70, "tag": "GeneOrGenome"}, {"end": 80, "start": 70, "tag": "BiologicallyActiveSubstance"}]}{"id": "181_4", "text": "Surprisingly, there is the selective effect of the mutant form of HTT even on nervous tissue, whereas the protein is expressed ubiquitously.", "tags": [{"end": 92, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 51, "tag": "CellOrMolecularDysfunction"}, {"end": 69, "start": 66, "tag": "GeneOrGenome"}, {"end": 69, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 117, "tag": "CellFunction"}, {"end": 69, "start": 66, "tag": "BiologicallyActiveSubstance"}]}{"id": "181_5", "text": "Huntingtin plays a role in cell physiology and affects cell transport, endocytosis, protein degradation and other cellular and molecular processes.", "tags": [{"end": 10, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 55, "tag": "CellFunction"}, {"end": 82, "start": 71, "tag": "CellFunction"}, {"end": 103, "start": 84, "tag": "CellFunction"}, {"end": 42, "start": 27, "tag": "CellFunction"}, {"end": 42, "start": 32, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 42, "start": 32, "tag": "BiologicFunction"}, {"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 114, "tag": "CellFunction"}]}{"id": "181_6", "text": "Our experimental data mining let us conclude that a significant part of the Huntingtin-involved cellular processes is mediated by microtubules and other cytoskeletal cell structures.", "tags": [{"end": 142, "start": 130, "tag": "CellComponent"}, {"end": 181, "start": 153, "tag": "CellComponent"}, {"end": 114, "start": 96, "tag": "CellFunction"}, {"end": 21, "start": 4, "tag": "ResearchActivity"}, {"end": 86, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 76, "tag": "BiologicallyActiveSubstance"}]}{"id": "181_7", "text": "The review attempts to look at unresolved issues in the study of the huntingtin and its mutant form, including their functions affecting microtubules and other components of the cell cytoskeleton.", "tags": [{"end": 99, "start": 88, "tag": "CellOrMolecularDysfunction"}, {"end": 149, "start": 137, "tag": "CellComponent"}, {"end": 195, "start": 178, "tag": "CellComponent"}, {"end": 195, "start": 183, "tag": "CellComponent"}, {"end": 170, "start": 160, "tag": "CellComponent"}, {"end": 10, "start": 4, "tag": "ResearchActivity"}, {"end": 10, "start": 4, "tag": "HealthCareActivity"}, {"end": 61, "start": 56, "tag": "ResearchActivity"}, {"end": 79, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 69, "tag": "BiologicallyActiveSubstance"}]}{"id": "182_0", "text": "Papoutsi et al.", "tags": []}{"id": "182_1", "text": "showed that cognitive function in Huntington's disease is affected by an interplay between genetic and environmental factors.", "tags": [{"end": 30, "start": 12, "tag": "BiologicFunction"}, {"end": 124, "start": 117, "tag": "BiologicFunction"}, {"end": 98, "start": 91, "tag": "BiologicFunction"}, {"end": 124, "start": 103, "tag": "NaturalPhenomenonOrProcess"}, {"end": 82, "start": 73, "tag": "Finding"}, {"end": 54, "start": 34, "tag": "DiseaseOrSyndrome"}]}{"id": "182_2", "text": "3a allele carriers had slower cognitive decline and cortical atrophy.", "tags": [{"end": 9, "start": 0, "tag": "GeneOrGenome"}, {"end": 18, "start": 10, "tag": "PopulationGroup"}, {"end": 68, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 52, "tag": "PathologicFunction"}, {"end": 47, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 52, "tag": "AnatomicalAbnormality"}]}{"id": "182_3", "text": "In addition, high intellectual enrichment predicted slower cognitive decline and counteracted the detrimental effect of the Met66 allele in brain-derived neurotrophic factor.", "tags": [{"end": 136, "start": 124, "tag": "GeneOrGenome"}, {"end": 173, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 13, "tag": "IndividualBehavior"}]}{"id": "182_4", "text": "An important step towards the development of treatments for cognitive impairment in ageing and neurodegenerative diseases is to identify genetic and environmental modifiers of cognitive function and understand the mechanism by which they exert an effect.", "tags": [{"end": 90, "start": 84, "tag": "BiologicFunction"}, {"end": 90, "start": 84, "tag": "CellFunction"}, {"end": 194, "start": 176, "tag": "BiologicFunction"}, {"end": 194, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 30, "tag": "BiologicFunction"}, {"end": 41, "start": 30, "tag": "CellFunction"}, {"end": 55, "start": 45, "tag": "HealthCareActivity"}, {"end": 55, "start": 45, "tag": "ResearchActivity"}, {"end": 121, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 137, "tag": "Finding"}]}{"id": "182_5", "text": "In Huntington's disease, the most common autosomal dominant dementia, a small number of studies have identified intellectual enrichment, i.e.", "tags": [{"end": 59, "start": 41, "tag": "CellFunction"}, {"end": 111, "start": 101, "tag": "Finding"}, {"end": 68, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 88, "tag": "HealthCareActivity"}, {"end": 95, "start": 88, "tag": "ResearchActivity"}, {"end": 23, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 112, "tag": "IndividualBehavior"}]}{"id": "182_6", "text": "a cognitively stimulating lifestyle and genetic polymorphisms as potential modifiers of cognitive function.", "tags": [{"end": 35, "start": 2, "tag": "IndividualBehavior"}, {"end": 61, "start": 40, "tag": "CellFunction"}, {"end": 106, "start": 88, "tag": "BiologicFunction"}, {"end": 84, "start": 65, "tag": "Finding"}]}{"id": "182_7", "text": "The aim of our study was to further investigate the relationship and interaction between genetic factors and intellectual enrichment on cognitive function and brain atrophy in Huntington's disease.", "tags": [{"end": 154, "start": 136, "tag": "BiologicFunction"}, {"end": 64, "start": 52, "tag": "Finding"}, {"end": 172, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 196, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 132, "start": 109, "tag": "IndividualBehavior"}, {"end": 104, "start": 89, "tag": "BiologicFunction"}]}{"id": "182_8", "text": "For this purpose, we analysed data from Track-HD, a multi-centre longitudinal study in Huntington's disease gene carriers and focused on the role of intellectual enrichment (estimated at baseline) and the genes FAN1, MSH3, BDNF, COMT and MAPT in predicting cognitive decline and brain atrophy.", "tags": [{"end": 83, "start": 52, "tag": "ResearchActivity"}, {"end": 215, "start": 211, "tag": "GeneOrGenome"}, {"end": 221, "start": 217, "tag": "AminoAcidPeptideOrProtein"}, {"end": 221, "start": 217, "tag": "GeneOrGenome"}, {"end": 233, "start": 229, "tag": "AminoAcidPeptideOrProtein"}, {"end": 233, "start": 229, "tag": "GeneOrGenome"}, {"end": 233, "start": 229, "tag": "BiologicallyActiveSubstance"}, {"end": 242, "start": 238, "tag": "GeneOrGenome"}, {"end": 121, "start": 108, "tag": "PopulationGroup"}, {"end": 227, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 227, "start": 223, "tag": "BiologicallyActiveSubstance"}, {"end": 292, "start": 279, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 65, "tag": "ResearchActivity"}, {"end": 77, "start": 65, "tag": "ResearchActivity"}, {"end": 274, "start": 257, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 30, "tag": "ResearchActivity"}, {"end": 107, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 172, "start": 149, "tag": "IndividualBehavior"}, {"end": 215, "start": 211, "tag": "AminoAcidPeptideOrProtein"}, {"end": 215, "start": 211, "tag": "BiologicallyActiveSubstance"}, {"end": 221, "start": 217, "tag": "BiologicallyActiveSubstance"}, {"end": 227, "start": 223, "tag": "GeneOrGenome"}, {"end": 242, "start": 238, "tag": "BiologicallyActiveSubstance"}, {"end": 242, "start": 238, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "182_9", "text": "We found that carrying the 3a allele in the MSH3 gene had a positive effect on global cognitive function and brain atrophy in multiple cortical regions, such that 3a allele carriers had a slower rate of cognitive decline and atrophy compared with non-carriers, in agreement with its role in somatic instability.", "tags": [{"end": 36, "start": 27, "tag": "GeneOrGenome"}, {"end": 53, "start": 44, "tag": "GeneOrGenome"}, {"end": 104, "start": 79, "tag": "BiologicFunction"}, {"end": 172, "start": 163, "tag": "GeneOrGenome"}, {"end": 181, "start": 173, "tag": "PopulationGroup"}, {"end": 143, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 199, "start": 195, "tag": "TemporalConcept"}, {"end": 232, "start": 225, "tag": "PathologicFunction"}, {"end": 232, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 220, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 259, "start": 247, "tag": "PopulationGroup"}, {"end": 310, "start": 291, "tag": "CellOrMolecularDysfunction"}]}{"id": "182_10", "text": "No other genetic predictor had a significant effect on cognitive function and the effect of MSH3 was independent of intellectual enrichment.", "tags": [{"end": 73, "start": 55, "tag": "BiologicFunction"}, {"end": 96, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 92, "tag": "GeneOrGenome"}, {"end": 26, "start": 9, "tag": "Finding"}, {"end": 96, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 116, "tag": "IndividualBehavior"}]}{"id": "182_11", "text": "Intellectual enrichment also had a positive effect on cognitive function; participants with higher intellectual enrichment, i.e.", "tags": [{"end": 72, "start": 54, "tag": "BiologicFunction"}, {"end": 86, "start": 74, "tag": "PopulationGroup"}, {"end": 23, "start": 0, "tag": "IndividualBehavior"}, {"end": 50, "start": 35, "tag": "Finding"}, {"end": 122, "start": 99, "tag": "IndividualBehavior"}]}{"id": "182_12", "text": "those who were better educated, had higher verbal intelligence and performed an occupation that was intellectually engaging, had better cognitive function overall, in agreement with previous studies in Huntington's disease and other dementias.", "tags": [{"end": 62, "start": 43, "tag": "BiologicFunction"}, {"end": 90, "start": 80, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 123, "start": 100, "tag": "Finding"}, {"end": 154, "start": 136, "tag": "BiologicFunction"}, {"end": 242, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 191, "tag": "ResearchActivity"}, {"end": 222, "start": 202, "tag": "DiseaseOrSyndrome"}]}{"id": "182_13", "text": "We also found that intellectual enrichment interacted with the BDNF gene, such that the positive effect of intellectual enrichment was greater in Met66 allele carriers than non-carriers.", "tags": [{"end": 72, "start": 63, "tag": "GeneOrGenome"}, {"end": 158, "start": 146, "tag": "GeneOrGenome"}, {"end": 167, "start": 159, "tag": "PopulationGroup"}, {"end": 42, "start": 19, "tag": "IndividualBehavior"}, {"end": 103, "start": 88, "tag": "Finding"}, {"end": 130, "start": 107, "tag": "IndividualBehavior"}, {"end": 185, "start": 173, "tag": "PopulationGroup"}]}{"id": "182_14", "text": "A similar relationship was also identified for changes in whole brain and caudate volume; the positive effect of intellectual enrichment was greater for Met66 allele carriers, rather than for non-carriers.", "tags": [{"end": 165, "start": 153, "tag": "GeneOrGenome"}, {"end": 174, "start": 166, "tag": "PopulationGroup"}, {"end": 22, "start": 10, "tag": "Finding"}, {"end": 81, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 74, "tag": "ClinicalAttribute"}, {"end": 69, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 94, "tag": "Finding"}, {"end": 136, "start": 113, "tag": "IndividualBehavior"}, {"end": 204, "start": 192, "tag": "PopulationGroup"}]}{"id": "182_15", "text": "In summary, our study provides additional evidence for the beneficial role of intellectual enrichment and carrying the 3a allele in MSH3 in cognitive function in Huntington's disease and their effect on brain structure.", "tags": [{"end": 128, "start": 119, "tag": "GeneOrGenome"}, {"end": 136, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 132, "tag": "GeneOrGenome"}, {"end": 158, "start": 140, "tag": "BiologicFunction"}, {"end": 218, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 42, "tag": "Finding"}, {"end": 182, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 74, "start": 59, "tag": "Finding"}, {"end": 101, "start": 78, "tag": "IndividualBehavior"}, {"end": 136, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 199, "start": 193, "tag": "Finding"}]}{"id": "183_0", "text": "Huntington's disease is a progressive neurodegenerative disease that typically manifests with Choreic movements, psychological disorders, and cognitive decline.", "tags": [{"end": 63, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 94, "tag": "SignOrSymptom"}, {"end": 136, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "183_1", "text": "Some patients can initially present atypical movements other than the usual symptoms, such as parkinsonism, ataxia, and dystonia.", "tags": [{"end": 54, "start": 36, "tag": "SignOrSymptom"}, {"end": 84, "start": 76, "tag": "SignOrSymptom"}, {"end": 106, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 108, "tag": "SignOrSymptom"}, {"end": 128, "start": 120, "tag": "SignOrSymptom"}, {"end": 128, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 5, "tag": "PatientOrDisabledGroup"}]}{"id": "183_2", "text": "In this report, we present an HD patient who presented with atypical parkinsonism.", "tags": [{"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 81, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 30, "tag": "PatientOrDisabledGroup"}]}{"id": "190_0", "text": "Neurodegenerative disorders are a group of disorders that affect elderly, with a small portion being hereditary in nature.", "tags": [{"end": 27, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 65, "tag": "PopulationGroup"}, {"end": 111, "start": 101, "tag": "CellFunction"}]}{"id": "190_1", "text": "Both genetic and non-genetic factors contribute in the development of this array of diseases.", "tags": []}{"id": "190_2", "text": "With the majority of cases being sporadic, the search for authenticated therapeutic option is demanding.", "tags": [{"end": 41, "start": 33, "tag": "TemporalConcept"}, {"end": 53, "start": 47, "tag": "ResearchActivity"}]}{"id": "190_3", "text": "Recently, CRISPR/Cas9-based therapy become potential to treat several human diseases, especially neurodegenerative such as Parkinson disease (PD), Huntington disease (HD), Alzheimer disease (AD), and amyotrophic lateral sclerosis (ALS).", "tags": [{"end": 84, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 234, "start": 231, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 10, "tag": "ResearchActivity"}, {"end": 169, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 35, "start": 10, "tag": "HealthCareActivity"}, {"end": 21, "start": 10, "tag": "BiologicFunction"}]}{"id": "190_4", "text": "In this minireview, we highlight how CRISPR/Cas9 become in action to treat these life-threatening diseases and widen the view to the future perspectives and limitations of this technology towards other complicated diseases such as frontotemporal dementia (FTD) and the spinocerebellar ataxias (SCA).", "tags": [{"end": 254, "start": 231, "tag": "DiseaseOrSyndrome"}, {"end": 259, "start": 256, "tag": "DiseaseOrSyndrome"}, {"end": 292, "start": 269, "tag": "DiseaseOrSyndrome"}, {"end": 297, "start": 294, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 37, "tag": "ResearchActivity"}, {"end": 18, "start": 8, "tag": "ResearchActivity"}, {"end": 48, "start": 37, "tag": "BiologicFunction"}, {"end": 106, "start": 81, "tag": "DiseaseOrSyndrome"}]}{"id": "196_0", "text": "Evaluating and improving the performance of activities of daily living is of paramount importance to maintaining the long-term physical capability of individuals with huntington's disease (HD).", "tags": [{"end": 40, "start": 29, "tag": "Finding"}, {"end": 70, "start": 44, "tag": "BiologicFunction"}, {"end": 126, "start": 117, "tag": "TemporalConcept"}, {"end": 191, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 150, "tag": "PatientOrDisabledGroup"}, {"end": 146, "start": 127, "tag": "BiologicFunction"}]}{"id": "196_1", "text": "Because most pharmacologic and psychiatric treatments for HD are focused on the management of signs and symptoms of the disease rather than delaying progressive onset of clinical manifestation, exercise interventions may be a promising solution to provide beneficial improvements in functional capacity and neuromotor function while delaying care dependency.", "tags": [{"end": 53, "start": 13, "tag": "HealthCareActivity"}, {"end": 90, "start": 80, "tag": "HealthCareActivity"}, {"end": 99, "start": 94, "tag": "SignOrSymptom"}, {"end": 112, "start": 104, "tag": "SignOrSymptom"}, {"end": 216, "start": 194, "tag": "HealthCareActivity"}, {"end": 302, "start": 283, "tag": "Finding"}, {"end": 357, "start": 342, "tag": "Finding"}, {"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 161, "tag": "TemporalConcept"}, {"end": 192, "start": 170, "tag": "SignOrSymptom"}, {"end": 326, "start": 307, "tag": "BiologicFunction"}]}{"id": "200_0", "text": "Background: Huntington's disease (HD) is a rare, genetic neurodegenerative disorder often presenting with emotional, cognitive and behavioral abnormalities before manifestation of disease defining motor symptoms.", "tags": [{"end": 155, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 163, "tag": "Finding"}, {"end": 32, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 43, "tag": "TemporalConcept"}, {"end": 83, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 197, "tag": "SignOrSymptom"}]}{"id": "200_1", "text": "Cognitive impairment is a frequent clinical feature caused by different dementia subtypes.", "tags": [{"end": 51, "start": 35, "tag": "ClinicalAttribute"}, {"end": 34, "start": 26, "tag": "TemporalConcept"}, {"end": 80, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "200_2", "text": "Imaging cortical and subcortical glucose metabolism via F-18-FDG PET/CT can help to discriminate the underlying disease.", "tags": [{"end": 71, "start": 56, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "HealthCareActivity"}, {"end": 16, "start": 8, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 33, "tag": "CellFunction"}]}{"id": "200_3", "text": "Case presentation: The patient is a 54-year old man presenting with progressive cognitive impairment and mild orofacial dyskinesia.", "tags": [{"end": 130, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 48, "tag": "PopulationGroup"}, {"end": 47, "start": 36, "tag": "PopulationGroup"}, {"end": 30, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 100, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 5, "tag": "Finding"}]}{"id": "200_4", "text": "F-18-FDG PET/CT of the brain revealed a severe bilateral hypometabolism in the striatum.", "tags": [{"end": 15, "start": 0, "tag": "HealthCareActivity"}, {"end": 71, "start": 40, "tag": "Finding"}, {"end": 28, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "200_5", "text": "Following imaging Huntington's disease was suspected and a molecular genetic testing confirmed the diagnosis.", "tags": [{"end": 84, "start": 59, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 108, "start": 99, "tag": "HealthCareActivity"}, {"end": 84, "start": 69, "tag": "HealthCareActivity"}, {"end": 38, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 10, "tag": "HealthCareActivity"}]}{"id": "200_6", "text": "Conclusions: Huntington's disease is a rare but important differential diagnosis of cognitive impairment, especially before motor symptoms are manifest.", "tags": [{"end": 80, "start": 58, "tag": "HealthCareActivity"}, {"end": 80, "start": 71, "tag": "HealthCareActivity"}, {"end": 33, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 39, "tag": "TemporalConcept"}, {"end": 104, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 124, "tag": "SignOrSymptom"}]}{"id": "200_7", "text": "F-18-FDG PET is capable to show early striatal dysfunction in HD even when structural imaging is normal.", "tags": [{"end": 12, "start": 0, "tag": "HealthCareActivity"}, {"end": 58, "start": 38, "tag": "PathologicFunction"}, {"end": 93, "start": 75, "tag": "HealthCareActivity"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 86, "tag": "HealthCareActivity"}]}{"id": "200_8", "text": "We conclude that, in cases with negative family history the HD characteristic metabolic pattern can lead to the diagnosis when no other dementia-suspected changes are present.", "tags": [{"end": 121, "start": 112, "tag": "HealthCareActivity"}, {"end": 62, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 41, "tag": "Finding"}]}{"id": "201_0", "text": "Neurodegenerative diseases (NDDs), which occur due to progressive loss of function or structure of neurons, are a fundamental cause of abnormalities in gait dynamics and cause movement disorder in humans.", "tags": [{"end": 165, "start": 152, "tag": "OrganismAttribute"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 99, "tag": "Cell"}, {"end": 32, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 203, "start": 197, "tag": "Eukaryote"}, {"end": 106, "start": 96, "tag": "CellOrMolecularDysfunction"}, {"end": 82, "start": 54, "tag": "CellOrMolecularDysfunction"}]}{"id": "201_1", "text": "Therefore, gait time-series signals can be used to predict NDDs like Parkinson's disease (PD), Huntington's disease (HD), and Amyotrophic Lateral Sclerosis (ALS).", "tags": [{"end": 15, "start": 11, "tag": "OrganismAttribute"}, {"end": 115, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 11, "tag": "HealthCareActivity"}, {"end": 27, "start": 16, "tag": "TemporalConcept"}]}{"id": "201_2", "text": "In this paper, linear, non-linear, statistical features of the gait signal and four physiological features of the human subjects were used to train random forest classifier to predict the NDDs.", "tags": [{"end": 147, "start": 142, "tag": "BiologicFunction"}, {"end": 67, "start": 63, "tag": "OrganismAttribute"}, {"end": 119, "start": 114, "tag": "Eukaryote"}, {"end": 128, "start": 120, "tag": "PopulationGroup"}, {"end": 192, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 172, "start": 148, "tag": "ResearchActivity"}, {"end": 55, "start": 15, "tag": "ResearchActivity"}]}{"id": "201_3", "text": "Kernel Principal Component Analysis (PCA) with Gaussian Kernel was employed to improve accuracy and prevent overfitting.", "tags": [{"end": 35, "start": 0, "tag": "ResearchActivity"}, {"end": 62, "start": 47, "tag": "ResearchActivity"}, {"end": 40, "start": 37, "tag": "ResearchActivity"}]}{"id": "201_4", "text": "The proposed method displayed an overall 95.26% prediction accuracy and provided a unique set of features that could be used to analyze NDDs further.", "tags": [{"end": 19, "start": 13, "tag": "ResearchActivity"}, {"end": 140, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 41, "tag": "ResearchActivity"}]}{"id": "202_0", "text": "The zebrafish is increasingly recognized as a model organism for translational research into human neuropathology.", "tags": [{"end": 87, "start": 65, "tag": "ResearchActivity"}, {"end": 113, "start": 99, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 113, "start": 99, "tag": "PathologicFunction"}, {"end": 98, "start": 93, "tag": "Eukaryote"}, {"end": 60, "start": 46, "tag": "ManufacturedObject"}, {"end": 13, "start": 4, "tag": "Eukaryote"}]}{"id": "202_1", "text": "The zebrafish brain exhibits fundamental resemblance with human neuroanatomical and neurochemical pathways, and hallmarks of human brain pathology such as protein aggregation, neuronal degeneration and activation of glial cells, for example, can be modeled and recapitulated in the fish central nervous system.", "tags": [{"end": 79, "start": 64, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 106, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 197, "start": 176, "tag": "CellOrMolecularDysfunction"}, {"end": 227, "start": 202, "tag": "CellFunction"}, {"end": 227, "start": 216, "tag": "Cell"}, {"end": 309, "start": 287, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 286, "start": 282, "tag": "Eukaryote"}, {"end": 63, "start": 58, "tag": "Eukaryote"}, {"end": 130, "start": 125, "tag": "Eukaryote"}, {"end": 146, "start": 137, "tag": "PathologicFunction"}, {"end": 146, "start": 137, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 174, "start": 155, "tag": "CellFunction"}, {"end": 174, "start": 155, "tag": "CellOrMolecularDysfunction"}, {"end": 13, "start": 4, "tag": "Eukaryote"}]}{"id": "202_2", "text": "Genetic manipulation, imaging, and drug screening are areas where zebrafish excel with the ease of introducing mutations and transgenes, the expression of fluorescent markers that can be detected in vivo in the transparent larval stages overtime, and simple treatment of large numbers of fish larvae at once followed by automated screening and imaging.", "tags": [{"end": 20, "start": 0, "tag": "ResearchActivity"}, {"end": 29, "start": 22, "tag": "HealthCareActivity"}, {"end": 49, "start": 35, "tag": "ResearchActivity"}, {"end": 120, "start": 111, "tag": "CellFunction"}, {"end": 120, "start": 111, "tag": "CellOrMolecularDysfunction"}, {"end": 135, "start": 125, "tag": "GeneOrGenome"}, {"end": 174, "start": 155, "tag": "Chemical"}, {"end": 203, "start": 196, "tag": "ResearchActivity"}, {"end": 339, "start": 320, "tag": "ResearchActivity"}, {"end": 351, "start": 344, "tag": "HealthCareActivity"}, {"end": 39, "start": 35, "tag": "PharmacologicSubstance"}, {"end": 299, "start": 288, "tag": "Eukaryote"}, {"end": 267, "start": 258, "tag": "HealthCareActivity"}, {"end": 267, "start": 258, "tag": "ResearchActivity"}, {"end": 75, "start": 66, "tag": "Eukaryote"}, {"end": 236, "start": 223, "tag": "TemporalConcept"}]}{"id": "202_3", "text": "In this review, we summarize how zebrafish have successfully been employed to model human neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, and Huntington's disease.", "tags": [{"end": 144, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 196, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 84, "tag": "Eukaryote"}, {"end": 222, "start": 202, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 42, "start": 33, "tag": "Eukaryote"}]}{"id": "202_4", "text": "We discuss advantages and disadvantages of choosing zebrafish as a model for these neurodegenerative conditions.", "tags": [{"end": 111, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 52, "tag": "Eukaryote"}]}{"id": "205_0", "text": "Neurodegenerative diseases are a diverse class of diseases attributed to chronic progressive neuronal degeneration and synaptic loss in the brain and/or spinal cord, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and multiple sclerosis.", "tags": [{"end": 164, "start": 153, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 218, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 197, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 73, "tag": "TemporalConcept"}, {"end": 195, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 269, "start": 240, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 292, "start": 274, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 81, "tag": "CellOrMolecularDysfunction"}, {"end": 132, "start": 119, "tag": "CellOrMolecularDysfunction"}]}{"id": "205_1", "text": "The pathogenesis of neurodegenerative diseases is complex and diverse, often involving mitochondrial dysfunction, neuroinflammation, and epigenetic changes.", "tags": [{"end": 155, "start": 137, "tag": "CellFunction"}, {"end": 46, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 114, "tag": "PathologicFunction"}, {"end": 16, "start": 4, "tag": "PathologicFunction"}, {"end": 112, "start": 87, "tag": "CellOrMolecularDysfunction"}]}{"id": "205_2", "text": "However, the pathogenesis of neurodegenerative diseases has not been fully elucidated.", "tags": [{"end": 55, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 13, "tag": "PathologicFunction"}]}{"id": "205_3", "text": "Recently, accumulating evidence revealed that ferroptosis, a newly discovered iron-dependent and lipid peroxidation-driven type of programmed cell death, provides another explanation for the occurrence and progression of neurodegenerative diseases.", "tags": [{"end": 57, "start": 46, "tag": "CellFunction"}, {"end": 102, "start": 97, "tag": "Chemical"}, {"end": 102, "start": 97, "tag": "ResearchActivity"}, {"end": 102, "start": 97, "tag": "CellComponent"}, {"end": 152, "start": 131, "tag": "CellFunction"}, {"end": 182, "start": 171, "tag": "Finding"}, {"end": 201, "start": 191, "tag": "TemporalConcept"}, {"end": 115, "start": 97, "tag": "CellFunction"}, {"end": 247, "start": 221, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 206, "tag": "PathologicFunction"}, {"end": 217, "start": 206, "tag": "TemporalConcept"}, {"end": 31, "start": 10, "tag": "Finding"}, {"end": 152, "start": 147, "tag": "BiologicFunction"}, {"end": 152, "start": 147, "tag": "PathologicFunction"}, {"end": 82, "start": 78, "tag": "PharmacologicSubstance"}, {"end": 82, "start": 78, "tag": "Chemical"}, {"end": 82, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 152, "start": 147, "tag": "CellFunction"}]}{"id": "205_4", "text": "Here, we provide an overview of the process and regulation mechanisms of ferroptosis, and summarize current research progresses that support the contribution of ferroptosis to the pathogenesis of neurodegenerative diseases.", "tags": [{"end": 84, "start": 73, "tag": "CellFunction"}, {"end": 172, "start": 161, "tag": "CellFunction"}, {"end": 222, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 100, "tag": "TemporalConcept"}, {"end": 116, "start": 108, "tag": "ResearchActivity"}, {"end": 28, "start": 20, "tag": "ResearchActivity"}, {"end": 192, "start": 180, "tag": "PathologicFunction"}]}{"id": "205_5", "text": "A comprehensive understanding of the emerging roles of ferroptosis in neurodegenerative diseases will shed light on the development of novel therapeutic technologies and strategies for slowing down the progression of these diseases.", "tags": [{"end": 66, "start": 55, "tag": "CellFunction"}, {"end": 96, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 213, "start": 202, "tag": "PathologicFunction"}, {"end": 213, "start": 202, "tag": "TemporalConcept"}, {"end": 165, "start": 135, "tag": "HealthCareActivity"}, {"end": 29, "start": 2, "tag": "ResearchActivity"}]}{"id": "207_0", "text": "Neuropeptide Y (NPY), a 36 amino acid peptide, is widely expressed in the mammalian brain.", "tags": [{"end": 14, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 0, "tag": "GeneOrGenome"}, {"end": 14, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 16, "tag": "GeneOrGenome"}, {"end": 19, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 74, "tag": "Eukaryote"}, {"end": 89, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 24, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "207_1", "text": "Changes in NPY levels in different brain regions and plasma have been described in several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, and Machado-Joseph disease.", "tags": [{"end": 14, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 11, "tag": "GeneOrGenome"}, {"end": 14, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 222, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 250, "start": 228, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 91, "tag": "DiseaseOrSyndrome"}]}{"id": "207_2", "text": "The changes in NPY levels may reflect the attempt to set up an endogenous neuroprotective mechanism to counteract the degenerative process.", "tags": [{"end": 18, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 15, "tag": "GeneOrGenome"}, {"end": 18, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 63, "tag": "CellFunction"}, {"end": 138, "start": 118, "tag": "PathologicFunction"}]}{"id": "207_3", "text": "Accumulating evidence indicates that NPY can function as an anti-apoptotic, anti-inflammatory, and pro-phagocytic agent, which may be used effectively to halt or to slow down the progression of the disease.", "tags": [{"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 37, "tag": "GeneOrGenome"}, {"end": 40, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 0, "tag": "Finding"}, {"end": 205, "start": 179, "tag": "PathologicFunction"}, {"end": 205, "start": 179, "tag": "TemporalConcept"}, {"end": 119, "start": 114, "tag": "PharmacologicSubstance"}, {"end": 119, "start": 99, "tag": "PharmacologicSubstance"}, {"end": 119, "start": 114, "tag": "PharmacologicSubstance"}, {"end": 74, "start": 60, "tag": "PharmacologicSubstance"}, {"end": 119, "start": 114, "tag": "PharmacologicSubstance"}, {"end": 94, "start": 76, "tag": "PharmacologicSubstance"}]}{"id": "207_4", "text": "In this review, we will focus on the neuroprotective roles of NPY in several neuropathological conditions, with a particular focus on the anti-inflammatory properties of NPY.", "tags": [{"end": 65, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 62, "tag": "GeneOrGenome"}, {"end": 65, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 170, "tag": "GeneOrGenome"}, {"end": 173, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 138, "tag": "BiologicFunction"}, {"end": 155, "start": 138, "tag": "PharmacologicSubstance"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "208_0", "text": "Huntington disease, a neurodegenerative disease characterized by progressive motor, behavioral, and cognitive decline, is caused by a CAG trinucleotide repeat expansion in the huntingtin gene on chromosome 4.", "tags": [{"end": 47, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 134, "tag": "CellOrMolecularDysfunction"}, {"end": 191, "start": 176, "tag": "GeneOrGenome"}, {"end": 207, "start": 195, "tag": "CellComponent"}, {"end": 117, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "208_1", "text": "Current treatments target symptom management because there are no disease-modifying therapies at this time.", "tags": [{"end": 18, "start": 8, "tag": "HealthCareActivity"}, {"end": 18, "start": 8, "tag": "ResearchActivity"}, {"end": 44, "start": 26, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 93, "start": 66, "tag": "HealthCareActivity"}]}{"id": "208_2", "text": "Investigation of RNA-based and DNA-based treatment strategies are emerging and hold promise of possible future disease-modifying therapy.", "tags": [{"end": 13, "start": 0, "tag": "ResearchActivity"}, {"end": 20, "start": 17, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 50, "start": 41, "tag": "HealthCareActivity"}, {"end": 50, "start": 41, "tag": "ResearchActivity"}, {"end": 34, "start": 31, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 136, "start": 111, "tag": "HealthCareActivity"}, {"end": 110, "start": 104, "tag": "TemporalConcept"}]}{"id": "212_0", "text": "Huntington's disease (HD) is an autosomal dominantly-inherited neurodegenerative disease, which is caused by CAG trinucleotide expansion in exon 1 of the Huntingtin (HTT) gene.", "tags": [{"end": 146, "start": 140, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 32, "tag": "CellFunction"}, {"end": 88, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 109, "tag": "CellOrMolecularDysfunction"}, {"end": 175, "start": 154, "tag": "GeneOrGenome"}]}{"id": "212_1", "text": "Although HD is a rare disease, its monogenic nature makes it an ideal model in which to understand pathogenic mechanisms and to develop therapeutic strategies for neurodegenerative diseases.", "tags": [{"end": 11, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 17, "tag": "TemporalConcept"}, {"end": 120, "start": 99, "tag": "PathologicFunction"}, {"end": 158, "start": 136, "tag": "HealthCareActivity"}]}{"id": "212_2", "text": "Clustered regularly-interspaced short palindromic repeats (CRISPR) is the latest technology for genome editing.", "tags": [{"end": 59, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 65, "start": 59, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 65, "start": 59, "tag": "ResearchActivity"}, {"end": 110, "start": 96, "tag": "ResearchActivity"}]}{"id": "212_3", "text": "Being simple to use and highly efficient, CRISPR-based genome-editing tools are rapidly gaining popularity in biomedical research and opening up new avenues for disease treatment.", "tags": [{"end": 129, "start": 110, "tag": "ResearchActivity"}, {"end": 178, "start": 161, "tag": "HealthCareActivity"}, {"end": 75, "start": 42, "tag": "ResearchActivity"}]}{"id": "212_4", "text": "Here, we review the development of CRISPR-based genome-editing tools and their applications in HD research to offer a translational perspective on advancing the genome-editing technology to HD treatment.", "tags": [{"end": 106, "start": 98, "tag": "ResearchActivity"}, {"end": 143, "start": 132, "tag": "BiologicFunction"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 202, "start": 193, "tag": "HealthCareActivity"}, {"end": 202, "start": 193, "tag": "ResearchActivity"}, {"end": 68, "start": 35, "tag": "ResearchActivity"}, {"end": 186, "start": 161, "tag": "ResearchActivity"}]}{"id": "213_0", "text": "Huntington's disease (HD) is an inherited neurodegenerative disease characterized by motor, cognitive and behavioral deficits.", "tags": [{"end": 67, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "213_1", "text": "Some evidence suggests that the endocannabinoid system participates in the pathophysiology of HD.", "tags": [{"end": 90, "start": 75, "tag": "PathologicFunction"}, {"end": 54, "start": 32, "tag": "CellFunction"}, {"end": 13, "start": 5, "tag": "Finding"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}]}{"id": "213_2", "text": "We conducted a cross-sectional study comparing plasma levels of anandamide and 2-arachidonoylglycerol in manifest HD gene-expansion carriers (HDGEC) and healthy controls, finding no difference in endocannabinoid levels between the groups.", "tags": [{"end": 36, "start": 15, "tag": "ResearchActivity"}, {"end": 53, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 64, "tag": "Chemical"}, {"end": 101, "start": 79, "tag": "Chemical"}, {"end": 101, "start": 79, "tag": "PharmacologicSubstance"}, {"end": 211, "start": 196, "tag": "Chemical"}, {"end": 169, "start": 153, "tag": "PopulationGroup"}, {"end": 140, "start": 114, "tag": "PatientOrDisabledGroup"}, {"end": 147, "start": 142, "tag": "PatientOrDisabledGroup"}, {"end": 74, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 211, "start": 196, "tag": "BiologicallyActiveSubstance"}]}{"id": "213_3", "text": "Correlations between endocannabinoid levels and clinical scales (Mini-Mental State Examination, Hospital Anxiety and Depression Scale, Unified Huntington Disease Rating Scale) were non-significant.", "tags": [{"end": 36, "start": 21, "tag": "Chemical"}, {"end": 94, "start": 65, "tag": "HealthCareActivity"}, {"end": 174, "start": 135, "tag": "HealthCareActivity"}, {"end": 133, "start": 96, "tag": "HealthCareActivity"}, {"end": 63, "start": 48, "tag": "HealthCareActivity"}, {"end": 36, "start": 21, "tag": "BiologicallyActiveSubstance"}]}{"id": "213_4", "text": "We found a significant association between body mass index and anandamide levels in healthy controls but not in HDGEC.", "tags": [{"end": 73, "start": 63, "tag": "Chemical"}, {"end": 100, "start": 84, "tag": "PopulationGroup"}, {"end": 117, "start": 112, "tag": "PatientOrDisabledGroup"}, {"end": 58, "start": 43, "tag": "HealthCareActivity"}, {"end": 73, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 11, "tag": "Finding"}]}{"id": "223_0", "text": "Objective: Huntington's disease (HD) is a genetic neurodegenerative condition that is characterized by cognitive, motor, and psychiatric dysfunction.", "tags": [{"end": 148, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 43, "tag": "DiseaseOrSyndrome"}]}{"id": "223_1", "text": "The purpose of this study was to explore which disease characteristics influence caregiver burden in HD.", "tags": [{"end": 97, "start": 81, "tag": "BiologicFunction"}, {"end": 103, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 20, "tag": "ResearchActivity"}, {"end": 70, "start": 47, "tag": "ClinicalAttribute"}]}{"id": "223_2", "text": "Methods: Fifty participants with HD and 50 of their caregivers participated in the study at the University of South Florida.", "tags": [{"end": 27, "start": 15, "tag": "PopulationGroup"}, {"end": 106, "start": 96, "tag": "HealthCareRelatedOrganization"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 83, "tag": "ResearchActivity"}, {"end": 62, "start": 52, "tag": "HealthCareActivity"}]}{"id": "223_3", "text": "Participants were administered a neuropsychological battery, the Unified Huntington's Disease Rating Scale (UHDRS) motor exam, and the Frontal Systems Behavior Scale (FrSBe) self-report.", "tags": [{"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 59, "start": 33, "tag": "HealthCareActivity"}, {"end": 172, "start": 167, "tag": "HealthCareActivity"}, {"end": 185, "start": 135, "tag": "HealthCareActivity"}, {"end": 113, "start": 108, "tag": "HealthCareActivity"}, {"end": 125, "start": 65, "tag": "HealthCareActivity"}]}{"id": "223_4", "text": "Caregivers completed the Caregiving Appraisal Scale and the FrSBe family-report.", "tags": [{"end": 79, "start": 60, "tag": "HealthCareActivity"}, {"end": 51, "start": 25, "tag": "HealthCareActivity"}, {"end": 10, "start": 0, "tag": "HealthCareActivity"}]}{"id": "223_5", "text": "Results: There were significant correlations between caregiver burden and caregiver age and sex, UHDRS motor scores, cognitive functioning, and self and caregiver-reported FrSBe scores.", "tags": [{"end": 44, "start": 20, "tag": "Finding"}, {"end": 138, "start": 117, "tag": "BiologicFunction"}, {"end": 184, "start": 144, "tag": "ResearchActivity"}, {"end": 69, "start": 53, "tag": "BiologicFunction"}, {"end": 87, "start": 84, "tag": "OrganismAttribute"}, {"end": 83, "start": 74, "tag": "HealthCareActivity"}, {"end": 95, "start": 92, "tag": "OrganismAttribute"}, {"end": 102, "start": 97, "tag": "HealthCareActivity"}, {"end": 115, "start": 97, "tag": "ResearchActivity"}]}{"id": "223_6", "text": "The significant variables were entered into a regression model and explained 63.1% of the variance in caregiver burden scores.", "tags": [{"end": 118, "start": 102, "tag": "BiologicFunction"}, {"end": 62, "start": 46, "tag": "ResearchActivity"}, {"end": 125, "start": 102, "tag": "ResearchActivity"}]}{"id": "223_7", "text": "Caregiver age, cognitive functioning, and caregiverreported FrSBe scores continued to be significant predictors of caregiver burden, whereas the other variables were no longer significant.", "tags": [{"end": 13, "start": 0, "tag": "Finding"}, {"end": 36, "start": 15, "tag": "BiologicFunction"}, {"end": 111, "start": 101, "tag": "Finding"}, {"end": 131, "start": 115, "tag": "BiologicFunction"}, {"end": 72, "start": 42, "tag": "ResearchActivity"}, {"end": 187, "start": 166, "tag": "Finding"}]}{"id": "223_8", "text": "Conclusions: There were significant relationships between caregiver burden, cognitive functioning, and frontally mediated behaviors, but not motor scores.", "tags": [{"end": 49, "start": 24, "tag": "Finding"}, {"end": 97, "start": 76, "tag": "BiologicFunction"}, {"end": 131, "start": 103, "tag": "BiologicFunction"}, {"end": 74, "start": 58, "tag": "BiologicFunction"}, {"end": 153, "start": 141, "tag": "ResearchActivity"}]}{"id": "223_9", "text": "The results suggest that possible interventions for caregiversmay include education to caregivers on howto cope with apathy/executive dysfunction and cognitive decline.", "tags": [{"end": 47, "start": 34, "tag": "HealthCareActivity"}, {"end": 83, "start": 74, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 167, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 52, "tag": "HealthCareActivity"}, {"end": 97, "start": 87, "tag": "HealthCareActivity"}, {"end": 123, "start": 117, "tag": "DiseaseOrSyndrome"}]}{"id": "223_10", "text": "Caregiver agewas associated with burden, with younger age being associated with increased burden when controlling for symptom severity.", "tags": [{"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 96, "start": 80, "tag": "Finding"}, {"end": 134, "start": 118, "tag": "Finding"}, {"end": 57, "start": 46, "tag": "PopulationGroup"}]}{"id": "223_11", "text": "This has implications for this population in that HD typically has a younger age of onset than other neurodegenerative diseases and therefore, these caregivers may be particularly at risk for caregiver burden.", "tags": [{"end": 41, "start": 31, "tag": "PopulationGroup"}, {"end": 208, "start": 192, "tag": "BiologicFunction"}, {"end": 52, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 84, "tag": "TemporalConcept"}, {"end": 80, "start": 69, "tag": "PopulationGroup"}, {"end": 159, "start": 149, "tag": "HealthCareActivity"}]}{"id": "227_0", "text": "Introduction: Huntington disease (HD) is a rare genetic neurodegenerative condition.", "tags": [{"end": 32, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 56, "tag": "CellOrMolecularDysfunction"}, {"end": 47, "start": 43, "tag": "TemporalConcept"}, {"end": 83, "start": 48, "tag": "DiseaseOrSyndrome"}]}{"id": "227_1", "text": "The availability of a genetic diagnosis makes HD an attractive model for the development of therapies that can delay or, at best, halt the progression of neurodegenerative conditions.", "tags": [{"end": 39, "start": 22, "tag": "HealthCareActivity"}, {"end": 116, "start": 111, "tag": "TemporalConcept"}, {"end": 101, "start": 92, "tag": "HealthCareActivity"}, {"end": 68, "start": 63, "tag": "ResearchActivity"}, {"end": 182, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 77, "tag": "BiologicFunction"}, {"end": 88, "start": 77, "tag": "CellFunction"}, {"end": 150, "start": 139, "tag": "PathologicFunction"}, {"end": 150, "start": 139, "tag": "TemporalConcept"}, {"end": 48, "start": 46, "tag": "DiseaseOrSyndrome"}]}{"id": "227_2", "text": "Tetrabenazine and deutetrabenazine are the only treatment options with a formal indication (chorea) for this patient population.", "tags": [{"end": 13, "start": 0, "tag": "Chemical"}, {"end": 65, "start": 48, "tag": "HealthCareActivity"}, {"end": 65, "start": 48, "tag": "ResearchActivity"}, {"end": 98, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 92, "tag": "SignOrSymptom"}, {"end": 127, "start": 117, "tag": "PopulationGroup"}, {"end": 34, "start": 18, "tag": "PharmacologicSubstance"}, {"end": 34, "start": 18, "tag": "Chemical"}, {"end": 116, "start": 109, "tag": "PatientOrDisabledGroup"}, {"end": 13, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "227_3", "text": "Methods: Literature review on HD and clinical trials using the medical databases Pubmed, Web of Science, and clinical trial registries.", "tags": [{"end": 134, "start": 124, "tag": "ResearchActivity"}, {"end": 123, "start": 109, "tag": "ResearchActivity"}, {"end": 80, "start": 71, "tag": "ResearchActivity"}, {"end": 103, "start": 89, "tag": "HealthCareRelatedOrganization"}, {"end": 52, "start": 37, "tag": "ResearchActivity"}, {"end": 32, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 9, "tag": "ResearchActivity"}, {"end": 26, "start": 20, "tag": "HealthCareActivity"}, {"end": 87, "start": 81, "tag": "HealthCareRelatedOrganization"}]}{"id": "227_4", "text": "Recent clinical trials conducted with the goal of disease-modification or new symptomatic treatment indications were included.", "tags": [{"end": 46, "start": 42, "tag": "HealthCareActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 99, "start": 78, "tag": "HealthCareActivity"}, {"end": 22, "start": 7, "tag": "ResearchActivity"}]}{"id": "227_5", "text": "Non-pharmacological interventions were excluded.", "tags": [{"end": 33, "start": 0, "tag": "HealthCareActivity"}]}{"id": "227_6", "text": "Results: Therapeutic approaches aiming at disease-modification include huntingtin-lowering strategies, the modulation of huntingtin homeostasis and neuroinflammation.", "tags": [{"end": 31, "start": 9, "tag": "HealthCareActivity"}, {"end": 165, "start": 148, "tag": "PathologicFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 143, "start": 132, "tag": "BiologicFunction"}, {"end": 81, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 71, "tag": "GeneOrGenome"}, {"end": 131, "start": 121, "tag": "GeneOrGenome"}, {"end": 81, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 71, "tag": "ResearchActivity"}, {"end": 101, "start": 71, "tag": "HealthCareActivity"}, {"end": 131, "start": 121, "tag": "BiologicallyActiveSubstance"}]}{"id": "227_7", "text": "Huntingtin-lowering strategies are of particular interest by targeting the mRNA of the huntingtin (HTT) gene at the core of HD biology.", "tags": [{"end": 134, "start": 127, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 79, "start": 75, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 102, "start": 99, "tag": "GeneOrGenome"}, {"end": 102, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 104, "tag": "GeneOrGenome"}, {"end": 97, "start": 87, "tag": "GeneOrGenome"}, {"end": 30, "start": 0, "tag": "HealthCareActivity"}, {"end": 30, "start": 0, "tag": "ResearchActivity"}]}{"id": "227_8", "text": "Antisense oligonucleotides (ASO) are the only huntingtin-lowering strategies in clinical development.", "tags": [{"end": 100, "start": 80, "tag": "ResearchActivity"}, {"end": 31, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 28, "tag": "Chemical"}, {"end": 31, "start": 28, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 26, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 26, "start": 0, "tag": "Chemical"}, {"end": 26, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 46, "tag": "HealthCareActivity"}, {"end": 76, "start": 46, "tag": "ResearchActivity"}]}{"id": "227_9", "text": "The initial results suggest that the first non-allele specific ASO was safe and associated with a reduction in the levels of mutated huntingtin protein (mHTT).", "tags": [{"end": 151, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 63, "tag": "Chemical"}, {"end": 66, "start": 63, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 157, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 153, "tag": "CellOrMolecularDysfunction"}, {"end": 107, "start": 98, "tag": "Finding"}, {"end": 107, "start": 98, "tag": "NaturalPhenomenonOrProcess"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}, {"end": 42, "start": 37, "tag": "TemporalConcept"}, {"end": 151, "start": 125, "tag": "CellOrMolecularDysfunction"}]}{"id": "227_10", "text": "Other clinical trials for disease-modification in HD have generated negative results or are ongoing.", "tags": [{"end": 21, "start": 6, "tag": "ResearchActivity"}, {"end": 99, "start": 92, "tag": "TemporalConcept"}, {"end": 52, "start": 50, "tag": "DiseaseOrSyndrome"}]}{"id": "227_11", "text": "Assays to measure CSF mHTT and brain nuclear imaging specific to HD can support the rational development of these therapies.", "tags": [{"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 17, "start": 10, "tag": "HealthCareActivity"}, {"end": 52, "start": 31, "tag": "HealthCareActivity"}, {"end": 26, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 22, "tag": "CellOrMolecularDysfunction"}, {"end": 123, "start": 114, "tag": "HealthCareActivity"}, {"end": 52, "start": 37, "tag": "HealthCareActivity"}, {"end": 104, "start": 93, "tag": "BiologicFunction"}, {"end": 104, "start": 93, "tag": "CellFunction"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 18, "tag": "ClinicalAttribute"}]}{"id": "227_12", "text": "Novel symptomatic treatment indications explored in clinical trials include motor disability, irritability and apathy.", "tags": [{"end": 92, "start": 76, "tag": "Finding"}, {"end": 27, "start": 6, "tag": "HealthCareActivity"}, {"end": 106, "start": 94, "tag": "SignOrSymptom"}, {"end": 117, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 52, "tag": "ResearchActivity"}, {"end": 17, "start": 6, "tag": "SignOrSymptom"}, {"end": 27, "start": 18, "tag": "HealthCareActivity"}, {"end": 27, "start": 18, "tag": "ResearchActivity"}]}{"id": "227_13", "text": "Conclusions: The years ahead are promising for novel and revolutionary therapies aimed at core disease mechanisms in HD.", "tags": [{"end": 102, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 95, "tag": "ResearchActivity"}, {"end": 80, "start": 71, "tag": "HealthCareActivity"}, {"end": 22, "start": 17, "tag": "TemporalConcept"}, {"end": 119, "start": 117, "tag": "DiseaseOrSyndrome"}]}{"id": "227_14", "text": "Clinical research platforms such as Enroll-HD are expected to potentiate the conduction of clinical trials in HD.", "tags": [{"end": 87, "start": 77, "tag": "BiologicFunction"}, {"end": 87, "start": 77, "tag": "NaturalPhenomenonOrProcess"}, {"end": 106, "start": 91, "tag": "ResearchActivity"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 0, "tag": "ResearchActivity"}, {"end": 45, "start": 36, "tag": "ResearchActivity"}]}{"id": "229_0", "text": "Neurodegenerative diseases (NDDs) such as amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and Parkinson's disease (PD) can manifest themselves anatomically by degeneration in the brain as well as motor symptoms.", "tags": [{"end": 99, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 175, "tag": "PathologicFunction"}, {"end": 32, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 226, "start": 212, "tag": "SignOrSymptom"}]}{"id": "229_1", "text": "The motor symptoms can affect walking dynamics in a disease-specific fashion; characteristically they disrupt gait.", "tags": [{"end": 46, "start": 30, "tag": "OrganismAttribute"}, {"end": 18, "start": 4, "tag": "SignOrSymptom"}, {"end": 114, "start": 110, "tag": "OrganismAttribute"}]}{"id": "229_2", "text": "As the severity of the disease increases, walking ability deteriorates.", "tags": [{"end": 57, "start": 42, "tag": "OrganismAttribute"}, {"end": 30, "start": 7, "tag": "ClinicalAttribute"}]}{"id": "231_0", "text": "Dimethyl fumarate (DMF) is an antioxidative and anti-inflammatory drug approved for treatment of multiple sclerosis and psoriasis; however, beneficial effects of DMF have also been found in other inflammatory diseases and cancers.", "tags": [{"end": 70, "start": 48, "tag": "PharmacologicSubstance"}, {"end": 115, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 222, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 222, "tag": "Cell"}, {"end": 158, "start": 140, "tag": "Finding"}, {"end": 22, "start": 19, "tag": "PharmacologicSubstance"}, {"end": 165, "start": 162, "tag": "PharmacologicSubstance"}, {"end": 22, "start": 19, "tag": "Chemical"}, {"end": 165, "start": 162, "tag": "Chemical"}, {"end": 17, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 17, "start": 0, "tag": "Chemical"}, {"end": 93, "start": 84, "tag": "HealthCareActivity"}, {"end": 93, "start": 84, "tag": "ResearchActivity"}, {"end": 17, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 19, "tag": "BiologicallyActiveSubstance"}]}{"id": "231_1", "text": "DMF is a prodrug that is immediately hydrolysed to monomethyl fumarate (MMF) in vivo.", "tags": [{"end": 16, "start": 9, "tag": "Chemical"}, {"end": 70, "start": 51, "tag": "Chemical"}, {"end": 75, "start": 72, "tag": "Chemical"}, {"end": 84, "start": 77, "tag": "ResearchActivity"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "Chemical"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "231_2", "text": "Both fumarates activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, and Nrf2 is a key transcription factor of the antioxidant response.", "tags": [{"end": 14, "start": 5, "tag": "Chemical"}, {"end": 96, "start": 92, "tag": "GeneOrGenome"}, {"end": 96, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 134, "tag": "CellFunction"}, {"end": 86, "start": 28, "tag": "CellFunction"}, {"end": 96, "start": 92, "tag": "BiologicallyActiveSubstance"}]}{"id": "231_3", "text": "The immunosuppressive and anti-inflammatory actions of DMF occur through several mechanisms: via inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) pathway and by downregulation of aerobic glycolysis and pyroptosis in activated myeloid and lymphoid cells.", "tags": [{"end": 107, "start": 97, "tag": "CellFunction"}, {"end": 189, "start": 179, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 179, "tag": "GeneOrGenome"}, {"end": 189, "start": 179, "tag": "BiologicallyActiveSubstance"}, {"end": 220, "start": 206, "tag": "CellFunction"}, {"end": 242, "start": 224, "tag": "CellFunction"}, {"end": 257, "start": 247, "tag": "CellFunction"}, {"end": 297, "start": 283, "tag": "Cell"}, {"end": 43, "start": 26, "tag": "BiologicFunction"}, {"end": 43, "start": 26, "tag": "PharmacologicSubstance"}, {"end": 58, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 55, "tag": "Chemical"}, {"end": 198, "start": 115, "tag": "CellFunction"}, {"end": 58, "start": 55, "tag": "PharmacologicSubstance"}]}{"id": "231_4", "text": "MMF is also an agonist of hydroxycarboxylic acid receptor 2 (HCAR2).", "tags": [{"end": 3, "start": 0, "tag": "Chemical"}, {"end": 22, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 26, "tag": "GeneOrGenome"}, {"end": 59, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 61, "tag": "GeneOrGenome"}, {"end": 66, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 61, "tag": "BiologicallyActiveSubstance"}]}{"id": "231_5", "text": "Differences in the strength of effects and mechanisms of action of both fumarates are discussed.", "tags": [{"end": 81, "start": 72, "tag": "Chemical"}]}{"id": "231_6", "text": "The aim of this review was to analyse and compare the neuroprotective, antioxidative and anti-inflammatory effects of DMF and its active metabolite, MMF, in cellular (in vitro) and animal models of neurodegenerative diseases (NDs), other than multiple sclerosis.", "tags": [{"end": 69, "start": 54, "tag": "CellFunction"}, {"end": 147, "start": 130, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 149, "tag": "Chemical"}, {"end": 175, "start": 167, "tag": "ResearchActivity"}, {"end": 224, "start": 157, "tag": "ExperimentalModelOfDisease"}, {"end": 229, "start": 226, "tag": "DiseaseOrSyndrome"}, {"end": 261, "start": 243, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 89, "tag": "BiologicFunction"}, {"end": 106, "start": 89, "tag": "PharmacologicSubstance"}, {"end": 121, "start": 118, "tag": "PharmacologicSubstance"}, {"end": 121, "start": 118, "tag": "Chemical"}, {"end": 224, "start": 198, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 16, "tag": "ResearchActivity"}, {"end": 22, "start": 16, "tag": "HealthCareActivity"}, {"end": 121, "start": 118, "tag": "BiologicallyActiveSubstance"}]}{"id": "231_7", "text": "There are more than twenty studies that currently represent this field.", "tags": [{"end": 34, "start": 27, "tag": "ResearchActivity"}]}{"id": "231_8", "text": "Most of the studies are concerned with cellular or animal models of Alzheimer's disease (AD) and Parkinson's disease (PD), one utilized a mouse model of Huntington's disease (HD) and one clinical trial was carried out with amyotrophic lateral sclerosis (ALS) patients.", "tags": [{"end": 87, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 187, "tag": "ResearchActivity"}, {"end": 252, "start": 223, "tag": "DiseaseOrSyndrome"}, {"end": 257, "start": 254, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 138, "tag": "ExperimentalModelOfDisease"}, {"end": 267, "start": 259, "tag": "PatientOrDisabledGroup"}, {"end": 19, "start": 12, "tag": "ResearchActivity"}, {"end": 87, "start": 39, "tag": "ExperimentalModelOfDisease"}]}{"id": "231_9", "text": "The discrepancies in the results of the various studies are discussed, and issues requiring further research have been identified.", "tags": [{"end": 108, "start": 100, "tag": "ResearchActivity"}, {"end": 55, "start": 48, "tag": "ResearchActivity"}]}{"id": "232_0", "text": "In recent years, there has been considerable research showing that coffee consumption seems to be beneficial to human health, as it contains a mixture of different bioactive compounds such as chlorogenic acids, caffeic acid, alkaloids, diterpenes and polyphenols.", "tags": [{"end": 15, "start": 3, "tag": "TemporalConcept"}, {"end": 53, "start": 45, "tag": "ResearchActivity"}, {"end": 85, "start": 67, "tag": "HealthCareActivity"}, {"end": 124, "start": 118, "tag": "HealthCareActivity"}, {"end": 183, "start": 164, "tag": "BiologicallyActiveSubstance"}, {"end": 209, "start": 192, "tag": "Chemical"}, {"end": 223, "start": 211, "tag": "Chemical"}, {"end": 234, "start": 225, "tag": "Chemical"}, {"end": 246, "start": 236, "tag": "Chemical"}, {"end": 117, "start": 112, "tag": "Eukaryote"}, {"end": 262, "start": 251, "tag": "PharmacologicSubstance"}, {"end": 262, "start": 251, "tag": "Chemical"}, {"end": 209, "start": 192, "tag": "BiologicallyActiveSubstance"}, {"end": 223, "start": 211, "tag": "BiologicallyActiveSubstance"}, {"end": 234, "start": 225, "tag": "PharmacologicSubstance"}]}{"id": "232_1", "text": "Neurodegenerative diseases (NDs) are debilitating, and non-curable diseases associated with impaired central, peripheral and muscle nervous systems.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "232_2", "text": "Several studies demonstrate that neuroinflammation mediated by glial cells-such as microglia and astrocytes-is a critical factor contributing to neurodegeneration that causes the dysfunction of brain homeostasis, resulting in a progressive loss of structure, function, and number of neuronal cells.", "tags": [{"end": 74, "start": 63, "tag": "Cell"}, {"end": 92, "start": 83, "tag": "Cell"}, {"end": 211, "start": 194, "tag": "BiologicFunction"}, {"end": 297, "start": 283, "tag": "Cell"}, {"end": 190, "start": 179, "tag": "PathologicFunction"}, {"end": 162, "start": 145, "tag": "CellOrMolecularDysfunction"}, {"end": 50, "start": 33, "tag": "PathologicFunction"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 107, "start": 97, "tag": "Cell"}]}{"id": "232_3", "text": "This happens over time and leads to brain damage and physical impairment.", "tags": [{"end": 22, "start": 18, "tag": "TemporalConcept"}, {"end": 48, "start": 36, "tag": "InjuryOrPoisoning"}, {"end": 72, "start": 53, "tag": "PathologicFunction"}]}{"id": "232_4", "text": "The most known chronic NDs are represented by Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD).", "tags": [{"end": 26, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 163, "tag": "DiseaseOrSyndrome"}]}{"id": "232_5", "text": "According to epidemiological studies, regular coffee consumption is associated with a lower risk of neurodegenerative diseases.", "tags": [{"end": 36, "start": 13, "tag": "ResearchActivity"}, {"end": 64, "start": 38, "tag": "HealthCareActivity"}, {"end": 126, "start": 100, "tag": "DiseaseOrSyndrome"}]}{"id": "232_6", "text": "In this review, we summarize the latest research about the potential effects of caffeine in neurodegenerative disorders prevention and discuss the role of controlled caffeine delivery systems in maintaining high plasma caffeine concentrations for an extended time.", "tags": [{"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 88, "start": 80, "tag": "Chemical"}, {"end": 88, "start": 80, "tag": "PharmacologicSubstance"}, {"end": 130, "start": 120, "tag": "HealthCareActivity"}, {"end": 218, "start": 212, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 227, "start": 219, "tag": "Chemical"}, {"end": 227, "start": 219, "tag": "PharmacologicSubstance"}, {"end": 263, "start": 250, "tag": "TemporalConcept"}, {"end": 119, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 191, "start": 155, "tag": "ManufacturedObject"}]}{"id": "233_0", "text": "Nowadays, epigenetics is of great research value as a new gateway that can solve the sophisticated mysteries behind neurodegenerative diseases.", "tags": [{"end": 21, "start": 10, "tag": "CellFunction"}, {"end": 21, "start": 10, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 48, "start": 34, "tag": "ResearchActivity"}, {"end": 142, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}]}{"id": "233_1", "text": "Epigenetic mechanisms, including DNA methylation, various post -translational modifications of histones, chromatin remodeling enzymes, and long non-coding RNAs, are robust modulators of gene expression levels.", "tags": [{"end": 21, "start": 0, "tag": "CellFunction"}, {"end": 48, "start": 33, "tag": "CellFunction"}, {"end": 91, "start": 58, "tag": "CellFunction"}, {"end": 103, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 139, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 159, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 201, "start": 186, "tag": "CellFunction"}, {"end": 182, "start": 172, "tag": "BiologicallyActiveSubstance"}]}{"id": "233_2", "text": "Over the past years, epigenetic processes have emerged as important factors in many neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's disease.", "tags": [{"end": 19, "start": 9, "tag": "TemporalConcept"}, {"end": 41, "start": 21, "tag": "CellFunction"}, {"end": 139, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 197, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 84, "tag": "DiseaseOrSyndrome"}]}{"id": "233_3", "text": "Here, we review the diverse types of epigenetic modifications and how these mechanisms become dysregulated across the lifespan.", "tags": [{"end": 126, "start": 118, "tag": "TemporalConcept"}, {"end": 61, "start": 37, "tag": "CellFunction"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}]}{"id": "233_4", "text": "We then discuss the various promising strategies for the treatment of neurodegenerative diseases targeting epigenetics, paving the way for the development of novel treatment strategies in neurodegenerative diseases.", "tags": [{"end": 118, "start": 107, "tag": "CellFunction"}, {"end": 118, "start": 107, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 96, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 57, "tag": "HealthCareActivity"}, {"end": 173, "start": 164, "tag": "HealthCareActivity"}, {"end": 66, "start": 57, "tag": "ResearchActivity"}, {"end": 173, "start": 164, "tag": "ResearchActivity"}]}{"id": "234_0", "text": "Despite the improvements in life expectancy, neurodegenerative conditions have arguably become the most dreaded maladies of older people.", "tags": [{"end": 73, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 124, "tag": "PopulationGroup"}, {"end": 43, "start": 28, "tag": "TemporalConcept"}]}{"id": "234_1", "text": "The neuroprotective and anti-ageing potentials of essential oils (EOs) are widely evaluated around the globe.", "tags": [{"end": 64, "start": 50, "tag": "Chemical"}, {"end": 69, "start": 66, "tag": "Chemical"}]}{"id": "234_2", "text": "The objective of this review is to analyse the effectiveness of EOs as neuroprotective remedies among the four common age-related neurodegenerative diseases.", "tags": [{"end": 60, "start": 47, "tag": "Finding"}, {"end": 67, "start": 64, "tag": "Chemical"}, {"end": 121, "start": 118, "tag": "OrganismAttribute"}, {"end": 156, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 22, "tag": "ResearchActivity"}, {"end": 28, "start": 22, "tag": "HealthCareActivity"}, {"end": 95, "start": 71, "tag": "PharmacologicSubstance"}]}{"id": "234_3", "text": "The literature was extracted from three databases (PubMed, Web of Science and Google Scholar) between the years of 2010 to 2020 using the medical subject heading (MeSH) terms essential oil, crossed with Alzheimer's disease (AD), Huntington's disease (HD), Parkinson's disease (PD) or amyotrophic lateral sclerosis (ALS).", "tags": [{"end": 111, "start": 106, "tag": "TemporalConcept"}, {"end": 161, "start": 138, "tag": "HealthCareRelatedOrganization"}, {"end": 188, "start": 175, "tag": "Chemical"}, {"end": 222, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 226, "start": 224, "tag": "DiseaseOrSyndrome"}, {"end": 275, "start": 256, "tag": "DiseaseOrSyndrome"}, {"end": 279, "start": 277, "tag": "DiseaseOrSyndrome"}, {"end": 313, "start": 284, "tag": "DiseaseOrSyndrome"}, {"end": 318, "start": 315, "tag": "DiseaseOrSyndrome"}, {"end": 253, "start": 251, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 4, "tag": "ResearchActivity"}, {"end": 49, "start": 40, "tag": "ResearchActivity"}, {"end": 57, "start": 51, "tag": "HealthCareRelatedOrganization"}, {"end": 73, "start": 59, "tag": "HealthCareRelatedOrganization"}, {"end": 92, "start": 78, "tag": "HealthCareRelatedOrganization"}, {"end": 167, "start": 163, "tag": "HealthCareRelatedOrganization"}]}{"id": "234_4", "text": "Eighty three percent (83%) of the studies were focused on AD, while another 12% focused on PD.", "tags": [{"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 34, "tag": "ResearchActivity"}]}{"id": "234_5", "text": "No classifiable study was recorded on HD or ALS.", "tags": [{"end": 47, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}]}{"id": "234_6", "text": "EO from Salvia officinalis has been recorded as one of the most effective acetylcholinesterase and butyrylcholinesterase inhibitors.", "tags": [{"end": 26, "start": 8, "tag": "Eukaryote"}, {"end": 94, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 99, "tag": "PharmacologicSubstance"}, {"end": 2, "start": 0, "tag": "Chemical"}]}{"id": "234_7", "text": "However, only Cinnamomum sp.", "tags": [{"end": 28, "start": 14, "tag": "Chemical"}]}{"id": "234_8", "text": "has been assessed for its effectiveness in both AD and PD.", "tags": [{"end": 39, "start": 26, "tag": "Finding"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 55, "tag": "DiseaseOrSyndrome"}]}{"id": "234_9", "text": "Our review provided useful evidence on EOs as potential neuroprotective remedies for age-related neurodegenerative diseases.", "tags": [{"end": 42, "start": 39, "tag": "Chemical"}, {"end": 88, "start": 85, "tag": "OrganismAttribute"}, {"end": 35, "start": 27, "tag": "Finding"}, {"end": 123, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 4, "tag": "ResearchActivity"}, {"end": 10, "start": 4, "tag": "HealthCareActivity"}, {"end": 80, "start": 56, "tag": "PharmacologicSubstance"}]}{"id": "244_0", "text": "Huntington's disease (HD) is a monogenetic neurodegenerative disease, which serves as a model of neurodegeneration with protein aggregation.", "tags": [{"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 97, "tag": "CellOrMolecularDysfunction"}, {"end": 139, "start": 120, "tag": "CellFunction"}, {"end": 139, "start": 120, "tag": "CellOrMolecularDysfunction"}, {"end": 68, "start": 31, "tag": "DiseaseOrSyndrome"}]}{"id": "244_1", "text": "Autophagy has been suggested to possess a great value to tackle protein aggregation toxicity and neurodegenerative diseases.", "tags": [{"end": 9, "start": 0, "tag": "CellFunction"}, {"end": 92, "start": 84, "tag": "InjuryOrPoisoning"}, {"end": 123, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 64, "tag": "CellFunction"}, {"end": 83, "start": 64, "tag": "CellOrMolecularDysfunction"}]}{"id": "244_2", "text": "Current studies suggest that autophagyendolysosomal pathways are critical for HD pathology.", "tags": [{"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 81, "tag": "PathologicFunction"}, {"end": 90, "start": 81, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 60, "start": 29, "tag": "CellFunction"}]}{"id": "244_3", "text": "Here we review recent advancement in the studies of autophagy and selective autophagy relating HD.", "tags": [{"end": 61, "start": 52, "tag": "CellFunction"}, {"end": 85, "start": 66, "tag": "CellFunction"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 48, "start": 41, "tag": "ResearchActivity"}, {"end": 21, "start": 15, "tag": "TemporalConcept"}]}{"id": "244_4", "text": "Restoration of autophagy flux and enhancement of selective removal of mutant huntingtin/disease-causing protein would be effective approaches towards tackling HD as well as other similar neurodegenerative disorders.", "tags": [{"end": 111, "start": 70, "tag": "CellOrMolecularDysfunction"}, {"end": 111, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 15, "tag": "CellFunction"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 0, "tag": "HealthCareActivity"}, {"end": 111, "start": 34, "tag": "HealthCareActivity"}]}{"id": "244_5", "text": "(C) 2019 Elsevier Ltd.", "tags": []}{"id": "244_6", "text": "All rights reserved.", "tags": []}{"id": "252_0", "text": "Synaptic disruption and altered neurotransmitter release occurs in the brains of patients and in murine models of neurodegenerative diseases (NDDs).", "tags": [{"end": 19, "start": 0, "tag": "PathologicFunction"}, {"end": 48, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 77, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 104, "tag": "ResearchActivity"}, {"end": 103, "start": 97, "tag": "Eukaryote"}, {"end": 56, "start": 24, "tag": "CellOrMolecularDysfunction"}, {"end": 140, "start": 97, "tag": "ExperimentalModelOfDisease"}]}{"id": "252_1", "text": "During the last few years, evidence has accumulated suggesting that the sympathoadrenal axis is also affected as disease progresses.", "tags": [{"end": 35, "start": 27, "tag": "Finding"}, {"end": 25, "start": 20, "tag": "TemporalConcept"}, {"end": 92, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "252_2", "text": "Here, we review a few studies done in adrenal medullary chromaffin cells (CCs), that are considered as the amplifying arm of the sympathetic nervous system; the sudden fast exocytotic release of their catecholamines-stored in noradrenergic and adrenergic cells-plays a fundamental role in the stress fight-or-flight response.", "tags": [{"end": 77, "start": 74, "tag": "Cell"}, {"end": 155, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 260, "start": 255, "tag": "Cell"}, {"end": 239, "start": 226, "tag": "Cell"}, {"end": 72, "start": 38, "tag": "Cell"}, {"end": 260, "start": 244, "tag": "Cell"}, {"end": 29, "start": 22, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 191, "start": 173, "tag": "CellFunction"}, {"end": 215, "start": 201, "tag": "BiologicallyActiveSubstance"}, {"end": 215, "start": 201, "tag": "PharmacologicSubstance"}, {"end": 324, "start": 293, "tag": "BiologicFunction"}]}{"id": "252_3", "text": "Bulk exocytosis and the fine kinetics of single-vesicle exocytotic events have been studied in mouse models carrying a mutation linked to NDDs.", "tags": [{"end": 15, "start": 0, "tag": "CellFunction"}, {"end": 37, "start": 29, "tag": "NaturalPhenomenonOrProcess"}, {"end": 107, "start": 95, "tag": "ResearchActivity"}, {"end": 142, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 119, "tag": "CellOrMolecularDysfunction"}, {"end": 73, "start": 41, "tag": "CellFunction"}]}{"id": "252_4", "text": "For instance, in R6/1 mouse models of Huntington's disease (HD), mutated huntingtin is overexpressed in CCs; this causes decreased quantal secretion, smaller quantal size and faster kinetics of the exocytotic fusion pore, pore expansion, and closure.", "tags": [{"end": 83, "start": 65, "tag": "CellOrMolecularDysfunction"}, {"end": 100, "start": 87, "tag": "CellFunction"}, {"end": 107, "start": 104, "tag": "Cell"}, {"end": 190, "start": 182, "tag": "NaturalPhenomenonOrProcess"}, {"end": 220, "start": 198, "tag": "CellComponent"}, {"end": 226, "start": 222, "tag": "CellComponent"}, {"end": 58, "start": 17, "tag": "ExperimentalModelOfDisease"}, {"end": 130, "start": 121, "tag": "Finding"}, {"end": 170, "start": 166, "tag": "OrganismAttribute"}, {"end": 62, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 131, "tag": "CellFunction"}, {"end": 236, "start": 222, "tag": "CellFunction"}, {"end": 249, "start": 242, "tag": "CellFunction"}, {"end": 226, "start": 222, "tag": "CellFunction"}]}{"id": "252_5", "text": "This was accompanied by decreased sodium current, decreased acetylcholine-evoked action potentials, and attenuated [Ca2+]c transients with faster Ca2+ clearance.", "tags": [{"end": 150, "start": 146, "tag": "PharmacologicSubstance"}, {"end": 150, "start": 146, "tag": "Chemical"}, {"end": 33, "start": 24, "tag": "Finding"}, {"end": 59, "start": 50, "tag": "Finding"}, {"end": 160, "start": 151, "tag": "NaturalPhenomenonOrProcess"}, {"end": 73, "start": 60, "tag": "Chemical"}, {"end": 73, "start": 60, "tag": "PharmacologicSubstance"}, {"end": 73, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 34, "tag": "CellFunction"}, {"end": 40, "start": 34, "tag": "Chemical"}, {"end": 40, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 81, "tag": "CellFunction"}, {"end": 120, "start": 116, "tag": "Chemical"}, {"end": 120, "start": 116, "tag": "BiologicallyActiveSubstance"}]}{"id": "252_6", "text": "In the SOD1(G93A) mouse model of amyotrophic lateral sclerosis (ALS), CCs exhibited secretory single-vesicle spikes with a slower release rate but higher exocytosis.", "tags": [{"end": 73, "start": 70, "tag": "Cell"}, {"end": 115, "start": 84, "tag": "CellFunction"}, {"end": 137, "start": 130, "tag": "CellFunction"}, {"end": 164, "start": 154, "tag": "CellFunction"}, {"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 138, "tag": "TemporalConcept"}, {"end": 29, "start": 18, "tag": "ResearchActivity"}, {"end": 67, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 7, "tag": "ExperimentalModelOfDisease"}]}{"id": "252_7", "text": "Finally, in the APP/PS1 mouse model of Alzheimer's disease (AD), the stabilization, expansion, and closure of the fusion pore was faster, but the secretion was attenuated.", "tags": [{"end": 125, "start": 114, "tag": "CellComponent"}, {"end": 155, "start": 146, "tag": "CellFunction"}, {"end": 19, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 16, "tag": "GeneOrGenome"}, {"end": 19, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 24, "tag": "ResearchActivity"}, {"end": 62, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 16, "tag": "ExperimentalModelOfDisease"}]}{"id": "252_8", "text": "Additionally, alpha-synuclein that is associated with Parkinson's disease (PD) decreases exocytosis and promotes fusion pore dilation in adrenal CCs.", "tags": [{"end": 88, "start": 79, "tag": "Finding"}, {"end": 99, "start": 89, "tag": "CellFunction"}, {"end": 144, "start": 137, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 145, "tag": "Cell"}, {"end": 29, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 113, "tag": "CellFunction"}]}{"id": "252_9", "text": "Furthermore, Huntington-associated protein 1 (HAP1) interacts with the huntingtin that, when mutated, causes Huntington's disease (HD); HAP1 reduces full fusion exocytosis by affecting vesicle docking and controlling fusion pore stabilization.", "tags": [{"end": 171, "start": 154, "tag": "CellFunction"}, {"end": 200, "start": 185, "tag": "CellFunction"}, {"end": 216, "start": 205, "tag": "Finding"}, {"end": 228, "start": 217, "tag": "CellComponent"}, {"end": 242, "start": 217, "tag": "CellFunction"}, {"end": 50, "start": 46, "tag": "GeneOrGenome"}, {"end": 140, "start": 136, "tag": "GeneOrGenome"}, {"end": 50, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 71, "tag": "GeneOrGenome"}, {"end": 44, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 71, "tag": "BiologicallyActiveSubstance"}]}{"id": "252_10", "text": "The alterations described here are consistent with the hypothesis that central alterations undergone in various NDDs are also manifested at the peripheral sympathoadrenal axis to impair the stress fight-or-flight response in patients suffering from those diseases.", "tags": [{"end": 221, "start": 190, "tag": "BiologicFunction"}, {"end": 243, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 233, "start": 225, "tag": "PatientOrDisabledGroup"}, {"end": 175, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "252_11", "text": "Such alterations may occur: (i) primarily by the expression of mutated disease proteins in CCs; (ii) secondarily to stress adaptation imposed by disease progression and the limitations of patient autonomy.", "tags": [{"end": 94, "start": 91, "tag": "Cell"}, {"end": 133, "start": 116, "tag": "BiologicFunction"}, {"end": 164, "start": 145, "tag": "PathologicFunction"}, {"end": 87, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 153, "tag": "PathologicFunction"}, {"end": 164, "start": 153, "tag": "TemporalConcept"}, {"end": 195, "start": 188, "tag": "PatientOrDisabledGroup"}, {"end": 204, "start": 196, "tag": "IndividualBehavior"}, {"end": 16, "start": 5, "tag": "Finding"}, {"end": 59, "start": 49, "tag": "CellFunction"}, {"end": 87, "start": 63, "tag": "CellOrMolecularDysfunction"}]}{"id": "254_0", "text": "Neuroinflammation is considered as a detrimental factor in neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), etc.", "tags": [{"end": 17, "start": 0, "tag": "PathologicFunction"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 97, "tag": "DiseaseOrSyndrome"}]}{"id": "254_1", "text": "Nucleotide-binding oligomerization domain-, leucine-rich repeat- and pyrin domain-containing 3 (NLRP3), the most well- studied inflammasome, is abundantly expressed in microglia and has gained considerable attention.", "tags": [{"end": 94, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 96, "tag": "GeneOrGenome"}, {"end": 101, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 11, "tag": "CellFunction"}, {"end": 177, "start": 168, "tag": "Cell"}, {"end": 215, "start": 206, "tag": "BiologicFunction"}, {"end": 164, "start": 155, "tag": "CellFunction"}, {"end": 94, "start": 0, "tag": "CellComponent"}, {"end": 101, "start": 96, "tag": "BiologicallyActiveSubstance"}]}{"id": "254_2", "text": "Misfolded proteins are characterized as the common hallmarks of neurodegenerative diseases due to not only their induced neuronal toxicity but also their effects in over-activating microglia and the NLRP3 inflammasome.", "tags": [{"end": 120, "start": 113, "tag": "Substance"}, {"end": 217, "start": 199, "tag": "CellComponent"}, {"end": 138, "start": 130, "tag": "InjuryOrPoisoning"}, {"end": 60, "start": 51, "tag": "Finding"}, {"end": 190, "start": 181, "tag": "Cell"}, {"end": 129, "start": 121, "tag": "Cell"}, {"end": 18, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 90, "start": 64, "tag": "DiseaseOrSyndrome"}]}{"id": "254_3", "text": "The activated NLRP3 inflammasome aggravates the pathology and accelerates the progression of neurodegenerative diseases.", "tags": [{"end": 32, "start": 14, "tag": "CellComponent"}, {"end": 57, "start": 48, "tag": "PathologicFunction"}, {"end": 57, "start": 48, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 89, "start": 78, "tag": "PathologicFunction"}, {"end": 89, "start": 78, "tag": "TemporalConcept"}, {"end": 119, "start": 93, "tag": "DiseaseOrSyndrome"}]}{"id": "254_4", "text": "Emerging evidence indicates that microglial autophagy plays an important role in the maintenance of brain homeostasis and the negative regulation of NLRP3 inflammasome-mediated neuroinflammation.", "tags": [{"end": 117, "start": 100, "tag": "BiologicFunction"}, {"end": 96, "start": 85, "tag": "BiologicFunction"}, {"end": 43, "start": 33, "tag": "Cell"}, {"end": 194, "start": 177, "tag": "PathologicFunction"}, {"end": 53, "start": 44, "tag": "CellFunction"}, {"end": 117, "start": 106, "tag": "BiologicFunction"}, {"end": 17, "start": 0, "tag": "Finding"}, {"end": 167, "start": 149, "tag": "CellComponent"}]}{"id": "254_5", "text": "The excessive activation of NLRP3 inflammasome impairs microglial autophagy and further aggravates the pathogenesis of neurodegenerative diseases.", "tags": [{"end": 13, "start": 4, "tag": "Finding"}, {"end": 24, "start": 14, "tag": "CellFunction"}, {"end": 46, "start": 28, "tag": "CellComponent"}, {"end": 115, "start": 103, "tag": "PathologicFunction"}, {"end": 65, "start": 55, "tag": "Cell"}, {"end": 75, "start": 66, "tag": "CellFunction"}, {"end": 145, "start": 119, "tag": "DiseaseOrSyndrome"}]}{"id": "254_6", "text": "In this review article, we summarize and discuss the NLRP3 inflammasome and its specific inhibitors in microglia.", "tags": [{"end": 71, "start": 53, "tag": "CellComponent"}, {"end": 99, "start": 89, "tag": "Chemical"}, {"end": 99, "start": 89, "tag": "PharmacologicSubstance"}, {"end": 99, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 15, "tag": "ResearchActivity"}, {"end": 22, "start": 8, "tag": "ResearchActivity"}, {"end": 112, "start": 103, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "254_7", "text": "The crucial role of microglial autophagy and its inducers in the removal of misfolded proteins, the clearance of damaged mitochondria and reactive oxygen species (ROS), and the degradation of the NLRP3 inflammasome or its components in neurodegenerative diseases are summarized.", "tags": [{"end": 57, "start": 49, "tag": "Substance"}, {"end": 72, "start": 65, "tag": "HealthCareActivity"}, {"end": 214, "start": 196, "tag": "CellComponent"}, {"end": 109, "start": 100, "tag": "NaturalPhenomenonOrProcess"}, {"end": 133, "start": 113, "tag": "CellOrMolecularDysfunction"}, {"end": 94, "start": 76, "tag": "CellOrMolecularDysfunction"}, {"end": 30, "start": 20, "tag": "Cell"}, {"end": 161, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 138, "tag": "Chemical"}, {"end": 40, "start": 31, "tag": "CellFunction"}, {"end": 188, "start": 177, "tag": "NaturalPhenomenonOrProcess"}, {"end": 166, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 163, "tag": "Chemical"}, {"end": 262, "start": 236, "tag": "DiseaseOrSyndrome"}]}{"id": "254_8", "text": "Understanding the underlying mechanisms behind the sex differences in NLRP3 inflammasome-mediated neurodegenerative diseases will help researchers to develop more targeted therapies and increase our diagnostic and prognostic abilities.", "tags": [{"end": 146, "start": 135, "tag": "ResearchActivity"}, {"end": 181, "start": 172, "tag": "HealthCareActivity"}, {"end": 66, "start": 55, "tag": "Finding"}, {"end": 54, "start": 51, "tag": "OrganismAttribute"}, {"end": 124, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 70, "tag": "CellComponent"}, {"end": 234, "start": 199, "tag": "Finding"}]}{"id": "254_9", "text": "In addition, the superiority of the combined use of microglial autophagy inducers with the specific inhibitors of the NLRP3 inflammasome in the inhibition of NLRP3 inflammasome-mediated neuroinflammation requires further pre clinical and clinical validations in the future.", "tags": [{"end": 28, "start": 17, "tag": "ResearchActivity"}, {"end": 81, "start": 73, "tag": "Substance"}, {"end": 110, "start": 100, "tag": "Chemical"}, {"end": 110, "start": 100, "tag": "PharmacologicSubstance"}, {"end": 110, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 118, "tag": "CellComponent"}, {"end": 154, "start": 144, "tag": "CellFunction"}, {"end": 62, "start": 52, "tag": "Cell"}, {"end": 203, "start": 186, "tag": "PathologicFunction"}, {"end": 72, "start": 63, "tag": "CellFunction"}, {"end": 272, "start": 266, "tag": "TemporalConcept"}, {"end": 176, "start": 158, "tag": "CellComponent"}, {"end": 258, "start": 238, "tag": "ResearchActivity"}, {"end": 258, "start": 247, "tag": "ResearchActivity"}, {"end": 233, "start": 221, "tag": "ResearchActivity"}]}{"id": "255_0", "text": "Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG expansion greater than 35 triplets in the IT-15 gene, with a clinical onset usually in the forties.", "tags": [{"end": 128, "start": 120, "tag": "PopulationGroup"}, {"end": 93, "start": 90, "tag": "MolecularSequence"}, {"end": 50, "start": 32, "tag": "CellFunction"}, {"end": 50, "start": 42, "tag": "CellFunction"}, {"end": 169, "start": 155, "tag": "TemporalConcept"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 90, "tag": "CellOrMolecularDysfunction"}]}{"id": "255_1", "text": "Late-onset form of HD is defined as disease onset after the age of 59 years.", "tags": [{"end": 49, "start": 36, "tag": "TemporalConcept"}, {"end": 63, "start": 60, "tag": "OrganismAttribute"}, {"end": 75, "start": 70, "tag": "TemporalConcept"}, {"end": 21, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "255_2", "text": "The aim of the present study is to investigate the clinical-demographic features of Late-onset HD population (LoHD) in comparison to Classic-onset patients (CoHD).", "tags": [{"end": 108, "start": 98, "tag": "PopulationGroup"}, {"end": 146, "start": 141, "tag": "TemporalConcept"}, {"end": 155, "start": 147, "tag": "PatientOrDisabledGroup"}, {"end": 97, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 23, "tag": "ResearchActivity"}, {"end": 129, "start": 119, "tag": "ResearchActivity"}, {"end": 114, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 51, "tag": "Finding"}]}{"id": "255_3", "text": "We analyzed a well-characterized Italian cohort of 127 HD patients, identifying 25.2% of LoHD cases.", "tags": [{"end": 40, "start": 33, "tag": "PopulationGroup"}, {"end": 47, "start": 41, "tag": "PopulationGroup"}, {"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 66, "start": 55, "tag": "PatientOrDisabledGroup"}, {"end": 93, "start": 89, "tag": "DiseaseOrSyndrome"}]}{"id": "255_4", "text": "The mean age of onset was 65.9 and the mean length of pathological allele was 42.2.", "tags": [{"end": 73, "start": 67, "tag": "GeneOrGenome"}, {"end": 21, "start": 9, "tag": "TemporalConcept"}, {"end": 50, "start": 44, "tag": "ResearchActivity"}]}{"id": "255_5", "text": "The 53.1% of LoHD patients had no family history of HD.", "tags": [{"end": 48, "start": 34, "tag": "Finding"}, {"end": 26, "start": 18, "tag": "PatientOrDisabledGroup"}, {"end": 54, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 13, "tag": "DiseaseOrSyndrome"}]}{"id": "255_6", "text": "No significant differences were observed in terms of gender, type of symptoms at disease onset, and clinical performance during the follow-up visits.", "tags": [{"end": 14, "start": 0, "tag": "PopulationGroup"}, {"end": 148, "start": 142, "tag": "HealthCareActivity"}, {"end": 94, "start": 81, "tag": "TemporalConcept"}, {"end": 120, "start": 100, "tag": "ClinicalAttribute"}, {"end": 77, "start": 69, "tag": "SignOrSymptom"}, {"end": 141, "start": 132, "tag": "HealthCareActivity"}, {"end": 141, "start": 132, "tag": "TemporalConcept"}, {"end": 26, "start": 15, "tag": "Finding"}, {"end": 59, "start": 53, "tag": "OrganismAttribute"}]}{"id": "255_7", "text": "The non-pathological allele resulted longer among LoHD patients.", "tags": [{"end": 27, "start": 21, "tag": "GeneOrGenome"}, {"end": 63, "start": 55, "tag": "PatientOrDisabledGroup"}, {"end": 54, "start": 50, "tag": "DiseaseOrSyndrome"}]}{"id": "255_8", "text": "There is evidence that longer non-pathological allele is associated with a higher volume of basal ganglia, suggesting a possible protective role even in the onset of HD.", "tags": [{"end": 53, "start": 47, "tag": "GeneOrGenome"}, {"end": 105, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 157, "tag": "TemporalConcept"}, {"end": 17, "start": 9, "tag": "Finding"}, {"end": 168, "start": 166, "tag": "DiseaseOrSyndrome"}]}{"id": "255_9", "text": "In conclusion, LoHD patients in this Italian cohort were frequent, representing a quarter of total cases, and showed clinical features comparable to CoHD subjects.", "tags": [{"end": 44, "start": 37, "tag": "PopulationGroup"}, {"end": 89, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 134, "start": 117, "tag": "ClinicalAttribute"}, {"end": 65, "start": 57, "tag": "TemporalConcept"}, {"end": 51, "start": 45, "tag": "PopulationGroup"}, {"end": 162, "start": 154, "tag": "PopulationGroup"}, {"end": 28, "start": 20, "tag": "PatientOrDisabledGroup"}, {"end": 19, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 149, "tag": "DiseaseOrSyndrome"}]}{"id": "255_10", "text": "Due to the small sample size, further studies are needed to evaluate the influence of non-pathological alleles on disease onset.", "tags": [{"end": 127, "start": 114, "tag": "TemporalConcept"}, {"end": 110, "start": 103, "tag": "GeneOrGenome"}, {"end": 45, "start": 38, "tag": "HealthCareActivity"}, {"end": 45, "start": 38, "tag": "ResearchActivity"}, {"end": 28, "start": 17, "tag": "ResearchActivity"}, {"end": 23, "start": 17, "tag": "Substance"}, {"end": 23, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "255_11", "text": "(C) 2021 Elsevier Ltd.", "tags": []}{"id": "255_12", "text": "All rights reserved.", "tags": []}{"id": "257_0", "text": "Microglia play an important role in the maintenance and neuroprotection of the central nervous system (CNS) by removing pathogens, damaged neurons, and plaques.", "tags": [{"end": 129, "start": 120, "tag": "Organism"}, {"end": 159, "start": 152, "tag": "AnatomicalAbnormality"}, {"end": 71, "start": 56, "tag": "CellFunction"}, {"end": 9, "start": 0, "tag": "Cell"}, {"end": 51, "start": 40, "tag": "BiologicFunction"}, {"end": 146, "start": 139, "tag": "Cell"}, {"end": 101, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 131, "tag": "InjuryOrPoisoning"}, {"end": 106, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "257_1", "text": "Recent observations emphasize that the promotion and development of neurodegenerative diseases (NDs) are closely related to microglial activation.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 19, "start": 7, "tag": "Finding"}, {"end": 145, "start": 124, "tag": "CellFunction"}, {"end": 64, "start": 53, "tag": "BiologicFunction"}, {"end": 64, "start": 53, "tag": "CellFunction"}, {"end": 99, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 68, "tag": "DiseaseOrSyndrome"}]}{"id": "257_2", "text": "In this review, we summarize the contribution of microglial activation and its associated mechanisms in NDs, such as epilepsy, Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD), based on recent observations.", "tags": [{"end": 125, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 117, "tag": "PathologicFunction"}, {"end": 238, "start": 226, "tag": "Finding"}, {"end": 59, "start": 49, "tag": "Cell"}, {"end": 70, "start": 49, "tag": "CellFunction"}, {"end": 150, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 225, "start": 219, "tag": "TemporalConcept"}, {"end": 107, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 203, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 176, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "257_3", "text": "This review also briefly introduces experimental animal models of epilepsy, AD, PD, and HD.", "tags": [{"end": 74, "start": 36, "tag": "ExperimentalModelOfDisease"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 17, "tag": "TemporalConcept"}, {"end": 90, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}]}{"id": "257_4", "text": "Thus, this review provides a better understanding of microglial functions in the development of NDs, suggesting that microglial targeting could be an effective therapeutic strategy for these diseases.", "tags": [{"end": 49, "start": 36, "tag": "BiologicFunction"}, {"end": 180, "start": 160, "tag": "HealthCareActivity"}, {"end": 63, "start": 53, "tag": "Cell"}, {"end": 127, "start": 117, "tag": "Cell"}, {"end": 92, "start": 81, "tag": "BiologicFunction"}, {"end": 92, "start": 81, "tag": "CellFunction"}, {"end": 99, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 11, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "HealthCareActivity"}]}{"id": "258_0", "text": "Iron has been increasingly implicated in the pathology of neurodegenerative diseases.", "tags": [{"end": 54, "start": 45, "tag": "PathologicFunction"}, {"end": 54, "start": 45, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 4, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 4, "start": 0, "tag": "Chemical"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 58, "tag": "DiseaseOrSyndrome"}]}{"id": "258_1", "text": "In the past decade, development of the new magnetic resonance imaging technique, quantitative susceptibility mapping (QSM), has enabled for the more comprehensive investigation of iron distribution in the brain.", "tags": [{"end": 79, "start": 43, "tag": "HealthCareActivity"}, {"end": 197, "start": 180, "tag": "BiologicFunction"}, {"end": 11, "start": 7, "tag": "TemporalConcept"}, {"end": 176, "start": 163, "tag": "ResearchActivity"}, {"end": 69, "start": 43, "tag": "HealthCareActivity"}, {"end": 184, "start": 180, "tag": "PharmacologicSubstance"}, {"end": 184, "start": 180, "tag": "Chemical"}, {"end": 184, "start": 180, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 62, "tag": "HealthCareActivity"}, {"end": 116, "start": 81, "tag": "HealthCareActivity"}, {"end": 116, "start": 81, "tag": "ManufacturedObject"}, {"end": 121, "start": 118, "tag": "HealthCareActivity"}, {"end": 121, "start": 118, "tag": "ManufacturedObject"}, {"end": 79, "start": 70, "tag": "ResearchActivity"}, {"end": 210, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 20, "tag": "BiologicFunction"}, {"end": 31, "start": 20, "tag": "CellFunction"}, {"end": 18, "start": 12, "tag": "TemporalConcept"}]}{"id": "258_2", "text": "The aim of this systematic review was to provide a synthesis of the findings from existing QSM studies in neurodegenerative diseases.", "tags": [{"end": 60, "start": 51, "tag": "BiologicFunction"}, {"end": 60, "start": 51, "tag": "CellFunction"}, {"end": 60, "start": 51, "tag": "TemporalConcept"}, {"end": 33, "start": 16, "tag": "ResearchActivity"}, {"end": 94, "start": 91, "tag": "HealthCareActivity"}, {"end": 94, "start": 91, "tag": "ManufacturedObject"}, {"end": 102, "start": 95, "tag": "HealthCareActivity"}, {"end": 102, "start": 95, "tag": "ResearchActivity"}, {"end": 132, "start": 106, "tag": "DiseaseOrSyndrome"}]}{"id": "258_3", "text": "We identified 80 records by searching MEDLINE, Embase, Scopus, and PsycInfo databases.", "tags": [{"end": 24, "start": 17, "tag": "HealthCareActivity"}, {"end": 13, "start": 3, "tag": "Finding"}, {"end": 85, "start": 76, "tag": "ResearchActivity"}, {"end": 45, "start": 38, "tag": "HealthCareRelatedOrganization"}, {"end": 53, "start": 47, "tag": "HealthCareRelatedOrganization"}, {"end": 61, "start": 55, "tag": "HealthCareRelatedOrganization"}, {"end": 75, "start": 67, "tag": "HealthCareRelatedOrganization"}]}{"id": "258_4", "text": "The disorders investigated in these studies included Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Wilson's disease, Huntington's disease, Friedreich's ataxia, spinocerebellar ataxia, Fabry disease, myotonic dystrophy, pantothenate-kinase-associated neurodegeneration, and mitochondrial membrane protein-associated neurodegeneration.", "tags": [{"end": 142, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 224, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 294, "start": 246, "tag": "DiseaseOrSyndrome"}, {"end": 322, "start": 300, "tag": "CellComponent"}, {"end": 209, "start": 203, "tag": "SignOrSymptom"}, {"end": 209, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 244, "start": 226, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 359, "start": 342, "tag": "CellOrMolecularDysfunction"}, {"end": 43, "start": 36, "tag": "HealthCareActivity"}, {"end": 43, "start": 36, "tag": "ResearchActivity"}, {"end": 209, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 359, "start": 300, "tag": "DiseaseOrSyndrome"}]}{"id": "258_5", "text": "As a general pattern, QSM revealed increased magnetic susceptibility (suggestive of increased iron content) in the brain regions associated with the pathology of each disorder, such as the amygdala and caudate nucleus in Alzheimer's disease, the substantia nigra in Parkinson's disease, motor cortex in amyotrophic lateral sclerosis, basal ganglia in Huntington's disease, and cerebellar dentate nucleus in Friedreich's ataxia.", "tags": [{"end": 20, "start": 5, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 45, "tag": "OrganismAttribute"}, {"end": 68, "start": 45, "tag": "ClinicalAttribute"}, {"end": 197, "start": 189, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 217, "start": 202, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 262, "start": 246, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 347, "start": 334, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 403, "start": 377, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 299, "start": 287, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 426, "start": 407, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 149, "tag": "PathologicFunction"}, {"end": 158, "start": 149, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 98, "start": 94, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 94, "tag": "Chemical"}, {"end": 98, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 94, "tag": "BiologicFunction"}, {"end": 25, "start": 22, "tag": "HealthCareActivity"}, {"end": 25, "start": 22, "tag": "ManufacturedObject"}, {"end": 371, "start": 351, "tag": "DiseaseOrSyndrome"}, {"end": 285, "start": 266, "tag": "DiseaseOrSyndrome"}, {"end": 332, "start": 303, "tag": "DiseaseOrSyndrome"}, {"end": 240, "start": 221, "tag": "DiseaseOrSyndrome"}]}{"id": "258_6", "text": "Furthermore, the increased magnetic susceptibility correlated with disease duration and severity of clinical features in some disorders.", "tags": [{"end": 50, "start": 27, "tag": "OrganismAttribute"}, {"end": 50, "start": 27, "tag": "ClinicalAttribute"}, {"end": 96, "start": 88, "tag": "ClinicalAttribute"}, {"end": 96, "start": 88, "tag": "Finding"}, {"end": 117, "start": 100, "tag": "ClinicalAttribute"}, {"end": 83, "start": 67, "tag": "TemporalConcept"}]}{"id": "258_7", "text": "Although the number of studies is still limited in most of the neurodegenerative diseases, the existing evidence suggests that QSM can be a promising tool in the investigation of neurodegeneration.", "tags": [{"end": 175, "start": 162, "tag": "ResearchActivity"}, {"end": 130, "start": 127, "tag": "HealthCareActivity"}, {"end": 130, "start": 127, "tag": "ManufacturedObject"}, {"end": 196, "start": 179, "tag": "CellOrMolecularDysfunction"}, {"end": 30, "start": 23, "tag": "HealthCareActivity"}, {"end": 112, "start": 104, "tag": "Finding"}, {"end": 30, "start": 23, "tag": "ResearchActivity"}, {"end": 89, "start": 63, "tag": "DiseaseOrSyndrome"}]}{"id": "260_0", "text": "Huntington's disease (HD) is a rare neurodegenerative disease characterized by motor, cognitive, and psychiatric symptoms.", "tags": [{"end": 121, "start": 101, "tag": "SignOrSymptom"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 31, "tag": "TemporalConcept"}]}{"id": "260_1", "text": "Inflammasomes are multiprotein complexes capable of sensing pathogen-associated and damageassociated molecular patterns, triggering innate immune pathways.", "tags": [{"end": 13, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 111, "tag": "ResearchActivity"}, {"end": 154, "start": 132, "tag": "CellFunction"}, {"end": 13, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "260_2", "text": "Activation of inflammasomes results in a pro-inflammatory cascade involving, among other molecules, caspases and interleukins.", "tags": [{"end": 10, "start": 0, "tag": "CellFunction"}, {"end": 27, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 45, "tag": "CellFunction"}, {"end": 57, "start": 41, "tag": "PathologicFunction"}, {"end": 98, "start": 89, "tag": "Substance"}, {"end": 27, "start": 14, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "260_3", "text": "NLRP3 (nucleotidebinding domain, leucine-rich-repeat containing family, pyrin domain-containing 3) is the most studied inflammasome complex, and its activation results in caspase-1 mediated cleavage of the pro-interleukins IL-1 beta and IL18 into their mature forms, also inducing a gasdermin D mediated form of pro-inflammatory cell death, i.e.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 33, "tag": "MolecularSequence"}, {"end": 97, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 119, "tag": "CellComponent"}, {"end": 159, "start": 149, "tag": "CellFunction"}, {"end": 180, "start": 171, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 171, "tag": "BiologicallyActiveSubstance"}, {"end": 198, "start": 190, "tag": "CellFunction"}, {"end": 198, "start": 190, "tag": "CellComponent"}, {"end": 222, "start": 206, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 223, "tag": "GeneOrGenome"}, {"end": 241, "start": 237, "tag": "AminoAcidPeptideOrProtein"}, {"end": 241, "start": 237, "tag": "GeneOrGenome"}, {"end": 294, "start": 283, "tag": "GeneOrGenome"}, {"end": 339, "start": 329, "tag": "CellFunction"}, {"end": 339, "start": 334, "tag": "BiologicFunction"}, {"end": 339, "start": 334, "tag": "PathologicFunction"}, {"end": 339, "start": 334, "tag": "CellFunction"}, {"end": 232, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 223, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 223, "tag": "PharmacologicSubstance"}, {"end": 259, "start": 253, "tag": "TemporalConcept"}, {"end": 328, "start": 312, "tag": "PathologicFunction"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 241, "start": 237, "tag": "BiologicallyActiveSubstance"}]}{"id": "260_4", "text": "pyroptosis.", "tags": [{"end": 10, "start": 0, "tag": "CellFunction"}]}{"id": "260_5", "text": "Accumulating evidence has implicated NLRP3 inflammasome complex in neurodegenerative diseases.", "tags": [{"end": 63, "start": 37, "tag": "CellComponent"}, {"end": 21, "start": 0, "tag": "Finding"}, {"end": 21, "start": 13, "tag": "Finding"}, {"end": 93, "start": 67, "tag": "DiseaseOrSyndrome"}]}{"id": "260_6", "text": "The evidence in HD is still scant and mostly derived from pre-clinical studies.", "tags": [{"end": 78, "start": 58, "tag": "ResearchActivity"}, {"end": 12, "start": 4, "tag": "Finding"}, {"end": 18, "start": 16, "tag": "DiseaseOrSyndrome"}]}{"id": "260_7", "text": "This review aims to present the available evidence on NLRP3 inflammasome activation in HD and to discuss whether targeting this innate immune system complex might be a promising therapeutic strategy to alleviate its symptoms.", "tags": [{"end": 83, "start": 54, "tag": "CellComponent"}, {"end": 156, "start": 128, "tag": "CellComponent"}, {"end": 148, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 198, "start": 178, "tag": "HealthCareActivity"}, {"end": 224, "start": 216, "tag": "SignOrSymptom"}, {"end": 50, "start": 42, "tag": "Finding"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}]}{"id": "261_0", "text": "Huntington's disease is a progressive, autosomal dominant, neurodegenerative disorder caused by an expanded CAG repeat in the huntingtin gene.", "tags": [{"end": 85, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 126, "tag": "GeneOrGenome"}, {"end": 57, "start": 39, "tag": "CellFunction"}, {"end": 111, "start": 108, "tag": "MolecularSequence"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 99, "tag": "CellOrMolecularDysfunction"}]}{"id": "261_1", "text": "As a result, the translated protein, huntingtin, contains an abnormally long polyglutamine stretch that makes it prone to misfold and aggregating.", "tags": [{"end": 47, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 37, "tag": "GeneOrGenome"}, {"end": 90, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 61, "tag": "CellOrMolecularDysfunction"}]}{"id": "261_2", "text": "Aggregation of huntingtin is believed to be the cause of Huntington's disease.", "tags": [{"end": 77, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 0, "tag": "CellOrMolecularDysfunction"}]}{"id": "261_3", "text": "However, understanding on how, and why, huntingtin aggregates are deleterious has been hampered by lack of enough relevant structural data.", "tags": [{"end": 61, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 40, "tag": "CellOrMolecularDysfunction"}, {"end": 138, "start": 134, "tag": "ResearchActivity"}]}{"id": "261_4", "text": "In this review, we discuss our recent findings on a glutamine-based functional amyloid isolated fromDrosophilabrain and how this information provides plausible structural insight on the structure of huntingtin deposits in the brain.", "tags": [{"end": 231, "start": 226, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 86, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 199, "tag": "CellOrMolecularDysfunction"}, {"end": 110, "start": 100, "tag": "Eukaryote"}, {"end": 115, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 218, "start": 199, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "262_0", "text": "Neurodegenerative diseases (NDs) are often age-related disorders that can cause dementia in people, usually over 65 years old, are still lacking effective therapies.", "tags": [{"end": 125, "start": 122, "tag": "PopulationGroup"}, {"end": 164, "start": 155, "tag": "HealthCareActivity"}, {"end": 88, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 92, "tag": "PopulationGroup"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 43, "tag": "OrganismAttribute"}, {"end": 121, "start": 116, "tag": "TemporalConcept"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}]}{"id": "262_1", "text": "Some NDs have recently been linked to toxic protein aggregates, for example Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis and Huntington disease; therefore, mulating toxic protein aggregates would be a promising therapeutic strategy.", "tags": [{"end": 43, "start": 38, "tag": "InjuryOrPoisoning"}, {"end": 147, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 258, "start": 238, "tag": "HealthCareActivity"}, {"end": 22, "start": 14, "tag": "TemporalConcept"}, {"end": 8, "start": 5, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 192, "tag": "CellOrMolecularDysfunction"}, {"end": 216, "start": 192, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "262_2", "text": "Moreover, drug repurposing, in other words exploiting drugs that are already in use for another indication, has been attracting mounting attention for potential therapeutic purposes in NDs.", "tags": [{"end": 26, "start": 10, "tag": "HealthCareActivity"}, {"end": 42, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 128, "tag": "Chemical"}, {"end": 59, "start": 54, "tag": "PharmacologicSubstance"}, {"end": 146, "start": 137, "tag": "BiologicFunction"}, {"end": 14, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 188, "start": 185, "tag": "DiseaseOrSyndrome"}]}{"id": "262_3", "text": "Thus, in this review, we focus on summarizing a series of repurposed small-molecule drugs for eliminating or inhibiting toxic protein aggregates and further discuss their intricate molecular mechanisms to improve the current ND treatment.", "tags": [{"end": 105, "start": 94, "tag": "BiologicFunction"}, {"end": 212, "start": 205, "tag": "Finding"}, {"end": 227, "start": 225, "tag": "AnatomicalAbnormality"}, {"end": 119, "start": 109, "tag": "BiologicFunction"}, {"end": 89, "start": 69, "tag": "PharmacologicSubstance"}, {"end": 201, "start": 181, "tag": "CellFunction"}, {"end": 237, "start": 228, "tag": "HealthCareActivity"}, {"end": 237, "start": 228, "tag": "ResearchActivity"}, {"end": 224, "start": 217, "tag": "TemporalConcept"}, {"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 144, "start": 120, "tag": "CellOrMolecularDysfunction"}]}{"id": "262_4", "text": "Taken together, these findings will shed new light on exploiting more repurposed small-molecule drugs targeting different types of toxic proteins to fight NDs in the future.", "tags": [{"end": 101, "start": 96, "tag": "PharmacologicSubstance"}, {"end": 172, "start": 166, "tag": "TemporalConcept"}, {"end": 158, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 131, "tag": "CellOrMolecularDysfunction"}, {"end": 145, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 131, "tag": "BiologicallyActiveSubstance"}]}{"id": "263_0", "text": "Identification of relevant biomarkers is fundamental to understand biological processes of neurodegenerative diseases and to evaluate therapeutic efficacy.", "tags": [{"end": 14, "start": 0, "tag": "Finding"}, {"end": 87, "start": 67, "tag": "BiologicFunction"}, {"end": 117, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 27, "tag": "ClinicalAttribute"}, {"end": 154, "start": 134, "tag": "Finding"}]}{"id": "263_1", "text": "Atrophy of brain structures has been proposed as a biomarker, but it provides little information about biochemical events related to the disease.", "tags": [{"end": 7, "start": 0, "tag": "PathologicFunction"}, {"end": 7, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 103, "tag": "CellFunction"}, {"end": 60, "start": 51, "tag": "ClinicalAttribute"}]}{"id": "263_2", "text": "Here, we propose to identify early and relevant biomarkers by combining biological specificity provided by H-1-MRS and high spatial resolution offered by gluCEST imaging.", "tags": [{"end": 169, "start": 154, "tag": "HealthCareActivity"}, {"end": 94, "start": 83, "tag": "Finding"}, {"end": 58, "start": 48, "tag": "ClinicalAttribute"}, {"end": 114, "start": 107, "tag": "HealthCareActivity"}]}{"id": "263_3", "text": "For this, two different genetic mouse models of Huntington's disease (HD)-the Ki140CAG model, characterized by a slow progression of the disease, and the R6/1 model, which mimics the juvenile form of HD-were used.", "tags": [{"end": 191, "start": 183, "tag": "PopulationGroup"}, {"end": 68, "start": 24, "tag": "ExperimentalModelOfDisease"}, {"end": 144, "start": 118, "tag": "PathologicFunction"}, {"end": 144, "start": 118, "tag": "TemporalConcept"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 78, "tag": "ExperimentalModelOfDisease"}, {"end": 164, "start": 154, "tag": "ExperimentalModelOfDisease"}]}{"id": "263_4", "text": "Animals were scanned at 11.7 T using a protocol combining H-1-MRS and gluCEST imaging.", "tags": [{"end": 47, "start": 39, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "Eukaryote"}, {"end": 85, "start": 70, "tag": "HealthCareActivity"}, {"end": 65, "start": 58, "tag": "HealthCareActivity"}]}{"id": "263_5", "text": "We measured a significant decrease in levels of N-acetyl-aspartate, a metabolite mainly located in the neuronal compartment, in HD animals, and the decrease seemed to be correlated with disease severity.", "tags": [{"end": 66, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 202, "start": 194, "tag": "ClinicalAttribute"}, {"end": 202, "start": 194, "tag": "Finding"}, {"end": 138, "start": 131, "tag": "Eukaryote"}, {"end": 202, "start": 186, "tag": "ClinicalAttribute"}, {"end": 202, "start": 186, "tag": "Finding"}, {"end": 34, "start": 14, "tag": "Finding"}, {"end": 156, "start": 148, "tag": "Finding"}, {"end": 111, "start": 103, "tag": "Cell"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}]}{"id": "263_6", "text": "In addition, variations of tNAA levels were correlated with striatal volumes in both models.", "tags": [{"end": 23, "start": 13, "tag": "NaturalPhenomenonOrProcess"}, {"end": 76, "start": 60, "tag": "ClinicalAttribute"}, {"end": 91, "start": 85, "tag": "ResearchActivity"}, {"end": 38, "start": 27, "tag": "ClinicalAttribute"}]}{"id": "263_7", "text": "Significant variations of glutamate levels were also observed in Ki140CAG but not in R6/1 mice.", "tags": [{"end": 22, "start": 12, "tag": "NaturalPhenomenonOrProcess"}, {"end": 35, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 26, "tag": "ClinicalAttribute"}, {"end": 73, "start": 65, "tag": "ExperimentalModelOfDisease"}, {"end": 94, "start": 85, "tag": "ExperimentalModelOfDisease"}]}{"id": "263_8", "text": "Thanks to its high resolution, gluCEST provided complementary insights, and we highlighted alterations in small brain regions such as the corpus callosum in Ki140CAG mice, whereas the glutamate level was unchanged in the whole brain of R6/1 mice.", "tags": [{"end": 193, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 213, "start": 204, "tag": "Finding"}, {"end": 153, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 232, "start": 227, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 245, "start": 236, "tag": "ExperimentalModelOfDisease"}, {"end": 38, "start": 31, "tag": "HealthCareActivity"}, {"end": 102, "start": 91, "tag": "Finding"}, {"end": 170, "start": 157, "tag": "ExperimentalModelOfDisease"}, {"end": 199, "start": 184, "tag": "ClinicalAttribute"}]}{"id": "263_9", "text": "In this study, we showed that H-1-MRS can provide key information about biological processes occurring in vivo but was limited by the spatial resolution.", "tags": [{"end": 92, "start": 72, "tag": "BiologicFunction"}, {"end": 110, "start": 103, "tag": "ResearchActivity"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 37, "start": 30, "tag": "HealthCareActivity"}]}{"id": "263_10", "text": "On the other hand, gluCEST may finely point to alterations in unexpected brain regions, but it can also be blind to disease processes when glutamate levels are preserved.", "tags": [{"end": 148, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 19, "tag": "HealthCareActivity"}, {"end": 58, "start": 47, "tag": "Finding"}, {"end": 155, "start": 139, "tag": "ClinicalAttribute"}]}{"id": "263_11", "text": "This highlights in a practical context the complementarity of the two methods to study animal models of neurodegenerative diseases and to identify relevant biomarkers.", "tags": [{"end": 77, "start": 70, "tag": "ResearchActivity"}, {"end": 100, "start": 87, "tag": "ResearchActivity"}, {"end": 130, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 81, "tag": "ResearchActivity"}, {"end": 166, "start": 156, "tag": "ClinicalAttribute"}]}{"id": "264_0", "text": "MicroRNAs are post-transcriptional regulators of gene expression, crucial for neuronal differentiation, survival, and activity.", "tags": [{"end": 45, "start": 14, "tag": "CellFunction"}, {"end": 64, "start": 49, "tag": "CellFunction"}, {"end": 9, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 104, "tag": "CellFunction"}, {"end": 102, "start": 78, "tag": "CellFunction"}, {"end": 102, "start": 87, "tag": "CellFunction"}, {"end": 86, "start": 78, "tag": "Cell"}, {"end": 126, "start": 118, "tag": "CellFunction"}]}{"id": "264_1", "text": "Age-related dysregulation of microRNA biogenesis increases neuronal vulnerability to cellular stress and may contribute to the development and progression of neurodegenerative diseases.", "tags": [{"end": 81, "start": 68, "tag": "ClinicalAttribute"}, {"end": 81, "start": 68, "tag": "Finding"}, {"end": 100, "start": 85, "tag": "CellOrMolecularDysfunction"}, {"end": 37, "start": 29, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 37, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 38, "tag": "CellFunction"}, {"end": 81, "start": 59, "tag": "Finding"}, {"end": 3, "start": 0, "tag": "OrganismAttribute"}, {"end": 67, "start": 59, "tag": "Cell"}, {"end": 138, "start": 127, "tag": "BiologicFunction"}, {"end": 138, "start": 127, "tag": "CellFunction"}, {"end": 154, "start": 143, "tag": "PathologicFunction"}, {"end": 154, "start": 143, "tag": "TemporalConcept"}, {"end": 184, "start": 158, "tag": "DiseaseOrSyndrome"}]}{"id": "264_2", "text": "All major neurodegenerative disorders are also associated with oxidative stress, which is widely recognized as a potential target for protective therapies.", "tags": [{"end": 154, "start": 134, "tag": "HealthCareActivity"}, {"end": 79, "start": 63, "tag": "CellOrMolecularDysfunction"}, {"end": 37, "start": 10, "tag": "DiseaseOrSyndrome"}]}{"id": "264_3", "text": "Albeit often considered separately, microRNA networks and oxidative stress are inextricably entwined in neurodegenerative processes.", "tags": [{"end": 44, "start": 36, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 44, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 58, "tag": "CellOrMolecularDysfunction"}]}{"id": "264_4", "text": "Oxidative stress affects expression levels of multiple microRNAs and, conversely, microRNAs regulate many genes involved in an oxidative stress response.", "tags": [{"end": 152, "start": 127, "tag": "CellFunction"}, {"end": 152, "start": 127, "tag": "BiologicFunction"}, {"end": 64, "start": 55, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 91, "start": 82, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 64, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 137, "tag": "BiologicFunction"}, {"end": 152, "start": 137, "tag": "CellFunction"}, {"end": 16, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 143, "start": 127, "tag": "CellOrMolecularDysfunction"}]}{"id": "264_5", "text": "Both oxidative stress and microRNA regulatory networks also influence other processes linked to neurodegeneration, such as mitochondrial dysfunction, deregulation of proteostasis, and increased neuroinflammation, which ultimately lead to neuronal death.", "tags": [{"end": 54, "start": 35, "tag": "CellFunction"}, {"end": 85, "start": 76, "tag": "BiologicFunction"}, {"end": 85, "start": 76, "tag": "NaturalPhenomenonOrProcess"}, {"end": 252, "start": 238, "tag": "CellFunction"}, {"end": 178, "start": 166, "tag": "CellFunction"}, {"end": 34, "start": 26, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 34, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 123, "tag": "CellOrMolecularDysfunction"}, {"end": 252, "start": 247, "tag": "BiologicFunction"}, {"end": 252, "start": 247, "tag": "PathologicFunction"}, {"end": 252, "start": 247, "tag": "CellFunction"}, {"end": 162, "start": 150, "tag": "BiologicFunction"}, {"end": 162, "start": 150, "tag": "CellOrMolecularDysfunction"}, {"end": 211, "start": 194, "tag": "PathologicFunction"}, {"end": 113, "start": 96, "tag": "CellOrMolecularDysfunction"}, {"end": 21, "start": 5, "tag": "CellOrMolecularDysfunction"}]}{"id": "264_6", "text": "Modulating the levels of a relatively small number of microRNAs may therefore alleviate pathological oxidative damage and have neuroprotective activity.", "tags": [{"end": 63, "start": 54, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 63, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 127, "tag": "CellFunction"}, {"end": 117, "start": 101, "tag": "CellOrMolecularDysfunction"}]}{"id": "264_7", "text": "Here, we review the role of individual microRNAs in oxidative stress and related pathways in four neurodegenerative conditions: Alzheimer's (AD), Parkinson's (PD), Huntington's (HD) disease, and amyotrophic lateral sclerosis (ALS).", "tags": [{"end": 38, "start": 28, "tag": "PopulationGroup"}, {"end": 38, "start": 28, "tag": "OrganismAttribute"}, {"end": 38, "start": 28, "tag": "BiologicFunction"}, {"end": 48, "start": 39, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 48, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "CellFunction"}, {"end": 176, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 52, "tag": "CellOrMolecularDysfunction"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 226, "tag": "DiseaseOrSyndrome"}, {"end": 224, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 157, "start": 146, "tag": "DiseaseOrSyndrome"}]}{"id": "264_8", "text": "We also discuss the problems associated with the use of oversimplified cellular models and highlight perspectives of studying microRNA regulation and oxidative stress in human stem cell-derived neurons.", "tags": [{"end": 28, "start": 20, "tag": "Finding"}, {"end": 134, "start": 126, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 134, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 201, "start": 176, "tag": "Cell"}, {"end": 166, "start": 150, "tag": "CellOrMolecularDysfunction"}, {"end": 175, "start": 170, "tag": "Eukaryote"}, {"end": 86, "start": 71, "tag": "ResearchActivity"}, {"end": 145, "start": 126, "tag": "CellFunction"}]}{"id": "265_0", "text": "The world population is progressively ageing, assuming an enormous social and health challenge.", "tags": [{"end": 20, "start": 4, "tag": "PopulationGroup"}, {"end": 44, "start": 38, "tag": "BiologicFunction"}, {"end": 44, "start": 38, "tag": "CellFunction"}, {"end": 20, "start": 10, "tag": "PopulationGroup"}, {"end": 84, "start": 78, "tag": "HealthCareActivity"}, {"end": 94, "start": 85, "tag": "HealthCareActivity"}]}{"id": "265_1", "text": "As the world ages, neurodegenerative diseases are on the rise.", "tags": [{"end": 12, "start": 7, "tag": "PopulationGroup"}, {"end": 45, "start": 19, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 13, "tag": "OrganismAttribute"}]}{"id": "265_2", "text": "Regarding the progressive nature of these diseases, none of the neurodegenerative diseases are curable at date, and the existing treatments can only help relieve the symptoms or slow the progression.", "tags": [{"end": 110, "start": 106, "tag": "TemporalConcept"}, {"end": 174, "start": 166, "tag": "SignOrSymptom"}, {"end": 25, "start": 14, "tag": "TemporalConcept"}, {"end": 139, "start": 129, "tag": "HealthCareActivity"}, {"end": 139, "start": 129, "tag": "ResearchActivity"}, {"end": 198, "start": 187, "tag": "PathologicFunction"}, {"end": 198, "start": 187, "tag": "TemporalConcept"}, {"end": 90, "start": 64, "tag": "DiseaseOrSyndrome"}]}{"id": "265_3", "text": "Recently, hormesis has increased attention in the treatment of age-related neurodegenerative diseases.", "tags": [{"end": 18, "start": 10, "tag": "BiologicFunction"}, {"end": 101, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 50, "tag": "HealthCareActivity"}, {"end": 59, "start": 50, "tag": "ResearchActivity"}, {"end": 42, "start": 33, "tag": "BiologicFunction"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 101, "start": 75, "tag": "DiseaseOrSyndrome"}]}{"id": "265_4", "text": "The concept of hormesis refers to a biphasic dose-response phenomenon, where low levels of the drug or stress exert protective of beneficial effects and high doses deleterious or toxic effects.", "tags": [{"end": 23, "start": 15, "tag": "BiologicFunction"}, {"end": 44, "start": 36, "tag": "TemporalConcept"}, {"end": 109, "start": 103, "tag": "Finding"}, {"end": 109, "start": 103, "tag": "PathologicFunction"}, {"end": 175, "start": 164, "tag": "CellOrMolecularDysfunction"}, {"end": 192, "start": 179, "tag": "InjuryOrPoisoning"}, {"end": 148, "start": 130, "tag": "Finding"}, {"end": 99, "start": 95, "tag": "PharmacologicSubstance"}, {"end": 69, "start": 59, "tag": "NaturalPhenomenonOrProcess"}]}{"id": "265_5", "text": "Neurohormesis, as the adaptive aspect of hormetic dose responses in neurons, has been shown to slow the onset of neurodegenerative diseases and reduce the damages caused by aging, stroke, and traumatic brain injury.", "tags": [{"end": 214, "start": 192, "tag": "InjuryOrPoisoning"}, {"end": 186, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 173, "tag": "BiologicFunction"}, {"end": 178, "start": 173, "tag": "CellFunction"}, {"end": 109, "start": 104, "tag": "TemporalConcept"}, {"end": 207, "start": 202, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 68, "tag": "Cell"}, {"end": 139, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 0, "tag": "BiologicFunction"}, {"end": 64, "start": 41, "tag": "BiologicFunction"}]}{"id": "265_6", "text": "Hormesis was also observed to modulate anxiety, stress, pain, and the severity of seizure.", "tags": [{"end": 8, "start": 0, "tag": "BiologicFunction"}, {"end": 54, "start": 48, "tag": "Finding"}, {"end": 89, "start": 82, "tag": "SignOrSymptom"}, {"end": 89, "start": 82, "tag": "Finding"}, {"end": 89, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 70, "tag": "ClinicalAttribute"}, {"end": 78, "start": 70, "tag": "Finding"}, {"end": 60, "start": 56, "tag": "SignOrSymptom"}, {"end": 46, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 48, "tag": "PathologicFunction"}]}{"id": "265_7", "text": "Thus, neurohormesis can be considered as a potentially innovative approach in the treatment of neurodegenerative and other neurologic disorders.", "tags": [{"end": 143, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 82, "tag": "HealthCareActivity"}, {"end": 91, "start": 82, "tag": "ResearchActivity"}, {"end": 112, "start": 95, "tag": "CellOrMolecularDysfunction"}, {"end": 19, "start": 6, "tag": "BiologicFunction"}]}{"id": "265_8", "text": "Herbal medicinal products and supplements are often considered health resources with many applications.", "tags": [{"end": 25, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 41, "start": 30, "tag": "PharmacologicSubstance"}, {"end": 69, "start": 63, "tag": "HealthCareActivity"}]}{"id": "265_9", "text": "The hormesis phenomenon in medicinal plants is valuable and several studies have shown that hormetic mechanisms of bioactive compounds can prevent or ameliorate the neurodegenerative pathogenesis in animal models of Alzheimer's and Parkinson's diseases.", "tags": [{"end": 12, "start": 4, "tag": "BiologicFunction"}, {"end": 43, "start": 37, "tag": "Eukaryote"}, {"end": 134, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 252, "start": 232, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 183, "tag": "PathologicFunction"}, {"end": 227, "start": 216, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 68, "tag": "ResearchActivity"}, {"end": 212, "start": 199, "tag": "ResearchActivity"}, {"end": 182, "start": 165, "tag": "CellOrMolecularDysfunction"}, {"end": 23, "start": 13, "tag": "NaturalPhenomenonOrProcess"}, {"end": 23, "start": 13, "tag": "Finding"}, {"end": 43, "start": 27, "tag": "PharmacologicSubstance"}, {"end": 111, "start": 92, "tag": "BiologicFunction"}]}{"id": "265_10", "text": "Moreover, the hormesis activity of phytochemicals has been evaluated in other neurological disorders such as Autism and Huntington's disease.", "tags": [{"end": 22, "start": 14, "tag": "BiologicFunction"}, {"end": 49, "start": 35, "tag": "Chemical"}, {"end": 115, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 120, "tag": "DiseaseOrSyndrome"}]}{"id": "265_11", "text": "In this review, the neurohormetic dose-response concept and the possible underlying neuroprotection mechanisms are discussed.", "tags": [{"end": 99, "start": 84, "tag": "CellFunction"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 47, "start": 20, "tag": "BiologicFunction"}]}{"id": "265_12", "text": "Different neurohormetic phytochemicals used for the better management of neurodegenerative diseases, the rationale for using them, and the key findings of their studies are also reviewed.", "tags": [{"end": 38, "start": 24, "tag": "Chemical"}, {"end": 151, "start": 139, "tag": "Finding"}, {"end": 186, "start": 178, "tag": "HealthCareActivity"}, {"end": 186, "start": 178, "tag": "ResearchActivity"}, {"end": 69, "start": 59, "tag": "HealthCareActivity"}, {"end": 168, "start": 161, "tag": "ResearchActivity"}, {"end": 99, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 10, "tag": "BiologicFunction"}]}{"id": "266_0", "text": "Originating from slow irreversible and progressive loss and dysfunction of neurons and synapses in the nervous system, neurodegenerative diseases (NDDs) affect millions of people worldwide.", "tags": [{"end": 95, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 172, "tag": "PopulationGroup"}, {"end": 117, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 60, "tag": "PathologicFunction"}, {"end": 50, "start": 39, "tag": "TemporalConcept"}, {"end": 82, "start": 75, "tag": "Cell"}, {"end": 145, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 72, "tag": "CellOrMolecularDysfunction"}, {"end": 55, "start": 51, "tag": "CellOrMolecularDysfunction"}]}{"id": "266_1", "text": "Common NDDs include Parkinson's disease, Alzheimer's disease multiple sclerosis, Huntington's disease, and amyotrophic lateral sclerosis.", "tags": [{"end": 11, "start": 7, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 41, "tag": "DiseaseOrSyndrome"}]}{"id": "266_2", "text": "Currently, no sensitive biomarkers are available to monitor the progression and treatment response of NDDs or to predict their prognosis.", "tags": [{"end": 59, "start": 52, "tag": "HealthCareActivity"}, {"end": 59, "start": 52, "tag": "ManufacturedObject"}, {"end": 9, "start": 0, "tag": "TemporalConcept"}, {"end": 106, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 80, "tag": "ClinicalAttribute"}, {"end": 136, "start": 127, "tag": "HealthCareActivity"}, {"end": 75, "start": 64, "tag": "PathologicFunction"}, {"end": 75, "start": 64, "tag": "TemporalConcept"}, {"end": 34, "start": 14, "tag": "ClinicalAttribute"}]}{"id": "266_3", "text": "Exosomes (EXOs) are small bilipid layer-enclosed extracellular vesicles containing numerous biomolecules, including proteins, nucleic acids, and lipids.", "tags": [{"end": 14, "start": 10, "tag": "CellComponent"}, {"end": 33, "start": 26, "tag": "Chemical"}, {"end": 104, "start": 92, "tag": "Substance"}, {"end": 139, "start": 126, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 151, "start": 145, "tag": "Chemical"}, {"end": 8, "start": 0, "tag": "CellComponent"}, {"end": 71, "start": 26, "tag": "CellComponent"}, {"end": 124, "start": 116, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "266_4", "text": "Recent evidence indicates that EXOs are pathogenic participants in the spread of neurodegenerative diseases, contributing to disease progression and spread.", "tags": [{"end": 35, "start": 31, "tag": "CellComponent"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 50, "start": 40, "tag": "PathologicFunction"}, {"end": 63, "start": 51, "tag": "PopulationGroup"}, {"end": 144, "start": 125, "tag": "PathologicFunction"}, {"end": 15, "start": 7, "tag": "Finding"}, {"end": 144, "start": 133, "tag": "PathologicFunction"}, {"end": 144, "start": 133, "tag": "TemporalConcept"}, {"end": 107, "start": 81, "tag": "DiseaseOrSyndrome"}]}{"id": "266_5", "text": "EXOs are also important tools for diagnosis and treatment.", "tags": [{"end": 4, "start": 0, "tag": "CellComponent"}, {"end": 43, "start": 34, "tag": "HealthCareActivity"}, {"end": 57, "start": 48, "tag": "HealthCareActivity"}, {"end": 57, "start": 48, "tag": "ResearchActivity"}]}{"id": "266_6", "text": "Recently, studies have proposed exosomal microRNAs (miRNAs) as the targets for therapies or biomarkers of NDDs.", "tags": [{"end": 40, "start": 32, "tag": "CellComponent"}, {"end": 50, "start": 41, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 50, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 52, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 58, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 79, "tag": "HealthCareActivity"}, {"end": 17, "start": 10, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 102, "start": 92, "tag": "ClinicalAttribute"}]}{"id": "266_7", "text": "In this review, we outline the latest research on the roles of exosomal miRNAs in NDDs and their applications as potential diagnostic and therapeutic biomarkers, targets, and drugs for NDDs.", "tags": [{"end": 71, "start": 63, "tag": "CellComponent"}, {"end": 160, "start": 150, "tag": "ClinicalAttribute"}, {"end": 133, "start": 123, "tag": "ClinicalAttribute"}, {"end": 180, "start": 175, "tag": "PharmacologicSubstance"}, {"end": 86, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 72, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 78, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 31, "tag": "TemporalConcept"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 160, "start": 138, "tag": "ClinicalAttribute"}, {"end": 46, "start": 38, "tag": "ResearchActivity"}]}{"id": "267_0", "text": "Acetylation is a key post-translational modification (PTM) involved in the regulation of both histone and non-histone proteins.", "tags": [{"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 52, "start": 21, "tag": "CellFunction"}, {"end": 57, "start": 54, "tag": "CellFunction"}, {"end": 101, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 106, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "267_1", "text": "It controls cellular processes such as DNA transcription, RNA modifications, proteostasis, aging, autophagy, regulation of cytoskeletal structures, and metabolism.", "tags": [{"end": 56, "start": 39, "tag": "CellFunction"}, {"end": 146, "start": 123, "tag": "CellComponent"}, {"end": 162, "start": 152, "tag": "BiologicFunction"}, {"end": 162, "start": 152, "tag": "CellFunction"}, {"end": 89, "start": 77, "tag": "CellFunction"}, {"end": 75, "start": 58, "tag": "CellFunction"}, {"end": 96, "start": 91, "tag": "BiologicFunction"}, {"end": 96, "start": 91, "tag": "CellFunction"}, {"end": 61, "start": 58, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 107, "start": 98, "tag": "CellFunction"}, {"end": 30, "start": 12, "tag": "CellFunction"}, {"end": 11, "start": 3, "tag": "PopulationGroup"}]}{"id": "267_2", "text": "Acetylation is essential to maintain neuronal plasticity and therefore essential for memory and learning.", "tags": [{"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 56, "start": 37, "tag": "CellFunction"}, {"end": 91, "start": 85, "tag": "BiologicFunction"}, {"end": 104, "start": 96, "tag": "BiologicFunction"}]}{"id": "267_3", "text": "Homeostasis of acetylation is maintained through the activities of histone acetyltransferases (HAT) and histone deacetylase (HDAC) enzymes, with alterations to these tightly regulated processes reported in several neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).", "tags": [{"end": 11, "start": 0, "tag": "BiologicFunction"}, {"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 93, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 15, "tag": "CellFunction"}, {"end": 138, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 274, "start": 272, "tag": "DiseaseOrSyndrome"}, {"end": 240, "start": 214, "tag": "DiseaseOrSyndrome"}, {"end": 323, "start": 303, "tag": "DiseaseOrSyndrome"}, {"end": 296, "start": 277, "tag": "DiseaseOrSyndrome"}, {"end": 327, "start": 325, "tag": "DiseaseOrSyndrome"}, {"end": 300, "start": 298, "tag": "DiseaseOrSyndrome"}, {"end": 368, "start": 365, "tag": "DiseaseOrSyndrome"}, {"end": 363, "start": 334, "tag": "DiseaseOrSyndrome"}, {"end": 270, "start": 251, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 145, "tag": "Finding"}]}{"id": "267_4", "text": "Both hyperacetylation and hypoacetylation can impair neuronal physiological homeostasis and increase the accumulation of pathophysiological proteins such as tau, alpha-synuclein, and Huntingtin protein implicated in AD, PD, and HD, respectively.", "tags": [{"end": 21, "start": 5, "tag": "CellOrMolecularDysfunction"}, {"end": 201, "start": 183, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 183, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 105, "tag": "Finding"}, {"end": 177, "start": 168, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 168, "tag": "BiologicallyActiveSubstance"}, {"end": 177, "start": 162, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 121, "tag": "PathologicFunction"}, {"end": 61, "start": 53, "tag": "Cell"}, {"end": 148, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 62, "tag": "BiologicFunction"}, {"end": 218, "start": 216, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 228, "tag": "DiseaseOrSyndrome"}, {"end": 222, "start": 220, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 26, "tag": "CellOrMolecularDysfunction"}, {"end": 87, "start": 53, "tag": "CellFunction"}]}{"id": "267_5", "text": "Additionally, dysregulation of acetylation is linked to impaired axonal transport, a key pathological mechanism in ALS.", "tags": [{"end": 27, "start": 14, "tag": "Finding"}, {"end": 81, "start": 65, "tag": "CellFunction"}, {"end": 42, "start": 31, "tag": "CellFunction"}, {"end": 118, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 56, "tag": "CellOrMolecularDysfunction"}]}{"id": "267_6", "text": "This review article will discuss the physiological roles of protein acetylation and examine the current literature that describes altered protein acetylation in neurodegenerative disorders.", "tags": [{"end": 79, "start": 60, "tag": "CellFunction"}, {"end": 114, "start": 104, "tag": "ResearchActivity"}, {"end": 79, "start": 68, "tag": "CellFunction"}, {"end": 157, "start": 138, "tag": "CellFunction"}, {"end": 19, "start": 5, "tag": "ResearchActivity"}, {"end": 103, "start": 96, "tag": "TemporalConcept"}, {"end": 188, "start": 161, "tag": "DiseaseOrSyndrome"}]}{"id": "268_0", "text": "There is growing recognition in the field of neurodegenerative diseases that mixed proteinopathies are occurring at greater frequency than originally thought.", "tags": [{"end": 98, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 17, "tag": "BiologicFunction"}, {"end": 133, "start": 124, "tag": "TemporalConcept"}, {"end": 71, "start": 45, "tag": "DiseaseOrSyndrome"}]}{"id": "268_1", "text": "This is particularly true for three amyloid proteins defining most of these neurological disorders, amyloid-beta (A beta), tau, and alpha-synuclein (alpha Syn).", "tags": [{"end": 98, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 149, "tag": "BiologicallyActiveSubstance"}]}{"id": "268_2", "text": "The co-existence and often co-localization of aggregated forms of these proteins has led to the emergence of concepts positing molecular interactions and cross-seeding between A beta, tau, and alpha Syn aggregates.", "tags": [{"end": 117, "start": 109, "tag": "NaturalPhenomenonOrProcess"}, {"end": 149, "start": 127, "tag": "CellFunction"}, {"end": 105, "start": 96, "tag": "TemporalConcept"}, {"end": 187, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 187, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 182, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 167, "start": 154, "tag": "CellFunction"}, {"end": 213, "start": 193, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "268_3", "text": "Amongst this trio, alpha Syn has received particular attention in this context during recent years due to its ability to modulate A beta and tau aggregation in vivo, to interact at a molecular level with A beta and tau in vivo and to cross-seed tau in mice.", "tags": [{"end": 17, "start": 13, "tag": "GeneOrGenome"}, {"end": 17, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 141, "tag": "CellFunction"}, {"end": 144, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 215, "tag": "AminoAcidPeptideOrProtein"}, {"end": 248, "start": 245, "tag": "AminoAcidPeptideOrProtein"}, {"end": 256, "start": 252, "tag": "Eukaryote"}, {"end": 117, "start": 110, "tag": "OrganismAttribute"}, {"end": 144, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 218, "start": 215, "tag": "BiologicallyActiveSubstance"}, {"end": 248, "start": 245, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 210, "start": 204, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 86, "tag": "TemporalConcept"}, {"end": 62, "start": 53, "tag": "BiologicFunction"}, {"end": 164, "start": 157, "tag": "ResearchActivity"}, {"end": 226, "start": 219, "tag": "ResearchActivity"}, {"end": 28, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 19, "tag": "BiologicallyActiveSubstance"}]}{"id": "268_4", "text": "Here we provide a comprehensive, critical, and accessible review about the expression, role and nature of endogenous soluble alpha Syn oligomers because of recent developments in the understanding of alpha Syn multimerization, misfolding, aggregation, cross-talk, spreading and cross-seeding in neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, Alzheimer's disease, and Huntington's disease.", "tags": [{"end": 250, "start": 239, "tag": "CellFunction"}, {"end": 250, "start": 239, "tag": "ResearchActivity"}, {"end": 262, "start": 252, "tag": "CellFunction"}, {"end": 405, "start": 382, "tag": "PathologicFunction"}, {"end": 237, "start": 227, "tag": "CellOrMolecularDysfunction"}, {"end": 196, "start": 183, "tag": "BiologicFunction"}, {"end": 380, "start": 369, "tag": "CellComponent"}, {"end": 175, "start": 163, "tag": "BiologicFunction"}, {"end": 175, "start": 163, "tag": "CellFunction"}, {"end": 363, "start": 355, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 156, "tag": "TemporalConcept"}, {"end": 452, "start": 432, "tag": "DiseaseOrSyndrome"}, {"end": 353, "start": 334, "tag": "DiseaseOrSyndrome"}, {"end": 426, "start": 407, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 58, "tag": "ResearchActivity"}, {"end": 64, "start": 58, "tag": "HealthCareActivity"}, {"end": 322, "start": 295, "tag": "DiseaseOrSyndrome"}, {"end": 291, "start": 278, "tag": "CellFunction"}, {"end": 225, "start": 200, "tag": "CellFunction"}, {"end": 144, "start": 117, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "268_5", "text": "We will also discuss our current understanding about the relative toxicity of endogenous alpha Syn oligomers in vivo and in vitro, and introduce potential opportunities to counter their deleterious effects.", "tags": [{"end": 46, "start": 33, "tag": "BiologicFunction"}, {"end": 74, "start": 66, "tag": "InjuryOrPoisoning"}, {"end": 129, "start": 121, "tag": "ResearchActivity"}, {"end": 116, "start": 109, "tag": "ResearchActivity"}, {"end": 32, "start": 25, "tag": "TemporalConcept"}, {"end": 108, "start": 89, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "269_0", "text": "Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS), currently affect more than 6 million people in the United States.", "tags": [{"end": 222, "start": 209, "tag": "PopulationGroup"}, {"end": 167, "start": 158, "tag": "TemporalConcept"}, {"end": 201, "start": 195, "tag": "PopulationGroup"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 38, "tag": "DiseaseOrSyndrome"}]}{"id": "269_1", "text": "Unfortunately, there are no treatments that slow or prevent disease development and progression.", "tags": [{"end": 79, "start": 60, "tag": "PathologicFunction"}, {"end": 79, "start": 68, "tag": "BiologicFunction"}, {"end": 79, "start": 68, "tag": "CellFunction"}, {"end": 38, "start": 28, "tag": "HealthCareActivity"}, {"end": 38, "start": 28, "tag": "ResearchActivity"}, {"end": 95, "start": 84, "tag": "PathologicFunction"}, {"end": 95, "start": 84, "tag": "TemporalConcept"}]}{"id": "269_2", "text": "Regardless of the underlying cause of the disorder, age is the strongest risk factor for developing these maladies, suggesting that changes that occur in the aging brain put it at increased risk for neurodegenerative disease development.", "tags": [{"end": 236, "start": 217, "tag": "PathologicFunction"}, {"end": 163, "start": 158, "tag": "BiologicFunction"}, {"end": 163, "start": 158, "tag": "CellFunction"}, {"end": 169, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 236, "start": 225, "tag": "BiologicFunction"}, {"end": 236, "start": 225, "tag": "CellFunction"}, {"end": 55, "start": 52, "tag": "OrganismAttribute"}, {"end": 84, "start": 73, "tag": "Finding"}, {"end": 77, "start": 73, "tag": "Finding"}, {"end": 194, "start": 190, "tag": "Finding"}, {"end": 224, "start": 199, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 106, "tag": "DiseaseOrSyndrome"}]}{"id": "269_3", "text": "Moreover, since there are a number of different changes that occur in the aging brain, it is unlikely that targeting a single change is going to be effective for disease treatment.", "tags": [{"end": 179, "start": 162, "tag": "HealthCareActivity"}, {"end": 79, "start": 74, "tag": "BiologicFunction"}, {"end": 79, "start": 74, "tag": "CellFunction"}, {"end": 85, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 170, "tag": "HealthCareActivity"}, {"end": 179, "start": 170, "tag": "ResearchActivity"}]}{"id": "269_4", "text": "Thus, compounds that have multiple biological activities that can impact the various age-associated changes in the brain that contribute to neurodegenerative disease development and progression are needed.", "tags": [{"end": 15, "start": 6, "tag": "Chemical"}, {"end": 15, "start": 6, "tag": "PharmacologicSubstance"}, {"end": 177, "start": 158, "tag": "PathologicFunction"}, {"end": 120, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 177, "start": 166, "tag": "BiologicFunction"}, {"end": 177, "start": 166, "tag": "CellFunction"}, {"end": 88, "start": 85, "tag": "OrganismAttribute"}, {"end": 193, "start": 182, "tag": "PathologicFunction"}, {"end": 193, "start": 182, "tag": "TemporalConcept"}, {"end": 165, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 35, "tag": "BiologicFunction"}, {"end": 107, "start": 100, "tag": "Finding"}]}{"id": "269_5", "text": "The plant-derived flavonoids have a wide range of activities that could make them particularly effective for blocking the age-associated toxicity pathways associated with neurodegenerative diseases.", "tags": [{"end": 28, "start": 18, "tag": "Chemical"}, {"end": 145, "start": 137, "tag": "InjuryOrPoisoning"}, {"end": 154, "start": 146, "tag": "CellFunction"}, {"end": 125, "start": 122, "tag": "OrganismAttribute"}, {"end": 197, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "Eukaryote"}]}{"id": "269_6", "text": "In this review, the evidence for beneficial effects of multiple flavonoids in models of AD, PD, HD, and ALS is presented and common mechanisms of action are identified.", "tags": [{"end": 74, "start": 64, "tag": "Chemical"}, {"end": 152, "start": 146, "tag": "HealthCareActivity"}, {"end": 167, "start": 157, "tag": "Finding"}, {"end": 51, "start": 33, "tag": "Finding"}, {"end": 90, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 20, "tag": "Finding"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 84, "start": 78, "tag": "ResearchActivity"}]}{"id": "269_7", "text": "Overall, the preclinical data strongly support further investigation of specific flavonoids for the treatment of neurodegenerative diseases.", "tags": [{"end": 91, "start": 81, "tag": "Chemical"}, {"end": 29, "start": 13, "tag": "ResearchActivity"}, {"end": 68, "start": 55, "tag": "ResearchActivity"}, {"end": 109, "start": 100, "tag": "HealthCareActivity"}, {"end": 109, "start": 100, "tag": "ResearchActivity"}, {"end": 139, "start": 113, "tag": "DiseaseOrSyndrome"}]}{"id": "270_0", "text": "Mammalian transglutaminases (TGs) catalyze calcium-dependent irreversible posttranslational modifications of proteins and their enzymatic activities contribute to the pathogenesis of several human neurodegenerative diseases.", "tags": [{"end": 9, "start": 0, "tag": "BiologicFunction"}, {"end": 27, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 43, "tag": "CellFunction"}, {"end": 105, "start": 74, "tag": "CellFunction"}, {"end": 179, "start": 167, "tag": "PathologicFunction"}, {"end": 117, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 196, "start": 191, "tag": "Eukaryote"}, {"end": 223, "start": 197, "tag": "DiseaseOrSyndrome"}]}{"id": "270_1", "text": "Although different transglutaminases are found in many different tissues, the TG6 isoform is mostly expressed in the CNS.", "tags": [{"end": 36, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 78, "tag": "GeneOrGenome"}, {"end": 72, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 100, "tag": "CellFunction"}]}{"id": "270_2", "text": "The present study was embarked on/undertaken to investigate expression, distribution and activity of transglutaminases in Huntington disease transgenic rodent models, with a focus on analyzing the involvement of TG6 in the age- and genotype-specific pathological features relating to disease progression in HD transgenic mice and a tgHD transgenic rat model using biochemical, histological and functional assays.", "tags": [{"end": 118, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 122, "tag": "ExperimentalModelOfDisease"}, {"end": 215, "start": 212, "tag": "GeneOrGenome"}, {"end": 411, "start": 364, "tag": "ResearchActivity"}, {"end": 351, "start": 348, "tag": "Eukaryote"}, {"end": 357, "start": 348, "tag": "ResearchActivity"}, {"end": 303, "start": 284, "tag": "PathologicFunction"}, {"end": 226, "start": 223, "tag": "OrganismAttribute"}, {"end": 208, "start": 197, "tag": "Finding"}, {"end": 303, "start": 292, "tag": "PathologicFunction"}, {"end": 303, "start": 292, "tag": "TemporalConcept"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 215, "start": 212, "tag": "AminoAcidPeptideOrProtein"}, {"end": 215, "start": 212, "tag": "BiologicallyActiveSubstance"}, {"end": 240, "start": 232, "tag": "OrganismAttribute"}, {"end": 325, "start": 307, "tag": "ExperimentalModelOfDisease"}, {"end": 357, "start": 332, "tag": "ExperimentalModelOfDisease"}]}{"id": "270_3", "text": "Our results demonstrate the physical interaction between TG6 and (mutant) huntingtin by co-immunoprecipitation analysis and the contribution of its enzymatic activity for the total aggregate load in SH-SY5Y cells.", "tags": [{"end": 48, "start": 28, "tag": "BiologicFunction"}, {"end": 60, "start": 57, "tag": "GeneOrGenome"}, {"end": 119, "start": 88, "tag": "ResearchActivity"}, {"end": 166, "start": 148, "tag": "CellFunction"}, {"end": 72, "start": 66, "tag": "CellOrMolecularDysfunction"}, {"end": 212, "start": 199, "tag": "Cell"}, {"end": 84, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 57, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "270_4", "text": "In addition, we identify that TG6 expression and activity are especially abundant in the olfactory tubercle and piriform cortex, the regions displaying the highest amount of mHTT aggregates in transgenic rodent models of HD.", "tags": [{"end": 33, "start": 30, "tag": "GeneOrGenome"}, {"end": 107, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 223, "start": 193, "tag": "ExperimentalModelOfDisease"}, {"end": 178, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 174, "tag": "CellOrMolecularDysfunction"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 174, "tag": "CellOrMolecularDysfunction"}]}{"id": "270_5", "text": "Furthermore, mHTT aggregates were colocalized within TG6-positive cells.", "tags": [{"end": 17, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 13, "tag": "CellOrMolecularDysfunction"}, {"end": 71, "start": 66, "tag": "Cell"}, {"end": 28, "start": 13, "tag": "CellOrMolecularDysfunction"}, {"end": 56, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 53, "tag": "GeneOrGenome"}]}{"id": "270_6", "text": "These findings point towards a role of TG6 in disease pathogenesis via mHTT aggregate formation.", "tags": [{"end": 42, "start": 39, "tag": "GeneOrGenome"}, {"end": 75, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 71, "tag": "CellOrMolecularDysfunction"}, {"end": 66, "start": 54, "tag": "PathologicFunction"}, {"end": 42, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 71, "tag": "CellOrMolecularDysfunction"}]}{"id": "271_0", "text": "Huntington Disease (HD) is a genetic neurodegenerative disease which leads to involuntary movements and impaired balance.", "tags": [{"end": 62, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 78, "tag": "SignOrSymptom"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 104, "tag": "SignOrSymptom"}]}{"id": "271_1", "text": "These changes have been quantified using footstep pressure sensor mats such as Protokinetics' Zeno Walkway.", "tags": [{"end": 106, "start": 79, "tag": "HealthCareActivity"}, {"end": 70, "start": 41, "tag": "HealthCareActivity"}, {"end": 106, "start": 79, "tag": "ManufacturedObject"}, {"end": 58, "start": 41, "tag": "ClinicalAttribute"}]}{"id": "271_2", "text": "Drawing from distances between recorded footsteps, patients' disease severity have been measured in terms of high level gait characteristics such as gait width and stride length.", "tags": [{"end": 77, "start": 61, "tag": "ClinicalAttribute"}, {"end": 77, "start": 61, "tag": "Finding"}, {"end": 177, "start": 164, "tag": "OrganismAttribute"}, {"end": 170, "start": 164, "tag": "OrganismAttribute"}, {"end": 124, "start": 120, "tag": "OrganismAttribute"}, {"end": 153, "start": 149, "tag": "OrganismAttribute"}, {"end": 59, "start": 51, "tag": "PatientOrDisabledGroup"}, {"end": 159, "start": 149, "tag": "OrganismAttribute"}, {"end": 49, "start": 40, "tag": "OrganismAttribute"}]}{"id": "271_3", "text": "However, little attention has been paid to the pressure data collected during formation of individual footsteps.", "tags": [{"end": 55, "start": 47, "tag": "BiologicFunction"}, {"end": 25, "start": 16, "tag": "BiologicFunction"}, {"end": 60, "start": 56, "tag": "ResearchActivity"}, {"end": 111, "start": 91, "tag": "OrganismAttribute"}]}{"id": "271_5", "text": "Using the Motor Subscale of the Unified HD Rating Scale (UHDRS) as the gold standard, our experiments showed that using VGG16 and similar modules can achieve classification accuracy of 89%.", "tags": [{"end": 101, "start": 90, "tag": "ResearchActivity"}, {"end": 62, "start": 57, "tag": "HealthCareActivity"}, {"end": 172, "start": 158, "tag": "ResearchActivity"}, {"end": 181, "start": 173, "tag": "Finding"}, {"end": 55, "start": 10, "tag": "HealthCareActivity"}, {"end": 125, "start": 120, "tag": "MachineActivity"}]}{"id": "271_6", "text": "Image pre-processing are key steps for better model performance.", "tags": [{"end": 63, "start": 52, "tag": "Finding"}, {"end": 51, "start": 46, "tag": "ResearchActivity"}, {"end": 20, "start": 0, "tag": "ResearchActivity"}]}{"id": "271_7", "text": "This classification accuracy is compared to results based on 3D CNN (82%) and SVM (86.9%).", "tags": [{"end": 67, "start": 61, "tag": "MachineActivity"}, {"end": 19, "start": 5, "tag": "ResearchActivity"}, {"end": 28, "start": 20, "tag": "Finding"}, {"end": 81, "start": 78, "tag": "MachineActivity"}]}{"id": "272_0", "text": "Neurodegenerative diseases (NDs) including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease are incurable and affect millions of people worldwide.", "tags": [{"end": 184, "start": 178, "tag": "PopulationGroup"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 43, "tag": "DiseaseOrSyndrome"}]}{"id": "272_1", "text": "The development of treatments for this unmet clinical need is a major global research challenge.", "tags": [{"end": 95, "start": 86, "tag": "HealthCareActivity"}, {"end": 15, "start": 4, "tag": "BiologicFunction"}, {"end": 15, "start": 4, "tag": "CellFunction"}, {"end": 29, "start": 19, "tag": "HealthCareActivity"}, {"end": 29, "start": 19, "tag": "ResearchActivity"}, {"end": 85, "start": 77, "tag": "ResearchActivity"}, {"end": 58, "start": 39, "tag": "Finding"}]}{"id": "272_2", "text": "Computer-aided drug design (CADD) methods minimize the huge number of ligands that could be screened in biological assays, reducing the cost, time, and effort required to develop new drugs.", "tags": [{"end": 41, "start": 34, "tag": "MachineActivity"}, {"end": 26, "start": 0, "tag": "MachineActivity"}, {"end": 32, "start": 28, "tag": "MachineActivity"}, {"end": 121, "start": 104, "tag": "ResearchActivity"}, {"end": 188, "start": 183, "tag": "PharmacologicSubstance"}, {"end": 100, "start": 92, "tag": "HealthCareActivity"}, {"end": 100, "start": 92, "tag": "ResearchActivity"}, {"end": 146, "start": 142, "tag": "TemporalConcept"}]}{"id": "272_3", "text": "In this review, we provide an introduction to CADD and examine the progress in applying CADD and other molecular docking studies to NDs.", "tags": [{"end": 42, "start": 30, "tag": "HealthCareActivity"}, {"end": 50, "start": 46, "tag": "MachineActivity"}, {"end": 92, "start": 88, "tag": "MachineActivity"}, {"end": 75, "start": 67, "tag": "TemporalConcept"}, {"end": 128, "start": 103, "tag": "ResearchActivity"}, {"end": 135, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "272_4", "text": "We provide an updated overview of potential therapeutic targets for various NDs and discuss some of the advantages and disadvantages of these tools.", "tags": [{"end": 63, "start": 44, "tag": "ResearchActivity"}, {"end": 63, "start": 34, "tag": "ResearchActivity"}, {"end": 30, "start": 22, "tag": "ResearchActivity"}, {"end": 79, "start": 76, "tag": "DiseaseOrSyndrome"}]}{"id": "274_0", "text": "Neurodegenerative diseases are inseparably linked with aging and increase as life expectancy extends.", "tags": [{"end": 60, "start": 55, "tag": "BiologicFunction"}, {"end": 60, "start": 55, "tag": "CellFunction"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 77, "tag": "TemporalConcept"}, {"end": 81, "start": 77, "tag": "TemporalConcept"}]}{"id": "274_1", "text": "There are common dysfunctions in various cellular events shared among neurogenerative diseases, such as calcium dyshomeostasis, neuroinflammation, and age-associated decline in the autophagy-lysosome system.", "tags": [{"end": 94, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 104, "tag": "PharmacologicSubstance"}, {"end": 111, "start": 104, "tag": "Chemical"}, {"end": 29, "start": 17, "tag": "PathologicFunction"}, {"end": 206, "start": 181, "tag": "CellFunction"}, {"end": 145, "start": 128, "tag": "PathologicFunction"}, {"end": 190, "start": 181, "tag": "CellFunction"}, {"end": 154, "start": 151, "tag": "OrganismAttribute"}, {"end": 126, "start": 112, "tag": "PathologicFunction"}]}{"id": "274_2", "text": "However, most of all, the prominent pathological feature of neurodegenerative diseases is the toxic buildup of misfolded protein aggregates and inclusion bodies accompanied by an impairment in proteostasis.", "tags": [{"end": 99, "start": 94, "tag": "InjuryOrPoisoning"}, {"end": 160, "start": 144, "tag": "CellComponent"}, {"end": 189, "start": 179, "tag": "Finding"}, {"end": 205, "start": 193, "tag": "CellFunction"}, {"end": 139, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 111, "tag": "CellOrMolecularDysfunction"}, {"end": 120, "start": 111, "tag": "CellOrMolecularDysfunction"}, {"end": 128, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 111, "tag": "CellOrMolecularDysfunction"}, {"end": 86, "start": 60, "tag": "DiseaseOrSyndrome"}]}{"id": "274_3", "text": "Recent studies have suggested a close association between endoplasmic reticulum (ER) stress and neurodegenerative pathology in cellular and animal models as well as in human patients.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 79, "start": 58, "tag": "CellComponent"}, {"end": 83, "start": 81, "tag": "CellComponent"}, {"end": 123, "start": 114, "tag": "PathologicFunction"}, {"end": 123, "start": 114, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 153, "start": 140, "tag": "ResearchActivity"}, {"end": 173, "start": 168, "tag": "Eukaryote"}, {"end": 182, "start": 174, "tag": "PatientOrDisabledGroup"}, {"end": 113, "start": 96, "tag": "CellOrMolecularDysfunction"}, {"end": 91, "start": 85, "tag": "CellOrMolecularDysfunction"}, {"end": 79, "start": 58, "tag": "CellOrMolecularDysfunction"}]}{"id": "274_4", "text": "The contribution of mutant or misfolded protein-triggered ER stress and its associated signaling events, such as unfolded protein response (UPR), to the pathophysiology of various neurodegenerative disorders, including Alzheimer's, Parkinson's, and Huntington's disease, amyotrophic lateral sclerosis, and prion disease, is described here.", "tags": [{"end": 138, "start": 113, "tag": "CellFunction"}, {"end": 319, "start": 306, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 20, "tag": "CellOrMolecularDysfunction"}, {"end": 60, "start": 58, "tag": "CellComponent"}, {"end": 67, "start": 58, "tag": "CellOrMolecularDysfunction"}, {"end": 39, "start": 30, "tag": "CellOrMolecularDysfunction"}, {"end": 47, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 30, "tag": "CellOrMolecularDysfunction"}, {"end": 143, "start": 140, "tag": "CellFunction"}, {"end": 168, "start": 153, "tag": "PathologicFunction"}, {"end": 168, "start": 153, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 96, "start": 87, "tag": "CellFunction"}, {"end": 230, "start": 219, "tag": "DiseaseOrSyndrome"}, {"end": 269, "start": 249, "tag": "DiseaseOrSyndrome"}, {"end": 300, "start": 271, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 243, "start": 232, "tag": "DiseaseOrSyndrome"}]}{"id": "274_5", "text": "Impaired UPR action is commonly attributed to exacerbated ER stress, pathogenic protein aggregate accumulation, and deteriorating neurodegenerative pathologies.", "tags": [{"end": 57, "start": 46, "tag": "Finding"}, {"end": 129, "start": 116, "tag": "Finding"}, {"end": 159, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 58, "tag": "CellOrMolecularDysfunction"}, {"end": 19, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 110, "start": 69, "tag": "CellOrMolecularDysfunction"}]}{"id": "274_6", "text": "Thus, activating certain UPR components has been shown to alleviate ER stress and its associated neurodegeneration.", "tags": [{"end": 16, "start": 6, "tag": "BiologicFunction"}, {"end": 39, "start": 29, "tag": "CellComponent"}, {"end": 70, "start": 68, "tag": "CellComponent"}, {"end": 77, "start": 68, "tag": "CellOrMolecularDysfunction"}, {"end": 28, "start": 25, "tag": "CellFunction"}, {"end": 114, "start": 97, "tag": "CellOrMolecularDysfunction"}]}{"id": "274_7", "text": "However, uncontrolled activation of some UPR factors has also been demonstrated to worsen neurodegenerative phenotypes, suggesting that detailed molecular mechanisms around ER stress and its related neurodegenerations should be understood to develop effective therapeutics against aging-associated neurological syndromes.", "tags": [{"end": 32, "start": 22, "tag": "CellFunction"}, {"end": 89, "start": 83, "tag": "Finding"}, {"end": 118, "start": 90, "tag": "PathologicFunction"}, {"end": 217, "start": 199, "tag": "CellOrMolecularDysfunction"}, {"end": 165, "start": 145, "tag": "CellFunction"}, {"end": 175, "start": 173, "tag": "CellComponent"}, {"end": 182, "start": 173, "tag": "CellOrMolecularDysfunction"}, {"end": 272, "start": 260, "tag": "HealthCareActivity"}, {"end": 44, "start": 41, "tag": "CellFunction"}, {"end": 286, "start": 281, "tag": "BiologicFunction"}, {"end": 286, "start": 281, "tag": "CellFunction"}, {"end": 320, "start": 281, "tag": "DiseaseOrSyndrome"}]}{"id": "274_8", "text": "We also discuss current therapeutic endeavors, such as the development of small molecules that selectively target individual UPR components and address ER stress in general.", "tags": [{"end": 89, "start": 74, "tag": "Chemical"}, {"end": 139, "start": 129, "tag": "CellComponent"}, {"end": 154, "start": 152, "tag": "CellComponent"}, {"end": 161, "start": 152, "tag": "CellOrMolecularDysfunction"}, {"end": 128, "start": 125, "tag": "CellFunction"}, {"end": 89, "start": 80, "tag": "Substance"}, {"end": 70, "start": 59, "tag": "BiologicFunction"}, {"end": 70, "start": 59, "tag": "CellFunction"}, {"end": 23, "start": 16, "tag": "TemporalConcept"}]}{"id": "275_0", "text": "Classification of neurodegenerative diseases (NDD) like Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington's disease (HD) is of high clinical importance.", "tags": [{"end": 49, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 0, "tag": "ResearchActivity"}, {"end": 179, "start": 160, "tag": "Finding"}]}{"id": "275_1", "text": "The gait analysis based classification is attractive due to its simplicity and noninvasiveness.", "tags": [{"end": 17, "start": 4, "tag": "HealthCareActivity"}, {"end": 94, "start": 79, "tag": "Finding"}, {"end": 8, "start": 4, "tag": "OrganismAttribute"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 38, "start": 24, "tag": "ResearchActivity"}]}{"id": "275_2", "text": "In this paper, we propose a data driven features approach along with autocorrelation and cross correlation between gait time series to create different feature set for a sample representation.", "tags": [{"end": 84, "start": 69, "tag": "ResearchActivity"}, {"end": 176, "start": 170, "tag": "Substance"}, {"end": 176, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 119, "start": 115, "tag": "OrganismAttribute"}, {"end": 32, "start": 28, "tag": "ResearchActivity"}, {"end": 124, "start": 120, "tag": "TemporalConcept"}, {"end": 106, "start": 89, "tag": "ResearchActivity"}]}{"id": "275_3", "text": "Further, a rule based classifier using Decision Tree is trained with those features to classify the neurodegenerative diseases from healthy controls.", "tags": [{"end": 52, "start": 39, "tag": "ResearchActivity"}, {"end": 63, "start": 56, "tag": "NaturalPhenomenonOrProcess"}, {"end": 139, "start": 132, "tag": "OrganismAttribute"}, {"end": 148, "start": 132, "tag": "PopulationGroup"}, {"end": 126, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 9, "tag": "MachineActivity"}]}{"id": "275_4", "text": "Mutual Information (MI) analysis revealed the dominance of data driven features over auto and cross correlation based features.", "tags": [{"end": 55, "start": 46, "tag": "BiologicFunction"}, {"end": 63, "start": 59, "tag": "ResearchActivity"}, {"end": 32, "start": 0, "tag": "ResearchActivity"}, {"end": 111, "start": 94, "tag": "ResearchActivity"}]}{"id": "275_5", "text": "The classifier fed with top 500 features could produce the classification accuracy of 88.5%, 92.3%, and 96.2% for HD vs.", "tags": [{"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 59, "tag": "ResearchActivity"}, {"end": 82, "start": 74, "tag": "Finding"}]}{"id": "275_6", "text": "control, PD vs.", "tags": [{"end": 11, "start": 9, "tag": "DiseaseOrSyndrome"}]}{"id": "275_7", "text": "Control, and ALS vs.", "tags": [{"end": 16, "start": 13, "tag": "DiseaseOrSyndrome"}]}{"id": "275_8", "text": "control.", "tags": []}{"id": "275_9", "text": "Pooling all neurodegenerative samples into one as NDD class and applying current approach produced nearly 87.5% of accuracy for NDD vs.", "tags": [{"end": 53, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 54, "tag": "Finding"}, {"end": 131, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 12, "tag": "CellOrMolecularDysfunction"}, {"end": 80, "start": 73, "tag": "TemporalConcept"}, {"end": 37, "start": 30, "tag": "Substance"}, {"end": 37, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 115, "tag": "Finding"}]}{"id": "275_10", "text": "control.", "tags": []}{"id": "275_11", "text": "Finally, we validated the present approach for a challenging situation of classification of less severe patients and observed respectable accuracies of 80%, 80%, 90%, and 73.33% for HD vs.", "tags": [{"end": 103, "start": 97, "tag": "Finding"}, {"end": 112, "start": 104, "tag": "PatientOrDisabledGroup"}, {"end": 184, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 138, "tag": "Finding"}]}{"id": "275_12", "text": "control, PD vs.", "tags": [{"end": 11, "start": 9, "tag": "DiseaseOrSyndrome"}]}{"id": "275_13", "text": "Control, and ALS vs.", "tags": [{"end": 16, "start": 13, "tag": "DiseaseOrSyndrome"}]}{"id": "275_14", "text": "control, and NDD vs.", "tags": [{"end": 16, "start": 13, "tag": "DiseaseOrSyndrome"}]}{"id": "275_15", "text": "control, respectively.", "tags": []}{"id": "275_16", "text": "The proposed algorithm shows potential for rule based classification system in data driven features for Neurodegenerative disease classification.", "tags": [{"end": 22, "start": 13, "tag": "MachineActivity"}, {"end": 129, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 79, "tag": "ResearchActivity"}, {"end": 75, "start": 43, "tag": "MachineActivity"}, {"end": 144, "start": 130, "tag": "ResearchActivity"}]}{"id": "276_0", "text": "Neurodegenerative diseases (NDs) are a diverse group of disorders characterized by the progressive degeneration of the structure and function of the central or peripheral nervous systems.", "tags": [{"end": 186, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 47, "tag": "PopulationGroup"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 87, "tag": "TemporalConcept"}, {"end": 111, "start": 99, "tag": "PathologicFunction"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}]}{"id": "276_1", "text": "One of the major features of NDs, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD), is the aggregation of specific misfolded proteins, which induces cellular dysfunction, neuronal death, loss of synaptic connections and eventually brain damage.", "tags": [{"end": 142, "start": 131, "tag": "CellFunction"}, {"end": 142, "start": 131, "tag": "ResearchActivity"}, {"end": 225, "start": 211, "tag": "CellFunction"}, {"end": 283, "start": 271, "tag": "InjuryOrPoisoning"}, {"end": 209, "start": 189, "tag": "CellOrMolecularDysfunction"}, {"end": 173, "start": 155, "tag": "CellOrMolecularDysfunction"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 255, "start": 227, "tag": "PathologicFunction"}, {"end": 255, "start": 235, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "276_2", "text": "By far, a great amount of evidence has suggested that TRIM family proteins play crucial roles in the turnover of normal regulatory and misfolded proteins.", "tags": [{"end": 74, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 101, "tag": "CellFunction"}, {"end": 153, "start": 135, "tag": "CellOrMolecularDysfunction"}, {"end": 34, "start": 26, "tag": "Finding"}, {"end": 74, "start": 54, "tag": "BiologicallyActiveSubstance"}]}{"id": "276_3", "text": "To maintain cellular protein quality control, cells rely on two major classes of proteostasis: molecular chaperones and the degradative systems, the latter includes the ubiquitin-proteasome system (UPS) and autophagy; and their dysfunction has been established to result in various physiological disorders including NDs.", "tags": [{"end": 305, "start": 282, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 29, "tag": "ResearchActivity"}, {"end": 93, "start": 81, "tag": "CellFunction"}, {"end": 115, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 198, "tag": "CellFunction"}, {"end": 196, "start": 169, "tag": "CellFunction"}, {"end": 216, "start": 207, "tag": "CellFunction"}, {"end": 239, "start": 228, "tag": "PathologicFunction"}, {"end": 51, "start": 46, "tag": "Cell"}, {"end": 319, "start": 316, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 21, "tag": "CellFunction"}]}{"id": "276_4", "text": "Emerging evidence has shown that TRIM proteins are key players in facilitating the clearance of misfolded protein aggregates associated with neurodegenerative disorders.", "tags": [{"end": 46, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 83, "tag": "NaturalPhenomenonOrProcess"}, {"end": 124, "start": 96, "tag": "CellOrMolecularDysfunction"}, {"end": 17, "start": 0, "tag": "Finding"}, {"end": 168, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 33, "tag": "BiologicallyActiveSubstance"}]}{"id": "276_5", "text": "Understanding the different pathways these TRIM proteins employ during episodes of neurodegenerative disorder represents a promising therapeutic target.", "tags": [{"end": 56, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 71, "tag": "TemporalConcept"}, {"end": 151, "start": 123, "tag": "Finding"}, {"end": 36, "start": 28, "tag": "CellFunction"}, {"end": 109, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 43, "tag": "BiologicallyActiveSubstance"}]}{"id": "276_6", "text": "In this review, we elucidated and summarized the diverse roles with underlying mechanisms of members of the TRIM family proteins in NDs.", "tags": [{"end": 100, "start": 93, "tag": "PopulationGroup"}, {"end": 100, "start": 93, "tag": "BiologicFunction"}, {"end": 128, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "277_0", "text": "DNA mismatch repair (MMR) is a highly conserved genome stabilizing pathway that corrects DNA replication errors, limits chromosomal rearrangements, and mediates the cellular response to many types of DNA damage.", "tags": [{"end": 19, "start": 0, "tag": "CellFunction"}, {"end": 24, "start": 21, "tag": "CellFunction"}, {"end": 111, "start": 89, "tag": "CellOrMolecularDysfunction"}, {"end": 146, "start": 120, "tag": "CellOrMolecularDysfunction"}, {"end": 182, "start": 165, "tag": "CellFunction"}, {"end": 210, "start": 200, "tag": "CellOrMolecularDysfunction"}, {"end": 203, "start": 200, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 54, "start": 48, "tag": "GeneOrGenome"}, {"end": 74, "start": 67, "tag": "CellFunction"}]}{"id": "277_1", "text": "Counter-intuitively, MMR is also involved in the generation of mutations, as evidenced by its role in causing somatic triplet repeat expansion in Huntington's disease (HD) and other neurodegenerative disorders.", "tags": [{"end": 24, "start": 21, "tag": "CellFunction"}, {"end": 72, "start": 63, "tag": "CellFunction"}, {"end": 72, "start": 63, "tag": "CellOrMolecularDysfunction"}, {"end": 166, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 209, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 110, "tag": "CellOrMolecularDysfunction"}]}{"id": "277_2", "text": "In this review, we discuss the current state of mechanistic knowledge of MMR and review the roles of key enzymes in this pathway.", "tags": [{"end": 76, "start": 73, "tag": "CellFunction"}, {"end": 112, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 121, "tag": "CellFunction"}, {"end": 69, "start": 60, "tag": "Finding"}, {"end": 38, "start": 31, "tag": "TemporalConcept"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 87, "start": 81, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 87, "start": 81, "tag": "HealthCareActivity"}]}{"id": "277_3", "text": "We also present the evidence for mutagenic function of MMR in CAG repeat expansion and consider mechanistic hypotheses that have been proposed.", "tags": [{"end": 58, "start": 55, "tag": "CellFunction"}, {"end": 82, "start": 62, "tag": "CellOrMolecularDysfunction"}, {"end": 72, "start": 62, "tag": "MolecularSequence"}, {"end": 28, "start": 20, "tag": "Finding"}]}{"id": "277_4", "text": "Understanding the role of MMR in CAG expansion may shed light on potential avenues for therapeutic intervention in HD.", "tags": [{"end": 29, "start": 26, "tag": "CellFunction"}, {"end": 36, "start": 33, "tag": "MolecularSequence"}, {"end": 111, "start": 87, "tag": "HealthCareActivity"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 33, "tag": "CellOrMolecularDysfunction"}]}{"id": "278_0", "text": "The selective degradation of mitochondria through mitophagy is a crucial process for maintaining mitochondrial function and cellular health.", "tags": [{"end": 59, "start": 50, "tag": "CellFunction"}, {"end": 41, "start": 29, "tag": "CellComponent"}, {"end": 119, "start": 97, "tag": "CellFunction"}, {"end": 25, "start": 14, "tag": "NaturalPhenomenonOrProcess"}, {"end": 139, "start": 124, "tag": "CellFunction"}]}{"id": "278_1", "text": "Mitophagy is a specialized form of selective autophagy that uses unique machinery to recognize and target damaged mitochondria for mitophagosome- and lysosome-dependent degradation.", "tags": [{"end": 126, "start": 114, "tag": "CellComponent"}, {"end": 126, "start": 106, "tag": "CellOrMolecularDysfunction"}, {"end": 9, "start": 0, "tag": "CellFunction"}, {"end": 54, "start": 35, "tag": "CellFunction"}, {"end": 54, "start": 45, "tag": "CellFunction"}, {"end": 180, "start": 169, "tag": "NaturalPhenomenonOrProcess"}, {"end": 113, "start": 106, "tag": "InjuryOrPoisoning"}, {"end": 144, "start": 131, "tag": "CellComponent"}, {"end": 158, "start": 150, "tag": "CellComponent"}]}{"id": "278_2", "text": "This process is particularly important in cells with high metabolic activity like neurons, and the accumulation of defective mitochondria is a common feature among neurodegenerative disorders.", "tags": [{"end": 137, "start": 125, "tag": "CellComponent"}, {"end": 111, "start": 99, "tag": "Finding"}, {"end": 47, "start": 42, "tag": "Cell"}, {"end": 89, "start": 82, "tag": "Cell"}, {"end": 191, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 115, "tag": "CellOrMolecularDysfunction"}]}{"id": "278_3", "text": "Here, we describe essential steps involved in the induction and progression of mitophagy, and then highlight the various mechanisms that specifically contribute to defective mitophagy in highly prevalent neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis.", "tags": [{"end": 88, "start": 79, "tag": "CellFunction"}, {"end": 183, "start": 164, "tag": "CellOrMolecularDysfunction"}, {"end": 75, "start": 64, "tag": "PathologicFunction"}, {"end": 75, "start": 64, "tag": "TemporalConcept"}, {"end": 336, "start": 307, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 204, "tag": "DiseaseOrSyndrome"}, {"end": 301, "start": 281, "tag": "DiseaseOrSyndrome"}, {"end": 258, "start": 239, "tag": "DiseaseOrSyndrome"}, {"end": 279, "start": 260, "tag": "DiseaseOrSyndrome"}]}{"id": "280_1", "text": "Methods Patients at the early stage of the disease were enrolled in the Multicentric Intracerebral Grafting in Huntington's Disease trial, a delayed-start phase II randomized study.", "tags": [{"end": 35, "start": 24, "tag": "TemporalConcept"}, {"end": 180, "start": 155, "tag": "ResearchActivity"}, {"end": 148, "start": 141, "tag": "TemporalConcept"}, {"end": 16, "start": 8, "tag": "PatientOrDisabledGroup"}, {"end": 137, "start": 72, "tag": "ResearchActivity"}]}{"id": "280_2", "text": "After a run-in period of 12 months, patients were randomized at month 12 to either the treatment group (transplanted at month 13-month 14) or the control group and secondarily treated 20 months later (month 33-month 34).", "tags": [{"end": 14, "start": 8, "tag": "TemporalConcept"}, {"end": 69, "start": 64, "tag": "TemporalConcept"}, {"end": 102, "start": 87, "tag": "PopulationGroup"}, {"end": 125, "start": 120, "tag": "TemporalConcept"}, {"end": 206, "start": 201, "tag": "TemporalConcept"}, {"end": 21, "start": 15, "tag": "TemporalConcept"}, {"end": 116, "start": 104, "tag": "HealthCareActivity"}, {"end": 159, "start": 146, "tag": "PopulationGroup"}, {"end": 34, "start": 28, "tag": "TemporalConcept"}, {"end": 193, "start": 187, "tag": "TemporalConcept"}, {"end": 102, "start": 97, "tag": "PopulationGroup"}, {"end": 96, "start": 87, "tag": "HealthCareActivity"}, {"end": 96, "start": 87, "tag": "ResearchActivity"}, {"end": 44, "start": 36, "tag": "PatientOrDisabledGroup"}, {"end": 215, "start": 210, "tag": "TemporalConcept"}]}{"id": "280_3", "text": "The primary outcome was total motor score compared between both groups 20 months postrandomization (month 32).", "tags": [{"end": 98, "start": 81, "tag": "ResearchActivity"}, {"end": 105, "start": 100, "tag": "TemporalConcept"}, {"end": 80, "start": 74, "tag": "TemporalConcept"}, {"end": 41, "start": 24, "tag": "HealthCareActivity"}]}{"id": "280_4", "text": "Secondary outcomes included clinical, imaging, and electrophysiological findings and a comparison of pregraft and postgraft total motor score slopes during the entire study period (month 0- month 52) regardless of the time of transplant.", "tags": [{"end": 186, "start": 181, "tag": "TemporalConcept"}, {"end": 195, "start": 190, "tag": "TemporalConcept"}, {"end": 236, "start": 226, "tag": "HealthCareActivity"}, {"end": 236, "start": 226, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 173, "tag": "TemporalConcept"}, {"end": 45, "start": 38, "tag": "HealthCareActivity"}, {"end": 141, "start": 124, "tag": "HealthCareActivity"}, {"end": 222, "start": 218, "tag": "TemporalConcept"}, {"end": 172, "start": 167, "tag": "ResearchActivity"}, {"end": 97, "start": 87, "tag": "ResearchActivity"}, {"end": 109, "start": 101, "tag": "TemporalConcept"}, {"end": 123, "start": 114, "tag": "TemporalConcept"}]}{"id": "280_5", "text": "Results Of 54 randomized patients, 45 were transplanted; 26 immediately (treatment) and 19 delayed (control).", "tags": [{"end": 98, "start": 91, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 82, "start": 73, "tag": "HealthCareActivity"}, {"end": 82, "start": 73, "tag": "ResearchActivity"}, {"end": 33, "start": 25, "tag": "PatientOrDisabledGroup"}]}{"id": "280_6", "text": "Mean total motor score at month 32 did not differ between groups (treated controls difference in means adjusted for M12: +2.9 [95% confidence interval, -2.8 to 8.6];P= 0.31).", "tags": [{"end": 31, "start": 26, "tag": "TemporalConcept"}, {"end": 150, "start": 131, "tag": "ResearchActivity"}, {"end": 22, "start": 5, "tag": "HealthCareActivity"}, {"end": 82, "start": 74, "tag": "PopulationGroup"}]}{"id": "280_7", "text": "Its rate of decline after transplantation was similar to that before transplantation.", "tags": [{"end": 41, "start": 26, "tag": "HealthCareActivity"}, {"end": 84, "start": 69, "tag": "HealthCareActivity"}, {"end": 8, "start": 4, "tag": "TemporalConcept"}]}{"id": "280_8", "text": "A total of 27 severe adverse events were recorded in the randomized patients, 10 of which were related to the transplant procedure.", "tags": [{"end": 35, "start": 21, "tag": "PathologicFunction"}, {"end": 130, "start": 110, "tag": "HealthCareActivity"}, {"end": 20, "start": 14, "tag": "Finding"}, {"end": 76, "start": 68, "tag": "PatientOrDisabledGroup"}]}{"id": "280_9", "text": "Improvement of procedures during the trial significantly decreased the frequency of surgical events.We found antihuman leucocytes antigen antibodies in 40% of the patients.", "tags": [{"end": 11, "start": 0, "tag": "Finding"}, {"end": 25, "start": 15, "tag": "HealthCareActivity"}, {"end": 25, "start": 15, "tag": "TemporalConcept"}, {"end": 42, "start": 37, "tag": "ResearchActivity"}, {"end": 137, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 57, "tag": "Finding"}, {"end": 80, "start": 71, "tag": "TemporalConcept"}, {"end": 171, "start": 163, "tag": "PatientOrDisabledGroup"}, {"end": 99, "start": 84, "tag": "HealthCareActivity"}]}{"id": "280_10", "text": "Conclusion No clinical benefit was found in this trial.", "tags": [{"end": 54, "start": 49, "tag": "ResearchActivity"}, {"end": 30, "start": 14, "tag": "Finding"}]}{"id": "280_11", "text": "This may have been related to graft rejection.", "tags": [{"end": 45, "start": 30, "tag": "BiologicFunction"}]}{"id": "280_12", "text": "Ectopia and high track number negatively influence the graft outcome.", "tags": [{"end": 7, "start": 0, "tag": "Finding"}, {"end": 7, "start": 0, "tag": "AnatomicalAbnormality"}, {"end": 60, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 55, "tag": "HealthCareActivity"}, {"end": 68, "start": 61, "tag": "Finding"}]}{"id": "280_13", "text": "Procedural adjustments substantially improved surgical safety.", "tags": [{"end": 22, "start": 0, "tag": "HealthCareActivity"}, {"end": 61, "start": 46, "tag": "ResearchActivity"}, {"end": 45, "start": 37, "tag": "Finding"}]}{"id": "280_14", "text": "( NCT00190450.) (c) 2020 International Parkinson and Movement Disorder Society", "tags": [{"end": 78, "start": 25, "tag": "HealthCareRelatedOrganization"}]}{"id": "281_0", "text": "Diversiform ways of intercellular communication are vital links in maintaining homeostasis and disseminating physiological states.", "tags": [{"end": 47, "start": 20, "tag": "CellFunction"}, {"end": 129, "start": 123, "tag": "TemporalConcept"}, {"end": 90, "start": 79, "tag": "BiologicFunction"}]}{"id": "281_1", "text": "Among intercellular bridges, tunneling nanotubes (TNTs) discovered in 2004 were recognized as potential pharmacology targets related to the pathogenesis of common or infrequent neurodegenerative disorders.", "tags": [{"end": 27, "start": 6, "tag": "CellComponent"}, {"end": 116, "start": 104, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 176, "start": 166, "tag": "TemporalConcept"}, {"end": 152, "start": 140, "tag": "PathologicFunction"}, {"end": 204, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 29, "tag": "CellComponent"}, {"end": 54, "start": 50, "tag": "CellComponent"}, {"end": 124, "start": 94, "tag": "Finding"}]}{"id": "281_2", "text": "The neurotoxic aggregates in neurodegenerative diseases including scrapie prion protein (PrPSc), mutant tau protein, amyloid-beta (A beta) protein, alpha-synuclein (alpha-syn) as well as mutant Huntington (mHTT) protein could promote TNT formation via certain physiological mechanisms, in turn, mediating the intercellular transmission of neurotoxicity.", "tags": [{"end": 25, "start": 4, "tag": "InjuryOrPoisoning"}, {"end": 94, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 237, "start": 234, "tag": "CellComponent"}, {"end": 352, "start": 339, "tag": "InjuryOrPoisoning"}, {"end": 210, "start": 206, "tag": "AminoAcidPeptideOrProtein"}, {"end": 210, "start": 206, "tag": "CellOrMolecularDysfunction"}, {"end": 115, "start": 97, "tag": "CellOrMolecularDysfunction"}, {"end": 193, "start": 187, "tag": "CellOrMolecularDysfunction"}, {"end": 79, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 204, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 148, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 117, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 335, "start": 309, "tag": "CellFunction"}]}{"id": "281_3", "text": "In this review, we described in detail the skeleton, the formation, the physicochemical properties, and the functions of TNTs, while paying particular attention to the key role of TNTs in the transport of pathological proteins during neurodegeneration.", "tags": [{"end": 51, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 72, "tag": "NaturalPhenomenonOrProcess"}, {"end": 201, "start": 192, "tag": "AminoAcidPeptideOrProtein"}, {"end": 226, "start": 192, "tag": "BiologicFunction"}, {"end": 226, "start": 205, "tag": "PathologicFunction"}, {"end": 226, "start": 205, "tag": "AminoAcidPeptideOrProtein"}, {"end": 251, "start": 234, "tag": "CellOrMolecularDysfunction"}, {"end": 160, "start": 151, "tag": "BiologicFunction"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 125, "start": 121, "tag": "CellComponent"}, {"end": 184, "start": 180, "tag": "CellComponent"}]}{"id": "290_0", "text": "Huntington Disease is a chronically progressive and neurodegenerative disease, which leads to death after 10 to 30 years of suffering and worsening.", "tags": [{"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 147, "start": 138, "tag": "Finding"}, {"end": 99, "start": 94, "tag": "BiologicFunction"}, {"end": 133, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 94, "tag": "PathologicFunction"}]}{"id": "290_1", "text": "When suffering Huntington Disease the patient will experience physical, cognitive and psychological issues, so that the patient won't be able to communicate or express his will in the end-of-life-phase of his disease.", "tags": [{"end": 14, "start": 5, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 51, "tag": "BiologicFunction"}, {"end": 45, "start": 38, "tag": "PatientOrDisabledGroup"}, {"end": 127, "start": 120, "tag": "PatientOrDisabledGroup"}, {"end": 106, "start": 62, "tag": "SignOrSymptom"}, {"end": 201, "start": 184, "tag": "TemporalConcept"}]}{"id": "290_2", "text": "The problem is, after suffering a while the patient often won't be able to eat by himself, so a feeding tube must be implanted.", "tags": [{"end": 31, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 96, "tag": "ManufacturedObject"}, {"end": 51, "start": 44, "tag": "PatientOrDisabledGroup"}, {"end": 11, "start": 4, "tag": "Finding"}]}{"id": "290_3", "text": "In some cases a tracheostomy tube is needed because of the respiratory insufficiency.", "tags": [{"end": 33, "start": 16, "tag": "ManufacturedObject"}, {"end": 84, "start": 59, "tag": "PathologicFunction"}]}{"id": "290_4", "text": "The cause of death in most cases is an infection like a respiratory disease.", "tags": [{"end": 48, "start": 39, "tag": "PathologicFunction"}, {"end": 75, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 13, "tag": "BiologicFunction"}, {"end": 18, "start": 13, "tag": "PathologicFunction"}]}{"id": "290_5", "text": "That's why it's most important when diagnosed with Huntington Disease to advance care planning to end-of-life care like life-sustaining measures that engages patients in decision-making regarding future care, while they are still able to make and express decisions by themselves.", "tags": [{"end": 45, "start": 36, "tag": "HealthCareActivity"}, {"end": 45, "start": 36, "tag": "Finding"}, {"end": 69, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 73, "tag": "HealthCareActivity"}, {"end": 114, "start": 98, "tag": "HealthCareActivity"}, {"end": 185, "start": 170, "tag": "BiologicFunction"}, {"end": 202, "start": 196, "tag": "TemporalConcept"}, {"end": 264, "start": 255, "tag": "BiologicFunction"}, {"end": 166, "start": 158, "tag": "PatientOrDisabledGroup"}, {"end": 144, "start": 120, "tag": "HealthCareActivity"}, {"end": 207, "start": 203, "tag": "HealthCareActivity"}]}{"id": "291_0", "text": "Huntington's disease (HD) is a rare hereditary autosomal dominant neurodegenerative disorder, which is caused by expression of mutant huntingtin protein (mHTT) with an abnormal number of glutamine repeats in its N terminus, and characterized by intracellular mHTT aggregates (inclusions) in the brain.", "tags": [{"end": 258, "start": 245, "tag": "CellComponent"}, {"end": 286, "start": 276, "tag": "CellComponent"}, {"end": 158, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 263, "start": 259, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 154, "tag": "CellOrMolecularDysfunction"}, {"end": 263, "start": 259, "tag": "CellOrMolecularDysfunction"}, {"end": 65, "start": 47, "tag": "CellFunction"}, {"end": 65, "start": 57, "tag": "CellFunction"}, {"end": 152, "start": 127, "tag": "CellOrMolecularDysfunction"}, {"end": 46, "start": 36, "tag": "CellFunction"}, {"end": 204, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 300, "start": 295, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 31, "tag": "TemporalConcept"}, {"end": 222, "start": 212, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 113, "tag": "CellFunction"}, {"end": 274, "start": 245, "tag": "CellOrMolecularDysfunction"}]}{"id": "291_1", "text": "Exosomes are small extracellular vesicles that are secreted generally by all cell types and can be isolated from almost all body fluids such as blood, urine, saliva, and cerebrospinal fluid.", "tags": [{"end": 135, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 151, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 77, "tag": "Cell"}, {"end": 8, "start": 0, "tag": "CellComponent"}, {"end": 41, "start": 19, "tag": "CellComponent"}, {"end": 149, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 13, "tag": "CellComponent"}, {"end": 164, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 189, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "291_2", "text": "Exosomes may participate in the spreading of toxic misfolded proteins across the central nervous system in neurodegenerative diseases.", "tags": [{"end": 50, "start": 45, "tag": "InjuryOrPoisoning"}, {"end": 8, "start": 0, "tag": "CellComponent"}, {"end": 69, "start": 51, "tag": "CellOrMolecularDysfunction"}, {"end": 103, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 107, "tag": "DiseaseOrSyndrome"}]}{"id": "291_3", "text": "In HD, such propagation of mHTT was observed both in vitro and in vivo.", "tags": [{"end": 31, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 27, "tag": "CellOrMolecularDysfunction"}, {"end": 58, "start": 50, "tag": "ResearchActivity"}, {"end": 70, "start": 63, "tag": "ResearchActivity"}, {"end": 5, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 12, "tag": "PathologicFunction"}]}{"id": "291_4", "text": "On the other hand, exosomes might carry molecules with neuroprotective effects.", "tags": [{"end": 27, "start": 19, "tag": "CellComponent"}, {"end": 78, "start": 55, "tag": "Finding"}, {"end": 49, "start": 40, "tag": "Substance"}]}{"id": "291_5", "text": "In addition, due to their capability to cross blood-brain barrier, exosomes hold great potential as sources of biomarkers available from periphery or carriers of therapeutics into the central nervous system.", "tags": [{"end": 65, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 100, "tag": "Finding"}, {"end": 146, "start": 137, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 67, "tag": "CellComponent"}, {"end": 174, "start": 150, "tag": "HealthCareActivity"}, {"end": 36, "start": 26, "tag": "Finding"}, {"end": 206, "start": 184, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 111, "tag": "ClinicalAttribute"}]}{"id": "291_6", "text": "In this review, we discuss the emerging roles of exosomes in HD pathogenesis, diagnosis, and therapy.", "tags": [{"end": 57, "start": 49, "tag": "CellComponent"}, {"end": 87, "start": 78, "tag": "HealthCareActivity"}, {"end": 76, "start": 64, "tag": "PathologicFunction"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 93, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "295_0", "text": "Huntington's disease (HD) is a neurodegenerative disease caused by a CAG repeat expansion in the gene encoding the huntingtin protein (HTT).", "tags": [{"end": 89, "start": 69, "tag": "CellOrMolecularDysfunction"}, {"end": 110, "start": 102, "tag": "BiologicFunction"}, {"end": 133, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 69, "tag": "MolecularSequence"}, {"end": 138, "start": 135, "tag": "GeneOrGenome"}, {"end": 138, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 31, "tag": "DiseaseOrSyndrome"}]}{"id": "295_1", "text": "This expansion leads to the formation of mutant huntingtin protein (mHTT) that is expressed in many body tissue cells.", "tags": [{"end": 72, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 68, "tag": "CellOrMolecularDysfunction"}, {"end": 66, "start": 41, "tag": "CellOrMolecularDysfunction"}, {"end": 104, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 82, "tag": "CellFunction"}, {"end": 66, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 112, "tag": "Cell"}]}{"id": "295_2", "text": "The mHTT interacts with several molecular pathways within different cell types, affecting the regulation of the immune system cells.", "tags": [{"end": 89, "start": 80, "tag": "BiologicFunction"}, {"end": 8, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 4, "tag": "CellOrMolecularDysfunction"}, {"end": 78, "start": 68, "tag": "Cell"}, {"end": 50, "start": 32, "tag": "CellFunction"}, {"end": 125, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 42, "tag": "CellFunction"}, {"end": 131, "start": 126, "tag": "Cell"}]}{"id": "295_3", "text": "It is still very limited the understanding of the immune changes in peripheral tissues in HD.", "tags": [{"end": 42, "start": 29, "tag": "BiologicFunction"}, {"end": 86, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 50, "tag": "Finding"}]}{"id": "295_4", "text": "Herein, we investigated the levels of inflammatory and regulatory cytokines in peripheral organs (i.e.", "tags": [{"end": 50, "start": 38, "tag": "PathologicFunction"}, {"end": 75, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 55, "tag": "BiologicallyActiveSubstance"}]}{"id": "295_5", "text": "kidney, heart, liver and spleen) of the 12-month-old BACHD model of HD.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 40, "tag": "PopulationGroup"}, {"end": 64, "start": 59, "tag": "ResearchActivity"}, {"end": 13, "start": 8, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 53, "tag": "ExperimentalModelOfDisease"}]}{"id": "295_6", "text": "This robust murine model closely resembles the human disease.", "tags": [{"end": 60, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 19, "tag": "ResearchActivity"}, {"end": 52, "start": 47, "tag": "Eukaryote"}, {"end": 18, "start": 12, "tag": "Eukaryote"}]}{"id": "295_7", "text": "We found significant changes in cytokine levels in all organs analyzed.", "tags": [{"end": 40, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 62, "tag": "ResearchActivity"}]}{"id": "295_8", "text": "Increased levels of IL-6 were found in the kidney, while levels of IL-6 and IL-12p70 were increased in the heart of BACHD mice in comparison with wild-type (WT) animals.", "tags": [{"end": 24, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 20, "tag": "GeneOrGenome"}, {"end": 24, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 67, "tag": "GeneOrGenome"}, {"end": 71, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 146, "tag": "ResearchActivity"}, {"end": 168, "start": 161, "tag": "Eukaryote"}, {"end": 126, "start": 122, "tag": "Eukaryote"}, {"end": 112, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 130, "tag": "ResearchActivity"}, {"end": 84, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 116, "tag": "ExperimentalModelOfDisease"}]}{"id": "295_9", "text": "In the liver, we observed enhanced IL-12p70 and TNF-alpha levels.", "tags": [{"end": 12, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 35, "tag": "BiologicallyActiveSubstance"}]}{"id": "295_10", "text": "In the spleen, there was an increase in the levels of IL-4 and a decrease in the levels of IL-5 and IL-6 in BACHD compared to WT.", "tags": [{"end": 13, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 54, "tag": "GeneOrGenome"}, {"end": 95, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 91, "tag": "GeneOrGenome"}, {"end": 95, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 100, "tag": "GeneOrGenome"}, {"end": 104, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 126, "tag": "ResearchActivity"}, {"end": 73, "start": 65, "tag": "Finding"}, {"end": 113, "start": 108, "tag": "ExperimentalModelOfDisease"}]}{"id": "295_11", "text": "Our findings provide the first evidence that the BACHD model also exhibits immune changes in peripheral organs, opening an avenue for the investigation of the potential role played by peripheral inflammatory response in HD.", "tags": [{"end": 216, "start": 184, "tag": "PathologicFunction"}, {"end": 151, "start": 138, "tag": "ResearchActivity"}, {"end": 39, "start": 31, "tag": "Finding"}, {"end": 110, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 194, "start": 184, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 25, "tag": "TemporalConcept"}, {"end": 222, "start": 220, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 49, "tag": "ExperimentalModelOfDisease"}, {"end": 89, "start": 75, "tag": "Finding"}]}{"id": "295_12", "text": "Further studies are needed to systematically address the mechanisms and pathways underlying immune signaling in peripheral organs in HD.", "tags": [{"end": 129, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 72, "tag": "CellFunction"}, {"end": 15, "start": 8, "tag": "HealthCareActivity"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 122, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 92, "tag": "BiologicFunction"}]}{"id": "300_0", "text": "Huntington's disease is a progressive neurodegenerative disease caused by mutation of the huntingtin (HTT) gene.", "tags": [{"end": 82, "start": 74, "tag": "CellOrMolecularDysfunction"}, {"end": 37, "start": 26, "tag": "TemporalConcept"}, {"end": 105, "start": 102, "tag": "GeneOrGenome"}, {"end": 105, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 90, "tag": "GeneOrGenome"}, {"end": 111, "start": 107, "tag": "GeneOrGenome"}]}{"id": "300_1", "text": "The identification of mutation carriers before symptom onset provides an opportunity to intervene in the early stage of the disease course.", "tags": [{"end": 39, "start": 31, "tag": "PopulationGroup"}, {"end": 116, "start": 105, "tag": "TemporalConcept"}, {"end": 138, "start": 124, "tag": "TemporalConcept"}, {"end": 60, "start": 47, "tag": "TemporalConcept"}, {"end": 30, "start": 22, "tag": "CellOrMolecularDysfunction"}]}{"id": "300_2", "text": "Optimal biomarkers are of great value to reflect neuropathological and clinical progression and are sensitive to potential disease-modifying treatments.", "tags": [{"end": 91, "start": 80, "tag": "PathologicFunction"}, {"end": 66, "start": 49, "tag": "PathologicFunction"}, {"end": 151, "start": 123, "tag": "HealthCareActivity"}, {"end": 91, "start": 71, "tag": "TemporalConcept"}, {"end": 151, "start": 141, "tag": "ResearchActivity"}, {"end": 18, "start": 8, "tag": "ClinicalAttribute"}]}{"id": "300_3", "text": "Blood-based biomarkers have the merits of minimal invasiveness, low cost, easy accessibility and safety.", "tags": [{"end": 62, "start": 50, "tag": "PathologicFunction"}, {"end": 72, "start": 64, "tag": "Finding"}, {"end": 62, "start": 42, "tag": "Finding"}, {"end": 103, "start": 97, "tag": "HealthCareActivity"}, {"end": 22, "start": 12, "tag": "ClinicalAttribute"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 74, "tag": "Finding"}]}{"id": "300_4", "text": "In this review, we summarized the updated development of blood-based biomarkers for HD from six aspects, including neuronal injuries, oxidative stress, endocrine functions, immune reactions, metabolism and differentially expressed miRNAs.", "tags": [{"end": 132, "start": 115, "tag": "InjuryOrPoisoning"}, {"end": 171, "start": 152, "tag": "BiologicFunction"}, {"end": 189, "start": 173, "tag": "BiologicFunction"}, {"end": 201, "start": 191, "tag": "BiologicFunction"}, {"end": 201, "start": 191, "tag": "CellFunction"}, {"end": 230, "start": 206, "tag": "Finding"}, {"end": 237, "start": 231, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 237, "start": 231, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 42, "tag": "BiologicFunction"}, {"end": 53, "start": 42, "tag": "CellFunction"}, {"end": 150, "start": 134, "tag": "CellOrMolecularDysfunction"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 79, "start": 69, "tag": "ClinicalAttribute"}]}{"id": "300_5", "text": "The blood-based biomarkers presented and discussed in this review were close to clinical applicability and might facilitate clinical design as surrogate endpoints.", "tags": [{"end": 152, "start": 143, "tag": "PopulationGroup"}, {"end": 152, "start": 143, "tag": "PharmacologicSubstance"}, {"end": 9, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 124, "tag": "ResearchActivity"}, {"end": 65, "start": 59, "tag": "ResearchActivity"}, {"end": 65, "start": 59, "tag": "HealthCareActivity"}, {"end": 26, "start": 16, "tag": "ClinicalAttribute"}, {"end": 102, "start": 80, "tag": "Finding"}]}{"id": "300_6", "text": "Exploration and validation of robust blood-based biomarkers require further standard and systemic study design in the future.", "tags": [{"end": 11, "start": 0, "tag": "HealthCareActivity"}, {"end": 84, "start": 76, "tag": "HealthCareActivity"}, {"end": 84, "start": 76, "tag": "TemporalConcept"}, {"end": 26, "start": 16, "tag": "ResearchActivity"}, {"end": 42, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 104, "tag": "ResearchActivity"}, {"end": 110, "start": 104, "tag": "HealthCareActivity"}, {"end": 124, "start": 118, "tag": "TemporalConcept"}, {"end": 103, "start": 98, "tag": "ResearchActivity"}, {"end": 59, "start": 49, "tag": "ClinicalAttribute"}]}{"id": "306_0", "text": "Extracellular vesicles (EVs) are nano-sized membrane-enclosed particles released by cells that participate in intercellular communication through the transfer of biologic material.", "tags": [{"end": 71, "start": 44, "tag": "CellComponent"}, {"end": 179, "start": 150, "tag": "CellFunction"}, {"end": 179, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 137, "start": 110, "tag": "CellFunction"}, {"end": 52, "start": 44, "tag": "CellComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 89, "start": 84, "tag": "Cell"}]}{"id": "306_1", "text": "EVs include exosomes that are small vesicles that were initially associated with the disposal of cellular garbage; however, recent findings point toward a function as natural carriers of a wide variety of genetic material and proteins.", "tags": [{"end": 44, "start": 30, "tag": "CellComponent"}, {"end": 221, "start": 202, "tag": "CellFunction"}, {"end": 183, "start": 167, "tag": "CellFunction"}, {"end": 221, "start": 205, "tag": "GeneOrGenome"}, {"end": 20, "start": 12, "tag": "CellComponent"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 234, "start": 226, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 124, "tag": "TemporalConcept"}, {"end": 113, "start": 85, "tag": "CellFunction"}, {"end": 204, "start": 202, "tag": "CellFunction"}, {"end": 234, "start": 226, "tag": "CellFunction"}, {"end": 183, "start": 167, "tag": "CellFunction"}]}{"id": "306_2", "text": "Indeed, exosomes are vesicle mediators of intercellular communication and maintenance of cellular homeostasis.", "tags": [{"end": 69, "start": 42, "tag": "CellFunction"}, {"end": 16, "start": 8, "tag": "CellComponent"}, {"end": 109, "start": 89, "tag": "CellFunction"}, {"end": 85, "start": 74, "tag": "BiologicFunction"}, {"end": 28, "start": 21, "tag": "CellComponent"}]}{"id": "306_3", "text": "The role of exosomes in health and age-associated diseases is far from being understood, but recent evidence implicates exosomes as causative players in the spread of neurodegenerative diseases.", "tags": [{"end": 20, "start": 12, "tag": "CellComponent"}, {"end": 128, "start": 120, "tag": "CellComponent"}, {"end": 30, "start": 24, "tag": "HealthCareActivity"}, {"end": 38, "start": 35, "tag": "OrganismAttribute"}, {"end": 108, "start": 100, "tag": "Finding"}, {"end": 99, "start": 93, "tag": "TemporalConcept"}, {"end": 193, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 35, "tag": "DiseaseOrSyndrome"}]}{"id": "306_4", "text": "Cells from the central nervous system (CNS) use exosomes as a strategy not only to eliminate membranes, toxic proteins, and RNA species but also to mediate short and long cell-to-cell communication as carriers of important messengers and signals.", "tags": [{"end": 245, "start": 201, "tag": "CellFunction"}, {"end": 56, "start": 48, "tag": "CellComponent"}, {"end": 5, "start": 0, "tag": "Cell"}, {"end": 135, "start": 124, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 118, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 93, "tag": "CellComponent"}, {"end": 37, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 104, "tag": "InjuryOrPoisoning"}, {"end": 197, "start": 166, "tag": "CellFunction"}, {"end": 197, "start": 171, "tag": "CellFunction"}, {"end": 161, "start": 156, "tag": "CellFunction"}]}{"id": "306_5", "text": "The accumulation of protein aggregates is a common pathological hallmark in many neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and prion diseases.", "tags": [{"end": 38, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 218, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 64, "tag": "Finding"}, {"end": 16, "start": 4, "tag": "Finding"}, {"end": 107, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 119, "tag": "DiseaseOrSyndrome"}]}{"id": "306_6", "text": "Protein aggregates can be removed and delivered to degradation by the endo-lysosomal pathway or can be incorporated in multivesicular bodies (MVBs) that are further released to the extracellular space as exosomes.", "tags": [{"end": 18, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 119, "tag": "CellComponent"}, {"end": 146, "start": 142, "tag": "CellComponent"}, {"end": 200, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 204, "tag": "CellComponent"}, {"end": 92, "start": 70, "tag": "CellFunction"}, {"end": 62, "start": 51, "tag": "NaturalPhenomenonOrProcess"}]}{"id": "306_7", "text": "Because exosome transport damaged cellular material, this eventually contributes to the spread of pathological misfolded proteins within the brain, thus promoting the neurodegeneration process.", "tags": [{"end": 15, "start": 8, "tag": "CellComponent"}, {"end": 25, "start": 8, "tag": "CellFunction"}, {"end": 51, "start": 34, "tag": "Cell"}, {"end": 129, "start": 98, "tag": "CellOrMolecularDysfunction"}, {"end": 146, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 167, "tag": "CellOrMolecularDysfunction"}]}{"id": "306_8", "text": "In this review, we focus on the role of exosomes in CNS homeostasis, their possible contribution to the development of neurodegenerative diseases, the usefulness of exosome cargo as biomarkers of disease, and the potential benefits of plasma circulating CNS-derived exosomes.", "tags": [{"end": 172, "start": 165, "tag": "CellComponent"}, {"end": 48, "start": 40, "tag": "CellComponent"}, {"end": 274, "start": 266, "tag": "CellComponent"}, {"end": 241, "start": 235, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 56, "tag": "BiologicFunction"}, {"end": 115, "start": 104, "tag": "BiologicFunction"}, {"end": 115, "start": 104, "tag": "CellFunction"}, {"end": 55, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 257, "start": 254, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 173, "tag": "CellFunction"}, {"end": 145, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 192, "start": 182, "tag": "ClinicalAttribute"}, {"end": 231, "start": 213, "tag": "Finding"}]}{"id": "312_0", "text": "Huntington's disease is an autosomal dominant hereditary neurodegenerative disease characterized by progressive dystonia, chorea and cognitive or psychiatric disturbances.", "tags": [{"end": 120, "start": 112, "tag": "SignOrSymptom"}, {"end": 170, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 27, "tag": "CellFunction"}, {"end": 128, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 122, "tag": "SignOrSymptom"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 46, "tag": "DiseaseOrSyndrome"}]}{"id": "312_1", "text": "The leading cause is the Huntington gene mutation on the patient's chromosome 4 that produces a mutated protein.", "tags": [{"end": 111, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 96, "tag": "CellOrMolecularDysfunction"}, {"end": 79, "start": 67, "tag": "CellComponent"}, {"end": 49, "start": 25, "tag": "CellOrMolecularDysfunction"}]}{"id": "312_2", "text": "Recently, attention has focused on the relationship between microRNAs and Huntington's disease's pathogenesis.", "tags": [{"end": 19, "start": 10, "tag": "BiologicFunction"}, {"end": 51, "start": 39, "tag": "Finding"}, {"end": 109, "start": 97, "tag": "PathologicFunction"}, {"end": 94, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 60, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 69, "start": 60, "tag": "BiologicallyActiveSubstance"}]}{"id": "312_3", "text": "In Huntington's disease, microRNAs can interact with various transcription factors; dysregulated microRNAs may be associated with the Cytosine deoxynucleotide-Adenine ribonucleotides-Guanine ribonucleotide length and Huntington's disease's progression and severity.", "tags": [{"end": 82, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 84, "tag": "PathologicFunction"}, {"end": 264, "start": 256, "tag": "Finding"}, {"end": 23, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 237, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 25, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 106, "start": 97, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 34, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 251, "start": 240, "tag": "PathologicFunction"}, {"end": 251, "start": 240, "tag": "TemporalConcept"}, {"end": 205, "start": 134, "tag": "MolecularSequence"}]}{"id": "312_4", "text": "This study explores the role of microRNAs in the pathogenesis of Huntington's disease through bioinformatics analysis.", "tags": [{"end": 61, "start": 49, "tag": "PathologicFunction"}, {"end": 85, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 32, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 41, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 117, "start": 94, "tag": "ResearchActivity"}]}{"id": "312_5", "text": "By analyzing data from the Gene Expression Omnibus database, we identified a total of 9 differentially expressed microRNA.", "tags": [{"end": 112, "start": 88, "tag": "Finding"}, {"end": 121, "start": 113, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 121, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 27, "tag": "ResearchActivity"}, {"end": 17, "start": 13, "tag": "ResearchActivity"}]}{"id": "312_6", "text": "Subsequently, target genes and long non-coding RNAs were predicted, and a comprehensive regulatory network centered on microRNA was constructed.", "tags": [{"end": 51, "start": 31, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 51, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 119, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 127, "start": 119, "tag": "BiologicallyActiveSubstance"}]}{"id": "312_7", "text": "The microRNA integrated regulatory network, Homo sapiens (hsa)-miR-144-3p, interacted with the largest number of long non-coding RNAs, including X-inactive specific transcript and taurine upregulated gene 1.", "tags": [{"end": 12, "start": 4, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 12, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 113, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 133, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 175, "start": 145, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 73, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 57, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 56, "start": 44, "tag": "Eukaryote"}, {"end": 206, "start": 180, "tag": "GeneOrGenome"}]}{"id": "312_8", "text": "The miRNAs, hsa-miR-10b-5p and hsa-miR-196a-5p, regulated most of the target genes, including class I homeobox and brain-derived neurotrophic factor genes.", "tags": [{"end": 10, "start": 4, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 46, "start": 31, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 154, "start": 115, "tag": "GeneOrGenome"}, {"end": 26, "start": 12, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 10, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 149, "tag": "GeneOrGenome"}, {"end": 110, "start": 94, "tag": "GeneOrGenome"}]}{"id": "312_9", "text": "Additionally, 59 Gene Ontology terms and eight enrichment pathways were identified by analyzing the target genes of hsa-miR-196a-5p and hsa-microRNA-10b-5p.", "tags": [{"end": 36, "start": 17, "tag": "ResearchActivity"}, {"end": 66, "start": 47, "tag": "ResearchActivity"}, {"end": 131, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 116, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 155, "start": 136, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 155, "start": 136, "tag": "BiologicallyActiveSubstance"}]}{"id": "312_10", "text": "In conclusion, hsa-miR-10b-5p and hsa-miR-196a-5p were significantly and differentially expressed in Huntington's disease, the long non-coding RNAs X-inactive specific transcript, taurine upregulated gene 1, and target genes such as homeobox or brain-derived neurotrophic factor may play critical roles in the pathogenesis of Huntington's disease.", "tags": [{"end": 49, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 127, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 147, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 148, "tag": "GeneOrGenome"}, {"end": 241, "start": 233, "tag": "GeneOrGenome"}, {"end": 241, "start": 233, "tag": "AminoAcidPeptideOrProtein"}, {"end": 278, "start": 245, "tag": "AminoAcidPeptideOrProtein"}, {"end": 278, "start": 245, "tag": "BiologicallyActiveSubstance"}, {"end": 322, "start": 310, "tag": "PathologicFunction"}, {"end": 29, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 346, "start": 326, "tag": "DiseaseOrSyndrome"}, {"end": 206, "start": 180, "tag": "GeneOrGenome"}, {"end": 29, "start": 15, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 49, "start": 34, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 97, "start": 55, "tag": "Finding"}]}{"id": "313_0", "text": "Aims Quantitative estimation of cortical neurone loss in cases with chorea-acanthocytosis (ChAc) and its impact on laminar composition.", "tags": [{"end": 28, "start": 5, "tag": "ResearchActivity"}, {"end": 89, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 32, "tag": "CellOrMolecularDysfunction"}]}{"id": "313_1", "text": "Methods We used unbiased stereological tools to estimate the degree of cortical pathology in serial gallocyanin-stained brain sections through the complete hemispheres of three subjects with genetically verified ChAc and a range of disease durations.", "tags": [{"end": 79, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 177, "tag": "PopulationGroup"}, {"end": 216, "start": 212, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 240, "tag": "TemporalConcept"}, {"end": 89, "start": 80, "tag": "PathologicFunction"}, {"end": 111, "start": 100, "tag": "Chemical"}, {"end": 119, "start": 100, "tag": "ResearchActivity"}, {"end": 134, "start": 120, "tag": "ResearchActivity"}, {"end": 44, "start": 16, "tag": "ResearchActivity"}]}{"id": "313_2", "text": "We compared these results with our previous data of five Huntington's disease (HD) and five control cases.", "tags": [{"end": 48, "start": 44, "tag": "ResearchActivity"}, {"end": 105, "start": 92, "tag": "ResearchActivity"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 57, "tag": "DiseaseOrSyndrome"}]}{"id": "313_3", "text": "Pathoarchitectonic changes were exemplarily documented in TE1 of a 61-year-old female HD-, a 60-year-old female control case, and ChAc3.", "tags": [{"end": 61, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 79, "tag": "OrganismAttribute"}, {"end": 111, "start": 105, "tag": "OrganismAttribute"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 0, "tag": "PathologicFunction"}, {"end": 78, "start": 67, "tag": "PopulationGroup"}, {"end": 104, "start": 93, "tag": "PopulationGroup"}, {"end": 124, "start": 112, "tag": "PopulationGroup"}]}{"id": "313_4", "text": "Results Macroscopically, the cortical volume of our ChAc cases (ChAc1-3) remained close to normal.", "tags": [{"end": 44, "start": 29, "tag": "ClinicalAttribute"}, {"end": 97, "start": 82, "tag": "Finding"}, {"end": 62, "start": 52, "tag": "PatientOrDisabledGroup"}]}{"id": "313_5", "text": "However, the average number of neurones was reduced by 46% in ChAc and by 33% in HD (P = 0.03 for ChAc & HD vs.", "tags": [{"end": 39, "start": 31, "tag": "Cell"}, {"end": 66, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}]}{"id": "313_6", "text": "controls; P = 0.64 for ChAc vs.", "tags": [{"end": 8, "start": 0, "tag": "PopulationGroup"}, {"end": 27, "start": 23, "tag": "DiseaseOrSyndrome"}]}{"id": "313_7", "text": "HD).", "tags": [{"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "313_8", "text": "Terminal HD cases featured selective laminar neurone loss with pallor of layers III, V and VIa, a high density of small, pale, closely packed radial fibres in deep cortical layers VI and V, shrinkage, and chromophilia of subcortical white matter.", "tags": [{"end": 217, "start": 205, "tag": "ResearchActivity"}, {"end": 232, "start": 221, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 245, "start": 233, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 37, "tag": "CellOrMolecularDysfunction"}, {"end": 94, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 199, "start": 190, "tag": "Finding"}, {"end": 155, "start": 142, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 63, "tag": "ClinicalAttribute"}, {"end": 17, "start": 9, "tag": "PatientOrDisabledGroup"}]}{"id": "313_9", "text": "In ChAc, pronounced diffuse astrogliosis blurred the laminar borders, thus masking the complete and partial loss of pyramidal cells in layer IIIc and of neurones in layers III, V and VI.", "tags": [{"end": 7, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 28, "tag": "PathologicFunction"}, {"end": 131, "start": 116, "tag": "Cell"}, {"end": 161, "start": 153, "tag": "Cell"}, {"end": 185, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 108, "tag": "CellOrMolecularDysfunction"}, {"end": 145, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "313_10", "text": "Conclusion ChAc is a neurodegenerative disease with distinct cortical neurodegeneration.", "tags": [{"end": 15, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 70, "tag": "CellOrMolecularDysfunction"}]}{"id": "313_11", "text": "The hypertrophy of the peripheral neuropil space of minicolumns with coarse vertical striation was characteristic of ChAc.", "tags": [{"end": 15, "start": 4, "tag": "PathologicFunction"}, {"end": 33, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 34, "tag": "CellComponent"}, {"end": 94, "start": 69, "tag": "Finding"}, {"end": 121, "start": 117, "tag": "DiseaseOrSyndrome"}]}{"id": "313_12", "text": "The role of astroglia in the pathogenesis of this disorder remains to be elucidated.", "tags": [{"end": 21, "start": 12, "tag": "Cell"}, {"end": 41, "start": 29, "tag": "PathologicFunction"}]}{"id": "317_0", "text": "The clinical diagnosis of neurodegenerative diseases is notoriously inaccurate and current methods are often expensive, time-consuming, or invasive.", "tags": [{"end": 22, "start": 4, "tag": "HealthCareActivity"}, {"end": 147, "start": 139, "tag": "Finding"}, {"end": 90, "start": 83, "tag": "TemporalConcept"}, {"end": 52, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 109, "tag": "Finding"}, {"end": 134, "start": 120, "tag": "Finding"}]}{"id": "317_1", "text": "Simple inexpensive and noninvasive methods of diagnosis could provide valuable support for clinicians when combined with cognitive assessment scores.", "tags": [{"end": 55, "start": 23, "tag": "HealthCareActivity"}, {"end": 148, "start": 121, "tag": "HealthCareActivity"}, {"end": 101, "start": 91, "tag": "HealthCareActivity"}]}{"id": "317_2", "text": "Biological processes leading to neuropathology progress silently for years and are reflected in both the central nervous system and vascular peripheral system.", "tags": [{"end": 20, "start": 0, "tag": "BiologicFunction"}, {"end": 46, "start": 32, "tag": "PathologicFunction"}, {"end": 74, "start": 69, "tag": "TemporalConcept"}, {"end": 127, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 47, "tag": "TemporalConcept"}]}{"id": "317_3", "text": "A blood-based screen to distinguish and classify neurodegenerative diseases is especially interesting having low cost, minimal invasiveness, and accessibility to almost any world clinic.", "tags": [{"end": 117, "start": 109, "tag": "Finding"}, {"end": 139, "start": 119, "tag": "Finding"}, {"end": 185, "start": 173, "tag": "HealthCareActivity"}, {"end": 75, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 2, "tag": "HealthCareActivity"}]}{"id": "317_4", "text": "In this study, we set out to discover a small set of blood transcripts that can be used to distinguish healthy individuals from those with Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Friedreich's ataxia, or frontotemporal dementia.", "tags": [{"end": 70, "start": 59, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 122, "start": 103, "tag": "PopulationGroup"}, {"end": 158, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 232, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 253, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 281, "start": 258, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 58, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "317_5", "text": "Using existing public datasets, we developed a machine learning algorithm for application on transcripts present in blood and discovered small sets of transcripts that distinguish a number of neurodegenerative diseases with high sensitivity and specificity.", "tags": [{"end": 104, "start": 93, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 121, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 151, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 256, "start": 224, "tag": "Finding"}, {"end": 73, "start": 47, "tag": "MachineActivity"}, {"end": 218, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 6, "tag": "ResearchActivity"}]}{"id": "317_6", "text": "We validated the usefulness of blood RNA transcriptomics for the classification of neurodegenerative diseases.", "tags": [{"end": 56, "start": 41, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 109, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 37, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 56, "start": 31, "tag": "ResearchActivity"}]}{"id": "317_7", "text": "Information about features selected for the classification can direct the development of possible treatment strategies.", "tags": [{"end": 118, "start": 98, "tag": "HealthCareActivity"}, {"end": 118, "start": 98, "tag": "ResearchActivity"}]}{"id": "328_0", "text": "Small heat shock proteins are ubiquitously expressed chaperones, yet mutations in some of them cause tissue-specific diseases.", "tags": [{"end": 25, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 30, "tag": "CellFunction"}, {"end": 63, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 69, "tag": "CellFunction"}, {"end": 78, "start": 69, "tag": "CellOrMolecularDysfunction"}, {"end": 116, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 101, "tag": "DiseaseOrSyndrome"}]}{"id": "328_1", "text": "Here, we will discuss how small heat shock proteins give rise to neurodegenerative disorders themselves while we will also highlight how these proteins can fulfil protective functions in neurodegenerative disorders caused by protein aggregation.", "tags": [{"end": 51, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 163, "tag": "BiologicFunction"}, {"end": 92, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 244, "start": 225, "tag": "CellFunction"}, {"end": 244, "start": 225, "tag": "CellOrMolecularDysfunction"}, {"end": 51, "start": 26, "tag": "BiologicallyActiveSubstance"}]}{"id": "328_2", "text": "The first half of this paper will be focused on how mutations in HSPB1, HSPB3, and HSPB8 are linked to inherited peripheral neuropathies like Charcot-Marie-Tooth (CMT) disease and distal hereditary motor neuropathy (dHMN).", "tags": [{"end": 61, "start": 52, "tag": "CellFunction"}, {"end": 61, "start": 52, "tag": "CellOrMolecularDysfunction"}, {"end": 70, "start": 65, "tag": "GeneOrGenome"}, {"end": 70, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 72, "tag": "GeneOrGenome"}, {"end": 88, "start": 83, "tag": "GeneOrGenome"}, {"end": 88, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 220, "start": 216, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 23, "tag": "ResearchActivity"}]}{"id": "328_3", "text": "The second part of the paper will discuss how small heat shock proteins are linked to neurodegenerative disorders like Alzheimer's, Parkinson's, and Huntington's disease.", "tags": [{"end": 130, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 23, "tag": "ResearchActivity"}, {"end": 71, "start": 46, "tag": "BiologicallyActiveSubstance"}]}{"id": "339_0", "text": "Curcumin is a spice derived nutraceutical which gained tremendous attention because of its profound medicinal values.", "tags": [{"end": 8, "start": 0, "tag": "Chemical"}, {"end": 8, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 41, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 75, "start": 66, "tag": "BiologicFunction"}, {"end": 116, "start": 91, "tag": "Finding"}]}{"id": "339_1", "text": "It alters a number of molecular pathways such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B), signal transducer and activator of transcription 3 (STAT3), nuclear factor erythroid 2-related factor 2 (Nrf2) and cyclooxygenases-2 (COX -2), which make it potential therapeutic choice in treating multiple disorders.", "tags": [{"end": 40, "start": 22, "tag": "CellFunction"}, {"end": 111, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 113, "tag": "GeneOrGenome"}, {"end": 123, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 178, "tag": "GeneOrGenome"}, {"end": 183, "start": 178, "tag": "BiologicallyActiveSubstance"}, {"end": 229, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 229, "start": 186, "tag": "GeneOrGenome"}, {"end": 235, "start": 231, "tag": "AminoAcidPeptideOrProtein"}, {"end": 235, "start": 231, "tag": "GeneOrGenome"}, {"end": 258, "start": 241, "tag": "AminoAcidPeptideOrProtein"}, {"end": 266, "start": 260, "tag": "AminoAcidPeptideOrProtein"}, {"end": 266, "start": 260, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 49, "tag": "GeneOrGenome"}, {"end": 176, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 126, "tag": "GeneOrGenome"}, {"end": 229, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 235, "start": 231, "tag": "BiologicallyActiveSubstance"}, {"end": 258, "start": 241, "tag": "BiologicallyActiveSubstance"}, {"end": 311, "start": 283, "tag": "HealthCareActivity"}]}{"id": "339_2", "text": "It also possesses the potential to prevent protein aggregation and thus protect against degeneration of neurons in neurodegenerative disorders including Huntington's disease (HD).", "tags": [{"end": 111, "start": 88, "tag": "CellOrMolecularDysfunction"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 43, "tag": "CellFunction"}, {"end": 62, "start": 43, "tag": "CellOrMolecularDysfunction"}]}{"id": "339_3", "text": "HD is an autosomal dominant disorder linked with altered gene expression which leads to an increase in the size of cytosine, adenine and guanine (CAG) trinucleotide repeats, aids in protein aggregation throughout the brain and thus damages neurons.", "tags": [{"end": 72, "start": 49, "tag": "CellOrMolecularDysfunction"}, {"end": 111, "start": 91, "tag": "Finding"}, {"end": 123, "start": 115, "tag": "Chemical"}, {"end": 123, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 125, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 247, "start": 240, "tag": "Cell"}, {"end": 36, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 222, "start": 217, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 145, "tag": "MolecularSequence"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 182, "tag": "CellFunction"}, {"end": 201, "start": 182, "tag": "CellOrMolecularDysfunction"}, {"end": 132, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 137, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "339_4", "text": "Upstream regulation of oxidative stress and inflammatory cascade are two important factors that drive HD progression.", "tags": [{"end": 19, "start": 0, "tag": "CellFunction"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 23, "tag": "CellOrMolecularDysfunction"}, {"end": 116, "start": 105, "tag": "PathologicFunction"}, {"end": 116, "start": 105, "tag": "TemporalConcept"}, {"end": 64, "start": 44, "tag": "CellFunction"}]}{"id": "339_5", "text": "Available therapies just suppress the severity of symptoms with a number of side effects.", "tags": [{"end": 19, "start": 10, "tag": "HealthCareActivity"}, {"end": 46, "start": 38, "tag": "Finding"}, {"end": 58, "start": 50, "tag": "SignOrSymptom"}, {"end": 88, "start": 76, "tag": "PathologicFunction"}]}{"id": "339_6", "text": "Curcumin targets multiple mechanisms in treating or preventing HD including antioxidant and anti-inflammatory potential, metal ion chelation, transcriptional alterations and upregulating activity of molecular chaperons, heat shock proteins (HSPs).", "tags": [{"end": 8, "start": 0, "tag": "Chemical"}, {"end": 8, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 87, "start": 76, "tag": "PharmacologicSubstance"}, {"end": 87, "start": 76, "tag": "CellFunction"}, {"end": 140, "start": 121, "tag": "CellFunction"}, {"end": 195, "start": 174, "tag": "Finding"}, {"end": 218, "start": 199, "tag": "AminoAcidPeptideOrProtein"}, {"end": 239, "start": 220, "tag": "AminoAcidPeptideOrProtein"}, {"end": 239, "start": 220, "tag": "BiologicallyActiveSubstance"}, {"end": 245, "start": 241, "tag": "AminoAcidPeptideOrProtein"}, {"end": 245, "start": 241, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 92, "tag": "BiologicFunction"}, {"end": 109, "start": 92, "tag": "PharmacologicSubstance"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 218, "start": 199, "tag": "BiologicallyActiveSubstance"}]}{"id": "339_7", "text": "Having a favorable safety profile, curcumin can be an alternative therapeutic choice in treating neurodegenerative disorders like HD.", "tags": [{"end": 43, "start": 35, "tag": "Chemical"}, {"end": 43, "start": 35, "tag": "PharmacologicSubstance"}, {"end": 84, "start": 54, "tag": "HealthCareActivity"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 97, "tag": "DiseaseOrSyndrome"}]}{"id": "339_8", "text": "This review will focus on mechanistic aspects of curcumin in treating or preventing HD and its potential to arrest disease progression and will open new dimensions for safe and effective therapeutic agents in diminishing HD.", "tags": [{"end": 57, "start": 49, "tag": "Chemical"}, {"end": 57, "start": 49, "tag": "PharmacologicSubstance"}, {"end": 205, "start": 187, "tag": "HealthCareActivity"}, {"end": 134, "start": 115, "tag": "PathologicFunction"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 221, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 123, "tag": "PathologicFunction"}, {"end": 134, "start": 123, "tag": "TemporalConcept"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}]}{"id": "342_0", "text": "Retinal imaging technology is rapidly advancing and can provide ever-increasing amounts of information about the structure, function and molecular composition of retinal tissue in humans in vivo.", "tags": [{"end": 26, "start": 0, "tag": "HealthCareActivity"}, {"end": 186, "start": 180, "tag": "Eukaryote"}, {"end": 176, "start": 162, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 69, "tag": "Finding"}, {"end": 194, "start": 187, "tag": "ResearchActivity"}]}{"id": "342_1", "text": "Most importantly, this information can be obtained rapidly, non-invasively and in many cases using Food and Drug Administration-approved devices that are commercially available.", "tags": [{"end": 74, "start": 60, "tag": "Finding"}, {"end": 127, "start": 99, "tag": "HealthCareRelatedOrganization"}, {"end": 144, "start": 137, "tag": "ManufacturedObject"}]}{"id": "342_2", "text": "Technologies such as optical coherence tomography have dramatically changed our understanding of retinal disease and in many cases have significantly improved their clinical management.", "tags": [{"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 112, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 165, "tag": "HealthCareActivity"}, {"end": 93, "start": 80, "tag": "BiologicFunction"}, {"end": 158, "start": 150, "tag": "Finding"}, {"end": 49, "start": 21, "tag": "HealthCareActivity"}, {"end": 104, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "342_4", "text": "This is particularly appealing because of the high spatial resolution, relatively low-cost and wide availability of retinal imaging modalities such as fundus photography or OCT compared to brain imaging modalities such as magnetic resonance imaging or positron emission tomography.", "tags": [{"end": 112, "start": 100, "tag": "Finding"}, {"end": 169, "start": 151, "tag": "HealthCareActivity"}, {"end": 202, "start": 189, "tag": "HealthCareActivity"}, {"end": 280, "start": 252, "tag": "HealthCareActivity"}, {"end": 248, "start": 222, "tag": "HealthCareActivity"}, {"end": 131, "start": 116, "tag": "HealthCareActivity"}, {"end": 176, "start": 173, "tag": "HealthCareActivity"}, {"end": 123, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 46, "tag": "Finding"}, {"end": 90, "start": 82, "tag": "Finding"}]}{"id": "342_5", "text": "The purpose of this article is to review and synthesize current research about retinal imaging in neurodegenerative disease by providing examples from the literature and elaborating on limitations, challenges and future directions.", "tags": [{"end": 94, "start": 79, "tag": "HealthCareActivity"}, {"end": 165, "start": 155, "tag": "ResearchActivity"}, {"end": 27, "start": 20, "tag": "ResearchActivity"}, {"end": 208, "start": 198, "tag": "HealthCareActivity"}, {"end": 219, "start": 213, "tag": "TemporalConcept"}, {"end": 63, "start": 56, "tag": "TemporalConcept"}, {"end": 123, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 34, "tag": "ResearchActivity"}, {"end": 40, "start": 34, "tag": "HealthCareActivity"}, {"end": 72, "start": 64, "tag": "ResearchActivity"}]}{"id": "342_6", "text": "We begin by providing a general background of the most relevant retinal imaging modalities to ensure that the reader has a foundation on which to understand the clinical studies that are subsequently discussed.", "tags": [{"end": 116, "start": 110, "tag": "PopulationGroup"}, {"end": 177, "start": 161, "tag": "ResearchActivity"}, {"end": 79, "start": 64, "tag": "HealthCareActivity"}]}{"id": "342_7", "text": "We then review the application and results of retinal imaging methodologies to several prevalent neurodegenerative diseases where extensive work has been done including sporadic late onset Alzheimer's Disease, Parkinson's Disease and Huntington's Disease.", "tags": [{"end": 75, "start": 62, "tag": "ResearchActivity"}, {"end": 208, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 169, "tag": "TemporalConcept"}, {"end": 188, "start": 178, "tag": "TemporalConcept"}, {"end": 61, "start": 46, "tag": "HealthCareActivity"}, {"end": 254, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "342_8", "text": "We also discuss Autosomal Dominant Alzheimer's Disease and cerebrovascular small vessel disease, where the application of retinal imaging holds promise but data is currently scarce.", "tags": [{"end": 25, "start": 16, "tag": "CellComponent"}, {"end": 95, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 122, "tag": "HealthCareActivity"}, {"end": 54, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 164, "tag": "TemporalConcept"}, {"end": 160, "start": 156, "tag": "ResearchActivity"}, {"end": 34, "start": 26, "tag": "CellFunction"}]}{"id": "342_9", "text": "Although cerebrovascular disease is not generally considered a neurodegenerative process, it is both a confounder and contributor to neurodegenerative disease processes that requires more attention.", "tags": [{"end": 32, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 63, "tag": "CellOrMolecularDysfunction"}, {"end": 197, "start": 188, "tag": "BiologicFunction"}, {"end": 158, "start": 133, "tag": "DiseaseOrSyndrome"}]}{"id": "342_10", "text": "Finally, we discuss ongoing efforts to overcome the limitations in the field and unmet clinical and scientific needs.", "tags": [{"end": 27, "start": 20, "tag": "TemporalConcept"}, {"end": 116, "start": 111, "tag": "Finding"}, {"end": 95, "start": 81, "tag": "Finding"}]}{"id": "349_0", "text": "Microglia are specialized dynamic immune cells in the central nervous system (CNS) that plays a crucial role in brain homeostasis and in disease states.", "tags": [{"end": 9, "start": 0, "tag": "Cell"}, {"end": 46, "start": 34, "tag": "Cell"}, {"end": 76, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 112, "tag": "BiologicFunction"}, {"end": 151, "start": 145, "tag": "TemporalConcept"}]}{"id": "349_1", "text": "Persistent neuroinflammation is considered a hallmark of many neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and primary progressive multiple sclerosis (MS).", "tags": [{"end": 10, "start": 0, "tag": "TemporalConcept"}, {"end": 119, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 213, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 261, "start": 259, "tag": "DiseaseOrSyndrome"}, {"end": 176, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 11, "tag": "PathologicFunction"}, {"end": 53, "start": 45, "tag": "Finding"}, {"end": 257, "start": 219, "tag": "DiseaseOrSyndrome"}]}{"id": "349_2", "text": "Colony stimulating factor 1-receptor (CSF-1R) is predominantly expressed on microglia and its expression is significantly increased in neurodegenerative diseases.", "tags": [{"end": 36, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 76, "tag": "Cell"}, {"end": 131, "start": 108, "tag": "Finding"}, {"end": 161, "start": 135, "tag": "DiseaseOrSyndrome"}]}{"id": "349_3", "text": "Cumulative findings have indicated that CSF-1R inhibitors can have beneficial effects in preclinical neurodegenerative disease models.", "tags": [{"end": 57, "start": 40, "tag": "PharmacologicSubstance"}, {"end": 133, "start": 89, "tag": "ExperimentalModelOfDisease"}, {"end": 85, "start": 67, "tag": "Finding"}, {"end": 19, "start": 0, "tag": "Finding"}]}{"id": "349_4", "text": "Research using CSF-1R inhibitors has now been extended into non-human primates and humans.", "tags": [{"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 32, "start": 15, "tag": "PharmacologicSubstance"}, {"end": 78, "start": 60, "tag": "Eukaryote"}, {"end": 89, "start": 83, "tag": "Eukaryote"}]}{"id": "349_5", "text": "This review article summarizes the most recent advances using CSF-1R inhibitors in different neurodegenerative conditions including AD, PD, HD, ALS and MS.", "tags": [{"end": 79, "start": 62, "tag": "PharmacologicSubstance"}, {"end": 121, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 5, "tag": "ResearchActivity"}, {"end": 46, "start": 40, "tag": "TemporalConcept"}]}{"id": "349_6", "text": "Potential challenges for translating these findings into clinical practice are presented.", "tags": [{"end": 74, "start": 57, "tag": "HealthCareActivity"}]}{"id": "364_0", "text": "Partly because of extensions in lifespan, the incidence of neurodegenerative diseases is increasing, while there is no effective approach to slow or prevent neuronal degeneration.", "tags": [{"end": 165, "start": 157, "tag": "Cell"}, {"end": 178, "start": 157, "tag": "CellOrMolecularDysfunction"}, {"end": 40, "start": 32, "tag": "TemporalConcept"}, {"end": 55, "start": 46, "tag": "Finding"}, {"end": 85, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 166, "tag": "PathologicFunction"}, {"end": 28, "start": 18, "tag": "Finding"}]}{"id": "364_1", "text": "As we all know, neurons cannot self-regenerate and may not be replaced once being damaged or degenerated in human brain.", "tags": [{"end": 89, "start": 82, "tag": "InjuryOrPoisoning"}, {"end": 104, "start": 93, "tag": "PathologicFunction"}, {"end": 23, "start": 16, "tag": "Cell"}, {"end": 119, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 108, "tag": "Eukaryote"}]}{"id": "364_2", "text": "Astrocytes are widely distributed in the central nervous system (CNS) and proliferate once CNS injury or neurodegeneration occur.", "tags": [{"end": 101, "start": 91, "tag": "InjuryOrPoisoning"}, {"end": 68, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 10, "start": 0, "tag": "Cell"}, {"end": 122, "start": 105, "tag": "CellOrMolecularDysfunction"}, {"end": 63, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "364_3", "text": "Actually, direct reprogramming astrocytes into functional neurons has been attracting more and more attention in recent years.", "tags": [{"end": 65, "start": 58, "tag": "Cell"}, {"end": 30, "start": 17, "tag": "CellFunction"}, {"end": 41, "start": 31, "tag": "Cell"}, {"end": 125, "start": 113, "tag": "TemporalConcept"}, {"end": 109, "start": 100, "tag": "BiologicFunction"}, {"end": 125, "start": 120, "tag": "TemporalConcept"}, {"end": 30, "start": 17, "tag": "ResearchActivity"}]}{"id": "364_4", "text": "Human astrocytes can be successfully converted into neurons in vitro.", "tags": [{"end": 5, "start": 0, "tag": "Eukaryote"}, {"end": 59, "start": 52, "tag": "Cell"}, {"end": 68, "start": 60, "tag": "ResearchActivity"}, {"end": 16, "start": 6, "tag": "Cell"}]}{"id": "364_5", "text": "Notably, in vivo direct reprogramming of astrocytes into functional neurons were achieved in the adult mouse and non-human primate brains.", "tags": [{"end": 130, "start": 113, "tag": "Eukaryote"}, {"end": 102, "start": 97, "tag": "PopulationGroup"}, {"end": 75, "start": 68, "tag": "Cell"}, {"end": 51, "start": 41, "tag": "Cell"}, {"end": 108, "start": 103, "tag": "Eukaryote"}, {"end": 37, "start": 9, "tag": "ResearchActivity"}, {"end": 137, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "364_6", "text": "In this review, we briefly summarized in vivo direct reprogramming of astrocytes into functional neurons as regenerative strategies for CNS diseases, mainly focusing on neurodegenerative diseases such as Parkinson's disease (PD), Alzheimer's disease (AD), and Huntington's disease (HD).", "tags": [{"end": 148, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 97, "tag": "Cell"}, {"end": 80, "start": 70, "tag": "Cell"}, {"end": 26, "start": 19, "tag": "TemporalConcept"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 195, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 280, "start": 260, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 204, "tag": "DiseaseOrSyndrome"}, {"end": 284, "start": 282, "tag": "DiseaseOrSyndrome"}, {"end": 227, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 230, "tag": "DiseaseOrSyndrome"}, {"end": 253, "start": 251, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 38, "tag": "ResearchActivity"}, {"end": 131, "start": 108, "tag": "HealthCareActivity"}]}{"id": "364_7", "text": "We highlight and outline the advantages and challenges of direct neuronal reprogramming from astrocytes in vivo for future neuroregenerative medicine.", "tags": [{"end": 149, "start": 123, "tag": "HealthCareActivity"}, {"end": 87, "start": 65, "tag": "CellFunction"}, {"end": 54, "start": 44, "tag": "HealthCareActivity"}, {"end": 103, "start": 93, "tag": "Cell"}, {"end": 122, "start": 116, "tag": "TemporalConcept"}, {"end": 111, "start": 104, "tag": "ResearchActivity"}, {"end": 149, "start": 123, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "365_0", "text": "Posttranslational modifications are ubiquitous regulators of cellular processes.", "tags": [{"end": 31, "start": 0, "tag": "CellFunction"}, {"end": 79, "start": 61, "tag": "CellFunction"}]}{"id": "365_1", "text": "The regulatory role of SUMOylation, the attachment of a small ubiquitin-related modifier to a target protein, has been implicated in fundamental processes like cell division, DNA damage repair, mitochondrial homeostasis, and stress responses.", "tags": [{"end": 173, "start": 160, "tag": "CellFunction"}, {"end": 192, "start": 175, "tag": "CellFunction"}, {"end": 219, "start": 194, "tag": "CellFunction"}, {"end": 241, "start": 225, "tag": "BiologicFunction"}, {"end": 241, "start": 225, "tag": "CellFunction"}, {"end": 34, "start": 23, "tag": "CellFunction"}, {"end": 19, "start": 4, "tag": "Finding"}, {"end": 108, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 56, "tag": "BiologicallyActiveSubstance"}]}{"id": "365_2", "text": "Recently, it is gaining more attention in drug discovery as well.", "tags": [{"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 38, "start": 29, "tag": "BiologicFunction"}, {"end": 56, "start": 42, "tag": "ResearchActivity"}, {"end": 56, "start": 47, "tag": "ResearchActivity"}, {"end": 46, "start": 42, "tag": "PharmacologicSubstance"}]}{"id": "365_3", "text": "As life expectancy keeps rising, more individuals are at risk for developing age-associated diseases.", "tags": [{"end": 61, "start": 57, "tag": "Finding"}, {"end": 18, "start": 3, "tag": "TemporalConcept"}, {"end": 80, "start": 77, "tag": "OrganismAttribute"}, {"end": 49, "start": 38, "tag": "PopulationGroup"}, {"end": 7, "start": 3, "tag": "TemporalConcept"}]}{"id": "365_4", "text": "This not only makes a person's life uncomfortable, but it also places an economic burden on society.", "tags": [{"end": 88, "start": 82, "tag": "ResearchActivity"}, {"end": 35, "start": 31, "tag": "TemporalConcept"}, {"end": 99, "start": 92, "tag": "PopulationGroup"}]}{"id": "365_5", "text": "Therefore, finding treatments for age-related diseases is an important issue.", "tags": [{"end": 37, "start": 34, "tag": "OrganismAttribute"}, {"end": 29, "start": 19, "tag": "HealthCareActivity"}, {"end": 29, "start": 19, "tag": "ResearchActivity"}]}{"id": "365_6", "text": "Understanding the basic mechanisms in the cell under normal and disease conditions is fundamental for drug discovery.", "tags": [{"end": 46, "start": 42, "tag": "Cell"}, {"end": 116, "start": 102, "tag": "ResearchActivity"}, {"end": 59, "start": 53, "tag": "Finding"}, {"end": 116, "start": 107, "tag": "ResearchActivity"}, {"end": 106, "start": 102, "tag": "PharmacologicSubstance"}]}{"id": "365_7", "text": "There is an increasing number of reports showing that the ageing process could be influenced by SUMOylation.", "tags": [{"end": 72, "start": 58, "tag": "BiologicFunction"}, {"end": 40, "start": 33, "tag": "HealthCareActivity"}, {"end": 40, "start": 33, "tag": "ResearchActivity"}, {"end": 107, "start": 96, "tag": "CellFunction"}]}{"id": "365_8", "text": "Similarly, SUMOylation is essential for proper neuronal function.", "tags": [{"end": 64, "start": 47, "tag": "CellFunction"}, {"end": 55, "start": 47, "tag": "Cell"}, {"end": 22, "start": 11, "tag": "CellFunction"}]}{"id": "365_9", "text": "In this review we summarize the latest results regarding the connection between SUMOylation and neurodegenerative diseases.", "tags": [{"end": 71, "start": 61, "tag": "Finding"}, {"end": 38, "start": 32, "tag": "TemporalConcept"}, {"end": 91, "start": 80, "tag": "CellFunction"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 122, "start": 96, "tag": "DiseaseOrSyndrome"}]}{"id": "365_10", "text": "We highlight the significance of specific SUMO target proteins and the importance of SUMO isoform specificity.", "tags": [{"end": 29, "start": 17, "tag": "Finding"}, {"end": 46, "start": 42, "tag": "CellFunction"}, {"end": 89, "start": 85, "tag": "CellFunction"}, {"end": 97, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 98, "tag": "Finding"}]}{"id": "365_11", "text": "(c) 2019 S.", "tags": []}{"id": "365_12", "text": "Karger AG, Basel", "tags": []}{"id": "367_0", "text": "Huntingtin-associated protein 1 (HAP1), the first identified HTT-binding partner, is highly expressed in the central nervous system, and has been found to associated with neurological diseases.", "tags": [{"end": 31, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 33, "tag": "GeneOrGenome"}, {"end": 64, "start": 61, "tag": "GeneOrGenome"}, {"end": 64, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 61, "tag": "CellFunction"}, {"end": 101, "start": 92, "tag": "CellFunction"}, {"end": 49, "start": 44, "tag": "TemporalConcept"}, {"end": 131, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 61, "tag": "BiologicallyActiveSubstance"}]}{"id": "367_1", "text": "Mounting evidence suggests that HAP1 functions as a component of cargo-motor molecules to bind various proteins and participates in intracellular trafficking.", "tags": [{"end": 36, "start": 32, "tag": "GeneOrGenome"}, {"end": 94, "start": 90, "tag": "CellFunction"}, {"end": 157, "start": 132, "tag": "CellFunction"}, {"end": 86, "start": 77, "tag": "Substance"}, {"end": 17, "start": 9, "tag": "Finding"}, {"end": 111, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 65, "tag": "CellFunction"}, {"end": 36, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 32, "tag": "BiologicallyActiveSubstance"}]}{"id": "367_2", "text": "It is known that the failure of intracellular transport is a key contributor to the progression of neurodegenerative disorders (NDs) including Alzheimer's disease (AD), Huntington's disease (HD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), spinal and bulbar muscular atrophy (SBMA) and spinocerebellar ataxia (SCA).", "tags": [{"end": 28, "start": 21, "tag": "Finding"}, {"end": 55, "start": 32, "tag": "CellFunction"}, {"end": 293, "start": 259, "tag": "DiseaseOrSyndrome"}, {"end": 299, "start": 295, "tag": "DiseaseOrSyndrome"}, {"end": 327, "start": 305, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 332, "start": 329, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 84, "tag": "PathologicFunction"}, {"end": 95, "start": 84, "tag": "TemporalConcept"}, {"end": 189, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 253, "tag": "DiseaseOrSyndrome"}, {"end": 251, "start": 222, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 21, "tag": "CellOrMolecularDysfunction"}, {"end": 76, "start": 61, "tag": "Finding"}]}{"id": "367_3", "text": "The link between HAP1 and various NDs is supported by growing evidence.", "tags": [{"end": 21, "start": 17, "tag": "GeneOrGenome"}, {"end": 70, "start": 54, "tag": "Finding"}, {"end": 37, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 17, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "367_4", "text": "This review aims to provide a comprehensive overview of the intracellular trafficking function of HAP1 and its involvement in NDs.", "tags": [{"end": 102, "start": 98, "tag": "GeneOrGenome"}, {"end": 52, "start": 44, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 122, "start": 111, "tag": "Finding"}, {"end": 129, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 60, "tag": "CellFunction"}]}{"id": "378_0", "text": "Background: Vitamins are the micronutrients required for boosting the immune system and managing any future infection.", "tags": [{"end": 20, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 101, "tag": "TemporalConcept"}, {"end": 117, "start": 108, "tag": "PathologicFunction"}]}{"id": "378_1", "text": "Vitamins are involved in neurogenesis, a defense mechanism working in neurons, metabolic reactions, neuronal survival, and neuronal transmission.", "tags": [{"end": 8, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 41, "tag": "BiologicFunction"}, {"end": 77, "start": 70, "tag": "Cell"}, {"end": 117, "start": 100, "tag": "CellFunction"}, {"end": 144, "start": 123, "tag": "CellFunction"}, {"end": 37, "start": 25, "tag": "BiologicFunction"}, {"end": 98, "start": 79, "tag": "CellFunction"}]}{"id": "378_2", "text": "Their deficiency leads to abnormal functions in the brain like oxidative stress, mitochondrial dysfunction, accumulation of proteins (synuclein, A beta plaques), neurodegeneration, and excitotoxicity.", "tags": [{"end": 16, "start": 6, "tag": "Finding"}, {"end": 44, "start": 26, "tag": "PathologicFunction"}, {"end": 106, "start": 81, "tag": "CellOrMolecularDysfunction"}, {"end": 132, "start": 108, "tag": "Finding"}, {"end": 143, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 199, "start": 185, "tag": "PathologicFunction"}, {"end": 57, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 162, "tag": "CellOrMolecularDysfunction"}, {"end": 79, "start": 63, "tag": "CellOrMolecularDysfunction"}, {"end": 159, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 145, "tag": "PathologicFunction"}]}{"id": "378_3", "text": "Methods: In this review, we have compiled various reports collected from PubMed, Scholar Google, Research gate, and Science direct.", "tags": [{"end": 57, "start": 50, "tag": "HealthCareActivity"}, {"end": 57, "start": 50, "tag": "ResearchActivity"}, {"end": 110, "start": 97, "tag": "HealthCareRelatedOrganization"}, {"end": 23, "start": 17, "tag": "ResearchActivity"}, {"end": 23, "start": 17, "tag": "HealthCareActivity"}, {"end": 79, "start": 73, "tag": "HealthCareRelatedOrganization"}, {"end": 95, "start": 81, "tag": "HealthCareRelatedOrganization"}, {"end": 130, "start": 116, "tag": "HealthCareRelatedOrganization"}]}{"id": "378_4", "text": "The findings were evaluated, compiled, and represented in this manuscript.", "tags": [{"end": 73, "start": 63, "tag": "ResearchActivity"}]}{"id": "378_5", "text": "Conclusion: The deficiency of vitamins in the body causes various neurological disorders like Alzheimer's disease, Parkinson's disease, Huntington's disease, and depression.", "tags": [{"end": 38, "start": 16, "tag": "Finding"}, {"end": 38, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 136, "tag": "DiseaseOrSyndrome"}]}{"id": "378_6", "text": "We have discussed the role of vitamins in neurological disorders and the normal human body.", "tags": [{"end": 38, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "378_7", "text": "Depression is linked to a deficiency of vitamin-C and vitamin B.", "tags": [{"end": 10, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 26, "tag": "Finding"}, {"end": 49, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 54, "tag": "BiologicallyActiveSubstance"}]}{"id": "378_8", "text": "In the case of Alzheimer's disease, there is a lack of vitamin-B1, B12, and vitamin-A, which results in A beta-plaques.", "tags": [{"end": 34, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 104, "tag": "PathologicFunction"}]}{"id": "378_9", "text": "Similarly, in Parkinson's disease, vitamin-D deficiency leads to a decrease in the level of dopamine, and imbalance in vitamin D leads to accumulation of synuclein.", "tags": [{"end": 33, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 67, "tag": "Finding"}, {"end": 115, "start": 106, "tag": "SignOrSymptom"}, {"end": 115, "start": 106, "tag": "CellOrMolecularDysfunction"}, {"end": 128, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 138, "tag": "PathologicFunction"}, {"end": 163, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 92, "tag": "Chemical"}, {"end": 100, "start": 92, "tag": "PharmacologicSubstance"}, {"end": 100, "start": 92, "tag": "BiologicallyActiveSubstance"}]}{"id": "378_10", "text": "In MS, vitamin-C and vitamin-D deficiency causes demyelination of neurons.", "tags": [{"end": 5, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 7, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 49, "tag": "PathologicFunction"}, {"end": 73, "start": 66, "tag": "Cell"}, {"end": 30, "start": 21, "tag": "BiologicallyActiveSubstance"}]}{"id": "378_11", "text": "In Huntington's disease, vitamin-C deficiency decreases the antioxidant level, enhances oxidative stress, and disrupts the glucose cycle.", "tags": [{"end": 45, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 60, "tag": "CellFunction"}, {"end": 130, "start": 123, "tag": "Chemical"}, {"end": 136, "start": 123, "tag": "CellFunction"}, {"end": 23, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 88, "tag": "CellOrMolecularDysfunction"}, {"end": 130, "start": 123, "tag": "PharmacologicSubstance"}, {"end": 130, "start": 123, "tag": "BiologicallyActiveSubstance"}]}{"id": "378_12", "text": "vitamin B5 deficiency in Huntington's disease disrupts the synthesis of acetylcholine and hormones in the brain.", "tags": [{"end": 21, "start": 0, "tag": "Finding"}, {"end": 85, "start": 59, "tag": "CellFunction"}, {"end": 85, "start": 72, "tag": "Chemical"}, {"end": 85, "start": 72, "tag": "PharmacologicSubstance"}, {"end": 85, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "379_0", "text": "Brain-derived neurotrophic factor (BDNF) is involved in the survival and maturation of neurons, and also promotes and controls neurogenesis.", "tags": [{"end": 33, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 127, "tag": "BiologicFunction"}, {"end": 68, "start": 60, "tag": "CellFunction"}, {"end": 83, "start": 73, "tag": "BiologicFunction"}, {"end": 39, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 87, "tag": "Cell"}, {"end": 126, "start": 118, "tag": "PopulationGroup"}]}{"id": "379_1", "text": "Its levels are lowered in many neurodegenerative diseases, including Huntington's disease (HD).", "tags": [{"end": 22, "start": 15, "tag": "Finding"}, {"end": 57, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}]}{"id": "379_2", "text": "Clinical pictures of HD can be very diverse, which makes it difficult to assess its severity; however, molecular markers may be helpful.", "tags": [{"end": 120, "start": 103, "tag": "ClinicalAttribute"}, {"end": 92, "start": 84, "tag": "ClinicalAttribute"}, {"end": 92, "start": 84, "tag": "Finding"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}]}{"id": "379_3", "text": "The aim of the study was to determine the relationship between HD severity and the plasma BDNF concentration in HD patients.", "tags": [{"end": 74, "start": 66, "tag": "ClinicalAttribute"}, {"end": 74, "start": 66, "tag": "Finding"}, {"end": 54, "start": 42, "tag": "Finding"}, {"end": 94, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 123, "start": 112, "tag": "PatientOrDisabledGroup"}, {"end": 108, "start": 83, "tag": "ClinicalAttribute"}]}{"id": "379_4", "text": "The study recruited 42 patients with diagnosed and genetically confirmed HD and 40 healthy volunteers.", "tags": [{"end": 46, "start": 37, "tag": "HealthCareActivity"}, {"end": 101, "start": 91, "tag": "PopulationGroup"}, {"end": 90, "start": 83, "tag": "OrganismAttribute"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}]}{"id": "379_5", "text": "BDNF levels were determined in plasma with the enzyme-linked immunosorbent assay (ELISA).", "tags": [{"end": 80, "start": 47, "tag": "ResearchActivity"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 82, "tag": "ResearchActivity"}, {"end": 11, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "379_6", "text": "Correlations between BDNF levels and clinical profiles and HD severity were also investigated.", "tags": [{"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 70, "start": 62, "tag": "ClinicalAttribute"}, {"end": 54, "start": 37, "tag": "ResearchActivity"}, {"end": 70, "start": 62, "tag": "Finding"}, {"end": 25, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 21, "tag": "ClinicalAttribute"}]}{"id": "379_7", "text": "The BDNF level was significantly lower in HD patients compared to the control.", "tags": [{"end": 8, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 42, "tag": "PatientOrDisabledGroup"}, {"end": 14, "start": 4, "tag": "BiologicallyActiveSubstance"}]}{"id": "379_8", "text": "There was no correlation between the BDNF level and motor symptoms and cognitive impairment.", "tags": [{"end": 41, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 52, "tag": "SignOrSymptom"}, {"end": 91, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 13, "tag": "ResearchActivity"}, {"end": 47, "start": 37, "tag": "ClinicalAttribute"}]}{"id": "379_9", "text": "In the early disease stages, BDNF levels were associated with a better neurological examination, independence, and functional evaluation, in contrast to later HD stages, where the correlations were inverse.", "tags": [{"end": 27, "start": 13, "tag": "ClinicalAttribute"}, {"end": 95, "start": 71, "tag": "HealthCareActivity"}, {"end": 168, "start": 162, "tag": "TemporalConcept"}, {"end": 136, "start": 126, "tag": "HealthCareActivity"}, {"end": 136, "start": 126, "tag": "ResearchActivity"}, {"end": 33, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 180, "tag": "ResearchActivity"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 97, "tag": "BiologicFunction"}, {"end": 12, "start": 7, "tag": "TemporalConcept"}, {"end": 40, "start": 29, "tag": "ClinicalAttribute"}, {"end": 158, "start": 153, "tag": "TemporalConcept"}]}{"id": "379_10", "text": "Multidirectional correlations between parameters of saccadic disorders and the BDNF level do not allow for drawing a conclusion, whether or not there is a relationship between the severity of saccadic disorders and the BDNF concentration.", "tags": [{"end": 188, "start": 180, "tag": "ClinicalAttribute"}, {"end": 188, "start": 180, "tag": "Finding"}, {"end": 167, "start": 155, "tag": "Finding"}, {"end": 83, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 223, "start": 219, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 223, "start": 219, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 0, "tag": "ResearchActivity"}, {"end": 89, "start": 79, "tag": "ClinicalAttribute"}, {"end": 70, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 237, "start": 219, "tag": "ClinicalAttribute"}]}{"id": "383_0", "text": "Neurodegenerative diseases have shown an increasing incidence in the older population in recent years.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 41, "tag": "Finding"}, {"end": 85, "start": 69, "tag": "PopulationGroup"}, {"end": 101, "start": 89, "tag": "TemporalConcept"}]}{"id": "383_1", "text": "A significant amount of research has been conducted to characterize these diseases.", "tags": [{"end": 32, "start": 24, "tag": "ResearchActivity"}]}{"id": "383_2", "text": "Computational methods, and particularly machine learning techniques, are now very useful tools in helping and improving the diagnosis as well as the disease monitoring process.", "tags": [{"end": 67, "start": 40, "tag": "MachineActivity"}, {"end": 133, "start": 124, "tag": "HealthCareActivity"}, {"end": 175, "start": 149, "tag": "HealthCareActivity"}, {"end": 21, "start": 0, "tag": "ResearchActivity"}, {"end": 56, "start": 40, "tag": "MachineActivity"}]}{"id": "383_3", "text": "In this paper, we provide an in-depth review on existing computational approaches used in the whole neurodegenerative spectrum, namely for Alzheimer's, Parkinson's, and Huntington's Diseases, Amyotrophic Lateral Sclerosis, and Multiple System Atrophy.", "tags": [{"end": 150, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 250, "start": 227, "tag": "PathologicFunction"}, {"end": 81, "start": 57, "tag": "ResearchActivity"}, {"end": 126, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 38, "tag": "ResearchActivity"}, {"end": 44, "start": 38, "tag": "HealthCareActivity"}]}{"id": "383_4", "text": "We propose a taxonomy of the specific clinical features, and of the existing computational methods.", "tags": [{"end": 98, "start": 77, "tag": "ResearchActivity"}, {"end": 55, "start": 38, "tag": "ClinicalAttribute"}]}{"id": "383_5", "text": "We provide a detailed analysis of the various modalities and decision systems employed for each disease.", "tags": [{"end": 30, "start": 22, "tag": "ResearchActivity"}, {"end": 77, "start": 61, "tag": "ResearchActivity"}]}{"id": "383_6", "text": "We identify and present the sleep disorders which are present in various diseases and which represent an important asset for onset detection.", "tags": [{"end": 43, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 125, "tag": "TemporalConcept"}]}{"id": "383_7", "text": "We overview the existing data set resources and evaluation metrics.", "tags": [{"end": 43, "start": 25, "tag": "ResearchActivity"}, {"end": 66, "start": 48, "tag": "ResearchActivity"}]}{"id": "383_8", "text": "Finally, we identify current remaining open challenges and discuss future perspectives.", "tags": [{"end": 54, "start": 44, "tag": "HealthCareActivity"}, {"end": 73, "start": 67, "tag": "TemporalConcept"}, {"end": 28, "start": 21, "tag": "TemporalConcept"}]}{"id": "396_0", "text": "Neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis) commonly characterized by the gradual loss of neurons have a seriously bad impact on motor and cognitive abilities of affected humans and bring great inconvenience to their lives.", "tags": [{"end": 247, "start": 228, "tag": "BiologicFunction"}, {"end": 266, "start": 260, "tag": "Eukaryote"}, {"end": 311, "start": 306, "tag": "Finding"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 179, "tag": "Cell"}, {"end": 186, "start": 171, "tag": "CellOrMolecularDysfunction"}, {"end": 96, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 34, "tag": "DiseaseOrSyndrome"}]}{"id": "396_1", "text": "Mitochondrial dysfunction has been considered the key and common factor for the pathologies of neurodegenerative diseases for that neurons are extremely energy-intensive due to their unique properties in structures and functions.", "tags": [{"end": 91, "start": 80, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 25, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 25, "start": 14, "tag": "PathologicFunction"}, {"end": 138, "start": 131, "tag": "Cell"}, {"end": 121, "start": 95, "tag": "DiseaseOrSyndrome"}]}{"id": "396_2", "text": "Thus, mitophagy, as a central role of mitochondrial quality control and currently believed to be the most effective pathway to clear dysfunctional or unwanted mitochondria, is rather crucial in the preservation of neuronal health.", "tags": [{"end": 146, "start": 133, "tag": "PathologicFunction"}, {"end": 210, "start": 198, "tag": "HealthCareActivity"}, {"end": 67, "start": 52, "tag": "ResearchActivity"}, {"end": 15, "start": 6, "tag": "CellFunction"}, {"end": 171, "start": 159, "tag": "CellComponent"}, {"end": 51, "start": 38, "tag": "CellComponent"}, {"end": 123, "start": 116, "tag": "CellFunction"}, {"end": 81, "start": 72, "tag": "TemporalConcept"}, {"end": 222, "start": 214, "tag": "Cell"}, {"end": 229, "start": 223, "tag": "HealthCareActivity"}, {"end": 67, "start": 38, "tag": "CellFunction"}]}{"id": "396_3", "text": "In addition, mitophagy establishes an intimated link with several other pathways of mitochondrial quality control (e.g., mitochondrial biogenesis and mitochondrial dynamics), and they work together to preserve mitochondrial health.", "tags": [{"end": 113, "start": 84, "tag": "CellFunction"}, {"end": 113, "start": 98, "tag": "ResearchActivity"}, {"end": 22, "start": 13, "tag": "CellFunction"}, {"end": 97, "start": 84, "tag": "CellComponent"}, {"end": 134, "start": 121, "tag": "CellComponent"}, {"end": 163, "start": 150, "tag": "CellComponent"}, {"end": 223, "start": 210, "tag": "CellComponent"}, {"end": 145, "start": 121, "tag": "CellFunction"}, {"end": 145, "start": 135, "tag": "CellFunction"}, {"end": 172, "start": 164, "tag": "NaturalPhenomenonOrProcess"}, {"end": 230, "start": 224, "tag": "HealthCareActivity"}, {"end": 80, "start": 72, "tag": "CellFunction"}, {"end": 172, "start": 150, "tag": "CellFunction"}]}{"id": "396_4", "text": "Therefore, in this review, we summarized the recent process on the mechanisms of mitophagy pathways in mammals, it's linking to mitochondrial quality control, its role in several major neurodegenerative diseases, and possible therapeutic interventions focusing on mitophagy pathways.", "tags": [{"end": 157, "start": 142, "tag": "ResearchActivity"}, {"end": 90, "start": 81, "tag": "CellFunction"}, {"end": 273, "start": 264, "tag": "CellFunction"}, {"end": 141, "start": 128, "tag": "CellComponent"}, {"end": 251, "start": 226, "tag": "HealthCareActivity"}, {"end": 99, "start": 91, "tag": "CellFunction"}, {"end": 282, "start": 274, "tag": "CellFunction"}, {"end": 51, "start": 45, "tag": "TemporalConcept"}, {"end": 211, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 19, "tag": "ResearchActivity"}, {"end": 25, "start": 19, "tag": "HealthCareActivity"}, {"end": 157, "start": 128, "tag": "CellFunction"}, {"end": 110, "start": 103, "tag": "Eukaryote"}]}{"id": "396_5", "text": "And we expect that it can provide us with more understanding of the mitophagy pathways and more promising approaches for the treatment of neurodegenerative diseases.", "tags": [{"end": 60, "start": 47, "tag": "BiologicFunction"}, {"end": 77, "start": 68, "tag": "CellFunction"}, {"end": 86, "start": 78, "tag": "CellFunction"}, {"end": 134, "start": 125, "tag": "HealthCareActivity"}, {"end": 134, "start": 125, "tag": "ResearchActivity"}, {"end": 164, "start": 138, "tag": "DiseaseOrSyndrome"}]}{"id": "401_0", "text": "Neurodegenerative diseases are prominent causes of pain, suffering, and death worldwide.", "tags": [{"end": 55, "start": 51, "tag": "SignOrSymptom"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 72, "tag": "BiologicFunction"}, {"end": 77, "start": 72, "tag": "PathologicFunction"}, {"end": 66, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 72, "tag": "CellFunction"}]}{"id": "401_1", "text": "Traditional approaches modelling neurodegenerative diseases are deficient, and therefore, improved strategies that effectively recapitulate the pathophysiological conditions of neurodegenerative diseases are the need of the hour.", "tags": [{"end": 32, "start": 23, "tag": "ResearchActivity"}, {"end": 228, "start": 224, "tag": "TemporalConcept"}, {"end": 59, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 203, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 144, "tag": "PathologicFunction"}]}{"id": "401_2", "text": "The generation of human-induced pluripotent stem cells (iPSCs) has transformed our ability to model neurodegenerative diseases in vitro and provide an unlimited source of cells (including desired neuronal cell types) for cell replacement therapy.", "tags": [{"end": 176, "start": 171, "tag": "Cell"}, {"end": 126, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 24, "tag": "Cell"}, {"end": 23, "start": 18, "tag": "Eukaryote"}, {"end": 61, "start": 56, "tag": "Cell"}, {"end": 215, "start": 196, "tag": "Cell"}, {"end": 135, "start": 127, "tag": "ResearchActivity"}, {"end": 245, "start": 221, "tag": "HealthCareActivity"}, {"end": 54, "start": 4, "tag": "ResearchActivity"}]}{"id": "401_3", "text": "Recently, CRISPR/Cas9-based genome editing has also been gaining popularity because of the flexibility they provide to generate and ablate disease phenotypes.", "tags": [{"end": 157, "start": 147, "tag": "OrganismAttribute"}, {"end": 21, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 28, "tag": "GeneOrGenome"}, {"end": 21, "start": 10, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 21, "start": 10, "tag": "BiologicFunction"}, {"end": 16, "start": 10, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 16, "start": 10, "tag": "ResearchActivity"}, {"end": 42, "start": 28, "tag": "ResearchActivity"}]}{"id": "401_4", "text": "In addition, the recent advancements in CRISPR/Cas9 technology enables researchers to seamlessly target and introduce precise modifications in the genomic DNA of different human cell lines, including iPSCs.", "tags": [{"end": 158, "start": 147, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 188, "start": 178, "tag": "Cell"}, {"end": 23, "start": 17, "tag": "TemporalConcept"}, {"end": 51, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 40, "tag": "ResearchActivity"}, {"end": 51, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 40, "tag": "HealthCareActivity"}, {"end": 177, "start": 172, "tag": "Eukaryote"}, {"end": 205, "start": 200, "tag": "Cell"}, {"end": 82, "start": 71, "tag": "ResearchActivity"}, {"end": 51, "start": 40, "tag": "ResearchActivity"}, {"end": 51, "start": 40, "tag": "BiologicFunction"}, {"end": 46, "start": 40, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 46, "start": 40, "tag": "ResearchActivity"}]}{"id": "401_5", "text": "CRISPR-iPSC-based disease modelling, therefore, allows scientists to recapitulate the pathological aspects of most neurodegenerative processes and investigate the role of pathological gene variants in healthy non-patient cell lines.", "tags": [{"end": 106, "start": 86, "tag": "PathologicFunction"}, {"end": 197, "start": 171, "tag": "PathologicFunction"}, {"end": 197, "start": 184, "tag": "GeneOrGenome"}, {"end": 231, "start": 221, "tag": "Cell"}, {"end": 35, "start": 0, "tag": "ExperimentalModelOfDisease"}, {"end": 220, "start": 213, "tag": "PatientOrDisabledGroup"}, {"end": 142, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 201, "tag": "OrganismAttribute"}, {"end": 6, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}]}{"id": "401_6", "text": "This review outlines how iPSCs, CRISPR/Cas9, and CRISPR-iPSC-based approaches accelerate research on neurodegenerative diseases and take us closer to a cure for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, and so forth.", "tags": [{"end": 156, "start": 152, "tag": "ResearchActivity"}, {"end": 258, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 236, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 89, "tag": "ResearchActivity"}, {"end": 43, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 25, "tag": "Cell"}, {"end": 289, "start": 260, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 32, "tag": "ResearchActivity"}, {"end": 43, "start": 32, "tag": "BiologicFunction"}, {"end": 38, "start": 32, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 55, "start": 49, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 77, "start": 49, "tag": "ResearchActivity"}, {"end": 60, "start": 56, "tag": "Cell"}]}{"id": "411_0", "text": "Objectives To evaluate the retinal and choriocapillaris vascular networks in macular region and the central choroidal thickness (CCT) in patients affected by Huntington disease (HD), using optical coherence tomography angiography (OCTA) and enhanced depth imaging spectral-domain OCT (EDI SD-OCT).", "tags": [{"end": 229, "start": 189, "tag": "HealthCareActivity"}, {"end": 176, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 235, "start": 231, "tag": "HealthCareActivity"}, {"end": 295, "start": 285, "tag": "HealthCareActivity"}, {"end": 73, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 263, "start": 256, "tag": "HealthCareActivity"}, {"end": 217, "start": 189, "tag": "HealthCareActivity"}, {"end": 283, "start": 241, "tag": "HealthCareActivity"}, {"end": 73, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 137, "tag": "PatientOrDisabledGroup"}, {"end": 180, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 100, "tag": "ClinicalAttribute"}, {"end": 132, "start": 129, "tag": "ClinicalAttribute"}]}{"id": "411_1", "text": "Methods We assessed the vessel density (VD) in superficial capillary plexus (SCP), deep capillary plexus (DCP), and choriocapillaris (CC) using OCTA, while CCT was measured by EDI SD-OCT.", "tags": [{"end": 136, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 144, "tag": "HealthCareActivity"}, {"end": 186, "start": 176, "tag": "HealthCareActivity"}, {"end": 132, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 24, "tag": "HealthCareActivity"}, {"end": 42, "start": 40, "tag": "HealthCareActivity"}, {"end": 75, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 164, "tag": "HealthCareActivity"}, {"end": 80, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 156, "tag": "ClinicalAttribute"}, {"end": 38, "start": 24, "tag": "ClinicalAttribute"}, {"end": 42, "start": 40, "tag": "ClinicalAttribute"}]}{"id": "411_2", "text": "Results Sixteen HD patients (32 eyes) and thirteen healthy controls (26 eyes) were enrolled in this prospective study.", "tags": [{"end": 36, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 100, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 111, "start": 100, "tag": "BiologicFunction"}, {"end": 58, "start": 51, "tag": "OrganismAttribute"}, {"end": 67, "start": 51, "tag": "PopulationGroup"}, {"end": 27, "start": 16, "tag": "PatientOrDisabledGroup"}]}{"id": "411_3", "text": "No significant difference in retinal and choriocapillaris VD was found between HD patients and controls while CCT turned to be thinner in patients respect to controls.", "tags": [{"end": 57, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 58, "tag": "HealthCareActivity"}, {"end": 36, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 138, "tag": "PatientOrDisabledGroup"}, {"end": 103, "start": 95, "tag": "PopulationGroup"}, {"end": 166, "start": 158, "tag": "PopulationGroup"}, {"end": 90, "start": 79, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 0, "tag": "Finding"}, {"end": 60, "start": 58, "tag": "ClinicalAttribute"}, {"end": 36, "start": 29, "tag": "ClinicalAttribute"}, {"end": 60, "start": 41, "tag": "ClinicalAttribute"}, {"end": 113, "start": 110, "tag": "ClinicalAttribute"}]}{"id": "411_4", "text": "There were no significant relationships between OCTA findings and neurological parameters.", "tags": [{"end": 52, "start": 48, "tag": "HealthCareActivity"}, {"end": 39, "start": 14, "tag": "Finding"}, {"end": 89, "start": 66, "tag": "ClinicalAttribute"}]}{"id": "411_5", "text": "Conclusion The changes in choroidal structure provide useful information regarding the possible neurovascular involvement in the physiopathology of HD.", "tags": [{"end": 45, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 129, "tag": "PathologicFunction"}, {"end": 121, "start": 110, "tag": "Finding"}, {"end": 150, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 15, "tag": "Finding"}]}{"id": "411_6", "text": "Choroidal vascular network could be a useful parameter to evaluate the vascular impairment that occurs in this neurodegenerative disease.", "tags": [{"end": 79, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 71, "tag": "PathologicFunction"}]}{"id": "435_0", "text": "Background: Huntington's disease (HD) has been shown to reduce health-related quality of life (HRQoL) and affect health-care resource utilization (HRU) among patients and care partners internationally but has not been studied specifically in the Canadian context.", "tags": [{"end": 62, "start": 56, "tag": "Finding"}, {"end": 184, "start": 176, "tag": "PopulationGroup"}, {"end": 254, "start": 246, "tag": "PopulationGroup"}, {"end": 254, "start": 246, "tag": "Chemical"}, {"end": 124, "start": 120, "tag": "HealthCareActivity"}, {"end": 175, "start": 171, "tag": "HealthCareActivity"}, {"end": 93, "start": 63, "tag": "Finding"}, {"end": 69, "start": 63, "tag": "HealthCareActivity"}, {"end": 119, "start": 113, "tag": "HealthCareActivity"}, {"end": 93, "start": 89, "tag": "TemporalConcept"}, {"end": 166, "start": 158, "tag": "PatientOrDisabledGroup"}, {"end": 32, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 95, "tag": "Finding"}]}{"id": "435_1", "text": "Objective: To characterize the burden of HD on individuals with HD and care partners of individuals with HD in Canada.", "tags": [{"end": 84, "start": 76, "tag": "PopulationGroup"}, {"end": 66, "start": 47, "tag": "PatientOrDisabledGroup"}, {"end": 107, "start": 88, "tag": "PatientOrDisabledGroup"}, {"end": 75, "start": 71, "tag": "HealthCareActivity"}, {"end": 58, "start": 47, "tag": "PopulationGroup"}, {"end": 99, "start": 88, "tag": "PopulationGroup"}, {"end": 37, "start": 31, "tag": "ResearchActivity"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}]}{"id": "435_2", "text": "Methods: An online survey was distributed (September 14-November 23, 2020) through patient organizations to collect data on demographic and clinical characteristics, as well as: HRQoL, measured using the 36-Item Short-Form Health Survey (SF-36v1); HRU, measured using the Client Service Receipt Inventory (CSRI); and care partner burden, measured using the Caregiver Strain Index (CSI) and Huntington's Disease Quality of Life Battery for Carers (HDQoL-C).", "tags": [{"end": 135, "start": 124, "tag": "ResearchActivity"}, {"end": 164, "start": 140, "tag": "ClinicalAttribute"}, {"end": 329, "start": 322, "tag": "PopulationGroup"}, {"end": 366, "start": 357, "tag": "HealthCareActivity"}, {"end": 321, "start": 317, "tag": "HealthCareActivity"}, {"end": 346, "start": 338, "tag": "HealthCareActivity"}, {"end": 410, "start": 390, "tag": "DiseaseOrSyndrome"}, {"end": 336, "start": 330, "tag": "ResearchActivity"}, {"end": 120, "start": 116, "tag": "ResearchActivity"}, {"end": 90, "start": 83, "tag": "PatientOrDisabledGroup"}, {"end": 236, "start": 204, "tag": "HealthCareActivity"}, {"end": 245, "start": 238, "tag": "HealthCareActivity"}, {"end": 304, "start": 272, "tag": "HealthCareActivity"}, {"end": 310, "start": 306, "tag": "HealthCareActivity"}, {"end": 379, "start": 357, "tag": "HealthCareActivity"}, {"end": 445, "start": 390, "tag": "HealthCareActivity"}, {"end": 454, "start": 447, "tag": "HealthCareActivity"}, {"end": 25, "start": 12, "tag": "HealthCareActivity"}, {"end": 104, "start": 83, "tag": "HealthCareRelatedOrganization"}, {"end": 183, "start": 178, "tag": "Finding"}, {"end": 384, "start": 381, "tag": "HealthCareActivity"}]}{"id": "435_3", "text": "Descriptive statistics were used to report data and compare subgroups.", "tags": [{"end": 42, "start": 36, "tag": "HealthCareActivity"}, {"end": 42, "start": 36, "tag": "ResearchActivity"}, {"end": 47, "start": 43, "tag": "ResearchActivity"}, {"end": 22, "start": 0, "tag": "ResearchActivity"}]}{"id": "435_4", "text": "Results: A total of 62 adult individuals with HD (or their proxies) and 48 care partners met defined eligibility criteria.", "tags": [{"end": 88, "start": 80, "tag": "PopulationGroup"}, {"end": 121, "start": 101, "tag": "ResearchActivity"}, {"end": 79, "start": 75, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 40, "start": 29, "tag": "PopulationGroup"}, {"end": 28, "start": 23, "tag": "PopulationGroup"}, {"end": 48, "start": 46, "tag": "DiseaseOrSyndrome"}]}{"id": "435_5", "text": "The mean [standard deviation] age was 51.2 [13.8] and 58.1 [13.9] years for individuals with HD and care partner respondents, respectively.", "tags": [{"end": 124, "start": 113, "tag": "PopulationGroup"}, {"end": 104, "start": 100, "tag": "HealthCareActivity"}, {"end": 87, "start": 76, "tag": "PopulationGroup"}, {"end": 33, "start": 30, "tag": "OrganismAttribute"}, {"end": 71, "start": 66, "tag": "TemporalConcept"}, {"end": 95, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 105, "tag": "PopulationGroup"}]}{"id": "435_6", "text": "For individuals with HD, the greatest HRQoL burden (i.e., lowest score) was for the SF-36v1 Role - Physical scale (46.8 [42.9]).", "tags": [{"end": 113, "start": 99, "tag": "HealthCareActivity"}, {"end": 113, "start": 99, "tag": "ManufacturedObject"}, {"end": 15, "start": 4, "tag": "PopulationGroup"}, {"end": 50, "start": 44, "tag": "ResearchActivity"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 38, "tag": "Finding"}, {"end": 91, "start": 84, "tag": "HealthCareActivity"}]}{"id": "435_7", "text": "HRU was higher for some services (e.g., general practitioner visits) for respondents who had experienced motor onset transition.", "tags": [{"end": 32, "start": 24, "tag": "HealthCareActivity"}, {"end": 84, "start": 73, "tag": "PopulationGroup"}, {"end": 116, "start": 111, "tag": "TemporalConcept"}, {"end": 60, "start": 40, "tag": "HealthCareActivity"}]}{"id": "435_8", "text": "Among care partners, 55.3% experienced high strain, as indicated by the CSI.", "tags": [{"end": 19, "start": 11, "tag": "PopulationGroup"}, {"end": 10, "start": 6, "tag": "HealthCareActivity"}, {"end": 75, "start": 72, "tag": "HealthCareActivity"}]}{"id": "435_9", "text": "The HDQoL-C showed the greatest HRQoL burden in feelings about life (45.1 [17.9]).", "tags": [{"end": 56, "start": 48, "tag": "BiologicFunction"}, {"end": 44, "start": 38, "tag": "ResearchActivity"}, {"end": 67, "start": 63, "tag": "TemporalConcept"}, {"end": 11, "start": 4, "tag": "HealthCareActivity"}, {"end": 37, "start": 32, "tag": "Finding"}]}{"id": "435_10", "text": "Conclusion: This study quantified the substantial burden on individuals with HD and care partners in Canada, addressing a critical knowledge gap that can affect the availability of and access to healthcare services.", "tags": [{"end": 97, "start": 89, "tag": "PopulationGroup"}, {"end": 214, "start": 195, "tag": "HealthCareRelatedOrganization"}, {"end": 214, "start": 195, "tag": "HealthCareActivity"}, {"end": 88, "start": 84, "tag": "HealthCareActivity"}, {"end": 71, "start": 60, "tag": "PopulationGroup"}, {"end": 140, "start": 131, "tag": "Finding"}, {"end": 56, "start": 50, "tag": "ResearchActivity"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}]}{"id": "436_0", "text": "Background Huntington's disease (HD) is a rare neurodegenerative disorder with protean clinical manifestations.", "tags": [{"end": 73, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 42, "tag": "TemporalConcept"}]}{"id": "436_1", "text": "Its management is challenging, consisting mainly of off-label treatments.", "tags": [{"end": 14, "start": 4, "tag": "HealthCareActivity"}, {"end": 72, "start": 52, "tag": "HealthCareActivity"}]}{"id": "436_2", "text": "Objectives The International Parkinson and Movement Disorder Society commissioned a task force to review and evaluate the evidence of available therapies for HD gene expansion carriers.", "tags": [{"end": 153, "start": 144, "tag": "HealthCareActivity"}, {"end": 130, "start": 122, "tag": "Finding"}, {"end": 104, "start": 98, "tag": "ResearchActivity"}, {"end": 104, "start": 98, "tag": "HealthCareActivity"}, {"end": 68, "start": 11, "tag": "HealthCareRelatedOrganization"}, {"end": 184, "start": 158, "tag": "PatientOrDisabledGroup"}]}{"id": "436_3", "text": "Methods We followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.", "tags": [{"end": 106, "start": 24, "tag": "HealthCareActivity"}]}{"id": "436_4", "text": "Eligible randomized controlled trials were identified via an electronic search of the CENTRAL, MEDLINE, and EMBASE databases.", "tags": [{"end": 37, "start": 9, "tag": "ResearchActivity"}, {"end": 78, "start": 61, "tag": "ResearchActivity"}, {"end": 93, "start": 86, "tag": "HealthCareRelatedOrganization"}, {"end": 102, "start": 95, "tag": "HealthCareRelatedOrganization"}, {"end": 124, "start": 115, "tag": "ResearchActivity"}, {"end": 114, "start": 108, "tag": "HealthCareRelatedOrganization"}]}{"id": "436_5", "text": "All eligible trials that evaluated one or more of 33 predetermined clinical questions were included.", "tags": [{"end": 85, "start": 67, "tag": "ResearchActivity"}]}{"id": "436_6", "text": "Risk of bias was evaluated using the Cochrane Risk of Bias tool.", "tags": [{"end": 12, "start": 0, "tag": "Finding"}, {"end": 63, "start": 37, "tag": "ResearchActivity"}]}{"id": "436_7", "text": "A framework was adapted to allow for efficacy and safety conclusions to be drawn from the balance between the GRADE level of evidence and the importance of the benefit/harm of the intervention.", "tags": [{"end": 133, "start": 110, "tag": "ResearchActivity"}, {"end": 192, "start": 160, "tag": "HealthCareActivity"}]}{"id": "436_8", "text": "Results Twenty-two eligible studies involving 17 interventions were included, providing data to address 8 clinical questions.", "tags": [{"end": 62, "start": 49, "tag": "ResearchActivity"}, {"end": 92, "start": 88, "tag": "ResearchActivity"}, {"end": 35, "start": 28, "tag": "ResearchActivity"}, {"end": 124, "start": 106, "tag": "ResearchActivity"}]}{"id": "436_9", "text": "These data supported a likely effect of deutetrabenazine on motor impairment, chorea, and dystonia and of tetrabenazine on chorea.", "tags": [{"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 76, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 90, "tag": "SignOrSymptom"}, {"end": 98, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 78, "tag": "SignOrSymptom"}, {"end": 129, "start": 123, "tag": "SignOrSymptom"}, {"end": 119, "start": 106, "tag": "PharmacologicSubstance"}, {"end": 119, "start": 106, "tag": "Chemical"}, {"end": 56, "start": 40, "tag": "PharmacologicSubstance"}, {"end": 56, "start": 40, "tag": "Chemical"}]}{"id": "436_10", "text": "The data did not support a disease-modifying effect for premanifest and manifest HD.", "tags": [{"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 27, "tag": "Finding"}]}{"id": "436_11", "text": "There was no eligible evidence to support the use of specific treatments for depression, psychosis, irritability, apathy, or suicidality.", "tags": [{"end": 72, "start": 62, "tag": "HealthCareActivity"}, {"end": 72, "start": 62, "tag": "ResearchActivity"}, {"end": 87, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 100, "tag": "SignOrSymptom"}, {"end": 120, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 22, "tag": "Finding"}, {"end": 136, "start": 125, "tag": "DiseaseOrSyndrome"}]}{"id": "436_12", "text": "Similarly, no evidence was eligible to support the use of physiotherapy, occupational therapy, exercise, dietary, or surgical treatments.", "tags": [{"end": 71, "start": 58, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 71, "start": 58, "tag": "HealthCareActivity"}, {"end": 93, "start": 73, "tag": "HealthCareActivity"}, {"end": 103, "start": 95, "tag": "HealthCareActivity"}, {"end": 136, "start": 117, "tag": "HealthCareActivity"}, {"end": 22, "start": 14, "tag": "Finding"}]}{"id": "436_13", "text": "Conclusions Data for therapeutic interventions in HD are limited and support only the use of VMAT2 inhibitors for specific motor symptoms.", "tags": [{"end": 16, "start": 12, "tag": "ResearchActivity"}, {"end": 46, "start": 21, "tag": "HealthCareActivity"}, {"end": 98, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 93, "tag": "PharmacologicSubstance"}, {"end": 52, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 123, "tag": "SignOrSymptom"}, {"end": 98, "start": 93, "tag": "BiologicallyActiveSubstance"}]}{"id": "436_14", "text": "(c) 2021 International Parkinson and Movement Disorder Society", "tags": [{"end": 62, "start": 9, "tag": "HealthCareRelatedOrganization"}]}{"id": "437_0", "text": "Neurotrophins, such as brain-derived neurotrophic factor (BDNF), are essential for neuronal survival and growth.", "tags": [{"end": 13, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 83, "tag": "CellFunction"}, {"end": 111, "start": 105, "tag": "BiologicFunction"}]}{"id": "437_1", "text": "The signaling cascades initiated by BDNF and its receptor are the key regulators of synaptic plasticity, which plays important role in learning and memory formation.", "tags": [{"end": 22, "start": 4, "tag": "CellFunction"}, {"end": 40, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 135, "tag": "BiologicFunction"}, {"end": 103, "start": 84, "tag": "CellFunction"}, {"end": 103, "start": 84, "tag": "BiologicFunction"}]}{"id": "437_2", "text": "Changes in BDNF levels and signaling pathways have been identified in several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, and have been linked with the symptoms and course of these diseases.", "tags": [{"end": 7, "start": 0, "tag": "Finding"}, {"end": 15, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 27, "tag": "CellFunction"}, {"end": 135, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 222, "start": 214, "tag": "SignOrSymptom"}, {"end": 233, "start": 227, "tag": "TemporalConcept"}, {"end": 182, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 78, "tag": "DiseaseOrSyndrome"}]}{"id": "437_3", "text": "This review summarizes the current understanding of the role of BDNF in several neurodegenerative diseases, as well as the underlying molecular mechanism.", "tags": [{"end": 68, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 27, "tag": "TemporalConcept"}, {"end": 106, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 153, "start": 134, "tag": "CellFunction"}]}{"id": "437_4", "text": "The therapeutic potential of BDNF treatment is also discussed, in the hope of discovering new avenues for the treatment of neurodegenerative diseases.", "tags": [{"end": 33, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 34, "tag": "HealthCareActivity"}, {"end": 119, "start": 110, "tag": "HealthCareActivity"}, {"end": 43, "start": 34, "tag": "ResearchActivity"}, {"end": 119, "start": 110, "tag": "ResearchActivity"}, {"end": 74, "start": 70, "tag": "BiologicFunction"}]}{"id": "438_0", "text": "Retinal alterations have recently been associated with numerous neurodegenerative diseases.", "tags": [{"end": 90, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "CellOrMolecularDysfunction"}]}{"id": "438_1", "text": "Rhodopsin is a G-protein coupled receptor found in the rod cells of the retina.", "tags": [{"end": 9, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 55, "tag": "Cell"}, {"end": 78, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "438_2", "text": "As a biomarker associated with retinal thinning and degeneration, it bears potential in the early detection and monitoring of several neurodegenerative diseases.", "tags": [{"end": 47, "start": 31, "tag": "Finding"}, {"end": 107, "start": 92, "tag": "HealthCareActivity"}, {"end": 14, "start": 5, "tag": "ClinicalAttribute"}, {"end": 122, "start": 112, "tag": "HealthCareActivity"}, {"end": 160, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 52, "tag": "CellOrMolecularDysfunction"}, {"end": 38, "start": 31, "tag": "CellOrMolecularDysfunction"}]}{"id": "438_3", "text": "In this review article, we summarize the findings of correlations between rhodopsin and several neurodegenerative disorders as well as the potential of a novel technique, cSLO, in the quantification of rhodopsin.", "tags": [{"end": 65, "start": 53, "tag": "ResearchActivity"}, {"end": 83, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 160, "tag": "ResearchActivity"}, {"end": 211, "start": 202, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 202, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 8, "tag": "ResearchActivity"}]}{"id": "444_0", "text": "Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis, are a group of incurable neurological disorders, characterized by the chronic progressive loss of different neuronal subtypes.", "tags": [{"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 206, "tag": "PathologicFunction"}, {"end": 261, "start": 244, "tag": "Cell"}, {"end": 100, "start": 80, "tag": "DiseaseOrSyndrome"}]}{"id": "444_1", "text": "However, despite its increasing prevalence among the ever-increasing aging population, little progress has been made in the coincident immense efforts towards development of therapeutic agents.", "tags": [{"end": 42, "start": 21, "tag": "Finding"}, {"end": 74, "start": 69, "tag": "BiologicFunction"}, {"end": 74, "start": 69, "tag": "CellFunction"}, {"end": 134, "start": 124, "tag": "TemporalConcept"}, {"end": 192, "start": 174, "tag": "HealthCareActivity"}, {"end": 102, "start": 94, "tag": "TemporalConcept"}, {"end": 85, "start": 75, "tag": "PopulationGroup"}]}{"id": "444_2", "text": "Research interest has recently turned towards stem cells including stem cells-derived exosomes, neurotrophic factors, and their combination as potential therapeutic agents in neurodegenerative diseases.", "tags": [{"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 56, "start": 46, "tag": "Cell"}, {"end": 94, "start": 67, "tag": "CellComponent"}, {"end": 116, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 153, "tag": "HealthCareActivity"}, {"end": 201, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 67, "tag": "Cell"}]}{"id": "444_3", "text": "In this review, we summarize the progress in therapeutic strategies based on stem cells combined with neurotrophic factors and mesenchymal stem cells-derived exosomes for neurodegenerative diseases, with an emphasis on the combination therapy.", "tags": [{"end": 87, "start": 77, "tag": "Cell"}, {"end": 87, "start": 77, "tag": "ResearchActivity"}, {"end": 122, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 102, "tag": "GeneOrGenome"}, {"end": 122, "start": 102, "tag": "CellFunction"}, {"end": 166, "start": 158, "tag": "CellComponent"}, {"end": 242, "start": 223, "tag": "HealthCareActivity"}, {"end": 197, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 33, "tag": "TemporalConcept"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "453_0", "text": "Aberrant accumulation of misfolded proteins into amyloid deposits is a hallmark in many age-related neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).", "tags": [{"end": 43, "start": 0, "tag": "PathologicFunction"}, {"end": 65, "start": 49, "tag": "AnatomicalAbnormality"}, {"end": 126, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 71, "tag": "Finding"}, {"end": 43, "start": 25, "tag": "CellOrMolecularDysfunction"}, {"end": 34, "start": 25, "tag": "CellOrMolecularDysfunction"}, {"end": 21, "start": 9, "tag": "Finding"}, {"end": 56, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 212, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 255, "start": 252, "tag": "DiseaseOrSyndrome"}, {"end": 250, "start": 221, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 88, "tag": "OrganismAttribute"}]}{"id": "453_1", "text": "Pathological inclusions and the associated toxicity appear to spread through the nervous system in a characteristic pattern during the disease.", "tags": [{"end": 23, "start": 0, "tag": "PathologicFunction"}, {"end": 51, "start": 43, "tag": "InjuryOrPoisoning"}, {"end": 95, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "453_2", "text": "This has been attributed to a prion-like behavior of amyloid-type aggregates, which involves self-replication of the pathological conformation, intercellular transfer, and the subsequent seeding of native forms of the same protein in the neighboring cell.", "tags": [{"end": 49, "start": 41, "tag": "BiologicFunction"}, {"end": 49, "start": 41, "tag": "IndividualBehavior"}, {"end": 49, "start": 41, "tag": "ResearchActivity"}, {"end": 35, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 254, "start": 250, "tag": "Cell"}, {"end": 76, "start": 53, "tag": "CellOrMolecularDysfunction"}, {"end": 210, "start": 187, "tag": "CellFunction"}, {"end": 166, "start": 144, "tag": "CellFunction"}, {"end": 142, "start": 93, "tag": "CellOrMolecularDysfunction"}]}{"id": "453_3", "text": "Molecular chaperones play a major role in maintaining cellular proteostasis by assisting the (re)-folding of cellular proteins to ensure their function or by promoting the degradation of terminally misfolded proteins to prevent damage.", "tags": [{"end": 20, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 63, "tag": "CellFunction"}, {"end": 20, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 216, "start": 198, "tag": "CellOrMolecularDysfunction"}, {"end": 183, "start": 172, "tag": "NaturalPhenomenonOrProcess"}, {"end": 126, "start": 93, "tag": "CellFunction"}, {"end": 126, "start": 98, "tag": "CellFunction"}, {"end": 234, "start": 228, "tag": "InjuryOrPoisoning"}]}{"id": "453_4", "text": "With increasing age, however, the capacity of this proteostasis network tends to decrease, which enables the manifestation of neurodegenerative diseases.", "tags": [{"end": 122, "start": 109, "tag": "Finding"}, {"end": 63, "start": 51, "tag": "CellFunction"}, {"end": 15, "start": 5, "tag": "Finding"}, {"end": 19, "start": 16, "tag": "OrganismAttribute"}, {"end": 152, "start": 126, "tag": "DiseaseOrSyndrome"}]}{"id": "453_5", "text": "Recently, there has been a plethora of studies investigating how and when chaperones interact with disease-related proteins, which have advanced our understanding of the role of chaperones in protein misfolding diseases.", "tags": [{"end": 219, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 200, "tag": "CellOrMolecularDysfunction"}, {"end": 162, "start": 149, "tag": "BiologicFunction"}, {"end": 210, "start": 192, "tag": "CellOrMolecularDysfunction"}, {"end": 84, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 188, "start": 178, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 39, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}]}{"id": "453_6", "text": "This review article focuses on the steps of prion-like propagation from initial misfolding and self-templated replication to intercellular spreading and discusses the influence that chaperones have on these various steps, highlighting both the positive and adverse consequences chaperone action can have.", "tags": [{"end": 121, "start": 110, "tag": "CellFunction"}, {"end": 148, "start": 125, "tag": "CellFunction"}, {"end": 287, "start": 278, "tag": "AminoAcidPeptideOrProtein"}, {"end": 287, "start": 278, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 80, "tag": "CellOrMolecularDysfunction"}, {"end": 49, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 182, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 5, "tag": "ResearchActivity"}, {"end": 79, "start": 72, "tag": "TemporalConcept"}, {"end": 277, "start": 265, "tag": "Finding"}, {"end": 252, "start": 244, "tag": "Finding"}, {"end": 277, "start": 257, "tag": "Finding"}]}{"id": "453_7", "text": "Understanding how chaperones alleviate and aggravate disease progression is vital for the development of therapeutic strategies to combat these debilitating diseases.", "tags": [{"end": 127, "start": 105, "tag": "HealthCareActivity"}, {"end": 28, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 53, "tag": "PathologicFunction"}, {"end": 101, "start": 90, "tag": "BiologicFunction"}, {"end": 101, "start": 90, "tag": "CellFunction"}, {"end": 72, "start": 61, "tag": "PathologicFunction"}, {"end": 72, "start": 61, "tag": "TemporalConcept"}, {"end": 165, "start": 144, "tag": "DiseaseOrSyndrome"}]}{"id": "459_0", "text": "Neurodegenerative diseases comprise a group of disorders characterized by progressive loss of neurons over a period of time due to various factors such as oxidative stress, inflammation, accumulation of toxic proteins, excitotoxicity, and metal overexposure.", "tags": [{"end": 257, "start": 245, "tag": "Finding"}, {"end": 115, "start": 109, "tag": "TemporalConcept"}, {"end": 233, "start": 219, "tag": "PathologicFunction"}, {"end": 244, "start": 239, "tag": "Chemical"}, {"end": 199, "start": 187, "tag": "Finding"}, {"end": 43, "start": 38, "tag": "PopulationGroup"}, {"end": 185, "start": 173, "tag": "PathologicFunction"}, {"end": 217, "start": 209, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 74, "tag": "TemporalConcept"}, {"end": 101, "start": 94, "tag": "Cell"}, {"end": 171, "start": 155, "tag": "CellOrMolecularDysfunction"}, {"end": 101, "start": 86, "tag": "CellOrMolecularDysfunction"}, {"end": 123, "start": 119, "tag": "TemporalConcept"}, {"end": 208, "start": 203, "tag": "InjuryOrPoisoning"}]}{"id": "459_1", "text": "Among those, chronic exposure to manganese (Mn) is known to initiate neurodegeneration resembling extrapyramidal effects like Parkinson's disease (PD).", "tags": [{"end": 46, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 44, "tag": "Chemical"}, {"end": 120, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 33, "tag": "Chemical"}, {"end": 42, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 13, "tag": "TemporalConcept"}, {"end": 86, "start": 69, "tag": "CellOrMolecularDysfunction"}, {"end": 145, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 21, "tag": "InjuryOrPoisoning"}]}{"id": "459_2", "text": "Mn overexposure leads to mitochondrial dysfunction by inhibiting the complexes of electron transport chains (ETC), thus generating oxidative stress (OS).", "tags": [{"end": 2, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 2, "start": 0, "tag": "Chemical"}, {"end": 15, "start": 3, "tag": "Finding"}, {"end": 107, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 54, "tag": "BiologicFunction"}, {"end": 50, "start": 25, "tag": "CellOrMolecularDysfunction"}, {"end": 151, "start": 149, "tag": "CellOrMolecularDysfunction"}, {"end": 147, "start": 131, "tag": "CellOrMolecularDysfunction"}]}{"id": "459_3", "text": "It also alter calcium homeostasis, dysregulate enzyme activity, and an imbalance in neu-rotransmitters level like dopamine, serotonin etc.", "tags": [{"end": 21, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 21, "start": 14, "tag": "Chemical"}, {"end": 62, "start": 47, "tag": "CellFunction"}, {"end": 133, "start": 124, "tag": "Chemical"}, {"end": 133, "start": 124, "tag": "CellFunction"}, {"end": 133, "start": 124, "tag": "PharmacologicSubstance"}, {"end": 122, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 114, "tag": "Chemical"}, {"end": 122, "start": 114, "tag": "PharmacologicSubstance"}, {"end": 108, "start": 71, "tag": "CellOrMolecularDysfunction"}, {"end": 33, "start": 22, "tag": "BiologicFunction"}, {"end": 21, "start": 14, "tag": "BiologicallyActiveSubstance"}]}{"id": "459_4", "text": "Mn in excess convert the monomer form of alpha-synuclein into oligomers that are toxic to neurons.", "tags": [{"end": 2, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 2, "start": 0, "tag": "Chemical"}, {"end": 32, "start": 25, "tag": "Chemical"}, {"end": 71, "start": 62, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 86, "start": 81, "tag": "InjuryOrPoisoning"}, {"end": 56, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 90, "tag": "Cell"}, {"end": 71, "start": 62, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "459_5", "text": "Furthermore, it increases the exocytosis of misfolded alpha-synuclein, which activates microglia, chemokines, and proinflammatory cytokines.", "tags": [{"end": 40, "start": 30, "tag": "CellFunction"}, {"end": 69, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 44, "tag": "CellOrMolecularDysfunction"}, {"end": 108, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 87, "tag": "Cell"}]}{"id": "459_6", "text": "Despite the critical research and investment, no preventive or disease-modifying treatment has been found because of diverse pathological factors.", "tags": [{"end": 44, "start": 34, "tag": "CellComponent"}, {"end": 59, "start": 49, "tag": "HealthCareActivity"}, {"end": 90, "start": 81, "tag": "HealthCareActivity"}, {"end": 90, "start": 63, "tag": "HealthCareActivity"}, {"end": 29, "start": 21, "tag": "ResearchActivity"}]}{"id": "459_7", "text": "This review focuses on the pathological involvement of Mn and its mechanistic similarities with various neurodegenerative diseases.", "tags": [{"end": 57, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 55, "tag": "Chemical"}, {"end": 51, "start": 40, "tag": "Finding"}, {"end": 130, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}]}{"id": "459_8", "text": "Further, the source of Mn exposure, various transporters, and its kinetics inside the human body is compiled.", "tags": [{"end": 25, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 23, "tag": "Chemical"}, {"end": 34, "start": 23, "tag": "InjuryOrPoisoning"}, {"end": 74, "start": 66, "tag": "NaturalPhenomenonOrProcess"}, {"end": 96, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 86, "tag": "Eukaryote"}]}{"id": "459_9", "text": "The relationship between Mn overexposure and pathogenesis of PD, Huntington's disease (HD), and Alzheimer's disease (AD) has been discussed.", "tags": [{"end": 27, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 25, "tag": "Chemical"}, {"end": 40, "start": 28, "tag": "Finding"}, {"end": 16, "start": 4, "tag": "Finding"}, {"end": 57, "start": 45, "tag": "PathologicFunction"}, {"end": 119, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 96, "tag": "DiseaseOrSyndrome"}]}{"id": "459_10", "text": "Over and above that, the emerging treatment approaches for Mn toxicity utilizing bioinformatics tools, chelation therapy with calcium ethylenediamine tetra-acetic acid (Ca2+EDTA), para-aminosalicylic acid (PAS), and phytochemicals like flavonoids that are known to rescue neurons from oxidative stress and inflammation are enveloped in the compilation.", "tags": [{"end": 61, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 59, "tag": "Chemical"}, {"end": 120, "start": 103, "tag": "HealthCareActivity"}, {"end": 167, "start": 126, "tag": "Chemical"}, {"end": 204, "start": 180, "tag": "Chemical"}, {"end": 209, "start": 206, "tag": "Chemical"}, {"end": 230, "start": 216, "tag": "Chemical"}, {"end": 246, "start": 236, "tag": "Chemical"}, {"end": 70, "start": 62, "tag": "InjuryOrPoisoning"}, {"end": 318, "start": 306, "tag": "PathologicFunction"}, {"end": 43, "start": 34, "tag": "HealthCareActivity"}, {"end": 43, "start": 34, "tag": "ResearchActivity"}, {"end": 279, "start": 272, "tag": "Cell"}, {"end": 301, "start": 285, "tag": "CellOrMolecularDysfunction"}, {"end": 101, "start": 81, "tag": "ResearchActivity"}, {"end": 177, "start": 169, "tag": "Chemical"}]}{"id": "468_0", "text": "Background Spectral-domain optical coherence tomography (OCT) may detect retinal changes as a biomarker in neurodegenerative diseases like manifest Huntington's disease (HD).", "tags": [{"end": 55, "start": 11, "tag": "HealthCareActivity"}, {"end": 55, "start": 27, "tag": "HealthCareActivity"}, {"end": 60, "start": 57, "tag": "HealthCareActivity"}, {"end": 80, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 94, "tag": "ClinicalAttribute"}, {"end": 88, "start": 81, "tag": "Finding"}]}{"id": "468_1", "text": "We investigate macular retinal layer thicknesses in a premanifest HD (pre-HD) cohort and healthy controls (HC).", "tags": [{"end": 48, "start": 15, "tag": "ClinicalAttribute"}, {"end": 36, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 78, "tag": "PopulationGroup"}, {"end": 105, "start": 89, "tag": "PopulationGroup"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 54, "tag": "PatientOrDisabledGroup"}, {"end": 76, "start": 70, "tag": "PatientOrDisabledGroup"}]}{"id": "468_2", "text": "Methods Pre-HD mutation carriers underwent standardized ratings and a preset macular OCT scan.", "tags": [{"end": 32, "start": 24, "tag": "PopulationGroup"}, {"end": 93, "start": 77, "tag": "HealthCareActivity"}, {"end": 23, "start": 15, "tag": "CellOrMolecularDysfunction"}, {"end": 14, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "PatientOrDisabledGroup"}]}{"id": "468_3", "text": "Thickness values were determined for each sector of all macular retinal layers, the mean of all sectors and the mean of the inner ring (IR, 3 mm) after segmentation (Heyex segmentation batch).", "tags": [{"end": 78, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 0, "tag": "ClinicalAttribute"}, {"end": 134, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 166, "tag": "ResearchActivity"}, {"end": 164, "start": 152, "tag": "MachineActivity"}]}{"id": "468_4", "text": "HC were retrospectively included from an existing database.", "tags": [{"end": 58, "start": 50, "tag": "ResearchActivity"}, {"end": 2, "start": 0, "tag": "PopulationGroup"}]}{"id": "468_5", "text": "The IR thickness of the ganglion cell layer (GCL), retinal nerve fiber layer (RNFL), GCL + inner plexiform layer (GCIPL), and total retina were included in the exploratory correlation analyses with paraclinical ratings and compared to HC.", "tags": [{"end": 43, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 160, "tag": "ResearchActivity"}, {"end": 16, "start": 4, "tag": "ClinicalAttribute"}, {"end": 119, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 237, "start": 235, "tag": "PopulationGroup"}]}{"id": "468_6", "text": "Results The analyses comprised n = 24 pre-HD participants (n = 10 male, n = 14 female) and n = 38 HC (n = 14 male, n = 24 female).", "tags": [{"end": 44, "start": 38, "tag": "PatientOrDisabledGroup"}, {"end": 85, "start": 79, "tag": "OrganismAttribute"}, {"end": 128, "start": 122, "tag": "OrganismAttribute"}, {"end": 70, "start": 66, "tag": "OrganismAttribute"}, {"end": 113, "start": 109, "tag": "OrganismAttribute"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 57, "start": 45, "tag": "PopulationGroup"}, {"end": 44, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 100, "start": 98, "tag": "PopulationGroup"}]}{"id": "468_7", "text": "Retinal layer parameters did not correlate with paraclinical ratings.", "tags": [{"end": 13, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 14, "tag": "ResearchActivity"}, {"end": 68, "start": 48, "tag": "ResearchActivity"}]}{"id": "468_8", "text": "Expected correlations between established HD biomarkers were robust.", "tags": [{"end": 21, "start": 9, "tag": "ResearchActivity"}, {"end": 44, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 45, "tag": "ClinicalAttribute"}]}{"id": "468_9", "text": "The IR thicknesses of the GCL, GCIPL, and total retina did not differ between pre-HD and HC.", "tags": [{"end": 29, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 78, "tag": "PatientOrDisabledGroup"}, {"end": 54, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 4, "tag": "ClinicalAttribute"}, {"end": 36, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 89, "tag": "PopulationGroup"}]}{"id": "468_10", "text": "The IR thickness of the RNFL was significantly higher in pre-HD participants (pre-HD: 23.22 mu m (standard deviation 2.91), HC: 21.26 mu m (1.90), p = .002).", "tags": [{"end": 63, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 64, "tag": "PopulationGroup"}, {"end": 28, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 4, "tag": "ClinicalAttribute"}]}{"id": "468_11", "text": "Discussion In this cross-sectional cohort of genetically determined pre-HD participants, neurodegenerative features were not detected with retinal layer segmentation.", "tags": [{"end": 165, "start": 153, "tag": "MachineActivity"}, {"end": 115, "start": 89, "tag": "CellOrMolecularDysfunction"}, {"end": 74, "start": 68, "tag": "PatientOrDisabledGroup"}, {"end": 41, "start": 35, "tag": "PopulationGroup"}, {"end": 87, "start": 75, "tag": "PopulationGroup"}, {"end": 152, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}]}{"id": "468_12", "text": "Since our pre-HD collective was more than 16 years before disease onset, OCT may not be sensitive enough to detect early changes.", "tags": [{"end": 16, "start": 10, "tag": "PatientOrDisabledGroup"}, {"end": 71, "start": 58, "tag": "TemporalConcept"}, {"end": 76, "start": 73, "tag": "HealthCareActivity"}, {"end": 50, "start": 45, "tag": "TemporalConcept"}, {"end": 16, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 128, "start": 121, "tag": "Finding"}]}{"id": "470_0", "text": "A major unresolved problem in neurodegenerative disease is why and how a specific set of neurons in the brain are highly vulnerable to neuronal death.", "tags": [{"end": 26, "start": 19, "tag": "Finding"}, {"end": 55, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 89, "tag": "Cell"}, {"end": 149, "start": 135, "tag": "CellFunction"}, {"end": 109, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "470_1", "text": "Multiple pathways and mechanisms have been proposed to play a role in Alzheimer disease (AD dagger), Parkinson disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington disease (HD), yet how they contribute to neuronal vulnerability remains far from clear.", "tags": [{"end": 87, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 240, "start": 218, "tag": "Finding"}, {"end": 188, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 9, "tag": "CellFunction"}]}{"id": "470_2", "text": "In this review, various mechanisms ascribed in AD, PD, ALS, and HD will be briefly summarized.", "tags": [{"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "470_3", "text": "Particular focus will be placed on Rhes-mediated intercellular transport of the HD protein and its role in mitophagy, in which I will discuss some intriguing observations that I apply to model striatal vulnerability in HD.", "tags": [{"end": 72, "start": 49, "tag": "CellFunction"}, {"end": 90, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 107, "tag": "CellFunction"}, {"end": 170, "start": 158, "tag": "Finding"}, {"end": 215, "start": 193, "tag": "Finding"}, {"end": 221, "start": 219, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 80, "tag": "CellOrMolecularDysfunction"}, {"end": 39, "start": 35, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "470_4", "text": "I may have unintentionally missed referring some studies in this review, and I extend my apologies to the authors in those circumstances.", "tags": [{"end": 71, "start": 65, "tag": "ResearchActivity"}, {"end": 71, "start": 65, "tag": "HealthCareActivity"}, {"end": 56, "start": 49, "tag": "ResearchActivity"}]}{"id": "471_0", "text": "Huntington disease (HD) is an inherited neurodegenerative disorder caused by an expansion of the CAG repeat region in the first exon of the huntingtin gene.", "tags": [{"end": 114, "start": 80, "tag": "CellOrMolecularDysfunction"}, {"end": 155, "start": 140, "tag": "GeneOrGenome"}, {"end": 66, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 128, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 107, "start": 97, "tag": "MolecularSequence"}, {"end": 127, "start": 122, "tag": "TemporalConcept"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 40, "tag": "DiseaseOrSyndrome"}]}{"id": "471_1", "text": "Neurodegeneration, which begins in the striatum and then spreads to other brain areas, is preceded by dysfunction in multiple aspects of neurotransmission across a variety of brain areas.", "tags": [{"end": 47, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 137, "tag": "CellFunction"}, {"end": 17, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 113, "start": 102, "tag": "PathologicFunction"}, {"end": 85, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "471_2", "text": "This review will provide an overview of the neurochemical mediators and modulators of synaptic transmission that are disrupted in HD.", "tags": [{"end": 82, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 86, "tag": "CellFunction"}, {"end": 126, "start": 117, "tag": "PathologicFunction"}, {"end": 36, "start": 28, "tag": "ResearchActivity"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 67, "start": 44, "tag": "BiologicallyActiveSubstance"}]}{"id": "471_3", "text": "This includes classical neurotransmitters like glutamate and gamma-aminobutyric acid, modulators such as dopamine, adenosine and endocannabinoids, and molecules like brain-derived neurotrophic factor which affect neurotransmission in a more indirect manner.", "tags": [{"end": 41, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 61, "tag": "PharmacologicSubstance"}, {"end": 96, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 115, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 145, "start": 129, "tag": "Chemical"}, {"end": 145, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 105, "tag": "Chemical"}, {"end": 113, "start": 105, "tag": "PharmacologicSubstance"}, {"end": 230, "start": 213, "tag": "CellFunction"}, {"end": 199, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 151, "tag": "Substance"}, {"end": 124, "start": 115, "tag": "PharmacologicSubstance"}, {"end": 124, "start": 115, "tag": "BiologicallyActiveSubstance"}]}{"id": "471_4", "text": "Alterations in the functioning of these signaling pathways can occur across multiple brain regions such as striatum, cortex and hippocampus, and affect transmission and plasticity at the synapses within these regions, which may ultimately change behaviour and contribute to the pathophysiology of HD.", "tags": [{"end": 11, "start": 0, "tag": "Finding"}, {"end": 30, "start": 19, "tag": "BiologicFunction"}, {"end": 123, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 117, "tag": "CellComponent"}, {"end": 164, "start": 152, "tag": "CellFunction"}, {"end": 179, "start": 169, "tag": "NaturalPhenomenonOrProcess"}, {"end": 179, "start": 169, "tag": "BiologicFunction"}, {"end": 195, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 255, "start": 246, "tag": "BiologicFunction"}, {"end": 255, "start": 246, "tag": "IndividualBehavior"}, {"end": 115, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 40, "tag": "CellFunction"}, {"end": 98, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 293, "start": 278, "tag": "PathologicFunction"}, {"end": 293, "start": 278, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 299, "start": 297, "tag": "DiseaseOrSyndrome"}, {"end": 255, "start": 246, "tag": "ResearchActivity"}]}{"id": "471_5", "text": "The current state of knowledge in this area has already yielded useful information about the causes of synaptic dysfunction and selective cell death.", "tags": [{"end": 148, "start": 138, "tag": "CellFunction"}, {"end": 123, "start": 103, "tag": "CellOrMolecularDysfunction"}, {"end": 148, "start": 143, "tag": "BiologicFunction"}, {"end": 148, "start": 143, "tag": "PathologicFunction"}, {"end": 148, "start": 143, "tag": "CellFunction"}, {"end": 123, "start": 112, "tag": "PathologicFunction"}, {"end": 30, "start": 21, "tag": "Finding"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}]}{"id": "471_6", "text": "A full understanding of the mechanisms and consequences of disruptions in synaptic function and plasticity will lend insight into the development of the symptoms of HD, and potential drug targets for ameliorating them.", "tags": [{"end": 195, "start": 183, "tag": "Finding"}, {"end": 20, "start": 7, "tag": "BiologicFunction"}, {"end": 161, "start": 153, "tag": "SignOrSymptom"}, {"end": 145, "start": 134, "tag": "BiologicFunction"}, {"end": 145, "start": 134, "tag": "CellFunction"}, {"end": 187, "start": 183, "tag": "PharmacologicSubstance"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 59, "tag": "PathologicFunction"}]}{"id": "472_0", "text": "BackgroundHuntington's disease is a complex neurodegenerative hereditary disease with symptoms in all domains of a person's functioning.", "tags": [{"end": 80, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 102, "tag": "MolecularSequence"}, {"end": 135, "start": 115, "tag": "BiologicFunction"}, {"end": 94, "start": 86, "tag": "SignOrSymptom"}, {"end": 61, "start": 44, "tag": "CellOrMolecularDysfunction"}, {"end": 30, "start": 10, "tag": "DiseaseOrSyndrome"}]}{"id": "472_1", "text": "It begins after a healthy start in life and leads through the relentless progression over many years to complete care dependency and finally death.", "tags": [{"end": 146, "start": 141, "tag": "BiologicFunction"}, {"end": 146, "start": 141, "tag": "PathologicFunction"}, {"end": 146, "start": 141, "tag": "CellFunction"}, {"end": 128, "start": 113, "tag": "Finding"}, {"end": 117, "start": 113, "tag": "HealthCareActivity"}, {"end": 100, "start": 95, "tag": "TemporalConcept"}, {"end": 39, "start": 35, "tag": "TemporalConcept"}, {"end": 84, "start": 73, "tag": "PathologicFunction"}, {"end": 84, "start": 73, "tag": "TemporalConcept"}, {"end": 25, "start": 18, "tag": "OrganismAttribute"}]}{"id": "472_2", "text": "To date, the disease is incurable.", "tags": [{"end": 7, "start": 0, "tag": "TemporalConcept"}]}{"id": "472_3", "text": "The long progressive complex nature of the disease demands multiple disciplines for treatment and care of patient and family.", "tags": [{"end": 79, "start": 68, "tag": "HealthCareActivity"}, {"end": 124, "start": 118, "tag": "PopulationGroup"}, {"end": 102, "start": 98, "tag": "HealthCareActivity"}, {"end": 93, "start": 84, "tag": "HealthCareActivity"}, {"end": 93, "start": 84, "tag": "ResearchActivity"}, {"end": 20, "start": 9, "tag": "TemporalConcept"}, {"end": 113, "start": 106, "tag": "PatientOrDisabledGroup"}]}{"id": "472_4", "text": "These health care providers need inter- and multidisciplinary collaboration to persevere and be efficacious in this devastating disease trajectory.DiscussionThe position paper outlines current knowledge and experience alongside the experience and consensus of a recognised group of HD multidisciplinary experts.", "tags": [{"end": 75, "start": 44, "tag": "HealthCareActivity"}, {"end": 217, "start": 207, "tag": "BiologicFunction"}, {"end": 242, "start": 232, "tag": "BiologicFunction"}, {"end": 27, "start": 6, "tag": "HealthCareActivity"}, {"end": 278, "start": 273, "tag": "PopulationGroup"}, {"end": 202, "start": 193, "tag": "Finding"}, {"end": 175, "start": 161, "tag": "ResearchActivity"}, {"end": 284, "start": 282, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 185, "tag": "TemporalConcept"}]}{"id": "472_5", "text": "Additionally the patient's voice is clear and calls for health care providers with a holistic view on patient and family.", "tags": [{"end": 32, "start": 27, "tag": "BiologicFunction"}, {"end": 51, "start": 46, "tag": "ResearchActivity"}, {"end": 120, "start": 114, "tag": "PopulationGroup"}, {"end": 24, "start": 17, "tag": "PatientOrDisabledGroup"}, {"end": 109, "start": 102, "tag": "PatientOrDisabledGroup"}, {"end": 77, "start": 56, "tag": "HealthCareActivity"}]}{"id": "472_6", "text": "Building long-term trust is a cornerstone of the network around the patient.", "tags": [{"end": 18, "start": 9, "tag": "TemporalConcept"}, {"end": 75, "start": 68, "tag": "PatientOrDisabledGroup"}]}{"id": "472_7", "text": "This paper describes a managed care network comprising all the needed professionals and services.", "tags": [{"end": 96, "start": 88, "tag": "HealthCareActivity"}, {"end": 43, "start": 31, "tag": "HealthCareActivity"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 83, "start": 70, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "472_8", "text": "In the health care system, the role of a central coordinator or case manager is of key importance but lacks an appropriate guideline.", "tags": [{"end": 25, "start": 7, "tag": "HealthCareRelatedOrganization"}]}{"id": "472_9", "text": "Other disciplines currently without guidelines are general practitioners, nurses, psychologists, and social workers.", "tags": [{"end": 17, "start": 6, "tag": "HealthCareActivity"}, {"end": 95, "start": 82, "tag": "HealthCareActivity"}, {"end": 115, "start": 101, "tag": "HealthCareActivity"}, {"end": 27, "start": 18, "tag": "TemporalConcept"}, {"end": 80, "start": 74, "tag": "HealthCareActivity"}, {"end": 72, "start": 51, "tag": "HealthCareActivity"}, {"end": 46, "start": 36, "tag": "ResearchActivity"}]}{"id": "472_10", "text": "Guidelines for neurologists, psychiatrists, geneticists, occupational therapists, speech and language therapists, physiotherapists, dieticians, and dentists are being discussed.", "tags": [{"end": 42, "start": 29, "tag": "HealthCareActivity"}, {"end": 80, "start": 57, "tag": "HealthCareActivity"}, {"end": 88, "start": 82, "tag": "BiologicFunction"}, {"end": 112, "start": 93, "tag": "HealthCareActivity"}, {"end": 55, "start": 44, "tag": "HealthCareActivity"}, {"end": 130, "start": 114, "tag": "HealthCareActivity"}, {"end": 142, "start": 132, "tag": "HealthCareActivity"}, {"end": 156, "start": 148, "tag": "HealthCareActivity"}, {"end": 27, "start": 15, "tag": "HealthCareActivity"}, {"end": 10, "start": 0, "tag": "ResearchActivity"}]}{"id": "472_11", "text": "Apart from all these profession-specific guidelines, distinctive inter- and multidisciplinary collaboration requirements must be met.Conclusions and recommendationsThe complex nature of Huntington's disease demands multidisciplinary treatment and care endorsed by international regulations and the lay association.", "tags": [{"end": 107, "start": 76, "tag": "HealthCareActivity"}, {"end": 251, "start": 247, "tag": "HealthCareActivity"}, {"end": 242, "start": 233, "tag": "HealthCareActivity"}, {"end": 242, "start": 233, "tag": "ResearchActivity"}, {"end": 206, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 41, "tag": "ResearchActivity"}]}{"id": "472_12", "text": "Available guidelines as reviewed in this paper should be used, made available by a central body, and updated every 3-5 years.", "tags": [{"end": 32, "start": 24, "tag": "HealthCareActivity"}, {"end": 32, "start": 24, "tag": "ResearchActivity"}, {"end": 95, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 119, "tag": "TemporalConcept"}, {"end": 46, "start": 41, "tag": "ResearchActivity"}, {"end": 20, "start": 10, "tag": "ResearchActivity"}]}{"id": "472_13", "text": "Time needs to be invested in developing missing guidelines but the lack of this 'proof' should not prevent the 'doing' of good care.", "tags": [{"end": 4, "start": 0, "tag": "TemporalConcept"}, {"end": 131, "start": 127, "tag": "HealthCareActivity"}, {"end": 58, "start": 48, "tag": "ResearchActivity"}]}{"id": "485_0", "text": "Huntington disease (HD) is a neurodegenerative disorder produced by an expansion of CAG repeats in the HTT gene.", "tags": [{"end": 95, "start": 84, "tag": "MolecularSequence"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 103, "tag": "GeneOrGenome"}, {"end": 106, "start": 103, "tag": "GeneOrGenome"}, {"end": 106, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 29, "tag": "DiseaseOrSyndrome"}]}{"id": "485_1", "text": "Patients of HD show involuntary movements, cognitive decline and psychiatric impairment.", "tags": [{"end": 41, "start": 20, "tag": "SignOrSymptom"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 60, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 65, "tag": "DiseaseOrSyndrome"}]}{"id": "485_2", "text": "People carrying abnormally long expansions of CAGs (more than 35 CAG repeats) produce mutant huntingtin (mHtt), which encodes tracks of polyglutamines (polyQs).", "tags": [{"end": 150, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 105, "tag": "CellOrMolecularDysfunction"}, {"end": 103, "start": 86, "tag": "CellOrMolecularDysfunction"}, {"end": 76, "start": 65, "tag": "MolecularSequence"}, {"end": 6, "start": 0, "tag": "PopulationGroup"}, {"end": 103, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 16, "tag": "CellOrMolecularDysfunction"}, {"end": 158, "start": 152, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "485_3", "text": "These polyQs make the protein prone to aggregate and cause it to acquire a toxic gain of function.", "tags": [{"end": 12, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 75, "tag": "CellOrMolecularDysfunction"}]}{"id": "485_4", "text": "Principally affecting the frontal cortex and the striatum, mHtt disrupts many cellular functions.", "tags": [{"end": 63, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 59, "tag": "CellOrMolecularDysfunction"}, {"end": 57, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 78, "tag": "CellFunction"}]}{"id": "485_5", "text": "In addition, this protein is expressed ubiquitously, and some reports show that many other cell types are affected by the toxicity of mHtt.", "tags": [{"end": 138, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 134, "tag": "CellOrMolecularDysfunction"}, {"end": 101, "start": 91, "tag": "Cell"}, {"end": 130, "start": 122, "tag": "InjuryOrPoisoning"}, {"end": 69, "start": 62, "tag": "HealthCareActivity"}, {"end": 69, "start": 62, "tag": "ResearchActivity"}, {"end": 38, "start": 29, "tag": "CellFunction"}]}{"id": "485_6", "text": "Several studies reported that metformin, a widely-used anti-diabetic drug, is neuroprotective in models of HD.", "tags": [{"end": 39, "start": 30, "tag": "Chemical"}, {"end": 73, "start": 55, "tag": "PharmacologicSubstance"}, {"end": 93, "start": 78, "tag": "CellFunction"}, {"end": 15, "start": 8, "tag": "HealthCareActivity"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 73, "start": 69, "tag": "PharmacologicSubstance"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 97, "tag": "ResearchActivity"}, {"end": 109, "start": 97, "tag": "ExperimentalModelOfDisease"}, {"end": 39, "start": 30, "tag": "PharmacologicSubstance"}]}{"id": "485_7", "text": "Here, we provide a review of the benefits of this substance to treat HD.", "tags": [{"end": 59, "start": 50, "tag": "Substance"}, {"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 19, "tag": "ResearchActivity"}, {"end": 25, "start": 19, "tag": "HealthCareActivity"}]}{"id": "485_8", "text": "Metformin is a pleiotropic drug, modulating different targets such as AMPK, insulin signalling and many others.", "tags": [{"end": 9, "start": 0, "tag": "Chemical"}, {"end": 94, "start": 76, "tag": "BiologicFunction"}, {"end": 74, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 15, "tag": "PharmacologicSubstance"}, {"end": 9, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "485_9", "text": "These molecules regulate autophagy, chaperone expression, and more, which in turn reduce mHtt toxicity.", "tags": [{"end": 24, "start": 16, "tag": "BiologicFunction"}, {"end": 56, "start": 36, "tag": "CellFunction"}, {"end": 93, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 89, "tag": "CellOrMolecularDysfunction"}, {"end": 102, "start": 94, "tag": "InjuryOrPoisoning"}, {"end": 15, "start": 6, "tag": "Substance"}, {"end": 34, "start": 25, "tag": "CellFunction"}]}{"id": "485_10", "text": "Moreover, metformin alters gut microbiome and its metabolic processes.", "tags": [{"end": 19, "start": 10, "tag": "Chemical"}, {"end": 41, "start": 27, "tag": "Organism"}, {"end": 69, "start": 50, "tag": "BiologicFunction"}, {"end": 69, "start": 50, "tag": "CellFunction"}, {"end": 19, "start": 10, "tag": "PharmacologicSubstance"}]}{"id": "485_11", "text": "The study of potential targets, interactions between the drug, host and microbiome, or genomic and pharmacogenomic approaches may allow us to design personalised medicine to treat HD.", "tags": [{"end": 82, "start": 72, "tag": "Organism"}, {"end": 125, "start": 99, "tag": "ResearchActivity"}, {"end": 67, "start": 63, "tag": "Organism"}, {"end": 44, "start": 32, "tag": "Finding"}, {"end": 148, "start": 142, "tag": "ResearchActivity"}, {"end": 148, "start": 142, "tag": "HealthCareActivity"}, {"end": 61, "start": 57, "tag": "PharmacologicSubstance"}, {"end": 182, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 170, "start": 149, "tag": "HealthCareActivity"}, {"end": 125, "start": 115, "tag": "ResearchActivity"}, {"end": 94, "start": 87, "tag": "ResearchActivity"}]}{"id": "499_0", "text": "Neurodegenerative diseases (NDDs) represent a huge social burden, particularly in Alzheimer's disease (AD) in which all proposed treatments investigated in murine models have failed during clinical trials (CTs).", "tags": [{"end": 209, "start": 206, "tag": "ResearchActivity"}, {"end": 32, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 204, "start": 189, "tag": "ResearchActivity"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 58, "tag": "ResearchActivity"}, {"end": 139, "start": 129, "tag": "HealthCareActivity"}, {"end": 139, "start": 129, "tag": "ResearchActivity"}, {"end": 101, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 163, "tag": "ResearchActivity"}, {"end": 162, "start": 156, "tag": "Eukaryote"}]}{"id": "499_1", "text": "Thus, novel therapeutic strategies remain crucial.", "tags": [{"end": 34, "start": 12, "tag": "HealthCareActivity"}]}{"id": "499_2", "text": "Neuroinflammation is a common pathogenic feature of NDDs.", "tags": [{"end": 17, "start": 0, "tag": "PathologicFunction"}, {"end": 40, "start": 30, "tag": "PathologicFunction"}, {"end": 56, "start": 52, "tag": "DiseaseOrSyndrome"}]}{"id": "499_3", "text": "As purinergic P2X7 receptors (P2X7Rs) are gatekeepers of inflammation, they could be developed as drug targets for NDDs.", "tags": [{"end": 28, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 57, "tag": "PathologicFunction"}, {"end": 102, "start": 98, "tag": "PharmacologicSubstance"}, {"end": 28, "start": 3, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 98, "tag": "ResearchActivity"}]}{"id": "499_4", "text": "Herein, we review this challenging hypothesis and comment on the numerous studies that have investigated P2X7Rs, emphasizing their molecular structure and functions, as well as their role in inflammation.", "tags": [{"end": 203, "start": 191, "tag": "PathologicFunction"}, {"end": 81, "start": 74, "tag": "HealthCareActivity"}, {"end": 81, "start": 74, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "HealthCareActivity"}, {"end": 111, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 105, "tag": "BiologicallyActiveSubstance"}]}{"id": "499_5", "text": "Then, we elaborate on research undertaken in the field of medicinal chemistry to determine potential P2X7R antagonists.", "tags": [{"end": 77, "start": 58, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 118, "start": 101, "tag": "PharmacologicSubstance"}, {"end": 30, "start": 22, "tag": "ResearchActivity"}]}{"id": "499_6", "text": "Subsequently, we review the state of neuroinflammation and P2X7R expression in the brain, in animal models and patients suffering from AD, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and retinal degeneration.", "tags": [{"end": 129, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 37, "tag": "PathologicFunction"}, {"end": 231, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 244, "start": 237, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 93, "tag": "ResearchActivity"}, {"end": 257, "start": 245, "tag": "PathologicFunction"}, {"end": 119, "start": 111, "tag": "PatientOrDisabledGroup"}, {"end": 211, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 17, "tag": "ResearchActivity"}, {"end": 23, "start": 17, "tag": "HealthCareActivity"}, {"end": 64, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 59, "tag": "BiologicallyActiveSubstance"}]}{"id": "499_7", "text": "Next, we summarize the in vivo studies testing the hypothesis that by mitigating neuroinflammation, P2X7R blockers afford neuroprotection, increasing neuroplasticity and neuronal repair in animal models of NDDs.", "tags": [{"end": 165, "start": 150, "tag": "BiologicFunction"}, {"end": 46, "start": 39, "tag": "HealthCareActivity"}, {"end": 137, "start": 122, "tag": "CellFunction"}, {"end": 210, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 81, "tag": "PathologicFunction"}, {"end": 185, "start": 179, "tag": "BiologicFunction"}, {"end": 185, "start": 179, "tag": "HealthCareActivity"}, {"end": 178, "start": 170, "tag": "Cell"}, {"end": 149, "start": 139, "tag": "Finding"}, {"end": 38, "start": 31, "tag": "ResearchActivity"}, {"end": 202, "start": 189, "tag": "ResearchActivity"}, {"end": 30, "start": 23, "tag": "ResearchActivity"}, {"end": 114, "start": 100, "tag": "PharmacologicSubstance"}]}{"id": "499_8", "text": "Finally, we reviewed previous and ongoing CTs investigating compounds directed toward targets associated with NDDs; we propose that CTs with P2X7R antagonists should be initiated.", "tags": [{"end": 45, "start": 42, "tag": "ResearchActivity"}, {"end": 69, "start": 60, "tag": "Chemical"}, {"end": 69, "start": 60, "tag": "PharmacologicSubstance"}, {"end": 135, "start": 132, "tag": "ResearchActivity"}, {"end": 178, "start": 169, "tag": "CellFunction"}, {"end": 20, "start": 12, "tag": "HealthCareActivity"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 114, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 34, "tag": "TemporalConcept"}, {"end": 158, "start": 141, "tag": "PharmacologicSubstance"}]}{"id": "499_9", "text": "Despite the high expectations for putative P2X7Rs antagonists in various central nervous system diseases, the field is moving forward at a relatively slow pace, presumably due to the complexity of P2X7Rs.", "tags": [{"end": 193, "start": 183, "tag": "MolecularSequence"}, {"end": 104, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 203, "start": 197, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 197, "tag": "BiologicallyActiveSubstance"}]}{"id": "499_10", "text": "A better pharmacological approach to combat NDDs would be a dual strategy, combining P2X7R antagonism with drugs targeting a selective pathway in a given NDD.", "tags": [{"end": 101, "start": 85, "tag": "CellFunction"}, {"end": 112, "start": 107, "tag": "PharmacologicSubstance"}, {"end": 142, "start": 135, "tag": "CellFunction"}, {"end": 48, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 9, "tag": "HealthCareActivity"}, {"end": 90, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 85, "tag": "BiologicallyActiveSubstance"}]}{"id": "502_0", "text": "The hypothesis that pathogenic protein aggregates associated with neurodegenerative diseases spread from cell-to-cell in the brain in a manner akin to infectious prions has gained substantial momentum due to an explosion of research in the past 10-15 years.", "tags": [{"end": 117, "start": 105, "tag": "CellFunction"}, {"end": 161, "start": 151, "tag": "PathologicFunction"}, {"end": 168, "start": 162, "tag": "AminoAcidPeptideOrProtein"}, {"end": 244, "start": 240, "tag": "TemporalConcept"}, {"end": 30, "start": 20, "tag": "PathologicFunction"}, {"end": 49, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 256, "start": 251, "tag": "TemporalConcept"}, {"end": 117, "start": 113, "tag": "Cell"}, {"end": 92, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 232, "start": 224, "tag": "ResearchActivity"}]}{"id": "502_1", "text": "Here, we review current evidence supporting the existence of prion-like mechanisms in Huntington's disease (HD), an autosomal dominant neurodegenerative disease caused by expansion of a CAG repeat tract in exon 1 of the huntingtin (HTT) gene.", "tags": [{"end": 134, "start": 116, "tag": "CellFunction"}, {"end": 66, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 212, "start": 206, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 210, "start": 206, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 196, "start": 186, "tag": "MolecularSequence"}, {"end": 32, "start": 24, "tag": "Finding"}, {"end": 235, "start": 232, "tag": "GeneOrGenome"}, {"end": 235, "start": 232, "tag": "AminoAcidPeptideOrProtein"}, {"end": 235, "start": 232, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 16, "tag": "TemporalConcept"}, {"end": 160, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 241, "start": 237, "tag": "GeneOrGenome"}, {"end": 230, "start": 220, "tag": "GeneOrGenome"}, {"end": 202, "start": 171, "tag": "CellOrMolecularDysfunction"}]}{"id": "502_2", "text": "We summarize information gained from human studies and in vivo and in vitro models of HD that strongly support prion-like features of the mutant HTT (mHTT) protein, including potential involvement of molecular features of mHTT seeds, synaptic structures and connectivity, endocytic and exocytic mechanisms, tunneling nanotubes, and nonneuronal cells in mHTT propagation in the brain.", "tags": [{"end": 50, "start": 37, "tag": "ResearchActivity"}, {"end": 270, "start": 258, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 281, "start": 272, "tag": "CellComponent"}, {"end": 294, "start": 286, "tag": "CellComponent"}, {"end": 154, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 226, "start": 222, "tag": "AminoAcidPeptideOrProtein"}, {"end": 357, "start": 353, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 150, "tag": "CellOrMolecularDysfunction"}, {"end": 232, "start": 222, "tag": "CellOrMolecularDysfunction"}, {"end": 369, "start": 353, "tag": "CellOrMolecularDysfunction"}, {"end": 144, "start": 138, "tag": "CellOrMolecularDysfunction"}, {"end": 116, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 382, "start": 377, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 349, "start": 332, "tag": "Cell"}, {"end": 196, "start": 185, "tag": "Finding"}, {"end": 75, "start": 67, "tag": "ResearchActivity"}, {"end": 42, "start": 37, "tag": "Eukaryote"}, {"end": 62, "start": 55, "tag": "ResearchActivity"}, {"end": 148, "start": 145, "tag": "GeneOrGenome"}, {"end": 148, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 76, "tag": "ResearchActivity"}, {"end": 253, "start": 234, "tag": "CellComponent"}, {"end": 357, "start": 353, "tag": "CellOrMolecularDysfunction"}, {"end": 226, "start": 222, "tag": "CellOrMolecularDysfunction"}, {"end": 326, "start": 307, "tag": "CellComponent"}]}{"id": "502_3", "text": "We discuss mechanisms by which mHTT aggregate spreading and neurotoxicity could be causally linked and the potential benefits of targeting prion-like mechanisms in the search for new disease-modifying therapies for HD and other fatal neurodegenerative diseases.", "tags": [{"end": 73, "start": 60, "tag": "InjuryOrPoisoning"}, {"end": 35, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 31, "tag": "CellOrMolecularDysfunction"}, {"end": 174, "start": 168, "tag": "ResearchActivity"}, {"end": 144, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 210, "start": 201, "tag": "HealthCareActivity"}, {"end": 210, "start": 183, "tag": "HealthCareActivity"}, {"end": 260, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 31, "tag": "PathologicFunction"}, {"end": 125, "start": 107, "tag": "Finding"}]}{"id": "518_0", "text": "Background Cell nuclear architecture has been explored in cancer and laminopathies but not in neurodegenerative disorders.", "tags": [{"end": 64, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 11, "tag": "CellComponent"}, {"end": 82, "start": 69, "tag": "DiseaseOrSyndrome"}]}{"id": "518_1", "text": "Huntington's disease (HD) is a neurodegenerative disorder that leads to neuronal death.", "tags": [{"end": 86, "start": 72, "tag": "CellFunction"}, {"end": 86, "start": 81, "tag": "BiologicFunction"}, {"end": 86, "start": 81, "tag": "CellFunction"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 31, "tag": "DiseaseOrSyndrome"}]}{"id": "518_2", "text": "Chromosome-wide changes in gene expression have been reported in HD, not only in the brain but also in peripheral blood cells, but whether this translates into nuclear and chromosome architecture alterations has not yet been studied.", "tags": [{"end": 125, "start": 103, "tag": "Cell"}, {"end": 167, "start": 160, "tag": "CellComponent"}, {"end": 42, "start": 27, "tag": "CellFunction"}, {"end": 90, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 16, "tag": "Finding"}, {"end": 10, "start": 0, "tag": "CellComponent"}, {"end": 207, "start": 172, "tag": "CellOrMolecularDysfunction"}]}{"id": "518_3", "text": "Methods We investigate nuclear structure and chromosome organization in HD blood cells using fluorescence in situ hybridization in ultrathin cryosections (cryoFISH), coupled with machine learning image analysis to evaluate size, distribution, and morphology of nuclei and chromosomes.", "tags": [{"end": 40, "start": 23, "tag": "CellComponent"}, {"end": 55, "start": 45, "tag": "CellComponent"}, {"end": 68, "start": 45, "tag": "CellFunction"}, {"end": 86, "start": 75, "tag": "Cell"}, {"end": 127, "start": 93, "tag": "ResearchActivity"}, {"end": 210, "start": 196, "tag": "MachineActivity"}, {"end": 257, "start": 247, "tag": "Finding"}, {"end": 283, "start": 272, "tag": "CellComponent"}, {"end": 267, "start": 261, "tag": "CellComponent"}, {"end": 195, "start": 179, "tag": "MachineActivity"}, {"end": 227, "start": 223, "tag": "OrganismAttribute"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 155, "tag": "ResearchActivity"}, {"end": 153, "start": 131, "tag": "ResearchActivity"}]}{"id": "518_4", "text": "Four chromosomes were analyzed based on up- or downregulation of gene expression in HD.", "tags": [{"end": 16, "start": 5, "tag": "CellComponent"}, {"end": 80, "start": 65, "tag": "CellFunction"}, {"end": 61, "start": 47, "tag": "CellFunction"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}]}{"id": "518_5", "text": "Results We show that blood cells from HD patients display increased nuclear size and filamentary shape, increased size of gene-rich chromosome 19, decreased filamentary shape of gene-rich chromosome 22, and a more radially centralized position for chromosome 19, whereas chromosomes 4 and 5 do not show detectable differences.", "tags": [{"end": 32, "start": 21, "tag": "Cell"}, {"end": 57, "start": 50, "tag": "HealthCareActivity"}, {"end": 57, "start": 50, "tag": "ResearchActivity"}, {"end": 57, "start": 50, "tag": "MachineActivity"}, {"end": 80, "start": 68, "tag": "OrganismAttribute"}, {"end": 96, "start": 85, "tag": "CellComponent"}, {"end": 102, "start": 97, "tag": "OrganismAttribute"}, {"end": 168, "start": 157, "tag": "CellComponent"}, {"end": 201, "start": 188, "tag": "CellComponent"}, {"end": 290, "start": 289, "tag": "CellComponent"}, {"end": 284, "start": 271, "tag": "CellComponent"}, {"end": 282, "start": 271, "tag": "CellComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 325, "start": 303, "tag": "Finding"}, {"end": 118, "start": 114, "tag": "OrganismAttribute"}, {"end": 49, "start": 38, "tag": "PatientOrDisabledGroup"}, {"end": 145, "start": 132, "tag": "CellComponent"}, {"end": 174, "start": 169, "tag": "OrganismAttribute"}, {"end": 261, "start": 248, "tag": "CellComponent"}, {"end": 243, "start": 214, "tag": "Finding"}]}{"id": "518_6", "text": "Conclusions We identify gross changes in nuclear architecture and chromosome organization associated with HD in blood.", "tags": [{"end": 76, "start": 66, "tag": "CellComponent"}, {"end": 89, "start": 66, "tag": "CellFunction"}, {"end": 117, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 30, "tag": "Finding"}, {"end": 61, "start": 41, "tag": "CellComponent"}]}{"id": "518_7", "text": "This adds a new layer of information onto disrupting mechanisms in HD and increases the potential of using blood to survey HD.", "tags": [{"end": 63, "start": 42, "tag": "PathologicFunction"}, {"end": 122, "start": 116, "tag": "ResearchActivity"}, {"end": 122, "start": 116, "tag": "HealthCareActivity"}, {"end": 112, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}]}{"id": "540_0", "text": "Cysteine is a semi-essential amino acid that not only plays an essential role as a component of protein synthesis, but also in the generation of numerous sulfur-containing molecules such as the antioxidant glutathione and coenzyme A.", "tags": [{"end": 8, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 222, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 96, "tag": "CellFunction"}, {"end": 160, "start": 154, "tag": "Chemical"}, {"end": 160, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 154, "tag": "PharmacologicSubstance"}, {"end": 217, "start": 206, "tag": "AminoAcidPeptideOrProtein"}, {"end": 217, "start": 206, "tag": "PharmacologicSubstance"}, {"end": 217, "start": 206, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 222, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 8, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "540_1", "text": "We previously showed that the metabolism of cysteine is dysregulated in Huntington's disease (HD), a neurodegenerative disorder triggered by the expansion of polyglutamine repeats in the protein huntingtin.", "tags": [{"end": 52, "start": 30, "tag": "CellFunction"}, {"end": 52, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 56, "tag": "PathologicFunction"}, {"end": 127, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 205, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 145, "tag": "CellOrMolecularDysfunction"}]}{"id": "540_2", "text": "In this study, we showed that cysteine metabolism is compromised at multiple levels in HD, both transcriptional and post-translational.", "tags": [{"end": 49, "start": 30, "tag": "CellFunction"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}]}{"id": "540_3", "text": "Accordingly, restoring cysteine homeostasis may be beneficial in HD.", "tags": [{"end": 43, "start": 23, "tag": "BiologicFunction"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}]}{"id": "547_0", "text": "Recent times have witnessed an upsurge in the incidence of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Prion disease, and amyotrophic lateral sclerosis.", "tags": [{"end": 55, "start": 46, "tag": "Finding"}, {"end": 114, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 59, "tag": "DiseaseOrSyndrome"}]}{"id": "547_1", "text": "The treatment of the same remains a daunting challenge due to the limited access of therapeutic moieties across the blood-brain barrier.", "tags": [{"end": 135, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 4, "tag": "HealthCareActivity"}, {"end": 13, "start": 4, "tag": "ResearchActivity"}, {"end": 104, "start": 84, "tag": "HealthCareActivity"}]}{"id": "547_2", "text": "Engineered nanoparticles with a size less than 100 nm provide multifunctional abilities for solving these biomedical and pharmacological issues due to their unique physico-chemical properties along with capability to cross the blood-brain barrier.", "tags": [{"end": 24, "start": 0, "tag": "ManufacturedObject"}, {"end": 36, "start": 32, "tag": "OrganismAttribute"}, {"end": 246, "start": 227, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 233, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 222, "start": 203, "tag": "Finding"}]}{"id": "547_3", "text": "Needless to mention, there is a scarcity of review articles summarizing recent developments of various nanomaterials including liposomes, polymeric nanoparticles, metal nanoparticles, and bio-nanoparticles toward the therapeutic and theranostics applications for various neurodegenerative disorders.", "tags": [{"end": 91, "start": 79, "tag": "BiologicFunction"}, {"end": 91, "start": 79, "tag": "CellFunction"}, {"end": 116, "start": 103, "tag": "ManufacturedObject"}, {"end": 136, "start": 127, "tag": "Chemical"}, {"end": 168, "start": 163, "tag": "Chemical"}, {"end": 245, "start": 233, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 298, "start": 271, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 44, "tag": "ResearchActivity"}, {"end": 205, "start": 188, "tag": "ManufacturedObject"}, {"end": 161, "start": 138, "tag": "ManufacturedObject"}, {"end": 182, "start": 163, "tag": "ManufacturedObject"}, {"end": 258, "start": 233, "tag": "HealthCareActivity"}, {"end": 258, "start": 246, "tag": "HealthCareActivity"}, {"end": 228, "start": 217, "tag": "HealthCareActivity"}]}{"id": "547_4", "text": "Here, a broad spectrum of nanomedicinal approaches to eradicate neurodegenerative disorders is provided, along with a brief account of neuroprotection and neuronal tissue regeneration, current clinical status, issues related to safety, toxicity, challenges, and future outlook.", "tags": [{"end": 150, "start": 135, "tag": "CellFunction"}, {"end": 183, "start": 155, "tag": "BiologicFunction"}, {"end": 234, "start": 228, "tag": "HealthCareActivity"}, {"end": 244, "start": 236, "tag": "InjuryOrPoisoning"}, {"end": 256, "start": 246, "tag": "HealthCareActivity"}, {"end": 276, "start": 269, "tag": "BiologicFunction"}, {"end": 192, "start": 185, "tag": "TemporalConcept"}, {"end": 91, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 26, "tag": "HealthCareActivity"}, {"end": 268, "start": 262, "tag": "TemporalConcept"}, {"end": 208, "start": 193, "tag": "ClinicalAttribute"}]}{"id": "551_0", "text": "Impairment of proteostasis network is one of the characteristic features of many age-related neurodegenerative disorders including autosomal dominantly inherited Huntington's disease (HD).", "tags": [{"end": 34, "start": 0, "tag": "PathologicFunction"}, {"end": 140, "start": 131, "tag": "CellComponent"}, {"end": 34, "start": 14, "tag": "CellFunction"}, {"end": 182, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 81, "tag": "OrganismAttribute"}]}{"id": "551_1", "text": "In HD, N-terminal portion of mutant huntingtin protein containing expanded polyglutamine repeats accumulates as inclusion bodies and leads to progressive deterioration of various cellular functioning including proteostasis network.", "tags": [{"end": 128, "start": 112, "tag": "CellComponent"}, {"end": 199, "start": 179, "tag": "CellFunction"}, {"end": 54, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 230, "start": 210, "tag": "CellFunction"}, {"end": 88, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 29, "tag": "CellOrMolecularDysfunction"}, {"end": 153, "start": 142, "tag": "TemporalConcept"}, {"end": 5, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 66, "tag": "CellOrMolecularDysfunction"}, {"end": 167, "start": 154, "tag": "PathologicFunction"}]}{"id": "551_2", "text": "Here we report that Withaferin A (a small bioactive molecule derived from Indian medicinal plant, Withania somnifera) partially rescues defective proteostasis by activating heat shock response (HSR) and delays the disease progression in a HD mouse model.", "tags": [{"end": 32, "start": 20, "tag": "Chemical"}, {"end": 80, "start": 74, "tag": "PopulationGroup"}, {"end": 172, "start": 162, "tag": "BiologicFunction"}, {"end": 192, "start": 173, "tag": "BiologicFunction"}, {"end": 197, "start": 194, "tag": "BiologicFunction"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 158, "start": 146, "tag": "CellFunction"}, {"end": 253, "start": 239, "tag": "ExperimentalModelOfDisease"}, {"end": 233, "start": 214, "tag": "PathologicFunction"}, {"end": 233, "start": 222, "tag": "PathologicFunction"}, {"end": 233, "start": 222, "tag": "TemporalConcept"}, {"end": 96, "start": 74, "tag": "Organism"}, {"end": 32, "start": 20, "tag": "PharmacologicSubstance"}, {"end": 116, "start": 98, "tag": "Organism"}, {"end": 60, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 136, "tag": "CellOrMolecularDysfunction"}]}{"id": "551_3", "text": "Exposure of Withaferin A activates HSF1 and induces the expression of HSP70 chaperones in an in vitro cell culture system and also suppresses mutant huntingtin aggregation in a cellular model of HD.", "tags": [{"end": 39, "start": 35, "tag": "GeneOrGenome"}, {"end": 51, "start": 44, "tag": "Substance"}, {"end": 75, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 70, "tag": "GeneOrGenome"}, {"end": 75, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 102, "tag": "ResearchActivity"}, {"end": 86, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 93, "tag": "ResearchActivity"}, {"end": 24, "start": 0, "tag": "HealthCareActivity"}, {"end": 24, "start": 12, "tag": "Chemical"}, {"end": 24, "start": 12, "tag": "PharmacologicSubstance"}, {"end": 39, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 142, "tag": "CellOrMolecularDysfunction"}, {"end": 197, "start": 177, "tag": "ExperimentalModelOfDisease"}]}{"id": "551_4", "text": "Withaferin A treatment to HD mice considerably increased their lifespan as well as restored progressive motor behavioral deficits and declined body weight.", "tags": [{"end": 12, "start": 0, "tag": "Chemical"}, {"end": 142, "start": 134, "tag": "Finding"}, {"end": 154, "start": 143, "tag": "OrganismAttribute"}, {"end": 33, "start": 26, "tag": "ExperimentalModelOfDisease"}, {"end": 22, "start": 13, "tag": "HealthCareActivity"}, {"end": 22, "start": 13, "tag": "ResearchActivity"}, {"end": 103, "start": 92, "tag": "TemporalConcept"}, {"end": 71, "start": 63, "tag": "TemporalConcept"}, {"end": 12, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 129, "start": 104, "tag": "DiseaseOrSyndrome"}]}{"id": "551_5", "text": "Biochemical studies confirmed the activation of HSR and global decrease in mutant huntingtin aggregates load accompanied with improvement of striatal function in Withaferin A-treated HD mouse brain.", "tags": [{"end": 44, "start": 34, "tag": "CellFunction"}, {"end": 51, "start": 48, "tag": "BiologicFunction"}, {"end": 137, "start": 126, "tag": "Finding"}, {"end": 103, "start": 75, "tag": "CellOrMolecularDysfunction"}, {"end": 71, "start": 63, "tag": "Finding"}, {"end": 197, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 0, "tag": "ResearchActivity"}, {"end": 185, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 162, "tag": "Chemical"}, {"end": 174, "start": 162, "tag": "PharmacologicSubstance"}, {"end": 191, "start": 186, "tag": "Eukaryote"}]}{"id": "551_6", "text": "Withaferin A-treated HD mice also exhibit significant decrease in inflammatory processes as evident from the decreased microglial activation.", "tags": [{"end": 88, "start": 66, "tag": "PathologicFunction"}, {"end": 118, "start": 109, "tag": "Finding"}, {"end": 28, "start": 21, "tag": "ExperimentalModelOfDisease"}, {"end": 129, "start": 119, "tag": "Cell"}, {"end": 140, "start": 119, "tag": "CellFunction"}, {"end": 62, "start": 42, "tag": "Finding"}, {"end": 62, "start": 54, "tag": "Finding"}, {"end": 12, "start": 0, "tag": "Chemical"}, {"end": 12, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "551_7", "text": "These results indicate immense potential of Withaferin A for the treatment of HD and related neurodegenerative disorders involving protein misfolding and aggregation.", "tags": [{"end": 56, "start": 44, "tag": "Chemical"}, {"end": 165, "start": 154, "tag": "CellFunction"}, {"end": 138, "start": 131, "tag": "CellFunction"}, {"end": 149, "start": 131, "tag": "CellOrMolecularDysfunction"}, {"end": 74, "start": 65, "tag": "HealthCareActivity"}, {"end": 74, "start": 65, "tag": "ResearchActivity"}, {"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 44, "tag": "PharmacologicSubstance"}]}{"id": "552_0", "text": "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases (NDs), presenting a broad range of symptoms from motor dysfunctions to psychobehavioral manifestations.", "tags": [{"end": 203, "start": 172, "tag": "SignOrSymptom"}, {"end": 168, "start": 150, "tag": "PathologicFunction"}, {"end": 144, "start": 136, "tag": "SignOrSymptom"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "552_1", "text": "A common clinical course is the proteinopathy-induced neural dysfunction leading to anatomically corresponding neuropathies.", "tags": [{"end": 123, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 9, "tag": "TemporalConcept"}, {"end": 24, "start": 18, "tag": "TemporalConcept"}, {"end": 72, "start": 61, "tag": "PathologicFunction"}, {"end": 45, "start": 32, "tag": "DiseaseOrSyndrome"}]}{"id": "552_2", "text": "However, current diagnostic criteria based on pathology and symptomatology are of little value for the sake of disease prevention and drug development.", "tags": [{"end": 36, "start": 17, "tag": "Finding"}, {"end": 129, "start": 111, "tag": "HealthCareActivity"}, {"end": 129, "start": 119, "tag": "HealthCareActivity"}, {"end": 150, "start": 134, "tag": "ResearchActivity"}, {"end": 55, "start": 46, "tag": "PathologicFunction"}, {"end": 55, "start": 46, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 150, "start": 139, "tag": "BiologicFunction"}, {"end": 150, "start": 139, "tag": "CellFunction"}, {"end": 138, "start": 134, "tag": "PharmacologicSubstance"}, {"end": 16, "start": 9, "tag": "TemporalConcept"}, {"end": 74, "start": 60, "tag": "SignOrSymptom"}]}{"id": "552_3", "text": "Overviewing the pathomechanism of NDs, this review incorporates systematic reviews on inflammatory cytokines and tryptophan metabolites kynurenines (KYNs) of human samples, to present an inferential method to explore potential links behind NDs.", "tags": [{"end": 108, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 75, "tag": "HealthCareActivity"}, {"end": 82, "start": 75, "tag": "ResearchActivity"}, {"end": 205, "start": 199, "tag": "ResearchActivity"}, {"end": 205, "start": 199, "tag": "HealthCareActivity"}, {"end": 135, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 158, "tag": "Eukaryote"}, {"end": 37, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 243, "start": 240, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 164, "tag": "Substance"}, {"end": 171, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 44, "tag": "ResearchActivity"}, {"end": 50, "start": 44, "tag": "HealthCareActivity"}, {"end": 123, "start": 113, "tag": "PharmacologicSubstance"}]}{"id": "552_4", "text": "The results revealed increases of pro-inflammatory cytokines and neurotoxic KYNs in NDs, increases of anti-inflammatory cytokines in AD, PD, Huntington's disease (HD), Creutzfeldt-Jakob disease, and human immunodeficiency virus (HIV)-associated neurocognitive disorders, and decreases of neuromodulatory KYNs in AD, PD, and HD.", "tags": [{"end": 75, "start": 65, "tag": "InjuryOrPoisoning"}, {"end": 80, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 193, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 227, "start": 199, "tag": "Virus"}, {"end": 284, "start": 275, "tag": "Finding"}, {"end": 303, "start": 288, "tag": "ManufacturedObject"}, {"end": 308, "start": 304, "tag": "AminoAcidPeptideOrProtein"}, {"end": 308, "start": 304, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 229, "tag": "Virus"}, {"end": 119, "start": 102, "tag": "BiologicFunction"}, {"end": 119, "start": 102, "tag": "PharmacologicSubstance"}, {"end": 259, "start": 245, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 34, "tag": "PathologicFunction"}, {"end": 60, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 314, "start": 312, "tag": "DiseaseOrSyndrome"}, {"end": 204, "start": 199, "tag": "Eukaryote"}, {"end": 87, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 326, "start": 324, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 318, "start": 316, "tag": "DiseaseOrSyndrome"}, {"end": 269, "start": 199, "tag": "DiseaseOrSyndrome"}]}{"id": "552_5", "text": "The results reinforced a strong link between inflammation and neurotoxic KYNs, confirmed activation of adaptive immune response, and suggested a possible role in the decrease of neuromodulatory KYNs, all of which may contribute to the development of chronic low grade inflammation.", "tags": [{"end": 72, "start": 62, "tag": "InjuryOrPoisoning"}, {"end": 72, "start": 62, "tag": "BiologicFunction"}, {"end": 77, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 89, "tag": "CellFunction"}, {"end": 127, "start": 103, "tag": "BiologicFunction"}, {"end": 198, "start": 194, "tag": "AminoAcidPeptideOrProtein"}, {"end": 198, "start": 194, "tag": "BiologicallyActiveSubstance"}, {"end": 257, "start": 250, "tag": "TemporalConcept"}, {"end": 174, "start": 166, "tag": "Finding"}, {"end": 57, "start": 45, "tag": "PathologicFunction"}, {"end": 280, "start": 268, "tag": "PathologicFunction"}, {"end": 246, "start": 235, "tag": "BiologicFunction"}, {"end": 246, "start": 235, "tag": "CellFunction"}, {"end": 193, "start": 178, "tag": "BiologicallyActiveSubstance"}]}{"id": "552_6", "text": "Commonalities of multifactorial NDs were discussed to present a current limit of diagnostic criteria, a need for preclinical biomarkers, and an approach to search the initiation factors of NDs.", "tags": [{"end": 100, "start": 81, "tag": "Finding"}, {"end": 124, "start": 113, "tag": "ResearchActivity"}, {"end": 162, "start": 156, "tag": "ResearchActivity"}, {"end": 177, "start": 167, "tag": "TemporalConcept"}, {"end": 35, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 64, "tag": "TemporalConcept"}, {"end": 135, "start": 125, "tag": "ClinicalAttribute"}]}{"id": "556_0", "text": "Proteins that misfold may accumulate and cause disorders like Alzheimer's and Parkinson's.", "tags": [{"end": 8, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 78, "tag": "DiseaseOrSyndrome"}]}{"id": "556_1", "text": "New medicines are also explored to forecast and even cure these illnesses' severe symptoms.", "tags": [{"end": 13, "start": 4, "tag": "PharmacologicSubstance"}, {"end": 73, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 82, "tag": "SignOrSymptom"}]}{"id": "556_2", "text": "Because they were misfolded during creation or maintenance, rogue proteins may harm a biological system.", "tags": [{"end": 27, "start": 18, "tag": "CellOrMolecularDysfunction"}, {"end": 58, "start": 47, "tag": "BiologicFunction"}, {"end": 103, "start": 86, "tag": "BiologicFunction"}, {"end": 74, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 60, "tag": "CellOrMolecularDysfunction"}]}{"id": "556_3", "text": "This causes over twenty human illnesses, including Alzheimer's, Huntington's, Parkinson's, and other neurodegenerative diseases.", "tags": [{"end": 39, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 24, "tag": "Eukaryote"}, {"end": 127, "start": 101, "tag": "DiseaseOrSyndrome"}]}{"id": "556_4", "text": "To create new therapies and medications, researchers will need to understand protein misfolding and aggregation formation.", "tags": [{"end": 23, "start": 14, "tag": "HealthCareActivity"}, {"end": 39, "start": 28, "tag": "PharmacologicSubstance"}, {"end": 52, "start": 41, "tag": "ResearchActivity"}, {"end": 95, "start": 77, "tag": "CellOrMolecularDysfunction"}, {"end": 121, "start": 100, "tag": "CellFunction"}]}{"id": "556_5", "text": "To summarize, protein misfolding causes aggregation and neurodegeneration.", "tags": [{"end": 32, "start": 14, "tag": "CellOrMolecularDysfunction"}, {"end": 73, "start": 56, "tag": "CellOrMolecularDysfunction"}]}{"id": "556_6", "text": "This suggests that nature employs protein aggregation to execute unique physiological activities in various biological conditions.", "tags": [{"end": 53, "start": 34, "tag": "CellFunction"}, {"end": 53, "start": 34, "tag": "CellOrMolecularDysfunction"}]}{"id": "573_0", "text": "A ribosome typically moves at a particular rate on a given mRNA transcript to decode the nucleic acid information required to synthesize proteins.", "tags": [{"end": 10, "start": 2, "tag": "CellComponent"}, {"end": 101, "start": 89, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 74, "start": 64, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 63, "start": 59, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 47, "start": 43, "tag": "TemporalConcept"}, {"end": 145, "start": 137, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "573_1", "text": "The speed and directionality of the ribosome movements during mRNA translation are determined by the mRNA sequence and structure and by various decoding factors.", "tags": [{"end": 9, "start": 4, "tag": "Chemical"}, {"end": 44, "start": 36, "tag": "CellComponent"}, {"end": 54, "start": 36, "tag": "CellFunction"}, {"end": 78, "start": 62, "tag": "CellFunction"}, {"end": 114, "start": 101, "tag": "MolecularSequence"}, {"end": 66, "start": 62, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 105, "start": 101, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "573_2", "text": "However, the molecular mechanisms of this remarkable movement during protein synthesis, or its relevance in brain disorders, remain unknown.", "tags": [{"end": 86, "start": 69, "tag": "CellFunction"}, {"end": 33, "start": 13, "tag": "CellFunction"}, {"end": 123, "start": 108, "tag": "DiseaseOrSyndrome"}]}{"id": "573_3", "text": "Recent studies have indicated that defects in protein synthesis occur in various neurodegenerative diseases, but the mechanistic details are unclear.", "tags": [{"end": 63, "start": 46, "tag": "CellFunction"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 107, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 35, "tag": "Finding"}]}{"id": "573_4", "text": "This is a major problem because identifying the factors that determine protein synthesis defects may offer new avenues for developing therapeutic remedies for currently incurable diseases like neurodegenerative disorders.", "tags": [{"end": 96, "start": 89, "tag": "Finding"}, {"end": 88, "start": 71, "tag": "CellFunction"}, {"end": 154, "start": 134, "tag": "HealthCareActivity"}, {"end": 23, "start": 16, "tag": "Finding"}, {"end": 168, "start": 159, "tag": "TemporalConcept"}, {"end": 220, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 169, "tag": "Finding"}]}{"id": "573_5", "text": "Based on our recent study (Eshraghi et al., Nat Commun 12(1):1461; doi: 10.1038/s41467-021-21637-y), this short commentary will review the mechanistic understanding of Huntingtin (HTT)-mediated ribosome stalling indicating that central defects in protein synthesis in Huntington disease (HD) are orchestrated by jamming of ribosomes on mRNA transcripts.", "tags": [{"end": 178, "start": 168, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 168, "tag": "GeneOrGenome"}, {"end": 178, "start": 168, "tag": "BiologicallyActiveSubstance"}, {"end": 332, "start": 323, "tag": "CellComponent"}, {"end": 264, "start": 247, "tag": "CellFunction"}, {"end": 164, "start": 151, "tag": "BiologicFunction"}, {"end": 286, "start": 268, "tag": "DiseaseOrSyndrome"}, {"end": 340, "start": 336, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 19, "start": 13, "tag": "TemporalConcept"}, {"end": 183, "start": 180, "tag": "GeneOrGenome"}, {"end": 183, "start": 180, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 180, "tag": "BiologicallyActiveSubstance"}, {"end": 290, "start": 288, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 128, "tag": "ResearchActivity"}, {"end": 134, "start": 128, "tag": "HealthCareActivity"}, {"end": 352, "start": 341, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 25, "start": 20, "tag": "ResearchActivity"}, {"end": 211, "start": 194, "tag": "CellFunction"}, {"end": 202, "start": 194, "tag": "CellComponent"}, {"end": 243, "start": 236, "tag": "Finding"}]}{"id": "574_0", "text": "Huntington's disease (HD) is one of neurodegenerative diseases, and is defined as a monogenetic disease due to the mutation of Huntingtin gene.", "tags": [{"end": 103, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 127, "tag": "GeneOrGenome"}, {"end": 123, "start": 115, "tag": "CellOrMolecularDysfunction"}, {"end": 62, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}]}{"id": "574_1", "text": "This disease affects several cellular functions in neurons, and further influences motor and cognitive ability, leading to the suffering of devastating symptoms in HD patients.", "tags": [{"end": 110, "start": 93, "tag": "BiologicFunction"}, {"end": 136, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 29, "tag": "CellFunction"}, {"end": 160, "start": 152, "tag": "SignOrSymptom"}, {"end": 58, "start": 51, "tag": "Cell"}, {"end": 175, "start": 164, "tag": "PatientOrDisabledGroup"}]}{"id": "574_2", "text": "MicroRNA (miRNA) is a non-coding RNA, and is responsible for gene regulation at post-transcriptional levels in cells.", "tags": [{"end": 8, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 8, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 22, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 36, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 61, "tag": "CellFunction"}, {"end": 100, "start": 80, "tag": "CellFunction"}, {"end": 100, "start": 85, "tag": "CellFunction"}, {"end": 15, "start": 10, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 15, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 80, "tag": "TemporalConcept"}, {"end": 116, "start": 111, "tag": "Cell"}]}{"id": "574_3", "text": "Since one miRNA targets to several downstream genes, it may regulate different pathways simultaneously.", "tags": [{"end": 51, "start": 35, "tag": "GeneOrGenome"}, {"end": 68, "start": 60, "tag": "BiologicFunction"}, {"end": 102, "start": 88, "tag": "TemporalConcept"}, {"end": 15, "start": 10, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 15, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 79, "tag": "CellFunction"}]}{"id": "574_4", "text": "As a result, it raises a potential therapy for different diseases using miRNAs, especially for inherited diseases.", "tags": [{"end": 42, "start": 25, "tag": "HealthCareActivity"}, {"end": 113, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 72, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 78, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 35, "tag": "HealthCareActivity"}]}{"id": "574_5", "text": "In this review, we will not only introduce the update information of HD and miRNA, but also discuss the development of potential miRNA-based therapy in HD.", "tags": [{"end": 53, "start": 47, "tag": "TemporalConcept"}, {"end": 81, "start": 76, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 134, "start": 129, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 81, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 104, "tag": "BiologicFunction"}, {"end": 115, "start": 104, "tag": "CellFunction"}, {"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 141, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "574_6", "text": "With the understanding toward the progression of miRNA studies in HD, we anticipate it may provide an insight to treat this devastating disease, even applying to other genetic diseases.", "tags": [{"end": 184, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 9, "tag": "BiologicFunction"}, {"end": 54, "start": 49, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 54, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 55, "tag": "HealthCareActivity"}, {"end": 62, "start": 55, "tag": "ResearchActivity"}, {"end": 45, "start": 34, "tag": "PathologicFunction"}, {"end": 45, "start": 34, "tag": "TemporalConcept"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}]}{"id": "575_0", "text": "Huntington's disease (HD) is a rare neurodegenerative disorder caused by an expansion of CAG trinucleotide repeat located in the exon 1 of Huntingtin (HTT) gene in human chromosome 4.", "tags": [{"end": 113, "start": 89, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 135, "start": 129, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 182, "start": 170, "tag": "CellComponent"}, {"end": 160, "start": 139, "tag": "GeneOrGenome"}, {"end": 133, "start": 129, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 169, "start": 164, "tag": "Eukaryote"}, {"end": 154, "start": 151, "tag": "GeneOrGenome"}, {"end": 154, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 151, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 31, "tag": "TemporalConcept"}, {"end": 113, "start": 76, "tag": "CellOrMolecularDysfunction"}]}{"id": "575_1", "text": "The HTT protein is ubiquitously expressed in the brain.", "tags": [{"end": 41, "start": 19, "tag": "CellFunction"}, {"end": 54, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 4, "tag": "GeneOrGenome"}, {"end": 7, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 32, "tag": "CellFunction"}, {"end": 7, "start": 4, "tag": "BiologicallyActiveSubstance"}]}{"id": "575_2", "text": "Specifically, mutant HTT (mHTT) protein-mediated toxicity leads to a dramatic degeneration of the striatum among many regions of the brain.", "tags": [{"end": 30, "start": 26, "tag": "GeneOrGenome"}, {"end": 30, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 26, "tag": "CellOrMolecularDysfunction"}, {"end": 20, "start": 14, "tag": "CellOrMolecularDysfunction"}, {"end": 106, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 49, "tag": "InjuryOrPoisoning"}, {"end": 138, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 78, "tag": "PathologicFunction"}, {"end": 24, "start": 21, "tag": "GeneOrGenome"}, {"end": 24, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 21, "tag": "BiologicallyActiveSubstance"}]}{"id": "575_3", "text": "HD symptoms exhibit a major involuntary movement followed by cognitive and psychiatric dysfunctions.", "tags": [{"end": 99, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 87, "tag": "PathologicFunction"}, {"end": 11, "start": 3, "tag": "SignOrSymptom"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 22, "tag": "SignOrSymptom"}]}{"id": "575_4", "text": "In this review, we address the conventional role of wild type HTT (wtHTT) and how mHTT protein disrupts the function of medium spiny neurons (MSNs).", "tags": [{"end": 86, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 82, "tag": "CellOrMolecularDysfunction"}, {"end": 140, "start": 120, "tag": "Cell"}, {"end": 65, "start": 52, "tag": "GeneOrGenome"}, {"end": 65, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 146, "start": 142, "tag": "Cell"}, {"end": 72, "start": 67, "tag": "GeneOrGenome"}, {"end": 72, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 67, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "575_5", "text": "We also discuss how mHTT modulates epigenetic modifications and transcriptional pathways in MSNs.", "tags": [{"end": 24, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 20, "tag": "CellOrMolecularDysfunction"}, {"end": 79, "start": 64, "tag": "CellFunction"}, {"end": 59, "start": 35, "tag": "CellFunction"}, {"end": 88, "start": 80, "tag": "CellFunction"}, {"end": 96, "start": 92, "tag": "Cell"}]}{"id": "575_6", "text": "In addition, we define how non-cell autonomous pathways lead to damage and death of MSNs under HD pathological conditions.", "tags": [{"end": 80, "start": 75, "tag": "BiologicFunction"}, {"end": 80, "start": 75, "tag": "PathologicFunction"}, {"end": 121, "start": 98, "tag": "PathologicFunction"}, {"end": 80, "start": 75, "tag": "CellFunction"}, {"end": 55, "start": 47, "tag": "CellFunction"}, {"end": 35, "start": 31, "tag": "Cell"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 84, "tag": "Cell"}, {"end": 70, "start": 64, "tag": "InjuryOrPoisoning"}]}{"id": "575_7", "text": "Lastly, we overview therapeutic approaches for HD.", "tags": [{"end": 42, "start": 20, "tag": "HealthCareActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 19, "start": 11, "tag": "ResearchActivity"}, {"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}]}{"id": "575_8", "text": "Together, understanding of precise neuropathological mechanisms of HD may improve therapeutic approaches to treat the onset and progression of HD.", "tags": [{"end": 63, "start": 35, "tag": "PathologicFunction"}, {"end": 104, "start": 82, "tag": "HealthCareActivity"}, {"end": 23, "start": 10, "tag": "BiologicFunction"}, {"end": 123, "start": 118, "tag": "TemporalConcept"}, {"end": 139, "start": 128, "tag": "PathologicFunction"}, {"end": 139, "start": 128, "tag": "TemporalConcept"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}]}{"id": "576_0", "text": "Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by a trinucleotide repeat expansion in the Huntingtin gene.", "tags": [{"end": 122, "start": 102, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 132, "start": 102, "tag": "CellOrMolecularDysfunction"}, {"end": 41, "start": 32, "tag": "CellComponent"}, {"end": 89, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 140, "tag": "GeneOrGenome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 63, "tag": "DiseaseOrSyndrome"}]}{"id": "576_1", "text": "As disease-modifying therapies for HD are being developed, peripheral blood cells may be used to indicate disease progression and to monitor treatment response.", "tags": [{"end": 81, "start": 59, "tag": "Cell"}, {"end": 140, "start": 133, "tag": "HealthCareActivity"}, {"end": 140, "start": 133, "tag": "ManufacturedObject"}, {"end": 75, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 141, "tag": "ClinicalAttribute"}, {"end": 125, "start": 106, "tag": "PathologicFunction"}, {"end": 30, "start": 3, "tag": "HealthCareActivity"}, {"end": 150, "start": 141, "tag": "HealthCareActivity"}, {"end": 150, "start": 141, "tag": "ResearchActivity"}, {"end": 125, "start": 114, "tag": "PathologicFunction"}, {"end": 125, "start": 114, "tag": "TemporalConcept"}, {"end": 37, "start": 35, "tag": "DiseaseOrSyndrome"}]}{"id": "576_2", "text": "In order to investigate whether gene expression changes can be found in the blood of individuals with HD that distinguish them from healthy controls, we performed transcriptome analysis by next-generation sequencing (RNA-seq).", "tags": [{"end": 185, "start": 163, "tag": "ResearchActivity"}, {"end": 215, "start": 189, "tag": "ResearchActivity"}, {"end": 224, "start": 217, "tag": "ResearchActivity"}, {"end": 47, "start": 32, "tag": "CellFunction"}, {"end": 176, "start": 163, "tag": "MolecularSequence"}, {"end": 81, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 85, "tag": "PopulationGroup"}, {"end": 139, "start": 132, "tag": "OrganismAttribute"}, {"end": 185, "start": 177, "tag": "ResearchActivity"}, {"end": 148, "start": 132, "tag": "PopulationGroup"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 48, "tag": "Finding"}]}{"id": "576_3", "text": "We detected a gene expression signature consistent with dysregulation of immune-related functions and inflammatory response in peripheral blood from HD cases vs.", "tags": [{"end": 69, "start": 56, "tag": "Finding"}, {"end": 97, "start": 73, "tag": "BiologicFunction"}, {"end": 123, "start": 102, "tag": "PathologicFunction"}, {"end": 143, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 14, "tag": "CellFunction"}, {"end": 157, "start": 149, "tag": "PatientOrDisabledGroup"}, {"end": 39, "start": 30, "tag": "ResearchActivity"}, {"end": 143, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "576_4", "text": "controls, including induction of the interferon response genes, IFITM3, IFI6 and IRF7.", "tags": [{"end": 62, "start": 37, "tag": "GeneOrGenome"}, {"end": 70, "start": 64, "tag": "GeneOrGenome"}, {"end": 76, "start": 72, "tag": "GeneOrGenome"}, {"end": 85, "start": 81, "tag": "GeneOrGenome"}, {"end": 85, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 0, "tag": "PopulationGroup"}, {"end": 70, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 64, "tag": "BiologicallyActiveSubstance"}]}{"id": "576_5", "text": "Our results suggest that it is possible to detect gene expression changes in blood samples from individuals with HD, which may reflect the immune pathology associated with the disease.", "tags": [{"end": 90, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 50, "tag": "CellFunction"}, {"end": 107, "start": 96, "tag": "PopulationGroup"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 66, "tag": "Finding"}]}{"id": "578_0", "text": "Huntington's disease (HD) is a rare neurodegenerative disorder of the central nervous system characterized by involuntary choreatic movements, cognitive, behavioral, and psychiatric disturbances.", "tags": [{"end": 141, "start": 110, "tag": "SignOrSymptom"}, {"end": 194, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 31, "tag": "TemporalConcept"}]}{"id": "578_1", "text": "Most HD suffer from dysphagia and aspiration pneumonia is the leading cause of death.", "tags": [{"end": 29, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 79, "tag": "BiologicFunction"}, {"end": 84, "start": 79, "tag": "PathologicFunction"}, {"end": 84, "start": 79, "tag": "CellFunction"}, {"end": 7, "start": 5, "tag": "DiseaseOrSyndrome"}]}{"id": "578_2", "text": "However, little is known about dysphagia management in HD.", "tags": [{"end": 40, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 41, "tag": "HealthCareActivity"}, {"end": 57, "start": 55, "tag": "DiseaseOrSyndrome"}]}{"id": "578_3", "text": "A revision of the literature was conducted to depict the state of the art on the assessment and treatment of dysphagia in HD.", "tags": [{"end": 10, "start": 2, "tag": "TemporalConcept"}, {"end": 10, "start": 2, "tag": "HealthCareActivity"}, {"end": 91, "start": 81, "tag": "HealthCareActivity"}, {"end": 118, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 18, "tag": "ResearchActivity"}, {"end": 105, "start": 96, "tag": "HealthCareActivity"}, {"end": 105, "start": 96, "tag": "ResearchActivity"}, {"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 57, "tag": "ResearchActivity"}]}{"id": "578_4", "text": "Literature search of the last 10 years was performed using PubMed and EMBASE.", "tags": [{"end": 65, "start": 59, "tag": "HealthCareRelatedOrganization"}, {"end": 17, "start": 0, "tag": "ResearchActivity"}, {"end": 76, "start": 70, "tag": "HealthCareRelatedOrganization"}, {"end": 38, "start": 33, "tag": "TemporalConcept"}]}{"id": "578_5", "text": "Twenty-four studies were included: 16 cross-sectional studies, 2 case reports, 2 case series, 2 open-label trials, 1 pre-post study, and 1 randomized controlled trial.", "tags": [{"end": 61, "start": 38, "tag": "ResearchActivity"}, {"end": 77, "start": 65, "tag": "ResearchActivity"}, {"end": 92, "start": 81, "tag": "ResearchActivity"}, {"end": 113, "start": 96, "tag": "ResearchActivity"}, {"end": 166, "start": 139, "tag": "ResearchActivity"}, {"end": 19, "start": 12, "tag": "ResearchActivity"}, {"end": 131, "start": 117, "tag": "ResearchActivity"}]}{"id": "578_6", "text": "Based on the studies retrieved, dysphagia should be assessed from the early stage of the disease, especially when specific clinical markers occur.", "tags": [{"end": 41, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 70, "tag": "TemporalConcept"}, {"end": 139, "start": 123, "tag": "ClinicalAttribute"}, {"end": 20, "start": 13, "tag": "ResearchActivity"}]}{"id": "578_7", "text": "Timing for dysphagia re-assessment should be based on the recommendation of the swallowing experts on the individual case.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 20, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 80, "tag": "BiologicFunction"}, {"end": 34, "start": 21, "tag": "HealthCareActivity"}]}{"id": "578_8", "text": "Instrumental assessment of swallowing by videofluoroscopy or videoendoscopy is feasible and recommended to diagnose dysphagia in patients with HD.", "tags": [{"end": 37, "start": 27, "tag": "BiologicFunction"}, {"end": 57, "start": 41, "tag": "HealthCareActivity"}, {"end": 115, "start": 107, "tag": "HealthCareActivity"}, {"end": 125, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 129, "tag": "PatientOrDisabledGroup"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 61, "tag": "HealthCareActivity"}, {"end": 23, "start": 0, "tag": "HealthCareActivity"}]}{"id": "578_9", "text": "Clinical assessment tools and patient-reported outcome measures may be used to complete the swallowing examination, but not to replace instrumental assessment.", "tags": [{"end": 25, "start": 0, "tag": "HealthCareActivity"}, {"end": 102, "start": 92, "tag": "BiologicFunction"}, {"end": 37, "start": 30, "tag": "PatientOrDisabledGroup"}, {"end": 158, "start": 135, "tag": "HealthCareActivity"}, {"end": 54, "start": 47, "tag": "Finding"}, {"end": 114, "start": 103, "tag": "HealthCareActivity"}]}{"id": "578_10", "text": "The impact of pharmacological and rehabilitative treatments on dysphagia in HD has been little studied in literature.", "tags": [{"end": 59, "start": 34, "tag": "HealthCareActivity"}, {"end": 72, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 106, "tag": "ResearchActivity"}, {"end": 29, "start": 14, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}]}{"id": "578_11", "text": "While the effect of tetrabenazine on swallowing is still controversial, compensatory strategies seem to be applicable and efficacious.", "tags": [{"end": 47, "start": 37, "tag": "BiologicFunction"}, {"end": 95, "start": 72, "tag": "HealthCareActivity"}, {"end": 33, "start": 20, "tag": "PharmacologicSubstance"}, {"end": 33, "start": 20, "tag": "Chemical"}]}{"id": "578_12", "text": "To date, there are no well-proven rehabilitative strategies to improve swallowing function in patients with HD.", "tags": [{"end": 59, "start": 34, "tag": "HealthCareActivity"}, {"end": 90, "start": 71, "tag": "BiologicFunction"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 102, "start": 94, "tag": "PatientOrDisabledGroup"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}]}{"id": "578_13", "text": "The topic of dysphagia in HD remains poorly studied compared with its clinical relevance.", "tags": [{"end": 22, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 26, "tag": "DiseaseOrSyndrome"}]}{"id": "589_0", "text": "Huntington's disease (HD) is a genetic neurodegenerative disorder that affects not only the motor but also the cognitive and the neuropsychiatric domain.", "tags": [{"end": 152, "start": 129, "tag": "BiologicFunction"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 39, "tag": "DiseaseOrSyndrome"}]}{"id": "589_1", "text": "In particular, deficits in mental state recognition may emerge already at early pre-manifest stages of the disease.", "tags": [{"end": 99, "start": 80, "tag": "TemporalConcept"}, {"end": 51, "start": 27, "tag": "BiologicFunction"}, {"end": 23, "start": 15, "tag": "Finding"}, {"end": 79, "start": 74, "tag": "TemporalConcept"}]}{"id": "589_2", "text": "The aim of this research was to explore the relation between visual scanning behavior and complex mental state recognition in individuals with pre-manifest HD (preHD).", "tags": [{"end": 85, "start": 61, "tag": "IndividualBehavior"}, {"end": 122, "start": 98, "tag": "BiologicFunction"}, {"end": 137, "start": 126, "tag": "PopulationGroup"}, {"end": 158, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 16, "tag": "ResearchActivity"}, {"end": 165, "start": 160, "tag": "DiseaseOrSyndrome"}]}{"id": "589_3", "text": "Eighteen preHD and eighteen age- and gender-matched healthy controls took the revised Reading the Mind in the Eyes test while their eye-movements were tracked.", "tags": [{"end": 145, "start": 132, "tag": "BiologicFunction"}, {"end": 43, "start": 37, "tag": "OrganismAttribute"}, {"end": 31, "start": 28, "tag": "OrganismAttribute"}, {"end": 59, "start": 52, "tag": "OrganismAttribute"}, {"end": 68, "start": 52, "tag": "PopulationGroup"}, {"end": 14, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 86, "tag": "HealthCareActivity"}]}{"id": "589_4", "text": "In addition to the expected deficits in mental state recognition, preHD showed abnormalities concerning all three scanning variables we considered, namely the absolute number of fixations (FC), the average fixation duration (AFD), and the percentage of time spent fixating (FTR).", "tags": [{"end": 64, "start": 40, "tag": "BiologicFunction"}, {"end": 122, "start": 114, "tag": "HealthCareActivity"}, {"end": 277, "start": 274, "tag": "CellFunction"}, {"end": 36, "start": 28, "tag": "Finding"}, {"end": 223, "start": 198, "tag": "TemporalConcept"}, {"end": 71, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 159, "tag": "ClinicalAttribute"}, {"end": 223, "start": 198, "tag": "ClinicalAttribute"}, {"end": 272, "start": 239, "tag": "ClinicalAttribute"}]}{"id": "589_5", "text": "In preHD, FC and FTR but not AFD predicted mental state recognition over and beyond general disease-related declines in cognition and motor functioning.", "tags": [{"end": 151, "start": 134, "tag": "BiologicFunction"}, {"end": 67, "start": 43, "tag": "BiologicFunction"}, {"end": 129, "start": 120, "tag": "BiologicFunction"}, {"end": 8, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 108, "tag": "Finding"}]}{"id": "589_6", "text": "Notably, preHD showed abnormal vertical and horizontal fixation patterns, and these patterns predicted mental state recognition, suggesting the involvement of mechanisms related to the embodied processing of emotional stimuli.", "tags": [{"end": 127, "start": 103, "tag": "BiologicFunction"}, {"end": 72, "start": 44, "tag": "ResearchActivity"}, {"end": 92, "start": 84, "tag": "ResearchActivity"}, {"end": 155, "start": 144, "tag": "Finding"}, {"end": 14, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 55, "tag": "ResearchActivity"}, {"end": 39, "start": 31, "tag": "ResearchActivity"}, {"end": 225, "start": 185, "tag": "BiologicFunction"}]}{"id": "589_7", "text": "Overall, our results suggest that impaired facial mental state recognition in pre-manifest HD is partly due to emotional-motivational factors affecting the visual scanning of facial expressions.", "tags": [{"end": 42, "start": 34, "tag": "Finding"}, {"end": 49, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 175, "tag": "Finding"}, {"end": 74, "start": 50, "tag": "BiologicFunction"}, {"end": 93, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 156, "tag": "BiologicFunction"}]}{"id": "596_0", "text": "Iron is a key element for mitochondrial function and homeostasis, which is also crucial for maintaining the neuronal system, but too much iron promotes oxidative stress.", "tags": [{"end": 39, "start": 26, "tag": "CellComponent"}, {"end": 48, "start": 26, "tag": "CellFunction"}, {"end": 142, "start": 138, "tag": "PharmacologicSubstance"}, {"end": 142, "start": 138, "tag": "Chemical"}, {"end": 142, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 4, "start": 0, "tag": "Chemical"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 53, "tag": "BiologicFunction"}, {"end": 168, "start": 152, "tag": "CellOrMolecularDysfunction"}, {"end": 123, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "596_1", "text": "A large body of evidence has indicated that abnormal iron accumulation in the brain is associated with various neurodegenerative diseases such as Huntington's disease, Alzheimer's disease, Parkinson's disease, and Friedreich's ataxia.", "tags": [{"end": 233, "start": 227, "tag": "SignOrSymptom"}, {"end": 233, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 233, "start": 214, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 53, "tag": "PharmacologicSubstance"}, {"end": 57, "start": 53, "tag": "Chemical"}, {"end": 57, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 2, "tag": "Finding"}, {"end": 137, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 44, "tag": "Finding"}]}{"id": "596_2", "text": "However, it is still unclear how irregular iron status contributes to the development of neuronal disorders.", "tags": [{"end": 42, "start": 33, "tag": "Finding"}, {"end": 107, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 47, "start": 43, "tag": "Chemical"}, {"end": 47, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 74, "tag": "BiologicFunction"}, {"end": 85, "start": 74, "tag": "CellFunction"}]}{"id": "596_3", "text": "Hence, the current review provides an update on the causal effects of iron overload in the development and progression of neurodegenerative diseases and discusses important roles of mitochondrial iron homeostasis in these disease conditions.", "tags": [{"end": 83, "start": 70, "tag": "Finding"}, {"end": 212, "start": 182, "tag": "CellFunction"}, {"end": 195, "start": 182, "tag": "CellComponent"}, {"end": 44, "start": 38, "tag": "TemporalConcept"}, {"end": 74, "start": 70, "tag": "PharmacologicSubstance"}, {"end": 200, "start": 196, "tag": "PharmacologicSubstance"}, {"end": 74, "start": 70, "tag": "Chemical"}, {"end": 200, "start": 196, "tag": "Chemical"}, {"end": 74, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 200, "start": 196, "tag": "BiologicallyActiveSubstance"}, {"end": 212, "start": 201, "tag": "BiologicFunction"}, {"end": 102, "start": 91, "tag": "BiologicFunction"}, {"end": 102, "start": 91, "tag": "CellFunction"}, {"end": 118, "start": 107, "tag": "PathologicFunction"}, {"end": 118, "start": 107, "tag": "TemporalConcept"}, {"end": 148, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 11, "tag": "TemporalConcept"}, {"end": 25, "start": 19, "tag": "ResearchActivity"}, {"end": 25, "start": 19, "tag": "HealthCareActivity"}, {"end": 240, "start": 222, "tag": "DiseaseOrSyndrome"}]}{"id": "596_4", "text": "Furthermore, this review discusses potential therapeutic targets for the treatments of iron overload-linked neurodegenerative diseases.", "tags": [{"end": 64, "start": 45, "tag": "ResearchActivity"}, {"end": 64, "start": 35, "tag": "ResearchActivity"}, {"end": 91, "start": 87, "tag": "PharmacologicSubstance"}, {"end": 91, "start": 87, "tag": "Chemical"}, {"end": 91, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 73, "tag": "HealthCareActivity"}, {"end": 83, "start": 73, "tag": "ResearchActivity"}, {"end": 134, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 18, "tag": "ResearchActivity"}, {"end": 24, "start": 18, "tag": "HealthCareActivity"}, {"end": 100, "start": 87, "tag": "Finding"}]}{"id": "601_0", "text": "Neurodegeneration is a major cause of Alzheimer's, Parkinson's, Huntington's, multiple and amyotrophic lateral sclerosis, pontocerebellar hypoplasia, dementia and other related brain disorders.", "tags": [{"end": 49, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 148, "start": 122, "tag": "DiseaseOrSyndrome"}]}{"id": "601_1", "text": "Their complex pathogenesis commonly includes genetic and neurochemical deficits, misfolded protein toxicity, demyelination, apoptosis and mitochondrial dysfunctions.", "tags": [{"end": 26, "start": 14, "tag": "PathologicFunction"}, {"end": 98, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 81, "tag": "CellOrMolecularDysfunction"}, {"end": 107, "start": 99, "tag": "InjuryOrPoisoning"}, {"end": 122, "start": 109, "tag": "PathologicFunction"}, {"end": 133, "start": 124, "tag": "CellFunction"}, {"end": 164, "start": 138, "tag": "CellOrMolecularDysfunction"}, {"end": 79, "start": 45, "tag": "CellOrMolecularDysfunction"}]}{"id": "601_2", "text": "Albeit differing in specific underlying mechanisms, neurodegenerative disorders typically display evolutionarily conserved mechanisms across taxa.", "tags": [{"end": 79, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 98, "tag": "Finding"}]}{"id": "601_3", "text": "Here, we review the role of zebrafish models in recapitulating major human and rodent neurodegenerative conditions, demonstrating this species as a highly relevant experimental model for research on neurodegenerative diseases, and discussing how these fish models can further clarify the underlying genetic, neurochemical, neuroanatomical and behavioral pathogenic mechanisms.", "tags": [{"end": 114, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 135, "tag": "OrganismAttribute"}, {"end": 263, "start": 252, "tag": "ResearchActivity"}, {"end": 44, "start": 28, "tag": "ResearchActivity"}, {"end": 74, "start": 69, "tag": "Eukaryote"}, {"end": 225, "start": 164, "tag": "ExperimentalModelOfDisease"}, {"end": 225, "start": 199, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 85, "start": 79, "tag": "Eukaryote"}, {"end": 375, "start": 343, "tag": "DiseaseOrSyndrome"}, {"end": 375, "start": 354, "tag": "CellOrMolecularDysfunction"}, {"end": 321, "start": 308, "tag": "CellOrMolecularDysfunction"}, {"end": 375, "start": 354, "tag": "PathologicFunction"}, {"end": 338, "start": 323, "tag": "PathologicFunction"}, {"end": 375, "start": 354, "tag": "CellOrMolecularDysfunction"}, {"end": 306, "start": 299, "tag": "CellOrMolecularDysfunction"}]}{"id": "612_0", "text": "Huntington's disease (HD) is an inherited neurodegenerative disease.", "tags": [{"end": 67, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "612_1", "text": "People at risk for HD can choose to get predictive testing years before the clinical onset.", "tags": [{"end": 6, "start": 0, "tag": "PopulationGroup"}, {"end": 21, "start": 19, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 76, "tag": "TemporalConcept"}, {"end": 58, "start": 40, "tag": "HealthCareActivity"}, {"end": 64, "start": 59, "tag": "TemporalConcept"}]}{"id": "612_2", "text": "HD is characterized by motor, cognitive and psychiatric symptoms and has a mean age at onset between 30 and 50 years, an age at which people are usually still working.", "tags": [{"end": 64, "start": 23, "tag": "SignOrSymptom"}, {"end": 116, "start": 111, "tag": "TemporalConcept"}, {"end": 140, "start": 134, "tag": "PopulationGroup"}, {"end": 83, "start": 80, "tag": "OrganismAttribute"}, {"end": 124, "start": 121, "tag": "OrganismAttribute"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 87, "tag": "TemporalConcept"}]}{"id": "612_3", "text": "This systematic review focuses on summarizing which disease-specific characteristics influence employment and working capacity in HD.Twenty-three studies were identified and showed that while employment and working capacity in HD are negatively influenced by cognitive decline and motor impairments, apathy already plays a role in the prodromal stage.", "tags": [{"end": 22, "start": 5, "tag": "HealthCareActivity"}, {"end": 105, "start": 95, "tag": "Finding"}, {"end": 202, "start": 192, "tag": "Finding"}, {"end": 298, "start": 281, "tag": "DiseaseOrSyndrome"}, {"end": 306, "start": 300, "tag": "DiseaseOrSyndrome"}, {"end": 350, "start": 335, "tag": "TemporalConcept"}, {"end": 276, "start": 259, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 16, "tag": "ResearchActivity"}, {"end": 22, "start": 16, "tag": "HealthCareActivity"}, {"end": 153, "start": 146, "tag": "ResearchActivity"}, {"end": 84, "start": 52, "tag": "ClinicalAttribute"}, {"end": 126, "start": 110, "tag": "Finding"}, {"end": 223, "start": 207, "tag": "Finding"}]}{"id": "612_4", "text": "Moreover, the influence of HD transcends the clinical manifestation of the disease, as some people at risk are already experiencing the impact of HD on employment through fear of or actual genetic discrimination.", "tags": [{"end": 98, "start": 92, "tag": "PopulationGroup"}, {"end": 162, "start": 152, "tag": "Finding"}, {"end": 175, "start": 171, "tag": "BiologicFunction"}, {"end": 211, "start": 189, "tag": "BiologicFunction"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 45, "tag": "ClinicalAttribute"}]}{"id": "612_5", "text": "Employment and working capacity are not influenced by predictive testing for HD in and of itself.", "tags": [{"end": 10, "start": 0, "tag": "Finding"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 15, "tag": "Finding"}, {"end": 72, "start": 54, "tag": "HealthCareActivity"}]}{"id": "624_0", "text": "Disruptions of sleep and circadian rhythms are among the most debilitating symptoms in patients with neurodegenerative diseases.", "tags": [{"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 15, "tag": "BiologicFunction"}, {"end": 42, "start": 25, "tag": "BiologicFunction"}, {"end": 83, "start": 62, "tag": "SignOrSymptom"}, {"end": 127, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 87, "tag": "PatientOrDisabledGroup"}]}{"id": "624_1", "text": "Their underlying pathophysiology is multilayered and multifactorial.", "tags": [{"end": 32, "start": 17, "tag": "PathologicFunction"}]}{"id": "624_2", "text": "Recent evidence suggests that sleep and circadian disturbances may influence the neurodegenerative processes as well as be their consequence.", "tags": [{"end": 35, "start": 30, "tag": "BiologicFunction"}, {"end": 62, "start": 40, "tag": "PathologicFunction"}, {"end": 108, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 7, "tag": "Finding"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}]}{"id": "624_3", "text": "In this perspective, we provide an update of the current understanding of sleep and circadian dysregulation in Alzheimer's, Parkinson's, and Huntington's diseases.", "tags": [{"end": 19, "start": 8, "tag": "BiologicFunction"}, {"end": 41, "start": 35, "tag": "TemporalConcept"}, {"end": 79, "start": 74, "tag": "BiologicFunction"}, {"end": 107, "start": 84, "tag": "PathologicFunction"}, {"end": 122, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 49, "tag": "TemporalConcept"}]}{"id": "629_0", "text": "Huntington's disease (HD) is a dominantly inherited neurodegenerative disease.", "tags": [{"end": 77, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 52, "tag": "DiseaseOrSyndrome"}]}{"id": "629_1", "text": "There is accumulating evidence that HD patients have increased prevalence of conduction abnormalities and compromised sinoatrial node function which could lead to increased risk for arrhythmia.", "tags": [{"end": 101, "start": 77, "tag": "PathologicFunction"}, {"end": 133, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 118, "tag": "BiologicFunction"}, {"end": 192, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 182, "tag": "PathologicFunction"}, {"end": 87, "start": 77, "tag": "BiologicFunction"}, {"end": 87, "start": 77, "tag": "NaturalPhenomenonOrProcess"}, {"end": 30, "start": 9, "tag": "Finding"}, {"end": 177, "start": 173, "tag": "Finding"}, {"end": 30, "start": 22, "tag": "Finding"}, {"end": 47, "start": 36, "tag": "PatientOrDisabledGroup"}]}{"id": "629_3", "text": "We obtained surface ECGs and analyzed arrhythmia susceptibility; we observed prolonged QRS duration, increases in PVCs as well as PACs.", "tags": [{"end": 48, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 38, "tag": "PathologicFunction"}, {"end": 63, "start": 49, "tag": "Finding"}, {"end": 99, "start": 87, "tag": "ClinicalAttribute"}, {"end": 118, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 77, "tag": "TemporalConcept"}, {"end": 99, "start": 91, "tag": "TemporalConcept"}, {"end": 37, "start": 29, "tag": "ResearchActivity"}, {"end": 24, "start": 12, "tag": "HealthCareActivity"}, {"end": 99, "start": 77, "tag": "Finding"}]}{"id": "629_4", "text": "Abnormal histological and structural changes that could lead to cardiac conduction system dysfunction were seen.", "tags": [{"end": 89, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 90, "tag": "PathologicFunction"}, {"end": 44, "start": 0, "tag": "Finding"}]}{"id": "629_5", "text": "Finally, we observed decreases in desmosomal proteins, plakophilin-2 and desmoglein-2, which have been reported to cause cardiac arrhythmias and reduced conduction.", "tags": [{"end": 30, "start": 21, "tag": "Finding"}, {"end": 53, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 153, "tag": "BiologicFunction"}, {"end": 163, "start": 153, "tag": "NaturalPhenomenonOrProcess"}, {"end": 128, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 55, "tag": "BiologicallyActiveSubstance"}]}{"id": "629_6", "text": "Our study indicates that mHTT could cause progressive cardiac conduction system pathology that could increase the susceptibility to arrhythmias and sudden cardiac death in HD patients.", "tags": [{"end": 79, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 25, "tag": "CellOrMolecularDysfunction"}, {"end": 89, "start": 80, "tag": "PathologicFunction"}, {"end": 89, "start": 80, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 53, "start": 42, "tag": "TemporalConcept"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 183, "start": 172, "tag": "PatientOrDisabledGroup"}, {"end": 128, "start": 114, "tag": "Finding"}, {"end": 143, "start": 132, "tag": "PathologicFunction"}]}{"id": "633_0", "text": "There is increasing evidence that impairments of cerebrovascular function and/or abnormalities of the cerebral vasculature might contribute to early neuronal cell loss in Huntington's disease (HD).", "tags": [{"end": 45, "start": 34, "tag": "Finding"}, {"end": 122, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 9, "tag": "Finding"}, {"end": 19, "start": 9, "tag": "Finding"}, {"end": 28, "start": 20, "tag": "Finding"}, {"end": 191, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 49, "tag": "BiologicFunction"}, {"end": 122, "start": 81, "tag": "PathologicFunction"}, {"end": 167, "start": 149, "tag": "CellOrMolecularDysfunction"}]}{"id": "633_1", "text": "Studies in both healthy individuals as well as in patients with other neurodegenerative disorders have used an exogenous carbon dioxide (CO2) challenge in conjunction with functional magnetic resonance imaging (fMRI) to assess regional cerebrovascular reactivity (CVR).", "tags": [{"end": 140, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 137, "tag": "Chemical"}, {"end": 166, "start": 155, "tag": "Finding"}, {"end": 215, "start": 211, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 35, "start": 16, "tag": "PopulationGroup"}, {"end": 209, "start": 172, "tag": "HealthCareActivity"}, {"end": 151, "start": 142, "tag": "HealthCareActivity"}, {"end": 35, "start": 24, "tag": "PopulationGroup"}, {"end": 23, "start": 16, "tag": "OrganismAttribute"}, {"end": 58, "start": 50, "tag": "PatientOrDisabledGroup"}, {"end": 97, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 121, "tag": "Chemical"}, {"end": 135, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 262, "start": 236, "tag": "BiologicFunction"}, {"end": 267, "start": 264, "tag": "BiologicFunction"}]}{"id": "633_2", "text": "In this study, we explored potential impairments of CVR in HD.", "tags": [{"end": 48, "start": 37, "tag": "Finding"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 55, "start": 52, "tag": "BiologicFunction"}]}{"id": "633_3", "text": "Twelve gene expanded HD individuals, including both pre-symptomatic and early symptomatic HD and eleven healthy controls were administered a gas mixture targeting a 4-8 mmHg increase in CO2 relative to the end-tidal partial pressure of CO2 (PETCO2) at rest.", "tags": [{"end": 67, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 141, "tag": "Chemical"}, {"end": 152, "start": 141, "tag": "Substance"}, {"end": 189, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 186, "tag": "Chemical"}, {"end": 239, "start": 236, "tag": "BiologicallyActiveSubstance"}, {"end": 239, "start": 236, "tag": "Chemical"}, {"end": 67, "start": 56, "tag": "SignOrSymptom"}, {"end": 89, "start": 78, "tag": "SignOrSymptom"}, {"end": 35, "start": 24, "tag": "PopulationGroup"}, {"end": 111, "start": 104, "tag": "OrganismAttribute"}, {"end": 120, "start": 104, "tag": "PopulationGroup"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 72, "tag": "TemporalConcept"}, {"end": 232, "start": 216, "tag": "NaturalPhenomenonOrProcess"}, {"end": 239, "start": 206, "tag": "ClinicalAttribute"}, {"end": 247, "start": 241, "tag": "ClinicalAttribute"}]}{"id": "633_4", "text": "A Hilbert Transform analysis was used to compute the cross-correlation between the time series of regional BOLD signal changes (Delta BOLD) and increased PETCO2, and to estimate the response delay of Delta BOLD relative to PETCO2.", "tags": [{"end": 94, "start": 83, "tag": "TemporalConcept"}, {"end": 94, "start": 83, "tag": "ResearchActivity"}, {"end": 111, "start": 107, "tag": "HealthCareActivity"}, {"end": 138, "start": 128, "tag": "ClinicalAttribute"}, {"end": 196, "start": 182, "tag": "Finding"}, {"end": 28, "start": 2, "tag": "ResearchActivity"}, {"end": 87, "start": 83, "tag": "TemporalConcept"}, {"end": 70, "start": 53, "tag": "ResearchActivity"}, {"end": 126, "start": 112, "tag": "ResearchActivity"}, {"end": 160, "start": 154, "tag": "ClinicalAttribute"}, {"end": 210, "start": 200, "tag": "ClinicalAttribute"}, {"end": 229, "start": 223, "tag": "ClinicalAttribute"}]}{"id": "633_5", "text": "After correcting for age, we found that the cross-correlation between the time series for regional Delta BOLD and for PETCO2 was weaker in HD subjects than in controls in several subcortical white matter regions, including the corpus callosum, subcortical white matter adjacent to rostral and caudal anterior cingulate, rostral and caudal middle frontal, insular, middle temporal, and posterior cingulate areas.", "tags": [{"end": 85, "start": 74, "tag": "TemporalConcept"}, {"end": 353, "start": 339, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 327, "start": 320, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 362, "start": 355, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 379, "start": 364, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 410, "start": 385, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 242, "start": 227, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 353, "start": 332, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 139, "tag": "PatientOrDisabledGroup"}, {"end": 190, "start": 179, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 255, "start": 244, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 203, "start": 191, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 268, "start": 256, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 142, "tag": "PopulationGroup"}, {"end": 24, "start": 21, "tag": "OrganismAttribute"}, {"end": 167, "start": 159, "tag": "PopulationGroup"}, {"end": 61, "start": 44, "tag": "ResearchActivity"}, {"end": 318, "start": 293, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 318, "start": 300, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 288, "start": 281, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 99, "tag": "ClinicalAttribute"}, {"end": 124, "start": 118, "tag": "ClinicalAttribute"}]}{"id": "633_6", "text": "In addition, greater volume of dilated perivascular space (PVS) was observed to overlap, primarily along the periphery, with the areas that showed greater Delta BOLD response delay.", "tags": [{"end": 38, "start": 31, "tag": "Finding"}, {"end": 62, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 165, "start": 155, "tag": "ClinicalAttribute"}, {"end": 180, "start": 166, "tag": "Finding"}]}{"id": "633_7", "text": "Our preliminary findings support that alterations in cerebrovascular function occur in HD and may be an important, not as yet considered, contributor to early neuropathology in HD.", "tags": [{"end": 173, "start": 159, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 173, "start": 159, "tag": "PathologicFunction"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 53, "tag": "BiologicFunction"}, {"end": 158, "start": 153, "tag": "TemporalConcept"}]}{"id": "641_0", "text": "Numerous neuroimaging techniques have been used to identify biomarkers of disease progression in Huntington's disease (HD).", "tags": [{"end": 32, "start": 9, "tag": "HealthCareActivity"}, {"end": 70, "start": 60, "tag": "ClinicalAttribute"}, {"end": 93, "start": 74, "tag": "PathologicFunction"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 82, "tag": "PathologicFunction"}, {"end": 93, "start": 82, "tag": "TemporalConcept"}]}{"id": "641_1", "text": "To date, the earliest and most sensitive of these is caudate volume; however, it is becoming increasingly evident that numerous changes to cortical structures, and their interconnected networks, occur throughout the course of the disease.", "tags": [{"end": 222, "start": 216, "tag": "TemporalConcept"}, {"end": 222, "start": 216, "tag": "PathologicFunction"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 21, "start": 13, "tag": "TemporalConcept"}, {"end": 67, "start": 53, "tag": "ClinicalAttribute"}, {"end": 158, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "641_2", "text": "The mechanisms by which atrophy spreads from the caudate to these cortical regions remains unknown.", "tags": [{"end": 56, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 24, "tag": "PathologicFunction"}, {"end": 82, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "641_3", "text": "In this review, the neuroimaging literature specific to T1-weighted and diffusion-weighted magnetic resonance imaging is summarized and new strategies for the investigation of cortical morphometry and the network spread of degeneration in HD are proposed.", "tags": [{"end": 43, "start": 20, "tag": "HealthCareActivity"}, {"end": 117, "start": 72, "tag": "HealthCareActivity"}, {"end": 172, "start": 159, "tag": "ResearchActivity"}, {"end": 196, "start": 176, "tag": "ResearchActivity"}, {"end": 235, "start": 223, "tag": "PathologicFunction"}, {"end": 241, "start": 239, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 117, "start": 91, "tag": "HealthCareActivity"}, {"end": 67, "start": 56, "tag": "HealthCareActivity"}]}{"id": "641_4", "text": "This new avenue of research may enable further characterization of disease pathology and could add to a suite of biomarker/s of disease progression for patient stratification that will help guide future clinical trials.", "tags": [{"end": 27, "start": 19, "tag": "ResearchActivity"}, {"end": 63, "start": 47, "tag": "ResearchActivity"}, {"end": 84, "start": 67, "tag": "PathologicFunction"}, {"end": 174, "start": 160, "tag": "ResearchActivity"}, {"end": 218, "start": 203, "tag": "ResearchActivity"}, {"end": 122, "start": 113, "tag": "ClinicalAttribute"}, {"end": 147, "start": 128, "tag": "PathologicFunction"}, {"end": 159, "start": 152, "tag": "PatientOrDisabledGroup"}, {"end": 147, "start": 136, "tag": "PathologicFunction"}, {"end": 147, "start": 136, "tag": "TemporalConcept"}]}{"id": "661_0", "text": "The Renin-Angiotensin System (RAS) is expressed in the central nervous system and has important functions that go beyond blood pressure regulation.", "tags": [{"end": 28, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 121, "tag": "BiologicFunction"}, {"end": 77, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 38, "tag": "CellFunction"}]}{"id": "661_1", "text": "Clinical and experimental studies have suggested that alterations in the brain RAS contribute to the development and progression of neurodegenerative diseases.", "tags": [{"end": 33, "start": 13, "tag": "ResearchActivity"}, {"end": 82, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 101, "tag": "BiologicFunction"}, {"end": 112, "start": 101, "tag": "CellFunction"}, {"end": 128, "start": 117, "tag": "PathologicFunction"}, {"end": 128, "start": 117, "tag": "TemporalConcept"}, {"end": 158, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 26, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}]}{"id": "661_2", "text": "However, there is limited information regarding the involvement of RAS components in Huntington's disease (HD).", "tags": [{"end": 70, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 52, "tag": "Finding"}, {"end": 105, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}]}{"id": "661_3", "text": "Herein, we used the HD murine model, (BACHD), as well as samples from patients with HD to investigate the role of both the classical and alternative axes of RAS in HD pathophysiology.", "tags": [{"end": 132, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 30, "tag": "ResearchActivity"}, {"end": 182, "start": 167, "tag": "PathologicFunction"}, {"end": 182, "start": 167, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 78, "start": 70, "tag": "PatientOrDisabledGroup"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 57, "tag": "Substance"}, {"end": 64, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 20, "tag": "ExperimentalModelOfDisease"}, {"end": 29, "start": 23, "tag": "Eukaryote"}, {"end": 43, "start": 38, "tag": "ExperimentalModelOfDisease"}]}{"id": "661_4", "text": "BACHD mice displayed worse motor performance in different behavioral tests alongside a decrease in the levels and activity of the components of the RAS alternative axis ACE2, Ang-(1-7), and Mas receptors in the striatum, prefrontal cortex, and hippocampus.", "tags": [{"end": 151, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 203, "start": 190, "tag": "AminoAcidPeptideOrProtein"}, {"end": 238, "start": 221, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 219, "start": 211, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 255, "start": 244, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 33, "tag": "ClinicalAttribute"}, {"end": 44, "start": 27, "tag": "ClinicalAttribute"}, {"end": 44, "start": 33, "tag": "Finding"}, {"end": 74, "start": 58, "tag": "ResearchActivity"}, {"end": 74, "start": 58, "tag": "HealthCareActivity"}, {"end": 10, "start": 6, "tag": "Eukaryote"}, {"end": 95, "start": 87, "tag": "Finding"}, {"end": 10, "start": 0, "tag": "ExperimentalModelOfDisease"}, {"end": 173, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 169, "tag": "GeneOrGenome"}, {"end": 203, "start": 190, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 175, "tag": "PharmacologicSubstance"}]}{"id": "661_5", "text": "BACHD mice also displayed a significant increase in mRNA expression of the AT1 receptor, a component of the RAS classical arm, in these key brain regions.", "tags": [{"end": 87, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 52, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 153, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 10, "start": 6, "tag": "Eukaryote"}, {"end": 67, "start": 57, "tag": "CellFunction"}, {"end": 87, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 0, "tag": "ExperimentalModelOfDisease"}, {"end": 48, "start": 28, "tag": "Finding"}]}{"id": "661_6", "text": "Moreover, patients with manifest HD presented higher plasma levels of Ang-(1-7).", "tags": [{"end": 59, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 10, "tag": "PatientOrDisabledGroup"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 53, "tag": "ClinicalAttribute"}]}{"id": "661_7", "text": "No significant changes were found in the levels of ACE, ACE2, and Ang II.", "tags": [{"end": 54, "start": 51, "tag": "GeneOrGenome"}, {"end": 54, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 56, "tag": "GeneOrGenome"}, {"end": 72, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 0, "tag": "Finding"}, {"end": 60, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 51, "tag": "BiologicallyActiveSubstance"}]}{"id": "661_8", "text": "Our findings provided the first evidence that an imbalance in the RAS classical and counter-regulatory arms may play a role in HD pathophysiology.", "tags": [{"end": 69, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 130, "tag": "PathologicFunction"}, {"end": 145, "start": 130, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 40, "start": 32, "tag": "Finding"}, {"end": 31, "start": 26, "tag": "TemporalConcept"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}]}{"id": "670_0", "text": "Objective: Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder.", "tags": [{"end": 61, "start": 43, "tag": "CellFunction"}, {"end": 61, "start": 53, "tag": "CellFunction"}, {"end": 31, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 62, "tag": "DiseaseOrSyndrome"}]}{"id": "670_1", "text": "Neurofilament light protein (NfL) is correlated with clinical severity of HD but relative data are the lack in the Chinese population.", "tags": [{"end": 27, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 53, "tag": "ClinicalAttribute"}, {"end": 133, "start": 115, "tag": "PopulationGroup"}, {"end": 94, "start": 90, "tag": "ResearchActivity"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "670_2", "text": "Reactive astrocytes are related to HD pathology, which predicts their potential to be a biomarker in HD progression.", "tags": [{"end": 19, "start": 0, "tag": "Cell"}, {"end": 47, "start": 38, "tag": "PathologicFunction"}, {"end": 47, "start": 38, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 19, "start": 9, "tag": "Cell"}, {"end": 115, "start": 104, "tag": "PathologicFunction"}, {"end": 115, "start": 104, "tag": "TemporalConcept"}, {"end": 37, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 88, "tag": "ClinicalAttribute"}]}{"id": "670_3", "text": "Our aim was to discuss the role of blood glial fibrillary acidic protein (GFAP) to evaluate clinical severity in patients with HD.Methods: Fifty-seven HD mutation carriers (15 premanifest HD, preHD, and 42 manifest HD) and 26 healthy controls were recruited.", "tags": [{"end": 72, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 74, "tag": "GeneOrGenome"}, {"end": 109, "start": 92, "tag": "ClinicalAttribute"}, {"end": 162, "start": 154, "tag": "CellOrMolecularDysfunction"}, {"end": 242, "start": 226, "tag": "PopulationGroup"}, {"end": 121, "start": 113, "tag": "PatientOrDisabledGroup"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 163, "tag": "PopulationGroup"}, {"end": 190, "start": 176, "tag": "PatientOrDisabledGroup"}, {"end": 197, "start": 192, "tag": "PatientOrDisabledGroup"}, {"end": 217, "start": 206, "tag": "PatientOrDisabledGroup"}, {"end": 40, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "670_4", "text": "Demographic data and clinical severity assessed with the internationally Unified Huntington's Disease Rating Scale (UHDRS) were retrospectively analyzed.", "tags": [{"end": 121, "start": 116, "tag": "HealthCareActivity"}, {"end": 38, "start": 21, "tag": "ClinicalAttribute"}, {"end": 152, "start": 144, "tag": "ResearchActivity"}, {"end": 114, "start": 73, "tag": "HealthCareActivity"}, {"end": 16, "start": 0, "tag": "ResearchActivity"}]}{"id": "670_5", "text": "Plasma NfL and GFAP were quantified with an ultra-sensitive single-molecule (Simoa, Norcross, GA, USA) technology.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 77, "tag": "ResearchActivity"}, {"end": 19, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 15, "tag": "GeneOrGenome"}, {"end": 10, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 103, "tag": "ResearchActivity"}, {"end": 75, "start": 44, "tag": "ResearchActivity"}]}{"id": "670_6", "text": "We explored their consistency and their correlation with clinical severity.Results: Compared with healthy controls, plasma NfL (p < 0.0001) and GFAP (p < 0.001) were increased in Chinese HD mutation carriers, and they were linearly correlated with each other (r = 0.612, p < 0.001).", "tags": [{"end": 29, "start": 18, "tag": "Finding"}, {"end": 186, "start": 179, "tag": "PopulationGroup"}, {"end": 207, "start": 199, "tag": "PopulationGroup"}, {"end": 242, "start": 232, "tag": "ResearchActivity"}, {"end": 148, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 144, "tag": "GeneOrGenome"}, {"end": 74, "start": 57, "tag": "ClinicalAttribute"}, {"end": 122, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 75, "tag": "ResearchActivity"}, {"end": 198, "start": 190, "tag": "CellOrMolecularDysfunction"}, {"end": 114, "start": 98, "tag": "PopulationGroup"}, {"end": 189, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 40, "tag": "ResearchActivity"}, {"end": 126, "start": 116, "tag": "ClinicalAttribute"}, {"end": 122, "start": 116, "tag": "ClinicalAttribute"}, {"end": 148, "start": 144, "tag": "ClinicalAttribute"}]}{"id": "670_7", "text": "They were also significantly correlated with disease burden, Total Motor Score (TMS) and Total Functional Capacity (TFC).", "tags": [{"end": 39, "start": 29, "tag": "ResearchActivity"}, {"end": 78, "start": 61, "tag": "Finding"}, {"end": 59, "start": 45, "tag": "ResearchActivity"}, {"end": 83, "start": 80, "tag": "HealthCareActivity"}, {"end": 119, "start": 116, "tag": "HealthCareActivity"}, {"end": 114, "start": 89, "tag": "HealthCareActivity"}]}{"id": "670_8", "text": "The scores of Stroop word reading, symbol digit modalities tests, and short version of the Problem Behaviors Assessments (PBAs) for HD were correlated with plasma NfL but not GFAP.", "tags": [{"end": 10, "start": 4, "tag": "Finding"}, {"end": 120, "start": 91, "tag": "HealthCareActivity"}, {"end": 126, "start": 122, "tag": "HealthCareActivity"}, {"end": 150, "start": 140, "tag": "ResearchActivity"}, {"end": 179, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 175, "tag": "BiologicallyActiveSubstance"}, {"end": 179, "start": 175, "tag": "GeneOrGenome"}, {"end": 64, "start": 35, "tag": "HealthCareActivity"}, {"end": 162, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 14, "tag": "HealthCareActivity"}, {"end": 166, "start": 156, "tag": "ClinicalAttribute"}]}{"id": "670_9", "text": "Compared with healthy controls, plasma NfL has been increased since stage 1 but plasma GFAP began to increase statistically in stage 2.Conclusions: Plasma GFAP was correlated with plasma NfL, disease burden, TMS, and TFC in HD mutation carriers.", "tags": [{"end": 73, "start": 68, "tag": "TemporalConcept"}, {"end": 132, "start": 127, "tag": "TemporalConcept"}, {"end": 154, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 164, "tag": "ResearchActivity"}, {"end": 244, "start": 236, "tag": "PopulationGroup"}, {"end": 91, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 155, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 87, "tag": "GeneOrGenome"}, {"end": 159, "start": 155, "tag": "GeneOrGenome"}, {"end": 206, "start": 192, "tag": "ResearchActivity"}, {"end": 38, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 180, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 235, "start": 227, "tag": "CellOrMolecularDysfunction"}, {"end": 211, "start": 208, "tag": "HealthCareActivity"}, {"end": 220, "start": 217, "tag": "HealthCareActivity"}, {"end": 30, "start": 14, "tag": "PopulationGroup"}, {"end": 226, "start": 224, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 32, "tag": "ClinicalAttribute"}, {"end": 91, "start": 80, "tag": "ClinicalAttribute"}, {"end": 159, "start": 148, "tag": "ClinicalAttribute"}, {"end": 190, "start": 180, "tag": "ClinicalAttribute"}]}{"id": "670_10", "text": "Plasma GFAP may have potential to be a sensitive biomarker for evaluating HD progression.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 88, "start": 77, "tag": "PathologicFunction"}, {"end": 88, "start": 77, "tag": "TemporalConcept"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 39, "tag": "ClinicalAttribute"}, {"end": 11, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "680_0", "text": "Neurodegenerative disorders are one of the most common causes of disability and represent 6.3% of the global burden of disease.", "tags": [{"end": 27, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 109, "tag": "ResearchActivity"}, {"end": 75, "start": 65, "tag": "Finding"}]}{"id": "680_1", "text": "Among them, Alzheimer's, Parkinson's, and Huntington's diseases cause cognitive decline, representing the most disabling symptom on both personal and social levels.", "tags": [{"end": 120, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 121, "tag": "SignOrSymptom"}, {"end": 87, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 137, "tag": "Finding"}]}{"id": "680_2", "text": "The molecular mechanisms underlying the onset and progression of dementia are still poorly understood, and include secretory factors potentially affecting differentiated neurons, glial cells and neural stem cell niche.", "tags": [{"end": 217, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 179, "tag": "Cell"}, {"end": 24, "start": 4, "tag": "CellFunction"}, {"end": 73, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 40, "tag": "TemporalConcept"}, {"end": 177, "start": 170, "tag": "Cell"}, {"end": 61, "start": 50, "tag": "PathologicFunction"}, {"end": 61, "start": 50, "tag": "TemporalConcept"}, {"end": 132, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 211, "start": 195, "tag": "Cell"}]}{"id": "680_3", "text": "In the last decade, much attention has been devoted to exosomes as novel carriers of information exchanged among both neighbouring and distant cells.", "tags": [{"end": 96, "start": 73, "tag": "CellFunction"}, {"end": 130, "start": 118, "tag": "PopulationGroup"}, {"end": 18, "start": 7, "tag": "TemporalConcept"}, {"end": 63, "start": 55, "tag": "CellComponent"}, {"end": 148, "start": 143, "tag": "Cell"}, {"end": 34, "start": 25, "tag": "BiologicFunction"}]}{"id": "680_4", "text": "These vesicles can be generated and internalized by different brain cells including neurons, neural stem cells, astrocytes, and microglia, thereby affecting neural plasticity and cognitive functions in physiological and pathological conditions.", "tags": [{"end": 14, "start": 6, "tag": "CellComponent"}, {"end": 156, "start": 147, "tag": "BiologicFunction"}, {"end": 174, "start": 157, "tag": "CellFunction"}, {"end": 174, "start": 164, "tag": "BiologicFunction"}, {"end": 198, "start": 179, "tag": "BiologicFunction"}, {"end": 243, "start": 220, "tag": "PathologicFunction"}, {"end": 110, "start": 93, "tag": "Cell"}, {"end": 137, "start": 128, "tag": "Cell"}, {"end": 73, "start": 62, "tag": "Cell"}, {"end": 91, "start": 84, "tag": "Cell"}, {"end": 122, "start": 112, "tag": "Cell"}]}{"id": "680_5", "text": "Here, we review data on the roles of exosomes as carriers of bioactive molecules potentially involved in the pathogenesis of neurodegenerative disorders and detectable in biological fluids as biomarkers of dementia.", "tags": [{"end": 80, "start": 49, "tag": "CellFunction"}, {"end": 167, "start": 157, "tag": "ClinicalAttribute"}, {"end": 188, "start": 171, "tag": "Substance"}, {"end": 45, "start": 37, "tag": "CellComponent"}, {"end": 121, "start": 109, "tag": "PathologicFunction"}, {"end": 214, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 16, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 202, "start": 192, "tag": "ClinicalAttribute"}, {"end": 152, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 61, "tag": "BiologicallyActiveSubstance"}]}{"id": "680_6", "text": "We also discuss the experimental evidence of the therapeutic potential of stem cell-derived vesicles in experimental models of neurodegeneration-dependent cognitive decline.", "tags": [{"end": 70, "start": 49, "tag": "Finding"}, {"end": 172, "start": 104, "tag": "ExperimentalModelOfDisease"}, {"end": 172, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 127, "tag": "CellOrMolecularDysfunction"}, {"end": 41, "start": 20, "tag": "Finding"}, {"end": 83, "start": 74, "tag": "Cell"}, {"end": 100, "start": 92, "tag": "CellComponent"}]}{"id": "722_0", "text": "Huntington disease (HD) is a neurodegenerative disease.", "tags": [{"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 29, "tag": "DiseaseOrSyndrome"}]}{"id": "722_1", "text": "It is inherited as an autosomal-dominant disease characterized by a triad of progressive motor decline, deteriorating cognitive function, and a broad spectrum of psychiatric symptoms.", "tags": [{"end": 73, "start": 68, "tag": "CellComponent"}, {"end": 117, "start": 104, "tag": "Finding"}, {"end": 136, "start": 118, "tag": "BiologicFunction"}, {"end": 158, "start": 150, "tag": "ResearchActivity"}, {"end": 31, "start": 22, "tag": "CellComponent"}, {"end": 40, "start": 32, "tag": "CellFunction"}, {"end": 182, "start": 162, "tag": "SignOrSymptom"}, {"end": 15, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 77, "tag": "TemporalConcept"}, {"end": 102, "start": 89, "tag": "SignOrSymptom"}]}{"id": "722_2", "text": "We report a case of a severe form of HD with significant cognitive impairment and psychosis that was fairly controlled with antipsychotics (Haloperidol and Olanzapine), anti-dementia medications (Memantine), and anti-chorea treatment (Tetrabenazine).", "tags": [{"end": 151, "start": 140, "tag": "Chemical"}, {"end": 151, "start": 140, "tag": "ResearchActivity"}, {"end": 166, "start": 156, "tag": "Chemical"}, {"end": 248, "start": 235, "tag": "Chemical"}, {"end": 9, "start": 3, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "ResearchActivity"}, {"end": 223, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 217, "tag": "SignOrSymptom"}, {"end": 91, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 124, "tag": "PharmacologicSubstance"}, {"end": 194, "start": 169, "tag": "PharmacologicSubstance"}, {"end": 182, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 12, "tag": "ManufacturedObject"}, {"end": 77, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 196, "tag": "Chemical"}, {"end": 205, "start": 196, "tag": "PharmacologicSubstance"}, {"end": 233, "start": 212, "tag": "HealthCareActivity"}, {"end": 28, "start": 22, "tag": "Finding"}, {"end": 39, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 235, "tag": "PharmacologicSubstance"}, {"end": 166, "start": 156, "tag": "PharmacologicSubstance"}]}{"id": "722_3", "text": "The patient had three stages: pre-symptomatic, prodromal, and manifest.", "tags": [{"end": 28, "start": 22, "tag": "TemporalConcept"}, {"end": 11, "start": 4, "tag": "PatientOrDisabledGroup"}]}{"id": "722_4", "text": "Early detection of HD will significantly improve the medical and mental condition; the current recommendation is not to screen those who are below 18 years of age.", "tags": [{"end": 15, "start": 0, "tag": "HealthCareActivity"}, {"end": 162, "start": 159, "tag": "OrganismAttribute"}, {"end": 155, "start": 150, "tag": "TemporalConcept"}, {"end": 21, "start": 19, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 87, "tag": "TemporalConcept"}, {"end": 81, "start": 65, "tag": "BiologicFunction"}]}{"id": "728_0", "text": "In this Review, Tabrizi et al.", "tags": [{"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}]}{"id": "728_1", "text": "discuss new insights into the molecular pathogenesis of Huntington disease and outline potential therapeutic strategies, which could include the modulation of DNA repair processes.", "tags": [{"end": 179, "start": 159, "tag": "CellFunction"}, {"end": 52, "start": 30, "tag": "PathologicFunction"}, {"end": 119, "start": 97, "tag": "HealthCareActivity"}, {"end": 74, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 87, "tag": "HealthCareActivity"}, {"end": 162, "start": 159, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 52, "start": 40, "tag": "PathologicFunction"}, {"end": 169, "start": 163, "tag": "BiologicFunction"}, {"end": 169, "start": 163, "tag": "HealthCareActivity"}]}{"id": "728_2", "text": "Huntington disease (HD) is a neurodegenerative disease caused by CAG repeat expansion in the huntingtin gene (HTT) and involves a complex web of pathogenic mechanisms.", "tags": [{"end": 108, "start": 93, "tag": "GeneOrGenome"}, {"end": 85, "start": 65, "tag": "CellOrMolecularDysfunction"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 145, "tag": "PathologicFunction"}, {"end": 75, "start": 65, "tag": "MolecularSequence"}, {"end": 113, "start": 110, "tag": "GeneOrGenome"}, {"end": 113, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 93, "tag": "GeneOrGenome"}]}{"id": "728_3", "text": "Mutant HTT (mHTT) disrupts transcription, interferes with immune and mitochondrial function, and is aberrantly modified post-translationally.", "tags": [{"end": 10, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 40, "start": 27, "tag": "CellFunction"}, {"end": 91, "start": 83, "tag": "BiologicFunction"}, {"end": 64, "start": 58, "tag": "BiologicFunction"}, {"end": 140, "start": 120, "tag": "CellFunction"}, {"end": 16, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 12, "tag": "CellOrMolecularDysfunction"}, {"end": 82, "start": 69, "tag": "CellComponent"}, {"end": 91, "start": 69, "tag": "CellFunction"}, {"end": 124, "start": 120, "tag": "TemporalConcept"}, {"end": 10, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 100, "tag": "CellOrMolecularDysfunction"}]}{"id": "728_4", "text": "Evidence suggests that the mHTT RNA is toxic, and at the DNA level, somatic CAG repeat expansion in vulnerable cells influences the disease course.", "tags": [{"end": 8, "start": 0, "tag": "Finding"}, {"end": 44, "start": 39, "tag": "InjuryOrPoisoning"}, {"end": 75, "start": 68, "tag": "CellComponent"}, {"end": 75, "start": 68, "tag": "Cell"}, {"end": 35, "start": 27, "tag": "CellOrMolecularDysfunction"}, {"end": 96, "start": 76, "tag": "CellOrMolecularDysfunction"}, {"end": 146, "start": 132, "tag": "TemporalConcept"}, {"end": 60, "start": 57, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 86, "start": 76, "tag": "MolecularSequence"}, {"end": 35, "start": 27, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 146, "start": 140, "tag": "TemporalConcept"}, {"end": 116, "start": 111, "tag": "Cell"}]}{"id": "728_5", "text": "Genome-wide association studies have identified DNA repair pathways as modifiers of somatic instability and disease course in HD and other repeat expansion diseases.", "tags": [{"end": 31, "start": 0, "tag": "ResearchActivity"}, {"end": 47, "start": 37, "tag": "Finding"}, {"end": 122, "start": 108, "tag": "TemporalConcept"}, {"end": 51, "start": 48, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 58, "start": 52, "tag": "BiologicFunction"}, {"end": 58, "start": 52, "tag": "HealthCareActivity"}, {"end": 122, "start": 116, "tag": "TemporalConcept"}, {"end": 67, "start": 48, "tag": "CellFunction"}, {"end": 128, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 84, "tag": "CellOrMolecularDysfunction"}]}{"id": "728_6", "text": "In animal models of HD, nucleocytoplasmic transport is disrupted and its restoration is neuroprotective.", "tags": [{"end": 51, "start": 24, "tag": "CellFunction"}, {"end": 84, "start": 73, "tag": "HealthCareActivity"}, {"end": 64, "start": 55, "tag": "PathologicFunction"}, {"end": 103, "start": 88, "tag": "CellFunction"}, {"end": 16, "start": 3, "tag": "ResearchActivity"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 3, "tag": "ExperimentalModelOfDisease"}]}{"id": "728_7", "text": "Novel cerebrospinal fluid (CSF) and plasma biomarkers are among the earliest detectable changes in individuals with premanifest HD and have the sensitivity to detect therapeutic benefit.", "tags": [{"end": 87, "start": 77, "tag": "ClinicalAttribute"}, {"end": 185, "start": 166, "tag": "Finding"}, {"end": 76, "start": 68, "tag": "TemporalConcept"}, {"end": 42, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 144, "tag": "Finding"}, {"end": 110, "start": 99, "tag": "PopulationGroup"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 43, "tag": "ClinicalAttribute"}, {"end": 30, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "728_8", "text": "Therapeutically, the first human trial of anHTT-lowering antisense oligonucleotide successfully, and safely, reduced the CSF concentration of mHTT in individuals with HD.", "tags": [{"end": 15, "start": 0, "tag": "HealthCareActivity"}, {"end": 38, "start": 33, "tag": "ResearchActivity"}, {"end": 82, "start": 57, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 82, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 57, "tag": "Chemical"}, {"end": 169, "start": 150, "tag": "PatientOrDisabledGroup"}, {"end": 161, "start": 150, "tag": "PopulationGroup"}, {"end": 32, "start": 27, "tag": "Eukaryote"}, {"end": 26, "start": 21, "tag": "TemporalConcept"}, {"end": 169, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 121, "tag": "ClinicalAttribute"}, {"end": 82, "start": 44, "tag": "HealthCareActivity"}]}{"id": "728_9", "text": "A larger trial, powered to detect clinical efficacy, is underway, along with trials of other HTT-lowering approaches.", "tags": [{"end": 14, "start": 9, "tag": "ResearchActivity"}, {"end": 51, "start": 34, "tag": "ResearchActivity"}, {"end": 96, "start": 93, "tag": "GeneOrGenome"}, {"end": 96, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 93, "tag": "HealthCareActivity"}]}{"id": "728_10", "text": "In this Review, we discuss new insights into the molecular pathogenesis of HD and future therapeutic strategies, including the modulation of DNA repair and targeting the DNA mutation itself.", "tags": [{"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 151, "start": 141, "tag": "CellFunction"}, {"end": 71, "start": 49, "tag": "PathologicFunction"}, {"end": 111, "start": 89, "tag": "HealthCareActivity"}, {"end": 144, "start": 141, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 173, "start": 170, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 71, "start": 59, "tag": "PathologicFunction"}, {"end": 151, "start": 145, "tag": "BiologicFunction"}, {"end": 151, "start": 145, "tag": "HealthCareActivity"}, {"end": 182, "start": 174, "tag": "CellOrMolecularDysfunction"}, {"end": 88, "start": 82, "tag": "TemporalConcept"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}]}{"id": "734_0", "text": "Molecular markers derived from cerebrospinal fluid (CSF) represent an accessible means of exploring the pathobiology of Huntington's disease (HD) in vivo.", "tags": [{"end": 17, "start": 0, "tag": "ClinicalAttribute"}, {"end": 153, "start": 146, "tag": "ResearchActivity"}, {"end": 140, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 104, "tag": "BiologicFunction"}]}{"id": "734_1", "text": "The endo-lysosomal/autophagy system is dysfunctional in HD, potentially contributing to disease pathogenesis and representing a potential target for therapeutic intervention.", "tags": [{"end": 52, "start": 39, "tag": "PathologicFunction"}, {"end": 18, "start": 4, "tag": "CellComponent"}, {"end": 173, "start": 149, "tag": "HealthCareActivity"}, {"end": 108, "start": 96, "tag": "PathologicFunction"}, {"end": 35, "start": 4, "tag": "CellFunction"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}]}{"id": "734_2", "text": "Several endo-lysosomal proteins have shown promise as biomarkers in other neurodegenerative diseases; however, they have yet to be fully explored in HD.", "tags": [{"end": 31, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 54, "tag": "ClinicalAttribute"}, {"end": 22, "start": 8, "tag": "CellComponent"}]}{"id": "734_3", "text": "We performed parallel reaction monitoring mass spectrometry analysis (PRM-MS) of multiple endo-lysosomal proteins in the CSF of 60 HD mutation carriers and 20 healthy controls.", "tags": [{"end": 151, "start": 143, "tag": "PopulationGroup"}, {"end": 104, "start": 90, "tag": "CellComponent"}, {"end": 68, "start": 13, "tag": "ResearchActivity"}, {"end": 142, "start": 134, "tag": "CellOrMolecularDysfunction"}, {"end": 113, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 166, "start": 159, "tag": "OrganismAttribute"}, {"end": 175, "start": 159, "tag": "PopulationGroup"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 70, "tag": "ResearchActivity"}]}{"id": "734_4", "text": "Using generalised linear models controlling for age and CAG, none of the 18 proteins measured displayed significant differences in concentration between HD patients and controls.", "tags": [{"end": 144, "start": 131, "tag": "BiologicFunction"}, {"end": 59, "start": 56, "tag": "MolecularSequence"}, {"end": 127, "start": 104, "tag": "Finding"}, {"end": 84, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 48, "tag": "OrganismAttribute"}, {"end": 177, "start": 169, "tag": "PopulationGroup"}, {"end": 164, "start": 153, "tag": "PatientOrDisabledGroup"}, {"end": 31, "start": 6, "tag": "ResearchActivity"}]}{"id": "734_5", "text": "This was affirmed by principal component analysis, in which no significant difference across disease stage was found in any of the three components representing lysosomal hydrolases, binding/transfer proteins and innate immune system/peripheral proteins.", "tags": [{"end": 181, "start": 161, "tag": "BiologicallyActiveSubstance"}, {"end": 199, "start": 183, "tag": "CellFunction"}, {"end": 147, "start": 137, "tag": "CellComponent"}, {"end": 233, "start": 213, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 60, "tag": "Finding"}, {"end": 106, "start": 93, "tag": "ClinicalAttribute"}, {"end": 106, "start": 93, "tag": "TemporalConcept"}, {"end": 208, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 253, "start": 245, "tag": "AminoAcidPeptideOrProtein"}, {"end": 244, "start": 234, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 21, "tag": "ResearchActivity"}]}{"id": "734_6", "text": "However, several proteins were associated with measures of disease severity and cognition: most notably amyloid precursor protein, which displayed strong correlations with composite Unified Huntington's Disease Rating Scale, UHDRS Total Functional Capacity, UHDRS Total Motor Score, Symbol Digit Modalities Test and Stroop Word Reading.", "tags": [{"end": 55, "start": 47, "tag": "ResearchActivity"}, {"end": 129, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 281, "start": 264, "tag": "Finding"}, {"end": 256, "start": 231, "tag": "Finding"}, {"end": 230, "start": 225, "tag": "HealthCareActivity"}, {"end": 263, "start": 258, "tag": "HealthCareActivity"}, {"end": 75, "start": 67, "tag": "ClinicalAttribute"}, {"end": 75, "start": 67, "tag": "Finding"}, {"end": 75, "start": 59, "tag": "ClinicalAttribute"}, {"end": 89, "start": 80, "tag": "BiologicFunction"}, {"end": 75, "start": 59, "tag": "Finding"}, {"end": 311, "start": 283, "tag": "HealthCareActivity"}, {"end": 166, "start": 154, "tag": "ResearchActivity"}, {"end": 111, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 223, "start": 182, "tag": "HealthCareActivity"}, {"end": 25, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 335, "start": 316, "tag": "HealthCareActivity"}]}{"id": "734_7", "text": "We conclude that although endo-lysosomal proteins are unlikely to have value as disease state CSF biomarkers for Huntington's disease, several proteins demonstrate associations with clinical severity, thus warranting further, targeted exploration and validation in larger, longitudinal samples.", "tags": [{"end": 93, "start": 80, "tag": "ClinicalAttribute"}, {"end": 261, "start": 251, "tag": "ResearchActivity"}, {"end": 199, "start": 182, "tag": "ClinicalAttribute"}, {"end": 285, "start": 273, "tag": "ResearchActivity"}, {"end": 246, "start": 235, "tag": "HealthCareActivity"}, {"end": 49, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 246, "start": 235, "tag": "ResearchActivity"}, {"end": 133, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 293, "start": 286, "tag": "Substance"}, {"end": 293, "start": 286, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 98, "tag": "ClinicalAttribute"}, {"end": 97, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 26, "tag": "CellComponent"}]}{"id": "735_0", "text": "Background: The medical researchers are developing different non-invasive methods for early detection of Neurodegenerative Diseases (NDDs) when pharmacological interventions are still possible to further prevent the disease progression.", "tags": [{"end": 81, "start": 74, "tag": "ResearchActivity"}, {"end": 131, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 61, "tag": "ClinicalAttribute"}, {"end": 35, "start": 24, "tag": "ResearchActivity"}, {"end": 159, "start": 144, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 173, "start": 160, "tag": "HealthCareActivity"}, {"end": 173, "start": 160, "tag": "ResearchActivity"}, {"end": 73, "start": 65, "tag": "Finding"}, {"end": 101, "start": 86, "tag": "HealthCareActivity"}, {"end": 137, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 92, "tag": "HealthCareActivity"}, {"end": 235, "start": 216, "tag": "PathologicFunction"}, {"end": 235, "start": 224, "tag": "PathologicFunction"}, {"end": 235, "start": 224, "tag": "TemporalConcept"}]}{"id": "735_1", "text": "The NDDs are associated with the degradation in the complex gait dynamics and motor activity.", "tags": [{"end": 92, "start": 78, "tag": "CellFunction"}, {"end": 92, "start": 78, "tag": "BiologicFunction"}, {"end": 73, "start": 60, "tag": "OrganismAttribute"}, {"end": 8, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 33, "tag": "NaturalPhenomenonOrProcess"}]}{"id": "735_2", "text": "The classification of gait data using machine learning techniques can assist the physicians for early diagnosis of the neural disorder when clinical manifestation of the diseases is not yet apparent.", "tags": [{"end": 134, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 96, "tag": "HealthCareActivity"}, {"end": 91, "start": 81, "tag": "HealthCareActivity"}, {"end": 162, "start": 140, "tag": "SignOrSymptom"}, {"end": 65, "start": 38, "tag": "MachineActivity"}, {"end": 54, "start": 38, "tag": "MachineActivity"}, {"end": 111, "start": 102, "tag": "HealthCareActivity"}, {"end": 26, "start": 22, "tag": "OrganismAttribute"}, {"end": 31, "start": 27, "tag": "ResearchActivity"}, {"end": 18, "start": 4, "tag": "ResearchActivity"}]}{"id": "735_3", "text": "Aims: The present study was undertaken to classify the control and NDD subjects using decision trees based classifiers (Random Forest (RF), J48 and REPTree).", "tags": [{"end": 79, "start": 71, "tag": "PopulationGroup"}, {"end": 70, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 18, "tag": "ResearchActivity"}, {"end": 133, "start": 120, "tag": "MachineActivity"}, {"end": 137, "start": 135, "tag": "MachineActivity"}, {"end": 118, "start": 86, "tag": "MachineActivity"}, {"end": 143, "start": 140, "tag": "MachineActivity"}, {"end": 155, "start": 148, "tag": "MachineActivity"}]}{"id": "735_4", "text": "Methodology: The data used in the study comprises of 16 control, 20 Huntington's Disease (HD), 15 Parkinson's Disease (PD), and 13 Amyotrophic Lateral Sclerosis (ALS) subjects, which were taken from publicly available database from Physionet.", "tags": [{"end": 11, "start": 0, "tag": "ResearchActivity"}, {"end": 226, "start": 218, "tag": "ResearchActivity"}, {"end": 117, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 167, "tag": "PopulationGroup"}, {"end": 88, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 17, "tag": "ResearchActivity"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 34, "tag": "ResearchActivity"}, {"end": 241, "start": 232, "tag": "HealthCareRelatedOrganization"}]}{"id": "735_5", "text": "The age range of control subjects was 2074, HD subjects was 36-70, PD subjects was 44-80, and ALS subjects was 29-71.", "tags": [{"end": 33, "start": 17, "tag": "PopulationGroup"}, {"end": 78, "start": 70, "tag": "PopulationGroup"}, {"end": 106, "start": 98, "tag": "PopulationGroup"}, {"end": 7, "start": 4, "tag": "OrganismAttribute"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 47, "tag": "PopulationGroup"}]}{"id": "735_6", "text": "There were 13 attributes associated with the data.", "tags": [{"end": 49, "start": 45, "tag": "ResearchActivity"}]}{"id": "735_7", "text": "Important features/attributes of the data were selected using correlation feature selection - subset evaluation (cfs) method.", "tags": [{"end": 124, "start": 62, "tag": "ResearchActivity"}, {"end": 41, "start": 37, "tag": "ResearchActivity"}]}{"id": "735_8", "text": "Three tree based machine learning algorithms (RF, J48 and REPTree) were used to classify the control and NDD subjects.", "tags": [{"end": 44, "start": 0, "tag": "MachineActivity"}, {"end": 117, "start": 109, "tag": "PopulationGroup"}, {"end": 108, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 46, "tag": "MachineActivity"}, {"end": 53, "start": 50, "tag": "MachineActivity"}, {"end": 65, "start": 58, "tag": "MachineActivity"}]}{"id": "735_9", "text": "The performance of classifiers were evaluated using Precision, Recall, F-Measure, MAE and RMSE.", "tags": [{"end": 61, "start": 52, "tag": "ResearchActivity"}, {"end": 15, "start": 4, "tag": "Finding"}, {"end": 94, "start": 90, "tag": "ResearchActivity"}, {"end": 85, "start": 82, "tag": "ResearchActivity"}, {"end": 80, "start": 71, "tag": "ResearchActivity"}, {"end": 69, "start": 63, "tag": "ResearchActivity"}]}{"id": "735_10", "text": "Results: In order to evaluate the performance of tree based classifiers, two different settings of data i.e.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 103, "start": 99, "tag": "ResearchActivity"}, {"end": 45, "start": 34, "tag": "Finding"}, {"end": 71, "start": 49, "tag": "MachineActivity"}]}{"id": "735_11", "text": "complete features and selected features were used.", "tags": []}{"id": "735_12", "text": "In classifying control vs HD subjects, RF provides the robust separation with classification accuracy of 84.79% using complete features and 83.94% using selected features.", "tags": [{"end": 37, "start": 29, "tag": "PopulationGroup"}, {"end": 92, "start": 78, "tag": "ResearchActivity"}, {"end": 101, "start": 93, "tag": "Finding"}, {"end": 28, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 39, "tag": "MachineActivity"}, {"end": 135, "start": 118, "tag": "ResearchActivity"}, {"end": 170, "start": 153, "tag": "ResearchActivity"}]}{"id": "735_13", "text": "While in classifying control vs PD subjects, and control vs ALS subjects, RF also provides the best separation with classification accuracy of 86.51% and 94.95% respectively using complete features and 85.19% and 93.64% respectively using selected features.", "tags": [{"end": 43, "start": 35, "tag": "PopulationGroup"}, {"end": 72, "start": 64, "tag": "PopulationGroup"}, {"end": 34, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 116, "tag": "ResearchActivity"}, {"end": 139, "start": 131, "tag": "Finding"}, {"end": 76, "start": 74, "tag": "MachineActivity"}, {"end": 197, "start": 180, "tag": "ResearchActivity"}, {"end": 256, "start": 239, "tag": "ResearchActivity"}]}{"id": "735_14", "text": "Conclusion: The variability analysis of physiological signals provides a valuable non-invasive tool for quantifying the system of dynamics of healthy subjects and to examine the alternations in the controlling mechanism of these systems with aging and disease.", "tags": [{"end": 27, "start": 16, "tag": "Finding"}, {"end": 94, "start": 82, "tag": "ClinicalAttribute"}, {"end": 94, "start": 86, "tag": "Finding"}, {"end": 158, "start": 142, "tag": "PopulationGroup"}, {"end": 247, "start": 242, "tag": "BiologicFunction"}, {"end": 247, "start": 242, "tag": "CellFunction"}, {"end": 138, "start": 130, "tag": "NaturalPhenomenonOrProcess"}, {"end": 158, "start": 150, "tag": "PopulationGroup"}, {"end": 149, "start": 142, "tag": "OrganismAttribute"}, {"end": 36, "start": 28, "tag": "ResearchActivity"}]}{"id": "735_15", "text": "It is concluded that selected features encode adequate information about neural control of the gait.", "tags": [{"end": 87, "start": 73, "tag": "BiologicFunction"}, {"end": 99, "start": 95, "tag": "OrganismAttribute"}, {"end": 38, "start": 21, "tag": "ResearchActivity"}]}{"id": "735_16", "text": "Moreover, the selected features along with tree based machine learning algorithms can play a vital for early detection of NDDs, when pharmacological interventions are still possible.", "tags": [{"end": 162, "start": 133, "tag": "HealthCareActivity"}, {"end": 81, "start": 43, "tag": "MachineActivity"}, {"end": 118, "start": 103, "tag": "HealthCareActivity"}, {"end": 126, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 109, "tag": "HealthCareActivity"}, {"end": 31, "start": 14, "tag": "ResearchActivity"}]}{"id": "742_0", "text": "Introduction: The ultimate cause of neuronal death in Huntington's disease (HD) is still uncertain.", "tags": [{"end": 50, "start": 36, "tag": "CellFunction"}, {"end": 50, "start": 45, "tag": "BiologicFunction"}, {"end": 50, "start": 45, "tag": "PathologicFunction"}, {"end": 50, "start": 45, "tag": "CellFunction"}, {"end": 44, "start": 36, "tag": "Cell"}, {"end": 74, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}]}{"id": "742_1", "text": "Apart from impairment in systems handling abnormal proteins, other mechanisms might contribute to neurodegeneration and progression of HD.", "tags": [{"end": 21, "start": 11, "tag": "Finding"}, {"end": 115, "start": 98, "tag": "CellOrMolecularDysfunction"}, {"end": 131, "start": 120, "tag": "PathologicFunction"}, {"end": 131, "start": 120, "tag": "TemporalConcept"}, {"end": 137, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 42, "tag": "CellOrMolecularDysfunction"}]}{"id": "742_2", "text": "Decreased cerebral blood flow (CBF) has been described in other neurodegenerative disorders and may play a role in HD.Objectives: To investigate CBF changes in HD gene carriers.Methods: A group of 39 HD gene carriers (18 premanifest and 21 manifest HD) and 16 controls underwent a comprehensive clinical evaluation and a brain magnetic resonance imaging protocol that included pseudo -continuous arterial spin labeling to quantify CBF.", "tags": [{"end": 29, "start": 10, "tag": "BiologicFunction"}, {"end": 34, "start": 31, "tag": "BiologicFunction"}, {"end": 148, "start": 145, "tag": "BiologicFunction"}, {"end": 314, "start": 295, "tag": "HealthCareActivity"}, {"end": 314, "start": 295, "tag": "ResearchActivity"}, {"end": 434, "start": 431, "tag": "BiologicFunction"}, {"end": 176, "start": 160, "tag": "PatientOrDisabledGroup"}, {"end": 216, "start": 200, "tag": "PatientOrDisabledGroup"}, {"end": 24, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 353, "start": 327, "tag": "HealthCareActivity"}, {"end": 193, "start": 188, "tag": "PopulationGroup"}, {"end": 326, "start": 321, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 268, "start": 260, "tag": "PopulationGroup"}, {"end": 91, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 149, "tag": "Finding"}, {"end": 362, "start": 354, "tag": "ResearchActivity"}, {"end": 418, "start": 377, "tag": "HealthCareActivity"}, {"end": 251, "start": 249, "tag": "PatientOrDisabledGroup"}, {"end": 232, "start": 221, "tag": "PatientOrDisabledGroup"}, {"end": 251, "start": 240, "tag": "PatientOrDisabledGroup"}]}{"id": "742_3", "text": "Regions of interest (ROI) analyses were performed to compare CBF in controls vs premanifest HD vs manifest HD.", "tags": [{"end": 64, "start": 61, "tag": "BiologicFunction"}, {"end": 106, "start": 98, "tag": "PatientOrDisabledGroup"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 68, "tag": "PopulationGroup"}, {"end": 34, "start": 0, "tag": "ResearchActivity"}, {"end": 91, "start": 80, "tag": "PatientOrDisabledGroup"}]}{"id": "742_4", "text": "Correlation analyses were performed to ascertain the relationship between CBF and clinical and biomarkers data.Results: We found a decrease in CBF in bilateral caudate and putamen of patients with manifest HD in comparison with controls.", "tags": [{"end": 77, "start": 74, "tag": "BiologicFunction"}, {"end": 146, "start": 143, "tag": "BiologicFunction"}, {"end": 179, "start": 172, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 53, "tag": "Finding"}, {"end": 167, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 111, "tag": "ResearchActivity"}, {"end": 139, "start": 131, "tag": "Finding"}, {"end": 110, "start": 106, "tag": "ResearchActivity"}, {"end": 191, "start": 183, "tag": "PatientOrDisabledGroup"}, {"end": 208, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 95, "tag": "ClinicalAttribute"}, {"end": 222, "start": 212, "tag": "ResearchActivity"}, {"end": 236, "start": 228, "tag": "PopulationGroup"}, {"end": 20, "start": 0, "tag": "ResearchActivity"}]}{"id": "742_5", "text": "CBF of premanifest HD carriers in the same ROIs was midway between controls and the HD pa-tients, with differences not reaching statistical significance.", "tags": [{"end": 3, "start": 0, "tag": "BiologicFunction"}, {"end": 152, "start": 128, "tag": "Finding"}, {"end": 114, "start": 103, "tag": "Finding"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 67, "tag": "PopulationGroup"}, {"end": 30, "start": 7, "tag": "PatientOrDisabledGroup"}, {"end": 47, "start": 43, "tag": "ResearchActivity"}]}{"id": "742_6", "text": "Lower CBF in caudate and putamen was associated with worse motor symptoms, functionality, and cognitive performance.", "tags": [{"end": 9, "start": 6, "tag": "BiologicFunction"}, {"end": 32, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 75, "tag": "OrganismAttribute"}, {"end": 115, "start": 94, "tag": "ClinicalAttribute"}, {"end": 20, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 59, "tag": "SignOrSymptom"}]}{"id": "742_7", "text": "CBF was also associated with markers of neurodegeneration: higher CBF in caudate and putamen significantly correlated to higher volumes in the same ROI and to lower levels of neurofilament light chain.Conclusion: As CBF changes in caudate and putamen nuclei were associated with markers of neurodegeneration and with clinical outcomes, decreased CBF and oxygen supply could emerge as a relevant mechanism contrib-uting to degeneration in HD.", "tags": [{"end": 3, "start": 0, "tag": "BiologicFunction"}, {"end": 36, "start": 29, "tag": "ClinicalAttribute"}, {"end": 69, "start": 66, "tag": "BiologicFunction"}, {"end": 92, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 219, "start": 216, "tag": "BiologicFunction"}, {"end": 257, "start": 243, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 286, "start": 279, "tag": "ClinicalAttribute"}, {"end": 349, "start": 346, "tag": "BiologicFunction"}, {"end": 367, "start": 354, "tag": "ClinicalAttribute"}, {"end": 80, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 231, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 334, "start": 317, "tag": "ClinicalAttribute"}, {"end": 57, "start": 40, "tag": "CellOrMolecularDysfunction"}, {"end": 307, "start": 290, "tag": "CellOrMolecularDysfunction"}, {"end": 434, "start": 422, "tag": "PathologicFunction"}, {"end": 440, "start": 438, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 200, "start": 175, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 148, "tag": "ResearchActivity"}, {"end": 227, "start": 220, "tag": "Finding"}]}{"id": "773_0", "text": "Drosophila melanogaster provides a powerful genetic model system in which to investigate the molecular mechanisms underlying neurodegenerative diseases.", "tags": [{"end": 64, "start": 44, "tag": "ExperimentalModelOfDisease"}, {"end": 113, "start": 93, "tag": "CellFunction"}, {"end": 23, "start": 0, "tag": "Eukaryote"}, {"end": 151, "start": 125, "tag": "DiseaseOrSyndrome"}]}{"id": "773_1", "text": "In this review, we discuss recent progress in Drosophila modeling Alzheimer's Disease, Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease, Ataxia Telangiectasia, and neurodegeneration related to mitochondrial dysfunction or traumatic brain injury.", "tags": [{"end": 85, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 223, "tag": "CellOrMolecularDysfunction"}, {"end": 274, "start": 252, "tag": "InjuryOrPoisoning"}, {"end": 33, "start": 27, "tag": "TemporalConcept"}, {"end": 56, "start": 46, "tag": "Eukaryote"}, {"end": 165, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 194, "tag": "CellOrMolecularDysfunction"}, {"end": 42, "start": 34, "tag": "TemporalConcept"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "773_2", "text": "We close by discussing recent progress using Drosophila models of neural regeneration and how these are likely to provide critical insights into future treatments for neurodegenerative disorders.", "tags": [{"end": 85, "start": 66, "tag": "CellFunction"}, {"end": 162, "start": 152, "tag": "HealthCareActivity"}, {"end": 162, "start": 152, "tag": "ResearchActivity"}, {"end": 29, "start": 23, "tag": "TemporalConcept"}, {"end": 151, "start": 145, "tag": "TemporalConcept"}, {"end": 62, "start": 45, "tag": "ExperimentalModelOfDisease"}, {"end": 194, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 30, "tag": "TemporalConcept"}]}{"id": "805_0", "text": "Huntington's Disease (HD) is an autosomal neurodegenerative disease characterized by motor, cognitive, and psychiatric symptoms.", "tags": [{"end": 67, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 107, "tag": "SignOrSymptom"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "805_1", "text": "Cognitive impairment develops gradually in HD patients, progressing later into a severe cognitive dysfunction.", "tags": [{"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 43, "tag": "PatientOrDisabledGroup"}, {"end": 109, "start": 81, "tag": "DiseaseOrSyndrome"}]}{"id": "805_2", "text": "The Montreal Cognitive Assessment (MoCA) is a brief screening test commonly employed to detect mild cognitive impairment, which has also been useful to assess cognitive decline in HD patients.", "tags": [{"end": 33, "start": 4, "tag": "HealthCareActivity"}, {"end": 39, "start": 35, "tag": "HealthCareActivity"}, {"end": 120, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 180, "tag": "PatientOrDisabledGroup"}, {"end": 66, "start": 52, "tag": "ResearchActivity"}, {"end": 176, "start": 159, "tag": "DiseaseOrSyndrome"}]}{"id": "805_3", "text": "However, the relationship between MoCA performance and brain structural integrity in HD patients remains unclear.", "tags": [{"end": 38, "start": 34, "tag": "HealthCareActivity"}, {"end": 96, "start": 85, "tag": "PatientOrDisabledGroup"}, {"end": 50, "start": 34, "tag": "Finding"}, {"end": 81, "start": 55, "tag": "Finding"}]}{"id": "805_4", "text": "Therefore, to explore this relationship we analyzed if cortical thinning and subcortical nuclei volume differences correlated with HD patients' MoCA performance.", "tags": [{"end": 51, "start": 43, "tag": "ResearchActivity"}, {"end": 72, "start": 55, "tag": "Finding"}, {"end": 95, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 131, "tag": "PatientOrDisabledGroup"}, {"end": 148, "start": 144, "tag": "HealthCareActivity"}, {"end": 160, "start": 144, "tag": "Finding"}, {"end": 114, "start": 77, "tag": "Finding"}, {"end": 102, "start": 77, "tag": "ClinicalAttribute"}]}{"id": "805_5", "text": "Twenty-two HD patients and twenty-two healthy subjects participated in this study.", "tags": [{"end": 22, "start": 11, "tag": "PatientOrDisabledGroup"}, {"end": 54, "start": 38, "tag": "PopulationGroup"}, {"end": 81, "start": 76, "tag": "ResearchActivity"}]}{"id": "805_6", "text": "T1-weighted images were acquired to analyze cortical thickness and subcortical nuclei volumes.", "tags": [{"end": 93, "start": 67, "tag": "ClinicalAttribute"}, {"end": 62, "start": 44, "tag": "ClinicalAttribute"}, {"end": 85, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 0, "tag": "ResearchActivity"}]}{"id": "805_7", "text": "Group comparison analysis showed a significantly lower score in the MoCA global performance of HD patients.", "tags": [{"end": 72, "start": 68, "tag": "HealthCareActivity"}, {"end": 106, "start": 95, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 0, "tag": "ResearchActivity"}, {"end": 91, "start": 49, "tag": "Finding"}]}{"id": "805_8", "text": "Also, the MoCA total score correlated with cortical thinning of fronto-parietal and temporo-occipital cortices, as well as with bilateral caudate volume differences in HD patients.", "tags": [{"end": 14, "start": 10, "tag": "HealthCareActivity"}, {"end": 60, "start": 43, "tag": "Finding"}, {"end": 152, "start": 128, "tag": "ClinicalAttribute"}, {"end": 179, "start": 168, "tag": "PatientOrDisabledGroup"}, {"end": 110, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 128, "tag": "Finding"}, {"end": 26, "start": 10, "tag": "ResearchActivity"}]}{"id": "805_9", "text": "These results provide new insights into the effectiveness of using the MoCA test to detect cognitive impairment and the brain atrophy pattern associated with the cognitive status of prodromal/early HD patients.", "tags": [{"end": 111, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 209, "start": 198, "tag": "PatientOrDisabledGroup"}, {"end": 80, "start": 71, "tag": "HealthCareActivity"}, {"end": 178, "start": 162, "tag": "BiologicFunction"}, {"end": 197, "start": 182, "tag": "TemporalConcept"}, {"end": 133, "start": 120, "tag": "DiseaseOrSyndrome"}]}{"id": "820_0", "text": "Huntington's disease is a neurodegenerative disorder, characterised by progressive cognitive, motor and psychiatric symptoms.", "tags": [{"end": 52, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 71, "tag": "SignOrSymptom"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "820_1", "text": "Patients with advanced disease presenting to emergency medical services can pose a diagnostic and management challenge for physicians unfamiliar with the condition.", "tags": [{"end": 71, "start": 45, "tag": "HealthCareActivity"}, {"end": 108, "start": 98, "tag": "HealthCareActivity"}, {"end": 133, "start": 123, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 118, "start": 109, "tag": "HealthCareActivity"}]}{"id": "820_2", "text": "We describe two patients with Huntington's disease in whom the diagnosis of traumatic spinal cord injury was delayed, discuss the role that cognitive bias and other factors played in this delay, and the lessons we can learn.", "tags": [{"end": 72, "start": 63, "tag": "HealthCareActivity"}, {"end": 104, "start": 76, "tag": "InjuryOrPoisoning"}, {"end": 193, "start": 188, "tag": "TemporalConcept"}, {"end": 50, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 16, "tag": "PatientOrDisabledGroup"}]}{"id": "822_0", "text": "Huntington's disease (HD) is an inherited neurodegenerative disorder which begins in the striatum and then spreads to other neural areas.", "tags": [{"end": 68, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "822_1", "text": "Known as a progressive movement cognitive disorder, HD has no efficient therapy.", "tags": [{"end": 50, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 72, "tag": "HealthCareActivity"}, {"end": 54, "start": 52, "tag": "DiseaseOrSyndrome"}]}{"id": "822_2", "text": "Although the exact mechanism of HD is still unknown, several different etiological processes such as oxidative stress have been shown to play critical roles.", "tags": [{"end": 92, "start": 71, "tag": "BiologicFunction"}, {"end": 34, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 101, "tag": "CellOrMolecularDysfunction"}]}{"id": "822_3", "text": "Also, the current evidence indicates a strong correlation between immune activation and neural damage induced by neuroinflammatory and apoptotic agents in neurodegenerative disorders.", "tags": [{"end": 83, "start": 66, "tag": "BiologicFunction"}, {"end": 130, "start": 113, "tag": "PathologicFunction"}, {"end": 17, "start": 10, "tag": "TemporalConcept"}, {"end": 26, "start": 18, "tag": "Finding"}, {"end": 182, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 88, "tag": "InjuryOrPoisoning"}]}{"id": "822_4", "text": "Thus, natural products like Elderberry (EB) could be considered as a novel and potential therapeutic candidate for the treatment of this disease.", "tags": [{"end": 22, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 28, "tag": "Chemical"}, {"end": 42, "start": 40, "tag": "Chemical"}, {"end": 110, "start": 89, "tag": "HealthCareActivity"}, {"end": 128, "start": 119, "tag": "HealthCareActivity"}, {"end": 128, "start": 119, "tag": "ResearchActivity"}, {"end": 38, "start": 28, "tag": "PharmacologicSubstance"}, {"end": 42, "start": 40, "tag": "PharmacologicSubstance"}]}{"id": "822_5", "text": "In this study EB was added to the daily ration of ordinary rats for two months in order to ameliorate inflammatory and oxidative responses in rats injected with 3-nitropropionic acid (3-NP) in an experimental model of HD.", "tags": [{"end": 16, "start": 14, "tag": "Chemical"}, {"end": 39, "start": 34, "tag": "TemporalConcept"}, {"end": 78, "start": 72, "tag": "TemporalConcept"}, {"end": 138, "start": 119, "tag": "CellFunction"}, {"end": 182, "start": 161, "tag": "Chemical"}, {"end": 220, "start": 196, "tag": "ExperimentalModelOfDisease"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 16, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 63, "start": 59, "tag": "Eukaryote"}, {"end": 146, "start": 142, "tag": "Eukaryote"}, {"end": 182, "start": 161, "tag": "PharmacologicSubstance"}, {"end": 188, "start": 184, "tag": "PharmacologicSubstance"}, {"end": 188, "start": 184, "tag": "Chemical"}, {"end": 138, "start": 129, "tag": "PathologicFunction"}, {"end": 114, "start": 102, "tag": "PathologicFunction"}]}{"id": "822_6", "text": "Using Rotarod and electromyography setups, we showed that EB diet significantly recovered motor failure and muscle incoordination in 3-NP injected rats compared to the control group.", "tags": [{"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 41, "start": 18, "tag": "HealthCareActivity"}, {"end": 60, "start": 58, "tag": "Chemical"}, {"end": 65, "start": 58, "tag": "HealthCareActivity"}, {"end": 60, "start": 58, "tag": "PharmacologicSubstance"}]}{"id": "822_7", "text": "Also, the molecular findings implied that EB diet led to a significant drop in 3-NP induced growth in caspase-3 and TNF-alpha concentration.", "tags": [{"end": 28, "start": 10, "tag": "ResearchActivity"}, {"end": 44, "start": 42, "tag": "Chemical"}, {"end": 49, "start": 42, "tag": "HealthCareActivity"}, {"end": 75, "start": 59, "tag": "Finding"}, {"end": 98, "start": 92, "tag": "BiologicFunction"}, {"end": 111, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 42, "tag": "PharmacologicSubstance"}, {"end": 83, "start": 79, "tag": "PharmacologicSubstance"}, {"end": 83, "start": 79, "tag": "Chemical"}]}{"id": "822_8", "text": "The treatment also improved striatal antioxidative capacity by a significant reduction in ROS and a remarkable rise in GSH, which might be correlated with motor recovery in the tests.", "tags": [{"end": 93, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 90, "tag": "Chemical"}, {"end": 122, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 155, "tag": "BiologicFunction"}, {"end": 182, "start": 177, "tag": "ResearchActivity"}, {"end": 182, "start": 177, "tag": "HealthCareActivity"}, {"end": 50, "start": 37, "tag": "CellFunction"}, {"end": 86, "start": 65, "tag": "Finding"}, {"end": 13, "start": 4, "tag": "HealthCareActivity"}, {"end": 13, "start": 4, "tag": "ResearchActivity"}, {"end": 122, "start": 119, "tag": "PharmacologicSubstance"}, {"end": 115, "start": 100, "tag": "Finding"}]}{"id": "822_9", "text": "In sum, the findings demonstrate the advantages of EB treatment in the HD rat model with a score of beneficial anti-oxidative and anti-inflammatory effects.", "tags": [{"end": 147, "start": 130, "tag": "BiologicFunction"}, {"end": 147, "start": 130, "tag": "PharmacologicSubstance"}, {"end": 83, "start": 71, "tag": "ExperimentalModelOfDisease"}, {"end": 63, "start": 51, "tag": "HealthCareActivity"}, {"end": 125, "start": 111, "tag": "CellFunction"}]}{"id": "826_0", "text": "Huntington's disease (HD) is a progressive, fatal neurodegenerative disorder characterized by motor, cognitive, and psychiatric disturbances.", "tags": [{"end": 76, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "826_1", "text": "There is no known cure for HD, but its progressive nature allows for early therapeutic intervention.", "tags": [{"end": 99, "start": 75, "tag": "HealthCareActivity"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}]}{"id": "826_2", "text": "Currently, much of the research has focused on the striatum, however, there is evidence suggesting that disruption of thalamocortical circuits could underlie some of the early symptoms of HD.", "tags": [{"end": 31, "start": 23, "tag": "ResearchActivity"}, {"end": 142, "start": 104, "tag": "PathologicFunction"}, {"end": 184, "start": 176, "tag": "SignOrSymptom"}, {"end": 87, "start": 79, "tag": "Finding"}, {"end": 190, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 0, "tag": "TemporalConcept"}, {"end": 142, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "826_3", "text": "Loss of both cortical pyramidal neurons (CPNs) and thalamic neurons occurs in HD patients, and cognitive, somatosensory, and attention deficits precede motor abnormalities.", "tags": [{"end": 39, "start": 13, "tag": "Cell"}, {"end": 45, "start": 41, "tag": "Cell"}, {"end": 67, "start": 51, "tag": "Cell"}, {"end": 143, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 152, "tag": "PathologicFunction"}, {"end": 89, "start": 78, "tag": "PatientOrDisabledGroup"}]}{"id": "826_4", "text": "However, the role of thalamocortical pathways in HD progression has been understudied.", "tags": [{"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 52, "tag": "PathologicFunction"}, {"end": 63, "start": 52, "tag": "TemporalConcept"}, {"end": 45, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "826_5", "text": "Here, we measured single unit activity and local field potentials (LFPs) from electrode arrays implanted in the thalamus and primary motor cortex of 4-5 month-old male and female Q175 mice.", "tags": [{"end": 38, "start": 9, "tag": "ResearchActivity"}, {"end": 94, "start": 78, "tag": "ManufacturedObject"}, {"end": 120, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 163, "tag": "OrganismAttribute"}, {"end": 178, "start": 172, "tag": "OrganismAttribute"}, {"end": 188, "start": 179, "tag": "ExperimentalModelOfDisease"}, {"end": 65, "start": 43, "tag": "BiologicFunction"}, {"end": 71, "start": 67, "tag": "BiologicFunction"}, {"end": 38, "start": 18, "tag": "CellFunction"}, {"end": 162, "start": 149, "tag": "PopulationGroup"}]}{"id": "826_6", "text": "We assessed neuronal activity under baseline conditions as well as during presentation of rewards delivered via actuation of an audible solenoid valve.", "tags": [{"end": 29, "start": 12, "tag": "CellFunction"}, {"end": 97, "start": 90, "tag": "BiologicFunction"}, {"end": 97, "start": 74, "tag": "ResearchActivity"}, {"end": 150, "start": 112, "tag": "ResearchActivity"}]}{"id": "826_7", "text": "HD mice showed a significantly delayed licking response to the reward stimulus.", "tags": [{"end": 7, "start": 0, "tag": "ExperimentalModelOfDisease"}, {"end": 38, "start": 17, "tag": "Finding"}, {"end": 78, "start": 39, "tag": "ResearchActivity"}]}{"id": "826_8", "text": "At the same time, neuronal activation to the reward was delayed in thalamic neurons, CPNs and fast-spiking cortical interneurons (FSIs) of HD mice.", "tags": [{"end": 51, "start": 45, "tag": "BiologicFunction"}, {"end": 63, "start": 56, "tag": "TemporalConcept"}, {"end": 83, "start": 67, "tag": "Cell"}, {"end": 89, "start": 85, "tag": "Cell"}, {"end": 146, "start": 139, "tag": "ExperimentalModelOfDisease"}, {"end": 37, "start": 18, "tag": "CellFunction"}, {"end": 128, "start": 94, "tag": "Cell"}, {"end": 134, "start": 130, "tag": "Cell"}]}{"id": "826_9", "text": "In addition, thalamocortical coherence increased at lower frequencies in HD relative to wildtype mice.", "tags": [{"end": 69, "start": 58, "tag": "TemporalConcept"}, {"end": 101, "start": 88, "tag": "Eukaryote"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 13, "tag": "ClinicalAttribute"}]}{"id": "826_10", "text": "Together, these data provide evidence that impaired cortical and thalamic responses to reward stimuli, and impaired thalamocortical coherence, may play an important early role in motor, cognitive, and learning deficits in HD patients.", "tags": [{"end": 20, "start": 16, "tag": "ResearchActivity"}, {"end": 218, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 29, "tag": "Finding"}, {"end": 233, "start": 222, "tag": "PatientOrDisabledGroup"}, {"end": 83, "start": 52, "tag": "BiologicFunction"}, {"end": 83, "start": 43, "tag": "PathologicFunction"}, {"end": 141, "start": 107, "tag": "PathologicFunction"}]}{"id": "874_0", "text": "Huntington's disease (HD) is a fatal autosomal-dominant neurodegenerative disease caused by a trinucleotide CAG repeat expansion of the huntingtin gene (HTT) that affects 1 in every 10 000 individuals in the United States.", "tags": [{"end": 128, "start": 94, "tag": "CellOrMolecularDysfunction"}, {"end": 151, "start": 136, "tag": "GeneOrGenome"}, {"end": 200, "start": 189, "tag": "PopulationGroup"}, {"end": 221, "start": 208, "tag": "PopulationGroup"}, {"end": 81, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 153, "tag": "GeneOrGenome"}, {"end": 156, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "874_1", "text": "Our lab developed a novel immune deficient HD mouse strain, the YACNSG, from a commonly used line, the YAC128 mouse, to enable transplantation studies using engineered human cells in addition to studying the impact of the immune system on disease progression.", "tags": [{"end": 7, "start": 4, "tag": "HealthCareRelatedOrganization"}, {"end": 235, "start": 222, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 64, "tag": "ExperimentalModelOfDisease"}, {"end": 115, "start": 103, "tag": "ExperimentalModelOfDisease"}, {"end": 179, "start": 157, "tag": "ResearchActivity"}, {"end": 179, "start": 157, "tag": "Cell"}, {"end": 58, "start": 26, "tag": "ExperimentalModelOfDisease"}, {"end": 150, "start": 127, "tag": "ResearchActivity"}, {"end": 258, "start": 239, "tag": "PathologicFunction"}]}{"id": "874_2", "text": "The primary goal of this project was to characterize this novel immune deQficient HD mouse model, using behavioral assays and histology to compare this new model to the immune competent YAC128 and immune deficient mice that had engraftment of a human immune system.", "tags": [{"end": 32, "start": 25, "tag": "ResearchActivity"}, {"end": 96, "start": 82, "tag": "ExperimentalModelOfDisease"}, {"end": 135, "start": 126, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 135, "start": 126, "tag": "ResearchActivity"}, {"end": 239, "start": 228, "tag": "ResearchActivity"}, {"end": 239, "start": 228, "tag": "HealthCareActivity"}, {"end": 264, "start": 245, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 104, "tag": "ResearchActivity"}, {"end": 218, "start": 197, "tag": "ExperimentalModelOfDisease"}, {"end": 218, "start": 214, "tag": "ExperimentalModelOfDisease"}, {"end": 192, "start": 169, "tag": "ExperimentalModelOfDisease"}]}{"id": "874_3", "text": "Flow cytometry was used to confirm that the YACNSG strain lacked immune cells, and in vivo imaging was used to assess human mesenchymal stem/stromal cell (MSC) retention compared with a commonly used immune deficient line, the NSG mouse.", "tags": [{"end": 14, "start": 0, "tag": "ResearchActivity"}, {"end": 77, "start": 65, "tag": "Cell"}, {"end": 158, "start": 155, "tag": "Cell"}, {"end": 221, "start": 200, "tag": "ExperimentalModelOfDisease"}, {"end": 153, "start": 118, "tag": "Cell"}, {"end": 57, "start": 44, "tag": "ExperimentalModelOfDisease"}, {"end": 98, "start": 83, "tag": "ResearchActivity"}, {"end": 236, "start": 227, "tag": "ExperimentalModelOfDisease"}]}{"id": "874_4", "text": "We found that YACNSG were able to retain human MSCs longer than the immune competent YAC128 mice.", "tags": [{"end": 51, "start": 41, "tag": "Cell"}, {"end": 96, "start": 68, "tag": "ExperimentalModelOfDisease"}, {"end": 20, "start": 14, "tag": "ExperimentalModelOfDisease"}]}{"id": "874_5", "text": "We performed behavioral assessments starting at 4 months of age and continued testing monthly until 12 months on the accelerod and in the open field.", "tags": [{"end": 56, "start": 48, "tag": "TemporalConcept"}, {"end": 109, "start": 100, "tag": "TemporalConcept"}, {"end": 148, "start": 138, "tag": "ManufacturedObject"}, {"end": 126, "start": 117, "tag": "ManufacturedObject"}, {"end": 35, "start": 13, "tag": "ResearchActivity"}, {"end": 93, "start": 86, "tag": "TemporalConcept"}, {"end": 63, "start": 60, "tag": "OrganismAttribute"}]}{"id": "874_6", "text": "At 12 months, brains were isolated and evaluated using immunohistochemistry for striatal volume.", "tags": [{"end": 12, "start": 3, "tag": "TemporalConcept"}, {"end": 20, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 55, "tag": "ResearchActivity"}, {"end": 95, "start": 80, "tag": "ClinicalAttribute"}]}{"id": "874_7", "text": "Results from these studies suggest that the novel immune deficient YACNSG strain of mice could provide a good model for human stem-cell based therapies and that the immune system appears to play an important role in the pathology of HD.", "tags": [{"end": 151, "start": 120, "tag": "HealthCareActivity"}, {"end": 178, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 50, "tag": "ExperimentalModelOfDisease"}, {"end": 235, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 220, "tag": "PathologicFunction"}, {"end": 229, "start": 220, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 26, "start": 19, "tag": "ResearchActivity"}]}{"id": "919_0", "text": "Several human neurological disorders, such as Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, spinal cord injury, multiple sclerosis, and brain stroke, are caused by the injury to neurons or glial cells.", "tags": [{"end": 36, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 141, "tag": "InjuryOrPoisoning"}, {"end": 179, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 217, "tag": "InjuryOrPoisoning"}, {"end": 234, "start": 227, "tag": "Cell"}, {"end": 249, "start": 238, "tag": "Cell"}, {"end": 13, "start": 8, "tag": "Eukaryote"}, {"end": 139, "start": 119, "tag": "DiseaseOrSyndrome"}]}{"id": "919_1", "text": "The recent years have witnessed the successful generation of neurons and glia cells driving efforts to develop stem-cell-based therapies for patients to combat a broad spectrum of human neurological diseases.", "tags": [{"end": 16, "start": 4, "tag": "TemporalConcept"}, {"end": 68, "start": 61, "tag": "Cell"}, {"end": 83, "start": 73, "tag": "Cell"}, {"end": 207, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 180, "tag": "Eukaryote"}, {"end": 149, "start": 141, "tag": "PatientOrDisabledGroup"}, {"end": 136, "start": 111, "tag": "HealthCareActivity"}]}{"id": "919_2", "text": "The inadequacy of suitable cell types for cell replacement therapy in patients suffering from neurological disorders has hampered the development of this promising therapeutic approach.", "tags": [{"end": 37, "start": 27, "tag": "Cell"}, {"end": 66, "start": 42, "tag": "HealthCareActivity"}, {"end": 88, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 164, "tag": "HealthCareActivity"}, {"end": 78, "start": 70, "tag": "PatientOrDisabledGroup"}]}{"id": "919_3", "text": "Attempts are thus being made to reconstruct viable neurons and glial cells from different stem cells, such as embryonic stem cells, mesenchymal stem cells, and neural stem cells.", "tags": [{"end": 58, "start": 51, "tag": "Cell"}, {"end": 74, "start": 63, "tag": "Cell"}, {"end": 100, "start": 90, "tag": "Cell"}, {"end": 130, "start": 110, "tag": "Cell"}, {"end": 154, "start": 132, "tag": "Cell"}, {"end": 177, "start": 160, "tag": "Cell"}]}{"id": "919_4", "text": "Dedicated research to cultivate stem cell-based brain transplantation therapies has been carried out.", "tags": [{"end": 18, "start": 10, "tag": "ResearchActivity"}, {"end": 79, "start": 32, "tag": "HealthCareActivity"}]}{"id": "919_5", "text": "We aim at compiling the breakthroughs in the field of stem cell-based therapy for the treatment of neurodegenerative maladies, emphasizing the shortcomings faced, victories achieved, and the future prospects of the therapy in clinical settings.", "tags": [{"end": 222, "start": 215, "tag": "HealthCareActivity"}, {"end": 95, "start": 86, "tag": "HealthCareActivity"}, {"end": 95, "start": 86, "tag": "ResearchActivity"}, {"end": 77, "start": 54, "tag": "HealthCareActivity"}, {"end": 125, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 243, "start": 226, "tag": "ResearchActivity"}]}{"id": "941_0", "text": "Huntington's disease (HD) is a neurodegenerative genetic condition, whose progress we are currently unable to assess with easy, non-invasive techniques.", "tags": [{"end": 66, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 90, "tag": "TemporalConcept"}, {"end": 151, "start": 128, "tag": "HealthCareActivity"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 74, "tag": "TemporalConcept"}]}{"id": "941_1", "text": "We show that Random Laser (RL) is sensitive to the effects of HD in cell cultures.", "tags": [{"end": 25, "start": 13, "tag": "ManufacturedObject"}, {"end": 29, "start": 27, "tag": "ManufacturedObject"}, {"end": 81, "start": 68, "tag": "ResearchActivity"}, {"end": 64, "start": 34, "tag": "Finding"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}]}{"id": "941_2", "text": "(C) 2021 The Author(s)", "tags": []}{"id": "959_0", "text": "causes neuronal dysfunction.", "tags": [{"end": 27, "start": 7, "tag": "CellOrMolecularDysfunction"}]}{"id": "959_1", "text": "Post-translational modification plays many roles in protein turnover rate, accumulation of aggregate and can also help in the degradation of disease-causing toxic metabolites.", "tags": [{"end": 31, "start": 0, "tag": "CellFunction"}, {"end": 174, "start": 141, "tag": "CellOrMolecularDysfunction"}, {"end": 174, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 52, "tag": "CellFunction"}, {"end": 73, "start": 69, "tag": "TemporalConcept"}]}{"id": "959_2", "text": "PTMs such as acetylation, glycosylation, phosphorylation, ubiquitination, palmitoylation, SUMOylation, nitration, oxidation, and many others regulate protein homeostasis, which includes protein structure, functions and aggregation propensity.", "tags": [{"end": 4, "start": 0, "tag": "CellFunction"}, {"end": 24, "start": 13, "tag": "CellFunction"}, {"end": 39, "start": 26, "tag": "CellFunction"}, {"end": 72, "start": 58, "tag": "CellFunction"}, {"end": 88, "start": 74, "tag": "CellFunction"}, {"end": 101, "start": 90, "tag": "CellFunction"}, {"end": 112, "start": 103, "tag": "CellFunction"}, {"end": 169, "start": 150, "tag": "CellFunction"}, {"end": 203, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 114, "tag": "CellFunction"}, {"end": 56, "start": 41, "tag": "CellFunction"}]}{"id": "959_3", "text": "Different studies demonstrated the involvement of PTMs in the regulation of signaling cascades such as PI3K/Akt/GSK3 beta, MAPK cascade, AMPK pathway, and Wnt signaling pathway in the pathogenesis of NDDs.", "tags": [{"end": 54, "start": 50, "tag": "CellFunction"}, {"end": 94, "start": 76, "tag": "CellFunction"}, {"end": 135, "start": 123, "tag": "CellFunction"}, {"end": 141, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 155, "tag": "CellFunction"}, {"end": 196, "start": 184, "tag": "PathologicFunction"}, {"end": 204, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 137, "tag": "CellFunction"}, {"end": 17, "start": 10, "tag": "ResearchActivity"}]}{"id": "959_4", "text": "Further, mounting evidence suggests that targeting different PTMs with small chemical molecules, which acts as an inhibitor or activator, reverse misfolded protein accumulation and thus enhances the neuroprotection.", "tags": [{"end": 65, "start": 61, "tag": "CellFunction"}, {"end": 95, "start": 77, "tag": "Substance"}, {"end": 136, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 214, "start": 199, "tag": "CellFunction"}, {"end": 26, "start": 18, "tag": "Finding"}, {"end": 123, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 114, "tag": "PharmacologicSubstance"}, {"end": 123, "start": 114, "tag": "Chemical"}, {"end": 176, "start": 146, "tag": "CellOrMolecularDysfunction"}]}{"id": "959_5", "text": "Herein, we briefly discuss the protein aggregation and various domain structures of different proteins involved in the NDDs, indicating critical amino acid residues where PTMs occur.", "tags": [{"end": 123, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 171, "tag": "CellFunction"}, {"end": 50, "start": 31, "tag": "CellFunction"}, {"end": 50, "start": 31, "tag": "CellOrMolecularDysfunction"}, {"end": 18, "start": 11, "tag": "TemporalConcept"}, {"end": 164, "start": 145, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "959_6", "text": "We also describe the implementation and involvement of various PTMs on signaling cascade and cellular processes in NDDs.", "tags": [{"end": 67, "start": 63, "tag": "CellFunction"}, {"end": 88, "start": 71, "tag": "CellFunction"}, {"end": 111, "start": 93, "tag": "CellFunction"}, {"end": 119, "start": 115, "tag": "DiseaseOrSyndrome"}]}{"id": "959_7", "text": "Lastly, we implement our current understanding of the therapeutic importance of PTMs in neurodegeneration, along with emerging One of the hallmark features in the neurodegenerative disorders (NDDs) is the accumulation of aggregated and/ or non-functional protein in the cellular milieu.", "tags": [{"end": 84, "start": 80, "tag": "CellFunction"}, {"end": 196, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 25, "tag": "TemporalConcept"}, {"end": 105, "start": 88, "tag": "CellOrMolecularDysfunction"}, {"end": 190, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 262, "start": 205, "tag": "CellOrMolecularDysfunction"}]}{"id": "959_8", "text": "Post-translational modifications (PTMs) are an essential regulator of non-functional protein aggregation in the pathogenesis of NDDs.", "tags": [{"end": 32, "start": 0, "tag": "CellFunction"}, {"end": 38, "start": 34, "tag": "CellFunction"}, {"end": 104, "start": 70, "tag": "CellOrMolecularDysfunction"}, {"end": 124, "start": 112, "tag": "PathologicFunction"}, {"end": 132, "start": 128, "tag": "DiseaseOrSyndrome"}]}{"id": "959_9", "text": "Any alteration in the post-translational mechanism and the protein quality control system, for instance, molecular chaperone, ubiquitin-proteasome system, autophagy-lysosomal degradation pathway, enhances the accumulation of misfolded protein, which Abbreviations: PTMs, Post-translational modifications; NDDs, Neurodegenerative diseases; AD, Alzheimer's disease; PD, Parkinson's disease; ALS, Amyotrophic lateral sclerosis; HD, Huntington's disease; TDP-43, Transactivation response DNA binding protein-43; A beta, beta-amyloid; NFTs, Neurofibrils tangles; SNpc, Substantia nigra pars compacta; polyQ, Polyglutamine; LBs, Lewy bodies; htt, Huntingtin protein; SOD1, Superoxide dismutase 1; UPS, Ubiquitin-proteasome system; CMA, Chaperone mediated autophagy; HSPs, Heat shock proteins; PSEN2, Presenilin-2; IT15, Interesting transcript 15; TARDBP, TAR DNA Binding Protein; NO, Nitric oxide; CK1, Casein kinase 1; GSK-3 beta, Glycogen synthase kinase 3 beta; PKA, Protein kinase A; CDK5, Cyclin-dependent kinase 5; DYRK1A, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A; REP, Repressor element of PARKIN; MTS, Mitochondrial targeting sequence; TM, Transmembrane; FUS, Fused in sarcoma; NLS, Nuclear localization sequence; RRMs, RNA recognition motif; NES, Nuclear export sequence; ER, Endoplasmic reticulum; UPR, Unfolded protein response; IRE1 alpha, Inositol-requiring enzyme 1 alpha; PERK, Protein kinase R like endoplasmic reticulum kinase; ATF6 alpha, Activating transcription factor 6 alpha; DR5, Death receptor 5; elF2 alpha, Eukaryotic initiation factor 2 alpha; XBP1, X-box binding protein 1; ASK1-JNK, apoptosis signal-regulating kinase 1/ c-Jun N-terminal kinases; TRAF2, TNF receptor-associated factor 2; PAD4, Protein arginase deaminase 4; SP1, Specificity protein 1; SP2, Specificity protein 2; PARP16, poly ADP ribose polymerase 16; Umf1, ubiquitin fold modifier 1; CHOP, C/EBP homologous protein; ERAD, endoplasmic reticulum-associated degradation; APP, Amyloid precursor protein; PSEN1, Presenilin-1; BACE1, Beta-secretase 1; BiP, Binding immunoglobulin protein; PARKIN, E3 ubiquitin-protein ligase parkin; PINK1, PTEN-induced kinase 1; PDI, Protein disulfide isomerase; GADD34, Growth arrest and DNA damage-inducible protein; DJ1, Protein deglycase; ATFS1, Cyclic AMP-dependent transcription factor;", "tags": [{"end": 124, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 242, "start": 209, "tag": "CellOrMolecularDysfunction"}, {"end": 269, "start": 265, "tag": "CellFunction"}, {"end": 303, "start": 271, "tag": "CellFunction"}, {"end": 309, "start": 305, "tag": "DiseaseOrSyndrome"}, {"end": 337, "start": 311, "tag": "DiseaseOrSyndrome"}, {"end": 341, "start": 339, "tag": "DiseaseOrSyndrome"}, {"end": 362, "start": 343, "tag": "DiseaseOrSyndrome"}, {"end": 366, "start": 364, "tag": "DiseaseOrSyndrome"}, {"end": 387, "start": 368, "tag": "DiseaseOrSyndrome"}, {"end": 392, "start": 389, "tag": "DiseaseOrSyndrome"}, {"end": 423, "start": 394, "tag": "DiseaseOrSyndrome"}, {"end": 457, "start": 451, "tag": "AminoAcidPeptideOrProtein"}, {"end": 457, "start": 451, "tag": "BiologicallyActiveSubstance"}, {"end": 528, "start": 516, "tag": "AminoAcidPeptideOrProtein"}, {"end": 534, "start": 530, "tag": "CellOrMolecularDysfunction"}, {"end": 548, "start": 536, "tag": "CellComponent"}, {"end": 594, "start": 564, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 601, "start": 596, "tag": "AminoAcidPeptideOrProtein"}, {"end": 616, "start": 603, "tag": "AminoAcidPeptideOrProtein"}, {"end": 621, "start": 618, "tag": "CellComponent"}, {"end": 634, "start": 623, "tag": "CellComponent"}, {"end": 639, "start": 636, "tag": "AminoAcidPeptideOrProtein"}, {"end": 665, "start": 661, "tag": "AminoAcidPeptideOrProtein"}, {"end": 689, "start": 667, "tag": "AminoAcidPeptideOrProtein"}, {"end": 689, "start": 667, "tag": "BiologicallyActiveSubstance"}, {"end": 728, "start": 725, "tag": "Chemical"}, {"end": 728, "start": 725, "tag": "CellFunction"}, {"end": 785, "start": 766, "tag": "AminoAcidPeptideOrProtein"}, {"end": 785, "start": 766, "tag": "BiologicallyActiveSubstance"}, {"end": 792, "start": 787, "tag": "BiologicallyActiveSubstance"}, {"end": 792, "start": 787, "tag": "AminoAcidPeptideOrProtein"}, {"end": 806, "start": 794, "tag": "AminoAcidPeptideOrProtein"}, {"end": 806, "start": 794, "tag": "BiologicallyActiveSubstance"}, {"end": 839, "start": 814, "tag": "GeneOrGenome"}, {"end": 847, "start": 841, "tag": "AminoAcidPeptideOrProtein"}, {"end": 872, "start": 849, "tag": "AminoAcidPeptideOrProtein"}, {"end": 872, "start": 849, "tag": "CellFunction"}, {"end": 876, "start": 874, "tag": "PharmacologicSubstance"}, {"end": 876, "start": 874, "tag": "Chemical"}, {"end": 890, "start": 878, "tag": "PharmacologicSubstance"}, {"end": 890, "start": 878, "tag": "Chemical"}, {"end": 895, "start": 892, "tag": "GeneOrGenome"}, {"end": 895, "start": 892, "tag": "AminoAcidPeptideOrProtein"}, {"end": 912, "start": 897, "tag": "AminoAcidPeptideOrProtein"}, {"end": 912, "start": 897, "tag": "GeneOrGenome"}, {"end": 924, "start": 914, "tag": "AminoAcidPeptideOrProtein"}, {"end": 957, "start": 926, "tag": "AminoAcidPeptideOrProtein"}, {"end": 957, "start": 926, "tag": "GeneOrGenome"}, {"end": 962, "start": 959, "tag": "AminoAcidPeptideOrProtein"}, {"end": 962, "start": 959, "tag": "BiologicallyActiveSubstance"}, {"end": 962, "start": 959, "tag": "GeneOrGenome"}, {"end": 980, "start": 964, "tag": "AminoAcidPeptideOrProtein"}, {"end": 980, "start": 964, "tag": "GeneOrGenome"}, {"end": 980, "start": 964, "tag": "BiologicallyActiveSubstance"}, {"end": 986, "start": 982, "tag": "GeneOrGenome"}, {"end": 986, "start": 982, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1013, "start": 988, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1013, "start": 988, "tag": "GeneOrGenome"}, {"end": 1021, "start": 1015, "tag": "GeneOrGenome"}, {"end": 1084, "start": 1023, "tag": "GeneOrGenome"}, {"end": 1089, "start": 1086, "tag": "GeneOrGenome"}, {"end": 1118, "start": 1091, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1118, "start": 1112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1123, "start": 1120, "tag": "MolecularSequence"}, {"end": 1161, "start": 1159, "tag": "CellComponent"}, {"end": 1176, "start": 1163, "tag": "CellComponent"}, {"end": 1181, "start": 1178, "tag": "GeneOrGenome"}, {"end": 1181, "start": 1178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1199, "start": 1192, "tag": "DiseaseOrSyndrome"}, {"end": 1204, "start": 1201, "tag": "MolecularSequence"}, {"end": 1264, "start": 1243, "tag": "MolecularSequence"}, {"end": 1269, "start": 1266, "tag": "MolecularSequence"}, {"end": 1285, "start": 1271, "tag": "CellFunction"}, {"end": 1298, "start": 1296, "tag": "CellComponent"}, {"end": 1321, "start": 1300, "tag": "CellComponent"}, {"end": 1326, "start": 1323, "tag": "CellFunction"}, {"end": 1353, "start": 1328, "tag": "CellFunction"}, {"end": 1365, "start": 1355, "tag": "GeneOrGenome"}, {"end": 1400, "start": 1367, "tag": "GeneOrGenome"}, {"end": 1400, "start": 1367, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1406, "start": 1402, "tag": "GeneOrGenome"}, {"end": 1406, "start": 1402, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1406, "start": 1402, "tag": "BiologicallyActiveSubstance"}, {"end": 1424, "start": 1408, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1424, "start": 1408, "tag": "GeneOrGenome"}, {"end": 1516, "start": 1513, "tag": "GeneOrGenome"}, {"end": 1516, "start": 1513, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1534, "start": 1518, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1534, "start": 1518, "tag": "GeneOrGenome"}, {"end": 1534, "start": 1518, "tag": "BiologicallyActiveSubstance"}, {"end": 1584, "start": 1548, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1584, "start": 1548, "tag": "GeneOrGenome"}, {"end": 1590, "start": 1586, "tag": "GeneOrGenome"}, {"end": 1590, "start": 1586, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1615, "start": 1592, "tag": "GeneOrGenome"}, {"end": 1615, "start": 1592, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1636, "start": 1627, "tag": "CellFunction"}, {"end": 1689, "start": 1665, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1689, "start": 1665, "tag": "BiologicallyActiveSubstance"}, {"end": 1689, "start": 1665, "tag": "GeneOrGenome"}, {"end": 1696, "start": 1691, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1696, "start": 1691, "tag": "GeneOrGenome"}, {"end": 1730, "start": 1698, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1730, "start": 1698, "tag": "GeneOrGenome"}, {"end": 1736, "start": 1732, "tag": "GeneOrGenome"}, {"end": 1771, "start": 1768, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 1771, "start": 1768, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1771, "start": 1768, "tag": "GeneOrGenome"}, {"end": 1794, "start": 1773, "tag": "GeneOrGenome"}, {"end": 1794, "start": 1773, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1799, "start": 1796, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 1799, "start": 1796, "tag": "GeneOrGenome"}, {"end": 1799, "start": 1796, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1822, "start": 1801, "tag": "GeneOrGenome"}, {"end": 1822, "start": 1801, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1830, "start": 1824, "tag": "GeneOrGenome"}, {"end": 1861, "start": 1832, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1861, "start": 1832, "tag": "BiologicallyActiveSubstance"}, {"end": 1861, "start": 1832, "tag": "GeneOrGenome"}, {"end": 1867, "start": 1863, "tag": "GeneOrGenome"}, {"end": 1894, "start": 1869, "tag": "GeneOrGenome"}, {"end": 1900, "start": 1896, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1900, "start": 1896, "tag": "GeneOrGenome"}, {"end": 1926, "start": 1902, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1926, "start": 1902, "tag": "GeneOrGenome"}, {"end": 1932, "start": 1928, "tag": "CellFunction"}, {"end": 1978, "start": 1934, "tag": "CellFunction"}, {"end": 1983, "start": 1980, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1983, "start": 1980, "tag": "GeneOrGenome"}, {"end": 2010, "start": 1985, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2010, "start": 1985, "tag": "BiologicallyActiveSubstance"}, {"end": 2017, "start": 2012, "tag": "GeneOrGenome"}, {"end": 2031, "start": 2019, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2031, "start": 2019, "tag": "GeneOrGenome"}, {"end": 2038, "start": 2033, "tag": "GeneOrGenome"}, {"end": 2038, "start": 2033, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2056, "start": 2040, "tag": "GeneOrGenome"}, {"end": 2056, "start": 2040, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2061, "start": 2058, "tag": "BiologicallyActiveSubstance"}, {"end": 2061, "start": 2058, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2093, "start": 2063, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2101, "start": 2095, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2101, "start": 2095, "tag": "GeneOrGenome"}, {"end": 2101, "start": 2095, "tag": "BiologicallyActiveSubstance"}, {"end": 2137, "start": 2103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2137, "start": 2103, "tag": "GeneOrGenome"}, {"end": 2144, "start": 2139, "tag": "GeneOrGenome"}, {"end": 2144, "start": 2139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2172, "start": 2169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2172, "start": 2169, "tag": "BiologicallyActiveSubstance"}, {"end": 2201, "start": 2174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2201, "start": 2174, "tag": "BiologicallyActiveSubstance"}, {"end": 2209, "start": 2203, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2257, "start": 2211, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2262, "start": 2259, "tag": "BiologicallyActiveSubstance"}, {"end": 2262, "start": 2259, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2281, "start": 2264, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2331, "start": 2290, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2331, "start": 2290, "tag": "GeneOrGenome"}, {"end": 2288, "start": 2283, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2288, "start": 2283, "tag": "GeneOrGenome"}, {"end": 1663, "start": 1627, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1663, "start": 1627, "tag": "GeneOrGenome"}, {"end": 1470, "start": 1460, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1470, "start": 1460, "tag": "GeneOrGenome"}, {"end": 1511, "start": 1472, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1511, "start": 1472, "tag": "GeneOrGenome"}, {"end": 2167, "start": 2146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2167, "start": 2146, "tag": "GeneOrGenome"}, {"end": 1766, "start": 1738, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1766, "start": 1738, "tag": "GeneOrGenome"}, {"end": 14, "start": 4, "tag": "Finding"}, {"end": 164, "start": 155, "tag": "CellFunction"}, {"end": 758, "start": 730, "tag": "CellFunction"}, {"end": 1523, "start": 1518, "tag": "CellFunction"}, {"end": 1523, "start": 1518, "tag": "PathologicFunction"}, {"end": 427, "start": 425, "tag": "DiseaseOrSyndrome"}, {"end": 659, "start": 641, "tag": "AminoAcidPeptideOrProtein"}, {"end": 659, "start": 641, "tag": "BiologicallyActiveSubstance"}, {"end": 449, "start": 429, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 165, "tag": "CellFunction"}, {"end": 153, "start": 126, "tag": "CellFunction"}, {"end": 124, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 59, "tag": "CellFunction"}, {"end": 506, "start": 459, "tag": "AminoAcidPeptideOrProtein"}, {"end": 514, "start": 508, "tag": "AminoAcidPeptideOrProtein"}, {"end": 556, "start": 536, "tag": "CellOrMolecularDysfunction"}, {"end": 562, "start": 558, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 723, "start": 696, "tag": "CellFunction"}, {"end": 694, "start": 691, "tag": "CellFunction"}, {"end": 764, "start": 760, "tag": "AminoAcidPeptideOrProtein"}, {"end": 764, "start": 760, "tag": "BiologicallyActiveSubstance"}, {"end": 812, "start": 808, "tag": "GeneOrGenome"}, {"end": 924, "start": 914, "tag": "GeneOrGenome"}, {"end": 957, "start": 926, "tag": "BiologicallyActiveSubstance"}, {"end": 924, "start": 914, "tag": "BiologicallyActiveSubstance"}, {"end": 986, "start": 982, "tag": "BiologicallyActiveSubstance"}, {"end": 1013, "start": 988, "tag": "BiologicallyActiveSubstance"}, {"end": 1021, "start": 1015, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1084, "start": 1023, "tag": "BiologicallyActiveSubstance"}, {"end": 1084, "start": 1023, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1021, "start": 1015, "tag": "BiologicallyActiveSubstance"}, {"end": 1157, "start": 1125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1199, "start": 1183, "tag": "GeneOrGenome"}, {"end": 1199, "start": 1183, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1235, "start": 1206, "tag": "MolecularSequence"}, {"end": 1241, "start": 1237, "tag": "MolecularSequence"}, {"end": 1226, "start": 1206, "tag": "CellFunction"}, {"end": 1294, "start": 1271, "tag": "MolecularSequence"}, {"end": 1400, "start": 1367, "tag": "BiologicallyActiveSubstance"}, {"end": 1458, "start": 1408, "tag": "BiologicallyActiveSubstance"}, {"end": 1424, "start": 1408, "tag": "BiologicallyActiveSubstance"}, {"end": 1458, "start": 1408, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1458, "start": 1408, "tag": "GeneOrGenome"}, {"end": 1365, "start": 1355, "tag": "BiologicallyActiveSubstance"}, {"end": 1365, "start": 1355, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1516, "start": 1513, "tag": "BiologicallyActiveSubstance"}, {"end": 1546, "start": 1536, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1546, "start": 1536, "tag": "GeneOrGenome"}, {"end": 1736, "start": 1732, "tag": "BiologicallyActiveSubstance"}, {"end": 1736, "start": 1732, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1766, "start": 1738, "tag": "BiologicallyActiveSubstance"}, {"end": 2281, "start": 2264, "tag": "BiologicallyActiveSubstance"}, {"end": 2167, "start": 2146, "tag": "BiologicallyActiveSubstance"}, {"end": 2144, "start": 2139, "tag": "BiologicallyActiveSubstance"}, {"end": 2137, "start": 2103, "tag": "BiologicallyActiveSubstance"}, {"end": 2093, "start": 2063, "tag": "BiologicallyActiveSubstance"}, {"end": 2056, "start": 2040, "tag": "BiologicallyActiveSubstance"}, {"end": 2038, "start": 2033, "tag": "BiologicallyActiveSubstance"}, {"end": 2031, "start": 2019, "tag": "BiologicallyActiveSubstance"}, {"end": 2017, "start": 2012, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2017, "start": 2012, "tag": "BiologicallyActiveSubstance"}, {"end": 1983, "start": 1980, "tag": "BiologicallyActiveSubstance"}, {"end": 1894, "start": 1869, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1894, "start": 1869, "tag": "BiologicallyActiveSubstance"}, {"end": 1867, "start": 1863, "tag": "AminoAcidPeptideOrProtein"}, {"end": 1867, "start": 1863, "tag": "BiologicallyActiveSubstance"}, {"end": 1830, "start": 1824, "tag": "BiologicallyActiveSubstance"}, {"end": 1830, "start": 1824, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1000_0", "text": "Extracellular vesicles are highly transmissible and play critical roles in the propagation of tau pathology, although the underlying mechanism remains elusive.", "tags": [{"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 107, "start": 94, "tag": "PathologicFunction"}]}{"id": "1000_1", "text": "Here, for the first time, we comprehensively characterized the physicochemical structure and pathogenic function of human brain-derived extracellular vesicles isolated from Alzheimer's disease, prodromal Alzheimer's disease, and non-demented control cases.", "tags": [{"end": 127, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 116, "tag": "Eukaryote"}, {"end": 112, "start": 93, "tag": "PathologicFunction"}, {"end": 24, "start": 20, "tag": "TemporalConcept"}, {"end": 255, "start": 229, "tag": "PopulationGroup"}, {"end": 158, "start": 136, "tag": "CellComponent"}]}{"id": "1000_2", "text": "Alzheimer's disease extracellular vesicles were significantly enriched in epitope-specific tau oligomers in comparison to prodromal Alzheimer's disease or control extracellular vesicles as determined by dot blot and atomic force microscopy.", "tags": [{"end": 104, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 163, "tag": "CellComponent"}, {"end": 211, "start": 203, "tag": "ResearchActivity"}, {"end": 239, "start": 216, "tag": "ResearchActivity"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 20, "tag": "CellComponent"}, {"end": 81, "start": 74, "tag": "BiologicallyActiveSubstance"}]}{"id": "1000_3", "text": "Alzheimer's disease extracellular vesicles were more efficiently internalized by murine cortical neurons, as well as more efficient in transferring and misfolding tau, than prodromal Alzheimer's disease and control extracellular vesicles in vitro.", "tags": [{"end": 166, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 237, "start": 215, "tag": "CellComponent"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 88, "tag": "Cell"}, {"end": 162, "start": 152, "tag": "CellOrMolecularDysfunction"}, {"end": 246, "start": 238, "tag": "ResearchActivity"}, {"end": 42, "start": 20, "tag": "CellComponent"}, {"end": 87, "start": 81, "tag": "Eukaryote"}]}{"id": "1000_4", "text": "Strikingly, the inoculation of Alzheimer's disease or prodromal Alzheimer's disease extracellular vesicles containing only 300 pg of tau into the outer molecular layer of the dentate gyrus of 18-month-old C57BL/6 mice resulted in the accumulation of abnormally phosphorylated tau throughout the hippocampus by 4.5 months, whereas inoculation of an equal amount of tau from control extracellular vesicles, isolated tau oligomers, or fibrils from the same Alzheimer's disease donor showed little tau pathology.", "tags": [{"end": 27, "start": 16, "tag": "HealthCareActivity"}, {"end": 136, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 279, "start": 250, "tag": "CellOrMolecularDysfunction"}, {"end": 306, "start": 295, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 341, "start": 330, "tag": "HealthCareActivity"}, {"end": 367, "start": 364, "tag": "AminoAcidPeptideOrProtein"}, {"end": 427, "start": 414, "tag": "AminoAcidPeptideOrProtein"}, {"end": 439, "start": 432, "tag": "CellComponent"}, {"end": 507, "start": 494, "tag": "PathologicFunction"}, {"end": 479, "start": 474, "tag": "PopulationGroup"}, {"end": 50, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 473, "start": 454, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 205, "tag": "Eukaryote"}, {"end": 320, "start": 314, "tag": "TemporalConcept"}, {"end": 106, "start": 84, "tag": "CellComponent"}, {"end": 204, "start": 192, "tag": "PopulationGroup"}, {"end": 403, "start": 381, "tag": "CellComponent"}]}{"id": "1000_5", "text": "Furthermore, Alzheimer's disease extracellular vesicles induced misfolding of endogenous tau in both oligomeric and sarkosyl-insoluble forms in the hippocampal region.", "tags": [{"end": 92, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 64, "tag": "CellOrMolecularDysfunction"}, {"end": 55, "start": 33, "tag": "CellComponent"}, {"end": 124, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 116, "tag": "PharmacologicSubstance"}, {"end": 166, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1000_6", "text": "Unexpectedly, phosphorylated tau was primarily accumulated in glutamic acid decarboxylase 67 (GAD67) GABAergic interneurons and, to a lesser extent, glutamate receptor 2/3-positive excitatory mossy cells, showing preferential extracellular vesicle-mediated GABAergic interneuronal tau propagation.", "tags": [{"end": 28, "start": 14, "tag": "CellFunction"}, {"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 101, "tag": "Cell"}, {"end": 247, "start": 226, "tag": "CellComponent"}, {"end": 203, "start": 181, "tag": "Cell"}, {"end": 171, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 296, "start": 257, "tag": "Finding"}]}{"id": "1000_7", "text": "Whole-cell patch clamp recordings of CA1 pyramidal cells showed significant reduction in the amplitude of spontaneous inhibitory post-synaptic currents.", "tags": [{"end": 56, "start": 37, "tag": "Cell"}, {"end": 33, "start": 0, "tag": "ResearchActivity"}, {"end": 151, "start": 106, "tag": "CellFunction"}]}{"id": "1000_8", "text": "This was accompanied by reductions in c-fos(+) GAD67(+) neurons and GAD67(+) neuronal puncta surrounding pyramidal neurons in the CA1 region, confirming reduced GABAergic transmission in this region.", "tags": [{"end": 63, "start": 56, "tag": "Cell"}, {"end": 122, "start": 105, "tag": "Cell"}, {"end": 43, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 68, "tag": "ResearchActivity"}, {"end": 140, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 183, "start": 161, "tag": "CellFunction"}, {"end": 43, "start": 38, "tag": "BiologicallyActiveSubstance"}]}{"id": "1000_9", "text": "Our study posits a novel mechanism for the spread of tau in hippocampal GABAergic interneurons via brain-derived extracellular vesicles and their subsequent neuronal dysfunction.", "tags": [{"end": 94, "start": 60, "tag": "Cell"}, {"end": 104, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 177, "start": 157, "tag": "CellOrMolecularDysfunction"}, {"end": 135, "start": 113, "tag": "CellComponent"}, {"end": 56, "start": 43, "tag": "CellOrMolecularDysfunction"}]}{"id": "1001_0", "text": "Alzheimer's disease is a progressive and fatal neurodegenerative disorder that starts many years before the onset of cognitive symptoms.", "tags": [{"end": 113, "start": 108, "tag": "TemporalConcept"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 117, "tag": "SignOrSymptom"}, {"end": 73, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 91, "tag": "TemporalConcept"}]}{"id": "1001_1", "text": "Identifying novel biomarkers for Alzheimer's disease has the potential for patient risk stratification, early diagnosis, and disease monitoring in response to therapy.", "tags": [{"end": 119, "start": 104, "tag": "HealthCareActivity"}, {"end": 82, "start": 75, "tag": "PatientOrDisabledGroup"}, {"end": 52, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 18, "tag": "ClinicalAttribute"}, {"end": 143, "start": 125, "tag": "HealthCareActivity"}, {"end": 102, "start": 83, "tag": "ResearchActivity"}, {"end": 166, "start": 159, "tag": "HealthCareActivity"}]}{"id": "1001_2", "text": "A novel class of biomarkers is extracellular vesicles given their sensitivity and specificity to specific diseases.", "tags": [{"end": 53, "start": 31, "tag": "CellComponent"}, {"end": 27, "start": 17, "tag": "ClinicalAttribute"}, {"end": 77, "start": 66, "tag": "Finding"}, {"end": 93, "start": 82, "tag": "Finding"}]}{"id": "1001_3", "text": "In addition, extracellular vesicles can be used as novel biological therapeutics given their ability to efficiently and functionally deliver therapeutic cargo.", "tags": [{"end": 35, "start": 13, "tag": "CellComponent"}, {"end": 80, "start": 51, "tag": "HealthCareActivity"}, {"end": 158, "start": 141, "tag": "PharmacologicSubstance"}, {"end": 115, "start": 104, "tag": "Finding"}]}{"id": "1001_4", "text": "This is critical given the huge unmet need for novel treatment strategies for Alzheimer's disease.", "tags": [{"end": 97, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 53, "tag": "HealthCareActivity"}, {"end": 42, "start": 27, "tag": "Finding"}]}{"id": "1001_5", "text": "This review summarizes and discusses the most recent findings in this field.", "tags": [{"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 52, "start": 46, "tag": "TemporalConcept"}]}{"id": "1002_0", "text": "Gabrielli et al.", "tags": []}{"id": "1002_1", "text": "show that microglial extracellular vesicles carrying amyloid-beta (A beta-EVs) move along axons and propagate synaptic dysfunction in the mouse brain in vitro.", "tags": [{"end": 20, "start": 10, "tag": "Cell"}, {"end": 65, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 90, "tag": "CellComponent"}, {"end": 149, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 110, "tag": "CellOrMolecularDysfunction"}, {"end": 158, "start": 150, "tag": "ResearchActivity"}, {"end": 73, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 21, "tag": "CellComponent"}, {"end": 77, "start": 74, "tag": "CellComponent"}, {"end": 143, "start": 138, "tag": "Eukaryote"}]}{"id": "1002_2", "text": "However, inhibiting A beta-EV motion restricts the spread of synaptic dysfunction, unveiling a potential new strategy to delay Alzheimer's disease progression.", "tags": [{"end": 19, "start": 9, "tag": "BiologicFunction"}, {"end": 81, "start": 61, "tag": "CellOrMolecularDysfunction"}, {"end": 146, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 139, "tag": "PathologicFunction"}, {"end": 126, "start": 121, "tag": "TemporalConcept"}, {"end": 26, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 27, "tag": "CellComponent"}]}{"id": "1002_3", "text": "Synaptic dysfunction is an early mechanism in Alzheimer's disease that involves progressively larger areas of the brain over time.", "tags": [{"end": 119, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 125, "tag": "TemporalConcept"}, {"end": 20, "start": 0, "tag": "CellOrMolecularDysfunction"}]}{"id": "1002_4", "text": "However, how it starts and propagates is unknown.", "tags": []}{"id": "1002_5", "text": "Here we show that amyloid-beta released by microglia in association with large extracellular vesicles (A beta-EVs) alters dendritic spine morphology in vitro, at the site of neuron interaction, and impairs synaptic plasticity both in vitro and in vivo in the entorhinal cortex-dentate gyrus circuitry.", "tags": [{"end": 30, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 79, "tag": "CellComponent"}, {"end": 137, "start": 122, "tag": "CellComponent"}, {"end": 148, "start": 122, "tag": "ClinicalAttribute"}, {"end": 225, "start": 206, "tag": "CellFunction"}, {"end": 225, "start": 206, "tag": "BiologicFunction"}, {"end": 180, "start": 174, "tag": "Cell"}, {"end": 251, "start": 244, "tag": "ResearchActivity"}, {"end": 157, "start": 149, "tag": "ResearchActivity"}, {"end": 239, "start": 231, "tag": "ResearchActivity"}, {"end": 52, "start": 43, "tag": "Cell"}, {"end": 109, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 110, "tag": "CellComponent"}, {"end": 300, "start": 259, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1002_6", "text": "One hour after A beta-EV injection into the mouse entorhinal cortex, long-term potentiation was impaired in the entorhinal cortex but not in the dentate gyrus, its main target region, while 24 h later it was also impaired in the dentate gyrus, revealing a spreading of long-term potentiation deficit between the two regions.", "tags": [{"end": 8, "start": 4, "tag": "TemporalConcept"}, {"end": 34, "start": 25, "tag": "HealthCareActivity"}, {"end": 67, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 242, "start": 229, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 69, "tag": "BiologicFunction"}, {"end": 291, "start": 269, "tag": "BiologicFunction"}, {"end": 21, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 22, "tag": "CellComponent"}, {"end": 49, "start": 44, "tag": "Eukaryote"}, {"end": 200, "start": 190, "tag": "TemporalConcept"}, {"end": 299, "start": 269, "tag": "PathologicFunction"}]}{"id": "1002_7", "text": "Similar results were obtained upon injection of extracellular vesicles carrying A beta naturally secreted by CHO7PA2 cells, while neither A beta(42) alone nor inflammatory extracellular vesicles devoid of A beta were able to propagate long-term potentiation impairment.", "tags": [{"end": 44, "start": 35, "tag": "HealthCareActivity"}, {"end": 70, "start": 48, "tag": "CellComponent"}, {"end": 122, "start": 109, "tag": "Cell"}, {"end": 257, "start": 235, "tag": "BiologicFunction"}, {"end": 86, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 205, "tag": "AminoAcidPeptideOrProtein"}, {"end": 268, "start": 235, "tag": "PathologicFunction"}, {"end": 194, "start": 172, "tag": "CellComponent"}]}{"id": "1002_8", "text": "Using optical tweezers combined to time-lapse imaging to study A beta-EV-neuron interaction, we show that A beta-EVs move anterogradely at the axon surface and that their motion can be blocked through annexin-V coating.", "tags": [{"end": 22, "start": 6, "tag": "ResearchActivity"}, {"end": 53, "start": 35, "tag": "HealthCareActivity"}, {"end": 155, "start": 143, "tag": "CellComponent"}, {"end": 177, "start": 171, "tag": "NaturalPhenomenonOrProcess"}, {"end": 62, "start": 57, "tag": "ResearchActivity"}, {"end": 79, "start": 73, "tag": "Cell"}, {"end": 69, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 70, "tag": "CellComponent"}, {"end": 116, "start": 113, "tag": "CellComponent"}, {"end": 218, "start": 201, "tag": "CellFunction"}, {"end": 210, "start": 201, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1002_9", "text": "Importantly, when A beta-EV motility was inhibited, no propagation of long-term potentiation deficit occurred along the entorhinal-hippocampal circuit, implicating large extracellular vesicle motion at the neuron surface in the spreading of long-term potentiation impairment.", "tags": [{"end": 191, "start": 170, "tag": "CellComponent"}, {"end": 150, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 70, "tag": "BiologicFunction"}, {"end": 263, "start": 241, "tag": "BiologicFunction"}, {"end": 220, "start": 206, "tag": "CellComponent"}, {"end": 24, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 25, "tag": "CellComponent"}, {"end": 100, "start": 71, "tag": "PathologicFunction"}, {"end": 274, "start": 241, "tag": "PathologicFunction"}]}{"id": "1002_10", "text": "Our data indicate the involvement of large microglial extracellular vesicles in the rise and propagation of early synaptic dysfunction in Alzheimer's disease and suggest a new mechanism controlling the diffusion of large extracellular vesicles and their pathogenic signals in the brain parenchyma, paving the way for novel therapeutic strategies to delay the disease.", "tags": [{"end": 53, "start": 43, "tag": "Cell"}, {"end": 243, "start": 221, "tag": "CellComponent"}, {"end": 296, "start": 280, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 134, "start": 114, "tag": "CellOrMolecularDysfunction"}, {"end": 157, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 272, "start": 254, "tag": "PathologicFunction"}, {"end": 354, "start": 349, "tag": "TemporalConcept"}, {"end": 345, "start": 323, "tag": "HealthCareActivity"}, {"end": 33, "start": 22, "tag": "Finding"}, {"end": 76, "start": 54, "tag": "CellComponent"}]}{"id": "1003_0", "text": "Lipid dyshomeostasis is associated with the most common form of dementia, Alzheimer's disease (AD).", "tags": [{"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "CellOrMolecularDysfunction"}]}{"id": "1003_1", "text": "Substantial progress has been made in identifying positron emission tomography and cerebrospinal fluid biomarkers for AD, but they have limited use as front-line diagnostic tools.", "tags": [{"end": 78, "start": 50, "tag": "HealthCareActivity"}, {"end": 102, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 12, "tag": "TemporalConcept"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 103, "tag": "ClinicalAttribute"}, {"end": 178, "start": 151, "tag": "HealthCareActivity"}]}{"id": "1003_2", "text": "Extracellular vesicles (EVs) are released by all cells and contain a subset of their parental cell composition, including lipids.", "tags": [{"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 128, "start": 122, "tag": "Chemical"}, {"end": 54, "start": 49, "tag": "Cell"}, {"end": 98, "start": 85, "tag": "Cell"}]}{"id": "1003_3", "text": "EVs are released from the brain into the periphery, providing a potential source of tissue and disease specific lipid biomarkers.", "tags": [{"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 90, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 112, "tag": "Chemical"}, {"end": 31, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 118, "tag": "ClinicalAttribute"}]}{"id": "1003_4", "text": "However, the EV lipidome of the central nervous system is currently unknown and the potential of brain-derived EVs (BDEVs) to inform on lipid dyshomeostasis in AD remains unclear.", "tags": [{"end": 15, "start": 13, "tag": "CellComponent"}, {"end": 24, "start": 16, "tag": "Chemical"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 58, "tag": "TemporalConcept"}, {"end": 114, "start": 97, "tag": "CellComponent"}, {"end": 121, "start": 116, "tag": "CellComponent"}, {"end": 156, "start": 136, "tag": "CellOrMolecularDysfunction"}]}{"id": "1003_5", "text": "The aim of this study was to reveal the lipid composition of BDEVs in human frontal cortex, and to determine whether BDEVs have an altered lipid profile in AD.", "tags": [{"end": 90, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 158, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 70, "tag": "Eukaryote"}, {"end": 66, "start": 61, "tag": "CellComponent"}, {"end": 122, "start": 117, "tag": "CellComponent"}, {"end": 152, "start": 131, "tag": "Finding"}]}{"id": "1003_6", "text": "Using semi-quantitative mass spectrometry, we describe the BDEV lipidome, covering four lipid categories, 17 lipid classes and 692 lipid molecules.", "tags": [{"end": 72, "start": 64, "tag": "Chemical"}, {"end": 93, "start": 88, "tag": "Chemical"}, {"end": 41, "start": 6, "tag": "ResearchActivity"}, {"end": 63, "start": 59, "tag": "CellComponent"}, {"end": 146, "start": 131, "tag": "Chemical"}, {"end": 114, "start": 109, "tag": "Chemical"}]}{"id": "1003_7", "text": "BDEVs were enriched in glycerophosphoserine (PS) lipids, a characteristic of small EVs.", "tags": [{"end": 43, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 49, "tag": "Chemical"}, {"end": 86, "start": 83, "tag": "CellComponent"}, {"end": 5, "start": 0, "tag": "CellComponent"}]}{"id": "1003_8", "text": "Here we further report that BDEVs are enriched in ether-containing PS lipids, a finding that further establishes ether lipids as a feature of EVs.", "tags": [{"end": 55, "start": 50, "tag": "Chemical"}, {"end": 69, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 70, "tag": "Chemical"}, {"end": 145, "start": 142, "tag": "CellComponent"}, {"end": 22, "start": 16, "tag": "HealthCareActivity"}, {"end": 22, "start": 16, "tag": "ResearchActivity"}, {"end": 33, "start": 28, "tag": "CellComponent"}, {"end": 125, "start": 113, "tag": "Chemical"}, {"end": 55, "start": 50, "tag": "PharmacologicSubstance"}]}{"id": "1003_9", "text": "BDEVs in the AD frontal cortex offered improved detection of dysregulated lipids in AD over global lipid profiling of this brain region.", "tags": [{"end": 30, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 61, "tag": "CellOrMolecularDysfunction"}, {"end": 5, "start": 0, "tag": "CellComponent"}, {"end": 114, "start": 92, "tag": "Finding"}]}{"id": "1003_10", "text": "AD BDEVs had significantly altered glycerophospholipid and sphingolipid levels, specifically increased plasmalogen glycerophosphoethanolamine and decreased polyunsaturated fatty acyl containing lipids, and altered amide-linked acyl chain content in sphingomyelin and ceramide lipids relative to CTL.", "tags": [{"end": 54, "start": 35, "tag": "Chemical"}, {"end": 182, "start": 156, "tag": "Chemical"}, {"end": 200, "start": 194, "tag": "Chemical"}, {"end": 262, "start": 249, "tag": "Chemical"}, {"end": 262, "start": 249, "tag": "BiologicallyActiveSubstance"}, {"end": 298, "start": 295, "tag": "Cell"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 146, "tag": "Finding"}, {"end": 8, "start": 3, "tag": "CellComponent"}, {"end": 71, "start": 59, "tag": "Chemical"}, {"end": 114, "start": 103, "tag": "Chemical"}, {"end": 141, "start": 115, "tag": "Chemical"}, {"end": 237, "start": 214, "tag": "Chemical"}, {"end": 282, "start": 267, "tag": "Chemical"}]}{"id": "1003_11", "text": "The most prominent alteration was a two-fold decrease in lipid species containing anti-inflammatory/pro-resolving docosahexaenoic acid.", "tags": [{"end": 53, "start": 45, "tag": "Finding"}, {"end": 134, "start": 114, "tag": "Chemical"}, {"end": 29, "start": 19, "tag": "Finding"}, {"end": 99, "start": 82, "tag": "BiologicFunction"}, {"end": 99, "start": 82, "tag": "PharmacologicSubstance"}, {"end": 70, "start": 63, "tag": "OrganismAttribute"}, {"end": 62, "start": 57, "tag": "Chemical"}]}{"id": "1003_12", "text": "The in-depth lipidome analysis provided in this study highlights the advantage of EVs over more complex tissues for improved detection of dysregulated lipids that may serve as potential biomarkers in the periphery.", "tags": [{"end": 21, "start": 13, "tag": "Chemical"}, {"end": 85, "start": 82, "tag": "CellComponent"}, {"end": 111, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 48, "tag": "ResearchActivity"}, {"end": 196, "start": 186, "tag": "ClinicalAttribute"}, {"end": 157, "start": 138, "tag": "CellOrMolecularDysfunction"}, {"end": 30, "start": 22, "tag": "ResearchActivity"}]}{"id": "1004_0", "text": "Alzheimer's disease (AD) is considered by many to be a synaptic failure.", "tags": [{"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 55, "tag": "CellOrMolecularDysfunction"}]}{"id": "1004_1", "text": "Synaptic function is in fact deeply affected in the very early disease phases and recognized as the main cause of AD-related cognitive impairment.", "tags": [{"end": 77, "start": 63, "tag": "TemporalConcept"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 0, "tag": "CellFunction"}]}{"id": "1004_2", "text": "While the reciprocal involvement of amyloid beta (A beta) and tau peptides in these processes is under intense investigation, the crucial role of extracellular vesicles (EVs) released by different brain cells as vehicles for these molecules and as mediators of early synaptic alterations is gaining more and more ground in the field.", "tags": [{"end": 74, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 146, "tag": "CellComponent"}, {"end": 173, "start": 170, "tag": "CellComponent"}, {"end": 220, "start": 212, "tag": "ManufacturedObject"}, {"end": 208, "start": 197, "tag": "Cell"}, {"end": 287, "start": 267, "tag": "CellOrMolecularDysfunction"}, {"end": 124, "start": 111, "tag": "ResearchActivity"}, {"end": 32, "start": 21, "tag": "Finding"}, {"end": 240, "start": 231, "tag": "Substance"}, {"end": 56, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 36, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1004_3", "text": "In this review, we will summarize the current literature on the contribution of EVs derived from distinct brain cells to neuronal alterations and build a working model for EV-mediated propagation of synaptic dysfunction in early AD.", "tags": [{"end": 83, "start": 80, "tag": "CellComponent"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 117, "start": 106, "tag": "Cell"}, {"end": 231, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 199, "tag": "CellOrMolecularDysfunction"}, {"end": 45, "start": 38, "tag": "TemporalConcept"}, {"end": 167, "start": 154, "tag": "ResearchActivity"}, {"end": 141, "start": 121, "tag": "CellOrMolecularDysfunction"}, {"end": 56, "start": 46, "tag": "ResearchActivity"}, {"end": 174, "start": 172, "tag": "CellComponent"}, {"end": 195, "start": 172, "tag": "CellFunction"}, {"end": 228, "start": 223, "tag": "TemporalConcept"}]}{"id": "1004_4", "text": "A deeper understanding of EV-neuron interaction will provide useful targets for the development of novel therapeutic approaches aimed at hampering AD progression.", "tags": [{"end": 161, "start": 150, "tag": "PathologicFunction"}, {"end": 161, "start": 150, "tag": "TemporalConcept"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 26, "tag": "CellFunction"}, {"end": 127, "start": 105, "tag": "HealthCareActivity"}, {"end": 28, "start": 26, "tag": "CellComponent"}, {"end": 22, "start": 2, "tag": "Finding"}]}{"id": "1005_0", "text": "Alzheimer's disease is an age-dependent neurodegenerative disease.", "tags": [{"end": 29, "start": 26, "tag": "OrganismAttribute"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 40, "tag": "DiseaseOrSyndrome"}]}{"id": "1005_1", "text": "Recently, di?ferent non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, and circular RNAs, have been found to contribute to Alzheimer's disease's pathogenesis.", "tags": [{"end": 43, "start": 37, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 106, "start": 93, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 162, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 163, "tag": "PathologicFunction"}, {"end": 65, "start": 56, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 65, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 87, "start": 67, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 87, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 20, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1005_2", "text": "Extracellular vehicles could be enriched in ncRNAs and in their role in mediating intercellular communication.", "tags": [{"end": 50, "start": 44, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 109, "start": 82, "tag": "CellFunction"}]}{"id": "1005_3", "text": "Signatures of extracellular vesicular ncRNAs have shown them to be a potential biomarker in Alzheimer's disease.", "tags": [{"end": 111, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 69, "tag": "ClinicalAttribute"}, {"end": 44, "start": 14, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1005_4", "text": "This perspective discusses the potential role of extracellular vehicle ncRNAs in Alzheimer's disease, providing a theoretical basis for extracellular vesicular ncRNAs in Alzheimer's disease, from pathogenesis to diagnosis and treatment.", "tags": [{"end": 77, "start": 49, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 221, "start": 212, "tag": "HealthCareActivity"}, {"end": 235, "start": 226, "tag": "HealthCareActivity"}, {"end": 235, "start": 226, "tag": "ResearchActivity"}, {"end": 100, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 196, "tag": "PathologicFunction"}, {"end": 16, "start": 5, "tag": "BiologicFunction"}, {"end": 166, "start": 136, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1006_0", "text": "Alzheimer's disease (AD) is a debilitating neurodegenerative disorder affecting over five million people globally and has no established cure.", "tags": [{"end": 141, "start": 137, "tag": "Finding"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 98, "tag": "PopulationGroup"}]}{"id": "1006_1", "text": "Current AD-related treatments only alleviate cognitive and behavioral symptoms and do not address disease onset or progression, underlining the unmet need to create an effective, innovative AD therapeutic.", "tags": [{"end": 78, "start": 59, "tag": "SignOrSymptom"}, {"end": 126, "start": 115, "tag": "PathologicFunction"}, {"end": 126, "start": 115, "tag": "TemporalConcept"}, {"end": 10, "start": 8, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 19, "tag": "HealthCareActivity"}, {"end": 29, "start": 19, "tag": "ResearchActivity"}, {"end": 111, "start": 98, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 204, "start": 190, "tag": "HealthCareActivity"}, {"end": 154, "start": 144, "tag": "Finding"}, {"end": 78, "start": 70, "tag": "SignOrSymptom"}, {"end": 54, "start": 45, "tag": "SignOrSymptom"}]}{"id": "1006_2", "text": "Extracellular vesicles (EVs) have emerged as a new class of nanotherapeutics.", "tags": [{"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 76, "start": 60, "tag": "HealthCareActivity"}]}{"id": "1006_3", "text": "These secreted, lipid-bound cellular signaling carriers show promise for potential clinical applications for neurodegenerative diseases like AD.", "tags": [{"end": 135, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 16, "tag": "Chemical"}, {"end": 104, "start": 83, "tag": "HealthCareActivity"}, {"end": 55, "start": 47, "tag": "Finding"}, {"end": 46, "start": 28, "tag": "CellFunction"}]}{"id": "1006_4", "text": "Additionally, analyzing contents and characteristics of patient-derived EVs may address the unmet need for earlier AD diagnostic techniques, informing physicians of altered genetic expression or cellular communications specific to healthy and diseased physiological states.", "tags": [{"end": 75, "start": 72, "tag": "CellComponent"}, {"end": 139, "start": 118, "tag": "HealthCareActivity"}, {"end": 191, "start": 173, "tag": "CellFunction"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 56, "tag": "PatientOrDisabledGroup"}, {"end": 114, "start": 107, "tag": "TemporalConcept"}, {"end": 238, "start": 231, "tag": "OrganismAttribute"}, {"end": 272, "start": 266, "tag": "TemporalConcept"}, {"end": 161, "start": 151, "tag": "HealthCareActivity"}, {"end": 102, "start": 92, "tag": "Finding"}, {"end": 218, "start": 195, "tag": "CellFunction"}]}{"id": "1006_5", "text": "There are numerous recent advances in regenerative medicine using EVs and include bioengineering perspectives to modify EVs, target glial cells in neurodegenerative diseases like AD, and potentially use EVs to diagnose and treat AD earlier.", "tags": [{"end": 69, "start": 66, "tag": "CellComponent"}, {"end": 96, "start": 82, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 123, "start": 120, "tag": "CellComponent"}, {"end": 206, "start": 203, "tag": "CellComponent"}, {"end": 173, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 38, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 25, "start": 19, "tag": "TemporalConcept"}, {"end": 181, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 239, "start": 232, "tag": "TemporalConcept"}, {"end": 143, "start": 132, "tag": "Cell"}, {"end": 34, "start": 26, "tag": "Finding"}]}{"id": "1006_6", "text": "This article is categorized under: Neurological Diseases > Biomedical Engineering Neurological Diseases > Molecular and Cellular Physiology Neurological Diseases > Stem Cells and Development", "tags": [{"end": 56, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 179, "tag": "BiologicFunction"}, {"end": 190, "start": 179, "tag": "CellFunction"}, {"end": 174, "start": 164, "tag": "Cell"}, {"end": 12, "start": 5, "tag": "ResearchActivity"}, {"end": 161, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 106, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 81, "start": 59, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1007_0", "text": "Alzheimer's disease (AD), as a neurodegenerative disorder, is characterized by mass neuronal and synaptic loss and, currently, there are no successful curative therapies.", "tags": [{"end": 169, "start": 160, "tag": "HealthCareActivity"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 116, "tag": "TemporalConcept"}, {"end": 92, "start": 84, "tag": "Cell"}]}{"id": "1007_1", "text": "Extracellular vesicles (EVs) are an emerging approach to intercellular communication via transferring cellular materials such as proteins, lipids, mRNAs, and miRNAs from parental cells to recipient cells, leading to the reprogramming of the molecular machinery.", "tags": [{"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 84, "start": 57, "tag": "CellFunction"}, {"end": 145, "start": 139, "tag": "Chemical"}, {"end": 233, "start": 220, "tag": "CellFunction"}, {"end": 184, "start": 170, "tag": "Cell"}, {"end": 203, "start": 188, "tag": "Cell"}, {"end": 164, "start": 158, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 164, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 147, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1007_2", "text": "Numerous studies have suggested the therapeutic potential of EVs derived from mesenchymal stem cells (MSCs) in the treatment of AD, based on the neuroprotective, regenerative and immunomodulatory effects as effective as MSCs.", "tags": [{"end": 64, "start": 61, "tag": "CellComponent"}, {"end": 106, "start": 102, "tag": "Cell"}, {"end": 224, "start": 220, "tag": "Cell"}, {"end": 16, "start": 9, "tag": "ResearchActivity"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 36, "tag": "HealthCareActivity"}, {"end": 124, "start": 115, "tag": "HealthCareActivity"}, {"end": 124, "start": 115, "tag": "ResearchActivity"}, {"end": 160, "start": 145, "tag": "CellFunction"}, {"end": 100, "start": 78, "tag": "Cell"}, {"end": 203, "start": 162, "tag": "Finding"}]}{"id": "1007_3", "text": "In this review, we focus on the biology and function of EVs, the potential of MSC-derived EVs for AD therapy in preclinical and clinical studies, as well as the potent mechanisms of MSC-derived EVs actions.", "tags": [{"end": 39, "start": 32, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 59, "start": 56, "tag": "CellComponent"}, {"end": 93, "start": 90, "tag": "CellComponent"}, {"end": 197, "start": 194, "tag": "CellComponent"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 144, "start": 128, "tag": "ResearchActivity"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 101, "tag": "HealthCareActivity"}, {"end": 81, "start": 78, "tag": "Cell"}, {"end": 185, "start": 182, "tag": "Cell"}]}{"id": "1007_4", "text": "Finally, we highlight the modification strategies and diagnosis utilities in order to make advance in this field.", "tags": [{"end": 63, "start": 54, "tag": "HealthCareActivity"}]}{"id": "1008_0", "text": "Extracellular vesicles (EVs) are small cargo-bearing vesicles released by cells into the extracellular space.", "tags": [{"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 108, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 74, "tag": "Cell"}, {"end": 61, "start": 33, "tag": "CellComponent"}]}{"id": "1008_1", "text": "The field of EVs has grown exponentially over the past two decades; this growth follows the realisation that EVs are not simply a waste disposal system as had originally been suggested by some, but also a complex cell-to-cell communication mechanism.", "tags": [{"end": 16, "start": 13, "tag": "CellComponent"}, {"end": 112, "start": 109, "tag": "CellComponent"}, {"end": 249, "start": 213, "tag": "CellFunction"}, {"end": 66, "start": 59, "tag": "TemporalConcept"}, {"end": 79, "start": 73, "tag": "BiologicFunction"}, {"end": 54, "start": 50, "tag": "TemporalConcept"}, {"end": 151, "start": 130, "tag": "CellFunction"}]}{"id": "1008_2", "text": "Indeed, EVs have been shown to transfer functional cargo between cells and can influence several biological processes.", "tags": [{"end": 11, "start": 8, "tag": "CellComponent"}, {"end": 56, "start": 51, "tag": "CellFunction"}, {"end": 70, "start": 65, "tag": "Cell"}, {"end": 117, "start": 97, "tag": "BiologicFunction"}]}{"id": "1008_3", "text": "These small biological particles are also deregulated in disease.", "tags": [{"end": 32, "start": 6, "tag": "CellComponent"}]}{"id": "1008_4", "text": "As we approach the 75th anniversary of the first experiments in which EVs were unknowingly isolated, it seems right to take stock and look back on how the field started, and has since exploded into its current state.", "tags": [{"end": 60, "start": 49, "tag": "ResearchActivity"}, {"end": 73, "start": 70, "tag": "CellComponent"}, {"end": 209, "start": 202, "tag": "TemporalConcept"}]}{"id": "1008_5", "text": "Here we review the early experiments, summarise key findings that have propelled the field, describe the growth of an organised EV community, discuss the current state of the field, and identify key challenges that need to be addressed.", "tags": [{"end": 130, "start": 128, "tag": "CellComponent"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 161, "start": 154, "tag": "TemporalConcept"}, {"end": 140, "start": 131, "tag": "HealthCareRelatedOrganization"}, {"end": 209, "start": 199, "tag": "HealthCareActivity"}, {"end": 111, "start": 105, "tag": "BiologicFunction"}, {"end": 36, "start": 25, "tag": "ResearchActivity"}, {"end": 60, "start": 48, "tag": "Finding"}]}{"id": "1009_0", "text": "Both Alzheimer's disease (AD) and osteoporosis (OP) are common age-associated degenerative diseases and are strongly correlated with clinical epidemiology.", "tags": [{"end": 46, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 63, "tag": "OrganismAttribute"}, {"end": 28, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 5, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 133, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1009_1", "text": "However, there is a lack of clear pathological relationship between the brain and bone in the current understanding.", "tags": [{"end": 86, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 102, "tag": "BiologicFunction"}, {"end": 77, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 94, "tag": "TemporalConcept"}, {"end": 59, "start": 34, "tag": "Finding"}]}{"id": "1009_2", "text": "Here, it is found that young osteocyte, the most abundant cells in bone, secretes extracellular vesicles (OCYYoung-EVs) to ameliorate cognitive impairment and the pathogenesis of AD in APP/PS1 mice and model cells.", "tags": [{"end": 38, "start": 23, "tag": "Cell"}, {"end": 71, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 58, "tag": "Cell"}, {"end": 181, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 213, "start": 202, "tag": "ResearchActivity"}, {"end": 175, "start": 163, "tag": "PathologicFunction"}, {"end": 154, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 82, "tag": "CellComponent"}, {"end": 118, "start": 115, "tag": "CellComponent"}, {"end": 197, "start": 185, "tag": "ExperimentalModelOfDisease"}, {"end": 114, "start": 106, "tag": "Cell"}]}{"id": "1009_3", "text": "These benefits of OCYYoung-EVs are diminished in aged osteocyte-derived EVs (OCYAged-EVs).", "tags": [{"end": 26, "start": 18, "tag": "Cell"}, {"end": 84, "start": 77, "tag": "Cell"}, {"end": 88, "start": 85, "tag": "CellComponent"}, {"end": 30, "start": 27, "tag": "CellComponent"}, {"end": 63, "start": 49, "tag": "Cell"}, {"end": 75, "start": 72, "tag": "CellComponent"}]}{"id": "1009_4", "text": "Based on the self-constructed OCY-EVs tracer transgenic mouse models and the in vivo fluorescent imaging system, OCY-EVs have been observed to be transported to the brain under physiological and pathological conditions.", "tags": [{"end": 44, "start": 38, "tag": "Chemical"}, {"end": 170, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 30, "tag": "ResearchActivity"}, {"end": 111, "start": 77, "tag": "ResearchActivity"}, {"end": 116, "start": 113, "tag": "Cell"}, {"end": 120, "start": 117, "tag": "CellComponent"}]}{"id": "1009_6", "text": "Proteomic quantitative analysis reveals that OCYYoung-EVs, compared to OCYAged-EVs, enrich multiple protective factors of AD pathway.", "tags": [{"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 0, "tag": "ResearchActivity"}, {"end": 132, "start": 125, "tag": "CellFunction"}, {"end": 53, "start": 45, "tag": "Cell"}, {"end": 57, "start": 54, "tag": "CellComponent"}, {"end": 78, "start": 71, "tag": "Cell"}, {"end": 82, "start": 79, "tag": "CellComponent"}]}{"id": "1009_7", "text": "The study uncovers the role of OCY-EV as a regulator of brain health, suggesting a novel mechanism in bone-brain communication.", "tags": [{"end": 61, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 68, "start": 62, "tag": "HealthCareActivity"}, {"end": 34, "start": 31, "tag": "Cell"}, {"end": 37, "start": 35, "tag": "CellComponent"}, {"end": 126, "start": 102, "tag": "BiologicFunction"}]}{"id": "1010_0", "text": "Alzheimer's disease (AD) is an irreversible neurodegenerative disorder that affects more than 44 million people worldwide.", "tags": [{"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 105, "tag": "PopulationGroup"}]}{"id": "1010_1", "text": "Despite the high disease burden, there is no effective treatment for people suffering from AD.", "tags": [{"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 55, "tag": "HealthCareActivity"}, {"end": 64, "start": 55, "tag": "ResearchActivity"}, {"end": 31, "start": 17, "tag": "ResearchActivity"}, {"end": 85, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 69, "tag": "PopulationGroup"}]}{"id": "1010_2", "text": "Mesenchymal stem cells (MSCs) are multipotent stromal cells that have been widely studied due to their therapeutic potential.", "tags": [{"end": 22, "start": 0, "tag": "Cell"}, {"end": 28, "start": 24, "tag": "Cell"}, {"end": 59, "start": 34, "tag": "Cell"}, {"end": 124, "start": 103, "tag": "HealthCareActivity"}]}{"id": "1010_3", "text": "However, administration of cells has been found to have a multitude of limitations.", "tags": [{"end": 32, "start": 9, "tag": "HealthCareActivity"}]}{"id": "1010_4", "text": "Recently, extracellular vesicles (EVs) derived from MSCs have been studied as a therapeutic candidate, as they exhibit similar immunoprotective and immunomodulatory abilities as the host human MSCs.", "tags": [{"end": 32, "start": 10, "tag": "CellComponent"}, {"end": 37, "start": 34, "tag": "CellComponent"}, {"end": 56, "start": 52, "tag": "Cell"}, {"end": 186, "start": 182, "tag": "Organism"}, {"end": 197, "start": 193, "tag": "Cell"}, {"end": 192, "start": 187, "tag": "Eukaryote"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 101, "start": 80, "tag": "HealthCareActivity"}, {"end": 197, "start": 187, "tag": "Cell"}, {"end": 174, "start": 127, "tag": "Finding"}]}{"id": "1010_5", "text": "Methods: To test the potential therapeutic effects of MSC EVs, human bone-marrow derived MSCs were grown in three-dimensional (3D) cell culture, and small EVs were harvested using differential ultracentrifugation.", "tags": [{"end": 61, "start": 58, "tag": "CellComponent"}, {"end": 93, "start": 89, "tag": "Cell"}, {"end": 158, "start": 149, "tag": "CellComponent"}, {"end": 143, "start": 108, "tag": "ResearchActivity"}, {"end": 68, "start": 63, "tag": "Eukaryote"}, {"end": 57, "start": 54, "tag": "Cell"}, {"end": 50, "start": 31, "tag": "Finding"}, {"end": 80, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 180, "tag": "ResearchActivity"}]}{"id": "1010_6", "text": "These small EVs were given to non-transgenic (NT) or 5XFAD (5 familial Alzheimer's disease mutations) mice intranasally (IN) every 4 days for 4 months.", "tags": [{"end": 15, "start": 6, "tag": "CellComponent"}, {"end": 70, "start": 62, "tag": "PopulationGroup"}, {"end": 137, "start": 131, "tag": "TemporalConcept"}, {"end": 100, "start": 91, "tag": "CellFunction"}, {"end": 100, "start": 91, "tag": "CellOrMolecularDysfunction"}, {"end": 150, "start": 142, "tag": "TemporalConcept"}, {"end": 90, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 102, "tag": "ExperimentalModelOfDisease"}, {"end": 58, "start": 53, "tag": "ExperimentalModelOfDisease"}]}{"id": "1010_7", "text": "The mice were then required to perform a variety of behavioral assays to measure changes in learning and memory.", "tags": [{"end": 8, "start": 4, "tag": "Eukaryote"}, {"end": 111, "start": 92, "tag": "BiologicFunction"}, {"end": 69, "start": 52, "tag": "ResearchActivity"}]}{"id": "1010_8", "text": "Afterwards, immunohistochemistry was performed on brain slices to measure amyloid beta (A beta) and glial fibrillary acidic protein (GFAP) levels.", "tags": [{"end": 131, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 100, "tag": "GeneOrGenome"}, {"end": 137, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 133, "tag": "GeneOrGenome"}, {"end": 32, "start": 12, "tag": "ResearchActivity"}, {"end": 94, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 50, "tag": "ResearchActivity"}, {"end": 86, "start": 74, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1010_9", "text": "Results: The data revealed that 5XFAD mice that received hMSC-EV treatment behaved significantly better in cognitive tests than saline treated 5XFAD mice, with no significant change between EV-treated 5XFAD mice and NT mice.", "tags": [{"end": 134, "start": 128, "tag": "PharmacologicSubstance"}, {"end": 17, "start": 13, "tag": "ResearchActivity"}, {"end": 74, "start": 65, "tag": "HealthCareActivity"}, {"end": 74, "start": 65, "tag": "ResearchActivity"}, {"end": 211, "start": 201, "tag": "ExperimentalModelOfDisease"}, {"end": 223, "start": 216, "tag": "ManufacturedObject"}, {"end": 122, "start": 107, "tag": "HealthCareActivity"}, {"end": 42, "start": 32, "tag": "ExperimentalModelOfDisease"}, {"end": 61, "start": 57, "tag": "Cell"}, {"end": 64, "start": 62, "tag": "CellComponent"}, {"end": 122, "start": 107, "tag": "ResearchActivity"}, {"end": 153, "start": 143, "tag": "ExperimentalModelOfDisease"}, {"end": 192, "start": 190, "tag": "CellComponent"}, {"end": 181, "start": 160, "tag": "Finding"}]}{"id": "1010_10", "text": "Additionally, we found lower A beta plaque load in the hippocampus of the EV-treated mice.", "tags": [{"end": 66, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 85, "tag": "Eukaryote"}, {"end": 42, "start": 29, "tag": "AnatomicalAbnormality"}, {"end": 76, "start": 74, "tag": "CellComponent"}, {"end": 47, "start": 23, "tag": "Finding"}]}{"id": "1010_11", "text": "Finally, less colocalization between GFAP and A beta plaques was found in the brain of EV-treated mice compared to saline.", "tags": [{"end": 28, "start": 14, "tag": "BiologicFunction"}, {"end": 41, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 37, "tag": "GeneOrGenome"}, {"end": 60, "start": 46, "tag": "AnatomicalAbnormality"}, {"end": 121, "start": 115, "tag": "PharmacologicSubstance"}, {"end": 83, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 98, "tag": "Eukaryote"}, {"end": 89, "start": 87, "tag": "CellComponent"}]}{"id": "1010_12", "text": "Conclusions: Taken together, these data suggest that IN administration of MSC-derived EVs can slow down AD pathogenesis.", "tags": [{"end": 89, "start": 86, "tag": "CellComponent"}, {"end": 39, "start": 35, "tag": "ResearchActivity"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 107, "tag": "PathologicFunction"}, {"end": 77, "start": 74, "tag": "Cell"}, {"end": 70, "start": 53, "tag": "HealthCareActivity"}]}{"id": "1011_0", "text": "INTRODUCTION: Brain cell-derived small extracellular vesicles (sEVs) in blood offer unique cellular and molecular information related to the onset and progression of Alzheimer's disease (AD).", "tags": [{"end": 67, "start": 63, "tag": "CellComponent"}, {"end": 162, "start": 151, "tag": "PathologicFunction"}, {"end": 162, "start": 151, "tag": "TemporalConcept"}, {"end": 189, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 141, "tag": "TemporalConcept"}, {"end": 77, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 14, "tag": "Cell"}, {"end": 61, "start": 33, "tag": "CellComponent"}]}{"id": "1011_1", "text": "We simultaneously enriched six specific sEV subtypes from the plasma and analyzed a selected panel of microRNAs (miRNAs) in older adults with/without cognitive impairment.METHODS: Total sEVs were isolated from the plasma of participants with normal cognition (CN; n = 11), mild cognitive impairment (MCI; n = 11), MCI conversion to AD dementia (MCI-AD; n = 6), and AD dementia (n = 11).", "tags": [{"end": 17, "start": 3, "tag": "TemporalConcept"}, {"end": 136, "start": 124, "tag": "PopulationGroup"}, {"end": 190, "start": 186, "tag": "CellComponent"}, {"end": 303, "start": 300, "tag": "DiseaseOrSyndrome"}, {"end": 317, "start": 314, "tag": "DiseaseOrSyndrome"}, {"end": 334, "start": 332, "tag": "DiseaseOrSyndrome"}, {"end": 351, "start": 349, "tag": "DiseaseOrSyndrome"}, {"end": 367, "start": 365, "tag": "DiseaseOrSyndrome"}, {"end": 343, "start": 335, "tag": "DiseaseOrSyndrome"}, {"end": 376, "start": 368, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 113, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 111, "start": 102, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 111, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 258, "start": 249, "tag": "BiologicFunction"}, {"end": 119, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 220, "start": 214, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 236, "start": 224, "tag": "PopulationGroup"}, {"end": 298, "start": 273, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 40, "tag": "CellComponent"}, {"end": 348, "start": 345, "tag": "DiseaseOrSyndrome"}, {"end": 258, "start": 242, "tag": "Finding"}, {"end": 262, "start": 260, "tag": "Finding"}]}{"id": "1011_2", "text": "Various brain cell-derived sEVs (from neurons, astrocytes, microglia, oligodendrocytes, pericytes, and endothelial cells) were enriched and analyzed for specific miRNAs.RESULTS: miRNAs in sEV subtypes differentially expressed in MCI, MCI-AD, and AD dementia compared to the CN group clearly distinguished dementia status, with an area under the curve (AUC) > 0.90 and correlated with the temporal cortical region thickness on magnetic resonance imaging (MRI).DISCUSSION: miRNA analyses in specific sEVs could serve as a novel blood-based molecular biomarker for AD.Highlights", "tags": [{"end": 31, "start": 27, "tag": "CellComponent"}, {"end": 86, "start": 70, "tag": "Cell"}, {"end": 97, "start": 88, "tag": "Cell"}, {"end": 120, "start": 103, "tag": "Cell"}, {"end": 232, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 452, "start": 426, "tag": "HealthCareActivity"}, {"end": 452, "start": 426, "tag": "ManufacturedObject"}, {"end": 502, "start": 498, "tag": "CellComponent"}, {"end": 18, "start": 8, "tag": "Cell"}, {"end": 240, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 246, "tag": "DiseaseOrSyndrome"}, {"end": 564, "start": 562, "tag": "DiseaseOrSyndrome"}, {"end": 531, "start": 526, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 38, "tag": "Cell"}, {"end": 257, "start": 249, "tag": "DiseaseOrSyndrome"}, {"end": 313, "start": 305, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 162, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 184, "start": 178, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 457, "start": 454, "tag": "HealthCareActivity"}, {"end": 168, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 178, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 59, "tag": "Cell"}, {"end": 57, "start": 47, "tag": "Cell"}, {"end": 225, "start": 201, "tag": "Finding"}, {"end": 412, "start": 388, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 557, "start": 538, "tag": "ClinicalAttribute"}, {"end": 191, "start": 188, "tag": "CellComponent"}, {"end": 237, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 350, "start": 330, "tag": "ResearchActivity"}, {"end": 355, "start": 352, "tag": "ResearchActivity"}, {"end": 476, "start": 471, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 476, "start": 471, "tag": "BiologicallyActiveSubstance"}]}{"id": "1012_0", "text": "Identifying biomarkers is essential for early diagnosis of neurodegenerative diseases (NDs).", "tags": [{"end": 55, "start": 46, "tag": "HealthCareActivity"}, {"end": 85, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 12, "tag": "ClinicalAttribute"}, {"end": 90, "start": 87, "tag": "DiseaseOrSyndrome"}]}{"id": "1012_1", "text": "Large (LEVs) and small extracellular vesicles (SEVs) are extracellular vesicles (EVs) of different sizes and biological functions transported in blood and they may be valid biomarkers for NDs.", "tags": [{"end": 51, "start": 47, "tag": "CellComponent"}, {"end": 45, "start": 23, "tag": "CellComponent"}, {"end": 79, "start": 57, "tag": "CellComponent"}, {"end": 183, "start": 173, "tag": "ClinicalAttribute"}, {"end": 84, "start": 81, "tag": "CellComponent"}, {"end": 150, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 17, "tag": "CellComponent"}, {"end": 191, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 109, "tag": "BiologicFunction"}, {"end": 5, "start": 0, "tag": "CellComponent"}, {"end": 45, "start": 23, "tag": "CellComponent"}, {"end": 11, "start": 7, "tag": "CellComponent"}]}{"id": "1012_2", "text": "The aim of our study was to investigate common and different miRNA signatures in plasma derived LEVs and SEVs of Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS) and Fronto-Temporal Dementia (FTD) patients.", "tags": [{"end": 109, "start": 105, "tag": "CellComponent"}, {"end": 158, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 132, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 199, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 61, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 66, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 244, "start": 236, "tag": "PatientOrDisabledGroup"}, {"end": 194, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 234, "start": 231, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 61, "tag": "ResearchActivity"}, {"end": 100, "start": 81, "tag": "CellComponent"}, {"end": 100, "start": 96, "tag": "CellComponent"}, {"end": 229, "start": 205, "tag": "DiseaseOrSyndrome"}]}{"id": "1012_3", "text": "LEVs and SEVs were isolated from plasma of patients and healthy volunteers (CTR) by filtration and differential centrifugation and RNA was extracted.", "tags": [{"end": 13, "start": 9, "tag": "CellComponent"}, {"end": 74, "start": 56, "tag": "PopulationGroup"}, {"end": 94, "start": 84, "tag": "ResearchActivity"}, {"end": 63, "start": 56, "tag": "OrganismAttribute"}, {"end": 39, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 43, "tag": "PatientOrDisabledGroup"}, {"end": 134, "start": 131, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 4, "start": 0, "tag": "CellComponent"}, {"end": 126, "start": 99, "tag": "ResearchActivity"}, {"end": 79, "start": 76, "tag": "PopulationGroup"}]}{"id": "1012_4", "text": "Small RNAs libraries were carried out by Next Generation Sequencing (NGS).", "tags": [{"end": 10, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 67, "start": 41, "tag": "ResearchActivity"}, {"end": 72, "start": 69, "tag": "ResearchActivity"}, {"end": 20, "start": 0, "tag": "ResearchActivity"}]}{"id": "1012_5", "text": "MiRNAs discriminate all NDs diseases from CTRs and they can provide a signature for each NDs.", "tags": [{"end": 6, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 79, "start": 70, "tag": "ResearchActivity"}, {"end": 27, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 42, "tag": "PopulationGroup"}]}{"id": "1012_6", "text": "Common enriched pathways for SEVs were instead linked to ubiquitin mediated proteolysis and Toll-like receptor signaling pathways and for LEVs to neurotrophin signaling and Glycosphingolipid biosynthesis pathway.", "tags": [{"end": 33, "start": 29, "tag": "CellComponent"}, {"end": 66, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 57, "tag": "CellFunction"}, {"end": 129, "start": 92, "tag": "CellFunction"}, {"end": 211, "start": 173, "tag": "CellFunction"}, {"end": 24, "start": 16, "tag": "CellFunction"}, {"end": 168, "start": 146, "tag": "CellFunction"}, {"end": 110, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 138, "tag": "CellComponent"}, {"end": 24, "start": 0, "tag": "ResearchActivity"}]}{"id": "1012_7", "text": "LEVs and SEVs are involved in different pathways and this might give a specificity to their role in the spreading of the disease.", "tags": [{"end": 13, "start": 9, "tag": "CellComponent"}, {"end": 82, "start": 71, "tag": "Finding"}, {"end": 48, "start": 40, "tag": "CellFunction"}, {"end": 4, "start": 0, "tag": "CellComponent"}, {"end": 128, "start": 104, "tag": "Finding"}]}{"id": "1012_8", "text": "The study of common and different miRNAs transported by LEVs and SEVs can be of great interest for biomarker discovery and for pathogenesis studies in neurodegeneration.", "tags": [{"end": 69, "start": 65, "tag": "CellComponent"}, {"end": 118, "start": 109, "tag": "ResearchActivity"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 168, "start": 151, "tag": "CellOrMolecularDysfunction"}, {"end": 147, "start": 140, "tag": "ResearchActivity"}, {"end": 139, "start": 127, "tag": "PathologicFunction"}, {"end": 40, "start": 34, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 40, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 99, "tag": "ClinicalAttribute"}, {"end": 60, "start": 56, "tag": "CellComponent"}]}{"id": "1013_0", "text": "Background Regenerative therapies to mitigate Alzheimer's disease (AD) neuropathology have shown very limited success.", "tags": [{"end": 33, "start": 24, "tag": "HealthCareActivity"}, {"end": 65, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 71, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 85, "start": 71, "tag": "PathologicFunction"}]}{"id": "1013_1", "text": "In the recent era, extracellular vesicles (EVs) derived from multipotent and pluripotent stem cells have shown considerable promise for the treatment of dementia and many neurodegenerative conditions.", "tags": [{"end": 72, "start": 61, "tag": "Cell"}, {"end": 41, "start": 19, "tag": "CellComponent"}, {"end": 46, "start": 43, "tag": "CellComponent"}, {"end": 161, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 140, "tag": "HealthCareActivity"}, {"end": 149, "start": 140, "tag": "ResearchActivity"}, {"end": 199, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 89, "tag": "Cell"}, {"end": 99, "start": 89, "tag": "ResearchActivity"}, {"end": 17, "start": 7, "tag": "TemporalConcept"}]}{"id": "1013_2", "text": "Methods Using the 5xFAD accelerated transgenic mouse model of AD, we now show the regenerative potential of human neural stem cell (hNSC)-derived EVs on the neurocognitive and neuropathologic hallmarks in the AD brain.", "tags": [{"end": 64, "start": 36, "tag": "ExperimentalModelOfDisease"}, {"end": 130, "start": 114, "tag": "Cell"}, {"end": 171, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 212, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 108, "tag": "Eukaryote"}, {"end": 149, "start": 146, "tag": "CellComponent"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 192, "tag": "Finding"}, {"end": 23, "start": 18, "tag": "ExperimentalModelOfDisease"}]}{"id": "1013_3", "text": "Two- or 6-month-old 5xFAD mice received single or two intra-venous (retro-orbital vein, RO) injections of hNSC-derived EVs, respectively.", "tags": [{"end": 90, "start": 88, "tag": "GeneOrGenome"}, {"end": 102, "start": 92, "tag": "HealthCareActivity"}, {"end": 122, "start": 119, "tag": "CellComponent"}, {"end": 30, "start": 26, "tag": "Eukaryote"}, {"end": 30, "start": 20, "tag": "ExperimentalModelOfDisease"}, {"end": 25, "start": 20, "tag": "ExperimentalModelOfDisease"}]}{"id": "1013_4", "text": "Results RO treatment using hNSC-derived EVs restored fear extinction memory consolidation and reduced anxiety-related behaviors 4-6 weeks post-injection.", "tags": [{"end": 10, "start": 8, "tag": "GeneOrGenome"}, {"end": 68, "start": 58, "tag": "BiologicFunction"}, {"end": 89, "start": 69, "tag": "BiologicFunction"}, {"end": 152, "start": 143, "tag": "HealthCareActivity"}, {"end": 43, "start": 40, "tag": "CellComponent"}, {"end": 20, "start": 11, "tag": "HealthCareActivity"}, {"end": 20, "start": 11, "tag": "ResearchActivity"}, {"end": 109, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 132, "tag": "TemporalConcept"}, {"end": 57, "start": 53, "tag": "BiologicFunction"}]}{"id": "1013_5", "text": "EV treatment also significantly reduced dense core amyloid-beta plaque accumulation and microglial activation in both age groups.", "tags": [{"end": 70, "start": 51, "tag": "AnatomicalAbnormality"}, {"end": 128, "start": 118, "tag": "PopulationGroup"}, {"end": 98, "start": 88, "tag": "Cell"}, {"end": 63, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2, "start": 0, "tag": "CellComponent"}, {"end": 12, "start": 3, "tag": "HealthCareActivity"}, {"end": 12, "start": 3, "tag": "ResearchActivity"}, {"end": 83, "start": 71, "tag": "Finding"}, {"end": 109, "start": 88, "tag": "CellFunction"}]}{"id": "1013_6", "text": "These results correlated with partial restoration of homeostatic levels of circulating pro-inflammatory cytokines in the AD mice.", "tags": [{"end": 64, "start": 53, "tag": "BiologicFunction"}, {"end": 113, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 124, "tag": "Eukaryote"}, {"end": 103, "start": 87, "tag": "PathologicFunction"}, {"end": 113, "start": 75, "tag": "BiologicallyActiveSubstance"}]}{"id": "1013_7", "text": "Importantly, EV treatment protected against synaptic loss in the AD brain that paralleled improved cognition.", "tags": [{"end": 98, "start": 90, "tag": "Finding"}, {"end": 73, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 13, "tag": "CellComponent"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 16, "tag": "HealthCareActivity"}, {"end": 25, "start": 16, "tag": "ResearchActivity"}, {"end": 108, "start": 99, "tag": "BiologicFunction"}, {"end": 57, "start": 44, "tag": "CellOrMolecularDysfunction"}]}{"id": "1013_8", "text": "MiRNA analysis of the EV cargo revealed promising candidates targeting neuroinflammation and synaptic function.", "tags": [{"end": 24, "start": 22, "tag": "CellComponent"}, {"end": 14, "start": 6, "tag": "ResearchActivity"}, {"end": 30, "start": 25, "tag": "CellFunction"}, {"end": 88, "start": 71, "tag": "PathologicFunction"}]}{"id": "1013_9", "text": "Conclusions Collectively, these data demonstrate the neuroprotective effects of systemic administration of stem cell-derived EVs for remediation of behavioral and molecular AD neuropathologies.", "tags": [{"end": 103, "start": 80, "tag": "HealthCareActivity"}, {"end": 192, "start": 176, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 36, "start": 32, "tag": "ResearchActivity"}, {"end": 128, "start": 125, "tag": "CellComponent"}, {"end": 175, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 53, "tag": "CellFunction"}, {"end": 76, "start": 53, "tag": "Finding"}]}{"id": "1014_0", "text": "Introduction Objective and accessible markers for Alzheimer's disease (AD) and other dementias are critically needed.", "tags": [{"end": 94, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 38, "tag": "ClinicalAttribute"}]}{"id": "1014_1", "text": "Methods We identified NMDAR2A, a protein related to synaptic function, as a novel marker of central nervous system (CNS)-derived plasma extracellular vesicles (EVs) and developed a flow cytometry-based technology for detecting such plasma EVs readily.", "tags": [{"end": 29, "start": 22, "tag": "GeneOrGenome"}, {"end": 29, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 136, "tag": "CellComponent"}, {"end": 163, "start": 160, "tag": "CellComponent"}, {"end": 242, "start": 239, "tag": "CellComponent"}, {"end": 88, "start": 82, "tag": "ClinicalAttribute"}, {"end": 60, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 232, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 212, "start": 181, "tag": "ResearchActivity"}, {"end": 69, "start": 52, "tag": "CellFunction"}]}{"id": "1014_2", "text": "The assay was initially tested in our local cross-sectional study to distinguish AD patients from healthy controls (HCs) or from Parkinson's disease (PD) patients, followed by a validation study using an independent cohort collected from multiple medical centers (the Alzheimer's Disease Neuroimaging Initiative).", "tags": [{"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 194, "start": 178, "tag": "ResearchActivity"}, {"end": 114, "start": 98, "tag": "PopulationGroup"}, {"end": 119, "start": 116, "tag": "PopulationGroup"}, {"end": 222, "start": 216, "tag": "PopulationGroup"}, {"end": 65, "start": 44, "tag": "ResearchActivity"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 98, "tag": "OrganismAttribute"}, {"end": 92, "start": 84, "tag": "PatientOrDisabledGroup"}, {"end": 162, "start": 154, "tag": "PatientOrDisabledGroup"}, {"end": 148, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 204, "tag": "Finding"}, {"end": 262, "start": 247, "tag": "HealthCareRelatedOrganization"}, {"end": 311, "start": 268, "tag": "ResearchActivity"}, {"end": 311, "start": 268, "tag": "HealthCareRelatedOrganization"}]}{"id": "1014_3", "text": "Cerebrospinal fluid AD molecular signature was used to confirm diagnoses of all AD participants.", "tags": [{"end": 19, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 23, "tag": "ResearchActivity"}, {"end": 42, "start": 23, "tag": "ClinicalAttribute"}, {"end": 72, "start": 63, "tag": "HealthCareActivity"}, {"end": 95, "start": 83, "tag": "PopulationGroup"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}]}{"id": "1014_4", "text": "Results Likely CNS-derived EVs in plasma were significantly reduced in AD compared to HCs in both cohorts.", "tags": [{"end": 89, "start": 86, "tag": "PopulationGroup"}, {"end": 105, "start": 98, "tag": "PopulationGroup"}, {"end": 30, "start": 27, "tag": "CellComponent"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}{"id": "1014_5", "text": "Integrative models including CNS-derived EV markers and AD markers present on EVs reached area under the curve of 0.915 in discovery cohort and 0.810 in validation cohort.", "tags": [{"end": 163, "start": 153, "tag": "ResearchActivity"}, {"end": 139, "start": 133, "tag": "PopulationGroup"}, {"end": 170, "start": 164, "tag": "PopulationGroup"}, {"end": 81, "start": 78, "tag": "CellComponent"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 41, "tag": "CellComponent"}, {"end": 110, "start": 90, "tag": "ResearchActivity"}, {"end": 51, "start": 44, "tag": "ClinicalAttribute"}, {"end": 66, "start": 59, "tag": "ClinicalAttribute"}, {"end": 32, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 123, "tag": "ResearchActivity"}, {"end": 18, "start": 0, "tag": "ResearchActivity"}]}{"id": "1014_6", "text": "Discussion This study demonstrated that robust and rapid analysis of individual neuron-derived synaptic function-related EVs in peripheral blood may serve as a helpful marker of synaptic dysfunction in AD and dementia.", "tags": [{"end": 79, "start": 69, "tag": "PopulationGroup"}, {"end": 79, "start": 69, "tag": "OrganismAttribute"}, {"end": 144, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 198, "start": 178, "tag": "CellOrMolecularDysfunction"}, {"end": 124, "start": 121, "tag": "CellComponent"}, {"end": 204, "start": 202, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 168, "tag": "ClinicalAttribute"}, {"end": 86, "start": 80, "tag": "Cell"}, {"end": 65, "start": 57, "tag": "ResearchActivity"}, {"end": 103, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 112, "start": 95, "tag": "CellFunction"}]}{"id": "1015_0", "text": "The clinical diagnosis of Alzheimer's disease, at its early stage, remains a difficult task.", "tags": [{"end": 65, "start": 54, "tag": "TemporalConcept"}, {"end": 91, "start": 87, "tag": "Finding"}, {"end": 22, "start": 4, "tag": "HealthCareActivity"}, {"end": 45, "start": 26, "tag": "DiseaseOrSyndrome"}]}{"id": "1015_1", "text": "Advanced imaging technologies and laboratory assays to detect A beta peptides A beta 42 and A beta 40, total and phosphorylated tau in CSF provide a set of biomarkers of developing AD brain pathology and facilitate the diagnostic process.", "tags": [{"end": 127, "start": 113, "tag": "CellFunction"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 190, "tag": "PathologicFunction"}, {"end": 199, "start": 190, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 131, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 184, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 156, "tag": "ClinicalAttribute"}, {"end": 131, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 0, "tag": "HealthCareActivity"}, {"end": 77, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 237, "start": 219, "tag": "HealthCareActivity"}]}{"id": "1015_2", "text": "The search for biofluid biomarkers, other than in CSF, and the development of biomarker assays have accelerated significantly and now represent the fastest-growing field in AD research.", "tags": [{"end": 10, "start": 4, "tag": "ResearchActivity"}, {"end": 184, "start": 176, "tag": "ResearchActivity"}, {"end": 175, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 63, "tag": "BiologicFunction"}, {"end": 74, "start": 63, "tag": "CellFunction"}, {"end": 34, "start": 24, "tag": "ClinicalAttribute"}, {"end": 87, "start": 78, "tag": "ClinicalAttribute"}, {"end": 23, "start": 15, "tag": "Substance"}, {"end": 94, "start": 88, "tag": "ResearchActivity"}]}{"id": "1015_3", "text": "The goal of this study was to determine the differential enrichment of noncoding RNAs (ncRNAs) in plasma-derived extracellular vesicles (EV) of AD patients and Cognitively Normal controls (NC).", "tags": [{"end": 93, "start": 87, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 187, "start": 179, "tag": "PopulationGroup"}, {"end": 135, "start": 113, "tag": "CellComponent"}, {"end": 146, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 137, "tag": "CellComponent"}, {"end": 155, "start": 147, "tag": "PatientOrDisabledGroup"}, {"end": 85, "start": 71, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}, {"end": 104, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 44, "tag": "ResearchActivity"}, {"end": 178, "start": 160, "tag": "Finding"}, {"end": 191, "start": 189, "tag": "PopulationGroup"}]}{"id": "1015_4", "text": "Using RNA-seq, we profiled four significant classes of ncRNAs: miRNAs, snoRNAs, tRNAs, and piRNAs.", "tags": [{"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 78, "start": 71, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 61, "start": 55, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 69, "start": 63, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 69, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 80, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 97, "start": 91, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 85, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 71, "tag": "BiologicallyActiveSubstance"}]}{"id": "1015_5", "text": "We report a significant enrichment of SNORDs - a group of snoRNAs, in AD samples compared to NC.", "tags": [{"end": 65, "start": 58, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 9, "start": 3, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "ResearchActivity"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 49, "tag": "PopulationGroup"}, {"end": 34, "start": 24, "tag": "ResearchActivity"}, {"end": 44, "start": 38, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 44, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 93, "tag": "PopulationGroup"}, {"end": 80, "start": 73, "tag": "Substance"}, {"end": 80, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1015_6", "text": "To verify the differential enrichment of two clusters of SNORDs - SNORD115 and SNORD116, localized on human chromosome 15q11-q13, we used plasma samples of an independent group of AD patients and NC.", "tags": [{"end": 182, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 183, "tag": "PatientOrDisabledGroup"}, {"end": 107, "start": 102, "tag": "Eukaryote"}, {"end": 176, "start": 171, "tag": "PopulationGroup"}, {"end": 152, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 14, "tag": "ResearchActivity"}, {"end": 170, "start": 159, "tag": "Finding"}, {"end": 63, "start": 57, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 63, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 66, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 87, "start": 79, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 87, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 108, "tag": "CellComponent"}, {"end": 198, "start": 196, "tag": "PopulationGroup"}]}{"id": "1015_7", "text": "We applied ddPCR technique and identified SNORD115 and SNORD116 with a high discriminatory power to differentiate AD samples from NC.", "tags": [{"end": 26, "start": 11, "tag": "ResearchActivity"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 42, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 50, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 55, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 132, "start": 130, "tag": "PopulationGroup"}, {"end": 124, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 117, "tag": "Substance"}, {"end": 96, "start": 71, "tag": "ResearchActivity"}]}{"id": "1015_8", "text": "The results of our study present evidence that AD is associated with changes in the enrichment of SNORDs, transcribed from imprinted genomic loci, in plasma EV and provide a rationale to further explore the validity of those SNORDs as plasma biomarkers of AD.", "tags": [{"end": 132, "start": 123, "tag": "BiologicFunction"}, {"end": 41, "start": 33, "tag": "Finding"}, {"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 258, "start": 256, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 157, "tag": "CellComponent"}, {"end": 252, "start": 242, "tag": "ClinicalAttribute"}, {"end": 24, "start": 19, "tag": "ResearchActivity"}, {"end": 156, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 241, "start": 235, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 84, "tag": "ResearchActivity"}, {"end": 215, "start": 207, "tag": "Finding"}, {"end": 104, "start": 98, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 104, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 231, "start": 225, "tag": "BiologicallyActiveSubstance"}, {"end": 231, "start": 225, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 145, "start": 133, "tag": "GeneOrGenome"}]}{"id": "1016_0", "text": "Increasing evidence indicates that extracellular vesicles (EVs) play an important role in the pathogenesis of Alzheimer's disease (AD).", "tags": [{"end": 19, "start": 11, "tag": "Finding"}, {"end": 57, "start": 35, "tag": "CellComponent"}, {"end": 129, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 59, "tag": "CellComponent"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 94, "tag": "PathologicFunction"}]}{"id": "1016_1", "text": "We previously reported that the blood-cerebrospinal fluid (CSF) interface, formed by the choroid plexus epithelial (CPE) cells, releases an increased amount of EVs into the CSF in response to peripheral inflammation.", "tags": [{"end": 114, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 160, "tag": "CellComponent"}, {"end": 37, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 121, "tag": "Cell"}, {"end": 62, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 52, "tag": "Substance"}, {"end": 202, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 215, "start": 203, "tag": "PathologicFunction"}, {"end": 119, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1016_2", "text": "Here, we studied the importance of CP-mediated EV release in AD pathogenesis.", "tags": [{"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 64, "tag": "PathologicFunction"}, {"end": 49, "start": 47, "tag": "CellComponent"}, {"end": 57, "start": 47, "tag": "CellFunction"}]}{"id": "1016_3", "text": "We observed increased EV levels in the CSF of young transgenic APP/PS1 mice which correlated with high amyloid beta (A beta) CSF levels at this age.", "tags": [{"end": 51, "start": 46, "tag": "TemporalConcept"}, {"end": 115, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 63, "tag": "GeneOrGenome"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 52, "tag": "ExperimentalModelOfDisease"}, {"end": 147, "start": 144, "tag": "OrganismAttribute"}, {"end": 24, "start": 22, "tag": "CellComponent"}, {"end": 42, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 22, "tag": "ClinicalAttribute"}]}{"id": "1016_4", "text": "The intracerebroventricular (icv) injection of A beta oligomers (A beta O) in wild-type mice revealed a significant increase of EVs in the CSF, signifying that the presence of CSF-A beta O is sufficient to induce increased EV secretion.", "tags": [{"end": 27, "start": 4, "tag": "HealthCareActivity"}, {"end": 172, "start": 164, "tag": "Finding"}, {"end": 235, "start": 223, "tag": "CellFunction"}, {"end": 92, "start": 78, "tag": "Eukaryote"}, {"end": 131, "start": 128, "tag": "CellComponent"}, {"end": 43, "start": 34, "tag": "HealthCareActivity"}, {"end": 225, "start": 223, "tag": "CellComponent"}, {"end": 142, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 176, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 180, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1016_5", "text": "Using in vivo, in vitro and ex vivo approaches, we identified the CP as a major source of the CSF-EVs.", "tags": [{"end": 23, "start": 15, "tag": "ResearchActivity"}, {"end": 101, "start": 98, "tag": "CellComponent"}, {"end": 97, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 46, "start": 28, "tag": "ResearchActivity"}]}{"id": "1016_6", "text": "Interestingly, A beta O-induced, CP-derived EVs induced pro-inflammatory effects in mixed cortical cultures.", "tags": [{"end": 98, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 44, "tag": "CellComponent"}, {"end": 72, "start": 56, "tag": "PathologicFunction"}, {"end": 23, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 90, "tag": "ResearchActivity"}]}{"id": "1016_7", "text": "Proteome analysis of these EVs revealed the presence of several pro-inflammatory proteins, including the complement protein C3.", "tags": [{"end": 52, "start": 44, "tag": "Finding"}, {"end": 126, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 27, "tag": "CellComponent"}, {"end": 17, "start": 0, "tag": "ResearchActivity"}, {"end": 80, "start": 64, "tag": "PathologicFunction"}]}{"id": "1016_8", "text": "Strikingly, inhibition of EV production using GW4869 resulted in protection against acute A beta O-induced cognitive decline.", "tags": [{"end": 52, "start": 46, "tag": "Chemical"}, {"end": 89, "start": 84, "tag": "TemporalConcept"}, {"end": 22, "start": 12, "tag": "CellFunction"}, {"end": 28, "start": 26, "tag": "CellComponent"}, {"end": 98, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 107, "tag": "DiseaseOrSyndrome"}]}{"id": "1016_9", "text": "Further research into the underlying mechanisms of this EV secretion might open up novel therapeutic strategies to impact the pathogenesis and progression of AD.", "tags": [{"end": 111, "start": 89, "tag": "HealthCareActivity"}, {"end": 154, "start": 143, "tag": "PathologicFunction"}, {"end": 154, "start": 143, "tag": "TemporalConcept"}, {"end": 16, "start": 8, "tag": "ResearchActivity"}, {"end": 160, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 126, "tag": "PathologicFunction"}, {"end": 58, "start": 56, "tag": "CellComponent"}, {"end": 68, "start": 56, "tag": "CellFunction"}]}{"id": "1017_0", "text": "Background The protracted preclinical stage of Alzheimer's disease (AD) provides the opportunity for early intervention to prevent the disease; however, the lack of minimally invasive and easily detectable biomarkers and their measurement technologies remain unresolved.", "tags": [{"end": 238, "start": 227, "tag": "ResearchActivity"}, {"end": 238, "start": 227, "tag": "HealthCareActivity"}, {"end": 251, "start": 239, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 66, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 195, "tag": "ClinicalAttribute"}, {"end": 183, "start": 165, "tag": "Finding"}, {"end": 43, "start": 26, "tag": "ClinicalAttribute"}, {"end": 119, "start": 101, "tag": "HealthCareActivity"}]}{"id": "1017_1", "text": "Extracellular vesicles (EVs) are nanosized membrane vesicles released from a variety of cells and play important roles in cell-cell communication.", "tags": [{"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 93, "start": 88, "tag": "Cell"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 60, "start": 33, "tag": "CellComponent"}, {"end": 145, "start": 122, "tag": "CellFunction"}]}{"id": "1017_2", "text": "Neuron-derived and ganglioside-enriched EVs capture amyloid-ss protein, a major AD agent, and transport it into glial cells for degradation; this suggests that EVs influence Ass accumulation in the brain.", "tags": [{"end": 177, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 128, "tag": "NaturalPhenomenonOrProcess"}, {"end": 88, "start": 83, "tag": "PharmacologicSubstance"}, {"end": 43, "start": 40, "tag": "CellComponent"}, {"end": 163, "start": 160, "tag": "CellComponent"}, {"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 178, "tag": "Finding"}, {"end": 203, "start": 198, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 112, "tag": "Cell"}, {"end": 103, "start": 94, "tag": "CellFunction"}, {"end": 103, "start": 94, "tag": "ManufacturedObject"}, {"end": 30, "start": 19, "tag": "Chemical"}, {"end": 30, "start": 19, "tag": "PharmacologicSubstance"}, {"end": 177, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 0, "tag": "Cell"}, {"end": 30, "start": 19, "tag": "BiologicallyActiveSubstance"}]}{"id": "1017_3", "text": "EV heterogeneity, however, requires the use of a highly sensitive technique for measuring specific EVs in biofluid.", "tags": [{"end": 75, "start": 49, "tag": "ResearchActivity"}, {"end": 102, "start": 99, "tag": "CellComponent"}, {"end": 2, "start": 0, "tag": "CellComponent"}, {"end": 16, "start": 3, "tag": "OrganismAttribute"}, {"end": 114, "start": 106, "tag": "Substance"}]}{"id": "1017_4", "text": "In this study, immuno-digital invasive cleavage assay (idICA) was developed for quantitating target-intact EVs.", "tags": [{"end": 106, "start": 100, "tag": "Finding"}, {"end": 110, "start": 107, "tag": "CellComponent"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 53, "start": 15, "tag": "ResearchActivity"}, {"end": 60, "start": 55, "tag": "ResearchActivity"}]}{"id": "1017_5", "text": "Methods EVs were captured onto ganglioside GM1-specific cholera toxin B subunit (CTB)-conjugated magnetic beads and detected with a DNA oligonucleotide-labeled Ass antibody.", "tags": [{"end": 46, "start": 31, "tag": "Chemical"}, {"end": 79, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 97, "tag": "ManufacturedObject"}, {"end": 11, "start": 8, "tag": "CellComponent"}, {"end": 151, "start": 132, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 79, "start": 56, "tag": "InjuryOrPoisoning"}, {"end": 84, "start": 81, "tag": "InjuryOrPoisoning"}, {"end": 84, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 31, "tag": "PharmacologicSubstance"}, {"end": 46, "start": 31, "tag": "BiologicallyActiveSubstance"}]}{"id": "1017_6", "text": "Fluorescence signals for individual EVs were then counted using an invasive cleavage assay (ICA).", "tags": [{"end": 35, "start": 25, "tag": "PopulationGroup"}, {"end": 35, "start": 25, "tag": "OrganismAttribute"}, {"end": 39, "start": 36, "tag": "CellComponent"}, {"end": 20, "start": 13, "tag": "CellFunction"}, {"end": 12, "start": 0, "tag": "NaturalPhenomenonOrProcess"}, {"end": 90, "start": 67, "tag": "ResearchActivity"}, {"end": 95, "start": 92, "tag": "ResearchActivity"}]}{"id": "1017_7", "text": "This idICA examines the Ass-bound and GM1-containing EVs isolated from the culture supernatant of human APP-overexpressing N2a (APP-N2a) cells and APP transgenic mice sera.", "tags": [{"end": 107, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 104, "tag": "GeneOrGenome"}, {"end": 131, "start": 128, "tag": "GeneOrGenome"}, {"end": 150, "start": 147, "tag": "GeneOrGenome"}, {"end": 107, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 53, "tag": "CellComponent"}, {"end": 142, "start": 137, "tag": "Cell"}, {"end": 126, "start": 123, "tag": "Cell"}, {"end": 171, "start": 167, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 98, "tag": "Eukaryote"}, {"end": 166, "start": 151, "tag": "ResearchActivity"}, {"end": 41, "start": 38, "tag": "Chemical"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 27, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 75, "tag": "Substance"}, {"end": 41, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 38, "tag": "PharmacologicSubstance"}]}{"id": "1017_8", "text": "Results The idICA quantitatively detected Ass-bound and GM1-containing EVs isolated from culture supernatants of APP-N2a cells and sera of AD model mice.", "tags": [{"end": 116, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 113, "tag": "GeneOrGenome"}, {"end": 116, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 71, "tag": "CellComponent"}, {"end": 126, "start": 117, "tag": "Cell"}, {"end": 135, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 152, "start": 139, "tag": "ExperimentalModelOfDisease"}, {"end": 59, "start": 56, "tag": "Chemical"}, {"end": 109, "start": 89, "tag": "Substance"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 45, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 56, "tag": "PharmacologicSubstance"}, {"end": 59, "start": 56, "tag": "BiologicallyActiveSubstance"}]}{"id": "1017_9", "text": "The idICA levels of Ass-associated EVs in blood gradually increased from 3- to 12-month-old mice, corresponding to the progression of Ass accumulations in the brain of AD model mice.", "tags": [{"end": 137, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 138, "tag": "Finding"}, {"end": 91, "start": 79, "tag": "PopulationGroup"}, {"end": 130, "start": 119, "tag": "PathologicFunction"}, {"end": 130, "start": 119, "tag": "TemporalConcept"}, {"end": 38, "start": 35, "tag": "CellComponent"}, {"end": 47, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 92, "tag": "Eukaryote"}, {"end": 181, "start": 168, "tag": "ExperimentalModelOfDisease"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 137, "start": 134, "tag": "BiologicallyActiveSubstance"}]}{"id": "1017_10", "text": "Conclusions The present findings suggest that peripheral EVs harboring Ass and GM1 reflect Ass burden in mice.", "tags": [{"end": 74, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 57, "tag": "CellComponent"}, {"end": 56, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 105, "tag": "Eukaryote"}, {"end": 101, "start": 95, "tag": "ResearchActivity"}, {"end": 82, "start": 79, "tag": "Chemical"}, {"end": 74, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 79, "tag": "PharmacologicSubstance"}]}{"id": "1017_11", "text": "The idICA is a valuable tool for easy quantitative detection of EVs as an accessible biomarker for preclinical AD diagnosis.", "tags": [{"end": 67, "start": 64, "tag": "CellComponent"}, {"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 114, "tag": "HealthCareActivity"}, {"end": 94, "start": 85, "tag": "ClinicalAttribute"}, {"end": 60, "start": 51, "tag": "ResearchActivity"}, {"end": 60, "start": 51, "tag": "HealthCareActivity"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}]}{"id": "1018_0", "text": "Alzheimer's disease (AD) is the most common form of dementia, characterized by the accumulation of beta-amyloid plaques and the formation of neurofibrillary tangles.", "tags": [{"end": 164, "start": 141, "tag": "CellOrMolecularDysfunction"}, {"end": 156, "start": 141, "tag": "CellComponent"}, {"end": 119, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 83, "tag": "Finding"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 52, "tag": "DiseaseOrSyndrome"}]}{"id": "1018_1", "text": "Extracellular vesicles (EVs) are small vesicles surrounded by a lipid bilayer membrane, which may be involved in the progression of AD.", "tags": [{"end": 47, "start": 33, "tag": "CellComponent"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 69, "start": 64, "tag": "Chemical"}, {"end": 86, "start": 64, "tag": "CellComponent"}, {"end": 128, "start": 117, "tag": "PathologicFunction"}, {"end": 128, "start": 117, "tag": "TemporalConcept"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}]}{"id": "1018_2", "text": "Glycans are essential building blocks of EVs, and we hypothesized that EV glycans may reflect pathological conditions of various diseases.", "tags": [{"end": 7, "start": 0, "tag": "Chemical"}, {"end": 117, "start": 94, "tag": "PathologicFunction"}, {"end": 44, "start": 41, "tag": "CellComponent"}, {"end": 73, "start": 71, "tag": "CellComponent"}, {"end": 81, "start": 74, "tag": "Chemical"}, {"end": 7, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 81, "start": 74, "tag": "PharmacologicSubstance"}]}{"id": "1018_3", "text": "Here, we performed glycan profiling of EVs prepared from sera of three AD patients (APs) compared to three healthy donors (HDs) using lectin microarray.", "tags": [{"end": 61, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 84, "tag": "PatientOrDisabledGroup"}, {"end": 140, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 141, "tag": "ResearchActivity"}, {"end": 151, "start": 141, "tag": "ManufacturedObject"}, {"end": 42, "start": 39, "tag": "CellComponent"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 107, "tag": "OrganismAttribute"}, {"end": 82, "start": 74, "tag": "PatientOrDisabledGroup"}, {"end": 35, "start": 19, "tag": "ResearchActivity"}, {"end": 121, "start": 115, "tag": "PopulationGroup"}, {"end": 140, "start": 134, "tag": "BiologicallyActiveSubstance"}]}{"id": "1018_4", "text": "Distinct glycan profiles were observed.", "tags": [{"end": 15, "start": 9, "tag": "Chemical"}, {"end": 24, "start": 16, "tag": "ResearchActivity"}]}{"id": "1018_5", "text": "Mannose-binding lectins exhibited significantly higher signals for AP-derived EVs than HD-derived EVs.", "tags": [{"end": 23, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 62, "start": 55, "tag": "CellFunction"}, {"end": 81, "start": 78, "tag": "CellComponent"}, {"end": 101, "start": 98, "tag": "CellComponent"}]}{"id": "1018_6", "text": "Lectin blotting using mannose-binding lectin (rPALa) showed a single protein band at similar to 80 kDa exclusively in AP-derived EVs.", "tags": [{"end": 44, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 129, "tag": "CellComponent"}, {"end": 6, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 7, "tag": "ResearchActivity"}, {"end": 81, "start": 69, "tag": "ResearchActivity"}]}{"id": "1018_7", "text": "LC-MS/MS analysis identified a protein band precipitated by rPALa as CD61, a marker of platelet-derived exosomes (P-Exo).", "tags": [{"end": 43, "start": 31, "tag": "ResearchActivity"}, {"end": 73, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 104, "tag": "CellComponent"}, {"end": 17, "start": 0, "tag": "ResearchActivity"}, {"end": 83, "start": 77, "tag": "ClinicalAttribute"}, {"end": 95, "start": 87, "tag": "Cell"}, {"end": 119, "start": 114, "tag": "CellComponent"}]}{"id": "1018_8", "text": "Sandwich assays using Tim4 with specificity for phosphatidylserine on EVs and antibodies against P-Exo markers (CD61, CD41, CD63, and CD9) revealed that P-Exo is significantly elevated in sera of APs (n = 16) relative to age- and sex-matched HDs (n = 16).", "tags": [{"end": 26, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 48, "tag": "Chemical"}, {"end": 88, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 188, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 199, "start": 196, "tag": "PatientOrDisabledGroup"}, {"end": 224, "start": 221, "tag": "OrganismAttribute"}, {"end": 43, "start": 32, "tag": "Finding"}, {"end": 73, "start": 70, "tag": "CellComponent"}, {"end": 233, "start": 230, "tag": "OrganismAttribute"}, {"end": 15, "start": 0, "tag": "ResearchActivity"}, {"end": 26, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 97, "tag": "CellComponent"}, {"end": 110, "start": 103, "tag": "ClinicalAttribute"}, {"end": 128, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 153, "tag": "CellComponent"}]}{"id": "1018_9", "text": "Tim4-alpha CD63 showed the highest value for the area under the curve (0.957) for discriminating APs from HDs, which should lead to a better understanding of AD pathology and may facilitate the development of a novel diagnostic method for AD.", "tags": [{"end": 15, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 97, "tag": "PatientOrDisabledGroup"}, {"end": 234, "start": 217, "tag": "HealthCareActivity"}, {"end": 154, "start": 141, "tag": "BiologicFunction"}, {"end": 160, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 241, "start": 239, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 161, "tag": "PathologicFunction"}, {"end": 170, "start": 161, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 205, "start": 194, "tag": "BiologicFunction"}, {"end": 205, "start": 194, "tag": "CellFunction"}, {"end": 69, "start": 49, "tag": "ResearchActivity"}, {"end": 15, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1019_0", "text": "Extracellular vesicles (EVs) are gaining increased importance in fundamental research as key players in disease pathogenic mechanisms, but also in translational and clinical research due to their value in biomarker discovery, either for diagnostics and/or therapeutics.", "tags": [{"end": 100, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 174, "tag": "ResearchActivity"}, {"end": 160, "start": 147, "tag": "ResearchActivity"}, {"end": 182, "start": 165, "tag": "ResearchActivity"}, {"end": 85, "start": 77, "tag": "ResearchActivity"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 248, "start": 237, "tag": "HealthCareActivity"}, {"end": 268, "start": 256, "tag": "HealthCareActivity"}, {"end": 224, "start": 215, "tag": "ResearchActivity"}, {"end": 214, "start": 205, "tag": "ClinicalAttribute"}, {"end": 133, "start": 112, "tag": "PathologicFunction"}]}{"id": "1019_1", "text": "In the first research scenario, the study of EVs isolated from neuronal models mimicking neurodegenerative diseases can open new avenues to better understand the pathological mechanisms underlying these conditions or to identify novel molecular targets for diagnosis and/or therapeutics.", "tags": [{"end": 252, "start": 235, "tag": "Chemical"}, {"end": 21, "start": 13, "tag": "ResearchActivity"}, {"end": 48, "start": 45, "tag": "CellComponent"}, {"end": 71, "start": 63, "tag": "Cell"}, {"end": 115, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 286, "start": 274, "tag": "HealthCareActivity"}, {"end": 41, "start": 36, "tag": "ResearchActivity"}, {"end": 12, "start": 7, "tag": "TemporalConcept"}, {"end": 78, "start": 72, "tag": "ResearchActivity"}, {"end": 266, "start": 257, "tag": "HealthCareActivity"}, {"end": 185, "start": 162, "tag": "PathologicFunction"}]}{"id": "1019_2", "text": "In the second research scenario, the easy availability of EVs in body fluids and the specificity of their cargo, which can reflect the cell of origin or disease profiles, turn these into attractive diagnostic tools.", "tags": [{"end": 76, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 14, "tag": "ResearchActivity"}, {"end": 61, "start": 58, "tag": "CellComponent"}, {"end": 169, "start": 161, "tag": "ResearchActivity"}, {"end": 96, "start": 85, "tag": "Finding"}, {"end": 139, "start": 135, "tag": "Cell"}, {"end": 149, "start": 143, "tag": "TemporalConcept"}, {"end": 111, "start": 106, "tag": "CellFunction"}, {"end": 214, "start": 198, "tag": "HealthCareActivity"}]}{"id": "1019_3", "text": "EVs with exosome-like characteristics, circulating in the bloodstream and other peripheral biofluids, constitute a non-invasive and rapid alternative to study several conditions, including brain-related disorders.", "tags": [{"end": 69, "start": 58, "tag": "BiologicFunction"}, {"end": 127, "start": 115, "tag": "Finding"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 90, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 153, "tag": "ResearchActivity"}, {"end": 16, "start": 9, "tag": "CellComponent"}, {"end": 100, "start": 91, "tag": "Substance"}, {"end": 212, "start": 189, "tag": "DiseaseOrSyndrome"}]}{"id": "1019_4", "text": "In both cases, several EVs isolation methods are already available, but each neuronal model or biofluid presents its own challenges.", "tags": [{"end": 26, "start": 23, "tag": "CellComponent"}, {"end": 85, "start": 77, "tag": "Cell"}, {"end": 131, "start": 121, "tag": "HealthCareActivity"}, {"end": 91, "start": 86, "tag": "ResearchActivity"}, {"end": 44, "start": 23, "tag": "ResearchActivity"}, {"end": 103, "start": 95, "tag": "Substance"}]}{"id": "1019_5", "text": "Herein, a literature overview on EVs isolation methodologies from distinct neuronal models (cellular culture and brain tissue) and body fluids (serum, plasma, cerebrospinal fluid, urine and saliva) was carried out.", "tags": [{"end": 46, "start": 37, "tag": "HealthCareActivity"}, {"end": 60, "start": 33, "tag": "ResearchActivity"}, {"end": 46, "start": 37, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 142, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 180, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 196, "start": 190, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 33, "tag": "CellComponent"}, {"end": 178, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 75, "tag": "Cell"}, {"end": 125, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 10, "tag": "ResearchActivity"}, {"end": 157, "start": 151, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 84, "tag": "ResearchActivity"}, {"end": 149, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 21, "tag": "ResearchActivity"}, {"end": 108, "start": 92, "tag": "ResearchActivity"}]}{"id": "1019_6", "text": "Focus was given to approaches employed in the context of Alzheimer's and Parkinson's diseases, and the main research findings discussed.", "tags": [{"end": 93, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 108, "tag": "ResearchActivity"}, {"end": 68, "start": 57, "tag": "DiseaseOrSyndrome"}]}{"id": "1019_7", "text": "The topics here revised will facilitate the choice of EVs isolation methodologies and potentially prompt new discoveries in EVs research and in the neurodegenerative diseases field.", "tags": [{"end": 81, "start": 54, "tag": "ResearchActivity"}, {"end": 120, "start": 109, "tag": "ResearchActivity"}, {"end": 136, "start": 128, "tag": "ResearchActivity"}, {"end": 57, "start": 54, "tag": "CellComponent"}, {"end": 127, "start": 124, "tag": "CellComponent"}, {"end": 174, "start": 148, "tag": "DiseaseOrSyndrome"}]}{"id": "1020_0", "text": "Alzheimer's disease (AD) is the most common cause of dementia, yet there is no cure or diagnostics available prior to the onset of clinical symptoms.", "tags": [{"end": 83, "start": 76, "tag": "Finding"}, {"end": 148, "start": 131, "tag": "SignOrSymptom"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 122, "tag": "TemporalConcept"}, {"end": 98, "start": 87, "tag": "HealthCareActivity"}]}{"id": "1020_1", "text": "Extracellular vesicles (EVs) are lipid bilayer-delimited particles that are released from almost all types of cell.", "tags": [{"end": 114, "start": 110, "tag": "Cell"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 38, "start": 33, "tag": "Chemical"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 66, "start": 33, "tag": "CellComponent"}]}{"id": "1020_2", "text": "Genome-wide association studies have linked multiple AD genetic risk factors to microglia-specific pathways.", "tags": [{"end": 31, "start": 0, "tag": "ResearchActivity"}, {"end": 76, "start": 56, "tag": "Finding"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "CellFunction"}, {"end": 89, "start": 80, "tag": "Cell"}]}{"id": "1020_3", "text": "It is plausible that microglia-derived EVs may play a role in the progression of AD by contributing to the dissemination of insoluble pathogenic proteins, such as tau and A beta.", "tags": [{"end": 153, "start": 134, "tag": "CellOrMolecularDysfunction"}, {"end": 77, "start": 66, "tag": "PathologicFunction"}, {"end": 77, "start": 66, "tag": "TemporalConcept"}, {"end": 166, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 39, "tag": "CellComponent"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 21, "tag": "Cell"}, {"end": 166, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 177, "start": 171, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1020_4", "text": "Despite the potential utility of EVs as a diagnostic tool, our knowledge of human brain EV subpopulations is limited.", "tags": [{"end": 72, "start": 63, "tag": "Finding"}, {"end": 87, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 33, "tag": "CellComponent"}, {"end": 81, "start": 76, "tag": "Eukaryote"}, {"end": 105, "start": 88, "tag": "CellComponent"}, {"end": 57, "start": 42, "tag": "HealthCareActivity"}]}{"id": "1020_5", "text": "Here we present a method for isolating microglial CD11b-positive small EVs from cryopreserved human brain tissue, as well as an integrated multiomics analysis of microglial EVs enriched from the parietal cortex of four late-stage AD (Braak V-VI) and three age-matched normal/low pathology (NL) cases.", "tags": [{"end": 93, "start": 80, "tag": "ResearchActivity"}, {"end": 210, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 65, "tag": "CellComponent"}, {"end": 24, "start": 18, "tag": "ResearchActivity"}, {"end": 274, "start": 268, "tag": "Finding"}, {"end": 24, "start": 18, "tag": "HealthCareActivity"}, {"end": 112, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 229, "start": 219, "tag": "TemporalConcept"}, {"end": 259, "start": 256, "tag": "OrganismAttribute"}, {"end": 74, "start": 71, "tag": "CellComponent"}, {"end": 176, "start": 173, "tag": "CellComponent"}, {"end": 232, "start": 230, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 94, "tag": "Eukaryote"}, {"end": 49, "start": 39, "tag": "Cell"}, {"end": 172, "start": 162, "tag": "Cell"}, {"end": 158, "start": 128, "tag": "ResearchActivity"}, {"end": 288, "start": 279, "tag": "PathologicFunction"}, {"end": 288, "start": 279, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 55, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 244, "start": 234, "tag": "HealthCareActivity"}]}{"id": "1020_6", "text": "This integrated analysis revealed 1,000 proteins, 594 lipids, and 105 miRNAs using shotgun proteomics, targeted lipidomics, and NanoString nCounter technology, respectively.", "tags": [{"end": 60, "start": 54, "tag": "Chemical"}, {"end": 48, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 70, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 76, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 5, "tag": "ResearchActivity"}, {"end": 101, "start": 83, "tag": "ResearchActivity"}, {"end": 122, "start": 103, "tag": "ResearchActivity"}, {"end": 122, "start": 112, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 158, "start": 128, "tag": "ResearchActivity"}]}{"id": "1020_7", "text": "The results showed a significant reduction in the abundance of homeostatic microglia markers P2RY12 and TMEM119, and increased levels of disease-associated microglia markers FTH1 and TREM2, in CD11b-positive EVs from AD brain compared to NL cases.", "tags": [{"end": 99, "start": 93, "tag": "GeneOrGenome"}, {"end": 111, "start": 104, "tag": "GeneOrGenome"}, {"end": 178, "start": 174, "tag": "GeneOrGenome"}, {"end": 188, "start": 183, "tag": "GeneOrGenome"}, {"end": 133, "start": 117, "tag": "Finding"}, {"end": 42, "start": 21, "tag": "Finding"}, {"end": 225, "start": 220, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 208, "tag": "CellComponent"}, {"end": 219, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 63, "tag": "BiologicFunction"}, {"end": 84, "start": 75, "tag": "Cell"}, {"end": 165, "start": 156, "tag": "Cell"}, {"end": 92, "start": 85, "tag": "ClinicalAttribute"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 166, "tag": "ClinicalAttribute"}, {"end": 178, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 183, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 183, "tag": "BiologicallyActiveSubstance"}, {"end": 198, "start": 193, "tag": "AminoAcidPeptideOrProtein"}, {"end": 198, "start": 193, "tag": "BiologicallyActiveSubstance"}]}{"id": "1020_8", "text": "Tau abundance was significantly higher in AD brain-derived microglial EVs.", "tags": [{"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 70, "tag": "CellComponent"}, {"end": 44, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 59, "tag": "Cell"}]}{"id": "1020_9", "text": "These changes were accompanied by the upregulation of synaptic and neuron-specific proteins in the AD group.", "tags": [{"end": 50, "start": 38, "tag": "CellFunction"}, {"end": 73, "start": 67, "tag": "Cell"}, {"end": 91, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 102, "tag": "PopulationGroup"}, {"end": 62, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1020_10", "text": "Levels of free cholesterol were elevated in microglial EVs from the AD brain.", "tags": [{"end": 26, "start": 15, "tag": "Chemical"}, {"end": 26, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 55, "tag": "CellComponent"}, {"end": 70, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 44, "tag": "Cell"}, {"end": 26, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1020_11", "text": "Lipidomic analysis also revealed a proinflammatory lipid profile, endolysosomal dysfunction, and a significant AD-associated decrease in levels of docosahexaenoic acid (DHA)-containing polyunsaturated lipids, suggesting a potential defect in acyl-chain remodeling.", "tags": [{"end": 263, "start": 232, "tag": "CellOrMolecularDysfunction"}, {"end": 263, "start": 242, "tag": "CellFunction"}, {"end": 207, "start": 185, "tag": "Chemical"}, {"end": 56, "start": 51, "tag": "Chemical"}, {"end": 167, "start": 147, "tag": "Chemical"}, {"end": 91, "start": 66, "tag": "CellOrMolecularDysfunction"}, {"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "ResearchActivity"}, {"end": 133, "start": 125, "tag": "Finding"}, {"end": 50, "start": 35, "tag": "PathologicFunction"}, {"end": 64, "start": 51, "tag": "ResearchActivity"}, {"end": 79, "start": 66, "tag": "CellComponent"}, {"end": 167, "start": 147, "tag": "PharmacologicSubstance"}, {"end": 167, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 169, "tag": "Chemical"}, {"end": 172, "start": 169, "tag": "PharmacologicSubstance"}]}{"id": "1020_12", "text": "Additionally, four miRNAs associated with immune and cellular senescence signaling pathways were significantly upregulated in the AD group.", "tags": [{"end": 72, "start": 42, "tag": "CellFunction"}, {"end": 91, "start": 73, "tag": "CellFunction"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 19, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 25, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 133, "tag": "PopulationGroup"}]}{"id": "1020_13", "text": "Our data suggest that loss of the homeostatic microglia signature in late AD stages may be accompanied by endolysosomal impairment and the release of undigested neuronal and myelin debris, including tau, through extracellular vesicles.", "tags": [{"end": 83, "start": 77, "tag": "TemporalConcept"}, {"end": 169, "start": 161, "tag": "Cell"}, {"end": 187, "start": 181, "tag": "Substance"}, {"end": 202, "start": 199, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 56, "tag": "ResearchActivity"}, {"end": 234, "start": 212, "tag": "CellComponent"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 34, "tag": "BiologicFunction"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 180, "start": 174, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 46, "tag": "Cell"}, {"end": 202, "start": 199, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 69, "tag": "TemporalConcept"}, {"end": 119, "start": 106, "tag": "CellComponent"}, {"end": 130, "start": 106, "tag": "CellOrMolecularDysfunction"}, {"end": 187, "start": 139, "tag": "CellOrMolecularDysfunction"}]}{"id": "1020_14", "text": "We suggest that the analysis of microglia-derived EVs has merit for identifying novel EV-associated biomarkers and providing a framework for future larger-scale multiomics studies on patient-derived cell-type-specific EVs.", "tags": [{"end": 208, "start": 199, "tag": "Cell"}, {"end": 179, "start": 148, "tag": "ResearchActivity"}, {"end": 110, "start": 100, "tag": "ClinicalAttribute"}, {"end": 53, "start": 50, "tag": "CellComponent"}, {"end": 221, "start": 218, "tag": "CellComponent"}, {"end": 88, "start": 86, "tag": "CellComponent"}, {"end": 28, "start": 20, "tag": "ResearchActivity"}, {"end": 147, "start": 141, "tag": "TemporalConcept"}, {"end": 41, "start": 32, "tag": "Cell"}, {"end": 190, "start": 183, "tag": "PatientOrDisabledGroup"}]}{"id": "1021_0", "text": "Alzheimer's Disease (AD) has currently no effective treatment; however, preventive measures have the potential to reduce AD risk.", "tags": [{"end": 91, "start": 72, "tag": "HealthCareActivity"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 52, "tag": "HealthCareActivity"}, {"end": 61, "start": 52, "tag": "ResearchActivity"}, {"end": 38, "start": 29, "tag": "TemporalConcept"}, {"end": 128, "start": 124, "tag": "Finding"}]}{"id": "1021_1", "text": "Thus, accurate and early prediction of risk is an important strategy to alleviate the AD burden.", "tags": [{"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 89, "tag": "ResearchActivity"}, {"end": 35, "start": 19, "tag": "HealthCareActivity"}]}{"id": "1021_2", "text": "Neuroinflammation is a major factor prompting the onset of the disease.", "tags": [{"end": 55, "start": 50, "tag": "TemporalConcept"}, {"end": 17, "start": 0, "tag": "PathologicFunction"}]}{"id": "1021_3", "text": "Inflammation exerts its toxic effect via multiple mechanisms.", "tags": [{"end": 36, "start": 30, "tag": "Finding"}, {"end": 12, "start": 0, "tag": "PathologicFunction"}, {"end": 29, "start": 24, "tag": "InjuryOrPoisoning"}]}{"id": "1021_4", "text": "Amongst others, it is affecting gene expression via modulation of non-coding RNAs (ncRNAs), such as miRNAs.", "tags": [{"end": 89, "start": 83, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 47, "start": 32, "tag": "CellFunction"}, {"end": 106, "start": 100, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 106, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 66, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 81, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 83, "tag": "BiologicallyActiveSubstance"}]}{"id": "1021_5", "text": "Recent evidence supports that inflammation can also affect long non-coding RNA (lncRNA) expression.", "tags": [{"end": 78, "start": 59, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 15, "start": 7, "tag": "Finding"}, {"end": 42, "start": 30, "tag": "PathologicFunction"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 86, "start": 80, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 78, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 88, "tag": "CellFunction"}]}{"id": "1021_6", "text": "While the association between miRNAs and inflammation in AD has been studied, the role of lncRNAs in neurodegenerative diseases has been less explored.", "tags": [{"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 41, "tag": "PathologicFunction"}, {"end": 36, "start": 30, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 36, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 90, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 97, "start": 90, "tag": "BiologicallyActiveSubstance"}]}{"id": "1021_7", "text": "In this review, we focus on lncRNAs and inflammation in the context of AD.", "tags": [{"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 40, "tag": "PathologicFunction"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 35, "start": 28, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 35, "start": 28, "tag": "BiologicallyActiveSubstance"}]}{"id": "1021_8", "text": "Furthermore, since plasma-isolated extracellular vesicles (EVs) are increasingly recognized as an effective monitoring strategy for brain pathologies, we have focused on the studies reporting dysregulated lncRNAs in EVs isolated from AD patients and controls.", "tags": [{"end": 204, "start": 192, "tag": "PathologicFunction"}, {"end": 258, "start": 250, "tag": "PopulationGroup"}, {"end": 57, "start": 35, "tag": "CellComponent"}, {"end": 62, "start": 59, "tag": "CellComponent"}, {"end": 219, "start": 216, "tag": "CellComponent"}, {"end": 236, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 245, "start": 237, "tag": "PatientOrDisabledGroup"}, {"end": 181, "start": 174, "tag": "ResearchActivity"}, {"end": 25, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 132, "tag": "PathologicFunction"}, {"end": 212, "start": 205, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 127, "start": 108, "tag": "HealthCareActivity"}, {"end": 212, "start": 205, "tag": "BiologicallyActiveSubstance"}]}{"id": "1021_9", "text": "The revised literature shows a positive association between pro-inflammatory lncRNAs and AD.", "tags": [{"end": 51, "start": 31, "tag": "Finding"}, {"end": 91, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 60, "tag": "PathologicFunction"}, {"end": 22, "start": 12, "tag": "ResearchActivity"}, {"end": 84, "start": 77, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 84, "start": 77, "tag": "BiologicallyActiveSubstance"}]}{"id": "1021_10", "text": "However, the reports evaluating lncRNA alterations in EVs isolated from the plasma of patients and controls, although still limited, confirm the value of specific lncRNAs associated with AD as reliable biomarkers.", "tags": [{"end": 20, "start": 13, "tag": "HealthCareActivity"}, {"end": 20, "start": 13, "tag": "ResearchActivity"}, {"end": 107, "start": 99, "tag": "PopulationGroup"}, {"end": 57, "start": 54, "tag": "CellComponent"}, {"end": 189, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 86, "tag": "PatientOrDisabledGroup"}, {"end": 212, "start": 202, "tag": "ClinicalAttribute"}, {"end": 82, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 170, "start": 163, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 38, "start": 32, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 50, "start": 32, "tag": "CellOrMolecularDysfunction"}, {"end": 38, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 163, "tag": "BiologicallyActiveSubstance"}]}{"id": "1021_11", "text": "This is an emerging field that will open new avenues to improve risk prediction and patient stratification, and may lead to the discovery of potential novel therapeutic targets for AD.", "tags": [{"end": 106, "start": 92, "tag": "ResearchActivity"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 84, "tag": "PatientOrDisabledGroup"}, {"end": 137, "start": 128, "tag": "ResearchActivity"}, {"end": 176, "start": 157, "tag": "ResearchActivity"}, {"end": 79, "start": 64, "tag": "Finding"}]}{"id": "1022_0", "text": "Extracellular vesicles (EVs) are secreted by any neural cells in the central nervous system for molecular clearance, cellular communications, and disease spread in multiple neurodegenerative diseases, including Alzheimer's disease (AD), although their exact molecular mechanism is poorly understood.", "tags": [{"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 140, "start": 117, "tag": "CellFunction"}, {"end": 61, "start": 49, "tag": "Cell"}, {"end": 115, "start": 106, "tag": "NaturalPhenomenonOrProcess"}, {"end": 160, "start": 146, "tag": "PathologicFunction"}, {"end": 277, "start": 258, "tag": "CellFunction"}, {"end": 199, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 234, "start": 232, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 96, "tag": "CellFunction"}]}{"id": "1022_1", "text": "We hypothesize that high-resolution proteomic profiling of EVs separated from animal models of AD would determine the composition of EV contents and their cellular origin.", "tags": [{"end": 170, "start": 164, "tag": "TemporalConcept"}, {"end": 62, "start": 59, "tag": "CellComponent"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 133, "tag": "CellComponent"}, {"end": 91, "start": 78, "tag": "ResearchActivity"}, {"end": 55, "start": 20, "tag": "ResearchActivity"}]}{"id": "1022_2", "text": "Here, we examined recently developed transgenic mice (CAST.APP/PS1), which express familial AD-linked mutations of amyloid precursor protein (APP) and presenilin-1 (PS1) in the CAST/EiJ mouse strain and develop hippocampal neurodegeneration.", "tags": [{"end": 140, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 163, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 59, "tag": "GeneOrGenome"}, {"end": 145, "start": 142, "tag": "GeneOrGenome"}, {"end": 62, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 83, "tag": "PopulationGroup"}, {"end": 111, "start": 102, "tag": "CellFunction"}, {"end": 111, "start": 102, "tag": "CellOrMolecularDysfunction"}, {"end": 82, "start": 75, "tag": "CellFunction"}, {"end": 222, "start": 211, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 222, "start": 211, "tag": "Cell"}, {"end": 52, "start": 37, "tag": "Eukaryote"}, {"end": 52, "start": 37, "tag": "ResearchActivity"}, {"end": 26, "start": 18, "tag": "TemporalConcept"}, {"end": 240, "start": 223, "tag": "CellOrMolecularDysfunction"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 177, "tag": "Eukaryote"}, {"end": 140, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 151, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}]}{"id": "1022_3", "text": "Quantitative proteomics analysis of EVs separated from CAST.APP/PS1 and age-matched control mice by tandem mass tag-mass spectrometry identified a total of 3444 unique proteins, which are enriched in neuron-, astrocyte-, oligodendrocyte-, and microglia-specific molecules.", "tags": [{"end": 236, "start": 221, "tag": "Cell"}, {"end": 206, "start": 200, "tag": "Cell"}, {"end": 271, "start": 262, "tag": "Substance"}, {"end": 218, "start": 209, "tag": "Cell"}, {"end": 75, "start": 72, "tag": "OrganismAttribute"}, {"end": 176, "start": 168, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 36, "tag": "CellComponent"}, {"end": 32, "start": 0, "tag": "ResearchActivity"}, {"end": 96, "start": 92, "tag": "Eukaryote"}, {"end": 252, "start": 243, "tag": "Cell"}, {"end": 96, "start": 92, "tag": "ExperimentalModelOfDisease"}, {"end": 67, "start": 55, "tag": "ExperimentalModelOfDisease"}, {"end": 96, "start": 84, "tag": "Eukaryote"}, {"end": 133, "start": 100, "tag": "ResearchActivity"}]}{"id": "1022_4", "text": "CAST.APP/PS1-derived EVs show significant enrichment of Psen1, APP, and Itgax and reduction of Wdr61, Pmpca, Aldh1a2, Calu, Anp32b, Actn4, and Ndufv2 compared to WT-derived EVs, suggesting the involvement of A beta-processing complex and disease-associated/neurodegenerative microglia (DAM/MGnD) in EV secretion.", "tags": [{"end": 61, "start": 56, "tag": "GeneOrGenome"}, {"end": 77, "start": 72, "tag": "GeneOrGenome"}, {"end": 77, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 95, "tag": "GeneOrGenome"}, {"end": 107, "start": 102, "tag": "GeneOrGenome"}, {"end": 116, "start": 109, "tag": "GeneOrGenome"}, {"end": 116, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 118, "tag": "GeneOrGenome"}, {"end": 130, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 124, "tag": "GeneOrGenome"}, {"end": 137, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 132, "tag": "GeneOrGenome"}, {"end": 149, "start": 143, "tag": "GeneOrGenome"}, {"end": 311, "start": 299, "tag": "CellFunction"}, {"end": 8, "start": 5, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 5, "tag": "GeneOrGenome"}, {"end": 66, "start": 63, "tag": "GeneOrGenome"}, {"end": 8, "start": 5, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 204, "start": 193, "tag": "Finding"}, {"end": 91, "start": 82, "tag": "Finding"}, {"end": 91, "start": 82, "tag": "NaturalPhenomenonOrProcess"}, {"end": 24, "start": 21, "tag": "CellComponent"}, {"end": 176, "start": 173, "tag": "CellComponent"}, {"end": 274, "start": 257, "tag": "CellOrMolecularDysfunction"}, {"end": 301, "start": 299, "tag": "CellComponent"}, {"end": 284, "start": 208, "tag": "Cell"}, {"end": 214, "start": 208, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 294, "start": 286, "tag": "Cell"}]}{"id": "1022_5", "text": "In addition, Itgax and Apoe, DAM/MGnD markers, in EVs show a positive correlation with Itgax and Apoe mRNA expression from brain tissue in CAST.APP/PS1 mice.", "tags": [{"end": 18, "start": 13, "tag": "GeneOrGenome"}, {"end": 18, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 23, "tag": "GeneOrGenome"}, {"end": 92, "start": 87, "tag": "GeneOrGenome"}, {"end": 92, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 97, "tag": "GeneOrGenome"}, {"end": 156, "start": 139, "tag": "ExperimentalModelOfDisease"}, {"end": 106, "start": 102, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 135, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 50, "tag": "CellComponent"}, {"end": 81, "start": 61, "tag": "Finding"}, {"end": 45, "start": 38, "tag": "ClinicalAttribute"}, {"end": 92, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 29, "tag": "Cell"}]}{"id": "1022_6", "text": "These datasets indicate the significant contribution of A beta plaque and neurodegeneration-induced DAM/MGnD microglia for EV secretion in CAST.APP/PS1 mice and shed light on understanding AD pathogenesis.", "tags": [{"end": 188, "start": 175, "tag": "BiologicFunction"}, {"end": 156, "start": 139, "tag": "ExperimentalModelOfDisease"}, {"end": 69, "start": 56, "tag": "PathologicFunction"}, {"end": 91, "start": 74, "tag": "CellOrMolecularDysfunction"}, {"end": 191, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 204, "start": 192, "tag": "PathologicFunction"}, {"end": 125, "start": 123, "tag": "CellComponent"}, {"end": 118, "start": 100, "tag": "Cell"}, {"end": 69, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 123, "tag": "CellFunction"}, {"end": 14, "start": 6, "tag": "ResearchActivity"}]}{"id": "1023_0", "text": "Introduction The substantial link between apolipoprotein E (APOE) epsilon 4 allele and oxidative stress may underlie enhanced Alzheimer's disease (AD) risk.", "tags": [{"end": 82, "start": 42, "tag": "GeneOrGenome"}, {"end": 145, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 87, "tag": "CellOrMolecularDysfunction"}, {"end": 155, "start": 151, "tag": "Finding"}]}{"id": "1023_1", "text": "Here, we studied the impact of APOE epsilon 4 on the level of apolipoproteins with antioxidant activities along with oxidative markers in circulating extracellular vesicles (cEVs) and plasma from cognitively impaired-not demented (CIND) individuals converted to AD (CIND-AD).", "tags": [{"end": 45, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 83, "tag": "CellFunction"}, {"end": 248, "start": 196, "tag": "PatientOrDisabledGroup"}, {"end": 172, "start": 138, "tag": "CellComponent"}, {"end": 264, "start": 262, "tag": "DiseaseOrSyndrome"}, {"end": 273, "start": 271, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 117, "tag": "ClinicalAttribute"}, {"end": 190, "start": 184, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 174, "tag": "CellComponent"}]}{"id": "1023_2", "text": "Methods Apolipoproteins E, J, and D and antioxidant response markers were determined in cEVs and plasma using immunoblotting, electrochemical examination, and spectrofluorimetry.", "tags": [{"end": 25, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 110, "tag": "ResearchActivity"}, {"end": 177, "start": 159, "tag": "ResearchActivity"}, {"end": 60, "start": 40, "tag": "CellFunction"}, {"end": 51, "start": 40, "tag": "CellFunction"}, {"end": 68, "start": 61, "tag": "ClinicalAttribute"}, {"end": 103, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 88, "tag": "CellComponent"}, {"end": 153, "start": 126, "tag": "ResearchActivity"}]}{"id": "1023_3", "text": "Results Total antioxidant capacity and apolipoprotein D levels in cEVs, as judged by regression analysis and cognitive performance correlations, allowed us to differentiate CIND APOE epsilon 4 carriers from controls and to predict their progression to AD 5 years later.", "tags": [{"end": 55, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 109, "tag": "ClinicalAttribute"}, {"end": 25, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 25, "start": 14, "tag": "CellFunction"}, {"end": 215, "start": 207, "tag": "PopulationGroup"}, {"end": 143, "start": 131, "tag": "ResearchActivity"}, {"end": 248, "start": 237, "tag": "PathologicFunction"}, {"end": 248, "start": 237, "tag": "TemporalConcept"}, {"end": 254, "start": 252, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 85, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 201, "start": 193, "tag": "Finding"}, {"end": 262, "start": 257, "tag": "TemporalConcept"}, {"end": 70, "start": 66, "tag": "CellComponent"}, {"end": 177, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 268, "start": 263, "tag": "TemporalConcept"}, {"end": 34, "start": 26, "tag": "Finding"}]}{"id": "1023_4", "text": "Discussion Our findings support the pathological redox linkage between APOE epsilon 4 and AD onset and suggest the use of cEVs oxidative signature in early AD diagnosis.", "tags": [{"end": 85, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 49, "tag": "CellFunction"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 122, "tag": "ClinicalAttribute"}, {"end": 98, "start": 93, "tag": "TemporalConcept"}, {"end": 168, "start": 159, "tag": "HealthCareActivity"}, {"end": 62, "start": 36, "tag": "PathologicFunction"}]}{"id": "1024_0", "text": "miRNAs play an important role in neurodegenerative diseases.", "tags": [{"end": 6, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 6, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 33, "tag": "DiseaseOrSyndrome"}]}{"id": "1024_1", "text": "Many miRNA-target gene interactions (MTI) have been experimentally confirmed and associated with Alzheimer's disease (AD).", "tags": [{"end": 35, "start": 5, "tag": "CellFunction"}, {"end": 10, "start": 5, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 10, "start": 5, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}]}{"id": "1024_2", "text": "miRNAs may also be contained within extracellular vesicles (EVs), mediators of cellular communication and a potential source of circulating biomarkers in body fluids.", "tags": [{"end": 101, "start": 79, "tag": "CellFunction"}, {"end": 165, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 36, "tag": "CellComponent"}, {"end": 63, "start": 60, "tag": "CellComponent"}, {"end": 150, "start": 128, "tag": "ClinicalAttribute"}, {"end": 6, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 6, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 66, "tag": "Finding"}]}{"id": "1024_3", "text": "Therefore, EV-associated miRNAs (EV-miRNAs) in peripheral blood could support earlier and less invasive AD diagnostics.", "tags": [{"end": 63, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 90, "tag": "Finding"}, {"end": 85, "start": 78, "tag": "TemporalConcept"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 11, "tag": "CellComponent"}, {"end": 35, "start": 33, "tag": "CellComponent"}, {"end": 31, "start": 25, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 42, "start": 36, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 31, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 107, "tag": "HealthCareActivity"}]}{"id": "1024_4", "text": "We aimed to prioritize EV-related miRNA with AD-related genes and to identify the most promising candidates for novel AD biomarkers.", "tags": [{"end": 39, "start": 34, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 39, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 23, "tag": "CellComponent"}, {"end": 131, "start": 121, "tag": "ClinicalAttribute"}, {"end": 61, "start": 45, "tag": "GeneOrGenome"}]}{"id": "1024_5", "text": "A list of unique EV-miRNAs from the literature was combined with a known set of AD risk genes and enriched for MTI.", "tags": [{"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 17, "tag": "CellComponent"}, {"end": 26, "start": 20, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 26, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 36, "tag": "ResearchActivity"}, {"end": 93, "start": 80, "tag": "GeneOrGenome"}]}{"id": "1024_6", "text": "Additionally, miRNAs associated with the AD phenotype were combined with all known target genes in MTI enrichment.", "tags": [{"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 14, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 20, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 103, "tag": "ResearchActivity"}, {"end": 53, "start": 44, "tag": "OrganismAttribute"}]}{"id": "1024_7", "text": "Expression in different sample types was analyzed to identify AD-associated miRNAs with the greatest potential as AD circulating biomarkers.", "tags": [{"end": 10, "start": 0, "tag": "CellFunction"}, {"end": 10, "start": 0, "tag": "ResearchActivity"}, {"end": 49, "start": 41, "tag": "ResearchActivity"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 129, "tag": "ClinicalAttribute"}, {"end": 82, "start": 76, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 82, "start": 76, "tag": "BiologicallyActiveSubstance"}]}{"id": "1024_8", "text": "Four common MTI were observed between EV-miRNAs and AD-associated miRNAs: hsa-miR-375-APH1B, hsa-miR-107-CDC42SE2, hsa-miR-375-CELF2, and hsa-miR-107-IL6.", "tags": [{"end": 54, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 38, "tag": "CellComponent"}, {"end": 47, "start": 41, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 72, "start": 66, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 47, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 74, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 113, "start": 93, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 113, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 115, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 153, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 138, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1024_9", "text": "An additional 61 out of 169 unique miRNAs (36.1%) and seven out of 84 unique MTI (8.3%), observed in the body fluids of AD patients, were proposed as very strong AD-circulating biomarker candidates.", "tags": [{"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 123, "tag": "PatientOrDisabledGroup"}, {"end": 41, "start": 35, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 41, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 186, "start": 165, "tag": "ClinicalAttribute"}, {"end": 116, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1024_10", "text": "Our analysis summarized several potential novel AD biomarkers, but further studies are needed to evaluate their potential in clinical practice.", "tags": [{"end": 142, "start": 125, "tag": "HealthCareActivity"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 51, "tag": "ClinicalAttribute"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 82, "start": 75, "tag": "ResearchActivity"}]}{"id": "1025_0", "text": "Background: Brain tissue-derived extracellular vesicles (bdEVs) play neurodegenerative and protective roles, including in Alzheimer's disease (AD).", "tags": [{"end": 55, "start": 12, "tag": "CellComponent"}, {"end": 141, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 69, "tag": "CellOrMolecularDysfunction"}, {"end": 24, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 57, "tag": "CellComponent"}]}{"id": "1025_1", "text": "Extracellular vesicles (EVs) may also leave the brain to betray the state of the CNS in the periphery.", "tags": [{"end": 101, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 53, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 68, "tag": "PopulationGroup"}]}{"id": "1025_2", "text": "Only a few studies have profiled the proteome of bdEVs and source brain tissue.", "tags": [{"end": 45, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 11, "tag": "ResearchActivity"}, {"end": 54, "start": 49, "tag": "CellComponent"}]}{"id": "1025_3", "text": "Additionally, studies focusing on bdEV cell type-specific surface markers are rare.", "tags": [{"end": 82, "start": 78, "tag": "TemporalConcept"}, {"end": 73, "start": 58, "tag": "ClinicalAttribute"}, {"end": 43, "start": 39, "tag": "Cell"}, {"end": 21, "start": 14, "tag": "ResearchActivity"}, {"end": 38, "start": 34, "tag": "CellComponent"}]}{"id": "1025_4", "text": "Objective: We aimed to reveal the pathological mechanisms inside the brain by profiling the tissue and bdEV proteomes in AD patients.", "tags": [{"end": 87, "start": 78, "tag": "ResearchActivity"}, {"end": 117, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 124, "tag": "PatientOrDisabledGroup"}, {"end": 74, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 34, "tag": "PathologicFunction"}, {"end": 107, "start": 103, "tag": "CellComponent"}, {"end": 117, "start": 108, "tag": "BiologicallyActiveSubstance"}]}{"id": "1025_5", "text": "In addition, to indicate targets for capturing and molecular profiling of bdEVs in the periphery, CNS cell-specific markers were profiled on the intact bdEV surface.", "tags": [{"end": 70, "start": 51, "tag": "ResearchActivity"}, {"end": 96, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 116, "tag": "ClinicalAttribute"}, {"end": 106, "start": 102, "tag": "Cell"}, {"end": 101, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 152, "tag": "CellComponent"}, {"end": 79, "start": 74, "tag": "CellComponent"}]}{"id": "1025_6", "text": "Methods: bdEVs were separated and followed by EV counting and sizing.", "tags": [{"end": 48, "start": 46, "tag": "CellComponent"}, {"end": 14, "start": 9, "tag": "CellComponent"}]}{"id": "1025_7", "text": "Brain tissue and bdEVs from age-matched AD patients and controls were then proteomically profiled.", "tags": [{"end": 12, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 56, "tag": "PopulationGroup"}, {"end": 31, "start": 28, "tag": "OrganismAttribute"}, {"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 43, "tag": "PatientOrDisabledGroup"}, {"end": 22, "start": 17, "tag": "CellComponent"}, {"end": 97, "start": 75, "tag": "ResearchActivity"}]}{"id": "1025_8", "text": "Total tau (t-tau), phosphorylated tau (p-tau), and antioxidant peroxiredoxins (PRDX) 1 and 6 were measured by immunoassay in an independent bdEV separation.", "tags": [{"end": 83, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 110, "tag": "ResearchActivity"}, {"end": 155, "start": 145, "tag": "Finding"}, {"end": 77, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 128, "tag": "Finding"}, {"end": 144, "start": 140, "tag": "CellComponent"}]}{"id": "1025_9", "text": "Neuron, microglia, astrocyte, and endothelia markers were detected on intact EVs by multiplexed ELISA.", "tags": [{"end": 6, "start": 0, "tag": "Cell"}, {"end": 44, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 84, "tag": "ResearchActivity"}, {"end": 80, "start": 77, "tag": "CellComponent"}, {"end": 52, "start": 45, "tag": "ClinicalAttribute"}, {"end": 17, "start": 8, "tag": "Cell"}, {"end": 28, "start": 19, "tag": "Cell"}]}{"id": "1025_10", "text": "Results: Overall, concentration of recovered bdEVs was not affected by AD.", "tags": [{"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 50, "start": 45, "tag": "CellComponent"}]}{"id": "1025_11", "text": "Proteome differences between AD and control were more pronounced for bdEVs than for brain tissue.", "tags": [{"end": 8, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 9, "tag": "Finding"}, {"end": 8, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 69, "tag": "CellComponent"}]}{"id": "1025_12", "text": "Levels of t-tau, p-tau, PRDX1, and PRDX6 were significantly elevated in AD bdEVs compared with controls.", "tags": [{"end": 29, "start": 24, "tag": "GeneOrGenome"}, {"end": 40, "start": 35, "tag": "GeneOrGenome"}, {"end": 103, "start": 95, "tag": "PopulationGroup"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 40, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 40, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 75, "tag": "CellComponent"}]}{"id": "1025_13", "text": "Release of certain cell-specific bdEV markers was increased in AD.", "tags": [{"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 38, "tag": "ClinicalAttribute"}, {"end": 23, "start": 19, "tag": "Cell"}, {"end": 37, "start": 33, "tag": "CellComponent"}]}{"id": "1025_14", "text": "Conclusion: Several bdEV proteins are involved in AD mechanisms and may be used for disease monitoring.", "tags": [{"end": 102, "start": 84, "tag": "HealthCareActivity"}, {"end": 33, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 20, "tag": "CellComponent"}]}{"id": "1025_15", "text": "The identified CNS cell markers may be useful tools for peripheral bdEV capture.", "tags": [{"end": 66, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 24, "tag": "ClinicalAttribute"}, {"end": 23, "start": 19, "tag": "Cell"}, {"end": 18, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 67, "tag": "CellComponent"}]}{"id": "1026_0", "text": "With the increase of population aging, the number of Alzheimer's disease (AD) patients is also increasing.", "tags": [{"end": 31, "start": 21, "tag": "PopulationGroup"}, {"end": 37, "start": 32, "tag": "BiologicFunction"}, {"end": 37, "start": 32, "tag": "CellFunction"}, {"end": 72, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 78, "tag": "PatientOrDisabledGroup"}]}{"id": "1026_1", "text": "According to current estimates, approximately 11% of people over 65 suffer from AD, and that percentage rises to 42% among people over 85.", "tags": [{"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 53, "tag": "PopulationGroup"}, {"end": 129, "start": 123, "tag": "PopulationGroup"}, {"end": 20, "start": 13, "tag": "TemporalConcept"}]}{"id": "1026_2", "text": "However, no effective treatment capable of decelerating or stopping AD progression is available.", "tags": [{"end": 55, "start": 43, "tag": "NaturalPhenomenonOrProcess"}, {"end": 82, "start": 71, "tag": "PathologicFunction"}, {"end": 82, "start": 71, "tag": "TemporalConcept"}, {"end": 70, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 22, "tag": "HealthCareActivity"}, {"end": 31, "start": 22, "tag": "ResearchActivity"}]}{"id": "1026_3", "text": "Furthermore, AD-targeted drugs composed of synthetic molecules pose concerns regarding biodegradation, clearance, immune response, and neurotoxicity.", "tags": [{"end": 101, "start": 87, "tag": "NaturalPhenomenonOrProcess"}, {"end": 129, "start": 114, "tag": "BiologicFunction"}, {"end": 148, "start": 135, "tag": "InjuryOrPoisoning"}, {"end": 62, "start": 43, "tag": "Substance"}, {"end": 30, "start": 25, "tag": "PharmacologicSubstance"}, {"end": 112, "start": 103, "tag": "NaturalPhenomenonOrProcess"}, {"end": 15, "start": 13, "tag": "DiseaseOrSyndrome"}]}{"id": "1026_4", "text": "Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are essential intercellular communication mediators holding great promise as AD therapeutics owing to their biocompatibility, versatility, effortless storage, superior safety, and the ability to transport messenger and noncoding RNAs, proteins, lipids, DNAs, and other bioactive compounds derived from cells.", "tags": [{"end": 21, "start": 0, "tag": "Cell"}, {"end": 187, "start": 171, "tag": "CellFunction"}, {"end": 296, "start": 282, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 314, "start": 308, "tag": "Chemical"}, {"end": 104, "start": 77, "tag": "CellFunction"}, {"end": 57, "start": 54, "tag": "Cell"}, {"end": 155, "start": 143, "tag": "HealthCareActivity"}, {"end": 351, "start": 332, "tag": "BiologicallyActiveSubstance"}, {"end": 237, "start": 231, "tag": "HealthCareActivity"}, {"end": 306, "start": 298, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 30, "tag": "CellComponent"}, {"end": 61, "start": 58, "tag": "CellComponent"}, {"end": 142, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 370, "start": 365, "tag": "Cell"}, {"end": 254, "start": 247, "tag": "OrganismAttribute"}, {"end": 320, "start": 316, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 200, "start": 189, "tag": "Finding"}, {"end": 296, "start": 292, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 277, "start": 268, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1026_5", "text": "The functionalisation and engineering strategies of MSC-EVs are highlighted (e.g.", "tags": [{"end": 37, "start": 26, "tag": "ResearchActivity"}, {"end": 55, "start": 52, "tag": "Cell"}, {"end": 59, "start": 56, "tag": "CellComponent"}]}{"id": "1026_6", "text": "preconditioning, drug loading, surface modification, and artificial EV fabrication), which could improve AD treatment by multiple therapeutic effects, including clearing abnormal protein accumulation and achieving neuroprotection and immunomodulatory effects.", "tags": [{"end": 15, "start": 0, "tag": "BiologicFunction"}, {"end": 149, "start": 130, "tag": "Finding"}, {"end": 229, "start": 214, "tag": "CellFunction"}, {"end": 199, "start": 187, "tag": "Finding"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 68, "tag": "CellComponent"}, {"end": 117, "start": 108, "tag": "HealthCareActivity"}, {"end": 117, "start": 108, "tag": "ResearchActivity"}, {"end": 21, "start": 17, "tag": "PharmacologicSubstance"}, {"end": 82, "start": 57, "tag": "ResearchActivity"}, {"end": 51, "start": 31, "tag": "CellFunction"}, {"end": 29, "start": 17, "tag": "ResearchActivity"}, {"end": 199, "start": 170, "tag": "CellOrMolecularDysfunction"}, {"end": 258, "start": 234, "tag": "Finding"}]}{"id": "1026_7", "text": "Herein, this review summarises state-of-the-art strategies to engineer MSC-EVs, discusses progress in their use as AD therapeutics, presents the perspectives and challenges associated with the related clinical applications, and concludes that engineered MSC-EVs show immense potential in AD therapy.", "tags": [{"end": 98, "start": 90, "tag": "TemporalConcept"}, {"end": 222, "start": 201, "tag": "HealthCareActivity"}, {"end": 74, "start": 71, "tag": "Cell"}, {"end": 257, "start": 254, "tag": "Cell"}, {"end": 172, "start": 162, "tag": "HealthCareActivity"}, {"end": 130, "start": 118, "tag": "HealthCareActivity"}, {"end": 19, "start": 13, "tag": "ResearchActivity"}, {"end": 19, "start": 13, "tag": "HealthCareActivity"}, {"end": 78, "start": 75, "tag": "CellComponent"}, {"end": 261, "start": 258, "tag": "CellComponent"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 290, "start": 288, "tag": "DiseaseOrSyndrome"}, {"end": 298, "start": 291, "tag": "HealthCareActivity"}, {"end": 261, "start": 243, "tag": "PharmacologicSubstance"}]}{"id": "1027_0", "text": "Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to an infection.", "tags": [{"end": 6, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "Eukaryote"}, {"end": 96, "start": 70, "tag": "PathologicFunction"}, {"end": 112, "start": 103, "tag": "PathologicFunction"}, {"end": 27, "start": 23, "tag": "TemporalConcept"}, {"end": 57, "start": 40, "tag": "PathologicFunction"}]}{"id": "1027_1", "text": "Several studies on mouse and patient sepsis samples have revealed that the level of extracellular vesicles (EVs) in the blood is altered compared to healthy controls, but the different functions of EVs during sepsis pathology are not yet completely understood.", "tags": [{"end": 215, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 209, "tag": "Eukaryote"}, {"end": 165, "start": 149, "tag": "PopulationGroup"}, {"end": 106, "start": 84, "tag": "CellComponent"}, {"end": 111, "start": 108, "tag": "CellComponent"}, {"end": 201, "start": 198, "tag": "CellComponent"}, {"end": 125, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 225, "start": 216, "tag": "PathologicFunction"}, {"end": 225, "start": 216, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 36, "start": 29, "tag": "PatientOrDisabledGroup"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 24, "start": 19, "tag": "Eukaryote"}, {"end": 43, "start": 37, "tag": "Eukaryote"}, {"end": 43, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 44, "tag": "Substance"}, {"end": 51, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1027_2", "text": "Sepsis EVs are described as modulators of inflammation, lymphocyte apoptosis, coagulation and organ dysfunction.", "tags": [{"end": 6, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "Eukaryote"}, {"end": 66, "start": 56, "tag": "Cell"}, {"end": 89, "start": 78, "tag": "BiologicFunction"}, {"end": 76, "start": 67, "tag": "CellFunction"}, {"end": 10, "start": 7, "tag": "CellComponent"}, {"end": 54, "start": 42, "tag": "PathologicFunction"}, {"end": 111, "start": 94, "tag": "PathologicFunction"}, {"end": 38, "start": 28, "tag": "BiologicallyActiveSubstance"}]}{"id": "1027_3", "text": "Furthermore, EVs can influence clinical outcome and it is suggested that EVs can predict survival.", "tags": [{"end": 47, "start": 31, "tag": "ClinicalAttribute"}, {"end": 16, "start": 13, "tag": "CellComponent"}, {"end": 76, "start": 73, "tag": "CellComponent"}, {"end": 97, "start": 89, "tag": "CellFunction"}]}{"id": "1027_4", "text": "Both detrimental and beneficial roles for EVs have been described in sepsis, depending on the EV cellular source and the disease phase during which the EVs are studied.", "tags": [{"end": 75, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 69, "tag": "Eukaryote"}, {"end": 134, "start": 121, "tag": "TemporalConcept"}, {"end": 45, "start": 42, "tag": "CellComponent"}, {"end": 155, "start": 152, "tag": "CellComponent"}, {"end": 96, "start": 94, "tag": "CellComponent"}]}{"id": "1027_5", "text": "In this review, we summarize the current knowledge of EV sources and functions during sepsis pathology based on in vitro and mouse models, as well as patient samples.", "tags": [{"end": 64, "start": 57, "tag": "Finding"}, {"end": 92, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 86, "tag": "Eukaryote"}, {"end": 120, "start": 112, "tag": "ResearchActivity"}, {"end": 56, "start": 54, "tag": "CellComponent"}, {"end": 102, "start": 93, "tag": "PathologicFunction"}, {"end": 102, "start": 93, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 50, "start": 41, "tag": "Finding"}, {"end": 157, "start": 150, "tag": "PatientOrDisabledGroup"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 40, "start": 33, "tag": "TemporalConcept"}, {"end": 130, "start": 125, "tag": "Eukaryote"}, {"end": 137, "start": 131, "tag": "ResearchActivity"}, {"end": 165, "start": 158, "tag": "Substance"}, {"end": 165, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1028_0", "text": "Background Previous research has revealed that KIBRA controls secretion of extracellular vesicles (EVs) by inhibiting the proteasomal degradation of Rab27a and EVs play an important role in amyloid beta (A beta) metabolism and transmission during Alzheimer's disease (AD) pathogenesis.", "tags": [{"end": 52, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 62, "tag": "CellFunction"}, {"end": 145, "start": 122, "tag": "CellFunction"}, {"end": 155, "start": 149, "tag": "GeneOrGenome"}, {"end": 155, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 239, "start": 227, "tag": "Finding"}, {"end": 61, "start": 53, "tag": "PopulationGroup"}, {"end": 202, "start": 190, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 20, "tag": "ResearchActivity"}, {"end": 97, "start": 75, "tag": "CellComponent"}, {"end": 266, "start": 247, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 99, "tag": "CellComponent"}, {"end": 163, "start": 160, "tag": "CellComponent"}, {"end": 270, "start": 268, "tag": "DiseaseOrSyndrome"}, {"end": 284, "start": 272, "tag": "PathologicFunction"}, {"end": 210, "start": 204, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 212, "tag": "CellFunction"}, {"end": 222, "start": 212, "tag": "BiologicFunction"}, {"end": 19, "start": 11, "tag": "TemporalConcept"}, {"end": 117, "start": 107, "tag": "BiologicFunction"}, {"end": 155, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 62, "tag": "BiologicFunction"}]}{"id": "1028_1", "text": "Here, we further test the hypothesis that KIBRA regulates A beta metabolism via the endosomal-lysosomal system.", "tags": [{"end": 47, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 58, "tag": "CellFunction"}, {"end": 110, "start": 84, "tag": "CellFunction"}]}{"id": "1028_2", "text": "Methods We generated KIBRA knockout mice on a 5XFAD background and KIBRA knockdown cells in murine HT22 cells with stably overexpressing APP.", "tags": [{"end": 26, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 40, "start": 21, "tag": "ResearchActivity"}, {"end": 72, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 92, "tag": "Eukaryote"}, {"end": 136, "start": 122, "tag": "CellFunction"}, {"end": 140, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 137, "tag": "GeneOrGenome"}, {"end": 140, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 83, "tag": "Cell"}, {"end": 109, "start": 99, "tag": "Cell"}, {"end": 82, "start": 73, "tag": "ResearchActivity"}, {"end": 51, "start": 46, "tag": "ExperimentalModelOfDisease"}]}{"id": "1028_3", "text": "Various forms of A beta and quantification of EVs were analyzed by biochemical methods and nanoparticle tracking analysis, respectively.", "tags": [{"end": 63, "start": 55, "tag": "ResearchActivity"}, {"end": 49, "start": 46, "tag": "CellComponent"}, {"end": 23, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 91, "tag": "ResearchActivity"}, {"end": 86, "start": 67, "tag": "ResearchActivity"}]}{"id": "1028_4", "text": "Multivesicular bodies (MVBs) were visualized by electron microscopy and confocal fluorescent microscopy.", "tags": [{"end": 21, "start": 0, "tag": "CellComponent"}, {"end": 27, "start": 23, "tag": "CellComponent"}, {"end": 67, "start": 48, "tag": "ResearchActivity"}, {"end": 103, "start": 72, "tag": "ResearchActivity"}]}{"id": "1028_5", "text": "In a population-based cohort (n =1419), KIBRA genotypes and plasma A beta levels were analyzed using multiple-PCR amplification and Simoa, respectively.", "tags": [{"end": 45, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 46, "tag": "OrganismAttribute"}, {"end": 137, "start": 132, "tag": "ResearchActivity"}, {"end": 28, "start": 22, "tag": "PopulationGroup"}, {"end": 94, "start": 86, "tag": "ResearchActivity"}, {"end": 73, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 5, "tag": "PopulationGroup"}, {"end": 80, "start": 67, "tag": "ClinicalAttribute"}, {"end": 66, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 101, "tag": "ResearchActivity"}]}{"id": "1028_6", "text": "Findings Multiple forms of A beta were dramatically attenuated in KIBRA knockout mouse brain, including monomers, oligomers, and extracellular deposition, but KIBRA knockout had no effect on intraneuronal APP C-terminal fragment beta (APP-CTF beta)/A beta levels.", "tags": [{"end": 71, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 165, "tag": "ExperimentalModelOfDisease"}, {"end": 173, "start": 165, "tag": "ResearchActivity"}, {"end": 187, "start": 178, "tag": "Finding"}, {"end": 233, "start": 205, "tag": "AminoAcidPeptideOrProtein"}, {"end": 247, "start": 235, "tag": "AminoAcidPeptideOrProtein"}, {"end": 247, "start": 235, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 129, "tag": "CellComponent"}, {"end": 262, "start": 249, "tag": "ClinicalAttribute"}, {"end": 204, "start": 191, "tag": "CellComponent"}, {"end": 86, "start": 72, "tag": "ResearchActivity"}, {"end": 233, "start": 205, "tag": "BiologicallyActiveSubstance"}]}{"id": "1028_7", "text": "KIBRA depletion also decreased APP-CTF beta/A beta-associated EVs secretion and subsequently enhanced MVBs number.", "tags": [{"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 66, "tag": "CellFunction"}, {"end": 75, "start": 66, "tag": "BiologicFunction"}, {"end": 106, "start": 102, "tag": "CellComponent"}, {"end": 43, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 62, "tag": "CellComponent"}, {"end": 50, "start": 44, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1028_8", "text": "Furthermore, we found that excessive accumulation of MVBs harboring APP-CTF beta/A beta promoted the MVBs-lysosome fusion for degradation and inhibition of lysosomal function rescued secretion of APP-CTF beta/A beta-associated EVs.", "tags": [{"end": 57, "start": 53, "tag": "CellComponent"}, {"end": 121, "start": 115, "tag": "CellFunction"}, {"end": 174, "start": 156, "tag": "CellFunction"}, {"end": 192, "start": 183, "tag": "BiologicFunction"}, {"end": 192, "start": 183, "tag": "CellFunction"}, {"end": 137, "start": 126, "tag": "NaturalPhenomenonOrProcess"}, {"end": 80, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 142, "tag": "CellFunction"}, {"end": 230, "start": 227, "tag": "CellComponent"}, {"end": 87, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 215, "start": 209, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 37, "tag": "Finding"}, {"end": 105, "start": 101, "tag": "CellComponent"}, {"end": 114, "start": 106, "tag": "CellComponent"}, {"end": 208, "start": 196, "tag": "BiologicallyActiveSubstance"}, {"end": 208, "start": 196, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1028_9", "text": "More importantly, whole exon sequencing of KIBRA in a large population-based cohort identified the association of KIBRA rs28421695 polymorphism with plasma A beta.", "tags": [{"end": 48, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 24, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 83, "start": 77, "tag": "PopulationGroup"}, {"end": 162, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 60, "tag": "PopulationGroup"}, {"end": 155, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 131, "tag": "CellFunction"}, {"end": 130, "start": 120, "tag": "GeneOrGenome"}]}{"id": "1028_10", "text": "Interpretation These results demonstrate that KIBRA regulates A beta metabolism via controlling the secretion of APP-CTF beta/A beta-associated EVs.", "tags": [{"end": 51, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 62, "tag": "CellFunction"}, {"end": 109, "start": 100, "tag": "BiologicFunction"}, {"end": 109, "start": 100, "tag": "CellFunction"}, {"end": 125, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 144, "tag": "CellComponent"}, {"end": 132, "start": 126, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1028_11", "text": "Copyright (c) 2022 The Author(s).", "tags": []}{"id": "1028_12", "text": "Published by Elsevier B.V.", "tags": []}{"id": "1029_0", "text": "Neurodegeneration is hallmarked by the progressive loss of dopaminergic neurons and/or a significant increase in protein aggregates in the brain.", "tags": [{"end": 131, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 144, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 59, "tag": "Cell"}, {"end": 50, "start": 39, "tag": "TemporalConcept"}, {"end": 79, "start": 51, "tag": "CellOrMolecularDysfunction"}]}{"id": "1029_1", "text": "Neurodegenerative diseases are a leading cause of death worldwide with over 15 million people currently suffering from either Parkinson's disease (PD) or Alzheimer's disease (AD).", "tags": [{"end": 113, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 50, "tag": "BiologicFunction"}, {"end": 55, "start": 50, "tag": "PathologicFunction"}, {"end": 55, "start": 50, "tag": "CellFunction"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 87, "tag": "PopulationGroup"}, {"end": 145, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 94, "tag": "TemporalConcept"}]}{"id": "1029_2", "text": "PD is often characterized by both motor and non-motor symptoms, including muscle rigidity, tremors and bradykinesia, with AD displaying symptoms of confusion and dementia.", "tags": [{"end": 89, "start": 74, "tag": "SignOrSymptom"}, {"end": 98, "start": 91, "tag": "SignOrSymptom"}, {"end": 115, "start": 103, "tag": "SignOrSymptom"}, {"end": 157, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 148, "tag": "Finding"}, {"end": 80, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 136, "tag": "SignOrSymptom"}, {"end": 62, "start": 54, "tag": "SignOrSymptom"}, {"end": 39, "start": 34, "tag": "SignOrSymptom"}, {"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 44, "tag": "SignOrSymptom"}]}{"id": "1029_3", "text": "The current mainstay of therapeutics includes pharmacological approaches such as levodopa to replace dopamine in PD patients, deep brain stimulation in affected regions of the brain and physical therapy.", "tags": [{"end": 89, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 126, "tag": "HealthCareActivity"}, {"end": 202, "start": 186, "tag": "HealthCareActivity"}, {"end": 109, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 101, "tag": "Chemical"}, {"end": 109, "start": 101, "tag": "PharmacologicSubstance"}, {"end": 181, "start": 161, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 116, "tag": "PatientOrDisabledGroup"}, {"end": 136, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 24, "tag": "HealthCareActivity"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}, {"end": 148, "start": 137, "tag": "HealthCareActivity"}, {"end": 148, "start": 137, "tag": "NaturalPhenomenonOrProcess"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 46, "tag": "HealthCareActivity"}, {"end": 89, "start": 81, "tag": "PharmacologicSubstance"}, {"end": 89, "start": 81, "tag": "BiologicallyActiveSubstance"}]}{"id": "1029_4", "text": "However, these treatments are typically not disease-modifying, though they do help at least for some time with symptom management.", "tags": [{"end": 129, "start": 111, "tag": "HealthCareActivity"}, {"end": 25, "start": 15, "tag": "HealthCareActivity"}, {"end": 25, "start": 15, "tag": "ResearchActivity"}, {"end": 105, "start": 101, "tag": "TemporalConcept"}]}{"id": "1029_5", "text": "These treatments often also fail due to their inability to cross the blood-brain barrier.", "tags": [{"end": 16, "start": 6, "tag": "HealthCareActivity"}, {"end": 16, "start": 6, "tag": "ResearchActivity"}, {"end": 88, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 46, "tag": "Finding"}]}{"id": "1029_6", "text": "There is a need to develop new strategies to target neurodegeneration in an ever-ageing population.", "tags": [{"end": 69, "start": 52, "tag": "CellOrMolecularDysfunction"}, {"end": 98, "start": 88, "tag": "PopulationGroup"}, {"end": 41, "start": 31, "tag": "ResearchActivity"}, {"end": 41, "start": 31, "tag": "BiologicFunction"}]}{"id": "1029_7", "text": "First, we review the current PD and AD treatments and their limitations.", "tags": [{"end": 38, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 10, "tag": "ResearchActivity"}, {"end": 16, "start": 10, "tag": "HealthCareActivity"}, {"end": 28, "start": 21, "tag": "TemporalConcept"}, {"end": 49, "start": 39, "tag": "HealthCareActivity"}, {"end": 49, "start": 39, "tag": "ResearchActivity"}, {"end": 31, "start": 29, "tag": "DiseaseOrSyndrome"}]}{"id": "1029_8", "text": "Second, we review the current use of extracellular vesicles (EVs), cell-penetrating peptides (CPPs) and miRNAs as neuroprotective agents.", "tags": [{"end": 92, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 114, "tag": "PharmacologicSubstance"}, {"end": 59, "start": 37, "tag": "CellComponent"}, {"end": 64, "start": 61, "tag": "CellComponent"}, {"end": 110, "start": 104, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 110, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 11, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "HealthCareActivity"}, {"end": 29, "start": 22, "tag": "TemporalConcept"}]}{"id": "1029_9", "text": "Finally, we discuss the possibility of exploiting these as a combinatory therapeutic, alongside some potential drawbacks.", "tags": []}{"id": "1030_0", "text": "Circulating neuronal extracellular vesicles (NEVs) of Alzheimer's disease (AD) patients show high Tau and beta-amyloid (A beta) levels, whereas their astrocytic EVs (AEVs) contain high complement levels.", "tags": [{"end": 160, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 180, "tag": "Finding"}, {"end": 43, "start": 21, "tag": "CellComponent"}, {"end": 73, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 161, "tag": "CellComponent"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 79, "tag": "PatientOrDisabledGroup"}, {"end": 101, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 12, "tag": "Cell"}, {"end": 170, "start": 166, "tag": "CellComponent"}, {"end": 49, "start": 45, "tag": "CellComponent"}]}{"id": "1030_1", "text": "To validate EV proteins as AD biomarkers, we immunocaptured NEVs and AEVs from plasma collected from fifteen wild type (WT), four 2xTg-AD, nine 5xFAD, and fifteen 3xTg-AD mice and assessed biomarker relationships with brain tissue levels.", "tags": [{"end": 118, "start": 109, "tag": "GeneOrGenome"}, {"end": 118, "start": 109, "tag": "ResearchActivity"}, {"end": 122, "start": 120, "tag": "GeneOrGenome"}, {"end": 122, "start": 120, "tag": "ResearchActivity"}, {"end": 212, "start": 199, "tag": "Finding"}, {"end": 149, "start": 144, "tag": "ExperimentalModelOfDisease"}, {"end": 23, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 130, "tag": "ExperimentalModelOfDisease"}, {"end": 14, "start": 12, "tag": "CellComponent"}, {"end": 230, "start": 218, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 30, "tag": "ClinicalAttribute"}, {"end": 85, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 198, "start": 189, "tag": "ClinicalAttribute"}, {"end": 73, "start": 69, "tag": "CellComponent"}, {"end": 64, "start": 60, "tag": "CellComponent"}, {"end": 175, "start": 163, "tag": "ExperimentalModelOfDisease"}]}{"id": "1030_2", "text": "NEVs from 3xTg-AD mice had higher total Tau (p = 0.03) and p181-Tau (p = 0.0004) compared to WT mice.", "tags": [{"end": 22, "start": 10, "tag": "ExperimentalModelOfDisease"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 93, "tag": "Eukaryote"}, {"end": 4, "start": 0, "tag": "CellComponent"}]}{"id": "1030_3", "text": "There were moderately strong correlations between biomarkers in NEVs and cerebral cortex and hippocampus (total Tau: cortex, r = 0.4, p = 0.009; p181-Tau: cortex, r = 0.7, p < 0.0001; hippocampus, r = 0.6, p < 0.0001).", "tags": [{"end": 68, "start": 64, "tag": "CellComponent"}, {"end": 88, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 29, "tag": "ResearchActivity"}, {"end": 115, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 50, "tag": "ClinicalAttribute"}, {"end": 104, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 195, "start": 184, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 161, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1030_4", "text": "NEVs from 5xFAD compared to other mice had higher A beta 42 (p < 0.005).", "tags": [{"end": 15, "start": 10, "tag": "ExperimentalModelOfDisease"}, {"end": 59, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 34, "tag": "Eukaryote"}, {"end": 4, "start": 0, "tag": "CellComponent"}]}{"id": "1030_5", "text": "NEV A beta 42 had moderately strong correlations with A beta 42 in cortex (r = 0.6, p = 0.001) and hippocampus (r = 0.7, p < 0.0001).", "tags": [{"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 48, "start": 36, "tag": "ResearchActivity"}, {"end": 13, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1030_6", "text": "AEV C1q was elevated in 3xTg-AD compared to WT mice (p = 0.005); AEV C1q had moderate-strong correlations with C1q in cortex (r = 0.9, p < 0.0001) and hippocampus (r = 0.7, p < 0.0001).", "tags": [{"end": 85, "start": 77, "tag": "Finding"}, {"end": 105, "start": 93, "tag": "ResearchActivity"}, {"end": 51, "start": 47, "tag": "Eukaryote"}, {"end": 127, "start": 126, "tag": "PharmacologicSubstance"}, {"end": 165, "start": 164, "tag": "PharmacologicSubstance"}, {"end": 162, "start": 151, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 31, "start": 24, "tag": "ExperimentalModelOfDisease"}, {"end": 68, "start": 65, "tag": "CellComponent"}]}{"id": "1030_7", "text": "Biomarkers in circulating NEVs and AEVs reflect their brain levels across multiple AD mouse models supporting their potential use as a liquid biopsy for neurological disorders.", "tags": [{"end": 30, "start": 26, "tag": "CellComponent"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 175, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 35, "tag": "CellComponent"}, {"end": 91, "start": 86, "tag": "Eukaryote"}, {"end": 148, "start": 135, "tag": "HealthCareActivity"}, {"end": 98, "start": 92, "tag": "ResearchActivity"}]}{"id": "1031_0", "text": "Introduction: In brain, extracellular vesicles (EVs) play an essential role in the neuron-glia interface and ensure the crosstalk between the brain and the periphery.", "tags": [{"end": 46, "start": 24, "tag": "CellComponent"}, {"end": 51, "start": 48, "tag": "CellComponent"}, {"end": 89, "start": 83, "tag": "Cell"}, {"end": 22, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 142, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 165, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 90, "tag": "Cell"}, {"end": 129, "start": 120, "tag": "CellFunction"}]}{"id": "1031_1", "text": "Some studies now link the pathway dysfunction of the EVs to apolipoprotein E gene variant (APOE epsilon 4) and the risk of progression to Alzheimer's disease (AD).", "tags": [{"end": 89, "start": 60, "tag": "GeneOrGenome"}, {"end": 157, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 53, "tag": "CellComponent"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 123, "tag": "PathologicFunction"}, {"end": 134, "start": 123, "tag": "TemporalConcept"}, {"end": 12, "start": 5, "tag": "ResearchActivity"}, {"end": 119, "start": 115, "tag": "Finding"}, {"end": 105, "start": 91, "tag": "GeneOrGenome"}, {"end": 95, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 91, "tag": "GeneOrGenome"}, {"end": 33, "start": 26, "tag": "CellFunction"}, {"end": 45, "start": 34, "tag": "PathologicFunction"}, {"end": 76, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 60, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1031_2", "text": "To better understand the role of APOE epsilon 4 in pre-clinical AD, we have determined levels of pathogenic, neurotrophic and inflammatory proteins in peripheral EVs (pEVs) and in plasma from cognitively impaired, no dementia (CIND) participants stratified upon the absence (APOE epsilon 4(-)) or the presence (APOE epsilon 4(+) ) of the epsilon 4 allele of APOE.", "tags": [{"end": 63, "start": 51, "tag": "ResearchActivity"}, {"end": 121, "start": 109, "tag": "PathologicFunction"}, {"end": 354, "start": 338, "tag": "GeneOrGenome"}, {"end": 212, "start": 192, "tag": "PatientOrDisabledGroup"}, {"end": 245, "start": 233, "tag": "PopulationGroup"}, {"end": 165, "start": 162, "tag": "CellComponent"}, {"end": 66, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 225, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 180, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 161, "start": 151, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 279, "start": 275, "tag": "AminoAcidPeptideOrProtein"}, {"end": 279, "start": 275, "tag": "BiologicallyActiveSubstance"}, {"end": 325, "start": 311, "tag": "GeneOrGenome"}, {"end": 231, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 97, "tag": "PathologicFunction"}, {"end": 315, "start": 311, "tag": "AminoAcidPeptideOrProtein"}, {"end": 362, "start": 358, "tag": "AminoAcidPeptideOrProtein"}, {"end": 315, "start": 311, "tag": "GeneOrGenome"}, {"end": 47, "start": 33, "tag": "GeneOrGenome"}, {"end": 289, "start": 275, "tag": "GeneOrGenome"}, {"end": 362, "start": 358, "tag": "BiologicallyActiveSubstance"}, {"end": 309, "start": 301, "tag": "Finding"}, {"end": 279, "start": 275, "tag": "GeneOrGenome"}, {"end": 171, "start": 167, "tag": "CellComponent"}, {"end": 315, "start": 311, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 126, "tag": "PathologicFunction"}, {"end": 273, "start": 266, "tag": "Finding"}]}{"id": "1031_3", "text": "Methods: Levels of 15 neurodegenerative, neurotrophic and neuroinflammatory proteins were quantified in pEVs and compared to their plasma levels from cognitively normal and CIND participants.", "tags": [{"end": 53, "start": 41, "tag": "PathologicFunction"}, {"end": 190, "start": 178, "tag": "PopulationGroup"}, {"end": 137, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 177, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 22, "tag": "CellOrMolecularDysfunction"}, {"end": 75, "start": 58, "tag": "PathologicFunction"}, {"end": 168, "start": 162, "tag": "Finding"}, {"end": 168, "start": 150, "tag": "Finding"}, {"end": 108, "start": 104, "tag": "CellComponent"}]}{"id": "1031_4", "text": "Results: Levels of neurotrophic and inflammatory markers were reduced in pEVs from APOE epsilon 4(+).", "tags": [{"end": 31, "start": 19, "tag": "PathologicFunction"}, {"end": 56, "start": 36, "tag": "ClinicalAttribute"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 97, "start": 83, "tag": "GeneOrGenome"}, {"end": 87, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 83, "tag": "GeneOrGenome"}, {"end": 48, "start": 36, "tag": "PathologicFunction"}, {"end": 56, "start": 49, "tag": "ClinicalAttribute"}, {"end": 31, "start": 19, "tag": "ClinicalAttribute"}, {"end": 77, "start": 73, "tag": "CellComponent"}, {"end": 87, "start": 83, "tag": "BiologicallyActiveSubstance"}]}{"id": "1031_5", "text": "The pentraxin-2/alpha-synuclein ratio measured in pEVs was able to predict AD 5 years before the onset among APOE epsilon 4(+)-CIND individuals.", "tags": [{"end": 31, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 97, "tag": "TemporalConcept"}, {"end": 123, "start": 109, "tag": "GeneOrGenome"}, {"end": 85, "start": 80, "tag": "TemporalConcept"}, {"end": 131, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 132, "tag": "PopulationGroup"}, {"end": 113, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 109, "tag": "GeneOrGenome"}, {"end": 15, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 4, "tag": "ClinicalAttribute"}, {"end": 54, "start": 50, "tag": "CellComponent"}, {"end": 113, "start": 109, "tag": "BiologicallyActiveSubstance"}]}{"id": "1031_6", "text": "Discussion: Our findings suggest an alteration of the endosomal pathway in APOE epsilon 4(+) and that pEVs pentraxin-2/alpha-synuclein ratio could serve as a useful early biomarker for AD susceptibility.", "tags": [{"end": 46, "start": 36, "tag": "Finding"}, {"end": 187, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 165, "tag": "ClinicalAttribute"}, {"end": 89, "start": 75, "tag": "GeneOrGenome"}, {"end": 71, "start": 64, "tag": "CellFunction"}, {"end": 71, "start": 54, "tag": "CellFunction"}, {"end": 106, "start": 102, "tag": "CellComponent"}, {"end": 140, "start": 107, "tag": "ClinicalAttribute"}, {"end": 202, "start": 188, "tag": "Finding"}]}{"id": "1032_0", "text": "Background Plasma extracellular vesicles (pEV) can harbor a diverse array of factors including active proteases and the amyloid-precursor-protein (APP) cleavage product A beta, involved in plaque formation in Alzheimer's diseases (AD).", "tags": [{"end": 45, "start": 42, "tag": "CellComponent"}, {"end": 229, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 189, "tag": "AnatomicalAbnormality"}, {"end": 40, "start": 18, "tag": "CellComponent"}, {"end": 233, "start": 231, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 147, "tag": "GeneOrGenome"}, {"end": 150, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 175, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 160, "start": 152, "tag": "CellFunction"}, {"end": 160, "start": 152, "tag": "CellComponent"}, {"end": 111, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 189, "tag": "PathologicFunction"}, {"end": 168, "start": 152, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1032_1", "text": "A potential role of such vesicles in AD pathology is unexplored.", "tags": [{"end": 39, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 40, "tag": "PathologicFunction"}, {"end": 49, "start": 40, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 33, "start": 25, "tag": "CellComponent"}]}{"id": "1032_2", "text": "Methods In a case-control study of randomly selected patients with AD and other neurological diseases (n = 14), and healthy controls (n = 7), we systematically analyzed the content of pEV, using different assay systems.", "tags": [{"end": 31, "start": 13, "tag": "ResearchActivity"}, {"end": 187, "start": 184, "tag": "CellComponent"}, {"end": 180, "start": 173, "tag": "BiologicFunction"}, {"end": 218, "start": 205, "tag": "ResearchActivity"}, {"end": 131, "start": 124, "tag": "PopulationGroup"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 116, "tag": "OrganismAttribute"}, {"end": 61, "start": 53, "tag": "PatientOrDisabledGroup"}, {"end": 168, "start": 160, "tag": "ResearchActivity"}, {"end": 101, "start": 80, "tag": "DiseaseOrSyndrome"}]}{"id": "1032_3", "text": "In addition, we determined their entry path into brain tissue, employing animal (mice) injection experiments with ex vivo gener-ated EV that were similar to AD-pEV, followed by multi antigen analysis (MAA) of brain tissue (n = 4 per condition).", "tags": [{"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 133, "tag": "CellComponent"}, {"end": 199, "start": 177, "tag": "ResearchActivity"}, {"end": 85, "start": 81, "tag": "Eukaryote"}, {"end": 61, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 221, "start": 209, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 73, "tag": "Eukaryote"}, {"end": 121, "start": 114, "tag": "ResearchActivity"}, {"end": 108, "start": 87, "tag": "ResearchActivity"}, {"end": 163, "start": 160, "tag": "CellComponent"}]}{"id": "1032_4", "text": "The results were compared with an IHC staining of human brain tissue in a small cohort of AD patients (n = 3) and controls with no neurodegenerative diseases (n = 3).", "tags": [{"end": 37, "start": 34, "tag": "ResearchActivity"}, {"end": 46, "start": 34, "tag": "ResearchActivity"}, {"end": 46, "start": 38, "tag": "Finding"}, {"end": 86, "start": 80, "tag": "PopulationGroup"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 93, "tag": "PatientOrDisabledGroup"}, {"end": 122, "start": 114, "tag": "PopulationGroup"}, {"end": 55, "start": 50, "tag": "Eukaryote"}, {"end": 68, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 157, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 34, "tag": "HealthCareActivity"}]}{"id": "1032_5", "text": "Findings We show that pEV levels are considerably upregulated in AD patients.", "tags": [{"end": 25, "start": 22, "tag": "CellComponent"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 68, "tag": "PatientOrDisabledGroup"}]}{"id": "1032_6", "text": "Besides numerous inflammatory effectors, AD-pEV contained alpha-, beta- and gamma-secretases, able to cleave APP in in target cells.", "tags": [{"end": 92, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 109, "tag": "GeneOrGenome"}, {"end": 112, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 119, "tag": "Cell"}, {"end": 47, "start": 44, "tag": "CellComponent"}, {"end": 39, "start": 17, "tag": "BiologicallyActiveSubstance"}]}{"id": "1032_7", "text": "In vitro gen-erated EV with similar characteristics as AD-pEV accumulated in the choroid plexus (CP) of injected animals and reached primarily hippocampal neurons.", "tags": [{"end": 95, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 57, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "CellComponent"}, {"end": 162, "start": 143, "tag": "Cell"}, {"end": 120, "start": 113, "tag": "Eukaryote"}, {"end": 61, "start": 58, "tag": "CellComponent"}]}{"id": "1032_8", "text": "Corroborating findings were made in human brain samples.", "tags": [{"end": 47, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 36, "tag": "Eukaryote"}, {"end": 55, "start": 48, "tag": "Substance"}, {"end": 55, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1032_9", "text": "An inhibitor of hyaluronic-acid-synthetase (HAS) blocked uploading of proteases and Hyaluronan onto EV in vitro and abolished CP targeting in animal injection experiments.", "tags": [{"end": 79, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 84, "tag": "Chemical"}, {"end": 128, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 3, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 3, "tag": "PharmacologicSubstance"}, {"end": 12, "start": 3, "tag": "Chemical"}, {"end": 170, "start": 142, "tag": "ResearchActivity"}, {"end": 102, "start": 100, "tag": "CellComponent"}, {"end": 111, "start": 103, "tag": "ResearchActivity"}, {"end": 148, "start": 142, "tag": "Eukaryote"}, {"end": 42, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 16, "tag": "BiologicallyActiveSubstance"}]}{"id": "1032_10", "text": "Interpretation We conclude that protease-containing pEV could be part of a communication axis between the periphery and the brain that could be become detrimental depending on pEV concentration and duration of target cell impact.", "tags": [{"end": 179, "start": 176, "tag": "CellComponent"}, {"end": 206, "start": 198, "tag": "TemporalConcept"}, {"end": 93, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 221, "start": 217, "tag": "Cell"}, {"end": 115, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 75, "tag": "HealthCareActivity"}, {"end": 88, "start": 75, "tag": "CellFunction"}, {"end": 193, "start": 180, "tag": "BiologicFunction"}, {"end": 40, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 52, "tag": "CellComponent"}]}{"id": "1032_11", "text": "Copyright (C) 2022 The Authors.", "tags": []}{"id": "1032_12", "text": "Published by Elsevier B.V.", "tags": []}{"id": "1033_0", "text": "Extracellular vesicles (EVs), as nano-sized vesicles secreted by almost all cells, have been recognized as the essential transmitter for cell-to-cell communication and participating in multiple biological processes.", "tags": [{"end": 132, "start": 121, "tag": "ManufacturedObject"}, {"end": 132, "start": 121, "tag": "Finding"}, {"end": 214, "start": 194, "tag": "BiologicFunction"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 81, "start": 76, "tag": "Cell"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 52, "start": 33, "tag": "CellComponent"}, {"end": 163, "start": 137, "tag": "CellFunction"}]}{"id": "1033_1", "text": "Neurodegenerative diseases (ND), such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, share common mechanisms of the aggregation and propagation of distinct pathologic proteins among cells in the nervous systems and neuroinflammatory reactions mediated by glia during the pathogenic process.", "tags": [{"end": 30, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 243, "start": 228, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 292, "start": 288, "tag": "Cell"}, {"end": 116, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 220, "start": 215, "tag": "Cell"}, {"end": 176, "start": 165, "tag": "Finding"}, {"end": 314, "start": 304, "tag": "PathologicFunction"}, {"end": 81, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 265, "start": 248, "tag": "PathologicFunction"}, {"end": 160, "start": 149, "tag": "CellFunction"}, {"end": 160, "start": 149, "tag": "ResearchActivity"}, {"end": 208, "start": 189, "tag": "PathologicFunction"}]}{"id": "1033_2", "text": "This feature indicates the vital role of crosstalk between neurons and glia in the pathogenesis of ND.", "tags": [{"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 71, "tag": "Cell"}, {"end": 50, "start": 41, "tag": "CellFunction"}, {"end": 95, "start": 83, "tag": "PathologicFunction"}, {"end": 66, "start": 59, "tag": "Cell"}]}{"id": "1033_3", "text": "In recent years, glia-derived EVs have been investigated as potential mediators of signals between neurons and glia, which provides a new direction and strategy for understanding ND.", "tags": [{"end": 181, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 17, "tag": "Cell"}, {"end": 115, "start": 111, "tag": "Cell"}, {"end": 33, "start": 30, "tag": "CellComponent"}, {"end": 90, "start": 83, "tag": "CellFunction"}, {"end": 178, "start": 165, "tag": "BiologicFunction"}, {"end": 106, "start": 99, "tag": "Cell"}, {"end": 79, "start": 70, "tag": "Finding"}, {"end": 15, "start": 3, "tag": "TemporalConcept"}]}{"id": "1033_4", "text": "By a comprehensive summary, it can be concluded that glia-derived EVs have both a beneficial and/or a detrimental effect in the process of ND.", "tags": [{"end": 141, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 53, "tag": "Cell"}, {"end": 69, "start": 66, "tag": "CellComponent"}, {"end": 26, "start": 5, "tag": "ResearchActivity"}]}{"id": "1033_5", "text": "Therefore, this review article conveys the role of glia-derived EVs in the pathogenesis of ND and raises current limitations of their potential application in the diagnosis and treatment of ND.</p>", "tags": [{"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 51, "tag": "Cell"}, {"end": 30, "start": 16, "tag": "ResearchActivity"}, {"end": 67, "start": 64, "tag": "CellComponent"}, {"end": 87, "start": 75, "tag": "PathologicFunction"}, {"end": 186, "start": 177, "tag": "HealthCareActivity"}, {"end": 186, "start": 177, "tag": "ResearchActivity"}, {"end": 112, "start": 105, "tag": "TemporalConcept"}, {"end": 172, "start": 163, "tag": "HealthCareActivity"}, {"end": 192, "start": 190, "tag": "DiseaseOrSyndrome"}]}{"id": "1034_0", "text": "The complement system is implicated in a broad range of neuroinflammatory disorders such as Alzheimer's disease (AD) and multiple sclerosis (MS).", "tags": [{"end": 83, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 56, "tag": "PathologicFunction"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 4, "tag": "BiologicallyActiveSubstance"}]}{"id": "1034_1", "text": "Consequently, measuring complement levels in biofluids could serve as a potential biomarker for these diseases.", "tags": [{"end": 91, "start": 72, "tag": "ClinicalAttribute"}, {"end": 54, "start": 45, "tag": "Substance"}, {"end": 34, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 24, "tag": "ClinicalAttribute"}]}{"id": "1034_2", "text": "Indeed, complement levels are shown to be altered in patients compared to controls, and some studies reported a correlation between the level of free complement in biofluids and disease progression, severity or the response to therapeutics.", "tags": [{"end": 61, "start": 53, "tag": "PatientOrDisabledGroup"}, {"end": 82, "start": 74, "tag": "PopulationGroup"}, {"end": 239, "start": 227, "tag": "HealthCareActivity"}, {"end": 173, "start": 164, "tag": "Substance"}, {"end": 100, "start": 93, "tag": "ResearchActivity"}, {"end": 207, "start": 199, "tag": "ClinicalAttribute"}, {"end": 207, "start": 199, "tag": "Finding"}, {"end": 197, "start": 178, "tag": "PathologicFunction"}, {"end": 25, "start": 8, "tag": "ClinicalAttribute"}, {"end": 160, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 150, "tag": "BiologicallyActiveSubstance"}]}{"id": "1034_3", "text": "Overall, they are not (yet) suitable as a diagnostic tool due to heterogeneity of reported results.", "tags": [{"end": 57, "start": 42, "tag": "HealthCareActivity"}, {"end": 78, "start": 65, "tag": "OrganismAttribute"}]}{"id": "1034_4", "text": "Moreover, measurement of free complement proteins has the disadvantage that information on their origin is lost, which might be of value in a multi-parameter approach for disease prediction and stratification.", "tags": [{"end": 21, "start": 10, "tag": "ResearchActivity"}, {"end": 21, "start": 10, "tag": "HealthCareActivity"}, {"end": 103, "start": 97, "tag": "TemporalConcept"}, {"end": 208, "start": 194, "tag": "ResearchActivity"}, {"end": 49, "start": 25, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1034_5", "text": "In light of this, extracellular vesicles (EVs) could provide a platform to improve the diagnostic power of complement proteins.", "tags": [{"end": 103, "start": 87, "tag": "Finding"}, {"end": 126, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 18, "tag": "CellComponent"}, {"end": 45, "start": 42, "tag": "CellComponent"}]}{"id": "1034_6", "text": "EVs are nanosized double membrane particles that are secreted by essentially every cell type and resemble the (status of the) cell of origin.", "tags": [{"end": 33, "start": 25, "tag": "CellComponent"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 130, "start": 126, "tag": "Cell"}, {"end": 140, "start": 134, "tag": "TemporalConcept"}, {"end": 117, "start": 111, "tag": "Finding"}, {"end": 43, "start": 34, "tag": "Chemical"}, {"end": 92, "start": 83, "tag": "Cell"}, {"end": 33, "start": 8, "tag": "CellComponent"}]}{"id": "1034_7", "text": "Interestingly, EVs can contain complement proteins, while the cellular origin can still be determined by the presence of EV surface markers.", "tags": [{"end": 50, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 15, "tag": "CellComponent"}, {"end": 123, "start": 121, "tag": "CellComponent"}, {"end": 77, "start": 71, "tag": "TemporalConcept"}, {"end": 139, "start": 124, "tag": "ClinicalAttribute"}, {"end": 70, "start": 62, "tag": "Cell"}, {"end": 117, "start": 109, "tag": "Finding"}]}{"id": "1034_8", "text": "In this review, we summarize the current knowledge and future opportunities on the use of free and EV-associated complement proteins as biomarkers for neuroinflammatory and neurodegenerative disorders.", "tags": [{"end": 101, "start": 99, "tag": "CellComponent"}, {"end": 146, "start": 136, "tag": "ClinicalAttribute"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 132, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 41, "tag": "Finding"}, {"end": 40, "start": 33, "tag": "TemporalConcept"}, {"end": 168, "start": 151, "tag": "PathologicFunction"}, {"end": 61, "start": 55, "tag": "TemporalConcept"}, {"end": 200, "start": 173, "tag": "DiseaseOrSyndrome"}]}{"id": "1035_0", "text": "Astrocytes are specialized glial cells that are essential components of the neurovascular unit (NVU) and are involved in neurodevelopment, brain maintenance and repair, and neurodegeneration.", "tags": [{"end": 137, "start": 121, "tag": "BiologicFunction"}, {"end": 10, "start": 0, "tag": "Cell"}, {"end": 94, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 27, "tag": "Cell"}, {"end": 190, "start": 173, "tag": "CellOrMolecularDysfunction"}, {"end": 156, "start": 139, "tag": "BiologicFunction"}, {"end": 167, "start": 161, "tag": "BiologicFunction"}, {"end": 167, "start": 161, "tag": "HealthCareActivity"}, {"end": 144, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1035_1", "text": "Astrocytes mediate these processes by releasing cellular mediators such as extracellular vesicles (EVs).", "tags": [{"end": 10, "start": 0, "tag": "Cell"}, {"end": 97, "start": 75, "tag": "CellComponent"}, {"end": 102, "start": 99, "tag": "CellComponent"}, {"end": 66, "start": 57, "tag": "Finding"}, {"end": 56, "start": 48, "tag": "Cell"}]}{"id": "1035_2", "text": "EVs are vehicles of cell-cell communication and have been proposed as mediators of damage in AD.", "tags": [{"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 95, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 20, "tag": "CellFunction"}, {"end": 79, "start": 70, "tag": "Finding"}, {"end": 16, "start": 8, "tag": "ManufacturedObject"}, {"end": 89, "start": 83, "tag": "InjuryOrPoisoning"}]}{"id": "1035_3", "text": "However, the transcellular mechanism by which Alzheimer disease (AD) astrocytes impair the function of NVU components is poorly understood.", "tags": [{"end": 106, "start": 103, "tag": "Cell"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 69, "tag": "Cell"}, {"end": 63, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 107, "tag": "CellComponent"}]}{"id": "1035_4", "text": "Therefore, we evaluated the effects of adult PS1-KI and 3xTg-AD astrocyte conditioned media (CM) and EVs on NVU components (neuroglia and endothelium) in vitro.", "tags": [{"end": 91, "start": 74, "tag": "Chemical"}, {"end": 95, "start": 93, "tag": "Chemical"}, {"end": 133, "start": 124, "tag": "Cell"}, {"end": 149, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 101, "tag": "CellComponent"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 64, "tag": "Cell"}, {"end": 159, "start": 151, "tag": "ResearchActivity"}, {"end": 63, "start": 56, "tag": "ExperimentalModelOfDisease"}, {"end": 44, "start": 39, "tag": "PopulationGroup"}, {"end": 35, "start": 28, "tag": "Finding"}]}{"id": "1035_5", "text": "Additionally, SAD and FAD astrocyte-derived EVs (A-EVs) were characterized, and we evaluated their effects on NVU in cocultured cells in vitro and on intrahippocampal CA1 cells in vivo.", "tags": [{"end": 17, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 117, "tag": "Cell"}, {"end": 113, "start": 110, "tag": "Cell"}, {"end": 47, "start": 44, "tag": "CellComponent"}, {"end": 54, "start": 51, "tag": "CellComponent"}, {"end": 176, "start": 171, "tag": "Cell"}, {"end": 35, "start": 26, "tag": "Cell"}, {"end": 142, "start": 134, "tag": "ResearchActivity"}, {"end": 184, "start": 177, "tag": "ResearchActivity"}, {"end": 106, "start": 99, "tag": "Finding"}, {"end": 127, "start": 117, "tag": "ResearchActivity"}, {"end": 170, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1035_6", "text": "Surprisingly, cultured 3xTg-AD astrocytes showed increased glial fibrillary acidic protein (GFAP) reactivity compared to PS1-KI astrocytes, which denotes astrocytic hyperreactivity.", "tags": [{"end": 90, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 23, "tag": "ExperimentalModelOfDisease"}, {"end": 41, "start": 31, "tag": "Cell"}, {"end": 138, "start": 128, "tag": "Cell"}, {"end": 22, "start": 14, "tag": "ResearchActivity"}, {"end": 96, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 92, "tag": "GeneOrGenome"}, {"end": 180, "start": 165, "tag": "Finding"}]}{"id": "1035_7", "text": "CM from adult mice 3xTg-AD astrocytes increased cell-cell gaps between endothelial cells, filopodia-like dendritic protrusions in neurons and neuronal and endothelial cell death.", "tags": [{"end": 2, "start": 0, "tag": "Chemical"}, {"end": 88, "start": 71, "tag": "Cell"}, {"end": 171, "start": 155, "tag": "Cell"}, {"end": 26, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 14, "tag": "Eukaryote"}, {"end": 52, "start": 48, "tag": "Cell"}, {"end": 57, "start": 53, "tag": "Cell"}, {"end": 150, "start": 142, "tag": "Cell"}, {"end": 177, "start": 172, "tag": "BiologicFunction"}, {"end": 177, "start": 172, "tag": "PathologicFunction"}, {"end": 177, "start": 172, "tag": "CellFunction"}, {"end": 26, "start": 19, "tag": "ExperimentalModelOfDisease"}, {"end": 137, "start": 130, "tag": "Cell"}, {"end": 37, "start": 27, "tag": "Cell"}, {"end": 13, "start": 8, "tag": "PopulationGroup"}, {"end": 126, "start": 90, "tag": "CellComponent"}, {"end": 177, "start": 167, "tag": "CellFunction"}]}{"id": "1035_8", "text": "3xTg-AD A-EVs induced neurotoxicity and increased astrocyte GFAP reactivity.", "tags": [{"end": 13, "start": 10, "tag": "CellComponent"}, {"end": 7, "start": 5, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 50, "tag": "Cell"}, {"end": 7, "start": 0, "tag": "ExperimentalModelOfDisease"}, {"end": 64, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 60, "tag": "GeneOrGenome"}, {"end": 35, "start": 22, "tag": "InjuryOrPoisoning"}, {"end": 75, "start": 65, "tag": "CellFunction"}]}{"id": "1035_9", "text": "Cultured human postmortem astrocytes from AD patients also increased GFAP reactivity and EVs release.", "tags": [{"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 92, "start": 89, "tag": "CellComponent"}, {"end": 44, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 45, "tag": "PatientOrDisabledGroup"}, {"end": 14, "start": 9, "tag": "Eukaryote"}, {"end": 36, "start": 26, "tag": "Cell"}, {"end": 25, "start": 15, "tag": "TemporalConcept"}, {"end": 73, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 69, "tag": "GeneOrGenome"}, {"end": 100, "start": 93, "tag": "HealthCareActivity"}, {"end": 100, "start": 93, "tag": "ResearchActivity"}, {"end": 84, "start": 74, "tag": "CellFunction"}]}{"id": "1035_10", "text": "No differences in the size or number of A-EVs were detected between AD and control samples; however, both SAD and FAD A-EVs showed increased expression of the surface marker aquaporin 4.", "tags": [{"end": 117, "start": 114, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 117, "start": 114, "tag": "GeneOrGenome"}, {"end": 185, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 42, "tag": "CellComponent"}, {"end": 123, "start": 120, "tag": "CellComponent"}, {"end": 70, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 159, "tag": "ClinicalAttribute"}, {"end": 90, "start": 83, "tag": "Substance"}, {"end": 90, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 141, "tag": "CellFunction"}, {"end": 14, "start": 0, "tag": "Finding"}, {"end": 26, "start": 22, "tag": "OrganismAttribute"}, {"end": 109, "start": 106, "tag": "DiseaseOrSyndrome"}]}{"id": "1035_11", "text": "A-EVs induced cytotoxicity and astrocyte hyperactivation: specifically, FAD A-EVs induced neuroglial cytotoxicity and increased gaps between the endothelium, while SAD A-EVs mainly altered the endothelium.", "tags": [{"end": 26, "start": 14, "tag": "CellOrMolecularDysfunction"}, {"end": 75, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 204, "start": 193, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 90, "tag": "Cell"}, {"end": 5, "start": 2, "tag": "CellComponent"}, {"end": 81, "start": 78, "tag": "CellComponent"}, {"end": 173, "start": 170, "tag": "CellComponent"}, {"end": 40, "start": 31, "tag": "Cell"}, {"end": 56, "start": 41, "tag": "CellFunction"}, {"end": 113, "start": 101, "tag": "CellOrMolecularDysfunction"}, {"end": 167, "start": 164, "tag": "DiseaseOrSyndrome"}]}{"id": "1035_12", "text": "Similarly, both AD A-EVs increased astrocyte GS reactivity and vascular deterioration in vivo.", "tags": [{"end": 47, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 45, "tag": "GeneOrGenome"}, {"end": 71, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 21, "tag": "CellComponent"}, {"end": 18, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 35, "tag": "Cell"}, {"end": 93, "start": 86, "tag": "ResearchActivity"}, {"end": 85, "start": 63, "tag": "PathologicFunction"}]}{"id": "1035_13", "text": "We associated this finding with perivascular reactive astrocytes and vascular deterioration in the human AD brain.", "tags": [{"end": 44, "start": 32, "tag": "Cell"}, {"end": 26, "start": 19, "tag": "Finding"}, {"end": 77, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 45, "tag": "Cell"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 99, "tag": "Eukaryote"}, {"end": 64, "start": 54, "tag": "Cell"}, {"end": 91, "start": 69, "tag": "PathologicFunction"}]}{"id": "1035_14", "text": "In summary, these results suggest that AD A-EVs impair neuroglial and vascular components.", "tags": [{"end": 65, "start": 55, "tag": "Cell"}, {"end": 89, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 44, "tag": "CellComponent"}, {"end": 41, "start": 39, "tag": "DiseaseOrSyndrome"}]}{"id": "1036_0", "text": "The gut microbiota represents a diverse and dynamic population of microorganisms that can influence the health of the host.", "tags": [{"end": 18, "start": 4, "tag": "Organism"}, {"end": 80, "start": 66, "tag": "Organism"}, {"end": 110, "start": 104, "tag": "HealthCareActivity"}, {"end": 122, "start": 118, "tag": "Organism"}, {"end": 62, "start": 52, "tag": "PopulationGroup"}]}{"id": "1036_1", "text": "Increasing evidence supports the role of the gut microbiota as a key player in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD).", "tags": [{"end": 59, "start": 45, "tag": "Organism"}, {"end": 125, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 11, "tag": "Finding"}, {"end": 156, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 83, "tag": "PathologicFunction"}]}{"id": "1036_2", "text": "Unfortunately, the mechanisms behind the interplay between gut pathogens and AD are still elusive.", "tags": [{"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 41, "tag": "Finding"}, {"end": 72, "start": 59, "tag": "Organism"}]}{"id": "1036_3", "text": "It is known that bacteria-derived outer membrane vesicles (OMVs) act as natural carriers of virulence factors that are central players in the pathogenesis of the bacteria.", "tags": [{"end": 109, "start": 92, "tag": "Chemical"}, {"end": 170, "start": 162, "tag": "Bacterium"}, {"end": 57, "start": 34, "tag": "CellComponent"}, {"end": 154, "start": 142, "tag": "PathologicFunction"}, {"end": 25, "start": 17, "tag": "Bacterium"}, {"end": 63, "start": 59, "tag": "CellComponent"}, {"end": 109, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 92, "tag": "InjuryOrPoisoning"}]}{"id": "1036_4", "text": "Helicobacter pylori (H.", "tags": [{"end": 19, "start": 0, "tag": "Bacterium"}]}{"id": "1036_5", "text": "pylori) is a common gastric pathogen and H.", "tags": [{"end": 27, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 28, "tag": "Organism"}]}{"id": "1036_6", "text": "pylori infection has been associated with an increased risk to develop AD.", "tags": [{"end": 16, "start": 7, "tag": "PathologicFunction"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 45, "tag": "Finding"}]}{"id": "1036_7", "text": "Here, we are the first to shed light on the role of OMVs derived from H.", "tags": [{"end": 22, "start": 17, "tag": "TemporalConcept"}, {"end": 56, "start": 52, "tag": "CellComponent"}]}{"id": "1036_8", "text": "pylori on the brain in healthy conditions and on disease pathology in the case of AD.", "tags": [{"end": 19, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 23, "tag": "OrganismAttribute"}, {"end": 66, "start": 49, "tag": "PathologicFunction"}, {"end": 78, "start": 74, "tag": "ManufacturedObject"}]}{"id": "1036_9", "text": "Our results reveal that H.", "tags": []}{"id": "1036_10", "text": "pylori OMVs can cross the biological barriers, eventually reaching the brain.", "tags": [{"end": 76, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 7, "tag": "CellComponent"}]}{"id": "1036_11", "text": "Once in the brain, these OMVs are taken up by astrocytes, which induce activation of glial cells and neuronal dysfunction, ultimately leading to exacerbated amyloid-beta pathology and cognitive decline.", "tags": [{"end": 121, "start": 101, "tag": "CellOrMolecularDysfunction"}, {"end": 96, "start": 85, "tag": "Cell"}, {"end": 56, "start": 46, "tag": "Cell"}, {"end": 96, "start": 71, "tag": "CellFunction"}, {"end": 17, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 169, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 170, "tag": "PathologicFunction"}, {"end": 179, "start": 170, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 164, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 201, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 25, "tag": "CellComponent"}]}{"id": "1036_12", "text": "Mechanistically, we identified a critical role for the complement component 3 (C3)-C3a receptor (C3aR) signalling in mediating the interaction between astrocytes, microglia and neurons upon the presence of gut H.", "tags": [{"end": 113, "start": 103, "tag": "BiologicFunction"}, {"end": 113, "start": 55, "tag": "CellFunction"}, {"end": 202, "start": 194, "tag": "Finding"}, {"end": 209, "start": 206, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 177, "tag": "Cell"}, {"end": 161, "start": 151, "tag": "Cell"}, {"end": 95, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 163, "tag": "Cell"}, {"end": 95, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 55, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1036_13", "text": "pylori OMVs.", "tags": [{"end": 11, "start": 7, "tag": "CellComponent"}]}{"id": "1036_14", "text": "Taken together, our study reveals that H.", "tags": [{"end": 25, "start": 20, "tag": "ResearchActivity"}]}{"id": "1036_15", "text": "pylori has a detrimental effect on brain functionality and accelerates AD development via OMVs and C3-C3aR signalling.", "tags": [{"end": 117, "start": 99, "tag": "CellFunction"}, {"end": 40, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 74, "tag": "BiologicFunction"}, {"end": 85, "start": 74, "tag": "CellFunction"}, {"end": 94, "start": 90, "tag": "CellComponent"}]}{"id": "1037_0", "text": "Microglia, the macrophage-like glial cells, behave as sentinels against exogenous pathogens invading the neural tissue.", "tags": [{"end": 63, "start": 54, "tag": "Chemical"}, {"end": 91, "start": 72, "tag": "Organism"}, {"end": 118, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 0, "tag": "Cell"}, {"end": 42, "start": 15, "tag": "Cell"}]}{"id": "1037_1", "text": "Their commitment is not only confined to the defensive function, but they also perform balancing trophic activities such as neuronal postnatal development, remodeling and pruning of synapses.", "tags": [{"end": 16, "start": 6, "tag": "BiologicFunction"}, {"end": 166, "start": 156, "tag": "BiologicFunction"}, {"end": 154, "start": 143, "tag": "BiologicFunction"}, {"end": 154, "start": 143, "tag": "CellFunction"}, {"end": 132, "start": 124, "tag": "Cell"}, {"end": 190, "start": 182, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 133, "tag": "TemporalConcept"}, {"end": 190, "start": 171, "tag": "CellFunction"}, {"end": 63, "start": 45, "tag": "BiologicFunction"}]}{"id": "1037_2", "text": "Likewise, microglia-derived extracellular vesicles (EVs) can play strategic roles in maintaining a healthy brain by modulating neuronal activity and by controlling neurite outgrowth as well as innate immune response.", "tags": [{"end": 215, "start": 193, "tag": "BiologicFunction"}, {"end": 144, "start": 127, "tag": "CellFunction"}, {"end": 215, "start": 200, "tag": "BiologicFunction"}, {"end": 171, "start": 164, "tag": "CellComponent"}, {"end": 50, "start": 28, "tag": "CellComponent"}, {"end": 55, "start": 52, "tag": "CellComponent"}, {"end": 106, "start": 99, "tag": "OrganismAttribute"}, {"end": 112, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 127, "tag": "Cell"}, {"end": 19, "start": 10, "tag": "Cell"}, {"end": 181, "start": 164, "tag": "CellFunction"}]}{"id": "1037_3", "text": "Nevertheless, strong evidence also points to their role in the development of neurodegenerative pathologies such as Alzheimer's disease (AD).", "tags": [{"end": 107, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 21, "tag": "Finding"}, {"end": 74, "start": 63, "tag": "BiologicFunction"}, {"end": 74, "start": 63, "tag": "CellFunction"}]}{"id": "1037_4", "text": "Here, we explored EV protein content released by BV2 microglial cells in a resting state and after stimulation with beta-amyloid peptides (A beta), mimicking conditions occurring in AD.", "tags": [{"end": 88, "start": 75, "tag": "Finding"}, {"end": 184, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 18, "tag": "CellComponent"}, {"end": 145, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 99, "tag": "HealthCareActivity"}, {"end": 110, "start": 99, "tag": "NaturalPhenomenonOrProcess"}, {"end": 137, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 49, "tag": "Cell"}, {"end": 28, "start": 21, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1037_5", "text": "In the resting BV2 cells, we extended the list of proteins present in mouse microglia EV cargo with respect to those reported in the Vesiclepedia exosome database while, in amyloid-triggered microglia, we highlighted a pronounced drop in EV protein content.", "tags": [{"end": 88, "start": 86, "tag": "CellComponent"}, {"end": 240, "start": 238, "tag": "CellComponent"}, {"end": 24, "start": 15, "tag": "Cell"}, {"end": 94, "start": 89, "tag": "CellFunction"}, {"end": 58, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 76, "tag": "Cell"}, {"end": 200, "start": 191, "tag": "Cell"}, {"end": 75, "start": 70, "tag": "Eukaryote"}, {"end": 180, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 248, "start": 241, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 133, "tag": "ResearchActivity"}]}{"id": "1037_6", "text": "Focusing on Rab11A, a key factor in the recycling routes of amyloid species, we observed a dramatic decrease of this protein in A beta-treated microglia EV cargo with respect to the EVs from the untreated sample.", "tags": [{"end": 18, "start": 12, "tag": "GeneOrGenome"}, {"end": 108, "start": 91, "tag": "Finding"}, {"end": 211, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 205, "tag": "Substance"}, {"end": 185, "start": 182, "tag": "CellComponent"}, {"end": 155, "start": 153, "tag": "CellComponent"}, {"end": 161, "start": 156, "tag": "CellFunction"}, {"end": 152, "start": 143, "tag": "Cell"}, {"end": 134, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 68, "tag": "OrganismAttribute"}, {"end": 18, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 12, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1037_7", "text": "This decrease might affect the delivery of Rab11A to neurons thus increasing the harmful amyloid burden in neuronal cells that eventually may lead to their death.", "tags": [{"end": 49, "start": 43, "tag": "GeneOrGenome"}, {"end": 13, "start": 5, "tag": "Finding"}, {"end": 121, "start": 107, "tag": "Cell"}, {"end": 103, "start": 97, "tag": "ResearchActivity"}, {"end": 161, "start": 156, "tag": "BiologicFunction"}, {"end": 161, "start": 156, "tag": "PathologicFunction"}, {"end": 161, "start": 156, "tag": "CellFunction"}, {"end": 96, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 53, "tag": "Cell"}, {"end": 39, "start": 31, "tag": "BiologicFunction"}, {"end": 49, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 43, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1037_8", "text": "We tentatively proposed that alterations observed in EVs derived from A beta-treated microglia may represent molecular features that, among others, shape the disease-associated microglial phenotype, a recently proposed subset of microglial population, present in neurodegenerative pathologies.", "tags": [{"end": 292, "start": 263, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 53, "tag": "CellComponent"}, {"end": 197, "start": 188, "tag": "OrganismAttribute"}, {"end": 94, "start": 85, "tag": "Cell"}, {"end": 76, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 250, "start": 240, "tag": "PopulationGroup"}, {"end": 209, "start": 201, "tag": "TemporalConcept"}, {"end": 187, "start": 177, "tag": "Cell"}, {"end": 239, "start": 229, "tag": "Cell"}, {"end": 40, "start": 29, "tag": "Finding"}]}{"id": "1038_0", "text": "IntroductionLimbic predominant age related TDP-43 encephalopathy neuropathological change (LATE-NC) is a recently characterized brain disease that mimics Alzheimer's disease (AD) clinically.", "tags": [{"end": 64, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 105, "tag": "TemporalConcept"}, {"end": 49, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 91, "tag": "DiseaseOrSyndrome"}]}{"id": "1038_1", "text": "To date, LATE-NC is difficult to diagnose antemortem using clinical information or biomarkers.", "tags": [{"end": 41, "start": 33, "tag": "HealthCareActivity"}, {"end": 7, "start": 3, "tag": "TemporalConcept"}, {"end": 93, "start": 83, "tag": "ClinicalAttribute"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 16, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 42, "tag": "TemporalConcept"}]}{"id": "1038_2", "text": "Recent studies suggest concentrations of extracellular vesicle (EVs) protein cargo derived from neuronal and glial cells may serve as useful diagnostic biomarkers for AD and other neurodegenerative diseases.", "tags": [{"end": 62, "start": 41, "tag": "CellComponent"}, {"end": 67, "start": 64, "tag": "CellComponent"}, {"end": 169, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 152, "tag": "ClinicalAttribute"}, {"end": 120, "start": 109, "tag": "Cell"}, {"end": 104, "start": 96, "tag": "Cell"}, {"end": 206, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 77, "tag": "CellFunction"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 37, "start": 23, "tag": "BiologicFunction"}, {"end": 76, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 141, "tag": "ClinicalAttribute"}]}{"id": "1038_3", "text": "MethodsTDP-43 was evaluated in neuronal (NDEVs), astrocyte (ADEVs), and microglial derived extracellular vesicles (MDEVs).", "tags": [{"end": 113, "start": 91, "tag": "CellComponent"}, {"end": 39, "start": 31, "tag": "Cell"}, {"end": 58, "start": 49, "tag": "Cell"}, {"end": 82, "start": 72, "tag": "Cell"}, {"end": 13, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 41, "tag": "CellComponent"}, {"end": 65, "start": 60, "tag": "CellComponent"}, {"end": 120, "start": 115, "tag": "CellComponent"}]}{"id": "1038_4", "text": "EV preparations were isolated from the plasma of research subjects with autopsy-confirmed diagnoses, including many with LATE (n = 22).", "tags": [{"end": 99, "start": 90, "tag": "HealthCareActivity"}, {"end": 2, "start": 0, "tag": "CellComponent"}, {"end": 45, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 49, "tag": "ResearchActivity"}, {"end": 66, "start": 58, "tag": "PopulationGroup"}, {"end": 79, "start": 72, "tag": "HealthCareActivity"}, {"end": 125, "start": 121, "tag": "DiseaseOrSyndrome"}]}{"id": "1038_5", "text": "Quantified TDP-43 concentrations were compared to the cohort that included healthy controls, mild cognitively impairment (MCI), and AD dementia with diagnoses other than LATE-NC (n = 42).", "tags": [{"end": 120, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 149, "tag": "HealthCareActivity"}, {"end": 91, "start": 83, "tag": "PopulationGroup"}, {"end": 60, "start": 54, "tag": "PopulationGroup"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 75, "tag": "OrganismAttribute"}, {"end": 143, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 18, "tag": "BiologicFunction"}, {"end": 17, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 177, "start": 170, "tag": "DiseaseOrSyndrome"}]}{"id": "1038_6", "text": "ResultsTDP-43 was significantly elevated in plasma ADEVs derived from autopsy confirmed LATE-NC subjects, with or without comorbid AD pathology.", "tags": [{"end": 77, "start": 70, "tag": "HealthCareActivity"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 134, "tag": "PathologicFunction"}, {"end": 143, "start": 134, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 104, "start": 96, "tag": "PopulationGroup"}, {"end": 95, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 51, "tag": "CellComponent"}, {"end": 13, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 122, "tag": "Finding"}]}{"id": "1038_7", "text": "Measurable levels of TDP-43 were also detected in EV-depleted plasma; however, TDP-43 levels were not significantly different between persons with and without eventual autopsy confirmed LATE-NC.", "tags": [{"end": 175, "start": 168, "tag": "HealthCareActivity"}, {"end": 141, "start": 134, "tag": "PopulationGroup"}, {"end": 52, "start": 50, "tag": "CellComponent"}, {"end": 68, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 193, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 79, "tag": "ClinicalAttribute"}]}{"id": "1038_8", "text": "No correlation was observed between EV TDP-43 levels with cognition-based variables, sex, and APOE carrier status.", "tags": [{"end": 106, "start": 99, "tag": "CellFunction"}, {"end": 106, "start": 99, "tag": "ManufacturedObject"}, {"end": 106, "start": 99, "tag": "Finding"}, {"end": 38, "start": 36, "tag": "CellComponent"}, {"end": 67, "start": 58, "tag": "BiologicFunction"}, {"end": 113, "start": 107, "tag": "Finding"}, {"end": 98, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 94, "tag": "GeneOrGenome"}, {"end": 88, "start": 85, "tag": "OrganismAttribute"}, {"end": 45, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 52, "start": 39, "tag": "ClinicalAttribute"}, {"end": 98, "start": 94, "tag": "BiologicallyActiveSubstance"}]}{"id": "1038_9", "text": "DiscussionBlood-based EVs, specifically measuring TDP-43 accumulation in ADEVs, may serve as a potential diagnostic tool to rapidly identify subjects who are currently living with LATE-NC.", "tags": [{"end": 120, "start": 105, "tag": "HealthCareActivity"}, {"end": 25, "start": 22, "tag": "CellComponent"}, {"end": 69, "start": 57, "tag": "Finding"}, {"end": 167, "start": 158, "tag": "TemporalConcept"}, {"end": 149, "start": 141, "tag": "PopulationGroup"}, {"end": 56, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 73, "tag": "CellComponent"}, {"end": 15, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1039_0", "text": "Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and polyglutamine diseases are caused by aggregation and abnormal accumulation of the disease-causative proteins in brain and spinal cord.", "tags": [{"end": 124, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 244, "start": 233, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 223, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 148, "tag": "CellFunction"}, {"end": 159, "start": 148, "tag": "ResearchActivity"}, {"end": 133, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 164, "tag": "CellOrMolecularDysfunction"}]}{"id": "1039_1", "text": "Recent studies have suggested that proteins associated with neurodegenerative diseases are secreted and transmitted intercellularly via extracellular vesicles (EVs), which may be involved in propagation of abnormal protein accumulation and progressive degeneration in patient brains.", "tags": [{"end": 264, "start": 240, "tag": "Finding"}, {"end": 264, "start": 252, "tag": "PathologicFunction"}, {"end": 235, "start": 206, "tag": "CellOrMolecularDysfunction"}, {"end": 163, "start": 160, "tag": "CellComponent"}, {"end": 86, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 275, "start": 268, "tag": "PatientOrDisabledGroup"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 43, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 251, "start": 240, "tag": "TemporalConcept"}, {"end": 202, "start": 191, "tag": "Finding"}, {"end": 282, "start": 276, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 222, "start": 215, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 136, "tag": "CellComponent"}]}{"id": "1039_2", "text": "On the other hand, it has been also reported that EVs have neuroprotective roles in these diseases, which potentially contribute to preventing aggregation formation and aberrant accumulation of the disease-associated proteins.", "tags": [{"end": 80, "start": 59, "tag": "CellFunction"}, {"end": 164, "start": 143, "tag": "CellFunction"}, {"end": 53, "start": 50, "tag": "CellComponent"}, {"end": 154, "start": 143, "tag": "CellFunction"}, {"end": 154, "start": 143, "tag": "ResearchActivity"}, {"end": 225, "start": 169, "tag": "CellOrMolecularDysfunction"}]}{"id": "1039_3", "text": "In this review, I summarize the current understanding of the roles of EVs in neurodegenerative diseases, especially focussing on the pathogenic and neuroprotective aspects.", "tags": [{"end": 73, "start": 70, "tag": "CellComponent"}, {"end": 103, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 39, "start": 32, "tag": "TemporalConcept"}, {"end": 53, "start": 40, "tag": "BiologicFunction"}, {"end": 143, "start": 133, "tag": "PathologicFunction"}, {"end": 163, "start": 148, "tag": "CellFunction"}]}{"id": "1039_4", "text": "Elucidation of these two aspects of EVs would provide insight into not only potential therapeutic targets for treatment of neurodegenerative diseases but also development of EV-based biomarkers for disease diagnostics", "tags": [{"end": 105, "start": 76, "tag": "ResearchActivity"}, {"end": 39, "start": 36, "tag": "CellComponent"}, {"end": 176, "start": 174, "tag": "CellComponent"}, {"end": 170, "start": 159, "tag": "BiologicFunction"}, {"end": 170, "start": 159, "tag": "CellFunction"}, {"end": 193, "start": 183, "tag": "ClinicalAttribute"}, {"end": 217, "start": 206, "tag": "HealthCareActivity"}, {"end": 149, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 110, "tag": "HealthCareActivity"}, {"end": 119, "start": 110, "tag": "ResearchActivity"}, {"end": 105, "start": 86, "tag": "ResearchActivity"}]}{"id": "1040_0", "text": "A beta metabolism in the brain is mediated by endocytosis, one part of the intracellular membrane trafficking system.", "tags": [{"end": 17, "start": 7, "tag": "CellFunction"}, {"end": 57, "start": 46, "tag": "CellFunction"}, {"end": 30, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 6, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 7, "tag": "BiologicFunction"}, {"end": 116, "start": 75, "tag": "CellFunction"}]}{"id": "1040_1", "text": "We previously showed that aging attenuates the interaction of dynein with dynactin, which disrupts the endosomal/lysosomal trafficking pathway involved in A beta metabolism, resulting in intracellular accumulation of A beta.", "tags": [{"end": 68, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 162, "tag": "CellFunction"}, {"end": 172, "start": 162, "tag": "BiologicFunction"}, {"end": 200, "start": 187, "tag": "CellComponent"}, {"end": 142, "start": 103, "tag": "CellFunction"}, {"end": 31, "start": 26, "tag": "BiologicFunction"}, {"end": 31, "start": 26, "tag": "CellFunction"}, {"end": 213, "start": 201, "tag": "Finding"}, {"end": 161, "start": 155, "tag": "AminoAcidPeptideOrProtein"}, {"end": 223, "start": 217, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1040_2", "text": "Several studies have shown that in Alzheimer's disease (AD), intraneuronal accumulation of A beta precedes extracellular A beta depositions.", "tags": [{"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 54, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 75, "tag": "Finding"}, {"end": 139, "start": 107, "tag": "CellOrMolecularDysfunction"}, {"end": 74, "start": 61, "tag": "CellComponent"}]}{"id": "1040_3", "text": "However, it is unclear what accounts for this transition from intracellular to extracellular depositions.", "tags": [{"end": 75, "start": 62, "tag": "CellComponent"}, {"end": 104, "start": 79, "tag": "Finding"}]}{"id": "1040_4", "text": "Accumulating evidence suggest that autophagy has an important role in AD pathology, and we observed that autophagy-related protein levels began to decrease before amyloid plaque formation in cynomolgus monkey brains.", "tags": [{"end": 130, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 35, "tag": "CellFunction"}, {"end": 114, "start": 105, "tag": "CellFunction"}, {"end": 187, "start": 163, "tag": "CellOrMolecularDysfunction"}, {"end": 21, "start": 0, "tag": "Finding"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 73, "tag": "PathologicFunction"}, {"end": 82, "start": 73, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 215, "start": 209, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 191, "tag": "Eukaryote"}]}{"id": "1040_5", "text": "Surprisingly, experimental induction of autophagosome formation in Neuro2a cells significantly increased intracellular A beta and decreased extracellular release of A beta, accompanied by the prominent reduction of extracellular vesicle (EV) secretion.", "tags": [{"end": 26, "start": 14, "tag": "ResearchActivity"}, {"end": 53, "start": 40, "tag": "CellComponent"}, {"end": 118, "start": 105, "tag": "CellComponent"}, {"end": 153, "start": 140, "tag": "CellComponent"}, {"end": 251, "start": 242, "tag": "CellFunction"}, {"end": 236, "start": 215, "tag": "CellFunction"}, {"end": 236, "start": 215, "tag": "CellComponent"}, {"end": 211, "start": 202, "tag": "Finding"}, {"end": 211, "start": 202, "tag": "NaturalPhenomenonOrProcess"}, {"end": 80, "start": 67, "tag": "Cell"}, {"end": 240, "start": 238, "tag": "CellComponent"}, {"end": 125, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 165, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1040_6", "text": "RNAi study confirmed that EV secretion affected intracellular and extracellular A beta levels, and siRNA-induced downregulation of autophagosome formation enhanced EV secretion to ameliorate intracellular A beta accumulation induced by dynein knockdown.", "tags": [{"end": 4, "start": 0, "tag": "CellFunction"}, {"end": 61, "start": 48, "tag": "CellComponent"}, {"end": 79, "start": 66, "tag": "CellComponent"}, {"end": 144, "start": 131, "tag": "CellComponent"}, {"end": 204, "start": 191, "tag": "CellComponent"}, {"end": 242, "start": 236, "tag": "AminoAcidPeptideOrProtein"}, {"end": 242, "start": 236, "tag": "BiologicallyActiveSubstance"}, {"end": 252, "start": 243, "tag": "ResearchActivity"}, {"end": 127, "start": 113, "tag": "CellFunction"}, {"end": 10, "start": 0, "tag": "ResearchActivity"}, {"end": 224, "start": 212, "tag": "Finding"}, {"end": 28, "start": 26, "tag": "CellComponent"}, {"end": 166, "start": 164, "tag": "CellComponent"}, {"end": 86, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 205, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 26, "tag": "CellFunction"}, {"end": 93, "start": 80, "tag": "ClinicalAttribute"}, {"end": 104, "start": 99, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 104, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 164, "tag": "CellFunction"}]}{"id": "1040_7", "text": "In aged cynomolgus monkeys, AP levels in EV/intraluminal membrane vesicle (ILV)-rich fractions isolated from temporal lobe parenchyma were drastically increased.", "tags": [{"end": 73, "start": 44, "tag": "CellComponent"}, {"end": 7, "start": 3, "tag": "TemporalConcept"}, {"end": 43, "start": 41, "tag": "CellComponent"}, {"end": 26, "start": 8, "tag": "Eukaryote"}, {"end": 133, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 75, "tag": "CellComponent"}]}{"id": "1040_8", "text": "Moreover, EV/ILV marker proteins overlapped spatially with amyloid plaques.", "tags": [{"end": 74, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 10, "tag": "CellComponent"}, {"end": 23, "start": 17, "tag": "ClinicalAttribute"}, {"end": 16, "start": 13, "tag": "CellComponent"}]}{"id": "1040_9", "text": "These findings suggest that EV would be an important carrier of A beta in brain and abnormal accumulation of A beta in EVs/ILVs may be involved in the transition of age-dependent A beta pathology.", "tags": [{"end": 60, "start": 53, "tag": "CellFunction"}, {"end": 60, "start": 53, "tag": "ManufacturedObject"}, {"end": 168, "start": 165, "tag": "OrganismAttribute"}, {"end": 79, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 119, "tag": "CellComponent"}, {"end": 30, "start": 28, "tag": "CellComponent"}, {"end": 195, "start": 186, "tag": "PathologicFunction"}, {"end": 195, "start": 186, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 70, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 179, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 53, "tag": "Finding"}, {"end": 115, "start": 84, "tag": "PathologicFunction"}, {"end": 127, "start": 123, "tag": "CellComponent"}]}{"id": "1040_10", "text": "(C) 2021 The Author(s).", "tags": []}{"id": "1040_11", "text": "Published by Elsevier Inc.", "tags": []}{"id": "1041_0", "text": "Mesenchymal stromal/stem cells (MSCs) have great capacity for immune regulation.", "tags": [{"end": 57, "start": 49, "tag": "Finding"}, {"end": 30, "start": 20, "tag": "Cell"}, {"end": 36, "start": 32, "tag": "Cell"}, {"end": 19, "start": 0, "tag": "Cell"}, {"end": 79, "start": 62, "tag": "BiologicFunction"}]}{"id": "1041_1", "text": "MSCs provide protective paracrine effects, which are partially exerted by extracellular vesicles (EVs).", "tags": [{"end": 33, "start": 24, "tag": "BiologicFunction"}, {"end": 96, "start": 74, "tag": "CellComponent"}, {"end": 101, "start": 98, "tag": "CellComponent"}, {"end": 4, "start": 0, "tag": "Cell"}, {"end": 41, "start": 34, "tag": "Finding"}]}{"id": "1041_2", "text": "It has been reported that MSCs-derived EVs (MSC-EVs) contain soluble factors, such as cytokines, chemokines, growth factors and even microRNAs, which confer them similar anti-inflammatory and regenerative effects to MSCs.", "tags": [{"end": 68, "start": 61, "tag": "CellComponent"}, {"end": 42, "start": 39, "tag": "CellComponent"}, {"end": 51, "start": 48, "tag": "CellComponent"}, {"end": 95, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 44, "tag": "Cell"}, {"end": 30, "start": 26, "tag": "Cell"}, {"end": 220, "start": 216, "tag": "Cell"}, {"end": 212, "start": 192, "tag": "Finding"}, {"end": 123, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 170, "tag": "BiologicFunction"}, {"end": 187, "start": 170, "tag": "PharmacologicSubstance"}, {"end": 142, "start": 133, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 142, "start": 133, "tag": "BiologicallyActiveSubstance"}]}{"id": "1041_3", "text": "Moreover, MSCs modulate microglia activation through a dual mechanism of action that relies both on cell contact and secreted factors.", "tags": [{"end": 104, "start": 100, "tag": "Cell"}, {"end": 33, "start": 24, "tag": "Cell"}, {"end": 14, "start": 10, "tag": "Cell"}]}{"id": "1041_4", "text": "Microglia cells are the central nervous system immune cells and the main mediators of the inflammation leading to neurodegenerative disorders.", "tags": [{"end": 15, "start": 0, "tag": "Cell"}, {"end": 59, "start": 47, "tag": "Cell"}, {"end": 46, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 90, "tag": "PathologicFunction"}, {"end": 82, "start": 73, "tag": "Finding"}, {"end": 141, "start": 114, "tag": "DiseaseOrSyndrome"}]}{"id": "1041_5", "text": "Here, we investigated whether MSC-EVs affect the activation of microglia cells by beta-amyloid aggregates.", "tags": [{"end": 37, "start": 34, "tag": "CellComponent"}, {"end": 78, "start": 63, "tag": "Cell"}, {"end": 94, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "Cell"}, {"end": 59, "start": 49, "tag": "CellFunction"}]}{"id": "1041_6", "text": "We show that the presence of MSC-EVs can prevent the upregulation of pro-inflammatory mediators such as tumor necrosis factor (TNF)-alpha and nitric oxide (NO).", "tags": [{"end": 154, "start": 142, "tag": "PharmacologicSubstance"}, {"end": 154, "start": 142, "tag": "Chemical"}, {"end": 158, "start": 156, "tag": "PharmacologicSubstance"}, {"end": 158, "start": 156, "tag": "Chemical"}, {"end": 36, "start": 33, "tag": "CellComponent"}, {"end": 85, "start": 69, "tag": "PathologicFunction"}, {"end": 95, "start": 86, "tag": "Finding"}, {"end": 32, "start": 29, "tag": "Cell"}, {"end": 25, "start": 17, "tag": "Finding"}, {"end": 65, "start": 53, "tag": "CellFunction"}, {"end": 137, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 104, "tag": "BiologicallyActiveSubstance"}]}{"id": "1041_7", "text": "Both are upregulated in neurodegenerative diseases representing chronic inflammation, as in Alzheimer's disease.", "tags": [{"end": 84, "start": 64, "tag": "PathologicFunction"}, {"end": 111, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 72, "tag": "PathologicFunction"}, {"end": 71, "start": 64, "tag": "TemporalConcept"}]}{"id": "1041_8", "text": "We demonstrate that MSC-EVs are internalized by the microglia cells.", "tags": [{"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 67, "start": 62, "tag": "Cell"}, {"end": 61, "start": 52, "tag": "Cell"}, {"end": 23, "start": 20, "tag": "Cell"}]}{"id": "1041_9", "text": "Further, our study supports the use of MSC-EVs as a promising therapeutic tool to treat neuroinflammatory diseases.", "tags": [{"end": 114, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 43, "tag": "CellComponent"}, {"end": 18, "start": 13, "tag": "ResearchActivity"}, {"end": 42, "start": 39, "tag": "Cell"}, {"end": 78, "start": 62, "tag": "HealthCareActivity"}]}{"id": "1041_10", "text": "Significance Statement It has been reported that mesenchymal stromal/stem cells and MSC-derived small extracellular vesicles have therapeutic effects in the treatment of various degenerative and inflammatory diseases.", "tags": [{"end": 190, "start": 178, "tag": "PathologicFunction"}, {"end": 124, "start": 102, "tag": "CellComponent"}, {"end": 166, "start": 157, "tag": "HealthCareActivity"}, {"end": 166, "start": 157, "tag": "ResearchActivity"}, {"end": 87, "start": 84, "tag": "Cell"}, {"end": 79, "start": 69, "tag": "Cell"}, {"end": 149, "start": 130, "tag": "Finding"}, {"end": 216, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 96, "tag": "CellComponent"}, {"end": 68, "start": 49, "tag": "Cell"}]}{"id": "1041_11", "text": "Extracellular vesicles are loaded with proteins, lipids and RNA and act as intercellular communication mediators.", "tags": [{"end": 112, "start": 75, "tag": "CellFunction"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 112, "start": 103, "tag": "Finding"}, {"end": 47, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 49, "tag": "Chemical"}, {"end": 63, "start": 60, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1041_12", "text": "Here we show that extracellular vesicles can be taken up by murine microglial cells.", "tags": [{"end": 40, "start": 18, "tag": "CellComponent"}, {"end": 66, "start": 60, "tag": "Eukaryote"}, {"end": 83, "start": 67, "tag": "Cell"}]}{"id": "1041_13", "text": "In addition, they partially reduce the activation of microglial cells against beta-amyloid aggregates.", "tags": [{"end": 90, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 53, "tag": "Cell"}]}{"id": "1041_14", "text": "This inhibition of microglia activation may present an effective strategy for the control/therapy of neurodegenerative diseases such as Alzheimer's disease.", "tags": [{"end": 155, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 19, "tag": "Cell"}, {"end": 15, "start": 5, "tag": "CellFunction"}, {"end": 97, "start": 90, "tag": "HealthCareActivity"}, {"end": 39, "start": 29, "tag": "CellFunction"}]}{"id": "1042_0", "text": "The pathogenesis of Alzheimer's disease (AD) remains unknown till today, hindering the research and development of AD therapeutics and diagnostics.", "tags": [{"end": 39, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 87, "tag": "ResearchActivity"}, {"end": 111, "start": 100, "tag": "BiologicFunction"}, {"end": 111, "start": 100, "tag": "CellFunction"}, {"end": 146, "start": 135, "tag": "HealthCareActivity"}, {"end": 130, "start": 118, "tag": "HealthCareActivity"}, {"end": 16, "start": 4, "tag": "PathologicFunction"}]}{"id": "1042_1", "text": "Circulating extracellular vesicles (EVs) can be utilized as a new window to spy upon AD pathogenesis.", "tags": [{"end": 72, "start": 66, "tag": "TemporalConcept"}, {"end": 34, "start": 0, "tag": "CellComponent"}, {"end": 39, "start": 36, "tag": "CellComponent"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 88, "tag": "PathologicFunction"}]}{"id": "1042_2", "text": "Altered microRNA profiles were noted in both the cerebrospinal fluid (CSF)- and blood-isolated EVs of AD patients, implying the outstanding potential of circulating EV-containing miRNAs (CEmiRs) to serve as important regulators in AD pathogenesis.", "tags": [{"end": 16, "start": 8, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 16, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 95, "tag": "CellComponent"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 233, "start": 231, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 153, "tag": "CellComponent"}, {"end": 113, "start": 105, "tag": "PatientOrDisabledGroup"}, {"end": 73, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 179, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 185, "start": 179, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 17, "tag": "ResearchActivity"}, {"end": 246, "start": 234, "tag": "PathologicFunction"}, {"end": 193, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 193, "start": 187, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1042_3", "text": "Although several CEmiRs were found to play a part in AD, the association of globally altered miRNA profiles in patients' serum-derived EVs with AD pathogenesis remains unclear.", "tags": [{"end": 138, "start": 135, "tag": "CellComponent"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 111, "tag": "PatientOrDisabledGroup"}, {"end": 107, "start": 99, "tag": "ResearchActivity"}, {"end": 126, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 93, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 98, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 147, "tag": "PathologicFunction"}, {"end": 23, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 17, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1042_4", "text": "In this study, we first investigated the miRNA profile in serum-derived EVs from AD, mild cognitive impairment (MCI) patients, and healthy individuals.", "tags": [{"end": 115, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 72, "tag": "CellComponent"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 131, "tag": "OrganismAttribute"}, {"end": 125, "start": 117, "tag": "PatientOrDisabledGroup"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 23, "start": 18, "tag": "TemporalConcept"}, {"end": 63, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 41, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 46, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 139, "tag": "PopulationGroup"}, {"end": 110, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 47, "tag": "ResearchActivity"}]}{"id": "1042_5", "text": "We observed differential expression patterns of CEmiRs and classified them into 10 clusters.", "tags": [{"end": 44, "start": 36, "tag": "ResearchActivity"}, {"end": 35, "start": 25, "tag": "CellFunction"}, {"end": 54, "start": 48, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 54, "start": 48, "tag": "BiologicallyActiveSubstance"}]}{"id": "1042_6", "text": "We identified the predicted targets of these differentially expressed CEmiRs (DECEmiRs) and analyzed their biological functions and interactions.", "tags": [{"end": 100, "start": 92, "tag": "ResearchActivity"}, {"end": 69, "start": 45, "tag": "Finding"}, {"end": 144, "start": 132, "tag": "Finding"}, {"end": 127, "start": 107, "tag": "BiologicFunction"}, {"end": 76, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 70, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1042_7", "text": "Our study revealed the temporal regulation of complex and precise signaling networks on AD pathogenesis, shedding light on the development of novel therapeutic strategies, including multi-target drug combination for AD treatment.", "tags": [{"end": 84, "start": 66, "tag": "CellFunction"}, {"end": 90, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 218, "start": 216, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 138, "start": 127, "tag": "BiologicFunction"}, {"end": 138, "start": 127, "tag": "CellFunction"}, {"end": 228, "start": 219, "tag": "HealthCareActivity"}, {"end": 228, "start": 219, "tag": "ResearchActivity"}, {"end": 103, "start": 91, "tag": "PathologicFunction"}, {"end": 170, "start": 160, "tag": "ResearchActivity"}, {"end": 170, "start": 160, "tag": "BiologicFunction"}, {"end": 199, "start": 195, "tag": "PharmacologicSubstance"}, {"end": 170, "start": 148, "tag": "HealthCareActivity"}]}{"id": "1043_0", "text": "Alzheimer's disease (AD) is a common neurodegenerative disorder with progressive cognitive impairment in the elderly.", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 69, "tag": "TemporalConcept"}, {"end": 101, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 109, "tag": "PopulationGroup"}]}{"id": "1043_1", "text": "Beta-amyloid (A beta) formation and its accumulation in the brain constitute one of the pathological hallmarks of AD.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 88, "tag": "Finding"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 40, "tag": "Finding"}, {"end": 20, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 22, "tag": "CellFunction"}, {"end": 12, "start": 0, "tag": "CellFunction"}]}{"id": "1043_2", "text": "Until now, how to modulate A beta formation in hippocampal neurons remains a big challenge.", "tags": [{"end": 90, "start": 81, "tag": "HealthCareActivity"}, {"end": 33, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 47, "tag": "Cell"}, {"end": 43, "start": 27, "tag": "CellFunction"}]}{"id": "1043_3", "text": "Herein, we investigated whether the exosomal transfer of microRNA (miR) relates to amyloid pathology in the recipient neuron cells.", "tags": [{"end": 70, "start": 67, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 108, "tag": "PopulationGroup"}, {"end": 65, "start": 57, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 65, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 83, "tag": "PathologicFunction"}, {"end": 130, "start": 118, "tag": "Cell"}, {"end": 53, "start": 36, "tag": "CellFunction"}]}{"id": "1043_4", "text": "We isolated circulating small extracellular vesicles (sEVs) from AD patients and healthy controls, determined the miR-342-5p level in the sEVs by RT-PCR, and evaluated its diagnostic performance in AD.", "tags": [{"end": 152, "start": 146, "tag": "ResearchActivity"}, {"end": 97, "start": 81, "tag": "PopulationGroup"}, {"end": 52, "start": 30, "tag": "CellComponent"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 198, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 68, "tag": "PatientOrDisabledGroup"}, {"end": 194, "start": 172, "tag": "Finding"}, {"end": 52, "start": 12, "tag": "CellComponent"}, {"end": 58, "start": 54, "tag": "CellComponent"}, {"end": 142, "start": 138, "tag": "CellComponent"}, {"end": 124, "start": 114, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 124, "start": 114, "tag": "BiologicallyActiveSubstance"}]}{"id": "1043_5", "text": "Then, we took advantage of biomolecular assays to estimate the role of miR-342-5p in modulating the amyloid pathway, including amyloid precursor protein (APP), beta-site APP cleaving enzyme 1 (BACE1), and A beta 42.", "tags": [{"end": 198, "start": 193, "tag": "GeneOrGenome"}, {"end": 198, "start": 193, "tag": "AminoAcidPeptideOrProtein"}, {"end": 198, "start": 193, "tag": "BiologicallyActiveSubstance"}, {"end": 214, "start": 205, "tag": "AminoAcidPeptideOrProtein"}, {"end": 214, "start": 205, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 27, "tag": "ResearchActivity"}, {"end": 157, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 154, "tag": "GeneOrGenome"}, {"end": 157, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 108, "tag": "CellFunction"}, {"end": 152, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 71, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 191, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 160, "tag": "BiologicallyActiveSubstance"}]}{"id": "1043_6", "text": "Furthermore, we subjected HT22 cells to the sEVs from the hippocampal tissues of transgenic APP mice (Exo-APP) or C57BL/6 littermates (Exo-CTL), and the Exo-APP enriched with miR-342-5p mimics or the control to assess the effect of the sEVs' delivery of miR-342-5p on A beta formation.", "tags": [{"end": 192, "start": 186, "tag": "HealthCareActivity"}, {"end": 192, "start": 186, "tag": "Chemical"}, {"end": 77, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 92, "tag": "GeneOrGenome"}, {"end": 109, "start": 106, "tag": "GeneOrGenome"}, {"end": 160, "start": 157, "tag": "GeneOrGenome"}, {"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 96, "tag": "Eukaryote"}, {"end": 228, "start": 222, "tag": "Finding"}, {"end": 36, "start": 26, "tag": "Cell"}, {"end": 274, "start": 268, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 139, "tag": "Cell"}, {"end": 48, "start": 44, "tag": "CellComponent"}, {"end": 240, "start": 236, "tag": "CellComponent"}, {"end": 250, "start": 242, "tag": "BiologicFunction"}, {"end": 100, "start": 81, "tag": "ExperimentalModelOfDisease"}, {"end": 133, "start": 114, "tag": "Eukaryote"}, {"end": 185, "start": 175, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 185, "start": 175, "tag": "BiologicallyActiveSubstance"}, {"end": 264, "start": 254, "tag": "BiologicallyActiveSubstance"}, {"end": 264, "start": 254, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 284, "start": 268, "tag": "CellFunction"}]}{"id": "1043_7", "text": "We observed a lower level of miR-342-5p in the circulating sEVs from AD patients compared with healthy controls.", "tags": [{"end": 111, "start": 95, "tag": "PopulationGroup"}, {"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 95, "tag": "OrganismAttribute"}, {"end": 80, "start": 72, "tag": "PatientOrDisabledGroup"}, {"end": 63, "start": 59, "tag": "CellComponent"}, {"end": 39, "start": 29, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 39, "start": 29, "tag": "BiologicallyActiveSubstance"}]}{"id": "1043_8", "text": "MiR-342-5p participated in A beta formation by modulating BACE1 expression, specifically binding its 3 '-untranslated region (UTR) sequence.", "tags": [{"end": 63, "start": 58, "tag": "GeneOrGenome"}, {"end": 63, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 64, "tag": "CellFunction"}, {"end": 33, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 89, "tag": "CellFunction"}, {"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 43, "start": 27, "tag": "CellFunction"}, {"end": 139, "start": 131, "tag": "MolecularSequence"}, {"end": 124, "start": 101, "tag": "MolecularSequence"}, {"end": 129, "start": 126, "tag": "MolecularSequence"}]}{"id": "1043_9", "text": "Exo-APP distinctly promoted A beta 42 formation in the recipient cells compared to Exo-CTL.", "tags": [{"end": 37, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 4, "tag": "GeneOrGenome"}, {"end": 7, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 87, "tag": "Cell"}, {"end": 70, "start": 55, "tag": "Cell"}, {"end": 47, "start": 28, "tag": "CellFunction"}]}{"id": "1043_10", "text": "Intriguingly, miR-342-5p enrichment in Exo-APP ameliorated amyloid pathology in the recipient cells.", "tags": [{"end": 76, "start": 59, "tag": "PathologicFunction"}, {"end": 35, "start": 25, "tag": "ResearchActivity"}, {"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 43, "tag": "GeneOrGenome"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 84, "tag": "Cell"}, {"end": 24, "start": 14, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 24, "start": 14, "tag": "BiologicallyActiveSubstance"}]}{"id": "1043_11", "text": "Our study indicated that miR-342-5p was dysregulated in human circulating sEVs from AD patients; sEV transfer of miR-342-5p ameliorates A beta formation by modulating BACE1 expression.", "tags": [{"end": 172, "start": 167, "tag": "GeneOrGenome"}, {"end": 172, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 87, "tag": "PatientOrDisabledGroup"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 61, "start": 56, "tag": "Eukaryote"}, {"end": 52, "start": 40, "tag": "PathologicFunction"}, {"end": 183, "start": 173, "tag": "CellFunction"}, {"end": 142, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 74, "tag": "CellComponent"}, {"end": 100, "start": 97, "tag": "CellComponent"}, {"end": 35, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 25, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 123, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 113, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 152, "start": 136, "tag": "CellFunction"}]}{"id": "1043_12", "text": "These findings highlight the promising potential of exosomal miRNAs in AD clinical therapy.", "tags": [{"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 61, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 67, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 83, "tag": "HealthCareActivity"}, {"end": 60, "start": 52, "tag": "CellComponent"}, {"end": 90, "start": 74, "tag": "HealthCareActivity"}]}{"id": "1044_0", "text": "Extracellular vesicles (EVs) are small bilipid layer-enclosed vesicles that can be secreted by all tested types of brain cells.", "tags": [{"end": 126, "start": 115, "tag": "Cell"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 70, "start": 62, "tag": "CellComponent"}, {"end": 52, "start": 33, "tag": "CellComponent"}]}{"id": "1044_1", "text": "Being a key intercellular communicator, EVs have emerged as a key contributor to the pathogenesis of various neurodegenerative diseases (NDs) including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease through delivery of bioactive cargos within the central nervous system (CNS).", "tags": [{"end": 249, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 40, "tag": "CellComponent"}, {"end": 320, "start": 298, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 325, "start": 322, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 85, "tag": "PathologicFunction"}, {"end": 223, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 286, "start": 270, "tag": "CellFunction"}, {"end": 140, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 266, "start": 258, "tag": "BiologicFunction"}, {"end": 38, "start": 12, "tag": "Finding"}]}{"id": "1044_2", "text": "Importantly, CNS cell-derived EVs can be purified via immunoprecipitation, and EV cargos with altered levels have been identified as potential biomarkers for the diagnosis and prognosis of NDs.", "tags": [{"end": 33, "start": 30, "tag": "CellComponent"}, {"end": 81, "start": 79, "tag": "CellComponent"}, {"end": 16, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 143, "tag": "ClinicalAttribute"}, {"end": 171, "start": 162, "tag": "HealthCareActivity"}, {"end": 21, "start": 17, "tag": "Cell"}, {"end": 73, "start": 54, "tag": "ResearchActivity"}, {"end": 88, "start": 82, "tag": "CellFunction"}, {"end": 129, "start": 119, "tag": "Finding"}, {"end": 153, "start": 133, "tag": "ClinicalAttribute"}, {"end": 192, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 176, "tag": "HealthCareActivity"}]}{"id": "1044_3", "text": "Given the essential impact of EVs on the pathogenesis of NDs, pathological EVs have been considered as therapeutic targets and EVs with therapeutic effects have been utilized as potential therapeutic agents or drug delivery platforms for the treatment of NDs.", "tags": [{"end": 206, "start": 188, "tag": "HealthCareActivity"}, {"end": 33, "start": 30, "tag": "CellComponent"}, {"end": 78, "start": 75, "tag": "CellComponent"}, {"end": 130, "start": 127, "tag": "CellComponent"}, {"end": 251, "start": 242, "tag": "HealthCareActivity"}, {"end": 251, "start": 242, "tag": "ResearchActivity"}, {"end": 122, "start": 103, "tag": "ResearchActivity"}, {"end": 53, "start": 41, "tag": "PathologicFunction"}, {"end": 155, "start": 136, "tag": "Finding"}, {"end": 214, "start": 210, "tag": "PharmacologicSubstance"}, {"end": 60, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 258, "start": 255, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 215, "tag": "BiologicFunction"}, {"end": 223, "start": 210, "tag": "HealthCareActivity"}]}{"id": "1044_4", "text": "In this review, we focus on recent research progress on the pathological roles of EVs released from CNS cells in the pathogenesis of NDs, summarize findings that identify CNS-derived EV cargos as potential biomarkers to diagnose NDs, and comprehensively discuss promising potential of EVs as therapeutic targets, agents, and drug delivery systems in treating NDs, together with current concerns and challenges for basic research and clinical applications of EVs regarding NDs.", "tags": [{"end": 228, "start": 220, "tag": "HealthCareActivity"}, {"end": 346, "start": 325, "tag": "ManufacturedObject"}, {"end": 52, "start": 44, "tag": "TemporalConcept"}, {"end": 454, "start": 433, "tag": "HealthCareActivity"}, {"end": 85, "start": 82, "tag": "CellComponent"}, {"end": 288, "start": 285, "tag": "CellComponent"}, {"end": 461, "start": 458, "tag": "CellComponent"}, {"end": 185, "start": 183, "tag": "CellComponent"}, {"end": 103, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 35, "tag": "ResearchActivity"}, {"end": 428, "start": 420, "tag": "ResearchActivity"}, {"end": 216, "start": 206, "tag": "ClinicalAttribute"}, {"end": 109, "start": 104, "tag": "Cell"}, {"end": 409, "start": 399, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 311, "start": 292, "tag": "ResearchActivity"}, {"end": 385, "start": 378, "tag": "TemporalConcept"}, {"end": 129, "start": 117, "tag": "PathologicFunction"}, {"end": 192, "start": 186, "tag": "CellFunction"}, {"end": 34, "start": 28, "tag": "TemporalConcept"}, {"end": 216, "start": 196, "tag": "ClinicalAttribute"}, {"end": 329, "start": 325, "tag": "PharmacologicSubstance"}, {"end": 78, "start": 60, "tag": "PathologicFunction"}, {"end": 136, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 232, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 362, "start": 359, "tag": "DiseaseOrSyndrome"}, {"end": 475, "start": 472, "tag": "DiseaseOrSyndrome"}, {"end": 338, "start": 330, "tag": "BiologicFunction"}, {"end": 338, "start": 325, "tag": "HealthCareActivity"}, {"end": 319, "start": 313, "tag": "HealthCareActivity"}, {"end": 303, "start": 292, "tag": "HealthCareActivity"}]}{"id": "1045_0", "text": "IntroductionExtracellular vesicles (EVs) may propagate and modulate Alzheimer's disease (AD) pathology.", "tags": [{"end": 87, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 36, "tag": "CellComponent"}, {"end": 91, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 93, "tag": "PathologicFunction"}, {"end": 102, "start": 93, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 34, "start": 12, "tag": "CellComponent"}]}{"id": "1045_1", "text": "We aimed to comprehensively characterize the proteome of cerebrospinal fluid (CSF) EVs to identify proteins and pathways altered in AD.", "tags": [{"end": 86, "start": 83, "tag": "CellComponent"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 112, "tag": "CellFunction"}]}{"id": "1045_2", "text": "MethodsCSF EVs were isolated by ultracentrifugation (Cohort 1) or Vn96 peptide (Cohort 2) from non-neurodegenerative controls (n = 15, 16) and AD patients (n = 22, 20, respectively).", "tags": [{"end": 51, "start": 32, "tag": "ResearchActivity"}, {"end": 61, "start": 53, "tag": "PopulationGroup"}, {"end": 88, "start": 80, "tag": "PopulationGroup"}, {"end": 14, "start": 11, "tag": "CellComponent"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 146, "tag": "PatientOrDisabledGroup"}, {"end": 125, "start": 117, "tag": "PopulationGroup"}, {"end": 116, "start": 99, "tag": "CellOrMolecularDysfunction"}, {"end": 78, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1045_3", "text": "EVs were subjected to untargeted quantitative mass spectrometry-based proteomics.", "tags": [{"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 80, "start": 22, "tag": "ResearchActivity"}]}{"id": "1045_4", "text": "Results were validated by enzyme-linked immunosorbent assay (ELISA) in Cohorts 3 and 4, consisting of controls (n = 16, n = 43, (Cohort3, Cohort4)), and patients with AD (n = 24, n = 100).", "tags": [{"end": 59, "start": 26, "tag": "ResearchActivity"}, {"end": 80, "start": 71, "tag": "PopulationGroup"}, {"end": 169, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 153, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 110, "start": 102, "tag": "PopulationGroup"}, {"end": 66, "start": 61, "tag": "ResearchActivity"}, {"end": 136, "start": 129, "tag": "PopulationGroup"}, {"end": 145, "start": 138, "tag": "PopulationGroup"}]}{"id": "1045_5", "text": "ResultsWe found > 30 differentially expressed proteins in AD CSF EVs involved in immune-regulation.", "tags": [{"end": 68, "start": 65, "tag": "CellComponent"}, {"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 21, "tag": "Finding"}, {"end": 45, "start": 36, "tag": "CellFunction"}, {"end": 98, "start": 81, "tag": "BiologicFunction"}]}{"id": "1045_6", "text": "Increase of C1q levels in AD compared to non-demented controls was validated by ELISA (similar to 1.5 fold, p (Cohort 3) = 0.03, p (Cohort 4) = 0.005).", "tags": [{"end": 8, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 132, "tag": "PopulationGroup"}, {"end": 28, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 41, "tag": "PopulationGroup"}, {"end": 85, "start": 80, "tag": "ResearchActivity"}, {"end": 119, "start": 111, "tag": "PopulationGroup"}, {"end": 22, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1045_7", "text": "DiscussionEVs may be utilized as a potential biomarker and may play a so far unprecedented role in immune-regulation in AD.", "tags": [{"end": 54, "start": 35, "tag": "ClinicalAttribute"}, {"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 45, "tag": "ClinicalAttribute"}, {"end": 13, "start": 10, "tag": "CellComponent"}, {"end": 116, "start": 99, "tag": "BiologicFunction"}]}{"id": "1046_0", "text": "Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB) are the three major neurodegenerative dementias.", "tags": [{"end": 140, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 75, "tag": "CellComponent"}, {"end": 54, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 113, "tag": "DiseaseOrSyndrome"}]}{"id": "1046_1", "text": "In this study, we provide evidence that an alteration in extracellular vesicles (EVs) release is common across the three most common neurodegenerative dementias, AD, DLB, and FTD.", "tags": [{"end": 53, "start": 43, "tag": "Finding"}, {"end": 160, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 57, "tag": "CellComponent"}, {"end": 84, "start": 81, "tag": "CellComponent"}, {"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 34, "start": 26, "tag": "Finding"}, {"end": 169, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 86, "tag": "HealthCareActivity"}, {"end": 93, "start": 86, "tag": "ResearchActivity"}]}{"id": "1046_2", "text": "Specifically, we analyzed plasma EVs in three groups of patients affected by AD, DLB, and FTD, and we found a significant reduction in EVs concentration and larger EVs size in all patient groups.", "tags": [{"end": 131, "start": 110, "tag": "Finding"}, {"end": 36, "start": 33, "tag": "CellComponent"}, {"end": 138, "start": 135, "tag": "CellComponent"}, {"end": 167, "start": 164, "tag": "CellComponent"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 56, "tag": "PatientOrDisabledGroup"}, {"end": 32, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 187, "start": 180, "tag": "PatientOrDisabledGroup"}, {"end": 25, "start": 17, "tag": "ResearchActivity"}, {"end": 172, "start": 168, "tag": "OrganismAttribute"}, {"end": 84, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 139, "tag": "BiologicFunction"}]}{"id": "1046_3", "text": "We then investigated whether the loss of neurotrophic factors is also a common pathogenic mechanism among FTD, DLB, and AD, and if levels of neurotrophic factors might affect EVs release.", "tags": [{"end": 178, "start": 175, "tag": "CellComponent"}, {"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 79, "tag": "PathologicFunction"}, {"end": 114, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 33, "tag": "Finding"}, {"end": 186, "start": 175, "tag": "CellFunction"}]}{"id": "1046_4", "text": "Plasma levels of progranulin and cystatin C (CysC) were partially altered; however, taking together all variables significantly associated with the diagnostic groups only EVs size and concentration were able to distinguish patients from controls.", "tags": [{"end": 49, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 45, "tag": "PharmacologicSubstance"}, {"end": 174, "start": 171, "tag": "CellComponent"}, {"end": 231, "start": 223, "tag": "PatientOrDisabledGroup"}, {"end": 245, "start": 237, "tag": "PopulationGroup"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 175, "tag": "OrganismAttribute"}, {"end": 43, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 33, "tag": "PharmacologicSubstance"}, {"end": 28, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 197, "start": 184, "tag": "BiologicFunction"}, {"end": 28, "start": 0, "tag": "ClinicalAttribute"}, {"end": 43, "start": 33, "tag": "ClinicalAttribute"}, {"end": 16, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1046_5", "text": "The diagnostic performance of these two EVs parameters together (ratio) was high, with a sensitivity of 83.3% and a specificity of 86.7%, able to distinguish patients from controls but not to differentiate the different forms of dementias.", "tags": [{"end": 205, "start": 192, "tag": "CellFunction"}, {"end": 238, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 40, "tag": "CellComponent"}, {"end": 166, "start": 158, "tag": "PatientOrDisabledGroup"}, {"end": 180, "start": 172, "tag": "PopulationGroup"}, {"end": 127, "start": 116, "tag": "Finding"}, {"end": 80, "start": 76, "tag": "Finding"}, {"end": 100, "start": 89, "tag": "Finding"}, {"end": 26, "start": 4, "tag": "HealthCareActivity"}]}{"id": "1046_6", "text": "Among the candidate neurotrophic factors, only CysC levels were associated with EVs concentration.", "tags": [{"end": 51, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 47, "tag": "PharmacologicSubstance"}, {"end": 83, "start": 80, "tag": "CellComponent"}, {"end": 97, "start": 84, "tag": "BiologicFunction"}, {"end": 40, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 47, "tag": "ClinicalAttribute"}]}{"id": "1046_7", "text": "Our study suggests that an alteration in the intercellular communication mediated by EVs might be a common molecular pathway underlying neurodegenerative dementias.", "tags": [{"end": 124, "start": 107, "tag": "CellFunction"}, {"end": 37, "start": 27, "tag": "Finding"}, {"end": 88, "start": 85, "tag": "CellComponent"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 72, "start": 45, "tag": "CellFunction"}, {"end": 163, "start": 136, "tag": "DiseaseOrSyndrome"}]}{"id": "1046_8", "text": "The identification of shared disease mechanisms is of pivotal importance to develop treatments to delay disease progression.", "tags": [{"end": 47, "start": 29, "tag": "ResearchActivity"}, {"end": 103, "start": 98, "tag": "TemporalConcept"}, {"end": 94, "start": 84, "tag": "HealthCareActivity"}, {"end": 94, "start": 84, "tag": "ResearchActivity"}, {"end": 123, "start": 104, "tag": "PathologicFunction"}]}{"id": "1046_9", "text": "To this aim, further studies investigating plasma EVs size and concentration as early biomarkers of dementia are required.", "tags": [{"end": 53, "start": 50, "tag": "CellComponent"}, {"end": 108, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 86, "tag": "ClinicalAttribute"}, {"end": 28, "start": 21, "tag": "ResearchActivity"}, {"end": 58, "start": 54, "tag": "OrganismAttribute"}, {"end": 76, "start": 63, "tag": "ClinicalAttribute"}, {"end": 53, "start": 43, "tag": "ClinicalAttribute"}, {"end": 58, "start": 43, "tag": "ClinicalAttribute"}]}{"id": "1047_0", "text": "Recent research demonstrated pathological spreading of the disease-causing proteins from one focal point across other brain regions for some neurodegenerative diseases, such as Parkinson's and Alzheimer's disease.", "tags": [{"end": 66, "start": 42, "tag": "Finding"}, {"end": 212, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 7, "tag": "ResearchActivity"}, {"end": 167, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 83, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1047_1", "text": "Spreading mediated by extracellular vesicles is one of the proposed disease-spreading mechanisms.", "tags": [{"end": 44, "start": 22, "tag": "CellComponent"}]}{"id": "1047_2", "text": "Extracellular vesicles are cell membrane-derived vesicles, used by cells for cell-to-cell communication and excretion of toxic components.", "tags": [{"end": 117, "start": 108, "tag": "BiologicFunction"}, {"end": 57, "start": 27, "tag": "CellComponent"}, {"end": 72, "start": 67, "tag": "Cell"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 126, "start": 121, "tag": "InjuryOrPoisoning"}, {"end": 103, "start": 77, "tag": "CellFunction"}, {"end": 103, "start": 90, "tag": "HealthCareActivity"}, {"end": 103, "start": 90, "tag": "CellFunction"}, {"end": 137, "start": 127, "tag": "CellComponent"}, {"end": 103, "start": 85, "tag": "CellFunction"}]}{"id": "1047_3", "text": "Importantly, extracellular vesicles carrying pathological molecules, when internalized by healthy  cells, may trigger pathological pathways and, consequently, promote disease spreading to neighboring cells.", "tags": [{"end": 199, "start": 188, "tag": "PopulationGroup"}, {"end": 35, "start": 13, "tag": "CellComponent"}, {"end": 97, "start": 90, "tag": "OrganismAttribute"}, {"end": 104, "start": 99, "tag": "Cell"}, {"end": 205, "start": 200, "tag": "Cell"}, {"end": 139, "start": 131, "tag": "CellFunction"}, {"end": 67, "start": 58, "tag": "Substance"}, {"end": 184, "start": 167, "tag": "PathologicFunction"}, {"end": 57, "start": 45, "tag": "PathologicFunction"}]}{"id": "1047_4", "text": "Polyglutamine diseases are a group of genetic neurodegenerative disorders characterized by the accumulation of mutant misfolded proteins carrying an expanded tract of glutamines, including Huntington's and Machado-Joseph disease.", "tags": [{"end": 73, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 228, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 118, "tag": "CellOrMolecularDysfunction"}, {"end": 13, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 95, "tag": "Finding"}, {"end": 136, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 111, "tag": "CellOrMolecularDysfunction"}, {"end": 136, "start": 118, "tag": "CellOrMolecularDysfunction"}, {"end": 22, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 149, "tag": "CellOrMolecularDysfunction"}, {"end": 201, "start": 189, "tag": "DiseaseOrSyndrome"}]}{"id": "1047_5", "text": "The pathological spread of the misfolded proteins or the corresponding mutant mRNA has been explored.", "tags": [{"end": 40, "start": 31, "tag": "CellOrMolecularDysfunction"}, {"end": 49, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 78, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 77, "start": 71, "tag": "CellOrMolecularDysfunction"}, {"end": 49, "start": 31, "tag": "CellOrMolecularDysfunction"}, {"end": 82, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 4, "tag": "PathologicFunction"}]}{"id": "1047_6", "text": "The understanding of the disease-spreading mechanism that plays a key role in the pathology progression of these diseases can result in the development of effective therapeutic approaches to stop disease progression, arresting the spread of the toxic components and disease aggravation.", "tags": [{"end": 285, "start": 266, "tag": "Finding"}, {"end": 91, "start": 82, "tag": "PathologicFunction"}, {"end": 91, "start": 82, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 151, "start": 140, "tag": "BiologicFunction"}, {"end": 151, "start": 140, "tag": "CellFunction"}, {"end": 103, "start": 92, "tag": "PathologicFunction"}, {"end": 215, "start": 204, "tag": "PathologicFunction"}, {"end": 103, "start": 92, "tag": "TemporalConcept"}, {"end": 215, "start": 204, "tag": "TemporalConcept"}, {"end": 250, "start": 245, "tag": "InjuryOrPoisoning"}, {"end": 17, "start": 4, "tag": "BiologicFunction"}, {"end": 215, "start": 196, "tag": "PathologicFunction"}, {"end": 261, "start": 251, "tag": "CellComponent"}, {"end": 187, "start": 165, "tag": "HealthCareActivity"}, {"end": 52, "start": 25, "tag": "PathologicFunction"}]}{"id": "1047_7", "text": "Therefore, the present review's main focus is the disease-spreading mechanisms with emphasis on polyglutamine diseases and the putative role played by extracellular vesicles in this process.", "tags": [{"end": 109, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 151, "tag": "CellComponent"}, {"end": 29, "start": 23, "tag": "ResearchActivity"}, {"end": 29, "start": 23, "tag": "HealthCareActivity"}, {"end": 78, "start": 50, "tag": "PathologicFunction"}, {"end": 118, "start": 96, "tag": "DiseaseOrSyndrome"}]}{"id": "1048_0", "text": "Background: Plasma neuronal-derived extracellular vesicles (NDEV) contain proteins of pathological, diagnostic, and therapeutic relevance.", "tags": [{"end": 82, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 36, "tag": "CellComponent"}, {"end": 27, "start": 19, "tag": "Cell"}, {"end": 18, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 60, "tag": "CellComponent"}]}{"id": "1048_1", "text": "Objective: We investigated the associations of six plasma NDEV markers with Alzheimer's disease (AD) severity, cognition and functioning, and changes in these biomarkers after Cerebrolysin (R), donepezil, and a combination therapy in AD.", "tags": [{"end": 188, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 190, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 190, "tag": "CellOrMolecularDysfunction"}, {"end": 191, "start": 190, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 203, "start": 194, "tag": "Chemical"}, {"end": 109, "start": 101, "tag": "ClinicalAttribute"}, {"end": 109, "start": 101, "tag": "Finding"}, {"end": 230, "start": 211, "tag": "HealthCareActivity"}, {"end": 120, "start": 111, "tag": "BiologicFunction"}, {"end": 203, "start": 194, "tag": "PharmacologicSubstance"}, {"end": 95, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 236, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 63, "tag": "ClinicalAttribute"}, {"end": 169, "start": 159, "tag": "ClinicalAttribute"}, {"end": 230, "start": 223, "tag": "HealthCareActivity"}, {"end": 57, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 58, "tag": "CellComponent"}]}{"id": "1048_2", "text": "Methods: Plasma NDEV levels of A beta(42), total tau, P-T181-tau, P-S393-tau, neurogranin, and REST were determined in: 1) 116 mild to advanced AD patients and in 20 control subjects; 2) 110 AD patients treated with Cerebrolysin (R), donepezil, or combination therapy in a randomized clinical trial (RCT).", "tags": [{"end": 89, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 78, "tag": "GeneOrGenome"}, {"end": 99, "start": 95, "tag": "GeneOrGenome"}, {"end": 99, "start": 95, "tag": "CellFunction"}, {"end": 131, "start": 127, "tag": "Finding"}, {"end": 228, "start": 216, "tag": "AminoAcidPeptideOrProtein"}, {"end": 231, "start": 230, "tag": "AminoAcidPeptideOrProtein"}, {"end": 231, "start": 230, "tag": "CellOrMolecularDysfunction"}, {"end": 231, "start": 230, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 243, "start": 234, "tag": "Chemical"}, {"end": 298, "start": 273, "tag": "ResearchActivity"}, {"end": 303, "start": 300, "tag": "ResearchActivity"}, {"end": 298, "start": 284, "tag": "ResearchActivity"}, {"end": 267, "start": 248, "tag": "HealthCareActivity"}, {"end": 182, "start": 166, "tag": "PopulationGroup"}, {"end": 182, "start": 174, "tag": "PopulationGroup"}, {"end": 243, "start": 234, "tag": "PharmacologicSubstance"}, {"end": 146, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 147, "tag": "PatientOrDisabledGroup"}, {"end": 202, "start": 194, "tag": "PatientOrDisabledGroup"}, {"end": 52, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 267, "start": 260, "tag": "HealthCareActivity"}, {"end": 215, "start": 203, "tag": "HealthCareActivity"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 9, "tag": "ClinicalAttribute"}]}{"id": "1048_3", "text": "Samples for NDEV determinations were obtained at baseline in the NDEV study and at baseline and study endpoint in the RCT.", "tags": [{"end": 121, "start": 118, "tag": "ResearchActivity"}, {"end": 75, "start": 70, "tag": "ResearchActivity"}, {"end": 101, "start": 96, "tag": "ResearchActivity"}]}{"id": "1048_4", "text": "Cognition and functioning were assessed at the same time points.", "tags": [{"end": 9, "start": 0, "tag": "BiologicFunction"}, {"end": 63, "start": 52, "tag": "TemporalConcept"}, {"end": 56, "start": 52, "tag": "TemporalConcept"}]}{"id": "1048_5", "text": "Results: NDEV levels of A beta(42), total tau, P-T181-tau, and P-S393-tau were higher and those of neurogranin and REST were lower in mild-to-moderate AD than in controls (p < 0.05 to p < 0.001).", "tags": [{"end": 110, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 99, "tag": "GeneOrGenome"}, {"end": 119, "start": 115, "tag": "GeneOrGenome"}, {"end": 119, "start": 115, "tag": "CellFunction"}, {"end": 170, "start": 162, "tag": "PopulationGroup"}, {"end": 150, "start": 142, "tag": "Finding"}, {"end": 153, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 13, "start": 9, "tag": "CellComponent"}, {"end": 34, "start": 9, "tag": "ClinicalAttribute"}]}{"id": "1048_6", "text": "NDEV total tau, neurogranin, and REST increased with AD severity (p < 0.05 to p < 0.001).", "tags": [{"end": 27, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 16, "tag": "GeneOrGenome"}, {"end": 37, "start": 33, "tag": "GeneOrGenome"}, {"end": 37, "start": 33, "tag": "CellFunction"}, {"end": 64, "start": 56, "tag": "ClinicalAttribute"}, {"end": 64, "start": 56, "tag": "Finding"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1048_7", "text": "NDEV A beta 42 and P-T181-tau correlated negatively with serum BDNF (p < 0.05), and total-tau levels were associated to plasma TNF-alpha (p < 0.01) and cognitive impairment (p < 0.05).", "tags": [{"end": 136, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 5, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 63, "tag": "GeneOrGenome"}, {"end": 14, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1048_8", "text": "Combination therapy reduced NDEV A beta(42) with respect to monotherapies ( p < 0.05); and NDEV total tau, P-T181-tau, and P-S396-tau were decreased in Cerebrolysin-treated patients compared to those on donepezil monotherapy (p < 0.05).", "tags": [{"end": 19, "start": 0, "tag": "HealthCareActivity"}, {"end": 212, "start": 203, "tag": "Chemical"}, {"end": 224, "start": 213, "tag": "HealthCareActivity"}, {"end": 148, "start": 139, "tag": "Finding"}, {"end": 39, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 173, "tag": "PatientOrDisabledGroup"}, {"end": 105, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 130, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 12, "tag": "HealthCareActivity"}, {"end": 43, "start": 28, "tag": "ClinicalAttribute"}, {"end": 105, "start": 91, "tag": "ClinicalAttribute"}, {"end": 164, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 152, "tag": "PharmacologicSubstance"}, {"end": 212, "start": 203, "tag": "PharmacologicSubstance"}]}{"id": "1048_9", "text": "Conclusion: The present results demonstrate the utility of NDEV determinations of pathologic and synaptic proteins as effective AD biomarkers, as markers of AD severity, and as potential tools for monitoring the effects of anti-AD drugs.", "tags": [{"end": 92, "start": 82, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 168, "start": 160, "tag": "ClinicalAttribute"}, {"end": 168, "start": 160, "tag": "Finding"}, {"end": 114, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 228, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 146, "tag": "ClinicalAttribute"}, {"end": 141, "start": 131, "tag": "ClinicalAttribute"}, {"end": 105, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 236, "start": 231, "tag": "PharmacologicSubstance"}, {"end": 222, "start": 212, "tag": "PathologicFunction"}, {"end": 207, "start": 197, "tag": "HealthCareActivity"}, {"end": 63, "start": 59, "tag": "CellComponent"}]}{"id": "1049_0", "text": "Previously thought to be nothing more than cellular debris, extracellular vesicles (EVs) are now known to mediate physiological and pathological functions throughout the body.", "tags": [{"end": 82, "start": 60, "tag": "CellComponent"}, {"end": 87, "start": 84, "tag": "CellComponent"}, {"end": 58, "start": 52, "tag": "Substance"}, {"end": 174, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 43, "tag": "Cell"}, {"end": 154, "start": 132, "tag": "PathologicFunction"}]}{"id": "1049_1", "text": "We now understand more about their capacity to transfer nucleic acids and proteins between distant organs, the interaction of their surface proteins with target cells, and the role of vesicle-bound lipids in health and disease.", "tags": [{"end": 148, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 204, "start": 198, "tag": "Chemical"}, {"end": 214, "start": 208, "tag": "HealthCareActivity"}, {"end": 166, "start": 154, "tag": "Cell"}, {"end": 166, "start": 154, "tag": "ResearchActivity"}, {"end": 191, "start": 184, "tag": "CellComponent"}, {"end": 105, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 56, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1049_2", "text": "To date, most observations have been made in reductionist cell culture systems, or as snapshots from patient cohorts.", "tags": [{"end": 78, "start": 58, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 26, "start": 14, "tag": "Finding"}, {"end": 116, "start": 109, "tag": "PopulationGroup"}, {"end": 108, "start": 101, "tag": "PatientOrDisabledGroup"}]}{"id": "1049_3", "text": "The heterogenous population of vesicles produced in vivo likely act in concert to mediate both beneficial and detrimental effects.", "tags": [{"end": 56, "start": 49, "tag": "ResearchActivity"}, {"end": 27, "start": 17, "tag": "PopulationGroup"}, {"end": 39, "start": 31, "tag": "CellComponent"}]}{"id": "1049_4", "text": "EVs play crucial roles in both the pathogenesis of diseases, from cancer to neurodegenerative disease, as well as in the maintenance of system and organ homeostasis.", "tags": [{"end": 152, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 121, "tag": "BiologicFunction"}, {"end": 164, "start": 153, "tag": "BiologicFunction"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 47, "start": 35, "tag": "PathologicFunction"}, {"end": 101, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 66, "tag": "DiseaseOrSyndrome"}]}{"id": "1049_5", "text": "This two-part review draws on the expertise of researchers working in the field of EV biology and aims to cover the functional role of EVs in physiology and pathology.", "tags": [{"end": 93, "start": 86, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 138, "start": 135, "tag": "CellComponent"}, {"end": 85, "start": 83, "tag": "CellComponent"}, {"end": 166, "start": 157, "tag": "PathologicFunction"}, {"end": 166, "start": 157, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 58, "start": 47, "tag": "ResearchActivity"}, {"end": 152, "start": 142, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 152, "start": 142, "tag": "BiologicFunction"}]}{"id": "1049_6", "text": "Part I will outline the role of EVs in normal physiology.", "tags": [{"end": 35, "start": 32, "tag": "CellComponent"}, {"end": 45, "start": 39, "tag": "Finding"}, {"end": 56, "start": 46, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 56, "start": 46, "tag": "BiologicFunction"}]}{"id": "1050_0", "text": "Background: Blood biomarkers that can be used for preclinical Alzheimer's disease (AD) diagnosis would enable trial enrollment at a time when the disease is potentially reversible.", "tags": [{"end": 126, "start": 110, "tag": "ResearchActivity"}, {"end": 81, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 18, "tag": "ClinicalAttribute"}, {"end": 96, "start": 87, "tag": "HealthCareActivity"}, {"end": 136, "start": 132, "tag": "TemporalConcept"}, {"end": 17, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1050_1", "text": "Here, we investigated plasma neuronal-derived extracellular vesicle (nEV) cargo in patients along the Alzheimer's continuum, focusing on cognitively normal controls (NCs) with high brain beta-amyloid (A beta) loads (A beta+).", "tags": [{"end": 164, "start": 156, "tag": "PopulationGroup"}, {"end": 207, "start": 201, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 216, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 83, "tag": "PatientOrDisabledGroup"}, {"end": 37, "start": 29, "tag": "Cell"}, {"end": 155, "start": 149, "tag": "Finding"}, {"end": 186, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 29, "tag": "CellComponent"}, {"end": 28, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 74, "tag": "CellFunction"}, {"end": 72, "start": 69, "tag": "CellComponent"}]}{"id": "1050_2", "text": "Methods: The study was based on the Sino Longitudinal Study on Cognitive Decline project.", "tags": [{"end": 59, "start": 36, "tag": "ResearchActivity"}, {"end": 88, "start": 63, "tag": "ResearchActivity"}, {"end": 18, "start": 13, "tag": "ResearchActivity"}]}{"id": "1050_3", "text": "We enrolled 246 participants, including 156 NCs, 45 amnestic mild cognitive impairment (aMCI) patients, and 45 AD dementia (ADD) patients.", "tags": [{"end": 92, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 16, "tag": "PopulationGroup"}, {"end": 86, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 94, "tag": "PatientOrDisabledGroup"}, {"end": 137, "start": 129, "tag": "PatientOrDisabledGroup"}, {"end": 122, "start": 114, "tag": "DiseaseOrSyndrome"}]}{"id": "1050_4", "text": "Brain A beta loads were determined using positron emission tomography.", "tags": [{"end": 69, "start": 41, "tag": "HealthCareActivity"}, {"end": 12, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1050_5", "text": "NCs were classified into 84 A beta- NCs and 72 A beta+ NCs.", "tags": [{"end": 34, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 47, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1050_6", "text": "Baseline plasma nEVs were isolated by immunoprecipitation with an anti-CD171 antibody.", "tags": [{"end": 57, "start": 38, "tag": "ResearchActivity"}, {"end": 85, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 16, "tag": "CellComponent"}]}{"id": "1050_7", "text": "After verification, their cargos, including A beta, tau phosphorylated at threonine 181, and neurofilament light, were quantified using a single-molecule array.", "tags": [{"end": 18, "start": 6, "tag": "ResearchActivity"}, {"end": 159, "start": 138, "tag": "ResearchActivity"}, {"end": 70, "start": 56, "tag": "CellFunction"}, {"end": 112, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 74, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1050_8", "text": "Concentrations of these cargos were compared among the groups, and their receiver operating characteristic (ROC) curves were constructed.", "tags": [{"end": 14, "start": 0, "tag": "BiologicFunction"}, {"end": 111, "start": 108, "tag": "ResearchActivity"}, {"end": 30, "start": 24, "tag": "CellFunction"}, {"end": 119, "start": 113, "tag": "ResearchActivity"}]}{"id": "1050_9", "text": "A subset of participants underwent follow-up cognitive assessment and magnetic resonance imaging.", "tags": [{"end": 65, "start": 45, "tag": "HealthCareActivity"}, {"end": 96, "start": 70, "tag": "HealthCareActivity"}, {"end": 44, "start": 35, "tag": "HealthCareActivity"}, {"end": 44, "start": 35, "tag": "TemporalConcept"}, {"end": 24, "start": 12, "tag": "PopulationGroup"}]}{"id": "1050_10", "text": "The relationships of nEV cargo levels with amyloid deposition, longitudinal changes in cognition, and brain regional volume were explored using correlation analysis.", "tags": [{"end": 164, "start": 144, "tag": "ResearchActivity"}, {"end": 17, "start": 4, "tag": "Finding"}, {"end": 96, "start": 87, "tag": "BiologicFunction"}, {"end": 75, "start": 63, "tag": "ResearchActivity"}, {"end": 50, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 156, "tag": "ResearchActivity"}, {"end": 30, "start": 25, "tag": "CellFunction"}, {"end": 24, "start": 21, "tag": "CellComponent"}, {"end": 61, "start": 43, "tag": "PathologicFunction"}, {"end": 123, "start": 102, "tag": "ClinicalAttribute"}]}{"id": "1050_11", "text": "Additionally, 458 subjects in the project had previously undergone plasma A beta quantification.", "tags": [{"end": 41, "start": 34, "tag": "ResearchActivity"}, {"end": 26, "start": 18, "tag": "PopulationGroup"}, {"end": 80, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 81, "tag": "ResearchActivity"}]}{"id": "1050_12", "text": "Results: Only nEV A beta was included in the subsequent analysis.", "tags": [{"end": 24, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 56, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 17, "start": 14, "tag": "CellComponent"}]}{"id": "1050_13", "text": "We focused on A beta(42) in the current study.", "tags": [{"end": 20, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 32, "tag": "TemporalConcept"}, {"end": 45, "start": 40, "tag": "ResearchActivity"}]}{"id": "1050_14", "text": "After normalization of nEVs, the levels of A beta(42) were found to increase gradually across the cognitive continuum, with the lowest in the A beta- NC group, an increase in the A beta+ NC group, a further increase in the aMCI group, and the highest in the ADD group, contributing to their diagnoses (A beta- NCs vs.", "tags": [{"end": 19, "start": 6, "tag": "ResearchActivity"}, {"end": 189, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 227, "start": 223, "tag": "DiseaseOrSyndrome"}, {"end": 261, "start": 258, "tag": "DiseaseOrSyndrome"}, {"end": 300, "start": 291, "tag": "HealthCareActivity"}, {"end": 53, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 179, "tag": "AminoAcidPeptideOrProtein"}, {"end": 308, "start": 302, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 153, "tag": "PopulationGroup"}, {"end": 195, "start": 190, "tag": "PopulationGroup"}, {"end": 233, "start": 228, "tag": "PopulationGroup"}, {"end": 267, "start": 262, "tag": "PopulationGroup"}, {"end": 27, "start": 23, "tag": "CellComponent"}, {"end": 53, "start": 43, "tag": "BiologicallyActiveSubstance"}]}{"id": "1050_15", "text": "A beta+ NCs, area under the ROC curve values of 0.663; vs.", "tags": [{"end": 6, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 28, "tag": "ResearchActivity"}]}{"id": "1050_16", "text": "aMCI, 0.857; vs.", "tags": [{"end": 4, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "1050_17", "text": "ADD, 0.957).", "tags": [{"end": 3, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "1050_18", "text": "Furthermore, nEV A beta(42) was significantly correlated with amyloid deposition, as well as longitudinal changes in cognition and entorhinal volume.", "tags": [{"end": 126, "start": 117, "tag": "BiologicFunction"}, {"end": 105, "start": 93, "tag": "ResearchActivity"}, {"end": 69, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 131, "tag": "ClinicalAttribute"}, {"end": 16, "start": 13, "tag": "CellComponent"}, {"end": 80, "start": 62, "tag": "PathologicFunction"}]}{"id": "1050_19", "text": "There were no differences in plasma A beta levels among NCs, aMCI, and ADD individuals.", "tags": [{"end": 65, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 11, "tag": "Finding"}, {"end": 86, "start": 75, "tag": "PopulationGroup"}, {"end": 42, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 36, "tag": "ClinicalAttribute"}, {"end": 35, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1050_20", "text": "Conclusions: Our findings suggest the potential use of plasma nEV A beta(42) levels in diagnosing AD-induced cognitive impairment and A beta+ NCs.", "tags": [{"end": 97, "start": 87, "tag": "HealthCareActivity"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 62, "tag": "CellComponent"}, {"end": 83, "start": 55, "tag": "ClinicalAttribute"}]}{"id": "1050_21", "text": "This biomarker reflects cortical amyloid deposition and predicts cognitive decline and entorhinal atrophy.", "tags": [{"end": 105, "start": 98, "tag": "PathologicFunction"}, {"end": 105, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 5, "tag": "ClinicalAttribute"}, {"end": 51, "start": 33, "tag": "PathologicFunction"}]}{"id": "1051_0", "text": "The treatment of central nervous system (CNS) pathologies is severely hampered by the presence of tightly regulated CNS barriers that restrict drug delivery to the brain.", "tags": [{"end": 39, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 169, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 4, "tag": "HealthCareActivity"}, {"end": 13, "start": 4, "tag": "ResearchActivity"}, {"end": 94, "start": 86, "tag": "Finding"}, {"end": 57, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 143, "tag": "HealthCareActivity"}]}{"id": "1051_1", "text": "An increasing amount of data suggests that extracellular vesicles (EVs), i.e., membrane derived vesicles that inherently protect and transfer biological cargoes between cells, naturally cross the CNS barriers.", "tags": [{"end": 87, "start": 79, "tag": "CellComponent"}, {"end": 65, "start": 43, "tag": "CellComponent"}, {"end": 70, "start": 67, "tag": "CellComponent"}, {"end": 208, "start": 196, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 169, "tag": "Cell"}, {"end": 104, "start": 96, "tag": "CellComponent"}, {"end": 28, "start": 24, "tag": "ResearchActivity"}, {"end": 160, "start": 153, "tag": "CellFunction"}, {"end": 13, "start": 3, "tag": "Finding"}]}{"id": "1051_2", "text": "Moreover, EVs can be engineered with targeting ligands to obtain enriched tissue targeting and delivery capacities.", "tags": [{"end": 13, "start": 10, "tag": "CellComponent"}, {"end": 80, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 95, "tag": "BiologicFunction"}, {"end": 54, "start": 47, "tag": "BiologicallyActiveSubstance"}]}{"id": "1051_3", "text": "In this review, we provide a detailed overview of the literature describing a natural and engineered CNS targeting and therapeutic efficiency of different cell type derived EVs.", "tags": [{"end": 176, "start": 173, "tag": "CellComponent"}, {"end": 104, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 54, "tag": "ResearchActivity"}, {"end": 46, "start": 38, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 164, "start": 155, "tag": "Cell"}, {"end": 141, "start": 119, "tag": "Finding"}]}{"id": "1051_4", "text": "Hereby, we specifically focus on peripheral administration routes in a broad range of CNS diseases.", "tags": [{"end": 98, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 44, "tag": "HealthCareActivity"}]}{"id": "1051_5", "text": "Furthermore, we underline the potential of research aimed at elucidating the vesicular transport mechanisms across the different CNS barriers.", "tags": [{"end": 141, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 43, "tag": "ResearchActivity"}, {"end": 107, "start": 77, "tag": "CellFunction"}]}{"id": "1051_6", "text": "Finally, we elaborate on the practical considerations towards the application of EVs as a brain drug delivery system.", "tags": [{"end": 53, "start": 39, "tag": "Finding"}, {"end": 84, "start": 81, "tag": "CellComponent"}, {"end": 116, "start": 96, "tag": "ManufacturedObject"}, {"end": 109, "start": 96, "tag": "HealthCareActivity"}, {"end": 95, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1052_0", "text": "Extracellular vesicles have emerged as a less-invasive nano-tool for discovering biomarkers of Alzheimer's disease and related dementia.", "tags": [{"end": 54, "start": 46, "tag": "Finding"}, {"end": 114, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 81, "tag": "ClinicalAttribute"}, {"end": 22, "start": 0, "tag": "CellComponent"}]}{"id": "1052_1", "text": "Here, we analysed different neuron-enriched extracellular vesicles from plasma to predict response and molecular mechanisms of ketogenic diet's efficacy in mild cognitive impairment participants.", "tags": [{"end": 194, "start": 182, "tag": "PopulationGroup"}, {"end": 66, "start": 44, "tag": "CellComponent"}, {"end": 34, "start": 28, "tag": "Cell"}, {"end": 78, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 181, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 144, "tag": "Finding"}, {"end": 123, "start": 103, "tag": "CellFunction"}, {"end": 141, "start": 127, "tag": "HealthCareActivity"}]}{"id": "1052_2", "text": "The study was a randomized crossover design in which cognitively normal and mild cognitive impairment participants consumed a modified Mediterranean-ketogenic diet or American Heart Association diet for 6 weeks, followed by other diet after washout.", "tags": [{"end": 26, "start": 16, "tag": "ResearchActivity"}, {"end": 26, "start": 16, "tag": "Finding"}, {"end": 193, "start": 167, "tag": "HealthCareRelatedOrganization"}, {"end": 234, "start": 230, "tag": "HealthCareActivity"}, {"end": 248, "start": 241, "tag": "TemporalConcept"}, {"end": 248, "start": 241, "tag": "HealthCareActivity"}, {"end": 43, "start": 16, "tag": "ResearchActivity"}, {"end": 43, "start": 37, "tag": "HealthCareActivity"}, {"end": 210, "start": 205, "tag": "TemporalConcept"}, {"end": 114, "start": 102, "tag": "PopulationGroup"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 101, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 53, "tag": "Finding"}, {"end": 163, "start": 126, "tag": "HealthCareActivity"}, {"end": 198, "start": 167, "tag": "HealthCareActivity"}]}{"id": "1052_3", "text": "L1 cell adhesion molecule, synaptophysin and neural cell adhesion molecule surface markers were used to enrich for neuron-secreted small extracellular vesicles (sEV(L1CAM), sEV(SYP) and sEV(NCAM)).", "tags": [{"end": 40, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 137, "tag": "CellComponent"}, {"end": 121, "start": 115, "tag": "Cell"}, {"end": 90, "start": 75, "tag": "ClinicalAttribute"}, {"end": 159, "start": 131, "tag": "CellComponent"}, {"end": 164, "start": 161, "tag": "CellComponent"}, {"end": 176, "start": 173, "tag": "CellComponent"}, {"end": 189, "start": 186, "tag": "CellComponent"}, {"end": 25, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 194, "start": 190, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 180, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 194, "start": 190, "tag": "BiologicallyActiveSubstance"}]}{"id": "1052_4", "text": "For the first time, we have presented multiple evidences, including immunogold labelling/transmission electron microscopy, clusters of differentiation 63-ELISA-based assay, confocal microscopy fluorescent images and flow cytometry data confirming the presence of L1 cell adhesion molecule on the surface of sEV(L1CAM), validating purity and relative abundance of sEV(L1CAM) in the plasma.", "tags": [{"end": 211, "start": 173, "tag": "ResearchActivity"}, {"end": 230, "start": 216, "tag": "ResearchActivity"}, {"end": 150, "start": 135, "tag": "CellFunction"}, {"end": 171, "start": 151, "tag": "ResearchActivity"}, {"end": 387, "start": 381, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 8, "tag": "TemporalConcept"}, {"end": 18, "start": 14, "tag": "TemporalConcept"}, {"end": 121, "start": 68, "tag": "ResearchActivity"}, {"end": 259, "start": 251, "tag": "Finding"}, {"end": 56, "start": 47, "tag": "Finding"}, {"end": 159, "start": 154, "tag": "ResearchActivity"}, {"end": 235, "start": 231, "tag": "ResearchActivity"}, {"end": 310, "start": 307, "tag": "CellComponent"}, {"end": 366, "start": 363, "tag": "CellComponent"}, {"end": 288, "start": 263, "tag": "AminoAcidPeptideOrProtein"}, {"end": 288, "start": 263, "tag": "BiologicallyActiveSubstance"}, {"end": 316, "start": 311, "tag": "AminoAcidPeptideOrProtein"}, {"end": 316, "start": 311, "tag": "BiologicallyActiveSubstance"}, {"end": 372, "start": 367, "tag": "AminoAcidPeptideOrProtein"}, {"end": 372, "start": 367, "tag": "BiologicallyActiveSubstance"}]}{"id": "1052_5", "text": "Cargo analysis of sEV(L1CAM) showed that modified Mediterranean-ketogenic diet intervention reduces amyloid beta 1-42 (50.3%, P = 0.011), p181-tau (34.9%, P = 0.033) and neurofilament light (54.2%, P = 0.020) in mild cognitive impairment participants.", "tags": [{"end": 5, "start": 0, "tag": "CellFunction"}, {"end": 250, "start": 238, "tag": "PopulationGroup"}, {"end": 14, "start": 6, "tag": "ResearchActivity"}, {"end": 146, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 237, "start": 212, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 18, "tag": "CellComponent"}, {"end": 27, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 41, "tag": "HealthCareActivity"}, {"end": 117, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 100, "tag": "BiologicallyActiveSubstance"}]}{"id": "1052_6", "text": "Moreover, sEV(L1CAM)showed better sensitivity compared with CSF in analysing increased glutamate (6-folds, P < 0.0001) from mild cognitive impairment participants following modified Mediterranean-ketogenic diet intervention.", "tags": [{"end": 162, "start": 150, "tag": "PopulationGroup"}, {"end": 63, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 124, "tag": "Finding"}, {"end": 149, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 34, "tag": "Finding"}, {"end": 96, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 10, "tag": "CellComponent"}, {"end": 19, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 223, "start": 173, "tag": "HealthCareActivity"}]}{"id": "1052_7", "text": "sEV(L1CAM) characterization also suggested that modified Mediterranean-ketogenic diet differentially targets the expression of various glutamate receptors-glutamate receptor ionotropic NMDA1, glutamate receptor ionotropic NMDA2A, glutamate receptor ionotropic NMDA2B and glutamate receptor ionotropic AMPA type subunit 1.", "tags": [{"end": 190, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 320, "start": 271, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 113, "tag": "CellFunction"}, {"end": 228, "start": 192, "tag": "AminoAcidPeptideOrProtein"}, {"end": 266, "start": 230, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 11, "tag": "ResearchActivity"}, {"end": 266, "start": 230, "tag": "BiologicallyActiveSubstance"}, {"end": 320, "start": 271, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 9, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 48, "tag": "HealthCareActivity"}, {"end": 9, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 228, "start": 192, "tag": "BiologicallyActiveSubstance"}]}{"id": "1052_8", "text": "Importantly, these sEV(L1CAM) measures strongly correlated with corresponding clinical CSF biomarkers (neurogranin, amyloid beta 1-42, neurofilament light and tau).", "tags": [{"end": 133, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 91, "tag": "ClinicalAttribute"}, {"end": 162, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 19, "tag": "CellComponent"}, {"end": 28, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 23, "tag": "BiologicallyActiveSubstance"}]}{"id": "1052_9", "text": "Furthermore, sEV(L1CAM) were loaded with less advanced glycation endproducts and exhibited anti-inflammatory activity following modified Mediterranean-ketogenic diet intervention.", "tags": [{"end": 117, "start": 91, "tag": "PharmacologicSubstance"}, {"end": 136, "start": 128, "tag": "TemporalConcept"}, {"end": 16, "start": 13, "tag": "CellComponent"}, {"end": 108, "start": 91, "tag": "BiologicFunction"}, {"end": 108, "start": 91, "tag": "PharmacologicSubstance"}, {"end": 22, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 17, "tag": "BiologicallyActiveSubstance"}]}{"id": "1052_10", "text": "Most importantly, the expression of monocarboxylate transporter 2 on the surface of sEV(L1CAM) predicted the amyloid beta 1-42 response to modified Mediterranean-ketogenic diet intervention (area under the curve = 0.87, P = 0.0044) and offered a novel screening tool to identify participants responsive to this dietary intervention.", "tags": [{"end": 65, "start": 36, "tag": "GeneOrGenome"}, {"end": 65, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 302, "start": 292, "tag": "Finding"}, {"end": 331, "start": 311, "tag": "HealthCareActivity"}, {"end": 147, "start": 139, "tag": "TemporalConcept"}, {"end": 291, "start": 279, "tag": "PopulationGroup"}, {"end": 211, "start": 191, "tag": "ResearchActivity"}, {"end": 32, "start": 22, "tag": "CellFunction"}, {"end": 126, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 261, "start": 252, "tag": "HealthCareActivity"}, {"end": 261, "start": 252, "tag": "ResearchActivity"}, {"end": 87, "start": 84, "tag": "CellComponent"}, {"end": 93, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 88, "tag": "BiologicallyActiveSubstance"}]}{"id": "1052_11", "text": "Finally, sEV(L1CAM), sEV(SYP) and sEV(NCAM) showed significantly high concordance in analysing amyloid beta 1-42 (Pearson correlation coefficient >= 0.63, P < 0.01) and neurofilament light (Pearson correlation coefficient >= 0.49, P < 0.05).", "tags": [{"end": 112, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 65, "tag": "Finding"}, {"end": 112, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 188, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 9, "tag": "CellComponent"}, {"end": 24, "start": 21, "tag": "CellComponent"}, {"end": 37, "start": 34, "tag": "CellComponent"}, {"end": 42, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 38, "tag": "BiologicallyActiveSubstance"}]}{"id": "1052_12", "text": "Together, small extracellular vesicles in plasma offers promise in assessing the efficacy of dietary/therapeutic intervention against mild cognitive impairment/Alzheimer's disease.", "tags": [{"end": 38, "start": 16, "tag": "CellComponent"}, {"end": 179, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 93, "tag": "HealthCareActivity"}, {"end": 89, "start": 81, "tag": "Finding"}, {"end": 38, "start": 10, "tag": "CellComponent"}]}{"id": "1053_0", "text": "Tauopathies are neurodegenerative disorders involving the accumulation of tau isoforms in cell subpopulations such as astrocytes.", "tags": [{"end": 11, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 90, "tag": "PopulationGroup"}, {"end": 86, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 58, "tag": "Finding"}, {"end": 128, "start": 118, "tag": "Cell"}, {"end": 43, "start": 16, "tag": "DiseaseOrSyndrome"}]}{"id": "1053_1", "text": "The origins of the 3R and 4R isoforms of tau that accumulate in astrocytes remain unclear.", "tags": [{"end": 11, "start": 4, "tag": "TemporalConcept"}, {"end": 60, "start": 50, "tag": "Finding"}, {"end": 44, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 64, "tag": "Cell"}]}{"id": "1053_2", "text": "Extracellular vesicles (EVs) were isolated from primary neurons overexpressing 1N3R or 1N4R tau or from human brain extracts (progressive supranuclear palsy or Pick disease patients or controls) and characterized (electron microscopy, nanoparticle tracking analysis (NTA), proteomics).", "tags": [{"end": 156, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 181, "start": 173, "tag": "PatientOrDisabledGroup"}, {"end": 265, "start": 257, "tag": "ResearchActivity"}, {"end": 193, "start": 185, "tag": "PopulationGroup"}, {"end": 95, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 104, "tag": "Eukaryote"}, {"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 78, "start": 64, "tag": "CellFunction"}, {"end": 233, "start": 214, "tag": "ResearchActivity"}, {"end": 265, "start": 235, "tag": "ResearchActivity"}, {"end": 137, "start": 126, "tag": "TemporalConcept"}, {"end": 63, "start": 56, "tag": "Cell"}, {"end": 270, "start": 267, "tag": "ResearchActivity"}, {"end": 283, "start": 273, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 79, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1053_3", "text": "After the isolated EVs were added to primary astrocytes or human iPSC-derived astrocytes, tau transfer and mitochondrial system function were evaluated (ELISA, immunofluorescence, MitoTracker staining).", "tags": [{"end": 178, "start": 160, "tag": "ResearchActivity"}, {"end": 69, "start": 65, "tag": "Cell"}, {"end": 120, "start": 107, "tag": "CellComponent"}, {"end": 22, "start": 19, "tag": "CellComponent"}, {"end": 93, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 59, "tag": "Eukaryote"}, {"end": 93, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 37, "tag": "Cell"}, {"end": 88, "start": 78, "tag": "Cell"}, {"end": 158, "start": 153, "tag": "ResearchActivity"}, {"end": 136, "start": 107, "tag": "CellFunction"}, {"end": 200, "start": 180, "tag": "ResearchActivity"}]}{"id": "1053_4", "text": "We demonstrated that neurons in which 3R or 4R tau accumulated had the capacity to transfer tau to astrocytes and that EVs were essential for the propagation of both isoforms of tau.", "tags": [{"end": 181, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 119, "tag": "CellComponent"}, {"end": 50, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 178, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 71, "tag": "Finding"}, {"end": 28, "start": 21, "tag": "Cell"}, {"end": 157, "start": 146, "tag": "Finding"}, {"end": 109, "start": 99, "tag": "Cell"}, {"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 38, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1053_5", "text": "Treatment with tau-containing EVs disrupted the astrocytic mitochondrial system, altering mitochondrial morphology, dynamics, and redox state.", "tags": [{"end": 141, "start": 130, "tag": "CellFunction"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 114, "start": 104, "tag": "Finding"}, {"end": 72, "start": 59, "tag": "CellComponent"}, {"end": 103, "start": 90, "tag": "CellComponent"}, {"end": 33, "start": 30, "tag": "CellComponent"}, {"end": 18, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 116, "tag": "NaturalPhenomenonOrProcess"}, {"end": 79, "start": 59, "tag": "CellFunction"}]}{"id": "1053_6", "text": "Although similar levels of 3R and 4R tau were transferred, 3R tau-containing EVs were significantly more damaging to astrocytes than 4R tau-containing EVs.", "tags": [{"end": 80, "start": 77, "tag": "CellComponent"}, {"end": 154, "start": 151, "tag": "CellComponent"}, {"end": 40, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 117, "tag": "Cell"}, {"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 133, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1053_7", "text": "Moreover, EVs isolated from the brain fluid of patients with different tauopathies affected mitochondrial function in astrocytes derived from human iPSCs.", "tags": [{"end": 82, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 142, "tag": "Cell"}, {"end": 114, "start": 92, "tag": "CellFunction"}, {"end": 105, "start": 92, "tag": "CellComponent"}, {"end": 13, "start": 10, "tag": "CellComponent"}, {"end": 55, "start": 47, "tag": "PatientOrDisabledGroup"}, {"end": 37, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 142, "tag": "Eukaryote"}, {"end": 43, "start": 38, "tag": "Substance"}, {"end": 128, "start": 118, "tag": "Cell"}, {"end": 153, "start": 148, "tag": "Cell"}]}{"id": "1053_8", "text": "Our data indicate that tau pathology spreads to surrounding astrocytes via EVs-mediated transfer and modifies their function.", "tags": [{"end": 36, "start": 23, "tag": "PathologicFunction"}, {"end": 78, "start": 75, "tag": "CellComponent"}, {"end": 26, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 60, "tag": "Cell"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}]}{"id": "1054_0", "text": "There are different modalities of intercellular communication governed by cellular homeostasis.", "tags": [{"end": 94, "start": 74, "tag": "CellFunction"}, {"end": 94, "start": 83, "tag": "BiologicFunction"}, {"end": 82, "start": 74, "tag": "Cell"}, {"end": 61, "start": 34, "tag": "CellFunction"}, {"end": 61, "start": 48, "tag": "HealthCareActivity"}, {"end": 61, "start": 48, "tag": "CellFunction"}]}{"id": "1054_1", "text": "In this review, we will explore one of these forms of communication called extracellular vesicles (EVs).", "tags": [{"end": 97, "start": 75, "tag": "CellComponent"}, {"end": 102, "start": 99, "tag": "CellComponent"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 67, "start": 54, "tag": "HealthCareActivity"}, {"end": 67, "start": 54, "tag": "CellFunction"}]}{"id": "1054_2", "text": "These vesicles are released by all cells in the body and are heterogeneous in nature.", "tags": [{"end": 74, "start": 61, "tag": "OrganismAttribute"}, {"end": 40, "start": 35, "tag": "Cell"}, {"end": 14, "start": 6, "tag": "CellComponent"}, {"end": 52, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1054_3", "text": "The primary function of EVs is to share information through their cargo consisting of proteins, lipids and nucleic acids (mRNA, miRNA, dsDNA etc.) with other cells, which have a direct consequence on their microenvironment.", "tags": [{"end": 140, "start": 135, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 222, "start": 206, "tag": "NaturalPhenomenonOrProcess"}, {"end": 222, "start": 206, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 163, "start": 158, "tag": "Cell"}, {"end": 71, "start": 66, "tag": "CellFunction"}, {"end": 133, "start": 128, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 133, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 96, "tag": "Chemical"}, {"end": 120, "start": 107, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 126, "start": 122, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 126, "start": 122, "tag": "BiologicallyActiveSubstance"}]}{"id": "1054_4", "text": "We will focus on the role of EVs of mesenchymal stem cells (MSCs) in the nervous system and how these participate in intercellular communication to maintain physiological function and provide neuroprotection.", "tags": [{"end": 179, "start": 157, "tag": "BiologicFunction"}, {"end": 207, "start": 192, "tag": "CellFunction"}, {"end": 32, "start": 29, "tag": "CellComponent"}, {"end": 144, "start": 117, "tag": "CellFunction"}, {"end": 144, "start": 131, "tag": "HealthCareActivity"}, {"end": 144, "start": 131, "tag": "CellFunction"}, {"end": 58, "start": 48, "tag": "Cell"}, {"end": 64, "start": 60, "tag": "Cell"}, {"end": 58, "start": 36, "tag": "Cell"}, {"end": 87, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1054_5", "text": "However, deregulation of this same communication system could play a role in several neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, multiple sclerosis, prion disease and Huntington's disease.", "tags": [{"end": 227, "start": 214, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 9, "tag": "CellOrMolecularDysfunction"}, {"end": 252, "start": 232, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 35, "tag": "HealthCareActivity"}, {"end": 55, "start": 35, "tag": "CellFunction"}, {"end": 219, "start": 214, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1054_6", "text": "The release of EVs from a cell provides crucial information to what is happening inside the cell and thus could be used in diagnostics and therapy.", "tags": [{"end": 18, "start": 15, "tag": "CellComponent"}, {"end": 30, "start": 26, "tag": "Cell"}, {"end": 96, "start": 92, "tag": "Cell"}, {"end": 134, "start": 123, "tag": "HealthCareActivity"}, {"end": 146, "start": 139, "tag": "HealthCareActivity"}, {"end": 18, "start": 4, "tag": "CellFunction"}]}{"id": "1054_7", "text": "We will discuss and explore new avenues for the clinical applications of using engineered MSC-EVs and their potential therapeutic benefit in treating neurodegenerative diseases.", "tags": [{"end": 137, "start": 108, "tag": "Finding"}, {"end": 69, "start": 48, "tag": "HealthCareActivity"}, {"end": 97, "start": 79, "tag": "ManufacturedObject"}, {"end": 97, "start": 94, "tag": "CellComponent"}, {"end": 176, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 90, "tag": "Cell"}]}{"id": "1055_0", "text": "Multiple biological factors, including age, sex, and genetics, influence Alzheimer's disease (AD) risk.", "tags": [{"end": 27, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 53, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 61, "start": 53, "tag": "CellFunction"}, {"end": 42, "start": 39, "tag": "OrganismAttribute"}, {"end": 92, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 44, "tag": "OrganismAttribute"}]}{"id": "1055_1", "text": "Of the 6.2 million Americans living with Alzheimer's dementia in 2021, 3.8 million are women and 2.4 million are men.", "tags": [{"end": 28, "start": 19, "tag": "PopulationGroup"}, {"end": 35, "start": 29, "tag": "Finding"}, {"end": 61, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 113, "tag": "PopulationGroup"}, {"end": 92, "start": 87, "tag": "PopulationGroup"}]}{"id": "1055_2", "text": "The strongest genetic risk factor for sporadic AD is apolipoprotein E-e4 (APOE-e4).", "tags": [{"end": 33, "start": 14, "tag": "Finding"}, {"end": 46, "start": 38, "tag": "TemporalConcept"}, {"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 53, "tag": "GeneOrGenome"}, {"end": 81, "start": 74, "tag": "GeneOrGenome"}]}{"id": "1055_3", "text": "Female APOE-e4 carriers develop AD more frequently than age-matched males and have more brain atrophy and memory loss.", "tags": [{"end": 6, "start": 0, "tag": "PopulationGroup"}, {"end": 6, "start": 0, "tag": "OrganismAttribute"}, {"end": 73, "start": 68, "tag": "OrganismAttribute"}, {"end": 50, "start": 40, "tag": "TemporalConcept"}, {"end": 101, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 56, "tag": "OrganismAttribute"}, {"end": 34, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 106, "tag": "SignOrSymptom"}, {"end": 23, "start": 15, "tag": "PopulationGroup"}, {"end": 14, "start": 7, "tag": "GeneOrGenome"}]}{"id": "1055_4", "text": "Consequently, biomarkers that are sensitive to biological risk factors may improve AD diagnostics and may provide insight into underlying mechanistic changes that could drive disease progression.", "tags": [{"end": 194, "start": 183, "tag": "PathologicFunction"}, {"end": 194, "start": 183, "tag": "TemporalConcept"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 14, "tag": "ClinicalAttribute"}, {"end": 97, "start": 86, "tag": "HealthCareActivity"}, {"end": 194, "start": 175, "tag": "PathologicFunction"}, {"end": 43, "start": 34, "tag": "PathologicFunction"}, {"end": 70, "start": 58, "tag": "Finding"}]}{"id": "1055_5", "text": "Here, we have assessed the effects of sex and APOE-e4 on the miRNA cargo of cerebrospinal fluid (CSF) extracellular vesicles (EVs) in AD.", "tags": [{"end": 66, "start": 61, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 66, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 102, "tag": "CellComponent"}, {"end": 129, "start": 126, "tag": "CellComponent"}, {"end": 136, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 90, "tag": "Substance"}, {"end": 95, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 38, "tag": "OrganismAttribute"}, {"end": 37, "start": 27, "tag": "PathologicFunction"}, {"end": 72, "start": 67, "tag": "CellFunction"}, {"end": 53, "start": 46, "tag": "GeneOrGenome"}]}{"id": "1055_6", "text": "We used ultrafiltration (UF) combined with size exclusion chromatography (SEC) to enrich CSF EVs (e.g., Flotillin+).", "tags": [{"end": 23, "start": 8, "tag": "HealthCareActivity"}, {"end": 27, "start": 25, "tag": "HealthCareActivity"}, {"end": 72, "start": 43, "tag": "ResearchActivity"}, {"end": 77, "start": 74, "tag": "ResearchActivity"}, {"end": 96, "start": 93, "tag": "CellComponent"}, {"end": 92, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 104, "tag": "BiologicallyActiveSubstance"}]}{"id": "1055_7", "text": "CSF EVs were isolated from female and male AD or controls (CTLs) that were either APOE-e3,4 or -e3,3 positive (n = 7/group, 56 total).", "tags": [{"end": 33, "start": 27, "tag": "OrganismAttribute"}, {"end": 42, "start": 38, "tag": "OrganismAttribute"}, {"end": 57, "start": 49, "tag": "PopulationGroup"}, {"end": 7, "start": 4, "tag": "CellComponent"}, {"end": 45, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 117, "tag": "PopulationGroup"}, {"end": 91, "start": 82, "tag": "GeneOrGenome"}]}{"id": "1055_8", "text": "MiRNA expression levels were quantified using a custom TaqMan (TM) array that assayed 190 miRNAs previously found in CSF, including 25 miRNAs that we previously validated as candidate AD biomarkers.", "tags": [{"end": 5, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 186, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 197, "start": 187, "tag": "ClinicalAttribute"}, {"end": 96, "start": 90, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 141, "start": 135, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 96, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 6, "tag": "CellFunction"}, {"end": 72, "start": 67, "tag": "ResearchActivity"}, {"end": 61, "start": 55, "tag": "ResearchActivity"}]}{"id": "1055_9", "text": "We identified changes in the EV miRNA cargo that were affected by both AD and sex.", "tags": [{"end": 37, "start": 32, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 37, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 29, "tag": "CellComponent"}, {"end": 81, "start": 78, "tag": "OrganismAttribute"}, {"end": 43, "start": 38, "tag": "CellFunction"}]}{"id": "1055_10", "text": "In total, four miRNAs (miR-16-5p, -331-3p, -409-3p, and -454-3p) were significantly increased in AD vs.", "tags": [{"end": 93, "start": 70, "tag": "Finding"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 15, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 21, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 23, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 32, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 34, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 26, "start": 23, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 50, "start": 43, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 26, "start": 23, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 63, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 56, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 26, "start": 23, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1055_11", "text": "CTL, independent of sex and APOE-e4 status.", "tags": [{"end": 42, "start": 36, "tag": "Finding"}, {"end": 3, "start": 0, "tag": "Cell"}, {"end": 23, "start": 20, "tag": "OrganismAttribute"}, {"end": 16, "start": 5, "tag": "Finding"}, {"end": 35, "start": 28, "tag": "GeneOrGenome"}]}{"id": "1055_12", "text": "Pathway analysis of the predicted gene targets of these four miRNAs with identified pathways was highly relevant to neurodegeneration (e.g., senescence and autophagy).", "tags": [{"end": 151, "start": 141, "tag": "Finding"}, {"end": 151, "start": 141, "tag": "TemporalConcept"}, {"end": 151, "start": 141, "tag": "CellFunction"}, {"end": 83, "start": 73, "tag": "Finding"}, {"end": 67, "start": 61, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 67, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 84, "tag": "CellFunction"}, {"end": 16, "start": 8, "tag": "ResearchActivity"}, {"end": 133, "start": 116, "tag": "CellOrMolecularDysfunction"}, {"end": 165, "start": 156, "tag": "CellFunction"}]}{"id": "1055_13", "text": "There were also three miRNAs (miR-146b-5p, -150-5p, and -342-3p) that were significantly increased in females vs.", "tags": [{"end": 109, "start": 102, "tag": "OrganismAttribute"}, {"end": 98, "start": 75, "tag": "Finding"}, {"end": 28, "start": 22, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 28, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 30, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 41, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}]}{"id": "1055_14", "text": "males, independent of disease state and APOE-e4 status.", "tags": [{"end": 5, "start": 0, "tag": "OrganismAttribute"}, {"end": 35, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 48, "tag": "Finding"}, {"end": 18, "start": 7, "tag": "Finding"}, {"end": 47, "start": 40, "tag": "GeneOrGenome"}]}{"id": "1055_15", "text": "We then performed a statistical analysis to assess the effect of APOE genotype in AD within each sex and found that APOE-e4 status affects different subsets of CSF EV miRNAs in females vs.", "tags": [{"end": 40, "start": 20, "tag": "ResearchActivity"}, {"end": 69, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 65, "tag": "ResearchActivity"}, {"end": 69, "start": 65, "tag": "GeneOrGenome"}, {"end": 78, "start": 70, "tag": "OrganismAttribute"}, {"end": 78, "start": 70, "tag": "ResearchActivity"}, {"end": 130, "start": 124, "tag": "Finding"}, {"end": 184, "start": 177, "tag": "OrganismAttribute"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 164, "tag": "CellComponent"}, {"end": 163, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 97, "tag": "OrganismAttribute"}, {"end": 173, "start": 167, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 173, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 116, "tag": "GeneOrGenome"}]}{"id": "1055_16", "text": "males.", "tags": [{"end": 5, "start": 0, "tag": "OrganismAttribute"}]}{"id": "1055_17", "text": "Together, this study demonstrates the complexity of the biological factors associated with AD risk and the impact on EV miRNAs, which may contribute to AD pathophysiology.", "tags": [{"end": 74, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 155, "tag": "PathologicFunction"}, {"end": 170, "start": 155, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 117, "tag": "CellComponent"}, {"end": 126, "start": 120, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 126, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}]}{"id": "1056_0", "text": "In neurodegenerative diseases, extracellular vesicles (EVs) transfer pathogenic molecules and are consequently involved in disease progression.", "tags": [{"end": 53, "start": 31, "tag": "CellComponent"}, {"end": 58, "start": 55, "tag": "CellComponent"}, {"end": 89, "start": 80, "tag": "Substance"}, {"end": 29, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 69, "tag": "PathologicFunction"}, {"end": 142, "start": 123, "tag": "PathologicFunction"}]}{"id": "1056_1", "text": "We have investigated the proteomic profiles of EVs that were isolated from four different humaninduced pluripotent stem cell-derived neural cell types (excitatory neurons, astrocytes, microglia-like cells, and oligodendrocyte-like cells).", "tags": [{"end": 43, "start": 25, "tag": "ResearchActivity"}, {"end": 150, "start": 133, "tag": "Cell"}, {"end": 170, "start": 152, "tag": "Cell"}, {"end": 50, "start": 47, "tag": "CellComponent"}, {"end": 204, "start": 184, "tag": "Cell"}, {"end": 236, "start": 210, "tag": "Cell"}, {"end": 193, "start": 184, "tag": "Cell"}, {"end": 182, "start": 172, "tag": "Cell"}, {"end": 124, "start": 95, "tag": "Cell"}]}{"id": "1056_2", "text": "Novel cell type-specific EV protein markers were then identified for the excitatory neurons (ATP1A3, NCAM1), astrocytes (LRP1, ITGA6), microglia-like cells (ITGAM, LCP1), and oligodendrocyte-like cells (LAMP2, FTH1), as well as 16 pan-EV marker candidates, including integrins and annexins.", "tags": [{"end": 99, "start": 93, "tag": "GeneOrGenome"}, {"end": 106, "start": 101, "tag": "GeneOrGenome"}, {"end": 106, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 121, "tag": "GeneOrGenome"}, {"end": 132, "start": 127, "tag": "GeneOrGenome"}, {"end": 162, "start": 157, "tag": "GeneOrGenome"}, {"end": 162, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 164, "tag": "GeneOrGenome"}, {"end": 168, "start": 164, "tag": "AminoAcidPeptideOrProtein"}, {"end": 208, "start": 203, "tag": "GeneOrGenome"}, {"end": 276, "start": 267, "tag": "AminoAcidPeptideOrProtein"}, {"end": 289, "start": 281, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 73, "tag": "Cell"}, {"end": 155, "start": 135, "tag": "Cell"}, {"end": 201, "start": 175, "tag": "Cell"}, {"end": 27, "start": 25, "tag": "CellComponent"}, {"end": 237, "start": 235, "tag": "CellComponent"}, {"end": 244, "start": 238, "tag": "ClinicalAttribute"}, {"end": 43, "start": 36, "tag": "ClinicalAttribute"}, {"end": 10, "start": 6, "tag": "Cell"}, {"end": 214, "start": 210, "tag": "GeneOrGenome"}, {"end": 144, "start": 135, "tag": "Cell"}, {"end": 214, "start": 210, "tag": "BiologicallyActiveSubstance"}, {"end": 214, "start": 210, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 109, "tag": "Cell"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 164, "tag": "BiologicallyActiveSubstance"}, {"end": 208, "start": 203, "tag": "AminoAcidPeptideOrProtein"}, {"end": 208, "start": 203, "tag": "BiologicallyActiveSubstance"}, {"end": 276, "start": 267, "tag": "BiologicallyActiveSubstance"}, {"end": 289, "start": 281, "tag": "BiologicallyActiveSubstance"}]}{"id": "1056_3", "text": "To further demonstrate how cell-type-specific EVs may be involved in Alzheimer's disease (AD), we performed protein co-expression network analysis and conducted cell type assessments for the proteomes of brain-derived EVs from the control, mild cognitive impairment, and AD cases.", "tags": [{"end": 146, "start": 108, "tag": "ResearchActivity"}, {"end": 200, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 265, "start": 240, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 46, "tag": "CellComponent"}, {"end": 221, "start": 218, "tag": "CellComponent"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 273, "start": 271, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 27, "tag": "Cell"}, {"end": 182, "start": 161, "tag": "ResearchActivity"}, {"end": 209, "start": 204, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1056_4", "text": "A protein module enriched in astrocyte-specific EV markers was most significantly associated with the AD pathology and cognitive impairment, suggesting an important role in AD progression.", "tags": [{"end": 187, "start": 176, "tag": "PathologicFunction"}, {"end": 187, "start": 176, "tag": "TemporalConcept"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 48, "tag": "CellComponent"}, {"end": 114, "start": 105, "tag": "PathologicFunction"}, {"end": 114, "start": 105, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 58, "start": 51, "tag": "ClinicalAttribute"}, {"end": 38, "start": 29, "tag": "Cell"}, {"end": 139, "start": 119, "tag": "DiseaseOrSyndrome"}]}{"id": "1056_5", "text": "The hub protein from this module, integrin-beta 1 (ITGB1), was found to be significantly elevated in astrocyte-specific EVs enriched from the total brain-derived AD EVs and associated with the brain beta-amyloid and tau load in independent cohorts.", "tags": [{"end": 15, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 247, "start": 240, "tag": "PopulationGroup"}, {"end": 123, "start": 120, "tag": "CellComponent"}, {"end": 168, "start": 165, "tag": "CellComponent"}, {"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 204, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 204, "tag": "BiologicallyActiveSubstance"}, {"end": 211, "start": 199, "tag": "AminoAcidPeptideOrProtein"}, {"end": 219, "start": 216, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 198, "start": 193, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 219, "start": 216, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 101, "tag": "Cell"}, {"end": 239, "start": 228, "tag": "Finding"}, {"end": 49, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 51, "tag": "GeneOrGenome"}]}{"id": "1056_6", "text": "Thus, our study provides a featured framework and rich resource for the future analyses of EV functions in neurodegenerative diseases in a cell type-specific manner.", "tags": [{"end": 93, "start": 91, "tag": "CellComponent"}, {"end": 143, "start": 139, "tag": "Cell"}, {"end": 78, "start": 72, "tag": "TemporalConcept"}, {"end": 133, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 10, "tag": "ResearchActivity"}, {"end": 87, "start": 79, "tag": "ResearchActivity"}]}{"id": "1057_0", "text": "We compared four orthogonal technologies for sizing, counting, and phenotyping of extracellular vesicles (EVs) and synthetic particles.", "tags": [{"end": 40, "start": 28, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 104, "start": 82, "tag": "CellComponent"}, {"end": 109, "start": 106, "tag": "CellComponent"}, {"end": 134, "start": 115, "tag": "Chemical"}]}{"id": "1057_1", "text": "The platforms were: single-particle interferometric reflectance imaging sensing (SP-IRIS) with fluorescence, nanoparticle tracking analysis (NTA) with fluorescence, microfluidic resistive pulse sensing (MRPS), and nanoflow cytometry measurement (NFCM).", "tags": [{"end": 107, "start": 95, "tag": "NaturalPhenomenonOrProcess"}, {"end": 163, "start": 151, "tag": "NaturalPhenomenonOrProcess"}, {"end": 139, "start": 109, "tag": "ResearchActivity"}, {"end": 79, "start": 20, "tag": "ResearchActivity"}, {"end": 88, "start": 81, "tag": "ResearchActivity"}, {"end": 201, "start": 165, "tag": "ResearchActivity"}, {"end": 244, "start": 214, "tag": "ResearchActivity"}, {"end": 250, "start": 246, "tag": "AminoAcidPeptideOrProtein"}, {"end": 207, "start": 203, "tag": "ResearchActivity"}, {"end": 144, "start": 141, "tag": "ResearchActivity"}]}{"id": "1057_2", "text": "EVs from the human T lymphocyte line H9 (high CD81, low CD63) and the promonocytic line U937 (low CD81, high CD63) were separated from culture conditioned medium (CCM) by differential ultracentrifugation (dUC) or a combination of ultrafiltration (UF) and size exclusion chromatography (SEC) and characterized by transmission electron microscopy (TEM) and Western blot (WB).", "tags": [{"end": 50, "start": 46, "tag": "GeneOrGenome"}, {"end": 97, "start": 94, "tag": "Finding"}, {"end": 102, "start": 98, "tag": "GeneOrGenome"}, {"end": 161, "start": 135, "tag": "Chemical"}, {"end": 245, "start": 230, "tag": "HealthCareActivity"}, {"end": 249, "start": 247, "tag": "HealthCareActivity"}, {"end": 284, "start": 255, "tag": "ResearchActivity"}, {"end": 289, "start": 286, "tag": "ResearchActivity"}, {"end": 344, "start": 312, "tag": "ResearchActivity"}, {"end": 349, "start": 346, "tag": "ResearchActivity"}, {"end": 367, "start": 355, "tag": "ResearchActivity"}, {"end": 371, "start": 369, "tag": "ResearchActivity"}, {"end": 203, "start": 171, "tag": "ResearchActivity"}, {"end": 166, "start": 163, "tag": "Chemical"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 60, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 13, "tag": "Eukaryote"}, {"end": 39, "start": 19, "tag": "Cell"}, {"end": 50, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 56, "tag": "GeneOrGenome"}, {"end": 92, "start": 70, "tag": "Cell"}, {"end": 208, "start": 205, "tag": "ResearchActivity"}, {"end": 245, "start": 230, "tag": "ResearchActivity"}]}{"id": "1057_3", "text": "Mixtures of synthetic particles (silica and polystyrene spheres) with known sizes and/or concentrations were also tested.", "tags": [{"end": 39, "start": 33, "tag": "Chemical"}, {"end": 103, "start": 89, "tag": "BiologicFunction"}, {"end": 63, "start": 44, "tag": "Chemical"}, {"end": 31, "start": 12, "tag": "Chemical"}]}{"id": "1057_4", "text": "MRPS and NFCM returned similar particle counts, while NTA detected counts approximately one order of magnitude lower for EVs, but not for synthetic particles.", "tags": [{"end": 46, "start": 31, "tag": "ManufacturedObject"}, {"end": 124, "start": 121, "tag": "CellComponent"}, {"end": 4, "start": 0, "tag": "ResearchActivity"}, {"end": 13, "start": 9, "tag": "ResearchActivity"}, {"end": 57, "start": 54, "tag": "ResearchActivity"}]}{"id": "1057_5", "text": "SP-IRIS events could not be used to estimate particle concentrations.", "tags": [{"end": 68, "start": 54, "tag": "BiologicFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 53, "start": 45, "tag": "Chemical"}]}{"id": "1057_6", "text": "For sizing, SP-IRIS, MRPS, and NFCM returned similar size profiles, with smaller sizes predominating (per power law distribution), but with sensitivity typically dropping off below diameters of 60 nm.", "tags": [{"end": 66, "start": 58, "tag": "ResearchActivity"}, {"end": 57, "start": 53, "tag": "OrganismAttribute"}, {"end": 151, "start": 140, "tag": "Finding"}, {"end": 19, "start": 12, "tag": "ResearchActivity"}, {"end": 25, "start": 21, "tag": "ResearchActivity"}, {"end": 35, "start": 31, "tag": "ResearchActivity"}]}{"id": "1057_7", "text": "NTA detected a population of particles with a mode diameter greater than 100 nm.", "tags": [{"end": 25, "start": 15, "tag": "PopulationGroup"}, {"end": 3, "start": 0, "tag": "ResearchActivity"}, {"end": 38, "start": 29, "tag": "Chemical"}]}{"id": "1057_8", "text": "Additionally, SP-IRIS, MRPS, and NFCM were able to identify at least three of four distinct size populations in a mixture of silica or polystyrene nanoparticles.", "tags": [{"end": 108, "start": 97, "tag": "PopulationGroup"}, {"end": 96, "start": 92, "tag": "OrganismAttribute"}, {"end": 21, "start": 14, "tag": "ResearchActivity"}, {"end": 27, "start": 23, "tag": "ResearchActivity"}, {"end": 37, "start": 33, "tag": "ResearchActivity"}, {"end": 131, "start": 125, "tag": "Chemical"}, {"end": 160, "start": 135, "tag": "Chemical"}]}{"id": "1057_9", "text": "Finally, for tetraspanin phenotyping, the SP-IRIS platform in fluorescence mode was able to detect at least two markers on the same particle, while NFCM detected either CD81 or CD63.", "tags": [{"end": 24, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 62, "tag": "NaturalPhenomenonOrProcess"}, {"end": 173, "start": 169, "tag": "GeneOrGenome"}, {"end": 181, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 112, "tag": "ClinicalAttribute"}, {"end": 181, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 42, "tag": "ResearchActivity"}, {"end": 181, "start": 177, "tag": "GeneOrGenome"}, {"end": 152, "start": 148, "tag": "ResearchActivity"}, {"end": 173, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 132, "tag": "Chemical"}, {"end": 36, "start": 25, "tag": "ResearchActivity"}]}{"id": "1057_10", "text": "Based on the results of this study, we can draw conclusions about existing single-particle analysis capabilities that may be useful for EV biomarker development and mechanistic studies.", "tags": [{"end": 138, "start": 136, "tag": "CellComponent"}, {"end": 160, "start": 149, "tag": "BiologicFunction"}, {"end": 160, "start": 149, "tag": "CellFunction"}, {"end": 99, "start": 75, "tag": "ResearchActivity"}, {"end": 34, "start": 29, "tag": "ResearchActivity"}, {"end": 184, "start": 177, "tag": "ResearchActivity"}, {"end": 148, "start": 139, "tag": "ClinicalAttribute"}, {"end": 90, "start": 82, "tag": "Chemical"}]}{"id": "1058_0", "text": "Background: Type 1 diabetes (T1D) is a complex autoimmune disorder whose pathogenesis involves an intricate interplay between beta cells of the pancreatic islet, other islet cells, and cells of the immune system.", "tags": [{"end": 27, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 198, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 73, "tag": "PathologicFunction"}, {"end": 136, "start": 126, "tag": "Cell"}, {"end": 179, "start": 168, "tag": "Cell"}, {"end": 190, "start": 185, "tag": "Cell"}, {"end": 117, "start": 108, "tag": "Finding"}]}{"id": "1058_1", "text": "Direct intercellular communication within the islet occurs via cell surface proteins and indirect intercellular communication has traditionally been seen as occurring via secreted proteins (e.g., endocrine hormones and cytokines).", "tags": [{"end": 214, "start": 196, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 180, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 7, "tag": "CellFunction"}, {"end": 125, "start": 98, "tag": "CellFunction"}, {"end": 75, "start": 63, "tag": "CellComponent"}, {"end": 228, "start": 219, "tag": "AminoAcidPeptideOrProtein"}, {"end": 228, "start": 219, "tag": "BiologicallyActiveSubstance"}]}{"id": "1058_2", "text": "However, recent literature suggests that extracellular vesicles (EVs) secreted by beta cells constitute an additional and biologically important mechanism for transmitting signals to within the islet.", "tags": [{"end": 63, "start": 41, "tag": "CellComponent"}, {"end": 68, "start": 65, "tag": "CellComponent"}, {"end": 92, "start": 82, "tag": "Cell"}, {"end": 179, "start": 172, "tag": "CellFunction"}, {"end": 26, "start": 16, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "TemporalConcept"}, {"end": 199, "start": 194, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1058_3", "text": "Scope of review: This review summarizes the general mechanisms of EV formation, with a particular focus on how lipids and lipid signaling pathways influence their formation and cargo.", "tags": [{"end": 68, "start": 66, "tag": "CellComponent"}, {"end": 127, "start": 122, "tag": "Chemical"}, {"end": 117, "start": 111, "tag": "Chemical"}, {"end": 146, "start": 128, "tag": "CellFunction"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 28, "start": 22, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 28, "start": 22, "tag": "HealthCareActivity"}, {"end": 182, "start": 177, "tag": "CellFunction"}]}{"id": "1058_4", "text": "We review the implications of EV release from beta cells for T1D pathogenesis, how EVs and their cargo might be leveraged as biomarkers of this process, and how EVs might be engineered as a therapeutic candidate to counter T1D outcomes.", "tags": [{"end": 64, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 226, "start": 223, "tag": "DiseaseOrSyndrome"}, {"end": 235, "start": 227, "tag": "Finding"}, {"end": 211, "start": 190, "tag": "HealthCareActivity"}, {"end": 86, "start": 83, "tag": "CellComponent"}, {"end": 164, "start": 161, "tag": "CellComponent"}, {"end": 77, "start": 65, "tag": "PathologicFunction"}, {"end": 56, "start": 46, "tag": "Cell"}, {"end": 40, "start": 30, "tag": "CellFunction"}, {"end": 135, "start": 125, "tag": "ClinicalAttribute"}, {"end": 9, "start": 3, "tag": "ResearchActivity"}, {"end": 9, "start": 3, "tag": "HealthCareActivity"}, {"end": 102, "start": 97, "tag": "CellFunction"}]}{"id": "1058_5", "text": "Major conclusions: Islet beta cells have been viewed as initiators and propagators of the cellular circuit giving rise to autoimmunity in T1D.", "tags": [{"end": 141, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 122, "tag": "PathologicFunction"}, {"end": 35, "start": 19, "tag": "Cell"}]}{"id": "1058_6", "text": "In this context, emerging literature suggests that EVs may represent a conduit for communication that holds more comprehensive messaging about the beta cells from which they arise.", "tags": [{"end": 54, "start": 51, "tag": "CellComponent"}, {"end": 157, "start": 147, "tag": "Cell"}, {"end": 36, "start": 26, "tag": "ResearchActivity"}, {"end": 96, "start": 83, "tag": "HealthCareActivity"}, {"end": 96, "start": 83, "tag": "CellFunction"}]}{"id": "1058_7", "text": "As the field of EV biology advances, it opens the possibility that intervening with EV formation and cargo loading could be a novel disease-modifying approach in T1D.", "tags": [{"end": 165, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 19, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 18, "start": 16, "tag": "CellComponent"}, {"end": 86, "start": 84, "tag": "CellComponent"}, {"end": 106, "start": 101, "tag": "CellFunction"}, {"end": 158, "start": 132, "tag": "HealthCareActivity"}]}{"id": "1058_8", "text": "(c) 2022 The University of Chicago.", "tags": [{"end": 34, "start": 13, "tag": "HealthCareRelatedOrganization"}]}{"id": "1058_9", "text": "Published by Elsevier GmbH.", "tags": []}{"id": "1059_0", "text": "Blommer et al.", "tags": []}{"id": "1059_1", "text": "report that the protein cargo of neuronal extracellular vesicles could serve as a biomarker for cognitive impairment in Parkinson's disease: immunoassays reveal differences in alpha-synuclein, phosphorylated tau and proteins associated with insulin signalling in patients with versus without cognitive impairment.", "tags": [{"end": 153, "start": 141, "tag": "ResearchActivity"}, {"end": 191, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 176, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 42, "tag": "CellComponent"}, {"end": 271, "start": 263, "tag": "PatientOrDisabledGroup"}, {"end": 139, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 193, "tag": "CellFunction"}, {"end": 6, "start": 0, "tag": "HealthCareActivity"}, {"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 211, "start": 208, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 208, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 82, "tag": "ClinicalAttribute"}, {"end": 41, "start": 33, "tag": "Cell"}, {"end": 29, "start": 24, "tag": "CellComponent"}, {"end": 224, "start": 216, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 193, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 193, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 161, "tag": "Finding"}, {"end": 116, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 312, "start": 292, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 259, "start": 241, "tag": "CellFunction"}]}{"id": "1059_2", "text": "Besides motor symptoms, many individuals with Parkinson's disease develop cognitive impairment perhaps due to coexisting alpha-synuclein and Alzheimer's disease pathologies and impaired brain insulin signalling.", "tags": [{"end": 136, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 186, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 8, "tag": "SignOrSymptom"}, {"end": 94, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 29, "tag": "PopulationGroup"}, {"end": 172, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 192, "tag": "CellFunction"}]}{"id": "1059_3", "text": "Discovering biomarkers for cognitive impairment in Parkinson's disease could help clarify the underlying pathogenic processes and improve Parkinson's disease diagnosis and prognosis.", "tags": [{"end": 137, "start": 130, "tag": "Finding"}, {"end": 70, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 12, "tag": "ClinicalAttribute"}, {"end": 167, "start": 158, "tag": "HealthCareActivity"}, {"end": 115, "start": 105, "tag": "PathologicFunction"}, {"end": 47, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 172, "tag": "HealthCareActivity"}]}{"id": "1059_4", "text": "This study used plasma samples from 273 participants: 103 Parkinson's disease individuals with normal cognition, 121 Parkinson's disease individuals with cognitive impairment (81 with mild cognitive impairment, 40 with dementia) and 49 age- and sex-matched controls.", "tags": [{"end": 111, "start": 95, "tag": "Finding"}, {"end": 52, "start": 40, "tag": "PopulationGroup"}, {"end": 227, "start": 219, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 77, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 265, "start": 257, "tag": "PopulationGroup"}, {"end": 30, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 239, "start": 236, "tag": "OrganismAttribute"}, {"end": 111, "start": 102, "tag": "BiologicFunction"}, {"end": 174, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 95, "tag": "Finding"}, {"end": 89, "start": 78, "tag": "PopulationGroup"}, {"end": 148, "start": 137, "tag": "PopulationGroup"}, {"end": 248, "start": 245, "tag": "OrganismAttribute"}, {"end": 209, "start": 184, "tag": "DiseaseOrSyndrome"}]}{"id": "1059_5", "text": "Plasma extracellular vesicles enriched for neuronal origin were immunocaptured by targeting the L1 cell adhesion molecule, then biomarkers were quantified using immunoassays.", "tags": [{"end": 173, "start": 161, "tag": "ResearchActivity"}, {"end": 29, "start": 7, "tag": "CellComponent"}, {"end": 138, "start": 128, "tag": "ClinicalAttribute"}, {"end": 103, "start": 99, "tag": "Cell"}, {"end": 51, "start": 43, "tag": "Cell"}, {"end": 58, "start": 52, "tag": "TemporalConcept"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1059_6", "text": "alpha-Synuclein was lower in Parkinson's disease compared to control individuals (P = 0.004) and in cognitively impaired Parkinson's disease individuals compared to Parkinson's disease with normal cognition (P < 0.001) and control (P < 0.001) individuals.", "tags": [{"end": 15, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 206, "start": 190, "tag": "Finding"}, {"end": 120, "start": 100, "tag": "PatientOrDisabledGroup"}, {"end": 48, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 206, "start": 197, "tag": "BiologicFunction"}, {"end": 196, "start": 190, "tag": "Finding"}, {"end": 80, "start": 69, "tag": "PopulationGroup"}, {"end": 152, "start": 141, "tag": "PopulationGroup"}, {"end": 254, "start": 243, "tag": "PopulationGroup"}]}{"id": "1059_7", "text": "Amyloid-beta(42) did not differ between groups.", "tags": [{"end": 16, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1059_8", "text": "Phosphorylated tau (T181) was higher in Parkinson's disease than control individuals (P = 0.003) and in cognitively impaired compared to cognitively normal Parkinson's disease individuals (P < 0.001) and controls (P < 0.001).", "tags": [{"end": 14, "start": 0, "tag": "CellFunction"}, {"end": 124, "start": 104, "tag": "PatientOrDisabledGroup"}, {"end": 59, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 204, "tag": "PopulationGroup"}, {"end": 18, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 149, "tag": "Finding"}, {"end": 84, "start": 73, "tag": "PopulationGroup"}, {"end": 187, "start": 176, "tag": "PopulationGroup"}, {"end": 155, "start": 137, "tag": "Finding"}, {"end": 24, "start": 20, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1059_9", "text": "Total tau was not different between groups.", "tags": [{"end": 9, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1059_10", "text": "Tyrosine-phosphorylated insulin receptor substrate-1 was lower in Parkinson's disease compared to control individuals (P = 0.03) and in cognitively impaired compared to cognitively normal Parkinson's disease individuals (P = 0.02) and controls (P = 0.01), and also decreased with increasing motor symptom severity (P = 0.005); serine312-phosphorylated insulin receptor substrate-1 was not different between groups.", "tags": [{"end": 304, "start": 291, "tag": "SignOrSymptom"}, {"end": 380, "start": 352, "tag": "AminoAcidPeptideOrProtein"}, {"end": 313, "start": 297, "tag": "Finding"}, {"end": 156, "start": 136, "tag": "PatientOrDisabledGroup"}, {"end": 304, "start": 297, "tag": "SignOrSymptom"}, {"end": 85, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 9, "tag": "CellFunction"}, {"end": 351, "start": 337, "tag": "CellFunction"}, {"end": 243, "start": 235, "tag": "PopulationGroup"}, {"end": 274, "start": 265, "tag": "Finding"}, {"end": 313, "start": 305, "tag": "ClinicalAttribute"}, {"end": 313, "start": 305, "tag": "Finding"}, {"end": 187, "start": 181, "tag": "Finding"}, {"end": 117, "start": 106, "tag": "PopulationGroup"}, {"end": 219, "start": 208, "tag": "PopulationGroup"}, {"end": 187, "start": 169, "tag": "Finding"}, {"end": 290, "start": 280, "tag": "Finding"}, {"end": 380, "start": 352, "tag": "BiologicallyActiveSubstance"}, {"end": 8, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 24, "tag": "BiologicallyActiveSubstance"}]}{"id": "1059_11", "text": "Mechanistic target of rapamycin was not different between groups, whereas phosphorylated mechanistic target of rapamycin trended lower in cognitively impaired compared to cognitively normal Parkinson's disease individuals (P = 0.05).", "tags": [{"end": 31, "start": 22, "tag": "Chemical"}, {"end": 120, "start": 111, "tag": "Chemical"}, {"end": 158, "start": 138, "tag": "PatientOrDisabledGroup"}, {"end": 209, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 74, "tag": "CellFunction"}, {"end": 189, "start": 183, "tag": "Finding"}, {"end": 221, "start": 210, "tag": "PopulationGroup"}, {"end": 189, "start": 171, "tag": "Finding"}]}{"id": "1059_12", "text": "The ratio of alpha-synuclein to phosphorylated tau181 was lower in Parkinson's disease compared to controls (P = 0.001), in cognitively impaired compared to cognitively normal Parkinson's disease individuals (P < 0.001) and decreased with increasing motor symptom severity (P < 0.001).", "tags": [{"end": 263, "start": 250, "tag": "SignOrSymptom"}, {"end": 272, "start": 256, "tag": "Finding"}, {"end": 28, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 124, "tag": "PatientOrDisabledGroup"}, {"end": 263, "start": 256, "tag": "SignOrSymptom"}, {"end": 86, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "PopulationGroup"}, {"end": 233, "start": 224, "tag": "Finding"}, {"end": 272, "start": 264, "tag": "ClinicalAttribute"}, {"end": 272, "start": 264, "tag": "Finding"}, {"end": 175, "start": 169, "tag": "Finding"}, {"end": 207, "start": 196, "tag": "PopulationGroup"}, {"end": 175, "start": 157, "tag": "Finding"}, {"end": 249, "start": 239, "tag": "Finding"}, {"end": 53, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 4, "tag": "ClinicalAttribute"}]}{"id": "1059_13", "text": "The ratio of insulin receptor substrate-1 phosphorylated serine312 to insulin receptor substrate-1 phosphorylated tyrosine was higher in Parkinson's disease compared to control individuals (P = 0.01), in cognitively impaired compared to cognitively normal Parkinson's disease individuals (P = 0.02) and increased with increasing motor symptom severity (P = 0.003).", "tags": [{"end": 41, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 342, "start": 329, "tag": "SignOrSymptom"}, {"end": 351, "start": 335, "tag": "Finding"}, {"end": 224, "start": 204, "tag": "PatientOrDisabledGroup"}, {"end": 342, "start": 335, "tag": "SignOrSymptom"}, {"end": 156, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 275, "start": 256, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 42, "tag": "CellFunction"}, {"end": 113, "start": 99, "tag": "CellFunction"}, {"end": 351, "start": 343, "tag": "ClinicalAttribute"}, {"end": 351, "start": 343, "tag": "Finding"}, {"end": 255, "start": 249, "tag": "Finding"}, {"end": 188, "start": 177, "tag": "PopulationGroup"}, {"end": 287, "start": 276, "tag": "PopulationGroup"}, {"end": 255, "start": 237, "tag": "Finding"}, {"end": 328, "start": 318, "tag": "Finding"}, {"end": 98, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 4, "tag": "ClinicalAttribute"}, {"end": 41, "start": 13, "tag": "BiologicallyActiveSubstance"}]}{"id": "1059_14", "text": "alpha-Synuclein, phosphorylated tau181 and insulin receptor substrate-1 phosphorylated tyrosine contributed in diagnostic classification between groups.", "tags": [{"end": 15, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 72, "tag": "CellFunction"}, {"end": 38, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 87, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1059_15", "text": "These findings suggest that both alpha-synuclein and tau pathologies and impaired insulin signalling underlie Parkinson's disease with cognitive impairment.", "tags": [{"end": 48, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 73, "tag": "CellOrMolecularDysfunction"}]}{"id": "1059_16", "text": "Plasma neuronal extracellular vesicles biomarkers may inform cognitive prognosis in Parkinson's disease.", "tags": [{"end": 38, "start": 16, "tag": "CellComponent"}, {"end": 103, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 39, "tag": "ClinicalAttribute"}, {"end": 15, "start": 7, "tag": "Cell"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 61, "tag": "HealthCareActivity"}]}{"id": "1060_0", "text": "It is clear from Part I of this series that extracellular vesicles (EVs) play a critical role in maintaining the homeostasis of most, if not all, normal physiological systems.", "tags": [{"end": 124, "start": 113, "tag": "BiologicFunction"}, {"end": 66, "start": 44, "tag": "CellComponent"}, {"end": 71, "start": 68, "tag": "CellComponent"}, {"end": 152, "start": 146, "tag": "Finding"}]}{"id": "1060_1", "text": "However, the majority of our knowledge about EV signalling has come from studying them in disease.", "tags": [{"end": 47, "start": 45, "tag": "CellComponent"}, {"end": 38, "start": 29, "tag": "Finding"}, {"end": 58, "start": 48, "tag": "BiologicFunction"}]}{"id": "1060_2", "text": "Indeed, EVs have consistently been associated with propagating disease pathophysiology.", "tags": [{"end": 86, "start": 71, "tag": "PathologicFunction"}, {"end": 86, "start": 71, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 11, "start": 8, "tag": "CellComponent"}]}{"id": "1060_3", "text": "The analysis of EVs in biofluids, obtained in the clinic, has been an essential of the work to improve our understanding of their role in disease.", "tags": [{"end": 19, "start": 16, "tag": "CellComponent"}, {"end": 120, "start": 107, "tag": "BiologicFunction"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 56, "start": 50, "tag": "HealthCareRelatedOrganization"}, {"end": 32, "start": 23, "tag": "Substance"}]}{"id": "1060_4", "text": "However, to interfere with EV signalling for therapeutic gain, a more fundamental understanding of the mechanisms by which they contribute to pathogenic processes is required.", "tags": [{"end": 29, "start": 27, "tag": "CellComponent"}, {"end": 95, "start": 82, "tag": "BiologicFunction"}, {"end": 40, "start": 30, "tag": "BiologicFunction"}, {"end": 152, "start": 142, "tag": "PathologicFunction"}]}{"id": "1060_5", "text": "Only by discovering how the EV populations in different biofluids change-size, number, and physicochemical composition-in clinical samples, may we then begin to unravel their functional roles in translational models in vitro and in vivo, which can then feedback to the clinic.", "tags": [{"end": 224, "start": 216, "tag": "ResearchActivity"}, {"end": 30, "start": 28, "tag": "CellComponent"}, {"end": 236, "start": 229, "tag": "ResearchActivity"}, {"end": 77, "start": 73, "tag": "OrganismAttribute"}, {"end": 215, "start": 209, "tag": "ResearchActivity"}, {"end": 275, "start": 269, "tag": "HealthCareRelatedOrganization"}, {"end": 65, "start": 56, "tag": "Substance"}, {"end": 138, "start": 131, "tag": "Substance"}, {"end": 138, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1060_6", "text": "In Part II of this review series, the functional role of EVs in pathology and disease will be discussed, with a focus on in vivo evidence and their potential to be used as both biomarkers and points of therapeutic intervention.", "tags": [{"end": 226, "start": 202, "tag": "HealthCareActivity"}, {"end": 137, "start": 129, "tag": "Finding"}, {"end": 60, "start": 57, "tag": "CellComponent"}, {"end": 128, "start": 121, "tag": "ResearchActivity"}, {"end": 73, "start": 64, "tag": "PathologicFunction"}, {"end": 73, "start": 64, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 187, "start": 177, "tag": "ClinicalAttribute"}, {"end": 25, "start": 19, "tag": "ResearchActivity"}, {"end": 25, "start": 19, "tag": "HealthCareActivity"}]}{"id": "1061_0", "text": "The formation of extracellular vesicles (EVs) is induced by the sphingolipid ceramide.", "tags": [{"end": 76, "start": 64, "tag": "Chemical"}, {"end": 39, "start": 17, "tag": "CellComponent"}, {"end": 44, "start": 41, "tag": "CellComponent"}, {"end": 39, "start": 4, "tag": "CellFunction"}, {"end": 85, "start": 77, "tag": "Chemical"}, {"end": 85, "start": 77, "tag": "BiologicallyActiveSubstance"}]}{"id": "1061_1", "text": "How this pathway is regulated is not entirely understood.", "tags": [{"end": 16, "start": 9, "tag": "CellFunction"}]}{"id": "1061_2", "text": "Here, we report that the ceramide transport protein (CERT) mediates a non-vesicular transport of ceramide between the endoplasmic reticulum (ER) and the multivesicular endosome at contact sites.", "tags": [{"end": 51, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 118, "tag": "CellComponent"}, {"end": 167, "start": 153, "tag": "CellComponent"}, {"end": 176, "start": 168, "tag": "CellComponent"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 143, "start": 141, "tag": "CellComponent"}, {"end": 93, "start": 70, "tag": "CellFunction"}, {"end": 105, "start": 97, "tag": "Chemical"}, {"end": 105, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 53, "tag": "BiologicallyActiveSubstance"}]}{"id": "1061_3", "text": "The process depends on the interaction of CERT's PH domain with PI4P generated by PI4KII alpha at endosomes.", "tags": [{"end": 58, "start": 49, "tag": "MolecularSequence"}, {"end": 107, "start": 98, "tag": "CellComponent"}, {"end": 46, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 64, "tag": "Chemical"}, {"end": 94, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 82, "tag": "BiologicallyActiveSubstance"}]}{"id": "1061_4", "text": "Furthermore, a complex is formed between the START domain of CERT, which carries ceramide, and the Tsg101 protein, which is part of the endosomal sorting complex required for transport (ESCRT-I).", "tags": [{"end": 57, "start": 45, "tag": "MolecularSequence"}, {"end": 65, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 81, "tag": "Chemical"}, {"end": 89, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 136, "tag": "CellComponent"}, {"end": 193, "start": 186, "tag": "CellComponent"}]}{"id": "1061_5", "text": "Inhibition of ceramide biosynthesis reduces CERT-Tsg101 complex formation.", "tags": [{"end": 35, "start": 14, "tag": "CellFunction"}, {"end": 10, "start": 0, "tag": "BiologicFunction"}, {"end": 10, "start": 0, "tag": "CellFunction"}, {"end": 63, "start": 44, "tag": "CellComponent"}]}{"id": "1061_6", "text": "Overexpression of CERT increases EV secretion while its inhibition reduces EV formation and the concentration of ceramides and sphingomyelins in EVs.", "tags": [{"end": 14, "start": 0, "tag": "CellFunction"}, {"end": 22, "start": 18, "tag": "CellFunction"}, {"end": 141, "start": 127, "tag": "Chemical"}, {"end": 141, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 33, "tag": "CellFunction"}, {"end": 66, "start": 56, "tag": "CellFunction"}, {"end": 148, "start": 145, "tag": "CellComponent"}, {"end": 35, "start": 33, "tag": "CellComponent"}, {"end": 77, "start": 75, "tag": "CellComponent"}, {"end": 87, "start": 75, "tag": "CellFunction"}, {"end": 122, "start": 113, "tag": "Chemical"}, {"end": 122, "start": 113, "tag": "BiologicallyActiveSubstance"}]}{"id": "1061_7", "text": "In conclusion, we discovered a function of CERT in regulating the sphingolipid composition and biogenesis of EVs, which links ceramide to the ESCRT-dependent pathway.", "tags": [{"end": 47, "start": 43, "tag": "CellComponent"}, {"end": 78, "start": 66, "tag": "Chemical"}, {"end": 112, "start": 109, "tag": "CellComponent"}, {"end": 105, "start": 95, "tag": "CellFunction"}, {"end": 165, "start": 142, "tag": "CellFunction"}, {"end": 134, "start": 126, "tag": "Chemical"}, {"end": 134, "start": 126, "tag": "BiologicallyActiveSubstance"}]}{"id": "1062_0", "text": "Down syndrome (DS), or trisomy 21, is manifested in a variety of anatomical and cellular abnormalities resulting in intellectual deficits and early onset of Alzheimer's disease (AD) with no effective treatments available to alleviate the pathologies associated with the disorder.", "tags": [{"end": 13, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 23, "tag": "CellOrMolecularDysfunction"}, {"end": 249, "start": 238, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 176, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 142, "tag": "TemporalConcept"}, {"end": 210, "start": 200, "tag": "HealthCareActivity"}, {"end": 210, "start": 200, "tag": "ResearchActivity"}, {"end": 137, "start": 116, "tag": "Finding"}]}{"id": "1062_1", "text": "The therapeutic potential of extracellular vesicles (EVs) has emerged recently in relation to various neurological conditions.", "tags": [{"end": 125, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 29, "tag": "CellComponent"}, {"end": 56, "start": 53, "tag": "CellComponent"}, {"end": 78, "start": 70, "tag": "TemporalConcept"}, {"end": 25, "start": 4, "tag": "HealthCareActivity"}]}{"id": "1062_2", "text": "We have previously demonstrated the therapeutic efficacy of mesenchymal stromal cell-derived EVs (MSC-EVs) in cellular and functional recovery in a rhesus monkey model of cortical injury.", "tags": [{"end": 142, "start": 134, "tag": "BiologicFunction"}, {"end": 142, "start": 134, "tag": "HealthCareActivity"}, {"end": 142, "start": 134, "tag": "TemporalConcept"}, {"end": 179, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 93, "tag": "CellComponent"}, {"end": 105, "start": 102, "tag": "CellComponent"}, {"end": 84, "start": 60, "tag": "Cell"}, {"end": 101, "start": 98, "tag": "Cell"}, {"end": 167, "start": 162, "tag": "ResearchActivity"}, {"end": 56, "start": 36, "tag": "Finding"}, {"end": 161, "start": 148, "tag": "Eukaryote"}, {"end": 186, "start": 148, "tag": "ExperimentalModelOfDisease"}]}{"id": "1062_3", "text": "In the current study, we evaluated the therapeutic effect of MSC-EVs in a cortical spheroid (CS) model of DS generated from patient-derived induced pluripotent stem cells (iPSCs).", "tags": [{"end": 170, "start": 140, "tag": "Cell"}, {"end": 177, "start": 172, "tag": "Cell"}, {"end": 68, "start": 65, "tag": "CellComponent"}, {"end": 131, "start": 124, "tag": "PatientOrDisabledGroup"}, {"end": 64, "start": 61, "tag": "Cell"}, {"end": 14, "start": 7, "tag": "TemporalConcept"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 170, "start": 160, "tag": "Cell"}, {"end": 57, "start": 39, "tag": "ClinicalAttribute"}, {"end": 108, "start": 74, "tag": "ExperimentalModelOfDisease"}]}{"id": "1062_4", "text": "Compared to euploid controls, trisomic CS display smaller size, deficient neurogenesis, and AD-related pathological features, such as enhanced cell death and depositions of amyloid beta (A beta) and hyperphosphorylated tau (p-tau).", "tags": [{"end": 153, "start": 143, "tag": "CellFunction"}, {"end": 86, "start": 74, "tag": "BiologicFunction"}, {"end": 28, "start": 20, "tag": "PopulationGroup"}, {"end": 185, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 193, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 219, "tag": "AminoAcidPeptideOrProtein"}, {"end": 229, "start": 226, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 219, "tag": "BiologicallyActiveSubstance"}, {"end": 229, "start": 226, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 58, "tag": "OrganismAttribute"}, {"end": 222, "start": 199, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 199, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 30, "tag": "ExperimentalModelOfDisease"}]}{"id": "1062_5", "text": "EV-treated trisomic CS demonstrated preserved size, partial rescue in the production of neurons, significantly decreased levels of A beta and p-tau, and a reduction in the extent of cell death as compared to the untreated trisomic CS.", "tags": [{"end": 221, "start": 212, "tag": "Finding"}, {"end": 192, "start": 182, "tag": "CellFunction"}, {"end": 2, "start": 0, "tag": "CellComponent"}, {"end": 137, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 155, "tag": "Finding"}, {"end": 164, "start": 155, "tag": "NaturalPhenomenonOrProcess"}, {"end": 95, "start": 88, "tag": "Cell"}, {"end": 50, "start": 46, "tag": "OrganismAttribute"}, {"end": 22, "start": 11, "tag": "ExperimentalModelOfDisease"}, {"end": 233, "start": 222, "tag": "ExperimentalModelOfDisease"}]}{"id": "1062_6", "text": "Together, these results show the efficacy of EVs in mitigating DS and AD-related cellular phenotypes and pathological depositions in human CS.", "tags": [{"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 90, "tag": "OrganismAttribute"}, {"end": 48, "start": 45, "tag": "CellComponent"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 133, "tag": "Eukaryote"}, {"end": 41, "start": 33, "tag": "Finding"}]}{"id": "1063_0", "text": "Cell-derived extracellular vesicles (EVs) are effectors of cell-to-cell communication that are in the spotlight as promising candidates for in vivo drug delivery because of their ability to enter cells and deliver cargo.", "tags": [{"end": 55, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 13, "tag": "CellComponent"}, {"end": 40, "start": 37, "tag": "CellComponent"}, {"end": 201, "start": 196, "tag": "Cell"}, {"end": 219, "start": 214, "tag": "CellComponent"}, {"end": 85, "start": 59, "tag": "CellFunction"}, {"end": 147, "start": 140, "tag": "ResearchActivity"}, {"end": 85, "start": 72, "tag": "HealthCareActivity"}, {"end": 85, "start": 72, "tag": "CellFunction"}, {"end": 186, "start": 179, "tag": "OrganismAttribute"}, {"end": 152, "start": 148, "tag": "PharmacologicSubstance"}, {"end": 85, "start": 67, "tag": "CellFunction"}, {"end": 161, "start": 153, "tag": "BiologicFunction"}, {"end": 161, "start": 148, "tag": "HealthCareActivity"}]}{"id": "1063_1", "text": "For example, proteins of interest can be loaded into EVs to mediate protein transfer into target cells.", "tags": [{"end": 84, "start": 68, "tag": "CellFunction"}, {"end": 56, "start": 53, "tag": "CellComponent"}, {"end": 21, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 90, "tag": "Cell"}, {"end": 75, "start": 68, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1063_2", "text": "To determine causality between EV content and function, which is also important to assess the clinical safety of EVs, it is crucial to comprehensively characterize their complete molecular composition.", "tags": [{"end": 41, "start": 34, "tag": "BiologicFunction"}, {"end": 116, "start": 113, "tag": "CellComponent"}, {"end": 33, "start": 31, "tag": "CellComponent"}, {"end": 109, "start": 94, "tag": "HealthCareActivity"}]}{"id": "1063_3", "text": "Here, we investigated EVs loaded with the chaperone protein DNAJB6.", "tags": [{"end": 66, "start": 60, "tag": "GeneOrGenome"}, {"end": 66, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 22, "tag": "CellComponent"}, {"end": 66, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 60, "tag": "BiologicallyActiveSubstance"}]}{"id": "1063_4", "text": "Chaperone proteins assist in protein folding and have been suggested to alleviate protein aggregation diseases, such as Alzheimer's disease and Huntington's disease.", "tags": [{"end": 44, "start": 29, "tag": "CellFunction"}, {"end": 164, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 82, "tag": "CellFunction"}, {"end": 110, "start": 82, "tag": "DiseaseOrSyndrome"}]}{"id": "1063_5", "text": "We analyzed and compared the proteome of EVs isolated from wildtype HEK293T cells with that of EVs from HEK 293T cells overexpressing DNAJB6-WT or loss-of-function mutant DNAJB6-M3.", "tags": [{"end": 67, "start": 59, "tag": "ResearchActivity"}, {"end": 44, "start": 41, "tag": "CellComponent"}, {"end": 98, "start": 95, "tag": "CellComponent"}, {"end": 81, "start": 68, "tag": "Cell"}, {"end": 118, "start": 104, "tag": "Cell"}, {"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 37, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 119, "tag": "CellFunction"}, {"end": 143, "start": 141, "tag": "ResearchActivity"}, {"end": 180, "start": 147, "tag": "CellOrMolecularDysfunction"}, {"end": 140, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 134, "tag": "GeneOrGenome"}, {"end": 140, "start": 134, "tag": "BiologicallyActiveSubstance"}]}{"id": "1063_6", "text": "Comprehensive analysis of proteomics data showed enhanced levels of DNAJB6 as well as protein-folding-related proteins in EVs derived from DNAJB6-overexpression cells.", "tags": [{"end": 74, "start": 68, "tag": "GeneOrGenome"}, {"end": 74, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 122, "tag": "CellComponent"}, {"end": 22, "start": 0, "tag": "ResearchActivity"}, {"end": 166, "start": 161, "tag": "Cell"}, {"end": 118, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 26, "tag": "ResearchActivity"}, {"end": 93, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 26, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 74, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 139, "tag": "GeneOrGenome"}]}{"id": "1063_7", "text": "Interestingly, upregulation of a chaperone and its protein-folding-related proteins resulted in downregulation of another chaperone plus its related proteins, and vice versa.", "tags": [{"end": 42, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 96, "tag": "CellFunction"}, {"end": 83, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 15, "tag": "CellFunction"}, {"end": 58, "start": 51, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1063_8", "text": "This implies the presence of compensatory mechanisms in the cellular expression of chaperones.", "tags": [{"end": 93, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 69, "tag": "CellFunction"}, {"end": 68, "start": 60, "tag": "Cell"}, {"end": 25, "start": 17, "tag": "Finding"}]}{"id": "1063_9", "text": "Collectively, we provide the proteomic EV signatures underlying EV mediated DNAJB6 transmission by HEK293T cells, with the aim of establishing a causal relationship between EV protein content and EV function.", "tags": [{"end": 82, "start": 76, "tag": "GeneOrGenome"}, {"end": 82, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 152, "tag": "Finding"}, {"end": 191, "start": 184, "tag": "BiologicFunction"}, {"end": 41, "start": 39, "tag": "CellComponent"}, {"end": 66, "start": 64, "tag": "CellComponent"}, {"end": 175, "start": 173, "tag": "CellComponent"}, {"end": 198, "start": 196, "tag": "CellComponent"}, {"end": 112, "start": 99, "tag": "Cell"}, {"end": 95, "start": 83, "tag": "Finding"}, {"end": 183, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 29, "tag": "ResearchActivity"}, {"end": 82, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 207, "start": 196, "tag": "CellFunction"}]}{"id": "1064_0", "text": "Over the past two decades, mesenchymal stromal cells (MSCs) have demonstrated great potential in the treatment of inflammation-related conditions.", "tags": [{"end": 52, "start": 27, "tag": "Cell"}, {"end": 25, "start": 18, "tag": "TemporalConcept"}, {"end": 13, "start": 9, "tag": "TemporalConcept"}, {"end": 126, "start": 114, "tag": "PathologicFunction"}, {"end": 110, "start": 101, "tag": "HealthCareActivity"}, {"end": 110, "start": 101, "tag": "ResearchActivity"}, {"end": 58, "start": 54, "tag": "Cell"}, {"end": 145, "start": 114, "tag": "DiseaseOrSyndrome"}]}{"id": "1064_1", "text": "Numerous early stage clinical trials have suggested that this treatment strategy has potential to lead to significant improvements in clinical outcomes.", "tags": [{"end": 151, "start": 134, "tag": "Finding"}, {"end": 20, "start": 9, "tag": "TemporalConcept"}, {"end": 71, "start": 62, "tag": "HealthCareActivity"}, {"end": 71, "start": 62, "tag": "ResearchActivity"}, {"end": 36, "start": 21, "tag": "ResearchActivity"}]}{"id": "1064_2", "text": "While promising, there remain substantial regulatory hurdles, safety concerns, and logistical issues that need to be addressed before cell-based treatments can have widespread clinical impact.", "tags": [{"end": 138, "start": 134, "tag": "Cell"}, {"end": 155, "start": 145, "tag": "HealthCareActivity"}, {"end": 155, "start": 145, "tag": "ResearchActivity"}, {"end": 68, "start": 62, "tag": "HealthCareActivity"}, {"end": 191, "start": 176, "tag": "Finding"}]}{"id": "1064_3", "text": "These drawbacks, along with research aimed at elucidating the mechanisms by which MSCs exert their therapeutic effects, have inspired the development of extracellular vesicles (EVs) as anti-inflammatory therapeutic agents.", "tags": [{"end": 221, "start": 203, "tag": "HealthCareActivity"}, {"end": 175, "start": 153, "tag": "CellComponent"}, {"end": 180, "start": 177, "tag": "CellComponent"}, {"end": 36, "start": 28, "tag": "ResearchActivity"}, {"end": 149, "start": 138, "tag": "BiologicFunction"}, {"end": 149, "start": 138, "tag": "CellFunction"}, {"end": 86, "start": 82, "tag": "Cell"}, {"end": 118, "start": 99, "tag": "Finding"}, {"end": 202, "start": 185, "tag": "BiologicFunction"}, {"end": 202, "start": 185, "tag": "PharmacologicSubstance"}]}{"id": "1064_4", "text": "The use of MSC-derived EVs for treating inflammation-related conditions has shown therapeutic potential in both in vitro and small animal studies.", "tags": [{"end": 26, "start": 23, "tag": "CellComponent"}, {"end": 52, "start": 40, "tag": "PathologicFunction"}, {"end": 145, "start": 138, "tag": "ResearchActivity"}, {"end": 120, "start": 112, "tag": "ResearchActivity"}, {"end": 14, "start": 11, "tag": "Cell"}, {"end": 103, "start": 82, "tag": "Finding"}, {"end": 137, "start": 131, "tag": "Eukaryote"}, {"end": 71, "start": 40, "tag": "DiseaseOrSyndrome"}]}{"id": "1064_5", "text": "This review will explore the current research landscape pertaining to the use of MSC-derived EVs as anti-inflammatory and pro-regenerative agents in a range of inflammation-related conditions: osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cardiovascular disease, and preeclampsia.", "tags": [{"end": 207, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 292, "start": 280, "tag": "PathologicFunction"}, {"end": 229, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 250, "start": 231, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 93, "tag": "CellComponent"}, {"end": 45, "start": 37, "tag": "ResearchActivity"}, {"end": 172, "start": 160, "tag": "PathologicFunction"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 36, "start": 29, "tag": "TemporalConcept"}, {"end": 84, "start": 81, "tag": "Cell"}, {"end": 274, "start": 252, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 100, "tag": "BiologicFunction"}, {"end": 117, "start": 100, "tag": "PharmacologicSubstance"}, {"end": 145, "start": 122, "tag": "PharmacologicSubstance"}, {"end": 191, "start": 160, "tag": "DiseaseOrSyndrome"}]}{"id": "1064_6", "text": "Along with this, the mechanisms by which MSC-derived EVs exert their beneficial effects on the damaged or degenerative tissues will be reviewed, giving insight into their therapeutic potential.", "tags": [{"end": 118, "start": 106, "tag": "PathologicFunction"}, {"end": 87, "start": 69, "tag": "Finding"}, {"end": 143, "start": 135, "tag": "HealthCareActivity"}, {"end": 143, "start": 135, "tag": "ResearchActivity"}, {"end": 56, "start": 53, "tag": "CellComponent"}, {"end": 44, "start": 41, "tag": "Cell"}, {"end": 192, "start": 171, "tag": "Finding"}, {"end": 87, "start": 80, "tag": "Finding"}, {"end": 126, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 95, "tag": "InjuryOrPoisoning"}]}{"id": "1064_7", "text": "Challenges and future perspectives on the use of MSC-derived EVs for the treatment of inflammation-related conditions will be discussed.", "tags": [{"end": 10, "start": 0, "tag": "HealthCareActivity"}, {"end": 64, "start": 61, "tag": "CellComponent"}, {"end": 98, "start": 86, "tag": "PathologicFunction"}, {"end": 82, "start": 73, "tag": "HealthCareActivity"}, {"end": 82, "start": 73, "tag": "ResearchActivity"}, {"end": 21, "start": 15, "tag": "TemporalConcept"}, {"end": 52, "start": 49, "tag": "Cell"}, {"end": 117, "start": 86, "tag": "DiseaseOrSyndrome"}]}{"id": "1065_0", "text": "Currently, Alzheimer's disease (AD) cannot be treated effectively.", "tags": [{"end": 9, "start": 0, "tag": "TemporalConcept"}, {"end": 30, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 32, "tag": "DiseaseOrSyndrome"}]}{"id": "1065_1", "text": "Mesenchymal stem cells (MSCs)-derived extracellular vesicles (EVs) (MSC-EVs) exhibit therapeutic effects on many diseases.", "tags": [{"end": 22, "start": 0, "tag": "Cell"}, {"end": 60, "start": 38, "tag": "CellComponent"}, {"end": 65, "start": 62, "tag": "CellComponent"}, {"end": 75, "start": 72, "tag": "CellComponent"}, {"end": 71, "start": 68, "tag": "Cell"}, {"end": 22, "start": 12, "tag": "Cell"}, {"end": 28, "start": 24, "tag": "Cell"}, {"end": 104, "start": 85, "tag": "Finding"}]}{"id": "1065_2", "text": "This study investigated the mechanism of bone marrow MSC-EVs (BM-MSC-EVs) in a rat model of AD.", "tags": [{"end": 52, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 79, "tag": "Eukaryote"}, {"end": 60, "start": 57, "tag": "CellComponent"}, {"end": 72, "start": 69, "tag": "CellComponent"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 88, "start": 83, "tag": "ResearchActivity"}, {"end": 56, "start": 53, "tag": "Cell"}, {"end": 68, "start": 65, "tag": "Cell"}, {"end": 45, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 79, "tag": "ExperimentalModelOfDisease"}]}{"id": "1065_3", "text": "The cognitive function, amyloid-beta (A beta) plaques, A beta deposition areas and levels of A beta 1-42, A beta decomposition-related factors (NEP and IDE), and inflammatory cytokines in BM-MSC-EVs-treated AD rats were measured.", "tags": [{"end": 214, "start": 210, "tag": "Eukaryote"}, {"end": 155, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 55, "tag": "CellFunction"}, {"end": 104, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 198, "start": 195, "tag": "CellComponent"}, {"end": 209, "start": 207, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 175, "tag": "BiologicallyActiveSubstance"}, {"end": 194, "start": 191, "tag": "Cell"}, {"end": 147, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 144, "tag": "GeneOrGenome"}, {"end": 22, "start": 4, "tag": "BiologicFunction"}, {"end": 53, "start": 46, "tag": "AnatomicalAbnormality"}, {"end": 36, "start": 24, "tag": "AnatomicalAbnormality"}, {"end": 155, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 152, "tag": "GeneOrGenome"}, {"end": 214, "start": 207, "tag": "ExperimentalModelOfDisease"}]}{"id": "1065_4", "text": "The effect of BM-MSC-EVs was studied in AD neuron model.", "tags": [{"end": 24, "start": 21, "tag": "CellComponent"}, {"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 43, "tag": "Cell"}, {"end": 55, "start": 50, "tag": "ResearchActivity"}, {"end": 10, "start": 4, "tag": "Finding"}, {"end": 20, "start": 17, "tag": "Cell"}, {"end": 55, "start": 40, "tag": "ExperimentalModelOfDisease"}]}{"id": "1065_5", "text": "microRNA (miR)-29c-3p and BACE1 expression, as well as levels of Wnt/beta-catenin pathway-related factors in AD and EVs-treated AD models were detected.", "tags": [{"end": 8, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 8, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 26, "tag": "GeneOrGenome"}, {"end": 31, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 116, "tag": "CellComponent"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 131, "tag": "ResearchActivity"}, {"end": 42, "start": 32, "tag": "CellFunction"}, {"end": 89, "start": 65, "tag": "CellFunction"}, {"end": 21, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 9, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 137, "start": 128, "tag": "ExperimentalModelOfDisease"}]}{"id": "1065_6", "text": "miR-29c-3p relationship with BACE1 was predicted and confirmed.", "tags": [{"end": 23, "start": 11, "tag": "Finding"}, {"end": 34, "start": 29, "tag": "GeneOrGenome"}, {"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1065_7", "text": "miR-29c-3p and BACE1 were interfered to verify the mechanism of EVs in AD.", "tags": [{"end": 20, "start": 15, "tag": "GeneOrGenome"}, {"end": 20, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 64, "tag": "CellComponent"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1065_8", "text": "The Wnt/beta-catenin pathway inhibitor DKK1 was further added to EVs-treated AD neurons.", "tags": [{"end": 43, "start": 39, "tag": "GeneOrGenome"}, {"end": 7, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 29, "tag": "PharmacologicSubstance"}, {"end": 38, "start": 29, "tag": "Chemical"}, {"end": 68, "start": 65, "tag": "CellComponent"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 80, "tag": "Cell"}, {"end": 28, "start": 4, "tag": "CellFunction"}, {"end": 43, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 39, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1065_9", "text": "BM-MSC-EVs showed therapeutic effects on AD rats and neurons.", "tags": [{"end": 48, "start": 44, "tag": "Eukaryote"}, {"end": 10, "start": 7, "tag": "CellComponent"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 53, "tag": "Cell"}, {"end": 6, "start": 3, "tag": "Cell"}, {"end": 37, "start": 18, "tag": "Finding"}]}{"id": "1065_10", "text": "BM-MSC-EVs carried miR-29c-3p into AD neurons.", "tags": [{"end": 10, "start": 7, "tag": "CellComponent"}, {"end": 37, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 38, "tag": "Cell"}, {"end": 6, "start": 3, "tag": "Cell"}, {"end": 29, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 19, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 45, "start": 35, "tag": "ExperimentalModelOfDisease"}]}{"id": "1065_11", "text": "miR-29c-3p targeted BACE1.", "tags": [{"end": 25, "start": 20, "tag": "GeneOrGenome"}, {"end": 25, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1065_12", "text": "Silencing miR-29c-3p in BM-MSCs reduced BM-MSC-EV therapeutic effect on AD, which was reversed after BACE1 knockdown.", "tags": [{"end": 9, "start": 0, "tag": "CellFunction"}, {"end": 106, "start": 101, "tag": "GeneOrGenome"}, {"end": 106, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 47, "tag": "CellComponent"}, {"end": 116, "start": 107, "tag": "ResearchActivity"}, {"end": 46, "start": 43, "tag": "Cell"}, {"end": 68, "start": 50, "tag": "Finding"}, {"end": 31, "start": 27, "tag": "Cell"}, {"end": 20, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 10, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1065_13", "text": "miR-29c-3p targeted BACE1 and activated the Wnt/beta-catenin pathway, and the Wnt/beta-catenin pathway inhibition impaired EV therapeutic effects on AD.", "tags": [{"end": 47, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 20, "tag": "GeneOrGenome"}, {"end": 25, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 123, "tag": "CellComponent"}, {"end": 113, "start": 103, "tag": "CellFunction"}, {"end": 68, "start": 44, "tag": "CellFunction"}, {"end": 102, "start": 78, "tag": "CellFunction"}, {"end": 145, "start": 126, "tag": "Finding"}, {"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1065_14", "text": "We highlighted that BM-MSC-EVs delivered miR-29c-3p to neurons to inhibit BACE1 expression and activate the Wnt/beta-catenin pathway, thereby playing a therapeutic role in AD.", "tags": [{"end": 111, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 74, "tag": "GeneOrGenome"}, {"end": 79, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 27, "tag": "CellComponent"}, {"end": 174, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 80, "tag": "CellFunction"}, {"end": 62, "start": 55, "tag": "Cell"}, {"end": 132, "start": 108, "tag": "CellFunction"}, {"end": 26, "start": 23, "tag": "Cell"}, {"end": 51, "start": 41, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 51, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 152, "tag": "Finding"}]}{"id": "1065_15", "text": "This study may provide a novel perspective for elucidating the mechanism of MSCs in the treatment of AD.", "tags": [{"end": 42, "start": 31, "tag": "BiologicFunction"}, {"end": 103, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 97, "start": 88, "tag": "HealthCareActivity"}, {"end": 97, "start": 88, "tag": "ResearchActivity"}, {"end": 80, "start": 76, "tag": "Cell"}]}{"id": "1066_2", "text": "However, other mechanisms involved in the air pollution effects on central nervous system (CNS) toxicity can be playing critical roles.", "tags": [{"end": 55, "start": 42, "tag": "EnvironmentalEffectOfHumans"}, {"end": 94, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 96, "tag": "InjuryOrPoisoning"}, {"end": 89, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1066_3", "text": "Increasingly, extracellular vesicle's (EVs) mediated intercellular communication is being recognized as impacting the development of cognitive impairment and neurological disorders like Alzheimer's disease and others.", "tags": [{"end": 35, "start": 14, "tag": "CellComponent"}, {"end": 80, "start": 53, "tag": "CellFunction"}, {"end": 180, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 39, "tag": "CellComponent"}, {"end": 129, "start": 118, "tag": "BiologicFunction"}, {"end": 129, "start": 118, "tag": "CellFunction"}, {"end": 153, "start": 133, "tag": "DiseaseOrSyndrome"}]}{"id": "1066_4", "text": "Here we describe the available evidence about toxic air pollutants and its components on brain, an involvement of brain cells specific and EVs types (based in the origin or in the size of EVs) in the initiation, exacerbation, and propagation of the neurotoxic effects (inflammation, neurodegeneration, and accumulation of neurotoxic proteins) induced by air pollution in the CNS.", "tags": [{"end": 51, "start": 46, "tag": "InjuryOrPoisoning"}, {"end": 66, "start": 52, "tag": "InjuryOrPoisoning"}, {"end": 267, "start": 249, "tag": "InjuryOrPoisoning"}, {"end": 367, "start": 354, "tag": "EnvironmentalEffectOfHumans"}, {"end": 125, "start": 114, "tag": "Cell"}, {"end": 378, "start": 375, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 169, "start": 163, "tag": "TemporalConcept"}, {"end": 224, "start": 212, "tag": "Finding"}, {"end": 39, "start": 31, "tag": "Finding"}, {"end": 110, "start": 99, "tag": "Finding"}, {"end": 341, "start": 333, "tag": "AminoAcidPeptideOrProtein"}, {"end": 318, "start": 306, "tag": "Finding"}, {"end": 94, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 300, "start": 283, "tag": "CellOrMolecularDysfunction"}, {"end": 142, "start": 139, "tag": "CellComponent"}, {"end": 191, "start": 188, "tag": "CellComponent"}, {"end": 210, "start": 200, "tag": "TemporalConcept"}, {"end": 281, "start": 269, "tag": "PathologicFunction"}, {"end": 184, "start": 180, "tag": "OrganismAttribute"}, {"end": 241, "start": 230, "tag": "Finding"}]}{"id": "1066_5", "text": "Additionally, we discuss the identification and isolation of neural-derived EVs from human plasma, the most common markers for neural-derived EVs, and their potential for use as diagnostic or therapeutic molecules for air pollution-related cognitive impairment and neurodegeneration.", "tags": [{"end": 213, "start": 178, "tag": "HealthCareActivity"}, {"end": 213, "start": 204, "tag": "Substance"}, {"end": 282, "start": 265, "tag": "CellOrMolecularDysfunction"}, {"end": 79, "start": 76, "tag": "CellComponent"}, {"end": 145, "start": 142, "tag": "CellComponent"}, {"end": 97, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 85, "tag": "Eukaryote"}, {"end": 260, "start": 240, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 218, "tag": "EnvironmentalEffectOfHumans"}, {"end": 79, "start": 48, "tag": "ResearchActivity"}]}{"id": "1067_0", "text": "Extracellular Vesicles (EVs) are released during various pathophysiological processes and reflect the state of their cell of origin.", "tags": [{"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 85, "start": 57, "tag": "BiologicFunction"}, {"end": 107, "start": 102, "tag": "PopulationGroup"}, {"end": 121, "start": 117, "tag": "Cell"}, {"end": 131, "start": 125, "tag": "TemporalConcept"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 75, "start": 57, "tag": "PathologicFunction"}]}{"id": "1067_1", "text": "Once released, they can propagate through biological fluids, target cells, deliver their content and elicit functional responses.", "tags": [{"end": 73, "start": 61, "tag": "Cell"}, {"end": 96, "start": 89, "tag": "BiologicFunction"}, {"end": 59, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1067_2", "text": "These specific features would allow their harnessing as biomarkers, drug nano-vehicles and therapeutic intrinsic modulators.", "tags": [{"end": 86, "start": 68, "tag": "ManufacturedObject"}, {"end": 66, "start": 56, "tag": "ClinicalAttribute"}, {"end": 72, "start": 68, "tag": "PharmacologicSubstance"}, {"end": 123, "start": 91, "tag": "HealthCareActivity"}]}{"id": "1067_3", "text": "However, the further development of their potential therapeutic application is hampered by the lack of knowledge about how EVs behave in vivo.", "tags": [{"end": 112, "start": 95, "tag": "Finding"}, {"end": 126, "start": 123, "tag": "CellComponent"}, {"end": 141, "start": 134, "tag": "ResearchActivity"}, {"end": 32, "start": 21, "tag": "BiologicFunction"}, {"end": 32, "start": 21, "tag": "CellFunction"}]}{"id": "1067_4", "text": "Recent advances in the field of imaging EVs in vivo now allow live-tracking of endogenous and exogenous EV in various model organisms at high spatiotemporal resolution to define their distribution, half-life and fate.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 15, "start": 7, "tag": "Finding"}, {"end": 133, "start": 124, "tag": "Organism"}, {"end": 207, "start": 198, "tag": "TemporalConcept"}, {"end": 43, "start": 40, "tag": "CellComponent"}, {"end": 106, "start": 104, "tag": "CellComponent"}, {"end": 123, "start": 118, "tag": "ResearchActivity"}, {"end": 39, "start": 32, "tag": "HealthCareActivity"}, {"end": 51, "start": 44, "tag": "ResearchActivity"}, {"end": 167, "start": 137, "tag": "ResearchActivity"}]}{"id": "1067_5", "text": "This review highlights current imaging tools available to image EVs in vivo and how live imaging especially in the zebrafish embryo can bring further insights into the characterization of EVs dynamics, biodistribution and functions to potentiate their development for therapeutic applications.", "tags": [{"end": 96, "start": 84, "tag": "HealthCareActivity"}, {"end": 131, "start": 125, "tag": "EmbryonicStructure"}, {"end": 184, "start": 168, "tag": "ResearchActivity"}, {"end": 124, "start": 115, "tag": "Eukaryote"}, {"end": 217, "start": 202, "tag": "BiologicFunction"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 67, "start": 64, "tag": "CellComponent"}, {"end": 191, "start": 188, "tag": "CellComponent"}, {"end": 38, "start": 31, "tag": "HealthCareActivity"}, {"end": 75, "start": 68, "tag": "ResearchActivity"}, {"end": 263, "start": 252, "tag": "BiologicFunction"}, {"end": 263, "start": 252, "tag": "CellFunction"}, {"end": 200, "start": 192, "tag": "NaturalPhenomenonOrProcess"}, {"end": 30, "start": 23, "tag": "TemporalConcept"}, {"end": 44, "start": 31, "tag": "ResearchActivity"}, {"end": 292, "start": 268, "tag": "HealthCareActivity"}]}{"id": "1067_6", "text": "(c) 2021 Elsevier B.V.", "tags": []}{"id": "1067_7", "text": "All rights reserved.", "tags": []}{"id": "1068_0", "text": "Extracellular vesicles (EVs) are indispensable mediators of intercellular communication, but they can also assume a nefarious role by ferrying pathological cargo that contributes to neurological, oncological, inflammatory, and infectious diseases.", "tags": [{"end": 56, "start": 47, "tag": "Finding"}, {"end": 207, "start": 196, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 207, "start": 196, "tag": "SignOrSymptom"}, {"end": 246, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 87, "start": 60, "tag": "CellFunction"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 161, "start": 156, "tag": "CellFunction"}]}{"id": "1068_1", "text": "The canonical pathway for generating EVs involves the endosomal sorting complexes required for transport (ESCRT) machinery, but an alternative pathway is induced by the enrichment of lipid membrane ceramides generated by neutral sphingomyelinase 2 (nSMase2).", "tags": [{"end": 104, "start": 95, "tag": "CellFunction"}, {"end": 104, "start": 95, "tag": "ManufacturedObject"}, {"end": 179, "start": 169, "tag": "ResearchActivity"}, {"end": 207, "start": 198, "tag": "Chemical"}, {"end": 247, "start": 221, "tag": "AminoAcidPeptideOrProtein"}, {"end": 247, "start": 221, "tag": "BiologicallyActiveSubstance"}, {"end": 256, "start": 249, "tag": "GeneOrGenome"}, {"end": 256, "start": 249, "tag": "AminoAcidPeptideOrProtein"}, {"end": 256, "start": 249, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 14, "tag": "CellFunction"}, {"end": 150, "start": 143, "tag": "CellFunction"}, {"end": 40, "start": 37, "tag": "CellComponent"}, {"end": 197, "start": 183, "tag": "CellComponent"}, {"end": 122, "start": 113, "tag": "CellComponent"}, {"end": 81, "start": 54, "tag": "CellComponent"}, {"end": 111, "start": 106, "tag": "CellComponent"}]}{"id": "1068_2", "text": "Inhibition of nSMase2 has become an attractive therapeutic strategy for inhibiting EV biogenesis, and a growing number of small-molecule nSMase2 inhibitors have shown promising therapeutic activity in preclinical disease models.", "tags": [{"end": 10, "start": 0, "tag": "BiologicFunction"}, {"end": 10, "start": 0, "tag": "CellFunction"}, {"end": 21, "start": 14, "tag": "GeneOrGenome"}, {"end": 21, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 72, "tag": "BiologicFunction"}, {"end": 96, "start": 86, "tag": "CellFunction"}, {"end": 67, "start": 47, "tag": "HealthCareActivity"}, {"end": 85, "start": 83, "tag": "CellComponent"}, {"end": 227, "start": 221, "tag": "ResearchActivity"}]}{"id": "1068_3", "text": "This review outlines the function of EVs, their potential role in disease, the discovery and efficacy of nSMase2 inhibitors, and the path to translate these findings into therapeutics.", "tags": [{"end": 183, "start": 171, "tag": "HealthCareActivity"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 88, "start": 79, "tag": "ResearchActivity"}, {"end": 40, "start": 37, "tag": "CellComponent"}, {"end": 101, "start": 93, "tag": "Finding"}, {"end": 112, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 113, "tag": "BiologicallyActiveSubstance"}]}{"id": "1069_0", "text": "The hallmarks of Alzheimer's disease (AD) pathology are senile plaques containing amyloid-beta (A beta) and neurofibrillary tangles containing hyperphosphorylated tau.", "tags": [{"end": 13, "start": 4, "tag": "Finding"}, {"end": 36, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 42, "tag": "PathologicFunction"}, {"end": 51, "start": 42, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 166, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 166, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 166, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 108, "tag": "CellOrMolecularDysfunction"}, {"end": 123, "start": 108, "tag": "CellComponent"}, {"end": 70, "start": 56, "tag": "AnatomicalAbnormality"}, {"end": 94, "start": 82, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1069_1", "text": "Additional pathologies often co-exist, whereas multiple pathogenic mechanisms are involved in AD, especially synaptic degeneration, which necessitate the need for synaptic integrity-related biomarkers alongside A beta- and tau-related biomarkers.", "tags": [{"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 226, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 200, "start": 190, "tag": "ClinicalAttribute"}, {"end": 245, "start": 235, "tag": "ClinicalAttribute"}, {"end": 226, "start": 223, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 56, "tag": "PathologicFunction"}, {"end": 217, "start": 211, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 109, "tag": "PathologicFunction"}, {"end": 181, "start": 163, "tag": "BiologicFunction"}]}{"id": "1069_2", "text": "Plasma neuron-derived Extracellular Vesicles EVs (NDEVs) provide biomarkers related to A beta and tau and synaptic degeneration.", "tags": [{"end": 127, "start": 115, "tag": "PathologicFunction"}, {"end": 44, "start": 22, "tag": "CellComponent"}, {"end": 48, "start": 45, "tag": "CellComponent"}, {"end": 13, "start": 7, "tag": "Cell"}, {"end": 114, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 65, "tag": "ClinicalAttribute"}, {"end": 101, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 50, "tag": "CellComponent"}]}{"id": "1069_3", "text": "Here, to further establish the latter as a liquid biopsy for AD, we examined their relationship with ante-mortem cognition in pathologically-confirmed AD cases.", "tags": [{"end": 95, "start": 83, "tag": "Finding"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 43, "tag": "HealthCareActivity"}, {"end": 122, "start": 113, "tag": "BiologicFunction"}, {"end": 112, "start": 101, "tag": "TemporalConcept"}]}{"id": "1069_4", "text": "We immunoprecipitated NDEVs by targeting neuronal marker L1CAM from ante-mortem plasma samples from 61 autopsy-confirmed cases of pure AD or AD with additional pathologies and measured A beta(42), p181-Tau, total Tau, synaptophysin, synaptopodin and three canonical EV markers, CD63, CD81 and CD9.", "tags": [{"end": 21, "start": 3, "tag": "ResearchActivity"}, {"end": 62, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 231, "start": 218, "tag": "AminoAcidPeptideOrProtein"}, {"end": 231, "start": 218, "tag": "BiologicallyActiveSubstance"}, {"end": 245, "start": 233, "tag": "BiologicallyActiveSubstance"}, {"end": 245, "start": 233, "tag": "AminoAcidPeptideOrProtein"}, {"end": 296, "start": 293, "tag": "BiologicallyActiveSubstance"}, {"end": 296, "start": 293, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 268, "start": 266, "tag": "CellComponent"}, {"end": 56, "start": 50, "tag": "ClinicalAttribute"}, {"end": 276, "start": 269, "tag": "ClinicalAttribute"}, {"end": 86, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 87, "tag": "Substance"}, {"end": 94, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 41, "tag": "Cell"}, {"end": 195, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 205, "start": 202, "tag": "BiologicallyActiveSubstance"}, {"end": 216, "start": 213, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 197, "tag": "BiologicallyActiveSubstance"}, {"end": 216, "start": 207, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 202, "tag": "AminoAcidPeptideOrProtein"}, {"end": 216, "start": 213, "tag": "AminoAcidPeptideOrProtein"}, {"end": 205, "start": 197, "tag": "AminoAcidPeptideOrProtein"}, {"end": 216, "start": 207, "tag": "AminoAcidPeptideOrProtein"}, {"end": 288, "start": 284, "tag": "GeneOrGenome"}, {"end": 282, "start": 278, "tag": "AminoAcidPeptideOrProtein"}, {"end": 282, "start": 278, "tag": "BiologicallyActiveSubstance"}, {"end": 288, "start": 284, "tag": "AminoAcidPeptideOrProtein"}, {"end": 288, "start": 284, "tag": "BiologicallyActiveSubstance"}, {"end": 282, "start": 278, "tag": "GeneOrGenome"}, {"end": 171, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 22, "tag": "CellComponent"}, {"end": 79, "start": 68, "tag": "TemporalConcept"}, {"end": 110, "start": 103, "tag": "HealthCareActivity"}, {"end": 195, "start": 185, "tag": "BiologicallyActiveSubstance"}]}{"id": "1069_5", "text": "Higher NDEV A beta(42) levels were consistently associated with better cognitive status, memory, fluency, working memory and executive function.", "tags": [{"end": 120, "start": 106, "tag": "BiologicFunction"}, {"end": 143, "start": 125, "tag": "BiologicFunction"}, {"end": 87, "start": 71, "tag": "BiologicFunction"}, {"end": 22, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 7, "tag": "CellComponent"}, {"end": 87, "start": 81, "tag": "Finding"}, {"end": 95, "start": 89, "tag": "BiologicFunction"}, {"end": 120, "start": 114, "tag": "BiologicFunction"}, {"end": 120, "start": 114, "tag": "Finding"}, {"end": 29, "start": 7, "tag": "ClinicalAttribute"}, {"end": 22, "start": 12, "tag": "BiologicallyActiveSubstance"}]}{"id": "1069_6", "text": "Higher levels of NDEV synaptic integrity-related biomarkers were associated with better performance on executive function tasks.", "tags": [{"end": 99, "start": 81, "tag": "Finding"}, {"end": 59, "start": 49, "tag": "ClinicalAttribute"}, {"end": 21, "start": 17, "tag": "CellComponent"}, {"end": 99, "start": 88, "tag": "Finding"}, {"end": 127, "start": 103, "tag": "BiologicFunction"}, {"end": 40, "start": 22, "tag": "BiologicFunction"}]}{"id": "1069_7", "text": "Our findings motivate the hypothesis that releasing A beta(42)-laden NDEVs may be an adaptive mechanism in AD.", "tags": [{"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 69, "tag": "CellComponent"}, {"end": 62, "start": 52, "tag": "BiologicallyActiveSubstance"}]}{"id": "1070_0", "text": "Extracellular vesicles (EVs) are mediators of cellular communication that can be released by almost all cell types in both physiological and pathological conditions and are present in most biological fluids.", "tags": [{"end": 164, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 206, "start": 189, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 206, "start": 200, "tag": "Substance"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 68, "start": 46, "tag": "CellFunction"}, {"end": 42, "start": 33, "tag": "Finding"}, {"end": 114, "start": 104, "tag": "Cell"}]}{"id": "1070_1", "text": "Such characteristics make them attractive in the research of biomarkers for age-related pathological conditions.", "tags": [{"end": 111, "start": 88, "tag": "PathologicFunction"}, {"end": 57, "start": 49, "tag": "ResearchActivity"}, {"end": 71, "start": 61, "tag": "ClinicalAttribute"}, {"end": 79, "start": 76, "tag": "OrganismAttribute"}]}{"id": "1070_2", "text": "Based on this, the aim of the present study was to examine the changes in EV concentration and size in the context of frailty, a geriatric syndrome associated with a progressive physical and cognitive decline.", "tags": [{"end": 125, "start": 118, "tag": "Finding"}, {"end": 76, "start": 74, "tag": "CellComponent"}, {"end": 43, "start": 38, "tag": "ResearchActivity"}, {"end": 177, "start": 166, "tag": "TemporalConcept"}, {"end": 208, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 95, "tag": "OrganismAttribute"}, {"end": 208, "start": 201, "tag": "Finding"}, {"end": 186, "start": 178, "tag": "Finding"}, {"end": 90, "start": 77, "tag": "BiologicFunction"}, {"end": 147, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 63, "tag": "Finding"}]}{"id": "1070_3", "text": "Specifically, total EVs and neural and microglial-derived EVs (NDVs and MDVs respectively) were investigated in plasma of frail and non-frail controls (CTRL), mild cognitive impairment (MCI) subjects, and in Alzheimer's disease (AD) patients.", "tags": [{"end": 127, "start": 122, "tag": "Finding"}, {"end": 189, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 227, "start": 208, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 20, "tag": "CellComponent"}, {"end": 61, "start": 49, "tag": "CellComponent"}, {"end": 34, "start": 28, "tag": "CellComponent"}, {"end": 231, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 241, "start": 233, "tag": "PatientOrDisabledGroup"}, {"end": 118, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 132, "tag": "PopulationGroup"}, {"end": 199, "start": 191, "tag": "PopulationGroup"}, {"end": 184, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 39, "tag": "CellComponent"}, {"end": 67, "start": 63, "tag": "CellComponent"}, {"end": 76, "start": 72, "tag": "CellComponent"}]}{"id": "1070_4", "text": "Results provided evidence that AD patients displayed diminished NDV concentration (3.61 x 10(9) +/- 1.92 x 10(9) vs 7.16 x 10(9) +/- 4.3 x 10(9) particles/ml) and showed high diagnostic performance.", "tags": [{"end": 33, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 34, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 25, "start": 17, "tag": "Finding"}, {"end": 174, "start": 170, "tag": "Finding"}, {"end": 154, "start": 145, "tag": "Chemical"}, {"end": 197, "start": 175, "tag": "Finding"}, {"end": 67, "start": 64, "tag": "CellComponent"}]}{"id": "1070_5", "text": "They are able to discriminate between AD and CTRL with an area under the curve of 0.80, a sensitivity of 78.95% and a specificity of 85.7%, considering the cut-off of 5.27 x 10(9) particles/ml.", "tags": [{"end": 40, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 58, "tag": "ResearchActivity"}, {"end": 129, "start": 118, "tag": "Finding"}, {"end": 101, "start": 90, "tag": "Finding"}, {"end": 189, "start": 180, "tag": "Chemical"}, {"end": 163, "start": 156, "tag": "ResearchActivity"}]}{"id": "1070_6", "text": "Importantly, we also found that MDV concentration was increased in frail MCI patients compared to CTRL (5.89 x 10(9) +/- 3.98 x 10(9) vs 3.16 x 10(9) +/- 3.04 x 10(9) particles/ml, P < 0.05) and showed high neurotoxic effect on neurons.", "tags": [{"end": 35, "start": 32, "tag": "CellComponent"}, {"end": 72, "start": 67, "tag": "Finding"}, {"end": 76, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 77, "tag": "PatientOrDisabledGroup"}, {"end": 224, "start": 218, "tag": "Finding"}, {"end": 206, "start": 202, "tag": "Finding"}, {"end": 235, "start": 228, "tag": "Cell"}, {"end": 176, "start": 167, "tag": "Chemical"}, {"end": 217, "start": 207, "tag": "InjuryOrPoisoning"}]}{"id": "1070_7", "text": "MDV concentration discriminate frail MCI vs non-frail CTRL (AUC = 0.76) with a sensitivity of 80% and a specificity of 70%, considering the cut-off of 2.69 x 10(9) particles/ml.", "tags": [{"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 36, "start": 31, "tag": "Finding"}, {"end": 40, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 60, "tag": "ResearchActivity"}, {"end": 115, "start": 104, "tag": "Finding"}, {"end": 90, "start": 79, "tag": "Finding"}, {"end": 173, "start": 164, "tag": "Chemical"}, {"end": 17, "start": 4, "tag": "BiologicFunction"}, {"end": 147, "start": 140, "tag": "ResearchActivity"}]}{"id": "1070_8", "text": "Altogether, these results demonstrated an alteration in NDV and MDV release during cognitive decline, providing important insight into the role of EVs in frailty status.", "tags": [{"end": 59, "start": 56, "tag": "CellComponent"}, {"end": 67, "start": 64, "tag": "CellComponent"}, {"end": 52, "start": 42, "tag": "Finding"}, {"end": 150, "start": 147, "tag": "CellComponent"}, {"end": 100, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 162, "tag": "Finding"}, {"end": 100, "start": 93, "tag": "Finding"}, {"end": 75, "start": 68, "tag": "HealthCareActivity"}, {"end": 75, "start": 68, "tag": "ResearchActivity"}, {"end": 161, "start": 154, "tag": "Finding"}]}{"id": "1071_0", "text": "The processing of the amyloid precursor protein (APP) is one of the key events contributing to Alzheimer's disease (AD) etiology.", "tags": [{"end": 114, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 49, "tag": "GeneOrGenome"}, {"end": 52, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 120, "tag": "Finding"}, {"end": 47, "start": 40, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1071_1", "text": "Canonical cleavages by beta- and gamma-secretases lead to A beta production which accumulate in amyloid plaques.", "tags": [{"end": 49, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 82, "tag": "Finding"}, {"end": 111, "start": 96, "tag": "AnatomicalAbnormality"}, {"end": 64, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 58, "tag": "CellFunction"}, {"end": 49, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 23, "tag": "BiologicallyActiveSubstance"}]}{"id": "1071_2", "text": "Recently, the matrix metalloprotease MT5-MMP, referred to as eta-secretase, has been identified as a novel APP cleaving enzyme producing a transmembrane fragment, eta CTF that undergoes subsequent cleavages by alpha- and beta-secretases yielding the A eta alpha and A eta beta peptides, respectively.", "tags": [{"end": 74, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 61, "tag": "GeneOrGenome"}, {"end": 170, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 206, "start": 197, "tag": "CellFunction"}, {"end": 236, "start": 221, "tag": "BiologicallyActiveSubstance"}, {"end": 236, "start": 221, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 41, "tag": "GeneOrGenome"}, {"end": 44, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 107, "tag": "GeneOrGenome"}, {"end": 110, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 126, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 285, "start": 266, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 285, "start": 277, "tag": "AminoAcidPeptideOrProtein"}, {"end": 261, "start": 250, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1071_3", "text": "The functions and contributions of eta CTF and its related fragments to AD pathology are poorly understood.", "tags": [{"end": 42, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 75, "tag": "PathologicFunction"}, {"end": 84, "start": 75, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1071_4", "text": "In this study, we designed a novel immunological probe referred to as eta CTF-NTer antibody that specifically interacts with the N-terminal part of eta CTF targeting eta CTF, A eta alpha, A eta beta but not C99, C83 and A beta.", "tags": [{"end": 91, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 226, "start": 220, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 186, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 198, "start": 188, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1071_5", "text": "We examined the fate and localization of eta CTF fragment in various cell models and in mice.", "tags": [{"end": 48, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 88, "tag": "Eukaryote"}, {"end": 73, "start": 69, "tag": "Cell"}, {"end": 80, "start": 74, "tag": "ResearchActivity"}]}{"id": "1071_6", "text": "We found that overexpressed eta CTF undergoes degradation in the proteasomal and autophagic pathways and accumulates mainly in the Golgi and in endosomes.", "tags": [{"end": 35, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 105, "tag": "Finding"}, {"end": 136, "start": 131, "tag": "CellComponent"}, {"end": 57, "start": 46, "tag": "NaturalPhenomenonOrProcess"}, {"end": 100, "start": 92, "tag": "CellFunction"}, {"end": 153, "start": 144, "tag": "CellComponent"}, {"end": 27, "start": 14, "tag": "CellFunction"}, {"end": 91, "start": 81, "tag": "CellFunction"}, {"end": 76, "start": 65, "tag": "CellComponent"}]}{"id": "1071_7", "text": "Moreover, we observed the presence of eta CTF in small extracellular vesicles purified from neuroblastoma cells or from mouse brains expressing eta CTF.", "tags": [{"end": 45, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 133, "tag": "CellFunction"}, {"end": 105, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 55, "tag": "CellComponent"}, {"end": 111, "start": 106, "tag": "Cell"}, {"end": 125, "start": 120, "tag": "Eukaryote"}, {"end": 34, "start": 26, "tag": "Finding"}, {"end": 132, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 77, "start": 49, "tag": "CellComponent"}]}{"id": "1071_8", "text": "Importantly, the expression of eta CTF in fibroblasts devoid on APP leads to A beta production demonstrating its contribution to the amyloidogenic pathway.", "tags": [{"end": 38, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 42, "tag": "Cell"}, {"end": 67, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 64, "tag": "GeneOrGenome"}, {"end": 67, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 17, "tag": "CellFunction"}, {"end": 83, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 133, "tag": "CellFunction"}, {"end": 94, "start": 77, "tag": "CellFunction"}]}{"id": "1071_9", "text": "Finally, we observed an eta CTF-like immunoreactivity around amyloid plaques and an age-dependent accumulation of eta CTF in the triple-transgenic mouse AD model.", "tags": [{"end": 121, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 37, "tag": "CellFunction"}, {"end": 76, "start": 61, "tag": "AnatomicalAbnormality"}, {"end": 155, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 98, "tag": "Finding"}, {"end": 161, "start": 156, "tag": "ResearchActivity"}, {"end": 87, "start": 84, "tag": "OrganismAttribute"}, {"end": 152, "start": 147, "tag": "Eukaryote"}, {"end": 31, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 129, "tag": "ExperimentalModelOfDisease"}]}{"id": "1071_10", "text": "Thus, our study suggests that the eta CTF fragment likely contributes to AD pathology by its exosomal spreading and involvement in A beta production.", "tags": [{"end": 41, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 10, "tag": "ResearchActivity"}, {"end": 85, "start": 76, "tag": "PathologicFunction"}, {"end": 85, "start": 76, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 137, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 131, "tag": "CellFunction"}, {"end": 127, "start": 116, "tag": "Finding"}, {"end": 101, "start": 93, "tag": "CellComponent"}, {"end": 111, "start": 93, "tag": "CellFunction"}]}{"id": "1072_0", "text": "Chronic Traumatic Encephalopathy (CTE) is a tauopathy that affects individuals with a history of exposure to repetitive head impacts, including National Football League (NFL) players.", "tags": [{"end": 32, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 86, "tag": "Finding"}, {"end": 78, "start": 67, "tag": "PopulationGroup"}, {"end": 53, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 144, "tag": "PopulationGroup"}, {"end": 108, "start": 97, "tag": "InjuryOrPoisoning"}, {"end": 132, "start": 120, "tag": "InjuryOrPoisoning"}, {"end": 119, "start": 109, "tag": "TemporalConcept"}]}{"id": "1072_1", "text": "Extracellular vesicles (EVs) are known to carry tau in Alzheimer's disease and other tauopathies.", "tags": [{"end": 96, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 51, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 0, "tag": "CellComponent"}]}{"id": "1072_2", "text": "We examined protein profiles of EVs separated from the plasma of former NFL players at risk for CTE.", "tags": [{"end": 99, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 32, "tag": "CellComponent"}, {"end": 61, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 20, "tag": "ResearchActivity"}, {"end": 91, "start": 87, "tag": "Finding"}, {"end": 19, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 72, "tag": "PopulationGroup"}]}{"id": "1072_3", "text": "EVs were separated from the plasma from former NFL players and age-matched controls using size-exclusion chromatography.", "tags": [{"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 34, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 75, "tag": "PopulationGroup"}, {"end": 66, "start": 63, "tag": "OrganismAttribute"}, {"end": 58, "start": 47, "tag": "PopulationGroup"}, {"end": 119, "start": 90, "tag": "ResearchActivity"}]}{"id": "1072_4", "text": "Label-free quantitative proteomic analysis identified 675 proteins in plasma EVs, and 17 proteins were significantly differentially expressed between former NFL players and controls.", "tags": [{"end": 160, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 77, "tag": "CellComponent"}, {"end": 42, "start": 0, "tag": "ResearchActivity"}, {"end": 76, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 181, "start": 173, "tag": "PopulationGroup"}, {"end": 168, "start": 161, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 43, "tag": "Finding"}, {"end": 141, "start": 117, "tag": "Finding"}, {"end": 141, "start": 132, "tag": "CellFunction"}]}{"id": "1072_5", "text": "Total tau (t-tau) and tau phosphorylated at threonie181 (ptau181) in plasma-derived EVs were measured by ultrasensitive immunoassay.", "tags": [{"end": 87, "start": 84, "tag": "CellComponent"}, {"end": 75, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 26, "tag": "CellFunction"}, {"end": 9, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 105, "tag": "ResearchActivity"}, {"end": 9, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 57, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1072_6", "text": "Level of t-tau and p-tau181 in EVs were significantly different, and the area under the receiver operating characteristic curve (AUC) of t-tau and ptau181 showed 0.736 and 0.715, respectively.", "tags": [{"end": 132, "start": 129, "tag": "ResearchActivity"}, {"end": 127, "start": 73, "tag": "ResearchActivity"}, {"end": 34, "start": 31, "tag": "CellComponent"}, {"end": 142, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 147, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1072_7", "text": "Machine learning analysis indicated that a combination of collagen type VI alpha 3 and 1 chain (COL6A3 and COL6A1) and reelin (RELN) can distinguish former NFL players from controls with 85% accuracy (AUC = 0.85).", "tags": [{"end": 94, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 96, "tag": "GeneOrGenome"}, {"end": 102, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 107, "tag": "GeneOrGenome"}, {"end": 125, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 127, "tag": "GeneOrGenome"}, {"end": 131, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 0, "tag": "MachineActivity"}, {"end": 204, "start": 201, "tag": "ResearchActivity"}, {"end": 16, "start": 8, "tag": "BiologicFunction"}, {"end": 25, "start": 17, "tag": "ResearchActivity"}, {"end": 181, "start": 173, "tag": "PopulationGroup"}, {"end": 167, "start": 156, "tag": "PopulationGroup"}, {"end": 102, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 199, "start": 191, "tag": "Finding"}]}{"id": "1072_8", "text": "Based on the plasma EV proteomics, these data provide protein profiling of plasma EVs for CTE, and indicate combination of COL6A3, RELN and COL6A1 in plasma EVs may serve as the potential diagnostic biomarkers for CTE.", "tags": [{"end": 71, "start": 54, "tag": "ResearchActivity"}, {"end": 93, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 123, "tag": "GeneOrGenome"}, {"end": 129, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 131, "tag": "GeneOrGenome"}, {"end": 135, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 140, "tag": "GeneOrGenome"}, {"end": 217, "start": 214, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 82, "tag": "CellComponent"}, {"end": 160, "start": 157, "tag": "CellComponent"}, {"end": 22, "start": 20, "tag": "CellComponent"}, {"end": 19, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 41, "tag": "ResearchActivity"}, {"end": 33, "start": 23, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 209, "start": 188, "tag": "ClinicalAttribute"}, {"end": 129, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 13, "tag": "ResearchActivity"}]}{"id": "1073_0", "text": "Mitochondria provide energy to neurons through oxidative phosphorylation and eliminate Reactive Oxygen Species (ROS) through Superoxide Dismutase 1 (SOD1).", "tags": [{"end": 27, "start": 21, "tag": "NaturalPhenomenonOrProcess"}, {"end": 72, "start": 47, "tag": "CellFunction"}, {"end": 110, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 0, "tag": "CellComponent"}, {"end": 153, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 149, "tag": "GeneOrGenome"}, {"end": 153, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 112, "tag": "Chemical"}, {"end": 38, "start": 31, "tag": "Cell"}, {"end": 110, "start": 87, "tag": "Chemical"}]}{"id": "1073_1", "text": "Dysfunctional mitochondria, manifesting decreased activity of electron transport chain (ETC) complexes and high ROS levels, are involved in Alzheimer's disease (AD) pathogenesis.", "tags": [{"end": 102, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 112, "tag": "Chemical"}, {"end": 159, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 165, "tag": "PathologicFunction"}, {"end": 111, "start": 107, "tag": "Finding"}, {"end": 58, "start": 40, "tag": "Finding"}, {"end": 26, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 102, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 88, "tag": "BiologicallyActiveSubstance"}]}{"id": "1073_2", "text": "We hypothesized that neuronal mitochondrial dysfunction in AD is reflected in ETC and SOD1 levels and activity in plasma neuron-derived extracellular vesicles (NDEVs).", "tags": [{"end": 81, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 86, "tag": "GeneOrGenome"}, {"end": 90, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 121, "tag": "CellComponent"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 121, "tag": "Cell"}, {"end": 120, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 21, "tag": "Cell"}, {"end": 55, "start": 30, "tag": "CellOrMolecularDysfunction"}, {"end": 165, "start": 160, "tag": "CellComponent"}]}{"id": "1073_3", "text": "We immunoprecipitated NDEVs targeting neuronal marker L1CAM from two cohorts: one including 22 individuals with early AD and 29 control subjects; and another including 14 individuals with early AD and 14 control subjects.", "tags": [{"end": 21, "start": 3, "tag": "ResearchActivity"}, {"end": 59, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 54, "tag": "GeneOrGenome"}, {"end": 76, "start": 69, "tag": "PopulationGroup"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 196, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 47, "tag": "ClinicalAttribute"}, {"end": 46, "start": 38, "tag": "Cell"}, {"end": 120, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 196, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 128, "tag": "PopulationGroup"}, {"end": 220, "start": 204, "tag": "PopulationGroup"}, {"end": 144, "start": 136, "tag": "PopulationGroup"}, {"end": 220, "start": 212, "tag": "PopulationGroup"}, {"end": 106, "start": 95, "tag": "PopulationGroup"}, {"end": 182, "start": 171, "tag": "PopulationGroup"}, {"end": 27, "start": 22, "tag": "CellComponent"}, {"end": 59, "start": 54, "tag": "BiologicallyActiveSubstance"}]}{"id": "1073_4", "text": "In the first cohort, we measured levels of complexes I, III, IV, ATP synthase, and SOD1; in the second cohort, we measured levels and catalytic activity of complexes IV and ATP synthase.", "tags": [{"end": 54, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 134, "tag": "CellFunction"}, {"end": 168, "start": 156, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 83, "tag": "GeneOrGenome"}, {"end": 87, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 13, "tag": "PopulationGroup"}, {"end": 109, "start": 103, "tag": "PopulationGroup"}, {"end": 12, "start": 7, "tag": "TemporalConcept"}, {"end": 54, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 43, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1073_5", "text": "AD individuals had lower levels of complexes I (p < 0.0001), III (p < 0.0001), IV (p = 0.0061), and V (p < 0.0001), and SOD1 (p < 0.0001) compared to controls.", "tags": [{"end": 46, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 120, "tag": "GeneOrGenome"}, {"end": 124, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 150, "tag": "PopulationGroup"}, {"end": 14, "start": 3, "tag": "PopulationGroup"}, {"end": 46, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 100, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1073_6", "text": "AD individuals also had lower levels of catalytic activity of complex IV (p = 0.0214) and ATP synthase (p < 0.0001).", "tags": [{"end": 58, "start": 40, "tag": "CellFunction"}, {"end": 72, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 3, "tag": "PopulationGroup"}, {"end": 72, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 90, "tag": "BiologicallyActiveSubstance"}]}{"id": "1073_7", "text": "NDEVs confirm quantitative and functional abnormalities in ECT complexes and SOD1 previously observed in AD models and during autopsy, opening the way for using them as biomarkers for mitochondrial dysfunction in AD.", "tags": [{"end": 133, "start": 126, "tag": "HealthCareActivity"}, {"end": 81, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 77, "tag": "GeneOrGenome"}, {"end": 81, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 169, "tag": "ClinicalAttribute"}, {"end": 114, "start": 108, "tag": "ResearchActivity"}, {"end": 209, "start": 184, "tag": "CellOrMolecularDysfunction"}, {"end": 3, "start": 2, "tag": "CellComponent"}, {"end": 114, "start": 105, "tag": "ExperimentalModelOfDisease"}]}{"id": "1074_0", "text": "ObjectivesThere is a lack of effective biomarkers for neurodegenerative diseases (NDs) such as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia.", "tags": [{"end": 181, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 39, "tag": "ClinicalAttribute"}, {"end": 80, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 176, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 211, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 82, "tag": "DiseaseOrSyndrome"}]}{"id": "1074_1", "text": "Extracellular vesicle (EV) RNA cargo can have an interesting potential as a non-invasive biomarker for NDs.", "tags": [{"end": 88, "start": 80, "tag": "Finding"}, {"end": 98, "start": 76, "tag": "ClinicalAttribute"}, {"end": 21, "start": 0, "tag": "CellComponent"}, {"end": 25, "start": 23, "tag": "CellComponent"}, {"end": 98, "start": 89, "tag": "ClinicalAttribute"}, {"end": 88, "start": 76, "tag": "Finding"}, {"end": 36, "start": 31, "tag": "CellFunction"}, {"end": 106, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 27, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1074_2", "text": "However, the knowledge about the abundance of EV-mRNAs and their contribution to neurodegeneration is not clear.", "tags": [{"end": 48, "start": 46, "tag": "CellComponent"}, {"end": 22, "start": 13, "tag": "Finding"}, {"end": 98, "start": 81, "tag": "CellOrMolecularDysfunction"}, {"end": 54, "start": 49, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 54, "start": 49, "tag": "BiologicallyActiveSubstance"}]}{"id": "1074_3", "text": "MethodsLarge and small EVs (LEVs and SEVs) were isolated from plasma of patients and healthy volunteers (control, CTR) by differential centrifugation and filtration, and RNA was extracted.", "tags": [{"end": 41, "start": 37, "tag": "CellComponent"}, {"end": 103, "start": 85, "tag": "PopulationGroup"}, {"end": 164, "start": 154, "tag": "ResearchActivity"}, {"end": 32, "start": 28, "tag": "CellComponent"}, {"end": 149, "start": 122, "tag": "ResearchActivity"}, {"end": 117, "start": 114, "tag": "PopulationGroup"}, {"end": 26, "start": 17, "tag": "CellComponent"}, {"end": 26, "start": 23, "tag": "CellComponent"}, {"end": 12, "start": 7, "tag": "CellComponent"}, {"end": 92, "start": 85, "tag": "OrganismAttribute"}, {"end": 80, "start": 72, "tag": "PatientOrDisabledGroup"}, {"end": 68, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 173, "start": 170, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1074_4", "text": "Whole transcriptome was carried out using next generation sequencing (NGS).", "tags": [{"end": 68, "start": 42, "tag": "ResearchActivity"}, {"end": 19, "start": 6, "tag": "MolecularSequence"}, {"end": 73, "start": 70, "tag": "ResearchActivity"}, {"end": 19, "start": 0, "tag": "ResearchActivity"}]}{"id": "1074_5", "text": "ResultsCoding RNA (i.e., mRNA) but not long non-coding RNAs (lncRNAs) in SEVs and LEVs of patients with ALS could be distinguished from healthy CTRs and from other NDs using the principal component analysis (PCA).", "tags": [{"end": 211, "start": 208, "tag": "ResearchActivity"}, {"end": 107, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 73, "tag": "CellComponent"}, {"end": 86, "start": 82, "tag": "CellComponent"}, {"end": 148, "start": 144, "tag": "PopulationGroup"}, {"end": 59, "start": 39, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 59, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 143, "start": 136, "tag": "OrganismAttribute"}, {"end": 98, "start": 90, "tag": "PatientOrDisabledGroup"}, {"end": 206, "start": 178, "tag": "ResearchActivity"}, {"end": 59, "start": 44, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 68, "start": 61, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 59, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 167, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 25, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 17, "start": 14, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 59, "start": 55, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 29, "start": 25, "tag": "BiologicallyActiveSubstance"}]}{"id": "1074_6", "text": "Some mRNAs were found in commonly deregulated between SEVs of patients with ALS and frontotemporal dementia (FTD), and they were classified in mRNA processing and splicing pathways.", "tags": [{"end": 158, "start": 143, "tag": "CellFunction"}, {"end": 79, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 54, "tag": "CellComponent"}, {"end": 70, "start": 62, "tag": "PatientOrDisabledGroup"}, {"end": 180, "start": 163, "tag": "CellFunction"}, {"end": 107, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 143, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 10, "start": 5, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 10, "start": 5, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 143, "tag": "BiologicallyActiveSubstance"}]}{"id": "1074_7", "text": "In LEVs, instead, one mRNA and one antisense RNA (i.e., MAP3K7CL and AP003068.3) were found to be in common among ALS, FTD, and PD.", "tags": [{"end": 48, "start": 35, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 64, "start": 56, "tag": "GeneOrGenome"}, {"end": 117, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 3, "tag": "CellComponent"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 22, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 48, "start": 45, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 26, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 69, "tag": "GeneOrGenome"}]}{"id": "1074_8", "text": "No deregulated mRNAs were found in EVs of patients with AD.", "tags": [{"end": 38, "start": 35, "tag": "CellComponent"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 42, "tag": "PatientOrDisabledGroup"}, {"end": 20, "start": 15, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 20, "start": 15, "tag": "BiologicallyActiveSubstance"}]}{"id": "1074_9", "text": "ConclusionDifferent RNA regulation occurs in LEVs and SEVs of NDs.", "tags": [{"end": 58, "start": 54, "tag": "CellComponent"}, {"end": 49, "start": 45, "tag": "CellComponent"}, {"end": 65, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 20, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1074_10", "text": "mRNAs and lncRNAs are present in plasma-derived EVs of NDs, and there are common and specific transcripts that characterize LEVs and SEVs from the NDs considered in this study.", "tags": [{"end": 105, "start": 94, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 137, "start": 133, "tag": "CellComponent"}, {"end": 128, "start": 124, "tag": "CellComponent"}, {"end": 51, "start": 48, "tag": "CellComponent"}, {"end": 175, "start": 170, "tag": "ResearchActivity"}, {"end": 39, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 10, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 17, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 5, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1075_0", "text": "Mesenchymal stem cells (MSCs) are crucial for tissue homeostasis and repair, secreting vesicles to the extracellular environment.", "tags": [{"end": 22, "start": 0, "tag": "Cell"}, {"end": 52, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 103, "tag": "CellComponent"}, {"end": 64, "start": 53, "tag": "BiologicFunction"}, {"end": 95, "start": 87, "tag": "CellComponent"}, {"end": 22, "start": 12, "tag": "Cell"}, {"end": 28, "start": 24, "tag": "Cell"}, {"end": 75, "start": 69, "tag": "BiologicFunction"}, {"end": 75, "start": 69, "tag": "HealthCareActivity"}, {"end": 128, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1075_1", "text": "Isolated exosomes were shown to affect angiogenesis, immunomodulation and tissue regeneration.", "tags": [{"end": 69, "start": 53, "tag": "BiologicFunction"}, {"end": 69, "start": 53, "tag": "HealthCareActivity"}, {"end": 93, "start": 74, "tag": "BiologicFunction"}, {"end": 93, "start": 74, "tag": "HealthCareActivity"}, {"end": 80, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 9, "tag": "CellComponent"}, {"end": 51, "start": 39, "tag": "BiologicFunction"}]}{"id": "1075_2", "text": "Numerous efforts have been dedicated to describe the mechanism of action of these extracellular vesicles (EVs) and guarantee their safety, since the final aim is their therapeutic application in the clinic.", "tags": [{"end": 191, "start": 168, "tag": "HealthCareActivity"}, {"end": 104, "start": 82, "tag": "CellComponent"}, {"end": 109, "start": 106, "tag": "CellComponent"}, {"end": 205, "start": 199, "tag": "HealthCareRelatedOrganization"}, {"end": 137, "start": 131, "tag": "HealthCareActivity"}]}{"id": "1075_3", "text": "The major advantage of applying MSC-derived EVs is their low or inexistent immunogenicity, prompting their use as drug delivery or therapeutic agents, as well as wound healing, different cancer types, and inflammatory processes in the neurological and cardiovascular systems.", "tags": [{"end": 175, "start": 162, "tag": "BiologicFunction"}, {"end": 175, "start": 162, "tag": "Finding"}, {"end": 274, "start": 252, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 131, "tag": "HealthCareActivity"}, {"end": 89, "start": 75, "tag": "CellFunction"}, {"end": 47, "start": 44, "tag": "CellComponent"}, {"end": 193, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 57, "tag": "Finding"}, {"end": 35, "start": 32, "tag": "Cell"}, {"end": 118, "start": 114, "tag": "PharmacologicSubstance"}, {"end": 127, "start": 119, "tag": "BiologicFunction"}, {"end": 127, "start": 114, "tag": "HealthCareActivity"}, {"end": 274, "start": 267, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 247, "start": 235, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 227, "start": 205, "tag": "PathologicFunction"}]}{"id": "1075_4", "text": "MSC-derived EVs display no vascular obstruction effects or apparent adverse effects.", "tags": [{"end": 47, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 68, "tag": "PathologicFunction"}, {"end": 47, "start": 36, "tag": "Finding"}, {"end": 35, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 12, "tag": "CellComponent"}, {"end": 3, "start": 0, "tag": "Cell"}, {"end": 55, "start": 48, "tag": "Finding"}]}{"id": "1075_5", "text": "Their nano-size ensures their passage through the blood-brain barrier, demonstrating no cytotoxic or immunogenic effects.", "tags": [{"end": 69, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 11, "tag": "OrganismAttribute"}, {"end": 120, "start": 113, "tag": "PathologicFunction"}, {"end": 97, "start": 88, "tag": "PathologicFunction"}, {"end": 120, "start": 101, "tag": "Finding"}]}{"id": "1075_6", "text": "Several in vitro tests have been conducted with EVs obtained from different sources to understand their biology, molecular content, signaling pathways, and mechanisms of action.", "tags": [{"end": 130, "start": 113, "tag": "CellFunction"}, {"end": 51, "start": 48, "tag": "CellComponent"}, {"end": 83, "start": 76, "tag": "Finding"}, {"end": 111, "start": 104, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 150, "start": 132, "tag": "CellFunction"}, {"end": 111, "start": 104, "tag": "BiologicFunction"}, {"end": 22, "start": 8, "tag": "ResearchActivity"}]}{"id": "1075_7", "text": "Application of EVs to human therapies has recently become a reality, with clinical trials being conducted to treat Alzheimer's disease, retina degeneration, and COVID-19 patients.", "tags": [{"end": 155, "start": 136, "tag": "PathologicFunction"}, {"end": 169, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 136, "tag": "Cell"}, {"end": 155, "start": 143, "tag": "PathologicFunction"}, {"end": 134, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 15, "tag": "CellComponent"}, {"end": 178, "start": 170, "tag": "PatientOrDisabledGroup"}, {"end": 27, "start": 22, "tag": "Eukaryote"}, {"end": 50, "start": 42, "tag": "TemporalConcept"}, {"end": 37, "start": 28, "tag": "HealthCareActivity"}, {"end": 89, "start": 74, "tag": "ResearchActivity"}]}{"id": "1075_8", "text": "Herein, we describe and compare the different extracellular vesicles isolation methods and therapeutic applications regarding the tissue repair and regeneration process, presenting the latest clinical trial reports.", "tags": [{"end": 143, "start": 130, "tag": "BiologicFunction"}, {"end": 191, "start": 185, "tag": "TemporalConcept"}, {"end": 160, "start": 148, "tag": "BiologicFunction"}, {"end": 160, "start": 148, "tag": "HealthCareActivity"}, {"end": 115, "start": 91, "tag": "HealthCareActivity"}, {"end": 68, "start": 46, "tag": "CellComponent"}, {"end": 214, "start": 207, "tag": "HealthCareActivity"}, {"end": 214, "start": 207, "tag": "ResearchActivity"}, {"end": 136, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 206, "start": 192, "tag": "ResearchActivity"}, {"end": 143, "start": 137, "tag": "BiologicFunction"}, {"end": 143, "start": 137, "tag": "HealthCareActivity"}, {"end": 86, "start": 46, "tag": "ResearchActivity"}]}{"id": "1076_0", "text": "Extracellular vesicles have been identified as pivotal mediators of intercellular communication with critical roles in physiological and pathological conditions.", "tags": [{"end": 160, "start": 137, "tag": "PathologicFunction"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 64, "start": 55, "tag": "Finding"}, {"end": 95, "start": 68, "tag": "CellFunction"}, {"end": 95, "start": 82, "tag": "HealthCareActivity"}, {"end": 95, "start": 82, "tag": "CellFunction"}]}{"id": "1076_1", "text": "Via this route, several molecules (e.g., nucleic acids, proteins, metabolites) can be transferred to proximal and distant targets to convey specific information.", "tags": [{"end": 77, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 41, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 33, "start": 24, "tag": "Substance"}]}{"id": "1076_2", "text": "Extracellular vesicle-associated cargo molecules have been proposed as markers of several disease conditions for their potential of tracking down the generating cell.", "tags": [{"end": 21, "start": 0, "tag": "CellComponent"}, {"end": 78, "start": 71, "tag": "ClinicalAttribute"}, {"end": 165, "start": 161, "tag": "Cell"}, {"end": 38, "start": 33, "tag": "CellFunction"}, {"end": 48, "start": 39, "tag": "Substance"}, {"end": 108, "start": 90, "tag": "DiseaseOrSyndrome"}]}{"id": "1076_3", "text": "Indeed, circulating extracellular vesicles may represent biomarkers of dysfunctional cellular quality control systems especially in conditions characterized by the accrual of intracellular misfolded proteins.", "tags": [{"end": 84, "start": 71, "tag": "PathologicFunction"}, {"end": 188, "start": 175, "tag": "CellComponent"}, {"end": 42, "start": 20, "tag": "CellComponent"}, {"end": 67, "start": 57, "tag": "ClinicalAttribute"}, {"end": 42, "start": 8, "tag": "CellComponent"}, {"end": 207, "start": 189, "tag": "CellOrMolecularDysfunction"}, {"end": 117, "start": 85, "tag": "CellFunction"}, {"end": 117, "start": 71, "tag": "CellOrMolecularDysfunction"}]}{"id": "1076_4", "text": "Furthermore, the identification of extracellular vesicles as tools for the delivery of nucleic acids or other cargo molecules to diseased tissues makes these circulating shuttles possible targets for therapeutic development.", "tags": [{"end": 223, "start": 200, "tag": "ResearchActivity"}, {"end": 57, "start": 35, "tag": "CellComponent"}, {"end": 223, "start": 212, "tag": "BiologicFunction"}, {"end": 223, "start": 212, "tag": "CellFunction"}, {"end": 115, "start": 110, "tag": "CellFunction"}, {"end": 100, "start": 87, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 125, "start": 116, "tag": "Substance"}, {"end": 145, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 75, "tag": "BiologicFunction"}, {"end": 145, "start": 129, "tag": "PathologicFunction"}]}{"id": "1076_5", "text": "The increasing interest in the study of extracellular vesicles as biomarkers resides mainly in the fact that the identification of peripheral levels of extracellular vesicle-associated proteins might reflect molecular events occurring in hardly accessible tissues, such as the brain, thereby serving as a brain liquid biopsy.", "tags": [{"end": 324, "start": 305, "tag": "HealthCareActivity"}, {"end": 23, "start": 4, "tag": "Finding"}, {"end": 173, "start": 152, "tag": "CellComponent"}, {"end": 62, "start": 40, "tag": "CellComponent"}, {"end": 36, "start": 31, "tag": "ResearchActivity"}, {"end": 282, "start": 277, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 66, "tag": "ClinicalAttribute"}, {"end": 141, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 263, "start": 256, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1076_6", "text": "The exploitation of extracellular vesicles for diagnostic and therapeutic purposed might offer unprecedented opportunities to develop personalized approaches.", "tags": [{"end": 16, "start": 4, "tag": "Finding"}, {"end": 42, "start": 20, "tag": "CellComponent"}]}{"id": "1076_7", "text": "Here, we discuss the bright and dark sides of extracellular vesicles in the setting of two main neurodegenerative diseases (i.e., Parkinson's and Alzheimer's diseases).", "tags": [{"end": 166, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 46, "tag": "CellComponent"}, {"end": 122, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 130, "tag": "DiseaseOrSyndrome"}]}{"id": "1076_8", "text": "A special focus will be placed on the possibility of using extracellular vesicles as biomarkers for the two conditions to enable disease tracking and treatment monitoring.", "tags": [{"end": 81, "start": 59, "tag": "CellComponent"}, {"end": 95, "start": 85, "tag": "ClinicalAttribute"}, {"end": 159, "start": 150, "tag": "HealthCareActivity"}, {"end": 159, "start": 150, "tag": "ResearchActivity"}, {"end": 170, "start": 160, "tag": "HealthCareActivity"}, {"end": 145, "start": 129, "tag": "HealthCareActivity"}]}{"id": "1077_0", "text": "Stem cell-based therapy is a promising approach for treating a variety of disorders, including acute brain insults and neurodegenerative diseases.", "tags": [{"end": 100, "start": 95, "tag": "TemporalConcept"}, {"end": 145, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 0, "tag": "HealthCareActivity"}, {"end": 114, "start": 95, "tag": "DiseaseOrSyndrome"}]}{"id": "1077_1", "text": "Stem cells such as mesenchymal stem cells (MSCs) secrete extracellular vesicles (EVs), circular membrane fragments (30 nm-1 mu m) that are shed from the cell surface, carrying several therapeutic molecules such as proteins and microRNAs.", "tags": [{"end": 10, "start": 0, "tag": "Cell"}, {"end": 165, "start": 153, "tag": "CellComponent"}, {"end": 205, "start": 196, "tag": "Substance"}, {"end": 236, "start": 227, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 236, "start": 227, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 43, "tag": "Cell"}, {"end": 41, "start": 19, "tag": "Cell"}, {"end": 114, "start": 96, "tag": "CellComponent"}, {"end": 222, "start": 214, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 57, "tag": "CellComponent"}, {"end": 84, "start": 81, "tag": "CellComponent"}, {"end": 205, "start": 184, "tag": "HealthCareActivity"}]}{"id": "1077_2", "text": "Because EV-based therapy is superior to cell therapy in terms of scalable production, biodistribution, and safety profiles, it can be used to treat brain diseases as an alternative to stem cell therapy.", "tags": [{"end": 162, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 184, "tag": "HealthCareActivity"}, {"end": 52, "start": 40, "tag": "HealthCareActivity"}, {"end": 122, "start": 114, "tag": "ResearchActivity"}, {"end": 101, "start": 86, "tag": "BiologicFunction"}, {"end": 122, "start": 107, "tag": "ResearchActivity"}, {"end": 113, "start": 107, "tag": "HealthCareActivity"}, {"end": 10, "start": 8, "tag": "CellComponent"}, {"end": 24, "start": 8, "tag": "HealthCareActivity"}]}{"id": "1077_3", "text": "This review presents evidences evaluating the role of stem cell-derived EVs in stroke, traumatic brain injury, and degenerative brain diseases, such as Alzheimer's disease and Parkinson' disease.", "tags": [{"end": 109, "start": 87, "tag": "InjuryOrPoisoning"}, {"end": 85, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 21, "tag": "Finding"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 194, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 171, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 72, "tag": "CellComponent"}, {"end": 127, "start": 115, "tag": "PathologicFunction"}, {"end": 63, "start": 54, "tag": "Cell"}, {"end": 142, "start": 115, "tag": "DiseaseOrSyndrome"}]}{"id": "1077_4", "text": "In addition, stem cell-derived EVs have better profiles in biocompatibility, immunogenicity, and safety than those of small chemical and macromolecules.", "tags": [{"end": 75, "start": 59, "tag": "CellFunction"}, {"end": 91, "start": 77, "tag": "ResearchActivity"}, {"end": 132, "start": 118, "tag": "Chemical"}, {"end": 151, "start": 137, "tag": "Chemical"}, {"end": 55, "start": 47, "tag": "ResearchActivity"}, {"end": 103, "start": 97, "tag": "HealthCareActivity"}, {"end": 34, "start": 31, "tag": "CellComponent"}, {"end": 22, "start": 13, "tag": "Cell"}]}{"id": "1077_5", "text": "The advantages and disadvantages of EVs compared with other strategies are discussed.", "tags": [{"end": 70, "start": 60, "tag": "ResearchActivity"}, {"end": 39, "start": 36, "tag": "CellComponent"}, {"end": 70, "start": 60, "tag": "BiologicFunction"}]}{"id": "1077_6", "text": "Even though EVs obtained from native stem cells have potential in the treatment of brain diseases, the successful clinical application is limited by the short half-life, limited targeting, rapid clearance after application, and insufficient payload.", "tags": [{"end": 97, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 228, "tag": "Finding"}, {"end": 204, "start": 195, "tag": "NaturalPhenomenonOrProcess"}, {"end": 134, "start": 114, "tag": "HealthCareActivity"}, {"end": 168, "start": 159, "tag": "TemporalConcept"}, {"end": 15, "start": 12, "tag": "CellComponent"}, {"end": 79, "start": 70, "tag": "HealthCareActivity"}, {"end": 79, "start": 70, "tag": "ResearchActivity"}, {"end": 47, "start": 37, "tag": "Cell"}, {"end": 168, "start": 164, "tag": "TemporalConcept"}]}{"id": "1077_7", "text": "We discuss the strategies to enhance the efficacy of EV therapeutics.", "tags": [{"end": 25, "start": 15, "tag": "BiologicFunction"}, {"end": 68, "start": 53, "tag": "HealthCareActivity"}, {"end": 55, "start": 53, "tag": "CellComponent"}, {"end": 25, "start": 15, "tag": "ResearchActivity"}, {"end": 49, "start": 41, "tag": "Finding"}]}{"id": "1077_8", "text": "Finally, EV therapies have yet to be approved by the regulatory authorities.", "tags": [{"end": 21, "start": 9, "tag": "HealthCareActivity"}, {"end": 11, "start": 9, "tag": "CellComponent"}, {"end": 75, "start": 53, "tag": "HealthCareRelatedOrganization"}]}{"id": "1077_9", "text": "Major issues are discussed together with relevant advances in the clinical application of EV therapeutics.", "tags": [{"end": 58, "start": 50, "tag": "Finding"}, {"end": 86, "start": 66, "tag": "HealthCareActivity"}, {"end": 105, "start": 90, "tag": "HealthCareActivity"}, {"end": 92, "start": 90, "tag": "CellComponent"}]}{"id": "1078_0", "text": "In the clinical course of Alzheimer's disease (AD) development, the dementia phase is commonly preceded by a prodromal AD phase, which is mainly characterized by reaching the highest levels of A beta and p-tau-mediated neuronal injury and a mild cognitive impairment (MCI) clinical status.", "tags": [{"end": 271, "start": 268, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 7, "tag": "TemporalConcept"}, {"end": 121, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 77, "tag": "TemporalConcept"}, {"end": 127, "start": 122, "tag": "TemporalConcept"}, {"end": 22, "start": 16, "tag": "TemporalConcept"}, {"end": 45, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 51, "tag": "BiologicFunction"}, {"end": 62, "start": 51, "tag": "CellFunction"}, {"end": 209, "start": 206, "tag": "AminoAcidPeptideOrProtein"}, {"end": 209, "start": 206, "tag": "BiologicallyActiveSubstance"}, {"end": 227, "start": 219, "tag": "Cell"}, {"end": 209, "start": 204, "tag": "AminoAcidPeptideOrProtein"}, {"end": 209, "start": 204, "tag": "BiologicallyActiveSubstance"}, {"end": 199, "start": 193, "tag": "AminoAcidPeptideOrProtein"}, {"end": 245, "start": 241, "tag": "Finding"}, {"end": 266, "start": 246, "tag": "DiseaseOrSyndrome"}, {"end": 266, "start": 241, "tag": "DiseaseOrSyndrome"}, {"end": 234, "start": 228, "tag": "InjuryOrPoisoning"}, {"end": 288, "start": 273, "tag": "ClinicalAttribute"}]}{"id": "1078_1", "text": "Because of that, most AD cases are diagnosed when neuronal damage is already established and irreversible.", "tags": [{"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 50, "tag": "Cell"}, {"end": 44, "start": 35, "tag": "HealthCareActivity"}, {"end": 65, "start": 59, "tag": "InjuryOrPoisoning"}]}{"id": "1078_2", "text": "Therefore, a differential diagnosis of MCI causes in these prodromal stages is one of the greatest challenges for clinicians.", "tags": [{"end": 75, "start": 59, "tag": "SignOrSymptom"}, {"end": 42, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 114, "tag": "HealthCareActivity"}, {"end": 35, "start": 13, "tag": "HealthCareActivity"}, {"end": 35, "start": 26, "tag": "HealthCareActivity"}, {"end": 109, "start": 99, "tag": "HealthCareActivity"}, {"end": 75, "start": 69, "tag": "TemporalConcept"}]}{"id": "1078_3", "text": "Blood biomarkers are emerging as desirable tools for pre-screening purposes, but the current results are still being analyzed and much more data is needed to be implemented in clinical practice.", "tags": [{"end": 16, "start": 6, "tag": "ClinicalAttribute"}, {"end": 193, "start": 176, "tag": "HealthCareActivity"}, {"end": 125, "start": 117, "tag": "ResearchActivity"}, {"end": 92, "start": 85, "tag": "TemporalConcept"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 140, "tag": "ResearchActivity"}, {"end": 66, "start": 57, "tag": "HealthCareActivity"}, {"end": 66, "start": 57, "tag": "ResearchActivity"}]}{"id": "1078_4", "text": "Because of that, plasma extracellular vesicles (pEVs) are gaining popularity as a new source of biomarkers for the early stages of AD development.", "tags": [{"end": 52, "start": 48, "tag": "CellComponent"}, {"end": 46, "start": 24, "tag": "CellComponent"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 134, "tag": "BiologicFunction"}, {"end": 145, "start": 134, "tag": "CellFunction"}, {"end": 106, "start": 96, "tag": "ClinicalAttribute"}, {"end": 127, "start": 121, "tag": "TemporalConcept"}, {"end": 127, "start": 115, "tag": "TemporalConcept"}]}{"id": "1078_5", "text": "To identify an exosome proteomics signature linked to prodromal AD, we performed a cross-sectional study in a cohort of early-onset MCI (EOMCI) patients in which 184 biomarkers were measured in pEVs, cerebrospinal fluid (CSF), and plasma samples using multiplex PEA technology of Olink((c)) proteomics.", "tags": [{"end": 198, "start": 194, "tag": "CellComponent"}, {"end": 135, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 34, "tag": "ResearchActivity"}, {"end": 116, "start": 110, "tag": "PopulationGroup"}, {"end": 104, "start": 83, "tag": "ResearchActivity"}, {"end": 66, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 144, "tag": "PatientOrDisabledGroup"}, {"end": 224, "start": 221, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 166, "tag": "ClinicalAttribute"}, {"end": 245, "start": 231, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 219, "start": 200, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 15, "tag": "CellComponent"}, {"end": 131, "start": 126, "tag": "TemporalConcept"}, {"end": 33, "start": 23, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 301, "start": 291, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 125, "start": 120, "tag": "TemporalConcept"}, {"end": 142, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 301, "start": 252, "tag": "ResearchActivity"}]}{"id": "1078_6", "text": "The obtained results showed that proteins measured in pEVs from EOMCI patients with established amyloidosis correlated with CSF p-tau(181) levels, brain ventricle volume changes, brain hyperintensities, and MMSE scores.", "tags": [{"end": 58, "start": 54, "tag": "CellComponent"}, {"end": 107, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 96, "tag": "GeneOrGenome"}, {"end": 162, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 207, "tag": "HealthCareActivity"}, {"end": 218, "start": 212, "tag": "Finding"}, {"end": 50, "start": 42, "tag": "HealthCareActivity"}, {"end": 78, "start": 70, "tag": "PatientOrDisabledGroup"}, {"end": 127, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 179, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 124, "tag": "ClinicalAttribute"}, {"end": 169, "start": 153, "tag": "ClinicalAttribute"}, {"end": 177, "start": 170, "tag": "Finding"}, {"end": 201, "start": 179, "tag": "ClinicalAttribute"}, {"end": 69, "start": 64, "tag": "DiseaseOrSyndrome"}]}{"id": "1078_7", "text": "In addition, the correlations of pEVs proteins with different parameters distinguished between EOMCI A beta( +) and A beta(-) patients, whereas the CSF or plasma proteome did not.", "tags": [{"end": 134, "start": 126, "tag": "PatientOrDisabledGroup"}, {"end": 161, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 17, "tag": "ResearchActivity"}, {"end": 170, "start": 162, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 33, "tag": "CellComponent"}, {"end": 100, "start": 95, "tag": "DiseaseOrSyndrome"}]}{"id": "1078_8", "text": "In conclusion, our findings suggest that pEVs may be able to provide information regarding the initial amyloidotic changes of AD.", "tags": [{"end": 45, "start": 41, "tag": "CellComponent"}, {"end": 102, "start": 95, "tag": "TemporalConcept"}, {"end": 128, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 103, "tag": "Finding"}]}{"id": "1078_9", "text": "Circulating exosomes may acquire a pathological protein signature of AD before raw plasma, becoming potential biomarkers for identifying subjects at the earliest stages of AD development.", "tags": [{"end": 161, "start": 153, "tag": "TemporalConcept"}, {"end": 65, "start": 56, "tag": "ResearchActivity"}, {"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 175, "tag": "BiologicFunction"}, {"end": 186, "start": 175, "tag": "CellFunction"}, {"end": 120, "start": 110, "tag": "ClinicalAttribute"}, {"end": 145, "start": 137, "tag": "PopulationGroup"}, {"end": 168, "start": 162, "tag": "TemporalConcept"}, {"end": 120, "start": 100, "tag": "ClinicalAttribute"}, {"end": 20, "start": 0, "tag": "CellComponent"}, {"end": 55, "start": 35, "tag": "PathologicFunction"}]}{"id": "1078_10", "text": "Highlights The pEVs proteome revealed early molecular differences between EOMCI A beta(+) and A beta(-) subjects.", "tags": [{"end": 19, "start": 15, "tag": "CellComponent"}, {"end": 28, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 44, "tag": "Finding"}, {"end": 86, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 104, "tag": "PopulationGroup"}, {"end": 43, "start": 38, "tag": "TemporalConcept"}, {"end": 79, "start": 74, "tag": "DiseaseOrSyndrome"}]}{"id": "1078_11", "text": "Olink((c)) neurology proteins from pEVs of EOMCI A beta(+) patients exhibited a strong negative correlation with CSF p-tau181.", "tags": [{"end": 39, "start": 35, "tag": "CellComponent"}, {"end": 20, "start": 11, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 67, "start": 59, "tag": "PatientOrDisabledGroup"}, {"end": 116, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 0, "tag": "ResearchActivity"}, {"end": 48, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 80, "tag": "Finding"}, {"end": 125, "start": 113, "tag": "ClinicalAttribute"}]}{"id": "1078_12", "text": "The levels of pEVs and CSF-Olink((c)) proteins correlated with CSF p-tau(181) levels and age.", "tags": [{"end": 18, "start": 14, "tag": "CellComponent"}, {"end": 26, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 89, "tag": "OrganismAttribute"}, {"end": 46, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 27, "tag": "ResearchActivity"}, {"end": 84, "start": 63, "tag": "ClinicalAttribute"}]}{"id": "1078_13", "text": "Brain MRI characteristics of EOMCI A beta(+) patients correlated with pEVs protein levels.", "tags": [{"end": 9, "start": 6, "tag": "HealthCareActivity"}, {"end": 53, "start": 45, "tag": "PatientOrDisabledGroup"}, {"end": 41, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 29, "tag": "DiseaseOrSyndrome"}]}{"id": "1078_14", "text": "pEVs biomarkers only linked early signs of inflammation to brain atrophy in EOMCI A beta(+) individuals.", "tags": [{"end": 4, "start": 0, "tag": "CellComponent"}, {"end": 39, "start": 34, "tag": "SignOrSymptom"}, {"end": 15, "start": 5, "tag": "ClinicalAttribute"}, {"end": 55, "start": 43, "tag": "PathologicFunction"}, {"end": 88, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 92, "tag": "PopulationGroup"}, {"end": 72, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 28, "tag": "TemporalConcept"}, {"end": 81, "start": 76, "tag": "DiseaseOrSyndrome"}]}{"id": "1078_15", "text": "The correlation of cognitive status and pEVs biomarkers differed between EOMCI A beta(+) and A beta(-) patients.", "tags": [{"end": 44, "start": 40, "tag": "CellComponent"}, {"end": 35, "start": 19, "tag": "BiologicFunction"}, {"end": 111, "start": 103, "tag": "PatientOrDisabledGroup"}, {"end": 55, "start": 45, "tag": "ClinicalAttribute"}, {"end": 85, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 29, "tag": "Finding"}, {"end": 78, "start": 73, "tag": "DiseaseOrSyndrome"}]}{"id": "1079_0", "text": "Background: aFGF content in serum and cerebrospinal fluid is increased in Alzheimer's disease (AD) patients and attenuates the activation of astrocytes.", "tags": [{"end": 16, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 12, "tag": "GeneOrGenome"}, {"end": 151, "start": 141, "tag": "Cell"}, {"end": 93, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "PatientOrDisabledGroup"}, {"end": 33, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 12, "tag": "ClinicalAttribute"}, {"end": 151, "start": 127, "tag": "CellFunction"}]}{"id": "1079_1", "text": "Extracellular vesicles (EVs) are a major mediator in astrocyte-neuron communications.", "tags": [{"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 69, "start": 63, "tag": "Cell"}, {"end": 62, "start": 53, "tag": "Cell"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 84, "start": 53, "tag": "CellFunction"}]}{"id": "1079_2", "text": "Since excessive or persistent reactive astrocytes lead to chronic inflammation and neuronal dysfunction, and the activation of astrocytes can be inhibited by aFGF, we proposed that the cargoes of astrocyte-derived EVs (AEVs) might be modified by aFGF stimulation, playing an important role in AD progression.", "tags": [{"end": 29, "start": 19, "tag": "TemporalConcept"}, {"end": 162, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 158, "tag": "GeneOrGenome"}, {"end": 250, "start": 246, "tag": "AminoAcidPeptideOrProtein"}, {"end": 250, "start": 246, "tag": "GeneOrGenome"}, {"end": 262, "start": 251, "tag": "HealthCareActivity"}, {"end": 262, "start": 251, "tag": "NaturalPhenomenonOrProcess"}, {"end": 103, "start": 83, "tag": "CellOrMolecularDysfunction"}, {"end": 49, "start": 30, "tag": "Cell"}, {"end": 137, "start": 127, "tag": "Cell"}, {"end": 205, "start": 196, "tag": "Cell"}, {"end": 307, "start": 296, "tag": "PathologicFunction"}, {"end": 307, "start": 296, "tag": "TemporalConcept"}, {"end": 217, "start": 214, "tag": "CellComponent"}, {"end": 295, "start": 293, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 58, "tag": "TemporalConcept"}, {"end": 78, "start": 58, "tag": "PathologicFunction"}, {"end": 78, "start": 66, "tag": "PathologicFunction"}, {"end": 137, "start": 113, "tag": "CellFunction"}, {"end": 162, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 223, "start": 219, "tag": "CellComponent"}, {"end": 250, "start": 246, "tag": "BiologicallyActiveSubstance"}]}{"id": "1079_3", "text": "However, the mechanisms underlying the role of aFGF remain unclear.", "tags": [{"end": 51, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 47, "tag": "GeneOrGenome"}, {"end": 51, "start": 47, "tag": "BiologicallyActiveSubstance"}]}{"id": "1079_4", "text": "Methods: AEVs were isolated from damaged astrocytes, treated with or without aFGF in AP-loading condition, and were intranasally administered to AD mice.", "tags": [{"end": 65, "start": 53, "tag": "HealthCareActivity"}, {"end": 81, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 77, "tag": "GeneOrGenome"}, {"end": 51, "start": 33, "tag": "CellOrMolecularDysfunction"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 148, "tag": "Eukaryote"}, {"end": 13, "start": 9, "tag": "CellComponent"}, {"end": 81, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 116, "tag": "HealthCareActivity"}, {"end": 141, "start": 116, "tag": "ResearchActivity"}]}{"id": "1079_5", "text": "We determined the ability of AEVs to enter the brain, ameliorate cognitive behavior deficits, alleviate the AP burden in the brain, and improve synapse ultrastructure.", "tags": [{"end": 151, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 111, "tag": "ResearchActivity"}, {"end": 52, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 18, "tag": "OrganismAttribute"}, {"end": 33, "start": 29, "tag": "CellComponent"}, {"end": 92, "start": 65, "tag": "DiseaseOrSyndrome"}]}{"id": "1079_6", "text": "Subsequently, the miRNAs enriched in AEVs were sequenced to identify the key molecules specifically modified by aFGF.", "tags": [{"end": 116, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 112, "tag": "GeneOrGenome"}, {"end": 86, "start": 77, "tag": "Substance"}, {"end": 24, "start": 18, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 24, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 37, "tag": "CellComponent"}, {"end": 116, "start": 112, "tag": "BiologicallyActiveSubstance"}]}{"id": "1079_7", "text": "Finally, we explored the protective effects of mi R-206-3p inhibition on cognitive deficiency and its regulatory mechanism and determined its role as a specific biomarker for potential AD diagnosis.", "tags": [{"end": 69, "start": 59, "tag": "CellFunction"}, {"end": 197, "start": 188, "tag": "HealthCareActivity"}, {"end": 187, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 161, "tag": "ClinicalAttribute"}, {"end": 43, "start": 25, "tag": "Finding"}, {"end": 93, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 47, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 58, "start": 47, "tag": "BiologicallyActiveSubstance"}]}{"id": "1079_8", "text": "Results: AEVs stimulated by aFGF (defined as AEVs-Ap+H) had favorable neuroprotection in AD pathology by enhancing neurite growth and reduction of AP loading on neurons in vitro.", "tags": [{"end": 24, "start": 14, "tag": "NaturalPhenomenonOrProcess"}, {"end": 32, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 28, "tag": "GeneOrGenome"}, {"end": 122, "start": 115, "tag": "CellComponent"}, {"end": 168, "start": 161, "tag": "Cell"}, {"end": 177, "start": 169, "tag": "ResearchActivity"}, {"end": 129, "start": 123, "tag": "BiologicFunction"}, {"end": 85, "start": 70, "tag": "CellFunction"}, {"end": 143, "start": 134, "tag": "Finding"}, {"end": 143, "start": 134, "tag": "NaturalPhenomenonOrProcess"}, {"end": 91, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 92, "tag": "PathologicFunction"}, {"end": 101, "start": 92, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 13, "start": 9, "tag": "CellComponent"}, {"end": 32, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 115, "tag": "CellFunction"}]}{"id": "1079_9", "text": "Following intranasal administration, AEVs-Ap+H ameliorated cognitive behavior deficits, promoted synaptic plasticity, and alleviated brain AP burden in the APP/PS1 and AP brain-injected mice.", "tags": [{"end": 35, "start": 10, "tag": "HealthCareActivity"}, {"end": 170, "start": 168, "tag": "HealthCareActivity"}, {"end": 116, "start": 97, "tag": "CellFunction"}, {"end": 116, "start": 97, "tag": "BiologicFunction"}, {"end": 159, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 156, "tag": "GeneOrGenome"}, {"end": 159, "start": 156, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 142, "tag": "ResearchActivity"}, {"end": 138, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 186, "tag": "Eukaryote"}, {"end": 86, "start": 59, "tag": "DiseaseOrSyndrome"}]}{"id": "1079_10", "text": "AEVs-Ap+H showed beneficial effects on AD similar to AEVs produced in normal situations (AEVs-ctrl).", "tags": [{"end": 76, "start": 70, "tag": "Finding"}, {"end": 41, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 17, "tag": "Finding"}]}{"id": "1079_11", "text": "aFGF stimulation modified the cargoes in EVs derived from AP damaged astrocytes, the most significant of which being the down-regulation of miR-206-3p.", "tags": [{"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "GeneOrGenome"}, {"end": 16, "start": 5, "tag": "HealthCareActivity"}, {"end": 16, "start": 5, "tag": "NaturalPhenomenonOrProcess"}, {"end": 25, "start": 17, "tag": "TemporalConcept"}, {"end": 136, "start": 121, "tag": "CellFunction"}, {"end": 136, "start": 121, "tag": "BiologicFunction"}, {"end": 79, "start": 69, "tag": "Cell"}, {"end": 44, "start": 41, "tag": "CellComponent"}, {"end": 150, "start": 140, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 150, "start": 140, "tag": "BiologicallyActiveSubstance"}]}{"id": "1079_12", "text": "The mi R-206-3p level was specifically high in the plasma of AD mice and patients, and miR-206-3p antagomir reversed the Alzheimer phenotype in AD mice.", "tags": [{"end": 130, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 87, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 97, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 131, "tag": "OrganismAttribute"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 73, "tag": "PatientOrDisabledGroup"}, {"end": 68, "start": 64, "tag": "Eukaryote"}, {"end": 151, "start": 147, "tag": "Eukaryote"}, {"end": 57, "start": 44, "tag": "ClinicalAttribute"}, {"end": 21, "start": 4, "tag": "ClinicalAttribute"}]}{"id": "1079_13", "text": "The brain-derived neurotrophic factor (BDNF) gene was negatively regulated by miR-206-3p and upregulated by AEVs.Ap+H and miR-206-3p antagomir in AD mice.", "tags": [{"end": 49, "start": 45, "tag": "GeneOrGenome"}, {"end": 39, "start": 4, "tag": "GeneOrGenome"}, {"end": 88, "start": 78, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 142, "start": 122, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 88, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 149, "tag": "Eukaryote"}, {"end": 43, "start": 39, "tag": "GeneOrGenome"}]}{"id": "1079_14", "text": "AEVs.Ap+H inhibited 6-secretase (Asparagine endopeptidase, AEP) activation via the miR-206-3p/BDNF axis to alleviate AP burden in the AD brain.", "tags": [{"end": 57, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 59, "tag": "GeneOrGenome"}, {"end": 103, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 83, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 126, "start": 120, "tag": "ResearchActivity"}, {"end": 98, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 137, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 59, "tag": "BiologicallyActiveSubstance"}]}{"id": "1079_15", "text": "Conclusion: Our findings highlight the role of aFGF in the modification of AEVs cargoes, especially miR-206-3p that can potentially serve as a biomarker for AD diagnosis and therapeutic target.", "tags": [{"end": 51, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 47, "tag": "GeneOrGenome"}, {"end": 110, "start": 100, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 169, "start": 160, "tag": "HealthCareActivity"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 143, "tag": "ClinicalAttribute"}, {"end": 110, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 75, "tag": "CellComponent"}, {"end": 192, "start": 174, "tag": "Finding"}]}{"id": "1080_0", "text": "Alzheimer's disease (AD) is the most common neurodegenerative disorder.", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 44, "tag": "DiseaseOrSyndrome"}]}{"id": "1080_1", "text": "Extracellular vesicles (EVs), carriers of nucleic acids, lipids, and proteins, are known to play significant roles in neurodegenerative pathogenesis.", "tags": [{"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 77, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 118, "tag": "CellOrMolecularDysfunction"}, {"end": 148, "start": 136, "tag": "PathologicFunction"}, {"end": 63, "start": 57, "tag": "Chemical"}, {"end": 55, "start": 42, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 55, "start": 30, "tag": "CellFunction"}]}{"id": "1080_2", "text": "Studies have shown that EVs from AD human brain tissue contain toxic proteins that may lead to neuron cell damage and loss.", "tags": [{"end": 113, "start": 102, "tag": "CellOrMolecularDysfunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 95, "tag": "Cell"}, {"end": 41, "start": 36, "tag": "Eukaryote"}, {"end": 54, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 63, "tag": "InjuryOrPoisoning"}, {"end": 77, "start": 69, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1080_3", "text": "However, the potential contribution of EV long RNAs (exLR) to AD pathobiology is less well known, and their biochemical functions and molecular properties remain obscure.", "tags": [{"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 39, "tag": "CellComponent"}, {"end": 51, "start": 42, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1080_4", "text": "Here, EVs were isolated from the frontal cortex of normal control (NC; N = 10) and AD (N = 8) brain tissue donors.", "tags": [{"end": 47, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 107, "tag": "PopulationGroup"}, {"end": 9, "start": 6, "tag": "CellComponent"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 67, "tag": "PopulationGroup"}, {"end": 106, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 51, "tag": "Finding"}]}{"id": "1080_5", "text": "We performed exLR profiling on the isolated EVs followed by pathway analysis and weighted gene co- expression network analysis (WGCNA).", "tags": [{"end": 47, "start": 44, "tag": "CellComponent"}, {"end": 76, "start": 68, "tag": "ResearchActivity"}, {"end": 126, "start": 81, "tag": "ResearchActivity"}, {"end": 27, "start": 18, "tag": "ResearchActivity"}, {"end": 67, "start": 60, "tag": "CellFunction"}, {"end": 133, "start": 128, "tag": "ResearchActivity"}]}{"id": "1080_6", "text": "A total of 1012 mRNAs, 320 long non-coding RNAs (lncRNAs), and 119 circular RNAs (circRNAs) were found to be differentially expressed (DE) in AD-EVs compared with NC-EVs.", "tags": [{"end": 47, "start": 27, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 47, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 145, "tag": "CellComponent"}, {"end": 169, "start": 166, "tag": "CellComponent"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 163, "tag": "PopulationGroup"}, {"end": 56, "start": 49, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 56, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 109, "tag": "Finding"}, {"end": 133, "start": 124, "tag": "CellFunction"}, {"end": 90, "start": 82, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 80, "start": 67, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 21, "start": 16, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 21, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 67, "tag": "BiologicallyActiveSubstance"}]}{"id": "1080_7", "text": "Functional analysis of the DEmRNAs revealed that metal ion transport, calcium signaling, and various neuronal processes were enriched.", "tags": [{"end": 19, "start": 0, "tag": "ResearchActivity"}, {"end": 68, "start": 49, "tag": "CellFunction"}, {"end": 87, "start": 70, "tag": "CellFunction"}, {"end": 109, "start": 101, "tag": "Cell"}]}{"id": "1080_8", "text": "To investigate the possible functions of the identified DElncRNAs and DEcircRNAs, competing endogenous RNA (ceRNA) networks were constructed and subjected to WGCNA, in which two gene modules were identified to be significantly correlated with AD.", "tags": [{"end": 80, "start": 70, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 190, "start": 178, "tag": "CellFunction"}, {"end": 245, "start": 243, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 178, "tag": "GeneOrGenome"}, {"end": 106, "start": 82, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 123, "start": 115, "tag": "CellFunction"}, {"end": 113, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 108, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 163, "start": 158, "tag": "ResearchActivity"}]}{"id": "1080_9", "text": "Moreover, we discovered that NC-EVs were more effective than AD-EVs in promoting cytokine expression, phagocytosis, and induction of calcium signaling in microglia.", "tags": [{"end": 89, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 120, "tag": "CellFunction"}, {"end": 114, "start": 102, "tag": "CellFunction"}, {"end": 150, "start": 133, "tag": "CellFunction"}, {"end": 35, "start": 32, "tag": "CellComponent"}, {"end": 67, "start": 64, "tag": "CellComponent"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 29, "tag": "PopulationGroup"}, {"end": 100, "start": 90, "tag": "CellFunction"}, {"end": 163, "start": 154, "tag": "Cell"}]}{"id": "1080_10", "text": "Our study provides an in- depth characterization of brain tissue exLR and identifies several RNAs that correlate with the pathogenesis of AD.", "tags": [{"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 64, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 134, "start": 122, "tag": "PathologicFunction"}, {"end": 48, "start": 32, "tag": "ResearchActivity"}, {"end": 97, "start": 93, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1081_0", "text": "Extracellular vesicles (EVs) are nano-sized membrane vesicles released by various cell types.", "tags": [{"end": 52, "start": 44, "tag": "CellComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 61, "start": 53, "tag": "CellComponent"}, {"end": 92, "start": 82, "tag": "Cell"}]}{"id": "1081_1", "text": "Mammalian EVs have been studied in-depth, but the role of plant EVs has rarely been explored.", "tags": [{"end": 9, "start": 0, "tag": "Cell"}, {"end": 13, "start": 10, "tag": "CellComponent"}, {"end": 67, "start": 64, "tag": "CellComponent"}, {"end": 63, "start": 58, "tag": "Organism"}]}{"id": "1081_2", "text": "For the first time, EVs from Drynariae Rhizoma roots were isolated and identified using transmission electron microscopy and a flow nano analyzer.", "tags": [{"end": 23, "start": 20, "tag": "CellComponent"}, {"end": 13, "start": 8, "tag": "TemporalConcept"}, {"end": 18, "start": 14, "tag": "TemporalConcept"}, {"end": 120, "start": 88, "tag": "ResearchActivity"}, {"end": 52, "start": 29, "tag": "Organism"}, {"end": 145, "start": 127, "tag": "ResearchActivity"}]}{"id": "1081_3", "text": "Proteomics and bioinformatics were applied to determine the protein composition and complete the functional analysis of the EVs.", "tags": [{"end": 10, "start": 0, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 29, "start": 15, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 127, "start": 124, "tag": "CellComponent"}, {"end": 116, "start": 97, "tag": "ResearchActivity"}, {"end": 67, "start": 60, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1081_4", "text": "Seventy-seven proteins were identified from Drynariae Rhizoma root-derived EVs, with enzymes accounting for 47% of the proteins.", "tags": [{"end": 92, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 75, "tag": "CellComponent"}, {"end": 22, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 44, "tag": "Organism"}]}{"id": "1081_5", "text": "All of the enzymes were involved in important biological processes in plants.", "tags": [{"end": 76, "start": 70, "tag": "Eukaryote"}, {"end": 18, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 46, "tag": "BiologicFunction"}]}{"id": "1081_6", "text": "Most of them, including NAD(P)H-quinone oxidored ucta se, were enriched in the oxidative phosphorylation pathway in plants and humans, and Alzheimer's disease, Huntington's disease, and Parkinson's disease, which are associated with oxidative stress in humans.", "tags": [{"end": 133, "start": 127, "tag": "Eukaryote"}, {"end": 259, "start": 253, "tag": "Eukaryote"}, {"end": 31, "start": 24, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 56, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 116, "tag": "Organism"}, {"end": 180, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 243, "tag": "PathologicFunction"}, {"end": 158, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 233, "tag": "CellOrMolecularDysfunction"}, {"end": 112, "start": 79, "tag": "CellFunction"}, {"end": 56, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 24, "tag": "BiologicallyActiveSubstance"}]}{"id": "1081_7", "text": "These findings suggested that EVs from Drynariae Rhizoma roots could alleviate such neurological diseases and that enzymes, especially NAD(P)H-quinone oxidoreductase, might play an important role in the process.", "tags": [{"end": 165, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 135, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 142, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 30, "tag": "CellComponent"}, {"end": 105, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 39, "tag": "Organism"}]}{"id": "1082_0", "text": "Chronic Traumatic Encephalopathy (CTE) is a tauopathy that affects individuals with a history of mild repetitive brain injury.", "tags": [{"end": 32, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 86, "tag": "Finding"}, {"end": 118, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 97, "tag": "Finding"}, {"end": 78, "start": 67, "tag": "PopulationGroup"}, {"end": 125, "start": 119, "tag": "InjuryOrPoisoning"}, {"end": 53, "start": 44, "tag": "DiseaseOrSyndrome"}]}{"id": "1082_1", "text": "The initial neuropathologic changes of CTE include perivascular deposition of phosphorylated microtubule-associated protein tau (p-tau).", "tags": [{"end": 42, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 51, "tag": "Cell"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}, {"end": 92, "start": 78, "tag": "CellFunction"}, {"end": 127, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 12, "tag": "PathologicFunction"}, {"end": 35, "start": 28, "tag": "Finding"}]}{"id": "1082_2", "text": "Extracellular vesicles (EVs) are known to carry pathogenic molecules, such as tau in Alzheimer's disease and CTE suggesting their contribution in pathogenesis.", "tags": [{"end": 112, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 81, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 158, "start": 146, "tag": "PathologicFunction"}, {"end": 58, "start": 48, "tag": "PathologicFunction"}, {"end": 68, "start": 59, "tag": "Substance"}]}{"id": "1082_3", "text": "We therefore examined the protein composition of EVs separated from CTE and an age-matched control brain tissues by tandem mass tag-mass spectrometry.", "tags": [{"end": 71, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 116, "tag": "ResearchActivity"}, {"end": 52, "start": 49, "tag": "CellComponent"}, {"end": 82, "start": 79, "tag": "OrganismAttribute"}, {"end": 33, "start": 26, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1082_4", "text": "The reporter ion intensity was used to quantify the identified molecules.", "tags": [{"end": 16, "start": 13, "tag": "Chemical"}, {"end": 72, "start": 63, "tag": "Substance"}, {"end": 26, "start": 4, "tag": "NaturalPhenomenonOrProcess"}, {"end": 16, "start": 4, "tag": "Chemical"}]}{"id": "1082_5", "text": "A total of 516 common proteins were identified among three sets of experiments.", "tags": [{"end": 78, "start": 67, "tag": "ResearchActivity"}, {"end": 30, "start": 22, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1082_6", "text": "Weighted protein co expression network analysis identified 18 unique modules of co-expressed proteins.", "tags": [{"end": 47, "start": 0, "tag": "ResearchActivity"}, {"end": 101, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 83, "tag": "CellFunction"}]}{"id": "1082_7", "text": "Two modules were significantly correlated with total tau (t-tau) and p-tau protein in the isolated EVs and enriched in cellular components and biological processes for synaptic vesicle secretion and multivesicular body-plasma membrane fusion.", "tags": [{"end": 138, "start": 119, "tag": "CellComponent"}, {"end": 234, "start": 226, "tag": "CellComponent"}, {"end": 102, "start": 99, "tag": "CellComponent"}, {"end": 176, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 194, "start": 185, "tag": "CellFunction"}, {"end": 194, "start": 185, "tag": "BiologicFunction"}, {"end": 241, "start": 235, "tag": "CellFunction"}, {"end": 163, "start": 143, "tag": "BiologicFunction"}, {"end": 127, "start": 119, "tag": "Cell"}, {"end": 213, "start": 199, "tag": "CellComponent"}, {"end": 184, "start": 168, "tag": "CellComponent"}, {"end": 138, "start": 128, "tag": "CellComponent"}, {"end": 82, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 225, "start": 214, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1082_8", "text": "The p-tau (Thr181) level is significantly higher in CTE EVs compared to control EVs and can distinguish the two groups with 73.6% accuracy.", "tags": [{"end": 55, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 56, "tag": "CellComponent"}, {"end": 83, "start": 80, "tag": "CellComponent"}, {"end": 18, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 130, "tag": "Finding"}]}{"id": "1082_9", "text": "A combination of t-tau or p-tau (Thr181) with SNAP-25, PLXNA4 or UBA1, enhanced the accuracy to 96.3, 93.8 and 93.8%, respectively.", "tags": [{"end": 53, "start": 46, "tag": "GeneOrGenome"}, {"end": 53, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 55, "tag": "GeneOrGenome"}, {"end": 69, "start": 65, "tag": "GeneOrGenome"}, {"end": 22, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 40, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 84, "tag": "Finding"}]}{"id": "1082_10", "text": "Bioinformatic protein-protein interaction analysis revealed the functional interaction of SNAP-25 and PLXNA4 with tau, suggesting their interaction in CTE EVs.", "tags": [{"end": 97, "start": 90, "tag": "GeneOrGenome"}, {"end": 97, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 102, "tag": "GeneOrGenome"}, {"end": 154, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 155, "tag": "CellComponent"}, {"end": 50, "start": 0, "tag": "ResearchActivity"}, {"end": 117, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 102, "tag": "BiologicallyActiveSubstance"}]}{"id": "1082_11", "text": "These data indicate the future application of identified EV proteins for monitoring the CTE risk assessments and understanding the EV-mediated disease progression mechanism.", "tags": [{"end": 91, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 88, "tag": "InjuryOrPoisoning"}, {"end": 108, "start": 97, "tag": "HealthCareActivity"}, {"end": 59, "start": 57, "tag": "CellComponent"}, {"end": 133, "start": 131, "tag": "CellComponent"}, {"end": 96, "start": 92, "tag": "Finding"}, {"end": 68, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 113, "tag": "BiologicFunction"}, {"end": 83, "start": 73, "tag": "HealthCareActivity"}, {"end": 162, "start": 143, "tag": "PathologicFunction"}, {"end": 30, "start": 24, "tag": "TemporalConcept"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}]}{"id": "1083_0", "text": "Multiple sclerosis (MS) is a debilitating degenerative disease characterized by an immunological attack on the myelin sheath leading to demyelination and axon degeneration.", "tags": [{"end": 62, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 83, "tag": "Finding"}, {"end": 124, "start": 111, "tag": "CellComponent"}, {"end": 171, "start": 154, "tag": "CellOrMolecularDysfunction"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 136, "tag": "PathologicFunction"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "1083_1", "text": "Mesenchymal stem/stromal cells (MSCs) and secreted extracellular vesicles (EVs) have become attractive targets as therapies to treat neurodegenerative diseases such as MS due to their potent immunomodulatory and regenerative properties.", "tags": [{"end": 123, "start": 114, "tag": "HealthCareActivity"}, {"end": 170, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 51, "tag": "CellComponent"}, {"end": 78, "start": 75, "tag": "CellComponent"}, {"end": 30, "start": 0, "tag": "Cell"}, {"end": 159, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 32, "tag": "Cell"}, {"end": 235, "start": 212, "tag": "Finding"}, {"end": 235, "start": 225, "tag": "Finding"}, {"end": 207, "start": 184, "tag": "Finding"}]}{"id": "1083_2", "text": "The placenta is a unique source of MSCs (PMSCs), demonstrates fetomaternal tolerance during pregnancy, and serves as a novel source of MSCs for the treatment of neurodegenerative diseases.", "tags": [{"end": 12, "start": 4, "tag": "EmbryonicStructure"}, {"end": 101, "start": 92, "tag": "BiologicFunction"}, {"end": 187, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 148, "tag": "HealthCareActivity"}, {"end": 157, "start": 148, "tag": "ResearchActivity"}, {"end": 39, "start": 35, "tag": "Cell"}, {"end": 139, "start": 135, "tag": "Cell"}, {"end": 46, "start": 41, "tag": "Cell"}]}{"id": "1083_3", "text": "PMSCs and PMSC-EVs have been shown to promote remyelination in animal models of MS, however, the molecular mechanisms by which modulation of autoimmunity and promotion of myelination occurs have not been well elucidated.", "tags": [{"end": 59, "start": 46, "tag": "CellFunction"}, {"end": 182, "start": 171, "tag": "CellFunction"}, {"end": 153, "start": 141, "tag": "PathologicFunction"}, {"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 15, "tag": "CellComponent"}, {"end": 76, "start": 63, "tag": "ResearchActivity"}, {"end": 117, "start": 97, "tag": "CellFunction"}, {"end": 5, "start": 0, "tag": "Cell"}, {"end": 14, "start": 10, "tag": "Cell"}]}{"id": "1083_4", "text": "The current review will address the molecular mechanisms by which PMSC-EVs can promote remyelination in MS.", "tags": [{"end": 100, "start": 87, "tag": "CellFunction"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 71, "tag": "CellComponent"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}, {"end": 56, "start": 36, "tag": "CellFunction"}, {"end": 70, "start": 66, "tag": "Cell"}]}{"id": "1084_1", "text": "The enzyme neutral sphingomyelinase 2 (nSMase2) is involved the biogenesis of ceramide and extracellular vesicles (EVs), both of which are dysregulated in PLH, CI, and MDD.", "tags": [{"end": 171, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 39, "tag": "GeneOrGenome"}, {"end": 46, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 91, "tag": "CellComponent"}, {"end": 118, "start": 115, "tag": "CellComponent"}, {"end": 151, "start": 139, "tag": "PathologicFunction"}, {"end": 74, "start": 64, "tag": "CellFunction"}, {"end": 86, "start": 78, "tag": "Chemical"}, {"end": 86, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 155, "tag": "PatientOrDisabledGroup"}]}{"id": "1084_2", "text": "Here we evaluated EcoHIV-infected mice for behavioral abnormalities relevant to depression and cognition deficits, and assessed the behavioral and biochemical effects of nSMase2 inhibition.", "tags": [{"end": 67, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 147, "tag": "Finding"}, {"end": 177, "start": 170, "tag": "GeneOrGenome"}, {"end": 177, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 105, "tag": "Finding"}, {"end": 38, "start": 34, "tag": "Eukaryote"}, {"end": 188, "start": 178, "tag": "CellFunction"}, {"end": 104, "start": 95, "tag": "BiologicFunction"}, {"end": 166, "start": 159, "tag": "Finding"}, {"end": 38, "start": 18, "tag": "ExperimentalModelOfDisease"}, {"end": 24, "start": 18, "tag": "Virus"}]}{"id": "1084_3", "text": "Mice were infected with EcoHIV and daily treatment with either vehicle or the nSMase2 inhibitor (R)-(1-(3-(3,4-dimethoxyphenyl)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yl)pyrrolidin-3-yl)-carbamate (PDDC) began 3 weeks post-infection.", "tags": [{"end": 4, "start": 0, "tag": "Eukaryote"}, {"end": 216, "start": 211, "tag": "TemporalConcept"}, {"end": 85, "start": 78, "tag": "GeneOrGenome"}, {"end": 85, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 86, "tag": "PharmacologicSubstance"}, {"end": 95, "start": 86, "tag": "Chemical"}, {"end": 221, "start": 217, "tag": "TemporalConcept"}, {"end": 201, "start": 197, "tag": "Chemical"}, {"end": 201, "start": 197, "tag": "PharmacologicSubstance"}, {"end": 50, "start": 41, "tag": "HealthCareActivity"}, {"end": 50, "start": 41, "tag": "ResearchActivity"}, {"end": 231, "start": 222, "tag": "PathologicFunction"}, {"end": 40, "start": 35, "tag": "TemporalConcept"}, {"end": 30, "start": 24, "tag": "Virus"}, {"end": 195, "start": 96, "tag": "PharmacologicSubstance"}, {"end": 195, "start": 96, "tag": "Chemical"}]}{"id": "1084_4", "text": "After weeks of treatment, mice were subjected to behavior tests.", "tags": [{"end": 63, "start": 49, "tag": "HealthCareActivity"}, {"end": 57, "start": 49, "tag": "BiologicFunction"}, {"end": 57, "start": 49, "tag": "IndividualBehavior"}, {"end": 57, "start": 49, "tag": "ResearchActivity"}, {"end": 11, "start": 6, "tag": "TemporalConcept"}, {"end": 30, "start": 26, "tag": "Eukaryote"}, {"end": 24, "start": 15, "tag": "HealthCareActivity"}, {"end": 24, "start": 15, "tag": "ResearchActivity"}, {"end": 63, "start": 58, "tag": "ResearchActivity"}, {"end": 63, "start": 58, "tag": "HealthCareActivity"}]}{"id": "1084_5", "text": "EcoHIV-infected mice exhibited behavioral abnor-malities relevant to MDD and CI that were reversed by PDDC treatment.", "tags": [{"end": 72, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 102, "tag": "Chemical"}, {"end": 106, "start": 102, "tag": "PharmacologicSubstance"}, {"end": 20, "start": 16, "tag": "Eukaryote"}, {"end": 116, "start": 107, "tag": "HealthCareActivity"}, {"end": 116, "start": 107, "tag": "ResearchActivity"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "Virus"}, {"end": 20, "start": 0, "tag": "ExperimentalModelOfDisease"}]}{"id": "1084_6", "text": "EcoHIV infection significantly increased cortical brain nSMase2 activity, resulting in trend changes in sphingomyelin and ceramide levels that were normalized by PDDC treatment.", "tags": [{"end": 63, "start": 56, "tag": "GeneOrGenome"}, {"end": 63, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 162, "tag": "Chemical"}, {"end": 117, "start": 104, "tag": "Chemical"}, {"end": 117, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 56, "tag": "CellFunction"}, {"end": 166, "start": 162, "tag": "PharmacologicSubstance"}, {"end": 55, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 167, "tag": "HealthCareActivity"}, {"end": 176, "start": 167, "tag": "ResearchActivity"}, {"end": 16, "start": 7, "tag": "PathologicFunction"}, {"end": 49, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 17, "tag": "Finding"}, {"end": 130, "start": 122, "tag": "Chemical"}, {"end": 130, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 0, "tag": "Virus"}]}{"id": "1084_7", "text": "EcoHIV-infected mice also exhibited increased levels of brain-derived EVs and altered microRNA cargo, including miR-183-5p, miR-200c-3p, miR-200b-3p, and miR-429-3p, known to associated with MDD and CI; all were normalized by PDDC.", "tags": [{"end": 194, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 56, "tag": "CellComponent"}, {"end": 94, "start": 86, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 94, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 52, "start": 36, "tag": "Finding"}, {"end": 230, "start": 226, "tag": "Chemical"}, {"end": 230, "start": 226, "tag": "PharmacologicSubstance"}, {"end": 73, "start": 70, "tag": "CellComponent"}, {"end": 20, "start": 16, "tag": "Eukaryote"}, {"end": 100, "start": 95, "tag": "CellComponent"}, {"end": 201, "start": 199, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "Virus"}, {"end": 20, "start": 0, "tag": "ExperimentalModelOfDisease"}, {"end": 122, "start": 112, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 135, "start": 124, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 148, "start": 137, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 164, "start": 154, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 122, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 154, "tag": "BiologicallyActiveSubstance"}]}{"id": "1084_8", "text": "In conclusion, inhibition of nSMase2 represents possible new therapeutic strategy for the treatment of HIV-associated CI and MDD.", "tags": [{"end": 128, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 29, "tag": "GeneOrGenome"}, {"end": 36, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 103, "tag": "Virus"}, {"end": 36, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 90, "tag": "HealthCareActivity"}, {"end": 99, "start": 90, "tag": "ResearchActivity"}, {"end": 25, "start": 15, "tag": "CellFunction"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 61, "tag": "HealthCareActivity"}]}{"id": "1085_0", "text": "Pathological tau proteins in patients with Alzheimer's disease (AD) mainly accumulate in the form of neurofibrillary tangles (NFTs) and neuritic plaques (NPs).", "tags": [{"end": 12, "start": 0, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 152, "start": 136, "tag": "AnatomicalAbnormality"}, {"end": 157, "start": 154, "tag": "AnatomicalAbnormality"}, {"end": 62, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 29, "tag": "PatientOrDisabledGroup"}, {"end": 16, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 101, "tag": "CellOrMolecularDysfunction"}, {"end": 116, "start": 101, "tag": "CellComponent"}, {"end": 130, "start": 126, "tag": "CellOrMolecularDysfunction"}]}{"id": "1085_1", "text": "However, the molecular properties of tau species present in NFTs and NPs are not known.", "tags": [{"end": 72, "start": 69, "tag": "AnatomicalAbnormality"}, {"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 41, "tag": "OrganismAttribute"}, {"end": 64, "start": 60, "tag": "CellOrMolecularDysfunction"}]}{"id": "1085_2", "text": "We tested the hypothesis that tau species within NFT-predominant tissue (NFT_AD) are distinct and more toxic than those in NP-predominant tissue (NP_AD).", "tags": [{"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 103, "tag": "InjuryOrPoisoning"}, {"end": 71, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 34, "tag": "OrganismAttribute"}, {"end": 52, "start": 49, "tag": "CellOrMolecularDysfunction"}, {"end": 125, "start": 123, "tag": "AnatomicalAbnormality"}]}{"id": "1085_3", "text": "We analyzed the tau species from post mortem prefrontal cortical brains of NFT_AD and NP_AD.", "tags": [{"end": 55, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 33, "tag": "TemporalConcept"}, {"end": 19, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 64, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 20, "tag": "OrganismAttribute"}]}{"id": "1085_4", "text": "Compared to NP_AD, NFT_AD displayed highly phosphorylated tau oligomers, possessed tau oligomers in extracellular vesicles, and the 3-repeat (3R) and 4-repeat (4R) isoforms were differentially expressed between the groups.", "tags": [{"end": 172, "start": 164, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 164, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 71, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 100, "tag": "CellComponent"}, {"end": 57, "start": 43, "tag": "CellFunction"}, {"end": 61, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 202, "start": 178, "tag": "Finding"}, {"end": 202, "start": 193, "tag": "CellFunction"}]}{"id": "1085_5", "text": "Comparison of tau proteins isolated from NFT- versus NP-AD subjects demonstrated higher tau seeding activity in NFT subjects and a greater degree of inducing synaptic loss in cultured neurons.", "tags": [{"end": 115, "start": 112, "tag": "CellOrMolecularDysfunction"}, {"end": 171, "start": 158, "tag": "CellOrMolecularDysfunction"}, {"end": 191, "start": 175, "tag": "ResearchActivity"}, {"end": 166, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 184, "tag": "Cell"}, {"end": 67, "start": 59, "tag": "PopulationGroup"}, {"end": 124, "start": 116, "tag": "PopulationGroup"}, {"end": 183, "start": 175, "tag": "ResearchActivity"}, {"end": 108, "start": 92, "tag": "CellFunction"}, {"end": 44, "start": 41, "tag": "CellOrMolecularDysfunction"}]}{"id": "1085_6", "text": "We propose that tau species from NFT-predominant tissues possess greater levels of degenerative properties, thereby causing synaptic loss and cognitive decline.", "tags": [{"end": 137, "start": 124, "tag": "CellOrMolecularDysfunction"}, {"end": 95, "start": 83, "tag": "PathologicFunction"}, {"end": 132, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 20, "tag": "OrganismAttribute"}, {"end": 36, "start": 33, "tag": "CellOrMolecularDysfunction"}]}{"id": "1086_0", "text": "Background Extracellular vesicles (EVs), including small EVs (sEVs) such as exosomes, exhibit great potential for the diagnosis and treatment of brain disorders, representing a valuable tool for precision medicine.", "tags": [{"end": 213, "start": 195, "tag": "HealthCareActivity"}, {"end": 33, "start": 11, "tag": "CellComponent"}, {"end": 60, "start": 51, "tag": "CellComponent"}, {"end": 66, "start": 62, "tag": "CellComponent"}, {"end": 84, "start": 76, "tag": "CellComponent"}, {"end": 160, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 118, "tag": "HealthCareActivity"}, {"end": 38, "start": 35, "tag": "CellComponent"}, {"end": 141, "start": 132, "tag": "HealthCareActivity"}, {"end": 141, "start": 132, "tag": "ResearchActivity"}]}{"id": "1086_1", "text": "The latter demands high-quality human biospecimens, especially in complex disorders in which pathological and specimen heterogeneity, as well as diverse individual clinical profile, often complicate the development of precision therapeutic schemes and patient-tailored treatments.", "tags": [{"end": 50, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 110, "tag": "Substance"}, {"end": 118, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 119, "tag": "OrganismAttribute"}, {"end": 227, "start": 218, "tag": "TemporalConcept"}, {"end": 180, "start": 164, "tag": "ClinicalAttribute"}, {"end": 37, "start": 32, "tag": "Eukaryote"}, {"end": 214, "start": 203, "tag": "BiologicFunction"}, {"end": 214, "start": 203, "tag": "CellFunction"}, {"end": 259, "start": 252, "tag": "PatientOrDisabledGroup"}, {"end": 279, "start": 269, "tag": "HealthCareActivity"}, {"end": 279, "start": 269, "tag": "ResearchActivity"}]}{"id": "1086_2", "text": "Thus, the collection and characterization of physiologically relevant sEVs are of the utmost importance.", "tags": [{"end": 20, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 25, "tag": "ResearchActivity"}, {"end": 74, "start": 70, "tag": "CellComponent"}]}{"id": "1086_3", "text": "However, standard brain EV isolation approaches rely on tissue dissociation, which can contaminate EV fractions with intracellular vesicles.", "tags": [{"end": 47, "start": 24, "tag": "ResearchActivity"}, {"end": 139, "start": 117, "tag": "CellComponent"}, {"end": 23, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 99, "tag": "CellComponent"}, {"end": 62, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 56, "tag": "ResearchActivity"}]}{"id": "1086_4", "text": "Methods Based on multiscale analytical platforms such as cryo-EM, label-free proteomics, advanced flow cytometry, and ExoView analyses, we compared and characterized the EV fraction isolated with this novel method with a classical digestion-based EV isolation procedure.", "tags": [{"end": 213, "start": 207, "tag": "ResearchActivity"}, {"end": 213, "start": 207, "tag": "HealthCareActivity"}, {"end": 172, "start": 170, "tag": "CellComponent"}, {"end": 249, "start": 247, "tag": "CellComponent"}, {"end": 48, "start": 17, "tag": "ResearchActivity"}, {"end": 87, "start": 66, "tag": "ResearchActivity"}, {"end": 64, "start": 57, "tag": "ResearchActivity"}, {"end": 112, "start": 89, "tag": "ResearchActivity"}, {"end": 134, "start": 118, "tag": "ResearchActivity"}, {"end": 269, "start": 221, "tag": "ResearchActivity"}]}{"id": "1086_5", "text": "Moreover, EV biogenesis was pharmacologically manipulated with either GW4869 or picrotoxin to assess the validity of the spontaneous-release method, while the injection of labelled-EVs into the mouse brain further supported the integrity of the isolated vesicles.", "tags": [{"end": 45, "start": 28, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 57, "start": 46, "tag": "HealthCareActivity"}, {"end": 76, "start": 70, "tag": "Chemical"}, {"end": 90, "start": 80, "tag": "Chemical"}, {"end": 237, "start": 228, "tag": "IndividualBehavior"}, {"end": 262, "start": 254, "tag": "CellComponent"}, {"end": 147, "start": 141, "tag": "ResearchActivity"}, {"end": 147, "start": 141, "tag": "HealthCareActivity"}, {"end": 23, "start": 13, "tag": "CellFunction"}, {"end": 205, "start": 200, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 181, "tag": "CellComponent"}, {"end": 168, "start": 159, "tag": "HealthCareActivity"}, {"end": 199, "start": 194, "tag": "Eukaryote"}, {"end": 12, "start": 10, "tag": "CellComponent"}, {"end": 113, "start": 105, "tag": "ResearchActivity"}, {"end": 113, "start": 105, "tag": "Finding"}, {"end": 262, "start": 254, "tag": "AnatomicalAbnormality"}, {"end": 84, "start": 83, "tag": "PharmacologicSubstance"}, {"end": 90, "start": 80, "tag": "InjuryOrPoisoning"}]}{"id": "1086_6", "text": "Results We hereby present an efficient purification method that captures a sEV-enriched population spontaneously released by mouse and human brain tissue.", "tags": [{"end": 78, "start": 75, "tag": "CellComponent"}, {"end": 58, "start": 52, "tag": "ResearchActivity"}, {"end": 98, "start": 88, "tag": "PopulationGroup"}, {"end": 58, "start": 52, "tag": "HealthCareActivity"}, {"end": 153, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 135, "tag": "Eukaryote"}, {"end": 130, "start": 125, "tag": "Eukaryote"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}{"id": "1086_7", "text": "In addition, we tested the significance of the release method under conditions where biogenesis/secretion of sEVs was pharmacologically manipulated, as well as under animals' exposure to chronic stress, a clinically relevant precipitant of brain pathologies, such as depression and Alzheimer's disease.", "tags": [{"end": 54, "start": 47, "tag": "HealthCareActivity"}, {"end": 54, "start": 47, "tag": "ResearchActivity"}, {"end": 135, "start": 118, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 147, "start": 136, "tag": "HealthCareActivity"}, {"end": 113, "start": 109, "tag": "CellComponent"}, {"end": 257, "start": 240, "tag": "PathologicFunction"}, {"end": 277, "start": 267, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 55, "tag": "ResearchActivity"}, {"end": 173, "start": 166, "tag": "Eukaryote"}, {"end": 61, "start": 55, "tag": "HealthCareActivity"}, {"end": 95, "start": 85, "tag": "CellFunction"}, {"end": 301, "start": 282, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 187, "tag": "TemporalConcept"}, {"end": 113, "start": 96, "tag": "CellFunction"}, {"end": 201, "start": 187, "tag": "PathologicFunction"}]}{"id": "1086_8", "text": "Our findings show that the released method monitors the drug-evoked inhibition or enhancement of sEVs secretion while chronic stress induces the secretion of brain exosomes accompanied by memory loss and mood deficits suggesting a potential role of sEVs in the brain response to stress and related stress-driven brain pathology.", "tags": [{"end": 51, "start": 43, "tag": "ManufacturedObject"}, {"end": 285, "start": 279, "tag": "PathologicFunction"}, {"end": 101, "start": 97, "tag": "CellComponent"}, {"end": 253, "start": 249, "tag": "CellComponent"}, {"end": 199, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 199, "start": 188, "tag": "SignOrSymptom"}, {"end": 42, "start": 36, "tag": "ResearchActivity"}, {"end": 42, "start": 36, "tag": "HealthCareActivity"}, {"end": 217, "start": 204, "tag": "Finding"}, {"end": 172, "start": 164, "tag": "CellComponent"}, {"end": 78, "start": 68, "tag": "CellFunction"}, {"end": 163, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 266, "start": 261, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 317, "start": 312, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 327, "start": 318, "tag": "PathologicFunction"}, {"end": 327, "start": 318, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 125, "start": 118, "tag": "TemporalConcept"}, {"end": 60, "start": 56, "tag": "PharmacologicSubstance"}, {"end": 93, "start": 82, "tag": "Finding"}, {"end": 111, "start": 97, "tag": "CellFunction"}, {"end": 132, "start": 118, "tag": "PathologicFunction"}, {"end": 172, "start": 145, "tag": "CellFunction"}, {"end": 304, "start": 298, "tag": "PathologicFunction"}]}{"id": "1086_9", "text": "Conclusions Overall, the spontaneous release method of sEV yield may contribute to the characterization and biomarker profile of physiologically relevant brain-derived sEVs in brain function and pathology.", "tags": [{"end": 103, "start": 87, "tag": "ResearchActivity"}, {"end": 172, "start": 168, "tag": "CellComponent"}, {"end": 58, "start": 55, "tag": "CellComponent"}, {"end": 51, "start": 45, "tag": "ResearchActivity"}, {"end": 51, "start": 45, "tag": "HealthCareActivity"}, {"end": 190, "start": 176, "tag": "BiologicFunction"}, {"end": 159, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 108, "tag": "ClinicalAttribute"}, {"end": 204, "start": 195, "tag": "PathologicFunction"}, {"end": 204, "start": 195, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 125, "start": 118, "tag": "ResearchActivity"}]}{"id": "1087_0", "text": "Upon its discovery, Alzheimer's, the neurodegenerative disease that affects many millions of patients in the world, remained without an effective therapy.", "tags": [{"end": 101, "start": 93, "tag": "PatientOrDisabledGroup"}, {"end": 18, "start": 9, "tag": "ResearchActivity"}, {"end": 31, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 146, "tag": "HealthCareActivity"}, {"end": 62, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 109, "tag": "PopulationGroup"}]}{"id": "1087_1", "text": "The first drugs, made available near the end of last century, induced some effects, which remained only marginal.", "tags": [{"end": 112, "start": 104, "tag": "Finding"}, {"end": 9, "start": 4, "tag": "TemporalConcept"}, {"end": 15, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 82, "start": 75, "tag": "Finding"}]}{"id": "1087_2", "text": "More promising effects are now present, induced by two approaches.", "tags": [{"end": 22, "start": 15, "tag": "Finding"}]}{"id": "1087_3", "text": "Blockers of the enzyme BACE-1 induce, in neurons and glial cells, decreased levels of A beta, the key peptide of the Alzheimer's disease.", "tags": [{"end": 8, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 136, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 53, "tag": "Cell"}, {"end": 92, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 41, "tag": "Cell"}, {"end": 82, "start": 66, "tag": "Finding"}, {"end": 109, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 23, "tag": "GeneOrGenome"}, {"end": 29, "start": 23, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1087_4", "text": "If administered at early AD steps, the BACE-1 blockers preclude further development of the disease.", "tags": [{"end": 33, "start": 28, "tag": "HealthCareActivity"}, {"end": 54, "start": 46, "tag": "PharmacologicSubstance"}, {"end": 27, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 72, "tag": "BiologicFunction"}, {"end": 83, "start": 72, "tag": "CellFunction"}, {"end": 27, "start": 19, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 39, "tag": "GeneOrGenome"}, {"end": 45, "start": 39, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1087_5", "text": "However, they have no effect on established, irreversible lesions.", "tags": [{"end": 65, "start": 58, "tag": "InjuryOrPoisoning"}, {"end": 28, "start": 22, "tag": "Finding"}, {"end": 28, "start": 19, "tag": "Finding"}]}{"id": "1087_6", "text": "The extracellular vesicles secreted by mesenchymal stem cells induce therapy effects analogous, but more convenient, than the effects of their original cells.", "tags": [{"end": 26, "start": 4, "tag": "CellComponent"}, {"end": 157, "start": 152, "tag": "Cell"}, {"end": 76, "start": 69, "tag": "HealthCareActivity"}, {"end": 61, "start": 51, "tag": "Cell"}, {"end": 84, "start": 77, "tag": "Finding"}, {"end": 133, "start": 126, "tag": "Finding"}, {"end": 61, "start": 39, "tag": "Cell"}]}{"id": "1087_7", "text": "After their specific fusion to target cells, the action of these vesicles depends on their ensuing release of cargo molecules, such as proteins and many miRNAs, active primarily on the cell cytoplasm.", "tags": [{"end": 199, "start": 185, "tag": "CellComponent"}, {"end": 159, "start": 153, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 159, "start": 153, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 110, "tag": "CellFunction"}, {"end": 143, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 21, "tag": "CellFunction"}, {"end": 43, "start": 31, "tag": "Cell"}, {"end": 73, "start": 65, "tag": "CellComponent"}, {"end": 125, "start": 116, "tag": "Substance"}, {"end": 125, "start": 99, "tag": "CellFunction"}]}{"id": "1087_8", "text": "Operationally, these vesicles exhibit numerous advantages: they exclude, by their accurate selection, the heterogeneity of the original cells; exhibit molecular specificity due to their engineering and drug accumulation; and induce effective actions, mediated by variable concentrations of factors and molecules and by activation of signaling cascades.", "tags": [{"end": 342, "start": 333, "tag": "CellFunction"}, {"end": 351, "start": 333, "tag": "CellFunction"}, {"end": 141, "start": 136, "tag": "Cell"}, {"end": 219, "start": 207, "tag": "Finding"}, {"end": 119, "start": 106, "tag": "OrganismAttribute"}, {"end": 172, "start": 161, "tag": "Finding"}, {"end": 29, "start": 21, "tag": "CellComponent"}, {"end": 311, "start": 302, "tag": "Substance"}, {"end": 286, "start": 272, "tag": "BiologicFunction"}, {"end": 206, "start": 202, "tag": "PharmacologicSubstance"}, {"end": 197, "start": 186, "tag": "ResearchActivity"}]}{"id": "1087_9", "text": "Their strength is reinforced by their combination with various factors and processes.", "tags": []}{"id": "1087_10", "text": "The recent molecular and operations changes, induced especially by the stem cell target cells, result in encouraging and important improvement of the disease.", "tags": [{"end": 80, "start": 76, "tag": "Cell"}, {"end": 93, "start": 81, "tag": "Cell"}, {"end": 10, "start": 4, "tag": "TemporalConcept"}, {"end": 80, "start": 71, "tag": "Cell"}]}{"id": "1087_11", "text": "Their further development is expected in the near future.", "tags": [{"end": 25, "start": 14, "tag": "BiologicFunction"}, {"end": 25, "start": 14, "tag": "CellFunction"}, {"end": 56, "start": 50, "tag": "TemporalConcept"}]}{"id": "1088_0", "text": "Background Recent studies suggest that microglia contribute to tau pathology progression in Alzheimer's disease.", "tags": [{"end": 76, "start": 63, "tag": "PathologicFunction"}, {"end": 111, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 77, "tag": "PathologicFunction"}, {"end": 88, "start": 77, "tag": "TemporalConcept"}, {"end": 25, "start": 18, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "TemporalConcept"}, {"end": 48, "start": 39, "tag": "Cell"}]}{"id": "1088_1", "text": "Amyloid plaque accumulation transforms microglia, the primary innate immune cells in the brain, into neurodegenerative microglia (MGnD), which exhibit enhanced phagocytosis of plaques, apoptotic neurons and dystrophic neurites containing aggregated and phosphorylated tau (p-tau).", "tags": [{"end": 27, "start": 0, "tag": "PathologicFunction"}, {"end": 183, "start": 176, "tag": "AnatomicalAbnormality"}, {"end": 202, "start": 185, "tag": "Finding"}, {"end": 226, "start": 218, "tag": "CellComponent"}, {"end": 172, "start": 160, "tag": "CellFunction"}, {"end": 14, "start": 0, "tag": "AnatomicalAbnormality"}, {"end": 81, "start": 69, "tag": "Cell"}, {"end": 81, "start": 62, "tag": "Cell"}, {"end": 278, "start": 275, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 278, "start": 275, "tag": "BiologicallyActiveSubstance"}, {"end": 271, "start": 253, "tag": "AminoAcidPeptideOrProtein"}, {"end": 278, "start": 273, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 39, "tag": "Cell"}, {"end": 128, "start": 119, "tag": "Cell"}, {"end": 271, "start": 253, "tag": "BiologicallyActiveSubstance"}, {"end": 278, "start": 273, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 101, "tag": "CellOrMolecularDysfunction"}, {"end": 202, "start": 195, "tag": "Cell"}, {"end": 226, "start": 207, "tag": "CellOrMolecularDysfunction"}, {"end": 134, "start": 130, "tag": "Cell"}]}{"id": "1088_2", "text": "It remains unclear how microglia promote disease progression while actively phagocytosing pathological proteins, therefore ameliorating pathology.", "tags": [{"end": 89, "start": 76, "tag": "CellFunction"}, {"end": 111, "start": 90, "tag": "PathologicFunction"}, {"end": 111, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 136, "tag": "PathologicFunction"}, {"end": 145, "start": 136, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 60, "start": 49, "tag": "PathologicFunction"}, {"end": 60, "start": 49, "tag": "TemporalConcept"}, {"end": 32, "start": 23, "tag": "Cell"}, {"end": 60, "start": 41, "tag": "PathologicFunction"}]}{"id": "1088_3", "text": "Methods Adeno-associated virus expressing P301L tau mutant (AAV-P301L-tau) was stereotaxically injected into the medial entorhinal cortex (MEC) in C57BL/6 (WT) and humanized APP mutant knock-in homozygote (App(NL-G-F)) mice at 5 months of age.", "tags": [{"end": 30, "start": 8, "tag": "Virus"}, {"end": 137, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 185, "tag": "ResearchActivity"}, {"end": 41, "start": 31, "tag": "CellFunction"}, {"end": 235, "start": 229, "tag": "TemporalConcept"}, {"end": 51, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 177, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 174, "tag": "GeneOrGenome"}, {"end": 177, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 223, "start": 219, "tag": "ExperimentalModelOfDisease"}, {"end": 204, "start": 164, "tag": "ExperimentalModelOfDisease"}, {"end": 242, "start": 239, "tag": "OrganismAttribute"}, {"end": 158, "start": 156, "tag": "ResearchActivity"}, {"end": 137, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 52, "tag": "CellOrMolecularDysfunction"}, {"end": 47, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 60, "tag": "Virus"}, {"end": 69, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 79, "tag": "ResearchActivity"}, {"end": 154, "start": 147, "tag": "Eukaryote"}]}{"id": "1088_4", "text": "Mice were fed either chow containing a colony stimulating factor-1 receptor inhibitor (PLX5622) or control chow from 4 to 6 months of age to test the effect of microglia depletion.", "tags": [{"end": 4, "start": 0, "tag": "Eukaryote"}, {"end": 94, "start": 87, "tag": "Chemical"}, {"end": 85, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 76, "tag": "PharmacologicSubstance"}, {"end": 85, "start": 76, "tag": "Chemical"}, {"end": 130, "start": 124, "tag": "TemporalConcept"}, {"end": 156, "start": 150, "tag": "Finding"}, {"end": 137, "start": 134, "tag": "OrganismAttribute"}, {"end": 169, "start": 160, "tag": "Cell"}, {"end": 25, "start": 21, "tag": "Substance"}, {"end": 75, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 87, "tag": "PharmacologicSubstance"}, {"end": 111, "start": 107, "tag": "Substance"}]}{"id": "1088_5", "text": "Animals were tested at 6 months of age for immunofluorescence, biochemistry, and FACS of microglia.", "tags": [{"end": 61, "start": 43, "tag": "ResearchActivity"}, {"end": 75, "start": 63, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 85, "start": 81, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "Eukaryote"}, {"end": 31, "start": 25, "tag": "TemporalConcept"}, {"end": 38, "start": 35, "tag": "OrganismAttribute"}, {"end": 98, "start": 89, "tag": "Cell"}, {"end": 75, "start": 63, "tag": "ResearchActivity"}]}{"id": "1088_6", "text": "In order to monitor microglial extracellular vesicle secretion in vivo, a novel lentiviral EV reporter system was engineered to express mEmerald-CD9 (mE-CD9) specifically in microglia, which was injected into the same region of MEC.", "tags": [{"end": 231, "start": 228, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 153, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 128, "tag": "CellFunction"}, {"end": 62, "start": 31, "tag": "CellFunction"}, {"end": 52, "start": 31, "tag": "CellComponent"}, {"end": 93, "start": 91, "tag": "CellComponent"}, {"end": 183, "start": 174, "tag": "Cell"}, {"end": 70, "start": 63, "tag": "ResearchActivity"}, {"end": 30, "start": 20, "tag": "Cell"}, {"end": 19, "start": 12, "tag": "HealthCareActivity"}, {"end": 19, "start": 12, "tag": "ManufacturedObject"}, {"end": 90, "start": 80, "tag": "Virus"}, {"end": 109, "start": 80, "tag": "ResearchActivity"}, {"end": 144, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 136, "tag": "Chemical"}, {"end": 152, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 150, "tag": "Chemical"}]}{"id": "1088_7", "text": "Results Expressing P301L tau mutant in the MEC induced tau propagation to the granule cell layer of the hippocampal dentate gyrus, which was significantly exacerbated in App(NL-G-F) mice compared to WT control mice.", "tags": [{"end": 46, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 104, "tag": "Cell"}, {"end": 214, "start": 202, "tag": "Eukaryote"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 28, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 186, "start": 182, "tag": "Eukaryote"}, {"end": 201, "start": 199, "tag": "ResearchActivity"}, {"end": 70, "start": 59, "tag": "Finding"}, {"end": 35, "start": 29, "tag": "CellOrMolecularDysfunction"}, {"end": 166, "start": 155, "tag": "Finding"}, {"end": 24, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 170, "tag": "ExperimentalModelOfDisease"}]}{"id": "1088_8", "text": "Administration of PLX5622 depleted nearly all microglia in mouse brains and dramatically reduced propagation of p-tau in WT and to a greater extent in App(NL-G-F) mice, although it increased plaque burden and plaque-associated p-tau(+) dystrophic neurites.", "tags": [{"end": 255, "start": 247, "tag": "CellComponent"}, {"end": 14, "start": 0, "tag": "HealthCareActivity"}, {"end": 197, "start": 191, "tag": "AnatomicalAbnormality"}, {"end": 215, "start": 209, "tag": "AnatomicalAbnormality"}, {"end": 117, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 229, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 229, "tag": "BiologicallyActiveSubstance"}, {"end": 167, "start": 163, "tag": "Eukaryote"}, {"end": 204, "start": 198, "tag": "ResearchActivity"}, {"end": 117, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 227, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 46, "tag": "Cell"}, {"end": 117, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 227, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 59, "tag": "Eukaryote"}, {"end": 123, "start": 121, "tag": "ResearchActivity"}, {"end": 108, "start": 97, "tag": "Finding"}, {"end": 71, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 18, "tag": "Chemical"}, {"end": 25, "start": 18, "tag": "PharmacologicSubstance"}, {"end": 167, "start": 151, "tag": "ExperimentalModelOfDisease"}, {"end": 255, "start": 236, "tag": "CellOrMolecularDysfunction"}]}{"id": "1088_9", "text": "Plaque-associated MGnD microglia strongly expressed an EV marker, tumor susceptibility gene 101, indicative of heightened synthesis of EVs.", "tags": [{"end": 95, "start": 66, "tag": "GeneOrGenome"}, {"end": 131, "start": 122, "tag": "BiologicFunction"}, {"end": 138, "start": 135, "tag": "CellComponent"}, {"end": 57, "start": 55, "tag": "CellComponent"}, {"end": 64, "start": 58, "tag": "ClinicalAttribute"}, {"end": 32, "start": 18, "tag": "Cell"}, {"end": 51, "start": 42, "tag": "CellFunction"}, {"end": 6, "start": 0, "tag": "AnatomicalAbnormality"}]}{"id": "1088_10", "text": "Intracortical injection of mE-CD9 lentivirus successfully induced microglia-specific expression of mE-CD9(+) EV particles, which were significantly enhanced in Mac2(+) MGnD microglia compared to Mac2(-) homeostatic microglia.", "tags": [{"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 214, "start": 203, "tag": "BiologicFunction"}, {"end": 111, "start": 109, "tag": "CellComponent"}, {"end": 95, "start": 85, "tag": "CellFunction"}, {"end": 75, "start": 66, "tag": "Cell"}, {"end": 182, "start": 168, "tag": "Cell"}, {"end": 224, "start": 215, "tag": "Cell"}, {"end": 121, "start": 112, "tag": "Chemical"}, {"end": 23, "start": 14, "tag": "HealthCareActivity"}, {"end": 13, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 34, "tag": "Virus"}, {"end": 164, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 160, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 160, "tag": "GeneOrGenome"}, {"end": 199, "start": 195, "tag": "GeneOrGenome"}, {"end": 199, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 199, "start": 195, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1088_11", "text": "Finally, consecutive intracortical injection of mE-CD9 lentivirus and AAV-P301L-tau into App(NL-G-F) mice revealed encapsulation of p-tau in microglia-specific mE-CD9(+) EVs as determined by super-resolution microscopy and immuno-electron microscopy.", "tags": [{"end": 128, "start": 115, "tag": "ResearchActivity"}, {"end": 128, "start": 115, "tag": "Finding"}, {"end": 249, "start": 223, "tag": "HealthCareActivity"}, {"end": 54, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 166, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 170, "tag": "CellComponent"}, {"end": 83, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 141, "tag": "Cell"}, {"end": 137, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 249, "start": 230, "tag": "ResearchActivity"}, {"end": 44, "start": 35, "tag": "HealthCareActivity"}, {"end": 34, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 55, "tag": "Virus"}, {"end": 73, "start": 70, "tag": "Virus"}, {"end": 79, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 89, "tag": "ExperimentalModelOfDisease"}, {"end": 218, "start": 191, "tag": "ResearchActivity"}, {"end": 162, "start": 160, "tag": "Chemical"}, {"end": 162, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 48, "tag": "Chemical"}, {"end": 50, "start": 48, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1088_12", "text": "Discussion Our findings suggest that MGnD microglia hyper-secrete p-tau(+) EVs while compacting A beta plaques and clearing NP tau, which we propose as a novel mechanistic link between amyloid plaque deposition and exacerbation of tau propagation in App(NL-G-F) mice.", "tags": [{"end": 110, "start": 96, "tag": "AnatomicalAbnormality"}, {"end": 65, "start": 58, "tag": "CellFunction"}, {"end": 199, "start": 185, "tag": "AnatomicalAbnormality"}, {"end": 227, "start": 215, "tag": "Finding"}, {"end": 78, "start": 75, "tag": "CellComponent"}, {"end": 71, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 234, "start": 231, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 234, "start": 231, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 37, "tag": "Cell"}, {"end": 71, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 246, "start": 235, "tag": "Finding"}, {"end": 210, "start": 185, "tag": "PathologicFunction"}, {"end": 266, "start": 250, "tag": "ExperimentalModelOfDisease"}]}{"id": "1089_0", "text": "Extracellular vesicles (EVs), including small EVs (sEVs), are involved in neuroinflammation and neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.", "tags": [{"end": 49, "start": 40, "tag": "CellComponent"}, {"end": 153, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 49, "start": 46, "tag": "CellComponent"}, {"end": 174, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 122, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 209, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 74, "tag": "PathologicFunction"}, {"end": 55, "start": 51, "tag": "CellComponent"}]}{"id": "1089_1", "text": "Yet, increased neuroinflammation can also be detected in the aging brain, and it is associated with increased glial activation.", "tags": [{"end": 115, "start": 110, "tag": "Cell"}, {"end": 72, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 61, "tag": "BiologicFunction"}, {"end": 66, "start": 61, "tag": "CellFunction"}, {"end": 32, "start": 15, "tag": "PathologicFunction"}, {"end": 126, "start": 116, "tag": "CellFunction"}]}{"id": "1089_2", "text": "Changes in EV concentration are reported in aging tissues and senescence cells, suggesting a role of EVs in the process of aging.", "tags": [{"end": 78, "start": 62, "tag": "Cell"}, {"end": 7, "start": 0, "tag": "Finding"}, {"end": 104, "start": 101, "tag": "CellComponent"}, {"end": 13, "start": 11, "tag": "CellComponent"}, {"end": 49, "start": 44, "tag": "BiologicFunction"}, {"end": 128, "start": 123, "tag": "BiologicFunction"}, {"end": 49, "start": 44, "tag": "CellFunction"}, {"end": 128, "start": 123, "tag": "CellFunction"}, {"end": 27, "start": 14, "tag": "BiologicFunction"}, {"end": 57, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1089_3", "text": "Here, we investigated the effect of peripheral sEVs from aged animals on neuroinflammation, specifically on glial activation.", "tags": [{"end": 124, "start": 108, "tag": "CellFunction"}, {"end": 61, "start": 57, "tag": "TemporalConcept"}, {"end": 113, "start": 108, "tag": "Cell"}, {"end": 46, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 26, "tag": "Finding"}, {"end": 69, "start": 62, "tag": "Eukaryote"}, {"end": 90, "start": 73, "tag": "PathologicFunction"}, {"end": 51, "start": 47, "tag": "CellComponent"}]}{"id": "1089_4", "text": "sEVs were isolated from the peripheral blood of young (3 months) and aged (24 months) C57BL/6J wildtype mice and injected into the peripheral blood from young animals via vein tail injections.", "tags": [{"end": 108, "start": 86, "tag": "Eukaryote"}, {"end": 191, "start": 171, "tag": "ResearchActivity"}, {"end": 53, "start": 48, "tag": "TemporalConcept"}, {"end": 158, "start": 153, "tag": "TemporalConcept"}, {"end": 73, "start": 69, "tag": "TemporalConcept"}, {"end": 63, "start": 57, "tag": "TemporalConcept"}, {"end": 84, "start": 78, "tag": "TemporalConcept"}, {"end": 44, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 159, "tag": "Eukaryote"}, {"end": 4, "start": 0, "tag": "CellComponent"}]}{"id": "1089_5", "text": "The localization of EVs and the expression of selected genes involved in glial cell activation, including Gfap, Tgf-beta, Cd68, and Iba1, were assessed in brain tissue 30 min, 4 h, and 24 h after injection.", "tags": [{"end": 120, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 112, "tag": "GeneOrGenome"}, {"end": 120, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 122, "tag": "GeneOrGenome"}, {"end": 110, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 106, "tag": "GeneOrGenome"}, {"end": 110, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 20, "tag": "CellComponent"}, {"end": 167, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 32, "tag": "CellFunction"}, {"end": 205, "start": 196, "tag": "HealthCareActivity"}, {"end": 83, "start": 73, "tag": "Cell"}, {"end": 94, "start": 84, "tag": "CellFunction"}, {"end": 23, "start": 4, "tag": "CellFunction"}]}{"id": "1089_6", "text": "We found that sEVs from peripheral blood of aged mice but not from young mice altered gene expression in the brains of young animals.", "tags": [{"end": 101, "start": 78, "tag": "CellOrMolecularDysfunction"}, {"end": 72, "start": 67, "tag": "TemporalConcept"}, {"end": 124, "start": 119, "tag": "TemporalConcept"}, {"end": 48, "start": 44, "tag": "TemporalConcept"}, {"end": 40, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 49, "tag": "Eukaryote"}, {"end": 77, "start": 73, "tag": "Eukaryote"}, {"end": 132, "start": 125, "tag": "Eukaryote"}, {"end": 115, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 14, "tag": "CellComponent"}]}{"id": "1089_7", "text": "In particular, the expression of the specific astrocyte marker, Gfap, was significantly increased, indicating a strong response of this glial cell type.", "tags": [{"end": 68, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 64, "tag": "GeneOrGenome"}, {"end": 68, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 56, "tag": "ClinicalAttribute"}, {"end": 29, "start": 19, "tag": "CellFunction"}, {"end": 55, "start": 46, "tag": "Cell"}, {"end": 97, "start": 74, "tag": "Finding"}, {"end": 151, "start": 136, "tag": "Cell"}]}{"id": "1089_8", "text": "Our study shows that sEVs from aged mice can pass the blood-brain barrier (BBB) and induce glial cell activation.", "tags": [{"end": 35, "start": 31, "tag": "TemporalConcept"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 40, "start": 36, "tag": "Eukaryote"}, {"end": 73, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 21, "tag": "CellComponent"}, {"end": 78, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 91, "tag": "Cell"}, {"end": 112, "start": 102, "tag": "CellFunction"}]}{"id": "1090_0", "text": "The observation that aging is regulated by microRNAs (miRNA) and at the same time represents the greatest risk factor for Alzheimer's disease (AD), prompted us to examine the circulating miRNA network in AD beyond aging.", "tags": [{"end": 15, "start": 4, "tag": "Finding"}, {"end": 117, "start": 106, "tag": "Finding"}, {"end": 141, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 206, "start": 204, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 106, "tag": "Finding"}, {"end": 59, "start": 54, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 192, "start": 187, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 59, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 77, "tag": "TemporalConcept"}, {"end": 26, "start": 21, "tag": "BiologicFunction"}, {"end": 219, "start": 214, "tag": "BiologicFunction"}, {"end": 26, "start": 21, "tag": "CellFunction"}, {"end": 219, "start": 214, "tag": "CellFunction"}, {"end": 200, "start": 175, "tag": "BiologicFunction"}, {"end": 52, "start": 43, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 52, "start": 43, "tag": "BiologicallyActiveSubstance"}]}{"id": "1090_1", "text": "We here show that plasma miRNAs in aging are downregulated and predicted to be preferentially targeted to the extracellular vesicle (EV) content.", "tags": [{"end": 131, "start": 110, "tag": "CellComponent"}, {"end": 144, "start": 137, "tag": "BiologicFunction"}, {"end": 135, "start": 133, "tag": "CellComponent"}, {"end": 24, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 25, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 31, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 45, "tag": "CellFunction"}, {"end": 40, "start": 35, "tag": "BiologicFunction"}, {"end": 40, "start": 35, "tag": "CellFunction"}]}{"id": "1090_2", "text": "In AD, miRNAs are further downregulated, display altered proportions of motifs relevant to their loading into EVs and secretion propensity, and are forecast to be found exclusively in EVs.", "tags": [{"end": 113, "start": 110, "tag": "CellComponent"}, {"end": 187, "start": 184, "tag": "CellComponent"}, {"end": 5, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 7, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 13, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 118, "tag": "CellFunction"}, {"end": 127, "start": 118, "tag": "BiologicFunction"}, {"end": 39, "start": 26, "tag": "CellFunction"}, {"end": 113, "start": 97, "tag": "CellFunction"}]}{"id": "1090_3", "text": "The circulating miRNA network in AD, therefore, reflects pathological exacerbation of the aging process whereby physiological suppression of AD pathology by miRNAs becomes insufficient.", "tags": [{"end": 137, "start": 112, "tag": "BiologicFunction"}, {"end": 137, "start": 126, "tag": "NaturalPhenomenonOrProcess"}, {"end": 82, "start": 70, "tag": "Finding"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 144, "tag": "PathologicFunction"}, {"end": 153, "start": 144, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 163, "start": 157, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 163, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 16, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 21, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 90, "tag": "BiologicFunction"}, {"end": 95, "start": 90, "tag": "CellFunction"}, {"end": 29, "start": 4, "tag": "BiologicFunction"}]}{"id": "1091_0", "text": "Exosomes are small extracellular vesicles (EVs) present in human biofluids that can transport specific disease-associated molecules.", "tags": [{"end": 41, "start": 19, "tag": "CellComponent"}, {"end": 46, "start": 43, "tag": "CellComponent"}, {"end": 64, "start": 59, "tag": "Eukaryote"}, {"end": 74, "start": 65, "tag": "Substance"}, {"end": 131, "start": 122, "tag": "Substance"}, {"end": 8, "start": 0, "tag": "CellComponent"}, {"end": 41, "start": 13, "tag": "CellComponent"}]}{"id": "1091_1", "text": "Consequently blood-derived exosomes have emerged as important peripheral biomarker sources for a wide range of diseases, among them Alzheimer's disease (AD).", "tags": [{"end": 151, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 73, "tag": "ClinicalAttribute"}, {"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 83, "tag": "Finding"}, {"end": 35, "start": 27, "tag": "CellComponent"}]}{"id": "1091_2", "text": "Although there is no effective cure for AD, an accurate diagnosis, relying on easily accessible peripheral biofluids, is still necessary to discriminate this disease from other dementias, test potential therapies and even monitor rate of disease progression.", "tags": [{"end": 35, "start": 18, "tag": "Finding"}, {"end": 234, "start": 230, "tag": "TemporalConcept"}, {"end": 186, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 257, "start": 246, "tag": "PathologicFunction"}, {"end": 257, "start": 246, "tag": "TemporalConcept"}, {"end": 106, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 56, "tag": "HealthCareActivity"}, {"end": 116, "start": 107, "tag": "Substance"}, {"end": 257, "start": 238, "tag": "PathologicFunction"}, {"end": 212, "start": 203, "tag": "HealthCareActivity"}, {"end": 229, "start": 222, "tag": "HealthCareActivity"}, {"end": 229, "start": 222, "tag": "ManufacturedObject"}]}{"id": "1091_3", "text": "The ultimate goal is to produce a cost-effective and widely available alternative, which can also be employed as a first clinical screen.", "tags": [{"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 136, "start": 121, "tag": "HealthCareActivity"}]}{"id": "1091_4", "text": "In this study, EVs with exosome-like characteristics were isolated from serum of Controls and AD cases through precipitation- and column-based methods, followed by mass spectrometry analysis.", "tags": [{"end": 181, "start": 164, "tag": "ResearchActivity"}, {"end": 18, "start": 15, "tag": "CellComponent"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 182, "tag": "ResearchActivity"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 24, "tag": "CellComponent"}, {"end": 89, "start": 81, "tag": "PopulationGroup"}, {"end": 150, "start": 130, "tag": "ResearchActivity"}, {"end": 150, "start": 137, "tag": "ResearchActivity"}, {"end": 125, "start": 111, "tag": "ResearchActivity"}]}{"id": "1091_5", "text": "The resulting proteomes were characterized by Gene Ontology (GO) and multivariate analyses.", "tags": [{"end": 23, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 69, "tag": "ResearchActivity"}, {"end": 59, "start": 46, "tag": "ResearchActivity"}, {"end": 63, "start": 61, "tag": "ResearchActivity"}]}{"id": "1091_6", "text": "Although GO terms were similar for exosomes' proteomes of Controls and ADs, using both methodologies, a clear segregation of disease cases was obtained when using the precipitation-based method.", "tags": [{"end": 121, "start": 110, "tag": "ResearchActivity"}, {"end": 54, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 35, "tag": "CellComponent"}, {"end": 193, "start": 167, "tag": "ResearchActivity"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 66, "start": 58, "tag": "PopulationGroup"}]}{"id": "1091_7", "text": "Nine significantly different abundant proteins were identified between Controls and AD cases, representing putative biomarker candidate targets.", "tags": [{"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 116, "tag": "ClinicalAttribute"}, {"end": 46, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 71, "tag": "PopulationGroup"}]}{"id": "1091_8", "text": "Among them are AACT and C4BP alpha, two A beta-binding proteins, whose exosome levels were further validated in individuals from independent cohorts using antibody-based approaches.", "tags": [{"end": 19, "start": 15, "tag": "GeneOrGenome"}, {"end": 19, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 141, "tag": "PopulationGroup"}, {"end": 78, "start": 71, "tag": "CellComponent"}, {"end": 63, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 112, "tag": "PopulationGroup"}, {"end": 54, "start": 47, "tag": "CellFunction"}, {"end": 34, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 180, "start": 155, "tag": "ResearchActivity"}, {"end": 19, "start": 15, "tag": "BiologicallyActiveSubstance"}]}{"id": "1091_9", "text": "The findings discussed represent an important contribution to the identification of novel exosomal biomarker candidates useful as potential blood-based tools for AD diagnosis.", "tags": [{"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 99, "tag": "ClinicalAttribute"}, {"end": 145, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 165, "tag": "HealthCareActivity"}, {"end": 98, "start": 90, "tag": "CellComponent"}]}{"id": "1092_0", "text": "Last century, neurons and glial cells were mostly believed to play distinct functions, relevant for the brain.", "tags": [{"end": 21, "start": 14, "tag": "Cell"}, {"end": 37, "start": 26, "tag": "Cell"}, {"end": 109, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1092_1", "text": "Progressively, however, it became clear that neurons, astrocytes and microglia co-operate intensely with each other by release/binding of signaling factors, direct surface binding and generation/release of extracellular vesicles, the exosomes and ectosomes, called together vesicles in this abstract.", "tags": [{"end": 256, "start": 247, "tag": "CellComponent"}, {"end": 282, "start": 274, "tag": "CellComponent"}, {"end": 52, "start": 45, "tag": "Cell"}, {"end": 64, "start": 54, "tag": "Cell"}, {"end": 155, "start": 127, "tag": "CellFunction"}, {"end": 179, "start": 157, "tag": "CellFunction"}, {"end": 242, "start": 234, "tag": "CellComponent"}, {"end": 228, "start": 206, "tag": "CellComponent"}, {"end": 78, "start": 69, "tag": "Cell"}, {"end": 155, "start": 135, "tag": "CellFunction"}, {"end": 126, "start": 119, "tag": "CellFunction"}, {"end": 228, "start": 195, "tag": "CellFunction"}, {"end": 228, "start": 203, "tag": "CellFunction"}, {"end": 194, "start": 184, "tag": "CellFunction"}]}{"id": "1092_2", "text": "The present review is focused on these vesicles, fundamental in various brain diseases.", "tags": [{"end": 47, "start": 39, "tag": "CellComponent"}, {"end": 86, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}]}{"id": "1092_3", "text": "Their properties are extraordinary.", "tags": []}{"id": "1092_4", "text": "The specificity of their membrane governs their fusion with distinct target cells, variable depending on the state and specificity of their cells of origin and target.", "tags": [{"end": 81, "start": 69, "tag": "Cell"}, {"end": 81, "start": 69, "tag": "ResearchActivity"}, {"end": 114, "start": 109, "tag": "PopulationGroup"}, {"end": 155, "start": 149, "tag": "TemporalConcept"}, {"end": 33, "start": 25, "tag": "CellComponent"}, {"end": 15, "start": 4, "tag": "Finding"}, {"end": 130, "start": 119, "tag": "Finding"}, {"end": 145, "start": 140, "tag": "Cell"}]}{"id": "1092_5", "text": "Result of vesicle fusion is the discharge of their cargos into the cytoplasm of target cells.", "tags": [{"end": 24, "start": 10, "tag": "CellFunction"}, {"end": 44, "start": 42, "tag": "CellFunction"}, {"end": 57, "start": 51, "tag": "CellFunction"}, {"end": 41, "start": 32, "tag": "CellFunction"}, {"end": 76, "start": 67, "tag": "CellComponent"}, {"end": 92, "start": 80, "tag": "Cell"}, {"end": 92, "start": 80, "tag": "ResearchActivity"}]}{"id": "1092_6", "text": "Cargos are composed of critical molecules, from proteins (various nature and function) to nucleotides (especially miRNAs), playing critical roles in immune and neurodegenerative diseases.", "tags": [{"end": 41, "start": 32, "tag": "Substance"}, {"end": 101, "start": 90, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 186, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 114, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 120, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 186, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 149, "tag": "DiseaseOrSyndrome"}]}{"id": "1092_7", "text": "Among immune diseases is multiple sclerosis, affected by extensive dysregulation of co-trafficking neural and glial vesicles, with distinct miRNAs inducing severe or reducing effects.", "tags": [{"end": 21, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 166, "tag": "Finding"}, {"end": 162, "start": 156, "tag": "Finding"}, {"end": 146, "start": 140, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 146, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 110, "tag": "CellComponent"}]}{"id": "1092_8", "text": "The vesicle-dependent differences between progressive and relapsing-remitting forms of the disease are relevant for clinical developments.", "tags": [{"end": 137, "start": 125, "tag": "BiologicFunction"}, {"end": 137, "start": 125, "tag": "CellFunction"}, {"end": 67, "start": 58, "tag": "TemporalConcept"}, {"end": 53, "start": 42, "tag": "TemporalConcept"}, {"end": 33, "start": 22, "tag": "Finding"}, {"end": 11, "start": 4, "tag": "CellComponent"}]}{"id": "1092_9", "text": "In Alzheimer's disease the vesicles can affect the brain by changing their generation and inducing co-release of effective proteins, such A beta and tau, from neurons and astrocytes.", "tags": [{"end": 35, "start": 27, "tag": "CellComponent"}, {"end": 85, "start": 75, "tag": "TemporalConcept"}, {"end": 166, "start": 159, "tag": "Cell"}, {"end": 181, "start": 171, "tag": "Cell"}, {"end": 152, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 138, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1092_10", "text": "Specific miRNAs can delay the long-term development of the disease.", "tags": [{"end": 25, "start": 20, "tag": "TemporalConcept"}, {"end": 15, "start": 9, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 15, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 30, "tag": "TemporalConcept"}, {"end": 51, "start": 40, "tag": "BiologicFunction"}, {"end": 51, "start": 40, "tag": "CellFunction"}]}{"id": "1092_11", "text": "Upon their traffic through the blood-brainbarrier, vesicles of various origin reach fluids where they are essential for the identification of biomarkers, important for diagnostic and therapeutic innovations, critical for the future of many brain patients.", "tags": [{"end": 49, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 51, "tag": "CellComponent"}, {"end": 90, "start": 84, "tag": "Substance"}, {"end": 90, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 206, "start": 168, "tag": "HealthCareActivity"}, {"end": 77, "start": 71, "tag": "TemporalConcept"}, {"end": 245, "start": 240, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 142, "tag": "ClinicalAttribute"}, {"end": 254, "start": 246, "tag": "PatientOrDisabledGroup"}, {"end": 231, "start": 225, "tag": "TemporalConcept"}]}{"id": "1093_0", "text": "Extracellular vesicles (EVs) are very promising biomarkers for the diagnosis of various diseases, including cardiovascular, infectious and neurodegenerative disorders.", "tags": [{"end": 166, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 58, "start": 48, "tag": "ClinicalAttribute"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 76, "start": 67, "tag": "HealthCareActivity"}, {"end": 166, "start": 139, "tag": "DiseaseOrSyndrome"}]}{"id": "1093_1", "text": "Of particular relevance is their importance in cancer liquid biopsy, where they play a key role in the early detection and monitoring of the tumour.", "tags": [{"end": 67, "start": 47, "tag": "HealthCareActivity"}, {"end": 147, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 103, "tag": "HealthCareActivity"}, {"end": 118, "start": 109, "tag": "ResearchActivity"}, {"end": 118, "start": 109, "tag": "HealthCareActivity"}, {"end": 67, "start": 54, "tag": "HealthCareActivity"}, {"end": 133, "start": 123, "tag": "HealthCareActivity"}, {"end": 53, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 54, "tag": "Substance"}]}{"id": "1093_2", "text": "A number of technologies have recently been developed to improve the performance of current EV detection methods, but a technique that can provide high resolution, high accuracy and a multiplexing capability for the detection of several biomarkers in parallel remains a challenge in this field.", "tags": [{"end": 64, "start": 57, "tag": "Finding"}, {"end": 279, "start": 270, "tag": "HealthCareActivity"}, {"end": 129, "start": 120, "tag": "ResearchActivity"}, {"end": 112, "start": 95, "tag": "HealthCareActivity"}, {"end": 112, "start": 95, "tag": "ResearchActivity"}, {"end": 94, "start": 92, "tag": "CellComponent"}, {"end": 247, "start": 237, "tag": "ClinicalAttribute"}, {"end": 24, "start": 12, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 104, "start": 95, "tag": "ResearchActivity"}, {"end": 225, "start": 216, "tag": "ResearchActivity"}, {"end": 104, "start": 95, "tag": "HealthCareActivity"}, {"end": 225, "start": 216, "tag": "HealthCareActivity"}, {"end": 91, "start": 84, "tag": "TemporalConcept"}, {"end": 151, "start": 147, "tag": "Finding"}, {"end": 177, "start": 164, "tag": "Finding"}, {"end": 38, "start": 30, "tag": "TemporalConcept"}, {"end": 80, "start": 69, "tag": "Finding"}, {"end": 162, "start": 152, "tag": "Finding"}]}{"id": "1093_3", "text": "Here, we demonstrate the detection of large unilamellar vesicles, which are excellent models of EVs, down to a concentration <10(3) EV ml(-1) (<10 pM) using a dielectric resonant metasurface.", "tags": [{"end": 64, "start": 38, "tag": "CellComponent"}, {"end": 99, "start": 96, "tag": "CellComponent"}, {"end": 134, "start": 132, "tag": "CellComponent"}, {"end": 34, "start": 25, "tag": "ResearchActivity"}, {"end": 34, "start": 25, "tag": "HealthCareActivity"}, {"end": 92, "start": 86, "tag": "ResearchActivity"}, {"end": 124, "start": 111, "tag": "BiologicFunction"}, {"end": 190, "start": 159, "tag": "ResearchActivity"}]}{"id": "1093_4", "text": "This result represents an improvement in performance and functionality compared to competing plasmonic and electrochemical modalities and is due to the strong resonance amplitude and high Q-factor of our metasurface.", "tags": [{"end": 187, "start": 183, "tag": "Finding"}, {"end": 52, "start": 41, "tag": "Finding"}, {"end": 133, "start": 93, "tag": "ResearchActivity"}, {"end": 178, "start": 159, "tag": "ResearchActivity"}, {"end": 199, "start": 188, "tag": "ResearchActivity"}, {"end": 215, "start": 204, "tag": "ResearchActivity"}]}{"id": "1093_5", "text": "We also verify the selectivity of the approach by detecting vesicles that have been surface-functionalised with a CD9 protein.", "tags": [{"end": 125, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 60, "tag": "CellComponent"}]}{"id": "1093_6", "text": "The ease of integration of our method into a point-of-care instrument offers a path towards personalised cancer medicine.", "tags": [{"end": 23, "start": 12, "tag": "CellFunction"}, {"end": 23, "start": 12, "tag": "MachineActivity"}, {"end": 69, "start": 45, "tag": "HealthCareActivity"}, {"end": 58, "start": 54, "tag": "HealthCareActivity"}, {"end": 111, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 31, "tag": "ResearchActivity"}, {"end": 37, "start": 31, "tag": "HealthCareActivity"}, {"end": 120, "start": 92, "tag": "HealthCareActivity"}]}{"id": "1094_0", "text": "Mutations in glucocerebrosidase (GBA) are the most prevalent genetic risk factor for Lewy body disorders (LBD)-collectively Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies.", "tags": [{"end": 9, "start": 0, "tag": "CellFunction"}, {"end": 31, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 33, "tag": "GeneOrGenome"}, {"end": 36, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 61, "tag": "Finding"}, {"end": 203, "start": 192, "tag": "CellComponent"}, {"end": 203, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 0, "tag": "CellOrMolecularDysfunction"}]}{"id": "1094_1", "text": "Despite this genetic association, it remains unclear how GBA mutations increase susceptibility to develop LBD.", "tags": [{"end": 60, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 57, "tag": "GeneOrGenome"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 61, "tag": "CellFunction"}, {"end": 70, "start": 61, "tag": "CellOrMolecularDysfunction"}, {"end": 32, "start": 13, "tag": "Finding"}, {"end": 94, "start": 80, "tag": "ClinicalAttribute"}]}{"id": "1094_2", "text": "We investigated relationships between LBD-specific glucocerebrosidase deficits, GBA-related pathways, and alpha-synuclein levels in brain tissue from LBD and controls, with and without GBA mutations.", "tags": [{"end": 153, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 185, "tag": "GeneOrGenome"}, {"end": 188, "start": 185, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 70, "tag": "Finding"}, {"end": 166, "start": 158, "tag": "PopulationGroup"}, {"end": 144, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 16, "tag": "Finding"}, {"end": 100, "start": 92, "tag": "CellFunction"}, {"end": 198, "start": 189, "tag": "CellFunction"}, {"end": 198, "start": 189, "tag": "CellOrMolecularDysfunction"}, {"end": 41, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 80, "tag": "GeneOrGenome"}]}{"id": "1094_3", "text": "We show that LBD is characterised by altered sphingolipid metabolism with prominent elevation of ceramide species, regardless of GBA mutations.", "tags": [{"end": 16, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 45, "tag": "CellFunction"}, {"end": 93, "start": 84, "tag": "Finding"}, {"end": 132, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 129, "tag": "GeneOrGenome"}, {"end": 132, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 58, "tag": "CellFunction"}, {"end": 68, "start": 58, "tag": "BiologicFunction"}, {"end": 57, "start": 45, "tag": "Chemical"}, {"end": 105, "start": 97, "tag": "Chemical"}, {"end": 105, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 133, "tag": "CellFunction"}, {"end": 142, "start": 133, "tag": "CellOrMolecularDysfunction"}, {"end": 113, "start": 106, "tag": "OrganismAttribute"}]}{"id": "1094_4", "text": "Since extracellular vesicles (EV) could be involved in LBD pathogenesis by spreading disease-linked lipids and proteins, we investigated EV derived from post-mortem cerebrospinal fluid (CSF) and brain tissue from GBA mutation carriers and non-carriers.", "tags": [{"end": 58, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 153, "tag": "TemporalConcept"}, {"end": 216, "start": 213, "tag": "AminoAcidPeptideOrProtein"}, {"end": 216, "start": 213, "tag": "GeneOrGenome"}, {"end": 216, "start": 213, "tag": "BiologicallyActiveSubstance"}, {"end": 225, "start": 217, "tag": "CellOrMolecularDysfunction"}, {"end": 28, "start": 6, "tag": "CellComponent"}, {"end": 32, "start": 30, "tag": "CellComponent"}, {"end": 139, "start": 137, "tag": "CellComponent"}, {"end": 189, "start": 186, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 207, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 234, "start": 226, "tag": "PopulationGroup"}, {"end": 119, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 59, "tag": "PathologicFunction"}, {"end": 106, "start": 100, "tag": "Chemical"}, {"end": 251, "start": 239, "tag": "PopulationGroup"}, {"end": 225, "start": 217, "tag": "CellFunction"}]}{"id": "1094_5", "text": "EV purified from LBD CSF and frontal cortex were heavily loaded with ceramides and neurodegeneration-linked proteins including alpha-synuclein and tau.", "tags": [{"end": 20, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 2, "start": 0, "tag": "CellComponent"}, {"end": 24, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 83, "tag": "CellOrMolecularDysfunction"}, {"end": 78, "start": 69, "tag": "Chemical"}, {"end": 78, "start": 69, "tag": "BiologicallyActiveSubstance"}]}{"id": "1094_6", "text": "Our in vitro studies demonstrate that LBD EV constitute a pathological package capable of inducing aggregation of wild-type alpha-synuclein, mediated through a combination of alpha-synuclein-ceramide interaction and the presence of pathological forms of alpha-synuclein.", "tags": [{"end": 41, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 114, "tag": "ResearchActivity"}, {"end": 139, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 269, "start": 260, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 130, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 181, "tag": "BiologicallyActiveSubstance"}, {"end": 269, "start": 260, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 269, "start": 254, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 175, "tag": "BiologicallyActiveSubstance"}, {"end": 269, "start": 254, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 42, "tag": "CellComponent"}, {"end": 20, "start": 13, "tag": "ResearchActivity"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 110, "start": 99, "tag": "CellFunction"}, {"end": 110, "start": 99, "tag": "ResearchActivity"}, {"end": 199, "start": 191, "tag": "Chemical"}, {"end": 199, "start": 191, "tag": "BiologicallyActiveSubstance"}, {"end": 228, "start": 220, "tag": "Finding"}, {"end": 78, "start": 58, "tag": "PathologicFunction"}]}{"id": "1094_7", "text": "Together, our findings indicate that abnormalities in ceramide metabolism are a feature of LBD, constituting a promising source of biomarkers, and that GBA mutations likely accelerate the pathological process occurring in sporadic LBD through endolysosomal deficiency.", "tags": [{"end": 73, "start": 54, "tag": "CellFunction"}, {"end": 94, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 152, "tag": "GeneOrGenome"}, {"end": 155, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 234, "start": 231, "tag": "DiseaseOrSyndrome"}, {"end": 267, "start": 257, "tag": "Finding"}, {"end": 256, "start": 243, "tag": "CellComponent"}, {"end": 208, "start": 188, "tag": "PathologicFunction"}, {"end": 141, "start": 131, "tag": "ClinicalAttribute"}, {"end": 73, "start": 63, "tag": "CellFunction"}, {"end": 73, "start": 63, "tag": "BiologicFunction"}, {"end": 230, "start": 222, "tag": "TemporalConcept"}, {"end": 62, "start": 54, "tag": "Chemical"}, {"end": 62, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 156, "tag": "CellFunction"}, {"end": 165, "start": 156, "tag": "CellOrMolecularDysfunction"}]}{"id": "1095_0", "text": "The significant roles of extracellular vesicles (EVs) as intracellular mediators, disease biomarkers, and therapeutic agents, make them a scientific hotspot.", "tags": [{"end": 124, "start": 106, "tag": "HealthCareActivity"}, {"end": 70, "start": 57, "tag": "CellComponent"}, {"end": 47, "start": 25, "tag": "CellComponent"}, {"end": 52, "start": 49, "tag": "CellComponent"}, {"end": 100, "start": 90, "tag": "ClinicalAttribute"}, {"end": 80, "start": 71, "tag": "Finding"}]}{"id": "1095_1", "text": "In particular, EVs secreted by human stem cells show significance in treating neurological disorders, such as Alzheimer's disease and ischemic stroke.", "tags": [{"end": 149, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 15, "tag": "CellComponent"}, {"end": 36, "start": 31, "tag": "Eukaryote"}, {"end": 100, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 37, "tag": "Cell"}]}{"id": "1095_2", "text": "However, the clinical applications of EVs are limited due to their poor targeting capabilities and low therapeutic efficacies after intravenous administration.", "tags": [{"end": 158, "start": 132, "tag": "HealthCareActivity"}, {"end": 143, "start": 132, "tag": "HealthCareActivity"}, {"end": 34, "start": 13, "tag": "HealthCareActivity"}, {"end": 41, "start": 38, "tag": "CellComponent"}, {"end": 125, "start": 99, "tag": "Finding"}]}{"id": "1095_3", "text": "Superparamagnetic iron oxide (SPIO) nanoparticles are biocompatible and have been shown to improve the targeting ability of EVs.", "tags": [{"end": 49, "start": 36, "tag": "Chemical"}, {"end": 28, "start": 0, "tag": "Chemical"}, {"end": 127, "start": 124, "tag": "CellComponent"}, {"end": 34, "start": 30, "tag": "Chemical"}]}{"id": "1095_4", "text": "In particular, ultrasmall SPIO (USPIO, <50 nm) are more suitable for labeling nanoscale EVs due to their small size.", "tags": [{"end": 30, "start": 15, "tag": "Chemical"}, {"end": 37, "start": 32, "tag": "Chemical"}, {"end": 115, "start": 105, "tag": "OrganismAttribute"}, {"end": 91, "start": 88, "tag": "CellComponent"}]}{"id": "1095_5", "text": "In this study, induced forebrain neural progenitor cortical organoids (iNPCo) were differentiated from human induced pluripotent stem cells (iPSCs), and the iNPCo expressed FOXG1, Nkx2.1, alpha-catenin, as well as beta-tubulin III.", "tags": [{"end": 32, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 173, "tag": "GeneOrGenome"}, {"end": 186, "start": 180, "tag": "GeneOrGenome"}, {"end": 201, "start": 188, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 188, "tag": "BiologicallyActiveSubstance"}, {"end": 230, "start": 214, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 108, "start": 103, "tag": "Eukaryote"}, {"end": 139, "start": 109, "tag": "Cell"}, {"end": 146, "start": 141, "tag": "Cell"}, {"end": 139, "start": 129, "tag": "Cell"}, {"end": 172, "start": 163, "tag": "CellFunction"}, {"end": 76, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 186, "start": 180, "tag": "BiologicallyActiveSubstance"}, {"end": 186, "start": 180, "tag": "AminoAcidPeptideOrProtein"}, {"end": 230, "start": 214, "tag": "BiologicallyActiveSubstance"}]}{"id": "1095_6", "text": "EVs were isolated from iNPCo media, then loaded with USPIOs by sonication.", "tags": [{"end": 34, "start": 29, "tag": "Substance"}, {"end": 73, "start": 63, "tag": "ResearchActivity"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 59, "start": 53, "tag": "Chemical"}, {"end": 28, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1095_7", "text": "Size and concentration of EV particles were measured by nanoparticle tracking analysis, and no significant changes were observed in size distribution before and after sonication, but the concentration decreased after labeling.", "tags": [{"end": 177, "start": 167, "tag": "ResearchActivity"}, {"end": 225, "start": 217, "tag": "BiologicFunction"}, {"end": 28, "start": 26, "tag": "CellComponent"}, {"end": 86, "start": 56, "tag": "ResearchActivity"}, {"end": 136, "start": 132, "tag": "OrganismAttribute"}, {"end": 38, "start": 29, "tag": "Chemical"}, {"end": 22, "start": 9, "tag": "BiologicFunction"}, {"end": 200, "start": 187, "tag": "BiologicFunction"}, {"end": 114, "start": 92, "tag": "Finding"}]}{"id": "1095_8", "text": "miR-21 and miR-133b decreased after sonication.", "tags": [{"end": 6, "start": 0, "tag": "GeneOrGenome"}, {"end": 46, "start": 36, "tag": "ResearchActivity"}, {"end": 29, "start": 20, "tag": "Finding"}]}{"id": "1095_9", "text": "Magnetic resonance imaging (MRI) demonstrated contrast visualized for the USPIO labeled EVs embedded in agarose gel phantoms.", "tags": [{"end": 26, "start": 0, "tag": "HealthCareActivity"}, {"end": 79, "start": 74, "tag": "Chemical"}, {"end": 115, "start": 104, "tag": "ManufacturedObject"}, {"end": 31, "start": 28, "tag": "HealthCareActivity"}, {"end": 91, "start": 88, "tag": "CellComponent"}]}{"id": "1095_10", "text": "Upon calculation, USPIO labeled EVs exhibited considerably shorter relaxation times, quantified as T-2 and T-2* values, reducing the signal intensity and generating higher MRI contrast compared to unlabeled EVs and gel only.", "tags": [{"end": 23, "start": 18, "tag": "Chemical"}, {"end": 218, "start": 215, "tag": "Chemical"}, {"end": 218, "start": 215, "tag": "Substance"}, {"end": 175, "start": 172, "tag": "HealthCareActivity"}, {"end": 35, "start": 32, "tag": "CellComponent"}, {"end": 210, "start": 207, "tag": "CellComponent"}, {"end": 128, "start": 120, "tag": "Finding"}, {"end": 149, "start": 133, "tag": "ResearchActivity"}]}{"id": "1095_11", "text": "Our study demonstrated that USPIO labeling was a feasible approach for in vitro tracking of brain organoid-derived EVs, which paves the way for further in vivo examination.", "tags": [{"end": 33, "start": 28, "tag": "Chemical"}, {"end": 171, "start": 160, "tag": "HealthCareActivity"}, {"end": 118, "start": 115, "tag": "CellComponent"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 97, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 71, "tag": "ResearchActivity"}, {"end": 159, "start": 152, "tag": "ResearchActivity"}, {"end": 106, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1096_0", "text": "Neurodegenerative disorders are one of the most common causes of disability and represent 6.3% of the global burden of disease.", "tags": [{"end": 115, "start": 109, "tag": "ResearchActivity"}, {"end": 27, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 65, "tag": "Finding"}]}{"id": "1096_1", "text": "Among them, Alzheimer's, Parkinson's, and Huntington's diseases cause cognitive decline, representing the most disabling symptom on both personal and social levels.", "tags": [{"end": 145, "start": 137, "tag": "OrganismAttribute"}, {"end": 36, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 121, "tag": "SignOrSymptom"}, {"end": 87, "start": 70, "tag": "DiseaseOrSyndrome"}]}{"id": "1096_2", "text": "The molecular mechanisms underlying the onset and progression of dementia are still poorly understood, and include secretory factors potentially affecting differentiated neurons, glial cells and neural stem cell niche.", "tags": [{"end": 177, "start": 170, "tag": "Cell"}, {"end": 190, "start": 179, "tag": "Cell"}, {"end": 24, "start": 4, "tag": "CellFunction"}, {"end": 184, "start": 179, "tag": "Cell"}, {"end": 61, "start": 50, "tag": "PathologicFunction"}, {"end": 61, "start": 50, "tag": "TemporalConcept"}, {"end": 211, "start": 195, "tag": "Cell"}, {"end": 73, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 40, "tag": "TemporalConcept"}]}{"id": "1096_3", "text": "In the last decade, much attention has been devoted to exosomes as novel carriers of information exchanged among both neighbouring and distant cells.", "tags": [{"end": 81, "start": 73, "tag": "Finding"}, {"end": 148, "start": 143, "tag": "Cell"}, {"end": 130, "start": 118, "tag": "Cell"}, {"end": 18, "start": 7, "tag": "TemporalConcept"}, {"end": 34, "start": 25, "tag": "BiologicFunction"}, {"end": 63, "start": 55, "tag": "CellComponent"}, {"end": 148, "start": 135, "tag": "Cell"}]}{"id": "1096_4", "text": "These vesicles can be generated and internalized by different brain cells including neurons, neural stem cells, astrocytes, and microglia, thereby affecting neural plasticity and cognitive functions in physiological and pathological conditions.", "tags": [{"end": 14, "start": 6, "tag": "CellComponent"}, {"end": 174, "start": 164, "tag": "NaturalPhenomenonOrProcess"}, {"end": 174, "start": 164, "tag": "CellFunction"}, {"end": 198, "start": 179, "tag": "BiologicFunction"}, {"end": 73, "start": 62, "tag": "Cell"}, {"end": 91, "start": 84, "tag": "Cell"}, {"end": 122, "start": 112, "tag": "Cell"}, {"end": 243, "start": 220, "tag": "PathologicFunction"}, {"end": 110, "start": 93, "tag": "Cell"}, {"end": 110, "start": 100, "tag": "Cell"}, {"end": 137, "start": 128, "tag": "Cell"}]}{"id": "1096_5", "text": "Here, we review data on the roles of exosomes as carriers of bioactive molecules potentially involved in the pathogenesis of neurodegenerative disorders and detectable in biological fluids as biomarkers of dementia.", "tags": [{"end": 57, "start": 49, "tag": "Finding"}, {"end": 167, "start": 157, "tag": "ClinicalAttribute"}, {"end": 152, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 71, "tag": "Substance"}, {"end": 45, "start": 37, "tag": "CellComponent"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 202, "start": 192, "tag": "ClinicalAttribute"}, {"end": 121, "start": 109, "tag": "PathologicFunction"}, {"end": 20, "start": 16, "tag": "ResearchActivity"}, {"end": 214, "start": 206, "tag": "DiseaseOrSyndrome"}]}{"id": "1096_6", "text": "We also discuss the experimental evidence of the therapeutic potential of stem cell-derived vesicles in experimental models of neurodegeneration-dependent cognitive decline.", "tags": [{"end": 32, "start": 20, "tag": "ResearchActivity"}, {"end": 70, "start": 49, "tag": "HealthCareActivity"}, {"end": 144, "start": 104, "tag": "ExperimentalModelOfDisease"}, {"end": 41, "start": 33, "tag": "Finding"}, {"end": 144, "start": 127, "tag": "CellOrMolecularDysfunction"}, {"end": 172, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 104, "tag": "ResearchActivity"}, {"end": 100, "start": 74, "tag": "CellComponent"}]}{"id": "1097_0", "text": "MicroRNAs (miRNAs) are small non-coding RNA that are powerful regulators of gene expression and can affect the expression of hundreds of genes.", "tags": [{"end": 43, "start": 29, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 43, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 11, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 17, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 76, "tag": "CellFunction"}, {"end": 91, "start": 81, "tag": "CellFunction"}, {"end": 121, "start": 111, "tag": "CellFunction"}, {"end": 80, "start": 76, "tag": "GeneOrGenome"}, {"end": 43, "start": 40, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1097_1", "text": "miRNAs can be packed in small extracellular vesicles (SEV) and released into the extracellular space by neurons and microglia to act locally as well as pass through the blood-brain barrier and act systemically.", "tags": [{"end": 57, "start": 54, "tag": "CellComponent"}, {"end": 100, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 30, "tag": "CellComponent"}, {"end": 180, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 6, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 6, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 116, "tag": "Cell"}, {"end": 188, "start": 169, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 104, "tag": "Cell"}, {"end": 52, "start": 24, "tag": "CellComponent"}]}{"id": "1097_2", "text": "We sought to understand the differences in neuronal SEV miRNA expression between frontotemporal dementia (FTD), Alzheimer's disease (AD), and healthy aging.", "tags": [{"end": 55, "start": 52, "tag": "CellComponent"}, {"end": 131, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 142, "tag": "OrganismAttribute"}, {"end": 104, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 43, "tag": "Cell"}, {"end": 72, "start": 62, "tag": "CellFunction"}, {"end": 61, "start": 56, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 61, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 28, "tag": "Finding"}, {"end": 155, "start": 150, "tag": "BiologicFunction"}, {"end": 155, "start": 150, "tag": "CellFunction"}, {"end": 104, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 106, "tag": "DiseaseOrSyndrome"}]}{"id": "1097_3", "text": "Plasma was obtained from FTD, AD, and healthy aging participants that were matched based on age, sex, and race/ethnicity.", "tags": [{"end": 110, "start": 106, "tag": "PopulationGroup"}, {"end": 120, "start": 111, "tag": "PopulationGroup"}, {"end": 120, "start": 106, "tag": "PopulationGroup"}, {"end": 64, "start": 52, "tag": "PopulationGroup"}, {"end": 32, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 38, "tag": "OrganismAttribute"}, {"end": 95, "start": 92, "tag": "OrganismAttribute"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 97, "tag": "OrganismAttribute"}, {"end": 51, "start": 46, "tag": "BiologicFunction"}, {"end": 51, "start": 46, "tag": "CellFunction"}, {"end": 28, "start": 25, "tag": "DiseaseOrSyndrome"}]}{"id": "1097_4", "text": "Additionally, a subset of participants also provided paired cerebrospinal fluid samples to compare neuronal SEV miRNAs in plasma and cerebrospinal fluid.", "tags": [{"end": 111, "start": 108, "tag": "CellComponent"}, {"end": 38, "start": 26, "tag": "PopulationGroup"}, {"end": 128, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 112, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 118, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 80, "tag": "Substance"}, {"end": 87, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 99, "tag": "Cell"}]}{"id": "1097_5", "text": "Neuronal SEV were isolated using differential ultracentrifugation and antibody conjugated Dynabeads (R) for the neuronal surface marker, L1CAM.", "tags": [{"end": 12, "start": 9, "tag": "CellComponent"}, {"end": 142, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 137, "tag": "GeneOrGenome"}, {"end": 135, "start": 121, "tag": "ClinicalAttribute"}, {"end": 120, "start": 112, "tag": "Cell"}, {"end": 102, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 33, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 90, "tag": "ManufacturedObject"}, {"end": 99, "start": 70, "tag": "ResearchActivity"}]}{"id": "1097_6", "text": "RNA sequencing was performed.", "tags": [{"end": 14, "start": 0, "tag": "ResearchActivity"}, {"end": 3, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1097_7", "text": "12 FTD, 11 with AD, and 10 healthy aging participants were enrolled in the study.", "tags": [{"end": 53, "start": 41, "tag": "PopulationGroup"}, {"end": 18, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 27, "tag": "OrganismAttribute"}, {"end": 80, "start": 75, "tag": "ResearchActivity"}, {"end": 40, "start": 35, "tag": "BiologicFunction"}, {"end": 40, "start": 35, "tag": "CellFunction"}, {"end": 6, "start": 3, "tag": "DiseaseOrSyndrome"}]}{"id": "1097_8", "text": "In FTD, SEV miRNA-181c was downregulated compared to healthy controls.", "tags": [{"end": 11, "start": 8, "tag": "CellComponent"}, {"end": 69, "start": 61, "tag": "PopulationGroup"}, {"end": 60, "start": 53, "tag": "OrganismAttribute"}, {"end": 22, "start": 12, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 22, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 40, "start": 27, "tag": "CellFunction"}, {"end": 6, "start": 3, "tag": "DiseaseOrSyndrome"}]}{"id": "1097_9", "text": "In AD, miRNA-122 and miRNA-3591 were downregulated compared to those in healthy controls and FTD.", "tags": [{"end": 88, "start": 80, "tag": "PopulationGroup"}, {"end": 5, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 72, "tag": "OrganismAttribute"}, {"end": 16, "start": 7, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 31, "start": 21, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 16, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 37, "tag": "CellFunction"}, {"end": 96, "start": 93, "tag": "DiseaseOrSyndrome"}]}{"id": "1097_10", "text": "Using an FDR <0.2, only miRNA-21-5p was found to have increased expression in the cerebrospinal fluid compared to plasma in a group of AD and FTD participants.", "tags": [{"end": 12, "start": 9, "tag": "ResearchActivity"}, {"end": 158, "start": 146, "tag": "PopulationGroup"}, {"end": 137, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 126, "tag": "PopulationGroup"}, {"end": 101, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 64, "tag": "CellFunction"}, {"end": 35, "start": 24, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 35, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 142, "tag": "DiseaseOrSyndrome"}]}{"id": "1097_11", "text": "SEV miRNA-181c is significantly downregulated in FTD compared to healthy controls and may mediate its effects through microglial-directed neuroinflammation and interaction with TAR DNA-binding protein 43 (TDP-43) based on pathway analysis.", "tags": [{"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 203, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 73, "tag": "PopulationGroup"}, {"end": 72, "start": 65, "tag": "OrganismAttribute"}, {"end": 238, "start": 222, "tag": "ResearchActivity"}, {"end": 14, "start": 4, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 14, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 32, "tag": "CellFunction"}, {"end": 109, "start": 102, "tag": "Finding"}, {"end": 211, "start": 205, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 205, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 181, "tag": "CellFunction"}, {"end": 52, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 118, "tag": "Cell"}, {"end": 155, "start": 138, "tag": "PathologicFunction"}, {"end": 184, "start": 181, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 203, "start": 177, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1097_12", "text": "Additionally, the FOXO and Hippo pathways may be important mediators of FTD, based on pathway analysis.", "tags": [{"end": 22, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 86, "tag": "ResearchActivity"}, {"end": 68, "start": 59, "tag": "Finding"}, {"end": 41, "start": 27, "tag": "CellFunction"}, {"end": 75, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 33, "tag": "CellFunction"}, {"end": 22, "start": 18, "tag": "CellFunction"}]}{"id": "1097_13", "text": "Lastly, because only one SEV miRNA was differentially expressed between the plasma and cerebrospinal fluid in paired samples, plasma represents an appropriate biofluid for studying neuronal SEV miRNA.", "tags": [{"end": 28, "start": 25, "tag": "CellComponent"}, {"end": 193, "start": 190, "tag": "CellComponent"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 82, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 159, "tag": "Substance"}, {"end": 124, "start": 117, "tag": "Substance"}, {"end": 124, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 189, "start": 181, "tag": "Cell"}, {"end": 34, "start": 29, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 199, "start": 194, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 199, "start": 194, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 101, "tag": "Substance"}, {"end": 63, "start": 39, "tag": "Finding"}]}{"id": "1098_0", "text": "Tauopathies are neurodegenerative diseases characterized by tau inclusions in brain cells.", "tags": [{"end": 11, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 78, "tag": "Cell"}, {"end": 63, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 60, "tag": "CellOrMolecularDysfunction"}]}{"id": "1098_1", "text": "Seed-competent tau species have been suggested to spread from cell to cell in a stereotypical manner, indicating that this may involve a prion-like mechanism.", "tags": [{"end": 26, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 62, "tag": "Cell"}, {"end": 74, "start": 70, "tag": "Cell"}, {"end": 142, "start": 137, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1098_2", "text": "Although the intercellular mechanisms of transfer are unclear, extracellular vesicles (EVs) could be potential shuttles.", "tags": [{"end": 49, "start": 41, "tag": "HealthCareActivity"}, {"end": 49, "start": 41, "tag": "ResearchActivity"}, {"end": 85, "start": 63, "tag": "CellComponent"}, {"end": 90, "start": 87, "tag": "CellComponent"}]}{"id": "1098_3", "text": "We assessed this in humans by preparing vesicles from fluids (brain-derived enriched EVs [BD-EVs]).", "tags": [{"end": 26, "start": 20, "tag": "Eukaryote"}, {"end": 60, "start": 54, "tag": "Substance"}, {"end": 88, "start": 85, "tag": "CellComponent"}, {"end": 96, "start": 93, "tag": "CellComponent"}, {"end": 67, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 40, "tag": "CellComponent"}]}{"id": "1098_4", "text": "These latter were isolated from different brain regions in various tauopathies, and their seeding potential was assessed in vitro and in vivo.", "tags": [{"end": 78, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 121, "tag": "ResearchActivity"}, {"end": 141, "start": 134, "tag": "ResearchActivity"}, {"end": 55, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 90, "tag": "CellFunction"}]}{"id": "1098_5", "text": "We observed considerable heterogeneity among tauopathies and brain regions.", "tags": [{"end": 56, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 25, "tag": "OrganismAttribute"}, {"end": 74, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1098_6", "text": "The most striking evidence was coming mainly from Alzheimer's disease where the BD-EVs clearly contain pathological species that can induce tau lesions in vivo.", "tags": [{"end": 151, "start": 144, "tag": "InjuryOrPoisoning"}, {"end": 69, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 83, "tag": "CellComponent"}, {"end": 26, "start": 18, "tag": "Finding"}, {"end": 143, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 152, "tag": "ResearchActivity"}, {"end": 123, "start": 116, "tag": "OrganismAttribute"}]}{"id": "1098_7", "text": "The results support the hypothesis that BD-EVs participate in the prion-like propagation of tau pathology among tauopathies, and there may be implications for diagnostic and therapeutic strategies.", "tags": [{"end": 123, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 92, "tag": "PathologicFunction"}, {"end": 46, "start": 43, "tag": "CellComponent"}, {"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 77, "tag": "Finding"}, {"end": 71, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 196, "start": 174, "tag": "HealthCareActivity"}, {"end": 196, "start": 186, "tag": "HealthCareActivity"}, {"end": 169, "start": 159, "tag": "HealthCareActivity"}]}{"id": "1099_0", "text": "One of the hallmarks of Alzheimer's disease (AD) pathogenesis is believed to be the production and deposition of amyloid-beta (A beta) peptide into extracellular plaques.", "tags": [{"end": 20, "start": 11, "tag": "Finding"}, {"end": 43, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 49, "tag": "PathologicFunction"}, {"end": 133, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 148, "tag": "CellComponent"}, {"end": 142, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 162, "tag": "AnatomicalAbnormality"}]}{"id": "1099_1", "text": "Existing research indicates that extracellular vesicles (EVs) can carry A beta associated with AD.", "tags": [{"end": 55, "start": 33, "tag": "CellComponent"}, {"end": 60, "start": 57, "tag": "CellComponent"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 78, "start": 72, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1099_2", "text": "However, characterization of the EVs-associated A beta and its conformational variants has yet to be realized.", "tags": [{"end": 36, "start": 33, "tag": "CellComponent"}, {"end": 54, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 9, "tag": "ResearchActivity"}, {"end": 86, "start": 63, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1099_3", "text": "Raman spectroscopy is a label-free and non-destructive method that is able to assess the biochemical composition of EVs.", "tags": [{"end": 18, "start": 0, "tag": "ResearchActivity"}, {"end": 34, "start": 24, "tag": "ResearchActivity"}, {"end": 119, "start": 116, "tag": "CellComponent"}, {"end": 61, "start": 55, "tag": "ResearchActivity"}, {"end": 61, "start": 55, "tag": "HealthCareActivity"}, {"end": 112, "start": 89, "tag": "Finding"}]}{"id": "1099_4", "text": "This study reports for the first time the Raman spectroscopic fingerprint of the A beta present in the molecular cargo of small extracellular vesicles (sEVs).", "tags": [{"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 32, "start": 27, "tag": "TemporalConcept"}, {"end": 118, "start": 103, "tag": "CellFunction"}, {"end": 18, "start": 11, "tag": "HealthCareActivity"}, {"end": 18, "start": 11, "tag": "ResearchActivity"}, {"end": 87, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 33, "tag": "TemporalConcept"}, {"end": 150, "start": 122, "tag": "CellComponent"}, {"end": 156, "start": 152, "tag": "CellComponent"}, {"end": 61, "start": 42, "tag": "ResearchActivity"}, {"end": 73, "start": 62, "tag": "ManufacturedObject"}]}{"id": "1099_5", "text": "Raman spectra were measured from sEVs isolated from Alzheimer's disease cell culture model, where secretion of A beta is regulated by tetracycline promoter, and from midbrain organoids.", "tags": [{"end": 146, "start": 134, "tag": "Chemical"}, {"end": 155, "start": 147, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 174, "start": 166, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 72, "tag": "ResearchActivity"}, {"end": 184, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 85, "tag": "ResearchActivity"}, {"end": 107, "start": 98, "tag": "CellFunction"}, {"end": 107, "start": 98, "tag": "BiologicFunction"}, {"end": 117, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 33, "tag": "CellComponent"}, {"end": 13, "start": 0, "tag": "ResearchActivity"}, {"end": 90, "start": 52, "tag": "ExperimentalModelOfDisease"}]}{"id": "1099_6", "text": "The averaged spectra of each sEV group showed considerable variation as a reflection of the biochemical content of sEVs.", "tags": [{"end": 111, "start": 92, "tag": "CellFunction"}, {"end": 38, "start": 33, "tag": "PopulationGroup"}, {"end": 119, "start": 115, "tag": "CellComponent"}, {"end": 32, "start": 29, "tag": "CellComponent"}]}{"id": "1099_7", "text": "Spectral analysis identified more intense Raman peaks at 1650 cm(-1) and 2930 cm(-1) attributable to the A beta peptide incorporated in sEVs produced by the Alzheimer's cell culture model.", "tags": [{"end": 17, "start": 0, "tag": "ResearchActivity"}, {"end": 181, "start": 169, "tag": "ResearchActivity"}, {"end": 187, "start": 182, "tag": "ResearchActivity"}, {"end": 168, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 136, "tag": "CellComponent"}, {"end": 53, "start": 34, "tag": "ResearchActivity"}, {"end": 187, "start": 157, "tag": "ExperimentalModelOfDisease"}]}{"id": "1099_8", "text": "Subsequent analysis of the spectra by principal component analysis differentiated the sEVs of the Alzheimer's disease cell culture model from the control groups of sEVs.", "tags": [{"end": 130, "start": 118, "tag": "ResearchActivity"}, {"end": 160, "start": 146, "tag": "PopulationGroup"}, {"end": 117, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 11, "tag": "ResearchActivity"}, {"end": 66, "start": 38, "tag": "ResearchActivity"}, {"end": 136, "start": 131, "tag": "ResearchActivity"}, {"end": 90, "start": 86, "tag": "CellComponent"}, {"end": 168, "start": 164, "tag": "CellComponent"}, {"end": 136, "start": 98, "tag": "ExperimentalModelOfDisease"}]}{"id": "1099_9", "text": "Moreover, the results indicate that A beta associated with secreted sEVs has a alpha-helical secondary structure and the size of a monomer or small oligomer.", "tags": [{"end": 138, "start": 131, "tag": "Chemical"}, {"end": 42, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 121, "tag": "OrganismAttribute"}, {"end": 72, "start": 68, "tag": "CellComponent"}, {"end": 112, "start": 79, "tag": "CellFunction"}]}{"id": "1099_10", "text": "Furthermore, by analyzing the lipid content of sEVs we identified altered fatty acid chain lengths in sEVs that carry A beta that may affect the fluidity of the EV membrane.", "tags": [{"end": 90, "start": 74, "tag": "Chemical"}, {"end": 172, "start": 164, "tag": "CellComponent"}, {"end": 163, "start": 161, "tag": "CellComponent"}, {"end": 124, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "Chemical"}, {"end": 51, "start": 47, "tag": "CellComponent"}, {"end": 106, "start": 102, "tag": "CellComponent"}, {"end": 153, "start": 145, "tag": "Finding"}]}{"id": "1099_11", "text": "Overall, our findings provide evidence supporting the use of Raman spectroscopy for the identification and characterization of sEVs associated with potential biomarkers of neurological disorders such as toxic proteins.", "tags": [{"end": 79, "start": 61, "tag": "ResearchActivity"}, {"end": 38, "start": 30, "tag": "Finding"}, {"end": 208, "start": 203, "tag": "InjuryOrPoisoning"}, {"end": 217, "start": 209, "tag": "AminoAcidPeptideOrProtein"}, {"end": 194, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 148, "tag": "ClinicalAttribute"}, {"end": 123, "start": 107, "tag": "ResearchActivity"}, {"end": 131, "start": 127, "tag": "CellComponent"}]}{"id": "1100_0", "text": "Mesenchymal stem cells are multipotent cells that possess anti-inflammatory, anti-apoptotic and immunomodulatory properties.", "tags": [{"end": 44, "start": 27, "tag": "Cell"}, {"end": 38, "start": 27, "tag": "Cell"}, {"end": 22, "start": 0, "tag": "Cell"}, {"end": 22, "start": 12, "tag": "Cell"}, {"end": 123, "start": 96, "tag": "ClinicalAttribute"}, {"end": 75, "start": 58, "tag": "BiologicFunction"}, {"end": 75, "start": 58, "tag": "PharmacologicSubstance"}, {"end": 91, "start": 77, "tag": "CellFunction"}, {"end": 112, "start": 96, "tag": "PharmacologicSubstance"}, {"end": 112, "start": 96, "tag": "BiologicFunction"}, {"end": 112, "start": 96, "tag": "HealthCareActivity"}]}{"id": "1100_1", "text": "The effects of existing drugs for neurodegenerative disorders such as Alzheimer's disease are limited, thus mesenchymal stem cell therapy has been anticipated as a means of ameliorating neuronal dysfunction.", "tags": [{"end": 206, "start": 186, "tag": "CellOrMolecularDysfunction"}, {"end": 137, "start": 120, "tag": "HealthCareActivity"}, {"end": 137, "start": 125, "tag": "HealthCareActivity"}, {"end": 89, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 186, "tag": "Cell"}, {"end": 29, "start": 24, "tag": "PharmacologicSubstance"}, {"end": 137, "start": 130, "tag": "HealthCareActivity"}, {"end": 11, "start": 4, "tag": "Finding"}, {"end": 206, "start": 195, "tag": "PathologicFunction"}, {"end": 61, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 108, "tag": "Cell"}]}{"id": "1100_2", "text": "Since mesenchymal stem cells are known to scarcely differentiate into neuronal cells in damaged brain after transplantation, paracrine factors secreted from mesenchymal stem cells have been suggested to exert therapeutic effects.", "tags": [{"end": 64, "start": 51, "tag": "CellFunction"}, {"end": 84, "start": 70, "tag": "Cell"}, {"end": 101, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 18, "tag": "Cell"}, {"end": 179, "start": 169, "tag": "Cell"}, {"end": 228, "start": 221, "tag": "Finding"}, {"end": 228, "start": 209, "tag": "Finding"}, {"end": 28, "start": 6, "tag": "Cell"}, {"end": 179, "start": 157, "tag": "Cell"}, {"end": 123, "start": 108, "tag": "HealthCareActivity"}, {"end": 142, "start": 125, "tag": "BiologicallyActiveSubstance"}]}{"id": "1100_3", "text": "Extracellular vesicles and exosomes are small vesicles released from mesenchymal stem cells that contain various molecules, including proteins, mRNAs and microRNAs.", "tags": [{"end": 54, "start": 40, "tag": "CellComponent"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 142, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 113, "tag": "Substance"}, {"end": 91, "start": 81, "tag": "Cell"}, {"end": 91, "start": 69, "tag": "Cell"}, {"end": 35, "start": 27, "tag": "CellComponent"}, {"end": 149, "start": 144, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 163, "start": 154, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 163, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 144, "tag": "BiologicallyActiveSubstance"}]}{"id": "1100_4", "text": "In recent years, administration of exosomes/extracellular vesicles in models of neurological disorders has been shown to improve neuronal dysfunctions, via exosomal transfer into damaged cells.", "tags": [{"end": 150, "start": 138, "tag": "PathologicFunction"}, {"end": 66, "start": 44, "tag": "CellComponent"}, {"end": 192, "start": 187, "tag": "Cell"}, {"end": 137, "start": 129, "tag": "Cell"}, {"end": 76, "start": 70, "tag": "ResearchActivity"}, {"end": 15, "start": 10, "tag": "TemporalConcept"}, {"end": 102, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 3, "tag": "TemporalConcept"}, {"end": 43, "start": 35, "tag": "CellComponent"}, {"end": 164, "start": 156, "tag": "CellComponent"}, {"end": 102, "start": 70, "tag": "ExperimentalModelOfDisease"}, {"end": 173, "start": 156, "tag": "CellFunction"}]}{"id": "1100_5", "text": "In addition, various microRNAs derived from mesenchymal stem cells that regulate various genes and reduce neuropathological changes in various neurological disorders have been identified.", "tags": [{"end": 165, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 56, "tag": "Cell"}, {"end": 66, "start": 44, "tag": "Cell"}, {"end": 30, "start": 21, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 30, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 106, "tag": "Finding"}]}{"id": "1100_6", "text": "This review summarizes the effects of exosomes/extracellular vesicles and exosomal microRNAs derived from mesenchymal stem cells on models of stroke, subarachnoid and intracerebral hemorrhage, traumatic brain injury, and cognitive impairments, including Alzheimer's disease.", "tags": [{"end": 162, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 191, "start": 167, "tag": "PathologicFunction"}, {"end": 242, "start": 221, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 193, "tag": "InjuryOrPoisoning"}, {"end": 148, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 47, "tag": "CellComponent"}, {"end": 273, "start": 254, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 132, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 128, "start": 118, "tag": "Cell"}, {"end": 34, "start": 27, "tag": "Finding"}, {"end": 128, "start": 106, "tag": "Cell"}, {"end": 46, "start": 38, "tag": "CellComponent"}, {"end": 82, "start": 74, "tag": "CellComponent"}, {"end": 92, "start": 83, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 92, "start": 83, "tag": "BiologicallyActiveSubstance"}]}{"id": "1101_0", "text": "Introduction In Alzheimer's disease, the severity of symptoms is linked to a loss of synaptic density and the spread of pathologically hyperphosphorylated tau.", "tags": [{"end": 101, "start": 85, "tag": "CellComponent"}, {"end": 35, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 53, "tag": "SignOrSymptom"}, {"end": 49, "start": 41, "tag": "ClinicalAttribute"}, {"end": 49, "start": 41, "tag": "Finding"}, {"end": 158, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 77, "tag": "CellOrMolecularDysfunction"}, {"end": 158, "start": 120, "tag": "CellOrMolecularDysfunction"}]}{"id": "1101_1", "text": "The established cerebrospinal fluid markers A beta, tau and phospho-tau reflect the histopathological hallmarks of Alzheimer's disease but do not indicate disease progression.", "tags": [{"end": 111, "start": 102, "tag": "Finding"}, {"end": 134, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 36, "tag": "ClinicalAttribute"}, {"end": 55, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 163, "tag": "PathologicFunction"}, {"end": 174, "start": 163, "tag": "TemporalConcept"}, {"end": 35, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 155, "tag": "PathologicFunction"}, {"end": 101, "start": 84, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1101_2", "text": "Such markers are of special interest, especially for trials of disease modifying drugs.", "tags": [{"end": 12, "start": 5, "tag": "ClinicalAttribute"}, {"end": 86, "start": 63, "tag": "PharmacologicSubstance"}]}{"id": "1101_3", "text": "Microvesicles are produced by stressed cells and reflect part of the metabolism of their cells of origin.", "tags": [{"end": 13, "start": 0, "tag": "CellComponent"}, {"end": 44, "start": 39, "tag": "Cell"}, {"end": 94, "start": 89, "tag": "Cell"}, {"end": 104, "start": 98, "tag": "TemporalConcept"}, {"end": 79, "start": 69, "tag": "CellFunction"}, {"end": 79, "start": 69, "tag": "BiologicFunction"}, {"end": 44, "start": 30, "tag": "CellOrMolecularDysfunction"}]}{"id": "1101_4", "text": "Therefore, we investigated microvesicles of neuronal origin in cerebrospinal fluid.", "tags": [{"end": 82, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 44, "tag": "Cell"}, {"end": 59, "start": 53, "tag": "TemporalConcept"}, {"end": 40, "start": 27, "tag": "CellComponent"}]}{"id": "1101_5", "text": "Materials and Methods We used flow cytometry to analyze microvesicles carrying tau, phospho-tau-Thr181, phospho-tau-Ser202Thr205, synaptophysin, and SNAP-25 in the cerebrospinal fluid of 19 patients with Alzheimer's disease and 15 non-inflammatory neurological disease controls.", "tags": [{"end": 44, "start": 30, "tag": "ResearchActivity"}, {"end": 143, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 149, "tag": "GeneOrGenome"}, {"end": 156, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 268, "start": 231, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 204, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 190, "tag": "PatientOrDisabledGroup"}, {"end": 277, "start": 269, "tag": "PopulationGroup"}, {"end": 82, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 183, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 268, "start": 248, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 56, "tag": "CellComponent"}]}{"id": "1101_6", "text": "Results The percentages of synaptophysin-bearing microvesicles were significantly higher in the cerebrospinal fluid of patients with Alzheimer's disease than in the CSF of non-inflammatory neurological disease controls.", "tags": [{"end": 209, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 119, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 218, "start": 210, "tag": "PopulationGroup"}, {"end": 168, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 49, "tag": "CellComponent"}, {"end": 40, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 27, "tag": "BiologicallyActiveSubstance"}]}{"id": "1101_7", "text": "Tau, phospho-tau-Thr181, phospho-tau-Ser202Thr205, and SNAP-25 did not differ between the groups.", "tags": [{"end": 62, "start": 55, "tag": "GeneOrGenome"}, {"end": 62, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 5, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 5, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1101_8", "text": "The percentages of synaptophysin-bearing vesicles distinguished patients with Alzheimer's disease from the controls (AUC = 0.81).", "tags": [{"end": 120, "start": 117, "tag": "ResearchActivity"}, {"end": 97, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 64, "tag": "PatientOrDisabledGroup"}, {"end": 115, "start": 107, "tag": "PopulationGroup"}, {"end": 49, "start": 41, "tag": "CellComponent"}, {"end": 32, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 19, "tag": "BiologicallyActiveSubstance"}]}{"id": "1101_9", "text": "Conclusion The loss of synapses in Alzheimer's disease may be reflected by synaptophysin-bearing microvesicles in the cerebrospinal fluid.", "tags": [{"end": 54, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 97, "tag": "CellComponent"}, {"end": 31, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 15, "tag": "CellOrMolecularDysfunction"}]}{"id": "1101_10", "text": "Future studies are needed to investigate the possibility of using these MVs as a marker to determine the activity of Alzheimer's disease.", "tags": [{"end": 136, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 81, "tag": "ClinicalAttribute"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 75, "start": 72, "tag": "CellComponent"}]}{"id": "1102_0", "text": "Cholesterol has been implicated in the clinical progression of breast cancer, a disease that continues to be the most commonly diagnosed cancer in women.", "tags": [{"end": 76, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 0, "tag": "Chemical"}, {"end": 11, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 39, "tag": "TemporalConcept"}, {"end": 143, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 147, "tag": "PopulationGroup"}, {"end": 136, "start": 127, "tag": "HealthCareActivity"}]}{"id": "1102_1", "text": "Previous work has identified the cholesterol metabolite 27-hydroxycholesterol (27HC) as a major mediator of the effects of cholesterol on breast tumor growth and progression.", "tags": [{"end": 77, "start": 56, "tag": "Chemical"}, {"end": 44, "start": 33, "tag": "Chemical"}, {"end": 134, "start": 123, "tag": "Chemical"}, {"end": 44, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 151, "tag": "BiologicFunction"}, {"end": 173, "start": 162, "tag": "PathologicFunction"}, {"end": 173, "start": 162, "tag": "TemporalConcept"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 119, "start": 112, "tag": "Finding"}, {"end": 55, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 79, "tag": "Chemical"}, {"end": 150, "start": 138, "tag": "DiseaseOrSyndrome"}]}{"id": "1102_2", "text": "27HC can act as an estrogen receptor (ER) modulator to promote the growth of ER alpha+ tumors, and as a liver X receptor (LXR) ligand in myeloid immune cells to establish an immune-suppressive program.", "tags": [{"end": 36, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 127, "tag": "CellFunction"}, {"end": 125, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 67, "tag": "BiologicFunction"}, {"end": 157, "start": 137, "tag": "Cell"}, {"end": 36, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "Chemical"}, {"end": 93, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 174, "tag": "Finding"}]}{"id": "1102_3", "text": "In fact, the metastatic properties of 27HC require the presence of myeloid cells with neutrophils (polymorphonuclear neutrophils; PMNs) being essential for the increase in lung metastasis in murine models.", "tags": [{"end": 128, "start": 99, "tag": "Cell"}, {"end": 187, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 86, "tag": "Cell"}, {"end": 80, "start": 67, "tag": "Cell"}, {"end": 176, "start": 172, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 204, "start": 198, "tag": "ResearchActivity"}, {"end": 197, "start": 191, "tag": "Eukaryote"}, {"end": 63, "start": 55, "tag": "Finding"}, {"end": 42, "start": 38, "tag": "Chemical"}, {"end": 34, "start": 13, "tag": "PathologicFunction"}, {"end": 134, "start": 130, "tag": "Cell"}]}{"id": "1102_4", "text": "In an effort to further elucidate the mechanisms by which 27HC alters breast cancer progression, we made the striking finding that 27HC promoted the secretion of extracellular vesicles (EVs), a diverse assortment of membrane bound particles that includes exosomes.", "tags": [{"end": 83, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 118, "tag": "Finding"}, {"end": 240, "start": 216, "tag": "CellComponent"}, {"end": 184, "start": 162, "tag": "CellComponent"}, {"end": 189, "start": 186, "tag": "CellComponent"}, {"end": 95, "start": 84, "tag": "PathologicFunction"}, {"end": 95, "start": 84, "tag": "TemporalConcept"}, {"end": 158, "start": 149, "tag": "CellFunction"}, {"end": 158, "start": 149, "tag": "BiologicFunction"}, {"end": 83, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 240, "start": 231, "tag": "Chemical"}, {"end": 263, "start": 255, "tag": "CellComponent"}, {"end": 12, "start": 6, "tag": "BiologicFunction"}, {"end": 12, "start": 6, "tag": "Finding"}, {"end": 62, "start": 58, "tag": "Chemical"}, {"end": 135, "start": 131, "tag": "Chemical"}]}{"id": "1102_5", "text": "The resulting EVs had a size distribution that was skewed slightly larger than EVs generated by treating cells with vehicle.", "tags": [{"end": 17, "start": 14, "tag": "CellComponent"}, {"end": 82, "start": 79, "tag": "CellComponent"}, {"end": 110, "start": 105, "tag": "Cell"}, {"end": 28, "start": 24, "tag": "OrganismAttribute"}]}{"id": "1102_6", "text": "The increase in EV secretion and size was consistent across 3 different subtypes: primary murine PMNs, RAW264.7 monocytic cells, and 4T1 murine mammary cancer cells.", "tags": [{"end": 158, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 16, "tag": "CellComponent"}, {"end": 127, "start": 103, "tag": "Cell"}, {"end": 96, "start": 90, "tag": "Eukaryote"}, {"end": 143, "start": 137, "tag": "Eukaryote"}, {"end": 37, "start": 33, "tag": "OrganismAttribute"}, {"end": 28, "start": 16, "tag": "CellFunction"}, {"end": 101, "start": 97, "tag": "Cell"}, {"end": 101, "start": 82, "tag": "Cell"}, {"end": 164, "start": 133, "tag": "Cell"}]}{"id": "1102_7", "text": "Label-free analysis of 27HC-EVs indicated that they had a different metabolite composition to those from vehicle-treated cells.", "tags": [{"end": 19, "start": 0, "tag": "ResearchActivity"}, {"end": 78, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 28, "tag": "CellComponent"}, {"end": 126, "start": 121, "tag": "Cell"}, {"end": 27, "start": 23, "tag": "Chemical"}]}{"id": "1102_8", "text": "Importantly, 27HC-EVs from primary PMNs promoted tumor growth and metastasis in 2 different syngeneic models, demonstrating the potential role of 27HC-induced EVs in the progression of breast cancer.", "tags": [{"end": 54, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 55, "tag": "BiologicFunction"}, {"end": 21, "start": 18, "tag": "CellComponent"}, {"end": 162, "start": 159, "tag": "CellComponent"}, {"end": 181, "start": 170, "tag": "PathologicFunction"}, {"end": 181, "start": 170, "tag": "TemporalConcept"}, {"end": 108, "start": 92, "tag": "ResearchActivity"}, {"end": 17, "start": 13, "tag": "Chemical"}, {"end": 39, "start": 27, "tag": "Cell"}, {"end": 150, "start": 146, "tag": "Chemical"}]}{"id": "1102_9", "text": "EVs from PMNs were taken up by cancer cells, macrophages, and PMNs, but not T cells.", "tags": [{"end": 43, "start": 31, "tag": "Cell"}, {"end": 83, "start": 76, "tag": "Cell"}, {"end": 56, "start": 45, "tag": "Cell"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 37, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 9, "tag": "Cell"}, {"end": 66, "start": 62, "tag": "Cell"}]}{"id": "1102_10", "text": "Since EVs did not alter proliferation of cancer cells, it is likely that their protumor effects are mediated through interactions with myeloid cells.", "tags": [{"end": 53, "start": 41, "tag": "Cell"}, {"end": 37, "start": 24, "tag": "CellFunction"}, {"end": 148, "start": 135, "tag": "Cell"}, {"end": 9, "start": 6, "tag": "CellComponent"}, {"end": 47, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 88, "tag": "Finding"}, {"end": 129, "start": 117, "tag": "Finding"}, {"end": 95, "start": 79, "tag": "PathologicFunction"}]}{"id": "1102_11", "text": "Interestingly, RNA-seq analysis of tumors from 27HC-EV-treated mice do not display significantly altered transcriptomes, suggesting that the effects of 27HC-EVs occur early on in tumor establishment and growth.", "tags": [{"end": 41, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 105, "tag": "MolecularSequence"}, {"end": 209, "start": 203, "tag": "BiologicFunction"}, {"end": 160, "start": 157, "tag": "CellComponent"}, {"end": 54, "start": 52, "tag": "CellComponent"}, {"end": 31, "start": 15, "tag": "ResearchActivity"}, {"end": 67, "start": 63, "tag": "Eukaryote"}, {"end": 148, "start": 141, "tag": "Finding"}, {"end": 51, "start": 47, "tag": "Chemical"}, {"end": 156, "start": 152, "tag": "Chemical"}]}{"id": "1102_12", "text": "Future work will be required to elucidate the mechanisms by which 27HC increases EV secretion, and how these EVs promote breast cancer progression.", "tags": [{"end": 134, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 109, "tag": "CellComponent"}, {"end": 146, "start": 135, "tag": "PathologicFunction"}, {"end": 146, "start": 135, "tag": "TemporalConcept"}, {"end": 93, "start": 81, "tag": "CellFunction"}, {"end": 70, "start": 66, "tag": "Chemical"}]}{"id": "1102_13", "text": "Collectively, however, our data indicate that EV secretion and content can be regulated by a cholesterol metabolite, which may have detrimental effects in terms of disease progression, important findings given the prevalence of both breast cancer and hypercholesterolemia.", "tags": [{"end": 246, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 271, "start": 251, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 93, "tag": "Chemical"}, {"end": 104, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 183, "start": 164, "tag": "PathologicFunction"}, {"end": 58, "start": 46, "tag": "CellFunction"}, {"end": 151, "start": 144, "tag": "Finding"}, {"end": 31, "start": 27, "tag": "ResearchActivity"}, {"end": 115, "start": 105, "tag": "BiologicallyActiveSubstance"}]}{"id": "1103_0", "text": "Human mesenchymal stromal cells (hMSCs) are mechanically sensitive undergoing phenotypic alterations when subjected to shear stress, cell aggregation, and substrate changes encountered in 3D dynamic bioreactor cultures.", "tags": [{"end": 5, "start": 0, "tag": "Eukaryote"}, {"end": 31, "start": 6, "tag": "Cell"}, {"end": 38, "start": 33, "tag": "Cell"}, {"end": 131, "start": 119, "tag": "NaturalPhenomenonOrProcess"}, {"end": 149, "start": 133, "tag": "CellFunction"}, {"end": 209, "start": 199, "tag": "ManufacturedObject"}, {"end": 218, "start": 188, "tag": "ResearchActivity"}, {"end": 164, "start": 155, "tag": "Chemical"}, {"end": 131, "start": 125, "tag": "PathologicFunction"}, {"end": 66, "start": 57, "tag": "PathologicFunction"}, {"end": 88, "start": 78, "tag": "OrganismAttribute"}, {"end": 100, "start": 89, "tag": "Finding"}, {"end": 172, "start": 165, "tag": "Finding"}]}{"id": "1103_1", "text": "However, little is known about how bioreactor microenvironment affects the secretion and cargo profiles of hMSC-derived extracellular vesicles (EVs) including the subset, exosomes, which contain therapeutic proteins, nucleic acids, and lipids from the parent cells.", "tags": [{"end": 45, "start": 35, "tag": "ManufacturedObject"}, {"end": 215, "start": 195, "tag": "PharmacologicSubstance"}, {"end": 111, "start": 107, "tag": "Cell"}, {"end": 62, "start": 46, "tag": "NaturalPhenomenonOrProcess"}, {"end": 62, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 120, "tag": "CellComponent"}, {"end": 147, "start": 144, "tag": "CellComponent"}, {"end": 264, "start": 252, "tag": "Cell"}, {"end": 103, "start": 95, "tag": "ResearchActivity"}, {"end": 94, "start": 89, "tag": "CellFunction"}, {"end": 84, "start": 75, "tag": "CellFunction"}, {"end": 84, "start": 75, "tag": "BiologicFunction"}, {"end": 242, "start": 236, "tag": "Chemical"}, {"end": 230, "start": 217, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 179, "start": 171, "tag": "CellComponent"}]}{"id": "1103_2", "text": "In this study, bone marrow-derived hMSCs were expanded on 3D Synthemax II microcarriers in the PBS mini 0.1L Vertical-Wheel bioreactor system under variable shear stress levels at 25, 40, and 64 RPM (0.1-0.3 dyn/cm2).", "tags": [{"end": 40, "start": 35, "tag": "Cell"}, {"end": 26, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 169, "start": 163, "tag": "PathologicFunction"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 87, "start": 58, "tag": "ManufacturedObject"}, {"end": 141, "start": 95, "tag": "ManufacturedObject"}, {"end": 169, "start": 157, "tag": "NaturalPhenomenonOrProcess"}]}{"id": "1103_3", "text": "The bioreactor system promotes EV secretion from hMSCs by 2.5-fold and upregulates the expression of EV biogenesis markers and glycolysis genes compared to the static 2D culture.", "tags": [{"end": 54, "start": 49, "tag": "Cell"}, {"end": 143, "start": 127, "tag": "GeneOrGenome"}, {"end": 103, "start": 101, "tag": "CellComponent"}, {"end": 122, "start": 115, "tag": "ClinicalAttribute"}, {"end": 97, "start": 87, "tag": "CellFunction"}, {"end": 43, "start": 31, "tag": "CellFunction"}, {"end": 114, "start": 104, "tag": "CellFunction"}, {"end": 21, "start": 4, "tag": "ManufacturedObject"}, {"end": 137, "start": 127, "tag": "CellFunction"}, {"end": 177, "start": 160, "tag": "ResearchActivity"}]}{"id": "1103_4", "text": "The microRNA cargo was also altered in the EVs from bioreactor culture including the upregulation of miR-10, 19a, 19b, 21, 132, and 377.", "tags": [{"end": 107, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 4, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 12, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 43, "tag": "CellComponent"}, {"end": 18, "start": 13, "tag": "CellFunction"}, {"end": 97, "start": 85, "tag": "CellFunction"}, {"end": 70, "start": 52, "tag": "ResearchActivity"}]}{"id": "1103_5", "text": "EV protein cargo was characterized by proteomics analysis, showing upregulation of metabolic, autophagy and ROS-related proteins comparing with 2D cultured EVs.", "tags": [{"end": 92, "start": 83, "tag": "CellFunction"}, {"end": 111, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 108, "tag": "Chemical"}, {"end": 159, "start": 156, "tag": "CellComponent"}, {"end": 2, "start": 0, "tag": "CellComponent"}, {"end": 57, "start": 38, "tag": "ResearchActivity"}, {"end": 16, "start": 11, "tag": "CellFunction"}, {"end": 128, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 94, "tag": "CellFunction"}, {"end": 155, "start": 144, "tag": "ResearchActivity"}, {"end": 79, "start": 67, "tag": "CellFunction"}, {"end": 10, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 38, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1103_6", "text": "In addition, the scalability of the Vertical-Wheel bioreactor system was demonstrated in a 0.5L bioreactor, showing similar or better hMSC-EV secretion and cargo content compared to the 0.1L bioreactor.", "tags": [{"end": 106, "start": 91, "tag": "ManufacturedObject"}, {"end": 201, "start": 186, "tag": "ManufacturedObject"}, {"end": 138, "start": 134, "tag": "Cell"}, {"end": 141, "start": 139, "tag": "CellComponent"}, {"end": 161, "start": 156, "tag": "CellFunction"}, {"end": 151, "start": 142, "tag": "CellFunction"}, {"end": 151, "start": 142, "tag": "BiologicFunction"}, {"end": 151, "start": 139, "tag": "CellFunction"}, {"end": 68, "start": 36, "tag": "ManufacturedObject"}, {"end": 28, "start": 17, "tag": "Finding"}]}{"id": "1103_7", "text": "This study advances our under-standing of bio-manufacturing of stem cell-derived EVs for applications in cell-free therapy towards treating neurological disorders such as ischemic stroke, Alzheimer's disease, and multiple sclerosis.", "tags": [{"end": 186, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 81, "tag": "CellComponent"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 72, "start": 68, "tag": "Cell"}, {"end": 109, "start": 105, "tag": "Cell"}, {"end": 162, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 105, "tag": "HealthCareActivity"}, {"end": 19, "start": 11, "tag": "Finding"}, {"end": 72, "start": 63, "tag": "Cell"}, {"end": 59, "start": 46, "tag": "ResearchActivity"}]}{"id": "1104_0", "text": "Objectives:Latent infection by HIV hinders viral eradication despite effective antiretroviral treatment (ART).", "tags": [{"end": 27, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 31, "tag": "Virus"}, {"end": 27, "start": 18, "tag": "PathologicFunction"}, {"end": 103, "start": 79, "tag": "HealthCareActivity"}, {"end": 103, "start": 94, "tag": "ResearchActivity"}]}{"id": "1104_1", "text": "Among proposed contributors to viral latency are cellular small RNAs that have also been proposed to shuttle between cells in extracellular vesicles.", "tags": [{"end": 44, "start": 31, "tag": "BiologicFunction"}, {"end": 148, "start": 126, "tag": "CellComponent"}, {"end": 122, "start": 117, "tag": "Cell"}, {"end": 44, "start": 37, "tag": "TemporalConcept"}, {"end": 68, "start": 58, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 68, "start": 58, "tag": "BiologicallyActiveSubstance"}]}{"id": "1104_2", "text": "Thus, we profiled extracellular vesicle small RNAs during different infection phases to understand the potential relationship between these extracellular vesicle associated small RNAs and viral infection.Design:A well characterized simian immunodeficiency virus (SIV)/macaque model of HIV was used to profile extracellular vesicle enriched blood plasma fractions harvested during preinfection, acute infection, latent infection/ART treatment, and rebound after ART interruption.Methods:Measurement of extracellular vesicle concentration, size distribution, and morphology was complemented with qPCR array for small RNA expression, followed by individual qPCR validations.", "tags": [{"end": 50, "start": 40, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 183, "start": 173, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 203, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 261, "start": 232, "tag": "Virus"}, {"end": 288, "start": 285, "tag": "Virus"}, {"end": 409, "start": 394, "tag": "DiseaseOrSyndrome"}, {"end": 477, "start": 465, "tag": "TemporalConcept"}, {"end": 497, "start": 486, "tag": "ResearchActivity"}, {"end": 497, "start": 486, "tag": "HealthCareActivity"}, {"end": 536, "start": 523, "tag": "BiologicFunction"}, {"end": 571, "start": 561, "tag": "Finding"}, {"end": 604, "start": 594, "tag": "ResearchActivity"}, {"end": 658, "start": 654, "tag": "ResearchActivity"}, {"end": 670, "start": 659, "tag": "ResearchActivity"}, {"end": 39, "start": 18, "tag": "CellComponent"}, {"end": 161, "start": 140, "tag": "CellComponent"}, {"end": 330, "start": 309, "tag": "CellComponent"}, {"end": 522, "start": 501, "tag": "CellComponent"}, {"end": 399, "start": 394, "tag": "TemporalConcept"}, {"end": 77, "start": 68, "tag": "PathologicFunction"}, {"end": 203, "start": 194, "tag": "PathologicFunction"}, {"end": 409, "start": 400, "tag": "PathologicFunction"}, {"end": 427, "start": 411, "tag": "PathologicFunction"}, {"end": 125, "start": 113, "tag": "Finding"}, {"end": 345, "start": 340, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 352, "start": 346, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 618, "start": 609, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 441, "start": 432, "tag": "HealthCareActivity"}, {"end": 441, "start": 432, "tag": "ResearchActivity"}, {"end": 281, "start": 276, "tag": "ResearchActivity"}, {"end": 542, "start": 538, "tag": "OrganismAttribute"}, {"end": 266, "start": 263, "tag": "Virus"}, {"end": 275, "start": 268, "tag": "Eukaryote"}, {"end": 50, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 183, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 618, "start": 609, "tag": "BiologicallyActiveSubstance"}]}{"id": "1104_3", "text": "Iodixanol density gradients were used to separate extracellular vesicle subtypes and virions.Results:Plasma extracellular vesicle particle counts correlated with viral load and peaked during acute infection.", "tags": [{"end": 9, "start": 0, "tag": "Chemical"}, {"end": 92, "start": 85, "tag": "CellComponent"}, {"end": 107, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 162, "tag": "Finding"}, {"end": 172, "start": 162, "tag": "ResearchActivity"}, {"end": 206, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 50, "tag": "CellComponent"}, {"end": 129, "start": 108, "tag": "CellComponent"}, {"end": 196, "start": 191, "tag": "TemporalConcept"}, {"end": 206, "start": 197, "tag": "PathologicFunction"}, {"end": 100, "start": 93, "tag": "ResearchActivity"}, {"end": 27, "start": 0, "tag": "ResearchActivity"}]}{"id": "1104_4", "text": "However, SIV gag RNA detection showed that virions did not fully explain this peak.", "tags": [{"end": 12, "start": 9, "tag": "Virus"}, {"end": 50, "start": 43, "tag": "CellComponent"}, {"end": 20, "start": 17, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 30, "start": 21, "tag": "ResearchActivity"}, {"end": 16, "start": 13, "tag": "GeneOrGenome"}]}{"id": "1104_5", "text": "Extracellular vesicle microRNAs miR-181a, miR-342-3p, and miR-29a decreased with SIV infection and remained downregulated in latency.", "tags": [{"end": 21, "start": 0, "tag": "CellComponent"}, {"end": 31, "start": 22, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 31, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 108, "tag": "CellFunction"}, {"end": 94, "start": 85, "tag": "PathologicFunction"}, {"end": 132, "start": 125, "tag": "TemporalConcept"}, {"end": 40, "start": 32, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 52, "start": 42, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 65, "start": 58, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 40, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 52, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 81, "tag": "Virus"}]}{"id": "1104_6", "text": "Interestingly, small nuclear RNA U6 had a tight association with viral load peak.Conclusion:This study is the first to monitor how extracellular vesicle concentration and extracellular vesicle small RNA expression change dynamically in acute viral infection, latency, and rebound in a carefully controlled animal model.", "tags": [{"end": 35, "start": 15, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 75, "start": 65, "tag": "Finding"}, {"end": 75, "start": 65, "tag": "ResearchActivity"}, {"end": 126, "start": 119, "tag": "HealthCareActivity"}, {"end": 126, "start": 119, "tag": "ManufacturedObject"}, {"end": 166, "start": 153, "tag": "BiologicFunction"}, {"end": 318, "start": 306, "tag": "ResearchActivity"}, {"end": 152, "start": 131, "tag": "CellComponent"}, {"end": 192, "start": 171, "tag": "CellComponent"}, {"end": 241, "start": 236, "tag": "TemporalConcept"}, {"end": 257, "start": 242, "tag": "PathologicFunction"}, {"end": 102, "start": 97, "tag": "ResearchActivity"}, {"end": 202, "start": 193, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 115, "start": 110, "tag": "TemporalConcept"}, {"end": 266, "start": 259, "tag": "TemporalConcept"}, {"end": 202, "start": 193, "tag": "BiologicallyActiveSubstance"}]}{"id": "1104_7", "text": "These changes may also reveal regulatory roles in retroviral infection and latency.", "tags": [{"end": 70, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 61, "tag": "PathologicFunction"}, {"end": 82, "start": 75, "tag": "TemporalConcept"}]}{"id": "1105_0", "text": "Individuals with Down syndrome (DS) exhibit Alzheimer's disease (AD) pathology at a young age, including amyloid plaques and neurofibrillary tangles (NFTs).", "tags": [{"end": 11, "start": 0, "tag": "PopulationGroup"}, {"end": 120, "start": 105, "tag": "AnatomicalAbnormality"}, {"end": 89, "start": 84, "tag": "TemporalConcept"}, {"end": 63, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 69, "tag": "PathologicFunction"}, {"end": 78, "start": 69, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 93, "start": 90, "tag": "OrganismAttribute"}, {"end": 30, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 125, "tag": "CellOrMolecularDysfunction"}, {"end": 140, "start": 125, "tag": "CellComponent"}, {"end": 154, "start": 150, "tag": "CellOrMolecularDysfunction"}]}{"id": "1105_1", "text": "Tau pathology can spread via extracellular vesicles, such as exosomes.", "tags": [{"end": 51, "start": 29, "tag": "CellComponent"}, {"end": 13, "start": 0, "tag": "PathologicFunction"}, {"end": 69, "start": 61, "tag": "CellComponent"}]}{"id": "1105_2", "text": "The cargo of neuron-derived small extracellular vesicles (NDEVs) from individuals with DS contains p-Tau at an early age.", "tags": [{"end": 116, "start": 111, "tag": "TemporalConcept"}, {"end": 56, "start": 34, "tag": "CellComponent"}, {"end": 19, "start": 13, "tag": "Cell"}, {"end": 9, "start": 4, "tag": "CellFunction"}, {"end": 120, "start": 117, "tag": "OrganismAttribute"}, {"end": 104, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 70, "tag": "PopulationGroup"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 28, "tag": "CellComponent"}, {"end": 63, "start": 58, "tag": "CellComponent"}]}{"id": "1105_3", "text": "The goal of the study was to investigate whether NDEVs isolated from the blood of individuals with DS can spread Tau pathology in the brain of wildtype mice.", "tags": [{"end": 156, "start": 143, "tag": "Eukaryote"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 126, "start": 117, "tag": "PathologicFunction"}, {"end": 126, "start": 117, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 139, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 152, "tag": "Eukaryote"}, {"end": 116, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 82, "tag": "PopulationGroup"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 49, "tag": "CellComponent"}]}{"id": "1105_4", "text": "We purified NDEVs from the plasma of patients with DS-AD and controls and injected small quantities using stereotaxic surgery into the dorsal hippocampus of adult wildtype mice.", "tags": [{"end": 176, "start": 163, "tag": "Eukaryote"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 37, "tag": "PatientOrDisabledGroup"}, {"end": 33, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 61, "tag": "PopulationGroup"}, {"end": 176, "start": 172, "tag": "Eukaryote"}, {"end": 153, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 157, "tag": "PopulationGroup"}, {"end": 125, "start": 106, "tag": "ResearchActivity"}, {"end": 125, "start": 106, "tag": "HealthCareActivity"}, {"end": 17, "start": 12, "tag": "CellComponent"}]}{"id": "1105_5", "text": "Seeding competent Tau conformers were amplified in vitro from DS-AD NDEVs but not NDEVs from controls.", "tags": [{"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 93, "tag": "PopulationGroup"}, {"end": 56, "start": 48, "tag": "ResearchActivity"}, {"end": 21, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "CellFunction"}, {"end": 73, "start": 68, "tag": "CellComponent"}, {"end": 87, "start": 82, "tag": "CellComponent"}]}{"id": "1105_6", "text": "One month or 4 months post-injection, we examined Tau pathology in mouse brains.", "tags": [{"end": 9, "start": 4, "tag": "TemporalConcept"}, {"end": 26, "start": 22, "tag": "TemporalConcept"}, {"end": 21, "start": 15, "tag": "TemporalConcept"}, {"end": 72, "start": 67, "tag": "Eukaryote"}, {"end": 79, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 27, "tag": "HealthCareActivity"}, {"end": 63, "start": 50, "tag": "PathologicFunction"}]}{"id": "1105_7", "text": "We found abundant p-Tau immunostaining in the hippocampus of the mice injected with DS-AD NDEVs compared to injections of age-matched control NDEVs.", "tags": [{"end": 38, "start": 24, "tag": "ResearchActivity"}, {"end": 118, "start": 108, "tag": "HealthCareActivity"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 65, "tag": "Eukaryote"}, {"end": 125, "start": 122, "tag": "OrganismAttribute"}, {"end": 23, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 90, "tag": "CellComponent"}, {"end": 147, "start": 142, "tag": "CellComponent"}]}{"id": "1105_8", "text": "Double labeling with neuronal and glial markers showed that p-Tau staining was largely found in neurons and, to a lesser extent, in glial cells and that p-Tau immunostaining was spreading along the corpus callosum and the medio-lateral axis of the hippocampus.", "tags": [{"end": 74, "start": 66, "tag": "ResearchActivity"}, {"end": 213, "start": 198, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 173, "start": 159, "tag": "ResearchActivity"}, {"end": 240, "start": 222, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 34, "tag": "Cell"}, {"end": 47, "start": 40, "tag": "ClinicalAttribute"}, {"end": 143, "start": 132, "tag": "Cell"}, {"end": 29, "start": 21, "tag": "Cell"}, {"end": 65, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 153, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 259, "start": 248, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 96, "tag": "Cell"}]}{"id": "1105_9", "text": "These studies demonstrate that NDEVs from DS-AD patients exhibit Tau seeding capacity and give rise to tangle-like intracellular inclusions.", "tags": [{"end": 47, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 48, "tag": "PatientOrDisabledGroup"}, {"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 85, "start": 77, "tag": "Finding"}, {"end": 68, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 103, "tag": "CellOrMolecularDysfunction"}, {"end": 76, "start": 65, "tag": "CellFunction"}, {"end": 36, "start": 31, "tag": "CellComponent"}]}{"id": "1106_0", "text": "Alzheimer's disease (AD) is the most common form of dementia and without readily available clinical biomarkers.", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 91, "tag": "ClinicalAttribute"}]}{"id": "1106_1", "text": "Blood-derived proteins are routinely used for diagnostics; however, comprehensive plasma profiling is challenging due to the dynamic range in protein concentrations.", "tags": [{"end": 164, "start": 142, "tag": "BiologicFunction"}, {"end": 88, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 46, "tag": "HealthCareActivity"}, {"end": 98, "start": 89, "tag": "ResearchActivity"}, {"end": 22, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 150, "tag": "BiologicFunction"}, {"end": 149, "start": 142, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1106_2", "text": "Extracellular vesicles (EVs) can cross the blood-brain barrier and may provide a source for AD biomarkers.", "tags": [{"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 95, "tag": "ClinicalAttribute"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 62, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1106_3", "text": "We investigated plasma-derived EV proteins for AD biomarkers from 10 AD patients, 10 Mild Cognitive Impairment (MCI) patients, and 9 healthy controls (Con) using liquid chromatography-tandem mass spectrometry (LC-MS/MS).", "tags": [{"end": 110, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 141, "tag": "PopulationGroup"}, {"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 31, "tag": "CellComponent"}, {"end": 140, "start": 133, "tag": "OrganismAttribute"}, {"end": 80, "start": 72, "tag": "PatientOrDisabledGroup"}, {"end": 125, "start": 117, "tag": "PatientOrDisabledGroup"}, {"end": 22, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 50, "tag": "ClinicalAttribute"}, {"end": 42, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 162, "tag": "Substance"}, {"end": 208, "start": 162, "tag": "ResearchActivity"}, {"end": 218, "start": 210, "tag": "ResearchActivity"}]}{"id": "1106_4", "text": "The ultracentrifuged EVs were washed and confirmed according to the MISEV2018 guidelines.", "tags": [{"end": 24, "start": 21, "tag": "CellComponent"}, {"end": 88, "start": 68, "tag": "ResearchActivity"}]}{"id": "1106_5", "text": "Some AD patients presented with highly elevated FXIIIA1 (log(2) FC: 4.6, p-value: 0.005) and FXIIIB (log(2) FC: 4.9, p-value: 0.018).", "tags": [{"end": 66, "start": 64, "tag": "Finding"}, {"end": 99, "start": 93, "tag": "GeneOrGenome"}, {"end": 110, "start": 108, "tag": "Finding"}, {"end": 7, "start": 5, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 8, "tag": "PatientOrDisabledGroup"}, {"end": 55, "start": 48, "tag": "GeneOrGenome"}]}{"id": "1106_6", "text": "A panel of proteins was identified discriminating Con from AD (AUC: 0.91, CI: 0.67-1.00) with ORM2 (AUC: 1.00, CI: 1.00-1.00), RBP4 (AUC: 0.99, CI: 0.95-1.00), and HYDIN (AUC: 0.89, CI: 0.72-1.00) were found especially relevant for AD.", "tags": [{"end": 98, "start": 94, "tag": "GeneOrGenome"}, {"end": 131, "start": 127, "tag": "GeneOrGenome"}, {"end": 131, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 164, "tag": "GeneOrGenome"}, {"end": 66, "start": 63, "tag": "ResearchActivity"}, {"end": 103, "start": 100, "tag": "ResearchActivity"}, {"end": 136, "start": 133, "tag": "ResearchActivity"}, {"end": 174, "start": 171, "tag": "ResearchActivity"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 234, "start": 232, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 111, "tag": "ResearchActivity"}, {"end": 113, "start": 111, "tag": "GeneOrGenome"}, {"end": 131, "start": 127, "tag": "BiologicallyActiveSubstance"}]}{"id": "1106_7", "text": "This indicates that EVs provide an easily accessible matrix for possible AD biomarkers.", "tags": [{"end": 23, "start": 20, "tag": "CellComponent"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 76, "tag": "ClinicalAttribute"}, {"end": 59, "start": 53, "tag": "Chemical"}, {"end": 59, "start": 53, "tag": "PharmacologicSubstance"}, {"end": 59, "start": 35, "tag": "Finding"}]}{"id": "1106_8", "text": "Some of the MCI patients, with similar protein profiles as the AD group, progressed to AD within a 2-year timespan.", "tags": [{"end": 114, "start": 106, "tag": "TemporalConcept"}, {"end": 15, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 101, "tag": "TemporalConcept"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 16, "tag": "PatientOrDisabledGroup"}, {"end": 71, "start": 66, "tag": "PopulationGroup"}, {"end": 55, "start": 47, "tag": "ResearchActivity"}, {"end": 46, "start": 39, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1107_0", "text": "Multidrug-resistant (MDR) superbugs can breach the blood-brain barrier (BBB), leading to a continuous barrage of pro-inflammatory modulators and induction of severe infection-related pathologies, including meningitis and brain abscess.", "tags": [{"end": 154, "start": 145, "tag": "HealthCareActivity"}, {"end": 216, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 234, "start": 221, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 91, "tag": "TemporalConcept"}, {"end": 129, "start": 113, "tag": "PathologicFunction"}, {"end": 174, "start": 165, "tag": "PathologicFunction"}, {"end": 70, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 158, "tag": "Finding"}, {"end": 194, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 130, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 26, "tag": "Bacterium"}, {"end": 19, "start": 0, "tag": "Bacterium"}]}{"id": "1107_1", "text": "Both broad-spectrum or species-specific antibiotics (beta-lactamase inhibitors, polymyxins, vancomycin, meropenem, plazomicin, and sarecycline) and biocompatible poly (lactic-co-glycolic acid) (PLGA) nanoparticles have been used to treat these infections.", "tags": [{"end": 78, "start": 53, "tag": "PharmacologicSubstance"}, {"end": 78, "start": 53, "tag": "Chemical"}, {"end": 90, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 104, "tag": "Chemical"}, {"end": 125, "start": 115, "tag": "Chemical"}, {"end": 142, "start": 131, "tag": "Chemical"}, {"end": 192, "start": 162, "tag": "Chemical"}, {"end": 198, "start": 194, "tag": "Chemical"}, {"end": 254, "start": 244, "tag": "PathologicFunction"}, {"end": 254, "start": 244, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 11, "tag": "ResearchActivity"}, {"end": 30, "start": 23, "tag": "OrganismAttribute"}, {"end": 51, "start": 40, "tag": "PharmacologicSubstance"}, {"end": 90, "start": 80, "tag": "PharmacologicSubstance"}, {"end": 102, "start": 92, "tag": "PharmacologicSubstance"}, {"end": 113, "start": 104, "tag": "PharmacologicSubstance"}, {"end": 125, "start": 115, "tag": "PharmacologicSubstance"}, {"end": 142, "start": 131, "tag": "PharmacologicSubstance"}]}{"id": "1107_2", "text": "However, new therapeutic platforms with a broad impact that do not exert off-target deleterious effects are needed.", "tags": [{"end": 103, "start": 73, "tag": "Finding"}, {"end": 34, "start": 13, "tag": "HealthCareActivity"}]}{"id": "1107_3", "text": "Membrane vesicles or extracellular vesicles (EVs) are lipid bilayer-enclosed particles with therapeutic potential owing to their ability to circumvent BBB constraints.", "tags": [{"end": 17, "start": 0, "tag": "CellComponent"}, {"end": 43, "start": 21, "tag": "CellComponent"}, {"end": 48, "start": 45, "tag": "CellComponent"}, {"end": 86, "start": 77, "tag": "Chemical"}, {"end": 59, "start": 54, "tag": "Chemical"}, {"end": 113, "start": 92, "tag": "HealthCareActivity"}, {"end": 136, "start": 129, "tag": "OrganismAttribute"}, {"end": 154, "start": 151, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 54, "tag": "CellComponent"}]}{"id": "1107_4", "text": "Bacteria-derived EVs (bEVs) from gut microbiota are efficient transporters that can penetrate the central nervous system.", "tags": [{"end": 47, "start": 33, "tag": "Organism"}, {"end": 36, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 17, "tag": "CellComponent"}, {"end": 120, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 0, "tag": "Bacterium"}, {"end": 26, "start": 22, "tag": "CellComponent"}]}{"id": "1107_5", "text": "In fact, bEVs can be remodeled via surface modification and CRISPR/Cas editing and, thus, represent a novel platform for conferring protection against infections breaching the BBB.", "tags": [{"end": 161, "start": 151, "tag": "PathologicFunction"}, {"end": 161, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 60, "tag": "ResearchActivity"}, {"end": 55, "start": 35, "tag": "CellFunction"}, {"end": 179, "start": 176, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 9, "tag": "CellComponent"}, {"end": 142, "start": 132, "tag": "Finding"}]}{"id": "1107_6", "text": "Here, we discuss the latest scientific research related to gut microbiota- and probiotic-derived bEVs, and their therapeutic modifications, in terms of regulating neurotransmitters and inhibiting quorum sensing, for the treatment of neurodegenerative diseases, such as Parkinson's and Alzheimer's diseases.", "tags": [{"end": 47, "start": 28, "tag": "ResearchActivity"}, {"end": 210, "start": 196, "tag": "CellFunction"}, {"end": 305, "start": 285, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 21, "tag": "TemporalConcept"}, {"end": 73, "start": 59, "tag": "Organism"}, {"end": 62, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 259, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 229, "start": 220, "tag": "HealthCareActivity"}, {"end": 229, "start": 220, "tag": "ResearchActivity"}, {"end": 195, "start": 185, "tag": "BiologicFunction"}, {"end": 280, "start": 269, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 79, "tag": "Bacterium"}, {"end": 101, "start": 97, "tag": "CellComponent"}]}{"id": "1107_7", "text": "We also emphasize the benefits of probiotic-derived bEVs to human health and propose a novel direction for the development of innovative heterologous expression systems to combat BBB-crossing pathogens.", "tags": [{"end": 201, "start": 192, "tag": "Organism"}, {"end": 122, "start": 111, "tag": "BiologicFunction"}, {"end": 122, "start": 111, "tag": "CellFunction"}, {"end": 65, "start": 60, "tag": "Eukaryote"}, {"end": 160, "start": 150, "tag": "CellFunction"}, {"end": 72, "start": 66, "tag": "HealthCareActivity"}, {"end": 182, "start": 179, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 34, "tag": "Bacterium"}, {"end": 56, "start": 52, "tag": "CellComponent"}, {"end": 168, "start": 126, "tag": "ResearchActivity"}]}{"id": "1108_0", "text": "Extracellular Vesicles (EVs) are implicated in the spread of pathogenic proteins in a growing number of neurological diseases.", "tags": [{"end": 80, "start": 61, "tag": "CellOrMolecularDysfunction"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 125, "start": 104, "tag": "DiseaseOrSyndrome"}]}{"id": "1108_1", "text": "Given this, there is rising interest in developing inhibitors of Neutral Sphingomyelinase 2 (nSMase2), an enzyme critical in EV biogenesis.", "tags": [{"end": 61, "start": 51, "tag": "Chemical"}, {"end": 61, "start": 51, "tag": "PharmacologicSubstance"}, {"end": 61, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 113, "tag": "Finding"}, {"end": 100, "start": 93, "tag": "GeneOrGenome"}, {"end": 100, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 125, "tag": "CellComponent"}, {"end": 138, "start": 128, "tag": "CellFunction"}, {"end": 112, "start": 106, "tag": "BiologicallyActiveSubstance"}]}{"id": "1108_2", "text": "Our group recently discovered phenyl(R)-(1-(3-(3,4-dimethoxypheny1)-2,6-dimethylimidazo[1,2-b]pyridazin-8-yepyrrolidin-3-yecarbamate (PDDC), the first potent, selective, orally-available, and brain-penetrable nSMase2 inhibitor, capable of dose-dependently reducing EVs release in vitro and in vivo.", "tags": [{"end": 216, "start": 209, "tag": "GeneOrGenome"}, {"end": 216, "start": 209, "tag": "AminoAcidPeptideOrProtein"}, {"end": 216, "start": 209, "tag": "BiologicallyActiveSubstance"}, {"end": 226, "start": 217, "tag": "BiologicallyActiveSubstance"}, {"end": 226, "start": 217, "tag": "PharmacologicSubstance"}, {"end": 226, "start": 217, "tag": "Chemical"}, {"end": 176, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 134, "tag": "Chemical"}, {"end": 138, "start": 134, "tag": "PharmacologicSubstance"}, {"end": 268, "start": 265, "tag": "CellComponent"}, {"end": 197, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 4, "tag": "PopulationGroup"}, {"end": 150, "start": 145, "tag": "TemporalConcept"}, {"end": 285, "start": 277, "tag": "ResearchActivity"}, {"end": 297, "start": 290, "tag": "ResearchActivity"}, {"end": 18, "start": 10, "tag": "TemporalConcept"}, {"end": 264, "start": 256, "tag": "Finding"}, {"end": 276, "start": 265, "tag": "CellFunction"}, {"end": 132, "start": 30, "tag": "Chemical"}, {"end": 132, "start": 30, "tag": "PharmacologicSubstance"}]}{"id": "1108_3", "text": "Herein, using multiplexed Surface Plasmon Resonance imaging (SPRi), we evaluated which brain cell-derived EVs were affected by PDDC following acute brain injury.", "tags": [{"end": 65, "start": 61, "tag": "ResearchActivity"}, {"end": 97, "start": 87, "tag": "Cell"}, {"end": 147, "start": 142, "tag": "TemporalConcept"}, {"end": 59, "start": 14, "tag": "ResearchActivity"}, {"end": 160, "start": 142, "tag": "InjuryOrPoisoning"}, {"end": 131, "start": 127, "tag": "Chemical"}, {"end": 131, "start": 127, "tag": "PharmacologicSubstance"}, {"end": 109, "start": 106, "tag": "CellComponent"}, {"end": 153, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 97, "start": 93, "tag": "Cell"}]}{"id": "1108_4", "text": "Mice were fed PDDC-containing chow at doses which gave steady PDDC brain exposures exceeding its nSMase2 IC50.", "tags": [{"end": 4, "start": 0, "tag": "Eukaryote"}, {"end": 104, "start": 97, "tag": "GeneOrGenome"}, {"end": 104, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 14, "tag": "Chemical"}, {"end": 66, "start": 62, "tag": "Chemical"}, {"end": 18, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 66, "start": 62, "tag": "PharmacologicSubstance"}, {"end": 72, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 30, "tag": "Substance"}]}{"id": "1108_5", "text": "Mice were then administered an intra-striatal IL-1 beta injection and two hours later plasma and brain were collected.", "tags": [{"end": 4, "start": 0, "tag": "Eukaryote"}, {"end": 50, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 46, "tag": "PharmacologicSubstance"}, {"end": 92, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 80, "tag": "TemporalConcept"}, {"end": 65, "start": 56, "tag": "HealthCareActivity"}]}{"id": "1108_6", "text": "IL-1 beta injection significantly increased striatal nSMase2 activity which was completely normalized by PDDC.", "tags": [{"end": 60, "start": 53, "tag": "GeneOrGenome"}, {"end": 60, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 52, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 105, "tag": "Chemical"}, {"end": 9, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 69, "start": 53, "tag": "CellFunction"}, {"end": 109, "start": 105, "tag": "PharmacologicSubstance"}, {"end": 43, "start": 20, "tag": "Finding"}, {"end": 19, "start": 10, "tag": "HealthCareActivity"}]}{"id": "1108_7", "text": "Using SPRi, we found that IL-1 beta-induced injury selectively increased plasma levels of CD171 + and PLP1 + EVs; this EV increase was normalized by PDDC.", "tags": [{"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 95, "start": 90, "tag": "GeneOrGenome"}, {"end": 106, "start": 102, "tag": "GeneOrGenome"}, {"end": 30, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 149, "tag": "Chemical"}, {"end": 35, "start": 26, "tag": "PharmacologicSubstance"}, {"end": 153, "start": 149, "tag": "PharmacologicSubstance"}, {"end": 112, "start": 109, "tag": "CellComponent"}, {"end": 121, "start": 119, "tag": "CellComponent"}, {"end": 79, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 44, "tag": "InjuryOrPoisoning"}, {"end": 95, "start": 73, "tag": "ClinicalAttribute"}, {"end": 95, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 102, "tag": "BiologicallyActiveSubstance"}]}{"id": "1108_8", "text": "In contrast, GLAST1 + EVs were unchanged by IL-1 beta or PDDC.", "tags": [{"end": 19, "start": 13, "tag": "GeneOrGenome"}, {"end": 40, "start": 31, "tag": "Finding"}, {"end": 48, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 57, "tag": "Chemical"}, {"end": 53, "start": 44, "tag": "PharmacologicSubstance"}, {"end": 61, "start": 57, "tag": "PharmacologicSubstance"}, {"end": 25, "start": 22, "tag": "CellComponent"}, {"end": 19, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 13, "tag": "BiologicallyActiveSubstance"}]}{"id": "1108_9", "text": "IL-1 beta injection selectively increased EVs released from activated versus non-activated micmglia, indicated by the CD11b+/IB4 + ratio.", "tags": [{"end": 123, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 9, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 9, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 45, "start": 42, "tag": "CellComponent"}, {"end": 19, "start": 10, "tag": "HealthCareActivity"}, {"end": 128, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 125, "tag": "BiologicallyActiveSubstance"}]}{"id": "1108_10", "text": "The increase in EVs from CD11b + micmglia was dramatically attenuated with PDDC.", "tags": [{"end": 30, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 75, "tag": "Chemical"}, {"end": 79, "start": 75, "tag": "PharmacologicSubstance"}, {"end": 19, "start": 16, "tag": "CellComponent"}]}{"id": "1108_11", "text": "Taken together, our data demonstrate that following acute injury, brain nSMase2 activity is elevated.", "tags": [{"end": 64, "start": 52, "tag": "InjuryOrPoisoning"}, {"end": 57, "start": 52, "tag": "TemporalConcept"}, {"end": 79, "start": 72, "tag": "GeneOrGenome"}, {"end": 79, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 72, "tag": "CellFunction"}, {"end": 71, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 20, "tag": "ResearchActivity"}]}{"id": "1108_12", "text": "EVs released from neurons, oligodendrocytes, and activated microglial are increased in plasma and inhibition of nSMase2 with PDDC reduced these IL-1 beta-induced changes implicating nSMase2 inhibition as a therapeutic target for acute brain injury.", "tags": [{"end": 43, "start": 27, "tag": "Cell"}, {"end": 234, "start": 229, "tag": "TemporalConcept"}, {"end": 119, "start": 112, "tag": "GeneOrGenome"}, {"end": 189, "start": 182, "tag": "GeneOrGenome"}, {"end": 119, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 182, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 247, "start": 229, "tag": "InjuryOrPoisoning"}, {"end": 148, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 125, "tag": "Chemical"}, {"end": 153, "start": 144, "tag": "PharmacologicSubstance"}, {"end": 129, "start": 125, "tag": "PharmacologicSubstance"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 93, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 240, "start": 235, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 98, "tag": "CellFunction"}, {"end": 200, "start": 190, "tag": "CellFunction"}, {"end": 25, "start": 18, "tag": "Cell"}, {"end": 69, "start": 59, "tag": "Cell"}, {"end": 169, "start": 162, "tag": "Finding"}, {"end": 224, "start": 206, "tag": "Finding"}]}{"id": "1109_0", "text": "Blood exosomes, which are extracellular vesicles secreted by living cells into the circulating blood, are regarded as a relatively noninvasive novel tool for monitoring brain physiology and disease states.", "tags": [{"end": 100, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 131, "tag": "Finding"}, {"end": 204, "start": 198, "tag": "TemporalConcept"}, {"end": 185, "start": 169, "tag": "BiologicFunction"}, {"end": 48, "start": 26, "tag": "CellComponent"}, {"end": 73, "start": 68, "tag": "Cell"}, {"end": 168, "start": 158, "tag": "HealthCareActivity"}, {"end": 185, "start": 175, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 185, "start": 175, "tag": "BiologicFunction"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 61, "tag": "Finding"}, {"end": 14, "start": 6, "tag": "CellComponent"}]}{"id": "1109_1", "text": "An increasing number of blood cargo-loaded exosomes are emerging as potential biomarkers for preclinical and clinical Alzheimer's disease.", "tags": [{"end": 137, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 78, "tag": "ClinicalAttribute"}, {"end": 29, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 30, "tag": "CellComponent"}, {"end": 88, "start": 68, "tag": "ClinicalAttribute"}, {"end": 51, "start": 43, "tag": "CellComponent"}, {"end": 13, "start": 3, "tag": "Finding"}]}{"id": "1109_2", "text": "Therefore, we conducted a meta-analysis and systematic review of molecular biomarkers derived from blood exosomes to comprehensively analyze their diagnostic performance in preclinical Alzheimer's disease, mild cognitive impairment, and Alzheimer's disease.", "tags": [{"end": 85, "start": 65, "tag": "ClinicalAttribute"}, {"end": 61, "start": 44, "tag": "ResearchActivity"}, {"end": 61, "start": 44, "tag": "HealthCareActivity"}, {"end": 204, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 210, "start": 206, "tag": "Finding"}, {"end": 231, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 147, "tag": "Finding"}, {"end": 113, "start": 105, "tag": "CellComponent"}, {"end": 39, "start": 26, "tag": "ResearchActivity"}]}{"id": "1109_3", "text": "We performed a literature search in PubMed, Web of Science, Embase, and Cochrane Library from their inception to August 15, 2020.", "tags": [{"end": 32, "start": 26, "tag": "ResearchActivity"}, {"end": 25, "start": 15, "tag": "ResearchActivity"}, {"end": 42, "start": 36, "tag": "HealthCareRelatedOrganization"}, {"end": 58, "start": 44, "tag": "HealthCareRelatedOrganization"}, {"end": 88, "start": 72, "tag": "ResearchActivity"}, {"end": 66, "start": 60, "tag": "HealthCareRelatedOrganization"}]}{"id": "1109_4", "text": "The research subjects mainly included Alzheimer's disease, mild cognitive impairment, and preclinical Alzheimer's disease.", "tags": [{"end": 21, "start": 4, "tag": "PopulationGroup"}, {"end": 57, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 63, "start": 59, "tag": "Finding"}, {"end": 21, "start": 13, "tag": "PopulationGroup"}, {"end": 84, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 59, "tag": "DiseaseOrSyndrome"}]}{"id": "1109_5", "text": "We identified 34 observational studies, of which 15 were included in the quantitative analysis (Newcastle-Ottawa Scale score 5.87 points) and 19 were used in the qualitative analysis.", "tags": [{"end": 38, "start": 17, "tag": "ResearchActivity"}, {"end": 94, "start": 73, "tag": "ResearchActivity"}, {"end": 182, "start": 162, "tag": "ResearchActivity"}, {"end": 118, "start": 96, "tag": "ResearchActivity"}]}{"id": "1109_6", "text": "The meta-analysis results showed that core biomarkers including A beta(1-42), P-T181-tau, P-S396-tau, and T-tau were increased in blood neuron-derived exosomes of preclinical Alzheimer's disease, mild cognitive impairment, and Alzheimer's disease patients.", "tags": [{"end": 53, "start": 38, "tag": "ClinicalAttribute"}, {"end": 194, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 246, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 255, "start": 247, "tag": "PatientOrDisabledGroup"}, {"end": 142, "start": 136, "tag": "Cell"}, {"end": 88, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 43, "tag": "ClinicalAttribute"}, {"end": 88, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 200, "start": 196, "tag": "Finding"}, {"end": 221, "start": 201, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 151, "tag": "CellComponent"}, {"end": 17, "start": 4, "tag": "ResearchActivity"}, {"end": 76, "start": 64, "tag": "BiologicallyActiveSubstance"}]}{"id": "1109_7", "text": "Molecules related to additional risk factors that are involved in neuroinflammation (C1q), metabolism disorder (P-S312-IRS-1), neurotrophic deficiency (HGF), vascular injury (VEGF-D), and autophagy-lysosomal system dysfunction (cathepsin D) were also increased.", "tags": [{"end": 9, "start": 0, "tag": "Substance"}, {"end": 110, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 158, "tag": "InjuryOrPoisoning"}, {"end": 181, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 175, "tag": "GeneOrGenome"}, {"end": 150, "start": 127, "tag": "Finding"}, {"end": 166, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 32, "tag": "Finding"}, {"end": 197, "start": 188, "tag": "CellFunction"}, {"end": 44, "start": 32, "tag": "Finding"}, {"end": 83, "start": 66, "tag": "PathologicFunction"}, {"end": 226, "start": 215, "tag": "PathologicFunction"}, {"end": 239, "start": 228, "tag": "AminoAcidPeptideOrProtein"}, {"end": 239, "start": 228, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 152, "tag": "GeneOrGenome"}, {"end": 124, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 175, "tag": "BiologicallyActiveSubstance"}, {"end": 214, "start": 188, "tag": "CellFunction"}]}{"id": "1109_8", "text": "At the gene level, the differential expression of transcription-related factors (REST) and microRNAs (miR-132) also affects RNA splicing, transport, and translation.", "tags": [{"end": 35, "start": 23, "tag": "CellFunction"}, {"end": 35, "start": 23, "tag": "ClinicalAttribute"}, {"end": 109, "start": 102, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 109, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 36, "tag": "CellFunction"}, {"end": 85, "start": 81, "tag": "GeneOrGenome"}, {"end": 85, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 153, "tag": "CellFunction"}, {"end": 11, "start": 7, "tag": "GeneOrGenome"}, {"end": 127, "start": 124, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 100, "start": 91, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 100, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 50, "tag": "CellFunction"}, {"end": 85, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 124, "tag": "CellFunction"}, {"end": 147, "start": 138, "tag": "CellFunction"}, {"end": 127, "start": 124, "tag": "CellFunction"}]}{"id": "1109_9", "text": "These pathological changes contribute to neural loss and synaptic dysfunction.", "tags": [{"end": 77, "start": 57, "tag": "CellOrMolecularDysfunction"}, {"end": 65, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 77, "start": 66, "tag": "PathologicFunction"}, {"end": 52, "start": 41, "tag": "CellOrMolecularDysfunction"}, {"end": 26, "start": 6, "tag": "Finding"}]}{"id": "1109_10", "text": "The data confirm that the above-mentioned core molecules and additional risk-related factors in blood exosomes can serve as candidate biomarkers for preclinical and clinical Alzheimer's disease.", "tags": [{"end": 56, "start": 42, "tag": "Substance"}, {"end": 193, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 134, "tag": "ClinicalAttribute"}, {"end": 101, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 72, "tag": "Finding"}, {"end": 56, "start": 47, "tag": "Substance"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 110, "start": 102, "tag": "CellComponent"}]}{"id": "1109_11", "text": "These findings support further development of exosome biomarkers for a clinical blood test for Alzheimer's disease.", "tags": [{"end": 114, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 31, "tag": "BiologicFunction"}, {"end": 42, "start": 31, "tag": "CellFunction"}, {"end": 64, "start": 54, "tag": "ClinicalAttribute"}, {"end": 85, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 46, "tag": "CellComponent"}, {"end": 90, "start": 71, "tag": "HealthCareActivity"}]}{"id": "1109_12", "text": "This meta-analysis was registered at the International Prospective Register of Systematic Reviews (Registration No.", "tags": [{"end": 18, "start": 5, "tag": "ResearchActivity"}, {"end": 97, "start": 41, "tag": "HealthCareRelatedOrganization"}]}{"id": "1109_13", "text": "CRD4200173498, 28/04/2020).", "tags": []}{"id": "1110_0", "text": "Introduction Intellectual disability, accelerated aging, and early-onset Alzheimer-like neurodegeneration are key brain pathological features of Down syndrome (DS).", "tags": [{"end": 36, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 67, "tag": "TemporalConcept"}, {"end": 105, "start": 88, "tag": "CellOrMolecularDysfunction"}, {"end": 158, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 50, "tag": "BiologicFunction"}, {"end": 55, "start": 50, "tag": "CellFunction"}, {"end": 141, "start": 120, "tag": "PathologicFunction"}]}{"id": "1110_1", "text": "Although growing research aims at the identification of molecular pathways underlying the aging trajectory of DS population, data on infants and adolescents with DS are missing.", "tags": [{"end": 140, "start": 133, "tag": "PopulationGroup"}, {"end": 156, "start": 145, "tag": "PopulationGroup"}, {"end": 25, "start": 17, "tag": "ResearchActivity"}, {"end": 123, "start": 113, "tag": "PopulationGroup"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 56, "tag": "CellFunction"}, {"end": 95, "start": 90, "tag": "BiologicFunction"}, {"end": 95, "start": 90, "tag": "CellFunction"}, {"end": 129, "start": 125, "tag": "ResearchActivity"}]}{"id": "1110_2", "text": "Methods Neuronal-derived extracellular vesicles (nEVs) were isolated form healthy donors (HDs, n = 17) and DS children (n = 18) from 2 to 17 years of age and nEV content was interrogated for markers of insulin/mTOR pathways.", "tags": [{"end": 118, "start": 110, "tag": "PopulationGroup"}, {"end": 214, "start": 210, "tag": "AminoAcidPeptideOrProtein"}, {"end": 214, "start": 210, "tag": "GeneOrGenome"}, {"end": 214, "start": 210, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 82, "tag": "PopulationGroup"}, {"end": 209, "start": 202, "tag": "AminoAcidPeptideOrProtein"}, {"end": 209, "start": 202, "tag": "BiologicallyActiveSubstance"}, {"end": 209, "start": 202, "tag": "PharmacologicSubstance"}, {"end": 47, "start": 25, "tag": "CellComponent"}, {"end": 81, "start": 74, "tag": "OrganismAttribute"}, {"end": 198, "start": 191, "tag": "ClinicalAttribute"}, {"end": 146, "start": 141, "tag": "TemporalConcept"}, {"end": 153, "start": 150, "tag": "OrganismAttribute"}, {"end": 161, "start": 158, "tag": "CellComponent"}, {"end": 53, "start": 49, "tag": "CellComponent"}, {"end": 223, "start": 215, "tag": "CellFunction"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 8, "tag": "CellComponent"}]}{"id": "1110_3", "text": "Results nEVs isolated from DS children were characterized by a significant increase in pIRS1(Ser636), a marker of insulin resistance, and the hyperactivation of the Akt/mTOR/p70S6K axis downstream from IRS1, likely driven by the higher inhibition of Phosphatase and tensin homolog (PTEN).", "tags": [{"end": 38, "start": 30, "tag": "PopulationGroup"}, {"end": 132, "start": 114, "tag": "PathologicFunction"}, {"end": 206, "start": 202, "tag": "AminoAcidPeptideOrProtein"}, {"end": 280, "start": 250, "tag": "AminoAcidPeptideOrProtein"}, {"end": 280, "start": 250, "tag": "BiologicallyActiveSubstance"}, {"end": 286, "start": 282, "tag": "GeneOrGenome"}, {"end": 286, "start": 282, "tag": "AminoAcidPeptideOrProtein"}, {"end": 286, "start": 282, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 114, "tag": "PharmacologicSubstance"}, {"end": 110, "start": 104, "tag": "ClinicalAttribute"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 246, "start": 236, "tag": "CellFunction"}, {"end": 12, "start": 8, "tag": "CellComponent"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 63, "tag": "Finding"}, {"end": 100, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 165, "tag": "CellFunction"}, {"end": 100, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 206, "start": 202, "tag": "BiologicallyActiveSubstance"}, {"end": 206, "start": 202, "tag": "GeneOrGenome"}]}{"id": "1110_4", "text": "High levels of pGSK3 beta(Ser9) were also found.", "tags": [{"end": 31, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 15, "tag": "BiologicallyActiveSubstance"}]}{"id": "1110_5", "text": "Conclusions The alteration of the insulin-signaling/mTOR pathways represents an early event in DS brain and likely contributes to the cerebral dysfunction and intellectual disability observed in this unique population.", "tags": [{"end": 154, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 42, "tag": "CellFunction"}, {"end": 56, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 52, "tag": "GeneOrGenome"}, {"end": 56, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 34, "tag": "PharmacologicSubstance"}, {"end": 26, "start": 16, "tag": "Finding"}, {"end": 103, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 217, "start": 207, "tag": "PopulationGroup"}, {"end": 65, "start": 57, "tag": "CellFunction"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}]}{"id": "1111_0", "text": "Small extracellular vesicles (sEVs) have been proposed as a possible solution to the current lack of therapeutic interventions for endogenous skin regeneration.", "tags": [{"end": 77, "start": 69, "tag": "Substance"}, {"end": 159, "start": 142, "tag": "BiologicFunction"}, {"end": 126, "start": 101, "tag": "HealthCareActivity"}, {"end": 28, "start": 6, "tag": "CellComponent"}, {"end": 92, "start": 85, "tag": "TemporalConcept"}, {"end": 34, "start": 30, "tag": "CellComponent"}, {"end": 28, "start": 0, "tag": "CellComponent"}]}{"id": "1111_1", "text": "We conducted a systematic review of the available evidence to assess sEV therapeutic efficacy and safety in wound healing and skin regeneration in animal models.", "tags": [{"end": 121, "start": 108, "tag": "BiologicFunction"}, {"end": 32, "start": 15, "tag": "ResearchActivity"}, {"end": 143, "start": 126, "tag": "BiologicFunction"}, {"end": 32, "start": 15, "tag": "HealthCareActivity"}, {"end": 58, "start": 50, "tag": "Finding"}, {"end": 93, "start": 73, "tag": "Finding"}, {"end": 160, "start": 147, "tag": "ResearchActivity"}, {"end": 130, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 69, "tag": "CellComponent"}, {"end": 104, "start": 98, "tag": "HealthCareActivity"}]}{"id": "1111_2", "text": "68 studies were identified in Web of Science, Scopus, and PubMed that satisfied a set of prespecified inclusion criteria.", "tags": [{"end": 10, "start": 3, "tag": "ResearchActivity"}, {"end": 64, "start": 58, "tag": "HealthCareRelatedOrganization"}, {"end": 44, "start": 30, "tag": "HealthCareRelatedOrganization"}, {"end": 52, "start": 46, "tag": "HealthCareRelatedOrganization"}, {"end": 120, "start": 102, "tag": "ResearchActivity"}]}{"id": "1111_3", "text": "We critically analyzed the quality of studies that satisfied our inclusion criteria, with an emphasis on methodology, reporting, and adherence to relevant guidelines (including MISEV2018 and ISCT criteria).", "tags": [{"end": 127, "start": 118, "tag": "HealthCareActivity"}, {"end": 45, "start": 38, "tag": "ResearchActivity"}, {"end": 186, "start": 177, "tag": "ResearchActivity"}, {"end": 204, "start": 191, "tag": "ResearchActivity"}, {"end": 83, "start": 65, "tag": "ResearchActivity"}, {"end": 116, "start": 105, "tag": "ResearchActivity"}, {"end": 165, "start": 155, "tag": "ResearchActivity"}]}{"id": "1111_4", "text": "Overall, our systematic review and meta-analysis indicated that sEV interventions promoted skin regeneration in diabetic and non-diabetic animal models and influenced various facets of the healing process regardless of cell source, production protocol and disease model.", "tags": [{"end": 204, "start": 189, "tag": "BiologicFunction"}, {"end": 230, "start": 219, "tag": "Cell"}, {"end": 269, "start": 256, "tag": "ExperimentalModelOfDisease"}, {"end": 30, "start": 13, "tag": "ResearchActivity"}, {"end": 108, "start": 91, "tag": "BiologicFunction"}, {"end": 81, "start": 68, "tag": "HealthCareActivity"}, {"end": 81, "start": 68, "tag": "ResearchActivity"}, {"end": 30, "start": 13, "tag": "HealthCareActivity"}, {"end": 151, "start": 138, "tag": "ResearchActivity"}, {"end": 95, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 35, "tag": "ResearchActivity"}, {"end": 67, "start": 64, "tag": "CellComponent"}, {"end": 151, "start": 138, "tag": "ExperimentalModelOfDisease"}, {"end": 120, "start": 112, "tag": "ExperimentalModelOfDisease"}, {"end": 151, "start": 125, "tag": "ExperimentalModelOfDisease"}, {"end": 251, "start": 232, "tag": "ResearchActivity"}]}{"id": "1111_5", "text": "The EV source, isolation methods, dosing regimen, and wound size varied among the studies.", "tags": [{"end": 48, "start": 41, "tag": "HealthCareActivity"}, {"end": 6, "start": 4, "tag": "CellComponent"}, {"end": 89, "start": 82, "tag": "ResearchActivity"}, {"end": 64, "start": 60, "tag": "OrganismAttribute"}, {"end": 32, "start": 15, "tag": "ResearchActivity"}, {"end": 59, "start": 54, "tag": "InjuryOrPoisoning"}]}{"id": "1111_6", "text": "Modification of sEVs was achieved mainly by manipulating source cells via preconditioning, nanoparticle loading, genetic manipulation, and biomaterial incorporation to enhance sEV therapeutic potential.", "tags": [{"end": 133, "start": 113, "tag": "ResearchActivity"}, {"end": 89, "start": 74, "tag": "BiologicFunction"}, {"end": 69, "start": 57, "tag": "Cell"}, {"end": 201, "start": 180, "tag": "HealthCareActivity"}, {"end": 20, "start": 16, "tag": "CellComponent"}, {"end": 179, "start": 176, "tag": "CellComponent"}, {"end": 111, "start": 91, "tag": "ResearchActivity"}, {"end": 164, "start": 139, "tag": "ResearchActivity"}, {"end": 150, "start": 139, "tag": "Substance"}, {"end": 20, "start": 0, "tag": "ResearchActivity"}]}{"id": "1111_7", "text": "Evaluation of potential adverse effects received only minimal attention, although none of the studies reported harmful events.", "tags": [{"end": 10, "start": 0, "tag": "HealthCareActivity"}, {"end": 10, "start": 0, "tag": "ResearchActivity"}, {"end": 39, "start": 24, "tag": "PathologicFunction"}, {"end": 71, "start": 62, "tag": "BiologicFunction"}, {"end": 101, "start": 94, "tag": "ResearchActivity"}]}{"id": "1111_8", "text": "Risk of bias as assessed by the SYRCLE's ROB tool was uncertain for most studies due to insufficient reporting, and adherence to guidelines was limited.", "tags": [{"end": 110, "start": 101, "tag": "HealthCareActivity"}, {"end": 12, "start": 0, "tag": "Finding"}, {"end": 80, "start": 73, "tag": "ResearchActivity"}, {"end": 49, "start": 32, "tag": "ResearchActivity"}, {"end": 139, "start": 129, "tag": "ResearchActivity"}]}{"id": "1111_9", "text": "In summary, sEV therapy has enormous potential for wound healing and skin regeneration.", "tags": [{"end": 64, "start": 51, "tag": "BiologicFunction"}, {"end": 86, "start": 69, "tag": "BiologicFunction"}, {"end": 23, "start": 16, "tag": "HealthCareActivity"}, {"end": 15, "start": 12, "tag": "CellComponent"}]}{"id": "1111_10", "text": "However, reproducibility and comprehensive evaluation of evidence are challenged by a general lack of transparency in reporting and adherence to guidelines.", "tags": [{"end": 127, "start": 118, "tag": "HealthCareActivity"}, {"end": 53, "start": 43, "tag": "HealthCareActivity"}, {"end": 53, "start": 43, "tag": "ResearchActivity"}, {"end": 65, "start": 57, "tag": "Finding"}]}{"id": "1111_11", "text": "Methodological rigor, standardization, and risk analysis at all stages of research are needed to promote translation to clinical practice.", "tags": [{"end": 37, "start": 22, "tag": "ResearchActivity"}, {"end": 56, "start": 43, "tag": "ResearchActivity"}, {"end": 82, "start": 74, "tag": "ResearchActivity"}, {"end": 137, "start": 120, "tag": "HealthCareActivity"}, {"end": 70, "start": 64, "tag": "TemporalConcept"}, {"end": 116, "start": 105, "tag": "CellFunction"}]}{"id": "1112_0", "text": "Helicobacter pylori (HP) is a Gram-negative bacterium that colonizes the human stomach chronically.", "tags": [{"end": 19, "start": 0, "tag": "Bacterium"}, {"end": 23, "start": 21, "tag": "Bacterium"}, {"end": 53, "start": 30, "tag": "Bacterium"}, {"end": 78, "start": 73, "tag": "Eukaryote"}, {"end": 86, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1112_1", "text": "Colonization of HP in the gastric mucosa not only causes gastrointestinal diseases, but also is associated with extra-gastric diseases, such as idiopathic thrombocytopenic purpura and neurological diseases.", "tags": [{"end": 12, "start": 0, "tag": "Finding"}, {"end": 18, "start": 16, "tag": "Bacterium"}, {"end": 40, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 112, "tag": "DiseaseOrSyndrome"}]}{"id": "1112_2", "text": "Among neurological diseases, epidemiological studies have shown that HP infection increases the prevalence of Alzheimer's disease (AD) and Parkinson's disease (PD).", "tags": [{"end": 71, "start": 69, "tag": "Bacterium"}, {"end": 27, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 29, "tag": "ResearchActivity"}, {"end": 81, "start": 72, "tag": "PathologicFunction"}, {"end": 158, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}]}{"id": "1112_3", "text": "Since HP does not invade the central nervous system (CNS), it has been considered that systemic immunological changes induced by HP infection may play pathogenic roles in AD and PD.", "tags": [{"end": 8, "start": 6, "tag": "Bacterium"}, {"end": 117, "start": 96, "tag": "Finding"}, {"end": 131, "start": 129, "tag": "Bacterium"}, {"end": 56, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 161, "start": 151, "tag": "PathologicFunction"}, {"end": 141, "start": 132, "tag": "PathologicFunction"}, {"end": 180, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1112_4", "text": "Here, we investigated the effects of HP infection on the CNS in vivo and in vitro.", "tags": [{"end": 39, "start": 37, "tag": "Bacterium"}, {"end": 60, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 73, "tag": "ResearchActivity"}, {"end": 49, "start": 40, "tag": "PathologicFunction"}, {"end": 68, "start": 61, "tag": "ResearchActivity"}]}{"id": "1112_5", "text": "In the CNS, chronically HP-infected mice had microglial activation without HP colonization, although systemic immunological changes were not observed.", "tags": [{"end": 77, "start": 75, "tag": "Bacterium"}, {"end": 90, "start": 78, "tag": "Finding"}, {"end": 131, "start": 101, "tag": "Finding"}, {"end": 10, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 45, "tag": "Cell"}, {"end": 40, "start": 36, "tag": "Eukaryote"}, {"end": 66, "start": 45, "tag": "CellFunction"}, {"end": 40, "start": 24, "tag": "ExperimentalModelOfDisease"}, {"end": 26, "start": 24, "tag": "Bacterium"}]}{"id": "1112_6", "text": "This led us to explore the possibility that HP-derived outer membrane vesicles (HP-OMVs) could cause neuroinflammation.", "tags": [{"end": 78, "start": 55, "tag": "CellComponent"}, {"end": 118, "start": 101, "tag": "PathologicFunction"}, {"end": 87, "start": 83, "tag": "CellComponent"}, {"end": 82, "start": 80, "tag": "Bacterium"}, {"end": 46, "start": 44, "tag": "Bacterium"}]}{"id": "1112_7", "text": "OMVs are small, spherical bilayer vesicles (20-500 nm) released into the extracellular space from the outer membrane of Gram-negative bacteria; OMVs contain lipopolysaccharide, proteins, peptidoglycan, DNA, and RNA.", "tags": [{"end": 116, "start": 102, "tag": "CellComponent"}, {"end": 142, "start": 120, "tag": "Bacterium"}, {"end": 175, "start": 157, "tag": "Chemical"}, {"end": 200, "start": 187, "tag": "Chemical"}, {"end": 200, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 205, "start": 202, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 185, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 214, "start": 211, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 4, "start": 0, "tag": "CellComponent"}, {"end": 42, "start": 16, "tag": "CellComponent"}, {"end": 148, "start": 144, "tag": "CellComponent"}]}{"id": "1112_8", "text": "OMVs have also been shown to activate both innate and acquired immune cells in vitro, and to disrupt the tight junctions of the gastric epithelium (leaky gut) as well as cross the blood-brain barrier in vivo.", "tags": [{"end": 120, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 76, "tag": "ResearchActivity"}, {"end": 75, "start": 63, "tag": "Cell"}, {"end": 207, "start": 200, "tag": "ResearchActivity"}, {"end": 199, "start": 180, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 4, "start": 0, "tag": "CellComponent"}, {"end": 157, "start": 148, "tag": "DiseaseOrSyndrome"}]}{"id": "1112_9", "text": "Thus, in theory, OMVs can activate immune responses in the remote organs, including the lymphoid organs and CNS, if only OMVs enter the systemic circulation.", "tags": [{"end": 51, "start": 35, "tag": "BiologicFunction"}, {"end": 103, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 17, "tag": "CellComponent"}, {"end": 125, "start": 121, "tag": "CellComponent"}, {"end": 156, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1112_10", "text": "From the exosome fraction of sera from HP-infected mice, we detected HP-specific DNA, suggesting the presence of HP-OMVs.", "tags": [{"end": 16, "start": 9, "tag": "CellComponent"}, {"end": 33, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 101, "tag": "Finding"}, {"end": 84, "start": 81, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 55, "start": 51, "tag": "Eukaryote"}, {"end": 55, "start": 39, "tag": "ExperimentalModelOfDisease"}, {"end": 71, "start": 69, "tag": "Bacterium"}, {"end": 120, "start": 116, "tag": "CellComponent"}, {"end": 115, "start": 113, "tag": "Bacterium"}]}{"id": "1112_11", "text": "We also found that microglia incubated with HP-OMVs in vitro increased the cell proliferation, inflammatory cytokine production, and migration.", "tags": [{"end": 60, "start": 52, "tag": "ResearchActivity"}, {"end": 93, "start": 75, "tag": "CellFunction"}, {"end": 142, "start": 133, "tag": "CellFunction"}, {"end": 127, "start": 95, "tag": "CellFunction"}, {"end": 28, "start": 19, "tag": "Cell"}, {"end": 46, "start": 44, "tag": "Bacterium"}, {"end": 51, "start": 47, "tag": "CellComponent"}]}{"id": "1112_12", "text": "On the other hand, HP-OMVs suppressed the cell proliferation of neuroblastoma in vitro.", "tags": [{"end": 77, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 78, "tag": "ResearchActivity"}, {"end": 60, "start": 42, "tag": "CellFunction"}, {"end": 21, "start": 19, "tag": "Bacterium"}, {"end": 26, "start": 22, "tag": "CellComponent"}]}{"id": "1112_13", "text": "Lastly, we found that AD model mice infected with HP had amyloid plaques adjacent to activated microglia and astrocytes in vivo.", "tags": [{"end": 52, "start": 50, "tag": "Bacterium"}, {"end": 119, "start": 109, "tag": "Cell"}, {"end": 72, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 127, "start": 120, "tag": "ResearchActivity"}, {"end": 104, "start": 95, "tag": "Cell"}, {"end": 35, "start": 22, "tag": "ExperimentalModelOfDisease"}]}{"id": "1112_14", "text": "Based on the literature review and our experimental data, we propose our working hypothesis that OMVs produced in chronic HP infection in the gut induce neuroinflammation in the CNS, explaining the higher prevalence of AD in HP-infected people.", "tags": [{"end": 145, "start": 142, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 181, "start": 178, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 13, "tag": "ResearchActivity"}, {"end": 134, "start": 125, "tag": "PathologicFunction"}, {"end": 30, "start": 24, "tag": "ResearchActivity"}, {"end": 30, "start": 24, "tag": "HealthCareActivity"}, {"end": 221, "start": 219, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 39, "tag": "ResearchActivity"}, {"end": 170, "start": 153, "tag": "PathologicFunction"}, {"end": 243, "start": 237, "tag": "PopulationGroup"}, {"end": 121, "start": 114, "tag": "TemporalConcept"}, {"end": 124, "start": 122, "tag": "Bacterium"}, {"end": 227, "start": 225, "tag": "Bacterium"}, {"end": 101, "start": 97, "tag": "CellComponent"}]}{"id": "1113_0", "text": "Exosomes are potent mediators of physiological and pathological processes.", "tags": [{"end": 73, "start": 51, "tag": "PathologicFunction"}, {"end": 29, "start": 20, "tag": "Finding"}, {"end": 8, "start": 0, "tag": "CellComponent"}]}{"id": "1113_1", "text": "In Alzheimer's disease and in-flammatory disorders, due to exosomes' distinctive ability to cross the blood-brain barrier, a bidirectional communication between the periphery and the central nervous system exists.", "tags": [{"end": 22, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 183, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 139, "tag": "HealthCareActivity"}, {"end": 152, "start": 139, "tag": "CellFunction"}, {"end": 88, "start": 81, "tag": "OrganismAttribute"}, {"end": 67, "start": 59, "tag": "CellComponent"}]}{"id": "1113_2", "text": "Since exosomes can carry various biochemical molecules, this review investigates the role of exosomes as possible mediators between chronic systemic inflammatory diseases and Alzheimer's disease.", "tags": [{"end": 194, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 61, "tag": "ResearchActivity"}, {"end": 67, "start": 61, "tag": "HealthCareActivity"}, {"end": 123, "start": 114, "tag": "Finding"}, {"end": 54, "start": 33, "tag": "Substance"}, {"end": 14, "start": 6, "tag": "CellComponent"}, {"end": 101, "start": 93, "tag": "CellComponent"}, {"end": 170, "start": 132, "tag": "DiseaseOrSyndrome"}]}{"id": "1113_3", "text": "Exosomes carry pro-inflammatory molecules generated in the periphery, travel to the central nervous system, and target glial and neuronal cells.", "tags": [{"end": 124, "start": 119, "tag": "Cell"}, {"end": 143, "start": 129, "tag": "Cell"}, {"end": 106, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 15, "tag": "PathologicFunction"}, {"end": 68, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 32, "tag": "Substance"}, {"end": 8, "start": 0, "tag": "CellComponent"}]}{"id": "1113_4", "text": "Microglia and astro-cytes then become activated, initiating chronic neuroinflammation.", "tags": [{"end": 9, "start": 0, "tag": "Cell"}, {"end": 85, "start": 68, "tag": "PathologicFunction"}, {"end": 67, "start": 60, "tag": "TemporalConcept"}, {"end": 25, "start": 14, "tag": "Cell"}]}{"id": "1113_5", "text": "As the aging brain is more susceptible to such changes, this state of neuroinflammation can stimulate neuropathologies, impair amyloid-beta clearance capa-bilities, and generate dysregulated microRNAs that alter the expression of genes critical in Alzheimer's disease pathology.", "tags": [{"end": 38, "start": 27, "tag": "OrganismAttribute"}, {"end": 38, "start": 27, "tag": "ResearchActivity"}, {"end": 118, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 267, "start": 248, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 178, "tag": "PathologicFunction"}, {"end": 226, "start": 216, "tag": "CellFunction"}, {"end": 134, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 7, "tag": "BiologicFunction"}, {"end": 12, "start": 7, "tag": "CellFunction"}, {"end": 87, "start": 70, "tag": "PathologicFunction"}, {"end": 149, "start": 140, "tag": "NaturalPhenomenonOrProcess"}, {"end": 139, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 277, "start": 260, "tag": "PathologicFunction"}, {"end": 200, "start": 191, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 200, "start": 191, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 47, "tag": "Finding"}]}{"id": "1113_6", "text": "These processes, individually and collectively, become significant risk factors for the development of Alzheimer's disease.", "tags": [{"end": 122, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 88, "tag": "BiologicFunction"}, {"end": 99, "start": 88, "tag": "CellFunction"}, {"end": 79, "start": 67, "tag": "Finding"}]}{"id": "1114_0", "text": "Background/ObjectiveDespite multiple attempts, no surrogate biomarker of Parkinson disease (PD) has been definitively identified.", "tags": [{"end": 59, "start": 50, "tag": "PopulationGroup"}, {"end": 90, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 60, "tag": "ClinicalAttribute"}]}{"id": "1114_1", "text": "Alternatively, identifying a non-invasive biomarker is crucial to understanding the natural history, severity, and progression of PD and to guide future therapeutic trials.", "tags": [{"end": 171, "start": 153, "tag": "ResearchActivity"}, {"end": 41, "start": 33, "tag": "Finding"}, {"end": 99, "start": 92, "tag": "Finding"}, {"end": 51, "start": 29, "tag": "ClinicalAttribute"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 42, "tag": "ClinicalAttribute"}, {"end": 126, "start": 115, "tag": "PathologicFunction"}, {"end": 126, "start": 115, "tag": "TemporalConcept"}, {"end": 41, "start": 29, "tag": "Finding"}, {"end": 79, "start": 66, "tag": "BiologicFunction"}, {"end": 109, "start": 101, "tag": "ClinicalAttribute"}, {"end": 109, "start": 101, "tag": "Finding"}, {"end": 152, "start": 146, "tag": "TemporalConcept"}]}{"id": "1114_2", "text": "Recent work highlighted alpha synuclein-containing extracellular vesicles and Poly (ADP-ribose) polymerase (PARP-1) activity as drivers of PD pathogenesis and putative PD biomarkers.", "tags": [{"end": 106, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 108, "tag": "GeneOrGenome"}, {"end": 114, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 128, "tag": "ManufacturedObject"}, {"end": 135, "start": 128, "tag": "PopulationGroup"}, {"end": 39, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 51, "tag": "CellComponent"}, {"end": 141, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 171, "tag": "ClinicalAttribute"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 154, "start": 142, "tag": "PathologicFunction"}, {"end": 114, "start": 108, "tag": "BiologicallyActiveSubstance"}]}{"id": "1114_3", "text": "This exploratory study evaluated the role of alpha-synuclein-positive extracellular vesicles and PARP-1 activity in the plasma of PD patients as non-invasive markers of the disease's severity and progression.", "tags": [{"end": 22, "start": 5, "tag": "ResearchActivity"}, {"end": 103, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 149, "tag": "Finding"}, {"end": 60, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 70, "tag": "CellComponent"}, {"end": 141, "start": 133, "tag": "PatientOrDisabledGroup"}, {"end": 165, "start": 158, "tag": "ClinicalAttribute"}, {"end": 126, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 196, "tag": "PathologicFunction"}, {"end": 207, "start": 196, "tag": "TemporalConcept"}, {"end": 157, "start": 145, "tag": "Finding"}, {"end": 191, "start": 183, "tag": "ClinicalAttribute"}, {"end": 191, "start": 183, "tag": "Finding"}]}{"id": "1114_4", "text": "MethodsWe collected plasma of 57 PD patients (discovery cohort 20, replication cohort 37) and compared it with 20 unaffected individuals, 20 individuals with clinically diagnosed Alzheimer's disease, and 20 individuals with dementia with Lewy bodies.", "tags": [{"end": 78, "start": 67, "tag": "CellFunction"}, {"end": 62, "start": 56, "tag": "PopulationGroup"}, {"end": 85, "start": 79, "tag": "PopulationGroup"}, {"end": 198, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 36, "tag": "PatientOrDisabledGroup"}, {"end": 232, "start": 224, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 46, "tag": "ResearchActivity"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 125, "tag": "PopulationGroup"}, {"end": 152, "start": 141, "tag": "PopulationGroup"}, {"end": 218, "start": 207, "tag": "PopulationGroup"}, {"end": 178, "start": 169, "tag": "HealthCareActivity"}, {"end": 249, "start": 238, "tag": "CellComponent"}, {"end": 249, "start": 224, "tag": "DiseaseOrSyndrome"}]}{"id": "1114_5", "text": "We analyzed alpha-synuclein-positive extracellular vesicles from platelet-free plasma by nanoscale flow cytometry and blood concentrations of poly ADP-ribose using sandwich ELISA kits.", "tags": [{"end": 113, "start": 89, "tag": "ResearchActivity"}, {"end": 138, "start": 118, "tag": "ResearchActivity"}, {"end": 157, "start": 142, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 27, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 65, "tag": "Cell"}, {"end": 59, "start": 37, "tag": "CellComponent"}, {"end": 85, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 138, "start": 124, "tag": "BiologicFunction"}, {"end": 183, "start": 164, "tag": "ResearchActivity"}]}{"id": "1114_6", "text": "ResultsMedian concentration of alpha-synuclein extracellular vesicles was significantly higher in PD patients compared to the other groups (Kruskal-Wallis, p < .0001).", "tags": [{"end": 46, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 47, "tag": "CellComponent"}, {"end": 109, "start": 101, "tag": "PatientOrDisabledGroup"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 14, "tag": "BiologicFunction"}]}{"id": "1114_7", "text": "In the discovery cohort, patients with higher alpha-synuclein extracellular vesicles had a higher Unified Parkinson Disease Rating Scale score (UPDRS III median = 22 vs.", "tags": [{"end": 61, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 17, "tag": "PopulationGroup"}, {"end": 84, "start": 62, "tag": "CellComponent"}, {"end": 33, "start": 25, "tag": "PatientOrDisabledGroup"}, {"end": 16, "start": 7, "tag": "ResearchActivity"}, {"end": 136, "start": 98, "tag": "HealthCareActivity"}, {"end": 149, "start": 144, "tag": "HealthCareActivity"}]}{"id": "1114_8", "text": "5, p = 0.045).", "tags": []}{"id": "1114_9", "text": "Seven out of 20 patients (35%) showed detectable PAR levels, with positive patients showing significantly higher levels of alpha-synuclein extracellular vesicles.", "tags": [{"end": 138, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 139, "tag": "CellComponent"}, {"end": 24, "start": 16, "tag": "PatientOrDisabledGroup"}, {"end": 83, "start": 75, "tag": "PatientOrDisabledGroup"}]}{"id": "1114_10", "text": "In the replication cohort, we did not observe a significant difference in the PAR-positive cases in relationship with UPDRS III.", "tags": [{"end": 18, "start": 7, "tag": "CellFunction"}, {"end": 112, "start": 100, "tag": "Finding"}, {"end": 25, "start": 19, "tag": "PopulationGroup"}, {"end": 123, "start": 118, "tag": "HealthCareActivity"}]}{"id": "1114_11", "text": "ConclusionsNon-invasive determination of alpha-synuclein-positive extracellular vesicles may provide a potential non-invasive marker of PD disease severity, and longitudinal studies are needed to evaluate the role of alpha-synuclein-positive extracellular vesicles as a marker of disease progression.", "tags": [{"end": 181, "start": 161, "tag": "ResearchActivity"}, {"end": 23, "start": 15, "tag": "Finding"}, {"end": 125, "start": 117, "tag": "Finding"}, {"end": 56, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 223, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 217, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 217, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 139, "tag": "ClinicalAttribute"}, {"end": 155, "start": 139, "tag": "Finding"}, {"end": 88, "start": 66, "tag": "CellComponent"}, {"end": 264, "start": 242, "tag": "CellComponent"}, {"end": 132, "start": 126, "tag": "ClinicalAttribute"}, {"end": 276, "start": 270, "tag": "ClinicalAttribute"}, {"end": 138, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 299, "start": 288, "tag": "PathologicFunction"}, {"end": 299, "start": 288, "tag": "TemporalConcept"}, {"end": 125, "start": 113, "tag": "Finding"}, {"end": 155, "start": 147, "tag": "ClinicalAttribute"}, {"end": 155, "start": 147, "tag": "Finding"}, {"end": 299, "start": 280, "tag": "PathologicFunction"}]}{"id": "1115_0", "text": "The molecular pathways that contribute to the onset of symptoms in tauopathy models, including Alzheimer's disease (AD), are difficult to distinguish because multiple changes can happen simultaneously at different stages of disease progression.", "tags": [{"end": 76, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 186, "tag": "TemporalConcept"}, {"end": 22, "start": 4, "tag": "CellFunction"}, {"end": 63, "start": 55, "tag": "SignOrSymptom"}, {"end": 243, "start": 232, "tag": "PathologicFunction"}, {"end": 243, "start": 232, "tag": "TemporalConcept"}, {"end": 114, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 220, "start": 214, "tag": "TemporalConcept"}, {"end": 51, "start": 46, "tag": "TemporalConcept"}, {"end": 83, "start": 77, "tag": "ResearchActivity"}, {"end": 243, "start": 224, "tag": "PathologicFunction"}]}{"id": "1115_1", "text": "Understanding early synaptic alterations and their supporting molecular pathways is essential to develop better pharmacological targets to treat AD.", "tags": [{"end": 40, "start": 20, "tag": "CellOrMolecularDysfunction"}, {"end": 80, "start": 62, "tag": "CellFunction"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 112, "tag": "Finding"}]}{"id": "1115_2", "text": "Here, we focus on an early onset rTg(Tau(P301L))4510 tauopathy mouse model that exhibits hyperexcitability in hippocampal neurons of adult mice that is correlated with presynaptic changes and increased extracellular glutamate levels.", "tags": [{"end": 62, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 225, "start": 216, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 216, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 133, "tag": "PopulationGroup"}, {"end": 179, "start": 168, "tag": "CellComponent"}, {"end": 106, "start": 89, "tag": "BiologicFunction"}, {"end": 74, "start": 63, "tag": "ResearchActivity"}, {"end": 40, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 27, "tag": "TemporalConcept"}, {"end": 143, "start": 139, "tag": "Eukaryote"}, {"end": 129, "start": 110, "tag": "Cell"}, {"end": 215, "start": 202, "tag": "CellComponent"}, {"end": 74, "start": 53, "tag": "ExperimentalModelOfDisease"}, {"end": 52, "start": 33, "tag": "ExperimentalModelOfDisease"}, {"end": 106, "start": 89, "tag": "PathologicFunction"}, {"end": 187, "start": 168, "tag": "Finding"}]}{"id": "1115_3", "text": "However, it is not clear if increased extracellular glutamate is caused by presynaptic changes alone, or if presynaptic changes are a contributing factor among other factors.", "tags": [{"end": 86, "start": 75, "tag": "CellComponent"}, {"end": 119, "start": 108, "tag": "CellComponent"}, {"end": 51, "start": 38, "tag": "CellComponent"}, {"end": 61, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 108, "tag": "Finding"}, {"end": 94, "start": 75, "tag": "Finding"}]}{"id": "1115_4", "text": "To determine whether pathogenic tau alters presynaptic function and glutamate release, we studied cultured hippocampal neurons at 14-18 days in vitro (DIV) from animals of both sexes to measure presynaptic changes in tau(P301L) positive mice.", "tags": [{"end": 77, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 98, "tag": "ResearchActivity"}, {"end": 54, "start": 43, "tag": "CellComponent"}, {"end": 205, "start": 194, "tag": "CellComponent"}, {"end": 140, "start": 136, "tag": "TemporalConcept"}, {"end": 149, "start": 141, "tag": "ResearchActivity"}, {"end": 35, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 227, "start": 217, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 227, "start": 217, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 107, "tag": "Cell"}, {"end": 168, "start": 161, "tag": "Eukaryote"}, {"end": 31, "start": 21, "tag": "PathologicFunction"}, {"end": 63, "start": 43, "tag": "CellFunction"}, {"end": 85, "start": 68, "tag": "CellFunction"}, {"end": 154, "start": 151, "tag": "TemporalConcept"}, {"end": 213, "start": 194, "tag": "Finding"}, {"end": 182, "start": 177, "tag": "OrganismAttribute"}, {"end": 241, "start": 217, "tag": "ExperimentalModelOfDisease"}]}{"id": "1115_5", "text": "We observed that presynaptic vesicles exhibit increased vesicular glutamate transporter 1 (VGlut1) using immunohistochemistry of fixed cells and an established pH-sensitive green fluorescent protein approach.", "tags": [{"end": 97, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 105, "tag": "ResearchActivity"}, {"end": 37, "start": 17, "tag": "CellComponent"}, {"end": 140, "start": 135, "tag": "Cell"}, {"end": 207, "start": 160, "tag": "ResearchActivity"}]}{"id": "1115_6", "text": "We show that tau(P301L) positive neurons exhibit a 40% increase in VGlut1 per vesicle compared to tau(P301L) negative littermates.", "tags": [{"end": 73, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 67, "tag": "GeneOrGenome"}, {"end": 23, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 40, "start": 33, "tag": "Cell"}, {"end": 85, "start": 78, "tag": "CellComponent"}]}{"id": "1115_7", "text": "Further, we use the extracellular glutamate reporter iGluSnFR to show that increased VGlut1 per vesicle directly translates into a 40% increase in extracellular glutamate.", "tags": [{"end": 91, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 85, "tag": "GeneOrGenome"}, {"end": 170, "start": 161, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 161, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 147, "tag": "CellComponent"}, {"end": 103, "start": 96, "tag": "CellComponent"}, {"end": 52, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 53, "tag": "BiologicallyActiveSubstance"}]}{"id": "1115_8", "text": "Together, these results show that increased extracellular glutamate levels observed in tau(P301L) mice are not caused by increased vesicle exocytosis probability but rather are directly related to increased VGlut1 transporters per synaptic vesicle.", "tags": [{"end": 67, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 131, "tag": "CellFunction"}, {"end": 97, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 98, "tag": "Eukaryote"}, {"end": 57, "start": 44, "tag": "CellComponent"}, {"end": 247, "start": 231, "tag": "CellComponent"}, {"end": 161, "start": 150, "tag": "Finding"}, {"end": 226, "start": 207, "tag": "AminoAcidPeptideOrProtein"}, {"end": 226, "start": 207, "tag": "BiologicallyActiveSubstance"}]}{"id": "1116_0", "text": "Background Roles for extracellular vesicles (EVs) enriched with micro-RNAs (miRNAs) have been proposed in Alzheimer's disease (AD) pathogenesis, leading to the discovery of blood miRNAs as AD biomarkers.", "tags": [{"end": 74, "start": 64, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 43, "start": 21, "tag": "CellComponent"}, {"end": 125, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 45, "tag": "CellComponent"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 131, "tag": "PathologicFunction"}, {"end": 178, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 202, "start": 192, "tag": "ClinicalAttribute"}, {"end": 82, "start": 76, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 185, "start": 179, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 82, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 185, "start": 179, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 160, "tag": "ResearchActivity"}, {"end": 74, "start": 64, "tag": "BiologicallyActiveSubstance"}]}{"id": "1116_1", "text": "However, the diagnostic utility of specific miRNAs is not consistent.", "tags": [{"end": 50, "start": 44, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 50, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 13, "tag": "Finding"}]}{"id": "1116_2", "text": "This study aimed to discover blood miRNAs that are differentially expressed in Korean AD patients, evaluate their clinical performance, and investigate their role in amyloidogenesis.", "tags": [{"end": 85, "start": 79, "tag": "PopulationGroup"}, {"end": 134, "start": 114, "tag": "HealthCareActivity"}, {"end": 181, "start": 166, "tag": "CellOrMolecularDysfunction"}, {"end": 75, "start": 51, "tag": "Finding"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 97, "start": 89, "tag": "PatientOrDisabledGroup"}, {"end": 41, "start": 35, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 41, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 75, "start": 66, "tag": "CellFunction"}]}{"id": "1116_3", "text": "Methods We discovered miRNAs differentially expressed in AD (N = 8) from cognitively normal participants (CN, N = 7) or Parkinson's disease (PD) patients (N = 8).", "tags": [{"end": 53, "start": 29, "tag": "Finding"}, {"end": 108, "start": 106, "tag": "Finding"}, {"end": 104, "start": 92, "tag": "PopulationGroup"}, {"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 145, "tag": "PatientOrDisabledGroup"}, {"end": 91, "start": 73, "tag": "Finding"}, {"end": 28, "start": 22, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 28, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 44, "tag": "CellFunction"}]}{"id": "1116_4", "text": "We evaluated the clinical performance of these miRNAs in plasma of subgroup (N = 99) and in plasma EVs isolated from the total cohort (N = 251).", "tags": [{"end": 37, "start": 17, "tag": "HealthCareActivity"}, {"end": 133, "start": 127, "tag": "PopulationGroup"}, {"end": 102, "start": 99, "tag": "CellComponent"}, {"end": 53, "start": 47, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 53, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1116_5", "text": "The effects of miRNAs on amyloidogenesis and on the regulation of their target genes were investigated in vitro.", "tags": [{"end": 40, "start": 25, "tag": "CellOrMolecularDysfunction"}, {"end": 111, "start": 103, "tag": "ResearchActivity"}, {"end": 21, "start": 15, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 21, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 4, "tag": "Finding"}, {"end": 84, "start": 72, "tag": "GeneOrGenome"}]}{"id": "1116_6", "text": "Results Among 17 upregulated and one downregulated miRNAs in AD (>twofold), miR-122-5p, miR-210-3p, and miR-590-5p were differentially expressed compared with CN or PD.", "tags": [{"end": 144, "start": 120, "tag": "Finding"}, {"end": 161, "start": 159, "tag": "Finding"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 51, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 57, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 50, "start": 37, "tag": "CellFunction"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 135, "tag": "CellFunction"}, {"end": 86, "start": 76, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 86, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 88, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 114, "start": 104, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 114, "start": 104, "tag": "BiologicallyActiveSubstance"}]}{"id": "1116_7", "text": "However, the diagnostic performance of the selected plasma or EV miRNAs in total participants were limited (area under the curve < 0.8).", "tags": [{"end": 35, "start": 24, "tag": "ClinicalAttribute"}, {"end": 35, "start": 24, "tag": "Finding"}, {"end": 93, "start": 81, "tag": "PopulationGroup"}, {"end": 64, "start": 62, "tag": "CellComponent"}, {"end": 128, "start": 108, "tag": "ResearchActivity"}, {"end": 71, "start": 65, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 71, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 13, "tag": "HealthCareActivity"}]}{"id": "1116_8", "text": "Nevertheless, levels of 3 miRNAs in plasma or plasma EVs of participants who were amyloid positron emission tomography (A beta-PET) positive were significantly higher than those from the A beta-PET negative participants (p < .05).", "tags": [{"end": 118, "start": 90, "tag": "HealthCareActivity"}, {"end": 130, "start": 127, "tag": "HealthCareActivity"}, {"end": 197, "start": 194, "tag": "HealthCareActivity"}, {"end": 72, "start": 60, "tag": "PopulationGroup"}, {"end": 219, "start": 207, "tag": "PopulationGroup"}, {"end": 56, "start": 53, "tag": "CellComponent"}, {"end": 89, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 26, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 32, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1116_9", "text": "The selected miRNAs induced A beta production (p < .05) through activation of beta-cleavage of amyloid precursor protein (CTF-beta; p < .01), and downregulated their target genes (ADAM metallopeptidase domain 10, Brain-derived neurotrophic factor, and Jagged canonical notch ligand 1; p < .05), which was further supported by pathway enrichment analysis of target genes of the miRNAs.", "tags": [{"end": 178, "start": 166, "tag": "GeneOrGenome"}, {"end": 211, "start": 180, "tag": "BiologicallyActiveSubstance"}, {"end": 246, "start": 213, "tag": "AminoAcidPeptideOrProtein"}, {"end": 246, "start": 213, "tag": "BiologicallyActiveSubstance"}, {"end": 283, "start": 252, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 180, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 13, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 383, "start": 377, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 19, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 383, "start": 377, "tag": "BiologicallyActiveSubstance"}, {"end": 353, "start": 326, "tag": "ResearchActivity"}, {"end": 120, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 146, "tag": "CellFunction"}, {"end": 45, "start": 28, "tag": "CellFunction"}, {"end": 283, "start": 252, "tag": "BiologicallyActiveSubstance"}, {"end": 369, "start": 357, "tag": "GeneOrGenome"}, {"end": 91, "start": 64, "tag": "CellFunction"}, {"end": 91, "start": 78, "tag": "CellFunction"}]}{"id": "1116_10", "text": "Conclusion In conclusion, despite of the limited diagnostic utility of selected miRNAs as plasma or plasma EV biomarkers, the discovered miRNAs may play a role in amyloidogenesis during AD onset and progression.", "tags": [{"end": 178, "start": 163, "tag": "CellOrMolecularDysfunction"}, {"end": 210, "start": 199, "tag": "PathologicFunction"}, {"end": 210, "start": 199, "tag": "TemporalConcept"}, {"end": 188, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 107, "tag": "CellComponent"}, {"end": 120, "start": 110, "tag": "ClinicalAttribute"}, {"end": 86, "start": 80, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 143, "start": 137, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 86, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 143, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 194, "start": 189, "tag": "TemporalConcept"}, {"end": 96, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 49, "tag": "Finding"}]}{"id": "1117_0", "text": "Aging shows a decline in overall physical function, and cellular senescence is the powerful catalyst leading to aging.", "tags": [{"end": 5, "start": 0, "tag": "BiologicFunction"}, {"end": 50, "start": 33, "tag": "BiologicFunction"}, {"end": 75, "start": 56, "tag": "CellFunction"}, {"end": 117, "start": 112, "tag": "BiologicFunction"}, {"end": 117, "start": 112, "tag": "CellFunction"}, {"end": 21, "start": 14, "tag": "Finding"}]}{"id": "1117_1", "text": "Considering that aging will be accompanied with the emergence of various aging-related diseases, research on new antiaging drugs is still valuable.", "tags": [{"end": 61, "start": 52, "tag": "TemporalConcept"}, {"end": 105, "start": 97, "tag": "ResearchActivity"}, {"end": 128, "start": 113, "tag": "PharmacologicSubstance"}, {"end": 22, "start": 17, "tag": "BiologicFunction"}, {"end": 78, "start": 73, "tag": "BiologicFunction"}, {"end": 22, "start": 17, "tag": "CellFunction"}, {"end": 78, "start": 73, "tag": "CellFunction"}, {"end": 95, "start": 73, "tag": "DiseaseOrSyndrome"}]}{"id": "1117_2", "text": "Extracellular vesicles (EVs), as tools for intercellular communication, are important components of the senescence-associated secretory phenotype (SASP), and they can play pathological roles in the process of cellular senescence.", "tags": [{"end": 151, "start": 147, "tag": "CellFunction"}, {"end": 228, "start": 209, "tag": "CellFunction"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 70, "start": 43, "tag": "CellFunction"}, {"end": 96, "start": 86, "tag": "CellComponent"}, {"end": 145, "start": 104, "tag": "CellFunction"}, {"end": 190, "start": 172, "tag": "PathologicFunction"}]}{"id": "1117_3", "text": "In addition, EVs are similar to their original cells in functions.", "tags": [{"end": 16, "start": 13, "tag": "CellComponent"}, {"end": 52, "start": 47, "tag": "Cell"}]}{"id": "1117_4", "text": "Therefore, EVs derived from pathological tissues or body fluids may be closely related to the progression of diseases and become potential biomarkers, while those from healthy cells may have therapeutic effects.", "tags": [{"end": 63, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 94, "tag": "PathologicFunction"}, {"end": 105, "start": 94, "tag": "TemporalConcept"}, {"end": 14, "start": 11, "tag": "CellComponent"}, {"end": 181, "start": 176, "tag": "Cell"}, {"end": 175, "start": 168, "tag": "OrganismAttribute"}, {"end": 149, "start": 129, "tag": "ClinicalAttribute"}, {"end": 210, "start": 191, "tag": "Finding"}, {"end": 48, "start": 28, "tag": "PathologicFunction"}]}{"id": "1117_5", "text": "Moreover, EVs are satisfactory drug carriers.", "tags": [{"end": 13, "start": 10, "tag": "CellComponent"}, {"end": 35, "start": 31, "tag": "PharmacologicSubstance"}, {"end": 44, "start": 36, "tag": "Finding"}]}{"id": "1117_6", "text": "At present, numerous studies have supported the idea that engineered EVs could improve drug targeting ability and utilization efficiency.", "tags": [{"end": 68, "start": 58, "tag": "GeneOrGenome"}, {"end": 72, "start": 69, "tag": "CellComponent"}, {"end": 109, "start": 102, "tag": "OrganismAttribute"}, {"end": 91, "start": 87, "tag": "PharmacologicSubstance"}, {"end": 28, "start": 21, "tag": "ResearchActivity"}, {"end": 136, "start": 114, "tag": "Finding"}]}{"id": "1117_7", "text": "Here, we summarize the characteristics of EVs and cellular senescence and focus on the diagnostic and therapeutic potential of EVs in various aging-related diseases, including Alzheimer disease, osteoporosis, cardiovascular disease, diabetes mellitus and its complications, and skin aging.", "tags": [{"end": 69, "start": 50, "tag": "CellFunction"}, {"end": 231, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 250, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 272, "start": 259, "tag": "PathologicFunction"}, {"end": 282, "start": 278, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 207, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 42, "tag": "CellComponent"}, {"end": 130, "start": 127, "tag": "CellComponent"}, {"end": 147, "start": 142, "tag": "BiologicFunction"}, {"end": 288, "start": 283, "tag": "BiologicFunction"}, {"end": 147, "start": 142, "tag": "CellFunction"}, {"end": 288, "start": 283, "tag": "CellFunction"}, {"end": 123, "start": 87, "tag": "HealthCareActivity"}, {"end": 164, "start": 142, "tag": "DiseaseOrSyndrome"}]}{"id": "1118_0", "text": "Alzheimer's disease (AD) is a neurodegenerative disorder for which there is currently no effective treatment.", "tags": [{"end": 56, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 99, "tag": "HealthCareActivity"}, {"end": 108, "start": 99, "tag": "ResearchActivity"}, {"end": 85, "start": 76, "tag": "TemporalConcept"}]}{"id": "1118_1", "text": "Despite advances in the molecular pathology of the characteristic histopathological markers of the disease (tau protein and beta-amyloid), their translation to the clinic has not provided the expected results.", "tags": [{"end": 43, "start": 24, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 83, "start": 66, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 136, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 84, "tag": "ClinicalAttribute"}, {"end": 111, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 8, "tag": "Finding"}, {"end": 156, "start": 145, "tag": "CellFunction"}, {"end": 170, "start": 164, "tag": "HealthCareRelatedOrganization"}, {"end": 119, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 145, "tag": "ResearchActivity"}]}{"id": "1118_2", "text": "Increasing evidences have demonstrated the presence of aggregates of TDP-43 (TAR DNA binding protein 43) in the postmortem brains of patients diagnosed with AD.", "tags": [{"end": 103, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 142, "tag": "HealthCareActivity"}, {"end": 75, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 112, "tag": "TemporalConcept"}, {"end": 51, "start": 43, "tag": "Finding"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 133, "tag": "PatientOrDisabledGroup"}, {"end": 129, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 11, "tag": "Finding"}, {"end": 103, "start": 77, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1118_3", "text": "The present research is focused on of the study of the pathological role of TDP-43 in AD.", "tags": [{"end": 82, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 42, "tag": "ResearchActivity"}, {"end": 72, "start": 55, "tag": "PathologicFunction"}]}{"id": "1118_4", "text": "For this purpose, immortalized lymphocytes samples from patients diagnosed with different severity of sporadic AD were used and the TDP-43 pathology was analyzed against controls, looking for differences in their fragmentation, phosphorylation and cellular location using Western blot and immunocytochemical techniques.", "tags": [{"end": 226, "start": 213, "tag": "Finding"}, {"end": 284, "start": 272, "tag": "ResearchActivity"}, {"end": 98, "start": 90, "tag": "ClinicalAttribute"}, {"end": 98, "start": 90, "tag": "Finding"}, {"end": 110, "start": 102, "tag": "TemporalConcept"}, {"end": 74, "start": 65, "tag": "HealthCareActivity"}, {"end": 138, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 170, "tag": "PopulationGroup"}, {"end": 161, "start": 153, "tag": "ResearchActivity"}, {"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 56, "tag": "PatientOrDisabledGroup"}, {"end": 148, "start": 139, "tag": "PathologicFunction"}, {"end": 148, "start": 139, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 203, "start": 192, "tag": "Finding"}, {"end": 243, "start": 228, "tag": "CellFunction"}, {"end": 318, "start": 289, "tag": "ResearchActivity"}]}{"id": "1118_5", "text": "The results revealed an increase in TDP-43 fragmentation, as well as increased phosphorylation and aberrant localization of TDP-43 in the cytosolic compartment of lymphocytes of patients diagnosed with severe AD.", "tags": [{"end": 56, "start": 43, "tag": "Finding"}, {"end": 159, "start": 138, "tag": "CellComponent"}, {"end": 174, "start": 163, "tag": "Cell"}, {"end": 120, "start": 99, "tag": "PathologicFunction"}, {"end": 196, "start": 187, "tag": "HealthCareActivity"}, {"end": 42, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 211, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 178, "tag": "PatientOrDisabledGroup"}, {"end": 208, "start": 202, "tag": "Finding"}, {"end": 94, "start": 79, "tag": "CellFunction"}]}{"id": "1118_6", "text": "Moreover, a fragment of approximately 25 KD was found in the extracellular medium of cells derived from severe AD individuals that seem to have prion-like characteristics.", "tags": [{"end": 149, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 114, "tag": "PopulationGroup"}, {"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 85, "tag": "Cell"}, {"end": 110, "start": 104, "tag": "Finding"}, {"end": 43, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1118_7", "text": "We conclude that TDP-43 plays a key role in AD pathogenesis and its cell to cell propagation.", "tags": [{"end": 23, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 47, "tag": "PathologicFunction"}, {"end": 92, "start": 68, "tag": "CellFunction"}]}{"id": "1119_0", "text": "Extracellular vesicles (EVs) are double membrane structures released by all cell types with identified roles in the generation, transportation, and degradation of amyloid-beta protein (A beta) oligomers in Alzheimer's disease (AD).", "tags": [{"end": 86, "start": 76, "tag": "Cell"}, {"end": 159, "start": 148, "tag": "NaturalPhenomenonOrProcess"}, {"end": 225, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 229, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 193, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 126, "start": 116, "tag": "TemporalConcept"}, {"end": 59, "start": 33, "tag": "CellComponent"}]}{"id": "1119_1", "text": "EVs are thus increasingly recognized to play a neuroprotective role in AD, through their ability to counteract the neurotoxic effects of A beta, possibly through interactions with specific receptors on cell membranes.", "tags": [{"end": 198, "start": 189, "tag": "AminoAcidPeptideOrProtein"}, {"end": 198, "start": 189, "tag": "BiologicallyActiveSubstance"}, {"end": 216, "start": 202, "tag": "CellComponent"}, {"end": 174, "start": 162, "tag": "Finding"}, {"end": 67, "start": 47, "tag": "Finding"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 89, "tag": "OrganismAttribute"}, {"end": 133, "start": 115, "tag": "InjuryOrPoisoning"}]}{"id": "1119_2", "text": "Our previous studies have identified the amylin receptor (AMY), particularly AMY3 subtype, as a mediator of the deleterious actions of A beta in vitro and in vivo experimental paradigms.", "tags": [{"end": 56, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 142, "tag": "ResearchActivity"}, {"end": 162, "start": 155, "tag": "ResearchActivity"}, {"end": 141, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 175, "start": 163, "tag": "ResearchActivity"}, {"end": 20, "start": 13, "tag": "ResearchActivity"}, {"end": 61, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 77, "tag": "BiologicallyActiveSubstance"}]}{"id": "1119_3", "text": "In the present study, we demonstrate that AMY3 enriched EVs can bind soluble oligomers of A beta and protect N2a cells against toxic effects of this peptide.", "tags": [{"end": 68, "start": 64, "tag": "CellFunction"}, {"end": 140, "start": 127, "tag": "InjuryOrPoisoning"}, {"end": 59, "start": 56, "tag": "CellComponent"}, {"end": 118, "start": 109, "tag": "Cell"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 156, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 69, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1119_4", "text": "The effect was specific to amylin receptor as it was blocked in the presence of amylin receptor antagonist AC253.", "tags": [{"end": 42, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 96, "tag": "BiologicFunction"}, {"end": 106, "start": 96, "tag": "PharmacologicSubstance"}, {"end": 42, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 68, "tag": "Finding"}, {"end": 112, "start": 107, "tag": "PharmacologicSubstance"}]}{"id": "1119_5", "text": "This notion was supported by reduced A beta binding to EVs from AMY depleted mice compared to those from wild type (Wt) mice.", "tags": [{"end": 67, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 44, "tag": "CellFunction"}, {"end": 58, "start": 55, "tag": "CellComponent"}, {"end": 43, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 77, "tag": "Eukaryote"}, {"end": 124, "start": 120, "tag": "Eukaryote"}, {"end": 118, "start": 116, "tag": "GeneOrGenome"}, {"end": 67, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 64, "tag": "ResearchActivity"}]}{"id": "1119_6", "text": "Finally, application of AMY3, but not Wt derived, EVs to hippocampal brain slices improved A beta-induced reduction of long-term potentiation, a cellular surrogate of memory.", "tags": [{"end": 173, "start": 167, "tag": "BiologicFunction"}, {"end": 81, "start": 57, "tag": "ResearchActivity"}, {"end": 53, "start": 50, "tag": "CellComponent"}, {"end": 97, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 106, "tag": "Finding"}, {"end": 115, "start": 106, "tag": "NaturalPhenomenonOrProcess"}, {"end": 40, "start": 38, "tag": "GeneOrGenome"}, {"end": 141, "start": 119, "tag": "BiologicFunction"}, {"end": 28, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 24, "tag": "BiologicallyActiveSubstance"}]}{"id": "1119_7", "text": "Collectively, our observations support the role of AMY receptors, particularly AMY3, in EVs as a potential therapeutic target for AD.", "tags": [{"end": 30, "start": 18, "tag": "Finding"}, {"end": 91, "start": 88, "tag": "CellComponent"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 97, "tag": "Finding"}]}{"id": "1120_0", "text": "Alzheimer's disease (AD), dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD) represent the three major neurodegenerative dementias characterized by abnormal brain protein accumulation.", "tags": [{"end": 56, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 40, "tag": "CellComponent"}, {"end": 90, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 163, "tag": "PathologicFunction"}]}{"id": "1120_1", "text": "In this study, we investigated extracellular vesicles (EVs) and neurotrophic factors in the cerebrospinal fluid (CSF) of 120 subjects: 36 with AD, 30 with DLB, 34 with FTD and 20 controls.", "tags": [{"end": 158, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 179, "tag": "PopulationGroup"}, {"end": 133, "start": 125, "tag": "PopulationGroup"}, {"end": 53, "start": 31, "tag": "CellComponent"}, {"end": 58, "start": 55, "tag": "CellComponent"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 84, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 64, "tag": "BiologicallyActiveSubstance"}]}{"id": "1120_2", "text": "Specifically, CSF EVs were analyzed by Nanoparticle Tracking Analysis and neurotrophic factors were measured with ELISA.", "tags": [{"end": 119, "start": 114, "tag": "ResearchActivity"}, {"end": 35, "start": 27, "tag": "ResearchActivity"}, {"end": 21, "start": 18, "tag": "CellComponent"}, {"end": 17, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 39, "tag": "ResearchActivity"}]}{"id": "1120_3", "text": "We found higher EV concentration and lower EV size in AD and DLB groups compared to the controls.", "tags": [{"end": 64, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 88, "tag": "PopulationGroup"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 16, "tag": "CellComponent"}, {"end": 45, "start": 43, "tag": "CellComponent"}, {"end": 50, "start": 46, "tag": "OrganismAttribute"}, {"end": 32, "start": 19, "tag": "BiologicFunction"}]}{"id": "1120_4", "text": "Classification tree analysis demonstrated EV size as the best parameter able to discriminate the patients from the controls (96.7% vs.", "tags": [{"end": 123, "start": 115, "tag": "PopulationGroup"}, {"end": 44, "start": 42, "tag": "CellComponent"}, {"end": 105, "start": 97, "tag": "PatientOrDisabledGroup"}, {"end": 28, "start": 0, "tag": "ResearchActivity"}, {"end": 49, "start": 45, "tag": "OrganismAttribute"}]}{"id": "1120_5", "text": "3.3%, respectively).", "tags": []}{"id": "1120_6", "text": "The diagnostic performance of the EV concentration/size ratio resulted in a fair discrimination level with an area under the curve of 0.74.", "tags": [{"end": 95, "start": 81, "tag": "BiologicFunction"}, {"end": 95, "start": 81, "tag": "CellFunction"}, {"end": 26, "start": 15, "tag": "ClinicalAttribute"}, {"end": 26, "start": 15, "tag": "Finding"}, {"end": 36, "start": 34, "tag": "CellComponent"}, {"end": 130, "start": 110, "tag": "ResearchActivity"}, {"end": 55, "start": 51, "tag": "OrganismAttribute"}, {"end": 50, "start": 37, "tag": "BiologicFunction"}, {"end": 26, "start": 4, "tag": "HealthCareActivity"}, {"end": 61, "start": 34, "tag": "ClinicalAttribute"}]}{"id": "1120_7", "text": "Moreover, the EV concentration/size ratio was associated with the p-Tau181/A beta 42 ratio in AD patients.", "tags": [{"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 14, "tag": "CellComponent"}, {"end": 84, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 97, "tag": "PatientOrDisabledGroup"}, {"end": 35, "start": 31, "tag": "OrganismAttribute"}, {"end": 30, "start": 17, "tag": "BiologicFunction"}, {"end": 41, "start": 14, "tag": "ClinicalAttribute"}, {"end": 74, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 66, "tag": "ClinicalAttribute"}]}{"id": "1120_8", "text": "In addition, we described altered levels of cystatin C and progranulin in the DLB and AD groups.", "tags": [{"end": 54, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 44, "tag": "PharmacologicSubstance"}, {"end": 70, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}]}{"id": "1120_9", "text": "We did not find any correlation between neurotrophic factors and EV parameters.", "tags": [{"end": 67, "start": 65, "tag": "CellComponent"}, {"end": 60, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 40, "tag": "BiologicallyActiveSubstance"}]}{"id": "1120_10", "text": "In conclusion, the results of this study suggest a common involvement of the endosomal pathway in neurodegenerative dementias, giving important insight into the molecular mechanisms underlying these pathologies.", "tags": [{"end": 210, "start": 199, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 58, "tag": "Finding"}, {"end": 40, "start": 35, "tag": "ResearchActivity"}, {"end": 94, "start": 77, "tag": "CellFunction"}, {"end": 181, "start": 161, "tag": "CellFunction"}, {"end": 125, "start": 98, "tag": "DiseaseOrSyndrome"}]}{"id": "1121_0", "text": "Neuronal extracellular vesicles (EVs) play important roles in intercellular communication and pathogenic protein propagation in neurological disease.", "tags": [{"end": 8, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 9, "tag": "CellComponent"}, {"end": 36, "start": 33, "tag": "CellComponent"}, {"end": 89, "start": 62, "tag": "CellFunction"}, {"end": 124, "start": 113, "tag": "Finding"}, {"end": 124, "start": 94, "tag": "PathologicFunction"}]}{"id": "1121_1", "text": "However, it remains unclear how cargoes are selectively packaged into neuronal EVs.", "tags": [{"end": 82, "start": 79, "tag": "CellComponent"}, {"end": 78, "start": 70, "tag": "Cell"}, {"end": 39, "start": 32, "tag": "CellComponent"}]}{"id": "1121_2", "text": "Here, we show that loss of the endosomal retromer complex leads to accumulation of EV cargoes including amyloid precursor protein (APP), synaptotagmin-4 (Syt4), and neuroglian (Nrg) at Drosophila motor neuron presynaptic terminals, resulting in increased release of these cargoes in EVs.", "tags": [{"end": 152, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 175, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 208, "start": 196, "tag": "Cell"}, {"end": 230, "start": 209, "tag": "CellComponent"}, {"end": 195, "start": 185, "tag": "Eukaryote"}, {"end": 134, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 131, "tag": "GeneOrGenome"}, {"end": 134, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 286, "start": 283, "tag": "CellComponent"}, {"end": 85, "start": 83, "tag": "CellComponent"}, {"end": 111, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 67, "tag": "Finding"}, {"end": 129, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 31, "tag": "CellComponent"}, {"end": 152, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 154, "tag": "GeneOrGenome"}, {"end": 180, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 175, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 279, "start": 272, "tag": "CellFunction"}, {"end": 265, "start": 255, "tag": "CellFunction"}]}{"id": "1121_3", "text": "By systematically exploring known retromer-dependent trafficking mechanisms, we show that EV regulation is separable from several previously identified roles of neuronal retromer.", "tags": [{"end": 75, "start": 34, "tag": "CellFunction"}, {"end": 92, "start": 90, "tag": "CellComponent"}, {"end": 169, "start": 161, "tag": "Cell"}, {"end": 42, "start": 34, "tag": "CellComponent"}, {"end": 178, "start": 170, "tag": "CellComponent"}]}{"id": "1121_4", "text": "Conversely, mutations in rab11 and rab4, regulators of endosome-plasma membrane recycling, cause reduced EV cargo levels, and rab11 suppresses cargo accumulation in retromer mutants.", "tags": [{"end": 39, "start": 35, "tag": "GeneOrGenome"}, {"end": 181, "start": 174, "tag": "CellOrMolecularDysfunction"}, {"end": 181, "start": 174, "tag": "GeneOrGenome"}, {"end": 107, "start": 105, "tag": "CellComponent"}, {"end": 161, "start": 149, "tag": "Finding"}, {"end": 21, "start": 12, "tag": "CellFunction"}, {"end": 21, "start": 12, "tag": "CellOrMolecularDysfunction"}, {"end": 70, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 108, "tag": "CellFunction"}, {"end": 148, "start": 143, "tag": "CellFunction"}, {"end": 30, "start": 25, "tag": "GeneOrGenome"}, {"end": 30, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 55, "tag": "CellFunction"}, {"end": 131, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 126, "tag": "GeneOrGenome"}, {"end": 131, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 165, "tag": "CellComponent"}]}{"id": "1121_5", "text": "Thus, EV traffic reflects a balance between Rab4/Rab11 recycling and retromer-dependent removal from EV precursor compartments.", "tags": [{"end": 126, "start": 114, "tag": "CellComponent"}, {"end": 8, "start": 6, "tag": "CellComponent"}, {"end": 103, "start": 101, "tag": "CellComponent"}, {"end": 64, "start": 44, "tag": "CellFunction"}, {"end": 16, "start": 6, "tag": "CellFunction"}, {"end": 95, "start": 69, "tag": "CellFunction"}]}{"id": "1121_6", "text": "Our data shed light on previous studies implicating Rab11 and retromer in competing pathways in Alzheimer's disease, and suggest that misregulated EV traffic may be an underlying defect.", "tags": [{"end": 185, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 147, "tag": "CellComponent"}, {"end": 92, "start": 84, "tag": "CellFunction"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 39, "start": 32, "tag": "ResearchActivity"}, {"end": 57, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 52, "tag": "GeneOrGenome"}, {"end": 57, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 62, "tag": "CellComponent"}, {"end": 157, "start": 134, "tag": "CellOrMolecularDysfunction"}]}{"id": "1122_0", "text": "Neurodegenerative diseases (NDs), such as Alzheimer's disease (AD), are driven by neuroinflammation triggered by activated microglial cells; hence, the phenotypic regulation of these cells is an appealing target for intervention.", "tags": [{"end": 139, "start": 123, "tag": "Cell"}, {"end": 162, "start": 152, "tag": "OrganismAttribute"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 183, "tag": "Cell"}, {"end": 99, "start": 82, "tag": "PathologicFunction"}, {"end": 228, "start": 205, "tag": "Finding"}]}{"id": "1122_1", "text": "Human adipose tissue-derived mesenchymal stem cells (hAD-MSCs) may be a potential therapeutic candidate to treat NDs given their immunomodulatory properties.", "tags": [{"end": 61, "start": 53, "tag": "Cell"}, {"end": 103, "start": 82, "tag": "HealthCareActivity"}, {"end": 156, "start": 129, "tag": "ClinicalAttribute"}, {"end": 116, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 29, "tag": "Cell"}, {"end": 51, "start": 0, "tag": "Cell"}]}{"id": "1122_2", "text": "Evidence suggests that the mechanism of action of hAD-MSCs is through their secretome, which includes secreted factors such as cytokines, chemokines, or growth factors as well as extracellular vesicles (EVs).", "tags": [{"end": 58, "start": 50, "tag": "Cell"}, {"end": 167, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 179, "tag": "CellComponent"}, {"end": 206, "start": 203, "tag": "CellComponent"}, {"end": 148, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 167, "start": 153, "tag": "BiologicallyActiveSubstance"}]}{"id": "1122_3", "text": "Recently, EVs have emerged as important mediators in cell communication given, they can transfer proteins, lipids, and RNA species (i.e., miRNA, mRNA, and tRNAs) to modulate recipient cells.", "tags": [{"end": 71, "start": 53, "tag": "CellFunction"}, {"end": 189, "start": 174, "tag": "Cell"}, {"end": 143, "start": 138, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 143, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 10, "tag": "CellComponent"}, {"end": 113, "start": 107, "tag": "Chemical"}, {"end": 149, "start": 145, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 49, "start": 40, "tag": "Finding"}, {"end": 130, "start": 119, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 160, "start": 155, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 160, "start": 155, "tag": "BiologicallyActiveSubstance"}]}{"id": "1122_4", "text": "However, the therapeutic potential of hAD-MSCs and their secreted EVs has not been fully elucidated with respect to human microglia.", "tags": [{"end": 46, "start": 38, "tag": "Cell"}, {"end": 69, "start": 66, "tag": "CellComponent"}, {"end": 121, "start": 116, "tag": "Eukaryote"}, {"end": 131, "start": 122, "tag": "Cell"}, {"end": 34, "start": 13, "tag": "HealthCareActivity"}]}{"id": "1122_5", "text": "In this study, we determined the therapeutic potential of different hAD-MSCs doses (200,000, 100,000, and 50,000 cells) or their secreted EVs (50, 20, or 10 mu g/ml), on human microglial cells (HMC3) that were activated by lipopolysaccharides (LPS).", "tags": [{"end": 76, "start": 68, "tag": "Cell"}, {"end": 242, "start": 223, "tag": "Chemical"}, {"end": 247, "start": 244, "tag": "Chemical"}, {"end": 141, "start": 138, "tag": "CellComponent"}, {"end": 118, "start": 113, "tag": "Cell"}, {"end": 192, "start": 187, "tag": "Cell"}, {"end": 175, "start": 170, "tag": "Eukaryote"}, {"end": 186, "start": 176, "tag": "Cell"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 54, "start": 33, "tag": "HealthCareActivity"}, {"end": 198, "start": 194, "tag": "Cell"}]}{"id": "1122_6", "text": "Upregulation of inducible nitric oxide synthase (iNOS), an activation marker of HMC3 cells, was prevented when they were cocultured with hAD-MSCs and EVs.", "tags": [{"end": 12, "start": 0, "tag": "CellFunction"}, {"end": 47, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 121, "tag": "ResearchActivity"}, {"end": 145, "start": 137, "tag": "Cell"}, {"end": 53, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 150, "tag": "CellComponent"}, {"end": 90, "start": 80, "tag": "Cell"}, {"end": 76, "start": 70, "tag": "ClinicalAttribute"}, {"end": 47, "start": 16, "tag": "BiologicallyActiveSubstance"}]}{"id": "1122_7", "text": "Moreover, hAD-MSCs inhibited the secretion of proinflammatory factors, such as IL-6, IL-8, and MCP-1, while their secreted EVs promoted the expression of anti-inflammatory mediators such as IL-10 or TIMP-1 in activated microglia.", "tags": [{"end": 18, "start": 10, "tag": "Cell"}, {"end": 42, "start": 33, "tag": "BiologicFunction"}, {"end": 42, "start": 33, "tag": "CellFunction"}, {"end": 83, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 79, "tag": "GeneOrGenome"}, {"end": 100, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 154, "tag": "PharmacologicSubstance"}, {"end": 195, "start": 190, "tag": "AminoAcidPeptideOrProtein"}, {"end": 195, "start": 190, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 190, "tag": "GeneOrGenome"}, {"end": 205, "start": 199, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 123, "tag": "CellComponent"}, {"end": 228, "start": 219, "tag": "Cell"}, {"end": 61, "start": 46, "tag": "PathologicFunction"}, {"end": 89, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 140, "tag": "CellFunction"}, {"end": 205, "start": 199, "tag": "BiologicallyActiveSubstance"}]}{"id": "1122_8", "text": "The present data therefore support a role for hAD-MSCs and their secreted EVs, as potential therapeutic candidates for the treatment of NDs.", "tags": [{"end": 54, "start": 46, "tag": "Cell"}, {"end": 139, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 74, "tag": "CellComponent"}, {"end": 16, "start": 12, "tag": "ResearchActivity"}, {"end": 132, "start": 123, "tag": "HealthCareActivity"}, {"end": 132, "start": 123, "tag": "ResearchActivity"}, {"end": 114, "start": 82, "tag": "Finding"}]}{"id": "1123_0", "text": "Mitochondrial dysfunction is an established hallmark of aging and neurodegenerative disorders such as Down syndrome (DS) and Alzheimer's disease (AD).", "tags": [{"end": 115, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 144, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 56, "tag": "BiologicFunction"}, {"end": 61, "start": 56, "tag": "CellFunction"}, {"end": 93, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 44, "tag": "Finding"}]}{"id": "1123_1", "text": "Using a high-resolution density gradient separation of extracellular vesicles (EVs) isolated from murine and human DS and diploid control brains, we identify and characterize a previously unknown population of double-membraned EVs containing multiple mitochondria! proteins distinct from previously described EV subtypes, including microvesicles and exosomes.", "tags": [{"end": 104, "start": 98, "tag": "Eukaryote"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 122, "tag": "OrganismAttribute"}, {"end": 129, "start": 122, "tag": "Cell"}, {"end": 345, "start": 332, "tag": "CellComponent"}, {"end": 263, "start": 251, "tag": "CellComponent"}, {"end": 273, "start": 265, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 55, "tag": "CellComponent"}, {"end": 82, "start": 79, "tag": "CellComponent"}, {"end": 230, "start": 210, "tag": "CellComponent"}, {"end": 311, "start": 309, "tag": "CellComponent"}, {"end": 358, "start": 350, "tag": "CellComponent"}, {"end": 114, "start": 109, "tag": "Eukaryote"}, {"end": 206, "start": 196, "tag": "PopulationGroup"}, {"end": 144, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 8, "tag": "ResearchActivity"}]}{"id": "1123_2", "text": "We term these newly identified mitochondria-derived EVs mitovesicles.", "tags": [{"end": 43, "start": 31, "tag": "CellComponent"}, {"end": 55, "start": 52, "tag": "CellComponent"}, {"end": 68, "start": 56, "tag": "CellComponent"}]}{"id": "1123_3", "text": "We demonstrate that brain-derived mitovesicles contain a specific subset of mitochondria! constituents and that their levels and cargo are altered during pathophysiological processes where mitochondria! dysfunction occurs, including in DS.", "tags": [{"end": 238, "start": 236, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 76, "tag": "CellComponent"}, {"end": 201, "start": 189, "tag": "CellComponent"}, {"end": 214, "start": 203, "tag": "PathologicFunction"}, {"end": 25, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 154, "tag": "PathologicFunction"}, {"end": 134, "start": 129, "tag": "CellFunction"}, {"end": 46, "start": 34, "tag": "CellComponent"}]}{"id": "1123_4", "text": "The development of a method for the selective isolation of mitovesicles paves the way for the characterization in vivo of biological processes connecting EV biology and mitochondria dynamics and for innovative therapeutic and diagnostic strategies.", "tags": [{"end": 71, "start": 36, "tag": "ResearchActivity"}, {"end": 164, "start": 157, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 142, "start": 122, "tag": "BiologicFunction"}, {"end": 181, "start": 169, "tag": "CellComponent"}, {"end": 156, "start": 154, "tag": "CellComponent"}, {"end": 118, "start": 111, "tag": "ResearchActivity"}, {"end": 15, "start": 4, "tag": "BiologicFunction"}, {"end": 15, "start": 4, "tag": "CellFunction"}, {"end": 27, "start": 21, "tag": "ResearchActivity"}, {"end": 27, "start": 21, "tag": "HealthCareActivity"}, {"end": 110, "start": 94, "tag": "ResearchActivity"}, {"end": 190, "start": 182, "tag": "NaturalPhenomenonOrProcess"}, {"end": 247, "start": 237, "tag": "ResearchActivity"}, {"end": 164, "start": 157, "tag": "BiologicFunction"}, {"end": 247, "start": 199, "tag": "HealthCareActivity"}]}{"id": "1124_0", "text": "Extracellular vesicles like exosomes are secreted by numerous cell types in a variety of tissues.", "tags": [{"end": 72, "start": 62, "tag": "Cell"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 36, "start": 28, "tag": "CellComponent"}, {"end": 96, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1124_1", "text": "Exosomes have been implicated in both aging and age-related disorders like Alzheimer's disease (AD).", "tags": [{"end": 94, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 38, "tag": "BiologicFunction"}, {"end": 43, "start": 38, "tag": "CellFunction"}, {"end": 8, "start": 0, "tag": "CellComponent"}, {"end": 69, "start": 48, "tag": "DiseaseOrSyndrome"}]}{"id": "1124_2", "text": "However, how aging and AD affect exosome biogenesis within and across cell types is poorly understood.", "tags": [{"end": 80, "start": 70, "tag": "Cell"}, {"end": 25, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 13, "tag": "BiologicFunction"}, {"end": 18, "start": 13, "tag": "CellFunction"}, {"end": 51, "start": 41, "tag": "CellFunction"}, {"end": 40, "start": 33, "tag": "CellComponent"}]}{"id": "1124_3", "text": "Moreover, cells acquire characteristics based on tissue niche, but the impact of tissue residence on cell type exosome biogenesis is unknown.", "tags": [{"end": 15, "start": 10, "tag": "Cell"}, {"end": 105, "start": 101, "tag": "Cell"}, {"end": 129, "start": 119, "tag": "CellFunction"}, {"end": 55, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 111, "tag": "CellComponent"}]}{"id": "1124_4", "text": "We explored the Tabula Muris Senis, Mayo RNA-seq and Rush Religious Order Study/Memory and Aging Project data sets to characterize the cell and tissue-specific effects of aging and AD on genes involved in exosome biogenesis.", "tags": [{"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 135, "tag": "Cell"}, {"end": 104, "start": 80, "tag": "ResearchActivity"}, {"end": 176, "start": 171, "tag": "BiologicFunction"}, {"end": 176, "start": 171, "tag": "CellFunction"}, {"end": 223, "start": 213, "tag": "CellFunction"}, {"end": 150, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 205, "tag": "CellComponent"}, {"end": 34, "start": 16, "tag": "ResearchActivity"}, {"end": 48, "start": 36, "tag": "ResearchActivity"}, {"end": 79, "start": 53, "tag": "ResearchActivity"}, {"end": 114, "start": 105, "tag": "ResearchActivity"}]}{"id": "1124_5", "text": "Specifically, we examined the age-dependent expression (age coefficient) of genes involved in exosome biogenesis (22 genes), exosome cargo (3 genes), and senescence (5 genes).", "tags": [{"end": 164, "start": 154, "tag": "Finding"}, {"end": 164, "start": 154, "tag": "TemporalConcept"}, {"end": 164, "start": 154, "tag": "CellFunction"}, {"end": 33, "start": 30, "tag": "OrganismAttribute"}, {"end": 59, "start": 56, "tag": "OrganismAttribute"}, {"end": 112, "start": 94, "tag": "CellFunction"}, {"end": 138, "start": 125, "tag": "CellFunction"}, {"end": 101, "start": 94, "tag": "CellComponent"}, {"end": 132, "start": 125, "tag": "CellComponent"}, {"end": 54, "start": 44, "tag": "CellFunction"}]}{"id": "1124_6", "text": "Of the 131 cell populations (cell type x tissue) studied, 95 had at least 1 exosome biogenesis gene affected by age.", "tags": [{"end": 27, "start": 11, "tag": "Cell"}, {"end": 115, "start": 112, "tag": "OrganismAttribute"}, {"end": 38, "start": 29, "tag": "Cell"}, {"end": 94, "start": 76, "tag": "CellFunction"}, {"end": 47, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 76, "tag": "CellComponent"}, {"end": 99, "start": 95, "tag": "GeneOrGenome"}]}{"id": "1124_7", "text": "The most common gene/transcript increased by age was charged multivesicular body protein 2A (CHMP2A) (54 cell populations).", "tags": [{"end": 91, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "GeneOrGenome"}, {"end": 121, "start": 105, "tag": "Cell"}, {"end": 31, "start": 21, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 48, "start": 45, "tag": "OrganismAttribute"}, {"end": 20, "start": 16, "tag": "GeneOrGenome"}, {"end": 99, "start": 93, "tag": "BiologicallyActiveSubstance"}]}{"id": "1124_8", "text": "The most common gene/transcript decreased by age was syndecan-binding protein (SDCBP) (58 cell populations).", "tags": [{"end": 77, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 79, "tag": "GeneOrGenome"}, {"end": 84, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 90, "tag": "Cell"}, {"end": 31, "start": 21, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 48, "start": 45, "tag": "OrganismAttribute"}, {"end": 20, "start": 16, "tag": "GeneOrGenome"}, {"end": 84, "start": 79, "tag": "BiologicallyActiveSubstance"}]}{"id": "1124_9", "text": "The senescence-associated genes cyclin-dependent kinase 1A (CDKN1A) and CDKN2A were not related to changes in CHMP2A and SDCBP and were altered by age in fewer cell populations.", "tags": [{"end": 66, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 60, "tag": "GeneOrGenome"}, {"end": 78, "start": 72, "tag": "GeneOrGenome"}, {"end": 78, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 110, "tag": "GeneOrGenome"}, {"end": 126, "start": 121, "tag": "GeneOrGenome"}, {"end": 126, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 160, "tag": "Cell"}, {"end": 150, "start": 147, "tag": "OrganismAttribute"}, {"end": 66, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 4, "tag": "TemporalConcept"}, {"end": 14, "start": 4, "tag": "Finding"}, {"end": 14, "start": 4, "tag": "CellFunction"}, {"end": 58, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 121, "tag": "BiologicallyActiveSubstance"}]}{"id": "1124_10", "text": "Finally, individuals with AD had decreased CHMP2A and increased SDCBP expression, opposite of what is observed during mouse aging in the absence of disease.", "tags": [{"end": 49, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 43, "tag": "GeneOrGenome"}, {"end": 69, "start": 64, "tag": "GeneOrGenome"}, {"end": 69, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 9, "tag": "PopulationGroup"}, {"end": 28, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 124, "tag": "BiologicFunction"}, {"end": 129, "start": 124, "tag": "CellFunction"}, {"end": 123, "start": 118, "tag": "Eukaryote"}, {"end": 49, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 70, "tag": "CellFunction"}, {"end": 69, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 137, "tag": "Finding"}]}{"id": "1124_11", "text": "These findings indicate that exosome biogenesis gene expression is modified by age in many cell populations mostly independent of senescence, and may be further altered in AD.", "tags": [{"end": 140, "start": 130, "tag": "Finding"}, {"end": 140, "start": 130, "tag": "TemporalConcept"}, {"end": 140, "start": 130, "tag": "CellFunction"}, {"end": 63, "start": 48, "tag": "CellFunction"}, {"end": 107, "start": 91, "tag": "Cell"}, {"end": 82, "start": 79, "tag": "OrganismAttribute"}, {"end": 174, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 29, "tag": "CellFunction"}, {"end": 36, "start": 29, "tag": "CellComponent"}, {"end": 126, "start": 115, "tag": "Finding"}]}{"id": "1125_0", "text": "Inflammation plays a key role in the development of age-related diseases.", "tags": [{"end": 12, "start": 0, "tag": "PathologicFunction"}, {"end": 48, "start": 37, "tag": "BiologicFunction"}, {"end": 48, "start": 37, "tag": "CellFunction"}, {"end": 72, "start": 52, "tag": "DiseaseOrSyndrome"}]}{"id": "1125_1", "text": "In Alzheimer's disease, neuronal cell death is attributed to amyloidbeta oligomers that trigger microglial activation.", "tags": [{"end": 43, "start": 24, "tag": "CellFunction"}, {"end": 22, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 96, "tag": "CellFunction"}, {"end": 82, "start": 61, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1125_2", "text": "Stem cells have shown promise as therapies for inflammatory diseases-because of their paracrine activity combined with their ability to respond to the inflammatory environment.", "tags": [{"end": 104, "start": 86, "tag": "CellFunction"}, {"end": 68, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 33, "tag": "HealthCareActivity"}, {"end": 132, "start": 125, "tag": "OrganismAttribute"}, {"end": 10, "start": 0, "tag": "Cell"}, {"end": 175, "start": 151, "tag": "Finding"}]}{"id": "1125_3", "text": "However, the mechanisms underlying stem cell-promoted neurological recovery are poorly understood.", "tags": [{"end": 75, "start": 54, "tag": "BiologicFunction"}, {"end": 75, "start": 54, "tag": "HealthCareActivity"}, {"end": 44, "start": 35, "tag": "Cell"}]}{"id": "1125_4", "text": "To elucidate these mechanisms, we first primed stem cells with the secretome of lipopolysaccharide- or amyloidbeta-activated microglia.", "tags": [{"end": 99, "start": 80, "tag": "Chemical"}, {"end": 134, "start": 125, "tag": "Cell"}, {"end": 39, "start": 34, "tag": "TemporalConcept"}, {"end": 57, "start": 47, "tag": "Cell"}, {"end": 114, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 40, "tag": "ResearchActivity"}]}{"id": "1125_5", "text": "Then, we compared the immunomodulatory effects of extracellular vesicles (EVs) secreted from primed and nonprimed stem cells.", "tags": [{"end": 72, "start": 50, "tag": "CellComponent"}, {"end": 77, "start": 74, "tag": "CellComponent"}, {"end": 46, "start": 22, "tag": "Finding"}, {"end": 124, "start": 114, "tag": "Cell"}, {"end": 99, "start": 93, "tag": "ResearchActivity"}, {"end": 113, "start": 104, "tag": "ResearchActivity"}]}{"id": "1125_6", "text": "Our results demonstrate that EVs from primed cells are more effective in inhibiting microglia and astrocyte activation, amyloid deposition, demyelination, memory loss and motor and anxiety-like behavioral dysfunction, compared to EVs from non-primed cells.", "tags": [{"end": 216, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 140, "tag": "PathologicFunction"}, {"end": 32, "start": 29, "tag": "CellComponent"}, {"end": 233, "start": 230, "tag": "CellComponent"}, {"end": 50, "start": 45, "tag": "Cell"}, {"end": 255, "start": 250, "tag": "Cell"}, {"end": 127, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 84, "tag": "Cell"}, {"end": 107, "start": 98, "tag": "Cell"}, {"end": 83, "start": 73, "tag": "BiologicFunction"}, {"end": 166, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 155, "tag": "SignOrSymptom"}, {"end": 44, "start": 38, "tag": "ResearchActivity"}, {"end": 249, "start": 239, "tag": "ResearchActivity"}, {"end": 138, "start": 120, "tag": "PathologicFunction"}]}{"id": "1125_7", "text": "MicroRNA (miRNA) profiling revealed the upregulation of at least 19 miRNAs on primed-stem cell EVs.", "tags": [{"end": 8, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 8, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 17, "tag": "ResearchActivity"}, {"end": 15, "start": 10, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 15, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 95, "tag": "CellComponent"}, {"end": 52, "start": 40, "tag": "CellFunction"}, {"end": 74, "start": 68, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 74, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 85, "tag": "Cell"}]}{"id": "1125_8", "text": "The miRNA targets were identified, and KEGG pathway analysis showed that the overexpressed miRNAs target key genes on the toll-like receptor-4 (TLR4) signaling pathway.", "tags": [{"end": 90, "start": 77, "tag": "CellFunction"}, {"end": 167, "start": 150, "tag": "CellFunction"}, {"end": 148, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 144, "tag": "GeneOrGenome"}, {"end": 148, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 9, "start": 4, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 9, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 91, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 97, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 39, "tag": "ResearchActivity"}, {"end": 142, "start": 122, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1125_9", "text": "Overall, our results demonstrate that priming mesenchymal stem cells (MSCs) with the secretome of activated microglia results in the release of miRNAs from EVs with enhanced immune regulatory potential able to fight neuro-inflammation.", "tags": [{"end": 201, "start": 174, "tag": "Finding"}, {"end": 159, "start": 156, "tag": "CellComponent"}, {"end": 234, "start": 216, "tag": "PathologicFunction"}, {"end": 150, "start": 144, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 150, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 98, "tag": "Cell"}, {"end": 74, "start": 70, "tag": "Cell"}, {"end": 68, "start": 46, "tag": "Cell"}, {"end": 45, "start": 38, "tag": "ResearchActivity"}, {"end": 94, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 133, "tag": "CellFunction"}]}{"id": "1126_0", "text": "Alzheimer's disease (AD), a progressive neurodegenerative disease, affects approximately 50 million people worldwide, which warrants the search for reliable new biomarkers for early diagnosis of AD.", "tags": [{"end": 143, "start": 137, "tag": "ResearchActivity"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 161, "tag": "ClinicalAttribute"}, {"end": 106, "start": 100, "tag": "PopulationGroup"}, {"end": 191, "start": 182, "tag": "HealthCareActivity"}, {"end": 39, "start": 28, "tag": "TemporalConcept"}, {"end": 191, "start": 176, "tag": "HealthCareActivity"}, {"end": 65, "start": 40, "tag": "DiseaseOrSyndrome"}]}{"id": "1126_1", "text": "Brain-derived exosomal (BDE) proteins, which are extracellular nanovesicles released by all cell lineages of the central nervous system, have been focused as biomarkers for diagnosis, screening, prognosis prediction, and monitoring in AD.", "tags": [{"end": 105, "start": 97, "tag": "CellFunction"}, {"end": 204, "start": 195, "tag": "HealthCareActivity"}, {"end": 37, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 237, "start": 235, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 92, "tag": "Cell"}, {"end": 168, "start": 158, "tag": "ClinicalAttribute"}, {"end": 135, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 49, "tag": "CellComponent"}, {"end": 182, "start": 173, "tag": "HealthCareActivity"}, {"end": 193, "start": 184, "tag": "HealthCareActivity"}, {"end": 193, "start": 184, "tag": "ResearchActivity"}, {"end": 231, "start": 221, "tag": "HealthCareActivity"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 14, "tag": "CellComponent"}]}{"id": "1126_2", "text": "This review focused on the possibility of BDE proteins as AD biomarkers.", "tags": [{"end": 54, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 61, "tag": "ClinicalAttribute"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}]}{"id": "1126_3", "text": "The articles published prior to 26 January 2021 were searched in PubMed, EMBASE, Web of Science, and Cochrane Library to identify all relevant studies that reported exosome biomarkers in blood samples of patients with AD.", "tags": [{"end": 200, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 65, "tag": "HealthCareRelatedOrganization"}, {"end": 95, "start": 81, "tag": "HealthCareRelatedOrganization"}, {"end": 79, "start": 73, "tag": "HealthCareRelatedOrganization"}, {"end": 220, "start": 218, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 204, "tag": "PatientOrDisabledGroup"}, {"end": 183, "start": 173, "tag": "ClinicalAttribute"}, {"end": 150, "start": 143, "tag": "ResearchActivity"}, {"end": 172, "start": 165, "tag": "CellComponent"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 117, "start": 101, "tag": "ResearchActivity"}]}{"id": "1126_4", "text": "From 342 articles, 20 studies were selected for analysis.", "tags": [{"end": 56, "start": 48, "tag": "ResearchActivity"}, {"end": 29, "start": 22, "tag": "ResearchActivity"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}]}{"id": "1126_5", "text": "We conducted a meta-analysis of six BDE proteins and found that levels of amyloid-beta 42 (standardized mean difference (SMD) = 1.534, 95% confidence interval [CI]: 0.595-2.474), total-tau (SMD = 1.224, 95% CI: 0.534-1.915), tau phosphorylated at threonine 181 (SMD = 4.038, 95% CI: 2.312-5.764), and tau phosphorylated at serine 396 (SMD = 2.511, 95% CI: 0.795-4.227) were significantly different in patients with AD compared to those in control.", "tags": [{"end": 28, "start": 15, "tag": "ResearchActivity"}, {"end": 260, "start": 247, "tag": "AminoAcidPeptideOrProtein"}, {"end": 319, "start": 305, "tag": "CellFunction"}, {"end": 158, "start": 139, "tag": "ResearchActivity"}, {"end": 162, "start": 160, "tag": "ResearchActivity"}, {"end": 209, "start": 207, "tag": "ResearchActivity"}, {"end": 281, "start": 279, "tag": "ResearchActivity"}, {"end": 354, "start": 352, "tag": "ResearchActivity"}, {"end": 162, "start": 160, "tag": "GeneOrGenome"}, {"end": 209, "start": 207, "tag": "GeneOrGenome"}, {"end": 281, "start": 279, "tag": "GeneOrGenome"}, {"end": 354, "start": 352, "tag": "GeneOrGenome"}, {"end": 48, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 417, "start": 415, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 409, "start": 401, "tag": "PatientOrDisabledGroup"}, {"end": 188, "start": 179, "tag": "AminoAcidPeptideOrProtein"}, {"end": 228, "start": 225, "tag": "AminoAcidPeptideOrProtein"}, {"end": 304, "start": 301, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 179, "tag": "BiologicallyActiveSubstance"}, {"end": 228, "start": 225, "tag": "BiologicallyActiveSubstance"}, {"end": 304, "start": 301, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 243, "start": 229, "tag": "CellFunction"}, {"end": 333, "start": 323, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1126_6", "text": "Whereas, those of p-tyrosine-insulin receptor substrate-1 and heat shock protein 70 did not show significant differences.", "tags": [{"end": 83, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 109, "tag": "Finding"}, {"end": 57, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 18, "tag": "BiologicallyActiveSubstance"}]}{"id": "1126_7", "text": "This review suggested that A beta 42, t-tau, p-T181-tau, and p-S396-tau could be effective in diagnosing AD as blood biomarkers, despite the limitation in the meta-analysis based on the availability of data.", "tags": [{"end": 104, "start": 94, "tag": "HealthCareActivity"}, {"end": 172, "start": 159, "tag": "ResearchActivity"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 117, "tag": "ClinicalAttribute"}, {"end": 206, "start": 202, "tag": "ResearchActivity"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 36, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 27, "tag": "BiologicallyActiveSubstance"}]}{"id": "1126_8", "text": "Therefore, certain BDE proteins could be used as effective biomarkers for AD.", "tags": [{"end": 31, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 59, "tag": "ClinicalAttribute"}]}{"id": "1127_0", "text": "Alzheimer's disease (AD) animal studies have reported that mesenchymal stem cells (MSCs) have therapeutic effects; however, clinical trial results are controversial.", "tags": [{"end": 146, "start": 133, "tag": "ResearchActivity"}, {"end": 138, "start": 124, "tag": "ResearchActivity"}, {"end": 31, "start": 25, "tag": "Eukaryote"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 94, "tag": "Finding"}, {"end": 39, "start": 32, "tag": "ResearchActivity"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 81, "start": 59, "tag": "Cell"}]}{"id": "1127_1", "text": "Neprilysin (NEP) is the main cleavage enzyme of beta-amyloid (A beta), which plays a major role in the pathology and etiology of AD.", "tags": [{"end": 10, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 29, "tag": "CellFunction"}, {"end": 37, "start": 29, "tag": "CellComponent"}, {"end": 125, "start": 117, "tag": "Finding"}, {"end": 131, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 103, "tag": "PathologicFunction"}, {"end": 112, "start": 103, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 44, "start": 38, "tag": "BiologicallyActiveSubstance"}]}{"id": "1127_2", "text": "We evaluated whether transplantation of MSCs with NEP gene modification enhances the therapeutic effects in an AD animal model and then investigated these pathomechanisms.", "tags": [{"end": 53, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 54, "tag": "ResearchActivity"}, {"end": 71, "start": 54, "tag": "CellFunction"}, {"end": 104, "start": 85, "tag": "Finding"}, {"end": 44, "start": 40, "tag": "Cell"}, {"end": 36, "start": 21, "tag": "HealthCareActivity"}, {"end": 126, "start": 111, "tag": "ExperimentalModelOfDisease"}, {"end": 170, "start": 155, "tag": "PathologicFunction"}]}{"id": "1127_3", "text": "We manufactured NEP gene-enhanced human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and intravenously transplanted them in A beta(1-42)-injected AD animal models.", "tags": [{"end": 19, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 115, "tag": "HealthCareActivity"}, {"end": 127, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 34, "tag": "Eukaryote"}, {"end": 95, "start": 87, "tag": "Cell"}, {"end": 85, "start": 63, "tag": "Cell"}, {"end": 54, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 136, "tag": "ExperimentalModelOfDisease"}, {"end": 85, "start": 34, "tag": "Cell"}]}{"id": "1127_4", "text": "We compared the differences in behavioral tests and immunohistochemical assays between four groups: normal, A beta(1-42) injection, naive hUC-MSCs, and NEP-enhanced hUC-MSCs.", "tags": [{"end": 47, "start": 31, "tag": "HealthCareActivity"}, {"end": 47, "start": 42, "tag": "ResearchActivity"}, {"end": 47, "start": 42, "tag": "HealthCareActivity"}, {"end": 130, "start": 121, "tag": "HealthCareActivity"}, {"end": 114, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 100, "tag": "Finding"}, {"end": 146, "start": 138, "tag": "Cell"}, {"end": 173, "start": 165, "tag": "Cell"}, {"end": 27, "start": 16, "tag": "Finding"}, {"end": 78, "start": 52, "tag": "ResearchActivity"}, {"end": 155, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 152, "tag": "BiologicallyActiveSubstance"}]}{"id": "1127_5", "text": "Both naive and NEP-enhanced hUC-MSC groups showed significant improvements in memory compared to the A beta(1-42) injection group.", "tags": [{"end": 84, "start": 78, "tag": "BiologicFunction"}, {"end": 84, "start": 78, "tag": "Finding"}, {"end": 123, "start": 114, "tag": "HealthCareActivity"}, {"end": 129, "start": 124, "tag": "PopulationGroup"}, {"end": 35, "start": 28, "tag": "Cell"}, {"end": 18, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 15, "tag": "BiologicallyActiveSubstance"}]}{"id": "1127_6", "text": "There was no significant difference between naive and NEP-enhanced hUC-MSC groups.", "tags": [{"end": 35, "start": 10, "tag": "Finding"}, {"end": 74, "start": 67, "tag": "Cell"}, {"end": 57, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 54, "tag": "BiologicallyActiveSubstance"}]}{"id": "1127_7", "text": "There was a significant decrease in Congo red, BACE-1, GFAP, and Iba-1 and a significant increase in BDNF, NeuN, and NEP in both hUC-MSC groups compared to the A beta(1-42) injection group.", "tags": [{"end": 45, "start": 36, "tag": "Chemical"}, {"end": 111, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 117, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 55, "tag": "GeneOrGenome"}, {"end": 32, "start": 12, "tag": "Finding"}, {"end": 182, "start": 173, "tag": "HealthCareActivity"}, {"end": 188, "start": 183, "tag": "PopulationGroup"}, {"end": 136, "start": 129, "tag": "Cell"}, {"end": 105, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 101, "tag": "GeneOrGenome"}, {"end": 70, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 77, "tag": "Finding"}, {"end": 53, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 47, "tag": "GeneOrGenome"}, {"end": 53, "start": 47, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1127_8", "text": "Among them, BDNF, NeuN, GFAP, Iba-1, and NEP showed more significant changes in the NEP-enhanced hUC-MSC group than in the naive group.", "tags": [{"end": 22, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 41, "tag": "GeneOrGenome"}, {"end": 28, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 24, "tag": "GeneOrGenome"}, {"end": 110, "start": 105, "tag": "PopulationGroup"}, {"end": 134, "start": 129, "tag": "PopulationGroup"}, {"end": 104, "start": 101, "tag": "Cell"}, {"end": 16, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 12, "tag": "GeneOrGenome"}, {"end": 35, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 84, "tag": "BiologicallyActiveSubstance"}]}{"id": "1127_9", "text": "After stem cell injection, stem cells were not found.", "tags": [{"end": 25, "start": 16, "tag": "HealthCareActivity"}, {"end": 37, "start": 27, "tag": "Cell"}, {"end": 15, "start": 6, "tag": "Cell"}]}{"id": "1127_10", "text": "Extracellular vesicles (EVs) were equally observed in the hippocampus in the naive and NEP-enhanced hUC-MSC groups.", "tags": [{"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 107, "start": 100, "tag": "Cell"}, {"end": 69, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 87, "tag": "BiologicallyActiveSubstance"}]}{"id": "1127_11", "text": "However, the EVs of NEP-enhanced hUC-MSCs contained higher amounts of NEP as compared to the EVs of naive hUC-MSCs.", "tags": [{"end": 73, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 13, "tag": "CellComponent"}, {"end": 96, "start": 93, "tag": "CellComponent"}, {"end": 41, "start": 33, "tag": "Cell"}, {"end": 114, "start": 106, "tag": "Cell"}, {"end": 23, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 20, "tag": "BiologicallyActiveSubstance"}]}{"id": "1127_12", "text": "Thus, hUC-MSCs affect AD animal models through stem cell-released EVs.", "tags": [{"end": 69, "start": 66, "tag": "CellComponent"}, {"end": 14, "start": 6, "tag": "Cell"}, {"end": 56, "start": 47, "tag": "Cell"}, {"end": 38, "start": 22, "tag": "ExperimentalModelOfDisease"}]}{"id": "1127_13", "text": "Although there was no significant difference in cognitive function between the hUC-MSC groups, NEP-enhanced hUC-MSCs had superior neurogenesis and anti-inflammation properties compared to naive hUC-MSCs due to increased NEP in the hippocampus by enriched NEP-possessing EVs.", "tags": [{"end": 66, "start": 48, "tag": "BiologicFunction"}, {"end": 223, "start": 220, "tag": "AminoAcidPeptideOrProtein"}, {"end": 223, "start": 220, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 130, "tag": "BiologicFunction"}, {"end": 44, "start": 19, "tag": "Finding"}, {"end": 273, "start": 270, "tag": "CellComponent"}, {"end": 86, "start": 79, "tag": "Cell"}, {"end": 116, "start": 108, "tag": "Cell"}, {"end": 202, "start": 194, "tag": "Cell"}, {"end": 242, "start": 231, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 175, "start": 147, "tag": "Finding"}, {"end": 258, "start": 255, "tag": "AminoAcidPeptideOrProtein"}, {"end": 258, "start": 255, "tag": "BiologicallyActiveSubstance"}]}{"id": "1127_14", "text": "NEP gene-modified MSCs that release an increased amount of NEP within EVs may be a promising therapeutic option in AD treatment.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 70, "tag": "CellComponent"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 118, "tag": "HealthCareActivity"}, {"end": 127, "start": 118, "tag": "ResearchActivity"}, {"end": 22, "start": 18, "tag": "Cell"}, {"end": 35, "start": 28, "tag": "HealthCareActivity"}, {"end": 35, "start": 28, "tag": "ResearchActivity"}, {"end": 111, "start": 83, "tag": "Finding"}]}{"id": "1128_0", "text": "Exosomes are nano-sized extracellular vesicles that perform a variety of biological functions linked to the pathogenesis of various neurodegenerative disorders.", "tags": [{"end": 93, "start": 73, "tag": "BiologicFunction"}, {"end": 46, "start": 13, "tag": "CellComponent"}, {"end": 120, "start": 108, "tag": "PathologicFunction"}, {"end": 159, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "CellComponent"}]}{"id": "1128_1", "text": "In Alzheimer's disease (AD), for examples, exosomes are responsible for the release of A beta oligomers, and their extracellular accumulation, although the underpinning molecular machinery remains elusive.", "tags": [{"end": 22, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 43, "tag": "CellComponent"}, {"end": 141, "start": 129, "tag": "Finding"}, {"end": 128, "start": 115, "tag": "CellComponent"}, {"end": 103, "start": 76, "tag": "CellFunction"}]}{"id": "1128_2", "text": "We propose a novel model for Alzheimer's A beta accumulation based on Ca2+-dependent exosome release from astrocytes.", "tags": [{"end": 40, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 106, "tag": "Cell"}, {"end": 24, "start": 19, "tag": "ResearchActivity"}, {"end": 92, "start": 85, "tag": "CellComponent"}, {"end": 60, "start": 41, "tag": "CellOrMolecularDysfunction"}, {"end": 74, "start": 70, "tag": "Chemical"}, {"end": 73, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 70, "tag": "CellFunction"}]}{"id": "1128_3", "text": "Moreover, we exploit our model to assess how temperature dependence of exosome release could interact with A beta neurotoxicity.", "tags": [{"end": 67, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 45, "tag": "OrganismAttribute"}, {"end": 56, "start": 45, "tag": "NaturalPhenomenonOrProcess"}, {"end": 113, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 114, "tag": "InjuryOrPoisoning"}, {"end": 30, "start": 25, "tag": "ResearchActivity"}, {"end": 78, "start": 71, "tag": "CellComponent"}, {"end": 86, "start": 71, "tag": "CellFunction"}]}{"id": "1128_4", "text": "We predict that voltage-gated Ca2+ channels (VGCCs) along with the transient-receptor potential M8 (TRPM8) channel are crucial molecular components in Alzheimer's progression.", "tags": [{"end": 174, "start": 163, "tag": "PathologicFunction"}, {"end": 174, "start": 163, "tag": "TemporalConcept"}, {"end": 147, "start": 137, "tag": "CellComponent"}, {"end": 43, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 100, "tag": "GeneOrGenome"}, {"end": 162, "start": 151, "tag": "DiseaseOrSyndrome"}]}{"id": "1129_0", "text": "Increasing evidence indicates that the accumulation misfolded proteins in Alzheimer's disease (AD) arises from clearance defects in the autophagy-lysosome pathway.", "tags": [{"end": 70, "start": 52, "tag": "CellOrMolecularDysfunction"}, {"end": 19, "start": 11, "tag": "Finding"}, {"end": 93, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 39, "tag": "Finding"}, {"end": 120, "start": 111, "tag": "NaturalPhenomenonOrProcess"}, {"end": 145, "start": 136, "tag": "CellFunction"}, {"end": 162, "start": 155, "tag": "CellFunction"}]}{"id": "1129_1", "text": "Misfolded proteins such as A beta and tau are secreted in small extracellular vesicles (i.e., exosomes) and are propagated from cell to cell in part through secreted small extracellular vesicles (sEVs).", "tags": [{"end": 86, "start": 58, "tag": "CellComponent"}, {"end": 194, "start": 166, "tag": "CellComponent"}, {"end": 18, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 94, "tag": "CellComponent"}, {"end": 132, "start": 128, "tag": "Cell"}, {"end": 140, "start": 136, "tag": "Cell"}, {"end": 41, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 200, "start": 196, "tag": "CellComponent"}]}{"id": "1129_2", "text": "Recent studies suggest that autophagic activity and exosome secretion are coregulated events, and multiple autophagy-related proteins are found in sEVs, including the cargo receptors Sqstm1/p62 and optineurin.", "tags": [{"end": 69, "start": 52, "tag": "CellFunction"}, {"end": 133, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 208, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 28, "tag": "CellFunction"}, {"end": 133, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 107, "tag": "CellFunction"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 172, "start": 167, "tag": "CellFunction"}, {"end": 151, "start": 147, "tag": "CellComponent"}, {"end": 59, "start": 52, "tag": "CellComponent"}, {"end": 193, "start": 173, "tag": "BiologicallyActiveSubstance"}]}{"id": "1129_3", "text": "However, whether and how autophagy cargo receptors per se regulate the secretion of sEVs is unknown.", "tags": [{"end": 34, "start": 25, "tag": "CellFunction"}, {"end": 40, "start": 35, "tag": "CellFunction"}, {"end": 88, "start": 84, "tag": "CellComponent"}, {"end": 88, "start": 71, "tag": "CellFunction"}, {"end": 50, "start": 25, "tag": "BiologicallyActiveSubstance"}]}{"id": "1129_4", "text": "Moreover, despite the prominent role of actin dynamics in secretory vesicle release, its role in EV secretion is unknown.", "tags": [{"end": 45, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 58, "tag": "CellFunction"}, {"end": 109, "start": 97, "tag": "CellFunction"}, {"end": 54, "start": 46, "tag": "NaturalPhenomenonOrProcess"}]}{"id": "1129_5", "text": "In this study, we leveraged the dual axes of Slingshot Homolog-1 (SSH1), which inhibits Sqstm1/p62-mediated autophagy and activates cofilin-mediated actin dynamics, to study the regulation of sEV secretion.", "tags": [{"end": 205, "start": 192, "tag": "CellFunction"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 173, "start": 168, "tag": "ResearchActivity"}, {"end": 117, "start": 108, "tag": "CellFunction"}, {"end": 163, "start": 155, "tag": "NaturalPhenomenonOrProcess"}, {"end": 64, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 66, "tag": "GeneOrGenome"}, {"end": 70, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 88, "tag": "GeneOrGenome"}, {"end": 98, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 132, "tag": "BiologicallyActiveSubstance"}]}{"id": "1129_6", "text": "Here we show that cargo receptors Sqstm1/p62 and optineurin inhibit sEV secretion, an activity that requires their ability to bind ubiquitinated cargo.", "tags": [{"end": 59, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 49, "tag": "GeneOrGenome"}, {"end": 81, "start": 68, "tag": "CellFunction"}, {"end": 130, "start": 126, "tag": "CellFunction"}, {"end": 122, "start": 115, "tag": "OrganismAttribute"}, {"end": 23, "start": 18, "tag": "CellFunction"}, {"end": 150, "start": 145, "tag": "CellFunction"}, {"end": 71, "start": 68, "tag": "CellComponent"}, {"end": 44, "start": 18, "tag": "BiologicallyActiveSubstance"}]}{"id": "1129_7", "text": "Conversely, SSH1 increases sEV secretion by dephosphorylating Sqstm1/p62 at pSer403, the phospho-residue that allows Sqstm1/p62 to bind ubiquitinated cargo.", "tags": [{"end": 155, "start": 131, "tag": "CellFunction"}, {"end": 30, "start": 27, "tag": "CellComponent"}, {"end": 16, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 14, "tag": "GeneOrGenome"}, {"end": 40, "start": 27, "tag": "CellFunction"}, {"end": 104, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 117, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 44, "tag": "CellFunction"}, {"end": 72, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 76, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1129_8", "text": "In addition, increasing actin dynamics through the SSH1-cofilin activation pathway also increases sEV secretion, which is mimicked by latrunculin B treatment.", "tags": [{"end": 29, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 51, "tag": "CellFunction"}, {"end": 111, "start": 98, "tag": "CellFunction"}, {"end": 147, "start": 134, "tag": "Chemical"}, {"end": 23, "start": 13, "tag": "Finding"}, {"end": 157, "start": 148, "tag": "HealthCareActivity"}, {"end": 157, "start": 148, "tag": "ResearchActivity"}, {"end": 38, "start": 30, "tag": "NaturalPhenomenonOrProcess"}, {"end": 101, "start": 98, "tag": "CellComponent"}]}{"id": "1129_9", "text": "Finally, A beta 42 oligomers and mutant tau increase sEV secretion and are physically associated with secreted sEVs.", "tags": [{"end": 66, "start": 53, "tag": "CellFunction"}, {"end": 39, "start": 33, "tag": "CellOrMolecularDysfunction"}, {"end": 28, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 111, "tag": "CellComponent"}, {"end": 56, "start": 53, "tag": "CellComponent"}]}{"id": "1129_10", "text": "These findings suggest that increasing cargo receptor engagement with autophagic cargo and reducing actin dynamics (i.e., SSH1 inhibition) represents an attractive strategy to promote misfolded protein degradation while reducing sEV-mediated cell to cell spread of pathology.", "tags": [{"end": 64, "start": 54, "tag": "Finding"}, {"end": 38, "start": 28, "tag": "Finding"}, {"end": 213, "start": 202, "tag": "NaturalPhenomenonOrProcess"}, {"end": 80, "start": 70, "tag": "CellFunction"}, {"end": 53, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 201, "start": 184, "tag": "CellOrMolecularDysfunction"}, {"end": 137, "start": 127, "tag": "CellFunction"}, {"end": 274, "start": 265, "tag": "PathologicFunction"}, {"end": 274, "start": 265, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 114, "start": 106, "tag": "NaturalPhenomenonOrProcess"}, {"end": 44, "start": 39, "tag": "CellFunction"}, {"end": 86, "start": 81, "tag": "CellFunction"}, {"end": 232, "start": 229, "tag": "CellComponent"}, {"end": 99, "start": 91, "tag": "Finding"}, {"end": 228, "start": 220, "tag": "Finding"}, {"end": 105, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 122, "tag": "GeneOrGenome"}, {"end": 261, "start": 242, "tag": "Finding"}]}{"id": "1130_0", "text": "Zhang et al.", "tags": []}{"id": "1130_1", "text": "identify and characterize supermeres as extracellular nanoparticles that exhibit unique biological and functional properties with potential prognostic and therapeutic value across distinct diseases.", "tags": [{"end": 67, "start": 40, "tag": "CellComponent"}, {"end": 172, "start": 130, "tag": "Finding"}]}{"id": "1130_2", "text": "Extracellular vesicles and exomere nanoparticles are under intense investigation as sources of clinically relevant cargo.", "tags": [{"end": 80, "start": 67, "tag": "ResearchActivity"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 120, "start": 115, "tag": "CellFunction"}, {"end": 91, "start": 84, "tag": "Finding"}, {"end": 48, "start": 27, "tag": "Substance"}]}{"id": "1130_3", "text": "Here we report the discovery of a distinct extracellular nanoparticle, termed supermere.", "tags": [{"end": 28, "start": 19, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 56, "start": 43, "tag": "CellComponent"}, {"end": 69, "start": 57, "tag": "Substance"}, {"end": 87, "start": 78, "tag": "CellComponent"}]}{"id": "1130_4", "text": "Supermeres are morphologically distinct from exomeres and display a markedly greater uptake in vivo compared with small extracellular vesicles and exomeres.", "tags": [{"end": 142, "start": 120, "tag": "CellComponent"}, {"end": 99, "start": 92, "tag": "ResearchActivity"}, {"end": 142, "start": 114, "tag": "CellComponent"}, {"end": 91, "start": 85, "tag": "BiologicFunction"}, {"end": 91, "start": 85, "tag": "CellFunction"}, {"end": 155, "start": 147, "tag": "CellComponent"}, {"end": 10, "start": 0, "tag": "CellComponent"}, {"end": 53, "start": 45, "tag": "CellComponent"}]}{"id": "1130_5", "text": "The protein and RNA composition of supermeres differs from small extracellular vesicles and exomeres.", "tags": [{"end": 87, "start": 59, "tag": "CellComponent"}, {"end": 19, "start": 16, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 11, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 35, "tag": "CellComponent"}, {"end": 100, "start": 92, "tag": "CellComponent"}]}{"id": "1130_6", "text": "Supermeres are highly enriched with cargo involved in multiple cancers (glycolytic enzymes, TGFBI, miR-1246, MET, GPC1 and AGO2), Alzheimer's disease (APP) and cardiovascular disease (ACE2, ACE and PCSK9).", "tags": [{"end": 97, "start": 92, "tag": "GeneOrGenome"}, {"end": 107, "start": 99, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 107, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 109, "tag": "GeneOrGenome"}, {"end": 118, "start": 114, "tag": "GeneOrGenome"}, {"end": 127, "start": 123, "tag": "GeneOrGenome"}, {"end": 188, "start": 184, "tag": "GeneOrGenome"}, {"end": 203, "start": 198, "tag": "GeneOrGenome"}, {"end": 203, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 151, "tag": "GeneOrGenome"}, {"end": 154, "start": 151, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 36, "tag": "CellFunction"}, {"end": 182, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 190, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 190, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 0, "tag": "CellComponent"}, {"end": 70, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 198, "tag": "BiologicallyActiveSubstance"}]}{"id": "1130_7", "text": "The majority of extracellular RNA is associated with supermeres rather than small extracellular vesicles and exomeres.", "tags": [{"end": 104, "start": 82, "tag": "CellComponent"}, {"end": 104, "start": 76, "tag": "CellComponent"}, {"end": 33, "start": 30, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 117, "start": 109, "tag": "CellComponent"}, {"end": 29, "start": 16, "tag": "CellComponent"}, {"end": 63, "start": 53, "tag": "CellComponent"}]}{"id": "1130_8", "text": "Cancer-derived supermeres increase lactate secretion, transfer cetuximab resistance and decrease hepatic lipids and glycogen in vivo.", "tags": [{"end": 52, "start": 35, "tag": "CellFunction"}, {"end": 72, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 73, "tag": "BiologicFunction"}, {"end": 124, "start": 116, "tag": "Chemical"}, {"end": 96, "start": 88, "tag": "Finding"}, {"end": 52, "start": 43, "tag": "CellFunction"}, {"end": 52, "start": 43, "tag": "BiologicFunction"}, {"end": 132, "start": 125, "tag": "ResearchActivity"}, {"end": 111, "start": 105, "tag": "Chemical"}, {"end": 6, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 15, "tag": "CellComponent"}, {"end": 72, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 63, "tag": "PharmacologicSubstance"}]}{"id": "1130_9", "text": "This study identifies a distinct functional nanoparticle replete with potential circulating biomarkers and therapeutic targets for a host of human diseases.", "tags": [{"end": 155, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 133, "tag": "Organism"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 102, "start": 92, "tag": "ClinicalAttribute"}, {"end": 146, "start": 141, "tag": "Eukaryote"}, {"end": 126, "start": 107, "tag": "ResearchActivity"}, {"end": 102, "start": 80, "tag": "ClinicalAttribute"}]}{"id": "1131_0", "text": "Circulating extracellular vesicles (EVs) contain molecular footprints-lipids, proteins, RNA, and DNA-from their cell of origin.", "tags": [{"end": 86, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 0, "tag": "CellComponent"}, {"end": 39, "start": 36, "tag": "CellComponent"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 76, "start": 70, "tag": "Chemical"}, {"end": 126, "start": 120, "tag": "TemporalConcept"}, {"end": 91, "start": 88, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 100, "start": 97, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1131_1", "text": "Consequently, EV-associated RNA and proteins have gained widespread interest as liquid-biopsy biomarkers.", "tags": [{"end": 44, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 14, "tag": "CellComponent"}, {"end": 104, "start": 94, "tag": "ClinicalAttribute"}, {"end": 31, "start": 28, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 86, "start": 80, "tag": "Substance"}, {"end": 93, "start": 80, "tag": "HealthCareActivity"}]}{"id": "1131_2", "text": "Yet, an integrative proteo-transcriptomic landscape of EVs and comparison with their cell of origin remains obscure.", "tags": [{"end": 73, "start": 63, "tag": "ResearchActivity"}, {"end": 58, "start": 55, "tag": "CellComponent"}, {"end": 89, "start": 85, "tag": "Cell"}, {"end": 99, "start": 93, "tag": "TemporalConcept"}, {"end": 51, "start": 8, "tag": "ResearchActivity"}]}{"id": "1131_3", "text": "Here, we report that EVs enrich distinct proteo-transcriptome that does not linearly correlate with their cell of origin.", "tags": [{"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 61, "start": 41, "tag": "MolecularSequence"}, {"end": 24, "start": 21, "tag": "CellComponent"}, {"end": 110, "start": 106, "tag": "Cell"}, {"end": 120, "start": 114, "tag": "TemporalConcept"}]}{"id": "1131_4", "text": "We show that EVs enrich endosomal and extracellular proteins, small RNA (similar to 13-200 nucleotides) associated with cell differentiation, development, and Wnt signaling.", "tags": [{"end": 140, "start": 120, "tag": "CellFunction"}, {"end": 172, "start": 159, "tag": "CellFunction"}, {"end": 60, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 13, "tag": "CellComponent"}, {"end": 153, "start": 142, "tag": "BiologicFunction"}, {"end": 153, "start": 142, "tag": "CellFunction"}, {"end": 51, "start": 38, "tag": "CellComponent"}, {"end": 102, "start": 91, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 71, "start": 62, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 71, "start": 62, "tag": "BiologicallyActiveSubstance"}]}{"id": "1131_5", "text": "EVs cargo specific RNAs (RNY3, vtRNA, and MIRLET-7) and their complementary proteins (YBX1, IGF2BP2, and SRSF1/2).", "tags": [{"end": 29, "start": 25, "tag": "GeneOrGenome"}, {"end": 84, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 86, "tag": "GeneOrGenome"}, {"end": 99, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 92, "tag": "GeneOrGenome"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 9, "start": 4, "tag": "CellFunction"}, {"end": 23, "start": 19, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 36, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 31, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 50, "start": 42, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 50, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 105, "tag": "GeneOrGenome"}]}{"id": "1131_6", "text": "To ensure an unbiased and independent analyses, we studied 12 cancer cell lines, matching EVs (inhouse and exRNA database), and serum EVs of patients with prostate cancer.", "tags": [{"end": 121, "start": 95, "tag": "ResearchActivity"}, {"end": 79, "start": 69, "tag": "Cell"}, {"end": 93, "start": 90, "tag": "CellComponent"}, {"end": 137, "start": 134, "tag": "CellComponent"}, {"end": 149, "start": 141, "tag": "PatientOrDisabledGroup"}, {"end": 133, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 26, "tag": "Finding"}]}{"id": "1131_7", "text": "Together, we show that EV-RNA-protein complexes may constitute a functional interaction network to protect and regulate molecular access until a function is achieved.", "tags": [{"end": 25, "start": 23, "tag": "CellComponent"}, {"end": 29, "start": 26, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 95, "start": 88, "tag": "PopulationGroup"}, {"end": 95, "start": 88, "tag": "CellFunction"}, {"end": 37, "start": 30, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1132_0", "text": "Small extracellular vesicles (sEVs) have similar to 30-200 nm diameter size and may act as carriers of different cargoes, depending on the cell of origin or on the physiological/pathological condition.", "tags": [{"end": 28, "start": 0, "tag": "CellComponent"}, {"end": 143, "start": 139, "tag": "Cell"}, {"end": 153, "start": 147, "tag": "TemporalConcept"}, {"end": 75, "start": 71, "tag": "OrganismAttribute"}, {"end": 34, "start": 30, "tag": "CellComponent"}, {"end": 99, "start": 91, "tag": "Finding"}, {"end": 120, "start": 113, "tag": "CellFunction"}, {"end": 200, "start": 178, "tag": "PathologicFunction"}]}{"id": "1132_1", "text": "As endogenous nanovesicles, sEVs are important in intercellular communication and have many of the desirable features of an ideal drug delivery system.", "tags": [{"end": 150, "start": 130, "tag": "ManufacturedObject"}, {"end": 77, "start": 50, "tag": "CellFunction"}, {"end": 32, "start": 28, "tag": "CellComponent"}, {"end": 143, "start": 130, "tag": "HealthCareActivity"}, {"end": 26, "start": 3, "tag": "CellComponent"}]}{"id": "1132_2", "text": "sEVs are naturally biocompatible, with superior targeting capability, safety profile, nanometric size, and can be loaded with both lipophilic and hydrophilic agents.", "tags": [{"end": 141, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 70, "tag": "HealthCareActivity"}, {"end": 101, "start": 97, "tag": "OrganismAttribute"}, {"end": 4, "start": 0, "tag": "CellComponent"}, {"end": 84, "start": 77, "tag": "ResearchActivity"}, {"end": 164, "start": 131, "tag": "Chemical"}]}{"id": "1132_3", "text": "Because of their biochemical and physical properties, sEVs are considered a promising strategy over other delivery vehicles in the central nervous system (CNS) since they freely cross the blood-brain barrier and they can be directed to specific nerve cells, potentiating a more precise targeting of their cargo.", "tags": [{"end": 52, "start": 33, "tag": "Finding"}, {"end": 256, "start": 245, "tag": "Cell"}, {"end": 123, "start": 115, "tag": "ManufacturedObject"}, {"end": 153, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 310, "start": 305, "tag": "CellFunction"}, {"end": 58, "start": 54, "tag": "CellComponent"}, {"end": 207, "start": 188, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 106, "tag": "BiologicFunction"}]}{"id": "1132_4", "text": "In addition, sEVs remain stable in the peripheral circulation, making them attractive nanocarrier systems to promote neuroregeneration.", "tags": [{"end": 134, "start": 117, "tag": "BiologicFunction"}, {"end": 61, "start": 39, "tag": "BiologicFunction"}, {"end": 17, "start": 13, "tag": "CellComponent"}, {"end": 105, "start": 86, "tag": "ManufacturedObject"}]}{"id": "1132_5", "text": "This review focuses on the recent progress in methods for manufacturing, isolating, and engineering sEVs that can be used as a therapeutic strategy to overcome neurodegeneration associated with pathologies of the CNS, with particular emphasis on Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases, as well as on brain tumors.", "tags": [{"end": 205, "start": 194, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 314, "start": 276, "tag": "DiseaseOrSyndrome"}, {"end": 342, "start": 330, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 27, "tag": "TemporalConcept"}, {"end": 177, "start": 160, "tag": "CellOrMolecularDysfunction"}, {"end": 99, "start": 88, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 216, "start": 213, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 127, "tag": "HealthCareActivity"}, {"end": 104, "start": 100, "tag": "CellComponent"}, {"end": 270, "start": 259, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 73, "tag": "ResearchActivity"}, {"end": 71, "start": 58, "tag": "ResearchActivity"}, {"end": 257, "start": 246, "tag": "DiseaseOrSyndrome"}]}{"id": "1133_0", "text": "Alzheimer's disease (AD) is the sixth leading cause of death worldwide and cannot be effectively cured or prevented; thus, early diagnosis, and intervention are important.", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 55, "tag": "BiologicFunction"}, {"end": 60, "start": 55, "tag": "PathologicFunction"}, {"end": 60, "start": 55, "tag": "CellFunction"}, {"end": 138, "start": 123, "tag": "HealthCareActivity"}]}{"id": "1133_1", "text": "The importance of exosomes, membrane-bound extracellular vesicles produced in the endosome of eukaryotic cells, in the development, diagnosis, and treatment of AD has been recognized; however, their specific functions remain controversial and even unclear.", "tags": [{"end": 36, "start": 28, "tag": "CellComponent"}, {"end": 110, "start": 94, "tag": "Cell"}, {"end": 65, "start": 43, "tag": "CellComponent"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 119, "tag": "BiologicFunction"}, {"end": 130, "start": 119, "tag": "CellFunction"}, {"end": 141, "start": 132, "tag": "HealthCareActivity"}, {"end": 156, "start": 147, "tag": "HealthCareActivity"}, {"end": 156, "start": 147, "tag": "ResearchActivity"}, {"end": 90, "start": 82, "tag": "CellComponent"}, {"end": 26, "start": 18, "tag": "CellComponent"}]}{"id": "1133_2", "text": "With the development of exosome extraction, isolation, and characterization, many studies have focused on exosomes derived from different cells and body fluids.", "tags": [{"end": 42, "start": 24, "tag": "ResearchActivity"}, {"end": 20, "start": 9, "tag": "BiologicFunction"}, {"end": 20, "start": 9, "tag": "CellFunction"}, {"end": 143, "start": 138, "tag": "Cell"}, {"end": 159, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 24, "tag": "CellComponent"}, {"end": 89, "start": 82, "tag": "ResearchActivity"}, {"end": 114, "start": 106, "tag": "CellComponent"}, {"end": 53, "start": 44, "tag": "ResearchActivity"}, {"end": 31, "start": 24, "tag": "ResearchActivity"}, {"end": 75, "start": 59, "tag": "ResearchActivity"}, {"end": 31, "start": 24, "tag": "ResearchActivity"}]}{"id": "1133_3", "text": "In this study, we summarized the roles of exosomes derived from different body fluids and cells, such as neuron, glial, stem, and endothelial cells, in the development, diagnosis, monitoring, and treatment of AD.", "tags": [{"end": 147, "start": 142, "tag": "Cell"}, {"end": 124, "start": 120, "tag": "Cell"}, {"end": 147, "start": 130, "tag": "Cell"}, {"end": 141, "start": 130, "tag": "Cell"}, {"end": 118, "start": 113, "tag": "Cell"}, {"end": 211, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 105, "tag": "Cell"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 167, "start": 156, "tag": "BiologicFunction"}, {"end": 167, "start": 156, "tag": "CellFunction"}, {"end": 95, "start": 90, "tag": "Cell"}, {"end": 178, "start": 169, "tag": "HealthCareActivity"}, {"end": 85, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 205, "start": 196, "tag": "HealthCareActivity"}, {"end": 205, "start": 196, "tag": "ResearchActivity"}, {"end": 190, "start": 180, "tag": "HealthCareActivity"}, {"end": 50, "start": 42, "tag": "CellComponent"}]}{"id": "1133_4", "text": "We also emphasize the necessity to focus on exosomes from biological fluids and specific cells that are less invasive to target.", "tags": [{"end": 75, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 89, "tag": "Cell"}, {"end": 117, "start": 104, "tag": "Finding"}, {"end": 52, "start": 44, "tag": "CellComponent"}]}{"id": "1133_5", "text": "Moreover, aside from the concentrations of classic and novel biomarkers in exosomes, the size and number of exosomes may also influence early and differential diagnosis of AD.", "tags": [{"end": 168, "start": 146, "tag": "HealthCareActivity"}, {"end": 174, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 61, "tag": "ClinicalAttribute"}, {"end": 39, "start": 25, "tag": "BiologicFunction"}, {"end": 93, "start": 89, "tag": "OrganismAttribute"}, {"end": 83, "start": 75, "tag": "CellComponent"}, {"end": 116, "start": 108, "tag": "CellComponent"}]}{"id": "1134_0", "text": "Alzheimer's disease (AD) is characterized by extracellular amyloid plaques composed of beta-amyloid (A beta) and intracellular neurofibrillary tangles containing hyperphosphorylated tau protein.", "tags": [{"end": 126, "start": 113, "tag": "CellComponent"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 162, "tag": "AminoAcidPeptideOrProtein"}, {"end": 193, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 127, "tag": "CellOrMolecularDysfunction"}, {"end": 74, "start": 45, "tag": "AnatomicalAbnormality"}]}{"id": "1134_1", "text": "No effective therapy is available for this disease.", "tags": [{"end": 20, "start": 13, "tag": "HealthCareActivity"}]}{"id": "1134_2", "text": "In this study, we investigated the potential therapeutic effects of dauricine (DAU), a benzyl tetrahydroisoquinoline alkaloid, on AD, and found that DAU administration significantly improved cognitive impairments in 3xTg-AD mice by decreasing A beta plaques and hyperphosphorylated tau and increasing the hippocampal ATP level.", "tags": [{"end": 77, "start": 68, "tag": "Chemical"}, {"end": 82, "start": 79, "tag": "Chemical"}, {"end": 152, "start": 149, "tag": "Chemical"}, {"end": 212, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 320, "start": 317, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 320, "start": 317, "tag": "PharmacologicSubstance"}, {"end": 320, "start": 317, "tag": "BiologicallyActiveSubstance"}, {"end": 257, "start": 243, "tag": "AnatomicalAbnormality"}, {"end": 316, "start": 305, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 316, "start": 305, "tag": "Cell"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 228, "start": 216, "tag": "ExperimentalModelOfDisease"}, {"end": 285, "start": 262, "tag": "AminoAcidPeptideOrProtein"}, {"end": 285, "start": 262, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 45, "tag": "Finding"}, {"end": 125, "start": 87, "tag": "Chemical"}, {"end": 167, "start": 153, "tag": "HealthCareActivity"}]}{"id": "1134_3", "text": "Proteomic and western blot analyses revealed that DAU treatment mainly modified the expression of proteins involved in mitochondrial energy metabolism, such as Aco2, Ndufs1, Cox5a, and SDHB, and that of synapse-related proteins such as Syn1 and Syn2.", "tags": [{"end": 9, "start": 0, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 35, "start": 14, "tag": "ResearchActivity"}, {"end": 53, "start": 50, "tag": "Chemical"}, {"end": 164, "start": 160, "tag": "GeneOrGenome"}, {"end": 172, "start": 166, "tag": "GeneOrGenome"}, {"end": 179, "start": 174, "tag": "GeneOrGenome"}, {"end": 189, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 185, "tag": "GeneOrGenome"}, {"end": 189, "start": 185, "tag": "BiologicallyActiveSubstance"}, {"end": 240, "start": 236, "tag": "AminoAcidPeptideOrProtein"}, {"end": 240, "start": 236, "tag": "GeneOrGenome"}, {"end": 249, "start": 245, "tag": "GeneOrGenome"}, {"end": 150, "start": 133, "tag": "BiologicFunction"}, {"end": 210, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 71, "tag": "TemporalConcept"}, {"end": 132, "start": 119, "tag": "CellComponent"}, {"end": 63, "start": 54, "tag": "HealthCareActivity"}, {"end": 63, "start": 54, "tag": "ResearchActivity"}, {"end": 94, "start": 84, "tag": "CellFunction"}, {"end": 106, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 227, "start": 219, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 140, "tag": "CellFunction"}, {"end": 150, "start": 140, "tag": "BiologicFunction"}, {"end": 26, "start": 14, "tag": "ResearchActivity"}, {"end": 240, "start": 236, "tag": "BiologicallyActiveSubstance"}, {"end": 249, "start": 245, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 160, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 179, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 249, "start": 245, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1134_4", "text": "Pathway analysis revealed that DAU modulated the tricarboxylic acid cycle, synaptic vesicle cycle, glycolysis, and gluconeogenesis in 3xTg-AD mice.", "tags": [{"end": 34, "start": 31, "tag": "Chemical"}, {"end": 73, "start": 49, "tag": "CellFunction"}, {"end": 67, "start": 49, "tag": "Chemical"}, {"end": 97, "start": 75, "tag": "CellFunction"}, {"end": 109, "start": 99, "tag": "CellFunction"}, {"end": 130, "start": 115, "tag": "CellFunction"}, {"end": 16, "start": 0, "tag": "ResearchActivity"}, {"end": 146, "start": 134, "tag": "ExperimentalModelOfDisease"}, {"end": 91, "start": 75, "tag": "CellComponent"}]}{"id": "1134_5", "text": "Our study suggests that DAU may be a potential drug for the treatment of AD.", "tags": [{"end": 27, "start": 24, "tag": "Chemical"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 69, "start": 60, "tag": "HealthCareActivity"}, {"end": 69, "start": 60, "tag": "ResearchActivity"}, {"end": 51, "start": 47, "tag": "PharmacologicSubstance"}]}{"id": "1135_0", "text": "Exosomes are nano-extracellular vesicles with diameters ranging from 30 to 150 nm, which are secreted by the cell.", "tags": [{"end": 40, "start": 18, "tag": "CellComponent"}, {"end": 113, "start": 109, "tag": "Cell"}, {"end": 8, "start": 0, "tag": "CellComponent"}]}{"id": "1135_1", "text": "With their role in drug cargo loading, exosomes have been applied to carry compounds across the blood-brain barrier in order to target the central nervous system (CNS).", "tags": [{"end": 84, "start": 75, "tag": "Chemical"}, {"end": 84, "start": 75, "tag": "PharmacologicSubstance"}, {"end": 161, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 163, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 24, "tag": "CellFunction"}, {"end": 115, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 19, "tag": "PharmacologicSubstance"}, {"end": 47, "start": 39, "tag": "CellComponent"}]}{"id": "1135_2", "text": "In this study, high-purity exosomes isolated by the ultra-high-speed separation method were applied as the natural compound carrier, with the loading efficiency confirmed by UHPLC-MS analysis.", "tags": [{"end": 131, "start": 124, "tag": "CellFunction"}, {"end": 131, "start": 124, "tag": "ManufacturedObject"}, {"end": 131, "start": 124, "tag": "Finding"}, {"end": 191, "start": 174, "tag": "ResearchActivity"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 35, "start": 27, "tag": "CellComponent"}, {"end": 86, "start": 52, "tag": "ResearchActivity"}, {"end": 123, "start": 107, "tag": "Chemical"}, {"end": 160, "start": 150, "tag": "Finding"}]}{"id": "1135_3", "text": "Through the optimization of various cargo loading methods using exosomes, this study compared the efficiency of different ways for the separation of exosomes and the exosome encapsulation of natural compounds with increasing molecular weights via extensive in vitro and in vivo efficacy studies.", "tags": [{"end": 24, "start": 12, "tag": "HealthCareActivity"}, {"end": 24, "start": 12, "tag": "ResearchActivity"}, {"end": 84, "start": 79, "tag": "ResearchActivity"}, {"end": 41, "start": 36, "tag": "CellFunction"}, {"end": 173, "start": 166, "tag": "CellComponent"}, {"end": 294, "start": 287, "tag": "ResearchActivity"}, {"end": 145, "start": 135, "tag": "Finding"}, {"end": 265, "start": 257, "tag": "ResearchActivity"}, {"end": 277, "start": 270, "tag": "ResearchActivity"}, {"end": 286, "start": 278, "tag": "Finding"}, {"end": 72, "start": 64, "tag": "CellComponent"}, {"end": 157, "start": 149, "tag": "CellComponent"}, {"end": 108, "start": 98, "tag": "Finding"}, {"end": 208, "start": 174, "tag": "ResearchActivity"}, {"end": 208, "start": 191, "tag": "Chemical"}, {"end": 57, "start": 36, "tag": "ResearchActivity"}]}{"id": "1135_4", "text": "In a pharmacokinetic study, our data suggested that the efficiency of compound's loading into exosomes is positively correlated to its molecular weight.", "tags": [{"end": 26, "start": 5, "tag": "ResearchActivity"}, {"end": 36, "start": 32, "tag": "ResearchActivity"}, {"end": 102, "start": 94, "tag": "CellComponent"}, {"end": 66, "start": 56, "tag": "Finding"}]}{"id": "1135_5", "text": "However, with a molecular weight of greater than 1109 Da, the exosome-encapsulated natural compounds were not able to pass through the blood-brain barrier (BBB).", "tags": [{"end": 69, "start": 62, "tag": "CellComponent"}, {"end": 154, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1135_6", "text": "In vitro cellular models confirmed that three of the selected exosome-encapsulated natural compounds-baicalin, hederagenin and neferine-could reduce the level of neurodegenerative disease mutant proteins-including huntingtin 74 (HTT74), P301L tau and A53T alpha-synuclein (A53T alpha-syn)-more effectively than the compounds alone.", "tags": [{"end": 122, "start": 111, "tag": "Chemical"}, {"end": 234, "start": 229, "tag": "AminoAcidPeptideOrProtein"}, {"end": 234, "start": 229, "tag": "GeneOrGenome"}, {"end": 324, "start": 315, "tag": "Chemical"}, {"end": 324, "start": 315, "tag": "PharmacologicSubstance"}, {"end": 227, "start": 214, "tag": "AminoAcidPeptideOrProtein"}, {"end": 224, "start": 214, "tag": "GeneOrGenome"}, {"end": 271, "start": 262, "tag": "AminoAcidPeptideOrProtein"}, {"end": 271, "start": 262, "tag": "BiologicallyActiveSubstance"}, {"end": 271, "start": 251, "tag": "BiologicallyActiveSubstance"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 246, "start": 243, "tag": "AminoAcidPeptideOrProtein"}, {"end": 246, "start": 243, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 9, "tag": "ResearchActivity"}, {"end": 69, "start": 62, "tag": "CellComponent"}, {"end": 203, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 187, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 9, "tag": "Cell"}, {"end": 194, "start": 188, "tag": "CellOrMolecularDysfunction"}, {"end": 242, "start": 237, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 127, "tag": "Chemical"}, {"end": 109, "start": 101, "tag": "Chemical"}, {"end": 109, "start": 101, "tag": "PharmacologicSubstance"}, {"end": 100, "start": 62, "tag": "ResearchActivity"}, {"end": 287, "start": 273, "tag": "AminoAcidPeptideOrProtein"}, {"end": 287, "start": 273, "tag": "BiologicallyActiveSubstance"}]}{"id": "1135_7", "text": "With the traditional pharmacological role of the herbal plant Nelumbo nucifera in mitigating anxiety, exosome-encapsulated-neferine was, for the first time, reported to improve the motor deficits of APP/PS1 (amyloid precursor protein/ presenilin1) double transgenic mice, and to reduce the level of beta-amyloid (A beta) in the brain when compared with the same concentration of neferine alone.", "tags": [{"end": 176, "start": 169, "tag": "Finding"}, {"end": 387, "start": 379, "tag": "Chemical"}, {"end": 195, "start": 181, "tag": "PathologicFunction"}, {"end": 195, "start": 187, "tag": "Finding"}, {"end": 333, "start": 328, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 145, "tag": "TemporalConcept"}, {"end": 109, "start": 102, "tag": "CellComponent"}, {"end": 319, "start": 313, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 151, "tag": "TemporalConcept"}, {"end": 311, "start": 299, "tag": "AminoAcidPeptideOrProtein"}, {"end": 233, "start": 208, "tag": "AminoAcidPeptideOrProtein"}, {"end": 233, "start": 208, "tag": "BiologicallyActiveSubstance"}, {"end": 375, "start": 362, "tag": "BiologicFunction"}, {"end": 100, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 49, "tag": "Organism"}, {"end": 131, "start": 123, "tag": "Chemical"}, {"end": 246, "start": 235, "tag": "AminoAcidPeptideOrProtein"}, {"end": 246, "start": 235, "tag": "BiologicallyActiveSubstance"}, {"end": 270, "start": 248, "tag": "ExperimentalModelOfDisease"}, {"end": 206, "start": 199, "tag": "ExperimentalModelOfDisease"}]}{"id": "1135_8", "text": "With the current trend in advocating medicine-food homology and green healthcare, this study has provided a rationale from in vitro to in vivo for the encapsulation of natural compounds using exosomes for the targeting of BBB permeability and neurodegenerative diseases in the future.", "tags": [{"end": 238, "start": 226, "tag": "NaturalPhenomenonOrProcess"}, {"end": 238, "start": 226, "tag": "BiologicFunction"}, {"end": 80, "start": 64, "tag": "HealthCareActivity"}, {"end": 92, "start": 87, "tag": "ResearchActivity"}, {"end": 269, "start": 243, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 123, "tag": "ResearchActivity"}, {"end": 16, "start": 9, "tag": "TemporalConcept"}, {"end": 142, "start": 135, "tag": "ResearchActivity"}, {"end": 283, "start": 277, "tag": "TemporalConcept"}, {"end": 200, "start": 192, "tag": "CellComponent"}, {"end": 225, "start": 222, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 151, "tag": "ResearchActivity"}, {"end": 185, "start": 168, "tag": "Chemical"}]}{"id": "1136_0", "text": "Activated microglia release extracellular vesicles (EVs) as modulators of brain homeostasis and innate immunity.", "tags": [{"end": 91, "start": 74, "tag": "BiologicFunction"}, {"end": 111, "start": 96, "tag": "OrganismAttribute"}, {"end": 50, "start": 28, "tag": "CellComponent"}, {"end": 55, "start": 52, "tag": "CellComponent"}, {"end": 19, "start": 0, "tag": "Cell"}, {"end": 70, "start": 60, "tag": "BiologicallyActiveSubstance"}]}{"id": "1136_1", "text": "However, the molecules critical for regulating EV production from microglia are poorly understood.", "tags": [{"end": 49, "start": 47, "tag": "CellComponent"}, {"end": 75, "start": 66, "tag": "Cell"}, {"end": 22, "start": 13, "tag": "Substance"}, {"end": 60, "start": 47, "tag": "CellFunction"}]}{"id": "1136_2", "text": "Here we establish a murine microglial cell model to monitor EV secretion by measuring the fluorescence signal of tdTomato, which is linked to tetraspanin CD63.", "tags": [{"end": 42, "start": 27, "tag": "Cell"}, {"end": 62, "start": 60, "tag": "CellComponent"}, {"end": 48, "start": 43, "tag": "ResearchActivity"}, {"end": 72, "start": 63, "tag": "CellFunction"}, {"end": 26, "start": 20, "tag": "Eukaryote"}, {"end": 72, "start": 63, "tag": "BiologicFunction"}, {"end": 102, "start": 90, "tag": "NaturalPhenomenonOrProcess"}, {"end": 153, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 154, "tag": "GeneOrGenome"}, {"end": 72, "start": 60, "tag": "CellFunction"}, {"end": 59, "start": 52, "tag": "HealthCareActivity"}, {"end": 59, "start": 52, "tag": "ManufacturedObject"}, {"end": 121, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 113, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1136_3", "text": "Stimulation of tdTomato(+) cells with ATP induces rapid secretion of EVs and a reduction in cellular tdTo-mato intensity, reflecting EV secretion.", "tags": [{"end": 11, "start": 0, "tag": "HealthCareActivity"}, {"end": 11, "start": 0, "tag": "NaturalPhenomenonOrProcess"}, {"end": 41, "start": 38, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 41, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 69, "tag": "CellComponent"}, {"end": 135, "start": 133, "tag": "CellComponent"}, {"end": 32, "start": 27, "tag": "Cell"}, {"end": 65, "start": 56, "tag": "CellFunction"}, {"end": 145, "start": 136, "tag": "CellFunction"}, {"end": 65, "start": 56, "tag": "BiologicFunction"}, {"end": 145, "start": 136, "tag": "BiologicFunction"}, {"end": 100, "start": 92, "tag": "Cell"}, {"end": 145, "start": 133, "tag": "CellFunction"}, {"end": 88, "start": 79, "tag": "Finding"}, {"end": 88, "start": 79, "tag": "NaturalPhenomenonOrProcess"}, {"end": 41, "start": 38, "tag": "PharmacologicSubstance"}, {"end": 23, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 15, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1136_4", "text": "We generate a GFP(+) tdTo-mato(+) cell library expressing TurboGFP and barcoded short hairpin RNAs for genome-wide screening using next-generation sequencing.", "tags": [{"end": 157, "start": 131, "tag": "ResearchActivity"}, {"end": 57, "start": 47, "tag": "CellFunction"}, {"end": 46, "start": 39, "tag": "GeneOrGenome"}, {"end": 38, "start": 34, "tag": "Cell"}, {"end": 124, "start": 103, "tag": "ResearchActivity"}, {"end": 98, "start": 80, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 66, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 58, "tag": "Chemical"}, {"end": 30, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 14, "tag": "Chemical"}]}{"id": "1136_5", "text": "We identify Mcfd2, Sepp1, and Sdc1 as critical regulators of ATP-induced EV secretion from murine microglia.", "tags": [{"end": 17, "start": 12, "tag": "GeneOrGenome"}, {"end": 24, "start": 19, "tag": "GeneOrGenome"}, {"end": 24, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 30, "tag": "GeneOrGenome"}, {"end": 75, "start": 73, "tag": "CellComponent"}, {"end": 107, "start": 98, "tag": "Cell"}, {"end": 85, "start": 76, "tag": "CellFunction"}, {"end": 97, "start": 91, "tag": "Eukaryote"}, {"end": 85, "start": 76, "tag": "BiologicFunction"}, {"end": 85, "start": 73, "tag": "CellFunction"}, {"end": 17, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 61, "tag": "PharmacologicSubstance"}, {"end": 64, "start": 61, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 64, "start": 61, "tag": "BiologicallyActiveSubstance"}]}{"id": "1136_6", "text": "Small interfering RNA (siRNA-based) silencing of each of these genes suppresses lipopolysaccharide- and ATP-induced inflammasome activation, as determined by interleukin-1 beta release from primary cultured murine microglia.", "tags": [{"end": 21, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 45, "start": 36, "tag": "CellFunction"}, {"end": 176, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 23, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 28, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 80, "tag": "Chemical"}, {"end": 223, "start": 214, "tag": "Cell"}, {"end": 213, "start": 207, "tag": "Eukaryote"}, {"end": 223, "start": 190, "tag": "ResearchActivity"}, {"end": 21, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 104, "tag": "CellFunction"}, {"end": 176, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 158, "tag": "CellFunction"}, {"end": 128, "start": 116, "tag": "CellComponent"}]}{"id": "1136_7", "text": "These molecules are critical for microglial EV secretion and are potential therapeutic targets for neuroinflammatory disorders.", "tags": [{"end": 126, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 65, "tag": "ResearchActivity"}, {"end": 15, "start": 6, "tag": "Substance"}, {"end": 56, "start": 44, "tag": "CellFunction"}, {"end": 43, "start": 33, "tag": "Cell"}]}{"id": "1137_0", "text": "Alzheimer's disease (AD) is characterized by the progressive accumulation of amyloid-beta and hyperphosphorylated tau (pTau), which can spread throughout the brain via extracellular vesicles (EVs).", "tags": [{"end": 117, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 61, "tag": "Finding"}, {"end": 163, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 168, "tag": "CellComponent"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 192, "tag": "CellComponent"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 49, "tag": "TemporalConcept"}, {"end": 84, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 119, "tag": "BiologicallyActiveSubstance"}]}{"id": "1137_1", "text": "Membrane ceramide enrichment regulated by the enzyme neutral sphingomyelinase 2 (nSMase2) is a critical component of at least one EV biogenesis pathway.", "tags": [{"end": 8, "start": 0, "tag": "CellComponent"}, {"end": 17, "start": 9, "tag": "Chemical"}, {"end": 52, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 143, "start": 133, "tag": "CellFunction"}, {"end": 151, "start": 144, "tag": "CellFunction"}, {"end": 132, "start": 130, "tag": "CellComponent"}, {"end": 17, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 53, "tag": "BiologicallyActiveSubstance"}]}{"id": "1137_2", "text": "Our group recently identified 2,6-Dimethoxy-4-(5-Phenyl-4-Thiophen-2-yl-1H-Imidazol-2-yl)-Phenol (DPTIP), the most potent (30 nM) and selective inhibitor of nSMase2 reported to date.", "tags": [{"end": 164, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 174, "tag": "TemporalConcept"}, {"end": 153, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 144, "tag": "PharmacologicSubstance"}, {"end": 153, "start": 144, "tag": "Chemical"}, {"end": 181, "start": 177, "tag": "TemporalConcept"}, {"end": 18, "start": 10, "tag": "TemporalConcept"}, {"end": 9, "start": 4, "tag": "PopulationGroup"}, {"end": 96, "start": 30, "tag": "Chemical"}, {"end": 103, "start": 98, "tag": "Chemical"}]}{"id": "1137_3", "text": "However, DPTIP exhibits poor oral pharmacokinetics (PK), modest brain penetration, and rapid clearance, limiting its clinical translation.", "tags": [{"end": 50, "start": 34, "tag": "BiologicFunction"}, {"end": 50, "start": 34, "tag": "ResearchActivity"}, {"end": 54, "start": 52, "tag": "BiologicFunction"}, {"end": 54, "start": 52, "tag": "ResearchActivity"}, {"end": 137, "start": 117, "tag": "ResearchActivity"}, {"end": 102, "start": 93, "tag": "NaturalPhenomenonOrProcess"}, {"end": 14, "start": 9, "tag": "Chemical"}, {"end": 81, "start": 64, "tag": "BiologicFunction"}, {"end": 33, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1137_4", "text": "To enhance its PK properties, we conjugated DPTIP to a hydroxyl-PAMAM dendrimer delivery system, creating dendrimer-DPTIP (D-DPTIP).", "tags": [{"end": 17, "start": 15, "tag": "BiologicFunction"}, {"end": 17, "start": 15, "tag": "ResearchActivity"}, {"end": 79, "start": 55, "tag": "Chemical"}, {"end": 88, "start": 80, "tag": "BiologicFunction"}, {"end": 115, "start": 106, "tag": "Chemical"}, {"end": 49, "start": 44, "tag": "Chemical"}, {"end": 95, "start": 55, "tag": "HealthCareActivity"}, {"end": 130, "start": 123, "tag": "Chemical"}, {"end": 121, "start": 116, "tag": "Chemical"}]}{"id": "1137_5", "text": "In an acute brain injury model, orally administered D-DPTIP significantly reduced the intra-striatal IL-1 beta-induced increase in plasma EVs up to 72 h post-dose, while oral DPTIP had a limited effect.", "tags": [{"end": 24, "start": 6, "tag": "InjuryOrPoisoning"}, {"end": 105, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 153, "tag": "TemporalConcept"}, {"end": 100, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 6, "tag": "TemporalConcept"}, {"end": 110, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 141, "start": 138, "tag": "CellComponent"}, {"end": 137, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 157, "start": 153, "tag": "TemporalConcept"}, {"end": 59, "start": 52, "tag": "Chemical"}, {"end": 180, "start": 175, "tag": "Chemical"}, {"end": 30, "start": 6, "tag": "ExperimentalModelOfDisease"}, {"end": 38, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1137_6", "text": "In a mouse tau propagation model, where a mutant hTau (P301L/S320F) containing adeno-associated virus was unilaterally seeded into the hippocampus, oral D-DPTIP (dosed 3x weekly) significantly inhibited brain nSMase2 activity and blocked the spread of pTau to the contralateral hippocampus.", "tags": [{"end": 101, "start": 79, "tag": "Virus"}, {"end": 67, "start": 42, "tag": "CellOrMolecularDysfunction"}, {"end": 146, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 289, "start": 264, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 208, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 256, "start": 252, "tag": "AminoAcidPeptideOrProtein"}, {"end": 256, "start": 252, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 153, "tag": "Chemical"}, {"end": 32, "start": 5, "tag": "ExperimentalModelOfDisease"}, {"end": 152, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 177, "start": 171, "tag": "TemporalConcept"}, {"end": 216, "start": 209, "tag": "AminoAcidPeptideOrProtein"}, {"end": 216, "start": 209, "tag": "BiologicallyActiveSubstance"}]}{"id": "1137_7", "text": "These data demonstrate that dendrimer conjugation of DPTIP improves its PK properties, resulting in significant inhibition of EV propagation of pTau in mice.", "tags": [{"end": 37, "start": 28, "tag": "Chemical"}, {"end": 74, "start": 72, "tag": "BiologicFunction"}, {"end": 74, "start": 72, "tag": "ResearchActivity"}, {"end": 122, "start": 112, "tag": "CellFunction"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 128, "start": 126, "tag": "CellComponent"}, {"end": 156, "start": 152, "tag": "Eukaryote"}, {"end": 58, "start": 53, "tag": "Chemical"}, {"end": 49, "start": 38, "tag": "Finding"}, {"end": 148, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 144, "tag": "BiologicallyActiveSubstance"}]}{"id": "1137_8", "text": "Dendrimer-based delivery of DPTIP has the potential to be an exciting new therapeutic for AD.", "tags": [{"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 0, "tag": "Chemical"}, {"end": 33, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 0, "tag": "HealthCareActivity"}]}{"id": "1138_0", "text": "Background and Objectives Variants of the apolipoprotein E (APOE) gene are the greatest known risk factors for sporadic Alzheimer disease (AD).", "tags": [{"end": 58, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 66, "tag": "GeneOrGenome"}, {"end": 58, "start": 42, "tag": "GeneOrGenome"}, {"end": 58, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 94, "tag": "Finding"}, {"end": 64, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 60, "tag": "GeneOrGenome"}, {"end": 64, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 111, "tag": "TemporalConcept"}, {"end": 106, "start": 94, "tag": "Finding"}, {"end": 137, "start": 120, "tag": "DiseaseOrSyndrome"}]}{"id": "1138_1", "text": "Three major APOE isoform alleles, epsilon 2, epsilon 3, and epsilon 4, encode and produce proteins that differ by only 1-2 amino acids but have different binding partner interactions.", "tags": [{"end": 134, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 12, "tag": "GeneOrGenome"}, {"end": 98, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 154, "tag": "CellFunction"}, {"end": 182, "start": 170, "tag": "Finding"}, {"end": 43, "start": 34, "tag": "GeneOrGenome"}, {"end": 16, "start": 12, "tag": "GeneOrGenome"}, {"end": 54, "start": 45, "tag": "GeneOrGenome"}, {"end": 16, "start": 12, "tag": "GeneOrGenome"}, {"end": 69, "start": 60, "tag": "GeneOrGenome"}, {"end": 16, "start": 12, "tag": "GeneOrGenome"}]}{"id": "1138_2", "text": "Whereas APOE epsilon 2 is protective against AD relative to epsilon 3, epsilon 4 is associated with an increased risk for AD development.", "tags": [{"end": 22, "start": 8, "tag": "GeneOrGenome"}, {"end": 117, "start": 103, "tag": "Finding"}, {"end": 47, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 125, "tag": "BiologicFunction"}, {"end": 136, "start": 125, "tag": "CellFunction"}, {"end": 117, "start": 113, "tag": "Finding"}, {"end": 69, "start": 60, "tag": "GeneOrGenome"}, {"end": 80, "start": 71, "tag": "GeneOrGenome"}]}{"id": "1138_3", "text": "However, the role of APOE in gene regulation in AD pathogenesis has remained largely undetermined.", "tags": [{"end": 44, "start": 29, "tag": "CellFunction"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 51, "tag": "PathologicFunction"}, {"end": 25, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 29, "tag": "GeneOrGenome"}, {"end": 25, "start": 21, "tag": "GeneOrGenome"}]}{"id": "1138_4", "text": "Extracellular vesicles (EVs) are lipid bilayer-delimited particles released by cells to dispose of unwanted materials and mediate intercellular communication, and they are implicated in AD pathophysiology.", "tags": [{"end": 117, "start": 108, "tag": "Substance"}, {"end": 66, "start": 33, "tag": "CellComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 188, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 79, "tag": "Cell"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 204, "start": 189, "tag": "PathologicFunction"}, {"end": 204, "start": 189, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 66, "start": 57, "tag": "Chemical"}, {"end": 38, "start": 33, "tag": "Chemical"}, {"end": 157, "start": 130, "tag": "CellFunction"}, {"end": 157, "start": 144, "tag": "HealthCareActivity"}, {"end": 157, "start": 144, "tag": "CellFunction"}]}{"id": "1138_5", "text": "Brain-derived EVs (bdEVs) could act locally in the tissue and reflect cellular changes.", "tags": [{"end": 17, "start": 14, "tag": "CellComponent"}, {"end": 57, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 19, "tag": "CellComponent"}, {"end": 78, "start": 70, "tag": "Cell"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1138_6", "text": "To reveal whether APOE genotype affects EV components in AD brains, bdEVs were separated from patients with AD with different APOE genotypes for parallel small RNA and protein profile.", "tags": [{"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 40, "tag": "CellComponent"}, {"end": 102, "start": 94, "tag": "PatientOrDisabledGroup"}, {"end": 73, "start": 68, "tag": "CellComponent"}, {"end": 140, "start": 131, "tag": "OrganismAttribute"}, {"end": 22, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 18, "tag": "GeneOrGenome"}, {"end": 130, "start": 126, "tag": "GeneOrGenome"}, {"end": 31, "start": 23, "tag": "OrganismAttribute"}, {"end": 53, "start": 43, "tag": "CellComponent"}, {"end": 66, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 154, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 163, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 175, "start": 168, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 176, "tag": "ResearchActivity"}]}{"id": "1138_7", "text": "Methods bdEVs from late-stage AD brains (BRAAK stages 5-6) from patients with APOE genotypes epsilon 2/3 (n = 5), epsilon 3/3 (n = 5), epsilon 3/4 (n = 6), and epsilon 4/4 (n = 6) were separated using our published protocol into a 10,000g pelleted extracellular fraction (10K) and a further purified EV fraction.", "tags": [{"end": 29, "start": 19, "tag": "TemporalConcept"}, {"end": 23, "start": 19, "tag": "TemporalConcept"}, {"end": 32, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 302, "start": 300, "tag": "CellComponent"}, {"end": 72, "start": 64, "tag": "PatientOrDisabledGroup"}, {"end": 13, "start": 8, "tag": "CellComponent"}, {"end": 92, "start": 83, "tag": "OrganismAttribute"}, {"end": 82, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 78, "tag": "GeneOrGenome"}, {"end": 53, "start": 47, "tag": "TemporalConcept"}, {"end": 39, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 223, "start": 215, "tag": "ResearchActivity"}, {"end": 270, "start": 231, "tag": "ResearchActivity"}, {"end": 311, "start": 300, "tag": "ResearchActivity"}]}{"id": "1138_8", "text": "Counting, sizing, and multiomic characterization by small RNA sequencing and proteomic analysis were performed for 10K, EVs, and source tissue.", "tags": [{"end": 72, "start": 58, "tag": "ResearchActivity"}, {"end": 123, "start": 120, "tag": "CellComponent"}, {"end": 95, "start": 77, "tag": "ResearchActivity"}, {"end": 142, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 22, "tag": "ResearchActivity"}, {"end": 61, "start": 52, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 61, "start": 52, "tag": "BiologicallyActiveSubstance"}]}{"id": "1138_9", "text": "Results Comparing APOE genotypes, no significant differences in bdEV total particle concentration or morphology were observed.", "tags": [{"end": 111, "start": 101, "tag": "Finding"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 60, "start": 49, "tag": "Finding"}, {"end": 68, "start": 64, "tag": "CellComponent"}, {"end": 32, "start": 23, "tag": "OrganismAttribute"}, {"end": 22, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 18, "tag": "GeneOrGenome"}, {"end": 83, "start": 75, "tag": "Chemical"}, {"end": 97, "start": 84, "tag": "BiologicFunction"}]}{"id": "1138_10", "text": "Overall small RNA and protein profiles of 10K, EVs, and source tissue also did not differ substantially between different APOE genotypes.", "tags": [{"end": 50, "start": 47, "tag": "CellComponent"}, {"end": 38, "start": 30, "tag": "ResearchActivity"}, {"end": 69, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 127, "tag": "OrganismAttribute"}, {"end": 126, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 122, "tag": "GeneOrGenome"}, {"end": 17, "start": 8, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 17, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 22, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1138_11", "text": "However, several differences in individual RNAs (including miRNAs and tRNAs) and proteins in 10K and EVs were observed when comparing the highest and lowest risk groups (epsilon 4/4 and epsilon 2/3).", "tags": [{"end": 42, "start": 32, "tag": "PopulationGroup"}, {"end": 42, "start": 32, "tag": "OrganismAttribute"}, {"end": 104, "start": 101, "tag": "CellComponent"}, {"end": 65, "start": 59, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 65, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 70, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 75, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 157, "tag": "Finding"}, {"end": 89, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 17, "tag": "Finding"}, {"end": 47, "start": 43, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1138_12", "text": "Bioinformatic analysis and previous publications indicate a potential regulatory role of these molecules in AD.", "tags": [{"end": 48, "start": 36, "tag": "ResearchActivity"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 0, "tag": "ResearchActivity"}, {"end": 104, "start": 95, "tag": "Substance"}]}{"id": "1138_13", "text": "Discussion For patients with late-stage AD in this study, only a few moderate differences were observed for small RNA and protein profiles between APOE genotypes.", "tags": [{"end": 39, "start": 29, "tag": "TemporalConcept"}, {"end": 33, "start": 29, "tag": "TemporalConcept"}, {"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 15, "tag": "PatientOrDisabledGroup"}, {"end": 56, "start": 51, "tag": "ResearchActivity"}, {"end": 138, "start": 130, "tag": "ResearchActivity"}, {"end": 89, "start": 78, "tag": "Finding"}, {"end": 161, "start": 152, "tag": "OrganismAttribute"}, {"end": 77, "start": 69, "tag": "Finding"}, {"end": 151, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 147, "tag": "GeneOrGenome"}, {"end": 117, "start": 108, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 117, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 122, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1138_14", "text": "Among these, several newly identified 10K and EV-associated molecules may play roles in AD progression.", "tags": [{"end": 90, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 46, "tag": "CellComponent"}, {"end": 102, "start": 91, "tag": "PathologicFunction"}, {"end": 102, "start": 91, "tag": "TemporalConcept"}, {"end": 69, "start": 60, "tag": "Substance"}]}{"id": "1138_15", "text": "Possibly, larger genotype-related differences exist and are more apparent in or before earlier disease stages.", "tags": [{"end": 109, "start": 95, "tag": "ClinicalAttribute"}, {"end": 94, "start": 87, "tag": "TemporalConcept"}, {"end": 45, "start": 34, "tag": "Finding"}, {"end": 25, "start": 17, "tag": "OrganismAttribute"}]}{"id": "1139_0", "text": "Background: A lack of physical exercise, a critical aspect of a healthy lifestyle, contributes to several cerebral diseases, such as cognitive impairment, Parkinson disease (PD), and Alzheimer disease (AD).", "tags": [{"end": 81, "start": 64, "tag": "IndividualBehavior"}, {"end": 123, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 22, "tag": "HealthCareActivity"}, {"end": 172, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 204, "start": 202, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 64, "tag": "OrganismAttribute"}, {"end": 176, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 183, "tag": "DiseaseOrSyndrome"}]}{"id": "1139_1", "text": "The purpose of the present study was to evaluate the effect of physical exercise on cerebral disease via released extracellular vesicles (EVs).", "tags": [{"end": 100, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 63, "tag": "HealthCareActivity"}, {"end": 136, "start": 114, "tag": "CellComponent"}, {"end": 141, "start": 138, "tag": "CellComponent"}, {"end": 32, "start": 27, "tag": "ResearchActivity"}, {"end": 59, "start": 53, "tag": "Finding"}]}{"id": "1139_2", "text": "Material/Methods: Short-term high-intensity treadmill exercise was applied to assess the effect of physical activity on EVs in the serum and brain tissue.", "tags": [{"end": 28, "start": 18, "tag": "TemporalConcept"}, {"end": 116, "start": 99, "tag": "BiologicFunction"}, {"end": 62, "start": 29, "tag": "HealthCareActivity"}, {"end": 123, "start": 120, "tag": "CellComponent"}, {"end": 153, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 89, "tag": "Finding"}]}{"id": "1139_3", "text": "Immunofluorescence staining and western blot analysis were used to analyze biomarkers of EVs, including TSG101, HSC70, and CD63.", "tags": [{"end": 27, "start": 0, "tag": "ResearchActivity"}, {"end": 53, "start": 32, "tag": "ResearchActivity"}, {"end": 110, "start": 104, "tag": "GeneOrGenome"}, {"end": 110, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 112, "tag": "GeneOrGenome"}, {"end": 117, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 89, "tag": "CellComponent"}, {"end": 85, "start": 75, "tag": "ClinicalAttribute"}, {"end": 127, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 123, "tag": "GeneOrGenome"}, {"end": 110, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 112, "tag": "BiologicallyActiveSubstance"}]}{"id": "1139_4", "text": "Nanoparticle tracking analysis (NTA) was used to analyze the size and concentration of EVs.", "tags": [{"end": 90, "start": 87, "tag": "CellComponent"}, {"end": 30, "start": 0, "tag": "ResearchActivity"}, {"end": 65, "start": 61, "tag": "OrganismAttribute"}, {"end": 35, "start": 32, "tag": "ResearchActivity"}, {"end": 83, "start": 70, "tag": "BiologicFunction"}]}{"id": "1139_5", "text": "Results: Short-term high-intensity exercise increased the number of neuronal EVs in the brain.", "tags": [{"end": 19, "start": 9, "tag": "TemporalConcept"}, {"end": 43, "start": 20, "tag": "HealthCareActivity"}, {"end": 80, "start": 77, "tag": "CellComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 93, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 68, "tag": "Cell"}]}{"id": "1139_6", "text": "In the peripheral blood serum, the level of HSC70 showed a temporary increase after exercise and quickly returned to the normal level, whereas the levels of CD63 and TSG101 showed no obvious change in response to physical exercise.", "tags": [{"end": 29, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 44, "tag": "GeneOrGenome"}, {"end": 49, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 59, "tag": "TemporalConcept"}, {"end": 172, "start": 166, "tag": "GeneOrGenome"}, {"end": 172, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 84, "tag": "HealthCareActivity"}, {"end": 230, "start": 213, "tag": "HealthCareActivity"}, {"end": 127, "start": 121, "tag": "Finding"}, {"end": 161, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 157, "tag": "GeneOrGenome"}, {"end": 49, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 197, "start": 180, "tag": "Finding"}]}{"id": "1139_7", "text": "In brain tissue, the levels of HSC70 and TSG101 increased dramatically after exercise, while the level of CD63 remained unchanged.", "tags": [{"end": 36, "start": 31, "tag": "GeneOrGenome"}, {"end": 36, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 41, "tag": "GeneOrGenome"}, {"end": 47, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 120, "tag": "Finding"}, {"end": 85, "start": 77, "tag": "HealthCareActivity"}, {"end": 15, "start": 3, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 106, "tag": "GeneOrGenome"}, {"end": 47, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 31, "tag": "BiologicallyActiveSubstance"}]}{"id": "1139_8", "text": "The concentration of EVs was significantly increased after exercise, while the mean diameter of the EVs showed no significant change.", "tags": [{"end": 132, "start": 111, "tag": "Finding"}, {"end": 67, "start": 59, "tag": "HealthCareActivity"}, {"end": 24, "start": 21, "tag": "CellComponent"}, {"end": 103, "start": 100, "tag": "CellComponent"}, {"end": 52, "start": 29, "tag": "Finding"}, {"end": 17, "start": 4, "tag": "BiologicFunction"}]}{"id": "1139_9", "text": "The levels of ceramide were significantly increased after exercise, and quickly returned to normal levels.", "tags": [{"end": 66, "start": 58, "tag": "HealthCareActivity"}, {"end": 98, "start": 92, "tag": "Finding"}, {"end": 51, "start": 28, "tag": "Finding"}, {"end": 22, "start": 14, "tag": "Chemical"}, {"end": 22, "start": 14, "tag": "BiologicallyActiveSubstance"}]}{"id": "1139_10", "text": "Conclusions: These data suggest that the secretion of EVs in the brain and blood is a transitory response to physical exercise and is dependent on ceramide synthesis.", "tags": [{"end": 143, "start": 134, "tag": "Finding"}, {"end": 165, "start": 147, "tag": "CellFunction"}, {"end": 126, "start": 109, "tag": "HealthCareActivity"}, {"end": 57, "start": 54, "tag": "CellComponent"}, {"end": 70, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 41, "tag": "CellFunction"}, {"end": 50, "start": 41, "tag": "BiologicFunction"}, {"end": 155, "start": 147, "tag": "Chemical"}, {"end": 155, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 19, "tag": "ResearchActivity"}]}{"id": "1140_0", "text": "Alzheimer's disease (AD) is a neurodegenerative disease responsible for 60-70% of the 50 million cases of dementia worldwide.", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 30, "tag": "DiseaseOrSyndrome"}]}{"id": "1140_1", "text": "It is characterized by neuronal cell death, shrinkage of brain tissue, and progressive cognitive, motor, and behavioral impairment, which often leads to death.", "tags": [{"end": 53, "start": 44, "tag": "Finding"}, {"end": 31, "start": 23, "tag": "Cell"}, {"end": 69, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 37, "tag": "BiologicFunction"}, {"end": 158, "start": 153, "tag": "BiologicFunction"}, {"end": 42, "start": 37, "tag": "PathologicFunction"}, {"end": 158, "start": 153, "tag": "PathologicFunction"}, {"end": 42, "start": 37, "tag": "CellFunction"}, {"end": 158, "start": 153, "tag": "CellFunction"}, {"end": 86, "start": 75, "tag": "TemporalConcept"}, {"end": 42, "start": 32, "tag": "CellFunction"}, {"end": 42, "start": 23, "tag": "CellFunction"}, {"end": 130, "start": 87, "tag": "Finding"}]}{"id": "1140_2", "text": "Although current treatment has helped improve the patient's quality of life, it has not been able to alter the underlying disease pathology of AD.", "tags": [{"end": 75, "start": 60, "tag": "Finding"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 50, "tag": "PatientOrDisabledGroup"}, {"end": 26, "start": 17, "tag": "HealthCareActivity"}, {"end": 26, "start": 17, "tag": "ResearchActivity"}, {"end": 16, "start": 9, "tag": "TemporalConcept"}, {"end": 75, "start": 71, "tag": "TemporalConcept"}, {"end": 139, "start": 122, "tag": "PathologicFunction"}]}{"id": "1140_3", "text": "Studies have shown that mesenchymal stem cells (MSCs)-a group of multipotent stem cells-have the ability to stimulate neuroregeneration and inhibit disease progression.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 76, "start": 65, "tag": "Cell"}, {"end": 61, "start": 56, "tag": "PopulationGroup"}, {"end": 167, "start": 156, "tag": "PathologicFunction"}, {"end": 167, "start": 156, "tag": "TemporalConcept"}, {"end": 167, "start": 148, "tag": "PathologicFunction"}, {"end": 46, "start": 36, "tag": "Cell"}, {"end": 87, "start": 77, "tag": "Cell"}, {"end": 52, "start": 48, "tag": "Cell"}, {"end": 104, "start": 97, "tag": "OrganismAttribute"}, {"end": 46, "start": 24, "tag": "Cell"}, {"end": 135, "start": 118, "tag": "BiologicFunction"}]}{"id": "1140_4", "text": "More recently, extracellular vesicles (EVs) from cytokine-preconditioned MSCs have also shown to induce immunomodulatory and neuroprotective effects in AD models.", "tags": [{"end": 37, "start": 15, "tag": "CellComponent"}, {"end": 42, "start": 39, "tag": "CellComponent"}, {"end": 154, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 155, "tag": "ResearchActivity"}, {"end": 13, "start": 5, "tag": "TemporalConcept"}, {"end": 77, "start": 73, "tag": "Cell"}, {"end": 148, "start": 141, "tag": "Finding"}, {"end": 120, "start": 104, "tag": "PharmacologicSubstance"}, {"end": 120, "start": 104, "tag": "BiologicFunction"}, {"end": 120, "start": 104, "tag": "HealthCareActivity"}, {"end": 140, "start": 125, "tag": "CellFunction"}, {"end": 148, "start": 125, "tag": "Finding"}, {"end": 57, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 152, "tag": "ExperimentalModelOfDisease"}]}{"id": "1140_5", "text": "This review will aim to compile pertinent preclinical AD research on transgenic mice as well as clinical trials on MSC-based therapy from diverse sources.", "tags": [{"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 57, "tag": "ResearchActivity"}, {"end": 53, "start": 42, "tag": "ResearchActivity"}, {"end": 84, "start": 69, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 153, "start": 146, "tag": "Finding"}, {"end": 132, "start": 125, "tag": "HealthCareActivity"}, {"end": 118, "start": 115, "tag": "Cell"}, {"end": 111, "start": 96, "tag": "ResearchActivity"}]}{"id": "1141_0", "text": "Many neurodegenerative diseases are characterized by abnormal protein aggregates, including the two most common neurodegenerative diseases Alzheimer's disease (AD) and Parkinson's disease (PD).", "tags": [{"end": 80, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 53, "tag": "CellOrMolecularDysfunction"}, {"end": 158, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 5, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 189, "tag": "DiseaseOrSyndrome"}]}{"id": "1141_1", "text": "In the global search to prevent and treat diseases, most research has been focused on the early stages of the diseases, including how these pathogenic protein aggregates are initially formed.", "tags": [{"end": 169, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 65, "start": 57, "tag": "ResearchActivity"}, {"end": 150, "start": 140, "tag": "PathologicFunction"}, {"end": 102, "start": 90, "tag": "TemporalConcept"}]}{"id": "1141_2", "text": "We argue, however, that an equally important aspect of disease etiology is the characteristic spread of protein aggregates throughout the nervous system, a key process in disease progression.", "tags": [{"end": 122, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 63, "tag": "Finding"}, {"end": 152, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 179, "tag": "PathologicFunction"}, {"end": 190, "start": 179, "tag": "TemporalConcept"}, {"end": 190, "start": 171, "tag": "PathologicFunction"}]}{"id": "1141_3", "text": "Growing evidence suggests that both alterations in lipid metabolism and dysregulation of extracellular vesicles (EVs) accelerate the spread of protein aggregation and progression of neurodegeneration, both in neurons and potentially in surrounding glia.", "tags": [{"end": 67, "start": 51, "tag": "CellFunction"}, {"end": 67, "start": 51, "tag": "BiologicFunction"}, {"end": 252, "start": 248, "tag": "Cell"}, {"end": 178, "start": 167, "tag": "PathologicFunction"}, {"end": 178, "start": 167, "tag": "TemporalConcept"}, {"end": 15, "start": 0, "tag": "Finding"}, {"end": 111, "start": 89, "tag": "CellComponent"}, {"end": 116, "start": 113, "tag": "CellComponent"}, {"end": 199, "start": 182, "tag": "CellOrMolecularDysfunction"}, {"end": 216, "start": 209, "tag": "Cell"}, {"end": 162, "start": 143, "tag": "CellFunction"}, {"end": 47, "start": 36, "tag": "Finding"}]}{"id": "1141_4", "text": "We will review how these two pathways are intertwined and accelerate the progression of AD and PD.", "tags": [{"end": 84, "start": 73, "tag": "PathologicFunction"}, {"end": 84, "start": 73, "tag": "TemporalConcept"}, {"end": 90, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 29, "tag": "CellFunction"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}]}{"id": "1141_5", "text": "Understanding how lipid metabolism, EV biogenesis, and EV uptake regulate the spread of pathogenic protein aggregation could reveal novel therapeutic targets to slow or halt neurodegenerative disease progression.", "tags": [{"end": 34, "start": 18, "tag": "CellFunction"}, {"end": 34, "start": 18, "tag": "BiologicFunction"}, {"end": 64, "start": 58, "tag": "BiologicFunction"}, {"end": 64, "start": 58, "tag": "CellFunction"}, {"end": 211, "start": 200, "tag": "PathologicFunction"}, {"end": 211, "start": 200, "tag": "TemporalConcept"}, {"end": 38, "start": 36, "tag": "CellComponent"}, {"end": 57, "start": 55, "tag": "CellComponent"}, {"end": 49, "start": 39, "tag": "CellFunction"}, {"end": 118, "start": 88, "tag": "PathologicFunction"}, {"end": 157, "start": 138, "tag": "ResearchActivity"}, {"end": 211, "start": 192, "tag": "PathologicFunction"}, {"end": 199, "start": 174, "tag": "DiseaseOrSyndrome"}]}{"id": "1142_0", "text": "Pulmonary hypertension (PH) is a severe cardiopulmonary disease characterized by complement dependent, fibroblast-induced perivascular accumulation and proinflammatory activation of macrophages.", "tags": [{"end": 22, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 182, "tag": "Cell"}, {"end": 147, "start": 135, "tag": "Finding"}, {"end": 39, "start": 33, "tag": "Finding"}, {"end": 167, "start": 152, "tag": "PathologicFunction"}, {"end": 113, "start": 103, "tag": "Cell"}, {"end": 178, "start": 168, "tag": "CellFunction"}]}{"id": "1142_1", "text": "We hypothesized that, in PH, nanoscale-sized small extracellular vesicles (sEVs), released by perivascular/adventitial fibroblasts, are critical mediators of complement-dependent proinflammatory activation of macrophages.", "tags": [{"end": 27, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 119, "tag": "Cell"}, {"end": 220, "start": 209, "tag": "Cell"}, {"end": 73, "start": 51, "tag": "CellComponent"}, {"end": 154, "start": 145, "tag": "Finding"}, {"end": 194, "start": 179, "tag": "PathologicFunction"}, {"end": 73, "start": 45, "tag": "CellComponent"}, {"end": 79, "start": 75, "tag": "CellComponent"}, {"end": 168, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 195, "tag": "CellFunction"}]}{"id": "1142_2", "text": "Pulmonary adventitial fibroblasts were isolated from calves with severe PH (PH-Fibs) and age-matched controls (CO-Fibs).", "tags": [{"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 101, "tag": "PopulationGroup"}, {"end": 92, "start": 89, "tag": "OrganismAttribute"}, {"end": 71, "start": 65, "tag": "Finding"}, {"end": 33, "start": 0, "tag": "Cell"}]}{"id": "1142_3", "text": "PH-Fibs exhibited increased secretion of sEVs, compared with CO-Fibs, and sEV biological activity was tested on mouse and bovine bone marrow-derived macrophages (BMDMs) and showed similar responses.", "tags": [{"end": 160, "start": 134, "tag": "Cell"}, {"end": 167, "start": 162, "tag": "Cell"}, {"end": 140, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 160, "start": 149, "tag": "Cell"}, {"end": 117, "start": 112, "tag": "Eukaryote"}, {"end": 37, "start": 28, "tag": "CellFunction"}, {"end": 37, "start": 28, "tag": "BiologicFunction"}, {"end": 45, "start": 41, "tag": "CellComponent"}, {"end": 77, "start": 74, "tag": "CellComponent"}, {"end": 45, "start": 28, "tag": "CellFunction"}, {"end": 133, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 122, "tag": "Eukaryote"}]}{"id": "1142_4", "text": "Compared with sEVs derived from CO-Fibs, sEVs derived from PH-Fibs (PH-Fib-sEVs) induced augmented expression of proinflammatory cytokines/chemokines and metabolic genes in BMDMs.", "tags": [{"end": 178, "start": 173, "tag": "Cell"}, {"end": 109, "start": 99, "tag": "CellFunction"}, {"end": 138, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 113, "tag": "PathologicFunction"}, {"end": 149, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 14, "tag": "CellComponent"}, {"end": 45, "start": 41, "tag": "CellComponent"}, {"end": 138, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 154, "tag": "GeneOrGenome"}]}{"id": "1142_5", "text": "Pharmacological blockade of exosome release from PH-Fibs resulted in significant attenuation of proinflammatory activation of BMDMs.", "tags": [{"end": 131, "start": 126, "tag": "Cell"}, {"end": 24, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 24, "start": 0, "tag": "HealthCareActivity"}, {"end": 35, "start": 28, "tag": "CellComponent"}, {"end": 111, "start": 96, "tag": "PathologicFunction"}, {"end": 43, "start": 36, "tag": "HealthCareActivity"}, {"end": 43, "start": 36, "tag": "ResearchActivity"}, {"end": 43, "start": 28, "tag": "CellFunction"}, {"end": 122, "start": 112, "tag": "CellFunction"}]}{"id": "1142_6", "text": "Bottom-up proteomic analyses revealed significant enrichment of complement and coagulation cascades in PH-Fib-sEVs, including augmented expression of the complement component C3.", "tags": [{"end": 74, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 177, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 50, "tag": "ResearchActivity"}, {"end": 146, "start": 136, "tag": "CellFunction"}, {"end": 90, "start": 79, "tag": "BiologicFunction"}, {"end": 28, "start": 0, "tag": "ResearchActivity"}, {"end": 114, "start": 110, "tag": "CellComponent"}]}{"id": "1142_7", "text": "We therefore examined whether the PH-Fib-sEV- mediated proinflammatory activation of BMDMs was complement C3 dependent.", "tags": [{"end": 90, "start": 85, "tag": "Cell"}, {"end": 70, "start": 55, "tag": "PathologicFunction"}, {"end": 44, "start": 41, "tag": "CellComponent"}, {"end": 81, "start": 71, "tag": "CellFunction"}, {"end": 108, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 95, "tag": "BiologicallyActiveSubstance"}]}{"id": "1142_8", "text": "Treatment of PH-Fibs with siC3-RNA significantly attenuated the capacity of PH-Fib-sEVs for proinflammatory activation of BMDMs.", "tags": [{"end": 127, "start": 122, "tag": "Cell"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 72, "start": 64, "tag": "Finding"}, {"end": 107, "start": 92, "tag": "PathologicFunction"}, {"end": 87, "start": 83, "tag": "CellComponent"}, {"end": 34, "start": 26, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 34, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 108, "tag": "CellFunction"}]}{"id": "1142_9", "text": "PH-Fib-sEVs mediated proglycolytic alterations and complement-dependent activation of macrophages toward a proinflammatory phenotype, as confirmed by metabolomic studies.", "tags": [{"end": 97, "start": 86, "tag": "Cell"}, {"end": 169, "start": 150, "tag": "ResearchActivity"}, {"end": 132, "start": 123, "tag": "OrganismAttribute"}, {"end": 122, "start": 107, "tag": "PathologicFunction"}, {"end": 11, "start": 7, "tag": "CellComponent"}, {"end": 46, "start": 35, "tag": "Finding"}, {"end": 61, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 72, "tag": "CellFunction"}]}{"id": "1142_10", "text": "Thus, fibroblast-released sEVs served as critical mediators of complement-induced perivascular/microenvironmental inflammation in PH.", "tags": [{"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 114, "tag": "PathologicFunction"}, {"end": 59, "start": 50, "tag": "Finding"}, {"end": 30, "start": 26, "tag": "CellComponent"}, {"end": 16, "start": 6, "tag": "Cell"}, {"end": 73, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1143_0", "text": "Neurodegenerative disorders of the central nervous system (CNS) and brain traumatic insults are characterized by complex overlapping pathophysiological alterations encompassing neuroinflammation, alterations of synaptic functions, oxidative stress, and progressive neurodegeneration that eventually lead to irreversible motor and cognitive dysfunctions.", "tags": [{"end": 91, "start": 68, "tag": "InjuryOrPoisoning"}, {"end": 352, "start": 330, "tag": "DiseaseOrSyndrome"}, {"end": 247, "start": 241, "tag": "PathologicFunction"}, {"end": 27, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 211, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 247, "start": 231, "tag": "CellOrMolecularDysfunction"}, {"end": 282, "start": 265, "tag": "CellOrMolecularDysfunction"}, {"end": 264, "start": 253, "tag": "TemporalConcept"}, {"end": 194, "start": 177, "tag": "PathologicFunction"}, {"end": 163, "start": 152, "tag": "Finding"}, {"end": 207, "start": 196, "tag": "Finding"}, {"end": 151, "start": 133, "tag": "PathologicFunction"}, {"end": 229, "start": 211, "tag": "CellFunction"}]}{"id": "1143_1", "text": "A single pharmacological approach is unlikely to provide a complementary set of molecular therapeutic actions suitable to resolve these complex pathologies.", "tags": [{"end": 155, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 2, "tag": "PharmacologicSubstance"}]}{"id": "1143_2", "text": "Recent preclinical data are providing evidence-based scientific rationales to support biotherapies based on administering neurotrophic factors and extracellular vesicles present in the lysates of human platelets collected from healthy donors to the brain.", "tags": [{"end": 98, "start": 86, "tag": "HealthCareActivity"}, {"end": 211, "start": 202, "tag": "Cell"}, {"end": 23, "start": 7, "tag": "ResearchActivity"}, {"end": 241, "start": 235, "tag": "PopulationGroup"}, {"end": 169, "start": 147, "tag": "CellComponent"}, {"end": 234, "start": 227, "tag": "OrganismAttribute"}, {"end": 46, "start": 38, "tag": "Finding"}, {"end": 254, "start": 249, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 196, "tag": "Eukaryote"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 142, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 185, "tag": "Substance"}, {"end": 211, "start": 185, "tag": "PharmacologicSubstance"}, {"end": 211, "start": 185, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1143_3", "text": "Here, we present the most recent findings on the composition of the platelet proteome that can activate complementary signaling pathways in vivo to trigger neuroprotection, synapse protection, anti-inflammation, antioxidation, and neurorestoration.", "tags": [{"end": 210, "start": 193, "tag": "PharmacologicSubstance"}, {"end": 76, "start": 68, "tag": "Cell"}, {"end": 171, "start": 156, "tag": "CellFunction"}, {"end": 180, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 210, "start": 198, "tag": "PathologicFunction"}, {"end": 85, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 137, "tag": "ResearchActivity"}, {"end": 136, "start": 118, "tag": "CellFunction"}, {"end": 32, "start": 26, "tag": "TemporalConcept"}, {"end": 191, "start": 181, "tag": "Finding"}, {"end": 247, "start": 231, "tag": "CellFunction"}, {"end": 225, "start": 212, "tag": "CellFunction"}]}{"id": "1143_4", "text": "We also report experimental data where the administration of human platelet lysates (HPL) was safe and resulted in beneficial neuroprotective effects in established rodent models of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, traumatic brain injury, and stroke.", "tags": [{"end": 208, "start": 165, "tag": "ExperimentalModelOfDisease"}, {"end": 171, "start": 165, "tag": "Eukaryote"}, {"end": 281, "start": 259, "tag": "InjuryOrPoisoning"}, {"end": 293, "start": 287, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 15, "tag": "ResearchActivity"}, {"end": 257, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 236, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 274, "start": 269, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 61, "tag": "Eukaryote"}, {"end": 208, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 142, "tag": "Finding"}, {"end": 141, "start": 126, "tag": "CellFunction"}, {"end": 149, "start": 126, "tag": "Finding"}, {"end": 57, "start": 43, "tag": "HealthCareActivity"}, {"end": 83, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 67, "tag": "PharmacologicSubstance"}]}{"id": "1143_5", "text": "Platelet-based biotherapies, prepared from collected platelet concentrates (PC), are emerging as a novel pragmatic and accessible translational therapeutic strategy for treating neurological diseases.", "tags": [{"end": 164, "start": 130, "tag": "HealthCareActivity"}, {"end": 199, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 0, "tag": "HealthCareActivity"}, {"end": 74, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 53, "tag": "PharmacologicSubstance"}]}{"id": "1143_6", "text": "Based on this assumption, we further elaborated on various clinical, manufacturing, and regulatory issues that need to be addressed to ensure the ethical supply, quality, and safety of HPL preparations for treating neurodegenerative and traumatic pathologies of the CNS.", "tags": [{"end": 269, "start": 266, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 232, "start": 215, "tag": "CellOrMolecularDysfunction"}, {"end": 258, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 175, "tag": "HealthCareActivity"}, {"end": 82, "start": 69, "tag": "ResearchActivity"}, {"end": 201, "start": 185, "tag": "PharmacologicSubstance"}]}{"id": "1143_7", "text": "HPL made from PC may become a unique approach for scientifically based treatments of neurological disorders readily accessible in low-, middle-, and high-income countries.", "tags": [{"end": 160, "start": 154, "tag": "OrganismAttribute"}, {"end": 81, "start": 71, "tag": "HealthCareActivity"}, {"end": 81, "start": 71, "tag": "ResearchActivity"}, {"end": 107, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 170, "start": 161, "tag": "PopulationGroup"}]}{"id": "1143_8", "text": "[GRAPHICS] .", "tags": []}{"id": "1144_0", "text": "Biomarkers are molecules that are variable in their origin, nature, and mechanism of action; they are of great relevance in biology and also in medicine because of their specific connection with a single or several diseases.", "tags": [{"end": 152, "start": 144, "tag": "PharmacologicSubstance"}, {"end": 152, "start": 144, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 58, "start": 52, "tag": "TemporalConcept"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 131, "start": 124, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 24, "start": 15, "tag": "Substance"}, {"end": 131, "start": 124, "tag": "BiologicFunction"}]}{"id": "1144_1", "text": "Biomarkers are of two types, which in some cases are operative with each other.", "tags": [{"end": 10, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1144_2", "text": "Fluid biomarkers, started around 2000, are generated in fluid from specific proteins/peptides and miRNAs accumulated within two extracellular fluids, either the central spinal fluid or blood plasma.", "tags": [{"end": 148, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 197, "start": 185, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 0, "tag": "ClinicalAttribute"}, {"end": 104, "start": 98, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 104, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 56, "tag": "Substance"}, {"end": 181, "start": 176, "tag": "Substance"}, {"end": 93, "start": 85, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1144_3", "text": "The switch of these proteins/peptides and miRNAs, from free to segregated within extracellular vesicles, has induced certain advantages including higher levels within fluids and lower operative expenses.", "tags": [{"end": 173, "start": 167, "tag": "Substance"}, {"end": 103, "start": 81, "tag": "CellComponent"}, {"end": 48, "start": 42, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 48, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 29, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1144_4", "text": "Imaging biomarkers, started around 2004, are identified in vivo upon their binding by radiolabeled molecules subsequently revealed in the brain by positron emission tomography and/or other imaging techniques.", "tags": [{"end": 207, "start": 189, "tag": "HealthCareActivity"}, {"end": 143, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 0, "tag": "ClinicalAttribute"}, {"end": 63, "start": 56, "tag": "ResearchActivity"}, {"end": 175, "start": 147, "tag": "HealthCareActivity"}, {"end": 108, "start": 99, "tag": "Substance"}, {"end": 82, "start": 75, "tag": "CellFunction"}, {"end": 98, "start": 86, "tag": "Chemical"}]}{"id": "1144_5", "text": "A positive point for the latter approach is the quantitation of results, but expenses are much higher.", "tags": []}{"id": "1144_6", "text": "At present, both types of biomarker are being extensively employed to study Alzheimer's and other neurodegenerative diseases, investigated from the presymptomatic to mature stages.", "tags": [{"end": 162, "start": 148, "tag": "TemporalConcept"}, {"end": 172, "start": 166, "tag": "TemporalConcept"}, {"end": 75, "start": 70, "tag": "ResearchActivity"}, {"end": 35, "start": 26, "tag": "ClinicalAttribute"}, {"end": 124, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 173, "tag": "TemporalConcept"}]}{"id": "1144_7", "text": "In conclusion, biomarkers have revolutionized scientific and medical research and practice.", "tags": [{"end": 77, "start": 61, "tag": "ResearchActivity"}, {"end": 90, "start": 82, "tag": "BiologicFunction"}, {"end": 25, "start": 15, "tag": "ClinicalAttribute"}, {"end": 90, "start": 82, "tag": "HealthCareActivity"}, {"end": 68, "start": 61, "tag": "HealthCareActivity"}]}{"id": "1144_8", "text": "Diagnosis, which is often inadequate when based on medical criteria only, has been recently improved by the multiplicity and specificity of biomarkers.", "tags": [{"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 150, "start": 140, "tag": "ClinicalAttribute"}, {"end": 136, "start": 125, "tag": "Finding"}, {"end": 91, "start": 83, "tag": "TemporalConcept"}, {"end": 67, "start": 51, "tag": "HealthCareActivity"}]}{"id": "1144_9", "text": "Analogous results have been obtained for prognosis.", "tags": [{"end": 50, "start": 41, "tag": "HealthCareActivity"}]}{"id": "1144_10", "text": "In contrast, improvement of therapy has been limited or fully absent, especially for Alzheimer's in which progress has been inadequate.", "tags": [{"end": 114, "start": 106, "tag": "TemporalConcept"}, {"end": 96, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 28, "tag": "HealthCareActivity"}]}{"id": "1144_11", "text": "An urgent need at hand is therefore the progress of a new drug trial design together with patient management in clinical practice.", "tags": [{"end": 22, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 90, "tag": "HealthCareActivity"}, {"end": 75, "start": 58, "tag": "ResearchActivity"}, {"end": 48, "start": 40, "tag": "TemporalConcept"}, {"end": 129, "start": 112, "tag": "HealthCareActivity"}, {"end": 62, "start": 58, "tag": "PharmacologicSubstance"}]}{"id": "1145_0", "text": "In Alzheimer's disease (AD), beta-amyloid peptides aggregate to form amyloid plaques, and the microtubule-associated protein tau forms neurofibrillary tangles.", "tags": [{"end": 84, "start": 69, "tag": "AnatomicalAbnormality"}, {"end": 22, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 135, "tag": "CellOrMolecularDysfunction"}, {"end": 124, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 42, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1145_1", "text": "However, severity and duration of AD correlate with the stereotypical emergence of tau tangles throughout the brain, suggestive of a gradual region-to-region spreading of pathological tau.", "tags": [{"end": 30, "start": 22, "tag": "TemporalConcept"}, {"end": 36, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 187, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 9, "tag": "ClinicalAttribute"}, {"end": 17, "start": 9, "tag": "Finding"}, {"end": 79, "start": 70, "tag": "TemporalConcept"}, {"end": 94, "start": 83, "tag": "CellOrMolecularDysfunction"}, {"end": 187, "start": 158, "tag": "PathologicFunction"}]}{"id": "1145_2", "text": "The current notion in the field is that misfolded tau seeds propagate transsynaptically and corrupt the proper folding of soluble tau in recipient neurons.", "tags": [{"end": 118, "start": 111, "tag": "CellFunction"}, {"end": 129, "start": 122, "tag": "CellComponent"}, {"end": 59, "start": 40, "tag": "CellOrMolecularDysfunction"}, {"end": 53, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 130, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}, {"end": 154, "start": 137, "tag": "Cell"}, {"end": 87, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1145_3", "text": "This is supported by accumulating evidence showing that in AD, functional connectivity and not proximity predicts the spreading of tau pathology.", "tags": [{"end": 144, "start": 131, "tag": "PathologicFunction"}, {"end": 42, "start": 21, "tag": "Finding"}, {"end": 86, "start": 63, "tag": "BiologicFunction"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 118, "tag": "PathologicFunction"}]}{"id": "1145_4", "text": "Tau seeds can be found in two flavors, vesicle-free, that is, naked as in oligomers and fibrils, or encapsulated by membranes of secreted vesicles known as exosomes.", "tags": [{"end": 37, "start": 30, "tag": "Chemical"}, {"end": 125, "start": 116, "tag": "CellComponent"}, {"end": 95, "start": 88, "tag": "CellComponent"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 138, "tag": "CellComponent"}, {"end": 46, "start": 39, "tag": "CellComponent"}, {"end": 164, "start": 156, "tag": "CellComponent"}, {"end": 9, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 83, "start": 74, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1145_5", "text": "Both types of seeds have been shown to propagate between interconnected neurons.", "tags": [{"end": 79, "start": 72, "tag": "Cell"}]}{"id": "1145_6", "text": "Here, we describe potential ways of how their propagation can be controlled in several subcellular compartments by manipulating mechanisms affecting production, neuron-to-neuron transmission, internalization, endosomal escape, and autophagy.", "tags": [{"end": 207, "start": 192, "tag": "BiologicFunction"}, {"end": 167, "start": 161, "tag": "Cell"}, {"end": 177, "start": 171, "tag": "Cell"}, {"end": 190, "start": 178, "tag": "Finding"}, {"end": 57, "start": 46, "tag": "Finding"}, {"end": 240, "start": 231, "tag": "CellFunction"}, {"end": 111, "start": 87, "tag": "CellComponent"}, {"end": 225, "start": 209, "tag": "CellFunction"}]}{"id": "1145_7", "text": "We emphasize that although vesicle-free tau seeds and exosomes differ, they share the ability to trigger endolysosomal permeabilization.", "tags": [{"end": 118, "start": 105, "tag": "CellComponent"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 27, "tag": "CellComponent"}, {"end": 93, "start": 86, "tag": "OrganismAttribute"}, {"end": 62, "start": 54, "tag": "CellComponent"}, {"end": 135, "start": 105, "tag": "CellFunction"}, {"end": 49, "start": 40, "tag": "CellOrMolecularDysfunction"}]}{"id": "1145_8", "text": "Such a mechanistic convergence in endolysosomal permeabilization presents itself as a unique opportunity to target both types of tau seeding.", "tags": [{"end": 30, "start": 19, "tag": "Finding"}, {"end": 30, "start": 19, "tag": "BiologicFunction"}, {"end": 47, "start": 34, "tag": "CellComponent"}, {"end": 132, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 34, "tag": "CellFunction"}, {"end": 140, "start": 129, "tag": "CellFunction"}]}{"id": "1145_9", "text": "We discuss the cellular response to endolysosomal damage that might be key to control permeabilization, and the significant overlap in the seeding mechanism of proteopathic agents other than tau, which suggests that targeting the endolysosomal pathway could pave the way toward developing broad-spectrum treatments for neurodegenerative diseases.", "tags": [{"end": 131, "start": 124, "tag": "TemporalConcept"}, {"end": 303, "start": 295, "tag": "ResearchActivity"}, {"end": 32, "start": 15, "tag": "CellFunction"}, {"end": 49, "start": 36, "tag": "CellComponent"}, {"end": 243, "start": 230, "tag": "CellComponent"}, {"end": 194, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 194, "start": 191, "tag": "BiologicallyActiveSubstance"}, {"end": 345, "start": 319, "tag": "DiseaseOrSyndrome"}, {"end": 314, "start": 304, "tag": "HealthCareActivity"}, {"end": 314, "start": 304, "tag": "ResearchActivity"}, {"end": 251, "start": 230, "tag": "CellFunction"}, {"end": 56, "start": 50, "tag": "InjuryOrPoisoning"}, {"end": 179, "start": 160, "tag": "PathologicFunction"}, {"end": 156, "start": 139, "tag": "CellFunction"}]}{"id": "1146_0", "text": "The ratio of excitatory to inhibitory neurotransmitters is essential for maintaining the firing patterns of neural networks, and is strictly regulated within individual neurons and brain regions.", "tags": [{"end": 37, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 96, "tag": "ResearchActivity"}, {"end": 168, "start": 158, "tag": "PopulationGroup"}, {"end": 168, "start": 158, "tag": "OrganismAttribute"}, {"end": 176, "start": 169, "tag": "Cell"}, {"end": 194, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 115, "tag": "CellFunction"}, {"end": 55, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 38, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1146_1", "text": "Excitatory to inhibitory (E/I) imbalance has been shown to participate in the progression of neurodegenerative diseases, including Alzheimer's disease (AD).", "tags": [{"end": 40, "start": 0, "tag": "PathologicFunction"}, {"end": 150, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 78, "tag": "PathologicFunction"}, {"end": 89, "start": 78, "tag": "TemporalConcept"}, {"end": 119, "start": 93, "tag": "DiseaseOrSyndrome"}]}{"id": "1146_2", "text": "Glutamate excitotoxicity and GABAergic neuron dysfunction appear to be key components of the neuronal cell death that takes place in AD.", "tags": [{"end": 106, "start": 93, "tag": "CellComponent"}, {"end": 24, "start": 10, "tag": "PathologicFunction"}, {"end": 135, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 29, "tag": "Cell"}, {"end": 101, "start": 93, "tag": "Cell"}, {"end": 112, "start": 107, "tag": "BiologicFunction"}, {"end": 112, "start": 107, "tag": "PathologicFunction"}, {"end": 112, "start": 107, "tag": "CellFunction"}, {"end": 112, "start": 102, "tag": "CellFunction"}, {"end": 57, "start": 46, "tag": "PathologicFunction"}, {"end": 112, "start": 93, "tag": "CellFunction"}, {"end": 9, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 29, "tag": "CellOrMolecularDysfunction"}]}{"id": "1146_3", "text": "Since extracellular vesicles (EVs) are now explored as an important vehicle in transmitting signals between cells, we hypothesized that the function of neuron-derived small EVs (sEVs) might be regulated by the status of neurotransmitter balance and that sEVs might affect amyloid beta (A beta) toxicity on neurons.", "tags": [{"end": 236, "start": 220, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 167, "tag": "CellComponent"}, {"end": 302, "start": 294, "tag": "InjuryOrPoisoning"}, {"end": 28, "start": 6, "tag": "CellComponent"}, {"end": 33, "start": 30, "tag": "CellComponent"}, {"end": 176, "start": 173, "tag": "CellComponent"}, {"end": 158, "start": 152, "tag": "Cell"}, {"end": 113, "start": 108, "tag": "Cell"}, {"end": 99, "start": 92, "tag": "CellFunction"}, {"end": 284, "start": 272, "tag": "AminoAcidPeptideOrProtein"}, {"end": 292, "start": 286, "tag": "AminoAcidPeptideOrProtein"}, {"end": 279, "start": 272, "tag": "AminoAcidPeptideOrProtein"}, {"end": 279, "start": 272, "tag": "BiologicallyActiveSubstance"}, {"end": 313, "start": 306, "tag": "Cell"}, {"end": 216, "start": 210, "tag": "Finding"}, {"end": 182, "start": 178, "tag": "CellComponent"}, {"end": 258, "start": 254, "tag": "CellComponent"}]}{"id": "1146_4", "text": "This study aimed to reveal the effects of sEVs from unbalanced neurotransmitter-stimulated neurons on A beta-induced toxicity.", "tags": [{"end": 79, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 117, "tag": "InjuryOrPoisoning"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 108, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 91, "tag": "Cell"}, {"end": 38, "start": 31, "tag": "Finding"}, {"end": 46, "start": 42, "tag": "CellComponent"}]}{"id": "1146_5", "text": "We demonstrated the opposite effects of the two groups of sEVs isolated from neurons stimulated by glutamate or GABA on A beta toxicity in vivo and in vitro.", "tags": [{"end": 116, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 112, "tag": "PharmacologicSubstance"}, {"end": 135, "start": 127, "tag": "InjuryOrPoisoning"}, {"end": 156, "start": 148, "tag": "ResearchActivity"}, {"end": 126, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 77, "tag": "Cell"}, {"end": 143, "start": 136, "tag": "ResearchActivity"}, {"end": 108, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 29, "tag": "Finding"}, {"end": 62, "start": 58, "tag": "CellComponent"}]}{"id": "1146_6", "text": "The sEVs released from GABA-treated neurons alleviated A beta-induced damage, while those released from glutamate-treated neurons aggravated A beta toxicity.", "tags": [{"end": 27, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 148, "tag": "InjuryOrPoisoning"}, {"end": 61, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 36, "tag": "Cell"}, {"end": 129, "start": 122, "tag": "Cell"}, {"end": 113, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 8, "start": 4, "tag": "CellComponent"}, {"end": 27, "start": 23, "tag": "PharmacologicSubstance"}, {"end": 76, "start": 70, "tag": "InjuryOrPoisoning"}]}{"id": "1146_7", "text": "Furthermore, we compared the microRNA (miRNA) composition of sEVs isolated from glutamate/GABA/PBS-treated neurons.", "tags": [{"end": 37, "start": 29, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 37, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 39, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 44, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 107, "tag": "Cell"}, {"end": 89, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 61, "tag": "CellComponent"}, {"end": 94, "start": 90, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 95, "tag": "Chemical"}]}{"id": "1146_8", "text": "Our results showed that glutamate and GABA oppositely regulated miR-132 levels in sEVs, resulting in the opposite destiny of recipient cells challenged with A beta.", "tags": [{"end": 71, "start": 64, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 71, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 38, "tag": "PharmacologicSubstance"}, {"end": 163, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 125, "tag": "Cell"}, {"end": 86, "start": 82, "tag": "CellComponent"}]}{"id": "1146_9", "text": "Our results indicated that manipulating the function of sEVs by different neurotransmitters may reveal the mechanisms underlying the pathogenesis of AD and provide a promising strategy for AD treatment.", "tags": [{"end": 39, "start": 27, "tag": "HealthCareActivity"}, {"end": 151, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 192, "tag": "HealthCareActivity"}, {"end": 201, "start": 192, "tag": "ResearchActivity"}, {"end": 145, "start": 133, "tag": "PathologicFunction"}, {"end": 60, "start": 56, "tag": "CellComponent"}, {"end": 91, "start": 74, "tag": "BiologicallyActiveSubstance"}]}{"id": "1147_0", "text": "Alzheimer's disease (AD) and Lewy body dementia (LBD) are two different forms of dementia, but their pathology may involve the same cortical areas with overlapping cognitive manifestations.", "tags": [{"end": 47, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 164, "tag": "SignOrSymptom"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 101, "tag": "PathologicFunction"}, {"end": 110, "start": 101, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 140, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1147_1", "text": "Nonetheless, the clinical phenotype is different due to the topography of the lesions driven by the different underlying molecular processes that arise apart from genetics, causing diverse neurodegeneration.", "tags": [{"end": 85, "start": 78, "tag": "InjuryOrPoisoning"}, {"end": 35, "start": 26, "tag": "OrganismAttribute"}, {"end": 206, "start": 189, "tag": "CellOrMolecularDysfunction"}, {"end": 171, "start": 163, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 171, "start": 163, "tag": "CellFunction"}]}{"id": "1147_2", "text": "Here, we define the commonalities and differences in the pathological processes of dementia in two kindred cases, a mother and a son, who developed classical AD and an aggressive form of AD/LBD, respectively, through a neuropathological, genetic (next-generation sequencing), and transcriptomic (RNA-seq) comparison of four different brain areas.", "tags": [{"end": 122, "start": 116, "tag": "PopulationGroup"}, {"end": 132, "start": 129, "tag": "PopulationGroup"}, {"end": 273, "start": 247, "tag": "ResearchActivity"}, {"end": 294, "start": 280, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 79, "start": 57, "tag": "PathologicFunction"}, {"end": 160, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 303, "start": 296, "tag": "ResearchActivity"}, {"end": 339, "start": 334, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 38, "tag": "Finding"}, {"end": 315, "start": 305, "tag": "ResearchActivity"}, {"end": 193, "start": 190, "tag": "DiseaseOrSyndrome"}]}{"id": "1147_3", "text": "A genetic analysis did not reveal any pathogenic variants in the principal AD/LBD-causative genes.", "tags": [{"end": 18, "start": 2, "tag": "ResearchActivity"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 38, "tag": "PathologicFunction"}, {"end": 81, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 82, "tag": "GeneOrGenome"}]}{"id": "1147_4", "text": "RNA sequencing highlighted high transcriptional dysregulation within the substantia nigra in the AD/LBD case, while the AD case showed lower transcriptional dysregulation, with the parietal lobe being the most involved brain area.", "tags": [{"end": 14, "start": 0, "tag": "ResearchActivity"}, {"end": 89, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 194, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 32, "tag": "CellFunction"}, {"end": 156, "start": 141, "tag": "CellFunction"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 224, "start": 219, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 27, "tag": "Finding"}, {"end": 170, "start": 157, "tag": "Finding"}, {"end": 61, "start": 48, "tag": "Finding"}, {"end": 103, "start": 100, "tag": "DiseaseOrSyndrome"}]}{"id": "1147_5", "text": "The hippocampus (the most degenerated area) and basal ganglia (lacking specific lesions) expressed the lowest level of dysregulation.", "tags": [{"end": 61, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 80, "tag": "InjuryOrPoisoning"}, {"end": 15, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 89, "tag": "CellFunction"}, {"end": 132, "start": 119, "tag": "Finding"}]}{"id": "1147_6", "text": "Our data suggest that there is a link between transcriptional dysregulation and the amount of tissue damage accumulated across time, assessed through neuropathology.", "tags": [{"end": 107, "start": 94, "tag": "InjuryOrPoisoning"}, {"end": 61, "start": 46, "tag": "CellFunction"}, {"end": 164, "start": 150, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 164, "start": 150, "tag": "PathologicFunction"}, {"end": 100, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 127, "tag": "TemporalConcept"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 75, "start": 62, "tag": "Finding"}]}{"id": "1147_7", "text": "Moreover, we highlight that the molecular bases of AD and LBD follow very different pathways, which underlie their neuropathological signatures.", "tags": [{"end": 61, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 84, "tag": "CellFunction"}]}{"id": "1147_8", "text": "Indeed, the transcriptome profiling through RNA sequencing may be an important tool in flanking the neuropathological analysis for a deeper understanding of AD and LBD pathogenesis.", "tags": [{"end": 35, "start": 12, "tag": "ResearchActivity"}, {"end": 58, "start": 44, "tag": "ResearchActivity"}, {"end": 167, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 133, "tag": "Finding"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 118, "tag": "ResearchActivity"}, {"end": 180, "start": 168, "tag": "PathologicFunction"}]}{"id": "1148_0", "text": "Mesenchymal stem-cell-derived small extracellular vesicles (MSC-EVs), as a therapeutic agent, have shown great promise in the treatment of neurological diseases.", "tags": [{"end": 92, "start": 75, "tag": "PharmacologicSubstance"}, {"end": 58, "start": 36, "tag": "CellComponent"}, {"end": 67, "start": 64, "tag": "CellComponent"}, {"end": 21, "start": 0, "tag": "Cell"}, {"end": 135, "start": 126, "tag": "HealthCareActivity"}, {"end": 135, "start": 126, "tag": "ResearchActivity"}, {"end": 63, "start": 60, "tag": "Cell"}, {"end": 58, "start": 30, "tag": "CellComponent"}, {"end": 160, "start": 139, "tag": "DiseaseOrSyndrome"}]}{"id": "1148_1", "text": "To date, the neurorestorative effects and underlying mechanism of MSC-EVs in Alzheimer's disease (AD) are not well known.", "tags": [{"end": 7, "start": 3, "tag": "TemporalConcept"}, {"end": 96, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 70, "tag": "CellComponent"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 69, "start": 66, "tag": "Cell"}, {"end": 37, "start": 30, "tag": "Finding"}]}{"id": "1148_2", "text": "Herein, we aimed to investigate the action of MSC-EVs on the neuronal deficits in beta-amyloid protein (A beta)-stimulated hippocampal neurons, or AD cell (SHSY5Y cell lines) and animal (APPswe / PS1dE9 mice) models.", "tags": [{"end": 122, "start": 112, "tag": "NaturalPhenomenonOrProcess"}, {"end": 78, "start": 70, "tag": "Finding"}, {"end": 53, "start": 50, "tag": "CellComponent"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 150, "tag": "Cell"}, {"end": 69, "start": 61, "tag": "Cell"}, {"end": 215, "start": 209, "tag": "ResearchActivity"}, {"end": 110, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 135, "tag": "Cell"}, {"end": 49, "start": 46, "tag": "Cell"}, {"end": 142, "start": 123, "tag": "Cell"}, {"end": 185, "start": 179, "tag": "Eukaryote"}, {"end": 102, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 156, "tag": "ExperimentalModelOfDisease"}, {"end": 207, "start": 187, "tag": "ExperimentalModelOfDisease"}]}{"id": "1148_3", "text": "In the present study, the cell and AD models received a single-dose of MSC-EVs, and were then assessed for behavioral deficits, pathological changes, intracellular calcium transients, neuronal morphology alterations, or electrophysiological variations.", "tags": [{"end": 163, "start": 150, "tag": "CellComponent"}, {"end": 126, "start": 118, "tag": "Finding"}, {"end": 78, "start": 75, "tag": "CellComponent"}, {"end": 37, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 30, "start": 26, "tag": "Cell"}, {"end": 44, "start": 38, "tag": "ResearchActivity"}, {"end": 74, "start": 71, "tag": "Cell"}, {"end": 182, "start": 164, "tag": "CellFunction"}, {"end": 251, "start": 220, "tag": "CellOrMolecularDysfunction"}, {"end": 215, "start": 184, "tag": "CellOrMolecularDysfunction"}, {"end": 148, "start": 128, "tag": "PathologicFunction"}]}{"id": "1148_4", "text": "Additionally, the nuclear factor E2-related factor 2 (Nrf2, a key mediator of neuronal injury in AD) signaling pathway was probed by western blotting in vitro and in vivo models of AD.", "tags": [{"end": 52, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 133, "tag": "ResearchActivity"}, {"end": 177, "start": 163, "tag": "ResearchActivity"}, {"end": 110, "start": 101, "tag": "CellFunction"}, {"end": 58, "start": 54, "tag": "GeneOrGenome"}, {"end": 58, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 78, "tag": "Cell"}, {"end": 158, "start": 150, "tag": "ResearchActivity"}, {"end": 118, "start": 111, "tag": "CellFunction"}, {"end": 93, "start": 87, "tag": "InjuryOrPoisoning"}, {"end": 118, "start": 101, "tag": "CellFunction"}, {"end": 52, "start": 18, "tag": "BiologicallyActiveSubstance"}]}{"id": "1148_5", "text": "Our results showed that MSC-EVs therapy improved the cognitive impairments and reduced the hippocampal A beta aggregation and neuronal loss in AD mice.", "tags": [{"end": 74, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 40, "tag": "Finding"}, {"end": 102, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 91, "tag": "Cell"}, {"end": 121, "start": 103, "tag": "CellFunction"}, {"end": 31, "start": 28, "tag": "CellComponent"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 146, "tag": "Eukaryote"}, {"end": 134, "start": 126, "tag": "Cell"}, {"end": 109, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 110, "tag": "CellFunction"}, {"end": 121, "start": 110, "tag": "ResearchActivity"}, {"end": 39, "start": 32, "tag": "HealthCareActivity"}, {"end": 27, "start": 24, "tag": "Cell"}, {"end": 139, "start": 126, "tag": "CellOrMolecularDysfunction"}]}{"id": "1148_6", "text": "Markedly, EV treatment restored the calcium oscillations, dendritic spine alterations, action potential abnormalities, or mitochondrial changes in the hippocampus of AD models.", "tags": [{"end": 43, "start": 36, "tag": "PharmacologicSubstance"}, {"end": 43, "start": 36, "tag": "Chemical"}, {"end": 73, "start": 58, "tag": "CellComponent"}, {"end": 103, "start": 87, "tag": "CellFunction"}, {"end": 135, "start": 122, "tag": "CellComponent"}, {"end": 168, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 10, "tag": "CellComponent"}, {"end": 175, "start": 169, "tag": "ResearchActivity"}, {"end": 22, "start": 13, "tag": "HealthCareActivity"}, {"end": 22, "start": 13, "tag": "ResearchActivity"}, {"end": 162, "start": 151, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 74, "tag": "Finding"}, {"end": 43, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 36, "tag": "CellFunction"}]}{"id": "1148_7", "text": "Also, we found that the Nrf2 signaling pathway participated in the actions of MSC-EVs in the cell and animal models.", "tags": [{"end": 28, "start": 24, "tag": "GeneOrGenome"}, {"end": 28, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 82, "tag": "CellComponent"}, {"end": 97, "start": 93, "tag": "Cell"}, {"end": 115, "start": 102, "tag": "ResearchActivity"}, {"end": 46, "start": 29, "tag": "CellFunction"}, {"end": 81, "start": 78, "tag": "Cell"}]}{"id": "1148_8", "text": "Together, these data indicate that MS-EVs as promising nanotherapeutics for restoration of hippocampal neuronal morphology and function in APP / PS1 mice, further highlighting the clinical values of MSC-EVs in the treatment of AD.", "tags": [{"end": 71, "start": 55, "tag": "HealthCareActivity"}, {"end": 102, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 91, "tag": "Cell"}, {"end": 122, "start": 112, "tag": "Finding"}, {"end": 41, "start": 38, "tag": "CellComponent"}, {"end": 206, "start": 203, "tag": "CellComponent"}, {"end": 229, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 103, "tag": "Cell"}, {"end": 223, "start": 214, "tag": "HealthCareActivity"}, {"end": 223, "start": 214, "tag": "ResearchActivity"}, {"end": 202, "start": 199, "tag": "Cell"}, {"end": 37, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 16, "tag": "ResearchActivity"}, {"end": 153, "start": 139, "tag": "ExperimentalModelOfDisease"}]}{"id": "1149_0", "text": "Alzheimer's disease (AD) is a progressive neurodegenerative disorder for which only symptomatic medication is available, except for the recently FDA-approved aducanumab.", "tags": [{"end": 106, "start": 96, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 96, "tag": "HealthCareActivity"}, {"end": 168, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 145, "tag": "HealthCareRelatedOrganization"}, {"end": 68, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 84, "tag": "SignOrSymptom"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 136, "tag": "TemporalConcept"}, {"end": 41, "start": 30, "tag": "TemporalConcept"}, {"end": 168, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 158, "tag": "PharmacologicSubstance"}]}{"id": "1149_1", "text": "This lack of effective treatment urges us to investigate alternative paths that might contribute to disease development.", "tags": [{"end": 32, "start": 5, "tag": "Finding"}, {"end": 119, "start": 100, "tag": "PathologicFunction"}, {"end": 119, "start": 108, "tag": "BiologicFunction"}, {"end": 119, "start": 108, "tag": "CellFunction"}, {"end": 32, "start": 23, "tag": "HealthCareActivity"}, {"end": 32, "start": 23, "tag": "ResearchActivity"}]}{"id": "1149_2", "text": "In light of the recent SARS-CoV-2 pandemic and the disturbing neurological complications seen in some patients, it is desirable to (re)investigate the viability of the viral infection theory claiming that a microbe could affect AD initiation and/or progression.", "tags": [{"end": 33, "start": 23, "tag": "Virus"}, {"end": 160, "start": 151, "tag": "CellFunction"}, {"end": 214, "start": 207, "tag": "Organism"}, {"end": 260, "start": 249, "tag": "PathologicFunction"}, {"end": 260, "start": 249, "tag": "TemporalConcept"}, {"end": 230, "start": 228, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 102, "tag": "PatientOrDisabledGroup"}, {"end": 241, "start": 231, "tag": "TemporalConcept"}, {"end": 183, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 16, "tag": "TemporalConcept"}]}{"id": "1149_3", "text": "Here, we review the most important evidence for this theory with a special focus on two viruses, namely HSV-1 and SARS-CoV-2.", "tags": [{"end": 95, "start": 88, "tag": "Virus"}, {"end": 124, "start": 114, "tag": "Virus"}, {"end": 109, "start": 104, "tag": "Virus"}, {"end": 43, "start": 35, "tag": "Finding"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}]}{"id": "1149_4", "text": "Moreover, we discuss the possible involvement of extracellular vesicles (EVs).", "tags": [{"end": 71, "start": 49, "tag": "CellComponent"}, {"end": 76, "start": 73, "tag": "CellComponent"}, {"end": 45, "start": 34, "tag": "Finding"}]}{"id": "1149_5", "text": "This overview will contribute to a more rational approach of potential treatment strategies for AD patients.", "tags": [{"end": 91, "start": 71, "tag": "HealthCareActivity"}, {"end": 91, "start": 71, "tag": "ResearchActivity"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "PatientOrDisabledGroup"}, {"end": 13, "start": 5, "tag": "ResearchActivity"}]}{"id": "1150_0", "text": "As the most common form of dementia and a progressive neurodegenerative disorder, Alzheimer's disease (AD) affects over 10% world population with age 65 and older.", "tags": [{"end": 80, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 157, "tag": "TemporalConcept"}, {"end": 149, "start": 146, "tag": "OrganismAttribute"}, {"end": 101, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 130, "tag": "PopulationGroup"}, {"end": 53, "start": 42, "tag": "TemporalConcept"}, {"end": 129, "start": 124, "tag": "PopulationGroup"}]}{"id": "1150_1", "text": "The disease is neuropathologically associated with progressive loss of neurons and synapses in specific brain regions, deposition of amyloid plaques and neurofibrillary tangles, neuroinflammation, blood-brain barrier (BBB) breakdown, mitochondrial dysfunction, and oxidative stress.", "tags": [{"end": 91, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 63, "tag": "CellOrMolecularDysfunction"}, {"end": 221, "start": 218, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 153, "tag": "CellOrMolecularDysfunction"}, {"end": 168, "start": 153, "tag": "CellComponent"}, {"end": 281, "start": 265, "tag": "CellOrMolecularDysfunction"}, {"end": 195, "start": 178, "tag": "PathologicFunction"}, {"end": 62, "start": 51, "tag": "TemporalConcept"}, {"end": 216, "start": 197, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 119, "tag": "PathologicFunction"}, {"end": 259, "start": 234, "tag": "CellOrMolecularDysfunction"}, {"end": 232, "start": 223, "tag": "PathologicFunction"}, {"end": 216, "start": 197, "tag": "PathologicFunction"}]}{"id": "1150_2", "text": "Despite the intensive effort, there is still no cure for the disorder.", "tags": [{"end": 28, "start": 22, "tag": "BiologicFunction"}, {"end": 28, "start": 22, "tag": "Finding"}, {"end": 52, "start": 45, "tag": "Finding"}]}{"id": "1150_3", "text": "Stem cell-derived exosomes hold great promise in treating various diseases, including AD, as they contain a variety of anti-apoptotic, anti-inflammatory, and antioxidant components.", "tags": [{"end": 169, "start": 158, "tag": "PharmacologicSubstance"}, {"end": 169, "start": 158, "tag": "CellFunction"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 18, "tag": "CellComponent"}, {"end": 9, "start": 0, "tag": "Cell"}, {"end": 152, "start": 135, "tag": "BiologicFunction"}, {"end": 152, "start": 135, "tag": "PharmacologicSubstance"}, {"end": 133, "start": 119, "tag": "CellFunction"}]}{"id": "1150_4", "text": "Moreover, stem cell-derived exosomes also promote neurogenesis and angiogenesis and can repair damaged BBB.", "tags": [{"end": 79, "start": 67, "tag": "BiologicFunction"}, {"end": 62, "start": 50, "tag": "BiologicFunction"}, {"end": 106, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 88, "tag": "BiologicFunction"}, {"end": 94, "start": 88, "tag": "HealthCareActivity"}, {"end": 36, "start": 28, "tag": "CellComponent"}, {"end": 19, "start": 10, "tag": "Cell"}, {"end": 106, "start": 95, "tag": "PathologicFunction"}]}{"id": "1150_5", "text": "In this review, we will first outline the major neuropathological features associated with AD; subsequently, a discussion of stem cells, stem cell-secreted exosomes, and the major exosome isolation methods will follow.", "tags": [{"end": 121, "start": 111, "tag": "ResearchActivity"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 156, "tag": "CellComponent"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 29, "start": 24, "tag": "TemporalConcept"}, {"end": 135, "start": 125, "tag": "Cell"}, {"end": 146, "start": 137, "tag": "Cell"}, {"end": 187, "start": 180, "tag": "CellComponent"}, {"end": 205, "start": 180, "tag": "ResearchActivity"}]}{"id": "1150_6", "text": "We will then summarize the recent data involving the use of mesenchymal stem cell- or neural stem cell-derived exosomes in treating AD.", "tags": [{"end": 82, "start": 60, "tag": "Cell"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 111, "tag": "CellComponent"}, {"end": 38, "start": 34, "tag": "ResearchActivity"}, {"end": 102, "start": 86, "tag": "Cell"}, {"end": 33, "start": 27, "tag": "TemporalConcept"}]}{"id": "1150_7", "text": "Finally, we will briefly discuss the challenges, perspectives, and clinical trials using stem cell-derived exosomes for AD therapy.", "tags": [{"end": 24, "start": 17, "tag": "TemporalConcept"}, {"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 107, "tag": "CellComponent"}, {"end": 47, "start": 37, "tag": "HealthCareActivity"}, {"end": 130, "start": 123, "tag": "HealthCareActivity"}, {"end": 98, "start": 89, "tag": "Cell"}, {"end": 82, "start": 67, "tag": "ResearchActivity"}]}{"id": "1151_0", "text": "Background Ketone bodies have been proposed as an energy rescue for the Alzheimer's disease (AD) brain, which underutilizes glucose.", "tags": [{"end": 24, "start": 11, "tag": "Chemical"}, {"end": 131, "start": 124, "tag": "Chemical"}, {"end": 131, "start": 124, "tag": "PharmacologicSubstance"}, {"end": 131, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 11, "tag": "BiologicallyActiveSubstance"}]}{"id": "1151_1", "text": "Prior research has shown that oral ketone monoester (KME) safely induces robust ketosis in humans and has demonstrated cognitive-enhancing and pathology-reducing properties in animal models of AD.", "tags": [{"end": 87, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 91, "tag": "Eukaryote"}, {"end": 34, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 195, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 6, "tag": "ResearchActivity"}, {"end": 152, "start": 143, "tag": "PathologicFunction"}, {"end": 152, "start": 143, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 189, "start": 176, "tag": "ResearchActivity"}, {"end": 161, "start": 153, "tag": "Finding"}, {"end": 5, "start": 0, "tag": "TemporalConcept"}, {"end": 195, "start": 176, "tag": "ExperimentalModelOfDisease"}, {"end": 51, "start": 35, "tag": "Chemical"}, {"end": 51, "start": 35, "tag": "PharmacologicSubstance"}, {"end": 56, "start": 53, "tag": "PharmacologicSubstance"}, {"end": 56, "start": 53, "tag": "Chemical"}]}{"id": "1151_2", "text": "However, human evidence that KME may enhance brain ketone metabolism, improve cognitive performance and engage AD pathogenic cascades is scarce.", "tags": [{"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 15, "tag": "Finding"}, {"end": 50, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 9, "tag": "Eukaryote"}, {"end": 99, "start": 78, "tag": "ClinicalAttribute"}, {"end": 68, "start": 51, "tag": "BiologicFunction"}, {"end": 133, "start": 114, "tag": "PathologicFunction"}, {"end": 32, "start": 29, "tag": "Chemical"}, {"end": 32, "start": 29, "tag": "PharmacologicSubstance"}]}{"id": "1151_3", "text": "Objectives To investigate the effects of ketone monoester (KME) on brain metabolism, cognitive performance and AD pathogenic cascades in cognitively normal older adults with metabolic syndrome and therefore at higher risk for AD.", "tags": [{"end": 83, "start": 67, "tag": "BiologicFunction"}, {"end": 192, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 156, "tag": "PopulationGroup"}, {"end": 168, "start": 162, "tag": "PopulationGroup"}, {"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 226, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 217, "tag": "Finding"}, {"end": 106, "start": 85, "tag": "ClinicalAttribute"}, {"end": 83, "start": 73, "tag": "CellFunction"}, {"end": 83, "start": 73, "tag": "BiologicFunction"}, {"end": 133, "start": 114, "tag": "PathologicFunction"}, {"end": 155, "start": 149, "tag": "Finding"}, {"end": 155, "start": 137, "tag": "Finding"}, {"end": 37, "start": 30, "tag": "Finding"}, {"end": 161, "start": 156, "tag": "TemporalConcept"}, {"end": 57, "start": 41, "tag": "Chemical"}, {"end": 57, "start": 41, "tag": "PharmacologicSubstance"}, {"end": 62, "start": 59, "tag": "PharmacologicSubstance"}, {"end": 62, "start": 59, "tag": "Chemical"}]}{"id": "1151_4", "text": "DESIGN: Double-blinded randomized placebo-controlled clinical trial.", "tags": [{"end": 67, "start": 8, "tag": "ResearchActivity"}]}{"id": "1151_5", "text": "Setting Clinical Unit of the National Institute on Aging, Baltimore, US.", "tags": [{"end": 56, "start": 29, "tag": "HealthCareRelatedOrganization"}, {"end": 56, "start": 51, "tag": "BiologicFunction"}, {"end": 21, "start": 0, "tag": "HealthCareRelatedOrganization"}]}{"id": "1151_6", "text": "Participants Fifty cognitively intact adults >= 55 years old, with metabolic syndrome.", "tags": [{"end": 60, "start": 51, "tag": "PopulationGroup"}, {"end": 85, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 38, "tag": "PopulationGroup"}, {"end": 12, "start": 0, "tag": "PopulationGroup"}, {"end": 37, "start": 31, "tag": "Finding"}, {"end": 56, "start": 51, "tag": "TemporalConcept"}]}{"id": "1151_7", "text": "Intervention Drinks containing 25 g of KME or isocaloric placebo consumed three times daily for 28 days.", "tags": [{"end": 12, "start": 0, "tag": "HealthCareActivity"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 64, "start": 57, "tag": "HealthCareActivity"}, {"end": 103, "start": 99, "tag": "TemporalConcept"}, {"end": 91, "start": 86, "tag": "TemporalConcept"}, {"end": 42, "start": 39, "tag": "PharmacologicSubstance"}, {"end": 42, "start": 39, "tag": "Chemical"}, {"end": 19, "start": 13, "tag": "Substance"}]}{"id": "1151_8", "text": "Outcomes Primary: concentration of beta-hydroxybutyrate (BHB) in precuneus measured with Magnetic Resonance Spectroscopy (MRS).", "tags": [{"end": 55, "start": 35, "tag": "Chemical"}, {"end": 60, "start": 57, "tag": "Chemical"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 89, "tag": "HealthCareActivity"}, {"end": 125, "start": 122, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "Finding"}, {"end": 31, "start": 18, "tag": "BiologicFunction"}, {"end": 55, "start": 35, "tag": "BiologicallyActiveSubstance"}]}{"id": "1151_9", "text": "Exploratory: plasma and urine BHB, multiple brain and muscle metabolites detected with MRS, cognition assessed with the PACC and NIH toolbox, biomarkers of AD and metabolic mediators in plasma extracellular vesicles, and stool microbiome.", "tags": [{"end": 33, "start": 30, "tag": "Chemical"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 87, "tag": "HealthCareActivity"}, {"end": 132, "start": 129, "tag": "HealthCareRelatedOrganization"}, {"end": 72, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 215, "start": 193, "tag": "CellComponent"}, {"end": 158, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 186, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 142, "tag": "ClinicalAttribute"}, {"end": 29, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 173, "tag": "Finding"}, {"end": 60, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 92, "tag": "BiologicFunction"}, {"end": 33, "start": 24, "tag": "ClinicalAttribute"}, {"end": 226, "start": 221, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 237, "start": 227, "tag": "Organism"}, {"end": 33, "start": 30, "tag": "ClinicalAttribute"}, {"end": 19, "start": 13, "tag": "ClinicalAttribute"}]}{"id": "1151_10", "text": "Discussion This is the first study to investigate the AD-biomarker and cognitive effects of KME in humans.", "tags": [{"end": 105, "start": 99, "tag": "Eukaryote"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 29, "tag": "ResearchActivity"}, {"end": 66, "start": 57, "tag": "ClinicalAttribute"}, {"end": 28, "start": 23, "tag": "TemporalConcept"}, {"end": 88, "start": 81, "tag": "Finding"}, {"end": 95, "start": 92, "tag": "Chemical"}, {"end": 95, "start": 92, "tag": "PharmacologicSubstance"}]}{"id": "1151_11", "text": "Ketone monoester is safe, tolerable, induces robust ketosis, and animal studies indicate that it can modify AD pathology.", "tags": [{"end": 59, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 111, "tag": "PathologicFunction"}, {"end": 120, "start": 111, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 79, "start": 72, "tag": "ResearchActivity"}, {"end": 71, "start": 65, "tag": "Eukaryote"}, {"end": 16, "start": 0, "tag": "Chemical"}, {"end": 16, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "1151_12", "text": "By conducting a study of KME in a population at risk for AD, we hope to bridge the existing gap between pre-clinical evidence and the potential for brain-metabolic, pro-cognitive, and anti-Alzheimer's effects in humans.", "tags": [{"end": 116, "start": 104, "tag": "ResearchActivity"}, {"end": 68, "start": 64, "tag": "BiologicFunction"}, {"end": 218, "start": 212, "tag": "Eukaryote"}, {"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 125, "start": 117, "tag": "Finding"}, {"end": 153, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 200, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 48, "tag": "Finding"}, {"end": 44, "start": 34, "tag": "PopulationGroup"}, {"end": 208, "start": 201, "tag": "Finding"}, {"end": 28, "start": 25, "tag": "PharmacologicSubstance"}, {"end": 28, "start": 25, "tag": "Chemical"}]}{"id": "1152_0", "text": "The aggregation of the microtubule-associated protein tau is a defining feature of Alzheimer's disease and other tauopathies.", "tags": [{"end": 124, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 4, "tag": "CellFunction"}, {"end": 15, "start": 4, "tag": "ResearchActivity"}, {"end": 53, "start": 23, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1152_1", "text": "Tau pathology is believed to be driven by free tau aggregates and tau carried within exosome-like extracellular vesicles, both of which propagate trans-synaptically and induce tau pathology in recipient neurons by a corrupting process of seeding.", "tags": [{"end": 202, "start": 193, "tag": "PopulationGroup"}, {"end": 245, "start": 238, "tag": "ResearchActivity"}, {"end": 189, "start": 176, "tag": "PathologicFunction"}, {"end": 120, "start": 98, "tag": "CellComponent"}, {"end": 13, "start": 0, "tag": "PathologicFunction"}, {"end": 13, "start": 4, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 85, "tag": "CellComponent"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 210, "start": 203, "tag": "Cell"}]}{"id": "1152_2", "text": "Here, we performed a genome-wide CRISPRi screen in tau biosensor cells and identified cellular regulators shared by both mechanisms of tau seeding.", "tags": [{"end": 146, "start": 139, "tag": "ResearchActivity"}, {"end": 54, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 65, "tag": "Cell"}, {"end": 94, "start": 86, "tag": "Cell"}, {"end": 47, "start": 21, "tag": "ResearchActivity"}, {"end": 64, "start": 55, "tag": "ManufacturedObject"}, {"end": 146, "start": 135, "tag": "CellOrMolecularDysfunction"}]}{"id": "1152_3", "text": "We identified ANKLE2, BANF1, NUSAP1, EIF1AD, and VPS18 as the top validated regulators that restrict tau aggre-gation initiated by both exosomal and vesicle-free tau seeds.", "tags": [{"end": 20, "start": 14, "tag": "GeneOrGenome"}, {"end": 27, "start": 22, "tag": "GeneOrGenome"}, {"end": 35, "start": 29, "tag": "GeneOrGenome"}, {"end": 43, "start": 37, "tag": "GeneOrGenome"}, {"end": 54, "start": 49, "tag": "GeneOrGenome"}, {"end": 104, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 165, "start": 162, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 149, "tag": "CellComponent"}, {"end": 144, "start": 136, "tag": "CellComponent"}, {"end": 20, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 162, "tag": "CellOrMolecularDysfunction"}]}{"id": "1152_4", "text": "None of our validated hits affected the uptake of either form of tau seeds, supporting the notion that they operate through a cell -autonomous mechanism downstream of the seed uptake.", "tags": [{"end": 68, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "Cell"}, {"end": 46, "start": 40, "tag": "BiologicFunction"}, {"end": 182, "start": 176, "tag": "BiologicFunction"}, {"end": 46, "start": 40, "tag": "CellFunction"}, {"end": 182, "start": 176, "tag": "CellFunction"}, {"end": 74, "start": 65, "tag": "CellOrMolecularDysfunction"}, {"end": 152, "start": 126, "tag": "CellFunction"}]}{"id": "1152_5", "text": "Lastly, validation studies with human brain tissue also revealed that several of the identified protein hits are down-regulated in the brains of Alzheimer's patients, suggesting that their decreased activity may be required for the emergence or progression of tau pathology in the human brain.", "tags": [{"end": 26, "start": 8, "tag": "ResearchActivity"}, {"end": 273, "start": 260, "tag": "PathologicFunction"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 165, "start": 157, "tag": "PatientOrDisabledGroup"}, {"end": 263, "start": 260, "tag": "AminoAcidPeptideOrProtein"}, {"end": 292, "start": 287, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 32, "tag": "Eukaryote"}, {"end": 286, "start": 281, "tag": "Eukaryote"}, {"end": 263, "start": 260, "tag": "BiologicallyActiveSubstance"}, {"end": 256, "start": 245, "tag": "PathologicFunction"}, {"end": 256, "start": 245, "tag": "TemporalConcept"}, {"end": 50, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 241, "start": 232, "tag": "TemporalConcept"}, {"end": 141, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 113, "tag": "CellFunction"}]}{"id": "1153_0", "text": "Although mindfulness-based stress reduction (MBSR) improves cognitive function, the mechanism is not clear.", "tags": [{"end": 43, "start": 9, "tag": "HealthCareActivity"}, {"end": 49, "start": 45, "tag": "HealthCareActivity"}, {"end": 78, "start": 60, "tag": "BiologicFunction"}]}{"id": "1153_1", "text": "In this study, people aged 65 years and older were recruited from elderly communities in Chitose City, Japan, and assigned to a non-MBSR group or a MBSR group.", "tags": [{"end": 152, "start": 148, "tag": "HealthCareActivity"}, {"end": 26, "start": 22, "tag": "TemporalConcept"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 142, "start": 137, "tag": "PopulationGroup"}, {"end": 158, "start": 153, "tag": "PopulationGroup"}, {"end": 35, "start": 30, "tag": "TemporalConcept"}, {"end": 21, "start": 15, "tag": "PopulationGroup"}, {"end": 45, "start": 40, "tag": "TemporalConcept"}, {"end": 73, "start": 66, "tag": "PopulationGroup"}, {"end": 85, "start": 74, "tag": "HealthCareRelatedOrganization"}, {"end": 136, "start": 132, "tag": "HealthCareActivity"}]}{"id": "1153_2", "text": "Before and after the intervention, the Japanese version of the Montreal Cognitive Assessment (MoCA-J) was administered, and blood samples were collected.", "tags": [{"end": 47, "start": 39, "tag": "PopulationGroup"}, {"end": 92, "start": 63, "tag": "HealthCareActivity"}, {"end": 98, "start": 94, "tag": "HealthCareActivity"}, {"end": 137, "start": 130, "tag": "Substance"}, {"end": 137, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1153_3", "text": "Then, neuron-derived extracellular vesicles (NDEVs) were isolated from blood samples, and microRNAs, as well as the target mRNAs, were evaluated in NDEVs.", "tags": [{"end": 43, "start": 21, "tag": "CellComponent"}, {"end": 12, "start": 6, "tag": "Cell"}, {"end": 84, "start": 77, "tag": "Substance"}, {"end": 84, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 123, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 99, "start": 90, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 99, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 45, "tag": "CellComponent"}, {"end": 43, "start": 6, "tag": "CellComponent"}, {"end": 153, "start": 148, "tag": "CellComponent"}]}{"id": "1153_4", "text": "A linear mixed model analysis showed significant effects of the MBSR x time interaction on the MoCA-J scores, the expression of miRNA(miR)-29c, DNA methyltransferase 3 alpha (DNMT3A), and DNMT3B in NDEVs.", "tags": [{"end": 68, "start": 64, "tag": "HealthCareActivity"}, {"end": 173, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 175, "tag": "GeneOrGenome"}, {"end": 181, "start": 175, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 194, "start": 188, "tag": "GeneOrGenome"}, {"end": 194, "start": 188, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 95, "tag": "HealthCareActivity"}, {"end": 29, "start": 2, "tag": "ResearchActivity"}, {"end": 124, "start": 114, "tag": "CellFunction"}, {"end": 142, "start": 128, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 142, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 71, "tag": "TemporalConcept"}, {"end": 56, "start": 49, "tag": "Finding"}, {"end": 194, "start": 188, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 198, "tag": "CellComponent"}]}{"id": "1153_5", "text": "These results indicate that MBSR can improve cognitive function by increasing the expression of miR-29c and decreasing the expression of DNMT3A, as well as DNMT3B, in neurons.", "tags": [{"end": 32, "start": 28, "tag": "HealthCareActivity"}, {"end": 143, "start": 137, "tag": "GeneOrGenome"}, {"end": 143, "start": 137, "tag": "CellOrMolecularDysfunction"}, {"end": 143, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 156, "tag": "GeneOrGenome"}, {"end": 162, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 108, "tag": "Finding"}, {"end": 92, "start": 82, "tag": "CellFunction"}, {"end": 133, "start": 123, "tag": "CellFunction"}, {"end": 174, "start": 167, "tag": "Cell"}, {"end": 63, "start": 45, "tag": "BiologicFunction"}, {"end": 77, "start": 67, "tag": "Finding"}, {"end": 103, "start": 96, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 103, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 156, "tag": "BiologicallyActiveSubstance"}]}{"id": "1153_6", "text": "It was also found that intracerebroventricular injection of miR-29c mimic into 5xFAD mice prevented cognitive decline, as well as neuronal loss in the subiculum area, by down-regulating Dnmt3a and Dnmt3b in the hippocampus.", "tags": [{"end": 185, "start": 170, "tag": "CellFunction"}, {"end": 192, "start": 186, "tag": "GeneOrGenome"}, {"end": 192, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 197, "tag": "GeneOrGenome"}, {"end": 203, "start": 197, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 79, "tag": "ExperimentalModelOfDisease"}, {"end": 46, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 222, "start": 211, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 47, "tag": "HealthCareActivity"}, {"end": 143, "start": 130, "tag": "CellOrMolecularDysfunction"}, {"end": 67, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 60, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 165, "start": 151, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 197, "tag": "BiologicallyActiveSubstance"}]}{"id": "1153_7", "text": "The present study suggests that MBSR can prevent neuronal loss and cognitive impairment by increasing the neuronal expression of miR-29c.", "tags": [{"end": 36, "start": 32, "tag": "HealthCareActivity"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 114, "start": 106, "tag": "Cell"}, {"end": 125, "start": 115, "tag": "CellFunction"}, {"end": 87, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 91, "tag": "Finding"}, {"end": 62, "start": 49, "tag": "CellOrMolecularDysfunction"}, {"end": 136, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 129, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1154_0", "text": "Niemann-Pick type C (NPC) disease, sometimes called childhood Alzheimer's, is a rare neurovisceral lipid storage disease with progressive neurodegeneration leading to premature death.", "tags": [{"end": 61, "start": 52, "tag": "TemporalConcept"}, {"end": 182, "start": 167, "tag": "Finding"}, {"end": 24, "start": 21, "tag": "Cell"}, {"end": 73, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 80, "tag": "TemporalConcept"}, {"end": 182, "start": 177, "tag": "BiologicFunction"}, {"end": 182, "start": 177, "tag": "PathologicFunction"}, {"end": 182, "start": 177, "tag": "CellFunction"}, {"end": 155, "start": 138, "tag": "CellOrMolecularDysfunction"}, {"end": 137, "start": 126, "tag": "TemporalConcept"}, {"end": 104, "start": 99, "tag": "Chemical"}, {"end": 33, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 176, "start": 167, "tag": "TemporalConcept"}]}{"id": "1154_1", "text": "The disease is caused by loss-of-function mutations in the Npc1 or Npc2 gene which both result into lipid accumulation in the late endosomes and lysosomes.", "tags": [{"end": 76, "start": 72, "tag": "GeneOrGenome"}, {"end": 63, "start": 59, "tag": "GeneOrGenome"}, {"end": 76, "start": 67, "tag": "GeneOrGenome"}, {"end": 140, "start": 126, "tag": "CellComponent"}, {"end": 154, "start": 145, "tag": "CellComponent"}, {"end": 130, "start": 126, "tag": "TemporalConcept"}, {"end": 118, "start": 106, "tag": "Finding"}, {"end": 105, "start": 100, "tag": "Chemical"}, {"end": 140, "start": 131, "tag": "CellComponent"}, {"end": 51, "start": 25, "tag": "CellOrMolecularDysfunction"}]}{"id": "1154_2", "text": "Since the disease presents with a broad heterogenous clinical spectrum, the involved disease mechanisms are still incompletely understood and this hampers finding an effective treatment.", "tags": [{"end": 70, "start": 62, "tag": "ResearchActivity"}, {"end": 103, "start": 85, "tag": "ResearchActivity"}, {"end": 162, "start": 155, "tag": "Finding"}, {"end": 185, "start": 176, "tag": "HealthCareActivity"}, {"end": 185, "start": 176, "tag": "ResearchActivity"}]}{"id": "1154_3", "text": "As NPC patients, who carry NPC1 mutations, have shown to share several pathological features with Alzheimer's disease (AD) and we and others have previously shown that AD is associated with a dysfunctionality of the blood-cerebrospinal fluid (CSF) barrier located at choroid plexus, we investigated the functionality of this latter barrier in NPC1 pathology.", "tags": [{"end": 208, "start": 192, "tag": "PathologicFunction"}, {"end": 281, "start": 267, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 316, "start": 303, "tag": "OrganismAttribute"}, {"end": 6, "start": 3, "tag": "Cell"}, {"end": 117, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 3, "tag": "PatientOrDisabledGroup"}, {"end": 246, "start": 243, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 357, "start": 343, "tag": "PathologicFunction"}, {"end": 255, "start": 248, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 241, "start": 216, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 241, "start": 222, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 32, "tag": "CellFunction"}, {"end": 41, "start": 27, "tag": "CellOrMolecularDysfunction"}, {"end": 339, "start": 332, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1154_4", "text": "Using NPC1(-/-) mice, we show that despite an increase in inflammatory gene expression in choroid plexus epithelial (CPE) cells, the blood-CSF barrier integrity is not dramatically affected.", "tags": [{"end": 104, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 160, "start": 151, "tag": "IndividualBehavior"}, {"end": 150, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 71, "tag": "CellFunction"}, {"end": 86, "start": 76, "tag": "CellFunction"}, {"end": 75, "start": 71, "tag": "GeneOrGenome"}, {"end": 115, "start": 90, "tag": "Cell"}, {"end": 127, "start": 122, "tag": "Cell"}, {"end": 20, "start": 6, "tag": "ExperimentalModelOfDisease"}, {"end": 70, "start": 58, "tag": "PathologicFunction"}]}{"id": "1154_5", "text": "Interestingly, we did observe a massive increase in autophagosomes in CPE cells and enlarged extracellular vesicles (EVs) in CSF upon NPC1 pathology.", "tags": [{"end": 66, "start": 52, "tag": "CellComponent"}, {"end": 115, "start": 93, "tag": "CellComponent"}, {"end": 120, "start": 117, "tag": "CellComponent"}, {"end": 128, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 134, "tag": "PathologicFunction"}, {"end": 79, "start": 70, "tag": "Cell"}]}{"id": "1154_6", "text": "Additionally, we revealed that these EVs exert toxic effects on brain tissue, in vitro as well as in vivo.", "tags": [{"end": 40, "start": 37, "tag": "CellComponent"}, {"end": 76, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 47, "tag": "InjuryOrPoisoning"}, {"end": 86, "start": 78, "tag": "ResearchActivity"}, {"end": 105, "start": 98, "tag": "ResearchActivity"}, {"end": 60, "start": 53, "tag": "Finding"}, {"end": 60, "start": 47, "tag": "InjuryOrPoisoning"}]}{"id": "1154_7", "text": "Moreover, we observed that EVs derived from the supernatant of NPC1(-/-) choroid plexus explants are able to induce typical brain pathology characteristics of NPC1(-/-), more specifically microgliosis and astrogliosis.", "tags": [{"end": 59, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 200, "start": 188, "tag": "PathologicFunction"}, {"end": 217, "start": 205, "tag": "PathologicFunction"}, {"end": 30, "start": 27, "tag": "CellComponent"}, {"end": 139, "start": 130, "tag": "PathologicFunction"}, {"end": 139, "start": 130, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 129, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 63, "tag": "GeneOrGenome"}, {"end": 96, "start": 88, "tag": "HealthCareActivity"}, {"end": 67, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 159, "tag": "GeneOrGenome"}, {"end": 163, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 159, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1154_8", "text": "Taken together, our data reveal for the first time that the choroid plexus and CSF EVs might play a role in the brain-related pathogenesis of NPC1.</p>", "tags": [{"end": 74, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 83, "tag": "CellComponent"}, {"end": 82, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 40, "tag": "TemporalConcept"}, {"end": 138, "start": 126, "tag": "PathologicFunction"}, {"end": 50, "start": 46, "tag": "TemporalConcept"}, {"end": 24, "start": 20, "tag": "ResearchActivity"}, {"end": 146, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 142, "tag": "GeneOrGenome"}]}{"id": "1155_0", "text": "Alzheimer's disease (AD) is the most prevalent neurodegenerative disease commonly diagnosed among the elderly population.", "tags": [{"end": 120, "start": 102, "tag": "PopulationGroup"}, {"end": 91, "start": 82, "tag": "HealthCareActivity"}, {"end": 109, "start": 102, "tag": "PopulationGroup"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 110, "tag": "PopulationGroup"}, {"end": 72, "start": 47, "tag": "DiseaseOrSyndrome"}]}{"id": "1155_1", "text": "AD is characterized by the loss of synaptic connections, neuronal death, and progressive cognitive impairment, attributed to the extracellular accumulation of senile plaques, composed by insoluble aggregates of amyloid-beta (A beta) peptides, and to the intraneuronal formation of neurofibrillary tangles shaped by hyperphosphorylated filaments of the microtubule-associated protein tau.", "tags": [{"end": 173, "start": 159, "tag": "AnatomicalAbnormality"}, {"end": 382, "start": 352, "tag": "AminoAcidPeptideOrProtein"}, {"end": 382, "start": 352, "tag": "GeneOrGenome"}, {"end": 71, "start": 66, "tag": "BiologicFunction"}, {"end": 71, "start": 66, "tag": "PathologicFunction"}, {"end": 71, "start": 66, "tag": "CellFunction"}, {"end": 109, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 241, "start": 233, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 218, "start": 211, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 211, "tag": "BiologicallyActiveSubstance"}, {"end": 231, "start": 225, "tag": "AminoAcidPeptideOrProtein"}, {"end": 304, "start": 281, "tag": "CellOrMolecularDysfunction"}, {"end": 296, "start": 281, "tag": "CellComponent"}, {"end": 155, "start": 143, "tag": "Finding"}, {"end": 65, "start": 57, "tag": "Cell"}, {"end": 386, "start": 383, "tag": "AminoAcidPeptideOrProtein"}, {"end": 386, "start": 383, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 223, "start": 211, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 129, "tag": "CellComponent"}, {"end": 267, "start": 254, "tag": "CellComponent"}, {"end": 109, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 77, "tag": "TemporalConcept"}, {"end": 71, "start": 57, "tag": "CellFunction"}, {"end": 344, "start": 335, "tag": "CellComponent"}, {"end": 55, "start": 27, "tag": "CellOrMolecularDysfunction"}, {"end": 223, "start": 187, "tag": "CellOrMolecularDysfunction"}, {"end": 386, "start": 315, "tag": "CellOrMolecularDysfunction"}]}{"id": "1155_2", "text": "However, evidence showed that chronic inflammatory responses, with long-lasting exacerbated release of proinflammatory cytokines by reactive glial cells, contribute to the pathophysiology of the disease.", "tags": [{"end": 60, "start": 30, "tag": "PathologicFunction"}, {"end": 91, "start": 80, "tag": "Finding"}, {"end": 128, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 67, "tag": "TemporalConcept"}, {"end": 187, "start": 172, "tag": "PathologicFunction"}, {"end": 187, "start": 172, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 17, "start": 9, "tag": "Finding"}, {"end": 118, "start": 103, "tag": "PathologicFunction"}, {"end": 152, "start": 132, "tag": "Cell"}, {"end": 37, "start": 30, "tag": "TemporalConcept"}, {"end": 99, "start": 92, "tag": "HealthCareActivity"}, {"end": 99, "start": 92, "tag": "ResearchActivity"}, {"end": 128, "start": 119, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1155_3", "text": "NLRP3 inflammasome (NLRP3), a cytosolic multiprotein complex sensor of a wide range of stimuli, was implicated in multiple neurological diseases, including AD.", "tags": [{"end": 18, "start": 0, "tag": "CellComponent"}, {"end": 25, "start": 20, "tag": "CellComponent"}, {"end": 39, "start": 30, "tag": "CellComponent"}, {"end": 67, "start": 61, "tag": "ManufacturedObject"}, {"end": 158, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 40, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1155_4", "text": "Herein, we review the most recent findings regarding the involvement of NLRP3 in the pathogenesis of AD.", "tags": [{"end": 77, "start": 72, "tag": "CellComponent"}, {"end": 103, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 85, "tag": "PathologicFunction"}, {"end": 68, "start": 57, "tag": "Finding"}, {"end": 17, "start": 11, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "HealthCareActivity"}, {"end": 33, "start": 27, "tag": "TemporalConcept"}]}{"id": "1155_5", "text": "We address the mechanisms of NLRP3 priming and activation in glial cells by Ap species and the potential role of neurofibrillary tangles and extracellular vesicles in disease progression.", "tags": [{"end": 34, "start": 29, "tag": "CellComponent"}, {"end": 86, "start": 79, "tag": "OrganismAttribute"}, {"end": 186, "start": 175, "tag": "PathologicFunction"}, {"end": 186, "start": 175, "tag": "TemporalConcept"}, {"end": 163, "start": 141, "tag": "CellComponent"}, {"end": 136, "start": 113, "tag": "CellOrMolecularDysfunction"}, {"end": 128, "start": 113, "tag": "CellComponent"}, {"end": 72, "start": 61, "tag": "Cell"}, {"end": 186, "start": 167, "tag": "PathologicFunction"}]}{"id": "1155_6", "text": "Neuronal death by NLRP3-mediated pyroptosis, driven by the interneuronal tau propagation, is also discussed.", "tags": [{"end": 14, "start": 0, "tag": "CellFunction"}, {"end": 72, "start": 59, "tag": "Cell"}, {"end": 14, "start": 9, "tag": "BiologicFunction"}, {"end": 14, "start": 9, "tag": "PathologicFunction"}, {"end": 14, "start": 9, "tag": "CellFunction"}, {"end": 43, "start": 33, "tag": "CellFunction"}, {"end": 76, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 77, "tag": "Finding"}, {"end": 23, "start": 18, "tag": "CellComponent"}]}{"id": "1155_7", "text": "We present considerable evidence to claim that NLRP3 inhibition, is undoubtfully a potential therapeutic strategy for AD.", "tags": [{"end": 32, "start": 24, "tag": "Finding"}, {"end": 63, "start": 53, "tag": "CellFunction"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 93, "tag": "HealthCareActivity"}, {"end": 52, "start": 47, "tag": "CellComponent"}]}{"id": "1156_0", "text": "Alzheimer's disease (AD) is the leading cause of dementia throughout the world.", "tags": [{"end": 78, "start": 73, "tag": "PopulationGroup"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 49, "tag": "DiseaseOrSyndrome"}]}{"id": "1156_1", "text": "It is characterized by major amyloid plaques and neurofibrillary tangles (NFTs), which are composed of amyloid-beta (A beta) peptide and hyperphosphorylated Tau (p-Tau), respectively.", "tags": [{"end": 72, "start": 49, "tag": "CellOrMolecularDysfunction"}, {"end": 160, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 74, "tag": "CellOrMolecularDysfunction"}, {"end": 115, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 29, "tag": "PathologicFunction"}]}{"id": "1156_2", "text": "Exosomes, which are secreted by cells, are single-membrane lipid bilayer vesicles found in bodily fluids and they have a diameter of 30-150 nm.", "tags": [{"end": 81, "start": 43, "tag": "CellComponent"}, {"end": 8, "start": 0, "tag": "CellComponent"}, {"end": 37, "start": 32, "tag": "Cell"}, {"end": 104, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1156_3", "text": "Recently, they have been considered as critical carriers and biomarkers in AD, as they facilitate communication between cells and tissues by delivering proteins, lipids, and nucleic acids.", "tags": [{"end": 111, "start": 98, "tag": "HealthCareActivity"}, {"end": 111, "start": 98, "tag": "CellFunction"}, {"end": 187, "start": 174, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 168, "start": 162, "tag": "Chemical"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 160, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 61, "tag": "ClinicalAttribute"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 120, "tag": "Cell"}, {"end": 137, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1156_4", "text": "This review demonstrates that exosomes are natural nanocontainers that carry APP as well as Tau cleavage products secreted by neuronal cells and that their formation is associated with the endosomal-lysosomal pathway.", "tags": [{"end": 95, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 30, "tag": "CellComponent"}, {"end": 140, "start": 126, "tag": "Cell"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 216, "start": 189, "tag": "CellFunction"}, {"end": 80, "start": 77, "tag": "GeneOrGenome"}]}{"id": "1156_5", "text": "Moreover, these exosomes can transfer AD pathological molecules and participate in the pathophysiological process of AD; therefore, they have potential diagnostic and therapeutic value for AD and might also provide novel insights for screening and prevention of the disease.", "tags": [{"end": 184, "start": 152, "tag": "HealthCareActivity"}, {"end": 243, "start": 234, "tag": "HealthCareActivity"}, {"end": 243, "start": 234, "tag": "ResearchActivity"}, {"end": 63, "start": 54, "tag": "Substance"}, {"end": 258, "start": 248, "tag": "HealthCareActivity"}, {"end": 24, "start": 16, "tag": "CellComponent"}, {"end": 40, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 87, "tag": "PathologicFunction"}]}{"id": "1157_0", "text": "Neurodegenerative diseases constitute a group of pathologies whose etiology remains unknown in many cases, and there are no treatments that stop the progression of such diseases.", "tags": [{"end": 45, "start": 40, "tag": "PopulationGroup"}, {"end": 160, "start": 149, "tag": "PathologicFunction"}, {"end": 160, "start": 149, "tag": "TemporalConcept"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 124, "tag": "HealthCareActivity"}, {"end": 134, "start": 124, "tag": "ResearchActivity"}, {"end": 60, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 67, "tag": "Finding"}]}{"id": "1157_1", "text": "Moreover, the existence of the blood-brain barrier is an impediment to the penetration of exogenous molecules, including those found in many drugs.", "tags": [{"end": 50, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 141, "tag": "PharmacologicSubstance"}, {"end": 109, "start": 100, "tag": "Substance"}]}{"id": "1157_2", "text": "Exosomes are extracellular vesicles secreted by a wide variety of cells, and their primary functions include intercellular communication, immune responses, human reproduction, and synaptic plasticity.", "tags": [{"end": 174, "start": 162, "tag": "BiologicFunction"}, {"end": 199, "start": 180, "tag": "BiologicFunction"}, {"end": 154, "start": 138, "tag": "BiologicFunction"}, {"end": 35, "start": 13, "tag": "CellComponent"}, {"end": 161, "start": 156, "tag": "Eukaryote"}, {"end": 71, "start": 66, "tag": "Cell"}, {"end": 136, "start": 109, "tag": "CellFunction"}, {"end": 8, "start": 0, "tag": "CellComponent"}]}{"id": "1157_3", "text": "Due to their natural origin and molecular similarities with most cell types, exosomes have emerged as promising therapeutic tools for numerous diseases.", "tags": [{"end": 27, "start": 21, "tag": "TemporalConcept"}, {"end": 75, "start": 65, "tag": "Cell"}, {"end": 85, "start": 77, "tag": "CellComponent"}, {"end": 129, "start": 112, "tag": "HealthCareActivity"}]}{"id": "1157_4", "text": "Specifically, neurodegenerative diseases have shown to be a potential target for this nanomedicine strategy due to the difficult access to the brain and the strategy's pathophysiological complexity.", "tags": [{"end": 148, "start": 143, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 168, "tag": "PathologicFunction"}, {"end": 107, "start": 86, "tag": "HealthCareActivity"}]}{"id": "1157_5", "text": "In this regard, this review explores the most important biological-origin drug delivery systems, innovative isolation methods of exosomes, their physicochemical characterization, drug loading, cutting-edge functionalization strategies to target them within the brain, the latest research studies in neurodegenerative diseases, and the future challenges of exosomes as nanomedicine-based therapeutic tools.", "tags": [{"end": 95, "start": 74, "tag": "ManufacturedObject"}, {"end": 295, "start": 279, "tag": "ResearchActivity"}, {"end": 278, "start": 272, "tag": "TemporalConcept"}, {"end": 191, "start": 179, "tag": "ResearchActivity"}, {"end": 266, "start": 261, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 67, "tag": "TemporalConcept"}, {"end": 325, "start": 299, "tag": "DiseaseOrSyndrome"}, {"end": 352, "start": 342, "tag": "HealthCareActivity"}, {"end": 27, "start": 21, "tag": "ResearchActivity"}, {"end": 27, "start": 21, "tag": "HealthCareActivity"}, {"end": 234, "start": 193, "tag": "ResearchActivity"}, {"end": 341, "start": 335, "tag": "TemporalConcept"}, {"end": 78, "start": 74, "tag": "PharmacologicSubstance"}, {"end": 183, "start": 179, "tag": "PharmacologicSubstance"}, {"end": 137, "start": 129, "tag": "CellComponent"}, {"end": 364, "start": 356, "tag": "CellComponent"}, {"end": 177, "start": 145, "tag": "ResearchActivity"}, {"end": 87, "start": 79, "tag": "BiologicFunction"}, {"end": 87, "start": 74, "tag": "HealthCareActivity"}, {"end": 137, "start": 97, "tag": "ResearchActivity"}, {"end": 404, "start": 368, "tag": "HealthCareActivity"}, {"end": 380, "start": 368, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1158_0", "text": "Background: The Amyloid Tau Neurodegeneration (ATN) framework was proposed to define the biological state underpinning Alzheimer's disease (AD).", "tags": [{"end": 138, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 100, "tag": "PopulationGroup"}, {"end": 61, "start": 16, "tag": "HealthCareActivity"}]}{"id": "1158_1", "text": "Blood-based biomarkers offer a scalable alternative to the costly and invasive currently available biomarkers.", "tags": [{"end": 78, "start": 70, "tag": "Finding"}, {"end": 22, "start": 12, "tag": "ClinicalAttribute"}, {"end": 109, "start": 99, "tag": "ClinicalAttribute"}, {"end": 88, "start": 79, "tag": "TemporalConcept"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1158_2", "text": "Objective: In this meta-analysis we sought to assess the diagnostic performance of plasma amyloid (A beta(40), A beta(42), A beta(42/40) ratio), tangle (p-tau181), and neurodegeneration (total tau [t-tau], neurofilament light [NfL]) biomarkers.", "tags": [{"end": 230, "start": 227, "tag": "BiologicallyActiveSubstance"}, {"end": 230, "start": 227, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 24, "tag": "ResearchActivity"}, {"end": 89, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 196, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 243, "start": 233, "tag": "ClinicalAttribute"}, {"end": 196, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 200, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 198, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 168, "tag": "CellOrMolecularDysfunction"}, {"end": 97, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 225, "start": 206, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 206, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 68, "tag": "ClinicalAttribute"}, {"end": 79, "start": 68, "tag": "Finding"}, {"end": 79, "start": 57, "tag": "HealthCareActivity"}, {"end": 32, "start": 19, "tag": "ResearchActivity"}, {"end": 142, "start": 123, "tag": "ClinicalAttribute"}, {"end": 162, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 111, "tag": "BiologicallyActiveSubstance"}]}{"id": "1158_3", "text": "Methods: Electronic databases were screened for studies reporting biomarker concentrations for AD and control cohorts.", "tags": [{"end": 29, "start": 9, "tag": "ResearchActivity"}, {"end": 43, "start": 35, "tag": "HealthCareActivity"}, {"end": 43, "start": 35, "tag": "ResearchActivity"}, {"end": 117, "start": 110, "tag": "PopulationGroup"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 66, "tag": "ClinicalAttribute"}, {"end": 55, "start": 48, "tag": "ResearchActivity"}]}{"id": "1158_4", "text": "Biomarker performance was examined by random-effect meta-analyses based on the ratio between biomarker concentrations in patients and controls.", "tags": [{"end": 65, "start": 52, "tag": "ResearchActivity"}, {"end": 9, "start": 0, "tag": "ClinicalAttribute"}, {"end": 129, "start": 121, "tag": "PatientOrDisabledGroup"}, {"end": 142, "start": 134, "tag": "PopulationGroup"}, {"end": 102, "start": 93, "tag": "ClinicalAttribute"}, {"end": 51, "start": 45, "tag": "Finding"}, {"end": 117, "start": 103, "tag": "BiologicFunction"}, {"end": 21, "start": 10, "tag": "Finding"}]}{"id": "1158_5", "text": "Results: 83 studies published between 1996 and 2020 were included in the analyses.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 19, "start": 12, "tag": "ResearchActivity"}, {"end": 81, "start": 73, "tag": "ResearchActivity"}]}{"id": "1158_6", "text": "A beta(42/40) ratio as well as A beta(42) discriminated AD patients from controls when using novel platforms such as immunomagnetic reduction (IMR).", "tags": [{"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 59, "tag": "PatientOrDisabledGroup"}, {"end": 81, "start": 73, "tag": "PopulationGroup"}, {"end": 41, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 0, "tag": "ClinicalAttribute"}, {"end": 141, "start": 117, "tag": "ResearchActivity"}, {"end": 146, "start": 143, "tag": "ResearchActivity"}]}{"id": "1158_7", "text": "We found significant differences in ptau-181 concentration for studies based on single molecule array (Simoa), but not for studies based on IMR or ELISA.", "tags": [{"end": 101, "start": 80, "tag": "ResearchActivity"}, {"end": 130, "start": 123, "tag": "ResearchActivity"}, {"end": 32, "start": 21, "tag": "Finding"}, {"end": 108, "start": 103, "tag": "ResearchActivity"}, {"end": 152, "start": 147, "tag": "ResearchActivity"}, {"end": 70, "start": 63, "tag": "ResearchActivity"}, {"end": 58, "start": 36, "tag": "ClinicalAttribute"}, {"end": 143, "start": 140, "tag": "ResearchActivity"}]}{"id": "1158_8", "text": "T-tau was significantly different between AD patients and control in IMR and Simoa but not in ELISA-based studies.", "tags": [{"end": 44, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 45, "tag": "PatientOrDisabledGroup"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 106, "tag": "ResearchActivity"}, {"end": 82, "start": 77, "tag": "ResearchActivity"}, {"end": 99, "start": 94, "tag": "ResearchActivity"}, {"end": 72, "start": 69, "tag": "ResearchActivity"}]}{"id": "1158_9", "text": "In contrast, NfL differentiated between groups across platforms.", "tags": [{"end": 16, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 13, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1158_10", "text": "Exosome studies showed strong separation between patients and controls for A beta(42), t-tau, and p-tau181.", "tags": [{"end": 57, "start": 49, "tag": "PatientOrDisabledGroup"}, {"end": 70, "start": 62, "tag": "PopulationGroup"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 40, "start": 30, "tag": "Finding"}, {"end": 92, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "CellComponent"}, {"end": 85, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 98, "tag": "BiologicallyActiveSubstance"}]}{"id": "1158_11", "text": "Conclusion: Currently available assays for sampling plasma ATN biomarkers appear to differentiate between AD patients and controls.", "tags": [{"end": 51, "start": 43, "tag": "HealthCareActivity"}, {"end": 21, "start": 12, "tag": "TemporalConcept"}, {"end": 97, "start": 84, "tag": "CellFunction"}, {"end": 108, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 109, "tag": "PatientOrDisabledGroup"}, {"end": 58, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 122, "tag": "PopulationGroup"}, {"end": 73, "start": 59, "tag": "ClinicalAttribute"}, {"end": 38, "start": 32, "tag": "ResearchActivity"}]}{"id": "1158_12", "text": "Novel assay methodologies have given the field a significant boost for testing these biomarkers, such as IMR for A beta, Simoa for p-tau181.", "tags": [{"end": 78, "start": 71, "tag": "HealthCareActivity"}, {"end": 11, "start": 6, "tag": "ResearchActivity"}, {"end": 95, "start": 85, "tag": "ClinicalAttribute"}, {"end": 126, "start": 121, "tag": "ResearchActivity"}, {"end": 119, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 105, "tag": "ResearchActivity"}, {"end": 139, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 131, "tag": "BiologicallyActiveSubstance"}]}{"id": "1158_13", "text": "Enriching samples through extracellular vesicles shows promise but requires further validation.", "tags": [{"end": 94, "start": 84, "tag": "ResearchActivity"}, {"end": 48, "start": 26, "tag": "CellComponent"}, {"end": 17, "start": 10, "tag": "Substance"}, {"end": 17, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1159_0", "text": "Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive decline, accompanied by amyloid-beta (A beta) overload and hyperphosphorylated tau accumulation in the brain.", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 198, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 177, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 178, "tag": "Finding"}, {"end": 139, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 73, "tag": "TemporalConcept"}, {"end": 126, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 95, "tag": "Finding"}, {"end": 131, "start": 119, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1159_1", "text": "Synaptic dysfunction, an important pathological hallmark in AD, is recognized as the main cause of the cognitive impairments.", "tags": [{"end": 124, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 62, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 9, "tag": "PathologicFunction"}, {"end": 56, "start": 48, "tag": "Finding"}]}{"id": "1159_2", "text": "Accumulating evidence suggests that synaptic dysfunction could be an early pathological event in AD.", "tags": [{"end": 21, "start": 0, "tag": "Finding"}, {"end": 56, "start": 36, "tag": "CellOrMolecularDysfunction"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 13, "tag": "Finding"}, {"end": 56, "start": 45, "tag": "PathologicFunction"}]}{"id": "1159_3", "text": "Pathological tau, which is detached from axonal microtubules and mislocalized into pre- and postsynaptic neuronal compartments, is suggested to induce synaptic dysfunction in several ways, including reducing mobility and release of presynaptic vesicles, decreasing glutamatergic receptors, impairing the maturation of dendritic spines at postsynaptic terminals, disrupting mitochondrial transport and function in synapses, and promoting the phagocytosis of synapses by microglia.", "tags": [{"end": 12, "start": 0, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 60, "start": 48, "tag": "CellComponent"}, {"end": 216, "start": 208, "tag": "ClinicalAttribute"}, {"end": 216, "start": 208, "tag": "Finding"}, {"end": 288, "start": 265, "tag": "AminoAcidPeptideOrProtein"}, {"end": 334, "start": 318, "tag": "CellComponent"}, {"end": 47, "start": 41, "tag": "CellComponent"}, {"end": 104, "start": 92, "tag": "CellComponent"}, {"end": 360, "start": 338, "tag": "CellComponent"}, {"end": 453, "start": 441, "tag": "CellFunction"}, {"end": 264, "start": 254, "tag": "Finding"}, {"end": 386, "start": 373, "tag": "CellComponent"}, {"end": 171, "start": 151, "tag": "CellOrMolecularDysfunction"}, {"end": 159, "start": 151, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 396, "start": 373, "tag": "CellFunction"}, {"end": 113, "start": 105, "tag": "Cell"}, {"end": 478, "start": 469, "tag": "Cell"}, {"end": 243, "start": 232, "tag": "CellComponent"}, {"end": 252, "start": 232, "tag": "CellComponent"}, {"end": 288, "start": 265, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 114, "tag": "CellComponent"}, {"end": 171, "start": 160, "tag": "PathologicFunction"}, {"end": 207, "start": 199, "tag": "Finding"}, {"end": 421, "start": 413, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 465, "start": 457, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 334, "start": 304, "tag": "CellFunction"}, {"end": 252, "start": 221, "tag": "CellFunction"}]}{"id": "1159_4", "text": "Here, we review the current understanding of how pathological tau mediates synaptic dysfunction and contributes to cognitive decline in AD.", "tags": [{"end": 95, "start": 75, "tag": "CellOrMolecularDysfunction"}, {"end": 138, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 27, "start": 20, "tag": "TemporalConcept"}, {"end": 41, "start": 28, "tag": "BiologicFunction"}, {"end": 132, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 84, "tag": "PathologicFunction"}, {"end": 65, "start": 49, "tag": "PathologicFunction"}]}{"id": "1159_5", "text": "We propose that elucidating the mechanism by which pathological tau impairs synaptic function is essential for exploring novel therapeutic strategies for AD.", "tags": [{"end": 156, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 76, "tag": "CellFunction"}, {"end": 67, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 139, "tag": "ResearchActivity"}, {"end": 149, "start": 139, "tag": "BiologicFunction"}, {"end": 149, "start": 127, "tag": "HealthCareActivity"}]}{"id": "1160_0", "text": "One of the most compelling needs in the study of Alzheimer's disease (AD) is the characterization of cognitive decline peripheral biomarkers.", "tags": [{"end": 97, "start": 81, "tag": "ResearchActivity"}, {"end": 140, "start": 119, "tag": "ClinicalAttribute"}, {"end": 45, "start": 40, "tag": "ResearchActivity"}, {"end": 68, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 130, "tag": "ClinicalAttribute"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 101, "tag": "DiseaseOrSyndrome"}]}{"id": "1160_1", "text": "In this context, the theme of altered RNA processing has emerged as a contributing factor to AD.", "tags": [{"end": 52, "start": 30, "tag": "CellOrMolecularDysfunction"}, {"end": 95, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 38, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1160_2", "text": "In particular, the significant role of long non-coding RNAs (lncRNAs) associated to AD is opening new perspectives in AD research.", "tags": [{"end": 59, "start": 39, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 59, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 44, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 68, "start": 61, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 59, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 121, "tag": "ResearchActivity"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}]}{"id": "1160_3", "text": "This class of RNAs may offer numerous starting points for new investigations about pathogenic mechanisms and, in particular, about peripheral biomarkers.", "tags": [{"end": 18, "start": 14, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 152, "start": 131, "tag": "ClinicalAttribute"}, {"end": 104, "start": 83, "tag": "PathologicFunction"}, {"end": 76, "start": 62, "tag": "ResearchActivity"}, {"end": 152, "start": 142, "tag": "ClinicalAttribute"}, {"end": 141, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1160_4", "text": "Indeed, altered lncRNA signatures are emerging as potential diagnostic biomarkers.", "tags": [{"end": 22, "start": 16, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 33, "start": 8, "tag": "CellOrMolecularDysfunction"}, {"end": 81, "start": 71, "tag": "ClinicalAttribute"}]}{"id": "1160_5", "text": "In this review, we have collected and fully explored all the presented data about lncRNAs and AD in the peripheral system to offer an overview about this class of non-coding RNAs and their possible role in AD.", "tags": [{"end": 178, "start": 163, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 142, "start": 134, "tag": "ResearchActivity"}, {"end": 89, "start": 82, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 178, "start": 163, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 206, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 71, "tag": "ResearchActivity"}, {"end": 114, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1161_0", "text": "Alzheimer disease (AD) is a progressive neurodegenerative disease resulting from the accumulation of extracellular amyloid beta (A beta) and intracellular neurofibrillary tangles.", "tags": [{"end": 154, "start": 141, "tag": "CellComponent"}, {"end": 21, "start": 19, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 85, "tag": "Finding"}, {"end": 127, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 101, "tag": "CellComponent"}, {"end": 39, "start": 28, "tag": "TemporalConcept"}, {"end": 122, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 155, "tag": "CellOrMolecularDysfunction"}, {"end": 170, "start": 155, "tag": "CellComponent"}]}{"id": "1161_1", "text": "There are currently no objective diagnostic measures for AD.", "tags": [{"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 10, "tag": "TemporalConcept"}]}{"id": "1161_2", "text": "The aim of this study was to identify potential diagnostic markers for AD and evaluate the role of immune cell infiltration in disease pathogenesis.", "tags": [{"end": 123, "start": 99, "tag": "CellFunction"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 48, "tag": "ClinicalAttribute"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 110, "start": 99, "tag": "Cell"}, {"end": 147, "start": 135, "tag": "PathologicFunction"}]}{"id": "1161_3", "text": "AD expression profiling data for human hippocampus tissue (GSE48350 and GSE5281) were downloaded from the Gene Expression Omnibus database.", "tags": [{"end": 138, "start": 106, "tag": "ResearchActivity"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 33, "tag": "Eukaryote"}, {"end": 13, "start": 3, "tag": "CellFunction"}, {"end": 23, "start": 14, "tag": "ResearchActivity"}, {"end": 57, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 24, "tag": "ResearchActivity"}, {"end": 79, "start": 72, "tag": "ResearchActivity"}, {"end": 67, "start": 59, "tag": "ResearchActivity"}]}{"id": "1161_4", "text": "Differentially expressed genes (DEGs) were identified using R software and the Human Protein Atlas database was used to screen AD-related DEGs.", "tags": [{"end": 36, "start": 32, "tag": "GeneOrGenome"}, {"end": 142, "start": 138, "tag": "GeneOrGenome"}, {"end": 30, "start": 0, "tag": "GeneOrGenome"}, {"end": 30, "start": 0, "tag": "ResearchActivity"}, {"end": 36, "start": 32, "tag": "ResearchActivity"}, {"end": 142, "start": 138, "tag": "ResearchActivity"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 79, "tag": "ResearchActivity"}, {"end": 70, "start": 60, "tag": "ResearchActivity"}]}{"id": "1161_5", "text": "We performed functional enrichment analysis and established a protein-protein interaction (PPI) network to identify disease-related hub DEGs.", "tags": [{"end": 89, "start": 62, "tag": "CellFunction"}, {"end": 94, "start": 91, "tag": "CellFunction"}, {"end": 135, "start": 132, "tag": "GeneOrGenome"}, {"end": 140, "start": 136, "tag": "GeneOrGenome"}, {"end": 140, "start": 136, "tag": "ResearchActivity"}, {"end": 43, "start": 24, "tag": "ResearchActivity"}, {"end": 69, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 96, "tag": "ResearchActivity"}]}{"id": "1161_6", "text": "The fraction of infiltrating immune cells in samples was determined with the Microenvironment Cell Populations-counter method.", "tags": [{"end": 41, "start": 16, "tag": "Cell"}, {"end": 52, "start": 45, "tag": "Substance"}, {"end": 52, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 77, "tag": "ResearchActivity"}, {"end": 125, "start": 119, "tag": "HealthCareActivity"}]}{"id": "1161_7", "text": "The random forest algorithm was used to develop a prediction model and receiver operating characteristic (ROC) curve analysis was performed to validate the diagnostic utility of the candidate AD markers.", "tags": [{"end": 194, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 195, "tag": "ClinicalAttribute"}, {"end": 125, "start": 117, "tag": "ResearchActivity"}, {"end": 66, "start": 50, "tag": "ResearchActivity"}, {"end": 109, "start": 106, "tag": "ResearchActivity"}, {"end": 174, "start": 156, "tag": "Finding"}, {"end": 27, "start": 4, "tag": "MachineActivity"}, {"end": 104, "start": 71, "tag": "ResearchActivity"}]}{"id": "1161_8", "text": "The correlation between expression of the diagnostic markers and immune cell infiltration was also analyzed.", "tags": [{"end": 76, "start": 65, "tag": "Cell"}, {"end": 60, "start": 42, "tag": "ClinicalAttribute"}, {"end": 76, "start": 72, "tag": "Cell"}, {"end": 34, "start": 24, "tag": "CellFunction"}, {"end": 107, "start": 99, "tag": "ResearchActivity"}, {"end": 89, "start": 65, "tag": "BiologicFunction"}]}{"id": "1161_9", "text": "A total of 107 AD-related DEGs were screened in this study, including 28 that were upregulated and 79 that were downregulated.", "tags": [{"end": 30, "start": 26, "tag": "GeneOrGenome"}, {"end": 30, "start": 26, "tag": "ResearchActivity"}, {"end": 44, "start": 36, "tag": "HealthCareActivity"}, {"end": 44, "start": 36, "tag": "ResearchActivity"}, {"end": 17, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 53, "tag": "ResearchActivity"}, {"end": 125, "start": 112, "tag": "CellFunction"}]}{"id": "1161_10", "text": "The DEGs were enriched in the Gene Ontology terms GABAergic synapse, Morphine addiction, Nicotine addiction, Phagosome, and Synaptic vesicle cycle.", "tags": [{"end": 77, "start": 69, "tag": "Chemical"}, {"end": 97, "start": 89, "tag": "Chemical"}, {"end": 118, "start": 109, "tag": "CellComponent"}, {"end": 146, "start": 124, "tag": "CellFunction"}, {"end": 8, "start": 4, "tag": "GeneOrGenome"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 49, "start": 30, "tag": "ResearchActivity"}, {"end": 67, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 124, "tag": "CellComponent"}, {"end": 87, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 69, "tag": "PharmacologicSubstance"}, {"end": 95, "start": 94, "tag": "InjuryOrPoisoning"}, {"end": 107, "start": 89, "tag": "DiseaseOrSyndrome"}]}{"id": "1161_11", "text": "We identified 10 disease-related hub genes and 20 candidate diagnostic genes.", "tags": [{"end": 76, "start": 60, "tag": "GeneOrGenome"}, {"end": 42, "start": 17, "tag": "GeneOrGenome"}]}{"id": "1161_12", "text": "Synaptophysin (SYP) and regulator of G protein signaling 4 (RGS4) (area under the ROC curve = 0.909) were verified as potential diagnostic markers for AD in the GSE28146 validation dataset.", "tags": [{"end": 13, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 0, "tag": "GeneOrGenome"}, {"end": 18, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 15, "tag": "GeneOrGenome"}, {"end": 64, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 170, "tag": "ResearchActivity"}, {"end": 153, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 128, "tag": "ClinicalAttribute"}, {"end": 85, "start": 82, "tag": "ResearchActivity"}, {"end": 91, "start": 82, "tag": "ResearchActivity"}, {"end": 64, "start": 60, "tag": "GeneOrGenome"}, {"end": 18, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 161, "tag": "ResearchActivity"}]}{"id": "1161_13", "text": "Natural killer cells, B lineage cells, monocytic lineage cells, endothelial cells, and fibroblasts were found to be involved in AD; additionally, the expression levels of both SYP and RGS4 were negatively correlated with the infiltration of these immune cell types.", "tags": [{"end": 20, "start": 0, "tag": "Cell"}, {"end": 98, "start": 87, "tag": "Cell"}, {"end": 179, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 176, "tag": "GeneOrGenome"}, {"end": 188, "start": 184, "tag": "GeneOrGenome"}, {"end": 188, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 237, "start": 225, "tag": "Finding"}, {"end": 258, "start": 247, "tag": "Cell"}, {"end": 81, "start": 64, "tag": "Cell"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 22, "tag": "Cell"}, {"end": 62, "start": 39, "tag": "Cell"}, {"end": 160, "start": 150, "tag": "CellFunction"}, {"end": 264, "start": 254, "tag": "Cell"}, {"end": 188, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 179, "start": 176, "tag": "BiologicallyActiveSubstance"}]}{"id": "1161_14", "text": "These results suggest that SYP and RGS4 are potential diagnostic markers for AD and that immune cell infiltration plays an important role in AD development and progression.", "tags": [{"end": 30, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 27, "tag": "GeneOrGenome"}, {"end": 39, "start": 35, "tag": "GeneOrGenome"}, {"end": 39, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 89, "tag": "Cell"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 54, "tag": "ClinicalAttribute"}, {"end": 155, "start": 144, "tag": "BiologicFunction"}, {"end": 155, "start": 144, "tag": "CellFunction"}, {"end": 171, "start": 160, "tag": "PathologicFunction"}, {"end": 171, "start": 160, "tag": "TemporalConcept"}, {"end": 30, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 89, "tag": "CellFunction"}]}{"id": "1162_0", "text": "Progressive development of pathology is one of the major characteristic features of neurodegenerative diseases.", "tags": [{"end": 36, "start": 27, "tag": "PathologicFunction"}, {"end": 36, "start": 27, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 23, "start": 12, "tag": "BiologicFunction"}, {"end": 23, "start": 12, "tag": "CellFunction"}, {"end": 110, "start": 84, "tag": "DiseaseOrSyndrome"}]}{"id": "1162_1", "text": "Alzheimer's disease (AD) is the most prevalent among them.", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}]}{"id": "1162_2", "text": "Extracellular amyloid-beta (A beta) plaques and intracellular tau neurofibrillary tangles are the pathological phenotypes of AD.", "tags": [{"end": 13, "start": 0, "tag": "CellComponent"}, {"end": 43, "start": 36, "tag": "AnatomicalAbnormality"}, {"end": 26, "start": 14, "tag": "AnatomicalAbnormality"}, {"end": 61, "start": 48, "tag": "CellComponent"}, {"end": 127, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 111, "tag": "OrganismAttribute"}, {"end": 89, "start": 66, "tag": "CellOrMolecularDysfunction"}, {"end": 26, "start": 14, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1162_3", "text": "However, cellular and animal studies implicate tau as a secondary pathology in developing AD while A beta aggregates is considered as a trigger point.", "tags": [{"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 66, "tag": "PathologicFunction"}, {"end": 75, "start": 66, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 29, "tag": "ResearchActivity"}, {"end": 105, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 9, "tag": "Cell"}, {"end": 28, "start": 22, "tag": "Eukaryote"}, {"end": 116, "start": 99, "tag": "CellOrMolecularDysfunction"}]}{"id": "1162_4", "text": "Interaction of A beta peptides with plasma membrane (PM) seems to be a promising site of involvement in the events that lead to AD.", "tags": [{"end": 11, "start": 0, "tag": "Finding"}, {"end": 51, "start": 36, "tag": "CellComponent"}, {"end": 55, "start": 53, "tag": "CellComponent"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 89, "tag": "Finding"}]}{"id": "1162_5", "text": "A beta binding to the lipid membranes initiates formation of oligomers of A beta species, and these oligomers are known as primary toxic agents for neuronal toxicities.", "tags": [{"end": 167, "start": 157, "tag": "InjuryOrPoisoning"}, {"end": 37, "start": 28, "tag": "CellComponent"}, {"end": 156, "start": 148, "tag": "Cell"}, {"end": 136, "start": 131, "tag": "InjuryOrPoisoning"}, {"end": 6, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 22, "tag": "Chemical"}, {"end": 14, "start": 7, "tag": "CellFunction"}, {"end": 88, "start": 81, "tag": "OrganismAttribute"}]}{"id": "1162_6", "text": "Once initiated, neuropathological toxicities spread in a prion-like  fashion probably through the mechanism of intercellular transfer of pathogenic aggregates.", "tags": [{"end": 44, "start": 34, "tag": "InjuryOrPoisoning"}, {"end": 147, "start": 137, "tag": "PathologicFunction"}, {"end": 62, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 16, "tag": "PathologicFunction"}]}{"id": "1162_7", "text": "In the last two decades, several studies have demonstrated neuron-to-neuron transfer of neurodegenerative proteins including A beta and tau via exosomes and tunneling nanotubes (TNTs), the two modes of long-range intercellular transfer.", "tags": [{"end": 23, "start": 16, "tag": "TemporalConcept"}, {"end": 65, "start": 59, "tag": "Cell"}, {"end": 75, "start": 69, "tag": "Cell"}, {"end": 139, "start": 136, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 40, "start": 33, "tag": "ResearchActivity"}, {"end": 114, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 88, "tag": "CellOrMolecularDysfunction"}, {"end": 131, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 144, "tag": "CellComponent"}, {"end": 176, "start": 157, "tag": "CellComponent"}, {"end": 182, "start": 178, "tag": "CellComponent"}, {"end": 235, "start": 202, "tag": "BiologicFunction"}]}{"id": "1162_8", "text": "Emerging pieces of evidence indicate that molecular pathways related to the biogenesis of exosomes and TNTs interface with endo-lysosomal pathways and cellular signaling in connection to vesicle recycling-imposed PM and actin remodulation.", "tags": [{"end": 215, "start": 213, "tag": "CellComponent"}, {"end": 169, "start": 160, "tag": "CellFunction"}, {"end": 27, "start": 19, "tag": "Finding"}, {"end": 194, "start": 187, "tag": "CellComponent"}, {"end": 159, "start": 151, "tag": "Cell"}, {"end": 60, "start": 52, "tag": "CellFunction"}, {"end": 146, "start": 138, "tag": "CellFunction"}, {"end": 86, "start": 76, "tag": "CellFunction"}, {"end": 60, "start": 42, "tag": "CellFunction"}, {"end": 98, "start": 90, "tag": "CellComponent"}, {"end": 225, "start": 220, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 103, "tag": "CellComponent"}, {"end": 137, "start": 123, "tag": "CellComponent"}]}{"id": "1162_9", "text": "In this review, we discuss interactions of A beta aggregates at the membrane level and its implications in intercellular spread of pathogenic aggregates.", "tags": [{"end": 76, "start": 68, "tag": "CellComponent"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 49, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 131, "tag": "PathologicFunction"}, {"end": 39, "start": 27, "tag": "Finding"}, {"end": 152, "start": 107, "tag": "PathologicFunction"}]}{"id": "1162_10", "text": "Furthermore, we hypothesize how spread of pathogenic aggregates contributes to complex molecular events that could regulate pathological and synaptic changes related to AD.", "tags": [{"end": 171, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 42, "tag": "PathologicFunction"}, {"end": 157, "start": 150, "tag": "Finding"}]}{"id": "1163_0", "text": "Intercellular communication between neurons and their surrounding cells occurs through the secretion of soluble molecules or release of vesicles such as exosomes into the extracellular space, participating in brain homeostasis.", "tags": [{"end": 111, "start": 104, "tag": "CellComponent"}, {"end": 226, "start": 209, "tag": "BiologicFunction"}, {"end": 190, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 66, "tag": "Cell"}, {"end": 100, "start": 91, "tag": "CellFunction"}, {"end": 100, "start": 91, "tag": "BiologicFunction"}, {"end": 43, "start": 36, "tag": "Cell"}, {"end": 226, "start": 215, "tag": "BiologicFunction"}, {"end": 121, "start": 112, "tag": "Substance"}, {"end": 27, "start": 0, "tag": "CellFunction"}, {"end": 161, "start": 153, "tag": "CellComponent"}, {"end": 144, "start": 125, "tag": "CellFunction"}]}{"id": "1163_1", "text": "Under neuro-degenerative conditions associated with ageing, such as amyotrophic lateral sclerosis (ALS), Alzheimer's or Parkinson's disease, exosomes are suspected to propagate toxic proteins.", "tags": [{"end": 58, "start": 52, "tag": "BiologicFunction"}, {"end": 102, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 12, "tag": "PathologicFunction"}, {"end": 139, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 177, "tag": "InjuryOrPoisoning"}, {"end": 191, "start": 183, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 141, "tag": "CellComponent"}, {"end": 35, "start": 6, "tag": "DiseaseOrSyndrome"}]}{"id": "1163_2", "text": "The topic of this review is the role of exosomes in ageing conditions and more specifically in ALS.", "tags": [{"end": 98, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 18, "tag": "ResearchActivity"}, {"end": 24, "start": 18, "tag": "HealthCareActivity"}, {"end": 48, "start": 40, "tag": "CellComponent"}, {"end": 69, "start": 52, "tag": "DiseaseOrSyndrome"}]}{"id": "1163_3", "text": "Our current understanding of exosomes and exosome-related mechanisms is first summarized in a general sense, including their biogenesis and secretion, heterogeneity, cellular interaction and intracellular fate.", "tags": [{"end": 204, "start": 191, "tag": "CellComponent"}, {"end": 164, "start": 151, "tag": "OrganismAttribute"}, {"end": 77, "start": 72, "tag": "TemporalConcept"}, {"end": 49, "start": 42, "tag": "CellComponent"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}, {"end": 149, "start": 140, "tag": "CellFunction"}, {"end": 149, "start": 140, "tag": "BiologicFunction"}, {"end": 25, "start": 12, "tag": "BiologicFunction"}, {"end": 186, "start": 166, "tag": "Cell"}, {"end": 135, "start": 125, "tag": "CellFunction"}, {"end": 37, "start": 29, "tag": "CellComponent"}]}{"id": "1163_4", "text": "Their role in the Central Nervous System (CNS) and ageing of the neuromotor system is then considered in the context of exosome-induced signaling.", "tags": [{"end": 40, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 51, "tag": "BiologicFunction"}, {"end": 82, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 136, "tag": "CellFunction"}, {"end": 45, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 120, "tag": "CellComponent"}]}{"id": "1163_5", "text": "The review then focuses on exosomes in age-associated neurodegenerative disease.", "tags": [{"end": 10, "start": 4, "tag": "ResearchActivity"}, {"end": 10, "start": 4, "tag": "HealthCareActivity"}, {"end": 42, "start": 39, "tag": "OrganismAttribute"}, {"end": 79, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 27, "tag": "CellComponent"}]}{"id": "1163_6", "text": "The role of exosomes in ALS is highlighted, and their use as potential biomarkers to diagnose and prognose ALS is presented.", "tags": [{"end": 93, "start": 85, "tag": "HealthCareActivity"}, {"end": 106, "start": 98, "tag": "HealthCareActivity"}, {"end": 27, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 71, "tag": "ClinicalAttribute"}, {"end": 81, "start": 61, "tag": "ClinicalAttribute"}, {"end": 20, "start": 12, "tag": "CellComponent"}]}{"id": "1163_7", "text": "The therapeutic implications of exosomes for ALS are considered, whether as delivery vehicles, neurotoxic targets or as corrective drugs in and of themselves.", "tags": [{"end": 48, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 120, "tag": "PharmacologicSubstance"}, {"end": 40, "start": 32, "tag": "CellComponent"}, {"end": 93, "start": 85, "tag": "ManufacturedObject"}, {"end": 84, "start": 76, "tag": "BiologicFunction"}, {"end": 28, "start": 4, "tag": "Finding"}, {"end": 105, "start": 95, "tag": "InjuryOrPoisoning"}]}{"id": "1163_8", "text": "A diverse set of mechanisms underpin the functional roles, both confirmed and potential, of exosomes, generally in ageing and specifically in motor neurone disease.", "tags": [{"end": 121, "start": 115, "tag": "BiologicFunction"}, {"end": 163, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 92, "tag": "CellComponent"}]}{"id": "1163_9", "text": "Aspects of their contents, biogenesis, uptake and modifications offer many plausible routes towards the development of novel biomarkers and therapeutics.", "tags": [{"end": 115, "start": 104, "tag": "BiologicFunction"}, {"end": 115, "start": 104, "tag": "CellFunction"}, {"end": 135, "start": 125, "tag": "ClinicalAttribute"}, {"end": 152, "start": 140, "tag": "HealthCareActivity"}, {"end": 37, "start": 27, "tag": "CellFunction"}, {"end": 45, "start": 39, "tag": "BiologicFunction"}, {"end": 45, "start": 39, "tag": "CellFunction"}]}{"id": "1164_0", "text": "Neurological disorders, including neurodegenerative diseases, are often characterized by neuroinflammation, which is largely driven by microglia, the resident immune cells of the central nervous system (CNS).", "tags": [{"end": 22, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 150, "tag": "Cell"}, {"end": 201, "start": 179, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 206, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 135, "tag": "Cell"}, {"end": 106, "start": 89, "tag": "PathologicFunction"}]}{"id": "1164_1", "text": "Under these conditions, microglia are able to secrete neurotoxic substances, provoking neuronal cell death.", "tags": [{"end": 53, "start": 46, "tag": "CellFunction"}, {"end": 33, "start": 24, "tag": "Cell"}, {"end": 106, "start": 87, "tag": "CellFunction"}, {"end": 75, "start": 54, "tag": "InjuryOrPoisoning"}]}{"id": "1164_2", "text": "However, microglia in the healthy brain carry out CNS-supporting functions.", "tags": [{"end": 33, "start": 26, "tag": "OrganismAttribute"}, {"end": 53, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 9, "tag": "Cell"}]}{"id": "1164_3", "text": "This is due to the ability of microglia to acquire different phenotypes that can play a neuroprotective role under physiological conditions or a pro-inflammatory, damaging one during disease.", "tags": [{"end": 161, "start": 145, "tag": "PathologicFunction"}, {"end": 39, "start": 30, "tag": "Cell"}, {"end": 71, "start": 61, "tag": "OrganismAttribute"}, {"end": 26, "start": 19, "tag": "OrganismAttribute"}, {"end": 108, "start": 88, "tag": "Finding"}]}{"id": "1164_4", "text": "Therefore, therapeutic strategies focus on the downregulation of these neuroinflammatory processes and try to re-activate the neuroprotective features of microglia.", "tags": [{"end": 61, "start": 47, "tag": "CellFunction"}, {"end": 163, "start": 154, "tag": "Cell"}, {"end": 88, "start": 71, "tag": "PathologicFunction"}, {"end": 141, "start": 126, "tag": "CellFunction"}, {"end": 33, "start": 11, "tag": "HealthCareActivity"}]}{"id": "1164_5", "text": "Mesenchymal stem cells (MSC) of different origins have been shown to exert such effects, due to their immunomodulatory properties.", "tags": [{"end": 49, "start": 42, "tag": "TemporalConcept"}, {"end": 22, "start": 0, "tag": "Cell"}, {"end": 27, "start": 24, "tag": "Cell"}, {"end": 22, "start": 12, "tag": "Cell"}, {"end": 87, "start": 80, "tag": "Finding"}, {"end": 129, "start": 102, "tag": "Finding"}]}{"id": "1164_6", "text": "In recent years, MSC derived from adipose tissue have been made the center of attention because of their easy availability and extraction methods.", "tags": [{"end": 48, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 78, "tag": "BiologicFunction"}, {"end": 15, "start": 10, "tag": "TemporalConcept"}, {"end": 15, "start": 3, "tag": "TemporalConcept"}, {"end": 20, "start": 17, "tag": "Cell"}, {"end": 145, "start": 127, "tag": "ResearchActivity"}]}{"id": "1164_7", "text": "These cells induce a neuroprotective phenotype in microglia and downregulate neuroinflammation, resulting in an improvement of clinical symptoms in a variety of animal models for neurological pathologies, e.g., Alzheimer's disease, traumatic brain injury and ischemic stroke.", "tags": [{"end": 76, "start": 64, "tag": "CellFunction"}, {"end": 274, "start": 259, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 127, "tag": "SignOrSymptom"}, {"end": 254, "start": 232, "tag": "InjuryOrPoisoning"}, {"end": 230, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 6, "tag": "Cell"}, {"end": 46, "start": 37, "tag": "OrganismAttribute"}, {"end": 59, "start": 50, "tag": "Cell"}, {"end": 174, "start": 161, "tag": "ResearchActivity"}, {"end": 203, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 77, "tag": "PathologicFunction"}, {"end": 36, "start": 21, "tag": "CellFunction"}]}{"id": "1164_8", "text": "In this review, we will discuss the application of adipose tissue-derived MSC and their conditioned medium, including extracellular vesicles, in neurological disorders, their beneficial effect on microglia and the signaling pathways involved.", "tags": [{"end": 106, "start": 88, "tag": "Chemical"}, {"end": 140, "start": 118, "tag": "CellComponent"}, {"end": 192, "start": 175, "tag": "Finding"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 205, "start": 196, "tag": "Cell"}, {"end": 65, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 232, "start": 214, "tag": "CellFunction"}, {"end": 77, "start": 74, "tag": "Cell"}]}{"id": "1165_0", "text": "Alzheimer's disease (AD) is a progressive neurological disease that worsens with time.", "tags": [{"end": 62, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 30, "tag": "TemporalConcept"}, {"end": 85, "start": 81, "tag": "TemporalConcept"}]}{"id": "1165_1", "text": "The hallmark illnesses include extracellular senile plaques caused by beta-amyloid protein deposition, neurofibrillary tangles caused by tau protein hyperphosphorylation, and neuronal loss accompanying glial cell hyperplasia.", "tags": [{"end": 59, "start": 45, "tag": "AnatomicalAbnormality"}, {"end": 90, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 212, "start": 202, "tag": "Cell"}, {"end": 22, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 103, "tag": "CellOrMolecularDysfunction"}, {"end": 118, "start": 103, "tag": "CellComponent"}, {"end": 44, "start": 31, "tag": "CellComponent"}, {"end": 148, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 4, "tag": "Finding"}, {"end": 101, "start": 70, "tag": "CellFunction"}, {"end": 169, "start": 137, "tag": "CellOrMolecularDysfunction"}, {"end": 188, "start": 175, "tag": "CellOrMolecularDysfunction"}, {"end": 224, "start": 202, "tag": "CellOrMolecularDysfunction"}]}{"id": "1165_2", "text": "Noncoding RNAs are substantially implicated in related pathophysiology, according to mounting data.", "tags": [{"end": 14, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 70, "start": 55, "tag": "PathologicFunction"}, {"end": 70, "start": 55, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 98, "start": 94, "tag": "ResearchActivity"}, {"end": 14, "start": 10, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1165_3", "text": "However, the function of these ncRNAs is mainly unclear.", "tags": [{"end": 37, "start": 31, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1165_4", "text": "Circular RNAs (circRNAs) include many miRNA-binding sites (miRNA response elements, MREs), which operate as miRNA sponges or competing endogenous RNAs (ceRNAs).", "tags": [{"end": 13, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 23, "start": 15, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 88, "start": 84, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 51, "start": 44, "tag": "CellFunction"}, {"end": 43, "start": 38, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 64, "start": 59, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 113, "start": 108, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 43, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 125, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 64, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 65, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 88, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 152, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1165_5", "text": "The purpose of this study was to look at the role of circular RNAs (circRNAs) and microRNAs (miRNAs) in Alzheimer's disease (AD) as possible biomarkers.", "tags": [{"end": 76, "start": 68, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 66, "start": 53, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 123, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 141, "tag": "ClinicalAttribute"}, {"end": 99, "start": 93, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 99, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 20, "tag": "ResearchActivity"}, {"end": 91, "start": 82, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 91, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 62, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1165_6", "text": "The Gene Expression Omnibus (GEO) database was used to obtain an expression profile of Alzheimer's disease patients (GSE5281, GSE122603, GSE97760, GSE150693, GSE1297, and GSE161435).", "tags": [{"end": 83, "start": 65, "tag": "ResearchActivity"}, {"end": 32, "start": 29, "tag": "ResearchActivity"}, {"end": 27, "start": 4, "tag": "ResearchActivity"}, {"end": 42, "start": 34, "tag": "ResearchActivity"}, {"end": 106, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 107, "tag": "PatientOrDisabledGroup"}, {"end": 83, "start": 76, "tag": "ResearchActivity"}, {"end": 124, "start": 117, "tag": "ResearchActivity"}, {"end": 135, "start": 126, "tag": "ResearchActivity"}, {"end": 145, "start": 137, "tag": "ResearchActivity"}, {"end": 156, "start": 147, "tag": "ResearchActivity"}, {"end": 165, "start": 158, "tag": "ResearchActivity"}, {"end": 180, "start": 171, "tag": "ResearchActivity"}]}{"id": "1165_7", "text": "Through preliminary data deletion, 163 genes with significant differences, 156 miRNAs with significant differences, and 153 circRNAs with significant differences were identified.", "tags": [{"end": 19, "start": 8, "tag": "TemporalConcept"}, {"end": 132, "start": 124, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 85, "start": 79, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 85, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 20, "tag": "ResearchActivity"}, {"end": 73, "start": 62, "tag": "Finding"}, {"end": 114, "start": 103, "tag": "Finding"}, {"end": 161, "start": 150, "tag": "Finding"}]}{"id": "1165_8", "text": "Then, 10 key genes, led by MAPT and AP2M1, were identified by the mediation center algorithm, 34 miRNAs with obvious prognosis were identified by the cox regression model, and 16 key circRNAs were selected by the database.", "tags": [{"end": 31, "start": 27, "tag": "GeneOrGenome"}, {"end": 41, "start": 36, "tag": "GeneOrGenome"}, {"end": 191, "start": 183, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 221, "start": 213, "tag": "ResearchActivity"}, {"end": 170, "start": 150, "tag": "ResearchActivity"}, {"end": 126, "start": 117, "tag": "HealthCareActivity"}, {"end": 103, "start": 97, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 103, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 66, "tag": "MachineActivity"}]}{"id": "1165_9", "text": "To develop competitive endogenous RNA (ceRNA) networks, hub circRNAs and mRNAs were used.", "tags": [{"end": 68, "start": 60, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 78, "start": 73, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 37, "start": 34, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 54, "start": 46, "tag": "CellFunction"}, {"end": 37, "start": 11, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 37, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 39, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 78, "start": 73, "tag": "BiologicallyActiveSubstance"}]}{"id": "1165_10", "text": "Finally, GO analysis and clinical data verification of key genes were carried out.", "tags": [{"end": 51, "start": 25, "tag": "ResearchActivity"}, {"end": 20, "start": 9, "tag": "ResearchActivity"}]}{"id": "1165_11", "text": "We discovered that a down-regulated circRNA (has_circ_002048) caused the increased expression of numerous miRNAs, which further inhibited the expression of a critical mRNA (AP2M1), leading to Alzheimer's disease pathology.", "tags": [{"end": 35, "start": 21, "tag": "CellFunction"}, {"end": 43, "start": 36, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 178, "start": 173, "tag": "GeneOrGenome"}, {"end": 211, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 106, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 112, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 167, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 221, "start": 204, "tag": "PathologicFunction"}, {"end": 152, "start": 142, "tag": "CellFunction"}, {"end": 60, "start": 45, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 178, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 83, "tag": "CellFunction"}]}{"id": "1165_12", "text": "The findings of this work contribute to a better understanding of the circRNA-miRNA-mRNA regulating processes in Alzheimer's disease.", "tags": [{"end": 83, "start": 78, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 83, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 49, "tag": "BiologicFunction"}, {"end": 88, "start": 84, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 77, "start": 70, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 88, "start": 84, "tag": "BiologicallyActiveSubstance"}]}{"id": "1165_13", "text": "Furthermore, the ncRNAs found here might become novel biomarkers and potential targets for the development of Alzheimer's drugs.", "tags": [{"end": 23, "start": 17, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 106, "start": 95, "tag": "BiologicFunction"}, {"end": 106, "start": 95, "tag": "CellFunction"}, {"end": 64, "start": 54, "tag": "ClinicalAttribute"}, {"end": 127, "start": 122, "tag": "PharmacologicSubstance"}, {"end": 121, "start": 110, "tag": "DiseaseOrSyndrome"}]}{"id": "1166_0", "text": "Exosomes (EXOs) were given attention as an extracellular vesicle (EV) with a pivotal pathophysiological role in the development of certain neurodegenerative disorders (NDD), such as Parkinson's and Alzheimer's disease (AD).", "tags": [{"end": 14, "start": 10, "tag": "CellComponent"}, {"end": 171, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 43, "tag": "CellComponent"}, {"end": 36, "start": 27, "tag": "BiologicFunction"}, {"end": 217, "start": 198, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 219, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 66, "tag": "CellComponent"}, {"end": 127, "start": 116, "tag": "BiologicFunction"}, {"end": 127, "start": 116, "tag": "CellFunction"}, {"end": 166, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "CellComponent"}, {"end": 193, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 85, "tag": "PathologicFunction"}]}{"id": "1166_1", "text": "EXOs have shown the potential to carry pathological and therapeutic cargo; thus, researchers have harnessed EXOs in drug delivery applications.", "tags": [{"end": 4, "start": 0, "tag": "CellComponent"}, {"end": 112, "start": 108, "tag": "CellComponent"}, {"end": 73, "start": 56, "tag": "PharmacologicSubstance"}, {"end": 73, "start": 68, "tag": "CellFunction"}, {"end": 92, "start": 81, "tag": "ResearchActivity"}, {"end": 120, "start": 116, "tag": "PharmacologicSubstance"}, {"end": 129, "start": 121, "tag": "BiologicFunction"}, {"end": 142, "start": 116, "tag": "HealthCareActivity"}]}{"id": "1166_2", "text": "EXOs have shown low immunogenicity as natural drug delivery vehicles, thus ensuring efficient drug delivery without causing significant adverse reactions.", "tags": [{"end": 4, "start": 0, "tag": "CellComponent"}, {"end": 153, "start": 136, "tag": "PathologicFunction"}, {"end": 34, "start": 16, "tag": "Finding"}, {"end": 50, "start": 46, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 94, "tag": "PharmacologicSubstance"}, {"end": 68, "start": 60, "tag": "ManufacturedObject"}, {"end": 59, "start": 51, "tag": "BiologicFunction"}, {"end": 107, "start": 99, "tag": "BiologicFunction"}, {"end": 59, "start": 46, "tag": "HealthCareActivity"}, {"end": 107, "start": 94, "tag": "HealthCareActivity"}]}{"id": "1166_3", "text": "Recently, EXOs provided potential drug delivery opportunities in AD and promising future clinical applications with the diagnosis of NDD and were studied for their usefulness in disease detection and prediction prior to the emergence of symptoms.", "tags": [{"end": 14, "start": 10, "tag": "CellComponent"}, {"end": 136, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 178, "tag": "HealthCareActivity"}, {"end": 110, "start": 89, "tag": "HealthCareActivity"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 120, "tag": "HealthCareActivity"}, {"end": 195, "start": 186, "tag": "ResearchActivity"}, {"end": 195, "start": 186, "tag": "HealthCareActivity"}, {"end": 245, "start": 237, "tag": "SignOrSymptom"}, {"end": 88, "start": 82, "tag": "TemporalConcept"}, {"end": 233, "start": 224, "tag": "TemporalConcept"}, {"end": 38, "start": 34, "tag": "PharmacologicSubstance"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 47, "start": 39, "tag": "BiologicFunction"}, {"end": 47, "start": 34, "tag": "HealthCareActivity"}]}{"id": "1166_4", "text": "In the future, the microfluidics technique will play an essential role in isolating and detecting EXOs to diagnose AD before the development of advanced symptoms.", "tags": [{"end": 102, "start": 98, "tag": "CellComponent"}, {"end": 114, "start": 106, "tag": "HealthCareActivity"}, {"end": 42, "start": 33, "tag": "ResearchActivity"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 129, "tag": "BiologicFunction"}, {"end": 140, "start": 129, "tag": "CellFunction"}, {"end": 161, "start": 153, "tag": "SignOrSymptom"}, {"end": 13, "start": 7, "tag": "TemporalConcept"}, {"end": 83, "start": 74, "tag": "ResearchActivity"}]}{"id": "1166_5", "text": "This review is not reiterative literature but will discuss why EXOs have strong potential in treating AD and how they can be used as a tool to predict and diagnose this disorder.", "tags": [{"end": 67, "start": 63, "tag": "CellComponent"}, {"end": 163, "start": 155, "tag": "HealthCareActivity"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 31, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}]}{"id": "1167_0", "text": "Alzheimer's disease (AD) is a devastating and irreversible neurodegenerative disorder with unknown etiology.", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "Finding"}]}{"id": "1167_1", "text": "While its cause is unclear, a number of theories have been proposed to explain the pathogenesis of AD.", "tags": [{"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 83, "tag": "PathologicFunction"}]}{"id": "1167_2", "text": "In large part, these have centered around potential causes for intracerebral accumulation of beta-amyloid (beta A) and tau aggregates.", "tags": [{"end": 122, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 77, "tag": "Finding"}, {"end": 105, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 119, "tag": "CellOrMolecularDysfunction"}]}{"id": "1167_3", "text": "Yet, persons with AD dementia often exhibit autopsy evidence of mixed brain pathologies including a myriad of vascular changes, vascular brain injuries, complex brain inflammation, and mixed protein inclusions in addition to hallmark neuropathologic lesions of AD, namely insoluble beta A plaques and neurofibrillary tangles (NFTs).", "tags": [{"end": 51, "start": 44, "tag": "HealthCareActivity"}, {"end": 151, "start": 128, "tag": "InjuryOrPoisoning"}, {"end": 209, "start": 191, "tag": "CellComponent"}, {"end": 12, "start": 5, "tag": "PopulationGroup"}, {"end": 179, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 161, "tag": "PathologicFunction"}, {"end": 257, "start": 234, "tag": "InjuryOrPoisoning"}, {"end": 118, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 296, "start": 282, "tag": "AnatomicalAbnormality"}, {"end": 20, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 263, "start": 261, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 52, "tag": "Finding"}, {"end": 142, "start": 137, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 167, "tag": "PathologicFunction"}, {"end": 87, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 233, "start": 225, "tag": "Finding"}, {"end": 198, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 324, "start": 301, "tag": "CellOrMolecularDysfunction"}, {"end": 316, "start": 301, "tag": "CellComponent"}, {"end": 330, "start": 326, "tag": "CellOrMolecularDysfunction"}, {"end": 126, "start": 119, "tag": "Finding"}]}{"id": "1167_4", "text": "Epidemiological data demonstrate that overlapping lesions diminish the beta A plaque and NFT threshold necessary to precipitate clinical dementia.", "tags": [{"end": 92, "start": 89, "tag": "CellOrMolecularDysfunction"}, {"end": 84, "start": 71, "tag": "AnatomicalAbnormality"}, {"end": 57, "start": 50, "tag": "InjuryOrPoisoning"}, {"end": 102, "start": 93, "tag": "Finding"}, {"end": 145, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 0, "tag": "ResearchActivity"}]}{"id": "1167_5", "text": "Moreover, a subset of persons who exhibit AD pathology remain resilient to disease while other persons with clinically-defined AD dementia do not exhibit AD-defining neuropathologic lesions.", "tags": [{"end": 29, "start": 22, "tag": "PopulationGroup"}, {"end": 102, "start": 95, "tag": "PopulationGroup"}, {"end": 189, "start": 166, "tag": "InjuryOrPoisoning"}, {"end": 44, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 45, "tag": "PathologicFunction"}, {"end": 54, "start": 45, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1167_6", "text": "It is increasingly recognized that AD is a pathologically heterogeneous and biologically multifactorial disease with uncharacterized biologic phenomena involved in its genesis and progression.", "tags": [{"end": 151, "start": 133, "tag": "NaturalPhenomenonOrProcess"}, {"end": 71, "start": 58, "tag": "OrganismAttribute"}, {"end": 37, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 180, "tag": "PathologicFunction"}, {"end": 191, "start": 180, "tag": "TemporalConcept"}]}{"id": "1167_7", "text": "Here, we review the literature with regard to neuropathologic criteria and incipient AD changes, and discuss converging concepts regarding vascular and immune factors in AD.", "tags": [{"end": 84, "start": 75, "tag": "TemporalConcept"}, {"end": 166, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 20, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 95, "start": 88, "tag": "Finding"}]}{"id": "1168_0", "text": "Alzheimer's disease (AD), the most common form of dementia, has increasing incidence, increasing mortality rates, and poses a huge burden on healthcare.", "tags": [{"end": 151, "start": 141, "tag": "HealthCareActivity"}, {"end": 112, "start": 86, "tag": "Finding"}, {"end": 137, "start": 131, "tag": "ResearchActivity"}, {"end": 84, "start": 64, "tag": "Finding"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 50, "tag": "DiseaseOrSyndrome"}]}{"id": "1168_1", "text": "None of the currently approved drugs for the treatment of AD influence disease progression.", "tags": [{"end": 36, "start": 31, "tag": "PharmacologicSubstance"}, {"end": 90, "start": 79, "tag": "PathologicFunction"}, {"end": 90, "start": 79, "tag": "TemporalConcept"}, {"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 45, "tag": "HealthCareActivity"}, {"end": 54, "start": 45, "tag": "ResearchActivity"}, {"end": 21, "start": 12, "tag": "TemporalConcept"}, {"end": 90, "start": 71, "tag": "PathologicFunction"}]}{"id": "1168_2", "text": "Many clinical trials aiming at inhibiting amyloid plaque formation, increasing amyloid beta clearance, or inhibiting neurofibrillary tangle pathology yielded inconclusive results or failed.", "tags": [{"end": 41, "start": 31, "tag": "BiologicFunction"}, {"end": 116, "start": 106, "tag": "BiologicFunction"}, {"end": 91, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 92, "tag": "NaturalPhenomenonOrProcess"}, {"end": 66, "start": 42, "tag": "CellOrMolecularDysfunction"}, {"end": 149, "start": 117, "tag": "PathologicFunction"}, {"end": 20, "start": 5, "tag": "ResearchActivity"}]}{"id": "1168_3", "text": "Meanwhile, research has identified many interlinked vicious cascades implicating oxidative stress, mitochondrial dysfunction, and chronic neuroinflammation, and has pointed to novel therapeutic targets such as improving mitochondrial bioenergetics and quality control, diminishing oxidative stress, or modulating the neuroinflammatory pathways.", "tags": [{"end": 267, "start": 252, "tag": "ResearchActivity"}, {"end": 201, "start": 182, "tag": "ResearchActivity"}, {"end": 97, "start": 81, "tag": "CellOrMolecularDysfunction"}, {"end": 297, "start": 281, "tag": "CellOrMolecularDysfunction"}, {"end": 124, "start": 99, "tag": "CellOrMolecularDysfunction"}, {"end": 233, "start": 220, "tag": "CellComponent"}, {"end": 247, "start": 234, "tag": "BiologicFunction"}, {"end": 334, "start": 317, "tag": "PathologicFunction"}, {"end": 19, "start": 11, "tag": "ResearchActivity"}, {"end": 343, "start": 335, "tag": "CellFunction"}, {"end": 155, "start": 138, "tag": "PathologicFunction"}, {"end": 137, "start": 130, "tag": "TemporalConcept"}]}{"id": "1168_4", "text": "Many novel molecules tested in vitro or in animal models have proven efficient, but their translation into clinic needs further research regarding appropriate doses, delivery routes, and possible side effects.", "tags": [{"end": 101, "start": 90, "tag": "CellFunction"}, {"end": 113, "start": 107, "tag": "HealthCareRelatedOrganization"}, {"end": 174, "start": 166, "tag": "BiologicFunction"}, {"end": 36, "start": 28, "tag": "ResearchActivity"}, {"end": 20, "start": 11, "tag": "Substance"}, {"end": 208, "start": 196, "tag": "PathologicFunction"}, {"end": 136, "start": 128, "tag": "ResearchActivity"}, {"end": 56, "start": 43, "tag": "ResearchActivity"}, {"end": 113, "start": 90, "tag": "ResearchActivity"}, {"end": 181, "start": 166, "tag": "Finding"}]}{"id": "1168_5", "text": "Cell-based therapies and extracellular vesicle-mediated delivery of messenger RNAs and microRNAs seem also promising strategies allowing to target specific signaling pathways, but need further research regarding the most appropriate harvesting and culture methods as well as control of the possible tumorigenic side effects.", "tags": [{"end": 82, "start": 68, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 64, "start": 56, "tag": "BiologicFunction"}, {"end": 46, "start": 25, "tag": "CellComponent"}, {"end": 96, "start": 87, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 96, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 156, "tag": "CellFunction"}, {"end": 323, "start": 299, "tag": "PathologicFunction"}, {"end": 201, "start": 193, "tag": "ResearchActivity"}, {"end": 20, "start": 0, "tag": "HealthCareActivity"}, {"end": 263, "start": 233, "tag": "ResearchActivity"}]}{"id": "1168_6", "text": "The rapidly developing area of nanotechnology could improve drug delivery and also be used in early diagnosis.", "tags": [{"end": 73, "start": 60, "tag": "ManufacturedObject"}, {"end": 73, "start": 60, "tag": "HealthCareActivity"}, {"end": 109, "start": 94, "tag": "HealthCareActivity"}, {"end": 109, "start": 100, "tag": "HealthCareActivity"}, {"end": 45, "start": 31, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1169_0", "text": "Alzheimer's disease (AD) is a common neurodegenerative disease characterized by progressive dementia.", "tags": [{"end": 62, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 80, "tag": "TemporalConcept"}]}{"id": "1169_1", "text": "Accumulation of beta-amyloid peptide 1-42 and phosphorylation of tau protein in the brain are the two main pathological features of AD.", "tags": [{"end": 12, "start": 0, "tag": "Finding"}, {"end": 76, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 46, "tag": "CellFunction"}, {"end": 41, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 16, "tag": "BiologicallyActiveSubstance"}]}{"id": "1169_2", "text": "However, comprehensive studies have shown that neuroinflammation also plays a crucial role in the pathogenesis of AD.", "tags": [{"end": 30, "start": 23, "tag": "ResearchActivity"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 98, "tag": "PathologicFunction"}, {"end": 64, "start": 47, "tag": "PathologicFunction"}]}{"id": "1169_3", "text": "Neuroinflammation is associated with neuronal death and abnormal protein aggregation and promotes the pathological process of beta-amyloid peptide 1-42 and tau protein.", "tags": [{"end": 122, "start": 102, "tag": "PathologicFunction"}, {"end": 167, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 0, "tag": "PathologicFunction"}, {"end": 51, "start": 37, "tag": "CellFunction"}, {"end": 151, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 65, "tag": "CellFunction"}, {"end": 84, "start": 56, "tag": "CellOrMolecularDysfunction"}, {"end": 159, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 156, "tag": "BiologicallyActiveSubstance"}, {"end": 167, "start": 156, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 126, "tag": "BiologicallyActiveSubstance"}]}{"id": "1169_4", "text": "The inflammatory components associated with AD include glial cells, complement system, cytokines and chemokines.", "tags": [{"end": 85, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 55, "tag": "Cell"}, {"end": 27, "start": 17, "tag": "CellComponent"}, {"end": 46, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 87, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1169_5", "text": "In recent years, some researchers have focused on exosomes, a type of membrane nano vesicles.", "tags": [{"end": 15, "start": 3, "tag": "TemporalConcept"}, {"end": 33, "start": 22, "tag": "ResearchActivity"}, {"end": 78, "start": 70, "tag": "CellComponent"}, {"end": 58, "start": 50, "tag": "CellComponent"}, {"end": 92, "start": 79, "tag": "CellComponent"}]}{"id": "1169_6", "text": "Exosomes can transport proteins, lipids, microRNAs and other signaling molecules to participate in a variety of signaling pathways for signal transmission or immune response, affecting the activity of target cells and participating in important pathophysiological processes.", "tags": [{"end": 80, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 61, "tag": "CellFunction"}, {"end": 173, "start": 158, "tag": "BiologicFunction"}, {"end": 213, "start": 201, "tag": "Cell"}, {"end": 213, "start": 201, "tag": "ResearchActivity"}, {"end": 273, "start": 245, "tag": "BiologicFunction"}, {"end": 39, "start": 33, "tag": "Chemical"}, {"end": 80, "start": 71, "tag": "Substance"}, {"end": 50, "start": 41, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 50, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 112, "tag": "CellFunction"}, {"end": 8, "start": 0, "tag": "CellComponent"}, {"end": 31, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 263, "start": 245, "tag": "PathologicFunction"}, {"end": 154, "start": 135, "tag": "CellFunction"}]}{"id": "1169_7", "text": "Therefore, exosomes play an essential role in intercellular communication and may mediate neuroinflammation to promote the development of AD.", "tags": [{"end": 73, "start": 46, "tag": "CellFunction"}, {"end": 19, "start": 11, "tag": "CellComponent"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 90, "tag": "PathologicFunction"}, {"end": 134, "start": 123, "tag": "BiologicFunction"}, {"end": 134, "start": 123, "tag": "CellFunction"}]}{"id": "1169_8", "text": "This paper reviews the occurrence and development of neuroinflammation and exosomes in AD, providing a deeper understanding of the pathogenesis of AD.", "tags": [{"end": 123, "start": 103, "tag": "Finding"}, {"end": 123, "start": 110, "tag": "BiologicFunction"}, {"end": 18, "start": 11, "tag": "HealthCareActivity"}, {"end": 18, "start": 11, "tag": "ResearchActivity"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 83, "start": 75, "tag": "CellComponent"}, {"end": 33, "start": 23, "tag": "TemporalConcept"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 131, "tag": "PathologicFunction"}, {"end": 70, "start": 53, "tag": "PathologicFunction"}, {"end": 49, "start": 38, "tag": "BiologicFunction"}, {"end": 49, "start": 38, "tag": "CellFunction"}]}{"id": "1169_9", "text": "Furthermore, the role of exosomes in the pathogenesis and treatment of AD is further described, demonstrating their potential as therapeutic targets for neuroinflammation and AD in the future.", "tags": [{"end": 148, "start": 129, "tag": "ResearchActivity"}, {"end": 33, "start": 25, "tag": "CellComponent"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 41, "tag": "PathologicFunction"}, {"end": 67, "start": 58, "tag": "HealthCareActivity"}, {"end": 67, "start": 58, "tag": "ResearchActivity"}, {"end": 170, "start": 153, "tag": "PathologicFunction"}, {"end": 191, "start": 185, "tag": "TemporalConcept"}]}{"id": "1170_0", "text": "Alzheimer's disease (AD) is a neurodegenerative disorder that causes progressive loss of cognitive functions like thinking, memory, reasoning, behavioral abilities, and social skills thus affecting the ability of a person to perform normal daily functions independently.", "tags": [{"end": 122, "start": 114, "tag": "BiologicFunction"}, {"end": 141, "start": 132, "tag": "BiologicFunction"}, {"end": 163, "start": 154, "tag": "OrganismAttribute"}, {"end": 221, "start": 215, "tag": "PopulationGroup"}, {"end": 108, "start": 89, "tag": "BiologicFunction"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 69, "tag": "TemporalConcept"}, {"end": 239, "start": 233, "tag": "Finding"}, {"end": 209, "start": 202, "tag": "OrganismAttribute"}, {"end": 56, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 124, "tag": "BiologicFunction"}, {"end": 245, "start": 240, "tag": "TemporalConcept"}]}{"id": "1170_1", "text": "There is no definitive cure for this disease, and treatment options available for the management of the disease are not very effective as well.", "tags": [{"end": 67, "start": 50, "tag": "Finding"}, {"end": 27, "start": 9, "tag": "Finding"}, {"end": 96, "start": 86, "tag": "HealthCareActivity"}, {"end": 59, "start": 50, "tag": "HealthCareActivity"}, {"end": 59, "start": 50, "tag": "ResearchActivity"}]}{"id": "1170_2", "text": "Based on histopathology, AD is characterized by the accumulation of insoluble deposits of amyloid beta (A beta) plaques and neurofibrillary tangles (NFTs).", "tags": [{"end": 23, "start": 9, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 119, "start": 112, "tag": "AnatomicalAbnormality"}, {"end": 102, "start": 90, "tag": "AnatomicalAbnormality"}, {"end": 27, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 52, "tag": "Finding"}, {"end": 102, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 124, "tag": "CellOrMolecularDysfunction"}, {"end": 139, "start": 124, "tag": "CellComponent"}, {"end": 153, "start": 149, "tag": "CellOrMolecularDysfunction"}, {"end": 86, "start": 68, "tag": "Substance"}]}{"id": "1170_3", "text": "Although several molecular events contribute to the formation of these insoluble deposits, the aberrant post-translational modifications (PTMs) of AD-related proteins (like APP, A beta, tau, and BACE1) are also known to be involved in the onset and progression of this disease.", "tags": [{"end": 103, "start": 95, "tag": "PathologicFunction"}, {"end": 136, "start": 104, "tag": "CellFunction"}, {"end": 142, "start": 138, "tag": "CellFunction"}, {"end": 108, "start": 104, "tag": "TemporalConcept"}, {"end": 200, "start": 195, "tag": "GeneOrGenome"}, {"end": 200, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 200, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 173, "tag": "GeneOrGenome"}, {"end": 176, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 260, "start": 249, "tag": "PathologicFunction"}, {"end": 260, "start": 249, "tag": "TemporalConcept"}, {"end": 244, "start": 239, "tag": "TemporalConcept"}, {"end": 166, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 178, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 71, "tag": "Substance"}]}{"id": "1170_4", "text": "However, early diagnosis of the disease as well as the development of effective therapeutic approaches is impeded by lack of proper clinical biomarkers.", "tags": [{"end": 66, "start": 55, "tag": "BiologicFunction"}, {"end": 66, "start": 55, "tag": "CellFunction"}, {"end": 151, "start": 132, "tag": "ClinicalAttribute"}, {"end": 24, "start": 15, "tag": "HealthCareActivity"}, {"end": 24, "start": 9, "tag": "HealthCareActivity"}, {"end": 102, "start": 80, "tag": "HealthCareActivity"}]}{"id": "1170_5", "text": "In this review, we summarized the current status and clinical relevance of biomarkers from cerebrospinal fluid (CSF), blood and extracellular vesicles involved in onset and progression of AD.", "tags": [{"end": 150, "start": 128, "tag": "CellComponent"}, {"end": 190, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 75, "tag": "ClinicalAttribute"}, {"end": 184, "start": 173, "tag": "PathologicFunction"}, {"end": 184, "start": 173, "tag": "TemporalConcept"}, {"end": 123, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 163, "tag": "TemporalConcept"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 41, "start": 34, "tag": "TemporalConcept"}, {"end": 48, "start": 42, "tag": "Finding"}]}{"id": "1170_6", "text": "Moreover, we highlight the effects of several PTMs on the AD-related proteins, and provide an insight how these modifications impact the structure and function of proteins leading to AD pathology.", "tags": [{"end": 50, "start": 46, "tag": "CellFunction"}, {"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 186, "tag": "PathologicFunction"}, {"end": 195, "start": 186, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 77, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 27, "tag": "Finding"}]}{"id": "1170_7", "text": "Finally, for disease-modifying therapeutics, novel approaches, and targets are discussed for the successful treatment and management of AD.", "tags": [{"end": 132, "start": 122, "tag": "HealthCareActivity"}, {"end": 138, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 13, "tag": "HealthCareActivity"}, {"end": 117, "start": 108, "tag": "HealthCareActivity"}, {"end": 117, "start": 108, "tag": "ResearchActivity"}]}{"id": "1171_0", "text": "Brain administration of human platelet lysates (HPL) is a potential emerging biotherapy of neurodegenerative and traumatic diseases of the central nervous system.", "tags": [{"end": 20, "start": 0, "tag": "HealthCareActivity"}, {"end": 87, "start": 77, "tag": "HealthCareActivity"}, {"end": 38, "start": 30, "tag": "Cell"}, {"end": 161, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 24, "tag": "Eukaryote"}, {"end": 108, "start": 91, "tag": "CellOrMolecularDysfunction"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 24, "tag": "PharmacologicSubstance"}, {"end": 51, "start": 48, "tag": "PharmacologicSubstance"}]}{"id": "1171_1", "text": "HPLs being prepared from pooled platelet concentrates, thereby increasing viral risks, manufacturing processes should incorporate robust virus-reduction treatments.", "tags": [{"end": 40, "start": 32, "tag": "Cell"}, {"end": 163, "start": 153, "tag": "HealthCareActivity"}, {"end": 163, "start": 153, "tag": "ResearchActivity"}, {"end": 152, "start": 143, "tag": "Finding"}, {"end": 152, "start": 143, "tag": "NaturalPhenomenonOrProcess"}, {"end": 73, "start": 63, "tag": "Finding"}, {"end": 100, "start": 87, "tag": "ResearchActivity"}, {"end": 4, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 79, "start": 74, "tag": "Virus"}, {"end": 85, "start": 80, "tag": "Finding"}, {"end": 142, "start": 137, "tag": "Virus"}, {"end": 53, "start": 41, "tag": "Substance"}]}{"id": "1171_2", "text": "We evaluated a 19 +/- 2-nm virus removal nanofiltration process using hydrophilic regenerated cellulose hollow fibers on the properties of a neuroprotective heat-treated HPL (HPPL).", "tags": [{"end": 63, "start": 27, "tag": "ResearchActivity"}, {"end": 103, "start": 70, "tag": "Chemical"}, {"end": 156, "start": 141, "tag": "CellFunction"}, {"end": 32, "start": 27, "tag": "Virus"}, {"end": 117, "start": 104, "tag": "ManufacturedObject"}, {"end": 173, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 157, "tag": "NaturalPhenomenonOrProcess"}]}{"id": "1171_3", "text": "Spiking experiments demonstrated >5.30 log removal of 20-22-nm non-enveloped minute virus of mice-mock particles using an immuno-quantitative polymerase chain reaction assay.", "tags": [{"end": 19, "start": 8, "tag": "ResearchActivity"}, {"end": 173, "start": 122, "tag": "ResearchActivity"}, {"end": 97, "start": 93, "tag": "Eukaryote"}, {"end": 112, "start": 103, "tag": "Chemical"}, {"end": 89, "start": 84, "tag": "Virus"}]}{"id": "1171_4", "text": "The nanofiltered HPPL (NHPPL) contained a range of neurotrophic factors like HPPL.", "tags": [{"end": 71, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 4, "tag": "ResearchActivity"}, {"end": 28, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 77, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1171_5", "text": "There was >2 log removal of extracellular vesicles (EVs), associated with decreased expression of pro-thrombogenic phosphatidylserine and procoagulant activity.", "tags": [{"end": 24, "start": 17, "tag": "HealthCareActivity"}, {"end": 132, "start": 98, "tag": "Chemical"}, {"end": 50, "start": 28, "tag": "CellComponent"}, {"end": 55, "start": 52, "tag": "CellComponent"}, {"end": 94, "start": 84, "tag": "CellFunction"}, {"end": 83, "start": 74, "tag": "Finding"}]}{"id": "1171_6", "text": "LC-MS/MS proteomics showed that ca.", "tags": [{"end": 19, "start": 9, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 19, "start": 0, "tag": "ResearchActivity"}]}{"id": "1171_7", "text": "80% of HPPL proteins, including neurotrophins, cytokines, and antioxidants, were still found in NHPPL, whereas proteins associated with some infections and cancer-associated pathways, pro-coagulation and EVs, were removed.", "tags": [{"end": 45, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 141, "tag": "PathologicFunction"}, {"end": 151, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 199, "start": 184, "tag": "BiologicFunction"}, {"end": 74, "start": 62, "tag": "PharmacologicSubstance"}, {"end": 207, "start": 204, "tag": "CellComponent"}, {"end": 20, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 188, "tag": "BiologicFunction"}, {"end": 162, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 174, "tag": "CellFunction"}, {"end": 56, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 96, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1171_8", "text": "NHPPL maintained intact neuroprotective activity in Lund human mesencephalic dopaminergic neuron model of Parkinson's disease (PD), stimulated the differentiation of SH-SY5Y neuronal cells and showed preserved anti-inflammatory function upon intranasal administration in a mouse model of traumatic brain injury (TBI).", "tags": [{"end": 315, "start": 312, "tag": "InjuryOrPoisoning"}, {"end": 162, "start": 147, "tag": "CellFunction"}, {"end": 310, "start": 288, "tag": "InjuryOrPoisoning"}, {"end": 142, "start": 132, "tag": "NaturalPhenomenonOrProcess"}, {"end": 267, "start": 242, "tag": "HealthCareActivity"}, {"end": 188, "start": 174, "tag": "Cell"}, {"end": 125, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 303, "start": 298, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 57, "tag": "Eukaryote"}, {"end": 23, "start": 17, "tag": "Finding"}, {"end": 182, "start": 174, "tag": "Cell"}, {"end": 284, "start": 273, "tag": "ResearchActivity"}, {"end": 227, "start": 210, "tag": "BiologicFunction"}, {"end": 227, "start": 210, "tag": "PharmacologicSubstance"}, {"end": 39, "start": 24, "tag": "CellFunction"}, {"end": 125, "start": 52, "tag": "ExperimentalModelOfDisease"}, {"end": 188, "start": 166, "tag": "Cell"}, {"end": 310, "start": 273, "tag": "ExperimentalModelOfDisease"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1171_9", "text": "Therefore, nanofiltration of HPL is feasible, lowers the viral, prothrombotic and procoagulant risks, and preserves the neuroprotective and anti-inflammatory properties in neuronal pre-clinical models of PD and TBI.", "tags": [{"end": 94, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 214, "start": 211, "tag": "InjuryOrPoisoning"}, {"end": 206, "start": 204, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 194, "tag": "ResearchActivity"}, {"end": 157, "start": 140, "tag": "BiologicFunction"}, {"end": 157, "start": 140, "tag": "PharmacologicSubstance"}, {"end": 135, "start": 120, "tag": "CellFunction"}, {"end": 25, "start": 11, "tag": "ResearchActivity"}, {"end": 32, "start": 29, "tag": "PharmacologicSubstance"}, {"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 57, "tag": "Virus"}, {"end": 100, "start": 95, "tag": "Finding"}, {"end": 206, "start": 172, "tag": "ExperimentalModelOfDisease"}]}{"id": "1172_0", "text": "Extracellular vesicles (EVs) have brought great momentum to the non-invasive liquid biopsy procedure for the detection, characterization, and monitoring of cancer.", "tags": [{"end": 56, "start": 48, "tag": "NaturalPhenomenonOrProcess"}, {"end": 162, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 120, "tag": "ResearchActivity"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 118, "start": 109, "tag": "HealthCareActivity"}, {"end": 152, "start": 142, "tag": "HealthCareActivity"}, {"end": 100, "start": 64, "tag": "HealthCareActivity"}]}{"id": "1172_1", "text": "Despite the common use of PSA (prostate-specific antigen) as a biomarker for prostate cancer, there is an unmet need for a more specific diagnostic tool to detect tumor progression and recurrence.", "tags": [{"end": 29, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 195, "start": 185, "tag": "PathologicFunction"}, {"end": 195, "start": 185, "tag": "Finding"}, {"end": 180, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 106, "tag": "Finding"}, {"end": 180, "start": 169, "tag": "PathologicFunction"}, {"end": 180, "start": 169, "tag": "TemporalConcept"}, {"end": 72, "start": 63, "tag": "ClinicalAttribute"}, {"end": 29, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 137, "tag": "HealthCareActivity"}]}{"id": "1172_2", "text": "Exosomes, which are EVs that are released from all cells, play a large role in physiology and pathology, including cancer.", "tags": [{"end": 121, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 79, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 89, "start": 79, "tag": "BiologicFunction"}, {"end": 8, "start": 0, "tag": "CellComponent"}, {"end": 23, "start": 20, "tag": "CellComponent"}, {"end": 56, "start": 51, "tag": "Cell"}, {"end": 103, "start": 94, "tag": "PathologicFunction"}, {"end": 103, "start": 94, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1172_3", "text": "They are involved in intercellular communication, immune function, and they are present in every bodily fluid studied-making them an excellent window into how cells are operating.", "tags": [{"end": 149, "start": 143, "tag": "TemporalConcept"}, {"end": 48, "start": 21, "tag": "CellFunction"}, {"end": 65, "start": 50, "tag": "BiologicFunction"}, {"end": 164, "start": 159, "tag": "Cell"}, {"end": 109, "start": 104, "tag": "Substance"}, {"end": 109, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1172_4", "text": "With liquid biopsy, EVs can be isolated and analyzed, enabling an insight into a potential therapeutic value, serving as a vehicle for drugs or nucleic acids that have anti-neoplastic effects.", "tags": [{"end": 18, "start": 5, "tag": "HealthCareActivity"}, {"end": 157, "start": 144, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 140, "start": 135, "tag": "PharmacologicSubstance"}, {"end": 23, "start": 20, "tag": "CellComponent"}, {"end": 191, "start": 168, "tag": "Finding"}]}{"id": "1172_5", "text": "The current application of advanced technology also points to higher-sensitivity detection methods that are minimally invasive.", "tags": [{"end": 126, "start": 108, "tag": "Finding"}, {"end": 80, "start": 69, "tag": "Finding"}, {"end": 98, "start": 81, "tag": "HealthCareActivity"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}, {"end": 98, "start": 81, "tag": "ResearchActivity"}]}{"id": "1172_6", "text": "In this review, we discuss the current understanding of the significance of exosomes in prostate cancer and the potential diagnostic value of these EVs in disease progression.", "tags": [{"end": 103, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 39, "tag": "BiologicFunction"}, {"end": 84, "start": 76, "tag": "CellComponent"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 174, "start": 163, "tag": "PathologicFunction"}, {"end": 174, "start": 163, "tag": "TemporalConcept"}, {"end": 151, "start": 148, "tag": "CellComponent"}, {"end": 174, "start": 155, "tag": "PathologicFunction"}, {"end": 38, "start": 31, "tag": "TemporalConcept"}]}{"id": "1173_0", "text": "Background A major challenge in neurodegenerative diseases concerns identifying biological disease signatures that track with disease progression or respond to an intervention.", "tags": [{"end": 28, "start": 19, "tag": "HealthCareActivity"}, {"end": 145, "start": 134, "tag": "PathologicFunction"}, {"end": 145, "start": 134, "tag": "TemporalConcept"}, {"end": 58, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 126, "tag": "PathologicFunction"}]}{"id": "1173_1", "text": "Several clinical trials in Huntington disease (HD), an inherited, progressive neurodegenerative disease, are currently ongoing.", "tags": [{"end": 45, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 119, "tag": "TemporalConcept"}, {"end": 118, "start": 109, "tag": "TemporalConcept"}, {"end": 77, "start": 66, "tag": "TemporalConcept"}, {"end": 103, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 8, "tag": "ResearchActivity"}]}{"id": "1173_2", "text": "Therefore, we examine whether peripheral tissues can serve as a source of readily accessible biological signatures at the RNA and protein level in HD patients.", "tags": [{"end": 158, "start": 147, "tag": "PatientOrDisabledGroup"}, {"end": 40, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 122, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 137, "start": 130, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1173_3", "text": "Results We generate large, high-quality human datasets from skeletal muscle, skin and adipose tissue to probe molecular changes in human premanifest and early manifest HD patients-those most likely involved in clinical trials.", "tags": [{"end": 100, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 46, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 45, "start": 40, "tag": "Eukaryote"}, {"end": 136, "start": 131, "tag": "Eukaryote"}, {"end": 75, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 27, "tag": "Finding"}, {"end": 81, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 225, "start": 210, "tag": "ResearchActivity"}, {"end": 179, "start": 159, "tag": "PatientOrDisabledGroup"}, {"end": 179, "start": 168, "tag": "PatientOrDisabledGroup"}, {"end": 148, "start": 137, "tag": "PatientOrDisabledGroup"}]}{"id": "1173_4", "text": "The analysis of the transcriptomics and proteomics data shows robust, stage-dependent dysregulation.", "tags": [{"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 55, "start": 51, "tag": "ResearchActivity"}, {"end": 50, "start": 40, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 35, "start": 20, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1173_5", "text": "Gene ontology analysis confirms the involvement of inflammation and energy metabolism in peripheral HD pathogenesis.", "tags": [{"end": 85, "start": 68, "tag": "BiologicFunction"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 0, "tag": "ResearchActivity"}, {"end": 99, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 51, "tag": "PathologicFunction"}, {"end": 115, "start": 103, "tag": "PathologicFunction"}, {"end": 85, "start": 75, "tag": "CellFunction"}, {"end": 85, "start": 75, "tag": "BiologicFunction"}, {"end": 47, "start": 36, "tag": "Finding"}]}{"id": "1173_6", "text": "Furthermore, we observe changes in the homeostasis of extracellular vesicles, where we find consistent changes of genes and proteins involved in this process.", "tags": [{"end": 76, "start": 54, "tag": "CellComponent"}, {"end": 132, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 39, "tag": "BiologicFunction"}]}{"id": "1173_7", "text": "In-depth single nucleotide polymorphism data across the HTT gene are derived from the generated primary cell lines.", "tags": [{"end": 64, "start": 56, "tag": "GeneOrGenome"}, {"end": 39, "start": 27, "tag": "CellFunction"}, {"end": 44, "start": 40, "tag": "ResearchActivity"}, {"end": 114, "start": 96, "tag": "Cell"}, {"end": 39, "start": 9, "tag": "MolecularSequence"}]}{"id": "1173_8", "text": "Conclusions Our 'omics data document the involvement of inflammation, energy metabolism, and extracellular vesicle homeostasis.", "tags": [{"end": 87, "start": 70, "tag": "BiologicFunction"}, {"end": 114, "start": 93, "tag": "CellComponent"}, {"end": 68, "start": 56, "tag": "PathologicFunction"}, {"end": 87, "start": 77, "tag": "CellFunction"}, {"end": 87, "start": 77, "tag": "BiologicFunction"}, {"end": 126, "start": 115, "tag": "BiologicFunction"}, {"end": 52, "start": 41, "tag": "Finding"}, {"end": 27, "start": 23, "tag": "ResearchActivity"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}]}{"id": "1173_9", "text": "This demonstrates the potential to identify biological signatures from peripheral tissues in HD suitable as biomarkers in clinical trials.", "tags": [{"end": 95, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 108, "tag": "ClinicalAttribute"}, {"end": 81, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 122, "tag": "ResearchActivity"}]}{"id": "1173_10", "text": "The generated data, complemented by the primary cell lines established from peripheral tissues, and a large panel of iPSC lines that can serve as human models of HD are a valuable and unique resource to advance the current understanding of molecular mechanisms driving HD pathogenesis.", "tags": [{"end": 127, "start": 117, "tag": "Cell"}, {"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 271, "start": 269, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 117, "tag": "Cell"}, {"end": 151, "start": 146, "tag": "Eukaryote"}, {"end": 86, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 152, "tag": "ResearchActivity"}, {"end": 222, "start": 215, "tag": "TemporalConcept"}, {"end": 284, "start": 272, "tag": "PathologicFunction"}, {"end": 236, "start": 223, "tag": "BiologicFunction"}, {"end": 260, "start": 240, "tag": "CellFunction"}, {"end": 18, "start": 14, "tag": "ResearchActivity"}, {"end": 94, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 40, "tag": "Cell"}, {"end": 164, "start": 146, "tag": "ExperimentalModelOfDisease"}]}{"id": "1174_0", "text": "A major hallmark of Alzheimer's disease (AD) is the accumulation of extracellular aggregates of amyloid-beta (A beta).", "tags": [{"end": 16, "start": 8, "tag": "Finding"}, {"end": 64, "start": 52, "tag": "Finding"}, {"end": 39, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 68, "tag": "CellOrMolecularDysfunction"}]}{"id": "1174_1", "text": "Structural polymorphism observed among A beta fibrils in AD brains seem to correlate with the clinical subtypes suggesting a link between fibril polymorphism and pathology.", "tags": [{"end": 23, "start": 11, "tag": "CellFunction"}, {"end": 53, "start": 41, "tag": "CellComponent"}, {"end": 144, "start": 138, "tag": "CellComponent"}, {"end": 157, "start": 145, "tag": "CellFunction"}, {"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 162, "tag": "PathologicFunction"}, {"end": 171, "start": 162, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 66, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1174_2", "text": "Since fibrils emerge from a templated growth of low-molecular-weight oligomers, understanding the factors affecting oligomer generation is important.", "tags": [{"end": 13, "start": 6, "tag": "CellComponent"}, {"end": 44, "start": 38, "tag": "BiologicFunction"}, {"end": 93, "start": 80, "tag": "BiologicFunction"}]}{"id": "1174_3", "text": "Membrane lipids are key factors to influence early stages of A beta aggregation and oligomer generation, which cause membrane disruption.", "tags": [{"end": 15, "start": 0, "tag": "Chemical"}, {"end": 57, "start": 45, "tag": "TemporalConcept"}, {"end": 57, "start": 51, "tag": "TemporalConcept"}, {"end": 125, "start": 117, "tag": "CellComponent"}, {"end": 67, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 117, "tag": "CellOrMolecularDysfunction"}, {"end": 79, "start": 61, "tag": "CellFunction"}, {"end": 103, "start": 84, "tag": "CellFunction"}]}{"id": "1174_4", "text": "We have previously demonstrated that conformationally discrete A beta oligomers can be generated by modulating the charge, composition, and chain length of lipids and surfactants.", "tags": [{"end": 121, "start": 115, "tag": "OrganismAttribute"}, {"end": 178, "start": 167, "tag": "Chemical"}, {"end": 162, "start": 156, "tag": "Chemical"}, {"end": 152, "start": 146, "tag": "ResearchActivity"}, {"end": 79, "start": 63, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1174_5", "text": "Here, we extend our studies into liposomal models by investigating A beta oligomerization on large unilamellar vesicles (LUVs) of total brain extracts (TBE), reconstituted lipid rafts (LRs), or 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC).", "tags": [{"end": 119, "start": 93, "tag": "CellComponent"}, {"end": 188, "start": 185, "tag": "CellComponent"}, {"end": 239, "start": 194, "tag": "Chemical"}, {"end": 243, "start": 239, "tag": "Chemical"}, {"end": 183, "start": 172, "tag": "CellComponent"}, {"end": 141, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 20, "tag": "ResearchActivity"}, {"end": 73, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 33, "tag": "ResearchActivity"}, {"end": 89, "start": 67, "tag": "CellFunction"}, {"end": 150, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1174_6", "text": "Varying the vesicle composition by specifically increasing the amount of GM1 gangliosides as a constituent, we found that only GM1-enriched liposomes induce the formation of toxic, low-molecular-weight oligomers.", "tags": [{"end": 19, "start": 12, "tag": "CellComponent"}, {"end": 89, "start": 73, "tag": "Chemical"}, {"end": 179, "start": 174, "tag": "InjuryOrPoisoning"}, {"end": 149, "start": 140, "tag": "Chemical"}, {"end": 89, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 73, "tag": "PharmacologicSubstance"}]}{"id": "1174_7", "text": "Furthermore, we found that the aggregation on liposome surface and membrane disruption are highly cooperative and sensitive to membrane surface characteristics.", "tags": [{"end": 42, "start": 31, "tag": "CellFunction"}, {"end": 42, "start": 31, "tag": "ResearchActivity"}, {"end": 54, "start": 46, "tag": "Chemical"}, {"end": 123, "start": 114, "tag": "PathologicFunction"}, {"end": 75, "start": 67, "tag": "CellComponent"}, {"end": 135, "start": 127, "tag": "CellComponent"}, {"end": 86, "start": 67, "tag": "CellOrMolecularDysfunction"}]}{"id": "1174_8", "text": "Numerical simulations confirm such a cooperativity and reveal that GM1-enriched liposomes form twice as many pores as those formed in the absence GM1.", "tags": [{"end": 149, "start": 146, "tag": "Chemical"}, {"end": 89, "start": 80, "tag": "Chemical"}, {"end": 70, "start": 67, "tag": "Chemical"}]}{"id": "1174_9", "text": "Overall, this study uncovers mechanisms of cooperativity between oligomerization and membrane disruption under controlled lipid compositional bias, and refocuses the significance of the early stages of A beta aggregation in polymorphism, propagation, and toxicity in AD.", "tags": [{"end": 80, "start": 65, "tag": "CellFunction"}, {"end": 121, "start": 111, "tag": "Finding"}, {"end": 198, "start": 186, "tag": "TemporalConcept"}, {"end": 236, "start": 224, "tag": "CellFunction"}, {"end": 198, "start": 192, "tag": "TemporalConcept"}, {"end": 127, "start": 122, "tag": "Chemical"}, {"end": 93, "start": 85, "tag": "CellComponent"}, {"end": 263, "start": 255, "tag": "InjuryOrPoisoning"}, {"end": 19, "start": 14, "tag": "ResearchActivity"}, {"end": 269, "start": 267, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 202, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 85, "tag": "CellOrMolecularDysfunction"}]}{"id": "1175_0", "text": "Author summary Many vital processes in our eukaryotic cells and organs require an astonishingly precise routing of intermediate products to various intra- and extracellular destinations using vesicles as transporters.", "tags": [{"end": 59, "start": 43, "tag": "Cell"}, {"end": 200, "start": 192, "tag": "CellComponent"}, {"end": 70, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 148, "tag": "CellComponent"}]}{"id": "1175_1", "text": "This can be illustrated by numerous examples, such as the production and destruction of proteins, the export of neurotransmitters or insulin to the extracellular domain, etc.", "tags": [{"end": 129, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 133, "tag": "PharmacologicSubstance"}, {"end": 96, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 102, "tag": "CellFunction"}]}{"id": "1175_2", "text": "However, the inside of a cell is tightly packed with numerous structural scaffoldings (filaments), which serve as obstacles and impede the vesicle motion.", "tags": [{"end": 29, "start": 25, "tag": "Cell"}, {"end": 96, "start": 87, "tag": "CellComponent"}, {"end": 153, "start": 139, "tag": "CellFunction"}]}{"id": "1175_3", "text": "It is thought that any disturbances of the vesicle-mediated cell transport contribute to numerous degenerative diseases and disorders, which highlights the clinical relevance for investigating this intracellular transport mechanism by developing computational models and performing experimental studies.", "tags": [{"end": 35, "start": 23, "tag": "Finding"}, {"end": 302, "start": 282, "tag": "ResearchActivity"}, {"end": 119, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 266, "start": 246, "tag": "ResearchActivity"}, {"end": 231, "start": 198, "tag": "CellFunction"}, {"end": 74, "start": 43, "tag": "CellFunction"}]}{"id": "1175_4", "text": "In this study, we numerically quantified how different specific alterations of the filament density inside a human lung cell-due to changed mechanical loadings or genetic disorders of proteins being responsible for filament branching-affect the diffusion of vesicles inside the intracellular fluid.", "tags": [{"end": 91, "start": 83, "tag": "CellComponent"}, {"end": 119, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 180, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 215, "tag": "CellComponent"}, {"end": 297, "start": 278, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 192, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 109, "tag": "Eukaryote"}, {"end": 254, "start": 245, "tag": "NaturalPhenomenonOrProcess"}, {"end": 266, "start": 245, "tag": "CellFunction"}, {"end": 124, "start": 109, "tag": "Cell"}]}{"id": "1175_5", "text": "Therefore, based on the concept of homogenization, a computationally efficient numerical method was developed and utilized to simulate the diffusion of vesicles inside the whole cell, considering the detailed structural information of the filament network.", "tags": [{"end": 247, "start": 239, "tag": "CellComponent"}, {"end": 255, "start": 248, "tag": "PopulationGroup"}, {"end": 255, "start": 248, "tag": "CellFunction"}, {"end": 95, "start": 53, "tag": "ResearchActivity"}, {"end": 148, "start": 139, "tag": "NaturalPhenomenonOrProcess"}, {"end": 160, "start": 139, "tag": "CellFunction"}]}{"id": "1175_6", "text": "The interior of a eukaryotic cell is a highly complex composite material which consists of water, structural scaffoldings, organelles, and various biomolecular solutes.", "tags": [{"end": 33, "start": 18, "tag": "Cell"}, {"end": 72, "start": 64, "tag": "Substance"}, {"end": 133, "start": 123, "tag": "CellComponent"}, {"end": 96, "start": 91, "tag": "Chemical"}, {"end": 167, "start": 147, "tag": "Chemical"}]}{"id": "1175_7", "text": "All these components serve as obstacles that impede the motion of vesicles.", "tags": [{"end": 74, "start": 66, "tag": "CellComponent"}, {"end": 62, "start": 56, "tag": "NaturalPhenomenonOrProcess"}, {"end": 20, "start": 10, "tag": "CellComponent"}]}{"id": "1175_8", "text": "Hence, it is hypothesized that any alteration of the cytoskeletal network may directly impact or even disrupt the vesicle transport.", "tags": [{"end": 73, "start": 53, "tag": "CellFunction"}, {"end": 131, "start": 114, "tag": "CellFunction"}, {"end": 45, "start": 35, "tag": "Finding"}]}{"id": "1175_9", "text": "A disruption of the vesicle-mediate cell transport is thought to contribute to several severe diseases and disorders, such as diabetes, Parkinson's and Alzheimer's disease, emphasizing the clinical relevance.", "tags": [{"end": 93, "start": 87, "tag": "Finding"}, {"end": 147, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 126, "tag": "DiseaseOrSyndrome"}]}{"id": "1175_10", "text": "To address the outlined objective, a multiscale finite element model of the diffusive vesicle transport is proposed on the basis of the concept of homogenization, owed to the complexity of the cytoskeletal network.", "tags": [{"end": 93, "start": 86, "tag": "CellComponent"}, {"end": 213, "start": 193, "tag": "CellFunction"}, {"end": 68, "start": 63, "tag": "ResearchActivity"}, {"end": 103, "start": 76, "tag": "CellFunction"}]}{"id": "1175_11", "text": "In order to study the microscopic effects of specific nanoscopic actin filament network alterations onto the vesicle transport, a parametrized three-dimensional geometrical model of the actin filament network was generated on the basis of experimentally observed filament densities and network geometries in an adenocarcinomic human alveolar basal epithelial cell.", "tags": [{"end": 87, "start": 65, "tag": "CellFunction"}, {"end": 126, "start": 109, "tag": "CellFunction"}, {"end": 160, "start": 143, "tag": "HealthCareActivity"}, {"end": 200, "start": 186, "tag": "CellComponent"}, {"end": 208, "start": 201, "tag": "CellFunction"}, {"end": 271, "start": 263, "tag": "CellComponent"}, {"end": 293, "start": 286, "tag": "PopulationGroup"}, {"end": 293, "start": 286, "tag": "CellFunction"}, {"end": 326, "start": 311, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 332, "start": 327, "tag": "Eukaryote"}, {"end": 178, "start": 130, "tag": "ResearchActivity"}, {"end": 281, "start": 272, "tag": "ClinicalAttribute"}, {"end": 363, "start": 333, "tag": "Cell"}]}{"id": "1175_12", "text": "Numerical analyzes of the obtained effective diffusion properties within two-dimensional sampling domains of the whole cell model revealed that the computed homogenized diffusion coefficients can be predicted statistically accurate by a simple two-parameter power law as soon as the inaccessible area fraction, due to the obstacle geometries and the finite size of the vesicles, is known.", "tags": [{"end": 377, "start": 369, "tag": "CellComponent"}, {"end": 129, "start": 113, "tag": "ResearchActivity"}, {"end": 54, "start": 45, "tag": "NaturalPhenomenonOrProcess"}, {"end": 178, "start": 169, "tag": "NaturalPhenomenonOrProcess"}, {"end": 361, "start": 357, "tag": "OrganismAttribute"}, {"end": 191, "start": 157, "tag": "ResearchActivity"}]}{"id": "1175_13", "text": "This relationship, in turn, leads to a massive reduction in computation time and allows to study the impact of a variety of different cytoskeletal alterations onto the vesicle transport.", "tags": [{"end": 71, "start": 60, "tag": "ResearchActivity"}, {"end": 146, "start": 134, "tag": "CellComponent"}, {"end": 185, "start": 168, "tag": "CellFunction"}, {"end": 17, "start": 5, "tag": "Finding"}, {"end": 96, "start": 91, "tag": "ResearchActivity"}, {"end": 56, "start": 47, "tag": "Finding"}, {"end": 56, "start": 47, "tag": "NaturalPhenomenonOrProcess"}, {"end": 76, "start": 72, "tag": "TemporalConcept"}, {"end": 158, "start": 134, "tag": "Finding"}]}{"id": "1175_14", "text": "Hence, the numerical simulations predicted a 35% increase in transport time due to a uniformly distributed four-fold increase of the total filament amount.", "tags": [{"end": 147, "start": 139, "tag": "CellComponent"}, {"end": 75, "start": 71, "tag": "TemporalConcept"}]}{"id": "1175_15", "text": "On the other hand, a hypothetically reduced expression of filament cross-linking proteins led to sparser filament networks and, thus, a speed up of the vesicle transport.", "tags": [{"end": 113, "start": 105, "tag": "CellComponent"}, {"end": 122, "start": 114, "tag": "CellFunction"}, {"end": 169, "start": 152, "tag": "CellFunction"}, {"end": 89, "start": 58, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1176_0", "text": "The pathogenic processes driving Alzheimer's disease (AD) are complex.", "tags": [{"end": 52, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 4, "tag": "PathologicFunction"}]}{"id": "1176_1", "text": "An incomplete understanding of underlying disease mechanisms has presented insurmountable obstacles for developing effective disease-modifying therapies.", "tags": [{"end": 60, "start": 42, "tag": "ResearchActivity"}, {"end": 152, "start": 125, "tag": "HealthCareActivity"}, {"end": 27, "start": 14, "tag": "BiologicFunction"}, {"end": 152, "start": 143, "tag": "HealthCareActivity"}]}{"id": "1176_2", "text": "Advanced chronological age is the greatest risk factor for developing AD.", "tags": [{"end": 54, "start": 43, "tag": "Finding"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 43, "tag": "Finding"}, {"end": 26, "start": 23, "tag": "OrganismAttribute"}, {"end": 26, "start": 0, "tag": "OrganismAttribute"}]}{"id": "1176_3", "text": "Intervening on biological aging may alter disease progression and represents a novel, complementary approach to current strategies.", "tags": [{"end": 61, "start": 50, "tag": "PathologicFunction"}, {"end": 61, "start": 50, "tag": "TemporalConcept"}, {"end": 119, "start": 112, "tag": "TemporalConcept"}, {"end": 130, "start": 120, "tag": "ResearchActivity"}, {"end": 130, "start": 120, "tag": "BiologicFunction"}, {"end": 61, "start": 42, "tag": "PathologicFunction"}, {"end": 31, "start": 26, "tag": "BiologicFunction"}, {"end": 31, "start": 26, "tag": "CellFunction"}]}{"id": "1176_4", "text": "Toward this end, cellular senescence has emerged as a promising target.", "tags": [{"end": 36, "start": 17, "tag": "CellFunction"}]}{"id": "1176_5", "text": "This complex stress response harbors damaged cells in a cell cycle arrested, apoptosis-resistant cell state.", "tags": [{"end": 66, "start": 56, "tag": "CellFunction"}, {"end": 28, "start": 13, "tag": "BiologicFunction"}, {"end": 28, "start": 13, "tag": "CellFunction"}, {"end": 50, "start": 45, "tag": "Cell"}, {"end": 101, "start": 97, "tag": "Cell"}, {"end": 107, "start": 102, "tag": "PopulationGroup"}, {"end": 86, "start": 77, "tag": "CellFunction"}, {"end": 44, "start": 37, "tag": "InjuryOrPoisoning"}]}{"id": "1176_6", "text": "Senescent cells accumulate with age where they notoriously secrete molecules that contribute to chronic tissue dysfunction and disease.", "tags": [{"end": 66, "start": 59, "tag": "CellFunction"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 35, "start": 32, "tag": "OrganismAttribute"}, {"end": 110, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 67, "tag": "Substance"}, {"end": 122, "start": 111, "tag": "PathologicFunction"}, {"end": 103, "start": 96, "tag": "TemporalConcept"}]}{"id": "1176_7", "text": "Thus, benefits of cell survival in a senescent fate are countered by their toxic secretome.", "tags": [{"end": 31, "start": 18, "tag": "CellFunction"}, {"end": 80, "start": 75, "tag": "InjuryOrPoisoning"}, {"end": 90, "start": 81, "tag": "BiologicallyActiveSubstance"}]}{"id": "1176_8", "text": "The removal of senescent cells improves brain structure and function in rodent models at risk of developing AD, and in those with advanced A beta and tau pathology.", "tags": [{"end": 55, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 79, "tag": "ResearchActivity"}, {"end": 163, "start": 150, "tag": "PathologicFunction"}, {"end": 78, "start": 72, "tag": "Eukaryote"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 150, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 15, "tag": "Cell"}, {"end": 93, "start": 89, "tag": "Finding"}, {"end": 145, "start": 139, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1176_9", "text": "The present review describes the path to translating this promising treatment strategy to AD clinical trials.", "tags": [{"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 77, "start": 68, "tag": "HealthCareActivity"}, {"end": 77, "start": 68, "tag": "ResearchActivity"}, {"end": 108, "start": 93, "tag": "ResearchActivity"}]}{"id": "1176_10", "text": "We review evidence for senescent cell accumulation in the human brain, considerations and strategies for senescence-targeting trials specific to AD, approaches to detect senescent brain cells in biofluids, and summarize the goals of the first senolytic trials for the treatment of AD (NCT04063124 and NCT04685590).", "tags": [{"end": 85, "start": 71, "tag": "Finding"}, {"end": 191, "start": 170, "tag": "Cell"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 283, "start": 281, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 10, "tag": "Finding"}, {"end": 69, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 58, "tag": "Eukaryote"}, {"end": 50, "start": 38, "tag": "Finding"}, {"end": 37, "start": 23, "tag": "Cell"}, {"end": 242, "start": 237, "tag": "TemporalConcept"}, {"end": 204, "start": 195, "tag": "Substance"}, {"end": 9, "start": 3, "tag": "ResearchActivity"}, {"end": 9, "start": 3, "tag": "HealthCareActivity"}, {"end": 277, "start": 268, "tag": "HealthCareActivity"}, {"end": 277, "start": 268, "tag": "ResearchActivity"}, {"end": 100, "start": 90, "tag": "ResearchActivity"}, {"end": 100, "start": 90, "tag": "BiologicFunction"}, {"end": 115, "start": 105, "tag": "Finding"}, {"end": 115, "start": 105, "tag": "TemporalConcept"}, {"end": 115, "start": 105, "tag": "CellFunction"}, {"end": 132, "start": 105, "tag": "ResearchActivity"}, {"end": 259, "start": 243, "tag": "ResearchActivity"}, {"end": 296, "start": 285, "tag": "ResearchActivity"}, {"end": 312, "start": 301, "tag": "ResearchActivity"}]}{"id": "1177_0", "text": "Chronic kidney disease (CKD) is a clinical syndrome secondary to the definitive change in function and structure of the kidney, which is characterized by its irreversibility and slow and progressive evolution.", "tags": [{"end": 22, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 199, "tag": "TemporalConcept"}, {"end": 208, "start": 199, "tag": "BiologicFunction"}, {"end": 198, "start": 187, "tag": "TemporalConcept"}, {"end": 173, "start": 158, "tag": "Finding"}]}{"id": "1177_1", "text": "Alzheimer's disease (AD) is characterized by the extracellular accumulation of misfolded beta-amyloid (A beta) proteins into senile plaques and the formation of neurofibrillary tangles (NFTs) containing hyperphosphorylated tau.", "tags": [{"end": 139, "start": 125, "tag": "AnatomicalAbnormality"}, {"end": 101, "start": 63, "tag": "CellOrMolecularDysfunction"}, {"end": 119, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 161, "tag": "CellOrMolecularDysfunction"}, {"end": 176, "start": 161, "tag": "CellComponent"}, {"end": 101, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 63, "tag": "Finding"}, {"end": 226, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 226, "start": 223, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 49, "tag": "CellComponent"}, {"end": 226, "start": 203, "tag": "AminoAcidPeptideOrProtein"}, {"end": 226, "start": 203, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 186, "tag": "CellOrMolecularDysfunction"}]}{"id": "1177_2", "text": "In the aging population, CKD and AD are growing problems.", "tags": [{"end": 28, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 13, "tag": "PopulationGroup"}, {"end": 12, "start": 7, "tag": "BiologicFunction"}, {"end": 12, "start": 7, "tag": "CellFunction"}]}{"id": "1177_3", "text": "CKD patients are prone to cognitive decline and AD.", "tags": [{"end": 3, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 4, "tag": "PatientOrDisabledGroup"}]}{"id": "1177_4", "text": "However, the connection between CKD and AD is still unclear.", "tags": [{"end": 35, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}]}{"id": "1177_5", "text": "In this review, we take the lead in showing that the development of the pathophysiology of CKD may also cause or exacerbate AD, especially the renin-angiotensin system (RAS).", "tags": [{"end": 94, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 143, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 169, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 72, "tag": "PathologicFunction"}, {"end": 87, "start": 72, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 53, "tag": "BiologicFunction"}, {"end": 64, "start": 53, "tag": "CellFunction"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "1177_6", "text": "In vivo studies had already shown that the increased expression of angiotensin-converting enzyme (ACE) produces a positive effect in aggravating AD, but ACE inhibitors (ACEIs) have protective effects against AD.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 96, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 53, "tag": "CellFunction"}, {"end": 101, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 167, "start": 153, "tag": "PharmacologicSubstance"}, {"end": 174, "start": 169, "tag": "PharmacologicSubstance"}, {"end": 129, "start": 114, "tag": "Finding"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 210, "start": 208, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 199, "start": 181, "tag": "Finding"}, {"end": 96, "start": 67, "tag": "BiologicallyActiveSubstance"}]}{"id": "1177_7", "text": "Among the possible association of risk factors in CKD and AD, we mainly discuss the RAS in the systemic circulation and the brain.", "tags": [{"end": 53, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 129, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 34, "tag": "Finding"}]}{"id": "1178_0", "text": "The accumulation of extracellular beta-amyloid (A beta) plaques within the brain is unique to Alzheimer's disease (AD) and thought to induce synaptic deficits and neuronal loss.", "tags": [{"end": 63, "start": 56, "tag": "AnatomicalAbnormality"}, {"end": 46, "start": 34, "tag": "AnatomicalAbnormality"}, {"end": 158, "start": 150, "tag": "Finding"}, {"end": 113, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 4, "tag": "Finding"}, {"end": 54, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 20, "tag": "CellComponent"}, {"end": 46, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 163, "tag": "CellOrMolecularDysfunction"}]}{"id": "1178_1", "text": "Optimal therapies should tackle the core AD pathophysiology and prevent the decline in memory and cognitive functions.", "tags": [{"end": 117, "start": 98, "tag": "BiologicFunction"}, {"end": 43, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 44, "tag": "PathologicFunction"}, {"end": 59, "start": 44, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 17, "start": 8, "tag": "HealthCareActivity"}, {"end": 83, "start": 76, "tag": "Finding"}, {"end": 93, "start": 87, "tag": "BiologicFunction"}]}{"id": "1178_2", "text": "This study aimed to evaluate the therapeutic performance of mesenchymal stem cell-derived exosomes (MSC-exosomes), which are secreted membranous elements encapsulating a variety of MSC factors, on AD.", "tags": [{"end": 199, "start": 197, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 103, "start": 100, "tag": "Cell"}, {"end": 184, "start": 181, "tag": "Cell"}, {"end": 98, "start": 90, "tag": "CellComponent"}, {"end": 112, "start": 104, "tag": "CellComponent"}, {"end": 82, "start": 60, "tag": "Cell"}, {"end": 153, "start": 125, "tag": "CellComponent"}]}{"id": "1178_3", "text": "A human neural cell culture model with familial AD (FAD) mutations was established and co-cultured with purified MSC-exosomes.", "tags": [{"end": 19, "start": 8, "tag": "Cell"}, {"end": 55, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 15, "tag": "ResearchActivity"}, {"end": 98, "start": 87, "tag": "ResearchActivity"}, {"end": 50, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 2, "tag": "Eukaryote"}, {"end": 33, "start": 8, "tag": "ResearchActivity"}, {"end": 116, "start": 113, "tag": "Cell"}, {"end": 98, "start": 90, "tag": "ResearchActivity"}, {"end": 66, "start": 57, "tag": "CellFunction"}, {"end": 66, "start": 57, "tag": "CellOrMolecularDysfunction"}, {"end": 125, "start": 117, "tag": "CellComponent"}, {"end": 50, "start": 2, "tag": "ExperimentalModelOfDisease"}]}{"id": "1178_4", "text": "2-[F-18]Fluoro-2-deoxy-d-glucose ([F-18]FDG) and novel object recognition (NOR) testing were performed before/after treatment to evaluate the therapeutic effect in vivo.", "tags": [{"end": 87, "start": 80, "tag": "HealthCareActivity"}, {"end": 73, "start": 49, "tag": "HealthCareActivity"}, {"end": 73, "start": 62, "tag": "BiologicFunction"}, {"end": 32, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 142, "tag": "Finding"}, {"end": 125, "start": 116, "tag": "HealthCareActivity"}, {"end": 125, "start": 116, "tag": "ResearchActivity"}, {"end": 168, "start": 161, "tag": "ResearchActivity"}, {"end": 32, "start": 0, "tag": "Chemical"}, {"end": 43, "start": 34, "tag": "Chemical"}, {"end": 73, "start": 49, "tag": "ResearchActivity"}]}{"id": "1178_5", "text": "The AD-related pathology and the expression of neuronal memory/synaptic plasticity-related genes were also evaluated.", "tags": [{"end": 82, "start": 63, "tag": "CellFunction"}, {"end": 82, "start": 63, "tag": "BiologicFunction"}, {"end": 82, "start": 72, "tag": "NaturalPhenomenonOrProcess"}, {"end": 82, "start": 72, "tag": "CellFunction"}, {"end": 6, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 15, "tag": "PathologicFunction"}, {"end": 24, "start": 15, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 55, "start": 47, "tag": "Cell"}, {"end": 43, "start": 33, "tag": "CellFunction"}, {"end": 62, "start": 56, "tag": "BiologicFunction"}, {"end": 62, "start": 56, "tag": "Finding"}]}{"id": "1178_6", "text": "The results showed that MSC-exosomes reduced A beta expression and restored the expression of neuronal memory/synaptic plasticity-related genes in the cell model.", "tags": [{"end": 62, "start": 47, "tag": "CellFunction"}, {"end": 62, "start": 47, "tag": "HealthCareActivity"}, {"end": 129, "start": 110, "tag": "CellFunction"}, {"end": 129, "start": 110, "tag": "BiologicFunction"}, {"end": 129, "start": 119, "tag": "NaturalPhenomenonOrProcess"}, {"end": 129, "start": 119, "tag": "CellFunction"}, {"end": 118, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 151, "tag": "Cell"}, {"end": 102, "start": 94, "tag": "Cell"}, {"end": 161, "start": 156, "tag": "ResearchActivity"}, {"end": 62, "start": 52, "tag": "CellFunction"}, {"end": 90, "start": 80, "tag": "CellFunction"}, {"end": 51, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 24, "tag": "Cell"}, {"end": 109, "start": 103, "tag": "BiologicFunction"}, {"end": 36, "start": 28, "tag": "CellComponent"}, {"end": 109, "start": 103, "tag": "Finding"}]}{"id": "1178_7", "text": "[F-18]FDG-PET imaging and cognitive assessment revealed a significant improvement in brain glucose metabolism and cognitive function in AD transgenic mice.", "tags": [{"end": 21, "start": 0, "tag": "HealthCareActivity"}, {"end": 109, "start": 91, "tag": "CellFunction"}, {"end": 98, "start": 91, "tag": "Chemical"}, {"end": 98, "start": 91, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 14, "tag": "HealthCareActivity"}, {"end": 138, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 139, "tag": "ResearchActivity"}, {"end": 154, "start": 150, "tag": "Eukaryote"}, {"end": 46, "start": 26, "tag": "HealthCareActivity"}, {"end": 13, "start": 10, "tag": "HealthCareActivity"}, {"end": 132, "start": 114, "tag": "BiologicFunction"}, {"end": 90, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 91, "tag": "BiologicFunction"}, {"end": 154, "start": 136, "tag": "ExperimentalModelOfDisease"}, {"end": 81, "start": 58, "tag": "Finding"}]}{"id": "1178_8", "text": "The phase of neurons and astrocytes in the brain of AD mice were also found to be regulated after treatment with MSC-exosomes.", "tags": [{"end": 9, "start": 4, "tag": "TemporalConcept"}, {"end": 54, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 55, "tag": "Eukaryote"}, {"end": 107, "start": 98, "tag": "HealthCareActivity"}, {"end": 107, "start": 98, "tag": "ResearchActivity"}, {"end": 20, "start": 13, "tag": "Cell"}, {"end": 35, "start": 25, "tag": "Cell"}, {"end": 116, "start": 113, "tag": "Cell"}, {"end": 125, "start": 117, "tag": "CellComponent"}, {"end": 59, "start": 52, "tag": "ExperimentalModelOfDisease"}]}{"id": "1178_9", "text": "Our study demonstrates the therapeutic mechanism of MSC-exosomes and provides an alternative therapeutic strategy based on cell-free MSC-exosomes for the treatment of AD.", "tags": [{"end": 169, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 163, "start": 154, "tag": "HealthCareActivity"}, {"end": 163, "start": 154, "tag": "ResearchActivity"}, {"end": 55, "start": 52, "tag": "Cell"}, {"end": 136, "start": 133, "tag": "Cell"}, {"end": 64, "start": 56, "tag": "CellComponent"}, {"end": 145, "start": 137, "tag": "CellComponent"}, {"end": 113, "start": 93, "tag": "HealthCareActivity"}]}{"id": "1179_0", "text": "Astrocytes are important for maintaining cholesterol metabolism, glutamate uptake, and neurotransmission.", "tags": [{"end": 63, "start": 41, "tag": "CellFunction"}, {"end": 104, "start": 87, "tag": "CellFunction"}, {"end": 10, "start": 0, "tag": "Cell"}, {"end": 52, "start": 41, "tag": "Chemical"}, {"end": 52, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 53, "tag": "CellFunction"}, {"end": 63, "start": 53, "tag": "BiologicFunction"}, {"end": 74, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 75, "tag": "BiologicFunction"}, {"end": 81, "start": 75, "tag": "CellFunction"}]}{"id": "1179_1", "text": "Indeed, inflammatory processes and neurodegeneration contribute to the altered morphology, gene expression, and function of astrocytes.", "tags": [{"end": 89, "start": 79, "tag": "Finding"}, {"end": 106, "start": 91, "tag": "CellFunction"}, {"end": 52, "start": 35, "tag": "CellOrMolecularDysfunction"}, {"end": 134, "start": 124, "tag": "Cell"}]}{"id": "1179_2", "text": "Astrocytes, in collaboration with numerous microRNAs, regulate brain cholesterol levels as well as glutamatergic and inflammatory signaling, all of which contribute to general brain homeostasis.", "tags": [{"end": 10, "start": 0, "tag": "Cell"}, {"end": 139, "start": 117, "tag": "CellFunction"}, {"end": 193, "start": 176, "tag": "BiologicFunction"}, {"end": 80, "start": 69, "tag": "Chemical"}, {"end": 80, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 43, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 52, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 130, "tag": "CellFunction"}, {"end": 112, "start": 99, "tag": "CellFunction"}]}{"id": "1179_3", "text": "Neural electrical activity, synaptic plasticity processes, learning, and memory are dependent on the astrocyte-neuron crosstalk.", "tags": [{"end": 26, "start": 0, "tag": "BiologicFunction"}, {"end": 57, "start": 28, "tag": "BiologicFunction"}, {"end": 67, "start": 59, "tag": "BiologicFunction"}, {"end": 47, "start": 28, "tag": "CellFunction"}, {"end": 47, "start": 28, "tag": "BiologicFunction"}, {"end": 47, "start": 37, "tag": "NaturalPhenomenonOrProcess"}, {"end": 47, "start": 37, "tag": "CellFunction"}, {"end": 117, "start": 111, "tag": "Cell"}, {"end": 36, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 101, "tag": "Cell"}, {"end": 127, "start": 118, "tag": "CellFunction"}, {"end": 79, "start": 73, "tag": "BiologicFunction"}]}{"id": "1179_4", "text": "Here, we review the involvement of astrocytic microRNAs that potentially regulate cholesterol metabolism, glutamate uptake, and inflammation in Alzheimer's disease (AD).", "tags": [{"end": 104, "start": 82, "tag": "CellFunction"}, {"end": 93, "start": 82, "tag": "Chemical"}, {"end": 93, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 128, "tag": "PathologicFunction"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 104, "start": 94, "tag": "CellFunction"}, {"end": 104, "start": 94, "tag": "BiologicFunction"}, {"end": 45, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 20, "tag": "Finding"}, {"end": 122, "start": 116, "tag": "BiologicFunction"}, {"end": 122, "start": 116, "tag": "CellFunction"}, {"end": 55, "start": 46, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 55, "start": 46, "tag": "BiologicallyActiveSubstance"}]}{"id": "1179_5", "text": "The interaction between astrocytic microRNAs and long non-coding RNA and transcription factors specific to astrocytes also contributes to the pathogenesis of AD.", "tags": [{"end": 94, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 49, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 68, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 142, "tag": "PathologicFunction"}, {"end": 34, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 107, "tag": "Cell"}, {"end": 68, "start": 65, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 44, "start": 35, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 44, "start": 35, "tag": "BiologicallyActiveSubstance"}]}{"id": "1179_6", "text": "Thus, astrocytic microRNAs arise as a promising target, as AD conditions are a worldwide public health problem.", "tags": [{"end": 102, "start": 89, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 102, "start": 89, "tag": "HealthCareActivity"}, {"end": 110, "start": 103, "tag": "Finding"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 96, "tag": "HealthCareActivity"}, {"end": 26, "start": 17, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 26, "start": 17, "tag": "BiologicallyActiveSubstance"}]}{"id": "1179_7", "text": "This review examines novel therapeutic strategies to target astrocyte dysfunction in AD, such as lipid nanodiscs, engineered G protein-coupled receptors, extracellular vesicles, and nanoparticles.", "tags": [{"end": 176, "start": 154, "tag": "CellComponent"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 69, "start": 60, "tag": "Cell"}, {"end": 102, "start": 97, "tag": "Chemical"}, {"end": 152, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 70, "tag": "PathologicFunction"}, {"end": 49, "start": 27, "tag": "HealthCareActivity"}, {"end": 195, "start": 182, "tag": "Substance"}, {"end": 112, "start": 103, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1180_0", "text": "Alcohol use disorder is associated with systemic inflammation and organ dysfunction especially in the liver and the brain.", "tags": [{"end": 20, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 66, "tag": "PathologicFunction"}, {"end": 107, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 40, "tag": "PathologicFunction"}, {"end": 121, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 49, "tag": "PathologicFunction"}]}{"id": "1180_1", "text": "For more than a decade, studies have highlighted alcohol abuse-mediated impairment of brain function and acceleration of neurodegeneration through inflammatory mechanisms that directly involve innate immune cells.", "tags": [{"end": 212, "start": 193, "tag": "Cell"}, {"end": 100, "start": 86, "tag": "BiologicFunction"}, {"end": 22, "start": 16, "tag": "TemporalConcept"}, {"end": 82, "start": 49, "tag": "PathologicFunction"}, {"end": 170, "start": 147, "tag": "PathologicFunction"}, {"end": 138, "start": 121, "tag": "CellOrMolecularDysfunction"}, {"end": 31, "start": 24, "tag": "ResearchActivity"}]}{"id": "1180_2", "text": "Furthermore, recent studies indicate overlapping genetic risk factors between alcohol use and neurodegenerative disorders, specifically regarding the role of innate immunity in the pathomechanisms of both areas.", "tags": [{"end": 69, "start": 49, "tag": "Finding"}, {"end": 89, "start": 78, "tag": "IndividualBehavior"}, {"end": 85, "start": 78, "tag": "Chemical"}, {"end": 173, "start": 158, "tag": "OrganismAttribute"}, {"end": 121, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 57, "tag": "Finding"}, {"end": 27, "start": 20, "tag": "ResearchActivity"}, {"end": 19, "start": 13, "tag": "TemporalConcept"}]}{"id": "1180_3", "text": "Considering the pressing need for a better understanding of the relevance of alcohol abuse in dementia progression, here we summarize the molecular mechanisms of neuroinflammation observed in alcohol abuse and Alzheimer's disease, the most common cause of dementia.", "tags": [{"end": 90, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 43, "tag": "BiologicFunction"}, {"end": 158, "start": 138, "tag": "CellFunction"}, {"end": 114, "start": 103, "tag": "PathologicFunction"}, {"end": 114, "start": 103, "tag": "TemporalConcept"}, {"end": 229, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 264, "start": 256, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 162, "tag": "PathologicFunction"}]}{"id": "1180_4", "text": "In addition, we highlight mechanisms that are already established in the field of Alzheimer's disease that may be relevant to explore in alcoholism to better understand alcohol mediated neurodegeneration and dementia, including the relevance of the liver-brain axis.", "tags": [{"end": 147, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 265, "start": 249, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 254, "start": 249, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 260, "start": 255, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 203, "start": 186, "tag": "CellOrMolecularDysfunction"}, {"end": 101, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 208, "tag": "DiseaseOrSyndrome"}]}{"id": "1181_0", "text": "Extracellular vesicles (EVs), including exosomes, microvesicles, and oncosomes, are nano-sized particles enclosed by a lipid bilayer.", "tags": [{"end": 132, "start": 119, "tag": "CellComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 104, "start": 95, "tag": "Chemical"}, {"end": 124, "start": 119, "tag": "Chemical"}, {"end": 63, "start": 50, "tag": "CellComponent"}, {"end": 48, "start": 40, "tag": "CellComponent"}]}{"id": "1181_1", "text": "EVs are released by virtually all eukaryotic cells and have been shown to contribute to intercellular communication by transporting proteins, lipids, and nucleic acids.", "tags": [{"end": 140, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 34, "tag": "Cell"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 140, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 142, "tag": "Chemical"}, {"end": 167, "start": 154, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 115, "start": 88, "tag": "CellFunction"}]}{"id": "1181_2", "text": "In the context of neurodegenerative diseases, EVs may carry toxic, misfolded forms of amyloidogenic proteins and facilitate their spread to recipient cells in the central nervous system (CNS).", "tags": [{"end": 108, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 67, "tag": "CellOrMolecularDysfunction"}, {"end": 49, "start": 46, "tag": "CellComponent"}, {"end": 185, "start": 163, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 60, "tag": "InjuryOrPoisoning"}, {"end": 108, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 140, "tag": "Cell"}]}{"id": "1181_3", "text": "CNS-originating EVs can cross the blood-brain barrier into the bloodstream and may be found in other body fluids, including saliva, tears, and urine.", "tags": [{"end": 137, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 106, "tag": "Substance"}, {"end": 112, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 16, "tag": "CellComponent"}, {"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 63, "tag": "BiologicFunction"}, {"end": 148, "start": 143, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1181_4", "text": "EVs originating in the CNS represent an attractive source of biomarkers for neurodegenerative diseases, because they contain cell- and cell state-specific biological materials.", "tags": [{"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 26, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 61, "tag": "ClinicalAttribute"}, {"end": 129, "start": 125, "tag": "Cell"}, {"end": 139, "start": 135, "tag": "Cell"}, {"end": 102, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 140, "tag": "PopulationGroup"}]}{"id": "1181_5", "text": "In recent years, multiple papers have reported the use of this strategy for identification and quantitation of biomarkers for neurodegenerative diseases, including Parkinson's disease and atypical parkinsonian disorders.", "tags": [{"end": 196, "start": 188, "tag": "Finding"}, {"end": 219, "start": 197, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 111, "tag": "ClinicalAttribute"}, {"end": 152, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 10, "tag": "TemporalConcept"}, {"end": 9, "start": 3, "tag": "TemporalConcept"}]}{"id": "1181_6", "text": "However, certain technical issues have yet to be standardized, such as the best surface markers for isolation of cell type-specific EVs and validating the cellular origin of the EVs.", "tags": [{"end": 135, "start": 132, "tag": "CellComponent"}, {"end": 181, "start": 178, "tag": "CellComponent"}, {"end": 95, "start": 88, "tag": "ClinicalAttribute"}, {"end": 109, "start": 100, "tag": "HealthCareActivity"}, {"end": 170, "start": 164, "tag": "TemporalConcept"}, {"end": 95, "start": 80, "tag": "ClinicalAttribute"}, {"end": 163, "start": 155, "tag": "Cell"}, {"end": 122, "start": 113, "tag": "Cell"}, {"end": 109, "start": 100, "tag": "ResearchActivity"}]}{"id": "1181_7", "text": "Here, we review recent research using CNS-originating EVs for biomarker studies, primarily in parkinsonian disorders, highlight technical challenges, and propose strategies for overcoming them.", "tags": [{"end": 116, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 54, "tag": "CellComponent"}, {"end": 41, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 23, "tag": "ResearchActivity"}, {"end": 71, "start": 62, "tag": "ClinicalAttribute"}, {"end": 148, "start": 138, "tag": "HealthCareActivity"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 79, "start": 72, "tag": "ResearchActivity"}, {"end": 172, "start": 162, "tag": "ResearchActivity"}, {"end": 172, "start": 162, "tag": "BiologicFunction"}, {"end": 22, "start": 16, "tag": "TemporalConcept"}]}{"id": "1182_0", "text": "Diagnosis of neurodegenerative disease (NDD) is complex, therefore simpler, less invasive, more accurate biomarkers are needed.", "tags": [{"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 43, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 105, "tag": "ClinicalAttribute"}, {"end": 89, "start": 76, "tag": "Finding"}, {"end": 38, "start": 13, "tag": "DiseaseOrSyndrome"}]}{"id": "1182_1", "text": "small non-coding RNA (sncRNA) dysregulates in NDDs and sncRNA signatures have been explored for the diagnosis of NDDs, however, the performance of previous biomarkers is still better.", "tags": [{"end": 28, "start": 22, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 61, "start": 55, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 50, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 156, "tag": "ClinicalAttribute"}, {"end": 109, "start": 100, "tag": "HealthCareActivity"}, {"end": 143, "start": 132, "tag": "Finding"}, {"end": 20, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 20, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 62, "tag": "ResearchActivity"}]}{"id": "1182_2", "text": "Astrocyte dysfunction promotes neurodegeneration and thus derived scnRNA signatures could provide a more precise way to identify of changes related to NDD course and pathogenesis, and it could be useful for the dissection of mechanistic insights operating in NDD.", "tags": [{"end": 72, "start": 66, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 154, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 262, "start": 259, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 0, "tag": "Cell"}, {"end": 161, "start": 155, "tag": "TemporalConcept"}, {"end": 178, "start": 166, "tag": "PathologicFunction"}, {"end": 48, "start": 31, "tag": "CellOrMolecularDysfunction"}, {"end": 21, "start": 10, "tag": "PathologicFunction"}, {"end": 72, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 83, "start": 73, "tag": "ResearchActivity"}, {"end": 245, "start": 211, "tag": "ResearchActivity"}]}{"id": "1182_3", "text": "Often sncRNA are transported outside the cell by the action of secreted particles such as extracellular vesicles (EV), which protect sncRNA from degradation.", "tags": [{"end": 12, "start": 6, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 139, "start": 133, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 112, "start": 90, "tag": "CellComponent"}, {"end": 116, "start": 114, "tag": "CellComponent"}, {"end": 156, "start": 145, "tag": "NaturalPhenomenonOrProcess"}, {"end": 45, "start": 41, "tag": "Cell"}, {"end": 81, "start": 72, "tag": "Chemical"}, {"end": 12, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 133, "tag": "BiologicallyActiveSubstance"}]}{"id": "1182_4", "text": "Furthermore, EV associated sncRNA can cross the BBB to be found in easier to obtain peripheral samples, EVs also inherit cell-specific surface markers that can be used for the identification of Astrocyte Derived Extracellular Vesicles (ADEVs) in a peripheral sample.", "tags": [{"end": 33, "start": 27, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 203, "start": 194, "tag": "Cell"}, {"end": 234, "start": 194, "tag": "CellComponent"}, {"end": 107, "start": 104, "tag": "CellComponent"}, {"end": 15, "start": 13, "tag": "CellComponent"}, {"end": 150, "start": 143, "tag": "ClinicalAttribute"}, {"end": 102, "start": 95, "tag": "Substance"}, {"end": 102, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 258, "start": 248, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 121, "tag": "Cell"}, {"end": 150, "start": 135, "tag": "ClinicalAttribute"}, {"end": 51, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 241, "start": 236, "tag": "CellComponent"}, {"end": 33, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 265, "start": 259, "tag": "Substance"}, {"end": 265, "start": 259, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1182_5", "text": "By the study of the sncRNA transported in ADEVs it is possible to identify astrocyte specific sncRNA signatures that could show astrocyte dysfunction in a more simpler manner than previous methods.", "tags": [{"end": 26, "start": 20, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 100, "start": 94, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 12, "start": 7, "tag": "ResearchActivity"}, {"end": 84, "start": 75, "tag": "Cell"}, {"end": 137, "start": 128, "tag": "Cell"}, {"end": 149, "start": 138, "tag": "PathologicFunction"}, {"end": 26, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 42, "tag": "CellComponent"}, {"end": 111, "start": 101, "tag": "ResearchActivity"}, {"end": 149, "start": 128, "tag": "CellOrMolecularDysfunction"}]}{"id": "1182_6", "text": "However, sncRNA signatures in ADEV are not a copy of intracellular transcriptome and methodological aspects such as the yield of sncRNA produced in ADEV or the variable amount of ADEV captured after separation protocols must be considered.", "tags": [{"end": 15, "start": 9, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 135, "start": 129, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 80, "start": 67, "tag": "MolecularSequence"}, {"end": 66, "start": 53, "tag": "CellComponent"}, {"end": 183, "start": 179, "tag": "CellComponent"}, {"end": 152, "start": 148, "tag": "CellComponent"}, {"end": 219, "start": 199, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 16, "tag": "ResearchActivity"}, {"end": 34, "start": 30, "tag": "CellComponent"}]}{"id": "1182_7", "text": "Here we review the role as signaling molecules of ADEV derived sncRNA dysregulated in conditions associated with risk of neurodegeneration, providing an explanation of why to choose ADEV for the identification of astrocyte-specific transcriptome.", "tags": [{"end": 69, "start": 63, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 36, "start": 27, "tag": "CellFunction"}, {"end": 245, "start": 232, "tag": "MolecularSequence"}, {"end": 164, "start": 153, "tag": "Finding"}, {"end": 46, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 70, "tag": "PathologicFunction"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 117, "start": 113, "tag": "Finding"}, {"end": 222, "start": 213, "tag": "Cell"}, {"end": 138, "start": 121, "tag": "CellOrMolecularDysfunction"}, {"end": 46, "start": 37, "tag": "Substance"}, {"end": 54, "start": 50, "tag": "CellComponent"}, {"end": 186, "start": 182, "tag": "CellComponent"}, {"end": 69, "start": 63, "tag": "BiologicallyActiveSubstance"}]}{"id": "1182_8", "text": "Finally, we discuss possible limitations of this approach and the need to improve the detection limits of sncRNA for the use of ADEV derived sncRNA signatures.", "tags": [{"end": 81, "start": 74, "tag": "Finding"}, {"end": 112, "start": 106, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 147, "start": 141, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 95, "start": 86, "tag": "ResearchActivity"}, {"end": 95, "start": 86, "tag": "HealthCareActivity"}, {"end": 112, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 128, "tag": "CellComponent"}]}{"id": "1183_0", "text": "Pluripotent neural stem or progenitor cells (NSC/NPC) have been reported in the brains of adult preclinical models for decades, as have mesenchymal stem/stromal cells (MSC) been reported in a variety of tissues from adults.", "tags": [{"end": 126, "start": 119, "tag": "TemporalConcept"}, {"end": 43, "start": 27, "tag": "Cell"}, {"end": 52, "start": 49, "tag": "Cell"}, {"end": 222, "start": 216, "tag": "PopulationGroup"}, {"end": 114, "start": 96, "tag": "ResearchActivity"}, {"end": 171, "start": 168, "tag": "Cell"}, {"end": 95, "start": 90, "tag": "PopulationGroup"}, {"end": 86, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 210, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 45, "tag": "Cell"}, {"end": 166, "start": 136, "tag": "Cell"}, {"end": 43, "start": 38, "tag": "Cell"}, {"end": 23, "start": 0, "tag": "Cell"}]}{"id": "1183_1", "text": "Based on their in vitro capabilities, these cell types have been used extensively in attempts to repair/regenerate brain and connective tissues, respectively.", "tags": [{"end": 143, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 15, "tag": "ResearchActivity"}, {"end": 54, "start": 44, "tag": "Cell"}, {"end": 103, "start": 97, "tag": "BiologicFunction"}, {"end": 103, "start": 97, "tag": "HealthCareActivity"}]}{"id": "1183_2", "text": "In addition, MSC have also been used in attempts to repair compromised brain centres.", "tags": [{"end": 76, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 13, "tag": "Cell"}, {"end": 58, "start": 52, "tag": "BiologicFunction"}, {"end": 58, "start": 52, "tag": "HealthCareActivity"}]}{"id": "1183_3", "text": "However, success in treating chronic neural degenerative conditions such as Alzheimer's disease, Parkinson's disease, and others with NSC/NPC has been limited, as have the use of MSC in the treatment of chronic osteoarthritis, a condition affecting millions of individuals.", "tags": [{"end": 225, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 138, "tag": "Cell"}, {"end": 95, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 199, "start": 190, "tag": "HealthCareActivity"}, {"end": 199, "start": 190, "tag": "ResearchActivity"}, {"end": 272, "start": 261, "tag": "PopulationGroup"}, {"end": 182, "start": 179, "tag": "Cell"}, {"end": 36, "start": 29, "tag": "TemporalConcept"}, {"end": 210, "start": 203, "tag": "TemporalConcept"}, {"end": 67, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 134, "tag": "Cell"}]}{"id": "1183_4", "text": "However, connective tissues are likely less complex than neural tissues regarding cell organization and regulatory integration, but some insights have been gleaned from the studies regarding connective tissue healing with MSC that may inform studies attempting to initiate repair and regeneration of neural tissues compromised acutely or chronically by trauma or disease.", "tags": [{"end": 27, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 82, "tag": "CellFunction"}, {"end": 216, "start": 209, "tag": "BiologicFunction"}, {"end": 314, "start": 300, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 359, "start": 353, "tag": "InjuryOrPoisoning"}, {"end": 296, "start": 284, "tag": "BiologicFunction"}, {"end": 296, "start": 284, "tag": "HealthCareActivity"}, {"end": 296, "start": 284, "tag": "Finding"}, {"end": 180, "start": 173, "tag": "ResearchActivity"}, {"end": 249, "start": 242, "tag": "ResearchActivity"}, {"end": 208, "start": 191, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 225, "start": 222, "tag": "Cell"}, {"end": 279, "start": 273, "tag": "BiologicFunction"}, {"end": 279, "start": 273, "tag": "HealthCareActivity"}, {"end": 216, "start": 209, "tag": "HealthCareActivity"}]}{"id": "1183_5", "text": "This review will discuss the similarities and differences in the applications of NSC/NPC and MSC, where some lessons have been learned, and potential approaches that could be used going forward to enhance progress in the application of cellular therapy to facilitate repair and regeneration of complex structures in the brain.", "tags": [{"end": 252, "start": 236, "tag": "HealthCareActivity"}, {"end": 290, "start": 278, "tag": "BiologicFunction"}, {"end": 290, "start": 278, "tag": "HealthCareActivity"}, {"end": 290, "start": 278, "tag": "Finding"}, {"end": 88, "start": 85, "tag": "Cell"}, {"end": 213, "start": 205, "tag": "TemporalConcept"}, {"end": 325, "start": 320, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 57, "start": 46, "tag": "Finding"}, {"end": 252, "start": 245, "tag": "HealthCareActivity"}, {"end": 244, "start": 236, "tag": "Cell"}, {"end": 96, "start": 93, "tag": "Cell"}, {"end": 273, "start": 267, "tag": "BiologicFunction"}, {"end": 273, "start": 267, "tag": "HealthCareActivity"}, {"end": 84, "start": 81, "tag": "Cell"}]}{"id": "1183_6", "text": "In particular, variables that may need to be controlled to enhance success are discussed, as are different approaches such as the use of extracellular vesicles from stem/progenitor cells that could be used to stimulate endogenous cells to repair the tissues rather than consider cell replacement as the primary option.", "tags": [{"end": 186, "start": 165, "tag": "Cell"}, {"end": 295, "start": 279, "tag": "HealthCareActivity"}, {"end": 295, "start": 279, "tag": "ResearchActivity"}, {"end": 159, "start": 137, "tag": "CellComponent"}, {"end": 235, "start": 230, "tag": "Cell"}, {"end": 257, "start": 250, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 245, "start": 239, "tag": "BiologicFunction"}, {"end": 245, "start": 239, "tag": "HealthCareActivity"}]}{"id": "1183_7", "text": "Caveats to all these efforts relate to whether cellular repair initiatives will have long-term success if the initiators for neural diseases are not controlled, and whether such cellular initiatives will have long-term success in a subset of patients if the neural diseases are heterogeneous and have multiple etiologies.", "tags": [{"end": 94, "start": 85, "tag": "TemporalConcept"}, {"end": 218, "start": 209, "tag": "TemporalConcept"}, {"end": 159, "start": 149, "tag": "Finding"}, {"end": 250, "start": 242, "tag": "PatientOrDisabledGroup"}, {"end": 55, "start": 47, "tag": "Cell"}, {"end": 186, "start": 178, "tag": "Cell"}, {"end": 62, "start": 56, "tag": "BiologicFunction"}, {"end": 62, "start": 56, "tag": "HealthCareActivity"}, {"end": 140, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 273, "start": 258, "tag": "DiseaseOrSyndrome"}, {"end": 320, "start": 310, "tag": "Finding"}]}{"id": "1184_0", "text": "An established contribution of neuroinflammation to multiple brain pathologies has raised the requirement for therapeutic strategies to overcome it in order to prevent age- and disease-dependent cognitive decline.", "tags": [{"end": 132, "start": 110, "tag": "HealthCareActivity"}, {"end": 78, "start": 61, "tag": "PathologicFunction"}, {"end": 171, "start": 168, "tag": "OrganismAttribute"}, {"end": 48, "start": 31, "tag": "PathologicFunction"}, {"end": 212, "start": 195, "tag": "DiseaseOrSyndrome"}]}{"id": "1184_1", "text": "Mesenchymal stem cells (MSCs) produce multiple growth and neurotrophic factors and seem to evade immune rejection due to low expression of major histocompatibility complex class I molecules.", "tags": [{"end": 135, "start": 121, "tag": "Finding"}, {"end": 179, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 180, "tag": "Substance"}, {"end": 28, "start": 24, "tag": "Cell"}, {"end": 53, "start": 47, "tag": "BiologicFunction"}, {"end": 22, "start": 0, "tag": "Cell"}, {"end": 78, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 12, "tag": "Cell"}, {"end": 113, "start": 97, "tag": "PathologicFunction"}]}{"id": "1184_2", "text": "Therefore, MSCs are widely used in experiments and clinical trials of regenerative medicine.", "tags": [{"end": 91, "start": 70, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 15, "start": 11, "tag": "Cell"}, {"end": 46, "start": 35, "tag": "ResearchActivity"}, {"end": 66, "start": 51, "tag": "ResearchActivity"}]}{"id": "1184_3", "text": "This review summarizes recent data concerning the optimization of MSC use for therapeutic purposes with the emphasis on the achievements of the last 2 years.", "tags": [{"end": 62, "start": 50, "tag": "HealthCareActivity"}, {"end": 69, "start": 66, "tag": "Cell"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 156, "start": 151, "tag": "TemporalConcept"}, {"end": 34, "start": 30, "tag": "ResearchActivity"}, {"end": 29, "start": 23, "tag": "TemporalConcept"}, {"end": 98, "start": 78, "tag": "HealthCareActivity"}, {"end": 62, "start": 50, "tag": "ResearchActivity"}]}{"id": "1184_4", "text": "Specific attention is paid to extracellular vesicles secreted by MSCs and to the role of alpha 7 nicotinic acetylcholine receptors.", "tags": [{"end": 69, "start": 65, "tag": "Cell"}, {"end": 18, "start": 9, "tag": "BiologicFunction"}, {"end": 52, "start": 30, "tag": "CellComponent"}, {"end": 130, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 89, "tag": "BiologicallyActiveSubstance"}]}{"id": "1184_5", "text": "The reviewed data demonstrate that MSCs have a significant therapeutic potential in treating neuroinflammation-related cognitive disfunctions including age-related neurodegenerative diseases.", "tags": [{"end": 39, "start": 35, "tag": "Cell"}, {"end": 80, "start": 59, "tag": "HealthCareActivity"}, {"end": 12, "start": 4, "tag": "HealthCareActivity"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 190, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 13, "tag": "ResearchActivity"}, {"end": 110, "start": 93, "tag": "PathologicFunction"}, {"end": 141, "start": 119, "tag": "DiseaseOrSyndrome"}]}{"id": "1184_6", "text": "The novel data demonstrate that maximal therapeutic effect is being achieved when MSCs penetrate the brain and produce their stimulating factors in situ.", "tags": [{"end": 58, "start": 40, "tag": "ClinicalAttribute"}, {"end": 136, "start": 125, "tag": "NaturalPhenomenonOrProcess"}, {"end": 86, "start": 82, "tag": "Cell"}, {"end": 106, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 10, "tag": "ResearchActivity"}]}{"id": "1184_7", "text": "Consequently, therapeutic application using MSCs should include measures to facilitate their homing to the brain, support the survival in the brain microenvironment, and stimulate the production of neurotrophic and anti-inflammatory factors.", "tags": [{"end": 164, "start": 148, "tag": "NaturalPhenomenonOrProcess"}, {"end": 164, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 240, "start": 233, "tag": "AminoAcidPeptideOrProtein"}, {"end": 210, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 240, "start": 215, "tag": "PharmacologicSubstance"}, {"end": 232, "start": 215, "tag": "BiologicFunction"}, {"end": 232, "start": 215, "tag": "PharmacologicSubstance"}, {"end": 48, "start": 44, "tag": "Cell"}, {"end": 134, "start": 126, "tag": "CellFunction"}, {"end": 112, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 142, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 14, "tag": "HealthCareActivity"}, {"end": 240, "start": 233, "tag": "BiologicallyActiveSubstance"}, {"end": 210, "start": 198, "tag": "BiologicallyActiveSubstance"}]}{"id": "1184_8", "text": "These measures include but are not limited to genetic modification of MSCs and pre-conditioning before transplantation.", "tags": [{"end": 66, "start": 46, "tag": "ResearchActivity"}, {"end": 118, "start": 103, "tag": "HealthCareActivity"}, {"end": 74, "start": 70, "tag": "Cell"}, {"end": 95, "start": 79, "tag": "Finding"}]}{"id": "1185_0", "text": "Alzheimer's Disease (AD) and osteoporosis are both age-related degenerative diseases.", "tags": [{"end": 41, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 51, "tag": "OrganismAttribute"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 63, "tag": "DiseaseOrSyndrome"}]}{"id": "1185_1", "text": "Many studies indicate that these two diseases share common pathogenesis mechanisms.", "tags": [{"end": 71, "start": 59, "tag": "PathologicFunction"}, {"end": 12, "start": 5, "tag": "ResearchActivity"}]}{"id": "1185_2", "text": "In this review, the osteoporotic phenotype of AD mouse models was discussed, and shared mechanisms such as hormonal imbalance, genetic factors, similar signaling pathways and impaired neurotransmitters were identified.", "tags": [{"end": 61, "start": 46, "tag": "ExperimentalModelOfDisease"}, {"end": 125, "start": 107, "tag": "Finding"}, {"end": 170, "start": 152, "tag": "CellFunction"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 201, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 201, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 20, "tag": "Finding"}]}{"id": "1185_3", "text": "Moreover, the review provides recent data associated with these two diseases.", "tags": [{"end": 41, "start": 37, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 36, "start": 30, "tag": "TemporalConcept"}]}{"id": "1185_4", "text": "Furthermore, potential therapeutic approaches targeting both diseases were discussed.", "tags": [{"end": 45, "start": 23, "tag": "HealthCareActivity"}]}{"id": "1185_5", "text": "Thus, we proposed that preventing bone loss should be one of the most important treatment goals in patients with AD; treatment targeting brain disorders is also beneficial for osteoporosis.", "tags": [{"end": 43, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "PatientOrDisabledGroup"}, {"end": 89, "start": 80, "tag": "HealthCareActivity"}, {"end": 126, "start": 117, "tag": "HealthCareActivity"}, {"end": 89, "start": 80, "tag": "ResearchActivity"}, {"end": 126, "start": 117, "tag": "ResearchActivity"}, {"end": 152, "start": 137, "tag": "DiseaseOrSyndrome"}]}{"id": "1186_0", "text": "Synaptic transfer of tau has long been hypothesized from the human pathology pattern and has been demonstrated in vitro and in vivo, but the precise mechanisms remain unclear.", "tags": [{"end": 76, "start": 67, "tag": "PathologicFunction"}, {"end": 76, "start": 67, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 24, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 61, "tag": "Eukaryote"}, {"end": 24, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 111, "tag": "ResearchActivity"}, {"end": 131, "start": 124, "tag": "ResearchActivity"}, {"end": 17, "start": 0, "tag": "CellFunction"}]}{"id": "1186_1", "text": "Extracellular vesicles such as exosomes have been suggested as a mechanism, but not all tau is exosomal.", "tags": [{"end": 91, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 39, "start": 31, "tag": "CellComponent"}, {"end": 103, "start": 95, "tag": "CellComponent"}]}{"id": "1186_2", "text": "The present experiments use a novel flow cytometry assay to quantify depolarization of synaptosomes by KCl after loading with FM2-10, which induces a fluorescence reduction associated with synaptic vesicle release; the degree of reduction in cryopreserved human samples equaled that seen in fresh mouse synaptosomes.", "tags": [{"end": 83, "start": 69, "tag": "CellFunction"}, {"end": 99, "start": 87, "tag": "CellComponent"}, {"end": 106, "start": 103, "tag": "PharmacologicSubstance"}, {"end": 132, "start": 126, "tag": "Chemical"}, {"end": 296, "start": 291, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 315, "start": 303, "tag": "CellComponent"}, {"end": 255, "start": 242, "tag": "ResearchActivity"}, {"end": 23, "start": 12, "tag": "ResearchActivity"}, {"end": 56, "start": 36, "tag": "ResearchActivity"}, {"end": 261, "start": 256, "tag": "Eukaryote"}, {"end": 269, "start": 262, "tag": "Substance"}, {"end": 269, "start": 262, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 302, "start": 297, "tag": "Eukaryote"}, {"end": 162, "start": 150, "tag": "NaturalPhenomenonOrProcess"}, {"end": 172, "start": 163, "tag": "Finding"}, {"end": 238, "start": 229, "tag": "Finding"}, {"end": 172, "start": 163, "tag": "NaturalPhenomenonOrProcess"}, {"end": 238, "start": 229, "tag": "NaturalPhenomenonOrProcess"}, {"end": 205, "start": 189, "tag": "CellComponent"}, {"end": 213, "start": 189, "tag": "CellFunction"}]}{"id": "1186_3", "text": "Depolarization induced the release of vesicles in the size range of exosomes, along with tetraspanin markers of extracellular vesicles.", "tags": [{"end": 14, "start": 0, "tag": "CellFunction"}, {"end": 134, "start": 112, "tag": "CellComponent"}, {"end": 108, "start": 101, "tag": "ClinicalAttribute"}, {"end": 46, "start": 38, "tag": "CellComponent"}, {"end": 100, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 54, "tag": "OrganismAttribute"}, {"end": 76, "start": 68, "tag": "CellComponent"}, {"end": 46, "start": 27, "tag": "CellFunction"}]}{"id": "1186_4", "text": "A number of tau peptides were released, including tau oligomers; released tau was primarily unphosphorylated and C-terminal truncated, with A beta release just above background.", "tags": [{"end": 63, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 113, "tag": "CellOrMolecularDysfunction"}]}{"id": "1186_5", "text": "When exosomes were immunopurified from release supernatants, a prominent tau band showed a dark smeared appearance of SDS-stable oligomers along with the exosomal marker syntenin-1, and these exosomes induced aggregation in the HEK tau biosensor assay.", "tags": [{"end": 180, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 180, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 231, "start": 228, "tag": "GeneOrGenome"}, {"end": 245, "start": 236, "tag": "ManufacturedObject"}, {"end": 114, "start": 104, "tag": "OrganismAttribute"}, {"end": 59, "start": 47, "tag": "Substance"}, {"end": 251, "start": 228, "tag": "ResearchActivity"}, {"end": 169, "start": 163, "tag": "ClinicalAttribute"}, {"end": 76, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 235, "start": 232, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 235, "start": 232, "tag": "BiologicallyActiveSubstance"}, {"end": 220, "start": 209, "tag": "CellFunction"}, {"end": 220, "start": 209, "tag": "ResearchActivity"}, {"end": 13, "start": 5, "tag": "CellComponent"}, {"end": 200, "start": 192, "tag": "CellComponent"}, {"end": 162, "start": 154, "tag": "CellComponent"}, {"end": 33, "start": 19, "tag": "ResearchActivity"}, {"end": 121, "start": 118, "tag": "Chemical"}, {"end": 121, "start": 118, "tag": "PharmacologicSubstance"}, {"end": 138, "start": 129, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1186_6", "text": "However, the flow-through did not seed aggregation.", "tags": [{"end": 50, "start": 39, "tag": "CellFunction"}, {"end": 50, "start": 39, "tag": "ResearchActivity"}]}{"id": "1186_7", "text": "Size exclusion chromatography of purified released exosomes shows faint signals from tau in the same fractions that show a CD63 band, an exosomal size signal, and seeding activity.", "tags": [{"end": 29, "start": 0, "tag": "ResearchActivity"}, {"end": 88, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 72, "tag": "CellFunction"}, {"end": 127, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 146, "tag": "OrganismAttribute"}, {"end": 127, "start": 123, "tag": "GeneOrGenome"}, {"end": 59, "start": 51, "tag": "CellComponent"}, {"end": 145, "start": 137, "tag": "CellComponent"}, {"end": 179, "start": 163, "tag": "CellFunction"}]}{"id": "1186_8", "text": "Crude synaptosomes from control, tauopathy, and AD cases demonstrated lower seeding in tauopathy compared to AD that is correlated with the measured A beta 42 level.", "tags": [{"end": 83, "start": 76, "tag": "ResearchActivity"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 6, "tag": "CellComponent"}]}{"id": "1186_9", "text": "These results show that AD synapses release exosomal tau that is C-terminal-truncated, oligomeric, and with seeding activity that is enhanced by A beta.", "tags": [{"end": 26, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 44, "tag": "CellComponent"}, {"end": 35, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 108, "tag": "CellFunction"}, {"end": 75, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 65, "tag": "CellOrMolecularDysfunction"}]}{"id": "1186_10", "text": "Taken together with previous findings, these results are consistent with a direct prion-like heterotypic seeding of tau by A beta within synaptic terminals, with subsequent loading of aggregated tau onto exosomes that are released and competent for tau seeding activity.", "tags": [{"end": 260, "start": 253, "tag": "ResearchActivity"}, {"end": 155, "start": 137, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 198, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 252, "start": 249, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 198, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 252, "start": 249, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 212, "start": 204, "tag": "CellComponent"}, {"end": 269, "start": 253, "tag": "CellFunction"}]}{"id": "1186_11", "text": "A novel assay quantifies depolarization of synaptosomes from Alzheimer's cortex, and the authors show that tau released from these samples is unphosphorylated and C-terminal-truncated.", "tags": [{"end": 39, "start": 25, "tag": "CellFunction"}, {"end": 55, "start": 43, "tag": "CellComponent"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 110, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 131, "tag": "Substance"}, {"end": 138, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 173, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 163, "tag": "CellOrMolecularDysfunction"}]}{"id": "1186_12", "text": "Most tau is exosomal, and free-floating tau did not seed aggregation.", "tags": [{"end": 8, "start": 5, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 5, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 57, "tag": "CellFunction"}, {"end": 68, "start": 57, "tag": "ResearchActivity"}, {"end": 20, "start": 12, "tag": "CellComponent"}]}{"id": "1186_13", "text": "Seeding activity was lower in tauopathy than AD, and strongly related to amyloid level.", "tags": [{"end": 47, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 0, "tag": "CellFunction"}]}{"id": "1187_0", "text": "Background: Alzheimer's disease (AD) is a neurodegenerative impairment mainly recognized by memory loss and cognitive deficits.", "tags": [{"end": 126, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 12, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 42, "tag": "CellOrMolecularDysfunction"}, {"end": 103, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 92, "tag": "SignOrSymptom"}]}{"id": "1187_1", "text": "However, the current therapies against AD are mostly limited to palliative medications, prompting researchers to investigate more efficient therapeutic approaches for AD, such as stem cell therapy.", "tags": [{"end": 86, "start": 64, "tag": "PharmacologicSubstance"}, {"end": 196, "start": 179, "tag": "HealthCareActivity"}, {"end": 41, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 13, "tag": "TemporalConcept"}, {"end": 109, "start": 98, "tag": "ResearchActivity"}, {"end": 30, "start": 21, "tag": "HealthCareActivity"}, {"end": 162, "start": 140, "tag": "HealthCareActivity"}]}{"id": "1187_2", "text": "Recent evidence has proposed that extensive neuronal and synaptic loss and altered adult neurogenesis, which is perceived pivotal in terms of plasticity and network maintenance, occurs early in the course of AD, which exacerbates neuronal vulnerability to AD.", "tags": [{"end": 252, "start": 239, "tag": "ClinicalAttribute"}, {"end": 70, "start": 57, "tag": "CellOrMolecularDysfunction"}, {"end": 204, "start": 198, "tag": "TemporalConcept"}, {"end": 152, "start": 142, "tag": "NaturalPhenomenonOrProcess"}, {"end": 152, "start": 142, "tag": "CellFunction"}, {"end": 210, "start": 208, "tag": "DiseaseOrSyndrome"}, {"end": 258, "start": 256, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 7, "tag": "Finding"}, {"end": 52, "start": 44, "tag": "Cell"}, {"end": 238, "start": 230, "tag": "Cell"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 176, "start": 165, "tag": "BiologicFunction"}, {"end": 101, "start": 89, "tag": "BiologicFunction"}, {"end": 88, "start": 83, "tag": "PopulationGroup"}, {"end": 164, "start": 157, "tag": "PopulationGroup"}, {"end": 164, "start": 157, "tag": "CellFunction"}, {"end": 101, "start": 89, "tag": "PathologicFunction"}, {"end": 82, "start": 75, "tag": "PathologicFunction"}]}{"id": "1187_3", "text": "Thus, regeneration and replenishing the depleted neuronal networks by strengthening the endogenous repair mechanisms or exogenous stem cells and their cargoes is a rational therapeutic approach.", "tags": [{"end": 193, "start": 173, "tag": "HealthCareActivity"}, {"end": 18, "start": 6, "tag": "BiologicFunction"}, {"end": 18, "start": 6, "tag": "HealthCareActivity"}, {"end": 57, "start": 49, "tag": "Cell"}, {"end": 140, "start": 130, "tag": "Cell"}, {"end": 158, "start": 151, "tag": "CellComponent"}, {"end": 158, "start": 151, "tag": "CellFunction"}, {"end": 105, "start": 99, "tag": "BiologicFunction"}, {"end": 105, "start": 99, "tag": "HealthCareActivity"}, {"end": 66, "start": 58, "tag": "CellFunction"}]}{"id": "1187_4", "text": "Currently, several stem cell-based therapies as well as stem cell products like exosomes, have shown promising results in the early diagnosis of AD.", "tags": [{"end": 9, "start": 0, "tag": "TemporalConcept"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 132, "tag": "HealthCareActivity"}, {"end": 28, "start": 24, "tag": "Cell"}, {"end": 65, "start": 61, "tag": "Cell"}, {"end": 44, "start": 35, "tag": "HealthCareActivity"}, {"end": 88, "start": 80, "tag": "CellComponent"}, {"end": 28, "start": 19, "tag": "Cell"}, {"end": 65, "start": 56, "tag": "Cell"}, {"end": 141, "start": 126, "tag": "HealthCareActivity"}]}{"id": "1187_5", "text": "Objective: This review begins with a comparison between AD and normal aging pathophysiology and a discussion on open questions in the field.", "tags": [{"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 16, "tag": "ResearchActivity"}, {"end": 22, "start": 16, "tag": "HealthCareActivity"}, {"end": 69, "start": 63, "tag": "Finding"}, {"end": 91, "start": 76, "tag": "PathologicFunction"}, {"end": 91, "start": 76, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 75, "start": 70, "tag": "BiologicFunction"}, {"end": 75, "start": 70, "tag": "CellFunction"}, {"end": 47, "start": 37, "tag": "ResearchActivity"}, {"end": 108, "start": 98, "tag": "ResearchActivity"}]}{"id": "1187_6", "text": "Next, summarizing the current stem cell-based therapeutic and diagnostic approaches, we declare the advantages and disadvantages of each method.", "tags": [{"end": 39, "start": 35, "tag": "Cell"}, {"end": 29, "start": 22, "tag": "TemporalConcept"}, {"end": 143, "start": 137, "tag": "ResearchActivity"}, {"end": 143, "start": 137, "tag": "HealthCareActivity"}, {"end": 39, "start": 30, "tag": "Cell"}, {"end": 83, "start": 46, "tag": "HealthCareActivity"}]}{"id": "1187_7", "text": "Also, we comprehensively evaluate the human clinical trials of stem cell therapies for AD.", "tags": [{"end": 82, "start": 63, "tag": "HealthCareActivity"}, {"end": 82, "start": 68, "tag": "HealthCareActivity"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 38, "tag": "Eukaryote"}, {"end": 82, "start": 73, "tag": "HealthCareActivity"}, {"end": 72, "start": 63, "tag": "Cell"}, {"end": 59, "start": 44, "tag": "ResearchActivity"}]}{"id": "1187_8", "text": "Methodology: Peer-reviewed reports were extracted through Embase, PubMed, and Google Scholar until 2021.", "tags": [{"end": 92, "start": 78, "tag": "HealthCareRelatedOrganization"}, {"end": 34, "start": 13, "tag": "ResearchActivity"}, {"end": 72, "start": 66, "tag": "HealthCareRelatedOrganization"}, {"end": 64, "start": 58, "tag": "HealthCareRelatedOrganization"}]}{"id": "1187_9", "text": "Results: With several ongoing clinical trials, stem cells and their derivatives (e.g., exosomes) are an emerging and encouraging field in diagnosing and treating neurodegenerative diseases.", "tags": [{"end": 29, "start": 22, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 188, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 138, "tag": "HealthCareActivity"}, {"end": 57, "start": 47, "tag": "Cell"}, {"end": 95, "start": 87, "tag": "CellComponent"}, {"end": 45, "start": 30, "tag": "ResearchActivity"}]}{"id": "1187_10", "text": "Although stem cell therapies have been successful in animal models, numerous clinical trials in AD patients have yielded unpromising results, which we will further discuss.", "tags": [{"end": 28, "start": 9, "tag": "HealthCareActivity"}, {"end": 28, "start": 14, "tag": "HealthCareActivity"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "PatientOrDisabledGroup"}, {"end": 28, "start": 19, "tag": "HealthCareActivity"}, {"end": 66, "start": 53, "tag": "ResearchActivity"}, {"end": 18, "start": 9, "tag": "Cell"}, {"end": 92, "start": 77, "tag": "ResearchActivity"}]}{"id": "1188_0", "text": "Amyloid beta (A beta) peptides generated from the amyloid precursor protein (APP) play a critical role in the development of Alzheimer's disease (AD) pathology.", "tags": [{"end": 144, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 150, "tag": "PathologicFunction"}, {"end": 159, "start": 150, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 121, "start": 110, "tag": "BiologicFunction"}, {"end": 121, "start": 110, "tag": "CellFunction"}, {"end": 80, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 77, "tag": "GeneOrGenome"}, {"end": 80, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1188_1", "text": "A beta-containing neuronal exosomes, which represent a novel form of intercellular communication, have been shown to influence the function/vulnerability of neurons in AD.", "tags": [{"end": 170, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 18, "tag": "Cell"}, {"end": 6, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 157, "tag": "Cell"}, {"end": 96, "start": 69, "tag": "CellFunction"}, {"end": 96, "start": 83, "tag": "HealthCareActivity"}, {"end": 96, "start": 83, "tag": "CellFunction"}, {"end": 35, "start": 27, "tag": "CellComponent"}]}{"id": "1188_2", "text": "Unlike neurons, the significance of exosomes derived from astrocytes remains unclear.", "tags": [{"end": 14, "start": 7, "tag": "Cell"}, {"end": 68, "start": 58, "tag": "Cell"}, {"end": 44, "start": 36, "tag": "CellComponent"}]}{"id": "1188_3", "text": "In this study, we evaluated the significance of exosomes derived from U18666A-induced cholesterol-accumulated astrocytes in the development of AD pathology.", "tags": [{"end": 97, "start": 86, "tag": "Chemical"}, {"end": 97, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 155, "start": 146, "tag": "PathologicFunction"}, {"end": 155, "start": 146, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 139, "start": 128, "tag": "BiologicFunction"}, {"end": 139, "start": 128, "tag": "CellFunction"}, {"end": 120, "start": 110, "tag": "Cell"}, {"end": 56, "start": 48, "tag": "CellComponent"}, {"end": 77, "start": 70, "tag": "Chemical"}, {"end": 77, "start": 70, "tag": "PharmacologicSubstance"}]}{"id": "1188_4", "text": "Our results show that cholesterol accumulation decreases exosome secretion, whereas lowering cholesterol increases exosome secretion, from cultured astrocytes.", "tags": [{"end": 33, "start": 22, "tag": "Chemical"}, {"end": 104, "start": 93, "tag": "Chemical"}, {"end": 33, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 34, "tag": "Finding"}, {"end": 64, "start": 57, "tag": "CellComponent"}, {"end": 122, "start": 115, "tag": "CellComponent"}, {"end": 74, "start": 65, "tag": "CellFunction"}, {"end": 132, "start": 123, "tag": "CellFunction"}, {"end": 74, "start": 65, "tag": "BiologicFunction"}, {"end": 132, "start": 123, "tag": "BiologicFunction"}, {"end": 158, "start": 148, "tag": "Cell"}, {"end": 147, "start": 139, "tag": "ResearchActivity"}, {"end": 74, "start": 57, "tag": "CellFunction"}, {"end": 132, "start": 115, "tag": "CellFunction"}]}{"id": "1188_5", "text": "Interestingly, exosomes secreted from U18666A-treated astrocytes contain higher levels of APP, APP-C-terminal fragments, soluble APP, APP secretases and A beta(1-40) than exosomes secreted from control astrocytes.", "tags": [{"end": 128, "start": 121, "tag": "CellComponent"}, {"end": 148, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 90, "tag": "GeneOrGenome"}, {"end": 98, "start": 95, "tag": "GeneOrGenome"}, {"end": 132, "start": 129, "tag": "GeneOrGenome"}, {"end": 137, "start": 134, "tag": "GeneOrGenome"}, {"end": 93, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 54, "tag": "Cell"}, {"end": 212, "start": 202, "tag": "Cell"}, {"end": 23, "start": 15, "tag": "CellComponent"}, {"end": 179, "start": 171, "tag": "CellComponent"}, {"end": 119, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 38, "tag": "Chemical"}, {"end": 45, "start": 38, "tag": "PharmacologicSubstance"}, {"end": 165, "start": 153, "tag": "BiologicallyActiveSubstance"}]}{"id": "1188_6", "text": "Furthermore, we show that exosomes derived from U18666A-treated astrocytes can lead to neurodegeneration, which is attenuated by decreasing A beta production or by neutralizing exosomal A beta peptide with an anti-A beta antibody.", "tags": [{"end": 139, "start": 129, "tag": "Finding"}, {"end": 192, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 87, "tag": "CellOrMolecularDysfunction"}, {"end": 74, "start": 64, "tag": "Cell"}, {"end": 157, "start": 140, "tag": "CellFunction"}, {"end": 200, "start": 193, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 26, "tag": "CellComponent"}, {"end": 185, "start": 177, "tag": "CellComponent"}, {"end": 55, "start": 48, "tag": "Chemical"}, {"end": 55, "start": 48, "tag": "PharmacologicSubstance"}, {"end": 229, "start": 209, "tag": "BiologicallyActiveSubstance"}, {"end": 229, "start": 209, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1188_7", "text": "These results, taken together, suggest that exosomes derived from cholesterol-accumulated astrocytes can play an important role in trafficking APP/A beta peptides and influencing neuronal viability in the affected regions of the AD brain.", "tags": [{"end": 142, "start": 131, "tag": "CellFunction"}, {"end": 77, "start": 66, "tag": "Chemical"}, {"end": 77, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 231, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 237, "start": 232, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 187, "start": 179, "tag": "Cell"}, {"end": 100, "start": 90, "tag": "Cell"}, {"end": 52, "start": 44, "tag": "CellComponent"}, {"end": 197, "start": 188, "tag": "CellFunction"}]}{"id": "1189_0", "text": "Background: The identification of blood-borne biomarkers for the diagnosis and prognosis of Alzheimer's disease and related dementias is more feasible at the population level than obtaining cerebrospinal fluid or neuroimaging markers.", "tags": [{"end": 225, "start": 213, "tag": "HealthCareActivity"}, {"end": 133, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 233, "start": 226, "tag": "ClinicalAttribute"}, {"end": 56, "start": 46, "tag": "ClinicalAttribute"}, {"end": 39, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 65, "tag": "HealthCareActivity"}, {"end": 209, "start": 190, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 158, "tag": "PopulationGroup"}, {"end": 88, "start": 79, "tag": "HealthCareActivity"}]}{"id": "1189_1", "text": "Objective: This study determined the association of blood microvesicles, derived from cells of the neurovascular unit, with brain amyloid-beta deposition in menopausal women.", "tags": [{"end": 167, "start": 157, "tag": "BiologicFunction"}, {"end": 117, "start": 99, "tag": "Cell"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 129, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 86, "tag": "Cell"}, {"end": 173, "start": 168, "tag": "PopulationGroup"}, {"end": 71, "start": 58, "tag": "CellComponent"}, {"end": 153, "start": 130, "tag": "PathologicFunction"}]}{"id": "1189_2", "text": "Methods: A subset ofwomen from the Kronos Early Estrogen Prevention Study underwent brain amyloid-beta positron emission tomography three years following cessation of study treatment with placebo (PL, n = 29), transdermal 17 beta-estradiol (tE2; n = 21), or oral conjugated equine estrogen (oCEE; n = 17).", "tags": [{"end": 239, "start": 225, "tag": "Chemical"}, {"end": 289, "start": 258, "tag": "PharmacologicSubstance"}, {"end": 289, "start": 281, "tag": "PharmacologicSubstance"}, {"end": 195, "start": 188, "tag": "HealthCareActivity"}, {"end": 262, "start": 258, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 167, "tag": "ResearchActivity"}, {"end": 89, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 173, "tag": "HealthCareActivity"}, {"end": 182, "start": 173, "tag": "ResearchActivity"}, {"end": 143, "start": 138, "tag": "TemporalConcept"}, {"end": 131, "start": 103, "tag": "HealthCareActivity"}, {"end": 102, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 35, "tag": "ResearchActivity"}, {"end": 280, "start": 274, "tag": "Eukaryote"}, {"end": 289, "start": 281, "tag": "BiologicallyActiveSubstance"}, {"end": 289, "start": 281, "tag": "Chemical"}, {"end": 239, "start": 210, "tag": "PharmacologicSubstance"}, {"end": 239, "start": 225, "tag": "BiologicallyActiveSubstance"}]}{"id": "1189_3", "text": "Isolated peripheral venous blood microvesicles were analyzed by digital flow cytometry using fluorophore conjugated antibodies directed toward total tau, amyloid-beta 1-42 (A beta(1-42)), neuron specific class III beta-tubulin (Tuj1), microglia ionized calcium -binding adaptor molecule 1(Iba1), glial fibrillary acid protein (GFAP), and low density lipoprotein receptor-related protein1 (LRP1).", "tags": [{"end": 288, "start": 245, "tag": "BiologicallyActiveSubstance"}, {"end": 325, "start": 296, "tag": "AminoAcidPeptideOrProtein"}, {"end": 387, "start": 338, "tag": "BiologicallyActiveSubstance"}, {"end": 387, "start": 338, "tag": "AminoAcidPeptideOrProtein"}, {"end": 226, "start": 188, "tag": "AminoAcidPeptideOrProtein"}, {"end": 226, "start": 188, "tag": "BiologicallyActiveSubstance"}, {"end": 293, "start": 289, "tag": "AminoAcidPeptideOrProtein"}, {"end": 293, "start": 289, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 52, "tag": "ResearchActivity"}, {"end": 244, "start": 235, "tag": "Cell"}, {"end": 171, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 393, "start": 389, "tag": "GeneOrGenome"}, {"end": 393, "start": 389, "tag": "BiologicallyActiveSubstance"}, {"end": 393, "start": 389, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 33, "tag": "CellComponent"}, {"end": 331, "start": 327, "tag": "AminoAcidPeptideOrProtein"}, {"end": 331, "start": 327, "tag": "BiologicallyActiveSubstance"}, {"end": 331, "start": 327, "tag": "GeneOrGenome"}, {"end": 86, "start": 64, "tag": "ResearchActivity"}, {"end": 104, "start": 93, "tag": "Chemical"}, {"end": 232, "start": 228, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 228, "tag": "BiologicallyActiveSubstance"}, {"end": 288, "start": 245, "tag": "AminoAcidPeptideOrProtein"}, {"end": 325, "start": 296, "tag": "BiologicallyActiveSubstance"}, {"end": 185, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 185, "start": 173, "tag": "BiologicallyActiveSubstance"}]}{"id": "1189_4", "text": "Principal components analysis reduced the dimensionality of these selected six markers to two principal components (PCs).", "tags": [{"end": 86, "start": 79, "tag": "ClinicalAttribute"}, {"end": 29, "start": 0, "tag": "ResearchActivity"}]}{"id": "1189_5", "text": "Proportional odds ordinal logistic regression analysis was used with amyloid-beta deposition regressed on these PCs.", "tags": [{"end": 54, "start": 0, "tag": "ResearchActivity"}, {"end": 76, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 69, "tag": "PathologicFunction"}]}{"id": "1189_6", "text": "Results: Only the number of microvesicles positive for A beta(1-42) differed statistically among prior treatment groups (median [IQR]: 6.06 [2.11, 12.55] in PL; 2.49 [0.73, 3.59] in tE2; and 4.96 [0.83, 10.31] in oCEE; p = 0.032).", "tags": [{"end": 159, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 157, "tag": "GeneOrGenome"}, {"end": 159, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 121, "tag": "ResearchActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 112, "start": 103, "tag": "HealthCareActivity"}, {"end": 112, "start": 103, "tag": "ResearchActivity"}, {"end": 41, "start": 28, "tag": "CellComponent"}, {"end": 67, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 55, "tag": "BiologicallyActiveSubstance"}]}{"id": "1189_7", "text": "The joint association between the 2 PCs and brain amyloid-beta deposition was significant (p = 0.045).", "tags": [{"end": 39, "start": 36, "tag": "Cell"}, {"end": 49, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 50, "tag": "PathologicFunction"}]}{"id": "1189_8", "text": "Conclusion: Six selected markers expressing peripheral blood microvesicles derived from cells of the neurovascular unit, when summarized into two principal components, were associated with brain amyloid-beta deposition.", "tags": [{"end": 43, "start": 33, "tag": "CellFunction"}, {"end": 119, "start": 101, "tag": "Cell"}, {"end": 60, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 25, "tag": "ClinicalAttribute"}, {"end": 194, "start": 189, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 88, "tag": "Cell"}, {"end": 54, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 202, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 61, "tag": "CellComponent"}, {"end": 207, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 195, "tag": "PathologicFunction"}]}{"id": "1190_0", "text": "Neurodegenerative diseases (ND) remains to be one of the biggest burdens on healthcare systems and serves as a leading cause of disability and death.", "tags": [{"end": 30, "start": 28, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 76, "tag": "HealthCareRelatedOrganization"}, {"end": 148, "start": 143, "tag": "BiologicFunction"}, {"end": 148, "start": 143, "tag": "PathologicFunction"}, {"end": 26, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 128, "tag": "Finding"}]}{"id": "1190_1", "text": "Alzheimer's disease (AD) is among the most common of such disorders, followed by Parkinson's disease (PD).", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}]}{"id": "1190_2", "text": "The basic molecular details of disease initiation and pathology are still under research.", "tags": [{"end": 88, "start": 80, "tag": "ResearchActivity"}, {"end": 63, "start": 54, "tag": "PathologicFunction"}, {"end": 63, "start": 54, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 49, "start": 39, "tag": "TemporalConcept"}]}{"id": "1190_3", "text": "Only recently, the role of exosomes has been linked to the initiation and progression of these neurodegenerative diseases.", "tags": [{"end": 85, "start": 74, "tag": "PathologicFunction"}, {"end": 85, "start": 74, "tag": "TemporalConcept"}, {"end": 35, "start": 27, "tag": "CellComponent"}, {"end": 121, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 5, "tag": "TemporalConcept"}, {"end": 69, "start": 59, "tag": "TemporalConcept"}]}{"id": "1190_4", "text": "Exosomes are small bilipid layer enclosed extracellular vesicles, which were once considered as a cellular waste and functionless.", "tags": [{"end": 32, "start": 13, "tag": "CellComponent"}, {"end": 64, "start": 42, "tag": "CellComponent"}, {"end": 8, "start": 0, "tag": "CellComponent"}]}{"id": "1190_5", "text": "These nano-vesicles of 30-150 nm in diameter carry specific proteins, lipids, functional mRNAs, and high amounts of non-coding RNAs (miRNAs, lncRNAs, and circRNAs).", "tags": [{"end": 162, "start": 154, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 94, "start": 89, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 68, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 70, "tag": "Chemical"}, {"end": 139, "start": 133, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 139, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 6, "tag": "CellComponent"}, {"end": 131, "start": 116, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 148, "start": 141, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 131, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 154, "tag": "BiologicallyActiveSubstance"}]}{"id": "1190_6", "text": "As the exosomes content is known to vary as per their originating and recipient cells, these vesicles can be utilized as a diagnostic biomarker for early disease detection.", "tags": [{"end": 85, "start": 70, "tag": "Cell"}, {"end": 15, "start": 7, "tag": "CellComponent"}, {"end": 143, "start": 123, "tag": "ClinicalAttribute"}, {"end": 101, "start": 93, "tag": "CellComponent"}, {"end": 171, "start": 148, "tag": "HealthCareActivity"}]}{"id": "1190_7", "text": "Here we review exosomes, their biogenesis, composition, and role in neurodegenerative diseases.", "tags": [{"end": 23, "start": 15, "tag": "CellComponent"}, {"end": 94, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 41, "start": 31, "tag": "CellFunction"}]}{"id": "1190_8", "text": "We have also provided details for their characterization through an array of available techniques.", "tags": [{"end": 97, "start": 87, "tag": "HealthCareActivity"}, {"end": 97, "start": 87, "tag": "ResearchActivity"}, {"end": 56, "start": 40, "tag": "ResearchActivity"}]}{"id": "1190_9", "text": "Their updated role in neurodegenerative disease pathology is also discussed.", "tags": [{"end": 57, "start": 48, "tag": "PathologicFunction"}, {"end": 47, "start": 22, "tag": "DiseaseOrSyndrome"}]}{"id": "1190_10", "text": "Finally, we have shed light on a novel field of salivary exosomes as a potential candidate for early diagnosis in neurodegenerative diseases and compared the biomarkers of salivary exosomes with other blood/cerebrospinal fluid (CSF) based exosomes within these neurological ailments.", "tags": [{"end": 56, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 180, "start": 172, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 206, "start": 201, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 231, "start": 228, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 226, "start": 207, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 57, "tag": "CellComponent"}, {"end": 189, "start": 181, "tag": "CellComponent"}, {"end": 247, "start": 239, "tag": "CellComponent"}, {"end": 168, "start": 158, "tag": "ClinicalAttribute"}, {"end": 140, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 95, "tag": "HealthCareActivity"}]}{"id": "1191_0", "text": "Alzheimer's disease (AD) is a major cause of age-related dementia and is characterized by progressive brain damage that gradually destroys memory and the ability to learn, which ultimately leads to the decline of a patient's ability to perform daily activities.", "tags": [{"end": 145, "start": 139, "tag": "BiologicFunction"}, {"end": 170, "start": 154, "tag": "BiologicFunction"}, {"end": 114, "start": 102, "tag": "InjuryOrPoisoning"}, {"end": 249, "start": 244, "tag": "TemporalConcept"}, {"end": 48, "start": 45, "tag": "OrganismAttribute"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 222, "start": 215, "tag": "PatientOrDisabledGroup"}, {"end": 161, "start": 154, "tag": "OrganismAttribute"}, {"end": 232, "start": 225, "tag": "OrganismAttribute"}, {"end": 101, "start": 90, "tag": "TemporalConcept"}, {"end": 209, "start": 202, "tag": "Finding"}]}{"id": "1191_1", "text": "Although some of the pharmacological treatments of AD are available for symptomatic relief, they are not able to limit the progression of AD and have several side effects.", "tags": [{"end": 90, "start": 84, "tag": "Finding"}, {"end": 83, "start": 72, "tag": "SignOrSymptom"}, {"end": 134, "start": 123, "tag": "PathologicFunction"}, {"end": 134, "start": 123, "tag": "TemporalConcept"}, {"end": 53, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 21, "tag": "HealthCareActivity"}, {"end": 47, "start": 21, "tag": "ResearchActivity"}, {"end": 170, "start": 158, "tag": "PathologicFunction"}]}{"id": "1191_2", "text": "Mesenchymal stem/stromal cells (MSCs) could be a potential therapeutic option for treating AD due to their immunomodulatory, anti-inflammatory, regenerative, antioxidant, anti-apoptotic, and neuroprotective effects.", "tags": [{"end": 30, "start": 0, "tag": "Cell"}, {"end": 123, "start": 107, "tag": "PharmacologicSubstance"}, {"end": 123, "start": 107, "tag": "BiologicFunction"}, {"end": 123, "start": 107, "tag": "HealthCareActivity"}, {"end": 169, "start": 158, "tag": "PharmacologicSubstance"}, {"end": 169, "start": 158, "tag": "CellFunction"}, {"end": 214, "start": 191, "tag": "Finding"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 32, "tag": "Cell"}, {"end": 142, "start": 125, "tag": "BiologicFunction"}, {"end": 142, "start": 125, "tag": "PharmacologicSubstance"}, {"end": 77, "start": 49, "tag": "Finding"}, {"end": 185, "start": 171, "tag": "CellFunction"}]}{"id": "1191_3", "text": "MSCs not only secret neuroprotective and anti-inflammatory factors to promote the survival of neurons, but they also transfer functional mitochondria and miRNAs to boost their bioenergetic profile as well as improve microglial clearance of accumulated protein aggregates.", "tags": [{"end": 270, "start": 252, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 137, "tag": "CellComponent"}, {"end": 101, "start": 82, "tag": "CellFunction"}, {"end": 36, "start": 21, "tag": "CellFunction"}, {"end": 160, "start": 154, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 160, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 226, "start": 216, "tag": "Cell"}, {"end": 236, "start": 227, "tag": "NaturalPhenomenonOrProcess"}, {"end": 4, "start": 0, "tag": "Cell"}, {"end": 196, "start": 176, "tag": "ResearchActivity"}, {"end": 66, "start": 41, "tag": "PharmacologicSubstance"}, {"end": 58, "start": 41, "tag": "BiologicFunction"}, {"end": 58, "start": 41, "tag": "PharmacologicSubstance"}]}{"id": "1191_4", "text": "This review focuses on different clinical and preclinical studies using MSC as a therapy for treating AD, their outcomes, limitations and the strategies to potentiate their clinical translation.", "tags": [{"end": 65, "start": 46, "tag": "ResearchActivity"}, {"end": 120, "start": 112, "tag": "PathologicFunction"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 72, "tag": "Cell"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 88, "start": 81, "tag": "HealthCareActivity"}, {"end": 152, "start": 142, "tag": "ResearchActivity"}, {"end": 152, "start": 142, "tag": "BiologicFunction"}, {"end": 193, "start": 173, "tag": "ResearchActivity"}]}{"id": "1192_0", "text": "Extracellular vesicles (EVs) are nanoscale vesicles secreted into the extracellular space by all cell types, including neurons and astrocytes in the brain.", "tags": [{"end": 51, "start": 33, "tag": "CellComponent"}, {"end": 89, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 154, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 126, "start": 119, "tag": "Cell"}, {"end": 141, "start": 131, "tag": "Cell"}, {"end": 107, "start": 97, "tag": "Cell"}]}{"id": "1192_1", "text": "EVs play pivotal roles in physiological and pathophysiological processes such as waste removal, cell-to-cell communication and transport of either protective or pathogenic material into the extracellular space.", "tags": [{"end": 94, "start": 87, "tag": "HealthCareActivity"}, {"end": 209, "start": 190, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 180, "start": 172, "tag": "Substance"}, {"end": 3, "start": 0, "tag": "CellComponent"}, {"end": 171, "start": 161, "tag": "PathologicFunction"}, {"end": 122, "start": 96, "tag": "CellFunction"}, {"end": 72, "start": 44, "tag": "PathologicFunction"}, {"end": 62, "start": 44, "tag": "PathologicFunction"}]}{"id": "1192_2", "text": "Here we describe a detailed protocol for the reliable and consistent isolation of EVs from both murine and human brains, intended for anyone with basic laboratory experience and performed in a total time of 27 h.", "tags": [{"end": 36, "start": 28, "tag": "ResearchActivity"}, {"end": 173, "start": 152, "tag": "ResearchActivity"}, {"end": 85, "start": 82, "tag": "CellComponent"}, {"end": 112, "start": 107, "tag": "Eukaryote"}, {"end": 102, "start": 96, "tag": "Eukaryote"}, {"end": 203, "start": 199, "tag": "TemporalConcept"}, {"end": 119, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 69, "tag": "ResearchActivity"}]}{"id": "1192_3", "text": "The method includes a mild extracellular matrix digestion of the brain tissue, a series of filtration and centrifugation steps to purify EVs and an iodixanol-based high-resolution density step gradient that fractionates different EV populations, including mitovesicles, a newly identified type of EV of mitochondrial origin.", "tags": [{"end": 57, "start": 48, "tag": "BiologicFunction"}, {"end": 57, "start": 48, "tag": "ResearchActivity"}, {"end": 120, "start": 106, "tag": "ResearchActivity"}, {"end": 101, "start": 91, "tag": "ResearchActivity"}, {"end": 316, "start": 303, "tag": "CellComponent"}, {"end": 140, "start": 137, "tag": "CellComponent"}, {"end": 232, "start": 230, "tag": "CellComponent"}, {"end": 299, "start": 297, "tag": "CellComponent"}, {"end": 77, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 323, "start": 317, "tag": "TemporalConcept"}, {"end": 26, "start": 22, "tag": "Finding"}, {"end": 244, "start": 233, "tag": "PopulationGroup"}, {"end": 10, "start": 4, "tag": "ResearchActivity"}, {"end": 10, "start": 4, "tag": "HealthCareActivity"}, {"end": 268, "start": 256, "tag": "CellComponent"}, {"end": 47, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 157, "start": 148, "tag": "Chemical"}, {"end": 201, "start": 148, "tag": "ResearchActivity"}]}{"id": "1192_4", "text": "We also report detailed downstream protocols for the characterization and analysis of brain EV preparations using nanotrack analysis, electron microscopy and western blotting, as well as for measuring mitovesicular ATP kinetics.", "tags": [{"end": 174, "start": 158, "tag": "ResearchActivity"}, {"end": 218, "start": 215, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 218, "start": 215, "tag": "BiologicallyActiveSubstance"}, {"end": 227, "start": 219, "tag": "NaturalPhenomenonOrProcess"}, {"end": 94, "start": 92, "tag": "CellComponent"}, {"end": 82, "start": 74, "tag": "ResearchActivity"}, {"end": 132, "start": 114, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 91, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 134, "tag": "ResearchActivity"}, {"end": 69, "start": 53, "tag": "ResearchActivity"}, {"end": 44, "start": 35, "tag": "ResearchActivity"}, {"end": 214, "start": 201, "tag": "CellComponent"}, {"end": 218, "start": 215, "tag": "PharmacologicSubstance"}]}{"id": "1192_5", "text": "Furthermore, we compared this novel iodixanol-based high-resolution density step gradient to the previously described sucrose-based gradient.", "tags": [{"end": 89, "start": 36, "tag": "ResearchActivity"}, {"end": 140, "start": 118, "tag": "ResearchActivity"}]}{"id": "1192_6", "text": "Although the yield of total EVs recovered was similar, the iodixanol-based gradient better separated distinct EV species as compared with the sucrose-based gradient, including subpopulations of microvesicles, exosomes and mitovesicles.", "tags": [{"end": 190, "start": 176, "tag": "PopulationGroup"}, {"end": 31, "start": 28, "tag": "CellComponent"}, {"end": 112, "start": 110, "tag": "CellComponent"}, {"end": 207, "start": 194, "tag": "CellComponent"}, {"end": 217, "start": 209, "tag": "CellComponent"}, {"end": 234, "start": 222, "tag": "CellComponent"}, {"end": 120, "start": 113, "tag": "OrganismAttribute"}, {"end": 83, "start": 59, "tag": "ResearchActivity"}, {"end": 164, "start": 142, "tag": "ResearchActivity"}]}{"id": "1192_7", "text": "This technique allows quantitative, highly reproducible analyses of brain EV subtypes under normal physiological processes and pathological brain conditions, including neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.", "tags": [{"end": 156, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 99, "tag": "BiologicFunction"}, {"end": 14, "start": 5, "tag": "ResearchActivity"}, {"end": 222, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 74, "tag": "CellComponent"}, {"end": 246, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 194, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 92, "tag": "Finding"}, {"end": 64, "start": 56, "tag": "ResearchActivity"}]}{"id": "1192_8", "text": "This protocol describes the isolation from brain tissue of extracellular vesicle subpopulations, including microvesicles, exosomes and mitochondria-derived mitovesicles, using a high-resolution (iodixanol) density step gradient.", "tags": [{"end": 13, "start": 5, "tag": "HealthCareActivity"}, {"end": 95, "start": 81, "tag": "PopulationGroup"}, {"end": 80, "start": 59, "tag": "CellComponent"}, {"end": 55, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 107, "tag": "CellComponent"}, {"end": 147, "start": 135, "tag": "CellComponent"}, {"end": 130, "start": 122, "tag": "CellComponent"}, {"end": 168, "start": 156, "tag": "CellComponent"}, {"end": 80, "start": 56, "tag": "ResearchActivity"}, {"end": 37, "start": 28, "tag": "ResearchActivity"}, {"end": 204, "start": 195, "tag": "Chemical"}, {"end": 227, "start": 178, "tag": "ResearchActivity"}]}{"id": "1192_9", "text": "Extracellular vesicle characterization and analysis are also presented.", "tags": [{"end": 21, "start": 0, "tag": "CellComponent"}, {"end": 51, "start": 43, "tag": "ResearchActivity"}, {"end": 38, "start": 22, "tag": "ResearchActivity"}]}{"id": "1193_0", "text": "Alzheimer's disease (AD), the most prevalent neurodegenerative disease in the growing population of elderly people, is still lacking minimally-invasive circulating biomarkers that could facilitate the diagnosis and the monitoring of disease progression.", "tags": [{"end": 151, "start": 143, "tag": "Finding"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 164, "tag": "ClinicalAttribute"}, {"end": 252, "start": 241, "tag": "PathologicFunction"}, {"end": 252, "start": 241, "tag": "TemporalConcept"}, {"end": 210, "start": 201, "tag": "HealthCareActivity"}, {"end": 174, "start": 152, "tag": "ClinicalAttribute"}, {"end": 96, "start": 86, "tag": "PopulationGroup"}, {"end": 114, "start": 108, "tag": "PopulationGroup"}, {"end": 229, "start": 219, "tag": "HealthCareActivity"}, {"end": 70, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 252, "start": 233, "tag": "PathologicFunction"}, {"end": 107, "start": 100, "tag": "PopulationGroup"}]}{"id": "1193_1", "text": "MicroRNAs (miRNAs) are emerging as tissue-specific and/or circulating biomarkers of several age-related diseases, but evidence on AD is still not conclusive.", "tags": [{"end": 9, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 118, "tag": "Finding"}, {"end": 80, "start": 70, "tag": "ClinicalAttribute"}, {"end": 17, "start": 11, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 17, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 58, "tag": "ClinicalAttribute"}, {"end": 41, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 92, "tag": "DiseaseOrSyndrome"}]}{"id": "1193_2", "text": "Since a systemic pro-inflammatory status was associated with an increased risk of AD development and progression, we focused our investigation on a subset of miRNAs modulating the inflammatory process, namely inflamma-miRNAs.", "tags": [{"end": 200, "start": 180, "tag": "PathologicFunction"}, {"end": 142, "start": 129, "tag": "ResearchActivity"}, {"end": 78, "start": 64, "tag": "Finding"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 85, "tag": "BiologicFunction"}, {"end": 96, "start": 85, "tag": "CellFunction"}, {"end": 164, "start": 158, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 224, "start": 209, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 164, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 224, "start": 209, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 101, "tag": "PathologicFunction"}, {"end": 112, "start": 101, "tag": "TemporalConcept"}, {"end": 33, "start": 17, "tag": "PathologicFunction"}, {"end": 40, "start": 34, "tag": "Finding"}]}{"id": "1193_3", "text": "The expression of inflamma-miR-17-5p, -21-5p, -126-3p, and -146a-5p was analyzed in plasma samples from 116 patients with AD compared with 41 age-matched healthy control (HC) subjects.", "tags": [{"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 154, "tag": "OrganismAttribute"}, {"end": 116, "start": 108, "tag": "PatientOrDisabledGroup"}, {"end": 98, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 4, "tag": "CellFunction"}, {"end": 145, "start": 142, "tag": "OrganismAttribute"}, {"end": 183, "start": 175, "tag": "PopulationGroup"}, {"end": 36, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 18, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 30, "start": 18, "tag": "BiologicallyActiveSubstance"}]}{"id": "1193_4", "text": "MiR-17-5p, miR-21-5p, and miR-126-3p plasma levels were significantly increased in AD patients compared to HC.", "tags": [{"end": 20, "start": 11, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 20, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 86, "tag": "PatientOrDisabledGroup"}, {"end": 43, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 56, "tag": "Finding"}, {"end": 36, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 26, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 9, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1193_5", "text": "Importantly, a strong inverse relationship was observed between miR-21-5p and miR-126-3p, and the cognitive impairment, assessed by Mini-Mental State Examination (MMSE).", "tags": [{"end": 167, "start": 163, "tag": "HealthCareActivity"}, {"end": 73, "start": 64, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 73, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 132, "tag": "HealthCareActivity"}, {"end": 42, "start": 30, "tag": "Finding"}, {"end": 118, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 78, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1193_6", "text": "Notably, miR-126-3p was able to discriminate between mild and severe cognitive impairment.", "tags": [{"end": 89, "start": 62, "tag": "Finding"}, {"end": 57, "start": 53, "tag": "Finding"}, {"end": 89, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 62, "tag": "Finding"}, {"end": 19, "start": 9, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 19, "start": 9, "tag": "BiologicallyActiveSubstance"}]}{"id": "1193_7", "text": "Overall, our results reinforce the hypothesis that circulating inflamma-miRNAs could be assessed as minimally invasive tools associated with the development and progression of cognitive impairment in AD.", "tags": [{"end": 118, "start": 110, "tag": "Finding"}, {"end": 202, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 145, "tag": "BiologicFunction"}, {"end": 156, "start": 145, "tag": "CellFunction"}, {"end": 78, "start": 51, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 78, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 161, "tag": "PathologicFunction"}, {"end": 172, "start": 161, "tag": "TemporalConcept"}, {"end": 118, "start": 100, "tag": "Finding"}, {"end": 196, "start": 176, "tag": "DiseaseOrSyndrome"}]}{"id": "1194_0", "text": "Sodium-glucose cotransporter-2 inhibitors (SGLT2is), such as empagliflozin, lower blood glucose in type 2 diabetes mellitus and improve cardiorenal outcomes regardless of diabetes presence.", "tags": [{"end": 50, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 74, "start": 61, "tag": "Chemical"}, {"end": 123, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 88, "tag": "Chemical"}, {"end": 41, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 95, "start": 88, "tag": "PharmacologicSubstance"}, {"end": 95, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 179, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 148, "tag": "Finding"}, {"end": 188, "start": 180, "tag": "Finding"}, {"end": 74, "start": 61, "tag": "PharmacologicSubstance"}, {"end": 147, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1194_1", "text": "Whether SGLT2is exert any effects on the brain's metabolism has not been studied.", "tags": [{"end": 46, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 49, "tag": "CellFunction"}, {"end": 59, "start": 49, "tag": "BiologicFunction"}, {"end": 33, "start": 26, "tag": "Finding"}, {"end": 15, "start": 8, "tag": "PharmacologicSubstance"}]}{"id": "1194_2", "text": "We conducted a single-arm clinical trial to investigate the effects of once daily administration of oral empagliflozin (25 mg) for 14 days on systemic and brain metabolism in 21 non-diabetics aged 55 years old or older.", "tags": [{"end": 118, "start": 105, "tag": "Chemical"}, {"end": 171, "start": 155, "tag": "BiologicFunction"}, {"end": 196, "start": 192, "tag": "TemporalConcept"}, {"end": 104, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 205, "start": 200, "tag": "TemporalConcept"}, {"end": 171, "start": 161, "tag": "CellFunction"}, {"end": 171, "start": 161, "tag": "BiologicFunction"}, {"end": 40, "start": 26, "tag": "ResearchActivity"}, {"end": 70, "start": 60, "tag": "PathologicFunction"}, {"end": 138, "start": 134, "tag": "TemporalConcept"}, {"end": 67, "start": 60, "tag": "Finding"}, {"end": 218, "start": 213, "tag": "TemporalConcept"}, {"end": 81, "start": 76, "tag": "TemporalConcept"}, {"end": 118, "start": 105, "tag": "PharmacologicSubstance"}, {"end": 191, "start": 178, "tag": "PopulationGroup"}, {"end": 96, "start": 82, "tag": "HealthCareActivity"}]}{"id": "1194_3", "text": "Empagliflozin lowered circulating insulin and elevated beta-hydroxybutyrate over 34-h periods, both following its first administration and after 14 days of daily administration, with minor alterations in glucose homeostasis.", "tags": [{"end": 13, "start": 0, "tag": "Chemical"}, {"end": 75, "start": 55, "tag": "Chemical"}, {"end": 93, "start": 86, "tag": "TemporalConcept"}, {"end": 223, "start": 204, "tag": "BiologicFunction"}, {"end": 223, "start": 204, "tag": "CellFunction"}, {"end": 41, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 34, "tag": "PharmacologicSubstance"}, {"end": 119, "start": 114, "tag": "TemporalConcept"}, {"end": 152, "start": 148, "tag": "TemporalConcept"}, {"end": 200, "start": 189, "tag": "Finding"}, {"end": 161, "start": 156, "tag": "TemporalConcept"}, {"end": 13, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 134, "start": 120, "tag": "HealthCareActivity"}, {"end": 176, "start": 162, "tag": "HealthCareActivity"}]}{"id": "1194_4", "text": "Levels of phosphorylated insulin-like growth factor-1 receptor (pIGF-1R), phosphorylated insulin receptor (pIR), phosphorylated-in-tyrosine insulin receptor substrate-1 (pY-IRS-1), and phosphorylated protein kinase B or AKT (pAKT) were increased in extracellular vesicles enriched for neuronal origin (NEVs) following the first empagliflozin administration, but not after 14 days.", "tags": [{"end": 62, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 223, "start": 220, "tag": "AminoAcidPeptideOrProtein"}, {"end": 223, "start": 220, "tag": "BiologicallyActiveSubstance"}, {"end": 341, "start": 328, "tag": "Chemical"}, {"end": 271, "start": 249, "tag": "CellComponent"}, {"end": 24, "start": 10, "tag": "CellFunction"}, {"end": 88, "start": 74, "tag": "CellFunction"}, {"end": 127, "start": 113, "tag": "CellFunction"}, {"end": 199, "start": 185, "tag": "CellFunction"}, {"end": 293, "start": 285, "tag": "Cell"}, {"end": 300, "start": 294, "tag": "TemporalConcept"}, {"end": 327, "start": 322, "tag": "TemporalConcept"}, {"end": 306, "start": 302, "tag": "CellComponent"}, {"end": 379, "start": 375, "tag": "TemporalConcept"}, {"end": 105, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 216, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 216, "start": 200, "tag": "BiologicallyActiveSubstance"}, {"end": 229, "start": 225, "tag": "AminoAcidPeptideOrProtein"}, {"end": 229, "start": 225, "tag": "BiologicallyActiveSubstance"}, {"end": 341, "start": 328, "tag": "PharmacologicSubstance"}, {"end": 356, "start": 342, "tag": "HealthCareActivity"}]}{"id": "1194_5", "text": "Our finding of IGF-1R upregulation in NEVs is promising because several post-mortem and epidemiological studies support the idea that upregulation of IGF signaling may protect against Alzheimer's disease (AD).", "tags": [{"end": 21, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 72, "tag": "TemporalConcept"}, {"end": 153, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 150, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 154, "tag": "CellFunction"}, {"end": 11, "start": 4, "tag": "Finding"}, {"end": 111, "start": 88, "tag": "ResearchActivity"}, {"end": 203, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 38, "tag": "CellComponent"}, {"end": 34, "start": 22, "tag": "CellFunction"}, {"end": 146, "start": 134, "tag": "CellFunction"}, {"end": 21, "start": 15, "tag": "BiologicallyActiveSubstance"}]}{"id": "1194_6", "text": "Moreover, our finding showing activation of insulin signaling and, in particular, the canonical pathway (pIR, pY-IRS-1, pAKT) in NEVs is important because such changes have been repeatedly associated with neuronal survival.", "tags": [{"end": 61, "start": 44, "tag": "CellFunction"}, {"end": 222, "start": 205, "tag": "CellFunction"}, {"end": 21, "start": 14, "tag": "Finding"}, {"end": 51, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 44, "tag": "PharmacologicSubstance"}, {"end": 133, "start": 129, "tag": "CellComponent"}, {"end": 103, "start": 86, "tag": "CellFunction"}, {"end": 40, "start": 30, "tag": "CellFunction"}, {"end": 108, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 120, "tag": "BiologicallyActiveSubstance"}]}{"id": "1194_7", "text": "Using brain magnetic resonance spectroscopy (MRS), we detected decreased concentrations of the excitatory neurotransmitter glutamate and its precursor glutamine after empagliflozin administration.", "tags": [{"end": 43, "start": 6, "tag": "HealthCareActivity"}, {"end": 48, "start": 45, "tag": "HealthCareActivity"}, {"end": 150, "start": 141, "tag": "Cell"}, {"end": 180, "start": 167, "tag": "Chemical"}, {"end": 122, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 63, "tag": "Finding"}, {"end": 87, "start": 73, "tag": "BiologicFunction"}, {"end": 132, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 151, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 181, "tag": "HealthCareActivity"}, {"end": 180, "start": 167, "tag": "PharmacologicSubstance"}, {"end": 160, "start": 151, "tag": "PharmacologicSubstance"}]}{"id": "1194_8", "text": "This finding is also encouraging since glutamatergic excitotoxicity has long been implicated in AD pathology.", "tags": [{"end": 67, "start": 39, "tag": "PathologicFunction"}, {"end": 98, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 99, "tag": "PathologicFunction"}, {"end": 108, "start": 99, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1194_9", "text": "Overall, our findings may motivate the repurposing of SGLT2is for use in AD and other, related diseases that are characterized by downregulation of IGF-1/insulin signaling in neurons and excitotoxicity.", "tags": [{"end": 61, "start": 54, "tag": "Chemical"}, {"end": 171, "start": 162, "tag": "CellFunction"}, {"end": 201, "start": 187, "tag": "PathologicFunction"}, {"end": 144, "start": 130, "tag": "CellFunction"}, {"end": 161, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 154, "tag": "PharmacologicSubstance"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 175, "tag": "Cell"}, {"end": 61, "start": 39, "tag": "HealthCareActivity"}, {"end": 61, "start": 54, "tag": "PharmacologicSubstance"}, {"end": 154, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 148, "tag": "BiologicallyActiveSubstance"}]}{"id": "1195_0", "text": "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent neurodegenerative diseases, affecting millions and costing billions each year in the United States alone.", "tags": [{"end": 175, "start": 162, "tag": "PopulationGroup"}, {"end": 154, "start": 150, "tag": "TemporalConcept"}, {"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 77, "tag": "DiseaseOrSyndrome"}]}{"id": "1195_1", "text": "Despite tremendous progress in developing therapeutics that manage the symptoms of these two diseases, the scientific community has yet to develop a treatment that effectively slows down, inhibits, or cures neurodegeneration.", "tags": [{"end": 127, "start": 118, "tag": "HealthCareRelatedOrganization"}, {"end": 27, "start": 19, "tag": "TemporalConcept"}, {"end": 54, "start": 42, "tag": "HealthCareActivity"}, {"end": 158, "start": 149, "tag": "HealthCareActivity"}, {"end": 158, "start": 149, "tag": "ResearchActivity"}, {"end": 79, "start": 71, "tag": "SignOrSymptom"}, {"end": 224, "start": 207, "tag": "CellOrMolecularDysfunction"}]}{"id": "1195_2", "text": "To gain a better understanding of the current therapeutic frontier for the treatment of AD and PD, we provide a review on past and present therapeutic strategies for these two major neurodegenerative disorders in the clinical trial process.", "tags": [{"end": 126, "start": 122, "tag": "TemporalConcept"}, {"end": 90, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 112, "tag": "ResearchActivity"}, {"end": 118, "start": 112, "tag": "HealthCareActivity"}, {"end": 84, "start": 75, "tag": "HealthCareActivity"}, {"end": 84, "start": 75, "tag": "ResearchActivity"}, {"end": 45, "start": 38, "tag": "TemporalConcept"}, {"end": 30, "start": 17, "tag": "BiologicFunction"}, {"end": 239, "start": 217, "tag": "ResearchActivity"}, {"end": 209, "start": 182, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 139, "tag": "HealthCareActivity"}, {"end": 66, "start": 46, "tag": "Finding"}]}{"id": "1195_3", "text": "We briefly recap currently US Food and Drug Administration-approved therapies, and then explore trends in clinical trials across the variables of therapy mechanism of disease intervention, administration route, use of delivery vehicle, and outcome measures, across the clinical phases over time for Drug and Biologic therapeutics.", "tags": [{"end": 102, "start": 96, "tag": "TemporalConcept"}, {"end": 303, "start": 299, "tag": "PharmacologicSubstance"}, {"end": 329, "start": 308, "tag": "HealthCareActivity"}, {"end": 26, "start": 17, "tag": "TemporalConcept"}, {"end": 294, "start": 290, "tag": "TemporalConcept"}, {"end": 153, "start": 146, "tag": "HealthCareActivity"}, {"end": 77, "start": 68, "tag": "HealthCareActivity"}, {"end": 226, "start": 218, "tag": "BiologicFunction"}, {"end": 10, "start": 3, "tag": "TemporalConcept"}, {"end": 121, "start": 106, "tag": "ResearchActivity"}, {"end": 58, "start": 27, "tag": "HealthCareRelatedOrganization"}, {"end": 203, "start": 189, "tag": "HealthCareActivity"}, {"end": 247, "start": 240, "tag": "Finding"}]}{"id": "1195_4", "text": "We then present the success rate of past clinical trials and analyze the intersections in therapeutic approaches for AD and PD, revealing the shift in clinical trials away from therapies targeting neurotransmitter systems that provide symptomatic relief, and towards anti-aggregation, anti-inflammatory, anti-oxidant, and regeneration strategies that aim to inhibit the root causes of disease progression.", "tags": [{"end": 147, "start": 142, "tag": "Finding"}, {"end": 316, "start": 304, "tag": "PharmacologicSubstance"}, {"end": 374, "start": 370, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 36, "tag": "TemporalConcept"}, {"end": 345, "start": 322, "tag": "HealthCareActivity"}, {"end": 213, "start": 197, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 28, "tag": "TemporalConcept"}, {"end": 119, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 404, "start": 393, "tag": "PathologicFunction"}, {"end": 404, "start": 393, "tag": "TemporalConcept"}, {"end": 283, "start": 272, "tag": "CellFunction"}, {"end": 283, "start": 272, "tag": "ResearchActivity"}, {"end": 404, "start": 385, "tag": "PathologicFunction"}, {"end": 186, "start": 177, "tag": "HealthCareActivity"}, {"end": 246, "start": 235, "tag": "SignOrSymptom"}, {"end": 56, "start": 41, "tag": "ResearchActivity"}, {"end": 166, "start": 151, "tag": "ResearchActivity"}, {"end": 302, "start": 285, "tag": "BiologicFunction"}, {"end": 302, "start": 285, "tag": "PharmacologicSubstance"}, {"end": 112, "start": 90, "tag": "HealthCareActivity"}, {"end": 253, "start": 247, "tag": "Finding"}]}{"id": "1195_5", "text": "We also highlight the evolving distribution of the types of Biologic therapies investigated, and the slowly increasing yet still severe under-utilization of delivery vehicles for AD and PD therapeutics.", "tags": [{"end": 78, "start": 60, "tag": "HealthCareActivity"}, {"end": 181, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 201, "start": 189, "tag": "HealthCareActivity"}, {"end": 135, "start": 129, "tag": "Finding"}, {"end": 118, "start": 108, "tag": "Finding"}, {"end": 174, "start": 166, "tag": "ManufacturedObject"}, {"end": 165, "start": 157, "tag": "BiologicFunction"}]}{"id": "1195_6", "text": "We then briefly discuss novel preclinical strategies for treating AD and PD.", "tags": [{"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 24, "tag": "ResearchActivity"}, {"end": 15, "start": 8, "tag": "TemporalConcept"}]}{"id": "1195_7", "text": "Overall, this review aims to provide a succinct overview of the clinical landscape of AD and PD therapies to better understand the field's therapeutic strategy in the past and the field's evolution in approach to the present, to better inform how to effectively treat AD and PD in the future.", "tags": [{"end": 171, "start": 167, "tag": "TemporalConcept"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 270, "start": 268, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 277, "start": 275, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 48, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 291, "start": 285, "tag": "TemporalConcept"}, {"end": 105, "start": 96, "tag": "HealthCareActivity"}, {"end": 159, "start": 139, "tag": "HealthCareActivity"}, {"end": 197, "start": 188, "tag": "TemporalConcept"}, {"end": 197, "start": 188, "tag": "BiologicFunction"}]}{"id": "1196_0", "text": "Extracellular vesicles (EVs) have been proposed to regulate the deposition of A beta.", "tags": [{"end": 22, "start": 0, "tag": "CellComponent"}, {"end": 27, "start": 24, "tag": "CellComponent"}, {"end": 84, "start": 78, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1196_1", "text": "Multiple publications have shown that APP, amyloid processing enzymes and A beta peptides are associated with EVs.", "tags": [{"end": 41, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 38, "tag": "GeneOrGenome"}, {"end": 41, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 9, "tag": "ResearchActivity"}, {"end": 68, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 110, "tag": "CellComponent"}, {"end": 50, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 43, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1196_2", "text": "However, very little A beta is associated with EVs compared with the total amount A beta present in human plasma, CSF, or supernatants from cultured neurons.", "tags": [{"end": 134, "start": 122, "tag": "Substance"}, {"end": 156, "start": 149, "tag": "Cell"}, {"end": 50, "start": 47, "tag": "CellComponent"}, {"end": 112, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 100, "tag": "Eukaryote"}, {"end": 117, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 140, "tag": "ResearchActivity"}]}{"id": "1196_3", "text": "The involvement of EVs has largely been inferred by pharmacological inhibition or whole body deletion of the sphingomyelin hydrolase neutral sphingomyelinase-2 (nSMase2) that is a key regulator for the biogenesis of at-least one population of EVs.", "tags": [{"end": 168, "start": 161, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 161, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 109, "tag": "Chemical"}, {"end": 122, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 239, "start": 229, "tag": "PopulationGroup"}, {"end": 67, "start": 52, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 212, "start": 202, "tag": "CellFunction"}, {"end": 92, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 4, "tag": "Finding"}, {"end": 78, "start": 68, "tag": "CellFunction"}, {"end": 22, "start": 19, "tag": "CellComponent"}, {"end": 246, "start": 243, "tag": "CellComponent"}, {"end": 159, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 109, "tag": "BiologicallyActiveSubstance"}]}{"id": "1196_4", "text": "Here we used a Cre-Lox system to selectively delete nSMase2 from pyramidal neurons in APP/PS1 mice (APP/PS1-SMPD3-Nex1) and found a - 70% reduction in A beta deposition at 6 months of age and - 35% reduction at 12 months of age in both cortex and hippocampus.", "tags": [{"end": 59, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 242, "start": 236, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 258, "start": 247, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 65, "tag": "Cell"}, {"end": 89, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 86, "tag": "GeneOrGenome"}, {"end": 103, "start": 100, "tag": "GeneOrGenome"}, {"end": 89, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 86, "tag": "ExperimentalModelOfDisease"}, {"end": 187, "start": 184, "tag": "OrganismAttribute"}, {"end": 227, "start": 224, "tag": "OrganismAttribute"}, {"end": 147, "start": 138, "tag": "Finding"}, {"end": 207, "start": 198, "tag": "Finding"}, {"end": 147, "start": 138, "tag": "NaturalPhenomenonOrProcess"}, {"end": 207, "start": 198, "tag": "NaturalPhenomenonOrProcess"}, {"end": 98, "start": 94, "tag": "Eukaryote"}, {"end": 180, "start": 174, "tag": "TemporalConcept"}, {"end": 220, "start": 214, "tag": "TemporalConcept"}, {"end": 157, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 15, "tag": "ResearchActivity"}, {"end": 107, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 108, "tag": "GeneOrGenome"}, {"end": 118, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 114, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1196_5", "text": "Brain ceramides were increased in APP/PS1 compared with Wt mice, but were similar to Wt in APP/PS1-SMPD3-Nex1 mice suggesting that elevated brain ceramides in this model involves neuronally expressed nSMase2.", "tags": [{"end": 87, "start": 85, "tag": "GeneOrGenome"}, {"end": 207, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 207, "start": 200, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 34, "tag": "GeneOrGenome"}, {"end": 94, "start": 91, "tag": "GeneOrGenome"}, {"end": 37, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 56, "tag": "Eukaryote"}, {"end": 114, "start": 110, "tag": "Eukaryote"}, {"end": 169, "start": 164, "tag": "ResearchActivity"}, {"end": 199, "start": 190, "tag": "CellFunction"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 6, "tag": "Chemical"}, {"end": 41, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 146, "tag": "Chemical"}, {"end": 155, "start": 146, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 179, "tag": "Cell"}, {"end": 104, "start": 99, "tag": "GeneOrGenome"}, {"end": 109, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 105, "tag": "BiologicallyActiveSubstance"}]}{"id": "1196_6", "text": "Reduced levels of PSD95 and deficits of long-term potentiation in APP/PS1 mice were normalized in APP/PS1-SMPD3-Nex1 mice.", "tags": [{"end": 14, "start": 0, "tag": "Finding"}, {"end": 23, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 50, "tag": "CellFunction"}, {"end": 62, "start": 40, "tag": "BiologicFunction"}, {"end": 69, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 66, "tag": "GeneOrGenome"}, {"end": 101, "start": 98, "tag": "GeneOrGenome"}, {"end": 69, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 66, "tag": "ExperimentalModelOfDisease"}, {"end": 36, "start": 28, "tag": "Finding"}, {"end": 121, "start": 117, "tag": "Eukaryote"}, {"end": 49, "start": 40, "tag": "TemporalConcept"}, {"end": 105, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 106, "tag": "GeneOrGenome"}, {"end": 73, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 112, "tag": "BiologicallyActiveSubstance"}]}{"id": "1196_7", "text": "In contrast, elevated levels of IL-1 beta, IL-8 and TNF alpha in APP/PS1 mice were not normalized in APP/PS1-SMPD3Nex1 mice compared with APP/PS1 mice.", "tags": [{"end": 47, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 65, "tag": "GeneOrGenome"}, {"end": 104, "start": 101, "tag": "GeneOrGenome"}, {"end": 141, "start": 138, "tag": "GeneOrGenome"}, {"end": 68, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 65, "tag": "ExperimentalModelOfDisease"}, {"end": 150, "start": 138, "tag": "ExperimentalModelOfDisease"}, {"end": 41, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 32, "tag": "PharmacologicSubstance"}, {"end": 77, "start": 73, "tag": "Eukaryote"}, {"end": 123, "start": 119, "tag": "Eukaryote"}, {"end": 150, "start": 146, "tag": "Eukaryote"}, {"end": 61, "start": 52, "tag": "BiologicallyActiveSubstance"}]}{"id": "1196_8", "text": "Mechanistic studies showed that the size of liquid ordered membrane microdomains was increased in APP/PS1 mice, as were the amounts of APP and BACE1 localized to these microdomains.", "tags": [{"end": 50, "start": 44, "tag": "Substance"}, {"end": 101, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 98, "tag": "GeneOrGenome"}, {"end": 138, "start": 135, "tag": "GeneOrGenome"}, {"end": 101, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 98, "tag": "ExperimentalModelOfDisease"}, {"end": 80, "start": 44, "tag": "CellComponent"}, {"end": 148, "start": 143, "tag": "GeneOrGenome"}, {"end": 148, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 12, "tag": "ResearchActivity"}, {"end": 110, "start": 106, "tag": "Eukaryote"}, {"end": 40, "start": 36, "tag": "OrganismAttribute"}, {"end": 180, "start": 168, "tag": "CellComponent"}]}{"id": "1196_9", "text": "Pharmacological inhibition of nSMase2 activity with PDDC reduced the size of the liquid ordered membrane microdomains, reduced the localization of APP with BACE1 and reduced the production of A beta 1-40 and A beta 1-42.", "tags": [{"end": 15, "start": 0, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 56, "start": 52, "tag": "Chemical"}, {"end": 143, "start": 131, "tag": "BiologicFunction"}, {"end": 143, "start": 131, "tag": "ResearchActivity"}, {"end": 143, "start": 131, "tag": "CellFunction"}, {"end": 150, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 147, "tag": "GeneOrGenome"}, {"end": 150, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 81, "tag": "CellComponent"}, {"end": 161, "start": 156, "tag": "GeneOrGenome"}, {"end": 161, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 156, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 16, "tag": "CellFunction"}, {"end": 73, "start": 69, "tag": "OrganismAttribute"}, {"end": 203, "start": 192, "tag": "AminoAcidPeptideOrProtein"}, {"end": 219, "start": 208, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 30, "tag": "CellFunction"}, {"end": 56, "start": 52, "tag": "PharmacologicSubstance"}, {"end": 219, "start": 208, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 192, "tag": "BiologicallyActiveSubstance"}]}{"id": "1196_10", "text": "Although inhibition of nSMase2 reduced the release and increased the size of EVs, very little A beta was associated with EVs in all conditions tested.", "tags": [{"end": 30, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 43, "tag": "HealthCareActivity"}, {"end": 50, "start": 43, "tag": "ResearchActivity"}, {"end": 19, "start": 9, "tag": "CellFunction"}, {"end": 80, "start": 77, "tag": "CellComponent"}, {"end": 124, "start": 121, "tag": "CellComponent"}, {"end": 73, "start": 69, "tag": "OrganismAttribute"}, {"end": 100, "start": 94, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1196_11", "text": "We also found that nSMase2 directly protected neurons from the toxic effects of oligomerized A beta and preserved neural network connectivity despite considerable A beta deposition.", "tags": [{"end": 26, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 63, "tag": "InjuryOrPoisoning"}, {"end": 53, "start": 46, "tag": "Cell"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 163, "tag": "CellFunction"}, {"end": 141, "start": 114, "tag": "BiologicFunction"}]}{"id": "1196_12", "text": "These data demonstrate that nSMase2 plays a role in the production of A beta by stabilizing the interaction of APP with BACE1 in liquid ordered membrane microdomains, and directly protects neurons from the toxic effects of A beta.", "tags": [{"end": 35, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 211, "start": 206, "tag": "InjuryOrPoisoning"}, {"end": 196, "start": 189, "tag": "Cell"}, {"end": 114, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 111, "tag": "GeneOrGenome"}, {"end": 114, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 129, "tag": "CellComponent"}, {"end": 125, "start": 120, "tag": "GeneOrGenome"}, {"end": 125, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 76, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 229, "start": 223, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1196_13", "text": "The effects of inhibiting nSMase2 on EV biogenesis may be independent from effects on A beta production and neuronal protection.", "tags": [{"end": 33, "start": 26, "tag": "GeneOrGenome"}, {"end": 33, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 58, "tag": "Finding"}, {"end": 25, "start": 15, "tag": "BiologicFunction"}, {"end": 127, "start": 108, "tag": "CellFunction"}, {"end": 50, "start": 40, "tag": "CellFunction"}, {"end": 39, "start": 37, "tag": "CellComponent"}, {"end": 103, "start": 86, "tag": "CellFunction"}]}{"id": "1197_0", "text": "Brain-derived neurotrophic factor (BDNF) has a protective role in Alzheimer's disease (AD).", "tags": [{"end": 85, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 35, "tag": "GeneOrGenome"}, {"end": 33, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 47, "tag": "Finding"}]}{"id": "1197_1", "text": "Oxidative stress and inflammatory cytokines are potentially implicated in AD risk.", "tags": [{"end": 16, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 43, "start": 21, "tag": "BiologicFunction"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 77, "tag": "Finding"}, {"end": 43, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 34, "tag": "BiologicallyActiveSubstance"}]}{"id": "1197_2", "text": "In this study, BDNF was detected in serum of AD and mild cognitive impairment (MCI) patients and investigated in association with gene polymorphisms of BDNF (Val66Met and C270T), of some oxidative stress-related genes (FOXO3A, SIRT3, GLO1, and SOD2), and of interleukin-1 family genes (IL-1 alpha, IL-1 beta, and IL-38).", "tags": [{"end": 148, "start": 130, "tag": "CellFunction"}, {"end": 225, "start": 219, "tag": "GeneOrGenome"}, {"end": 225, "start": 219, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 227, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 227, "tag": "AminoAcidPeptideOrProtein"}, {"end": 238, "start": 234, "tag": "GeneOrGenome"}, {"end": 248, "start": 244, "tag": "GeneOrGenome"}, {"end": 296, "start": 286, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 290, "start": 286, "tag": "AminoAcidPeptideOrProtein"}, {"end": 302, "start": 298, "tag": "AminoAcidPeptideOrProtein"}, {"end": 290, "start": 286, "tag": "BiologicallyActiveSubstance"}, {"end": 302, "start": 298, "tag": "BiologicallyActiveSubstance"}, {"end": 307, "start": 298, "tag": "AminoAcidPeptideOrProtein"}, {"end": 307, "start": 298, "tag": "BiologicallyActiveSubstance"}, {"end": 307, "start": 298, "tag": "PharmacologicSubstance"}, {"end": 47, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 84, "tag": "PatientOrDisabledGroup"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 41, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 203, "start": 187, "tag": "CellOrMolecularDysfunction"}, {"end": 56, "start": 52, "tag": "Finding"}, {"end": 77, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 15, "tag": "GeneOrGenome"}, {"end": 156, "start": 152, "tag": "GeneOrGenome"}, {"end": 77, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 130, "tag": "GeneOrGenome"}, {"end": 238, "start": 234, "tag": "AminoAcidPeptideOrProtein"}, {"end": 238, "start": 234, "tag": "BiologicallyActiveSubstance"}, {"end": 248, "start": 244, "tag": "AminoAcidPeptideOrProtein"}, {"end": 248, "start": 244, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 171, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 318, "start": 313, "tag": "AminoAcidPeptideOrProtein"}, {"end": 318, "start": 313, "tag": "BiologicallyActiveSubstance"}, {"end": 225, "start": 219, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 227, "tag": "GeneOrGenome"}, {"end": 284, "start": 258, "tag": "GeneOrGenome"}, {"end": 296, "start": 286, "tag": "BiologicallyActiveSubstance"}, {"end": 296, "start": 286, "tag": "PharmacologicSubstance"}]}{"id": "1197_3", "text": "The APOE status and mini-mental state examination (MMSE) score were also evaluated.", "tags": [{"end": 49, "start": 20, "tag": "HealthCareActivity"}, {"end": 15, "start": 9, "tag": "Finding"}, {"end": 8, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 4, "tag": "GeneOrGenome"}, {"end": 8, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 51, "tag": "HealthCareActivity"}]}{"id": "1197_4", "text": "Serum BDNF was significantly lower in AD (p = 0.029), especially when comparing the female subsets (p = 0.005).", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 6, "tag": "GeneOrGenome"}, {"end": 90, "start": 84, "tag": "OrganismAttribute"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1197_5", "text": "Patients with BDNFVal/Val homozygous also had significantly lower circulating BDNF compared with controls (p = 0.010).", "tags": [{"end": 36, "start": 26, "tag": "OrganismAttribute"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 105, "start": 97, "tag": "PopulationGroup"}, {"end": 82, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 78, "tag": "GeneOrGenome"}]}{"id": "1197_6", "text": "Moreover, lower BDNF was associated with the presence of the T mutant allele of IL-1 alpha(rs1800587) in AD (p = 0.040).", "tags": [{"end": 76, "start": 70, "tag": "GeneOrGenome"}, {"end": 90, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 16, "tag": "GeneOrGenome"}, {"end": 53, "start": 45, "tag": "Finding"}, {"end": 69, "start": 63, "tag": "CellOrMolecularDysfunction"}, {"end": 90, "start": 80, "tag": "PharmacologicSubstance"}]}{"id": "1197_7", "text": "These results were even more significant in the female subsets (BDNFVal/Val, p = 0.001; IL-1 alpha, p = 0.013; males: ns).", "tags": [{"end": 98, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 111, "tag": "OrganismAttribute"}, {"end": 54, "start": 48, "tag": "OrganismAttribute"}, {"end": 98, "start": 88, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 88, "tag": "BiologicallyActiveSubstance"}]}{"id": "1197_8", "text": "In conclusion, reduced serum levels of BDNF were found in AD; polymorphisms of the IL-1 alpha and BDNF genes appear to be involved in changes in serum BDNF, particularly in female patients, while no effects of other gene variants affecting oxidative stress have been found.", "tags": [{"end": 75, "start": 62, "tag": "CellFunction"}, {"end": 93, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 98, "tag": "GeneOrGenome"}, {"end": 229, "start": 216, "tag": "GeneOrGenome"}, {"end": 256, "start": 250, "tag": "PathologicFunction"}, {"end": 87, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 180, "tag": "PatientOrDisabledGroup"}, {"end": 28, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 256, "start": 240, "tag": "CellOrMolecularDysfunction"}, {"end": 43, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 151, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 39, "tag": "GeneOrGenome"}, {"end": 102, "start": 98, "tag": "GeneOrGenome"}, {"end": 155, "start": 151, "tag": "GeneOrGenome"}, {"end": 179, "start": 173, "tag": "OrganismAttribute"}, {"end": 206, "start": 199, "tag": "Finding"}, {"end": 43, "start": 23, "tag": "ClinicalAttribute"}, {"end": 93, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 145, "tag": "ClinicalAttribute"}]}{"id": "1197_9", "text": "These findings add another step in identifying gender-related susceptibility to AD.", "tags": [{"end": 76, "start": 62, "tag": "ClinicalAttribute"}, {"end": 53, "start": 47, "tag": "OrganismAttribute"}, {"end": 82, "start": 80, "tag": "DiseaseOrSyndrome"}]}{"id": "1198_0", "text": "The choroid plexus (ChP) is a complex structure in the human brain that is responsible for the secretion of cerebrospinal fluid (CSF) and forming the blood-CSF barrier (B-CSF-B).", "tags": [{"end": 18, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 169, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 55, "tag": "Eukaryote"}, {"end": 167, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 95, "tag": "CellFunction"}, {"end": 104, "start": 95, "tag": "BiologicFunction"}]}{"id": "1198_1", "text": "Human-induced pluripotent stem cells (hiPSCs) have shown promising results in the formation of brain organoids in vitro; however, very few studies to date have generated ChP organoids.", "tags": [{"end": 36, "start": 0, "tag": "Cell"}, {"end": 44, "start": 38, "tag": "Cell"}, {"end": 173, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 183, "start": 174, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 147, "tag": "TemporalConcept"}, {"end": 154, "start": 150, "tag": "TemporalConcept"}, {"end": 100, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 139, "tag": "ResearchActivity"}, {"end": 119, "start": 111, "tag": "ResearchActivity"}, {"end": 36, "start": 6, "tag": "Cell"}, {"end": 36, "start": 26, "tag": "Cell"}]}{"id": "1198_2", "text": "In particular, no study has assessed the inflammatory response and the extracellular vesicle (EV) biogenesis of hiPSC-derived ChP organoids.", "tags": [{"end": 62, "start": 41, "tag": "PathologicFunction"}, {"end": 129, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 71, "tag": "CellComponent"}, {"end": 96, "start": 94, "tag": "CellComponent"}, {"end": 23, "start": 18, "tag": "ResearchActivity"}, {"end": 108, "start": 98, "tag": "CellFunction"}, {"end": 117, "start": 112, "tag": "Cell"}]}{"id": "1198_3", "text": "In this study, the impacts of Wnt signaling on the inflammatory response and EV biogenesis of ChP organoids derived from hiPSCs was investigated.", "tags": [{"end": 72, "start": 51, "tag": "PathologicFunction"}, {"end": 97, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 121, "tag": "Cell"}, {"end": 107, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 34, "tag": "CellFunction"}, {"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 77, "tag": "CellComponent"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 90, "start": 80, "tag": "CellFunction"}, {"end": 43, "start": 30, "tag": "CellFunction"}]}{"id": "1198_4", "text": "During days 10-15, bone morphogenetic protein 4 was added along with (+/-) CHIR99021 (CHIR, a small molecule GSK-3 beta inhibitor that acts as a Wnt agonist).", "tags": [{"end": 47, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 75, "tag": "Chemical"}, {"end": 114, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 94, "tag": "Chemical"}, {"end": 47, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 109, "tag": "GeneOrGenome"}, {"end": 119, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 120, "tag": "PharmacologicSubstance"}, {"end": 129, "start": 120, "tag": "Chemical"}, {"end": 11, "start": 7, "tag": "TemporalConcept"}, {"end": 90, "start": 86, "tag": "Chemical"}]}{"id": "1198_5", "text": "At day 30, the ChP organoids were characterized by immunocytochemistry and flow cytometry for TTR (similar to 72%) and CLIC6 (similar to 20%) expression.", "tags": [{"end": 6, "start": 3, "tag": "TemporalConcept"}, {"end": 18, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 75, "tag": "ResearchActivity"}, {"end": 97, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 94, "tag": "GeneOrGenome"}, {"end": 124, "start": 119, "tag": "GeneOrGenome"}, {"end": 70, "start": 51, "tag": "ResearchActivity"}, {"end": 28, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 142, "tag": "CellFunction"}, {"end": 97, "start": 94, "tag": "BiologicallyActiveSubstance"}]}{"id": "1198_6", "text": "Compared to the -CHIR group, the +CHIR group showed an upregulation of 6 out of 10 tested ChP genes, including CLIC6 (2-fold), PLEC (4-fold), PLTP (2-4-fold), DCN (similar to 7-fold), DLK1 (2-4-fold), and AQP1 (1.4-fold), and a downregulation of TTR (0.1-fold), IGFBP7 (0.8-fold), MSX1 (0.4-fold), and LUM (0.2-0.4-fold).", "tags": [{"end": 116, "start": 111, "tag": "GeneOrGenome"}, {"end": 131, "start": 127, "tag": "GeneOrGenome"}, {"end": 146, "start": 142, "tag": "GeneOrGenome"}, {"end": 162, "start": 159, "tag": "GeneOrGenome"}, {"end": 188, "start": 184, "tag": "GeneOrGenome"}, {"end": 209, "start": 205, "tag": "AminoAcidPeptideOrProtein"}, {"end": 209, "start": 205, "tag": "GeneOrGenome"}, {"end": 249, "start": 246, "tag": "AminoAcidPeptideOrProtein"}, {"end": 249, "start": 246, "tag": "GeneOrGenome"}, {"end": 268, "start": 262, "tag": "GeneOrGenome"}, {"end": 285, "start": 281, "tag": "GeneOrGenome"}, {"end": 285, "start": 281, "tag": "AminoAcidPeptideOrProtein"}, {"end": 305, "start": 302, "tag": "GeneOrGenome"}, {"end": 242, "start": 228, "tag": "CellFunction"}, {"end": 27, "start": 22, "tag": "PopulationGroup"}, {"end": 44, "start": 39, "tag": "PopulationGroup"}, {"end": 67, "start": 55, "tag": "CellFunction"}, {"end": 21, "start": 17, "tag": "Chemical"}, {"end": 93, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 188, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 188, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 209, "start": 205, "tag": "BiologicallyActiveSubstance"}, {"end": 249, "start": 246, "tag": "BiologicallyActiveSubstance"}, {"end": 268, "start": 262, "tag": "BiologicallyActiveSubstance"}, {"end": 268, "start": 262, "tag": "AminoAcidPeptideOrProtein"}, {"end": 285, "start": 281, "tag": "BiologicallyActiveSubstance"}, {"end": 305, "start": 302, "tag": "BiologicallyActiveSubstance"}, {"end": 305, "start": 302, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 34, "tag": "Chemical"}]}{"id": "1198_7", "text": "When exposed to amyloid beta 42 oligomers, the +CHIR group had a more sensitive response as evidenced by the upregulation of inflammation-related genes such as TNF alpha, IL-6, and MMP2/9 when compared to the -CHIR group.", "tags": [{"end": 169, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 160, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 53, "tag": "PopulationGroup"}, {"end": 220, "start": 215, "tag": "PopulationGroup"}, {"end": 137, "start": 125, "tag": "PathologicFunction"}, {"end": 41, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 70, "tag": "PathologicFunction"}, {"end": 175, "start": 171, "tag": "AminoAcidPeptideOrProtein"}, {"end": 175, "start": 171, "tag": "BiologicallyActiveSubstance"}, {"end": 175, "start": 171, "tag": "GeneOrGenome"}, {"end": 121, "start": 109, "tag": "CellFunction"}, {"end": 52, "start": 48, "tag": "Chemical"}, {"end": 187, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 187, "start": 181, "tag": "BiologicallyActiveSubstance"}, {"end": 214, "start": 210, "tag": "Chemical"}]}{"id": "1198_8", "text": "Developmentally, the EV biogenesis markers of ChP organoids showed an increase over time from day 19 to day 38.", "tags": [{"end": 15, "start": 0, "tag": "BiologicFunction"}, {"end": 49, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 97, "start": 94, "tag": "TemporalConcept"}, {"end": 107, "start": 104, "tag": "TemporalConcept"}, {"end": 59, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 21, "tag": "CellComponent"}, {"end": 42, "start": 35, "tag": "ClinicalAttribute"}, {"end": 88, "start": 84, "tag": "TemporalConcept"}, {"end": 34, "start": 24, "tag": "CellFunction"}]}{"id": "1198_9", "text": "This study is significant in that it provides a model of the human B-CSF-B and ChP tissue for the purpose of drug screening and designing drug delivery systems to treat neurological disorders such as Alzheimer's disease and ischemic stroke.", "tags": [{"end": 82, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 138, "tag": "ManufacturedObject"}, {"end": 239, "start": 224, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 109, "tag": "ResearchActivity"}, {"end": 239, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 74, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 61, "tag": "Eukaryote"}, {"end": 53, "start": 48, "tag": "ResearchActivity"}, {"end": 89, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 191, "start": 169, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 109, "tag": "PharmacologicSubstance"}, {"end": 142, "start": 138, "tag": "PharmacologicSubstance"}, {"end": 123, "start": 114, "tag": "HealthCareActivity"}, {"end": 123, "start": 114, "tag": "ResearchActivity"}, {"end": 151, "start": 143, "tag": "BiologicFunction"}, {"end": 151, "start": 138, "tag": "HealthCareActivity"}]}{"id": "1199_0", "text": "Alzheimer's disease (AD) is the most common neurodegenerative disease and the most common cause of dementia.", "tags": [{"end": 19, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 44, "tag": "DiseaseOrSyndrome"}]}{"id": "1199_1", "text": "Among various pathophysiological aspects, microglia are considered to play important roles in the pathogenesis of AD.", "tags": [{"end": 40, "start": 14, "tag": "BiologicFunction"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 98, "tag": "PathologicFunction"}, {"end": 51, "start": 42, "tag": "Cell"}, {"end": 32, "start": 14, "tag": "PathologicFunction"}]}{"id": "1199_2", "text": "Genome wide association studies (GWAS) showed that the majority of AD risk genes are highly or exclusively expressed in microglia, underscoring the critical roles of microglia in AD pathogenesis.", "tags": [{"end": 37, "start": 33, "tag": "ResearchActivity"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 179, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 182, "tag": "PathologicFunction"}, {"end": 129, "start": 120, "tag": "Cell"}, {"end": 175, "start": 166, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "ResearchActivity"}, {"end": 116, "start": 107, "tag": "CellFunction"}, {"end": 80, "start": 70, "tag": "GeneOrGenome"}]}{"id": "1199_3", "text": "Recently, omics technologies have greatly advanced our knowledge of microglia biology in AD.", "tags": [{"end": 85, "start": 78, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 28, "start": 10, "tag": "ResearchActivity"}, {"end": 91, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 55, "tag": "Finding"}, {"end": 77, "start": 68, "tag": "Cell"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}]}{"id": "1199_4", "text": "Omics approaches, including genomics, epigenomics, transcriptomics, proteomics, and metabolomics/lipidomics, present remarkable opportunities to delineate the underlying mechanisms, discover novel diagnostic biomarkers, monitor disease progression, and shape therapeutic strategies for diseases.", "tags": [{"end": 36, "start": 28, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 49, "start": 38, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 78, "start": 68, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 66, "start": 51, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 281, "start": 259, "tag": "HealthCareActivity"}, {"end": 247, "start": 236, "tag": "PathologicFunction"}, {"end": 247, "start": 236, "tag": "TemporalConcept"}, {"end": 218, "start": 197, "tag": "ClinicalAttribute"}, {"end": 107, "start": 97, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 227, "start": 220, "tag": "HealthCareActivity"}, {"end": 227, "start": 220, "tag": "ManufacturedObject"}, {"end": 247, "start": 228, "tag": "PathologicFunction"}, {"end": 16, "start": 0, "tag": "ResearchActivity"}, {"end": 96, "start": 84, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1199_5", "text": "In this review, we summarized research based on microglial omics analysis in AD, especially the recent research advances in the identification of AD-associated microglial subsets.", "tags": [{"end": 73, "start": 59, "tag": "ResearchActivity"}, {"end": 38, "start": 30, "tag": "ResearchActivity"}, {"end": 111, "start": 103, "tag": "ResearchActivity"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 48, "tag": "Cell"}, {"end": 178, "start": 160, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 120, "start": 112, "tag": "Finding"}, {"end": 102, "start": 96, "tag": "TemporalConcept"}]}{"id": "1199_6", "text": "This review reinforces the important role of microglia in AD and advances our understanding of the mechanism of microglia in AD pathogenesis.", "tags": [{"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 128, "tag": "PathologicFunction"}, {"end": 91, "start": 78, "tag": "BiologicFunction"}, {"end": 54, "start": 45, "tag": "Cell"}, {"end": 121, "start": 112, "tag": "Cell"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 73, "start": 65, "tag": "Finding"}]}{"id": "1199_7", "text": "Moreover, we proposed the value of microglia-based omics in the development of therapeutic strategies and biomarkers for AD.", "tags": [{"end": 56, "start": 51, "tag": "ResearchActivity"}, {"end": 101, "start": 79, "tag": "HealthCareActivity"}, {"end": 123, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 64, "tag": "BiologicFunction"}, {"end": 75, "start": 64, "tag": "CellFunction"}, {"end": 116, "start": 106, "tag": "ClinicalAttribute"}, {"end": 44, "start": 35, "tag": "Cell"}]}{"id": "1200_0", "text": "The effect of the inflammatory response on regenerative processes in the brain is complex.", "tags": [{"end": 78, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 18, "tag": "PathologicFunction"}, {"end": 65, "start": 43, "tag": "BiologicFunction"}]}{"id": "1200_1", "text": "This complexity is even greater when the cause of the tissue damage is an autoimmune response.", "tags": [{"end": 67, "start": 54, "tag": "InjuryOrPoisoning"}, {"end": 60, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 74, "tag": "PathologicFunction"}]}{"id": "1200_2", "text": "Multiple sclerosis (MS) is an immune-mediated disease in which demyelination foci are formed in the central nervous system.", "tags": [{"end": 81, "start": 77, "tag": "Finding"}, {"end": 122, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 63, "tag": "PathologicFunction"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 30, "tag": "DiseaseOrSyndrome"}]}{"id": "1200_3", "text": "The degree of repair through oligodendrocyte regeneration and remyelination is insufficient.", "tags": [{"end": 91, "start": 79, "tag": "Finding"}, {"end": 44, "start": 29, "tag": "Cell"}, {"end": 75, "start": 62, "tag": "CellFunction"}, {"end": 20, "start": 14, "tag": "BiologicFunction"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 57, "start": 45, "tag": "BiologicFunction"}, {"end": 57, "start": 45, "tag": "HealthCareActivity"}]}{"id": "1200_4", "text": "Ephrins are membrane-bound ligands activating tyrosine kinase signaling proteins that are known to have an inhibitory effect on oligodendrocyte regeneration.", "tags": [{"end": 7, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 128, "tag": "Cell"}, {"end": 71, "start": 46, "tag": "CellFunction"}, {"end": 80, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 144, "tag": "BiologicFunction"}, {"end": 117, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 144, "tag": "HealthCareActivity"}, {"end": 20, "start": 12, "tag": "CellComponent"}, {"end": 124, "start": 107, "tag": "Finding"}, {"end": 7, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1200_5", "text": "In this study, we examined the expression of ephrins on immune cells of 43 patients with relapsing-remitting (RR) MS compared to 27 matched healthy controls (HC).", "tags": [{"end": 52, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 56, "tag": "Cell"}, {"end": 156, "start": 140, "tag": "PopulationGroup"}, {"end": 83, "start": 75, "tag": "PatientOrDisabledGroup"}, {"end": 116, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 52, "start": 45, "tag": "BiologicallyActiveSubstance"}]}{"id": "1200_6", "text": "We found an increased expression of ephrin-A2, -A3 and -B3, especially on T cell subpopulations.", "tags": [{"end": 45, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 74, "tag": "Cell"}, {"end": 45, "start": 36, "tag": "BiologicallyActiveSubstance"}]}{"id": "1200_7", "text": "We also showed overexpression of ephrins on immune cells of patients with RR-MS that increases the forward signaling pathway and that expression of ephrins on immune cells has an inhibitory effect on the differentiation of oligodendrocyte precursor cells (OPCs) in vitro.", "tags": [{"end": 29, "start": 15, "tag": "Finding"}, {"end": 40, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 44, "tag": "Cell"}, {"end": 171, "start": 159, "tag": "Cell"}, {"end": 124, "start": 99, "tag": "CellFunction"}, {"end": 260, "start": 256, "tag": "Cell"}, {"end": 254, "start": 223, "tag": "Cell"}, {"end": 68, "start": 60, "tag": "PatientOrDisabledGroup"}, {"end": 79, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 204, "tag": "CellFunction"}, {"end": 270, "start": 262, "tag": "ResearchActivity"}, {"end": 196, "start": 179, "tag": "Finding"}, {"end": 40, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 148, "tag": "BiologicallyActiveSubstance"}]}{"id": "1200_8", "text": "Our study findings support the concept that the immune activity of T cells in patients with RR-MS has an inhibitory effect on the differentiation capacity of OPCs through the expression and forward signaling of ephrins.", "tags": [{"end": 74, "start": 67, "tag": "Cell"}, {"end": 218, "start": 211, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 158, "tag": "Cell"}, {"end": 86, "start": 78, "tag": "PatientOrDisabledGroup"}, {"end": 97, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 190, "tag": "CellFunction"}, {"end": 145, "start": 130, "tag": "CellFunction"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 122, "start": 105, "tag": "Finding"}, {"end": 63, "start": 48, "tag": "CellFunction"}, {"end": 185, "start": 175, "tag": "CellFunction"}, {"end": 218, "start": 211, "tag": "BiologicallyActiveSubstance"}]}{"id": "1201_0", "text": "The pathology in neurodegenerative diseases is often accompanied by inflammation.", "tags": [{"end": 13, "start": 4, "tag": "PathologicFunction"}, {"end": 13, "start": 4, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 80, "start": 68, "tag": "PathologicFunction"}, {"end": 43, "start": 17, "tag": "DiseaseOrSyndrome"}]}{"id": "1201_1", "text": "It is well-known that many cells within the central nervous system (CNS) also contribute to ongoing neuroinflammation, which can promote neurodegeneration.", "tags": [{"end": 117, "start": 100, "tag": "PathologicFunction"}, {"end": 32, "start": 27, "tag": "Cell"}, {"end": 66, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 137, "tag": "CellOrMolecularDysfunction"}, {"end": 136, "start": 129, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 99, "start": 92, "tag": "TemporalConcept"}]}{"id": "1201_2", "text": "Multiple sclerosis (MS) is both an inflammatory and neurodegenerative disease in which there is a complex interplay between resident CNS cells to mediate myelin and axonal damage, and this communication network can vary depending on the subtype and chronicity of disease.", "tags": [{"end": 210, "start": 203, "tag": "CellFunction"}, {"end": 259, "start": 249, "tag": "TemporalConcept"}, {"end": 115, "start": 106, "tag": "Finding"}, {"end": 142, "start": 137, "tag": "Cell"}, {"end": 160, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 35, "tag": "PathologicFunction"}, {"end": 202, "start": 189, "tag": "HealthCareActivity"}, {"end": 202, "start": 189, "tag": "CellFunction"}, {"end": 132, "start": 124, "tag": "PopulationGroup"}, {"end": 178, "start": 165, "tag": "CellOrMolecularDysfunction"}]}{"id": "1201_3", "text": "Oligodendrocytes, the myelinating cell of the CNS, and their precursors, oligodendrocyte precursor cells (OPCs), are often thought of as the targets of autoimmune pathology during MS and in several animal models of MS; however, there is emerging evidence that OPCs actively contribute to inflammation that directly and indirectly contributes to neurodegeneration.", "tags": [{"end": 71, "start": 61, "tag": "Cell"}, {"end": 254, "start": 237, "tag": "Finding"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 110, "start": 106, "tag": "Cell"}, {"end": 264, "start": 260, "tag": "Cell"}, {"end": 104, "start": 73, "tag": "Cell"}, {"end": 49, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 362, "start": 345, "tag": "CellOrMolecularDysfunction"}, {"end": 182, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 152, "tag": "PathologicFunction"}, {"end": 300, "start": 288, "tag": "PathologicFunction"}, {"end": 38, "start": 22, "tag": "Cell"}, {"end": 217, "start": 198, "tag": "ExperimentalModelOfDisease"}]}{"id": "1201_4", "text": "Here we discuss several contributors to MS disease progression starting with lesion pathology and murine models amenable to studying particular aspects of disease.", "tags": [{"end": 42, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 84, "tag": "PathologicFunction"}, {"end": 93, "start": 84, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 83, "start": 77, "tag": "InjuryOrPoisoning"}, {"end": 62, "start": 43, "tag": "PathologicFunction"}, {"end": 111, "start": 98, "tag": "ResearchActivity"}, {"end": 104, "start": 98, "tag": "Eukaryote"}]}{"id": "1201_5", "text": "We then review how OPCs themselves can play an active role in promoting neuroinflammation and neurodegeneration, and how other resident CNS cells including microglia, astrocytes, and neurons can impact OPC function.", "tags": [{"end": 89, "start": 72, "tag": "PathologicFunction"}, {"end": 23, "start": 19, "tag": "Cell"}, {"end": 145, "start": 127, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 111, "start": 94, "tag": "CellOrMolecularDysfunction"}, {"end": 165, "start": 156, "tag": "Cell"}, {"end": 190, "start": 183, "tag": "Cell"}, {"end": 177, "start": 167, "tag": "Cell"}, {"end": 214, "start": 202, "tag": "CellFunction"}]}{"id": "1201_6", "text": "Further, we outline the very complex and pleiotropic role(s) of several inflammatory cytokines and other secreted factors classically described as solely deleterious during MS and its animal models, but in fact, have many neuroprotective functions and promote a return to homeostasis, in part via modulation of OPC function.", "tags": [{"end": 94, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 237, "start": 222, "tag": "CellFunction"}, {"end": 175, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 283, "start": 272, "tag": "BiologicFunction"}, {"end": 197, "start": 184, "tag": "ResearchActivity"}, {"end": 57, "start": 41, "tag": "Finding"}, {"end": 94, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 323, "start": 311, "tag": "CellFunction"}]}{"id": "1201_7", "text": "Finally, since MS affects patients from the onset of disease throughout their lifespan, we discuss the impact of aging on OPC function and CNS recovery.", "tags": [{"end": 60, "start": 44, "tag": "TemporalConcept"}, {"end": 86, "start": 78, "tag": "TemporalConcept"}, {"end": 34, "start": 26, "tag": "PatientOrDisabledGroup"}, {"end": 17, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 139, "tag": "BiologicFunction"}, {"end": 118, "start": 113, "tag": "BiologicFunction"}, {"end": 118, "start": 113, "tag": "CellFunction"}, {"end": 134, "start": 122, "tag": "CellFunction"}]}{"id": "1201_8", "text": "It is becoming clear that OPCs are not simply a bystander during MS progression and uncovering the active roles they play during different stages of disease will help uncover potential new avenues for therapeutic intervention.", "tags": [{"end": 225, "start": 201, "tag": "HealthCareActivity"}, {"end": 30, "start": 26, "tag": "Cell"}, {"end": 79, "start": 68, "tag": "PathologicFunction"}, {"end": 79, "start": 68, "tag": "TemporalConcept"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 139, "tag": "TemporalConcept"}]}{"id": "1202_0", "text": "Maintaining the normal function of oligodendrocyte precursor cells (OPCs) and protecting OPCs from damage is the basis of myelin regeneration in multiple sclerosis (MS).", "tags": [{"end": 72, "start": 68, "tag": "Cell"}, {"end": 93, "start": 89, "tag": "Cell"}, {"end": 66, "start": 35, "tag": "Cell"}, {"end": 163, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 16, "tag": "Finding"}, {"end": 141, "start": 122, "tag": "CellFunction"}, {"end": 105, "start": 99, "tag": "InjuryOrPoisoning"}]}{"id": "1202_1", "text": "In this paper, we investigated the effect of stemazole, a novel small molecule, on the promotion of oligodendrocyte precursor cell survival and remyelination.", "tags": [{"end": 54, "start": 45, "tag": "Chemical"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 78, "start": 64, "tag": "Chemical"}, {"end": 157, "start": 144, "tag": "CellFunction"}, {"end": 78, "start": 70, "tag": "Substance"}, {"end": 130, "start": 100, "tag": "Cell"}, {"end": 139, "start": 131, "tag": "CellFunction"}, {"end": 54, "start": 45, "tag": "PharmacologicSubstance"}]}{"id": "1202_2", "text": "The results show that stemazole enhanced the survival rate and the number of clone formation in a dose-dependent manner and decreased the percentage of cell apoptosis.", "tags": [{"end": 31, "start": 22, "tag": "Chemical"}, {"end": 166, "start": 152, "tag": "CellFunction"}, {"end": 58, "start": 54, "tag": "TemporalConcept"}, {"end": 53, "start": 45, "tag": "CellFunction"}, {"end": 92, "start": 77, "tag": "CellFunction"}, {"end": 31, "start": 22, "tag": "PharmacologicSubstance"}, {"end": 119, "start": 98, "tag": "Finding"}]}{"id": "1202_3", "text": "In particular, the number of cell clones was increased up to 6-fold (p < 0.001) in the stemazole group compared with the control group.", "tags": [{"end": 40, "start": 29, "tag": "Cell"}, {"end": 134, "start": 121, "tag": "PopulationGroup"}, {"end": 102, "start": 97, "tag": "PopulationGroup"}, {"end": 96, "start": 87, "tag": "Chemical"}, {"end": 96, "start": 87, "tag": "PharmacologicSubstance"}]}{"id": "1202_4", "text": "In vivo, we assessed the effect of stemazole on recovering the motor dysfunction and demyelination induced by cuprizone (CPZ).", "tags": [{"end": 44, "start": 35, "tag": "Chemical"}, {"end": 80, "start": 63, "tag": "PathologicFunction"}, {"end": 124, "start": 121, "tag": "Chemical"}, {"end": 98, "start": 85, "tag": "PathologicFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 119, "start": 110, "tag": "Chemical"}, {"end": 44, "start": 35, "tag": "PharmacologicSubstance"}]}{"id": "1202_5", "text": "The results show that stemazole promoted the recovery of motor dysfunction and the repair of myelin sheaths.", "tags": [{"end": 31, "start": 22, "tag": "Chemical"}, {"end": 74, "start": 57, "tag": "PathologicFunction"}, {"end": 53, "start": 45, "tag": "BiologicFunction"}, {"end": 53, "start": 45, "tag": "HealthCareActivity"}, {"end": 53, "start": 45, "tag": "TemporalConcept"}, {"end": 89, "start": 83, "tag": "BiologicFunction"}, {"end": 89, "start": 83, "tag": "HealthCareActivity"}, {"end": 107, "start": 93, "tag": "CellComponent"}, {"end": 31, "start": 22, "tag": "PharmacologicSubstance"}]}{"id": "1202_6", "text": "Compared with the CPZ group, the stemazole group showed a 30.46% increase in the myelin area (p < 0.001), a 37.08% increase in MBP expression (p < 0.01), and a 1.66-fold increase in Olig2 expression (p < 0.001).", "tags": [{"end": 187, "start": 182, "tag": "AminoAcidPeptideOrProtein"}, {"end": 187, "start": 182, "tag": "GeneOrGenome"}, {"end": 21, "start": 18, "tag": "Chemical"}, {"end": 130, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 127, "tag": "GeneOrGenome"}, {"end": 27, "start": 22, "tag": "PopulationGroup"}, {"end": 48, "start": 43, "tag": "PopulationGroup"}, {"end": 87, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 33, "tag": "Chemical"}, {"end": 42, "start": 33, "tag": "PharmacologicSubstance"}, {"end": 141, "start": 131, "tag": "CellFunction"}, {"end": 198, "start": 188, "tag": "CellFunction"}, {"end": 187, "start": 182, "tag": "BiologicallyActiveSubstance"}]}{"id": "1202_7", "text": "Histologically, stemazole had a better effect than the positive control drugs.", "tags": [{"end": 25, "start": 16, "tag": "Chemical"}, {"end": 77, "start": 72, "tag": "PharmacologicSubstance"}, {"end": 25, "start": 16, "tag": "PharmacologicSubstance"}]}{"id": "1202_8", "text": "In conclusion, stemazole promoted OPC survival in vitro and remyelination in vivo, suggesting that this compound may be used as a therapeutic agent against demyelinating disease.", "tags": [{"end": 24, "start": 15, "tag": "Chemical"}, {"end": 112, "start": 104, "tag": "Chemical"}, {"end": 147, "start": 130, "tag": "PharmacologicSubstance"}, {"end": 147, "start": 130, "tag": "HealthCareActivity"}, {"end": 81, "start": 74, "tag": "ResearchActivity"}, {"end": 73, "start": 60, "tag": "CellFunction"}, {"end": 177, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 34, "tag": "CellFunction"}, {"end": 55, "start": 47, "tag": "ResearchActivity"}, {"end": 24, "start": 15, "tag": "PharmacologicSubstance"}]}{"id": "1203_0", "text": "The p70 ribosomal S6 kinases (p70 ribosomal S6 kinase 1 and p70 ribosomal S6 kinase 2) are downstream targets of the mechanistic target of rapamycin signalling pathway.", "tags": [{"end": 28, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 139, "tag": "Chemical"}, {"end": 167, "start": 149, "tag": "CellFunction"}, {"end": 148, "start": 139, "tag": "PharmacologicSubstance"}, {"end": 28, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 60, "tag": "BiologicallyActiveSubstance"}]}{"id": "1203_1", "text": "p70 ribosomal S6 kinase 1 specifically has demonstrated functions in regulating cell size in Drosophila and in insulin-sensitive cell populations in mammals.", "tags": [{"end": 25, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 129, "tag": "Cell"}, {"end": 103, "start": 93, "tag": "Eukaryote"}, {"end": 89, "start": 85, "tag": "OrganismAttribute"}, {"end": 25, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 111, "tag": "PharmacologicSubstance"}, {"end": 156, "start": 149, "tag": "Eukaryote"}]}{"id": "1203_2", "text": "Prior studies demonstrated that the mechanistic target of the rapamycin pathway promotes oligodendrocyte differentiation and developmental myelination; however, how the immediate downstream targets of mechanistic target of rapamycin regulate these processes has not been elucidated.", "tags": [{"end": 178, "start": 169, "tag": "TemporalConcept"}, {"end": 71, "start": 62, "tag": "Chemical"}, {"end": 232, "start": 223, "tag": "Chemical"}, {"end": 79, "start": 72, "tag": "CellFunction"}, {"end": 150, "start": 139, "tag": "CellFunction"}, {"end": 104, "start": 89, "tag": "Cell"}, {"end": 138, "start": 125, "tag": "BiologicFunction"}, {"end": 138, "start": 125, "tag": "TemporalConcept"}, {"end": 120, "start": 105, "tag": "CellFunction"}, {"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 71, "start": 62, "tag": "PharmacologicSubstance"}, {"end": 232, "start": 223, "tag": "PharmacologicSubstance"}]}{"id": "1203_3", "text": "Here, we tested the hypothesis that p70 ribosomal S6 kinase 1 regulates oligodendrocyte differentiation during developmental myelination and remyelination processes in the CNS.", "tags": [{"end": 136, "start": 125, "tag": "CellFunction"}, {"end": 87, "start": 72, "tag": "Cell"}, {"end": 175, "start": 172, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 141, "tag": "CellFunction"}, {"end": 124, "start": 111, "tag": "BiologicFunction"}, {"end": 124, "start": 111, "tag": "TemporalConcept"}, {"end": 103, "start": 88, "tag": "CellFunction"}, {"end": 61, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 36, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1203_4", "text": "We demonstrate that p70 ribosomal S6 kinase activity peaks in oligodendrocyte lineage cells at the time when they transition to myelinating oligodendrocytes during developmental myelination in the mouse spinal cord.", "tags": [{"end": 124, "start": 114, "tag": "CellOrMolecularDysfunction"}, {"end": 189, "start": 178, "tag": "CellFunction"}, {"end": 214, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 62, "tag": "Cell"}, {"end": 177, "start": 164, "tag": "BiologicFunction"}, {"end": 177, "start": 164, "tag": "TemporalConcept"}, {"end": 103, "start": 99, "tag": "TemporalConcept"}, {"end": 156, "start": 128, "tag": "Cell"}, {"end": 202, "start": 197, "tag": "Eukaryote"}, {"end": 52, "start": 20, "tag": "CellFunction"}]}{"id": "1203_5", "text": "We further show p70 ribosomal S6 kinase activity in differentiating oligodendrocytes in acute demyelinating lesions induced by lysophosphatidylcholine injection or by experimental autoimmune encephalomyelitis in mice.", "tags": [{"end": 150, "start": 127, "tag": "Chemical"}, {"end": 115, "start": 94, "tag": "InjuryOrPoisoning"}, {"end": 208, "start": 167, "tag": "ExperimentalModelOfDisease"}, {"end": 160, "start": 151, "tag": "HealthCareActivity"}, {"end": 84, "start": 68, "tag": "Cell"}, {"end": 216, "start": 212, "tag": "Eukaryote"}, {"end": 93, "start": 88, "tag": "TemporalConcept"}, {"end": 48, "start": 16, "tag": "CellFunction"}]}{"id": "1203_6", "text": "In demyelinated lesions, the expression of the p70 ribosomal S6 kinase target, phosphorylated S6 ribosomal protein, was transient and highest in maturing oligodendrocytes.", "tags": [{"end": 70, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 145, "tag": "Cell"}, {"end": 23, "start": 3, "tag": "InjuryOrPoisoning"}, {"end": 129, "start": 120, "tag": "TemporalConcept"}, {"end": 70, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 79, "tag": "BiologicallyActiveSubstance"}]}{"id": "1203_7", "text": "Interestingly, we also identified p70 ribosomal S6 kinase activity in oligodendrocyte lineage cells in active multiple sclerosis lesions.", "tags": [{"end": 128, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 23, "tag": "Finding"}, {"end": 136, "start": 129, "tag": "InjuryOrPoisoning"}, {"end": 99, "start": 70, "tag": "Cell"}, {"end": 66, "start": 34, "tag": "CellFunction"}]}{"id": "1203_8", "text": "Consistent with its predicted function in promoting oligodendrocyte differentiation, we demonstrate that specifically inhibiting p70 ribosomal S6 kinase 1 in cultured oligodendrocyte precursor cells significantly impairs cell lineage progression and expression of myelin basic protein.", "tags": [{"end": 154, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 166, "start": 158, "tag": "ResearchActivity"}, {"end": 233, "start": 221, "tag": "ResearchActivity"}, {"end": 67, "start": 52, "tag": "Cell"}, {"end": 198, "start": 167, "tag": "Cell"}, {"end": 245, "start": 234, "tag": "PathologicFunction"}, {"end": 245, "start": 234, "tag": "TemporalConcept"}, {"end": 83, "start": 68, "tag": "CellFunction"}, {"end": 128, "start": 118, "tag": "BiologicFunction"}, {"end": 284, "start": 264, "tag": "AminoAcidPeptideOrProtein"}, {"end": 284, "start": 264, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 260, "start": 250, "tag": "CellFunction"}]}{"id": "1203_9", "text": "Finally, we used zebrafish to show in vivo that inhibiting p70 ribosomal S6 kinase 1 function in oligodendroglial cells reduces their differentiation and the number of myelin internodes produced.", "tags": [{"end": 26, "start": 17, "tag": "Eukaryote"}, {"end": 185, "start": 175, "tag": "CellComponent"}, {"end": 42, "start": 35, "tag": "ResearchActivity"}, {"end": 174, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 134, "tag": "CellFunction"}, {"end": 58, "start": 48, "tag": "BiologicFunction"}, {"end": 119, "start": 97, "tag": "Cell"}, {"end": 93, "start": 59, "tag": "CellFunction"}]}{"id": "1203_10", "text": "These data reveal an essential function of p70 ribosomal S6 kinase 1 in promoting oligodendrocyte differentiation during development and remyelination across multiple species.", "tags": [{"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 43, "tag": "GeneOrGenome"}, {"end": 68, "start": 47, "tag": "GeneOrGenome"}, {"end": 68, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 167, "tag": "OrganismAttribute"}, {"end": 97, "start": 82, "tag": "Cell"}, {"end": 132, "start": 121, "tag": "BiologicFunction"}, {"end": 132, "start": 121, "tag": "CellFunction"}, {"end": 150, "start": 137, "tag": "CellFunction"}, {"end": 113, "start": 98, "tag": "CellFunction"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}]}{"id": "1203_11", "text": "p70 S6 kinase (S6K) activity in oligodendroglia corresponds to developmental myelination and remyelination in rodents and is present in active lesions of multiple sclerosis.", "tags": [{"end": 13, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 110, "tag": "Eukaryote"}, {"end": 88, "start": 77, "tag": "CellFunction"}, {"end": 172, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 93, "tag": "CellFunction"}, {"end": 150, "start": 143, "tag": "InjuryOrPoisoning"}, {"end": 76, "start": 63, "tag": "BiologicFunction"}, {"end": 76, "start": 63, "tag": "TemporalConcept"}, {"end": 47, "start": 32, "tag": "Cell"}]}{"id": "1203_12", "text": "S6K1 promotes the expression of the myelin basic protein in rodent oligodendrocyte precursor cells and regulates the number of myelin internodes in zebrafish.", "tags": [{"end": 4, "start": 0, "tag": "GeneOrGenome"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 148, "tag": "Eukaryote"}, {"end": 144, "start": 134, "tag": "CellComponent"}, {"end": 66, "start": 60, "tag": "Eukaryote"}, {"end": 98, "start": 67, "tag": "Cell"}, {"end": 133, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 36, "tag": "BiologicallyActiveSubstance"}]}{"id": "1204_0", "text": "Demyelinated lesions in human pons observed after osmotic shifts in serum have been referred to as central pontine myelinolysis (CPM).", "tags": [{"end": 12, "start": 0, "tag": "PathologicFunction"}, {"end": 34, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 13, "tag": "InjuryOrPoisoning"}, {"end": 29, "start": 24, "tag": "Eukaryote"}, {"end": 73, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1204_1", "text": "Astrocytic damage, which is prominent in neuroinflammatory diseases like neuromyelitis optica (NMO) and multiple sclerosis (MS), is considered the primary event during formation of CPM lesions.", "tags": [{"end": 67, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 184, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 185, "tag": "InjuryOrPoisoning"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 0, "tag": "Cell"}, {"end": 17, "start": 11, "tag": "InjuryOrPoisoning"}]}{"id": "1204_2", "text": "Although more data on the effects of astrocyte-derived factors on oligodendrocyte precursor cells (OPCs) and remyelination are emerging, still little is known about remyelination of lesions with primary astrocytic loss.", "tags": [{"end": 103, "start": 99, "tag": "Cell"}, {"end": 97, "start": 66, "tag": "Cell"}, {"end": 189, "start": 182, "tag": "InjuryOrPoisoning"}, {"end": 46, "start": 37, "tag": "Cell"}, {"end": 122, "start": 109, "tag": "CellFunction"}, {"end": 178, "start": 165, "tag": "CellFunction"}, {"end": 33, "start": 26, "tag": "Finding"}, {"end": 18, "start": 14, "tag": "ResearchActivity"}, {"end": 218, "start": 195, "tag": "CellOrMolecularDysfunction"}]}{"id": "1204_3", "text": "In autopsy tissue from patients with CPM as well as in an experimental model, we were able to characterize OPC activation and differentiation.", "tags": [{"end": 40, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 126, "tag": "CellFunction"}, {"end": 10, "start": 3, "tag": "HealthCareActivity"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 17, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 58, "tag": "ResearchActivity"}, {"end": 121, "start": 107, "tag": "CellFunction"}]}{"id": "1204_4", "text": "Injections of the thymidine-analogue BrdU traced the maturation of OPCs activated in early astrocyte-depleted lesions.", "tags": [{"end": 10, "start": 0, "tag": "HealthCareActivity"}, {"end": 71, "start": 67, "tag": "Cell"}, {"end": 63, "start": 53, "tag": "BiologicFunction"}, {"end": 117, "start": 110, "tag": "InjuryOrPoisoning"}, {"end": 90, "start": 85, "tag": "TemporalConcept"}, {"end": 41, "start": 37, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 41, "start": 37, "tag": "PharmacologicSubstance"}, {"end": 100, "start": 91, "tag": "Cell"}, {"end": 27, "start": 18, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 27, "start": 18, "tag": "BiologicallyActiveSubstance"}]}{"id": "1204_5", "text": "We observed rapid activation of the parenchymal NG2(+) OPC reservoir in experimental astrocyte-depleted demyelinated lesions, leading to extensive OPC proliferation.", "tags": [{"end": 51, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 48, "tag": "GeneOrGenome"}, {"end": 124, "start": 117, "tag": "InjuryOrPoisoning"}, {"end": 116, "start": 104, "tag": "PathologicFunction"}, {"end": 164, "start": 147, "tag": "CellFunction"}, {"end": 94, "start": 85, "tag": "Cell"}, {"end": 84, "start": 72, "tag": "ResearchActivity"}, {"end": 28, "start": 18, "tag": "CellFunction"}, {"end": 47, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 55, "tag": "Cell"}, {"end": 124, "start": 72, "tag": "ExperimentalModelOfDisease"}]}{"id": "1204_6", "text": "One week after lesion initiation, most parenchyma-derived OPCs expressed breast carcinoma amplified sequence-1 (BCAS1), indicating the transition into a pre-myelinating state.", "tags": [{"end": 89, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 112, "tag": "GeneOrGenome"}, {"end": 145, "start": 135, "tag": "CellOrMolecularDysfunction"}, {"end": 62, "start": 58, "tag": "Cell"}, {"end": 21, "start": 15, "tag": "InjuryOrPoisoning"}, {"end": 49, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 4, "tag": "TemporalConcept"}, {"end": 174, "start": 169, "tag": "PopulationGroup"}, {"end": 72, "start": 63, "tag": "CellFunction"}, {"end": 32, "start": 22, "tag": "TemporalConcept"}, {"end": 110, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 112, "tag": "BiologicallyActiveSubstance"}]}{"id": "1204_7", "text": "Cells derived from this early parenchymal response often presented a dysfunctional morphology with condensed cytoplasm and few extending processes, and were only sparsely detected among myelin-producing or mature oligodendrocytes.", "tags": [{"end": 93, "start": 69, "tag": "PathologicFunction"}, {"end": 5, "start": 0, "tag": "Cell"}, {"end": 192, "start": 186, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 229, "start": 206, "tag": "Cell"}, {"end": 29, "start": 24, "tag": "TemporalConcept"}, {"end": 41, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 109, "tag": "CellComponent"}]}{"id": "1204_8", "text": "Correspondingly, early stages of human CPM lesions also showed reduced astrocyte numbers and non-myelinating BCAS1(+) oligodendrocytes with dysfunctional morphology.", "tags": [{"end": 42, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 140, "tag": "PathologicFunction"}, {"end": 134, "start": 118, "tag": "Cell"}, {"end": 50, "start": 43, "tag": "InjuryOrPoisoning"}, {"end": 22, "start": 17, "tag": "TemporalConcept"}, {"end": 38, "start": 33, "tag": "Eukaryote"}, {"end": 80, "start": 71, "tag": "Cell"}, {"end": 29, "start": 23, "tag": "TemporalConcept"}, {"end": 114, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 109, "tag": "GeneOrGenome"}, {"end": 114, "start": 109, "tag": "BiologicallyActiveSubstance"}]}{"id": "1204_9", "text": "In the rat model, neural stem cells (NSCs) located in the subventricular zone (SVZ) were activated while the lesion was already partially repopulated with OPCs, giving rise to nestin(+) progenitors that generated oligodendroglial lineage cells in the lesion, which was successively repopulated with astrocytes and remyelinated.", "tags": [{"end": 41, "start": 37, "tag": "Cell"}, {"end": 182, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 155, "tag": "Cell"}, {"end": 115, "start": 109, "tag": "InjuryOrPoisoning"}, {"end": 257, "start": 251, "tag": "InjuryOrPoisoning"}, {"end": 10, "start": 7, "tag": "Eukaryote"}, {"end": 237, "start": 213, "tag": "Cell"}, {"end": 326, "start": 314, "tag": "CellFunction"}, {"end": 77, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 18, "tag": "Cell"}, {"end": 229, "start": 213, "tag": "Cell"}, {"end": 243, "start": 238, "tag": "Cell"}, {"end": 16, "start": 11, "tag": "ResearchActivity"}, {"end": 309, "start": 299, "tag": "Cell"}, {"end": 182, "start": 176, "tag": "BiologicallyActiveSubstance"}, {"end": 197, "start": 186, "tag": "Cell"}]}{"id": "1204_10", "text": "These nestin(+) stem cell-derived progenitors were absent in human CPM cases, which may have contributed to the inefficient lesion repair.", "tags": [{"end": 45, "start": 34, "tag": "Cell"}, {"end": 57, "start": 51, "tag": "Finding"}, {"end": 70, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 124, "tag": "InjuryOrPoisoning"}, {"end": 66, "start": 61, "tag": "Eukaryote"}, {"end": 25, "start": 16, "tag": "Cell"}, {"end": 137, "start": 131, "tag": "BiologicFunction"}, {"end": 137, "start": 131, "tag": "HealthCareActivity"}, {"end": 12, "start": 6, "tag": "BiologicallyActiveSubstance"}]}{"id": "1204_11", "text": "The present study points to the importance of astrocyte-oligodendrocyte interactions for remyelination, highlighting the necessity to further determine the impact of astrocyte dysfunction on remyelination inefficiency in demyelinating disorders including MS.", "tags": [{"end": 217, "start": 205, "tag": "Finding"}, {"end": 84, "start": 46, "tag": "CellFunction"}, {"end": 244, "start": 221, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 55, "start": 46, "tag": "Cell"}, {"end": 175, "start": 166, "tag": "Cell"}, {"end": 71, "start": 56, "tag": "Cell"}, {"end": 102, "start": 89, "tag": "CellFunction"}, {"end": 204, "start": 191, "tag": "CellFunction"}, {"end": 257, "start": 255, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 72, "tag": "Finding"}, {"end": 187, "start": 176, "tag": "PathologicFunction"}]}{"id": "1205_0", "text": "Myelination by oligodendrocytes (OLs) is an important biological process essential for central nervous system (CNS) development and functions.", "tags": [{"end": 72, "start": 54, "tag": "BiologicFunction"}, {"end": 31, "start": 15, "tag": "Cell"}, {"end": 36, "start": 33, "tag": "Cell"}, {"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 109, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 116, "tag": "BiologicFunction"}, {"end": 127, "start": 116, "tag": "CellFunction"}]}{"id": "1205_1", "text": "Oligodendroglial lineage cells undergo several morphological and molecular changes at different stages of their lineage progression into myelinating OLs.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 152, "start": 137, "tag": "Cell"}, {"end": 30, "start": 0, "tag": "Cell"}, {"end": 102, "start": 96, "tag": "TemporalConcept"}, {"end": 82, "start": 47, "tag": "Finding"}, {"end": 131, "start": 112, "tag": "CellFunction"}]}{"id": "1205_2", "text": "The transition steps of the oligodendrocyte progenitor cells (OPCs) to myelinating oligodendrocytes are defined by a specific pattern of regulated gene expression, which is under the control of coordinated signaling pathways.", "tags": [{"end": 14, "start": 4, "tag": "CellOrMolecularDysfunction"}, {"end": 20, "start": 15, "tag": "HealthCareActivity"}, {"end": 66, "start": 62, "tag": "Cell"}, {"end": 60, "start": 28, "tag": "Cell"}, {"end": 99, "start": 71, "tag": "Cell"}, {"end": 162, "start": 147, "tag": "CellFunction"}, {"end": 224, "start": 206, "tag": "CellFunction"}]}{"id": "1205_3", "text": "Any abnormal development, loss or failure of oligodendrocytes to myelinate axons can lead to several neurodegenerative diseases like multiple sclerosis (MS).", "tags": [{"end": 24, "start": 4, "tag": "PathologicFunction"}, {"end": 74, "start": 65, "tag": "CellComponent"}, {"end": 74, "start": 65, "tag": "CellFunction"}, {"end": 80, "start": 75, "tag": "CellComponent"}, {"end": 61, "start": 45, "tag": "Cell"}, {"end": 151, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 153, "tag": "DiseaseOrSyndrome"}]}{"id": "1205_4", "text": "MS is characterized by inflammation and demyelination, and current treatments target only the immune component of the disease, but have little impact on remyelination.", "tags": [{"end": 110, "start": 94, "tag": "BiologicFunction"}, {"end": 35, "start": 23, "tag": "PathologicFunction"}, {"end": 66, "start": 59, "tag": "TemporalConcept"}, {"end": 77, "start": 67, "tag": "HealthCareActivity"}, {"end": 77, "start": 67, "tag": "ResearchActivity"}, {"end": 166, "start": 153, "tag": "CellFunction"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 40, "tag": "PathologicFunction"}]}{"id": "1205_5", "text": "Recently, several pharmacological compounds enhancing remyelination have been identified and some of them are in clinical trials.", "tags": [{"end": 43, "start": 18, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 54, "tag": "CellFunction"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 128, "start": 113, "tag": "ResearchActivity"}]}{"id": "1205_6", "text": "Here, we will review the current knowledge on oligodendrocyte differentiation, myelination and remyelination.", "tags": [{"end": 77, "start": 62, "tag": "CellFunction"}, {"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 42, "start": 33, "tag": "Finding"}, {"end": 32, "start": 25, "tag": "TemporalConcept"}, {"end": 61, "start": 46, "tag": "Cell"}, {"end": 108, "start": 95, "tag": "CellFunction"}, {"end": 90, "start": 79, "tag": "CellFunction"}]}{"id": "1205_7", "text": "We will focus on MS as a pathological condition, the most common chronic inflammatory demyelinating disease of the CNS in young adults.", "tags": [{"end": 134, "start": 122, "tag": "PopulationGroup"}, {"end": 107, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 73, "tag": "PathologicFunction"}, {"end": 118, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 65, "tag": "TemporalConcept"}]}{"id": "1206_0", "text": "Oligodendrocyte precursor cells (OPCs), whose primary function is to generate myelinating oligodendrocytes, are distributed widely throughout the developing and mature central nervous system.", "tags": [{"end": 37, "start": 33, "tag": "Cell"}, {"end": 190, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 78, "tag": "Cell"}, {"end": 167, "start": 161, "tag": "TemporalConcept"}, {"end": 31, "start": 0, "tag": "Cell"}]}{"id": "1206_1", "text": "They originate from several defined subdomains in the embryonic germinal zones at different developmental stages and in the adult.", "tags": [{"end": 112, "start": 92, "tag": "TemporalConcept"}, {"end": 129, "start": 124, "tag": "PopulationGroup"}, {"end": 78, "start": 54, "tag": "EmbryonicStructure"}]}{"id": "1206_2", "text": "While many phenotypic differences have been observed among OPCs in different anatomical regions and among those arising from different germinal zones, we know relatively little about the molecular and cellular mechanisms by which the historical and current niches shape the behavior of oligodendrocyte lineage cells.", "tags": [{"end": 244, "start": 234, "tag": "Finding"}, {"end": 21, "start": 11, "tag": "OrganismAttribute"}, {"end": 282, "start": 274, "tag": "BiologicFunction"}, {"end": 282, "start": 274, "tag": "IndividualBehavior"}, {"end": 282, "start": 274, "tag": "ResearchActivity"}, {"end": 63, "start": 59, "tag": "Cell"}, {"end": 315, "start": 286, "tag": "Cell"}, {"end": 33, "start": 22, "tag": "Finding"}, {"end": 256, "start": 249, "tag": "TemporalConcept"}, {"end": 149, "start": 135, "tag": "EmbryonicStructure"}, {"end": 95, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1206_3", "text": "This minireview will discuss how the behavior of oligodendrocyte lineage cells is influenced by the developmental niches from which subpopulations of OPCs emerge, by the current niches surrounding OPCs in different regions, and in pathological states that cause deviations from the normal density of oligodendrocyte lineage cells and myelin.", "tags": [{"end": 146, "start": 132, "tag": "PopulationGroup"}, {"end": 296, "start": 282, "tag": "Finding"}, {"end": 15, "start": 5, "tag": "ResearchActivity"}, {"end": 45, "start": 37, "tag": "BiologicFunction"}, {"end": 45, "start": 37, "tag": "IndividualBehavior"}, {"end": 45, "start": 37, "tag": "ResearchActivity"}, {"end": 154, "start": 150, "tag": "Cell"}, {"end": 201, "start": 197, "tag": "Cell"}, {"end": 340, "start": 334, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 49, "tag": "Cell"}, {"end": 329, "start": 300, "tag": "Cell"}, {"end": 113, "start": 100, "tag": "BiologicFunction"}, {"end": 113, "start": 100, "tag": "TemporalConcept"}, {"end": 177, "start": 170, "tag": "TemporalConcept"}, {"end": 250, "start": 244, "tag": "TemporalConcept"}]}{"id": "1207_0", "text": "Oligodendrocyte-formed myelin sheaths allow fast synaptic transmission in the brain and their degeneration leads to demyelinating diseases such as multiple sclerosis.", "tags": [{"end": 138, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 23, "tag": "CellComponent"}, {"end": 106, "start": 94, "tag": "PathologicFunction"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 70, "start": 49, "tag": "CellFunction"}]}{"id": "1207_1", "text": "Remyelination requires the differentiation of oligodendrocyte progenitor cells into mature oligodendrocytes but, in chronic neurodegenerative disorders, remyelination fails due to adverse environment.", "tags": [{"end": 151, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 166, "start": 153, "tag": "CellFunction"}, {"end": 107, "start": 84, "tag": "Cell"}, {"end": 78, "start": 46, "tag": "Cell"}, {"end": 42, "start": 27, "tag": "CellFunction"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 123, "start": 116, "tag": "TemporalConcept"}, {"end": 151, "start": 124, "tag": "DiseaseOrSyndrome"}]}{"id": "1207_2", "text": "Therefore, a strategy to prompt oligodendrocyte progenitor cell differentiation towards myelinating oligodendrocytes is required.", "tags": [{"end": 63, "start": 32, "tag": "Cell"}, {"end": 79, "start": 59, "tag": "CellFunction"}, {"end": 116, "start": 88, "tag": "Cell"}]}{"id": "1207_3", "text": "The neuromodulator adenosine, and its receptors (A(1), A(2A), A(2B) and A(3) receptors: A(1R), A(2A)R, A(2B)R and A(3)R), are crucial mediators in remyelination processes.", "tags": [{"end": 18, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 19, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 143, "start": 134, "tag": "Finding"}, {"end": 160, "start": 147, "tag": "CellFunction"}, {"end": 47, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 77, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1207_4", "text": "It is known that A(1)Rs facilitate oligodendrocyte progenitor cell maturation and migration whereas the A(3)Rs initiates apoptosis in oligodendrocyte progenitor cells.", "tags": [{"end": 61, "start": 35, "tag": "Cell"}, {"end": 77, "start": 62, "tag": "CellFunction"}, {"end": 166, "start": 134, "tag": "Cell"}, {"end": 91, "start": 82, "tag": "CellFunction"}, {"end": 130, "start": 121, "tag": "CellFunction"}, {"end": 23, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 104, "tag": "BiologicallyActiveSubstance"}]}{"id": "1207_5", "text": "Our group of research contributed to the field by demonstrating that A(2A)R and A(2B)R inhibit oligodendrocyte progenitor cell maturation by reducing voltage-dependent K+ currents necessary for cell differentiation.", "tags": [{"end": 126, "start": 95, "tag": "Cell"}, {"end": 214, "start": 194, "tag": "CellFunction"}, {"end": 9, "start": 4, "tag": "PopulationGroup"}, {"end": 137, "start": 122, "tag": "CellFunction"}, {"end": 21, "start": 13, "tag": "ResearchActivity"}, {"end": 75, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 179, "start": 150, "tag": "CellFunction"}]}{"id": "1207_6", "text": "The present review summarizes the possible role of adenosine receptor ligands as potential therapeutic targets in demyelinating pathologies such as multiple sclerosis.", "tags": [{"end": 77, "start": 51, "tag": "CellFunction"}, {"end": 110, "start": 81, "tag": "ResearchActivity"}, {"end": 139, "start": 114, "tag": "PathologicFunction"}, {"end": 166, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 77, "start": 51, "tag": "BiologicallyActiveSubstance"}]}{"id": "1208_0", "text": "Myelination plays an important role in cognitive development and in demyelinating diseases like multiple sclerosis (MS), where failure of remyelination promotes permanent neuro-axonal damage.", "tags": [{"end": 60, "start": 39, "tag": "BiologicFunction"}, {"end": 170, "start": 161, "tag": "TemporalConcept"}, {"end": 90, "start": 68, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 177, "tag": "CellComponent"}, {"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 151, "start": 138, "tag": "CellFunction"}, {"end": 118, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 127, "tag": "CellOrMolecularDysfunction"}, {"end": 176, "start": 171, "tag": "Cell"}, {"end": 190, "start": 184, "tag": "InjuryOrPoisoning"}]}{"id": "1208_1", "text": "Modification of cell surface receptors with branched N-glycans coordinates cell growth and differentiation by controlling glycoprotein clustering, signaling, and endocytosis.", "tags": [{"end": 173, "start": 162, "tag": "CellFunction"}, {"end": 86, "start": 75, "tag": "CellFunction"}, {"end": 156, "start": 147, "tag": "CellFunction"}, {"end": 106, "start": 91, "tag": "CellFunction"}, {"end": 38, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 16, "tag": "CellComponent"}, {"end": 38, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 53, "tag": "Chemical"}, {"end": 134, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 122, "tag": "CellFunction"}]}{"id": "1208_2", "text": "GlcNAc is a rate-limiting metabolite for N-glycan branching.", "tags": [{"end": 36, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 12, "tag": "TemporalConcept"}, {"end": 6, "start": 0, "tag": "Chemical"}, {"end": 59, "start": 41, "tag": "CellFunction"}]}{"id": "1208_3", "text": "Here we report that GlcNAc and N-glycan branching trigger oligodendrogenesis from precursor cells by inhibiting platelet-derived growth factor receptor-alpha cell endocytosis.", "tags": [{"end": 157, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 163, "tag": "CellFunction"}, {"end": 76, "start": 58, "tag": "BiologicFunction"}, {"end": 97, "start": 82, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 162, "start": 158, "tag": "Cell"}, {"end": 111, "start": 101, "tag": "BiologicFunction"}, {"end": 157, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 20, "tag": "Chemical"}, {"end": 49, "start": 31, "tag": "CellFunction"}]}{"id": "1208_4", "text": "Supplying oral GlcNAc to lactating mice drives primary myelination in newborn pups via secretion in breast milk, whereas genetically blocking N-glycan branching markedly inhibits primary myelination.", "tags": [{"end": 14, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 25, "tag": "Finding"}, {"end": 111, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 77, "start": 70, "tag": "TemporalConcept"}, {"end": 39, "start": 35, "tag": "Eukaryote"}, {"end": 96, "start": 87, "tag": "CellFunction"}, {"end": 96, "start": 87, "tag": "BiologicFunction"}, {"end": 66, "start": 47, "tag": "CellFunction"}, {"end": 198, "start": 179, "tag": "CellFunction"}, {"end": 21, "start": 15, "tag": "Chemical"}, {"end": 82, "start": 78, "tag": "Eukaryote"}, {"end": 141, "start": 121, "tag": "ResearchActivity"}, {"end": 160, "start": 142, "tag": "CellFunction"}]}{"id": "1208_5", "text": "In adult mice with toxin (cuprizone)-induced demyelination, oral GlcNAc prevents neuro-axonal damage by driving myelin repair.", "tags": [{"end": 24, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 26, "tag": "Chemical"}, {"end": 125, "start": 112, "tag": "CellFunction"}, {"end": 13, "start": 9, "tag": "Eukaryote"}, {"end": 58, "start": 45, "tag": "PathologicFunction"}, {"end": 8, "start": 3, "tag": "PopulationGroup"}, {"end": 125, "start": 119, "tag": "BiologicFunction"}, {"end": 125, "start": 119, "tag": "HealthCareActivity"}, {"end": 71, "start": 65, "tag": "Chemical"}, {"end": 100, "start": 94, "tag": "InjuryOrPoisoning"}]}{"id": "1208_6", "text": "In MS patients, endogenous serum GlcNAc levels inversely correlated with imaging measures of demyelination and microstructural damage.", "tags": [{"end": 80, "start": 73, "tag": "HealthCareActivity"}, {"end": 14, "start": 6, "tag": "PatientOrDisabledGroup"}, {"end": 32, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 5, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 93, "tag": "PathologicFunction"}, {"end": 39, "start": 33, "tag": "Chemical"}, {"end": 133, "start": 127, "tag": "InjuryOrPoisoning"}]}{"id": "1208_7", "text": "Our data identify N-glycan branching and GlcNAc as critical regulators of primary myelination and myelin repair and suggest that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.", "tags": [{"end": 133, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 189, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 98, "tag": "CellFunction"}, {"end": 93, "start": 74, "tag": "CellFunction"}, {"end": 197, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 111, "start": 105, "tag": "BiologicFunction"}, {"end": 111, "start": 105, "tag": "HealthCareActivity"}, {"end": 163, "start": 148, "tag": "CellFunction"}, {"end": 140, "start": 134, "tag": "Chemical"}, {"end": 36, "start": 18, "tag": "CellFunction"}, {"end": 47, "start": 41, "tag": "Chemical"}]}{"id": "1209_0", "text": "Purpose of the review Despite the significant progress in the development of disease-modifying treatments for multiple sclerosis (MS), repair of existing damage is still poorly addressed.", "tags": [{"end": 54, "start": 46, "tag": "TemporalConcept"}, {"end": 105, "start": 77, "tag": "HealthCareActivity"}, {"end": 128, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 62, "tag": "BiologicFunction"}, {"end": 73, "start": 62, "tag": "CellFunction"}, {"end": 21, "start": 15, "tag": "ResearchActivity"}, {"end": 21, "start": 15, "tag": "HealthCareActivity"}, {"end": 105, "start": 95, "tag": "HealthCareActivity"}, {"end": 105, "start": 95, "tag": "ResearchActivity"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 135, "tag": "BiologicFunction"}, {"end": 141, "start": 135, "tag": "HealthCareActivity"}, {"end": 160, "start": 154, "tag": "InjuryOrPoisoning"}]}{"id": "1209_1", "text": "Current research focuses on stem cell-based therapies as a suitable alternative or complement to current drug therapies.", "tags": [{"end": 119, "start": 105, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 16, "start": 8, "tag": "ResearchActivity"}, {"end": 104, "start": 97, "tag": "TemporalConcept"}, {"end": 53, "start": 44, "tag": "HealthCareActivity"}, {"end": 119, "start": 110, "tag": "HealthCareActivity"}, {"end": 109, "start": 105, "tag": "PharmacologicSubstance"}, {"end": 37, "start": 28, "tag": "Cell"}]}{"id": "1209_2", "text": "Recent findings Myelin damage is a hallmark of multiple sclerosis, and novel approaches leading to remyelination represent a promising tool to prevent neurodegeneration of the underlying axon.", "tags": [{"end": 65, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 187, "tag": "CellComponent"}, {"end": 22, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 168, "start": 151, "tag": "CellOrMolecularDysfunction"}, {"end": 112, "start": 99, "tag": "CellFunction"}, {"end": 43, "start": 35, "tag": "Finding"}, {"end": 29, "start": 23, "tag": "InjuryOrPoisoning"}]}{"id": "1209_3", "text": "With increasing evidence of diminishing remyelination capacity of the MS brain with ageing and disease progression, exogenous cell transplantation is a promising therapeutic approach for restoration of oligodendrocyte precursor cell pool reserve and myelin regeneration.", "tags": [{"end": 90, "start": 84, "tag": "BiologicFunction"}, {"end": 245, "start": 238, "tag": "TemporalConcept"}, {"end": 182, "start": 162, "tag": "HealthCareActivity"}, {"end": 24, "start": 5, "tag": "Finding"}, {"end": 256, "start": 250, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 269, "start": 257, "tag": "BiologicFunction"}, {"end": 245, "start": 202, "tag": "Cell"}, {"end": 269, "start": 257, "tag": "HealthCareActivity"}, {"end": 269, "start": 250, "tag": "CellFunction"}, {"end": 146, "start": 126, "tag": "HealthCareActivity"}, {"end": 78, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 103, "tag": "PathologicFunction"}, {"end": 114, "start": 103, "tag": "TemporalConcept"}, {"end": 62, "start": 54, "tag": "Finding"}, {"end": 114, "start": 95, "tag": "PathologicFunction"}, {"end": 53, "start": 40, "tag": "CellFunction"}, {"end": 72, "start": 70, "tag": "DiseaseOrSyndrome"}]}{"id": "1209_4", "text": "The present review summarizes recent developments of remyelinating therapies in multiple sclerosis, focusing on exogenous cell-based strategies and discussing related scientific, practical, and ethical concerns.", "tags": [{"end": 49, "start": 37, "tag": "BiologicFunction"}, {"end": 49, "start": 37, "tag": "CellFunction"}, {"end": 98, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 53, "tag": "HealthCareActivity"}, {"end": 126, "start": 122, "tag": "Cell"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 143, "start": 133, "tag": "ResearchActivity"}, {"end": 143, "start": 133, "tag": "BiologicFunction"}, {"end": 36, "start": 30, "tag": "TemporalConcept"}]}{"id": "1210_0", "text": "Multiple sclerosis (MS) is a neuroimmune disorder characterized by inflammation, CNS demyelination, and progressive neurodegeneration.", "tags": [{"end": 84, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 67, "tag": "PathologicFunction"}, {"end": 133, "start": 116, "tag": "CellOrMolecularDysfunction"}, {"end": 115, "start": 104, "tag": "TemporalConcept"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 85, "tag": "PathologicFunction"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 29, "tag": "DiseaseOrSyndrome"}]}{"id": "1210_1", "text": "Chronic MS patients exhibit impaired remyelination capacity, partly due to the changes that oligodendrocyte precursor cells (OPCs) undergo in response to the MS lesion environment.", "tags": [{"end": 129, "start": 125, "tag": "Cell"}, {"end": 123, "start": 92, "tag": "Cell"}, {"end": 167, "start": 161, "tag": "InjuryOrPoisoning"}, {"end": 19, "start": 11, "tag": "PatientOrDisabledGroup"}, {"end": 59, "start": 51, "tag": "Finding"}, {"end": 50, "start": 37, "tag": "CellFunction"}, {"end": 10, "start": 8, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 79, "tag": "Finding"}, {"end": 179, "start": 168, "tag": "NaturalPhenomenonOrProcess"}]}{"id": "1210_2", "text": "The cytokine tumor necrosis factor (TNF) is present in the MS-affected CNS and has been implicated in disease pathophysiology.", "tags": [{"end": 12, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 36, "tag": "GeneOrGenome"}, {"end": 39, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 110, "tag": "PathologicFunction"}, {"end": 125, "start": 110, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 13, "tag": "BiologicallyActiveSubstance"}]}{"id": "1210_3", "text": "Of the two active forms of TNF, transmembrane (tmTNF) and soluble (solTNF), tmTNF signals via TNFR2 mediating protective and reparative effects, including remyelination, whereas solTNF signals predominantly via TNFR1 promoting neurotoxicity.", "tags": [{"end": 30, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 27, "tag": "GeneOrGenome"}, {"end": 30, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 32, "tag": "CellComponent"}, {"end": 99, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 94, "tag": "GeneOrGenome"}, {"end": 216, "start": 211, "tag": "AminoAcidPeptideOrProtein"}, {"end": 216, "start": 211, "tag": "GeneOrGenome"}, {"end": 216, "start": 211, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 58, "tag": "CellComponent"}, {"end": 89, "start": 82, "tag": "CellFunction"}, {"end": 192, "start": 185, "tag": "CellFunction"}, {"end": 168, "start": 155, "tag": "CellFunction"}, {"end": 143, "start": 136, "tag": "Finding"}, {"end": 240, "start": 227, "tag": "InjuryOrPoisoning"}, {"end": 99, "start": 94, "tag": "BiologicallyActiveSubstance"}]}{"id": "1210_4", "text": "To better understand the mechanisms underlying repair failure in MS, we investigated the cellular responses of OPCs to inflammatory exposure and the specific role of TNFR2 signaling in their modulation.", "tags": [{"end": 171, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 166, "tag": "GeneOrGenome"}, {"end": 115, "start": 111, "tag": "Cell"}, {"end": 181, "start": 172, "tag": "CellFunction"}, {"end": 131, "start": 119, "tag": "PathologicFunction"}, {"end": 97, "start": 89, "tag": "Cell"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 47, "tag": "BiologicFunction"}, {"end": 53, "start": 47, "tag": "HealthCareActivity"}, {"end": 61, "start": 47, "tag": "PathologicFunction"}, {"end": 171, "start": 166, "tag": "BiologicallyActiveSubstance"}]}{"id": "1210_5", "text": "Following treatment of cultured OPCs with IFN gamma, IL1 beta, and TNF, we observed, by RNA sequencing, marked inflammatory and immune activation of OPCs, accompanied by metabolic changes and dysregulation of their proliferation and differentiation programming.", "tags": [{"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 88, "tag": "ResearchActivity"}, {"end": 179, "start": 170, "tag": "CellFunction"}, {"end": 145, "start": 128, "tag": "BiologicFunction"}, {"end": 36, "start": 32, "tag": "Cell"}, {"end": 153, "start": 149, "tag": "Cell"}, {"end": 248, "start": 233, "tag": "CellFunction"}, {"end": 228, "start": 215, "tag": "CellFunction"}, {"end": 123, "start": 111, "tag": "PathologicFunction"}, {"end": 19, "start": 10, "tag": "HealthCareActivity"}, {"end": 19, "start": 10, "tag": "ResearchActivity"}, {"end": 31, "start": 23, "tag": "ResearchActivity"}, {"end": 51, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 180, "tag": "Finding"}]}{"id": "1210_6", "text": "We also established the high likelihood of cell-cell interaction between OPCs and microglia in neuroinflammatory conditions, with OPCs able to produce chemokines that can recruit and activate microglia.", "tags": [{"end": 64, "start": 43, "tag": "CellFunction"}, {"end": 77, "start": 73, "tag": "Cell"}, {"end": 134, "start": 130, "tag": "Cell"}, {"end": 91, "start": 82, "tag": "Cell"}, {"end": 201, "start": 192, "tag": "Cell"}, {"end": 112, "start": 95, "tag": "PathologicFunction"}, {"end": 161, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 151, "tag": "BiologicallyActiveSubstance"}]}{"id": "1210_7", "text": "Importantly, we showed that these functions are exacerbated when TNFR2 is ablated.", "tags": [{"end": 70, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 65, "tag": "GeneOrGenome"}, {"end": 70, "start": 65, "tag": "BiologicallyActiveSubstance"}]}{"id": "1210_8", "text": "Together, our data indicate that neuroinflammation leads OPCs to shift towards an immunomodulatory phenotype while diminishing their capacity to proliferate and differentiate, thus impairing their repair function.", "tags": [{"end": 61, "start": 57, "tag": "Cell"}, {"end": 174, "start": 161, "tag": "CellFunction"}, {"end": 141, "start": 133, "tag": "Finding"}, {"end": 108, "start": 99, "tag": "OrganismAttribute"}, {"end": 18, "start": 14, "tag": "ResearchActivity"}, {"end": 50, "start": 33, "tag": "PathologicFunction"}, {"end": 203, "start": 197, "tag": "BiologicFunction"}, {"end": 203, "start": 197, "tag": "HealthCareActivity"}, {"end": 98, "start": 82, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 82, "tag": "BiologicFunction"}, {"end": 98, "start": 82, "tag": "HealthCareActivity"}]}{"id": "1210_9", "text": "Furthermore, we demonstrated that TNFR2 plays a key role in this process, suggesting that boosting TNFR2 activation or its downstream signals could be an effective strategy to restore OPC reparative capacity in demyelinating disease.", "tags": [{"end": 39, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 34, "tag": "GeneOrGenome"}, {"end": 104, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 99, "tag": "GeneOrGenome"}, {"end": 187, "start": 184, "tag": "Cell"}, {"end": 232, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 134, "tag": "CellFunction"}, {"end": 207, "start": 199, "tag": "Finding"}, {"end": 39, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 99, "tag": "BiologicallyActiveSubstance"}]}{"id": "1211_0", "text": "Oligodendrocyte precursor cell (OPC) migration is a mechanism involved in remyelination; these cells migrate from niches in the adult CNS.", "tags": [{"end": 35, "start": 32, "tag": "Cell"}, {"end": 46, "start": 37, "tag": "CellFunction"}, {"end": 30, "start": 16, "tag": "Cell"}, {"end": 30, "start": 0, "tag": "Cell"}, {"end": 137, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 95, "tag": "Cell"}, {"end": 30, "start": 26, "tag": "Cell"}, {"end": 87, "start": 74, "tag": "CellFunction"}, {"end": 133, "start": 128, "tag": "PopulationGroup"}, {"end": 120, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1211_1", "text": "However, age and disease reduce the pool of OPCs; as a result, the remyelination capacity of the CNS decreases over time.", "tags": [{"end": 48, "start": 44, "tag": "Cell"}, {"end": 100, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 81, "tag": "Finding"}, {"end": 12, "start": 9, "tag": "OrganismAttribute"}, {"end": 120, "start": 116, "tag": "TemporalConcept"}, {"end": 80, "start": 67, "tag": "CellFunction"}]}{"id": "1211_2", "text": "Several experimental studies have introduced OPCs to the brain via direct injection or intrathecal administration.", "tags": [{"end": 28, "start": 8, "tag": "ResearchActivity"}, {"end": 98, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 45, "tag": "Cell"}, {"end": 62, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 74, "tag": "HealthCareActivity"}, {"end": 113, "start": 99, "tag": "HealthCareActivity"}]}{"id": "1211_3", "text": "In this study, we used the nose-to brain pathway to deliver oligodendrocyte lineage cells (human oligodendroglioma (HOG) cells), which behave similarly to OPCs in vitro.", "tags": [{"end": 48, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 155, "tag": "Cell"}, {"end": 89, "start": 60, "tag": "Cell"}, {"end": 83, "start": 60, "tag": "Cell"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 96, "start": 91, "tag": "Eukaryote"}, {"end": 126, "start": 115, "tag": "Cell"}, {"end": 168, "start": 160, "tag": "ResearchActivity"}, {"end": 48, "start": 41, "tag": "CellFunction"}, {"end": 114, "start": 97, "tag": "DiseaseOrSyndrome"}]}{"id": "1211_4", "text": "To this end, we administered GFP-labelled HOG cells intranasally to experimental animals, which were subsequently euthanised at 30 or 60 days.", "tags": [{"end": 51, "start": 42, "tag": "Cell"}, {"end": 141, "start": 137, "tag": "TemporalConcept"}, {"end": 88, "start": 81, "tag": "Eukaryote"}, {"end": 80, "start": 68, "tag": "ResearchActivity"}, {"end": 32, "start": 29, "tag": "Chemical"}, {"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1211_5", "text": "Our results show that the intranasal route is a viable route to the CNS and that HOG cells administered intranasally migrate preferentially to niches of OPCs (clusters created during embryonic development and adult life).", "tags": [{"end": 204, "start": 183, "tag": "BiologicFunction"}, {"end": 157, "start": 153, "tag": "Cell"}, {"end": 71, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 204, "start": 193, "tag": "BiologicFunction"}, {"end": 204, "start": 193, "tag": "CellFunction"}, {"end": 90, "start": 81, "tag": "Cell"}, {"end": 219, "start": 215, "tag": "TemporalConcept"}, {"end": 214, "start": 209, "tag": "PopulationGroup"}, {"end": 149, "start": 143, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 91, "tag": "HealthCareActivity"}]}{"id": "1211_6", "text": "Our study provides evidence, albeit limited, that HOG cells either form clusters or adhere to clusters of OPCs in the brains of experimental animals.", "tags": [{"end": 140, "start": 128, "tag": "ResearchActivity"}, {"end": 110, "start": 106, "tag": "Cell"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 27, "start": 19, "tag": "Finding"}, {"end": 59, "start": 50, "tag": "Cell"}, {"end": 148, "start": 141, "tag": "Eukaryote"}, {"end": 124, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1212_0", "text": "Remyelination is a physiological response to demyelinating events aiming to restore saltatory conduction and preserve axonal integrity.", "tags": [{"end": 41, "start": 19, "tag": "BiologicFunction"}, {"end": 104, "start": 84, "tag": "BiologicFunction"}, {"end": 58, "start": 45, "tag": "PathologicFunction"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 134, "start": 118, "tag": "CellFunction"}]}{"id": "1212_1", "text": "Resident oligodendrocyte precursor cells (OPC) of the CNS tissue under appropriate conditions are mobilized to proliferate, migrate, and differentiate, in order to produce new myelin sheaths in the demyelinated lesion.", "tags": [{"end": 8, "start": 0, "tag": "PopulationGroup"}, {"end": 45, "start": 42, "tag": "Cell"}, {"end": 40, "start": 9, "tag": "Cell"}, {"end": 150, "start": 137, "tag": "CellFunction"}, {"end": 217, "start": 211, "tag": "InjuryOrPoisoning"}, {"end": 210, "start": 198, "tag": "PathologicFunction"}, {"end": 190, "start": 176, "tag": "CellComponent"}, {"end": 57, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1212_2", "text": "In multiple sclerosis (MS), the most common immune-mediated demyelinating disease, remyelination efficiency declines with increasing age and disease duration.", "tags": [{"end": 157, "start": 141, "tag": "TemporalConcept"}, {"end": 21, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 97, "tag": "Finding"}, {"end": 136, "start": 133, "tag": "OrganismAttribute"}, {"end": 96, "start": 83, "tag": "CellFunction"}, {"end": 25, "start": 23, "tag": "DiseaseOrSyndrome"}]}{"id": "1212_3", "text": "As myelin regeneration attempts in clinical trials so far are scarce, and have been met with limited success, the need to explore new remyelinating strategies is more compelling.", "tags": [{"end": 147, "start": 134, "tag": "CellFunction"}, {"end": 22, "start": 3, "tag": "CellFunction"}, {"end": 158, "start": 134, "tag": "ResearchActivity"}, {"end": 50, "start": 35, "tag": "ResearchActivity"}]}{"id": "1212_4", "text": "Recently, ageing and cellular senescence have been implicated in the pathophysiology of a number of neurodegenerative diseases, including multiple sclerosis.", "tags": [{"end": 16, "start": 10, "tag": "BiologicFunction"}, {"end": 156, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 69, "tag": "PathologicFunction"}, {"end": 84, "start": 69, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 40, "start": 21, "tag": "CellFunction"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}]}{"id": "1212_5", "text": "Evidence on OPC senescence brings forward the possibility of exploiting cellular senescence as a possible target for promoting the endogenous remyelinating capacity of the CNS.", "tags": [{"end": 155, "start": 142, "tag": "CellFunction"}, {"end": 175, "start": 172, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 156, "tag": "Finding"}, {"end": 26, "start": 12, "tag": "CellFunction"}, {"end": 91, "start": 72, "tag": "CellFunction"}]}{"id": "1212_6", "text": "Here we discuss the data indicating how cellular senescence affects remyelination, and the putative benefits to be drawn through the use of senolytic or senomorphic therapies targeting senescent cell populations in MS.", "tags": [{"end": 81, "start": 68, "tag": "CellFunction"}, {"end": 174, "start": 165, "tag": "HealthCareActivity"}, {"end": 149, "start": 140, "tag": "HealthCareActivity"}, {"end": 217, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 40, "tag": "CellFunction"}, {"end": 24, "start": 20, "tag": "ResearchActivity"}, {"end": 211, "start": 185, "tag": "Cell"}, {"end": 108, "start": 91, "tag": "Finding"}, {"end": 174, "start": 153, "tag": "HealthCareActivity"}]}{"id": "1213_0", "text": "Myelin is the lipid-rich structure formed by oligodendrocytes (OLs) that wraps the axons in multilayered sheaths, assuring protection, efficient saltatory signal conduction and metabolic support to neurons.", "tags": [{"end": 194, "start": 177, "tag": "CellFunction"}, {"end": 88, "start": 83, "tag": "CellComponent"}, {"end": 61, "start": 45, "tag": "Cell"}, {"end": 66, "start": 63, "tag": "Cell"}, {"end": 172, "start": 145, "tag": "BiologicFunction"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 205, "start": 198, "tag": "Cell"}, {"end": 19, "start": 14, "tag": "Chemical"}]}{"id": "1213_1", "text": "In the last few years, the impact of OL dysfunction and myelin damage has progressively received more attention and is now considered to be a major contributing factor to neurodegeneration in several neurological diseases, including amyotrophic lateral sclerosis (ALS).", "tags": [{"end": 111, "start": 102, "tag": "BiologicFunction"}, {"end": 51, "start": 37, "tag": "CellOrMolecularDysfunction"}, {"end": 267, "start": 264, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 16, "tag": "TemporalConcept"}, {"end": 188, "start": 171, "tag": "CellOrMolecularDysfunction"}, {"end": 262, "start": 233, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 200, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 63, "tag": "InjuryOrPoisoning"}]}{"id": "1213_2", "text": "Upon OL injury, oligodendrocyte precursor cells (OPCs) of adult nervous tissue sustain the generation of new OLs for myelin reconstitution, but this spontaneous regeneration process fails to successfully counteract myelin damage.", "tags": [{"end": 78, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 117, "tag": "CellFunction"}, {"end": 53, "start": 49, "tag": "Cell"}, {"end": 47, "start": 16, "tag": "Cell"}, {"end": 123, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 221, "start": 215, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 173, "start": 161, "tag": "BiologicFunction"}, {"end": 112, "start": 109, "tag": "Cell"}, {"end": 7, "start": 5, "tag": "Cell"}, {"end": 173, "start": 161, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "InjuryOrPoisoning"}, {"end": 63, "start": 58, "tag": "PopulationGroup"}, {"end": 101, "start": 91, "tag": "TemporalConcept"}, {"end": 228, "start": 222, "tag": "InjuryOrPoisoning"}]}{"id": "1213_3", "text": "Of note, the functions of OPCs exceed the formation and repair of myelin, and also involve the trophic support to axons and the capability to exert an immunomodulatory role, which are particularly relevant in the context of neurodegeneration.", "tags": [{"end": 110, "start": 95, "tag": "CellFunction"}, {"end": 119, "start": 114, "tag": "CellComponent"}, {"end": 30, "start": 26, "tag": "Cell"}, {"end": 72, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 241, "start": 224, "tag": "CellOrMolecularDysfunction"}, {"end": 62, "start": 56, "tag": "BiologicFunction"}, {"end": 62, "start": 56, "tag": "HealthCareActivity"}, {"end": 172, "start": 151, "tag": "Finding"}]}{"id": "1213_4", "text": "In this review, we deeply analyze the impact of dysfunctional OLs in ALS pathogenesis.", "tags": [{"end": 72, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 62, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 85, "start": 73, "tag": "PathologicFunction"}, {"end": 65, "start": 48, "tag": "CellOrMolecularDysfunction"}]}{"id": "1213_5", "text": "The possible mechanisms underlying OL degeneration, defective OPC maturation, and impairment in energy supply to motor neurons (MNs) have also been examined to provide insights on future therapeutic interventions.", "tags": [{"end": 131, "start": 128, "tag": "Cell"}, {"end": 212, "start": 187, "tag": "HealthCareActivity"}, {"end": 126, "start": 113, "tag": "Cell"}, {"end": 65, "start": 62, "tag": "Cell"}, {"end": 76, "start": 66, "tag": "BiologicFunction"}, {"end": 37, "start": 35, "tag": "Cell"}, {"end": 50, "start": 38, "tag": "PathologicFunction"}, {"end": 186, "start": 180, "tag": "TemporalConcept"}, {"end": 109, "start": 96, "tag": "BiologicFunction"}, {"end": 76, "start": 52, "tag": "CellOrMolecularDysfunction"}, {"end": 109, "start": 82, "tag": "CellOrMolecularDysfunction"}]}{"id": "1213_6", "text": "On this basis, we discuss the potential therapeutic utility in ALS of several molecules, based on their remyelinating potential or capability to enhance energy metabolism.", "tags": [{"end": 170, "start": 153, "tag": "BiologicFunction"}, {"end": 66, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 104, "tag": "CellFunction"}, {"end": 87, "start": 78, "tag": "Substance"}, {"end": 59, "start": 30, "tag": "Finding"}]}{"id": "1214_0", "text": "Astrocytes are instrumental in maintaining central nervous system (CNS) homeostasis and responding to injury.", "tags": [{"end": 10, "start": 0, "tag": "Cell"}, {"end": 65, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 72, "tag": "BiologicFunction"}, {"end": 108, "start": 102, "tag": "InjuryOrPoisoning"}]}{"id": "1214_1", "text": "A major limitation of studying neurodegenerative diseases like multiple sclerosis (MS) is lack of human pathological specimens obtained during the acute stages, thereby relegating research to post-mortem specimens obtained years after the initiation of pathology.", "tags": [{"end": 203, "start": 192, "tag": "TemporalConcept"}, {"end": 81, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 117, "tag": "Substance"}, {"end": 213, "start": 204, "tag": "Substance"}, {"end": 126, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 213, "start": 204, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 147, "tag": "TemporalConcept"}, {"end": 188, "start": 180, "tag": "ResearchActivity"}, {"end": 262, "start": 253, "tag": "PathologicFunction"}, {"end": 262, "start": 253, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 103, "start": 98, "tag": "Eukaryote"}, {"end": 57, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 223, "tag": "TemporalConcept"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 153, "tag": "TemporalConcept"}, {"end": 249, "start": 239, "tag": "TemporalConcept"}]}{"id": "1214_2", "text": "Rodent reactive astrocytes have been shown to be cytotoxic to neurons and oligodendrocytes but may differ from human cells, especially in diseases with genetic susceptibility.", "tags": [{"end": 58, "start": 49, "tag": "InjuryOrPoisoning"}, {"end": 174, "start": 152, "tag": "OrganismAttribute"}, {"end": 90, "start": 74, "tag": "Cell"}, {"end": 116, "start": 111, "tag": "Eukaryote"}, {"end": 69, "start": 62, "tag": "Cell"}, {"end": 26, "start": 7, "tag": "Cell"}, {"end": 6, "start": 0, "tag": "Eukaryote"}, {"end": 122, "start": 117, "tag": "Cell"}]}{"id": "1214_3", "text": "Herein, we purified human CD49f(+) astrocytes from induced pluripotent stem cells derived from individual patient and control peripheral leukocytes.", "tags": [{"end": 105, "start": 95, "tag": "PopulationGroup"}, {"end": 105, "start": 95, "tag": "OrganismAttribute"}, {"end": 25, "start": 20, "tag": "Eukaryote"}, {"end": 136, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 106, "tag": "PatientOrDisabledGroup"}, {"end": 45, "start": 26, "tag": "Cell"}, {"end": 81, "start": 51, "tag": "Cell"}, {"end": 81, "start": 71, "tag": "Cell"}, {"end": 147, "start": 137, "tag": "Cell"}]}{"id": "1214_4", "text": "We compared TNF and IL1 alpha stimulated human reactive astrocytes from seven persons with MS and six non-MS controls and show their transcriptomes are remarkably similar to those described in rodents.", "tags": [{"end": 15, "start": 12, "tag": "GeneOrGenome"}, {"end": 15, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 47, "tag": "Cell"}, {"end": 85, "start": 78, "tag": "PopulationGroup"}, {"end": 200, "start": 193, "tag": "Eukaryote"}, {"end": 147, "start": 133, "tag": "MolecularSequence"}, {"end": 117, "start": 109, "tag": "PopulationGroup"}, {"end": 46, "start": 41, "tag": "Eukaryote"}, {"end": 66, "start": 56, "tag": "Cell"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 20, "tag": "BiologicallyActiveSubstance"}]}{"id": "1214_5", "text": "The functional effect of astrocyte conditioned media (ACM) was examined in a human oligodendrocyte precursor cell (OPC) line differentiation assay.", "tags": [{"end": 118, "start": 115, "tag": "Cell"}, {"end": 140, "start": 125, "tag": "CellFunction"}, {"end": 113, "start": 83, "tag": "Cell"}, {"end": 113, "start": 99, "tag": "Cell"}, {"end": 108, "start": 83, "tag": "Cell"}, {"end": 52, "start": 35, "tag": "Chemical"}, {"end": 146, "start": 141, "tag": "ResearchActivity"}, {"end": 82, "start": 77, "tag": "Eukaryote"}, {"end": 113, "start": 109, "tag": "Cell"}, {"end": 21, "start": 15, "tag": "Finding"}, {"end": 34, "start": 25, "tag": "Cell"}]}{"id": "1214_6", "text": "ACM was not cytotoxic to the OPCs but robustly inhibited the myelin basic protein (MBP) reporter.", "tags": [{"end": 21, "start": 12, "tag": "InjuryOrPoisoning"}, {"end": 86, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 83, "tag": "GeneOrGenome"}, {"end": 33, "start": 29, "tag": "Cell"}, {"end": 81, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 61, "tag": "BiologicallyActiveSubstance"}]}{"id": "1214_7", "text": "No differences were seen between MS and control stimulated astrocytes at either the transcript level or in ACM mediated OPC suppression assays.", "tags": [{"end": 123, "start": 120, "tag": "Cell"}, {"end": 142, "start": 124, "tag": "ResearchActivity"}, {"end": 14, "start": 3, "tag": "Finding"}, {"end": 69, "start": 59, "tag": "Cell"}, {"end": 35, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 84, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1214_8", "text": "We next used RNAseq to interrogate differentially expressed genes in the OPC lines that had suppressed differentiation from the human ACM.", "tags": [{"end": 82, "start": 73, "tag": "Cell"}, {"end": 118, "start": 103, "tag": "CellFunction"}, {"end": 19, "start": 13, "tag": "ResearchActivity"}, {"end": 133, "start": 128, "tag": "Eukaryote"}, {"end": 59, "start": 35, "tag": "Finding"}]}{"id": "1214_9", "text": "Remarkably, not only was OPC differentiation and myelin gene expression suppressed, but we observed induction of several immune pathways in OPCs exposed to the ACM.", "tags": [{"end": 144, "start": 140, "tag": "Cell"}, {"end": 28, "start": 25, "tag": "Cell"}, {"end": 55, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 29, "tag": "CellFunction"}, {"end": 44, "start": 25, "tag": "CellFunction"}, {"end": 71, "start": 56, "tag": "CellFunction"}, {"end": 71, "start": 61, "tag": "CellFunction"}, {"end": 136, "start": 121, "tag": "CellFunction"}, {"end": 60, "start": 56, "tag": "GeneOrGenome"}, {"end": 109, "start": 100, "tag": "Finding"}]}{"id": "1214_10", "text": "These data support the notion that reactive astrocytes can inhibit OPC differentiation thereby limiting their remyelination capacity, and that OPCs take on an immune profile in the context of inflammatory cues.", "tags": [{"end": 147, "start": 143, "tag": "Cell"}, {"end": 70, "start": 67, "tag": "Cell"}, {"end": 86, "start": 71, "tag": "CellFunction"}, {"end": 86, "start": 67, "tag": "CellFunction"}, {"end": 204, "start": 192, "tag": "PathologicFunction"}, {"end": 132, "start": 124, "tag": "Finding"}, {"end": 54, "start": 35, "tag": "Cell"}, {"end": 123, "start": 110, "tag": "CellFunction"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}]}{"id": "1215_0", "text": "Oligodendrocyte precursor cells (OPCs) account for 5% of the resident parenchymal central nervous system glial cells.", "tags": [{"end": 81, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 110, "start": 105, "tag": "Cell"}, {"end": 69, "start": 61, "tag": "PopulationGroup"}, {"end": 104, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 105, "tag": "Cell"}]}{"id": "1215_1", "text": "OPCs are not only a back-up for the loss of oligodendrocytes that occurs due to brain injury or inflammation-induced demyelination (remyelination) but are also pivotal in plastic processes such as learning and memory (adaptive myelination).", "tags": [{"end": 92, "start": 80, "tag": "InjuryOrPoisoning"}, {"end": 216, "start": 197, "tag": "BiologicFunction"}, {"end": 205, "start": 197, "tag": "BiologicFunction"}, {"end": 60, "start": 44, "tag": "Cell"}, {"end": 4, "start": 0, "tag": "Cell"}, {"end": 178, "start": 171, "tag": "Substance"}, {"end": 60, "start": 36, "tag": "CellOrMolecularDysfunction"}, {"end": 108, "start": 96, "tag": "PathologicFunction"}, {"end": 145, "start": 132, "tag": "CellFunction"}, {"end": 238, "start": 218, "tag": "CellFunction"}, {"end": 130, "start": 117, "tag": "PathologicFunction"}, {"end": 216, "start": 210, "tag": "BiologicFunction"}]}{"id": "1215_2", "text": "OPC differentiation into mature myelinating oligodendrocytes is controlled by a complex transcriptional network and depends on high metabolic and mitochondrial demand.", "tags": [{"end": 141, "start": 132, "tag": "CellFunction"}, {"end": 166, "start": 160, "tag": "HealthCareActivity"}, {"end": 111, "start": 88, "tag": "CellFunction"}, {"end": 3, "start": 0, "tag": "Cell"}, {"end": 19, "start": 4, "tag": "CellFunction"}, {"end": 19, "start": 0, "tag": "CellFunction"}, {"end": 159, "start": 146, "tag": "CellComponent"}, {"end": 60, "start": 25, "tag": "Cell"}, {"end": 131, "start": 127, "tag": "Finding"}]}{"id": "1215_3", "text": "Mounting evidence shows that OPC dysfunction, culminating in the lack of OPC differentiation, mediates the progression of neurodegenerative disorders such as multiple sclerosis, Alzheimer's disease and Parkinson's disease.", "tags": [{"end": 32, "start": 29, "tag": "Cell"}, {"end": 76, "start": 73, "tag": "Cell"}, {"end": 176, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 77, "tag": "CellFunction"}, {"end": 92, "start": 73, "tag": "CellFunction"}, {"end": 197, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 202, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 9, "tag": "Finding"}, {"end": 118, "start": 107, "tag": "PathologicFunction"}, {"end": 118, "start": 107, "tag": "TemporalConcept"}, {"end": 44, "start": 33, "tag": "PathologicFunction"}, {"end": 149, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 29, "tag": "CellOrMolecularDysfunction"}]}{"id": "1215_4", "text": "Importantly, neurodegeneration is characterised by oxidative and carbonyl stress, which may primarily affect OPC plasticity due to the high metabolic demand and a limited antioxidant capacity associated with this cell type.", "tags": [{"end": 149, "start": 140, "tag": "CellFunction"}, {"end": 156, "start": 150, "tag": "HealthCareActivity"}, {"end": 112, "start": 109, "tag": "Cell"}, {"end": 123, "start": 113, "tag": "NaturalPhenomenonOrProcess"}, {"end": 123, "start": 113, "tag": "CellFunction"}, {"end": 182, "start": 171, "tag": "PharmacologicSubstance"}, {"end": 182, "start": 171, "tag": "CellFunction"}, {"end": 191, "start": 183, "tag": "Finding"}, {"end": 30, "start": 13, "tag": "CellOrMolecularDysfunction"}, {"end": 139, "start": 135, "tag": "Finding"}, {"end": 222, "start": 213, "tag": "Cell"}, {"end": 80, "start": 65, "tag": "CellOrMolecularDysfunction"}, {"end": 80, "start": 74, "tag": "CellOrMolecularDysfunction"}, {"end": 60, "start": 51, "tag": "CellOrMolecularDysfunction"}]}{"id": "1215_5", "text": "The underlying mechanisms of how oxidative/carbonyl stress disrupt OPC differentiation remain enigmatic and a focus of current research efforts.", "tags": [{"end": 70, "start": 67, "tag": "Cell"}, {"end": 86, "start": 71, "tag": "CellFunction"}, {"end": 86, "start": 67, "tag": "CellFunction"}, {"end": 135, "start": 127, "tag": "ResearchActivity"}, {"end": 126, "start": 119, "tag": "TemporalConcept"}, {"end": 58, "start": 33, "tag": "CellOrMolecularDysfunction"}]}{"id": "1215_6", "text": "This review proposes a role for oxidative/carbonyl stress in interfering with the transcriptional and metabolic changes required for OPC differentiation.", "tags": [{"end": 111, "start": 102, "tag": "CellFunction"}, {"end": 97, "start": 82, "tag": "CellFunction"}, {"end": 136, "start": 133, "tag": "Cell"}, {"end": 152, "start": 137, "tag": "CellFunction"}, {"end": 152, "start": 133, "tag": "CellFunction"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 57, "start": 32, "tag": "CellOrMolecularDysfunction"}, {"end": 119, "start": 112, "tag": "Finding"}]}{"id": "1215_7", "text": "In particular, oligodendrocyte (epi)genetics, cellular defence and repair responses, mitochondrial signalling and respiration, and lipid metabolism represent key mechanisms how oxidative/carbonyl stress may hamper OPC differentiation in neurodegenerative disorders.", "tags": [{"end": 125, "start": 114, "tag": "BiologicFunction"}, {"end": 125, "start": 114, "tag": "CellFunction"}, {"end": 217, "start": 214, "tag": "Cell"}, {"end": 233, "start": 218, "tag": "CellFunction"}, {"end": 233, "start": 214, "tag": "CellFunction"}, {"end": 98, "start": 85, "tag": "CellComponent"}, {"end": 147, "start": 137, "tag": "CellFunction"}, {"end": 147, "start": 137, "tag": "BiologicFunction"}, {"end": 54, "start": 46, "tag": "Cell"}, {"end": 44, "start": 36, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 44, "start": 36, "tag": "CellFunction"}, {"end": 30, "start": 15, "tag": "Cell"}, {"end": 136, "start": 131, "tag": "Chemical"}, {"end": 109, "start": 99, "tag": "BiologicFunction"}, {"end": 264, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 131, "tag": "CellFunction"}, {"end": 147, "start": 131, "tag": "BiologicFunction"}, {"end": 73, "start": 67, "tag": "BiologicFunction"}, {"end": 73, "start": 67, "tag": "HealthCareActivity"}, {"end": 202, "start": 177, "tag": "CellOrMolecularDysfunction"}]}{"id": "1215_8", "text": "Understanding how oxidative/carbonyl stress impacts OPC function may pave the way for future OPC-targeted treatment strategies in neurodegenerative disorders.", "tags": [{"end": 55, "start": 52, "tag": "Cell"}, {"end": 96, "start": 93, "tag": "Cell"}, {"end": 115, "start": 106, "tag": "HealthCareActivity"}, {"end": 115, "start": 106, "tag": "ResearchActivity"}, {"end": 126, "start": 116, "tag": "ResearchActivity"}, {"end": 126, "start": 116, "tag": "BiologicFunction"}, {"end": 92, "start": 86, "tag": "TemporalConcept"}, {"end": 157, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 106, "tag": "HealthCareActivity"}, {"end": 126, "start": 106, "tag": "ResearchActivity"}, {"end": 43, "start": 18, "tag": "CellOrMolecularDysfunction"}]}{"id": "1216_0", "text": "The development of neuronal circuitry required for cognition, complex motor behaviors, and sensory integration requires myelination.", "tags": [{"end": 85, "start": 70, "tag": "BiologicFunction"}, {"end": 110, "start": 91, "tag": "BiologicFunction"}, {"end": 110, "start": 91, "tag": "HealthCareActivity"}, {"end": 15, "start": 4, "tag": "BiologicFunction"}, {"end": 15, "start": 4, "tag": "CellFunction"}, {"end": 60, "start": 51, "tag": "BiologicFunction"}, {"end": 131, "start": 120, "tag": "CellFunction"}, {"end": 37, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1216_1", "text": "The role of glial cells such as astrocytes and microglia in shaping synapses and circuits have been covered in other reviews in this journal and elsewhere.", "tags": [{"end": 124, "start": 117, "tag": "HealthCareActivity"}, {"end": 124, "start": 117, "tag": "ResearchActivity"}, {"end": 23, "start": 12, "tag": "Cell"}, {"end": 56, "start": 47, "tag": "Cell"}, {"end": 42, "start": 32, "tag": "Cell"}, {"end": 76, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1216_2", "text": "This review summarizes the role of another glial cell type, oligodendrocytes, in shaping synapse formation, neuronal circuit development, and myelination in both normal development and in demyelinating disease.", "tags": [{"end": 96, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 60, "tag": "Cell"}, {"end": 209, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 162, "tag": "Finding"}, {"end": 136, "start": 108, "tag": "BiologicFunction"}, {"end": 180, "start": 169, "tag": "BiologicFunction"}, {"end": 180, "start": 169, "tag": "CellFunction"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 168, "start": 162, "tag": "Finding"}, {"end": 153, "start": 142, "tag": "CellFunction"}, {"end": 58, "start": 43, "tag": "Cell"}, {"end": 106, "start": 89, "tag": "CellFunction"}]}{"id": "1216_3", "text": "Oligodendrocytes ensheath and insulate neuronal axons with myelin, and this facilitates fast conduction of electrical nerve impulses via saltatory conduction.", "tags": [{"end": 157, "start": 137, "tag": "BiologicFunction"}, {"end": 53, "start": 48, "tag": "CellComponent"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 65, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 93, "tag": "BiologicFunction"}, {"end": 47, "start": 39, "tag": "Cell"}]}{"id": "1216_4", "text": "Oligodendrocytes also proliferate during postnatal development, and defects in their maturation have been linked to abnormal myelination.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 95, "start": 85, "tag": "BiologicFunction"}, {"end": 124, "start": 116, "tag": "Finding"}, {"end": 50, "start": 41, "tag": "TemporalConcept"}, {"end": 62, "start": 51, "tag": "BiologicFunction"}, {"end": 62, "start": 51, "tag": "CellFunction"}, {"end": 136, "start": 125, "tag": "CellFunction"}]}{"id": "1216_5", "text": "Myelination also regulates the timing of activity in neural circuits and is important for maintaining the health of axons and providing nutritional support.", "tags": [{"end": 155, "start": 136, "tag": "HealthCareActivity"}, {"end": 121, "start": 116, "tag": "CellComponent"}, {"end": 68, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 31, "tag": "TemporalConcept"}, {"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 112, "start": 106, "tag": "HealthCareActivity"}]}{"id": "1216_6", "text": "Recent studies have shown that dysfunction in oligodendrocyte development and in myelination can contribute to defects in neuronal synapse formation and circuit development.", "tags": [{"end": 73, "start": 46, "tag": "CellFunction"}, {"end": 73, "start": 62, "tag": "BiologicFunction"}, {"end": 172, "start": 153, "tag": "BiologicFunction"}, {"end": 73, "start": 62, "tag": "CellFunction"}, {"end": 130, "start": 122, "tag": "Cell"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 92, "start": 81, "tag": "CellFunction"}, {"end": 42, "start": 31, "tag": "PathologicFunction"}, {"end": 148, "start": 131, "tag": "CellFunction"}]}{"id": "1216_7", "text": "We discuss glutamatergic and GABAergic receptors and voltage gated ion channel expression and function in oligodendrocyte development and myelination.", "tags": [{"end": 78, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 106, "tag": "CellFunction"}, {"end": 89, "start": 79, "tag": "CellFunction"}, {"end": 149, "start": 138, "tag": "CellFunction"}, {"end": 48, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 11, "tag": "BiologicallyActiveSubstance"}]}{"id": "1216_8", "text": "We explain the role of excitatory and inhibitory neurotransmission on oligodendrocyte proliferation, migration, differentiation, and myelination.", "tags": [{"end": 66, "start": 49, "tag": "BiologicFunction"}, {"end": 33, "start": 23, "tag": "BiologicFunction"}, {"end": 127, "start": 112, "tag": "CellFunction"}, {"end": 99, "start": 86, "tag": "CellFunction"}, {"end": 110, "start": 101, "tag": "CellFunction"}, {"end": 85, "start": 70, "tag": "Cell"}, {"end": 144, "start": 133, "tag": "CellFunction"}, {"end": 66, "start": 38, "tag": "BiologicFunction"}]}{"id": "1216_9", "text": "We then focus on how our understanding of the synaptic connectivity between neurons and OPCs can inform future therapeutics in demyelinating disease, and discuss gaps in the literature that would inform new therapies for remyelination.", "tags": [{"end": 92, "start": 88, "tag": "Cell"}, {"end": 148, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 67, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 111, "tag": "HealthCareActivity"}, {"end": 184, "start": 174, "tag": "ResearchActivity"}, {"end": 38, "start": 25, "tag": "BiologicFunction"}, {"end": 83, "start": 76, "tag": "Cell"}, {"end": 110, "start": 104, "tag": "TemporalConcept"}, {"end": 234, "start": 221, "tag": "CellFunction"}, {"end": 216, "start": 207, "tag": "HealthCareActivity"}]}{"id": "1217_0", "text": "Oligodendrocyte lineage cells (OL-lineage cells) are a cell population that are crucial for mammalian central nervous system (CNS) myelination.", "tags": [{"end": 33, "start": 31, "tag": "Cell"}, {"end": 101, "start": 92, "tag": "Eukaryote"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 29, "start": 0, "tag": "Cell"}, {"end": 47, "start": 31, "tag": "Cell"}, {"end": 70, "start": 55, "tag": "Cell"}, {"end": 124, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 60, "tag": "PopulationGroup"}, {"end": 142, "start": 131, "tag": "CellFunction"}]}{"id": "1217_1", "text": "OL-lineage cells go through developmental stages, initially differentiating into oligodendrocyte precursor cells (OPCs), before becoming immature oligodendrocytes, then mature oligodendrocytes (OLs).", "tags": [{"end": 48, "start": 28, "tag": "TemporalConcept"}, {"end": 162, "start": 146, "tag": "Cell"}, {"end": 192, "start": 176, "tag": "Cell"}, {"end": 118, "start": 114, "tag": "Cell"}, {"end": 112, "start": 81, "tag": "Cell"}, {"end": 192, "start": 169, "tag": "Cell"}, {"end": 41, "start": 28, "tag": "BiologicFunction"}, {"end": 41, "start": 28, "tag": "TemporalConcept"}, {"end": 197, "start": 194, "tag": "Cell"}, {"end": 2, "start": 0, "tag": "Cell"}, {"end": 175, "start": 169, "tag": "TemporalConcept"}, {"end": 112, "start": 97, "tag": "Cell"}, {"end": 106, "start": 81, "tag": "Cell"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 145, "start": 137, "tag": "BiologicFunction"}, {"end": 48, "start": 42, "tag": "TemporalConcept"}]}{"id": "1217_2", "text": "While the main function of cell lineage is in myelin formation, and increasing number of studies have turned to explore the immunological characteristics of these cells.", "tags": [{"end": 39, "start": 27, "tag": "Cell"}, {"end": 52, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 46, "tag": "CellFunction"}, {"end": 168, "start": 163, "tag": "Cell"}, {"end": 96, "start": 89, "tag": "ResearchActivity"}, {"end": 153, "start": 124, "tag": "Finding"}]}{"id": "1217_3", "text": "Initially, these studies focused on discovering how OPCs and OLs are affected by the immune system, and then, how these immunological changes influence the myelination process.", "tags": [{"end": 56, "start": 52, "tag": "Cell"}, {"end": 64, "start": 61, "tag": "Cell"}, {"end": 24, "start": 17, "tag": "ResearchActivity"}, {"end": 98, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 156, "tag": "CellFunction"}, {"end": 141, "start": 120, "tag": "Finding"}]}{"id": "1217_4", "text": "However, recent studies have uncovered another feature of OL-lineage cells in our immune systems.", "tags": [{"end": 96, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 58, "tag": "Cell"}, {"end": 74, "start": 58, "tag": "Cell"}, {"end": 23, "start": 16, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "TemporalConcept"}]}{"id": "1217_5", "text": "It would appear that OL-lineage cells also express immunological factors such as cytokines and chemokines in response to immune activation, and the expression of these factors changes under various pathologic conditions.", "tags": [{"end": 72, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 43, "tag": "CellFunction"}, {"end": 138, "start": 121, "tag": "BiologicFunction"}, {"end": 23, "start": 21, "tag": "Cell"}, {"end": 37, "start": 21, "tag": "Cell"}, {"end": 158, "start": 148, "tag": "CellFunction"}, {"end": 90, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 219, "start": 198, "tag": "DiseaseOrSyndrome"}]}{"id": "1217_6", "text": "Evidence suggests that OL-lineage cells actually modulate immune functions.", "tags": [{"end": 74, "start": 58, "tag": "BiologicFunction"}, {"end": 25, "start": 23, "tag": "Cell"}, {"end": 39, "start": 23, "tag": "Cell"}]}{"id": "1217_7", "text": "Indeed, OL-lineage cells appear to play both victim and agent in the CNS which raises a number of questions.", "tags": [{"end": 51, "start": 45, "tag": "PopulationGroup"}, {"end": 10, "start": 8, "tag": "Cell"}, {"end": 24, "start": 8, "tag": "Cell"}, {"end": 72, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 56, "tag": "PharmacologicSubstance"}]}{"id": "1217_8", "text": "Here, we summarize immunologic changes in OL-lineage cells and their effects, as well as consider OL-lineage cell changes which influence immune cells under pathological conditions.", "tags": [{"end": 150, "start": 138, "tag": "Cell"}, {"end": 180, "start": 157, "tag": "PathologicFunction"}, {"end": 44, "start": 42, "tag": "Cell"}, {"end": 100, "start": 98, "tag": "Cell"}, {"end": 58, "start": 42, "tag": "Cell"}, {"end": 113, "start": 98, "tag": "Cell"}, {"end": 76, "start": 69, "tag": "Finding"}, {"end": 38, "start": 19, "tag": "Finding"}, {"end": 121, "start": 114, "tag": "Finding"}]}{"id": "1217_9", "text": "We also describe some of the underlying mechanisms of these changes and their effects.", "tags": [{"end": 85, "start": 78, "tag": "Finding"}]}{"id": "1217_10", "text": "Finally, we describe several studies which use OL-lineage cells as immunotherapeutic targets for demyelination diseases.", "tags": [{"end": 119, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 47, "tag": "Cell"}, {"end": 63, "start": 47, "tag": "Cell"}, {"end": 36, "start": 29, "tag": "ResearchActivity"}, {"end": 92, "start": 67, "tag": "Finding"}]}{"id": "1218_0", "text": "In the developing central nervous system, oligodendrocyte precursor cells (OPCs) differentiate into oligodendrocytes, which form myelin around axons.", "tags": [{"end": 148, "start": 143, "tag": "CellComponent"}, {"end": 116, "start": 100, "tag": "Cell"}, {"end": 79, "start": 75, "tag": "Cell"}, {"end": 73, "start": 42, "tag": "Cell"}, {"end": 94, "start": 81, "tag": "CellFunction"}, {"end": 135, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1218_1", "text": "Oligodendrocytes and myelin are essential for the function of the central nervous system, as evidenced by the severe neurological symptoms that arise in demyelinating diseases such as multiple sclerosis and leukodystrophy.", "tags": [{"end": 221, "start": 207, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 110, "tag": "Finding"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 175, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 117, "tag": "SignOrSymptom"}, {"end": 166, "start": 153, "tag": "PathologicFunction"}, {"end": 202, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1218_2", "text": "Although many cell-intrinsic mechanisms that regulate oligodendrocyte development and myelination have been reported, it remains unclear whether interactions among oligodendrocyte-lineage cells (OPCs and oligodendrocytes) affect oligodendrocyte development and myelination.", "tags": [{"end": 220, "start": 204, "tag": "Cell"}, {"end": 199, "start": 195, "tag": "Cell"}, {"end": 97, "start": 86, "tag": "CellFunction"}, {"end": 272, "start": 261, "tag": "CellFunction"}, {"end": 157, "start": 145, "tag": "Finding"}, {"end": 193, "start": 164, "tag": "Cell"}, {"end": 81, "start": 54, "tag": "CellFunction"}, {"end": 256, "start": 229, "tag": "CellFunction"}]}{"id": "1218_3", "text": "Here, we show that blocking vesicle-associated membrane protein (VAMP) 1/2/3-dependent exocytosis from oligodendrocyte-lineage cells impairs oligodendrocyte development, myelination, and motor behavior in mice.", "tags": [{"end": 76, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 87, "tag": "CellFunction"}, {"end": 201, "start": 187, "tag": "BiologicFunction"}, {"end": 181, "start": 170, "tag": "CellFunction"}, {"end": 118, "start": 103, "tag": "Cell"}, {"end": 168, "start": 141, "tag": "CellFunction"}, {"end": 132, "start": 127, "tag": "Cell"}, {"end": 209, "start": 205, "tag": "Eukaryote"}]}{"id": "1218_4", "text": "Adding oligodendrocyte-lineage cell-secreted molecules to secretion-deficient OPC cultures partially restores the morphological maturation of oligodendrocytes.", "tags": [{"end": 90, "start": 82, "tag": "ResearchActivity"}, {"end": 54, "start": 45, "tag": "Substance"}, {"end": 158, "start": 142, "tag": "Cell"}, {"end": 81, "start": 78, "tag": "Cell"}, {"end": 22, "start": 7, "tag": "Cell"}, {"end": 138, "start": 128, "tag": "BiologicFunction"}]}{"id": "1218_5", "text": "Moreover, we identified L-type prostaglandin D synthase as an oligodendrocyte-lineage cell-secreted protein that promotes oligodendrocyte development and myelination in vivo.", "tags": [{"end": 165, "start": 154, "tag": "CellFunction"}, {"end": 90, "start": 62, "tag": "Cell"}, {"end": 173, "start": 166, "tag": "ResearchActivity"}, {"end": 149, "start": 122, "tag": "CellFunction"}, {"end": 55, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 91, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1218_6", "text": "These findings reveal a novel autocrine/paracrine loop model for the regulation of oligodendrocyte and myelin development.", "tags": [{"end": 98, "start": 83, "tag": "Cell"}, {"end": 60, "start": 55, "tag": "ResearchActivity"}, {"end": 109, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 110, "tag": "BiologicFunction"}, {"end": 121, "start": 110, "tag": "CellFunction"}, {"end": 54, "start": 30, "tag": "BiologicFunction"}]}{"id": "1219_0", "text": "Remyelination in patients with multiple sclerosis frequently fails, especially in the chronic phase of the disease promoting axonal and neuronal degeneration and progressive disease disability.", "tags": [{"end": 99, "start": 86, "tag": "TemporalConcept"}, {"end": 157, "start": 136, "tag": "CellOrMolecularDysfunction"}, {"end": 99, "start": 94, "tag": "TemporalConcept"}, {"end": 49, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 131, "start": 125, "tag": "CellComponent"}, {"end": 157, "start": 145, "tag": "PathologicFunction"}, {"end": 25, "start": 17, "tag": "PatientOrDisabledGroup"}, {"end": 144, "start": 136, "tag": "Cell"}, {"end": 173, "start": 162, "tag": "TemporalConcept"}, {"end": 60, "start": 50, "tag": "TemporalConcept"}, {"end": 93, "start": 86, "tag": "TemporalConcept"}, {"end": 192, "start": 182, "tag": "Finding"}]}{"id": "1219_1", "text": "Drug-based therapies able to promote endogenous remyelination capability of oligodendrocytes are thus emerging as primary approaches to multiple sclerosis.", "tags": [{"end": 4, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 92, "start": 76, "tag": "Cell"}, {"end": 154, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 29, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 61, "start": 48, "tag": "CellFunction"}, {"end": 20, "start": 11, "tag": "HealthCareActivity"}]}{"id": "1219_2", "text": "We have recently reported that the co-ultramicronized composite of palmitoylethanolamide and the flavonoid luteolin (PEALut) promotes oligodendrocyte precursor cell (OPC) maturation without affecting proliferation.", "tags": [{"end": 88, "start": 67, "tag": "Chemical"}, {"end": 169, "start": 166, "tag": "Cell"}, {"end": 181, "start": 171, "tag": "BiologicFunction"}, {"end": 213, "start": 200, "tag": "CellFunction"}, {"end": 164, "start": 134, "tag": "Cell"}, {"end": 164, "start": 150, "tag": "Cell"}, {"end": 159, "start": 134, "tag": "Cell"}, {"end": 164, "start": 160, "tag": "Cell"}, {"end": 16, "start": 8, "tag": "TemporalConcept"}, {"end": 115, "start": 107, "tag": "Chemical"}, {"end": 115, "start": 107, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 97, "tag": "Chemical"}, {"end": 123, "start": 117, "tag": "Chemical"}]}{"id": "1219_3", "text": "Since TAM receptor signaling has been reported to be important modulator of oligodendrocyte survival, we here evaluated the eventual involvement of TAM receptors in PEALut-induced OPC maturation.", "tags": [{"end": 183, "start": 180, "tag": "Cell"}, {"end": 194, "start": 184, "tag": "BiologicFunction"}, {"end": 28, "start": 6, "tag": "CellFunction"}, {"end": 100, "start": 92, "tag": "CellFunction"}, {"end": 91, "start": 76, "tag": "Cell"}, {"end": 161, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 148, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 133, "tag": "Finding"}, {"end": 72, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 165, "tag": "Chemical"}]}{"id": "1219_4", "text": "The mRNAs related to TAM receptors -Tyro3, Axl, and Mertk- were all present at day 2 in vitro.", "tags": [{"end": 46, "start": 43, "tag": "GeneOrGenome"}, {"end": 46, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 79, "tag": "TemporalConcept"}, {"end": 93, "start": 85, "tag": "ResearchActivity"}, {"end": 34, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 9, "start": 4, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 9, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 36, "tag": "GeneOrGenome"}, {"end": 46, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 52, "tag": "GeneOrGenome"}]}{"id": "1219_5", "text": "However, while Tyro3 gene expression significantly increased upon cell differentiation, Axl and Mertk did not change during the first week in vitro.", "tags": [{"end": 20, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 15, "tag": "GeneOrGenome"}, {"end": 91, "start": 88, "tag": "GeneOrGenome"}, {"end": 91, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 96, "tag": "GeneOrGenome"}, {"end": 86, "start": 71, "tag": "CellFunction"}, {"end": 138, "start": 134, "tag": "TemporalConcept"}, {"end": 133, "start": 128, "tag": "TemporalConcept"}, {"end": 36, "start": 21, "tag": "CellFunction"}, {"end": 36, "start": 26, "tag": "CellFunction"}, {"end": 147, "start": 139, "tag": "ResearchActivity"}, {"end": 60, "start": 37, "tag": "Finding"}, {"end": 25, "start": 21, "tag": "GeneOrGenome"}, {"end": 86, "start": 66, "tag": "CellFunction"}, {"end": 20, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 96, "tag": "BiologicallyActiveSubstance"}]}{"id": "1219_6", "text": "Tyro3 gene expression developmental pattern resembled that of MBP myelin protein.", "tags": [{"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 65, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 62, "tag": "GeneOrGenome"}, {"end": 72, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 22, "tag": "BiologicFunction"}, {"end": 35, "start": 22, "tag": "TemporalConcept"}, {"end": 21, "start": 6, "tag": "CellFunction"}, {"end": 21, "start": 11, "tag": "CellFunction"}, {"end": 10, "start": 6, "tag": "GeneOrGenome"}, {"end": 80, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1219_7", "text": "In OPCs treated with PEALut the developmental increase of Tyro3 mRNA was significantly higher as compared to vehicle while was reduced gene expression related to Axl and Mertk.", "tags": [{"end": 63, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 58, "tag": "GeneOrGenome"}, {"end": 165, "start": 162, "tag": "GeneOrGenome"}, {"end": 165, "start": 162, "tag": "AminoAcidPeptideOrProtein"}, {"end": 175, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 175, "start": 170, "tag": "GeneOrGenome"}, {"end": 7, "start": 3, "tag": "Cell"}, {"end": 45, "start": 32, "tag": "BiologicFunction"}, {"end": 45, "start": 32, "tag": "TemporalConcept"}, {"end": 150, "start": 135, "tag": "CellFunction"}, {"end": 150, "start": 140, "tag": "CellFunction"}, {"end": 20, "start": 8, "tag": "HealthCareActivity"}, {"end": 68, "start": 64, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 139, "start": 135, "tag": "GeneOrGenome"}, {"end": 68, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 21, "tag": "Chemical"}, {"end": 63, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 175, "start": 170, "tag": "BiologicallyActiveSubstance"}]}{"id": "1219_8", "text": "Rapamycin, an inhibitor of mTOR, prevented oligodendrocyte growth differentiation and myelination.", "tags": [{"end": 9, "start": 0, "tag": "Chemical"}, {"end": 31, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 27, "tag": "GeneOrGenome"}, {"end": 31, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 23, "start": 14, "tag": "Chemical"}, {"end": 65, "start": 59, "tag": "BiologicFunction"}, {"end": 81, "start": 43, "tag": "CellFunction"}, {"end": 58, "start": 43, "tag": "Cell"}, {"end": 97, "start": 86, "tag": "CellFunction"}]}{"id": "1219_9", "text": "PEALut, administered to the cultures 30 min after rapamycin, prevented the alteration of mRNA basal expression of the TAM receptors as well as the expression of myelin proteins MBP and CNPase.", "tags": [{"end": 131, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 161, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 75, "tag": "Finding"}, {"end": 59, "start": 50, "tag": "Chemical"}, {"end": 180, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 180, "start": 177, "tag": "GeneOrGenome"}, {"end": 36, "start": 28, "tag": "ResearchActivity"}, {"end": 110, "start": 100, "tag": "CellFunction"}, {"end": 157, "start": 147, "tag": "CellFunction"}, {"end": 131, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 89, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 93, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 0, "tag": "Chemical"}, {"end": 191, "start": 185, "tag": "BiologicallyActiveSubstance"}]}{"id": "1219_10", "text": "Altogether, data obtained confirm that PEALut promotes oligodendrocyte differentiation as shown by the increase of MBP and CNPase and Tyro3 mRNAs as well as CNPase and Tyro3 immunostainings.", "tags": [{"end": 129, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 134, "tag": "GeneOrGenome"}, {"end": 163, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 168, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 168, "tag": "GeneOrGenome"}, {"end": 118, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 115, "tag": "GeneOrGenome"}, {"end": 86, "start": 71, "tag": "CellFunction"}, {"end": 70, "start": 55, "tag": "Cell"}, {"end": 16, "start": 12, "tag": "ResearchActivity"}, {"end": 145, "start": 140, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 145, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 39, "tag": "Chemical"}, {"end": 129, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 168, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 174, "tag": "ResearchActivity"}]}{"id": "1219_11", "text": "The finding that these effects are reduced when OPCs are exposed to rapamycin suggests an involvement of mTOR signaling in PEALut effects.", "tags": [{"end": 77, "start": 68, "tag": "Chemical"}, {"end": 109, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 105, "tag": "GeneOrGenome"}, {"end": 109, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 4, "tag": "Finding"}, {"end": 52, "start": 48, "tag": "Cell"}, {"end": 119, "start": 110, "tag": "CellFunction"}, {"end": 30, "start": 23, "tag": "Finding"}, {"end": 137, "start": 130, "tag": "Finding"}, {"end": 101, "start": 90, "tag": "Finding"}, {"end": 129, "start": 123, "tag": "Chemical"}]}{"id": "1220_0", "text": "In demyelinating diseases, such as multiple sclerosis, primary loss of myelin and subsequent neuronal degeneration throughout the CNS impair patient functionality.", "tags": [{"end": 114, "start": 93, "tag": "CellOrMolecularDysfunction"}, {"end": 25, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 3, "tag": "PathologicFunction"}, {"end": 53, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 102, "tag": "PathologicFunction"}, {"end": 133, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 93, "tag": "Cell"}, {"end": 148, "start": 141, "tag": "PatientOrDisabledGroup"}, {"end": 77, "start": 55, "tag": "PathologicFunction"}]}{"id": "1220_1", "text": "While the importance of mechanistic target of rapamycin (mTOR) signaling during developmental myelination is known, no studies have yet directly examined the function of mTOR signaling specifically in the oligodendrocyte (OL) lineage during remyelination.", "tags": [{"end": 61, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 57, "tag": "GeneOrGenome"}, {"end": 174, "start": 170, "tag": "GeneOrGenome"}, {"end": 61, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 63, "tag": "CellFunction"}, {"end": 55, "start": 46, "tag": "CellFunction"}, {"end": 184, "start": 170, "tag": "CellFunction"}, {"end": 93, "start": 80, "tag": "BiologicFunction"}, {"end": 93, "start": 80, "tag": "TemporalConcept"}, {"end": 224, "start": 222, "tag": "Cell"}, {"end": 126, "start": 119, "tag": "ResearchActivity"}, {"end": 233, "start": 226, "tag": "Cell"}, {"end": 220, "start": 205, "tag": "Cell"}, {"end": 254, "start": 241, "tag": "CellFunction"}, {"end": 105, "start": 94, "tag": "CellFunction"}]}{"id": "1220_2", "text": "Here, we conditionally deleted Mtor from adult oligodendrocyte precursor cells (OPCs) using Ng2-Cre(ERT) in male adult mice to test its function in new OLs responsible for remyelination.", "tags": [{"end": 35, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 31, "tag": "GeneOrGenome"}, {"end": 84, "start": 80, "tag": "Cell"}, {"end": 78, "start": 47, "tag": "Cell"}, {"end": 155, "start": 152, "tag": "Cell"}, {"end": 123, "start": 119, "tag": "Eukaryote"}, {"end": 112, "start": 108, "tag": "OrganismAttribute"}, {"end": 185, "start": 172, "tag": "CellFunction"}, {"end": 46, "start": 41, "tag": "PopulationGroup"}, {"end": 118, "start": 113, "tag": "PopulationGroup"}, {"end": 104, "start": 92, "tag": "ResearchActivity"}, {"end": 35, "start": 31, "tag": "BiologicallyActiveSubstance"}]}{"id": "1220_3", "text": "During early remyelination after cuprizone-induced demyelination, mice lacking mTOR in adult OPCs had unchanged OL numbers but thinner myelin.", "tags": [{"end": 111, "start": 102, "tag": "Finding"}, {"end": 83, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 79, "tag": "GeneOrGenome"}, {"end": 83, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 93, "tag": "Cell"}, {"end": 141, "start": 135, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 112, "tag": "Cell"}, {"end": 12, "start": 7, "tag": "TemporalConcept"}, {"end": 42, "start": 33, "tag": "Chemical"}, {"end": 70, "start": 66, "tag": "Eukaryote"}, {"end": 26, "start": 13, "tag": "CellFunction"}, {"end": 64, "start": 51, "tag": "PathologicFunction"}, {"end": 92, "start": 87, "tag": "PopulationGroup"}]}{"id": "1220_4", "text": "Myelin thickness recovered by late-stage repair, suggesting a delay in myelin production when Mtor is deleted from adult OPCs.", "tags": [{"end": 98, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 94, "tag": "GeneOrGenome"}, {"end": 67, "start": 62, "tag": "TemporalConcept"}, {"end": 40, "start": 30, "tag": "TemporalConcept"}, {"end": 125, "start": 121, "tag": "Cell"}, {"end": 77, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 115, "tag": "PopulationGroup"}, {"end": 47, "start": 41, "tag": "BiologicFunction"}, {"end": 47, "start": 41, "tag": "HealthCareActivity"}, {"end": 16, "start": 0, "tag": "ClinicalAttribute"}, {"end": 98, "start": 94, "tag": "BiologicallyActiveSubstance"}]}{"id": "1220_5", "text": "Surprisingly, loss of mTOR in OPCs had no effect on efficiency of remyelination after lysophosphatidylcholine lesions in either the spinal cord or corpus callosum, suggesting that mTOR signaling functions specifically in a pathway dysregulated by cuprizone to promote remyelination efficiency.", "tags": [{"end": 109, "start": 86, "tag": "Chemical"}, {"end": 26, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 180, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 22, "tag": "GeneOrGenome"}, {"end": 184, "start": 180, "tag": "GeneOrGenome"}, {"end": 26, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 180, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 30, "tag": "Cell"}, {"end": 117, "start": 110, "tag": "InjuryOrPoisoning"}, {"end": 143, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 194, "start": 180, "tag": "CellFunction"}, {"end": 267, "start": 260, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 62, "start": 52, "tag": "Finding"}, {"end": 292, "start": 282, "tag": "Finding"}, {"end": 162, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 256, "start": 247, "tag": "Chemical"}, {"end": 243, "start": 231, "tag": "PathologicFunction"}, {"end": 48, "start": 39, "tag": "Finding"}, {"end": 230, "start": 223, "tag": "CellFunction"}, {"end": 79, "start": 66, "tag": "CellFunction"}, {"end": 281, "start": 268, "tag": "CellFunction"}]}{"id": "1220_6", "text": "We further determined that cuprizone and inhibition of mTOR cooperatively compromise metabolic function in primary rat OLs undergoing differentiation.", "tags": [{"end": 103, "start": 85, "tag": "BiologicFunction"}, {"end": 59, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 55, "tag": "GeneOrGenome"}, {"end": 59, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 134, "tag": "CellFunction"}, {"end": 122, "start": 119, "tag": "Cell"}, {"end": 118, "start": 115, "tag": "Eukaryote"}, {"end": 36, "start": 27, "tag": "Chemical"}, {"end": 51, "start": 41, "tag": "CellFunction"}, {"end": 122, "start": 107, "tag": "ResearchActivity"}]}{"id": "1220_7", "text": "Together, our results support the conclusion that mTOR signaling in OPCs is required to overcome the metabolic dysfunction in the cuprizone-demyelinated adult brain.", "tags": [{"end": 54, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 50, "tag": "GeneOrGenome"}, {"end": 54, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 68, "tag": "Cell"}, {"end": 152, "start": 140, "tag": "PathologicFunction"}, {"end": 64, "start": 50, "tag": "CellFunction"}, {"end": 139, "start": 130, "tag": "Chemical"}, {"end": 164, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 153, "tag": "PopulationGroup"}, {"end": 122, "start": 101, "tag": "CellOrMolecularDysfunction"}]}{"id": "1221_0", "text": "Chronic demyelination and the concomitant loss of trophic support and increased energy demands in axons are thought to contribute to neurodegeneration in a number of neurological diseases such as multiple sclerosis (MS).", "tags": [{"end": 41, "start": 30, "tag": "TemporalConcept"}, {"end": 65, "start": 50, "tag": "CellFunction"}, {"end": 103, "start": 98, "tag": "CellComponent"}, {"end": 214, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 80, "tag": "NaturalPhenomenonOrProcess"}, {"end": 150, "start": 133, "tag": "CellOrMolecularDysfunction"}, {"end": 218, "start": 216, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 8, "tag": "PathologicFunction"}, {"end": 187, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 46, "start": 42, "tag": "Finding"}]}{"id": "1221_1", "text": "Adult oligodendrocyte precursor cells (OPCs) play an important role in these demyelinating diseases by generating new myelinating oligodendrocytes that may help limit axonal degeneration.", "tags": [{"end": 5, "start": 0, "tag": "PopulationGroup"}, {"end": 43, "start": 39, "tag": "Cell"}, {"end": 99, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 6, "tag": "Cell"}, {"end": 146, "start": 118, "tag": "Cell"}, {"end": 186, "start": 167, "tag": "CellOrMolecularDysfunction"}]}{"id": "1221_2", "text": "Thus, promoting the differentiation of OPCs and functional integration of newly generated oligodendrocytes is a crucial avenue for the next generation of therapies.", "tags": [{"end": 106, "start": 90, "tag": "Cell"}, {"end": 43, "start": 39, "tag": "Cell"}, {"end": 35, "start": 20, "tag": "CellFunction"}, {"end": 70, "start": 59, "tag": "CellFunction"}, {"end": 70, "start": 59, "tag": "MachineActivity"}, {"end": 163, "start": 154, "tag": "HealthCareActivity"}, {"end": 150, "start": 135, "tag": "TemporalConcept"}]}{"id": "1221_3", "text": "Evidence to date suggests that the immune system may both positively and negatively impact OPC differentiation and endogenous remyelination in disease.", "tags": [{"end": 16, "start": 9, "tag": "TemporalConcept"}, {"end": 16, "start": 12, "tag": "TemporalConcept"}, {"end": 110, "start": 91, "tag": "CellFunction"}, {"end": 48, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 126, "tag": "CellFunction"}, {"end": 8, "start": 0, "tag": "Finding"}]}{"id": "1221_4", "text": "Inflammatory cytokines not only suppress OPC differentiation but may also directly affect other functions of OPCs.", "tags": [{"end": 113, "start": 109, "tag": "Cell"}, {"end": 44, "start": 41, "tag": "Cell"}, {"end": 60, "start": 45, "tag": "CellFunction"}, {"end": 60, "start": 41, "tag": "CellFunction"}, {"end": 22, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1221_5", "text": "Recent studies have demonstrated that OPCs and oligodendrocytes in both human multiple sclerosis lesions and mouse models of demyelination can express an immunogenic transcriptional signature and upregulate antigen presenting genes.", "tags": [{"end": 165, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 206, "start": 196, "tag": "CellFunction"}, {"end": 138, "start": 109, "tag": "ExperimentalModelOfDisease"}, {"end": 150, "start": 143, "tag": "CellFunction"}, {"end": 181, "start": 166, "tag": "CellFunction"}, {"end": 191, "start": 182, "tag": "ResearchActivity"}, {"end": 63, "start": 47, "tag": "Cell"}, {"end": 42, "start": 38, "tag": "Cell"}, {"end": 96, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 97, "tag": "InjuryOrPoisoning"}, {"end": 77, "start": 72, "tag": "Eukaryote"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 138, "start": 125, "tag": "PathologicFunction"}, {"end": 231, "start": 207, "tag": "GeneOrGenome"}]}{"id": "1221_6", "text": "In inflammatory demyelinating mouse models OPCs are capable of presenting antigen and activating CD8 + T cells.", "tags": [{"end": 42, "start": 3, "tag": "ExperimentalModelOfDisease"}, {"end": 47, "start": 43, "tag": "Cell"}, {"end": 29, "start": 16, "tag": "PathologicFunction"}, {"end": 15, "start": 3, "tag": "PathologicFunction"}, {"end": 110, "start": 97, "tag": "Cell"}]}{"id": "1221_7", "text": "Here we review the evidence for this new role of oligodendroglia as antigen presenting cells and how these inflammatory OPCs (iOPCs) and inflammatory oligodendrocytes (iOLs) may influence myelin repair and other disease processes.", "tags": [{"end": 166, "start": 150, "tag": "Cell"}, {"end": 124, "start": 120, "tag": "Cell"}, {"end": 194, "start": 188, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 49, "tag": "Cell"}, {"end": 119, "start": 107, "tag": "PathologicFunction"}, {"end": 149, "start": 137, "tag": "PathologicFunction"}, {"end": 201, "start": 188, "tag": "CellFunction"}, {"end": 27, "start": 19, "tag": "Finding"}, {"end": 92, "start": 68, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 201, "start": 195, "tag": "BiologicFunction"}, {"end": 201, "start": 195, "tag": "HealthCareActivity"}, {"end": 131, "start": 126, "tag": "Cell"}, {"end": 172, "start": 168, "tag": "Cell"}]}{"id": "1222_0", "text": "Remyelination and neurodegeneration prevention mitigate disability in Multiple Sclerosis (MS).", "tags": [{"end": 46, "start": 36, "tag": "HealthCareActivity"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 88, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 18, "tag": "CellOrMolecularDysfunction"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 56, "tag": "Finding"}]}{"id": "1222_1", "text": "We have shown acute intermittent hypoxia (AIH) is a novel, non-invasive and effective therapy for peripheral nerve repair, including remyelination.", "tags": [{"end": 40, "start": 33, "tag": "PathologicFunction"}, {"end": 71, "start": 63, "tag": "Finding"}, {"end": 19, "start": 14, "tag": "TemporalConcept"}, {"end": 114, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 59, "tag": "Finding"}, {"end": 93, "start": 86, "tag": "HealthCareActivity"}, {"end": 146, "start": 133, "tag": "CellFunction"}, {"end": 121, "start": 115, "tag": "BiologicFunction"}, {"end": 121, "start": 115, "tag": "HealthCareActivity"}, {"end": 40, "start": 14, "tag": "HealthCareActivity"}, {"end": 45, "start": 42, "tag": "HealthCareActivity"}]}{"id": "1222_2", "text": "Thus, we posited AIH would improve repair following CNS demyelination and address the paucity of MS repair treatments.", "tags": [{"end": 34, "start": 27, "tag": "Finding"}, {"end": 55, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 100, "tag": "HealthCareActivity"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 56, "tag": "PathologicFunction"}, {"end": 41, "start": 35, "tag": "BiologicFunction"}, {"end": 41, "start": 35, "tag": "HealthCareActivity"}, {"end": 20, "start": 17, "tag": "HealthCareActivity"}]}{"id": "1222_3", "text": "AIH's capacity to enhance intrinsic repair, functional recovery and alter disease course in the experimental autoimmune encephalomyelitis (EAE) model of MS was assessed.", "tags": [{"end": 63, "start": 44, "tag": "SignOrSymptom"}, {"end": 88, "start": 74, "tag": "TemporalConcept"}, {"end": 137, "start": 96, "tag": "ExperimentalModelOfDisease"}, {"end": 142, "start": 139, "tag": "ExperimentalModelOfDisease"}, {"end": 149, "start": 144, "tag": "ResearchActivity"}, {"end": 14, "start": 6, "tag": "Finding"}, {"end": 63, "start": 55, "tag": "BiologicFunction"}, {"end": 63, "start": 55, "tag": "HealthCareActivity"}, {"end": 63, "start": 55, "tag": "TemporalConcept"}, {"end": 155, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 26, "tag": "BiologicFunction"}, {"end": 3, "start": 0, "tag": "HealthCareActivity"}]}{"id": "1222_4", "text": "EAE was induced by MOG(35-55) immunization in C57BL/6 female mice.", "tags": [{"end": 42, "start": 30, "tag": "HealthCareActivity"}, {"end": 3, "start": 0, "tag": "ExperimentalModelOfDisease"}, {"end": 65, "start": 61, "tag": "Eukaryote"}, {"end": 53, "start": 46, "tag": "Eukaryote"}, {"end": 60, "start": 54, "tag": "OrganismAttribute"}, {"end": 29, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 19, "tag": "BiologicallyActiveSubstance"}]}{"id": "1222_5", "text": "EAE mice received either AIH (10 cycles-5 min 11% oxygen alternating with 5 min 21% oxygen) or Normoxia (control; 21% oxygen for same duration) once daily for 7d beginning at near peak EAE disease score of 2.5.", "tags": [{"end": 124, "start": 118, "tag": "PharmacologicSubstance"}, {"end": 124, "start": 118, "tag": "Chemical"}, {"end": 3, "start": 0, "tag": "ExperimentalModelOfDisease"}, {"end": 188, "start": 185, "tag": "ExperimentalModelOfDisease"}, {"end": 142, "start": 134, "tag": "TemporalConcept"}, {"end": 8, "start": 4, "tag": "Eukaryote"}, {"end": 154, "start": 149, "tag": "TemporalConcept"}, {"end": 28, "start": 25, "tag": "HealthCareActivity"}, {"end": 56, "start": 50, "tag": "Chemical"}, {"end": 56, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 50, "tag": "PharmacologicSubstance"}, {"end": 90, "start": 84, "tag": "PharmacologicSubstance"}, {"end": 90, "start": 84, "tag": "Chemical"}, {"end": 90, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 159, "tag": "TemporalConcept"}]}{"id": "1222_6", "text": "Mice were followed post-treatment for an additional 7d before assessing histopathology or 14d to examine maintenance of AIH effects.", "tags": [{"end": 4, "start": 0, "tag": "Eukaryote"}, {"end": 86, "start": 72, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 86, "start": 72, "tag": "ClinicalAttribute"}, {"end": 23, "start": 19, "tag": "TemporalConcept"}, {"end": 33, "start": 24, "tag": "HealthCareActivity"}, {"end": 33, "start": 24, "tag": "ResearchActivity"}, {"end": 116, "start": 105, "tag": "BiologicFunction"}, {"end": 131, "start": 124, "tag": "Finding"}, {"end": 54, "start": 52, "tag": "TemporalConcept"}, {"end": 93, "start": 90, "tag": "TemporalConcept"}, {"end": 123, "start": 120, "tag": "HealthCareActivity"}]}{"id": "1222_7", "text": "Alterations in histopathological correlates of multiple repair indices were analyzed quantitatively in focally demyelinated ventral lumbar spinal cord areas to assess AIH impacts.", "tags": [{"end": 43, "start": 15, "tag": "ClinicalAttribute"}, {"end": 123, "start": 111, "tag": "PathologicFunction"}, {"end": 150, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 76, "tag": "ResearchActivity"}, {"end": 32, "start": 15, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 62, "start": 56, "tag": "BiologicFunction"}, {"end": 62, "start": 56, "tag": "HealthCareActivity"}, {"end": 11, "start": 0, "tag": "Finding"}, {"end": 156, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 170, "start": 167, "tag": "HealthCareActivity"}]}{"id": "1222_8", "text": "AIH begun at near peak disease significantly improved daily clinical scores/functional recovery and associated histopathology relative to Normoxia controls and the former were maintained for at least 14d post-treatment.", "tags": [{"end": 125, "start": 111, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 125, "start": 111, "tag": "ClinicalAttribute"}, {"end": 53, "start": 45, "tag": "Finding"}, {"end": 208, "start": 204, "tag": "TemporalConcept"}, {"end": 155, "start": 147, "tag": "PopulationGroup"}, {"end": 218, "start": 209, "tag": "HealthCareActivity"}, {"end": 218, "start": 209, "tag": "ResearchActivity"}, {"end": 95, "start": 87, "tag": "BiologicFunction"}, {"end": 95, "start": 87, "tag": "HealthCareActivity"}, {"end": 95, "start": 87, "tag": "TemporalConcept"}, {"end": 59, "start": 54, "tag": "TemporalConcept"}, {"end": 3, "start": 0, "tag": "HealthCareActivity"}]}{"id": "1222_9", "text": "AIH enhanced correlates of myelination, axon protection and oligodendrocyte precursor cell recruitment to demyelinated areas.", "tags": [{"end": 124, "start": 106, "tag": "PathologicFunction"}, {"end": 90, "start": 60, "tag": "Cell"}, {"end": 90, "start": 76, "tag": "Cell"}, {"end": 85, "start": 60, "tag": "Cell"}, {"end": 44, "start": 40, "tag": "CellComponent"}, {"end": 90, "start": 86, "tag": "Cell"}, {"end": 38, "start": 27, "tag": "CellFunction"}]}{"id": "1222_10", "text": "AIH also effected a dramatic reduction in inflammation, while polarizing remaining macrophages/microglia toward a pro-repair state.", "tags": [{"end": 94, "start": 83, "tag": "Cell"}, {"end": 54, "start": 42, "tag": "PathologicFunction"}, {"end": 104, "start": 95, "tag": "Cell"}, {"end": 130, "start": 125, "tag": "PopulationGroup"}, {"end": 38, "start": 29, "tag": "Finding"}, {"end": 38, "start": 29, "tag": "NaturalPhenomenonOrProcess"}, {"end": 124, "start": 118, "tag": "BiologicFunction"}, {"end": 124, "start": 118, "tag": "HealthCareActivity"}, {"end": 3, "start": 0, "tag": "HealthCareActivity"}]}{"id": "1222_11", "text": "Collectively, this supports a role for AIH as a novel non-invasive therapy to enhance CNS repair and alter disease course following demyelination and holds promise as a neuroregenerative MS strategy.", "tags": [{"end": 121, "start": 107, "tag": "TemporalConcept"}, {"end": 66, "start": 58, "tag": "Finding"}, {"end": 121, "start": 115, "tag": "TemporalConcept"}, {"end": 89, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 54, "tag": "Finding"}, {"end": 74, "start": 67, "tag": "HealthCareActivity"}, {"end": 189, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 132, "tag": "PathologicFunction"}, {"end": 96, "start": 90, "tag": "BiologicFunction"}, {"end": 96, "start": 90, "tag": "HealthCareActivity"}, {"end": 42, "start": 39, "tag": "HealthCareActivity"}, {"end": 198, "start": 169, "tag": "HealthCareActivity"}]}{"id": "1223_0", "text": "Oligodendrocytes, the myelinating cells of the central nervous system (CNS), perform vital functions in neural protection and communication, as well as cognition.", "tags": [{"end": 121, "start": 104, "tag": "CellFunction"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 69, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 34, "tag": "Cell"}, {"end": 161, "start": 152, "tag": "BiologicFunction"}, {"end": 139, "start": 126, "tag": "HealthCareActivity"}, {"end": 139, "start": 126, "tag": "CellFunction"}, {"end": 33, "start": 22, "tag": "CellFunction"}]}{"id": "1223_1", "text": "Enhanced production of oligodendrocytes has been identified as a therapeutic approach for neurodegenerative and neurodevelopmental disorders.", "tags": [{"end": 140, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 65, "tag": "HealthCareActivity"}, {"end": 39, "start": 23, "tag": "Cell"}, {"end": 107, "start": 90, "tag": "CellOrMolecularDysfunction"}]}{"id": "1223_2", "text": "In the postnatal brain, oligodendrocytes are generated from the neural stem and precursor cells (NPCs) in the subventricular zone (SVZ) and parenchymal oligodendrocyte precursor cells (OPCs).", "tags": [{"end": 151, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 134, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 24, "tag": "Cell"}, {"end": 189, "start": 185, "tag": "Cell"}, {"end": 183, "start": 152, "tag": "Cell"}, {"end": 101, "start": 97, "tag": "Cell"}, {"end": 95, "start": 64, "tag": "Cell"}, {"end": 183, "start": 168, "tag": "Cell"}, {"end": 177, "start": 152, "tag": "Cell"}, {"end": 16, "start": 7, "tag": "TemporalConcept"}, {"end": 129, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1223_3", "text": "Here, we demonstrate exogenous Hepatoma Derived Growth Factor (HDGF) enhances oligodendrocyte genesis from murine postnatal SVZ NPCs in vitro without affecting neurogenesis or astrogliogenesis.", "tags": [{"end": 61, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 128, "tag": "Cell"}, {"end": 123, "start": 114, "tag": "TemporalConcept"}, {"end": 141, "start": 133, "tag": "ResearchActivity"}, {"end": 113, "start": 107, "tag": "Eukaryote"}, {"end": 93, "start": 78, "tag": "Cell"}, {"end": 172, "start": 160, "tag": "BiologicFunction"}, {"end": 101, "start": 78, "tag": "BiologicFunction"}, {"end": 192, "start": 176, "tag": "BiologicFunction"}, {"end": 67, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 63, "tag": "GeneOrGenome"}, {"end": 67, "start": 63, "tag": "BiologicallyActiveSubstance"}]}{"id": "1223_4", "text": "We further show that this is achieved by increasing proliferation of both NPCs and OPCs, as well as OPC differentiation into oligodendrocytes.", "tags": [{"end": 141, "start": 125, "tag": "Cell"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 103, "start": 100, "tag": "Cell"}, {"end": 78, "start": 74, "tag": "Cell"}, {"end": 119, "start": 104, "tag": "CellFunction"}, {"end": 119, "start": 100, "tag": "CellFunction"}, {"end": 65, "start": 52, "tag": "CellFunction"}, {"end": 51, "start": 41, "tag": "Finding"}]}{"id": "1223_5", "text": "In vivo results demonstrate that intracerebroventricular infusion of HDGF leads to increased oligodendrocyte genesis from SVZ NPCs, as well as OPC proliferation.", "tags": [{"end": 65, "start": 33, "tag": "HealthCareActivity"}, {"end": 125, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 143, "tag": "Cell"}, {"end": 130, "start": 126, "tag": "Cell"}, {"end": 160, "start": 147, "tag": "CellFunction"}, {"end": 108, "start": 93, "tag": "Cell"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 116, "start": 93, "tag": "BiologicFunction"}, {"end": 73, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 69, "tag": "GeneOrGenome"}]}{"id": "1223_6", "text": "Our results demonstrate a novel role for HDGF in regulating SVZ precursor cell proliferation and oligodendrocyte differentiation.", "tags": [{"end": 63, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 113, "tag": "CellFunction"}, {"end": 92, "start": 79, "tag": "CellFunction"}, {"end": 78, "start": 64, "tag": "Cell"}, {"end": 112, "start": 97, "tag": "Cell"}, {"end": 45, "start": 41, "tag": "GeneOrGenome"}, {"end": 45, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 41, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1223_7", "text": "Summary Statement Hepatoma derived growth factor (HDGF) is produced by neurons.", "tags": [{"end": 78, "start": 71, "tag": "Cell"}, {"end": 48, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 50, "tag": "GeneOrGenome"}]}{"id": "1223_8", "text": "However, its role in the central nervous system is largely unknown.", "tags": [{"end": 47, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1223_9", "text": "We demonstrate HDGF enhances i) oligodendrocyte formation from subventricular zone neural stem cells, and ii) oligodendrocyte precursor proliferation in vitro and in vivo.", "tags": [{"end": 149, "start": 136, "tag": "CellFunction"}, {"end": 135, "start": 110, "tag": "Cell"}, {"end": 82, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 83, "tag": "Cell"}, {"end": 158, "start": 150, "tag": "ResearchActivity"}, {"end": 170, "start": 163, "tag": "ResearchActivity"}, {"end": 47, "start": 32, "tag": "Cell"}, {"end": 19, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 15, "tag": "GeneOrGenome"}]}{"id": "1224_0", "text": "Besides giving rise to oligodendrocytes (the only myelin-forming cell in the Central Nervous System (CNS) in physiological conditions), Oligodendrocyte Precursor Cells (OPCs) are responsible for spontaneous remyelination after a demyelinating lesion.", "tags": [{"end": 99, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 23, "tag": "Cell"}, {"end": 173, "start": 169, "tag": "Cell"}, {"end": 242, "start": 229, "tag": "PathologicFunction"}, {"end": 56, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 249, "start": 243, "tag": "InjuryOrPoisoning"}, {"end": 167, "start": 136, "tag": "Cell"}, {"end": 104, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 65, "tag": "Cell"}, {"end": 220, "start": 207, "tag": "CellFunction"}]}{"id": "1224_1", "text": "They are present along the mouse and human CNS, both during development and in adulthood, yet how OPC physiological behavior is modified throughout life is not fully understood.", "tags": [{"end": 124, "start": 102, "tag": "BiologicFunction"}, {"end": 101, "start": 98, "tag": "Cell"}, {"end": 88, "start": 79, "tag": "TemporalConcept"}, {"end": 46, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 60, "tag": "BiologicFunction"}, {"end": 71, "start": 60, "tag": "CellFunction"}, {"end": 42, "start": 37, "tag": "Eukaryote"}, {"end": 152, "start": 148, "tag": "TemporalConcept"}, {"end": 32, "start": 27, "tag": "Eukaryote"}]}{"id": "1224_2", "text": "The activity of adult human OPCs is still particularly unexplored.", "tags": [{"end": 32, "start": 28, "tag": "Cell"}, {"end": 27, "start": 22, "tag": "Eukaryote"}, {"end": 21, "start": 16, "tag": "PopulationGroup"}]}{"id": "1224_3", "text": "Significantly, most of the molecules involved in OPC-mediated remyelination are also involved in their development, a phenomenon that may be clinically relevant.", "tags": [{"end": 52, "start": 49, "tag": "Cell"}, {"end": 114, "start": 103, "tag": "BiologicFunction"}, {"end": 114, "start": 103, "tag": "CellFunction"}, {"end": 36, "start": 27, "tag": "Substance"}, {"end": 75, "start": 62, "tag": "CellFunction"}]}{"id": "1224_4", "text": "In the present article, we have compared the intrinsic properties of OPCs isolated from the cerebral cortex of neonatal, postnatal and adult mice, as well as those recovered from neurosurgical adult human cerebral cortex tissue.", "tags": [{"end": 22, "start": 15, "tag": "ResearchActivity"}, {"end": 73, "start": 69, "tag": "Cell"}, {"end": 130, "start": 121, "tag": "TemporalConcept"}, {"end": 119, "start": 111, "tag": "PopulationGroup"}, {"end": 119, "start": 111, "tag": "TemporalConcept"}, {"end": 204, "start": 199, "tag": "Eukaryote"}, {"end": 145, "start": 141, "tag": "Eukaryote"}, {"end": 227, "start": 221, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 220, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 135, "tag": "PopulationGroup"}, {"end": 198, "start": 193, "tag": "PopulationGroup"}, {"end": 192, "start": 179, "tag": "HealthCareActivity"}]}{"id": "1224_5", "text": "By analyzing intact OPCs for the first time with 1H High Resolution Magic Angle Spinning Nuclear Magnetic Resonance (1H HR-MAS NMR) spectroscopy, we show that these cells behave distinctly and that they have different metabolic patterns in function for their stage of maturity.", "tags": [{"end": 227, "start": 218, "tag": "CellFunction"}, {"end": 264, "start": 259, "tag": "TemporalConcept"}, {"end": 264, "start": 259, "tag": "ClinicalAttribute"}, {"end": 276, "start": 268, "tag": "TemporalConcept"}, {"end": 236, "start": 228, "tag": "ResearchActivity"}, {"end": 24, "start": 20, "tag": "Cell"}, {"end": 19, "start": 13, "tag": "Finding"}, {"end": 170, "start": 165, "tag": "Cell"}, {"end": 38, "start": 33, "tag": "TemporalConcept"}, {"end": 43, "start": 39, "tag": "TemporalConcept"}, {"end": 115, "start": 49, "tag": "HealthCareActivity"}, {"end": 144, "start": 132, "tag": "HealthCareActivity"}, {"end": 130, "start": 117, "tag": "HealthCareActivity"}]}{"id": "1224_6", "text": "Moreover, their response to Fibroblast Growth Gactor-2 (FGF-2) and anosmin-1 (two molecules that have known effects on OPC biology during development and that are overexpressed in individuals with Multiple Sclerosis (MS)) differs in relation to their developmental stage and in the function of the species.", "tags": [{"end": 54, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 56, "tag": "GeneOrGenome"}, {"end": 76, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 270, "start": 251, "tag": "TemporalConcept"}, {"end": 122, "start": 119, "tag": "Cell"}, {"end": 215, "start": 197, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 138, "tag": "BiologicFunction"}, {"end": 149, "start": 138, "tag": "CellFunction"}, {"end": 130, "start": 123, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 191, "start": 180, "tag": "PopulationGroup"}, {"end": 91, "start": 82, "tag": "Substance"}, {"end": 219, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 108, "tag": "Finding"}, {"end": 130, "start": 123, "tag": "BiologicFunction"}, {"end": 176, "start": 163, "tag": "CellFunction"}, {"end": 305, "start": 298, "tag": "OrganismAttribute"}, {"end": 54, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 56, "tag": "BiologicallyActiveSubstance"}]}{"id": "1224_7", "text": "Our data reveal that the behavior of adult human and mouse OPCs differs in a very dynamic way that should be very relevant when testing drugs and for the proper design of effective pharmacological and/or cell therapies for MS.", "tags": [{"end": 167, "start": 161, "tag": "ResearchActivity"}, {"end": 167, "start": 161, "tag": "HealthCareActivity"}, {"end": 196, "start": 181, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 33, "start": 25, "tag": "BiologicFunction"}, {"end": 33, "start": 25, "tag": "IndividualBehavior"}, {"end": 33, "start": 25, "tag": "ResearchActivity"}, {"end": 63, "start": 59, "tag": "Cell"}, {"end": 218, "start": 204, "tag": "HealthCareActivity"}, {"end": 48, "start": 43, "tag": "Eukaryote"}, {"end": 58, "start": 53, "tag": "Eukaryote"}, {"end": 141, "start": 136, "tag": "PharmacologicSubstance"}, {"end": 218, "start": 209, "tag": "HealthCareActivity"}, {"end": 225, "start": 223, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 37, "tag": "PopulationGroup"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 141, "start": 128, "tag": "ResearchActivity"}]}{"id": "1225_0", "text": "Multiple sclerosis (MS) is the most common autoimmune and demyelinating disease of the central nervous system (CNS), characterized, in the majority of cases, by initial relapses that later evolve into progressive neurodegeneration, severely impacting patients' motor and cognitive functions.", "tags": [{"end": 79, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 240, "start": 232, "tag": "Finding"}, {"end": 290, "start": 271, "tag": "BiologicFunction"}, {"end": 114, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 58, "tag": "PathologicFunction"}, {"end": 230, "start": 213, "tag": "CellOrMolecularDysfunction"}, {"end": 259, "start": 251, "tag": "PatientOrDisabledGroup"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 201, "tag": "TemporalConcept"}, {"end": 168, "start": 161, "tag": "TemporalConcept"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 188, "start": 183, "tag": "TemporalConcept"}]}{"id": "1225_1", "text": "Despite the availability of immunomodulatory therapies effective to reduce relapse rate and slow disease progression, they all failed to restore CNS myelin that is necessary for MS full recovery.", "tags": [{"end": 54, "start": 28, "tag": "HealthCareActivity"}, {"end": 148, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 83, "tag": "TemporalConcept"}, {"end": 116, "start": 105, "tag": "PathologicFunction"}, {"end": 116, "start": 105, "tag": "TemporalConcept"}, {"end": 54, "start": 45, "tag": "HealthCareActivity"}, {"end": 180, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 194, "start": 186, "tag": "BiologicFunction"}, {"end": 194, "start": 186, "tag": "HealthCareActivity"}, {"end": 194, "start": 186, "tag": "TemporalConcept"}, {"end": 155, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 75, "tag": "TemporalConcept"}, {"end": 82, "start": 75, "tag": "Finding"}, {"end": 116, "start": 97, "tag": "PathologicFunction"}]}{"id": "1225_2", "text": "Microglia are the primary inflammatory cells present in MS lesions, therefore strongly contributing to demyelination and lesion extension.", "tags": [{"end": 44, "start": 26, "tag": "Cell"}, {"end": 9, "start": 0, "tag": "Cell"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 103, "tag": "PathologicFunction"}, {"end": 66, "start": 59, "tag": "InjuryOrPoisoning"}, {"end": 127, "start": 121, "tag": "InjuryOrPoisoning"}]}{"id": "1225_3", "text": "Thus, many microglial-based therapeutic strategies have been focused on the suppression of microglial pro-inflammatory phenotype and neurodegenerative state to reduce disease severity.", "tags": [{"end": 50, "start": 28, "tag": "HealthCareActivity"}, {"end": 128, "start": 119, "tag": "OrganismAttribute"}, {"end": 183, "start": 167, "tag": "ClinicalAttribute"}, {"end": 156, "start": 133, "tag": "CellOrMolecularDysfunction"}, {"end": 21, "start": 11, "tag": "Cell"}, {"end": 101, "start": 91, "tag": "Cell"}, {"end": 118, "start": 102, "tag": "PathologicFunction"}]}{"id": "1225_4", "text": "On the other hand, the contribution of myelin phagocytosis advocating the neuroprotective role of microglia in MS has been less explored.", "tags": [{"end": 58, "start": 46, "tag": "CellFunction"}, {"end": 89, "start": 74, "tag": "CellFunction"}, {"end": 113, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 98, "tag": "Cell"}]}{"id": "1225_5", "text": "Indeed, despite the presence of functional oligodendrocyte precursor cells (OPCs), within lesioned areas, MS plaques fail to remyelinate as a result of the over-accumulation of myelin-toxic debris that must be cleared away by microglia.", "tags": [{"end": 28, "start": 20, "tag": "Finding"}, {"end": 116, "start": 106, "tag": "AnatomicalAbnormality"}, {"end": 80, "start": 76, "tag": "Cell"}, {"end": 196, "start": 190, "tag": "Substance"}, {"end": 74, "start": 43, "tag": "Cell"}, {"end": 136, "start": 125, "tag": "CellFunction"}, {"end": 173, "start": 161, "tag": "Finding"}, {"end": 108, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 177, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 235, "start": 226, "tag": "Cell"}, {"end": 196, "start": 177, "tag": "PathologicFunction"}]}{"id": "1225_6", "text": "Dysregulation of this process has been associated with the impaired neuronal recovery and deficient remyelination.", "tags": [{"end": 76, "start": 68, "tag": "Cell"}, {"end": 113, "start": 100, "tag": "CellFunction"}, {"end": 85, "start": 77, "tag": "BiologicFunction"}, {"end": 85, "start": 77, "tag": "HealthCareActivity"}, {"end": 85, "start": 77, "tag": "TemporalConcept"}]}{"id": "1225_7", "text": "In line with this, here we provide a comprehensive review of microglial myelin phagocytosis and its involvement in MS development and repair.", "tags": [{"end": 91, "start": 79, "tag": "CellFunction"}, {"end": 57, "start": 51, "tag": "ResearchActivity"}, {"end": 57, "start": 51, "tag": "HealthCareActivity"}, {"end": 111, "start": 100, "tag": "Finding"}, {"end": 71, "start": 61, "tag": "Cell"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 134, "tag": "BiologicFunction"}, {"end": 140, "start": 134, "tag": "HealthCareActivity"}, {"end": 78, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 118, "tag": "BiologicFunction"}, {"end": 129, "start": 118, "tag": "CellFunction"}]}{"id": "1225_8", "text": "Alongside, we discuss the potential of phagocytic-mediated therapeutic approaches and encourage their modulation as a novel and rational approach to ameliorate MS-associated pathology.", "tags": [{"end": 81, "start": 59, "tag": "HealthCareActivity"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 174, "tag": "PathologicFunction"}, {"end": 183, "start": 174, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1226_0", "text": "Multiple sclerosis (MS) is a chronic autoimmune demyelinating disease characterized by the autoimmune attack of oligodendrocytes, leading to demyelination and progressive functional deficits.", "tags": [{"end": 108, "start": 102, "tag": "Finding"}, {"end": 128, "start": 112, "tag": "Cell"}, {"end": 69, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 182, "tag": "Finding"}, {"end": 170, "start": 159, "tag": "TemporalConcept"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 141, "tag": "PathologicFunction"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 29, "tag": "TemporalConcept"}]}{"id": "1226_1", "text": "CXC chemokine receptor 2 (CXCR2) is recently reported to orchestrate the migration, proliferation and differentiation of oligodendrocyte precursor cells (OPCs), which implies its possible involvement in the demyelinating process.", "tags": [{"end": 24, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 154, "tag": "Cell"}, {"end": 152, "start": 121, "tag": "Cell"}, {"end": 220, "start": 207, "tag": "PathologicFunction"}, {"end": 117, "start": 102, "tag": "CellFunction"}, {"end": 97, "start": 84, "tag": "CellFunction"}, {"end": 82, "start": 73, "tag": "CellFunction"}, {"end": 44, "start": 36, "tag": "TemporalConcept"}, {"end": 199, "start": 188, "tag": "Finding"}, {"end": 31, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 26, "tag": "GeneOrGenome"}]}{"id": "1226_2", "text": "Here, we used a CXCR2 antagonist, compound 2, as a tool to investigate the role of CXCR2 in demyelination and the underlying mechanism.", "tags": [{"end": 21, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 34, "tag": "Chemical"}, {"end": 44, "start": 34, "tag": "PharmacologicSubstance"}, {"end": 88, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 92, "tag": "PathologicFunction"}, {"end": 32, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 21, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 16, "tag": "GeneOrGenome"}]}{"id": "1226_3", "text": "The primary cultured oligodendrocytes and cuprizone (CPZ)-intoxicated mice were applied in the present study.", "tags": [{"end": 56, "start": 53, "tag": "Chemical"}, {"end": 37, "start": 21, "tag": "Cell"}, {"end": 51, "start": 42, "tag": "Chemical"}, {"end": 108, "start": 103, "tag": "ResearchActivity"}, {"end": 74, "start": 70, "tag": "Eukaryote"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 74, "start": 42, "tag": "ExperimentalModelOfDisease"}]}{"id": "1226_4", "text": "The results showed that compound 2 significantly promoted OPC proliferation and differentiation.", "tags": [{"end": 34, "start": 24, "tag": "Chemical"}, {"end": 34, "start": 24, "tag": "PharmacologicSubstance"}, {"end": 61, "start": 58, "tag": "Cell"}, {"end": 95, "start": 80, "tag": "CellFunction"}, {"end": 75, "start": 62, "tag": "CellFunction"}]}{"id": "1226_5", "text": "In the demyelinated lesions of CPZ-intoxicated mice, vigorous OPC proliferation and myelin repair was observed after compound 2 treatment.", "tags": [{"end": 127, "start": 117, "tag": "Chemical"}, {"end": 127, "start": 117, "tag": "PharmacologicSubstance"}, {"end": 34, "start": 31, "tag": "Chemical"}, {"end": 65, "start": 62, "tag": "Cell"}, {"end": 90, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 20, "tag": "InjuryOrPoisoning"}, {"end": 19, "start": 7, "tag": "PathologicFunction"}, {"end": 27, "start": 7, "tag": "PathologicFunction"}, {"end": 79, "start": 66, "tag": "CellFunction"}, {"end": 97, "start": 84, "tag": "CellFunction"}, {"end": 51, "start": 47, "tag": "Eukaryote"}, {"end": 137, "start": 128, "tag": "HealthCareActivity"}, {"end": 137, "start": 128, "tag": "ResearchActivity"}, {"end": 97, "start": 91, "tag": "BiologicFunction"}, {"end": 97, "start": 91, "tag": "HealthCareActivity"}, {"end": 51, "start": 31, "tag": "ExperimentalModelOfDisease"}]}{"id": "1226_6", "text": "Subsequent investigation of the underlying mechanisms identified that upon inhibition of CXCR2, compound 2 treatment upregulated Ki67, transcription factor 2 (Olig2) and Caspr expression, activated PI3K/AKT/mTOR signaling, ultimately promoted OPCs differentiation and enhanced remyelination.", "tags": [{"end": 94, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 96, "tag": "Chemical"}, {"end": 106, "start": 96, "tag": "PharmacologicSubstance"}, {"end": 133, "start": 129, "tag": "GeneOrGenome"}, {"end": 133, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 159, "tag": "GeneOrGenome"}, {"end": 175, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 175, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 247, "start": 243, "tag": "Cell"}, {"end": 221, "start": 198, "tag": "CellFunction"}, {"end": 263, "start": 248, "tag": "CellFunction"}, {"end": 24, "start": 11, "tag": "ResearchActivity"}, {"end": 290, "start": 268, "tag": "Finding"}, {"end": 116, "start": 107, "tag": "HealthCareActivity"}, {"end": 116, "start": 107, "tag": "ResearchActivity"}, {"end": 186, "start": 176, "tag": "CellFunction"}, {"end": 85, "start": 75, "tag": "CellFunction"}, {"end": 290, "start": 277, "tag": "CellFunction"}, {"end": 164, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 89, "tag": "GeneOrGenome"}, {"end": 133, "start": 129, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1226_7", "text": "In conclusion, our results demonstrated that CXCR2 antagonism efficiently promoted OPC differentiation and enhanced remyelination in CPZ-intoxicated mice, supporting CXCR2 as a promising therapeutic target for the treatment of chronic demyelinating diseases such as MS.", "tags": [{"end": 50, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 133, "tag": "Chemical"}, {"end": 205, "start": 177, "tag": "Finding"}, {"end": 86, "start": 83, "tag": "Cell"}, {"end": 257, "start": 235, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 87, "tag": "CellFunction"}, {"end": 102, "start": 83, "tag": "CellFunction"}, {"end": 129, "start": 107, "tag": "Finding"}, {"end": 153, "start": 149, "tag": "Eukaryote"}, {"end": 223, "start": 214, "tag": "HealthCareActivity"}, {"end": 223, "start": 214, "tag": "ResearchActivity"}, {"end": 129, "start": 116, "tag": "CellFunction"}, {"end": 268, "start": 266, "tag": "DiseaseOrSyndrome"}, {"end": 234, "start": 227, "tag": "TemporalConcept"}, {"end": 50, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 45, "tag": "GeneOrGenome"}, {"end": 153, "start": 133, "tag": "ExperimentalModelOfDisease"}, {"end": 171, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 166, "tag": "GeneOrGenome"}]}{"id": "1227_0", "text": "The oligodendrocyte lineage cell is crucial to proper brain function.", "tags": [{"end": 32, "start": 4, "tag": "Cell"}, {"end": 68, "start": 54, "tag": "BiologicFunction"}]}{"id": "1227_1", "text": "During central nervous system development, oligodendrocyte progenitor cells (OPCs) migrate and proliferate to populate the entire brain and spinal cord, and subsequently differentiate into mature oligodendrocytes that wrap neuronal axons in an insulating myelin layer.", "tags": [{"end": 41, "start": 7, "tag": "BiologicFunction"}, {"end": 237, "start": 232, "tag": "CellComponent"}, {"end": 231, "start": 223, "tag": "Cell"}, {"end": 81, "start": 77, "tag": "Cell"}, {"end": 212, "start": 189, "tag": "Cell"}, {"end": 151, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 43, "tag": "Cell"}, {"end": 183, "start": 170, "tag": "CellFunction"}, {"end": 135, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 267, "start": 255, "tag": "CellComponent"}, {"end": 29, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1227_2", "text": "When damage occurs to the myelin sheath, OPCs are activated and recruited to the demyelinated site, where they differentiate into oligodendrocytes that remyelinate the denuded axons.", "tags": [{"end": 93, "start": 81, "tag": "PathologicFunction"}, {"end": 181, "start": 176, "tag": "CellComponent"}, {"end": 146, "start": 130, "tag": "Cell"}, {"end": 45, "start": 41, "tag": "Cell"}, {"end": 39, "start": 26, "tag": "CellComponent"}, {"end": 163, "start": 152, "tag": "CellFunction"}]}{"id": "1227_3", "text": "The process of OPC attraction and differentiation is influenced by a multitude of factors from the cell's niche.", "tags": [{"end": 18, "start": 15, "tag": "Cell"}, {"end": 49, "start": 34, "tag": "CellFunction"}]}{"id": "1227_4", "text": "Matrix metalloproteinases (MMPs) are powerful and versatile enzymes that do not only degrade extracellular matrix proteins, but also cleave cell surface receptors, growth factors, signaling molecules, proteases and other precursor proteins, leading to their activation or degradation.", "tags": [{"end": 25, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 164, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 180, "tag": "BiologicallyActiveSubstance"}, {"end": 210, "start": 201, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 190, "tag": "Substance"}, {"end": 170, "start": 164, "tag": "BiologicFunction"}, {"end": 25, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 283, "start": 272, "tag": "NaturalPhenomenonOrProcess"}, {"end": 189, "start": 180, "tag": "CellFunction"}, {"end": 67, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 239, "start": 221, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 210, "start": 201, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 140, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1227_5", "text": "MMPs are markedly upregulated during brain development and upon demyelinating injury, where their broad functions influence the behavior of neural progenitor cells (NPCs), OPCs and oligodendrocytes.", "tags": [{"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 140, "tag": "Cell"}, {"end": 136, "start": 128, "tag": "BiologicFunction"}, {"end": 136, "start": 128, "tag": "IndividualBehavior"}, {"end": 136, "start": 128, "tag": "ResearchActivity"}, {"end": 197, "start": 181, "tag": "Cell"}, {"end": 176, "start": 172, "tag": "Cell"}, {"end": 169, "start": 165, "tag": "Cell"}, {"end": 84, "start": 64, "tag": "InjuryOrPoisoning"}, {"end": 54, "start": 37, "tag": "BiologicFunction"}, {"end": 77, "start": 64, "tag": "PathologicFunction"}, {"end": 54, "start": 43, "tag": "BiologicFunction"}, {"end": 54, "start": 43, "tag": "CellFunction"}]}{"id": "1227_6", "text": "In this review, we focus on the role of MMPs in (re)myelination.", "tags": [{"end": 44, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 52, "tag": "CellFunction"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}]}{"id": "1227_7", "text": "We will start out in the developing brain with describing the effects of MMPs on NPCs, OPCs and eventually oligodendrocytes.", "tags": [{"end": 77, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 107, "tag": "Cell"}, {"end": 91, "start": 87, "tag": "Cell"}, {"end": 85, "start": 81, "tag": "Cell"}, {"end": 41, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1227_8", "text": "Then, we will outline their functions in oligodendrocyte process extension and developmental myelination.", "tags": [{"end": 104, "start": 93, "tag": "CellFunction"}, {"end": 92, "start": 79, "tag": "BiologicFunction"}, {"end": 92, "start": 79, "tag": "TemporalConcept"}, {"end": 74, "start": 41, "tag": "CellFunction"}]}{"id": "1227_9", "text": "Finally, we will review their potential role in demyelination, describe their significance in remyelination and discuss the evidence for a role of MMPs in remyelination failure, focusing on multiple sclerosis.", "tags": [{"end": 151, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 94, "tag": "CellFunction"}, {"end": 168, "start": 155, "tag": "CellFunction"}, {"end": 176, "start": 155, "tag": "CellOrMolecularDysfunction"}, {"end": 23, "start": 17, "tag": "ResearchActivity"}, {"end": 23, "start": 17, "tag": "HealthCareActivity"}, {"end": 132, "start": 124, "tag": "Finding"}, {"end": 208, "start": 190, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 48, "tag": "PathologicFunction"}]}{"id": "1227_10", "text": "In conclusion, MMPs shape the oligodendrocyte (niche) both during development and upon demyelination, and thus are important players in directing the fate and behavior of oligodendrocyte lineage cells throughout their life cycle.", "tags": [{"end": 19, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 228, "start": 218, "tag": "TemporalConcept"}, {"end": 228, "start": 218, "tag": "BiologicFunction"}, {"end": 167, "start": 159, "tag": "BiologicFunction"}, {"end": 167, "start": 159, "tag": "IndividualBehavior"}, {"end": 167, "start": 159, "tag": "ResearchActivity"}, {"end": 45, "start": 30, "tag": "Cell"}, {"end": 200, "start": 171, "tag": "Cell"}, {"end": 100, "start": 87, "tag": "PathologicFunction"}, {"end": 77, "start": 66, "tag": "BiologicFunction"}, {"end": 77, "start": 66, "tag": "CellFunction"}, {"end": 222, "start": 218, "tag": "TemporalConcept"}]}{"id": "1228_0", "text": "The repair of demyelinated lesions is a key objective in multiple sclerosis research.", "tags": [{"end": 75, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 14, "tag": "InjuryOrPoisoning"}, {"end": 10, "start": 4, "tag": "BiologicFunction"}, {"end": 10, "start": 4, "tag": "HealthCareActivity"}, {"end": 84, "start": 76, "tag": "ResearchActivity"}]}{"id": "1228_1", "text": "Remyelination fundamentally depends on oligodendrocyte progenitor cells (OPC) reaching the lesion; this is influenced by numerous factors including age, disease progression time, inflammatory activity, and the pool of OPCs available, whether they be NG2 cells or cells derived from neural stem cells.", "tags": [{"end": 253, "start": 250, "tag": "AminoAcidPeptideOrProtein"}, {"end": 253, "start": 250, "tag": "BiologicallyActiveSubstance"}, {"end": 253, "start": 250, "tag": "GeneOrGenome"}, {"end": 222, "start": 218, "tag": "Cell"}, {"end": 76, "start": 73, "tag": "Cell"}, {"end": 259, "start": 254, "tag": "Cell"}, {"end": 268, "start": 263, "tag": "Cell"}, {"end": 97, "start": 91, "tag": "InjuryOrPoisoning"}, {"end": 172, "start": 153, "tag": "PathologicFunction"}, {"end": 71, "start": 39, "tag": "Cell"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 177, "start": 173, "tag": "TemporalConcept"}, {"end": 151, "start": 148, "tag": "OrganismAttribute"}, {"end": 200, "start": 179, "tag": "CellFunction"}, {"end": 191, "start": 179, "tag": "PathologicFunction"}, {"end": 299, "start": 282, "tag": "Cell"}, {"end": 222, "start": 210, "tag": "Cell"}]}{"id": "1228_2", "text": "Administering OPCs has been proposed as a potential cell therapy; however, these cells can only be administered directly.", "tags": [{"end": 64, "start": 52, "tag": "HealthCareActivity"}, {"end": 18, "start": 14, "tag": "Cell"}, {"end": 86, "start": 81, "tag": "Cell"}]}{"id": "1228_3", "text": "This article discusses the potential administration of OPCs encapsulated within hydrogel particles composed of biocompatible biomaterials, via the nose-to-brain pathway.", "tags": [{"end": 12, "start": 5, "tag": "ResearchActivity"}, {"end": 59, "start": 55, "tag": "Cell"}, {"end": 98, "start": 55, "tag": "ManufacturedObject"}, {"end": 137, "start": 111, "tag": "ManufacturedObject"}, {"end": 168, "start": 147, "tag": "BiologicFunction"}]}{"id": "1228_4", "text": "We also discuss conditions for the indication of this therapy, and such related issues as the influence on endogenous remyelination, migration of OPCs to demyelinated areas, and the immune response, given the autoimmune nature of multiple sclerosis.", "tags": [{"end": 197, "start": 182, "tag": "BiologicFunction"}, {"end": 197, "start": 182, "tag": "CellFunction"}, {"end": 226, "start": 209, "tag": "PathologicFunction"}, {"end": 150, "start": 146, "tag": "Cell"}, {"end": 248, "start": 230, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 118, "tag": "CellFunction"}, {"end": 172, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 133, "tag": "CellFunction"}, {"end": 61, "start": 54, "tag": "HealthCareActivity"}]}{"id": "1228_5", "text": "Chitosan and derivatives constitute the most promising biomaterial for this purpose, although these issues must be addressed.", "tags": [{"end": 8, "start": 0, "tag": "Chemical"}, {"end": 24, "start": 13, "tag": "Chemical"}]}{"id": "1228_6", "text": "In conclusion, this line of research may yield an alternative to the remyelinating drugs currently being studied.", "tags": [{"end": 88, "start": 83, "tag": "PharmacologicSubstance"}, {"end": 82, "start": 69, "tag": "CellFunction"}, {"end": 98, "start": 89, "tag": "TemporalConcept"}, {"end": 36, "start": 28, "tag": "ResearchActivity"}]}{"id": "1229_0", "text": "Oligodendrocyte precursor cells (OPCs), also known as NG2 cells or polydendrocytes, are distributed widely throughout the developing and mature central nervous system.", "tags": [{"end": 57, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 143, "start": 137, "tag": "TemporalConcept"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 166, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 54, "tag": "Cell"}, {"end": 82, "start": 67, "tag": "Cell"}]}{"id": "1229_1", "text": "They remain proliferative throughout life and are an important source of myelinating cells in normal and demyelinating brain as well as a source of glioma, the most common type of primary brain tumor with a poor prognosis.", "tags": [{"end": 25, "start": 12, "tag": "PathologicFunction"}, {"end": 154, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 207, "tag": "Finding"}, {"end": 118, "start": 105, "tag": "PathologicFunction"}, {"end": 199, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 85, "tag": "Cell"}, {"end": 41, "start": 37, "tag": "TemporalConcept"}, {"end": 100, "start": 94, "tag": "Finding"}, {"end": 221, "start": 212, "tag": "HealthCareActivity"}, {"end": 84, "start": 73, "tag": "CellFunction"}]}{"id": "1229_2", "text": "OPC proliferation is dependent on signaling mediated by platelet-derived growth factor (PDGF) AA binding to its alpha receptor (PDGFR alpha).", "tags": [{"end": 96, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "Cell"}, {"end": 43, "start": 34, "tag": "CellFunction"}, {"end": 17, "start": 4, "tag": "CellFunction"}, {"end": 104, "start": 97, "tag": "CellFunction"}, {"end": 126, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 128, "tag": "GeneOrGenome"}]}{"id": "1229_3", "text": "Here, we describe a group of structurally related compounds characterized by the presence of a basic guanidine group appended to an aromatic core that is effective in specifically repressing the transcription of Pdgfra but not the related beta receptor (Pdgfrb) in OPCs.", "tags": [{"end": 116, "start": 101, "tag": "Chemical"}, {"end": 208, "start": 195, "tag": "CellFunction"}, {"end": 252, "start": 239, "tag": "AminoAcidPeptideOrProtein"}, {"end": 218, "start": 212, "tag": "GeneOrGenome"}, {"end": 218, "start": 212, "tag": "AminoAcidPeptideOrProtein"}, {"end": 269, "start": 265, "tag": "Cell"}, {"end": 59, "start": 50, "tag": "Chemical"}, {"end": 59, "start": 50, "tag": "PharmacologicSubstance"}, {"end": 25, "start": 20, "tag": "PopulationGroup"}, {"end": 89, "start": 81, "tag": "Finding"}, {"end": 110, "start": 101, "tag": "Chemical"}, {"end": 110, "start": 101, "tag": "PharmacologicSubstance"}, {"end": 110, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 218, "start": 212, "tag": "BiologicallyActiveSubstance"}, {"end": 260, "start": 254, "tag": "AminoAcidPeptideOrProtein"}, {"end": 260, "start": 254, "tag": "BiologicallyActiveSubstance"}, {"end": 260, "start": 254, "tag": "GeneOrGenome"}, {"end": 145, "start": 132, "tag": "Chemical"}]}{"id": "1229_4", "text": "These compounds specifically and dramatically reduced proliferation of OPCs but not that of astrocytes and did not affect signal transduction by PDGFR alpha.", "tags": [{"end": 141, "start": 122, "tag": "CellFunction"}, {"end": 75, "start": 71, "tag": "Cell"}, {"end": 67, "start": 54, "tag": "CellFunction"}, {"end": 15, "start": 6, "tag": "Chemical"}, {"end": 15, "start": 6, "tag": "PharmacologicSubstance"}, {"end": 102, "start": 92, "tag": "Cell"}, {"end": 156, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 145, "tag": "GeneOrGenome"}]}{"id": "1229_5", "text": "These findings suggest that the compounds could be further developed for potential use in combinatorial treatment strategies for neoplasms with dysregulated PDGFR alpha function.", "tags": [{"end": 138, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 32, "tag": "Chemical"}, {"end": 41, "start": 32, "tag": "PharmacologicSubstance"}, {"end": 156, "start": 144, "tag": "PathologicFunction"}, {"end": 124, "start": 90, "tag": "ResearchActivity"}, {"end": 124, "start": 90, "tag": "HealthCareActivity"}, {"end": 168, "start": 157, "tag": "GeneOrGenome"}, {"end": 168, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 157, "tag": "BiologicallyActiveSubstance"}]}{"id": "1230_0", "text": "Myelination of the CNS relies on the production and differentiation of oligodendrocyte (OL) precursor cells (OPCs) into mature OLs.", "tags": [{"end": 113, "start": 109, "tag": "Cell"}, {"end": 67, "start": 52, "tag": "CellFunction"}, {"end": 130, "start": 127, "tag": "Cell"}, {"end": 90, "start": 88, "tag": "Cell"}, {"end": 126, "start": 120, "tag": "TemporalConcept"}, {"end": 107, "start": 92, "tag": "Cell"}, {"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 22, "start": 19, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 71, "tag": "Cell"}]}{"id": "1230_1", "text": "During the first month of postnatal life, OPCs that populate the corpus callosum (CC) arise from neural stem cells (NSCs) in the subcallosal subventricular zone (SVZ), and then differentiate to generate myelinating OLs.", "tags": [{"end": 22, "start": 17, "tag": "TemporalConcept"}, {"end": 120, "start": 116, "tag": "Cell"}, {"end": 214, "start": 203, "tag": "CellFunction"}, {"end": 165, "start": 162, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 218, "start": 203, "tag": "Cell"}, {"end": 46, "start": 42, "tag": "Cell"}, {"end": 190, "start": 177, "tag": "CellFunction"}, {"end": 218, "start": 215, "tag": "Cell"}, {"end": 84, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 26, "tag": "TemporalConcept"}, {"end": 160, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 97, "tag": "Cell"}, {"end": 16, "start": 11, "tag": "TemporalConcept"}, {"end": 40, "start": 36, "tag": "TemporalConcept"}]}{"id": "1230_2", "text": "However, the signals that regulate these processes are not fully understood.", "tags": [{"end": 20, "start": 13, "tag": "CellFunction"}]}{"id": "1230_3", "text": "In this study, we show that endogenous expression of the retinoic acid (RA)-synthesizing enzyme retinaldehyde dehydrogenase 2 (RALDH2) is required for OPC generation and differentiation in the postnatal subcortical white matter.", "tags": [{"end": 70, "start": 57, "tag": "Chemical"}, {"end": 133, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 214, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 151, "tag": "Cell"}, {"end": 185, "start": 170, "tag": "CellFunction"}, {"end": 227, "start": 215, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 202, "start": 193, "tag": "TemporalConcept"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 49, "start": 39, "tag": "CellFunction"}, {"end": 165, "start": 155, "tag": "TemporalConcept"}, {"end": 74, "start": 72, "tag": "Chemical"}, {"end": 74, "start": 72, "tag": "PharmacologicSubstance"}, {"end": 74, "start": 72, "tag": "InjuryOrPoisoning"}, {"end": 70, "start": 57, "tag": "PharmacologicSubstance"}, {"end": 70, "start": 57, "tag": "InjuryOrPoisoning"}, {"end": 125, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 127, "tag": "GeneOrGenome"}]}{"id": "1230_4", "text": "In male and female pups, conditional deletion of Raldh2 reduced OPC numbers and differentiation.", "tags": [{"end": 45, "start": 37, "tag": "CellOrMolecularDysfunction"}, {"end": 55, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 64, "tag": "Cell"}, {"end": 95, "start": 80, "tag": "CellFunction"}, {"end": 36, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 12, "tag": "OrganismAttribute"}, {"end": 7, "start": 3, "tag": "OrganismAttribute"}, {"end": 23, "start": 19, "tag": "TemporalConcept"}, {"end": 55, "start": 49, "tag": "GeneOrGenome"}]}{"id": "1230_5", "text": "Moreover, decreased OPC numbers coincided with reductions in NSC survival and expression of the sonic hedgehog (SHH) signaling effector protein Gli1 in the SVZ.", "tags": [{"end": 57, "start": 47, "tag": "NaturalPhenomenonOrProcess"}, {"end": 57, "start": 47, "tag": "HealthCareActivity"}, {"end": 64, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 96, "tag": "GeneOrGenome"}, {"end": 148, "start": 144, "tag": "GeneOrGenome"}, {"end": 148, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 20, "tag": "Cell"}, {"end": 126, "start": 117, "tag": "CellFunction"}, {"end": 110, "start": 96, "tag": "CellFunction"}, {"end": 88, "start": 78, "tag": "CellFunction"}, {"end": 73, "start": 65, "tag": "CellFunction"}, {"end": 143, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 112, "tag": "GeneOrGenome"}, {"end": 115, "start": 112, "tag": "BiologicallyActiveSubstance"}]}{"id": "1230_6", "text": "Additionally, GFAP expression in the CC was decreased, and cortical neuron numbers were altered.", "tags": [{"end": 39, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 68, "tag": "Cell"}, {"end": 29, "start": 19, "tag": "CellFunction"}, {"end": 67, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 18, "start": 14, "tag": "GeneOrGenome"}]}{"id": "1230_7", "text": "Our work suggests a role for endogenous RALDH2-dependent RA synthesis in OPC production and differentiation in the CC, as well as in the development of other cell types derived from NSCs in the embryonic ventricular zone (VZ) and SVZ, as well as the postnatal subcallosal SVZ.", "tags": [{"end": 59, "start": 57, "tag": "Chemical"}, {"end": 59, "start": 57, "tag": "PharmacologicSubstance"}, {"end": 59, "start": 57, "tag": "InjuryOrPoisoning"}, {"end": 186, "start": 182, "tag": "Cell"}, {"end": 271, "start": 260, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 233, "start": 230, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 275, "start": 272, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 73, "tag": "Cell"}, {"end": 107, "start": 92, "tag": "CellFunction"}, {"end": 117, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 259, "start": 250, "tag": "TemporalConcept"}, {"end": 69, "start": 57, "tag": "BiologicFunction"}, {"end": 148, "start": 137, "tag": "BiologicFunction"}, {"end": 148, "start": 137, "tag": "CellFunction"}, {"end": 168, "start": 158, "tag": "Cell"}, {"end": 46, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 40, "tag": "GeneOrGenome"}, {"end": 220, "start": 194, "tag": "EmbryonicStructure"}]}{"id": "1231_0", "text": "In the cerebral cortex, GABAergic interneurons and oligodendrocyte lineage cells share different characteristics and interact despite being neurons and glial cells, respectively.", "tags": [{"end": 46, "start": 24, "tag": "Cell"}, {"end": 46, "start": 34, "tag": "Cell"}, {"end": 80, "start": 51, "tag": "Cell"}, {"end": 74, "start": 51, "tag": "Cell"}, {"end": 157, "start": 152, "tag": "Cell"}, {"end": 163, "start": 152, "tag": "Cell"}, {"end": 22, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 140, "tag": "Cell"}]}{"id": "1231_1", "text": "These two distinct cell types share common embryonic origins and are born from precursors expressing similar transcription factors.", "tags": [{"end": 73, "start": 69, "tag": "BiologicFunction"}, {"end": 89, "start": 79, "tag": "Cell"}, {"end": 100, "start": 90, "tag": "CellFunction"}, {"end": 130, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 19, "tag": "Cell"}]}{"id": "1231_2", "text": "Moreover, they highly interact with each other through different communication mechanisms during development.", "tags": [{"end": 108, "start": 97, "tag": "BiologicFunction"}, {"end": 108, "start": 97, "tag": "CellFunction"}, {"end": 78, "start": 65, "tag": "HealthCareActivity"}, {"end": 78, "start": 65, "tag": "CellFunction"}]}{"id": "1231_3", "text": "Notably, cortical oligodendrocyte precursor cells (OPCs) receive a major and transient GABAergic synaptic input, preferentially from parvalbumin-expressing interneurons, a specific interneuron subtype recently recognized as highly myelinated.", "tags": [{"end": 200, "start": 181, "tag": "Cell"}, {"end": 241, "start": 231, "tag": "CellComponent"}, {"end": 155, "start": 145, "tag": "CellFunction"}, {"end": 168, "start": 156, "tag": "Cell"}, {"end": 144, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 51, "tag": "Cell"}, {"end": 49, "start": 18, "tag": "Cell"}, {"end": 86, "start": 77, "tag": "TemporalConcept"}, {"end": 49, "start": 34, "tag": "Cell"}, {"end": 43, "start": 18, "tag": "Cell"}, {"end": 17, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 201, "tag": "TemporalConcept"}, {"end": 111, "start": 87, "tag": "CellFunction"}]}{"id": "1231_4", "text": "In this review, we highlight the similarities and interactions between GABAergic intemeurons and oligodendrocyte lineage cells in the cerebral cortex and suggest potential roles of this intimate interneurono-ligodendroglia relationship in cortical construction.", "tags": [{"end": 235, "start": 223, "tag": "Finding"}, {"end": 126, "start": 97, "tag": "Cell"}, {"end": 120, "start": 97, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 149, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 247, "start": 239, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 50, "tag": "Finding"}, {"end": 92, "start": 71, "tag": "Cell"}]}{"id": "1231_5", "text": "We also propose new lines of research to understand the role of the close link between interneurons and oligodendroglia during cortical development and in pathological conditions such as schizophrenia.", "tags": [{"end": 178, "start": 155, "tag": "PathologicFunction"}, {"end": 99, "start": 87, "tag": "Cell"}, {"end": 119, "start": 104, "tag": "Cell"}, {"end": 200, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 29, "tag": "ResearchActivity"}, {"end": 147, "start": 136, "tag": "BiologicFunction"}, {"end": 147, "start": 136, "tag": "CellFunction"}, {"end": 135, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1232_0", "text": "All currently licensed medications for multiple sclerosis (MS) target the immune system.", "tags": [{"end": 34, "start": 23, "tag": "PharmacologicSubstance"}, {"end": 57, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 4, "tag": "TemporalConcept"}, {"end": 87, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}]}{"id": "1232_1", "text": "Albeit promising preclinical results demonstrated disease amelioration and remyelination enhancement via modulating oligodendrocyte lineage cells, most drug candidates showed only modest or no effects in human clinical trials.", "tags": [{"end": 145, "start": 116, "tag": "Cell"}, {"end": 139, "start": 116, "tag": "Cell"}, {"end": 100, "start": 89, "tag": "Finding"}, {"end": 209, "start": 204, "tag": "Eukaryote"}, {"end": 88, "start": 75, "tag": "CellFunction"}, {"end": 200, "start": 193, "tag": "Finding"}, {"end": 186, "start": 180, "tag": "Finding"}, {"end": 156, "start": 152, "tag": "PharmacologicSubstance"}, {"end": 225, "start": 210, "tag": "ResearchActivity"}, {"end": 36, "start": 17, "tag": "ResearchActivity"}, {"end": 70, "start": 50, "tag": "Finding"}, {"end": 200, "start": 190, "tag": "Finding"}]}{"id": "1232_2", "text": "This might be due to the fact that remyelination is a sophistically orchestrated process that calls for the interplay between oligodendrocyte lineage cells, neurons, central nervous system (CNS) resident innate immune cells, and peripheral immune infiltrates and that this process may somewhat differ in humans and rodent models used in research.", "tags": [{"end": 223, "start": 195, "tag": "Cell"}, {"end": 310, "start": 304, "tag": "Eukaryote"}, {"end": 321, "start": 315, "tag": "Eukaryote"}, {"end": 155, "start": 126, "tag": "Cell"}, {"end": 149, "start": 126, "tag": "Cell"}, {"end": 188, "start": 166, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 190, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 345, "start": 337, "tag": "ResearchActivity"}, {"end": 239, "start": 229, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 157, "tag": "Cell"}, {"end": 117, "start": 108, "tag": "Finding"}, {"end": 48, "start": 35, "tag": "CellFunction"}, {"end": 328, "start": 322, "tag": "ResearchActivity"}, {"end": 258, "start": 240, "tag": "Cell"}]}{"id": "1232_3", "text": "To ensure successful remyelination, the recruitment and activation/repression of each cell type should be regulated in a highly organized spatio-temporal manner.", "tags": [{"end": 77, "start": 67, "tag": "BiologicFunction"}, {"end": 77, "start": 67, "tag": "CellFunction"}, {"end": 34, "start": 21, "tag": "CellFunction"}, {"end": 95, "start": 86, "tag": "Cell"}]}{"id": "1232_4", "text": "As a result, drug candidates targeting one single pathway or a single cell population have difficulty restoring the optimal microenvironment at lesion sites for remyelination.", "tags": [{"end": 140, "start": 124, "tag": "NaturalPhenomenonOrProcess"}, {"end": 140, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 144, "tag": "InjuryOrPoisoning"}, {"end": 85, "start": 70, "tag": "Cell"}, {"end": 85, "start": 75, "tag": "PopulationGroup"}, {"end": 57, "start": 50, "tag": "CellFunction"}, {"end": 174, "start": 161, "tag": "CellFunction"}, {"end": 17, "start": 13, "tag": "PharmacologicSubstance"}]}{"id": "1232_5", "text": "Therefore, when exploring new drug candidates for MS, it is instrumental to consider not only the effects on all CNS cell populations but also the optimal time of administration during disease progression.", "tags": [{"end": 116, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 204, "start": 193, "tag": "PathologicFunction"}, {"end": 204, "start": 193, "tag": "TemporalConcept"}, {"end": 159, "start": 155, "tag": "TemporalConcept"}, {"end": 204, "start": 185, "tag": "PathologicFunction"}, {"end": 133, "start": 122, "tag": "PopulationGroup"}, {"end": 52, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 98, "tag": "Finding"}, {"end": 34, "start": 30, "tag": "PharmacologicSubstance"}, {"end": 133, "start": 117, "tag": "Cell"}, {"end": 177, "start": 163, "tag": "HealthCareActivity"}]}{"id": "1232_6", "text": "In this review, we describe the dysregulated mechanisms in each relevant cell type and the disruption of their coordination as causes of remyelination failure, providing an overview of the complex cell interplay in CNS lesion sites.", "tags": [{"end": 123, "start": 111, "tag": "BiologicFunction"}, {"end": 123, "start": 111, "tag": "HealthCareActivity"}, {"end": 225, "start": 219, "tag": "InjuryOrPoisoning"}, {"end": 158, "start": 137, "tag": "CellOrMolecularDysfunction"}, {"end": 101, "start": 91, "tag": "InjuryOrPoisoning"}, {"end": 218, "start": 215, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 197, "tag": "Cell"}, {"end": 181, "start": 173, "tag": "ResearchActivity"}, {"end": 55, "start": 32, "tag": "PathologicFunction"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 211, "start": 202, "tag": "Finding"}, {"end": 82, "start": 73, "tag": "Cell"}]}{"id": "1233_0", "text": "Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophins family with well-known roles in neural development, differentiation, survival, and synaptic plasticity; however, it has not been explained thoroughly how the expression of this critical gene is regulated.", "tags": [{"end": 80, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 106, "tag": "BiologicFunction"}, {"end": 176, "start": 157, "tag": "BiologicFunction"}, {"end": 141, "start": 126, "tag": "CellFunction"}, {"end": 242, "start": 232, "tag": "CellFunction"}, {"end": 151, "start": 143, "tag": "CellFunction"}, {"end": 39, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 35, "tag": "GeneOrGenome"}, {"end": 33, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 264, "start": 260, "tag": "GeneOrGenome"}]}{"id": "1233_1", "text": "To reveal some aspects of Bdnf gene regulation, here it was explored whether metastasis-associated lung adenocarcinoma transcript 1 (Malat1) and HOX transcript antisense RNA (Hotair) lncRNAs play roles in the regulation of Bdnf expression level, the effect of fingolimod treatment on downstream pathways, and oligodendrocyte precursor cell (OPC) maturation.", "tags": [{"end": 46, "start": 26, "tag": "CellFunction"}, {"end": 181, "start": 175, "tag": "GeneOrGenome"}, {"end": 181, "start": 175, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 227, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 227, "start": 223, "tag": "GeneOrGenome"}, {"end": 227, "start": 223, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 133, "tag": "GeneOrGenome"}, {"end": 344, "start": 341, "tag": "Cell"}, {"end": 356, "start": 346, "tag": "BiologicFunction"}, {"end": 339, "start": 309, "tag": "Cell"}, {"end": 270, "start": 260, "tag": "Chemical"}, {"end": 270, "start": 260, "tag": "PharmacologicSubstance"}, {"end": 270, "start": 260, "tag": "BiologicallyActiveSubstance"}, {"end": 256, "start": 250, "tag": "Finding"}, {"end": 280, "start": 271, "tag": "HealthCareActivity"}, {"end": 280, "start": 271, "tag": "ResearchActivity"}, {"end": 190, "start": 183, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 238, "start": 228, "tag": "CellFunction"}, {"end": 190, "start": 183, "tag": "BiologicallyActiveSubstance"}, {"end": 303, "start": 284, "tag": "CellFunction"}, {"end": 173, "start": 145, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 131, "start": 77, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 131, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 133, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 139, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 175, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 145, "tag": "BiologicallyActiveSubstance"}]}{"id": "1233_2", "text": "First, in rat primary glial culture, the effect of Hotair and Malat1 was investigated on Bdnf expression using downregulation by specific DNAzymes.", "tags": [{"end": 57, "start": 51, "tag": "GeneOrGenome"}, {"end": 57, "start": 51, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 93, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 89, "tag": "GeneOrGenome"}, {"end": 93, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 138, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 68, "start": 62, "tag": "GeneOrGenome"}, {"end": 35, "start": 28, "tag": "ResearchActivity"}, {"end": 21, "start": 14, "tag": "ResearchActivity"}, {"end": 13, "start": 10, "tag": "Eukaryote"}, {"end": 27, "start": 22, "tag": "Cell"}, {"end": 125, "start": 111, "tag": "CellFunction"}, {"end": 47, "start": 41, "tag": "Finding"}, {"end": 104, "start": 94, "tag": "CellFunction"}, {"end": 57, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 62, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1233_3", "text": "Then, immunostaining and RT-qPCR assays were employed to assess the functions of fingolimod and lncRNAs on OPC maturation.", "tags": [{"end": 121, "start": 107, "tag": "CellFunction"}, {"end": 32, "start": 25, "tag": "ResearchActivity"}, {"end": 20, "start": 6, "tag": "ResearchActivity"}, {"end": 91, "start": 81, "tag": "Chemical"}, {"end": 91, "start": 81, "tag": "PharmacologicSubstance"}, {"end": 91, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 33, "tag": "ResearchActivity"}, {"end": 103, "start": 96, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 103, "start": 96, "tag": "BiologicallyActiveSubstance"}]}{"id": "1233_4", "text": "The results demonstrated that Bdnf was significantly correlated to Hotair and Malat1 lncRNAs in glial cells.", "tags": [{"end": 34, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 30, "tag": "GeneOrGenome"}, {"end": 34, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 67, "tag": "GeneOrGenome"}, {"end": 73, "start": 67, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 84, "start": 78, "tag": "GeneOrGenome"}, {"end": 107, "start": 96, "tag": "Cell"}, {"end": 92, "start": 85, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 92, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 78, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1233_5", "text": "Also, a strong correlation was observed between these two lncRNAs in glial culture and isolated OPCs.", "tags": [{"end": 100, "start": 96, "tag": "Cell"}, {"end": 82, "start": 75, "tag": "ResearchActivity"}, {"end": 74, "start": 69, "tag": "Cell"}, {"end": 65, "start": 58, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 65, "start": 58, "tag": "BiologicallyActiveSubstance"}]}{"id": "1233_6", "text": "Fingolimod treatment coordinated lncRNAs' role on Bdnf expression in glial cells and enhanced OPC myelination three times compared to control.", "tags": [{"end": 10, "start": 0, "tag": "Chemical"}, {"end": 54, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 50, "tag": "GeneOrGenome"}, {"end": 97, "start": 94, "tag": "Cell"}, {"end": 80, "start": 69, "tag": "Cell"}, {"end": 20, "start": 11, "tag": "HealthCareActivity"}, {"end": 20, "start": 11, "tag": "ResearchActivity"}, {"end": 40, "start": 33, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 65, "start": 55, "tag": "CellFunction"}, {"end": 40, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 98, "tag": "CellFunction"}, {"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 10, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "1233_7", "text": "Furthermore, results suggested that Malat1 may have a role in the last stages of the intrinsic oligodendrocyte (OL) myelination regardless of fingolimod treatment.", "tags": [{"end": 42, "start": 36, "tag": "GeneOrGenome"}, {"end": 114, "start": 112, "tag": "Cell"}, {"end": 152, "start": 142, "tag": "Chemical"}, {"end": 152, "start": 142, "tag": "PharmacologicSubstance"}, {"end": 152, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 153, "tag": "HealthCareActivity"}, {"end": 162, "start": 153, "tag": "ResearchActivity"}, {"end": 110, "start": 95, "tag": "Cell"}, {"end": 127, "start": 116, "tag": "CellFunction"}, {"end": 77, "start": 71, "tag": "TemporalConcept"}, {"end": 42, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 36, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1233_8", "text": "As BDNF is involved in brain development, survival, and functions, understanding the regulatory mechanism behind BDNF expression leads to a better comprehension of the pathogenesis of the neurodegenerative disorder and designing more effective treatments.", "tags": [{"end": 160, "start": 147, "tag": "BiologicFunction"}, {"end": 40, "start": 23, "tag": "BiologicFunction"}, {"end": 40, "start": 29, "tag": "BiologicFunction"}, {"end": 40, "start": 29, "tag": "CellFunction"}, {"end": 128, "start": 118, "tag": "CellFunction"}, {"end": 50, "start": 42, "tag": "CellFunction"}, {"end": 180, "start": 168, "tag": "PathologicFunction"}, {"end": 254, "start": 244, "tag": "HealthCareActivity"}, {"end": 254, "start": 244, "tag": "ResearchActivity"}, {"end": 80, "start": 67, "tag": "BiologicFunction"}, {"end": 7, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 3, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 3, "tag": "GeneOrGenome"}, {"end": 117, "start": 113, "tag": "GeneOrGenome"}, {"end": 214, "start": 188, "tag": "DiseaseOrSyndrome"}]}{"id": "1234_0", "text": "Multiple sclerosis is an autoimmune disease with a strong neuroinflammatory component that contributes to severe demyelination, neurodegeneration and lesions formation in white and grey matter of the spinal cord and brain.", "tags": [{"end": 192, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 150, "tag": "InjuryOrPoisoning"}, {"end": 211, "start": 200, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 221, "start": 216, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 128, "tag": "CellOrMolecularDysfunction"}, {"end": 75, "start": 58, "tag": "PathologicFunction"}, {"end": 126, "start": 113, "tag": "PathologicFunction"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 106, "tag": "Finding"}, {"end": 192, "start": 186, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1234_1", "text": "Increasing attention is being paid to the signaling of the biogenic amine histamine in the context of several pathological conditions.", "tags": [{"end": 73, "start": 59, "tag": "Chemical"}, {"end": 20, "start": 11, "tag": "BiologicFunction"}, {"end": 133, "start": 110, "tag": "PathologicFunction"}, {"end": 51, "start": 42, "tag": "CellFunction"}, {"end": 73, "start": 59, "tag": "PharmacologicSubstance"}, {"end": 73, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 74, "tag": "Chemical"}, {"end": 83, "start": 74, "tag": "PharmacologicSubstance"}]}{"id": "1234_2", "text": "In multiple sclerosis, histamine regulates the differentiation of oligodendrocyte precursors, reduces demyelination, and improves the remyelination process.", "tags": [{"end": 32, "start": 23, "tag": "Chemical"}, {"end": 32, "start": 23, "tag": "PharmacologicSubstance"}, {"end": 21, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 47, "tag": "CellFunction"}, {"end": 92, "start": 66, "tag": "Cell"}, {"end": 147, "start": 134, "tag": "CellFunction"}, {"end": 115, "start": 102, "tag": "PathologicFunction"}, {"end": 32, "start": 23, "tag": "BiologicallyActiveSubstance"}]}{"id": "1234_3", "text": "However, the concomitant activation of histamine H1-H4 receptors can sustain either damaging or favorable effects, depending on the specifically activated receptor subtype/s, the timing of receptor engagement, and the central versus peripheral target district.", "tags": [{"end": 24, "start": 13, "tag": "TemporalConcept"}, {"end": 185, "start": 179, "tag": "TemporalConcept"}, {"end": 243, "start": 233, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 106, "tag": "Finding"}, {"end": 64, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 208, "start": 198, "tag": "Finding"}, {"end": 163, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 197, "start": 189, "tag": "BiologicallyActiveSubstance"}]}{"id": "1234_4", "text": "Conventional drug development has failed so far to identify curative drugs for multiple sclerosis, thus causing a severe delay in therapeutic options available to patients.", "tags": [{"end": 126, "start": 121, "tag": "TemporalConcept"}, {"end": 149, "start": 130, "tag": "HealthCareActivity"}, {"end": 29, "start": 13, "tag": "ResearchActivity"}, {"end": 97, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 163, "tag": "PatientOrDisabledGroup"}, {"end": 74, "start": 69, "tag": "PharmacologicSubstance"}, {"end": 120, "start": 114, "tag": "Finding"}]}{"id": "1234_5", "text": "In this perspective, drug repurposing offers an exciting and complementary alternative for rapidly approving some medicines already approved for other indications.", "tags": [{"end": 37, "start": 21, "tag": "HealthCareActivity"}, {"end": 19, "start": 8, "tag": "BiologicFunction"}, {"end": 123, "start": 114, "tag": "PharmacologicSubstance"}]}{"id": "1234_6", "text": "In the present work, we have adopted a new network-medicine-based algorithm for drug repurposing called SAveRUNNER, for quantifying the interplay between multiple sclerosis-associated genes and drug targets in the human interactome.", "tags": [{"end": 96, "start": 80, "tag": "HealthCareActivity"}, {"end": 206, "start": 194, "tag": "Finding"}, {"end": 172, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 219, "start": 214, "tag": "Eukaryote"}, {"end": 145, "start": 136, "tag": "Finding"}, {"end": 198, "start": 194, "tag": "PharmacologicSubstance"}, {"end": 75, "start": 43, "tag": "MachineActivity"}, {"end": 114, "start": 104, "tag": "MachineActivity"}, {"end": 189, "start": 154, "tag": "GeneOrGenome"}, {"end": 231, "start": 220, "tag": "ResearchActivity"}]}{"id": "1234_7", "text": "We have identified new histamine drug-disease associations and predicted off-label novel use of the histaminergic drugs amodiaquine, rupatadine, and diphenhydramine among others, for multiple sclerosis.", "tags": [{"end": 32, "start": 23, "tag": "Chemical"}, {"end": 32, "start": 23, "tag": "PharmacologicSubstance"}, {"end": 82, "start": 73, "tag": "InjuryOrPoisoning"}, {"end": 82, "start": 73, "tag": "Finding"}, {"end": 119, "start": 100, "tag": "PharmacologicSubstance"}, {"end": 131, "start": 120, "tag": "Chemical"}, {"end": 143, "start": 133, "tag": "Chemical"}, {"end": 164, "start": 149, "tag": "Chemical"}, {"end": 201, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 114, "tag": "PharmacologicSubstance"}, {"end": 37, "start": 33, "tag": "PharmacologicSubstance"}, {"end": 32, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 120, "tag": "PharmacologicSubstance"}, {"end": 143, "start": 133, "tag": "PharmacologicSubstance"}, {"end": 164, "start": 149, "tag": "PharmacologicSubstance"}]}{"id": "1234_8", "text": "Our work suggests that selected histamine-related molecules might get to the root causes of multiple sclerosis and emerge as new potential therapeutic strategies for the disease.", "tags": [{"end": 161, "start": 129, "tag": "HealthCareActivity"}, {"end": 110, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 50, "tag": "Substance"}, {"end": 41, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 32, "tag": "Chemical"}, {"end": 41, "start": 32, "tag": "PharmacologicSubstance"}]}{"id": "1235_0", "text": "One of the most substantial and established environmental risk factors for neurological and psychiatric disorders is stress exposure, whose detrimental consequences hinge on several variables including time.", "tags": [{"end": 70, "start": 44, "tag": "Finding"}, {"end": 113, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 206, "start": 202, "tag": "TemporalConcept"}, {"end": 87, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 117, "tag": "Finding"}]}{"id": "1235_1", "text": "In this regard the gestational period is known to present an intrinsic vulnerability to environmental insults and thus stressful events during pregnancy can lead to severe consequences on the offspring's brain development with long-term repercussions throughout adulthood.", "tags": [{"end": 221, "start": 204, "tag": "BiologicFunction"}, {"end": 271, "start": 262, "tag": "TemporalConcept"}, {"end": 236, "start": 227, "tag": "TemporalConcept"}, {"end": 37, "start": 19, "tag": "TemporalConcept"}, {"end": 221, "start": 210, "tag": "BiologicFunction"}, {"end": 221, "start": 210, "tag": "CellFunction"}, {"end": 152, "start": 143, "tag": "BiologicFunction"}, {"end": 171, "start": 165, "tag": "Finding"}, {"end": 109, "start": 88, "tag": "InjuryOrPoisoning"}, {"end": 135, "start": 119, "tag": "Finding"}, {"end": 201, "start": 192, "tag": "PopulationGroup"}]}{"id": "1235_2", "text": "On this basis, we investigated the long-lasting impact of prenatal stress exposure on the susceptibility to the experimental autoimmune encephalomyelitis (EAE), a well-established murine model of multiple sclerosis.", "tags": [{"end": 104, "start": 90, "tag": "Finding"}, {"end": 153, "start": 112, "tag": "ExperimentalModelOfDisease"}, {"end": 158, "start": 155, "tag": "ExperimentalModelOfDisease"}, {"end": 214, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 187, "tag": "ResearchActivity"}, {"end": 186, "start": 180, "tag": "Eukaryote"}, {"end": 47, "start": 35, "tag": "TemporalConcept"}, {"end": 66, "start": 58, "tag": "TemporalConcept"}, {"end": 82, "start": 67, "tag": "Finding"}, {"end": 214, "start": 180, "tag": "ExperimentalModelOfDisease"}]}{"id": "1235_3", "text": "Although stress is considered a triggering factor for this chronic, progressive, autoimmune disease, little is known about the underlying mechanisms.", "tags": [{"end": 15, "start": 9, "tag": "Finding"}, {"end": 99, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 68, "tag": "TemporalConcept"}, {"end": 66, "start": 59, "tag": "TemporalConcept"}]}{"id": "1235_4", "text": "To this end, EAE was induced by immunization with MOG35-55/CFA and pertussis toxin administration in adult female C57BL/6 mice born from control or stressed dams exposed to restraint stress during the last days of gestation.", "tags": [{"end": 82, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 114, "tag": "Eukaryote"}, {"end": 44, "start": 32, "tag": "HealthCareActivity"}, {"end": 16, "start": 13, "tag": "ExperimentalModelOfDisease"}, {"end": 223, "start": 214, "tag": "BiologicFunction"}, {"end": 126, "start": 122, "tag": "Eukaryote"}, {"end": 113, "start": 107, "tag": "OrganismAttribute"}, {"end": 106, "start": 101, "tag": "PopulationGroup"}, {"end": 210, "start": 206, "tag": "TemporalConcept"}, {"end": 58, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 83, "tag": "HealthCareActivity"}]}{"id": "1235_5", "text": "Our results demonstrate that gestational stress induces a marked increase in the severity of EAE symptoms in adulthood.", "tags": [{"end": 96, "start": 93, "tag": "ExperimentalModelOfDisease"}, {"end": 118, "start": 109, "tag": "TemporalConcept"}, {"end": 105, "start": 97, "tag": "SignOrSymptom"}, {"end": 89, "start": 81, "tag": "ClinicalAttribute"}, {"end": 89, "start": 81, "tag": "Finding"}, {"end": 40, "start": 29, "tag": "TemporalConcept"}, {"end": 47, "start": 41, "tag": "Finding"}]}{"id": "1235_6", "text": "Further, we highlight an altered maturation of oligodendrocytes in the spinal cord of prenatally stressed EAE mice, as indicated by the higher levels of GPR17, a marker of immature oligodendrocyte precursor cells.", "tags": [{"end": 109, "start": 106, "tag": "ExperimentalModelOfDisease"}, {"end": 114, "start": 106, "tag": "ExperimentalModelOfDisease"}, {"end": 63, "start": 47, "tag": "Cell"}, {"end": 43, "start": 33, "tag": "BiologicFunction"}, {"end": 212, "start": 181, "tag": "Cell"}, {"end": 82, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 197, "tag": "Cell"}, {"end": 206, "start": 181, "tag": "Cell"}, {"end": 158, "start": 153, "tag": "GeneOrGenome"}, {"end": 158, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 180, "start": 172, "tag": "BiologicFunction"}, {"end": 158, "start": 153, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 162, "tag": "ClinicalAttribute"}, {"end": 114, "start": 110, "tag": "Eukaryote"}, {"end": 96, "start": 86, "tag": "TemporalConcept"}]}{"id": "1235_7", "text": "These behavioral and molecular alterations are paralleled by changes in the expression and signaling of the neurotrophin BDNF, an important mediator of neural plasticity that may contribute to stress-induced impaired remyelination.", "tags": [{"end": 120, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 91, "tag": "CellFunction"}, {"end": 169, "start": 152, "tag": "CellFunction"}, {"end": 169, "start": 159, "tag": "NaturalPhenomenonOrProcess"}, {"end": 169, "start": 159, "tag": "CellFunction"}, {"end": 86, "start": 76, "tag": "CellFunction"}, {"end": 125, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 121, "tag": "GeneOrGenome"}, {"end": 230, "start": 217, "tag": "CellFunction"}, {"end": 42, "start": 31, "tag": "Finding"}, {"end": 68, "start": 61, "tag": "Finding"}, {"end": 199, "start": 193, "tag": "Finding"}]}{"id": "1235_8", "text": "Since several already marketed drugs are able to modulate BDNF levels, these results pave the way to the possibility of repositioning these drugs in multiple sclerosis.", "tags": [{"end": 133, "start": 120, "tag": "HealthCareActivity"}, {"end": 167, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 31, "tag": "PharmacologicSubstance"}, {"end": 145, "start": 140, "tag": "PharmacologicSubstance"}, {"end": 62, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 58, "tag": "GeneOrGenome"}]}{"id": "1236_0", "text": "Oligodendrocytes (OLs) generate myelin membranes for the rapid propagation of electrical signals along axons in the central nervous system (CNS) and provide metabolites to support axonal integrity and function.", "tags": [{"end": 168, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 103, "tag": "CellComponent"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 21, "start": 18, "tag": "Cell"}, {"end": 196, "start": 180, "tag": "CellFunction"}, {"end": 48, "start": 32, "tag": "CellComponent"}, {"end": 138, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 78, "tag": "CellFunction"}, {"end": 74, "start": 63, "tag": "Finding"}]}{"id": "1236_1", "text": "Differentiation of OLs from oligodendrocyte progenitor cells (OPCs) is orchestrated by a multitude of intrinsic and extrinsic factors in the CNS.", "tags": [{"end": 15, "start": 0, "tag": "CellFunction"}, {"end": 66, "start": 62, "tag": "Cell"}, {"end": 60, "start": 28, "tag": "Cell"}, {"end": 22, "start": 19, "tag": "Cell"}, {"end": 144, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1236_2", "text": "Disruption of this process, or OL loss in the developing or adult brain, as observed in various neurological conditions including hypoxia/ischemia, stroke, and demyelination, results in axonal dystrophy, neuronal dysfunction, and severe neurological impairments.", "tags": [{"end": 202, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 261, "start": 237, "tag": "Finding"}, {"end": 224, "start": 204, "tag": "CellOrMolecularDysfunction"}, {"end": 154, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 130, "tag": "PathologicFunction"}, {"end": 33, "start": 31, "tag": "Cell"}, {"end": 71, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 160, "tag": "PathologicFunction"}, {"end": 236, "start": 230, "tag": "Finding"}, {"end": 146, "start": 138, "tag": "PathologicFunction"}, {"end": 38, "start": 34, "tag": "Finding"}, {"end": 71, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1236_3", "text": "While much is known regarding the intrinsic regulatory signals required for OL lineage cell progression in development, studies from pathological conditions highlight the importance of the CNS environment and external signals in regulating OL genesis and maturation.", "tags": [{"end": 156, "start": 133, "tag": "PathologicFunction"}, {"end": 265, "start": 255, "tag": "BiologicFunction"}, {"end": 242, "start": 240, "tag": "Cell"}, {"end": 91, "start": 76, "tag": "Cell"}, {"end": 192, "start": 189, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 107, "tag": "BiologicFunction"}, {"end": 118, "start": 107, "tag": "CellFunction"}, {"end": 103, "start": 92, "tag": "PathologicFunction"}, {"end": 103, "start": 92, "tag": "TemporalConcept"}, {"end": 62, "start": 34, "tag": "CellFunction"}, {"end": 225, "start": 209, "tag": "CellFunction"}, {"end": 127, "start": 120, "tag": "ResearchActivity"}, {"end": 250, "start": 240, "tag": "BiologicFunction"}]}{"id": "1236_4", "text": "Here, we review the recent findings in OL biology in the context of the CNS physiological and pathological conditions, focusing on extrinsic factors that facilitate OL development and regeneration.", "tags": [{"end": 117, "start": 94, "tag": "PathologicFunction"}, {"end": 196, "start": 184, "tag": "BiologicFunction"}, {"end": 41, "start": 39, "tag": "Cell"}, {"end": 167, "start": 165, "tag": "Cell"}, {"end": 196, "start": 184, "tag": "HealthCareActivity"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 168, "tag": "BiologicFunction"}, {"end": 179, "start": 168, "tag": "CellFunction"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 49, "start": 42, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 26, "start": 20, "tag": "TemporalConcept"}, {"end": 49, "start": 42, "tag": "BiologicFunction"}]}{"id": "1237_0", "text": "Oligodendrocyte precursor cells (OPCs) are mostly known for their capability to differentiate into oligodendrocytes and myelinate axons.", "tags": [{"end": 129, "start": 120, "tag": "CellFunction"}, {"end": 135, "start": 130, "tag": "CellComponent"}, {"end": 115, "start": 99, "tag": "Cell"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}]}{"id": "1237_1", "text": "However, they have been observed to frequently interact with cells of the neurovascular unit during development, homeostasis, and under pathological conditions.", "tags": [{"end": 159, "start": 136, "tag": "PathologicFunction"}, {"end": 46, "start": 36, "tag": "TemporalConcept"}, {"end": 66, "start": 61, "tag": "Cell"}, {"end": 111, "start": 100, "tag": "BiologicFunction"}, {"end": 111, "start": 100, "tag": "CellFunction"}, {"end": 124, "start": 113, "tag": "BiologicFunction"}, {"end": 92, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1237_2", "text": "The functional consequences of these interactions are largely unclear, but are increasingly studied.", "tags": [{"end": 49, "start": 37, "tag": "Finding"}]}{"id": "1237_3", "text": "Although OPCs appear to be a rather homogenous cell population in the central nervous system (CNS), they present with an enormous potential to adapt to their microenvironment.", "tags": [{"end": 174, "start": 158, "tag": "NaturalPhenomenonOrProcess"}, {"end": 174, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 9, "tag": "Cell"}, {"end": 92, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 97, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 47, "tag": "Cell"}]}{"id": "1237_4", "text": "In this review, it is summarized what is known about the various roles of OPC-vascular interactions, and the circumstances under which they have been observed.", "tags": [{"end": 77, "start": 74, "tag": "Cell"}, {"end": 99, "start": 87, "tag": "Finding"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 86, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1238_0", "text": "The number of elderly multiple sclerosis (MS) patients is growing, mainly due to the increase in the life expectancy of the general population and the availability of effective disease-modifying treatments.", "tags": [{"end": 116, "start": 101, "tag": "TemporalConcept"}, {"end": 205, "start": 177, "tag": "HealthCareActivity"}, {"end": 142, "start": 124, "tag": "PopulationGroup"}, {"end": 40, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 46, "tag": "PatientOrDisabledGroup"}, {"end": 44, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 14, "tag": "PopulationGroup"}]}{"id": "1238_1", "text": "However, current treatments reduce the frequency of relapses and slow the progression of the disease, but they cannot stop the disability accumulation associated with disease progression.", "tags": [{"end": 100, "start": 74, "tag": "PathologicFunction"}, {"end": 100, "start": 74, "tag": "TemporalConcept"}, {"end": 48, "start": 39, "tag": "TemporalConcept"}, {"end": 150, "start": 138, "tag": "Finding"}, {"end": 16, "start": 9, "tag": "TemporalConcept"}, {"end": 27, "start": 17, "tag": "HealthCareActivity"}, {"end": 27, "start": 17, "tag": "ResearchActivity"}, {"end": 186, "start": 167, "tag": "PathologicFunction"}, {"end": 137, "start": 127, "tag": "Finding"}]}{"id": "1238_2", "text": "One possible explanation is the impact of immunosenescence, which is associated with the accumulation of unusual immune cell subsets that are thought to have a role in the development of an early ageing process in autoimmunity.", "tags": [{"end": 58, "start": 42, "tag": "BiologicFunction"}, {"end": 124, "start": 113, "tag": "Cell"}, {"end": 24, "start": 13, "tag": "Finding"}, {"end": 195, "start": 190, "tag": "TemporalConcept"}, {"end": 183, "start": 172, "tag": "BiologicFunction"}, {"end": 183, "start": 172, "tag": "CellFunction"}, {"end": 101, "start": 89, "tag": "Finding"}, {"end": 124, "start": 120, "tag": "Cell"}, {"end": 226, "start": 214, "tag": "PathologicFunction"}, {"end": 202, "start": 196, "tag": "CellFunction"}, {"end": 202, "start": 196, "tag": "BiologicFunction"}]}{"id": "1238_3", "text": "Here, we provide a recent overview of how senescence affects immune cell function and how it is involved in the pathogenesis of autoimmune diseases, particularly MS.", "tags": [{"end": 81, "start": 61, "tag": "BiologicFunction"}, {"end": 147, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 26, "tag": "ResearchActivity"}, {"end": 124, "start": 112, "tag": "PathologicFunction"}, {"end": 52, "start": 42, "tag": "BiologicFunction"}, {"end": 52, "start": 42, "tag": "TemporalConcept"}, {"end": 25, "start": 19, "tag": "TemporalConcept"}, {"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 42, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1238_4", "text": "Numerous studies have demonstrated age-related immune changes in experimental autoimmune encephalomyelitis models, and the premature onset of immunosenescence has been demonstrated in MS patients.", "tags": [{"end": 158, "start": 142, "tag": "BiologicFunction"}, {"end": 106, "start": 65, "tag": "ExperimentalModelOfDisease"}, {"end": 195, "start": 187, "tag": "PatientOrDisabledGroup"}, {"end": 113, "start": 107, "tag": "ResearchActivity"}, {"end": 138, "start": 133, "tag": "TemporalConcept"}, {"end": 16, "start": 9, "tag": "ResearchActivity"}, {"end": 38, "start": 35, "tag": "OrganismAttribute"}, {"end": 186, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 47, "tag": "Finding"}, {"end": 132, "start": 123, "tag": "TemporalConcept"}]}{"id": "1238_5", "text": "Therefore, potential therapeutic strategies based on rejuvenating the immune system have been proposed.", "tags": [{"end": 43, "start": 11, "tag": "HealthCareActivity"}, {"end": 83, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1238_6", "text": "Senolytics and regenerative strategies using haematopoietic stem cells, therapies based on rejuvenating oligodendrocyte precursor cells, microglia and monocytes, thymus cells and senescent B and T cells are capable of reversing the process of immunosenescence and could have a beneficial impact on the progression of MS.", "tags": [{"end": 70, "start": 45, "tag": "Cell"}, {"end": 202, "start": 195, "tag": "Cell"}, {"end": 259, "start": 243, "tag": "BiologicFunction"}, {"end": 135, "start": 104, "tag": "Cell"}, {"end": 135, "start": 120, "tag": "Cell"}, {"end": 129, "start": 104, "tag": "Cell"}, {"end": 160, "start": 151, "tag": "Cell"}, {"end": 313, "start": 302, "tag": "PathologicFunction"}, {"end": 313, "start": 302, "tag": "TemporalConcept"}, {"end": 174, "start": 162, "tag": "Cell"}, {"end": 146, "start": 137, "tag": "Cell"}, {"end": 70, "start": 60, "tag": "Cell"}, {"end": 81, "start": 72, "tag": "HealthCareActivity"}, {"end": 319, "start": 317, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 15, "tag": "HealthCareActivity"}, {"end": 38, "start": 28, "tag": "HealthCareActivity"}, {"end": 10, "start": 0, "tag": "HealthCareActivity"}, {"end": 202, "start": 197, "tag": "Cell"}, {"end": 190, "start": 179, "tag": "Cell"}]}{"id": "1239_0", "text": "Oligodendrocytes are the cells that myelinate axons and provide trophic support to neurons in the CNS.", "tags": [{"end": 79, "start": 64, "tag": "CellFunction"}, {"end": 51, "start": 46, "tag": "CellComponent"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 101, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 25, "tag": "Cell"}, {"end": 90, "start": 83, "tag": "Cell"}]}{"id": "1239_1", "text": "Their dysfunction has been associated with a group of disorders known as demyelinating diseases, such as multiple sclerosis.", "tags": [{"end": 95, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 73, "tag": "PathologicFunction"}, {"end": 123, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 45, "tag": "PopulationGroup"}, {"end": 17, "start": 6, "tag": "PathologicFunction"}]}{"id": "1239_2", "text": "Oligodendrocytes are derived from oligodendrocyte precursor cells, which differentiate into premyelinating oligodendrocytes and eventually mature oligodendrocytes.", "tags": [{"end": 123, "start": 92, "tag": "Cell"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 65, "start": 34, "tag": "Cell"}, {"end": 86, "start": 73, "tag": "CellFunction"}, {"end": 162, "start": 139, "tag": "Cell"}, {"end": 65, "start": 50, "tag": "Cell"}, {"end": 59, "start": 34, "tag": "Cell"}]}{"id": "1239_3", "text": "The development and function of oligodendrocytes are tightly regulated by a variety of molecules, including laminin, a major protein of the extracellular matrix.", "tags": [{"end": 115, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 32, "tag": "Cell"}, {"end": 160, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 4, "tag": "BiologicFunction"}, {"end": 15, "start": 4, "tag": "CellFunction"}, {"end": 96, "start": 87, "tag": "Substance"}, {"end": 132, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 108, "tag": "BiologicallyActiveSubstance"}]}{"id": "1239_4", "text": "Accumulating evidence suggests that laminin actively regulates every aspect of oligodendrocyte biology, including survival, migration, proliferation, differentiation, and myelination.", "tags": [{"end": 43, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 0, "tag": "Finding"}, {"end": 165, "start": 150, "tag": "CellFunction"}, {"end": 148, "start": 135, "tag": "CellFunction"}, {"end": 133, "start": 124, "tag": "CellFunction"}, {"end": 21, "start": 13, "tag": "Finding"}, {"end": 122, "start": 114, "tag": "CellFunction"}, {"end": 102, "start": 95, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 94, "start": 79, "tag": "Cell"}, {"end": 182, "start": 171, "tag": "CellFunction"}, {"end": 102, "start": 95, "tag": "BiologicFunction"}, {"end": 43, "start": 36, "tag": "BiologicallyActiveSubstance"}]}{"id": "1239_5", "text": "How can laminin exert such diverse functions in oligodendrocytes? It is speculated that the distinct laminin isoforms, laminin receptors, and/or key signaling molecules expressed in oligodendrocytes at different developmental stages are the reasons.", "tags": [{"end": 15, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 109, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 136, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 212, "tag": "TemporalConcept"}, {"end": 64, "start": 48, "tag": "Cell"}, {"end": 198, "start": 182, "tag": "Cell"}, {"end": 168, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 149, "tag": "CellFunction"}, {"end": 225, "start": 212, "tag": "BiologicFunction"}, {"end": 225, "start": 212, "tag": "TemporalConcept"}, {"end": 168, "start": 159, "tag": "Substance"}, {"end": 232, "start": 226, "tag": "TemporalConcept"}, {"end": 178, "start": 169, "tag": "CellFunction"}, {"end": 136, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 101, "tag": "BiologicallyActiveSubstance"}]}{"id": "1239_6", "text": "Understanding molecular targets and signaling pathways unique to each aspect of oligodendrocyte biology will enable more accurate manipulation of oligodendrocyte development and function, which may have implications in the therapies of demyelinating diseases.", "tags": [{"end": 142, "start": 130, "tag": "HealthCareActivity"}, {"end": 258, "start": 236, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 146, "tag": "CellFunction"}, {"end": 249, "start": 236, "tag": "PathologicFunction"}, {"end": 45, "start": 36, "tag": "CellFunction"}, {"end": 173, "start": 162, "tag": "BiologicFunction"}, {"end": 173, "start": 162, "tag": "CellFunction"}, {"end": 31, "start": 14, "tag": "Chemical"}, {"end": 103, "start": 96, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 54, "start": 46, "tag": "CellFunction"}, {"end": 95, "start": 80, "tag": "Cell"}, {"end": 54, "start": 36, "tag": "CellFunction"}, {"end": 232, "start": 223, "tag": "HealthCareActivity"}, {"end": 103, "start": 96, "tag": "BiologicFunction"}]}{"id": "1239_7", "text": "Here in this review, we first introduce oligodendrocyte biology, followed by the expression of laminin and laminin receptors in oligodendrocytes and other CNS cells.", "tags": [{"end": 102, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 128, "tag": "Cell"}, {"end": 158, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 164, "start": 159, "tag": "Cell"}, {"end": 29, "start": 24, "tag": "TemporalConcept"}, {"end": 19, "start": 13, "tag": "ResearchActivity"}, {"end": 19, "start": 13, "tag": "HealthCareActivity"}, {"end": 91, "start": 81, "tag": "CellFunction"}, {"end": 63, "start": 56, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 55, "start": 40, "tag": "Cell"}, {"end": 124, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 56, "tag": "BiologicFunction"}, {"end": 102, "start": 95, "tag": "BiologicallyActiveSubstance"}]}{"id": "1239_8", "text": "Next, the functions of laminin in oligodendrocyte biology, including survival, migration, proliferation, differentiation, and myelination, are discussed in detail.", "tags": [{"end": 30, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 105, "tag": "CellFunction"}, {"end": 103, "start": 90, "tag": "CellFunction"}, {"end": 88, "start": 79, "tag": "CellFunction"}, {"end": 77, "start": 69, "tag": "CellFunction"}, {"end": 57, "start": 50, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 49, "start": 34, "tag": "Cell"}, {"end": 137, "start": 126, "tag": "CellFunction"}, {"end": 57, "start": 50, "tag": "BiologicFunction"}, {"end": 30, "start": 23, "tag": "BiologicallyActiveSubstance"}]}{"id": "1239_9", "text": "Last, key questions and challenges in the field are discussed.", "tags": [{"end": 34, "start": 24, "tag": "HealthCareActivity"}]}{"id": "1239_10", "text": "By providing a comprehensive review on laminin's roles in OL lineage cells, we hope to stimulate novel hypotheses and encourage new research in the field.", "tags": [{"end": 83, "start": 79, "tag": "BiologicFunction"}, {"end": 60, "start": 58, "tag": "Cell"}, {"end": 68, "start": 58, "tag": "Cell"}, {"end": 74, "start": 58, "tag": "Cell"}, {"end": 140, "start": 132, "tag": "ResearchActivity"}, {"end": 35, "start": 15, "tag": "ResearchActivity"}, {"end": 46, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 39, "tag": "BiologicallyActiveSubstance"}]}{"id": "1240_0", "text": "In the central nervous system, oligodendrocytes produce myelin sheaths that enwrap neuronal axons to provide trophic support and increase conduction velocity.", "tags": [{"end": 124, "start": 109, "tag": "CellFunction"}, {"end": 97, "start": 92, "tag": "CellComponent"}, {"end": 47, "start": 31, "tag": "Cell"}, {"end": 62, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 56, "tag": "CellComponent"}, {"end": 157, "start": 138, "tag": "BiologicFunction"}, {"end": 148, "start": 138, "tag": "NaturalPhenomenonOrProcess"}, {"end": 148, "start": 138, "tag": "BiologicFunction"}, {"end": 29, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 83, "tag": "Cell"}]}{"id": "1240_1", "text": "New oligodendrocytes are produced throughout life through a process referred to as oligodendrogenesis.", "tags": [{"end": 101, "start": 83, "tag": "BiologicFunction"}, {"end": 20, "start": 4, "tag": "Cell"}, {"end": 49, "start": 45, "tag": "TemporalConcept"}]}{"id": "1240_2", "text": "Oligodendrogenesis consists of three canonical stages: the oligodendrocyte precursor cell (OPC), the premyelinating oligodendrocyte (preOL), and the mature oligodendrocyte (OL).", "tags": [{"end": 18, "start": 0, "tag": "BiologicFunction"}, {"end": 94, "start": 91, "tag": "Cell"}, {"end": 175, "start": 173, "tag": "Cell"}, {"end": 155, "start": 149, "tag": "TemporalConcept"}, {"end": 89, "start": 59, "tag": "Cell"}, {"end": 89, "start": 75, "tag": "Cell"}, {"end": 84, "start": 59, "tag": "Cell"}, {"end": 89, "start": 85, "tag": "Cell"}, {"end": 131, "start": 101, "tag": "Cell"}, {"end": 171, "start": 149, "tag": "Cell"}, {"end": 53, "start": 47, "tag": "TemporalConcept"}, {"end": 138, "start": 133, "tag": "Cell"}]}{"id": "1240_3", "text": "However, the generation of oligodendrocytes is inherently an inefficient process.", "tags": [{"end": 43, "start": 27, "tag": "Cell"}, {"end": 23, "start": 13, "tag": "TemporalConcept"}]}{"id": "1240_4", "text": "Following precursor differentiation, a majority of premyelinating oligodendrocytes are lost, likely due to apoptosis.", "tags": [{"end": 91, "start": 87, "tag": "Finding"}, {"end": 82, "start": 51, "tag": "Cell"}, {"end": 35, "start": 20, "tag": "CellFunction"}, {"end": 116, "start": 107, "tag": "CellFunction"}]}{"id": "1240_5", "text": "If premyelinating oligodendrocytes progress through this survival checkpoint, they generate new myelinating oligodendrocytes in a process we have termed integration.", "tags": [{"end": 43, "start": 35, "tag": "TemporalConcept"}, {"end": 34, "start": 3, "tag": "Cell"}, {"end": 124, "start": 96, "tag": "Cell"}, {"end": 164, "start": 153, "tag": "CellFunction"}, {"end": 164, "start": 153, "tag": "MachineActivity"}, {"end": 76, "start": 57, "tag": "CellFunction"}]}{"id": "1240_6", "text": "In this review, we will explore the intrinsic and extrinsic signaling pathways that influence preOL survival and integration by examining the intrinsic apoptotic pathways, metabolic demands, and the interactions between neurons, astrocytes, microglia, and premyelinating oligodendrocytes.", "tags": [{"end": 137, "start": 128, "tag": "Finding"}, {"end": 181, "start": 172, "tag": "CellFunction"}, {"end": 287, "start": 256, "tag": "Cell"}, {"end": 124, "start": 113, "tag": "CellFunction"}, {"end": 124, "start": 113, "tag": "MachineActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 250, "start": 241, "tag": "Cell"}, {"end": 108, "start": 100, "tag": "CellFunction"}, {"end": 227, "start": 220, "tag": "Cell"}, {"end": 78, "start": 50, "tag": "CellFunction"}, {"end": 170, "start": 142, "tag": "CellFunction"}, {"end": 239, "start": 229, "tag": "Cell"}, {"end": 78, "start": 60, "tag": "CellFunction"}, {"end": 45, "start": 36, "tag": "CellFunction"}, {"end": 211, "start": 199, "tag": "Finding"}, {"end": 99, "start": 94, "tag": "Cell"}]}{"id": "1240_7", "text": "Additionally, we will discuss similarities between the maturation of newly generated neurons and premyelinating oligodendrocytes.", "tags": [{"end": 128, "start": 97, "tag": "Cell"}, {"end": 65, "start": 55, "tag": "BiologicFunction"}, {"end": 92, "start": 85, "tag": "Cell"}]}{"id": "1240_8", "text": "Finally, we will consider how increasing survival and integration of preOLs has the potential to increase remyelination in multiple sclerosis.", "tags": [{"end": 141, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 54, "tag": "CellFunction"}, {"end": 65, "start": 54, "tag": "MachineActivity"}, {"end": 49, "start": 41, "tag": "CellFunction"}, {"end": 119, "start": 106, "tag": "CellFunction"}, {"end": 40, "start": 30, "tag": "Finding"}, {"end": 75, "start": 69, "tag": "Cell"}]}{"id": "1240_9", "text": "Deepening our understanding of premyelinating oligodendrocyte biology may open the door for new treatments for demyelinating disease and will help paint a clearer picture of how new oligodendrocytes are produced throughout life to facilitate brain function.", "tags": [{"end": 198, "start": 182, "tag": "Cell"}, {"end": 132, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 242, "tag": "BiologicFunction"}, {"end": 227, "start": 223, "tag": "TemporalConcept"}, {"end": 106, "start": 96, "tag": "HealthCareActivity"}, {"end": 106, "start": 96, "tag": "ResearchActivity"}, {"end": 27, "start": 14, "tag": "BiologicFunction"}, {"end": 69, "start": 62, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 61, "start": 31, "tag": "Cell"}, {"end": 69, "start": 62, "tag": "BiologicFunction"}]}{"id": "1241_0", "text": "Ghorbani and colleagues describe versican-V1 as an inhibitor of remyelination using transgenic mice that illuminate new GFP (+) oligodendrocytes.", "tags": [{"end": 123, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 51, "tag": "PharmacologicSubstance"}, {"end": 60, "start": 51, "tag": "Chemical"}, {"end": 144, "start": 128, "tag": "Cell"}, {"end": 99, "start": 84, "tag": "ResearchActivity"}, {"end": 99, "start": 95, "tag": "Eukaryote"}, {"end": 77, "start": 64, "tag": "CellFunction"}, {"end": 44, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 33, "tag": "BiologicallyActiveSubstance"}]}{"id": "1241_1", "text": "Mechanisms of versican-V1 include the direct inhibition of oligodendrocytes, and elevating Th17 cells.", "tags": [{"end": 75, "start": 59, "tag": "Cell"}, {"end": 101, "start": 91, "tag": "Cell"}, {"end": 55, "start": 45, "tag": "CellFunction"}, {"end": 25, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 14, "tag": "BiologicallyActiveSubstance"}]}{"id": "1241_2", "text": "Remyelination failure in multiple sclerosis (MS) contributes to progression of disability.", "tags": [{"end": 43, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 21, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 75, "start": 64, "tag": "PathologicFunction"}, {"end": 75, "start": 64, "tag": "TemporalConcept"}, {"end": 47, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 79, "tag": "Finding"}]}{"id": "1241_3", "text": "The deficient repair results from neuroinflammation and deposition of inhibitors including chondroitin sulfate proteoglycans (CSPGs).", "tags": [{"end": 131, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 70, "tag": "Chemical"}, {"end": 80, "start": 70, "tag": "PharmacologicSubstance"}, {"end": 80, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 34, "tag": "PathologicFunction"}, {"end": 20, "start": 14, "tag": "BiologicFunction"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 20, "start": 4, "tag": "PathologicFunction"}]}{"id": "1241_4", "text": "Which CSPG member is repair-inhibitory or alters local inflammation to exacerbate injury is unknown.", "tags": [{"end": 38, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 55, "tag": "PathologicFunction"}, {"end": 88, "start": 82, "tag": "InjuryOrPoisoning"}, {"end": 27, "start": 21, "tag": "BiologicFunction"}, {"end": 27, "start": 21, "tag": "HealthCareActivity"}, {"end": 17, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 6, "tag": "BiologicallyActiveSubstance"}]}{"id": "1241_5", "text": "Here, we correlate high versican-V1 expression in MS lesions with deficient premyelinating oligodendrocytes, and highlight its selective upregulation amongst CSPG members in experimental autoimmune encephalomyelitis (EAE) lesions modeling MS.", "tags": [{"end": 238, "start": 230, "tag": "ResearchActivity"}, {"end": 215, "start": 174, "tag": "ExperimentalModelOfDisease"}, {"end": 220, "start": 217, "tag": "ExperimentalModelOfDisease"}, {"end": 107, "start": 76, "tag": "Cell"}, {"end": 60, "start": 53, "tag": "InjuryOrPoisoning"}, {"end": 229, "start": 222, "tag": "InjuryOrPoisoning"}, {"end": 46, "start": 36, "tag": "CellFunction"}, {"end": 23, "start": 19, "tag": "Finding"}, {"end": 52, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 241, "start": 239, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 137, "tag": "CellFunction"}, {"end": 35, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 158, "tag": "BiologicallyActiveSubstance"}]}{"id": "1241_6", "text": "In culture, purified versican-V1 inhibits oligodendrocyte precursor cells (OPCs) and promotes T helper 17 (Th17) polarization.", "tags": [{"end": 105, "start": 94, "tag": "Cell"}, {"end": 79, "start": 75, "tag": "Cell"}, {"end": 73, "start": 42, "tag": "Cell"}, {"end": 10, "start": 3, "tag": "ResearchActivity"}, {"end": 125, "start": 113, "tag": "CellFunction"}, {"end": 32, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 107, "tag": "Cell"}]}{"id": "1241_7", "text": "Versican-V1-exposed Th17 cells are particularly toxic to OPCs.", "tags": [{"end": 61, "start": 57, "tag": "Cell"}, {"end": 30, "start": 20, "tag": "Cell"}, {"end": 53, "start": 48, "tag": "InjuryOrPoisoning"}, {"end": 11, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1241_8", "text": "In NG2(CreER):MAPT(mGFP) mice illuminating newly formed GFP(+) oligodendrocytes/myelin, difluorosamine (peracetylated,4,4-difluoro-N-acetylglucosamine) treatment from peak EAE reduces lesional versican-V1 and Th17 frequency, while enhancing GFP(+) profiles.", "tags": [{"end": 175, "start": 172, "tag": "ExperimentalModelOfDisease"}, {"end": 6, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 3, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 3, "tag": "GeneOrGenome"}, {"end": 223, "start": 214, "tag": "TemporalConcept"}, {"end": 79, "start": 63, "tag": "Cell"}, {"end": 86, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 25, "tag": "Eukaryote"}, {"end": 256, "start": 248, "tag": "ResearchActivity"}, {"end": 161, "start": 152, "tag": "HealthCareActivity"}, {"end": 161, "start": 152, "tag": "ResearchActivity"}, {"end": 18, "start": 14, "tag": "GeneOrGenome"}, {"end": 204, "start": 193, "tag": "AminoAcidPeptideOrProtein"}, {"end": 204, "start": 193, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 56, "tag": "Chemical"}, {"end": 102, "start": 88, "tag": "Chemical"}, {"end": 150, "start": 104, "tag": "Chemical"}, {"end": 244, "start": 241, "tag": "AminoAcidPeptideOrProtein"}, {"end": 244, "start": 241, "tag": "Chemical"}]}{"id": "1241_9", "text": "We suggest that lesion-elevated versican-V1 directly impedes OPCs while it indirectly inhibits remyelination through elevating local Th17 cytotoxic neuroinflammation.", "tags": [{"end": 147, "start": 138, "tag": "InjuryOrPoisoning"}, {"end": 65, "start": 61, "tag": "Cell"}, {"end": 22, "start": 16, "tag": "InjuryOrPoisoning"}, {"end": 108, "start": 95, "tag": "CellFunction"}, {"end": 165, "start": 148, "tag": "PathologicFunction"}, {"end": 43, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 32, "tag": "BiologicallyActiveSubstance"}]}{"id": "1241_10", "text": "We propose CSPG-lowering drugs as potential dual pronged repair and immunomodulatory therapeutics for MS.", "tags": [{"end": 97, "start": 85, "tag": "HealthCareActivity"}, {"end": 30, "start": 25, "tag": "PharmacologicSubstance"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 57, "tag": "BiologicFunction"}, {"end": 63, "start": 57, "tag": "HealthCareActivity"}, {"end": 84, "start": 68, "tag": "PharmacologicSubstance"}, {"end": 84, "start": 68, "tag": "BiologicFunction"}, {"end": 84, "start": 68, "tag": "HealthCareActivity"}, {"end": 15, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 11, "tag": "BiologicallyActiveSubstance"}]}{"id": "1242_0", "text": "The inflammatory cytokine interleukin (IL)-1 beta has been implicated in demyelinating diseases, such as multiple sclerosis and experimental autoimmune encephalomyelitis, and brain degenerative diseases, such as Alzheimer's disease.", "tags": [{"end": 169, "start": 128, "tag": "ExperimentalModelOfDisease"}, {"end": 95, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 4, "tag": "PathologicFunction"}, {"end": 231, "start": 212, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 202, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 17, "tag": "BiologicallyActiveSubstance"}]}{"id": "1242_1", "text": "However, the cellular and molecular mechanisms underlying the damaging effects of IL-1 beta on myelination are poorly understood.", "tags": [{"end": 91, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 82, "tag": "PharmacologicSubstance"}, {"end": 21, "start": 13, "tag": "Cell"}, {"end": 106, "start": 95, "tag": "CellFunction"}, {"end": 46, "start": 26, "tag": "CellFunction"}, {"end": 78, "start": 71, "tag": "Finding"}, {"end": 70, "start": 62, "tag": "InjuryOrPoisoning"}]}{"id": "1242_2", "text": "Therefore, the present study was designed to investigate whether IL-1 beta modifies the proliferation and differentiation of oligodendrocyte precursor cells (OPCs) through regulating the miR-202-3p/beta-catenin/glioma-associated oncogene homolog 1 (Gli1) axis.", "tags": [{"end": 259, "start": 187, "tag": "CellFunction"}, {"end": 74, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 65, "tag": "PharmacologicSubstance"}, {"end": 162, "start": 158, "tag": "Cell"}, {"end": 156, "start": 125, "tag": "Cell"}, {"end": 121, "start": 106, "tag": "CellFunction"}, {"end": 101, "start": 88, "tag": "CellFunction"}, {"end": 28, "start": 23, "tag": "ResearchActivity"}, {"end": 247, "start": 211, "tag": "AminoAcidPeptideOrProtein"}, {"end": 247, "start": 211, "tag": "BiologicallyActiveSubstance"}, {"end": 253, "start": 249, "tag": "AminoAcidPeptideOrProtein"}, {"end": 253, "start": 249, "tag": "BiologicallyActiveSubstance"}, {"end": 197, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 197, "start": 187, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 210, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 210, "start": 198, "tag": "BiologicallyActiveSubstance"}]}{"id": "1242_3", "text": "It was observed that IL-1 beta significantly attenuated the proliferation and differentiation of OPCs, as evidenced by a decrease in bromodeoxyuridine incorporation and reduced percentage of myelin basic protein-positive cells among the total number of oligodendrocyte transcription factor 2-positive cells.", "tags": [{"end": 150, "start": 133, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 30, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 291, "start": 253, "tag": "AminoAcidPeptideOrProtein"}, {"end": 291, "start": 253, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 121, "tag": "Finding"}, {"end": 101, "start": 97, "tag": "Cell"}, {"end": 93, "start": 78, "tag": "CellFunction"}, {"end": 73, "start": 60, "tag": "CellFunction"}, {"end": 211, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 191, "tag": "BiologicallyActiveSubstance"}, {"end": 226, "start": 221, "tag": "Cell"}, {"end": 306, "start": 301, "tag": "Cell"}]}{"id": "1242_4", "text": "In addition, IL-1 beta markedly decreased the expression of miR-202-3p and increased the protein expression of beta-catenin and Gli1, all of which were reversed by the IL-1 beta inhibitor, IL-1Ra.", "tags": [{"end": 123, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 189, "tag": "PharmacologicSubstance"}, {"end": 22, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 168, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 177, "start": 168, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 13, "tag": "PharmacologicSubstance"}, {"end": 177, "start": 168, "tag": "PharmacologicSubstance"}, {"end": 187, "start": 178, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 178, "tag": "PharmacologicSubstance"}, {"end": 187, "start": 178, "tag": "Chemical"}, {"end": 107, "start": 89, "tag": "CellFunction"}, {"end": 56, "start": 46, "tag": "CellFunction"}, {"end": 41, "start": 32, "tag": "Finding"}, {"end": 70, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 60, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 132, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 128, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1242_5", "text": "Treatment with the beta-catenin inhibitor XAV939, Gli1 siRNA, or miR-202-3p mimic transfection, attenuated the IL-1 beta-induced suppression of OPC proliferation and differentiation.", "tags": [{"end": 31, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 55, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 60, "start": 55, "tag": "PharmacologicSubstance"}, {"end": 94, "start": 82, "tag": "ResearchActivity"}, {"end": 140, "start": 129, "tag": "PathologicFunction"}, {"end": 140, "start": 129, "tag": "BiologicFunction"}, {"end": 140, "start": 129, "tag": "NaturalPhenomenonOrProcess"}, {"end": 48, "start": 42, "tag": "Chemical"}, {"end": 48, "start": 42, "tag": "PharmacologicSubstance"}, {"end": 120, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 111, "tag": "PharmacologicSubstance"}, {"end": 41, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 32, "tag": "PharmacologicSubstance"}, {"end": 41, "start": 32, "tag": "Chemical"}, {"end": 147, "start": 144, "tag": "Cell"}, {"end": 181, "start": 166, "tag": "CellFunction"}, {"end": 161, "start": 148, "tag": "CellFunction"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 54, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 65, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1242_6", "text": "Treatment with XAV939 decreased the expression of Gli1.", "tags": [{"end": 21, "start": 15, "tag": "Chemical"}, {"end": 21, "start": 15, "tag": "PharmacologicSubstance"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 46, "start": 36, "tag": "CellFunction"}, {"end": 31, "start": 22, "tag": "Finding"}, {"end": 54, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 50, "tag": "BiologicallyActiveSubstance"}]}{"id": "1242_7", "text": "Transfection of miR-202-3p mimic attenuated the expression of beta-catenin and Gli1.", "tags": [{"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 74, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 48, "tag": "CellFunction"}, {"end": 26, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 16, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 83, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 79, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1242_8", "text": "As demonstrated by the findings of the present study, IL-1 beta suppressed the proliferation and differentiation of OPCs through regulation of the miR-202-3p/beta-catenin/Gli1 axis.", "tags": [{"end": 63, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 54, "tag": "PharmacologicSubstance"}, {"end": 120, "start": 116, "tag": "Cell"}, {"end": 112, "start": 97, "tag": "CellFunction"}, {"end": 92, "start": 79, "tag": "CellFunction"}, {"end": 52, "start": 47, "tag": "ResearchActivity"}, {"end": 180, "start": 147, "tag": "CellFunction"}]}{"id": "1242_9", "text": "Therefore, the miR-202-3p/ beta-catenin/Gli1 axis may be of value as a therapeutic target in multiple sclerosis.", "tags": [{"end": 49, "start": 15, "tag": "CellFunction"}, {"end": 111, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 71, "tag": "Finding"}]}{"id": "1243_0", "text": "Regeneration of myelin in the central nervous system is being pursued as a potential therapeutic approach for multiple sclerosis.", "tags": [{"end": 12, "start": 0, "tag": "BiologicFunction"}, {"end": 12, "start": 0, "tag": "HealthCareActivity"}, {"end": 105, "start": 85, "tag": "HealthCareActivity"}, {"end": 128, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1243_1", "text": "Several labs have reported small molecules that promote oligodendrocyte formation and remyelination in vivo.", "tags": [{"end": 12, "start": 8, "tag": "ResearchActivity"}, {"end": 42, "start": 27, "tag": "Chemical"}, {"end": 107, "start": 100, "tag": "ResearchActivity"}, {"end": 71, "start": 56, "tag": "Cell"}, {"end": 42, "start": 33, "tag": "Substance"}, {"end": 99, "start": 86, "tag": "CellFunction"}]}{"id": "1243_2", "text": "Recently, we reported that many such molecules function by inhibiting a narrow window of enzymes in the cholesterol biosynthesis pathway.", "tags": [{"end": 136, "start": 104, "tag": "CellFunction"}, {"end": 115, "start": 104, "tag": "Chemical"}, {"end": 115, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 37, "tag": "Substance"}, {"end": 136, "start": 129, "tag": "CellFunction"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}]}{"id": "1243_3", "text": "Here we describe a new high-throughput screen of 1,836 bioactive molecules and a thorough re-analysis of more than 60 molecules previously identified as promoting oligodendrocyte formation from human, rat, or mouse oligodendrocyte progenitor cells.", "tags": [{"end": 45, "start": 23, "tag": "ResearchActivity"}, {"end": 247, "start": 215, "tag": "Cell"}, {"end": 247, "start": 231, "tag": "Cell"}, {"end": 45, "start": 39, "tag": "HealthCareActivity"}, {"end": 45, "start": 39, "tag": "ResearchActivity"}, {"end": 204, "start": 201, "tag": "Eukaryote"}, {"end": 101, "start": 93, "tag": "ResearchActivity"}, {"end": 199, "start": 194, "tag": "Eukaryote"}, {"end": 214, "start": 209, "tag": "Eukaryote"}, {"end": 27, "start": 23, "tag": "Finding"}, {"end": 178, "start": 163, "tag": "Cell"}, {"end": 74, "start": 65, "tag": "Substance"}, {"end": 127, "start": 118, "tag": "Substance"}, {"end": 74, "start": 55, "tag": "BiologicallyActiveSubstance"}]}{"id": "1243_4", "text": "These studies highlight that an overwhelming fraction of validated screening hits, including several molecules being evaluated clinically for remyelination, inhibit cholesterol pathway enzymes like emopamil-binding protein (EBP).", "tags": [{"end": 227, "start": 224, "tag": "GeneOrGenome"}, {"end": 176, "start": 165, "tag": "Chemical"}, {"end": 176, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 185, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 110, "start": 101, "tag": "Substance"}, {"end": 184, "start": 177, "tag": "CellFunction"}, {"end": 155, "start": 142, "tag": "CellFunction"}, {"end": 76, "start": 67, "tag": "HealthCareActivity"}, {"end": 76, "start": 67, "tag": "ResearchActivity"}, {"end": 222, "start": 198, "tag": "BiologicallyActiveSubstance"}, {"end": 222, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 227, "start": 224, "tag": "AminoAcidPeptideOrProtein"}, {"end": 227, "start": 224, "tag": "BiologicallyActiveSubstance"}]}{"id": "1243_5", "text": "To rationalize these findings, we suggest a model that relies on the high druggability of sterol-metabolizing enzymes and the ability of cationic amphiphiles to mimic the transition state of EBP.", "tags": [{"end": 194, "start": 191, "tag": "GeneOrGenome"}, {"end": 117, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 44, "tag": "ResearchActivity"}, {"end": 86, "start": 69, "tag": "Finding"}, {"end": 133, "start": 126, "tag": "OrganismAttribute"}, {"end": 157, "start": 137, "tag": "Chemical"}, {"end": 194, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 194, "start": 191, "tag": "BiologicallyActiveSubstance"}]}{"id": "1243_6", "text": "These studies further establish cholesterol pathway inhibition as a dominant mechanism among screening hits that enhance human, rat, or mouse oligodendrocyte formation.", "tags": [{"end": 76, "start": 68, "tag": "CellFunction"}, {"end": 43, "start": 32, "tag": "Chemical"}, {"end": 43, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 128, "tag": "Eukaryote"}, {"end": 126, "start": 121, "tag": "Eukaryote"}, {"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 141, "start": 136, "tag": "Eukaryote"}, {"end": 62, "start": 52, "tag": "CellFunction"}, {"end": 157, "start": 142, "tag": "Cell"}, {"end": 51, "start": 44, "tag": "CellFunction"}, {"end": 102, "start": 93, "tag": "HealthCareActivity"}, {"end": 102, "start": 93, "tag": "ResearchActivity"}]}{"id": "1244_0", "text": "Age-associated cognitive decline is common among otherwise healthy elderly people, even in the absence of Alzheimer's disease and neuron loss.", "tags": [{"end": 32, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 3, "start": 0, "tag": "OrganismAttribute"}, {"end": 125, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 59, "tag": "OrganismAttribute"}, {"end": 81, "start": 75, "tag": "PopulationGroup"}, {"end": 32, "start": 15, "tag": "DiseaseOrSyndrome"}, {"end": 74, "start": 67, "tag": "PopulationGroup"}, {"end": 141, "start": 130, "tag": "Finding"}]}{"id": "1244_1", "text": "Instead, white matter loss and myelin damage are strongly associated with cognitive decline.", "tags": [{"end": 26, "start": 9, "tag": "Finding"}, {"end": 37, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 84, "tag": "Finding"}, {"end": 44, "start": 38, "tag": "InjuryOrPoisoning"}]}{"id": "1244_2", "text": "Myelin is subject to lifelong oxidative stress that damages the myelin sheath, which is repaired by cells of the oligodendrocyte lineage.", "tags": [{"end": 70, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 113, "tag": "Cell"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 100, "tag": "Cell"}, {"end": 46, "start": 30, "tag": "CellOrMolecularDysfunction"}, {"end": 77, "start": 64, "tag": "CellComponent"}]}{"id": "1244_3", "text": "This process is mediated by oligodendrocyte precursor cells (OPCs) that sense the damage and respond by proliferating locally and migrating to the region, where they differentiate into mature myelinating oligodendrocytes.", "tags": [{"end": 65, "start": 61, "tag": "Cell"}, {"end": 59, "start": 28, "tag": "Cell"}, {"end": 179, "start": 166, "tag": "CellFunction"}, {"end": 220, "start": 185, "tag": "Cell"}, {"end": 88, "start": 82, "tag": "InjuryOrPoisoning"}]}{"id": "1244_4", "text": "In aging, extensive myelin damage, in combination with inefficient remyelination, leads to chronically damaged myelin and loss of efficient neuronal conduction.", "tags": [{"end": 117, "start": 103, "tag": "CellOrMolecularDysfunction"}, {"end": 26, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 140, "tag": "BiologicFunction"}, {"end": 80, "start": 67, "tag": "CellFunction"}, {"end": 8, "start": 3, "tag": "BiologicFunction"}, {"end": 8, "start": 3, "tag": "CellFunction"}, {"end": 33, "start": 27, "tag": "InjuryOrPoisoning"}, {"end": 80, "start": 55, "tag": "CellOrMolecularDysfunction"}]}{"id": "1244_5", "text": "This study used the rhesus monkey model of normal aging to examine how myelin regeneration capacity is affected by age.", "tags": [{"end": 77, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 78, "tag": "BiologicFunction"}, {"end": 90, "start": 78, "tag": "HealthCareActivity"}, {"end": 90, "start": 71, "tag": "CellFunction"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 39, "start": 34, "tag": "ResearchActivity"}, {"end": 99, "start": 91, "tag": "Finding"}, {"end": 118, "start": 115, "tag": "OrganismAttribute"}, {"end": 49, "start": 43, "tag": "Finding"}, {"end": 33, "start": 20, "tag": "Eukaryote"}, {"end": 55, "start": 50, "tag": "BiologicFunction"}, {"end": 55, "start": 50, "tag": "CellFunction"}]}{"id": "1244_6", "text": "Results show that older subjects have reduced numbers of new BCAS1 + myelinating oligodendrocytes, which are newly formed cells, and that this reduction is associated with poorer cognitive performance.", "tags": [{"end": 66, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 61, "tag": "GeneOrGenome"}, {"end": 97, "start": 69, "tag": "Cell"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 127, "start": 122, "tag": "Cell"}, {"end": 200, "start": 179, "tag": "ClinicalAttribute"}, {"end": 32, "start": 24, "tag": "PopulationGroup"}, {"end": 152, "start": 143, "tag": "Finding"}, {"end": 152, "start": 143, "tag": "NaturalPhenomenonOrProcess"}, {"end": 23, "start": 18, "tag": "TemporalConcept"}, {"end": 66, "start": 61, "tag": "BiologicallyActiveSubstance"}]}{"id": "1244_7", "text": "Interestingly, this does not result from limited proliferation of progenitor OPCs.", "tags": [{"end": 76, "start": 66, "tag": "PopulationGroup"}, {"end": 81, "start": 77, "tag": "Cell"}, {"end": 62, "start": 49, "tag": "CellFunction"}]}{"id": "1244_8", "text": "Instead, the transcription factor NKX2.2, which regulates OPCs differentiation, is significantly decreased in aged OPCs.", "tags": [{"end": 40, "start": 34, "tag": "GeneOrGenome"}, {"end": 33, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 110, "tag": "TemporalConcept"}, {"end": 62, "start": 58, "tag": "Cell"}, {"end": 119, "start": 115, "tag": "Cell"}, {"end": 78, "start": 63, "tag": "CellFunction"}, {"end": 106, "start": 97, "tag": "Finding"}, {"end": 40, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 34, "tag": "BiologicallyActiveSubstance"}]}{"id": "1244_9", "text": "This suggests that these OPCs have a diminished potential for differentiation into mature oligodendrocytes.", "tags": [{"end": 29, "start": 25, "tag": "Cell"}, {"end": 106, "start": 83, "tag": "Cell"}, {"end": 77, "start": 62, "tag": "CellFunction"}]}{"id": "1244_10", "text": "In addition, mature oligodendrocytes have reduced RNA expression of two essential myelin protein markers, MBP and PLP.", "tags": [{"end": 96, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 106, "tag": "GeneOrGenome"}, {"end": 36, "start": 13, "tag": "Cell"}, {"end": 117, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 114, "tag": "GeneOrGenome"}, {"end": 117, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 97, "tag": "ClinicalAttribute"}, {"end": 64, "start": 54, "tag": "CellFunction"}, {"end": 53, "start": 50, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1244_11", "text": "These data collectively suggest that in the normal aging brain, there is a reduction in regenerative OPCs as well as myelin production that impairs the capacity for remyelination.", "tags": [{"end": 105, "start": 101, "tag": "Cell"}, {"end": 123, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 160, "start": 152, "tag": "Finding"}, {"end": 50, "start": 44, "tag": "Finding"}, {"end": 84, "start": 75, "tag": "Finding"}, {"end": 84, "start": 75, "tag": "NaturalPhenomenonOrProcess"}, {"end": 178, "start": 165, "tag": "CellFunction"}, {"end": 56, "start": 51, "tag": "BiologicFunction"}, {"end": 56, "start": 51, "tag": "CellFunction"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}]}{"id": "1245_0", "text": "The extracellular matrix (ECM) provides protection, rigidity, and structure toward cells.", "tags": [{"end": 24, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 52, "tag": "SignOrSymptom"}, {"end": 88, "start": 83, "tag": "Cell"}, {"end": 60, "start": 52, "tag": "NaturalPhenomenonOrProcess"}]}{"id": "1245_1", "text": "It consists, among others, of a wide variety of glycoproteins and proteoglycans, which act together to produce a complex and dynamic environment, most relevant in transmembrane events.", "tags": [{"end": 79, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 48, "tag": "BiologicallyActiveSubstance"}]}{"id": "1245_2", "text": "In the brain, the ECM occupies a notable proportion of its volume and maintains the homeostasis of central nervous system (CNS).", "tags": [{"end": 21, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 84, "tag": "BiologicFunction"}, {"end": 12, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1245_3", "text": "In addition, remodeling of the ECM, that is transient changes in ECM proteins regulated by matrix metalloproteinases (MMPs), is an important process that modulates cell behavior upon injury, thereby facilitating recovery.", "tags": [{"end": 23, "start": 13, "tag": "BiologicFunction"}, {"end": 34, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 44, "tag": "TemporalConcept"}, {"end": 116, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 220, "start": 212, "tag": "BiologicFunction"}, {"end": 220, "start": 212, "tag": "HealthCareActivity"}, {"end": 220, "start": 212, "tag": "TemporalConcept"}, {"end": 189, "start": 183, "tag": "InjuryOrPoisoning"}, {"end": 68, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 177, "start": 164, "tag": "CellFunction"}]}{"id": "1245_4", "text": "Failure of ECM remodeling plays an important role in the pathogenesis of multiple sclerosis (MS), a neurodegenerative demyelinating disease of the CNS with an inflammatory response against protective myelin sheaths that surround axons.", "tags": [{"end": 14, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 15, "tag": "BiologicFunction"}, {"end": 180, "start": 159, "tag": "Finding"}, {"end": 150, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 234, "start": 229, "tag": "CellComponent"}, {"end": 214, "start": 200, "tag": "CellComponent"}, {"end": 69, "start": 57, "tag": "PathologicFunction"}, {"end": 139, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 206, "start": 200, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 0, "tag": "PathologicFunction"}]}{"id": "1245_5", "text": "Remyelination of denuded axons improves the neuropathological conditions of MS, but this regeneration process fails over time, leading to chronic disease progression.", "tags": [{"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 153, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 17, "tag": "CellComponent"}, {"end": 101, "start": 89, "tag": "BiologicFunction"}, {"end": 72, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 165, "start": 154, "tag": "PathologicFunction"}, {"end": 165, "start": 154, "tag": "TemporalConcept"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 138, "tag": "TemporalConcept"}, {"end": 125, "start": 121, "tag": "TemporalConcept"}, {"end": 165, "start": 146, "tag": "PathologicFunction"}]}{"id": "1245_6", "text": "In this review, we uncover abnormal ECM remodeling in MS lesions by discussing ECM remodeling in experimental demyelination models, that is when remyelination is successful, and compare alterations in ECM components to the ECM composition and MMP expression in the parenchyma of demyelinated MS lesions, that is when remyelination fails.", "tags": [{"end": 39, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 27, "tag": "PathologicFunction"}, {"end": 82, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 83, "tag": "BiologicFunction"}, {"end": 109, "start": 97, "tag": "ResearchActivity"}, {"end": 204, "start": 201, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 226, "start": 223, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 275, "start": 265, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 291, "start": 279, "tag": "PathologicFunction"}, {"end": 246, "start": 243, "tag": "AminoAcidPeptideOrProtein"}, {"end": 246, "start": 243, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 145, "tag": "CellFunction"}, {"end": 330, "start": 317, "tag": "CellFunction"}, {"end": 215, "start": 205, "tag": "CellComponent"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 294, "start": 292, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 110, "tag": "PathologicFunction"}, {"end": 64, "start": 57, "tag": "InjuryOrPoisoning"}, {"end": 302, "start": 295, "tag": "InjuryOrPoisoning"}, {"end": 130, "start": 124, "tag": "ResearchActivity"}]}{"id": "1245_7", "text": "Inter- and intralesional differences in ECM remodeling in the distinct white matter MS lesions are discussed in terms of consequences for oligodendrocyte behavior and remyelination (failure).", "tags": [{"end": 43, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 44, "tag": "BiologicFunction"}, {"end": 162, "start": 154, "tag": "BiologicFunction"}, {"end": 162, "start": 154, "tag": "IndividualBehavior"}, {"end": 162, "start": 154, "tag": "ResearchActivity"}, {"end": 180, "start": 167, "tag": "CellFunction"}, {"end": 153, "start": 138, "tag": "Cell"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 87, "tag": "InjuryOrPoisoning"}, {"end": 83, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 25, "tag": "Finding"}]}{"id": "1245_8", "text": "Hence, the review will aid to understand how abnormal ECM remodeling contributes to remyelination failure in MS lesions and assists in developing therapeutic strategies to promote remyelination.", "tags": [{"end": 53, "start": 45, "tag": "Finding"}, {"end": 57, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 58, "tag": "BiologicFunction"}, {"end": 168, "start": 146, "tag": "HealthCareActivity"}, {"end": 193, "start": 180, "tag": "CellFunction"}, {"end": 105, "start": 84, "tag": "CellOrMolecularDysfunction"}, {"end": 17, "start": 11, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "HealthCareActivity"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 112, "tag": "InjuryOrPoisoning"}]}{"id": "1246_0", "text": "Chronically demyelinated axons are rendered susceptible to degeneration through loss of trophic support from oligodendrocytes and myelin, and this process underlies disability progression in multiple sclerosis.", "tags": [{"end": 55, "start": 44, "tag": "OrganismAttribute"}, {"end": 103, "start": 88, "tag": "CellFunction"}, {"end": 30, "start": 25, "tag": "CellComponent"}, {"end": 125, "start": 109, "tag": "Cell"}, {"end": 209, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 12, "tag": "PathologicFunction"}, {"end": 71, "start": 59, "tag": "PathologicFunction"}, {"end": 187, "start": 176, "tag": "PathologicFunction"}, {"end": 187, "start": 176, "tag": "TemporalConcept"}, {"end": 175, "start": 165, "tag": "Finding"}, {"end": 11, "start": 0, "tag": "TemporalConcept"}, {"end": 84, "start": 80, "tag": "Finding"}]}{"id": "1246_1", "text": "Promoting remyelination is a promising neuroprotective therapeutic strategy, but to date, has not been achieved through simply promoting oligodendrocyte precursor cell differentiation, and it is clear that a detailed understanding of the molecular mechanisms underlying failed remyelination is required to guide future therapeutic approaches.", "tags": [{"end": 88, "start": 81, "tag": "TemporalConcept"}, {"end": 88, "start": 84, "tag": "TemporalConcept"}, {"end": 183, "start": 168, "tag": "CellFunction"}, {"end": 167, "start": 137, "tag": "Cell"}, {"end": 167, "start": 153, "tag": "Cell"}, {"end": 162, "start": 137, "tag": "Cell"}, {"end": 183, "start": 137, "tag": "CellFunction"}, {"end": 230, "start": 217, "tag": "BiologicFunction"}, {"end": 318, "start": 312, "tag": "TemporalConcept"}, {"end": 23, "start": 10, "tag": "CellFunction"}, {"end": 290, "start": 277, "tag": "CellFunction"}, {"end": 258, "start": 238, "tag": "CellFunction"}, {"end": 183, "start": 163, "tag": "CellFunction"}, {"end": 75, "start": 55, "tag": "HealthCareActivity"}, {"end": 341, "start": 319, "tag": "HealthCareActivity"}, {"end": 54, "start": 39, "tag": "CellFunction"}]}{"id": "1246_2", "text": "In multiple sclerosis, remyelination is impaired by extrinsic inhibitory cues in the lesion microenvironment including secreted effector molecules released from compartmentalized immune cells and reactive glia, as well as by intrinsic defects in oligodendrocyte lineage cells, most notably increased metabolic demands causing oxidative stress and accelerated cellular senescence.", "tags": [{"end": 108, "start": 92, "tag": "NaturalPhenomenonOrProcess"}, {"end": 108, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 309, "start": 300, "tag": "CellFunction"}, {"end": 191, "start": 179, "tag": "Cell"}, {"end": 21, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 85, "tag": "InjuryOrPoisoning"}, {"end": 275, "start": 246, "tag": "Cell"}, {"end": 72, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 269, "start": 246, "tag": "Cell"}, {"end": 342, "start": 326, "tag": "CellOrMolecularDysfunction"}, {"end": 209, "start": 196, "tag": "Cell"}, {"end": 378, "start": 368, "tag": "Finding"}, {"end": 378, "start": 368, "tag": "TemporalConcept"}, {"end": 146, "start": 128, "tag": "Substance"}, {"end": 36, "start": 23, "tag": "CellFunction"}, {"end": 378, "start": 359, "tag": "CellFunction"}]}{"id": "1246_3", "text": "Promising advances in our understanding of the cellular and molecular mechanisms underlying these processes offers hope for strategically designed interventions to facilitate remyelination thereby resulting in robust clinical benefits.", "tags": [{"end": 119, "start": 115, "tag": "BiologicFunction"}, {"end": 160, "start": 147, "tag": "HealthCareActivity"}, {"end": 160, "start": 147, "tag": "ResearchActivity"}, {"end": 39, "start": 26, "tag": "BiologicFunction"}, {"end": 55, "start": 47, "tag": "Cell"}, {"end": 188, "start": 175, "tag": "CellFunction"}, {"end": 80, "start": 60, "tag": "CellFunction"}, {"end": 18, "start": 10, "tag": "Finding"}, {"end": 234, "start": 217, "tag": "Finding"}]}{"id": "1247_0", "text": "Oligodendrocyte progenitor cells (OPCs), also referred to as NG2-glia, are the most proliferative cell type in the adult central nervous system.", "tags": [{"end": 32, "start": 0, "tag": "Cell"}, {"end": 97, "start": 84, "tag": "PathologicFunction"}, {"end": 38, "start": 34, "tag": "Cell"}, {"end": 32, "start": 16, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 69, "start": 61, "tag": "Cell"}, {"end": 143, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 65, "tag": "Cell"}, {"end": 120, "start": 115, "tag": "PopulationGroup"}, {"end": 107, "start": 98, "tag": "Cell"}]}{"id": "1247_1", "text": "While the primary role of OPCs is to serve as progenitors for oligodendrocytes, in recent years, it has become increasingly clear that OPCs fulfil a number of other functions.", "tags": [{"end": 57, "start": 46, "tag": "Cell"}, {"end": 78, "start": 62, "tag": "Cell"}, {"end": 30, "start": 26, "tag": "Cell"}, {"end": 139, "start": 135, "tag": "Cell"}, {"end": 95, "start": 90, "tag": "TemporalConcept"}, {"end": 89, "start": 83, "tag": "TemporalConcept"}]}{"id": "1247_2", "text": "Indeed, independent of their role as stem cells, it is evident that OPCs can regulate the metabolic environment, directly interact with and modulate neuronal function, maintain the blood brain barrier (BBB) and regulate inflammation.", "tags": [{"end": 99, "start": 90, "tag": "CellFunction"}, {"end": 200, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 68, "tag": "Cell"}, {"end": 166, "start": 149, "tag": "CellFunction"}, {"end": 232, "start": 220, "tag": "PathologicFunction"}, {"end": 47, "start": 37, "tag": "Cell"}, {"end": 205, "start": 202, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1247_3", "text": "In this review article, we discuss the state-of-the-art tools and investigative approaches being used to characterize the biology and function of OPCs.", "tags": [{"end": 150, "start": 146, "tag": "Cell"}, {"end": 22, "start": 8, "tag": "ResearchActivity"}, {"end": 129, "start": 122, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 129, "start": 122, "tag": "BiologicFunction"}, {"end": 61, "start": 39, "tag": "ResearchActivity"}]}{"id": "1247_4", "text": "From functional genetic investigation to single cell sequencing and from lineage tracing to functional imaging, we discuss the important discoveries uncovered by these techniques, such as functional and spatial OPC heterogeneity, novel OPC marker genes, the interaction of OPCs with other cells types, and how OPCs integrate and respond to signals from neighboring cells.", "tags": [{"end": 110, "start": 92, "tag": "HealthCareActivity"}, {"end": 210, "start": 203, "tag": "GeneOrGenome"}, {"end": 364, "start": 353, "tag": "PopulationGroup"}, {"end": 277, "start": 273, "tag": "Cell"}, {"end": 314, "start": 310, "tag": "Cell"}, {"end": 214, "start": 211, "tag": "Cell"}, {"end": 239, "start": 236, "tag": "Cell"}, {"end": 110, "start": 103, "tag": "HealthCareActivity"}, {"end": 37, "start": 6, "tag": "ResearchActivity"}, {"end": 246, "start": 240, "tag": "ClinicalAttribute"}, {"end": 294, "start": 289, "tag": "Cell"}, {"end": 370, "start": 365, "tag": "Cell"}, {"end": 347, "start": 340, "tag": "CellFunction"}, {"end": 228, "start": 215, "tag": "OrganismAttribute"}, {"end": 148, "start": 137, "tag": "ResearchActivity"}, {"end": 178, "start": 168, "tag": "HealthCareActivity"}, {"end": 178, "start": 168, "tag": "ResearchActivity"}, {"end": 63, "start": 41, "tag": "ResearchActivity"}, {"end": 88, "start": 73, "tag": "ResearchActivity"}]}{"id": "1247_5", "text": "Finally, we review the use of in vitro assay to assess OPC functions.", "tags": [{"end": 58, "start": 55, "tag": "Cell"}, {"end": 44, "start": 39, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 38, "start": 30, "tag": "ResearchActivity"}]}{"id": "1247_6", "text": "These methodologies promise to lead to ever greater understanding of this enigmatic cell type, which in turn will shed light on the pathogenesis and potential treatment strategies for a number of diseases, such as multiple sclerosis (MS) and gliomas.", "tags": [{"end": 249, "start": 242, "tag": "DiseaseOrSyndrome"}, {"end": 232, "start": 214, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 119, "tag": "NaturalPhenomenonOrProcess"}, {"end": 144, "start": 132, "tag": "PathologicFunction"}, {"end": 65, "start": 52, "tag": "BiologicFunction"}, {"end": 236, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 84, "tag": "Cell"}, {"end": 179, "start": 159, "tag": "HealthCareActivity"}, {"end": 179, "start": 159, "tag": "ResearchActivity"}]}{"id": "1248_0", "text": "Multiple sclerosis (MS) is a demyelinating autoimmune disease of the central nervous system (CNS) mediated by autoreactive lymphocytes.", "tags": [{"end": 134, "start": 110, "tag": "ResearchActivity"}, {"end": 134, "start": 110, "tag": "Cell"}, {"end": 61, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 29, "tag": "PathologicFunction"}, {"end": 61, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 123, "tag": "Cell"}]}{"id": "1248_1", "text": "The role of autoreactive lymphocytes in the CNS demyelination is well described, whereas very little is known about their role in remyelination during MS remission.", "tags": [{"end": 163, "start": 154, "tag": "Finding"}, {"end": 47, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 130, "tag": "CellFunction"}, {"end": 153, "start": 151, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 48, "tag": "PathologicFunction"}, {"end": 36, "start": 12, "tag": "Cell"}]}{"id": "1248_2", "text": "In this study, we identified a new subpopulation of myelin-specific CD49d(+)CD154(+) lymphocytes presented in the peripheral blood of MS patients during remission, that proliferated in vitro in response to myelin peptides.", "tags": [{"end": 48, "start": 35, "tag": "PopulationGroup"}, {"end": 162, "start": 153, "tag": "Finding"}, {"end": 58, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 206, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 137, "tag": "PatientOrDisabledGroup"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 190, "start": 182, "tag": "ResearchActivity"}, {"end": 136, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 85, "tag": "Cell"}, {"end": 221, "start": 213, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 76, "tag": "BiologicallyActiveSubstance"}]}{"id": "1248_3", "text": "These lymphocytes possessed the unique ability to migrate towards maturing oligodendrocyte precursor cells (OPCs) and synthetize proinflammatory chemokines/cytokines.", "tags": [{"end": 112, "start": 108, "tag": "Cell"}, {"end": 106, "start": 75, "tag": "Cell"}, {"end": 165, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 165, "start": 156, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 39, "tag": "OrganismAttribute"}, {"end": 17, "start": 6, "tag": "Cell"}, {"end": 144, "start": 129, "tag": "PathologicFunction"}, {"end": 155, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 145, "tag": "BiologicallyActiveSubstance"}]}{"id": "1248_4", "text": "The co-culture of maturing OPCs with myelin-specific CD49d(+)CD154(+) lymphocytes was characterized by the increase in proinflammatory chemokine/cytokine secretion that was not only a result of their cumulative effect of what OPCs and CD49d(+)CD154(+) lymphocytes produced alone.", "tags": [{"end": 14, "start": 4, "tag": "ResearchActivity"}, {"end": 144, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 18, "tag": "Cell"}, {"end": 230, "start": 226, "tag": "Cell"}, {"end": 43, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 217, "start": 211, "tag": "Finding"}, {"end": 163, "start": 154, "tag": "CellFunction"}, {"end": 163, "start": 154, "tag": "BiologicFunction"}, {"end": 81, "start": 70, "tag": "Cell"}, {"end": 263, "start": 252, "tag": "Cell"}, {"end": 134, "start": 119, "tag": "PathologicFunction"}, {"end": 58, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 248, "start": 243, "tag": "AminoAcidPeptideOrProtein"}, {"end": 240, "start": 235, "tag": "AminoAcidPeptideOrProtein"}, {"end": 240, "start": 235, "tag": "BiologicallyActiveSubstance"}, {"end": 248, "start": 243, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 145, "tag": "BiologicallyActiveSubstance"}]}{"id": "1248_5", "text": "Moreover, maturing OPCs exposed to exogenous myelin peptides managed to induce CD40-CD154-dependent CD49d(+)CD154(+) lymphocyte proliferation.", "tags": [{"end": 23, "start": 10, "tag": "Cell"}, {"end": 51, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 141, "start": 128, "tag": "CellFunction"}, {"end": 127, "start": 117, "tag": "Cell"}, {"end": 60, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 108, "tag": "BiologicallyActiveSubstance"}]}{"id": "1248_6", "text": "We confirmed, in vivo, the presence of CD49d(+)CD154(+) cells close to maturating OPCs and remyelinating plaque during disease remission in the MS mouse model (C57Bl/6 mice immunized with MOG(35-55)) by immunohistochemistry.", "tags": [{"end": 136, "start": 119, "tag": "Finding"}, {"end": 111, "start": 105, "tag": "AnatomicalAbnormality"}, {"end": 86, "start": 71, "tag": "Cell"}, {"end": 104, "start": 91, "tag": "CellFunction"}, {"end": 61, "start": 56, "tag": "Cell"}, {"end": 172, "start": 160, "tag": "Eukaryote"}, {"end": 21, "start": 14, "tag": "ResearchActivity"}, {"end": 146, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 203, "tag": "ResearchActivity"}, {"end": 158, "start": 147, "tag": "ResearchActivity"}, {"end": 35, "start": 27, "tag": "Finding"}, {"end": 198, "start": 188, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 144, "tag": "ExperimentalModelOfDisease"}, {"end": 44, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 52, "start": 47, "tag": "BiologicallyActiveSubstance"}]}{"id": "1248_7", "text": "Three weeks after an acute phase of experimental autoimmune encephalomyelitis, CD49d(+)/CD154(+) cells were found to be co-localized with O4(+) cells (oligodendrocyte progenitors) in the areas of remyelination identified by myelin basic protein (MBP) labelling.", "tags": [{"end": 32, "start": 21, "tag": "TemporalConcept"}, {"end": 32, "start": 21, "tag": "PathologicFunction"}, {"end": 178, "start": 167, "tag": "Cell"}, {"end": 178, "start": 151, "tag": "Cell"}, {"end": 77, "start": 36, "tag": "ExperimentalModelOfDisease"}, {"end": 249, "start": 246, "tag": "AminoAcidPeptideOrProtein"}, {"end": 249, "start": 246, "tag": "BiologicallyActiveSubstance"}, {"end": 249, "start": 246, "tag": "GeneOrGenome"}, {"end": 32, "start": 27, "tag": "TemporalConcept"}, {"end": 244, "start": 224, "tag": "AminoAcidPeptideOrProtein"}, {"end": 244, "start": 224, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 6, "tag": "TemporalConcept"}, {"end": 26, "start": 21, "tag": "TemporalConcept"}, {"end": 102, "start": 97, "tag": "Cell"}, {"end": 149, "start": 144, "tag": "Cell"}, {"end": 220, "start": 210, "tag": "Finding"}, {"end": 209, "start": 196, "tag": "CellFunction"}, {"end": 84, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 260, "start": 251, "tag": "ResearchActivity"}]}{"id": "1248_8", "text": "These data suggested that myelin-specific CD49d(+)CD154(+) lymphocytes present in the brain can interfere with remyelination mediated by oligodendrocytes probably as a result of establishing proinflammatory environment.", "tags": [{"end": 153, "start": 137, "tag": "Cell"}, {"end": 32, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 111, "tag": "CellFunction"}, {"end": 70, "start": 59, "tag": "Cell"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 206, "start": 191, "tag": "PathologicFunction"}, {"end": 47, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 50, "tag": "BiologicallyActiveSubstance"}]}{"id": "1249_0", "text": "The most frequent variant of multiple sclerosis (MS) is the relapsing-remitting form, characterized by symptomatic phases followed by periods of total/partial recovery.", "tags": [{"end": 121, "start": 115, "tag": "TemporalConcept"}, {"end": 141, "start": 134, "tag": "BiologicFunction"}, {"end": 141, "start": 134, "tag": "TemporalConcept"}, {"end": 17, "start": 9, "tag": "TemporalConcept"}, {"end": 69, "start": 60, "tag": "TemporalConcept"}, {"end": 47, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 159, "tag": "BiologicFunction"}, {"end": 167, "start": 159, "tag": "HealthCareActivity"}, {"end": 167, "start": 159, "tag": "TemporalConcept"}, {"end": 114, "start": 103, "tag": "SignOrSymptom"}]}{"id": "1249_1", "text": "Hence, it is possible that these patients can benefit from endogenous agents that control the inflammatory process and favor spontaneous remyelination.", "tags": [{"end": 114, "start": 94, "tag": "PathologicFunction"}, {"end": 150, "start": 137, "tag": "CellFunction"}, {"end": 41, "start": 33, "tag": "PatientOrDisabledGroup"}]}{"id": "1249_2", "text": "In this context, there is increasing interest in the role of myeloid-derived suppressor cells (MDSCs) during the clinical course of experimental autoimmune encephalomyelitis (EAE).", "tags": [{"end": 93, "start": 61, "tag": "Cell"}, {"end": 100, "start": 95, "tag": "Cell"}, {"end": 128, "start": 113, "tag": "TemporalConcept"}, {"end": 173, "start": 132, "tag": "ExperimentalModelOfDisease"}, {"end": 178, "start": 175, "tag": "ExperimentalModelOfDisease"}, {"end": 45, "start": 26, "tag": "Finding"}]}{"id": "1249_3", "text": "MDSCs speed up infiltrated T-cell anergy and apoptosis.", "tags": [{"end": 5, "start": 0, "tag": "Cell"}, {"end": 26, "start": 15, "tag": "PathologicFunction"}, {"end": 40, "start": 27, "tag": "BiologicFunction"}, {"end": 54, "start": 45, "tag": "CellFunction"}]}{"id": "1249_4", "text": "In different animal models of MS, a milder disease course is related to higher presence/density of MDSCs in the periphery, and smaller demyelinated lesions in the central nervous system (CNS).", "tags": [{"end": 104, "start": 99, "tag": "Cell"}, {"end": 57, "start": 43, "tag": "TemporalConcept"}, {"end": 121, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 163, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 79, "tag": "Finding"}, {"end": 190, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 135, "tag": "PathologicFunction"}, {"end": 26, "start": 13, "tag": "ResearchActivity"}, {"end": 32, "start": 13, "tag": "ExperimentalModelOfDisease"}]}{"id": "1249_5", "text": "These observations lead us to wonder whether MDSCs might not only exert an anti-inflammatory effect but might also have direct influence on oligodendrocyte precursor cells (OPCs) and remyelination.", "tags": [{"end": 50, "start": 45, "tag": "Cell"}, {"end": 92, "start": 75, "tag": "BiologicFunction"}, {"end": 92, "start": 75, "tag": "PharmacologicSubstance"}, {"end": 18, "start": 6, "tag": "Finding"}, {"end": 177, "start": 173, "tag": "Cell"}, {"end": 171, "start": 140, "tag": "Cell"}, {"end": 196, "start": 183, "tag": "CellFunction"}, {"end": 92, "start": 80, "tag": "PathologicFunction"}, {"end": 99, "start": 93, "tag": "Finding"}]}{"id": "1249_6", "text": "In the present work, we reveal for the first time the relationship between OPCs and MDSCs in EAE, relationship that is guided by the distance from the inflammatory core.", "tags": [{"end": 89, "start": 84, "tag": "Cell"}, {"end": 96, "start": 93, "tag": "ExperimentalModelOfDisease"}, {"end": 66, "start": 54, "tag": "Finding"}, {"end": 110, "start": 98, "tag": "Finding"}, {"end": 44, "start": 39, "tag": "TemporalConcept"}, {"end": 79, "start": 75, "tag": "Cell"}, {"end": 49, "start": 45, "tag": "TemporalConcept"}, {"end": 163, "start": 151, "tag": "PathologicFunction"}]}{"id": "1249_7", "text": "We describe the effects of MDSCs on survival, proliferation, as well as potent promoters of OPC differentiation toward mature phenotypes.", "tags": [{"end": 32, "start": 27, "tag": "Cell"}, {"end": 136, "start": 126, "tag": "OrganismAttribute"}, {"end": 111, "start": 92, "tag": "CellFunction"}, {"end": 59, "start": 46, "tag": "CellFunction"}, {"end": 125, "start": 119, "tag": "TemporalConcept"}, {"end": 44, "start": 36, "tag": "CellFunction"}, {"end": 88, "start": 79, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1249_8", "text": "We show for the first time that osteopontin is remarkably present in the analyzed secretome of MDSCs.", "tags": [{"end": 43, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 95, "tag": "Cell"}, {"end": 21, "start": 16, "tag": "TemporalConcept"}, {"end": 81, "start": 73, "tag": "ResearchActivity"}, {"end": 26, "start": 22, "tag": "TemporalConcept"}, {"end": 91, "start": 82, "tag": "BiologicallyActiveSubstance"}]}{"id": "1249_9", "text": "The ablation of this cue from MDSCs-secretome demonstrates that osteopontin is the main MDSC effector on these oligodendroglial cells.", "tags": [{"end": 12, "start": 4, "tag": "HealthCareActivity"}, {"end": 75, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 88, "tag": "Cell"}, {"end": 133, "start": 111, "tag": "Cell"}, {"end": 35, "start": 30, "tag": "Cell"}, {"end": 45, "start": 36, "tag": "BiologicallyActiveSubstance"}]}{"id": "1249_10", "text": "These data highlight a crucial pathogenic interaction between innate immunity and the CNS, opening ways to develop MDSC- and/or osteopontin-based therapies to promote effective myelin preservation and repair in MS patients.", "tags": [{"end": 77, "start": 62, "tag": "OrganismAttribute"}, {"end": 196, "start": 184, "tag": "ResearchActivity"}, {"end": 183, "start": 177, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 222, "start": 214, "tag": "PatientOrDisabledGroup"}, {"end": 155, "start": 146, "tag": "HealthCareActivity"}, {"end": 213, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 201, "tag": "BiologicFunction"}, {"end": 207, "start": 201, "tag": "HealthCareActivity"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 41, "start": 31, "tag": "PathologicFunction"}, {"end": 53, "start": 42, "tag": "Finding"}, {"end": 119, "start": 115, "tag": "Cell"}, {"end": 139, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 128, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1250_0", "text": "The failure to remyelinate and regenerate is a critical impediment to recovery in multiple sclerosis (MS), resulting in severe dysfunction and disability.", "tags": [{"end": 126, "start": 120, "tag": "Finding"}, {"end": 100, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 15, "tag": "CellFunction"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 70, "tag": "BiologicFunction"}, {"end": 78, "start": 70, "tag": "HealthCareActivity"}, {"end": 78, "start": 70, "tag": "TemporalConcept"}, {"end": 138, "start": 127, "tag": "PathologicFunction"}, {"end": 153, "start": 143, "tag": "Finding"}, {"end": 11, "start": 4, "tag": "Finding"}]}{"id": "1250_1", "text": "The chondroitin sulfate proteoglycans (CSPGs) that accumulate in MS lesions are thought to be linked to the failure to regenerate, impeding oligodendrocyte precursor cell (OPC) differentiation and neuronal growth.", "tags": [{"end": 44, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 212, "start": 197, "tag": "BiologicFunction"}, {"end": 175, "start": 172, "tag": "Cell"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 68, "tag": "InjuryOrPoisoning"}, {"end": 192, "start": 177, "tag": "CellFunction"}, {"end": 37, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 140, "tag": "Cell"}, {"end": 115, "start": 108, "tag": "Finding"}, {"end": 37, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 4, "tag": "BiologicallyActiveSubstance"}]}{"id": "1250_2", "text": "The potential of endocannabinoids to influence MS progression may reflect their capacity to enhance repair processes.", "tags": [{"end": 33, "start": 17, "tag": "Chemical"}, {"end": 33, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 50, "tag": "PathologicFunction"}, {"end": 61, "start": 50, "tag": "TemporalConcept"}, {"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 100, "tag": "BiologicFunction"}, {"end": 106, "start": 100, "tag": "HealthCareActivity"}]}{"id": "1250_3", "text": "Here, we investigated how 2-arachidonoylglycerol (2-AG) may affect the production of the CSPGs neurocan and brevican by astrocytes in culture.", "tags": [{"end": 94, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 26, "tag": "Chemical"}, {"end": 48, "start": 26, "tag": "PharmacologicSubstance"}, {"end": 141, "start": 134, "tag": "ResearchActivity"}, {"end": 130, "start": 120, "tag": "Cell"}, {"end": 54, "start": 50, "tag": "Chemical"}, {"end": 54, "start": 50, "tag": "PharmacologicSubstance"}]}{"id": "1250_4", "text": "In addition, we studied whether 2-AG promotes oligodendrocyte differentiation under inhibitory conditions in vitro.", "tags": [{"end": 77, "start": 46, "tag": "CellFunction"}, {"end": 94, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 106, "tag": "ResearchActivity"}, {"end": 36, "start": 32, "tag": "Chemical"}, {"end": 36, "start": 32, "tag": "PharmacologicSubstance"}]}{"id": "1250_5", "text": "Following treatment with 2-AG or by enhancing its endogenous tone through the use of inhibitors of its hydrolytic enzymes, CSPG production by rat and human TGF-beta 1 stimulated astrocytes was reduced.", "tags": [{"end": 166, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 166, "start": 156, "tag": "PharmacologicSubstance"}, {"end": 166, "start": 156, "tag": "BiologicallyActiveSubstance"}, {"end": 177, "start": 167, "tag": "NaturalPhenomenonOrProcess"}, {"end": 121, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 142, "tag": "Eukaryote"}, {"end": 155, "start": 150, "tag": "Eukaryote"}, {"end": 188, "start": 178, "tag": "Cell"}, {"end": 19, "start": 10, "tag": "HealthCareActivity"}, {"end": 19, "start": 10, "tag": "ResearchActivity"}, {"end": 29, "start": 25, "tag": "PharmacologicSubstance"}, {"end": 29, "start": 25, "tag": "Chemical"}, {"end": 138, "start": 123, "tag": "CellFunction"}]}{"id": "1250_6", "text": "These effects of 2-AG might reflect its influence on TGF-beta 1/SMAD pathway, signaling that is involved in CSPG upregulation.", "tags": [{"end": 76, "start": 53, "tag": "CellFunction"}, {"end": 87, "start": 78, "tag": "CellFunction"}, {"end": 125, "start": 108, "tag": "CellFunction"}, {"end": 21, "start": 17, "tag": "Chemical"}, {"end": 21, "start": 17, "tag": "PharmacologicSubstance"}]}{"id": "1250_7", "text": "The matrix generated from 2-AG-treated astrocytes is less inhibitory to oligodendrocyte differentiation and significantly, 2-AG administration directly promotes the differentiation of rat and human oligodendrocytes cultured under inhibitory conditions.", "tags": [{"end": 10, "start": 4, "tag": "Finding"}, {"end": 223, "start": 215, "tag": "ResearchActivity"}, {"end": 214, "start": 198, "tag": "Cell"}, {"end": 87, "start": 72, "tag": "Cell"}, {"end": 103, "start": 88, "tag": "CellFunction"}, {"end": 180, "start": 165, "tag": "CellFunction"}, {"end": 68, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 240, "start": 230, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 184, "tag": "Eukaryote"}, {"end": 197, "start": 192, "tag": "Eukaryote"}, {"end": 49, "start": 39, "tag": "Cell"}, {"end": 127, "start": 123, "tag": "PharmacologicSubstance"}, {"end": 127, "start": 123, "tag": "Chemical"}, {"end": 30, "start": 26, "tag": "Chemical"}, {"end": 30, "start": 26, "tag": "PharmacologicSubstance"}]}{"id": "1250_8", "text": "Overall, the data obtained favor targeting the endocannabinoid system to neutralize CSPG accumulation and to enhance oligodendrocyte differentiation.", "tags": [{"end": 69, "start": 47, "tag": "CellFunction"}, {"end": 101, "start": 89, "tag": "Finding"}, {"end": 148, "start": 117, "tag": "CellFunction"}, {"end": 17, "start": 13, "tag": "ResearchActivity"}, {"end": 88, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 84, "tag": "BiologicallyActiveSubstance"}]}{"id": "1251_0", "text": "Background Vitamin D deficiency increases the risk of developing multiple sclerosis (MS) but it is unclear whether vitamin D supplementation improves the clinical course of MS, and there is uncertainty about the dose and form of vitamin D (D2 or D3) to be used.", "tags": [{"end": 31, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 125, "tag": "HealthCareActivity"}, {"end": 201, "start": 190, "tag": "Finding"}, {"end": 242, "start": 240, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 154, "tag": "TemporalConcept"}, {"end": 31, "start": 21, "tag": "Finding"}, {"end": 124, "start": 115, "tag": "BiologicallyActiveSubstance"}, {"end": 238, "start": 229, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 163, "tag": "TemporalConcept"}, {"end": 83, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 46, "tag": "Finding"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 248, "start": 246, "tag": "BiologicallyActiveSubstance"}]}{"id": "1251_1", "text": "The mechanisms underlying the effects of vitamin D in MS are not clear.", "tags": [{"end": 50, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 30, "tag": "Finding"}]}{"id": "1251_2", "text": "Vitamin D3 increases the rate of differentiation of primary oligodendrocyte precursor cells (OPCs), suggesting that it might help remyelination in addition to modulating the immune response.", "tags": [{"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 174, "tag": "BiologicFunction"}, {"end": 91, "start": 52, "tag": "Cell"}, {"end": 97, "start": 93, "tag": "Cell"}, {"end": 91, "start": 60, "tag": "Cell"}, {"end": 29, "start": 25, "tag": "TemporalConcept"}, {"end": 48, "start": 33, "tag": "CellFunction"}, {"end": 91, "start": 76, "tag": "Cell"}, {"end": 85, "start": 60, "tag": "Cell"}, {"end": 143, "start": 130, "tag": "CellFunction"}]}{"id": "1251_3", "text": "Here we analyzed the transcriptome of differentiating rat CG4 OPCs treated with vitamin D2 or with vitamin D3 at 24 h and 72 h following onset of differentiation.", "tags": [{"end": 90, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 34, "start": 21, "tag": "MolecularSequence"}, {"end": 66, "start": 58, "tag": "Cell"}, {"end": 161, "start": 146, "tag": "CellFunction"}, {"end": 57, "start": 54, "tag": "Eukaryote"}, {"end": 142, "start": 137, "tag": "TemporalConcept"}, {"end": 16, "start": 8, "tag": "ResearchActivity"}, {"end": 117, "start": 113, "tag": "TemporalConcept"}, {"end": 126, "start": 122, "tag": "TemporalConcept"}]}{"id": "1251_4", "text": "Methods Gene expression in differentiating CG4 cells in response to vitamin D2 or D3 was quantified using Agilent DNA microarrays (n = 4 replicates), and the transcriptome data were processed and analysed using the R software environment.", "tags": [{"end": 23, "start": 8, "tag": "CellFunction"}, {"end": 78, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 106, "tag": "ManufacturedObject"}, {"end": 171, "start": 158, "tag": "MolecularSequence"}, {"end": 52, "start": 43, "tag": "Cell"}, {"end": 176, "start": 172, "tag": "ResearchActivity"}, {"end": 117, "start": 114, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 84, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 237, "start": 215, "tag": "ManufacturedObject"}]}{"id": "1251_5", "text": "Differential expression between the experimental conditions was determined using LIMMA, applying the Benjamini and Hochberg multiple testing correction to p-values, and significant genes were grouped into co-expression clusters by hierarchical clustering.", "tags": [{"end": 254, "start": 231, "tag": "ResearchActivity"}, {"end": 218, "start": 205, "tag": "CellFunction"}, {"end": 218, "start": 208, "tag": "CellFunction"}, {"end": 151, "start": 101, "tag": "ResearchActivity"}, {"end": 163, "start": 155, "tag": "ResearchActivity"}, {"end": 86, "start": 81, "tag": "ResearchActivity"}, {"end": 23, "start": 0, "tag": "ResearchActivity"}, {"end": 59, "start": 36, "tag": "ResearchActivity"}]}{"id": "1251_6", "text": "The functional significance of gene groups was explored by pathway enrichment analysis using the clusterProfiler package.", "tags": [{"end": 86, "start": 59, "tag": "ResearchActivity"}, {"end": 35, "start": 31, "tag": "GeneOrGenome"}, {"end": 120, "start": 97, "tag": "ResearchActivity"}]}{"id": "1251_7", "text": "Results Differentiation alone changed the expression of about 10% of the genes at 72 h compared to 24 h.", "tags": [{"end": 23, "start": 8, "tag": "CellFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 52, "start": 42, "tag": "CellFunction"}, {"end": 86, "start": 82, "tag": "TemporalConcept"}, {"end": 103, "start": 99, "tag": "TemporalConcept"}]}{"id": "1251_8", "text": "Vitamin D2 and D3 exerted different effects on gene expression, with D3 influencing 1272 genes and D2 574 at 24 h.", "tags": [{"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 99, "tag": "GeneOrGenome"}, {"end": 62, "start": 47, "tag": "CellFunction"}, {"end": 62, "start": 52, "tag": "CellFunction"}, {"end": 43, "start": 36, "tag": "Finding"}, {"end": 51, "start": 47, "tag": "GeneOrGenome"}, {"end": 113, "start": 109, "tag": "TemporalConcept"}, {"end": 17, "start": 15, "tag": "BiologicallyActiveSubstance"}]}{"id": "1251_9", "text": "The expression of the vast majority of these genes was either not changed in differentiating cells not exposed to vitamin D or followed the same trajectory as the latter.", "tags": [{"end": 123, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 93, "tag": "Cell"}, {"end": 14, "start": 4, "tag": "CellFunction"}]}{"id": "1251_10", "text": "D3-repressed genes were enriched for Gene Ontology (GO) categories including transcription factors and the Notch pathway, while D3-induced genes were enriched for the Ras pathway.", "tags": [{"end": 178, "start": 167, "tag": "CellFunction"}, {"end": 98, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 52, "tag": "ResearchActivity"}, {"end": 112, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 107, "tag": "CellFunction"}, {"end": 120, "start": 113, "tag": "CellFunction"}, {"end": 50, "start": 37, "tag": "ResearchActivity"}, {"end": 130, "start": 128, "tag": "BiologicallyActiveSubstance"}]}{"id": "1251_11", "text": "Conclusions This study shows that vitamin D3, compared with D2, changes the expression of a larger number of genes in OLs.", "tags": [{"end": 44, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 118, "tag": "Cell"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}, {"end": 86, "start": 76, "tag": "CellFunction"}]}{"id": "1251_12", "text": "Identification of genes affected by D3 in OLs should help to identify mechanisms mediating its action in MS.", "tags": [{"end": 14, "start": 0, "tag": "ResearchActivity"}, {"end": 45, "start": 42, "tag": "Cell"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 36, "tag": "BiologicallyActiveSubstance"}]}{"id": "1252_0", "text": "Chronic disability in multiple sclerosis is linked to neuroaxonal degeneration.", "tags": [{"end": 78, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 66, "tag": "PathologicFunction"}, {"end": 18, "start": 8, "tag": "Finding"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}]}{"id": "1252_1", "text": "4-aminopyridine (4-AP) is used and licensed as a symptomatic treatment to ameliorate ambulatory disability in multiple sclerosis.", "tags": [{"end": 15, "start": 0, "tag": "Chemical"}, {"end": 21, "start": 17, "tag": "Chemical"}, {"end": 70, "start": 49, "tag": "HealthCareActivity"}, {"end": 128, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 61, "tag": "HealthCareActivity"}, {"end": 70, "start": 61, "tag": "ResearchActivity"}, {"end": 60, "start": 49, "tag": "SignOrSymptom"}, {"end": 106, "start": 85, "tag": "Finding"}, {"end": 15, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "1252_2", "text": "The presumed mode of action is via blockade of axonal voltage gated potassium channels, thereby enhancing conduction in demyelinated axons.", "tags": [{"end": 86, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 133, "tag": "CellComponent"}, {"end": 132, "start": 120, "tag": "PathologicFunction"}, {"end": 53, "start": 47, "tag": "CellComponent"}, {"end": 116, "start": 106, "tag": "NaturalPhenomenonOrProcess"}, {"end": 43, "start": 35, "tag": "PharmacologicSubstance"}, {"end": 43, "start": 35, "tag": "HealthCareActivity"}, {"end": 116, "start": 106, "tag": "BiologicFunction"}, {"end": 86, "start": 54, "tag": "BiologicallyActiveSubstance"}]}{"id": "1252_3", "text": "In this study, we provide evidence that in addition to those symptomatic effects, 4-AP can prevent neuroaxonal loss in the CNS.", "tags": [{"end": 86, "start": 82, "tag": "Chemical"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 126, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 26, "tag": "Finding"}, {"end": 80, "start": 73, "tag": "Finding"}, {"end": 72, "start": 61, "tag": "SignOrSymptom"}, {"end": 86, "start": 82, "tag": "PharmacologicSubstance"}, {"end": 115, "start": 99, "tag": "PathologicFunction"}]}{"id": "1252_4", "text": "Using in vivo optical coherence tomography imaging, visual function testing and histologic assessment, we observed a reduction in retinal neurodegeneration with 4-AP in models of experimental optic neuritis and optic nerve crush.", "tags": [{"end": 50, "start": 14, "tag": "HealthCareActivity"}, {"end": 67, "start": 52, "tag": "BiologicFunction"}, {"end": 165, "start": 161, "tag": "Chemical"}, {"end": 228, "start": 211, "tag": "PathologicFunction"}, {"end": 75, "start": 68, "tag": "HealthCareActivity"}, {"end": 206, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 222, "start": 211, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 14, "tag": "HealthCareActivity"}, {"end": 137, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 43, "tag": "HealthCareActivity"}, {"end": 175, "start": 169, "tag": "ResearchActivity"}, {"end": 155, "start": 138, "tag": "CellOrMolecularDysfunction"}, {"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 126, "start": 117, "tag": "Finding"}, {"end": 126, "start": 117, "tag": "NaturalPhenomenonOrProcess"}, {"end": 191, "start": 179, "tag": "ResearchActivity"}, {"end": 101, "start": 80, "tag": "ResearchActivity"}, {"end": 165, "start": 161, "tag": "PharmacologicSubstance"}, {"end": 206, "start": 169, "tag": "ExperimentalModelOfDisease"}]}{"id": "1252_5", "text": "These effects were not related to an anti-inflammatory mode of action or a direct impact on retinal ganglion cells.", "tags": [{"end": 114, "start": 92, "tag": "Cell"}, {"end": 99, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 42, "tag": "PathologicFunction"}, {"end": 13, "start": 6, "tag": "Finding"}, {"end": 54, "start": 37, "tag": "BiologicFunction"}, {"end": 54, "start": 37, "tag": "PharmacologicSubstance"}]}{"id": "1252_6", "text": "Rather, histology and in vitro experiments indicated 4-AP stabilization of myelin and oligodendrocyte precursor cells associated with increased nuclear translocation of the nuclear factor of activated T cells.", "tags": [{"end": 57, "start": 53, "tag": "Chemical"}, {"end": 71, "start": 58, "tag": "HealthCareActivity"}, {"end": 71, "start": 58, "tag": "CellFunction"}, {"end": 208, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 208, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 31, "tag": "ResearchActivity"}, {"end": 17, "start": 8, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 17, "start": 8, "tag": "ResearchActivity"}, {"end": 117, "start": 86, "tag": "Cell"}, {"end": 81, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 165, "start": 144, "tag": "CellFunction"}, {"end": 117, "start": 102, "tag": "Cell"}, {"end": 111, "start": 86, "tag": "Cell"}, {"end": 30, "start": 22, "tag": "ResearchActivity"}, {"end": 57, "start": 53, "tag": "PharmacologicSubstance"}]}{"id": "1252_7", "text": "In experimental optic neuritis, 4-AP potentiated the effects of immunomodulatory treatment with fingolimod.", "tags": [{"end": 36, "start": 32, "tag": "Chemical"}, {"end": 106, "start": 96, "tag": "Chemical"}, {"end": 106, "start": 96, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 81, "tag": "HealthCareActivity"}, {"end": 90, "start": 81, "tag": "ResearchActivity"}, {"end": 60, "start": 53, "tag": "Finding"}, {"end": 80, "start": 64, "tag": "PharmacologicSubstance"}, {"end": 80, "start": 64, "tag": "BiologicFunction"}, {"end": 80, "start": 64, "tag": "HealthCareActivity"}, {"end": 36, "start": 32, "tag": "PharmacologicSubstance"}, {"end": 30, "start": 3, "tag": "ExperimentalModelOfDisease"}]}{"id": "1252_8", "text": "As extended release 4-AP is already licensed for symptomatic multiple sclerosis treatment, we performed a retrospective, multicentre optical coherence tomography study to longitudinally compare retinal neurodegeneration between 52 patients on continuous 4-AP therapy and 51 matched controls.", "tags": [{"end": 24, "start": 20, "tag": "Chemical"}, {"end": 119, "start": 106, "tag": "ResearchActivity"}, {"end": 258, "start": 254, "tag": "Chemical"}, {"end": 253, "start": 243, "tag": "TemporalConcept"}, {"end": 161, "start": 133, "tag": "HealthCareActivity"}, {"end": 201, "start": 194, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 239, "start": 231, "tag": "PatientOrDisabledGroup"}, {"end": 167, "start": 162, "tag": "ResearchActivity"}, {"end": 290, "start": 282, "tag": "PopulationGroup"}, {"end": 89, "start": 80, "tag": "HealthCareActivity"}, {"end": 60, "start": 49, "tag": "HealthCareActivity"}, {"end": 219, "start": 202, "tag": "CellOrMolecularDysfunction"}, {"end": 266, "start": 259, "tag": "HealthCareActivity"}, {"end": 24, "start": 20, "tag": "PharmacologicSubstance"}, {"end": 258, "start": 254, "tag": "PharmacologicSubstance"}]}{"id": "1252_9", "text": "In line with the experimental data, during concurrent 4-AP therapy, degeneration of the macular retinal nerve fibre layer was reduced over 2 years.", "tags": [{"end": 58, "start": 54, "tag": "Chemical"}, {"end": 53, "start": 43, "tag": "TemporalConcept"}, {"end": 121, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 68, "tag": "PathologicFunction"}, {"end": 146, "start": 141, "tag": "TemporalConcept"}, {"end": 66, "start": 59, "tag": "HealthCareActivity"}, {"end": 34, "start": 17, "tag": "ResearchActivity"}, {"end": 58, "start": 54, "tag": "PharmacologicSubstance"}]}{"id": "1252_10", "text": "These results indicate disease-modifying effects of 4-AP beyond symptomatic therapy and provide support for the design of a prospective clinical study using visual function and retinal structure as outcome parameters.", "tags": [{"end": 56, "start": 52, "tag": "Chemical"}, {"end": 150, "start": 124, "tag": "ResearchActivity"}, {"end": 172, "start": 157, "tag": "BiologicFunction"}, {"end": 205, "start": 198, "tag": "Finding"}, {"end": 118, "start": 112, "tag": "ResearchActivity"}, {"end": 118, "start": 112, "tag": "HealthCareActivity"}, {"end": 184, "start": 177, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 64, "tag": "HealthCareActivity"}, {"end": 48, "start": 41, "tag": "Finding"}, {"end": 56, "start": 52, "tag": "PharmacologicSubstance"}, {"end": 216, "start": 206, "tag": "ResearchActivity"}]}{"id": "1253_0", "text": "Background: Inefficient differentiation of oligodendrocyte precursor cells (OPCs) is one of the significant pathological obstacles of myelin repair and provides an essential therapeutic target against behavioral dysfunction in various neurodegenerative diseases, especially in secondary progressive multiple sclerosis (SPMS).", "tags": [{"end": 323, "start": 319, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 76, "tag": "Cell"}, {"end": 74, "start": 43, "tag": "Cell"}, {"end": 317, "start": 277, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 24, "tag": "CellFunction"}, {"end": 74, "start": 59, "tag": "Cell"}, {"end": 68, "start": 43, "tag": "Cell"}, {"end": 147, "start": 134, "tag": "CellFunction"}, {"end": 261, "start": 235, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 201, "tag": "PathologicFunction"}, {"end": 192, "start": 164, "tag": "Finding"}]}{"id": "1253_1", "text": "Ginsenoside Rg1 (Rg1) has traditionally been recognized as a protector of neuronal damages, preventing its degeneration.", "tags": [{"end": 15, "start": 0, "tag": "Chemical"}, {"end": 119, "start": 107, "tag": "PathologicFunction"}, {"end": 82, "start": 74, "tag": "Cell"}, {"end": 90, "start": 74, "tag": "InjuryOrPoisoning"}, {"end": 20, "start": 17, "tag": "Chemical"}]}{"id": "1253_2", "text": "Purpose: We investigated the effects of Rg1 on myelin regeneration-mediated by OPCs and its therapeutic significance in SPMS.", "tags": [{"end": 124, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 79, "tag": "Cell"}, {"end": 66, "start": 47, "tag": "CellFunction"}, {"end": 36, "start": 29, "tag": "Finding"}, {"end": 43, "start": 40, "tag": "Chemical"}, {"end": 116, "start": 92, "tag": "Finding"}]}{"id": "1253_3", "text": "Methods: A cuprizone (CPZ) model was established and then administered with Rg1 specific for evaluations of functional recovery and remyelination.", "tags": [{"end": 25, "start": 22, "tag": "Chemical"}, {"end": 20, "start": 11, "tag": "Chemical"}, {"end": 32, "start": 27, "tag": "ResearchActivity"}, {"end": 127, "start": 108, "tag": "BiologicFunction"}, {"end": 145, "start": 132, "tag": "CellFunction"}, {"end": 79, "start": 76, "tag": "Chemical"}]}{"id": "1253_4", "text": "In vitro, the primary mouse OPCs were isolated and cultured for examining their ability of myelin repair.", "tags": [{"end": 73, "start": 64, "tag": "Finding"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 32, "start": 28, "tag": "Cell"}, {"end": 21, "start": 14, "tag": "Cell"}, {"end": 104, "start": 91, "tag": "CellFunction"}, {"end": 27, "start": 22, "tag": "Eukaryote"}, {"end": 59, "start": 51, "tag": "ResearchActivity"}, {"end": 87, "start": 80, "tag": "OrganismAttribute"}]}{"id": "1253_5", "text": "Furthermore, a chronic experimental autoimmune encephalomyelitis (EAE) model was utilized to assess the therapeutic value on SPMS.", "tags": [{"end": 64, "start": 23, "tag": "ExperimentalModelOfDisease"}, {"end": 69, "start": 66, "tag": "ExperimentalModelOfDisease"}, {"end": 129, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 71, "tag": "ResearchActivity"}, {"end": 22, "start": 15, "tag": "TemporalConcept"}]}{"id": "1253_6", "text": "Results: We found that Rg1 promoted functional recovery of the demyelinated mice, including spatial memory, motor function, and anxiety-like behavior.", "tags": [{"end": 106, "start": 92, "tag": "BiologicFunction"}, {"end": 149, "start": 141, "tag": "BiologicFunction"}, {"end": 149, "start": 141, "tag": "IndividualBehavior"}, {"end": 149, "start": 141, "tag": "ResearchActivity"}, {"end": 75, "start": 63, "tag": "PathologicFunction"}, {"end": 122, "start": 108, "tag": "BiologicFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 80, "start": 76, "tag": "Eukaryote"}, {"end": 55, "start": 36, "tag": "BiologicFunction"}, {"end": 135, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 23, "tag": "Chemical"}, {"end": 80, "start": 63, "tag": "ExperimentalModelOfDisease"}]}{"id": "1253_7", "text": "Histologically, Rg1 enhanced myelin-genesis as proven by myelin staining and microstructures of myelin observed by transmission electron microscope.", "tags": [{"end": 147, "start": 115, "tag": "ResearchActivity"}, {"end": 35, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 16, "tag": "Chemical"}, {"end": 72, "start": 64, "tag": "ResearchActivity"}]}{"id": "1253_8", "text": "Furthermore, Rg1 significantly increased Olig2+ oligodendrocyte lineage cells in callosum, implying that the pro-remyelination effect of Rg1 was closely correlated to the enhanced differentiation of OPCs.", "tags": [{"end": 46, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 41, "tag": "GeneOrGenome"}, {"end": 203, "start": 199, "tag": "Cell"}, {"end": 77, "start": 48, "tag": "Cell"}, {"end": 195, "start": 180, "tag": "CellFunction"}, {"end": 71, "start": 48, "tag": "Cell"}, {"end": 133, "start": 127, "tag": "Finding"}, {"end": 40, "start": 17, "tag": "Finding"}, {"end": 126, "start": 113, "tag": "CellFunction"}, {"end": 16, "start": 13, "tag": "Chemical"}, {"end": 46, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 137, "tag": "Chemical"}]}{"id": "1253_9", "text": "We further demonstrated that Rg1 increased the survival and proliferation of OPCs as well as induced maturation in oligodendrocytes (OLs).", "tags": [{"end": 131, "start": 115, "tag": "Cell"}, {"end": 81, "start": 77, "tag": "Cell"}, {"end": 111, "start": 101, "tag": "BiologicFunction"}, {"end": 136, "start": 133, "tag": "Cell"}, {"end": 73, "start": 60, "tag": "CellFunction"}, {"end": 55, "start": 47, "tag": "CellFunction"}, {"end": 32, "start": 29, "tag": "Chemical"}]}{"id": "1253_10", "text": "Molecular analysis showed that Rg1 transduced the pro-differentiation signaling programmed by the GSK3 beta/ beta-Catenin pathway.", "tags": [{"end": 18, "start": 0, "tag": "ResearchActivity"}, {"end": 107, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 70, "tag": "CellFunction"}, {"end": 69, "start": 54, "tag": "CellFunction"}, {"end": 129, "start": 98, "tag": "CellFunction"}, {"end": 34, "start": 31, "tag": "Chemical"}, {"end": 107, "start": 98, "tag": "BiologicallyActiveSubstance"}]}{"id": "1253_11", "text": "Notably, relying on its pro-remyelination effects, Rg1 ameliorated severity and histopathology of EAE disease.", "tags": [{"end": 94, "start": 80, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 94, "start": 80, "tag": "ClinicalAttribute"}, {"end": 101, "start": 98, "tag": "ExperimentalModelOfDisease"}, {"end": 75, "start": 67, "tag": "ClinicalAttribute"}, {"end": 75, "start": 67, "tag": "Finding"}, {"end": 41, "start": 28, "tag": "CellFunction"}, {"end": 49, "start": 42, "tag": "Finding"}, {"end": 54, "start": 51, "tag": "Chemical"}]}{"id": "1253_12", "text": "Conclusion: By paving the way for OPCs differentiation, Rg1 could maintain the integrity of myelin and is a promising candidate for functional recovery in demyelinating diseases.", "tags": [{"end": 38, "start": 34, "tag": "Cell"}, {"end": 177, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 155, "tag": "PathologicFunction"}, {"end": 98, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 39, "tag": "CellFunction"}, {"end": 88, "start": 79, "tag": "IndividualBehavior"}, {"end": 151, "start": 132, "tag": "BiologicFunction"}, {"end": 59, "start": 56, "tag": "Chemical"}]}{"id": "1254_0", "text": "Accumulating evidences suggest a strong correlation between metabolic changes and neurodegeneration in CNS demyelinating diseases such as multiple sclerosis (MS).", "tags": [{"end": 69, "start": 60, "tag": "CellFunction"}, {"end": 129, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 13, "tag": "Finding"}, {"end": 156, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 82, "tag": "CellOrMolecularDysfunction"}, {"end": 160, "start": 158, "tag": "DiseaseOrSyndrome"}]}{"id": "1254_1", "text": "Biotin, an essential cofactor for five carboxylases, is expressed by oligodendrocytes and involved in fatty acid synthesis and energy production.", "tags": [{"end": 6, "start": 0, "tag": "Chemical"}, {"end": 6, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 51, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 102, "tag": "CellFunction"}, {"end": 29, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 69, "tag": "Cell"}, {"end": 133, "start": 127, "tag": "NaturalPhenomenonOrProcess"}, {"end": 65, "start": 56, "tag": "CellFunction"}, {"end": 6, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 127, "tag": "CellFunction"}]}{"id": "1254_2", "text": "The metabolic effect of biotin or high-dose-biotin (MD1003) has been reported on rodent oligodendrocytes in vitro, and in neurodegenerative or demyelinating animal models.", "tags": [{"end": 13, "start": 4, "tag": "CellFunction"}, {"end": 30, "start": 24, "tag": "Chemical"}, {"end": 30, "start": 24, "tag": "PharmacologicSubstance"}, {"end": 87, "start": 81, "tag": "Eukaryote"}, {"end": 104, "start": 88, "tag": "Cell"}, {"end": 113, "start": 105, "tag": "ResearchActivity"}, {"end": 30, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 34, "tag": "PharmacologicSubstance"}, {"end": 58, "start": 52, "tag": "PharmacologicSubstance"}, {"end": 170, "start": 122, "tag": "ExperimentalModelOfDisease"}]}{"id": "1254_3", "text": "However, clinical studies, showed mild or no beneficial effect of MD1003 in amyotrophic lateral sclerosis (ALS) or MS.", "tags": [{"end": 38, "start": 34, "tag": "Finding"}, {"end": 25, "start": 9, "tag": "ResearchActivity"}, {"end": 110, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 42, "tag": "Finding"}, {"end": 72, "start": 66, "tag": "PharmacologicSubstance"}]}{"id": "1254_4", "text": "Here, we took advantage of a mouse model of myelin deficiency to study the effects of MD1003 on the behavior of murine and grafted human oligodendrocytes in vivo.", "tags": [{"end": 118, "start": 112, "tag": "Eukaryote"}, {"end": 61, "start": 51, "tag": "Finding"}, {"end": 108, "start": 100, "tag": "BiologicFunction"}, {"end": 108, "start": 100, "tag": "IndividualBehavior"}, {"end": 108, "start": 100, "tag": "ResearchActivity"}, {"end": 153, "start": 137, "tag": "Cell"}, {"end": 161, "start": 154, "tag": "ResearchActivity"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 29, "tag": "Eukaryote"}, {"end": 136, "start": 131, "tag": "Eukaryote"}, {"end": 70, "start": 65, "tag": "ResearchActivity"}, {"end": 40, "start": 35, "tag": "ResearchActivity"}, {"end": 92, "start": 86, "tag": "PharmacologicSubstance"}]}{"id": "1254_5", "text": "We show that MD1003 increases the number and the differentiation potential of endogenous murine oligodendroglia over time.", "tags": [{"end": 95, "start": 89, "tag": "Eukaryote"}, {"end": 64, "start": 49, "tag": "CellFunction"}, {"end": 121, "start": 117, "tag": "TemporalConcept"}, {"end": 111, "start": 96, "tag": "Cell"}, {"end": 19, "start": 13, "tag": "PharmacologicSubstance"}]}{"id": "1254_6", "text": "Moreover, the levels of MD1003 are increased in the plasma and brain of pups born to treated mothers, indicating that MD1003 can pass through the mother's milk.", "tags": [{"end": 81, "start": 77, "tag": "BiologicFunction"}, {"end": 100, "start": 93, "tag": "PopulationGroup"}, {"end": 159, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 155, "tag": "Substance"}, {"end": 58, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 24, "tag": "PharmacologicSubstance"}, {"end": 76, "start": 72, "tag": "Eukaryote"}, {"end": 124, "start": 118, "tag": "PharmacologicSubstance"}, {"end": 152, "start": 146, "tag": "PopulationGroup"}]}{"id": "1254_7", "text": "The histological analysis of the grafted animals shows that MD1003 increased proliferation and accelerates differentiation of human oligodendroglia, but without enhancing their myelination potential.", "tags": [{"end": 48, "start": 41, "tag": "Eukaryote"}, {"end": 188, "start": 177, "tag": "CellFunction"}, {"end": 122, "start": 107, "tag": "CellFunction"}, {"end": 90, "start": 77, "tag": "CellFunction"}, {"end": 147, "start": 132, "tag": "Cell"}, {"end": 131, "start": 126, "tag": "Eukaryote"}, {"end": 25, "start": 4, "tag": "ResearchActivity"}, {"end": 66, "start": 60, "tag": "PharmacologicSubstance"}]}{"id": "1254_8", "text": "These findings provide important insights into the role of MD1003 on murine and human oligodendrocyte maturation/myelination that may explain the mitigated outcome of ALS/MS clinical trials.", "tags": [{"end": 75, "start": 69, "tag": "Eukaryote"}, {"end": 163, "start": 156, "tag": "Finding"}, {"end": 170, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 189, "start": 174, "tag": "ResearchActivity"}, {"end": 124, "start": 113, "tag": "CellFunction"}, {"end": 101, "start": 86, "tag": "Cell"}, {"end": 112, "start": 102, "tag": "BiologicFunction"}, {"end": 173, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 80, "tag": "Eukaryote"}, {"end": 65, "start": 59, "tag": "PharmacologicSubstance"}]}{"id": "1255_0", "text": "Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of central nervous system (CNS).", "tags": [{"end": 49, "start": 37, "tag": "PathologicFunction"}, {"end": 100, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 29, "tag": "TemporalConcept"}]}{"id": "1255_1", "text": "Aging is the most significant risk factor for the progression of MS.", "tags": [{"end": 41, "start": 30, "tag": "Finding"}, {"end": 61, "start": 50, "tag": "PathologicFunction"}, {"end": 61, "start": 50, "tag": "TemporalConcept"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 5, "start": 0, "tag": "BiologicFunction"}]}{"id": "1255_2", "text": "Dietary modulation (such as ketogenic diet) and caloric restriction, can increase ketone bodies, especially beta-hydroxybutyrate (BHB).", "tags": [{"end": 42, "start": 28, "tag": "HealthCareActivity"}, {"end": 67, "start": 48, "tag": "HealthCareActivity"}, {"end": 67, "start": 48, "tag": "Finding"}, {"end": 95, "start": 82, "tag": "Chemical"}, {"end": 128, "start": 108, "tag": "Chemical"}, {"end": 133, "start": 130, "tag": "Chemical"}, {"end": 42, "start": 38, "tag": "HealthCareActivity"}, {"end": 18, "start": 0, "tag": "HealthCareActivity"}]}{"id": "1255_3", "text": "Increased BHB has been reported to prevent or improve age-related disease.", "tags": [{"end": 9, "start": 0, "tag": "Finding"}, {"end": 13, "start": 10, "tag": "Chemical"}, {"end": 53, "start": 46, "tag": "Finding"}, {"end": 57, "start": 54, "tag": "OrganismAttribute"}, {"end": 73, "start": 54, "tag": "DiseaseOrSyndrome"}]}{"id": "1255_4", "text": "The present studies were performed to understand the therapeutic effect and potential mechanisms of exogenous BHB in cuprizone (CPZ)-induced demyelinating model.", "tags": [{"end": 113, "start": 110, "tag": "Chemical"}, {"end": 131, "start": 128, "tag": "Chemical"}, {"end": 154, "start": 141, "tag": "PathologicFunction"}, {"end": 126, "start": 117, "tag": "Chemical"}, {"end": 160, "start": 155, "tag": "ResearchActivity"}, {"end": 71, "start": 53, "tag": "Finding"}, {"end": 19, "start": 12, "tag": "ResearchActivity"}, {"end": 160, "start": 127, "tag": "ExperimentalModelOfDisease"}]}{"id": "1255_5", "text": "In this study, a continuous 35 days CPZ mouse model with or without BHB was established.", "tags": [{"end": 71, "start": 68, "tag": "Chemical"}, {"end": 39, "start": 36, "tag": "Chemical"}, {"end": 27, "start": 17, "tag": "TemporalConcept"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 51, "start": 40, "tag": "ResearchActivity"}, {"end": 35, "start": 31, "tag": "TemporalConcept"}]}{"id": "1255_6", "text": "The changes of behavior function, pathological hallmarks of CPZ, and intracellular signal pathways in mice were detected by Open feld test, Morris water maze, RT-PCR, immuno-histochemistry, and western blot.", "tags": [{"end": 82, "start": 69, "tag": "CellComponent"}, {"end": 165, "start": 159, "tag": "ResearchActivity"}, {"end": 63, "start": 60, "tag": "Chemical"}, {"end": 56, "start": 47, "tag": "Finding"}, {"end": 23, "start": 15, "tag": "BiologicFunction"}, {"end": 23, "start": 15, "tag": "IndividualBehavior"}, {"end": 23, "start": 15, "tag": "ResearchActivity"}, {"end": 206, "start": 194, "tag": "ResearchActivity"}, {"end": 106, "start": 102, "tag": "Eukaryote"}, {"end": 98, "start": 83, "tag": "CellFunction"}, {"end": 138, "start": 124, "tag": "ResearchActivity"}, {"end": 157, "start": 140, "tag": "ResearchActivity"}, {"end": 188, "start": 167, "tag": "ResearchActivity"}]}{"id": "1255_7", "text": "The results showed that BHB treatment improved behavioral performance, prevented myelin loss, decreased the activation of astrocyte as well as microglia, and up-regulated the neurotrophin brain-derived neurotrophic factor in both the corpus callosum and hippocampus.", "tags": [{"end": 27, "start": 24, "tag": "Chemical"}, {"end": 170, "start": 158, "tag": "CellFunction"}, {"end": 187, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 187, "start": 175, "tag": "BiologicallyActiveSubstance"}, {"end": 221, "start": 188, "tag": "AminoAcidPeptideOrProtein"}, {"end": 221, "start": 188, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 38, "tag": "Finding"}, {"end": 87, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 249, "start": 234, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 28, "tag": "HealthCareActivity"}, {"end": 37, "start": 28, "tag": "ResearchActivity"}, {"end": 152, "start": 143, "tag": "Cell"}, {"end": 131, "start": 122, "tag": "Cell"}, {"end": 265, "start": 254, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 94, "tag": "Finding"}, {"end": 69, "start": 47, "tag": "ClinicalAttribute"}, {"end": 92, "start": 81, "tag": "CellOrMolecularDysfunction"}, {"end": 118, "start": 108, "tag": "CellFunction"}]}{"id": "1255_8", "text": "Meanwhile, BHB treatment increased the number of MCT1(+) cells and APC(+) oligodendrocytes.", "tags": [{"end": 14, "start": 11, "tag": "Chemical"}, {"end": 90, "start": 74, "tag": "Cell"}, {"end": 62, "start": 57, "tag": "Cell"}, {"end": 24, "start": 15, "tag": "HealthCareActivity"}, {"end": 24, "start": 15, "tag": "ResearchActivity"}, {"end": 53, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}]}{"id": "1255_9", "text": "Furthermore, the treatment decreased the expression of HDAC3, PARP1, AIF and TRPA1 which is related to oligodendrocyte (OL) apoptosis in the corpus callosum, accompanied by increased expression of TrkB.", "tags": [{"end": 60, "start": 55, "tag": "GeneOrGenome"}, {"end": 60, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 62, "tag": "GeneOrGenome"}, {"end": 67, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 69, "tag": "GeneOrGenome"}, {"end": 82, "start": 77, "tag": "GeneOrGenome"}, {"end": 82, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 197, "tag": "GeneOrGenome"}, {"end": 201, "start": 197, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 197, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 120, "tag": "Cell"}, {"end": 156, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 17, "tag": "HealthCareActivity"}, {"end": 26, "start": 17, "tag": "ResearchActivity"}, {"end": 51, "start": 41, "tag": "CellFunction"}, {"end": 193, "start": 183, "tag": "CellFunction"}, {"end": 133, "start": 124, "tag": "CellFunction"}, {"end": 36, "start": 27, "tag": "Finding"}, {"end": 118, "start": 103, "tag": "Cell"}, {"end": 82, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 69, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1255_10", "text": "This leads to an increased density of doublecortin (DCX)(+) neuronal precursor cells and mature NeuN(+) neuronal cells in the hippocampus.", "tags": [{"end": 50, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 89, "tag": "TemporalConcept"}, {"end": 84, "start": 69, "tag": "Cell"}, {"end": 34, "start": 17, "tag": "Finding"}, {"end": 118, "start": 104, "tag": "Cell"}, {"end": 68, "start": 60, "tag": "Cell"}, {"end": 112, "start": 104, "tag": "Cell"}, {"end": 137, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 52, "tag": "GeneOrGenome"}]}{"id": "1255_11", "text": "As a result, BHB treatment effectively promotes the generation of PDGF-Ra+ (oligodendrocyte precursor cells, OPCs), Sox2(+) cells and GFAP(+) (astrocytes), and decreased the production of GFAP(+) TRAP1(+) cells, and Oligo2(+) TRAP1(+) cells in the corpus callosum of mouse brain.", "tags": [{"end": 16, "start": 13, "tag": "Chemical"}, {"end": 113, "start": 109, "tag": "Cell"}, {"end": 107, "start": 76, "tag": "Cell"}, {"end": 107, "start": 92, "tag": "Cell"}, {"end": 101, "start": 76, "tag": "Cell"}, {"end": 263, "start": 248, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 278, "start": 273, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 124, "tag": "Cell"}, {"end": 210, "start": 205, "tag": "Cell"}, {"end": 240, "start": 235, "tag": "Cell"}, {"end": 26, "start": 17, "tag": "HealthCareActivity"}, {"end": 26, "start": 17, "tag": "ResearchActivity"}, {"end": 272, "start": 267, "tag": "Eukaryote"}, {"end": 169, "start": 160, "tag": "Finding"}, {"end": 153, "start": 143, "tag": "Cell"}, {"end": 62, "start": 52, "tag": "TemporalConcept"}, {"end": 138, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 188, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 188, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 134, "tag": "GeneOrGenome"}, {"end": 192, "start": 188, "tag": "GeneOrGenome"}, {"end": 73, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 66, "tag": "GeneOrGenome"}, {"end": 73, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 216, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 216, "tag": "BiologicallyActiveSubstance"}, {"end": 222, "start": 216, "tag": "GeneOrGenome"}, {"end": 201, "start": 196, "tag": "GeneOrGenome"}, {"end": 201, "start": 196, "tag": "BiologicallyActiveSubstance"}, {"end": 201, "start": 196, "tag": "AminoAcidPeptideOrProtein"}, {"end": 231, "start": 226, "tag": "AminoAcidPeptideOrProtein"}, {"end": 231, "start": 226, "tag": "GeneOrGenome"}, {"end": 231, "start": 226, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 116, "tag": "GeneOrGenome"}]}{"id": "1255_12", "text": "Thus, our results demonstrate that BHB treatment efficiently supports OPC differentiation and decreases the OLs apoptosis in CPZ-intoxicated mice, partly by down-regulating the expression of TRPA1 and PARP, which is associated with the inhibition of the p38-MAPK/JNK/JUN pathway and the activation of ERK1/2, PI3K/AKT/mTOR signaling, supporting BHB treatment adjunctive nutritional therapy for the treatment of chronic demyelinating diseases, such as multiple sclerosis (MS).", "tags": [{"end": 38, "start": 35, "tag": "Chemical"}, {"end": 103, "start": 94, "tag": "Finding"}, {"end": 172, "start": 157, "tag": "CellFunction"}, {"end": 196, "start": 191, "tag": "GeneOrGenome"}, {"end": 196, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 205, "start": 201, "tag": "GeneOrGenome"}, {"end": 205, "start": 201, "tag": "AminoAcidPeptideOrProtein"}, {"end": 348, "start": 345, "tag": "Chemical"}, {"end": 441, "start": 411, "tag": "DiseaseOrSyndrome"}, {"end": 322, "start": 318, "tag": "AminoAcidPeptideOrProtein"}, {"end": 322, "start": 318, "tag": "GeneOrGenome"}, {"end": 322, "start": 318, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 125, "tag": "Chemical"}, {"end": 187, "start": 162, "tag": "CellFunction"}, {"end": 278, "start": 254, "tag": "CellFunction"}, {"end": 73, "start": 70, "tag": "Cell"}, {"end": 441, "start": 419, "tag": "DiseaseOrSyndrome"}, {"end": 432, "start": 419, "tag": "PathologicFunction"}, {"end": 469, "start": 451, "tag": "DiseaseOrSyndrome"}, {"end": 332, "start": 301, "tag": "CellFunction"}, {"end": 89, "start": 74, "tag": "CellFunction"}, {"end": 111, "start": 108, "tag": "Cell"}, {"end": 89, "start": 70, "tag": "CellFunction"}, {"end": 317, "start": 314, "tag": "AminoAcidPeptideOrProtein"}, {"end": 317, "start": 314, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 141, "tag": "Eukaryote"}, {"end": 48, "start": 39, "tag": "HealthCareActivity"}, {"end": 358, "start": 349, "tag": "HealthCareActivity"}, {"end": 407, "start": 398, "tag": "HealthCareActivity"}, {"end": 48, "start": 39, "tag": "ResearchActivity"}, {"end": 358, "start": 349, "tag": "ResearchActivity"}, {"end": 407, "start": 398, "tag": "ResearchActivity"}, {"end": 187, "start": 177, "tag": "CellFunction"}, {"end": 121, "start": 112, "tag": "CellFunction"}, {"end": 246, "start": 236, "tag": "CellFunction"}, {"end": 389, "start": 382, "tag": "HealthCareActivity"}, {"end": 278, "start": 271, "tag": "CellFunction"}, {"end": 473, "start": 471, "tag": "DiseaseOrSyndrome"}, {"end": 418, "start": 411, "tag": "TemporalConcept"}, {"end": 145, "start": 125, "tag": "ExperimentalModelOfDisease"}, {"end": 196, "start": 191, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 201, "tag": "BiologicallyActiveSubstance"}]}{"id": "1256_0", "text": "Antibodies and oxidative stress are hallmarks of multiple sclerosis (MS) lesions.", "tags": [{"end": 10, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 36, "tag": "Finding"}, {"end": 67, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 73, "tag": "InjuryOrPoisoning"}, {"end": 31, "start": 15, "tag": "CellOrMolecularDysfunction"}, {"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}]}{"id": "1256_1", "text": "We aimed to clarify the relation between them, their role in MS patients and to investigate their specificity, comparing MS with classical neurodegenerative diseases (ND).", "tags": [{"end": 72, "start": 64, "tag": "PatientOrDisabledGroup"}, {"end": 109, "start": 98, "tag": "Finding"}, {"end": 165, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 121, "tag": "DiseaseOrSyndrome"}]}{"id": "1256_2", "text": "Brain samples from 14 MS cases, 6 with ND and 9 controls (without neurological diseases).", "tags": [{"end": 30, "start": 22, "tag": "PatientOrDisabledGroup"}, {"end": 56, "start": 48, "tag": "PopulationGroup"}, {"end": 13, "start": 6, "tag": "Substance"}, {"end": 13, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 66, "tag": "DiseaseOrSyndrome"}]}{"id": "1256_3", "text": "Immunohistochemistry assays were used to detect oxidized lipids (EO6), IgG and IgM, oligodendrocytes (Olig2), axons (NF, neurofilament) and cellular (TUNEL) and axonal damage (APP, amyloid precursor protein).", "tags": [{"end": 27, "start": 0, "tag": "HealthCareActivity"}, {"end": 82, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 79, "tag": "PharmacologicSubstance"}, {"end": 82, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 102, "tag": "GeneOrGenome"}, {"end": 119, "start": 117, "tag": "GeneOrGenome"}, {"end": 119, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 121, "tag": "GeneOrGenome"}, {"end": 134, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 150, "tag": "ResearchActivity"}, {"end": 74, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 71, "tag": "PharmacologicSubstance"}, {"end": 115, "start": 110, "tag": "CellComponent"}, {"end": 100, "start": 84, "tag": "Cell"}, {"end": 167, "start": 161, "tag": "CellComponent"}, {"end": 27, "start": 21, "tag": "ResearchActivity"}, {"end": 179, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 176, "tag": "GeneOrGenome"}, {"end": 179, "start": 176, "tag": "BiologicallyActiveSubstance"}, {"end": 188, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 181, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 48, "tag": "Chemical"}, {"end": 148, "start": 140, "tag": "Cell"}, {"end": 206, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 206, "start": 181, "tag": "BiologicallyActiveSubstance"}, {"end": 206, "start": 199, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 117, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 168, "tag": "InjuryOrPoisoning"}, {"end": 68, "start": 65, "tag": "Chemical"}]}{"id": "1256_4", "text": "We did not observe EO6 in controls.", "tags": [{"end": 34, "start": 26, "tag": "PopulationGroup"}]}{"id": "1256_5", "text": "All samples from MS patients showed EO6 in oligodendrocytes and axons within lesions.", "tags": [{"end": 69, "start": 64, "tag": "CellComponent"}, {"end": 59, "start": 43, "tag": "Cell"}, {"end": 84, "start": 77, "tag": "InjuryOrPoisoning"}, {"end": 28, "start": 20, "tag": "PatientOrDisabledGroup"}, {"end": 11, "start": 4, "tag": "Substance"}, {"end": 11, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 36, "tag": "Chemical"}]}{"id": "1256_6", "text": "We did not detect co-localization between EO6 and antibodies.", "tags": [{"end": 60, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 42, "tag": "Chemical"}]}{"id": "1256_7", "text": "Neither did we between EO6 and TUNEL or APP.", "tags": [{"end": 36, "start": 31, "tag": "ResearchActivity"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "GeneOrGenome"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 23, "tag": "Chemical"}]}{"id": "1256_8", "text": "94.4% of TUNEL-positive cells in normal appearing white matter were also stained for IgG and 75.5% for IgM.", "tags": [{"end": 88, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 85, "tag": "PharmacologicSubstance"}, {"end": 62, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 24, "tag": "Cell"}, {"end": 39, "start": 33, "tag": "Finding"}, {"end": 14, "start": 9, "tag": "ResearchActivity"}, {"end": 106, "start": 103, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 103, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1256_9", "text": "IgM, but not IgG, co-localized with APP.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 13, "tag": "PharmacologicSubstance"}, {"end": 39, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 36, "tag": "GeneOrGenome"}, {"end": 39, "start": 36, "tag": "BiologicallyActiveSubstance"}]}{"id": "1256_10", "text": "EO6 was associated with axonal damage in amyotrophic lateral sclerosis (ALS).", "tags": [{"end": 75, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 24, "tag": "CellComponent"}, {"end": 70, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 3, "start": 0, "tag": "Chemical"}, {"end": 37, "start": 31, "tag": "InjuryOrPoisoning"}]}{"id": "1256_11", "text": "We did not observe association between antibodies and cellular or axonal damage in ND patients.", "tags": [{"end": 49, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 66, "tag": "CellComponent"}, {"end": 94, "start": 86, "tag": "PatientOrDisabledGroup"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 54, "tag": "Cell"}, {"end": 79, "start": 73, "tag": "InjuryOrPoisoning"}]}{"id": "1256_12", "text": "MS patients showed a higher number of B cells and plasma cells in the lesions and meninges than controls.", "tags": [{"end": 45, "start": 38, "tag": "Cell"}, {"end": 62, "start": 50, "tag": "Cell"}, {"end": 90, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 77, "start": 70, "tag": "InjuryOrPoisoning"}, {"end": 11, "start": 3, "tag": "PatientOrDisabledGroup"}, {"end": 56, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 96, "tag": "PopulationGroup"}, {"end": 2, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "1256_13", "text": "The number of B cells and plasma cells was associated with the presence of antibodies and with the activity of the lesions.", "tags": [{"end": 21, "start": 14, "tag": "Cell"}, {"end": 38, "start": 26, "tag": "Cell"}, {"end": 85, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 115, "tag": "InjuryOrPoisoning"}, {"end": 32, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 63, "tag": "Finding"}]}{"id": "1256_14", "text": "We observed a main role of B lymphocytes in the development of MS lesions.", "tags": [{"end": 40, "start": 27, "tag": "Cell"}, {"end": 73, "start": 66, "tag": "InjuryOrPoisoning"}, {"end": 59, "start": 48, "tag": "BiologicFunction"}, {"end": 59, "start": 48, "tag": "CellFunction"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 29, "tag": "Cell"}]}{"id": "1256_15", "text": "Antibodies contribute to the oligodendrocyte and axonal damage in MS.", "tags": [{"end": 10, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 49, "tag": "CellComponent"}, {"end": 44, "start": 29, "tag": "Cell"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 56, "tag": "InjuryOrPoisoning"}]}{"id": "1256_16", "text": "Oxidative stress was associated with axonal damage in ALS.", "tags": [{"end": 16, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 57, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 37, "tag": "CellComponent"}, {"end": 50, "start": 44, "tag": "InjuryOrPoisoning"}]}{"id": "1257_0", "text": "HMGB1 is a highly conserved, ubiquitous protein in eukaryotic cells.", "tags": [{"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 51, "tag": "Cell"}, {"end": 47, "start": 29, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1257_1", "text": "HMGB1 is normally localized to the nucleus, where it acts as a chromatin associated non-histone binding protein.", "tags": [{"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 5, "start": 0, "tag": "CellFunction"}, {"end": 72, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 63, "tag": "CellComponent"}, {"end": 42, "start": 35, "tag": "Chemical"}, {"end": 42, "start": 35, "tag": "CellComponent"}, {"end": 111, "start": 63, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1257_2", "text": "In contrast, extracellular HMGB1 is an alarmin released by stressed cells to act as a danger associated molecular pattern (DAMP).", "tags": [{"end": 26, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 27, "tag": "GeneOrGenome"}, {"end": 32, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 68, "tag": "Cell"}, {"end": 121, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 123, "tag": "BiologicallyActiveSubstance"}]}{"id": "1257_3", "text": "We have recently determined that progenitor cells from multiple sclerosis patients exhibit a cellular senescent phenotype and release extracellular HMGB1 which directly impaired the maturation of oligodendrocyte progenitor cells (OPCs) to myelinating oligodendrocytes (OLs).", "tags": [{"end": 111, "start": 93, "tag": "CellFunction"}, {"end": 147, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 148, "tag": "GeneOrGenome"}, {"end": 153, "start": 148, "tag": "BiologicallyActiveSubstance"}, {"end": 267, "start": 239, "tag": "Cell"}, {"end": 49, "start": 33, "tag": "Cell"}, {"end": 121, "start": 112, "tag": "OrganismAttribute"}, {"end": 272, "start": 269, "tag": "Cell"}, {"end": 234, "start": 230, "tag": "Cell"}, {"end": 192, "start": 182, "tag": "BiologicFunction"}, {"end": 228, "start": 196, "tag": "Cell"}, {"end": 16, "start": 8, "tag": "TemporalConcept"}, {"end": 82, "start": 74, "tag": "PatientOrDisabledGroup"}, {"end": 73, "start": 55, "tag": "DiseaseOrSyndrome"}]}{"id": "1257_4", "text": "Herein, we report that administration of recombinant HMGB1 into the spinal cord at the time of lysolecithin administration resulted in arrest of OPC differentiation in vivo, and a profound impairment of remyelination.", "tags": [{"end": 58, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 53, "tag": "GeneOrGenome"}, {"end": 58, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 95, "tag": "Chemical"}, {"end": 107, "start": 95, "tag": "PharmacologicSubstance"}, {"end": 141, "start": 135, "tag": "TemporalConcept"}, {"end": 216, "start": 189, "tag": "PathologicFunction"}, {"end": 17, "start": 11, "tag": "HealthCareActivity"}, {"end": 17, "start": 11, "tag": "ResearchActivity"}, {"end": 216, "start": 203, "tag": "CellFunction"}, {"end": 164, "start": 145, "tag": "CellFunction"}, {"end": 79, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 165, "tag": "ResearchActivity"}, {"end": 91, "start": 87, "tag": "TemporalConcept"}, {"end": 122, "start": 95, "tag": "ResearchActivity"}, {"end": 58, "start": 23, "tag": "ResearchActivity"}]}{"id": "1257_5", "text": "To define the receptor by which extracellular HMGB1 mediates its inhibitory influence on OPCs to impair OL differentiation, we tested selective inhibitors against the four primary receptors known to mediate the effects of HMGB1, the toll-like receptors (TLRs)-2, -4, -9 or the receptor for advanced glycation end-products (RAGE).", "tags": [{"end": 45, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 46, "tag": "GeneOrGenome"}, {"end": 51, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 144, "tag": "Chemical"}, {"end": 154, "start": 144, "tag": "PharmacologicSubstance"}, {"end": 154, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 227, "start": 222, "tag": "AminoAcidPeptideOrProtein"}, {"end": 227, "start": 222, "tag": "GeneOrGenome"}, {"end": 227, "start": 222, "tag": "BiologicallyActiveSubstance"}, {"end": 327, "start": 323, "tag": "AminoAcidPeptideOrProtein"}, {"end": 327, "start": 323, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 89, "tag": "Cell"}, {"end": 122, "start": 104, "tag": "CellFunction"}, {"end": 106, "start": 104, "tag": "Cell"}, {"end": 22, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 321, "start": 277, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 107, "tag": "CellFunction"}, {"end": 269, "start": 233, "tag": "BiologicallyActiveSubstance"}, {"end": 269, "start": 233, "tag": "AminoAcidPeptideOrProtein"}, {"end": 321, "start": 277, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1257_6", "text": "We found that inhibition of neither TLR9 nor RAGE increased OL differentiation in the presence of HMGB1, while inhibition of TLR4 resulted in partial restoration of OL differentiation and inhibiting TLR2 fully restored differentiation of OLs in the presence of HMGB1.", "tags": [{"end": 40, "start": 36, "tag": "GeneOrGenome"}, {"end": 40, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 86, "tag": "Finding"}, {"end": 103, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 98, "tag": "GeneOrGenome"}, {"end": 103, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 199, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 199, "tag": "GeneOrGenome"}, {"end": 203, "start": 199, "tag": "BiologicallyActiveSubstance"}, {"end": 257, "start": 249, "tag": "Finding"}, {"end": 266, "start": 261, "tag": "AminoAcidPeptideOrProtein"}, {"end": 266, "start": 261, "tag": "GeneOrGenome"}, {"end": 266, "start": 261, "tag": "BiologicallyActiveSubstance"}, {"end": 198, "start": 188, "tag": "BiologicFunction"}, {"end": 241, "start": 238, "tag": "Cell"}, {"end": 78, "start": 60, "tag": "CellFunction"}, {"end": 183, "start": 165, "tag": "CellFunction"}, {"end": 62, "start": 60, "tag": "Cell"}, {"end": 167, "start": 165, "tag": "Cell"}, {"end": 129, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 125, "tag": "GeneOrGenome"}, {"end": 129, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 14, "tag": "CellFunction"}, {"end": 121, "start": 111, "tag": "CellFunction"}, {"end": 78, "start": 63, "tag": "CellFunction"}, {"end": 183, "start": 168, "tag": "CellFunction"}, {"end": 234, "start": 219, "tag": "CellFunction"}, {"end": 40, "start": 36, "tag": "BiologicallyActiveSubstance"}]}{"id": "1257_7", "text": "Analysis of transcriptomic data (RNAseq) from OPCs identified an overrepresentation of NF kappa B regulated genes in OPCs when in the presence of HMGB1.", "tags": [{"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 26, "start": 12, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 142, "start": 134, "tag": "Finding"}, {"end": 151, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 146, "tag": "GeneOrGenome"}, {"end": 151, "start": 146, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 46, "tag": "Cell"}, {"end": 121, "start": 117, "tag": "Cell"}, {"end": 31, "start": 12, "tag": "ResearchActivity"}, {"end": 39, "start": 33, "tag": "ResearchActivity"}, {"end": 97, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 87, "tag": "BiologicallyActiveSubstance"}]}{"id": "1257_8", "text": "We found that application of HMGB1 to OPCs in culture resulted in a rapid and concentration dependent shift in NF kappa B nuclear translocation which was also attenuated with coincident TLR2 inhibition.", "tags": [{"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 29, "tag": "GeneOrGenome"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 46, "tag": "ResearchActivity"}, {"end": 107, "start": 78, "tag": "Finding"}, {"end": 190, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 186, "tag": "GeneOrGenome"}, {"end": 190, "start": 186, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 38, "tag": "Cell"}, {"end": 185, "start": 175, "tag": "TemporalConcept"}, {"end": 201, "start": 191, "tag": "CellFunction"}, {"end": 121, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 122, "tag": "CellFunction"}]}{"id": "1257_9", "text": "These data provide new information on how extracellular HMGB1 directly affects the differentiation potential of OPCs.", "tags": [{"end": 55, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 56, "tag": "GeneOrGenome"}, {"end": 61, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 98, "start": 83, "tag": "CellFunction"}]}{"id": "1257_10", "text": "Recent and past evidence for elevated HMGB1 released from senescent progenitor cells within demyelinated lesions in the MS brain suggests that a greater understanding of how this molecule acts on OPCs may unfetter the endogenous remyelination potential in MS.", "tags": [{"end": 43, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 38, "tag": "GeneOrGenome"}, {"end": 43, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 92, "tag": "PathologicFunction"}, {"end": 187, "start": 179, "tag": "Substance"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 15, "start": 11, "tag": "TemporalConcept"}, {"end": 166, "start": 153, "tag": "BiologicFunction"}, {"end": 84, "start": 68, "tag": "Cell"}, {"end": 242, "start": 229, "tag": "CellFunction"}, {"end": 200, "start": 196, "tag": "Cell"}, {"end": 112, "start": 92, "tag": "PathologicFunction"}, {"end": 24, "start": 16, "tag": "Finding"}, {"end": 128, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 258, "start": 256, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 105, "tag": "InjuryOrPoisoning"}]}{"id": "1258_0", "text": "Background Chondroitin sulfate proteoglycans (CSPGs) are potent inhibitors of axonal regrowth and remyelination.", "tags": [{"end": 44, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 64, "tag": "Chemical"}, {"end": 74, "start": 64, "tag": "PharmacologicSubstance"}, {"end": 74, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 78, "tag": "CellComponent"}, {"end": 111, "start": 98, "tag": "CellFunction"}, {"end": 93, "start": 78, "tag": "CellFunction"}]}{"id": "1258_1", "text": "More recently, they have also been highlighted as a modulator of macrophage infiltration into the central nervous system in experimental autoimmune encephalomyelitis, an inflammatory model of multiple sclerosis.", "tags": [{"end": 75, "start": 65, "tag": "Cell"}, {"end": 210, "start": 170, "tag": "ExperimentalModelOfDisease"}, {"end": 165, "start": 124, "tag": "ExperimentalModelOfDisease"}, {"end": 210, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 170, "tag": "PathologicFunction"}, {"end": 120, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 5, "tag": "TemporalConcept"}, {"end": 61, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 65, "tag": "CellFunction"}]}{"id": "1258_2", "text": "Methods We interrogated results from single nucleotide polymorphisms (SNPs) lying in or close to genes regulating CSPG metabolism in the summary results from two publicly available systematic studies of multiple sclerosis (MS) genetics.", "tags": [{"end": 68, "start": 37, "tag": "MolecularSequence"}, {"end": 74, "start": 70, "tag": "MolecularSequence"}, {"end": 221, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 199, "start": 192, "tag": "ResearchActivity"}, {"end": 129, "start": 119, "tag": "CellFunction"}, {"end": 129, "start": 119, "tag": "BiologicFunction"}, {"end": 235, "start": 227, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 235, "start": 227, "tag": "CellFunction"}, {"end": 225, "start": 223, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 114, "tag": "BiologicallyActiveSubstance"}]}{"id": "1258_3", "text": "A demyelinating injury model in the spinal cord of exostosin-like 2 deficient (EXTL2(-/-)) mice was used to investigate the effects of dysregulation of EXTL2 on remyelination.", "tags": [{"end": 157, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 152, "tag": "GeneOrGenome"}, {"end": 47, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 2, "tag": "InjuryOrPoisoning"}, {"end": 28, "start": 23, "tag": "ResearchActivity"}, {"end": 174, "start": 161, "tag": "CellFunction"}, {"end": 131, "start": 124, "tag": "Finding"}, {"end": 157, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 91, "tag": "ResearchActivity"}, {"end": 77, "start": 51, "tag": "ResearchActivity"}, {"end": 28, "start": 2, "tag": "ExperimentalModelOfDisease"}]}{"id": "1258_4", "text": "Cell cultures of bone marrow-derived macrophages and primary oligodendrocyte precursor cells and neurons were supplemented with purified CSPGs or conditioned media to assess potential mechanisms of action.", "tags": [{"end": 13, "start": 0, "tag": "Cell"}, {"end": 142, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 53, "tag": "Cell"}, {"end": 92, "start": 61, "tag": "Cell"}, {"end": 86, "start": 61, "tag": "Cell"}, {"end": 48, "start": 37, "tag": "Cell"}, {"end": 48, "start": 17, "tag": "Cell"}, {"end": 163, "start": 146, "tag": "Chemical"}, {"end": 104, "start": 97, "tag": "Cell"}]}{"id": "1258_5", "text": "Results The strongest evidence for genetic association was seen for SNPs mapping to the region containing the glycosyltransferase exostosin-like 2 (EXTL2), an enzyme that normally suppresses CSPG biosynthesis.", "tags": [{"end": 80, "start": 73, "tag": "ResearchActivity"}, {"end": 129, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 148, "tag": "GeneOrGenome"}, {"end": 208, "start": 191, "tag": "CellFunction"}, {"end": 72, "start": 68, "tag": "MolecularSequence"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 30, "start": 22, "tag": "Finding"}, {"end": 165, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 130, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 148, "tag": "BiologicallyActiveSubstance"}]}{"id": "1258_6", "text": "Six of these SNPs showed genome-wide significant evidence for association in one of the studies with concordant and nominally significant effects in the second study.", "tags": [{"end": 31, "start": 25, "tag": "GeneOrGenome"}, {"end": 17, "start": 13, "tag": "MolecularSequence"}, {"end": 165, "start": 160, "tag": "ResearchActivity"}, {"end": 57, "start": 49, "tag": "Finding"}, {"end": 95, "start": 88, "tag": "ResearchActivity"}, {"end": 145, "start": 138, "tag": "Finding"}]}{"id": "1258_7", "text": "We then went on to show that a demyelinating injury to the spinal cord of EXTL2(-/-)mice resulted in excessive deposition of CSPGs in the lesion area.", "tags": [{"end": 130, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 31, "tag": "PathologicFunction"}, {"end": 144, "start": 138, "tag": "InjuryOrPoisoning"}, {"end": 70, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 31, "tag": "InjuryOrPoisoning"}, {"end": 88, "start": 74, "tag": "ResearchActivity"}]}{"id": "1258_8", "text": "EXTL2(-/-)mice had exacerbated axonal damage and myelin disruption relative to wild-type mice, and increased representation of microglia/macrophages within lesions.", "tags": [{"end": 55, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 156, "tag": "InjuryOrPoisoning"}, {"end": 37, "start": 31, "tag": "CellComponent"}, {"end": 66, "start": 56, "tag": "InjuryOrPoisoning"}, {"end": 148, "start": 137, "tag": "Cell"}, {"end": 88, "start": 79, "tag": "ResearchActivity"}, {"end": 93, "start": 79, "tag": "Eukaryote"}, {"end": 93, "start": 89, "tag": "Eukaryote"}, {"end": 136, "start": 127, "tag": "Cell"}, {"end": 30, "start": 19, "tag": "Finding"}, {"end": 44, "start": 38, "tag": "InjuryOrPoisoning"}, {"end": 14, "start": 0, "tag": "ResearchActivity"}]}{"id": "1258_9", "text": "In tissue culture, activated bone marrow-derived macrophages from EXTL2(-/-)mice overproduce tumor necrosis factor alpha (TNF alpha) and matrix metalloproteinases (MMPs).", "tags": [{"end": 17, "start": 3, "tag": "ResearchActivity"}, {"end": 60, "start": 19, "tag": "Cell"}, {"end": 131, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 122, "tag": "GeneOrGenome"}, {"end": 131, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 164, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 164, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 144, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 144, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 10, "tag": "ResearchActivity"}, {"end": 120, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 49, "tag": "Cell"}, {"end": 40, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 29, "tag": "Cell"}, {"end": 9, "start": 3, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 66, "tag": "ResearchActivity"}]}{"id": "1258_10", "text": "Conclusions These results emphasize CSPGs as a prominent modulator of neuroinflammation and they highlight CSPGs accumulating in lesions in promoting axonal injury.", "tags": [{"end": 41, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 129, "tag": "InjuryOrPoisoning"}, {"end": 156, "start": 150, "tag": "CellComponent"}, {"end": 163, "start": 157, "tag": "InjuryOrPoisoning"}, {"end": 87, "start": 70, "tag": "PathologicFunction"}, {"end": 66, "start": 57, "tag": "BiologicallyActiveSubstance"}]}{"id": "1259_0", "text": "Brain ageing is characterised by a decline in neuronal function and associated cognitive deficits.", "tags": [{"end": 12, "start": 6, "tag": "BiologicFunction"}, {"end": 97, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 46, "tag": "CellFunction"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 35, "tag": "Finding"}]}{"id": "1259_1", "text": "There is increasing evidence that myelin disruption is an important factor that contributes to the age-related loss of brain plasticity and repair responses.", "tags": [{"end": 115, "start": 99, "tag": "PathologicFunction"}, {"end": 28, "start": 9, "tag": "Finding"}, {"end": 40, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 41, "tag": "InjuryOrPoisoning"}, {"end": 135, "start": 125, "tag": "NaturalPhenomenonOrProcess"}, {"end": 135, "start": 125, "tag": "CellFunction"}, {"end": 124, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 140, "tag": "BiologicFunction"}, {"end": 146, "start": 140, "tag": "HealthCareActivity"}]}{"id": "1259_2", "text": "In the brain, myelin is produced by oligodendrocytes, which are generated throughout life by oligodendrocyte progenitor cells (OPCs).", "tags": [{"end": 52, "start": 36, "tag": "Cell"}, {"end": 131, "start": 127, "tag": "Cell"}, {"end": 20, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 93, "tag": "Cell"}, {"end": 125, "start": 109, "tag": "Cell"}, {"end": 12, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 85, "tag": "TemporalConcept"}]}{"id": "1259_3", "text": "Currently, a leading hypothesis points to ageing as a major reason for the ultimate breakdown of remyelination in Multiple Sclerosis (MS).", "tags": [{"end": 48, "start": 42, "tag": "BiologicFunction"}, {"end": 110, "start": 84, "tag": "PathologicFunction"}, {"end": 9, "start": 0, "tag": "TemporalConcept"}, {"end": 132, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 97, "tag": "CellFunction"}, {"end": 136, "start": 134, "tag": "DiseaseOrSyndrome"}]}{"id": "1259_4", "text": "However, an incomplete understanding of the cellular and molecular processes underlying brain ageing hinders the development of regenerative strategies.", "tags": [{"end": 100, "start": 94, "tag": "BiologicFunction"}, {"end": 124, "start": 113, "tag": "BiologicFunction"}, {"end": 124, "start": 113, "tag": "CellFunction"}, {"end": 93, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 128, "tag": "ResearchActivity"}, {"end": 36, "start": 23, "tag": "BiologicFunction"}, {"end": 52, "start": 44, "tag": "Cell"}]}{"id": "1259_5", "text": "Here, our combined systems biology and neurobiological approach demonstrate that oligodendroglial and myelin genes are amongst the most altered in the ageing mouse cerebrum.", "tags": [{"end": 34, "start": 19, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 157, "start": 151, "tag": "BiologicFunction"}, {"end": 172, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 97, "start": 81, "tag": "Cell"}, {"end": 163, "start": 158, "tag": "Eukaryote"}, {"end": 34, "start": 27, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 34, "start": 27, "tag": "BiologicFunction"}, {"end": 63, "start": 39, "tag": "ResearchActivity"}]}{"id": "1259_6", "text": "This was underscored by the identification of causal links between signalling pathways and their downstream transcriptional networks that define oligodendroglial disruption in ageing.", "tags": [{"end": 86, "start": 67, "tag": "CellFunction"}, {"end": 132, "start": 108, "tag": "CellFunction"}, {"end": 182, "start": 176, "tag": "BiologicFunction"}, {"end": 172, "start": 162, "tag": "InjuryOrPoisoning"}, {"end": 161, "start": 145, "tag": "Cell"}]}{"id": "1259_7", "text": "The results highlighted that the G-protein coupled receptor Gpr17 is central to the disruption of OPCs in ageing and this was confirmed by genetic fate-mapping and cellular analyses.", "tags": [{"end": 65, "start": 60, "tag": "GeneOrGenome"}, {"end": 65, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 106, "tag": "BiologicFunction"}, {"end": 59, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 98, "tag": "Cell"}, {"end": 94, "start": 84, "tag": "InjuryOrPoisoning"}, {"end": 159, "start": 139, "tag": "ResearchActivity"}, {"end": 172, "start": 164, "tag": "Cell"}, {"end": 181, "start": 173, "tag": "ResearchActivity"}, {"end": 65, "start": 60, "tag": "BiologicallyActiveSubstance"}]}{"id": "1259_8", "text": "Finally, we used systems biology strategies to identify therapeutic agents that rejuvenate OPCs and restore myelination in age-related neuropathological contexts.", "tags": [{"end": 32, "start": 17, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 90, "start": 80, "tag": "HealthCareActivity"}, {"end": 74, "start": 56, "tag": "HealthCareActivity"}, {"end": 95, "start": 91, "tag": "Cell"}, {"end": 126, "start": 123, "tag": "OrganismAttribute"}, {"end": 43, "start": 33, "tag": "ResearchActivity"}, {"end": 32, "start": 25, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 119, "start": 108, "tag": "CellFunction"}, {"end": 32, "start": 25, "tag": "BiologicFunction"}]}{"id": "1260_0", "text": "Delta(9)-Tetrahydrocannabinol (THC), the main bioactive compound found in the plantCannabis sativa, exerts its effects by activating cannabinoid receptors present in many neural cells.", "tags": [{"end": 29, "start": 0, "tag": "Chemical"}, {"end": 34, "start": 31, "tag": "Chemical"}, {"end": 154, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 133, "tag": "PharmacologicSubstance"}, {"end": 183, "start": 171, "tag": "Cell"}, {"end": 154, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 83, "tag": "Eukaryote"}]}{"id": "1260_1", "text": "Cannabinoid receptors are also physiologically engaged by endogenous cannabinoid compounds, the so-called endocannabinoids.", "tags": [{"end": 21, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 122, "start": 106, "tag": "Chemical"}, {"end": 122, "start": 106, "tag": "ResearchActivity"}, {"end": 90, "start": 58, "tag": "Chemical"}, {"end": 90, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 12, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1260_2", "text": "Specifically, the endocannabinoid 2-arachidonoylglycerol has been highlighted as an important modulator of oligodendrocyte (OL) development at embryonic stages and in animal models of demyelination.", "tags": [{"end": 159, "start": 143, "tag": "TemporalConcept"}, {"end": 33, "start": 18, "tag": "Chemical"}, {"end": 33, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 34, "tag": "Chemical"}, {"end": 56, "start": 34, "tag": "PharmacologicSubstance"}, {"end": 122, "start": 107, "tag": "Cell"}, {"end": 139, "start": 128, "tag": "BiologicFunction"}, {"end": 139, "start": 128, "tag": "CellFunction"}, {"end": 197, "start": 184, "tag": "PathologicFunction"}, {"end": 126, "start": 124, "tag": "Cell"}, {"end": 159, "start": 153, "tag": "TemporalConcept"}, {"end": 180, "start": 167, "tag": "ResearchActivity"}, {"end": 103, "start": 94, "tag": "BiologicallyActiveSubstance"}]}{"id": "1260_3", "text": "However, the potential impact of THC exposure on OL lineage progression during the critical periods of postnatal myelination has never been explored.", "tags": [{"end": 36, "start": 33, "tag": "Chemical"}, {"end": 45, "start": 33, "tag": "InjuryOrPoisoning"}, {"end": 99, "start": 83, "tag": "TemporalConcept"}, {"end": 124, "start": 113, "tag": "CellFunction"}, {"end": 71, "start": 60, "tag": "PathologicFunction"}, {"end": 71, "start": 60, "tag": "TemporalConcept"}, {"end": 51, "start": 49, "tag": "Cell"}, {"end": 112, "start": 103, "tag": "TemporalConcept"}, {"end": 59, "start": 49, "tag": "Cell"}]}{"id": "1260_4", "text": "Here, we show that acute THC administration at early postnatal ages in mice enhanced OL development and CNS myelination in the subcortical white matter by promoting oligodendrocyte precursor cell cycle exit and differentiation.", "tags": [{"end": 28, "start": 25, "tag": "Chemical"}, {"end": 67, "start": 63, "tag": "Chemical"}, {"end": 138, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 108, "tag": "CellFunction"}, {"end": 75, "start": 71, "tag": "Eukaryote"}, {"end": 99, "start": 88, "tag": "BiologicFunction"}, {"end": 99, "start": 88, "tag": "CellFunction"}, {"end": 107, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 226, "start": 211, "tag": "CellFunction"}, {"end": 151, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 85, "tag": "Cell"}, {"end": 195, "start": 165, "tag": "Cell"}, {"end": 52, "start": 47, "tag": "TemporalConcept"}, {"end": 62, "start": 53, "tag": "TemporalConcept"}, {"end": 24, "start": 19, "tag": "TemporalConcept"}, {"end": 206, "start": 191, "tag": "CellFunction"}]}{"id": "1260_5", "text": "Mechanistically, THC-induced-myelination was mediated by CB(1)and CB(2)cannabinoid receptors, as demonstrated by the blockade of THC actions by selective receptor antagonists.", "tags": [{"end": 132, "start": 129, "tag": "Chemical"}, {"end": 40, "start": 29, "tag": "CellFunction"}, {"end": 162, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 117, "tag": "PharmacologicSubstance"}, {"end": 125, "start": 117, "tag": "HealthCareActivity"}, {"end": 92, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 17, "tag": "Chemical"}, {"end": 92, "start": 57, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1260_6", "text": "Moreover, the THC-mediated modulation of oligodendroglial differentiation relied on the activation of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, as mTORC1 pharmacological inhibition prevented the THC effects.", "tags": [{"end": 153, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 153, "start": 147, "tag": "GeneOrGenome"}, {"end": 172, "start": 155, "tag": "CellFunction"}, {"end": 183, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 177, "tag": "GeneOrGenome"}, {"end": 228, "start": 225, "tag": "Chemical"}, {"end": 145, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 58, "tag": "CellFunction"}, {"end": 57, "start": 41, "tag": "Cell"}, {"end": 153, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 183, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 14, "tag": "Chemical"}, {"end": 210, "start": 184, "tag": "HealthCareActivity"}]}{"id": "1260_7", "text": "Our study identifies THC as an effective pharmacological strategy to enhance oligodendrogenesis and CNS myelination in vivo.", "tags": [{"end": 24, "start": 21, "tag": "Chemical"}, {"end": 95, "start": 77, "tag": "BiologicFunction"}, {"end": 56, "start": 41, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 115, "start": 104, "tag": "CellFunction"}, {"end": 123, "start": 116, "tag": "ResearchActivity"}, {"end": 103, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}]}{"id": "1261_0", "text": "Experimental autoimmune encephalomyelitis (EAE) is a basic and reliable model used to study clinical and pathological hallmarks of multiple sclerosis (MS) in rodents.", "tags": [{"end": 41, "start": 0, "tag": "ExperimentalModelOfDisease"}, {"end": 46, "start": 43, "tag": "ExperimentalModelOfDisease"}, {"end": 165, "start": 158, "tag": "Eukaryote"}, {"end": 127, "start": 118, "tag": "Finding"}, {"end": 149, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 86, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "ResearchActivity"}, {"end": 153, "start": 151, "tag": "DiseaseOrSyndrome"}]}{"id": "1261_1", "text": "Several studies suggest neural precursor cells (NPCs) as a significant research tool while reporting that transplanted NPCs are a promising therapeutic approach to treating neurological disorders, such as MS.", "tags": [{"end": 46, "start": 24, "tag": "Cell"}, {"end": 160, "start": 140, "tag": "HealthCareActivity"}, {"end": 52, "start": 48, "tag": "Cell"}, {"end": 123, "start": 119, "tag": "Cell"}, {"end": 46, "start": 31, "tag": "Cell"}, {"end": 79, "start": 71, "tag": "ResearchActivity"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 195, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 106, "tag": "HealthCareActivity"}]}{"id": "1261_2", "text": "The main objective was to approach a preclinical, in vivo scenario of oligodendrogenesis with NPCs, targeting the main chronic demyelinated lumbosacral milieu of EAE, via the least invasive delivery method which is lumbar puncture.", "tags": [{"end": 88, "start": 70, "tag": "BiologicFunction"}, {"end": 165, "start": 162, "tag": "ExperimentalModelOfDisease"}, {"end": 189, "start": 171, "tag": "Finding"}, {"end": 230, "start": 215, "tag": "HealthCareActivity"}, {"end": 139, "start": 127, "tag": "PathologicFunction"}, {"end": 98, "start": 94, "tag": "Cell"}, {"end": 57, "start": 50, "tag": "ResearchActivity"}, {"end": 205, "start": 190, "tag": "ResearchActivity"}, {"end": 205, "start": 190, "tag": "HealthCareActivity"}, {"end": 126, "start": 119, "tag": "TemporalConcept"}, {"end": 158, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1261_3", "text": "We utilized MOG(35-55) peptide to induce EAE in C57BL/6 mice and prior to the acute relapse, we intervened with either the traceable GFP(+) cellular therapy or saline solution in the intrathecal space of their lumbar spine.", "tags": [{"end": 175, "start": 160, "tag": "PharmacologicSubstance"}, {"end": 200, "start": 183, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 222, "start": 210, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 48, "tag": "Eukaryote"}, {"end": 166, "start": 160, "tag": "PharmacologicSubstance"}, {"end": 44, "start": 41, "tag": "ExperimentalModelOfDisease"}, {"end": 91, "start": 84, "tag": "TemporalConcept"}, {"end": 91, "start": 84, "tag": "Finding"}, {"end": 83, "start": 78, "tag": "TemporalConcept"}, {"end": 136, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 133, "tag": "Chemical"}, {"end": 156, "start": 149, "tag": "HealthCareActivity"}, {"end": 148, "start": 140, "tag": "Cell"}, {"end": 30, "start": 12, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1261_4", "text": "A BrdU injection, which enabled us to monitor endogenous proliferation, marked the endpoint 50 days post-induction (50 dpi).", "tags": [{"end": 114, "start": 100, "tag": "TemporalConcept"}, {"end": 70, "start": 57, "tag": "CellFunction"}, {"end": 6, "start": 2, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 6, "start": 2, "tag": "PharmacologicSubstance"}, {"end": 99, "start": 95, "tag": "TemporalConcept"}, {"end": 16, "start": 7, "tag": "HealthCareActivity"}, {"end": 45, "start": 38, "tag": "HealthCareActivity"}, {"end": 45, "start": 38, "tag": "ManufacturedObject"}]}{"id": "1261_5", "text": "Neuropathology with high-throughput, triple immunofluorescent, and transmission electron microscopy (TEM) data were extracted and analyzed.", "tags": [{"end": 14, "start": 0, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 14, "start": 0, "tag": "PathologicFunction"}, {"end": 79, "start": 67, "tag": "Finding"}, {"end": 99, "start": 80, "tag": "ResearchActivity"}, {"end": 99, "start": 67, "tag": "ResearchActivity"}, {"end": 104, "start": 101, "tag": "ResearchActivity"}, {"end": 110, "start": 106, "tag": "ResearchActivity"}, {"end": 61, "start": 20, "tag": "ResearchActivity"}]}{"id": "1261_6", "text": "The experimental treatment attenuated the chronic phase of EAE (50 dpi; score <1) following an acute, clinical relapse.", "tags": [{"end": 55, "start": 42, "tag": "TemporalConcept"}, {"end": 77, "start": 72, "tag": "Finding"}, {"end": 62, "start": 59, "tag": "ExperimentalModelOfDisease"}, {"end": 55, "start": 50, "tag": "TemporalConcept"}, {"end": 118, "start": 111, "tag": "TemporalConcept"}, {"end": 118, "start": 111, "tag": "Finding"}, {"end": 100, "start": 95, "tag": "TemporalConcept"}, {"end": 26, "start": 17, "tag": "HealthCareActivity"}, {"end": 26, "start": 17, "tag": "ResearchActivity"}, {"end": 16, "start": 4, "tag": "ResearchActivity"}, {"end": 49, "start": 42, "tag": "TemporalConcept"}]}{"id": "1261_7", "text": "Myelination and axonal integrity were rescued in the NPC-treated animals along with suppressed immune populations.", "tags": [{"end": 56, "start": 53, "tag": "Cell"}, {"end": 22, "start": 16, "tag": "CellComponent"}, {"end": 32, "start": 23, "tag": "IndividualBehavior"}, {"end": 32, "start": 16, "tag": "CellFunction"}, {"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 113, "start": 102, "tag": "PopulationGroup"}, {"end": 72, "start": 65, "tag": "Eukaryote"}]}{"id": "1261_8", "text": "The differentiation profile of the exogenous NPCs and endogenous BrdU(+) cells was location-dependent where GFP(+)-rich areas drove undifferentiated phenotypes toward the oligodendrocyte lineage.", "tags": [{"end": 148, "start": 132, "tag": "Finding"}, {"end": 49, "start": 45, "tag": "Cell"}, {"end": 194, "start": 171, "tag": "Cell"}, {"end": 69, "start": 65, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 69, "start": 65, "tag": "PharmacologicSubstance"}, {"end": 111, "start": 108, "tag": "Chemical"}, {"end": 111, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 73, "tag": "Cell"}, {"end": 159, "start": 149, "tag": "OrganismAttribute"}, {"end": 27, "start": 4, "tag": "ResearchActivity"}]}{"id": "1261_9", "text": "In situ oligodendrocyte enrichment was demonstrated through increased (p < 0.001) gap junction channels of Cx32 and Cx47, reliable markers for proliferative oligodendroglia syncytium.", "tags": [{"end": 156, "start": 143, "tag": "PathologicFunction"}, {"end": 182, "start": 173, "tag": "Cell"}, {"end": 172, "start": 157, "tag": "Cell"}, {"end": 120, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 131, "tag": "ClinicalAttribute"}, {"end": 34, "start": 24, "tag": "ResearchActivity"}, {"end": 23, "start": 8, "tag": "Cell"}, {"end": 103, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 107, "tag": "BiologicallyActiveSubstance"}]}{"id": "1261_10", "text": "TEM morphometric analysis ultimately manifested an increased g-ratio in lumbosacral fibers of the recovered animals (p < 0.001).", "tags": [{"end": 25, "start": 4, "tag": "ResearchActivity"}, {"end": 3, "start": 0, "tag": "ResearchActivity"}, {"end": 115, "start": 108, "tag": "Eukaryote"}, {"end": 90, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 61, "tag": "ResearchActivity"}]}{"id": "1261_11", "text": "Herein, we suggest that a single, lumbar intrathecal administration of NPCs capacitated a viable cellular load and resulted in clinical and pathological amelioration, stimulating resident OPCs to overcome the remyelination failure in EAE demyelinating locale.", "tags": [{"end": 237, "start": 234, "tag": "ExperimentalModelOfDisease"}, {"end": 52, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 188, "tag": "Cell"}, {"end": 251, "start": 238, "tag": "PathologicFunction"}, {"end": 75, "start": 71, "tag": "Cell"}, {"end": 230, "start": 209, "tag": "CellOrMolecularDysfunction"}, {"end": 230, "start": 223, "tag": "IndividualBehavior"}, {"end": 187, "start": 179, "tag": "PopulationGroup"}, {"end": 105, "start": 97, "tag": "Cell"}, {"end": 222, "start": 209, "tag": "CellFunction"}, {"end": 67, "start": 53, "tag": "HealthCareActivity"}, {"end": 32, "start": 26, "tag": "HealthCareActivity"}, {"end": 165, "start": 127, "tag": "Finding"}]}{"id": "1262_0", "text": "During differentiation, oligodendrocyte precursor cells (OPCs) extend a network of processes that make contact with axons and initiate myelination.", "tags": [{"end": 121, "start": 116, "tag": "CellComponent"}, {"end": 61, "start": 57, "tag": "Cell"}, {"end": 55, "start": 24, "tag": "Cell"}, {"end": 22, "start": 7, "tag": "CellFunction"}, {"end": 55, "start": 40, "tag": "Cell"}, {"end": 49, "start": 24, "tag": "Cell"}, {"end": 146, "start": 135, "tag": "CellFunction"}, {"end": 92, "start": 72, "tag": "CellComponent"}]}{"id": "1262_1", "text": "Recent studies revealed that actin polymerization is required for initiation of myelination whereas actin depolymerization promotes myelin wrapping.", "tags": [{"end": 49, "start": 29, "tag": "CellFunction"}, {"end": 122, "start": 100, "tag": "CellFunction"}, {"end": 138, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 91, "start": 80, "tag": "CellFunction"}, {"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 66, "tag": "TemporalConcept"}, {"end": 147, "start": 132, "tag": "CellFunction"}]}{"id": "1262_2", "text": "Here, we used primary OPCs in culture isolated from neonatal rat cortices of both sexes and young male and female mice with oligodendrocyte-specific deletion of mechanistic target of rapamycin (mTOR) to demonstrate that mTOR regulates expression of specific cytoskeletal targets and actin reorganization in oligodendrocytes during developmental myelination.", "tags": [{"end": 97, "start": 92, "tag": "TemporalConcept"}, {"end": 198, "start": 194, "tag": "AminoAcidPeptideOrProtein"}, {"end": 224, "start": 220, "tag": "AminoAcidPeptideOrProtein"}, {"end": 198, "start": 194, "tag": "GeneOrGenome"}, {"end": 224, "start": 220, "tag": "GeneOrGenome"}, {"end": 198, "start": 194, "tag": "BiologicallyActiveSubstance"}, {"end": 224, "start": 220, "tag": "BiologicallyActiveSubstance"}, {"end": 323, "start": 307, "tag": "Cell"}, {"end": 26, "start": 14, "tag": "Cell"}, {"end": 344, "start": 331, "tag": "BiologicFunction"}, {"end": 344, "start": 331, "tag": "TemporalConcept"}, {"end": 37, "start": 30, "tag": "ResearchActivity"}, {"end": 140, "start": 124, "tag": "Cell"}, {"end": 64, "start": 61, "tag": "Eukaryote"}, {"end": 270, "start": 258, "tag": "CellComponent"}, {"end": 60, "start": 52, "tag": "PopulationGroup"}, {"end": 60, "start": 52, "tag": "TemporalConcept"}, {"end": 118, "start": 114, "tag": "Eukaryote"}, {"end": 245, "start": 235, "tag": "CellFunction"}, {"end": 113, "start": 107, "tag": "OrganismAttribute"}, {"end": 102, "start": 98, "tag": "OrganismAttribute"}, {"end": 356, "start": 345, "tag": "CellFunction"}, {"end": 87, "start": 82, "tag": "OrganismAttribute"}, {"end": 288, "start": 283, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 161, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 161, "tag": "BiologicallyActiveSubstance"}, {"end": 303, "start": 283, "tag": "CellFunction"}]}{"id": "1262_3", "text": "Loss or inhibition of mTOR reduced expression of profiling and ARPC3, actin polymerizing factors, and elevated levels of active cofilin, which mediates actin depolymerization.", "tags": [{"end": 68, "start": 63, "tag": "GeneOrGenome"}, {"end": 96, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 174, "start": 152, "tag": "CellFunction"}, {"end": 26, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 22, "tag": "GeneOrGenome"}, {"end": 26, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 35, "tag": "CellFunction"}, {"end": 58, "start": 49, "tag": "ResearchActivity"}, {"end": 18, "start": 8, "tag": "CellFunction"}, {"end": 75, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "Finding"}, {"end": 68, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 63, "tag": "BiologicallyActiveSubstance"}]}{"id": "1262_4", "text": "The deficits in actin polymerization were revealed in reduced phalloidin and deficits in oligodendrocyte cellular branching complexity at the peak of morphologic differentiation and a delay in initiation of myelination.", "tags": [{"end": 36, "start": 16, "tag": "CellFunction"}, {"end": 72, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 184, "tag": "TemporalConcept"}, {"end": 177, "start": 162, "tag": "CellFunction"}, {"end": 12, "start": 4, "tag": "Finding"}, {"end": 85, "start": 77, "tag": "Finding"}, {"end": 104, "start": 89, "tag": "Cell"}, {"end": 218, "start": 207, "tag": "CellFunction"}, {"end": 21, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 193, "tag": "TemporalConcept"}, {"end": 72, "start": 62, "tag": "Chemical"}, {"end": 72, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 105, "tag": "CellFunction"}]}{"id": "1262_5", "text": "We further show a critical role for mTOR in expression and localization of myelin basic protein (Mbp) mRNA and MBP protein to the cellular processes where it is necessary at the myelin membrane for axon wrapping.", "tags": [{"end": 95, "start": 59, "tag": "CellFunction"}, {"end": 193, "start": 178, "tag": "CellComponent"}, {"end": 40, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 36, "tag": "GeneOrGenome"}, {"end": 40, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 130, "tag": "CellFunction"}, {"end": 114, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 111, "tag": "GeneOrGenome"}, {"end": 184, "start": 178, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 202, "start": 198, "tag": "CellComponent"}, {"end": 193, "start": 185, "tag": "CellComponent"}, {"end": 54, "start": 44, "tag": "CellFunction"}, {"end": 138, "start": 130, "tag": "Cell"}, {"end": 106, "start": 102, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 122, "start": 115, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 211, "start": 198, "tag": "CellFunction"}]}{"id": "1262_6", "text": "Mbp mRNA transport deficits were confirmed by single molecule RNA FISH.", "tags": [{"end": 27, "start": 19, "tag": "Finding"}, {"end": 8, "start": 4, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 8, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 46, "tag": "ResearchActivity"}]}{"id": "1262_7", "text": "Moreover, expression of the kinesin family member 1B, an Mbp mRNA transport protein, was reduced in CC1 + cells in the mTOR cKO and in mTOR inhibited oligodendrocytes undergoing differentiation in vitro.", "tags": [{"end": 52, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 57, "tag": "GeneOrGenome"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 139, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 119, "tag": "GeneOrGenome"}, {"end": 139, "start": 135, "tag": "GeneOrGenome"}, {"end": 123, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 150, "tag": "Cell"}, {"end": 193, "start": 178, "tag": "CellFunction"}, {"end": 111, "start": 106, "tag": "Cell"}, {"end": 20, "start": 10, "tag": "CellFunction"}, {"end": 202, "start": 194, "tag": "ResearchActivity"}, {"end": 65, "start": 61, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 65, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 52, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 124, "tag": "ResearchActivity"}]}{"id": "1262_8", "text": "These data support the conclusion that mTOR regulates both initiation of myelination and axon wrapping by targeting cytoskeletal reorganization and MBP localization to oligodendrocyte processes.", "tags": [{"end": 143, "start": 116, "tag": "CellFunction"}, {"end": 164, "start": 148, "tag": "CellFunction"}, {"end": 43, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 39, "tag": "GeneOrGenome"}, {"end": 43, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 148, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 148, "tag": "GeneOrGenome"}, {"end": 93, "start": 89, "tag": "CellComponent"}, {"end": 128, "start": 116, "tag": "CellComponent"}, {"end": 183, "start": 168, "tag": "Cell"}, {"end": 84, "start": 73, "tag": "CellFunction"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 69, "start": 59, "tag": "TemporalConcept"}, {"end": 193, "start": 168, "tag": "CellComponent"}]}{"id": "1263_0", "text": "In multiple sclerosis (MS), oligodendrocyte precursor cells (OPCs) are recruited to the site of injury to remyelinate damaged axons; however, in patients this process is often ineffective due to defects in OPC maturation.", "tags": [{"end": 131, "start": 126, "tag": "CellComponent"}, {"end": 65, "start": 61, "tag": "Cell"}, {"end": 209, "start": 206, "tag": "Cell"}, {"end": 220, "start": 210, "tag": "BiologicFunction"}, {"end": 59, "start": 28, "tag": "Cell"}, {"end": 21, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 106, "tag": "CellFunction"}, {"end": 153, "start": 145, "tag": "PatientOrDisabledGroup"}, {"end": 102, "start": 96, "tag": "InjuryOrPoisoning"}, {"end": 25, "start": 23, "tag": "DiseaseOrSyndrome"}]}{"id": "1263_1", "text": "The membrane receptor GPR17 timely regulates the early stages of OPC differentiation; however, after reaching its highest levels in immature oligodendrocytes, it has to be downregulated to allow terminal maturation.", "tags": [{"end": 157, "start": 141, "tag": "Cell"}, {"end": 214, "start": 204, "tag": "BiologicFunction"}, {"end": 84, "start": 65, "tag": "CellFunction"}, {"end": 54, "start": 49, "tag": "TemporalConcept"}, {"end": 21, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 22, "tag": "GeneOrGenome"}, {"end": 27, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 132, "tag": "BiologicFunction"}, {"end": 27, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 55, "tag": "TemporalConcept"}, {"end": 185, "start": 172, "tag": "CellFunction"}]}{"id": "1263_2", "text": "Since, in several animal models of disease GPR17 is upregulated, the aim of this work was to characterize GPR17 alterations in MS patients.", "tags": [{"end": 48, "start": 43, "tag": "GeneOrGenome"}, {"end": 111, "start": 106, "tag": "GeneOrGenome"}, {"end": 48, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 130, "tag": "PatientOrDisabledGroup"}, {"end": 129, "start": 127, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 18, "tag": "ResearchActivity"}, {"end": 123, "start": 112, "tag": "Finding"}]}{"id": "1263_3", "text": "We developed immunohistochemistry and immunofluorescence procedures for the detection of GPR17 in human tissues and stained post-mortem MS brain lesions from patients with secondary progressive MS and control subjects.", "tags": [{"end": 67, "start": 38, "tag": "ResearchActivity"}, {"end": 135, "start": 124, "tag": "TemporalConcept"}, {"end": 152, "start": 139, "tag": "Finding"}, {"end": 128, "start": 124, "tag": "TemporalConcept"}, {"end": 196, "start": 172, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 145, "tag": "InjuryOrPoisoning"}, {"end": 94, "start": 89, "tag": "GeneOrGenome"}, {"end": 94, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 158, "tag": "PatientOrDisabledGroup"}, {"end": 103, "start": 98, "tag": "Eukaryote"}, {"end": 85, "start": 76, "tag": "ResearchActivity"}, {"end": 85, "start": 76, "tag": "HealthCareActivity"}, {"end": 217, "start": 201, "tag": "PopulationGroup"}, {"end": 138, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 13, "tag": "ResearchActivity"}, {"end": 111, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1263_4", "text": "The inflammatory activity in each lesion was evaluated by immunohistochemistry for the myelin protein MOG and the HLA antigen to classify them as active, chronic inactive or chronic active.", "tags": [{"end": 101, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 102, "tag": "GeneOrGenome"}, {"end": 125, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 40, "start": 34, "tag": "InjuryOrPoisoning"}, {"end": 25, "start": 4, "tag": "PathologicFunction"}, {"end": 78, "start": 58, "tag": "ResearchActivity"}, {"end": 161, "start": 154, "tag": "TemporalConcept"}, {"end": 181, "start": 174, "tag": "TemporalConcept"}, {"end": 105, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 102, "tag": "BiologicallyActiveSubstance"}]}{"id": "1263_5", "text": "Hence, we assessed the distribution of GPR17-positive cells in these lesions compared to normal appearing white matter (NAWM) and white matter (WM) of control subjects.", "tags": [{"end": 146, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 120, "tag": "ClinicalAttribute"}, {"end": 76, "start": 69, "tag": "InjuryOrPoisoning"}, {"end": 118, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 39, "tag": "GeneOrGenome"}, {"end": 44, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 54, "tag": "Cell"}, {"end": 167, "start": 151, "tag": "PopulationGroup"}, {"end": 167, "start": 159, "tag": "PopulationGroup"}, {"end": 105, "start": 89, "tag": "Finding"}]}{"id": "1263_6", "text": "Our data have shown a marked increase of GPR17-expressing oligodendroglial cells accumulating at NAWM, in which moderate inflammation was also found.", "tags": [{"end": 57, "start": 47, "tag": "CellFunction"}, {"end": 101, "start": 97, "tag": "ClinicalAttribute"}, {"end": 46, "start": 41, "tag": "GeneOrGenome"}, {"end": 46, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 58, "tag": "Cell"}, {"end": 133, "start": 121, "tag": "PathologicFunction"}, {"end": 120, "start": 112, "tag": "Finding"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}]}{"id": "1263_7", "text": "Furthermore, we identified two distinct subpopulations of GPR17-expressing oligodendroglial cells, characterized by either ramified or rounded morphology, that differently populate the WM of healthy controls and MS patients.", "tags": [{"end": 54, "start": 40, "tag": "PopulationGroup"}, {"end": 153, "start": 143, "tag": "OrganismAttribute"}, {"end": 74, "start": 64, "tag": "CellFunction"}, {"end": 187, "start": 185, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 58, "tag": "GeneOrGenome"}, {"end": 63, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 75, "tag": "Cell"}, {"end": 207, "start": 191, "tag": "PopulationGroup"}, {"end": 198, "start": 191, "tag": "OrganismAttribute"}, {"end": 223, "start": 215, "tag": "PatientOrDisabledGroup"}, {"end": 26, "start": 16, "tag": "Finding"}, {"end": 214, "start": 212, "tag": "DiseaseOrSyndrome"}]}{"id": "1263_8", "text": "We concluded that the coordinated presence of GPR17 in OPCs at the lesion sites and inflamed NAWM areas suggests that GPR17 could be exploited to support endogenous remyelination through advanced pharmacological approaches.", "tags": [{"end": 97, "start": 93, "tag": "ClinicalAttribute"}, {"end": 59, "start": 55, "tag": "Cell"}, {"end": 73, "start": 67, "tag": "InjuryOrPoisoning"}, {"end": 51, "start": 46, "tag": "GeneOrGenome"}, {"end": 123, "start": 118, "tag": "GeneOrGenome"}, {"end": 51, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 222, "start": 196, "tag": "HealthCareActivity"}, {"end": 178, "start": 165, "tag": "CellFunction"}, {"end": 42, "start": 34, "tag": "Finding"}]}{"id": "1264_0", "text": "In the last decade, microRNAs have been increasingly recognized as key modulators of glial development.", "tags": [{"end": 18, "start": 7, "tag": "TemporalConcept"}, {"end": 90, "start": 85, "tag": "Cell"}, {"end": 102, "start": 85, "tag": "CellFunction"}, {"end": 102, "start": 91, "tag": "BiologicFunction"}, {"end": 102, "start": 91, "tag": "CellFunction"}, {"end": 29, "start": 20, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 29, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 71, "tag": "BiologicallyActiveSubstance"}]}{"id": "1264_1", "text": "Recently, we identified miR-125a-3p as a new player in oligodendrocyte physiology, regulating in vitro differentiation of oligodendrocyte precursor cells (OPCs).", "tags": [{"end": 159, "start": 155, "tag": "Cell"}, {"end": 153, "start": 122, "tag": "Cell"}, {"end": 118, "start": 103, "tag": "CellFunction"}, {"end": 102, "start": 94, "tag": "ResearchActivity"}, {"end": 81, "start": 71, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 81, "start": 71, "tag": "BiologicFunction"}, {"end": 23, "start": 13, "tag": "Finding"}, {"end": 70, "start": 55, "tag": "Cell"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 35, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 24, "tag": "NucleicAcidNucleosideOrNucleotide"}]}{"id": "1264_2", "text": "Here, we show that miR-125a-3p is upregulated in active lesions of multiple sclerosis (MS) patients and in OPCs isolated from the spinal cord of chronic experimental autoimmune encephalomyelitis (EAE) mice, but not in those isolated from the spontaneously remyelinating corpus callosum of lysolecithin-treated mice.", "tags": [{"end": 194, "start": 153, "tag": "ExperimentalModelOfDisease"}, {"end": 199, "start": 196, "tag": "ExperimentalModelOfDisease"}, {"end": 111, "start": 107, "tag": "Cell"}, {"end": 85, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 56, "tag": "InjuryOrPoisoning"}, {"end": 141, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 301, "start": 289, "tag": "Chemical"}, {"end": 301, "start": 289, "tag": "PharmacologicSubstance"}, {"end": 269, "start": 256, "tag": "CellFunction"}, {"end": 285, "start": 270, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 91, "tag": "PatientOrDisabledGroup"}, {"end": 205, "start": 201, "tag": "Eukaryote"}, {"end": 314, "start": 310, "tag": "Eukaryote"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 145, "tag": "TemporalConcept"}, {"end": 30, "start": 19, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 30, "start": 19, "tag": "BiologicallyActiveSubstance"}]}{"id": "1264_3", "text": "To test whether a sustained expression of miR-125a-3p in OPCs contribute to defective remyelination, we modulated miR-125a-3p expression in vivo and ex vivo after lysolecithin-induced demyelination.", "tags": [{"end": 61, "start": 57, "tag": "Cell"}, {"end": 175, "start": 163, "tag": "Chemical"}, {"end": 175, "start": 163, "tag": "PharmacologicSubstance"}, {"end": 38, "start": 28, "tag": "CellFunction"}, {"end": 136, "start": 126, "tag": "CellFunction"}, {"end": 144, "start": 137, "tag": "ResearchActivity"}, {"end": 197, "start": 184, "tag": "PathologicFunction"}, {"end": 53, "start": 42, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 53, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 114, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 99, "start": 76, "tag": "CellOrMolecularDysfunction"}, {"end": 156, "start": 149, "tag": "ResearchActivity"}]}{"id": "1264_4", "text": "We found that lentiviral over-expression of miR-125a-3p impaired OPC maturation, whereas its downregulation accelerated remyelination.", "tags": [{"end": 68, "start": 65, "tag": "Cell"}, {"end": 79, "start": 69, "tag": "BiologicFunction"}, {"end": 107, "start": 93, "tag": "CellFunction"}, {"end": 40, "start": 25, "tag": "CellFunction"}, {"end": 133, "start": 120, "tag": "CellFunction"}, {"end": 55, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 44, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 24, "start": 14, "tag": "Virus"}]}{"id": "1264_5", "text": "Transcriptome analysis and luciferase reporter assay revealed that these effects are partly mediated by the direct interaction of miR-125a-3p with Slc8a3, a sodium-calcium membrane transporter, and identified novel candidate targets, such as Gas7, that we demonstrated necessary to correctly address oligodendrocytes to terminal maturation.", "tags": [{"end": 22, "start": 0, "tag": "ResearchActivity"}, {"end": 153, "start": 147, "tag": "GeneOrGenome"}, {"end": 153, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 246, "start": 242, "tag": "GeneOrGenome"}, {"end": 246, "start": 242, "tag": "AminoAcidPeptideOrProtein"}, {"end": 316, "start": 300, "tag": "Cell"}, {"end": 339, "start": 329, "tag": "BiologicFunction"}, {"end": 171, "start": 164, "tag": "Chemical"}, {"end": 171, "start": 164, "tag": "PharmacologicSubstance"}, {"end": 171, "start": 164, "tag": "BiologicallyActiveSubstance"}, {"end": 180, "start": 172, "tag": "CellComponent"}, {"end": 52, "start": 27, "tag": "ResearchActivity"}, {"end": 80, "start": 73, "tag": "Finding"}, {"end": 153, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 130, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 141, "start": 130, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 163, "start": 157, "tag": "Chemical"}]}{"id": "1264_6", "text": "These findings show that miR-125a-3p upregulation negatively affects OPC maturation in vivo, suggest its role in the pathogenesis of demyelinating diseases and unveil new targets for future promyelinating protective interventions.", "tags": [{"end": 229, "start": 190, "tag": "HealthCareActivity"}, {"end": 72, "start": 69, "tag": "Cell"}, {"end": 155, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 73, "tag": "BiologicFunction"}, {"end": 146, "start": 133, "tag": "PathologicFunction"}, {"end": 129, "start": 117, "tag": "PathologicFunction"}, {"end": 91, "start": 84, "tag": "ResearchActivity"}, {"end": 189, "start": 183, "tag": "TemporalConcept"}, {"end": 49, "start": 37, "tag": "CellFunction"}, {"end": 36, "start": 25, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 36, "start": 25, "tag": "BiologicallyActiveSubstance"}]}{"id": "1265_0", "text": "One of the most important goals in the treatment of demyelinating diseases such as multiple sclerosis (MS) is, in addition to immunomodulation, reconstruction of the lost myelin sheath.", "tags": [{"end": 142, "start": 126, "tag": "BiologicFunction"}, {"end": 142, "start": 126, "tag": "HealthCareActivity"}, {"end": 142, "start": 126, "tag": "PharmacologicSubstance"}, {"end": 158, "start": 144, "tag": "MachineActivity"}, {"end": 158, "start": 144, "tag": "HealthCareActivity"}, {"end": 170, "start": 166, "tag": "Finding"}, {"end": 74, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 39, "tag": "HealthCareActivity"}, {"end": 48, "start": 39, "tag": "ResearchActivity"}, {"end": 184, "start": 171, "tag": "CellComponent"}, {"end": 105, "start": 103, "tag": "DiseaseOrSyndrome"}]}{"id": "1265_1", "text": "The modulator of the central nervous system myelination is the metabotropic receptor coupled to the G-protein: GPR17.", "tags": [{"end": 84, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 111, "tag": "GeneOrGenome"}, {"end": 116, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 44, "tag": "CellFunction"}, {"end": 109, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 4, "tag": "BiologicallyActiveSubstance"}]}{"id": "1265_2", "text": "GPR17 receptors are considered to be sensors of local damage to the myelin sheath, and play a role in the reconstruction and repair of demyelinating plaques caused by ongoing inflammatory processes.", "tags": [{"end": 44, "start": 37, "tag": "ManufacturedObject"}, {"end": 120, "start": 106, "tag": "MachineActivity"}, {"end": 120, "start": 106, "tag": "HealthCareActivity"}, {"end": 148, "start": 135, "tag": "PathologicFunction"}, {"end": 74, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 187, "start": 175, "tag": "PathologicFunction"}, {"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 149, "tag": "AnatomicalAbnormality"}, {"end": 174, "start": 167, "tag": "TemporalConcept"}, {"end": 81, "start": 68, "tag": "CellComponent"}, {"end": 15, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 125, "tag": "BiologicFunction"}, {"end": 131, "start": 125, "tag": "HealthCareActivity"}, {"end": 60, "start": 54, "tag": "InjuryOrPoisoning"}]}{"id": "1265_3", "text": "GPR17 receptors are present on nerve cells and precursor oligodendrocyte cells.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 47, "tag": "Cell"}, {"end": 15, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 31, "tag": "Cell"}]}{"id": "1265_4", "text": "Under physiological conditions, they are responsible for the differentiation and subsequent maturation of oligodendrocytes, while under pathological conditions (during damage to nerve cells), their expression increases to become mediators in the demyelinating processes.", "tags": [{"end": 159, "start": 136, "tag": "PathologicFunction"}, {"end": 122, "start": 106, "tag": "Cell"}, {"end": 102, "start": 92, "tag": "BiologicFunction"}, {"end": 269, "start": 246, "tag": "PathologicFunction"}, {"end": 76, "start": 61, "tag": "CellFunction"}, {"end": 208, "start": 198, "tag": "CellFunction"}, {"end": 238, "start": 229, "tag": "Finding"}, {"end": 189, "start": 178, "tag": "Cell"}, {"end": 174, "start": 168, "tag": "InjuryOrPoisoning"}]}{"id": "1265_5", "text": "Moreover, they are essential not only in both the processes of inducing damage and the death of neurons, but also in the local repair of the damaged myelin sheath.", "tags": [{"end": 155, "start": 141, "tag": "CellOrMolecularDysfunction"}, {"end": 155, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 87, "tag": "BiologicFunction"}, {"end": 92, "start": 87, "tag": "PathologicFunction"}, {"end": 92, "start": 87, "tag": "CellFunction"}, {"end": 103, "start": 96, "tag": "Cell"}, {"end": 162, "start": 149, "tag": "CellComponent"}, {"end": 133, "start": 127, "tag": "BiologicFunction"}, {"end": 133, "start": 127, "tag": "HealthCareActivity"}, {"end": 78, "start": 72, "tag": "InjuryOrPoisoning"}]}{"id": "1265_6", "text": "Therefore, GPR17 receptors may be recognized as the potential goal in creating innovative therapies for the treatment of the neurodegenerative process in MS, based on the acceleration of the remyelination processes.", "tags": [{"end": 99, "start": 79, "tag": "HealthCareActivity"}, {"end": 16, "start": 11, "tag": "GeneOrGenome"}, {"end": 16, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 125, "tag": "CellOrMolecularDysfunction"}, {"end": 117, "start": 108, "tag": "HealthCareActivity"}, {"end": 117, "start": 108, "tag": "ResearchActivity"}, {"end": 214, "start": 191, "tag": "CellFunction"}, {"end": 156, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 17, "tag": "BiologicallyActiveSubstance"}]}{"id": "1265_7", "text": "This review examines the role of GRP17 in pathomechanisms of MS development.", "tags": [{"end": 38, "start": 33, "tag": "GeneOrGenome"}, {"end": 75, "start": 64, "tag": "BiologicFunction"}, {"end": 75, "start": 64, "tag": "CellFunction"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 63, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 42, "tag": "PathologicFunction"}]}{"id": "1266_0", "text": "Microglia are important for central nervous system (CNS) homeostasis and first to respond to tissue damage and perturbations.", "tags": [{"end": 106, "start": 93, "tag": "InjuryOrPoisoning"}, {"end": 78, "start": 73, "tag": "TemporalConcept"}, {"end": 99, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 0, "tag": "Cell"}, {"end": 68, "start": 57, "tag": "BiologicFunction"}]}{"id": "1266_1", "text": "Microglia are heterogeneous cells; in case of pathology, microglia adopt a range of phenotypes with altered functions.", "tags": [{"end": 94, "start": 84, "tag": "OrganismAttribute"}, {"end": 42, "start": 38, "tag": "ManufacturedObject"}, {"end": 27, "start": 14, "tag": "OrganismAttribute"}, {"end": 33, "start": 28, "tag": "Cell"}, {"end": 9, "start": 0, "tag": "Cell"}, {"end": 55, "start": 46, "tag": "PathologicFunction"}, {"end": 55, "start": 46, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 66, "start": 57, "tag": "Cell"}]}{"id": "1266_2", "text": "However, how these different microglia subtypes are implicated in CNS disease is largely unresolved.", "tags": [{"end": 77, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 29, "tag": "Cell"}]}{"id": "1266_3", "text": "Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS, characterized by inflammation and axonal degeneration, ultimately leading to neurological decline.", "tags": [{"end": 168, "start": 148, "tag": "Finding"}, {"end": 69, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 29, "tag": "TemporalConcept"}, {"end": 124, "start": 105, "tag": "CellOrMolecularDysfunction"}, {"end": 100, "start": 88, "tag": "PathologicFunction"}]}{"id": "1266_4", "text": "One way microglia are implicated in MS is through stimulation of remyelination.", "tags": [{"end": 61, "start": 50, "tag": "HealthCareActivity"}, {"end": 61, "start": 50, "tag": "NaturalPhenomenonOrProcess"}, {"end": 78, "start": 65, "tag": "CellFunction"}, {"end": 38, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 8, "tag": "Cell"}]}{"id": "1266_5", "text": "They facilitate efficient remyelination by phagocytosis of myelin debris.", "tags": [{"end": 65, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 26, "tag": "CellFunction"}, {"end": 55, "start": 43, "tag": "CellFunction"}, {"end": 72, "start": 66, "tag": "Substance"}]}{"id": "1266_6", "text": "In addition, microglia recruit oligodendrocyte precursor cells (OPCs) to demyelinated areas and stimulate remyelination.", "tags": [{"end": 105, "start": 96, "tag": "NaturalPhenomenonOrProcess"}, {"end": 68, "start": 64, "tag": "Cell"}, {"end": 62, "start": 31, "tag": "Cell"}, {"end": 119, "start": 106, "tag": "CellFunction"}, {"end": 22, "start": 13, "tag": "Cell"}, {"end": 85, "start": 73, "tag": "PathologicFunction"}]}{"id": "1266_7", "text": "The development of high-resolution technologies to profile individual cells has greatly contributed to our understanding of microglia heterogeneity and function under normal and pathological conditions.", "tags": [{"end": 147, "start": 134, "tag": "OrganismAttribute"}, {"end": 201, "start": 178, "tag": "PathologicFunction"}, {"end": 75, "start": 70, "tag": "Cell"}, {"end": 15, "start": 4, "tag": "BiologicFunction"}, {"end": 15, "start": 4, "tag": "CellFunction"}, {"end": 133, "start": 124, "tag": "Cell"}, {"end": 120, "start": 107, "tag": "BiologicFunction"}, {"end": 173, "start": 167, "tag": "Finding"}, {"end": 47, "start": 19, "tag": "ResearchActivity"}]}{"id": "1266_8", "text": "Gene expression profiling technologies have evolved from whole tissue RNA sequencing toward single-cell or nucleus sequencing.", "tags": [{"end": 38, "start": 0, "tag": "ResearchActivity"}, {"end": 84, "start": 70, "tag": "ResearchActivity"}, {"end": 125, "start": 115, "tag": "ResearchActivity"}, {"end": 103, "start": 92, "tag": "ResearchActivity"}, {"end": 114, "start": 107, "tag": "Chemical"}, {"end": 114, "start": 107, "tag": "CellComponent"}, {"end": 84, "start": 57, "tag": "ResearchActivity"}, {"end": 125, "start": 107, "tag": "ResearchActivity"}, {"end": 99, "start": 92, "tag": "ResearchActivity"}]}{"id": "1266_9", "text": "Single microglia proteomic profiles are also increasingly generated, offering another layer of high-resolution data.", "tags": [{"end": 35, "start": 0, "tag": "ResearchActivity"}, {"end": 91, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 95, "tag": "ResearchActivity"}]}{"id": "1266_10", "text": "Here, we will review recent studies that have employed these technologies in the context of MS and their respective advantages and disadvantages.", "tags": [{"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 28, "tag": "ResearchActivity"}, {"end": 27, "start": 21, "tag": "TemporalConcept"}, {"end": 73, "start": 61, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1266_11", "text": "Moreover, recent developments that allow for (single) cell profiling while retaining spatial information and tissue context will be discussed.", "tags": [{"end": 29, "start": 17, "tag": "BiologicFunction"}, {"end": 29, "start": 17, "tag": "CellFunction"}, {"end": 115, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 10, "tag": "TemporalConcept"}, {"end": 68, "start": 45, "tag": "ResearchActivity"}]}{"id": "1267_0", "text": "We have previously demonstrated that thyromimetics stimulate oligodendrocyte precursor cell differentiation and promote remyelination in murine demyelination models.", "tags": [{"end": 143, "start": 137, "tag": "Eukaryote"}, {"end": 133, "start": 120, "tag": "CellFunction"}, {"end": 157, "start": 144, "tag": "PathologicFunction"}, {"end": 107, "start": 92, "tag": "CellFunction"}, {"end": 164, "start": 158, "tag": "ResearchActivity"}, {"end": 107, "start": 61, "tag": "CellFunction"}, {"end": 50, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 137, "tag": "ExperimentalModelOfDisease"}]}{"id": "1267_1", "text": "We investigated whether a thyroid receptor-beta selective thyromimetic, sobetirome (Sob), and its CNS-targeted prodrug, Sob-AM2, could prevent myelin and axonal degeneration in experimental autoimmune encephalomyelitis (EAE).", "tags": [{"end": 82, "start": 72, "tag": "Chemical"}, {"end": 87, "start": 84, "tag": "Chemical"}, {"end": 218, "start": 177, "tag": "ExperimentalModelOfDisease"}, {"end": 223, "start": 220, "tag": "ExperimentalModelOfDisease"}, {"end": 118, "start": 111, "tag": "Chemical"}, {"end": 149, "start": 143, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 154, "tag": "CellOrMolecularDysfunction"}, {"end": 127, "start": 120, "tag": "Chemical"}]}{"id": "1267_2", "text": "Compared to controls, EAE mice receiving triiodothyronine (T3, 0.4 mg/kg), Sob (5 mg/kg) or Sob-AM2 (5 mg/kg) had reduced clinical disease and, within the spinal cord, less tissue damage, more normally myelinated axons, fewer degenerating axons and more oligodendrocytes.", "tags": [{"end": 57, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 75, "tag": "Chemical"}, {"end": 238, "start": 226, "tag": "PathologicFunction"}, {"end": 30, "start": 22, "tag": "ExperimentalModelOfDisease"}, {"end": 20, "start": 12, "tag": "PopulationGroup"}, {"end": 179, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 244, "start": 239, "tag": "CellComponent"}, {"end": 270, "start": 254, "tag": "Cell"}, {"end": 166, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 218, "start": 202, "tag": "CellComponent"}, {"end": 99, "start": 92, "tag": "Chemical"}, {"end": 186, "start": 180, "tag": "InjuryOrPoisoning"}]}{"id": "1267_3", "text": "T3 and Sob also protected cultured oligodendrocytes against cell death.", "tags": [{"end": 2, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 2, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 10, "start": 7, "tag": "Chemical"}, {"end": 34, "start": 26, "tag": "ResearchActivity"}, {"end": 70, "start": 60, "tag": "CellFunction"}, {"end": 51, "start": 35, "tag": "Cell"}]}{"id": "1267_4", "text": "Thyromimetics thus might protect against oligodendrocyte death, demyelination and axonal degeneration as well as stimulate remyelination in multiple sclerosis.", "tags": [{"end": 62, "start": 57, "tag": "CellFunction"}, {"end": 56, "start": 41, "tag": "Cell"}, {"end": 158, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 123, "tag": "CellFunction"}, {"end": 77, "start": 64, "tag": "PathologicFunction"}, {"end": 88, "start": 82, "tag": "CellComponent"}, {"end": 101, "start": 82, "tag": "CellOrMolecularDysfunction"}, {"end": 13, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 57, "tag": "PathologicFunction"}, {"end": 62, "start": 57, "tag": "BiologicFunction"}]}{"id": "1268_0", "text": "Inside the adult CNS, oligodendrocyte progenitor cells (OPCS) are able to proliferate, migrate and differentiate into mature oligodendrocytes (OLs) which are responsible for the production of myelin sheet and energy supply for neurons.", "tags": [{"end": 60, "start": 56, "tag": "Cell"}, {"end": 112, "start": 99, "tag": "CellFunction"}, {"end": 198, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 141, "start": 118, "tag": "Cell"}, {"end": 54, "start": 22, "tag": "Cell"}, {"end": 146, "start": 143, "tag": "Cell"}, {"end": 234, "start": 227, "tag": "Cell"}, {"end": 215, "start": 209, "tag": "NaturalPhenomenonOrProcess"}, {"end": 16, "start": 11, "tag": "PopulationGroup"}]}{"id": "1268_1", "text": "Moreover, in demyelinating diseases, OPCs are recruited to the lesion areas where they undergo differentiation and myelin synthesis.", "tags": [{"end": 41, "start": 37, "tag": "Cell"}, {"end": 35, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 63, "tag": "InjuryOrPoisoning"}, {"end": 110, "start": 95, "tag": "CellFunction"}, {"end": 131, "start": 115, "tag": "CellFunction"}]}{"id": "1268_2", "text": "Serotonin (5-hydroxytryptamine, 5-HT) is involved in OLs' development and myelination, but so far the molecular mechanisms involved or the effects of 5-HT on mitochondria function have not yet been well documented.", "tags": [{"end": 9, "start": 0, "tag": "Chemical"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 11, "tag": "Chemical"}, {"end": 30, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 32, "tag": "Chemical"}, {"end": 154, "start": 150, "tag": "Chemical"}, {"end": 213, "start": 203, "tag": "HealthCareActivity"}, {"end": 170, "start": 158, "tag": "CellComponent"}, {"end": 85, "start": 74, "tag": "CellFunction"}, {"end": 69, "start": 58, "tag": "BiologicFunction"}, {"end": 69, "start": 58, "tag": "CellFunction"}, {"end": 56, "start": 53, "tag": "Cell"}, {"end": 122, "start": 102, "tag": "CellFunction"}, {"end": 36, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 150, "tag": "BiologicallyActiveSubstance"}]}{"id": "1268_3", "text": "Our data show that 5-HT inhibits migration and proliferation committing cells toward differentiation in an immortalized human oligodendrocyte precursor cell line, M03-13.", "tags": [{"end": 23, "start": 19, "tag": "Chemical"}, {"end": 161, "start": 107, "tag": "Cell"}, {"end": 77, "start": 72, "tag": "Cell"}, {"end": 100, "start": 85, "tag": "CellFunction"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 60, "start": 47, "tag": "CellFunction"}, {"end": 42, "start": 33, "tag": "CellFunction"}, {"end": 156, "start": 126, "tag": "Cell"}, {"end": 125, "start": 120, "tag": "Eukaryote"}, {"end": 23, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 163, "tag": "Cell"}]}{"id": "1268_4", "text": "Migration blockage is mediated by reactive oxygen species (ROS) generation since antioxidants, such as Vit C and Cu-Zn superoxide dismutase, prevent the inhibitory effects of 5-HT on cell migration.", "tags": [{"end": 9, "start": 0, "tag": "BiologicFunction"}, {"end": 9, "start": 0, "tag": "Finding"}, {"end": 18, "start": 10, "tag": "Finding"}, {"end": 108, "start": 103, "tag": "Chemical"}, {"end": 139, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 175, "tag": "Chemical"}, {"end": 197, "start": 183, "tag": "CellFunction"}, {"end": 93, "start": 81, "tag": "PharmacologicSubstance"}, {"end": 57, "start": 50, "tag": "OrganismAttribute"}, {"end": 57, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 34, "tag": "Chemical"}, {"end": 62, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 59, "tag": "Chemical"}, {"end": 163, "start": 153, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 164, "tag": "PathologicFunction"}, {"end": 74, "start": 64, "tag": "TemporalConcept"}, {"end": 179, "start": 175, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 103, "tag": "BiologicallyActiveSubstance"}]}{"id": "1268_5", "text": "5-HT inhibits OPC migration and proliferation and increases OL phenotypic markers myelin basic protein (MBP) and Olig-2 via protein kinase C (PKC) activation since the inhibitor of PKC, bis-indolyl-maleimide (BIM), counteracts 5-HT effects.", "tags": [{"end": 4, "start": 0, "tag": "Chemical"}, {"end": 119, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 145, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 181, "tag": "BiologicallyActiveSubstance"}, {"end": 231, "start": 227, "tag": "Chemical"}, {"end": 73, "start": 63, "tag": "OrganismAttribute"}, {"end": 177, "start": 168, "tag": "BiologicallyActiveSubstance"}, {"end": 177, "start": 168, "tag": "PharmacologicSubstance"}, {"end": 177, "start": 168, "tag": "Chemical"}, {"end": 107, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 104, "tag": "GeneOrGenome"}, {"end": 17, "start": 14, "tag": "Cell"}, {"end": 62, "start": 60, "tag": "Cell"}, {"end": 45, "start": 32, "tag": "CellFunction"}, {"end": 27, "start": 18, "tag": "CellFunction"}, {"end": 102, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 74, "tag": "ClinicalAttribute"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 231, "start": 227, "tag": "BiologicallyActiveSubstance"}, {"end": 207, "start": 186, "tag": "Chemical"}, {"end": 207, "start": 186, "tag": "PharmacologicSubstance"}, {"end": 212, "start": 209, "tag": "PharmacologicSubstance"}, {"end": 212, "start": 209, "tag": "Chemical"}, {"end": 145, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 113, "tag": "BiologicallyActiveSubstance"}]}{"id": "1268_6", "text": "NOX inhibitors as well, reverse the effects of 5-HT, indicating that 5-HT influences the maturation process of OPCs by NOX-dependent ROS production.", "tags": [{"end": 51, "start": 47, "tag": "Chemical"}, {"end": 73, "start": 69, "tag": "Chemical"}, {"end": 147, "start": 133, "tag": "CellFunction"}, {"end": 136, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 133, "tag": "Chemical"}, {"end": 115, "start": 111, "tag": "Cell"}, {"end": 99, "start": 89, "tag": "BiologicFunction"}, {"end": 14, "start": 4, "tag": "Chemical"}, {"end": 14, "start": 4, "tag": "PharmacologicSubstance"}, {"end": 14, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 119, "tag": "BiologicallyActiveSubstance"}]}{"id": "1268_7", "text": "Finally, 5-HT increases mitochondria function and antioxidant activity.", "tags": [{"end": 13, "start": 9, "tag": "Chemical"}, {"end": 70, "start": 50, "tag": "CellFunction"}, {"end": 36, "start": 24, "tag": "CellComponent"}, {"end": 13, "start": 9, "tag": "BiologicallyActiveSubstance"}]}{"id": "1268_8", "text": "The identification of the molecular mechanisms underlying the effects of 5-HT on maturation and energy metabolism of OPCs could pave the way for the development of new treatments for autoimmune demyelinating diseases such as Multiple Sclerosis where oligodendrocytes are the primary target of immune attack.", "tags": [{"end": 77, "start": 73, "tag": "Chemical"}, {"end": 216, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 96, "tag": "BiologicFunction"}, {"end": 306, "start": 300, "tag": "Finding"}, {"end": 266, "start": 250, "tag": "Cell"}, {"end": 121, "start": 117, "tag": "Cell"}, {"end": 91, "start": 81, "tag": "BiologicFunction"}, {"end": 160, "start": 149, "tag": "BiologicFunction"}, {"end": 160, "start": 149, "tag": "CellFunction"}, {"end": 46, "start": 26, "tag": "CellFunction"}, {"end": 178, "start": 168, "tag": "HealthCareActivity"}, {"end": 178, "start": 168, "tag": "ResearchActivity"}, {"end": 243, "start": 225, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 306, "start": 293, "tag": "BiologicFunction"}]}{"id": "1269_0", "text": "Generation of oligodendrocytes in the adult brain enables both adaptive changes in neural circuits and regeneration of myelin sheaths destroyed by injury, disease, and normal aging.", "tags": [{"end": 115, "start": 103, "tag": "BiologicFunction"}, {"end": 133, "start": 119, "tag": "CellComponent"}, {"end": 115, "start": 103, "tag": "HealthCareActivity"}, {"end": 98, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 0, "tag": "CellFunction"}, {"end": 79, "start": 63, "tag": "Finding"}, {"end": 49, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 168, "tag": "Finding"}, {"end": 153, "start": 147, "tag": "InjuryOrPoisoning"}, {"end": 43, "start": 38, "tag": "PopulationGroup"}, {"end": 180, "start": 175, "tag": "BiologicFunction"}, {"end": 180, "start": 175, "tag": "CellFunction"}]}{"id": "1269_1", "text": "This transformation of oligodendrocyte precursor cells (OPCs) into myelinating oligodendrocytes requires processing of distinct mRNAs at different stages of cell maturation.", "tags": [{"end": 19, "start": 5, "tag": "Finding"}, {"end": 172, "start": 157, "tag": "CellFunction"}, {"end": 60, "start": 56, "tag": "Cell"}, {"end": 54, "start": 23, "tag": "Cell"}, {"end": 95, "start": 67, "tag": "Cell"}, {"end": 153, "start": 147, "tag": "TemporalConcept"}, {"end": 133, "start": 128, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 133, "start": 128, "tag": "BiologicallyActiveSubstance"}]}{"id": "1269_2", "text": "Although mislocalization and aggregation of the RNA-binding protein, TDP-43, occur in both neurons and glia in neurodegenerative diseases, the consequences of TDP-43 loss within different stages of the oligodendrocyte lineage are not well understood.", "tags": [{"end": 67, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 202, "tag": "Cell"}, {"end": 170, "start": 159, "tag": "CellOrMolecularDysfunction"}, {"end": 137, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 103, "tag": "Cell"}, {"end": 98, "start": 91, "tag": "Cell"}, {"end": 40, "start": 29, "tag": "CellFunction"}, {"end": 40, "start": 29, "tag": "ResearchActivity"}, {"end": 194, "start": 188, "tag": "TemporalConcept"}, {"end": 75, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 165, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 52, "tag": "CellFunction"}, {"end": 51, "start": 48, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 67, "start": 60, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1269_3", "text": "By performing stage-specific genetic inactivation of Tardbp in vivo, we show that oligodendrocyte lineage cells are differentially sensitive to loss of TDP-43.", "tags": [{"end": 59, "start": 53, "tag": "GeneOrGenome"}, {"end": 111, "start": 82, "tag": "Cell"}, {"end": 49, "start": 37, "tag": "CellFunction"}, {"end": 36, "start": 29, "tag": "HealthCareActivity"}, {"end": 158, "start": 144, "tag": "CellOrMolecularDysfunction"}, {"end": 67, "start": 60, "tag": "ResearchActivity"}, {"end": 140, "start": 131, "tag": "PathologicFunction"}, {"end": 158, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 152, "tag": "BiologicallyActiveSubstance"}]}{"id": "1269_4", "text": "While OPCs depend on TDP-43 for survival, with conditional deletion resulting in cascading cell loss followed by rapid regeneration to restore their density, oligodendrocytes become less sensitive to TDP-43 depletion as they mature.", "tags": [{"end": 174, "start": 158, "tag": "Cell"}, {"end": 10, "start": 6, "tag": "Cell"}, {"end": 131, "start": 119, "tag": "BiologicFunction"}, {"end": 231, "start": 225, "tag": "TemporalConcept"}, {"end": 131, "start": 119, "tag": "HealthCareActivity"}, {"end": 100, "start": 91, "tag": "CellOrMolecularDysfunction"}, {"end": 216, "start": 200, "tag": "CellOrMolecularDysfunction"}, {"end": 40, "start": 32, "tag": "CellFunction"}, {"end": 196, "start": 187, "tag": "PathologicFunction"}, {"end": 27, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 206, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 206, "start": 200, "tag": "BiologicallyActiveSubstance"}]}{"id": "1269_5", "text": "Deletion of TDP-43 early in the maturation process led to eventual oligodendrocyte degeneration, seizures, and premature lethality, while oligodendrocytes that experienced late deletion survived and mice exhibited a normal lifespan.", "tags": [{"end": 18, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 105, "start": 97, "tag": "SignOrSymptom"}, {"end": 105, "start": 97, "tag": "Finding"}, {"end": 185, "start": 177, "tag": "CellOrMolecularDysfunction"}, {"end": 231, "start": 223, "tag": "TemporalConcept"}, {"end": 154, "start": 138, "tag": "Cell"}, {"end": 42, "start": 32, "tag": "BiologicFunction"}, {"end": 24, "start": 19, "tag": "TemporalConcept"}, {"end": 95, "start": 83, "tag": "PathologicFunction"}, {"end": 120, "start": 111, "tag": "TemporalConcept"}, {"end": 130, "start": 121, "tag": "Finding"}, {"end": 176, "start": 172, "tag": "TemporalConcept"}, {"end": 203, "start": 199, "tag": "Eukaryote"}, {"end": 222, "start": 216, "tag": "Finding"}, {"end": 82, "start": 67, "tag": "Cell"}, {"end": 18, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 12, "tag": "BiologicallyActiveSubstance"}]}{"id": "1269_6", "text": "At both stages, TDP-43-deficient oligodendrocytes formed fewer and thinner myelin sheaths and extended new processes that inappropriately wrapped neuronal somata and blood vessels.", "tags": [{"end": 179, "start": 166, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 33, "tag": "Cell"}, {"end": 89, "start": 75, "tag": "CellComponent"}, {"end": 154, "start": 146, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "TemporalConcept"}, {"end": 22, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 16, "tag": "BiologicallyActiveSubstance"}]}{"id": "1269_7", "text": "Transcriptional analysis revealed that in the absence of TDP-43, key proteins involved in oligodendrocyte maturation and myelination were misspliced, leading to aberrant incorporation of cryptic exons.", "tags": [{"end": 169, "start": 161, "tag": "PathologicFunction"}, {"end": 116, "start": 106, "tag": "BiologicFunction"}, {"end": 24, "start": 0, "tag": "ResearchActivity"}, {"end": 53, "start": 46, "tag": "Finding"}, {"end": 200, "start": 187, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 200, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 90, "tag": "Cell"}, {"end": 132, "start": 121, "tag": "CellFunction"}, {"end": 63, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 57, "tag": "BiologicallyActiveSubstance"}]}{"id": "1269_8", "text": "Inducible deletion of TDP-43 from oligodendrocytes in the adult central nervous system (CNS) induced the same progressive morphological changes and mice acquired profound hindlimb weakness, suggesting that loss of TDP-43 function in oligodendrocytes may contribute to neuronal dysfunction in neurodegenerative disease.", "tags": [{"end": 28, "start": 10, "tag": "CellOrMolecularDysfunction"}, {"end": 179, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 188, "start": 162, "tag": "SignOrSymptom"}, {"end": 288, "start": 268, "tag": "CellOrMolecularDysfunction"}, {"end": 50, "start": 34, "tag": "Cell"}, {"end": 249, "start": 233, "tag": "Cell"}, {"end": 229, "start": 206, "tag": "CellOrMolecularDysfunction"}, {"end": 143, "start": 122, "tag": "Finding"}, {"end": 86, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 148, "tag": "Eukaryote"}, {"end": 276, "start": 268, "tag": "Cell"}, {"end": 121, "start": 110, "tag": "TemporalConcept"}, {"end": 317, "start": 292, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 58, "tag": "PopulationGroup"}, {"end": 28, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 220, "start": 214, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 220, "start": 214, "tag": "BiologicallyActiveSubstance"}, {"end": 288, "start": 277, "tag": "PathologicFunction"}]}{"id": "1270_0", "text": "Brain and spinal cord oligodendroglia have distinct functional characteristics, and cell-autonomous loss of individual genes can result in different regional phenotypes.", "tags": [{"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 158, "tag": "OrganismAttribute"}, {"end": 21, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 22, "tag": "Cell"}, {"end": 124, "start": 84, "tag": "CellOrMolecularDysfunction"}]}{"id": "1270_1", "text": "However, a molecular basis for these distinctions is unknown.", "tags": []}{"id": "1270_2", "text": "Using single-cell analysis of oligodendroglia during developmental myelination, we demonstrate that brain and spinal cord precursors are transcriptionally distinct, defined predominantly by cholesterol biosynthesis.", "tags": [{"end": 26, "start": 6, "tag": "ResearchActivity"}, {"end": 154, "start": 137, "tag": "CellFunction"}, {"end": 214, "start": 190, "tag": "CellFunction"}, {"end": 201, "start": 190, "tag": "Chemical"}, {"end": 201, "start": 190, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 190, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 67, "tag": "CellFunction"}, {"end": 121, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 53, "tag": "BiologicFunction"}, {"end": 66, "start": 53, "tag": "TemporalConcept"}, {"end": 105, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 30, "tag": "Cell"}]}{"id": "1270_3", "text": "We further identify the mechanistic target of rapamycin (mTOR) as a major regulator promoting cholesterol biosynthesis in oligodendroglia.", "tags": [{"end": 118, "start": 94, "tag": "CellFunction"}, {"end": 105, "start": 94, "tag": "Chemical"}, {"end": 105, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 46, "tag": "Chemical"}, {"end": 61, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 57, "tag": "GeneOrGenome"}, {"end": 61, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 122, "tag": "Cell"}]}{"id": "1270_4", "text": "Oligodendroglia-specific loss of mTOR decreases cholesterol biosynthesis in both the brain and the spinal cord, but mTOR loss in spinal cord oligodendroglia has a greater impact on cholesterol biosynthesis, consistent with more pronounced deficits in developmental myelination.", "tags": [{"end": 47, "start": 38, "tag": "Finding"}, {"end": 72, "start": 48, "tag": "CellFunction"}, {"end": 205, "start": 181, "tag": "CellFunction"}, {"end": 59, "start": 48, "tag": "Chemical"}, {"end": 192, "start": 181, "tag": "Chemical"}, {"end": 59, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 192, "start": 181, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 33, "tag": "GeneOrGenome"}, {"end": 120, "start": 116, "tag": "GeneOrGenome"}, {"end": 37, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 276, "start": 265, "tag": "CellFunction"}, {"end": 110, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 264, "start": 251, "tag": "BiologicFunction"}, {"end": 264, "start": 251, "tag": "TemporalConcept"}, {"end": 90, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 141, "tag": "Cell"}, {"end": 247, "start": 239, "tag": "Finding"}, {"end": 125, "start": 116, "tag": "CellOrMolecularDysfunction"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 37, "start": 25, "tag": "CellOrMolecularDysfunction"}]}{"id": "1270_5", "text": "In the brain, mTOR loss results in a later adult myelin deficit, including oligodendrocyte death, spontaneous demyelination, and impaired axonal function, demonstrating that mTOR is required for myelin maintenance in the adult brain.", "tags": [{"end": 96, "start": 91, "tag": "BiologicFunction"}, {"end": 96, "start": 91, "tag": "PathologicFunction"}, {"end": 96, "start": 91, "tag": "CellFunction"}, {"end": 18, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 18, "start": 14, "tag": "GeneOrGenome"}, {"end": 178, "start": 174, "tag": "GeneOrGenome"}, {"end": 18, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 75, "tag": "Cell"}, {"end": 55, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 110, "tag": "PathologicFunction"}, {"end": 42, "start": 37, "tag": "TemporalConcept"}, {"end": 12, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 232, "start": 227, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 138, "tag": "CellComponent"}, {"end": 213, "start": 202, "tag": "BiologicFunction"}, {"end": 48, "start": 43, "tag": "PopulationGroup"}, {"end": 226, "start": 221, "tag": "PopulationGroup"}, {"end": 23, "start": 14, "tag": "CellOrMolecularDysfunction"}, {"end": 63, "start": 49, "tag": "PathologicFunction"}]}{"id": "1271_0", "text": "Oligodendrocyte precursor cells (OPCs) are essential for developmental myelination and oligodendrocyte regeneration after CNS injury.", "tags": [{"end": 132, "start": 122, "tag": "InjuryOrPoisoning"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 82, "start": 71, "tag": "CellFunction"}, {"end": 102, "start": 87, "tag": "Cell"}, {"end": 125, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 57, "tag": "BiologicFunction"}, {"end": 70, "start": 57, "tag": "TemporalConcept"}, {"end": 115, "start": 103, "tag": "BiologicFunction"}, {"end": 115, "start": 103, "tag": "HealthCareActivity"}, {"end": 31, "start": 0, "tag": "Cell"}]}{"id": "1271_1", "text": "These progenitors express calcium-permeable AMPA receptors (AMPARs) and form direct synapses with neurons throughout the CNS, but the roles of this signaling are unclear.", "tags": [{"end": 17, "start": 6, "tag": "Cell"}, {"end": 66, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 18, "tag": "CellFunction"}, {"end": 124, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 157, "start": 148, "tag": "CellFunction"}, {"end": 105, "start": 98, "tag": "Cell"}, {"end": 58, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 60, "tag": "BiologicallyActiveSubstance"}]}{"id": "1271_2", "text": "To enable selective alteration of the properties of AMPARs in oligodendroglia, we generate mice that allow cell-specific overexpression of EGFP-GluA2 in vivo.", "tags": [{"end": 58, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 20, "tag": "Finding"}, {"end": 95, "start": 91, "tag": "Eukaryote"}, {"end": 157, "start": 150, "tag": "ResearchActivity"}, {"end": 77, "start": 62, "tag": "Cell"}, {"end": 58, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 143, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 139, "tag": "Chemical"}, {"end": 149, "start": 144, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1271_3", "text": "In healthy conditions, OPC-specific GluA2 overexpression significantly increase their proliferation in an age-dependent manner but did not alter their rate of differentiation into oligodendrocytes.", "tags": [{"end": 41, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 42, "tag": "CellFunction"}, {"end": 56, "start": 42, "tag": "Finding"}, {"end": 196, "start": 180, "tag": "Cell"}, {"end": 26, "start": 23, "tag": "Cell"}, {"end": 155, "start": 151, "tag": "TemporalConcept"}, {"end": 174, "start": 159, "tag": "CellFunction"}, {"end": 99, "start": 86, "tag": "CellFunction"}, {"end": 109, "start": 106, "tag": "OrganismAttribute"}, {"end": 10, "start": 3, "tag": "OrganismAttribute"}]}{"id": "1271_4", "text": "In contrast, after demyelinating brain injury in neonates or adults, higher GluA2 levels promote both OPC proliferation and oligodendrocyte regeneration, but do not prevent injury-induced initial cell loss.", "tags": [{"end": 57, "start": 49, "tag": "PopulationGroup"}, {"end": 81, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 61, "tag": "PopulationGroup"}, {"end": 139, "start": 124, "tag": "Cell"}, {"end": 32, "start": 19, "tag": "PathologicFunction"}, {"end": 195, "start": 188, "tag": "TemporalConcept"}, {"end": 38, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 39, "tag": "InjuryOrPoisoning"}, {"end": 179, "start": 173, "tag": "InjuryOrPoisoning"}, {"end": 152, "start": 140, "tag": "BiologicFunction"}, {"end": 119, "start": 102, "tag": "CellFunction"}, {"end": 152, "start": 140, "tag": "HealthCareActivity"}, {"end": 205, "start": 196, "tag": "CellOrMolecularDysfunction"}]}{"id": "1271_5", "text": "These findings indicate that AMPAR GluA2 content regulates the proliferative and regenerative behavior of adult OPCs, serving as a putative target for better myelin repair.", "tags": [{"end": 40, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 81, "tag": "BiologicFunction"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 171, "start": 165, "tag": "BiologicFunction"}, {"end": 171, "start": 165, "tag": "HealthCareActivity"}, {"end": 111, "start": 106, "tag": "PopulationGroup"}, {"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 94, "tag": "BiologicFunction"}, {"end": 76, "start": 63, "tag": "BiologicFunction"}, {"end": 146, "start": 131, "tag": "Finding"}, {"end": 164, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1272_0", "text": "Neural-derived signals are crucial regulators of CNS vascularization.", "tags": [{"end": 45, "start": 27, "tag": "Finding"}, {"end": 68, "start": 49, "tag": "BiologicFunction"}, {"end": 6, "start": 0, "tag": "Cell"}]}{"id": "1272_1", "text": "However, whether the vasculature responds to these signals by means of elongating and branching or in addition by building a feedback response to modulate neurodevelopmental processes remains unknown.", "tags": [{"end": 32, "start": 21, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 51, "tag": "CellFunction"}, {"end": 183, "start": 155, "tag": "BiologicFunction"}]}{"id": "1272_2", "text": "In this study, we identified bidirectional crosstalk between the neural and the vascular compartment of the developing CNS required for oligodendrocyte precursor cell specification.", "tags": [{"end": 122, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 136, "tag": "Cell"}, {"end": 88, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 43, "tag": "CellFunction"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}]}{"id": "1272_3", "text": "Mechanistically, we show that neural progenitor cells (NPCs) express angiopoietin-1 (Ang1) and that this expression is regulated by Sonic hedgehog.", "tags": [{"end": 83, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 61, "tag": "CellFunction"}, {"end": 53, "start": 30, "tag": "Cell"}, {"end": 59, "start": 55, "tag": "Cell"}]}{"id": "1272_4", "text": "We demonstrate that NPC-derived Ang1 signals to its receptor, Tie2, on endothelial cells to induce the production of transforming growth factor beta 1 (TGF beta 1).", "tags": [{"end": 36, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 37, "tag": "CellFunction"}, {"end": 66, "start": 62, "tag": "GeneOrGenome"}, {"end": 150, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 117, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 71, "tag": "Cell"}, {"end": 23, "start": 20, "tag": "Cell"}, {"end": 60, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 152, "tag": "GeneOrGenome"}, {"end": 162, "start": 152, "tag": "BiologicallyActiveSubstance"}]}{"id": "1272_5", "text": "Endothelial-derived TGF beta 1, in turn, acts as an angiocrine molecule and signals back to NPCs to induce their commitment toward oligodendrocyte precursor cells.", "tags": [{"end": 83, "start": 76, "tag": "CellFunction"}, {"end": 123, "start": 113, "tag": "BiologicFunction"}, {"end": 162, "start": 131, "tag": "Cell"}, {"end": 96, "start": 92, "tag": "Cell"}, {"end": 71, "start": 52, "tag": "Substance"}, {"end": 30, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 20, "tag": "GeneOrGenome"}, {"end": 11, "start": 0, "tag": "Cell"}]}{"id": "1272_6", "text": "This work demonstrates a true bidirectional collaboration between NPCs and the vasculature as a critical regulator of oligodendrogenesis.", "tags": [{"end": 90, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 118, "tag": "BiologicFunction"}, {"end": 70, "start": 66, "tag": "Cell"}, {"end": 57, "start": 30, "tag": "Finding"}, {"end": 114, "start": 96, "tag": "Finding"}]}{"id": "1273_0", "text": "The myelin sheath, which is wrapped around axons, is a lipid-enriched structure produced by mature oligodendrocytes.", "tags": [{"end": 48, "start": 43, "tag": "CellComponent"}, {"end": 60, "start": 55, "tag": "Chemical"}, {"end": 115, "start": 99, "tag": "Cell"}, {"end": 115, "start": 92, "tag": "Cell"}, {"end": 17, "start": 4, "tag": "CellComponent"}, {"end": 98, "start": 92, "tag": "TemporalConcept"}, {"end": 10, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1273_1", "text": "Disruption of the myelin sheath is observed in several neurological diseases, such as multiple sclerosis.", "tags": [{"end": 31, "start": 18, "tag": "CellComponent"}, {"end": 76, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 0, "tag": "CellOrMolecularDysfunction"}]}{"id": "1273_2", "text": "A crucial component of myelin is sphingomyelin, levels of which can be increased by ABCA8, a member of the ATP-binding cassette transporter family.", "tags": [{"end": 89, "start": 84, "tag": "GeneOrGenome"}, {"end": 146, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 33, "tag": "Chemical"}, {"end": 46, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 107, "tag": "BiologicallyActiveSubstance"}]}{"id": "1273_3", "text": "ABCA8 is highly expressed in the cerebellum, specifically in oligodendroglia.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 43, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 61, "tag": "Cell"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1273_4", "text": "However, whether ABCA8 plays a role in myelination and mechanisms that would underlie this role remain unknown.", "tags": [{"end": 22, "start": 17, "tag": "GeneOrGenome"}, {"end": 50, "start": 39, "tag": "CellFunction"}, {"end": 22, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 17, "tag": "BiologicallyActiveSubstance"}]}{"id": "1273_5", "text": "Here, we found that the absence of Abca8b, a mouse ortholog of ABCA8, led to decreased numbers of cerebellar oligodendrocyte precursor cells (OPCs) and mature oligodendrocytes in mice.", "tags": [{"end": 68, "start": 45, "tag": "GeneOrGenome"}, {"end": 108, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 142, "tag": "Cell"}, {"end": 175, "start": 152, "tag": "Cell"}, {"end": 140, "start": 109, "tag": "Cell"}, {"end": 183, "start": 179, "tag": "Eukaryote"}, {"end": 41, "start": 24, "tag": "CellOrMolecularDysfunction"}, {"end": 41, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 35, "tag": "GeneOrGenome"}]}{"id": "1273_6", "text": "We show that in oligodendrocytes, ABCA8 interacts with chondroitin sulfate proteoglycan 4 (CSPG4), a molecule essential for OPC proliferation, migration, and myelination.", "tags": [{"end": 39, "start": 34, "tag": "GeneOrGenome"}, {"end": 89, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 91, "tag": "GeneOrGenome"}, {"end": 96, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 101, "tag": "Substance"}, {"end": 32, "start": 16, "tag": "Cell"}, {"end": 127, "start": 124, "tag": "Cell"}, {"end": 141, "start": 128, "tag": "CellFunction"}, {"end": 152, "start": 143, "tag": "CellFunction"}, {"end": 169, "start": 158, "tag": "CellFunction"}, {"end": 39, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 34, "tag": "BiologicallyActiveSubstance"}]}{"id": "1273_7", "text": "In the absence of Abca8b, localization of CSPG4 to the plasma membrane was decreased, contributing to reduced cerebellar CSPG4 expression.", "tags": [{"end": 47, "start": 42, "tag": "GeneOrGenome"}, {"end": 47, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 55, "tag": "CellComponent"}, {"end": 120, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 121, "tag": "GeneOrGenome"}, {"end": 126, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 7, "tag": "CellOrMolecularDysfunction"}, {"end": 24, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 18, "tag": "GeneOrGenome"}]}{"id": "1273_8", "text": "Cerebellar CSPG4+ OPCs were also diminished, leading to decreased mature myelinating oligodendrocyte numbers and cerebellar myelination levels in Abca8b(-/-) mice.", "tags": [{"end": 10, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 11, "tag": "GeneOrGenome"}, {"end": 16, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 18, "tag": "Cell"}, {"end": 135, "start": 124, "tag": "CellFunction"}, {"end": 100, "start": 66, "tag": "Cell"}, {"end": 162, "start": 158, "tag": "Eukaryote"}, {"end": 162, "start": 146, "tag": "ExperimentalModelOfDisease"}]}{"id": "1273_9", "text": "In addition, electron microscopy analyses showed that the number of nonmyelinated cerebellar axons was increased, whereas cerebellar myelin thickness (g-ratio), myelin sheath periodicity, and axonal diameter were all decreased, indicative of disordered myelin ultrastructure.", "tags": [{"end": 92, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 175, "tag": "TemporalConcept"}, {"end": 198, "start": 192, "tag": "CellComponent"}, {"end": 98, "start": 93, "tag": "CellComponent"}, {"end": 81, "start": 68, "tag": "CellComponent"}, {"end": 32, "start": 13, "tag": "ResearchActivity"}, {"end": 174, "start": 161, "tag": "CellComponent"}, {"end": 167, "start": 161, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 259, "start": 253, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 133, "tag": "ClinicalAttribute"}, {"end": 207, "start": 192, "tag": "ClinicalAttribute"}, {"end": 274, "start": 242, "tag": "CellOrMolecularDysfunction"}]}{"id": "1273_10", "text": "In line with disrupted cerebellar myelination, Abca8b(-/-) mice showed lower cerebellar conduction velocity and disturbed locomotion.", "tags": [{"end": 33, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 122, "tag": "BiologicFunction"}, {"end": 45, "start": 34, "tag": "CellFunction"}, {"end": 107, "start": 88, "tag": "BiologicFunction"}, {"end": 98, "start": 88, "tag": "NaturalPhenomenonOrProcess"}, {"end": 45, "start": 13, "tag": "PathologicFunction"}, {"end": 63, "start": 59, "tag": "Eukaryote"}, {"end": 132, "start": 112, "tag": "PathologicFunction"}, {"end": 63, "start": 47, "tag": "ExperimentalModelOfDisease"}]}{"id": "1273_11", "text": "In summary, ABCA8 modulates cerebellar myelination, in part through functional regulation of the ABCA8-interacting protein CSPG4.", "tags": [{"end": 17, "start": 12, "tag": "GeneOrGenome"}, {"end": 38, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 123, "tag": "GeneOrGenome"}, {"end": 128, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 39, "tag": "CellFunction"}, {"end": 17, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 97, "tag": "GeneOrGenome"}, {"end": 122, "start": 103, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1273_12", "text": "Our findings suggest that ABCA8 disruption may contribute to the pathophysiology of myelin disorders.", "tags": [{"end": 31, "start": 26, "tag": "GeneOrGenome"}, {"end": 90, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 65, "tag": "PathologicFunction"}, {"end": 80, "start": 65, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 31, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 26, "tag": "CellOrMolecularDysfunction"}]}{"id": "1274_0", "text": "Background: When aiming to restore myelin tolerance using antigen-specific treatment approaches in MS, the wide variety of myelin-derived antigens towards which immune responses are targeted in multiple sclerosis (MS) patients needs to be taken into account.", "tags": [{"end": 51, "start": 42, "tag": "Finding"}, {"end": 177, "start": 161, "tag": "BiologicFunction"}, {"end": 177, "start": 161, "tag": "CellFunction"}, {"end": 212, "start": 194, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 226, "start": 218, "tag": "PatientOrDisabledGroup"}, {"end": 84, "start": 75, "tag": "HealthCareActivity"}, {"end": 84, "start": 75, "tag": "ResearchActivity"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 216, "start": 214, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 138, "tag": "BiologicallyActiveSubstance"}]}{"id": "1274_1", "text": "Uncertainty remains as to whether the myelin reactivity pattern of a specific MS patient can be predicted based upon the human leukocyte antigen (HLA) class II haplotype of the patient.", "tags": [{"end": 11, "start": 0, "tag": "Finding"}, {"end": 159, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 151, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 160, "tag": "OrganismAttribute"}, {"end": 44, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 184, "start": 177, "tag": "PatientOrDisabledGroup"}, {"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 146, "tag": "BiologicallyActiveSubstance"}]}{"id": "1274_2", "text": "Methods: In this study, we analyzed the reactivity towards myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP) and proteolipid protein (PLP) peptides using direct interferon (IFN)-gamma enzyme-linked immune absorbent spot (ELISPOT).", "tags": [{"end": 94, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 181, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 124, "tag": "GeneOrGenome"}, {"end": 122, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 154, "tag": "GeneOrGenome"}, {"end": 157, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 17, "tag": "ResearchActivity"}, {"end": 167, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 239, "start": 204, "tag": "ResearchActivity"}, {"end": 248, "start": 241, "tag": "ResearchActivity"}, {"end": 203, "start": 181, "tag": "BiologicallyActiveSubstance"}]}{"id": "1274_3", "text": "Next, the HLA class II haplotype profile was determined by next-generation sequencing.", "tags": [{"end": 32, "start": 23, "tag": "OrganismAttribute"}, {"end": 85, "start": 59, "tag": "ResearchActivity"}, {"end": 40, "start": 33, "tag": "ResearchActivity"}, {"end": 22, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 10, "tag": "BiologicallyActiveSubstance"}]}{"id": "1274_4", "text": "In doing so, we aimed to evaluate the possible association between the precursor frequency of myelin-reactive T cells and the HLA haplotype.", "tags": [{"end": 80, "start": 71, "tag": "Cell"}, {"end": 129, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 130, "tag": "OrganismAttribute"}, {"end": 90, "start": 81, "tag": "TemporalConcept"}, {"end": 100, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 110, "tag": "Cell"}]}{"id": "1274_5", "text": "Results: Reactivity towards any of the analyzed peptides could be demonstrated in 65.0% (13/20) of MS patients and in 60.0% (6/10) of healthy controls.", "tags": [{"end": 150, "start": 134, "tag": "PopulationGroup"}, {"end": 141, "start": 134, "tag": "OrganismAttribute"}, {"end": 110, "start": 102, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 47, "start": 39, "tag": "ResearchActivity"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 9, "tag": "Finding"}]}{"id": "1274_6", "text": "At least one of the MS risk alleles HLA-DRB1*15:01, HLA-DQA1*01:02 and HLA-DQB1*06:02 was found in 70.0% (14/20) of patients and in 20.0% (2/10) of healthy controls.", "tags": [{"end": 35, "start": 28, "tag": "GeneOrGenome"}, {"end": 164, "start": 148, "tag": "PopulationGroup"}, {"end": 155, "start": 148, "tag": "OrganismAttribute"}, {"end": 124, "start": 116, "tag": "PatientOrDisabledGroup"}, {"end": 27, "start": 23, "tag": "Finding"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 71, "tag": "BiologicallyActiveSubstance"}]}{"id": "1274_7", "text": "No difference in the presence of a myelin-specific response, nor in the frequency of myelin peptide-reactive precursor cells could be detected among carriers and non-carriers of these risk alleles.", "tags": [{"end": 196, "start": 189, "tag": "GeneOrGenome"}, {"end": 81, "start": 72, "tag": "TemporalConcept"}, {"end": 41, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 109, "tag": "Cell"}, {"end": 188, "start": 184, "tag": "Finding"}, {"end": 157, "start": 149, "tag": "PopulationGroup"}, {"end": 174, "start": 162, "tag": "PopulationGroup"}, {"end": 29, "start": 21, "tag": "Finding"}, {"end": 99, "start": 92, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1274_8", "text": "Conclusion: No association between HLA haplotype and myelin reactivity profile was present in our study population.", "tags": [{"end": 38, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 39, "tag": "OrganismAttribute"}, {"end": 59, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 98, "tag": "PopulationGroup"}, {"end": 78, "start": 71, "tag": "ResearchActivity"}, {"end": 70, "start": 60, "tag": "Finding"}]}{"id": "1274_9", "text": "This complicates the development of antigen-specific treatment approaches and implies the need for multi-epitope targeting in an HLA-unrestricted manner to fully address the wide variation in myelin responses and HLA profiles in a heterogeneous group of MS patients.", "tags": [{"end": 112, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 244, "start": 231, "tag": "OrganismAttribute"}, {"end": 198, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 265, "start": 257, "tag": "PatientOrDisabledGroup"}, {"end": 32, "start": 21, "tag": "BiologicFunction"}, {"end": 32, "start": 21, "tag": "CellFunction"}, {"end": 250, "start": 245, "tag": "PopulationGroup"}, {"end": 225, "start": 213, "tag": "ResearchActivity"}, {"end": 62, "start": 53, "tag": "HealthCareActivity"}, {"end": 62, "start": 53, "tag": "ResearchActivity"}, {"end": 256, "start": 254, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 99, "tag": "ResearchActivity"}, {"end": 132, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 129, "tag": "BiologicallyActiveSubstance"}]}{"id": "1275_0", "text": "Extrinsic inhibitors at sites of blood-brain barrier disruption and neurovascular damage contribute to remyelination failure in neurological diseases.", "tags": [{"end": 63, "start": 53, "tag": "InjuryOrPoisoning"}, {"end": 124, "start": 103, "tag": "CellOrMolecularDysfunction"}, {"end": 149, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1275_1", "text": "However, therapies to overcome the extrinsic inhibition of remyelination are not widely available and the dynamics of glial progenitor niche remodelling at sites of neurovascular dysfunction are largely unknown.", "tags": [{"end": 152, "start": 141, "tag": "BiologicFunction"}, {"end": 152, "start": 141, "tag": "CellFunction"}, {"end": 190, "start": 179, "tag": "PathologicFunction"}, {"end": 72, "start": 59, "tag": "CellFunction"}, {"end": 140, "start": 118, "tag": "Cell"}, {"end": 55, "start": 45, "tag": "CellFunction"}, {"end": 18, "start": 9, "tag": "HealthCareActivity"}, {"end": 114, "start": 106, "tag": "NaturalPhenomenonOrProcess"}, {"end": 178, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1275_2", "text": "By integrating in uiuo two-photon imaging co-registered with electron microscopy and transcriptomics in chronic neuroinflammatory lesions, we found that oligodendrocyte precursor cells clustered perivascularly at sites of limited remyelination with deposition of fibrinogen, a blood coagulation factor abundantly deposited in multiple sclerosis lesions.", "tags": [{"end": 273, "start": 263, "tag": "AminoAcidPeptideOrProtein"}, {"end": 273, "start": 263, "tag": "PharmacologicSubstance"}, {"end": 273, "start": 263, "tag": "BiologicallyActiveSubstance"}, {"end": 301, "start": 277, "tag": "AminoAcidPeptideOrProtein"}, {"end": 301, "start": 277, "tag": "PharmacologicSubstance"}, {"end": 301, "start": 277, "tag": "BiologicFunction"}, {"end": 243, "start": 230, "tag": "CellFunction"}, {"end": 80, "start": 61, "tag": "ResearchActivity"}, {"end": 184, "start": 153, "tag": "Cell"}, {"end": 100, "start": 85, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 129, "start": 112, "tag": "PathologicFunction"}, {"end": 344, "start": 326, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 104, "tag": "TemporalConcept"}, {"end": 137, "start": 130, "tag": "InjuryOrPoisoning"}, {"end": 352, "start": 345, "tag": "InjuryOrPoisoning"}, {"end": 41, "start": 23, "tag": "HealthCareActivity"}]}{"id": "1275_3", "text": "By developing a screen (OPC-X-screen) to identify compounds that promote remyelination in the presence of extrinsic inhibitors, we showed that known promyelinating drugs did not rescue the extrinsic inhibition of remyelination by fibrinogen.", "tags": [{"end": 22, "start": 16, "tag": "HealthCareActivity"}, {"end": 22, "start": 16, "tag": "ResearchActivity"}, {"end": 59, "start": 50, "tag": "Chemical"}, {"end": 59, "start": 50, "tag": "PharmacologicSubstance"}, {"end": 72, "start": 65, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 102, "start": 94, "tag": "Finding"}, {"end": 240, "start": 230, "tag": "AminoAcidPeptideOrProtein"}, {"end": 240, "start": 230, "tag": "PharmacologicSubstance"}, {"end": 240, "start": 230, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 149, "tag": "PharmacologicSubstance"}, {"end": 86, "start": 73, "tag": "CellFunction"}, {"end": 226, "start": 213, "tag": "CellFunction"}, {"end": 27, "start": 24, "tag": "Cell"}, {"end": 209, "start": 199, "tag": "CellFunction"}]}{"id": "1275_4", "text": "In contrast, bone morphogenetic protein type I receptor blockade rescued the inhibitory fibrinogen effects and restored a promyelinating progenitor niche by promoting myelinating oligodendrocytes, while suppressing astrocyte cell fate, with potent therapeutic effects in chronic models of multiple sclerosis.", "tags": [{"end": 55, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 13, "tag": "GeneOrGenome"}, {"end": 87, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 234, "start": 225, "tag": "Finding"}, {"end": 17, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 267, "start": 248, "tag": "Finding"}, {"end": 195, "start": 167, "tag": "Cell"}, {"end": 39, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 56, "tag": "PharmacologicSubstance"}, {"end": 64, "start": 56, "tag": "HealthCareActivity"}, {"end": 224, "start": 215, "tag": "Cell"}, {"end": 55, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 307, "start": 289, "tag": "DiseaseOrSyndrome"}, {"end": 278, "start": 271, "tag": "TemporalConcept"}, {"end": 285, "start": 279, "tag": "ResearchActivity"}, {"end": 98, "start": 88, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 98, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 153, "start": 122, "tag": "Cell"}]}{"id": "1275_5", "text": "Thus, abortive oligodendrocyte precursor cell differentiation by fibrinogen is refractory to known promyelinating compounds, suggesting that blockade of the bone morphogenetic protein signalling pathway may enhance remyelinating efficacy by overcoming extrinsic inhibition in neuroinflammatory lesions with vascular damage.", "tags": [{"end": 75, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 65, "tag": "PharmacologicSubstance"}, {"end": 75, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 79, "tag": "SignOrSymptom"}, {"end": 228, "start": 215, "tag": "CellFunction"}, {"end": 45, "start": 15, "tag": "Cell"}, {"end": 183, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 141, "tag": "PharmacologicSubstance"}, {"end": 149, "start": 141, "tag": "HealthCareActivity"}, {"end": 293, "start": 276, "tag": "PathologicFunction"}, {"end": 202, "start": 184, "tag": "CellFunction"}, {"end": 272, "start": 262, "tag": "CellFunction"}, {"end": 301, "start": 294, "tag": "InjuryOrPoisoning"}, {"end": 61, "start": 46, "tag": "CellFunction"}, {"end": 315, "start": 307, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 99, "tag": "PharmacologicSubstance"}, {"end": 237, "start": 229, "tag": "Finding"}]}{"id": "1276_0", "text": "Efficient strategies for neuroprotection and repair are still an unmet medical need for neurodegenerative diseases and lesions of the central nervous system.", "tags": [{"end": 40, "start": 25, "tag": "CellFunction"}, {"end": 156, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 119, "tag": "InjuryOrPoisoning"}, {"end": 51, "start": 45, "tag": "BiologicFunction"}, {"end": 51, "start": 45, "tag": "HealthCareActivity"}, {"end": 114, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 65, "tag": "Finding"}]}{"id": "1276_1", "text": "Over the last few decades, a great deal of attention has been focused on white matter as a potential therapeutic target, mainly due to the discovery of the oligodendrocyte precursor cells in the adult central nervous system, a cell type able to fully repair myelin damage, and to the development of advanced imaging techniques to visualize and measure white matter lesions.", "tags": [{"end": 236, "start": 227, "tag": "Cell"}, {"end": 52, "start": 43, "tag": "BiologicFunction"}, {"end": 148, "start": 139, "tag": "ResearchActivity"}, {"end": 187, "start": 156, "tag": "Cell"}, {"end": 264, "start": 258, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 295, "start": 284, "tag": "BiologicFunction"}, {"end": 295, "start": 284, "tag": "CellFunction"}, {"end": 223, "start": 201, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 372, "start": 365, "tag": "InjuryOrPoisoning"}, {"end": 257, "start": 251, "tag": "BiologicFunction"}, {"end": 257, "start": 251, "tag": "HealthCareActivity"}, {"end": 85, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 364, "start": 352, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 315, "start": 308, "tag": "HealthCareActivity"}, {"end": 25, "start": 18, "tag": "TemporalConcept"}, {"end": 200, "start": 195, "tag": "PopulationGroup"}, {"end": 119, "start": 101, "tag": "Finding"}]}{"id": "1276_2", "text": "The combination of these two events has greatly increased the body of research into white matter alterations in central nervous system lesions and neurodegenerative diseases and has identified the oligodendrocyte precursor cell as a putative target for white matter lesion repair, thus indirectly contributing to neuroprotection.", "tags": [{"end": 328, "start": 313, "tag": "CellFunction"}, {"end": 134, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 135, "tag": "InjuryOrPoisoning"}, {"end": 272, "start": 266, "tag": "InjuryOrPoisoning"}, {"end": 279, "start": 273, "tag": "BiologicFunction"}, {"end": 279, "start": 273, "tag": "HealthCareActivity"}, {"end": 96, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 265, "start": 253, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 227, "start": 197, "tag": "Cell"}, {"end": 173, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 62, "tag": "ResearchActivity"}, {"end": 108, "start": 97, "tag": "Finding"}]}{"id": "1276_3", "text": "This review aims to discuss the potential of white matter as a therapeutic target for neuroprotection in lesions and diseases of the central nervous system.", "tags": [{"end": 101, "start": 86, "tag": "CellFunction"}, {"end": 155, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 112, "start": 105, "tag": "InjuryOrPoisoning"}, {"end": 57, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 63, "tag": "Finding"}]}{"id": "1276_4", "text": "Pivot conditions are discussed, specifically multiple sclerosis as a white matter disease; spinal cord injury, the acute lesion of a central nervous system component where white matter prevails over the gray matter, and Alzheimer's disease, where the white matter was considered an ancillary component until recently.", "tags": [{"end": 89, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 91, "tag": "InjuryOrPoisoning"}, {"end": 63, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 121, "tag": "InjuryOrPoisoning"}, {"end": 102, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 184, "start": 172, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 263, "start": 251, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 316, "start": 308, "tag": "TemporalConcept"}, {"end": 239, "start": 220, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 115, "tag": "TemporalConcept"}]}{"id": "1276_5", "text": "We first describe oligodendrocyte precursor cell biology and developmental myelination, and its regulation by thyroid hormones, then briefly describe white matter imaging techniques, which are providing information on white matter involvement in central nervous system lesions and degenerative diseases.", "tags": [{"end": 126, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 49, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 302, "start": 281, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 133, "tag": "TemporalConcept"}, {"end": 8, "start": 3, "tag": "TemporalConcept"}, {"end": 86, "start": 75, "tag": "CellFunction"}, {"end": 268, "start": 246, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 242, "start": 231, "tag": "Finding"}, {"end": 276, "start": 269, "tag": "InjuryOrPoisoning"}, {"end": 74, "start": 61, "tag": "BiologicFunction"}, {"end": 74, "start": 61, "tag": "TemporalConcept"}, {"end": 162, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 230, "start": 218, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 18, "tag": "Cell"}, {"end": 181, "start": 163, "tag": "HealthCareActivity"}, {"end": 56, "start": 49, "tag": "BiologicFunction"}]}{"id": "1276_6", "text": "Finally, we discuss pathological mechanisms which interfere with myelin repair in adulthood.", "tags": [{"end": 91, "start": 82, "tag": "TemporalConcept"}, {"end": 78, "start": 65, "tag": "CellFunction"}, {"end": 43, "start": 20, "tag": "PathologicFunction"}]}{"id": "1277_0", "text": "Insufficient remyelination due to impaired oligodendrocyte precursor cell (OPC) differentiation and maturation is strongly associated with irreversible white matter injury (WMI) and neurological deficits.", "tags": [{"end": 12, "start": 0, "tag": "Finding"}, {"end": 171, "start": 152, "tag": "Finding"}, {"end": 176, "start": 173, "tag": "Finding"}, {"end": 203, "start": 182, "tag": "Finding"}, {"end": 78, "start": 75, "tag": "Cell"}, {"end": 110, "start": 100, "tag": "BiologicFunction"}, {"end": 26, "start": 13, "tag": "CellFunction"}, {"end": 95, "start": 80, "tag": "CellFunction"}, {"end": 164, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 43, "tag": "Cell"}, {"end": 73, "start": 59, "tag": "Cell"}]}{"id": "1277_1", "text": "We analyzed whole transcriptome expression to elucidate the potential role and underlying mechanism of action of lipocalin-2 (LCN2) in OPC differentiation and WMI and identified the receptor SCL22A17 and downstream transcription factor early growth response protein 1 (EGR1) as the key signals contributing to LCN2-mediated insufficient OPC remyelination.", "tags": [{"end": 124, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 124, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 126, "tag": "GeneOrGenome"}, {"end": 130, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 159, "tag": "Finding"}, {"end": 267, "start": 236, "tag": "BiologicallyActiveSubstance"}, {"end": 273, "start": 269, "tag": "GeneOrGenome"}, {"end": 273, "start": 269, "tag": "AminoAcidPeptideOrProtein"}, {"end": 293, "start": 286, "tag": "CellFunction"}, {"end": 31, "start": 18, "tag": "MolecularSequence"}, {"end": 235, "start": 215, "tag": "AminoAcidPeptideOrProtein"}, {"end": 235, "start": 215, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 138, "start": 135, "tag": "Cell"}, {"end": 340, "start": 337, "tag": "Cell"}, {"end": 354, "start": 341, "tag": "CellFunction"}, {"end": 154, "start": 139, "tag": "CellFunction"}, {"end": 154, "start": 135, "tag": "CellFunction"}, {"end": 190, "start": 182, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 32, "tag": "CellFunction"}, {"end": 199, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 191, "tag": "BiologicallyActiveSubstance"}, {"end": 199, "start": 191, "tag": "GeneOrGenome"}, {"end": 273, "start": 269, "tag": "BiologicallyActiveSubstance"}, {"end": 267, "start": 236, "tag": "AminoAcidPeptideOrProtein"}, {"end": 314, "start": 310, "tag": "AminoAcidPeptideOrProtein"}, {"end": 314, "start": 310, "tag": "BiologicallyActiveSubstance"}, {"end": 314, "start": 310, "tag": "GeneOrGenome"}]}{"id": "1277_2", "text": "In LCN-knockdown and OPC EGR1 conditional-knockout mice, we discovered enhanced OPC differentiation in developing and injured white matter (WM); consistent with this, the specific inactivation of LCN2/SCl22A17/EGR1 signaling promoted remyelination and neurological recovery in both atypical, acute WMI due to subarachnoid hemorrhage and typical, chronic WMI due to multiple sclerosis.", "tags": [{"end": 29, "start": 25, "tag": "GeneOrGenome"}, {"end": 29, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 301, "start": 298, "tag": "Finding"}, {"end": 321, "start": 309, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 332, "start": 322, "tag": "PathologicFunction"}, {"end": 332, "start": 322, "tag": "Finding"}, {"end": 357, "start": 354, "tag": "Finding"}, {"end": 142, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 21, "tag": "Cell"}, {"end": 83, "start": 80, "tag": "Cell"}, {"end": 383, "start": 365, "tag": "DiseaseOrSyndrome"}, {"end": 247, "start": 234, "tag": "CellFunction"}, {"end": 273, "start": 252, "tag": "BiologicFunction"}, {"end": 273, "start": 252, "tag": "HealthCareActivity"}, {"end": 224, "start": 196, "tag": "CellFunction"}, {"end": 99, "start": 84, "tag": "CellFunction"}, {"end": 353, "start": 346, "tag": "TemporalConcept"}, {"end": 138, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 80, "tag": "CellFunction"}, {"end": 192, "start": 180, "tag": "CellFunction"}, {"end": 290, "start": 282, "tag": "Finding"}, {"end": 297, "start": 292, "tag": "TemporalConcept"}, {"end": 29, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 3, "tag": "BiologicallyActiveSubstance"}, {"end": 6, "start": 3, "tag": "GeneOrGenome"}, {"end": 16, "start": 7, "tag": "ResearchActivity"}, {"end": 55, "start": 51, "tag": "Eukaryote"}, {"end": 50, "start": 30, "tag": "ResearchActivity"}]}{"id": "1277_3", "text": "This potentially represents a novel strategy to enhance differentiation and remyelination in patients with white matter injury.", "tags": [{"end": 126, "start": 107, "tag": "Finding"}, {"end": 89, "start": 76, "tag": "CellFunction"}, {"end": 101, "start": 93, "tag": "PatientOrDisabledGroup"}, {"end": 71, "start": 56, "tag": "CellFunction"}, {"end": 119, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1278_0", "text": "White matter deficits are a common neuropathologic finding in neurologic disorders, including HIV-associated neurocognitive disorders (HAND).", "tags": [{"end": 82, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 94, "tag": "Virus"}, {"end": 133, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 35, "tag": "Finding"}, {"end": 12, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 13, "tag": "Finding"}, {"end": 139, "start": 135, "tag": "DiseaseOrSyndrome"}]}{"id": "1278_1", "text": "In HAND, the persistence of white matter alterations despite suppressive antiretroviral (ARV) therapy suggests that ARVs may be directly contributing to these impairments.", "tags": [{"end": 24, "start": 13, "tag": "Finding"}, {"end": 92, "start": 89, "tag": "PharmacologicSubstance"}, {"end": 170, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 94, "tag": "HealthCareActivity"}, {"end": 87, "start": 73, "tag": "HealthCareActivity"}, {"end": 7, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 41, "tag": "Finding"}, {"end": 120, "start": 116, "tag": "PharmacologicSubstance"}]}{"id": "1278_2", "text": "Here, we report that a frontline ARV, bictegravir (BIC), significantly attenuates remyelination following cuprizone-mediated demyelination, a model that recapitulates acute demyelination, but has no impact on already formed mature myelin.", "tags": [{"end": 36, "start": 33, "tag": "PharmacologicSubstance"}, {"end": 49, "start": 38, "tag": "Chemical"}, {"end": 54, "start": 51, "tag": "Chemical"}, {"end": 147, "start": 142, "tag": "ResearchActivity"}, {"end": 237, "start": 231, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 82, "tag": "CellFunction"}, {"end": 138, "start": 125, "tag": "PathologicFunction"}, {"end": 186, "start": 173, "tag": "PathologicFunction"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 230, "start": 224, "tag": "TemporalConcept"}, {"end": 115, "start": 106, "tag": "Chemical"}, {"end": 172, "start": 167, "tag": "TemporalConcept"}, {"end": 49, "start": 38, "tag": "PharmacologicSubstance"}, {"end": 49, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 51, "tag": "PharmacologicSubstance"}]}{"id": "1278_3", "text": "Mechanistic studies utilizing primary rat oligodendrocyte precursor cells (OPCs) revealed that treatment with BIC leads to significant decrease in mature oligodendrocytes accompanied by lysosomal deacidification and impairment of lysosomal degradative capacity with no alterations in lysosomal membrane permeability or total lysosome number.", "tags": [{"end": 113, "start": 110, "tag": "Chemical"}, {"end": 226, "start": 216, "tag": "Finding"}, {"end": 239, "start": 230, "tag": "CellComponent"}, {"end": 293, "start": 284, "tag": "CellComponent"}, {"end": 143, "start": 123, "tag": "Finding"}, {"end": 79, "start": 75, "tag": "Cell"}, {"end": 73, "start": 42, "tag": "Cell"}, {"end": 170, "start": 147, "tag": "Cell"}, {"end": 41, "start": 38, "tag": "Eukaryote"}, {"end": 19, "start": 12, "tag": "ResearchActivity"}, {"end": 104, "start": 95, "tag": "HealthCareActivity"}, {"end": 104, "start": 95, "tag": "ResearchActivity"}, {"end": 302, "start": 294, "tag": "CellComponent"}, {"end": 113, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 110, "tag": "PharmacologicSubstance"}, {"end": 211, "start": 186, "tag": "CellFunction"}, {"end": 260, "start": 230, "tag": "CellFunction"}, {"end": 280, "start": 269, "tag": "Finding"}, {"end": 315, "start": 294, "tag": "CellFunction"}, {"end": 333, "start": 325, "tag": "CellComponent"}]}{"id": "1278_4", "text": "Activation of the endolysosomal cation channel TRPML1 prevents both lysosomal deacidification and impairment of oligodendrocyte differentiation by BIC.", "tags": [{"end": 77, "start": 68, "tag": "CellComponent"}, {"end": 108, "start": 98, "tag": "Finding"}, {"end": 150, "start": 147, "tag": "Chemical"}, {"end": 127, "start": 112, "tag": "Cell"}, {"end": 143, "start": 128, "tag": "CellFunction"}, {"end": 46, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 68, "tag": "CellFunction"}, {"end": 150, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 147, "tag": "PharmacologicSubstance"}]}{"id": "1278_5", "text": "Lastly, we show that deacidification of lysosomes by compounds that raise lysosomal pH is sufficient to prevent maturation of oligodendrocytes.", "tags": [{"end": 83, "start": 74, "tag": "CellComponent"}, {"end": 49, "start": 40, "tag": "CellComponent"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 142, "start": 126, "tag": "Cell"}, {"end": 122, "start": 112, "tag": "BiologicFunction"}, {"end": 62, "start": 53, "tag": "Chemical"}, {"end": 62, "start": 53, "tag": "PharmacologicSubstance"}, {"end": 49, "start": 21, "tag": "CellFunction"}, {"end": 86, "start": 74, "tag": "CellFunction"}]}{"id": "1278_6", "text": "Overall, this study has uncovered a critical role for lysosomal acidification in modulating oligodendrocyte function and has implications for neurologic diseases characterized by lysosomal dysfunction and white matter abnormalities.", "tags": [{"end": 77, "start": 54, "tag": "CellFunction"}, {"end": 161, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 231, "start": 205, "tag": "PathologicFunction"}, {"end": 19, "start": 14, "tag": "ResearchActivity"}, {"end": 116, "start": 92, "tag": "CellFunction"}, {"end": 200, "start": 179, "tag": "CellOrMolecularDysfunction"}]}{"id": "1279_0", "text": "Huperzine A (HupA) is a natural acetylcholinesterase inhibitor (AChEI) with the advantages of high efficiency, selectivity as well as reversibility and can exhibit significant therapeutic effects against certain neurodegenerative diseases.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 17, "start": 13, "tag": "Chemical"}, {"end": 62, "start": 32, "tag": "PharmacologicSubstance"}, {"end": 69, "start": 64, "tag": "PharmacologicSubstance"}, {"end": 122, "start": 111, "tag": "CellFunction"}, {"end": 147, "start": 134, "tag": "TemporalConcept"}, {"end": 52, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 53, "tag": "PharmacologicSubstance"}, {"end": 62, "start": 53, "tag": "Chemical"}, {"end": 195, "start": 176, "tag": "Finding"}, {"end": 109, "start": 94, "tag": "Finding"}, {"end": 238, "start": 212, "tag": "DiseaseOrSyndrome"}, {"end": 11, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 17, "start": 13, "tag": "PharmacologicSubstance"}]}{"id": "1279_1", "text": "It is also beneficial in reducing the neurological impairment and neuroinflammation of experimental autoimmune encephalomyelitis (EAE), a classic model for multiple sclerosis (MS).", "tags": [{"end": 33, "start": 25, "tag": "Finding"}, {"end": 128, "start": 87, "tag": "ExperimentalModelOfDisease"}, {"end": 133, "start": 130, "tag": "ExperimentalModelOfDisease"}, {"end": 61, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 66, "tag": "PathologicFunction"}, {"end": 151, "start": 146, "tag": "ResearchActivity"}, {"end": 174, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 176, "tag": "DiseaseOrSyndrome"}]}{"id": "1279_2", "text": "However, whether HupA can directly regulate oligodendrocyte differentiation and maturation and promote remyelination has not been investigated previously.", "tags": [{"end": 21, "start": 17, "tag": "Chemical"}, {"end": 59, "start": 44, "tag": "Cell"}, {"end": 90, "start": 80, "tag": "BiologicFunction"}, {"end": 116, "start": 103, "tag": "CellFunction"}, {"end": 75, "start": 60, "tag": "CellFunction"}, {"end": 21, "start": 17, "tag": "PharmacologicSubstance"}]}{"id": "1279_3", "text": "In this study, we have analyzed the potential protective effects of HupA on the demylination model of MS induced by cuprizone (CPZ).", "tags": [{"end": 72, "start": 68, "tag": "Chemical"}, {"end": 130, "start": 127, "tag": "Chemical"}, {"end": 31, "start": 23, "tag": "ResearchActivity"}, {"end": 98, "start": 93, "tag": "ResearchActivity"}, {"end": 104, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 116, "tag": "Chemical"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 64, "start": 46, "tag": "Finding"}, {"end": 72, "start": 68, "tag": "PharmacologicSubstance"}, {"end": 125, "start": 80, "tag": "ExperimentalModelOfDisease"}]}{"id": "1279_4", "text": "It was found that HupA significantly attenuated anxiety-like behavior, as well as augmented motor and cognitive functions in CPZ mice.", "tags": [{"end": 22, "start": 18, "tag": "Chemical"}, {"end": 128, "start": 125, "tag": "Chemical"}, {"end": 55, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 61, "tag": "BiologicFunction"}, {"end": 69, "start": 61, "tag": "IndividualBehavior"}, {"end": 69, "start": 61, "tag": "ResearchActivity"}, {"end": 133, "start": 129, "tag": "Eukaryote"}, {"end": 121, "start": 102, "tag": "BiologicFunction"}, {"end": 22, "start": 18, "tag": "PharmacologicSubstance"}, {"end": 133, "start": 125, "tag": "ExperimentalModelOfDisease"}]}{"id": "1279_5", "text": "It also decreased demyelination and axonal injury in CPZ mice.", "tags": [{"end": 56, "start": 53, "tag": "Chemical"}, {"end": 61, "start": 57, "tag": "Eukaryote"}, {"end": 31, "start": 18, "tag": "PathologicFunction"}, {"end": 49, "start": 43, "tag": "InjuryOrPoisoning"}, {"end": 42, "start": 36, "tag": "CellComponent"}, {"end": 61, "start": 53, "tag": "ExperimentalModelOfDisease"}]}{"id": "1279_6", "text": "Moreover, in CPZ mice, HupA increased mRNA levels of the various anti-inflammatory cytokines (Arg1, CD206) while reducing the levels of different pro-inflammatory cytokines (iNOS, IL-1 beta, IL-18, CD16, and TNF-alpha).", "tags": [{"end": 27, "start": 23, "tag": "Chemical"}, {"end": 98, "start": 94, "tag": "GeneOrGenome"}, {"end": 105, "start": 100, "tag": "GeneOrGenome"}, {"end": 121, "start": 113, "tag": "Finding"}, {"end": 196, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 196, "start": 191, "tag": "BiologicallyActiveSubstance"}, {"end": 196, "start": 191, "tag": "GeneOrGenome"}, {"end": 202, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 198, "tag": "GeneOrGenome"}, {"end": 82, "start": 65, "tag": "BiologicFunction"}, {"end": 82, "start": 65, "tag": "PharmacologicSubstance"}, {"end": 189, "start": 180, "tag": "AminoAcidPeptideOrProtein"}, {"end": 217, "start": 208, "tag": "BiologicallyActiveSubstance"}, {"end": 217, "start": 208, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 13, "tag": "Chemical"}, {"end": 189, "start": 180, "tag": "BiologicallyActiveSubstance"}, {"end": 189, "start": 180, "tag": "PharmacologicSubstance"}, {"end": 92, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 172, "start": 163, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 163, "tag": "CellFunction"}, {"end": 21, "start": 17, "tag": "Eukaryote"}, {"end": 162, "start": 146, "tag": "PathologicFunction"}, {"end": 42, "start": 38, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 82, "start": 70, "tag": "PathologicFunction"}, {"end": 162, "start": 150, "tag": "PathologicFunction"}, {"end": 178, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 13, "tag": "ExperimentalModelOfDisease"}, {"end": 27, "start": 23, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 94, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 198, "tag": "BiologicallyActiveSubstance"}]}{"id": "1279_7", "text": "Mecamylamine, a nicotinic acetylcholinergic receptor antagonist, could effectively reverse the effects of HupA.", "tags": [{"end": 12, "start": 0, "tag": "Chemical"}, {"end": 63, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 52, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 110, "start": 106, "tag": "Chemical"}, {"end": 110, "start": 106, "tag": "PharmacologicSubstance"}]}{"id": "1279_8", "text": "Therefore, we concluded that HupA primarily exerts its therapeutic effects on multiple sclerosis through alleviating demyelination and neuroinflammation.", "tags": [{"end": 33, "start": 29, "tag": "Chemical"}, {"end": 152, "start": 135, "tag": "PathologicFunction"}, {"end": 96, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 117, "tag": "PathologicFunction"}, {"end": 74, "start": 55, "tag": "Finding"}, {"end": 33, "start": 29, "tag": "PharmacologicSubstance"}]}{"id": "1280_0", "text": "Oligodendrocytes are the myelinating cells of the central nervous system.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 42, "start": 37, "tag": "Cell"}, {"end": 72, "start": 50, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 25, "tag": "CellFunction"}]}{"id": "1280_1", "text": "The physiological importance of oligodendrocytes is highlighted by diseases such as multiple sclerosis, in which the myelin sheaths are degraded and the axonal signal transmission is compromised.", "tags": [{"end": 144, "start": 136, "tag": "Finding"}, {"end": 48, "start": 32, "tag": "Cell"}, {"end": 102, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 117, "tag": "CellComponent"}, {"end": 159, "start": 153, "tag": "CellComponent"}, {"end": 179, "start": 160, "tag": "CellFunction"}]}{"id": "1280_2", "text": "In a healthy brain, spontaneous remyelination is rare, and newly formed myelin sheaths are thinner and shorter than the former ones.", "tags": [{"end": 53, "start": 49, "tag": "TemporalConcept"}, {"end": 78, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 32, "tag": "CellFunction"}, {"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 72, "tag": "CellComponent"}, {"end": 12, "start": 5, "tag": "OrganismAttribute"}]}{"id": "1280_3", "text": "The myelination process requires the migration, proliferation, and differentiation of oligodendrocyte precursor cells (OPCs) and is influenced by proteins of the extracellular matrix (ECM), which consists of a network of glycoproteins and proteoglycans.", "tags": [{"end": 217, "start": 210, "tag": "PopulationGroup"}, {"end": 217, "start": 210, "tag": "CellFunction"}, {"end": 123, "start": 119, "tag": "Cell"}, {"end": 15, "start": 4, "tag": "CellFunction"}, {"end": 117, "start": 86, "tag": "Cell"}, {"end": 182, "start": 162, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 67, "tag": "CellFunction"}, {"end": 187, "start": 184, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 252, "start": 239, "tag": "AminoAcidPeptideOrProtein"}, {"end": 252, "start": 239, "tag": "BiologicallyActiveSubstance"}, {"end": 234, "start": 221, "tag": "AminoAcidPeptideOrProtein"}, {"end": 234, "start": 221, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 48, "tag": "CellFunction"}, {"end": 46, "start": 37, "tag": "CellFunction"}]}{"id": "1280_4", "text": "In particular, the glycoprotein tenascin-C (Tnc) has an inhibitory effect on the differentiation of OPCs and the remyelination efficiency of oligodendrocytes.", "tags": [{"end": 157, "start": 141, "tag": "Cell"}, {"end": 104, "start": 100, "tag": "Cell"}, {"end": 126, "start": 113, "tag": "CellFunction"}, {"end": 96, "start": 81, "tag": "CellFunction"}, {"end": 66, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 127, "tag": "Finding"}, {"end": 42, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 56, "tag": "Finding"}, {"end": 31, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 19, "tag": "BiologicallyActiveSubstance"}]}{"id": "1280_5", "text": "The structurally similar tenascin-R (Tnr) exerts an inhibitory influence on the formation of myelin membranes in vitro.", "tags": [{"end": 99, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 110, "tag": "ResearchActivity"}, {"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 100, "tag": "CellComponent"}, {"end": 109, "start": 93, "tag": "CellComponent"}, {"end": 35, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 25, "tag": "BiologicallyActiveSubstance"}]}{"id": "1280_6", "text": "When Tnc knockout oligodendrocytes were applied to an in vitro myelination assay using artificial fibers, a higher number of sheaths per single cell were obtained compared to the wild-type control.", "tags": [{"end": 34, "start": 18, "tag": "Cell"}, {"end": 74, "start": 63, "tag": "CellFunction"}, {"end": 62, "start": 54, "tag": "ResearchActivity"}, {"end": 188, "start": 179, "tag": "ResearchActivity"}, {"end": 8, "start": 5, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 5, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 9, "tag": "ResearchActivity"}, {"end": 104, "start": 87, "tag": "ManufacturedObject"}]}{"id": "1280_7", "text": "This effect was enhanced by adding brain-derived neurotrophic factor (BDNF) to the culture system.", "tags": [{"end": 97, "start": 83, "tag": "ResearchActivity"}, {"end": 68, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 70, "tag": "BiologicallyActiveSubstance"}]}{"id": "1280_8", "text": "Tnr(-/-) oligodendrocytes behaved differently in that the number of formed sheaths per single cell was decreased, indicating that Tnr supports the differentiation of OPCs.", "tags": [{"end": 25, "start": 9, "tag": "Cell"}, {"end": 170, "start": 166, "tag": "Cell"}, {"end": 162, "start": 147, "tag": "CellFunction"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 130, "tag": "BiologicallyActiveSubstance"}]}{"id": "1280_9", "text": "In order to study the functions of tenascin proteins in vivo Tnc(-/-) and Tnr(-/-) mice were exposed to Cuprizone-induced demyelination for a period of 10 weeks.", "tags": [{"end": 113, "start": 104, "tag": "Chemical"}, {"end": 87, "start": 83, "tag": "Eukaryote"}, {"end": 60, "start": 53, "tag": "ResearchActivity"}, {"end": 135, "start": 122, "tag": "PathologicFunction"}, {"end": 52, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 155, "tag": "TemporalConcept"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 64, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 142, "tag": "TemporalConcept"}, {"end": 52, "start": 35, "tag": "BiologicallyActiveSubstance"}]}{"id": "1280_10", "text": "Both Tnc(-/-) and Tnr(-/-) mouse knockout lines displayed a significant increase in the regenerating myelin sheath thickness after Cuprizone treatment.", "tags": [{"end": 47, "start": 33, "tag": "ResearchActivity"}, {"end": 140, "start": 131, "tag": "Chemical"}, {"end": 107, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 101, "tag": "CellComponent"}, {"end": 32, "start": 27, "tag": "Eukaryote"}, {"end": 150, "start": 141, "tag": "HealthCareActivity"}, {"end": 150, "start": 141, "tag": "ResearchActivity"}, {"end": 8, "start": 5, "tag": "AminoAcidPeptideOrProtein"}, {"end": 8, "start": 5, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 18, "tag": "BiologicallyActiveSubstance"}]}{"id": "1280_11", "text": "Furthermore, in the absence of either tenascin, the number of OPCs was increased.", "tags": [{"end": 46, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 62, "tag": "Cell"}]}{"id": "1280_12", "text": "These results suggest that the fine-tuning of myelin regeneration is regulated by the major tenascin proteins of the CNS.", "tags": [{"end": 52, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 53, "tag": "BiologicFunction"}, {"end": 65, "start": 53, "tag": "HealthCareActivity"}, {"end": 65, "start": 46, "tag": "CellFunction"}, {"end": 42, "start": 31, "tag": "Finding"}, {"end": 109, "start": 92, "tag": "BiologicallyActiveSubstance"}]}{"id": "1281_0", "text": "Remyelination is a key aspect in multiple sclerosis pathology and a special effort is being made to promote it.", "tags": [{"end": 82, "start": 76, "tag": "BiologicFunction"}, {"end": 82, "start": 76, "tag": "Finding"}, {"end": 51, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 52, "tag": "PathologicFunction"}, {"end": 61, "start": 52, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 13, "start": 0, "tag": "CellFunction"}]}{"id": "1281_1", "text": "However, there is still no available treatment to regenerate myelin and several strategies are being scrutinized.", "tags": [{"end": 90, "start": 80, "tag": "BiologicFunction"}, {"end": 67, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 37, "tag": "HealthCareActivity"}, {"end": 46, "start": 37, "tag": "ResearchActivity"}]}{"id": "1281_2", "text": "Myelination is naturally performed by oligodendrocytes and microRNAs have been postulated as a promising tool to induce oligodendrocyte precursor cell differentiation and therefore remyelination.", "tags": [{"end": 68, "start": 59, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 68, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 38, "tag": "Cell"}, {"end": 194, "start": 181, "tag": "CellFunction"}, {"end": 166, "start": 151, "tag": "CellFunction"}, {"end": 150, "start": 120, "tag": "Cell"}, {"end": 11, "start": 0, "tag": "CellFunction"}]}{"id": "1281_3", "text": "Herein, DSPC liposomes and PLGA nanoparticles were studied for miR-219a-5p encapsulation, release and remyelination promotion.", "tags": [{"end": 31, "start": 27, "tag": "Chemical"}, {"end": 88, "start": 75, "tag": "ResearchActivity"}, {"end": 88, "start": 75, "tag": "Finding"}, {"end": 22, "start": 13, "tag": "Chemical"}, {"end": 115, "start": 102, "tag": "CellFunction"}, {"end": 74, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 63, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 12, "start": 8, "tag": "Chemical"}, {"end": 97, "start": 90, "tag": "Finding"}]}{"id": "1281_4", "text": "In parallel, they were compared with biologically engineered extracellular vesicles overexpressing miR-219a-5p.", "tags": [{"end": 60, "start": 37, "tag": "ResearchActivity"}, {"end": 98, "start": 84, "tag": "CellFunction"}, {"end": 83, "start": 61, "tag": "CellComponent"}, {"end": 110, "start": 99, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 110, "start": 99, "tag": "BiologicallyActiveSubstance"}]}{"id": "1281_5", "text": "Interestingly, extracellular vesicles showed the highest oligodendrocyte precursor cell differentiation levels and were more effective than liposomes and polymeric nanoparticles crossing the blood-brain barrier.", "tags": [{"end": 163, "start": 154, "tag": "Chemical"}, {"end": 149, "start": 140, "tag": "Chemical"}, {"end": 177, "start": 154, "tag": "ManufacturedObject"}, {"end": 37, "start": 15, "tag": "CellComponent"}, {"end": 103, "start": 88, "tag": "CellFunction"}, {"end": 87, "start": 57, "tag": "Cell"}, {"end": 210, "start": 191, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1281_6", "text": "Finally, extracellular vesicles were able to improve EAE animal model clinical evolution.", "tags": [{"end": 31, "start": 9, "tag": "CellComponent"}, {"end": 69, "start": 53, "tag": "ExperimentalModelOfDisease"}, {"end": 88, "start": 70, "tag": "ClinicalAttribute"}]}{"id": "1281_7", "text": "Our results indicate that the use of extracellular vesicles as miR-219a-5p delivery system can be a feasible and promising strategy to induce remyelination in multiple sclerosis patients.", "tags": [{"end": 59, "start": 37, "tag": "CellComponent"}, {"end": 177, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 142, "tag": "CellFunction"}, {"end": 186, "start": 178, "tag": "PatientOrDisabledGroup"}, {"end": 74, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 63, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 90, "start": 75, "tag": "ManufacturedObject"}, {"end": 131, "start": 113, "tag": "Finding"}]}{"id": "1282_0", "text": "Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS).", "tags": [{"end": 94, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 30, "tag": "PathologicFunction"}]}{"id": "1282_1", "text": "While most of the current treatment strategies focus on immune cell regulation, except for the drug siponimod, there is no therapeutic intervention that primarily aims at neuroprotection and remyelination.", "tags": [{"end": 78, "start": 56, "tag": "CellFunction"}, {"end": 46, "start": 26, "tag": "HealthCareActivity"}, {"end": 186, "start": 171, "tag": "CellFunction"}, {"end": 46, "start": 26, "tag": "ResearchActivity"}, {"end": 147, "start": 123, "tag": "HealthCareActivity"}, {"end": 99, "start": 95, "tag": "PharmacologicSubstance"}, {"end": 204, "start": 191, "tag": "CellFunction"}, {"end": 25, "start": 18, "tag": "TemporalConcept"}, {"end": 109, "start": 100, "tag": "Chemical"}, {"end": 109, "start": 100, "tag": "PharmacologicSubstance"}, {"end": 109, "start": 100, "tag": "BiologicallyActiveSubstance"}]}{"id": "1282_2", "text": "Recently, nimodipine showed a beneficial and remyelinating effect in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS.", "tags": [{"end": 20, "start": 10, "tag": "Chemical"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 110, "start": 69, "tag": "ExperimentalModelOfDisease"}, {"end": 115, "start": 112, "tag": "ExperimentalModelOfDisease"}, {"end": 137, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 45, "tag": "CellFunction"}, {"end": 20, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 131, "start": 126, "tag": "ResearchActivity"}, {"end": 137, "start": 120, "tag": "ExperimentalModelOfDisease"}]}{"id": "1282_3", "text": "Nimodipine also positively affected astrocytes, neurons, and mature oligodendrocytes.", "tags": [{"end": 10, "start": 0, "tag": "Chemical"}, {"end": 84, "start": 61, "tag": "Cell"}, {"end": 55, "start": 48, "tag": "Cell"}, {"end": 46, "start": 36, "tag": "Cell"}, {"end": 10, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "1282_4", "text": "Here we investigated the effects of nimodipine, an L-type voltage-gated calcium channel antagonist, on the expression profile of myelin genes and proteins in the oligodendrocyte precursor cell (OPC) line Oli-Neu and in primary OPCs.", "tags": [{"end": 46, "start": 36, "tag": "Chemical"}, {"end": 125, "start": 107, "tag": "ResearchActivity"}, {"end": 231, "start": 219, "tag": "Cell"}, {"end": 197, "start": 194, "tag": "Cell"}, {"end": 135, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 162, "tag": "Cell"}, {"end": 79, "start": 72, "tag": "Chemical"}, {"end": 79, "start": 72, "tag": "PharmacologicSubstance"}, {"end": 79, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 36, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 88, "tag": "PharmacologicSubstance"}, {"end": 87, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 136, "tag": "GeneOrGenome"}, {"end": 211, "start": 204, "tag": "Cell"}]}{"id": "1282_5", "text": "Our data indicate that nimodipine does not have any effect on myelin-related gene and protein expression.", "tags": [{"end": 33, "start": 23, "tag": "Chemical"}, {"end": 68, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 104, "start": 86, "tag": "CellFunction"}, {"end": 33, "start": 23, "tag": "PharmacologicSubstance"}]}{"id": "1282_6", "text": "Furthermore, nimodipine treatment did not result in any morphological changes in these cells.", "tags": [{"end": 23, "start": 13, "tag": "Chemical"}, {"end": 92, "start": 87, "tag": "Cell"}, {"end": 33, "start": 24, "tag": "HealthCareActivity"}, {"end": 33, "start": 24, "tag": "ResearchActivity"}, {"end": 23, "start": 13, "tag": "PharmacologicSubstance"}]}{"id": "1282_7", "text": "However, RNA sequencing and bioinformatic analyses identified potential micro (mi)RNA that could support myelination after nimodipine treatment compared to a dimethyl sulfoxide (DMSO) control.", "tags": [{"end": 23, "start": 9, "tag": "ResearchActivity"}, {"end": 133, "start": 123, "tag": "Chemical"}, {"end": 176, "start": 158, "tag": "Chemical"}, {"end": 182, "start": 178, "tag": "Chemical"}, {"end": 116, "start": 105, "tag": "CellFunction"}, {"end": 85, "start": 82, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 143, "start": 134, "tag": "HealthCareActivity"}, {"end": 143, "start": 134, "tag": "ResearchActivity"}, {"end": 133, "start": 123, "tag": "PharmacologicSubstance"}, {"end": 50, "start": 28, "tag": "ResearchActivity"}]}{"id": "1282_8", "text": "Additionally, we treated zebrafish with nimodipine and observed a significant increase in the number of mature oligodendrocytes (* p <= 0.05).", "tags": [{"end": 50, "start": 40, "tag": "Chemical"}, {"end": 34, "start": 25, "tag": "Eukaryote"}, {"end": 127, "start": 104, "tag": "Cell"}, {"end": 50, "start": 40, "tag": "PharmacologicSubstance"}]}{"id": "1282_9", "text": "Taken together, nimodipine seems to have different positive effects on OPCs and mature oligodendrocytes.", "tags": [{"end": 26, "start": 16, "tag": "Chemical"}, {"end": 75, "start": 71, "tag": "Cell"}, {"end": 103, "start": 80, "tag": "Cell"}, {"end": 26, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 51, "tag": "Finding"}]}{"id": "1283_0", "text": "NG2-glia, also known as oligodendrocyte precursor cells (OPCs), have the potential to generate new mature oligodendrocytes and thus, to contribute to tissue repair in demyelinating diseases like multiple sclerosis (MS).", "tags": [{"end": 163, "start": 150, "tag": "BiologicFunction"}, {"end": 61, "start": 57, "tag": "Cell"}, {"end": 189, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 24, "tag": "Cell"}, {"end": 213, "start": 195, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 99, "tag": "Cell"}, {"end": 8, "start": 0, "tag": "Cell"}]}{"id": "1283_1", "text": "Once activated in response to brain damage, NG2-glial cells proliferate, and they acquire a reactive phenotype and a heterogeneous appearance.", "tags": [{"end": 141, "start": 117, "tag": "Finding"}, {"end": 42, "start": 30, "tag": "InjuryOrPoisoning"}, {"end": 110, "start": 92, "tag": "OrganismAttribute"}, {"end": 59, "start": 44, "tag": "Cell"}]}{"id": "1283_2", "text": "Here, we set out to investigate the distribution and phenotypic diversity of NG2-glia relative to their ontogenic origin, and whether there is a clonal NG2-glial response to lesion in an experimental autoimmune encephalomyelitis (EAE) murine model of MS.", "tags": [{"end": 151, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 241, "start": 235, "tag": "Eukaryote"}, {"end": 63, "start": 53, "tag": "OrganismAttribute"}, {"end": 120, "start": 114, "tag": "TemporalConcept"}, {"end": 228, "start": 187, "tag": "ExperimentalModelOfDisease"}, {"end": 233, "start": 230, "tag": "ExperimentalModelOfDisease"}, {"end": 247, "start": 242, "tag": "ResearchActivity"}, {"end": 253, "start": 251, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 174, "tag": "InjuryOrPoisoning"}, {"end": 161, "start": 152, "tag": "Cell"}, {"end": 85, "start": 77, "tag": "Cell"}, {"end": 73, "start": 64, "tag": "Finding"}, {"end": 170, "start": 162, "tag": "Finding"}, {"end": 253, "start": 235, "tag": "ExperimentalModelOfDisease"}]}{"id": "1283_3", "text": "As such, we performed in utero electroporation of the genomic lineage tracer, StarTrack, to follow the fate of NG2-glia derived from single progenitors and to evaluate their response to brain damage after EAE induction.", "tags": [{"end": 151, "start": 140, "tag": "Cell"}, {"end": 76, "start": 70, "tag": "Chemical"}, {"end": 198, "start": 186, "tag": "InjuryOrPoisoning"}, {"end": 208, "start": 205, "tag": "ExperimentalModelOfDisease"}, {"end": 69, "start": 54, "tag": "GeneOrGenome"}, {"end": 119, "start": 111, "tag": "Cell"}, {"end": 46, "start": 22, "tag": "ResearchActivity"}, {"end": 87, "start": 78, "tag": "Chemical"}, {"end": 218, "start": 205, "tag": "ResearchActivity"}]}{"id": "1283_4", "text": "We then analyzed the dispersion of the NG2-glia derived clonally from single pallial progenitors in the brain of EAE mice.", "tags": [{"end": 116, "start": 113, "tag": "ExperimentalModelOfDisease"}, {"end": 121, "start": 113, "tag": "ExperimentalModelOfDisease"}, {"end": 16, "start": 8, "tag": "ResearchActivity"}, {"end": 121, "start": 117, "tag": "Eukaryote"}, {"end": 109, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 39, "tag": "Cell"}, {"end": 96, "start": 70, "tag": "Cell"}]}{"id": "1283_5", "text": "In addition, we examined several morphological parameters to assess the degree of NG2-glia reactivity in clonally-related cells.", "tags": [{"end": 127, "start": 105, "tag": "Cell"}, {"end": 90, "start": 82, "tag": "Cell"}, {"end": 101, "start": 91, "tag": "Finding"}]}{"id": "1283_6", "text": "Our results reveal the heterogeneity of these progenitors and their cell progeny in a scenario of autoimmune demyelination, revealing the ontogenic phenomena at play in these processes.", "tags": [{"end": 36, "start": 23, "tag": "OrganismAttribute"}, {"end": 57, "start": 46, "tag": "Cell"}, {"end": 122, "start": 98, "tag": "PathologicFunction"}, {"end": 80, "start": 68, "tag": "Cell"}, {"end": 157, "start": 138, "tag": "Finding"}]}{"id": "1284_0", "text": "Multiple sclerosis (MS) is characterized by a targeted attack on oligodendroglia (OLG) and myelin by immune cells, which are thought to be the main drivers of MS susceptibility.", "tags": [{"end": 85, "start": 82, "tag": "Cell"}, {"end": 155, "start": 148, "tag": "ManufacturedObject"}, {"end": 155, "start": 148, "tag": "PopulationGroup"}, {"end": 176, "start": 159, "tag": "ClinicalAttribute"}, {"end": 61, "start": 55, "tag": "Finding"}, {"end": 113, "start": 101, "tag": "Cell"}, {"end": 97, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 65, "tag": "Cell"}]}{"id": "1284_1", "text": "We found that immune genes exhibit a primed chromatin state in single mouse and human OLG in a non-disease context, compatible with transitions to immune-competent states in MS.", "tags": [{"end": 89, "start": 86, "tag": "Cell"}, {"end": 143, "start": 132, "tag": "Finding"}, {"end": 176, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 44, "tag": "CellComponent"}, {"end": 75, "start": 70, "tag": "Eukaryote"}, {"end": 85, "start": 80, "tag": "Eukaryote"}, {"end": 170, "start": 164, "tag": "TemporalConcept"}, {"end": 26, "start": 14, "tag": "GeneOrGenome"}]}{"id": "1284_2", "text": "We identified BACH1 and STAT1 as transcription factors involved in immune gene regulation in oligodendrocyte precursor cells (OPCs).", "tags": [{"end": 19, "start": 14, "tag": "GeneOrGenome"}, {"end": 29, "start": 24, "tag": "GeneOrGenome"}, {"end": 29, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "Cell"}, {"end": 124, "start": 93, "tag": "Cell"}, {"end": 19, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 67, "tag": "CellFunction"}]}{"id": "1284_3", "text": "A subset of immune genes presents bivalency of H3K4me3/H3K27me3 in OPCs, with Polycomb inhibition leading to their increased activation upon interferon gamma (IFN-g) treatment.", "tags": [{"end": 86, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 159, "tag": "GeneOrGenome"}, {"end": 164, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 67, "tag": "Cell"}, {"end": 97, "start": 87, "tag": "CellFunction"}, {"end": 175, "start": 166, "tag": "HealthCareActivity"}, {"end": 175, "start": 166, "tag": "ResearchActivity"}, {"end": 24, "start": 12, "tag": "GeneOrGenome"}, {"end": 43, "start": 34, "tag": "Finding"}, {"end": 54, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 141, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 115, "tag": "Finding"}, {"end": 157, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 141, "tag": "PharmacologicSubstance"}]}{"id": "1284_4", "text": "Some MS susceptibility single-nucleotide polymorphisms (SNPs) overlap with these regulatory regions in mouse and human OLG.", "tags": [{"end": 69, "start": 62, "tag": "HealthCareActivity"}, {"end": 69, "start": 62, "tag": "TemporalConcept"}, {"end": 99, "start": 81, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 122, "start": 119, "tag": "Cell"}, {"end": 60, "start": 56, "tag": "MolecularSequence"}, {"end": 7, "start": 5, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 103, "tag": "Eukaryote"}, {"end": 118, "start": 113, "tag": "Eukaryote"}, {"end": 54, "start": 23, "tag": "MolecularSequence"}, {"end": 22, "start": 5, "tag": "ClinicalAttribute"}]}{"id": "1284_5", "text": "Treatment of mouse OPCs with IFN-g leads to chromatin architecture remodeling at these loci and altered expression of interacting genes.", "tags": [{"end": 34, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 29, "tag": "GeneOrGenome"}, {"end": 34, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 19, "tag": "Cell"}, {"end": 53, "start": 44, "tag": "CellComponent"}, {"end": 18, "start": 13, "tag": "Eukaryote"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 77, "start": 44, "tag": "CellFunction"}, {"end": 91, "start": 87, "tag": "Finding"}, {"end": 114, "start": 96, "tag": "Finding"}, {"end": 135, "start": 118, "tag": "GeneOrGenome"}]}{"id": "1284_6", "text": "Thus, the susceptibility for MS may involve OLG, which therefore constitutes novel targets for immunological based therapies for MS.", "tags": [{"end": 31, "start": 10, "tag": "ClinicalAttribute"}, {"end": 47, "start": 44, "tag": "Cell"}, {"end": 124, "start": 95, "tag": "HealthCareActivity"}, {"end": 31, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 129, "tag": "DiseaseOrSyndrome"}]}{"id": "1285_0", "text": "Cholesterol is essential for myelin formation, but may also modulate mechanisms involved in adaptive immune responses.", "tags": [{"end": 117, "start": 92, "tag": "CellFunction"}, {"end": 117, "start": 92, "tag": "BiologicFunction"}, {"end": 11, "start": 0, "tag": "Chemical"}, {"end": 11, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 29, "tag": "CellFunction"}]}{"id": "1285_1", "text": "It is unclear whether lack of remyelination in multiple sclerosis (MS) results from an insufficient capacity of oligodendrocyte precursor cells to differentiate or from cholesterol insufficiency.", "tags": [{"end": 108, "start": 87, "tag": "Finding"}, {"end": 180, "start": 169, "tag": "Chemical"}, {"end": 180, "start": 169, "tag": "BiologicallyActiveSubstance"}, {"end": 143, "start": 112, "tag": "Cell"}, {"end": 160, "start": 147, "tag": "CellFunction"}, {"end": 65, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 30, "tag": "CellFunction"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 22, "tag": "CellOrMolecularDysfunction"}, {"end": 194, "start": 181, "tag": "Finding"}]}{"id": "1285_2", "text": "Several studies have assessed the potential association of lipid profile and its metabolism with demyelination, disability, and disease progression.", "tags": [{"end": 91, "start": 81, "tag": "BiologicFunction"}, {"end": 91, "start": 81, "tag": "CellFunction"}, {"end": 147, "start": 136, "tag": "PathologicFunction"}, {"end": 147, "start": 136, "tag": "TemporalConcept"}, {"end": 110, "start": 97, "tag": "PathologicFunction"}, {"end": 147, "start": 128, "tag": "PathologicFunction"}, {"end": 64, "start": 59, "tag": "Chemical"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 122, "start": 112, "tag": "Finding"}, {"end": 72, "start": 59, "tag": "ResearchActivity"}]}{"id": "1285_3", "text": "The aim of the present study was to measure cholesterol levels in plasma and cerebrospinal fluid (CSF) of patients with relapsing remitting MS (RRMS) or with clinically isolated syndrome (CIS), and to inves-tigate whether there is an association between cholesterol levels and disease characteristics.Sixty-two patients with CIS and 46 patients with RRMS were included in the study.", "tags": [{"end": 139, "start": 130, "tag": "TemporalConcept"}, {"end": 55, "start": 44, "tag": "Chemical"}, {"end": 265, "start": 254, "tag": "Chemical"}, {"end": 55, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 265, "start": 254, "tag": "BiologicallyActiveSubstance"}, {"end": 300, "start": 277, "tag": "ClinicalAttribute"}, {"end": 72, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 120, "tag": "TemporalConcept"}, {"end": 148, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 354, "start": 350, "tag": "DiseaseOrSyndrome"}, {"end": 186, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 328, "start": 325, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 106, "tag": "PatientOrDisabledGroup"}, {"end": 319, "start": 311, "tag": "PatientOrDisabledGroup"}, {"end": 344, "start": 336, "tag": "PatientOrDisabledGroup"}, {"end": 142, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 23, "tag": "ResearchActivity"}, {"end": 381, "start": 376, "tag": "ResearchActivity"}, {"end": 96, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 44, "tag": "ClinicalAttribute"}]}{"id": "1285_4", "text": "All patients had low EDSS and were medication-free at assessment.", "tags": [{"end": 20, "start": 17, "tag": "Finding"}, {"end": 64, "start": 54, "tag": "HealthCareActivity"}, {"end": 64, "start": 54, "tag": "ResearchActivity"}, {"end": 25, "start": 21, "tag": "HealthCareActivity"}, {"end": 12, "start": 4, "tag": "PatientOrDisabledGroup"}, {"end": 45, "start": 35, "tag": "HealthCareActivity"}]}{"id": "1285_5", "text": "Forty-eight subjects within the same age range served as controls.", "tags": [{"end": 65, "start": 57, "tag": "PopulationGroup"}, {"end": 40, "start": 37, "tag": "OrganismAttribute"}, {"end": 20, "start": 12, "tag": "PopulationGroup"}]}{"id": "1285_6", "text": "Cholesterol concentrations were measured in plasma and in CSF by the same enzymatic - colorimetric method, and were related to clinical status, disease activity in magnetic resonance imaging (MRI) and presence of oli-goclonal bands in CSF (OBs).Significantly lower levels of plasma and CSF cholesterol were found in patients compared to controls.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 11, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 301, "start": 290, "tag": "Chemical"}, {"end": 105, "start": 74, "tag": "ResearchActivity"}, {"end": 301, "start": 290, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 281, "start": 275, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 235, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 289, "start": 286, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 160, "start": 144, "tag": "HealthCareActivity"}, {"end": 345, "start": 337, "tag": "PopulationGroup"}, {"end": 190, "start": 164, "tag": "HealthCareActivity"}, {"end": 209, "start": 201, "tag": "Finding"}, {"end": 324, "start": 316, "tag": "PatientOrDisabledGroup"}, {"end": 195, "start": 192, "tag": "HealthCareActivity"}, {"end": 142, "start": 127, "tag": "ClinicalAttribute"}, {"end": 231, "start": 213, "tag": "ResearchActivity"}]}{"id": "1285_7", "text": "Patients with OBs showed significantly lower levels of CSF cholesterol but not plasma cholesterol compared to OBs-negative patients.", "tags": [{"end": 17, "start": 14, "tag": "GeneOrGenome"}, {"end": 70, "start": 59, "tag": "Chemical"}, {"end": 97, "start": 86, "tag": "Chemical"}, {"end": 70, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 131, "start": 123, "tag": "PatientOrDisabledGroup"}, {"end": 97, "start": 79, "tag": "ClinicalAttribute"}, {"end": 70, "start": 55, "tag": "ClinicalAttribute"}]}{"id": "1285_8", "text": "A positive correlation of plasma cholesterol with age and of CSF cholesterol with EDSS was found.Our results suggest that low CSF cholesterol in MS patients with positive OBs might reflect extensive demy-elination and a more aggressive disease course associated with an increased humoral immune response against membrane components.", "tags": [{"end": 44, "start": 26, "tag": "ClinicalAttribute"}, {"end": 125, "start": 122, "tag": "Finding"}, {"end": 303, "start": 280, "tag": "BiologicFunction"}, {"end": 303, "start": 280, "tag": "CellFunction"}, {"end": 250, "start": 236, "tag": "TemporalConcept"}, {"end": 44, "start": 33, "tag": "Chemical"}, {"end": 76, "start": 65, "tag": "Chemical"}, {"end": 141, "start": 130, "tag": "Chemical"}, {"end": 44, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 130, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 82, "tag": "HealthCareActivity"}, {"end": 156, "start": 148, "tag": "PatientOrDisabledGroup"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 50, "tag": "OrganismAttribute"}, {"end": 331, "start": 312, "tag": "CellComponent"}, {"end": 76, "start": 61, "tag": "ClinicalAttribute"}, {"end": 22, "start": 2, "tag": "Finding"}, {"end": 141, "start": 126, "tag": "ClinicalAttribute"}]}{"id": "1286_0", "text": "The differentiation of oligodendrocyte precursor cells (OPCs) into myelinating oligodendrocytes is the prerequisite for remyelination in demyelinated disorders such as multiple sclerosis (MS).", "tags": [{"end": 159, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 56, "tag": "Cell"}, {"end": 54, "start": 23, "tag": "Cell"}, {"end": 186, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 120, "tag": "CellFunction"}, {"end": 190, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 4, "tag": "CellFunction"}, {"end": 95, "start": 67, "tag": "Cell"}, {"end": 54, "start": 39, "tag": "Cell"}]}{"id": "1286_1", "text": "Epigenetic mechanisms, such as DNA methylation, have been suggested to control the intricate network of transcription factors involved in OPC differentiation.", "tags": [{"end": 125, "start": 93, "tag": "CellFunction"}, {"end": 125, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 0, "tag": "CellFunction"}, {"end": 46, "start": 31, "tag": "CellFunction"}, {"end": 157, "start": 138, "tag": "CellFunction"}]}{"id": "1286_2", "text": "Yet, the exact mechanism remains undisclosed.", "tags": []}{"id": "1286_3", "text": "Here, we are the first to identify the DNA-binding protein inhibitors, Id2 and Id4, as targets of DNA methylation during OPC differentiation.", "tags": [{"end": 74, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 71, "tag": "GeneOrGenome"}, {"end": 82, "start": 79, "tag": "GeneOrGenome"}, {"end": 113, "start": 98, "tag": "CellFunction"}, {"end": 22, "start": 17, "tag": "TemporalConcept"}, {"end": 140, "start": 121, "tag": "CellFunction"}, {"end": 69, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 79, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1286_4", "text": "Using state-of-the-art epigenetic editing via CRISPR/dCas9-DNMT3a, we confirm that targeted methylation of Id2/Id4 drives OPC differentiation.", "tags": [{"end": 65, "start": 46, "tag": "ResearchActivity"}, {"end": 125, "start": 122, "tag": "Cell"}, {"end": 141, "start": 126, "tag": "CellFunction"}, {"end": 103, "start": 92, "tag": "CellFunction"}, {"end": 41, "start": 23, "tag": "ResearchActivity"}, {"end": 110, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 107, "tag": "GeneOrGenome"}, {"end": 114, "start": 111, "tag": "GeneOrGenome"}]}{"id": "1286_5", "text": "Moreover, we show that in the pathological context of MS, methylation and gene expression levels of both ID2 and ID4 are altered compared to control human brain samples.", "tags": [{"end": 108, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 105, "tag": "GeneOrGenome"}, {"end": 116, "start": 113, "tag": "GeneOrGenome"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 149, "tag": "Eukaryote"}, {"end": 69, "start": 58, "tag": "CellFunction"}, {"end": 168, "start": 161, "tag": "Substance"}, {"end": 168, "start": 161, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 89, "start": 74, "tag": "CellFunction"}, {"end": 108, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 113, "tag": "BiologicallyActiveSubstance"}]}{"id": "1286_6", "text": "We conclude that DNA methylation is crucial to suppress ID2 and ID4 during OPC differentiation, a process that appears to be dysregulated during MS.", "tags": [{"end": 59, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 56, "tag": "GeneOrGenome"}, {"end": 67, "start": 64, "tag": "GeneOrGenome"}, {"end": 137, "start": 125, "tag": "PathologicFunction"}, {"end": 32, "start": 17, "tag": "CellFunction"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 75, "tag": "CellFunction"}, {"end": 59, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 64, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1286_7", "text": "Our data do not only reveal new insights into oligodendrocyte biology, but could also lead to a better understanding of CNS myelin disorders.", "tags": [{"end": 69, "start": 62, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 61, "start": 46, "tag": "Cell"}, {"end": 130, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 103, "tag": "BiologicFunction"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 140, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 62, "tag": "BiologicFunction"}]}{"id": "1287_0", "text": "White matter (WM) is a highly prominent feature in the human cerebrum and is comprised of bundles of myelinated axons that form the connectome of the brain.", "tags": [{"end": 69, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 142, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 55, "tag": "Eukaryote"}, {"end": 12, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1287_1", "text": "Myelin is formed by oligodendrocytes and is essential for rapid neuronal electrical communication that underlies the massive computing power of the human brain.", "tags": [{"end": 36, "start": 20, "tag": "Cell"}, {"end": 159, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 148, "tag": "Eukaryote"}, {"end": 97, "start": 64, "tag": "CellFunction"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 117, "tag": "Finding"}]}{"id": "1287_2", "text": "Oligodendrocytes are generated throughout life by oligodendrocyte precursor cells (OPCs), which are identified by expression of the chondroitin sulphate proteoglycan NG2 (Cspg4), and are often termed NG2-glia.", "tags": [{"end": 165, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 176, "start": 171, "tag": "GeneOrGenome"}, {"end": 176, "start": 171, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 166, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 81, "start": 50, "tag": "Cell"}, {"end": 46, "start": 42, "tag": "TemporalConcept"}, {"end": 208, "start": 200, "tag": "Cell"}, {"end": 124, "start": 114, "tag": "CellFunction"}, {"end": 176, "start": 171, "tag": "BiologicallyActiveSubstance"}]}{"id": "1287_3", "text": "Adult NG2+ OPCs are slowly proliferating cells that have the stem cell-like property of self-renewal and differentiation into a pool of 'late OPCs' or 'differentiation committed' OPCs(COPs) identified by specific expression of the G-protein-coupled receptor GPR17, which are capable of differentiation into myelinating oligodendrocytes.", "tags": [{"end": 5, "start": 0, "tag": "PopulationGroup"}, {"end": 257, "start": 231, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 88, "tag": "CellFunction"}, {"end": 9, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 6, "tag": "Cell"}, {"end": 146, "start": 136, "tag": "Cell"}, {"end": 183, "start": 179, "tag": "Cell"}, {"end": 46, "start": 20, "tag": "Cell"}, {"end": 120, "start": 105, "tag": "CellFunction"}, {"end": 167, "start": 152, "tag": "CellFunction"}, {"end": 301, "start": 286, "tag": "CellFunction"}, {"end": 335, "start": 307, "tag": "Cell"}, {"end": 257, "start": 231, "tag": "BiologicallyActiveSubstance"}, {"end": 263, "start": 258, "tag": "GeneOrGenome"}, {"end": 263, "start": 258, "tag": "AminoAcidPeptideOrProtein"}, {"end": 263, "start": 258, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 61, "tag": "Cell"}, {"end": 188, "start": 184, "tag": "Cell"}]}{"id": "1287_4", "text": "In the adult brain, these reservoirs of OPCs and COPs ensure rapid myelination of new neuronal connections formed in response to neuronal signalling, which underpins learning and cognitive function.", "tags": [{"end": 197, "start": 179, "tag": "BiologicFunction"}, {"end": 174, "start": 166, "tag": "BiologicFunction"}, {"end": 44, "start": 26, "tag": "Cell"}, {"end": 78, "start": 67, "tag": "CellFunction"}, {"end": 94, "start": 86, "tag": "Cell"}, {"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 7, "tag": "PopulationGroup"}, {"end": 53, "start": 49, "tag": "Cell"}, {"end": 106, "start": 86, "tag": "CellComponent"}, {"end": 148, "start": 129, "tag": "CellFunction"}]}{"id": "1287_5", "text": "However, there is an age-related decline in myelination that is associated with a loss of neuronal function and cognitive decline.", "tags": [{"end": 129, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 44, "tag": "CellFunction"}, {"end": 24, "start": 21, "tag": "OrganismAttribute"}, {"end": 107, "start": 82, "tag": "CellOrMolecularDysfunction"}]}{"id": "1287_6", "text": "The underlying causes of myelin loss in ageing are manifold, but a key factor is the decay in OPC 'stemness' and a decline in their replenishment of COPs, which results in the ultimate failure of myelin regeneration.", "tags": [{"end": 46, "start": 40, "tag": "BiologicFunction"}, {"end": 97, "start": 94, "tag": "Cell"}, {"end": 31, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 192, "start": 185, "tag": "Finding"}, {"end": 215, "start": 196, "tag": "CellFunction"}, {"end": 36, "start": 25, "tag": "CellOrMolecularDysfunction"}, {"end": 107, "start": 99, "tag": "Finding"}, {"end": 153, "start": 149, "tag": "Cell"}, {"end": 122, "start": 115, "tag": "Finding"}, {"end": 145, "start": 132, "tag": "Finding"}]}{"id": "1287_7", "text": "These changes in ageing OPCs are underpinned by dysregulation of neuronal signalling and OPC metabolic function.", "tags": [{"end": 23, "start": 17, "tag": "BiologicFunction"}, {"end": 28, "start": 24, "tag": "Cell"}, {"end": 84, "start": 48, "tag": "CellOrMolecularDysfunction"}, {"end": 111, "start": 89, "tag": "CellFunction"}]}{"id": "1287_8", "text": "Here, we highlight the role of purine signalling in regulating OPC self-renewal and the potential importance of GPR17 and the P2X7 receptor subtype in age-related changes in OPC metabolism.", "tags": [{"end": 37, "start": 31, "tag": "Chemical"}, {"end": 139, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 174, "tag": "CellFunction"}, {"end": 79, "start": 63, "tag": "CellFunction"}, {"end": 139, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 151, "tag": "OrganismAttribute"}, {"end": 117, "start": 112, "tag": "GeneOrGenome"}, {"end": 117, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 31, "tag": "CellFunction"}]}{"id": "1287_9", "text": "Moreover, age is the main factor in the failure of myelination in chronic multiple sclerosis and myelin loss in Alzheimer's disease, hence understanding the importance of purine signalling in OPC regeneration and myelination is critical for developing new strategies for promoting repair in age-dependent neuropathology.", "tags": [{"end": 92, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 171, "tag": "Chemical"}, {"end": 62, "start": 51, "tag": "CellFunction"}, {"end": 224, "start": 213, "tag": "CellFunction"}, {"end": 103, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 287, "start": 281, "tag": "BiologicFunction"}, {"end": 287, "start": 281, "tag": "HealthCareActivity"}, {"end": 152, "start": 139, "tag": "BiologicFunction"}, {"end": 13, "start": 10, "tag": "OrganismAttribute"}, {"end": 294, "start": 291, "tag": "OrganismAttribute"}, {"end": 47, "start": 40, "tag": "Finding"}, {"end": 319, "start": 305, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 319, "start": 305, "tag": "PathologicFunction"}, {"end": 131, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 188, "start": 171, "tag": "CellFunction"}, {"end": 108, "start": 97, "tag": "CellOrMolecularDysfunction"}, {"end": 208, "start": 192, "tag": "CellFunction"}]}{"id": "1288_0", "text": "Oligodendrocyte precursor cells (NG2 glia) are uniformly distributed proliferative cells in the mammalian central nervous system and generate myelinating oligodendrocytes throughout life.", "tags": [{"end": 88, "start": 69, "tag": "Cell"}, {"end": 128, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 182, "tag": "TemporalConcept"}, {"end": 170, "start": 142, "tag": "Cell"}, {"end": 105, "start": 96, "tag": "Eukaryote"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 41, "start": 33, "tag": "Cell"}]}{"id": "1288_1", "text": "A subpopulation of OPCs in the neocortex arises from progenitor cells in the embryonic ganglionic eminences that also produce inhibitory neurons.", "tags": [{"end": 15, "start": 2, "tag": "PopulationGroup"}, {"end": 40, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 19, "tag": "Cell"}, {"end": 69, "start": 53, "tag": "Cell"}, {"end": 144, "start": 126, "tag": "Cell"}, {"end": 107, "start": 77, "tag": "EmbryonicStructure"}]}{"id": "1288_2", "text": "The neuronal fate of some progenitor cells is sealed before birth as they become committed to the oligodendrocyte lineage, marked by sustained expression of the oligodendrocyte transcription factor Olig2, which represses the interneuron transcription factor Dlx2.", "tags": [{"end": 203, "start": 198, "tag": "AminoAcidPeptideOrProtein"}, {"end": 203, "start": 198, "tag": "GeneOrGenome"}, {"end": 262, "start": 258, "tag": "GeneOrGenome"}, {"end": 197, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 257, "start": 237, "tag": "AminoAcidPeptideOrProtein"}, {"end": 197, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 257, "start": 237, "tag": "BiologicallyActiveSubstance"}, {"end": 176, "start": 161, "tag": "Cell"}, {"end": 12, "start": 4, "tag": "Cell"}, {"end": 42, "start": 26, "tag": "Cell"}, {"end": 121, "start": 98, "tag": "Cell"}, {"end": 65, "start": 60, "tag": "BiologicFunction"}, {"end": 65, "start": 60, "tag": "TemporalConcept"}, {"end": 153, "start": 143, "tag": "CellFunction"}, {"end": 203, "start": 198, "tag": "BiologicallyActiveSubstance"}, {"end": 236, "start": 225, "tag": "Cell"}, {"end": 262, "start": 258, "tag": "BiologicallyActiveSubstance"}, {"end": 262, "start": 258, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1288_3", "text": "Here we show that misexpression of Dlx2 alone in postnatal mouse OPCs caused them to switch their fate to GABAergic neurons within 2 days by downregulating Olig2 and upregulating a network of inhibitory neuron transcripts.", "tags": [{"end": 39, "start": 35, "tag": "GeneOrGenome"}, {"end": 123, "start": 106, "tag": "Cell"}, {"end": 155, "start": 141, "tag": "CellFunction"}, {"end": 161, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 156, "tag": "GeneOrGenome"}, {"end": 178, "start": 166, "tag": "CellFunction"}, {"end": 188, "start": 181, "tag": "PopulationGroup"}, {"end": 188, "start": 181, "tag": "CellFunction"}, {"end": 69, "start": 65, "tag": "Cell"}, {"end": 64, "start": 59, "tag": "Eukaryote"}, {"end": 221, "start": 210, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 137, "start": 133, "tag": "TemporalConcept"}, {"end": 58, "start": 49, "tag": "TemporalConcept"}, {"end": 209, "start": 192, "tag": "Cell"}, {"end": 31, "start": 18, "tag": "CellOrMolecularDysfunction"}, {"end": 39, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 161, "start": 156, "tag": "BiologicallyActiveSubstance"}]}{"id": "1288_4", "text": "After two weeks, some OPC-derived neurons generated trains of action potentials and formed clusters of GABAergic synaptic proteins.", "tags": [{"end": 130, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 22, "tag": "Cell"}, {"end": 15, "start": 10, "tag": "TemporalConcept"}, {"end": 79, "start": 62, "tag": "CellFunction"}]}{"id": "1288_5", "text": "Our study revealed that the developmental molecular logic can be applied to promote neuronal reprogramming from OPCs.", "tags": [{"end": 106, "start": 93, "tag": "CellFunction"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 92, "start": 84, "tag": "Cell"}, {"end": 41, "start": 28, "tag": "BiologicFunction"}, {"end": 41, "start": 28, "tag": "TemporalConcept"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 106, "start": 93, "tag": "ResearchActivity"}]}{"id": "1289_0", "text": "The differentiation of oligodendroglia from oligodendrocyte precursor cells (OPCs) to complex and extensive myelinating oligodendrocytes (OLs) is a multistep process that involves large-scale morphological changes with significant strain on the cytoskeleton.", "tags": [{"end": 257, "start": 245, "tag": "CellComponent"}, {"end": 81, "start": 77, "tag": "Cell"}, {"end": 75, "start": 44, "tag": "Cell"}, {"end": 19, "start": 4, "tag": "CellFunction"}, {"end": 136, "start": 108, "tag": "Cell"}, {"end": 141, "start": 138, "tag": "Cell"}, {"end": 38, "start": 23, "tag": "Cell"}, {"end": 213, "start": 192, "tag": "Finding"}]}{"id": "1289_1", "text": "While key chromatin and transcriptional regulators of differentiation have been identified, their target genes responsible for the morphological changes occurring during OL myelination are still largely unknown.", "tags": [{"end": 50, "start": 24, "tag": "CellFunction"}, {"end": 184, "start": 173, "tag": "CellFunction"}, {"end": 69, "start": 54, "tag": "CellFunction"}, {"end": 19, "start": 10, "tag": "CellComponent"}, {"end": 172, "start": 170, "tag": "Cell"}, {"end": 110, "start": 98, "tag": "GeneOrGenome"}, {"end": 152, "start": 131, "tag": "Finding"}]}{"id": "1289_2", "text": "Here, we show that the regulator of focal adhesion, Tensin3 (Tns3), is a direct target gene of Olig2, Chd7, and Chd8, transcriptional regulators of OL differentiation.", "tags": [{"end": 50, "start": 36, "tag": "CellComponent"}, {"end": 100, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 95, "tag": "GeneOrGenome"}, {"end": 106, "start": 102, "tag": "GeneOrGenome"}, {"end": 116, "start": 112, "tag": "GeneOrGenome"}, {"end": 144, "start": 118, "tag": "CellFunction"}, {"end": 166, "start": 148, "tag": "CellFunction"}, {"end": 59, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 61, "tag": "GeneOrGenome"}, {"end": 91, "start": 80, "tag": "GeneOrGenome"}, {"end": 100, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 116, "start": 112, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1289_3", "text": "Tns3 is transiently upregulated and localized to cell processes of immature OLs, together with integrin-beta 1, a key mediator of survival at this transient stage.", "tags": [{"end": 63, "start": 49, "tag": "CellComponent"}, {"end": 156, "start": 147, "tag": "TemporalConcept"}, {"end": 79, "start": 76, "tag": "Cell"}, {"end": 138, "start": 130, "tag": "CellFunction"}, {"end": 75, "start": 67, "tag": "BiologicFunction"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "GeneOrGenome"}, {"end": 110, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 118, "tag": "Finding"}]}{"id": "1289_4", "text": "Constitutive Tns3 loss of function leads to reduced viability in mouse and humans, with surviving knockout mice still expressing Tns3 in oligodendroglia.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 52, "tag": "CellFunction"}, {"end": 111, "start": 98, "tag": "ResearchActivity"}, {"end": 128, "start": 118, "tag": "CellFunction"}, {"end": 81, "start": 75, "tag": "Eukaryote"}, {"end": 152, "start": 137, "tag": "Cell"}, {"end": 70, "start": 65, "tag": "Eukaryote"}, {"end": 17, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 13, "tag": "GeneOrGenome"}, {"end": 133, "start": 129, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 129, "tag": "GeneOrGenome"}]}{"id": "1289_5", "text": "Acute deletion of Tns3 in vivo, either in postnatal neural stem cells (NSCs) or in OPCs, leads to a twofold reduction in OL numbers.", "tags": [{"end": 22, "start": 6, "tag": "CellOrMolecularDysfunction"}, {"end": 75, "start": 71, "tag": "Cell"}, {"end": 117, "start": 108, "tag": "Finding"}, {"end": 117, "start": 108, "tag": "NaturalPhenomenonOrProcess"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 30, "start": 23, "tag": "ResearchActivity"}, {"end": 123, "start": 121, "tag": "Cell"}, {"end": 5, "start": 0, "tag": "TemporalConcept"}, {"end": 51, "start": 42, "tag": "TemporalConcept"}, {"end": 69, "start": 52, "tag": "Cell"}]}{"id": "1289_6", "text": "We find that the transient upregulation of Tns3 is required to protect differentiating OPCs and immature OLs from cell death by preventing the upregulation of p53, a key regulator of apoptosis.", "tags": [{"end": 162, "start": 159, "tag": "GeneOrGenome"}, {"end": 162, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 124, "start": 114, "tag": "CellFunction"}, {"end": 91, "start": 71, "tag": "Cell"}, {"end": 26, "start": 17, "tag": "TemporalConcept"}, {"end": 108, "start": 96, "tag": "Cell"}, {"end": 192, "start": 183, "tag": "CellFunction"}, {"end": 39, "start": 27, "tag": "CellFunction"}, {"end": 155, "start": 143, "tag": "CellFunction"}, {"end": 47, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 43, "tag": "GeneOrGenome"}, {"end": 179, "start": 166, "tag": "Finding"}]}{"id": "1289_7", "text": "Altogether, our findings reveal a specific time window during which transcriptional upregulation of Tns3 in immature OLs is required for OL differentiation likely by mediating integrin-beta 1 survival signaling to the actin cytoskeleton as OL undergo the large morphological changes required for their terminal differentiation.", "tags": [{"end": 236, "start": 218, "tag": "CellComponent"}, {"end": 83, "start": 68, "tag": "CellFunction"}, {"end": 210, "start": 201, "tag": "CellFunction"}, {"end": 326, "start": 311, "tag": "CellFunction"}, {"end": 47, "start": 43, "tag": "TemporalConcept"}, {"end": 120, "start": 108, "tag": "Cell"}, {"end": 155, "start": 137, "tag": "CellFunction"}, {"end": 242, "start": 240, "tag": "Cell"}, {"end": 200, "start": 192, "tag": "CellFunction"}, {"end": 96, "start": 84, "tag": "CellFunction"}, {"end": 104, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 100, "tag": "GeneOrGenome"}, {"end": 191, "start": 176, "tag": "AminoAcidPeptideOrProtein"}, {"end": 191, "start": 176, "tag": "BiologicallyActiveSubstance"}, {"end": 191, "start": 176, "tag": "GeneOrGenome"}, {"end": 282, "start": 261, "tag": "Finding"}]}{"id": "1290_0", "text": "Introduction Several experimental studies have suggested the potential remyelinating effects of vitamin D (VitD) supplements regardless of the presence of VitD deficiency.", "tags": [{"end": 41, "start": 21, "tag": "ResearchActivity"}, {"end": 170, "start": 160, "tag": "Finding"}, {"end": 105, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 143, "tag": "Finding"}, {"end": 84, "start": 71, "tag": "CellFunction"}, {"end": 111, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 159, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 107, "tag": "PharmacologicSubstance"}, {"end": 159, "start": 155, "tag": "PharmacologicSubstance"}, {"end": 105, "start": 96, "tag": "PharmacologicSubstance"}]}{"id": "1290_1", "text": "This study aims to analyze neurogenesis in a model of toxic demyelination in order to evaluate the effects of VitD on demyelination and remyelination.", "tags": [{"end": 59, "start": 54, "tag": "InjuryOrPoisoning"}, {"end": 114, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 45, "tag": "ResearchActivity"}, {"end": 149, "start": 136, "tag": "CellFunction"}, {"end": 73, "start": 60, "tag": "PathologicFunction"}, {"end": 131, "start": 118, "tag": "PathologicFunction"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 39, "start": 27, "tag": "BiologicFunction"}, {"end": 114, "start": 110, "tag": "PharmacologicSubstance"}]}{"id": "1290_2", "text": "Material and methods We used 24 male Wistar rats that had received surgical lesions to the corpus callosum and were injected with lysolecithin.", "tags": [{"end": 48, "start": 37, "tag": "Eukaryote"}, {"end": 83, "start": 67, "tag": "InjuryOrPoisoning"}, {"end": 142, "start": 130, "tag": "Chemical"}, {"end": 142, "start": 130, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 32, "tag": "OrganismAttribute"}, {"end": 20, "start": 0, "tag": "ResearchActivity"}]}{"id": "1290_3", "text": "Rats were divided into three groups: Group 1 included eight rats with lesions to the corpus callosum but not lysolecithin injections (sham group), group 2 included eight rats with lesions to the corpus callosum that were injected with lysolecithin (lysolecithin group), and group 3 included eight rats with lesions that were injected with lysolecithin and received VitD (VitD group).", "tags": [{"end": 369, "start": 365, "tag": "PharmacologicSubstance"}, {"end": 369, "start": 365, "tag": "BiologicallyActiveSubstance"}, {"end": 375, "start": 371, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 60, "tag": "Eukaryote"}, {"end": 174, "start": 170, "tag": "Eukaryote"}, {"end": 301, "start": 297, "tag": "Eukaryote"}, {"end": 132, "start": 122, "tag": "HealthCareActivity"}, {"end": 144, "start": 134, "tag": "ResearchActivity"}, {"end": 77, "start": 70, "tag": "InjuryOrPoisoning"}, {"end": 187, "start": 180, "tag": "InjuryOrPoisoning"}, {"end": 314, "start": 307, "tag": "InjuryOrPoisoning"}, {"end": 121, "start": 109, "tag": "Chemical"}, {"end": 247, "start": 235, "tag": "Chemical"}, {"end": 261, "start": 249, "tag": "Chemical"}, {"end": 351, "start": 339, "tag": "Chemical"}, {"end": 121, "start": 109, "tag": "PharmacologicSubstance"}, {"end": 247, "start": 235, "tag": "PharmacologicSubstance"}, {"end": 261, "start": 249, "tag": "PharmacologicSubstance"}, {"end": 351, "start": 339, "tag": "PharmacologicSubstance"}, {"end": 100, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 210, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 4, "start": 0, "tag": "Eukaryote"}, {"end": 132, "start": 122, "tag": "ResearchActivity"}, {"end": 375, "start": 371, "tag": "PharmacologicSubstance"}]}{"id": "1290_4", "text": "We analyzed neurogenesis both in the subventricular zone and at the lesion site.", "tags": [{"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 74, "start": 68, "tag": "InjuryOrPoisoning"}, {"end": 24, "start": 12, "tag": "BiologicFunction"}, {"end": 56, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1290_5", "text": "Results Administration of VitD promotes the proliferation and differentiation of neural stem cells in the subventricular zone and the migration of these cells to the lesion site in the corpus callosum; these cells subsequently differentiate into oligodendrocyte lineage cells and produce myelin basic protein.", "tags": [{"end": 30, "start": 26, "tag": "PharmacologicSubstance"}, {"end": 30, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 8, "tag": "HealthCareActivity"}, {"end": 240, "start": 227, "tag": "CellFunction"}, {"end": 158, "start": 153, "tag": "Cell"}, {"end": 213, "start": 208, "tag": "Cell"}, {"end": 294, "start": 288, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 166, "tag": "InjuryOrPoisoning"}, {"end": 275, "start": 246, "tag": "Cell"}, {"end": 77, "start": 62, "tag": "CellFunction"}, {"end": 57, "start": 44, "tag": "CellFunction"}, {"end": 143, "start": 134, "tag": "CellFunction"}, {"end": 308, "start": 288, "tag": "AminoAcidPeptideOrProtein"}, {"end": 308, "start": 288, "tag": "BiologicallyActiveSubstance"}, {"end": 200, "start": 185, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 81, "tag": "Cell"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}{"id": "1290_6", "text": "This phenomenon was not caused by microglial activation, which was less marked in rats receiving VitD.", "tags": [{"end": 86, "start": 82, "tag": "Eukaryote"}, {"end": 55, "start": 34, "tag": "CellFunction"}, {"end": 101, "start": 97, "tag": "PharmacologicSubstance"}, {"end": 101, "start": 97, "tag": "BiologicallyActiveSubstance"}]}{"id": "1290_7", "text": "Megalin expression did not increase at the lesion site, which suggests that VitD is internalized by other mechanisms.", "tags": [{"end": 7, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 7, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 76, "tag": "PharmacologicSubstance"}, {"end": 80, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 43, "tag": "InjuryOrPoisoning"}, {"end": 18, "start": 8, "tag": "CellFunction"}]}{"id": "1290_8", "text": "Conclusion Our results support the hypothesis that regardless of the presence of VitD deficiency, treatment with VitD may contribute to remyelination by promoting the proliferation of oligodendrocyte precursor cells.", "tags": [{"end": 117, "start": 113, "tag": "PharmacologicSubstance"}, {"end": 117, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 86, "tag": "Finding"}, {"end": 215, "start": 184, "tag": "Cell"}, {"end": 77, "start": 69, "tag": "Finding"}, {"end": 149, "start": 136, "tag": "CellFunction"}, {"end": 180, "start": 167, "tag": "CellFunction"}, {"end": 107, "start": 98, "tag": "HealthCareActivity"}, {"end": 107, "start": 98, "tag": "ResearchActivity"}, {"end": 85, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 81, "tag": "PharmacologicSubstance"}]}{"id": "1291_0", "text": "Demyelinating injuries and diseases, like multiple sclerosis, affect millions of people worldwide.", "tags": [{"end": 60, "start": 42, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 81, "tag": "PopulationGroup"}, {"end": 22, "start": 0, "tag": "InjuryOrPoisoning"}]}{"id": "1291_1", "text": "Oligodendrocyte precursor cells (OPCs) have the potential to repair demyelinated tissues because they can both self-renew and differentiate into oligodendrocytes (OLs), the myelin producing cells of the central nervous system (CNS).", "tags": [{"end": 161, "start": 145, "tag": "Cell"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 139, "start": 126, "tag": "CellFunction"}, {"end": 179, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 68, "tag": "PathologicFunction"}, {"end": 166, "start": 163, "tag": "Cell"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 225, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 230, "start": 227, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 195, "start": 190, "tag": "Cell"}, {"end": 88, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 61, "tag": "BiologicFunction"}, {"end": 67, "start": 61, "tag": "HealthCareActivity"}]}{"id": "1291_2", "text": "Cell-matrix interactions impact OPC differentiation into OLs, but the process is not fully understood.", "tags": [{"end": 35, "start": 32, "tag": "Cell"}, {"end": 51, "start": 36, "tag": "CellFunction"}, {"end": 60, "start": 57, "tag": "Cell"}, {"end": 51, "start": 32, "tag": "CellFunction"}, {"end": 24, "start": 0, "tag": "Finding"}]}{"id": "1291_3", "text": "Biomaterial hydrogel systems help to elucidate cell-matrix interactions because they can mimic specific properties of native CNS tissues in an in vitro setting.", "tags": [{"end": 128, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 47, "tag": "Cell"}, {"end": 151, "start": 143, "tag": "ResearchActivity"}, {"end": 71, "start": 59, "tag": "Finding"}, {"end": 136, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 0, "tag": "ResearchActivity"}, {"end": 28, "start": 0, "tag": "ManufacturedObject"}]}{"id": "1291_4", "text": "We investigated whether OPC maturation into OLs is influenced by interacting with a urokinase plasminogen activator (uPA) degradable extracellular matrix (ECM).", "tags": [{"end": 115, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 117, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 117, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 24, "tag": "Cell"}, {"end": 38, "start": 28, "tag": "BiologicFunction"}, {"end": 153, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 155, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 44, "tag": "Cell"}]}{"id": "1291_5", "text": "uPA is a proteolytic enzyme that is transiently upregulated in the developing rat brain, with peak uPA expression correlating with an increase in myelin production in vivo.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 77, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 78, "tag": "Eukaryote"}, {"end": 27, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 103, "tag": "CellFunction"}, {"end": 171, "start": 164, "tag": "ResearchActivity"}]}{"id": "1291_6", "text": "OPC-like cells isolated through the Mosaic Analysis with Double Marker technique (MADM OPCs) produced low-molecular-weight uPA in culture.", "tags": [{"end": 86, "start": 82, "tag": "ResearchActivity"}, {"end": 126, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 87, "tag": "Cell"}, {"end": 3, "start": 0, "tag": "Cell"}, {"end": 80, "start": 36, "tag": "ResearchActivity"}, {"end": 137, "start": 130, "tag": "ResearchActivity"}, {"end": 14, "start": 9, "tag": "Cell"}, {"end": 105, "start": 102, "tag": "Finding"}]}{"id": "1291_7", "text": "MADM OPCs were encapsulated into two otherwise similar elastin-like protein (ELP) hydrogel systems: one that was uPA degradable and one that was nondegradable.", "tags": [{"end": 4, "start": 0, "tag": "ResearchActivity"}, {"end": 116, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 9, "start": 5, "tag": "Cell"}, {"end": 98, "start": 82, "tag": "ResearchActivity"}, {"end": 98, "start": 82, "tag": "ManufacturedObject"}, {"end": 75, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 77, "tag": "BiologicallyActiveSubstance"}]}{"id": "1291_8", "text": "Encapsulated MADM OPCs had similar viability, proliferation, and metabolic activity in uPA degradable and nondegradable ELP hydrogels.", "tags": [{"end": 17, "start": 13, "tag": "ResearchActivity"}, {"end": 90, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 18, "tag": "Cell"}, {"end": 59, "start": 46, "tag": "CellFunction"}, {"end": 44, "start": 35, "tag": "CellFunction"}, {"end": 83, "start": 65, "tag": "CellFunction"}, {"end": 133, "start": 124, "tag": "ResearchActivity"}, {"end": 133, "start": 124, "tag": "ManufacturedObject"}, {"end": 123, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 120, "tag": "BiologicallyActiveSubstance"}]}{"id": "1291_9", "text": "Expression of OPC maturation-associated genes, however, indicated that uPA degradable ELP hydrogels promoted MADM OPC maturation although not sufficiently for these cells to differentiate into OLs.", "tags": [{"end": 74, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 109, "tag": "ResearchActivity"}, {"end": 17, "start": 14, "tag": "Cell"}, {"end": 117, "start": 114, "tag": "Cell"}, {"end": 28, "start": 18, "tag": "BiologicFunction"}, {"end": 128, "start": 118, "tag": "BiologicFunction"}, {"end": 187, "start": 174, "tag": "CellFunction"}, {"end": 196, "start": 193, "tag": "Cell"}, {"end": 170, "start": 165, "tag": "Cell"}, {"end": 10, "start": 0, "tag": "CellFunction"}, {"end": 99, "start": 90, "tag": "ResearchActivity"}, {"end": 99, "start": 90, "tag": "ManufacturedObject"}, {"end": 89, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 86, "tag": "BiologicallyActiveSubstance"}]}{"id": "1292_0", "text": "The pathology of fetal alcohol syndrome and the less severe fetal alcohol spectrum disorders includes brain dysmyelination.", "tags": [{"end": 39, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 108, "tag": "PathologicFunction"}, {"end": 59, "start": 53, "tag": "Finding"}, {"end": 107, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 4, "tag": "PathologicFunction"}, {"end": 13, "start": 4, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 92, "start": 60, "tag": "AnatomicalAbnormality"}]}{"id": "1292_1", "text": "Recent studies have shed light on the molecular mechanisms underlying these white matter abnormalities.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 58, "start": 38, "tag": "CellFunction"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 88, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 76, "tag": "PathologicFunction"}]}{"id": "1292_2", "text": "Rodent models of fetal alcohol syndrome and human studies have shown suppressed oligodendrocyte differentiation and apoptosis of oligodendrocyte precursor cells.", "tags": [{"end": 39, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 44, "tag": "ResearchActivity"}, {"end": 125, "start": 116, "tag": "CellFunction"}, {"end": 160, "start": 145, "tag": "Cell"}, {"end": 95, "start": 80, "tag": "Cell"}, {"end": 160, "start": 129, "tag": "Cell"}, {"end": 111, "start": 96, "tag": "CellFunction"}, {"end": 13, "start": 7, "tag": "ResearchActivity"}, {"end": 39, "start": 0, "tag": "ExperimentalModelOfDisease"}]}{"id": "1292_3", "text": "Ethanol exposure led to reduced expression of myelin basic protein and delayed myelin basic protein expression in rat and mouse models of fetal alcohol syndrome and in human histopathological specimens.", "tags": [{"end": 7, "start": 0, "tag": "Chemical"}, {"end": 7, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 160, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 174, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 201, "start": 192, "tag": "Substance"}, {"end": 201, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 92, "tag": "CellFunction"}, {"end": 117, "start": 114, "tag": "Eukaryote"}, {"end": 78, "start": 71, "tag": "TemporalConcept"}, {"end": 173, "start": 168, "tag": "Eukaryote"}, {"end": 127, "start": 122, "tag": "Eukaryote"}, {"end": 52, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 134, "start": 128, "tag": "ResearchActivity"}, {"end": 66, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 0, "tag": "InjuryOrPoisoning"}]}{"id": "1292_4", "text": "Several studies have reported increased expression of many chemokines in dysmyelinating disorders in central nervous system, including multiple sclerosis and fetal alcohol syndrome.", "tags": [{"end": 69, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 180, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 153, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 97, "start": 73, "tag": "DiseaseOrSyndrome"}]}{"id": "1292_5", "text": "Acute ethanol exposure reduced levels of the neuroprotective insulin-like growth factor-1 in fetal and maternal sheep and in human fetal brain tissues, while ethanol increased the expression of tumor necrosis factor alpha in mouse and human neurons.", "tags": [{"end": 5, "start": 0, "tag": "TemporalConcept"}, {"end": 5, "start": 0, "tag": "HealthCareActivity"}, {"end": 13, "start": 6, "tag": "Chemical"}, {"end": 13, "start": 6, "tag": "PharmacologicSubstance"}, {"end": 22, "start": 6, "tag": "InjuryOrPoisoning"}, {"end": 98, "start": 93, "tag": "EmbryonicStructure"}, {"end": 150, "start": 131, "tag": "EmbryonicStructure"}, {"end": 165, "start": 158, "tag": "Chemical"}, {"end": 165, "start": 158, "tag": "PharmacologicSubstance"}, {"end": 221, "start": 194, "tag": "AminoAcidPeptideOrProtein"}, {"end": 221, "start": 194, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 103, "tag": "PopulationGroup"}, {"end": 248, "start": 241, "tag": "Cell"}, {"end": 80, "start": 74, "tag": "BiologicFunction"}, {"end": 130, "start": 125, "tag": "Eukaryote"}, {"end": 240, "start": 235, "tag": "Eukaryote"}, {"end": 230, "start": 225, "tag": "Eukaryote"}, {"end": 60, "start": 45, "tag": "CellFunction"}, {"end": 89, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 112, "tag": "Eukaryote"}]}{"id": "1292_6", "text": "White matter lesions have been induced in the developing sheep brain by alcohol exposure in early gestation.", "tags": [{"end": 68, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 13, "tag": "InjuryOrPoisoning"}, {"end": 12, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 46, "tag": "EmbryonicStructure"}, {"end": 88, "start": 72, "tag": "InjuryOrPoisoning"}, {"end": 107, "start": 98, "tag": "BiologicFunction"}, {"end": 97, "start": 92, "tag": "TemporalConcept"}]}{"id": "1292_7", "text": "Rat fetal alcohol syndrome models have shown reduced axon diameters, with thinner myelin sheaths, as well as reduced numbers of oligodendrocytes, which were also morphologically aberrant oligodendrocytes.", "tags": [{"end": 26, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 128, "tag": "Cell"}, {"end": 203, "start": 187, "tag": "Cell"}, {"end": 96, "start": 82, "tag": "CellComponent"}, {"end": 3, "start": 0, "tag": "Eukaryote"}, {"end": 88, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 53, "tag": "CellComponent"}, {"end": 33, "start": 4, "tag": "ExperimentalModelOfDisease"}, {"end": 203, "start": 162, "tag": "CellOrMolecularDysfunction"}]}{"id": "1292_8", "text": "Expressions of markers for mature myelination, including myelin basic protein, also were reduced.", "tags": [{"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 77, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 34, "tag": "CellFunction"}, {"end": 33, "start": 27, "tag": "TemporalConcept"}, {"end": 63, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1292_9", "text": "The accumulating knowledge concerning the mechanisms of ethanol-induced dysmyelination could lead to the development of strategies to prevent dysmyelination in children exposed to ethanol during fetal development.", "tags": [{"end": 86, "start": 72, "tag": "PathologicFunction"}, {"end": 156, "start": 142, "tag": "PathologicFunction"}, {"end": 168, "start": 160, "tag": "PopulationGroup"}, {"end": 187, "start": 180, "tag": "Chemical"}, {"end": 187, "start": 180, "tag": "PharmacologicSubstance"}, {"end": 212, "start": 195, "tag": "BiologicFunction"}, {"end": 26, "start": 17, "tag": "Finding"}, {"end": 116, "start": 105, "tag": "BiologicFunction"}, {"end": 116, "start": 105, "tag": "CellFunction"}, {"end": 63, "start": 56, "tag": "Chemical"}, {"end": 63, "start": 56, "tag": "PharmacologicSubstance"}]}{"id": "1292_10", "text": "Future studies using fetal oligodendrocyte- and oligodendrocyte precursor cell-derived exosomes isolated from the mother's blood may identify biomarkers for fetal alcohol syndrome and even implicate epigenetic changes in early development that affect oligodendrocyte precursor cell and oligodendrocyte function in adulthood.", "tags": [{"end": 26, "start": 21, "tag": "EmbryonicStructure"}, {"end": 43, "start": 27, "tag": "Cell"}, {"end": 179, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 281, "start": 267, "tag": "Cell"}, {"end": 78, "start": 48, "tag": "Cell"}, {"end": 281, "start": 251, "tag": "Cell"}, {"end": 276, "start": 251, "tag": "Cell"}, {"end": 301, "start": 286, "tag": "Cell"}, {"end": 323, "start": 314, "tag": "TemporalConcept"}, {"end": 95, "start": 87, "tag": "CellComponent"}, {"end": 217, "start": 199, "tag": "CellFunction"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 152, "start": 142, "tag": "ClinicalAttribute"}, {"end": 128, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 238, "start": 227, "tag": "BiologicFunction"}, {"end": 238, "start": 227, "tag": "CellFunction"}]}{"id": "1292_11", "text": "By combining various imaging modalities with molecular studies, it may be possible to determine which fetuses are at risk and to intervene therapeutically early in the pregnancy.", "tags": [{"end": 109, "start": 102, "tag": "EmbryonicStructure"}, {"end": 177, "start": 168, "tag": "BiologicFunction"}, {"end": 62, "start": 45, "tag": "ResearchActivity"}, {"end": 28, "start": 21, "tag": "HealthCareActivity"}]}{"id": "1293_0", "text": "Development of pharmacotherapies that promote remyelination is a high priority for multiple sclerosis (MS), due to their potential for neuroprotection and restoration of function through repair of demyelinated lesions.", "tags": [{"end": 32, "start": 15, "tag": "HealthCareActivity"}, {"end": 78, "start": 70, "tag": "TemporalConcept"}, {"end": 11, "start": 0, "tag": "BiologicFunction"}, {"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 150, "start": 135, "tag": "CellFunction"}, {"end": 101, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 46, "tag": "CellFunction"}, {"end": 105, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 193, "start": 187, "tag": "BiologicFunction"}, {"end": 193, "start": 187, "tag": "HealthCareActivity"}, {"end": 217, "start": 197, "tag": "PathologicFunction"}]}{"id": "1293_1", "text": "A novel preparation of clean-surfaced, faceted gold nanocrystals demonstrated robust remyelinating activity in response to demyelinating agents in both chronic cuprizone and acute lysolecithin rodent animal models.", "tags": [{"end": 199, "start": 193, "tag": "Eukaryote"}, {"end": 136, "start": 123, "tag": "PathologicFunction"}, {"end": 159, "start": 152, "tag": "TemporalConcept"}, {"end": 192, "start": 180, "tag": "Chemical"}, {"end": 192, "start": 180, "tag": "PharmacologicSubstance"}, {"end": 107, "start": 85, "tag": "CellFunction"}, {"end": 169, "start": 160, "tag": "Chemical"}, {"end": 213, "start": 200, "tag": "ResearchActivity"}, {"end": 179, "start": 174, "tag": "TemporalConcept"}, {"end": 64, "start": 47, "tag": "ManufacturedObject"}, {"end": 143, "start": 137, "tag": "Chemical"}]}{"id": "1293_2", "text": "Furthermore, oral delivery of gold nanocrystals improved motor functions of cuprizone-treated mice in both open field and kinematic gait studies.", "tags": [{"end": 26, "start": 13, "tag": "HealthCareActivity"}, {"end": 72, "start": 57, "tag": "BiologicFunction"}, {"end": 117, "start": 107, "tag": "ManufacturedObject"}, {"end": 136, "start": 132, "tag": "OrganismAttribute"}, {"end": 98, "start": 94, "tag": "Eukaryote"}, {"end": 144, "start": 122, "tag": "ResearchActivity"}, {"end": 85, "start": 76, "tag": "Chemical"}, {"end": 117, "start": 107, "tag": "ResearchActivity"}, {"end": 47, "start": 30, "tag": "ManufacturedObject"}]}{"id": "1293_3", "text": "Gold nanocrystal treatment of oligodendrocyte precursor cells in culture resulted in oligodendrocyte maturation and expression of myelin differentiation markers.", "tags": [{"end": 61, "start": 30, "tag": "Cell"}, {"end": 136, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 137, "tag": "CellFunction"}, {"end": 72, "start": 65, "tag": "ResearchActivity"}, {"end": 26, "start": 17, "tag": "HealthCareActivity"}, {"end": 26, "start": 17, "tag": "ResearchActivity"}, {"end": 160, "start": 153, "tag": "ClinicalAttribute"}, {"end": 16, "start": 0, "tag": "ManufacturedObject"}, {"end": 126, "start": 116, "tag": "CellFunction"}, {"end": 111, "start": 85, "tag": "CellFunction"}]}{"id": "1293_4", "text": "Additional in vitro data demonstrated that these gold nanocrystals act via a novel energy metabolism pathway involving the enhancement of key indicators of aerobic glycolysis.", "tags": [{"end": 152, "start": 142, "tag": "Chemical"}, {"end": 100, "start": 83, "tag": "BiologicFunction"}, {"end": 174, "start": 156, "tag": "CellFunction"}, {"end": 108, "start": 101, "tag": "CellFunction"}, {"end": 24, "start": 20, "tag": "ResearchActivity"}, {"end": 134, "start": 123, "tag": "Finding"}, {"end": 19, "start": 11, "tag": "ResearchActivity"}, {"end": 66, "start": 49, "tag": "ManufacturedObject"}]}{"id": "1293_5", "text": "In response to gold nanocrystals, co-cultured central nervous system cells exhibited elevated levels of the redox coenzyme nicotine adenine dinucleotide (NAD+), elevated total intracellular ATP levels, and elevated extracellular lactate levels, along with upregulation of myelin-synthesis related genes, collectively resulting in functional myelin generation.", "tags": [{"end": 74, "start": 69, "tag": "Cell"}, {"end": 189, "start": 176, "tag": "CellComponent"}, {"end": 193, "start": 190, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 193, "start": 190, "tag": "PharmacologicSubstance"}, {"end": 193, "start": 190, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 108, "tag": "CellFunction"}, {"end": 45, "start": 34, "tag": "ResearchActivity"}, {"end": 358, "start": 341, "tag": "CellFunction"}, {"end": 157, "start": 154, "tag": "PharmacologicSubstance"}, {"end": 157, "start": 154, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 157, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 114, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 152, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 228, "start": 215, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 268, "start": 256, "tag": "CellFunction"}, {"end": 32, "start": 15, "tag": "ManufacturedObject"}, {"end": 152, "start": 114, "tag": "PharmacologicSubstance"}, {"end": 236, "start": 229, "tag": "Chemical"}, {"end": 236, "start": 229, "tag": "PharmacologicSubstance"}, {"end": 302, "start": 272, "tag": "GeneOrGenome"}]}{"id": "1293_6", "text": "Based on these preclinical studies, clean-surfaced, faceted gold nanocrystals represent a novel remyelinating therapeutic for multiple sclerosis.", "tags": [{"end": 34, "start": 15, "tag": "ResearchActivity"}, {"end": 144, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 96, "tag": "CellFunction"}, {"end": 77, "start": 60, "tag": "ManufacturedObject"}]}{"id": "1294_0", "text": "Cytokines, demyelination and neuroaxonal degeneration in the central nervous system are pivotal elements implicated in the pathogenesis of multiple sclerosis (MS) and its nonclinical model of experimental autoimmune encephalomyelitis (EAE).", "tags": [{"end": 9, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 233, "start": 192, "tag": "ExperimentalModelOfDisease"}, {"end": 238, "start": 235, "tag": "ExperimentalModelOfDisease"}, {"end": 157, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 41, "tag": "PathologicFunction"}, {"end": 83, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 188, "start": 171, "tag": "ResearchActivity"}, {"end": 135, "start": 123, "tag": "PathologicFunction"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 11, "tag": "PathologicFunction"}]}{"id": "1294_1", "text": "Phycocyanobilin (PCB), a chromophore of the biliprotein C-Phycocyanin (C-PC) from Spirulina platensis, has antioxidant, immunoregulatory and anti-inflammatory effects in this disease, and it could complement the effect of other Disease Modifying Treatments (DMT), such as Interferon-beta (IFN-beta).", "tags": [{"end": 15, "start": 0, "tag": "Chemical"}, {"end": 20, "start": 17, "tag": "Chemical"}, {"end": 36, "start": 25, "tag": "Chemical"}, {"end": 75, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 82, "tag": "Bacterium"}, {"end": 256, "start": 228, "tag": "HealthCareActivity"}, {"end": 287, "start": 272, "tag": "AminoAcidPeptideOrProtein"}, {"end": 287, "start": 272, "tag": "BiologicallyActiveSubstance"}, {"end": 297, "start": 289, "tag": "AminoAcidPeptideOrProtein"}, {"end": 297, "start": 289, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 146, "tag": "PathologicFunction"}, {"end": 218, "start": 212, "tag": "Finding"}, {"end": 118, "start": 107, "tag": "PharmacologicSubstance"}, {"end": 118, "start": 107, "tag": "CellFunction"}, {"end": 166, "start": 159, "tag": "Finding"}, {"end": 158, "start": 141, "tag": "BiologicFunction"}, {"end": 158, "start": 141, "tag": "PharmacologicSubstance"}, {"end": 69, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 120, "tag": "BiologicFunction"}]}{"id": "1294_2", "text": "Here, our main goal was to evaluate the potential PCB benefits and its mechanisms of action to counteract the chronic EAE in mice.", "tags": [{"end": 53, "start": 50, "tag": "Chemical"}, {"end": 121, "start": 118, "tag": "ExperimentalModelOfDisease"}, {"end": 129, "start": 125, "tag": "Eukaryote"}, {"end": 117, "start": 110, "tag": "TemporalConcept"}]}{"id": "1294_3", "text": "MOG(35-55)-induced EAE was implemented in C57BL/6 female mice.", "tags": [{"end": 22, "start": 19, "tag": "ExperimentalModelOfDisease"}, {"end": 61, "start": 57, "tag": "Eukaryote"}, {"end": 49, "start": 42, "tag": "Eukaryote"}, {"end": 56, "start": 50, "tag": "OrganismAttribute"}, {"end": 10, "start": 0, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1294_4", "text": "Clinical signs, pro-inflammatory cytokines levels by ELISA, qPCR in the brain and immunohistochemistry using precursor/mature oligodendrocytes cells antibodies in the spinal cord, were assessed.", "tags": [{"end": 14, "start": 0, "tag": "Finding"}, {"end": 159, "start": 149, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 9, "tag": "SignOrSymptom"}, {"end": 142, "start": 126, "tag": "Cell"}, {"end": 118, "start": 109, "tag": "Cell"}, {"end": 142, "start": 119, "tag": "Cell"}, {"end": 178, "start": 167, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 119, "tag": "TemporalConcept"}, {"end": 32, "start": 20, "tag": "PathologicFunction"}, {"end": 64, "start": 60, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 143, "tag": "Cell"}, {"end": 32, "start": 16, "tag": "PathologicFunction"}, {"end": 42, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 82, "tag": "ResearchActivity"}, {"end": 58, "start": 53, "tag": "ResearchActivity"}]}{"id": "1294_5", "text": "PCB enhanced the neurological condition, and waned the brain concentrations of IL-17A and IL-6, pro-inflammatory cytokines, in a dose-dependent manner.", "tags": [{"end": 3, "start": 0, "tag": "Chemical"}, {"end": 85, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 100, "tag": "PathologicFunction"}, {"end": 60, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 112, "start": 96, "tag": "PathologicFunction"}, {"end": 75, "start": 61, "tag": "BiologicFunction"}, {"end": 122, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 90, "tag": "GeneOrGenome"}, {"end": 39, "start": 17, "tag": "BiologicFunction"}, {"end": 85, "start": 79, "tag": "GeneOrGenome"}]}{"id": "1294_6", "text": "A down- or up-regulating activity of PCB at 1 mg/kg was identified in the brain on three (LINGO1, NOTCH1, and TNF-alpha), and five genes (MAL, CXCL12, MOG, OLIG1, and NKX2-2), respectively.", "tags": [{"end": 24, "start": 11, "tag": "CellFunction"}, {"end": 40, "start": 37, "tag": "Chemical"}, {"end": 96, "start": 90, "tag": "GeneOrGenome"}, {"end": 104, "start": 98, "tag": "GeneOrGenome"}, {"end": 104, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 138, "tag": "GeneOrGenome"}, {"end": 141, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 143, "tag": "GeneOrGenome"}, {"end": 149, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 151, "tag": "GeneOrGenome"}, {"end": 161, "start": 156, "tag": "GeneOrGenome"}, {"end": 173, "start": 167, "tag": "GeneOrGenome"}, {"end": 79, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 151, "tag": "BiologicallyActiveSubstance"}, {"end": 154, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 156, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 156, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 167, "tag": "BiologicallyActiveSubstance"}]}{"id": "1294_7", "text": "Interestingly, a reduction of demyelination, active microglia/macrophages density, and axonal damage was detected along with an increase in oligodendrocyte precursor cells and mature oligodendrocytes, when assessed the spinal cords of EAE mice that took up PCB.", "tags": [{"end": 260, "start": 257, "tag": "Chemical"}, {"end": 238, "start": 235, "tag": "ExperimentalModelOfDisease"}, {"end": 243, "start": 235, "tag": "ExperimentalModelOfDisease"}, {"end": 231, "start": 219, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 199, "start": 183, "tag": "Cell"}, {"end": 171, "start": 140, "tag": "Cell"}, {"end": 199, "start": 176, "tag": "Cell"}, {"end": 93, "start": 87, "tag": "CellComponent"}, {"end": 182, "start": 176, "tag": "TemporalConcept"}, {"end": 171, "start": 156, "tag": "Cell"}, {"end": 165, "start": 140, "tag": "Cell"}, {"end": 73, "start": 62, "tag": "Cell"}, {"end": 243, "start": 239, "tag": "Eukaryote"}, {"end": 61, "start": 52, "tag": "Cell"}, {"end": 26, "start": 17, "tag": "Finding"}, {"end": 26, "start": 17, "tag": "NaturalPhenomenonOrProcess"}, {"end": 43, "start": 30, "tag": "PathologicFunction"}, {"end": 100, "start": 94, "tag": "InjuryOrPoisoning"}]}{"id": "1294_8", "text": "The studies in vitro in rodent encephalitogenic T cells and in vivo in the EAE mouse model with the PCB/IFN-beta combination, showed an enhanced positive effect of this combined therapy.", "tags": [{"end": 185, "start": 169, "tag": "HealthCareActivity"}, {"end": 78, "start": 75, "tag": "ExperimentalModelOfDisease"}, {"end": 30, "start": 24, "tag": "Eukaryote"}, {"end": 160, "start": 154, "tag": "Finding"}, {"end": 11, "start": 4, "tag": "ResearchActivity"}, {"end": 20, "start": 12, "tag": "ResearchActivity"}, {"end": 185, "start": 178, "tag": "HealthCareActivity"}, {"end": 67, "start": 60, "tag": "ResearchActivity"}, {"end": 90, "start": 79, "tag": "ResearchActivity"}, {"end": 160, "start": 145, "tag": "Finding"}, {"end": 55, "start": 48, "tag": "Cell"}, {"end": 103, "start": 100, "tag": "Chemical"}, {"end": 112, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 104, "tag": "PharmacologicSubstance"}]}{"id": "1294_9", "text": "Overall, these results demonstrate the anti-inflammatory activity and the protective properties of PCB on the myelin and support its use with IFN-beta as an improved DMT combination for MS.", "tags": [{"end": 102, "start": 99, "tag": "Chemical"}, {"end": 150, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 142, "tag": "PharmacologicSubstance"}, {"end": 116, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 44, "tag": "CellFunction"}, {"end": 56, "start": 44, "tag": "PathologicFunction"}, {"end": 188, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 39, "tag": "BiologicFunction"}, {"end": 56, "start": 39, "tag": "PharmacologicSubstance"}, {"end": 150, "start": 142, "tag": "BiologicallyActiveSubstance"}]}{"id": "1295_0", "text": "The most challenging aspect of secondary progressive multiple sclerosis (SPMS) is the lack of efficient regenerative response for remyelination, which is carried out by the endogenous population of adult oligoprogenitor cells (OPCs) after proper activation.", "tags": [{"end": 77, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 227, "tag": "Cell"}, {"end": 71, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 225, "start": 204, "tag": "Cell"}, {"end": 194, "start": 184, "tag": "PopulationGroup"}, {"end": 143, "start": 130, "tag": "CellFunction"}, {"end": 203, "start": 198, "tag": "PopulationGroup"}]}{"id": "1295_1", "text": "OPCs must proliferate and migrate to the lesion and then differentiate into mature oligodendrocytes.", "tags": [{"end": 99, "start": 83, "tag": "Cell"}, {"end": 4, "start": 0, "tag": "Cell"}, {"end": 70, "start": 57, "tag": "CellFunction"}, {"end": 47, "start": 41, "tag": "InjuryOrPoisoning"}, {"end": 99, "start": 76, "tag": "Cell"}, {"end": 82, "start": 76, "tag": "TemporalConcept"}]}{"id": "1295_2", "text": "To investigate the OPC cellular component in SPMS, we developed induced pluripotent stem cells (iPSCs) from SPMS-affected donors and age-matched controls (CT).", "tags": [{"end": 49, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 19, "tag": "Cell"}, {"end": 153, "start": 145, "tag": "PopulationGroup"}, {"end": 136, "start": 133, "tag": "OrganismAttribute"}, {"end": 94, "start": 64, "tag": "Cell"}, {"end": 101, "start": 96, "tag": "Cell"}, {"end": 94, "start": 84, "tag": "Cell"}, {"end": 128, "start": 122, "tag": "PopulationGroup"}]}{"id": "1295_3", "text": "We confirmed their efficient and similar OPC differentiation capacity, although we reported SPMS-OPCs were transcriptionally distinguishable from their CT counterparts.", "tags": [{"end": 124, "start": 107, "tag": "CellFunction"}, {"end": 96, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 97, "tag": "Cell"}, {"end": 44, "start": 41, "tag": "Cell"}, {"end": 60, "start": 45, "tag": "CellFunction"}, {"end": 60, "start": 41, "tag": "CellFunction"}, {"end": 69, "start": 61, "tag": "Finding"}]}{"id": "1295_4", "text": "Analysis of OPC-generated conditioned media (CM) also evinced differences in protein secretion.", "tags": [{"end": 47, "start": 45, "tag": "Chemical"}, {"end": 94, "start": 77, "tag": "CellFunction"}, {"end": 15, "start": 12, "tag": "Cell"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 43, "start": 26, "tag": "Chemical"}, {"end": 73, "start": 62, "tag": "Finding"}]}{"id": "1295_5", "text": "We further confirmed SPMS-OPC CM presented a deficient capacity to stimulate OPC in vitro migration that can be compensated by exogenous addition of specific components.", "tags": [{"end": 32, "start": 30, "tag": "Chemical"}, {"end": 25, "start": 21, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 26, "tag": "Cell"}, {"end": 80, "start": 77, "tag": "Cell"}, {"end": 99, "start": 90, "tag": "CellFunction"}, {"end": 63, "start": 55, "tag": "Finding"}, {"end": 89, "start": 81, "tag": "ResearchActivity"}]}{"id": "1295_6", "text": "Our results provide an SPMS-OPC cellular model and encouraging venues to study potential cell communication deficiencies in the progressive form of multiple sclerosis (MS) for future treatment strategies.", "tags": [{"end": 120, "start": 89, "tag": "CellOrMolecularDysfunction"}, {"end": 27, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 28, "tag": "Cell"}, {"end": 166, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 73, "tag": "ResearchActivity"}, {"end": 46, "start": 23, "tag": "ExperimentalModelOfDisease"}, {"end": 139, "start": 128, "tag": "TemporalConcept"}, {"end": 40, "start": 32, "tag": "Cell"}, {"end": 182, "start": 176, "tag": "TemporalConcept"}, {"end": 170, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 89, "tag": "CellFunction"}, {"end": 203, "start": 183, "tag": "HealthCareActivity"}, {"end": 203, "start": 183, "tag": "ResearchActivity"}]}{"id": "1296_0", "text": "Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) leading to demyelination and neurodegeneration.", "tags": [{"end": 57, "start": 29, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 123, "tag": "CellOrMolecularDysfunction"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 105, "tag": "PathologicFunction"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 36, "start": 29, "tag": "TemporalConcept"}, {"end": 87, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1296_1", "text": "Life expectancy and age of onset in MS patients have been rising over the last decades, and previous studies have shown that age affects disease progression.", "tags": [{"end": 32, "start": 20, "tag": "TemporalConcept"}, {"end": 86, "start": 79, "tag": "TemporalConcept"}, {"end": 156, "start": 145, "tag": "PathologicFunction"}, {"end": 156, "start": 145, "tag": "TemporalConcept"}, {"end": 128, "start": 125, "tag": "OrganismAttribute"}, {"end": 108, "start": 101, "tag": "ResearchActivity"}, {"end": 47, "start": 39, "tag": "PatientOrDisabledGroup"}, {"end": 38, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 137, "tag": "PathologicFunction"}, {"end": 15, "start": 0, "tag": "TemporalConcept"}]}{"id": "1296_2", "text": "Therefore, age appears as one of the most important factors in accumulating disability in MS patients.", "tags": [{"end": 14, "start": 11, "tag": "OrganismAttribute"}, {"end": 101, "start": 93, "tag": "PatientOrDisabledGroup"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 76, "tag": "Finding"}]}{"id": "1296_3", "text": "Indeed, the degeneration of oligodendrocytes (OGDs) and OGD precursors (OPCs) increases with age, in association with increased inflammatory activity of astrocytes and microglia.", "tags": [{"end": 50, "start": 46, "tag": "Cell"}, {"end": 44, "start": 28, "tag": "Cell"}, {"end": 163, "start": 153, "tag": "Cell"}, {"end": 76, "start": 72, "tag": "Cell"}, {"end": 96, "start": 93, "tag": "OrganismAttribute"}, {"end": 24, "start": 12, "tag": "PathologicFunction"}, {"end": 177, "start": 168, "tag": "Cell"}, {"end": 70, "start": 56, "tag": "Cell"}, {"end": 149, "start": 128, "tag": "CellFunction"}]}{"id": "1296_4", "text": "Similarly, age-related neuronal changes such as mitochondrial alterations, an increase in oxidative stress, and disrupted paranodal junctions can impact myelin integrity.", "tags": [{"end": 141, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 169, "start": 160, "tag": "IndividualBehavior"}, {"end": 31, "start": 23, "tag": "Cell"}, {"end": 106, "start": 90, "tag": "CellOrMolecularDysfunction"}, {"end": 61, "start": 48, "tag": "CellComponent"}, {"end": 141, "start": 112, "tag": "PathologicFunction"}, {"end": 14, "start": 11, "tag": "OrganismAttribute"}, {"end": 159, "start": 153, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 48, "tag": "CellOrMolecularDysfunction"}, {"end": 169, "start": 153, "tag": "CellFunction"}]}{"id": "1296_5", "text": "Conversely, once myelination is complete, the long-term integrity of axons depends on OGD supply of energy.", "tags": [{"end": 65, "start": 56, "tag": "IndividualBehavior"}, {"end": 89, "start": 86, "tag": "Cell"}, {"end": 106, "start": 90, "tag": "BiologicFunction"}, {"end": 106, "start": 100, "tag": "NaturalPhenomenonOrProcess"}, {"end": 74, "start": 69, "tag": "CellComponent"}, {"end": 28, "start": 17, "tag": "CellFunction"}, {"end": 55, "start": 46, "tag": "TemporalConcept"}]}{"id": "1296_6", "text": "These alterations determine pathological myelin changes consisting of myelin outfolding, splitting, and accumulation of multilamellar fragments.", "tags": [{"end": 98, "start": 89, "tag": "SignOrSymptom"}, {"end": 143, "start": 104, "tag": "Finding"}, {"end": 47, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1296_7", "text": "Overall, these data demonstrate that old mature OGDs lose their ability to produce and maintain healthy myelin over time, to induce de novo myelination, and to remodel pre-existing myelinated axons that contribute to neural plasticity in the CNS.", "tags": [{"end": 52, "start": 48, "tag": "Cell"}, {"end": 167, "start": 160, "tag": "BiologicFunction"}, {"end": 234, "start": 217, "tag": "CellFunction"}, {"end": 245, "start": 242, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 140, "tag": "CellFunction"}, {"end": 197, "start": 181, "tag": "CellComponent"}, {"end": 47, "start": 41, "tag": "TemporalConcept"}, {"end": 103, "start": 96, "tag": "OrganismAttribute"}, {"end": 19, "start": 15, "tag": "ResearchActivity"}, {"end": 110, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 116, "tag": "TemporalConcept"}, {"end": 71, "start": 64, "tag": "OrganismAttribute"}]}{"id": "1296_8", "text": "Furthermore, as observed in other tissues, aging induces a general decline in regenerative processes and, not surprisingly, progressively hinders remyelination in MS.", "tags": [{"end": 159, "start": 146, "tag": "CellFunction"}, {"end": 48, "start": 43, "tag": "BiologicFunction"}, {"end": 48, "start": 43, "tag": "CellFunction"}, {"end": 165, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1296_9", "text": "In this context, this review will provide an overview of the current knowledge of age-related changes occurring in cells of the oligodendroglial lineage and how they impact myelin synthesis, axonal degeneration, and remyelination efficiency.", "tags": [{"end": 78, "start": 69, "tag": "Finding"}, {"end": 53, "start": 45, "tag": "ResearchActivity"}, {"end": 229, "start": 216, "tag": "CellFunction"}, {"end": 152, "start": 128, "tag": "Cell"}, {"end": 210, "start": 191, "tag": "CellOrMolecularDysfunction"}, {"end": 28, "start": 22, "tag": "ResearchActivity"}, {"end": 28, "start": 22, "tag": "HealthCareActivity"}, {"end": 85, "start": 82, "tag": "OrganismAttribute"}, {"end": 120, "start": 115, "tag": "Cell"}, {"end": 179, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 61, "tag": "TemporalConcept"}, {"end": 189, "start": 173, "tag": "CellFunction"}, {"end": 240, "start": 230, "tag": "Finding"}]}{"id": "1297_0", "text": "Promoting remyelination is considered as a potential neurorepair strategy to prevent/limit the development of permanent neurological disability in patients with multiple sclerosis (MS).", "tags": [{"end": 119, "start": 110, "tag": "TemporalConcept"}, {"end": 143, "start": 120, "tag": "SignOrSymptom"}, {"end": 179, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 147, "tag": "PatientOrDisabledGroup"}, {"end": 106, "start": 95, "tag": "BiologicFunction"}, {"end": 106, "start": 95, "tag": "CellFunction"}, {"end": 23, "start": 10, "tag": "CellFunction"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 133, "tag": "Finding"}, {"end": 73, "start": 53, "tag": "HealthCareActivity"}]}{"id": "1297_1", "text": "To this end, a number of clinical trials are investigating the potential of existing drugs to enhance oligodendrocyte progenitor cell (OPC) differentiation, a process that fails in chronic MS lesions.", "tags": [{"end": 133, "start": 102, "tag": "Cell"}, {"end": 138, "start": 135, "tag": "Cell"}, {"end": 199, "start": 192, "tag": "InjuryOrPoisoning"}, {"end": 155, "start": 140, "tag": "CellFunction"}, {"end": 133, "start": 118, "tag": "Cell"}, {"end": 133, "start": 129, "tag": "Cell"}, {"end": 90, "start": 85, "tag": "PharmacologicSubstance"}, {"end": 191, "start": 189, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 25, "tag": "ResearchActivity"}, {"end": 188, "start": 181, "tag": "TemporalConcept"}]}{"id": "1297_2", "text": "We previously reported that oligodendroglia express GABA(B) receptors (GABA(B)Rs) both in vitro and in vivo, and that GABA(B)R-mediated signaling enhances OPC differentiation and myelin protein expression in vitro.", "tags": [{"end": 193, "start": 179, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 44, "tag": "CellFunction"}, {"end": 80, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 155, "tag": "Cell"}, {"end": 145, "start": 136, "tag": "CellFunction"}, {"end": 174, "start": 159, "tag": "CellFunction"}, {"end": 174, "start": 155, "tag": "CellFunction"}, {"end": 43, "start": 28, "tag": "Cell"}, {"end": 204, "start": 194, "tag": "CellFunction"}, {"end": 95, "start": 87, "tag": "ResearchActivity"}, {"end": 213, "start": 205, "tag": "ResearchActivity"}, {"end": 126, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 100, "tag": "ResearchActivity"}, {"end": 69, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 52, "tag": "BiologicallyActiveSubstance"}]}{"id": "1297_3", "text": "Our goal here was to evaluate the pro-remyelinating potential of GABA(B)R agonist baclofen (Bac), a clinically approved drug to treat spasticity in patients with MS.", "tags": [{"end": 95, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 134, "tag": "SignOrSymptom"}, {"end": 81, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 38, "tag": "CellFunction"}, {"end": 156, "start": 148, "tag": "PatientOrDisabledGroup"}, {"end": 73, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 120, "tag": "PharmacologicSubstance"}, {"end": 90, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 90, "start": 82, "tag": "PharmacologicSubstance"}, {"end": 95, "start": 92, "tag": "PharmacologicSubstance"}]}{"id": "1297_4", "text": "We first demonstrated that Bac increases myelin protein production in lysolecithin (LPC)-treated cerebellar slices.", "tags": [{"end": 30, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 70, "tag": "Chemical"}, {"end": 82, "start": 70, "tag": "PharmacologicSubstance"}, {"end": 114, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 3, "tag": "TemporalConcept"}, {"end": 55, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 27, "tag": "PharmacologicSubstance"}, {"end": 87, "start": 84, "tag": "Chemical"}, {"end": 87, "start": 84, "tag": "PharmacologicSubstance"}]}{"id": "1297_5", "text": "Importantly, Bac administration to adult mice following induction of demyelination by LPC injection in the spinal cord resulted in enhanced OPC differentiation and remyelination.", "tags": [{"end": 16, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 86, "tag": "Chemical"}, {"end": 143, "start": 140, "tag": "Cell"}, {"end": 118, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 144, "tag": "CellFunction"}, {"end": 159, "start": 140, "tag": "CellFunction"}, {"end": 45, "start": 41, "tag": "Eukaryote"}, {"end": 177, "start": 164, "tag": "CellFunction"}, {"end": 82, "start": 69, "tag": "PathologicFunction"}, {"end": 40, "start": 35, "tag": "PopulationGroup"}, {"end": 99, "start": 90, "tag": "HealthCareActivity"}, {"end": 16, "start": 13, "tag": "PharmacologicSubstance"}, {"end": 31, "start": 17, "tag": "HealthCareActivity"}, {"end": 89, "start": 86, "tag": "PharmacologicSubstance"}]}{"id": "1297_6", "text": "Thus, our results suggest that Bac repurposing should be considered as a potential therapeutic strategy to stimulate remyelination in patients with MS.", "tags": [{"end": 34, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 134, "tag": "PatientOrDisabledGroup"}, {"end": 130, "start": 117, "tag": "CellFunction"}, {"end": 150, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 83, "tag": "HealthCareActivity"}, {"end": 34, "start": 31, "tag": "PharmacologicSubstance"}, {"end": 46, "start": 31, "tag": "HealthCareActivity"}]}{"id": "1298_0", "text": "Multiple sclerosis (MS) is an autoimmune disorder characterised by demyelination of central nervous system neurons with subsequent damage, cell death and disability.", "tags": [{"end": 106, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 144, "tag": "BiologicFunction"}, {"end": 149, "start": 144, "tag": "PathologicFunction"}, {"end": 149, "start": 144, "tag": "CellFunction"}, {"end": 114, "start": 107, "tag": "Cell"}, {"end": 49, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 139, "tag": "CellFunction"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 67, "tag": "PathologicFunction"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 154, "tag": "Finding"}, {"end": 137, "start": 131, "tag": "InjuryOrPoisoning"}]}{"id": "1298_1", "text": "While mechanisms exist in the CNS to repair this damage, they are disrupted in MS and currently there are no treatments to address this deficit.", "tags": [{"end": 143, "start": 136, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 66, "tag": "PathologicFunction"}, {"end": 33, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 86, "tag": "TemporalConcept"}, {"end": 119, "start": 109, "tag": "HealthCareActivity"}, {"end": 119, "start": 109, "tag": "ResearchActivity"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 37, "tag": "BiologicFunction"}, {"end": 43, "start": 37, "tag": "HealthCareActivity"}, {"end": 55, "start": 49, "tag": "InjuryOrPoisoning"}]}{"id": "1298_2", "text": "In recent years, increasing attention has been paid to the influence of the small, non-coding RNA molecules, microRNAs (miRNAs), in autoimmune disorders, including MS.", "tags": [{"end": 97, "start": 76, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 152, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 28, "tag": "BiologicFunction"}, {"end": 126, "start": 120, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 126, "start": 120, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 10, "tag": "TemporalConcept"}, {"end": 15, "start": 3, "tag": "TemporalConcept"}, {"end": 107, "start": 98, "tag": "Substance"}, {"end": 166, "start": 164, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 17, "tag": "Finding"}, {"end": 97, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 109, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 118, "start": 109, "tag": "BiologicallyActiveSubstance"}]}{"id": "1298_3", "text": "In this review, we examine the role of miRNAs in remyelination in the different cell types that contribute to MS.", "tags": [{"end": 45, "start": 39, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 45, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 62, "start": 49, "tag": "CellFunction"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 80, "tag": "Cell"}]}{"id": "1298_4", "text": "We focus on key miRNAs that have a central role in mediating the repair process, along with several more that play either secondary or inhibitory roles in one or more aspects.", "tags": [{"end": 145, "start": 135, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 16, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 22, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 65, "tag": "BiologicFunction"}, {"end": 71, "start": 65, "tag": "HealthCareActivity"}]}{"id": "1298_5", "text": "Finally, we consider the current state of miRNAs as therapeutic targets in MS, acknowledging current challenges and potential strategies to overcome them in developing effective novel therapeutics to enhance repair mechanisms in MS.", "tags": [{"end": 48, "start": 42, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 48, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 101, "tag": "HealthCareActivity"}, {"end": 196, "start": 184, "tag": "HealthCareActivity"}, {"end": 71, "start": 52, "tag": "ResearchActivity"}, {"end": 38, "start": 33, "tag": "PopulationGroup"}, {"end": 32, "start": 25, "tag": "TemporalConcept"}, {"end": 100, "start": 93, "tag": "TemporalConcept"}, {"end": 136, "start": 126, "tag": "ResearchActivity"}, {"end": 136, "start": 126, "tag": "BiologicFunction"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 229, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 208, "tag": "BiologicFunction"}, {"end": 214, "start": 208, "tag": "HealthCareActivity"}]}{"id": "1299_0", "text": "Multiple sclerosis (MS) is the most demyelinating disease of the central nervous system (CNS) characterized by neuroinflammation.", "tags": [{"end": 49, "start": 36, "tag": "PathologicFunction"}, {"end": 57, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 111, "tag": "PathologicFunction"}]}{"id": "1299_1", "text": "Oligodendrocyte progenitor cells (OPCs) are cycling cells in the developing and adult CNS that, under demyelinating conditions, migrate to the site of lesions and differentiate into mature oligodendrocytes to remyelinate damaged axons.", "tags": [{"end": 32, "start": 0, "tag": "Cell"}, {"end": 234, "start": 229, "tag": "CellComponent"}, {"end": 205, "start": 189, "tag": "Cell"}, {"end": 38, "start": 34, "tag": "Cell"}, {"end": 176, "start": 163, "tag": "CellFunction"}, {"end": 115, "start": 102, "tag": "PathologicFunction"}, {"end": 220, "start": 209, "tag": "CellFunction"}, {"end": 158, "start": 151, "tag": "InjuryOrPoisoning"}, {"end": 205, "start": 182, "tag": "Cell"}, {"end": 32, "start": 16, "tag": "Cell"}, {"end": 188, "start": 182, "tag": "TemporalConcept"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 89, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 52, "tag": "Cell"}, {"end": 85, "start": 80, "tag": "PopulationGroup"}]}{"id": "1299_2", "text": "However, this process fails during disease chronicization due to impaired OPC differentiation.", "tags": [{"end": 77, "start": 74, "tag": "Cell"}, {"end": 93, "start": 78, "tag": "CellFunction"}, {"end": 93, "start": 74, "tag": "CellFunction"}, {"end": 57, "start": 35, "tag": "Finding"}]}{"id": "1299_3", "text": "Moreover, OPCs are crucial players in neuro-glial communication as they receive synaptic inputs from neurons and express ion channels and neurotransmitter/neuromodulator receptors that control their maturation.", "tags": [{"end": 133, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 113, "tag": "CellFunction"}, {"end": 124, "start": 121, "tag": "Chemical"}, {"end": 154, "start": 138, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 10, "tag": "Cell"}, {"end": 209, "start": 199, "tag": "BiologicFunction"}, {"end": 108, "start": 101, "tag": "Cell"}, {"end": 63, "start": 38, "tag": "CellFunction"}, {"end": 179, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 179, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 80, "tag": "CellFunction"}]}{"id": "1299_4", "text": "Ion channels are recognized as attractive therapeutic targets, and indeed ligand-gated and voltage-gated channels can both be found among the top five pharmaceutical target groups of FDA-approved agents.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 42, "tag": "ResearchActivity"}, {"end": 186, "start": 183, "tag": "HealthCareRelatedOrganization"}, {"end": 202, "start": 183, "tag": "PharmacologicSubstance"}, {"end": 113, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 74, "tag": "BiologicallyActiveSubstance"}]}{"id": "1299_5", "text": "Their modulation ameliorates some of the symptoms of MS and improves the outcome of related animal models.", "tags": [{"end": 80, "start": 73, "tag": "PathologicFunction"}, {"end": 49, "start": 41, "tag": "SignOrSymptom"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 92, "tag": "ResearchActivity"}]}{"id": "1299_6", "text": "However, the exact mechanism of action of ion-channel targeting compounds is often still unclear due to the wide expression of these channels on neurons, glia, and infiltrating immune cells.", "tags": [{"end": 141, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 42, "tag": "Chemical"}, {"end": 189, "start": 164, "tag": "Cell"}, {"end": 73, "start": 64, "tag": "Chemical"}, {"end": 73, "start": 64, "tag": "PharmacologicSubstance"}, {"end": 123, "start": 113, "tag": "CellFunction"}, {"end": 158, "start": 154, "tag": "Cell"}, {"end": 152, "start": 145, "tag": "Cell"}, {"end": 53, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 42, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1299_7", "text": "The present review summarizes recent findings in the field to get further insights into physio-pathophysiological processes and possible therapeutic mechanisms of drug actions.", "tags": [{"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 36, "start": 30, "tag": "TemporalConcept"}, {"end": 167, "start": 163, "tag": "PharmacologicSubstance"}, {"end": 123, "start": 95, "tag": "PathologicFunction"}, {"end": 113, "start": 95, "tag": "PathologicFunction"}]}{"id": "1300_0", "text": "Oligodendrocyte precursor cells (OPCs) undergo an extensive and coordinated migration in the developing CNS, using the pre-formed scaffold of developed blood vessels as their physical substrate for migration.", "tags": [{"end": 165, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 184, "tag": "Chemical"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 85, "start": 76, "tag": "CellFunction"}, {"end": 207, "start": 198, "tag": "CellFunction"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 107, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1300_1", "text": "While OPC association with vasculature is critical for dispersal, equally important for permitting differentia-tion and proper myelination of target axons is their appropriate and timely detachment, but regulation of this process remains unclear.", "tags": [{"end": 38, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 197, "start": 187, "tag": "BiologicFunction"}, {"end": 197, "start": 187, "tag": "PathologicFunction"}, {"end": 197, "start": 187, "tag": "Finding"}, {"end": 154, "start": 149, "tag": "CellComponent"}, {"end": 9, "start": 6, "tag": "Cell"}, {"end": 138, "start": 127, "tag": "CellFunction"}]}{"id": "1300_2", "text": "Here we demonstrate a correlation between the developmental formation of astro-cytic endfeet on vessels and the termination of OPC perivascular migration.", "tags": [{"end": 103, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 131, "tag": "Cell"}, {"end": 130, "start": 127, "tag": "Cell"}, {"end": 59, "start": 46, "tag": "BiologicFunction"}, {"end": 59, "start": 46, "tag": "TemporalConcept"}, {"end": 153, "start": 144, "tag": "CellFunction"}]}{"id": "1300_3", "text": "Ex vivo and in vivo live imaging shows that astrocyte endfeet physically displace OPCs from vasculature, and genetic abrogation of endfoot formation hinders both OPC detachment from vessels and subsequent differentiation.", "tags": [{"end": 103, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 166, "tag": "BiologicFunction"}, {"end": 176, "start": 166, "tag": "PathologicFunction"}, {"end": 176, "start": 166, "tag": "Finding"}, {"end": 189, "start": 182, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 82, "tag": "Cell"}, {"end": 165, "start": 162, "tag": "Cell"}, {"end": 220, "start": 205, "tag": "CellFunction"}, {"end": 32, "start": 20, "tag": "HealthCareActivity"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 53, "start": 44, "tag": "Cell"}, {"end": 19, "start": 12, "tag": "ResearchActivity"}]}{"id": "1300_4", "text": "Astrocyte-derived semaphorins 3a and 6a act to repel OPCs from blood vessels at the cessation of their perivascular migration and, in so doing, permit subsequent OPC differentiation by insulating them from a maturation inhibitory endo-thelial niche.", "tags": [{"end": 76, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 103, "tag": "Cell"}, {"end": 9, "start": 0, "tag": "Cell"}, {"end": 57, "start": 53, "tag": "Cell"}, {"end": 165, "start": 162, "tag": "Cell"}, {"end": 218, "start": 208, "tag": "BiologicFunction"}, {"end": 181, "start": 166, "tag": "CellFunction"}, {"end": 229, "start": 219, "tag": "BiologicallyActiveSubstance"}, {"end": 181, "start": 162, "tag": "CellFunction"}, {"end": 125, "start": 116, "tag": "CellFunction"}, {"end": 32, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 248, "start": 230, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1301_0", "text": "Oligodendrocyte progenitor cells (OPCs) are responsible for generating oligodendrocytes, the myelinating cells of the CNS.", "tags": [{"end": 32, "start": 0, "tag": "Cell"}, {"end": 87, "start": 71, "tag": "Cell"}, {"end": 38, "start": 34, "tag": "Cell"}, {"end": 32, "start": 16, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 121, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 105, "tag": "Cell"}, {"end": 104, "start": 93, "tag": "CellFunction"}]}{"id": "1301_1", "text": "Life-long myelination is promoted by neuronal activity and is essential for neural network plasticity and learning.", "tags": [{"end": 114, "start": 106, "tag": "BiologicFunction"}, {"end": 54, "start": 37, "tag": "CellFunction"}, {"end": 45, "start": 37, "tag": "Cell"}, {"end": 21, "start": 10, "tag": "CellFunction"}, {"end": 90, "start": 83, "tag": "PopulationGroup"}, {"end": 90, "start": 83, "tag": "CellFunction"}, {"end": 4, "start": 0, "tag": "TemporalConcept"}, {"end": 101, "start": 76, "tag": "BiologicFunction"}]}{"id": "1301_2", "text": "OPCs are known to contact synapses and it is proposed that neuronal synaptic activity in turn regulates their behavior.", "tags": [{"end": 118, "start": 110, "tag": "BiologicFunction"}, {"end": 118, "start": 110, "tag": "IndividualBehavior"}, {"end": 118, "start": 110, "tag": "ResearchActivity"}, {"end": 4, "start": 0, "tag": "Cell"}, {"end": 67, "start": 59, "tag": "Cell"}, {"end": 34, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 68, "tag": "CellFunction"}]}{"id": "1301_3", "text": "To examine this in the adult, we performed unilateral injection of the synaptic blocker botulinum neurotoxin A (BoNT/A) into the hippocampus of adult mice.", "tags": [{"end": 118, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 150, "tag": "Eukaryote"}, {"end": 140, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 23, "tag": "PopulationGroup"}, {"end": 149, "start": 144, "tag": "PopulationGroup"}, {"end": 63, "start": 54, "tag": "HealthCareActivity"}, {"end": 110, "start": 88, "tag": "InjuryOrPoisoning"}, {"end": 110, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 88, "tag": "PharmacologicSubstance"}, {"end": 87, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 118, "start": 112, "tag": "PharmacologicSubstance"}, {"end": 118, "start": 112, "tag": "InjuryOrPoisoning"}]}{"id": "1301_4", "text": "We confirm BoNT/A cleaves SNAP-25 in the CA1 are of the hippocampus, which has been proven to block neurotransmission.", "tags": [{"end": 17, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 26, "tag": "GeneOrGenome"}, {"end": 33, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 100, "tag": "CellFunction"}, {"end": 67, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 11, "tag": "InjuryOrPoisoning"}, {"end": 17, "start": 11, "tag": "PharmacologicSubstance"}]}{"id": "1301_5", "text": "Notably, BoNT/A significantly decreased OPC density and caused their shrinkage, as determined by immunolabeling for the OPC marker NG2.", "tags": [{"end": 15, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 131, "tag": "GeneOrGenome"}, {"end": 78, "start": 69, "tag": "Finding"}, {"end": 43, "start": 40, "tag": "Cell"}, {"end": 123, "start": 120, "tag": "Cell"}, {"end": 130, "start": 124, "tag": "ClinicalAttribute"}, {"end": 15, "start": 9, "tag": "PharmacologicSubstance"}, {"end": 15, "start": 9, "tag": "InjuryOrPoisoning"}]}{"id": "1301_6", "text": "Furthermore, BoNT/A resulted in an overall decrease in the number of OPC processes, as well as a decrease in their lengths and branching frequency.", "tags": [{"end": 19, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 137, "tag": "TemporalConcept"}, {"end": 51, "start": 43, "tag": "Finding"}, {"end": 105, "start": 97, "tag": "Finding"}, {"end": 72, "start": 69, "tag": "Cell"}, {"end": 19, "start": 13, "tag": "InjuryOrPoisoning"}, {"end": 19, "start": 13, "tag": "PharmacologicSubstance"}, {"end": 82, "start": 69, "tag": "CellComponent"}]}{"id": "1301_7", "text": "These data indicate that synaptic activity is important for maintaining adult OPC numbers and cellular integrity, which is relevant to pathophysiological scenarios characterized by dysregulation of synaptic activity, such as age-related cognitive decline, Multiple Sclerosis and Alzheimer's disease.", "tags": [{"end": 81, "start": 78, "tag": "Cell"}, {"end": 274, "start": 256, "tag": "DiseaseOrSyndrome"}, {"end": 298, "start": 279, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 225, "tag": "OrganismAttribute"}, {"end": 254, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 72, "tag": "PopulationGroup"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 153, "start": 135, "tag": "PathologicFunction"}, {"end": 42, "start": 25, "tag": "CellFunction"}, {"end": 112, "start": 94, "tag": "CellFunction"}, {"end": 194, "start": 181, "tag": "Finding"}, {"end": 215, "start": 198, "tag": "CellFunction"}]}{"id": "1302_0", "text": "Multiple sclerosis (MS) is a complex inflammatory, degenerative, and demyelinating disease of the central nervous system.", "tags": [{"end": 63, "start": 51, "tag": "PathologicFunction"}, {"end": 120, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 37, "tag": "PathologicFunction"}]}{"id": "1302_1", "text": "Although treatments exist, MS cannot be cured by available drugs, which primarily target neuroinflammation.", "tags": [{"end": 64, "start": 59, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 89, "tag": "PathologicFunction"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 9, "tag": "HealthCareActivity"}, {"end": 19, "start": 9, "tag": "ResearchActivity"}]}{"id": "1302_2", "text": "Thus, it is feasible that a well concerted polypharmacological approach able to act at multiple points within the intricate network of inflammation, neurodegeneration, and demyelination/remyelination pathways would succeed where other drugs have failed.", "tags": [{"end": 240, "start": 235, "tag": "PharmacologicSubstance"}, {"end": 199, "start": 186, "tag": "CellFunction"}, {"end": 166, "start": 149, "tag": "CellOrMolecularDysfunction"}, {"end": 185, "start": 172, "tag": "PathologicFunction"}, {"end": 147, "start": 135, "tag": "PathologicFunction"}, {"end": 208, "start": 200, "tag": "CellFunction"}, {"end": 71, "start": 43, "tag": "HealthCareActivity"}]}{"id": "1302_3", "text": "Starting from reported beneficial effects of a-linolenic acid (ALA) and valproic acid (VPA) in MS, and by applying a rational strategy, we developed a small set of codrugs obtained by conjugating VPA and ALA through proper linkers.", "tags": [{"end": 85, "start": 72, "tag": "Chemical"}, {"end": 90, "start": 87, "tag": "Chemical"}, {"end": 199, "start": 196, "tag": "Chemical"}, {"end": 41, "start": 23, "tag": "Finding"}, {"end": 97, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 45, "tag": "Chemical"}, {"end": 61, "start": 45, "tag": "PharmacologicSubstance"}, {"end": 61, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 63, "tag": "Chemical"}, {"end": 66, "start": 63, "tag": "PharmacologicSubstance"}, {"end": 85, "start": 72, "tag": "PharmacologicSubstance"}, {"end": 90, "start": 87, "tag": "PharmacologicSubstance"}, {"end": 207, "start": 204, "tag": "PharmacologicSubstance"}, {"end": 207, "start": 204, "tag": "Chemical"}, {"end": 207, "start": 204, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 164, "tag": "PharmacologicSubstance"}]}{"id": "1302_4", "text": "A cellular profiling identified 1 as a polypharmacological tool able not only to modulate microglia polarization, but also to counteract neurodegeneration and demyelination and induce oligodendrocyte precursor cell differentiation, by acting on multiple biochemical and epigenetic pathways.", "tags": [{"end": 154, "start": 137, "tag": "CellOrMolecularDysfunction"}, {"end": 172, "start": 159, "tag": "PathologicFunction"}, {"end": 99, "start": 90, "tag": "Cell"}, {"end": 230, "start": 215, "tag": "CellFunction"}, {"end": 214, "start": 184, "tag": "Cell"}, {"end": 289, "start": 270, "tag": "CellFunction"}, {"end": 230, "start": 184, "tag": "CellFunction"}, {"end": 112, "start": 90, "tag": "CellFunction"}, {"end": 63, "start": 39, "tag": "HealthCareActivity"}, {"end": 20, "start": 2, "tag": "ResearchActivity"}]}{"id": "1303_0", "text": "Oligodendrocytes, myelin-forming cells in the brain, are vulnerable to oxidative stress.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 24, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 33, "tag": "Cell"}, {"end": 87, "start": 71, "tag": "CellOrMolecularDysfunction"}]}{"id": "1303_1", "text": "Recent work indicates that air pollution causes demyelinating diseases such as multiple sclerosis.", "tags": [{"end": 40, "start": 27, "tag": "EnvironmentalEffectOfHumans"}, {"end": 70, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 48, "tag": "PathologicFunction"}, {"end": 97, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}]}{"id": "1303_2", "text": "However, little is known about the mechanism of toxicity of ultrafine particulate matters (PMs) to oligodendrocytes.", "tags": [{"end": 94, "start": 91, "tag": "Substance"}, {"end": 115, "start": 99, "tag": "Cell"}, {"end": 56, "start": 48, "tag": "InjuryOrPoisoning"}, {"end": 89, "start": 60, "tag": "Substance"}]}{"id": "1303_3", "text": "Here, we aimed to determine whether oligodendrocyte precursor cells (OPCs) and mature oligodendrocytes (mOLs) are more vulnerable to ultrafine urban PMs (uf-UPs) than other types of brain cells and damage to adult OPCs and mOLs in the mouse brain exposed to uf-UPs.", "tags": [{"end": 108, "start": 104, "tag": "Cell"}, {"end": 152, "start": 133, "tag": "Substance"}, {"end": 227, "start": 223, "tag": "Cell"}, {"end": 193, "start": 182, "tag": "Cell"}, {"end": 102, "start": 86, "tag": "Cell"}, {"end": 73, "start": 69, "tag": "Cell"}, {"end": 218, "start": 214, "tag": "Cell"}, {"end": 67, "start": 36, "tag": "Cell"}, {"end": 102, "start": 79, "tag": "Cell"}, {"end": 85, "start": 79, "tag": "TemporalConcept"}, {"end": 67, "start": 52, "tag": "Cell"}, {"end": 61, "start": 36, "tag": "Cell"}, {"end": 246, "start": 241, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 240, "start": 235, "tag": "Eukaryote"}, {"end": 213, "start": 208, "tag": "PopulationGroup"}, {"end": 160, "start": 154, "tag": "Substance"}, {"end": 204, "start": 198, "tag": "InjuryOrPoisoning"}, {"end": 264, "start": 258, "tag": "Substance"}]}{"id": "1303_4", "text": "For in vitro experiments, following exposure to various concentrations (2, 20, and 200 mu g/mL) of uf-UPs, we measured survival rates, the amount of reactive oxygen species (ROS), and the total antioxidant capacities (TACs) of brain cells isolated from neonatal Sprague-Dawley rats.", "tags": [{"end": 238, "start": 227, "tag": "Cell"}, {"end": 24, "start": 13, "tag": "ResearchActivity"}, {"end": 281, "start": 262, "tag": "Eukaryote"}, {"end": 172, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 149, "tag": "Chemical"}, {"end": 177, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 177, "start": 174, "tag": "Chemical"}, {"end": 261, "start": 253, "tag": "PopulationGroup"}, {"end": 261, "start": 253, "tag": "TemporalConcept"}, {"end": 205, "start": 194, "tag": "PharmacologicSubstance"}, {"end": 205, "start": 194, "tag": "CellFunction"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 127, "start": 119, "tag": "CellFunction"}, {"end": 70, "start": 56, "tag": "BiologicFunction"}, {"end": 105, "start": 99, "tag": "Substance"}, {"end": 133, "start": 128, "tag": "TemporalConcept"}, {"end": 216, "start": 188, "tag": "CellFunction"}]}{"id": "1303_5", "text": "For animal experiments, after a four-week exposure to a uf-UP suspension (20 mu L, 0.4 mg/mL), we enumerated the number of damaged cells and typed damaged cells in the white matter of the cerebellum of uf-UP-exposed mice.", "tags": [{"end": 22, "start": 4, "tag": "ResearchActivity"}, {"end": 72, "start": 62, "tag": "Substance"}, {"end": 22, "start": 11, "tag": "ResearchActivity"}, {"end": 180, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 198, "start": 188, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 37, "tag": "TemporalConcept"}, {"end": 136, "start": 131, "tag": "Cell"}, {"end": 160, "start": 155, "tag": "Cell"}, {"end": 220, "start": 216, "tag": "Eukaryote"}, {"end": 61, "start": 56, "tag": "Substance"}, {"end": 130, "start": 123, "tag": "InjuryOrPoisoning"}, {"end": 154, "start": 147, "tag": "InjuryOrPoisoning"}, {"end": 207, "start": 202, "tag": "Substance"}]}{"id": "1303_6", "text": "MTT assays and Hoechst staining demonstrated that OPCs and mOLs were more vulnerable to uf-UP-induced damage than astrocytes and cortical neurons at 2, 20, and 200 mu g/mL of uf-UPs examined in this study (p < 0.05).", "tags": [{"end": 10, "start": 0, "tag": "ResearchActivity"}, {"end": 63, "start": 59, "tag": "Cell"}, {"end": 145, "start": 129, "tag": "Cell"}, {"end": 54, "start": 50, "tag": "Cell"}, {"end": 204, "start": 199, "tag": "ResearchActivity"}, {"end": 10, "start": 4, "tag": "ResearchActivity"}, {"end": 145, "start": 138, "tag": "Cell"}, {"end": 137, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 114, "tag": "Cell"}, {"end": 31, "start": 15, "tag": "ResearchActivity"}, {"end": 93, "start": 88, "tag": "Substance"}, {"end": 108, "start": 102, "tag": "InjuryOrPoisoning"}, {"end": 181, "start": 175, "tag": "Substance"}]}{"id": "1303_7", "text": "Damage to OPCs and mOLs depended on uf-UP concentration.", "tags": [{"end": 23, "start": 19, "tag": "Cell"}, {"end": 14, "start": 10, "tag": "Cell"}, {"end": 55, "start": 42, "tag": "BiologicFunction"}, {"end": 41, "start": 36, "tag": "Substance"}, {"end": 6, "start": 0, "tag": "InjuryOrPoisoning"}]}{"id": "1303_8", "text": "DCF assays and DHE staining indicated that the amount of ROS generated in OPCs and mOLs was significantly higher than in other brain cell types (p < 0.05).", "tags": [{"end": 18, "start": 15, "tag": "Chemical"}, {"end": 27, "start": 15, "tag": "ResearchActivity"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 137, "start": 127, "tag": "Cell"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 57, "tag": "Chemical"}, {"end": 78, "start": 74, "tag": "Cell"}, {"end": 10, "start": 0, "tag": "ResearchActivity"}, {"end": 143, "start": 133, "tag": "Cell"}]}{"id": "1303_9", "text": "In contrast, TAC values in OPCs and mOLs were significantly lower than those of other brain cell types (p < 0.05).", "tags": [{"end": 40, "start": 36, "tag": "Cell"}, {"end": 96, "start": 86, "tag": "Cell"}, {"end": 31, "start": 27, "tag": "Cell"}, {"end": 102, "start": 92, "tag": "Cell"}]}{"id": "1303_10", "text": "Fluoro-Jade B (FJB)-positive cells in the cerebellar white matter of the uf-UP-exposed group were significantly greater in number relative to the control group.", "tags": [{"end": 65, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 146, "tag": "PopulationGroup"}, {"end": 65, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 87, "tag": "PopulationGroup"}, {"end": 159, "start": 154, "tag": "PopulationGroup"}, {"end": 34, "start": 29, "tag": "Cell"}, {"end": 13, "start": 0, "tag": "Chemical"}, {"end": 18, "start": 15, "tag": "Chemical"}, {"end": 78, "start": 73, "tag": "Substance"}]}{"id": "1303_11", "text": "Double immunofluorescence indicated that FJB-positive cells are NG2-positive adult OPCs and carbon anhydrase II-positive mOLs.", "tags": [{"end": 67, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 64, "tag": "GeneOrGenome"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 59, "start": 54, "tag": "Cell"}, {"end": 82, "start": 77, "tag": "PopulationGroup"}, {"end": 25, "start": 7, "tag": "ResearchActivity"}, {"end": 44, "start": 41, "tag": "Chemical"}, {"end": 125, "start": 121, "tag": "Cell"}, {"end": 111, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 92, "tag": "BiologicallyActiveSubstance"}]}{"id": "1303_12", "text": "Taken together, our findings suggest that oxidative stress induced by uf-UPs in the brain impairs adult OPCs and mOLs, causing demyelination and reducing the capacity for remyelination.", "tags": [{"end": 117, "start": 113, "tag": "Cell"}, {"end": 108, "start": 104, "tag": "Cell"}, {"end": 89, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 42, "tag": "CellOrMolecularDysfunction"}, {"end": 166, "start": 158, "tag": "Finding"}, {"end": 184, "start": 171, "tag": "CellFunction"}, {"end": 140, "start": 127, "tag": "PathologicFunction"}, {"end": 103, "start": 98, "tag": "PopulationGroup"}, {"end": 76, "start": 70, "tag": "Substance"}]}{"id": "1304_0", "text": "Oligodendrocytes are a type of glial cells that produce a lipid-rich membrane called myelin.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 91, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 31, "tag": "Cell"}, {"end": 77, "start": 69, "tag": "CellComponent"}, {"end": 42, "start": 31, "tag": "Cell"}, {"end": 63, "start": 58, "tag": "Chemical"}]}{"id": "1304_1", "text": "Myelin assembles into a sheath and lines neuronal axons in the brain and spinal cord to insulate them.", "tags": [{"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 35, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 55, "start": 50, "tag": "CellComponent"}, {"end": 84, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 41, "tag": "Cell"}]}{"id": "1304_2", "text": "This not only increases the speed and efficiency of nerve signal transduction but also protects the axons from damage and degradation, which could trigger neuronal cell death.", "tags": [{"end": 77, "start": 52, "tag": "CellFunction"}, {"end": 105, "start": 100, "tag": "CellComponent"}, {"end": 48, "start": 38, "tag": "Finding"}, {"end": 133, "start": 122, "tag": "NaturalPhenomenonOrProcess"}, {"end": 163, "start": 155, "tag": "Cell"}, {"end": 174, "start": 169, "tag": "BiologicFunction"}, {"end": 174, "start": 169, "tag": "PathologicFunction"}, {"end": 174, "start": 169, "tag": "CellFunction"}, {"end": 174, "start": 164, "tag": "CellFunction"}, {"end": 174, "start": 155, "tag": "CellFunction"}]}{"id": "1304_3", "text": "Demyelination, which is caused by a loss of myelin and oligodendrocytes, is a prominent feature of many neurological conditions, including Multiple sclerosis (MS), spinal cord injuries (SCI), and leukodystrophies.", "tags": [{"end": 184, "start": 164, "tag": "InjuryOrPoisoning"}, {"end": 189, "start": 186, "tag": "InjuryOrPoisoning"}, {"end": 13, "start": 0, "tag": "PathologicFunction"}, {"end": 71, "start": 55, "tag": "Cell"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 175, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 139, "tag": "DiseaseOrSyndrome"}]}{"id": "1304_4", "text": "Demyelination is followed by a time of remyelination mediated by the recruitment of endogenous oligodendrocyte precursor cells, their migration to the injury site, and differentiation into myelin-producing oligodendrocytes.", "tags": [{"end": 13, "start": 0, "tag": "PathologicFunction"}, {"end": 222, "start": 189, "tag": "Cell"}, {"end": 222, "start": 206, "tag": "Cell"}, {"end": 126, "start": 95, "tag": "Cell"}, {"end": 195, "start": 189, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 183, "start": 168, "tag": "CellFunction"}, {"end": 143, "start": 134, "tag": "CellFunction"}, {"end": 126, "start": 111, "tag": "Cell"}, {"end": 120, "start": 95, "tag": "Cell"}, {"end": 35, "start": 31, "tag": "TemporalConcept"}, {"end": 157, "start": 151, "tag": "InjuryOrPoisoning"}, {"end": 52, "start": 39, "tag": "CellFunction"}]}{"id": "1304_5", "text": "Unfortunately, endogenous remyelination is not sufficient to overcome demyelination, which explains why there are to date no regenerative-based treatments for MS, SCI, or leukodystrophies.", "tags": [{"end": 166, "start": 163, "tag": "InjuryOrPoisoning"}, {"end": 121, "start": 114, "tag": "TemporalConcept"}, {"end": 121, "start": 117, "tag": "TemporalConcept"}, {"end": 187, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 144, "tag": "HealthCareActivity"}, {"end": 154, "start": 144, "tag": "ResearchActivity"}, {"end": 39, "start": 26, "tag": "CellFunction"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 70, "tag": "PathologicFunction"}]}{"id": "1304_6", "text": "To better understand the role of oligodendrocytes and develop cell-based remyelination therapies, human oligodendrocytes have been derived from somatic cells using cell reprogramming.", "tags": [{"end": 157, "start": 144, "tag": "Cell"}, {"end": 182, "start": 169, "tag": "CellFunction"}, {"end": 182, "start": 164, "tag": "CellFunction"}, {"end": 49, "start": 33, "tag": "Cell"}, {"end": 120, "start": 104, "tag": "Cell"}, {"end": 103, "start": 98, "tag": "Eukaryote"}, {"end": 66, "start": 62, "tag": "Cell"}, {"end": 86, "start": 73, "tag": "CellFunction"}, {"end": 96, "start": 87, "tag": "HealthCareActivity"}]}{"id": "1304_7", "text": "This review will detail the different cell reprogramming methods that have been developed to generate human oligodendrocytes and their applications to disease modeling and cell-based remyelination therapies.", "tags": [{"end": 56, "start": 43, "tag": "CellFunction"}, {"end": 56, "start": 38, "tag": "CellFunction"}, {"end": 167, "start": 151, "tag": "ResearchActivity"}, {"end": 124, "start": 108, "tag": "Cell"}, {"end": 107, "start": 102, "tag": "Eukaryote"}, {"end": 176, "start": 172, "tag": "Cell"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 196, "start": 183, "tag": "CellFunction"}, {"end": 206, "start": 197, "tag": "HealthCareActivity"}]}{"id": "1304_8", "text": "Recent developments in the field have seen the derivation of brain organoids from pluripotent stem cells, and protocols have been devised to incorporate oligodendrocytes within the organoids, which will also be reviewed.", "tags": [{"end": 57, "start": 47, "tag": "HealthCareActivity"}, {"end": 76, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 82, "tag": "Cell"}, {"end": 119, "start": 110, "tag": "HealthCareActivity"}, {"end": 219, "start": 211, "tag": "HealthCareActivity"}, {"end": 219, "start": 211, "tag": "ResearchActivity"}, {"end": 76, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 7, "tag": "BiologicFunction"}, {"end": 19, "start": 7, "tag": "CellFunction"}, {"end": 169, "start": 153, "tag": "Cell"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 104, "start": 94, "tag": "Cell"}]}{"id": "1305_0", "text": "The molecular mechanisms that govern the maturation of oligodendrocyte lineage cells remain unclear.", "tags": [{"end": 24, "start": 4, "tag": "CellFunction"}, {"end": 51, "start": 41, "tag": "BiologicFunction"}, {"end": 78, "start": 55, "tag": "Cell"}, {"end": 84, "start": 79, "tag": "Cell"}]}{"id": "1305_1", "text": "Emerging studies have shown that N-6-methyladenosine (m(6)A), the most common internal RNA modification of mammalian mRNA, plays a critical role in various developmental processes.", "tags": [{"end": 179, "start": 156, "tag": "BiologicFunction"}, {"end": 116, "start": 107, "tag": "Eukaryote"}, {"end": 121, "start": 117, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 16, "start": 9, "tag": "ResearchActivity"}, {"end": 90, "start": 87, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 52, "start": 33, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 59, "start": 54, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 52, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 87, "tag": "CellFunction"}]}{"id": "1305_2", "text": "Here, we demonstrate that oligodendrocyte lineage progression is accompanied by dynamic changes in m(6)A modification on numerous transcripts.", "tags": [{"end": 49, "start": 26, "tag": "Cell"}, {"end": 141, "start": 130, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 61, "start": 50, "tag": "PathologicFunction"}, {"end": 61, "start": 50, "tag": "TemporalConcept"}, {"end": 104, "start": 99, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 104, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 99, "tag": "CellFunction"}]}{"id": "1305_3", "text": "In vivo conditional inactivation of an essential m(6)A writer component, METTl14, results in decreased oligodendrocyte numbers and CNS hypomyelination, although oligodendrocyte precursor cell (OPC) numbers are normal.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 19, "start": 8, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 20, "tag": "CellFunction"}, {"end": 80, "start": 73, "tag": "GeneOrGenome"}, {"end": 150, "start": 135, "tag": "Finding"}, {"end": 134, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 93, "tag": "Finding"}, {"end": 191, "start": 161, "tag": "Cell"}, {"end": 196, "start": 193, "tag": "Cell"}, {"end": 186, "start": 161, "tag": "Cell"}, {"end": 118, "start": 103, "tag": "Cell"}, {"end": 216, "start": 210, "tag": "Finding"}, {"end": 54, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 49, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 80, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 73, "tag": "BiologicallyActiveSubstance"}]}{"id": "1305_4", "text": "n vitro Mettl14 ablation disrupts postmitotic oligodendrocyte maturation and has distinct effects on OPC and oligodendrocyte transcriptomes.", "tags": [{"end": 15, "start": 8, "tag": "GeneOrGenome"}, {"end": 104, "start": 101, "tag": "Cell"}, {"end": 61, "start": 46, "tag": "Cell"}, {"end": 124, "start": 109, "tag": "Cell"}, {"end": 72, "start": 62, "tag": "BiologicFunction"}, {"end": 139, "start": 125, "tag": "MolecularSequence"}, {"end": 15, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 8, "tag": "CellOrMolecularDysfunction"}]}{"id": "1305_5", "text": "Moreover, the loss of Mettl14 in oligodendrocyte lineage cells causes aberrant splicing of myriad RNA transcripts, including those that encode the essential paranodal component neurofascin 155 (NF155).", "tags": [{"end": 29, "start": 22, "tag": "GeneOrGenome"}, {"end": 56, "start": 33, "tag": "Cell"}, {"end": 113, "start": 102, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 101, "start": 98, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 62, "start": 57, "tag": "Cell"}, {"end": 87, "start": 70, "tag": "CellOrMolecularDysfunction"}, {"end": 192, "start": 177, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 199, "start": 194, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 194, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 14, "tag": "CellOrMolecularDysfunction"}, {"end": 29, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 22, "tag": "BiologicallyActiveSubstance"}]}{"id": "1305_6", "text": "Together, our findings indicate that dynamic RNA methylation plays an important regulatory role in oligodendrocyte development and CNS myelination.", "tags": [{"end": 90, "start": 80, "tag": "GeneOrGenome"}, {"end": 60, "start": 49, "tag": "CellFunction"}, {"end": 134, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 135, "tag": "CellFunction"}, {"end": 114, "start": 99, "tag": "Cell"}, {"end": 48, "start": 45, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 126, "start": 115, "tag": "BiologicFunction"}, {"end": 126, "start": 115, "tag": "CellFunction"}]}{"id": "1306_0", "text": "BackgroundPeptidylarginine deiminase 2 (PAD2) mediates the post-translational conversion of arginine residues in proteins to citrullines and is highly expressed in the central nervous system (CNS).", "tags": [{"end": 44, "start": 40, "tag": "GeneOrGenome"}, {"end": 88, "start": 59, "tag": "CellFunction"}, {"end": 109, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 195, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 151, "tag": "CellFunction"}, {"end": 136, "start": 125, "tag": "PharmacologicSubstance"}, {"end": 38, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 10, "tag": "BiologicallyActiveSubstance"}]}{"id": "1306_1", "text": "Dysregulated PAD2 activity has been implicated in the pathogenesis of several neurologic diseases, including multiple sclerosis (MS).", "tags": [{"end": 26, "start": 13, "tag": "CellFunction"}, {"end": 97, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 54, "tag": "PathologicFunction"}, {"end": 131, "start": 129, "tag": "DiseaseOrSyndrome"}, {"end": 17, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 13, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1306_2", "text": "In this study, we sought to define the cellular and regional expression of the gene encoding for PAD2 (i.e.", "tags": [{"end": 101, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 84, "tag": "BiologicFunction"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 71, "start": 61, "tag": "CellFunction"}, {"end": 47, "start": 39, "tag": "Cell"}, {"end": 83, "start": 79, "tag": "GeneOrGenome"}, {"end": 101, "start": 97, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1306_3", "text": "PADI2) in the human CNS using publicly available datasets and evaluate whether anti-PAD2 antibodies were present in patients with various neurologic diseases.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 116, "tag": "PatientOrDisabledGroup"}, {"end": 23, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 14, "tag": "Eukaryote"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 30, "tag": "ResearchActivity"}, {"end": 99, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 79, "tag": "BiologicallyActiveSubstance"}]}{"id": "1306_4", "text": "MethodsA total of 491 study participants were included in this study: 91 people with MS, 32 people with neuromyelitis optica (NMO), 281 people with post-treatment Lyme disease (PTLD), and 87 healthy controls.", "tags": [{"end": 129, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 207, "start": 199, "tag": "PopulationGroup"}, {"end": 40, "start": 28, "tag": "PopulationGroup"}, {"end": 198, "start": 191, "tag": "OrganismAttribute"}, {"end": 27, "start": 22, "tag": "ResearchActivity"}, {"end": 68, "start": 63, "tag": "ResearchActivity"}, {"end": 79, "start": 73, "tag": "PopulationGroup"}, {"end": 98, "start": 92, "tag": "PopulationGroup"}, {"end": 142, "start": 136, "tag": "PopulationGroup"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 175, "start": 148, "tag": "DiseaseOrSyndrome"}]}{"id": "1306_5", "text": "To measure PADI2 expression in the CNS from healthy individuals, publicly available tissue and single cell RNA sequencing data was analyzed.", "tags": [{"end": 16, "start": 11, "tag": "GeneOrGenome"}, {"end": 16, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 95, "tag": "ResearchActivity"}, {"end": 63, "start": 52, "tag": "PopulationGroup"}, {"end": 51, "start": 44, "tag": "OrganismAttribute"}, {"end": 38, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 17, "tag": "CellFunction"}, {"end": 139, "start": 131, "tag": "ResearchActivity"}, {"end": 90, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 122, "tag": "ResearchActivity"}, {"end": 83, "start": 65, "tag": "ResearchActivity"}, {"end": 16, "start": 11, "tag": "BiologicallyActiveSubstance"}]}{"id": "1306_6", "text": "Anti-PAD2 antibodies were measured in the serum of study participants using anti-PAD2 ELISA.", "tags": [{"end": 69, "start": 57, "tag": "PopulationGroup"}, {"end": 56, "start": 51, "tag": "ResearchActivity"}, {"end": 47, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 86, "tag": "ResearchActivity"}, {"end": 20, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 76, "tag": "BiologicallyActiveSubstance"}]}{"id": "1306_7", "text": "Clinical and demographic variables were compared according to anti-PAD2 antibody positivity for the MS and PTLD groups and correlations between anti-PAD2 levels and disease severity were examined.", "tags": [{"end": 34, "start": 0, "tag": "ResearchActivity"}, {"end": 91, "start": 81, "tag": "ResearchActivity"}, {"end": 111, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 181, "start": 165, "tag": "ClinicalAttribute"}, {"end": 135, "start": 123, "tag": "ResearchActivity"}, {"end": 181, "start": 173, "tag": "ClinicalAttribute"}, {"end": 181, "start": 173, "tag": "Finding"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 160, "start": 144, "tag": "ClinicalAttribute"}]}{"id": "1306_8", "text": "ResultsPADI2 expression was highest in oligodendrocytes (mean +/- SD; 6.4 +/- 2.2), followed closely by astrocytes (5.5 +/- 2.6), microglia/macrophages (4.5 +/- 3.5), and oligodendrocyte precursor cells (3.2 +/- 3.3).", "tags": [{"end": 55, "start": 39, "tag": "Cell"}, {"end": 202, "start": 171, "tag": "Cell"}, {"end": 151, "start": 140, "tag": "Cell"}, {"end": 23, "start": 13, "tag": "CellFunction"}, {"end": 139, "start": 130, "tag": "Cell"}, {"end": 114, "start": 104, "tag": "Cell"}, {"end": 12, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 7, "tag": "GeneOrGenome"}]}{"id": "1306_9", "text": "There was an increased proportion of anti-PAD2 positivity in the MS (19.8%; p = 0.007) and PTLD groups (13.9%; p = 0.057) relative to the healthy controls (5.7%), and these antibodies were not detected in NMO patients.", "tags": [{"end": 57, "start": 47, "tag": "ResearchActivity"}, {"end": 95, "start": 91, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 208, "start": 205, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 146, "tag": "PopulationGroup"}, {"end": 145, "start": 138, "tag": "OrganismAttribute"}, {"end": 217, "start": 209, "tag": "PatientOrDisabledGroup"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 37, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1306_10", "text": "There was a modest inverse correlation between anti-PAD2 levels and disease severity in people with MS (tau = -0.145, p = 0.02), with levels being the highest in those with relapsing-remitting disease.", "tags": [{"end": 182, "start": 173, "tag": "TemporalConcept"}, {"end": 84, "start": 68, "tag": "ClinicalAttribute"}, {"end": 107, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 104, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 88, "tag": "PopulationGroup"}, {"end": 84, "start": 76, "tag": "ClinicalAttribute"}, {"end": 84, "start": 76, "tag": "Finding"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 12, "tag": "ResearchActivity"}, {"end": 63, "start": 47, "tag": "ClinicalAttribute"}, {"end": 200, "start": 173, "tag": "DiseaseOrSyndrome"}]}{"id": "1306_11", "text": "Similarly, there was a modest inverse correlation between anti-PAD2 levels and neurocognitive score (tau = -0.10, p = 0.027) in people with PTLD, with difficulty focusing, memory changes, fatigue, and difficulty finding words contributing most strongly to the effect.", "tags": [{"end": 144, "start": 140, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 151, "tag": "Finding"}, {"end": 219, "start": 212, "tag": "Finding"}, {"end": 195, "start": 188, "tag": "SignOrSymptom"}, {"end": 104, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 266, "start": 260, "tag": "Finding"}, {"end": 134, "start": 128, "tag": "PopulationGroup"}, {"end": 178, "start": 172, "tag": "BiologicFunction"}, {"end": 178, "start": 172, "tag": "Finding"}, {"end": 99, "start": 79, "tag": "ResearchActivity"}, {"end": 186, "start": 179, "tag": "Finding"}, {"end": 74, "start": 58, "tag": "ClinicalAttribute"}]}{"id": "1306_12", "text": "ConclusionPADI2 expression was observed in diverse regions and cells of the CNS, and anti-PAD2 autoantibodies were associated with less severe symptoms in subsets of patients with MS and PTLD.", "tags": [{"end": 191, "start": 187, "tag": "DiseaseOrSyndrome"}, {"end": 174, "start": 166, "tag": "PatientOrDisabledGroup"}, {"end": 79, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 63, "tag": "Cell"}, {"end": 26, "start": 16, "tag": "CellFunction"}, {"end": 151, "start": 143, "tag": "SignOrSymptom"}, {"end": 182, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 136, "tag": "Finding"}, {"end": 15, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 10, "tag": "GeneOrGenome"}, {"end": 15, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 85, "tag": "BiologicallyActiveSubstance"}]}{"id": "1306_13", "text": "These data suggest that anti-PAD2 antibodies may attenuate inflammation in diseases of different etiologies, which are united by high PADI2 expression in the target tissue.", "tags": [{"end": 139, "start": 134, "tag": "GeneOrGenome"}, {"end": 139, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 59, "tag": "PathologicFunction"}, {"end": 150, "start": 140, "tag": "CellFunction"}, {"end": 171, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 129, "tag": "Finding"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 44, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 97, "tag": "Finding"}, {"end": 139, "start": 134, "tag": "BiologicallyActiveSubstance"}]}{"id": "1307_0", "text": "Remyelination is a refractory feature of demyelinating diseases such as multiple sclerosis (MS).", "tags": [{"end": 63, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 90, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 29, "start": 19, "tag": "SignOrSymptom"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}]}{"id": "1307_1", "text": "Studies have shown that promoting oligodendrocyte precursor cell (OPC) differentiation, which cannot be achieved by currently available therapeutic agents, is the key to enhancing remyelination.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 154, "start": 136, "tag": "HealthCareActivity"}, {"end": 69, "start": 66, "tag": "Cell"}, {"end": 86, "start": 71, "tag": "CellFunction"}, {"end": 64, "start": 34, "tag": "Cell"}, {"end": 125, "start": 116, "tag": "TemporalConcept"}, {"end": 193, "start": 180, "tag": "CellFunction"}]}{"id": "1307_2", "text": "Bu Shen Yi Sui capsule (BSYSC) is a traditional Chinese herbal medicine over many years of clinical practice.", "tags": [{"end": 71, "start": 48, "tag": "HealthCareActivity"}, {"end": 87, "start": 82, "tag": "TemporalConcept"}, {"end": 108, "start": 91, "tag": "HealthCareActivity"}, {"end": 14, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 22, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 29, "start": 24, "tag": "PharmacologicSubstance"}, {"end": 71, "start": 48, "tag": "PharmacologicSubstance"}]}{"id": "1307_3", "text": "We have found that BSYSC can effectively treat MS.", "tags": [{"end": 49, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 19, "tag": "PharmacologicSubstance"}]}{"id": "1307_4", "text": "In this study, the effects of BSYSC in promoting OPCs differentiation and remyelination were assessed using an experimental autoimmune encephalomyelitis (EAE) model in vivo and cultured OPCs in vitro.", "tags": [{"end": 152, "start": 111, "tag": "ExperimentalModelOfDisease"}, {"end": 157, "start": 154, "tag": "ExperimentalModelOfDisease"}, {"end": 53, "start": 49, "tag": "Cell"}, {"end": 190, "start": 186, "tag": "Cell"}, {"end": 69, "start": 54, "tag": "CellFunction"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 164, "start": 159, "tag": "ResearchActivity"}, {"end": 199, "start": 191, "tag": "ResearchActivity"}, {"end": 29, "start": 19, "tag": "PathologicFunction"}, {"end": 172, "start": 165, "tag": "ResearchActivity"}, {"end": 87, "start": 74, "tag": "CellFunction"}, {"end": 185, "start": 177, "tag": "ResearchActivity"}, {"end": 26, "start": 19, "tag": "Finding"}, {"end": 35, "start": 30, "tag": "PharmacologicSubstance"}]}{"id": "1307_5", "text": "The results showed that BSYSC reduced clinical function scores and increased neuroprotection.", "tags": [{"end": 92, "start": 77, "tag": "CellFunction"}, {"end": 29, "start": 24, "tag": "PharmacologicSubstance"}]}{"id": "1307_6", "text": "The expression of platelet-derived growth factor receptor alpha (PDGFR-alpha) was decreased and the level of 2 ',3 '-cyclic nucleotide 3 '-phosphodiesterase (CNPase) was increased in the brains and spinal cords of mice as well as in OPCs after treatment with BSYSC.", "tags": [{"end": 63, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 210, "start": 198, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 237, "start": 233, "tag": "Cell"}, {"end": 218, "start": 214, "tag": "Eukaryote"}, {"end": 253, "start": 244, "tag": "HealthCareActivity"}, {"end": 253, "start": 244, "tag": "ResearchActivity"}, {"end": 14, "start": 4, "tag": "CellFunction"}, {"end": 193, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 264, "start": 259, "tag": "PharmacologicSubstance"}, {"end": 76, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 109, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 158, "tag": "BiologicallyActiveSubstance"}]}{"id": "1307_7", "text": "We further found that BSYSC elevated the expression of miR-219 or miR-338 in the serum exosomes of mice with EAE, thereby suppressing the expression of Sox6, Lingo1, and Hes5, which negatively regulate OPCs differentiation.", "tags": [{"end": 156, "start": 152, "tag": "GeneOrGenome"}, {"end": 164, "start": 158, "tag": "GeneOrGenome"}, {"end": 174, "start": 170, "tag": "GeneOrGenome"}, {"end": 112, "start": 109, "tag": "ExperimentalModelOfDisease"}, {"end": 206, "start": 202, "tag": "Cell"}, {"end": 222, "start": 207, "tag": "CellFunction"}, {"end": 103, "start": 99, "tag": "Eukaryote"}, {"end": 86, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 41, "tag": "CellFunction"}, {"end": 148, "start": 138, "tag": "CellFunction"}, {"end": 95, "start": 87, "tag": "CellComponent"}, {"end": 27, "start": 22, "tag": "PharmacologicSubstance"}, {"end": 62, "start": 55, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 62, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 66, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 156, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 152, "tag": "BiologicallyActiveSubstance"}, {"end": 164, "start": 158, "tag": "AminoAcidPeptideOrProtein"}, {"end": 164, "start": 158, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 170, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1307_8", "text": "Therefore, serum exosomes of BSYSC-treated mice (exos-BSYSC) were extracted and administered to OPCs in which miR-219 or miR-338 expression was knocked down by adenovirus, and the results showed that Sox6, Lingo1, and Hes5 expression was downregulated, MBP expression was upregulated, OPCs differentiation was increased, and the ability of OPCs to wrap around neuronal axons was improved.", "tags": [{"end": 75, "start": 66, "tag": "HealthCareActivity"}, {"end": 75, "start": 66, "tag": "Finding"}, {"end": 170, "start": 160, "tag": "Virus"}, {"end": 204, "start": 200, "tag": "GeneOrGenome"}, {"end": 212, "start": 206, "tag": "GeneOrGenome"}, {"end": 222, "start": 218, "tag": "GeneOrGenome"}, {"end": 256, "start": 253, "tag": "AminoAcidPeptideOrProtein"}, {"end": 256, "start": 253, "tag": "BiologicallyActiveSubstance"}, {"end": 256, "start": 253, "tag": "GeneOrGenome"}, {"end": 374, "start": 369, "tag": "CellComponent"}, {"end": 100, "start": 96, "tag": "Cell"}, {"end": 289, "start": 285, "tag": "Cell"}, {"end": 344, "start": 340, "tag": "Cell"}, {"end": 305, "start": 290, "tag": "CellFunction"}, {"end": 47, "start": 43, "tag": "Eukaryote"}, {"end": 368, "start": 360, "tag": "Cell"}, {"end": 16, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 129, "tag": "CellFunction"}, {"end": 233, "start": 223, "tag": "CellFunction"}, {"end": 267, "start": 257, "tag": "CellFunction"}, {"end": 251, "start": 238, "tag": "CellFunction"}, {"end": 336, "start": 329, "tag": "OrganismAttribute"}, {"end": 25, "start": 17, "tag": "CellComponent"}, {"end": 34, "start": 29, "tag": "PharmacologicSubstance"}, {"end": 59, "start": 54, "tag": "PharmacologicSubstance"}, {"end": 117, "start": 110, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 117, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 128, "start": 121, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 204, "start": 200, "tag": "AminoAcidPeptideOrProtein"}, {"end": 212, "start": 206, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 218, "tag": "AminoAcidPeptideOrProtein"}, {"end": 204, "start": 200, "tag": "BiologicallyActiveSubstance"}, {"end": 212, "start": 206, "tag": "BiologicallyActiveSubstance"}, {"end": 222, "start": 218, "tag": "BiologicallyActiveSubstance"}, {"end": 283, "start": 272, "tag": "CellFunction"}, {"end": 156, "start": 144, "tag": "ResearchActivity"}]}{"id": "1307_9", "text": "In conclusion, BSYSC may exert clinically relevant effects by regulating microRNA (miR) levels in exosomes and thus promoting the differentiation and maturation of OPCs.", "tags": [{"end": 86, "start": 83, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 86, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 73, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 81, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 164, "tag": "Cell"}, {"end": 160, "start": 150, "tag": "BiologicFunction"}, {"end": 145, "start": 130, "tag": "CellFunction"}, {"end": 58, "start": 51, "tag": "Finding"}, {"end": 106, "start": 98, "tag": "CellComponent"}, {"end": 20, "start": 15, "tag": "PharmacologicSubstance"}]}{"id": "1308_0", "text": "The brain's endogenous capacity to restore damaged myelin deteriorates during the course of demyelinating disorders.", "tags": [{"end": 70, "start": 58, "tag": "Finding"}, {"end": 57, "start": 43, "tag": "CellOrMolecularDysfunction"}, {"end": 88, "start": 82, "tag": "TemporalConcept"}, {"end": 105, "start": 92, "tag": "PathologicFunction"}, {"end": 57, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 9, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 23, "tag": "Finding"}]}{"id": "1308_1", "text": "Currently, no treatment options are available to establish remyelination.", "tags": [{"end": 9, "start": 0, "tag": "TemporalConcept"}, {"end": 23, "start": 14, "tag": "HealthCareActivity"}, {"end": 23, "start": 14, "tag": "ResearchActivity"}, {"end": 72, "start": 59, "tag": "CellFunction"}]}{"id": "1308_2", "text": "Chronic demyelination leads to damaged axons and irreversible destruction of the central nervous system (CNS).", "tags": [{"end": 73, "start": 62, "tag": "HealthCareActivity"}, {"end": 44, "start": 39, "tag": "CellComponent"}, {"end": 103, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 8, "tag": "PathologicFunction"}]}{"id": "1308_3", "text": "We identified two promising therapeutic candidates which enhance remyelination: oncostatin M (OSM), a member of the interleukin-6 family, and downstream mediator tissue inhibitor of metalloproteinases-1 (TIMP-1).", "tags": [{"end": 92, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 80, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 94, "tag": "PharmacologicSubstance"}, {"end": 136, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 162, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 65, "tag": "CellFunction"}, {"end": 210, "start": 204, "tag": "AminoAcidPeptideOrProtein"}, {"end": 210, "start": 204, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 18, "tag": "Finding"}, {"end": 136, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 202, "start": 162, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 142, "tag": "BiologicallyActiveSubstance"}]}{"id": "1308_4", "text": "While remyelination was completely abrogated in OSMR beta knockout (KO) mice, OSM overexpression in the chronically demyelinated CNS established remyelination.", "tags": [{"end": 57, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "PharmacologicSubstance"}, {"end": 96, "start": 82, "tag": "CellFunction"}, {"end": 128, "start": 116, "tag": "PathologicFunction"}, {"end": 132, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 48, "tag": "ExperimentalModelOfDisease"}, {"end": 19, "start": 6, "tag": "CellFunction"}, {"end": 158, "start": 145, "tag": "CellFunction"}, {"end": 57, "start": 48, "tag": "BiologicallyActiveSubstance"}]}{"id": "1308_5", "text": "Astrocytic TIMP-1 was demonstrated to play a pivotal role in OSM-mediated remyelination.", "tags": [{"end": 10, "start": 0, "tag": "Cell"}, {"end": 87, "start": 74, "tag": "CellFunction"}, {"end": 17, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 61, "tag": "PharmacologicSubstance"}]}{"id": "1308_6", "text": "Astrocyte-derived TIMP-1 drove differentiation of oligodendrocyte precursor cells into mature oligodendrocytes in vitro.", "tags": [{"end": 9, "start": 0, "tag": "Cell"}, {"end": 81, "start": 50, "tag": "Cell"}, {"end": 110, "start": 87, "tag": "Cell"}, {"end": 46, "start": 31, "tag": "CellFunction"}, {"end": 119, "start": 111, "tag": "ResearchActivity"}, {"end": 24, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 18, "tag": "BiologicallyActiveSubstance"}]}{"id": "1308_7", "text": "In vivo, TIMP-1 deficiency completely abolished spontaneous remyelination, phenocopying OSMR beta KO mice.", "tags": [{"end": 97, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 26, "start": 16, "tag": "Finding"}, {"end": 105, "start": 101, "tag": "Eukaryote"}, {"end": 73, "start": 60, "tag": "CellFunction"}, {"end": 15, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 105, "start": 88, "tag": "ExperimentalModelOfDisease"}]}{"id": "1308_8", "text": "Finally, TIMP-1 was expressed by human astrocytes in demyelinated multiple sclerosis lesions, confirming the human value of our findings.", "tags": [{"end": 84, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 85, "tag": "InjuryOrPoisoning"}, {"end": 65, "start": 53, "tag": "PathologicFunction"}, {"end": 38, "start": 33, "tag": "Eukaryote"}, {"end": 114, "start": 109, "tag": "Eukaryote"}, {"end": 49, "start": 39, "tag": "Cell"}, {"end": 29, "start": 20, "tag": "CellFunction"}, {"end": 15, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 9, "tag": "BiologicallyActiveSubstance"}]}{"id": "1308_9", "text": "Taken together, OSM and its downstream mediator TIMP-1 have the therapeutic potential to boost remyelination in demyelinating disorders.", "tags": [{"end": 19, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 94, "start": 89, "tag": "HealthCareActivity"}, {"end": 135, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 64, "tag": "HealthCareActivity"}, {"end": 108, "start": 95, "tag": "CellFunction"}, {"end": 54, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 28, "tag": "BiologicallyActiveSubstance"}]}{"id": "1309_0", "text": "Myelination is an essential process that consists of the ensheathment of axons by myelin.", "tags": [{"end": 78, "start": 73, "tag": "CellComponent"}, {"end": 88, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 78, "start": 57, "tag": "CellFunction"}]}{"id": "1309_1", "text": "In the central nervous system (CNS), myelin is synthesized by oligodendrocytes.", "tags": [{"end": 78, "start": 62, "tag": "Cell"}, {"end": 43, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1309_2", "text": "The proliferation, migration, and differentiation of oligodendrocyte precursor cells constitute a prerequisite before mature oligodendrocytes extend their processes around the axons and progressively generate a multilamellar lipidic sheath.", "tags": [{"end": 181, "start": 176, "tag": "CellComponent"}, {"end": 84, "start": 53, "tag": "Cell"}, {"end": 141, "start": 118, "tag": "Cell"}, {"end": 49, "start": 34, "tag": "CellFunction"}, {"end": 17, "start": 4, "tag": "CellFunction"}, {"end": 28, "start": 19, "tag": "CellFunction"}, {"end": 239, "start": 211, "tag": "CellComponent"}]}{"id": "1309_3", "text": "Although myelination is predominately driven by oligodendrocytes, the other glial cells including astrocytes and microglia, also contribute to this process.", "tags": [{"end": 64, "start": 48, "tag": "Cell"}, {"end": 87, "start": 76, "tag": "Cell"}, {"end": 122, "start": 113, "tag": "Cell"}, {"end": 108, "start": 98, "tag": "Cell"}, {"end": 20, "start": 9, "tag": "CellFunction"}]}{"id": "1309_4", "text": "The present review is an update of the most recent emerging mechanisms involving astrocyte and microglia in myelin production.", "tags": [{"end": 31, "start": 25, "tag": "TemporalConcept"}, {"end": 114, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 104, "start": 95, "tag": "Cell"}, {"end": 90, "start": 81, "tag": "Cell"}, {"end": 50, "start": 44, "tag": "TemporalConcept"}]}{"id": "1309_5", "text": "The contribution of these cells will be first described during developmental myelination that occurs in the early postnatal period and is critical for the proper development of cognition and behavior.", "tags": [{"end": 199, "start": 191, "tag": "BiologicFunction"}, {"end": 199, "start": 191, "tag": "IndividualBehavior"}, {"end": 199, "start": 191, "tag": "ResearchActivity"}, {"end": 76, "start": 63, "tag": "BiologicFunction"}, {"end": 76, "start": 63, "tag": "TemporalConcept"}, {"end": 113, "start": 108, "tag": "TemporalConcept"}, {"end": 123, "start": 114, "tag": "TemporalConcept"}, {"end": 130, "start": 124, "tag": "TemporalConcept"}, {"end": 173, "start": 162, "tag": "BiologicFunction"}, {"end": 173, "start": 162, "tag": "CellFunction"}, {"end": 31, "start": 26, "tag": "Cell"}, {"end": 45, "start": 40, "tag": "TemporalConcept"}, {"end": 186, "start": 177, "tag": "BiologicFunction"}, {"end": 88, "start": 77, "tag": "CellFunction"}]}{"id": "1309_6", "text": "Then, we will report the novel findings regarding the beneficial or deleterious effects of astroglia and microglia, which respectively promote or impair the endogenous capacity of oligodendrocyte progenitor cells (OPCs) to induce spontaneous remyelination after myelin loss.", "tags": [{"end": 100, "start": 91, "tag": "Cell"}, {"end": 218, "start": 214, "tag": "Cell"}, {"end": 268, "start": 262, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 180, "tag": "Cell"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 176, "start": 168, "tag": "Finding"}, {"end": 114, "start": 105, "tag": "Cell"}, {"end": 255, "start": 242, "tag": "CellFunction"}, {"end": 87, "start": 80, "tag": "Finding"}, {"end": 273, "start": 262, "tag": "CellOrMolecularDysfunction"}]}{"id": "1309_7", "text": "Acute delineation of astrocyte and microglia activities and cross-talk should uncover the way towards novel therapeutic perspectives aimed at recovering proper myelination during development or at breaking down the barriers impeding the regeneration of the damaged myelin that occurs in CNS demyelinating diseases.", "tags": [{"end": 70, "start": 60, "tag": "CellFunction"}, {"end": 271, "start": 257, "tag": "CellOrMolecularDysfunction"}, {"end": 313, "start": 291, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 237, "tag": "BiologicFunction"}, {"end": 5, "start": 0, "tag": "TemporalConcept"}, {"end": 5, "start": 0, "tag": "HealthCareActivity"}, {"end": 249, "start": 237, "tag": "HealthCareActivity"}, {"end": 290, "start": 287, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 190, "start": 179, "tag": "BiologicFunction"}, {"end": 190, "start": 179, "tag": "CellFunction"}, {"end": 44, "start": 35, "tag": "Cell"}, {"end": 30, "start": 21, "tag": "Cell"}, {"end": 171, "start": 160, "tag": "CellFunction"}, {"end": 132, "start": 102, "tag": "Finding"}]}{"id": "1310_0", "text": "Introduction: AQP4 (aquaporin-4)-immunoglobulin G (IgG)-mediated neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory demyelinating disease that affects the central nervous system, particularly the spinal cord and optic nerve; remyelination capacity in neuromyelitis optica is yet to be determined, as is the role of AQP4-IgG in cell differentiation.", "tags": [{"end": 18, "start": 14, "tag": "GeneOrGenome"}, {"end": 18, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 110, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 86, "tag": "ResearchActivity"}, {"end": 103, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 286, "start": 266, "tag": "DiseaseOrSyndrome"}, {"end": 238, "start": 227, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 338, "start": 335, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 338, "start": 335, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 51, "tag": "PharmacologicSubstance"}, {"end": 338, "start": 335, "tag": "PharmacologicSubstance"}, {"end": 152, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 222, "start": 211, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 118, "tag": "PathologicFunction"}, {"end": 192, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 262, "start": 254, "tag": "Finding"}, {"end": 253, "start": 240, "tag": "CellFunction"}, {"end": 362, "start": 342, "tag": "CellFunction"}, {"end": 18, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 31, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 31, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 33, "tag": "PharmacologicSubstance"}, {"end": 334, "start": 330, "tag": "GeneOrGenome"}, {"end": 334, "start": 330, "tag": "BiologicallyActiveSubstance"}, {"end": 334, "start": 330, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1310_1", "text": "Material and Methods: We included three groups-a group of patients with AQP4-IgG-positive neuromyelitis optica, a healthy group, and a sham group.", "tags": [{"end": 8, "start": 0, "tag": "Substance"}, {"end": 139, "start": 135, "tag": "Chemical"}, {"end": 66, "start": 58, "tag": "PatientOrDisabledGroup"}, {"end": 110, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 77, "tag": "PharmacologicSubstance"}, {"end": 121, "start": 114, "tag": "OrganismAttribute"}, {"end": 54, "start": 49, "tag": "PopulationGroup"}, {"end": 127, "start": 122, "tag": "PopulationGroup"}, {"end": 145, "start": 140, "tag": "PopulationGroup"}, {"end": 76, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 72, "tag": "GeneOrGenome"}]}{"id": "1310_2", "text": "We analyzed differentiation capacity in cultures of neurospheres from the subventricular zone of mice by adding serum at two different times: early and advanced stages of differentiation.", "tags": [{"end": 64, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 152, "tag": "TemporalConcept"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 27, "start": 12, "tag": "CellFunction"}, {"end": 186, "start": 171, "tag": "CellFunction"}, {"end": 147, "start": 142, "tag": "TemporalConcept"}, {"end": 93, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 97, "tag": "Eukaryote"}, {"end": 117, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 28, "tag": "Finding"}, {"end": 11, "start": 3, "tag": "ResearchActivity"}, {"end": 167, "start": 161, "tag": "TemporalConcept"}]}{"id": "1310_3", "text": "We also analyzed differentiation into different cell lines.", "tags": [{"end": 32, "start": 17, "tag": "CellFunction"}, {"end": 16, "start": 8, "tag": "ResearchActivity"}, {"end": 58, "start": 48, "tag": "Cell"}]}{"id": "1310_4", "text": "Results and Conclusions: The effect of sera from patients with NMOSD on precursor cells differs according to the degree of differentiation, and probably affects oligodendrocyte progenitor cells from NG2 cells to a lesser extent than cells from the subventricular zone; however, the resulting oligodendrocytes may be compromised in terms of maturation and possibly limited in their ability to generate myelin.", "tags": [{"end": 68, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 199, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 199, "tag": "BiologicallyActiveSubstance"}, {"end": 202, "start": 199, "tag": "GeneOrGenome"}, {"end": 308, "start": 292, "tag": "Cell"}, {"end": 350, "start": 340, "tag": "BiologicFunction"}, {"end": 407, "start": 401, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 161, "tag": "Cell"}, {"end": 138, "start": 123, "tag": "CellFunction"}, {"end": 87, "start": 72, "tag": "Cell"}, {"end": 267, "start": 248, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 49, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 208, "start": 203, "tag": "Cell"}, {"end": 238, "start": 233, "tag": "Cell"}, {"end": 43, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 29, "tag": "Finding"}, {"end": 388, "start": 381, "tag": "OrganismAttribute"}]}{"id": "1310_5", "text": "Furthermore, these cells decrease in number with age.", "tags": [{"end": 24, "start": 19, "tag": "Cell"}, {"end": 52, "start": 49, "tag": "OrganismAttribute"}, {"end": 33, "start": 25, "tag": "Finding"}]}{"id": "1310_6", "text": "It is very unlikely that the use of drugs favoring the migration and differentiation of oligodendrocyte progenitor cells in multiple sclerosis would be effective in the context of neuromyelitis optica, but cell therapy with oligodendrocyte progenitor cells seems to be a potential alternative.", "tags": [{"end": 218, "start": 206, "tag": "HealthCareActivity"}, {"end": 200, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 142, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 88, "tag": "Cell"}, {"end": 256, "start": 224, "tag": "Cell"}, {"end": 84, "start": 69, "tag": "CellFunction"}, {"end": 64, "start": 55, "tag": "CellFunction"}, {"end": 41, "start": 36, "tag": "PharmacologicSubstance"}]}{"id": "1311_0", "text": "This article reviews the wealth of papers dealing with the different effects of epidermal growth factor (EGF) on oligodendrocytes, astrocytes, neurons, and neural stem cells (NSCs).", "tags": [{"end": 103, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 80, "tag": "PharmacologicSubstance"}, {"end": 108, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 105, "tag": "PharmacologicSubstance"}, {"end": 108, "start": 105, "tag": "GeneOrGenome"}, {"end": 179, "start": 175, "tag": "Cell"}, {"end": 12, "start": 5, "tag": "ResearchActivity"}, {"end": 20, "start": 13, "tag": "HealthCareActivity"}, {"end": 20, "start": 13, "tag": "ResearchActivity"}, {"end": 129, "start": 113, "tag": "Cell"}, {"end": 173, "start": 156, "tag": "Cell"}, {"end": 150, "start": 143, "tag": "Cell"}, {"end": 141, "start": 131, "tag": "Cell"}, {"end": 76, "start": 69, "tag": "Finding"}]}{"id": "1311_1", "text": "EGF induces the in vitro and in vivo proliferation of NSCs, their migration, and their differentiation towards the neuroglial cell line.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 58, "start": 54, "tag": "Cell"}, {"end": 135, "start": 115, "tag": "Cell"}, {"end": 102, "start": 87, "tag": "CellFunction"}, {"end": 50, "start": 37, "tag": "CellFunction"}, {"end": 75, "start": 66, "tag": "CellFunction"}, {"end": 24, "start": 16, "tag": "ResearchActivity"}, {"end": 36, "start": 29, "tag": "ResearchActivity"}]}{"id": "1311_2", "text": "It interacts with extracellular matrix components.", "tags": [{"end": 38, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 39, "tag": "CellComponent"}]}{"id": "1311_3", "text": "NSCs are distributed in different CNS areas, serve as a reservoir of multipotent cells, and may be increased during CNS demyelinating diseases.", "tags": [{"end": 4, "start": 0, "tag": "Cell"}, {"end": 65, "start": 56, "tag": "ManufacturedObject"}, {"end": 86, "start": 69, "tag": "Cell"}, {"end": 142, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 56, "tag": "Finding"}]}{"id": "1311_4", "text": "EGF has pleiotropic differentiative and proliferative effects on the main CNS cell types, particularly oligodendrocytes and their precursors, and astrocytes.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 119, "start": 103, "tag": "Cell"}, {"end": 77, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 146, "tag": "Cell"}, {"end": 61, "start": 40, "tag": "Finding"}, {"end": 88, "start": 78, "tag": "Cell"}]}{"id": "1311_5", "text": "EGF mediates the in vivo myelinotrophic effect of cobalamin on the CNS, and modulates the synthesis and levels of CNS normal prions (PrPs), both of which are indispensable for myelinogenesis and myelin maintenance.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 59, "start": 50, "tag": "Chemical"}, {"end": 59, "start": 50, "tag": "PharmacologicSubstance"}, {"end": 59, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 176, "tag": "CellFunction"}, {"end": 201, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 90, "tag": "BiologicFunction"}, {"end": 70, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 40, "tag": "Finding"}, {"end": 213, "start": 202, "tag": "BiologicFunction"}, {"end": 24, "start": 17, "tag": "ResearchActivity"}, {"end": 124, "start": 118, "tag": "Finding"}, {"end": 39, "start": 25, "tag": "CellFunction"}, {"end": 131, "start": 125, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1311_6", "text": "EGF levels are significantly lower in the cerebrospinal fluid and spinal cord of patients with multiple sclerosis (MS), which probably explains remyelination failure, also because of the EGF marginal role in immunology.", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 190, "start": 187, "tag": "AminoAcidPeptideOrProtein"}, {"end": 190, "start": 187, "tag": "BiologicallyActiveSubstance"}, {"end": 190, "start": 187, "tag": "GeneOrGenome"}, {"end": 218, "start": 208, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 218, "start": 208, "tag": "BiologicFunction"}, {"end": 113, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 165, "start": 144, "tag": "CellOrMolecularDysfunction"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 61, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 190, "start": 187, "tag": "PharmacologicSubstance"}]}{"id": "1311_7", "text": "When repeatedly administered, EGF protects mouse spinal cord from demyelination in various experimental models of autoimmune encephalomyelitis.", "tags": [{"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 30, "tag": "GeneOrGenome"}, {"end": 142, "start": 91, "tag": "ExperimentalModelOfDisease"}, {"end": 60, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 43, "tag": "Eukaryote"}, {"end": 79, "start": 66, "tag": "PathologicFunction"}, {"end": 33, "start": 30, "tag": "PharmacologicSubstance"}]}{"id": "1311_8", "text": "It would be worth further investigating the role of EGF in the pathogenesis of MS because of its multifarious effects.", "tags": [{"end": 55, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 52, "tag": "PharmacologicSubstance"}, {"end": 55, "start": 52, "tag": "CellFunction"}, {"end": 55, "start": 52, "tag": "GeneOrGenome"}, {"end": 75, "start": 63, "tag": "PathologicFunction"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 110, "tag": "Finding"}]}{"id": "1312_0", "text": "Oligodendrocytes are glial cells located in the central nervous system (CNS) that play essential roles in the transmission of nerve signals and in the neuroprotection of myelinated neurons.", "tags": [{"end": 131, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 151, "tag": "CellFunction"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 70, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 132, "tag": "CellFunction"}, {"end": 32, "start": 21, "tag": "Cell"}, {"end": 122, "start": 110, "tag": "Finding"}, {"end": 188, "start": 170, "tag": "Cell"}]}{"id": "1312_1", "text": "The dysfunction or loss of oligodendrocytes leads to demyelinating diseases such as multiple sclerosis (MS).", "tags": [{"end": 43, "start": 27, "tag": "Cell"}, {"end": 75, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 53, "tag": "PathologicFunction"}, {"end": 102, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 19, "tag": "CellOrMolecularDysfunction"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 4, "tag": "PathologicFunction"}]}{"id": "1312_2", "text": "To treat demyelinating diseases, the development of a therapy that promotes remyelination is required.", "tags": [{"end": 31, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 9, "tag": "PathologicFunction"}, {"end": 48, "start": 37, "tag": "BiologicFunction"}, {"end": 48, "start": 37, "tag": "CellFunction"}, {"end": 61, "start": 54, "tag": "HealthCareActivity"}, {"end": 89, "start": 76, "tag": "CellFunction"}]}{"id": "1312_3", "text": "In the present study, we established an in vitro method to convert human fibroblasts into induced oligodendrocyte-like cells (iOLCs) in 3 days.", "tags": [{"end": 84, "start": 73, "tag": "Cell"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 72, "start": 67, "tag": "Eukaryote"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 124, "start": 90, "tag": "Cell"}, {"end": 142, "start": 138, "tag": "TemporalConcept"}, {"end": 55, "start": 49, "tag": "ResearchActivity"}, {"end": 55, "start": 49, "tag": "HealthCareActivity"}, {"end": 131, "start": 126, "tag": "Cell"}]}{"id": "1312_4", "text": "The induced cells displayed morphologies and molecular signatures similar to oligodendrocytes after treatment with valproic acid and exposure to the small molecules Y27632, SU9516, and forskolin (FSK).", "tags": [{"end": 65, "start": 45, "tag": "ResearchActivity"}, {"end": 128, "start": 115, "tag": "Chemical"}, {"end": 171, "start": 165, "tag": "Chemical"}, {"end": 179, "start": 173, "tag": "Chemical"}, {"end": 194, "start": 185, "tag": "Chemical"}, {"end": 199, "start": 196, "tag": "Chemical"}, {"end": 164, "start": 149, "tag": "Chemical"}, {"end": 93, "start": 77, "tag": "Cell"}, {"end": 17, "start": 12, "tag": "Cell"}, {"end": 109, "start": 100, "tag": "HealthCareActivity"}, {"end": 109, "start": 100, "tag": "ResearchActivity"}, {"end": 164, "start": 155, "tag": "Substance"}, {"end": 40, "start": 28, "tag": "ClinicalAttribute"}]}{"id": "1312_5", "text": "To pursue the development of a cell-free remyelination therapy in vivo, we used a cuprizone-induced demyelinated mouse model.", "tags": [{"end": 62, "start": 41, "tag": "HealthCareActivity"}, {"end": 112, "start": 100, "tag": "PathologicFunction"}, {"end": 91, "start": 82, "tag": "Chemical"}, {"end": 25, "start": 14, "tag": "BiologicFunction"}, {"end": 25, "start": 14, "tag": "CellFunction"}, {"end": 35, "start": 31, "tag": "Cell"}, {"end": 62, "start": 55, "tag": "HealthCareActivity"}, {"end": 70, "start": 63, "tag": "ResearchActivity"}, {"end": 54, "start": 41, "tag": "CellFunction"}, {"end": 124, "start": 113, "tag": "ResearchActivity"}, {"end": 124, "start": 82, "tag": "ExperimentalModelOfDisease"}]}{"id": "1312_6", "text": "The small molecules (Y27632, SU9516, and FSK) were directly injected into the demyelinated corpus callosum of the mouse brain.", "tags": [{"end": 27, "start": 21, "tag": "Chemical"}, {"end": 35, "start": 29, "tag": "Chemical"}, {"end": 44, "start": 41, "tag": "Chemical"}, {"end": 19, "start": 4, "tag": "Chemical"}, {"end": 90, "start": 78, "tag": "PathologicFunction"}, {"end": 106, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 19, "start": 10, "tag": "Substance"}, {"end": 119, "start": 114, "tag": "Eukaryote"}]}{"id": "1312_7", "text": "This combination of small molecules rescued the demyelination phenotype within two weeks as observed by light and electron microscopy.", "tags": [{"end": 35, "start": 20, "tag": "Chemical"}, {"end": 88, "start": 83, "tag": "TemporalConcept"}, {"end": 109, "start": 104, "tag": "NaturalPhenomenonOrProcess"}, {"end": 71, "start": 62, "tag": "OrganismAttribute"}, {"end": 133, "start": 114, "tag": "ResearchActivity"}, {"end": 35, "start": 26, "tag": "Substance"}, {"end": 61, "start": 48, "tag": "PathologicFunction"}, {"end": 133, "start": 123, "tag": "ResearchActivity"}, {"end": 109, "start": 104, "tag": "ResearchActivity"}]}{"id": "1312_8", "text": "These results provide a foundation for exploring the development of a treatment for demyelinating diseases via regenerative medicine.", "tags": [{"end": 132, "start": 111, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 106, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 53, "tag": "BiologicFunction"}, {"end": 64, "start": 53, "tag": "CellFunction"}, {"end": 79, "start": 70, "tag": "HealthCareActivity"}, {"end": 79, "start": 70, "tag": "ResearchActivity"}]}{"id": "1313_0", "text": "Oligodendrocyte precursor cells (OPCs) originate in localized germinal zones in the embryonic neural tube, then migrate and proliferate to populate the entire central nervous system, both white and gray matter.", "tags": [{"end": 209, "start": 203, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 188, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 198, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 84, "tag": "EmbryonicStructure"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 181, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 62, "tag": "EmbryonicStructure"}]}{"id": "1313_1", "text": "They divide and generate myelinating oligodendrocytes (OLs) throughout postnatal and adult life.", "tags": [{"end": 36, "start": 25, "tag": "CellFunction"}, {"end": 53, "start": 37, "tag": "Cell"}, {"end": 53, "start": 25, "tag": "Cell"}, {"end": 58, "start": 55, "tag": "Cell"}, {"end": 80, "start": 71, "tag": "TemporalConcept"}, {"end": 95, "start": 91, "tag": "TemporalConcept"}, {"end": 90, "start": 85, "tag": "PopulationGroup"}]}{"id": "1313_2", "text": "OPCs express NG2 and platelet-derived growth factor receptor alpha subunit (PDGFR alpha), two functionally important cell surface proteins, which are also widely used as markers for OPCs.", "tags": [{"end": 74, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 5, "tag": "CellFunction"}, {"end": 16, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 13, "tag": "GeneOrGenome"}, {"end": 4, "start": 0, "tag": "Cell"}, {"end": 186, "start": 182, "tag": "Cell"}, {"end": 177, "start": 170, "tag": "ClinicalAttribute"}, {"end": 138, "start": 130, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 117, "tag": "CellComponent"}, {"end": 74, "start": 21, "tag": "BiologicallyActiveSubstance"}]}{"id": "1313_3", "text": "The proliferation of OPCs, their terminal differentiation into OLs, survival of new OLs, and myelin synthesis are orchestrated by signals in the local microenvironment.", "tags": [{"end": 167, "start": 151, "tag": "NaturalPhenomenonOrProcess"}, {"end": 25, "start": 21, "tag": "Cell"}, {"end": 57, "start": 42, "tag": "CellFunction"}, {"end": 66, "start": 63, "tag": "Cell"}, {"end": 87, "start": 84, "tag": "Cell"}, {"end": 17, "start": 4, "tag": "CellFunction"}, {"end": 109, "start": 93, "tag": "CellFunction"}, {"end": 137, "start": 130, "tag": "CellFunction"}, {"end": 76, "start": 68, "tag": "CellFunction"}]}{"id": "1313_4", "text": "We discuss advances in our mechanistic understanding of paracrine effects, including those mediated through PDGFR alpha and neuronal activity-dependent signals such as those mediated through AMPA receptors in OL survival and myelination.", "tags": [{"end": 65, "start": 56, "tag": "BiologicFunction"}, {"end": 119, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 211, "start": 209, "tag": "Cell"}, {"end": 141, "start": 124, "tag": "CellFunction"}, {"end": 159, "start": 152, "tag": "CellFunction"}, {"end": 220, "start": 212, "tag": "CellFunction"}, {"end": 52, "start": 39, "tag": "BiologicFunction"}, {"end": 236, "start": 225, "tag": "CellFunction"}, {"end": 73, "start": 66, "tag": "Finding"}, {"end": 19, "start": 11, "tag": "Finding"}, {"end": 205, "start": 191, "tag": "BiologicallyActiveSubstance"}]}{"id": "1313_5", "text": "Finally, we review recent studies supporting the role of new OL production and adaptive myelination in specific behaviours and cognitive processes contributing to learning and long-term memory formation.", "tags": [{"end": 122, "start": 112, "tag": "Finding"}, {"end": 146, "start": 127, "tag": "BiologicFunction"}, {"end": 171, "start": 163, "tag": "BiologicFunction"}, {"end": 63, "start": 61, "tag": "Cell"}, {"end": 185, "start": 176, "tag": "TemporalConcept"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 33, "start": 26, "tag": "ResearchActivity"}, {"end": 25, "start": 19, "tag": "TemporalConcept"}, {"end": 99, "start": 88, "tag": "CellFunction"}, {"end": 192, "start": 186, "tag": "BiologicFunction"}, {"end": 192, "start": 186, "tag": "Finding"}, {"end": 202, "start": 176, "tag": "BiologicFunction"}]}{"id": "1313_6", "text": "Our article is not intended to be comprehensive but reflects the authors' past and present interests.", "tags": [{"end": 100, "start": 91, "tag": "BiologicFunction"}, {"end": 11, "start": 4, "tag": "ResearchActivity"}, {"end": 78, "start": 74, "tag": "TemporalConcept"}]}{"id": "1314_0", "text": "Oligodendrocytes are extensively coupled to astrocytes, a phenomenon ensuring glial homeostasis and maintenance of central nervous system myelin.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 144, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 78, "tag": "Cell"}, {"end": 137, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 111, "start": 100, "tag": "BiologicFunction"}, {"end": 95, "start": 84, "tag": "BiologicFunction"}, {"end": 54, "start": 44, "tag": "Cell"}]}{"id": "1314_1", "text": "Molecular disruption of this communication occurs in demyelinating diseases such as multiple sclerosis.", "tags": [{"end": 75, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 29, "tag": "HealthCareActivity"}, {"end": 42, "start": 29, "tag": "CellFunction"}, {"end": 20, "start": 0, "tag": "CellOrMolecularDysfunction"}]}{"id": "1314_2", "text": "Less is known about the vulnerability and reconstruction of the panglial network during adult demyelination-remyelination.", "tags": [{"end": 37, "start": 24, "tag": "ClinicalAttribute"}, {"end": 56, "start": 42, "tag": "MachineActivity"}, {"end": 56, "start": 42, "tag": "HealthCareActivity"}, {"end": 121, "start": 108, "tag": "CellFunction"}, {"end": 107, "start": 94, "tag": "PathologicFunction"}, {"end": 93, "start": 88, "tag": "PopulationGroup"}, {"end": 80, "start": 64, "tag": "CellFunction"}]}{"id": "1314_3", "text": "Here, we took advantage of lysolcithin-induced demyelination to investigate the expression dynamics of the oligodendrocyte specific connexin 47 (Cx47) and to some extent that of astrocyte Cx43, and whether this dynamic could be modulated by grafted induced pluripotent stem cell (iPSC)-neural progeny.", "tags": [{"end": 143, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 300, "start": 293, "tag": "PopulationGroup"}, {"end": 284, "start": 280, "tag": "Cell"}, {"end": 192, "start": 188, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 188, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 278, "start": 274, "tag": "Cell"}, {"end": 90, "start": 80, "tag": "CellFunction"}, {"end": 187, "start": 178, "tag": "Cell"}, {"end": 122, "start": 107, "tag": "Cell"}, {"end": 278, "start": 249, "tag": "Cell"}, {"end": 60, "start": 47, "tag": "PathologicFunction"}, {"end": 99, "start": 91, "tag": "NaturalPhenomenonOrProcess"}, {"end": 278, "start": 269, "tag": "Cell"}, {"end": 143, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 292, "start": 286, "tag": "Cell"}]}{"id": "1314_4", "text": "Our data show that disruption of Cx43-Cx47 mediated hetero-cellular gap-junction intercellular communication following demyelination is larger in size than demyelination.", "tags": [{"end": 29, "start": 19, "tag": "InjuryOrPoisoning"}, {"end": 37, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 42, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 59, "tag": "Cell"}, {"end": 150, "start": 146, "tag": "OrganismAttribute"}, {"end": 108, "start": 81, "tag": "CellFunction"}, {"end": 108, "start": 95, "tag": "HealthCareActivity"}, {"end": 108, "start": 95, "tag": "CellFunction"}, {"end": 132, "start": 119, "tag": "PathologicFunction"}, {"end": 169, "start": 156, "tag": "PathologicFunction"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 80, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1314_5", "text": "Loss of Cx47 expression is timely rescued during remyelination and accelerated by the grafted neural precursors.", "tags": [{"end": 111, "start": 94, "tag": "Cell"}, {"end": 12, "start": 8, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 8, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 13, "tag": "CellFunction"}, {"end": 62, "start": 49, "tag": "CellFunction"}]}{"id": "1314_6", "text": "Moreover, mouse and human iPSC-derived oligodendrocytes express Cx47, which co-labels with astrocyte Cx43, indicating their integration into the panglial network.", "tags": [{"end": 63, "start": 56, "tag": "CellFunction"}, {"end": 30, "start": 26, "tag": "Cell"}, {"end": 55, "start": 39, "tag": "Cell"}, {"end": 135, "start": 124, "tag": "CellFunction"}, {"end": 135, "start": 124, "tag": "MachineActivity"}, {"end": 105, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 68, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 20, "tag": "Eukaryote"}, {"end": 100, "start": 91, "tag": "Cell"}, {"end": 15, "start": 10, "tag": "Eukaryote"}, {"end": 161, "start": 145, "tag": "CellFunction"}]}{"id": "1314_7", "text": "These data suggest that in rodents, full lesion repair following transplantation occurs by panglial reconstruction in addition to remyelination.", "tags": [{"end": 34, "start": 27, "tag": "Eukaryote"}, {"end": 47, "start": 41, "tag": "InjuryOrPoisoning"}, {"end": 143, "start": 130, "tag": "CellFunction"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}, {"end": 80, "start": 65, "tag": "HealthCareActivity"}, {"end": 54, "start": 48, "tag": "BiologicFunction"}, {"end": 54, "start": 48, "tag": "HealthCareActivity"}]}{"id": "1314_8", "text": "Targeting panglial elements by cell therapy or pharmacological compounds may help accelerating or stabilizing re/myelination in myelin disorders.", "tags": [{"end": 43, "start": 31, "tag": "HealthCareActivity"}, {"end": 144, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 47, "tag": "PharmacologicSubstance"}, {"end": 124, "start": 113, "tag": "CellFunction"}]}{"id": "1315_0", "text": "The regeneration of myelin is known to restore axonal conduction velocity after a demyelinating event.", "tags": [{"end": 95, "start": 82, "tag": "PathologicFunction"}, {"end": 26, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 4, "tag": "BiologicFunction"}, {"end": 53, "start": 47, "tag": "CellComponent"}, {"end": 73, "start": 54, "tag": "BiologicFunction"}, {"end": 64, "start": 54, "tag": "NaturalPhenomenonOrProcess"}, {"end": 16, "start": 4, "tag": "HealthCareActivity"}, {"end": 64, "start": 54, "tag": "BiologicFunction"}]}{"id": "1315_1", "text": "Remyelination failure in the central nervous system contributes to the severity and progression of demyelinating diseases such as multiple sclerosis.", "tags": [{"end": 121, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 21, "start": 14, "tag": "IndividualBehavior"}, {"end": 51, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 84, "tag": "PathologicFunction"}, {"end": 95, "start": 84, "tag": "TemporalConcept"}, {"end": 79, "start": 71, "tag": "ClinicalAttribute"}, {"end": 79, "start": 71, "tag": "Finding"}]}{"id": "1315_2", "text": "Remyelination is controlled by many signaling pathways, such as the Sonic hedgehog (Shh) pathway, as shown by the canonical activation of its key effector Smoothened (Smo), which increases the proliferation of oligodendrocyte precursor cells via the upregulation of the transcription factor Gli1.", "tags": [{"end": 27, "start": 17, "tag": "Finding"}, {"end": 27, "start": 17, "tag": "HealthCareActivity"}, {"end": 165, "start": 155, "tag": "AminoAcidPeptideOrProtein"}, {"end": 170, "start": 167, "tag": "AminoAcidPeptideOrProtein"}, {"end": 295, "start": 291, "tag": "GeneOrGenome"}, {"end": 295, "start": 291, "tag": "AminoAcidPeptideOrProtein"}, {"end": 290, "start": 270, "tag": "AminoAcidPeptideOrProtein"}, {"end": 290, "start": 270, "tag": "BiologicallyActiveSubstance"}, {"end": 241, "start": 210, "tag": "Cell"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 206, "start": 193, "tag": "CellFunction"}, {"end": 54, "start": 36, "tag": "CellFunction"}, {"end": 96, "start": 68, "tag": "CellFunction"}, {"end": 262, "start": 250, "tag": "CellFunction"}, {"end": 295, "start": 291, "tag": "BiologicallyActiveSubstance"}, {"end": 170, "start": 167, "tag": "BiologicallyActiveSubstance"}, {"end": 165, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 87, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 84, "tag": "GeneOrGenome"}]}{"id": "1315_3", "text": "On the other hand, the inhibition of Gli1 was also found to promote the recruitment of a subset of adult neural stem cells and their subsequent differentiation into oligodendrocytes.", "tags": [{"end": 41, "start": 37, "tag": "GeneOrGenome"}, {"end": 41, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 181, "start": 165, "tag": "Cell"}, {"end": 159, "start": 144, "tag": "CellFunction"}, {"end": 122, "start": 105, "tag": "Cell"}, {"end": 33, "start": 23, "tag": "CellFunction"}, {"end": 104, "start": 99, "tag": "PopulationGroup"}, {"end": 41, "start": 37, "tag": "BiologicallyActiveSubstance"}]}{"id": "1315_4", "text": "Since Smo is also able to transduce Shh signals via various non-canonical pathways such as the blockade of Gli1, we addressed the potential of non-canonical Smo signaling to contribute to oligodendroglial cell maturation in myelinating cells using the non-canonical Smo agonist GSA-10, which downregulates Gli1.", "tags": [{"end": 9, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 36, "tag": "GeneOrGenome"}, {"end": 39, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 107, "tag": "GeneOrGenome"}, {"end": 111, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 269, "start": 266, "tag": "AminoAcidPeptideOrProtein"}, {"end": 305, "start": 292, "tag": "CellFunction"}, {"end": 310, "start": 306, "tag": "GeneOrGenome"}, {"end": 310, "start": 306, "tag": "AminoAcidPeptideOrProtein"}, {"end": 277, "start": 270, "tag": "BiologicallyActiveSubstance"}, {"end": 220, "start": 210, "tag": "BiologicFunction"}, {"end": 170, "start": 143, "tag": "CellFunction"}, {"end": 103, "start": 95, "tag": "PharmacologicSubstance"}, {"end": 103, "start": 95, "tag": "Chemical"}, {"end": 209, "start": 188, "tag": "Cell"}, {"end": 241, "start": 236, "tag": "Cell"}, {"end": 47, "start": 40, "tag": "CellFunction"}, {"end": 82, "start": 60, "tag": "CellFunction"}, {"end": 9, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 284, "start": 278, "tag": "PharmacologicSubstance"}, {"end": 284, "start": 278, "tag": "Chemical"}, {"end": 269, "start": 266, "tag": "BiologicallyActiveSubstance"}]}{"id": "1315_5", "text": "Using the Oli-neuM cell line, we show that GSA-10 promotes Gli2 upregulation, MBP and MAL/OPALIN expression via Smo/AMP-activated Protein Kinase (AMPK) signaling, and efficiently increases the number of axonal contact/ensheathment for each oligodendroglial cell.", "tags": [{"end": 63, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 59, "tag": "GeneOrGenome"}, {"end": 217, "start": 203, "tag": "CellFunction"}, {"end": 150, "start": 146, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 78, "tag": "GeneOrGenome"}, {"end": 161, "start": 152, "tag": "CellFunction"}, {"end": 144, "start": 112, "tag": "CellFunction"}, {"end": 261, "start": 240, "tag": "Cell"}, {"end": 23, "start": 19, "tag": "Cell"}, {"end": 107, "start": 97, "tag": "CellFunction"}, {"end": 76, "start": 64, "tag": "CellFunction"}, {"end": 49, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 63, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 230, "start": 218, "tag": "CellFunction"}, {"end": 49, "start": 43, "tag": "Chemical"}, {"end": 96, "start": 90, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 90, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 90, "tag": "GeneOrGenome"}, {"end": 89, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 86, "tag": "GeneOrGenome"}]}{"id": "1315_6", "text": "Moreover, GSA-10 promotes the recruitment and differentiation of oligodendroglial progenitors into the demyelinated corpus callosum in vivo.", "tags": [{"end": 115, "start": 103, "tag": "PathologicFunction"}, {"end": 61, "start": 46, "tag": "CellFunction"}, {"end": 131, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 65, "tag": "Cell"}, {"end": 139, "start": 132, "tag": "ResearchActivity"}, {"end": 16, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 16, "start": 10, "tag": "Chemical"}]}{"id": "1315_7", "text": "Altogether, our data indicate that non-canonical signaling involving Smo/AMPK modulation and Gli1 downregulation promotes oligodendroglia maturation until axon engagement.", "tags": [{"end": 97, "start": 93, "tag": "GeneOrGenome"}, {"end": 97, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 138, "tag": "BiologicFunction"}, {"end": 58, "start": 49, "tag": "CellFunction"}, {"end": 137, "start": 122, "tag": "Cell"}, {"end": 159, "start": 155, "tag": "CellComponent"}, {"end": 112, "start": 98, "tag": "CellFunction"}, {"end": 20, "start": 16, "tag": "ResearchActivity"}, {"end": 170, "start": 160, "tag": "Finding"}, {"end": 97, "start": 93, "tag": "BiologicallyActiveSubstance"}]}{"id": "1315_8", "text": "Thus, GSA-10, by activation of this signaling pathway, represents a novel potential remyelinating agent.", "tags": [{"end": 97, "start": 84, "tag": "CellFunction"}, {"end": 103, "start": 98, "tag": "PharmacologicSubstance"}, {"end": 53, "start": 36, "tag": "CellFunction"}, {"end": 12, "start": 6, "tag": "PharmacologicSubstance"}, {"end": 12, "start": 6, "tag": "Chemical"}]}{"id": "1316_0", "text": "Glial subtype diversity is an emerging topic in neurobiology and immune-mediated neurological diseases such as multiple sclerosis (MS).", "tags": [{"end": 60, "start": 48, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 129, "start": 111, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 0, "tag": "Cell"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 14, "tag": "Finding"}]}{"id": "1316_1", "text": "We discuss recent conceptual and technological advances that allow a better understanding of the transcriptomic and functional heterogeneity of oligodendrocytes (OLs), astrocytes, and microglial cells under inflammatory-demyelinating conditions.", "tags": [{"end": 160, "start": 144, "tag": "Cell"}, {"end": 233, "start": 220, "tag": "PathologicFunction"}, {"end": 111, "start": 97, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 165, "start": 162, "tag": "Cell"}, {"end": 219, "start": 207, "tag": "PathologicFunction"}, {"end": 140, "start": 127, "tag": "OrganismAttribute"}, {"end": 89, "start": 76, "tag": "BiologicFunction"}, {"end": 178, "start": 168, "tag": "Cell"}, {"end": 17, "start": 11, "tag": "TemporalConcept"}, {"end": 55, "start": 47, "tag": "Finding"}, {"end": 200, "start": 184, "tag": "Cell"}]}{"id": "1316_2", "text": "Recent single cell transcriptomic studies suggest the occurrence of novel homeostatic and reactive glial subtypes and provide insight into the molecular events during disease progression.", "tags": [{"end": 85, "start": 74, "tag": "BiologicFunction"}, {"end": 113, "start": 90, "tag": "Cell"}, {"end": 64, "start": 54, "tag": "TemporalConcept"}, {"end": 186, "start": 175, "tag": "PathologicFunction"}, {"end": 186, "start": 175, "tag": "TemporalConcept"}, {"end": 41, "start": 7, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 186, "start": 167, "tag": "PathologicFunction"}]}{"id": "1316_3", "text": "Multiplexed RNA in situ hybridization has enabled 'mapping back' dysregulated gene expression to glial subtypes within the MS lesion microenvironment.", "tags": [{"end": 37, "start": 0, "tag": "ResearchActivity"}, {"end": 149, "start": 133, "tag": "NaturalPhenomenonOrProcess"}, {"end": 132, "start": 126, "tag": "InjuryOrPoisoning"}, {"end": 111, "start": 97, "tag": "Cell"}, {"end": 93, "start": 78, "tag": "CellFunction"}, {"end": 77, "start": 65, "tag": "PathologicFunction"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 51, "tag": "ResearchActivity"}]}{"id": "1316_4", "text": "These findings suggest novel homeostatic and reactive glial-cell-type functions both in immune-related processes and neuroprotection relevant to understanding the pathology of MS.", "tags": [{"end": 132, "start": 117, "tag": "CellFunction"}, {"end": 40, "start": 29, "tag": "BiologicFunction"}, {"end": 59, "start": 54, "tag": "Cell"}, {"end": 172, "start": 163, "tag": "PathologicFunction"}, {"end": 172, "start": 163, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 158, "start": 145, "tag": "BiologicFunction"}, {"end": 69, "start": 60, "tag": "Cell"}, {"end": 178, "start": 176, "tag": "DiseaseOrSyndrome"}]}{"id": "1317_0", "text": "Demyelinating disorders show impaired remyelination due to failure in the differentiation of oligodendrocyte progenitor cells (OPCs) into mature myelin-forming oligodendrocytes, a process driven by microglia-OPC crosstalk.", "tags": [{"end": 23, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 59, "tag": "IndividualBehavior"}, {"end": 176, "start": 160, "tag": "Cell"}, {"end": 125, "start": 109, "tag": "Cell"}, {"end": 51, "start": 38, "tag": "CellFunction"}, {"end": 131, "start": 127, "tag": "Cell"}, {"end": 211, "start": 208, "tag": "Cell"}, {"end": 125, "start": 93, "tag": "Cell"}, {"end": 221, "start": 212, "tag": "CellFunction"}, {"end": 144, "start": 138, "tag": "TemporalConcept"}, {"end": 151, "start": 145, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 207, "start": 198, "tag": "Cell"}, {"end": 89, "start": 74, "tag": "CellFunction"}]}{"id": "1317_1", "text": "Through conducting a transcriptomic analysis of microarray studies on the demyelination-remyelination cuprizone model and using human samples of multiple sclerosis (MS), we identified molecules involved in this crosstalk.", "tags": [{"end": 44, "start": 21, "tag": "ResearchActivity"}, {"end": 58, "start": 48, "tag": "ResearchActivity"}, {"end": 58, "start": 48, "tag": "ManufacturedObject"}, {"end": 193, "start": 184, "tag": "Substance"}, {"end": 101, "start": 88, "tag": "CellFunction"}, {"end": 111, "start": 102, "tag": "Chemical"}, {"end": 220, "start": 211, "tag": "CellFunction"}, {"end": 66, "start": 59, "tag": "ResearchActivity"}, {"end": 133, "start": 128, "tag": "Eukaryote"}, {"end": 44, "start": 36, "tag": "ResearchActivity"}, {"end": 117, "start": 74, "tag": "ResearchActivity"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 74, "tag": "PathologicFunction"}, {"end": 141, "start": 134, "tag": "Substance"}, {"end": 141, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1317_2", "text": "Differentially expressed genes (DEGs) of specific regions/cell types were detected in GEO transcriptomic raw data after cuprizone treatment and in MS samples, followed by functional analysis with GO terms and WikiPathways.", "tags": [{"end": 104, "start": 90, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 190, "start": 171, "tag": "HealthCareActivity"}, {"end": 198, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 196, "tag": "GeneOrGenome"}, {"end": 89, "start": 86, "tag": "ResearchActivity"}, {"end": 68, "start": 58, "tag": "Cell"}, {"end": 36, "start": 32, "tag": "GeneOrGenome"}, {"end": 30, "start": 0, "tag": "GeneOrGenome"}, {"end": 30, "start": 0, "tag": "ResearchActivity"}, {"end": 36, "start": 32, "tag": "ResearchActivity"}, {"end": 129, "start": 120, "tag": "Chemical"}, {"end": 113, "start": 90, "tag": "ResearchActivity"}, {"end": 190, "start": 182, "tag": "ResearchActivity"}, {"end": 139, "start": 130, "tag": "HealthCareActivity"}, {"end": 139, "start": 130, "tag": "ResearchActivity"}, {"end": 149, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 24, "start": 15, "tag": "CellFunction"}]}{"id": "1317_3", "text": "Additionally, microglia-OPC crosstalk between microglia ligands, OPC receptors and target genes was examined with the NicheNet model.", "tags": [{"end": 95, "start": 83, "tag": "GeneOrGenome"}, {"end": 27, "start": 24, "tag": "Cell"}, {"end": 68, "start": 65, "tag": "Cell"}, {"end": 37, "start": 28, "tag": "CellFunction"}, {"end": 132, "start": 118, "tag": "ResearchActivity"}, {"end": 23, "start": 14, "tag": "Cell"}, {"end": 55, "start": 46, "tag": "Cell"}, {"end": 78, "start": 69, "tag": "BiologicallyActiveSubstance"}]}{"id": "1317_4", "text": "We identified 108 and 166 DEGs in the demyelinated corpus callosum (CC) at 2 and 4 weeks of cuprizone treatment; 427 and 355 DEGs in the remyelinated (4 weeks of cuprizone treatment + 14 days of normal diet) compared to 2- and 4-week demyelinated CC; 252 DEGs in MS samples and 2730 and 12 DEGs in OPC and microglia of 4-week demyelinated CC.", "tags": [{"end": 50, "start": 38, "tag": "PathologicFunction"}, {"end": 70, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 246, "start": 234, "tag": "PathologicFunction"}, {"end": 249, "start": 247, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 338, "start": 326, "tag": "PathologicFunction"}, {"end": 341, "start": 339, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 301, "start": 298, "tag": "Cell"}, {"end": 66, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 26, "tag": "GeneOrGenome"}, {"end": 129, "start": 125, "tag": "GeneOrGenome"}, {"end": 259, "start": 255, "tag": "GeneOrGenome"}, {"end": 294, "start": 290, "tag": "GeneOrGenome"}, {"end": 30, "start": 26, "tag": "ResearchActivity"}, {"end": 129, "start": 125, "tag": "ResearchActivity"}, {"end": 259, "start": 255, "tag": "ResearchActivity"}, {"end": 294, "start": 290, "tag": "ResearchActivity"}, {"end": 101, "start": 92, "tag": "Chemical"}, {"end": 171, "start": 162, "tag": "Chemical"}, {"end": 206, "start": 195, "tag": "Finding"}, {"end": 233, "start": 229, "tag": "TemporalConcept"}, {"end": 325, "start": 321, "tag": "TemporalConcept"}, {"end": 111, "start": 102, "tag": "HealthCareActivity"}, {"end": 181, "start": 172, "tag": "HealthCareActivity"}, {"end": 111, "start": 102, "tag": "ResearchActivity"}, {"end": 181, "start": 172, "tag": "ResearchActivity"}, {"end": 88, "start": 83, "tag": "TemporalConcept"}, {"end": 158, "start": 153, "tag": "TemporalConcept"}, {"end": 265, "start": 263, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 137, "tag": "CellFunction"}, {"end": 191, "start": 187, "tag": "TemporalConcept"}, {"end": 315, "start": 306, "tag": "Cell"}]}{"id": "1317_5", "text": "At this time point, we found 95 common DEGs in the CC and OPCs, and one common DEG in microglia and OPCs, mostly associated with myelin and lipid metabolism.", "tags": [{"end": 18, "start": 8, "tag": "TemporalConcept"}, {"end": 53, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 140, "tag": "CellFunction"}, {"end": 156, "start": 140, "tag": "BiologicFunction"}, {"end": 145, "start": 140, "tag": "Chemical"}, {"end": 62, "start": 58, "tag": "Cell"}, {"end": 104, "start": 100, "tag": "Cell"}, {"end": 43, "start": 39, "tag": "GeneOrGenome"}, {"end": 43, "start": 39, "tag": "ResearchActivity"}, {"end": 135, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 86, "tag": "Cell"}, {"end": 12, "start": 8, "tag": "TemporalConcept"}, {"end": 82, "start": 79, "tag": "GeneOrGenome"}, {"end": 82, "start": 79, "tag": "ResearchActivity"}]}{"id": "1317_6", "text": "Crosstalk analysis identified 47 microglia ligands, 43 OPC receptors and 115 OPC target genes, all differentially expressed in cuprizone-treated samples and associated with myelination.", "tags": [{"end": 123, "start": 99, "tag": "Finding"}, {"end": 58, "start": 55, "tag": "Cell"}, {"end": 80, "start": 77, "tag": "Cell"}, {"end": 184, "start": 173, "tag": "CellFunction"}, {"end": 136, "start": 127, "tag": "Chemical"}, {"end": 18, "start": 10, "tag": "ResearchActivity"}, {"end": 123, "start": 114, "tag": "CellFunction"}, {"end": 42, "start": 33, "tag": "Cell"}, {"end": 68, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 93, "start": 81, "tag": "GeneOrGenome"}]}{"id": "1317_7", "text": "Our differential expression pipeline identified demyelination/remyelination transcriptomic biomarkers in studies using diverse platforms and cell types/tissues.", "tags": [{"end": 151, "start": 141, "tag": "Cell"}, {"end": 75, "start": 62, "tag": "CellFunction"}, {"end": 112, "start": 105, "tag": "ResearchActivity"}, {"end": 101, "start": 76, "tag": "ClinicalAttribute"}, {"end": 61, "start": 48, "tag": "PathologicFunction"}, {"end": 159, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 4, "tag": "ResearchActivity"}]}{"id": "1317_8", "text": "Cellular crosstalk analysis yielded novel markers of microglia ligands, OPC receptors and target genes.", "tags": [{"end": 75, "start": 72, "tag": "Cell"}, {"end": 18, "start": 0, "tag": "CellFunction"}, {"end": 27, "start": 19, "tag": "ResearchActivity"}, {"end": 62, "start": 53, "tag": "Cell"}, {"end": 49, "start": 42, "tag": "ClinicalAttribute"}, {"end": 85, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 90, "tag": "GeneOrGenome"}]}{"id": "1318_0", "text": "Low-density lipoprotein receptor-related protein 1 (LRP1) is a large, endocytic cell surface receptor that is highly expressed by oligodendrocyte progenitor cells (OPCs) and LRP1 expression is rapidly downregulated as OPCs differentiate into oligodendrocytes (OLs).", "tags": [{"end": 50, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 258, "start": 242, "tag": "Cell"}, {"end": 168, "start": 164, "tag": "Cell"}, {"end": 222, "start": 218, "tag": "Cell"}, {"end": 236, "start": 223, "tag": "CellFunction"}, {"end": 162, "start": 130, "tag": "Cell"}, {"end": 263, "start": 260, "tag": "Cell"}, {"end": 189, "start": 179, "tag": "CellFunction"}, {"end": 56, "start": 52, "tag": "GeneOrGenome"}, {"end": 178, "start": 174, "tag": "GeneOrGenome"}, {"end": 56, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 174, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 174, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 80, "tag": "CellComponent"}, {"end": 214, "start": 201, "tag": "CellFunction"}, {"end": 126, "start": 117, "tag": "CellFunction"}, {"end": 50, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 93, "tag": "BiologicallyActiveSubstance"}]}{"id": "1318_1", "text": "We report that the conditional deletion of Lrp1 from adult mouse OPCs (Pdgfr alpha-CreER :: Lrp1(fl/fl)) increases the number of newborn, mature myelinating OLs added to the corpus callosum and motor cortex.", "tags": [{"end": 47, "start": 43, "tag": "GeneOrGenome"}, {"end": 206, "start": 194, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 160, "start": 145, "tag": "Cell"}, {"end": 69, "start": 65, "tag": "Cell"}, {"end": 144, "start": 138, "tag": "TemporalConcept"}, {"end": 189, "start": 174, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 136, "start": 129, "tag": "TemporalConcept"}, {"end": 9, "start": 3, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "ResearchActivity"}, {"end": 64, "start": 59, "tag": "Eukaryote"}, {"end": 58, "start": 53, "tag": "PopulationGroup"}, {"end": 39, "start": 19, "tag": "ResearchActivity"}, {"end": 103, "start": 71, "tag": "ResearchActivity"}]}{"id": "1318_2", "text": "As these additional OLs extend a normal number of internodes that are of a normal length, Lrp1-deletion increases adult myelination.", "tags": [{"end": 60, "start": 50, "tag": "CellComponent"}, {"end": 88, "start": 82, "tag": "ResearchActivity"}, {"end": 23, "start": 20, "tag": "Cell"}, {"end": 39, "start": 33, "tag": "Finding"}, {"end": 81, "start": 75, "tag": "Finding"}, {"end": 131, "start": 120, "tag": "CellFunction"}, {"end": 119, "start": 114, "tag": "PopulationGroup"}, {"end": 103, "start": 90, "tag": "CellFunction"}]}{"id": "1318_3", "text": "OPC proliferation is also elevated following Lrp1 deletion in vivo, however, this may be a secondary, homeostatic response to increased OPC differentiation, as our in vitro experiments show that LRP1 is a direct negative regulator of OPC differentiation, not proliferation.", "tags": [{"end": 49, "start": 45, "tag": "GeneOrGenome"}, {"end": 58, "start": 50, "tag": "CellOrMolecularDysfunction"}, {"end": 184, "start": 173, "tag": "ResearchActivity"}, {"end": 113, "start": 102, "tag": "BiologicFunction"}, {"end": 155, "start": 136, "tag": "CellFunction"}, {"end": 253, "start": 234, "tag": "CellFunction"}, {"end": 17, "start": 0, "tag": "CellFunction"}, {"end": 272, "start": 259, "tag": "CellFunction"}, {"end": 230, "start": 212, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 164, "tag": "ResearchActivity"}, {"end": 66, "start": 59, "tag": "ResearchActivity"}, {"end": 199, "start": 195, "tag": "GeneOrGenome"}, {"end": 199, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 199, "start": 195, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1318_4", "text": "Deleting Lrp1 from adult OPCs also increases the number of newborn mature OLs added to the corpus callosum in response to cuprizone-induced demyelination.", "tags": [{"end": 13, "start": 9, "tag": "GeneOrGenome"}, {"end": 29, "start": 19, "tag": "Cell"}, {"end": 77, "start": 74, "tag": "Cell"}, {"end": 73, "start": 67, "tag": "TemporalConcept"}, {"end": 106, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 122, "tag": "Chemical"}, {"end": 66, "start": 59, "tag": "TemporalConcept"}, {"end": 153, "start": 140, "tag": "PathologicFunction"}, {"end": 13, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 9, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1318_5", "text": "These data suggest that the selective blockade of LRP1 function on adult OPCs may enhance myelin repair in demyelinating diseases such as multiple sclerosis.", "tags": [{"end": 77, "start": 73, "tag": "Cell"}, {"end": 129, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 46, "start": 38, "tag": "PharmacologicSubstance"}, {"end": 46, "start": 38, "tag": "Chemical"}, {"end": 103, "start": 90, "tag": "CellFunction"}, {"end": 54, "start": 50, "tag": "GeneOrGenome"}, {"end": 54, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 67, "tag": "PopulationGroup"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}]}{"id": "1319_0", "text": "The main obstacle to remyelination in demyelinating diseases, such as multiple sclerosis, is the inability of oligodendrocyte precursor cells (OPCs) to differentiate into mature oligodendrocytes (OLs) in the demyelinating region.", "tags": [{"end": 34, "start": 21, "tag": "CellFunction"}, {"end": 60, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 110, "tag": "Cell"}, {"end": 147, "start": 143, "tag": "Cell"}, {"end": 194, "start": 171, "tag": "Cell"}, {"end": 199, "start": 196, "tag": "Cell"}, {"end": 221, "start": 208, "tag": "PathologicFunction"}]}{"id": "1319_1", "text": "Consequently, promoting OL differentiation and myelin remodeling is a key goal in the search for treatments.", "tags": [{"end": 42, "start": 24, "tag": "CellFunction"}, {"end": 64, "start": 47, "tag": "CellFunction"}, {"end": 107, "start": 97, "tag": "ResearchActivity"}, {"end": 107, "start": 97, "tag": "HealthCareActivity"}]}{"id": "1319_2", "text": "Rho GTPases play diverse and important roles throughout the development of neuronal axons and the formation of the myelin sheath.", "tags": [{"end": 11, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 11, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 75, "tag": "CellComponent"}, {"end": 128, "start": 115, "tag": "CellComponent"}, {"end": 71, "start": 60, "tag": "BiologicFunction"}, {"end": 71, "start": 60, "tag": "CellFunction"}, {"end": 44, "start": 29, "tag": "Finding"}]}{"id": "1319_3", "text": "The current study aimed to investigate the direct protective effects of catalpol on demyelination damage induced by myelin oligodendrocyte glycoprotein (MOG) immunization and to explore whether the GEF-Cdc42/Rac1 signaling pathway contributes to the regeneration effect induced by catalpol.", "tags": [{"end": 68, "start": 50, "tag": "Finding"}, {"end": 80, "start": 72, "tag": "Chemical"}, {"end": 104, "start": 84, "tag": "InjuryOrPoisoning"}, {"end": 151, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 151, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 156, "start": 153, "tag": "BiologicallyActiveSubstance"}, {"end": 230, "start": 198, "tag": "CellFunction"}, {"end": 289, "start": 281, "tag": "Chemical"}, {"end": 269, "start": 263, "tag": "Finding"}, {"end": 262, "start": 250, "tag": "BiologicFunction"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}]}{"id": "1319_4", "text": "In the MOG-induced experimental autoimmune encephalomyelitis (EAE) mouse model of demyelination, we observed that catalpol significantly promoted OL development by enhancing the expression of glutathione S-transferase pi (GST-pi) in the affected brain.", "tags": [{"end": 10, "start": 7, "tag": "AminoAcidPeptideOrProtein"}, {"end": 10, "start": 7, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 19, "tag": "ExperimentalModelOfDisease"}, {"end": 65, "start": 62, "tag": "ExperimentalModelOfDisease"}, {"end": 95, "start": 67, "tag": "ExperimentalModelOfDisease"}, {"end": 122, "start": 114, "tag": "Chemical"}, {"end": 160, "start": 146, "tag": "CellFunction"}, {"end": 220, "start": 192, "tag": "AminoAcidPeptideOrProtein"}, {"end": 220, "start": 192, "tag": "BiologicallyActiveSubstance"}, {"end": 228, "start": 222, "tag": "AminoAcidPeptideOrProtein"}, {"end": 228, "start": 222, "tag": "BiologicallyActiveSubstance"}, {"end": 251, "start": 246, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 188, "start": 178, "tag": "CellFunction"}]}{"id": "1319_5", "text": "By Luxol fast blue staining and myelin basic protein (MBP) expression assessment, catalpol was found to increase MBP expression and promote myelin repair.", "tags": [{"end": 27, "start": 3, "tag": "ResearchActivity"}, {"end": 52, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 54, "tag": "GeneOrGenome"}, {"end": 57, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 59, "tag": "CellFunction"}, {"end": 80, "start": 70, "tag": "ResearchActivity"}, {"end": 80, "start": 70, "tag": "HealthCareActivity"}, {"end": 90, "start": 82, "tag": "Chemical"}, {"end": 127, "start": 113, "tag": "CellFunction"}, {"end": 153, "start": 140, "tag": "CellFunction"}]}{"id": "1319_6", "text": "Furthermore, catalpol promoted OL differentiation associated with the upregulation of Cdc42/Rac1 expression and activation in vivo.", "tags": [{"end": 21, "start": 13, "tag": "Chemical"}, {"end": 49, "start": 31, "tag": "CellFunction"}, {"end": 82, "start": 70, "tag": "CellFunction"}, {"end": 91, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 86, "tag": "GeneOrGenome"}, {"end": 96, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 92, "tag": "GeneOrGenome"}, {"end": 130, "start": 123, "tag": "ResearchActivity"}, {"end": 107, "start": 97, "tag": "CellFunction"}, {"end": 122, "start": 112, "tag": "CellFunction"}]}{"id": "1319_7", "text": "In addition, PAK1/MRCK alpha, proteins downstream of Cdc42/Rac1, was positively regulated by catalpol.", "tags": [{"end": 101, "start": 93, "tag": "Chemical"}, {"end": 17, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 13, "tag": "GeneOrGenome"}, {"end": 28, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 58, "start": 53, "tag": "GeneOrGenome"}, {"end": 63, "start": 59, "tag": "GeneOrGenome"}, {"end": 38, "start": 30, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1319_8", "text": "We also found that catalpol alleviated clinical neurological dysfunction, inhibited inflammatory infiltration, increased the proportion of Treg cells, and suppressed demyelination.", "tags": [{"end": 27, "start": 19, "tag": "Chemical"}, {"end": 72, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 149, "start": 139, "tag": "Cell"}, {"end": 179, "start": 166, "tag": "PathologicFunction"}, {"end": 109, "start": 84, "tag": "PathologicFunction"}]}{"id": "1319_9", "text": "Overall, our study is the first to reveal that catalpol can promote OL generation and myelination and contributes to the crucial regulatory process of GEF-Cdc42/Rac1 signaling expression and activation.", "tags": [{"end": 18, "start": 13, "tag": "ResearchActivity"}, {"end": 55, "start": 47, "tag": "Chemical"}, {"end": 81, "start": 68, "tag": "CellFunction"}, {"end": 97, "start": 86, "tag": "CellFunction"}, {"end": 175, "start": 151, "tag": "CellFunction"}, {"end": 186, "start": 176, "tag": "CellFunction"}, {"end": 201, "start": 191, "tag": "CellFunction"}, {"end": 31, "start": 26, "tag": "TemporalConcept"}]}{"id": "1319_10", "text": "Therefore, catalpol is a promising drug candidate for the potential treatment of demyelinating diseases.", "tags": [{"end": 19, "start": 11, "tag": "Chemical"}, {"end": 103, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 35, "tag": "PharmacologicSubstance"}, {"end": 77, "start": 68, "tag": "ResearchActivity"}, {"end": 77, "start": 68, "tag": "HealthCareActivity"}]}{"id": "1320_0", "text": "In the central nervous system (CNS), insulin-like growth factor 1 (IGF-1) regulates myelination by oligodendrocyte (ODC) precursor cells and shows anti-apoptotic properties in neuronal cells in different in vitro and in vivo systems.", "tags": [{"end": 65, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 67, "tag": "GeneOrGenome"}, {"end": 72, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 119, "start": 116, "tag": "Cell"}, {"end": 136, "start": 121, "tag": "Cell"}, {"end": 190, "start": 176, "tag": "Cell"}, {"end": 29, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 212, "start": 204, "tag": "ResearchActivity"}, {"end": 224, "start": 217, "tag": "ResearchActivity"}, {"end": 114, "start": 99, "tag": "Cell"}, {"end": 95, "start": 84, "tag": "CellFunction"}, {"end": 161, "start": 147, "tag": "CellFunction"}]}{"id": "1320_1", "text": "Previous work also suggests that IGF-1 protects ODCs from cell death and enhances remyelination in models of toxin-induced and autoimmune demyelination.", "tags": [{"end": 38, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 33, "tag": "GeneOrGenome"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 68, "start": 63, "tag": "BiologicFunction"}, {"end": 68, "start": 63, "tag": "PathologicFunction"}, {"end": 68, "start": 63, "tag": "CellFunction"}, {"end": 68, "start": 58, "tag": "CellFunction"}, {"end": 95, "start": 82, "tag": "CellFunction"}, {"end": 151, "start": 127, "tag": "PathologicFunction"}, {"end": 52, "start": 48, "tag": "Cell"}, {"end": 114, "start": 109, "tag": "InjuryOrPoisoning"}, {"end": 114, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 138, "tag": "ExperimentalModelOfDisease"}, {"end": 122, "start": 99, "tag": "ExperimentalModelOfDisease"}, {"end": 151, "start": 127, "tag": "ExperimentalModelOfDisease"}, {"end": 108, "start": 99, "tag": "ExperimentalModelOfDisease"}]}{"id": "1320_2", "text": "However, since evidence remains controversial, the therapeutic potential of IGF-1 in demyelinating CNS conditions is unclear.", "tags": [{"end": 81, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 81, "start": 76, "tag": "GeneOrGenome"}, {"end": 81, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 15, "tag": "Finding"}, {"end": 72, "start": 51, "tag": "HealthCareActivity"}, {"end": 113, "start": 85, "tag": "DiseaseOrSyndrome"}]}{"id": "1320_3", "text": "To finally shed light on the function of IGF1-signaling for ODCs, we deleted insulin-like growth factor 1 receptor (IGF1R) specifically in mature ODCs of the mouse.", "tags": [{"end": 114, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 116, "tag": "GeneOrGenome"}, {"end": 55, "start": 41, "tag": "CellFunction"}, {"end": 145, "start": 139, "tag": "TemporalConcept"}, {"end": 21, "start": 16, "tag": "NaturalPhenomenonOrProcess"}, {"end": 163, "start": 158, "tag": "Eukaryote"}, {"end": 64, "start": 60, "tag": "Cell"}, {"end": 150, "start": 146, "tag": "Cell"}]}{"id": "1320_4", "text": "We found that ODC survival and myelin status were unaffected by the absence of IGF1R until 15 months of age, indicating that IGF-1 signaling does not play a major role in post-mitotic ODCs during homeostasis.", "tags": [{"end": 17, "start": 14, "tag": "Cell"}, {"end": 84, "start": 79, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 79, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 79, "tag": "GeneOrGenome"}, {"end": 130, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 130, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 125, "tag": "GeneOrGenome"}, {"end": 100, "start": 94, "tag": "TemporalConcept"}, {"end": 183, "start": 171, "tag": "TemporalConcept"}, {"end": 37, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 140, "start": 125, "tag": "CellFunction"}, {"end": 107, "start": 104, "tag": "OrganismAttribute"}, {"end": 26, "start": 18, "tag": "CellFunction"}, {"end": 207, "start": 196, "tag": "BiologicFunction"}, {"end": 44, "start": 38, "tag": "Finding"}, {"end": 75, "start": 68, "tag": "Finding"}, {"end": 188, "start": 184, "tag": "Cell"}]}{"id": "1320_5", "text": "Notably, the absence of IGF1R did neither affect ODC survival nor myelin status upon cuprizone intoxication or induction of experimental autoimmune encephalomyelitis (EAE), models for toxic and autoimmune demyelination, respectively.", "tags": [{"end": 29, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 24, "tag": "GeneOrGenome"}, {"end": 52, "start": 49, "tag": "Cell"}, {"end": 107, "start": 95, "tag": "Finding"}, {"end": 120, "start": 111, "tag": "HealthCareActivity"}, {"end": 120, "start": 111, "tag": "HealthCareRelatedOrganization"}, {"end": 179, "start": 173, "tag": "ExperimentalModelOfDisease"}, {"end": 165, "start": 124, "tag": "ExperimentalModelOfDisease"}, {"end": 170, "start": 167, "tag": "ExperimentalModelOfDisease"}, {"end": 72, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 85, "tag": "Chemical"}, {"end": 189, "start": 184, "tag": "InjuryOrPoisoning"}, {"end": 61, "start": 53, "tag": "CellFunction"}, {"end": 79, "start": 73, "tag": "Finding"}, {"end": 218, "start": 194, "tag": "PathologicFunction"}, {"end": 20, "start": 13, "tag": "Finding"}]}{"id": "1320_6", "text": "Surprisingly, however, the absence of IGF1R from ODCs protected against clinical neuroinflammation in the EAE model.", "tags": [{"end": 43, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 115, "start": 106, "tag": "ExperimentalModelOfDisease"}, {"end": 98, "start": 81, "tag": "PathologicFunction"}, {"end": 34, "start": 27, "tag": "Finding"}, {"end": 53, "start": 49, "tag": "Cell"}]}{"id": "1320_7", "text": "Together, our data indicate that IGF-1 signaling is not required for the function and survival of mature ODCs in steady-state and disease.", "tags": [{"end": 38, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 33, "tag": "GeneOrGenome"}, {"end": 125, "start": 113, "tag": "NaturalPhenomenonOrProcess"}, {"end": 48, "start": 33, "tag": "CellFunction"}, {"end": 104, "start": 98, "tag": "TemporalConcept"}, {"end": 94, "start": 86, "tag": "CellFunction"}, {"end": 18, "start": 14, "tag": "ResearchActivity"}, {"end": 109, "start": 105, "tag": "Cell"}]}{"id": "1321_0", "text": "Multiple sclerosis (MS) is an inflammatory, demyelinating, and neurodegenerative disease of the central nervous system (CNS) triggered by autoimmune mechanisms.", "tags": [{"end": 159, "start": 138, "tag": "PathologicFunction"}, {"end": 123, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 44, "tag": "PathologicFunction"}, {"end": 88, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 30, "tag": "PathologicFunction"}]}{"id": "1321_1", "text": "Microglia are critical for the clearance of myelin debris in areas of demyelination, a key step to allow remyelination.", "tags": [{"end": 40, "start": 31, "tag": "NaturalPhenomenonOrProcess"}, {"end": 118, "start": 105, "tag": "CellFunction"}, {"end": 57, "start": 51, "tag": "Substance"}, {"end": 9, "start": 0, "tag": "Cell"}, {"end": 83, "start": 70, "tag": "PathologicFunction"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1321_2", "text": "TREM2 is expressed by microglia and promotes microglial survival, proliferation, and phagocytic activity.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 64, "start": 56, "tag": "CellFunction"}, {"end": 79, "start": 66, "tag": "CellFunction"}, {"end": 55, "start": 45, "tag": "Cell"}, {"end": 18, "start": 9, "tag": "CellFunction"}, {"end": 31, "start": 22, "tag": "Cell"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 85, "tag": "CellFunction"}]}{"id": "1321_3", "text": "Herein we demonstrate that TREM2 was highly expressed on myelin-laden phagocytes in active demyelinating lesions in the CNS of subjects with MS.", "tags": [{"end": 32, "start": 27, "tag": "GeneOrGenome"}, {"end": 80, "start": 57, "tag": "Cell"}, {"end": 123, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 44, "tag": "CellFunction"}, {"end": 112, "start": 84, "tag": "InjuryOrPoisoning"}, {"end": 63, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 127, "tag": "PopulationGroup"}, {"end": 32, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 27, "tag": "BiologicallyActiveSubstance"}]}{"id": "1321_4", "text": "In gene expression studies, macrophages from subjects with TREM2 genetic deficiency displayed a defect in phagocytic pathways.", "tags": [{"end": 64, "start": 59, "tag": "GeneOrGenome"}, {"end": 18, "start": 3, "tag": "CellFunction"}, {"end": 39, "start": 28, "tag": "Cell"}, {"end": 83, "start": 59, "tag": "CellOrMolecularDysfunction"}, {"end": 26, "start": 19, "tag": "ResearchActivity"}, {"end": 53, "start": 45, "tag": "PopulationGroup"}, {"end": 64, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 64, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 96, "tag": "CellOrMolecularDysfunction"}]}{"id": "1321_5", "text": "Treatment with a new TREM2 agonistic antibody promoted the clearance of myelin debris in the cuprizone model of CNS demyelination.", "tags": [{"end": 26, "start": 21, "tag": "GeneOrGenome"}, {"end": 115, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 59, "tag": "NaturalPhenomenonOrProcess"}, {"end": 85, "start": 79, "tag": "Substance"}, {"end": 102, "start": 93, "tag": "Chemical"}, {"end": 129, "start": 116, "tag": "PathologicFunction"}, {"end": 78, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 26, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 26, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 93, "tag": "ExperimentalModelOfDisease"}, {"end": 45, "start": 27, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1321_6", "text": "Effects included enhancement of myelin uptake and degradation, resulting in accelerated myelin debris removal by microglia.", "tags": [{"end": 28, "start": 17, "tag": "Finding"}, {"end": 45, "start": 32, "tag": "CellFunction"}, {"end": 61, "start": 50, "tag": "CellFunction"}, {"end": 38, "start": 32, "tag": "CellFunction"}, {"end": 101, "start": 95, "tag": "Substance"}, {"end": 38, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 113, "tag": "Cell"}, {"end": 109, "start": 88, "tag": "CellFunction"}]}{"id": "1321_7", "text": "Most importantly, antibody-dependent TREM2 activation on microglia increased density of oligodendrocyte precursors in areas of demyelination, as well as the formation of mature oligodendrocytes thus enhancing remyelination and axonal integrity.", "tags": [{"end": 53, "start": 18, "tag": "CellFunction"}, {"end": 42, "start": 37, "tag": "GeneOrGenome"}, {"end": 193, "start": 157, "tag": "CellFunction"}, {"end": 222, "start": 209, "tag": "CellFunction"}, {"end": 193, "start": 170, "tag": "Cell"}, {"end": 84, "start": 67, "tag": "Finding"}, {"end": 114, "start": 88, "tag": "Cell"}, {"end": 140, "start": 127, "tag": "PathologicFunction"}, {"end": 66, "start": 57, "tag": "Cell"}, {"end": 42, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 243, "start": 227, "tag": "CellFunction"}]}{"id": "1321_8", "text": "These results are relevant as they propose TREM2 on microglia as a potential new target to promote remyelination.", "tags": [{"end": 48, "start": 43, "tag": "GeneOrGenome"}, {"end": 112, "start": 99, "tag": "CellFunction"}, {"end": 61, "start": 52, "tag": "Cell"}, {"end": 48, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 43, "tag": "BiologicallyActiveSubstance"}]}{"id": "1322_0", "text": "Fetal alcohol spectrum disorders (FASD) are alarmingly common, result in significant personal and so-cietal loss, and there are no effective treatments for these disorders.", "tags": [{"end": 38, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 34, "tag": "AnatomicalAbnormality"}, {"end": 93, "start": 85, "tag": "OrganismAttribute"}, {"end": 151, "start": 141, "tag": "HealthCareActivity"}, {"end": 151, "start": 141, "tag": "ResearchActivity"}, {"end": 32, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 0, "tag": "AnatomicalAbnormality"}]}{"id": "1322_1", "text": "Cerebellar neuropathology common in FASD and can cause impaired cognitive and motor function.", "tags": [{"end": 10, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 36, "tag": "AnatomicalAbnormality"}, {"end": 92, "start": 78, "tag": "BiologicFunction"}, {"end": 25, "start": 11, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 25, "start": 11, "tag": "PathologicFunction"}]}{"id": "1322_2", "text": "The current study evaluates the effects of ethanol on oligodendrocyte-lineage cells, as well as molecules that modulate oligodendrocyte differentiation and function in the cerebellum in a postnatal mouse model of FASD.", "tags": [{"end": 42, "start": 32, "tag": "PathologicFunction"}, {"end": 50, "start": 43, "tag": "Chemical"}, {"end": 50, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 182, "start": 172, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 197, "start": 188, "tag": "TemporalConcept"}, {"end": 217, "start": 213, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 213, "tag": "AnatomicalAbnormality"}, {"end": 105, "start": 96, "tag": "Substance"}, {"end": 135, "start": 120, "tag": "Cell"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 83, "start": 54, "tag": "Cell"}, {"end": 203, "start": 198, "tag": "Eukaryote"}, {"end": 209, "start": 204, "tag": "ResearchActivity"}, {"end": 151, "start": 136, "tag": "CellFunction"}, {"end": 11, "start": 4, "tag": "TemporalConcept"}]}{"id": "1322_3", "text": "Neonatal mice were treated with ethanol from P4-P9 (postnatal day), the cerebellum was isolated at P10, and mRNAs encoding oligodendrocyte-associated molecules were quantitated by qRT-PCR.", "tags": [{"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 39, "start": 32, "tag": "Chemical"}, {"end": 39, "start": 32, "tag": "PharmacologicSubstance"}, {"end": 65, "start": 52, "tag": "TemporalConcept"}, {"end": 82, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 99, "tag": "TemporalConcept"}, {"end": 159, "start": 150, "tag": "Substance"}, {"end": 113, "start": 108, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 122, "start": 114, "tag": "BiologicFunction"}, {"end": 138, "start": 123, "tag": "Cell"}, {"end": 187, "start": 180, "tag": "ResearchActivity"}, {"end": 13, "start": 9, "tag": "Eukaryote"}, {"end": 50, "start": 45, "tag": "TemporalConcept"}]}{"id": "1322_4", "text": "Our studies demonstrated that ethanol significantly reduced the expression of markers for multiple stages of oligodendrocyte maturation, including oligodendrocyte precursor cells, pre-myelinating oligodendrocytes, and mature myelinating oligodendrocytes.", "tags": [{"end": 37, "start": 30, "tag": "Chemical"}, {"end": 37, "start": 30, "tag": "PharmacologicSubstance"}, {"end": 105, "start": 99, "tag": "TemporalConcept"}, {"end": 212, "start": 196, "tag": "Cell"}, {"end": 253, "start": 218, "tag": "Cell"}, {"end": 124, "start": 109, "tag": "Cell"}, {"end": 135, "start": 125, "tag": "BiologicFunction"}, {"end": 178, "start": 147, "tag": "Cell"}, {"end": 212, "start": 180, "tag": "Cell"}, {"end": 11, "start": 4, "tag": "ResearchActivity"}]}{"id": "1322_5", "text": "Additionally, we determined that ethanol significantly decreased the expression of molecules that play critical roles in oligodendrocyte differentiation.", "tags": [{"end": 40, "start": 33, "tag": "Chemical"}, {"end": 40, "start": 33, "tag": "PharmacologicSubstance"}, {"end": 92, "start": 83, "tag": "Substance"}, {"end": 136, "start": 121, "tag": "Cell"}, {"end": 152, "start": 137, "tag": "CellFunction"}]}{"id": "1322_6", "text": "Interestingly, we also observed that ethanol significantly reduced the expression of myelin-associated inhibitors, which may act as a compensatory mechanism to ethanol toxicity.", "tags": [{"end": 44, "start": 37, "tag": "Chemical"}, {"end": 44, "start": 37, "tag": "PharmacologicSubstance"}, {"end": 167, "start": 160, "tag": "Chemical"}, {"end": 167, "start": 160, "tag": "PharmacologicSubstance"}, {"end": 176, "start": 168, "tag": "InjuryOrPoisoning"}, {"end": 91, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 103, "tag": "Chemical"}]}{"id": "1322_7", "text": "Furthermore, we demonstrate that ethanol alters the expression of a variety of molecules important in oligodendrocyte function and myelination.", "tags": [{"end": 40, "start": 33, "tag": "Chemical"}, {"end": 40, "start": 33, "tag": "PharmacologicSubstance"}, {"end": 88, "start": 79, "tag": "Substance"}, {"end": 142, "start": 131, "tag": "CellFunction"}, {"end": 126, "start": 102, "tag": "CellFunction"}]}{"id": "1322_8", "text": "Collectively, our studies increase our understanding of specific mechanisms by which ethanol modulates myelination in the developing cerebellum, and potentially identify novel targets for FASD therapy.", "tags": [{"end": 92, "start": 85, "tag": "Chemical"}, {"end": 92, "start": 85, "tag": "PharmacologicSubstance"}, {"end": 143, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 39, "tag": "BiologicFunction"}, {"end": 114, "start": 103, "tag": "CellFunction"}, {"end": 25, "start": 18, "tag": "ResearchActivity"}, {"end": 200, "start": 193, "tag": "HealthCareActivity"}, {"end": 192, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 188, "tag": "AnatomicalAbnormality"}]}{"id": "1322_9", "text": "(c) 2021 Elsevier Inc.", "tags": []}{"id": "1322_10", "text": "All rights reserved.", "tags": []}{"id": "1323_0", "text": "Background and purpose Research on demyelinating disorders aims to find novel molecules that are able to induce oligodendrocyte precursor cell differentiation to promote central nervous system remyelination and functional recovery.", "tags": [{"end": 230, "start": 211, "tag": "SignOrSymptom"}, {"end": 142, "start": 112, "tag": "Cell"}, {"end": 31, "start": 23, "tag": "ResearchActivity"}, {"end": 58, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 78, "tag": "Substance"}, {"end": 230, "start": 222, "tag": "BiologicFunction"}, {"end": 230, "start": 222, "tag": "HealthCareActivity"}, {"end": 230, "start": 222, "tag": "TemporalConcept"}, {"end": 206, "start": 193, "tag": "CellFunction"}, {"end": 158, "start": 138, "tag": "CellFunction"}]}{"id": "1323_1", "text": "Delta(9)-Tetrahydrocannabinol (THC), the most prominent active constituent of the hemp plant Cannabis sativa, confers neuroprotection in animal models of demyelination.", "tags": [{"end": 29, "start": 0, "tag": "Chemical"}, {"end": 34, "start": 31, "tag": "Chemical"}, {"end": 86, "start": 82, "tag": "Chemical"}, {"end": 108, "start": 93, "tag": "Organism"}, {"end": 133, "start": 118, "tag": "CellFunction"}, {"end": 167, "start": 154, "tag": "PathologicFunction"}, {"end": 150, "start": 137, "tag": "ResearchActivity"}, {"end": 92, "start": 87, "tag": "Organism"}]}{"id": "1323_2", "text": "However, the possible effect of THC on myelin repair has never been studied.", "tags": [{"end": 35, "start": 32, "tag": "Chemical"}, {"end": 45, "start": 39, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 39, "tag": "CellFunction"}, {"end": 28, "start": 22, "tag": "Finding"}, {"end": 52, "start": 46, "tag": "BiologicFunction"}, {"end": 52, "start": 46, "tag": "HealthCareActivity"}]}{"id": "1323_3", "text": "Experimental approach By using oligodendroglia-specific reporter mouse lines in combination with two models of toxin-induced demyelination, we analysed the effect of THC on the processes of oligodendrocyte regeneration and functional remyelination.", "tags": [{"end": 169, "start": 166, "tag": "Chemical"}, {"end": 218, "start": 206, "tag": "BiologicFunction"}, {"end": 46, "start": 31, "tag": "Cell"}, {"end": 218, "start": 206, "tag": "HealthCareActivity"}, {"end": 107, "start": 101, "tag": "ResearchActivity"}, {"end": 162, "start": 156, "tag": "Finding"}, {"end": 70, "start": 65, "tag": "Eukaryote"}, {"end": 205, "start": 190, "tag": "Cell"}, {"end": 247, "start": 234, "tag": "CellFunction"}, {"end": 138, "start": 125, "tag": "PathologicFunction"}, {"end": 76, "start": 31, "tag": "ResearchActivity"}, {"end": 21, "start": 0, "tag": "ResearchActivity"}, {"end": 138, "start": 101, "tag": "ExperimentalModelOfDisease"}, {"end": 116, "start": 111, "tag": "InjuryOrPoisoning"}, {"end": 116, "start": 111, "tag": "BiologicallyActiveSubstance"}]}{"id": "1323_4", "text": "Key results We show that THC administration enhanced oligodendrocyte regeneration, white matter remyelination and motor function recovery.", "tags": [{"end": 28, "start": 25, "tag": "Chemical"}, {"end": 81, "start": 69, "tag": "BiologicFunction"}, {"end": 95, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 114, "tag": "BiologicFunction"}, {"end": 81, "start": 69, "tag": "HealthCareActivity"}, {"end": 68, "start": 53, "tag": "Cell"}, {"end": 137, "start": 129, "tag": "BiologicFunction"}, {"end": 137, "start": 129, "tag": "HealthCareActivity"}, {"end": 137, "start": 129, "tag": "TemporalConcept"}, {"end": 109, "start": 96, "tag": "CellFunction"}]}{"id": "1323_5", "text": "THC also promoted axonal remyelination in organotypic cerebellar cultures.", "tags": [{"end": 3, "start": 0, "tag": "Chemical"}, {"end": 73, "start": 65, "tag": "ResearchActivity"}, {"end": 53, "start": 42, "tag": "ResearchActivity"}, {"end": 64, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 18, "tag": "CellComponent"}, {"end": 38, "start": 25, "tag": "CellFunction"}]}{"id": "1323_6", "text": "THC remyelinating action relied on the induction of oligodendrocyte precursor differentiation upon cell cycle exit and via CB1 cannabinoid receptor activation.", "tags": [{"end": 3, "start": 0, "tag": "Chemical"}, {"end": 48, "start": 39, "tag": "HealthCareActivity"}, {"end": 147, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 78, "tag": "CellFunction"}, {"end": 17, "start": 4, "tag": "CellFunction"}, {"end": 77, "start": 52, "tag": "Cell"}, {"end": 147, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 39, "tag": "CellFunction"}, {"end": 114, "start": 99, "tag": "CellFunction"}, {"end": 158, "start": 148, "tag": "CellFunction"}]}{"id": "1323_7", "text": "Conclusions and implications Overall, our study identifies THC administration as a promising pharmacological strategy aimed to promote functional CNS remyelination in demyelinating disorders.", "tags": [{"end": 62, "start": 59, "tag": "Chemical"}, {"end": 190, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 42, "tag": "ResearchActivity"}, {"end": 149, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 150, "tag": "CellFunction"}, {"end": 117, "start": 93, "tag": "HealthCareActivity"}]}{"id": "1324_0", "text": "Demyelinating disorders of the central nervous system (CNS) occur when myelin and oligodendrocytes are damaged or lost.", "tags": [{"end": 98, "start": 82, "tag": "Cell"}, {"end": 77, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1324_1", "text": "Remyelina-tion and regeneration of oligodendrocytes can be achieved from endogenous oligodendrocyte precursor cells (OPCs) that reside in the adult CNS tissue.", "tags": [{"end": 51, "start": 35, "tag": "Cell"}, {"end": 121, "start": 117, "tag": "Cell"}, {"end": 115, "start": 84, "tag": "Cell"}, {"end": 31, "start": 19, "tag": "BiologicFunction"}, {"end": 115, "start": 100, "tag": "Cell"}, {"end": 109, "start": 84, "tag": "Cell"}, {"end": 31, "start": 19, "tag": "HealthCareActivity"}, {"end": 151, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 142, "tag": "PopulationGroup"}]}{"id": "1324_2", "text": "Using a cuprizone mouse model of demyelination, we show that infusion of fractalkine (CX3CL1) into the demyeli-nated murine brain increases de novo oligodendrocyte formation and enhances remyelination in the corpus callosum and cortical gray matter.", "tags": [{"end": 69, "start": 61, "tag": "HealthCareActivity"}, {"end": 69, "start": 61, "tag": "TemporalConcept"}, {"end": 84, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 84, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 86, "tag": "GeneOrGenome"}, {"end": 92, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 248, "start": 237, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 223, "start": 208, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 8, "tag": "Chemical"}, {"end": 129, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 117, "tag": "Eukaryote"}, {"end": 236, "start": 228, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 148, "tag": "Cell"}, {"end": 200, "start": 187, "tag": "CellFunction"}, {"end": 46, "start": 33, "tag": "PathologicFunction"}, {"end": 29, "start": 18, "tag": "ResearchActivity"}, {"end": 173, "start": 140, "tag": "CellFunction"}, {"end": 123, "start": 117, "tag": "Eukaryote"}]}{"id": "1324_3", "text": "This is achieved by increased OPC proliferation in the cortical gray matter as well as OPC differentiation and attenuation of microglia/macrophage activation both in corpus callosum and cortical gray matter.", "tags": [{"end": 75, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 206, "start": 195, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 30, "tag": "Cell"}, {"end": 90, "start": 87, "tag": "Cell"}, {"end": 106, "start": 91, "tag": "CellFunction"}, {"end": 106, "start": 87, "tag": "CellFunction"}, {"end": 47, "start": 34, "tag": "CellFunction"}, {"end": 181, "start": 166, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 135, "start": 126, "tag": "Cell"}, {"end": 63, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 194, "start": 186, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 157, "start": 136, "tag": "CellFunction"}]}{"id": "1324_4", "text": "Finally, we show that activated OPCs and micro-glia/macrophages express fractalkine receptor CX3CR1 in vivo, and that in OPC-microglia co-cultures fractalkine increases in vitro oligo-dendrocyte differentiation by modulating both OPC and microglia biology.", "tags": [{"end": 92, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 64, "tag": "CellFunction"}, {"end": 146, "start": 135, "tag": "ResearchActivity"}, {"end": 146, "start": 138, "tag": "ResearchActivity"}, {"end": 36, "start": 22, "tag": "Cell"}, {"end": 124, "start": 121, "tag": "Cell"}, {"end": 233, "start": 230, "tag": "Cell"}, {"end": 210, "start": 178, "tag": "CellFunction"}, {"end": 63, "start": 52, "tag": "Cell"}, {"end": 134, "start": 125, "tag": "Cell"}, {"end": 247, "start": 238, "tag": "Cell"}, {"end": 177, "start": 169, "tag": "ResearchActivity"}, {"end": 51, "start": 41, "tag": "Cell"}, {"end": 255, "start": 248, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 107, "start": 100, "tag": "ResearchActivity"}, {"end": 255, "start": 248, "tag": "BiologicFunction"}, {"end": 92, "start": 72, "tag": "BiologicallyActiveSubstance"}]}{"id": "1324_5", "text": "Our results demonstrate a novel pro-regenerative role of frac-talkine in a demyelinating mouse model.", "tags": [{"end": 88, "start": 75, "tag": "PathologicFunction"}, {"end": 100, "start": 89, "tag": "ResearchActivity"}, {"end": 69, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 100, "start": 75, "tag": "ExperimentalModelOfDisease"}]}{"id": "1325_0", "text": "It is widely thought that brain repair does not occur, but myelin regeneration provides clear evidence to the contrary.", "tags": [{"end": 38, "start": 26, "tag": "HealthCareActivity"}, {"end": 65, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 66, "tag": "BiologicFunction"}, {"end": 78, "start": 66, "tag": "HealthCareActivity"}, {"end": 78, "start": 59, "tag": "CellFunction"}, {"end": 102, "start": 94, "tag": "Finding"}, {"end": 38, "start": 32, "tag": "BiologicFunction"}]}{"id": "1325_1", "text": "Spontaneous remyelination may occur after injury or in multiple sclerosis (MS).", "tags": [{"end": 73, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 48, "start": 42, "tag": "InjuryOrPoisoning"}, {"end": 25, "start": 0, "tag": "CellFunction"}, {"end": 77, "start": 75, "tag": "DiseaseOrSyndrome"}]}{"id": "1325_2", "text": "However, the efficiency of remyelination varies considerably between MS patients and between the lesions of each patient.", "tags": [{"end": 104, "start": 97, "tag": "InjuryOrPoisoning"}, {"end": 23, "start": 13, "tag": "Finding"}, {"end": 80, "start": 72, "tag": "PatientOrDisabledGroup"}, {"end": 120, "start": 113, "tag": "PatientOrDisabledGroup"}, {"end": 40, "start": 27, "tag": "CellFunction"}, {"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}]}{"id": "1325_3", "text": "Myelin repair is essential for optimal functional recovery, so a profound understanding of the cells and mechanisms involved in this process is required for the development of new therapeutic strategies.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 161, "tag": "BiologicFunction"}, {"end": 172, "start": 161, "tag": "CellFunction"}, {"end": 100, "start": 95, "tag": "Cell"}, {"end": 202, "start": 192, "tag": "ResearchActivity"}, {"end": 202, "start": 192, "tag": "BiologicFunction"}, {"end": 87, "start": 74, "tag": "BiologicFunction"}, {"end": 58, "start": 50, "tag": "BiologicFunction"}, {"end": 58, "start": 50, "tag": "HealthCareActivity"}, {"end": 58, "start": 50, "tag": "TemporalConcept"}, {"end": 13, "start": 7, "tag": "BiologicFunction"}, {"end": 13, "start": 7, "tag": "HealthCareActivity"}, {"end": 202, "start": 180, "tag": "HealthCareActivity"}]}{"id": "1325_4", "text": "In this review, we describe how animal models and modern cell tracing and imaging methods have helped to identify the cell types involved in myelin regeneration.", "tags": [{"end": 147, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 160, "start": 148, "tag": "BiologicFunction"}, {"end": 81, "start": 74, "tag": "HealthCareActivity"}, {"end": 160, "start": 148, "tag": "HealthCareActivity"}, {"end": 160, "start": 141, "tag": "CellFunction"}, {"end": 61, "start": 57, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 45, "start": 32, "tag": "ResearchActivity"}, {"end": 128, "start": 118, "tag": "Cell"}, {"end": 89, "start": 82, "tag": "ResearchActivity"}, {"end": 69, "start": 57, "tag": "ResearchActivity"}, {"end": 89, "start": 74, "tag": "ResearchActivity"}]}{"id": "1325_5", "text": "In addition to the oligodendrocyte progenitor cells identified in the 1990s as the principal source of remyelinating cells in the central nervous system (CNS), other cell populations, including subventricular zone-derived neural progenitors, Schwann cells, and even spared mature oligodendrocytes, have more recently emerged as potential contributors to CNS remyelination.", "tags": [{"end": 255, "start": 242, "tag": "Cell"}, {"end": 296, "start": 273, "tag": "Cell"}, {"end": 51, "start": 19, "tag": "Cell"}, {"end": 51, "start": 35, "tag": "Cell"}, {"end": 116, "start": 103, "tag": "CellFunction"}, {"end": 213, "start": 194, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 157, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 357, "start": 354, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 117, "tag": "Cell"}, {"end": 316, "start": 308, "tag": "TemporalConcept"}, {"end": 371, "start": 358, "tag": "CellFunction"}, {"end": 182, "start": 166, "tag": "Cell"}, {"end": 240, "start": 222, "tag": "Cell"}]}{"id": "1325_6", "text": "We will also highlight the conditions known to limit endogenous repair, such as aging, chronic inflammation, and the production of extracellular matrix proteins, and the role of astrocytes and microglia in these processes.", "tags": [{"end": 160, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 87, "tag": "PathologicFunction"}, {"end": 151, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 95, "tag": "PathologicFunction"}, {"end": 160, "start": 152, "tag": "AminoAcidPeptideOrProtein"}, {"end": 202, "start": 193, "tag": "Cell"}, {"end": 188, "start": 178, "tag": "Cell"}, {"end": 85, "start": 80, "tag": "BiologicFunction"}, {"end": 85, "start": 80, "tag": "CellFunction"}, {"end": 70, "start": 64, "tag": "BiologicFunction"}, {"end": 70, "start": 64, "tag": "HealthCareActivity"}, {"end": 94, "start": 87, "tag": "TemporalConcept"}]}{"id": "1325_7", "text": "Finally, we will present the discrepancies between observations in humans and in rodents, discussing the relationship of findings in experimental models to myelin repair in humans.", "tags": [{"end": 42, "start": 29, "tag": "Finding"}, {"end": 73, "start": 67, "tag": "Eukaryote"}, {"end": 179, "start": 173, "tag": "Eukaryote"}, {"end": 88, "start": 81, "tag": "Eukaryote"}, {"end": 117, "start": 105, "tag": "Finding"}, {"end": 162, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 169, "start": 156, "tag": "CellFunction"}, {"end": 63, "start": 51, "tag": "Finding"}, {"end": 152, "start": 133, "tag": "ResearchActivity"}, {"end": 169, "start": 163, "tag": "BiologicFunction"}, {"end": 169, "start": 163, "tag": "HealthCareActivity"}]}{"id": "1325_8", "text": "These considerations are particularly important from a therapeutic standpoint.", "tags": [{"end": 20, "start": 6, "tag": "Finding"}]}{"id": "1326_0", "text": "Neurotropic strains of mouse hepatitis virus (MHV), a coronavirus, cause acute and chronic demyelinating encephalomyelitis with similarities to the human disease multiple sclerosis.", "tags": [{"end": 44, "start": 23, "tag": "Virus"}, {"end": 49, "start": 46, "tag": "Virus"}, {"end": 65, "start": 54, "tag": "Virus"}, {"end": 104, "start": 91, "tag": "PathologicFunction"}, {"end": 180, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 73, "tag": "TemporalConcept"}, {"end": 153, "start": 148, "tag": "Eukaryote"}, {"end": 90, "start": 83, "tag": "TemporalConcept"}, {"end": 11, "start": 0, "tag": "PathologicFunction"}, {"end": 19, "start": 12, "tag": "Organism"}, {"end": 122, "start": 105, "tag": "DiseaseOrSyndrome"}]}{"id": "1326_1", "text": "Here, using a lineage -tracking system, we show that some cells, primarily oligo- dendrocytes (OLs) and oligodendrocyte precursor cells (OPCs), survive the acute MHV infection, are associated with regions of demyelination, and persist in the central nervous system (CNS) for at least 150 d.", "tags": [{"end": 165, "start": 162, "tag": "Virus"}, {"end": 141, "start": 137, "tag": "Cell"}, {"end": 135, "start": 104, "tag": "Cell"}, {"end": 98, "start": 95, "tag": "Cell"}, {"end": 161, "start": 156, "tag": "TemporalConcept"}, {"end": 264, "start": 242, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 269, "start": 266, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 58, "tag": "Cell"}, {"end": 175, "start": 166, "tag": "PathologicFunction"}, {"end": 221, "start": 208, "tag": "PathologicFunction"}, {"end": 38, "start": 14, "tag": "ResearchActivity"}, {"end": 93, "start": 75, "tag": "Cell"}]}{"id": "1326_2", "text": "These surviving OLs express major histocompatibility complex (MHC) class I and other genes associated with an inflammatory response.", "tags": [{"end": 65, "start": 62, "tag": "GeneOrGenome"}, {"end": 65, "start": 62, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 20, "tag": "CellFunction"}, {"end": 19, "start": 16, "tag": "Cell"}, {"end": 131, "start": 110, "tag": "PathologicFunction"}, {"end": 74, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 62, "tag": "BiologicallyActiveSubstance"}]}{"id": "1326_3", "text": "Notably, the extent of inflammatory cell infiltration was variable, dependent on anatomic location within the CNS, and without obvious correlation with numbers of surviving cells.", "tags": [{"end": 35, "start": 23, "tag": "PathologicFunction"}, {"end": 113, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 178, "start": 173, "tag": "Cell"}, {"end": 40, "start": 36, "tag": "Cell"}, {"end": 98, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1326_4", "text": "We detected more demyelination in regions with larger numbers of T cells and microglia/macrophages compared to those with fewer infiltrating cells.", "tags": [{"end": 72, "start": 65, "tag": "Cell"}, {"end": 98, "start": 87, "tag": "Cell"}, {"end": 146, "start": 128, "tag": "Cell"}, {"end": 86, "start": 77, "tag": "Cell"}, {"end": 30, "start": 17, "tag": "PathologicFunction"}]}{"id": "1326_5", "text": "Conversely, in regions with less inflammation, these previously infected OLs more rapidly extended processes, consistent with normal myelinating function.", "tags": [{"end": 72, "start": 64, "tag": "PathologicFunction"}, {"end": 144, "start": 133, "tag": "CellFunction"}, {"end": 76, "start": 73, "tag": "Cell"}, {"end": 45, "start": 33, "tag": "PathologicFunction"}, {"end": 132, "start": 126, "tag": "Finding"}]}{"id": "1326_6", "text": "Together, these results show that OLs are inducers as well as targets of the host immune response and demonstrate how a CNS infection, even after resolution, can induce prolonged inflammatory changes with CNS region-dependent impairment in remyelination.", "tags": [{"end": 97, "start": 82, "tag": "BiologicFunction"}, {"end": 133, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 146, "tag": "PathologicFunction"}, {"end": 81, "start": 77, "tag": "Organism"}, {"end": 178, "start": 169, "tag": "TemporalConcept"}, {"end": 37, "start": 34, "tag": "Cell"}, {"end": 191, "start": 179, "tag": "PathologicFunction"}, {"end": 123, "start": 120, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 124, "tag": "PathologicFunction"}, {"end": 253, "start": 240, "tag": "CellFunction"}, {"end": 253, "start": 226, "tag": "CellOrMolecularDysfunction"}, {"end": 199, "start": 192, "tag": "Finding"}]}{"id": "1327_0", "text": "Myelin is an essential structure that protects axons, provides metabolic support to neurons and allows fast nerve transmission.", "tags": [{"end": 72, "start": 63, "tag": "CellFunction"}, {"end": 52, "start": 47, "tag": "CellComponent"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 114, "tag": "Finding"}, {"end": 91, "start": 84, "tag": "Cell"}]}{"id": "1327_1", "text": "Several neurological diseases, such as multiple sclerosis, are characterized by myelin damage, which is responsible of severe functional impairment.", "tags": [{"end": 57, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 119, "tag": "Finding"}, {"end": 29, "start": 8, "tag": "DiseaseOrSyndrome"}]}{"id": "1327_2", "text": "Myelin repair requires the timely recruitment of adult oligodendrocyte precursor cells (OPCs) at the lesion sites, their differentiation and maturation into myelinating oligodendrocytes.", "tags": [{"end": 168, "start": 157, "tag": "CellFunction"}, {"end": 185, "start": 169, "tag": "Cell"}, {"end": 92, "start": 88, "tag": "Cell"}, {"end": 151, "start": 141, "tag": "BiologicFunction"}, {"end": 86, "start": 55, "tag": "Cell"}, {"end": 107, "start": 101, "tag": "InjuryOrPoisoning"}, {"end": 136, "start": 121, "tag": "CellFunction"}, {"end": 185, "start": 157, "tag": "Cell"}, {"end": 86, "start": 71, "tag": "Cell"}, {"end": 80, "start": 55, "tag": "Cell"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 49, "tag": "PopulationGroup"}, {"end": 13, "start": 7, "tag": "BiologicFunction"}, {"end": 13, "start": 7, "tag": "HealthCareActivity"}]}{"id": "1327_3", "text": "As a consequence, OPCs undergo profound changes in their morphology, functions, and interactions with other cells and extracellular environment, thus requiring the reorganization of both their lipid metabolism and their membrane composition, which is substantially different compared to other plasma membranes.", "tags": [{"end": 67, "start": 57, "tag": "OrganismAttribute"}, {"end": 309, "start": 293, "tag": "CellComponent"}, {"end": 22, "start": 18, "tag": "Cell"}, {"end": 228, "start": 220, "tag": "CellComponent"}, {"end": 309, "start": 300, "tag": "CellComponent"}, {"end": 299, "start": 293, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 108, "tag": "Cell"}, {"end": 209, "start": 199, "tag": "CellFunction"}, {"end": 209, "start": 199, "tag": "BiologicFunction"}, {"end": 131, "start": 118, "tag": "CellComponent"}, {"end": 198, "start": 193, "tag": "Chemical"}, {"end": 96, "start": 84, "tag": "Finding"}, {"end": 209, "start": 193, "tag": "CellFunction"}, {"end": 209, "start": 193, "tag": "BiologicFunction"}, {"end": 47, "start": 40, "tag": "Finding"}, {"end": 143, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1327_4", "text": "Despite the growing knowledge in oligodendroglia biology and in the mechanisms involved in OPC-mediated regeneration, the identification of strategies to promote remyelination still remains a challenge.", "tags": [{"end": 29, "start": 12, "tag": "Finding"}, {"end": 201, "start": 192, "tag": "HealthCareActivity"}, {"end": 94, "start": 91, "tag": "Cell"}, {"end": 116, "start": 104, "tag": "BiologicFunction"}, {"end": 48, "start": 33, "tag": "Cell"}, {"end": 116, "start": 104, "tag": "HealthCareActivity"}, {"end": 29, "start": 20, "tag": "Finding"}, {"end": 150, "start": 140, "tag": "ResearchActivity"}, {"end": 150, "start": 140, "tag": "BiologicFunction"}, {"end": 56, "start": 49, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 175, "start": 162, "tag": "CellFunction"}, {"end": 56, "start": 49, "tag": "BiologicFunction"}]}{"id": "1327_5", "text": "Here, we describe how altered lipid metabolism in oligodendrocytes influences the pathogenesis of demyelination, and we show that several FDA-approved drugs with a previously unknown remyelination potential do act on cholesterol and lipid biosynthetic pathways.", "tags": [{"end": 228, "start": 217, "tag": "Chemical"}, {"end": 228, "start": 217, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 50, "tag": "Cell"}, {"end": 94, "start": 82, "tag": "PathologicFunction"}, {"end": 46, "start": 36, "tag": "CellFunction"}, {"end": 46, "start": 36, "tag": "BiologicFunction"}, {"end": 156, "start": 151, "tag": "PharmacologicSubstance"}, {"end": 260, "start": 233, "tag": "CellFunction"}, {"end": 35, "start": 30, "tag": "Chemical"}, {"end": 238, "start": 233, "tag": "Chemical"}, {"end": 196, "start": 183, "tag": "CellFunction"}, {"end": 111, "start": 98, "tag": "PathologicFunction"}, {"end": 46, "start": 30, "tag": "CellFunction"}, {"end": 46, "start": 30, "tag": "BiologicFunction"}, {"end": 141, "start": 138, "tag": "HealthCareRelatedOrganization"}]}{"id": "1327_6", "text": "Since the interplay between myelin lipids and axons is strictly coordinated by the extracellular matrix (ECM), we also discuss the role of different ECM components, and report the last findings on new ECM-modifiers able to foster endogenous remyelination.", "tags": [{"end": 51, "start": 46, "tag": "CellComponent"}, {"end": 34, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 204, "start": 201, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 175, "start": 169, "tag": "HealthCareActivity"}, {"end": 175, "start": 169, "tag": "ResearchActivity"}, {"end": 41, "start": 35, "tag": "Chemical"}, {"end": 19, "start": 10, "tag": "Finding"}, {"end": 254, "start": 241, "tag": "CellFunction"}]}{"id": "1328_0", "text": "Neural and oligodendrocyte precursor cells (NPCs and OPCs) in the subventricular zone (SVZ) of the brain contribute to oligodendrogenesis throughout life, in part due to direct regulation by chemokines.", "tags": [{"end": 137, "start": 119, "tag": "BiologicFunction"}, {"end": 90, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 53, "tag": "Cell"}, {"end": 42, "start": 11, "tag": "Cell"}, {"end": 48, "start": 44, "tag": "Cell"}, {"end": 42, "start": 27, "tag": "Cell"}, {"end": 6, "start": 0, "tag": "Cell"}, {"end": 36, "start": 11, "tag": "Cell"}, {"end": 85, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 149, "tag": "TemporalConcept"}, {"end": 201, "start": 191, "tag": "AminoAcidPeptideOrProtein"}, {"end": 201, "start": 191, "tag": "BiologicallyActiveSubstance"}]}{"id": "1328_1", "text": "The role of the chemokine fractalkine is well established in microglia; however, the effect of fractalkine on SVZ precursor cells is unknown.", "tags": [{"end": 106, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 114, "tag": "Cell"}, {"end": 91, "start": 85, "tag": "Finding"}, {"end": 70, "start": 61, "tag": "Cell"}, {"end": 37, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 26, "tag": "BiologicallyActiveSubstance"}]}{"id": "1328_2", "text": "We show that murine SVZ NPCs and OPCs express the fractalkine receptor (CX3CR1) and bind fractalkine.", "tags": [{"end": 70, "start": 50, "tag": "AminoAcidPeptideOrProtein"}, {"end": 70, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 72, "tag": "GeneOrGenome"}, {"end": 100, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 38, "tag": "CellFunction"}, {"end": 23, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 28, "start": 24, "tag": "Cell"}, {"end": 19, "start": 13, "tag": "Eukaryote"}, {"end": 88, "start": 84, "tag": "CellFunction"}, {"end": 70, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 72, "tag": "BiologicallyActiveSubstance"}]}{"id": "1328_3", "text": "Exogenous fractalkine directly enhances OPC and oligodendrocyte genesis from SVZ NPCs in vitro.", "tags": [{"end": 21, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 80, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 40, "tag": "Cell"}, {"end": 85, "start": 81, "tag": "Cell"}, {"end": 94, "start": 86, "tag": "ResearchActivity"}, {"end": 63, "start": 48, "tag": "Cell"}, {"end": 71, "start": 48, "tag": "BiologicFunction"}]}{"id": "1328_4", "text": "Infusion of fractalkine into the lateral ventricle of adult NPC lineage-tracing mice leads to increased newborn OPC and oligodendrocyte formation in vivo.", "tags": [{"end": 8, "start": 0, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 23, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 60, "tag": "Cell"}, {"end": 115, "start": 112, "tag": "Cell"}, {"end": 111, "start": 104, "tag": "TemporalConcept"}, {"end": 84, "start": 80, "tag": "Eukaryote"}, {"end": 153, "start": 146, "tag": "ResearchActivity"}, {"end": 135, "start": 120, "tag": "Cell"}, {"end": 59, "start": 54, "tag": "PopulationGroup"}, {"end": 84, "start": 54, "tag": "ResearchActivity"}, {"end": 145, "start": 120, "tag": "BiologicFunction"}]}{"id": "1328_5", "text": "We also show that OPCs secrete fractalkine and that inhibition of endogenous fractalkine signaling reduces oligodendrocyte formation in vitro.", "tags": [{"end": 42, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 23, "tag": "CellFunction"}, {"end": 22, "start": 18, "tag": "Cell"}, {"end": 98, "start": 89, "tag": "CellFunction"}, {"end": 141, "start": 133, "tag": "ResearchActivity"}, {"end": 62, "start": 52, "tag": "CellFunction"}, {"end": 122, "start": 107, "tag": "Cell"}, {"end": 132, "start": 107, "tag": "BiologicFunction"}, {"end": 88, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 77, "tag": "BiologicallyActiveSubstance"}]}{"id": "1328_6", "text": "Finally, we show that fractalkine signaling regulates oligodendrogenesis in cerebellar slices ex vivo.", "tags": [{"end": 33, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 54, "tag": "BiologicFunction"}, {"end": 43, "start": 34, "tag": "CellFunction"}, {"end": 86, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 94, "tag": "ResearchActivity"}]}{"id": "1328_7", "text": "In summary, we demonstrate a novel role for fractalkine signaling in regulating oligodendrocyte genesis from postnatal CNS precursor cells.", "tags": [{"end": 55, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 65, "start": 56, "tag": "CellFunction"}, {"end": 138, "start": 123, "tag": "Cell"}, {"end": 118, "start": 109, "tag": "TemporalConcept"}, {"end": 122, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 80, "tag": "Cell"}, {"end": 103, "start": 80, "tag": "BiologicFunction"}]}{"id": "1329_0", "text": "The optic nerve represents one of the simplest regions of the CNS and has been useful in developing an understanding of glial development and myelination.", "tags": [{"end": 15, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 120, "tag": "Cell"}, {"end": 137, "start": 120, "tag": "CellFunction"}, {"end": 65, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 137, "start": 126, "tag": "BiologicFunction"}, {"end": 137, "start": 126, "tag": "CellFunction"}, {"end": 116, "start": 103, "tag": "BiologicFunction"}, {"end": 153, "start": 142, "tag": "CellFunction"}]}{"id": "1329_1", "text": "While the visual system is frequently affected in demyelinating conditions, utilizing the optic nerve to model demyelination/remyelination studies has been difficult due to its accessibility, relatively small size, and dense nature that makes direct injections challenging.", "tags": [{"end": 23, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 213, "start": 203, "tag": "OrganismAttribute"}, {"end": 260, "start": 250, "tag": "HealthCareActivity"}, {"end": 101, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 50, "tag": "PathologicFunction"}, {"end": 110, "start": 105, "tag": "ResearchActivity"}, {"end": 37, "start": 27, "tag": "TemporalConcept"}, {"end": 138, "start": 125, "tag": "CellFunction"}, {"end": 124, "start": 111, "tag": "PathologicFunction"}, {"end": 74, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 139, "tag": "ResearchActivity"}]}{"id": "1329_2", "text": "Taking advantage of the lack of oligodendrocytes and myelination in the mouse retina, we have developed a model in which the induction of apoptosis in mature oligodendrocytes allows for the selective, non-invasive generation of demyelinating lesions in optic nerve.", "tags": [{"end": 84, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 78, "tag": "Cell"}, {"end": 249, "start": 228, "tag": "InjuryOrPoisoning"}, {"end": 213, "start": 205, "tag": "Finding"}, {"end": 264, "start": 253, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 48, "start": 32, "tag": "Cell"}, {"end": 241, "start": 228, "tag": "PathologicFunction"}, {"end": 249, "start": 242, "tag": "InjuryOrPoisoning"}, {"end": 174, "start": 151, "tag": "Cell"}, {"end": 213, "start": 201, "tag": "Finding"}, {"end": 111, "start": 106, "tag": "ResearchActivity"}, {"end": 147, "start": 138, "tag": "CellFunction"}, {"end": 64, "start": 53, "tag": "CellFunction"}, {"end": 224, "start": 214, "tag": "TemporalConcept"}, {"end": 77, "start": 72, "tag": "Eukaryote"}, {"end": 134, "start": 125, "tag": "Finding"}]}{"id": "1329_3", "text": "Delivery of an inducer of oligodendrocyte apoptosis by intravitreous injection minimizes trauma to the optic nerve and allows for the assessment of oligodendrocyte death in the absence of injury related factors.", "tags": [{"end": 8, "start": 0, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "BiologicFunction"}, {"end": 22, "start": 15, "tag": "Substance"}, {"end": 95, "start": 89, "tag": "InjuryOrPoisoning"}, {"end": 144, "start": 134, "tag": "HealthCareActivity"}, {"end": 144, "start": 134, "tag": "ResearchActivity"}, {"end": 114, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 42, "tag": "CellFunction"}, {"end": 169, "start": 164, "tag": "BiologicFunction"}, {"end": 169, "start": 164, "tag": "PathologicFunction"}, {"end": 169, "start": 164, "tag": "CellFunction"}, {"end": 41, "start": 26, "tag": "Cell"}, {"end": 163, "start": 148, "tag": "Cell"}, {"end": 194, "start": 188, "tag": "InjuryOrPoisoning"}, {"end": 78, "start": 55, "tag": "HealthCareActivity"}, {"end": 184, "start": 177, "tag": "Finding"}]}{"id": "1329_4", "text": "Here we show that following induction of apoptosis, oligodendrocytes are lost within 3 days.", "tags": [{"end": 37, "start": 28, "tag": "HealthCareActivity"}, {"end": 77, "start": 73, "tag": "Finding"}, {"end": 68, "start": 52, "tag": "Cell"}, {"end": 50, "start": 41, "tag": "CellFunction"}, {"end": 91, "start": 87, "tag": "TemporalConcept"}]}{"id": "1329_5", "text": "The loss of oligodendrocytes is associated with limited microglial and astrocyte response, is patchy along the nerve, and results in localized myelin loss.", "tags": [{"end": 116, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 12, "tag": "Cell"}, {"end": 149, "start": 143, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 4, "tag": "CellOrMolecularDysfunction"}, {"end": 80, "start": 71, "tag": "Cell"}, {"end": 66, "start": 56, "tag": "Cell"}, {"end": 154, "start": 143, "tag": "CellOrMolecularDysfunction"}]}{"id": "1329_6", "text": "Unlike in other regions of the murine CNS, where local demyelination stimulates activation of local oligodendrocyte precursors and remyelination, optic nerve demyelination induced by oligodendrocyte apoptosis fails to recover and results in persistent areas of myelin loss.", "tags": [{"end": 225, "start": 218, "tag": "BiologicFunction"}, {"end": 225, "start": 218, "tag": "HealthCareActivity"}, {"end": 157, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 267, "start": 261, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 100, "tag": "Cell"}, {"end": 251, "start": 241, "tag": "TemporalConcept"}, {"end": 41, "start": 38, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 199, "tag": "CellFunction"}, {"end": 37, "start": 31, "tag": "Eukaryote"}, {"end": 198, "start": 183, "tag": "Cell"}, {"end": 144, "start": 131, "tag": "CellFunction"}, {"end": 68, "start": 55, "tag": "PathologicFunction"}, {"end": 171, "start": 158, "tag": "PathologicFunction"}, {"end": 272, "start": 261, "tag": "CellOrMolecularDysfunction"}]}{"id": "1329_7", "text": "Over time these chronic lesions change cellular composition and ultimately become devoid of GFAP+ astrocytes and OPCs.", "tags": [{"end": 117, "start": 113, "tag": "Cell"}, {"end": 31, "start": 24, "tag": "InjuryOrPoisoning"}, {"end": 9, "start": 5, "tag": "TemporalConcept"}, {"end": 47, "start": 39, "tag": "Cell"}, {"end": 108, "start": 98, "tag": "Cell"}, {"end": 96, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 92, "tag": "GeneOrGenome"}, {"end": 23, "start": 16, "tag": "TemporalConcept"}]}{"id": "1329_8", "text": "Why the optic nerve lesions fail to repair may reflect the lack of early immune responsiveness and provide a novel model of chronic demyelination.", "tags": [{"end": 94, "start": 73, "tag": "PathologicFunction"}, {"end": 19, "start": 8, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 27, "start": 20, "tag": "InjuryOrPoisoning"}, {"end": 72, "start": 67, "tag": "TemporalConcept"}, {"end": 120, "start": 115, "tag": "ResearchActivity"}, {"end": 145, "start": 132, "tag": "PathologicFunction"}, {"end": 42, "start": 36, "tag": "BiologicFunction"}, {"end": 42, "start": 36, "tag": "HealthCareActivity"}, {"end": 131, "start": 124, "tag": "TemporalConcept"}]}{"id": "1330_0", "text": "Following central nervous system (CNS) demyelination, adult oligodendrocyte progenitor cells (OPCs) can differentiate into new myelin-forming oligodendrocytes in a regenerative process called remyelination.", "tags": [{"end": 158, "start": 142, "tag": "Cell"}, {"end": 98, "start": 94, "tag": "Cell"}, {"end": 117, "start": 104, "tag": "CellFunction"}, {"end": 133, "start": 127, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 60, "tag": "Cell"}, {"end": 92, "start": 76, "tag": "Cell"}, {"end": 32, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 205, "start": 192, "tag": "CellFunction"}, {"end": 52, "start": 39, "tag": "PathologicFunction"}, {"end": 59, "start": 54, "tag": "PopulationGroup"}]}{"id": "1330_1", "text": "Although remyelination is very efficient in young adults, its efficiency declines progressively with ageing.", "tags": [{"end": 56, "start": 44, "tag": "PopulationGroup"}, {"end": 107, "start": 101, "tag": "BiologicFunction"}, {"end": 56, "start": 50, "tag": "PopulationGroup"}, {"end": 72, "start": 62, "tag": "Finding"}, {"end": 22, "start": 9, "tag": "CellFunction"}]}{"id": "1330_2", "text": "Here we performed proteomic analysis of OPCs freshly isolated from the brains of neonate, young and aged female rats.", "tags": [{"end": 88, "start": 81, "tag": "PopulationGroup"}, {"end": 95, "start": 90, "tag": "TemporalConcept"}, {"end": 104, "start": 100, "tag": "TemporalConcept"}, {"end": 116, "start": 112, "tag": "Eukaryote"}, {"end": 44, "start": 40, "tag": "Cell"}, {"end": 36, "start": 18, "tag": "ResearchActivity"}, {"end": 111, "start": 105, "tag": "OrganismAttribute"}, {"end": 77, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1330_3", "text": "Approximately 50% of the proteins are expressed at different levels in OPCs from neonates compared with their adult counterparts.", "tags": [{"end": 89, "start": 81, "tag": "PopulationGroup"}, {"end": 75, "start": 71, "tag": "Cell"}, {"end": 33, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 110, "tag": "PopulationGroup"}, {"end": 47, "start": 38, "tag": "CellFunction"}]}{"id": "1330_4", "text": "The amount of myelin-associated proteins, and proteins associated with oxidative phosphorylation, inflammatory responses and actin cytoskeletal organization increased with age, whereas cholesterol-biosynthesis, transcription factors and cell cycle proteins decreased.", "tags": [{"end": 96, "start": 71, "tag": "CellFunction"}, {"end": 120, "start": 98, "tag": "PathologicFunction"}, {"end": 156, "start": 125, "tag": "CellFunction"}, {"end": 256, "start": 237, "tag": "AminoAcidPeptideOrProtein"}, {"end": 196, "start": 185, "tag": "Chemical"}, {"end": 196, "start": 185, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 211, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 211, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 98, "tag": "PathologicFunction"}, {"end": 143, "start": 131, "tag": "CellComponent"}, {"end": 175, "start": 172, "tag": "OrganismAttribute"}, {"end": 40, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 256, "start": 248, "tag": "AminoAcidPeptideOrProtein"}, {"end": 266, "start": 257, "tag": "Finding"}, {"end": 96, "start": 81, "tag": "CellFunction"}, {"end": 130, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 247, "start": 237, "tag": "CellFunction"}, {"end": 256, "start": 237, "tag": "BiologicallyActiveSubstance"}, {"end": 209, "start": 185, "tag": "CellFunction"}]}{"id": "1330_5", "text": "Our experiments provide the first ageing OPC proteome, revealing the distinct features of OPCs at different ages.", "tags": [{"end": 40, "start": 34, "tag": "BiologicFunction"}, {"end": 112, "start": 108, "tag": "OrganismAttribute"}, {"end": 15, "start": 4, "tag": "ResearchActivity"}, {"end": 94, "start": 90, "tag": "Cell"}, {"end": 44, "start": 41, "tag": "Cell"}, {"end": 33, "start": 28, "tag": "TemporalConcept"}, {"end": 53, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 45, "tag": "BiologicallyActiveSubstance"}]}{"id": "1330_6", "text": "These studies provide new insights into why remyelination efficiency declines with ageing and potential roles for aged OPCs in other neurodegenerative diseases.", "tags": [{"end": 89, "start": 83, "tag": "BiologicFunction"}, {"end": 118, "start": 114, "tag": "TemporalConcept"}, {"end": 123, "start": 119, "tag": "Cell"}, {"end": 68, "start": 58, "tag": "Finding"}, {"end": 159, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 6, "tag": "ResearchActivity"}, {"end": 57, "start": 44, "tag": "CellFunction"}]}{"id": "1331_0", "text": "Brain regeneration and tumorigenesis are complex processes involving in changes in chromatin structure to regulate cellular states at the molecular and genomic level.", "tags": [{"end": 18, "start": 0, "tag": "BiologicFunction"}, {"end": 36, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 83, "tag": "CellComponent"}, {"end": 130, "start": 124, "tag": "TemporalConcept"}, {"end": 18, "start": 6, "tag": "BiologicFunction"}, {"end": 18, "start": 6, "tag": "HealthCareActivity"}]}{"id": "1331_1", "text": "The modulation of chromatin structure dynamics is critical for maintaining progenitor cell plasticity, growth and differentiation.", "tags": [{"end": 37, "start": 18, "tag": "CellComponent"}, {"end": 90, "start": 75, "tag": "Cell"}, {"end": 101, "start": 91, "tag": "NaturalPhenomenonOrProcess"}, {"end": 101, "start": 91, "tag": "CellFunction"}, {"end": 109, "start": 103, "tag": "BiologicFunction"}, {"end": 129, "start": 114, "tag": "CellFunction"}, {"end": 46, "start": 38, "tag": "NaturalPhenomenonOrProcess"}]}{"id": "1331_2", "text": "Oligodendrocyte precursor cells (OPC) can be differentiated into mature oligodendrocytes, which produce myelin sheathes to permit saltatory nerve conduction.", "tags": [{"end": 88, "start": 72, "tag": "Cell"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 36, "start": 33, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 88, "start": 65, "tag": "Cell"}, {"end": 156, "start": 130, "tag": "BiologicFunction"}, {"end": 71, "start": 65, "tag": "TemporalConcept"}, {"end": 156, "start": 146, "tag": "BiologicFunction"}, {"end": 156, "start": 146, "tag": "NaturalPhenomenonOrProcess"}, {"end": 110, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 104, "tag": "CellComponent"}]}{"id": "1331_3", "text": "OPCs and their primitive progenitors such as pri-OPC or pre-OPC are highly adaptive and plastic during injury repair or brain tumor formation.", "tags": [{"end": 36, "start": 15, "tag": "Cell"}, {"end": 95, "start": 88, "tag": "Substance"}, {"end": 131, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 4, "start": 0, "tag": "Cell"}, {"end": 52, "start": 45, "tag": "Cell"}, {"end": 63, "start": 56, "tag": "Cell"}, {"end": 116, "start": 103, "tag": "BiologicFunction"}, {"end": 116, "start": 103, "tag": "HealthCareActivity"}, {"end": 109, "start": 103, "tag": "InjuryOrPoisoning"}]}{"id": "1331_4", "text": "Recent studies indicate that chromatin modifications and epigenetic homeostasis through histone modifying enzymes shape genomic regulatory landscape conducive to OPC fate specification, lineage differentiation, maintenance of myelin sheaths, as well as brain tumorigenesis.", "tags": [{"end": 38, "start": 29, "tag": "CellComponent"}, {"end": 95, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 120, "tag": "GeneOrGenome"}, {"end": 127, "start": 120, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 184, "start": 166, "tag": "CellFunction"}, {"end": 272, "start": 253, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 165, "start": 162, "tag": "Cell"}, {"end": 240, "start": 226, "tag": "CellComponent"}, {"end": 113, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 222, "start": 211, "tag": "BiologicFunction"}, {"end": 79, "start": 57, "tag": "CellFunction"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 232, "start": 226, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 186, "tag": "CellFunction"}, {"end": 52, "start": 29, "tag": "CellFunction"}, {"end": 113, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 120, "tag": "CellFunction"}]}{"id": "1331_5", "text": "Thus, histone modifications can be convergent mechanisms in regulating OPC plasticity and malignant transformation.", "tags": [{"end": 27, "start": 6, "tag": "CellFunction"}, {"end": 85, "start": 75, "tag": "NaturalPhenomenonOrProcess"}, {"end": 85, "start": 75, "tag": "CellFunction"}, {"end": 74, "start": 71, "tag": "Cell"}, {"end": 114, "start": 90, "tag": "DiseaseOrSyndrome"}]}{"id": "1331_6", "text": "In this review, we will focus on the impact of histone modifying enzymes in modulating OPC plasticity during normal development, myelin regeneration and tumorigenesis.", "tags": [{"end": 54, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 91, "tag": "NaturalPhenomenonOrProcess"}, {"end": 101, "start": 91, "tag": "CellFunction"}, {"end": 127, "start": 109, "tag": "Finding"}, {"end": 166, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 136, "tag": "BiologicFunction"}, {"end": 148, "start": 136, "tag": "HealthCareActivity"}, {"end": 90, "start": 87, "tag": "Cell"}, {"end": 148, "start": 129, "tag": "CellFunction"}, {"end": 72, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 135, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 116, "tag": "BiologicFunction"}, {"end": 127, "start": 116, "tag": "CellFunction"}, {"end": 72, "start": 47, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1332_0", "text": "Depression is a common mental illness, affecting more than 300 million people worldwide.", "tags": [{"end": 37, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 71, "tag": "PopulationGroup"}]}{"id": "1332_1", "text": "Decades of investigation have yielded symptomatic therapies for this disabling condition but have not led to a consensus about its pathogenesis.", "tags": [{"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 143, "start": 131, "tag": "PathologicFunction"}, {"end": 59, "start": 50, "tag": "HealthCareActivity"}, {"end": 24, "start": 11, "tag": "ResearchActivity"}, {"end": 49, "start": 38, "tag": "SignOrSymptom"}, {"end": 88, "start": 69, "tag": "DiseaseOrSyndrome"}]}{"id": "1332_2", "text": "There are data to support several different theories of causation, including the monoamine hypothesis, hypothalamic-pituitary-adrenal axis changes, inflammation and immune system alterations, abnormalities of neurogenesis and a conducive environmental milieu.", "tags": [{"end": 90, "start": 81, "tag": "Chemical"}, {"end": 138, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 221, "start": 209, "tag": "BiologicFunction"}, {"end": 178, "start": 165, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 10, "tag": "ResearchActivity"}, {"end": 160, "start": 148, "tag": "PathologicFunction"}, {"end": 190, "start": 165, "tag": "PathologicFunction"}, {"end": 221, "start": 192, "tag": "CellOrMolecularDysfunction"}]}{"id": "1332_3", "text": "Research in these areas and others has greatly advanced the current understanding of depression; however, there are other, less widely known theories of pathogenesis.", "tags": [{"end": 81, "start": 68, "tag": "BiologicFunction"}, {"end": 95, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 165, "start": 153, "tag": "PathologicFunction"}, {"end": 67, "start": 60, "tag": "TemporalConcept"}]}{"id": "1332_4", "text": "Oligodendrocyte lineage cells, including oligodendrocyte progenitor cells and mature oligodendrocytes, have numerous important functions, which include forming myelin sheaths that enwrap central nervous system axons, supporting axons metabolically, and mediating certain forms of neuroplasticity.", "tags": [{"end": 15, "start": 0, "tag": "Cell"}, {"end": 295, "start": 280, "tag": "BiologicFunction"}, {"end": 215, "start": 210, "tag": "CellComponent"}, {"end": 233, "start": 228, "tag": "CellComponent"}, {"end": 101, "start": 85, "tag": "Cell"}, {"end": 73, "start": 57, "tag": "Cell"}, {"end": 101, "start": 78, "tag": "Cell"}, {"end": 174, "start": 160, "tag": "CellComponent"}, {"end": 73, "start": 41, "tag": "Cell"}, {"end": 84, "start": 78, "tag": "TemporalConcept"}, {"end": 29, "start": 0, "tag": "Cell"}, {"end": 166, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1332_5", "text": "These specialized glial cells have been implicated in psychiatric disorders such as depression.", "tags": [{"end": 75, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 18, "tag": "Cell"}, {"end": 94, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 18, "tag": "Cell"}]}{"id": "1332_6", "text": "In this review, we summarize recent findings that shed light on how oligodendrocyte lineage cells might participate in the pathogenesis of depression, and we discuss new approaches for targeting these cells as a novel strategy to treat depression.", "tags": [{"end": 149, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 246, "start": 236, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 135, "start": 123, "tag": "PathologicFunction"}, {"end": 97, "start": 68, "tag": "Cell"}, {"end": 206, "start": 201, "tag": "Cell"}, {"end": 35, "start": 29, "tag": "TemporalConcept"}]}{"id": "1333_0", "text": "Oligodendrocyte lineage cells (oligodendroglia) and neurons engage in bidirectional communication throughout life to support healthy brain function.", "tags": [{"end": 15, "start": 0, "tag": "Cell"}, {"end": 59, "start": 52, "tag": "Cell"}, {"end": 46, "start": 31, "tag": "Cell"}, {"end": 147, "start": 133, "tag": "BiologicFunction"}, {"end": 132, "start": 125, "tag": "OrganismAttribute"}, {"end": 29, "start": 0, "tag": "Cell"}, {"end": 113, "start": 109, "tag": "TemporalConcept"}]}{"id": "1333_1", "text": "Recent work shows that changes in neuronal activity can modulate proliferation, differentiation, and myelination to support the formation and function of neural circuits.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 42, "start": 34, "tag": "Cell"}, {"end": 78, "start": 65, "tag": "CellFunction"}, {"end": 112, "start": 101, "tag": "CellFunction"}, {"end": 51, "start": 34, "tag": "CellFunction"}, {"end": 95, "start": 80, "tag": "CellFunction"}, {"end": 169, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1333_2", "text": "While oligodendroglia express a diverse collection of receptors for growth factors, signaling molecules, neurotransmitters and neuromodulators, our knowledge of the intracellular signaling pathways that are regulated by neuronal activity remains largely incomplete.", "tags": [{"end": 63, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 84, "tag": "CellFunction"}, {"end": 122, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 105, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 94, "tag": "Substance"}, {"end": 228, "start": 220, "tag": "Cell"}, {"end": 74, "start": 68, "tag": "BiologicFunction"}, {"end": 157, "start": 148, "tag": "Finding"}, {"end": 197, "start": 165, "tag": "CellFunction"}, {"end": 93, "start": 84, "tag": "CellFunction"}, {"end": 237, "start": 220, "tag": "CellFunction"}, {"end": 21, "start": 6, "tag": "Cell"}, {"end": 82, "start": 68, "tag": "BiologicallyActiveSubstance"}]}{"id": "1333_3", "text": "Many of the pathways that modulate oligodendroglia behavior are driven by changes in intracellular calcium signaling, which may differentially affect cytoskeletal dynamics, gene expression, maturation, integration, and axonal support.", "tags": [{"end": 162, "start": 150, "tag": "CellComponent"}, {"end": 213, "start": 202, "tag": "CellFunction"}, {"end": 213, "start": 202, "tag": "MachineActivity"}, {"end": 225, "start": 219, "tag": "CellComponent"}, {"end": 59, "start": 51, "tag": "BiologicFunction"}, {"end": 59, "start": 51, "tag": "IndividualBehavior"}, {"end": 59, "start": 51, "tag": "ResearchActivity"}, {"end": 188, "start": 173, "tag": "CellFunction"}, {"end": 200, "start": 190, "tag": "BiologicFunction"}, {"end": 116, "start": 85, "tag": "CellFunction"}, {"end": 50, "start": 35, "tag": "Cell"}, {"end": 20, "start": 12, "tag": "CellFunction"}, {"end": 171, "start": 163, "tag": "NaturalPhenomenonOrProcess"}, {"end": 106, "start": 99, "tag": "Chemical"}, {"end": 106, "start": 99, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 99, "tag": "BiologicallyActiveSubstance"}]}{"id": "1333_4", "text": "Additionally, activity-dependent neuron-oligodendroglia communication plays an integral role in the recovery from demyelinating injuries.", "tags": [{"end": 39, "start": 33, "tag": "Cell"}, {"end": 127, "start": 114, "tag": "PathologicFunction"}, {"end": 55, "start": 40, "tag": "Cell"}, {"end": 108, "start": 100, "tag": "BiologicFunction"}, {"end": 108, "start": 100, "tag": "HealthCareActivity"}, {"end": 108, "start": 100, "tag": "TemporalConcept"}, {"end": 69, "start": 14, "tag": "CellFunction"}, {"end": 136, "start": 114, "tag": "InjuryOrPoisoning"}]}{"id": "1333_5", "text": "In this review, we summarize the modalities of communication between neurons and oligodendroglia and explore possible roles of activity-dependent calcium signaling in mediating cellular behavior and myelination.", "tags": [{"end": 60, "start": 47, "tag": "HealthCareActivity"}, {"end": 60, "start": 47, "tag": "CellFunction"}, {"end": 194, "start": 186, "tag": "BiologicFunction"}, {"end": 194, "start": 186, "tag": "IndividualBehavior"}, {"end": 194, "start": 186, "tag": "ResearchActivity"}, {"end": 76, "start": 69, "tag": "Cell"}, {"end": 210, "start": 199, "tag": "CellFunction"}, {"end": 163, "start": 127, "tag": "CellFunction"}, {"end": 96, "start": 81, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 163, "start": 146, "tag": "CellFunction"}]}{"id": "1334_0", "text": "Promoting the differentiation of oligodendrocyte precursor cells (OPCs) is important for fostering remyelination in multiple sclerosis.", "tags": [{"end": 70, "start": 66, "tag": "Cell"}, {"end": 64, "start": 33, "tag": "Cell"}, {"end": 134, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 14, "tag": "CellFunction"}, {"end": 64, "start": 49, "tag": "Cell"}, {"end": 58, "start": 33, "tag": "Cell"}, {"end": 112, "start": 99, "tag": "CellFunction"}]}{"id": "1334_1", "text": "Catalpol has the potential to promote remyelination and exert neuroprotective effects, but its specific mechanism is still unclear.", "tags": [{"end": 8, "start": 0, "tag": "Chemical"}, {"end": 51, "start": 38, "tag": "CellFunction"}, {"end": 85, "start": 78, "tag": "Finding"}, {"end": 77, "start": 62, "tag": "CellFunction"}, {"end": 85, "start": 62, "tag": "Finding"}]}{"id": "1334_2", "text": "Recent studies have shown that the NOTCH1 signaling pathway is involved in mediating OPC proliferation and differentiation.", "tags": [{"end": 59, "start": 35, "tag": "CellFunction"}, {"end": 88, "start": 85, "tag": "Cell"}, {"end": 51, "start": 42, "tag": "CellFunction"}, {"end": 122, "start": 107, "tag": "CellFunction"}, {"end": 102, "start": 89, "tag": "CellFunction"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 59, "start": 52, "tag": "CellFunction"}, {"end": 59, "start": 42, "tag": "CellFunction"}]}{"id": "1334_3", "text": "In this study, we elucidated that catalpol promoted OPC differentiation in vivo and vitro and explored the regulatory role of catalpol in specific biomolecular processes.", "tags": [{"end": 42, "start": 34, "tag": "Chemical"}, {"end": 134, "start": 126, "tag": "Chemical"}, {"end": 55, "start": 52, "tag": "Cell"}, {"end": 71, "start": 56, "tag": "CellFunction"}, {"end": 71, "start": 52, "tag": "CellFunction"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 79, "start": 72, "tag": "ResearchActivity"}, {"end": 122, "start": 107, "tag": "Finding"}, {"end": 169, "start": 147, "tag": "CellFunction"}]}{"id": "1334_4", "text": "Following catalpol administration, better and faster recovery of body weight and motor balance was observed in mice with cuprizone (CPZ)-induced demyelination.", "tags": [{"end": 18, "start": 10, "tag": "Chemical"}, {"end": 76, "start": 65, "tag": "OrganismAttribute"}, {"end": 135, "start": 132, "tag": "Chemical"}, {"end": 130, "start": 121, "tag": "Chemical"}, {"end": 115, "start": 111, "tag": "Eukaryote"}, {"end": 69, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 53, "tag": "BiologicFunction"}, {"end": 61, "start": 53, "tag": "HealthCareActivity"}, {"end": 61, "start": 53, "tag": "TemporalConcept"}, {"end": 158, "start": 145, "tag": "PathologicFunction"}, {"end": 33, "start": 19, "tag": "HealthCareActivity"}, {"end": 94, "start": 81, "tag": "BiologicFunction"}]}{"id": "1334_5", "text": "Luxol fast blue staining (LFB) and transmission electron microscopy (TEM) showed that catalpol increased the myelinated area and improved myelin ultrastructure in the corpus callosum in demyelinated mice.", "tags": [{"end": 24, "start": 0, "tag": "ResearchActivity"}, {"end": 29, "start": 26, "tag": "Chemical"}, {"end": 94, "start": 86, "tag": "Chemical"}, {"end": 119, "start": 109, "tag": "CellComponent"}, {"end": 137, "start": 129, "tag": "Finding"}, {"end": 144, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 198, "start": 186, "tag": "PathologicFunction"}, {"end": 182, "start": 167, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 203, "start": 199, "tag": "Eukaryote"}, {"end": 67, "start": 48, "tag": "ResearchActivity"}, {"end": 67, "start": 35, "tag": "ResearchActivity"}, {"end": 72, "start": 69, "tag": "ResearchActivity"}, {"end": 15, "start": 0, "tag": "Chemical"}]}{"id": "1334_6", "text": "In addition, catalpol enhanced the expression of CNPase and MBP, indicating that it increased OPC differentiation.", "tags": [{"end": 21, "start": 13, "tag": "Chemical"}, {"end": 55, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 60, "tag": "GeneOrGenome"}, {"end": 97, "start": 94, "tag": "Cell"}, {"end": 113, "start": 98, "tag": "CellFunction"}, {"end": 113, "start": 94, "tag": "CellFunction"}, {"end": 45, "start": 35, "tag": "CellFunction"}, {"end": 55, "start": 49, "tag": "BiologicallyActiveSubstance"}]}{"id": "1334_7", "text": "Additionally, catalpol downregulated the expression of NOTCH1 signaling pathway-related molecules, such as JAGGED1, NOTCH1, NICD1, RBPJ, HES5, and HES1.", "tags": [{"end": 22, "start": 14, "tag": "Chemical"}, {"end": 114, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 116, "tag": "GeneOrGenome"}, {"end": 122, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 131, "tag": "GeneOrGenome"}, {"end": 141, "start": 137, "tag": "GeneOrGenome"}, {"end": 151, "start": 147, "tag": "GeneOrGenome"}, {"end": 51, "start": 41, "tag": "CellFunction"}, {"end": 97, "start": 88, "tag": "Substance"}, {"end": 36, "start": 23, "tag": "CellFunction"}, {"end": 79, "start": 55, "tag": "CellFunction"}, {"end": 122, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 147, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1334_8", "text": "We further demonstrated that in vitro, catalpol enhanced the differentiation of OPCs into OLs and inhibited NOTCH1 signaling pathway activity.", "tags": [{"end": 47, "start": 39, "tag": "Chemical"}, {"end": 132, "start": 108, "tag": "CellFunction"}, {"end": 84, "start": 80, "tag": "Cell"}, {"end": 124, "start": 115, "tag": "CellFunction"}, {"end": 76, "start": 61, "tag": "CellFunction"}, {"end": 93, "start": 90, "tag": "Cell"}, {"end": 37, "start": 29, "tag": "ResearchActivity"}, {"end": 132, "start": 125, "tag": "CellFunction"}, {"end": 132, "start": 115, "tag": "CellFunction"}]}{"id": "1334_9", "text": "Our data suggested that catalpol may promote OPC differentiation and remyelination through modulation of the NOTCH1 pathway.", "tags": [{"end": 32, "start": 24, "tag": "Chemical"}, {"end": 48, "start": 45, "tag": "Cell"}, {"end": 64, "start": 49, "tag": "CellFunction"}, {"end": 64, "start": 45, "tag": "CellFunction"}, {"end": 123, "start": 109, "tag": "CellFunction"}, {"end": 82, "start": 69, "tag": "CellFunction"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}]}{"id": "1334_10", "text": "This study provides new insight into the mechanism of action of catalpol in the treatment of multiple sclerosis.", "tags": [{"end": 72, "start": 64, "tag": "Chemical"}, {"end": 111, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 89, "start": 80, "tag": "HealthCareActivity"}, {"end": 89, "start": 80, "tag": "ResearchActivity"}]}{"id": "1335_0", "text": "Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that causes severe motor, sensory, and cognitive impairments.", "tags": [{"end": 62, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 54, "start": 41, "tag": "PathologicFunction"}, {"end": 62, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 97, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 111, "tag": "Finding"}]}{"id": "1335_1", "text": "Kallikrein-related peptidase (KLK)6 is the most abundant serine protease secreted in the CNS, mainly by oligodendrocytes, the myelin-producing cells of the CNS, and KLK6 is assumed to be a robust biomarker of MS, since it is highly increased in the cerebrospinal fluid (CSF) of MS patients.", "tags": [{"end": 28, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 165, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 165, "tag": "BiologicallyActiveSubstance"}, {"end": 148, "start": 126, "tag": "Cell"}, {"end": 120, "start": 104, "tag": "Cell"}, {"end": 132, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 289, "start": 281, "tag": "PatientOrDisabledGroup"}, {"end": 92, "start": 89, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 159, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 273, "start": 270, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 205, "start": 196, "tag": "ClinicalAttribute"}, {"end": 268, "start": 249, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 280, "start": 278, "tag": "DiseaseOrSyndrome"}, {"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 165, "tag": "GeneOrGenome"}]}{"id": "1335_2", "text": "Here, we report the design and biological evaluation of KLK6's low-molecular-weight inhibitors, para-aminobenzyl derivatives.", "tags": [{"end": 26, "start": 20, "tag": "ResearchActivity"}, {"end": 26, "start": 20, "tag": "HealthCareActivity"}, {"end": 52, "start": 42, "tag": "HealthCareActivity"}, {"end": 52, "start": 42, "tag": "ResearchActivity"}, {"end": 94, "start": 84, "tag": "Chemical"}, {"end": 94, "start": 84, "tag": "PharmacologicSubstance"}, {"end": 94, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 66, "start": 63, "tag": "Finding"}, {"end": 60, "start": 56, "tag": "GeneOrGenome"}, {"end": 60, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 96, "tag": "Chemical"}, {"end": 124, "start": 96, "tag": "PharmacologicSubstance"}]}{"id": "1335_3", "text": "Interestingly, selected hit compounds were selective of the KLK6 proteolytic network encompassing KLK1 and plasmin that also participate in the development of MS physiopathology.", "tags": [{"end": 64, "start": 60, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 60, "tag": "GeneOrGenome"}, {"end": 102, "start": 98, "tag": "GeneOrGenome"}, {"end": 114, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 162, "tag": "PathologicFunction"}, {"end": 37, "start": 28, "tag": "Chemical"}, {"end": 37, "start": 28, "tag": "PharmacologicSubstance"}, {"end": 155, "start": 144, "tag": "BiologicFunction"}, {"end": 155, "start": 144, "tag": "CellFunction"}, {"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 65, "tag": "CellFunction"}, {"end": 64, "start": 60, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 107, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 107, "tag": "PharmacologicSubstance"}]}{"id": "1335_4", "text": "Moreover, hits were found noncytotoxic on primary cultures of murine neurons and oligodendrocyte precursor cells (OPCs).", "tags": [{"end": 58, "start": 42, "tag": "ResearchActivity"}, {"end": 14, "start": 10, "tag": "Finding"}, {"end": 58, "start": 50, "tag": "ResearchActivity"}, {"end": 118, "start": 114, "tag": "Cell"}, {"end": 112, "start": 81, "tag": "Cell"}, {"end": 112, "start": 97, "tag": "Cell"}, {"end": 106, "start": 81, "tag": "Cell"}, {"end": 68, "start": 62, "tag": "Eukaryote"}, {"end": 76, "start": 69, "tag": "Cell"}]}{"id": "1335_5", "text": "Among them, two compounds (32 and 42) were shown to promote the differentiation of OPCs into mature oligodendrocytes in vitro constituting thus emerging leads for the development of regenerative therapies.", "tags": [{"end": 116, "start": 100, "tag": "Cell"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 116, "start": 93, "tag": "Cell"}, {"end": 79, "start": 64, "tag": "CellFunction"}, {"end": 99, "start": 93, "tag": "TemporalConcept"}, {"end": 25, "start": 16, "tag": "Chemical"}, {"end": 25, "start": 16, "tag": "PharmacologicSubstance"}, {"end": 178, "start": 167, "tag": "BiologicFunction"}, {"end": 178, "start": 167, "tag": "CellFunction"}, {"end": 125, "start": 117, "tag": "ResearchActivity"}, {"end": 204, "start": 182, "tag": "HealthCareActivity"}]}{"id": "1336_0", "text": "Oligodendrocyte precursor cells (OPCs) are glial cells that differentiate into mature oligodendrocytes (OLs) to generate new myelin sheaths.", "tags": [{"end": 102, "start": 86, "tag": "Cell"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 73, "start": 60, "tag": "CellFunction"}, {"end": 131, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 79, "tag": "Cell"}, {"end": 139, "start": 125, "tag": "CellComponent"}, {"end": 107, "start": 104, "tag": "Cell"}, {"end": 85, "start": 79, "tag": "TemporalConcept"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 48, "start": 43, "tag": "Cell"}, {"end": 54, "start": 43, "tag": "Cell"}]}{"id": "1336_1", "text": "While OPCs are distributed uniformly throughout the gray and white matter in the developing and adult brain, those in white matter proliferate and differentiate into oligodendrocytes at a greater rate than those in gray matter.", "tags": [{"end": 226, "start": 215, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 182, "start": 166, "tag": "Cell"}, {"end": 10, "start": 6, "tag": "Cell"}, {"end": 160, "start": 147, "tag": "CellFunction"}, {"end": 200, "start": 196, "tag": "TemporalConcept"}, {"end": 73, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 96, "tag": "PopulationGroup"}]}{"id": "1336_2", "text": "There is currently lack of evidence to suggest that OPCs comprise genetically and transcriptionally distinct subtypes.", "tags": [{"end": 99, "start": 82, "tag": "CellFunction"}, {"end": 56, "start": 52, "tag": "Cell"}, {"end": 35, "start": 27, "tag": "Finding"}, {"end": 18, "start": 9, "tag": "TemporalConcept"}]}{"id": "1336_3", "text": "Rather, the emerging view is that they exist in different cell and functional states, depending on their location and age.", "tags": [{"end": 113, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 78, "tag": "TemporalConcept"}, {"end": 62, "start": 58, "tag": "Cell"}, {"end": 121, "start": 118, "tag": "OrganismAttribute"}]}{"id": "1336_4", "text": "Contrary to the normal brain, demyelinated lesions in the gray matter of multiple sclerosis brains contain more OPCs and OLs and are remyelinated more robustly than those in white matter.", "tags": [{"end": 69, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 91, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 43, "tag": "InjuryOrPoisoning"}, {"end": 42, "start": 30, "tag": "PathologicFunction"}, {"end": 186, "start": 174, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 121, "tag": "Cell"}, {"end": 50, "start": 30, "tag": "PathologicFunction"}, {"end": 145, "start": 133, "tag": "CellFunction"}, {"end": 28, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 16, "tag": "Finding"}, {"end": 98, "start": 92, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1336_5", "text": "The differences in the dynamic behavior of OL lineage cells are likely to be influenced by their microenvironment.", "tags": [{"end": 113, "start": 97, "tag": "NaturalPhenomenonOrProcess"}, {"end": 113, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 31, "tag": "BiologicFunction"}, {"end": 39, "start": 31, "tag": "IndividualBehavior"}, {"end": 39, "start": 31, "tag": "ResearchActivity"}, {"end": 45, "start": 43, "tag": "Cell"}, {"end": 53, "start": 43, "tag": "Cell"}, {"end": 59, "start": 43, "tag": "Cell"}, {"end": 15, "start": 4, "tag": "Finding"}]}{"id": "1336_6", "text": "There are regional differences in astrocytes, microglia, the vasculature, and the composition of the extracellular matrix (ECM).", "tags": [{"end": 72, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 46, "tag": "Cell"}, {"end": 30, "start": 19, "tag": "Finding"}, {"end": 44, "start": 34, "tag": "Cell"}]}{"id": "1336_7", "text": "We will discuss how the regional differences in these elements surrounding OPCs might shape their phenotypic variability in normal and demyelinated states.</p>", "tags": [{"end": 120, "start": 109, "tag": "Finding"}, {"end": 79, "start": 75, "tag": "Cell"}, {"end": 147, "start": 135, "tag": "PathologicFunction"}, {"end": 154, "start": 148, "tag": "TemporalConcept"}, {"end": 44, "start": 33, "tag": "Finding"}, {"end": 130, "start": 124, "tag": "Finding"}, {"end": 108, "start": 98, "tag": "OrganismAttribute"}]}{"id": "1337_0", "text": "Background Promotion of myelin repair in the context of demyelinating diseases such as multiple sclerosis (MS) still represents a clinical unmet need, given that this disease is not only characterized by autoimmune activities but also by impaired regeneration processes.", "tags": [{"end": 149, "start": 130, "tag": "Finding"}, {"end": 78, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 56, "tag": "PathologicFunction"}, {"end": 105, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 259, "start": 247, "tag": "BiologicFunction"}, {"end": 259, "start": 247, "tag": "HealthCareActivity"}, {"end": 37, "start": 24, "tag": "CellFunction"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 31, "tag": "BiologicFunction"}, {"end": 37, "start": 31, "tag": "HealthCareActivity"}, {"end": 225, "start": 204, "tag": "PathologicFunction"}, {"end": 269, "start": 238, "tag": "PathologicFunction"}]}{"id": "1337_1", "text": "Hence, this relates to replacement of lost oligodendrocytes and myelin sheaths-the primary targets of autoimmune attacks.", "tags": [{"end": 34, "start": 23, "tag": "HealthCareActivity"}, {"end": 34, "start": 23, "tag": "ResearchActivity"}, {"end": 42, "start": 38, "tag": "Finding"}, {"end": 59, "start": 43, "tag": "Cell"}, {"end": 70, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 64, "tag": "CellComponent"}, {"end": 120, "start": 102, "tag": "PathologicFunction"}]}{"id": "1337_2", "text": "Endogenous remyelination is mainly mediated via activation and differentiation of resident oligodendroglial precursor cells (OPCs), whereas its efficiency remains limited and declines with disease progression and aging.", "tags": [{"end": 129, "start": 125, "tag": "Cell"}, {"end": 78, "start": 63, "tag": "CellFunction"}, {"end": 123, "start": 108, "tag": "Cell"}, {"end": 154, "start": 144, "tag": "Finding"}, {"end": 90, "start": 82, "tag": "PopulationGroup"}, {"end": 123, "start": 91, "tag": "Cell"}, {"end": 107, "start": 91, "tag": "Cell"}, {"end": 208, "start": 197, "tag": "PathologicFunction"}, {"end": 208, "start": 197, "tag": "TemporalConcept"}, {"end": 208, "start": 189, "tag": "PathologicFunction"}, {"end": 24, "start": 0, "tag": "CellFunction"}, {"end": 218, "start": 213, "tag": "BiologicFunction"}, {"end": 218, "start": 213, "tag": "CellFunction"}, {"end": 58, "start": 48, "tag": "CellFunction"}]}{"id": "1337_3", "text": "Teriflunomide has been approved as a first-line treatment for relapsing remitting MS.", "tags": [{"end": 13, "start": 0, "tag": "Chemical"}, {"end": 57, "start": 37, "tag": "HealthCareActivity"}, {"end": 81, "start": 72, "tag": "TemporalConcept"}, {"end": 71, "start": 62, "tag": "TemporalConcept"}, {"end": 42, "start": 37, "tag": "TemporalConcept"}, {"end": 57, "start": 48, "tag": "HealthCareActivity"}, {"end": 57, "start": 48, "tag": "ResearchActivity"}, {"end": 84, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 0, "tag": "PharmacologicSubstance"}]}{"id": "1337_4", "text": "Beyond its role in acting via inhibition of de novo pyrimidine synthesis leading to a cytostatic effect on proliferating lymphocyte subsets, this study aims to uncover its potential to foster myelin repair.Methods Within the cuprizone mediated de-/remyelination model teriflunomide dependent effects on oligodendroglial homeostasis and maturation, related to cellular processes important for myelin repair were analyzed in vivo.", "tags": [{"end": 62, "start": 52, "tag": "Chemical"}, {"end": 62, "start": 52, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 281, "start": 268, "tag": "Chemical"}, {"end": 377, "start": 359, "tag": "CellFunction"}, {"end": 346, "start": 336, "tag": "BiologicFunction"}, {"end": 198, "start": 192, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 398, "start": 392, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 234, "start": 225, "tag": "Chemical"}, {"end": 72, "start": 63, "tag": "BiologicFunction"}, {"end": 205, "start": 192, "tag": "CellFunction"}, {"end": 405, "start": 392, "tag": "CellFunction"}, {"end": 319, "start": 303, "tag": "Cell"}, {"end": 151, "start": 146, "tag": "ResearchActivity"}, {"end": 267, "start": 262, "tag": "ResearchActivity"}, {"end": 103, "start": 86, "tag": "Finding"}, {"end": 419, "start": 411, "tag": "ResearchActivity"}, {"end": 139, "start": 107, "tag": "Cell"}, {"end": 40, "start": 30, "tag": "CellFunction"}, {"end": 331, "start": 320, "tag": "BiologicFunction"}, {"end": 427, "start": 420, "tag": "ResearchActivity"}, {"end": 367, "start": 359, "tag": "Cell"}, {"end": 261, "start": 248, "tag": "CellFunction"}, {"end": 299, "start": 292, "tag": "Finding"}, {"end": 205, "start": 199, "tag": "BiologicFunction"}, {"end": 405, "start": 399, "tag": "BiologicFunction"}, {"end": 205, "start": 199, "tag": "HealthCareActivity"}, {"end": 405, "start": 399, "tag": "HealthCareActivity"}, {"end": 281, "start": 268, "tag": "PharmacologicSubstance"}, {"end": 72, "start": 52, "tag": "CellFunction"}, {"end": 62, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 267, "start": 225, "tag": "ExperimentalModelOfDisease"}]}{"id": "1337_5", "text": "Teriflunomide administration was performed either as pulse or continuously and markers specific for oligodendroglial maturation and mitochondrial integrity were examined by means of gene expression and immunohistochemical analyses.", "tags": [{"end": 13, "start": 0, "tag": "Chemical"}, {"end": 127, "start": 117, "tag": "BiologicFunction"}, {"end": 155, "start": 146, "tag": "IndividualBehavior"}, {"end": 145, "start": 132, "tag": "CellComponent"}, {"end": 116, "start": 100, "tag": "Cell"}, {"end": 86, "start": 79, "tag": "ClinicalAttribute"}, {"end": 197, "start": 182, "tag": "CellFunction"}, {"end": 230, "start": 202, "tag": "ResearchActivity"}, {"end": 13, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 28, "start": 14, "tag": "HealthCareActivity"}, {"end": 230, "start": 222, "tag": "ResearchActivity"}, {"end": 197, "start": 182, "tag": "ResearchActivity"}]}{"id": "1337_6", "text": "In addition, axon myelination was determined using electron microscopy.Results Both pulse and constant teriflunomide treatment efficiently boosted myelin repair activities in this model, leading to accelerated generation of oligodendrocytes and restoration of myelin sheaths.", "tags": [{"end": 116, "start": 103, "tag": "Chemical"}, {"end": 240, "start": 224, "tag": "Cell"}, {"end": 153, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 266, "start": 260, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 274, "start": 260, "tag": "CellComponent"}, {"end": 17, "start": 13, "tag": "CellComponent"}, {"end": 102, "start": 94, "tag": "TemporalConcept"}, {"end": 160, "start": 147, "tag": "CellFunction"}, {"end": 78, "start": 71, "tag": "ResearchActivity"}, {"end": 185, "start": 180, "tag": "ResearchActivity"}, {"end": 126, "start": 117, "tag": "HealthCareActivity"}, {"end": 126, "start": 117, "tag": "ResearchActivity"}, {"end": 70, "start": 51, "tag": "ResearchActivity"}, {"end": 29, "start": 18, "tag": "CellFunction"}, {"end": 220, "start": 210, "tag": "TemporalConcept"}, {"end": 160, "start": 154, "tag": "BiologicFunction"}, {"end": 160, "start": 154, "tag": "HealthCareActivity"}, {"end": 116, "start": 103, "tag": "PharmacologicSubstance"}]}{"id": "1337_7", "text": "Moreover, teriflunomide restored mitochondrial integrity within oligodendroglial cells.Conclusions The link between de novo pyrimidine synthesis inhibition, oligodendroglial rescue, and maintenance of mitochondrial homeostasis appears as a key for successful myelin repair and hence for protection of axons from degeneration.", "tags": [{"end": 23, "start": 10, "tag": "Chemical"}, {"end": 134, "start": 124, "tag": "Chemical"}, {"end": 134, "start": 124, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 306, "start": 301, "tag": "CellComponent"}, {"end": 265, "start": 259, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 324, "start": 312, "tag": "PathologicFunction"}, {"end": 144, "start": 135, "tag": "BiologicFunction"}, {"end": 272, "start": 259, "tag": "CellFunction"}, {"end": 86, "start": 64, "tag": "Cell"}, {"end": 173, "start": 157, "tag": "Cell"}, {"end": 155, "start": 145, "tag": "CellFunction"}, {"end": 197, "start": 186, "tag": "BiologicFunction"}, {"end": 272, "start": 266, "tag": "BiologicFunction"}, {"end": 272, "start": 266, "tag": "HealthCareActivity"}, {"end": 23, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 56, "start": 33, "tag": "CellFunction"}, {"end": 134, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 124, "tag": "CellFunction"}, {"end": 226, "start": 201, "tag": "CellFunction"}]}{"id": "1338_0", "text": "Conflicting results on melatonin synthesis in multiple sclerosis (MS) have been reported due to variabilities in patient lifestyles, which are not considered when supplementing melatonin.", "tags": [{"end": 42, "start": 33, "tag": "BiologicFunction"}, {"end": 32, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 186, "start": 177, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 23, "tag": "PharmacologicSubstance"}, {"end": 186, "start": 177, "tag": "PharmacologicSubstance"}, {"end": 32, "start": 23, "tag": "Chemical"}, {"end": 186, "start": 177, "tag": "Chemical"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 113, "tag": "PatientOrDisabledGroup"}, {"end": 131, "start": 121, "tag": "IndividualBehavior"}]}{"id": "1338_1", "text": "Since melatonin acts through its receptors, we identified melatonin receptors in oligodendrocytes (OLs) in the corpus callosum, where demyelination occurs; the subventricular zone, where neural stem/progenitor cells (NSPCs) are located; and the choroid plexus, which functions as a blood-cerebrospinal fluid barrier.", "tags": [{"end": 42, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 259, "start": 245, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 315, "start": 282, "tag": "BiologicFunction"}, {"end": 97, "start": 81, "tag": "Cell"}, {"end": 215, "start": 199, "tag": "Cell"}, {"end": 15, "start": 6, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 6, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 58, "tag": "PharmacologicSubstance"}, {"end": 15, "start": 6, "tag": "Chemical"}, {"end": 67, "start": 58, "tag": "Chemical"}, {"end": 102, "start": 99, "tag": "Cell"}, {"end": 126, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 134, "tag": "PathologicFunction"}, {"end": 307, "start": 302, "tag": "Substance"}, {"end": 307, "start": 288, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 77, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 215, "start": 210, "tag": "Cell"}, {"end": 198, "start": 187, "tag": "Cell"}, {"end": 222, "start": 217, "tag": "Cell"}]}{"id": "1338_2", "text": "Moreover, using chimeric mice, resident macrophages were found to express melatonin receptors, whereas bone marrow-derived macrophages lost this expression in the demyelinated brain.", "tags": [{"end": 29, "start": 16, "tag": "Organism"}, {"end": 39, "start": 31, "tag": "PopulationGroup"}, {"end": 175, "start": 163, "tag": "PathologicFunction"}, {"end": 107, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 83, "start": 74, "tag": "PharmacologicSubstance"}, {"end": 83, "start": 74, "tag": "Chemical"}, {"end": 114, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 31, "tag": "Cell"}, {"end": 134, "start": 103, "tag": "Cell"}, {"end": 181, "start": 176, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 25, "tag": "Eukaryote"}, {"end": 93, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 74, "tag": "BiologicallyActiveSubstance"}]}{"id": "1338_3", "text": "Next, we showed that cuprizone-fed mice, which is an MS model, tended to have increased melatonin levels.", "tags": [{"end": 97, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 88, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 88, "tag": "Chemical"}, {"end": 104, "start": 88, "tag": "ResearchActivity"}, {"end": 30, "start": 21, "tag": "Chemical"}, {"end": 39, "start": 21, "tag": "ExperimentalModelOfDisease"}, {"end": 39, "start": 35, "tag": "Eukaryote"}, {"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 53, "tag": "ExperimentalModelOfDisease"}]}{"id": "1338_4", "text": "While we used different approaches to alter the circadian rhythm of melatonin and cortisol, only the constant light approach increased NSPC proliferation and differentiation to oligodendrocyte precursor cells (OPCs), OPCs maturation to OLs and recruitment to the site of demyelination, the number of patrolling monocytes, and phagocytosis.", "tags": [{"end": 64, "start": 48, "tag": "BiologicFunction"}, {"end": 90, "start": 82, "tag": "Chemical"}, {"end": 320, "start": 311, "tag": "Cell"}, {"end": 77, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 68, "tag": "PharmacologicSubstance"}, {"end": 77, "start": 68, "tag": "Chemical"}, {"end": 109, "start": 101, "tag": "TemporalConcept"}, {"end": 239, "start": 236, "tag": "Cell"}, {"end": 208, "start": 193, "tag": "Cell"}, {"end": 214, "start": 210, "tag": "Cell"}, {"end": 221, "start": 217, "tag": "Cell"}, {"end": 153, "start": 140, "tag": "CellFunction"}, {"end": 338, "start": 326, "tag": "CellFunction"}, {"end": 202, "start": 177, "tag": "Cell"}, {"end": 232, "start": 222, "tag": "BiologicFunction"}, {"end": 208, "start": 177, "tag": "Cell"}, {"end": 284, "start": 271, "tag": "PathologicFunction"}, {"end": 173, "start": 158, "tag": "CellFunction"}, {"end": 90, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 82, "tag": "PharmacologicSubstance"}, {"end": 139, "start": 135, "tag": "Cell"}, {"end": 115, "start": 110, "tag": "NaturalPhenomenonOrProcess"}]}{"id": "1338_5", "text": "In contrast, constant darkness and exogenous melatonin exacerbated these events and amplified monocyte infiltration.", "tags": [{"end": 30, "start": 22, "tag": "NaturalPhenomenonOrProcess"}, {"end": 54, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 45, "tag": "PharmacologicSubstance"}, {"end": 54, "start": 45, "tag": "Chemical"}, {"end": 21, "start": 13, "tag": "TemporalConcept"}, {"end": 102, "start": 94, "tag": "Cell"}, {"end": 115, "start": 94, "tag": "CellFunction"}]}{"id": "1338_6", "text": "Therefore, melatonin should not be considered a universal remedy, as is currently claimed.", "tags": [{"end": 20, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 20, "start": 11, "tag": "PharmacologicSubstance"}, {"end": 20, "start": 11, "tag": "Chemical"}, {"end": 81, "start": 72, "tag": "TemporalConcept"}, {"end": 64, "start": 58, "tag": "HealthCareActivity"}]}{"id": "1338_7", "text": "Our data emphasize the importance of monitoring melatonin/cortisol oscillations in each MS patient by considering diet and lifestyle to avoid melatonin overdose.", "tags": [{"end": 118, "start": 114, "tag": "HealthCareActivity"}, {"end": 160, "start": 152, "tag": "InjuryOrPoisoning"}, {"end": 160, "start": 152, "tag": "Finding"}, {"end": 57, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 151, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 48, "tag": "PharmacologicSubstance"}, {"end": 151, "start": 142, "tag": "PharmacologicSubstance"}, {"end": 57, "start": 48, "tag": "Chemical"}, {"end": 151, "start": 142, "tag": "Chemical"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 90, "start": 88, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 37, "tag": "HealthCareActivity"}, {"end": 98, "start": 91, "tag": "PatientOrDisabledGroup"}, {"end": 66, "start": 58, "tag": "Chemical"}, {"end": 66, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 66, "start": 58, "tag": "PharmacologicSubstance"}, {"end": 132, "start": 123, "tag": "IndividualBehavior"}, {"end": 79, "start": 67, "tag": "Finding"}]}{"id": "1339_0", "text": "The unmet medical need of patients with multiple sclerosis (MS) is the inexorable loss of CNS myelin and latterly neurons leading to permanent neurologic disability.", "tags": [{"end": 142, "start": 133, "tag": "TemporalConcept"}, {"end": 164, "start": 143, "tag": "SignOrSymptom"}, {"end": 58, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 34, "start": 26, "tag": "PatientOrDisabledGroup"}, {"end": 93, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 114, "tag": "Cell"}, {"end": 62, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 154, "tag": "Finding"}, {"end": 22, "start": 4, "tag": "Finding"}]}{"id": "1339_1", "text": "Solicitation of endogenous oligodendrocytes progenitor cells, the precursor of oligodendrocytes, to remyelinate axons may abort the onset of disability.", "tags": [{"end": 75, "start": 66, "tag": "Cell"}, {"end": 117, "start": 112, "tag": "CellComponent"}, {"end": 43, "start": 27, "tag": "Cell"}, {"end": 95, "start": 79, "tag": "Cell"}, {"end": 111, "start": 100, "tag": "CellFunction"}, {"end": 60, "start": 44, "tag": "Cell"}, {"end": 137, "start": 132, "tag": "TemporalConcept"}, {"end": 151, "start": 141, "tag": "Finding"}]}{"id": "1339_2", "text": "In female mice with experimental autoimmune encephalomyelitis (EAE), a murine model of MS, adoptive transfer of IL-10(+) regulatory B cells (B-regs) has been shown to reverse EAE by promoting the expansion of peripheral and CNS-infiltrating IL-10(+) T cells.", "tags": [{"end": 108, "start": 91, "tag": "HealthCareActivity"}, {"end": 61, "start": 20, "tag": "ExperimentalModelOfDisease"}, {"end": 66, "start": 63, "tag": "ExperimentalModelOfDisease"}, {"end": 178, "start": 175, "tag": "ExperimentalModelOfDisease"}, {"end": 227, "start": 224, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 139, "start": 121, "tag": "Cell"}, {"end": 257, "start": 250, "tag": "Cell"}, {"end": 240, "start": 228, "tag": "Cell"}, {"end": 219, "start": 209, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 10, "tag": "Eukaryote"}, {"end": 83, "start": 78, "tag": "ResearchActivity"}, {"end": 77, "start": 71, "tag": "Eukaryote"}, {"end": 9, "start": 3, "tag": "OrganismAttribute"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 246, "start": 241, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 246, "start": 241, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 112, "tag": "GeneOrGenome"}, {"end": 246, "start": 241, "tag": "GeneOrGenome"}, {"end": 89, "start": 71, "tag": "ExperimentalModelOfDisease"}, {"end": 147, "start": 141, "tag": "Cell"}]}{"id": "1339_3", "text": "Here, we examined whether Bre g s treatment and its bystander effect on regulatory T cells are associated with CNS repair as reflected by oligodendrogenesis and remyelination.", "tags": [{"end": 90, "start": 72, "tag": "Cell"}, {"end": 156, "start": 138, "tag": "BiologicFunction"}, {"end": 114, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 52, "tag": "Finding"}, {"end": 43, "start": 34, "tag": "HealthCareActivity"}, {"end": 43, "start": 34, "tag": "ResearchActivity"}, {"end": 174, "start": 161, "tag": "CellFunction"}, {"end": 121, "start": 115, "tag": "BiologicFunction"}, {"end": 121, "start": 115, "tag": "HealthCareActivity"}, {"end": 33, "start": 26, "tag": "Cell"}]}{"id": "1339_4", "text": "We have found that transfusion of B-regs reverses established clinical EAE and that clinical improvement is associated with a significant increase in spinal cord remyelination as reflected by g-ratio analysis within the thoracic and lumbar spine.", "tags": [{"end": 30, "start": 19, "tag": "HealthCareActivity"}, {"end": 245, "start": 240, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 228, "start": 220, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 245, "start": 233, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 74, "start": 71, "tag": "ExperimentalModelOfDisease"}, {"end": 161, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 208, "start": 192, "tag": "ResearchActivity"}, {"end": 175, "start": 162, "tag": "CellFunction"}, {"end": 146, "start": 126, "tag": "Finding"}, {"end": 40, "start": 34, "tag": "Cell"}, {"end": 104, "start": 84, "tag": "Finding"}]}{"id": "1339_5", "text": "We further observed in the spinal cords of EAE B-regs-treated mice that CNS resident CD11b/CD45(int)Ly6C microglia, and infiltrating CD11b(+)/CD45(high) monocytes/macrophages content reverts to normal and polarize to a M2-like CD206(+) phenotype.", "tags": [{"end": 182, "start": 175, "tag": "BiologicFunction"}, {"end": 46, "start": 43, "tag": "ExperimentalModelOfDisease"}, {"end": 39, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 163, "tag": "Cell"}, {"end": 84, "start": 76, "tag": "PopulationGroup"}, {"end": 162, "start": 153, "tag": "Cell"}, {"end": 132, "start": 120, "tag": "Cell"}, {"end": 75, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 62, "tag": "Eukaryote"}, {"end": 245, "start": 236, "tag": "CellFunction"}, {"end": 226, "start": 219, "tag": "CellFunction"}, {"end": 114, "start": 105, "tag": "Cell"}, {"end": 200, "start": 194, "tag": "Finding"}, {"end": 53, "start": 47, "tag": "Cell"}, {"end": 90, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 90, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 91, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 91, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 232, "start": 227, "tag": "AminoAcidPeptideOrProtein"}, {"end": 232, "start": 227, "tag": "BiologicallyActiveSubstance"}]}{"id": "1339_6", "text": "Concurrently, there was a substantial increase in neo-oligodendrogenesis as manifest by an increase in CD45(-/low) CNS cells expressing A2B5, an early marker in oligodendrocytes progenitor cell differentiation as well as GalC(+)/01(+) premyelinating and myelin basic protein(+)/myelin oligodendrocyte glycoprotein(+) mature oligodendrocytes with reciprocal downregulation of paired related homeobox protein 1.", "tags": [{"end": 140, "start": 136, "tag": "Chemical"}, {"end": 408, "start": 390, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 125, "tag": "CellFunction"}, {"end": 72, "start": 54, "tag": "BiologicFunction"}, {"end": 398, "start": 390, "tag": "GeneOrGenome"}, {"end": 398, "start": 390, "tag": "AminoAcidPeptideOrProtein"}, {"end": 177, "start": 161, "tag": "Cell"}, {"end": 340, "start": 317, "tag": "Cell"}, {"end": 209, "start": 194, "tag": "CellFunction"}, {"end": 274, "start": 254, "tag": "AminoAcidPeptideOrProtein"}, {"end": 274, "start": 254, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 145, "tag": "TemporalConcept"}, {"end": 193, "start": 178, "tag": "Cell"}, {"end": 371, "start": 357, "tag": "CellFunction"}, {"end": 157, "start": 151, "tag": "ClinicalAttribute"}, {"end": 118, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 119, "tag": "Cell"}, {"end": 209, "start": 189, "tag": "CellFunction"}, {"end": 406, "start": 399, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 140, "start": 136, "tag": "BiologicallyActiveSubstance"}, {"end": 225, "start": 221, "tag": "GeneOrGenome"}, {"end": 225, "start": 221, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 221, "tag": "BiologicallyActiveSubstance"}, {"end": 313, "start": 278, "tag": "AminoAcidPeptideOrProtein"}, {"end": 313, "start": 278, "tag": "BiologicallyActiveSubstance"}]}{"id": "1339_7", "text": "These results demonstrate that the clinical benefit of B-regs is associated with normalization of CNS immune milieu and concurrent activation of oligodendrocyte progenitor cells with subsequent remyelination.", "tags": [{"end": 51, "start": 35, "tag": "Finding"}, {"end": 130, "start": 120, "tag": "TemporalConcept"}, {"end": 177, "start": 145, "tag": "Cell"}, {"end": 115, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 94, "start": 81, "tag": "ResearchActivity"}, {"end": 207, "start": 194, "tag": "CellFunction"}, {"end": 61, "start": 55, "tag": "Cell"}, {"end": 141, "start": 131, "tag": "CellFunction"}]}{"id": "1340_0", "text": "PRC2 creates the repressivemark histone H3 Lys27 trimethylation.", "tags": [{"end": 63, "start": 32, "tag": "CellFunction"}, {"end": 48, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1340_1", "text": "Although PRC2 is involved in various biological processes, its role in glial development remains ambiguous.", "tags": [{"end": 88, "start": 71, "tag": "CellFunction"}, {"end": 57, "start": 37, "tag": "BiologicFunction"}, {"end": 76, "start": 71, "tag": "Cell"}, {"end": 88, "start": 77, "tag": "BiologicFunction"}, {"end": 88, "start": 77, "tag": "CellFunction"}, {"end": 13, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 9, "tag": "BiologicallyActiveSubstance"}]}{"id": "1340_2", "text": "Here, we show that PRC2 is required for oligodendrocyte (OL) differentiation and myelination, but not for OL precursor formation.", "tags": [{"end": 59, "start": 57, "tag": "Cell"}, {"end": 118, "start": 106, "tag": "Cell"}, {"end": 92, "start": 81, "tag": "CellFunction"}, {"end": 55, "start": 40, "tag": "Cell"}, {"end": 76, "start": 61, "tag": "CellFunction"}, {"end": 23, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 19, "tag": "BiologicallyActiveSubstance"}]}{"id": "1340_3", "text": "PRC2-deficient OL lineage cells differentiate into OL precursors, but they fail to trigger the molecular program for myelination, highlighting that PRC2 is essential for directing the differentiation timing of OL precursors.", "tags": [{"end": 206, "start": 200, "tag": "TemporalConcept"}, {"end": 17, "start": 15, "tag": "Cell"}, {"end": 64, "start": 51, "tag": "Cell"}, {"end": 223, "start": 210, "tag": "Cell"}, {"end": 128, "start": 117, "tag": "CellFunction"}, {"end": 45, "start": 32, "tag": "CellFunction"}, {"end": 31, "start": 26, "tag": "Cell"}, {"end": 199, "start": 184, "tag": "CellFunction"}, {"end": 112, "start": 95, "tag": "CellFunction"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 148, "tag": "AminoAcidPeptideOrProtein"}, {"end": 152, "start": 148, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 0, "tag": "CellOrMolecularDysfunction"}]}{"id": "1340_4", "text": "PRC2 null OL lineage cells aberrantly induce Notch pathway genes and acquire astrocytic features.", "tags": [{"end": 87, "start": 77, "tag": "Cell"}, {"end": 12, "start": 10, "tag": "Cell"}, {"end": 58, "start": 45, "tag": "CellFunction"}, {"end": 26, "start": 10, "tag": "Cell"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 9, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 64, "start": 45, "tag": "GeneOrGenome"}]}{"id": "1340_5", "text": "The repression of the Notch pathway restores the myelination program and inhibits abnormal astrocytic differentiation in the PRC2-deficient OL lineage, indicating that Notch is a major target of PRC2.", "tags": [{"end": 14, "start": 4, "tag": "BiologicFunction"}, {"end": 14, "start": 4, "tag": "CellFunction"}, {"end": 117, "start": 91, "tag": "CellFunction"}, {"end": 173, "start": 168, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 168, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 140, "tag": "Cell"}, {"end": 68, "start": 49, "tag": "CellFunction"}, {"end": 35, "start": 22, "tag": "CellFunction"}, {"end": 117, "start": 102, "tag": "CellFunction"}, {"end": 117, "start": 82, "tag": "CellOrMolecularDysfunction"}, {"end": 129, "start": 125, "tag": "AminoAcidPeptideOrProtein"}, {"end": 129, "start": 125, "tag": "BiologicallyActiveSubstance"}, {"end": 139, "start": 125, "tag": "CellOrMolecularDysfunction"}, {"end": 199, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 199, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1340_6", "text": "Altogether, our studies propose a specific action of PRC2 as a novel gatekeeper that determines the glial fate choice and the timing of OL lineage progression and myelination by impinging on the Notch pathway.", "tags": [{"end": 132, "start": 126, "tag": "TemporalConcept"}, {"end": 146, "start": 136, "tag": "Cell"}, {"end": 174, "start": 163, "tag": "CellFunction"}, {"end": 105, "start": 100, "tag": "Cell"}, {"end": 158, "start": 147, "tag": "PathologicFunction"}, {"end": 158, "start": 147, "tag": "TemporalConcept"}, {"end": 208, "start": 195, "tag": "CellFunction"}, {"end": 23, "start": 16, "tag": "ResearchActivity"}, {"end": 57, "start": 53, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 53, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 100, "tag": "CellFunction"}]}{"id": "1341_0", "text": "Background: Abnormalities of myelin, which increases the efficiency of action potential conduction, are found in neurological disorders.", "tags": [{"end": 135, "start": 113, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 71, "tag": "CellFunction"}, {"end": 98, "start": 88, "tag": "BiologicFunction"}, {"end": 98, "start": 88, "tag": "NaturalPhenomenonOrProcess"}, {"end": 35, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 12, "tag": "PathologicFunction"}]}{"id": "1341_1", "text": "Korean Red Ginseng (KRG) demonstrates therapeutic efficacy against some of these conditions, however effects on oligodendrocyte (OL)s are not well known.", "tags": [{"end": 18, "start": 0, "tag": "Organism"}, {"end": 23, "start": 20, "tag": "Organism"}, {"end": 131, "start": 129, "tag": "Cell"}, {"end": 127, "start": 112, "tag": "Cell"}, {"end": 58, "start": 38, "tag": "Finding"}]}{"id": "1341_2", "text": "Here, we examined the effects of KRG-derived components on development and protection of OL-lineage cells.", "tags": [{"end": 32, "start": 22, "tag": "PathologicFunction"}, {"end": 91, "start": 89, "tag": "Cell"}, {"end": 105, "start": 89, "tag": "Cell"}, {"end": 70, "start": 59, "tag": "BiologicFunction"}, {"end": 70, "start": 59, "tag": "CellFunction"}, {"end": 36, "start": 33, "tag": "Organism"}]}{"id": "1341_3", "text": "Methods: Primary OL precursor cell (OPC) cultures were prepared from neonatal mouse cortex.", "tags": [{"end": 49, "start": 41, "tag": "ResearchActivity"}, {"end": 39, "start": 36, "tag": "Cell"}, {"end": 19, "start": 17, "tag": "Cell"}, {"end": 77, "start": 69, "tag": "PopulationGroup"}, {"end": 77, "start": 69, "tag": "TemporalConcept"}, {"end": 83, "start": 78, "tag": "Eukaryote"}, {"end": 34, "start": 9, "tag": "Cell"}, {"end": 90, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1341_4", "text": "The protective efficacies of the KRG components were examined against inhibitors of mitochondrial respiratory chain activity.", "tags": [{"end": 36, "start": 33, "tag": "Organism"}, {"end": 80, "start": 70, "tag": "Chemical"}, {"end": 80, "start": 70, "tag": "PharmacologicSubstance"}, {"end": 80, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 84, "tag": "CellComponent"}, {"end": 124, "start": 84, "tag": "CellFunction"}]}{"id": "1341_5", "text": "For in vivo function of Rb1 on myelination, after 10 days of oral gavage into adult male mice, forebrains were collected.", "tags": [{"end": 27, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 24, "tag": "GeneOrGenome"}, {"end": 72, "start": 61, "tag": "HealthCareActivity"}, {"end": 83, "start": 78, "tag": "PopulationGroup"}, {"end": 42, "start": 31, "tag": "CellFunction"}, {"end": 105, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 84, "tag": "OrganismAttribute"}, {"end": 93, "start": 89, "tag": "Eukaryote"}, {"end": 11, "start": 4, "tag": "ResearchActivity"}, {"end": 57, "start": 53, "tag": "TemporalConcept"}, {"end": 72, "start": 61, "tag": "ResearchActivity"}, {"end": 27, "start": 24, "tag": "Chemical"}]}{"id": "1341_6", "text": "OPC proliferation were assessed by BrdU incorporation, and differentiation and myelination were examined by qPCR, western blot and immunocytochemistry.", "tags": [{"end": 112, "start": 108, "tag": "ResearchActivity"}, {"end": 126, "start": 114, "tag": "ResearchActivity"}, {"end": 150, "start": 131, "tag": "ResearchActivity"}, {"end": 3, "start": 0, "tag": "Cell"}, {"end": 17, "start": 4, "tag": "CellFunction"}, {"end": 90, "start": 79, "tag": "CellFunction"}, {"end": 39, "start": 35, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 39, "start": 35, "tag": "PharmacologicSubstance"}, {"end": 74, "start": 59, "tag": "CellFunction"}]}{"id": "1341_7", "text": "Results: The non-saponin promoted OPC proliferation, while the saponin promoted differentiation.", "tags": [{"end": 70, "start": 63, "tag": "Chemical"}, {"end": 37, "start": 34, "tag": "Cell"}, {"end": 51, "start": 38, "tag": "CellFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 95, "start": 80, "tag": "CellFunction"}, {"end": 24, "start": 13, "tag": "Chemical"}]}{"id": "1341_8", "text": "Both processes were mediated by AKT and extracellular regulated kinase (ERK) signaling.", "tags": [{"end": 35, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 77, "tag": "CellFunction"}, {"end": 70, "start": 40, "tag": "CellFunction"}, {"end": 75, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 40, "tag": "BiologicallyActiveSubstance"}]}{"id": "1341_9", "text": "KRG extract, the saponin and non-saponin protected OPCs against oxidative stress, and both KRG extract and the saponin significantly increased the expression of the antioxidant enzyme.", "tags": [{"end": 3, "start": 0, "tag": "Organism"}, {"end": 11, "start": 4, "tag": "Substance"}, {"end": 24, "start": 17, "tag": "Chemical"}, {"end": 94, "start": 91, "tag": "Organism"}, {"end": 102, "start": 95, "tag": "Substance"}, {"end": 118, "start": 111, "tag": "Chemical"}, {"end": 80, "start": 64, "tag": "CellOrMolecularDysfunction"}, {"end": 55, "start": 51, "tag": "Cell"}, {"end": 176, "start": 165, "tag": "PharmacologicSubstance"}, {"end": 176, "start": 165, "tag": "CellFunction"}, {"end": 142, "start": 119, "tag": "Finding"}, {"end": 40, "start": 29, "tag": "Chemical"}, {"end": 183, "start": 177, "tag": "BiologicallyActiveSubstance"}]}{"id": "1341_10", "text": "Among 11 major ginsenosides tested, Rb1 significantly increased OL membrane size in vitro.", "tags": [{"end": 27, "start": 15, "tag": "Chemical"}, {"end": 39, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 36, "tag": "GeneOrGenome"}, {"end": 89, "start": 81, "tag": "ResearchActivity"}, {"end": 66, "start": 64, "tag": "Cell"}, {"end": 75, "start": 67, "tag": "CellComponent"}, {"end": 63, "start": 40, "tag": "Finding"}, {"end": 80, "start": 76, "tag": "OrganismAttribute"}, {"end": 39, "start": 36, "tag": "Chemical"}]}{"id": "1341_11", "text": "Moreover, Rb1 significantly increased myelin formation in adult mouse brain.", "tags": [{"end": 13, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 10, "tag": "GeneOrGenome"}, {"end": 63, "start": 58, "tag": "PopulationGroup"}, {"end": 54, "start": 38, "tag": "CellFunction"}, {"end": 37, "start": 14, "tag": "Finding"}, {"end": 75, "start": 70, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 64, "tag": "Eukaryote"}, {"end": 13, "start": 10, "tag": "Chemical"}]}{"id": "1341_12", "text": "Conclusion: All KRG components prevented OPC deaths under oxidative stress.", "tags": [{"end": 19, "start": 16, "tag": "Organism"}, {"end": 51, "start": 45, "tag": "BiologicFunction"}, {"end": 51, "start": 45, "tag": "Finding"}, {"end": 74, "start": 58, "tag": "CellOrMolecularDysfunction"}, {"end": 44, "start": 41, "tag": "Cell"}]}{"id": "1341_13", "text": "While non-saponin promoted proliferation, saponin fraction increased differentiation and OL membrane size.", "tags": [{"end": 49, "start": 42, "tag": "Chemical"}, {"end": 91, "start": 89, "tag": "Cell"}, {"end": 40, "start": 27, "tag": "CellFunction"}, {"end": 100, "start": 92, "tag": "CellComponent"}, {"end": 84, "start": 69, "tag": "CellFunction"}, {"end": 105, "start": 101, "tag": "OrganismAttribute"}]}{"id": "1341_14", "text": "Furthermore, among all the tested ginsenosides, Rb1 showed the biggest increase in the membrane size and significantly enhanced myelination in vivo.", "tags": [{"end": 46, "start": 34, "tag": "Chemical"}, {"end": 51, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 48, "tag": "GeneOrGenome"}, {"end": 139, "start": 128, "tag": "CellFunction"}, {"end": 95, "start": 87, "tag": "CellComponent"}, {"end": 147, "start": 140, "tag": "ResearchActivity"}, {"end": 100, "start": 96, "tag": "OrganismAttribute"}, {"end": 51, "start": 48, "tag": "Chemical"}]}{"id": "1341_15", "text": "These results imply therapeutic potentials of KRG and Rb1 for myelin-related disorders.", "tags": [{"end": 49, "start": 46, "tag": "Organism"}, {"end": 57, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 57, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 54, "tag": "GeneOrGenome"}, {"end": 68, "start": 62, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 54, "tag": "Chemical"}, {"end": 86, "start": 62, "tag": "DiseaseOrSyndrome"}]}{"id": "1341_16", "text": "(C) 2021 The Korean Society of Ginseng.", "tags": []}{"id": "1341_17", "text": "Publishing services by Elsevier B.V.", "tags": []}{"id": "1342_0", "text": "Multiple sclerosis (MS) is the most frequent demyelinating disease and a leading cause for disability in young adults.", "tags": [{"end": 117, "start": 105, "tag": "PopulationGroup"}, {"end": 44, "start": 36, "tag": "TemporalConcept"}, {"end": 117, "start": 111, "tag": "PopulationGroup"}, {"end": 58, "start": 45, "tag": "PathologicFunction"}, {"end": 66, "start": 45, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 91, "tag": "Finding"}]}{"id": "1342_1", "text": "Despite significant advances in immunotherapies in recent years, disease progression still cannot be prevented.", "tags": [{"end": 47, "start": 32, "tag": "HealthCareActivity"}, {"end": 84, "start": 73, "tag": "PathologicFunction"}, {"end": 84, "start": 73, "tag": "TemporalConcept"}, {"end": 63, "start": 58, "tag": "TemporalConcept"}, {"end": 63, "start": 51, "tag": "TemporalConcept"}, {"end": 84, "start": 65, "tag": "PathologicFunction"}, {"end": 28, "start": 20, "tag": "Finding"}]}{"id": "1342_2", "text": "Remyelination, meaning the formation of new myelin sheaths after a demyelinating event, can fail in MS lesions.", "tags": [{"end": 80, "start": 67, "tag": "PathologicFunction"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 103, "tag": "InjuryOrPoisoning"}, {"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 58, "start": 44, "tag": "CellComponent"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}]}{"id": "1342_3", "text": "Impaired differentiation of progenitor cells into myelinating oligodendrocytes may contribute to remyelination failure and, therefore, the development of pharmacological approaches which promote oligodendroglial differentiation and by that remyelination, represents a promising new treatment approach.", "tags": [{"end": 61, "start": 50, "tag": "CellFunction"}, {"end": 169, "start": 154, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 78, "start": 62, "tag": "Cell"}, {"end": 118, "start": 97, "tag": "CellOrMolecularDysfunction"}, {"end": 24, "start": 9, "tag": "CellFunction"}, {"end": 227, "start": 212, "tag": "CellFunction"}, {"end": 78, "start": 50, "tag": "Cell"}, {"end": 44, "start": 28, "tag": "Cell"}, {"end": 118, "start": 111, "tag": "IndividualBehavior"}, {"end": 211, "start": 195, "tag": "Cell"}, {"end": 150, "start": 139, "tag": "BiologicFunction"}, {"end": 150, "start": 139, "tag": "CellFunction"}, {"end": 291, "start": 282, "tag": "HealthCareActivity"}, {"end": 291, "start": 282, "tag": "ResearchActivity"}, {"end": 180, "start": 154, "tag": "HealthCareActivity"}, {"end": 110, "start": 97, "tag": "CellFunction"}, {"end": 253, "start": 240, "tag": "CellFunction"}]}{"id": "1342_4", "text": "However, this generally accepted concept has been challenged recently.", "tags": [{"end": 69, "start": 61, "tag": "TemporalConcept"}]}{"id": "1342_5", "text": "To further understand mechanisms contributing to remyelination failure in MS, we combined detailed histological analyses assessing oligodendroglial cell numbers, presence of remyelination as well as the inflammatory environment in different MS lesion types in white matter with in vitro experiments using induced-pluripotent stem cell (iPSC)-derived oligodendrocytes (hiOL) and supernatants from polarized human microglia.", "tags": [{"end": 390, "start": 378, "tag": "CellComponent"}, {"end": 298, "start": 287, "tag": "ResearchActivity"}, {"end": 340, "start": 336, "tag": "Cell"}, {"end": 366, "start": 350, "tag": "Cell"}, {"end": 250, "start": 244, "tag": "InjuryOrPoisoning"}, {"end": 70, "start": 49, "tag": "CellOrMolecularDysfunction"}, {"end": 272, "start": 260, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 63, "tag": "IndividualBehavior"}, {"end": 215, "start": 203, "tag": "PathologicFunction"}, {"end": 147, "start": 131, "tag": "Cell"}, {"end": 152, "start": 131, "tag": "Cell"}, {"end": 411, "start": 406, "tag": "Eukaryote"}, {"end": 152, "start": 148, "tag": "Cell"}, {"end": 334, "start": 330, "tag": "Cell"}, {"end": 421, "start": 412, "tag": "Cell"}, {"end": 405, "start": 396, "tag": "Cell"}, {"end": 286, "start": 278, "tag": "ResearchActivity"}, {"end": 120, "start": 99, "tag": "ResearchActivity"}, {"end": 62, "start": 49, "tag": "CellFunction"}, {"end": 187, "start": 174, "tag": "CellFunction"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 243, "start": 241, "tag": "DiseaseOrSyndrome"}, {"end": 170, "start": 162, "tag": "Finding"}, {"end": 334, "start": 305, "tag": "Cell"}]}{"id": "1342_6", "text": "Our findings suggest that there are multiple reasons for remyelination failure in MS which are dependent on lesion stage.", "tags": [{"end": 114, "start": 108, "tag": "InjuryOrPoisoning"}, {"end": 78, "start": 57, "tag": "CellOrMolecularDysfunction"}, {"end": 78, "start": 71, "tag": "IndividualBehavior"}, {"end": 70, "start": 57, "tag": "CellFunction"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 115, "tag": "TemporalConcept"}]}{"id": "1342_7", "text": "These include lack of myelin sheath formation despite the presence of mature oligodendrocytes in a subset of active lesions as well as oligodendroglial loss and a hostile tissue environment in mixed active/inactive lesions.", "tags": [{"end": 156, "start": 135, "tag": "CellOrMolecularDysfunction"}, {"end": 93, "start": 77, "tag": "Cell"}, {"end": 28, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 116, "tag": "InjuryOrPoisoning"}, {"end": 222, "start": 215, "tag": "InjuryOrPoisoning"}, {"end": 93, "start": 70, "tag": "Cell"}, {"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 151, "start": 135, "tag": "Cell"}, {"end": 177, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 22, "tag": "CellComponent"}, {"end": 66, "start": 58, "tag": "Finding"}, {"end": 45, "start": 14, "tag": "CellOrMolecularDysfunction"}]}{"id": "1342_8", "text": "Therefore, we conclude that better in vivo and in vitro models which mimic the pathological hallmarks of the different MS lesion types are required for the successful development of remyelination promoting drugs.", "tags": [{"end": 101, "start": 79, "tag": "Finding"}, {"end": 128, "start": 122, "tag": "InjuryOrPoisoning"}, {"end": 178, "start": 167, "tag": "BiologicFunction"}, {"end": 178, "start": 167, "tag": "CellFunction"}, {"end": 62, "start": 56, "tag": "ResearchActivity"}, {"end": 55, "start": 47, "tag": "ResearchActivity"}, {"end": 211, "start": 206, "tag": "PharmacologicSubstance"}, {"end": 42, "start": 35, "tag": "ResearchActivity"}, {"end": 195, "start": 182, "tag": "CellFunction"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}]}{"id": "1343_0", "text": "The high-mobility-group domain-containing transcription factor Sox9 confers glial competence to neuroepithelial precursors in the developing central nervous system and is an important determinant of astroglial and oligodendroglial specification.", "tags": [{"end": 67, "start": 63, "tag": "GeneOrGenome"}, {"end": 67, "start": 63, "tag": "AminoAcidPeptideOrProtein"}, {"end": 209, "start": 199, "tag": "Cell"}, {"end": 62, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 76, "tag": "Cell"}, {"end": 230, "start": 214, "tag": "Cell"}, {"end": 163, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 63, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 96, "tag": "Cell"}, {"end": 30, "start": 4, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1343_1", "text": "In oligodendroglial cells, it remains expressed in oligodendrocyte progenitor cells (OPCs) of the developing nervous system, but is shut off in differentiating oligodendrocytes as well as in OPCs that persist in the adult nervous system.", "tags": [{"end": 176, "start": 144, "tag": "Cell"}, {"end": 89, "start": 85, "tag": "Cell"}, {"end": 195, "start": 191, "tag": "Cell"}, {"end": 83, "start": 51, "tag": "Cell"}, {"end": 25, "start": 3, "tag": "Cell"}, {"end": 221, "start": 216, "tag": "PopulationGroup"}, {"end": 47, "start": 38, "tag": "CellFunction"}, {"end": 123, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 236, "start": 222, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1343_2", "text": "To better understand the role of Sox9 in OPCs, we generated mouse models that allowed oligodendroglial expression of a Sox9 transgene during development or in the adult.", "tags": [{"end": 37, "start": 33, "tag": "GeneOrGenome"}, {"end": 37, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 119, "tag": "GeneOrGenome"}, {"end": 123, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 124, "tag": "GeneOrGenome"}, {"end": 72, "start": 60, "tag": "ResearchActivity"}, {"end": 45, "start": 41, "tag": "Cell"}, {"end": 102, "start": 86, "tag": "Cell"}, {"end": 152, "start": 141, "tag": "BiologicFunction"}, {"end": 152, "start": 141, "tag": "CellFunction"}, {"end": 113, "start": 103, "tag": "CellFunction"}, {"end": 168, "start": 163, "tag": "PopulationGroup"}, {"end": 37, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 119, "tag": "BiologicallyActiveSubstance"}]}{"id": "1343_3", "text": "With transgene expression beginning in the last trimester of pregnancy, the number of OPCs increased dramatically, followed by comparable gains in the number of pre-myelinating and myelinating oligodendrocytes as assessed by marker gene expression.", "tags": [{"end": 14, "start": 5, "tag": "GeneOrGenome"}, {"end": 57, "start": 48, "tag": "TemporalConcept"}, {"end": 209, "start": 193, "tag": "Cell"}, {"end": 176, "start": 161, "tag": "Cell"}, {"end": 90, "start": 86, "tag": "Cell"}, {"end": 209, "start": 181, "tag": "Cell"}, {"end": 231, "start": 225, "tag": "ClinicalAttribute"}, {"end": 247, "start": 232, "tag": "CellFunction"}, {"end": 25, "start": 15, "tag": "CellFunction"}, {"end": 70, "start": 61, "tag": "BiologicFunction"}]}{"id": "1343_4", "text": "This argues that Sox9 boosts oligodendrogenesis during ontogenetic development at all stages, including terminal oligodendrocyte differentiation.", "tags": [{"end": 21, "start": 17, "tag": "GeneOrGenome"}, {"end": 21, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 29, "tag": "BiologicFunction"}, {"end": 144, "start": 104, "tag": "CellFunction"}, {"end": 78, "start": 55, "tag": "BiologicFunction"}, {"end": 128, "start": 113, "tag": "Cell"}, {"end": 92, "start": 86, "tag": "TemporalConcept"}, {"end": 21, "start": 17, "tag": "BiologicallyActiveSubstance"}]}{"id": "1343_5", "text": "When Sox9 transgene expression started in the adult, many transgene-expressing OPCs failed to maintain their progenitor cell identity and instead converted into myelinating oligodendrocytes.", "tags": [{"end": 9, "start": 5, "tag": "GeneOrGenome"}, {"end": 9, "start": 5, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 10, "tag": "GeneOrGenome"}, {"end": 133, "start": 125, "tag": "BiologicFunction"}, {"end": 172, "start": 161, "tag": "CellFunction"}, {"end": 78, "start": 68, "tag": "CellFunction"}, {"end": 189, "start": 173, "tag": "Cell"}, {"end": 83, "start": 79, "tag": "Cell"}, {"end": 189, "start": 161, "tag": "Cell"}, {"end": 124, "start": 109, "tag": "Cell"}, {"end": 30, "start": 20, "tag": "CellFunction"}, {"end": 51, "start": 46, "tag": "PopulationGroup"}, {"end": 9, "start": 5, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 58, "tag": "GeneOrGenome"}]}{"id": "1343_6", "text": "As infrequent and inefficient differentiation of adult OPCs is one of the main obstacles to effective remyelination in demyelinating diseases such as Multiple Sclerosis, increased Sox9 levels in adult OPCs may substantially increase their remyelination capacity.", "tags": [{"end": 184, "start": 180, "tag": "GeneOrGenome"}, {"end": 184, "start": 180, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 3, "tag": "TemporalConcept"}, {"end": 59, "start": 55, "tag": "Cell"}, {"end": 205, "start": 201, "tag": "Cell"}, {"end": 141, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 119, "tag": "PathologicFunction"}, {"end": 45, "start": 30, "tag": "CellFunction"}, {"end": 168, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 261, "start": 253, "tag": "Finding"}, {"end": 115, "start": 102, "tag": "CellFunction"}, {"end": 252, "start": 239, "tag": "CellFunction"}, {"end": 54, "start": 49, "tag": "PopulationGroup"}, {"end": 200, "start": 195, "tag": "PopulationGroup"}, {"end": 184, "start": 180, "tag": "BiologicallyActiveSubstance"}]}{"id": "1344_0", "text": "Multiple sclerosis (MS) is an autoimmune inflammatory disease characterized by demyelination, axonal loss, and synaptic impairment in the central nervous system (CNS).", "tags": [{"end": 105, "start": 94, "tag": "PathologicFunction"}, {"end": 100, "start": 94, "tag": "CellComponent"}, {"end": 53, "start": 41, "tag": "PathologicFunction"}, {"end": 119, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 160, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 165, "start": 162, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 79, "tag": "PathologicFunction"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 30, "tag": "PathologicFunction"}, {"end": 61, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 111, "tag": "PathologicFunction"}]}{"id": "1344_1", "text": "The available therapies aim to reduce the severity of the pathology during the early inflammatory stages, but they are not effective in the chronic stage of the disease.", "tags": [{"end": 84, "start": 79, "tag": "TemporalConcept"}, {"end": 97, "start": 85, "tag": "PathologicFunction"}, {"end": 67, "start": 58, "tag": "PathologicFunction"}, {"end": 67, "start": 58, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 50, "start": 42, "tag": "ClinicalAttribute"}, {"end": 50, "start": 42, "tag": "Finding"}, {"end": 23, "start": 14, "tag": "HealthCareActivity"}, {"end": 104, "start": 98, "tag": "TemporalConcept"}, {"end": 147, "start": 140, "tag": "TemporalConcept"}]}{"id": "1344_2", "text": "In this phase, failure in endogenous remyelination is associated with the impairment of oligodendrocytes progenitor cells (OPCs) to migrate and differentiate into mature myelinating oligodendrocytes.", "tags": [{"end": 84, "start": 74, "tag": "Finding"}, {"end": 181, "start": 170, "tag": "CellFunction"}, {"end": 13, "start": 8, "tag": "TemporalConcept"}, {"end": 104, "start": 88, "tag": "Cell"}, {"end": 198, "start": 182, "tag": "Cell"}, {"end": 127, "start": 123, "tag": "Cell"}, {"end": 157, "start": 144, "tag": "CellFunction"}, {"end": 198, "start": 170, "tag": "Cell"}, {"end": 121, "start": 105, "tag": "Cell"}, {"end": 169, "start": 163, "tag": "TemporalConcept"}, {"end": 22, "start": 15, "tag": "IndividualBehavior"}, {"end": 198, "start": 163, "tag": "Cell"}, {"end": 50, "start": 37, "tag": "CellFunction"}]}{"id": "1344_3", "text": "Therefore, stimulating differentiation of OPCs into myelinating oligodendrocytes has become one of the main goals of new therapeutic approaches for MS.", "tags": [{"end": 22, "start": 11, "tag": "NaturalPhenomenonOrProcess"}, {"end": 63, "start": 52, "tag": "CellFunction"}, {"end": 80, "start": 64, "tag": "Cell"}, {"end": 46, "start": 42, "tag": "Cell"}, {"end": 38, "start": 23, "tag": "CellFunction"}, {"end": 80, "start": 52, "tag": "Cell"}, {"end": 150, "start": 148, "tag": "DiseaseOrSyndrome"}, {"end": 143, "start": 121, "tag": "HealthCareActivity"}]}{"id": "1344_4", "text": "Different disease-modifying therapies targeting sphingosine-1-phosphate receptors (S1PRs) have been approved or are being developed to treat MS.", "tags": [{"end": 81, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 83, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 83, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 10, "tag": "HealthCareActivity"}, {"end": 143, "start": 141, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 48, "tag": "BiologicallyActiveSubstance"}]}{"id": "1344_5", "text": "Besides their immunomodulatory effects, growing evidence suggests that targeting S1PRs modulates mechanisms beyond immunomodulation, such as remyelination.", "tags": [{"end": 86, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 131, "start": 115, "tag": "BiologicFunction"}, {"end": 131, "start": 115, "tag": "HealthCareActivity"}, {"end": 131, "start": 115, "tag": "PharmacologicSubstance"}, {"end": 56, "start": 40, "tag": "Finding"}, {"end": 56, "start": 48, "tag": "Finding"}, {"end": 154, "start": 141, "tag": "CellFunction"}, {"end": 38, "start": 31, "tag": "Finding"}, {"end": 38, "start": 14, "tag": "Finding"}, {"end": 30, "start": 14, "tag": "PharmacologicSubstance"}, {"end": 30, "start": 14, "tag": "BiologicFunction"}, {"end": 30, "start": 14, "tag": "HealthCareActivity"}]}{"id": "1344_6", "text": "In this context, this review focuses on the current understanding of S1PR modulators and their direct effect on OPCs and oligodendrocytes.", "tags": [{"end": 137, "start": 121, "tag": "Cell"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 108, "start": 102, "tag": "Finding"}, {"end": 28, "start": 22, "tag": "ResearchActivity"}, {"end": 28, "start": 22, "tag": "HealthCareActivity"}, {"end": 51, "start": 44, "tag": "TemporalConcept"}, {"end": 65, "start": 52, "tag": "BiologicFunction"}, {"end": 84, "start": 74, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 69, "tag": "BiologicallyActiveSubstance"}]}{"id": "1345_0", "text": "Introduction: Semaphorin 3A (Sema 3A) is a secreted protein, which plays an integral part in developing the nervous syslem.", "tags": [{"end": 27, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 14, "tag": "GeneOrGenome"}, {"end": 36, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 29, "tag": "GeneOrGenome"}, {"end": 27, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 36, "start": 29, "tag": "BiologicallyActiveSubstance"}]}{"id": "1345_1", "text": "It has collapse activity on the growth cone of dorsal root ganglia After the development of the nervous sysclem, Sema 3A expression decreases.", "tags": [{"end": 43, "start": 32, "tag": "CellComponent"}, {"end": 66, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 113, "tag": "GeneOrGenome"}, {"end": 38, "start": 32, "tag": "BiologicFunction"}, {"end": 88, "start": 77, "tag": "BiologicFunction"}, {"end": 88, "start": 77, "tag": "CellFunction"}, {"end": 24, "start": 7, "tag": "CellFunction"}, {"end": 120, "start": 113, "tag": "BiologicallyActiveSubstance"}]}{"id": "1345_2", "text": "Neuropilin 1 is a membrane receptor of Sema 3A.", "tags": [{"end": 12, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 0, "tag": "GeneOrGenome"}, {"end": 35, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 39, "tag": "GeneOrGenome"}, {"end": 26, "start": 18, "tag": "CellComponent"}, {"end": 35, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 39, "tag": "BiologicallyActiveSubstance"}]}{"id": "1345_3", "text": "When semaphorin binds to neuropilin 1, the recruitment of oligodendrocyte precursor cells to the demyelinated site decreases.", "tags": [{"end": 15, "start": 5, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 5, "tag": "GeneOrGenome"}, {"end": 37, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 25, "tag": "GeneOrGenome"}, {"end": 109, "start": 97, "tag": "PathologicFunction"}, {"end": 89, "start": 74, "tag": "Cell"}, {"end": 83, "start": 58, "tag": "Cell"}, {"end": 89, "start": 58, "tag": "Cell"}, {"end": 15, "start": 5, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 25, "tag": "BiologicallyActiveSubstance"}]}{"id": "1345_4", "text": "In Multiple Sclerosis (MS), Sema 3A expression increases and inhibits oligodendrocyte precursor cell differentiation.", "tags": [{"end": 35, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 28, "tag": "GeneOrGenome"}, {"end": 100, "start": 70, "tag": "Cell"}, {"end": 95, "start": 70, "tag": "Cell"}, {"end": 116, "start": 70, "tag": "CellFunction"}, {"end": 21, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 25, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 101, "tag": "CellFunction"}, {"end": 35, "start": 28, "tag": "BiologicallyActiveSubstance"}]}{"id": "1345_5", "text": "Therefore, the remyelination of axons gets impaired.", "tags": [{"end": 37, "start": 32, "tag": "CellComponent"}, {"end": 28, "start": 15, "tag": "CellFunction"}]}{"id": "1345_6", "text": "We hypothesized that the function of Sema 3A could be inhibited by neutralizing its binding to membrane NRP1.", "tags": [{"end": 44, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 37, "tag": "GeneOrGenome"}, {"end": 108, "start": 104, "tag": "GeneOrGenome"}, {"end": 108, "start": 104, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 95, "tag": "CellComponent"}, {"end": 91, "start": 84, "tag": "CellFunction"}, {"end": 44, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 108, "start": 104, "tag": "BiologicallyActiveSubstance"}]}{"id": "1345_7", "text": "Methods: we cloned a soluble form of mouse Neuropilin 1 (msNRP1) in a lentiviral vector and expressed the recombinant protein in HEK293T cells.", "tags": [{"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 28, "start": 21, "tag": "CellComponent"}, {"end": 125, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 129, "tag": "Cell"}, {"end": 42, "start": 37, "tag": "Eukaryote"}, {"end": 101, "start": 92, "tag": "CellFunction"}, {"end": 55, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 57, "tag": "GeneOrGenome"}, {"end": 87, "start": 70, "tag": "Virus"}, {"end": 87, "start": 70, "tag": "ResearchActivity"}]}{"id": "1345_8", "text": "Then, the conditioned medium of the transduced cells was used to evaluate the effects of the msNRP1 on the inhibition of Sema 3A-induced growth cone collapse activity.", "tags": [{"end": 28, "start": 10, "tag": "Chemical"}, {"end": 128, "start": 121, "tag": "GeneOrGenome"}, {"end": 128, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 137, "tag": "BiologicFunction"}, {"end": 117, "start": 107, "tag": "CellFunction"}, {"end": 52, "start": 36, "tag": "Cell"}, {"end": 52, "start": 36, "tag": "ResearchActivity"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 93, "tag": "GeneOrGenome"}, {"end": 128, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 137, "tag": "CellFunction"}, {"end": 148, "start": 137, "tag": "CellComponent"}]}{"id": "1345_9", "text": "Dorsal root ganglion explants of timed pregnant (E13) mice were prepared.", "tags": [{"end": 20, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 21, "tag": "ResearchActivity"}, {"end": 52, "start": 49, "tag": "TemporalConcept"}, {"end": 58, "start": 54, "tag": "Eukaryote"}, {"end": 47, "start": 33, "tag": "Eukaryote"}]}{"id": "1345_10", "text": "Then, the growth cone collapse activity of Sema 3A was assessed in the presence and absence of msNRP1-containing conditioned media of transduced and non-transduced HEK293T cells.", "tags": [{"end": 39, "start": 10, "tag": "CellFunction"}, {"end": 50, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 43, "tag": "GeneOrGenome"}, {"end": 79, "start": 71, "tag": "Finding"}, {"end": 130, "start": 113, "tag": "Chemical"}, {"end": 16, "start": 10, "tag": "BiologicFunction"}, {"end": 177, "start": 164, "tag": "Cell"}, {"end": 21, "start": 10, "tag": "CellComponent"}, {"end": 50, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 101, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 95, "tag": "GeneOrGenome"}, {"end": 177, "start": 172, "tag": "ResearchActivity"}, {"end": 144, "start": 134, "tag": "ResearchActivity"}, {"end": 177, "start": 172, "tag": "ResearchActivity"}, {"end": 163, "start": 149, "tag": "ResearchActivity"}]}{"id": "1345_11", "text": "Comparisons between groups were performed by 1-way ANOVA and post hoc Tukey teas.", "tags": [{"end": 75, "start": 61, "tag": "ResearchActivity"}, {"end": 56, "start": 45, "tag": "ResearchActivity"}]}{"id": "1345_12", "text": "Results: msNRP1 was successfully cloned and transduced in HEK293T cells.", "tags": [{"end": 39, "start": 33, "tag": "ResearchActivity"}, {"end": 54, "start": 44, "tag": "ResearchActivity"}, {"end": 71, "start": 58, "tag": "Cell"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 15, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 15, "start": 9, "tag": "GeneOrGenome"}]}{"id": "1345_13", "text": "The supematant of transduced cells was concentrated and evaluated for the production of msNRP1.", "tags": [{"end": 34, "start": 18, "tag": "Cell"}, {"end": 14, "start": 4, "tag": "Chemical"}, {"end": 94, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 88, "tag": "GeneOrGenome"}]}{"id": "1345_14", "text": "ELISA results indicated that transduced cells secreted msNRP1.", "tags": [{"end": 45, "start": 29, "tag": "Cell"}, {"end": 5, "start": 0, "tag": "ResearchActivity"}, {"end": 61, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 55, "tag": "GeneOrGenome"}]}{"id": "1345_15", "text": "Growth cone collapse assay showed that Sema 3A activity was significantly reduced in the presence of the conditioned medium of msNRP1-transduced HEK293T cells.", "tags": [{"end": 46, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 39, "tag": "GeneOrGenome"}, {"end": 97, "start": 89, "tag": "Finding"}, {"end": 123, "start": 105, "tag": "Chemical"}, {"end": 158, "start": 134, "tag": "Cell"}, {"end": 11, "start": 0, "tag": "CellComponent"}, {"end": 26, "start": 0, "tag": "ResearchActivity"}, {"end": 55, "start": 39, "tag": "CellFunction"}, {"end": 133, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 133, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 127, "tag": "GeneOrGenome"}, {"end": 20, "start": 0, "tag": "CellFunction"}]}{"id": "1345_16", "text": "Conversely, a conditioned medium of non-transduced HEK293T cells could not effectively prevent Sema 3A growth cone collapse activity.", "tags": [{"end": 32, "start": 14, "tag": "Chemical"}, {"end": 102, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 95, "tag": "GeneOrGenome"}, {"end": 132, "start": 103, "tag": "CellFunction"}, {"end": 64, "start": 36, "tag": "Cell"}, {"end": 102, "start": 95, "tag": "BiologicallyActiveSubstance"}]}{"id": "1345_17", "text": "Conclusion: Our results indicated that msNRP1 was successfully produced in HEK293T cells.", "tags": [{"end": 88, "start": 75, "tag": "Cell"}, {"end": 45, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 39, "tag": "GeneOrGenome"}]}{"id": "1345_18", "text": "The secreted msNRP1 effectively prevented Sema 3A collapse activity.", "tags": [{"end": 49, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 42, "tag": "GeneOrGenome"}, {"end": 19, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 19, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 19, "start": 13, "tag": "GeneOrGenome"}, {"end": 67, "start": 50, "tag": "CellFunction"}, {"end": 49, "start": 42, "tag": "BiologicallyActiveSubstance"}]}{"id": "1345_19", "text": "Therefore, msNRP1 can increase remyelination in MS lesions, although more studies using animal models are required.", "tags": [{"end": 44, "start": 31, "tag": "CellFunction"}, {"end": 81, "start": 74, "tag": "ResearchActivity"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 58, "start": 51, "tag": "InjuryOrPoisoning"}, {"end": 101, "start": 88, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 11, "tag": "GeneOrGenome"}]}{"id": "1346_0", "text": "Remyelination, namely, the formation of new myelin sheaths around denuded axons, counteracts axonal degeneration and restores neuronal function.", "tags": [{"end": 13, "start": 0, "tag": "CellFunction"}, {"end": 143, "start": 126, "tag": "CellFunction"}, {"end": 79, "start": 74, "tag": "CellComponent"}, {"end": 58, "start": 44, "tag": "CellComponent"}, {"end": 112, "start": 93, "tag": "CellOrMolecularDysfunction"}]}{"id": "1346_1", "text": "Considerable advances have been made in understanding this regenerative process that often fails in diseases like multiple sclerosis, leaving axons demyelinated and vulnerable to damage, thus contributing to disease progression.", "tags": [{"end": 160, "start": 148, "tag": "PathologicFunction"}, {"end": 147, "start": 142, "tag": "CellComponent"}, {"end": 21, "start": 13, "tag": "Finding"}, {"end": 53, "start": 40, "tag": "BiologicFunction"}, {"end": 227, "start": 216, "tag": "PathologicFunction"}, {"end": 227, "start": 216, "tag": "TemporalConcept"}, {"end": 132, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 227, "start": 208, "tag": "PathologicFunction"}]}{"id": "1346_2", "text": "The identification of the membrane receptor GPR17 on a subset of oligodendrocyte precursor cells (OPCs), which mediate remyelination in the adult central nervous system (CNS), has led to a huge amount of evidence that validated this receptor as a new attractive target for remyelinating therapies.", "tags": [{"end": 43, "start": 26, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 44, "tag": "GeneOrGenome"}, {"end": 49, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 140, "tag": "PopulationGroup"}, {"end": 173, "start": 170, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 119, "tag": "CellFunction"}, {"end": 102, "start": 98, "tag": "Cell"}, {"end": 296, "start": 273, "tag": "HealthCareActivity"}, {"end": 96, "start": 65, "tag": "Cell"}, {"end": 241, "start": 233, "tag": "BiologicallyActiveSubstance"}, {"end": 212, "start": 204, "tag": "Finding"}, {"end": 168, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 268, "start": 247, "tag": "Finding"}]}{"id": "1346_3", "text": "Here, we summarize the role of GPR17 in OPC function, myelination and remyelination, describing its atypical pharmacology, its downstream signaling, and the genetic and epigenetic factors modulating its activity.", "tags": [{"end": 36, "start": 31, "tag": "GeneOrGenome"}, {"end": 36, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 108, "start": 100, "tag": "Finding"}, {"end": 121, "start": 109, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 164, "start": 157, "tag": "HealthCareActivity"}, {"end": 83, "start": 70, "tag": "CellFunction"}, {"end": 43, "start": 40, "tag": "Cell"}, {"end": 65, "start": 54, "tag": "CellFunction"}, {"end": 147, "start": 127, "tag": "CellFunction"}, {"end": 36, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 187, "start": 169, "tag": "AminoAcidPeptideOrProtein"}, {"end": 187, "start": 169, "tag": "BiologicallyActiveSubstance"}]}{"id": "1346_4", "text": "We also highlight crucial insights into GPR17 pathophysiology coming from the demonstration that oligodendrocyte injury, associated with inflammation in chronic neurodegenerative conditions, is invariably characterized by abnormal and persistent GPR17 upregulation, which, in turn, is accompanied by a block of OPCs at immature premyelinating stages.", "tags": [{"end": 45, "start": 40, "tag": "GeneOrGenome"}, {"end": 45, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 230, "start": 222, "tag": "Finding"}, {"end": 245, "start": 235, "tag": "TemporalConcept"}, {"end": 251, "start": 246, "tag": "GeneOrGenome"}, {"end": 251, "start": 246, "tag": "AminoAcidPeptideOrProtein"}, {"end": 264, "start": 252, "tag": "CellFunction"}, {"end": 307, "start": 302, "tag": "Finding"}, {"end": 327, "start": 319, "tag": "BiologicFunction"}, {"end": 349, "start": 343, "tag": "TemporalConcept"}, {"end": 315, "start": 311, "tag": "Cell"}, {"end": 112, "start": 97, "tag": "Cell"}, {"end": 189, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 153, "tag": "TemporalConcept"}, {"end": 119, "start": 113, "tag": "InjuryOrPoisoning"}, {"end": 149, "start": 137, "tag": "PathologicFunction"}, {"end": 61, "start": 46, "tag": "PathologicFunction"}, {"end": 61, "start": 46, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 45, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 251, "start": 246, "tag": "BiologicallyActiveSubstance"}]}{"id": "1346_5", "text": "Finally, we discuss the current literature in light of the potential exploitment of GPR17 as a therapeutic target to promote remyelination.", "tags": [{"end": 89, "start": 84, "tag": "GeneOrGenome"}, {"end": 89, "start": 84, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 32, "tag": "ResearchActivity"}, {"end": 138, "start": 125, "tag": "CellFunction"}, {"end": 31, "start": 24, "tag": "TemporalConcept"}, {"end": 89, "start": 84, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 95, "tag": "Finding"}]}{"id": "1347_0", "text": "Biological inflammation induced during penetrating cortical injury can disrupt functional neuronal and glial activity within the cortex, resulting in potential recording failure of chronically implanted neural interfaces.", "tags": [{"end": 220, "start": 193, "tag": "ManufacturedObject"}, {"end": 177, "start": 170, "tag": "IndividualBehavior"}, {"end": 108, "start": 103, "tag": "Cell"}, {"end": 98, "start": 90, "tag": "Cell"}, {"end": 23, "start": 11, "tag": "PathologicFunction"}, {"end": 135, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 60, "tag": "InjuryOrPoisoning"}, {"end": 117, "start": 103, "tag": "CellFunction"}]}{"id": "1347_1", "text": "Oligodendrocytes provide critical support for neuronal health and function through direct contact with neuronal soma and axons within the cortex.", "tags": [{"end": 116, "start": 103, "tag": "CellComponent"}, {"end": 126, "start": 121, "tag": "CellComponent"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 54, "start": 46, "tag": "Cell"}, {"end": 111, "start": 103, "tag": "Cell"}, {"end": 144, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 55, "tag": "HealthCareActivity"}]}{"id": "1347_2", "text": "Given their fundamental role to regulate neuronal activity via myelin, coupled with their heightened vulnerability to metabolic brain injury due to high energetic demands, oligodendrocytes are hypothesized as a possible source of biological failure in declining recording performances of intracortical microelectrode devices.", "tags": [{"end": 114, "start": 101, "tag": "ClinicalAttribute"}, {"end": 248, "start": 230, "tag": "Finding"}, {"end": 188, "start": 172, "tag": "Cell"}, {"end": 69, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 248, "start": 241, "tag": "IndividualBehavior"}, {"end": 58, "start": 41, "tag": "CellFunction"}, {"end": 133, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 41, "tag": "Cell"}, {"end": 152, "start": 148, "tag": "Finding"}, {"end": 140, "start": 134, "tag": "InjuryOrPoisoning"}, {"end": 127, "start": 118, "tag": "InjuryOrPoisoning"}, {"end": 301, "start": 288, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 324, "start": 302, "tag": "ManufacturedObject"}, {"end": 284, "start": 262, "tag": "Finding"}]}{"id": "1347_3", "text": "To determine the extent of their contribution to neuronal activity and function, a cuprizone-inducible model of oligodendrocyte depletion and demyelination in mice was performed prior to microelectrode implantation.", "tags": [{"end": 92, "start": 83, "tag": "Chemical"}, {"end": 66, "start": 49, "tag": "CellFunction"}, {"end": 163, "start": 159, "tag": "Eukaryote"}, {"end": 57, "start": 49, "tag": "Cell"}, {"end": 108, "start": 103, "tag": "ResearchActivity"}, {"end": 127, "start": 112, "tag": "Cell"}, {"end": 155, "start": 142, "tag": "PathologicFunction"}, {"end": 201, "start": 187, "tag": "ManufacturedObject"}, {"end": 214, "start": 202, "tag": "ResearchActivity"}, {"end": 214, "start": 202, "tag": "HealthCareActivity"}]}{"id": "1347_4", "text": "At 5 weeks of cuprizone exposure, mice demonstrated significantly reduced cortical oligodendrocyte density and myelin expression.", "tags": [{"end": 32, "start": 14, "tag": "InjuryOrPoisoning"}, {"end": 117, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 23, "start": 14, "tag": "Chemical"}, {"end": 10, "start": 5, "tag": "TemporalConcept"}, {"end": 128, "start": 111, "tag": "CellFunction"}, {"end": 38, "start": 34, "tag": "Eukaryote"}, {"end": 128, "start": 118, "tag": "CellFunction"}, {"end": 82, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 83, "tag": "Cell"}, {"end": 106, "start": 83, "tag": "ClinicalAttribute"}]}{"id": "1347_5", "text": "Mice were then implanted with functional recording microelectrodes in the visual cortex and neuronal activity was evaluated up to 7 weeks alongside continued cuprizone administration.", "tags": [{"end": 4, "start": 0, "tag": "Eukaryote"}, {"end": 87, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 158, "tag": "Chemical"}, {"end": 137, "start": 132, "tag": "TemporalConcept"}, {"end": 109, "start": 92, "tag": "CellFunction"}, {"end": 182, "start": 168, "tag": "HealthCareActivity"}, {"end": 66, "start": 51, "tag": "ManufacturedObject"}]}{"id": "1347_6", "text": "Cuprizone-induced oligodendrocyte loss and demyelination was associated with significantly reduced recording performances at the onset of implantation, which remained relatively stable over time.", "tags": [{"end": 150, "start": 138, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "Chemical"}, {"end": 38, "start": 18, "tag": "CellOrMolecularDysfunction"}, {"end": 134, "start": 129, "tag": "TemporalConcept"}, {"end": 194, "start": 190, "tag": "TemporalConcept"}, {"end": 56, "start": 43, "tag": "PathologicFunction"}, {"end": 150, "start": 138, "tag": "ResearchActivity"}, {"end": 121, "start": 99, "tag": "Finding"}]}{"id": "1347_7", "text": "In contast, recording performances for mice on a normal diet were intially elevated before decreasing over time to the recording level of tcuprizone-treated mice.", "tags": [{"end": 101, "start": 91, "tag": "Finding"}, {"end": 60, "start": 49, "tag": "Finding"}, {"end": 60, "start": 56, "tag": "HealthCareActivity"}, {"end": 43, "start": 39, "tag": "Eukaryote"}, {"end": 161, "start": 157, "tag": "Eukaryote"}, {"end": 111, "start": 107, "tag": "TemporalConcept"}, {"end": 55, "start": 49, "tag": "Finding"}, {"end": 34, "start": 12, "tag": "Finding"}]}{"id": "1347_8", "text": "Further electro-physiological analysis revealed deficits in multi-unit firing rates, frequency-dependent disruptions in neuronal oscillations, and altered laminar communication within the cortex of cuprizone-treated mice.", "tags": [{"end": 94, "start": 85, "tag": "TemporalConcept"}, {"end": 207, "start": 198, "tag": "Chemical"}, {"end": 56, "start": 48, "tag": "Finding"}, {"end": 38, "start": 8, "tag": "ResearchActivity"}, {"end": 220, "start": 216, "tag": "Eukaryote"}, {"end": 128, "start": 120, "tag": "Cell"}, {"end": 194, "start": 188, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 60, "tag": "ResearchActivity"}, {"end": 176, "start": 155, "tag": "BiologicFunction"}, {"end": 141, "start": 120, "tag": "CellFunction"}]}{"id": "1347_9", "text": "Post-mortem immunohistochemistry revealed robust depletion of oligodendrocytes around implanted microelectrode arrays alongside comparable neuronal densities to control mice, suggesting that oligodendrocyte loss was a possible contributor to chronically impaired device performances.", "tags": [{"end": 157, "start": 139, "tag": "ClinicalAttribute"}, {"end": 78, "start": 62, "tag": "Cell"}, {"end": 211, "start": 191, "tag": "CellOrMolecularDysfunction"}, {"end": 173, "start": 169, "tag": "Eukaryote"}, {"end": 32, "start": 12, "tag": "ResearchActivity"}, {"end": 117, "start": 96, "tag": "ManufacturedObject"}, {"end": 11, "start": 0, "tag": "TemporalConcept"}, {"end": 269, "start": 263, "tag": "ManufacturedObject"}]}{"id": "1347_10", "text": "This study highlights potentially significant contributions from the oligodendrocyte lineage population concerning the biological integration and long-term functional performance of neural interfacing technology.", "tags": [{"end": 178, "start": 156, "tag": "OrganismAttribute"}, {"end": 155, "start": 146, "tag": "TemporalConcept"}, {"end": 92, "start": 69, "tag": "Cell"}, {"end": 141, "start": 130, "tag": "CellFunction"}, {"end": 141, "start": 130, "tag": "MachineActivity"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 103, "start": 93, "tag": "PopulationGroup"}, {"end": 178, "start": 167, "tag": "ClinicalAttribute"}, {"end": 178, "start": 167, "tag": "Finding"}, {"end": 141, "start": 119, "tag": "BiologicFunction"}, {"end": 211, "start": 182, "tag": "ResearchActivity"}]}{"id": "1348_0", "text": "Background Multiple sclerosis is characterised by inflammation, oligodendrocyte loss and axonal demyelination and shows an additional impact on astrocytes, and their polarization.", "tags": [{"end": 109, "start": 89, "tag": "PathologicFunction"}, {"end": 178, "start": 166, "tag": "ClinicalAttribute"}, {"end": 178, "start": 166, "tag": "CellFunction"}, {"end": 95, "start": 89, "tag": "CellComponent"}, {"end": 154, "start": 144, "tag": "Cell"}, {"end": 109, "start": 96, "tag": "PathologicFunction"}, {"end": 29, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 50, "tag": "PathologicFunction"}, {"end": 84, "start": 64, "tag": "CellOrMolecularDysfunction"}]}{"id": "1348_1", "text": "Although a certain degree of spontaneous myelin repair can be observed, disease progression, and aging impair regeneration efforts highlighting the need to better understand glial cell dynamics to establish specific regenerative treatments.", "tags": [{"end": 184, "start": 174, "tag": "Cell"}, {"end": 122, "start": 110, "tag": "BiologicFunction"}, {"end": 122, "start": 110, "tag": "HealthCareActivity"}, {"end": 54, "start": 41, "tag": "CellFunction"}, {"end": 179, "start": 174, "tag": "Cell"}, {"end": 91, "start": 80, "tag": "PathologicFunction"}, {"end": 91, "start": 80, "tag": "TemporalConcept"}, {"end": 102, "start": 97, "tag": "BiologicFunction"}, {"end": 102, "start": 97, "tag": "CellFunction"}, {"end": 54, "start": 48, "tag": "BiologicFunction"}, {"end": 54, "start": 48, "tag": "HealthCareActivity"}, {"end": 47, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 72, "tag": "PathologicFunction"}, {"end": 193, "start": 185, "tag": "NaturalPhenomenonOrProcess"}, {"end": 239, "start": 216, "tag": "HealthCareActivity"}, {"end": 239, "start": 216, "tag": "ResearchActivity"}]}{"id": "1348_2", "text": "Methods Applying a chronic demyelination model, we here analysed demyelination and remyelination related effects on astrocytes and stem cell niches and studied the consequences of medrysone application on myelin repair, and astrocyte polarization.", "tags": [{"end": 140, "start": 131, "tag": "Cell"}, {"end": 189, "start": 180, "tag": "Chemical"}, {"end": 246, "start": 234, "tag": "ClinicalAttribute"}, {"end": 246, "start": 224, "tag": "CellFunction"}, {"end": 126, "start": 116, "tag": "Cell"}, {"end": 96, "start": 83, "tag": "CellFunction"}, {"end": 233, "start": 224, "tag": "Cell"}, {"end": 218, "start": 205, "tag": "CellFunction"}, {"end": 46, "start": 41, "tag": "ResearchActivity"}, {"end": 40, "start": 27, "tag": "PathologicFunction"}, {"end": 78, "start": 65, "tag": "PathologicFunction"}, {"end": 26, "start": 19, "tag": "TemporalConcept"}, {"end": 218, "start": 212, "tag": "BiologicFunction"}, {"end": 218, "start": 212, "tag": "HealthCareActivity"}, {"end": 211, "start": 205, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 189, "start": 180, "tag": "PharmacologicSubstance"}]}{"id": "1348_3", "text": "Findings Medrysone induced recovery of mature oligodendrocytes, myelin expression and node formation.", "tags": [{"end": 18, "start": 9, "tag": "Chemical"}, {"end": 62, "start": 39, "tag": "Cell"}, {"end": 35, "start": 27, "tag": "BiologicFunction"}, {"end": 35, "start": 27, "tag": "HealthCareActivity"}, {"end": 35, "start": 27, "tag": "TemporalConcept"}, {"end": 70, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 9, "tag": "PharmacologicSubstance"}, {"end": 81, "start": 64, "tag": "CellFunction"}, {"end": 100, "start": 86, "tag": "CellFunction"}]}{"id": "1348_4", "text": "In addition, C3d/S100a10 co-expression in astrocytes was enhanced.", "tags": [{"end": 52, "start": 42, "tag": "Cell"}, {"end": 24, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 24, "start": 17, "tag": "GeneOrGenome"}, {"end": 16, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 13, "tag": "GeneOrGenome"}, {"end": 16, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 25, "tag": "CellFunction"}]}{"id": "1348_5", "text": "Moreover, Timp1 expression in C3d positive astrocytes revealed another astrocytic phenotype with a myelination promoting character.", "tags": [{"end": 15, "start": 10, "tag": "GeneOrGenome"}, {"end": 15, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 71, "tag": "Cell"}, {"end": 53, "start": 43, "tag": "Cell"}, {"end": 91, "start": 82, "tag": "OrganismAttribute"}, {"end": 110, "start": 99, "tag": "CellFunction"}, {"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 33, "start": 30, "tag": "GeneOrGenome"}, {"end": 15, "start": 10, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1348_6", "text": "Interpretation Based on these findings, specific astrocyte subpopulations are suggested to act in a myelin regenerative way and manner the regulation of which can be positively modulated by this corticosteroid.", "tags": [{"end": 209, "start": 195, "tag": "Chemical"}, {"end": 209, "start": 195, "tag": "PharmacologicSubstance"}, {"end": 73, "start": 49, "tag": "Cell"}, {"end": 106, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 195, "tag": "BiologicallyActiveSubstance"}]}{"id": "1348_7", "text": "Copyright (C) 2022 The Authors.", "tags": []}{"id": "1348_8", "text": "Published by Elsevier B.V.", "tags": []}{"id": "1349_0", "text": "Chronic cerebral hypoperfusion (CCH) may amplify the neurotoxicity of nanoscale particulate matter (nPM), resulting in white matter injury.", "tags": [{"end": 138, "start": 119, "tag": "Finding"}, {"end": 131, "start": 119, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 66, "start": 53, "tag": "InjuryOrPoisoning"}, {"end": 30, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 32, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 70, "tag": "Substance"}, {"end": 103, "start": 100, "tag": "Substance"}]}{"id": "1349_1", "text": "This study characterized the joint effects of nPM (diameter <= 200 nm) and CCH secondary to bilateral carotid artery stenosis (BCAS) exposure on neuronal and white matter injury in a murine model.", "tags": [{"end": 34, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 127, "tag": "PathologicFunction"}, {"end": 141, "start": 133, "tag": "InjuryOrPoisoning"}, {"end": 125, "start": 92, "tag": "InjuryOrPoisoning"}, {"end": 177, "start": 158, "tag": "Finding"}, {"end": 170, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 153, "start": 145, "tag": "Cell"}, {"end": 195, "start": 190, "tag": "ResearchActivity"}, {"end": 189, "start": 183, "tag": "Eukaryote"}, {"end": 42, "start": 35, "tag": "Finding"}, {"end": 49, "start": 46, "tag": "Substance"}, {"end": 125, "start": 92, "tag": "PathologicFunction"}, {"end": 78, "start": 75, "tag": "DiseaseOrSyndrome"}, {"end": 131, "start": 127, "tag": "DiseaseOrSyndrome"}]}{"id": "1349_2", "text": "nPM was collected near a highway and re-aerosolized for exposure.", "tags": [{"end": 3, "start": 0, "tag": "Substance"}]}{"id": "1349_3", "text": "Ten-week-old C57BL/6 male mice were randomized into four groups: filtered air (FA), nPM, FA + BCAS, and nPM + BCAS.", "tags": [{"end": 46, "start": 36, "tag": "ResearchActivity"}, {"end": 98, "start": 94, "tag": "PathologicFunction"}, {"end": 114, "start": 110, "tag": "PathologicFunction"}, {"end": 8, "start": 4, "tag": "TemporalConcept"}, {"end": 30, "start": 26, "tag": "Eukaryote"}, {"end": 20, "start": 13, "tag": "Eukaryote"}, {"end": 25, "start": 21, "tag": "OrganismAttribute"}, {"end": 87, "start": 84, "tag": "Substance"}, {"end": 107, "start": 104, "tag": "Substance"}, {"end": 98, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 65, "tag": "Substance"}, {"end": 81, "start": 79, "tag": "Substance"}, {"end": 91, "start": 89, "tag": "Substance"}]}{"id": "1349_4", "text": "Mice were exposed to FA or nPM for 10 weeks.", "tags": [{"end": 4, "start": 0, "tag": "GeneOrGenome"}, {"end": 43, "start": 38, "tag": "TemporalConcept"}, {"end": 30, "start": 27, "tag": "Substance"}, {"end": 23, "start": 21, "tag": "Substance"}]}{"id": "1349_5", "text": "BCAS surgeries were performed.", "tags": [{"end": 4, "start": 0, "tag": "PathologicFunction"}, {"end": 4, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 5, "tag": "HealthCareActivity"}]}{"id": "1349_6", "text": "Markers of inflammation, oxidative stress, and apoptosis were examined.", "tags": [{"end": 23, "start": 11, "tag": "PathologicFunction"}, {"end": 41, "start": 25, "tag": "CellOrMolecularDysfunction"}, {"end": 56, "start": 47, "tag": "CellFunction"}]}{"id": "1349_7", "text": "nPM + BCAS exposure increased brain hemisphere TNF alpha protein compared to FA.", "tags": [{"end": 10, "start": 6, "tag": "PathologicFunction"}, {"end": 10, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 6, "tag": "InjuryOrPoisoning"}, {"end": 46, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "Substance"}, {"end": 79, "start": 77, "tag": "Substance"}]}{"id": "1349_8", "text": "iNOS and HNE immunofluorescence were increased in the corpus callosum and cerebral cortex of nPM + BCAS mice compared to FA.", "tags": [{"end": 12, "start": 9, "tag": "GeneOrGenome"}, {"end": 31, "start": 13, "tag": "ResearchActivity"}, {"end": 103, "start": 99, "tag": "PathologicFunction"}, {"end": 103, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 108, "start": 104, "tag": "Eukaryote"}, {"end": 89, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 4, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 93, "tag": "Substance"}, {"end": 123, "start": 121, "tag": "Substance"}]}{"id": "1349_9", "text": "While nPM exposure alone did not decrease cortical neuronal cell count, nPM decreased corpus callosum oligodendrocyte cell count.", "tags": [{"end": 18, "start": 6, "tag": "InjuryOrPoisoning"}, {"end": 41, "start": 33, "tag": "Finding"}, {"end": 101, "start": 86, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 60, "tag": "Cell"}, {"end": 122, "start": 118, "tag": "Cell"}, {"end": 59, "start": 51, "tag": "Cell"}, {"end": 85, "start": 76, "tag": "Finding"}, {"end": 50, "start": 42, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 117, "start": 102, "tag": "Cell"}, {"end": 9, "start": 6, "tag": "Substance"}, {"end": 75, "start": 72, "tag": "Substance"}]}{"id": "1349_10", "text": "nPM exposure decreased mature oligodendrocyte cell count and increased oligodendrocyte precursor cell count in the corpus callosum.", "tags": [{"end": 12, "start": 0, "tag": "InjuryOrPoisoning"}, {"end": 56, "start": 46, "tag": "ResearchActivity"}, {"end": 29, "start": 23, "tag": "TemporalConcept"}, {"end": 101, "start": 71, "tag": "Cell"}, {"end": 130, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 13, "tag": "Finding"}, {"end": 45, "start": 30, "tag": "Cell"}, {"end": 3, "start": 0, "tag": "Substance"}]}{"id": "1349_11", "text": "nPM + BCAS mice exhibited a 200% increase in cortical neuronal TUNEL staining and a 700% increase in corpus callosum oligodendrocyte TUNEL staining compared to FA.", "tags": [{"end": 10, "start": 6, "tag": "PathologicFunction"}, {"end": 10, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 11, "tag": "Eukaryote"}, {"end": 62, "start": 54, "tag": "Cell"}, {"end": 53, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 117, "tag": "Cell"}, {"end": 3, "start": 0, "tag": "Substance"}, {"end": 77, "start": 63, "tag": "ResearchActivity"}, {"end": 147, "start": 133, "tag": "ResearchActivity"}, {"end": 162, "start": 160, "tag": "Substance"}]}{"id": "1349_12", "text": "There was a supra-additive interaction between nPM and BCAS on cortical neuronal TUNEL staining (2.6x the additive effects of nPM + BCAS).", "tags": [{"end": 59, "start": 55, "tag": "PathologicFunction"}, {"end": 59, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 132, "tag": "PathologicFunction"}, {"end": 136, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 72, "tag": "Cell"}, {"end": 71, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 122, "start": 115, "tag": "Finding"}, {"end": 50, "start": 47, "tag": "Substance"}, {"end": 129, "start": 126, "tag": "Substance"}, {"end": 95, "start": 81, "tag": "ResearchActivity"}]}{"id": "1349_13", "text": "nPM + BCAS exposure increased apoptosis, neuroinflammation, and oxidative stress in the cerebral cortex and corpus callosum.", "tags": [{"end": 10, "start": 6, "tag": "PathologicFunction"}, {"end": 10, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 6, "tag": "InjuryOrPoisoning"}, {"end": 123, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 64, "tag": "CellOrMolecularDysfunction"}, {"end": 39, "start": 30, "tag": "CellFunction"}, {"end": 103, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 41, "tag": "PathologicFunction"}, {"end": 3, "start": 0, "tag": "Substance"}]}{"id": "1349_14", "text": "nPM + BCAS exposure increased neuronal apoptosis above the separate responses to each exposure.", "tags": [{"end": 10, "start": 6, "tag": "PathologicFunction"}, {"end": 10, "start": 6, "tag": "DiseaseOrSyndrome"}, {"end": 19, "start": 6, "tag": "InjuryOrPoisoning"}, {"end": 38, "start": 30, "tag": "Cell"}, {"end": 48, "start": 39, "tag": "CellFunction"}, {"end": 3, "start": 0, "tag": "Substance"}]}{"id": "1349_15", "text": "However, oligodendrocytes in the corpus callosum demonstrated a greater susceptibility to the combined neurotoxic effects of nPM + BCAS exposure.", "tags": [{"end": 86, "start": 72, "tag": "ClinicalAttribute"}, {"end": 135, "start": 131, "tag": "PathologicFunction"}, {"end": 135, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 131, "tag": "InjuryOrPoisoning"}, {"end": 25, "start": 9, "tag": "Cell"}, {"end": 48, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 114, "tag": "Finding"}, {"end": 121, "start": 103, "tag": "InjuryOrPoisoning"}, {"end": 128, "start": 125, "tag": "Substance"}]}{"id": "1350_0", "text": "Pelizaeus-Merzbacher disease is a fatal X-linked leukodystrophy caused by mutations in the PLP1 gene, which is expressed in the CNS by oligodendrocytes.", "tags": [{"end": 28, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 91, "tag": "GeneOrGenome"}, {"end": 131, "start": 128, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 74, "tag": "CellFunction"}, {"end": 83, "start": 74, "tag": "CellOrMolecularDysfunction"}, {"end": 151, "start": 135, "tag": "Cell"}, {"end": 120, "start": 111, "tag": "CellFunction"}]}{"id": "1350_1", "text": "Disease onset, symptoms and mortality span a broad spectrum depending on the nature of the mutation and thus the degree of CNS hypomyelination.", "tags": [{"end": 13, "start": 0, "tag": "TemporalConcept"}, {"end": 142, "start": 127, "tag": "Finding"}, {"end": 126, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 28, "tag": "Finding"}, {"end": 23, "start": 15, "tag": "SignOrSymptom"}, {"end": 99, "start": 91, "tag": "CellOrMolecularDysfunction"}]}{"id": "1350_2", "text": "In the absence of an effective treatment, direct cell transplantation into the CNS to restore myelin has been tested in animal models of severe forms of the disease with failure of developmental myelination, and more recently, in severely affected patients with early disease onset due to point mutations in the PLP1 gene, and absence of myelin by MRI.", "tags": [{"end": 69, "start": 49, "tag": "HealthCareActivity"}, {"end": 177, "start": 170, "tag": "IndividualBehavior"}, {"end": 267, "start": 262, "tag": "TemporalConcept"}, {"end": 321, "start": 312, "tag": "GeneOrGenome"}, {"end": 82, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 281, "start": 268, "tag": "TemporalConcept"}, {"end": 304, "start": 289, "tag": "CellOrMolecularDysfunction"}, {"end": 206, "start": 195, "tag": "CellFunction"}, {"end": 194, "start": 181, "tag": "BiologicFunction"}, {"end": 194, "start": 181, "tag": "TemporalConcept"}, {"end": 225, "start": 217, "tag": "TemporalConcept"}, {"end": 256, "start": 248, "tag": "PatientOrDisabledGroup"}, {"end": 40, "start": 31, "tag": "HealthCareActivity"}, {"end": 40, "start": 31, "tag": "ResearchActivity"}, {"end": 351, "start": 348, "tag": "HealthCareActivity"}, {"end": 100, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 344, "start": 338, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 120, "tag": "ResearchActivity"}]}{"id": "1350_3", "text": "In patients with a PLP1 duplication mutation, the most common cause of Pelizaeus-Merzbacher disease, the pathology is poorly defined because of a paucity of autopsy material.", "tags": [{"end": 23, "start": 19, "tag": "GeneOrGenome"}, {"end": 35, "start": 24, "tag": "CellFunction"}, {"end": 99, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 157, "tag": "HealthCareActivity"}, {"end": 173, "start": 165, "tag": "Substance"}, {"end": 11, "start": 3, "tag": "PatientOrDisabledGroup"}, {"end": 114, "start": 105, "tag": "PathologicFunction"}, {"end": 114, "start": 105, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 44, "start": 19, "tag": "CellOrMolecularDysfunction"}]}{"id": "1350_4", "text": "To address this, we examined two elderly patients with duplication of PLP1 in whom the overall syndrome, including end-stage pathology, indicated a complex disease involving dysmyelination, demyelination and axonal degeneration.", "tags": [{"end": 74, "start": 55, "tag": "CellOrMolecularDysfunction"}, {"end": 74, "start": 70, "tag": "GeneOrGenome"}, {"end": 188, "start": 174, "tag": "PathologicFunction"}, {"end": 214, "start": 208, "tag": "CellComponent"}, {"end": 227, "start": 208, "tag": "CellOrMolecularDysfunction"}, {"end": 227, "start": 215, "tag": "PathologicFunction"}, {"end": 49, "start": 41, "tag": "PatientOrDisabledGroup"}, {"end": 134, "start": 125, "tag": "PathologicFunction"}, {"end": 134, "start": 125, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 203, "start": 190, "tag": "PathologicFunction"}, {"end": 40, "start": 33, "tag": "PopulationGroup"}, {"end": 124, "start": 115, "tag": "TemporalConcept"}]}{"id": "1350_5", "text": "Using the corresponding Plp1 transgenic mouse model, we then tested the capacity of transplanted neural stem cells to restore myelin in the context of PLP overexpression.", "tags": [{"end": 28, "start": 24, "tag": "GeneOrGenome"}, {"end": 154, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 154, "start": 151, "tag": "GeneOrGenome"}, {"end": 169, "start": 151, "tag": "CellFunction"}, {"end": 96, "start": 84, "tag": "HealthCareActivity"}, {"end": 114, "start": 97, "tag": "Cell"}, {"end": 51, "start": 24, "tag": "ExperimentalModelOfDisease"}, {"end": 132, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 151, "tag": "BiologicallyActiveSubstance"}]}{"id": "1350_6", "text": "Although developmental myelination and axonal coverage by endogenous oligodendrocytes was extensive, as assessed using electron microscopy (n = 3 at each of four end points) and immunostaining (n = 3 at each of four end points), wild-type neural precursors, transplanted into the brains of the newborn mutants, were able to effectively compete and replace the defective myelin (n = 2 at each of four end points).", "tags": [{"end": 238, "start": 229, "tag": "ResearchActivity"}, {"end": 301, "start": 294, "tag": "TemporalConcept"}, {"end": 309, "start": 302, "tag": "CellOrMolecularDysfunction"}, {"end": 45, "start": 39, "tag": "CellComponent"}, {"end": 85, "start": 69, "tag": "Cell"}, {"end": 138, "start": 119, "tag": "ResearchActivity"}, {"end": 270, "start": 258, "tag": "HealthCareActivity"}, {"end": 34, "start": 23, "tag": "CellFunction"}, {"end": 192, "start": 178, "tag": "ResearchActivity"}, {"end": 22, "start": 9, "tag": "BiologicFunction"}, {"end": 22, "start": 9, "tag": "TemporalConcept"}, {"end": 376, "start": 370, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 286, "start": 280, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 256, "start": 239, "tag": "Cell"}]}{"id": "1350_7", "text": "These data demonstrate the potential of neural stem cell therapies to restore normal myelination and protect axons in patients with PLP1 gene duplication mutation and further, provide proof of principle for the benefits of stem cell transplantation for other fatal leukodystrophies with 'normal' developmental myelination.", "tags": [{"end": 136, "start": 132, "tag": "GeneOrGenome"}, {"end": 162, "start": 132, "tag": "CellOrMolecularDysfunction"}, {"end": 248, "start": 223, "tag": "HealthCareActivity"}, {"end": 281, "start": 265, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 52, "tag": "HealthCareActivity"}, {"end": 114, "start": 109, "tag": "CellComponent"}, {"end": 96, "start": 85, "tag": "CellFunction"}, {"end": 321, "start": 310, "tag": "CellFunction"}, {"end": 84, "start": 78, "tag": "Finding"}, {"end": 294, "start": 288, "tag": "Finding"}, {"end": 309, "start": 296, "tag": "BiologicFunction"}, {"end": 309, "start": 296, "tag": "TemporalConcept"}, {"end": 126, "start": 118, "tag": "PatientOrDisabledGroup"}, {"end": 56, "start": 40, "tag": "Cell"}, {"end": 10, "start": 6, "tag": "ResearchActivity"}]}{"id": "1351_0", "text": "Oligodendrocyte-formed myelin sheaths allow fast synaptic transmission in the brain.", "tags": [{"end": 29, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 23, "tag": "CellComponent"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 83, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 49, "tag": "BiologicFunction"}]}{"id": "1351_1", "text": "Impairments in the process of myelination, or demyelinating insults, might cause chronic diseases such as multiple sclerosis (MS).", "tags": [{"end": 11, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 46, "tag": "PathologicFunction"}, {"end": 124, "start": 106, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 30, "tag": "CellFunction"}, {"end": 128, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 81, "tag": "TemporalConcept"}, {"end": 67, "start": 60, "tag": "InjuryOrPoisoning"}]}{"id": "1351_2", "text": "Under physiological conditions, remyelination is an ongoing process throughout adult life consisting in the differentiation of oligodendrocyte progenitor cells (OPCs) into mature oligodendrocytes (OLs).", "tags": [{"end": 195, "start": 179, "tag": "Cell"}, {"end": 165, "start": 161, "tag": "Cell"}, {"end": 195, "start": 172, "tag": "Cell"}, {"end": 159, "start": 127, "tag": "Cell"}, {"end": 123, "start": 108, "tag": "CellFunction"}, {"end": 159, "start": 143, "tag": "Cell"}, {"end": 200, "start": 197, "tag": "Cell"}, {"end": 178, "start": 172, "tag": "TemporalConcept"}, {"end": 59, "start": 52, "tag": "TemporalConcept"}, {"end": 89, "start": 85, "tag": "TemporalConcept"}, {"end": 45, "start": 32, "tag": "CellFunction"}, {"end": 84, "start": 79, "tag": "PopulationGroup"}]}{"id": "1351_3", "text": "During pathological events, this process fails due to unfavorable environment.", "tags": []}{"id": "1351_4", "text": "Adenosine and sphingosine kinase/sphingosine 1-phosphate signaling axes (SphK/S1P) play important roles in remyelination processes.", "tags": [{"end": 9, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 71, "start": 14, "tag": "CellFunction"}, {"end": 120, "start": 107, "tag": "CellFunction"}, {"end": 81, "start": 78, "tag": "Chemical"}, {"end": 77, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 33, "tag": "Chemical"}, {"end": 32, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 32, "start": 14, "tag": "BiologicallyActiveSubstance"}]}{"id": "1351_5", "text": "Remarkably, fingolimod (FTY720), a sphingosine analog recently approved for MS treatment, plays important roles in OPC maturation.", "tags": [{"end": 30, "start": 24, "tag": "Chemical"}, {"end": 118, "start": 115, "tag": "Cell"}, {"end": 129, "start": 119, "tag": "BiologicFunction"}, {"end": 22, "start": 12, "tag": "Chemical"}, {"end": 22, "start": 12, "tag": "PharmacologicSubstance"}, {"end": 22, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 79, "tag": "HealthCareActivity"}, {"end": 88, "start": 79, "tag": "ResearchActivity"}, {"end": 62, "start": 54, "tag": "TemporalConcept"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 24, "tag": "PharmacologicSubstance"}, {"end": 30, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 35, "tag": "Chemical"}]}{"id": "1351_6", "text": "We recently demonstrated that the selective stimulation of A(2)(B) adenosine receptors (A(2)(B)Rs) inhibit OPC differentiation in vitro and reduce voltage-dependent outward K+ currents (I-K) necessary to OPC maturation, whereas specific SphK1 or SphK2 inhibition exerts the opposite effect.", "tags": [{"end": 242, "start": 237, "tag": "GeneOrGenome"}, {"end": 251, "start": 246, "tag": "GeneOrGenome"}, {"end": 110, "start": 107, "tag": "Cell"}, {"end": 207, "start": 204, "tag": "Cell"}, {"end": 218, "start": 208, "tag": "BiologicFunction"}, {"end": 126, "start": 111, "tag": "CellFunction"}, {"end": 126, "start": 107, "tag": "CellFunction"}, {"end": 289, "start": 283, "tag": "Finding"}, {"end": 135, "start": 127, "tag": "ResearchActivity"}, {"end": 262, "start": 252, "tag": "CellFunction"}, {"end": 55, "start": 44, "tag": "HealthCareActivity"}, {"end": 55, "start": 44, "tag": "NaturalPhenomenonOrProcess"}, {"end": 11, "start": 3, "tag": "TemporalConcept"}, {"end": 86, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 184, "start": 147, "tag": "CellFunction"}, {"end": 242, "start": 237, "tag": "AminoAcidPeptideOrProtein"}, {"end": 251, "start": 246, "tag": "AminoAcidPeptideOrProtein"}, {"end": 251, "start": 246, "tag": "BiologicallyActiveSubstance"}, {"end": 242, "start": 237, "tag": "BiologicallyActiveSubstance"}]}{"id": "1351_7", "text": "During OPC differentiation A(2)(B)R expression increases, this effect being prevented by SphK1/2 blockade.", "tags": [{"end": 10, "start": 7, "tag": "Cell"}, {"end": 26, "start": 11, "tag": "CellFunction"}, {"end": 26, "start": 7, "tag": "CellFunction"}, {"end": 105, "start": 97, "tag": "PharmacologicSubstance"}, {"end": 105, "start": 97, "tag": "HealthCareActivity"}, {"end": 69, "start": 63, "tag": "Finding"}, {"end": 46, "start": 36, "tag": "CellFunction"}, {"end": 35, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 89, "tag": "BiologicallyActiveSubstance"}]}{"id": "1351_8", "text": "Furthermore, selective silencing of A(2)(B)R in OPC cultures prompts maturation and, intriguingly, enhances the expression of S1P lyase, the enzyme responsible for irreversible S1P catabolism.", "tags": [{"end": 32, "start": 23, "tag": "CellFunction"}, {"end": 180, "start": 177, "tag": "Chemical"}, {"end": 191, "start": 181, "tag": "BiologicFunction"}, {"end": 191, "start": 181, "tag": "CellFunction"}, {"end": 60, "start": 52, "tag": "ResearchActivity"}, {"end": 51, "start": 48, "tag": "Cell"}, {"end": 79, "start": 69, "tag": "BiologicFunction"}, {"end": 122, "start": 112, "tag": "CellFunction"}, {"end": 44, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 141, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 126, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1351_9", "text": "Finally, the existence of an interplay between SphK1/S1P pathway and A(2)(B)Rs in OPCs was confirmed since acute stimulation of A(2)(B)Rs activates SphK1 by increasing its phosphorylation.", "tags": [{"end": 153, "start": 148, "tag": "GeneOrGenome"}, {"end": 86, "start": 82, "tag": "Cell"}, {"end": 112, "start": 107, "tag": "TemporalConcept"}, {"end": 124, "start": 113, "tag": "HealthCareActivity"}, {"end": 124, "start": 113, "tag": "NaturalPhenomenonOrProcess"}, {"end": 38, "start": 29, "tag": "Finding"}, {"end": 64, "start": 57, "tag": "CellFunction"}, {"end": 187, "start": 172, "tag": "CellFunction"}, {"end": 167, "start": 157, "tag": "Finding"}, {"end": 52, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 53, "tag": "Chemical"}, {"end": 137, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 78, "start": 69, "tag": "BiologicallyActiveSubstance"}]}{"id": "1351_10", "text": "Here the role of A(2)(B)R and SphK/S1P signaling during oligodendrogenesis is reviewed in detail, with the purpose to shed new light on the interaction between A(2)(B)Rs and S1P signaling, as eventual innovative targets for the treatment of demyelinating disorders.", "tags": [{"end": 177, "start": 174, "tag": "Chemical"}, {"end": 86, "start": 78, "tag": "HealthCareActivity"}, {"end": 86, "start": 78, "tag": "ResearchActivity"}, {"end": 74, "start": 56, "tag": "BiologicFunction"}, {"end": 48, "start": 39, "tag": "CellFunction"}, {"end": 187, "start": 178, "tag": "CellFunction"}, {"end": 132, "start": 127, "tag": "NaturalPhenomenonOrProcess"}, {"end": 264, "start": 241, "tag": "DiseaseOrSyndrome"}, {"end": 237, "start": 228, "tag": "HealthCareActivity"}, {"end": 237, "start": 228, "tag": "ResearchActivity"}, {"end": 25, "start": 17, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 35, "tag": "Chemical"}, {"end": 34, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 169, "start": 160, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 160, "tag": "BiologicallyActiveSubstance"}]}{"id": "1352_0", "text": "Progesterone and testosterone, beyond their roles as sex hormones, are neuroactive steroids, playing crucial regulatory functions within the nervous system.", "tags": [{"end": 12, "start": 0, "tag": "Chemical"}, {"end": 12, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 29, "start": 17, "tag": "Chemical"}, {"end": 29, "start": 17, "tag": "PharmacologicSubstance"}, {"end": 91, "start": 71, "tag": "Chemical"}, {"end": 65, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 56, "start": 53, "tag": "OrganismAttribute"}, {"end": 155, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 71, "tag": "BiologicallyActiveSubstance"}]}{"id": "1352_1", "text": "Among these, neuroprotection and myelin regeneration are important ones.", "tags": [{"end": 28, "start": 13, "tag": "CellFunction"}, {"end": 39, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 52, "start": 40, "tag": "BiologicFunction"}, {"end": 52, "start": 40, "tag": "HealthCareActivity"}, {"end": 52, "start": 33, "tag": "CellFunction"}]}{"id": "1352_2", "text": "The present review aims to discuss the stimulatory effects of progesterone and testosterone on the process of myelination and remyelination.", "tags": [{"end": 74, "start": 62, "tag": "Chemical"}, {"end": 74, "start": 62, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 62, "tag": "PharmacologicSubstance"}, {"end": 91, "start": 79, "tag": "Chemical"}, {"end": 91, "start": 79, "tag": "PharmacologicSubstance"}, {"end": 18, "start": 12, "tag": "ResearchActivity"}, {"end": 18, "start": 12, "tag": "HealthCareActivity"}, {"end": 139, "start": 126, "tag": "CellFunction"}, {"end": 121, "start": 110, "tag": "CellFunction"}, {"end": 58, "start": 51, "tag": "Finding"}, {"end": 91, "start": 79, "tag": "BiologicallyActiveSubstance"}]}{"id": "1352_3", "text": "These effects have been demonstrated in vitro (i.e., organotypic cultures) and in vivo (cuprizone- or lysolecithin-induced demyelination and experimental autoimmune encephalomyelitis (EAE)).", "tags": [{"end": 73, "start": 53, "tag": "ResearchActivity"}, {"end": 182, "start": 141, "tag": "ExperimentalModelOfDisease"}, {"end": 187, "start": 184, "tag": "ExperimentalModelOfDisease"}, {"end": 73, "start": 65, "tag": "ResearchActivity"}, {"end": 114, "start": 102, "tag": "Chemical"}, {"end": 114, "start": 102, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 88, "tag": "Chemical"}, {"end": 45, "start": 37, "tag": "ResearchActivity"}, {"end": 86, "start": 79, "tag": "ResearchActivity"}, {"end": 136, "start": 123, "tag": "PathologicFunction"}, {"end": 13, "start": 6, "tag": "Finding"}]}{"id": "1352_4", "text": "Both steroids stimulate myelin formation and regeneration by acting through their respective intracellular receptors: progesterone receptors (PR) and androgen receptors (AR).", "tags": [{"end": 13, "start": 5, "tag": "Chemical"}, {"end": 106, "start": 93, "tag": "CellComponent"}, {"end": 140, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 118, "tag": "BiologicallyActiveSubstance"}, {"end": 168, "start": 150, "tag": "AminoAcidPeptideOrProtein"}, {"end": 168, "start": 150, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 45, "tag": "BiologicFunction"}, {"end": 57, "start": 45, "tag": "HealthCareActivity"}, {"end": 40, "start": 24, "tag": "CellFunction"}, {"end": 116, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 116, "start": 107, "tag": "BiologicallyActiveSubstance"}]}{"id": "1352_5", "text": "Activation of these receptors results in multiple events involving direct transcription and translation, regulating general homeostasis, cell proliferation, differentiation, growth and myelination.", "tags": [{"end": 87, "start": 74, "tag": "CellFunction"}, {"end": 155, "start": 137, "tag": "CellFunction"}, {"end": 180, "start": 174, "tag": "BiologicFunction"}, {"end": 172, "start": 157, "tag": "CellFunction"}, {"end": 155, "start": 142, "tag": "CellFunction"}, {"end": 135, "start": 124, "tag": "BiologicFunction"}, {"end": 196, "start": 185, "tag": "CellFunction"}, {"end": 103, "start": 92, "tag": "CellFunction"}, {"end": 29, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 20, "tag": "BiologicallyActiveSubstance"}]}{"id": "1352_6", "text": "It also ameliorates immune response as seen in the EAE model, resulting in a significant decrease in inflammation leading to a fast recovery.", "tags": [{"end": 35, "start": 20, "tag": "BiologicFunction"}, {"end": 113, "start": 101, "tag": "PathologicFunction"}, {"end": 140, "start": 132, "tag": "BiologicFunction"}, {"end": 140, "start": 132, "tag": "HealthCareActivity"}, {"end": 140, "start": 132, "tag": "TemporalConcept"}, {"end": 97, "start": 77, "tag": "Finding"}, {"end": 60, "start": 51, "tag": "ExperimentalModelOfDisease"}]}{"id": "1352_7", "text": "Although natural progesterone and testosterone have a therapeutic potential, their synthetic derivatives-the 19-norprogesterone (nestorone) and 7 alpha-methyl-nortestosterone (MENT), already used as hormonal contraception or in postmenopausal hormone replacement therapies, may offer enhanced benefits for myelin repair.", "tags": [{"end": 29, "start": 17, "tag": "Chemical"}, {"end": 29, "start": 17, "tag": "BiologicallyActiveSubstance"}, {"end": 29, "start": 17, "tag": "PharmacologicSubstance"}, {"end": 46, "start": 34, "tag": "Chemical"}, {"end": 46, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 221, "start": 199, "tag": "HealthCareActivity"}, {"end": 312, "start": 306, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 319, "start": 306, "tag": "CellFunction"}, {"end": 75, "start": 54, "tag": "HealthCareActivity"}, {"end": 272, "start": 228, "tag": "HealthCareActivity"}, {"end": 319, "start": 313, "tag": "BiologicFunction"}, {"end": 319, "start": 313, "tag": "HealthCareActivity"}, {"end": 46, "start": 34, "tag": "PharmacologicSubstance"}, {"end": 127, "start": 109, "tag": "Chemical"}, {"end": 127, "start": 109, "tag": "PharmacologicSubstance"}, {"end": 127, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 129, "tag": "BiologicallyActiveSubstance"}, {"end": 138, "start": 129, "tag": "Chemical"}, {"end": 138, "start": 129, "tag": "PharmacologicSubstance"}, {"end": 174, "start": 144, "tag": "PharmacologicSubstance"}, {"end": 174, "start": 144, "tag": "Chemical"}, {"end": 104, "start": 83, "tag": "Chemical"}]}{"id": "1352_8", "text": "We summarize here a recent advancement in the field of myelin biology, to treat demyelinating disorders using the natural as well as synthetic analogs of progesterone and testosterone.", "tags": [{"end": 150, "start": 133, "tag": "Chemical"}, {"end": 166, "start": 154, "tag": "Chemical"}, {"end": 166, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 166, "start": 154, "tag": "PharmacologicSubstance"}, {"end": 183, "start": 171, "tag": "Chemical"}, {"end": 183, "start": 171, "tag": "PharmacologicSubstance"}, {"end": 93, "start": 80, "tag": "PathologicFunction"}, {"end": 61, "start": 55, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 62, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 26, "start": 20, "tag": "TemporalConcept"}, {"end": 69, "start": 62, "tag": "BiologicFunction"}, {"end": 183, "start": 171, "tag": "BiologicallyActiveSubstance"}]}{"id": "1353_0", "text": "Ethnopharmacology relevance: Wuzi Yanzong Pill (WYP), a well-known prescription for invigorating the kidney and essence, which is widely used to treat infertility such as oligoasthenospermia.", "tags": [{"end": 17, "start": 0, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 79, "start": 67, "tag": "HealthCareActivity"}, {"end": 119, "start": 112, "tag": "Chemical"}, {"end": 107, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 29, "tag": "PharmacologicSubstance"}, {"end": 51, "start": 48, "tag": "PharmacologicSubstance"}, {"end": 162, "start": 151, "tag": "PathologicFunction"}, {"end": 190, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 162, "start": 151, "tag": "DiseaseOrSyndrome"}]}{"id": "1353_1", "text": "Studies have shown that WYP can be used to treat neurological diseases, but its therapeutic effects and mechanisms for multiple sclerosis (MS) remain unclear.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 137, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 141, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 80, "tag": "Finding"}, {"end": 70, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 27, "start": 24, "tag": "PharmacologicSubstance"}]}{"id": "1353_2", "text": "Aim of the study: Based on the establishment of Cuprizone (CPZ)-induced demyelination model, this study determined the effect of WYP on remyelination by detecting changes in the microenvironment of the central nervous system.", "tags": [{"end": 194, "start": 178, "tag": "NaturalPhenomenonOrProcess"}, {"end": 62, "start": 59, "tag": "Chemical"}, {"end": 57, "start": 48, "tag": "Chemical"}, {"end": 224, "start": 202, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 11, "tag": "ResearchActivity"}, {"end": 103, "start": 98, "tag": "ResearchActivity"}, {"end": 91, "start": 86, "tag": "ResearchActivity"}, {"end": 125, "start": 119, "tag": "Finding"}, {"end": 149, "start": 136, "tag": "CellFunction"}, {"end": 85, "start": 72, "tag": "PathologicFunction"}, {"end": 91, "start": 48, "tag": "ExperimentalModelOfDisease"}, {"end": 132, "start": 129, "tag": "PharmacologicSubstance"}]}{"id": "1353_3", "text": "Materials and methods: C57BL/6 mice were divided into three groups.", "tags": [{"end": 35, "start": 23, "tag": "Eukaryote"}]}{"id": "1353_4", "text": "The CPZ group and CPZ thorn WYP group were fed with 0.2% CPZ feed, and the control group was fed normal feed, for 6 weeks.", "tags": [{"end": 7, "start": 4, "tag": "Chemical"}, {"end": 21, "start": 18, "tag": "Chemical"}, {"end": 60, "start": 57, "tag": "Chemical"}, {"end": 88, "start": 75, "tag": "PopulationGroup"}, {"end": 121, "start": 116, "tag": "TemporalConcept"}, {"end": 13, "start": 8, "tag": "PopulationGroup"}, {"end": 37, "start": 32, "tag": "PopulationGroup"}, {"end": 88, "start": 83, "tag": "PopulationGroup"}, {"end": 103, "start": 97, "tag": "Finding"}, {"end": 31, "start": 28, "tag": "PharmacologicSubstance"}]}{"id": "1353_5", "text": "At the end of the second week, the CPZ thorn WYP group was gavaged with WYP solution (16 g/kg/d), and the other two groups were gavaged with normal saline twice a day with an interval of 12 h each time, for 4 weeks.", "tags": [{"end": 84, "start": 76, "tag": "Substance"}, {"end": 154, "start": 141, "tag": "PharmacologicSubstance"}, {"end": 166, "start": 163, "tag": "TemporalConcept"}, {"end": 183, "start": 175, "tag": "TemporalConcept"}, {"end": 38, "start": 35, "tag": "Chemical"}, {"end": 29, "start": 25, "tag": "TemporalConcept"}, {"end": 214, "start": 209, "tag": "TemporalConcept"}, {"end": 54, "start": 49, "tag": "PopulationGroup"}, {"end": 201, "start": 197, "tag": "TemporalConcept"}, {"end": 48, "start": 45, "tag": "PharmacologicSubstance"}, {"end": 75, "start": 72, "tag": "PharmacologicSubstance"}]}{"id": "1353_6", "text": "Forced swimming and elevated plus maze were used to detect changes in anxiety and depression before and after treatment.", "tags": [{"end": 92, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 110, "tag": "HealthCareActivity"}, {"end": 119, "start": 110, "tag": "ResearchActivity"}, {"end": 77, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 20, "tag": "ResearchActivity"}, {"end": 38, "start": 20, "tag": "ManufacturedObject"}, {"end": 15, "start": 0, "tag": "ResearchActivity"}, {"end": 66, "start": 59, "tag": "Finding"}, {"end": 99, "start": 93, "tag": "TemporalConcept"}, {"end": 109, "start": 104, "tag": "TemporalConcept"}]}{"id": "1353_7", "text": "Luxol fast blue staining and the expression of MBP were used to evaluate the demyelination of the brain.", "tags": [{"end": 15, "start": 0, "tag": "Chemical"}, {"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 47, "tag": "GeneOrGenome"}, {"end": 103, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 33, "tag": "CellFunction"}, {"end": 90, "start": 77, "tag": "PathologicFunction"}, {"end": 24, "start": 0, "tag": "ResearchActivity"}]}{"id": "1353_8", "text": "Western blot was used to detect the expression of microglia and their subtype markers Iba-1, Arg-1, iNOS, the expression of neurotrophic factors BDNF, GDNF, CNTF, and the expression of oligodendrocyte precursor cells NG2.", "tags": [{"end": 155, "start": 151, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 151, "tag": "GeneOrGenome"}, {"end": 161, "start": 157, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 157, "tag": "GeneOrGenome"}, {"end": 161, "start": 157, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 93, "tag": "GeneOrGenome"}, {"end": 220, "start": 217, "tag": "AminoAcidPeptideOrProtein"}, {"end": 220, "start": 217, "tag": "BiologicallyActiveSubstance"}, {"end": 220, "start": 217, "tag": "GeneOrGenome"}, {"end": 216, "start": 185, "tag": "Cell"}, {"end": 216, "start": 201, "tag": "Cell"}, {"end": 210, "start": 185, "tag": "Cell"}, {"end": 85, "start": 78, "tag": "ClinicalAttribute"}, {"end": 46, "start": 36, "tag": "CellFunction"}, {"end": 120, "start": 110, "tag": "CellFunction"}, {"end": 181, "start": 171, "tag": "CellFunction"}, {"end": 59, "start": 50, "tag": "Cell"}, {"end": 149, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 145, "tag": "GeneOrGenome"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 144, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 144, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 104, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 91, "start": 86, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 86, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 151, "tag": "BiologicallyActiveSubstance"}]}{"id": "1353_9", "text": "ELISA detected the content of IL6, IL-1 ss, IL-10, TGF-ss, BDNF, GDNF, CNTF in the brain.", "tags": [{"end": 33, "start": 30, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 30, "tag": "GeneOrGenome"}, {"end": 39, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 35, "tag": "GeneOrGenome"}, {"end": 69, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 65, "tag": "GeneOrGenome"}, {"end": 75, "start": 71, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 71, "tag": "GeneOrGenome"}, {"end": 75, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 63, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 63, "start": 59, "tag": "BiologicallyActiveSubstance"}, {"end": 63, "start": 59, "tag": "GeneOrGenome"}, {"end": 5, "start": 0, "tag": "ResearchActivity"}, {"end": 49, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 44, "tag": "GeneOrGenome"}, {"end": 33, "start": 30, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 69, "start": 65, "tag": "BiologicallyActiveSubstance"}]}{"id": "1353_10", "text": "The distribution of Iba-1 in the corpus callosum was observed by immunofluorescence.", "tags": [{"end": 83, "start": 65, "tag": "ResearchActivity"}, {"end": 48, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 25, "start": 20, "tag": "BiologicallyActiveSubstance"}]}{"id": "1353_11", "text": "Results: The results showed that on the basis of improving mood abnormalities and demyelination, WYP reduced the protein content of Iba-1 and iNOS, increased the protein content of Arg-1, and reduce accumulation of microglia in the corpus callosum.", "tags": [{"end": 186, "start": 181, "tag": "GeneOrGenome"}, {"end": 247, "start": 232, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 211, "start": 199, "tag": "Finding"}, {"end": 224, "start": 215, "tag": "Cell"}, {"end": 95, "start": 82, "tag": "PathologicFunction"}, {"end": 146, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 132, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 132, "tag": "BiologicallyActiveSubstance"}, {"end": 120, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 162, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 59, "tag": "PathologicFunction"}, {"end": 100, "start": 97, "tag": "PharmacologicSubstance"}]}{"id": "1353_12", "text": "In addition, WYP reduced the secretion of IL-6 and IL-1 ss while promoting the secretion of IL-10 and TGF-ss.", "tags": [{"end": 55, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 51, "tag": "GeneOrGenome"}, {"end": 38, "start": 29, "tag": "CellFunction"}, {"end": 88, "start": 79, "tag": "CellFunction"}, {"end": 38, "start": 29, "tag": "BiologicFunction"}, {"end": 88, "start": 79, "tag": "BiologicFunction"}, {"end": 46, "start": 42, "tag": "AminoAcidPeptideOrProtein"}, {"end": 46, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 42, "tag": "GeneOrGenome"}, {"end": 97, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 92, "tag": "GeneOrGenome"}, {"end": 16, "start": 13, "tag": "PharmacologicSubstance"}, {"end": 105, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 102, "tag": "BiologicallyActiveSubstance"}]}{"id": "1353_13", "text": "After WYP intervention treatment, the levels of neurotrophic factors BDNF, GDNF, CNTF increased.", "tags": [{"end": 79, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 75, "tag": "GeneOrGenome"}, {"end": 85, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 85, "start": 81, "tag": "GeneOrGenome"}, {"end": 85, "start": 81, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 23, "tag": "HealthCareActivity"}, {"end": 32, "start": 23, "tag": "ResearchActivity"}, {"end": 73, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 69, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 69, "tag": "GeneOrGenome"}, {"end": 68, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 9, "start": 6, "tag": "PharmacologicSubstance"}, {"end": 79, "start": 75, "tag": "BiologicallyActiveSubstance"}]}{"id": "1353_14", "text": "Due to the improvement of inflammatory and nutritional environment in the CNS, promoting the proliferation of NG2 oligodendrocyte, increased the expression of MBP, and repairing myelin sheath.", "tags": [{"end": 177, "start": 168, "tag": "BiologicFunction"}, {"end": 177, "start": 168, "tag": "HealthCareActivity"}, {"end": 113, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 110, "tag": "GeneOrGenome"}, {"end": 162, "start": 159, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 159, "tag": "BiologicallyActiveSubstance"}, {"end": 162, "start": 159, "tag": "GeneOrGenome"}, {"end": 184, "start": 178, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 93, "tag": "CellFunction"}, {"end": 38, "start": 26, "tag": "PathologicFunction"}, {"end": 77, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 145, "tag": "CellFunction"}, {"end": 129, "start": 114, "tag": "Cell"}, {"end": 191, "start": 178, "tag": "CellComponent"}, {"end": 66, "start": 43, "tag": "Finding"}]}{"id": "1353_15", "text": "Conclusion: Our results indicated that WYP promoted the proliferation and development of oligodendrocytes by improving the CNS microenvironment, effectively alleviating demyelination.", "tags": [{"end": 143, "start": 127, "tag": "NaturalPhenomenonOrProcess"}, {"end": 105, "start": 89, "tag": "Cell"}, {"end": 69, "start": 56, "tag": "CellFunction"}, {"end": 126, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 74, "tag": "BiologicFunction"}, {"end": 85, "start": 74, "tag": "CellFunction"}, {"end": 182, "start": 169, "tag": "PathologicFunction"}, {"end": 42, "start": 39, "tag": "PharmacologicSubstance"}]}{"id": "1354_0", "text": "Glial gap junction proteins, called connexins (Cxs), form gap junctions in the central nervous system (CNS) to allow the bidirectional cytosolic exchange of molecules between adjacent cells.", "tags": [{"end": 5, "start": 0, "tag": "Cell"}, {"end": 45, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 157, "tag": "Substance"}, {"end": 27, "start": 19, "tag": "AminoAcidPeptideOrProtein"}, {"end": 189, "start": 184, "tag": "Cell"}, {"end": 101, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 6, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 121, "tag": "CellFunction"}]}{"id": "1354_1", "text": "Their involvement in inheritable diseases and the use of experimental animal models that closely mimic such diseases revealed the critical role of glial GJs in myelination and homeostasis.", "tags": [{"end": 171, "start": 160, "tag": "CellFunction"}, {"end": 83, "start": 57, "tag": "ResearchActivity"}, {"end": 156, "start": 153, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 147, "tag": "Cell"}, {"end": 17, "start": 6, "tag": "Finding"}, {"end": 187, "start": 176, "tag": "BiologicFunction"}]}{"id": "1354_2", "text": "Cxs are also implicated in acquired demyelinating disorders, such as Multiple Sclerosis (MS) and Alzheimer's disease (AD).", "tags": [{"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 36, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 120, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 89, "tag": "DiseaseOrSyndrome"}]}{"id": "1354_3", "text": "Animal and human studies have revealed a role of the astrocytic Cx43 in the progression of AD but the role of Cx47, which is the main partner of Cx43 in the astrocyte-oligodendrocyte GJs is still unknown.", "tags": [{"end": 24, "start": 11, "tag": "ResearchActivity"}, {"end": 63, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 157, "tag": "Cell"}, {"end": 182, "start": 167, "tag": "Cell"}, {"end": 186, "start": 183, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 145, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 149, "start": 145, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 76, "tag": "PathologicFunction"}, {"end": 87, "start": 76, "tag": "TemporalConcept"}, {"end": 93, "start": 91, "tag": "DiseaseOrSyndrome"}]}{"id": "1354_4", "text": "The aim of this study was to investigate the astrocytic connexins, Cx43 and Cx30 in relation to oligodendrocytic Cx47 in the cortex and thalamus of the 5XFAD mouse model of AD.", "tags": [{"end": 112, "start": 96, "tag": "Cell"}, {"end": 131, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 71, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 55, "start": 45, "tag": "Cell"}, {"end": 65, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 175, "start": 152, "tag": "ExperimentalModelOfDisease"}]}{"id": "1354_5", "text": "The model was characterized by increased A beta deposition, gliosis, neuronal loss, and memory impairment.", "tags": [{"end": 67, "start": 60, "tag": "PathologicFunction"}, {"end": 82, "start": 69, "tag": "Finding"}, {"end": 105, "start": 88, "tag": "SignOrSymptom"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 47, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 41, "tag": "PathologicFunction"}]}{"id": "1354_6", "text": "Compared to wild-type mice, Cx43 and Cx30 showed increased immunoreactivity in older 5XFAD mice, reflecting astrogliosis, while Cx47 immunoreactivity was reduced.", "tags": [{"end": 95, "start": 85, "tag": "ExperimentalModelOfDisease"}, {"end": 26, "start": 12, "tag": "Eukaryote"}, {"end": 75, "start": 59, "tag": "CellFunction"}, {"end": 149, "start": 133, "tag": "CellFunction"}, {"end": 32, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 108, "tag": "PathologicFunction"}, {"end": 41, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 79, "tag": "TemporalConcept"}]}{"id": "1354_7", "text": "Moreover, Cx47 GJ plaques showed reduced colocalization with Cx43 plaques.", "tags": [{"end": 25, "start": 18, "tag": "AnatomicalAbnormality"}, {"end": 55, "start": 41, "tag": "BiologicFunction"}, {"end": 65, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 14, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 14, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 66, "tag": "AnatomicalAbnormality"}]}{"id": "1354_8", "text": "Oligodendrocyte precursor cells (OPCs) and mature oligodendrocyte populations were also depleted, and myelin deficits were observed.", "tags": [{"end": 37, "start": 33, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 77, "start": 43, "tag": "Cell"}, {"end": 117, "start": 102, "tag": "CellOrMolecularDysfunction"}]}{"id": "1354_9", "text": "Our findings indicate reduced astrocyte-oligodendrocyte gap junction connectivity and possibly a shift in Cx43 expression toward astrocyte-astrocyte gap junctions and/or hemichannels, that could impair oligodendrocyte homeostasis and myelination.", "tags": [{"end": 102, "start": 97, "tag": "Finding"}, {"end": 148, "start": 129, "tag": "Cell"}, {"end": 162, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 30, "tag": "Cell"}, {"end": 138, "start": 129, "tag": "Cell"}, {"end": 148, "start": 139, "tag": "Cell"}, {"end": 245, "start": 234, "tag": "CellFunction"}, {"end": 55, "start": 40, "tag": "Cell"}, {"end": 217, "start": 202, "tag": "Cell"}, {"end": 110, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 182, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 182, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 229, "start": 218, "tag": "BiologicFunction"}, {"end": 68, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 69, "tag": "BiologicFunction"}]}{"id": "1354_10", "text": "However, other factors, such as A beta toxicity, could directly affect oligodendrocyte survival in AD.", "tags": [{"end": 95, "start": 87, "tag": "CellFunction"}, {"end": 86, "start": 71, "tag": "Cell"}, {"end": 47, "start": 39, "tag": "InjuryOrPoisoning"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 32, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1354_11", "text": "Our study provides evidence that Cxs might have implications in the progression of AD, although the role of oligodendrocyte Cxs in AD requires further investigation.", "tags": [{"end": 36, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 127, "start": 124, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 108, "tag": "Cell"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 79, "start": 68, "tag": "PathologicFunction"}, {"end": 79, "start": 68, "tag": "TemporalConcept"}, {"end": 27, "start": 19, "tag": "Finding"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 151, "tag": "ResearchActivity"}, {"end": 36, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 127, "start": 124, "tag": "BiologicallyActiveSubstance"}]}{"id": "1355_0", "text": "While much of the research on neurodegenerative diseases has focused on neurons, non-neuronal cells are also affected.", "tags": [{"end": 99, "start": 81, "tag": "Cell"}, {"end": 79, "start": 72, "tag": "Cell"}, {"end": 93, "start": 85, "tag": "Cell"}, {"end": 99, "start": 85, "tag": "Cell"}, {"end": 56, "start": 30, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 18, "tag": "ResearchActivity"}]}{"id": "1355_1", "text": "The extent to which glia and other non-neuronal cells are causally involved in disease pathogenesis versus more passively responding to disease is an area of active research.", "tags": [{"end": 53, "start": 35, "tag": "Cell"}, {"end": 47, "start": 39, "tag": "Cell"}, {"end": 24, "start": 20, "tag": "Cell"}, {"end": 53, "start": 39, "tag": "Cell"}, {"end": 173, "start": 165, "tag": "ResearchActivity"}, {"end": 99, "start": 87, "tag": "PathologicFunction"}]}{"id": "1355_2", "text": "This is complicated by the fact that there is rarely one known cause of neurodegenerative diseases; rather, these disorders likely involve feedback loops that perpetuate dysfunction.", "tags": [{"end": 181, "start": 170, "tag": "PathologicFunction"}, {"end": 98, "start": 72, "tag": "DiseaseOrSyndrome"}]}{"id": "1355_3", "text": "Here, we will review genetic as well as experimental evidence that suggest that non-neuronal cells are at least partially driving disease pathogenesis in numerous neurodegenerative disorders, including Alzheimer's disease, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and Parkinson's disease.", "tags": [{"end": 98, "start": 80, "tag": "Cell"}, {"end": 190, "start": 163, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 53, "tag": "Finding"}, {"end": 28, "start": 21, "tag": "Finding"}, {"end": 92, "start": 84, "tag": "Cell"}, {"end": 246, "start": 223, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 84, "tag": "Cell"}, {"end": 20, "start": 14, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "HealthCareActivity"}, {"end": 61, "start": 40, "tag": "Finding"}, {"end": 299, "start": 279, "tag": "DiseaseOrSyndrome"}, {"end": 344, "start": 325, "tag": "DiseaseOrSyndrome"}, {"end": 277, "start": 248, "tag": "DiseaseOrSyndrome"}, {"end": 221, "start": 202, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 138, "tag": "PathologicFunction"}, {"end": 246, "start": 238, "tag": "DiseaseOrSyndrome"}, {"end": 319, "start": 301, "tag": "DiseaseOrSyndrome"}]}{"id": "1356_0", "text": "Receptor interacting serine/threonine protein kinase 1 (RIPK1) activation and necroptosis have been genetically and mechanistically linked with human multiple sclerosis and neurodegenerative diseases for which demyelination is a common key pathology.", "tags": [{"end": 54, "start": 0, "tag": "GeneOrGenome"}, {"end": 54, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 61, "start": 56, "tag": "CellFunction"}, {"end": 89, "start": 78, "tag": "CellFunction"}, {"end": 168, "start": 150, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 240, "tag": "PathologicFunction"}, {"end": 249, "start": 240, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 149, "start": 144, "tag": "Eukaryote"}, {"end": 199, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 210, "tag": "PathologicFunction"}, {"end": 73, "start": 63, "tag": "CellFunction"}]}{"id": "1356_1", "text": "Demyelination can be healed through remyelination which is mediated by new oligodendrocytes derived from the adult oligodendrocyte progenitor cells (OPCs).", "tags": [{"end": 13, "start": 0, "tag": "PathologicFunction"}, {"end": 91, "start": 75, "tag": "Cell"}, {"end": 153, "start": 149, "tag": "Cell"}, {"end": 147, "start": 115, "tag": "Cell"}, {"end": 147, "start": 131, "tag": "Cell"}, {"end": 49, "start": 36, "tag": "CellFunction"}, {"end": 114, "start": 109, "tag": "PopulationGroup"}]}{"id": "1356_2", "text": "Unfortunately, the efficiency of remyelination declines with progressive aging partially due to the depletion of OPCs following chronic or repeated demyelination.", "tags": [{"end": 117, "start": 113, "tag": "Cell"}, {"end": 29, "start": 19, "tag": "Finding"}, {"end": 72, "start": 61, "tag": "TemporalConcept"}, {"end": 46, "start": 33, "tag": "CellFunction"}, {"end": 161, "start": 148, "tag": "PathologicFunction"}, {"end": 78, "start": 73, "tag": "BiologicFunction"}, {"end": 78, "start": 73, "tag": "CellFunction"}, {"end": 135, "start": 128, "tag": "TemporalConcept"}]}{"id": "1356_3", "text": "However, to our knowledge, so far there is no drug which enhances proliferation of OPCs, and it is unknown whether inhibiting RIPK1 activity directly affect OPCs, the central player of remyelination.", "tags": [{"end": 131, "start": 126, "tag": "GeneOrGenome"}, {"end": 131, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 83, "tag": "Cell"}, {"end": 161, "start": 157, "tag": "Cell"}, {"end": 79, "start": 66, "tag": "CellFunction"}, {"end": 25, "start": 16, "tag": "Finding"}, {"end": 125, "start": 115, "tag": "BiologicFunction"}, {"end": 198, "start": 185, "tag": "CellFunction"}, {"end": 50, "start": 46, "tag": "PharmacologicSubstance"}]}{"id": "1356_4", "text": "Using TNF alpha induced RIPK1-dependent necroptosis in Jurkat FADD(-/-) cells as a cell death assay, we screened from 2112 FDA-approved drugs and the drug candidates of new RIPK1 inhibitors selected by ourselves, and identified ZJU-37, a small molecule modified by introducing an amide bond to Nec-1s, is a new RIPK1 kinase inhibitor with higher potency than Nec-1s which has the best reported potency.", "tags": [{"end": 15, "start": 6, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 173, "tag": "GeneOrGenome"}, {"end": 178, "start": 173, "tag": "AminoAcidPeptideOrProtein"}, {"end": 178, "start": 173, "tag": "BiologicallyActiveSubstance"}, {"end": 252, "start": 238, "tag": "Chemical"}, {"end": 333, "start": 324, "tag": "BiologicallyActiveSubstance"}, {"end": 333, "start": 324, "tag": "PharmacologicSubstance"}, {"end": 333, "start": 324, "tag": "Chemical"}, {"end": 112, "start": 104, "tag": "HealthCareActivity"}, {"end": 112, "start": 104, "tag": "ResearchActivity"}, {"end": 189, "start": 179, "tag": "Chemical"}, {"end": 189, "start": 179, "tag": "PharmacologicSubstance"}, {"end": 189, "start": 179, "tag": "BiologicallyActiveSubstance"}, {"end": 252, "start": 244, "tag": "Substance"}, {"end": 99, "start": 83, "tag": "ResearchActivity"}, {"end": 77, "start": 72, "tag": "Cell"}, {"end": 93, "start": 88, "tag": "BiologicFunction"}, {"end": 93, "start": 88, "tag": "PathologicFunction"}, {"end": 93, "start": 88, "tag": "CellFunction"}, {"end": 141, "start": 136, "tag": "PharmacologicSubstance"}, {"end": 93, "start": 83, "tag": "CellFunction"}, {"end": 154, "start": 150, "tag": "PharmacologicSubstance"}, {"end": 126, "start": 123, "tag": "HealthCareRelatedOrganization"}, {"end": 29, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 55, "tag": "ExperimentalModelOfDisease"}, {"end": 234, "start": 228, "tag": "Chemical"}, {"end": 290, "start": 280, "tag": "Chemical"}, {"end": 323, "start": 311, "tag": "BiologicallyActiveSubstance"}, {"end": 323, "start": 311, "tag": "AminoAcidPeptideOrProtein"}, {"end": 365, "start": 359, "tag": "Chemical"}, {"end": 401, "start": 394, "tag": "Finding"}]}{"id": "1356_5", "text": "We unveil in addition to protecting myelin from demyelination and axons from degeneration, ZJU-37 exhibits a new role on promoting proliferation of OPCs and enhancing remyelination by inhibiting RIPK1 kinase activity with higher potency than Nec-1s.", "tags": [{"end": 207, "start": 195, "tag": "AminoAcidPeptideOrProtein"}, {"end": 207, "start": 195, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 66, "tag": "CellComponent"}, {"end": 152, "start": 148, "tag": "Cell"}, {"end": 42, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 131, "tag": "CellFunction"}, {"end": 89, "start": 77, "tag": "PathologicFunction"}, {"end": 194, "start": 184, "tag": "BiologicFunction"}, {"end": 180, "start": 167, "tag": "CellFunction"}, {"end": 61, "start": 48, "tag": "PathologicFunction"}, {"end": 97, "start": 91, "tag": "Chemical"}]}{"id": "1356_6", "text": "Mechanistically, ZJU-37 promotes proliferation of OPCs by enhancing the transcription of platelet derived growth factor receptor alpha via NF-kappa B pathway.", "tags": [{"end": 85, "start": 72, "tag": "CellFunction"}, {"end": 149, "start": 139, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 139, "tag": "GeneOrGenome"}, {"end": 149, "start": 139, "tag": "BiologicallyActiveSubstance"}, {"end": 54, "start": 50, "tag": "Cell"}, {"end": 46, "start": 33, "tag": "CellFunction"}, {"end": 157, "start": 150, "tag": "CellFunction"}, {"end": 134, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 23, "start": 17, "tag": "Chemical"}, {"end": 134, "start": 89, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1356_7", "text": "This work identifies ZJU-37 as a new drug candidate which enhances remyelination by promoting proliferation of OPCs, paving the way for a potential drug to enhance myelin repair.", "tags": [{"end": 115, "start": 111, "tag": "Cell"}, {"end": 170, "start": 164, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 94, "tag": "CellFunction"}, {"end": 177, "start": 164, "tag": "CellFunction"}, {"end": 80, "start": 67, "tag": "CellFunction"}, {"end": 41, "start": 37, "tag": "PharmacologicSubstance"}, {"end": 152, "start": 148, "tag": "PharmacologicSubstance"}, {"end": 177, "start": 171, "tag": "BiologicFunction"}, {"end": 177, "start": 171, "tag": "HealthCareActivity"}, {"end": 27, "start": 21, "tag": "Chemical"}]}{"id": "1357_0", "text": "Multiple sclerosis is an autoimmune disease in which the immune system attacks the myelin sheath in the central nervous system.", "tags": [{"end": 89, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 126, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 96, "start": 83, "tag": "CellComponent"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "1357_1", "text": "It is characterized by blood-brain barrier dysfunction throughout the course of multiple sclerosis, followed by the entry of immune cells and activation of local microglia and astrocytes.", "tags": [{"end": 137, "start": 125, "tag": "Cell"}, {"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 98, "start": 80, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 162, "tag": "Cell"}, {"end": 42, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 186, "start": 176, "tag": "Cell"}, {"end": 54, "start": 43, "tag": "PathologicFunction"}]}{"id": "1357_2", "text": "Glial cells (microglia, astrocytes, and oligodendrocyte lineage cells) are known as the important mediators of neuroinflammation, all of which play major roles in the pathogenesis of multiple sclerosis.", "tags": [{"end": 11, "start": 0, "tag": "Cell"}, {"end": 201, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 40, "tag": "Cell"}, {"end": 107, "start": 98, "tag": "Finding"}, {"end": 22, "start": 13, "tag": "Cell"}, {"end": 179, "start": 167, "tag": "PathologicFunction"}, {"end": 34, "start": 24, "tag": "Cell"}, {"end": 128, "start": 111, "tag": "PathologicFunction"}]}{"id": "1357_3", "text": "Network communications between glial cells affect the activities of oligodendrocyte lineage cells and influence the demyelination-remyelination process.", "tags": [{"end": 151, "start": 116, "tag": "CellFunction"}, {"end": 97, "start": 68, "tag": "Cell"}, {"end": 91, "start": 68, "tag": "Cell"}, {"end": 42, "start": 31, "tag": "Cell"}, {"end": 143, "start": 130, "tag": "CellFunction"}, {"end": 129, "start": 116, "tag": "PathologicFunction"}]}{"id": "1357_4", "text": "A finely balanced glial response may create a favorable lesion environment for efficient remyelination and neuroregeneration.", "tags": [{"end": 62, "start": 56, "tag": "InjuryOrPoisoning"}, {"end": 23, "start": 18, "tag": "Cell"}, {"end": 102, "start": 89, "tag": "CellFunction"}, {"end": 124, "start": 107, "tag": "BiologicFunction"}, {"end": 74, "start": 63, "tag": "Finding"}]}{"id": "1357_5", "text": "This review focuses on glial response and neurodegeneration based on the findings from multiple sclerosis and major rodent demyelination models.", "tags": [{"end": 122, "start": 116, "tag": "Eukaryote"}, {"end": 105, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 23, "tag": "Cell"}, {"end": 143, "start": 137, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 59, "start": 42, "tag": "CellOrMolecularDysfunction"}, {"end": 136, "start": 123, "tag": "PathologicFunction"}, {"end": 143, "start": 116, "tag": "ExperimentalModelOfDisease"}]}{"id": "1357_6", "text": "In particular, glial interaction and molecular crosstalk are discussed to provide insights into the potential cell- and molecule-specific therapeutic targets to improve remyelination and neuroregeneration.", "tags": [{"end": 128, "start": 120, "tag": "Substance"}, {"end": 20, "start": 15, "tag": "Cell"}, {"end": 114, "start": 110, "tag": "Cell"}, {"end": 157, "start": 138, "tag": "ResearchActivity"}, {"end": 56, "start": 37, "tag": "CellFunction"}, {"end": 182, "start": 169, "tag": "CellFunction"}, {"end": 204, "start": 187, "tag": "BiologicFunction"}]}{"id": "1358_0", "text": "Multiple sclerosis (MS) is a complex disease, and its pathophysiology impacts the function of immune and central nervous system cell types.", "tags": [{"end": 100, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 128, "tag": "Cell"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 54, "tag": "PathologicFunction"}, {"end": 69, "start": 54, "tag": "BiomedicalOccupationOrDiscipline"}]}{"id": "1358_1", "text": "Despite extensive investigation into the aetiology of MS, the underlying cause/s remain elusive and consequently, faithful in vitro or in vivo preclinical models of MS do not exist.", "tags": [{"end": 131, "start": 123, "tag": "ResearchActivity"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 18, "tag": "ResearchActivity"}, {"end": 142, "start": 135, "tag": "ResearchActivity"}, {"end": 161, "start": 143, "tag": "ResearchActivity"}, {"end": 50, "start": 41, "tag": "Finding"}]}{"id": "1358_2", "text": "Advances human stem cell technologies have enabled the generation of induced pluripotent stem cells (iPSCs) from people with MS.", "tags": [{"end": 37, "start": 25, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 65, "start": 55, "tag": "TemporalConcept"}, {"end": 99, "start": 69, "tag": "Cell"}, {"end": 106, "start": 101, "tag": "Cell"}, {"end": 14, "start": 9, "tag": "Eukaryote"}, {"end": 127, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 119, "start": 113, "tag": "PopulationGroup"}, {"end": 24, "start": 15, "tag": "Cell"}]}{"id": "1358_3", "text": "This review summarises the discoveries made using iPSCs derived from people with MS and explores their current and potential application/s in MS research.", "tags": [{"end": 55, "start": 50, "tag": "Cell"}, {"end": 38, "start": 27, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 153, "start": 145, "tag": "ResearchActivity"}, {"end": 83, "start": 81, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 69, "tag": "PopulationGroup"}, {"end": 110, "start": 103, "tag": "TemporalConcept"}]}{"id": "1359_0", "text": "Oligodendrocytes form myelin membranes and thereby secure the insulation of axons and the rapid conduction of action potentials.", "tags": [{"end": 127, "start": 110, "tag": "CellFunction"}, {"end": 81, "start": 76, "tag": "CellComponent"}, {"end": 16, "start": 0, "tag": "Cell"}, {"end": 38, "start": 29, "tag": "CellComponent"}, {"end": 38, "start": 22, "tag": "CellComponent"}, {"end": 106, "start": 96, "tag": "BiologicFunction"}, {"end": 106, "start": 96, "tag": "NaturalPhenomenonOrProcess"}, {"end": 28, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1359_1", "text": "Diseases such as multiple sclerosis highlight the importance of this glial cell population for brain function.", "tags": [{"end": 8, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 69, "tag": "Cell"}, {"end": 90, "start": 75, "tag": "Cell"}, {"end": 90, "start": 80, "tag": "PopulationGroup"}, {"end": 74, "start": 69, "tag": "Cell"}, {"end": 109, "start": 95, "tag": "BiologicFunction"}, {"end": 35, "start": 17, "tag": "DiseaseOrSyndrome"}]}{"id": "1359_2", "text": "In the adult brain, efficient remyelination following the damage to oligodendrocytes is compromised.", "tags": [{"end": 12, "start": 7, "tag": "PopulationGroup"}, {"end": 84, "start": 68, "tag": "Cell"}, {"end": 43, "start": 30, "tag": "CellFunction"}, {"end": 18, "start": 13, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1359_3", "text": "Myelination is characterized by proliferation, migration, and proper integration of oligodendrocyte precursor cells (OPCs).", "tags": [{"end": 80, "start": 69, "tag": "CellFunction"}, {"end": 80, "start": 69, "tag": "MachineActivity"}, {"end": 121, "start": 117, "tag": "Cell"}, {"end": 45, "start": 32, "tag": "CellFunction"}, {"end": 56, "start": 47, "tag": "CellFunction"}, {"end": 115, "start": 84, "tag": "Cell"}, {"end": 11, "start": 0, "tag": "CellFunction"}]}{"id": "1359_4", "text": "These processes are among others controlled by proteins of the extracellular matrix (ECM).", "tags": [{"end": 83, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 47, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1359_5", "text": "As a prominent representative ECM molecule, tenascin-C (Tnc) exerts an inhibitory effect on the migration and differentiation of OPCs.", "tags": [{"end": 33, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 54, "start": 44, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 59, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 56, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 129, "tag": "Cell"}, {"end": 105, "start": 96, "tag": "CellFunction"}, {"end": 125, "start": 110, "tag": "CellFunction"}, {"end": 42, "start": 34, "tag": "Substance"}, {"end": 88, "start": 71, "tag": "Finding"}]}{"id": "1359_6", "text": "The structurally similar paralogue tenascin-R (Tnr) is known to promote the differentiation of oligodendrocytes.", "tags": [{"end": 50, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 47, "tag": "CellComponent"}, {"end": 111, "start": 95, "tag": "Cell"}, {"end": 91, "start": 76, "tag": "CellFunction"}, {"end": 45, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 35, "tag": "BiologicallyActiveSubstance"}]}{"id": "1359_7", "text": "The model of lysolecithin-induced demyelination of cerebellar slice cultures represents an important tool for the analysis of the remyelination process.", "tags": [{"end": 143, "start": 130, "tag": "CellFunction"}, {"end": 122, "start": 114, "tag": "ResearchActivity"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 47, "start": 34, "tag": "PathologicFunction"}, {"end": 25, "start": 13, "tag": "Chemical"}, {"end": 25, "start": 13, "tag": "PharmacologicSubstance"}, {"end": 76, "start": 51, "tag": "ResearchActivity"}]}{"id": "1359_8", "text": "Ex vivo cerebellar explant cultures of Tnc(-/-) and Tnr(-/-) mouse lines displayed enhanced remyelination by forming thicker myelin membranes upon exposure to lysolecithin.", "tags": [{"end": 35, "start": 8, "tag": "ResearchActivity"}, {"end": 171, "start": 159, "tag": "Chemical"}, {"end": 105, "start": 92, "tag": "CellFunction"}, {"end": 141, "start": 132, "tag": "CellComponent"}, {"end": 141, "start": 125, "tag": "CellComponent"}, {"end": 66, "start": 61, "tag": "Eukaryote"}, {"end": 131, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 42, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 39, "tag": "BiologicallyActiveSubstance"}, {"end": 55, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 171, "start": 159, "tag": "PharmacologicSubstance"}, {"end": 171, "start": 147, "tag": "ResearchActivity"}, {"end": 105, "start": 83, "tag": "Finding"}, {"end": 141, "start": 117, "tag": "Finding"}]}{"id": "1359_9", "text": "The inhibitory effect of tenascins on remyelination could be confirmed when demyelinated wildtype control cultures were exposed to purified Tnc or Tnr protein.", "tags": [{"end": 34, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 76, "tag": "PathologicFunction"}, {"end": 143, "start": 140, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 140, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 38, "tag": "CellFunction"}, {"end": 114, "start": 89, "tag": "ResearchActivity"}, {"end": 158, "start": 147, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 147, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 4, "tag": "Finding"}]}{"id": "1359_10", "text": "In that approach, the remyelination efficiency decreased in a dose-dependent manner with increasing concentrations of ECM molecules added.", "tags": [{"end": 121, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 122, "tag": "Substance"}, {"end": 35, "start": 22, "tag": "CellFunction"}, {"end": 46, "start": 36, "tag": "Finding"}]}{"id": "1359_11", "text": "In order to examine potential roles in a complex in vivo environment, we successfully established cuprizone-based acute demyelination to analyze the remyelination behavior after cuprizone withdrawal in SV129, Tnc(-/-), and Tnr(-/-) mice.", "tags": [{"end": 171, "start": 163, "tag": "BiologicFunction"}, {"end": 171, "start": 163, "tag": "IndividualBehavior"}, {"end": 171, "start": 163, "tag": "ResearchActivity"}, {"end": 119, "start": 114, "tag": "TemporalConcept"}, {"end": 162, "start": 149, "tag": "CellFunction"}, {"end": 107, "start": 98, "tag": "Chemical"}, {"end": 187, "start": 178, "tag": "Chemical"}, {"end": 198, "start": 178, "tag": "ResearchActivity"}, {"end": 198, "start": 178, "tag": "HealthCareActivity"}, {"end": 236, "start": 232, "tag": "Eukaryote"}, {"end": 133, "start": 120, "tag": "PathologicFunction"}, {"end": 56, "start": 49, "tag": "ResearchActivity"}, {"end": 236, "start": 232, "tag": "Eukaryote"}, {"end": 207, "start": 202, "tag": "Eukaryote"}, {"end": 212, "start": 209, "tag": "AminoAcidPeptideOrProtein"}, {"end": 212, "start": 209, "tag": "BiologicallyActiveSubstance"}, {"end": 226, "start": 223, "tag": "AminoAcidPeptideOrProtein"}, {"end": 226, "start": 223, "tag": "BiologicallyActiveSubstance"}]}{"id": "1359_12", "text": "In addition, we documented by immunohistochemistry in the cuprizone model the expression of chondroitin sulfate proteoglycans that are inhibitory for the differentiation of OPCs.", "tags": [{"end": 125, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 30, "tag": "ResearchActivity"}, {"end": 177, "start": 173, "tag": "Cell"}, {"end": 67, "start": 58, "tag": "Chemical"}, {"end": 73, "start": 58, "tag": "ResearchActivity"}, {"end": 169, "start": 154, "tag": "CellFunction"}]}{"id": "1359_13", "text": "In conclusion, inhibitory properties of Tnc and Tnr for myelin membrane formation could be demonstrated by using an ex vivo approach.", "tags": [{"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 63, "tag": "CellComponent"}, {"end": 62, "start": 56, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 116, "tag": "ResearchActivity"}, {"end": 81, "start": 56, "tag": "CellFunction"}, {"end": 36, "start": 15, "tag": "Finding"}]}{"id": "1360_0", "text": "The crosstalk between glial cells and neurons represents an exceptional feature for maintaining the normal function of the central nervous system (CNS).", "tags": [{"end": 145, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 22, "tag": "Cell"}, {"end": 13, "start": 4, "tag": "CellFunction"}, {"end": 45, "start": 38, "tag": "Cell"}, {"end": 106, "start": 100, "tag": "Finding"}]}{"id": "1360_1", "text": "Increasing evidence has revealed the importance of glial progenitor cells in adult neurogenesis, reestablishment of cellular pools, neuroregeneration, and axonal (re)myelination.", "tags": [{"end": 73, "start": 51, "tag": "Cell"}, {"end": 161, "start": 155, "tag": "CellComponent"}, {"end": 19, "start": 11, "tag": "Finding"}, {"end": 130, "start": 116, "tag": "Cell"}, {"end": 95, "start": 83, "tag": "BiologicFunction"}, {"end": 177, "start": 166, "tag": "CellFunction"}, {"end": 82, "start": 77, "tag": "PopulationGroup"}, {"end": 149, "start": 132, "tag": "BiologicFunction"}]}{"id": "1360_2", "text": "Several types of glial progenitors have been described, as well as their potentialities for recovering the CNS from certain traumas or pathologies.", "tags": [{"end": 131, "start": 124, "tag": "InjuryOrPoisoning"}, {"end": 34, "start": 17, "tag": "Cell"}, {"end": 110, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 135, "tag": "DiseaseOrSyndrome"}]}{"id": "1360_3", "text": "Among these precursors, glial-restricted precursor cells (GRPs) are considered the earliest glial progenitors and exhibit tripotency for both Type I/II astrocytes and oligodendrocytes.", "tags": [{"end": 91, "start": 83, "tag": "TemporalConcept"}, {"end": 183, "start": 167, "tag": "Cell"}, {"end": 56, "start": 24, "tag": "Cell"}, {"end": 109, "start": 92, "tag": "Cell"}, {"end": 162, "start": 142, "tag": "Cell"}, {"end": 62, "start": 58, "tag": "Cell"}]}{"id": "1360_4", "text": "GRPs have been derived from embryos and embryonic stem cells in animal models and have maintained their capacity for self-renewal.", "tags": [{"end": 35, "start": 28, "tag": "EmbryonicStructure"}, {"end": 129, "start": 117, "tag": "CellFunction"}, {"end": 60, "start": 40, "tag": "Cell"}, {"end": 112, "start": 104, "tag": "Finding"}, {"end": 77, "start": 64, "tag": "ResearchActivity"}, {"end": 4, "start": 0, "tag": "Cell"}]}{"id": "1360_5", "text": "Despite the relatively limited knowledge regarding the isolation, characterization, and function of these progenitors, GRPs are promising candidates for transplantation therapy and reestablishment/repair of CNS functions in neurodegenerative and neuropsychiatric disorders, as well as in traumatic injuries.", "tags": [{"end": 306, "start": 288, "tag": "InjuryOrPoisoning"}, {"end": 210, "start": 207, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 55, "tag": "HealthCareActivity"}, {"end": 241, "start": 224, "tag": "CellOrMolecularDysfunction"}, {"end": 40, "start": 31, "tag": "Finding"}, {"end": 176, "start": 169, "tag": "HealthCareActivity"}, {"end": 82, "start": 66, "tag": "ResearchActivity"}, {"end": 168, "start": 153, "tag": "HealthCareActivity"}, {"end": 203, "start": 197, "tag": "BiologicFunction"}, {"end": 203, "start": 197, "tag": "HealthCareActivity"}, {"end": 123, "start": 119, "tag": "Cell"}, {"end": 272, "start": 246, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 106, "tag": "Cell"}, {"end": 64, "start": 55, "tag": "ResearchActivity"}]}{"id": "1360_6", "text": "Herein, we review the definition, isolation, characterization and potentialities of GRPs as cell-based therapies in different neurological conditions.", "tags": [{"end": 43, "start": 34, "tag": "HealthCareActivity"}, {"end": 17, "start": 11, "tag": "ResearchActivity"}, {"end": 17, "start": 11, "tag": "HealthCareActivity"}, {"end": 149, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 112, "start": 92, "tag": "HealthCareActivity"}, {"end": 61, "start": 45, "tag": "ResearchActivity"}, {"end": 88, "start": 84, "tag": "Cell"}, {"end": 43, "start": 34, "tag": "ResearchActivity"}]}{"id": "1360_7", "text": "We briefly discuss the implications of using GRPs in CNS regenerative medicine and their possible application in a clinical setting.", "tags": [{"end": 78, "start": 57, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 131, "start": 115, "tag": "HealthCareActivity"}, {"end": 56, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 10, "start": 3, "tag": "TemporalConcept"}, {"end": 49, "start": 45, "tag": "Cell"}]}{"id": "1360_8", "text": "Main Points GRPs are progenitors present in the CNS with differentiation potential restricted to the glial lineage.", "tags": [{"end": 32, "start": 21, "tag": "Cell"}, {"end": 72, "start": 57, "tag": "CellFunction"}, {"end": 114, "start": 101, "tag": "Cell"}, {"end": 51, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 12, "tag": "Cell"}]}{"id": "1360_9", "text": "These cells have been employed in the treatment of a myriad of neurodegenerative and traumatic pathologies, accompanied by promising results, herein reviewed.", "tags": [{"end": 157, "start": 149, "tag": "HealthCareActivity"}, {"end": 157, "start": 149, "tag": "ResearchActivity"}, {"end": 11, "start": 6, "tag": "Cell"}, {"end": 47, "start": 38, "tag": "HealthCareActivity"}, {"end": 47, "start": 38, "tag": "ResearchActivity"}, {"end": 106, "start": 95, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 85, "tag": "DiseaseOrSyndrome"}]}{"id": "1361_0", "text": "BackgroundThe evidence associating consumption of dairy products and risk of MS is contradictory and inconclusive.", "tags": [{"end": 46, "start": 35, "tag": "BiologicFunction"}, {"end": 22, "start": 14, "tag": "Finding"}, {"end": 73, "start": 69, "tag": "Finding"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 64, "start": 50, "tag": "Substance"}]}{"id": "1361_1", "text": "ObjectiveTo test associations between dairy consumption and the likelihood of a first clinical diagnosis of central nervous system demyelination (FCD), a common precursor to MS.", "tags": [{"end": 16, "start": 12, "tag": "ResearchActivity"}, {"end": 16, "start": 12, "tag": "HealthCareActivity"}, {"end": 144, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 108, "tag": "CellFunction"}, {"end": 130, "start": 108, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 86, "tag": "HealthCareActivity"}, {"end": 85, "start": 80, "tag": "TemporalConcept"}, {"end": 176, "start": 174, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 131, "tag": "PathologicFunction"}, {"end": 55, "start": 44, "tag": "BiologicFunction"}, {"end": 74, "start": 64, "tag": "Finding"}, {"end": 43, "start": 38, "tag": "Substance"}]}{"id": "1361_2", "text": "MethodsWe used data from the 2003-2006 Ausimmune Study, a population-based Australian, multicentre, matched case-control study (272 cases, 519 controls).", "tags": [{"end": 54, "start": 29, "tag": "ResearchActivity"}, {"end": 126, "start": 100, "tag": "ResearchActivity"}, {"end": 151, "start": 143, "tag": "PopulationGroup"}, {"end": 68, "start": 58, "tag": "PopulationGroup"}, {"end": 19, "start": 15, "tag": "ResearchActivity"}, {"end": 85, "start": 75, "tag": "PopulationGroup"}]}{"id": "1361_3", "text": "Total dairy consumption (servings/day) was calculated by summing consumption of milk, cheese and yogurt.", "tags": [{"end": 76, "start": 65, "tag": "BiologicFunction"}, {"end": 84, "start": 80, "tag": "Substance"}, {"end": 11, "start": 6, "tag": "Substance"}, {"end": 92, "start": 86, "tag": "Substance"}, {"end": 103, "start": 97, "tag": "Substance"}, {"end": 23, "start": 12, "tag": "BiologicFunction"}]}{"id": "1361_4", "text": "Covariate-adjusted treatment effects using augmented inverse probability weighting was used to test for associations with FCD.", "tags": [{"end": 99, "start": 95, "tag": "ResearchActivity"}, {"end": 99, "start": 95, "tag": "HealthCareActivity"}, {"end": 28, "start": 19, "tag": "HealthCareActivity"}, {"end": 28, "start": 19, "tag": "ResearchActivity"}, {"end": 72, "start": 61, "tag": "Finding"}, {"end": 36, "start": 29, "tag": "Finding"}]}{"id": "1361_5", "text": "We conducted sensitivity analyses in the subset of participants who had had a classic first demyelinating event (FDE), defined as a single, first episode of symptoms suggestive of CNS demyelination.", "tags": [{"end": 153, "start": 146, "tag": "TemporalConcept"}, {"end": 105, "start": 92, "tag": "PathologicFunction"}, {"end": 63, "start": 51, "tag": "PopulationGroup"}, {"end": 183, "start": 180, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 91, "start": 86, "tag": "TemporalConcept"}, {"end": 145, "start": 140, "tag": "TemporalConcept"}, {"end": 165, "start": 157, "tag": "SignOrSymptom"}, {"end": 33, "start": 25, "tag": "ResearchActivity"}, {"end": 24, "start": 13, "tag": "Finding"}, {"end": 197, "start": 184, "tag": "PathologicFunction"}, {"end": 197, "start": 180, "tag": "DiseaseOrSyndrome"}]}{"id": "1361_6", "text": "ResultsThere were no statistically significant associations between total dairy consumption (per one serving/day) and FCD (adjusted OR 1.00; 95% CI 0.93, 1.07; p = 0.979).", "tags": [{"end": 147, "start": 145, "tag": "ResearchActivity"}, {"end": 79, "start": 74, "tag": "Substance"}, {"end": 91, "start": 80, "tag": "BiologicFunction"}]}{"id": "1361_7", "text": "However, yogurt consumption (vs.", "tags": [{"end": 27, "start": 16, "tag": "BiologicFunction"}, {"end": 15, "start": 9, "tag": "Substance"}]}{"id": "1361_8", "text": "no yogurt consumption) was associated with an 11% decreased likelihood of FDE (adjusted OR 0.89; 95% CI 0.89, 0.79; p = 0.046).", "tags": [{"end": 21, "start": 10, "tag": "BiologicFunction"}, {"end": 103, "start": 101, "tag": "ResearchActivity"}, {"end": 70, "start": 60, "tag": "Finding"}]}{"id": "1361_9", "text": "ConclusionWhile total dairy consumption was not associated with FCD in this Australian case-control study, yogurt consumption was associated with reduced likelihood of FDE.", "tags": [{"end": 86, "start": 76, "tag": "PopulationGroup"}, {"end": 105, "start": 87, "tag": "ResearchActivity"}, {"end": 125, "start": 114, "tag": "BiologicFunction"}, {"end": 27, "start": 22, "tag": "Substance"}, {"end": 39, "start": 28, "tag": "BiologicFunction"}, {"end": 113, "start": 107, "tag": "Substance"}, {"end": 164, "start": 154, "tag": "Finding"}]}{"id": "1362_0", "text": "Myelin sheaths, by supporting axonal integrity and allowing rapid saltatory impulse conduction, are of fundamental importance for neuronal function.", "tags": [{"end": 94, "start": 66, "tag": "CellFunction"}, {"end": 94, "start": 84, "tag": "NaturalPhenomenonOrProcess"}, {"end": 46, "start": 30, "tag": "CellFunction"}, {"end": 94, "start": 84, "tag": "BiologicFunction"}, {"end": 147, "start": 130, "tag": "CellFunction"}, {"end": 14, "start": 0, "tag": "CellComponent"}]}{"id": "1362_1", "text": "In response to demyelinating injuries in the central nervous system (CNS), oligodendrocyte progenitor cells (OPCs) migrate to the lesion area, proliferate and differentiate into new oligodendrocytes that make new myelin sheaths.", "tags": [{"end": 198, "start": 182, "tag": "Cell"}, {"end": 113, "start": 109, "tag": "Cell"}, {"end": 172, "start": 159, "tag": "CellFunction"}, {"end": 28, "start": 15, "tag": "PathologicFunction"}, {"end": 136, "start": 130, "tag": "InjuryOrPoisoning"}, {"end": 107, "start": 75, "tag": "Cell"}, {"end": 227, "start": 213, "tag": "CellComponent"}, {"end": 107, "start": 91, "tag": "Cell"}, {"end": 37, "start": 15, "tag": "InjuryOrPoisoning"}, {"end": 67, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1362_2", "text": "This process is termed remyelination.", "tags": [{"end": 36, "start": 23, "tag": "CellFunction"}]}{"id": "1362_3", "text": "Under specific conditions, demyelinated axons in the CNS can also be remyelinated by Schwann cells (SCs), the myelinating cell of the peripheral nervous system.", "tags": [{"end": 159, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 98, "start": 85, "tag": "Cell"}, {"end": 103, "start": 100, "tag": "Cell"}, {"end": 45, "start": 40, "tag": "CellComponent"}, {"end": 39, "start": 27, "tag": "PathologicFunction"}, {"end": 81, "start": 69, "tag": "CellFunction"}, {"end": 56, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 122, "tag": "Cell"}]}{"id": "1362_4", "text": "OPCs can be a major source of these CNS-resident SCs-a surprising finding given the distinct embryonic origins, and physiological compartmentalization of the peripheral and central nervous system.", "tags": [{"end": 52, "start": 49, "tag": "Cell"}, {"end": 73, "start": 66, "tag": "Finding"}, {"end": 4, "start": 0, "tag": "Cell"}, {"end": 48, "start": 40, "tag": "PopulationGroup"}, {"end": 195, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 195, "start": 181, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 158, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 93, "tag": "EmbryonicStructure"}]}{"id": "1362_5", "text": "Although the mechanisms and cues governing OPC-to-SC differentiation remain largely undiscovered, it might nevertheless be an attractive target for promoting endogenous remyelination.", "tags": [{"end": 46, "start": 43, "tag": "Cell"}, {"end": 68, "start": 53, "tag": "CellFunction"}, {"end": 182, "start": 169, "tag": "CellFunction"}, {"end": 52, "start": 50, "tag": "Cell"}]}{"id": "1362_6", "text": "This article will (i) review current knowledge on the origins of SCs in the CNS, with a particular focus on OPC to SC differentiation, (ii) discuss the necessary criteria for SC myelination in the CNS and (iii) highlight the potential of using SCs for myelin regeneration in the CNS.", "tags": [{"end": 61, "start": 54, "tag": "TemporalConcept"}, {"end": 117, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 177, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 12, "start": 5, "tag": "ResearchActivity"}, {"end": 68, "start": 65, "tag": "Cell"}, {"end": 247, "start": 244, "tag": "Cell"}, {"end": 111, "start": 108, "tag": "Cell"}, {"end": 258, "start": 252, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 133, "start": 118, "tag": "CellFunction"}, {"end": 271, "start": 259, "tag": "BiologicFunction"}, {"end": 271, "start": 259, "tag": "HealthCareActivity"}, {"end": 271, "start": 252, "tag": "CellFunction"}, {"end": 79, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 200, "start": 197, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 282, "start": 279, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 22, "tag": "ResearchActivity"}, {"end": 28, "start": 22, "tag": "HealthCareActivity"}, {"end": 46, "start": 37, "tag": "Finding"}, {"end": 36, "start": 29, "tag": "TemporalConcept"}, {"end": 189, "start": 178, "tag": "CellFunction"}]}{"id": "1363_0", "text": "Disruption or loss of oligodendrocytes (OLs) and myelin has devastating effects on CNS function and integrity, which occur in diverse neurological disorders, including Multiple Sclerosis (MS), Alzheimer's disease and neuropsychiatric disorders.", "tags": [{"end": 38, "start": 22, "tag": "Cell"}, {"end": 55, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 40, "tag": "Cell"}, {"end": 109, "start": 100, "tag": "IndividualBehavior"}, {"end": 186, "start": 168, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 14, "tag": "CellOrMolecularDysfunction"}, {"end": 212, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 188, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 72, "tag": "Finding"}, {"end": 95, "start": 83, "tag": "BiologicFunction"}, {"end": 86, "start": 83, "tag": "BiologicFunction"}, {"end": 109, "start": 100, "tag": "BiologicFunction"}, {"end": 243, "start": 217, "tag": "DiseaseOrSyndrome"}]}{"id": "1363_1", "text": "Hence, there is a need to develop new therapies that promote oligodendrocyte regeneration and myelin repair.", "tags": [{"end": 89, "start": 77, "tag": "BiologicFunction"}, {"end": 89, "start": 77, "tag": "HealthCareActivity"}, {"end": 107, "start": 94, "tag": "CellFunction"}, {"end": 76, "start": 61, "tag": "Cell"}, {"end": 47, "start": 38, "tag": "HealthCareActivity"}]}{"id": "1363_2", "text": "A promising approach is drug repurposing, but most agents have potentially contrasting biological actions depending on the cellular context and their dose-dependent effects on intracellular pathways.", "tags": [{"end": 40, "start": 24, "tag": "HealthCareActivity"}, {"end": 189, "start": 176, "tag": "CellComponent"}, {"end": 131, "start": 123, "tag": "Cell"}, {"end": 198, "start": 190, "tag": "CellFunction"}, {"end": 172, "start": 165, "tag": "Finding"}, {"end": 28, "start": 24, "tag": "PharmacologicSubstance"}]}{"id": "1363_3", "text": "Here, we have used a combined systems biology and neurobiological approach to identify compounds that exert positive and negative effects on oligodendroglia, depending on concentration.", "tags": [{"end": 45, "start": 30, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 156, "start": 141, "tag": "Cell"}, {"end": 96, "start": 87, "tag": "Chemical"}, {"end": 96, "start": 87, "tag": "PharmacologicSubstance"}, {"end": 137, "start": 130, "tag": "Finding"}, {"end": 184, "start": 171, "tag": "BiologicFunction"}]}{"id": "1363_4", "text": "Notably, next generation pharmacogenomic analysis identified the PI3K/Akt modulator LY294002 as the most highly ranked small molecule with both pro- and anti-oligodendroglial concentration-dependent effects.", "tags": [{"end": 49, "start": 9, "tag": "ResearchActivity"}, {"end": 92, "start": 84, "tag": "Chemical"}, {"end": 133, "start": 119, "tag": "Chemical"}, {"end": 133, "start": 125, "tag": "Substance"}, {"end": 174, "start": 158, "tag": "Cell"}, {"end": 206, "start": 199, "tag": "Finding"}, {"end": 188, "start": 175, "tag": "BiologicFunction"}, {"end": 69, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 73, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 84, "tag": "PharmacologicSubstance"}, {"end": 83, "start": 74, "tag": "BiologicallyActiveSubstance"}]}{"id": "1363_5", "text": "We validated these in silico findings using multidisciplinary approaches to reveal a profoundly bipartite effect of LY294002 on the generation of OPCs and their differentiation into myelinating oligodendrocytes in both postnatal and adult contexts.", "tags": [{"end": 124, "start": 116, "tag": "Chemical"}, {"end": 193, "start": 182, "tag": "CellFunction"}, {"end": 210, "start": 194, "tag": "Cell"}, {"end": 150, "start": 146, "tag": "Cell"}, {"end": 176, "start": 161, "tag": "CellFunction"}, {"end": 210, "start": 182, "tag": "Cell"}, {"end": 228, "start": 219, "tag": "TemporalConcept"}, {"end": 112, "start": 106, "tag": "Finding"}, {"end": 238, "start": 233, "tag": "PopulationGroup"}, {"end": 142, "start": 132, "tag": "TemporalConcept"}, {"end": 124, "start": 116, "tag": "PharmacologicSubstance"}]}{"id": "1363_6", "text": "Finally, we employed transcriptional profiling and signalling pathway activity assays to determine cell-specific mechanisms of action of LY294002 on oligodendrocytes and resolve optimal in vivo conditions required to promote myelin repair.", "tags": [{"end": 145, "start": 137, "tag": "Chemical"}, {"end": 165, "start": 149, "tag": "Cell"}, {"end": 69, "start": 51, "tag": "CellFunction"}, {"end": 238, "start": 225, "tag": "CellFunction"}, {"end": 85, "start": 51, "tag": "ResearchActivity"}, {"end": 103, "start": 99, "tag": "Cell"}, {"end": 46, "start": 21, "tag": "ResearchActivity"}, {"end": 193, "start": 186, "tag": "ResearchActivity"}, {"end": 145, "start": 137, "tag": "PharmacologicSubstance"}]}{"id": "1363_7", "text": "These results demonstrate the power of multidisciplinary strategies in determining the therapeutic potential of small molecules in neurodegenerative disorders.", "tags": [{"end": 127, "start": 112, "tag": "Chemical"}, {"end": 67, "start": 57, "tag": "ResearchActivity"}, {"end": 67, "start": 57, "tag": "BiologicFunction"}, {"end": 127, "start": 118, "tag": "Substance"}, {"end": 108, "start": 87, "tag": "HealthCareActivity"}, {"end": 158, "start": 131, "tag": "DiseaseOrSyndrome"}]}{"id": "1364_0", "text": "Given the known neuroreparative actions of IL-33 in experimental models of central nervous system (CNS) injury, we predicted that compounds which induce IL-33 are likely to promote remyelination.", "tags": [{"end": 48, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 158, "start": 153, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 52, "tag": "ExperimentalModelOfDisease"}, {"end": 139, "start": 130, "tag": "Chemical"}, {"end": 139, "start": 130, "tag": "PharmacologicSubstance"}, {"end": 180, "start": 173, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 97, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 102, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 104, "tag": "InjuryOrPoisoning"}, {"end": 194, "start": 181, "tag": "CellFunction"}, {"end": 71, "start": 52, "tag": "ResearchActivity"}, {"end": 48, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 16, "tag": "CellFunction"}]}{"id": "1364_1", "text": "We found anacardic acid as a candidate molecule to serve as a therapeutic agent to promote remyelination.", "tags": [{"end": 23, "start": 9, "tag": "Chemical"}, {"end": 79, "start": 62, "tag": "PharmacologicSubstance"}, {"end": 47, "start": 39, "tag": "Substance"}, {"end": 104, "start": 91, "tag": "CellFunction"}, {"end": 23, "start": 9, "tag": "PharmacologicSubstance"}]}{"id": "1364_2", "text": "Addition of anacardic acid to cultured oligodendrocyte precursor cells (OPCs) rapidly increased expression of myelin genes and myelin proteins, suggesting a direct induction of genes involved in myelination by anacardic acid.", "tags": [{"end": 26, "start": 12, "tag": "Chemical"}, {"end": 142, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 224, "start": 210, "tag": "Chemical"}, {"end": 76, "start": 72, "tag": "Cell"}, {"end": 70, "start": 39, "tag": "Cell"}, {"end": 116, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 96, "tag": "CellFunction"}, {"end": 206, "start": 195, "tag": "CellFunction"}, {"end": 38, "start": 30, "tag": "ResearchActivity"}, {"end": 182, "start": 164, "tag": "CellFunction"}, {"end": 224, "start": 210, "tag": "PharmacologicSubstance"}, {"end": 26, "start": 12, "tag": "PharmacologicSubstance"}, {"end": 122, "start": 117, "tag": "GeneOrGenome"}]}{"id": "1364_3", "text": "Also, when added to OPCs, anacardic acid resulted in the induction of IL-33.", "tags": [{"end": 40, "start": 26, "tag": "Chemical"}, {"end": 66, "start": 57, "tag": "HealthCareActivity"}, {"end": 66, "start": 57, "tag": "HealthCareRelatedOrganization"}, {"end": 75, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 70, "tag": "CellFunction"}, {"end": 24, "start": 20, "tag": "Cell"}, {"end": 40, "start": 26, "tag": "PharmacologicSubstance"}]}{"id": "1364_4", "text": "In vivo, treatment of with anacardic acid in doses which ranged from 0.025 mg/kg to 2.5 mg/kg, improved pathologic scores in experimental allergic encephalitis (EAE) and in the cuprizone model of demyelination/remyelination.", "tags": [{"end": 41, "start": 27, "tag": "Chemical"}, {"end": 159, "start": 125, "tag": "DiseaseOrSyndrome"}, {"end": 164, "start": 161, "tag": "ExperimentalModelOfDisease"}, {"end": 186, "start": 177, "tag": "Chemical"}, {"end": 192, "start": 177, "tag": "ResearchActivity"}, {"end": 18, "start": 9, "tag": "HealthCareActivity"}, {"end": 18, "start": 9, "tag": "ResearchActivity"}, {"end": 223, "start": 210, "tag": "CellFunction"}, {"end": 209, "start": 196, "tag": "PathologicFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 41, "start": 27, "tag": "PharmacologicSubstance"}]}{"id": "1364_5", "text": "Electron microscopic studies performed in mice fed with cuprizone and treated with anacardic acid showed lower g-ratio scores when compared to controls, suggesting increased remyelination of axons.", "tags": [{"end": 97, "start": 83, "tag": "Chemical"}, {"end": 125, "start": 111, "tag": "Finding"}, {"end": 196, "start": 191, "tag": "CellComponent"}, {"end": 65, "start": 56, "tag": "Chemical"}, {"end": 151, "start": 143, "tag": "PopulationGroup"}, {"end": 46, "start": 42, "tag": "Eukaryote"}, {"end": 28, "start": 0, "tag": "ResearchActivity"}, {"end": 82, "start": 70, "tag": "HealthCareActivity"}, {"end": 187, "start": 174, "tag": "CellFunction"}, {"end": 97, "start": 83, "tag": "PharmacologicSubstance"}]}{"id": "1364_6", "text": "In EAE, improvement in paralytic scores was seen when the drug was given prior to or following the onset of paralytic signs.", "tags": [{"end": 123, "start": 108, "tag": "SignOrSymptom"}, {"end": 6, "start": 3, "tag": "ExperimentalModelOfDisease"}, {"end": 104, "start": 99, "tag": "TemporalConcept"}, {"end": 62, "start": 58, "tag": "PharmacologicSubstance"}, {"end": 39, "start": 23, "tag": "Finding"}]}{"id": "1364_7", "text": "In EAE and in the cuprizone model, areas of myelin loss, which are likely to remyelinate, was associated with a greater recruitment of IL-33-expressing OPCs in mice which received anacardic acid when compared to controls.", "tags": [{"end": 194, "start": 180, "tag": "Chemical"}, {"end": 151, "start": 141, "tag": "CellFunction"}, {"end": 6, "start": 3, "tag": "ExperimentalModelOfDisease"}, {"end": 156, "start": 152, "tag": "Cell"}, {"end": 50, "start": 44, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 77, "tag": "CellFunction"}, {"end": 27, "start": 18, "tag": "Chemical"}, {"end": 33, "start": 18, "tag": "ResearchActivity"}, {"end": 220, "start": 212, "tag": "PopulationGroup"}, {"end": 164, "start": 160, "tag": "Eukaryote"}, {"end": 194, "start": 180, "tag": "PharmacologicSubstance"}, {"end": 55, "start": 44, "tag": "CellOrMolecularDysfunction"}, {"end": 140, "start": 135, "tag": "AminoAcidPeptideOrProtein"}, {"end": 140, "start": 135, "tag": "BiologicallyActiveSubstance"}]}{"id": "1365_0", "text": "Arrest of oligodendrocyte (OL) differentiation and remyelination following myelin damage in multiple sclerosis (MS) is associated with neurodegeneration and clinical worsening.", "tags": [{"end": 6, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 175, "start": 157, "tag": "Finding"}, {"end": 110, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 31, "tag": "CellFunction"}, {"end": 29, "start": 27, "tag": "Cell"}, {"end": 152, "start": 135, "tag": "CellOrMolecularDysfunction"}, {"end": 25, "start": 10, "tag": "Cell"}, {"end": 64, "start": 51, "tag": "CellFunction"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}]}{"id": "1365_1", "text": "We show that Glutathione S-transferase 4 alpha (Gsta4) is highly expressed during adult OL differentiation and that Gsta4 loss impairs differentiation into myelinating OLs in vitro.", "tags": [{"end": 46, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 46, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 48, "tag": "GeneOrGenome"}, {"end": 53, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 121, "start": 116, "tag": "GeneOrGenome"}, {"end": 121, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 171, "start": 156, "tag": "Cell"}, {"end": 150, "start": 135, "tag": "CellFunction"}, {"end": 106, "start": 88, "tag": "CellFunction"}, {"end": 180, "start": 172, "tag": "ResearchActivity"}, {"end": 87, "start": 82, "tag": "PopulationGroup"}, {"end": 74, "start": 65, "tag": "CellFunction"}, {"end": 53, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 116, "tag": "CellOrMolecularDysfunction"}]}{"id": "1365_2", "text": "In addition, we identify Gsta4 as a target of both dimethyl fumarate, an existing MS therapy, and clemastine fumarate, a candidate remyelinating agent in MS.", "tags": [{"end": 30, "start": 25, "tag": "GeneOrGenome"}, {"end": 30, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 98, "tag": "Chemical"}, {"end": 68, "start": 51, "tag": "PharmacologicSubstance"}, {"end": 68, "start": 51, "tag": "Chemical"}, {"end": 144, "start": 131, "tag": "CellFunction"}, {"end": 150, "start": 145, "tag": "PharmacologicSubstance"}, {"end": 92, "start": 85, "tag": "HealthCareActivity"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 156, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 98, "tag": "PharmacologicSubstance"}]}{"id": "1365_3", "text": "Overexpression of Gsta4 reduces expression of Fas and activity of the mitochondria-associated Casp8-Bid-axis in adult oligodendrocyte precursor cells, leading to improved OL survival during differentiation.", "tags": [{"end": 23, "start": 18, "tag": "GeneOrGenome"}, {"end": 23, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 49, "start": 46, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 46, "tag": "GeneOrGenome"}, {"end": 149, "start": 118, "tag": "Cell"}, {"end": 205, "start": 190, "tag": "CellFunction"}, {"end": 173, "start": 171, "tag": "Cell"}, {"end": 42, "start": 32, "tag": "CellFunction"}, {"end": 182, "start": 174, "tag": "CellFunction"}, {"end": 14, "start": 0, "tag": "CellFunction"}, {"end": 117, "start": 112, "tag": "PopulationGroup"}, {"end": 82, "start": 70, "tag": "CellComponent"}, {"end": 23, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 94, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 94, "tag": "GeneOrGenome"}, {"end": 103, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 100, "tag": "GeneOrGenome"}, {"end": 103, "start": 100, "tag": "BiologicallyActiveSubstance"}]}{"id": "1365_4", "text": "The Gsta4 effect on apoptosis during adult OL differentiation was corroborated in vivo in both lysolecithin-induced demyelination and experimental autoimmune encephalomyelitis models, where Casp8 activity was reduced in Gsta4-overexpressing OLs.", "tags": [{"end": 9, "start": 4, "tag": "GeneOrGenome"}, {"end": 9, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 182, "start": 134, "tag": "ExperimentalModelOfDisease"}, {"end": 107, "start": 95, "tag": "Chemical"}, {"end": 107, "start": 95, "tag": "PharmacologicSubstance"}, {"end": 244, "start": 241, "tag": "Cell"}, {"end": 61, "start": 43, "tag": "CellFunction"}, {"end": 16, "start": 10, "tag": "Finding"}, {"end": 29, "start": 20, "tag": "CellFunction"}, {"end": 86, "start": 79, "tag": "ResearchActivity"}, {"end": 129, "start": 116, "tag": "PathologicFunction"}, {"end": 42, "start": 37, "tag": "PopulationGroup"}, {"end": 225, "start": 220, "tag": "GeneOrGenome"}, {"end": 225, "start": 220, "tag": "AminoAcidPeptideOrProtein"}, {"end": 225, "start": 220, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 190, "tag": "AminoAcidPeptideOrProtein"}, {"end": 195, "start": 190, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 190, "tag": "GeneOrGenome"}, {"end": 9, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 204, "start": 190, "tag": "CellFunction"}]}{"id": "1365_5", "text": "Our results identify Gsta4 as an intrinsic regulator of OL differentiation, survival and remyelination, as well as a potential target for future reparative MS therapies.", "tags": [{"end": 26, "start": 21, "tag": "GeneOrGenome"}, {"end": 26, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 56, "tag": "CellFunction"}, {"end": 84, "start": 76, "tag": "CellFunction"}, {"end": 144, "start": 138, "tag": "TemporalConcept"}, {"end": 102, "start": 89, "tag": "CellFunction"}, {"end": 168, "start": 159, "tag": "HealthCareActivity"}, {"end": 155, "start": 145, "tag": "HealthCareActivity"}, {"end": 158, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 133, "start": 117, "tag": "Finding"}]}{"id": "1366_0", "text": "A puzzling feature of schizophrenia, is the long latency between the beginning of neuropathological changes and the clinical presentation that may be two decades later.", "tags": [{"end": 161, "start": 154, "tag": "TemporalConcept"}, {"end": 137, "start": 125, "tag": "Finding"}, {"end": 35, "start": 22, "tag": "DiseaseOrSyndrome"}, {"end": 56, "start": 49, "tag": "TemporalConcept"}]}{"id": "1366_1", "text": "Abnormalities in oligodendrocyte function may explain this latency, because mature oligodendrocytes produce myelination, and if myelination were abnormal from the outset, it would cause the synaptic dysfunction and abnormal neural tracts that are underpinning features of schizophrenia.", "tags": [{"end": 13, "start": 0, "tag": "Finding"}, {"end": 153, "start": 145, "tag": "Finding"}, {"end": 223, "start": 215, "tag": "Finding"}, {"end": 210, "start": 190, "tag": "CellOrMolecularDysfunction"}, {"end": 99, "start": 76, "tag": "Cell"}, {"end": 119, "start": 108, "tag": "CellFunction"}, {"end": 139, "start": 128, "tag": "CellFunction"}, {"end": 285, "start": 272, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 59, "tag": "TemporalConcept"}, {"end": 41, "start": 17, "tag": "CellFunction"}, {"end": 237, "start": 224, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1366_2", "text": "The hypothesis is that latency is caused by events that occur in some patients as early as in-utero or infancy, because clones of abnormal, myelinating oligodendrocytes may arise at that time; their number doubles every similar to 2 years, so their geometric increase between birth and age twenty, when clinical presentation occurs, is about 1000-fold plus the effect of compounding.", "tags": [{"end": 126, "start": 120, "tag": "Cell"}, {"end": 138, "start": 130, "tag": "Finding"}, {"end": 281, "start": 276, "tag": "BiologicFunction"}, {"end": 168, "start": 140, "tag": "Cell"}, {"end": 110, "start": 103, "tag": "TemporalConcept"}, {"end": 110, "start": 103, "tag": "PopulationGroup"}, {"end": 324, "start": 312, "tag": "Finding"}, {"end": 289, "start": 286, "tag": "OrganismAttribute"}, {"end": 238, "start": 233, "tag": "TemporalConcept"}, {"end": 78, "start": 70, "tag": "PatientOrDisabledGroup"}, {"end": 191, "start": 187, "tag": "TemporalConcept"}, {"end": 30, "start": 23, "tag": "TemporalConcept"}, {"end": 99, "start": 91, "tag": "TemporalConcept"}]}{"id": "1366_3", "text": "For those patients in particular, the long latency is because of a small but ongoing increase in volume of the resulting, abnormally myelinated neural tracts until, after a long latent interval, a critical mass is reached that allows the full clinical features of schizophrenia.", "tags": [{"end": 260, "start": 243, "tag": "ClinicalAttribute"}, {"end": 277, "start": 264, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 10, "tag": "PatientOrDisabledGroup"}, {"end": 84, "start": 77, "tag": "TemporalConcept"}, {"end": 50, "start": 43, "tag": "TemporalConcept"}, {"end": 157, "start": 144, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 122, "tag": "PathologicFunction"}]}{"id": "1366_4", "text": "During latency, there may be behavioral aberrancies because of abnormally myelinated neural tracts but they are insufficiently numerous for the clinical syndrome.", "tags": [{"end": 161, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 7, "tag": "TemporalConcept"}, {"end": 51, "start": 29, "tag": "PathologicFunction"}, {"end": 84, "start": 63, "tag": "PathologicFunction"}, {"end": 98, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1366_5", "text": "The occurrence of behavioral symptoms during the long latent period, substantiates the hypothesis that abnormal oligodendrocytes explain the latency in some patients.", "tags": [{"end": 37, "start": 18, "tag": "SignOrSymptom"}, {"end": 128, "start": 112, "tag": "Cell"}, {"end": 67, "start": 61, "tag": "TemporalConcept"}, {"end": 14, "start": 4, "tag": "TemporalConcept"}, {"end": 165, "start": 157, "tag": "PatientOrDisabledGroup"}, {"end": 148, "start": 141, "tag": "TemporalConcept"}, {"end": 128, "start": 103, "tag": "CellOrMolecularDysfunction"}]}{"id": "1366_6", "text": "Treatment with fingolimod or siponimod benefits both oligodendrocytes and neural tracts.", "tags": [{"end": 38, "start": 29, "tag": "Chemical"}, {"end": 69, "start": 53, "tag": "Cell"}, {"end": 25, "start": 15, "tag": "Chemical"}, {"end": 25, "start": 15, "tag": "PharmacologicSubstance"}, {"end": 25, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}]}{"id": "1366_7", "text": "Clinical trial would validate their potential benefit in appropriate patients with schizophrenia and, concurrently, would validate the hypothesis.", "tags": [{"end": 14, "start": 0, "tag": "ResearchActivity"}, {"end": 96, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 69, "tag": "PatientOrDisabledGroup"}]}{"id": "1367_0", "text": "Myelin repair in the adult central nervous system (CNS) is driven by successful differentiation of resident oligodendroglial precursor cells (OPCs) and thus constitutes a neurodegenerative process capable to compensate for functional deficits upon loss of oligodendrocytes and myelin sheaths as it is observed in multiple sclerosis (MS).", "tags": [{"end": 107, "start": 99, "tag": "PopulationGroup"}, {"end": 26, "start": 21, "tag": "PopulationGroup"}, {"end": 54, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 272, "start": 256, "tag": "Cell"}, {"end": 196, "start": 171, "tag": "CellOrMolecularDysfunction"}, {"end": 140, "start": 108, "tag": "Cell"}, {"end": 146, "start": 142, "tag": "Cell"}, {"end": 291, "start": 277, "tag": "CellComponent"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 242, "start": 234, "tag": "Finding"}, {"end": 335, "start": 333, "tag": "DiseaseOrSyndrome"}, {"end": 331, "start": 313, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 7, "tag": "BiologicFunction"}, {"end": 13, "start": 7, "tag": "HealthCareActivity"}, {"end": 95, "start": 80, "tag": "CellFunction"}, {"end": 49, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 272, "start": 248, "tag": "CellOrMolecularDysfunction"}]}{"id": "1367_1", "text": "The human endogenous retrovirus type W (HERV-W) represents an MS-specific pathogenic entity, and its envelope (ENV) protein was previously identified as a negative regulator of OPC maturation-hence, it is of relevance in the context of diminished myelin repair.", "tags": [{"end": 46, "start": 40, "tag": "Virus"}, {"end": 109, "start": 101, "tag": "CellComponent"}, {"end": 84, "start": 74, "tag": "PathologicFunction"}, {"end": 180, "start": 177, "tag": "Cell"}, {"end": 191, "start": 181, "tag": "BiologicFunction"}, {"end": 260, "start": 247, "tag": "CellFunction"}, {"end": 9, "start": 4, "tag": "Eukaryote"}, {"end": 64, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 38, "start": 4, "tag": "Virus"}, {"end": 123, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 109, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 155, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 111, "tag": "BiologicallyActiveSubstance"}]}{"id": "1367_2", "text": "We here focused on the activity of the ENV protein and investigated how it can be neutralized for improved remyelination.", "tags": [{"end": 50, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 107, "tag": "CellFunction"}, {"end": 50, "start": 39, "tag": "BiologicallyActiveSubstance"}]}{"id": "1367_3", "text": "ENV-mediated activation of toll like receptor 4 (TLR4) increases inducible nitric oxide synthase (iNOS) expression, prompts nitrosative stress, and results in myelin-associated deficits, such as decreased levels of oligodendroglial maturation marker expression and morphological alterations.", "tags": [{"end": 47, "start": 27, "tag": "AminoAcidPeptideOrProtein"}, {"end": 47, "start": 27, "tag": "GeneOrGenome"}, {"end": 142, "start": 124, "tag": "CellOrMolecularDysfunction"}, {"end": 204, "start": 195, "tag": "Finding"}, {"end": 242, "start": 232, "tag": "BiologicFunction"}, {"end": 231, "start": 215, "tag": "Cell"}, {"end": 53, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 49, "tag": "GeneOrGenome"}, {"end": 53, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 185, "start": 177, "tag": "Finding"}, {"end": 47, "start": 27, "tag": "BiologicallyActiveSubstance"}, {"end": 249, "start": 243, "tag": "ClinicalAttribute"}, {"end": 165, "start": 159, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 96, "start": 65, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 65, "tag": "BiologicallyActiveSubstance"}, {"end": 290, "start": 265, "tag": "PathologicFunction"}]}{"id": "1367_4", "text": "The intervention of TLR4 surface expression represents a potential means to rescue such ENV-dependent deficits.", "tags": [{"end": 24, "start": 20, "tag": "AminoAcidPeptideOrProtein"}, {"end": 24, "start": 20, "tag": "GeneOrGenome"}, {"end": 24, "start": 20, "tag": "BiologicallyActiveSubstance"}, {"end": 110, "start": 102, "tag": "Finding"}, {"end": 91, "start": 88, "tag": "AminoAcidPeptideOrProtein"}, {"end": 91, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 25, "tag": "CellFunction"}]}{"id": "1367_5", "text": "To this end, the rescue capacity of specific substances, either modulating V-ATPase activity or myeloid differentiation 2 (MD2)-mediated TLR4 glycosylation status, such as compound 20 (C20), L48H437, or folimycin, was analyzed, as these processes were demonstrated to be relevant for TLR4 surface expression.", "tags": [{"end": 55, "start": 45, "tag": "Substance"}, {"end": 121, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 162, "start": 156, "tag": "Finding"}, {"end": 183, "start": 172, "tag": "AminoAcidPeptideOrProtein"}, {"end": 212, "start": 203, "tag": "Chemical"}, {"end": 155, "start": 142, "tag": "CellFunction"}, {"end": 141, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 288, "start": 284, "tag": "AminoAcidPeptideOrProtein"}, {"end": 141, "start": 137, "tag": "GeneOrGenome"}, {"end": 288, "start": 284, "tag": "GeneOrGenome"}, {"end": 141, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 288, "start": 284, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 75, "tag": "CellFunction"}, {"end": 83, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 126, "start": 123, "tag": "AminoAcidPeptideOrProtein"}, {"end": 126, "start": 123, "tag": "BiologicallyActiveSubstance"}, {"end": 198, "start": 191, "tag": "Chemical"}, {"end": 198, "start": 191, "tag": "PharmacologicSubstance"}, {"end": 212, "start": 203, "tag": "PharmacologicSubstance"}, {"end": 183, "start": 172, "tag": "PharmacologicSubstance"}, {"end": 188, "start": 185, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 185, "tag": "PharmacologicSubstance"}, {"end": 307, "start": 289, "tag": "CellFunction"}]}{"id": "1367_6", "text": "We found that pharmacological treatment can rescue the maturation arrest of oligodendroglial cells and their myelination capacity and can prevent iNOS induction in the presence of the ENV protein.", "tags": [{"end": 72, "start": 66, "tag": "TemporalConcept"}, {"end": 98, "start": 76, "tag": "Cell"}, {"end": 176, "start": 168, "tag": "Finding"}, {"end": 195, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 109, "tag": "CellFunction"}, {"end": 65, "start": 55, "tag": "BiologicFunction"}, {"end": 150, "start": 146, "tag": "AminoAcidPeptideOrProtein"}, {"end": 150, "start": 146, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 14, "tag": "HealthCareActivity"}, {"end": 160, "start": 146, "tag": "CellFunction"}]}{"id": "1367_7", "text": "In addition, downregulation of TLR4 surface expression was observed.", "tags": [{"end": 35, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 31, "tag": "GeneOrGenome"}, {"end": 35, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 13, "tag": "CellFunction"}, {"end": 54, "start": 36, "tag": "CellFunction"}]}{"id": "1367_8", "text": "Furthermore, mitochondrial integrity crucial for oligodendroglial cell differentiation was affected in the presence of ENV and ameliorated upon pharmacological treatment.", "tags": [{"end": 36, "start": 27, "tag": "IndividualBehavior"}, {"end": 115, "start": 107, "tag": "Finding"}, {"end": 122, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 122, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 169, "start": 144, "tag": "HealthCareActivity"}, {"end": 26, "start": 13, "tag": "CellComponent"}, {"end": 70, "start": 49, "tag": "Cell"}, {"end": 86, "start": 71, "tag": "CellFunction"}]}{"id": "1367_9", "text": "Our study, therefore, provides novel insights into possible means to overcome myelination deficits associated with HERV-W ENV-mediated myelin deficits.", "tags": [{"end": 121, "start": 115, "tag": "Virus"}, {"end": 89, "start": 78, "tag": "CellFunction"}, {"end": 150, "start": 135, "tag": "CellOrMolecularDysfunction"}, {"end": 98, "start": 90, "tag": "Finding"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 125, "start": 122, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 122, "tag": "BiologicallyActiveSubstance"}]}{"id": "1368_0", "text": "Oligodendrocytes, the myelinating cells in the vertebrate central nervous system, produce myelin sheaths to enable saltatory propagation of action potentials.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 104, "start": 90, "tag": "CellComponent"}, {"end": 157, "start": 140, "tag": "CellFunction"}, {"end": 80, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 22, "tag": "Cell"}, {"end": 57, "start": 47, "tag": "Eukaryote"}, {"end": 136, "start": 115, "tag": "CellFunction"}]}{"id": "1368_1", "text": "The process of oligodendrocyte myelination entails a stepwise progression from precursor specification to differentiation, which is coordinated by a series of transcriptional and chromatin remodeling events.", "tags": [{"end": 143, "start": 132, "tag": "Finding"}, {"end": 174, "start": 159, "tag": "CellFunction"}, {"end": 121, "start": 106, "tag": "CellFunction"}, {"end": 199, "start": 189, "tag": "BiologicFunction"}, {"end": 188, "start": 179, "tag": "CellComponent"}, {"end": 73, "start": 62, "tag": "PathologicFunction"}, {"end": 73, "start": 62, "tag": "TemporalConcept"}, {"end": 30, "start": 15, "tag": "Cell"}, {"end": 42, "start": 31, "tag": "CellFunction"}, {"end": 102, "start": 79, "tag": "CellFunction"}]}{"id": "1368_2", "text": "ATP-dependent chromatin remodeling enzymes, which utilize ATP as an energy source to control chromatin dynamics and regulate the accessibility of chromatin to transcriptional regulators, are critical for oligodendrocyte lineage development and regeneration.", "tags": [{"end": 61, "start": 58, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 61, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 61, "start": 58, "tag": "PharmacologicSubstance"}, {"end": 185, "start": 159, "tag": "CellFunction"}, {"end": 42, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 256, "start": 244, "tag": "BiologicFunction"}, {"end": 102, "start": 93, "tag": "CellComponent"}, {"end": 155, "start": 146, "tag": "CellComponent"}, {"end": 74, "start": 68, "tag": "NaturalPhenomenonOrProcess"}, {"end": 227, "start": 204, "tag": "Cell"}, {"end": 256, "start": 244, "tag": "HealthCareActivity"}, {"end": 239, "start": 228, "tag": "BiologicFunction"}, {"end": 239, "start": 228, "tag": "CellFunction"}, {"end": 111, "start": 103, "tag": "NaturalPhenomenonOrProcess"}, {"end": 3, "start": 0, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 3, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 75, "tag": "Finding"}, {"end": 34, "start": 0, "tag": "CellFunction"}]}{"id": "1368_3", "text": "In this review, we focus on the latest insights into the spatial and temporal specificity of chromatin remodelers during oligodendrocyte development, myelinogenesis, and regeneration.", "tags": [{"end": 164, "start": 150, "tag": "CellFunction"}, {"end": 38, "start": 32, "tag": "TemporalConcept"}, {"end": 148, "start": 121, "tag": "CellFunction"}, {"end": 182, "start": 170, "tag": "BiologicFunction"}, {"end": 182, "start": 170, "tag": "HealthCareActivity"}, {"end": 89, "start": 78, "tag": "Finding"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 113, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 113, "start": 93, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1368_4", "text": "We will also bring together various plausible mechanisms by which lineage specific transcriptional regulators coordinate with chromatin remodeling factors for programming genomic landscapes to specifically modulate these different processes during developmental myelination and remyelination upon injury.", "tags": [{"end": 109, "start": 83, "tag": "CellFunction"}, {"end": 154, "start": 126, "tag": "AminoAcidPeptideOrProtein"}, {"end": 261, "start": 248, "tag": "BiologicFunction"}, {"end": 261, "start": 248, "tag": "TemporalConcept"}, {"end": 189, "start": 171, "tag": "GeneOrGenome"}, {"end": 303, "start": 297, "tag": "InjuryOrPoisoning"}, {"end": 291, "start": 278, "tag": "CellFunction"}, {"end": 273, "start": 262, "tag": "CellFunction"}, {"end": 154, "start": 126, "tag": "BiologicallyActiveSubstance"}]}{"id": "1369_0", "text": "Myelination facilitates rapid axonal conduction, enabling efficient communication across different parts of the nervous system.", "tags": [{"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 81, "start": 68, "tag": "HealthCareActivity"}, {"end": 81, "start": 68, "tag": "CellFunction"}, {"end": 126, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 30, "tag": "CellFunction"}]}{"id": "1369_1", "text": "Here we examined mechanisms controlling myelination after injury and during axon regeneration in the central nervous system (CNS).", "tags": [{"end": 93, "start": 76, "tag": "BiologicFunction"}, {"end": 123, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 125, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 58, "tag": "InjuryOrPoisoning"}, {"end": 51, "start": 40, "tag": "CellFunction"}]}{"id": "1369_2", "text": "Previously, we discovered multiple molecular pathways and strategies that could promote robust axon regrowth after optic nerve injury.", "tags": [{"end": 133, "start": 115, "tag": "InjuryOrPoisoning"}, {"end": 126, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 99, "start": 95, "tag": "CellComponent"}, {"end": 68, "start": 58, "tag": "ResearchActivity"}, {"end": 68, "start": 58, "tag": "BiologicFunction"}, {"end": 53, "start": 35, "tag": "CellFunction"}, {"end": 108, "start": 95, "tag": "BiologicFunction"}]}{"id": "1369_3", "text": "However, regenerated axons remain unmyelinated, and the underlying mechanisms are elusive.", "tags": [{"end": 26, "start": 21, "tag": "CellComponent"}]}{"id": "1369_4", "text": "In this study, we found that, in injured optic nerves, oligodendrocyte precursor cells (OPCs) undergo transient proliferation but fail to differentiate into mature myelination-competent oligodendrocytes, reminiscent of what is observed in human progressive multiple sclerosis.", "tags": [{"end": 53, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 202, "start": 186, "tag": "Cell"}, {"end": 92, "start": 88, "tag": "Cell"}, {"end": 86, "start": 55, "tag": "Cell"}, {"end": 151, "start": 138, "tag": "CellFunction"}, {"end": 275, "start": 257, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 102, "tag": "TemporalConcept"}, {"end": 125, "start": 112, "tag": "CellFunction"}, {"end": 163, "start": 157, "tag": "TemporalConcept"}, {"end": 13, "start": 8, "tag": "ResearchActivity"}, {"end": 244, "start": 239, "tag": "Eukaryote"}, {"end": 256, "start": 245, "tag": "TemporalConcept"}, {"end": 175, "start": 164, "tag": "CellFunction"}, {"end": 40, "start": 33, "tag": "InjuryOrPoisoning"}]}{"id": "1369_5", "text": "Mechanistically, we showed that OPC-intrinsic GPR17 signaling and sustained activation of microglia inhibit different stages of OPC differentiation.", "tags": [{"end": 35, "start": 32, "tag": "Cell"}, {"end": 61, "start": 52, "tag": "CellFunction"}, {"end": 147, "start": 128, "tag": "CellFunction"}, {"end": 51, "start": 46, "tag": "GeneOrGenome"}, {"end": 51, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 51, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 90, "tag": "Cell"}, {"end": 124, "start": 118, "tag": "TemporalConcept"}, {"end": 86, "start": 76, "tag": "CellFunction"}]}{"id": "1369_6", "text": "Importantly, co-manipulation of GPR1 7 and microglia led to extensive myelination of regenerated axons.", "tags": [{"end": 38, "start": 32, "tag": "GeneOrGenome"}, {"end": 102, "start": 97, "tag": "CellComponent"}, {"end": 52, "start": 43, "tag": "Cell"}, {"end": 81, "start": 70, "tag": "CellFunction"}, {"end": 38, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 32, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1369_7", "text": "The regulatory mechanisms of stage-dependent OPC differentiation uncovered here suggest a translatable strategy for efficient de novo myelination after CNS injury.", "tags": [{"end": 162, "start": 152, "tag": "InjuryOrPoisoning"}, {"end": 64, "start": 45, "tag": "CellFunction"}, {"end": 155, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 126, "tag": "CellFunction"}]}{"id": "1370_0", "text": "Background and Objectives To test whether low concentrations of teriflunomide (TF) could promote remyelination, we investigate the effect of TF on oligodendrocyte in culture and on remyelination in vivo in 2 demyelinating models.", "tags": [{"end": 10, "start": 0, "tag": "NaturalPhenomenonOrProcess"}, {"end": 77, "start": 64, "tag": "Chemical"}, {"end": 81, "start": 79, "tag": "Chemical"}, {"end": 143, "start": 141, "tag": "Chemical"}, {"end": 221, "start": 208, "tag": "PathologicFunction"}, {"end": 173, "start": 166, "tag": "ResearchActivity"}, {"end": 228, "start": 222, "tag": "ResearchActivity"}, {"end": 137, "start": 131, "tag": "Finding"}, {"end": 202, "start": 195, "tag": "ResearchActivity"}, {"end": 162, "start": 147, "tag": "Cell"}, {"end": 45, "start": 42, "tag": "Finding"}, {"end": 60, "start": 46, "tag": "BiologicFunction"}, {"end": 110, "start": 97, "tag": "CellFunction"}, {"end": 194, "start": 181, "tag": "CellFunction"}, {"end": 77, "start": 64, "tag": "PharmacologicSubstance"}, {"end": 81, "start": 79, "tag": "PharmacologicSubstance"}, {"end": 143, "start": 141, "tag": "PharmacologicSubstance"}, {"end": 228, "start": 208, "tag": "ExperimentalModelOfDisease"}]}{"id": "1370_1", "text": "Methods The effect of TF on oligodendrocyte precursor cell (OPC) proliferation and differentiation was assessed in vitro in glial cultures derived from neonatal mice and confirmed on fluorescence-activated cell sorting-sorted adult OPCs.", "tags": [{"end": 24, "start": 22, "tag": "Chemical"}, {"end": 138, "start": 130, "tag": "ResearchActivity"}, {"end": 236, "start": 232, "tag": "Cell"}, {"end": 63, "start": 60, "tag": "Cell"}, {"end": 98, "start": 83, "tag": "CellFunction"}, {"end": 78, "start": 65, "tag": "CellFunction"}, {"end": 58, "start": 28, "tag": "Cell"}, {"end": 129, "start": 124, "tag": "Cell"}, {"end": 160, "start": 152, "tag": "PopulationGroup"}, {"end": 160, "start": 152, "tag": "TemporalConcept"}, {"end": 165, "start": 161, "tag": "Eukaryote"}, {"end": 58, "start": 54, "tag": "Cell"}, {"end": 210, "start": 206, "tag": "Cell"}, {"end": 18, "start": 12, "tag": "Finding"}, {"end": 120, "start": 112, "tag": "ResearchActivity"}, {"end": 195, "start": 183, "tag": "NaturalPhenomenonOrProcess"}, {"end": 231, "start": 226, "tag": "PopulationGroup"}, {"end": 24, "start": 22, "tag": "PharmacologicSubstance"}, {"end": 218, "start": 183, "tag": "ResearchActivity"}]}{"id": "1370_2", "text": "The levels of the 8,9-unsaturated sterols lanosterol and zymosterol were quantified in TF- and sham-treated cultures.", "tags": [{"end": 67, "start": 57, "tag": "Chemical"}, {"end": 116, "start": 108, "tag": "ResearchActivity"}, {"end": 41, "start": 18, "tag": "Chemical"}, {"end": 52, "start": 42, "tag": "Chemical"}, {"end": 52, "start": 42, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 87, "tag": "PharmacologicSubstance"}, {"end": 89, "start": 87, "tag": "Chemical"}]}{"id": "1370_3", "text": "In vivo, TF was administered orally, and remyelination was assessed both in myelin basic protein-GFP-nitroreductase (Mbp:GFP-NTR) transgenic Xenopus laevis demyelinated by metronidazole and in adult mice demyelinated by lysolecithin.", "tags": [{"end": 11, "start": 9, "tag": "Chemical"}, {"end": 35, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 172, "tag": "Chemical"}, {"end": 168, "start": 156, "tag": "PathologicFunction"}, {"end": 216, "start": 204, "tag": "PathologicFunction"}, {"end": 232, "start": 220, "tag": "Chemical"}, {"end": 232, "start": 220, "tag": "PharmacologicSubstance"}, {"end": 96, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 96, "start": 76, "tag": "BiologicallyActiveSubstance"}, {"end": 203, "start": 199, "tag": "Eukaryote"}, {"end": 54, "start": 41, "tag": "CellFunction"}, {"end": 198, "start": 193, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 11, "start": 9, "tag": "PharmacologicSubstance"}, {"end": 100, "start": 97, "tag": "Chemical"}, {"end": 100, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 101, "tag": "AminoAcidPeptideOrProtein"}, {"end": 115, "start": 101, "tag": "BiologicallyActiveSubstance"}, {"end": 155, "start": 141, "tag": "Eukaryote"}, {"end": 155, "start": 116, "tag": "ResearchActivity"}, {"end": 185, "start": 172, "tag": "PharmacologicSubstance"}]}{"id": "1370_4", "text": "Results In cultures, low concentrations of TF down to 10 nM decreased OPC proliferation and increased their differentiation, an effect that was also detected on adult OPCs.", "tags": [{"end": 45, "start": 43, "tag": "Chemical"}, {"end": 19, "start": 11, "tag": "ResearchActivity"}, {"end": 171, "start": 167, "tag": "Cell"}, {"end": 73, "start": 70, "tag": "Cell"}, {"end": 123, "start": 108, "tag": "CellFunction"}, {"end": 87, "start": 74, "tag": "CellFunction"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 134, "start": 128, "tag": "Finding"}, {"end": 24, "start": 21, "tag": "Finding"}, {"end": 39, "start": 25, "tag": "BiologicFunction"}, {"end": 166, "start": 161, "tag": "PopulationGroup"}, {"end": 45, "start": 43, "tag": "PharmacologicSubstance"}]}{"id": "1370_5", "text": "Oligodendrocyte differentiation induced by TF was abrogated by the oxidosqualene cyclase inhibitor Ro 48-8071 and was mediated by the accumulation of zymosterol.", "tags": [{"end": 45, "start": 43, "tag": "Chemical"}, {"end": 160, "start": 150, "tag": "Chemical"}, {"end": 98, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 89, "tag": "PharmacologicSubstance"}, {"end": 98, "start": 89, "tag": "Chemical"}, {"end": 31, "start": 16, "tag": "CellFunction"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 146, "start": 134, "tag": "Finding"}, {"end": 45, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 88, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 99, "tag": "PharmacologicSubstance"}]}{"id": "1370_6", "text": "In the demyelinated tadpole, TF enhanced the regeneration of mature oligodendrocytes up to 2.5-fold.", "tags": [{"end": 31, "start": 29, "tag": "Chemical"}, {"end": 19, "start": 7, "tag": "PathologicFunction"}, {"end": 84, "start": 61, "tag": "Cell"}, {"end": 57, "start": 45, "tag": "BiologicFunction"}, {"end": 57, "start": 45, "tag": "HealthCareActivity"}, {"end": 31, "start": 29, "tag": "PharmacologicSubstance"}, {"end": 27, "start": 20, "tag": "Eukaryote"}]}{"id": "1370_7", "text": "In the mouse demyelinated spinal cord, TF promoted the differentiation of newly generated oligodendrocytes by a factor of 1.7-fold and significantly increased remyelination.", "tags": [{"end": 41, "start": 39, "tag": "Chemical"}, {"end": 106, "start": 90, "tag": "Cell"}, {"end": 25, "start": 13, "tag": "PathologicFunction"}, {"end": 37, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 55, "tag": "CellFunction"}, {"end": 12, "start": 7, "tag": "Eukaryote"}, {"end": 158, "start": 135, "tag": "Finding"}, {"end": 172, "start": 159, "tag": "CellFunction"}, {"end": 41, "start": 39, "tag": "PharmacologicSubstance"}]}{"id": "1370_8", "text": "Discussion TF enhances zymosterol accumulation in oligodendrocytes and CNS myelin repair, a beneficial off-target effect that should be investigated in patients with multiple sclerosis.", "tags": [{"end": 33, "start": 23, "tag": "Chemical"}, {"end": 66, "start": 50, "tag": "Cell"}, {"end": 184, "start": 166, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 75, "tag": "CellFunction"}, {"end": 160, "start": 152, "tag": "PatientOrDisabledGroup"}, {"end": 74, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 34, "tag": "Finding"}, {"end": 120, "start": 92, "tag": "Finding"}, {"end": 13, "start": 11, "tag": "Chemical"}, {"end": 13, "start": 11, "tag": "PharmacologicSubstance"}]}{"id": "1371_0", "text": "Astrocyte-derived cholesterol supports brain cells under physiological conditions.", "tags": [{"end": 29, "start": 18, "tag": "Chemical"}, {"end": 29, "start": 18, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 39, "tag": "Cell"}, {"end": 9, "start": 0, "tag": "Cell"}]}{"id": "1371_1", "text": "However, in demyelinating lesions, astrocytes downregulate cholesterol synthesis, and the cholesterol that is essential for remyelination has to originate from other cellular sources.", "tags": [{"end": 33, "start": 12, "tag": "InjuryOrPoisoning"}, {"end": 58, "start": 46, "tag": "CellFunction"}, {"end": 80, "start": 59, "tag": "CellFunction"}, {"end": 137, "start": 124, "tag": "CellFunction"}, {"end": 182, "start": 166, "tag": "Cell"}, {"end": 70, "start": 59, "tag": "Chemical"}, {"end": 101, "start": 90, "tag": "Chemical"}, {"end": 70, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 90, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 45, "start": 35, "tag": "Cell"}]}{"id": "1371_2", "text": "Here, we show that repair following acute versus chronic demyelination involves distinct processes.", "tags": [{"end": 25, "start": 19, "tag": "BiologicFunction"}, {"end": 25, "start": 19, "tag": "HealthCareActivity"}, {"end": 56, "start": 49, "tag": "TemporalConcept"}, {"end": 41, "start": 36, "tag": "TemporalConcept"}, {"end": 70, "start": 57, "tag": "PathologicFunction"}]}{"id": "1371_3", "text": "In particular, in chronic myelin disease, when recycling of lipids is often defective, de novo neuronal cholesterol synthesis is critical for regeneration.", "tags": [{"end": 66, "start": 60, "tag": "Chemical"}, {"end": 66, "start": 60, "tag": "ResearchActivity"}, {"end": 154, "start": 142, "tag": "BiologicFunction"}, {"end": 154, "start": 142, "tag": "HealthCareActivity"}, {"end": 154, "start": 142, "tag": "Finding"}, {"end": 115, "start": 95, "tag": "Chemical"}, {"end": 115, "start": 95, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 18, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 87, "tag": "CellFunction"}]}{"id": "1371_4", "text": "By gene expression profiling, genetic loss-of-function experiments, and comprehensive phenotyping, we provide evidence that neurons increase cholesterol synthesis in chronic myelin disease models and in patients with multiple sclerosis (MS).", "tags": [{"end": 28, "start": 3, "tag": "ResearchActivity"}, {"end": 97, "start": 72, "tag": "ResearchActivity"}, {"end": 162, "start": 141, "tag": "CellFunction"}, {"end": 152, "start": 141, "tag": "Chemical"}, {"end": 152, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 110, "tag": "Finding"}, {"end": 239, "start": 237, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 3, "tag": "CellFunction"}, {"end": 211, "start": 203, "tag": "PatientOrDisabledGroup"}, {"end": 131, "start": 124, "tag": "Cell"}, {"end": 235, "start": 217, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 30, "tag": "ResearchActivity"}, {"end": 195, "start": 166, "tag": "ExperimentalModelOfDisease"}]}{"id": "1371_5", "text": "In mouse models, neuronal cholesterol facilitates remyelination specifically by triggering oligodendrocyte precursor cell proliferation.", "tags": [{"end": 63, "start": 50, "tag": "CellFunction"}, {"end": 121, "start": 91, "tag": "Cell"}, {"end": 37, "start": 17, "tag": "Chemical"}, {"end": 37, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 3, "tag": "ManufacturedObject"}, {"end": 135, "start": 91, "tag": "CellFunction"}]}{"id": "1371_6", "text": "Our data contribute to the understanding of disease progression and have implications for therapeutic strategies in patients with MS.", "tags": [{"end": 63, "start": 52, "tag": "PathologicFunction"}, {"end": 63, "start": 52, "tag": "TemporalConcept"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 44, "tag": "PathologicFunction"}, {"end": 124, "start": 116, "tag": "PatientOrDisabledGroup"}, {"end": 112, "start": 90, "tag": "HealthCareActivity"}]}{"id": "1372_0", "text": "Carbon monoxide (CO) poisoning usually causes brain lesions and delayed encephalopathy, also known as delayed neurological sequelae (DNS).", "tags": [{"end": 15, "start": 0, "tag": "InjuryOrPoisoning"}, {"end": 15, "start": 0, "tag": "Chemical"}, {"end": 19, "start": 17, "tag": "InjuryOrPoisoning"}, {"end": 19, "start": 17, "tag": "Chemical"}, {"end": 30, "start": 0, "tag": "InjuryOrPoisoning"}, {"end": 59, "start": 46, "tag": "Finding"}, {"end": 131, "start": 102, "tag": "PathologicFunction"}, {"end": 86, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 133, "tag": "PathologicFunction"}]}{"id": "1372_1", "text": "Demyelination of white matter (WM) is one of the most common sites of abnormalities in patients with DNS, but its mechanisms remain unclear.", "tags": [{"end": 13, "start": 0, "tag": "PathologicFunction"}, {"end": 33, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 87, "tag": "PatientOrDisabledGroup"}, {"end": 29, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 101, "tag": "PathologicFunction"}]}{"id": "1372_2", "text": "Oligodendrocytes (OLs) are myelinated cells that ensure the rapid conduction of neuronal axon signals and provide the nutritional factors necessary for maintaining nerve integrity in the central nervous system (CNS).", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 21, "start": 18, "tag": "Cell"}, {"end": 179, "start": 164, "tag": "BiologicFunction"}, {"end": 43, "start": 27, "tag": "Cell"}, {"end": 214, "start": 211, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 209, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 80, "tag": "CellFunction"}, {"end": 101, "start": 60, "tag": "Finding"}]}{"id": "1372_3", "text": "OLs readily regenerate and replace damaged myelin membranes around axons in the adult mammalian CNS following demyelination.", "tags": [{"end": 3, "start": 0, "tag": "Cell"}, {"end": 72, "start": 67, "tag": "CellComponent"}, {"end": 85, "start": 80, "tag": "PopulationGroup"}, {"end": 99, "start": 96, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 86, "tag": "Eukaryote"}, {"end": 123, "start": 110, "tag": "PathologicFunction"}, {"end": 59, "start": 35, "tag": "CellOrMolecularDysfunction"}]}{"id": "1372_4", "text": "The ability to regenerate OLs depends on the availability of precursor cells (OPCs) in the CNS of adults.", "tags": [{"end": 29, "start": 26, "tag": "Cell"}, {"end": 76, "start": 61, "tag": "Cell"}, {"end": 82, "start": 78, "tag": "Cell"}, {"end": 104, "start": 98, "tag": "PopulationGroup"}, {"end": 94, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1372_5", "text": "Multiple injury-related signals can induce OPC expansion followed by OL differentiation, axonal contact and myelin regeneration (remyelination).", "tags": [{"end": 46, "start": 43, "tag": "Cell"}, {"end": 142, "start": 129, "tag": "CellFunction"}, {"end": 103, "start": 89, "tag": "CellFunction"}, {"end": 87, "start": 69, "tag": "CellFunction"}, {"end": 15, "start": 9, "tag": "InjuryOrPoisoning"}, {"end": 56, "start": 43, "tag": "CellFunction"}, {"end": 71, "start": 69, "tag": "Cell"}, {"end": 127, "start": 108, "tag": "CellFunction"}, {"end": 31, "start": 9, "tag": "CellFunction"}]}{"id": "1372_6", "text": "Therefore, OL dysfunction and regeneration failure in the deep WM of the brain are the key pathophysiological mechanisms leading to delayed brain injury after CO poisoning.", "tags": [{"end": 161, "start": 159, "tag": "InjuryOrPoisoning"}, {"end": 161, "start": 159, "tag": "ResearchActivity"}, {"end": 171, "start": 159, "tag": "InjuryOrPoisoning"}, {"end": 78, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 91, "tag": "PathologicFunction"}, {"end": 25, "start": 11, "tag": "CellOrMolecularDysfunction"}, {"end": 50, "start": 30, "tag": "PathologicFunction"}, {"end": 65, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 132, "tag": "PathologicFunction"}]}{"id": "1372_7", "text": "CO-induced toxicity may interfere with OL function and render OPCs unable to regenerate OLs through some unclear mechanisms, leading to progressive demyelinating damage and resulting in DNS.", "tags": [{"end": 66, "start": 62, "tag": "Cell"}, {"end": 91, "start": 88, "tag": "Cell"}, {"end": 19, "start": 0, "tag": "InjuryOrPoisoning"}, {"end": 41, "start": 39, "tag": "Cell"}, {"end": 168, "start": 136, "tag": "PathologicFunction"}, {"end": 189, "start": 186, "tag": "PathologicFunction"}]}{"id": "1372_8", "text": "In the future, combination therapies to reduce OL damage and promote OPC differentiation and remyelination may be important for the prevention and treatment of DNS after CO poisoning.", "tags": [{"end": 36, "start": 15, "tag": "HealthCareActivity"}, {"end": 72, "start": 69, "tag": "Cell"}, {"end": 106, "start": 93, "tag": "CellFunction"}, {"end": 172, "start": 170, "tag": "InjuryOrPoisoning"}, {"end": 172, "start": 170, "tag": "ResearchActivity"}, {"end": 182, "start": 170, "tag": "InjuryOrPoisoning"}, {"end": 156, "start": 147, "tag": "HealthCareActivity"}, {"end": 156, "start": 147, "tag": "ResearchActivity"}, {"end": 13, "start": 7, "tag": "TemporalConcept"}, {"end": 88, "start": 69, "tag": "CellFunction"}, {"end": 142, "start": 132, "tag": "HealthCareActivity"}, {"end": 56, "start": 47, "tag": "CellOrMolecularDysfunction"}, {"end": 163, "start": 160, "tag": "PathologicFunction"}]}{"id": "1373_0", "text": "Oligodendrocyte precursor cells (OPCs) are present in demyelinated lesions of multiple sclerosis (MS) patients.", "tags": [{"end": 31, "start": 0, "tag": "Cell"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 74, "start": 54, "tag": "PathologicFunction"}, {"end": 100, "start": 98, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 102, "tag": "PatientOrDisabledGroup"}, {"end": 96, "start": 78, "tag": "DiseaseOrSyndrome"}]}{"id": "1373_1", "text": "However, their differentiation into functional oligodendrocytes is insufficient, and most lesions evolve into nonfunctional astroglial scars.", "tags": [{"end": 63, "start": 47, "tag": "Cell"}, {"end": 97, "start": 90, "tag": "InjuryOrPoisoning"}, {"end": 140, "start": 110, "tag": "PathologicFunction"}, {"end": 30, "start": 15, "tag": "CellFunction"}]}{"id": "1373_2", "text": "Blockade of bone morphogenetic protein (BMP) signaling induces differentiation of OPCs into myelin-producing oligodendrocytes.", "tags": [{"end": 8, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 38, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 38, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 82, "tag": "Cell"}, {"end": 125, "start": 92, "tag": "Cell"}, {"end": 78, "start": 63, "tag": "CellFunction"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 8, "start": 0, "tag": "HealthCareActivity"}, {"end": 54, "start": 45, "tag": "CellFunction"}, {"end": 38, "start": 12, "tag": "CellFunction"}]}{"id": "1373_3", "text": "We studied the effect of specific blockade of BMP-2/4 signaling, by intravenous (IV) treatment with anti-BMP-2/4 neutralizing mAb in both the inflammatory model of relapsing experimental autoimmune encephalomyelitis (R-EAE) and the cuprizone-toxic model of demyelination in mice.", "tags": [{"end": 42, "start": 34, "tag": "PharmacologicSubstance"}, {"end": 42, "start": 34, "tag": "HealthCareActivity"}, {"end": 63, "start": 46, "tag": "CellFunction"}, {"end": 79, "start": 68, "tag": "HealthCareActivity"}, {"end": 222, "start": 217, "tag": "ExperimentalModelOfDisease"}, {"end": 94, "start": 85, "tag": "HealthCareActivity"}, {"end": 94, "start": 85, "tag": "ResearchActivity"}, {"end": 160, "start": 142, "tag": "ExperimentalModelOfDisease"}, {"end": 129, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 215, "start": 164, "tag": "ExperimentalModelOfDisease"}, {"end": 270, "start": 232, "tag": "ExperimentalModelOfDisease"}, {"end": 278, "start": 274, "tag": "Eukaryote"}, {"end": 129, "start": 100, "tag": "PharmacologicSubstance"}]}{"id": "1373_4", "text": "Administration of anti-BMP-2/4 to R-EAE-induced mice, on day 9 post-immunization (p.i.), ameliorated R-EAE signs, diminished the expression of phospho-SMAD1/5/8, primarily within the astrocytic lineage, increased the numbers of de novo immature and mature oligodendrocytes, and reduced the numbers of newly generated astrocytes within the spinal cord as early as day 18 p.i.", "tags": [{"end": 14, "start": 0, "tag": "HealthCareActivity"}, {"end": 80, "start": 57, "tag": "TemporalConcept"}, {"end": 106, "start": 101, "tag": "ExperimentalModelOfDisease"}, {"end": 201, "start": 183, "tag": "Cell"}, {"end": 272, "start": 249, "tag": "Cell"}, {"end": 350, "start": 339, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 373, "start": 363, "tag": "TemporalConcept"}, {"end": 112, "start": 107, "tag": "SignOrSymptom"}, {"end": 327, "start": 317, "tag": "Cell"}, {"end": 30, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 30, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 18, "tag": "PharmacologicSubstance"}, {"end": 52, "start": 34, "tag": "ExperimentalModelOfDisease"}, {"end": 80, "start": 68, "tag": "HealthCareActivity"}, {"end": 86, "start": 82, "tag": "TemporalConcept"}, {"end": 160, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 160, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 235, "start": 203, "tag": "Finding"}, {"end": 316, "start": 278, "tag": "Finding"}, {"end": 272, "start": 256, "tag": "Cell"}, {"end": 244, "start": 236, "tag": "Cell"}]}{"id": "1373_5", "text": "This effect was accompanied with elevated remyelination, manifested by increased density of remyelinating axons (0.8 < g-ratios < 1), and reduced fully demyelinated and demyelinating axons, in the anti-BMP-2/4-treated R-EAE mice, studied by electron microscopy.", "tags": [{"end": 55, "start": 33, "tag": "Finding"}, {"end": 55, "start": 42, "tag": "CellFunction"}, {"end": 88, "start": 71, "tag": "Finding"}, {"end": 111, "start": 92, "tag": "Finding"}, {"end": 111, "start": 106, "tag": "CellComponent"}, {"end": 228, "start": 218, "tag": "ExperimentalModelOfDisease"}, {"end": 260, "start": 241, "tag": "ResearchActivity"}, {"end": 188, "start": 138, "tag": "Finding"}, {"end": 188, "start": 169, "tag": "PathologicFunction"}, {"end": 209, "start": 197, "tag": "AminoAcidPeptideOrProtein"}, {"end": 209, "start": 197, "tag": "BiologicallyActiveSubstance"}, {"end": 209, "start": 197, "tag": "PharmacologicSubstance"}, {"end": 188, "start": 183, "tag": "PathologicFunction"}, {"end": 164, "start": 152, "tag": "PathologicFunction"}]}{"id": "1373_6", "text": "No significant immunosuppressive effect was observed in the CNS and in the periphery, during the peak of the first attack, or at the end of the experiment.", "tags": [{"end": 39, "start": 15, "tag": "BiologicFunction"}, {"end": 121, "start": 115, "tag": "Finding"}, {"end": 154, "start": 144, "tag": "ResearchActivity"}, {"end": 63, "start": 60, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 109, "tag": "TemporalConcept"}, {"end": 136, "start": 126, "tag": "TemporalConcept"}]}{"id": "1373_7", "text": "Moreover, IV treatment with anti-BMP-2/4 mAb in the cuprizone-challenged mice augmented the numbers of mature oligodendrocytes and remyelination in the corpus callosum during the recovery phase of the disease.", "tags": [{"end": 44, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 28, "tag": "PharmacologicSubstance"}, {"end": 126, "start": 103, "tag": "Cell"}, {"end": 144, "start": 131, "tag": "CellFunction"}, {"end": 167, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 10, "tag": "HealthCareActivity"}, {"end": 22, "start": 10, "tag": "ResearchActivity"}, {"end": 44, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 52, "tag": "ExperimentalModelOfDisease"}, {"end": 193, "start": 179, "tag": "TemporalConcept"}]}{"id": "1373_8", "text": "Based on our findings, the specific blockade of BMP-2/4 has a therapeutic potential in demyelinating disorders such as MS, by inducing early oligodendrogenesis-mediated remyelination in the affected tissue.", "tags": [{"end": 44, "start": 36, "tag": "PharmacologicSubstance"}, {"end": 44, "start": 36, "tag": "HealthCareActivity"}, {"end": 110, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 182, "start": 169, "tag": "CellFunction"}, {"end": 205, "start": 199, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 62, "tag": "HealthCareActivity"}, {"end": 55, "start": 48, "tag": "AminoAcidPeptideOrProtein"}, {"end": 159, "start": 141, "tag": "BiologicFunction"}]}{"id": "1374_0", "text": "Neural stem and precursor cells (NPCs) build and regenerate the central nervous system (CNS) by maintaining their pool (self-renewal) and differentiating into neurons, astrocytes, and oligodendrocytes (multipotency) throughout life.", "tags": [{"end": 31, "start": 0, "tag": "Cell"}, {"end": 132, "start": 120, "tag": "CellFunction"}, {"end": 200, "start": 184, "tag": "Cell"}, {"end": 231, "start": 227, "tag": "TemporalConcept"}, {"end": 91, "start": 88, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 86, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 166, "start": 159, "tag": "Cell"}, {"end": 178, "start": 168, "tag": "Cell"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 214, "start": 202, "tag": "CellFunction"}]}{"id": "1374_1", "text": "This has inspired research into pro-regenerative therapies that utilize transplantation of exogenous NPCs or recruitment of endogenous adult NPCs for CNS regeneration and repair.", "tags": [{"end": 105, "start": 72, "tag": "HealthCareActivity"}, {"end": 58, "start": 32, "tag": "HealthCareActivity"}, {"end": 153, "start": 150, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 18, "tag": "ResearchActivity"}, {"end": 105, "start": 101, "tag": "Cell"}, {"end": 145, "start": 135, "tag": "Cell"}, {"end": 145, "start": 109, "tag": "HealthCareActivity"}, {"end": 177, "start": 150, "tag": "BiologicFunction"}]}{"id": "1374_2", "text": "Recent advances in single-cell RNA sequencing and other omics have revealed that NPCs express not just traditional progenitor-related genes, but also genes involved in immune function.", "tags": [{"end": 183, "start": 168, "tag": "BiologicFunction"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 15, "start": 7, "tag": "Finding"}, {"end": 45, "start": 19, "tag": "ResearchActivity"}, {"end": 61, "start": 56, "tag": "ResearchActivity"}, {"end": 85, "start": 81, "tag": "Cell"}]}{"id": "1374_3", "text": "Here, we review how NPCs exert immunomodulatory function by regulating the biology of microglia, immune cells that are present in NPC niches and throughout the CNS.", "tags": [{"end": 82, "start": 75, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 140, "start": 130, "tag": "Cell"}, {"end": 15, "start": 9, "tag": "ResearchActivity"}, {"end": 15, "start": 9, "tag": "HealthCareActivity"}, {"end": 163, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 95, "start": 86, "tag": "Cell"}, {"end": 109, "start": 97, "tag": "Cell"}, {"end": 24, "start": 20, "tag": "Cell"}, {"end": 56, "start": 31, "tag": "BiologicFunction"}]}{"id": "1374_4", "text": "We discuss the role of transplanted and endogenous NPCs in regulating microglia fates, such as survival, proliferation, migration, phagocytosis and activation, in the developing, injured and degenerating CNS.", "tags": [{"end": 35, "start": 23, "tag": "HealthCareActivity"}, {"end": 35, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 95, "tag": "CellFunction"}, {"end": 118, "start": 105, "tag": "CellFunction"}, {"end": 129, "start": 120, "tag": "CellFunction"}, {"end": 143, "start": 131, "tag": "CellFunction"}, {"end": 207, "start": 191, "tag": "PathologicFunction"}, {"end": 207, "start": 204, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 70, "tag": "CellFunction"}, {"end": 207, "start": 204, "tag": "BiologicFunction"}, {"end": 177, "start": 167, "tag": "BiologicFunction"}, {"end": 207, "start": 204, "tag": "PathologicFunction"}, {"end": 186, "start": 179, "tag": "PathologicFunction"}]}{"id": "1374_5", "text": "We also provide a literature review on NPC-specific mediators that are responsible for modulating microglia biology.", "tags": [{"end": 115, "start": 108, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 35, "start": 29, "tag": "ResearchActivity"}, {"end": 35, "start": 29, "tag": "HealthCareActivity"}, {"end": 107, "start": 98, "tag": "Cell"}, {"end": 28, "start": 18, "tag": "ResearchActivity"}, {"end": 42, "start": 39, "tag": "Cell"}]}{"id": "1374_6", "text": "Our review highlights the immunomodulatory properties of NPCs and the significance of these findings in the context of designing pro-regenerative therapies for degenerating and diseased CNS.", "tags": [{"end": 53, "start": 26, "tag": "ClinicalAttribute"}, {"end": 189, "start": 160, "tag": "PathologicFunction"}, {"end": 10, "start": 4, "tag": "ResearchActivity"}, {"end": 10, "start": 4, "tag": "HealthCareActivity"}, {"end": 155, "start": 129, "tag": "HealthCareActivity"}, {"end": 189, "start": 186, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 57, "tag": "Cell"}]}{"id": "1375_0", "text": "Astrocytes are a group of glial cells that exhibit great morphological, transcriptional and functional diversity both in the resting brain and in response to injury.", "tags": [{"end": 10, "start": 0, "tag": "Cell"}, {"end": 87, "start": 72, "tag": "CellFunction"}, {"end": 138, "start": 133, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 26, "tag": "Cell"}, {"end": 164, "start": 158, "tag": "InjuryOrPoisoning"}]}{"id": "1375_1", "text": "In recent years, astrocytes have attracted increasing interest as therapeutic targets for demyelinating diseases.", "tags": [{"end": 112, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 43, "tag": "Finding"}, {"end": 15, "start": 3, "tag": "TemporalConcept"}, {"end": 85, "start": 66, "tag": "ResearchActivity"}, {"end": 27, "start": 17, "tag": "Cell"}]}{"id": "1375_2", "text": "Following a demyelinating insult, astrocytes can adopt a wide spectrum of reactive states, which can exacerbate damage, but may also facilitate oligo-dendrocyte progenitor cell differentiation and myelin regener-ation.", "tags": [{"end": 176, "start": 144, "tag": "Cell"}, {"end": 192, "start": 144, "tag": "CellFunction"}, {"end": 217, "start": 197, "tag": "CellFunction"}, {"end": 44, "start": 34, "tag": "Cell"}, {"end": 89, "start": 74, "tag": "CellFunction"}, {"end": 32, "start": 12, "tag": "InjuryOrPoisoning"}, {"end": 118, "start": 101, "tag": "Finding"}]}{"id": "1375_3", "text": "In this review, we provide an overview of recent literature on astrocyte-oligodendrocyte interactions in the context of demyelinating diseases.", "tags": [{"end": 142, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 48, "start": 42, "tag": "TemporalConcept"}, {"end": 38, "start": 30, "tag": "ResearchActivity"}, {"end": 59, "start": 49, "tag": "ResearchActivity"}, {"end": 101, "start": 63, "tag": "CellFunction"}]}{"id": "1375_4", "text": "We highlight novel key roles for as-trocytes both during demyelination and remyelination with a focus on potential therapeutic strategies to favor a pro -regenerative astrocyte response in (progressive) multiple sclerosis.", "tags": [{"end": 88, "start": 75, "tag": "CellFunction"}, {"end": 176, "start": 167, "tag": "Cell"}, {"end": 221, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 105, "tag": "HealthCareActivity"}, {"end": 70, "start": 57, "tag": "PathologicFunction"}, {"end": 185, "start": 149, "tag": "Finding"}]}{"id": "1376_0", "text": "This review describes the role of CXCL1, a chemokine crucial in inflammation as a chemoattractant for neutrophils, in physiology and in selected major non-cancer diseases.", "tags": [{"end": 39, "start": 34, "tag": "AminoAcidPeptideOrProtein"}, {"end": 39, "start": 34, "tag": "GeneOrGenome"}, {"end": 39, "start": 34, "tag": "BiologicallyActiveSubstance"}, {"end": 52, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 52, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 64, "tag": "PathologicFunction"}, {"end": 97, "start": 82, "tag": "BiologicallyActiveSubstance"}, {"end": 97, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 102, "tag": "Cell"}, {"end": 128, "start": 118, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 128, "start": 118, "tag": "BiologicFunction"}, {"end": 11, "start": 5, "tag": "ResearchActivity"}, {"end": 11, "start": 5, "tag": "HealthCareActivity"}, {"end": 170, "start": 151, "tag": "DiseaseOrSyndrome"}]}{"id": "1376_1", "text": "Due to the vast amount of available information, we focus on the role CXCL1 plays in the physiology of bones, bone marrow, muscle and the nervous system.", "tags": [{"end": 75, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 70, "tag": "GeneOrGenome"}, {"end": 75, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 89, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 99, "start": 89, "tag": "BiologicFunction"}, {"end": 108, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 129, "start": 123, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 138, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1376_2", "text": "For this reason, we describe its effects on hematopoietic stem cells, myoblasts, oligodendrocyte progenitors and osteoclast precursors.", "tags": [{"end": 68, "start": 44, "tag": "Cell"}, {"end": 79, "start": 70, "tag": "Cell"}, {"end": 108, "start": 81, "tag": "Cell"}, {"end": 134, "start": 113, "tag": "Cell"}]}{"id": "1376_3", "text": "We also present the involvement of CXCL1 in diseases of selected tissues and organs including Alzheimer's disease, epilepsy, herpes simplex virus type 1 (HSV-1) encephalitis, ischemic stroke, major depression, multiple sclerosis, neuromyelitis optica, neuropathic pain, osteoporosis, prion diseases, rheumatoid arthritis, tick-borne encephalitis (TBE), traumatic spinal cord injury and West Nile fever.", "tags": [{"end": 40, "start": 35, "tag": "AminoAcidPeptideOrProtein"}, {"end": 40, "start": 35, "tag": "GeneOrGenome"}, {"end": 40, "start": 35, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 125, "tag": "Virus"}, {"end": 159, "start": 154, "tag": "Virus"}, {"end": 173, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 250, "start": 230, "tag": "DiseaseOrSyndrome"}, {"end": 268, "start": 252, "tag": "SignOrSymptom"}, {"end": 282, "start": 270, "tag": "DiseaseOrSyndrome"}, {"end": 320, "start": 300, "tag": "DiseaseOrSyndrome"}, {"end": 345, "start": 322, "tag": "DiseaseOrSyndrome"}, {"end": 350, "start": 347, "tag": "DiseaseOrSyndrome"}, {"end": 401, "start": 386, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 228, "start": 210, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 115, "tag": "PathologicFunction"}, {"end": 298, "start": 284, "tag": "DiseaseOrSyndrome"}, {"end": 208, "start": 192, "tag": "DiseaseOrSyndrome"}, {"end": 190, "start": 184, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 20, "tag": "Finding"}, {"end": 381, "start": 353, "tag": "InjuryOrPoisoning"}, {"end": 289, "start": 284, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1377_0", "text": "Successful neuroprotection is only possible with contemporary microvascular protection.", "tags": [{"end": 26, "start": 11, "tag": "CellFunction"}, {"end": 61, "start": 49, "tag": "TemporalConcept"}, {"end": 86, "start": 62, "tag": "BiologicFunction"}]}{"id": "1377_1", "text": "The prevention of disease-induced vascular modifications that accelerate brain damage remains largely elusive.", "tags": [{"end": 42, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 4, "tag": "HealthCareActivity"}, {"end": 85, "start": 73, "tag": "InjuryOrPoisoning"}, {"end": 56, "start": 18, "tag": "PathologicFunction"}]}{"id": "1377_2", "text": "An improved understanding of pericyte (PC) signalling could provide important insight into the function of the neurovascular unit (NVU), and into the injury-provoked responses that modify cell-cell interactions and crosstalk.", "tags": [{"end": 37, "start": 29, "tag": "Cell"}, {"end": 210, "start": 188, "tag": "CellFunction"}, {"end": 156, "start": 150, "tag": "InjuryOrPoisoning"}, {"end": 129, "start": 111, "tag": "Cell"}, {"end": 134, "start": 131, "tag": "Cell"}, {"end": 41, "start": 39, "tag": "Cell"}, {"end": 224, "start": 215, "tag": "CellFunction"}, {"end": 197, "start": 188, "tag": "CellFunction"}]}{"id": "1377_3", "text": "Due to sharing the same basement membrane with endothelial cells, PCs have a crucial role in the control of endothelial, astrocyte, and oligodendrocyte precursor functions and hence blood-brain barrier stability.", "tags": [{"end": 41, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 64, "start": 47, "tag": "Cell"}, {"end": 69, "start": 66, "tag": "Cell"}, {"end": 119, "start": 108, "tag": "Cell"}, {"end": 130, "start": 121, "tag": "Cell"}, {"end": 161, "start": 136, "tag": "Cell"}, {"end": 201, "start": 182, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 211, "start": 182, "tag": "CellFunction"}]}{"id": "1377_4", "text": "Both cerebrovascular and neurodegenerative diseases impair oxygen delivery and functionally impair the NVU.", "tags": [{"end": 74, "start": 59, "tag": "ClinicalAttribute"}, {"end": 51, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 103, "tag": "Cell"}, {"end": 51, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 20, "start": 5, "tag": "DiseaseOrSyndrome"}]}{"id": "1377_5", "text": "In this review, the role of PCs in central nervous system health and disease is discussed, considering their origin, multipotency, functions and also dysfunction, focusing on new possible avenues to modulate neuroprotection.", "tags": [{"end": 31, "start": 28, "tag": "Cell"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 57, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 109, "tag": "TemporalConcept"}, {"end": 161, "start": 150, "tag": "PathologicFunction"}, {"end": 64, "start": 58, "tag": "HealthCareActivity"}, {"end": 223, "start": 208, "tag": "CellFunction"}, {"end": 129, "start": 117, "tag": "CellFunction"}]}{"id": "1377_6", "text": "Dysfunctional PC signalling could also be considered as a potential biomarker of NVU pathology, allowing us to individualize therapeutic interventions, monitor responses, or predict outcomes.", "tags": [{"end": 77, "start": 58, "tag": "ClinicalAttribute"}, {"end": 150, "start": 125, "tag": "HealthCareActivity"}, {"end": 27, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 94, "start": 81, "tag": "CellOrMolecularDysfunction"}, {"end": 169, "start": 152, "tag": "HealthCareActivity"}, {"end": 190, "start": 174, "tag": "HealthCareActivity"}]}{"id": "1378_0", "text": "Oligodendrocyte loss in neurological disease leaves axons vulnerable to damage and degeneration, and activity-dependent myelination may represent an endogenous mechanism to improve remyelination following injury.", "tags": [{"end": 44, "start": 24, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 52, "tag": "CellComponent"}, {"end": 131, "start": 120, "tag": "CellFunction"}, {"end": 194, "start": 181, "tag": "CellFunction"}, {"end": 95, "start": 83, "tag": "PathologicFunction"}, {"end": 211, "start": 205, "tag": "InjuryOrPoisoning"}, {"end": 20, "start": 0, "tag": "CellOrMolecularDysfunction"}]}{"id": "1378_1", "text": "Here we report that, while learning a forelimb reach task transiently suppresses oligodendrogenesis, it subsequently increases oligodendrocyte precursor cell differentiation, oligodendrocyte generation and myelin sheath remodeling in the forelimb motor cortex.", "tags": [{"end": 157, "start": 127, "tag": "Cell"}, {"end": 201, "start": 175, "tag": "BiologicFunction"}, {"end": 219, "start": 206, "tag": "CellComponent"}, {"end": 246, "start": 238, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 259, "start": 247, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 173, "start": 127, "tag": "CellFunction"}, {"end": 35, "start": 27, "tag": "BiologicFunction"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 99, "start": 81, "tag": "BiologicFunction"}, {"end": 57, "start": 38, "tag": "ResearchActivity"}, {"end": 230, "start": 206, "tag": "CellFunction"}]}{"id": "1378_2", "text": "Immediately following demyelination, neurons exhibit hyperexcitability, learning is impaired and behavioral intervention provides no benefit to remyelination.", "tags": [{"end": 70, "start": 53, "tag": "BiologicFunction"}, {"end": 120, "start": 97, "tag": "HealthCareActivity"}, {"end": 157, "start": 144, "tag": "CellFunction"}, {"end": 44, "start": 37, "tag": "Cell"}, {"end": 80, "start": 72, "tag": "BiologicFunction"}, {"end": 35, "start": 22, "tag": "PathologicFunction"}]}{"id": "1378_3", "text": "However, partial remyelination restores neuronal and behavioral function, allowing learning to enhance oligodendrogenesis, remyelination of denuded axons and the ability of surviving oligodendrocytes to generate new myelin sheaths.", "tags": [{"end": 30, "start": 17, "tag": "CellFunction"}, {"end": 136, "start": 123, "tag": "CellFunction"}, {"end": 153, "start": 148, "tag": "CellComponent"}, {"end": 199, "start": 183, "tag": "Cell"}, {"end": 230, "start": 216, "tag": "CellComponent"}, {"end": 91, "start": 83, "tag": "BiologicFunction"}, {"end": 121, "start": 103, "tag": "BiologicFunction"}, {"end": 72, "start": 64, "tag": "CellFunction"}, {"end": 48, "start": 40, "tag": "CellFunction"}]}{"id": "1378_4", "text": "Previously considered controversial, we show that sheath generation by mature oligodendrocytes is not only possible but also increases myelin pattern preservation following demyelination, thus presenting a new target for therapeutic interventions.", "tags": [{"end": 94, "start": 71, "tag": "Cell"}, {"end": 186, "start": 173, "tag": "PathologicFunction"}, {"end": 246, "start": 221, "tag": "HealthCareActivity"}, {"end": 162, "start": 135, "tag": "CellFunction"}, {"end": 67, "start": 50, "tag": "CellFunction"}]}{"id": "1378_5", "text": "Together, our findings demonstrate that precisely timed motor learning improves recovery from demyelinating injury via enhanced remyelination from new and surviving oligodendrocytes.", "tags": [{"end": 55, "start": 50, "tag": "TemporalConcept"}, {"end": 70, "start": 56, "tag": "BiologicFunction"}, {"end": 88, "start": 80, "tag": "BiologicFunction"}, {"end": 88, "start": 80, "tag": "HealthCareActivity"}, {"end": 141, "start": 128, "tag": "CellFunction"}, {"end": 181, "start": 165, "tag": "Cell"}, {"end": 114, "start": 94, "tag": "InjuryOrPoisoning"}]}{"id": "1378_6", "text": "Precisely timed motor learning promotes remyelination in the motor cortex by enhancing oligodendrogenesis and stimulating mature oligodendrocytes to generate new myelin, presenting mature oligodendrocytes as new targets in remyelinating therapies.", "tags": [{"end": 15, "start": 10, "tag": "TemporalConcept"}, {"end": 30, "start": 16, "tag": "BiologicFunction"}, {"end": 53, "start": 40, "tag": "CellFunction"}, {"end": 73, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 122, "tag": "Cell"}, {"end": 168, "start": 162, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 162, "tag": "CellComponent"}, {"end": 204, "start": 181, "tag": "Cell"}, {"end": 246, "start": 223, "tag": "HealthCareActivity"}, {"end": 105, "start": 87, "tag": "BiologicFunction"}]}{"id": "1379_0", "text": "Multiple sclerosis (MS) is the most common demyelinating autoimmune disease of the central nervous system (CNS).", "tags": [{"end": 75, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 107, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1379_1", "text": "Immune-mediated myelin and axonal damage that is accompanied by chronic axonal loss causing destruction of the myelin sheaths are hallmarks of MS.", "tags": [{"end": 145, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 64, "tag": "TemporalConcept"}, {"end": 139, "start": 130, "tag": "Finding"}, {"end": 40, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 83, "start": 72, "tag": "PathologicFunction"}, {"end": 125, "start": 92, "tag": "PathologicFunction"}]}{"id": "1379_2", "text": "While great strides have been made in understanding the molecular underpinnings of re-/myelination, currently no remyelination therapy is available for MS.", "tags": [{"end": 154, "start": 152, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 100, "tag": "TemporalConcept"}, {"end": 134, "start": 113, "tag": "HealthCareActivity"}, {"end": 98, "start": 83, "tag": "CellFunction"}]}{"id": "1379_3", "text": "As myelination is a complex process that is not fully understood, we sought to develop a systematic, reliable, automated and quantitative higher throughput screening method.", "tags": [{"end": 14, "start": 3, "tag": "CellFunction"}, {"end": 172, "start": 111, "tag": "ResearchActivity"}]}{"id": "1379_4", "text": "We aimed to quantitate myelin sheaths in vitro with high sensitivity at the single cell level suitable for testing small compound libraries.", "tags": [{"end": 37, "start": 23, "tag": "CellComponent"}, {"end": 68, "start": 52, "tag": "Finding"}, {"end": 139, "start": 107, "tag": "ResearchActivity"}, {"end": 46, "start": 38, "tag": "ResearchActivity"}]}{"id": "1379_5", "text": "To this end, we miniaturised in vitro retinal ganglion cell-oligodendrocyte precursor cell (RGC-OPC) co-cultures into a multi-well plate format.", "tags": [{"end": 112, "start": 101, "tag": "ResearchActivity"}, {"end": 37, "start": 29, "tag": "ResearchActivity"}, {"end": 59, "start": 38, "tag": "Cell"}, {"end": 90, "start": 60, "tag": "Cell"}, {"end": 95, "start": 92, "tag": "Cell"}, {"end": 99, "start": 96, "tag": "Cell"}, {"end": 136, "start": 120, "tag": "ManufacturedObject"}]}{"id": "1379_6", "text": "This allowed us to maintain the reciprocal interaction of live axons and oligodendrocytes (OLs) to ensure compact myelin formation.", "tags": [{"end": 68, "start": 63, "tag": "CellComponent"}, {"end": 89, "start": 73, "tag": "Cell"}, {"end": 94, "start": 91, "tag": "Cell"}, {"end": 130, "start": 114, "tag": "CellFunction"}]}{"id": "1379_7", "text": "To quantify our co-cultures, we developed a novel computer vision algorithm to precisely measure myelination.", "tags": [{"end": 27, "start": 16, "tag": "ResearchActivity"}, {"end": 108, "start": 97, "tag": "CellFunction"}, {"end": 75, "start": 50, "tag": "ResearchActivity"}]}{"id": "1379_8", "text": "We demonstrated efficacy of our system with known pro-differentiating compounds BQ3020 and XAV939 which exhibited robust, efficient, and dose dependent effects on myelination.", "tags": [{"end": 97, "start": 91, "tag": "Chemical"}, {"end": 174, "start": 163, "tag": "CellFunction"}, {"end": 86, "start": 80, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 91, "tag": "PharmacologicSubstance"}]}{"id": "1379_9", "text": "Through this combination of experimental and technical advances, we have developed a method allowing systematic and reliable testing of remyelinating compound efficacy.", "tags": [{"end": 91, "start": 85, "tag": "ResearchActivity"}, {"end": 63, "start": 28, "tag": "Finding"}, {"end": 158, "start": 136, "tag": "PharmacologicSubstance"}, {"end": 132, "start": 101, "tag": "ResearchActivity"}]}{"id": "1380_0", "text": "Myelin is the lipidic insulating structure enwrapping axons and allowing fast saltatory nerve conduction.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 59, "start": 54, "tag": "CellComponent"}, {"end": 104, "start": 78, "tag": "BiologicFunction"}]}{"id": "1380_1", "text": "In the central nervous system, myelin sheath is the result of the complex packaging of multilamellar extensions of oligodendrocyte (OL) membranes.", "tags": [{"end": 44, "start": 31, "tag": "CellComponent"}, {"end": 111, "start": 74, "tag": "Finding"}, {"end": 130, "start": 115, "tag": "Cell"}, {"end": 29, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 134, "start": 132, "tag": "Cell"}, {"end": 145, "start": 136, "tag": "CellComponent"}]}{"id": "1380_2", "text": "Before reaching myelinating capabilities, OLs undergo a very precise program of differentiation and maturation that starts from OL precursor cells (OPCs).", "tags": [{"end": 40, "start": 16, "tag": "CellFunction"}, {"end": 110, "start": 100, "tag": "BiologicFunction"}, {"end": 146, "start": 128, "tag": "Cell"}, {"end": 152, "start": 148, "tag": "Cell"}, {"end": 95, "start": 80, "tag": "CellFunction"}, {"end": 45, "start": 42, "tag": "Cell"}]}{"id": "1380_3", "text": "In the last 20 years, the biology of OPCs and their behavior under pathological conditions have been studied through several experimental models.", "tags": [{"end": 33, "start": 26, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 41, "start": 37, "tag": "Cell"}, {"end": 60, "start": 52, "tag": "BiologicFunction"}, {"end": 60, "start": 52, "tag": "IndividualBehavior"}, {"end": 60, "start": 52, "tag": "ResearchActivity"}, {"end": 144, "start": 125, "tag": "ExperimentalModelOfDisease"}, {"end": 20, "start": 7, "tag": "TemporalConcept"}, {"end": 90, "start": 67, "tag": "PathologicFunction"}]}{"id": "1380_4", "text": "When co-cultured with neurons, OPCs undergo terminal maturation and produce myelin tracts around axons, allowing to investigate myelination in response to exogenous stimuli in a very simple in vitro system.", "tags": [{"end": 16, "start": 5, "tag": "ResearchActivity"}, {"end": 35, "start": 31, "tag": "Cell"}, {"end": 63, "start": 53, "tag": "BiologicFunction"}, {"end": 89, "start": 76, "tag": "CellComponent"}, {"end": 102, "start": 97, "tag": "CellComponent"}, {"end": 139, "start": 128, "tag": "CellFunction"}, {"end": 29, "start": 22, "tag": "Cell"}, {"end": 205, "start": 190, "tag": "ResearchActivity"}]}{"id": "1380_5", "text": "On the other hand, in vivo models more closely reproducing some of the features of human pathophysiology enabled to assess the consequences of demyelination and the molecular mechanisms of remyelination, and they are often used to validate the effect of pharmacological agents.", "tags": [{"end": 202, "start": 189, "tag": "CellFunction"}, {"end": 276, "start": 254, "tag": "PharmacologicSubstance"}, {"end": 88, "start": 83, "tag": "Eukaryote"}, {"end": 33, "start": 19, "tag": "ManufacturedObject"}, {"end": 104, "start": 89, "tag": "PathologicFunction"}, {"end": 185, "start": 165, "tag": "CellFunction"}, {"end": 104, "start": 89, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 156, "start": 143, "tag": "PathologicFunction"}]}{"id": "1380_6", "text": "However, they are very complex, and not suitable for large scale drug discovery screening.", "tags": [{"end": 79, "start": 65, "tag": "ResearchActivity"}, {"end": 69, "start": 65, "tag": "PharmacologicSubstance"}, {"end": 89, "start": 80, "tag": "ResearchActivity"}, {"end": 64, "start": 53, "tag": "ResearchActivity"}]}{"id": "1380_7", "text": "Recent advances in cell reprogramming, biophysics and bioengineering have allowed impressive improvements in the methodological approaches to study brain physiology and myelination.", "tags": [{"end": 37, "start": 19, "tag": "CellFunction"}, {"end": 49, "start": 39, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 68, "start": 54, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 164, "start": 148, "tag": "BiologicFunction"}, {"end": 180, "start": 169, "tag": "CellFunction"}, {"end": 147, "start": 142, "tag": "ResearchActivity"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 15, "start": 7, "tag": "Finding"}]}{"id": "1380_8", "text": "Rat and mouse OPCs can be replaced by human OPCs obtained by induced pluripotent stem cells (iPSCs) derived from healthy or diseased individuals, thus offering unprecedented possibilities for personalized disease modeling and treatment.", "tags": [{"end": 3, "start": 0, "tag": "Eukaryote"}, {"end": 18, "start": 14, "tag": "Cell"}, {"end": 48, "start": 44, "tag": "Cell"}, {"end": 235, "start": 226, "tag": "HealthCareActivity"}, {"end": 235, "start": 226, "tag": "ResearchActivity"}, {"end": 91, "start": 61, "tag": "Cell"}, {"end": 43, "start": 38, "tag": "Eukaryote"}, {"end": 98, "start": 93, "tag": "Cell"}, {"end": 144, "start": 124, "tag": "PatientOrDisabledGroup"}, {"end": 13, "start": 8, "tag": "Eukaryote"}, {"end": 221, "start": 192, "tag": "ExperimentalModelOfDisease"}, {"end": 144, "start": 133, "tag": "PopulationGroup"}, {"end": 120, "start": 113, "tag": "PopulationGroup"}]}{"id": "1380_9", "text": "OPCs and neural cells can be also artificially assembled, using 3D-printed culture chambers and biomaterial scaffolds, which allow modeling cell-to-cell interactions in a highly controlled manner.", "tags": [{"end": 4, "start": 0, "tag": "Cell"}, {"end": 139, "start": 131, "tag": "ResearchActivity"}, {"end": 21, "start": 9, "tag": "Cell"}, {"end": 91, "start": 64, "tag": "ManufacturedObject"}, {"end": 117, "start": 96, "tag": "ManufacturedObject"}, {"end": 165, "start": 140, "tag": "CellFunction"}]}{"id": "1380_10", "text": "Interestingly, scaffold stiffness can be adopted to reproduce the mechanosensory properties assumed by tissues in physiological or pathological conditions.", "tags": [{"end": 110, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 154, "start": 131, "tag": "PathologicFunction"}, {"end": 33, "start": 15, "tag": "ResearchActivity"}, {"end": 91, "start": 66, "tag": "BiologicFunction"}]}{"id": "1380_11", "text": "Moreover, the recent development of iPSC-derived 3D brain cultures, called organoids, has made it possible to study key aspects of embryonic brain development, such as neuronal differentiation, maturation and network formation in temporal dynamics that are inaccessible to traditional in vitro cultures.", "tags": [{"end": 84, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 131, "tag": "BiologicFunction"}, {"end": 192, "start": 168, "tag": "CellFunction"}, {"end": 204, "start": 194, "tag": "BiologicFunction"}, {"end": 146, "start": 131, "tag": "EmbryonicStructure"}, {"end": 115, "start": 110, "tag": "ResearchActivity"}, {"end": 20, "start": 14, "tag": "TemporalConcept"}, {"end": 302, "start": 285, "tag": "ResearchActivity"}, {"end": 66, "start": 36, "tag": "ManufacturedObject"}, {"end": 66, "start": 49, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1380_12", "text": "Despite the huge potential of organoids, their application to myelination studies is still in its infancy.", "tags": [{"end": 39, "start": 30, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 81, "start": 74, "tag": "ResearchActivity"}, {"end": 105, "start": 98, "tag": "TemporalConcept"}, {"end": 105, "start": 98, "tag": "PopulationGroup"}, {"end": 73, "start": 62, "tag": "CellFunction"}]}{"id": "1380_13", "text": "In this review, we shall summarize the novel most relevant experimental approaches and their implications for the identification of remyelinating agents for human diseases such as multiple sclerosis.</p>", "tags": [{"end": 82, "start": 59, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 198, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 171, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 132, "tag": "PharmacologicSubstance"}]}{"id": "1381_0", "text": "The repair of inflamed, demyelinated lesions as in multiple sclerosis (MS) necessitates the clearance of cholesterol-rich myelin debris by microglia/macrophages and the switch from a pro-inflammatory to an anti-inflammatory lesion environment.", "tags": [{"end": 10, "start": 4, "tag": "BiologicFunction"}, {"end": 10, "start": 4, "tag": "HealthCareActivity"}, {"end": 44, "start": 14, "tag": "PathologicFunction"}, {"end": 128, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 122, "tag": "CellComponent"}, {"end": 135, "start": 129, "tag": "Substance"}, {"end": 116, "start": 105, "tag": "Chemical"}, {"end": 116, "start": 105, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 92, "tag": "NaturalPhenomenonOrProcess"}, {"end": 69, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 223, "start": 206, "tag": "BiologicFunction"}, {"end": 223, "start": 206, "tag": "PharmacologicSubstance"}, {"end": 148, "start": 139, "tag": "Cell"}, {"end": 160, "start": 149, "tag": "Cell"}, {"end": 199, "start": 183, "tag": "PathologicFunction"}, {"end": 230, "start": 224, "tag": "InjuryOrPoisoning"}]}{"id": "1381_1", "text": "Subsequently, oligodendrocytes increase cholesterol levels as a prerequisite for synthesizing new myelin membranes.", "tags": [{"end": 30, "start": 14, "tag": "Cell"}, {"end": 51, "start": 40, "tag": "Chemical"}, {"end": 51, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 114, "start": 98, "tag": "CellComponent"}]}{"id": "1381_2", "text": "We hypothesized that lesion resolution is regulated by the fate of cholesterol from damaged myelin and oligodendroglial sterol synthesis.", "tags": [{"end": 119, "start": 103, "tag": "Cell"}, {"end": 119, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 120, "tag": "CellFunction"}, {"end": 78, "start": 67, "tag": "Chemical"}, {"end": 78, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 21, "tag": "InjuryOrPoisoning"}, {"end": 98, "start": 84, "tag": "CellOrMolecularDysfunction"}]}{"id": "1381_3", "text": "By integrating gene expression profiling, genetics and comprehensive phenotyping, we found that, paradoxically, sterol synthesis in myelin-phagocytosing microglia/macrophages determines the repair of acutely demyelinated lesions.", "tags": [{"end": 40, "start": 15, "tag": "ResearchActivity"}, {"end": 128, "start": 112, "tag": "CellFunction"}, {"end": 196, "start": 190, "tag": "BiologicFunction"}, {"end": 196, "start": 190, "tag": "HealthCareActivity"}, {"end": 228, "start": 208, "tag": "PathologicFunction"}, {"end": 50, "start": 42, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 50, "start": 42, "tag": "CellFunction"}, {"end": 162, "start": 153, "tag": "Cell"}, {"end": 80, "start": 55, "tag": "ResearchActivity"}, {"end": 174, "start": 163, "tag": "Cell"}, {"end": 138, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 132, "tag": "CellComponent"}]}{"id": "1381_4", "text": "Rather than producing cholesterol, microglia/macrophages synthesized desmosterol, the immediate cholesterol precursor.", "tags": [{"end": 80, "start": 69, "tag": "Chemical"}, {"end": 95, "start": 86, "tag": "TemporalConcept"}, {"end": 33, "start": 22, "tag": "Chemical"}, {"end": 107, "start": 96, "tag": "Chemical"}, {"end": 33, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 96, "tag": "BiologicallyActiveSubstance"}, {"end": 44, "start": 35, "tag": "Cell"}, {"end": 56, "start": 45, "tag": "Cell"}, {"end": 80, "start": 69, "tag": "BiologicallyActiveSubstance"}]}{"id": "1381_5", "text": "Desmosterol activated liver X receptor (LXR) signaling to resolve inflammation, creating a permissive environment for oligodendrocyte differentiation.", "tags": [{"end": 11, "start": 0, "tag": "Chemical"}, {"end": 43, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 54, "start": 45, "tag": "CellFunction"}, {"end": 78, "start": 66, "tag": "PathologicFunction"}, {"end": 133, "start": 118, "tag": "Cell"}, {"end": 149, "start": 134, "tag": "CellFunction"}, {"end": 38, "start": 22, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 22, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 40, "tag": "BiologicallyActiveSubstance"}]}{"id": "1381_6", "text": "Moreover, LXR target gene products facilitated the efflux of lipid and cholesterol from lipid-laden microglia/macrophages to support remyelination by oligodendrocytes.", "tags": [{"end": 13, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 51, "tag": "CellFunction"}, {"end": 66, "start": 61, "tag": "Chemical"}, {"end": 146, "start": 133, "tag": "CellFunction"}, {"end": 166, "start": 150, "tag": "Cell"}, {"end": 82, "start": 71, "tag": "Chemical"}, {"end": 82, "start": 71, "tag": "BiologicallyActiveSubstance"}, {"end": 121, "start": 88, "tag": "Cell"}, {"end": 13, "start": 10, "tag": "BiologicallyActiveSubstance"}]}{"id": "1381_7", "text": "Consequently, pharmacological stimulation of sterol synthesis boosted the repair of demyelinated lesions, suggesting novel therapeutic strategies for myelin repair in MS.", "tags": [{"end": 41, "start": 14, "tag": "HealthCareActivity"}, {"end": 61, "start": 45, "tag": "CellFunction"}, {"end": 80, "start": 74, "tag": "BiologicFunction"}, {"end": 80, "start": 74, "tag": "HealthCareActivity"}, {"end": 104, "start": 84, "tag": "PathologicFunction"}, {"end": 169, "start": 167, "tag": "DiseaseOrSyndrome"}, {"end": 145, "start": 123, "tag": "HealthCareActivity"}, {"end": 163, "start": 150, "tag": "CellFunction"}]}{"id": "1381_8", "text": "Efficient repair of demyelinated CNS lesions involves the resolution of inflammation and induction of remyelination.", "tags": [{"end": 16, "start": 10, "tag": "BiologicFunction"}, {"end": 16, "start": 10, "tag": "HealthCareActivity"}, {"end": 44, "start": 20, "tag": "PathologicFunction"}, {"end": 84, "start": 72, "tag": "PathologicFunction"}, {"end": 115, "start": 102, "tag": "CellFunction"}, {"end": 36, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1381_9", "text": "Berghoff et al.", "tags": []}{"id": "1381_10", "text": "show that sterol synthesis in microglia is key to both processes, which can be supported by squalene therapy.", "tags": [{"end": 26, "start": 10, "tag": "CellFunction"}, {"end": 39, "start": 30, "tag": "Cell"}, {"end": 108, "start": 101, "tag": "HealthCareActivity"}, {"end": 100, "start": 92, "tag": "Chemical"}, {"end": 100, "start": 92, "tag": "PharmacologicSubstance"}]}{"id": "1382_0", "text": "Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease in which motor neurons throughout the brain and spinal cord progressively degenerate resulting in muscle atrophy, paralysis and death.", "tags": [{"end": 89, "start": 76, "tag": "Cell"}, {"end": 126, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 165, "tag": "PathologicFunction"}, {"end": 190, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 105, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 41, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 195, "tag": "BiologicFunction"}, {"end": 200, "start": 195, "tag": "PathologicFunction"}, {"end": 200, "start": 195, "tag": "CellFunction"}]}{"id": "1382_1", "text": "Recent studies using animal models of ALS implicate multiple cell-types (e.g., astrocytes and microglia) in ALS pathogenesis in the spinal motor systems.", "tags": [{"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 41, "start": 38, "tag": "DiseaseOrSyndrome"}, {"end": 111, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 112, "tag": "PathologicFunction"}, {"end": 34, "start": 21, "tag": "ManufacturedObject"}, {"end": 103, "start": 94, "tag": "Cell"}, {"end": 89, "start": 79, "tag": "Cell"}, {"end": 41, "start": 21, "tag": "ExperimentalModelOfDisease"}, {"end": 71, "start": 61, "tag": "Cell"}, {"end": 152, "start": 132, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1382_2", "text": "To ascertain cellular vulnerability and cell-type specific mechanisms of ALS in the brainstem that orchestrates oral-motor functions, we conducted parallel single cell RNA sequencing (scRNA-seq) analysis using the high-throughput Drop-seq method.", "tags": [{"end": 93, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 203, "start": 195, "tag": "ResearchActivity"}, {"end": 182, "start": 156, "tag": "ResearchActivity"}, {"end": 193, "start": 184, "tag": "ResearchActivity"}, {"end": 245, "start": 214, "tag": "ResearchActivity"}]}{"id": "1382_3", "text": "We isolated 1894 and 3199 cells from the brainstem of wildtype and mutant SOD1 symptomatic mice respectively, at postnatal day 100.", "tags": [{"end": 50, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 113, "tag": "TemporalConcept"}, {"end": 78, "start": 67, "tag": "CellOrMolecularDysfunction"}, {"end": 31, "start": 26, "tag": "Cell"}, {"end": 95, "start": 91, "tag": "Eukaryote"}, {"end": 78, "start": 74, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 67, "tag": "ExperimentalModelOfDisease"}, {"end": 78, "start": 74, "tag": "GeneOrGenome"}, {"end": 78, "start": 74, "tag": "BiologicallyActiveSubstance"}]}{"id": "1382_4", "text": "We recovered major known cell types and neuronal subpopulations, such as interneurons and motor neurons, and trigeminal ganglion (TG) peripheral sensory neurons, as well as, previously uncharacterized interneuron subtypes.", "tags": [{"end": 85, "start": 73, "tag": "Cell"}, {"end": 103, "start": 90, "tag": "Cell"}, {"end": 130, "start": 109, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 221, "start": 201, "tag": "Cell"}, {"end": 35, "start": 25, "tag": "Cell"}, {"end": 160, "start": 109, "tag": "Cell"}, {"end": 63, "start": 40, "tag": "Cell"}]}{"id": "1382_5", "text": "We found that the majority of the cell types displayed transcriptomic alterations in ALS mice.", "tags": [{"end": 44, "start": 34, "tag": "Cell"}, {"end": 88, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 93, "start": 85, "tag": "ExperimentalModelOfDisease"}, {"end": 81, "start": 55, "tag": "CellOrMolecularDysfunction"}]}{"id": "1382_6", "text": "Differentially expressed genes (DEGs) of individual cell populations revealed cell-type specific alterations in numerous pathways, including previously known ALS pathways such as inflammation (in microglia), stress response (ependymal and an uncharacterized cell population), neurogenesis (astrocytes, oligodendrocytes, neurons), synapse organization and transmission (microglia, oligodendrocyte precursor cells, and neuronal subtypes), and mitochondrial function (uncharacterized cell populations).", "tags": [{"end": 36, "start": 32, "tag": "GeneOrGenome"}, {"end": 68, "start": 41, "tag": "Cell"}, {"end": 191, "start": 179, "tag": "PathologicFunction"}, {"end": 223, "start": 208, "tag": "BiologicFunction"}, {"end": 223, "start": 208, "tag": "CellFunction"}, {"end": 234, "start": 225, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 318, "start": 302, "tag": "Cell"}, {"end": 367, "start": 330, "tag": "CellFunction"}, {"end": 411, "start": 380, "tag": "Cell"}, {"end": 161, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 288, "start": 276, "tag": "BiologicFunction"}, {"end": 327, "start": 320, "tag": "Cell"}, {"end": 129, "start": 121, "tag": "CellFunction"}, {"end": 170, "start": 162, "tag": "CellFunction"}, {"end": 463, "start": 441, "tag": "CellFunction"}, {"end": 273, "start": 258, "tag": "Cell"}, {"end": 205, "start": 196, "tag": "Cell"}, {"end": 378, "start": 369, "tag": "Cell"}, {"end": 300, "start": 290, "tag": "Cell"}, {"end": 434, "start": 417, "tag": "Cell"}, {"end": 30, "start": 0, "tag": "GeneOrGenome"}, {"end": 30, "start": 0, "tag": "ResearchActivity"}, {"end": 36, "start": 32, "tag": "ResearchActivity"}, {"end": 87, "start": 78, "tag": "Cell"}, {"end": 273, "start": 258, "tag": "Cell"}, {"end": 234, "start": 225, "tag": "Cell"}]}{"id": "1382_7", "text": "Other cell-type specific processes altered in SOD1 mutant brainstem include those from motor neurons (axon regeneration, voltage-gated sodium and potassium channels underlying excitability, potassium ion transport), trigeminal sensory neurons (detection of temperature stimulus involved in sensory perception), and cellular response to toxic substances (uncharacterized cell populations).", "tags": [{"end": 67, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 87, "tag": "Cell"}, {"end": 119, "start": 102, "tag": "BiologicFunction"}, {"end": 164, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 188, "start": 176, "tag": "SignOrSymptom"}, {"end": 213, "start": 190, "tag": "CellFunction"}, {"end": 268, "start": 257, "tag": "OrganismAttribute"}, {"end": 268, "start": 257, "tag": "NaturalPhenomenonOrProcess"}, {"end": 308, "start": 290, "tag": "BiologicFunction"}, {"end": 352, "start": 336, "tag": "InjuryOrPoisoning"}, {"end": 57, "start": 46, "tag": "CellOrMolecularDysfunction"}, {"end": 242, "start": 216, "tag": "Cell"}, {"end": 332, "start": 315, "tag": "CellFunction"}, {"end": 15, "start": 6, "tag": "Cell"}, {"end": 386, "start": 370, "tag": "Cell"}]}{"id": "1382_8", "text": "DEGs consistently altered across cell types (e.g., Malat1), as well as cell-type specific DEGs, were identified.", "tags": [{"end": 4, "start": 0, "tag": "GeneOrGenome"}, {"end": 57, "start": 51, "tag": "GeneOrGenome"}, {"end": 43, "start": 33, "tag": "Cell"}, {"end": 4, "start": 0, "tag": "ResearchActivity"}, {"end": 94, "start": 90, "tag": "ResearchActivity"}, {"end": 94, "start": 90, "tag": "GeneOrGenome"}, {"end": 80, "start": 71, "tag": "Cell"}]}{"id": "1382_9", "text": "Importantly, DEGs from various cell types overlapped with known ALS genes from the literature and with top hits from an existing human ALS genome-wide association study (GWAS), implicating the potential cell types in which the ALS genes function with ALS pathogenesis.", "tags": [{"end": 17, "start": 13, "tag": "GeneOrGenome"}, {"end": 52, "start": 42, "tag": "HealthCareActivity"}, {"end": 111, "start": 107, "tag": "Finding"}, {"end": 168, "start": 139, "tag": "ResearchActivity"}, {"end": 174, "start": 170, "tag": "ResearchActivity"}, {"end": 245, "start": 231, "tag": "CellFunction"}, {"end": 41, "start": 31, "tag": "Cell"}, {"end": 213, "start": 203, "tag": "Cell"}, {"end": 67, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 138, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 230, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 254, "start": 251, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 129, "tag": "Eukaryote"}, {"end": 267, "start": 255, "tag": "PathologicFunction"}, {"end": 93, "start": 83, "tag": "ResearchActivity"}, {"end": 17, "start": 13, "tag": "ResearchActivity"}]}{"id": "1382_10", "text": "Our molecular investigation at single cell resolution provides comprehensive insights into the cell types, genes and pathways altered in the brainstem in a widely used ALS mouse model.", "tags": [{"end": 150, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 105, "start": 95, "tag": "Cell"}, {"end": 183, "start": 168, "tag": "ExperimentalModelOfDisease"}, {"end": 27, "start": 14, "tag": "ResearchActivity"}, {"end": 125, "start": 117, "tag": "CellFunction"}, {"end": 53, "start": 31, "tag": "ResearchActivity"}, {"end": 85, "start": 63, "tag": "Finding"}]}{"id": "1383_0", "text": "Dysfunctions in the endocannabinoid system have been associated with experimental animal models and multiple sclerosis patients.", "tags": [{"end": 42, "start": 0, "tag": "CellOrMolecularDysfunction"}, {"end": 127, "start": 119, "tag": "PatientOrDisabledGroup"}, {"end": 95, "start": 69, "tag": "ResearchActivity"}, {"end": 118, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 20, "tag": "Chemical"}, {"end": 42, "start": 20, "tag": "CellFunction"}, {"end": 35, "start": 20, "tag": "BiologicallyActiveSubstance"}]}{"id": "1383_1", "text": "Interestingly, the endocannabinoid system has been reported to confer neuroprotection against demyelination.", "tags": [{"end": 34, "start": 19, "tag": "Chemical"}, {"end": 41, "start": 19, "tag": "CellFunction"}, {"end": 34, "start": 19, "tag": "BiologicallyActiveSubstance"}, {"end": 107, "start": 94, "tag": "PathologicFunction"}, {"end": 85, "start": 70, "tag": "CellFunction"}]}{"id": "1383_2", "text": "The present study aims to assess the effects of the cannabinoid agonist WIN-55,212-2 in cuprizone fed animals on myelin repair capacity.", "tags": [{"end": 71, "start": 52, "tag": "PharmacologicSubstance"}, {"end": 97, "start": 88, "tag": "Chemical"}, {"end": 17, "start": 12, "tag": "ResearchActivity"}, {"end": 84, "start": 72, "tag": "Chemical"}, {"end": 84, "start": 72, "tag": "PharmacologicSubstance"}, {"end": 135, "start": 113, "tag": "CellFunction"}, {"end": 109, "start": 88, "tag": "ExperimentalModelOfDisease"}]}{"id": "1383_3", "text": "Animals exposed to cuprizone were simultaneously treated withWIN-55,212-2, behaviorally tested and finally the corpus callosum was exhaustively studied by Western blotting, qRT-PCR and a myelin staining procedure.", "tags": [{"end": 7, "start": 0, "tag": "Eukaryote"}, {"end": 28, "start": 19, "tag": "Chemical"}, {"end": 171, "start": 155, "tag": "ResearchActivity"}, {"end": 180, "start": 173, "tag": "ResearchActivity"}, {"end": 126, "start": 111, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 61, "tag": "Chemical"}, {"end": 73, "start": 61, "tag": "PharmacologicSubstance"}, {"end": 212, "start": 187, "tag": "ResearchActivity"}, {"end": 94, "start": 75, "tag": "ResearchActivity"}]}{"id": "1383_4", "text": "We report that the long-term administration of WIN-55,212-2 reduced the global amount of CB1 protein.", "tags": [{"end": 9, "start": 3, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "ResearchActivity"}, {"end": 28, "start": 19, "tag": "TemporalConcept"}, {"end": 59, "start": 47, "tag": "PharmacologicSubstance"}, {"end": 59, "start": 47, "tag": "Chemical"}, {"end": 100, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 100, "start": 89, "tag": "BiologicallyActiveSubstance"}]}{"id": "1383_5", "text": "Histological analysis revealed clear demyelination after being fed cuprizone for three weeks.", "tags": [{"end": 76, "start": 67, "tag": "Chemical"}, {"end": 92, "start": 81, "tag": "TemporalConcept"}, {"end": 21, "start": 0, "tag": "ResearchActivity"}, {"end": 50, "start": 37, "tag": "PathologicFunction"}]}{"id": "1383_6", "text": "However, cuprizone-fed mice subjected to 0.5 mg/Kg of WIN-55,212-2 displayed no differences when compared to controls during demyelination, although there was a robust increase in the myelinated axons during the remyelination phase.", "tags": [{"end": 200, "start": 184, "tag": "CellComponent"}, {"end": 225, "start": 212, "tag": "CellFunction"}, {"end": 231, "start": 226, "tag": "TemporalConcept"}, {"end": 117, "start": 109, "tag": "PopulationGroup"}, {"end": 91, "start": 77, "tag": "Finding"}, {"end": 138, "start": 125, "tag": "PathologicFunction"}, {"end": 27, "start": 9, "tag": "ExperimentalModelOfDisease"}, {"end": 66, "start": 54, "tag": "Chemical"}, {"end": 66, "start": 54, "tag": "PharmacologicSubstance"}, {"end": 176, "start": 161, "tag": "Finding"}]}{"id": "1383_7", "text": "These animals displayed better performance on contextual fear conditioning which was in turn non-attributable to an antinociceptive effect.", "tags": [{"end": 13, "start": 6, "tag": "Eukaryote"}, {"end": 42, "start": 24, "tag": "Finding"}, {"end": 74, "start": 46, "tag": "ResearchActivity"}, {"end": 138, "start": 116, "tag": "Finding"}]}{"id": "1383_8", "text": "In contrast, a 1 mg/Kg dosage caused a remarkable demyelination accompanied by limited potential for myelin repair.", "tags": [{"end": 63, "start": 50, "tag": "PathologicFunction"}, {"end": 114, "start": 101, "tag": "CellFunction"}]}{"id": "1383_9", "text": "Upon drug administration while mice ongoing demyeliniation, the expression of Aif1 (microglia) and Gfap (astrocytes) followed a dose-dependent manner whereas the expression of both markers was apparently attenuated during remyelination.", "tags": [{"end": 24, "start": 5, "tag": "ResearchActivity"}, {"end": 24, "start": 5, "tag": "HealthCareActivity"}, {"end": 82, "start": 78, "tag": "GeneOrGenome"}, {"end": 103, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 99, "tag": "GeneOrGenome"}, {"end": 235, "start": 222, "tag": "CellFunction"}, {"end": 35, "start": 31, "tag": "Eukaryote"}, {"end": 93, "start": 84, "tag": "Cell"}, {"end": 115, "start": 105, "tag": "Cell"}, {"end": 82, "start": 64, "tag": "CellFunction"}, {"end": 58, "start": 44, "tag": "PathologicFunction"}, {"end": 82, "start": 78, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 99, "tag": "BiologicallyActiveSubstance"}]}{"id": "1383_10", "text": "Treatment with vehicle or 0.5 mg/Kg of the drug during demyelination increased the expression of Pdgfra (oligodendrocyte precursor cells) but this did not occur when 1 mg/Kg was administered.", "tags": [{"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 103, "start": 97, "tag": "GeneOrGenome"}, {"end": 103, "start": 97, "tag": "AminoAcidPeptideOrProtein"}, {"end": 136, "start": 105, "tag": "Cell"}, {"end": 47, "start": 43, "tag": "PharmacologicSubstance"}, {"end": 68, "start": 55, "tag": "PathologicFunction"}]}{"id": "1383_11", "text": "In conclusion, the drug at 0.5 mg/Kg did not alter myelin architecture while 1 mg/Kg had a deleterious effect in this model.", "tags": [{"end": 57, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 51, "tag": "CellComponent"}, {"end": 123, "start": 118, "tag": "ResearchActivity"}, {"end": 23, "start": 19, "tag": "PharmacologicSubstance"}, {"end": 109, "start": 91, "tag": "Finding"}, {"end": 70, "start": 51, "tag": "CellFunction"}]}{"id": "1384_0", "text": "In Alzheimer's disease, amyloid plaque formation is associated with the focal death of oligodendrocytes and soluble amyloid beta impairs the survival of oligodendrocytes in vitro.", "tags": [{"end": 103, "start": 87, "tag": "Cell"}, {"end": 128, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 149, "start": 141, "tag": "CellFunction"}, {"end": 169, "start": 153, "tag": "Cell"}, {"end": 22, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 83, "start": 78, "tag": "BiologicFunction"}, {"end": 83, "start": 78, "tag": "PathologicFunction"}, {"end": 178, "start": 170, "tag": "ResearchActivity"}, {"end": 83, "start": 78, "tag": "CellFunction"}, {"end": 48, "start": 24, "tag": "CellOrMolecularDysfunction"}]}{"id": "1384_1", "text": "However, the response of oligodendrocyte progenitor cells (OPCs) to early amyloid pathology remains unclear.", "tags": [{"end": 57, "start": 25, "tag": "Cell"}, {"end": 63, "start": 59, "tag": "Cell"}, {"end": 91, "start": 74, "tag": "PathologicFunction"}]}{"id": "1384_2", "text": "To explore this, we performed a histological, electrophysiological, and behavioral characterization of transgenic mice expressing a pathological form of humanamyloid precursor protein(APP), containing three single point mutations associated with the development of familial Alzheimer's disease (PDGFB-APP(Sw.Ind), also known as J20 mice).PDGFB-APP(Sw.Ind)transgenic mice had impaired survival from weaning, were hyperactive by 2 months of age, and developed amyloid plaques by 6 months of age, however, their spatial memory remained intact over this time course.", "tags": [{"end": 149, "start": 132, "tag": "PathologicFunction"}, {"end": 392, "start": 384, "tag": "CellFunction"}, {"end": 405, "start": 398, "tag": "Finding"}, {"end": 423, "start": 412, "tag": "DiseaseOrSyndrome"}, {"end": 473, "start": 458, "tag": "AminoAcidPeptideOrProtein"}, {"end": 523, "start": 509, "tag": "BiologicFunction"}, {"end": 539, "start": 533, "tag": "Finding"}, {"end": 561, "start": 550, "tag": "TemporalConcept"}, {"end": 442, "start": 439, "tag": "OrganismAttribute"}, {"end": 492, "start": 489, "tag": "OrganismAttribute"}, {"end": 293, "start": 265, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 103, "tag": "Eukaryote"}, {"end": 99, "start": 32, "tag": "ResearchActivity"}, {"end": 129, "start": 119, "tag": "CellFunction"}, {"end": 554, "start": 550, "tag": "TemporalConcept"}, {"end": 561, "start": 555, "tag": "TemporalConcept"}, {"end": 229, "start": 207, "tag": "CellOrMolecularDysfunction"}, {"end": 561, "start": 555, "tag": "PathologicFunction"}, {"end": 435, "start": 427, "tag": "TemporalConcept"}, {"end": 485, "start": 479, "tag": "TemporalConcept"}, {"end": 187, "start": 184, "tag": "AminoAcidPeptideOrProtein"}, {"end": 304, "start": 301, "tag": "AminoAcidPeptideOrProtein"}, {"end": 187, "start": 184, "tag": "GeneOrGenome"}, {"end": 304, "start": 301, "tag": "GeneOrGenome"}, {"end": 187, "start": 184, "tag": "BiologicallyActiveSubstance"}, {"end": 304, "start": 301, "tag": "BiologicallyActiveSubstance"}, {"end": 183, "start": 153, "tag": "AminoAcidPeptideOrProtein"}, {"end": 300, "start": 295, "tag": "AminoAcidPeptideOrProtein"}, {"end": 300, "start": 295, "tag": "GeneOrGenome"}, {"end": 300, "start": 295, "tag": "BiologicallyActiveSubstance"}, {"end": 336, "start": 328, "tag": "ExperimentalModelOfDisease"}, {"end": 370, "start": 338, "tag": "ExperimentalModelOfDisease"}, {"end": 336, "start": 332, "tag": "ExperimentalModelOfDisease"}, {"end": 311, "start": 295, "tag": "ExperimentalModelOfDisease"}]}{"id": "1384_3", "text": "Hippocampal OPC density was normal in P60-P180PDGFB-APP(Sw.Ind)transgenic mice and, by performing whole-cell patch-clamp electrophysiology, we found that their membrane properties, including their response to kainate (100 mu M), were largely normal.", "tags": [{"end": 11, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 168, "start": 160, "tag": "CellComponent"}, {"end": 216, "start": 209, "tag": "Chemical"}, {"end": 248, "start": 242, "tag": "Finding"}, {"end": 78, "start": 74, "tag": "Eukaryote"}, {"end": 55, "start": 52, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 52, "tag": "GeneOrGenome"}, {"end": 55, "start": 52, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 38, "tag": "ExperimentalModelOfDisease"}, {"end": 15, "start": 12, "tag": "Cell"}]}{"id": "1384_4", "text": "However, by P100, the response of hippocampal OPCs to GABA was elevated inPDGFB-APP(Sw.Ind)transgenic mice.", "tags": [{"end": 16, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 16, "start": 12, "tag": "GeneOrGenome"}, {"end": 50, "start": 46, "tag": "Cell"}, {"end": 58, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 54, "tag": "ResearchActivity"}, {"end": 45, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 106, "start": 102, "tag": "Eukaryote"}, {"end": 45, "start": 34, "tag": "Cell"}, {"end": 83, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 80, "tag": "GeneOrGenome"}, {"end": 83, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 74, "tag": "ExperimentalModelOfDisease"}]}{"id": "1384_5", "text": "We also found that the nodes of Ranvier were shorter, the paranodes longer, and the myelin thicker for hippocampal axons in young adultPDGFB-APP(Sw.Ind)transgenic mice compared with wildtype littermates.", "tags": [{"end": 67, "start": 58, "tag": "CellComponent"}, {"end": 90, "start": 84, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 84, "tag": "CellComponent"}, {"end": 120, "start": 103, "tag": "CellComponent"}, {"end": 135, "start": 124, "tag": "PopulationGroup"}, {"end": 39, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 167, "start": 135, "tag": "ExperimentalModelOfDisease"}, {"end": 202, "start": 182, "tag": "Eukaryote"}]}{"id": "1384_6", "text": "Additionally, oligodendrogenesis was normal in young adulthood, but increased in the hippocampus, entorhinal cortex, and fimbria ofPDGFB-APP(Sw.Ind)transgenic mice as pathology developed.", "tags": [{"end": 62, "start": 47, "tag": "PopulationGroup"}, {"end": 96, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 115, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 128, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 167, "tag": "PathologicFunction"}, {"end": 176, "start": 167, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 163, "start": 159, "tag": "Eukaryote"}, {"end": 32, "start": 14, "tag": "BiologicFunction"}, {"end": 163, "start": 131, "tag": "ExperimentalModelOfDisease"}]}{"id": "1384_7", "text": "As the new oligodendrocytes were not associated with a change in total oligodendrocyte number, these cells are likely required for cell replacement.", "tags": [{"end": 27, "start": 11, "tag": "Cell"}, {"end": 86, "start": 71, "tag": "Cell"}, {"end": 147, "start": 131, "tag": "HealthCareActivity"}, {"end": 147, "start": 131, "tag": "ResearchActivity"}, {"end": 106, "start": 101, "tag": "Cell"}]}{"id": "1385_0", "text": "The exacerbation of progressive multiple sclerosis (MS) is closely associated with obstruction of the differentiation of oligodendrocyte progenitor cells (OPCs).", "tags": [{"end": 16, "start": 4, "tag": "Finding"}, {"end": 94, "start": 83, "tag": "Finding"}, {"end": 153, "start": 121, "tag": "Cell"}, {"end": 159, "start": 155, "tag": "Cell"}, {"end": 54, "start": 52, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 102, "tag": "CellFunction"}, {"end": 50, "start": 32, "tag": "DiseaseOrSyndrome"}]}{"id": "1385_1", "text": "To discover novel therapeutic compounds for enhancing remyelination by endogenous OPCs, we screened for myelin basic protein expression using cultured rat OPCs and a library of small-molecule compounds.", "tags": [{"end": 67, "start": 54, "tag": "CellFunction"}, {"end": 86, "start": 82, "tag": "Cell"}, {"end": 110, "start": 104, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 104, "tag": "CellComponent"}, {"end": 135, "start": 117, "tag": "CellFunction"}, {"end": 159, "start": 155, "tag": "Cell"}, {"end": 173, "start": 166, "tag": "GeneOrGenome"}, {"end": 39, "start": 12, "tag": "Substance"}, {"end": 159, "start": 142, "tag": "ResearchActivity"}, {"end": 201, "start": 177, "tag": "Substance"}]}{"id": "1385_2", "text": "One of the most effective drugs was pinocembrin, which remarkably promoted OPC differentiation and maturation without affecting cell proliferation and survival.", "tags": [{"end": 47, "start": 36, "tag": "Chemical"}, {"end": 159, "start": 151, "tag": "CellFunction"}, {"end": 31, "start": 26, "tag": "PharmacologicSubstance"}, {"end": 94, "start": 75, "tag": "CellFunction"}, {"end": 146, "start": 128, "tag": "CellFunction"}, {"end": 109, "start": 99, "tag": "CellFunction"}, {"end": 78, "start": 75, "tag": "CellFunction"}]}{"id": "1385_3", "text": "Based on these in vitro effects, we further assessed the therapeutic effects of pinocembrin in animal models of demyelinating diseases.", "tags": [{"end": 91, "start": 80, "tag": "Chemical"}, {"end": 134, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 95, "tag": "ResearchActivity"}, {"end": 23, "start": 15, "tag": "ResearchActivity"}, {"end": 76, "start": 57, "tag": "Finding"}]}{"id": "1385_4", "text": "We demonstrated that pinocembrin significantly ameliorated the progression of experimental autoimmune encephalomyelitis (EAE) and enhanced the repair of demyelination in lysolectin-induced lesions.", "tags": [{"end": 32, "start": 21, "tag": "Chemical"}, {"end": 119, "start": 78, "tag": "ExperimentalModelOfDisease"}, {"end": 124, "start": 121, "tag": "ExperimentalModelOfDisease"}, {"end": 149, "start": 143, "tag": "BiologicFunction"}, {"end": 149, "start": 143, "tag": "HealthCareActivity"}, {"end": 74, "start": 63, "tag": "PathologicFunction"}, {"end": 74, "start": 63, "tag": "TemporalConcept"}, {"end": 166, "start": 153, "tag": "PathologicFunction"}, {"end": 180, "start": 170, "tag": "Chemical"}, {"end": 196, "start": 170, "tag": "InjuryOrPoisoning"}]}{"id": "1385_5", "text": "Further studies indicated that pinocembrin increased the phosphorylation level of mammalian target of rapamycin (mTOR).", "tags": [{"end": 42, "start": 31, "tag": "Chemical"}, {"end": 111, "start": 102, "tag": "Chemical"}, {"end": 117, "start": 113, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 113, "tag": "GeneOrGenome"}, {"end": 15, "start": 8, "tag": "ResearchActivity"}, {"end": 91, "start": 82, "tag": "Eukaryote"}, {"end": 72, "start": 57, "tag": "CellFunction"}, {"end": 117, "start": 113, "tag": "BiologicallyActiveSubstance"}, {"end": 111, "start": 82, "tag": "GeneOrGenome"}, {"end": 111, "start": 82, "tag": "AminoAcidPeptideOrProtein"}, {"end": 111, "start": 82, "tag": "BiologicallyActiveSubstance"}]}{"id": "1385_6", "text": "Taken together, our results demonstrated that pinocembrin promotes OPC differentiation and remyelination through the phosphorylated mTOR pathway, and suggest a novel therapeutic prospect for this natural flavonoid product in treating demyelinating diseases.", "tags": [{"end": 57, "start": 46, "tag": "Chemical"}, {"end": 70, "start": 67, "tag": "Cell"}, {"end": 104, "start": 91, "tag": "CellFunction"}, {"end": 256, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 86, "start": 71, "tag": "CellFunction"}, {"end": 144, "start": 117, "tag": "CellFunction"}, {"end": 221, "start": 196, "tag": "Chemical"}]}{"id": "1386_0", "text": "Ceruloplasmin (Cp) is a multicopper oxidase with ferroxidase properties being of importance to the mobilisation and export of iron from cells and its ability to bind copper.", "tags": [{"end": 13, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 0, "tag": "GeneOrGenome"}, {"end": 17, "start": 15, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 17, "start": 15, "tag": "GeneOrGenome"}, {"end": 60, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 99, "tag": "CellFunction"}, {"end": 172, "start": 161, "tag": "CellFunction"}, {"end": 141, "start": 136, "tag": "Cell"}, {"end": 172, "start": 166, "tag": "PharmacologicSubstance"}, {"end": 172, "start": 166, "tag": "Chemical"}, {"end": 130, "start": 126, "tag": "PharmacologicSubstance"}, {"end": 130, "start": 126, "tag": "Chemical"}, {"end": 172, "start": 166, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 24, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1386_1", "text": "In ageing humans, Cp deficiency is known to result in aceruloplasminemia, which among other is characterised by neurological symptoms.", "tags": [{"end": 72, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 112, "tag": "SignOrSymptom"}, {"end": 16, "start": 10, "tag": "Eukaryote"}, {"end": 31, "start": 18, "tag": "DiseaseOrSyndrome"}]}{"id": "1386_2", "text": "To obtain novel information about the functions of Cp in the central nervous system (CNS) we compared the brain proteome in forebrains from asymptomatic 4-6-month-old Cp-deficient (B6N(Cg)-Cp-tm1b(KOMP)Wtsi/J) and wild-type mice.", "tags": [{"end": 53, "start": 51, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 51, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 51, "tag": "GeneOrGenome"}, {"end": 120, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 124, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 228, "start": 214, "tag": "Eukaryote"}, {"end": 111, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 88, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 61, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 228, "start": 224, "tag": "ExperimentalModelOfDisease"}, {"end": 209, "start": 140, "tag": "ExperimentalModelOfDisease"}]}{"id": "1386_3", "text": "Of more than 5600 quantified proteins, 23 proteins, were regulated, whereas more than 1200 proteins had regulated post-translational modifications (PTMs).", "tags": [{"end": 146, "start": 114, "tag": "CellFunction"}, {"end": 152, "start": 148, "tag": "CellFunction"}]}{"id": "1386_4", "text": "The genes of the regulated proteins, glycoproteins and phosphoproteins appeared mostly to be located to neurons and oligodendrocyte precursor cells.", "tags": [{"end": 50, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 50, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 70, "start": 55, "tag": "AminoAcidPeptideOrProtein"}, {"end": 147, "start": 116, "tag": "Cell"}, {"end": 111, "start": 104, "tag": "Cell"}, {"end": 70, "start": 55, "tag": "BiologicallyActiveSubstance"}]}{"id": "1386_5", "text": "Cp deficiency especially affected the function of proteins involved in the extension of neuronal projections, synaptic signalling and cellular mRNA processing and affected the expression of proteins involved in neurodegenerative disease and diabetes.", "tags": [{"end": 129, "start": 110, "tag": "CellFunction"}, {"end": 158, "start": 134, "tag": "CellFunction"}, {"end": 249, "start": 241, "tag": "DiseaseOrSyndrome"}, {"end": 236, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 88, "tag": "CellComponent"}, {"end": 13, "start": 0, "tag": "DiseaseOrSyndrome"}]}{"id": "1386_6", "text": "Iron concentration and transferrin saturation were reduced in the blood of even younger, 3- to 5-month-old, Cp-deficient mice.", "tags": [{"end": 18, "start": 0, "tag": "ResearchActivity"}, {"end": 71, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 108, "tag": "ExperimentalModelOfDisease"}, {"end": 106, "start": 89, "tag": "PopulationGroup"}, {"end": 87, "start": 80, "tag": "TemporalConcept"}, {"end": 45, "start": 23, "tag": "ResearchActivity"}]}{"id": "1386_7", "text": "Iron act as cofactor in many enzymatic processes and reactions.", "tags": [{"end": 4, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 4, "start": 0, "tag": "Chemical"}, {"end": 20, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1386_8", "text": "Changes in iron availability and oxidation as consequence of Cp deficiency could therefore affect the synthesis of proteins and lipids.", "tags": [{"end": 123, "start": 102, "tag": "CellFunction"}, {"end": 134, "start": 128, "tag": "Chemical"}, {"end": 15, "start": 11, "tag": "PharmacologicSubstance"}, {"end": 15, "start": 11, "tag": "Chemical"}, {"end": 15, "start": 11, "tag": "BiologicallyActiveSubstance"}, {"end": 74, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 0, "tag": "Finding"}, {"end": 42, "start": 33, "tag": "CellFunction"}]}{"id": "1386_9", "text": "This proteomic characterisation is to our knowledge the first to document the changes taking place in the CNS-proteome and its phosphorylation and glycosylation state in Cp-deficient mice.", "tags": [{"end": 31, "start": 5, "tag": "ResearchActivity"}, {"end": 109, "start": 106, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 51, "start": 42, "tag": "Finding"}, {"end": 187, "start": 170, "tag": "ExperimentalModelOfDisease"}, {"end": 160, "start": 147, "tag": "CellFunction"}, {"end": 142, "start": 127, "tag": "CellFunction"}, {"end": 118, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 118, "start": 110, "tag": "BiologicallyActiveSubstance"}]}{"id": "1387_0", "text": "The role of RNA binding proteins in regulating the phagocytic and cytokine-releasing functions of microglia is unknown.", "tags": [{"end": 32, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 107, "start": 98, "tag": "Cell"}, {"end": 94, "start": 66, "tag": "CellFunction"}, {"end": 32, "start": 12, "tag": "BiologicallyActiveSubstance"}]}{"id": "1387_1", "text": "Here, we show that microglia deficient for the QUAKING (QKI) RNA binding protein have increased proinflammatory cytokine release and defects in processing phagocytosed cargo.", "tags": [{"end": 54, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 56, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 61, "tag": "AminoAcidPeptideOrProtein"}, {"end": 80, "start": 61, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 155, "tag": "CellComponent"}, {"end": 28, "start": 19, "tag": "Cell"}, {"end": 128, "start": 86, "tag": "Finding"}, {"end": 173, "start": 133, "tag": "Finding"}, {"end": 128, "start": 112, "tag": "CellFunction"}, {"end": 54, "start": 19, "tag": "CellOrMolecularDysfunction"}]}{"id": "1387_2", "text": "Splicing analysis reveals a role for QKI in regulating microexon networks of the Rho GTPase pathway.", "tags": [{"end": 40, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 17, "start": 0, "tag": "ResearchActivity"}, {"end": 99, "start": 81, "tag": "CellFunction"}, {"end": 64, "start": 55, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 64, "start": 55, "tag": "BiologicallyActiveSubstance"}, {"end": 73, "start": 55, "tag": "CellFunction"}]}{"id": "1387_3", "text": "We show an increase in RhoA activation and proinflammatory cytokines in QKI-deficient microglia that are repressed by treating with a Rock kinase inhibitor.", "tags": [{"end": 27, "start": 23, "tag": "GeneOrGenome"}, {"end": 27, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 95, "start": 86, "tag": "Cell"}, {"end": 155, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 155, "start": 134, "tag": "PharmacologicSubstance"}, {"end": 68, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 95, "start": 72, "tag": "CellOrMolecularDysfunction"}, {"end": 27, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 38, "start": 23, "tag": "CellFunction"}]}{"id": "1387_4", "text": "During the cuprizone diet, mice with QKI-deficient microglia are inefficient at supporting central nervous system (CNS) remyelination and cause the recruited oligodendrocyte precursor cells to undergo apoptosis.", "tags": [{"end": 25, "start": 11, "tag": "HealthCareActivity"}, {"end": 133, "start": 120, "tag": "CellFunction"}, {"end": 189, "start": 158, "tag": "Cell"}, {"end": 118, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 27, "tag": "ExperimentalModelOfDisease"}, {"end": 113, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 210, "start": 201, "tag": "CellFunction"}, {"end": 60, "start": 51, "tag": "Cell"}]}{"id": "1387_5", "text": "Furthermore, the expression of QKI in microglia is downregulated in preactive, chronic active, and remyelinating white matter lesions of multiple sclerosis (MS) patients.", "tags": [{"end": 34, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 64, "start": 51, "tag": "CellFunction"}, {"end": 159, "start": 157, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 161, "tag": "PatientOrDisabledGroup"}, {"end": 155, "start": 137, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 113, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 38, "tag": "Cell"}, {"end": 34, "start": 17, "tag": "CellFunction"}, {"end": 133, "start": 68, "tag": "Finding"}]}{"id": "1387_6", "text": "Overall, our findings identify QKI as an alternative splicing regulator governing a network of Rho GTPase microexons with implications for CNS remyelination and MS patients.", "tags": [{"end": 34, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 95, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 95, "tag": "GeneOrGenome"}, {"end": 156, "start": 143, "tag": "CellFunction"}, {"end": 142, "start": 139, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 163, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 172, "start": 164, "tag": "PatientOrDisabledGroup"}, {"end": 116, "start": 106, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 116, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 41, "tag": "CellFunction"}, {"end": 105, "start": 95, "tag": "BiologicallyActiveSubstance"}]}{"id": "1388_0", "text": "Multiple sclerosis (MS) is an inflammatory demyelinating disorder in the central nervous system (CNS), in which remyelination failure results in persistent neurologic impairment.", "tags": [{"end": 125, "start": 112, "tag": "CellFunction"}, {"end": 133, "start": 112, "tag": "CellOrMolecularDysfunction"}, {"end": 177, "start": 145, "tag": "Finding"}, {"end": 100, "start": 97, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 65, "start": 30, "tag": "DiseaseOrSyndrome"}]}{"id": "1388_1", "text": "Ginkgolide B (GB), a major terpene lactone and active component of Ginkgo biloba, has neuroprotective effects in several models of neurological diseases.", "tags": [{"end": 12, "start": 0, "tag": "Chemical"}, {"end": 16, "start": 14, "tag": "Chemical"}, {"end": 80, "start": 67, "tag": "Organism"}, {"end": 127, "start": 121, "tag": "ResearchActivity"}, {"end": 109, "start": 86, "tag": "Finding"}, {"end": 152, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 27, "tag": "Chemical"}, {"end": 42, "start": 27, "tag": "BiologicallyActiveSubstance"}]}{"id": "1388_2", "text": "Here, our results show, by using an in vivo cuprizone (CPZ)-induced demyelinating model, administration of GB improved behavior abnormalities, promoted myelin generation, and significantly regulated the dynamic balance of microglia and astrocytes by inhibiting the expression of TLR4, NF-kappa B and iNOS as well as IL-1 beta and TNF-alpha, and up-regulating the expression of Arg-1 and neurotrophic factors.", "tags": [{"end": 53, "start": 44, "tag": "Chemical"}, {"end": 109, "start": 107, "tag": "Chemical"}, {"end": 141, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 152, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 158, "start": 152, "tag": "CellComponent"}, {"end": 218, "start": 203, "tag": "Finding"}, {"end": 283, "start": 279, "tag": "AminoAcidPeptideOrProtein"}, {"end": 283, "start": 279, "tag": "GeneOrGenome"}, {"end": 283, "start": 279, "tag": "BiologicallyActiveSubstance"}, {"end": 304, "start": 300, "tag": "AminoAcidPeptideOrProtein"}, {"end": 325, "start": 316, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 36, "tag": "ResearchActivity"}, {"end": 373, "start": 345, "tag": "CellFunction"}, {"end": 295, "start": 285, "tag": "AminoAcidPeptideOrProtein"}, {"end": 295, "start": 285, "tag": "GeneOrGenome"}, {"end": 295, "start": 285, "tag": "BiologicallyActiveSubstance"}, {"end": 231, "start": 222, "tag": "Cell"}, {"end": 246, "start": 236, "tag": "Cell"}, {"end": 275, "start": 250, "tag": "CellFunction"}, {"end": 407, "start": 387, "tag": "AminoAcidPeptideOrProtein"}, {"end": 407, "start": 387, "tag": "BiologicallyActiveSubstance"}, {"end": 339, "start": 330, "tag": "BiologicallyActiveSubstance"}, {"end": 339, "start": 330, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 55, "tag": "Chemical"}, {"end": 87, "start": 54, "tag": "ExperimentalModelOfDisease"}, {"end": 169, "start": 152, "tag": "CellFunction"}, {"end": 304, "start": 300, "tag": "BiologicallyActiveSubstance"}, {"end": 325, "start": 316, "tag": "BiologicallyActiveSubstance"}, {"end": 325, "start": 316, "tag": "PharmacologicSubstance"}, {"end": 382, "start": 377, "tag": "GeneOrGenome"}]}{"id": "1388_3", "text": "GB treatment also induced the generation of oligodendrocyte precursor cells (OPCs).", "tags": [{"end": 2, "start": 0, "tag": "Chemical"}, {"end": 75, "start": 30, "tag": "CellFunction"}, {"end": 75, "start": 44, "tag": "Cell"}, {"end": 81, "start": 77, "tag": "Cell"}, {"end": 12, "start": 3, "tag": "HealthCareActivity"}, {"end": 12, "start": 3, "tag": "ResearchActivity"}]}{"id": "1388_4", "text": "In vitro cell experiments yielded the results similar to those of the in vivo model.", "tags": [{"end": 25, "start": 9, "tag": "ResearchActivity"}, {"end": 83, "start": 70, "tag": "ResearchActivity"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}]}{"id": "1388_5", "text": "The dynamic balance by decreasing microglia-mediated neuroinflammation and promoting astrocyte-derived neurotrophic factors should contribute to endogenous remyelination.", "tags": [{"end": 19, "start": 4, "tag": "Finding"}, {"end": 33, "start": 23, "tag": "Finding"}, {"end": 169, "start": 156, "tag": "CellFunction"}, {"end": 70, "start": 53, "tag": "PathologicFunction"}, {"end": 43, "start": 34, "tag": "Cell"}, {"end": 123, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 85, "tag": "Cell"}]}{"id": "1388_6", "text": "Despite GB treatment may represent a novel strategy for promoting myelin recovery, the precise mechanism of GB targeting microglia and astrocytes remains to be further explored.", "tags": [{"end": 10, "start": 8, "tag": "Chemical"}, {"end": 72, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 66, "tag": "CellComponent"}, {"end": 81, "start": 73, "tag": "BiologicFunction"}, {"end": 81, "start": 73, "tag": "HealthCareActivity"}, {"end": 110, "start": 108, "tag": "Chemical"}, {"end": 20, "start": 11, "tag": "HealthCareActivity"}, {"end": 20, "start": 11, "tag": "ResearchActivity"}, {"end": 130, "start": 121, "tag": "Cell"}, {"end": 145, "start": 135, "tag": "Cell"}]}{"id": "1389_0", "text": "Recent studies have indicated oligodendroglial-vascular crosstalk during brain development, but the underlying mechanisms are incompletely understood.", "tags": [{"end": 65, "start": 56, "tag": "CellFunction"}, {"end": 90, "start": 73, "tag": "BiologicFunction"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}, {"end": 55, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 30, "tag": "Cell"}]}{"id": "1389_1", "text": "We report that oligodendrocyte precursor cells (OPCs) contact sprouting endothelial tip cells in mouse, ferret, and human neonatal white matter.", "tags": [{"end": 46, "start": 15, "tag": "Cell"}, {"end": 52, "start": 48, "tag": "Cell"}, {"end": 93, "start": 72, "tag": "Cell"}, {"end": 110, "start": 104, "tag": "Eukaryote"}, {"end": 130, "start": 122, "tag": "PopulationGroup"}, {"end": 130, "start": 122, "tag": "TemporalConcept"}, {"end": 121, "start": 116, "tag": "Eukaryote"}, {"end": 143, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 3, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "ResearchActivity"}, {"end": 102, "start": 97, "tag": "Eukaryote"}]}{"id": "1389_2", "text": "Using transgenic mice, we show that increased or decreased OPC density results in cognate changes in white matter vascular investment.", "tags": [{"end": 70, "start": 36, "tag": "Finding"}, {"end": 62, "start": 59, "tag": "Cell"}, {"end": 122, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 6, "tag": "ResearchActivity"}, {"end": 113, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1389_3", "text": "Hypoxia induced increases in OPC numbers, vessel density and endothelial cell expression of the Wnt pathway targets Apcdd1 and Axin2 in white matter, suggesting paracrine OPC-endothelial signaling.", "tags": [{"end": 7, "start": 0, "tag": "PathologicFunction"}, {"end": 32, "start": 29, "tag": "Cell"}, {"end": 77, "start": 61, "tag": "Cell"}, {"end": 107, "start": 96, "tag": "CellFunction"}, {"end": 122, "start": 116, "tag": "GeneOrGenome"}, {"end": 132, "start": 127, "tag": "GeneOrGenome"}, {"end": 132, "start": 127, "tag": "AminoAcidPeptideOrProtein"}, {"end": 148, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 40, "start": 16, "tag": "Finding"}, {"end": 56, "start": 42, "tag": "HealthCareActivity"}, {"end": 122, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 122, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 132, "start": 127, "tag": "BiologicallyActiveSubstance"}, {"end": 196, "start": 161, "tag": "CellFunction"}]}{"id": "1389_4", "text": "Conditional knockout of OPC Wntless resulted in diminished white matter vascular growth in normoxia, whereas loss of Wnt7a/b function blunted the angiogenic response to hypoxia, resulting in severe white matter damage.", "tags": [{"end": 35, "start": 0, "tag": "ExperimentalModelOfDisease"}, {"end": 165, "start": 146, "tag": "BiologicFunction"}, {"end": 176, "start": 169, "tag": "PathologicFunction"}, {"end": 80, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 217, "start": 191, "tag": "Finding"}, {"end": 71, "start": 59, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 210, "start": 198, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 81, "tag": "BiologicFunction"}, {"end": 99, "start": 91, "tag": "Finding"}, {"end": 133, "start": 109, "tag": "CellOrMolecularDysfunction"}]}{"id": "1389_5", "text": "These findings indicate that OPC-endothelial cell interactions regulate neonatal white matter vascular development in a Wnt-dependent manner and further suggest this mechanism is important in attenuating hypoxic injury.", "tags": [{"end": 80, "start": 72, "tag": "PopulationGroup"}, {"end": 80, "start": 72, "tag": "TemporalConcept"}, {"end": 114, "start": 94, "tag": "BiologicFunction"}, {"end": 218, "start": 204, "tag": "InjuryOrPoisoning"}, {"end": 62, "start": 29, "tag": "CellFunction"}, {"end": 93, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 120, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 120, "tag": "BiologicallyActiveSubstance"}]}{"id": "1390_0", "text": "NOD mice represent a unique strain that recapitulates some aspects of progressive MS when subjected to experimental autoimmune encephalomyelitis (EAE).", "tags": [{"end": 144, "start": 103, "tag": "ExperimentalModelOfDisease"}, {"end": 149, "start": 146, "tag": "ExperimentalModelOfDisease"}, {"end": 84, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "ExperimentalModelOfDisease"}]}{"id": "1390_1", "text": "It is unknown, however, whether a proneness to demyelination and/or defect in remyelination contribute to disease progression in NOD mice.", "tags": [{"end": 91, "start": 68, "tag": "CellOrMolecularDysfunction"}, {"end": 125, "start": 106, "tag": "PathologicFunction"}, {"end": 60, "start": 47, "tag": "PathologicFunction"}, {"end": 137, "start": 129, "tag": "ExperimentalModelOfDisease"}]}{"id": "1390_2", "text": "Answering to this question might help deciphering the molecular and cellular events underpinning disease evolution in progressive MS.", "tags": [{"end": 114, "start": 97, "tag": "PathologicFunction"}, {"end": 132, "start": 118, "tag": "DiseaseOrSyndrome"}]}{"id": "1390_3", "text": "Here, we compared the cuprizone-dependent demyelination and remyelination responses, as well as their functional correlates, in NOD, C57BL/6, and SJL mice typically adopted to model progressive, chronic or relapsing EAE.", "tags": [{"end": 73, "start": 60, "tag": "CellFunction"}, {"end": 215, "start": 206, "tag": "TemporalConcept"}, {"end": 219, "start": 216, "tag": "ExperimentalModelOfDisease"}, {"end": 55, "start": 42, "tag": "PathologicFunction"}, {"end": 202, "start": 195, "tag": "TemporalConcept"}, {"end": 193, "start": 182, "tag": "TemporalConcept"}, {"end": 31, "start": 22, "tag": "Chemical"}, {"end": 154, "start": 146, "tag": "Eukaryote"}, {"end": 154, "start": 150, "tag": "ExperimentalModelOfDisease"}, {"end": 131, "start": 128, "tag": "ExperimentalModelOfDisease"}, {"end": 154, "start": 150, "tag": "Eukaryote"}, {"end": 140, "start": 133, "tag": "Eukaryote"}]}{"id": "1390_4", "text": "We report that demyelination occurred to a similar extent in the three mice strains, and that in none of them there was evidence of axonal degeneration during prolonged demyelination.", "tags": [{"end": 168, "start": 159, "tag": "TemporalConcept"}, {"end": 128, "start": 120, "tag": "Finding"}, {"end": 83, "start": 71, "tag": "Eukaryote"}, {"end": 151, "start": 132, "tag": "CellOrMolecularDysfunction"}, {"end": 9, "start": 3, "tag": "HealthCareActivity"}, {"end": 9, "start": 3, "tag": "ResearchActivity"}, {"end": 28, "start": 15, "tag": "PathologicFunction"}, {"end": 182, "start": 169, "tag": "PathologicFunction"}]}{"id": "1390_5", "text": "Moreover, immunostaining for GFAP(+) astrocytes, Iba1(+) microglia, and NG2(+) oligodendrocyte precursor cells similarly increased in the 3 mouse strains after cuprizone exposure.", "tags": [{"end": 110, "start": 79, "tag": "Cell"}, {"end": 169, "start": 160, "tag": "Chemical"}, {"end": 66, "start": 57, "tag": "Cell"}, {"end": 47, "start": 37, "tag": "Cell"}, {"end": 24, "start": 10, "tag": "ResearchActivity"}, {"end": 33, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 29, "tag": "GeneOrGenome"}, {"end": 33, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 49, "tag": "AminoAcidPeptideOrProtein"}, {"end": 53, "start": 49, "tag": "BiologicallyActiveSubstance"}, {"end": 75, "start": 72, "tag": "AminoAcidPeptideOrProtein"}, {"end": 75, "start": 72, "tag": "BiologicallyActiveSubstance"}, {"end": 178, "start": 160, "tag": "HealthCareActivity"}, {"end": 178, "start": 160, "tag": "ResearchActivity"}]}{"id": "1390_6", "text": "The mice underwent concomitant and complete remyelination 2 weeks after cuprizone withdrawal.", "tags": [{"end": 30, "start": 19, "tag": "TemporalConcept"}, {"end": 57, "start": 44, "tag": "CellFunction"}, {"end": 71, "start": 58, "tag": "TemporalConcept"}, {"end": 81, "start": 72, "tag": "Chemical"}, {"end": 92, "start": 72, "tag": "ResearchActivity"}, {"end": 8, "start": 4, "tag": "Eukaryote"}, {"end": 92, "start": 72, "tag": "HealthCareActivity"}]}{"id": "1390_7", "text": "On a functional level, NOD mice showed the earliest reduction of spontaneous motility and full recovery, but no impairment of motor skill.", "tags": [{"end": 103, "start": 95, "tag": "BiologicFunction"}, {"end": 103, "start": 95, "tag": "HealthCareActivity"}, {"end": 137, "start": 109, "tag": "Finding"}, {"end": 137, "start": 126, "tag": "BiologicFunction"}, {"end": 51, "start": 43, "tag": "TemporalConcept"}, {"end": 31, "start": 23, "tag": "ExperimentalModelOfDisease"}, {"end": 85, "start": 52, "tag": "Finding"}]}{"id": "1390_8", "text": "Conversely, C57BL/6 animals showed phasic reduction of both spontaneous motility and motor skill.", "tags": [{"end": 80, "start": 72, "tag": "BiologicFunction"}, {"end": 96, "start": 85, "tag": "BiologicFunction"}, {"end": 51, "start": 35, "tag": "Finding"}, {"end": 27, "start": 12, "tag": "Eukaryote"}, {"end": 80, "start": 72, "tag": "CellFunction"}]}{"id": "1390_9", "text": "Lastly, SJL mice presented the most severe neurological impairment with long-lasting reduction of spontaneous motility and motor skill.", "tags": [{"end": 66, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 110, "tag": "CellFunction"}, {"end": 118, "start": 110, "tag": "BiologicFunction"}, {"end": 134, "start": 123, "tag": "BiologicFunction"}, {"end": 16, "start": 8, "tag": "Eukaryote"}, {"end": 94, "start": 85, "tag": "Finding"}, {"end": 94, "start": 85, "tag": "NaturalPhenomenonOrProcess"}, {"end": 66, "start": 36, "tag": "Finding"}, {"end": 6, "start": 0, "tag": "TemporalConcept"}, {"end": 84, "start": 72, "tag": "TemporalConcept"}]}{"id": "1390_10", "text": "Overall, data suggest that the unique feature of EAE progression in NOD mice is not due to proneness to demyelination or intrinsic defects in myelin formation.", "tags": [{"end": 52, "start": 49, "tag": "ExperimentalModelOfDisease"}, {"end": 148, "start": 142, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 148, "start": 142, "tag": "CellComponent"}, {"end": 64, "start": 53, "tag": "PathologicFunction"}, {"end": 64, "start": 53, "tag": "TemporalConcept"}, {"end": 13, "start": 9, "tag": "ResearchActivity"}, {"end": 117, "start": 104, "tag": "PathologicFunction"}, {"end": 76, "start": 68, "tag": "ExperimentalModelOfDisease"}, {"end": 158, "start": 121, "tag": "CellOrMolecularDysfunction"}]}{"id": "1390_11", "text": "Findings also unravel important functional differences in the response of the three mouse stains to cuprizone that can be harnessed to design and interpret future experiments.", "tags": [{"end": 109, "start": 100, "tag": "Chemical"}, {"end": 174, "start": 163, "tag": "ResearchActivity"}, {"end": 162, "start": 156, "tag": "TemporalConcept"}, {"end": 54, "start": 43, "tag": "Finding"}, {"end": 96, "start": 84, "tag": "Eukaryote"}]}{"id": "1391_0", "text": "Demyelination occurs in response to brain injury and is observed in many neurodegenerative diseases.", "tags": [{"end": 48, "start": 36, "tag": "InjuryOrPoisoning"}, {"end": 13, "start": 0, "tag": "PathologicFunction"}, {"end": 99, "start": 73, "tag": "DiseaseOrSyndrome"}]}{"id": "1391_1", "text": "Myelin is synthesized from oligodendrocytes in the central nervous system, and oligodendrocyte death-induced demyelination is one of the mechanisms involved in white matter damage after stroke and neurodegeneration.", "tags": [{"end": 192, "start": 186, "tag": "DiseaseOrSyndrome"}, {"end": 43, "start": 27, "tag": "Cell"}, {"end": 172, "start": 160, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 100, "start": 95, "tag": "BiologicFunction"}, {"end": 100, "start": 95, "tag": "PathologicFunction"}, {"end": 100, "start": 95, "tag": "CellFunction"}, {"end": 214, "start": 197, "tag": "CellOrMolecularDysfunction"}, {"end": 94, "start": 79, "tag": "Cell"}, {"end": 122, "start": 109, "tag": "PathologicFunction"}]}{"id": "1391_2", "text": "Oligodendrocyte precursor cells (OPCs) exist in the brain of normal adults, and their differentiation into mature oligodendrocytes play a central role in remyelination.", "tags": [{"end": 74, "start": 68, "tag": "PopulationGroup"}, {"end": 130, "start": 114, "tag": "Cell"}, {"end": 37, "start": 33, "tag": "Cell"}, {"end": 130, "start": 107, "tag": "Cell"}, {"end": 101, "start": 86, "tag": "CellFunction"}, {"end": 113, "start": 107, "tag": "TemporalConcept"}, {"end": 31, "start": 16, "tag": "Cell"}, {"end": 31, "start": 0, "tag": "Cell"}, {"end": 15, "start": 0, "tag": "Cell"}, {"end": 57, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 67, "start": 61, "tag": "Finding"}, {"end": 167, "start": 154, "tag": "CellFunction"}]}{"id": "1391_3", "text": "Although the differentiation and maturity of OPCs drive endogenous efforts for remyelination, the failure of axons to remyelinate is still the biggest obstacle to brain repair after injury or diseases.", "tags": [{"end": 41, "start": 33, "tag": "TemporalConcept"}, {"end": 175, "start": 163, "tag": "HealthCareActivity"}, {"end": 114, "start": 109, "tag": "CellComponent"}, {"end": 49, "start": 45, "tag": "Cell"}, {"end": 129, "start": 118, "tag": "CellFunction"}, {"end": 28, "start": 13, "tag": "CellFunction"}, {"end": 105, "start": 98, "tag": "IndividualBehavior"}, {"end": 188, "start": 182, "tag": "InjuryOrPoisoning"}, {"end": 92, "start": 79, "tag": "CellFunction"}, {"end": 175, "start": 169, "tag": "BiologicFunction"}, {"end": 175, "start": 169, "tag": "HealthCareActivity"}]}{"id": "1391_4", "text": "In recent years, studies have made attempts to promote remyelination after brain injury and disease, but its cellular or molecular mechanism is not yet fully understood.", "tags": [{"end": 87, "start": 75, "tag": "InjuryOrPoisoning"}, {"end": 140, "start": 121, "tag": "CellFunction"}, {"end": 54, "start": 47, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 24, "start": 17, "tag": "ResearchActivity"}, {"end": 15, "start": 10, "tag": "TemporalConcept"}, {"end": 15, "start": 3, "tag": "TemporalConcept"}, {"end": 117, "start": 109, "tag": "Cell"}, {"end": 68, "start": 55, "tag": "CellFunction"}]}{"id": "1391_5", "text": "In this review, we discuss recent studies examining the demyelination process and potential therapeutic strategies for remyelination in aging and stroke.", "tags": [{"end": 114, "start": 82, "tag": "HealthCareActivity"}, {"end": 152, "start": 146, "tag": "DiseaseOrSyndrome"}, {"end": 14, "start": 8, "tag": "ResearchActivity"}, {"end": 14, "start": 8, "tag": "HealthCareActivity"}, {"end": 41, "start": 34, "tag": "ResearchActivity"}, {"end": 114, "start": 104, "tag": "ResearchActivity"}, {"end": 114, "start": 104, "tag": "BiologicFunction"}, {"end": 33, "start": 27, "tag": "TemporalConcept"}, {"end": 132, "start": 119, "tag": "CellFunction"}, {"end": 69, "start": 56, "tag": "PathologicFunction"}, {"end": 141, "start": 136, "tag": "BiologicFunction"}, {"end": 141, "start": 136, "tag": "CellFunction"}, {"end": 114, "start": 92, "tag": "HealthCareActivity"}]}{"id": "1391_6", "text": "Based on our current understanding of the cellular and molecular mechanisms underlying remyelination, we hypothesize that myelin and oligodendrocytes are viable therapeutic targets to mitigate brain injury and to treat demyelinating-related neurodegeneration diseases.", "tags": [{"end": 205, "start": 193, "tag": "InjuryOrPoisoning"}, {"end": 149, "start": 133, "tag": "Cell"}, {"end": 232, "start": 219, "tag": "PathologicFunction"}, {"end": 128, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 180, "start": 161, "tag": "ResearchActivity"}, {"end": 20, "start": 13, "tag": "TemporalConcept"}, {"end": 258, "start": 241, "tag": "CellOrMolecularDysfunction"}, {"end": 34, "start": 21, "tag": "BiologicFunction"}, {"end": 50, "start": 42, "tag": "Cell"}, {"end": 100, "start": 87, "tag": "CellFunction"}, {"end": 75, "start": 55, "tag": "CellFunction"}]}{"id": "1392_0", "text": "Sphingosine-1-phosphate receptor 1 (S1PR1) is ubiquitously expressed among all tissues and plays key roles in many physiological and cellular processes.", "tags": [{"end": 34, "start": 0, "tag": "GeneOrGenome"}, {"end": 34, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 36, "tag": "GeneOrGenome"}, {"end": 41, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 86, "start": 79, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 133, "tag": "CellFunction"}, {"end": 68, "start": 46, "tag": "CellFunction"}]}{"id": "1392_1", "text": "In the central nervous system (CNS), S1PR1 is expressed in different types of cells including neurons, astrocytes, and oligodendrocyte precursor cells.", "tags": [{"end": 42, "start": 37, "tag": "GeneOrGenome"}, {"end": 42, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 42, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 150, "start": 119, "tag": "Cell"}, {"end": 83, "start": 78, "tag": "Cell"}, {"end": 34, "start": 31, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 94, "tag": "Cell"}, {"end": 113, "start": 103, "tag": "Cell"}]}{"id": "1392_2", "text": "S1PR1 has been recognized as a novel therapeutic target in multiple sclerosis and other diseases.", "tags": [{"end": 5, "start": 0, "tag": "GeneOrGenome"}, {"end": 5, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 5, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 77, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 31, "tag": "Finding"}]}{"id": "1392_3", "text": "We previously reported a promising S1PR1-specific radioligand, [C-11]CS1P1 (previously named [C-11]TZ3321), which is under clinical investigation for human use.", "tags": [{"end": 155, "start": 150, "tag": "Eukaryote"}, {"end": 145, "start": 123, "tag": "ResearchActivity"}, {"end": 61, "start": 35, "tag": "Chemical"}, {"end": 74, "start": 63, "tag": "Chemical"}, {"end": 105, "start": 93, "tag": "Chemical"}]}{"id": "1392_4", "text": "In the current study, we performed a detailed characterization of [H-3]CS1P1 for its binding specificity to S1PR1 in CNS using autoradiography and immunohistochemistry in human and rat CNS tissues.", "tags": [{"end": 113, "start": 108, "tag": "GeneOrGenome"}, {"end": 113, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 113, "start": 108, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 127, "tag": "ResearchActivity"}, {"end": 184, "start": 181, "tag": "Eukaryote"}, {"end": 196, "start": 189, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 15, "tag": "ResearchActivity"}, {"end": 62, "start": 46, "tag": "ResearchActivity"}, {"end": 120, "start": 117, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 188, "start": 185, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 14, "start": 7, "tag": "TemporalConcept"}, {"end": 176, "start": 171, "tag": "Eukaryote"}, {"end": 167, "start": 147, "tag": "ResearchActivity"}, {"end": 76, "start": 66, "tag": "Chemical"}, {"end": 104, "start": 85, "tag": "ResearchActivity"}]}{"id": "1392_5", "text": "Our data indicate that [H-3]CS1P1 binds to S1PR1 in human frontal cortex tissue with a K-d of 3.98 nM and a B-max of 172.5 nM.", "tags": [{"end": 39, "start": 34, "tag": "CellFunction"}, {"end": 48, "start": 43, "tag": "GeneOrGenome"}, {"end": 48, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 48, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 72, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 73, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 8, "start": 4, "tag": "ResearchActivity"}, {"end": 57, "start": 52, "tag": "Eukaryote"}, {"end": 33, "start": 23, "tag": "Chemical"}]}{"id": "1392_6", "text": "The distribution of [H-3]CS1P1 in human and rat CNS tissues is consistent with the distribution of S1PR1 detected by immunohistochemistry studies.", "tags": [{"end": 47, "start": 44, "tag": "Eukaryote"}, {"end": 59, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 99, "tag": "GeneOrGenome"}, {"end": 104, "start": 99, "tag": "AminoAcidPeptideOrProtein"}, {"end": 104, "start": 99, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 138, "tag": "ResearchActivity"}, {"end": 39, "start": 34, "tag": "Eukaryote"}, {"end": 137, "start": 117, "tag": "ResearchActivity"}, {"end": 30, "start": 20, "tag": "Chemical"}]}{"id": "1392_7", "text": "Our microPET studies of [C-11]CS1P1 in a nonhuman primate (NHP) show a standardized uptake value of 2.4 in the NHP brain, with test-retest variability of 0.23% among six different NHPs.", "tags": [{"end": 150, "start": 127, "tag": "ResearchActivity"}, {"end": 120, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 13, "tag": "ResearchActivity"}, {"end": 57, "start": 41, "tag": "Eukaryote"}, {"end": 62, "start": 59, "tag": "Eukaryote"}, {"end": 114, "start": 111, "tag": "Eukaryote"}, {"end": 184, "start": 180, "tag": "Eukaryote"}, {"end": 12, "start": 4, "tag": "ManufacturedObject"}, {"end": 35, "start": 24, "tag": "Chemical"}]}{"id": "1392_8", "text": "Radiometabolite analysis in the plasma samples of NHP and rat, as well as in rat brain samples, showed that [C-11]CS1P1 was stable in vivo.", "tags": [{"end": 61, "start": 58, "tag": "Eukaryote"}, {"end": 80, "start": 77, "tag": "Eukaryote"}, {"end": 86, "start": 81, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 24, "start": 16, "tag": "ResearchActivity"}, {"end": 138, "start": 131, "tag": "ResearchActivity"}, {"end": 38, "start": 32, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 50, "tag": "Eukaryote"}, {"end": 119, "start": 108, "tag": "Chemical"}, {"end": 15, "start": 0, "tag": "Chemical"}]}{"id": "1392_9", "text": "Kinetic modeling studies using a two-compartment tissue model showed that the positron emission tomography (PET) data fit the model well.", "tags": [{"end": 106, "start": 78, "tag": "HealthCareActivity"}, {"end": 106, "start": 78, "tag": "ManufacturedObject"}, {"end": 111, "start": 108, "tag": "HealthCareActivity"}, {"end": 117, "start": 113, "tag": "ResearchActivity"}, {"end": 24, "start": 0, "tag": "ResearchActivity"}, {"end": 61, "start": 33, "tag": "ResearchActivity"}]}{"id": "1392_10", "text": "Overall, our study provides a detailed characterization of [H-3]CS1P1 binding to S1PR1 in the CNS.", "tags": [{"end": 77, "start": 70, "tag": "CellFunction"}, {"end": 86, "start": 81, "tag": "GeneOrGenome"}, {"end": 86, "start": 81, "tag": "AminoAcidPeptideOrProtein"}, {"end": 86, "start": 81, "tag": "CellFunction"}, {"end": 18, "start": 13, "tag": "ResearchActivity"}, {"end": 55, "start": 39, "tag": "ResearchActivity"}, {"end": 97, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 59, "tag": "Chemical"}]}{"id": "1392_11", "text": "Combined with our microPET studies in the NHP brain, our data suggest that [C-11]CS1P1 is a promising radioligand for PET imaging of S1PR1 in the CNS.", "tags": [{"end": 113, "start": 102, "tag": "Chemical"}, {"end": 129, "start": 118, "tag": "HealthCareActivity"}, {"end": 138, "start": 133, "tag": "GeneOrGenome"}, {"end": 138, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 46, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 149, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 61, "start": 57, "tag": "ResearchActivity"}, {"end": 34, "start": 27, "tag": "ResearchActivity"}, {"end": 26, "start": 18, "tag": "ManufacturedObject"}, {"end": 45, "start": 42, "tag": "Eukaryote"}, {"end": 86, "start": 75, "tag": "Chemical"}]}{"id": "1393_0", "text": "The subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate gyrus in the hippocampus are known as neurogenic niches.", "tags": [{"end": 23, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 55, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 126, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 85, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 157, "start": 140, "tag": "Finding"}]}{"id": "1393_1", "text": "We show that the median eminence (ME) of the hypothalamus comprises BrdU(+) newly proliferating cells co-expressing NG2 (oligodendrocyte progenitors) and RIP (pre-myelinating oligodendrocytes), suggesting their differentiation toward mature oligodendrocytes (OLs).", "tags": [{"end": 32, "start": 17, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 36, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 57, "start": 45, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 119, "start": 116, "tag": "GeneOrGenome"}, {"end": 148, "start": 121, "tag": "Cell"}, {"end": 157, "start": 154, "tag": "AminoAcidPeptideOrProtein"}, {"end": 157, "start": 154, "tag": "GeneOrGenome"}, {"end": 191, "start": 159, "tag": "Cell"}, {"end": 257, "start": 234, "tag": "Cell"}, {"end": 262, "start": 259, "tag": "Cell"}, {"end": 101, "start": 76, "tag": "Cell"}, {"end": 226, "start": 211, "tag": "CellFunction"}, {"end": 72, "start": 68, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 72, "start": 68, "tag": "PharmacologicSubstance"}, {"end": 119, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 119, "start": 116, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 154, "tag": "BiologicallyActiveSubstance"}]}{"id": "1393_2", "text": "ME cells can generate neurospheres (NS) in vitro, which differentiate mostly to OLs compared with SVZ-NS that typically generate neurons.", "tags": [{"end": 8, "start": 0, "tag": "Cell"}, {"end": 83, "start": 80, "tag": "Cell"}, {"end": 136, "start": 129, "tag": "Cell"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 34, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 38, "start": 36, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 98, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 102, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1393_3", "text": "Interestingly, this population of oligodendrocyte progenitors is increased in the ME from experimental autoimmune encephalomyelitis (EAE)-affected mice.", "tags": [{"end": 61, "start": 34, "tag": "Cell"}, {"end": 84, "start": 82, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 90, "tag": "ExperimentalModelOfDisease"}, {"end": 30, "start": 20, "tag": "PopulationGroup"}, {"end": 151, "start": 132, "tag": "ExperimentalModelOfDisease"}, {"end": 136, "start": 133, "tag": "ExperimentalModelOfDisease"}]}{"id": "1393_4", "text": "Notably, the thrombospondin 1 (TSP1) expressed by astrocytes, acts as negative regulator of oligodendrogenesis in vitro and is downregulated in the ME of EAE mice.", "tags": [{"end": 29, "start": 13, "tag": "AminoAcidPeptideOrProtein"}, {"end": 29, "start": 13, "tag": "GeneOrGenome"}, {"end": 35, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 31, "tag": "GeneOrGenome"}, {"end": 110, "start": 70, "tag": "CellFunction"}, {"end": 150, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 154, "tag": "ExperimentalModelOfDisease"}, {"end": 119, "start": 111, "tag": "ResearchActivity"}, {"end": 60, "start": 50, "tag": "Cell"}, {"end": 110, "start": 92, "tag": "BiologicFunction"}, {"end": 29, "start": 13, "tag": "BiologicallyActiveSubstance"}, {"end": 35, "start": 31, "tag": "BiologicallyActiveSubstance"}]}{"id": "1393_5", "text": "Importantly, transplanted ME-NS preferentially differentiate to MBP+ OLs compared with SVZ-NS in Shiverer mice.", "tags": [{"end": 72, "start": 69, "tag": "Cell"}, {"end": 28, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 31, "start": 13, "tag": "HealthCareActivity"}, {"end": 67, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 67, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 64, "tag": "GeneOrGenome"}, {"end": 90, "start": 87, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 110, "start": 97, "tag": "ExperimentalModelOfDisease"}]}{"id": "1393_6", "text": "Hence, discovering the ME as a new site for myelin-producing cells has a great importance for advising future therapy for demyelinating diseases and spinal cord injury.", "tags": [{"end": 25, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 144, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 66, "start": 44, "tag": "Cell"}, {"end": 109, "start": 103, "tag": "TemporalConcept"}, {"end": 117, "start": 110, "tag": "HealthCareActivity"}, {"end": 167, "start": 149, "tag": "InjuryOrPoisoning"}, {"end": 160, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1394_0", "text": "Gap junctions (GJs) are specialized transmembrane channels assembled by two hemichannels of six connexin (Cx) proteins that facilitate neuroglial crosstalk in the central nervous system (CNS).", "tags": [{"end": 13, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 18, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 96, "tag": "AminoAcidPeptideOrProtein"}, {"end": 145, "start": 135, "tag": "Cell"}, {"end": 155, "start": 135, "tag": "CellFunction"}, {"end": 190, "start": 187, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 185, "start": 163, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 36, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 76, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 36, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 76, "tag": "BiologicallyActiveSubstance"}]}{"id": "1394_1", "text": "Previous studies confirmed the crucial role of glial GJs in neurodegenerative disorders with dementia or motor dysfunction including Alzheimer's disease (AD).", "tags": [{"end": 52, "start": 47, "tag": "Cell"}, {"end": 56, "start": 53, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 60, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 9, "tag": "ResearchActivity"}, {"end": 156, "start": 154, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "TemporalConcept"}, {"end": 101, "start": 93, "tag": "DiseaseOrSyndrome"}, {"end": 122, "start": 105, "tag": "DiseaseOrSyndrome"}]}{"id": "1394_2", "text": "The aim of this study was to examine the alterations in astrocyte and related oligodendrocyte GJs in association with A beta plaques in the spinal cord of the 5xFAD mouse model of AD.", "tags": [{"end": 65, "start": 56, "tag": "Cell"}, {"end": 93, "start": 78, "tag": "Cell"}, {"end": 97, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 140, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 182, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 118, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 118, "tag": "PathologicFunction"}, {"end": 182, "start": 159, "tag": "ExperimentalModelOfDisease"}]}{"id": "1394_3", "text": "Our analysis revealed abundant A beta plaque deposition, activated microglia, and astrogliosis in 12-month-old (12M) 5xFAD mice, with significant impairment of motor performance starting from 3-months (3M) of age.", "tags": [{"end": 212, "start": 209, "tag": "OrganismAttribute"}, {"end": 12, "start": 4, "tag": "ResearchActivity"}, {"end": 177, "start": 160, "tag": "ClinicalAttribute"}, {"end": 76, "start": 67, "tag": "Cell"}, {"end": 94, "start": 82, "tag": "PathologicFunction"}, {"end": 200, "start": 194, "tag": "TemporalConcept"}, {"end": 44, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 31, "tag": "PathologicFunction"}, {"end": 110, "start": 98, "tag": "PopulationGroup"}, {"end": 127, "start": 117, "tag": "ExperimentalModelOfDisease"}, {"end": 156, "start": 134, "tag": "Finding"}]}{"id": "1394_4", "text": "Additionally, 12M 5xFAD mice displayed increased immunoreactivity of astroglial Cx43 and Cx30 surrounding A beta plaques and higher protein levels, indicating upregulated astrocyte-to-astrocyte GJ connectivity.", "tags": [{"end": 65, "start": 49, "tag": "CellFunction"}, {"end": 79, "start": 69, "tag": "Cell"}, {"end": 84, "start": 80, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 106, "tag": "PathologicFunction"}, {"end": 28, "start": 18, "tag": "ExperimentalModelOfDisease"}, {"end": 93, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 209, "start": 194, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 93, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 84, "start": 80, "tag": "BiologicallyActiveSubstance"}, {"end": 180, "start": 171, "tag": "Cell"}, {"end": 193, "start": 184, "tag": "Cell"}]}{"id": "1394_5", "text": "In addition, they demonstrated increased numbers of mature CC1-positive and precursor oligodendrocytes (OPCs) with higher immunoreactivity of Cx47-positive GJs in individual cells.", "tags": [{"end": 58, "start": 52, "tag": "TemporalConcept"}, {"end": 102, "start": 76, "tag": "Cell"}, {"end": 138, "start": 122, "tag": "CellFunction"}, {"end": 159, "start": 156, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 179, "start": 174, "tag": "Cell"}, {"end": 108, "start": 104, "tag": "Cell"}, {"end": 146, "start": 142, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 142, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 59, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 59, "tag": "BiologicallyActiveSubstance"}]}{"id": "1394_6", "text": "Moreover, total Cx47 protein levels were significantly elevated in 12M 5xFAD, reflecting increased oligodendrocyte-tooligodendrocyte Cx47-Cx47 GJ connectivity.", "tags": [{"end": 28, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 16, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 71, "tag": "ExperimentalModelOfDisease"}, {"end": 114, "start": 99, "tag": "Cell"}, {"end": 132, "start": 117, "tag": "Cell"}, {"end": 158, "start": 143, "tag": "CellFunction"}, {"end": 137, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 137, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 142, "start": 138, "tag": "AminoAcidPeptideOrProtein"}, {"end": 142, "start": 138, "tag": "BiologicallyActiveSubstance"}]}{"id": "1394_7", "text": "In contrast, we observed a marked reduction in Cx32 protein levels in 12M 5xFAD spinal cords compared with controls, while qRT-PCR analysis revealed a significant upregulation in Cx32 mRNA levels.", "tags": [{"end": 92, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 130, "start": 123, "tag": "ResearchActivity"}, {"end": 115, "start": 107, "tag": "PopulationGroup"}, {"end": 139, "start": 131, "tag": "ResearchActivity"}, {"end": 43, "start": 27, "tag": "Finding"}, {"end": 59, "start": 47, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 47, "tag": "BiologicallyActiveSubstance"}, {"end": 188, "start": 179, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 188, "start": 179, "tag": "BiologicallyActiveSubstance"}, {"end": 79, "start": 74, "tag": "ExperimentalModelOfDisease"}, {"end": 175, "start": 151, "tag": "Finding"}]}{"id": "1394_8", "text": "Finally, myelin deficits were found focally in the areas occupied by A beta plaques, whereas axons themselves remained preserved.", "tags": [{"end": 15, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 15, "start": 9, "tag": "CellComponent"}, {"end": 98, "start": 93, "tag": "CellComponent"}, {"end": 83, "start": 69, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 69, "tag": "PathologicFunction"}, {"end": 24, "start": 9, "tag": "CellOrMolecularDysfunction"}]}{"id": "1394_9", "text": "Overall, our data provide novel insights into the altered glial GJ expression in the spinal cord of the 5xFAD model of AD and the implicated role of GJ pathology in neurodegeneration.", "tags": [{"end": 63, "start": 58, "tag": "Cell"}, {"end": 96, "start": 85, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 161, "start": 149, "tag": "PathologicFunction"}, {"end": 17, "start": 13, "tag": "ResearchActivity"}, {"end": 182, "start": 165, "tag": "CellOrMolecularDysfunction"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 64, "tag": "CellFunction"}, {"end": 66, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 104, "tag": "ExperimentalModelOfDisease"}]}{"id": "1394_10", "text": "Further investigation to understand the functional consequences of these extensive alterations in oligodendrocyte-astrocyte (O/A) GJ connectivity is warranted.", "tags": [{"end": 94, "start": 73, "tag": "Finding"}, {"end": 21, "start": 8, "tag": "ResearchActivity"}, {"end": 145, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 98, "tag": "Cell"}, {"end": 123, "start": 114, "tag": "Cell"}]}{"id": "1395_0", "text": "Myelin is essential to nervous system function, playing roles in saltatory conduction and trophic support.", "tags": [{"end": 6, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 23, "tag": "BiologicFunction"}, {"end": 85, "start": 65, "tag": "BiologicFunction"}, {"end": 105, "start": 90, "tag": "CellFunction"}]}{"id": "1395_1", "text": "Oligodendrocytes (OLs) and Schwann cells (SCs) form myelin in the central and peripheral nervous systems respectively and follow different developmental paths.", "tags": [{"end": 16, "start": 0, "tag": "Cell"}, {"end": 21, "start": 18, "tag": "Cell"}, {"end": 40, "start": 27, "tag": "Cell"}, {"end": 45, "start": 42, "tag": "Cell"}, {"end": 58, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 58, "start": 52, "tag": "CellComponent"}, {"end": 104, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 139, "tag": "BiologicFunction"}, {"end": 152, "start": 139, "tag": "TemporalConcept"}]}{"id": "1395_2", "text": "OLs are neural stem-cell derived and follow an intrinsic developmental program resulting in a largely irreversible differentiation state.", "tags": [{"end": 3, "start": 0, "tag": "Cell"}, {"end": 78, "start": 57, "tag": "BiologicFunction"}, {"end": 136, "start": 115, "tag": "CellFunction"}, {"end": 24, "start": 8, "tag": "Cell"}]}{"id": "1395_3", "text": "During embryonic development, OL precursor cells (OPCs) are produced in distinct waves originating from different locations in the central nervous system, with a subset developing into myelinating OLs.", "tags": [{"end": 48, "start": 30, "tag": "Cell"}, {"end": 54, "start": 50, "tag": "Cell"}, {"end": 86, "start": 81, "tag": "NaturalPhenomenonOrProcess"}, {"end": 200, "start": 185, "tag": "Cell"}, {"end": 153, "start": 131, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 7, "tag": "BiologicFunction"}]}{"id": "1395_4", "text": "OPCs remain evenly distributed throughout life, providing a population of responsive, multifunctional cells with the capacity to remyelinate after injury.", "tags": [{"end": 4, "start": 0, "tag": "Cell"}, {"end": 46, "start": 42, "tag": "TemporalConcept"}, {"end": 140, "start": 129, "tag": "CellFunction"}, {"end": 107, "start": 102, "tag": "Cell"}, {"end": 70, "start": 60, "tag": "PopulationGroup"}, {"end": 153, "start": 147, "tag": "InjuryOrPoisoning"}]}{"id": "1395_5", "text": "SCs derive from the neural crest, are highly dependent on extrinsic signals, and have plastic differentiation states.", "tags": [{"end": 3, "start": 0, "tag": "Cell"}, {"end": 32, "start": 20, "tag": "EmbryonicStructure"}, {"end": 116, "start": 94, "tag": "CellFunction"}, {"end": 75, "start": 38, "tag": "Finding"}]}{"id": "1395_6", "text": "SC precursors (SCPs) are produced in early embryonic nerve structures and differentiate into multipotent immature SCs (iSCs), which initiate radial sorting and differentiate into myelinating and non-myelinating SCs.", "tags": [{"end": 13, "start": 0, "tag": "Cell"}, {"end": 69, "start": 43, "tag": "EmbryonicStructure"}, {"end": 87, "start": 74, "tag": "CellFunction"}, {"end": 117, "start": 93, "tag": "Cell"}, {"end": 173, "start": 160, "tag": "CellFunction"}, {"end": 19, "start": 15, "tag": "Cell"}, {"end": 123, "start": 119, "tag": "Cell"}, {"end": 214, "start": 195, "tag": "Cell"}, {"end": 155, "start": 141, "tag": "CellFunction"}, {"end": 190, "start": 179, "tag": "Cell"}, {"end": 214, "start": 211, "tag": "Cell"}]}{"id": "1395_7", "text": "Differentiated SCs retain the capacity to radically change phenotypes in response to external signals, including becoming repair SCs, which drive peripheral regeneration.", "tags": [{"end": 18, "start": 0, "tag": "Cell"}, {"end": 69, "start": 59, "tag": "OrganismAttribute"}, {"end": 132, "start": 122, "tag": "Cell"}, {"end": 169, "start": 146, "tag": "BiologicFunction"}]}{"id": "1395_8", "text": "While several transcription factors and myelin components are common between OLs and SCs, their differentiation mechanisms are highly distinct, owing to their unique lineages and their respective environments.", "tags": [{"end": 46, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 40, "tag": "CellComponent"}, {"end": 57, "start": 47, "tag": "CellComponent"}, {"end": 80, "start": 77, "tag": "Cell"}, {"end": 88, "start": 85, "tag": "Cell"}, {"end": 111, "start": 96, "tag": "CellFunction"}, {"end": 35, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 166, "tag": "CellFunction"}]}{"id": "1395_9", "text": "In addition, both OLs and SCs respond to neuronal activity and regulate nervous system output in reciprocal manners, possibly through different pathways.", "tags": [{"end": 21, "start": 18, "tag": "Cell"}, {"end": 29, "start": 26, "tag": "Cell"}, {"end": 86, "start": 72, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 144, "tag": "CellFunction"}, {"end": 58, "start": 41, "tag": "CellFunction"}]}{"id": "1395_10", "text": "Here, we outline their basic developmental programs, mechanisms regulating their differentiation, and recent advances in the field.", "tags": [{"end": 51, "start": 29, "tag": "BiologicFunction"}, {"end": 108, "start": 102, "tag": "TemporalConcept"}, {"end": 96, "start": 81, "tag": "CellFunction"}, {"end": 117, "start": 109, "tag": "Finding"}]}{"id": "1396_0", "text": "Myelination of projection neurons by oligodendrocytes is key to optimize action potential conduction over long distances.", "tags": [{"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 33, "start": 15, "tag": "CellComponent"}, {"end": 53, "start": 37, "tag": "Cell"}, {"end": 89, "start": 73, "tag": "CellFunction"}, {"end": 100, "start": 90, "tag": "BiologicFunction"}, {"end": 100, "start": 90, "tag": "NaturalPhenomenonOrProcess"}]}{"id": "1396_1", "text": "However, a large fraction of myelin enwraps the axons of parvalbumin-positive fast-spiking interneurons (FSI), exclusively involved in local cortical circuits.", "tags": [{"end": 35, "start": 29, "tag": "CellComponent"}, {"end": 53, "start": 48, "tag": "CellComponent"}, {"end": 158, "start": 141, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 35, "start": 29, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 78, "tag": "Cell"}, {"end": 108, "start": 105, "tag": "Cell"}, {"end": 68, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 68, "start": 57, "tag": "BiologicallyActiveSubstance"}]}{"id": "1396_2", "text": "Whether FSI myelination contributes to the fine-tuning of intracortical networks is unknown.", "tags": [{"end": 23, "start": 12, "tag": "CellFunction"}, {"end": 11, "start": 8, "tag": "Cell"}, {"end": 80, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1396_3", "text": "Here we demonstrate that FSI myelination is required for the establishment and maintenance of the powerful FSI-mediated feedforward inhibition of cortical sensory circuits.", "tags": [{"end": 40, "start": 29, "tag": "CellFunction"}, {"end": 90, "start": 79, "tag": "BiologicFunction"}, {"end": 142, "start": 107, "tag": "CellFunction"}, {"end": 171, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 25, "tag": "Cell"}]}{"id": "1396_4", "text": "The disruption of GABAergic synaptic signaling of oligodendrocyte precursor cells prior to myelination onset resulted in severe FSI myelination defects characterized by longer internodes and nodes, aberrant myelination of branch points and proximal axon malformation.", "tags": [{"end": 81, "start": 50, "tag": "Cell"}, {"end": 102, "start": 91, "tag": "CellFunction"}, {"end": 151, "start": 132, "tag": "CellOrMolecularDysfunction"}, {"end": 186, "start": 176, "tag": "CellComponent"}, {"end": 266, "start": 240, "tag": "CellOrMolecularDysfunction"}, {"end": 108, "start": 103, "tag": "TemporalConcept"}, {"end": 196, "start": 191, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 18, "tag": "CellFunction"}, {"end": 131, "start": 128, "tag": "Cell"}, {"end": 218, "start": 198, "tag": "CellOrMolecularDysfunction"}, {"end": 235, "start": 222, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1396_5", "text": "Consequently, high-frequency FSI discharges as well as FSI-dependent postsynaptic latencies and strengths of excitatory neurons were reduced.", "tags": [{"end": 81, "start": 69, "tag": "CellComponent"}, {"end": 127, "start": 109, "tag": "Cell"}, {"end": 32, "start": 29, "tag": "Cell"}]}{"id": "1396_6", "text": "These dysfunctions generated a strong excitation-inhibition imbalance that correlated with whisker-dependent texture discrimination impairments.", "tags": [{"end": 18, "start": 6, "tag": "PathologicFunction"}, {"end": 69, "start": 38, "tag": "CellOrMolecularDysfunction"}, {"end": 131, "start": 91, "tag": "ResearchActivity"}, {"end": 98, "start": 91, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1396_7", "text": "FSI myelination is therefore critical for the function of mature cortical inhibitory circuits.", "tags": [{"end": 15, "start": 4, "tag": "CellFunction"}, {"end": 64, "start": 58, "tag": "TemporalConcept"}, {"end": 3, "start": 0, "tag": "Cell"}, {"end": 93, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1396_8", "text": "Myelination optimizes conduction speed of excitatory neurons.", "tags": [{"end": 11, "start": 0, "tag": "CellFunction"}, {"end": 32, "start": 22, "tag": "BiologicFunction"}, {"end": 32, "start": 22, "tag": "NaturalPhenomenonOrProcess"}, {"end": 60, "start": 42, "tag": "Cell"}]}{"id": "1396_9", "text": "However, whether myelination of interneurons (INs) refines cortical networks is unclear.", "tags": [{"end": 28, "start": 17, "tag": "CellFunction"}, {"end": 44, "start": 32, "tag": "Cell"}, {"end": 49, "start": 46, "tag": "Cell"}, {"end": 76, "start": 59, "tag": "BiologicFunction"}]}{"id": "1396_10", "text": "Here, the authors show that INs myelination shapes feedforward inhibition of mouse cortical sensory circuits and impacts whisker-mediated behaviour.", "tags": [{"end": 31, "start": 28, "tag": "Cell"}, {"end": 43, "start": 32, "tag": "CellFunction"}, {"end": 73, "start": 63, "tag": "CellFunction"}, {"end": 108, "start": 83, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 77, "tag": "Eukaryote"}, {"end": 128, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 147, "start": 121, "tag": "BiologicFunction"}]}{"id": "1397_0", "text": "Cuprizone is a copper-chelating agent that induces pathology similar to that within some multiple sclerosis (MS) lesions.", "tags": [{"end": 9, "start": 0, "tag": "Chemical"}, {"end": 60, "start": 51, "tag": "PathologicFunction"}, {"end": 60, "start": 51, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 89, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 15, "tag": "PharmacologicSubstance"}, {"end": 21, "start": 15, "tag": "Chemical"}, {"end": 21, "start": 15, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 15, "tag": "PharmacologicSubstance"}]}{"id": "1397_1", "text": "The reliability and reproducibility of cuprizone for inducing demyelinating disease pathology depends on the animals ingesting consistent doses of cuprizone.", "tags": [{"end": 48, "start": 39, "tag": "Chemical"}, {"end": 83, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 109, "tag": "Eukaryote"}, {"end": 126, "start": 117, "tag": "BiologicFunction"}, {"end": 156, "start": 147, "tag": "Chemical"}, {"end": 93, "start": 76, "tag": "PathologicFunction"}]}{"id": "1397_2", "text": "Cuprizone-containing pelleted feed is a convenient way of delivering cuprizone, but the efficacy of these pellets at inducing demyelination has been questioned.", "tags": [{"end": 78, "start": 69, "tag": "Chemical"}, {"end": 139, "start": 126, "tag": "PathologicFunction"}, {"end": 34, "start": 0, "tag": "Chemical"}]}{"id": "1397_3", "text": "This study compared the degree of demyelinating disease pathology between mice fed cuprizone delivered in pellets to mice fed a powdered cuprizone formulation at an early 3 week demyelinating timepoint.", "tags": [{"end": 55, "start": 34, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 83, "tag": "Chemical"}, {"end": 158, "start": 147, "tag": "ResearchActivity"}, {"end": 177, "start": 173, "tag": "TemporalConcept"}, {"end": 191, "start": 178, "tag": "PathologicFunction"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 78, "start": 74, "tag": "Eukaryote"}, {"end": 121, "start": 117, "tag": "Eukaryote"}, {"end": 65, "start": 48, "tag": "PathologicFunction"}, {"end": 146, "start": 137, "tag": "Chemical"}, {"end": 201, "start": 192, "tag": "TemporalConcept"}]}{"id": "1397_4", "text": "Within rostral corpus callosum, cuprizone pellets were more effective than cuprizone powder at increasing astrogliosis, microglial activation, DNA damage, and decreasing the density of mature oligodendrocytes.", "tags": [{"end": 30, "start": 7, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 32, "tag": "Chemical"}, {"end": 141, "start": 120, "tag": "CellFunction"}, {"end": 153, "start": 143, "tag": "CellOrMolecularDysfunction"}, {"end": 208, "start": 185, "tag": "Cell"}, {"end": 30, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 143, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 118, "start": 106, "tag": "PathologicFunction"}, {"end": 91, "start": 75, "tag": "Chemical"}]}{"id": "1397_5", "text": "However, cuprizone powder demonstrated greater protein nitration relative to controls.", "tags": [{"end": 85, "start": 77, "tag": "PopulationGroup"}, {"end": 64, "start": 47, "tag": "CellFunction"}, {"end": 25, "start": 9, "tag": "Chemical"}]}{"id": "1397_6", "text": "Furthermore, mice fed control powder had significantly fewer mature oligodendrocytes than those fed control pellets.", "tags": [{"end": 84, "start": 61, "tag": "Cell"}, {"end": 17, "start": 13, "tag": "Eukaryote"}, {"end": 36, "start": 22, "tag": "Substance"}]}{"id": "1397_7", "text": "In caudal corpus callosum, cuprizone pellets performed better than cuprizone powder relative to controls at increasing astrogliosis, microglial activation, protein nitration, DNA damage, tissue swelling, and reducing the density of mature oligodendrocytes.", "tags": [{"end": 9, "start": 3, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 16, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 44, "start": 27, "tag": "Chemical"}, {"end": 83, "start": 67, "tag": "Chemical"}, {"end": 154, "start": 133, "tag": "CellFunction"}, {"end": 185, "start": 175, "tag": "CellOrMolecularDysfunction"}, {"end": 255, "start": 232, "tag": "Cell"}, {"end": 25, "start": 10, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 104, "start": 96, "tag": "PopulationGroup"}, {"end": 178, "start": 175, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 131, "start": 119, "tag": "PathologicFunction"}, {"end": 173, "start": 156, "tag": "CellFunction"}, {"end": 202, "start": 187, "tag": "PathologicFunction"}]}{"id": "1397_8", "text": "Importantly, only cuprizone pellets induced detectable demyelination compared to controls.", "tags": [{"end": 35, "start": 18, "tag": "Chemical"}, {"end": 89, "start": 81, "tag": "PopulationGroup"}, {"end": 68, "start": 55, "tag": "PathologicFunction"}]}{"id": "1397_9", "text": "The two feeds had similar effects on oligodendrocyte precursor cell (OPC) dynamics.", "tags": [{"end": 13, "start": 8, "tag": "HealthCareActivity"}, {"end": 67, "start": 37, "tag": "Cell"}, {"end": 72, "start": 69, "tag": "Cell"}]}{"id": "1397_10", "text": "Taken together, these data suggest that demyelinating disease pathology is modelled more effectively with cuprizone pellets than powder at 3 weeks.", "tags": [{"end": 61, "start": 40, "tag": "DiseaseOrSyndrome"}, {"end": 123, "start": 106, "tag": "Chemical"}, {"end": 146, "start": 141, "tag": "TemporalConcept"}, {"end": 26, "start": 22, "tag": "ResearchActivity"}, {"end": 71, "start": 54, "tag": "PathologicFunction"}, {"end": 135, "start": 129, "tag": "Chemical"}, {"end": 115, "start": 106, "tag": "Chemical"}]}{"id": "1397_11", "text": "Combined with the added convenience, cuprizone pellets are a suitable choice for inducing early demyelinating disease pathology.", "tags": [{"end": 54, "start": 37, "tag": "Chemical"}, {"end": 117, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 110, "tag": "PathologicFunction"}]}{"id": "1398_0", "text": "To understand the cellular composition and region-specific specialization of white matter - a disease-relevant, glia-rich tissue highly expanded in primates relative to rodents - we profiled transcriptomes of similar to 500,000 nuclei from 19 tissue types of the central nervous system of healthy common marmoset and mapped 87 subclusters spatially onto a 3D MRI atlas.", "tags": [{"end": 205, "start": 191, "tag": "MolecularSequence"}, {"end": 255, "start": 243, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 368, "start": 363, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 285, "start": 263, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 362, "start": 359, "tag": "HealthCareActivity"}, {"end": 296, "start": 289, "tag": "OrganismAttribute"}, {"end": 89, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 112, "tag": "Cell"}, {"end": 128, "start": 112, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 148, "tag": "Eukaryote"}, {"end": 176, "start": 169, "tag": "Eukaryote"}, {"end": 234, "start": 228, "tag": "CellComponent"}, {"end": 312, "start": 297, "tag": "Eukaryote"}, {"end": 368, "start": 356, "tag": "ResearchActivity"}]}{"id": "1398_1", "text": "We performed cross-species comparison, explored regulatory pathways, modeled regional intercellular communication, and surveyed cellular determinants of neurological disorders.", "tags": [{"end": 175, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 13, "tag": "ResearchActivity"}, {"end": 67, "start": 59, "tag": "CellFunction"}, {"end": 26, "start": 19, "tag": "OrganismAttribute"}, {"end": 113, "start": 77, "tag": "CellFunction"}]}{"id": "1398_2", "text": "Here, we analyze this resource and find strong spatial segregation of microglia, oligodendrocyte progenitor cells, and astrocytes.", "tags": [{"end": 113, "start": 81, "tag": "Cell"}, {"end": 79, "start": 70, "tag": "Cell"}, {"end": 129, "start": 119, "tag": "Cell"}, {"end": 66, "start": 40, "tag": "Finding"}]}{"id": "1398_3", "text": "White matter glia are diverse, enriched with genes involved in stimulus-response and biomolecule modification, and predicted to interact with other resident cells more extensively than their gray matter counterparts.", "tags": [{"end": 12, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 148, "tag": "Cell"}, {"end": 202, "start": 191, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 17, "start": 13, "tag": "Cell"}]}{"id": "1398_4", "text": "Conversely, gray matter glia preserve the expression of neural tube patterning genes into adulthood and share six transcription factors that restrict transcriptome complexity.", "tags": [{"end": 84, "start": 56, "tag": "GeneOrGenome"}, {"end": 99, "start": 90, "tag": "TemporalConcept"}, {"end": 163, "start": 150, "tag": "MolecularSequence"}, {"end": 23, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 28, "start": 24, "tag": "Cell"}, {"end": 135, "start": 114, "tag": "AminoAcidPeptideOrProtein"}, {"end": 135, "start": 114, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 56, "tag": "EmbryonicStructure"}]}{"id": "1398_5", "text": "A companion Callithrix jacchus Primate Cell Atlas (CjPCA) is available through https://cjpca.ninds.nih.gov.", "tags": [{"end": 11, "start": 2, "tag": "PopulationGroup"}, {"end": 49, "start": 12, "tag": "ResearchActivity"}, {"end": 56, "start": 51, "tag": "ResearchActivity"}]}{"id": "1399_0", "text": "The Na+/Ca2+ exchanger NCX3 is an important regulator of sodium and calcium homeostasis in oligodendrocyte lineage.", "tags": [{"end": 22, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 23, "tag": "GeneOrGenome"}, {"end": 87, "start": 44, "tag": "CellFunction"}, {"end": 114, "start": 91, "tag": "Cell"}, {"end": 22, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 27, "start": 23, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1399_1", "text": "To date, no information is available on the effects resulting from prolonged exposure to NCX3 blockers and subsequent drug washout in oligodendroglia.", "tags": [{"end": 76, "start": 67, "tag": "TemporalConcept"}, {"end": 149, "start": 134, "tag": "Cell"}, {"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 122, "start": 118, "tag": "PharmacologicSubstance"}, {"end": 130, "start": 118, "tag": "ResearchActivity"}, {"end": 102, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 102, "start": 89, "tag": "Chemical"}]}{"id": "1399_2", "text": "Here, we investigated, by means of biochemical, morphological and functional analyses, the pharmacological effects of the NCX3 inhibitor, the 5-amino-N-butyl-2(4-ethoxyphenoxy)-benzamide hydrochloride (BED), on NCXs expression and activity, as well as intracellular [Na+](i) and [Ca2+](i) levels, during treatment and following drug washout both in human MO3.13 oligodendrocytes and rat primary oligodendrocyte precursor cells (OPCs).", "tags": [{"end": 85, "start": 35, "tag": "ResearchActivity"}, {"end": 378, "start": 355, "tag": "Cell"}, {"end": 386, "start": 383, "tag": "Eukaryote"}, {"end": 426, "start": 387, "tag": "Cell"}, {"end": 432, "start": 428, "tag": "Cell"}, {"end": 313, "start": 304, "tag": "HealthCareActivity"}, {"end": 313, "start": 304, "tag": "ResearchActivity"}, {"end": 354, "start": 349, "tag": "Eukaryote"}, {"end": 332, "start": 328, "tag": "PharmacologicSubstance"}, {"end": 226, "start": 211, "tag": "CellFunction"}, {"end": 136, "start": 122, "tag": "BiologicallyActiveSubstance"}, {"end": 136, "start": 122, "tag": "Chemical"}, {"end": 114, "start": 91, "tag": "Finding"}, {"end": 200, "start": 142, "tag": "Chemical"}, {"end": 205, "start": 202, "tag": "Chemical"}, {"end": 340, "start": 328, "tag": "ResearchActivity"}, {"end": 295, "start": 252, "tag": "ResearchActivity"}]}{"id": "1399_3", "text": "BED exposure antagonized NCX activity, induced OPCs proliferation and [Na+](i) accumulation.", "tags": [{"end": 51, "start": 47, "tag": "Cell"}, {"end": 91, "start": 70, "tag": "Finding"}, {"end": 12, "start": 0, "tag": "ResearchActivity"}, {"end": 37, "start": 25, "tag": "CellFunction"}, {"end": 65, "start": 47, "tag": "CellFunction"}, {"end": 12, "start": 0, "tag": "HealthCareActivity"}]}{"id": "1399_4", "text": "By contrast, 2 days of BED washout after 4 days of treatment significantly upregulated low molecular weight NCX3 proteins, reversed NCX activity, and increased intracellular [Ca2+](i).", "tags": [{"end": 19, "start": 15, "tag": "TemporalConcept"}, {"end": 47, "start": 43, "tag": "TemporalConcept"}, {"end": 144, "start": 132, "tag": "CellFunction"}, {"end": 60, "start": 51, "tag": "HealthCareActivity"}, {"end": 60, "start": 51, "tag": "ResearchActivity"}, {"end": 180, "start": 174, "tag": "Chemical"}, {"end": 121, "start": 108, "tag": "AminoAcidPeptideOrProtein"}, {"end": 34, "start": 23, "tag": "ResearchActivity"}, {"end": 34, "start": 23, "tag": "HealthCareActivity"}, {"end": 121, "start": 108, "tag": "BiologicallyActiveSubstance"}]}{"id": "1399_5", "text": "This BED-free effect was accompanied by an upregulation of NCX3 expression in oligodendrocyte processes and accelerated expression of myelin markers in rat primary oligodendrocytes.", "tags": [{"end": 74, "start": 43, "tag": "CellFunction"}, {"end": 93, "start": 78, "tag": "Cell"}, {"end": 140, "start": 134, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 155, "start": 152, "tag": "Eukaryote"}, {"end": 180, "start": 156, "tag": "Cell"}, {"end": 8, "start": 5, "tag": "Chemical"}, {"end": 20, "start": 14, "tag": "Finding"}, {"end": 148, "start": 141, "tag": "ClinicalAttribute"}]}{"id": "1399_6", "text": "Collectively, our findings show that the pharmacological inhibition of the NCX3 exchanger with BED blocker maybe followed by a rebound increase in NCX3 expression and reversal activity that accelerate myelin sheet formation in oligodendrocytes.", "tags": [{"end": 56, "start": 41, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 223, "start": 201, "tag": "CellFunction"}, {"end": 243, "start": 227, "tag": "Cell"}, {"end": 67, "start": 57, "tag": "CellFunction"}, {"end": 162, "start": 147, "tag": "CellFunction"}, {"end": 89, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 75, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 95, "tag": "Chemical"}]}{"id": "1399_7", "text": "In addition, they indicate that a particular attention should be paid to the use of NCX inhibitors for possible rebound effects, and suggest that further studies will be necessary to investigate whether selective pharmacological modulation of NCX3 exchanger may be exploited to benefit demyelination and remyelination in demyelinating diseases.", "tags": [{"end": 98, "start": 84, "tag": "Chemical"}, {"end": 247, "start": 243, "tag": "GeneOrGenome"}, {"end": 257, "start": 248, "tag": "CellFunction"}, {"end": 317, "start": 304, "tag": "CellFunction"}, {"end": 343, "start": 321, "tag": "DiseaseOrSyndrome"}, {"end": 161, "start": 154, "tag": "ResearchActivity"}, {"end": 54, "start": 45, "tag": "BiologicFunction"}, {"end": 299, "start": 286, "tag": "PathologicFunction"}, {"end": 98, "start": 84, "tag": "BiologicallyActiveSubstance"}]}{"id": "1400_0", "text": "Background Clinicians caring for patients with Multiple Sclerosis (MS) need improved biomarkers to aid them in disease management.", "tags": [{"end": 28, "start": 22, "tag": "IndividualBehavior"}, {"end": 65, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 76, "tag": "Finding"}, {"end": 129, "start": 111, "tag": "HealthCareActivity"}, {"end": 95, "start": 85, "tag": "ClinicalAttribute"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 41, "start": 33, "tag": "PatientOrDisabledGroup"}, {"end": 129, "start": 119, "tag": "HealthCareActivity"}, {"end": 21, "start": 11, "tag": "HealthCareActivity"}]}{"id": "1400_1", "text": "Objective We assessed the predictive value of the candidate biomarker CXCL13 index in comparison to oligoclonal bands (OCBs) and CSF neurofilament light (NfL) concentration, examining the ability of each biomarker to predict future disease activity in clinically and radiologically isolated syndromes, relapsing-remitting MS, and progressive MS.", "tags": [{"end": 76, "start": 70, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 70, "tag": "GeneOrGenome"}, {"end": 82, "start": 70, "tag": "ResearchActivity"}, {"end": 117, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 100, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 119, "tag": "AminoAcidPeptideOrProtein"}, {"end": 123, "start": 119, "tag": "ResearchActivity"}, {"end": 132, "start": 129, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 152, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 324, "start": 302, "tag": "DiseaseOrSyndrome"}, {"end": 344, "start": 342, "tag": "DiseaseOrSyndrome"}, {"end": 231, "start": 225, "tag": "TemporalConcept"}, {"end": 96, "start": 86, "tag": "ResearchActivity"}, {"end": 311, "start": 302, "tag": "TemporalConcept"}, {"end": 344, "start": 330, "tag": "DiseaseOrSyndrome"}, {"end": 341, "start": 330, "tag": "TemporalConcept"}, {"end": 69, "start": 60, "tag": "ClinicalAttribute"}, {"end": 213, "start": 204, "tag": "ClinicalAttribute"}, {"end": 42, "start": 26, "tag": "Finding"}, {"end": 123, "start": 119, "tag": "BiologicallyActiveSubstance"}, {"end": 76, "start": 70, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 157, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 172, "start": 129, "tag": "HealthCareActivity"}, {"end": 248, "start": 232, "tag": "HealthCareActivity"}, {"end": 157, "start": 154, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1400_2", "text": "Methods Matched serum and CSF samples were obtained from 67 non-inflammatory neurologic disease patients and 67 MS patients.", "tags": [{"end": 37, "start": 8, "tag": "ResearchActivity"}, {"end": 21, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 29, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 96, "tag": "PatientOrDisabledGroup"}, {"end": 123, "start": 115, "tag": "PatientOrDisabledGroup"}, {"end": 95, "start": 60, "tag": "DiseaseOrSyndrome"}]}{"id": "1400_3", "text": "CSF and serum CXCL13 and CSF NfL were analyzed by Luminex and ELISA, respectively.", "tags": [{"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 8, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 20, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 14, "tag": "GeneOrGenome"}, {"end": 20, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 67, "start": 62, "tag": "ResearchActivity"}, {"end": 32, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 57, "start": 50, "tag": "ResearchActivity"}]}{"id": "1400_4", "text": "CXCL13 data were also analyzed as CSF/serum ratios and indices.", "tags": [{"end": 6, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 6, "start": 0, "tag": "GeneOrGenome"}, {"end": 6, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 11, "start": 7, "tag": "ResearchActivity"}, {"end": 50, "start": 34, "tag": "ResearchActivity"}]}{"id": "1400_5", "text": "Electronic medical records were accessed to determine diagnosis, CSF profiles, and disease activity after the lumbar puncture.", "tags": [{"end": 68, "start": 65, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 110, "tag": "HealthCareActivity"}, {"end": 63, "start": 54, "tag": "HealthCareActivity"}, {"end": 77, "start": 65, "tag": "HealthCareActivity"}, {"end": 26, "start": 0, "tag": "HealthCareActivity"}, {"end": 99, "start": 83, "tag": "HealthCareActivity"}]}{"id": "1400_6", "text": "Results Among CXCL13 measures, CXCL13 index was the best predictor of future disease activity in MS patients (AUC=0.82; CI=0.69-0.95; p=0.0002).", "tags": [{"end": 20, "start": 14, "tag": "AminoAcidPeptideOrProtein"}, {"end": 20, "start": 14, "tag": "GeneOrGenome"}, {"end": 29, "start": 14, "tag": "HealthCareActivity"}, {"end": 20, "start": 14, "tag": "BiologicallyActiveSubstance"}, {"end": 43, "start": 31, "tag": "HealthCareActivity"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 113, "start": 110, "tag": "ResearchActivity"}, {"end": 76, "start": 70, "tag": "TemporalConcept"}, {"end": 108, "start": 100, "tag": "PatientOrDisabledGroup"}, {"end": 93, "start": 77, "tag": "HealthCareActivity"}]}{"id": "1400_7", "text": "CXCL13 index values were significantly elevated in activity-positive MS patients compared to activity-negative patients (p<0.0001).", "tags": [{"end": 71, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 72, "tag": "PatientOrDisabledGroup"}, {"end": 119, "start": 111, "tag": "PatientOrDisabledGroup"}, {"end": 19, "start": 0, "tag": "HealthCareActivity"}]}{"id": "1400_8", "text": "As a single predictor, CXCL13 index outperformed both OCBs and CSF NfL in sensitivity, specificity, and positive and negative predictive value, for future disease activity in MS patients.", "tags": [{"end": 35, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 23, "tag": "GeneOrGenome"}, {"end": 35, "start": 23, "tag": "HealthCareActivity"}, {"end": 58, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 58, "start": 54, "tag": "ResearchActivity"}, {"end": 66, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 70, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 85, "start": 74, "tag": "Finding"}, {"end": 98, "start": 87, "tag": "Finding"}, {"end": 177, "start": 175, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 148, "tag": "TemporalConcept"}, {"end": 186, "start": 178, "tag": "PatientOrDisabledGroup"}, {"end": 171, "start": 155, "tag": "HealthCareActivity"}, {"end": 70, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 21, "start": 5, "tag": "Finding"}, {"end": 58, "start": 54, "tag": "BiologicallyActiveSubstance"}]}{"id": "1400_9", "text": "Moreover, combining CXCL13 index and CSF NfL status improved sensitivity and predictive values for disease activity in MS patients.", "tags": [{"end": 32, "start": 20, "tag": "HealthCareActivity"}, {"end": 40, "start": 37, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 72, "start": 61, "tag": "Finding"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 122, "tag": "PatientOrDisabledGroup"}, {"end": 115, "start": 99, "tag": "HealthCareActivity"}, {"end": 94, "start": 77, "tag": "Finding"}, {"end": 44, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 44, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 37, "tag": "HealthCareActivity"}]}{"id": "1400_10", "text": "Conclusions The CXCL13 index is an excellent candidate prognostic biomarker for disease activity in patients with MS.", "tags": [{"end": 22, "start": 16, "tag": "AminoAcidPeptideOrProtein"}, {"end": 22, "start": 16, "tag": "GeneOrGenome"}, {"end": 28, "start": 16, "tag": "ResearchActivity"}, {"end": 116, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 100, "tag": "PatientOrDisabledGroup"}, {"end": 75, "start": 55, "tag": "ClinicalAttribute"}, {"end": 96, "start": 80, "tag": "HealthCareActivity"}, {"end": 22, "start": 16, "tag": "BiologicallyActiveSubstance"}]}{"id": "1401_0", "text": "Background:To evaluate retinal vessel density (VD) in macular and in peripapillary regions in patients with recent onset of multiple sclerosis, at initial demyelinating event (IDE) and in matched relapsing-remitting multiple sclerosis (RRMS) patients.", "tags": [{"end": 234, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 240, "start": 236, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 108, "tag": "TemporalConcept"}, {"end": 120, "start": 115, "tag": "TemporalConcept"}, {"end": 102, "start": 94, "tag": "PatientOrDisabledGroup"}, {"end": 250, "start": 242, "tag": "PatientOrDisabledGroup"}, {"end": 142, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 234, "start": 216, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 23, "tag": "HealthCareActivity"}, {"end": 205, "start": 196, "tag": "TemporalConcept"}, {"end": 90, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 174, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 47, "tag": "HealthCareActivity"}]}{"id": "1401_1", "text": "Methods:We evaluated VD in superficial capillary plexus, deep capillary plexus, choriocapillaris and radial peripapillary capillary plexus in IDE, RRMS patients and in matched healthy controls (HCs) through Optical Coherence Tomography Angiography (OCT-A).", "tags": [{"end": 96, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 151, "start": 147, "tag": "DiseaseOrSyndrome"}, {"end": 247, "start": 207, "tag": "HealthCareActivity"}, {"end": 254, "start": 249, "tag": "HealthCareActivity"}, {"end": 183, "start": 176, "tag": "OrganismAttribute"}, {"end": 160, "start": 152, "tag": "PatientOrDisabledGroup"}, {"end": 192, "start": 176, "tag": "PopulationGroup"}, {"end": 23, "start": 21, "tag": "HealthCareActivity"}, {"end": 55, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 78, "start": 57, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 138, "start": 101, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 145, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 197, "start": 194, "tag": "PopulationGroup"}]}{"id": "1401_2", "text": "Clinical history, including history of optic neuritis, Expanded Disability Status scale and disease duration of patients were collected.", "tags": [{"end": 35, "start": 28, "tag": "Finding"}, {"end": 53, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 92, "tag": "HealthCareActivity"}, {"end": 120, "start": 112, "tag": "PatientOrDisabledGroup"}, {"end": 16, "start": 0, "tag": "Finding"}, {"end": 87, "start": 55, "tag": "HealthCareActivity"}, {"end": 108, "start": 100, "tag": "TemporalConcept"}]}{"id": "1401_3", "text": "Results:Thirty patients (20 with IDE and 10 with RRMS) and 15 HCs were enrolled.", "tags": [{"end": 53, "start": 49, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 15, "tag": "PatientOrDisabledGroup"}, {"end": 36, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 62, "tag": "PopulationGroup"}]}{"id": "1401_4", "text": "IDE patients showed a lower VD in radial peripapillary capillary plexus compared with controls (coeff.", "tags": [{"end": 94, "start": 86, "tag": "PopulationGroup"}, {"end": 12, "start": 4, "tag": "PatientOrDisabledGroup"}, {"end": 3, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 30, "start": 28, "tag": "HealthCareActivity"}, {"end": 71, "start": 34, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1401_5", "text": "beta = -3.578;p= 0.002).", "tags": []}{"id": "1401_6", "text": "RRMS patients displayed a lower VD in both superficial capillary plexus and radial peripapillary capillary plexus compared with HCs (coeff.", "tags": [{"end": 4, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 13, "start": 5, "tag": "PatientOrDisabledGroup"}, {"end": 34, "start": 32, "tag": "HealthCareActivity"}, {"end": 71, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 113, "start": 76, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 128, "tag": "PopulationGroup"}]}{"id": "1401_7", "text": "beta = -4.955;p= 0.002, and coeff.", "tags": []}{"id": "1401_8", "text": "beta = -7.446;p< 0.001, respectively).", "tags": []}{"id": "1401_9", "text": "Furthermore, RRMS patients showed a decreased VD in radial peripapillary capillary plexus compared with IDE patients (coeff.", "tags": [{"end": 17, "start": 13, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 18, "tag": "PatientOrDisabledGroup"}, {"end": 116, "start": 108, "tag": "PatientOrDisabledGroup"}, {"end": 48, "start": 46, "tag": "HealthCareActivity"}, {"end": 89, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 104, "tag": "DiseaseOrSyndrome"}]}{"id": "1401_10", "text": "beta = -3.868;p= 0.003).", "tags": []}{"id": "1401_11", "text": "Conclusions:Peripapillary region vessel density reduction, revealed through OCT-A, might be considered as an early event in MS, and might be relevant as a biomarker of disease pathology.", "tags": [{"end": 81, "start": 76, "tag": "HealthCareActivity"}, {"end": 126, "start": 124, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 48, "tag": "Finding"}, {"end": 57, "start": 48, "tag": "NaturalPhenomenonOrProcess"}, {"end": 47, "start": 33, "tag": "HealthCareActivity"}, {"end": 185, "start": 168, "tag": "PathologicFunction"}, {"end": 164, "start": 155, "tag": "ClinicalAttribute"}, {"end": 32, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1402_0", "text": "Introduction: Multiple Sclerosis (MS) is presented with motor and sensory function loss.", "tags": [{"end": 32, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 66, "tag": "PathologicFunction"}, {"end": 36, "start": 34, "tag": "DiseaseOrSyndrome"}]}{"id": "1402_1", "text": "It is caused by demyelination and following axonal lesion.", "tags": [{"end": 29, "start": 16, "tag": "PathologicFunction"}, {"end": 57, "start": 44, "tag": "InjuryOrPoisoning"}]}{"id": "1402_2", "text": "As Myelin Basic Protein (MBP) is one of the key elements of the myelin cover, we examined the level of MBP in serum, Stimulated, and unstimulated saliva as a suitable biomarker for detecting MS.", "tags": [{"end": 23, "start": 3, "tag": "AminoAcidPeptideOrProtein"}, {"end": 23, "start": 3, "tag": "GeneOrGenome"}, {"end": 115, "start": 110, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 193, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 152, "start": 146, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 76, "start": 64, "tag": "CellComponent"}, {"end": 28, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 25, "tag": "GeneOrGenome"}, {"end": 106, "start": 103, "tag": "GeneOrGenome"}, {"end": 176, "start": 167, "tag": "ClinicalAttribute"}, {"end": 23, "start": 3, "tag": "BiologicallyActiveSubstance"}]}{"id": "1402_3", "text": "Methods: A case-control Study was performed in 29 healthy women and 32 definitive relapsing-remitting MS patients hospitalized in Imam Reza hospital, Tehran, Iran.", "tags": [{"end": 29, "start": 11, "tag": "ResearchActivity"}, {"end": 63, "start": 58, "tag": "PopulationGroup"}, {"end": 57, "start": 50, "tag": "OrganismAttribute"}, {"end": 104, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 15, "start": 11, "tag": "ManufacturedObject"}, {"end": 113, "start": 105, "tag": "PatientOrDisabledGroup"}, {"end": 148, "start": 130, "tag": "HealthCareRelatedOrganization"}]}{"id": "1402_4", "text": "MBP level was assayed in serum and Stimulated and unstimulated whole saliva.", "tags": [{"end": 30, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 69, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 3, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 3, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 3, "start": 0, "tag": "GeneOrGenome"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}]}{"id": "1402_5", "text": "Results: MBP was expressed at a lower level in serum and Stimulated saliva of MS patients compared to the control group.", "tags": [{"end": 52, "start": 47, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 78, "tag": "DiseaseOrSyndrome"}, {"end": 89, "start": 81, "tag": "PatientOrDisabledGroup"}, {"end": 74, "start": 68, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 26, "start": 17, "tag": "CellFunction"}, {"end": 12, "start": 9, "tag": "AminoAcidPeptideOrProtein"}, {"end": 12, "start": 9, "tag": "BiologicallyActiveSubstance"}, {"end": 12, "start": 9, "tag": "GeneOrGenome"}, {"end": 119, "start": 106, "tag": "PopulationGroup"}]}{"id": "1402_6", "text": "The serum MBP level had a considerable correlation with its Stimulated saliva level.", "tags": [{"end": 9, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 77, "start": 71, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 13, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 13, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 13, "start": 10, "tag": "GeneOrGenome"}, {"end": 19, "start": 10, "tag": "HealthCareActivity"}]}{"id": "1402_7", "text": "The receiver operating characteristic analysis showed significant diagnostic ability for MBP to discriminate MS patients with serum and Stimulated saliva from controls.", "tags": [{"end": 131, "start": 126, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 38, "tag": "ResearchActivity"}, {"end": 111, "start": 109, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 159, "tag": "PopulationGroup"}, {"end": 120, "start": 112, "tag": "PatientOrDisabledGroup"}, {"end": 153, "start": 147, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 92, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 92, "start": 89, "tag": "GeneOrGenome"}]}{"id": "1402_8", "text": "Conclusion: Serum and saliva level of MBP is lower in MS, so it may be considered a potential biomarker in MS.", "tags": [{"end": 17, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 103, "start": 84, "tag": "ClinicalAttribute"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 109, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 28, "start": 22, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 41, "start": 38, "tag": "AminoAcidPeptideOrProtein"}, {"end": 41, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 38, "tag": "GeneOrGenome"}, {"end": 103, "start": 94, "tag": "ClinicalAttribute"}, {"end": 41, "start": 29, "tag": "HealthCareActivity"}]}{"id": "1403_0", "text": "Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal damage as well as its quantification is a critical step for patients.", "tags": [{"end": 71, "start": 62, "tag": "HealthCareActivity"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 155, "start": 147, "tag": "PatientOrDisabledGroup"}, {"end": 93, "start": 75, "tag": "InjuryOrPoisoning"}]}{"id": "1403_1", "text": "Blood-based serum neurofilament light chain (sNfL) is currently under close investigation as an easily accessible biomarker of prognosis and treatment response in patients with multiple sclerosis.", "tags": [{"end": 63, "start": 54, "tag": "TemporalConcept"}, {"end": 89, "start": 76, "tag": "ResearchActivity"}, {"end": 159, "start": 141, "tag": "ClinicalAttribute"}, {"end": 171, "start": 163, "tag": "PatientOrDisabledGroup"}, {"end": 195, "start": 177, "tag": "DiseaseOrSyndrome"}, {"end": 136, "start": 127, "tag": "HealthCareActivity"}, {"end": 123, "start": 114, "tag": "ClinicalAttribute"}, {"end": 5, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 43, "start": 18, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 18, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 45, "tag": "BiologicallyActiveSubstance"}, {"end": 49, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 43, "start": 12, "tag": "ClinicalAttribute"}, {"end": 49, "start": 45, "tag": "ClinicalAttribute"}]}{"id": "1403_2", "text": "There is abundant evidence that sNfL levels reflect ongoing inflammatory-driven neuroaxonal damage (e.g.", "tags": [{"end": 26, "start": 18, "tag": "Finding"}, {"end": 43, "start": 32, "tag": "ClinicalAttribute"}, {"end": 59, "start": 52, "tag": "TemporalConcept"}, {"end": 98, "start": 80, "tag": "InjuryOrPoisoning"}, {"end": 72, "start": 60, "tag": "PathologicFunction"}]}{"id": "1403_3", "text": "relapses or MRI disease activity) and that sNfL levels predict disease activity over the next few years.", "tags": [{"end": 54, "start": 43, "tag": "ClinicalAttribute"}, {"end": 103, "start": 98, "tag": "TemporalConcept"}, {"end": 15, "start": 12, "tag": "HealthCareActivity"}, {"end": 32, "start": 16, "tag": "HealthCareActivity"}, {"end": 79, "start": 63, "tag": "HealthCareActivity"}]}{"id": "1403_4", "text": "In contrast, the association of sNfL with long-term clinical outcomes or its ability to reflect slow, diffuse neurodegenerative damage in multiple sclerosis is less clear.", "tags": [{"end": 36, "start": 32, "tag": "BiologicallyActiveSubstance"}, {"end": 156, "start": 138, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 52, "tag": "ClinicalAttribute"}, {"end": 51, "start": 42, "tag": "TemporalConcept"}, {"end": 36, "start": 32, "tag": "AminoAcidPeptideOrProtein"}, {"end": 134, "start": 110, "tag": "PathologicFunction"}, {"end": 36, "start": 32, "tag": "ClinicalAttribute"}]}{"id": "1403_5", "text": "However, early results from real-world cohorts and clinical trials using sNfL as a marker of treatment response in multiple sclerosis are encouraging.", "tags": [{"end": 77, "start": 73, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 83, "tag": "ClinicalAttribute"}, {"end": 66, "start": 51, "tag": "ResearchActivity"}, {"end": 46, "start": 39, "tag": "PopulationGroup"}, {"end": 111, "start": 93, "tag": "ClinicalAttribute"}, {"end": 133, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 73, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 73, "tag": "ClinicalAttribute"}]}{"id": "1403_6", "text": "Importantly, clinical algorithms should now be developed that incorporate the routine use of sNfL to guide individualized clinical decision-making in people with multiple sclerosis, together with additional fluid biomarkers and clinical and MRI measures.", "tags": [{"end": 85, "start": 78, "tag": "TemporalConcept"}, {"end": 97, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 107, "tag": "HealthCareActivity"}, {"end": 212, "start": 207, "tag": "Substance"}, {"end": 253, "start": 245, "tag": "ClinicalAttribute"}, {"end": 236, "start": 228, "tag": "ClinicalAttribute"}, {"end": 223, "start": 213, "tag": "ClinicalAttribute"}, {"end": 156, "start": 150, "tag": "PopulationGroup"}, {"end": 244, "start": 241, "tag": "HealthCareActivity"}, {"end": 180, "start": 162, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 131, "tag": "BiologicFunction"}, {"end": 32, "start": 13, "tag": "ResearchActivity"}, {"end": 97, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 97, "start": 93, "tag": "ClinicalAttribute"}]}{"id": "1403_7", "text": "Here, we propose specific clinical scenarios where implementing sNfL measures may be of utility, including, among others: initial diagnosis, first treatment choice, surveillance of subclinical disease activity and guidance of therapy selection.", "tags": [{"end": 68, "start": 64, "tag": "BiologicallyActiveSubstance"}, {"end": 129, "start": 122, "tag": "TemporalConcept"}, {"end": 177, "start": 165, "tag": "HealthCareActivity"}, {"end": 177, "start": 165, "tag": "CellFunction"}, {"end": 139, "start": 130, "tag": "HealthCareActivity"}, {"end": 222, "start": 214, "tag": "ClinicalAttribute"}, {"end": 243, "start": 226, "tag": "HealthCareActivity"}, {"end": 156, "start": 147, "tag": "HealthCareActivity"}, {"end": 156, "start": 147, "tag": "ResearchActivity"}, {"end": 146, "start": 141, "tag": "TemporalConcept"}, {"end": 68, "start": 64, "tag": "AminoAcidPeptideOrProtein"}, {"end": 77, "start": 64, "tag": "ClinicalAttribute"}, {"end": 209, "start": 181, "tag": "HealthCareActivity"}]}{"id": "1404_0", "text": "Background: White matter lesions (WMLs) on brain magnetic resonance imaging (MRI) in multiple sclerosis (MS) may contribute to misdiagnosis.", "tags": [{"end": 139, "start": 127, "tag": "Finding"}, {"end": 48, "start": 43, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 75, "start": 49, "tag": "HealthCareActivity"}, {"end": 80, "start": 77, "tag": "HealthCareActivity"}, {"end": 103, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 25, "tag": "InjuryOrPoisoning"}, {"end": 24, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 75, "start": 68, "tag": "HealthCareActivity"}, {"end": 38, "start": 34, "tag": "InjuryOrPoisoning"}, {"end": 75, "start": 49, "tag": "ManufacturedObject"}]}{"id": "1404_1", "text": "In chronic active lesions, peripheral iron-laden macrophages appear as paramagnetic rim lesions (PRLs).", "tags": [{"end": 10, "start": 3, "tag": "TemporalConcept"}, {"end": 42, "start": 38, "tag": "PharmacologicSubstance"}, {"end": 42, "start": 38, "tag": "Chemical"}, {"end": 42, "start": 38, "tag": "BiologicallyActiveSubstance"}, {"end": 25, "start": 3, "tag": "InjuryOrPoisoning"}, {"end": 95, "start": 71, "tag": "ClinicalAttribute"}, {"end": 60, "start": 38, "tag": "Cell"}, {"end": 37, "start": 27, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 97, "tag": "ClinicalAttribute"}]}{"id": "1404_2", "text": "Objective: To evaluate the sensitivity and specificity of PRLs in differentiating MS from mimics using clinical 3T MRI scanners.", "tags": [{"end": 127, "start": 103, "tag": "ManufacturedObject"}, {"end": 38, "start": 27, "tag": "Finding"}, {"end": 54, "start": 43, "tag": "Finding"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 103, "tag": "HealthCareActivity"}, {"end": 62, "start": 58, "tag": "InjuryOrPoisoning"}]}{"id": "1404_3", "text": "Method: This retrospective international study reviewed MRI scans of patients with MS (n = 254), MS mimics (n = 91) and older healthy controls (n = 217).", "tags": [{"end": 6, "start": 0, "tag": "ResearchActivity"}, {"end": 65, "start": 56, "tag": "HealthCareActivity"}, {"end": 46, "start": 13, "tag": "ResearchActivity"}, {"end": 133, "start": 126, "tag": "OrganismAttribute"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 99, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 77, "start": 69, "tag": "PatientOrDisabledGroup"}, {"end": 142, "start": 126, "tag": "PopulationGroup"}, {"end": 106, "start": 97, "tag": "Finding"}, {"end": 125, "start": 120, "tag": "TemporalConcept"}]}{"id": "1404_4", "text": "WMLs, detected using fluid-attenuated inversion recovery MRI, were analysed with phase-sensitive imaging.", "tags": [{"end": 60, "start": 21, "tag": "HealthCareActivity"}, {"end": 56, "start": 48, "tag": "BiologicFunction"}, {"end": 56, "start": 48, "tag": "HealthCareActivity"}, {"end": 86, "start": 81, "tag": "TemporalConcept"}, {"end": 104, "start": 81, "tag": "HealthCareActivity"}, {"end": 56, "start": 48, "tag": "TemporalConcept"}, {"end": 4, "start": 0, "tag": "InjuryOrPoisoning"}, {"end": 60, "start": 21, "tag": "ManufacturedObject"}]}{"id": "1404_5", "text": "Sensitivity and specificity were assessed for PRLs.", "tags": [{"end": 11, "start": 0, "tag": "Finding"}, {"end": 27, "start": 16, "tag": "Finding"}, {"end": 50, "start": 46, "tag": "ClinicalAttribute"}]}{"id": "1404_6", "text": "Results: At least one PRL was found in 22.9% of MS and 26.1% of clinically isolated syndrome (CIS) patients.", "tags": [{"end": 25, "start": 22, "tag": "ClinicalAttribute"}, {"end": 92, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 97, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 48, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 99, "tag": "PatientOrDisabledGroup"}]}{"id": "1404_7", "text": "Only one PRL was found elsewhere.", "tags": [{"end": 12, "start": 9, "tag": "ClinicalAttribute"}]}{"id": "1404_8", "text": "The identification of > 1 PRL was the optimal cut-off and had high specificity (99.7%, confidence interval (CI) = 98.20%-99.99%) when distinguishing MS and CIS from mimics and healthy controls, but lower sensitivity (24.0%, CI = 18.9%-36.6%).", "tags": [{"end": 29, "start": 26, "tag": "ClinicalAttribute"}, {"end": 159, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 204, "tag": "Finding"}, {"end": 78, "start": 67, "tag": "Finding"}, {"end": 183, "start": 176, "tag": "OrganismAttribute"}, {"end": 151, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 106, "start": 87, "tag": "ResearchActivity"}, {"end": 192, "start": 176, "tag": "PopulationGroup"}]}{"id": "1404_9", "text": "All patients with a PRL showing a central vein sign (CVS) in the same lesion (n = 54) had MS or CIS, giving a specificity of 100% (CI = 98.8%-100.0%) but equally low sensitivity (21.3%, CI = 16.4%-26.81%) Conclusion: PRLs may reduce diagnostic uncertainty in MS by being a highly specific imaging diagnostic biomarker, especially when used in conjunction with the CVS.", "tags": [{"end": 23, "start": 20, "tag": "ClinicalAttribute"}, {"end": 99, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 166, "tag": "Finding"}, {"end": 121, "start": 110, "tag": "Finding"}, {"end": 92, "start": 90, "tag": "DiseaseOrSyndrome"}, {"end": 261, "start": 259, "tag": "DiseaseOrSyndrome"}, {"end": 12, "start": 4, "tag": "PatientOrDisabledGroup"}, {"end": 76, "start": 70, "tag": "InjuryOrPoisoning"}, {"end": 317, "start": 289, "tag": "ClinicalAttribute"}, {"end": 51, "start": 34, "tag": "ClinicalAttribute"}, {"end": 367, "start": 364, "tag": "ClinicalAttribute"}, {"end": 56, "start": 53, "tag": "ClinicalAttribute"}]}{"id": "1405_0", "text": "Objectives Neuropathological studies have shown that multiple sclerosis (MS) lesions are heterogeneous in terms of myelin/axon damage and repair as well as iron content.", "tags": [{"end": 102, "start": 89, "tag": "OrganismAttribute"}, {"end": 168, "start": 156, "tag": "BiologicFunction"}, {"end": 36, "start": 29, "tag": "ResearchActivity"}, {"end": 75, "start": 73, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 160, "start": 156, "tag": "PharmacologicSubstance"}, {"end": 160, "start": 156, "tag": "Chemical"}, {"end": 160, "start": 156, "tag": "BiologicallyActiveSubstance"}, {"end": 144, "start": 138, "tag": "BiologicFunction"}, {"end": 144, "start": 138, "tag": "HealthCareActivity"}, {"end": 84, "start": 77, "tag": "InjuryOrPoisoning"}, {"end": 121, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 115, "tag": "CellComponent"}, {"end": 126, "start": 122, "tag": "CellComponent"}, {"end": 133, "start": 115, "tag": "CellOrMolecularDysfunction"}]}{"id": "1405_1", "text": "However, it remains a challenge to identify specific chronic lesion types, especially remyelinated lesions, in vivo in patients with MS.", "tags": [{"end": 98, "start": 86, "tag": "CellFunction"}, {"end": 115, "start": 108, "tag": "ResearchActivity"}, {"end": 135, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 60, "start": 53, "tag": "TemporalConcept"}, {"end": 127, "start": 119, "tag": "PatientOrDisabledGroup"}, {"end": 106, "start": 99, "tag": "InjuryOrPoisoning"}, {"end": 67, "start": 61, "tag": "InjuryOrPoisoning"}, {"end": 31, "start": 22, "tag": "HealthCareActivity"}]}{"id": "1405_2", "text": "Methods We performed 3 studies: (1) a cross-sectional study in a prospective cohort of 115 patients with MS and 76 healthy controls, who underwent 3 T magnetic resonance imaging (MRI) for quantitative susceptibility mapping (QSM), myelin water fraction (MWF), and neurite density index (NDI) maps.", "tags": [{"end": 30, "start": 23, "tag": "ResearchActivity"}, {"end": 122, "start": 115, "tag": "OrganismAttribute"}, {"end": 107, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 147, "tag": "HealthCareActivity"}, {"end": 177, "start": 147, "tag": "ManufacturedObject"}, {"end": 182, "start": 179, "tag": "HealthCareActivity"}, {"end": 99, "start": 91, "tag": "PatientOrDisabledGroup"}, {"end": 83, "start": 77, "tag": "PopulationGroup"}, {"end": 76, "start": 65, "tag": "BiologicFunction"}, {"end": 237, "start": 231, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 237, "start": 231, "tag": "CellComponent"}, {"end": 177, "start": 170, "tag": "HealthCareActivity"}, {"end": 59, "start": 38, "tag": "ResearchActivity"}, {"end": 131, "start": 115, "tag": "PopulationGroup"}, {"end": 223, "start": 188, "tag": "HealthCareActivity"}, {"end": 223, "start": 188, "tag": "ManufacturedObject"}, {"end": 228, "start": 225, "tag": "HealthCareActivity"}, {"end": 228, "start": 225, "tag": "ManufacturedObject"}, {"end": 252, "start": 231, "tag": "ResearchActivity"}, {"end": 296, "start": 292, "tag": "ResearchActivity"}, {"end": 285, "start": 264, "tag": "ResearchActivity"}, {"end": 243, "start": 238, "tag": "Chemical"}, {"end": 290, "start": 287, "tag": "ResearchActivity"}, {"end": 257, "start": 254, "tag": "ResearchActivity"}]}{"id": "1405_3", "text": "White matter (WM) lesions in QSM were classified into 5 QSM lesion types (iso-intense, hypo-intense, hyperintense, lesions with hypo-intense rims, and lesions with paramagnetic rim legions [PRLs]); (2) a longitudinal study of 40 patients with MS to study the evolution of lesions over 2 years; (3) a postmortem histopathology-QSM validation study in 3 brains of patients with MS to assess the accuracy of QSM classification to identify neuropathological lesion types in 63 WM lesions.", "tags": [{"end": 222, "start": 204, "tag": "ResearchActivity"}, {"end": 268, "start": 259, "tag": "TemporalConcept"}, {"end": 310, "start": 300, "tag": "TemporalConcept"}, {"end": 346, "start": 311, "tag": "ResearchActivity"}, {"end": 254, "start": 249, "tag": "ResearchActivity"}, {"end": 292, "start": 287, "tag": "TemporalConcept"}, {"end": 245, "start": 243, "tag": "DiseaseOrSyndrome"}, {"end": 378, "start": 376, "tag": "DiseaseOrSyndrome"}, {"end": 237, "start": 229, "tag": "PatientOrDisabledGroup"}, {"end": 370, "start": 362, "tag": "PatientOrDisabledGroup"}, {"end": 16, "start": 14, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 475, "start": 473, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 25, "start": 18, "tag": "InjuryOrPoisoning"}, {"end": 122, "start": 115, "tag": "InjuryOrPoisoning"}, {"end": 158, "start": 151, "tag": "InjuryOrPoisoning"}, {"end": 279, "start": 272, "tag": "InjuryOrPoisoning"}, {"end": 483, "start": 476, "tag": "InjuryOrPoisoning"}, {"end": 66, "start": 60, "tag": "InjuryOrPoisoning"}, {"end": 460, "start": 454, "tag": "InjuryOrPoisoning"}, {"end": 12, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 358, "start": 352, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 29, "tag": "HealthCareActivity"}, {"end": 268, "start": 259, "tag": "BiologicFunction"}, {"end": 59, "start": 56, "tag": "HealthCareActivity"}]}{"id": "1405_4", "text": "Results At baseline, hypo- and isointense lesions showed higher mean MWF and NDI values compared to other QSM lesion types (p < 0.0001).", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 49, "start": 42, "tag": "InjuryOrPoisoning"}, {"end": 116, "start": 110, "tag": "InjuryOrPoisoning"}, {"end": 80, "start": 77, "tag": "ResearchActivity"}, {"end": 72, "start": 69, "tag": "ResearchActivity"}, {"end": 109, "start": 106, "tag": "HealthCareActivity"}]}{"id": "1405_5", "text": "Further, at 2-year follow-up, hypo-/iso-intense lesions showed an increase in MWF.", "tags": [{"end": 28, "start": 19, "tag": "HealthCareActivity"}, {"end": 28, "start": 19, "tag": "TemporalConcept"}, {"end": 18, "start": 14, "tag": "TemporalConcept"}, {"end": 55, "start": 48, "tag": "InjuryOrPoisoning"}, {"end": 81, "start": 78, "tag": "ResearchActivity"}]}{"id": "1405_6", "text": "Postmortem analyses revealed that QSM highly accurately identifies (1) fully remyelinated areas as hypo-/iso-intense (sensitivity = 88.89% and specificity = 100%), (2) chronic inactive lesions as hyperintense (sensitivity = 71.43% and specificity = 92.00%), and (3) chronic active/smoldering lesions as PRLs (sensitivity = 92.86% and specificity = 86.36%).", "tags": [{"end": 19, "start": 0, "tag": "HealthCareActivity"}, {"end": 10, "start": 0, "tag": "TemporalConcept"}, {"end": 129, "start": 118, "tag": "Finding"}, {"end": 221, "start": 210, "tag": "Finding"}, {"end": 320, "start": 309, "tag": "Finding"}, {"end": 154, "start": 143, "tag": "Finding"}, {"end": 246, "start": 235, "tag": "Finding"}, {"end": 345, "start": 334, "tag": "Finding"}, {"end": 175, "start": 168, "tag": "TemporalConcept"}, {"end": 273, "start": 266, "tag": "TemporalConcept"}, {"end": 192, "start": 185, "tag": "InjuryOrPoisoning"}, {"end": 299, "start": 292, "tag": "InjuryOrPoisoning"}, {"end": 37, "start": 34, "tag": "HealthCareActivity"}]}{"id": "1405_7", "text": "Interpretation These results provide the first evidence that it is possible to distinguish chronic MS lesions in a clinical setting, hereby supporting with new biomarkers to develop and assess remyelinating treatments.", "tags": [{"end": 55, "start": 47, "tag": "Finding"}, {"end": 170, "start": 160, "tag": "ClinicalAttribute"}, {"end": 217, "start": 193, "tag": "HealthCareActivity"}, {"end": 217, "start": 193, "tag": "ResearchActivity"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 91, "tag": "TemporalConcept"}, {"end": 109, "start": 102, "tag": "InjuryOrPoisoning"}, {"end": 46, "start": 41, "tag": "TemporalConcept"}, {"end": 131, "start": 115, "tag": "HealthCareActivity"}]}{"id": "1405_8", "text": "ANN NEUROL 2022", "tags": []}{"id": "1406_0", "text": "Objective To investigate serum neurofilament light chain (sNfL) as a potential biomarker for disease activity and treatment response in pediatric patients with multiple sclerosis (MS).", "tags": [{"end": 30, "start": 25, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 62, "start": 58, "tag": "AminoAcidPeptideOrProtein"}, {"end": 132, "start": 114, "tag": "ClinicalAttribute"}, {"end": 123, "start": 114, "tag": "HealthCareActivity"}, {"end": 123, "start": 114, "tag": "ResearchActivity"}, {"end": 88, "start": 69, "tag": "ClinicalAttribute"}, {"end": 182, "start": 180, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 136, "tag": "PatientOrDisabledGroup"}, {"end": 178, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 88, "start": 79, "tag": "ClinicalAttribute"}, {"end": 56, "start": 31, "tag": "AminoAcidPeptideOrProtein"}, {"end": 56, "start": 31, "tag": "BiologicallyActiveSubstance"}, {"end": 109, "start": 93, "tag": "HealthCareActivity"}, {"end": 62, "start": 58, "tag": "BiologicallyActiveSubstance"}, {"end": 62, "start": 58, "tag": "ClinicalAttribute"}, {"end": 56, "start": 25, "tag": "ClinicalAttribute"}]}{"id": "1406_1", "text": "Methods In this retrospective cohort study, sNfL levels were measured in a pediatric MS cohort (n = 55, follow-up 12-105 months) and in a non-neurologic pediatric control cohort (n = 301) using a high-sensitivity single-molecule array assay.", "tags": [{"end": 42, "start": 16, "tag": "ResearchActivity"}, {"end": 113, "start": 104, "tag": "HealthCareActivity"}, {"end": 113, "start": 104, "tag": "TemporalConcept"}, {"end": 127, "start": 121, "tag": "TemporalConcept"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 75, "tag": "PatientOrDisabledGroup"}, {"end": 55, "start": 44, "tag": "ClinicalAttribute"}, {"end": 177, "start": 138, "tag": "PopulationGroup"}, {"end": 240, "start": 196, "tag": "ResearchActivity"}]}{"id": "1406_2", "text": "Association of sNfL levels and treatment and clinical and MRI parameters were calculated.", "tags": [{"end": 40, "start": 31, "tag": "HealthCareActivity"}, {"end": 40, "start": 31, "tag": "ResearchActivity"}, {"end": 61, "start": 58, "tag": "HealthCareActivity"}, {"end": 26, "start": 15, "tag": "ClinicalAttribute"}]}{"id": "1406_3", "text": "Results Untreated patients had higher sNfL levels than controls (median 19.0 vs 4.6 pg/mL; CI [4.732, 6.911]),p< 0.001).", "tags": [{"end": 49, "start": 38, "tag": "ClinicalAttribute"}, {"end": 93, "start": 91, "tag": "ResearchActivity"}, {"end": 63, "start": 55, "tag": "PopulationGroup"}, {"end": 26, "start": 8, "tag": "PatientOrDisabledGroup"}, {"end": 71, "start": 65, "tag": "ResearchActivity"}]}{"id": "1406_4", "text": "sNfL levels were significantly associated with MRI activity (+9.1% per contrast-enhancing lesion, CI [1.045, 1.138],p< 0.001; +0.6% per T2-weighted lesion, CI [1.001, 1.010],p= 0.015).", "tags": [{"end": 11, "start": 0, "tag": "ClinicalAttribute"}, {"end": 100, "start": 98, "tag": "ResearchActivity"}, {"end": 158, "start": 156, "tag": "ResearchActivity"}, {"end": 50, "start": 47, "tag": "HealthCareActivity"}, {"end": 96, "start": 90, "tag": "InjuryOrPoisoning"}, {"end": 154, "start": 148, "tag": "InjuryOrPoisoning"}, {"end": 154, "start": 136, "tag": "ClinicalAttribute"}]}{"id": "1406_5", "text": "Higher values were associated with a relapse <90 days ago (+51.1%; CI [1.184, 1.929],p< 0.001) and a higher Expanded Disability Status Scale score (CI [1.001, 1.240],p= 0.048).", "tags": [{"end": 44, "start": 37, "tag": "TemporalConcept"}, {"end": 69, "start": 67, "tag": "ResearchActivity"}, {"end": 150, "start": 148, "tag": "ResearchActivity"}, {"end": 53, "start": 49, "tag": "TemporalConcept"}, {"end": 146, "start": 108, "tag": "HealthCareActivity"}]}{"id": "1406_6", "text": "In patients treated with interferon beta-1a/b (n = 27), sNfL levels declined from 14.7 to 7.9 pg/mL after 6 +/- 2 months (CI [0.339, 0.603],p< 0.001).", "tags": [{"end": 124, "start": 122, "tag": "ResearchActivity"}, {"end": 120, "start": 114, "tag": "TemporalConcept"}, {"end": 11, "start": 3, "tag": "PatientOrDisabledGroup"}, {"end": 120, "start": 112, "tag": "TemporalConcept"}, {"end": 45, "start": 25, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 25, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 25, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 56, "tag": "ClinicalAttribute"}]}{"id": "1406_7", "text": "Patients with insufficient control of clinical or MRI disease activity under treatment with interferon beta-1a/b or glatiramer acetate who switched to fingolimod (n = 18) showed a reduction of sNfL levels from 16.5 to 10.0 pg/mL 6 +/- 2 months after switch (CI [0.481, 0.701],p< 0.001).", "tags": [{"end": 134, "start": 116, "tag": "AminoAcidPeptideOrProtein"}, {"end": 161, "start": 151, "tag": "Chemical"}, {"end": 204, "start": 193, "tag": "ClinicalAttribute"}, {"end": 260, "start": 258, "tag": "ResearchActivity"}, {"end": 243, "start": 237, "tag": "TemporalConcept"}, {"end": 86, "start": 77, "tag": "HealthCareActivity"}, {"end": 86, "start": 77, "tag": "ResearchActivity"}, {"end": 53, "start": 50, "tag": "HealthCareActivity"}, {"end": 189, "start": 180, "tag": "Finding"}, {"end": 189, "start": 180, "tag": "NaturalPhenomenonOrProcess"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 243, "start": 235, "tag": "TemporalConcept"}, {"end": 70, "start": 54, "tag": "HealthCareActivity"}, {"end": 112, "start": 92, "tag": "AminoAcidPeptideOrProtein"}, {"end": 112, "start": 92, "tag": "PharmacologicSubstance"}, {"end": 112, "start": 92, "tag": "BiologicallyActiveSubstance"}, {"end": 134, "start": 116, "tag": "PharmacologicSubstance"}, {"end": 161, "start": 151, "tag": "PharmacologicSubstance"}, {"end": 161, "start": 151, "tag": "BiologicallyActiveSubstance"}]}{"id": "1406_8", "text": "Conclusions sNfL is a useful biomarker for monitoring disease activity and treatment response in pediatric MS.", "tags": [{"end": 16, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 75, "tag": "ClinicalAttribute"}, {"end": 84, "start": 75, "tag": "HealthCareActivity"}, {"end": 84, "start": 75, "tag": "ResearchActivity"}, {"end": 109, "start": 97, "tag": "DiseaseOrSyndrome"}, {"end": 53, "start": 43, "tag": "HealthCareActivity"}, {"end": 38, "start": 29, "tag": "ClinicalAttribute"}, {"end": 70, "start": 54, "tag": "HealthCareActivity"}, {"end": 16, "start": 12, "tag": "BiologicallyActiveSubstance"}, {"end": 16, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1406_9", "text": "It is most likely helpful to predict disease severity and to guide treatment decisions in patients with pediatric MS.", "tags": [{"end": 53, "start": 37, "tag": "Finding"}, {"end": 76, "start": 67, "tag": "HealthCareActivity"}, {"end": 76, "start": 67, "tag": "ResearchActivity"}, {"end": 116, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 98, "start": 90, "tag": "PatientOrDisabledGroup"}]}{"id": "1406_10", "text": "This study provides Class III evidence that sNfL levels are associated with disease activity in pediatric MS.", "tags": [{"end": 29, "start": 20, "tag": "Finding"}, {"end": 55, "start": 44, "tag": "ClinicalAttribute"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 38, "start": 30, "tag": "Finding"}, {"end": 108, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 76, "tag": "HealthCareActivity"}]}{"id": "1407_0", "text": "Background: Inflammation in chronic active lesions occurs behind a closed blood-brain barrier and cannot be detected with MRI.", "tags": [{"end": 24, "start": 12, "tag": "PathologicFunction"}, {"end": 85, "start": 80, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 122, "tag": "HealthCareActivity"}, {"end": 35, "start": 28, "tag": "TemporalConcept"}, {"end": 93, "start": 74, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 50, "start": 43, "tag": "InjuryOrPoisoning"}]}{"id": "1407_1", "text": "Activated microglia are highly enriched for iron and can be visualized with quantitative susceptibility mapping (QSM), an MRI technique used to delineate iron.", "tags": [{"end": 19, "start": 10, "tag": "Cell"}, {"end": 125, "start": 122, "tag": "HealthCareActivity"}, {"end": 48, "start": 44, "tag": "PharmacologicSubstance"}, {"end": 158, "start": 154, "tag": "PharmacologicSubstance"}, {"end": 48, "start": 44, "tag": "Chemical"}, {"end": 158, "start": 154, "tag": "Chemical"}, {"end": 48, "start": 44, "tag": "BiologicallyActiveSubstance"}, {"end": 158, "start": 154, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 126, "tag": "ResearchActivity"}, {"end": 111, "start": 76, "tag": "HealthCareActivity"}, {"end": 116, "start": 113, "tag": "HealthCareActivity"}]}{"id": "1407_2", "text": "Objective: To characterize the histopathological correlates of different QSM hyperintensity patterns in MS lesions.", "tags": [{"end": 59, "start": 31, "tag": "ClinicalAttribute"}, {"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 114, "start": 107, "tag": "InjuryOrPoisoning"}, {"end": 100, "start": 73, "tag": "ClinicalAttribute"}]}{"id": "1407_3", "text": "Methods: MS brain slabs were imaged with MRI and QSM, and processed for histology.", "tags": [{"end": 17, "start": 12, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 11, "start": 9, "tag": "DiseaseOrSyndrome"}, {"end": 44, "start": 41, "tag": "HealthCareActivity"}, {"end": 81, "start": 72, "tag": "BiomedicalOccupationOrDiscipline"}, {"end": 81, "start": 72, "tag": "ResearchActivity"}, {"end": 52, "start": 49, "tag": "HealthCareActivity"}]}{"id": "1407_4", "text": "Immunolabeled cells were quantified in the lesion rim, center, and adjacent normal-appearing white matter (NAWM).", "tags": [{"end": 105, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 49, "start": 43, "tag": "InjuryOrPoisoning"}, {"end": 19, "start": 0, "tag": "ResearchActivity"}, {"end": 105, "start": 76, "tag": "ClinicalAttribute"}, {"end": 111, "start": 107, "tag": "ClinicalAttribute"}]}{"id": "1407_5", "text": "Iron(+) myeloid cell densities at the rims were correlated with susceptibilities.", "tags": [{"end": 20, "start": 8, "tag": "Cell"}, {"end": 30, "start": 21, "tag": "ClinicalAttribute"}, {"end": 80, "start": 64, "tag": "ClinicalAttribute"}, {"end": 80, "start": 64, "tag": "OrganismAttribute"}, {"end": 4, "start": 0, "tag": "PharmacologicSubstance"}, {"end": 4, "start": 0, "tag": "Chemical"}, {"end": 4, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1407_6", "text": "Human-induced pluripotent stem cell (iPSC)-derived microglia were used to determine the effect of iron on the production of reactive oxygen species (ROS) and pro-inflammatory cytokines.", "tags": [{"end": 184, "start": 175, "tag": "AminoAcidPeptideOrProtein"}, {"end": 184, "start": 175, "tag": "CellFunction"}, {"end": 60, "start": 51, "tag": "Cell"}, {"end": 147, "start": 140, "tag": "OrganismAttribute"}, {"end": 147, "start": 124, "tag": "BiologicallyActiveSubstance"}, {"end": 147, "start": 124, "tag": "Chemical"}, {"end": 102, "start": 98, "tag": "PharmacologicSubstance"}, {"end": 102, "start": 98, "tag": "Chemical"}, {"end": 102, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 174, "start": 158, "tag": "PathologicFunction"}, {"end": 152, "start": 149, "tag": "BiologicallyActiveSubstance"}, {"end": 152, "start": 149, "tag": "Chemical"}, {"end": 41, "start": 37, "tag": "Cell"}, {"end": 35, "start": 0, "tag": "Cell"}, {"end": 60, "start": 0, "tag": "ResearchActivity"}]}{"id": "1407_7", "text": "Results: QSM hyperintensity at the lesion perimeter correlated with activated iron(+) myeloid cells in the rim and NAWM.", "tags": [{"end": 99, "start": 86, "tag": "Cell"}, {"end": 82, "start": 78, "tag": "PharmacologicSubstance"}, {"end": 82, "start": 78, "tag": "Chemical"}, {"end": 82, "start": 78, "tag": "BiologicallyActiveSubstance"}, {"end": 41, "start": 35, "tag": "InjuryOrPoisoning"}, {"end": 119, "start": 115, "tag": "ClinicalAttribute"}, {"end": 27, "start": 9, "tag": "ClinicalAttribute"}]}{"id": "1407_8", "text": "Lesions with high punctate or homogenous QSM signal contained no or minimally activated iron(-) myeloid cells.", "tags": [{"end": 7, "start": 0, "tag": "Finding"}, {"end": 109, "start": 96, "tag": "Cell"}, {"end": 92, "start": 88, "tag": "PharmacologicSubstance"}, {"end": 92, "start": 88, "tag": "Chemical"}, {"end": 92, "start": 88, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 41, "tag": "ClinicalAttribute"}]}{"id": "1407_9", "text": "In vitro, iron accumulation was highest in Ml-polarized human iPSC-derived microglia, but it did not enhance ROS or cytokine production.", "tags": [{"end": 27, "start": 10, "tag": "Finding"}, {"end": 135, "start": 116, "tag": "BiologicFunction"}, {"end": 135, "start": 116, "tag": "CellFunction"}, {"end": 61, "start": 56, "tag": "Eukaryote"}, {"end": 84, "start": 75, "tag": "Cell"}, {"end": 14, "start": 10, "tag": "PharmacologicSubstance"}, {"end": 14, "start": 10, "tag": "Chemical"}, {"end": 14, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 8, "start": 0, "tag": "ResearchActivity"}, {"end": 112, "start": 109, "tag": "BiologicallyActiveSubstance"}, {"end": 112, "start": 109, "tag": "Chemical"}, {"end": 66, "start": 62, "tag": "Cell"}, {"end": 84, "start": 62, "tag": "ResearchActivity"}]}{"id": "1407_10", "text": "Conclusion: A high QSM signal outlining the lesion rim but not punctate signal in the center is a biomarker for chronic inflammation in white matter lesions.", "tags": [{"end": 119, "start": 112, "tag": "TemporalConcept"}, {"end": 148, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 149, "tag": "InjuryOrPoisoning"}, {"end": 132, "start": 112, "tag": "PathologicFunction"}, {"end": 54, "start": 44, "tag": "InjuryOrPoisoning"}, {"end": 107, "start": 98, "tag": "ClinicalAttribute"}, {"end": 29, "start": 19, "tag": "ClinicalAttribute"}]}{"id": "1408_0", "text": "This cross-sectional European study evaluates the application of optimized magnetic resonance imaging protocols at 3 Tesla (T) for detecting and distinguishing MS from other conditions that mimic MS among adults.", "tags": [{"end": 35, "start": 5, "tag": "ResearchActivity"}, {"end": 162, "start": 160, "tag": "DiseaseOrSyndrome"}, {"end": 198, "start": 196, "tag": "DiseaseOrSyndrome"}, {"end": 101, "start": 75, "tag": "HealthCareActivity"}, {"end": 101, "start": 75, "tag": "ManufacturedObject"}, {"end": 211, "start": 205, "tag": "PopulationGroup"}, {"end": 126, "start": 75, "tag": "HealthCareActivity"}]}{"id": "1408_1", "text": "Importance The central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (MRI) studies.", "tags": [{"end": 27, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 232, "start": 225, "tag": "ResearchActivity"}, {"end": 132, "start": 130, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 218, "start": 176, "tag": "HealthCareActivity"}, {"end": 218, "start": 176, "tag": "ManufacturedObject"}, {"end": 223, "start": 220, "tag": "HealthCareActivity"}, {"end": 128, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 65, "tag": "HealthCareActivity"}, {"end": 218, "start": 211, "tag": "HealthCareActivity"}, {"end": 82, "start": 73, "tag": "ClinicalAttribute"}, {"end": 32, "start": 15, "tag": "ClinicalAttribute"}]}{"id": "1408_2", "text": "The diagnostic value of the central vein sign in a multicenter setting with a variety of clinical 3 tesla (T) MRI protocols, however, remains unknown.", "tags": [{"end": 40, "start": 28, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 123, "start": 89, "tag": "HealthCareActivity"}, {"end": 113, "start": 110, "tag": "HealthCareActivity"}, {"end": 45, "start": 28, "tag": "ClinicalAttribute"}]}{"id": "1408_3", "text": "Objective To evaluate the sensitivity and specificity of various central vein sign lesion criteria for differentiating MS from non-MS conditions using 3T brain MRI with various commonly used pulse sequences.", "tags": [{"end": 159, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 37, "start": 26, "tag": "Finding"}, {"end": 53, "start": 42, "tag": "Finding"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 160, "tag": "HealthCareActivity"}, {"end": 89, "start": 65, "tag": "ClinicalAttribute"}, {"end": 206, "start": 191, "tag": "ResearchActivity"}]}{"id": "1408_4", "text": "Design, Setting, and Participants This large multicenter, cross-sectional study enrolled participants (n = 648) of ongoing observational studies and patients included in neuroimaging research databases of 8 neuroimaging centers in Europe.", "tags": [{"end": 101, "start": 89, "tag": "PopulationGroup"}, {"end": 157, "start": 149, "tag": "PatientOrDisabledGroup"}, {"end": 144, "start": 123, "tag": "ResearchActivity"}, {"end": 79, "start": 58, "tag": "ResearchActivity"}, {"end": 33, "start": 21, "tag": "PopulationGroup"}, {"end": 201, "start": 170, "tag": "ResearchActivity"}, {"end": 227, "start": 207, "tag": "HealthCareRelatedOrganization"}]}{"id": "1408_5", "text": "Patient enrollment and MRI data collection were performed between January 1, 2010, and November 30, 2016.", "tags": [{"end": 18, "start": 0, "tag": "ResearchActivity"}, {"end": 42, "start": 27, "tag": "ResearchActivity"}, {"end": 31, "start": 27, "tag": "ResearchActivity"}, {"end": 26, "start": 23, "tag": "HealthCareActivity"}, {"end": 81, "start": 66, "tag": "TemporalConcept"}, {"end": 104, "start": 87, "tag": "TemporalConcept"}]}{"id": "1408_6", "text": "Data analysis was conducted between January 1, 2016, and April 30, 2018.", "tags": [{"end": 13, "start": 5, "tag": "ResearchActivity"}, {"end": 4, "start": 0, "tag": "ResearchActivity"}, {"end": 51, "start": 36, "tag": "TemporalConcept"}, {"end": 71, "start": 57, "tag": "TemporalConcept"}]}{"id": "1408_7", "text": "Investigators were blinded to participant diagnosis by a novel blinding procedure.", "tags": [{"end": 41, "start": 30, "tag": "PopulationGroup"}, {"end": 51, "start": 42, "tag": "HealthCareActivity"}]}{"id": "1408_8", "text": "Main Outcomes and Measures Occurrence of central vein sign was detected on 3T T2*-weighted or susceptibility-weighted imaging.", "tags": [{"end": 37, "start": 27, "tag": "TemporalConcept"}, {"end": 37, "start": 27, "tag": "HealthCareActivity"}, {"end": 53, "start": 41, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 125, "start": 75, "tag": "HealthCareActivity"}, {"end": 125, "start": 118, "tag": "HealthCareActivity"}, {"end": 13, "start": 5, "tag": "HealthCareActivity"}, {"end": 58, "start": 41, "tag": "ClinicalAttribute"}]}{"id": "1408_9", "text": "Sensitivity and specificity were assessed for these MRI sequences and for different central vein sign lesion criteria, which were defined by the proportion of lesions with central vein sign or by absolute numbers of lesions with central vein sign.", "tags": [{"end": 11, "start": 0, "tag": "Finding"}, {"end": 27, "start": 16, "tag": "Finding"}, {"end": 55, "start": 52, "tag": "HealthCareActivity"}, {"end": 166, "start": 159, "tag": "InjuryOrPoisoning"}, {"end": 223, "start": 216, "tag": "InjuryOrPoisoning"}, {"end": 108, "start": 84, "tag": "ClinicalAttribute"}, {"end": 189, "start": 172, "tag": "ClinicalAttribute"}, {"end": 246, "start": 229, "tag": "ClinicalAttribute"}]}{"id": "1408_10", "text": "Results A total of 606 participants were included in the study after exclusion of 42 participants.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 62, "start": 57, "tag": "ResearchActivity"}, {"end": 35, "start": 23, "tag": "PopulationGroup"}, {"end": 97, "start": 85, "tag": "PopulationGroup"}]}{"id": "1408_11", "text": "Among the 606 participants, 413 (68.2%) were women.", "tags": [{"end": 50, "start": 45, "tag": "PopulationGroup"}, {"end": 26, "start": 14, "tag": "PopulationGroup"}]}{"id": "1408_12", "text": "Patients with clinically isolated syndrome and relapsing-remitting MS (RRMS) included 235 women (66.6%) and had a median (range) age of 37 (14.7-61.4) years, a median (range) disease duration of 2 (0-33) years, and a median (range) Expanded Disability Status Scale score of 1.5 (0-6.5).", "tags": [{"end": 42, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 90, "tag": "PopulationGroup"}, {"end": 132, "start": 129, "tag": "OrganismAttribute"}, {"end": 156, "start": 151, "tag": "TemporalConcept"}, {"end": 209, "start": 204, "tag": "TemporalConcept"}, {"end": 69, "start": 47, "tag": "DiseaseOrSyndrome"}, {"end": 191, "start": 175, "tag": "TemporalConcept"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 75, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 270, "start": 232, "tag": "HealthCareActivity"}]}{"id": "1408_13", "text": "Patients without MS included 178 women (70.4%) and had a median (range) age of 54 (18-83) years.", "tags": [{"end": 38, "start": 33, "tag": "PopulationGroup"}, {"end": 75, "start": 72, "tag": "OrganismAttribute"}, {"end": 95, "start": 90, "tag": "TemporalConcept"}, {"end": 19, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}]}{"id": "1408_14", "text": "A total of 4447 lesions were analyzed in a total of 487 patients: 690 lesions in 98 participants with clinically isolated syndrome, 2815 lesions in 225 participants with RRMS, 54 lesions in 13 participants with neuromyelitis optica spectrum disorder, 54 lesions in 14 participants with systemic lupus erythematosus, 121 lesions in 29 participants with migraine or cluster headache, 240 lesions in 20 participants with diabetes, and 473 lesions in 88 participants with other types of small-vessel disease.", "tags": [{"end": 130, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 249, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 314, "start": 286, "tag": "DiseaseOrSyndrome"}, {"end": 360, "start": 352, "tag": "DiseaseOrSyndrome"}, {"end": 380, "start": 364, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 84, "tag": "PopulationGroup"}, {"end": 164, "start": 152, "tag": "PopulationGroup"}, {"end": 205, "start": 193, "tag": "PopulationGroup"}, {"end": 280, "start": 268, "tag": "PopulationGroup"}, {"end": 346, "start": 334, "tag": "PopulationGroup"}, {"end": 412, "start": 400, "tag": "PopulationGroup"}, {"end": 462, "start": 450, "tag": "PopulationGroup"}, {"end": 64, "start": 56, "tag": "PatientOrDisabledGroup"}, {"end": 23, "start": 16, "tag": "InjuryOrPoisoning"}, {"end": 77, "start": 70, "tag": "InjuryOrPoisoning"}, {"end": 144, "start": 137, "tag": "InjuryOrPoisoning"}, {"end": 186, "start": 179, "tag": "InjuryOrPoisoning"}, {"end": 261, "start": 254, "tag": "InjuryOrPoisoning"}, {"end": 327, "start": 320, "tag": "InjuryOrPoisoning"}, {"end": 393, "start": 386, "tag": "InjuryOrPoisoning"}, {"end": 443, "start": 436, "tag": "InjuryOrPoisoning"}, {"end": 231, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 426, "start": 418, "tag": "DiseaseOrSyndrome"}, {"end": 37, "start": 29, "tag": "ResearchActivity"}, {"end": 174, "start": 170, "tag": "DiseaseOrSyndrome"}, {"end": 503, "start": 483, "tag": "DiseaseOrSyndrome"}]}{"id": "1408_15", "text": "The sensitivity was 68.1% and specificity was 82.9% for distinguishing MS from not MS using a 35% central vein sign proportion threshold.", "tags": [{"end": 136, "start": 127, "tag": "Finding"}, {"end": 15, "start": 4, "tag": "Finding"}, {"end": 41, "start": 30, "tag": "Finding"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 115, "start": 98, "tag": "ClinicalAttribute"}]}{"id": "1408_16", "text": "The 3 central vein sign lesion criteria had a sensitivity of 61.9% and specificity of 89.0%.", "tags": [{"end": 57, "start": 46, "tag": "Finding"}, {"end": 82, "start": 71, "tag": "Finding"}, {"end": 30, "start": 24, "tag": "InjuryOrPoisoning"}, {"end": 23, "start": 6, "tag": "ClinicalAttribute"}]}{"id": "1408_17", "text": "Sensitivity was higher when an optimized T2*-weighted sequence was used.", "tags": [{"end": 11, "start": 0, "tag": "Finding"}]}{"id": "1408_18", "text": "Conclusions and Relevance In this study, use of the central vein sign at 3T MRI yielded a high specificity and a moderate sensitivity in differentiating MS from not MS; international, multicenter studies may be needed to ascertain whether the central vein sign-based criteria can accurately detect MS.", "tags": [{"end": 64, "start": 52, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 113, "tag": "Finding"}, {"end": 203, "start": 184, "tag": "ResearchActivity"}, {"end": 39, "start": 34, "tag": "ResearchActivity"}, {"end": 133, "start": 122, "tag": "Finding"}, {"end": 106, "start": 95, "tag": "Finding"}, {"end": 155, "start": 153, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 165, "tag": "DiseaseOrSyndrome"}, {"end": 300, "start": 298, "tag": "DiseaseOrSyndrome"}, {"end": 79, "start": 73, "tag": "HealthCareActivity"}, {"end": 79, "start": 73, "tag": "ManufacturedObject"}, {"end": 69, "start": 52, "tag": "ClinicalAttribute"}, {"end": 275, "start": 243, "tag": "HealthCareActivity"}, {"end": 260, "start": 243, "tag": "ClinicalAttribute"}]}{"id": "1408_19", "text": "Question Is the central vein sign on clinical 3T magnetic resonance imaging a useful biomarker for the diagnosis of multiple sclerosis? Findings In this multicenter cross-sectional study of 4447 lesions in 606 participants, use of a 35% central vein sign proportion threshold yielded a sensitivity of 68.1% and a specificity of 82.9% for distinguishing multiple sclerosis from non-multiple sclerosis.", "tags": [{"end": 28, "start": 16, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 275, "start": 266, "tag": "Finding"}, {"end": 112, "start": 103, "tag": "HealthCareActivity"}, {"end": 297, "start": 286, "tag": "Finding"}, {"end": 324, "start": 313, "tag": "Finding"}, {"end": 75, "start": 37, "tag": "HealthCareActivity"}, {"end": 75, "start": 37, "tag": "ManufacturedObject"}, {"end": 222, "start": 210, "tag": "PopulationGroup"}, {"end": 134, "start": 116, "tag": "DiseaseOrSyndrome"}, {"end": 371, "start": 353, "tag": "DiseaseOrSyndrome"}, {"end": 399, "start": 381, "tag": "DiseaseOrSyndrome"}, {"end": 202, "start": 195, "tag": "InjuryOrPoisoning"}, {"end": 75, "start": 68, "tag": "HealthCareActivity"}, {"end": 186, "start": 165, "tag": "ResearchActivity"}, {"end": 94, "start": 85, "tag": "ClinicalAttribute"}, {"end": 33, "start": 16, "tag": "ClinicalAttribute"}, {"end": 254, "start": 237, "tag": "ClinicalAttribute"}]}{"id": "1408_20", "text": "The criteria of 3 or more central vein sign lesions had a sensitivity of 61.9% and a specificity of 89.0%.", "tags": [{"end": 38, "start": 26, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 69, "start": 58, "tag": "Finding"}, {"end": 96, "start": 85, "tag": "Finding"}, {"end": 51, "start": 26, "tag": "ClinicalAttribute"}]}{"id": "1408_21", "text": "Meaning The 3T central vein sign-based criteria showed a high specificity in the differentiation between multiple sclerosis and non-multiple sclerosis; future studies may be needed to confirm the applicability of this finding to support the diagnosis of multiple sclerosis in clinical practice.", "tags": [{"end": 191, "start": 184, "tag": "Finding"}, {"end": 225, "start": 218, "tag": "Finding"}, {"end": 250, "start": 241, "tag": "HealthCareActivity"}, {"end": 166, "start": 159, "tag": "ResearchActivity"}, {"end": 73, "start": 62, "tag": "Finding"}, {"end": 158, "start": 152, "tag": "TemporalConcept"}, {"end": 96, "start": 81, "tag": "CellFunction"}, {"end": 123, "start": 105, "tag": "DiseaseOrSyndrome"}, {"end": 150, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 272, "start": 254, "tag": "DiseaseOrSyndrome"}, {"end": 293, "start": 276, "tag": "HealthCareActivity"}, {"end": 32, "start": 15, "tag": "ClinicalAttribute"}, {"end": 47, "start": 12, "tag": "HealthCareActivity"}]}{"id": "1409_0", "text": "There is increasing interest in the development of multiple sclerosis (MS) biomarkers that reflect central nervous system tissue injury to determine prognosis.", "tags": [{"end": 47, "start": 36, "tag": "BiologicFunction"}, {"end": 47, "start": 36, "tag": "CellFunction"}, {"end": 135, "start": 122, "tag": "InjuryOrPoisoning"}, {"end": 85, "start": 75, "tag": "ClinicalAttribute"}, {"end": 128, "start": 122, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 121, "start": 99, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 73, "start": 71, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 158, "start": 149, "tag": "HealthCareActivity"}, {"end": 28, "start": 9, "tag": "Finding"}]}{"id": "1409_1", "text": "We aimed to assess the prognostic value of kinesin superfamily motor protein KIF5A in MS by measuring levels of KIF5A in cerebrospinal fluid (CSF) combined with analysis of single nucleotide polymorphisms (SNPs; rs12368653 and rs703842) located within a MS susceptibility gene locus at chromosome 12q13-14 region.", "tags": [{"end": 82, "start": 77, "tag": "GeneOrGenome"}, {"end": 117, "start": 112, "tag": "GeneOrGenome"}, {"end": 145, "start": 142, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 204, "start": 173, "tag": "MolecularSequence"}, {"end": 210, "start": 206, "tag": "MolecularSequence"}, {"end": 140, "start": 121, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 169, "start": 161, "tag": "ResearchActivity"}, {"end": 88, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 256, "start": 254, "tag": "DiseaseOrSyndrome"}, {"end": 76, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 82, "start": 77, "tag": "BiologicallyActiveSubstance"}, {"end": 117, "start": 112, "tag": "BiologicallyActiveSubstance"}, {"end": 82, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 112, "tag": "AminoAcidPeptideOrProtein"}, {"end": 222, "start": 212, "tag": "MolecularSequence"}, {"end": 235, "start": 227, "tag": "MolecularSequence"}, {"end": 312, "start": 286, "tag": "CellComponent"}, {"end": 282, "start": 272, "tag": "GeneOrGenome"}, {"end": 271, "start": 257, "tag": "Finding"}]}{"id": "1409_2", "text": "Enzyme-linked immunosorbent assay was used to measure KIF5A in CSF obtained from two independent biobanks comprising non-inflammatory neurological disease controls (NINDC), clinically isolated syndrome (CIS) and MS cases.", "tags": [{"end": 33, "start": 0, "tag": "ResearchActivity"}, {"end": 59, "start": 54, "tag": "GeneOrGenome"}, {"end": 66, "start": 63, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 201, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 206, "start": 203, "tag": "DiseaseOrSyndrome"}, {"end": 214, "start": 212, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 117, "tag": "DiseaseOrSyndrome"}, {"end": 59, "start": 54, "tag": "AminoAcidPeptideOrProtein"}, {"end": 59, "start": 54, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 97, "tag": "HealthCareRelatedOrganization"}, {"end": 170, "start": 165, "tag": "PatientOrDisabledGroup"}, {"end": 163, "start": 155, "tag": "PopulationGroup"}, {"end": 220, "start": 212, "tag": "PatientOrDisabledGroup"}]}{"id": "1409_3", "text": "CSF KIF5A expression was significantly elevated in progressive MS cases compared with NINDCs, CIS and relapsing-remitting MS (RRMS).", "tags": [{"end": 3, "start": 0, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 4, "tag": "GeneOrGenome"}, {"end": 97, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 63, "tag": "DiseaseOrSyndrome"}, {"end": 124, "start": 102, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 51, "tag": "TemporalConcept"}, {"end": 9, "start": 4, "tag": "AminoAcidPeptideOrProtein"}, {"end": 9, "start": 4, "tag": "BiologicallyActiveSubstance"}, {"end": 130, "start": 126, "tag": "DiseaseOrSyndrome"}, {"end": 92, "start": 86, "tag": "PatientOrDisabledGroup"}]}{"id": "1409_4", "text": "In addition, levels of KIF5A positively correlated with change in MS disease severity scores (EDSS, MSSS and ARMSSS), in RRMS patients who had documented disease progression at 2-year clinical follow-up.", "tags": [{"end": 28, "start": 23, "tag": "GeneOrGenome"}, {"end": 202, "start": 184, "tag": "HealthCareActivity"}, {"end": 173, "start": 162, "tag": "PathologicFunction"}, {"end": 173, "start": 162, "tag": "TemporalConcept"}, {"end": 173, "start": 154, "tag": "PathologicFunction"}, {"end": 68, "start": 66, "tag": "DiseaseOrSyndrome"}, {"end": 183, "start": 179, "tag": "TemporalConcept"}, {"end": 134, "start": 126, "tag": "PatientOrDisabledGroup"}, {"end": 85, "start": 69, "tag": "ClinicalAttribute"}, {"end": 28, "start": 23, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 23, "tag": "AminoAcidPeptideOrProtein"}, {"end": 92, "start": 66, "tag": "HealthCareActivity"}, {"end": 125, "start": 121, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 100, "tag": "HealthCareActivity"}]}{"id": "1409_5", "text": "Copies of adenine risk alleles (AG/AA; rs12368653 and rs703842) corresponded with a higher proportion of individuals in relapse at the time of lumbar puncture (LP), higher use of disease-modifying therapies post LP and shorter MS duration.", "tags": [{"end": 127, "start": 120, "tag": "Finding"}, {"end": 158, "start": 143, "tag": "HealthCareActivity"}, {"end": 162, "start": 160, "tag": "HealthCareActivity"}, {"end": 211, "start": 207, "tag": "TemporalConcept"}, {"end": 214, "start": 212, "tag": "HealthCareActivity"}, {"end": 238, "start": 230, "tag": "TemporalConcept"}, {"end": 206, "start": 197, "tag": "HealthCareActivity"}, {"end": 139, "start": 135, "tag": "TemporalConcept"}, {"end": 229, "start": 227, "tag": "DiseaseOrSyndrome"}, {"end": 116, "start": 105, "tag": "PopulationGroup"}, {"end": 206, "start": 179, "tag": "HealthCareActivity"}, {"end": 17, "start": 10, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 17, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 30, "start": 23, "tag": "GeneOrGenome"}, {"end": 37, "start": 32, "tag": "NucleicAcidNucleosideOrNucleotide"}, {"end": 49, "start": 39, "tag": "MolecularSequence"}, {"end": 62, "start": 54, "tag": "MolecularSequence"}]}{"id": "1409_6", "text": "Our study suggests that CSF KIF5A has potential as a predictive biomarker in MS and further studies into the potential prognostic value of analysing MS susceptibility SNPs should be considered.", "tags": [{"end": 27, "start": 24, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 33, "start": 28, "tag": "GeneOrGenome"}, {"end": 171, "start": 167, "tag": "MolecularSequence"}, {"end": 9, "start": 4, "tag": "ResearchActivity"}, {"end": 99, "start": 92, "tag": "ResearchActivity"}, {"end": 79, "start": 77, "tag": "DiseaseOrSyndrome"}, {"end": 151, "start": 149, "tag": "DiseaseOrSyndrome"}, {"end": 73, "start": 53, "tag": "ClinicalAttribute"}, {"end": 33, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 33, "start": 28, "tag": "BiologicallyActiveSubstance"}, {"end": 135, "start": 109, "tag": "Finding"}, {"end": 171, "start": 149, "tag": "ClinicalAttribute"}]}{"id": "1410_0", "text": "Background: Clinical measures in multiple sclerosis (MS) face limitations that may be overcome by utilising smartphone keyboard interactions acquired continuously and remotely during regular typing.", "tags": [{"end": 55, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 33, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 108, "tag": "ManufacturedObject"}, {"end": 118, "start": 108, "tag": "ManufacturedObject"}]}{"id": "1410_1", "text": "Objective: The aim of this study was to determine the reliability and validity of keystroke dynamics to assess clinical aspects of MS.", "tags": [{"end": 78, "start": 70, "tag": "ResearchActivity"}, {"end": 127, "start": 111, "tag": "ClinicalAttribute"}, {"end": 32, "start": 27, "tag": "ResearchActivity"}, {"end": 133, "start": 131, "tag": "DiseaseOrSyndrome"}, {"end": 100, "start": 82, "tag": "ClinicalAttribute"}]}{"id": "1410_2", "text": "Methods: In total, 102 MS patients and 24 controls were included in this observational study.", "tags": [{"end": 92, "start": 73, "tag": "ResearchActivity"}, {"end": 25, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 42, "tag": "PopulationGroup"}, {"end": 34, "start": 26, "tag": "PatientOrDisabledGroup"}]}{"id": "1410_3", "text": "Keyboard interactions were obtained with the Neurokeys keyboard app.", "tags": [{"end": 67, "start": 45, "tag": "HealthCareActivity"}, {"end": 21, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1410_4", "text": "Eight timing-related keystroke features were assessed for reliability with intraclass correlation coefficients (ICCs); construct validity by analysing group differences (in fatigue, gadolinium-enhancing lesions on magnetic resonance imaging (MRI), and patients vs controls); and concurrent validity by correlating with disability measures.", "tags": [{"end": 137, "start": 129, "tag": "Finding"}, {"end": 156, "start": 151, "tag": "PopulationGroup"}, {"end": 180, "start": 173, "tag": "SignOrSymptom"}, {"end": 210, "start": 182, "tag": "ClinicalAttribute"}, {"end": 298, "start": 290, "tag": "Finding"}, {"end": 329, "start": 319, "tag": "Finding"}, {"end": 240, "start": 214, "tag": "HealthCareActivity"}, {"end": 240, "start": 214, "tag": "ManufacturedObject"}, {"end": 245, "start": 242, "tag": "HealthCareActivity"}, {"end": 272, "start": 264, "tag": "PopulationGroup"}, {"end": 260, "start": 252, "tag": "PatientOrDisabledGroup"}, {"end": 289, "start": 279, "tag": "TemporalConcept"}, {"end": 210, "start": 203, "tag": "InjuryOrPoisoning"}, {"end": 240, "start": 233, "tag": "HealthCareActivity"}, {"end": 110, "start": 75, "tag": "ResearchActivity"}, {"end": 116, "start": 112, "tag": "ResearchActivity"}, {"end": 338, "start": 319, "tag": "HealthCareActivity"}, {"end": 39, "start": 21, "tag": "ClinicalAttribute"}]}{"id": "1410_5", "text": "Results: Reliability was moderate in two (ICC = 0.601 and 0.742) and good to excellent in the remaining six features (ICC = 0.760-0.965).", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 45, "start": 42, "tag": "ResearchActivity"}, {"end": 121, "start": 118, "tag": "ResearchActivity"}, {"end": 20, "start": 9, "tag": "Finding"}]}{"id": "1410_6", "text": "Patients had significantly higher keystroke latencies than controls.", "tags": [{"end": 67, "start": 59, "tag": "PopulationGroup"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 53, "start": 34, "tag": "ClinicalAttribute"}]}{"id": "1410_7", "text": "Latency between key presses correlated the highest with Expanded Disability Status Scale (r = 0.407) and latency between key releases with Nine-Hole Peg Test and Symbol Digit Modalities Test (rho = 0.503 and r = -0.553, respectively), ps < 0.001.", "tags": [{"end": 7, "start": 0, "tag": "TemporalConcept"}, {"end": 112, "start": 105, "tag": "TemporalConcept"}, {"end": 88, "start": 56, "tag": "HealthCareActivity"}, {"end": 157, "start": 139, "tag": "HealthCareActivity"}, {"end": 190, "start": 162, "tag": "HealthCareActivity"}]}{"id": "1410_8", "text": "Conclusion: Keystroke dynamics were reliable, distinguished patients and controls, and were associated with clinical disability measures.", "tags": [{"end": 81, "start": 73, "tag": "PopulationGroup"}, {"end": 68, "start": 60, "tag": "PatientOrDisabledGroup"}, {"end": 30, "start": 12, "tag": "ClinicalAttribute"}]}{"id": "1410_9", "text": "Consequently, keystroke dynamics are a promising valid surrogate marker for clinical disability in MS.", "tags": [{"end": 32, "start": 24, "tag": "NaturalPhenomenonOrProcess"}, {"end": 95, "start": 65, "tag": "ClinicalAttribute"}, {"end": 101, "start": 99, "tag": "DiseaseOrSyndrome"}, {"end": 32, "start": 14, "tag": "ClinicalAttribute"}]}{"id": "1411_0", "text": "Multiple sclerosis (MS) features extensive connectivity changes, but how structural and functional connectivity relate, and whether this relation could be a useful biomarker for cognitive impairment in MS is unclear.", "tags": [{"end": 111, "start": 88, "tag": "BiologicFunction"}, {"end": 198, "start": 178, "tag": "DiseaseOrSyndrome"}, {"end": 18, "start": 0, "tag": "DiseaseOrSyndrome"}, {"end": 22, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 204, "start": 202, "tag": "DiseaseOrSyndrome"}, {"end": 173, "start": 164, "tag": "ClinicalAttribute"}]}{"id": "1411_1", "text": "This study included 79 MS patients and 40 healthy controls (HCs).", "tags": [{"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 49, "start": 42, "tag": "OrganismAttribute"}, {"end": 25, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 26, "tag": "PatientOrDisabledGroup"}, {"end": 58, "start": 42, "tag": "PopulationGroup"}]}{"id": "1411_2", "text": "Patients were classified as cognitively impaired (CI) or cognitively preserved (CP).", "tags": [{"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 48, "start": 28, "tag": "PatientOrDisabledGroup"}, {"end": 78, "start": 57, "tag": "PatientOrDisabledGroup"}]}{"id": "1411_3", "text": "Structural connectivity was determined using diffusion MRI and functional connectivity using resting-state magnetoencephalography (MEG) data (theta, alpha1, and alpha2 bands).", "tags": [{"end": 58, "start": 45, "tag": "HealthCareActivity"}, {"end": 86, "start": 63, "tag": "BiologicFunction"}, {"end": 134, "start": 131, "tag": "HealthCareActivity"}, {"end": 140, "start": 136, "tag": "ResearchActivity"}, {"end": 58, "start": 55, "tag": "HealthCareActivity"}, {"end": 54, "start": 45, "tag": "NaturalPhenomenonOrProcess"}, {"end": 23, "start": 0, "tag": "BiologicFunction"}, {"end": 129, "start": 93, "tag": "HealthCareActivity"}, {"end": 173, "start": 142, "tag": "HealthCareActivity"}]}{"id": "1411_4", "text": "Structure-function coupling was assessed by correlating modalities, and further explored in frequency bands that significantly correlated with whole-brain structural connectivity.", "tags": [{"end": 154, "start": 149, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 101, "start": 92, "tag": "TemporalConcept"}, {"end": 107, "start": 92, "tag": "HealthCareActivity"}, {"end": 178, "start": 143, "tag": "Finding"}, {"end": 27, "start": 0, "tag": "Finding"}]}{"id": "1411_5", "text": "Functional correlates of short- and long-range structural connections (based on tract length) were then specifically assessed.", "tags": [{"end": 10, "start": 0, "tag": "BiologicFunction"}, {"end": 92, "start": 80, "tag": "ResearchActivity"}, {"end": 69, "start": 36, "tag": "ResearchActivity"}]}{"id": "1411_6", "text": "Receiving operating curve analyses were performed on coupling values to identify biomarker potential.", "tags": [{"end": 90, "start": 81, "tag": "ClinicalAttribute"}, {"end": 34, "start": 0, "tag": "ResearchActivity"}, {"end": 61, "start": 53, "tag": "Finding"}]}{"id": "1411_7", "text": "Only the theta band showed significant correlations between whole-brain structural and functional connectivity (rho = -0.26, p = 0.023, only in MS).", "tags": [{"end": 110, "start": 87, "tag": "BiologicFunction"}, {"end": 71, "start": 66, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 146, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 51, "start": 27, "tag": "Finding"}, {"end": 51, "start": 39, "tag": "ResearchActivity"}, {"end": 19, "start": 9, "tag": "ResearchActivity"}, {"end": 110, "start": 98, "tag": "BiologicFunction"}, {"end": 82, "start": 72, "tag": "BiologicFunction"}]}{"id": "1411_8", "text": "Long-range structure-function coupling was stronger in CI patients compared to HCs (p = 0.005).", "tags": [{"end": 66, "start": 58, "tag": "PatientOrDisabledGroup"}, {"end": 38, "start": 0, "tag": "ResearchActivity"}]}{"id": "1411_9", "text": "Short-range coupling showed no group differences.", "tags": [{"end": 48, "start": 31, "tag": "Finding"}, {"end": 48, "start": 37, "tag": "Finding"}, {"end": 20, "start": 0, "tag": "ResearchActivity"}]}{"id": "1411_10", "text": "Structure-function coupling was not a significant classifier of cognitive impairment for any tract length (short-range area under the curve (AUC) = 0.498, p = 0.976, long-range AUC = 0.611, p = 0.095).", "tags": [{"end": 98, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 84, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 139, "start": 107, "tag": "ResearchActivity"}, {"end": 144, "start": 141, "tag": "ResearchActivity"}, {"end": 180, "start": 166, "tag": "ResearchActivity"}, {"end": 105, "start": 99, "tag": "ResearchActivity"}, {"end": 27, "start": 0, "tag": "ResearchActivity"}]}{"id": "1411_11", "text": "Long-range structure-function coupling was stronger in CI MS compared to HCs, but more research is needed to further explore this measure as biomarkers in MS.", "tags": [{"end": 151, "start": 141, "tag": "ClinicalAttribute"}, {"end": 60, "start": 58, "tag": "DiseaseOrSyndrome"}, {"end": 157, "start": 155, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 87, "tag": "ResearchActivity"}, {"end": 38, "start": 0, "tag": "ResearchActivity"}]}{"id": "1411_12", "text": "Author Summary Cognitive impairment in multiple sclerosis (MS) is common and relates to structural and functional connectivity.", "tags": [{"end": 126, "start": 103, "tag": "BiologicFunction"}, {"end": 61, "start": 59, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 35, "start": 15, "tag": "DiseaseOrSyndrome"}]}{"id": "1411_13", "text": "However, it remains unclear whether the interplay (coupling) between structural and functional connectivity could be a biomarker of MS-related cognitive impairment.", "tags": [{"end": 163, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 119, "tag": "ClinicalAttribute"}, {"end": 107, "start": 95, "tag": "BiologicFunction"}, {"end": 79, "start": 69, "tag": "BiologicFunction"}, {"end": 107, "start": 84, "tag": "BiologicFunction"}, {"end": 59, "start": 51, "tag": "Finding"}, {"end": 49, "start": 40, "tag": "Finding"}]}{"id": "1411_14", "text": "This study investigated the cognitive relevance of structure-function coupling in 79 MS patients and 40 healthy controls using diffusion MRI and magnetoencephalography.", "tags": [{"end": 140, "start": 127, "tag": "HealthCareActivity"}, {"end": 167, "start": 145, "tag": "HealthCareActivity"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}, {"end": 111, "start": 104, "tag": "OrganismAttribute"}, {"end": 87, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 140, "start": 137, "tag": "HealthCareActivity"}, {"end": 96, "start": 88, "tag": "PatientOrDisabledGroup"}, {"end": 136, "start": 127, "tag": "NaturalPhenomenonOrProcess"}, {"end": 120, "start": 104, "tag": "PopulationGroup"}, {"end": 78, "start": 51, "tag": "Finding"}]}{"id": "1411_15", "text": "Results show that coupling was stronger in cognitively impaired MS patients compared to controls, but only when considering long-distance connections.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 66, "start": 64, "tag": "DiseaseOrSyndrome"}, {"end": 96, "start": 88, "tag": "PopulationGroup"}, {"end": 75, "start": 67, "tag": "PatientOrDisabledGroup"}, {"end": 26, "start": 18, "tag": "Finding"}]}{"id": "1411_16", "text": "Nonetheless, classifier analyses indicated only weak biomarker potential in terms of sensitivity and specificity.", "tags": [{"end": 96, "start": 85, "tag": "Finding"}, {"end": 112, "start": 101, "tag": "Finding"}, {"end": 62, "start": 53, "tag": "ClinicalAttribute"}, {"end": 32, "start": 13, "tag": "ResearchActivity"}]}{"id": "1411_17", "text": "Future studies should include additional operationalization of coupling as well as longitudinal and regional or network level data.", "tags": [{"end": 59, "start": 41, "tag": "ResearchActivity"}, {"end": 95, "start": 83, "tag": "ResearchActivity"}, {"end": 130, "start": 112, "tag": "ResearchActivity"}, {"end": 14, "start": 7, "tag": "ResearchActivity"}]}{"id": "1412_0", "text": "Background and purpose: The development of new biomarkers for multiple sclerosis (MS) is of paramount importance to improve our ability to predict disease progression and disability.", "tags": [{"end": 39, "start": 28, "tag": "BiologicFunction"}, {"end": 39, "start": 28, "tag": "CellFunction"}, {"end": 181, "start": 171, "tag": "Finding"}, {"end": 166, "start": 155, "tag": "PathologicFunction"}, {"end": 166, "start": 155, "tag": "TemporalConcept"}, {"end": 57, "start": 47, "tag": "ClinicalAttribute"}, {"end": 166, "start": 147, "tag": "PathologicFunction"}, {"end": 84, "start": 82, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 62, "tag": "DiseaseOrSyndrome"}, {"end": 135, "start": 128, "tag": "OrganismAttribute"}]}{"id": "1412_1", "text": "The aim of this study was to evaluate the potential role of the optic nerve diameter (OND) measured by ultrasonography as a biomarker of early disability in patients with relapsing-remitting multiple sclerosis (RRMS).", "tags": [{"end": 75, "start": 64, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 118, "start": 103, "tag": "HealthCareActivity"}, {"end": 209, "start": 171, "tag": "DiseaseOrSyndrome"}, {"end": 215, "start": 211, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 16, "tag": "ResearchActivity"}, {"end": 165, "start": 157, "tag": "PatientOrDisabledGroup"}, {"end": 209, "start": 191, "tag": "DiseaseOrSyndrome"}, {"end": 180, "start": 171, "tag": "TemporalConcept"}, {"end": 133, "start": 124, "tag": "ClinicalAttribute"}, {"end": 84, "start": 64, "tag": "ClinicalAttribute"}, {"end": 89, "start": 86, "tag": "ClinicalAttribute"}, {"end": 153, "start": 143, "tag": "Finding"}]}{"id": "1412_2", "text": "Methods: Forty-nine RRMS patients, 23 with a history of optic neuritis (MS-ON) and 26 without a history of optic neuritis (MS N-ON), and 50 age- and sex-matched healthy control subjects were included in the study.", "tags": [{"end": 24, "start": 20, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 45, "tag": "Finding"}, {"end": 70, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 96, "tag": "Finding"}, {"end": 121, "start": 107, "tag": "DiseaseOrSyndrome"}, {"end": 212, "start": 207, "tag": "ResearchActivity"}, {"end": 143, "start": 140, "tag": "OrganismAttribute"}, {"end": 168, "start": 161, "tag": "OrganismAttribute"}, {"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 185, "start": 169, "tag": "PopulationGroup"}, {"end": 33, "start": 25, "tag": "PatientOrDisabledGroup"}, {"end": 152, "start": 149, "tag": "OrganismAttribute"}]}{"id": "1412_3", "text": "The OND and optic nerve sheath diameter (ONSD) were measured by transorbital sonography (TOS), and the retinal nerve fibre layer (RNFL) and ganglion cell complex (GCC) thicknesses were measured by optical coherence tomography (OCT) using the Optovue RTVue (TM) system (Optovue, Inc., Fremont, CA, USA).", "tags": [{"end": 60, "start": 52, "tag": "HealthCareActivity"}, {"end": 193, "start": 185, "tag": "HealthCareActivity"}, {"end": 225, "start": 197, "tag": "HealthCareActivity"}, {"end": 230, "start": 227, "tag": "HealthCareActivity"}, {"end": 259, "start": 257, "tag": "CellComponent"}, {"end": 39, "start": 12, "tag": "ClinicalAttribute"}, {"end": 45, "start": 41, "tag": "ClinicalAttribute"}, {"end": 7, "start": 4, "tag": "ClinicalAttribute"}, {"end": 87, "start": 64, "tag": "HealthCareActivity"}, {"end": 128, "start": 103, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 134, "start": 130, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 153, "start": 140, "tag": "Cell"}, {"end": 267, "start": 261, "tag": "ManufacturedObject"}, {"end": 255, "start": 242, "tag": "ManufacturedObject"}, {"end": 92, "start": 89, "tag": "HealthCareActivity"}]}{"id": "1412_4", "text": "Results: There was no significant difference between the patient (whether ON or N-ON eyes) and control groups in either the OND (p=0.979) or the ONSD (p=0.911).", "tags": [{"end": 64, "start": 57, "tag": "PatientOrDisabledGroup"}, {"end": 44, "start": 19, "tag": "Finding"}, {"end": 109, "start": 95, "tag": "PopulationGroup"}, {"end": 127, "start": 124, "tag": "ClinicalAttribute"}, {"end": 149, "start": 145, "tag": "ClinicalAttribute"}]}{"id": "1412_5", "text": "However, patients with an expanded disability status scale (EDSS) score >2 had a significantly lower OND and RNFL thicknesses (p=0.014, p=0.010 respectively) than patients with an EDSS score <= 2.", "tags": [{"end": 17, "start": 9, "tag": "PatientOrDisabledGroup"}, {"end": 171, "start": 163, "tag": "PatientOrDisabledGroup"}, {"end": 58, "start": 26, "tag": "HealthCareActivity"}, {"end": 64, "start": 60, "tag": "HealthCareActivity"}, {"end": 123, "start": 109, "tag": "ClinicalAttribute"}, {"end": 123, "start": 114, "tag": "ClinicalAttribute"}, {"end": 104, "start": 101, "tag": "ClinicalAttribute"}, {"end": 190, "start": 180, "tag": "HealthCareActivity"}]}{"id": "1412_6", "text": "Statistical logistic regression revealed that OND was an independent predictor of EDSS>2 (p=0.044, OR =0.000, 95% CI=0.000-0.589).", "tags": [{"end": 31, "start": 0, "tag": "ResearchActivity"}]}{"id": "1412_7", "text": "Conclusion: The OND, as measured by ultrasonography, could be potentially used as a biomarker for the detection of early disability in RRMS patients.", "tags": [{"end": 51, "start": 36, "tag": "HealthCareActivity"}, {"end": 111, "start": 102, "tag": "HealthCareActivity"}, {"end": 139, "start": 135, "tag": "DiseaseOrSyndrome"}, {"end": 148, "start": 140, "tag": "PatientOrDisabledGroup"}, {"end": 93, "start": 84, "tag": "ClinicalAttribute"}, {"end": 131, "start": 121, "tag": "Finding"}, {"end": 19, "start": 16, "tag": "ClinicalAttribute"}]}{"id": "1413_0", "text": "Background:Resourceful endpoints of axonal loss are needed to predict the course of multiple sclerosis (MS).", "tags": [{"end": 106, "start": 104, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 74, "tag": "TemporalConcept"}, {"end": 47, "start": 36, "tag": "PathologicFunction"}]}{"id": "1413_1", "text": "Corneal confocal microscopy (CCM) can detect axonal loss in patients with clinically isolated syndrome and established MS, which relates to neurological disability.", "tags": [{"end": 27, "start": 0, "tag": "HealthCareActivity"}, {"end": 32, "start": 29, "tag": "HealthCareActivity"}, {"end": 102, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 163, "start": 140, "tag": "SignOrSymptom"}, {"end": 121, "start": 119, "tag": "DiseaseOrSyndrome"}, {"end": 68, "start": 60, "tag": "PatientOrDisabledGroup"}, {"end": 56, "start": 45, "tag": "PathologicFunction"}]}{"id": "1413_2", "text": "Objective:To assess corneal axonal loss over time in relation to retinal atrophy, and neurological and radiological abnormalities in MS.", "tags": [{"end": 27, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 80, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 49, "start": 45, "tag": "TemporalConcept"}, {"end": 135, "start": 133, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 28, "tag": "PathologicFunction"}, {"end": 129, "start": 103, "tag": "PathologicFunction"}, {"end": 129, "start": 116, "tag": "PathologicFunction"}, {"end": 98, "start": 86, "tag": "PathologicFunction"}]}{"id": "1413_3", "text": "Methods:Patients with relapsing-remitting (RRMS) (n = 68) or secondary progressive MS (SPMS) (n = 15) underwent CCM and optical coherence tomography.", "tags": [{"end": 115, "start": 112, "tag": "HealthCareActivity"}, {"end": 148, "start": 120, "tag": "HealthCareActivity"}, {"end": 85, "start": 83, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 8, "tag": "PatientOrDisabledGroup"}, {"end": 31, "start": 22, "tag": "TemporalConcept"}, {"end": 85, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 91, "start": 87, "tag": "DiseaseOrSyndrome"}]}{"id": "1413_4", "text": "Corneal nerve fibre density (CNFD-fibres/mm(2)), corneal nerve branch density (CNBD-branches/mm(2)), corneal nerve fibre length (CNFL-mm/mm(2)) and retinal nerve fibre layer (RNFL-mu m) thickness were quantified along with neurological and radiological assessments at baseline and after 2 years of follow-up.", "tags": [{"end": 264, "start": 240, "tag": "HealthCareActivity"}, {"end": 307, "start": 298, "tag": "HealthCareActivity"}, {"end": 307, "start": 298, "tag": "TemporalConcept"}, {"end": 294, "start": 289, "tag": "TemporalConcept"}, {"end": 27, "start": 0, "tag": "ClinicalAttribute"}, {"end": 77, "start": 49, "tag": "ClinicalAttribute"}, {"end": 127, "start": 101, "tag": "ClinicalAttribute"}, {"end": 195, "start": 186, "tag": "ClinicalAttribute"}, {"end": 173, "start": 148, "tag": "ClinicalAttribute"}, {"end": 33, "start": 29, "tag": "ClinicalAttribute"}, {"end": 83, "start": 79, "tag": "ClinicalAttribute"}, {"end": 133, "start": 129, "tag": "ClinicalAttribute"}, {"end": 179, "start": 175, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 173, "start": 148, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 264, "start": 253, "tag": "HealthCareActivity"}, {"end": 235, "start": 223, "tag": "HealthCareActivity"}]}{"id": "1413_5", "text": "Age-matched, healthy controls (n = 20) were also assessed.", "tags": [{"end": 20, "start": 13, "tag": "OrganismAttribute"}, {"end": 3, "start": 0, "tag": "OrganismAttribute"}, {"end": 29, "start": 13, "tag": "PopulationGroup"}]}{"id": "1413_6", "text": "Results:In patients with RRMS compared with controls at baseline, CNFD (p = 0.004) and RNFL thickness (p < 0.001) were lower, and CNBD (p = 0.003) was higher.", "tags": [{"end": 101, "start": 87, "tag": "ClinicalAttribute"}, {"end": 52, "start": 44, "tag": "PopulationGroup"}, {"end": 19, "start": 11, "tag": "PatientOrDisabledGroup"}, {"end": 29, "start": 25, "tag": "DiseaseOrSyndrome"}, {"end": 70, "start": 66, "tag": "ClinicalAttribute"}, {"end": 134, "start": 130, "tag": "ClinicalAttribute"}]}{"id": "1413_7", "text": "In patients with SPMS compared with controls, CNFD (p < 0.001), CNFL (p = 0.04) and RNFL thickness (p < 0.001) were lower.", "tags": [{"end": 44, "start": 36, "tag": "PopulationGroup"}, {"end": 11, "start": 3, "tag": "PatientOrDisabledGroup"}, {"end": 21, "start": 17, "tag": "DiseaseOrSyndrome"}, {"end": 50, "start": 46, "tag": "ClinicalAttribute"}, {"end": 68, "start": 64, "tag": "ClinicalAttribute"}, {"end": 98, "start": 84, "tag": "ClinicalAttribute"}]}{"id": "1413_8", "text": "For identifying RRMS, CNBD had the highest area under the receiver operating characteristic (AUROC) curve (0.99); and for SPMS, CNFD had the highest AUROC (0.95).", "tags": [{"end": 20, "start": 16, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 22, "tag": "ClinicalAttribute"}, {"end": 126, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 100, "tag": "ResearchActivity"}, {"end": 91, "start": 43, "tag": "ResearchActivity"}, {"end": 98, "start": 93, "tag": "ResearchActivity"}, {"end": 132, "start": 128, "tag": "ClinicalAttribute"}, {"end": 154, "start": 149, "tag": "ResearchActivity"}]}{"id": "1413_9", "text": "At follow-up, there was a further significant decrease in CNFD (p = 0.04), CNBD (p = 0.001), CNFL (p = 0.008) and RNFL (p = 0.002) in RRMS; in CNFD (p = 0.04) and CNBD (p = 0.002) in SPMS; and in CNBD (p = 0.01) in SPMS compared with RRMS.", "tags": [{"end": 12, "start": 3, "tag": "HealthCareActivity"}, {"end": 12, "start": 3, "tag": "TemporalConcept"}, {"end": 54, "start": 34, "tag": "Finding"}, {"end": 62, "start": 58, "tag": "ClinicalAttribute"}, {"end": 79, "start": 75, "tag": "ClinicalAttribute"}, {"end": 97, "start": 93, "tag": "ClinicalAttribute"}, {"end": 138, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 143, "tag": "ClinicalAttribute"}, {"end": 167, "start": 163, "tag": "ClinicalAttribute"}, {"end": 187, "start": 183, "tag": "DiseaseOrSyndrome"}, {"end": 200, "start": 196, "tag": "ClinicalAttribute"}, {"end": 219, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 238, "start": 234, "tag": "DiseaseOrSyndrome"}, {"end": 118, "start": 114, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1413_10", "text": "Follow-up corneal nerve loss was greater in patients with new enhancing lesions and optic neuritis history.", "tags": [{"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "TemporalConcept"}, {"end": 106, "start": 99, "tag": "Finding"}, {"end": 52, "start": 44, "tag": "PatientOrDisabledGroup"}, {"end": 79, "start": 72, "tag": "InjuryOrPoisoning"}, {"end": 28, "start": 10, "tag": "PathologicFunction"}, {"end": 98, "start": 84, "tag": "DiseaseOrSyndrome"}]}{"id": "1413_11", "text": "Conclusion:Progressive corneal and retinal axonal loss was identified in patients with MS, especially those with more active disease.", "tags": [{"end": 30, "start": 23, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 42, "start": 35, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 132, "start": 118, "tag": "Finding"}, {"end": 89, "start": 87, "tag": "DiseaseOrSyndrome"}, {"end": 81, "start": 73, "tag": "PatientOrDisabledGroup"}, {"end": 54, "start": 43, "tag": "PathologicFunction"}]}{"id": "1413_12", "text": "CCM may serve as an imaging biomarker of axonal loss in MS.", "tags": [{"end": 3, "start": 0, "tag": "HealthCareActivity"}, {"end": 58, "start": 56, "tag": "DiseaseOrSyndrome"}, {"end": 52, "start": 41, "tag": "PathologicFunction"}, {"end": 27, "start": 20, "tag": "HealthCareActivity"}, {"end": 37, "start": 20, "tag": "ClinicalAttribute"}]}{"id": "1414_0", "text": "Kappa free light chain (KFLC) index, a measure for intrathecal production of free kappa chains, has been increasingly recognized for its diagnostic potential in multiple sclerosis (MS) as a quantitative alternative to IgG oligoclonal bands (OCBs).", "tags": [{"end": 22, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 35, "start": 30, "tag": "ClinicalAttribute"}, {"end": 22, "start": 0, "tag": "ClinicalAttribute"}, {"end": 157, "start": 137, "tag": "HealthCareActivity"}, {"end": 239, "start": 218, "tag": "AminoAcidPeptideOrProtein"}, {"end": 239, "start": 218, "tag": "BiologicallyActiveSubstance"}, {"end": 245, "start": 241, "tag": "AminoAcidPeptideOrProtein"}, {"end": 183, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 179, "start": 161, "tag": "DiseaseOrSyndrome"}, {"end": 62, "start": 51, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 22, "start": 0, "tag": "BiologicallyActiveSubstance"}, {"end": 28, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 28, "start": 24, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 77, "tag": "AminoAcidPeptideOrProtein"}, {"end": 245, "start": 241, "tag": "BiologicallyActiveSubstance"}]}{"id": "1414_1", "text": "Our objective was to investigate the sensitivity, specificity, and overall diagnostic accuracy of KFLC index in MS.", "tags": [{"end": 102, "start": 98, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 98, "tag": "BiologicallyActiveSubstance"}, {"end": 48, "start": 37, "tag": "Finding"}, {"end": 61, "start": 50, "tag": "Finding"}, {"end": 114, "start": 112, "tag": "DiseaseOrSyndrome"}, {"end": 94, "start": 75, "tag": "Finding"}, {"end": 108, "start": 98, "tag": "ClinicalAttribute"}]}{"id": "1414_2", "text": "KFLC index was prospectively determined as part of the diagnostic workup in patients with suspected MS (n = 327) between May 2013 and February 2020.", "tags": [{"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 84, "start": 76, "tag": "PatientOrDisabledGroup"}, {"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 129, "start": 121, "tag": "TemporalConcept"}, {"end": 147, "start": 134, "tag": "TemporalConcept"}]}{"id": "1414_3", "text": "Patients with clinically isolated syndrome (CIS), radiologically isolated syndrome (RIS), and MS had markedly higher KFLC index (44.6, IQR 16-128) compared with subjects with other neuro-inflammatory disorders (ONID) and symptomatic controls (SC) (2.19, IQR 1.68-2.98, p < 0.001).", "tags": [{"end": 42, "start": 14, "tag": "DiseaseOrSyndrome"}, {"end": 47, "start": 44, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 50, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 117, "tag": "ClinicalAttribute"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 169, "start": 161, "tag": "PopulationGroup"}, {"end": 241, "start": 233, "tag": "PopulationGroup"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 232, "start": 221, "tag": "SignOrSymptom"}, {"end": 209, "start": 181, "tag": "DiseaseOrSyndrome"}]}{"id": "1414_4", "text": "KFLC index had a sensitivity of 0.93 (95% CI 0.88-0.95) and specificity of 0.87 (95% CI 0.8-0.92) to discriminate CIS/RIS/MS from ONID and SC (AUC 0.94, 95% CI 0.91-0.97, p < 0.001).", "tags": [{"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 44, "start": 42, "tag": "GeneOrGenome"}, {"end": 44, "start": 42, "tag": "ResearchActivity"}, {"end": 159, "start": 157, "tag": "ResearchActivity"}, {"end": 28, "start": 17, "tag": "Finding"}, {"end": 71, "start": 60, "tag": "Finding"}, {"end": 124, "start": 122, "tag": "DiseaseOrSyndrome"}, {"end": 146, "start": 143, "tag": "ResearchActivity"}, {"end": 121, "start": 118, "tag": "DiseaseOrSyndrome"}, {"end": 117, "start": 114, "tag": "DiseaseOrSyndrome"}, {"end": 87, "start": 85, "tag": "ResearchActivity"}]}{"id": "1414_5", "text": "KFLC index and intrathecal fraction (IF) KFLC had similar accuracies to detect MS.", "tags": [{"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 45, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 81, "start": 79, "tag": "DiseaseOrSyndrome"}, {"end": 26, "start": 15, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1414_6", "text": "Treatment with disease-modifying therapy (DMT) did not influence the level of KFLC index and it was not affected by demographic factors or associated with degenerative or inflammatory biomarkers in cerebrospinal fluid (CSF).", "tags": [{"end": 88, "start": 78, "tag": "ClinicalAttribute"}, {"end": 167, "start": 155, "tag": "PathologicFunction"}, {"end": 222, "start": 219, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 194, "start": 184, "tag": "ClinicalAttribute"}, {"end": 40, "start": 33, "tag": "HealthCareActivity"}, {"end": 217, "start": 198, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 9, "start": 0, "tag": "HealthCareActivity"}, {"end": 9, "start": 0, "tag": "ResearchActivity"}, {"end": 40, "start": 15, "tag": "HealthCareActivity"}, {"end": 135, "start": 116, "tag": "Finding"}]}{"id": "1414_7", "text": "KFLC index in MS diagnostics has methodological advantages compared to OCB and is independent to subjective interpretation.", "tags": [{"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 28, "start": 17, "tag": "HealthCareActivity"}, {"end": 16, "start": 14, "tag": "DiseaseOrSyndrome"}]}{"id": "1414_8", "text": "Moreover, it is an attractive diagnostic tool since the diagnostic specificity and sensitivity of KFLC index are similar with that of OCBs and KFLCIF and better than for IgG index.", "tags": [{"end": 108, "start": 98, "tag": "ClinicalAttribute"}, {"end": 138, "start": 134, "tag": "AminoAcidPeptideOrProtein"}, {"end": 138, "start": 134, "tag": "BiologicallyActiveSubstance"}, {"end": 173, "start": 170, "tag": "AminoAcidPeptideOrProtein"}, {"end": 173, "start": 170, "tag": "BiologicallyActiveSubstance"}, {"end": 94, "start": 83, "tag": "Finding"}, {"end": 78, "start": 67, "tag": "Finding"}, {"end": 173, "start": 170, "tag": "PharmacologicSubstance"}, {"end": 179, "start": 170, "tag": "ClinicalAttribute"}]}{"id": "1414_9", "text": "We show that KFLC index was influenced neither by DMT nor by demographic factors or other inflammatory or degenerative processes in MS as determined by biomarkers in CSF.", "tags": [{"end": 80, "start": 61, "tag": "Finding"}, {"end": 169, "start": 166, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 162, "start": 152, "tag": "ClinicalAttribute"}, {"end": 134, "start": 132, "tag": "DiseaseOrSyndrome"}, {"end": 23, "start": 13, "tag": "ClinicalAttribute"}]}{"id": "1415_0", "text": "Background: Natalizumab treatment provides a model for non-inflammation-induced disease progression in multiple sclerosis (MS).", "tags": [{"end": 23, "start": 12, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 88, "tag": "PathologicFunction"}, {"end": 99, "start": 88, "tag": "TemporalConcept"}, {"end": 99, "start": 80, "tag": "PathologicFunction"}, {"end": 33, "start": 24, "tag": "HealthCareActivity"}, {"end": 33, "start": 24, "tag": "ResearchActivity"}, {"end": 125, "start": 123, "tag": "DiseaseOrSyndrome"}, {"end": 121, "start": 103, "tag": "DiseaseOrSyndrome"}, {"end": 71, "start": 59, "tag": "PathologicFunction"}, {"end": 50, "start": 45, "tag": "ResearchActivity"}, {"end": 23, "start": 12, "tag": "PharmacologicSubstance"}, {"end": 23, "start": 12, "tag": "BiologicallyActiveSubstance"}]}{"id": "1415_1", "text": "Objective: To study serum contactin-1 (sCNTN1) as a novel biomarker for disease progression in natalizumab-treated relapsing-remitting MS (RRMS) patients.", "tags": [{"end": 19, "start": 14, "tag": "ResearchActivity"}, {"end": 91, "start": 80, "tag": "PathologicFunction"}, {"end": 91, "start": 80, "tag": "TemporalConcept"}, {"end": 91, "start": 72, "tag": "PathologicFunction"}, {"end": 137, "start": 115, "tag": "DiseaseOrSyndrome"}, {"end": 153, "start": 145, "tag": "PatientOrDisabledGroup"}, {"end": 124, "start": 115, "tag": "TemporalConcept"}, {"end": 67, "start": 58, "tag": "ClinicalAttribute"}, {"end": 37, "start": 20, "tag": "ClinicalAttribute"}, {"end": 37, "start": 26, "tag": "AminoAcidPeptideOrProtein"}, {"end": 143, "start": 139, "tag": "DiseaseOrSyndrome"}, {"end": 45, "start": 39, "tag": "ClinicalAttribute"}, {"end": 106, "start": 95, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 95, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 95, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1415_2", "text": "Methods: Eighty-nine natalizumab-treated RRMS patients with minimum follow-up of 3 years were included.", "tags": [{"end": 77, "start": 68, "tag": "HealthCareActivity"}, {"end": 77, "start": 68, "tag": "TemporalConcept"}, {"end": 88, "start": 83, "tag": "TemporalConcept"}, {"end": 54, "start": 46, "tag": "PatientOrDisabledGroup"}, {"end": 32, "start": 21, "tag": "PharmacologicSubstance"}, {"end": 32, "start": 21, "tag": "BiologicallyActiveSubstance"}, {"end": 32, "start": 21, "tag": "AminoAcidPeptideOrProtein"}, {"end": 45, "start": 41, "tag": "DiseaseOrSyndrome"}]}{"id": "1415_3", "text": "sCNTN1 was analyzed at baseline (before natalizumab initiation), 3, 12, 24 months (M) and last follow-up (median 5.2 years) and compared to 222 healthy controls (HC) and 15 primary progressive MS patients (PPMS).", "tags": [{"end": 51, "start": 40, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 52, "tag": "TemporalConcept"}, {"end": 84, "start": 83, "tag": "TemporalConcept"}, {"end": 104, "start": 95, "tag": "HealthCareActivity"}, {"end": 104, "start": 95, "tag": "TemporalConcept"}, {"end": 81, "start": 75, "tag": "TemporalConcept"}, {"end": 122, "start": 117, "tag": "TemporalConcept"}, {"end": 151, "start": 144, "tag": "OrganismAttribute"}, {"end": 195, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 204, "start": 196, "tag": "PatientOrDisabledGroup"}, {"end": 195, "start": 181, "tag": "DiseaseOrSyndrome"}, {"end": 192, "start": 181, "tag": "TemporalConcept"}, {"end": 160, "start": 144, "tag": "PopulationGroup"}, {"end": 51, "start": 40, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 40, "tag": "PharmacologicSubstance"}]}{"id": "1415_4", "text": "Results were compared between patients with progressive, stable, or improved disability according to EDSS-plus criteria.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 87, "start": 77, "tag": "Finding"}, {"end": 38, "start": 30, "tag": "PatientOrDisabledGroup"}, {"end": 55, "start": 44, "tag": "TemporalConcept"}, {"end": 105, "start": 101, "tag": "HealthCareActivity"}]}{"id": "1415_5", "text": "Results: Median sCNTN1 levels (ng/mL,) in RRMS (baseline: 10.7, 3M: 9.7, 12M: 10.4, 24M: 10.8; last follow-up: 9.7) were significantly lower compared to HC (12.5; p <= 0.001).", "tags": [{"end": 109, "start": 100, "tag": "HealthCareActivity"}, {"end": 109, "start": 100, "tag": "TemporalConcept"}, {"end": 29, "start": 16, "tag": "ClinicalAttribute"}, {"end": 46, "start": 42, "tag": "DiseaseOrSyndrome"}]}{"id": "1415_6", "text": "It was observed that 48% of patients showed progression during follow-up, 11% improved, and 40% remained stable.", "tags": [{"end": 72, "start": 63, "tag": "HealthCareActivity"}, {"end": 72, "start": 63, "tag": "TemporalConcept"}, {"end": 55, "start": 44, "tag": "PathologicFunction"}, {"end": 55, "start": 44, "tag": "TemporalConcept"}, {"end": 36, "start": 28, "tag": "PatientOrDisabledGroup"}]}{"id": "1415_7", "text": "sCNTN1 levels were significantly lower in progressors both at baseline and at 12M compared to non-progressors.", "tags": [{"end": 13, "start": 0, "tag": "ClinicalAttribute"}]}{"id": "1415_8", "text": "A 1 ng/mL decrease in baseline sCNTN1 was consistent with an odds ratio of 1.23 (95% confidence interval 1.04-1.45) (p = 0.017) for progression during follow-up.", "tags": [{"end": 160, "start": 151, "tag": "HealthCareActivity"}, {"end": 160, "start": 151, "tag": "TemporalConcept"}, {"end": 143, "start": 132, "tag": "PathologicFunction"}, {"end": 143, "start": 132, "tag": "TemporalConcept"}, {"end": 18, "start": 10, "tag": "Finding"}, {"end": 104, "start": 85, "tag": "ResearchActivity"}, {"end": 37, "start": 31, "tag": "ClinicalAttribute"}]}{"id": "1415_9", "text": "Conclusion: Lower baseline sCNTN1 concentrations were associated with long-term disability progression during natalizumab treatment, making it a possible blood-based prognostic biomarker for RRMS.", "tags": [{"end": 48, "start": 27, "tag": "ClinicalAttribute"}, {"end": 90, "start": 80, "tag": "Finding"}, {"end": 121, "start": 110, "tag": "AminoAcidPeptideOrProtein"}, {"end": 102, "start": 91, "tag": "PathologicFunction"}, {"end": 102, "start": 91, "tag": "TemporalConcept"}, {"end": 131, "start": 122, "tag": "HealthCareActivity"}, {"end": 131, "start": 122, "tag": "ResearchActivity"}, {"end": 159, "start": 154, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 79, "start": 70, "tag": "TemporalConcept"}, {"end": 186, "start": 166, "tag": "ClinicalAttribute"}, {"end": 121, "start": 110, "tag": "PharmacologicSubstance"}, {"end": 121, "start": 110, "tag": "BiologicallyActiveSubstance"}, {"end": 195, "start": 191, "tag": "DiseaseOrSyndrome"}]}{"id": "1416_0", "text": "Background and Objectives The diagnosis of secondary progressive multiple sclerosis (SPMS) is often delayed because of the lack of objective clinical tools, which increases the diagnostic uncertainty and hampers the therapeutic development in progressive multiple sclerosis (MS).", "tags": [{"end": 83, "start": 43, "tag": "DiseaseOrSyndrome"}, {"end": 107, "start": 100, "tag": "TemporalConcept"}, {"end": 89, "start": 85, "tag": "DiseaseOrSyndrome"}, {"end": 277, "start": 275, "tag": "DiseaseOrSyndrome"}, {"end": 273, "start": 243, "tag": "DiseaseOrSyndrome"}, {"end": 239, "start": 216, "tag": "ResearchActivity"}, {"end": 39, "start": 30, "tag": "HealthCareActivity"}, {"end": 199, "start": 177, "tag": "Finding"}]}{"id": "1416_1", "text": "Optical coherence tomography (OCT) has been proposed as a promising biomarker of progressive neurodegeneration.", "tags": [{"end": 28, "start": 0, "tag": "HealthCareActivity"}, {"end": 33, "start": 30, "tag": "HealthCareActivity"}, {"end": 77, "start": 58, "tag": "ClinicalAttribute"}, {"end": 92, "start": 81, "tag": "TemporalConcept"}, {"end": 110, "start": 93, "tag": "CellOrMolecularDysfunction"}]}{"id": "1416_2", "text": "To explore longitudinal changes in the thicknesses of retinal layers on OCT in individuals with relapsing-remitting MS (RRMS) who converted to SPMS vs matched patients with RRMS who did not convert to SPMS.", "tags": [{"end": 118, "start": 96, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 143, "tag": "DiseaseOrSyndrome"}, {"end": 205, "start": 201, "tag": "DiseaseOrSyndrome"}, {"end": 31, "start": 11, "tag": "Finding"}, {"end": 75, "start": 72, "tag": "HealthCareActivity"}, {"end": 68, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 124, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 177, "start": 173, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 159, "tag": "PatientOrDisabledGroup"}, {"end": 90, "start": 79, "tag": "PopulationGroup"}, {"end": 68, "start": 39, "tag": "ClinicalAttribute"}]}{"id": "1416_3", "text": "Our hypothesis is that the 2 cohorts exhibit different rates of retinal thinning.", "tags": [{"end": 80, "start": 64, "tag": "Finding"}, {"end": 36, "start": 29, "tag": "PopulationGroup"}]}{"id": "1416_4", "text": "Methods From our prospective observational cohort of patients with MS at the American University of Beirut, we selected patients with RRMS who converted to SPMS during the observation period and patients with RRMS, matched by age, disease duration, and Expanded Disability Status Scale (EDSS) at the first visit.", "tags": [{"end": 190, "start": 172, "tag": "TemporalConcept"}, {"end": 247, "start": 231, "tag": "HealthCareActivity"}, {"end": 247, "start": 239, "tag": "TemporalConcept"}, {"end": 28, "start": 17, "tag": "BiologicFunction"}, {"end": 247, "start": 231, "tag": "TemporalConcept"}, {"end": 160, "start": 156, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 67, "tag": "DiseaseOrSyndrome"}, {"end": 305, "start": 300, "tag": "TemporalConcept"}, {"end": 138, "start": 134, "tag": "DiseaseOrSyndrome"}, {"end": 213, "start": 209, "tag": "DiseaseOrSyndrome"}, {"end": 285, "start": 253, "tag": "HealthCareActivity"}, {"end": 291, "start": 287, "tag": "HealthCareActivity"}, {"end": 61, "start": 53, "tag": "PatientOrDisabledGroup"}, {"end": 128, "start": 120, "tag": "PatientOrDisabledGroup"}, {"end": 203, "start": 195, "tag": "PatientOrDisabledGroup"}, {"end": 311, "start": 306, "tag": "HealthCareActivity"}, {"end": 229, "start": 226, "tag": "OrganismAttribute"}, {"end": 106, "start": 77, "tag": "HealthCareRelatedOrganization"}, {"end": 49, "start": 43, "tag": "PopulationGroup"}]}{"id": "1416_5", "text": "Baseline retinal measurements were obtained using spectral domain OCT, and all patients underwent clinical and OCT evaluation every 6-12 months on average throughout the study period (mean = 4 years).", "tags": [{"end": 69, "start": 50, "tag": "HealthCareActivity"}, {"end": 114, "start": 111, "tag": "HealthCareActivity"}, {"end": 16, "start": 9, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 87, "start": 79, "tag": "PatientOrDisabledGroup"}, {"end": 182, "start": 176, "tag": "TemporalConcept"}, {"end": 175, "start": 170, "tag": "ResearchActivity"}, {"end": 198, "start": 193, "tag": "TemporalConcept"}, {"end": 143, "start": 137, "tag": "TemporalConcept"}, {"end": 29, "start": 17, "tag": "HealthCareActivity"}, {"end": 125, "start": 115, "tag": "HealthCareActivity"}, {"end": 125, "start": 115, "tag": "ResearchActivity"}]}{"id": "1416_6", "text": "Mixed-effect regression models were used to assess the annualized rates of retinal changes and the differences between the 2 groups and between converters to SPMS before and after their conversion.", "tags": [{"end": 154, "start": 144, "tag": "Finding"}, {"end": 162, "start": 158, "tag": "DiseaseOrSyndrome"}, {"end": 82, "start": 75, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 30, "start": 13, "tag": "ResearchActivity"}, {"end": 110, "start": 99, "tag": "Finding"}, {"end": 169, "start": 163, "tag": "TemporalConcept"}, {"end": 131, "start": 125, "tag": "PopulationGroup"}, {"end": 196, "start": 186, "tag": "Finding"}]}{"id": "1416_7", "text": "Results A total of 61 participants were selected (21 SPMS and 40 RRMS).", "tags": [{"end": 57, "start": 53, "tag": "DiseaseOrSyndrome"}, {"end": 69, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 22, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}{"id": "1416_8", "text": "There were no differences in baseline characteristics and retinal measurements between the 2 groups.", "tags": [{"end": 25, "start": 11, "tag": "Finding"}, {"end": 65, "start": 58, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 53, "start": 38, "tag": "OrganismAttribute"}, {"end": 99, "start": 93, "tag": "PopulationGroup"}, {"end": 78, "start": 66, "tag": "HealthCareActivity"}]}{"id": "1416_9", "text": "The annualized rates of thinning of all retinal layers, except for macular volume, were greater in converters before conversion compared with nonconverters by 112% for peripapillary retinal nerve fiber layer (p = 0.008), 344% for tRNFL (p < 0.0001), and 82% for cell-inner plexiform layer (GCIPL) (p = 0.002).", "tags": [{"end": 54, "start": 48, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 99, "tag": "Finding"}, {"end": 207, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 47, "start": 40, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 116, "start": 110, "tag": "TemporalConcept"}, {"end": 127, "start": 117, "tag": "Finding"}, {"end": 20, "start": 15, "tag": "TemporalConcept"}, {"end": 32, "start": 24, "tag": "Finding"}, {"end": 81, "start": 67, "tag": "ClinicalAttribute"}, {"end": 235, "start": 230, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 288, "start": 262, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 295, "start": 290, "tag": "BodyPartOrganOrOrganComponent"}]}{"id": "1416_10", "text": "When comparing the annualized rate of thinning for the same patients with SPMS before and after conversion, no significant differences were found except for tRNFL and GCIPL with slower thinning rates postconversion (46% and 68%, respectively).", "tags": [{"end": 78, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 30, "tag": "TemporalConcept"}, {"end": 68, "start": 60, "tag": "PatientOrDisabledGroup"}, {"end": 134, "start": 123, "tag": "Finding"}, {"end": 85, "start": 79, "tag": "TemporalConcept"}, {"end": 106, "start": 96, "tag": "Finding"}, {"end": 162, "start": 157, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 172, "start": 167, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 214, "start": 200, "tag": "TemporalConcept"}, {"end": 46, "start": 38, "tag": "Finding"}, {"end": 199, "start": 194, "tag": "TemporalConcept"}, {"end": 193, "start": 185, "tag": "Finding"}]}{"id": "1416_11", "text": "Discussion Patients who converted to SPMS exhibited faster retinal thinning as reflected on OCT.", "tags": [{"end": 75, "start": 59, "tag": "Finding"}, {"end": 41, "start": 37, "tag": "DiseaseOrSyndrome"}, {"end": 95, "start": 92, "tag": "HealthCareActivity"}, {"end": 19, "start": 11, "tag": "PatientOrDisabledGroup"}]}{"id": "1416_12", "text": "Longitudinal assessment of retinal thinning could confirm the transition to SPMS and help with the therapeutic decision making for patients with MS with clinical suspicion of disease progression.", "tags": [{"end": 43, "start": 27, "tag": "Finding"}, {"end": 80, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 62, "tag": "Finding"}, {"end": 139, "start": 131, "tag": "PatientOrDisabledGroup"}, {"end": 23, "start": 0, "tag": "HealthCareActivity"}, {"end": 194, "start": 175, "tag": "PathologicFunction"}, {"end": 126, "start": 111, "tag": "BiologicFunction"}, {"end": 171, "start": 153, "tag": "Finding"}]}{"id": "1417_0", "text": "Background Multiple sclerosis (MS) has two pathophysiological processes, one inflammatory and the other degenerative.", "tags": [{"end": 71, "start": 43, "tag": "BiologicFunction"}, {"end": 116, "start": 104, "tag": "PathologicFunction"}, {"end": 33, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 29, "start": 11, "tag": "DiseaseOrSyndrome"}, {"end": 61, "start": 43, "tag": "PathologicFunction"}, {"end": 89, "start": 77, "tag": "PathologicFunction"}]}{"id": "1417_1", "text": "We investigated the relationship between active lesions on magnetic resonance imaging showing the inflammatory phase in MS patients and serum parameters that can be used as inflammatory biomarkers.", "tags": [{"end": 122, "start": 120, "tag": "DiseaseOrSyndrome"}, {"end": 55, "start": 41, "tag": "InjuryOrPoisoning"}, {"end": 141, "start": 136, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 123, "tag": "PatientOrDisabledGroup"}, {"end": 196, "start": 173, "tag": "ClinicalAttribute"}, {"end": 116, "start": 111, "tag": "TemporalConcept"}, {"end": 32, "start": 20, "tag": "Finding"}, {"end": 85, "start": 59, "tag": "HealthCareActivity"}, {"end": 110, "start": 98, "tag": "PathologicFunction"}]}{"id": "1417_2", "text": "Thus, we aim to detect the inflammatory period in clinical and radiological follow-up and to reveal the period in which disease-modifying treatments are effective with serum parameters.", "tags": [{"end": 148, "start": 120, "tag": "HealthCareActivity"}, {"end": 173, "start": 168, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 46, "start": 40, "tag": "TemporalConcept"}, {"end": 110, "start": 104, "tag": "TemporalConcept"}, {"end": 85, "start": 76, "tag": "HealthCareActivity"}, {"end": 85, "start": 76, "tag": "TemporalConcept"}, {"end": 39, "start": 27, "tag": "PathologicFunction"}]}{"id": "1417_3", "text": "Methods One hundred eighty-six MS patients presented to our hospital between January 2016 and November 2021 and 94 age- and sex-matched healthy volunteers were recruited for our study.", "tags": [{"end": 68, "start": 60, "tag": "HealthCareRelatedOrganization"}, {"end": 33, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 154, "start": 144, "tag": "PopulationGroup"}, {"end": 127, "start": 124, "tag": "OrganismAttribute"}, {"end": 42, "start": 34, "tag": "PatientOrDisabledGroup"}, {"end": 143, "start": 136, "tag": "OrganismAttribute"}, {"end": 183, "start": 178, "tag": "ResearchActivity"}, {"end": 118, "start": 115, "tag": "OrganismAttribute"}, {"end": 89, "start": 77, "tag": "TemporalConcept"}, {"end": 107, "start": 94, "tag": "TemporalConcept"}]}{"id": "1417_4", "text": "While 99 patients had active lesions on magnetic resonance imaging, 87 patients did not have any active lesions.", "tags": [{"end": 36, "start": 22, "tag": "InjuryOrPoisoning"}, {"end": 111, "start": 97, "tag": "InjuryOrPoisoning"}, {"end": 17, "start": 9, "tag": "PatientOrDisabledGroup"}, {"end": 79, "start": 71, "tag": "PatientOrDisabledGroup"}, {"end": 66, "start": 40, "tag": "HealthCareActivity"}]}{"id": "1417_5", "text": "Neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and monocyte/lymphocyte ratio (MLR) were determined.", "tags": [{"end": 10, "start": 0, "tag": "Cell"}, {"end": 21, "start": 11, "tag": "Cell"}, {"end": 27, "start": 0, "tag": "ClinicalAttribute"}, {"end": 60, "start": 35, "tag": "ClinicalAttribute"}, {"end": 97, "start": 72, "tag": "ClinicalAttribute"}, {"end": 43, "start": 35, "tag": "Cell"}, {"end": 54, "start": 44, "tag": "Cell"}, {"end": 80, "start": 72, "tag": "Cell"}, {"end": 91, "start": 81, "tag": "Cell"}]}{"id": "1417_6", "text": "The SII (systemic immune inflammatory index) value was calculated according to the platelet X neutrophil/lymphocyte ratio formula.", "tags": [{"end": 91, "start": 83, "tag": "Cell"}, {"end": 43, "start": 9, "tag": "ResearchActivity"}, {"end": 104, "start": 94, "tag": "Cell"}, {"end": 115, "start": 105, "tag": "Cell"}, {"end": 50, "start": 45, "tag": "ClinicalAttribute"}, {"end": 7, "start": 4, "tag": "ClinicalAttribute"}]}{"id": "1417_7", "text": "Results NLR, MLR, PLR and SII values were found to be statistically significantly higher in MS patients than in the control group.", "tags": [{"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 103, "start": 95, "tag": "PatientOrDisabledGroup"}, {"end": 129, "start": 116, "tag": "PopulationGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 36, "start": 26, "tag": "ResearchActivity"}, {"end": 11, "start": 8, "tag": "ClinicalAttribute"}, {"end": 16, "start": 13, "tag": "ClinicalAttribute"}, {"end": 21, "start": 18, "tag": "ClinicalAttribute"}]}{"id": "1417_8", "text": "The NLR, MLR, PLR and SII were higher in the active group with gadolonium than in the group without active lesions.", "tags": [{"end": 114, "start": 100, "tag": "InjuryOrPoisoning"}, {"end": 57, "start": 52, "tag": "PopulationGroup"}, {"end": 91, "start": 86, "tag": "PopulationGroup"}, {"end": 73, "start": 63, "tag": "Chemical"}, {"end": 73, "start": 63, "tag": "PharmacologicSubstance"}, {"end": 25, "start": 22, "tag": "ClinicalAttribute"}, {"end": 7, "start": 4, "tag": "ClinicalAttribute"}, {"end": 12, "start": 9, "tag": "ClinicalAttribute"}, {"end": 17, "start": 14, "tag": "ClinicalAttribute"}]}{"id": "1417_9", "text": "In addition, the cutoff values that we can use to determine the presence of active lesions were 1.53, 0.18, 117.15, and 434.45 for NLR, MLR PLR and SII, respectively.", "tags": [{"end": 30, "start": 17, "tag": "ResearchActivity"}, {"end": 90, "start": 76, "tag": "InjuryOrPoisoning"}, {"end": 72, "start": 64, "tag": "Finding"}, {"end": 134, "start": 131, "tag": "ClinicalAttribute"}, {"end": 139, "start": 136, "tag": "ClinicalAttribute"}, {"end": 143, "start": 140, "tag": "ClinicalAttribute"}, {"end": 151, "start": 148, "tag": "ClinicalAttribute"}]}{"id": "1417_10", "text": "Conclusions We found that all parameters correlated with radiological activity.", "tags": []}{"id": "1417_11", "text": "In addition, we showed that we can detect the inflammatory period with high sensitivity and specificity with the cutoff value used for SII and PLR.", "tags": [{"end": 103, "start": 71, "tag": "Finding"}, {"end": 125, "start": 113, "tag": "ResearchActivity"}, {"end": 65, "start": 59, "tag": "TemporalConcept"}, {"end": 58, "start": 46, "tag": "PathologicFunction"}, {"end": 138, "start": 135, "tag": "ResearchActivity"}, {"end": 146, "start": 143, "tag": "ClinicalAttribute"}]}{"id": "1417_12", "text": "Among these easily accessible and inexpensive evaluations, we concluded that SII, including the values in the PLR formula, can come to the fore.", "tags": [{"end": 57, "start": 46, "tag": "HealthCareActivity"}, {"end": 80, "start": 77, "tag": "ResearchActivity"}, {"end": 113, "start": 110, "tag": "ClinicalAttribute"}]}{"id": "1418_0", "text": "INTRODUCTION As the number of biomarkers used to study Alzheimer's disease (AD) continues to increase, it is important to understand the utility of any given biomarker, as well as what additional information a biomarker provides when compared to others.", "tags": [{"end": 54, "start": 49, "tag": "ResearchActivity"}, {"end": 74, "start": 55, "tag": "DiseaseOrSyndrome"}, {"end": 40, "start": 30, "tag": "ClinicalAttribute"}, {"end": 78, "start": 76, "tag": "DiseaseOrSyndrome"}, {"end": 167, "start": 158, "tag": "ClinicalAttribute"}, {"end": 219, "start": 210, "tag": "ClinicalAttribute"}]}{"id": "1418_1", "text": "METHODS We used hierarchical clustering to group 19 cross-sectional biomarkers in autosomal dominant AD.", "tags": [{"end": 39, "start": 16, "tag": "ResearchActivity"}, {"end": 78, "start": 68, "tag": "ClinicalAttribute"}, {"end": 103, "start": 82, "tag": "DiseaseOrSyndrome"}]}{"id": "1418_2", "text": "Feature selection identified biomarkers that were the strongest predictors of mutation status and estimated years from symptom onset (EYO).", "tags": [{"end": 93, "start": 78, "tag": "ResearchActivity"}, {"end": 93, "start": 78, "tag": "CellOrMolecularDysfunction"}, {"end": 86, "start": 78, "tag": "CellOrMolecularDysfunction"}, {"end": 39, "start": 29, "tag": "ClinicalAttribute"}, {"end": 132, "start": 98, "tag": "TemporalConcept"}, {"end": 74, "start": 64, "tag": "Finding"}, {"end": 137, "start": 134, "tag": "TemporalConcept"}]}{"id": "1418_3", "text": "Biomarkers identified included clinical assessments, neuroimaging, cerebrospinal fluid amyloid, and tau, and emerging biomarkers of neuronal integrity and inflammation.", "tags": [{"end": 10, "start": 0, "tag": "ClinicalAttribute"}, {"end": 65, "start": 53, "tag": "HealthCareActivity"}, {"end": 94, "start": 87, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 100, "tag": "AminoAcidPeptideOrProtein"}, {"end": 128, "start": 118, "tag": "ClinicalAttribute"}, {"end": 86, "start": 67, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 150, "start": 132, "tag": "CellFunction"}, {"end": 167, "start": 155, "tag": "PathologicFunction"}, {"end": 51, "start": 31, "tag": "HealthCareActivity"}, {"end": 94, "start": 87, "tag": "BiologicallyActiveSubstance"}, {"end": 103, "start": 100, "tag": "BiologicallyActiveSubstance"}]}{"id": "1418_4", "text": "RESULTS Three primary clusters were identified: neurodegeneration, amyloid/tau, and emerging biomarkers.", "tags": [{"end": 65, "start": 48, "tag": "CellOrMolecularDysfunction"}, {"end": 78, "start": 75, "tag": "AminoAcidPeptideOrProtein"}, {"end": 103, "start": 93, "tag": "ClinicalAttribute"}, {"end": 74, "start": 67, "tag": "AminoAcidPeptideOrProtein"}, {"end": 74, "start": 67, "tag": "BiologicallyActiveSubstance"}, {"end": 78, "start": 75, "tag": "BiologicallyActiveSubstance"}]}{"id": "1418_5", "text": "Feature selection identified amyloid and tau measures as the primary predictors of mutation status and EYO.", "tags": [{"end": 36, "start": 29, "tag": "AminoAcidPeptideOrProtein"}, {"end": 36, "start": 29, "tag": "BiologicallyActiveSubstance"}, {"end": 98, "start": 83, "tag": "ResearchActivity"}, {"end": 98, "start": 83, "tag": "CellOrMolecularDysfunction"}, {"end": 91, "start": 83, "tag": "CellOrMolecularDysfunction"}, {"end": 44, "start": 41, "tag": "AminoAcidPeptideOrProtein"}, {"end": 79, "start": 69, "tag": "Finding"}, {"end": 44, "start": 41, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 103, "tag": "TemporalConcept"}]}{"id": "1418_6", "text": "Emerging biomarkers of neuronal integrity and inflammation were relatively weak predictors.", "tags": [{"end": 19, "start": 9, "tag": "ClinicalAttribute"}, {"end": 41, "start": 23, "tag": "CellFunction"}, {"end": 58, "start": 46, "tag": "PathologicFunction"}, {"end": 90, "start": 75, "tag": "Finding"}]}{"id": "1418_7", "text": "DISCUSSION These results provide novel insight into our understanding of the relationships among biomarkers and the staging of biomarkers based on disease progression.", "tags": [{"end": 123, "start": 116, "tag": "TemporalConcept"}, {"end": 166, "start": 155, "tag": "PathologicFunction"}, {"end": 166, "start": 155, "tag": "TemporalConcept"}, {"end": 107, "start": 97, "tag": "ClinicalAttribute"}, {"end": 137, "start": 127, "tag": "ClinicalAttribute"}, {"end": 166, "start": 147, "tag": "PathologicFunction"}]}{"id": "1419_0", "text": "BackgroundChitinase -3-like 1-protein (CHI3L1) is a glycoside secreted by monocytes, microglia, and activated astrocytes.", "tags": [{"end": 61, "start": 52, "tag": "Chemical"}, {"end": 83, "start": 74, "tag": "Cell"}, {"end": 45, "start": 39, "tag": "GeneOrGenome"}, {"end": 45, "start": 39, "tag": "AminoAcidPeptideOrProtein"}, {"end": 120, "start": 100, "tag": "Cell"}, {"end": 94, "start": 85, "tag": "Cell"}, {"end": 37, "start": 10, "tag": "AminoAcidPeptideOrProtein"}, {"end": 37, "start": 10, "tag": "BiologicallyActiveSubstance"}, {"end": 45, "start": 39, "tag": "BiologicallyActiveSubstance"}]}{"id": "1419_1", "text": "Its distribution in inflammatory lesions denotes its role in astrocytic response to modulate CNS inflammation.", "tags": [{"end": 96, "start": 93, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 109, "start": 97, "tag": "PathologicFunction"}, {"end": 40, "start": 20, "tag": "InjuryOrPoisoning"}, {"end": 80, "start": 61, "tag": "CellFunction"}]}{"id": "1419_2", "text": "In multiple sclerosis (MS), CHI3L1 levels have been found to be influenced by disease severity, activity, and progression.", "tags": [{"end": 25, "start": 23, "tag": "DiseaseOrSyndrome"}, {"end": 21, "start": 3, "tag": "DiseaseOrSyndrome"}, {"end": 34, "start": 28, "tag": "GeneOrGenome"}, {"end": 34, "start": 28, "tag": "AminoAcidPeptideOrProtein"}, {"end": 94, "start": 78, "tag": "ClinicalAttribute"}, {"end": 94, "start": 78, "tag": "Finding"}, {"end": 121, "start": 110, "tag": "PathologicFunction"}, {"end": 121, "start": 110, "tag": "TemporalConcept"}, {"end": 34, "start": 28, "tag": "BiologicallyActiveSubstance"}]}{"id": "1419_3", "text": "We aimed to measure CSF level of CHI3L1 in patients with MS and correlate its level with disability measures for a possible role as a biomarker for disease progression.MethodsFifty-two MS patients (30 relapsing-remitting MS and 22 progressive MS) and thirty-five age and sex-matched healthy controls were included.", "tags": [{"end": 223, "start": 201, "tag": "DiseaseOrSyndrome"}, {"end": 245, "start": 231, "tag": "DiseaseOrSyndrome"}, {"end": 108, "start": 89, "tag": "HealthCareActivity"}, {"end": 59, "start": 57, "tag": "DiseaseOrSyndrome"}, {"end": 187, "start": 185, "tag": "DiseaseOrSyndrome"}, {"end": 39, "start": 33, "tag": "GeneOrGenome"}, {"end": 39, "start": 33, "tag": "AminoAcidPeptideOrProtein"}, {"end": 274, "start": 271, "tag": "OrganismAttribute"}, {"end": 99, "start": 89, "tag": "Finding"}, {"end": 23, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 143, "start": 134, "tag": "ClinicalAttribute"}, {"end": 51, "start": 43, "tag": "PatientOrDisabledGroup"}, {"end": 196, "start": 188, "tag": "PatientOrDisabledGroup"}, {"end": 290, "start": 283, "tag": "OrganismAttribute"}, {"end": 299, "start": 291, "tag": "PopulationGroup"}, {"end": 167, "start": 156, "tag": "PathologicFunction"}, {"end": 167, "start": 156, "tag": "TemporalConcept"}, {"end": 167, "start": 148, "tag": "PathologicFunction"}, {"end": 266, "start": 263, "tag": "OrganismAttribute"}, {"end": 39, "start": 33, "tag": "BiologicallyActiveSubstance"}, {"end": 39, "start": 20, "tag": "ClinicalAttribute"}]}{"id": "1419_4", "text": "They all underwent full clinical assessment (including disability and cognitive scales), radiological assessment, and CSF level of CHI3L1.ResultsPatients with MS had higher CSF level of CHI3L1 than controls.", "tags": [{"end": 161, "start": 159, "tag": "DiseaseOrSyndrome"}, {"end": 137, "start": 131, "tag": "GeneOrGenome"}, {"end": 192, "start": 186, "tag": "GeneOrGenome"}, {"end": 137, "start": 131, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 186, "tag": "AminoAcidPeptideOrProtein"}, {"end": 65, "start": 55, "tag": "Finding"}, {"end": 121, "start": 118, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 176, "start": 173, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 206, "start": 198, "tag": "PopulationGroup"}, {"end": 43, "start": 24, "tag": "HealthCareActivity"}, {"end": 112, "start": 89, "tag": "HealthCareActivity"}, {"end": 137, "start": 131, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 118, "tag": "ClinicalAttribute"}, {"end": 192, "start": 173, "tag": "ClinicalAttribute"}, {"end": 192, "start": 186, "tag": "BiologicallyActiveSubstance"}]}{"id": "1419_5", "text": "Patients with progressive forms had higher levels than relapsing forms.", "tags": [{"end": 64, "start": 55, "tag": "TemporalConcept"}, {"end": 25, "start": 14, "tag": "TemporalConcept"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}]}{"id": "1419_6", "text": "There were positive correlations between disease duration, number of attacks, total EDSS, and CSF level of CHI3L1.", "tags": [{"end": 76, "start": 69, "tag": "Finding"}, {"end": 76, "start": 69, "tag": "DiseaseOrSyndrome"}, {"end": 57, "start": 41, "tag": "TemporalConcept"}, {"end": 113, "start": 107, "tag": "GeneOrGenome"}, {"end": 113, "start": 107, "tag": "AminoAcidPeptideOrProtein"}, {"end": 88, "start": 84, "tag": "HealthCareActivity"}, {"end": 97, "start": 94, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 32, "start": 20, "tag": "ResearchActivity"}, {"end": 113, "start": 94, "tag": "ClinicalAttribute"}, {"end": 113, "start": 107, "tag": "BiologicallyActiveSubstance"}]}{"id": "1419_7", "text": "Patients who had higher level of CSF CHI3L1 showed worse performance in MMSE and BICAMS and more lesions in T2 MRI brain.", "tags": [{"end": 43, "start": 37, "tag": "GeneOrGenome"}, {"end": 43, "start": 37, "tag": "AminoAcidPeptideOrProtein"}, {"end": 76, "start": 72, "tag": "HealthCareActivity"}, {"end": 104, "start": 97, "tag": "InjuryOrPoisoning"}, {"end": 56, "start": 51, "tag": "Finding"}, {"end": 36, "start": 33, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 120, "start": 115, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 68, "start": 57, "tag": "Finding"}, {"end": 114, "start": 108, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 43, "start": 37, "tag": "BiologicallyActiveSubstance"}, {"end": 87, "start": 81, "tag": "HealthCareActivity"}]}{"id": "1419_8", "text": "A cut off value of 154 ng/mL was found between patients with RRMS and PMS patients.ConclusionCHI3L1 can be considered as a biomarker of disease progression.", "tags": [{"end": 73, "start": 70, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 61, "tag": "DiseaseOrSyndrome"}, {"end": 132, "start": 123, "tag": "ClinicalAttribute"}, {"end": 55, "start": 47, "tag": "PatientOrDisabledGroup"}, {"end": 82, "start": 74, "tag": "PatientOrDisabledGroup"}, {"end": 155, "start": 144, "tag": "PathologicFunction"}, {"end": 155, "start": 144, "tag": "TemporalConcept"}, {"end": 155, "start": 136, "tag": "PathologicFunction"}, {"end": 15, "start": 2, "tag": "ResearchActivity"}, {"end": 99, "start": 93, "tag": "AminoAcidPeptideOrProtein"}, {"end": 99, "start": 93, "tag": "BiologicallyActiveSubstance"}, {"end": 99, "start": 93, "tag": "GeneOrGenome"}]}{"id": "1419_9", "text": "CHI3L1 level increases in progressive MS more than RRMS.", "tags": [{"end": 40, "start": 26, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "GeneOrGenome"}, {"end": 6, "start": 0, "tag": "AminoAcidPeptideOrProtein"}, {"end": 55, "start": 51, "tag": "DiseaseOrSyndrome"}, {"end": 6, "start": 0, "tag": "BiologicallyActiveSubstance"}]}{"id": "1419_10", "text": "Also, high CSF level of CHI3L1 was associated with more disability including motor, cognitive, and radiological aspects.", "tags": [{"end": 30, "start": 24, "tag": "GeneOrGenome"}, {"end": 30, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 56, "tag": "Finding"}, {"end": 14, "start": 11, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 10, "start": 6, "tag": "Finding"}, {"end": 30, "start": 11, "tag": "ClinicalAttribute"}, {"end": 30, "start": 24, "tag": "BiologicallyActiveSubstance"}]}{"id": "1420_0", "text": "Purpose: Magnetic resonance imaging (MRI) findings in multiple sclerosis (MS) overlap with numerous MS mimics.", "tags": [{"end": 109, "start": 100, "tag": "Finding"}, {"end": 76, "start": 74, "tag": "DiseaseOrSyndrome"}, {"end": 102, "start": 100, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 54, "tag": "DiseaseOrSyndrome"}, {"end": 85, "start": 78, "tag": "TemporalConcept"}, {"end": 35, "start": 9, "tag": "HealthCareActivity"}, {"end": 40, "start": 37, "tag": "HealthCareActivity"}]}{"id": "1420_1", "text": "The central vein sign (CVS) can help to differentiate MS from other mimics.", "tags": [{"end": 21, "start": 4, "tag": "ClinicalAttribute"}, {"end": 26, "start": 23, "tag": "ClinicalAttribute"}, {"end": 16, "start": 4, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 56, "start": 54, "tag": "DiseaseOrSyndrome"}]}{"id": "1420_2", "text": "This study aimed to determine the value of CVS as a diagnostic biomarker for distinguishing MS from its mimics.", "tags": [{"end": 46, "start": 43, "tag": "ClinicalAttribute"}, {"end": 94, "start": 92, "tag": "DiseaseOrSyndrome"}, {"end": 72, "start": 52, "tag": "ClinicalAttribute"}, {"end": 10, "start": 5, "tag": "ResearchActivity"}]}{"id": "1420_3", "text": "Patients and Methods: Patients were prospectively recruited into two groups: a typical clinical (TC) MS presentation with an atypical MRI for MS and an atypical clinical (ATC) MS presentation with a typical MRI for MS.", "tags": [{"end": 116, "start": 104, "tag": "Finding"}, {"end": 95, "start": 79, "tag": "Finding"}, {"end": 191, "start": 179, "tag": "Finding"}, {"end": 169, "start": 152, "tag": "Finding"}, {"end": 103, "start": 101, "tag": "DiseaseOrSyndrome"}, {"end": 144, "start": 142, "tag": "DiseaseOrSyndrome"}, {"end": 178, "start": 176, "tag": "DiseaseOrSyndrome"}, {"end": 217, "start": 215, "tag": "DiseaseOrSyndrome"}, {"end": 133, "start": 125, "tag": "Finding"}, {"end": 75, "start": 69, "tag": "PopulationGroup"}, {"end": 137, "start": 134, "tag": "HealthCareActivity"}, {"end": 210, "start": 207, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 30, "start": 22, "tag": "PatientOrDisabledGroup"}]}{"id": "1420_4", "text": "Patients underwent a 1.5T MRI brain scan with a T2*-weighted gradient-echo sequence.", "tags": [{"end": 40, "start": 30, "tag": "HealthCareActivity"}, {"end": 29, "start": 21, "tag": "HealthCareActivity"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}, {"end": 83, "start": 48, "tag": "ResearchActivity"}]}{"id": "1420_5", "text": "The presence of the central vein was assessed by a radiologist blinded to patients' clinical presentation.", "tags": [{"end": 70, "start": 63, "tag": "ResearchActivity"}, {"end": 105, "start": 84, "tag": "Finding"}, {"end": 32, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 82, "start": 74, "tag": "PatientOrDisabledGroup"}, {"end": 12, "start": 4, "tag": "Finding"}]}{"id": "1420_6", "text": "The MS consultant made the final diagnosis without reviewing the T2*-weighted gradient-echo sequence or the CVS analysis results.", "tags": [{"end": 17, "start": 7, "tag": "PopulationGroup"}, {"end": 111, "start": 108, "tag": "ClinicalAttribute"}, {"end": 6, "start": 4, "tag": "DiseaseOrSyndrome"}, {"end": 42, "start": 33, "tag": "HealthCareActivity"}, {"end": 120, "start": 112, "tag": "ResearchActivity"}, {"end": 100, "start": 65, "tag": "HealthCareActivity"}]}{"id": "1420_7", "text": "Results: Forty-two patients were included.", "tags": [{"end": 27, "start": 19, "tag": "PatientOrDisabledGroup"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}]}{"id": "1420_8", "text": "Ten (40%) out of 25 TC patients were diagnosed with clinically definite MS (CDMS), with a mean percentage of CV-positive lesions of 65.5% among CDMS patients.", "tags": [{"end": 74, "start": 72, "tag": "DiseaseOrSyndrome"}, {"end": 128, "start": 121, "tag": "InjuryOrPoisoning"}, {"end": 31, "start": 23, "tag": "PatientOrDisabledGroup"}, {"end": 157, "start": 149, "tag": "PatientOrDisabledGroup"}, {"end": 46, "start": 37, "tag": "HealthCareActivity"}]}{"id": "1420_9", "text": "Four (23.5%) out of 17 ATC patients were diagnosed with CDMS with a mean CV-positive lesions percentage of 68.25% among CDMS patients.", "tags": [{"end": 92, "start": 85, "tag": "InjuryOrPoisoning"}, {"end": 35, "start": 27, "tag": "PatientOrDisabledGroup"}, {"end": 133, "start": 125, "tag": "PatientOrDisabledGroup"}, {"end": 50, "start": 41, "tag": "HealthCareActivity"}]}{"id": "1420_10", "text": "TC patients who were not diagnosed as CDMS had a mean CV-positive lesions percentage of 10.13%, while ATC patients who were not diagnosed as CDMS had a mean CV-positive lesions percentage of 16.38%.", "tags": [{"end": 73, "start": 66, "tag": "InjuryOrPoisoning"}, {"end": 176, "start": 169, "tag": "InjuryOrPoisoning"}, {"end": 11, "start": 3, "tag": "PatientOrDisabledGroup"}, {"end": 114, "start": 106, "tag": "PatientOrDisabledGroup"}, {"end": 34, "start": 25, "tag": "HealthCareActivity"}, {"end": 137, "start": 128, "tag": "HealthCareActivity"}]}{"id": "1420_11", "text": "The CVS showed 85.7% sensitivity and 100% specificity (95% confidence interval: 0.919-1.018) for diagnosis of MS at a cut off value of 45% (p < 0.001).", "tags": [{"end": 7, "start": 4, "tag": "ClinicalAttribute"}, {"end": 112, "start": 110, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 59, "tag": "ResearchActivity"}, {"end": 106, "start": 97, "tag": "HealthCareActivity"}, {"end": 32, "start": 21, "tag": "Finding"}, {"end": 53, "start": 42, "tag": "Finding"}, {"end": 131, "start": 118, "tag": "ResearchActivity"}]}{"id": "1420_12", "text": "The percentage of CV-positive lesions was significantly higher in oligoclonal bands (OCBs) positive patients compared to OCBs negative patients (p < 0.001) and those with spinal cord lesions compared to patients with no spinal cord lesions (p = 0.017).", "tags": [{"end": 190, "start": 171, "tag": "Finding"}, {"end": 239, "start": 220, "tag": "Finding"}, {"end": 182, "start": 171, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 231, "start": 220, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 83, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 83, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 85, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 121, "tag": "AminoAcidPeptideOrProtein"}, {"end": 89, "start": 85, "tag": "BiologicallyActiveSubstance"}, {"end": 125, "start": 121, "tag": "BiologicallyActiveSubstance"}, {"end": 37, "start": 30, "tag": "InjuryOrPoisoning"}, {"end": 190, "start": 183, "tag": "InjuryOrPoisoning"}, {"end": 239, "start": 232, "tag": "InjuryOrPoisoning"}, {"end": 108, "start": 100, "tag": "PatientOrDisabledGroup"}, {"end": 143, "start": 135, "tag": "PatientOrDisabledGroup"}, {"end": 211, "start": 203, "tag": "PatientOrDisabledGroup"}, {"end": 83, "start": 66, "tag": "ResearchActivity"}, {"end": 125, "start": 121, "tag": "ResearchActivity"}, {"end": 89, "start": 85, "tag": "ResearchActivity"}]}{"id": "1420_13", "text": "Conclusion: The CVS has 85.7% sensitivity and 100% specificity for the diagnosis of MS at a cutoff value of 45%.", "tags": [{"end": 19, "start": 16, "tag": "ClinicalAttribute"}, {"end": 86, "start": 84, "tag": "DiseaseOrSyndrome"}, {"end": 104, "start": 92, "tag": "ResearchActivity"}, {"end": 80, "start": 71, "tag": "HealthCareActivity"}, {"end": 41, "start": 30, "tag": "Finding"}, {"end": 62, "start": 51, "tag": "Finding"}]}{"id": "1421_0", "text": "Objective We aimed to determine in relapsing multiple sclerosis (MS) whether intrathecal synthesis of immunoglobulin (Ig) M and IgG is associated with outcomes reflecting inflammatory activity and chronic worsening.", "tags": [{"end": 214, "start": 205, "tag": "Finding"}, {"end": 131, "start": 128, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 128, "tag": "BiologicallyActiveSubstance"}, {"end": 88, "start": 77, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 131, "start": 128, "tag": "PharmacologicSubstance"}, {"end": 67, "start": 65, "tag": "DiseaseOrSyndrome"}, {"end": 63, "start": 35, "tag": "DiseaseOrSyndrome"}, {"end": 159, "start": 151, "tag": "Finding"}, {"end": 204, "start": 197, "tag": "TemporalConcept"}, {"end": 123, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 123, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 192, "start": 171, "tag": "Finding"}]}{"id": "1421_1", "text": "Methods We compared cerebrospinal fluid analysis, clinical and magnetic resonance imaging data, and serum neurofilament light chain (sNfL) levels at baseline and follow-up in 530 patients with relapsing MS.", "tags": [{"end": 131, "start": 100, "tag": "ClinicalAttribute"}, {"end": 137, "start": 133, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 133, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 125, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 205, "start": 193, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 100, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 39, "start": 20, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 187, "start": 179, "tag": "PatientOrDisabledGroup"}, {"end": 94, "start": 90, "tag": "ResearchActivity"}, {"end": 171, "start": 162, "tag": "HealthCareActivity"}, {"end": 171, "start": 162, "tag": "TemporalConcept"}, {"end": 48, "start": 40, "tag": "ResearchActivity"}, {"end": 89, "start": 63, "tag": "HealthCareActivity"}, {"end": 131, "start": 106, "tag": "AminoAcidPeptideOrProtein"}, {"end": 131, "start": 106, "tag": "BiologicallyActiveSubstance"}, {"end": 137, "start": 133, "tag": "ClinicalAttribute"}]}{"id": "1421_2", "text": "Patients were categorized by the presence of oligoclonal IgG bands (OCGB) and intrathecal synthesis of IgG and IgM (intrathecal fraction [IF]: IgG(IF) and IgM(IF)).", "tags": [{"end": 66, "start": 45, "tag": "AminoAcidPeptideOrProtein"}, {"end": 66, "start": 45, "tag": "ResearchActivity"}, {"end": 72, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 72, "start": 68, "tag": "ResearchActivity"}, {"end": 114, "start": 111, "tag": "AminoAcidPeptideOrProtein"}, {"end": 114, "start": 111, "tag": "ResearchActivity"}, {"end": 114, "start": 111, "tag": "BiologicallyActiveSubstance"}, {"end": 60, "start": 57, "tag": "AminoAcidPeptideOrProtein"}, {"end": 106, "start": 103, "tag": "AminoAcidPeptideOrProtein"}, {"end": 146, "start": 143, "tag": "AminoAcidPeptideOrProtein"}, {"end": 60, "start": 57, "tag": "BiologicallyActiveSubstance"}, {"end": 106, "start": 103, "tag": "BiologicallyActiveSubstance"}, {"end": 146, "start": 143, "tag": "BiologicallyActiveSubstance"}, {"end": 89, "start": 78, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 127, "start": 116, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 60, "start": 57, "tag": "PharmacologicSubstance"}, {"end": 106, "start": 103, "tag": "PharmacologicSubstance"}, {"end": 146, "start": 143, "tag": "PharmacologicSubstance"}, {"end": 41, "start": 33, "tag": "Finding"}, {"end": 8, "start": 0, "tag": "PatientOrDisabledGroup"}]}{"id": "1421_3", "text": "Relationships with the time to first relapse, sNfL concentrations, T2-weighted (T2w) lesions, MS Severity Score (MSSS), and time to initiation of high-efficacy therapy were analyzed in covariate-adjusted statistical models.", "tags": [{"end": 50, "start": 46, "tag": "BiologicallyActiveSubstance"}, {"end": 50, "start": 46, "tag": "AminoAcidPeptideOrProtein"}, {"end": 117, "start": 113, "tag": "HealthCareActivity"}, {"end": 96, "start": 94, "tag": "DiseaseOrSyndrome"}, {"end": 65, "start": 51, "tag": "BiologicFunction"}, {"end": 142, "start": 132, "tag": "TemporalConcept"}, {"end": 44, "start": 37, "tag": "TemporalConcept"}, {"end": 44, "start": 37, "tag": "Finding"}, {"end": 92, "start": 67, "tag": "InjuryOrPoisoning"}, {"end": 36, "start": 31, "tag": "TemporalConcept"}, {"end": 27, "start": 23, "tag": "TemporalConcept"}, {"end": 128, "start": 124, "tag": "TemporalConcept"}, {"end": 159, "start": 151, "tag": "Finding"}, {"end": 167, "start": 160, "tag": "HealthCareActivity"}, {"end": 222, "start": 216, "tag": "ResearchActivity"}, {"end": 181, "start": 173, "tag": "ResearchActivity"}, {"end": 150, "start": 146, "tag": "Finding"}, {"end": 50, "start": 46, "tag": "ClinicalAttribute"}, {"end": 111, "start": 94, "tag": "HealthCareActivity"}]}{"id": "1421_4", "text": "Results By categorical analysis, in patients with IgM(IF) the median time to first relapse was 28 months shorter and MSSS on average higher by 1.11 steps compared with patients without intrathecal immunoglobulin synthesis.", "tags": [{"end": 221, "start": 197, "tag": "BiologicFunction"}, {"end": 121, "start": 117, "tag": "HealthCareActivity"}, {"end": 196, "start": 185, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 90, "start": 83, "tag": "TemporalConcept"}, {"end": 90, "start": 83, "tag": "Finding"}, {"end": 82, "start": 77, "tag": "TemporalConcept"}, {"end": 44, "start": 36, "tag": "PatientOrDisabledGroup"}, {"end": 176, "start": 168, "tag": "PatientOrDisabledGroup"}, {"end": 73, "start": 69, "tag": "TemporalConcept"}, {"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 104, "start": 98, "tag": "TemporalConcept"}, {"end": 31, "start": 23, "tag": "ResearchActivity"}, {"end": 68, "start": 62, "tag": "ResearchActivity"}, {"end": 53, "start": 50, "tag": "BiologicallyActiveSubstance"}, {"end": 53, "start": 50, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1421_5", "text": "Moreover, patients with IgM(IF) had higher sNfL concentrations, more new/enlarging T2w lesions, and higher total T2w lesion counts (all p <= 0.01).", "tags": [{"end": 86, "start": 83, "tag": "HealthCareActivity"}, {"end": 47, "start": 43, "tag": "BiologicallyActiveSubstance"}, {"end": 47, "start": 43, "tag": "AminoAcidPeptideOrProtein"}, {"end": 62, "start": 48, "tag": "BiologicFunction"}, {"end": 123, "start": 117, "tag": "InjuryOrPoisoning"}, {"end": 94, "start": 87, "tag": "InjuryOrPoisoning"}, {"end": 18, "start": 10, "tag": "PatientOrDisabledGroup"}, {"end": 27, "start": 24, "tag": "AminoAcidPeptideOrProtein"}, {"end": 27, "start": 24, "tag": "BiologicallyActiveSubstance"}]}{"id": "1421_6", "text": "These associations were absent or equally smaller in patients who were positive for only OCGB or OCGB/IgG(IF).", "tags": [{"end": 30, "start": 24, "tag": "Finding"}, {"end": 93, "start": 89, "tag": "AminoAcidPeptideOrProtein"}, {"end": 93, "start": 89, "tag": "ResearchActivity"}, {"end": 105, "start": 102, "tag": "AminoAcidPeptideOrProtein"}, {"end": 105, "start": 102, "tag": "BiologicallyActiveSubstance"}, {"end": 105, "start": 102, "tag": "PharmacologicSubstance"}, {"end": 61, "start": 53, "tag": "PatientOrDisabledGroup"}, {"end": 93, "start": 89, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 97, "tag": "ResearchActivity"}, {"end": 101, "start": 97, "tag": "BiologicallyActiveSubstance"}, {"end": 101, "start": 97, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1421_7", "text": "Furthermore, quantitative analyses revealed that in patients with IgM(IF) >= median, the time to first relapse and to initiation of high-efficacy therapy was shorter by 32 and by 203 months, respectively (both p < 0.01), in comparison to patients with IgM(IF) < median.", "tags": [{"end": 128, "start": 118, "tag": "TemporalConcept"}, {"end": 110, "start": 103, "tag": "TemporalConcept"}, {"end": 110, "start": 103, "tag": "Finding"}, {"end": 234, "start": 224, "tag": "ResearchActivity"}, {"end": 102, "start": 97, "tag": "TemporalConcept"}, {"end": 60, "start": 52, "tag": "PatientOrDisabledGroup"}, {"end": 246, "start": 238, "tag": "PatientOrDisabledGroup"}, {"end": 93, "start": 89, "tag": "TemporalConcept"}, {"end": 189, "start": 183, "tag": "TemporalConcept"}, {"end": 34, "start": 26, "tag": "ResearchActivity"}, {"end": 145, "start": 137, "tag": "Finding"}, {"end": 153, "start": 146, "tag": "HealthCareActivity"}, {"end": 83, "start": 77, "tag": "ResearchActivity"}, {"end": 268, "start": 262, "tag": "ResearchActivity"}, {"end": 136, "start": 132, "tag": "Finding"}, {"end": 69, "start": 66, "tag": "AminoAcidPeptideOrProtein"}, {"end": 69, "start": 66, "tag": "BiologicallyActiveSubstance"}, {"end": 255, "start": 252, "tag": "AminoAcidPeptideOrProtein"}, {"end": 255, "start": 252, "tag": "BiologicallyActiveSubstance"}]}{"id": "1421_8", "text": "Dose-dependent associations were also found for IgM(IF) but not for IgG(IF) with magnetic resonance imaging-defined disease activity and sNfL.", "tags": [{"end": 141, "start": 137, "tag": "BiologicallyActiveSubstance"}, {"end": 141, "start": 137, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 68, "tag": "AminoAcidPeptideOrProtein"}, {"end": 71, "start": 68, "tag": "BiologicallyActiveSubstance"}, {"end": 71, "start": 68, "tag": "PharmacologicSubstance"}, {"end": 132, "start": 116, "tag": "HealthCareActivity"}, {"end": 14, "start": 5, "tag": "Finding"}, {"end": 107, "start": 81, "tag": "HealthCareActivity"}, {"end": 141, "start": 137, "tag": "ClinicalAttribute"}, {"end": 51, "start": 48, "tag": "BiologicallyActiveSubstance"}, {"end": 51, "start": 48, "tag": "AminoAcidPeptideOrProtein"}]}{"id": "1421_9", "text": "Interpretation This large study supports the value of intrathecal IgM synthesis as an independent biomarker of disease activity and severity in relapsing MS.", "tags": [{"end": 65, "start": 54, "tag": "BodyPartOrganOrOrganComponent"}, {"end": 156, "start": 144, "tag": "DiseaseOrSyndrome"}, {"end": 127, "start": 111, "tag": "HealthCareActivity"}, {"end": 140, "start": 132, "tag": "ClinicalAttribute"}, {"end": 140, "start": 132, "tag": "Finding"}, {"end": 107, "start": 98, "tag": "ClinicalAttribute"}, {"end": 31, "start": 26, "tag": "ResearchActivity"}, {"end": 69, "start": 54, "tag": "ClinicalAttribute"}]}{"id": "1421_10", "text": "ANN NEUROL 2021", "tags": []}{"id": "1422_0", "text": "Background Impaired gait plays an important role for quality of life in patients with Huntington's disease (HD).", "tags": [{"end": 24, "start": 11, "tag": "Finding"}, {"end": 106, "start": 86, "tag": "DiseaseOrSyndrome"}, {"end": 110, "start": 108, "tag": "DiseaseOrSyndrome"}, {"end": 80, "start": 72, "tag": "PatientOrDisabledGroup"}, {"end": 68, "start": 64, "tag": "TemporalConcept"}, {"end": 68, "start": 53, "tag": "Finding"}, {"end": 24, "start": 20, "tag": "OrganismAttribute"}]}{"id": "1422_1", "text": "Measuring objective gait parameters in HD might provide an unbiased assessment of motor deficits in order to determine potential beneficial effects of future treatments.", "tags": [{"end": 96, "start": 82, "tag": "PathologicFunction"}, {"end": 41, "start": 39, "tag": "DiseaseOrSyndrome"}, {"end": 168, "start": 158, "tag": "HealthCareActivity"}, {"end": 168, "start": 158, "tag": "ResearchActivity"}, {"end": 157, "start": 151, "tag": "TemporalConcept"}, {"end": 147, "start": 129, "tag": "Finding"}, {"end": 24, "start": 20, "tag": "OrganismAttribute"}]}{"id": "1422_2", "text": "Objective To objectively identify characteristic features of gait in HD patients using sensor-based gait analysis.", "tags": [{"end": 113, "start": 105, "tag": "ResearchActivity"}, {"end": 80, "start": 69, "tag": "PatientOrDisabledGroup"}, {"end": 65, "start": 61, "tag": "OrganismAttribute"}, {"end": 104, "start": 100, "tag": "OrganismAttribute"}]}{"id": "1422_3", "text": "Particularly, gait parameters were correlated to the Unified Huntington's Disease Rating Scale, total motor score (TMS), and total functional capacity (TFC).", "tags": [{"end": 94, "start": 53, "tag": "HealthCareActivity"}, {"end": 18, "start": 14, "tag": "OrganismAttribute"}, {"end": 113, "start": 96, "tag": "HealthCareActivity"}, {"end": 150, "start": 125, "tag": "HealthCareActivity"}]}{"id": "1422_4", "text": "Methods Patients with manifest HD at two German sites (n = 43) were included and clinically assessed during their annual ENROLL-HD visit.", "tags": [{"end": 120, "start": 114, "tag": "TemporalConcept"}, {"end": 136, "start": 131, "tag": "HealthCareActivity"}, {"end": 33, "start": 31, "tag": "DiseaseOrSyndrome"}, {"end": 130, "start": 128, "tag": "DiseaseOrSyndrome"}, {"end": 16, "start": 8, "tag": "PatientOrDisabledGroup"}, {"end": 30, "start": 22, "tag": "SignOrSymptom"}, {"end": 130, "start": 121, "tag": "ResearchActivity"}]}{"id": "1422_5", "text": "In addition, patients with HD and a cohort of age- and gender-matched controls performed a defined gait test (4 x 10 m walk).", "tags": [{"end": 49, "start": 46, "tag": "OrganismAttribute"}, {"end": 29, "start": 27, "tag": "DiseaseOrSyndrome"}, {"end": 78, "start": 70, "tag": "PopulationGroup"}, {"end": 61, "start": 55, "tag": "OrganismAttribute"}, {"end": 21, "start": 13, "tag": "PatientOrDisabledGroup"}, {"end": 42, "start": 36, "tag": "PopulationGroup"}, {"end": 103, "start": 99, "tag": "OrganismAttribute"}, {"end": 108, "start": 99, "tag": "HealthCareActivity"}]}{"id": "1422_6", "text": "Gait patterns were recorded by inertial sensors attached to both shoes.", "tags": []}{"id": "1422_7", "text": "Machine learning algorithms were applied to calculate spatio-temporal gait parameters and gait variability expressed as coefficient of variance (CV).", "tags": [{"end": 27, "start": 0, "tag": "MachineActivity"}, {"end": 16, "start": 8, "tag": "BiologicFunction"}, {"end": 74, "start": 70, "tag": "OrganismAttribute"}, {"end": 94, "start": 90, "tag": "OrganismAttribute"}, {"end": 143, "start": 120, "tag": "ResearchActivity"}, {"end": 106, "start": 90, "tag": "ClinicalAttribute"}]}{"id": "1422_8", "text": "Results Stride length (- 15%) and gait velocity (- 19%) were reduced, while stride (+ 7%) and stance time (+ 2%) were increased in patients with HD.", "tags": [{"end": 7, "start": 0, "tag": "ResearchActivity"}, {"end": 147, "start": 145, "tag": "DiseaseOrSyndrome"}, {"end": 105, "start": 101, "tag": "TemporalConcept"}, {"end": 139, "start": 131, "tag": "PatientOrDisabledGroup"}, {"end": 47, "start": 34, "tag": "OrganismAttribute"}, {"end": 21, "start": 8, "tag": "OrganismAttribute"}, {"end": 105, "start": 94, "tag": "OrganismAttribute"}, {"end": 82, "start": 76, "tag": "OrganismAttribute"}]}